<SEC-DOCUMENT>0001104659-22-050329.txt : 20220426
<SEC-HEADER>0001104659-22-050329.hdr.sgml : 20220426
<ACCEPTANCE-DATETIME>20220426160627
ACCESSION NUMBER:		0001104659-22-050329
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		133
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220426
DATE AS OF CHANGE:		20220426

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adagene Inc.
		CENTRAL INDEX KEY:			0001818838
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39997
		FILM NUMBER:		22854344

	BUSINESS ADDRESS:	
		STREET 1:		4F, BUILDING C14, NO. 218, XINGHU STREET
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			JIANGSU
		STATE:			F4
		ZIP:			00000
		BUSINESS PHONE:		86-512-87773632

	MAIL ADDRESS:	
		STREET 1:		4F, BUILDING C14, NO. 218, XINGHU STREET
		STREET 2:		SUZHOU INDUSTRIAL PARK
		CITY:			JIANGSU
		STATE:			F4
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>adag-20211231x20f.htm
<DESCRIPTION>FORM 20-F
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.8119.21675 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 4/26/2022 12:38:07 PM -->
      <!-- iXBRL Library version: 1.0.8119.21683 -->
      <!-- iXBRL Service Job ID: 3a6cc66b-0832-48c6-8d7f-57eb736cbff3 -->

  <html xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:adag="http://www.adagene.com/20211231"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" xs:nil="true" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_yykzS30hl06JE8_4Gyvd6Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" xs:nil="true" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" name="us-gaap:CommitmentsAndContingencies" id="Hidden_KEPLbwqWTUKyGw7REBPhKg"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_d69gooBlQ0mTpDFmQMyhSw">15178232</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_hbRrNpmvMky8s-QwJTNZZQ">15950698</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_-hRwfmKQCk-DiIttjIYoug">50032009</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" sign="-" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_KQR8lFNPfkS9TZdYVy-ACQ">1.10</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" sign="-" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_GTBrkm24z0u1aluHb9pjnw">2.67</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_91RASQBlW0uOmcD1zr7dDg">1.46</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Yic_H5pK-Ue4BHoUzpGweQ" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_QEvgf1yxAEqLh9b8UjGxBA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_4ehewyms1Eme4lR1LfryGQ" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_JLyVXrR8sEuV8mnmCK1K2w">2370414</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_myF8ybzw20G2z_xDQJRE5Q" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_C4hibs_km0W0n4vCRJwCyw">7494537</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_he2uy54CEUGAjR10ESXHnw" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_U4bKB1bdKE2KKF0DOPSivA">5597354</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_yz5fD7wsz0K_dYLM59ooPw" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_ZFF7xARedUCS8PewaKNanQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_di_bFxD70EWwEtdspmZWRw" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_endl8IoTH0O3K-aS-8m02w">1861121</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_di_bFxD70EWwEtdspmZWRw" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_6xw84MWAzEeKSGIAjkDJlA">1861121</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_yz5fD7wsz0K_dYLM59ooPw" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_ZZZ6KNvyvUCF2u7hjt9r2w">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_BeGIQu5lxUuigOpTULuf_g" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_3HsWhAnamUSYk6toX8wDkw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_EFH-DFpj80mpuyw7v7-SrQ" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_coidT8_no0y69VNki9JaoQ">4452441</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_EFH-DFpj80mpuyw7v7-SrQ" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_ca9NT4ulY0m7Yx2D4afc4w">4452441</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_BeGIQu5lxUuigOpTULuf_g" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_aLT9LyQmbkKGiAvNLS69LA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_SxmNMOLwwke2qPy39angXQ">16603070</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:EntityCentralIndexKey" id="Tc_6A_GYw39B0mIkE2xw15zpw_3_1">0001818838</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:DocumentFiscalPeriodFocus" id="Tc_ilInAsoEGU2LJJeBmliEgQ_4_1">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:DocumentFiscalYearFocus" id="Tc_at9vrbzVSUGlx-hTSwcK4g_5_1">2021</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:AmendmentFlag" id="Tc_nWNcDVgQt0W9VRtIrmkhpQ_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA" name="dei:EntityAddressAddressLine1" id="Tc_xJP5Ei-5OkK-1ChZQZHakA_7_1">4F, Building C14, No. 218</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA" name="dei:EntityAddressAddressLine2" id="Tc_nmL3QmbpiE6wcUeEe0a6rA_8_1">Xinghu Street, Suzhou Industrial Park</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA" name="dei:EntityAddressCityOrTown" id="Tc_Af2EY_fHh0W51fXgvRBUBw_9_1">Suzhou</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA" name="dei:EntityAddressPostalZipCode" id="Tc_G5RzXEs2bUKdSmtjlP-D5w_10_1">215123</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA" name="dei:EntityAddressCountry" id="Hidden_5lXRz63kp0qPymSXKecMXg">CN</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_4s8XwXHiB0e5MShPFwPsfw" decimals="0" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" id="Hidden_h1NOMMhhk0K4VgxrbDp5-w">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_YFcme7KyF0aRVFQE-QOpug" decimals="0" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" id="Hidden_VOUFRqxLFk2geNCR76Ezew">0</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_rJ9HGaFep0uT39eGrH0BAQ" name="dei:NoTradingSymbolFlag" id="Hidden_LcEk2UDpO02c8OZkOaHuyA">true</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Fqi_V4t6y0-puYQ1ivg6DQ" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_VENfoXbPC061Bzk81pVbqA">5473957</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_4ehewyms1Eme4lR1LfryGQ" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_fH5899ZKkEmYwyakW595Rg">2370414</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_myF8ybzw20G2z_xDQJRE5Q" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_Ujn6nO5i60WmgbpVHu8L6g">7494537</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_he2uy54CEUGAjR10ESXHnw" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_JKoEN2tDO0abKAYkMiyMhQ">5597354</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_SfcvSq9YQU2De6zqVGFSdQ">54595667</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Yic_H5pK-Ue4BHoUzpGweQ" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_4kmxjAvEPk2yQwJB4UYeqQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_b-r3H9b28Ey8YCwkcUjTkw" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_RF_o9M8JfUuM8iJOj7KzuQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_Uvvs-PCSRkiaKVDtX3E5sQ" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_k8YAQyxbe0W4LNbcRCzReQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_Uvvs-PCSRkiaKVDtX3E5sQ" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_CM3VYilgek6jumNumo7jMA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_AdBejOP9vk6p3isk1DREwg" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_-stUpPtT602sN50jfcM6bQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_AdBejOP9vk6p3isk1DREwg" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_lWPSxiRXVESkOsTlb6pViQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Fqi_V4t6y0-puYQ1ivg6DQ" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" id="Hidden_1DC4-oxGy0e0-KBQVfIJBw">5473957</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_b-r3H9b28Ey8YCwkcUjTkw" decimals="INF" name="us-gaap:TemporaryEquitySharesIssued" id="Hidden_nDK_8hmoukyOeCQJGfI27Q">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="adag-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_7_7_2021_To_12_31_2021_VOZydV_s0k6TnW7n0mP29A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-07</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_-XH9Go_6R0eqJay27YP0iA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_hZT-sOgQYEa1gHbRXtKNww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_pJ8hEn_UR067dD0gRcTb-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_7_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_S5sj8QyYv0-TTqmBGm6N1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-07</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_7_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_CCQsBDVo0ESOnNGl9WpWgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-07</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_KheMHBp800ewm1lePqQqfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_7jJxs3yXWUuOCOO5o_qb7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember__gZCIGPtFEW337N5JP2Q0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_BeGIQu5lxUuigOpTULuf_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_yz5fD7wsz0K_dYLM59ooPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_AdBejOP9vk6p3isk1DREwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_Uvvs-PCSRkiaKVDtX3E5sQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_b-r3H9b28Ey8YCwkcUjTkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Yic_H5pK-Ue4BHoUzpGweQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_EFH-DFpj80mpuyw7v7-SrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_di_bFxD70EWwEtdspmZWRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_he2uy54CEUGAjR10ESXHnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_myF8ybzw20G2z_xDQJRE5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_4ehewyms1Eme4lR1LfryGQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Fqi_V4t6y0-puYQ1ivg6DQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_DnVhZllqokOmO7zElhgtow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_ZGQqQfHg406k4K3zCUbpCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_6BqJpjfqTkmbkm23rKGTgQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_mfkgJutHxk6YN0AZLtjrhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_wmf-_5aZ706YaqfSKWC1Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_JVAYrE5J70eJCxdaW-vCJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_pP0RVv1loE2F7LhqFPFl5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_z37ZSNqIdkmrfe2PIq5bYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_l9mQvoDziUGbilnG3EPTXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_bH8gJMCbP0e6I7i5rqUq1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_AE-vqlBJf0-NDgL1echf5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_7_2021_To_7_7_2021_Q_S9qhvpvUC3dMaaONMnrg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-07</xbrli:startDate><xbrli:endDate>2021-07-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_7_2021_ah_eEOxPL0CIPCxPK6qNbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_BmsMtetGyEmJ6rNq6bChIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_bwrRgyxuJEyI4cbzEoFAfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_KAuPKCifoEuHLIrulCDCMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_6qnoqf3lxkW7dfqLzPlqGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_cjqzXXZQU0imlA6Mfbj2WQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_ZNLsTGONtk6j3oo5yuSW8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Vyleht5K70id4Y2JmD-6pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4cZXNIk8T0WsnTIe9RQpHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ejhoERAomEign1naasf3xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_11_2021_To_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_r4I_ZqMIBUCX-Ze0L9Tr3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-11</xbrli:startDate><xbrli:endDate>2021-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MO7C6tyJRUOkv1IQjh61yg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eG8PooN1rEWw4Jpd-57o7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8l7C0jHh2E-gT1dD7E0Dog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dLa3qPlXC0ubjB2El7bVaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_ucSapsjP0kSLroQuwY1qqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_s_hI_eMhXEuN0ZTpwuwXiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_odl9-H0Af02VWyk45akORA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3OzaKSBA6EKIleBIeH1EMw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_QcpBoYoLhEuMjeBkZobcYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eu-ubqjya0GZ7jR6Gj7umw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ksUQnXGhskekv5LudMtZwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9ItmklfRf0uRsoU9hvgWog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_HYoBMhtJa0yEyU06RSK4NA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CxGmgLMsLE2qdLE2LM_0rA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1tBXOuzi0ESMiQGauboZTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_aSr2RzGWsEeMWJO8StiKvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_n4xqIulhYU-egftp4MP37g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_g_h3Hub6ukul0-GRuWdxTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2016_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_Z_tj6E4y60S8vpMf1oAsgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_3jZL665NG0K7BDnwmBK99w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_zDcYc37T6EuzabJm9zIaGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_s7dkZbBLJUCm7qfYw6gdmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FbCfpTbSv0mxoweyDbesMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_By3QnPrdlEaXBzg7JPmAWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CcCxb4VhikOi1y0dPsdYqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_7_2022_To_3_25_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_ZhmKNezcek-HK-1dHlkcpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-07</xbrli:startDate><xbrli:endDate>2022-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_7_2022_To_3_25_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Nz6vByh-PUO3MFMmJbHcFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-07</xbrli:startDate><xbrli:endDate>2022-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_12_2021_To_12_22_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_u_kx_vXZB0a8pG4zN4WJ5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-12</xbrli:startDate><xbrli:endDate>2021-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_12_2021_To_12_22_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_Rz3IDXEqBkqyYcd3zdrfzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-12</xbrli:startDate><xbrli:endDate>2021-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_9_2020_To_11_9_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_XjwJ8pZZ10aBP4HgKJNJBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-09</xbrli:startDate><xbrli:endDate>2020-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_9_2020_To_11_9_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Tj93Av1VmE-ghmkmKkxeVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-09</xbrli:startDate><xbrli:endDate>2020-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_7_2022_To_1_7_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rKG0vF3HuUuOSzupeNgTNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-07</xbrli:startDate><xbrli:endDate>2022-01-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_FHaDhJxmwEKepai0fnE7_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_gps4CSyPx0qQcHlONLLb2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_8_2022_To_3_8_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yR9MjqeEykqztm3xL6TxRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-08</xbrli:startDate><xbrli:endDate>2022-03-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_7_2022_To_3_25_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qgR18IIqT0W8xFm3O123fA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-07</xbrli:startDate><xbrli:endDate>2022-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_16_2021_To_3_16_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_KJ_klWmvoEGqcj3eoFwhkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-16</xbrli:startDate><xbrli:endDate>2021-03-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_12_2021_To_12_22_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_cTAuhhwHJkiqvsAvTWQsmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-12</xbrli:startDate><xbrli:endDate>2021-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_adag_ServiceConditionsAndPerformanceConditionsMember_lzcuoYgQd0GD5oMsj4d0yA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">adag:ServiceConditionsAndPerformanceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_StatementScenarioAxis_adag_ServiceConditionsAndPerformanceConditionsMember_aYQM4Z59Lkq9WgUCQtEtog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">adag:ServiceConditionsAndPerformanceConditionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_us-gaap_PlanNameAxis_adag_Plan2019Member_qU51oRRIxk-yJ1GRjugs3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:Plan2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2017_us-gaap_PlanNameAxis_adag_Plan2017Member_pj9uKp5Wm0Kh5Lol033Ddw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:Plan2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_7_2015_us-gaap_PlanNameAxis_adag_Plan2015Member_9j3tnKD5LU-UGahhBXvNQw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:Plan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_7_2022_To_7_7_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_1hE8qqTDwUyc0lzaYCJtgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-07</xbrli:startDate><xbrli:endDate>2022-07-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_OvswsTR8G0ucewnhfOtZsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_15_2020_To_8_15_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_oE_DhZwnNUKZiikkA5YlwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-15</xbrli:startDate><xbrli:endDate>2020-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_14_2020_To_8_14_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_ctCNSEfroUq-2XAeZiRzEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-14</xbrli:startDate><xbrli:endDate>2020-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_UwjwbfWHYk-CsHFX-MxHNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_SignalPharmaceuticalsLlcMember_7offnHLxtE2QBDZc2Gcu7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:SignalPharmaceuticalsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_jQLNNuCCo0Gc9A2UON5i2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_adag_SignalPharmaceuticalsLlcMember_tDfXXMaJ1Eey6o1BuWgWYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:SignalPharmaceuticalsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_bKpMhErhpUq4nsR8w4_mRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_MxpOQhUxHEuCBkT-S645ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_EEyq6-qTT02Gx8jU3UgzXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:AdctCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_u083XUXgXkmjyHICOwXAVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_vfbRj1jR1UChcP5_UNgiYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_R9K_aCh4f0KdI_UTlvIBAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_ufKZJPNy5EaknPuOgGRVKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_He6IyXPrkkSO8ChXsSJeiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_JVqltsC74kiTWg82LEi0EQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_8iysXIGeCkikS5CDa_J0Ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_Gvzpm_m3g0S200Y-2xFrbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_SAiLZZ5KLU2DxJiGDTfUCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiBiologicsShanghaiCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_SwsdmKolekSilpQ3qYqN5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiApptecGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_q83pj5eew0G-H2b3ek53pA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_N1u78K2d-EOfIuR8F8QHxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiBiologicsShanghaiCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember__5lJ8r5zLkCATZnr5vRZCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiApptecGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_dOiC75LhVU2oZehy5mDi8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_XeTQYEWhbE-YyIEK2oP-aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiBiologicsShanghaiCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_KmqFU3ZUgkCofpEfOKqHNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiApptecGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_uo7m-2m6a06JnSUbvBslaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_jsS3_yJrR0KhUEt67uACsw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_W-K9fp6sNECpsw-JihnlWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_crIDIxsy2U6oUr2eG_WiNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_uyRyfLpBGEeJ8flPQrftCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_PoM_lvt6D0O7Kn1hJ7TRfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_KGhMFlu_2kq3DNJN3Ro4IA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_CaBsmpmN7kyoRjl5pYT5EA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adag:ElectronicEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_Ii31JlQF6EyGi8FubMjm2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ciXSaRCCIUShj4RIB8kXvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_0Fkj5p3dOEG5xJSp6cquuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_TXr2Um0aJEuPO1zHVf0dgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_-OER4mKuwE6orMCLglM2Mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_EcLyGd1RtEKchc8-Nwr_uQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adag:ElectronicEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_OkKAU_FVpUiB6Qf9qvp3MQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_rhq53MJUbUaZODEvfgDerw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_xjhR4xY8gkilBkiNX6jw5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_c4u5F8308kqb6Yb80ib06w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_ugbL_thGJ0y97MV05rKCuA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_Y9nw88vBK0en70RiAB4NXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adag:ElectronicEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2018_To_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_adag_SeriesC1WarrantsMember_WLfnPOEP_kCFFQnnkF3j_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adag:SeriesC1WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_11_2021_To_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_2gbsAY6W7kyRuQc1AoDg2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-11</xbrli:startDate><xbrli:endDate>2021-02-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_AOGCddhlkkafIHJPmD_uUw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:AdctCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_sYvYNerfTEq-2t09ZKu2Pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_y8B0CBPuIkuYDNTamxLEtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_jrlz-uWqkUmR3nAwGvC25Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_US_qd0LMDoF3kaYh2E7WWuXKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_SG_uNjj8HS8_UGTaPvk5ZRsdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_CN_OhVh4Lb4B02ZVkGnT6Nwxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_CH_YBCRGjH5NE--RhN9ukhZ4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_AU_LMSJo9Jtm02FhFmXG-t5HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IizeckEJt0arP1tQ0car0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oTl5ofybRE-y-HStnx9nSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_p0eN6ym23UKzRvTQU9uTVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdageneSuzhouLimitedMember_A507RmmeiUq6oiW6PXn0aA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneSuzhouLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdagenePte.Ltd.Member_d3JwN-5-lUqU1dSbJ5ORkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdagenePte.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdageneIncorporatedMember_HofBS4guwEOkNvbMdQ_4rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdageneHongKongLimitedMember_v6J9OTGMEE63UoAoetmLFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneHongKongLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdageneAustraliaPtyLtd.Member_zLdH5fF9zEmREPsgUVwMsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneAustraliaPtyLtd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdageneAgMember_bsCxNvIf3UO-29bfLUj7-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_6cOSMximrk2bohWsY9UvnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_zAcojCdKLE-VHQNNjHb_JA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_c5z9GXzV4UWW7jLt1LL9xA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_m9PDviMAVECncJ6iC8V97g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_6fAfKRGGhUqL4IOh5BEK8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_GfqS1hbef0evoZ9T4mY-ig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_nqUKaiveBk6aWC7ifhDHyw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_stpr_CA_Zi09NHLp7kmMwo_bnVpuPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_HK_4gYbMZNRaUuPUEWsYd_dSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_HK_tMrEpBM5ckCNd3jduDmhig"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2008_To_1_1_2008_srt_StatementGeographicalAxis_country_CN_6zxDnTTPxkmKtBmcfSofpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2008-01-01</xbrli:startDate><xbrli:endDate>2008-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_I6hnNvOh2UqAhbgZo1ZC3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiBiologicsShanghaiCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_GXYUWeoSRU-ouLAoR_nM4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiApptecGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_oF1Ki6py4Ea_VIk2bXN2pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiBiologicsShanghaiCo.Ltd.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_aakkwWDe5k2bhxPkdccOxg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiApptecGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_LFa5nidGXk2zyr81bhmV-w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_xPZSxb0_rEyiXfgBq8UngA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_yREvdQEbf0aifJQLSacj_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2020_To_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_6cK__TDe2k2D6upUdm_BkA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdLoanTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_c2z9l55OS0-09kT4Xr8EBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromBankOfNingboCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_XCA1IgwsJ0i02_dGhfX8Ww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_Ruff_uK5bECwmUs88WOIvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromBankOfNingboCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_IGsoNcZxl0av20J3TRsTVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember__Yp6JfBX00e2bWTEBjp7og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_7zaPIqJMgEOMGotoMZUnYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_NfuX6XNrY0y0YKE8g2SAHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_n4OTuF0LqkKjcG_8uSdSgg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdLoanTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_CmsXX0QXp0S-fTuzrs4H6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_xK5464GvIU2G2CMxw-2yyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromBankOfNingboCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_oYuYrvTHKU2WUWilDTYWFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_aRG-u8wGNE-CSsqku0pR0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromBankOfNingboCo.LtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_tmSdxQVjfUKJf2DV_oxA0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_8XLbm_NuOEaOfNq0iiQ4Uw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_9GdyKS3_I0KCOd-y1gFghA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2011_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtSecuritiesMember_8DxtpnQnr0KcaNlyma5fZg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FkDkbXaQZU-bN_5oHvMW7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_LqlKepEaPEyADAUMj0EidA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adag:ConcentrationRiskSuppliersAxis">adag:OneSupplierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_SxQdUgI9Z06HufSkFzPTTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adag:ConcentrationRiskSuppliersAxis">adag:OneSupplierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_ZYOjK2vU90O3dGqnw4FeEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adag:ConcentrationRiskSuppliersAxis">adag:OneSupplierMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_16_2021_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_qSN6Ich4FkuRKoki3TJD4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_adag_SeriesC1WarrantsMember_dvXoa1fpc0ab3vTaHbqHkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adag:SeriesC1WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2018_T4mq9hT6lUOBey2VJKkGww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_adag_OutsideMainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_EFliqC7rp0Sx41tQSgTPRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">adag:OutsideMainlandOfChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adag:CashAndCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_adag_MainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_a3KAemeQF0yabn5RGbhXiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">adag:MainlandOfChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adag:CashAndCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_StatementGeographicalAxis_adag_OutsideMainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_yZFC6h4cwEK-fa4C8KeTyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">adag:OutsideMainlandOfChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adag:CashAndCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_srt_StatementGeographicalAxis_adag_MainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_kj-fSey9EEyEtxiGoEoEpg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">adag:MainlandOfChinaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adag:CashAndCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_6guEaEag302za51zg4qPZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_wCLSLauImkivkl4yN53mvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_ESjTZBeLf0SCBovh04R_ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_yAAu1HlY9EC9pTVzah_bYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_qtF149jaCUabjqo7frjCBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_zdsez9gtTkGdnwLN8_NhYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_B0aUMLGKf0iTQ_KOw1cMDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Ku2fXt-ZkUyQ2JGo0NdGOw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_xUUXpRjJbEqKzK5uloapeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_mEMX3jxTBEePGi2c4CW7ew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1m27p6Q0nEy5EgKynSvENw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z-JH0nWTpk2ObWlOPALkqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TRZ2AP03T0q5M7SihzVu2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember__cHz1vX8l0yKaUSYpxTiiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:ExelixisIncAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0J9hCl1ZSkaeQhRprqc5kQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_rJ9HGaFep0uT39eGrH0BAQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Y5rj-vidfkKdz_NhXcGhJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_US_4Mf3uObvgkKrQagy395fZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_CN_hq0Btu-DBkq8lmsfbYdpfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_CH_iL69fGVCpEaHddyIW4NKvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_AU_S-6YiA61gUCW7VM434szsQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_HK_zjbfDO1qFECcc41CmvbdYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_diYKl71mcEa25Z1LgkrP_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2019_To_11_30_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_SGBgTCSDF0a2llGb4MeGuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2018_To_5_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_BRbJS1jV-k2FpP0-kKZpDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2016_To_6_30_2016_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_SWyRj_9rTEa_35eINBgGXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_dcicFbmqOki6XSFYWhz5_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-11-01</xbrli:startDate><xbrli:endDate>2014-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_otWAtk9h5EmHuBYtwAAZvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-11-01</xbrli:startDate><xbrli:endDate>2014-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_jTUbwr8vS0Sq_Dw8Xns3HQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneAustraliaPtyLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_yYOL_1Zc_k-8AA3Sb91Fzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneAustraliaPtyLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_F3MPNQIHAUq3ElcVbpTt6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneAustraliaPtyLtd.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HGnhNeAwYk6MfQLARidhrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_7_2022_To_7_7_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_f5xUbvNTBEimEH5nmcz29g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-07</xbrli:startDate><xbrli:endDate>2022-07-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_16_2021_To_1_16_2021_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_ajeBNU5LbU2-7VeHwDlygA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-16</xbrli:startDate><xbrli:endDate>2021-01-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_9_2020_To_11_9_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_WROxGtz27EKylxKWrdRpfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-09</xbrli:startDate><xbrli:endDate>2020-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2015_To_12_31_2023_adag_StatusForTaxabilityAxis_adag_TechnologyAdvancedServiceEnterprisesMember_dei_LegalEntityAxis_adag_AdageneSuzhouLimitedMember_srt_StatementGeographicalAxis_country_CN_LOA0Hce0QEeI6iU8D0rTDQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adag:StatusForTaxabilityAxis">adag:TechnologyAdvancedServiceEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneSuzhouLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_16_2021_To_1_16_2021_O_ff5_4bk0yyioWBZTe3bA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-16</xbrli:startDate><xbrli:endDate>2021-01-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_nR1gjPUSp0uEhhqDafgCZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_U2Wz9tRC_E-e-VNBsazHMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_QrdSnJigEEC83xAI-BxP_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2018_To_2_28_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_IOm0wr8bS0SSsXLzukJ-8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_xzwissiwc0-243qJnNFPcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:AdctCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_1_2018_To_2_28_2018_h-YUYJGmUkuPVILUOsDYiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-01</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2019_To_4_30_2019_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_eGyxkFQCZE6u3B9IkEjTXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:AdctCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_YFcme7KyF0aRVFQE-QOpug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_4s8XwXHiB0e5MShPFwPsfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2008_To_1_1_2008_adag_StatusForTaxabilityAxis_adag_TechnologyAdvancedServiceEnterprisesMember_srt_StatementGeographicalAxis_country_CN_wwO7JGio2USSa9yydNN8kA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="adag:StatusForTaxabilityAxis">adag:TechnologyAdvancedServiceEnterprisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2008-01-01</xbrli:startDate><xbrli:endDate>2008-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_avdfJlPfpUeAeQTReEsGLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_SignalPharmaceuticalsLlcMember_zbCrjEk3mUSzkE9kYsfUww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:SignalPharmaceuticalsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_i7cOcV2zlk2TryKX0IeFTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:ExelixisIncAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_pYJxpURUM0OA22lpXY2GQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_1_2019_To_5_31_2019_us-gaap_TypeOfArrangementAxis_adag_SignalPharmaceuticalsLlcMember_VxiNPotzW0uBeu5zVH0n4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:SignalPharmaceuticalsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_adag_SignalPharmaceuticalsLlcMember_6wYypVvYlkKloo4C6zZxMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:SignalPharmaceuticalsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_adag_ExelixisAgreementMember_RSXFKdhcqEG6xrEDD5fFIQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:ExelixisAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_j9kFO_H-ME6HZ7oPWsGjEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:ExelixisIncAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_2_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_adag_ExelixisAgreementMember_r29U-8QtcEKfWUKlkQp_tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:ExelixisAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneAgMember_srt_StatementGeographicalAxis_country_CH_2T-t4Od_mUu8G2OSLg0lGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_YuWhG2JtdkyJ7W4ky9r1PQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneHongKongLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_yYXARERJEEyfvZf0uA9tVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneHongKongLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_raAHGN6oRESCKkVreFRITQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_zsB5uPJq50C4DpmE2mjLFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001818838</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ"><xbrli:measure>iso4217:CNY</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_VDVAwvxnO0aSdoyDMbjpLA"><xbrli:measure>adag:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:12.65pt;"><a id="_a92e7179_0c87_476a_902f_f0f3f718485c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:13pt;">UNITED STATES</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:13pt;">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="white-space:pre-wrap;">Washington, D.C.  20549</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:15pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:DocumentType" id="Narr_Fr0baM67b0axxnR7CQiiZg"><b style="font-weight:bold;">20-F</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">(Mark One)</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:4pt;margin-top:0pt;"><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:DocumentRegistrationStatement" id="Narr_lx1qhIxUvkamNcjvOZNeaw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:4pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">REGISTRATION STATEMENT PURSUANT TO SECTION 12(B) OR 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">OR</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:4pt;margin-top:0pt;"><ix:nonNumeric format="ixt:booleantrue" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:DocumentAnnualReport" id="Narr_lJ3AwiqczkK4iBySq4oBww"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:4pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 4pt 36pt;"><b style="font-size:9pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:DocumentPeriodEndDate" id="Narr_ZkVDFT3600ub6sY6e0U1Yg"><ix:nonNumeric format="ixt:datemonthdayen" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:CurrentFiscalYearEndDate" id="Narr_6nF6h5Z0w0WVAE_KtnGDiQ"><b style="font-size:9pt;font-weight:bold;">December 31</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, 2021</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">OR</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:4pt;margin-top:0pt;"><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:DocumentTransitionReport" id="Narr_uU3cgC7JfkmHsJ36CDkjXw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:4pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;padding-left:36pt;text-align:center;text-indent:-36pt;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">OR</b></p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:4pt;margin-top:0pt;"><ix:nonNumeric format="ixt:booleanfalse" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:DocumentShellCompanyReport" id="Narr_2__pKs_tYkmQ-bBZ8NmV_A"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:4pt;margin-top:0pt;"><b style="font-size:9pt;font-weight:bold;">SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 4pt 36pt;"><b style="font-weight:bold;">Date of event requiring this shell company report ___________</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Commission file number: </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:EntityFileNumber" id="Narr_deqsdiwSVU2EAiNW9LclWw"><span style="font-size:9pt;">001-39997</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:15pt;line-height:1.19;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:EntityRegistrantName" id="Narr_OAWsnyPY90mcOvoKDU3q7g"><b style="font-weight:bold;">Adagene Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;">(Exact name of Registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;">(Translation of Registrant&#8217;s name into English)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><ix:nonNumeric format="ixt-sec:edgarprovcountryen" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:EntityIncorporationStateCountryCode" id="Narr__pJK9Y_91UC58DKG3sbhGg"><b style="font-weight:bold;">Cayman Islands</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;">(Jurisdiction of incorporation or organization)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:EntityAddressAddressLine1" id="Narr_s54ObJoeOUCgQKCuIOxgcA"><b style="font-weight:bold;">4F, Building C14, No. 218</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:EntityAddressAddressLine2" id="Narr_gEqTuhaHpUuq9DpssvGUbA"><b style="font-weight:bold;">Xinghu Street, Suzhou Industrial Park</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:EntityAddressCityOrTown" id="Narr_JuvF6VpugkOVRQTQNHNSnQ"><b style="font-weight:bold;">Suzhou</b></ix:nonNumeric><b style="font-weight:bold;">, Jiangsu Province, </b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:EntityAddressPostalZipCode" id="Narr_C7ijmk1Sz0mncptXEvllQA"><b style="font-weight:bold;">215123</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt 0pt 3pt 0pt;"><ix:nonNumeric format="ixt-sec:countrynameen" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:EntityAddressCountry" id="Narr_jxKUL9sz1UOFPRkGPzYY0A"><b style="font-weight:bold;">People&#8217;s Republic of China</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;">(Address of principal executive offices)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA" name="dei:ContactPersonnelName" id="Narr_w2Ucbusnc0mzyDwfGCqJ2g"><b style="font-size:10pt;font-weight:bold;">Peter (Peizhi) Luo</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Chief Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:10pt;font-weight:bold;">+</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA" name="dei:CountryRegion" id="Narr_Jcm8ekVeJUCCi59z87KTrA"><b style="font-size:10pt;font-weight:bold;">86</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;">-</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA" name="dei:CityAreaCode" id="Narr_WFN5oHIPkUqAKdef8dsn8w"><b style="font-size:10pt;font-weight:bold;">512</b></ix:nonNumeric><b style="font-size:10pt;font-weight:bold;">-</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA" name="dei:LocalPhoneNumber" id="Narr_v-UVN6YwCEa9x_Lr_2gjaw"><b style="font-size:10pt;font-weight:bold;">87773616</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-size:10pt;font-weight:bold;">Email:</b><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA" name="dei:ContactPersonnelEmailAddress" id="Narr_Q4JoqvqT5kevDoWq06QiEg"><b style="font-size:10pt;font-weight:bold;">peter_luo@adagene.com</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">At the address of the Company set forth above</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;">(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">Securities registered or to be registered pursuant to Section 12(b) of the Act:</p><a id="_69843d0e_c6dc_40f2_835a_8c0dc6b0110f"></a><div style="margin-left:0pt;"><a id="Tc_WeYCiAz4IECVKlkC58AWOA_1_0"></a><a id="Tc_WksMRr2d6kyywCJJoMBHEw_1_2"></a><a id="Tc_f0sK03Ss60OgLUj_nQujDw_1_4"></a><a id="Tc_6vCnuDWTEE-QpOcFNChZpg_2_0"></a><a id="Tc_qztRRl7xekuiFf1S4wVs1w_3_0"></a><a id="Tc_RgwuO6JEZ0yESDD-pAlUzQ_3_4"></a><a id="Tc__KbDHhIcdU-jONR1Ki6Oag_4_0"></a><a id="Tc_3TSzwGk6V0OTxr1sC5_qFg_5_0"></a><a id="Tc__DO6r82tGUSM3BEkTyNQ5w_6_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:16.96%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:2.39%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:36.22%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:41.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:16.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol</b></p></td><td style="vertical-align:top;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:36.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:41.97%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0J9hCl1ZSkaeQhRprqc5kQ" name="dei:Security12bTitle" id="Narr_q8S1ZcQeD0Olmw5rF6Py4Q"><span style="font-size:9pt;">American depositary shares</span></ix:nonNumeric><span style="font-size:9pt;">, each ADS representing one</span></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0J9hCl1ZSkaeQhRprqc5kQ" name="dei:TradingSymbol" id="Tc_7zE1giYdikukQB7n2l7cLg_2_2"><span style="font-size:9pt;">ADAG</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.22%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0J9hCl1ZSkaeQhRprqc5kQ" name="dei:SecurityExchangeName" id="Tc_Wb_Xmd9wjEOsDtk095RzKA_2_4"><span style="font-size:9pt;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;">and one quarter</p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;">(The Nasdaq Global Market)</p></td></tr><tr><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;">ordinary shares, par value US$0.0001 per share</p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_rJ9HGaFep0uT39eGrH0BAQ" name="dei:Security12bTitle" id="Narr_JWCqnVT7LE206MAH2eC3_w"><span style="font-size:9pt;">Ordinary shares, par value US$0.0001 per share</span></ix:nonNumeric><span style="font-size:9pt;">*</span></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_LcEk2UDpO02c8OZkOaHuyA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">N/A</span></span></p></td><td style="vertical-align:top;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_rJ9HGaFep0uT39eGrH0BAQ" name="dei:SecurityExchangeName" id="Tc_Vz7xWhZjukufAwFAsDMhuQ_5_4"><span style="font-size:9pt;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;">(The Nasdaq Global Market)</p></td></tr></table></div><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-left:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">*</span></span>Not for trading, but only in connection with the listing on the Nasdaq Global Market of American depositary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Securities registered or to be registered pursuant to Section 12(g) of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(Title of Class)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">None</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">(Title of Class)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">Indicate the number of outstanding shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="Narr_yFsGMlsBYU-xxAx55hM-sg">54,595,667</ix:nonFraction> ordinary shares, par value US$0.0001 per share, as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Yes </span><span style="font-size:9pt;">&#9744;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_YMOF5VUHHUqK0NJ4oelHIg"><span style="font-size:9pt;">No</span></ix:nonNumeric><span style="font-size:9pt;"> </span><span style="font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Yes </span><span style="font-size:9pt;">&#9744;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:EntityVoluntaryFilers" id="Narr_wAEISLsRH0qpt5CFqgiqmQ"><span style="font-size:9pt;">No</span></ix:nonNumeric><span style="font-size:9pt;"> </span><span style="font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:EntityCurrentReportingStatus" id="Narr_nphWqMpi502mUbah_3ycyA"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;"> </span><span style="font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;No </span><span style="font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:EntityInteractiveDataCurrent" id="Narr_3-OGTRGqPUOxXKeZDojFKA"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;"> </span><span style="font-size:9pt;">&#9746;</span><span style="font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;No </span><span style="font-size:9pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. Check one:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:25.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Large Accelerated Filer &#9744; </p></td><td style="vertical-align:top;width:21.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="Narr_EpvACwuXd0CkZ31MIlihhw"><span style="font-size:10pt;">Accelerated Filer</span></ix:nonNumeric><span style="font-size:10pt;"> </span><span style="font-size:10pt;">&#9746;</span></p></td><td style="vertical-align:bottom;width:27.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt;">Non-accelerated Filer &#9744;</p></td><td style="vertical-align:top;width:25.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="font-size:10pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany" id="Narr_ghW6AwfaZ0K-eEIryrxo0w"><span style="font-family:'Segoe UI Symbol';font-size:10pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="font-size:5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards &#8224; provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod" id="Narr_x4uox3mqFkaao4oeUpFttg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accountant firm that prepared or issued its audit report. Yes </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" format="ixt:booleanfalse" name="dei:IcfrAuditorAttestationFlag" id="Narr_ONGrgcUceUC-XhWdnHOoAg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;No </span><span style="font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt;">Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:5pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 4pt 18pt;"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span><span style="font-size:9pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:DocumentAccountingStandard" id="Narr_tivJBb6vhUCKY7iWrVR2yg"><span style="font-size:9pt;">U.S. GAAP</span></ix:nonNumeric><span style="font-size:9pt;"> &#160;&#160;&#160;&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 18pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span><span style="font-family:'Segoe UI Symbol';"> </span>International Financial Reporting Standards as issued by the International Accounting Standards Board</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 18pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span><span style="font-family:'Segoe UI Symbol';"> </span>Other</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">If &#8220;Other&#8221; has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span> Item 17<span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#160;</span><span style="font-family:'Segoe UI Symbol';">&#9744;</span> Item 18</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;"><span style="font-size:9pt;">Yes </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" format="ixt:booleanfalse" name="dei:EntityShellCompany" id="Narr_ErnnWzPGpUOeQ7cRrWVc2g"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;No </span><span style="font-size:9pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 4pt 0pt;">Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;text-align:center;margin:0pt 0pt 4pt 0pt;">Yes &#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No &#9744;</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;">&#8224; The term &#8220;new or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 3pt 0pt;"><span style="font-size:7pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_04e27fae_8b67_44f2_bfc6_329324a79b94"></a><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.22%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:90.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:6.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Page</p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.56%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#INTRODUCTION_914373"><span style="font-style:normal;font-weight:normal;">INTRODUCTION</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">1</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#FORWARDLOOKINGINFORMATION_280297"><span style="font-style:normal;font-weight:normal;">Forward-Looking Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">2</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#PARTI_224417"><span style="font-style:normal;font-weight:normal;">PART I</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">4</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM1IDENTITY_297271"><span style="font-style:normal;font-weight:normal;">ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">4</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM2OFFERSTATISTICS_443951"><span style="font-style:normal;font-weight:normal;">ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">4</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM3KEYINFORMATION_236761"><span style="font-style:normal;font-weight:normal;">ITEM 3. KEY INFORMATION</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">4</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a3AReserved_450679"><span style="font-style:normal;font-weight:normal;">3.A. [Reserved]</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">4</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a3BCapitalizationandIndebtedness"><span style="font-style:normal;font-weight:normal;">3.B. Capitalization and Indebtedness</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">4</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a3CReasonfortheOfferandUseofProceeds_915"><span style="font-style:normal;font-weight:normal;">3.C. Reason for the Offer and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">4</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a3DRiskFactors_683481"><span style="font-style:normal;font-weight:normal;">3.D. Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">4</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM4INFORMATIONONTHECOMPANY_682720"><span style="font-style:normal;font-weight:normal;">ITEM 4. INFORMATION ON THE COMPANY</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">80</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a4AHistoryandDevelopmentoftheCompany_695"><span style="font-style:normal;font-weight:normal;">4.A. History and Development of the Company</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">80</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a4BBusinessOverview_294009"><span style="font-style:normal;font-weight:normal;">4.B. Business Overview</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">84</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a4COrganizationalStructure_866231"><span style="font-style:normal;font-weight:normal;">4.C. Organizational Structure</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">155</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM4AUNRESOLVEDSTAFFCOMMENTS_814425"><span style="font-style:normal;font-weight:normal;">ITEM 4A. UNRESOLVED STAFF COMMENTS</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">156</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM5OPERATINGANDFINANCIALREVIEWANDPROSP"><span style="font-style:normal;font-weight:normal;">Item 5. Operating and Financial Review and Prospects</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">156</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a5AOperatingResults_653990"><span style="font-style:normal;font-weight:normal;">5.A. Operating Results</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">156</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a5BLiquidityandCapitalResources_247343"><span style="font-style:normal;font-weight:normal;">5.B. Liquidity and Capital Resources</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">168</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a5CResearchandDevelopmentPatentsandLicen"><span style="font-style:normal;font-weight:normal;">5.C. Research and Development, Patents and Licenses, Etc.</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">171</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a5DTrendInformation_715692"><span style="font-style:normal;font-weight:normal;">5.D. Trend Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">171</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a5ECriticalAccountingEstimates_321468"><span style="font-style:normal;font-weight:normal;">5.E. C</span><span style="font-size:11pt;font-style:normal;font-weight:normal;">ritical Accounting Estimates</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">171</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM6DIRECTORSSENIORMANAGEMENTANDEMPLOYE"><span style="font-style:normal;font-weight:normal;">Item 6. Directors, Senior Management and Employees</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">173</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a6ADirectorsandSeniorManagement_393694"><span style="font-style:normal;font-weight:normal;">6.A. Directors and Senior Management</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">173</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a6BCompensation_267993"><span style="font-style:normal;font-weight:normal;">6.B. Compensation</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">178</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a6CBoardPractices_80216"><span style="font-style:normal;font-weight:normal;">6.C. Board Practices</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">184</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a6DEmployees_447015"><span style="font-style:normal;font-weight:normal;">6.D. Employees</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">188</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a6EShareOwnership_384399"><span style="font-style:normal;font-weight:normal;">6.E. Share Ownership</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">188</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#Item7MajorShareholdersandRelatedPartyTra"><span style="font-style:normal;font-weight:normal;">Item 7. Major Shareholders and Related Party Transactions</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">191</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a7AMAJORSHAREHOLDERS_545494"><span style="font-style:normal;font-weight:normal;">7.A. Major Shareholders</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">191</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a7BRELATEDPARTYTRANSACTIONS_165301"><span style="font-style:normal;font-weight:normal;">7.B. Related Party Transactions</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">191</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a7CInterestsofExpertsandCounsel_412934"><span style="font-style:normal;font-weight:normal;">7.C. Interests of Experts and Counsel</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">192</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#Item8FinancialInformation_179985"><span style="font-style:normal;font-weight:normal;">Item 8. Financial Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">192</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a8AConsolidatedStatementsandOther"><span style="font-style:normal;font-weight:normal;">8.A. Consolidated Statements and Other Financial Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">192</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a8BSignificantChanges_30259"><span style="font-style:normal;font-weight:normal;">8.B. Significant Changes</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">193</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#Item9TheOfferandListing_756002"><span style="font-style:normal;font-weight:normal;">Item 9. The Offer and Listing</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">193</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a9AOfferingandListingDetails_144386"><span style="font-style:normal;font-weight:normal;">9.A. Offering and Listing Details</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">193</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a9BPlanofDistribution_978914"><span style="font-style:normal;font-weight:normal;">9.B. Plan of Distribution</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">193</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a9CMarkets_923664"><span style="font-style:normal;font-weight:normal;">9.C. Markets</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">193</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a9DSellingShareholders"><span style="font-style:normal;font-weight:normal;">9.D. Selling Shareholders</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">194</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a9EDilution_990429"><span style="font-style:normal;font-weight:normal;">9.E. Dilution</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">194</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a9FExpensesoftheIssue_581594"><span style="font-style:normal;font-weight:normal;">9.F. Expenses of the Issue</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">194</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#Item10AdditionalInformation_357630"><span style="font-style:normal;font-weight:normal;">Item 10. Additional Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">194</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a10AShareCapital_984479"><span style="font-style:normal;font-weight:normal;">10.A. Share Capital</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">194</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a10BMemorandumandArticlesofAssociation_2"><span style="font-style:normal;font-weight:normal;">10.B. Memorandum and Articles of Association</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">194</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a10CMaterialContracts_95807"><span style="font-style:normal;font-weight:normal;">10.C. Material Contracts</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">199</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a10DExchangeControls_660603"><span style="font-style:normal;font-weight:normal;">10.D. Exchange Controls</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">199</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a10ETaxation_830656"><span style="font-style:normal;font-weight:normal;">10.E. Taxation</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">199</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a10FDividendsandPayingAgents_24522"><span style="font-style:normal;font-weight:normal;">10.F. Dividends and Paying Agents</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">204</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a10GStatementbyExperts_487266"><span style="font-style:normal;font-weight:normal;">10.G. Statement by Experts</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">204</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a10HDocumentsonDisplay_386080"><span style="font-style:normal;font-weight:normal;">10.H. Documents on Display</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">204</span></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">i</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:97.22%;"><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a10ISubsidiaryInformation_103259"><span style="font-style:normal;font-weight:normal;">10.I. Subsidiary Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">204</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM11QUANTITATIVEANDQUALITATIVEDISCLOSU"><span style="font-style:normal;font-weight:normal;">ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">205</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM12DESCRIPTIONOFSECURITIESOTHERTHANEQ"><span style="font-style:normal;font-weight:normal;">ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">205</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a12ADebtSecurities_373051"><span style="font-style:normal;font-weight:normal;">12.A. Debt Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">205</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a12BWarrantsandRights_197872"><span style="font-style:normal;font-weight:normal;">12.B. Warrants and Rights</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">205</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a12COtherSecurities_121938"><span style="font-style:normal;font-weight:normal;">12.C. Other Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">206</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a12DAmericanDepositaryShares_154963"><span style="font-style:normal;font-weight:normal;">12.D. American Depositary Shares</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">206</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#PARTII_838708"><span style="font-style:normal;font-weight:normal;">PART II</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">209</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM13ITEMDEFAULTSDIVIDENDARREARAGESANDD"><span style="font-style:normal;font-weight:normal;">ITEM 13. ITEM DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">209</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM14MATERIALMODIFICATIONSTOTHERIGHTSOF"><span style="font-style:normal;font-weight:normal;">ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">209</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a14A14DMaterialModificationstotheRightso"><span style="font-style:normal;font-weight:normal;">14.A. &#8212; 14.D. Material Modifications to the Rights of Security Holders</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">209</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a14EUseofProceeds_380361"><span style="font-style:normal;font-weight:normal;">14.E. Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">209</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM15CONTROLSANDPROCEDURES_210978"><span style="font-style:normal;font-weight:normal;">ITEM 15. CONTROLS AND PROCEDURES</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">209</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#Item16AAuditCommitteeFinancialExpert_659"><span style="font-style:normal;font-weight:normal;">Item 16.A. Audit Committee Financial Expert</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">211</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#Item16BCodeofEthics_352573"><span style="font-style:normal;font-weight:normal;">Item 16.B. Code of Ethics</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">211</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#Item16CPrincipalAccountantFeesandService"><span style="font-style:normal;font-weight:normal;">Item 16.C. Principal Accountant Fees and Services</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">211</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a16DExemptionsfromtheListingStandardsfor"><span style="font-style:normal;font-weight:normal;">16.D. Exemptions from the Listing Standards for Audit Committees</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">212</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a16EPurchasesofEquitySecuritiesbytheIssu"><span style="font-style:normal;font-weight:normal;">16.E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">212</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a16FChangeinRegistrantsCertifyingAccount"><span style="font-style:normal;font-weight:normal;">16.F. Change in Registrant&#8217;s Certifying Accountant</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">212</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a16GCorporateGovernance_85646"><span style="font-style:normal;font-weight:normal;">16.G. Corporate Governance</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">213</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 18pt;"><a style="font-size:10pt;" href="#a16HMineSafetyDisclosure_791076"><span style="font-style:normal;font-weight:normal;">16.H. Mine Safety Disclosure</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">213</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#PARTIII_403713"><span style="font-style:normal;font-weight:normal;">PART III</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">214</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM17FINANCIALSTATEMENTS_534522"><span style="font-style:normal;font-weight:normal;">ITEM 17. FINANCIAL STATEMENTS</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">214</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM18FINANCIALSTATEMENTS_506735"><span style="font-style:normal;font-weight:normal;">ITEM 18. FINANCIAL STATEMENTS</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">214</span></p></td></tr><tr><td style="vertical-align:bottom;width:90.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ITEM19EXHIBITS_246848"><span style="font-style:normal;font-weight:normal;">ITEM 19. EXHIBITS</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="font-size:10pt;">214</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">ii</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ba8491dc_7159_4931_a8a7_36f809d84fdb"></a><a id="INTRODUCTION_914373"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">INTRODUCTION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Except where the context otherwise indicates and for the purpose of this annual report only:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Adagene Suzhou&#8221; refers to Adagene (Suzhou) Limited, our subsidiary in the PRC;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Adagene Incorporated&#8221; reference to Adagene Incoporated, our subsidiary in the U.S.;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;ADSs&#8221; refers to the American depositary shares, each representing one and one quarter (1.25) of our ordinary shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Antibody binding interface&#8221; or &#8220;antibody binding sites&#8221; refers to the antibody binding surface spots in contact with its recognition antigen;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;China&#8221; or &#8220;PRC&#8221; refers to the People&#8217;s Republic of China, excluding, for the purpose of this annual report only, Taiwan, Hong Kong and Macau;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;conformational diversity&#8221; or &#8220;dynamic diversity&#8221; refers to the existence of more than one conformation or structure due to dynamic fluctuation of the structures for a given protein sequence, independent of any conformational changes caused by external binding;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;epitopes&#8221; or &#8220;epitope of an antigen&#8221; refers to the specific binding spots of an antigen in contact with its antibody binding surface;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Greater China&#8221;, for the purpose of this annual report, refers to the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;multi-specificity&#8221; refers to a protein exerting a similar function (such as binding) on distinctly different ligands, perhaps while using different active site residues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;NEObody&#8221; refers to antibody designed with dynamic binding sites that adapt kinetically to unique epitopes through novel MOA, using our NEObody technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;POWERbody&#8221; refers to antibody that utilizes our SAFEbody technology to create new bispecific T-cell engagers, antibody-drug conjugates, or antibodies, which are designed to reach beyond the therapeutic potency of traditional monospecific antibodies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;RMB&#8221; or &#8220;Renminbi&#8221; refers to the legal currency of the People&#8217;s Republic of China;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;SAFEbody&#8221; refers to antibody engineered with its binding sites masked, which are designed to be selectively activated in the TME, potentially limiting on-target off-tumor toxicity in normal tissues; SAFEbody&#174; is a registered trademark in the United States, China, Australia, Japan, Singapore, and the European Union;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;Securities Act&#8221; refers to the Securities Act of 1933, as amended;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;species cross-reactivity&#8221; refers to reactivity of the same protein that recognizes and binds to similar epitopes of a given class of targets in different species;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;US$,&#8221; &#8220;dollars&#8221; or &#8220;U.S. dollars&#8221; refers to the legal currency of the United States; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our company,&#8221; and &#8220;our,&#8221; refer to Adagene Inc., a Cayman Islands exempted company and its subsidiaries.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;NEObodies&#8221; refer to antibodies designed with dynamic binding sites that adapt kinetically to unique epitopes through novel MOAs, using our NEObody technology;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;ordinary shares&#8221; or &#8220;shares&#8221; refers to our ordinary shares of par value US$0.0001 per share;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;POWERbodies&#8221; refer to antibodies that utilize our SAFEbody technology to create new bispecific T-cell engagers, antibody-drug conjugates, or antibodies, which are designed to reach beyond the therapeutic potency of traditional monospecific antibodies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#8220;SAFEbodies&#8221; refer to antibodies engineered with their binding sites masked, which are designed to be selectively activated in the tumor microenvironment, potentially limiting on-target off-tumor toxicity in normal tissues.</span></td></tr></table><div style="margin-top:12pt;"><a id="_6a7f7547_9bd4_4a41_ba96_14fb03451764"></a><a id="FORWARDLOOKINGINFORMATION_280297"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">FORWARD-LOOKING INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This annual report contains forward-looking statements that reflect our current expectations and views of future events. All statements other than statements of historical facts are forward-looking statements. These forward-looking statements are made under the &#8220;safe harbor&#8221; provision under Section&#160;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and as defined in the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other factors, including but not limited to Adagene&#8217;s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene&#8217;s drug candidates; Adagene&#8217;s ability to achieve commercial success for its drug candidates, if approved; Adagene&#8217;s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene&#8217;s reliance on third parties to conduct drug development, manufacturing and other services; Adagene&#8217;s limited operating history and Adagene&#8217;s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene&#8217;s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene&#8217;s clinical development, commercial and other operations, as well as those risks more fully discussed in the &#8220;Risk Factors&#8221; section in Adagene&#8217;s filings with the SEC. Such known and unknown risks, uncertainties and other factors may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. In some cases, you can identify these forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;aim,&#8221; &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;is/are likely to,&#8221; &#8220;potential,&#8221; &#8220;continue&#8221; or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements include, but are not limited to, statements about:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our goals and growth strategies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our future business development, results of operations and financial condition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of the initiation, progress and potential results of our preclinical studies, clinical trials and our discovery programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to utilize our proprietary Dynamic Precision Library platform, or DPL, to design, construct and develop next-generation antibodies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to advance product candidates into, and successfully complete, clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing or likelihood of regulatory filings and approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the commercializing of our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">future strategic arrangements and/or collaborations and the potential benefits of such arrangements;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our anticipated use of our existing resources and the proceeds from our initial public offering;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to retain the continued service of our key personnel and to identify, hire and retain additional qualified professionals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the implementation of our business model, strategic plans for our business and product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of protection we are able to establish and maintain for intellectual property rights, such as our proprietary DPL, which includes NEObody platform, SAFEbody platform and POWERbody platform, product candidates and discovery programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential to enter into new collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the pricing, coverage and reimbursement of our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments relating to our competitors and our industry, including competing product candidates and therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the direct and indirect impact of the COVID-19 pandemic on our business and operations and on development of our clinical and preclinical programs, and the duration and impact of COVID-19 or any of its variants that may affect, precipitate or exacerbate one or more of any of the risks and uncertainties mentioned in this annual report;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relevant government policies and regulations relating to our business and industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic and business condition in the markets we have businesses; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assumptions underlying or related to any of the foregoing.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We would like to caution you not to place undue reliance on these forward-looking statements and you should read these statements in conjunction with the risk factors disclosed in &#8220;Item 3. Key Information&#8212;D. Risk Factors&#8221; of this annual report and other risks outlined in our other filings with the Securities and Exchange Commission, or the SEC. Those risks are not exhaustive. We operate in an evolving environment. New risks emerge from time to time and it is impossible for our management to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. We qualify all of our forward-looking statements by these cautionary statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You should not rely upon forward-looking statements as predictions of future events. We do not undertake any obligation to update or revise the forward-looking statements except as required under applicable law. You should read this annual report and the documents that we reference in this annual report completely and with the understanding that our actual future results may be materially different from what we expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1877bcf6_a1b8_4608_aebf_4f04f4fbcadf"></a><a id="PARTI_224417"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;I</p><a id="ITEM1IDENTITY_297271"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 1.&#160;IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_ec03640e_2453_4b5d_8699_ff54c2a89cdd"></a><a id="ITEM2OFFERSTATISTICS_443951"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 2.&#160;OFFER STATISTICS AND EXPECTED TIMETABLE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_caba71b1_00db_4955_95a2_bb87768da291"></a><a id="ITEM3KEYINFORMATION_236761"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 3.&#160;KEY INFORMATION</p><a id="_835b235a_f819_4449_8a05_3be4457d8ae9"></a><a id="a3AReserved_450679"></a><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">3.A. [Reserved]</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_985b1c67_442c_4b7a_a5fe_7f7a6520337f"></a><a id="a3BCapitalizationandIndebtedness"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">3.B. Capitalization and Indebtedness</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_340f3125_2086_40d3_bef3_4541e63e20e8"></a><a id="a3CReasonfortheOfferandUseofProceeds_915"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">3.C. Reason for the Offer and Use of Proceeds</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_88167945_4f94_4fbb_8ab8_b63c6def4eab"></a><a id="a3DRiskFactors_683481"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">3.D. Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Summary of Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Investors in Adagene Inc.&#8217;s equity securities are investing equity securities of a Cayman Islands holding company rather than equity securities of our subsidiaries that have substantive business operations in China or in the United States. Adagene Inc. is a Cayman Islands holding company that conducts a substantial portion of its operations in China through its PRC subsidiary,  Adagene (Suzhou) Limited. In addition, Adagene Inc. conducts a substantial portion of its operations in the U.S. through its U.S. subsidiary, Adagene Incorporated. Our corporate group does not include any variable interest entities. Such structure involves unique risks to investors in the ADSs and ordinary shares. You should carefully consider all of the information in this annual report before making an investment in our ADSs. In particular, as we are a holding company with substantial business operations in China, you should pay special attention to subsections headed &#8220;Item 4.A.&#8211;&#8211; 4.A. History and Development of the Company Recent&#8211;&#8211;Regulatory Developments,&#8221; &#8220;Item 3.D. Risk Factors&#8211;&#8211;Risks Related to Doing Business in the PRC,&#8221; including but not limited to risk factor such as &#8220;uncertainties with respect to the PRC legal system, including uncertainties regarding the enforcement of laws, and sudden or unexpected changes in policies, laws and regulations in China could adversely affect us.&#8221; The PRC government has significant authority to exert influence on the ability of a company with substantive operations in China, such as us, to conduct its business, accept foreign investments or list on a U.S. or other foreign exchanges. For example, we face risks associated with regulatory approvals of offshore offerings, anti-monopoly regulatory actions, oversight on cybersecurity and data privacy, as well as the lack of PCAOB inspection on our auditor. Such risks could result in a material change in our operations and/or the value of our ADSs or could significantly limit or completely hinder our ability to offer or continue to offer ADSs and/or other securities to investors and cause the value of such securities to significantly decline or be worthless.  The PRC government also has significant oversight and discretion over the conduct of our business and as such may influence our operations at any time, which could result in a material adverse effect on our operations. The PRC government has recently published new policies that significantly affected certain industries, and we cannot rule out the possibility that it will in the future release regulations or policies regarding the industry where we operate, which could adversely affect our business, financial condition and results of operations. Furthermore, the PRC government has recently indicated an intent to exert more oversight and control over overseas securities offerings and other capital markets activities and foreign investment in China-based companies like us. These risks could result in a material change in our operations and the value of our ordinary shares or the ADSs, or could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or become worthless. Below please find a summary of the principal risks we face, organized under relevant headings. These risks are discussed more fully in the section titled &#8220;Item 3.D. Risk Factors.&#8221;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Below please find a summary of the principal risks we face, organized under relevant headings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks Related to Doing Business in the PRC </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks and uncertainties related to doing business in China include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">uncertainties with respect to the PRC legal system, including uncertainties regarding the enforcement of laws, and sudden or unexpected changes in policies, laws and regulations in China could adversely affect us; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRC government has significant oversight over the conduct of our business and as such may influence our operations at any time, which may potentially result in a material adverse effect on our operations; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the PCAOB is currently unable to inspect our auditor in relation to their audit work performed for our financial statements and the inability of the PCAOB to conduct inspections over our auditor deprives our investors of the benefits of such inspections;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">trading in our ADSs on the Nasdaq Stock Market or OTC will be prohibited, and as a result, our ADSs will be delisted under the HFCA Act, if the PCAOB is unable to inspect or fully investigate auditors located in China. On December 16, 2021, the PCAOB issued the HFCA Act Determination Report, according to which our auditor is subject to the determinations that the PCAOB is unable to inspect or investigate completely. The delisting of our ADSs, or the threat of their being delisted, may materially and adversely affect the value of your investment. If this happens there is no certainty that we will be able to list our ordinary shares on a non-U.S. exchange or that a market for our ordinary shares will develop outside of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential enactment of the Accelerating Holding Foreign Companies Accountable Act would decrease the number of non-inspection years from three years to two, thus reducing the time period before our ADSs will be prohibited from trading on the Nasdaq Stock Market or OTC or delisted;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">proceedings instituted by the SEC against certain PRC-based accounting firms, including the affiliate of our independent registered public accounting firm, or any related adverse regulatory development in the PRC, could result in our financial statements being determined to not be in compliance with the requirements of the Exchange Act; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the approval of or report and filing with the China Securities Regulatory Commission or other governmental authorities may be required in connection with our future offerings, and, if required, we cannot predict if we will be able to obtain such approval or complete such report and filing process.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Financial Prospects and Need for Additional Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks and uncertainties related to our financial prospectus and need for additional capital include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we have incurred net losses historically and we may continue to incur net losses in the near future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may need to obtain substantial additional financing to fund our growth and operations, which may not be available on acceptable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">raising additional capital may lead to dilution of shareholdings by our existing shareholders and restrict our operations or require us to relinquish rights to our technologies or product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we have certain shareholders who have board representation rights and their individual interests may differ from yours.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks Related to Clinical Development of Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks and uncertainties related to clinical development of our product candidates include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to identify or discover new product candidates, and may allocate our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may later prove to be more profitable, or for which there is a greater likelihood of success;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be successful in our efforts to use and expand our proprietary platforms to build a pipeline of product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any failures or setbacks in our platforms or our other proprietary technologies could negatively affect our business and financial condition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our product candidates, for which we intend to seek approval as biologics products, may face competition sooner than anticipated; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we depend substantially on the success of our product candidates, particularly ADG116, ADG126, ADG106 and ADG104, which are in clinical development, and our ability to identify additional product candidates. Clinical trials of our product candidates may not be successful. If we are unable to successfully identify new product candidates, complete clinical development, obtain regulatory approval and commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks Related to Obtaining Regulatory Approval of Our Drug Candidates </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks and uncertainties related to obtaining regulatory approval of our drug candidates include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the regulatory approval processes of the FDA, NMPA and other comparable regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approvals for our product candidates, our business will be substantially harmed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we are conducting clinical trials and may in the future conduct additional clinical trials for our product candidates outside the United States and/or China, and FDA, NMPA and similar foreign regulatory authorities may not accept data from such trials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our product candidates may cause undesirable adverse events, side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any regulatory approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Intellectual Property </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks and uncertainties related to our intellectual property include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is difficult and costly to protect our proprietary rights and technology, and we may not be able to protect our intellectual property rights throughout the world;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be successful in obtaining or maintaining necessary rights for our development pipeline through acquisitions and licensing deals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful, and any unfavorable outcome from such litigation could limit our research and development activities and/or our ability to commercialize our product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our commercial success depends significantly on our ability to operate without infringing upon, misappropriating or otherwise violating the intellectual property rights of third parties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to the ADSs </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Risks and uncertainties related to the ADSs include, but are not limited to, the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our business and financial results, including our ability to raise capital or raise capital on favorable terms and the market price of our ADSs, may be adversely affected by the geopolitical factors arising in connection with Russia&#8217;s invasion of Ukraine, including particularly how countries like the United States and China choose to respond to this war. As a result, the value of our ADSs may significantly decline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">you may be subject to limitations on transfer of your ADSs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the trading price of the ADSs is likely to be volatile, which could result in substantial losses to investors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we are an emerging growth company within the meaning of the Securities Act and may take advantage of certain reduced reporting requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if securities or industry analysts cease to publish research or reports about our business, or if they adversely change their recommendations regarding the ADSs, the market price for the ADSs and trading volume could decline; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sale or availability for sale, or perceived sale or availability for sale, of substantial amounts of the ADSs could adversely affect their market price;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">due to our ADSs&#8217; price fluctuations there is a significant risk that we will be a passive foreign investment company for 2022 or any future taxable year, which could subject U.S. investors in our ADSs or ordinary shares to significant adverse U.S. federal income tax consequences; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if a person is treated as owning 10% or more of our stock by vote or value, such person may be subject to adverse U.S. federal income tax consequences.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Risks Related to Doing Business in the PRC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Uncertainties with respect to the PRC legal system, including uncertainties regarding the enforcement of laws, and sudden or unexpected changes in policies, laws and regulations in China could adversely affect us. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our operations in China are governed by the PRC laws and regulations. The PRC legal system is a civil law system based on written statutes. Unlike the common law system, prior court decisions under the civil law system may be cited for reference but have limited precedential value. In addition, any new PRC laws or changes in PRC laws and regulations related to, among other things, foreign investment and manufacturing in China could have a material adverse effect on our business and our ability to operate our business in China.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">For example, two draft regulations relating to overseas offerings by domestic companies of equity shares, depository receipts, convertible corporate bonds, or other equity-like securities, and overseas listing of the securities for trading &#8211; namely the Provisions of the State Council on the Administration of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments) and the Administrative Measures for the Filing of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments) &#8211; were recently released in December 2021 for public comments. Pursuant to such draft regulations, a filing-based regulatory system would be implemented covering both direct and indirect overseas offering and listing, among which, (i) if an issuer listed in other overseas markets after overseas offerings,  the issuer shall submit to the CSRC filing documents within three working days after such application is submitted; (ii) if an issuer issues overseas listed securities after listing abroad and issues such securities aiming at purchasing assets, the issuer shall submit to the CSRC filing documents within three working days after the issue is completed, however, if the assets purchased are domestic assets, the filing procedure shall be performed within three working days from the date of the first announcement of the transaction; and (iii) if the significant events, such as change of control and termination of the listing, occur after the issuer&#39;s overseas listing, it should report the details to CSRC within three working days from the date of occurrence. Uncertainties exist regarding the final form of these regulations as well as the interpretation and implementation thereof after promulgation. If those two rules were adopted in the current form, we may be required to file documents regarding the events listed in the regulations with the CRSC before or after the events occured.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may have to resort to administrative and court proceedings to enforce our legal rights. Any administrative and court proceedings in China may be protracted, resulting in substantial costs and diversion of resources and management attention. Since PRC administrative and court authorities have significant discretion in interpreting and implementing statutory provisions and contractual terms, it may be more difficult to evaluate the outcome of administrative and court proceedings and the level of legal protection we enjoy, than in more developed legal systems. These uncertainties may impede our ability to enforce contracts in China and could materially and adversely affect our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, the PRC legal system is based in part on government policies and internal rules, some of which are not published on a timely basis, or at all, and may have retroactive effect. As a result, we may not be aware of our violation of any of these policies and rules until sometime after the violation. Such unpredictability towards our contractual, property and procedural rights could adversely affect our business, and impede our ability to continue our operations and proceed with our future business plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">PRC government has significant oversight over the conduct of our business and as such may influence our operations at any time, which may potentially result in a material adverse effect on our operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">PRC government has significant oversight over the conduct of our business and may intervene or influence our operations at any time, which may potentially result in a material adverse effect on our operations. PRC government has also recently indicated an intent to exert more oversight over offerings that are conducted overseas and foreign investment in China-based issuers, which could impact our ability to raise additional capital in international capital markets. In addition, the PRC government has recently published new policies that significantly affected certain industries, and we cannot rule out the possibility that it will in the future release regulations or policies regarding our industry that could adversely affect our business, financial condition and results of operations. Any such action could significantly limit or completely hinder our ability to offer or continue to offer securities to investors and cause the value of such securities to significantly decline or be worthless.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">However, as there are still regulatory uncertainties in this regard, we cannot assure you that we will be able to comply with new laws and regulations in all respects, and we may be ordered to rectify, suspend or terminate any actions or services that are deemed illegal by the regulatory authorities and become subject to material penalties, which may materially harm our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">The PCAOB is currently unable to inspect our auditor in relation to their audit work performed for our financial statements and the inability of the PCAOB to conduct inspections over our auditor deprives our investors with the benefits of such inspections.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our auditor, the independent registered public accounting firm that issues the audit report included elsewhere in this annual report, as an auditor of companies that are traded publicly in the United States and a firm registered with the Public Company Accounting Oversight Board (United States), or the PCAOB, is subject to laws in the United States pursuant to which the PCAOB conducts regular inspections to assess its compliance with the applicable professional standards. Since our auditor is located in China, a jurisdiction where the PCAOB has been unable to conduct inspections without the approval of the Chinese authorities, our auditor is not currently inspected by the PCAOB. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This lack of the PCAOB inspections in China prevents the PCAOB from fully evaluating audits and quality control procedures of our independent registered public accounting firm. As a result, we and investors in our ordinary shares and/or ADS are deprived of the benefits of such PCAOB inspections. The inability of the PCAOB to conduct inspections of auditors in China makes it more difficult to evaluate the effectiveness of our independent registered public accounting firm&#8217;s audit procedures or quality control procedures as compared to auditors outside of China that are subject to the PCAOB inspections, which could cause investors and potential investors in our ordinary shares and/or ADSs to lose confidence in our audit procedures and reported financial information and the quality of our financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Trading in our ADSs on the Nasdaq Stock Market or OTC will be prohibited, and as a result, our ADSs will be delisted under the HFCA Act, if the PCAOB is unable to inspect or fully investigate auditors located in China. On December 16, 2021, the PCAOB issued the HFCA Act Determination Report, according to which our auditor is subject to the determinations that the PCAOB is unable to inspect or investigate completely. The delisting of our ADSs, or the threat of their being delisted, may materially and adversely affect the value of your investment. If this happens there is no certainty that we will be able to list our ordinary shares on a non-U.S. exchange or that a market for our ordinary shares will develop outside of the United States.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As part of a continued regulatory focus in the United States on access to audit and other information currently protected by national law, in particular China&#8217;s, the Holding Foreign Companies Accountable Act, or the HFCA Act, has been signed into law on December 18, 2020. The HFCA Act requires the SEC to prohibit the trading of securities of a Chinese or a non-U.S. company on U.S. securities exchanges or the over-the-counter market if the PCAOB has determined that it has been unable to inspect the company&#8217;s accounting firm for three consecutive years because of a position taken by an authority in the company&#8217;s jurisdiction. The HFCA Act also requires such companies to make certain disclosures about their ownership by governmental entities and their relationships with the Chinese Communist Party.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 2, 2021, the SEC adopted final amendments to its rules implementing the HFCA Act (the &#8220;Final Amendments&#8221;). The Final Amendments finalize the interim final rules adopted in March with two major modifications. First, the Final Amendments clarify how the requirements apply to variable interest entities. Second, the Final Amendments include requirements to disclose information, including the auditor name and location, the percentage of shares of the issuer owned by governmental entities, whether governmental entities in the applicable foreign jurisdiction with respect to the auditor has a controlling financial interest with respect to the issuer, the name of each official of the Chinese Communist Party who is a member of the board of the issuer, and whether the articles of incorporation of the issuer contains any charter of the Chinese Communist Party. The Final Amendments also establish procedures the SEC will follow in identifying issuers and prohibiting trading by certain issuers under the HFCA Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 16, 2021, PCAOB issued the HFCA Act Determination Report, according to which our auditor is subject to the determinations that the PCAOB is unable to inspect or investigate completely. In March 2022, the SEC issued its first &#8220;Conclusive list of issuers identified under the HFCAA&#8221; indicating that those companies are now formally subject to the delisting provisions if they remain on the list for three consecutive years. We anticipate being added to the list shortly after the filing of this annual report on Form 20-F.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The HFCA Act or other efforts to increase U.S. regulatory access to audit information could cause investor uncertainty for affected issuers, including us, and the market price of the ADSs could be adversely affected. Additionally, whether the PCAOB will be able to conduct inspections of our auditor in the three consecutive years or at all, is subject to substantial uncertainty and depends on factors out of our or our auditor&#8217;s control. If our auditor is unable to meet the PCAOB inspection requirement in time, we will be delisted from the Nasdaq and our ADSs will not be permitted for trading over-the-counter either. Such a delisting would substantially impair your ability to sell or purchase our ADSs when you wish to do so, and the risk and uncertainty associated with delisting would have a negative impact on the price of our ADSs.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If our ADS are delisted from the U.S. securities exchange and are prohibited from trading in the over-the-counter market in the United States, there is no certainly that we will be able to list our ordinary shares on a non U.S. securities exchange or that a market for our ordinary shares will develop outside of the United States. Such a delisting would significantly affect our ability to raise capital on terms acceptable to us, or at all, which would have a material adverse impact on our business, financial condition and prospects. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">The potential enactment of the Accelerating Holding Foreign Companies Accountable Act would decrease the number of non-inspection years from three years to two, thus reducing the time period before our ADSs will be prohibited from trading on the Nasdaq Stock Market or OTC or delisted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On June 22, 2021, the U.S. Senate passed a bill, also known as the Accelerating Holding Foreign Companies Accountable Act, to amend Section 104(i) of the Sarbanes-Oxley Act of 2002 (15 U.S.C. 7214(i)) to prohibit securities of any registrant from being listed on any of the U.S. securities exchanges or traded over-the-counter if the auditor of the registrant&#8217;s financial statements is not subject to PCAOB inspection for two consecutive years, instead of three consecutive years as currently required under the HFCA Act, after the law becomes effective. On February 4, 2022, the U.S. House of Representatives passed the America COMPETES Act of 2022, which includes the exact same amendments as the bill passed by the Senate.  The America COMPETES Act of 2022 however includes a broader range of legislation not related to the HFCA Act in response to the U.S. Innovation and Competition Act passed by the Senate in 2021. The U.S. House of Representatives and U.S. Senate will need to agree on amendments to these respective bills to align the legislation and pass their amended bills before the President can sign into law. It is unclear when the U.S. Senate and U.S. House of Representatives will resolve the differences in the U.S. Innovation and Competition Act and the America COMPETES Act of 2022 bills currently passed, or when the U.S. President will sign on the bill to make the amendment into law, or at all. In the case that the bill becomes the law, it will reduce the time period before our ADSs will be prohibited from trading on the Nasdaq or over-the-counter or be delisted.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Proceedings instituted by the SEC against certain PRC-based accounting firms, including the affiliate of our independent registered public accounting firm, or any related adverse regulatory development in the PRC, could result in our financial statements being determined to not be in compliance with the requirements of the Exchange Act.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2012, the SEC instituted administrative proceedings against the Big Four PRC-based accounting firms, including our independent registered public accounting firm, alleging that these firms had violated U.S. securities laws and the SEC&#8217;s rules and regulations thereunder by failing to provide to the SEC the firms&#8217; audit work papers with respect to certain PRC-based companies that are publicly traded in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On January 22, 2014, the administrative law judge presiding over the matter rendered an initial decision that each of the firms had violated the SEC&#8217;s rules of practice by failing to produce audit papers and other documents to the SEC. The initial decision censured each of the firms and barred them from practicing before the SEC for a period of six months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 6, 2015, the four China-based accounting firms each agreed to a censure and to pay a fine to the SEC to settle the dispute and avoid suspension of their ability to practice before the SEC and audit U.S.-listed companies. The settlement required the firms to follow detailed procedures and to seek to provide the SEC with access to Chinese firms&#8217; audit documents via the CSRC. Under the terms of the settlement, the underlying proceeding against the four China-based accounting firms was deemed dismissed with prejudice four years after entry of the settlement. The four-year mark occurred on February 6, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While we cannot predict if the SEC will further challenge the four China-based accounting firms&#8217; compliance with U.S. law in connection with U.S. regulatory requests for audit work papers or if the results of such a challenge would result in the SEC imposing penalties such as suspensions, if the accounting firms are subject to additional remedial measures, our ability to file our financial statements in compliance with SEC requirements could be impacted. A determination that we have not timely filed financial statements in compliance with SEC requirements could ultimately lead to the delisting of our ordinary shares or ADSs or the termination of the registration of our ordinary shares or ADSs under the Exchange Act, or both, which would substantially reduce or effectively terminate the trading of our ordinary shares or ADSs in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the event that the SEC restarts the administrative proceedings, depending upon the final outcome, listed companies in the United States with major PRC operations, such as us, may find it difficult or impossible to retain auditor in respect of their operations in the PRC, which could result in financial statements being determined to not be in compliance with the requirements of the Exchange Act, including possible delisting. Moreover, any negative news about any such future proceedings against these audit firms may cause investor uncertainty regarding China-based, U.S.-listed companies and the market price of our ADSs may be adversely affected. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If our independent registered public accounting firm was denied, even temporarily, the ability to practice before the SEC and we were unable to timely find another registered public accounting firm to audit and issue an opinion on our financial statements, our financial statements could be determined not to be in compliance with the requirements of the Exchange Act. Such a determination could ultimately lead to the delisting of our ADSs from the Nasdaq Stock Market or deregistration from the SEC, or both, which would substantially reduce or effectively terminate the trading of our ADSs in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may be restricted from transferring our scientific data abroad.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 17, 2018, the General Office of the PRC State Council promulgated the Measures for the Management of Scientific Data, or the Scientific Data Measures, which provide a broad definition of scientific data and relevant rules for the management of scientific data. According to the Scientific Data Measures, enterprises in China must seek governmental approval before any scientific data involving a state secret may be transferred abroad or to foreign parties. Further, any researcher conducting research funded, at least in part, by the PRC government is required to submit relevant scientific data for management by the entity to which such researcher is affiliated before such data may be published in any foreign academic journal. Currently, as the term &#8220;state secret&#8221; is not clearly defined, there is no assurance that we can always obtain relevant approvals for sending scientific data (such as the results of our preclinical studies or clinical trials conducted within China) abroad, or to our foreign partners in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, the Cyberspace Administration of China, or the CAC, issued the Measures on Security Assessment of the Cross-border Transfer of Personal Information (Draft for Comment) in June 2019, pursuant to which, any cross-border transfer of information that may endanger national security, damage public interest, or fail to offer effective protection of personal information security, as assessed by relevant regulatory bodies, will be prohibited. In October 2021, CAC issued the Measures on Security Assessment of the Cross-border Data Transfer (Draft for Comment), which adjusts the thresholds for triggering mandatory security assessments not only in the cross-border transfers of personal information, but also in the cross-border transfers of &#8220;important data&#8221; collected and generated in China under certain circumstance. Given that the government body will have full discretion in the assessment, it is unclear if and the extent to which our clinical data will be considered as an endangerment to national or personal information security, if the regulation becomes effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Cross-border data transfer from other jurisdictions may also be limited if we fail to comply with relevant requirements, such as obtaining authorization from patients regarding the use, transfer and retrieval of their personal information or data and adopting measures to ensure the safety of personal information or data in the transfer. Also, cross-border transfer of personal data by its nature is subject to general data privacy regulations in various jurisdictions, and thus any failure to comply with data privacy protection may lead to a restriction of transferring our data across different jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are unable to obtain the necessary approvals in a timely manner, or at all, our research and development of product candidates may be hindered, which may materially and adversely affect our business, results of operations, financial conditions and prospects. If relevant government authorities consider the transmission of our scientific data to be in violation of the requirements under the Scientific Data Measures, we may be subject to specific administrative penalties imposed by those government authorities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Failure to comply with existing or future laws and regulations related to privacy or data security could lead to government enforcement actions, which could include civil or criminal fines or penalties, private litigation, other liabilities, and/or adverse publicity. Compliance or the failure to comply with such laws could increase the costs of our products and services, limit their use or adoption, and otherwise negatively affect our operating results and business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of personal information and important data worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Regulatory authorities in virtually every jurisdiction in which we operate have implemented and are considering a number of legislative and regulatory proposals concerning data protection. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Regulatory authorities in China have implemented and are considering a number of legislative and regulatory proposals concerning data protection. For example, China&#8217;s Cybersecurity Law, which became effective in June 2017, established China&#8217;s first national-level data protection for &#8220;network operators,&#8221; which may include all organizations in China that connect to or provide services over the internet or other information network. The Cybersecurity Law requires network operators to perform certain functions related to cybersecurity protection. In addition, the Cybersecurity Law imposes certain requirements on network operators of critical information infrastructure, or the CIIOs. For example, the CIIOs generally shall, during their operations in the PRC, store the personal information and important data collected and produced within the territory of PRC, and shall perform certain security obligations as required under the Cybersecurity Law, including that the CIIOs shall pass the national security review when purchasing network product or service which may affect national security. In addition, China&#8217;s Data Security Law, which was promulgated by the Standing Committee of PRC National People&#8217;s Congress, or the SCNPC, on June 10, 2021 and came into effect on September 1, 2021, outlines the main system framework of data security protection. For example, the Data Security Law introduces a data classification and hierarchical protection system based on the importance of data in economic and social development, as well as the degree of harm it will cause to national security, public interests, or legitimate rights and interests of individuals or organizations when such data is tampered with, destroyed, leaked, or illegally acquired or used. Processors of &#8220;important data&#8221; are further required to conduct periodic risk assessment and submit assessment report to relevant regulatory authorities. In addition, the Data Security Law provides a national security review procedure for those data activities which may affect national security. Furthermore, Regulations on the Security Protection of Critical Information Infrastructure, which was promulgated by the State Council of PRC on July 30, 2021 and came into effect on September 1, 2021, or the CII Protection Regulations, stipulates the obligations and liabilities of the regulators, society and CIIOs in protecting the security of critical information infrastructure, or the CII. According to the CII Protection Regulations, regulators supervising specific industries shall formulate detailed guidance to recognize the CII in the respective sectors, and CIIOs shall take the responsibility to protect the CII&#8217;s security by performing certain prescribed obligations. For example, CIIOs are required to conduct network security test and risk assessment, report the assessment results to relevant regulatory authorities, and timely rectify the issues identified at least once a year. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Opinions on Strictly Cracking Down Illegal Securities Activities in Accordance with the Law, which were issued by the General Committee and State Council on July 6, 2021, require the speed-up of the revision of the provisions on strengthening the confidentiality and archives coordination between regulators related to overseas issuance and listing of securities, and improvement to the laws and regulations related to data security, cross-border data flow, and management of confidential information. Numerous regulations, guidelines and other measures have been or are expected to be adopted under the umbrella of, or in addition to the Cybersecurity Law and Data Security Law , including the Cybersecurity Review Measures published by Cyberspace Administration of China, or the CAC, and other 12 relevant PRC government authorities in December 2021, which provides that, among others, if a &#8220;network platform operator&#8221; that possesses personal information of more than one million users intends to go public in a foreign country, it must apply for a cybersecurity review with the Cybersecurity Review Office, and that the relevant PRC governmental authorities may initiate cybersecurity review if they determine certain network products, services, or data processing activities affect or may affect national security. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 29, 2021, the CAC published the Measures on Security Assessment of Cross-border Transfer of Data (Draft for Comments), or the draft security assessment measures, which provide that data processors shall make self-assessment of the risks before transferring data cross-border, and shall apply for security assessment for cross-border data transfer in any of the following circumstances: (i) transferring personal information and important data collected and produced by CIIO operators; (ii) important data is included in the data transferred cross-border; (iii) transferring personal information cross-border by personal information processors which process more than one million individuals&#8217; personal information; (iv) transferring more than one hundred thousand individuals&#8217; personal information or more than ten thousand individuals&#8217; sensitive personal information cumulatively; or (v) other circumstances which require the application for cross-border data transfer security assessment as determined by the CAC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the CAC published the Regulations for the Administration of Cyber Data Security (Draft for Comment), or the Draft Data Security Regulations, for public comments in November 2021, which reiterate that a data processor who processes personal information of more than one million individuals must complete the cybersecurity review if it intends to be listed in a foreign country, and if a data processor conducts any data processing activities that affect or may affect national security, an application for cybersecurity review shall also be made by such a processor. The Draft Data Security Regulations also require that data processors who process important data or whose securities are listed outside of China shall carry out annual data security assessment by itself or through a third party data security service provider and submit the assessment report to local agency of the CAC. Also see &#8220;Item 4. Information on the Company&#8212;4.B. Business Overview&#8212;Regulation&#8212;Other PRC Government Regulations&#8212;Regulations on Information Security and Data Protection&#8221; for detailed discussion. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of the date of this annual report, the exact scope of CIIOs and important data under the current laws, regulations and regulatory regime remains unclear, and the authorities may have wide discretion in the interpretation and enforcement of the related laws and regulations. If we are deemed as a CIIO, or as an operator who collects, uses and processes important data according to the Cybersecurity Law, Data Security Law and other relevant laws and regulations, we may need to perform or be subject to certain prescribed obligations, and if we were found to be in violation of these applicable laws and regulations, we may be subject to administrative penalties, including fines and service suspension. We also cannot rule out the possibility that certain of our customers may be deemed as CIIOs, or as operators processing important data, in which case our products or services or data processing activities, if being deemed as related to national security, will need to be submitted for cybersecurity review before we can enter into agreements with such customers, and before the conclusion of such procedure, the customers will not be allowed to use our products or services. If the reviewing authority considers that the use of our services by certain of our customers involves risk of disruption, is vulnerable to external attacks, or may negatively affect, compromise, or weaken the protection of national security, we may not be able to provide our products or services to such customers, which could have a material adverse effect on our results of operations and business prospects. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">As of the date of this annual report, we have not been involved in any investigations on cybersecurity review initiated by the Cyberspace Administration of China, and we have not received any inquiry, notice, warning, sanctions in such respect or any regulatory objections to our listing status on the Nasdaq. As there are still uncertainties regarding the further enaction of new laws and regulations as well as the revision, interpretation and implementation of those existing laws and regulations, however, we cannot assure you that we will be able to comply with such regulations in all respects, and we may be ordered to rectify, suspend or terminate any actions or services that are deemed illegal or incompliance by the regulatory authorities and become subject to fines and/or other penalties. If we are unable to address such issue in a timely manner or at all, we may be required to suspend or terminate our related businesses or face other penalties, our business, financial condition, results of operations, and prospects could be materially harmed.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, certain PRC regulatory authorities recently issued the Opinions on Strictly Cracking Down on Illegal Securities Activities. These opinions call for strengthened regulation over illegal securities activities and supervision of overseas listings by China-based companies and propose to take effective measures. As of the date of this annual report, no official guidance or related implementation rules have been issued and taken into effect in relation to such opinions and as a result, the interpretation and implementation of these opinions remain unclear at this stage. We cannot assure you that we will not be required to obtain the pre-approval of the CSRC and potentially other regulatory authorities to pursue an offering of securities overseas or to maintain the listing status of our ADSs on the Nasdaq. See also &#8220;&#8211;The approval of or report and filing with the China Securities Regulatory Commission or other governmental authorities may be required in connection with this offering, and, if required, we cannot predict if we will be able to obtain such approval.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, certain industry-specific laws and regulations affect the collection and transfer of personal data in China. For example, the PRC State Council promulgated Regulations on the Administration of Human Genetic Resources (effective in July 2019), which require approval from or filings with the Science and Technology Administration Department of the State Council where human genetic resources, or HGR, are involved in any international collaborative project and additional approval for any export or cross-border transfer of the HGR samples or human genetic resource information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices, potentially resulting in confiscation of HGR samples and human genetic resource information and administrative fines or in worst cases, criminal penalties. In addition, the interpretation and application of data and personal information protection laws in China and elsewhere are often uncertain and in flux.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Dividends we receive from our subsidiaries located in the PRC may be taxed at a higher rate, which could materially and adversely affect the amount of dividends, if any, we may pay our shareholders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Double Tax Avoidance Arrangement between Hong Kong and China, or the Double Tax Avoidance Treaty, and the Notice on Certain Issues with Respect to the Enforcement of Dividend Provisions in Tax Treaties, or the Notice on Tax Treaties, issued on February 20, 2009 by the State Administration of Taxation of the PRC, or the SAT, if a Hong Kong resident enterprise owns more than 25% of the equity interest of a PRC company at all times during the twelve-month period immediately prior to obtaining a dividend from such company, the 10% withholding tax on such dividend is reduced to 5%, provided that certain other conditions and requirements under the Double Tax Avoidance Treaty and other applicable PRC laws are satisfied at the discretion of the relevant PRC tax authority. However, based on the Notice on Tax Treaties, if the relevant PRC tax authorities determine, in their discretion, that a company benefits from such reduced income tax rate due to a structure or arrangement that is primarily tax-driven, the PRC tax authorities may adjust the preferential tax treatment. Based on the Notice on Issues concerning Beneficial Owner in Tax Treaties, or Circular 9, issued on February 3, 2018 by the SAT and effective on April 1, 2018, when determining the applicant&#8217;s status as a &#8220;beneficial owner&#8221; for purpose of tax treatments in connection with dividends, interests or royalties in the tax treaties, several factors will be taken into account, and it will be analyzed according to the actual circumstances of the specific cases. If our Hong Kong subsidiary is determined by PRC government authorities as receiving benefits from reduced income tax rates due to a structure or arrangement that is primarily tax-driven, the dividends paid by our PRC subsidiaries to our Hong Kong subsidiary will be taxed at a higher rate, which will have an adverse effect on our financial and operational conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Your investments in our ADSs and/or ordinary shares are investments in equity securities of a Cayman Islands holding company rather than equity securities of our subsidiaries that have substantive business operations in China. As a result, you may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing actions in China against us or our management based on foreign laws.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Adagene Inc. is a holding company incorporated under the laws of the Cayman Islands with no operations of its own. It conducts a substantial portion of its operations in China primarily through its subsidiary in China, Adagene (Suzhou) Limited. In addition, Adagene Inc. conducts a substantial portion of its operations in the U.S. through its U.S. subsidiary, Adagene Incorporated. As such, investors in the ADSs or ordinary shares are not purchasing equity securities of our subsidiaries that have substantive business operations in China or in the U.S. but instead are purchasing equity securities of a Cayman Islands holding company. In addition, some of our senior executive officers and directors reside within China for a significant portion of the time and some are PRC nationals. As a result, it may be difficult for our shareholders or investors to effect service of process upon us or those persons inside China. In addition, China does not have treaties providing for the reciprocal recognition and enforcement of judgments of courts with the Cayman Islands and many other countries and regions. Therefore, recognition and enforcement in China of judgments of a court in any of these non-PRC jurisdictions in relation to any matter not subject to a binding arbitration provision may be difficult or impossible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Shareholder claims that are common in the United States, including securities law class actions and fraud claims, generally are difficult to pursue as a matter of law or practicality in China. For example, in China, there are significant legal and other obstacles to obtaining information needed for shareholder investigations or litigation outside China or otherwise with respect to foreign entities. Although the local authorities in China may establish a regulatory cooperation mechanism with the securities regulatory authorities of another country or region to implement cross-border supervision and administration, such regulatory cooperation with the securities regulatory authorities in the Unities States have not been efficient in the absence of mutual and practical cooperation mechanism. According to Article 177 of the PRC Securities Law which became effective in March 2020, no overseas securities regulator is allowed to directly conduct investigation or evidence collection activities within the territory of the PRC. Accordingly, without the consent of the competent PRC securities regulators and relevant authorities, no organization or individual may provide the documents and materials relating to securities business activities to overseas parties. See also &#8220;Item 3 Key Information&#8212;Risk Factors&#8212;Risks Related to the ADSs&#8212;You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because we are incorporated under Cayman Islands law.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Recent litigation and negative publicity surrounding China-based companies listed in the United States may result in increased regulatory scrutiny of us and negatively impact the trading price of the ADSs and could have a material adverse effect upon our business, including our results of operations, financial condition, cash flows and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that litigation and negative publicity surrounding companies with operations in China that are listed in the United States have negatively impacted stock prices for these companies. Various equity-based research organizations have published reports on China-based companies after examining their corporate governance practices, related party transactions, sales practices and financial statements, and these reports have led to special investigations and listing suspensions on U.S. national exchanges. Any similar scrutiny of us, regardless of its lack of merit, could result in a diversion of management resources and energy, potential costs to defend ourselves against rumors, decreases and volatility in the ADS trading price, and increased directors and officers insurance premiums and could have an adverse effect upon our business, including our results of operations, financial condition, cash flows and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Changes in U.S. and international trade policies, particularly with regard to China, may adversely impact our business and operating results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although cross-border business may not be an area of our focus, if we plan to expand our business internationally in the future, any unfavorable government policies on international trade, such as capital controls or tariffs, may affect the demand for our products and services, impact our competitive position, or prevent us from being able to conduct business in certain countries. If any new tariffs, legislation, or regulations are implemented, or if existing trade agreements are renegotiated, such changes could adversely affect our business, financial condition, and results of operations. Recently, there have been heightened tensions in international economic relations, such as the one between the United States and China. The U.S. government has recently imposed, and has recently proposed to impose additional, new, or higher tariffs on certain products imported from China to penalize China for what it characterizes as unfair trade practices. China has responded by imposing, and proposing to impose additional, new, or higher tariffs on certain products imported from the United States. Following mutual retaliatory actions for months, on January 15, 2020, the United States and China entered into the Economic and Trade Agreement Between the United States of America and the People&#8217;s Republic of China as a phase one trade deal, effective on February 14, 2020. It remains unclear what additional actions, if any, will be taken by the U.S. or other governments with respect to international trade, tax policy related to international commerce, or other trade matters. The situation is further complicated by the political tensions between the United States and China that escalated during the COVID-19 pandemic and in the wake of the PRC National People&#8217;s Congress&#8217; decision on Hong Kong national security legislation, sanctions imposed by the U.S. Department of Treasury on certain officials of the Hong Kong Special Administrative Region and the central government of the PRC and the executive orders issued by U.S. President in August 2020 that prohibit certain transactions with certain China-based companies and their respective subsidiaries. Rising trade and political tensions could reduce levels of trade, investments, technological exchanges and other economic activities between China and other countries, which would have an adverse effect on global economic conditions, the stability of global financial markets, and international trade policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Although the direct impact of the current international trade and political tension, and any escalation of such tension, on the biopharmaceutical companies in China is uncertain, the negative impact on general, economic, political and social conditions may adversely impact our business, financial condition and results of operations.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">The approval of or report and filing with the China Securities Regulatory Commission or other governmental authorities may be required in connection with our future offerings, and, if required, we cannot predict if we will be able to obtain such approval or complete such report and filing process.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The M&amp;A Rules requires an overseas special purpose vehicle formed for listing purposes through acquisitions of PRC domestic companies and controlled by PRC companies or individuals to obtain the approval of the CSRC prior to the listing and trading of such special purpose vehicle&#8217;s securities on an overseas stock exchange. However, the application of the M&amp;A Rules remains unclear. If CSRC approval is required, it is uncertain whether it would be possible for us to obtain the approval, and any failure to obtain or delay in obtaining CSRC approval for future offerings would subject us to sanctions imposed by the CSRC and other PRC regulatory agencies.  </span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our PRC legal counsel, Tian Yuan Law Firm, has advised us based on their understanding of the current PRC laws, rules and regulations that no permission is required from CSRC for us to maintain our listing of the ADSs on the Nasdaq, given that (i) the CSRC currently has not issued any definitive rule or interpretation concerning whether offering such as this offering contemplated by our Company are subject to the M&amp;A Rules; and (ii) our PRC subsidiary was incorporated as wholly foreign-owned enterprise by means of direct investment not subject to the M&amp;A Rules. There can be no assurance that the relevant PRC government agencies, including the CSRC, would reach the same conclusion as our PRC legal counsel. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the recently issued Opinions on Strictly Cracking Down on Illegal Securities Activities emphasized the need to strengthen regulation over illegal securities activities and supervision on overseas listings by China-based companies and propose to take effective measures, such as promoting the development of relevant regulatory systems to deal with the risks and incidents faced by China-based overseas-listed companies. There are still uncertainties regarding the interpretation and implementation of these opinions, Draft Overseas Listing Regulations and further explanations or detailed rules and regulations with respect to these opinions may be issued in the future, which may impose additional requirements on us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, on December 24, 2021, the CSRC published the Provisions of the State Council on the Administration of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments), and Administrative Measures for the Filing of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments), or collectively, the Draft Overseas Listing Regulations, which set out the new regulatory requirements and filing procedures for Chinese companies seeking direct or indirect listing in overseas markets. The Draft Overseas Listing Regulations, among others, stipulate that (i) Chinese companies that seek to offer and list securities in overseas markets directly or indirectly shall fulfill the filing procedures with and report relevant information to the CSRC, (ii) in the context of an initial public offering, an initial filing shall be submitted within three (3) working days after the application for an initial public offering is submitted, (iii) in the context of follow-on offering after the completion of the initial public offering, an filing shall be submitted within three (3) working days after the completion of the offering or within three (3) working days from the date of the first announcement of the transaction depending on the purpose for which the follow-on offering are conducted, and (iv) if an issuer issuing securities in batches after listing abroad (such as &#8220;shelf takedowns&#8221; or at-the-marketing offerings), it shall, after the completion of the initial batch offering, submit the fillings to the CSRC within three (3) working days, stating the total number of securities to be issued in connection with such batch issuance. Upon completion of each of the remaining batches, the issuer shall file a record of the issuance with CSRC within three (3) working days. Moreover, an overseas offering and listing is prohibited under circumstances if (i) it is prohibited by PRC laws, (ii) it may constitute a threat to or endanger national security as reviewed and determined by competent PRC authorities, (iii) it has material ownership disputes over equity, major assets, and core technology, (iv) in recent three years, the Chinese operating entities, and their controlling shareholders and actual controllers have committed relevant prescribed criminal offenses or are currently under investigations for suspicion of criminal offenses or major violations, (v) the directors, supervisors, or senior executives have been subject to administrative punishment for severe violations, or are currently under investigations for suspicion of criminal offenses or major violations, or (vi) it has other circumstances as prescribed by the State Council. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Draft Overseas Listing Regulations, among others, stipulate that if the issuer meets the following conditions, its offering and listing shall be determined as an &#8220;indirect overseas offering and listing by a Chinese company&#8221; and is therefore subject to the filing requirement: (1) the revenues, profits, total assets or net assets of the Chinese operating entities in the most recent financial year accounts for more than 50% of the corresponding data in the issuer&#8217;s audited consolidated financial statements for the same period; (2) the majority of senior management in charge of business operation are Chinese citizens or have domicile in PRC, and its principal place of business is located in PRC or main business activities are conducted in PRC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Draft Overseas Listing Regulations, if we fail to complete the filing procedures with the CSRC for our future offering or fell within any of the circumstances where our proposed listing overseas is prohibited by the State Council, we may be subject to penalties, sanctions and fines imposed by the CSRC and relevant departments of the State Council. In severe circumstances, the business of our PRC subsidiaries may be ordered to suspend and their business qualifications and licenses may be revoked. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As advised by our PRC legal counsel, Tian Yuan Law Firm, the Draft Overseas Listing Regulations were released only for soliciting public comment as of the date of this annual report and their provisions and anticipated adoption or effective date are subject to changes and thus their interpretation and implementation remain substantially uncertain, we cannot predict the impact of the Draft Overseas Listing Regulations on this Offering, if any, at this stage, or guarantee that we will be able to satisfy the scrutinized and new regulatory requirements in case they were adopted in the current form.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the PRC Enterprise Income Tax Law and its implementation rules, an enterprise established outside of the PRC with a &#8220;de facto management body&#8221; within the PRC is considered a &#8220;resident enterprise&#8221; and will be subject to the enterprise income tax on its global income at the rate of 25%. The implementation rules define the term &#8220;de facto management body&#8221; as the body that exercises full and substantial control over and overall management of the business, productions, personnel, accounts and properties of an enterprise. In 2009, SAT issued a circular, known as SAT Circular 82, which provides certain specific criteria for determining whether the &#8220;de facto management body&#8221; of a PRC-controlled enterprise that is incorporated offshore is located in China. Although this circular only applies to offshore enterprises controlled by PRC enterprises or PRC enterprise groups, not those controlled by PRC individuals or foreigners, the criteria set forth in the circular may reflect the SAT&#8217;s general position on how the &#8220;de facto management body&#8221; test should be applied in determining the tax resident status of all offshore enterprises. According to SAT Circular 82, an offshore incorporated enterprise controlled by a PRC enterprise or a PRC enterprise group will be regarded as a PRC tax resident by virtue of having its &#8220;de facto management body&#8221; in China and will be subject to PRC enterprise income tax on its global income only if all of the following conditions are met: (i) the primary location of the day-to-day operational management and the places where they perform their duties are in the PRC; (ii) decisions relating to the enterprise&#8217;s financial and human resource matters are made or are subject to approval by organizations or personnel in the PRC; (iii) the enterprise&#8217;s primary assets, accounting books and records, company seals, and board and shareholder resolutions, are located or maintained in the PRC; and (iv) at least 50% of voting board members or senior executives habitually reside in the PRC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that we are not a PRC resident enterprise for PRC tax purposes. See &#8220;Item 10 Additional Information&#8212;Taxation&#8212; Material PRC Income Tax Considerations.&#8221; However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term &#8220;de facto management body.&#8221; If the PRC tax authorities determine that we or any of our non-PRC subsidiaries are a PRC resident enterprise for enterprise income tax purposes, we or the subsidiary will be subject to PRC tax at a rate of 25%. In addition, we may be required to withhold taxes from dividends, and non-PRC shareholders (including ADS holders) may be subject to PRC tax on gains realized on the sale or other disposition of ADSs or ordinary shares, if such income is treated as sourced from within the PRC, as described below under &#8220;Item 3.D.Risk Factors&#8212;Risks Related to the ADS&#8212;You may be subject to PRC income tax on dividends from us or any gain realized on the transfer of our ADSs.&#8221; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">You may be subject to PRC income tax on dividends from us or on any gain realized on the transfer of our ADSs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Enterprise Income Tax Law of the PRC, or the EIT Law, and its implementation rules, PRC withholding tax at the rate of 10% is generally applicable to dividends from PRC sources paid to investors that are resident enterprises outside of China and that do not have an establishment or place of business in China, or that have an establishment or place of business in China but the relevant income is not effectively connected with the establishment or place of business. Any gain realized on the transfer of shares by such investors is subject to 10% PRC income tax if this gain is regarded as income derived from sources within China. Under the PRC Individual Income Tax Law and its implementation rules, dividends from sources within China paid to foreign individual investors who are not PRC residents are generally subject to a PRC withholding tax at a rate of 20% and gains from PRC sources realized by these investors on the transfer of shares are generally subject to 20% PRC income tax. Any such PRC tax liability may be reduced by the provisions of an applicable tax treaty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although we have substantial business operations in China, it is unclear whether the dividends we pay with respect to our shares or ADSs, or the gains realized from the transfer of our shares or ADSs, would be treated as income derived from sources within China and as a result be subject to PRC income tax if we are considered a PRC resident enterprise. If PRC income tax is imposed on gains realized through the transfer of our ADSs or on dividends paid to our non-resident investors, the value of your investment in our ADSs may be adversely affected. Furthermore, our shareholders whose jurisdictions of residence have tax treaties or arrangements with China may not qualify for, or able to obtain in practice, the benefits under these tax treaties or arrangements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">The biopharmaceutical industry in China is highly regulated and such regulations are subject to changes which may affect approval and commercialization of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Part of our research and development operations are in China, which we believe confers clinical, commercial and regulatory advantages. The biopharmaceutical industry in China is subject to comprehensive government regulation and supervision, encompassing the approval, registration, manufacturing, packaging, licensing and marketing of new product candidates. See &#8220;Item 4 Information on the Company&#8212;Regulation&#8221; for a discussion of the regulatory requirements that are applicable to our current and planned business activities in China. In recent years, the regulatory framework in China regarding the biopharmaceutical industry has undergone significant changes, and we expect that it will continue to undergo significant changes. Any such changes or amendments may result in increased compliance costs on our business or cause delays in or prevent the successful development or commercialization of our product candidates in China and reduce the current benefits we believe are available to us from developing and manufacturing drugs in China. PRC authorities have become increasingly vigilant in enforcing laws in the biopharmaceutical industry and any failure by us or our partners to maintain compliance with applicable laws and regulations or obtain and maintain required licenses and permits may result in the suspension or termination of our business activities fines, warnings, administrative or criminal penalties in China. We believe our strategy and approach are aligned with the PRC government&#8217;s regulatory policies, but we cannot ensure that our strategy and approach will continue to be aligned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Substantial uncertainties exist with respect to the interpretation and implementation of the newly enacted Foreign Investment Law and how it may impact the viability of our current corporate structure, corporate governance and business operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On March 15, 2019, the PRC National People&#8217;s Congress approved the Foreign Investment Law, which came into effect on January 1, 2020 and replaces the trio of existing laws regulating foreign investment in the PRC, namely, the Sino-Foreign Equity Joint Venture Enterprise Law, the Sino-Foreign Cooperative Joint Venture Enterprise Law and the Wholly Foreign-Invested Enterprise Law, together with their implementation rules and ancillary regulations and become the legal foundation for foreign investment in the PRC. Meanwhile, the <i style="font-style:italic;">Implementation Regulation of the Foreign Investment Law and the Measures for Reporting of Information on Foreign Investment</i> came into effect as of January 1, 2020, which clarified and elaborated the relevant provisions of the <i style="font-style:italic;">Foreign Investment Law</i>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Foreign Investment Law sets out the basic regulatory framework for foreign investments and proposes to implement a system of pre-entry national treatment with a negative list for foreign investments, pursuant to which (i) foreign entities and individuals are prohibited from investing in the areas that are not open to foreign investments, (ii) foreign investments in the restricted industries must satisfy certain requirements under the law, and (iii) foreign investments in business sectors outside of the negative list will be treated equally with domestic investments. The Foreign Investment Law also sets forth necessary mechanisms to facilitate, protect and manage foreign investments and proposes to establish a foreign investment information reporting system, through which foreign investors or foreign-invested enterprises are required to submit initial report, report of changes, report of deregistration and annual report relating to their investments to the Ministry of Commerce, or MOFCOM, or its local branches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Our business may be negatively affected by the potential obligations to make additional social insurance and housing fund contributions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are required by PRC labor laws and regulations, such as the Social Insurance Law, Administrative Regulations on the Housing Provident Fund and other related rules, to pay various statutory employee benefits, including pensions insurance, medical insurance, work-related injury insurance, unemployment insurance, maternity insurance and housing fund, to designated government agencies for the benefit of our employees. The relevant government agencies may examine whether an employer has made adequate and timely payments of the requisite statutory employee benefits, and employers who fail to make adequate and timely payments may be subject to supplemental contributions, late payment fees, fines compulsory enforcement and/or other penalties. If the relevant PRC authorities determine that we shall make supplemental social insurance and housing fund contributions or that we are subject to fines and legal sanctions in relation to our failure to make social insurance and housing fund contributions in full for our employees, our business, financial condition and results of operations may be adversely affected.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">The lease agreements of our leased properties have not been registered with the relevant PRC government authorities as required by PRC law, which may expose us to potential fines.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under PRC law, lease agreements of commodity housing tenancy are required to be registered with the local construction (real estate) departments. Although failure to do so does not in itself invalidate the leases, the parties of the lease agreements may be exposed to potential fines if they fail to rectify such non-compliance within the prescribed time frame after receiving notice from the relevant PRC government authorities. The penalty ranges from RMB1,000 to RMB10,000 for each unregistered lease, at the discretion of the relevant authority. As of the date of this annual report, the lease agreements for our leased properties in China have not been registered with the relevant PRC government authorities. As of the date of this annual report, we are not aware of any regulatory or governmental actions, claims or investigations being contemplated or any challenges by third parties to our use of our leased properties that the lease agreements of which have not been registered with the government authorities. However, we cannot assure you that the government authorities will not impose fines on us due to our failure to register any of our lease agreements, which may negatively impact our financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Any failure to comply with PRC regulations regarding the registration requirements for employee stock incentive plans may subject the PRC plan participants or us to fines and other legal or administrative sanctions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February 2012, SAFE promulgated the Notices on Issues Concerning the Foreign Exchange Administration for Domestic Individuals Participating in Stock Incentive Plan of Overseas Publicly Listed Company, replacing earlier rules promulgated in 2007. Pursuant to these rules, PRC citizens and non-PRC citizens who reside in China for a continuous period of not less than one year who participate in any stock incentive plan of an overseas publicly listed company, subject to a few exceptions, are required to register with SAFE through a domestic qualified agent, which could be the PRC subsidiary of such overseas-listed company, and complete certain other procedures. In addition, an overseas-entrusted institution must be retained to handle matters in connection with the exercise or sale of stock options and the purchase or sale of shares and interests. We and our executive officers and other employees who are PRC citizens or who reside in the PRC for a continuous period of not less than one year and who have been granted options will be subject to these regulations. Failure to complete the SAFE registrations may subject them to fines and legal sanctions, there may be additional restrictions on the ability of them to exercise their stock options or remit proceeds gained from the sale of their stock into the PRC. We also face regulatory uncertainties that could restrict our ability to adopt incentive plans for our directors, executive officers and employees under PRC law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We face uncertainty with respect to indirect transfers of equity interests in PRC resident enterprises by their non-PRC holding companies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Notice on Strengthening Administration of Enterprise Income Tax for Share Transfers by Non-PRC Resident Enterprises, or SAT Circular 698, issued by the SAT in 2009 with retroactive effect from January 1, 2008, where a non-resident enterprise transfers the equity interests of a PRC resident enterprise indirectly by disposition of the equity interests of an overseas holding company, or an Indirect Transfer, and such overseas holding company is located in a tax jurisdiction that: (i) has an effective tax rate less than 12.5% or (ii) does not tax foreign income of its residents, the non-resident enterprise, being the transferor, shall report to the competent tax authority of the PRC resident enterprise this Indirect Transfer.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On February 3, 2015, the SAT issued the Announcement of the State Administration of Taxation on Several Issues Concerning the Enterprise Income Tax on Indirect Property Transfer by Non-Resident Enterprises, or SAT Bulletin 7. SAT Bulletin 7 supersedes the rules with respect to the Indirect Transfer under SAT Circular 698. SAT Bulletin 7 has introduced a new tax regime that is significantly different from the previous one under SAT Circular 698. SAT Bulletin 7 extends the PRC&#8217;s tax jurisdiction to not only Indirect Transfers set forth under SAT Circular 698 but also transactions involving a transfer of other taxable assets through an offshore transfer of a foreign intermediate holding company. In addition, SAT Bulletin 7 provides clearer criteria than SAT Circular 698 for assessment of reasonable commercial purposes and has introduced safe harbors for internal group restructurings and the purchase and sale of equity through a public securities market. SAT Bulletin 7 also brings challenges to both foreign transferor and transferee (or another person who is obligated to pay for the transfer) of taxable assets. Where a non-resident enterprise transfers taxable assets indirectly by disposing of the equity interests of an overseas holding company, which is an Indirect Transfer, the non-resident enterprise, being the transferor, or the transferee, or the PRC entity that directly owns the taxable assets, may report such Indirect Transfer to the relevant tax authority. Using a &#8220;substance over form&#8221; principle, the PRC tax authority may disregard the existence of the overseas holding company if it lacks a reasonable commercial purpose and was established for the purpose of reducing, avoiding or deferring PRC tax. As a result, gains derived from such Indirect Transfer may be subject to PRC enterprise income tax, and the transferee or another person who is obligated to pay for the transfer is obligated to withhold the applicable taxes, currently at a rate of 10% for the transfer of equity interests in a PRC resident enterprise. Both the transferor and the transferee may be subject to penalties under PRC tax laws if the transferee fails to withhold the taxes and the transferor fails to pay the taxes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On October 17, 2017, the SAT issued the Announcement of the State Administration of Taxation on Matters Concerning Withholding of Income Tax of Non-resident Enterprises at Source, or SAT Bulletin 37, which, among others, repealed the SAT Circular 698 on December 1, 2017. SAT Bulletin 37 further details and clarifies the tax withholding methods in respect of income of non-resident enterprises under SAT Circular 698. In addition, certain rules stipulated in SAT Bulletin 7 are replaced by SAT Bulletin 37. Where the non-resident enterprise fails to declare the tax payable pursuant to Article 39 of the PRC Enterprise Income Tax Law, the tax authority may order it to pay the tax due within required time limits, and the non-resident enterprise shall declare and pay the tax payable within such time limits specified by the tax authority; however, if the non-resident enterprise voluntarily declares and pays the tax payable before the tax authority orders it to do so within required time limits, it shall be deemed that such enterprise has paid the tax in time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We face uncertainties as to the reporting and other implications of certain past and future transactions where PRC taxable assets are involved, such as offshore restructuring, sale of the shares in our offshore subsidiaries and investments. Our company may be subject to filing obligations or taxed if our company is a transferor in such transactions, and may be subject to withholding obligations if our company is a transferee in such transactions, under SAT Bulletin 7 and SAT Bulletin 37. For transfer of shares in our company by investors who are non-PRC resident enterprises, our PRC subsidiary may be requested to assist in the filing under SAT Bulletin 7 and SAT Bulletin 37. As a result, we may be required to expend valuable resources to comply with SAT Bulletin 7 and SAT Bulletin 37 or to request the relevant transferors from whom we purchase taxable assets to comply with these circulars, or to establish that our company should not be taxed under these circulars, which may have a material adverse effect on our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">If our preferential tax treatments are revoked, become unavailable or if the calculation of our tax liability is challenged by the PRC tax authorities, we may be required to pay tax, interest and penalties in excess of our tax provisions, and our results of operations could be materially and adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Chinese government has provided various tax incentives to our subsidiaries in China. These incentives include reduced enterprise income tax rates. For example, under the Enterprise Income Tax Law and its implementation rules, the statutory enterprise income tax rate is 25%. However, the income tax of an enterprise that has been determined to be a technologically advanced service enterprise can be reduced to a preferential rate of 15%. Any increase in the enterprise income tax rate applicable to our PRC subsidiary, or any discontinuation or retroactive or future reduction of any of the preferential tax treatments currently enjoyed by our PRC subsidiary, could adversely affect our business, financial condition and results of operations. In addition, in the ordinary course of our business, we are subject to complex income tax and other tax regulations and significant judgment is required in the determination of a provision for income taxes. Although we believe our tax provisions are reasonable, if the PRC tax authorities successfully challenge our position and we are required to pay tax, interest and penalties in excess of our tax provisions, our financial condition and results of operations would be materially and adversely affected.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Certain PRC regulations may make it more difficult for us to pursue growth through acquisitions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Among other things, the Regulations on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or the M&amp;A Rules, adopted by six PRC regulatory agencies in 2006 and amended in 2009, established additional procedures and requirements that could make merger and acquisition activities by foreign investors more time-consuming and complex. Such regulation requires, among other things, the MOFCOM be notified in advance or its approval be obtained in certain situations, such as any change-of-control transaction in which a foreign investor acquires control of a PRC domestic enterprise of Undertakings, issued by the State Council in 2008 and amended in 2018, were triggered. Moreover, the Anti-Monopoly Law promulgated by the Standing Committee of the PRC National People&#8217;s Congress, or NPC, which became effective in 2008 requires that transactions which are deemed concentrations and involve parties with specified turnover thresholds must be cleared by the MOFCOM before they can be completed. In addition, PRC national security review rules which became effective in September 2011 require acquisitions by foreign investors of PRC companies engaged in military-related or certain other industries that are crucial to national security be subject to security review before consummation of any such acquisition. We may pursue potential strategic acquisitions that are complementary to our business and operations. Complying with the requirements of these regulations to complete such transactions could be time-consuming, and any required approval processes, including obtaining approval or clearance from the MOFCOM, may delay or inhibit our ability to complete such transactions, which could affect our ability to expand our business or maintain our market share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">PRC regulations relating to offshore investment activities by PRC residents may limit our PRC subsidiaries&#8217; ability to change their registered capital or distribute profits to us or otherwise expose us or our PRC resident beneficial owners to liability and penalties under PRC laws.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July 2014, SAFE promulgated the Circular on Relevant Issues Concerning Foreign Exchange Control on Domestic Residents&#8217; Offshore Investment and Financing and Roundtrip Investment Through Special Purpose Vehicles, or SAFE Circular 37. SAFE Circular 37 requires PRC residents (including PRC individuals and PRC corporate entities as well as foreign individuals that are deemed as PRC residents for foreign exchange administration purpose) to register with SAFE or its local branches in connection with their direct or indirect offshore investment activities. SAFE Circular 37 is applicable to our shareholders who are PRC residents and may be applicable to any offshore acquisitions that we make in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under SAFE Circular 37, PRC residents who make, or have prior to the implementation of SAFE Circular 37 made, direct or indirect investments in offshore special purpose vehicles, or SPVs, will be required to register such investments with SAFE or its local branches. In addition, any PRC resident who is a direct or indirect shareholder of an SPV, is required to update its filed registration with the local branch of SAFE with respect to that SPV, to reflect any material change, including, among other things, any major change of a PRC resident shareholder, name or term of operation of the SPVs, or any increase or reduction of the SPVs&#8217; registered capital, share transfer or swap, merger or division. Moreover, any subsidiary of such SPV in China is required to urge the PRC resident shareholders to update their registration with the local branch of SAFE. If any PRC shareholder of such SPV fails to make the required registration or to update the previously filed registration, the subsidiary of such SPV in China may be prohibited from distributing its profits or the proceeds from any capital reduction, share transfer or liquidation to the SPV, and the SPV may also be prohibited from making additional capital contributions into its subsidiary in China. On February 13, 2015, SAFE promulgated a Notice on Further Simplifying and Improving Foreign Exchange Administration Policy on Direct Investment, or SAFE Notice 13, which became effective on June 1, 2015. Under SAFE Notice 13, applications for foreign exchange registration of inbound foreign direct investments and outbound overseas direct investments, including those required under SAFE Circular 37, will be filed with qualified banks instead of SAFE or its branches. The qualified banks will directly examine the applications and accept registrations under the supervision of SAFE.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Some of our existing shareholders, each of whom owns our ordinary shares, including but not limited to as a result of exercising share options, are PRC residents under SAFE Circular 37. However, we cannot provide any assurance that these PRC residents comply with our request to make or obtain any applicable registrations or change registration or comply with all of the requirements under SAFE Circular 37 or other related rules. Furthermore, we may not be informed of the identities of all the PRC residents holding direct or indirect interest in our company. The failure or inability of our PRC resident shareholders to comply with the registration procedures set forth in these regulations may subject us to fines and legal sanctions, restrict our cross-border investment activities, limit the ability of our wholly foreign-owned subsidiary in China to distribute dividends and the proceeds from any reduction in capital, share transfer or liquidation to us, and we may also be prohibited from injecting additional capital into the subsidiary. Moreover, failure to comply with the various foreign exchange registration requirements described above could result in liability under PRC law for circumventing applicable foreign exchange restrictions. As a result, our business operations and our ability to distribute profits to you could be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, as these foreign exchange regulations are still relatively new and their interpretation and implementation has been constantly evolving, it is unclear how these regulations, and any future regulation concerning offshore or cross-border transactions, will be interpreted, amended and implemented by the relevant government authorities. For example, we may be subject to a more stringent review and approval process with respect to our foreign exchange activities, such as remittance of dividends and foreign-currency-denominated borrowings, which may adversely affect our financial condition and results of operations. In addition, if we decide to acquire a PRC domestic company, we cannot assure you that we or the owners of such company, as the case may be, will be able to obtain the necessary approvals or complete the necessary filings and registrations required by the foreign exchange regulations. This may restrict our ability to implement our acquisition strategy and could adversely affect our business and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may be materially adversely affected if our shareholders and beneficial owners who are PRC entities fail to comply with the relevant PRC overseas investment regulations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 26, 2017, the NDRC promulgated the Administrative Measures on Overseas Investments, or NDRC Order No. 11, which took effect as of March 1, 2018. According to NDRC Order No. 11, non-sensitive overseas investment projects are subject to record-filing requirements with the local branch of the NDRC. On September 6, 2014, MOFCOM promulgated the <i style="font-style:italic;">Administrative Measures on Overseas Investments</i>, which took effect as of October 6, 2014. According to this regulation, overseas investments of PRC enterprises that involve non-sensitive countries and regions and non-sensitive industries are subject to record-filing requirements with a local MOFCOM branch. According to the <i style="font-style:italic;">Circular of the State Administration of Foreign Exchange on Issuing the Regulations on Foreign Exchange Administration of the Overseas Direct Investment of Domestic Institutions</i>, which was promulgated by SAFE on July 13, 2009 and took effect on August 1, 2009, PRC enterprises must register for overseas direct investment with a local SAFE branch.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may not be fully informed of the identities of all our shareholders or beneficial owners who are PRC entities, and we cannot provide any assurance that all of our shareholders and beneficial owners who are PRC entities has or will comply with our request to complete the overseas direct investment procedures under the aforementioned regulations or other related rules in a timely manner, or at all. If they fail to complete the filings or registrations required by the overseas direct investment regulations, the relevant authorities may order them to suspend or cease the implementation of such investment impose warnings and sanctions and make corrections within a specified time, or limit our ability to distribute dividends and proceeds to our PRC subsidiary, which may adversely affect our business, financial condition and results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 8pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from using the proceeds of our initial public offering to make loans or additional capital contributions to our PRC subsidiary, which could materially and adversely affect our liquidity and our ability to fund and expand our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">We are an offshore holding company conducting our operations in China through our PRC subsidiary. We also hold certain intellectual properties and outsource certain research and development activities related to these intellectual properties to our subsidiaries. We may in the future make loans or provide guarantee to our PRC subsidiary subject to the approval or registration from governmental authorities and limitation of amount, or we may make additional capital contributions to our wholly foreign-owned subsidiary in China. Any loans to our wholly foreign-owned subsidiary in China, which are treated as foreign-invested enterprises under PRC law, are subject to foreign exchange loan registrations. In addition, a foreign-invested enterprise, or FIE, shall use its capital pursuant to the principle of authenticity and self-use within its business scope. The capital of an FIE shall not be used for the following purposes: (i) directly or indirectly used for payment beyond the business scope of the enterprises or the payment prohibited by relevant laws and regulations; (ii) directly or indirectly used for investment in securities or investments other than banks&#8217; principal-secured products unless otherwise provided by relevant laws and regulations; (iii) the granting of loans to non-affiliated enterprises, except where it is expressly permitted in the business license; and (iv) paying the expenses related to the purchase of real estate that is not for self-use (except for the foreign-invested real estate enterprises).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In light of the various requirements imposed by PRC regulations on loans to and direct investment in PRC entities by offshore holding companies, we cannot assure you that we will be able to complete the necessary government registrations or obtain the necessary government approvals on a timely basis, if at all, with respect to future loans by us to our PRC subsidiary or with respect to future capital contributions by us to our PRC subsidiary. If we fail to complete such registrations or obtain such approvals, our ability to use the proceeds from our initial public offering and to capitalize or otherwise fund our PRC operations may be negatively affected, which could materially and adversely affect our liquidity and our ability to fund and expand our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 10pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may rely on dividends and other distributions on equity paid by our PRC subsidiary to fund any cash and financing requirements we may have, and any limitation on the ability of our PRC subsidiary to make payments to us could have a material and adverse effect on our ability to conduct our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are a Cayman Islands holding company and we currently rely principally on equity financing for our cash requirements, including the funds necessary to pay cash considerations for services we may incur. In the future, when and after we become profitable and generate cash flows from operating activities, we may rely principally on dividends and other distributions on equity from our PRC and U.S. subsidiaries for our cash requirements, including the funds necessary to pay dividends and other cash distributions to our shareholders for services of any debt we may incur. If our PRC subsidiary incurs debt on its own behalf in the future, the instruments governing the debt may restrict its ability to pay dividends or make other distributions to us. Under PRC laws and regulations, our PRC subsidiary, which is a wholly foreign-owned enterprise, may pay dividends only out of its respective accumulated profits as determined in accordance with PRC accounting standards and regulations. In addition, a wholly foreign-owned enterprise is required to set aside at least 10% of its accumulated after-tax profits each year, if any, to fund a certain statutory reserve fund, until the aggregate amount of such fund reaches 50% of its registered capital. Such reserve funds cannot be distributed to us as dividends. At its discretion, a wholly foreign-owned enterprise may allocate a portion of its after-tax profits based on PRC accounting standards to an enterprise expansion fund, or a staff welfare and bonus fund.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">A portion of our revenue was generated by our PRC subsidiary in Renminbi, which is not freely convertible into other currencies. As a result, any restriction on currency exchange may limit the ability of our PRC subsidiary to use its Renminbi revenues to pay dividends to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The PRC government may continue to strengthen its capital controls, and more restrictions and substantial vetting process may be put forward by SAFE for cross-border transactions falling under both the current account and the capital account. Any limitation on the ability of our PRC subsidiary to pay dividends or make other kinds of payments to us could materially and adversely limit our ability to grow, make investments or acquisitions that could be beneficial to our business, pay dividends, or otherwise fund and conduct our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the Enterprise Income Tax Law and its implementation rules provide that a withholding tax rate of up to 10% will be applicable to dividends payable by Chinese companies to non-PRC-resident enterprises unless otherwise exempted or reduced according to treaties or arrangements between the PRC central government and governments of other countries or regions where the non-PRC-resident enterprises are incorporated.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Fluctuations in exchange rates could have a material adverse effect on our results of operations and the value of your investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The value of the Renminbi against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in political and economic conditions in China and by China&#8217;s foreign exchange policies. On July 21, 2005, the PRC government changed its policy of pegging the value of the Renminbi to the U.S. dollar, and the Renminbi appreciated more than 20% against the U.S. dollar over the following three years. Between July 2008 and June 2010, this appreciation halted and the exchange rate between the Renminbi and the U.S. dollar remained within a narrow band. Since June 2010, the Renminbi has fluctuated against the U.S. dollar, at times significantly and unpredictably. Since October 1, 2016, Renminbi has joined the International Monetary Fund&#8217;s basket of currencies that make up the Special Drawing Right, or SDR, along with the U.S. dollar, the Euro, the Japanese yen and the British pound. In the fourth quarter of 2016, the Renminbi has depreciated significantly in the backdrop of a surging U.S. dollar and persistent capital outflows of China. With the development of the foreign exchange market and progress towards interest rate liberalization and Renminbi internationalization, the PRC government may in the future announce further changes to the exchange rate system, and we cannot assure you that the Renminbi will not appreciate or depreciate significantly in value against the U.S. dollar in the future. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the Renminbi and the U.S. dollar in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant revaluation of the Renminbi may have a material and adverse effect on your investment. For example, to the extent that we need to convert U.S. dollars we receive from our initial public offering into Renminbi for our operations, appreciation of the Renminbi against the U.S. dollar would have an adverse effect on the Renminbi amount we would receive from the conversion. Conversely, if we decide to convert our Renminbi into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or the ADSs or for other business purposes, appreciation of the U.S. dollar against the Renminbi would have a negative effect on the U.S. dollar amount available to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Very limited hedging options are available in China to reduce our exposure to exchange rate fluctuations. To date, we have not entered into any hedging transactions in an effort to reduce our exposure to foreign currency exchange risk. While we may decide to enter into hedging transactions in the future, the availability and effectiveness of these hedges may be limited and we may not be able to adequately hedge our exposure or at all. In addition, our currency exchange losses may be magnified by PRC exchange control regulations that restrict our ability to convert Renminbi into foreign currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Governmental control of currency conversion may limit our ability to utilize our cash balance effectively and affect the value of your investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The PRC government imposes controls on the convertibility of the Renminbi into foreign currencies and, in certain cases, the remittance of currency out of China. In the years ended December 31, 2021, we did not receive any of our revenues in Renminbi in cash.  Under our current corporate structure, our Cayman Islands holding company primarily relies on previous rounds of private financing to fund any cash and financing requirements we may have. Under existing PRC foreign exchange regulations, payments of current account items, including profit distributions, interest payments and trade and service-related foreign exchange transactions, can be made in foreign currencies without prior approval of SAFE by complying with applicable laws and regulations, as well as certain procedural requirements. Specifically, under the existing exchange restrictions, without prior approval of SAFE, cash generated from the operations of our PRC subsidiary may be used to pay dividends to our company. However, approval from or registration with appropriate government authorities is required where Renminbi is to be converted into foreign currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. As a result, we need to obtain SAFE approval to use the cash generated from the operations of our PRC subsidiary to pay off their respective debt in a currency other than Renminbi owed to entities outside China, or to make other capital expenditure payments outside China in a currency other than Renminbi. The PRC government may at its discretion restrict access to foreign currencies for current account transactions in the future. If the foreign exchange control system prevents us from obtaining sufficient foreign currencies to satisfy our foreign currency demands, we may not be able to pay dividends in foreign currencies to our shareholders, including holders of the ADSs.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Financial Prospects and Need for Additional Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a clinical stage biopharmaceutical company with a limited operating history. Since our inception in 2011, we have focused substantially all of our efforts and financial resources on the discovery and development of antibody therapeutics for the treatment of cancer. We have no products approved for commercial sale and therefore we have not generated any revenue from product sales. We have not obtained regulatory approvals for any of our product candidates and there is no assurance that we will obtain approvals in the future. We expect to continue to incur significant expenses and operating losses over the next several years and for the foreseeable future. Our prior losses, combined with expected future losses, have had and may continue to have an adverse effect on our working capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our operations to date have focused on developing our product candidates, building our intellectual property portfolio, conducting preclinical testing and clinical trials, and raising capital. These operations provide a limited basis for you to assess our ability to successfully market and commercialize our product candidates. Consequently, predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields as we seek to shift our focus to late stage development and commercial activities. If we do not address these risks and difficulties successfully, we may not be successful in such a transition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We have incurred net losses historically and we may continue to incur net losses in the near future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since our inception in 2011, we have devoted our resources to the development of innovative antibodies in the therapeutic area. While we have generated revenues from licensing and collaboration deals, we have not generated any revenue from commercial product sales to date, and we have had significant operating losses since our inception. For the years ended December 31, 2019, 2020 and 2021, we incurred net losses of US$16.4 million, US$42.4 million and US$73.2 million, respectively. Substantially all of our operating losses have resulted from costs incurred in connection with our research and development programs. To date, we have financed our operations principally through private placements and proceeds from our initial public offering. Our product candidates and programs are in preclinical development or early stage clinical development, and we have not received marketing approval for any of our product candidates. Our product candidates will require substantial investments and significant marketing efforts before we generate any revenues from product sales, if ever. We expect our net losses will increase as more product candidates enter into clinical trial stage. Our ability to generate product revenue and achieve profitability depends on, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completing research and development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiating, enrolling patients in and completing clinical trials of product candidates on a timely basis;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining regulatory approvals and marketing authorizations for any product candidates for which we complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing and maintaining adequate manufacturing capabilities either by ourselves or in connection with third-party manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching and commercializing any product candidates for which we obtain regulatory approvals and marketing authorizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing a sales, marketing and commercialization team for any future products for which we may obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeking to identify additional product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing any competing technological and market developments; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining, protecting and expanding our portfolio of intellectual property rights.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to achieve profitability. Because of the numerous risks and uncertainties associated with the development, delivery and commercialization of complex innovative antibody therapeutic, we are unable to accurately predict the timing or amount of expenses or when, or if, we will be able to achieve profitability. If we are required by regulatory authorities to perform studies in addition to those currently expected, or if there are any delays in the initiation and completion of our clinical trials or the development of any of our product candidates, our expenses could increase and profitability could be further delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we fail to become profitable or are unable to sustain profitability on a continuing basis, we may be unable to continue our operations at planned levels and be forced to reduce our operations. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become or remain profitable would decrease the value of our company and could impair our ability to raise capital, expand our business or continue our operations. Failure to become and remain profitable may adversely affect the market price of the ADSs and our ability to raise capital and continue operations. A decline in the value of our company could also cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may need to obtain substantial additional financing to fund our growth and operations, which may not be available on acceptable terms, if at all.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The development of biopharmaceutical product candidates is capital-intensive. We have used substantial funds to advance our discovery programs and develop our technology and product candidates, and will require significant funds to conduct further research and development, preclinical testing and clinical trials of our product candidates, to seek regulatory approvals for our product candidates and to manufacture and market products, if any, that are approved for commercial sales. If our product candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our development, regulatory and manufacturing capabilities. We also expect to incur significant costs associated with operating as a public company.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">To date, we have funded our operations primarily through capital contributions from our shareholders via private placements and proceeds from our initial public offering. Our operations have consumed substantial amounts of cash since inception. As of December 31, 2021, we had US$174.4 million in cash and cash equivalents. The net cash used in our operating activities was US$18.2 million, US$28.5 million and US$43.4 million for the years ended December 31, 2019, 2020 and 2021, respectively. Our future funding requirements and the period for which we expect increasing capital need may be different from what we plan. Our monthly spending levels vary based on new and ongoing research and development activities. Because of the numerous risks and uncertainties associated with our product development, we are unable to accurately predict the timing and amount of our operating expenditures, which will depend largely on:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, timing, progress, costs and results of discovery, preclinical development, laboratory testing and clinical development activities of our current product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number, scope, progress and results of preclinical and clinical programs we decide to pursue;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the progress of the development efforts of parties with whom we have entered or may in the future enter into collaborations and research and development agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain our current licenses, research and development programs, and to establish new collaboration arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to maintain competitive advantage over other AI-powered technology platforms at generating highly differentiated product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost, timing and outcome of regulatory review of any of our product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs and timing of future commercialization activities, including manufacturing, marketing, sales, and distribution, for any of our product candidates for which we receive marketing approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our efforts to enhance operational systems and hire additional personnel, including personnel to support development of our product candidates and satisfy our obligations as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. Any additional capital-raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our current and future product candidates, if approved. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or altogether cease our research and development programs or future commercialization efforts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Raising additional capital may lead to dilution of shareholdings by our existing shareholders and restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may seek additional funding through a combination of equity and debt financings and collaborations. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the beneficial ownership interest of existing holders of our shares and/or ADSs will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of existing holders of our shares and/or ADSs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The incurrence of additional indebtedness or the issuance of certain equity securities could result in increased fixed payment obligations and could also result in certain additional restrictive covenants, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through partnerships, collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, product candidates, or future revenue streams, or grant licenses on terms that are not favorable to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We have certain shareholders who have board representation rights and their individual interests may differ from yours.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2014, we completed private placements of our Series&#160;A-1 and A-2 preferred shares, in which we raised gross proceeds of approximately US$8.5 million. In 2016, we completed a private placement of our Series&#160;B preferred shares, in which we raised gross proceeds of approximately US$28.0 million. In 2018, we completed a private placement of our Series&#160;C-1 preferred shares, in which we raised gross proceeds of approximately US$50.0 million. In 2019, we completed private placements of our Series&#160;C-2 and C-3 preferred shares, in which we raised gross proceeds of approximately US$69.0 million in aggregate. As a result of these private placements, a significant portion of our outstanding equity is currently held by multiple separate institutional investors through several separate funds and our founders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These institutional investors will continue have a significant level of influence because of their level of ownership, including a greater ability than you and our other shareholders to influence the election of directors and the potential outcome of matters submitted to a vote of our shareholders, such as mergers, the sale of substantially all of our assets and other extraordinary corporate matters. These investors and our founder, Peter Luo, also have certain rights, such as board representation right and registration right that our other shareholders do not have.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For instance, our current effective memorandum and articles of association provides that JSR Limited shall have the right to designate, appoint, remove and replace and reappoint one director so long it holds at least five percent of the shares outstanding on a fully-diluted basis and an as-converted basis, although JSR Limited currently does not have representation at our board; as long as Wuxi Pharmatech Healthcare Fund I L.P., which is controlled by the ultimate controlling party of our sole supplier, holds at least five percent of the shares outstanding on a fully-diluted basis, it shall have the right to nominate one independent non-executive director and such one director shall be appointed and agreed by the board; as long as Peter Luo holds or beneficially owns any shares or is employed by us or any of our subsidiaries, he will serve as one of our directors and the Chairman of the Board of Directors; in addition, during the period commencing upon February&#160;2021 and ending on the earlier of (i)&#160;the date upon which Peter Luo beneficially owns less than five percent of the shares outstanding on a fully diluted basis, (ii)&#160;the death or legal determination of Peter Luo&#8217;s incapacity or (iii)&#160;the termination of Peter Luo as an executive officer or principal scientific advisor to us or any of our subsidiaries or for cause (as determined under his related employment or consulting arrangements and subject to all related cure provisions), Peter Luo shall have the right to designate, appoint, remove and replace and reappoint one additional director; and as long as General Atlantic Singapore AI Pte. Ltd. and its affiliates hold at least five percent of the shares outstanding on a fully-diluted basis, they shall have the right to designate, appoint, remove and replace and reappoint one director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The interests of these investors could conflict with the interests of our other shareholders, including you, and any future transfer by these investors of their shares of preferred or ordinary share to other investors who have different business objectives could have a material adverse effect on our business, results of operations, financial condition and the market value of our ordinary shares or ADSs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Risks Related to Clinical Development of Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to identify or discover new product candidates, and may allocate our limited resources to pursue a particular product candidate and fail to capitalize on product candidates that may later prove to be more profitable, or for which there is a greater likelihood of success.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although we will focus our efforts on continued preclinical and clinical developments, regulatory approval process and commercialization with respect to our existing product candidates, the success of our business depends in part upon our ability to identify, license, discover, develop, or commercialize additional product candidates. Research programs to identify new product candidates require substantial technical, financial, and human resources. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our research or business development methodology or search criteria and process may be unsuccessful in identifying potential product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to obtain marketing approval; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential product candidates may not be effective in treating their targeted diseases.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because we have limited financial and managerial resources, we focus on research programs and product candidates for specific targets. As a result, we may forgo or delay pursuit of opportunities with other product candidates that later may be proved to have greater commercial potential or a greater likelihood of success. On the other hand, if we do not prioritize the allocation of our resources and conduct research programs that cover a broad range of targets or engage clinical programs that are overly expansive, we may be subject to significant risk of loss as a large part of the research and clinical programs fail. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Accordingly, there can be no assurance that we will ever be able to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in our efforts to use and expand our proprietary platforms to build a pipeline of product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A key element of our strategy is to leverage our technology platform to expand our pipeline of antibody product candidates and in order to do so, we will continue to invest in our platform and development capabilities. Although our research and development efforts to date have resulted in a pipeline of product candidates, these product candidates may not be safe and effective. In addition, although we expect that our platform will allow us to develop a diverse pipeline of novel and differentiated product candidates, we may not prove to be successful at doing so. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects, efficacy or other characteristics that indicate that they are unlikely to be products that will receive marketing approval or achieve market acceptance. Even after approval, if we cannot successfully develop or commercialize our products, or if serious adverse events are discovered after commercialization, we will not be able to generate any product revenue, which would adversely affect business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Any failures or setbacks in our platforms or our other proprietary technologies could negatively affect our business and financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our product candidates are created with, and dependent upon, our proprietary antibody discovery platforms, such as our proprietary Dynamic Precision Library platform, which includes our NEObody platform, SAFEbody platform and POWERbody platform. These proprietary technology platforms are also the basis of our collaborations with certain other partners. To date, no products based on any of these technologies have been approved for commercial sale in any jurisdiction. Any failures or setbacks with respect to our proprietary technologies, including adverse effects resulting from the use of product candidates derived from these technologies in human clinical trials and/or the imposition of clinical holds on trials of any product candidates using our proprietary technologies, could have a detrimental impact on our clinical pipeline, as well as our ability to maintain and enter into new corporate collaborations regarding our technologies or otherwise, which would negatively affect our business and financial conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Our product candidates, for which we intend to seek approval as biologics products, may face competition sooner than anticipated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if we are successful in achieving a final regulatory approval to commercialize a product candidate ahead of our competitors, our product candidates may face competition from biosimilar or other biologic products. In the United States, our product candidates are regulated by the FDA as biologic products and we intend to seek approval for these product candidates pursuant to the Biologics License Application (BLA) pathway. The Biologics Price Competition and Innovation Act of 2009 (BPCIA) created an abbreviated pathway for the approval of biosimilar and interchangeable biologic products. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#8220;interchangeable&#8221; based on its similarity to an existing brand product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. A product may also make modifications and seek approval as a BLA. While it is uncertain when such processes intended to implement BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There is a risk that any of our product candidates approved as a biological product under a BLA would not qualify for the 12-year period of exclusivity or that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for interchangeable or generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are not fully understood.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Jurisdictions in addition to the United States have established abbreviated pathways for regulatory approval of biological products that are biosimilar to earlier approved reference products. For example, the European Union has had an established regulatory pathway for biosimilars since 2005.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The increased likelihood of biosimilar competition has increased the risk of loss of innovators&#8217; market exclusivity. Due to this risk, and uncertainties regarding patent protection, if our clinical candidates are approved for marketing, it is not possible to predict the length of market exclusivity for any particular product with certainty based solely on the expiration of the relevant patent(s)&#160;or the current forms of regulatory exclusivity. It is also not possible to predict changes in United States regulatory law that might reduce biological product regulatory exclusivity. The loss of market exclusivity for a product would likely materially and negatively affect revenues and we may not generate adequate or sufficient revenues from them or be able to reach or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We depend substantially on the success of our product candidates, particularly ADG116, ADG126, ADG106 and ADG104, which are in clinical development, and our ability to identify additional product candidates. Clinical trials of our product candidates may not be successful. If we are unable to successfully identify new product candidates, complete clinical development, obtain regulatory approval and commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our business and the ability to generate revenue related to product sales, if ever, will depend on the successful development, regulatory approval and commercialization of our antibody product candidates for the treatment of patients with cancer, particularly ADG116, ADG126, ADG106 and ADG104, which are still in clinical stage. Other than our three wholly-owned product candidates (ADG116, ADG126, ADG106) and our outlicensed product candidates, ADG104 and ADG125, our current product candidates are in relatively early stages of development. We have invested a significant portion of our efforts and financial resources in the development of our existing product candidates and all of our product candidates will require significant further development, financial resources. The success of our product candidates, including ADG116, ADG126, ADG106 and ADG104, will depend on several factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment in, and completion of, preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt of regulatory approvals from the FDA, NMPA and other comparable regulatory authorities for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing commercial manufacturing capabilities, either by building facilities ourselves or making arrangements with third-party manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">relying on third parties to conduct our clinical trials safely and efficiently;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">protecting our rights in our intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ensuring we do not infringe, misappropriate or otherwise violate the patent, trade secret or other intellectual property rights of third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching commercial sales of our product candidates, if and when approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competition with other product candidates and drugs; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continued acceptable safety profile for our product candidates following final regulatory approval, if and when received.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Due to the uncertain, time-consuming and costly clinical development and regulatory approval process, we may not successfully develop any of our product candidates, or we or our partners may choose to discontinue the development of product candidates for a variety of reasons. Our failure to effectively advance our development programs could have a material adverse effect on our business, financial condition, results of operations and future growth prospects, and cause the market price of our ADSs to decline.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Clinical trials are expensive, time consuming and difficult to design and implement and may fail to demonstrate adequate safety and efficacy of our product candidates. The results of our current and previous preclinical studies or clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not satisfy the requirements of the FDA or comparable foreign regulatory authorities or provide the basis for regulatory approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct preclinical studies and extensive clinical trials to demonstrate their safety and efficacy in humans. Clinical testing is expensive and difficult to design and implement. Clinical testing can take many years to complete, and its ultimate outcome is uncertain. A failure of one or more clinical trials can occur at any stage of the process. We will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe, pure, and effiective for use in a diverse patient population before we can seek final regulatory approvals for their commercial sale. Our clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional and expansive preclinical or clinical testings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot assure that the results of later clinical trials will replicate the results of prior clinical trials and preclinical testing. The results are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data becomes available. Product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA, the NMPA and comparable foreign regulatory authorities, despite having progressed through preclinical studies or initial clinical trials. Product candidates that have shown promising results in early clinical trials may still suffer significant setbacks in subsequent clinical trials or registration clinical trials. For example, a number of companies in the biopharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in later staged clinical trials, even after obtaining promising results in earlier clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A failure of a clinical trial to meet its predetermined primary endpoints may cause us to abandon a pipeline product or an indication and may delay development of any other pipeline products. Any delay in, or termination of, our clinical trials will delay the submission for regulatory approval and application, and, ultimately, our ability to commercialize any of our pipeline products and generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, principal investigators for our clinical trials may serve and have served as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of our pipeline products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may experience delays in our ongoing clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may experience delays in our ongoing clinical trials, and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time, or be completed on schedule, if at all. Clinical trials can be delayed, suspended, or terminated for a variety of reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in or failure to obtain regulatory authorization to commence a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in or failure to obtain institutional review board, or IRB, approval at each site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in or failure to reach agreement on acceptable terms with prospective contract research organizations (CROs), and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty in recruiting clinical trial investigators of appropriate competencies and experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in establishing the appropriate dosage levels in clinical trials;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in or failure to recruit and enroll suitable patients to participate in a trial, particularly considering study inclusion and exclusion criteria and patients&#8217; prior lines of therapy and treatment;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the difficulty in certain countries in identifying the sub-populations that we are trying to treat in a particular trial, which may delay enrollment and reduce the power of a clinical trial to detect statistically significant results;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">lower than anticipated retention rates of patients in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to have patients complete a trial or return for post-treatment follow-up;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical sites deviating from trial protocol or dropping out of a trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays adding new investigators or clinical trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">safety or tolerability concerns could cause us or our collaborators or governmental authorities, as applicable, to suspend or terminate a trial if it is found that the participants are being exposed to unacceptable health risks, undesirable side effects or other unfavorable characteristics of the product candidate, or if such undesirable effects or risks are found to be caused by a chemically or mechanistically similar therapeutic or therapeutic candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our third-party research contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in regulatory requirements, policies and guidelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to comply with the applicable regulatory requirements through the clinical process;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing sufficient quantities of a product candidate for use in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">he quality or stability of a product candidate falling below acceptable standards;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the treatment landscape for our target indications that may make our product candidates no longer relevant; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">third-party actions claiming infringement by our product candidates in clinical trials outside the United States and obtaining injunctions interfering with our progress.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, disruptions caused by the COVID-19 pandemic may increase the likelihood that we encounter such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. Moreover, while we plan to submit additional investigational new drug applications, or INDs, for other product candidates, we may not be able to file such INDs on the timeline we expect. For example, we may experience manufacturing delays or other delays with IND-enabling preclinical studies. Moreover, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate clinical trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that such regulatory authorities will not change their requirements in the future. These considerations also apply to new clinical trials we may submit as amendments to existing INDs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are required to conduct additional clinical trials or other studies with respect to any of our product candidates beyond those that we initially contemplated, if we are unable to successfully complete our clinical trials or other studies or if the results of these studies are not positive or are only modestly positive, we may be delayed in obtaining regulatory approval for that product candidate, we may not be able to obtain regulatory approval at all or we may obtain approval for indications that are not as broad as intended. Our drug development costs will also increase if we experience delays in testing or approvals, and we may not have sufficient funding to complete the testing and approval process. Significant clinical trial delays could allow our competitors to bring drugs to market before we do and impair our ability to commercialize our drugs, if and when approved. If any of this occurs, our business will be materially harmed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials must be conducted in accordance with the FDA and other applicable regulatory authorities&#8217; legal requirements, regulations and guidelines, and are subject to oversight by these governmental agencies and Ethics Committees or IRBs at the medical institutions where the clinical trials are conducted. We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs or Ethics Committees of the institutions in which such trials are being conducted, by the Data Review Committee or Data Safety Monitoring Board for such trial or by the FDA, or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial or to perform obligations in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize our product candidates and impair our ability to commercialize our product candidates and may harm our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, clinical trials must be conducted with supplies of our product candidates produced under current good manufacturing practices, or cGMP, requirements and other regulations. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited influence over their actual performance. We depend on our collaborators and on medical institutions and CROs to conduct our clinical trials in compliance with good clinical practice, or GCP, requirements. To the extent our collaborators or the CROs fail to enroll participants for our clinical trials, fail to conduct the study in accordance with GCP or are delayed for a significant time in the execution of trials, including achieving full enrollment, we may be affected by increased costs, program delays or both, which may harm our business. In addition, clinical trials that are conducted in countries outside the United States may subject us to further delays and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of non-U.S. CROs, as well as expose us to risks associated with clinical investigators who are unknown to the FDA, and different standards of diagnosis, screening and medical care.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">If we encounter difficulties in enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients. Our clinical trials may be subject to delays for a variety of reasons, including as a result of enrollment taking longer than anticipated, subject withdrawal or adverse events. These types of developments could cause us to delay the trial or halt further development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While we believe our differentiated product candidates address highly unmet medical needs that will facilitate our patient enrollment, clinical trials may compete with other clinical trials that are in the same therapeutic areas as our product candidates, and this competition reduces the number and types of patients available to us, as some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Moreover, enrolling patients in clinical trials for cancer therapies is challenging, as cancer patients will first receive the applicable standard of care. Many patients who respond positively to the standard of care antibody therapy (and thus do not enroll in clinical trials) are believed to have tumor types that would have responded well to our product candidates. Patients who fail to respond positively to the standard of care treatment will be eligible for clinical trials of unapproved product candidates. However, these prior treatment regimens may render our therapies less effective in clinical trials. Additionally, patients who have failed with prior approved therapies will typically have more advanced cancer and a poorer long-term prognosis.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because the number of qualified clinical investigators and clinical trial sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">severity of the disease under investigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and nature of the patient population;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient eligibility criteria defined in the protocol;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size of the study population required for analysis of the trial&#8217;s primary endpoints;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">perceived risks and benefits of our pipeline products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our resources to facilitate timely enrollment in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">patient referral practices of physicians;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the proximity of patients to trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">th</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">e design of the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain patients&#8217; consent; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that patients enrolled in clinical trials will not complete a clinical trial.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These factors may make it difficult for us to enroll enough patients to complete our clinical trials in a timely and cost-effective manner. Delays in the completion of any clinical trial of our product candidates will increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue. In addition, some of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Interim, topline or preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may publicly disclose preliminary or topline or data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions, or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. If the interim, topline, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects, or financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Risks Related to Obtaining Regulatory Approval of Our Drug Candidates</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA, NMPA and other comparable regulatory authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approvals for our product candidates, our business will be substantially harmed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, marketing approval of biologics requires the submission of a BLA to the FDA, and we are not permitted to market any product candidate in the United States until we obtain approval from the FDA of the BLA for that product candidate. A BLA must be supported by extensive clinical and preclinical data, as well as extensive information regarding pharmacology, chemistry, manufacturing and controls. Outside the United States, many comparable foreign regulatory authorities employ similar approval processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have not previously submitted a BLA to the FDA or similar regulatory approval filings to the NMPA or other comparable foreign authorities, for any product candidate, and we cannot be certain that any of our product candidates will receive regulatory approval. Obtaining approval of a BLA can be a lengthy, expensive and uncertain process, and as a company we have no experience with the preparation of a BLA submission or any other application for marketing approval. In addition, the FDA has the authority to require a risk evaluation and mitigation strategies, or REMS, plan as part of a BLA or after approval, which may impose further requirements or restrictions on the distribution or use of an approved biologic, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">FDA approval is not guaranteed, and the time required to obtain approval by the FDA, NMPA and other comparable regulatory authorities is unpredictable but typically takes many years following the commencement of preclinical trials and clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, due to external issues such as pandemics or other public health emergencies, FDA, NMPA and other comparable regulatory authorities may be delayed in their review of product applications. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may discover, in-license or acquire and seek to develop in the future will ever obtain regulatory approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our product candidates could fail to receive regulatory approval from the FDA, NMPA or a comparable regulatory authority for many reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreement with the design or implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to demonstrate that a product candidate is safe and effective or safe, pure, and potent for its proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure of clinical trial results to meet the level of statistical significance required for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreement with our interpretation of data from preclinical trials or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the insufficiency of data collected from clinical trials of our product candidates to support the submission and filing of a BLA or other submission or to obtain regulatory approval;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA, NMPA or comparable regulatory authority&#8217;s finding of deficiencies related to the manufacturing processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure of our product candidates to ensure compliance with Good Manufacturing Practice, or cGMP, following inspections during the regulatory review process or across the production cycle of our product; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in approval policies or regulations that render our preclinical and clinical data insufficient for approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory authorities have substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for any of our product candidates. For example, regulatory authorities in various jurisdictions have in the past had, and may in the future have, differing requirements for, interpretations of and opinions on our preclinical and clinical data. As a result, we may be required to conduct additional preclinical studies, alter our proposed clinical trial designs or conduct additional clinical trials to satisfy the regulatory authorities in each of the jurisdictions in which we hope to conduct clinical trials and develop and market our products, if approved. Further, even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA or any other regulatory authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA, NMPA or a comparable regulatory authority may require more information, including additional preclinical or clinical data, to support approval, which may delay or prevent approval and our commercialization plans, or we may decide to abandon the development program. If we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may grant approval contingent on the performance of costly post-marketing clinical trials, may approve a product candidate with a label that is not desirable for the successful commercialization of that product candidate, or may be difficult to meet manufacturing requirements. In addition, if our product candidate produces undesirable side effects or safety issues, the FDA may require the establishment of Risk Evaluation Mitigation Strategies, or REMS, or the NMPA or a comparable regulatory authority may require the establishment of a similar strategy, that may, for instance, restrict distribution of our drugs and impose burdensome implementation requirements on us. Any of the foregoing scenarios could materially harm the commercial prospects of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory, and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new biologics or modifications to licensed biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December&#160;22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Separately, in response to the COVID-19 pandemic, on March&#160;10, 2020, the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March&#160;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July&#160;10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other countries. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking regulatory approvals in various jurisdictions could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We are conducting clinical trials and may in the future conduct additional clinical trials for our product candidates outside the United States and/or China, and FDA, NMPA and similar foreign regulatory authorities may not accept data from such trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are conducting clinical trials and may in the future conduct additional clinical trials for our product candidates outside the United States, including in Australia, Europe or other foreign jurisdictions. The acceptance of trial data from clinical trials conducted outside the United States by the FDA may be subject to certain conditions. In cases where data from clinical trials conducted outside the United States are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&#160;the data are applicable to the United States population and United States medical practice; (ii)&#160;the trials were performed by clinical investigators of recognized competence and (iii)&#160;the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Otherwise, for studies that are conducted at sites outside of the United States and not subject to an IND and which are intended to support a marketing application (but which are not intended to serve as the sole basis for marketing approval), the FDA requires the clinical trial to have been conducted in accordance with good clinical practice, or GCP, requirements and the FDA must be able to validate the data from the clinical trial through an on site inspection if it deems such inspection necessary. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations, statistical powering, and specific documentation requirements must be met. Many foreign regulatory bodies, such as NMPA, have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, NMPA or any similar foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA, NMPA or any similar foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Our product candidates may cause undesirable adverse events, side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any regulatory approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Undesirable adverse events caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, NMPA or other comparable regulatory authority. Results of our trials could reveal a high and unacceptable severity or prevalence of adverse events. In such an event, our trials could be suspended or terminated and the FDA, NMPA or other comparable regulatory authorities could order us to cease further development of, or deny approval of, our product candidates for any or all targeted indications. Drug-related adverse events could affect patient recruitment or the ability of enrolled subjects to complete the trial, and could result in potential product liability claims. Moreover, such events may require us to amend our trials, including reducing the dosage in our clinical trials.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For instance, in September 2019, the FDA placed a clinical hold on our Phase 1 trial of ADG116 (ADG116-1001) in the United States after we reported to the FDA the death of the only patient dosed in the trial. We revised the study protocol to mitigate the risk of drug-induced liver toxicity, lower the starting dose of ADG116, and tighten the inclusion and exclusion criteria. The FDA removed the clinical hold on this protocol on December 5, 2019. In parallel, we initiated a new Phase 1 clinical trial of ADG116 (ADG116-1003) in Australia and completed multiple levels of dose escalation without serious adverse events. In March 2021, we submitted this new protocol for ADG116 (ADG116-1003) to FDA with safety data from Australia. Upon receiving clearance from FDA to open sites in the United States for ADG116-1003, we terminated the prior Phase 1 trial (ADG116-1001) in the United States for business reasons. Overall, we have enrolled over 30 patients, including at sites in the United States, and completed additional levels of dose escalation in the new global trial of ADG116, with one DLT event (Grade 4 hyperglycemia) reported at the 10 mg/kg dose level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We cannot provide any assurance that there will not be treatment-related severe adverse events with our product candidates, that the trials for our product candidates will not be suspended in the future, or that patient recruitment for trials with our product candidates will not be adversely impacted by the ADG116 related adverse events, any of which could materially and adversely affect our business and prospects. Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to the product candidate. In the event that any of our product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may suspend marketing of such products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw or limit approvals of such products or require us to take an approved product off the market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies, or issue other communications containing warnings or other safety information about the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require a medication guide outlining the risks of such side effects for distribution to patients, or that we implement a REMS plan to ensure that the benefits of the product outweigh its risks or to develop a similar strategy as required by a comparable regulatory authority, that may, for instance, restrict distribution of our drugs and impose burdensome implementation requirements on us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to conduct post-market studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to limitations on how we may promote or manufacture the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of the product may decrease significantly;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to subjects or patients; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, combination therapy involves unique adverse events that could be exacerbated compared to adverse events from monotherapies. These types of adverse events could be caused by our product candidates and could also cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, NMPA or other comparable regulatory authority. Results of our trials could reveal a high and unacceptable severity or prevalence of adverse events.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may seek Orphan Drug Designation for some of our product candidates, and we may be unsuccessful.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Regulatory authorities in some jurisdictions, including the United States, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a drug as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a disease with a patient population of fewer than 200,000 individuals in the United States, or a patient population of greater than 200,000 individuals in the United States, but for which there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Generally, if a drug with an Orphan Drug Designation subsequently receives the first FDA approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug for the same indication during the period of exclusivity. The applicable period is seven years in the United States. Orphan Drug exclusivity may be lost if the FDA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if we obtain Orphan Drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different drugs can be approved for the same condition and the same drugs can be approved for a different condition but used off-label for any orphan indication we may obtain. Even after an orphan drug is approved, the FDA can subsequently approve a different drug for the same condition if the FDA concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may in the future seek an accelerated approval for our one or more of our product candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to conduct, in a diligent manner, additional post- approval confirmatory studies to verity and describe the drug&#8217;s clinical benefit. If such post-approval studies fail to confirm the drug&#8217;s clinical benefit, the FDA may withdraw its approval of the drug.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to seeking accelerated approval for any of our product candidates, we intend to obtain a meeting with the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit a BLA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent FDA feedback we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or receive an expedited regulatory designation (e.g., breakthrough therapy designation) for our product candidates, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Even if we receive regulatory approvals for our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory reviews, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, import, export, adverse event reporting, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including both federal and state requirements in the United States and requirements of comparable regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA, NMPA and comparable regulatory authority requirements, including, in the United States, ensuring that quality control and manufacturing procedures conform to current cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application, and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the drug may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA, NMPA, or a comparable regulatory authority approves our product candidates, we will have to comply with requirements including, for example, submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and Good Clinical Practices, or cGCPs, for any clinical trials that we conduct post approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA and NMPA may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the drug reaches the market. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical trials to assess new safety risks, or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of our drugs, withdrawal of the product from the market, or voluntary or mandatory product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, untitled or warning letters, or holds on clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal by the FDA, NMPA or comparable regulatory authorities to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal to permit the import or export of our product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA, NMPA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. The policies of the FDA, NMPA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any regulatory approval that we may have obtained and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">All material aspects of the research, development and commercialization of pharmaceutical products are heavily regulated.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">All jurisdictions in which we intend to conduct our pharmaceutical-industry activities regulate these activities in great depth and detail. We intend to focus our activities in the major markets such as the United States and China. These jurisdictions strictly regulate the pharmaceutical industry, and in doing so they employ broadly similar regulatory strategies, including regulation of product development and approval, manufacturing, and marketing, sales and distribution of products. However, there are differences in the regulatory regimes that make for a more complex and costly regulatory compliance burden for a company like ours that plans to operate in these regions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The process of obtaining regulatory approvals and compliance with appropriate laws and regulations require substantial time and financial resources. Failure to comply with the applicable requirements at any time during the product development process and approval process, or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include: refusal to approve pending applications; withdrawal of an approval; license revocation; clinical hold; voluntary or mandatory product recalls; product seizures; total or partial suspension of production or distribution; injunctions; fines; refusals of government contracts; providing restitution; undergoing disgorgement; or other civil or criminal penalties. Failure to comply with these regulations could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Future strategic partnerships may be important to us. We will face significant competition in seeking new strategic partners.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not yet have any capability for manufacturing, sales, marketing or distribution. For some of our product candidates, we may in the future determine to collaborate with pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. The competition for strategic partners is intense. Our ability to reach a definitive agreement for collaboration will depend, among other things, upon our assessment of the strategic partner&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed strategic partner&#8217;s evaluation of a number of factors. These factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The strategic partner may also consider alternative product candidates or technologies for similar indications that may be available for collaboration and whether such collaboration could be more attractive than the one with us for our product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Strategic partnerships are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future strategic partners. Even if we are successful in entering into collaboration, the terms and conditions of that collaboration may restrict us from entering into future agreements with other potential collaborators.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are unable to reach agreements with suitable strategic partners on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into strategic partnerships and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our technology platform and our business may be materially and adversely affected. Any collaboration may be on terms that are not optimal for us, and we may not be able to maintain any new collaboration if, for example, development or approval of a product candidate is delayed, sales of an approved product candidate do not meet expectations or the partner terminates the collaboration. Any such collaboration, or other strategic transaction, may require us to incur non-recurring or other charges, and increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business. Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and have a material and adverse effect on our business, financial condition, results of operations, and prospects. Conversely, any failure to enter any collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product candidates and have a negative impact on the competitiveness of any product candidate that reaches the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to enter into additional collaboration agreements beyond our existing technology licensing agreements with Sanofi, Exelixis and ADC Therapeutics, our outlicensing agreements with Guilin Sanjin and Dragon Boat, or Discovery Agreements such as those with NIH, Tanabe, Celgene, GSK, Hengrui and others. If we are unable to maintain existing and future strategic partnerships or collaborations, or if these strategic partnerships or collaborations are not successful, our business could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our existing strategic partnerships, collaborations and any future strategic partnerships we enter into may pose a number of risks, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not be able to enter into critical strategic partnerships or enter into them on favorable terms;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partners or collaborators have significant discretion in determining the effort and resources that they will apply to such a partnership, and they may not perform their obligations as agreed, expected, or in compliance with applicable legal requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partners or collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the partners&#8217; strategic focus or available funding, or external factors, such as an acquisition that diverts resources or creates competing priorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partners or collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partners or collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the strategic partners or collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product candidates discovered in collaboration with us may be viewed by our strategic partners or collaborators as competitive with their own product candidates or products, which may cause strategic partners or collaborators to cease to devote resources to the commercialization of our product candidates;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a strategic partner or collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disagreements with strategic partners or collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partners or collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partners or collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partners or collaborators may claim for a substantial compensation for our failure of development of the product candidates specified under the relevant out-licensing agreements that solely arose out of problems of our previous R&amp;D basis; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">strategic partnerships or collaborations may be terminated for the convenience of the partner or the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any partnerships or collaboration we enter into do not result in the successful development of our product candidates or if one of our partners or collaborator terminates the agreement with us, our continued development of our product candidates could be delayed and our business may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We will need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, we had 259 full-time employees. As our development and commercialization plans and strategies develop, we expect to expand our employee base for managerial, operational, financial and other resources. As our product candidates enter and advance through preclinical studies and clinical trials, we will need to expand our development, regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities for us. In the future, we expect to enter into additional relationships with collaborators or partners, suppliers and other organizations and establish a sales and marketing team in preparation for commercialization activities. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls. Our inability to successfully manage our growth and expand our operations could have a material and adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Disruptions in the financial markets and economic conditions could affect our ability to raise capital.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Global economies could suffer dramatic downturns as the result of a deterioration in the credit markets and related financial crisis as well as a variety of other factors including, extreme volatility in security prices, severely diminished liquidity and credit availability, ratings downgrades of certain investments and declining valuations of others. In the past, governments have taken unprecedented actions in an attempt to address and rectify these extreme market and economic conditions by providing liquidity and stability to the financial markets. If these actions are not successful, the return of adverse economic conditions may cause a significant impact on our ability to raise capital, if needed, on a timely basis and on acceptable terms or at all.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, there is considerable uncertainty over the long-term effects of the expansionary monetary and fiscal policies adopted by the central banks and financial authorities of some of the world&#8217;s leading economies, including the United States and China. There have been concerns over unrest and terrorist threats in the Middle East, Europe and Africa and over the conflicts involving Ukraine, Syria and North Korea. There have also been concerns on the relationship among China and other Asian countries, which may result in or intensify potential conflicts in relation to territorial disputes or the trade related disputes between the United States and China. In addition, the U.K. held a referendum on June 23, 2016 on its membership in the EU, in which voters approved an exit from the EU, commonly referred to as &#8220;Brexit&#8217;&#8217;; the U.K. formally left the EU on January 31, 2020. The EU and the U.K have entered into the post-Brexit Trade and Cooperation Agreement, an agreement purporting to create a broad economic partnership between the EU and the U.K., which was approved by the European Parliament in April 2021 and went into force fully on May 1, 2021. Nonetheless, Brexit could still adversely affect European and worldwide economic and market conditions and could contribute to instability in global financial and foreign exchange markets. It is unclear whether these challenges and uncertainties will be contained or resolved, and what effects they may have on the global political and economic conditions in the long term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">If we face allegations of non-compliance with laws and encounter sanctions, our reputation, revenues and liquidity may suffer, and our product candidates and approved products, if any, could be subject to restrictions or withdrawal from the market.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any government investigation of alleged violations of laws or regulations could require us to expend significant time and resources in response, and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to obtain approvals commercialize and generate revenues from our drugs. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. Additionally, if we are unable to generate revenues from our product sales, our potential for achieving profitability will be diminished and the capital necessary to fund our operations will be increased.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Our reputation is important to our success. Negative publicity may adversely affect our reputation and business prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any negative publicity concerning us, our affiliates or any entity that shares the &#8220;Adagene&#8217;&#8217; name, even if untrue, could adversely affect our reputation and business prospects. There can be no assurance that negative publicity about us or any of our affiliates or any entity that shares the &#8220;Adagene&#8217;&#8217; name would not damage our brand image or have a material adverse effect on our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Potential future acquisitions or strategic collaborations may increase our capital requirements, dilute our shareholders, cause us to incur debt or assume contingent liabilities and subject us to other risks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may evaluate various acquisitions and strategic collaborations, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic collaboration may entail numerous risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased operating expenses and cash requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the assumption of additional indebtedness or contingent liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated with integrating new personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the diversion of our management&#8217;s attention from our existing product programs and initiatives in pursuing such a strategic merger or acquisition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">retention of key employees, the loss of key personnel, and uncertainties in our ability to maintain key business relationships;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and their existing products or product candidates and regulatory approvals; and/or</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking the acquisition or even to offset the associated acquisition and maintenance costs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if we undertake acquisitions, we may issue dilutive securities, assume or incur debt obligations, incur large one-time expenses and acquire intangible assets that could result in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities and this inability could impair our ability to grow or obtain access to technology or products that may be important to the development of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Our business operations and current or future relationships with healthcare professionals, principal investigators, consultants, customers and third-party payors in the United States and elsewhere may be subject, directly or indirectly, to applicable anti-kickback, fraud and abuse, false claims, physician payment transparency and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners, or vendors violate these laws, we could face substantial penalties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our business operations and current or future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include, without limitation:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal civil and criminal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal false claims laws, including the False Claims Act, which can be enforced through whistleblower actions, and civil monetary penalties laws, which, among other things, impose criminal and civil penalties against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the United States Physician Payments Sunshine Act and its implementing regulations, which require certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid or the Children&#8217;s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians, as defined by such law, and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members. Effective January&#160;1, 2022, the U.S. federal physician transparency reporting requirements will extend to include transfers of value made during the previous year to certain non-physician providers such as physician assistants and nurse practitioners;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. Foreign Corrupt Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office and foreign political parties or officials thereof; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state and local laws that require the registration of pharmaceutical sales representatives; and state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities. For detailed discussion on material applicable PRC regulation, see &#8220;Item 4 Information on the Company&#8212;PRC Regulation&#8221; Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming and may require significant personnel resources. Even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Recently enacted and future legislation in the United States and other countries may affect the prices we may obtain for our product candidates and increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States and many other countries, rising healthcare costs have been a concern for governments, patients and the health insurance sector, which resulted a number of changes to laws and regulations, and may result in further legislative and regulatory action regarding the healthcare and health insurance systems that could affect our ability to profitably sell any product candidates for which we obtain marketing approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, was enacted in the United States in March&#160;2010 with the stated goals of containing healthcare costs, improving quality and expanding access to healthcare, and includes measures to change health care delivery, increase the number of individuals with insurance, ensure access to certain basic health care services, and contain the rising cost of care. Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, various portions of the ACA are currently facing legal and constitutional challenges in the Fifth Circuit Court of Appeals and the United States Supreme Court. Additionally, the current administration has issued various Executive Orders which eliminated cost sharing subsidies and various provisions that would impose a fiscal burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices, and Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA. It is unclear whether the ACA will be overturned, repealed, replaced, or further amended.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, other federal health reform measures have been proposed and adopted in the United States. For example, as a result of the Budget Control Act of 2011, providers are subject to Medicare payment reductions of 2% per fiscal year through 2030, with the exception of a temporary suspension from May&#160;1, 2020 through December&#160;31, 2020, unless additional Congressional action is taken. Further, the American Taxpayer Relief Act of 2012 reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments from providers from three to five years. The Medicare Access and CHIP Reauthorization Act of 2015 also introduced a quality payment program under which certain individual Medicare providers will be subject to certain incentives or penalties based on new program quality standards. Payment adjustments for the Medicare quality payment program began in 2019. At this time, it is unclear how the introduction of the quality payment program will impact overall physician reimbursement under the Medicare program. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since January&#160;2017, there has been legislation considered in Congress to restrict the pricing of drug products to a governmental negotiated rate or to other similar rates that would reduce the costs to government, commercial payers and individuals. In July&#160;2020, President Trump signed four Executive Orders directing the Department of Health and Human Services and other agencies to take specific actions to reduce prescription drug prices. The first order directs federally qualified health centers to pass along significant discounts on insulin and epinephrine from drug companies to low-income individuals. The second order would allow the important of prescription drugs from Canada into the United States where the prices are deemed to be lower. The third order would eliminate safe harbor protections under the federal Anti-Kickback Statute that currently covers rebates paid by manufacturers to Medicare Part&#160;D plans and Medicaid managed care organizations, either directly or through pharmacy benefit managers under contract with such plans or organizations, so long as such actions are not projected to increase federal spending, Medicare beneficiary premiums or patients&#8217; total out-of-pocket cases. The fourth order will reduce the payment for Medicare part B drugs to be paid at the same rate as other developed nations, thereby reducing the reimbursement. All of these Executive Orders require rulemaking prior to implementation and could be stalled by Congress or the next election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The combination of healthcare cost containment measures, increased health insurance costs, reduction of the number of people with health insurance coverage, as well as future legislation and regulations focused on reducing healthcare costs by reducing the cost of or reimbursement and access to pharmaceutical products, may limit or delay our ability to generate revenue, attain profitability, or commercialize our pipeline products, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We face intense competitions and rapid technological changes, as well as the possibility that our competitors may develop therapies that are similar, more advanced, or more effective than ours, which may adversely affect our ability to successfully commercialize our product candidates and our financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We are currently aware of various existing therapies and development candidates that may compete with our wholly owned clinical candidates as they engage similar targets, such as urelumab and utomilumab targeting CD137, and ipilimumab and AGEN 1181 targeting CTLA-4. We have competitors in the United States, China and internationally, including major multinational pharmaceutical companies, specialty pharmaceutical companies, and biotechnology companies. Many of our competitors have substantially greater financial, technical, and other resources, such as larger research and development, marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval more rapidly than we are able to and may be more effective in selling and marketing their products as well. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, products that are more effective or less costly than any product candidate that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization and market penetration than we do. Additionally, technologies developed by our competitors may render our potential product candidates uneconomical or obsolete, and we may not be successful in marketing our product candidates against competitors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We have no experience in launching and marketing product candidates. We may not be able to effectively build and manage our sales network, or benefit from third-party collaborators&#8217; sales network.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently have no manufacturing, sales, marketing or commercial product distribution capabilities and have no experience in marketing drugs. We intend to develop an in-house marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other biopharmaceutical companies to recruit, hire, train and retain marketing and sales personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Given that marketing generally requires extensive training and oversight, and if we are unable or decide not to establish internal sales, marketing and commercial distribution capabilities for any or all of the drugs we develop, we will likely pursue collaborative arrangements regarding the sales and marketing of our product candidates, if approved. However, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or, if we are able to do so, that they will have effective sales forces. Any revenue we receive will depend on the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties, and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We will also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates, if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There can be no assurance that we will be able to develop in-house sales, marketing and commercial distribution capabilities or establish or maintain relationships with third-party collaborators to successfully commercialize any product candidate, if approved, and as a result, we may not be able to generate product sales revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Even if we are able to commercialize any approved product candidates, coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, and we may be subject to unfavorable pricing regulations, which could harm our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The regulations that govern regulatory approvals, pricing and reimbursement for new therapeutic products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or licensing approval is granted. In some non-U.S. markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a drug in a particular country, but then be subject to price regulations that delay our commercial launch of the drug and negatively impact our revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A primary trend in the global healthcare industry is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Our ability to commercialize any drugs successfully also will depend in part on the extent to which coverage and reimbursement for these drugs and related treatments will be available on adequate terms, or at all, from government health administration authorities, private health insurers and other organizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, no uniform policy of coverage and reimbursement for biopharmaceutical products exists among third-party payors. As a result, obtaining coverage and reimbursement approval of a drug from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our drugs on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. Even if we obtain coverage for a given drug, the resulting reimbursement rates might not be adequate for us to achieve or sustain profitability or may require co-payments that patients find unacceptably high. Increasingly, third-party payors are requiring that companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term follow-up evaluations required following the use of our genetically modified drugs. Patients are unlikely to use our drugs and any approved product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of the drug. Because some of our product candidates have a higher cost of goods than conventional therapies, may require long-term follow up evaluations, and will likely be administered under the supervision of a physician, the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate that we successfully develop.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">There may be significant delays in obtaining reimbursement for approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or other comparable regulatory authorities outside the United States. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on payments allowed for lower cost drugs that are already reimbursed, and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future weakening of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for our drugs and any new product candidates that we develop could have a material adverse effect on our business, our operating results, and our overall financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In China, the Ministry of Human Resources and Social Security of China or provincial or local human resources and social security authorities, together with other government authorities, review the inclusion or removal of drugs from China&#8217;s National Drug Catalog for Basic Medical Insurance, Work-related Injury Insurance and Maternity Insurance, or the National Reimbursement Drug List, or the NRDL, or provincial or local medical insurance catalogues for the National Medical Insurance Program regularly, and the tier under which a drug will be classified, both of which affect the amounts reimbursable to program participants for their purchases of those drugs. There can be no assurance that our drugs and any approved product candidates will be included in the NRDL or provincial reimbursements lists. Products included in the NRDL have been typically generic and essential drugs. Innovative drugs similar to our product candidates have historically been more limited on their inclusion in the NRDL due to the affordability of the government&#8217;s Basic Medical Insurance, although this has been changing in recent years. According to currently effective PRC laws and regulations, the prices of approved drugs are determined by market competition. The government regulate prices mainly by establishing a consolidated procurement mechanism, revising the NRDL and strengthening regulation of medical and pricing practices. We cannot predict the extent to which our business may be affected by potential future legislative or regulatory developments. Changes in pricing regulation could restrict the amount that we are able to charge for our future approved drugs, which would adversely affect our revenue, profitability and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We intend to seek approval to market our product candidates in the United States, China and in other jurisdictions. In some non-U.S. countries, the pricing of drugs and biologics is subject to governmental control, which can take considerable time even after obtaining regulatory approval. Market acceptance and sales of our drugs will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for drugs and may be affected by existing and future health care reform measures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">As we engage in collaboration worldwide, we may be exposed to specific risks of conducting our business and operations in international markets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a biopharmaceutical company with global footprints. We are currently building our clinical and technology infrastructures to support our future global operations and prepare to serve global markets. If we fail to obtain applicable licenses or fail to enter into strategic collaboration arrangements with third parties in these markets, or if these collaboration arrangements turn out unsuccessful, our revenue-generating growth potential will be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, international business relationships subject us to additional risks that may materially adversely affect our ability to attain or sustain profitable operations, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efforts to enter into collaboration or licensing arrangements with third parties in connection with our international sales, marketing and distribution efforts may increase our expenses or divert our management&#8217;s attention from the acquisition or development of product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in a specific country&#8217;s or region&#8217;s political and cultural climate or economic condition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">differing regulatory requirements for drug approvals and marketing internationally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulty of effective enforcement of contractual provisions in local jurisdictions;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potentially reduced protection for intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential third-party patent rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">economic weakness, including inflation or political instability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with tax, employment, immigration and labor laws for employees traveling abroad;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the effects of applicable tax structures and potentially adverse tax consequences;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incidental to doing business in another country;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">workforce uncertainty and labor unrest and failure to comply with the applicable laws and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><br /></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulations in relation to management of the employment of foreigners within the PRC;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from an international market with low or lower prices rather than buying them locally;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure of our employees and contracted third parties to comply with Office of Foreign Assets Control rules&#160;and regulations and the Foreign Corrupt Practices Act of the United States, and other applicable rules&#160;and regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">business interruptions resulting from geo-political actions, including war and terrorism, or</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><br /></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">natural disasters, including earthquakes, volcanoes, typhoons, floods, hurricanes and fires.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These and other risks may materially adversely affect our ability to attain or sustain revenue from international markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Building our commercialization capabilities will require significant investment of time and money. There would be no assurance that we will successfully set up our commercialization capabilities in any of the proposed jurisdictions or at all, or that we will successfully commercialize any of our product candidates in the future.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are currently in the early stages of building and expanding our commercial capabilities to allow us to market our own products, if approved, in the future. We will need to set up full commercialization capabilities in the jurisdictions, including China and the United States, which would require substantial investment of time and money and will divert significant management focus and resources. We also face competition with multinational and local pharmaceutical and biotechnology companies with established commercialization capabilities in terms of marketing and attracting talents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Therefore, there can be no assurance that our efforts to set up commercialization capabilities will be successful in any of the proposed jurisdictions or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if ADG116, ADG126, ADG106 or one of our other proprietary product candidates obtains regulatory approval, we may determine that commercializing such product candidate ourselves would not be the most effective way to create value for our shareholders or holders of ADSs. In addition, if we choose to commercialize any of our product candidates, our marketing efforts may be unsuccessful as a result of unfavorable pricing or reimbursement limitations, delays, competition or other factors. Failure to successfully market one or more of our approved products, or delays in our commercialization efforts, may diminish the commercial prospects for such products and may result in financial losses or damage to our reputation, each of which may have a negative impact on the market price of our ADSs and our financial condition, results of operations and future growth prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may continue to pursue collaborations or licensing arrangements, joint ventures, strategic alliances, partnerships or other strategic investment or arrangements, which may fail to produce anticipated benefits and adversely affect our operations.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may continue to pursue opportunities for collaboration, out-license, joint ventures, acquisitions of products, assets or technology, strategic alliances, or partnerships that we believe would advance our development. We may consider pursuing growth through the acquisition of technology, assets or other businesses that may enable us to enhance our technologies and capabilities. Proposing, negotiating and implementing these opportunities may be a lengthy and complex process. Other companies, including those with substantially greater financial, marketing, technology, or other business resources, may compete with us for these opportunities or arrangements. We may not be able to identify, secure, or complete any such transactions or arrangements in a timely manner, on a cost-effective basis, on acceptable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have limited experience with respect to these business development activities. Management and integration of a licensing arrangement, collaboration, joint venture or other strategic arrangement may disrupt our current operations, decrease our profitability, result in significant expenses, or divert management resources that otherwise would be available for our existing business. We may not realize the anticipated benefits of any such transaction or arrangement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, partners, collaborators, or other parties to such transactions or arrangements may fail to fully perform their obligations or meet our expectations or cooperate with us satisfactorily for various reasons and subject us to potential risks, including the followings:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partners, collaborators, or other parties have significant discretion in determining the efforts and resources that they will apply to a transaction or arrangement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partners, collaborators, or other parties could independently develop, or develop with third parties, services and products that compete directly or indirectly with our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partners, collaborators, or other parties may stop, delay or discontinue clinical trials as well as repeat clinical trials or conduct new clinical trials by using our intellectual property or proprietary information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partners, collaborators, or other parties may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liabilities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise between us and partners, collaborators, or other parties that cause the delay or termination of the research, development or commercialization of our product candidates, or that result in costly litigation or arbitration that diverts management&#8217;s attention and resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partners, collaborators, or other parties may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable services and products; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">partners, collaborators, or other parties may own or co-own intellectual properties covering our product candidates that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual properties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any such transactions or arrangements may also require actions, consents, approval, waiver, participation or involvement of various degrees from third parties, such as regulators, government authorities, creditors, licensors or licensees, related individuals, suppliers, distributors, shareholders or other stakeholders or interested parties. There is no assurance that such third parties will be cooperative as we desire, or at all, in which case we may be unable to carry out the relevant transactions or arrangements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We rely on third parties to support, conduct and monitor our preclinical studies and clinical trials. Therefore, we may not be able to directly control the timing, process, expense and quality of our clinical trials and we cannot assure these third parties can duly perform their obligations as agreed and expected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs, to conduct our preclinical studies and clinical trials and to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our products candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat or suspend clinical trials, which would delay the regulatory approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Further, these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers may require us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads or take on additional capacity to support our needs. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We currently rely on a third-party manufacturer to produce our product candidates. Any failure by the third-party manufacturer to produce acceptable product candidates for us pursuant to our specifications and regulatory standards may delay or impair our ability to initiate or complete our clinical trials, obtain and maintain regulatory approvals or commercialize approved products, if any.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently rely on a third-party manufacturer and expect to continue to rely for some time on third parties to manufacture our product candidates for preclinical testing and clinical trials, in compliance with applicable regulatory and quality standards, and may do so for the commercial manufacture of some of our product candidates, if approved. To date, we have obtained bulk drug substance for ADG116, ADG126 and ADG106 from a single-source third-party contract manufacturer. Any reduction or halt in supply of the drug substance from such contract manufacturer could severely constrain our ability to develop our product candidates until a replacement contract manufacturer is found and qualified. If we are unable to arrange for and maintain such third-party manufacturing sources that are capable of meeting regulatory standards, or fail to do so on commercially reasonable terms, we may not be able to successfully produce sufficient supply of product candidate or we may be delayed in doing so. If we were to experience an unexpected loss of supply of our product candidates, for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. Such failure or substantial delay or loss of supply could materially harm our business. We are continuously evaluating multiple vendors both in China and abroad to ensure that we have a continuous supply of products for global trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may have little to no control regarding the occurrence of third-party manufacturer incidents. Any failure by our third-party manufacturer to comply with good manufacturing practices, or GMPs, or failure to scale up manufacturing processes, including any failure to deliver sufficient quantities of product candidates in a timely manner, would lead to a delay in, or failure to seek or obtain, regulatory approval of any of our product candidates. Furthermore, any change in manufacturer of our product candidates or approved products, if any, would require new regulatory approvals, which could delay completion of clinical trials or disrupt commercial supply of approved products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our current and anticipated future dependence upon others for the manufacture of our product candidates may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer, we may have difficulty transferring such skills or technology to another third party and a feasible alternative many not exist. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third party manufacture our product candidates. If we are required to change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">If our current research collaborators or scientific advisors and employees terminate their relationships with us or develop relationships with our competitors, our ability to discover antibodies and to conduct research and development could be adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The responsibility of overseeing research and development of our product candidates is concentrated among a number of key research collaborators and/or scientific advisors. There can be no assurance that there will not be a detrimental impact on us if one or more of these key research collaborators and/or scientific advisors were to cease relationship or employment with us, potentially as a result of lateral recruitment by existing or new competitors. As a result, this may adversely affect our ability to conduct research and development on antibody product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, our ability to continue to conduct and expand operations depends on our ability to attract and retain a large and growing number of personnel. The ability to meet our expertise needs, including the ability to find qualified personnel to fill positions that become vacant at our research and development department or to collaborate with us in research and development efforts, while controlling our costs, is generally subject to numerous external factors, including the availability of a sufficient number of qualified persons in the biopharmaceutical industry, the unemployment levels within those markets, prevailing wage rates, changing demographics, health and other insurance costs and adoption of new or revised employment and labor laws and regulations. If we are unable to locate, to attract or to retain qualified personnel, the quality of services and products provided to customers may decrease and our financial performance may be adversely affected. In addition, if costs of labor or related costs to maintain relationships with research collaborators increase for other reasons or if new or revised labor laws, rules&#160;or regulations or healthcare laws are adopted or implemented that further increase labor costs, our business, financial condition and results of operations could be materially adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to attract and retain key senior management members or research and development personnel.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our future success depends upon the continuing services of members of our senior management team and key research and development personnel and consultants. Although we typically require our key personnel to enter into non-compete and confidentiality agreements with us, we cannot prevent them from joining our competitors after the non-compete period. The loss of their services could adversely impact our ability to achieve our business objectives. If one or more of our senior management or key clinical and scientific personnel are unable or unwilling to continue in their present positions or joins a competitor or forms a competing company, we may not be able to replace them in a timely manner or at all, which will have a material and adverse effect on our business, financial condition and results of operations. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the continued growth of our business depends on our ability to hire additional qualified personnel with expertise in molecular biology, chemistry, biological information processing, computational biology, software, engineering, sales, marketing, and technical support. We compete for qualified management and scientific personnel with other life science and technology companies, universities, and research institutions in China and overseas. Competition for these individuals is intense, and the turnover rate can be high. Failure to attract and retain management and scientific and engineering personnel could prevent us from pursuing collaborations or developing our product candidates or technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We face risks related to health epidemics, severe weather conditions and other outbreaks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">China has in the past experienced significant natural disasters, including earthquakes, extreme weather conditions, as well as health scares related to epidemic diseases, and any similar event could materially impact our business in the future. If a disaster or other disruption were to occur in the future that affects the regions where we operate our business, our operations could be materially and adversely affected due to loss of personnel and damage to property. Even if we are not directly affected, such a disaster or disruption could affect the operations or financial conditions of our customers, which could harm our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, our business could be affected by public health epidemics and pandemics, such as the outbreak of avian influenza, severe acute respiratory syndrome, or SARS, Zika virus, Ebola virus or other diseases. In December 2019, a respiratory illness caused by a novel strain of coronavirus, SARS-CoV2, causing the Coronavirus Disease 2019, also known as COVID-19 or coronavirus, emerged. As COVID-19 has evolved into a worldwide health crisis, it has resulted in adverse effects in the global economy and financial markets, such as significant declines in the global stock markets. If the COVID-19 outbreak is not effectively controlled globally, our business and results of operations could be adversely affected to the extent the COVID-19 outbreak harms the Chinese or world economy generally. The extent to which the COVID-19 outbreak impacts our financial condition and results of operations for the full year of 2022 cannot be reasonably estimated at this time and will depend on future developments that currently cannot be predicted, including the development of a COVID-19 vaccine and the actions taken to contain the COVID-19 outbreak, among others. Any future outbreak of public health epidemics may restrict economic activities in affected regions, disrupt our business operations and adversely affect our results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">The COVID-19 pandemic could adversely impact our business, including our clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The spread of the COVID-19 coronavirus in many countries continues to adversely impact global economic activity and has contributed to significant volatility and negative pressure in financial markets and supply chains. The pandemic has had, and could have a significantly greater, material adverse effect on the global economy. The pandemic has resulted in government authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns. The pandemic has also resulted, and may continue to result for an extended period, in significant disruption of global financial markets, which may reduce our ability to access capital in the future, which could negatively affect our liquidity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic has adversely affected the clinical development of our product candidates. Our clinical development program timelines could continue to be negatively affected by COVID-19, which could materially and adversely affect our business, financial condition, and results of operations. Further, due to &#8220;shelter in place&#8221; orders and other public health guidance measures, we have been required to implement a work-from-home policy from time to time for certain staff members in our Suzhou site excluding those necessary to maintain minimum basic operations. In such an instance, our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay or otherwise adversely impact our business. For example, with our personnel working from home, some of our research activities that require our personnel to be in our laboratories may be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic may impact our workforce, supply chains or distribution networks or otherwise impact our ability to restock our medical device and supply inventories and depending upon the severity of the COVID-19 pandemic&#8217;s continued spread in the United States and other countries, we may experience disruptions that could severely impact our business and clinical trials, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitation of company operations, including work from home policies and office closures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one or more key officers and/or employees could contract COVID-19 or otherwise be adversely affected by the virus;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in receiving deliveries of critical experimental materials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in enrolling patients in our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or difficulties in clinical site initiation or expansion, including difficulties in recruiting clinical site investigators and clinical site staff;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increased rates of patients withdrawing from our clinical trials following enrollment as a result of contracting COVID-19 or other health conditions or being forced to quarantine;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays or disruptions in preclinical experiments and IND-enabling studies due to restrictions of on-site staff and unforeseen circumstances at contract research organizations, or CROs, and vendors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in regulations as part of a response to the COVID-19 pandemic, which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA or other regulatory authorities to accept data from clinical trials in affected geographies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties in obtaining inspections at foreign manufacturing sites that could delay approvals; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">limitations in employee resources that would otherwise be focused on our business, including the conduct of our clinical trials, such as because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The global outbreak of the COVID-19 coronavirus continues to rapidly evolve. The extent to which the COVID-19 coronavirus may impact our business and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions and social distancing in China, the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We have limited insurance coverage, and any claims beyond our insurance coverage may result in us incurring substantial costs and a diversion of resources.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We maintain insurance policies that are required under PRC laws and regulations as well as insurance based on our assessment of our operational needs and industry practice. We also maintain liability insurance covering our clinical trials as well as maintain key-man insurance policy. In line with industry practice in the PRC, we have elected not to maintain certain types of insurances, such as business interruption insurance. Our insurance coverage may be insufficient to cover any claim for product liability, damage to our fixed assets or employee injuries. Any uninsured risks may result in substantial costs and the diversion of resources, which could adversely affect our results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We have adopted a share incentive plan and will continue to grant share-based awards in the future, which may increase expenses associated with share-based compensation. Exercise of the awards granted will increase the number of our outstanding ordinary shares, which may adversely affect the market price of our ADSs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We adopted the Second Amended and Restated Share Incentive Plan in December 2019 and the 2021 Performance Incentive Plan in January 2021, which we refer to as the 2019 Plan and the 2021 Plan, respectively, in this annual report, to enhance our ability to attract and retain exceptionally qualified individuals and to encourage them to acquire a proprietary interest in the growth and performance of us. We have terminated the authority to grant additional awards under the 2019 Plan and all future awards will be granted under the 2021 Plan. Therefore, the effective maximum number of shares issuable under the 2019 Plan will be 10,280,951. A total of 2,994,000 of our ordinary shares was authorized for issuance with respect to awards granted under the 2021 Plan. As of March 31, 2022, the aggregate number of our ordinary shares underlying our outstanding awards under the 2019 Plan was 2,872,514. As of March 31, 2022, we have granted 2,555,500 shares awards under the 2021 Plan, excluding awards that were forfeited, cancelled or exercised after the relevant grant dates. See &#8220;Item 6 Directors, Senior Management and Employees&#8212;Share Incentive Plan.&#8221; We believe the granting of share-based awards is of significant importance to our ability to attract and retain key personnel and employees, and we will continue to grant share-based compensation to employees in the future. As a result, our expenses associated with share-based compensation may increase, which may have an adverse effect on our results of operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Our employees, third-party suppliers, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, and insider trading.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are exposed to the risk of fraud or other misconduct by our employees, third-party suppliers, consultants and commercial partners. Misconduct by these parties could include intentional failures to comply with the regulations of the NMPA and overseas regulators that have jurisdictions over us, comply with healthcare fraud and abuse laws and regulations in China and abroad, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and cause serious harm to our reputation. We currently have a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and our code of conduct and the other precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses, or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could result in the imposition of significant civil, criminal and administrative penalties, including, without limitation, damages, monetary fines, individual imprisonment, disgorgement of profits, contractual damages, reputational harm, diminished profits and future earnings, additional reporting or oversight obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of noncompliance with the law and curtailment or restructuring of our operations, which could have a significant impact on our business. Whether or not we are successful in defending against such actions or investigations, we could incur substantial costs, including legal fees and divert the attention of management in defending ourselves against any of these claims or investigations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to liability lawsuits arising from our clinical trials.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently carry liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or which is in excess of the limits of our insurance coverage. Our insurance policies also contain various exclusions, and we may be subject to particular liability claims for which we have no coverage. We will have to pay any amount awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. In addition, if we cannot successfully defend ourselves against such claims, we may incur substantial liabilities and be required to suspend or delay our ongoing clinical trials. Even a successful defense would require significant financial and management resources.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Regardless of the merits or eventual outcome, liability claims may result in significant negative consequences to our business and prospects, including, but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for our product candidates or any resulting products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">damage to our reputation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of other clinical trial participants;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a diversion of our management&#8217;s time and resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial participants or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">inability to commercialize our product candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a decline in the market price of our ADSs.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We are subject to changing law and regulations regarding regulatory matters, corporate governance and public disclosure that have increased both our costs and the risk of noncompliance.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to rules&#160;and regulations by various governing bodies, including, for example, the FDA, the NMPA, the SEC, which is charged with the protection of investors and the oversight of companies whose securities are publicly traded, and the various regulatory authorities in China, the United States, the EU, the Cayman Islands, and to new and evolving regulatory measures under applicable law. Our efforts to comply with new and changing laws and regulations have resulted in and are likely to continue to result in, increased general and administrative expenses and a diversion of management time and attention from revenue-generating activities to compliance activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, because these laws, regulations and standards are subject to varying interpretations, their application in practice may evolve over time as new guidance becomes available. This evolution may result in continuing uncertainty regarding compliance matters and additional costs necessitated by ongoing revisions to our disclosure and governance practices. If we fail to address and comply with these regulations and any subsequent changes, we may be subject to penalties and our business may be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may be exposed to liabilities under the U.S. Foreign Corrupt Practices Act and Chinese anti-corruption laws, and any determination that we have violated these laws could have a material adverse effect on our business or our reputation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to anti-bribery laws in China that generally prohibit companies and their intermediaries from making payments to government officials for the purpose of obtaining or retaining business or securing any other improper advantage. In addition, although currently our primary operating business is in China, we are subject to the Foreign Corrupt Practices Act, or the FCPA. The FCPA generally prohibits us from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. We are also subject to the anti-bribery laws of other jurisdictions, particularly China. As our business expands, the applicability of the FCPA and other anti-bribery laws to our operations will increase. Our procedures and controls to monitor anti-bribery compliance may fail to protect us from reckless or criminal acts committed by our employees or agents. If we, due to either our own deliberate or inadvertent acts or those of others, fail to comply with applicable anti-bribery laws, our reputation could be harmed and we could incur criminal or civil penalties, other sanctions and/or significant expenses, which could have a material adverse effect on our business, including our financial condition, results of operations, cash flows and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Any failure to comply with applicable regulations and industry standards or obtain various licenses and permits could harm our reputation, business, results of operations and prospects.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A number of governmental agencies or industry regulatory bodies in China, the United States and other applicable jurisdictions impose strict rules, regulations and industry standards governing biopharmaceutical research and development activities, which apply to us. Our or our CROs&#8217; failure to comply with such regulations could result in the termination of ongoing research, administrative penalties imposed by regulatory bodies or the disqualification of data for submission to regulatory authorities. This could harm our business, reputation, prospects for future work and results of operations. For example, if we or our CROs were to treat research animals inhumanely or in violation of international standards set out by the Association for Assessment and Accreditation of Laboratory Animal Care, it could revoke any such accreditation and the accuracy of our animal research data could be questioned.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">If we or our third-party research collaborators or other contractors or consultants fail to comply with environmental, fire protection, drainage or health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We and third parties, such as our CROs, are subject to numerous environmental, fire protection, drainage or health and safety laws and regulations, including but not limited to those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes discharge of stationary pollution sources. The cost of compliance with health and safety regulations is substantial. Our business activities involve the controlled use of hazardous materials. Our research and development activities involve the controlled storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption of our commercialization efforts, research and development efforts and business operations. We cannot guarantee that the safety procedures utilized by our partners and by third-party manufacturers and suppliers with whom we may contract will comply with the standards prescribed by laws and regulations or will eliminate the risk of accidental contamination or injury from these materials. In such an event, we could be held liable for any resulting damages, and such liability could exceed our resources. In addition, we may be required to incur substantial costs to comply with current or future environmental, health and safety laws and regulations which are complex, change frequently and have tended to become more stringent. We do not currently carry biological or hazardous waste insurance coverage. In the event of an accident or environmental discharge, we may be held liable for any consequential damage and any resulting claims for damages, which may exceed our financial resources and may materially adversely affect our business, financial condition, results of operations and future growth prospects, and the value of our ADSs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the ordinary course of our business, we collect and store preclinical trial data and clinical trial data which could be sensitive, including research and development information, health-related information, personally identifiable information, intellectual property, and proprietary business information owned or controlled by ourselves or other parties. We manage and maintain our applications and data utilizing a combination of on-site systems and cloud-based application systems. We utilize external security and infrastructure vendors to manage parts of our data centers. We also communicate sensitive data with third parties. We face a number of risks relative to protecting this critical information, including material system failure or security breach, loss of access risk, inappropriate use or disclosure, inappropriate modification, and the risk of our being unable to adequately monitor, audit, and modify our controls over our critical information. This risk extends to the third-party vendors and subcontractors we use to manage this sensitive data and third-party collaborators who share with us sensitive data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Despite the implementation of security measures to protect sensitive data from unauthorized access, use or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance, or other malicious or inadvertent disruptions that could result in unauthorized access to, use or disclosure of, corruption of, or loss of sensitive, and/ or proprietary data, including health-related and other personal information, and could subject us to significant liabilities and regulatory and enforcement actions, and reputational damage. The COVID-19 pandemic is generally increasing the attack surface available to criminals, as more companies and individuals work online and work remotely, and as such, the risk of a cybersecurity incident potentially occurring, and our investment in risk mitigations against such an incident, is increasing. For example, there has been an increase in phishing and spam emails as well as social engineering attempts from &#8220;hackers&#8221; hoping to use the COVID-19 pandemic to their advantage. In addition, while we have implemented security measures to prevent unauthorized access to patient data, such data is currently accessible through multiple channels, and there is no guarantee we can protect our data from breach. Unauthorized access, loss, or dissemination could also result in delays of our product development and regulatory approval efforts as well as damage our reputation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For example, the loss of clinical trial data from completed or ongoing clinical trials could result in delays in any regulatory approval or clearance efforts and significantly increase our costs to recover or reproduce the data, and subsequently commercialize the product. If we or our third-party collaborators, consultants, contractors, suppliers, or service providers were to suffer an attack or breach, for example, that resulted in the unauthorized access to or use or disclosure of health-related or other personal information, we may have to notify consumers, partners, collaborators, government authorities, and the media, and may be subject to investigations, civil penalties, administrative and enforcement actions, and litigation, any of which could harm our business and reputation. Likewise, we rely on our third-party research institution collaborators and other third parties to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our insurance policies may not be adequate to compensate us for the potential losses arising from such disruptions, failure, or security breach. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and defending a suit, regardless of its merit, could be costly, divert management attention, and harm our reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We are subject to existing or future foreign laws and regulations related to privacy or data security, which could lead to government enforcement actions, including civil or criminal fines or penalties, private litigation, other liabilities, and/or adverse publicity. Compliance or the failure to comply with such laws could increase the costs of our products and services, limit their use or adoption, and otherwise negatively affect our operating results and business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, we and our partners may be subject to state and federal laws and regulations that govern data privacy, protection and security. Numerous laws and regulations, including security breach notification laws, health information privacy laws, and consumer protection laws, govern the collection, use, disclosure and protection of health-related and other personal information. In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, and regulations implemented thereunder (collectively, &#8220;HIPAA&#8217;&#8217;). Depending on the facts and circumstances, we could be subject to criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even when HIPAA does not apply, according to the Federal Trade Commission, or the FTC, violating consumers&#8217; privacy rights or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of Section&#160;5(a)&#160;of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, certain state and non-U.S. laws, such as the European Union General Data Protection Regulation, or the GDPR, govern the privacy and security of health information and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For example, California recently enacted legislation, the California Consumer Privacy Act, or CCPA, which went into effect January&#160;1, 2020. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. In Europe, the GDPR went into effect in May&#160;2018 and introduces strict requirements for processing the personal data of individuals within the EU, and the European Economic Area, or the EEA. In addition, the GDPR increases the scrutiny of transfers of personal data from clinical trial sites located in the EEA to the United States and other jurisdictions that the European Commission does not recognize as having &#8220;adequate&#8221; data protection laws, and recent legal developments in Europe have created complexity and compliance uncertainty regarding certain transfers of personal data from the EEA. For example, on July&#160;16, 2020, the Court of Justice of the European Union, or the CJEU, invalidated the EU-US Privacy Shield Framework, or Privacy Shield, under which personal data could be transferred from the EU and the EEA to United States entities who had self-certified under the Privacy Shield scheme. Moreover, it is uncertain whether the standard contractual clauses will also be invalidated by the European courts or legislature. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to A20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Additionally, following Brexit, companies will have to comply with the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. The relationship between the U.K. and the EU in relation to certain aspects of data protection law remains unclear, for example around how data can lawfully be transferred between each jurisdiction, which exposes us to further compliance risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Given the variability and evolving state of these laws, we face uncertainty as to the exact interpretation of the new requirements, and we may be unsuccessful in implementing all measures required by regulators or courts in their interpretation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that we will continue to face uncertainty as to whether our efforts to comply with evolving obligations under global data protection, privacy and security laws will be sufficient. Any failure or perceived failure by us to comply with applicable laws and regulations could result in reputational damage or proceedings or actions against us by governmental entities, individuals or others. These proceedings or actions could subject us to significant civil or criminal penalties and negative publicity, result in the delayed or halted transfer or confiscation of certain personal information, require us to change our business practices, increase our costs and materially harm our business, prospects, financial condition and results of operations. In addition, our current and future relationships with customers, vendors, pharmaceutical partners and other third parties could be negatively affected by any proceedings or actions against us or current or future data protection obligations imposed on them under applicable law, including the GDPR. In addition, a data breach affecting personal information, including health information, could result in significant legal and financial exposure and reputational damage that could potentially have an adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Business disruptions could seriously harm our future revenue, increase our costs and expenses, and have adverse effect on our financial condition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our operations and third parties with which we have collaborations could be subjected to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. In addition, we partially rely on our CROs for conducting research and development, and they may be affected by government shutdowns or withdrawn funding. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Although we maintain incident management and disaster response plans, in the event of a major disruption caused by a natural disaster or man-made problem, such as power disruptions, computer viruses, data security breaches or terrorism, we may be unable to continue our operations and may endure system interruptions, reputational harm, delays in our development activities, lengthy interruptions in service, breaches of data security and loss of critical data, any of which could adversely affect our business, results of operations and financial condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">If we fail to implement and maintain an effective system of internal controls, we may be unable to accurately or timely report our results of operations or prevent fraud, and investors&#8217; confidence and the market price of our ADSs may be materially and adversely affected.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The SEC, as required by Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, adopted rules requiring most public companies to include a management report on such company&#8217;s internal control over financial reporting in its annual report, which contains the management&#8217;s assessment of the effectiveness of the company&#8217;s internal control over financial reporting. In addition, when a company meets the SEC&#8217;s criteria, an independent registered public accounting firm must report on the effectiveness of the company&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a public company in the United States subject to the Sarbanes-Oxley Act of 2002. As described in our previous annual report of Form 20-F for the fiscal year ended December 31, 2020, we and our independent registered public accounting firm identified two material weaknesses in our internal control over financial reporting as of December 31, 2020. The material weaknesses identified relate to (i) our lack of sufficient and competent financial reporting and accounting personnel with appropriate knowledge of U.S. GAAP and SEC reporting and compliance requirements; and (ii) our lack of sufficient documented financial closing policies and procedures, specifically those related to period end expenses cut-off and accruals. For details, see &#8220;Item 15. Controls and Procedures&#8212;Remediation of Previously Reported Material Weaknesses in Internal Control over Financial Reporting.&#8221; As a result of these efforts, our management has concluded that our internal control over financial reporting as of December 31, 2021 was effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">However, we cannot assure you that in the future our management or, if applicable, our independent registered public accounting firm will not identify material weaknesses during the Section 404 of the Sarbanes-Oxley Act audit process. In addition, because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. If we fail to achieve and maintain an effective internal control environment, we could suffer material misstatements in our financial statements and fail to meet our reporting obligations, which would likely cause investors to lose confidence in our reported financial information. This could in turn limit our access to capital markets, harm our results of operations, and lead to a decline in the trading price of the ADSs. Additionally, ineffective internal control over financial reporting could expose us to increased risk of fraud or misuse of corporate assets and subject us to potential delisting from the stock exchange on which we list, regulatory investigations and civil or criminal sanctions. Furthermore, we have incurred and expect to continue to incur considerable costs and to use significant management time and the other resources in an effort to comply with Section 404 and other requirements of the Sarbanes-Oxley Act, which can significantly divert our management&#8217;s attention from operating our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we fail to achieve and maintain an effective internal control environment, we could suffer material misstatements in our financial statements and fail to meet our reporting obligations, which would likely cause investors to lose confidence in our reported financial information. This could in turn limit our access to capital markets, harm our results of operations, and lead to a decline in the trading price of our ADSs. Additionally, ineffective internal control over financial reporting could expose us to increased risk of fraud or misuse of corporate assets and subject us to potential delisting from the Nasdaq, regulatory investigations and civil or criminal sanctions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Risks Related to Our Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">It is difficult and costly to protect our proprietary rights and technology, and we may not be able to protect our intellectual property rights throughout the world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our commercial success will depend, in part, on our ability to obtain, maintain and defend patent and other intellectual property protection (including trademarks and trade secrets) with respect to our product candidates. We cannot be certain that patents will be issued or granted with respect to our patent applications that are currently pending, or that issued or granted patents will not later be found to be invalid and/or unenforceable, be interpreted in a manner that does not adequately protect our product candidates, or otherwise provide us with any competitive advantage. Additionally, the patent applications in respect of patents licensed under our in-license arrangements may not be issued or granted, and as a result, we may not be able to have adequate protection with respect to such patents.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The patent position of biotechnology and pharmaceutical companies is generally uncertain because it involves complex legal and factual considerations. Patent applications we have filed may not be granted or issued as valid enforceable patents. Moreover, some of our patents and patent applications may in the future be, co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owned interest in such patents or patent applications, such co-owners may be able to license or transfer their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects. As such, we do not know the degree of future protection that we will have on our product candidates and technology, if any, and a failure to obtain adequate intellectual property protection with respect to our product candidates could have a material adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Composition-of-matter patents on the active pharmaceutical ingredient are generally considered to be the strongest form of intellectual property protection for pharmaceutical products, as such patents provide protection without regard to any method of use. Method-of-use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our products for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#8220;off-label.&#8221; Although off-label prescriptions may infringe or contribute to the infringement of method-of use patents, the practice is common and such infringement is difficult to prevent or prosecute. We endeavor to seek composition-of-matter patent protection for all of our product candidates. Where appropriate, we also seek method-of-use patents and patents protecting other aspects of our product candidates, including processes for discovery and manufacturing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices in the PRC and abroad. For example, we may become involved in opposition, interference, derivation, inter partes review or other similar proceedings challenging our patent rights, and the outcome of any proceedings are highly uncertain. Such challenges may result in the patent claims of our owned or in-licensed patents being narrowed, invalidated or held unenforceable, which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours or otherwise provide us with a competitive advantage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Despite the measures we can take to increase our likelihood of obtaining patent and other intellectual property protections with respect to our product candidates, there can be no assurance that the existence, validity, enforceability, or scope of our intellectual property rights will not be challenged by a third party, or that we can obtain sufficient scope of claim in those patents to prevent a third party from competing against our product candidates. For example, in an infringement proceeding, a court may hold that patent rights or other intellectual property rights owned by us are invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the ground that our patent rights or other intellectual property rights do not cover the technology in question. An adverse result in any litigation proceedings could put our patent, as well as any patents that may issue in the future from our pending patent applications, at risk of being invalidated, held unenforceable or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, if we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the National Intellectual Property Administration of China, or NIPA, or the applicable foreign counterpart, or made a misleading statement, during prosecution. Although we believe that we have conducted our patent prosecution in accordance with all applicable duty of candor and in good faith, the outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Even if a defendant does not prevail on a legal assertion of invalidity and/or unenforceability, our patent claims may be construed in a manner that would limit our ability to enforce such claims against the defendant and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Third parties may also raise similar claims before administrative bodies in the PRC or abroad, even outside the context of litigation. Such mechanisms include ex parte re-examination, inter partes review, post-grant review, derivation and equivalent proceedings, such as opposition proceedings. Such legal proceedings could result in revocation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The outcome following legal assertions of invalidity and unenforceability can be unpredictable. With respect to the validity of our patents, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we may lose part or all of the patent protection on our product candidates. Any loss of patent protection could have a material adverse impact on one or more of our product candidates and our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our drug discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. We may also rely on trade secret protection as temporary protection for concepts that may be included in a future patent filing. However, trade secret protection will not protect us from innovations that a competitor develops independently of our proprietary know-how. If a competitor independently develops a technology that we protect as a trade secret and files a patent application on that technology, then we may not be able to patent that technology in the future, may require a license from the competitor to use our own know-how, and if the license is not available on commercially viable terms, then we may not be able to launch our product. Although we require our employees to assign their inventions to us, and require our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of different countries do not protect proprietary rights to the same extent or in the same manner as the laws of the PRC. We may encounter significant problems in protecting and defending our intellectual property both in the PRC and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, and this scenario could materially adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Moreover, trade secrets are difficult to protect, and we have limited control over the protection of trade secrets used by our collaborators and suppliers. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our information to competitors or use such information to compete with us. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. If our confidential or proprietary information is divulged to or acquired by third parties, including our competitors, our competitive position in the marketplace will be adversely affected and this would have a material adverse effect on our business.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain countries. The legal systems of certain countries do not favor the enforcement or protection of patents, trade secrets and other intellectual property, particularly those relating to pharmaceutical and biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in certain countries could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. We and our contractors and partners operate in certain countries that are at heightened risk of theft of technology, data and intellectual property through direct or indirect intrusion by private parties or international actors, including those affiliated with or controlled by state actors. Accordingly, our efforts to protect or enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in various countries could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. For example, patent reform legislation in the United States includes provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents via post-grant proceedings. The Leahy-Smith Act and any continuing changes in patent laws and regulations in various patent jurisdictions could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our or our collaboration partners&#8217; patent applications and the enforcement or defense of our or our collaboration partners&#8217; issued patents, all of which could harm our business, results of operations, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain due to changes in law and courts&#8217; interpretation of the law. For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. Other courts in the United States, for example, have heightened the bar for broadly claiming antibodies. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Additionally, there are periodic proposals for changes to the patent laws of China, United States and other countries that, if adopted, could impact our ability to enforce our proprietary technology. Depending on future actions by the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Similarly in China, intellectual property laws are constantly evolving, with efforts being made to improve intellectual property protection in China. For example, a Draft Amendment to the PRC Patent Law was released in January&#160;2019 and updated in July&#160;2020, which proposes introduction of patent term extensions to eligible innovative drug patents. If adopted, the terms of our Chinese patents may be eligible for extension and allow us to extend patent protection of our products, and the terms of the patents owned by third parties may also be extended, which may in turn affect our ability to commercialize our products candidates, if and when approved, without facing infringement risks. The length of any such patent term extension is uncertain. If we are required to delay commercialization for an extended period of time, technological advances may develop and new competitor products may be launched, which may render our product non-competitive. We also cannot guarantee that other changes to Chinese intellectual property laws would not have a negative impact on our intellectual property protection.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may not be successful in obtaining or maintaining necessary rights for our development pipeline through acquisitions and licensing deals.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire and maintain licenses or other rights to use these proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, or other intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations and prospects for growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, we may sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. These institutions may provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial condition could suffer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Licensing of intellectual property involves complex legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our right to sublicense patents and other rights to third parties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our right to transfer or assign the license; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If disputes over intellectual property that we license in the future prevent or impair our ability to maintain our licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, certain of our future agreements with third parties may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. For example, we may in the future enter into license agreements that are not assignable or transferable, or that require the licensor&#8217;s express consent in order for an assignment or transfer to take place.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful, and any unfavorable outcome from such litigation could limit our research and development activities and/or our ability to commercialize our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe our patent rights or misappropriate or otherwise violate our intellectual property rights. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming and divert the time and attention of our management and scientific personnel. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us, alleging that we infringed their patents. In addition, in a patent infringement proceeding, there is a risk that a court will decide that our asserted patents are invalid or unenforceable, in whole or in part, and that we do not have the right to stop the others from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the others from using the invention at issue on the grounds that our patents do not cover the alleged infringing activity or product. An adverse outcome in a litigation or proceeding involving our patents could limit our ability to assert our patents against those parties and other competitors, and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects, and financial condition. Similarly, if we assert trademark infringement claims, a court may determine that our asserted marks are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of our trademarks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In any litigation involving our intellectual property, the award of monetary damages we receive may not be commercially valuable or even sufficient to cover our cost of bringing such action. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a material adverse effect on the price of our ADSs. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Our commercial success depends significantly on our ability to operate without infringing upon, misappropriating or otherwise violating the intellectual property rights of third parties.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The life sciences industry is subject to rapid technological change and substantial litigation regarding patent and other intellectual property rights. Our potential competitors in both the PRC and abroad, may have substantially greater resources than us and are likely to make substantial investments in patent portfolios and competing technologies, and may apply for or obtain patents that could prevent, limit or otherwise interfere with our ability to make, use and sell our products. Numerous third-party patents exist in fields relating to our products and technologies, and it is difficult for industry participants, including us, to identify all third-party patent rights relevant to our products and technologies. Moreover, because some patent applications are maintained as confidential for a certain period of time, we cannot be certain that third parties have not filed patent applications that will cover our products and technologies if they issue as patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Patents could be issued to third parties that we may ultimately be found to infringe. Third parties may have or obtain valid and enforceable patents or proprietary rights that could block us from using our technology. Our failure to obtain or maintain a license from third parties to any technology that we require may materially harm our business, financial condition and results of operations. Furthermore, we would be exposed to a threat of litigation.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Third-party intellectual property right holders may also actively bring infringement or other intellectual property-related claims against us, even if we have received patent protection for our technologies, products, and services. Regardless of the merit of third parties claims against us for infringement, misappropriation or violations of their intellectual property rights, such third parties may seek and obtain injunctive or other equitable relief, which could effectively block our ability to perform clinical trials or develop, manufacture or sell our products. Further, if a patent infringement suit were brought against us, we could be forced to temporarily or permanently stop or delay our development or regulatory approval process or other activities that are the subject of such suit. Defense of these claims, even if such claims are resolved in our favor, could cause us to incur substantial expenses and be a substantial diversion of our employee resources even if we are ultimately successful. Any adverse ruling or perception of an adverse ruling in defending ourselves could have a material adverse impact on our cash position and stock price. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing, or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a material adverse effect on the price of our ADSs. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock. The occurrence of any of these events may have a material adverse effect on our business, results of operation, financial condition or cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Obtaining and maintaining patent protection depend on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent authorities, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The NIPA, and various foreign governmental patent agencies including the USPTO, JPO, and EPO require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application and prosecution process. Periodic maintenance fees, renewal fees, annuity fees, and various other governmental fees on patents and/or applications will be due to be paid to the NIPA and various other governmental patent agencies outside of China in several stages over the lifetime of the patents and/or applications. We employ reputable professionals and rely on such third parties to help us comply with these requirements and effect payment of these fees with respect to the patents and patent applications that we own. Noncompliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official communications within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case, which could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may not enter into invention assignment and confidentiality agreements with all of our employees and third parties and such agreements may not prevent ownership disputes or unauthorized disclosure of trade secrets and other proprietary information.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We rely in part upon unpatented or unpatentable trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position, which we seek to protect, in part, by entering into agreements, including confidentiality agreements and non-disclosure agreements, with parties that have a need for access to them, such as certain of our employees, consultants, academic institutions, corporate partners and, other third-party service providers. Nevertheless, there can be no guarantee that an employee or a third party will not make an unauthorized use or disclosure of our proprietary confidential information. This might happen intentionally or inadvertently. It is possible that a competitor will gain access to such information and make use of such information, and that our competitive position will be compromised, in spite of any legal action we might take against persons making such unauthorized disclosures. In addition, to the extent that our employees, consultants or contractors use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Trade secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants, contractors or business partners might intentionally or inadvertently disclose our trade secret information to competitors or our trade secrets may otherwise be misappropriated. Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming, and the outcome is unpredictable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We sometimes engage individuals or research institutions to conduct research relevant to our business. The ability of these individuals or research institutions to publish or otherwise publicly disclose data and other information generated during the course of their research is subject to certain contractual limitations. These contractual provisions may be insufficient or inadequate to protect our confidential information. If we do not apply for patent protection prior to such publication, or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized, which could adversely affect our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also seek to enter agreements with our employees and consultants that obligate them to assign any inventions created during their work for us to us. However, we may not obtain these agreements in all circumstances and the assignment of intellectual property under such agreements may not be self-executing. And it is possible that technology relevant to our business will be independently developed by a person that is not a party to such an agreement. Furthermore, if the employees and consultants who are parties to these agreements breach or violate the terms of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets and inventions through such breaches or violations. Any of the foregoing could have a material and adverse effect on our business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Some of our employees and consultants were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and our specific personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may be subject to claims that former employees, collaborators or other third parties have an interest in our patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Also, former employees may become employed by competitors who develop similar technology, and could assist the competitor in designing around our patents. While it is our policy to require our employees and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our and their assignment agreements may not be self-executing or may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or our ownership of our patents, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Intellectual property rights do not necessarily protect us from all potential threats to our competitive advantages.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to independently develop similar or alternative technologies or designs that are similar to our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or may in the future exclusively license, which could result in the patent applications not issuing or being invalidated after issuing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we might not have been the first to file patent applications covering certain of our inventions, which could result in the patent applications not issuing or being invalidated after issuing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our pending patent applications will not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents that we own or have exclusively licensed may not provide us with any competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive services and products for commercialization in our major markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may fail to develop additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may fail to apply for or obtain adequate intellectual property protection in all the jurisdictions in which we operate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business, for example by preventing us from commercializing one or more of our product candidates for one or more indications.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of the aforementioned threats to our competitive advantage could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Patent terms may not be sufficient to effectively protect our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In most countries in which we plan to file applications for patents, the term of an issued patent is generally 20 years from the earliest claimed filing date of the priority application to which a non-provisional patent application in the applicable country claims priority. Although various extensions may be available in various countries, the life of a patent and the protection it affords are limited. Even if patents covering our product candidates are obtained, we may be open to competition from other companies once our patent rights expire. Accordingly, given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Excluding any patent term adjustment and patent term extension, our currently issued patents are expected to expire from 2033 to 2034. As a result, our patent portfolio may not provide us with sufficient rights over a sufficient length of time to exclude others from commercializing products similar or identical to ours.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Uncertainty of the length of patent term extensions and data and market exclusivities for our pharmaceutical products could increase the risk of generic competition.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, the Federal Food, Drug, and Cosmetic Act, as amended by the law generally referred to as the &#8220;Hatch-Waxman Amendments,&#8221; provides the opportunity for patent-term restoration of up to five years to reflect patent term lost during certain portions of product development and the FDA regulatory review process. The Hatch-Waxman Amendments also have a process for patent linkage, pursuant to which FDA will stay approval of certain follow-on applications during the pendency of litigation between the follow-on applicant and the patent holder or licensee, generally for a period of 30 months. Finally, the Hatch-Waxman Amendments provide for statutory exclusivities that can prevent submission or approval of certain follow-on marketing applications. For example, federal law provides a five-year period of exclusivity within the United States to the first applicant to obtain approval of a new chemical entity (as defined) and three years of exclusivity protecting certain innovations to previously approved active ingredients where the applicant was required to conduct new clinical investigations to obtain approval for the modification. Similarly, the Orphan Drug Act provides seven years of market exclusivity for certain drugs to treat rare diseases, where FDA designates the product candidate as an orphan drug and the drug is approved for the designated orphan indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These provisions, designed to promote innovation, can prevent competing products from entering the market for a certain period of time after FDA grants marketing approval for the innovative product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In China, however, there is no currently effective law or regulation providing patent term extension, patent linkage, or data exclusivity (referred to as regulatory data protection). Therefore, a lower-cost generic drug can emerge onto the market much more quickly. Chinese regulators have set forth a framework for integrating patent linkage and data exclusivity into the Chinese regulatory regime, as well as for establishing a pilot program for patent term extension. To be implemented, this framework will require adoption of regulations. To date, the NMPA has issued several draft implementing regulations in this regard for public comment but no regulations have been formally issued. These factors result in weaker protection for us against generic competition in China than could be available to us in the United States until the relevant implementing regulations for extension, patent linkage, or data exclusivity are put into effect officially in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting and defending patents on our products in all countries throughout the world would be prohibitively expensive. We may also encounter difficulties in protecting and defending such rights in foreign jurisdictions. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the jurisdictions of the registration of our intellectual properties. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products. Our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in certain jurisdictions. The legal systems of many other countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents in such countries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We may not be able to protect and enforce our trademarks.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently hold issued trademark registrations and have trademark applications pending, any of which may be the subject of a governmental or third-party objection, which could prevent the registration or maintenance of the same. If we are unsuccessful in obtaining trademark protection for our primary brands, we may be required to change our brand names, which could materially adversely affect our business. Moreover, as our products mature, our reliance on our trademarks to differentiate us from our competitors will increase, and as a result, if we are unable to prevent third parties from adopting, registering or using trademarks and trade dress that infringe, dilute or otherwise violate our trademark rights, or engaging in conduct that constitutes unfair competition, defamation or other violation of our rights, our business could be materially adversely affected. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Risks Related to the ADSs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Our business and financial results, including our ability to raise capital or raise capital on favorable terms and the market price of our ADSs, may be adversely affected by the geopolitical factors arising in connection with Russia&#8217;s invasion of Ukraine, including particularly how countries like the United States and China choose to respond to this war. As a result, the value of our ADSs may significantly decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;">Our business and financial results, including our ability to raise capital or raise capital on favorable terms and the market price of our ADSs, may be adversely affected by the geopolitical factors arising in connection with Russia&#8217;s invasion of Ukraine. We do not conduct business in either Russia or Ukraine. However, our global operations expose us to geopolitical risks, including particularly here, how the United States and China choose to respond to the war between Ukraine and Russia. If this war continues, increases, or expands, or leads to continued political or economic instability, terrorist activity, or gives rise to further government actions such as sanctions or increased economic or political tensions between the United States and China, our business and financial results, including our ability to raise capital or raise capital on favorable terms and the market price of our ADSs, may be adversely impacted and the value of our ADSs may significantly decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">You may be subject to limitations on transfer of your ADSs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Your ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer or register transfers of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other reason in accordance with the terms of the deposit agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">The trading price of the ADSs is likely to be volatile, which could result in substantial losses to investors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The trading price of our ADSs ranged from US$3.50 to US$29.99 per ADS since the listing of ADSs on Nasdaq. The trading price of the ADSs is likely to be volatile and could fluctuate widely due to factors beyond our control. This may happen because of broad market and industry factors, including the performance and fluctuation of the market prices of other companies with business operations located mainly in China that have listed their securities in the United States. In addition to market and industry factors, the price and trading volume for the ADSs may be highly volatile for factors specific to our own operations, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our net revenues, earnings and cash flow;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of new investments, acquisitions, strategic partnerships, or joint ventures by us or our competitors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements of new products and services and expansions by us or our competitors;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in financial estimates by securities analysts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations in operating metrics;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">failure on our part to realize monetization opportunities as expected;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in revenues generated from our significant business partners;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additions or departures of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">release of lock-up or other transfer restrictions on our outstanding equity securities or sales of additional equity securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">detrimental negative publicity about us, our management, our competitors or our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory developments affecting us or our industry; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential litigation or regulatory investigations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any of these factors may result in large and sudden changes in the trading volume and price of the ADSs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the past, shareholders of public companies have often brought securities class action suits against those companies following periods of instability in the market price of their securities. If we were involved in a class action suit, it could divert a significant amount of our management&#8217;s attention and other resources from our business and operations and require us to incur significant expenses to defend the suit, which could harm our results of operations. Any such class action suit, whether or not successful, could harm our reputation and restrict our ability to raise capital in the future. In addition, if a claim is successfully made against us, we may be required to pay significant damages, which could have a material adverse effect on our financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We are an emerging growth company within the meaning of the Securities Act and may take advantage of certain reduced reporting requirements.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and we may take advantage of certain exemptions from requirements applicable to other public companies that are not emerging growth companies including, most significantly, not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002 for so long as we remain an emerging growth company. As a result, if we elect not to comply with such auditor attestation requirements, our investors may not have access to certain information they may deem important.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">If securities or industry analysts cease to publish research or reports about our business, or if they adversely change their recommendations regarding the ADSs, the market price for the ADSs and trading volume could decline.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The trading market for the ADSs will be influenced by research or reports that industry or securities analysts publish about our business. If one or more analysts who cover us downgrade the ADSs, the market price for the ADSs would likely decline. If one or more of these analysts cease to cover us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which, in turn, could cause the market price or trading volume for the ADSs to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">The sale or availability for sale, or perceived sale or availability for sale, of substantial amounts of the ADSs could adversely affect their market price.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Sales of substantial amounts of the ADSs in the public market, or the perception that these sales could occur, could adversely affect the market price of the ADSs and could materially impair our ability to raise capital through equity offerings in the future. The ADSs sold in our initial public offering are freely tradable by persons other than our &#8220;affiliates&#8221; without restriction or further registration under the Securities Act, and shares held by our existing shareholders may also be sold in the public market in the future subject to the restrictions in Rule&#160;144 and Rule&#160;701 under the Securities Act and the applicable lock-up agreements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Our memorandum and articles of association contain anti-takeover provisions that could have a material adverse effect on the rights of holders of our ordinary shares and the ADSs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have adopted amended and restated memorandum and articles of association. Our new memorandum and articles of association contain provisions to limit the ability of others to acquire control of our company or cause us to engage in change-of-control transactions. These provisions could have the effect of depriving our shareholders of an opportunity to sell their shares at a premium over prevailing market prices by discouraging third parties from seeking to obtain control of our company in a tender offer or similar transaction. Our board of directors has the authority, without further action by our shareholders, to issue preferred shares in one or more series and to fix their designations, powers, preferences, privileges, and relative participating, optional or special rights and the qualifications, limitations or restrictions, including dividend rights, conversion rights, voting rights, terms of redemption and liquidation preferences, any or all of which may be greater than the rights associated with our ordinary shares, including ordinary shares represented by ADSs. Preferred shares could be issued quickly with terms calculated to delay or prevent a change in control of our company or make removal of management more difficult. If our board of directors decides to issue preferred shares, the price of the ADSs may fall and the voting and other rights of the holders of our ordinary shares and the ADSs may be materially and adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">You must rely on the judgment of our management as to the use of the net proceeds from our initial public offering, and such use may not produce income or increase our ADS price.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management will have considerable discretion in the application of the net proceeds received by us. You will not have the opportunity, as part of your investment decision, to assess whether proceeds are being used appropriately. The net proceeds may be used for corporate purposes that do not improve our efforts to achieve or maintain profitability or increase our ADS price. The net proceeds from our initial public offering may be placed in investments that do not produce income or that lose value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We are entitled to amend the deposit agreement and to change the rights of ADS holders under the terms of such agreement, or to terminate the deposit agreement, without the prior consent of the ADS holders.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are entitled to amend the deposit agreement and to change the rights of the ADS holders under the terms of such agreement, without the prior consent of the ADS holders. We and the depositary may agree to amend the deposit agreement in any way we decide is necessary or advantageous to us. Amendments may reflect, among other things, operational changes in the ADS program, legal developments affecting ADSs or changes in the terms of our business relationship with the depositary. In the event that the terms of an amendment are disadvantageous to ADS holders, ADS holders will only receive 30 days&#8217; advance notice of the amendment, and no prior consent of the ADS holders is required under the deposit agreement. Furthermore, we may decide to terminate the ADS facility at any time for any reason. For example, terminations may occur when we decide to list our shares on a non-U.S. securities exchange and determine not to continue to sponsor an ADS facility or when we become the subject of a takeover or a going-private transaction. If the ADS facility is going to terminate, ADS holders will receive at least 90 days&#8217; prior notice, but no prior consent is required from them. Under the circumstances that we decide to make an amendment to the deposit agreement that is disadvantageous to ADS holders or terminate the deposit agreement, the ADS holders may choose to sell their ADSs or surrender their ADSs and become direct holders of the underlying ordinary shares, but will have no right to any compensation whatsoever.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">ADSs holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could result in less favorable outcomes to the plaintiff(s)&#160;in any such action.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The deposit agreement governing the ADSs representing our ordinary shares provides that, to the fullest extent permitted by law, ADS holders waive the right to a jury trial of any claim they may have against us or the depositary arising out of or relating to our shares, the ADSs or the deposit agreement, including any claim under the U.S. federal securities laws.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we or the depositary opposed a jury trial demand based on the waiver, the court would determine whether the waiver was enforceable based on the facts and circumstances of that case in accordance with the applicable state and federal law. To our knowledge, the enforceability of a contractual pre-dispute jury trial waiver in connection with claims arising under the federal securities laws has not been finally adjudicated by the United States Supreme Court. However, we believe that a contractual pre-dispute jury trial waiver provision is generally enforceable, including under the laws of the State of New York, which govern the deposit agreement, by a federal or state court in the City of New York, which has non-exclusive jurisdiction over matters arising under the deposit agreement. In determining whether to enforce a contractual pre-dispute jury trial waiver provision, courts will generally consider whether a party knowingly, intelligently and voluntarily waived the right to a jury trial. We believe that this is the case with respect to the deposit agreement and the ADSs. It is advisable that you consult legal counsel regarding the jury waiver provision before entering into the deposit agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you or any other holders or beneficial owners of ADSs bring a claim against us or the depositary in connection with matters arising under the deposit agreement or the ADSs, including claims under federal securities laws, you or such other holder or beneficial owner may not be entitled to a jury trial with respect to such claims, which may have the effect of limiting and discouraging lawsuits against us or the depositary. If a lawsuit is brought against us or the depositary under the deposit agreement, it may be heard only by a judge or justice of the applicable trial court, which would be conducted according to different civil procedures and may result in different outcomes than a trial by jury would have had, including results that could be less favorable to the plaintiff(s)&#160;in any such action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Nevertheless, if this jury trial waiver provision is not permitted by applicable law, an action could proceed under the terms of the deposit agreement with a jury trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">No condition, stipulation or provision of the deposit agreement or ADSs serves as a waiver by any holder or beneficial owner of ADSs or by us or the depositary of compliance with any substantive provision of the U.S. federal securities laws and the rules&#160;and regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">The voting rights of holders of ADSs are limited by the terms of the deposit agreement, and you may not be able to exercise your right to direct the voting of the underlying ordinary shares represented by your ADSs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Holders of ADSs do not have the same rights as our registered shareholders. As a holder of ADSs, you will not have any direct right to attend general meetings of our shareholders or to cast any votes at such meetings. You will only be able to exercise the voting rights attached to the ordinary shares underlying your ADSs indirectly by giving voting instructions to the depositary in accordance with the provisions of the deposit agreement. Where any matter is to be put to a vote at a general meeting, then upon receipt of your voting instructions, the depositary will try, as far as is practicable, to vote the underlying ordinary shares represented by your ADSs in accordance with your instructions. You will not be able to directly exercise your right to vote with respect to the underlying ordinary shares unless you cancel and withdraw the shares and become the registered holder of such shares prior to the record date for the general meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">When a general meeting is convened, you may not receive sufficient advance notice of the meeting to withdraw the ordinary shares represented by your ADSs and become the registered holder of such shares to allow you to attend the general meeting and to vote directly with respect to any specific matter or resolution to be considered and voted upon at the general meeting. In addition, under our post-offering memorandum and articles of association, for the purposes of determining those shareholders who are entitled to attend and vote at any general meeting, our directors may close our register of members and/or fix in advance a record date for such meeting, and such closure of our register of members or the setting of such a record date may prevent you from withdrawing the underlying ordinary shares represented by your ADSs and from becoming the registered holder of such shares prior to the record date, so that you would not be able to attend the general meeting or to vote directly. Where any matter is to be put to a vote at a general meeting, upon our instruction the depositary will notify you of the upcoming vote and will arrange to deliver our voting materials to you. We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the depositary to vote the underlying ordinary shares represented by your ADSs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for their manner of carrying out your voting instructions. This means that you may not be able to exercise your right to direct how the underlying ordinary shares represented by your ADSs are voted and you may have no legal remedy if the underlying ordinary shares represented by your ADSs are not voted as you requested. In addition, in your capacity as an ADS holder, you will not be able to call a shareholders&#8217; meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the deposit agreement, if you do not vote, the depositary may give us a discretionary proxy to vote the ordinary shares underlying the ADSs at shareholders&#8217; meetings if we have timely provided the depositary with notice of meeting and related voting materials and (i)&#160;we have instructed the depositary that we wish a discretionary proxy to be given, (ii)&#160;we have informed the depositary that there is no substantial opposition as to a matter to be voted on at the meeting, and (iii)&#160;a matter to be voted on at the meeting would not have a material adverse impact on shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The effect of this discretionary proxy is that you cannot prevent the underlying ordinary shares represented by the ADSs from being voted, except under the circumstances described above. This may make it more difficult for ADS holders to influence the management of the company. Holders of ordinary shares are not subject to this discretionary proxy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Because we do not expect to pay dividends in the foreseeable future, you must rely on price appreciation of the ADSs for return on your investment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently intend to retain most, if not all, of our available funds and any future earnings to fund the development and growth of our business. As a result, we do not expect to pay any cash dividends in the foreseeable future. Therefore, you should not rely on an investment in the ADSs as a source for any future dividend income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors has complete discretion as to whether to distribute dividends, subject to certain requirements of Cayman Islands law. In addition, our shareholders may, subject to the provisions of our articles of association, by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our directors. Under Cayman Islands law, a Cayman Islands company may pay a dividend out of either profit, retained earnings, or share premium account, provided that in no circumstances may a dividend be paid if this would result in the company being unable to pay its debts as they fall due in the ordinary course of business. Even if our board of directors decides to declare and pay dividends, the timing, amount and form of future dividends, if any, will depend on our future results of operations and cash flow, our capital requirements and surplus, the amount of distributions, if any, received by us from our subsidiary, our financial condition, contractual restrictions and other factors deemed relevant by our board of directors. Accordingly, the return on your investment in the ADSs will likely depend entirely upon any future price appreciation of the ADSs. There is no guarantee that the ADSs will appreciate in value or even maintain the price at which you purchased the ADSs. You may not realize a return on your investment in the ADSs and you may even lose your entire investment in the ADSs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">You may not receive dividends or other distributions on our ordinary shares and you may not receive any value for them, if it is illegal or impractical to make them available to you.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The depositary has agreed to pay to you the cash dividends or other distributions it or the custodian receives on ordinary shares or other deposited securities underlying the ADSs, after deducting its fees and expenses. You will receive these distributions in proportion to the number of ordinary shares your ADSs represent. However, the depositary is not responsible if it decides that it is unlawful or impractical to make a distribution available to any holders of ADSs. For example, it would be unlawful to make a distribution to a holder of ADSs if it consists of securities that require registration under the Securities Act of 1933 but that are not properly registered or distributed under an applicable exemption from registration. The depositary may also determine that it is not feasible to distribute certain property through the mail. Additionally, the value of certain distributions may be less than the cost of mailing them. In these cases, the depositary may determine not to distribute such property. We have no obligation to register under U.S. securities laws any ADSs, ordinary shares, rights or other securities received through such distributions. We also have no obligation to take any other action to permit the distribution of ADSs, ordinary shares, rights or anything else to holders of ADSs. This means that you may not receive distributions we make on our ordinary shares or any value for them if it is illegal or impractical for us to make them available to you. These restrictions may cause a material decline in the value of the ADSs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">You may experience dilution of your holdings due to the inability to participate in rights offerings.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may, from time to time, distribute rights to our shareholders, including rights to acquire securities. Under the deposit agreement, the depositary will not distribute rights to holders of ADSs unless the distribution and sale of rights and the securities to which these rights relate are either exempt from registration under the Securities Act with respect to all holders of ADSs, or are registered under the provisions of the Securities Act. The depositary may, but is not required to, attempt to sell these undistributed rights to third parties, and may allow the rights to lapse. We may be unable to establish an exemption from registration under the Securities Act, and we are under no obligation to file a registration statement with respect to these rights or underlying securities or to endeavor to have a registration statement declared effective. Accordingly, holders of ADSs may be unable to participate in our rights offerings and may experience dilution of their holdings as a result.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We will incur increased costs as a result of being a public company, particularly after we cease to qualify as an &#8220;emerging growth company.&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a public company and expect to incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, as well as rules&#160;subsequently implemented by the Securities and Exchange Commission, or the SEC, and the Nasdaq Global Market, impose various requirements on the corporate governance practices of public companies. As a company with less than US$1.07 billion in revenues for our last fiscal year, we qualify as an &#8220;emerging growth company&#8221; pursuant to the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other requirements that are otherwise applicable generally to public companies. These provisions include exemption from the auditor attestation requirement under Section&#160;404 of the Sarbanes-Oxley Act of 2002, or Section&#160;404, in the assessment of the emerging growth company&#8217;s internal control over financial reporting and permission to delay adopting new or revised accounting standards until such time as those standards apply to private companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect these rules&#160;and regulations to increase our legal and financial compliance costs and to make some corporate activities more time-consuming and costly. After we are no longer an &#8220;emerging growth company,&#8221; we expect to incur significant expenses and devote substantial management effort toward ensuring compliance with the requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002 and the other rules&#160;and regulations of the SEC. For example, as a result of becoming a public company, we will need to increase the number of independent directors and adopt policies regarding internal controls and disclosure controls and procedures. We also expect that operating as a public company will make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. In addition, we will incur additional costs associated with our public company reporting requirements. It may also be more difficult for us to find qualified persons to serve on our board of directors or as executive officers. We are currently evaluating and monitoring developments with respect to these rules&#160;and regulations, and we cannot predict or estimate with any degree of certainty the number of additional costs we may incur or the timing of such costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because we are incorporated under Cayman Islands law.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are an exempted company incorporated under the laws of the Cayman Islands with limited liability. Our corporate affairs are governed by our memorandum and articles of association, the Companies Act (as amended) of the Cayman Islands and the common law of the Cayman Islands. The rights of shareholders to take action against our directors, actions by our minority shareholders and the fiduciary duties of our directors to us under Cayman Islands law are to a large extent governed by the common law of the Cayman Islands. The common law of the Cayman Islands is derived in part from comparatively limited judicial precedent in the Cayman Islands as well as from the common law of England, the decisions of whose courts are of persuasive authority, but are not binding, on a court in the Cayman Islands. The rights of our shareholders and the fiduciary duties of our directors under Cayman Islands law are not as clearly established as they would be under statutes or judicial precedent in some jurisdictions in the United States. In particular, the Cayman Islands has a less developed body of securities laws than the United States. Some U.S. states, such as Delaware, have more fully developed and judicially interpreted bodies of corporate law than the Cayman Islands. In addition, Cayman Islands companies may not have the standing to initiate a shareholder derivative action in a federal court of the United States.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Shareholders of Cayman Islands exempted companies like us have no general rights under Cayman Islands law to inspect corporate records or to obtain copies of lists of shareholders of these companies. Our directors have discretion under our articles of association to determine whether or not, and under what conditions, our corporate records may be inspected by our shareholders, but are not obliged to make them available to our shareholders. This may make it more difficult for you to obtain the information needed to establish any facts necessary for a shareholder motion or to solicit proxies from other shareholders in connection with a proxy contest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of all of the above, our public shareholders may have more difficulties in protecting their interests in the face of actions taken by management, members of our board of directors or controlling shareholders than they would as public shareholders of a company incorporated in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Certain judgments obtained against us by our shareholders may not be enforceable.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a Cayman Islands exempted company and substantially all of our assets are located outside of the United States. Our current operations are primarily conducted in China. In addition, some of our current directors and officers are nationals and residents of countries other than the United States. Substantially all of the assets of these persons are located outside the United States. As a result, it may be difficult or impossible for you to bring an action against us or against these individuals in the United States in the event that you believe that your rights have been infringed under the U.S. federal securities laws or otherwise. Even if you are successful in bringing an action of this kind, the laws of the Cayman Islands and of China may render you unable to enforce a judgment against our assets or the assets of our directors and officers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">As an exempted company incorporated in the Cayman Islands, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from the Nasdaq listing standards; these practices may afford less protection to shareholders than they would enjoy if we complied fully with the Nasdaq listing standards.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a Cayman Islands exempted company listed on the Nasdaq Global Market, we are subject to the Nasdaq listing standards. However, Nasdaq rules permit a foreign private issuer like us to follow the corporate governance practices of its home country. Certain corporate governance practices in the Cayman Islands, which is our home country, may differ significantly from the Nasdaq listing standards. We have relied on and plan to rely on home country practice with respect to our corporate governance. For example, we do not plan to have a majority of independent directors serving on our board of directors or to establish a nominating committee and a compensation committee composed entirely of independent directors. In addition, we do not plan to seek shareholder approval in connection with certain transactions effecting securities issuance. We also do not plan to hold annual meeting of shareholders no later than one year after the end of fiscal year-end. For details, please refer to &#8220;Item 6. Directors, Senior Management and Employees&#8212;6.C. Board Practices&#8212;Board of Directors&#8221; and &#8220;Item 16G&#8212;Corporate Governance.&#8221; As a result, our shareholders may be afforded less protection than they would otherwise enjoy under the Nasdaq listing standards applicable to U.S. domestic issuers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">We are a foreign private issuer within the meaning of the rules&#160;under the Exchange Act, and as such we are exempt from certain provisions applicable to U.S. domestic public companies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because we qualify as a foreign private issuer under the Exchange Act, we are exempt from certain provisions of the securities rules&#160;and regulations in the United States that are applicable to U.S. domestic issuers, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rules&#160;under the Exchange Act requiring the filing with the SEC of quarterly reports on Form&#160;10-Q or current reports on Form&#160;8-K;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the selective disclosure rules&#160;by issuers of material nonpublic information under Regulation FD.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will be required to file an annual report on Form&#160;20-F within four months of the end of each fiscal year. In addition, we intend to publish a summary of our financial results on a semi-annually basis as press releases, distributed pursuant to the rules&#160;and regulations of the Nasdaq Global Market. Press releases relating to financial results and material events will also be furnished to the SEC on Form&#160;6-K. However, the information we are required to file with or furnish to the SEC will be less extensive and less timely compared to that required to be filed with the SEC by U.S. domestic issuers. As a result, you may not be afforded the same protections or information that would be made available to you were you investing in a U.S. domestic issuer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Although we believe we were not a passive foreign investment company, or PFIC, for 2021, due to our ADSs&#8217; price fluctuations there is a significant risk that we will be a PFIC for 2022 or any future taxable year, which could subject U.S. investors in our ADSs or ordinary shares to significant adverse U.S. federal income tax consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In general, a non-U.S. corporation will be a PFIC for any taxable year in which (i) 75% or more of its gross income consists of passive income, or the income test, or (ii) 50% or more of the average value of its assets (generally determined on a quarterly basis) consists of assets that produce, or are held for the production of, passive income, or the asset test. For purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the ordinary shares of another corporation is treated as if it held its proportionate share of the assets of the other corporation and received directly its proportionate share of the income of the other corporation. Passive income generally includes interest, dividends, gains from certain property transactions, rents and royalties (other than certain rents or royalties derived in the active conduct of a trade or business). Cash is generally a passive asset for PFIC purposes. Goodwill is an active asset under the PFIC rules to the extent attributable to activities that produce active income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The assets shown on our balance sheet are expected to consist primarily of cash and cash equivalents for the foreseeable future. Therefore, whether we will satisfy the asset test for any taxable year will depend largely on the value of our goodwill and on how quickly we utilize the cash in our business. We cannot give any assurance as to whether we will be a PFIC for any taxable year because (i) the value of our goodwill may be determined by reference to our market capitalization, which has been, and may continue to be, volatile, (ii) we expect to hold a significant amount of cash, and (iii) a company&#8217;s PFIC status is an annual factual determination that can be made only after the end of each taxable year and depends on the composition of its income and assets and the value of its assets from time to time.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Based on the average price of our ADSs during 2021, we believe that we were not a PFIC for our taxable year ended December 31, 2021.  However, while we hold a substantial amount of cash and cash equivalents our PFIC status for any taxable year will depend primarily on the average value of our goodwill.  Because our market capitalization has declined substantially since our initial public offering (including in recent months), if the value of our goodwill is determined by reference to our market capitalization there is a significant risk that we will be a PFIC for our taxable year 2022, and possibly future taxable years. In addition, prior to the commercialization of our product candidates, we could be a PFIC for any taxable year in which our interest and other investment income constitutes 75% or more of our total gross income. If we are a PFIC for any taxable year during which a U.S. investor owns our ADSs or ordinary shares, the U.S. taxpayer generally will be subject to adverse U.S. federal income tax consequences, including increased tax liability on disposition gains and &#8220;excess distributions,&#8221; and additional reporting requirements. This will generally continue to be the case even if we ceased to be a PFIC in a later taxable year, unless certain elections are made. See &#8220;Item 10 Additional Information&#8212;Taxation&#8212;Material U.S. Federal Income Tax Consequences&#8212;Passive Foreign Investment Company Rules.&#8221;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">If a U.S. person is treated as owning 10% or more of our stock by vote or value, such person may be subject to adverse U.S. federal income tax consequences.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a U.S. person is treated as owning (directly, indirectly or constructively) 10% or more of our stock (including our ADSs and ordinary shares) by value or voting power, such person generally will be treated as a &#8220;United States shareholder&#8221; with respect to each &#8220;controlled foreign corporation&#8221;, or CFC, in our group. A CFC is a non-U.S. corporation more than 50% of the stock (by voting power or value) of which is owned (directly, indirectly or constructively) by &#8220;United States shareholders.&#8221; We have not determined whether we are a CFC. However, even if we are not a CFC, under certain ownership attribution rules our non-U.S. subsidiaries could be treated as owned by our U.S. subsidiary and thus may be treated as CFCs. A United States shareholder of a CFC may be subject to additional U.S. federal income tax liabilities and reporting requirements. We do not intend to furnish to any information that may be necessary for United States shareholders, if any, to comply with the CFC rules. U.S. investors that may be treated for purposes of the CFC rules as owning 10% of our stock by voting power or value should consult their tax advisers regarding the potential application of these rules in their particular circumstances.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a62efc41_2b77_4b75_87aa_c0bf32e60712"></a><a id="ITEM4INFORMATIONONTHECOMPANY_682720"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 4. INFORMATION ON THE COMPANY</p><a id="_55c542b8_dfd5_4d96_80f6_68ad424cabdd"></a><a id="a4AHistoryandDevelopmentoftheCompany_695"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;">4.A. History and Development of the Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In February&#160;2011, Adagene Inc. was incorporated under the laws of the Cayman Islands as our offshore holding company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In December&#160;2011, we established Adagene (Hong Kong) Limited, or Adagene Hong Kong, a wholly-owned subsidiary incorporated under the laws of Hong Kong, as our intermediary holding company. In February&#160;2012, Adagene Hong Kong incorporated Adagene (Suzhou) Limited, or Adagene Suzhou, in China, through which we commenced our research and development activities in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In September&#160;2017, we established a wholly-owned subsidiary in the state of Delaware, the United States, Adagene Incorporated, to conduct our research and development activities in the United States to facilitate the discovery and development of product candidates and expand our global presence, we have further incorporated several subsidiaries overseas, such as Australia, Singapore and Switzerland.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a holding company and do not directly conduct any substantive business operations in the PRC. In addition to our R&amp;D activities in the United States, Australia and Singapore, we currently focus our business operations within the PRC through Adagene Suzhou. We (Adagene Inc.), however, hold certain intellectual properties and outsource certain research and development activities related to these intellectual properties to our subsidiaries. See &#8220;Item 3 Key Information&#8212;D. Risk Factors&#8212;Risks Related to Doing Business in the PRC.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2021, we completed an initial public offering in which we offered and sold an aggregate of 10,571,375 ordinary shares in the form of ADSs. Upon the initial public offering, all of our then issued and outstanding preferred shares were automatically converted into ordinary shares on a one-for-one basis. On February&#160;5, 2021, the ADSs began trading on the Nasdaq under the symbol &#8220;ADAG.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our corporate headquarters is located at 4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123, People&#8217;s Republic of China. Our San Diego office addresss is 10179 Huennekens Street Suite 103, San Diego, CA 92121. Our registered office is located at Vistra (Cayman) Limited, P. O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1 - 1205 Cayman Islands. Our telephone number is +86-512-8777-3632. Our agent for service of process in the United States is Cogency Global Inc., located at 122 East 42nd Street, 18th Floor, New York, NY 10168. Our corporate website is <i style="font-style:italic;">www.adagene.com</i>. The information contained on or that can be accessed through our website is not incorporated by reference into this annual report, and you should not consider information on our website to be part of this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The SEC maintains an internet site at <i style="font-style:italic;">www.sec.gov</i> that contains reports, information statements, and other information regarding issuers that file electronically with the SEC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Recent Regulatory Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Cybersecurity Review Measures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 28, 2021, the Cyberspace Administration of China, or the CAC, and 12 other relevant PRC government authorities published the amended Cybersecurity Review Measures, or the Cybersecurity Review Measures, which went on February 15, 2022 and supersede and replace the current Cybersecurity Review Measures previously promulgated on April 13, 2020. The Cybersecurity Review Measures provide that the purchase of network products and services by a &#8220;critical information infrastructure operator&#8221; and the data processing activities of a &#8220;network platform operator&#8221; that affect or may affect national security shall be subject to the cybersecurity review. Furthermore, if a &#8220;network platform operator&#8221; that possesses personal information of more than one million users intends to go public in a foreign country, it must apply for a cybersecurity review with the Cybersecurity Review Office. In addition, the relevant PRC governmental authorities may initiate cybersecurity review if they determine certain network products, services, or data processing activities affect or may affect national security.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, on November 14, 2021, the CAC released the Regulations for the Administration of Network Data Security (Draft for Comment), or the Draft Data Security Regulations, for public comments. The Draft Data Security Regulations provide that (i) a data processor who processes personal information of more than one million individuals must complete a cybersecurity review if it intends to be listed in a foreign country, and (ii) a data processor who carries out other data processing activities which affect or may affect national security should also complete the cybersecurity review. The Draft Data Security Regulations provide a broad definition of &#8220;data processing activities&#8221;, including collection, storage, usage, processing, transfer, provision, publication, deletion and other activities, which covers the entire life cycle of data processing. The Draft Data Security Regulations also provide a broad definition of &#8220;data processors&#8221; as individuals and entities that may autonomously determine the purpose and method of data processing activities. In addition, the Draft Data Security Regulations require data processors who process important data or whose securities are listed outside of China to carry out annual data security assessment either by itself or through a third party data security service provider and submit the assessment report to a local agency of the CAC. See &#8220;Item 4. Information of the Company&#8212;4.B. Business Overview&#8212;Regulation&#8212;Other PRC Government Regulations&#8212; Regulations on Information Security and Data Protection&#8221; for detailed discussion. As advised by our PRC legal counsel, Tian Yuan Law Firm, the Draft Data Security Regulations were released for public comment only with the deadline of submitting public comments or opinions by December 13, 2021, and its provisions and anticipated adoption or effective date are subject to changes and thus its interpretation and implementation remain substantially uncertain. We cannot predict the impact of the Draft Data Security Regulations, if any, at this stage, and we will closely monitor and assess any development in the rule-making process. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As advised by our PRC legal counsel, Tian Yuan Law Firm, given the nature of our business, since we do not possess or process personal information of more than one million users/individuals, and we do not believe we are a &#8220;critical information infrastructure operator&#8221;, &#8220;network platform operator&#8221; or a data processor whose purchase of network products and services or data processing activities affect or may affect national security, the listing of our ADSs on the Nasdaq and future potential offering of our ADSs will not be subject to the cybersecurity review process under the Cybersecurity Review Measures, although we cannot guarantee that the relevant PRC regulatory authority will agree with our interpretation. Currently, the Cybersecurity Review Measures and the Draft Data Security Regulations have not materially affected our business and operations, but in anticipation of the strengthened implementation of cybersecurity laws and regulations and the continued expansion of our business, we face potential risks if we are deemed as a critical information infrastructure operator, a network platform operator or data processing operator under the PRC cybersecurity laws and regulations. In such case, we must fulfill certain obligations as required under the PRC cybersecurity laws and regulations, including, among others, storing personal information and other important data collected and produced within the PRC territory as we advance our drug discovery pipelines as part of our future operations in China, and we may be subject to lengthy cybersecurity review, annual data security assessment and other enhanced regulatory requirements when purchasing network products and services or conducting other data processing activities. We may face challenges in addressing such enhanced regulatory requirements and be required to make necessary changes to our internal policies and practices in data privacy and cybersecurity matters. As advised by our PRC legal counsel, Tian Yuan Law Firm, as of the date of this annual report, no detailed rules or implementation of the Cybersecurity Review Measures have been issued by the CAC and the Draft Data Security Regulations were only released for public comments, and the PRC governmental authorities have broad discretion in the interpretation and enforcement of these laws and regulations. It also remains uncertain whether the future regulatory changes will impose additional restrictions on companies like us. We cannot predict the impact of the Cybersecurity Review Measures and/or the Draft Data Security Regulations, if any, at this stage, and we will closely monitor and assess any development in the rule-making process. If the future enacted laws and regulations, including the enacted version of the data security regulations mandate clearance of cybersecurity review and other specific actions to be completed by companies like us before we are able to complete this offering, we will face uncertainties as to whether such clearance and/or other specific actions can be timely obtained or completed, or at all. If we are not able to comply with the cybersecurity and data privacy requirements in a timely manner, or at all, we may be subject to government enforcement actions and investigations, fines, penalties, or suspension of our non-compliant operations, among other sanctions, which could materially and adversely affect our business and results of operations. As of the date of this annual report, we have not been involved in any investigation on cybersecurity review made by the CAC on such basis, and we have not received any inquiry, notice, warning, or sanction in such respect. We have been making continuous efforts to comply with the relevant cybersecurity and data protection laws and regulations of the PRC, and will endeavor to comply with any updated applicable laws, regulations or guidelines as issued by any relevant regulatory authority in the PRC. See &#8220;Item 3 Key Information&#8212;3.D.Risk Factors&#8212;Risks Related to Doing Business in the PRC&#8212;Failure to comply with existing or future laws and regulations related to privacy or data security could lead to government enforcement actions, which could include civil or criminal fines or penalties, investigation or sanction by regulatory authorities, private litigation, other liabilities, and/or adverse publicity.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Potential CSRC Approval Required for the Listing of our ADSs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 24, 2021, the CSRC published the Provisions of the State Council on the Administration of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments), and Administrative Measures for the Filing of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments), or collectively, the Draft Overseas Listing Regulations, which set out the new regulatory requirements and filing procedures for Chinese companies seeking direct or indirect listing in overseas markets. The Draft </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Overseas Listing Regulations, among others, stipulate that (i) Chinese companies that seek to offer and list securities in overseas markets directly or indirectly shall fulfill the filing procedures with and report relevant information to the CSRC, (ii) in the context of an initial public offering, an initial filing shall be submitted within three (3) working days after the application for an initial public offering is submitted, and a second filing shall be submitted after the listing is completed, and (iii) in the context of follow-on offering after the completion of the initial public offering, an filing shall be submitted within three (3) working days after the completion of the offering or within three (3) working days from the date of the first announcement of the transaction depending on the purpose for which the follow-on offering are conducted. Moreover, an overseas offering and listing is prohibited under circumstances if (i) it is prohibited by PRC laws, (ii) it may constitute a threat to or endanger national security as reviewed and determined by competent PRC authorities, (iii) it has material ownership disputes over equity, major assets, and core technology, (iv) in recent three years, the Chinese operating entities, and their controlling shareholders and actual controllers have committed relevant prescribed criminal offenses or are currently under investigations for suspicion of criminal offenses or major violations, (v) the directors, supervisors, or senior executives have been subject to administrative punishment for severe violations, or are currently under investigations for suspicion of criminal offenses or major violations, or (vi) it has other circumstances as prescribed by the State Council. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Draft Overseas Listing Regulations, among others, stipulate that if the issuer meets the following conditions, its offering and listing shall be determined as an &#8220;indirect overseas offering and listing by a Chinese company&#8221; and is therefore subject to the filing requirement: (1) the revenues, profits, total assets or net assets of the Chinese operating entities in the most recent financial year accounts for more than 50% of the corresponding data in the issuer&#8217;s audited consolidated financial statements for the same period; (2) the majority of senior management in charge of business operation are Chinese citizens or have domicile in PRC, and its principal place of business is located in PRC or main business activities are conducted in PRC. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Draft Overseas Listing Regulations, if we failed to complete the filing procedures with the CSRC for our future offering or fell within any of the circumstances where our current or proposed future listing overseas is prohibited by the State Council, we may be subject to penalties, sanctions and fines imposed by the CSRC and relevant departments of the State Council. In severe circumstances, the business of our PRC subsidiaries may be ordered to suspend and their business qualifications and licenses may be revoked. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As advised by our PRC legal counsel, Tian Yuan Law Firm, the Draft Overseas Listing Regulations were released only for soliciting public comment as of the date of this annual report and their provisions and anticipated adoption or effective date are subject to changes and thus their interpretation and implementation remain substantially uncertain, we cannot predict the impact of the Draft Overseas Listing Regulations on this Offering, if any, at this stage, or guarantee that we will be able to satisfy the scrutinized and new regulatory requirements in case they were adopted in the current form</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, On July 6, 2021, certain PRC regulatory authorities issued Opinions on Strictly Cracking Down on Illegal Securities Activities, which emphasized the need to strengthen regulation over illegal securities activities and supervision on overseas listings by China-based companies and propose to take effective measures, such as promoting the development of relevant regulatory systems to deal with the risks and incidents faced by China-based overseas-listed companies. There are still uncertainties regarding the interpretation and implementation of these opinions, Draft Overseas Listing Regulations and further explanations or detailed rules and regulations with respect to these opinions may be issued in the future, which may impose additional requirements on us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of the date of this annual report, no official guidance and related implementation rules have been issued in relation to these recently issued opinions and the interpretation and implementation of these opinions remain unclear at this stage. We cannot assure you that we will not be required to obtain the approval of the CSRC or of potentially other regulatory authorities to maintain the listing status of our ADSs on the Nasdaq or to conduct offerings of securities in the future. We have been closely monitoring regulatory developments in China regarding any necessary approvals from the CSRC, the CAC, or other PRC regulatory authorities required for overseas Listings. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of the date of this annual report, we have not received any inquiry, notice, warning, sanctions or regulatory objection from the CSRC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Material Licenses and Approvals </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our PRC subsidiary has obtained all material licenses and approvals required for our operations in China. For details of our material licenses and approvals, see &#8220;Item 4. Information of the Company&#8212;4.B. Business Overview&#8212;Material Licenses and Approvals.&#8221; For risks relating to licenses and approvals required for our operations in China, see &#8220;Item 3. Key Information&#8212;3.D. Risk Factors&#8212;Risks Related to Doing Business in the PRC,&#8221; &#8220;&#8212;Risks Related to Clinical Development of Our Product Candidates,&#8221; and &#8220;&#8212;Risks Related to Obtaining Regulatory Approval of Our Drug Candidates.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Transfer of Funds and Other Assets </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under relevant PRC laws and regulations, we are permitted to remit funds to Adagene Suzhou through loans, capital contributions or as payment of considerations for the services rendered. In 2019, 2020 and 2021, Adagene Inc. made payments of US$13.1 million, US$15.5 million and US$30.0 million, respectively, in cash to Adagene Suzhou as consideration for providing services associated with research and development activities related to those intellectual properties owned by Adagene Inc. There were no intercompany loans provided by Adagene Inc. to Adagene Suzhou during the years ended and as of December 31, 2019, 2020 and 2021. In addition, as advised by our PRC legal counsel, Tian Yuan Law Firm, Adagene Suzhou is able to mark up and charge to Adagene Inc., its ultimate parent, for providing services associated with research and development activities related to those intellectual properties owned by Adagene Inc. and Adagene Inc. is able to make cash payments to Adagene Suzhou for considerations of such services. In the future, cash proceeds raised from overseas financing activities, including this offering, may be transferred by Adagene Inc., the Cayman holding company, (i) through Adagene (Hong Kong) Limited, our Hong Kong subsidiary, to Adagene Suzhou, our PRC subsidiary, and (ii) to Adagene Incorporated, our U.S. subsidiary, via capital contribution, shareholder loans or consideration for the services rendered, as the case may be. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other than the above disclosed transfer of funds, we did not transfer any type of assets between Adagene Suzhou and other Adagene subsidiaries in 2019, 2020 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Restrictions on Foreign Exchange and the Ability to Transfer Cash between Entities, Across Borders and to U.S. Investors  </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we become profitable, Adagene Inc.&#8217;s ability to pay dividends, if any, to the shareholders and ADS investors and to service any debt it may incur will depend upon dividends paid by our PRC and U.S. subsidiaries. Under the PRC laws and regulations, our PRC subsidiary is subject to certain restrictions with respect to paying dividends or otherwise transferring any of their net assets offshore to Adagene Inc. In particular, under the current effective PRC laws and regulations, dividends may be paid only out of distributable profits. Distributable profits are the net profit as determined under PRC GAAP, less any recovery of accumulated losses and appropriations to statutory and other reserves required to be made. Our PRC subsidiary shall appropriate 10% of the net profits as reported in its respective statutory financial statements (after offsetting any prior year&#8217;s losses) to the statutory surplus reserves until such reserves have reached 50% of its respective registered capital. In addition, the EIT Law and its implementation rules provide that a withholding tax rate of up to 10% will be applicable to dividends payable by Chinese companies to non-PRC-resident enterprises unless otherwise exempted or reduced according to treaties or arrangements between the PRC central government and governments of other countries or regions where the non-PRC-resident enterprises are incorporated. See &#8220;Item 3.D.Risk Factors&#8212;Risks Related to Doing Business in the PRC&#8212;We may rely on dividends and other distributions on equity paid by our PRC subsidiary to fund any cash and financing requirements we may have, and any limitation on the ability of our PRC subsidiary to make payments to us could have a material and adverse effect on our ability to conduct our business.&#8221; Further, if any of our subsidiaries incurs debt on its own behalf in the future, the instruments governing such debt may also restrict its ability to pay dividends ultimately to Adagene Inc. As a result, our PRC subsidiary may not have sufficient, or any, distributable profits to pay dividends to us in the near future. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Furthermore, if certain procedural requirements are satisfied, the payment of current account items, including profit distributions and trade and service related foreign exchange transactions, can be made in foreign currencies without prior approval from State Administration of Foreign Exchange (&#8220;SAFE&#8221;) or its local branches. However, where RMB is to be converted into foreign currency and remitted out of China to pay capital expenses, such as the repayment of loans denominated in foreign currencies, approval from or registration with competent government authorities or its authorized banks is required. The PRC government may take measures at its discretion from time to time to restrict access to foreign currencies for current account or capital account transactions. If the foreign exchange control system prevents us from obtaining sufficient foreign currencies to satisfy our foreign currency demands, we may not be able to pay dividends in foreign currencies to our offshore intermediary holding companies or ultimate parent company, and therefore, our shareholders or investors in our ADSs. Further, we cannot assure you that new regulations or policies will not be promulgated in the future, which may further restrict the remittance of RMB into or out of the PRC. We cannot assure you, in light of the restrictions in place, or any amendment to be made from time to time, that our current or future PRC subsidiaries will be able to satisfy their respective payment obligations that are denominated in foreign currencies, including the remittance of dividends outside of the PRC. See &#8220;Item 4 Information on the Company&#8212;PRC Regulation &#8212;Regulations on Foreign Exchange and Dividend Distribution&#8221; for detailed discussion.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For PRC and United States federal income tax consideration of an investment in the ADSs, see &#8220;Item 10. Additional Information&#8212;10.E. Taxation.&#8221;</p><a id="_e9f66384_af54_41a4_9a81_989a046ea228"></a><a id="a4BBusinessOverview_294009"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">4.B. Business Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">OVERVIEW</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a platform-driven, clinical-stage biopharmaceutical company transforming the discovery and development of novel antibody-based cancer immunotherapies. We are combining computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by our proprietary Dynamic Precision Library (DPL) platform, which fuels our NEObody&#8482;, SAFEbody<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and POWERbody&#8482; technologies, we are developing a highly differentiated pipeline of novel immunotherapies. We have forged strategic collaborations with reputable global partners that leverage our technology in multiple approaches at the vanguard of science.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We aim to push the boundaries of antibody discovery and engineering through the precise design, construction, and selection of antibody product candidates intractable to traditional antibody technology. We have pioneered a dynamic antibody technology interface to harness the conformational diversity of antibodies, which enlarges epitope sampling of a given drug target for differentiated therapeutic antibody development. Additionally, we have a proprietary precision masking technology and specialized antibody engineering capabilities which enable us to design therapeutics with unique features.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Dynamic Precision Library (DPL) fuels our three antibody technology platforms, which can be used alone or together to create novel, differentiated antibody-based therapeutic candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The NEObody technology platform is a fully synthetic phage display and yeast display-based antibody discovery technology, which we believe is differentiated from other synthetic antibody technologies through its innovative designs and precise constructions. NEObody technology enables the generation of antibodies designed with dynamic binding sites that adapt kinetically to unique epitopes, triggering a novel MOA. The species cross-reactive antibodies generated by NEObody technology not only have the potential to reveal new biological functions of the targets, but also facilitate preclinical studies using various immune system intact animal models, resulting in high fidelity translation from preclinical to clinical studies. We refer to antibodies generated by our NEObody technology as NEObodies.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:246.02pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The SAFEbody technology platform is designed to mask an antibody binding interface with a masking motif, which then prevents an antibody from binding to its target in healthy tissues, minimizing on target, off tumor toxicities. The masking motif is designed to activate, or unmask, the antibody to allow binding in the tumor microenvironment, or TME, where certain activation conditions such as a protease is upregulated as compared to healthy tissues, allowing the antibody to bind to its target for tumor killing. Our SAFEbody enabled therapeutic candidates are therefore designed to be activated predominantly in the TME while remaining largely in an inactive state in healthy tissues. Our SAFEbody technology can be applied to mask the binding sites of any antibodies including but not limited to NEObodies. We refer to such masked antibodies as SAFEbodies. Notably, SAFEbody technology can be applied to our NEObodies, such as what we did with ADG116 to potentially achieve an increased therapeutic index with ADG126. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The POWERbody technology platform enables the creation of new versions of antibodies, which may be bispecific T-cell engagers, or TCEs, or Fc-engineered antibodies, antibody-drug conjugates, or ADCs, or antibodies that are designed to reach beyond the therapeutic potency of traditional monospecific antibodies. Our POWERbody candidates incorporate SAFEbody precision masking technology and are designed to improve antitumor activity while maintaining the enhanced safety profile. As an example, we have developed bispecific TCEs with either a CD3 or a CD28 arm and demonstrated the ability to combine them together for potentially safe and durable immunotherapies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our AI-powered technology allows us to engineer and select species cross-reactive antibodies designed to dynamically adapt to unique and evolutionally conserved epitopes. We believe that comprehensive <i style="font-style:italic;">in vivo</i> preclinical evaluations using these species cross-reactive antibodies are the key to assess the efficacy and safety potential of tailor-made antibody candidates before progressing them into lengthy and costly clinical trials. Our NEObody, SAFEbody and POWERbody technology platforms are all designed to facilitate favorable druggability, manageable CMC attributes, and reduced immunogenicity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The figure below shows how our NEObody, SAFEbody, and POWERbody technologies are inter-connected with our DPL and utilized for the building of our product pipeline of mono- and combination immunotherapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="adag-20211231x20f002.jpg" alt="Graphic" style="display:inline-block;height:245.52pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:241.47pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:241.54pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our DPL Platform fuels three antibody technology platforms, which can be used alone or together to create novel, differentiated antibody-based therapeutic candidates. Antibodies generated by NEObody technology are designed with dynamic binding sites that adapt kinetically to unique epitopes, thereby triggering a novel MOA. SAFEbody technology is designed to address safety and tolerability challenges associated with many antibody therapeutics by using precision masking technology to shield the binding domain of the biologic therapy. Through activation in the TME, this allows for tumor-specific targeting of antibodies, while minimizing on-target off-tumor toxicity in healthy tissues. POWERbody candidates are designed to unleash the efficacy of a therapeutic through Fc-engineering, drug conjugation, or T-cell engagement, while securing safety by precision masking with SAFEbody technology. Thus, POWERbody candidates also incorporate SAFEbody precision masking technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Our Robust, Transformative Pipeline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">By leveraging our proprietary DPL platform and three platform technologies, we have developed a robust pipeline of innovative product candidates in various stages of development, ranging from research and discovery to preclinical and clinical development. Our highly differentiated and wholly-owned clinical-stage pipeline consists of two anti-CTLA-4 antibodies ADG116 (NEObody) and ADG126 (SAFEbody), and an anti-CD137 antibody, ADG106 (NEObody). All three candidates are in Phase 1b/2 clinical evaluation in single agent and/or combination clinical trials designed to evaluate safety and preliminary efficacy. We also have a robust preclinical pipeline of five programs in IND-enabling studies, including a masked, Fc engineered anti-CD137 POWERbody and a masked anti-CD47 SAFEbody, which are both on track for clinical development, as well as over 50 programs in various stages of discovery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In addition, we have out-licensed the Greater China rights of ADG104, an anti-PD-L1 mAb currently in Phase 2 clinical development, to Sanjin, and the Greater China rights of ADG125, a novel anti-CSF-1R mAb in Phase 1 development, to Dragon Boat Biopharmaceuticals.  We have the right to apply for the patents derived from our core and key technologies pertaining to ADG104 and ADG125 in the rest of the world, where we retain a majority of the economic benefits. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The following chart provides an overview of the status of each of our wholly-owned clinical and pre-clinical programs for which we have global rights:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="adag-20211231x20f003.jpg" alt="Graphic" style="display:inline-block;height:240.89pt;left:0%;padding-bottom:0.65pt;position:relative;top:0pt;width:522.62pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have deployed our NEObody and SAFEbody technology platforms to develop our three wholly-owned clinical candidates, ADG116, ADG126, ADG106, which are in ongoing Phase 1b/2 clinical evaluation as monotherapy and in combination with other targeted therapies:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">ADG116 is a fully human anti-CTLA-4 NEObody, which binds to a novel epitope of CTLA-4 different from ipilimumab, the only CTLA-4 mAb approved globally. The dynamic interface of ADG116 enables not only its species cross-reactivity with human, cynomolgus monkey, and mouse CTLA-4 for preclinical studies, but also its dynamic engagement on a unique epitope of CTLA-4 to trigger a novel MOA distinct from ipilimumab by softer ligand blocking and stronger regulatory T-cell depletion via strong antibody-dependent cellular cytotoxicity (ADCC). ADG116 is designed to overcome the safety challenges of existing CTLA-4 therapeutics,  and it has shown in robust preclinical studies and clinical evaluation to have an improved safety profile and early efficacy activity, including dose-dependent T-cell activation and tumor suppression in treatment-resistant &#8220;cold&#8221; and &#8220;warm&#8221; tumors such as pancreatic, ovarian and renal cell cancers.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ADG126 is a fully human anti-CTLA-4 SAFEbody, which applies SAFEbody precision masking technology to ADG116 to further enhance safety and efficacy profiles by masking the antibody binding site which is then conditionally activated in the TME to limit on target, off tumor toxicity. With the SAFEbody precision masking technology, ADG126 is designed to overcome the safety challenges of existing CTLA-4 therapeutics, and optimize efficacy by achieving doses that may unlock the full potential of CTLA-4 as a proven target for strong ADCC-mediated Treg depletion in the TME. ADG126 has consistently shown a potential best-in-class profile, which is supported by preclinical evaluation, including GLP toxicology data, and enabled by the broad species cross-reactivity of ADG126. In clinic, no dose-limiting toxicities have been observed as of March 31, 2022. Patients have received multiple cycles with continuous dosing, and favorable pharmacokinetic and pharmacodynamic activity compared to ADG116 has been observed.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ADG106 is a fully human ligand-blocking agonistic anti-CD137 NEObody, which targets a unique epitope of CD137 that is different from other anti-CD137 antibodies currently under clinical development. Preclinical and clinical studies show that ADG106 is capable of binding to CD137 in a fashion similar to its natural ligand, CD137L. ADG106 is designed to balance safety and efficacy to overcome the known safety challenges of anti-CD137 targeted therapy, particularly when used in combination with anti-PD-1 or anti-CTLA-4 therapies. In clinic, ADG106 has shown a well-tolerated safety profile and evidence of single-agent efficacy, while combination therapy development is supported by the combined findings of our phase 1 monotherapy trials, data from extensive preclinical studies, as well as PD marker-based modelling from prior and ongoing trials.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Additionally, we have identified two of our five preclinical programs that are currently in IND-enabling studies as candidates for the company&#8217;s next two IND or equivalent submissions and for subsequent advancement into clinical trials: </span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ADG206 is a masked, Fc engineered anti-CD137 agonistic POWERbody. ADG206 incorporates SAFEbody</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> precision masking technology and is designed to achieve improved safety and efficacy. We have conducted preclinical studies demonstrating that the FcgR-mediated crosslinking of ADG206 enhances T-cell responses and antitumor activity, while the SAFEbody masking technology secures its activation only in the TME to limit on-target off-tumor toxicities.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ADG153 is a masked anti-CD47 IgG1 SAFEbody. ADG153 is differentiated by its strong ADCC and antibody-dependent cellular phagocytosis (ADCP) activity designed to realize the full potential of anti-CD47 therapy for both hematologic and solid tumor indications. ADG153 incorporates SAFEbody masking technology to limit on-target off-tumor toxicities and overcome the known safety liabilities of anti-CD47 therapies. We have conducted preclinical studies showing that ADG153 has potent anti-tumor activity, without inducing human hemagglutination, while minimizing anemia-related and antigen sink liabilities.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Our Global Partnerships and Collaborations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have a successful track record of collaborations and partnerships with global biopharmaceutical companies and academic institutions. So far, we have established multiple collaborations and we continue to seek partnership opportunities where we can leverage our proprietary technology platform to develop novel antibodies to address unmet medical needs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We enter into collaborations with biotechnology and pharmaceutical companies to leverage the power of our technology platforms, creating a network of potential future revenue streams that complement future long-term value from our wholly-owned pipeline. These collaborations include both technology licensing agreements and outlicensing of product candidates, both of which allow us to retain significant future participation in product sales through royalties paid on net sales. In the future, we may also enter into strategic collaborations which may involve joint development for our preclinical and/or clinical assets to both accelerate the path to clinic and drive global commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have entered into technology licensing agreements with Sanofi, Exelixis and ADC Therapeutics to develop antibody-based therapeutics against tumor targets using our SAFEbody technology. We have also out-licensed the Greater China rights for two antibody candidates to Sanjin and its affiliates. Additionally, we have leveraged our DPL technology platform and antibody discovery and engineering capabilities in discovery collaborations with the U.S. National Institutes of Health (NIH), Mitsubishi Tanabe, Celgene (now BMS), GSK and Hengrui. To further advance our pipeline, we have also put in place various clinical collaborations, including clinical collaborations and supply agreements with Merck who will provide pembrolizumab for certain of our combination clinical trials, and an agreement with research organizations in Singapore for an investigator-initiated trial of our ADG106 clinical candidate in combination with nivolumab.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Our collaborations empower our growth by generating cash flow and revenues that partially offset expenditures on our internal research and development programs, expand our knowledge base regarding antibody technology across multiple targets and antibodies provided by our partners, and provide us with future joint development opportunities.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">OUR CLINICAL PIPELINE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">By leveraging our proprietary DPL platform and three platform technologies, we have developed a robust pipeline of innovative product candidates in various stages of development, ranging from research and discovery to preclinical and clinical development. Our highly differentiated pipeline consists of our lead clinical-stage candidates, ADG116, ADG126 and ADG106. We also have a robust preclinical pipeline in various stages of development. In addition, we have out-licensed the Greater China rights of ADG104, an anti-PD-L1 mAb in Phase 2 development, to our partner Sanjin, and the Greater China rights of ADG125, a novel anti-CSF-1R mAb in Phase 1 development, to Dragon Boat Biopharmaceuticals. We have the right to apply for the patents derived from our core and key technologies pertaining to ADG104 and ADG125 in the rest of the world, where we retain a majority of the economic benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">ADG116: Novel Anti-CTLA-4 NEObody Candidate</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ADG116 is a fully human anti-CTLA-4 antibody generated using our NEObody technology, designed to target a unique epitope of CTLA-4, to enhance the efficacy profile and to address toxicity concerns associated with existing CTLA-4 therapeutics. It is currently under Phase 1b/2 clinical evaluation in multiple trials in the U.S., China and Asia Pacific (APAC), both as monotherapy and in combination with other targeted therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In preclinical studies, ADG116 was observed to have softer CTLA-4 ligand blocking and stronger ADCC for depleting regulatory T-cells than ipilimumab. In a head-to-head <i style="font-style:italic;">in vivo </i>efficacy study, ADG116 was observed to have a five-fold greater anti-tumor activity in comparison with ipilimumab. In addition, ADG116 was observed to induce antitumor responses concomitant with reduced immunosuppressive regulatory T-cell and enhanced cytotoxic T lymphocyte (CD8<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> T-cells) activities in the TME. These preclinical results support evaluation of ADG116 in clinical both as monotherapy and combination therapy for a wide range of tumor types.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:231pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2020, we initiated dose escalation of ADG116 monotherapy in a clinical trial in Australia (ADG116-1003) to evaluate safety and determine a recommended Phase 2 dose, or RP2D, in patients with advance metastatic tumors, using a traditional &#8220;3+3&#8221; dose escalation design. A secondary objective of the trial is to evaluate preliminary efficacy based upon anti-tumor activity both as monotherapy and in combination regimens. In 2021, we expanded the trial (ADG116- 1003) to sites in the U.S. after receiving clearance from the FDA. Upon the receipt of such clearance from the FDA, we terminated a prior Phase 1 trial (ADG116-1001) in the U.S. for business reasons. In addition, we obtained approval to initiate cohorts in other countries, including Singapore and South Korea. We have completed multiple levels of dose escalation from 0.003 mg/kg to 10 mg/kg in over 30 subjects as of March 31, 2022, advanced the trial into monotherapy dose expansion in targeted tumors, and initiated dose escalation for two combination cohorts (with either anti-PD-1 or anti-CD137 therapy) under the same protocol. In November 2021, we received clearance from the FDA to initiate a trial of ADG116 in combination with pembrolizumab (ADG116-P001 / KEYNOTE-C97), which is ongoing at sites in the United States. For detailed discussion on our terminated ADG116-1001 clinical trial, see &#8220;Item 3 Key Information&#8212;Risk Factors&#8212;Risks relating to obtaining regulatory approval of our drug candidates&#8212;Our product candidates may cause undesirable adverse events, side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following any regulatory approval.&#8221;<i style="font-style:italic;">Summary of Clinical Studies &amp; Results</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">We reported data on the initial 25 patients as of October 15, 2021, the data cut-off date for the purpose of the presentation (the &#8220;2021 ESMO Data Cut-off Date&#8221;) at ESMO-IO 2021 in December 2021 demonstrating only one dose-limiting toxicity (a Grade 4 hyperglycemia) and one Grade 3 (rash) treatment-related adverse event (TRAE) at the 10 mg/kg dose. ADG116 monotherapy was otherwise well-tolerated up to 6 mg/kg with only Grade 1 or 2 TRAEs observed; rash (20 percent) and pruritus (20 percent) were the most common.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following chart demonstrates the incidence of treatment emergent adverse events with ADG116 by grade, showing the vast majority of TRAEs were Grade 1 or 2:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="adag-20211231x20f004.jpg" alt="Graphic" style="display:inline-block;height:230.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:218.37pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">* Data presented on 25 patients as of the 2021 ESMO Data Cut-off Date, treated with ADG116 monotherapy at ESMO-IO 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2022, no additional DLTs had occurred for patients at the ongoing 10 mg/kg dose level with ADG116 as monotherapy. We are highly encouraged by the safety profile of ADG116 relative to other anti-CTLA-4 therapies. In 2021, we received approval from a Safety Review Committee (SRC) to dose patients at 15 mg/kg, to initiate dose expansion cohorts at 10 mg/kg, and to initiate combination evaluation at 6 mg/kg. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:280.53pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the ESMO-IO 2021, we also reported preliminary efficacy data as of the 2021 ESMO Data Cut-off Date from the ongoing monotherapy trial. Patients with advanced metastatic tumor across 15 different tumor types were evaluated. The majority (68 percent) received three or more lines of prior systemic therapy, and nearly one quarter (24 percent) received prior immunotherapy treatment. A majority of these heavily pre-treated patients were also insensitive to immunotherapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ADG116 treatment resulted in dose-dependent increases in peripheral CD8 and CD4 T-cells, indicating immune activation by targeting the CTLA-4 pathway, starting at a dose as low as 0.03 mg/kg and becoming more striking at the 6 mg/kg and 10 mg/kg dose levels. In one example, a patient refractory to multiple cycles of pembrolizumab treated at 0.03 mg/kg showed increased CD8 and CD4 T-cells. The dose-dependent increase in these pharmacodynamic biomarkers (peripheral CD8 and CD4 T-cells) following ADG116 treatment is shown in the below chart:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><img src="adag-20211231x20f005.jpg" alt="Graphic" style="display:inline-block;height:280.08pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:503.45pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The above chart shows data presented on 25 patients treated with ADG116 monotherapy at ESMO-IO 2021. Patients No. 4 (urothelial cancer), No. 19 (ovarian cancer) and No. 22 (pancreatic cancer), with increased CD8 and/or CD4 T-cells, showed stable disease.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:241.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the 10 mg/kg cohort, the dose-limiting toxicity event occurred in a patient with renal cell carcinoma who relapsed on nivolumab. A significant increase in the patient&#8217;s CD8 T-cells after one cycle of treatment showed that ADG116 is highly active for triggering T-cell activation:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Significant immune response in renal cell carcinoma patient after one cycle at 10mg/kg</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt;"><img src="adag-20211231x20f006.jpg" alt="Graphic" style="display:inline-block;height:230.4pt;left:0%;padding-bottom:0.6pt;position:relative;top:0pt;width:420.53pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Of special note is a 22 percent tumor reduction observed in target lesions after the 2021 ESMO Data Cut-off Date following two cycles of ADG116 for a pancreatic cancer patient treated at 10 mg/kg. Only Grade 1 TRAEs were observed and the patient&#8217;s non-target lesion (23 x 12mm) disappeared. The following graph shows tumor shrinkage in the pancreatic cancer patient based upon the ESMO-IO poster presentation in December 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt;"><b style="font-weight:bold;">Tumor shrinkage in pancreatic cancer patient after two cycles at 10 mg/kg</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:0pt;margin:0pt;"><img src="adag-20211231x20f007.jpg" alt="Graphic" style="display:inline-block;height:241.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:401.75pt;" /></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, as reported in our poster presentation in December 2021, an ovarian cancer patient treated at 6mg/kg showed stable disease for more than 116 days with increased CD8 and CD4 T-cells. Overall, in the dose escalation portion of the trial, four prolonged stable diseases (17%) were observed amongst these heavily pre-treated patients. ADG116 demonstrated dose-proportional increases in drug exposure with a half-life supporting convenient dosing every three weeks. These findings, particularly in heavily pre-treated patients with advanced, metastatic disease, support that ADG116 has achieved the recommended dosing range as a single agent and for evaluation in combination therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">While the dose escalation continues, our evaluation of ADG116 monotherapy has advanced in targeted tumor types through dose expansion at 10 mg/kg. Following approval by the NMPA, we are also initiating a monotherapy trial in China, ADG116-1002, to provide additional clinical data for ADG116 in Chinese patients to support China joining our global clinical program to investigate the combination of ADG116 and other immunotherapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In parallel, dose escalation in combination cohorts with either anti-PD-1 or anti-CD137 therapies are also underway in the ADG116-P001 and ADG116-1003 trials. As part of the ongoing ADG116-1003 trial, combination cohorts have been initiated to evaluate ADG116 with toripalimab, or with our wholly-owned anti-CD137 agonistic antibody, ADG106. In the ADG116 and toripalimab dose cohort, we have observed diarrhea, myocarditis and fever as treatment-related SAEs. In the ADG116 and ADG106 (anti-CD137 agonist) cohort, diarrhea was observed as a treatment-related SAE. The recommended RP2Ds for these two combinations will be determined before the dose expansion in specific cancer types. Additionally, we have started the dose escalation of ADG116 plus pembrolizumab. We plan to present initial results of our trials evaluating ADG116 in combination with other immunotherapies at medical conferences during 2022, as well as additional results from our monotherapy evaluations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Mechanism of Action &amp; Preclinical Profile</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ADG116 is designed to target a unique conserved epitope of CTLA-4. In preclinical studies, ADG116 was observed to have softer CTLA-4 ligand blocking and stronger ADCC for regulatory T-cell depletion than ipilimumab. Based on the PD results observed in our preclinical studies, we believe that ADG116 has the potential to specifically bind to human CTLA-4, or hCTLA-4, without binding to other CD28 family receptors, which could potentially block the CTLA-4/CD80 and CTLA-4/CD86 ligand interactions. We believe that ADG116 potentiates CD28 signaling and T-cell immune response in the presence of a primary stimulatory signaling. Moreover, ADG116 has been observed in preclinical animal studies to mediate effector functions to eliminate CTLA-4 expressing cells, particularly regulatory T-cells, primarily through ADCC by NK cells. These actions of ADG116 could lead to enhanced activation and proliferation of tumor infiltrating T-effector cells and reduced T-regulatory cell function, which may contribute to a general increase in T-cell responsiveness, including an enhanced antitumor immune response.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We extensively evaluated ADG116 in both <i style="font-style:italic;">in vitro</i> and <i style="font-style:italic;">in vivo</i> preclinical studies. Our <i style="font-style:italic;">in vivo</i> efficacy studies were conducted in mice, and safety evaluations were conducted in both cynomolgus monkeys and rats. ADG116 was observed to show robust <i style="font-style:italic;">in vivo</i> anti-tumor activity in multiple syngeneic mouse tumor models. Ipilimumab was included as a benchmark and was compared with ADG116 in a series of our preclinical studies. In these preclinical studies, we observed that ADG116 had a potential advantage over ipilimumab in potentiating T-cell activation. While ADG116 has softer CTLA-4 ligand blocking, it was observed to have superior ability in eliminating CTLA-4 positive regulatory T-cells via ADCC in tumors resulting in enhanced antitumor responses. ADG116 was well tolerated in rats and cynomolgus monkeys at doses up to 30 mg/kg in GLP-compliant four-week repeat-dose toxicology studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Pharmacology:</i> We evaluated ADG116 as a monotherapy <i style="font-style:italic;">in vivo</i> in an H22 liver cancer syngeneic mouse model. As shown in the figure below, ADG116 was observed to induce an encouraging antitumor response at low doses in a dose-dependent manner (see figure below on the left). Additionally, ADG116 was observed to inhibit tumor growth of large tumors in the same model (see figure below on the right).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:324pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="adag-20211231x20f008.jpg" alt="Graphic" style="display:inline-block;height:323.95pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:461.94pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As illustrated in the below figure, in a liver cancer tumor rechallenge study, ADG116 was observed to induce significant antitumor response. Fifty-nine days after the initial tumor inoculation and more than 30 days after the last ADG116 treatment, mice were then rechallenged with the same tumor. We observed that mice that responded to the initial ADG116 treatment remained tumor-free even without additional ADG116 treatment while naive mice developed tumors, indicating the development of antitumor memory response elicited by ADG116.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:219.6pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="adag-20211231x20f009.jpg" alt="Graphic" style="display:inline-block;height:219.6pt;width:414.05pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since ADG116 was observed to exhibit strong ADCC activity <i style="font-style:italic;">in vitro</i>, we evaluated the ability of ADG116 to deplete regulatory T-cells <i style="font-style:italic;">in vivo</i> in a CT26 mouse colon cancer syngeneic model. ADG116 treatment was observed to specifically deplete regulatory T-cells in the tumor, but not in peripheral blood mononuclear cells, or PBMCs, or lymph nodes. The following figure shows significant regulatory T-cell depletion (left figure) and inhibition of CTLA-4 expression (right figure) in tumors by ADG116.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="adag-20211231x20f010.jpg" alt="Graphic" style="display:inline-block;height:159.84pt;left:0%;padding-bottom:0.7pt;position:relative;top:0pt;width:392.21pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In a series of preclinical studies, we compared the effect of ADG116 to ipilimumab. We believe that these studies suggest that ADG116 has a unique MOA compared to ipilimumab and has a potential advantage over ipilimumab in eliciting antitumor responses. These preclinical trial results support the further clinical evaluation of ADG116 as a monotherapy and in combination with other therapies for a wide range of tumor types.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the CTLA-4 blockade bioassay illustrated in the figure below on the left, ADG116 was observed to exhibit weaker blocking than ipilimumab of CTLA-4&#8217;s ability to inhibit CD80- and CD86-induced IL-2 production. This result supports our belief that ADG116 can function as a CTLA-4 checkpoint inhibitor with weaker activity than ipilimumab, which may result in less systemic autoimmune side effects on normal tissues. On the other hand, ADG116 was observed to exhibit notably stronger ADCC activity than ipilimumab in the <i style="font-style:italic;">in vitro</i> assay shown in the figure below on the right. Since CTLA-4 is expressed on regulatory T-cells, we believe that ADG116 offers a potential advantage over ipilimumab in depleting regulatory T-cells by means of ADCC. We subsequently investigated this <i style="font-style:italic;">in vivo</i> in a syngeneic mouse tumor model.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:277.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="adag-20211231x20f011.jpg" alt="Graphic" style="display:inline-block;height:160.56pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:432.86pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To compare ADG116&#8217;s <i style="font-style:italic;">in vivo</i> antitumor activity to ipilimumab, we utilized a subcutaneous MC38 mouse syngeneic colon cancer model in hCTLA-4, knock-in, or KI, C57BL/6 mice. We selected the hCTLA-4 KI mice as ipilimumab does not cross-react with mouse CTLA-4. As shown in the figure below, ADG116 was observed in this study to exhibit stronger antitumor activity than ipilimumab (ADG116 at 0.2 mg/kg induced equivalent antitumor response as 1 mg/kg of ipilimumab).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="adag-20211231x20f012.jpg" alt="Graphic" style="display:inline-block;height:277.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:320.94pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As shown in the figure below, we measured tumor infiltrating regulatory T-cells in the subcutaneous hCTLA-4 KI MC38 mouse colon cancer model after ADG116 or ipilimumab treatment. Among the TILs, the percentage of regulatory T-cells was observed to be significantly reduced after ADG116 treatment while the regulatory T-cell reduction after ipilimumab treatment was not significant. Notably, we observed that regulatory T-cell depletion by ADG116 occurred only in the TME, and not in PBMCs or the spleen. We believe that these results provide a mechanistic rationale for the enhanced <i style="font-style:italic;">in vivo</i> antitumor activity of ADG116 compared to ipilimumab. ADG116 may reduce the immunosuppressive regulatory T-cell activity specifically in the TME to enhance antitumor immune responses.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:247.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As illustrated below, in addition to evaluating the efficacy of ADG116 as a monotherapy, we also evaluated ADG116 in combination therapies. ADG116 was observed to have an antitumor effect with an anti-PD-1 treatment in a Lewis lung cancer syngeneic mouse model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We also examined the effects of ADG116 in combination with our CD137 agonistic antibody, ADG106, in a B16F10 melanoma syngeneic mouse model. As shown below, we observed that the combination of ADG116 with ADG106 enhanced the antitumor activity compared with ADG116 or ADG106 alone.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="adag-20211231x20f013.jpg" alt="Graphic" style="display:inline-block;height:246.96pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:318.05pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Preclinical Toxicology:</i> We performed preclinical toxicology studies in cynomolgus monkeys and rats to evaluate the toxicity of ADG116. There were no abnormal findings in the single-dose toxicology studies. We observed that ADG116 was well tolerated in both cynomolgus monkeys and rats at up to 200 mg/kg. In a GLP-compliant, four-week repeat-dose toxicology study, ADG116 was tolerated at doses up to 30 mg/kg/dose (five doses per week). In this study, ADG116 related hematology parameter changes, serum chemistry changes, mononuclear infiltration of predominantly lymphocytes with fewer macrophages into the parenchyma of numerous organs were the primary test article-related effects evaluated. These changes were reversible at &#8804; 30 mg/kg/dose, and consistent with the biological role of CTLA-4 in regulating and maintaining peripheral immune tolerance. The NOAEL was considered to be 30 mg/kg/dose in both rats and cynomolgus monkeys.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Clinical Development Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="color:#333333;">Our clinical development of ADG116 is focused on continued evaluation of its activity </span>as monotherapy and in combination with other targeted therapies, such as anti-PD-1 or anti-CD137 therapies. Multiple clinical trials are underway, including ADG116-1003, ADG116-1002 and ADG116-P001.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">ADG126: Novel Anti-CTLA-4 SAFEbody Candidate</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our most advanced SAFEbody program, ADG126, is a masked fully-human anti-CTLA-4 mAb engineered to address the safety concerns associated with existing CTLA-4 therapeutics, while maintaining potency when locally activated in the TME. It is currently under Phase 1b/2 clinical evaluation in multiple trials in the U.S., China and APAC, both as monotherapy and in combination with other targeted therapies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">ADG126 is designed to address the toxicity issues of the approved CTLA-4 immuno-oncology therapy and achieve enhance anti-tumor efficacy to expand the potential of CTLA-4 as a target for the treatment of cancer. It applies our proprietary SAFEbody technology to a parental antibody, ADG116, enabling ADG126 to be activated primarily in tumor tissues rather than healthy tissues, minimizing the risk of on target, off tumor toxicities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In preclinical studies, we observed that ADG126 had an enhanced therapeutic window and improved safety features. Furthermore, in PD studies of ADG126, it was observed that while the CTLA-4 binding affinity was masked in an intact ADG126 antibody, once the masking peptide was cleaved off of ADG126, its high binding affinity to CTLA-4 was restored. In preclinical studies, ADG126 was tolerated at doses of up to 200 mg/kg in nonhuman primate models. We believe the encouraging preclinical tolerability of ADG126 suggests its potential in combination with other immunotherapies such as an anti-PD-1/PD-L1 antibody or an anti-CD137 antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In April 2021, we<span style="color:#333333;"> presented updated preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2021. The data showed that ADG126 demonstrated an impressive safety margin while maintaining its potent antitumor efficacy. We plan to present the first clinical results from our ongoing Phase 1b/2 evaluations at a medical conference during 2022.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="color:#333333;font-style:italic;">Summary of Clinical Studies &amp; Results</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In March 2021, we initiated a Phase 1 trial of ADG126 (ADG126-1001) as monotherapy to evaluate safety and determine a RP2D in patients with advance metastatic tumors, using a traditional &#8220;3+3&#8221; dose escalation design. A secondary objective of the trial is to evaluate preliminary efficacy based upon anti-tumor activity both as monotherapy and in combination regimens. As of March 31, 2022, we have since completed dose escalation in over 18 patients at sites in both Australia and the U.S. at doses up to 10 mg/kg with no dosing-limiting toxicities even in patients who received more than four cycles. Patients have received multiple cycles with continuous dosing, and favorable pharmacokinetic and pharmacodynamic activity compared to our unmasked anti-CTLA-4 antibody, ADG116, has been observed. ADG126 has consistently shown a potential best-in-class profile, which is supported by preclinical evaluation, including GLP toxicology data, and enabled by the broad species cross-reactivity of ADG126.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In March 2022, we received Safety Review Committee approval on the dose escalation of ADG126 to 20 mg/kg as monotherapy and initiation of monotherapy dose expansion cohorts at 10 mg/kg, which are both ongoing. In October 2021, the NMPA approved our IND to start an ADG126 Phase 1 trial in China (ADG126-1002).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Additionally, in March 2022, we received clearance from the FDA for a new Phase 1b/2 trial to evaluate ADG126 in combination with pembrolizumab (ADG126-P001/KEYNOTE-C98). We are initiating the trial at multiple sites in the U.S. and we also plan to enroll patients in APAC. As part of the ongoing ADG126-1001 trial, combination cohorts are also planned to evaluate ADG126 in combination with toripalimab, and in combination with our anti-CD137 agonistic antibody, ADG106. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We expect to present findings from the monotherapy dose escalation of ADG126 during 2022, and we have confirmed acceptance of an abstract on the dose escalation portion of our monotherapy trial at the 2022 American Society of Clinical Oncology annual meeting. We also plan to present results from monotherapy dose expansion, and both dose escalation and dose expansion data from combination trials of ADG126 at upcoming medical conferences. We are encouraged that patients in the monotherapy trial have received multiple cycles of ADG126 with continuous dosing and strong pharmacokinetic and pharmacodynamic activity has been observed. We believe these observations, along with the lack of high grade treatment related toxicities with ADG126, put this product candidate on track to demonstrate a highly significant potential clinical differentiation to ipilimumab, the only commercially available anti-CTLA-4 therapy and other next generation anti-CTLA-4 antibodies in clinic to the best of our knowledge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">Mechanism of Action &amp; Preclinical Profile</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">ADG126 is a fully human anti-CTLA-4 mAb. The masking moiety in ADG126 functions to block the interaction between ADG126 and its target CTLA-4 protein. Once ADG126 enters the TME, proteases overexpressed in the TME cleave off the masking moiety, and the antibody is then activated, binding to CTLA-4 and inhibiting its function. ADG126 is locally activated specifically in the TME, rather than systemically, to stimulate antitumor immune response. The following diagram illustrates the activation process of ADG126 in tumor tissue.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:277.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe that activated ADG126 potentiates T-cell immune response by blocking the inhibitory effect of CTLA-4. ADG126/ADG116 is designed to target CTLA-4 conserved epitope with species cross-reactivity for translational fidelity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><img src="adag-20211231x20f014.jpg" alt="Graphic" style="display:inline-block;height:147.6pt;width:166.58pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10.5pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Moreover, ADG126 has been observed in preclinical animal studies to mediate effector functions to eliminate CTLA-4 expressing cells, particularly regulatory T-cells, primarily through ADCC. These actions of ADG126 could lead to enhanced activation and proliferation of tumor infiltrating T-effector cells and reduced T-regulatory cell function, which may contribute to a general increase in T-cell responsiveness, including an enhanced antitumor immune response. The below diagram illustrates the MOA of activated ADG126.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><img src="adag-20211231x20f015.jpg" alt="Graphic" style="display:inline-block;height:277.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:466.86pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 4pt 0pt;">Notes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 4pt 0pt;">&#8220;ADCP&#8221; refers to antibody-dependent cell-mediated phagocytosis;</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 4pt 0pt;">&#8220;MHC&#8221; refers to major histocompatibility complex;</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 4pt 0pt;">&#8220;TCR&#8217;&#8217; refers to T-cell receptor;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:280.53pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Preclinical Pharmacology</i><b style="font-weight:bold;">: </b>We observed in PD studies that ADG126, in its intact SAFEbody form, bound weakly to CTLA-4. However, once the proteases cleaved off the masking peptide, ADG126 was activated and bound at a high affinity to human, cynomolgus monkey and mouse CTLA-4, as shown in the figures below. Activated ADG126 was observed to lead to the release of CD80/CD86 ligands from CTLA-4 sequestration, and stimulation of CD28 signaling to boost T-cell activity. It also targets regulatory T-cells for depletion within the by means of ADCC, to mediate antitumor T-cell immunity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><img src="adag-20211231x20f016.jpg" alt="Graphic" style="display:inline-block;height:280.08pt;left:0%;padding-bottom:0.45pt;position:relative;top:0pt;width:461.59pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10.5pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We evaluated the <i style="font-style:italic;">in vivo </i>antitumor efficacy of ADG126 in syngeneic mouse tumor models. As shown in the figures below, in these studies, ADG126 was observed to inhibit tumor growth in different mouse tumor models as a monotherapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><img src="adag-20211231x20f017.jpg" alt="Graphic" style="display:inline-block;height:179.28pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:400.54pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:162.03pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As shown in the figure below, ADG126 synergized with an anti-PD-1 antibody to elicit a stronger anti-tumor response than ADG126 or the anti-PD-1 antibody alone in a Lewis lung cancer syngeneic</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="adag-20211231x20f018.jpg" alt="Graphic" style="display:inline-block;height:161.28pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:352.38pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">ADG126 treatment was observed to specifically deplete regulatory T-cells in the tumor, but not in peripheral tissues. The following figures illustrate the reduction of CTLA-4 expression in infiltrating lymphocytes, or TILs (see figure below on the left) and regulatory T-cell depletion (see figure below on the right) by ADG126 in CT26 tumor model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><img src="adag-20211231x20f019.jpg" alt="Graphic" style="display:inline-block;height:151.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:409.16pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10.5pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Note: &quot;Treg&quot; refers to regulatory T-cells</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Preclinical Toxicology: </i>We performed preclinical toxicology studies designed to assess the toxicity features of ADG126. We selected cynomolgus monkeys and mice as toxicology species for animal toxicity evaluation. No abnormal findings attributable to ADG126 were observed. We utilized a nonobese diabetic mouse model to determine percentage of survival with AD126 treatment. All mice survived after six treatments of ADG126 at 50 mg/kg.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In a four-week GLP repeat-dose toxicology studies, intravenous infusion of ADG126 to cynomolgus monkeys at 5, 30, or 200 mg/kg/dose once weekly for five doses followed by a 28-day recovery period was well-tolerated. Adverse, but reversible, microscopic findings of minimal to moderate mixed perivascular infiltrates were observed at 200 mg/kg in both sexes in the kidney, liver, pancreas, epididymis, skin, and were observed in the ovaries in females, and the connective tissue associated with the mesenteric lymph node and thyroid gland. The NOAEL was considered to be 30 mg/kg/dose and the highest non-severely toxic dose was considered to be 200 mg/kg/dose.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="color:#333333;font-style:italic;">Clinical Development Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 9.35pt;">Our clinical development of ADG126 is focused on continued evaluation of its activity as monotherapy and in combination with other targeted therapies, such as anti-PD-1 or anti-CD137 therapies. Multiple clinical trials are underway, including ADG126-1001, ADG126-1002 and ADG126-P001.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">ADG106: Novel Agonistic Anti-CD137 NEObody Candidate</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">ADG106, is a fully human ligand-blocking, agonistic anti-CD137 IgG4 mAb generated using our NEObody technology to target a unique conserved epitope of CD137. ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin&#8217;s lymphoma, or NHL. We have completed two Phase 1 clinical trials, ADG106-1001 and ADG106-1002, in the U.S. and China, respectively, evaluating ADG106 as monotherapy in a total of 98 patients with advanced or metastatic solid tumors and/or NHL. Our results demonstrated that ADG106 had a well-tolerated safety profile and evidence of single-agent efficacy. In preclinical studies, we observed that ADG106 had encouraging antitumor activity and was well tolerated as a monotherapy and had additive or synergistic effects in combination with the existing standard-of-care, or SOC, and other immuno-oncology therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Based on those data, ADG106 is being evaluated in combination with anti-PD-1 or anti-CTLA-4 therapy in Phase 1b/2 and investigator-initiated trials. Our clinical strategy for ADG106 is supported by the combined findings of our phase 1 monotherapy trials, data from our extensive preclinical studies, as well as PD marker-based modelling from our prior and ongoing trials. These clinical results indicate that targeting the unique and highly conserved epitope of CD137 by ADG106 has the potential to balance safety and efficacy, thereby addressing the limitations of other existing anti-CD137 agonists that target very different epitopes from ADG106.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Clinical Summary: Monotherapy Evaluation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">During 2021, we completed two Phase 1 trials in 98 patients which evaluated the safety and tolerability, and preliminary efficacy of ADG106 monotherapy in advanced or metastatic solid tumors and NHL. Data from this trial have been reported previously and are summarized below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">ADG106 was well-tolerated at doses of 3 and 5 mg/kg, and at 300 mg and 400 mg flat doses. We also observed tumor shrinkage in some patients, including one patient with nasopharyngeal cancer (NPC) who previously failed chemotherapies, radiotherapy, anti-PD-L1 and anti-CTLA-4 bispecific antibody treatment and showed a partial response to ADG106 treatment with a 40% tumor size reduction after two treatment cycles. In addition, two NHL patients showed more than a 30% tumor size reduction after one and two ADG106 treatment cycles, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our Phase 1 clinical trials were designed with a primary objective to evaluate the safety and tolerability of ADG106 and to determine a RP2D. The secondary objectives were to characterize the PK profile of ADG106 and to evaluate the immunogenicity of ADG106 and potential antitumor activity of ADG106. An additional and exploratory objective of the Phase 1 clinical trials was to identify potential biomarkers of patients who responded to treatment with ADG106.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Thirty-eight patients were enrolled in the dose escalation phase using a conventional &#8220;3+3&#8221; design, and 60 patients were enrolled in the dose expansion phase. ADG106 was administered once every three weeks by intravenous infusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">ADG106 was dose escalated up to 10 mg/kg and observed to be well tolerated in dose expansion at 3 mg/kg, 5 mg/kg and at 300mg and 400 mg flat doses. Both clinical trials showed limited Treatment Emergent Adverse Effects, or TEAEs, liver toxicity or hematologic abnormalities. In the ADG106-1002 clinical trial in China, one DLT (Grade 4 neutrophil count decreased, 10mg/kg) was observed in one patient with mantle cell lymphoma, while in the ADG106-1001 U.S. clinical trial, we observed one DLT (Grade 3 adrenal insufficiency, 10mg/kg) and one TRAE (a Grade 2 hypoglossal nerve disorder, 5 mg/kg).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Across all dose cohorts in both trials, we observed three patients with &#8805; Grade 3 liver enzyme increase; among them, two patients with &#8805;Grade 3 AST increase enrolled in ADG106-1001 (treated at 10 mg/kg and 300 mg fixed dose levels), including one patient who had abnormal baseline liver enzyme exhibited Grade 3 AST increase, and one patient enrolled in ADG106-1002 with abnormal liver enzyme baseline showed a Grade 3 AST and ALT liver enzyme increase (treated at 5 mg/kg). These liver enzyme increases were not observed to be dose-dependent.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:250.54pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Dose-expansion cohorts started at dose levels that were observed to be well-tolerated in the dose escalation phase and showed evidence of clinical and biological activities. Patients with advanced or metastatic solid tumors or NHL, who were refractory or relapsed after exhausting almost all available therapies, were enrolled for a maximum of 24 months unless they withdrew earlier due to disease progression, intolerable toxicity, or withdrawal of consent. As of the date of this annual report, all patients have completed the two clinical trials consistent with these criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Early efficacy signals were also observed with tumor size reduction, significant target modulations and increased T-cell and NK proliferation, consistent with MOA. The majority of patients enrolled in both trials received post-treatment scans (81 of 98) and were evaluated for preliminary efficacy assessment. The responses observed in these patients included one partial response, 44 stable disease, and 36 progressive diseases. Three patients enrolled in ADG106-1002 clinical trial achieved greater than 30% tumor shrinkage. One patient with solid tumor had a partial response with an approximately 40% tumor size reduction in the target lesions and two NHL patients showed tumor shrinkage of 32% and 33% at the end of the Cycle two. A third ADG106-1002 NHL patient showed tumor size reduction of 17% and a patient with esophageal carcinoma enrolled in ADG106-1001 achieved 18% tumor shrinkage.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Case 1: Patient A with NHL, who relapsed after multiple chemotherapies and stem cell transplantation achieved 33% tumor size reduction after one dose of ADG106 at 3 mg/kg.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><img src="adag-20211231x20f020.jpg" alt="Graphic" style="display:inline-block;height:249.84pt;left:0%;padding-bottom:0.7pt;position:relative;top:0pt;width:268.83pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:250.54pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Case 2: Patient B with solid tumor (stage IV), who relapsed after multiple lines of treatment (chemotherapies, radiotherapy, target therapy, and immune checkpoint inhibition therapy), showed 40% tumor size reduction after two doses of ADG106 at 5 mg/kg.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt;"><img src="adag-20211231x20f021.jpg" alt="Graphic" style="display:inline-block;height:249.84pt;left:0%;padding-bottom:0.7pt;position:relative;top:0pt;width:242.75pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In conclusion, we observed a significant disease control rate of 56% (45 among 81 patients) for anti-CD137 monotherapy with robust safety profiles, including tumor size reductions in the multiple patients described above. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:334.8pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As illustrated below, we have also observed increased proliferation of NK cells in patients treated with ADG106 after the first cycle of treatment. Dose dependent stimulations of the identified immune cell subpopulation following ADG106 treatment at doses of 0.1, 0.5, and 1.5 mg/kg (see figure below on the right) were observed. No significant difference was observed from 1.5 to 10 mg/kg, suggesting that the drug may have saturated CD137 receptors on the target cells at the doses 1.5 mg/kg and beyond. This is the first report of an anti-CD137 antibody drug showing stimulation of NK cell proliferation in human. This finding also clarifies the MOA of ADG106, suggesting involvement of diverse immune cells in ADG106 mediated anti-tumor activities in human.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt;"><img src="adag-20211231x20f022.jpg" alt="Graphic" style="display:inline-block;height:334.8pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:431.84pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:255.6pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">We have also observed dose dependent sCD137 change in blood samples of patents treated by ADG106 and their combination with anti-PD-1 (see below), consistent with observation by other clinical studies. However, the semi-quantitative analysis and studies conducted suggest the increase of plasma sCD137 or its induction ratio of induced sCD137 over the baseline value is associated with the clinical benefits of NPC patients from progress, to stable disease and partial response, as shown below. Furthermore, this induction ratio of sCD137 seems to saturate at 3mpk and beyond. The induction ratio, however, can go beyond the saturation value shown in combination with anti-PD-1 as shown below in detailed PK/PD analysis of ADG106 with anti-PD-1:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt;"><img src="adag-20211231x20f023.jpg" alt="Graphic" style="display:inline-block;height:255.6pt;width:340.92pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:228.24pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">As noted, an exploratory objective of our Phase 1 trials was to identify potential biomarkers of patients who respond to treatment with ADG106. Biomarker studies showed target engagement with specific PD biomarkers such as sCD137 indicative of immune system activation, and clinical response correlated with changes in CD137 target engagement. A retrospective analysis of a potential biomarker related to ADG106 treatment for patients with more than 30% tumor shrinkage was suggested although the CD137 and associated factors were suggested to associate with the T-cell proliferation and propagation into the tumor infiltration cells in certain tumor types. Additionally, three patients in our Phase 1 trials who achieved greater than 30% tumor shrinkage after ADG106 treatment were found to be biomarker positive. One patient who was treated with a low dose of ADG106 was biomarker positive and showed stable disease, as shown in the waterfall plot below. Twenty-four biomarker negative patients did not show significant response as measured by tumor size reduction in CT images.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 2pt 0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 8pt 0pt;"><b style="color:#4f81bd;font-weight:bold;">Significant tumor shrinkage in 75% (3 out of 4) of the biomarker positive patients</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><img src="adag-20211231x20f024.jpg" alt="Graphic" style="display:inline-block;height:228.24pt;width:423.39pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">With feedback from FDA, we are focused on evaluation of ADG106 in biomarker-enriched tumor types associated with the CD137 pathway in combination with other immunotherapies in sponsored and investigator-initiated trials of ADG106 as detailed below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Clinical Summary: Combination Therapy Evaluation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We have previously conducted preclinical studies evaluating ADG106 in combination with other therapies including chemotherapies, immune modulators, and immuno-oncology therapies. Data from combination studies in tumor bearing mice showed that the combination of ADG106 with immune checkpoint inhibitors, including an anti-PD-1/PD-L1 mAb or anti-CTLA-4 mAb, enhanced <i style="font-style:italic;">in vivo </i>antitumor activity. We also plan to explore the combination of ADG106 with other targeted antibody therapies, including a potential combination with our novel, masked HER2xCD3 bispecific T-cell engager (ADG138) in solid tumors based on the preclinical data suggesting synergistic effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In March 2021, following NMPA approval, we initiated patient enrollment in China for ADG106-1008, a Phase 1b/2 trial to evaluate clinical safety and efficacy of ADG106 in combination with anti-PD-1 therapy. The trial is designed to enroll up to 60 patients with advanced solid tumors and relapsed or refractory NHL. As of the date of this annual report, we have enrolled over 20 patients at doses up to 3 mg/kg, and we have recently initiated dose expansion.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:211.51pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">In November 2021, we also completed an agreement with a research institution in Singapore to evaluate ADG106 with another anti-PD-1, nivolumab, in patients with advanced non-small cell lung cancer (NSCLC). The Phase 1b/2 open label trial (ADG106-T6001) is designed to evaluate safety, tolerability, and anti-tumor activity of the combination in up to 53 patients with advanced NSCLC who have progressed after prior treatment. The trial will also include exploratory biomarker analyses and immune cell profiling in response to the treatment. This investigator-initiated trial is being conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in collaboration with the Singapore Translational Cancer Consortium. The clinical trial is being led by Professor&#160;Goh Boon Cher, Senior Consultant,&#160;Department of Hematology-Oncology&#160;and Deputy Director (Research) at NCIS, and Associate Professor&#160;Daniel Tan, Head of the&#160;Division of Clinical Trials and Epidemiological Sciences&#160;and Senior Consultant,&#160;Division of Medical Oncology, NCCS. In January 2022, we reported that the trial had enrolled and dosed the first patients. The trial is currently ongoing as of the date of this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:6pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Our strategy to evaluate ADG-106 in combination with anti-PD-1 therapy is further supported by pharmacokinetic modelling data and analysis. In December 2021, we presented data at December 2021 ESMO Presentation on the biomarker kinetics for ADG106 as a monotherapy or combined with toripalimab. The combination of ADG106 with toripalimab resulted in a 2-fold synergistic effect for immune activation compared to ADG106 monotherapy. The synergy was observed even amongst patients who failed prior anti-PD-1 and CTLA-4 therapies and further supports our exploration of combination therapy regimens with ADG106. These results also inform the ongoing dose expansion and recommended Phase 2 dose selection for ADG106.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:6pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt;"><img src="adag-20211231x20f025.jpg" alt="Graphic" style="display:inline-block;height:210.96pt;left:0%;padding-bottom:0.55pt;position:relative;top:0pt;width:257.56pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:6pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:18pt;margin:0pt;">Additionally, we included a combination cohort in our ADG116-1003 clinical trial design to enable evaluation of a patient cohort receiving both ADG106 and anti-CTLA-4, and we initiated enrollment and dosing in this cohort in January 2022. The novel combination builds on foundational research and emerging preclinical data that underscores the therapeutic potential of combining T-cell co-inhibitory blockade with CTLA-4, as well as co-stimulation with CD137 agonists, to improve overall therapeutic outcomes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:8pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 8pt 18pt;"><i style="font-style:italic;">Mechanism of Action</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">CD137 stimulates the immune system to attack cancer cells and is a key driver for T-cell and natural killer cell, or NK cell, proliferation. ADG106 is designed to target a unique conserved epitope of CD137 with a novel MOA for CD137 agonism by its natural ligand-like binding and cross-linking by Fcy receptors. The broad species cross-reactivity of ADG106 observed in preclinical studies has enabled us to explore robust translational studies concerning the biology of CD137 in mouse, rat, nonhuman primate, and human, especially for anti-CD137 as a single agent and in combination therapies in immuno-competent syngeneic tumor models. CD137 is a member of the tumor necrosis factor, or TNF, receptor superfamily. The binding of an antibody to this receptor induces a co-stimulatory signal on activated enhanced cytotoxic T lymphocyte, or CD8<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> T-cells, and natural killer, or NK cells, resulting in proliferation, and increased pro-inflammatory cytokine secretion and cytolytic function. CD137 co-stimulation is a clinically validated pathway for T-cell activation and its antitumor response is highlighted by the approval of a CD137-targeting CAR-T therapy by the FDA. Because most tumors are killed by cytotoxic T-cells in an antigen specific manner, we believe agents that mediate CD8<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> T-cell activation can impart strong cytolytic activity. Therefore, we believe that CD137 agonists are promising candidates with potential to enhance and mediate long lasting antitumor immunity.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:177.12pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">ADG106 is designed to bind to activated human CD4<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> and CD8<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> T-cells with low nanomolar affinity and block CD137 ligand binding in a concentration-dependent manner to disable its reverse signaling. As shown in the figure below, ADG106 is designed to target a unique conserved epitope of CD137 with a novel MOA for CD137 agonism by its natural ligand-like binding and cross-linking by Fcy receptors (see Figure below and its importance for our engineering of masked anti-CD137 ADG206 POWERbody with Fc-engineering to enhance the cross-linking by Fcy receptors). ADG106 has not been observed to bind to unstimulated na&#168;&#305;ve T-cells, which have no detectable level of CD137 expression. ADG106 is also designed to bind to activated NK cells to boost their cytotoxic and ADCC functions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="adag-20211231x20f026.jpg" alt="Graphic" style="display:inline-block;height:177.12pt;width:444.44pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 4pt 0pt;">Notes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 4pt 0pt;">&#8220;APC&#8221; refers to antigen-presenting cells;</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 4pt 0pt;">&#8220;DC&#8221; refers to dendritic cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 4pt 0pt;">&#8220;Treg&#8221; refers to regulatory T-cell.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 4pt 0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Summary of Preclinical Studies and Results</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10.5pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">ADG106 was evaluated extensively in both <i style="font-style:italic;">in vitro </i>and <i style="font-style:italic;">in vivo </i>preclinical studies. ADG106 was observed in <i style="font-style:italic;">in vitro </i>studies to enhance activation of, and cytokine release by, primed T-cells alone or in combination with other immunomodulatory agents. ADG106 was also observed to have antitumor activities <i style="font-style:italic;">in vivo </i>as a monotherapy in a dose dependent manner in multiple tumor models. When combined with a variety of cancer therapeutics, ADG106 exhibited antitumor activity <i style="font-style:italic;">in vivo </i>in animal models, including in immunotherapy resistant models. Our mechanistic analyses suggest that ADG106 promotes an antitumor response by stimulating infiltration and expansion of CD4<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> and CD8<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> T-cells in tumors. ADG106 was well tolerated in animals, with a no-observed-adverse-effect-level, or NOAEL, &gt; 100 mg/kg/dose and &gt; 200 mg/kg/dose in rats and cynomolgus monkeys, respectively. These findings support our belief that the ADG106-boosted immune response could offer an effective alternative solution for cancer immunotherapy as a monotherapy and in combination with other therapies, especially for PD-1/PD-L1 resistant patient populations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Preclinical Pharmacology: </i>Our <i style="font-style:italic;">in vitro </i>studies showed that ADG106 bound with high affinity and specificity to a unique epitope of CD137 that blocks the CD137L ligand binding with subsequent enhancement and proliferation of T-cells and pro-inflammatory interferon-y responses. Interferon-y is a master checkpoint regulator for many cytokines that targets a common component of many heterodimeric cytokine receptors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">ADG106 was species cross-reactive against human, mouse, and cynomolgus monkey CD137 and was active as a monotherapy in multiple preclinical tumor models. As shown below (left figure), in an H22 liver cancer syngeneic mouse model, ADG106 was observed to have <i style="font-style:italic;">in vivo </i>antitumor activities as a monotherapy in a dose dependent manner. As shown below (right figure), tumors treated with ADG106 showed increased CD4<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> and CD8<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> infiltration compared to an isotype control.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:216.72pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><img src="adag-20211231x20f027.jpg" alt="Graphic" style="display:inline-block;height:167.04pt;width:441.73pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As illustrated in the figure below, ADG106 also showed a durable antitumor response in a CT26 colon cancer syngeneic mouse model. ADG106 treatment induced a complete response, or CR, in six out of eight mice. These CR mice received reinnoculation of CT26 tumor cells, or rechallenge, and remained tumor-free without additional ADG106 treatment, indicating development of antitumor memory response elicited by ADG106. Tumors treated with ADG106 showed increased CD4<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> and CD8<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> infiltration compared to an isotype control, similar to the H22 liver cancer model (data not shown). These data are consistent with the mechanism of ADG106 as a CD137 agonist in stimulating T-cell proliferation, activation, and infiltration into the TME to induce an antitumor effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><img src="adag-20211231x20f028.jpg" alt="Graphic" style="display:inline-block;height:216.72pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:386.29pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to monotherapy antitumor activities, we observed that ADG106 had antitumor activities in combination with other therapies in preclinical studies. As shown below, ADG106 produced a synergistic effect with an anti-PD-1/PD-L1 therapy, and SOC, in <i style="font-style:italic;">in vivo </i>tumor models, including models that are resistant to current PD-1/PD-L1 and SOC therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:199.54pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><img src="adag-20211231x20f029.jpg" alt="Graphic" style="display:inline-block;height:182.16pt;width:458.05pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><img src="adag-20211231x20f030.jpg" alt="Graphic" style="display:inline-block;height:199.44pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:342.65pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In a syngeneic tumor, although ADG106 did not show anti-tumor activity in this model, the combination of ADG106 with atezolizumab (Tecentriq), an approved anti-PD-L1 antibody that blocks PD-1/PD-L1 interaction, showed enhanced antitumor response compared to the corresponding monotherapies.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:219.6pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><img src="adag-20211231x20f031.jpg" alt="Graphic" style="display:inline-block;height:188.64pt;left:0%;padding-bottom:0.4pt;position:relative;top:0pt;width:236.78pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10.5pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">As demonstrated below, ADG106 was also observed to show antitumor activities when combined with our CTLA-4 antibody ADG116 in a mouse tumor model, while ADG106 alone did not show antitumor activities. We believe that this data provides a strong rationale for combining our pipeline programs including ADG106 with ADG116.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><img src="adag-20211231x20f032.jpg" alt="Graphic" style="display:inline-block;height:219.6pt;width:235.63pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10.5pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="color:#333333;font-style:italic;">Clinical Development Plan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Following completion of Phase 1 monotherapy trials, our clinical development of ADG106 is focused on evaluating its activity in combination with other targeted therapies, such as anti-PD-1 or anti-CTLA-4 therapies. Multiple clinical trials are underway, including ADG106-1008, ADG116-1003 and ADG106-T6001.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">DEEP, BROAD, DIFFERENTIATED PRECLINICAL PIPELINE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition to our three clinical-stage product candidates, we are building a deep, broad and differentiated preclinical pipeline with potential first and best-in-class programs in various stages of drug discovery and preclinical evaluation. Our programs utilize our three DPL platform technologies NEObody, SAFEbody, and POWERbody. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We currently have five highly differentiated programs undergoing IND-enabling studies, each with robust CMC profiles and compelling preclinical safety and efficacy data. In December 2021, we disclosed the first two of these candidates, ADG152 and ADG153, and reported preclinical data at the American Society of Hematology (ASH) annual meeting. <span style="background:#ffffff;">In March 2022, we introduced two additional programs, ADG206 and ADG138, and reported data demonstrating their first and best-in-class potential in conjunction with the American Association for Cancer Research (AACR) annual meeting. </span>Additionally, in March 2022, we introduced a new capability for our<span style="background:#ffffff;"> proprietary bispecific T-cell engagers (TCEs)&#160;targeting CD28, which we believe offers a new paradigm and novel approach to overcome the challenges of this target by combining a unique, highly conserved epitope, with our precision masking technology and a tumor antigen targeted TCE for local activation. At AACR 2022, we also presented data for these preclinical candidates to be used as monotherapies or in combination with our CD3 TCEs to achieve</span><i style="font-style:italic;background:#ffffff;"> </i><span style="color:#333333;">safe, powerful and durable immunotherapy</span><i style="font-style:italic;background:#ffffff;">.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A summary of our pipeline of preclinical programs follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">ADG206:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> This masked, Fc-engineered anti-CD137 agonistic POWERbody incorporates SAFEbody</span><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:normal;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> precision masking technology for conditional activation and is designed to achieve improved safety and efficacy. We have conducted preclinical studies demonstrating that the FcgR-mediated crosslinking of ADG206 in IgG1 format enhances T-cell responses and antitumor activity, while the SAFEbody masking technology secures its activation in the TME to limit on-target off-tumor toxicities. Preclinical data demonstrated that ADG206 was well tolerated, with normal pharmacokinetic properties and minimal activation in circulation. It also had robust anti-tumor activity as a single agent in multiple tumor models, with 4-fold stronger anti-CD137 agonistic activity of its activated form than a benchmark antibody (analog of urelumab), which is one of the most potent anti-CD137 agonists in development for T-cell co-activation that has demonstrated clinical activity as a single agent but has also shown dose-dependent liver toxicity. ADG206 demonstrated enhanced anti-tumor activity as a single agent and in combination with other checkpoint inhibitors, including anti-PD-1 or anti-CTLA-4 therapy. We plan to submit an IND or equivalent filing for ADG206, a masked and more potent anti-CD137 agonist targeting a unique and highly conserved epitope of anti-CD137, during 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">ADG153:</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> This masked anti-CD47 IgG1 SAFEbody is differentiated by the novel epitope it recognizes, its strong antibody-dependent cellular cytot</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">oxicity (ADCC)</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"> antibody-dependent cellular phagocytosis (ADCP) </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">activity, and precision masking for conditional activation. It is </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">designed to realize the full potential of anti-CD47 therapy for both hematologic and solid tumor indications. ADG153 targets a unique epitope with reduced hemagglutination activities in comparison with two benchmark antibodies. It incorporates SAFEbody masking technology to limit on-target off-tumor toxicities and overcome the known safety liabilities of anti-CD47 therapies. The safety mask prevents its rapid clearance by CD47 directed antigen sink effect. </span><span style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preclinical data demonstrated that ADG153 IgG1 was well tolerated, did not induce human hemagglutination and significantly reduced anemia-related and antigen sink liabilities. In particular, ADG153 IgG1 at a 10 mg/kg dose demonstrated only an 8 percent decrease in red blood cell counts, compared to a 49 percent decrease with a benchmark antibody which is in IgG4 format (analog of magrolimab). </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">After a single intravenous dose, ADG153 IgG1 demonstrated an approximately 8-fold longer apparent half-life and 5-fold higher area under the curve (AUC) at 10mg/kg than the benchmark. </span><span style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Results also showed that ADG153 IgG1 demonstrated greater anti-tumor activity than the benchmark</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">We believe it is the first anti-CD47 antibody in IgG1 isotype that shows strong ADCC and ADCP effects for tumor killing without serious safety liabilities.</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are preparing to submit an IND or equivalent filing for ADG153 during 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><i style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">ADG138</i><span style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: This novel HER2xCD3 POWERbody is masked on both arms with an impressively high therapeutic index relative to its parental non-masked TCE in both HER2 high and low expressing solid tumors including HER2 high resistant/refractory tumors relative to a benchmark antibody (DS-8201, a HER2 targeting antibody drug conjugate commercially available in specific indications). ADG138 preclinical data support its development for HER2-expressing solid tumors as a single agent and in combination with other immune modulating agents. Preclinical data demonstrated the excellent safety profile of ADG138, including 100-fold greater reduction in cytokine release compared to its parental TCE. Results showed that ADG138 has potent anti-tumor activity in HER2 high and low expressing tumors, as well as resistant/refractory tumors. ADG138 also had synergistic </span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;"></td><td style="padding:0pt 0pt 12pt 0pt;"><span style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">anti-tumor activity in HER2 positive tumors when combined with anti-CD137 or anti-PD-1 therapy, or tumor targeted CD28 bispecific antibody. ADG138 is currently in IND-enabling studies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="padding:0pt 0pt 12pt 0pt;"><i style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">ADG152: </i><span style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This CD20xCD3 POWERbody integrates the company&#8217;s proprietary bispecific TCE platform with SAFEbody precision masking technology to minimize cytokine release syndrome (CRS) and on-target off-tumor toxicities for an increased therapeutic index. The anti-CD20 arm of ADG152 has enhanced the binding to CD20, while its anti-CD3 arm has tailor made affinity for CD3 using SAFEbody technology. In comparison with a benchmarked antibody in clinical development (analog of plamotumab), ADG152 showed improved safety with cytokine release control even at a 100-fold higher dose than the benchmarked antibody analog and 2- to 3-fold prolonged half-life than the benchmarked antibody analog in exploratory preclinical monkey studies. In preclinical mouse xenograft tumor models, ADG152 demonstrated strong and sustained anti-tumor activity, with almost complete tumor growth inhibition when dosed at 1.5 mg/kg. ADG152 is currently in IND-enabling studies.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;background:#ffffff;border:0pt;"><tr><td style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">CD28 T-cell engagers: </i><span style="color:#333333;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We are developing anti-CD28 bispecific POWERbody TCEs that exhibit enormous potential to fulfill the promises of safe and durable T-cell mediated synergistic immunotherapies when combined with CD3 bispecific POWERbody TCEs and/or checkpoint inhibitors. Enabled by our suite of antibody platform technologies, preclinical data demonstrated the potential to mitigate the serious safety concerns of CD28 activation and make custom designed antibodies targeting a highly conserved epitope with broad species reactivity. We currently have multiple tumor associated antigen (TAA)xCD28&#160;POWERbodies in preclinical development, such as B7-H3xCD28 and HER2xCD28, which can also be combined with our CD3 TCEs to achieve safe, powerful and durable immunotherapy for solid tumors through combination of the fundamental mechanisms and pathways across the cancer immunity cycle.&#160;&#160;For the avoidance of doubt, as of the date of this annual report, the CD28 T-cell engagers have not entered into </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">IND-enabling stage.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">OUR PLATFORM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our proprietary DPL platform is built upon our insights into precise and dynamic antibody-antigen interaction. As such, our DPL platform has been designed to enable the discovery of antibodies with better developability properties. By addressing the challenges in traditional antibody design and engineering, we believe that our DPL platform will enable us to improve the efficacy and safety profile of antibody therapeutics. Our DPL platform is empowered by our computational platform, artificial intelligence and three innovative technologies: NEObody, SAFEbody, and POWERbody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Life is motion</i>: <i style="font-style:italic;">Harnessing the Dynamic Power of Antibodies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The motion of proteins and their dynamic interactions trigger a cascade of complex biological and pharmacological effects. Our core technology is built upon our fundamental understanding of the role that protein folding and the motion of molecules play in giving rise to dynamic conformational diversity, where an amino acid sequence can adopt multiple structures and functions. Our approach recognizes that a protein&#8217;s native state is not accurately represented by a single static structure but rather by a variety of structures in dynamic equilibrium, resulting in a high level of functional diversity, in contrast to the conventional static antibody drug discovery paradigm of &#8220;one sequence, one structure and one function.&#8221; We have developed our proprietary AI-Powered DPL platform to explore the dynamic conformational diversity of protein sequences, and the flexible binding sites of antibody sequences in particular, as a new paradigm for antibody drug discovery. Our DPL platform combines artificial intelligence, or AI, algorithms and ever-increasing big data in antibody sequence, structure, binding epitope and affinity from public and our own proprietary databases to design, construct and screen high-quality proprietary antibody libraries with well-defined sequence, scaffold and biophysical attributes for antibody drug discovery. Powered by computational physics in combination with AI and big data, our DPL platform samples a potentially infinite number of dynamic binding interface structures arising from the conformational diversity of a finite number of antibody amino acid sequences, allowing us to exponentially expand the universe of candidate antibody binding sites far beyond conventional natural or synthetic antibody repertoires. By exploiting conformational diversity, we have designed and precisely constructed approximately one trillion (10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">12</sup>) antibody sequences in our DPL. These antibodies feature broad epitope (the portion of an antigen that are recognized by an antibody) coverage and robust chemistry, manufacturing, and control, or CMC, attributes.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe our AI-powered antibody discovery and engineering DPL platform significantly increase R&amp;D productivity for antibody drug discovery, as illustrated by our clinical and preclinical pipeline. For example, DPL library screening against CTLA-4 or CD137 antigens has yielded a large number of high affinity primary hits. The abundant discovery hits with diversified binding epitopes show the power of our AI-powered DPL platform not only in creating novel antibodies in targeting different epitopes of a given antigen, but also in targeting the conserved epitope across different species of a given antigen with broad species cross-reactivity from human, monkey to mouse, which enables us to study their efficacy and safety in extensive immuno-competent or syngeneic animal models, to explore their pharmacodynamics and predictive biomarkers in responding vs nonresponding tumor models in vivo, and to understand their deep target biology and novel MOA before testing them in human clinical trials to look for their clinical signals consistent with their MOA. Our DPL platform empowers us to engage the dynamic epitope of the conformationally dynamic target which might be challenging using conventional antibody discovery approaches. We believe that the high-affinity and cross-reactive primary hits from our AI-Powered DPL library screening save time and cost from discovery to early clinical proof of concept. The broad species cross-reactivity of the primary hits also streamlines lead identification and potentially enables high fidelity translation from preclinical to clinical studies. Furthermore, we believe our AI-powered dynamic precision library expands the diversity at the start of discovery to maximize the chance that suitable leads are found on the first pass.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Translational fidelity from preclinical modeling to informed clinical development is one of the top challenges to developing cancer immunotherapies. Most traditionally developed antibodies do not cross react between their human and murine targets due to their limited species cross-reactivity, making it very difficult to reliably evaluate the same antibody in both the preclinical and clinical settings. Some of the most contentious issues related to preclinical and clinical studies of the targets of our clinical-stage product candidates, immunotherapies are traceable to the differences between the antibodies used for preclinical and clinical studies. For example, we believe our clinical stage anti-CTLA-4 and anti-CD137 candidates bind to different epitopes and exhibit dramatic differences in their respective clinical safety and efficacy results, underscoring the importance of finding suitable species cross-reactive antibodies like those we have utilized for comprehensive preclinical evaluation before entering clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe that it is essential to model the interactions between tumors and an intact host immune system <i style="font-style:italic;">in vivo </i>to evaluate the therapeutic potential of antibodies in preclinical studies. The flexibility of antibody binding interface is fundamental to the NEObody technology of our DPL Platform and allows us to generate species cross-reactive antibodies to assess the safety and efficacy potential of mono- and combination therapy candidates in syngeneic animal models before launching clinical trials. We use syngenic animal models which are known for their intact <i style="font-style:italic;">in vivo </i>immune systems to provide the original proof of concept for cancer immunotherapies by blocking immune check points with monoclonal antibodies, or mAbs. We believe that the use of species cross-reactive antibodies, rather than surrogate antibodies used in traditional syngeneic mouse models, should facilitate the translational relevance and clinical utility of these well-established preclinical models for determining optimal dose, schedule, sequencing, combination synergy, risk and benefit features. The results from the assessment of new species cross-reactive antibodies in rigorous preclinical models may allow us to control the scope and cost of clinical trials, enable the identification of potential clinical biomarkers useful to monitor clinical pharmacological and safety signals, and help preselect patients for precision mono- and combination therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">AI-Powered Antibody Discovery</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that efficient drug discovery requires significant commitment to resolve three key challenges: 1) the selection of targets with preclinical and/or clinical validation; 2) the availability of abundant hits at discovery stage for the identification of Pre-Clinical Candidates, or PCC, that usually takes a highly iterative process from target-to-hits, lead identification and lead optimization; and 3) deep understanding of target biology and MOA from detailed molecular, cellular, <i style="font-style:italic;">in vivo </i>preclinical and human disease models. To address these challenges and to improve antibody R&amp;D productivity, we have designed and built our AI-powered DPL platform to provide sufficient discovery capacity, capable of generating abundant high quality hits against targets, and then selecting the right leads for extensive preclinical testing in order to understand their MOAs, their efficacy and safety potential before going for clinical proof of concept testing. Our current focus on oncology portfolio is to establish early clinical proof of concept, preferably in Phase I trials.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">114</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We believe that it is critical to pair the right PCC with the specific epitope of a chosen target. The affinity and precise orientation by which the specific epitope of a given target is engaged by the PCC can have a profound impact on the pharmacology and toxicity of drug candidate. Therefore, we believe precision design and engineering of antibody-based drugs make a fundamental difference on the success of a drug discovery program. As demonstrated by extensive preclinical and early clinical data for our three clinical programs targeting a conserved epitope, across humans, monkeys and mice can give rise to novel biological and pharmacological activities. The broad species cross-reactivity of our candidates can facilitate seamless translational studies from different immune-competent syngeneic tumor models to monkeys, and then subsequent clinical trials in humans. The novel MOA and biology concerning targets such as CTLA-4 and CD137 include their regulation in peripheral and tumor microenvironments, the involvement of different immune cells upon target engagement such as T-regulatory cells by anti-CTLA-4 specific antibodies ADG116 and ADG126 and NK cells by anti-CD137 ADG106. We believe these examples provide strong support for our proposal to search for &#8220;The Right PCC&#8221; that is paired with the specific epitope of a given target in order to unlock the biology of such target and its pathway and to facilitate a deep understanding of its MOA in triggering a cascade of biological and pharmacological events leading to disease control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In order to search for &#8220;The Right PCC&#8221;, our proprietary DPL platform uses a deep learning approach to explore the conformational diversity of antibody binding sites. Our DPL platform combines AI algorithms and ever-increasing big data in antibody sequence, structure, and binding epitope and affinity from public and our own proprietary databases to design, construct and screen high-quality proprietary antibody libraries with well-defined sequence, scaffold and biophysical attributes for antibody drug discovery. Our computational engine combines software, AI and visualization tools to mine, organize, compute, and interactively explore these immense multidimensional big data sets. We iteratively inform wetlab experimentation with <i style="font-style:italic;">in silico </i>computation, and vice versa. By exploiting conformational diversity through the combination of our proprietary computational algorithms with AI, we have designed and precisely constructed approximately one trillion (10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">12</sup>) antibody sequences in our DPL. These antibodies feature broad epitope (the portion of an antigen that are recognized by an antibody) coverage and robust CMC attributes. The antibodies discovered can be further engineered into NEObody, SAFEbody and POWERbody antibodies depending on the targeted product profile of a given therapeutic target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our three clinical programs illustrate how our AI-powered DPL platform has improved our R&amp;D productivity. Our DPL library is a large physical phage library (~10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">12</sup>) that contain our AI-powered synthetic designer antibodies with flexible antibody binding interface. The combination of binding interface flexibility with the variation of amino acid sequences in the antigen binding interface exponentially increases the conformational diversity of our AI-powered DPL libraries, far beyond conventional natural or synthetic antibody libraries. Our AI-Powered DPL library screening against target antigens have yielded a large number of high affinity primary hits. For example, the anti-CTLA-4 antibody ADG116, was identified from 74 high affinity primary hits with a wide range of epitope diversity in terms of their species cross-reactivities: 19 clones are human, monkey, canine and mouse cross-reactive; 12 clones are human and monkey cross reactive but weak mouse cross-reactive; 32 clones are human and monkey cross-reactive; 11 clones only recognize human CTLA-4. The abundant discovery hits with diversified binding epitopes for varying degree of species cross-reactivity show the power of our AI-powered DPL platform not only in creating novel NEObodies in targeting different epitopes of a given antigen, but also in targeting the conserved epitope across different species of a given antigen to enable translational studies from immune-competent animal tumor models to human patients due to their broad species cross-reactivities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that the high affinity and species cross-reactive primary hits from our DPL library screening saves time and cost from primary hits to straight PCC. The broad species cross-reactivity of the primary hits also streamlines lead identification through simple syngeneic tumor models for safety and efficacy testing. The robust CMC attributes of our DPL library are designed to also eliminate the requirement to optimize antibody sequences before starting CMC process for IND enabling and formulation studies. Furthermore, we believe our AI-powered dynamic precision library of approximately one trillion (10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">12</sup>) antibody sequences expands the diversity at the start of discovery to maximize the chance that suitable leads are found on the first pass. In conclusion, we believe our AI-powered antibody discovery and engineering DPL platform significantly increases R&amp;D productivity for antibody drug discovery. It has enabled us to generate highly differentiated PCC molecules that we believe can target the conserved epitope across different species for novel MOAs and also facilitate seamless translational studies from animals to human via their broad species cross-reactivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Briefly, our AI-powered antibody discovery engine includes six steps:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">First principle of antibody folding and dynamics. We fold the antibody primary amino acid sequence into three-dimensional structures based on machine learning or homology modeling in combination with the Molecular Dynamic Simulation in the presence and absence of dynamic interaction with their antigen targets.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">115</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:232.56pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">AI-powered deep learning of antibody sequence and structure and binding epitopes. AI algorithm and machine learning have been widely used to map protein sequence and structure variation and connectivity. Deep learning has been used to map the antibody and antigen epitope in order to learn the landscape of the epitope space and their correlation with antibody binding interface.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Antibody design that combines the conformational diversity with primary amino acid sequence variation. We have designed antibody libraries that contain dynamic binding units and their combination in the context of different CDRs and framework scaffold to capture their conformational diversity of antibody binding interface in combination with variation in primary amino acid sequences far beyond conventional natural or synthetic antibody libraries.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Synthetic dynamic precision library by AI-powered computational design. The amino acid sequence library is converted into synthetic DNAs that can be assembled and constructed for phage and yeast library screening.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">5.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Directed evolution by phage and yeast libraries. The synthetic phage and yeast libraries can be screened semi-automatically for more than 100 antigens to yield high affinity primary hits.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">6.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PCC identification by targeting conserved epitope with broad species cross-reactivity to unlock the deep biology of target and its MOA upon target engagement by the PCC. PCC is designed and selected to target the conserved epitope of a given target across different species. Traditionally, affinity of primary hits from synthetic antibody libraries have to be improved before subjecting them to extensive in vitro and in vivo assays for lead identification and optimization through an iterative process between functional assays and antibody engineering. Our DPL platform can yield high affinity primary hits, which can then become product candidate leads subject to functional characterization without intensive iterative lead optimization process.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following diagram illustrates how AI algorithms and big data empower rapid antibody discovery with improved productivity:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="adag-20211231x20f033.jpg" alt="Graphic" style="display:inline-block;height:232.56pt;width:442.89pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">NEObody<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">NEObody technology is a fully synthetic phage display and yeast display-based antibody discovery technology, which we believe is differentiated from other synthetic antibody technologies through its innovative designs and precise constructions. Our designs are based on critical insights gained from extensive studies of antibody structural variability made possible by our proprietary in-house developed computational tools.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">116</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:151.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Innovative antibody library design: </b>We believe that diversity of an antibody library should be defined at the quaternary structural level, instead of the traditional primary amino acid sequence level. Comparison of structural and sequence diversity revealed that variability as assessed by structural alignments was generally lower than the variability observed with sequence alignments. Based on our deep understanding of chemical principles governing antibody folding and extensive analysis of a vast number of antibody structural variability, through novel statistical tools developed in-house, we have redefined the antibody hyper-variable regions, or HVRs, that are critical for antigen recognition. These HVRs, as defined based on structural variability, are distinct from but complementary with complementarity-determining regions that are traditionally defined based on amino acid sequence variability. In addition, we have defined and designed dynamic motifs which adopt multiple conformations and incorporated them into our DPL antibody library design to enable the coverage of a wide range of structural diversity with a limited number of amino acid sequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Broad epitope coverage, particularly of evolutionarily conserved epitopes: </b>NEObody technology enables us to discover antibodies targeting numerous epitopes against a broad range of antigens. In particular, we focus on the antibodies targeting the conserved epitopes of divergent antigens. These species cross-reactive antibodies not only have the potential to reveal new biological functions of the targets, but also facilitate preclinical studies using various immune intact animal models, resulting in high fidelity translation from preclinical to clinical studies. Our NEObody technology has been evaluated in preclinical studies with numerous antigens, including some difficult antigens such as membrane or oligomeric proteins. The success criteria in our preclinical assays include high affinity of primary hits with diverse antibody sequences, broad epitope coverage, as well as favorable CMC development properties. For example, ADG106 was discovered using our NEObody technology to target a conserved epitope of CD137 that mostly overlaps with its ligand binding site, which we believe enables ADG106 to activate CD137 in its natural ligand-like fashion, with complete blocking of CD137L, which may differentiate it from two other investigational leading CD137 agonistic antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Enhanced developability profiles: </b>NEObody technology is designed to preemptively eliminate the chemically unstable sites, or combinations of &#8220;problematic&#8221; sites that may pose risk for downstream manufacturing processes. This precision design strategy coupled with precision oligonucleotides and library construction have resulted in our high-quality antibody discovery libraries. The primary hits from these libraries generally lack severe &#8220;problematic&#8221; and spurious amino acid sites, and therefore, may offer promising characteristics for further development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 18pt;"><i style="font-style:italic;">SAFEbody</i><sup style="font-size:7.5pt;font-style:italic;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">SAFEbody is our proprietary differentiated precision antibody masking technology designed to enable an antibody to bind its target specifically only after conditional activation of the antibody in target tissues. By engineering our antibody therapeutic candidates to selectively activate in the TME, our SAFEbody technology is designed to improve safety and tolerability of antibody therapeutics while simultaneously maintaining clinical activity. Through this technology, we believe we can provide a solution to on-target off-tumor toxicity, one of the long-lasting challenges with many approved antibody therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><img src="adag-20211231x20f034.jpg" alt="Graphic" style="display:inline-block;height:151.2pt;left:0%;padding-bottom:0.3pt;position:relative;top:0pt;width:416.35pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Activation in the TME: </b>SAFEbody technology is designed to mask an antibody binding interface with a masking motif, which then prevents an antibody from binding to its target in healthy tissues. The masking motif is designed to activate or unmask the antibody binding in the TME where certain activation conditions such as a protease is upregulated as compared to healthy tissues, allowing the antibody to bind to and attack the tumor. Our SAFEbody enabled therapeutic candidates are therefore designed to be activated predominantly in the TME while remaining largely in an inactive state in healthy tissues.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">117</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Innovative masking moiety library design: </b>Leveraging computational biology, we have designed multiple masking libraries with structured scaffolds and balanced chemistry of amino acids with favorable attributes for masking, easier manufacturing processes, and lower immunogenicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Precision masking without self-inhibition: </b>To differentiate from other masking technologies, our antibody masking moieties have been designed and discovered in the right context in an effort to provide greater expression and specificity with no self-inhibition upon activation. We employ sophisticated screening processes for rapid discovery of highly masked SAFEbody product candidates subject to systematic tuning of the masking efficiency to match the target biology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Improved pharmacology and safety features: </b>We believe our SAFEbody technology has the potential to also reduce the dose-limiting toxicities observed in combination therapies and thus potentially enable new combinations with other cancer therapies that were previously difficult to use. Our SAFEbody technology may also provide favorable for PK and PD profiles for antibodies and ADCs to reduce the drug clearance from circulation in healthy tissues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our SAFEbody technology has been applied to multiple target antibodies that have been either discovered with NEObody technology or supplied by our partners. Our ADG126 was discovered by combining SAFEbody technology with its parental antibody discovered through our NEObody technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">POWERbody<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">TM</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In recent years, multiple modalities have been developed to enhance the potency of traditional antibody drugs. These include Fc engineering for enhanced ADCC or cross-linking efficiency, ADCs and TCEs. Some of them, such as TCEs, can be so potent that only micrograms of the active ingredient are needed for a single dose, in contrast to regular antibody where hundreds of milligrams or even grams are required for a single dose. NEObodies can be converted into SAFEbodies which can be further reformatted into SAFEbody ADCs, bispecific TCEs, and Fc engineered antibodies. We refer to these to as POWERbodies to indicate their potentially enhanced potency and safety profile.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe SAFEbodies can be applied to these modalities. Since an unmasked ADC, TCE, or Fc engineered antibody can be so potent, there is the risk that it will cause severe toxicity due to damage to healthy tissues or fast lysis of tumor cells, resulting in a narrow therapeutic window, as is frequently observed with some ADC drugs or TCEs that have been FDA approved or are in clinical development. We believe our POWERbodies enabled by our SAFEbody technology with ADC, TCE,&#160;etc., due to their inactivity in circulation and specific local activation in TME, could significantly reduce toxicity and at the same time retain efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">POWERbody technology aims to boost the efficacy of antibody candidates with safety profiles enhanced by our SAFEbody technology. We believe our POWERbody technology will unleash the full power of antibody-based therapeutics to kill cancer cells with enhanced safety, achieving full potential in antibody-based therapies such as bispecific TCEs and ADCs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">COLLABORATIONS WITH BIOPHARMACEUTICAL COMPANIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We enter into collaborations with biotechnology and pharmaceutical companies to leverage the power of our technology platforms, creating a network of potential future revenue streams that complements future long-term value from our wholly-owned pipeline. These collaborations include both technology licensing agreements and outlicensing of product candidates, which allow us to retain significant future participation in product sales through royalties paid on net sales. In the future, we may also enter into strategic collaborations for our preclinical and clinical assets to both accelerate the path to clinic and drive global commercialization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Previously, we have entered into technology licensing agreements with Sanofi, Exelixis and ADC Therapeutics to develop antibody-based therapeutics against tumor targets using our SAFEbody technology. We have also out-licensed the Greater China rights for two antibody candidates to Dragon Boat Pharmaceuticals and its affiliates. Additionally, we have leveraged our DPL technology platform and antibody discovery and engineering capabilities in discovery efforts with the NIH, and Mitsubishi Tanabe, Celgene (now BMS) and GSK. To further advance our pipeline, we have also put in place various clinical collaborations, including clinical collaboration and supply agreements with Merck who will provide pembrolizumab for certain of our combination clinical trials, and an agreement with research organizations in Singapore for an investigator-initiated trial of our ADG106 clinical candidate in combination with nivolumab.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">118</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our collaborations empower our growth by generating cash flow and revenues that partially offset expenditures on our internal research and development programs, expanding our knowledge base regarding our antibody technologies across multiple targets and antibodies provided by our partners, and providing us with future joint development opportunities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Below are the highlights of those collaborations with our business partners:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Sanofi Collaboration and Technology License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2022, we entered into a collaboration and license agreement (the &#8220;Sanofi Agreement&#8221;) with Genzyme Corporation, a wholly-owned subsidiary of Sanofi (&#8220;Sanofi&#8221;), pursuant to which we agreed to generate masked monoclonal and bispecific antibodies for development and commercialization by Sanofi with our SAFEbody technology. Under the terms of the agreement,&#160;Adagene&#160;will be responsible for early-stage research activities to develop masked versions of Sanofi candidate antibodies, using Adagene&#8217;s SAFEbody technology. Sanofi will be solely responsible for later stage research and all clinical, product development and commercialization activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Sanofi Agreement, we granted Sanofi an exclusive, worldwide, sublicensable license to research, develop, use, make, have made, sell, offer for sale, import and commercialize products containing the masked antibodies to be generated by us. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to certain exclusivity provisions limiting our right to pursue, engage in, on our own or in collaboration with one or more third parties, directly or indirectly, non-clinical (including pre-clinical research) or clinical development of, commercialization of or manufacture for clinical or commercial use, of any research, develop, make, and commercialize any other antibodies directed to the selected targets for a period of five years, subject to exceptions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are required to use commercially reasonable efforts to generate masked antibodies in accordance the program plan for each target at our cost. Sanofi is required to use commercially reasonable efforts to further develop, obtain regulatory approval and commercialize the antibodies at its costs.<span style="color:#4472c4;text-decoration-line:line-through;text-decoration-style:solid;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Sanofi Agreement, we received a $17.5 million upfront payment for Sanofi to advance two initial Sanofi antibody candidates in the collaboration, followed by options to intiate for two additional candidates. To exercise an option, Sanofi is obligated to pay an additional fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally,&#160;we&#160;will be eligible to receive total potential development, regulatory and commercial milestone payments of up to&#160;$2.5 billion&#160;for advancement of the candidates, or $625 million per program. All four potential candidates in the collaboration will be exclusively developed and commercialized by Sanofi.&#160;In addition, we are entitled to receive low to mid-single-digit tiered royalties on global net sales on products developed under the Sanofi Agreement, subject to certain reductions. Royalties, if any, will be payable on a country-by-country and product-by-product basis until the latest of (i) the tenth anniversary of the first commercial sale of such product in such country, (ii) the expiration of the last-to-expire of certain specified patents that cover such product&#8217;s composition of matter or method of use as sold in such country or (iii) the expiration of regulatory exclusivity for such product in such country. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Sanofi Agreement will expire upon the termination of all royalty obligations. Sanofi will own the inventions relating to the compounds arising in connection with the Sanofi Agreement and we will own the inventions relating to our platform. Sanofi may terminate the Sanofi Agreement without cause, in its entirety or on a target-by-target basis or on country-by-country basis, upon a specified notice period, and may terminate for safety reasons on a target-by-target basis upon a specified notice period. Either party has the right to terminate the Sanofi Agreement for cause upon the other party&#8217;s uncured material breach or insolvency. Upon termination of the Sanofi Agreement for any reason, the license granted to Sanofi will terminate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Exelixis Collaboration and Technology License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In February 2021, we entered into a collaboration and license agreement (the &#8220;Exelixis Agreement&#8221;) with Exelixis, Inc., pursuant to which we agreed to generate masked antibodies with our SAFEbody technology against two targets selected by Exelixis. Pursuant to the Exelixis Agreement, we granted Exelixis an exclusive, worldwide, sublicensable license to research, develop, make, have made, sell, offer for sale, import and commercialize products containing the masked antibodies to be generated by us with respect to both targets.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">119</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In December 2021, we achieved a key milestone in the collaboration for successful nomination of SAFEbody candidates, which triggered a $3.0 million milestone payment received by Adagene in January 2022. As of the date of this annual report, we have received US$14.0 million in aggregate payments under the Exelixis Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are subject to certain exclusivity provisions limiting our right to research, develop, make, and commercialize any other antibodies directed to the selected targets during the term of the Exelixis Agreement, subject to exceptions for antibodies with sequence identities that differ by a specified amount. Exelixis is subject to certain exclusivity provisions limiting its rights to research, develop, make, and commercialize any other masked antibodies directed to the selected targets during the term of the Exelixis Agreement, subject to exceptions for antibodies with sequence identities that differ by a specified amount or use different masking technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We are required to use commercially reasonable efforts to generate masked antibodies in accordance the program plan for each target at our cost. Exelixis is required to use commercially reasonable efforts to further develop, obtain regulatory approval and commercialize a product for each target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Under the Exelixis Agreement, we received an $11,000,000 upfront payment. In addition, in the aggregate, we could be eligible to receive up to $55,000,000 in development milestone payments, $200,000,000 in regulatory milestone payments, and up to $525,000,000 in sales milestone payments for both targets under the Exelixis Agreement. In addition, we are entitled to receive mid-single-digit percentage net sales-based royalties on products developed under the Exelixis Agreement, subject to certain reductions. Royalties, if any, will be payable on a country-by-country and product-by-product basis, until the latest of (i) the tenth anniversary of the first commercial sale of such product in such country, (ii) the expiration of the last-to-expire of certain specified patents that cover such product&#8217;s composition of matter or method of use as sold in such country or (iii) the expiration of regulatory or data exclusivity for such product in such country.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Exelixis Agreement will expire upon the termination of all royalty obligations. Exelixis will own the inventions relating to the compounds arising in connection with the Exelixis Agreement and we will own the inventions relating to our platform. Exelixis may terminate the Exelixis Agreement without cause, in its entirety or on a target-by-target basis, upon a specified notice period, and may terminate for safety reasons on a target-by-target basis immediately upon notice. Either party has the right to terminate the Exelixis Agreement for cause upon the other party&#8217;s uncured material breach or insolvency, provided that, upon our material uncured breach, Exelixis may elect to instead continue the Exelixis Agreement, and any subsequent milestones or royalty amounts payable to us after such time will be reduced by a specified percentage. Upon termination of the Exelixis Agreement for any reason, the license granted to Exelixis will terminate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">ADC Therapeutics Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2019, we entered into a material transfer and collaboration agreement (the &#8220;ADCT Collaboration Agreement&#8221;) and a license agreement (the &#8220;ADCT License Agreement&#8221;) with ADC Therapeutics, a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of targeted ADCs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">ADCT Collaboration Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the ADCT Collaboration Agreement, we agreed to generate masked antibodies with our SAFEbody technology that could be combined with the pyrrolobenzodiazepine-based cytotoxic payload used in ADC Therapeutics&#8217; ADCs to create novel ADCs. ADC Therapeutics entered into the ADCT Collaboration Agreement with us to evaluate the use of our SAFEbody technology with respect to up to two exclusive targets selected by ADC Therapeutics. Upon our delivery of certain initial results, ADC Therapeutics has the option to license our SAFEbody technology with respect to one or both targets as further detailed below. ADC Therapeutics has not yet exercised such options as of the date of this annual report.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">120</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Both parties are required to use commercially reasonable efforts to perform certain development obligations under the ADCT Collaboration Agreement. Additionally, we are subject to exclusivity obligations to ADC Therapeutics under the ADCT Collaboration Agreement with respect to (i)&#160;the targets for which ADC Therapeutics has a license or an option to license and (ii)&#160;the use or licensing of our intellectual property that is necessary or useful to the development plan under the ADCT Collaboration Agreement or that would preclude us from granting to ADC Therapeutics the licenses under the ADCT License Agreement. ADC Therapeutics owns intellectual property that are specific to the SAFEbodies that we develop under the ADCT Collaboration Agreement with respect to the two elected targets, and we will own all intellectual property developed under the ADCT Collaboration Agreement that relates generally to our SAFEbody platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the ADCT Collaboration Agreement, we are eligible to receive up to US$1,600,000 in consideration for our exclusivity obligations, upon achievement of certain development milestones and upon ADC Therapeutics&#8217; election to proceed with development for the two elected targets. As of the date of this annual report, we have received US$550,000 in aggregate payments under the ADCT Collaboration Agreement. ADC Therapeutics has the right to terminate the ADCT Collaboration Agreement at any time and for any reason in its entirety or on a target-by-target basis upon thirty days&#8217; prior written notice to us. Either party may terminate the ADCT Collaboration Agreement, in its entirety or on a target-by-target basis, upon the other party&#8217;s uncured material breach of the agreement or the other party&#8217;s insolvency-related events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">ADCT License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Subject to the exercise of the options contained in the ADCT Collaboration Agreement, we have granted ADC Therapeutics, with respect to each elected target, an exclusive, worldwide, perpetual and irrevocable (subject only to the termination provisions) license (with the right to grant sublicenses) to develop, make, use, commercialize and import the antibody drug conjugates that comprise masked antibodies generated by us under these programs. Subject to certain conditions, including the exercise by ADC Therapeutics of its first option to license our SAFEbody technology, ADC Therapeutics will grant us the option to negotiate a license to develop, manufacture and commercialize ADCs containing our SAFEbody technology in Greater China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the ADCT License Agreement, if ADC Therapeutics exercises both of its options granted thereunder, we could be eligible to receive up to US$166,090,000 in aggregate milestone payments, in addition to mid-single-digit percentage net sales-based tiered royalties on products licensed under the ADCT License Agreement, subject to certain reductions. Royalties, if any, will be payable on a country-by-country and product-by-product basis, until the earlier of (i)&#160;the tenth anniversary of the first commercial sale of such product or (ii)&#160;the expiration of the last-to-expire patent licensed under the agreement in such country, unless earlier terminated by the parties, following which any licenses granted to ADC Therapeutics under the ADCT License Agreement shall become fully paid up, perpetual and irrevocable. In addition to the contingent milestone and royalty payments, if ADC Therapeutics exercises both of its options granted under the ADCT Collaboration Agreement, we are also entitled to a mid-six-figure dollar amount annual maintenance fee. ADC Therapeutics has not yet exercised the options contained in the ADCT Collaboration Agreement as of the date of this annual report. Therefore, we have not received any payment under the ADCT License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ADC Therapeutics has the right to terminate the ADCT License Agreement before the expiration of the royalty term on a product-by-product basis or in its entirety (i)&#160;for any reason or no reason upon thirty days&#8217; written notice to us, or (ii)&#160;if ADC Therapeutics chooses to discontinue the development or sale of the applicable licensed product worldwide. Each party has certain rights to terminate the ADCT License Agreement with prior written notice upon the other party&#8217;s uncured material breach or insolvency.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">121</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Sanjin Collaboration/ Out-Licensing Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">2018 Collaboration Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2018, we entered into (i)&#160;a collaboration agreement (the &#8220;Sanjin Greater China Agreement&#8221;) that covers Greater China with Guilin Sanjin Pharmaceutical Co.,&#160;Ltd. (&#8220;Sanjin&#8221;) and certain of its subsidiaries (collectively, &#8220;Sanjin Parties&#8221;) and (ii)&#160;a collaboration agreement (the &#8220;Sanjin ROW Agreement&#8221;, together with the Sanjin Greater China Agreement, the &#8220;2018 Sanjin Agreements&#8221;) that covers the regions other than Greater China with Sanjin. Pursuant to the Sanjin Greater China Agreement, we transferred the Chinese intellectual property directly related to a monoclonal antibody molecule that binds to the PD-L1 target (the &#8220;PD-L1 Project&#8221;), including patent rights, patent application rights and technologies based on the core sequence of the molecule, to Sanjin Parties. Sanjin Parties will own all the Chinese intellectual property developed in the exercise of Sanjin Parties&#8217; rights under the agreement, including but not limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights relating thereto. We also granted Sanjin Parties a royalty-free license to use our other existing intellectual property and improvements thereto which are related to the PD-L1 Project for the purposes of exploiting its rights and performing its obligations under the agreement. Sanjin Parties will enjoy all the economic benefits deriving from the PD-L1 Project in Greater China, including but not limited to patent transfer fee, licensing fee, sales revenue and sales commission,&#160;etc. Sanjin Parties will pay us (i)&#160;within the validity period of the patent of PD-L1 molecule, single-digit percentage of net sales of the products that use the licensed antibody after such products enter the market and (ii)&#160;a low to mid-low double-digit percentage of the profits resulting from any transfer of the license to any third parties depending on the timing of the transfer relative to the development stage of the product. We also received a low-seven figure dollar upfront fee upon the effectiveness of the agreement from Sanjin Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Sanjin ROW Agreement, we granted Sanjin a royalty-free license to use all intellectual property relating to (i)&#160;the collaboration under the agreement that we controlled before we entered into the agreement or acquired independently of the agreement and (ii)&#160;improvements thereto for the purposes of exploiting its rights and performing its obligations under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such intellectual property, and any intellectual property generated from cooperation between us and Sanjin&#8217;s affiliates in connection with the collaboration will be jointly owned. We have the right to apply for the patents derived from our core and key technologies pertaining to the PD-L1 molecule in the rest of the world and we retain a majority of the economic benefits derived from the Sanjin ROW Agreement, including but not limited to any patent transfer fee, licensing fee and gains realized under such transfer. In case we intend to transfer to a third party our share of economic interests in any country outside of Greater China, we must notify Sanjin and Sanjin will receive a right of first refusal if it pays us a deposit equal to a low double-digit percentage of the consideration that we expect to receive from such third party. If Sanjin waives the right of first refusal, we can proceed with the transfer, provided that the final transaction price with the third party is not lower than the amount of the offering price that was included in our notice to Sanjin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the 2018 Sanjin Agreements, we agreed not to (i)&#160;independently develop any monospecific antibodies that bind to the PD-L1 target or (ii)&#160;grant any rights associated with such antibodies to any third parties during the three-year period from the effective date of the agreements. The exclusivity obligation does not prevent us from (i)&#160;developing or granting any licenses to third parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and probody against PD-L1 target and (ii)&#160;continuing to provide antibody screening service that were commenced before the execution of the Sanjin Greater China Agreement and either party has the independent right to conduct combination therapy studies outside of the Greater China. Either non-breaching party may terminate the 2018 Sanjin Agreements if the other party&#8217;s ability to comply with its respective obligations under the agreements is negatively affected by contingencies such as failure to maintain operation or changes in core project management and the other party fails to take effective remedial measures. Each agreement automatically terminates upon the termination of the other agreement. Upon the rescission or termination, Sanjin Parties will return to us all the intellectual property transferred by us to the Sanjin Parties as well as documents and data provided by us under the 2018 Sanjin Agreements. The 2018 Sanjin Agreements are governed by PRC law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During 2021, Sanjin advanced this anti-PDL-1 monoclonal antibody (ADG104) into Phase 2 development, following completion of a Phase 1 program that, according to Sanjin, showed an ORR in NPC of over 20%.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">122</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">2019 Collaboration Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2019, we entered into (i)&#160;a collaboration agreement that covers Greater China (the &#8220;Dragon Boat Greater China Agreement&#8221;) and (ii)&#160;a collaboration agreement that covers the regions other than Greater China (the &#8220;Dragon Boat ROW Agreement,&#8221; together with the Dragon Boat Greater China Agreement, the &#8220;2019 Dragon Boat Agreements&#8221;), with Dragon Boat Biopharmaceutical (Shanghai) Limited. (&#8220;Dragon Boat&#8221;), a subsidiary of Sanjin. Pursuant to the Dragon Boat Greater China Agreement, we will transfer the Chinese intellectual property directly related to a certain monoclonal antibody molecule (the &#8220;Specified Molecule&#8221;) that binds to a specified target (the &#8220;Specified Project&#8221;), including the patent rights, patent application rights and technologies based on the core sequence of the molecule, to Dragon Boat. Dragon Boat will own all the Chinese intellectual property developed in the exercise of Dragon Boat&#8217;s rights under the agreement, including but not limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights relating thereto. We also granted Dragon Boat a royalty-free license to use our other existing intellectual property and improvements thereto which are related to the Specified Project for the purposes of exploiting its rights and performing its obligations under the agreement. Dragon Boat will enjoy all the economic benefits deriving from the Specified Project in Greater China, including but not limited to patent transfer fee, licensing fee, sales revenue and sales commission,&#160;etc. and will pay us (i)&#160;RMB6,000,000 (equivalent to approximately US$0.9 million) milestone payments and (ii)&#160;a single-digit percentage of net sales of the products that within the validity period of the patent of the Specified Molecule use the licensed antibody after such products enter the market. Dragon Boat also paid us a mid-six figure dollar upfront fee upon the signing of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Dragon Boat ROW Agreement, we granted Dragon Boat a royalty-free license to use all intellectual property relating to (i)&#160;the collaboration under the agreement that we controlled before we entered into the agreement or acquired independently of the agreement and (ii)&#160;improvements thereto for the purposes of exploiting its rights and performing its obligations under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such intellectual property, and any intellectual property generated from cooperation between us and Dragon Boat in connection with the collaboration will be jointly owned. We have the right to apply for the patents derived from our core and key technologies pertaining to the Specified Molecule in the rest of the world and we retain a majority of the economic benefits derived from the Dragon Boat ROW Agreement, including but not limited to any patent transfer fee, licensing fee and gains realized under such transfer. In case we intend to transfer to a third party our share of economic interests in any country outside of Greater China, we must notify Dragon Boat and Dragon Boat will receive a right of first refusal if it pays us a deposit equal to a low double-digit percentage of the consideration that we expect to receive from such third party. If Dragon Boat waives the right of first refusal, we can proceed with the transfer, provided that the final transaction price with the third party is not lower than the amount of the offering price that was included in our notice to Dragon Boat.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the 2019 Dragon Boat Agreements, we agreed not to (i)&#160;independently develop any monospecific antibodies that bind to the specified target or (ii)&#160;grant any rights associated with such antibodies to any third parties during the three-year period from the effective date of the agreements. The exclusivity obligation does not prevent us from (i)&#160;developing or granting any licenses to third parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and probody against the specific target and (ii)&#160;continuing to provide antibody screening service that were commenced before the execution of the Dragon Boat Greater China Agreement and either party has the independent right to conduct combination therapy studies outside of the Greater China. Either nonbreaching party may terminate the 2019 Dragon Boat Agreements if the other party&#8217;s ability to comply with its obligations under the agreements is negatively affected by contingencies such as failure to maintain operation or changes in core project management and the other party fails to take effective remedial measures. Each agreement automatically terminates upon the termination of the other agreement. Upon the rescission or termination, Dragon Boat will return to us all the intellectual property transferred by us to Dragon Boat as well as documents and data provided by us under the 2019 Dragon Boat Agreements. The 2019 Dragon Boat Agreements are governed by PRC law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">During 2021, Dragon Boat advanced this candidate, an anti-CSF-1R monoclonal antibody (ADG125/BC006) into phase 1 development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">As of the date of this annual report, we have received approximately US$1.5 million and US$1.2 million in aggregate payments under the 2018 Sanjin Agreements and the 2019 Dragon Boat Agreements, respectively.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">123</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;text-transform:uppercase;">Additional Discovery AGREEMENTs</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">In addition to our SAFEbody technology licensing collaborations and out-licensing collaborations, from time to time, we further enhance our discovery efforts to leverage our DPL platform and antibody engineering capabilities with other biotechnology and pharmaceutical companies. These activities further validate our technologies and establish foundations to expand our relationships with various organizations and global biopharmaceutical companies with whom we may partner in the future.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">Examples of such agreements include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We extended the term of our research collaboration agreement, or the NIH RCA, with the National Heart Lung and Blood Institute, part of the National Institutes of Health, or NIH, to 2023. In January 2021, we announced the successful completion of our component of the collaboration. The NIH now leads and is responsible for the manufacturing and clinical development of the CAR-T cell therapy candidate. We first entered into the NIH RCA in March 2018 to collaborate with Dr. Richard Childs, Chief of the Laboratory of Transplantation Immunotherapy at NHLBI, who has used antibodies discovered by us to develop a CAR-T cell therapy candidate targeting a human endogenous retrovirus expressed in the majority of clear cell kidney tumors. The extension of the NIH RCA will allow us to use our proprietary antibody technology to further collaborate with Dr. Richard Childs and his team to develop other antibodies. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Under a material transfer agreement, we are developing SAFEbody drug conjugates against a tumor target selected by Tanabe Research Laboratories, Inc., or TRL, with potential for negotiating a future license agreement with TRL if our pilot work proves successful;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We had worked with Celgene (now Bristol-Myers Squibb) to discover antibodies targeting novel antigens using our proprietary DPL platform;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We entered into an evaluation agreement with a global biotechnology company, or the Evaluation Agreement, under which we are developing bispecific antibodies leveraging our SAFEbody and bispecific technologies against tumor targets provided by the counterparty. The Evaluation Agreement could facilitate the parties&#8217; interest in a further collaboration concerning the development of a new antibody therapeutic; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We had previously collaborated with GlaxoSmithKline (China), or GSK China, where we were engaged to generate high affinity antibodies against multiple epitopes of multi-transmembrane targets; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We previously worked with Jiangsu Hengrui Medicine Company Limited, or Jiangsu Hengrui, where we were able to discover cross-reactive agonistic antibody for immuno-oncology.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CLINICAL COLLABORATION AGREEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To further advancement of our pipeline, we have also put in place various clinical collaborations with pharmaceutical companies and academic or research organizations. During 2021, we completed several such agreements to support the clinical evaluation of our wholly-owned pipeline candidates. These include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In July 2021, we entered into two clinical collaborations with Merck, a leader in immuno-oncology. The clinical collaboration and supply agreements include two open-label, dose escalation and expansion clinical studies to evaluate our anti-CTLA-4 mAb product candidates, ADG116 and ADG126, in combination with pembrolizumab for patients with advanced/metastatic solid tumors, respectively. Under terms of the agreement, Merck provides pembrolizumab and input in the design of planned clinical trials evaluating pembrolizumab in combination with ADG116 and ADG126, respectively. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In August 2021, we entered into a third clinical collaboration and supply agreement with Merck to evaluate ADG106 in combination with pembrolizumab in advanced or metastatic solid and/or hematological malignancies. Under terms of the agreement, Merck provides pembrolizumab and input in the design of a planned clinical trial evaluating pembrolizumab in combination with ADG106.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">124</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In October 2021, we announced an agreement with research organizations in Singapore for an investigator-initiated trial of our ADG106 clinical candidate. The phase 1b/2 clinical trial (ADG106-T6001) is evaluating ADG106 in combination with the anti-PD-1 antibody, nivolumab, for patients with advanced non-small cell lung cancer (NSCLC) who have progressed after prior treatment. The investigator-initiated trial is being conducted at the National University Cancer Institute, Singapore and the National Cancer Centre Singapore, in collaboration with the Singapore Translational Cancer Consortium.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">INTELLECTUAL PROPERTY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Protection of our intellectual property is fundamental to the long-term success of our business. Specifically, our success is dependent on our ability to obtain and maintain protection for our technology and the know-how related to our business, defend and enforce our intellectual property rights, and operate our business without infringing, misappropriating, or otherwise violating valid and enforceable intellectual property rights of others. Our patent strategy is focused on seeking coverage for our core technologies and products, such as the DPL platform, ADG116, ADG126, and ADG106. We also rely on trade secret protection of our confidential information and know-how relating to our proprietary technology, platforms and product candidates, and continuing innovation to develop, strengthen, and maintain our proprietary position in our technology, platforms and product candidates. We expect to rely on data exclusivity, market exclusivity, patent term adjustment and patent term extensions when available.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March 31, 2022, we own two issued patents and nine pending patent applications in China and we also own two issued patents and eight pending applications in Europe filed with the European Patent Office, one issued patent, 15 pending patent applications and four pending provisional applications in the United States, as well as 11 pending international PCT applications and 76 pending patent applications in other jurisdictions. Our patents and patent applications cover our key technologies and product candidates, including the DPL platform, our clinical candidates, ADG116, ADG126, and ADG106 and our preclinical candidates including ADG206, ADG153, ADG138 and ADG152. Excluding any patent term adjustment and patent term extension, our currently issued patents are expected to expire from 2033 to 2037. If any patents issue from our pending patent applications, excluding any patent term adjustments and patent term extension, such patents will be expected to expire from 2033 to 2042. The following table summarizes material pending patent applications in the United States, China, Europe and under Patent Cooperation Treaty, or PCT, covering our product candidates, including ADG116, ADG126, ADG106 and ADG104 and ADG125.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:24.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:24.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:24.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:19.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:24.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Product Candidates</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:24.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title&#160;of&#160;Patent&#160;Application</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:24.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Type&#160;of&#160;Patent&#160;Applications</b><b style="font-family:'Times New Roman Bold';font-weight:bold;">(1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:19.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Jurisdiction</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:24.88%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">ADG106</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Anti-CD137 molecules and uses thereof Combination therapy comprising anti-CD137 antibodies</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Composition of matter/ method of use/ method of making method of treatment/ method of use</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.37%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">United States of America China and European Patent Office United States of America</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">ADG126</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Anti-CTLA4 antibodies and methods of making and using the same</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Composition of matter/ method of use/ method of making</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">United States of America, China and European Patent Office</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">ADG116</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Anti-CTLA4 antibodies and methods of making and using the same</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Composition of matter/ method of use/ method of making</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">United States of America, China and European Patent Office</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">ADG104</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Anti-PD-L1 antibodies and use thereof</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Composition of matter/ method of use/ method of making</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">United States of America and European Patent Office</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">ADG125</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Anti-CSF1R molecules and use thereof</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Composition of matter/method of use/method of making</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:19.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patent Cooperation Treaty<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(2)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">You should read the Risk Factors included elsewhere in this annual report for important information about risks posed by the loss of patent protection, in particular the risks described under &#8220;Item 3 Key Information&#8212;3.D.Risk Factors&#8212;Risks Related to Our Intellectual Property&#8221;.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Patent Application of ADG125 has not yet entered into national phase of Patent Cooperation Treaty.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">125</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes material issued patents in Europe and China covering our proprietary technologies.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:24.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:24.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:24.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:20.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:24.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Application No.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:24.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title&#160;of&#160;Patent</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:24.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Type&#160;of&#160;Patent</b><b style="font-family:'Times New Roman Bold';font-weight:bold;">(1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:20.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Jurisdiction</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:24.39%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">13877452.6</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">An Integrated System for Library Construction, Affinity Binder Screening and Expression Thereof</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Method</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.75%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">European Patent Office</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">201380074656.1</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">An Integrated System for Library Construction, Affinity Binder Screening and Expression Thereof</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Method</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">China</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">14908246.3</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Methods and Systems for Autoinduction of Protein Expression</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Method</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">European Patent Office</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">201410789857.6</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Filter Vector System And Its Applications</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Method</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">China</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:24.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">16108018</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Anti-CD137 Molecules and Use Thereof</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:24.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Composition of matter</p></td><td style="vertical-align:top;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">United States of America</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">You should read the Risk Factors included elsewhere in this annual report for important information about risks posed by the loss of patent protection, in particular the risks described under &#8220;Item 3 Key Information&#8212;3.D.Risk Factors&#8212;Risks Related to Our Intellectual Property&#8221;.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We continually assess and refine our intellectual property strategy as we develop new platform technologies and product candidates. To that end, we are prepared to file additional patent applications relating to the new technologies that we develop if our intellectual property strategy requires such filings, or where we seek to adapt to competition or seize business opportunities. In addition to filing and prosecuting patent applications in China and the United States, we may elect to file counterpart patent applications in additional countries and regions where we believe such foreign filing is likely to be beneficial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As with other biopharmaceutical companies, our ability to maintain and solidify our proprietary and intellectual property position for our platform technologies and product candidates will depend on our success in obtaining effective patent claims and enforcing those claims if granted. However, our owned pending patent applications, and any patent applications that we may in the future file or license from third parties may not result in the issuance of patents. In addition, the term of individual issued patents depends upon the legal term for patents in the countries in which they are obtained. In most countries in which we have filed or intend to file in the future, including the United States, the patent term is 20 years from the earliest filing date of a nonprovisional patent application. We intend to seek patent term extensions to any of our issued patents in any jurisdiction where these are available; however, there is no guarantee that the applicable authorities will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. The life of a patent, and the protection it affords, is therefore limited and once the patent life of our issued patents has expired, we may face competition, including from other competing technologies. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">126</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">We seek to ensure that investments made into the development of our technology are protected by relying on a combination of patents, trademarks, copyrights, trade secrets and contractual rights, including license agreements. In addition to our patent portfolio described above, as of March&#160;31, 2022, our PRC subsidiary owns 46 registered trademarks relating to various aspects of our operations, and two registered domain names in China. To protect our rights, we seek to enter into confidentiality agreements, nondisclosure agreements and employee disclosure and invention assignment agreements with our employees, contractors and other third parties who may have or need access to our confidential information. We have also employed internal policies, encryptions and data security measures to protect our proprietary rights. However, there can be no assurance that our efforts will be successful. If our employees, contractors or other third parties violate these agreements or otherwise infringe upon, misappropriate or otherwise violate our intellectual property rights, we may seek to enforce our rights against such parties. In addition, from time to time, third parties may initiate litigation against us alleging infringement, misappropriation or other violation of their proprietary rights or declaring their noninfringement of our intellectual property rights. An adverse result in any such proceeding could enjoin the commercialization of our technology platform and product candidates, result in significant damages, and have a material adverse effect on our business. Even if we are successful in any such litigation, we may be required to incur significant costs and dedicate significant personnel time in defending such litigation. For more information on these and other risks related to intellectual property, see &#8220;Item 3 Key Information&#8212;3.D. Risk Factors&#8212;Risks Related to Our Intellectual Property&#8221;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">MANUFACTURING AND SUPPLY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Adagene currently outsources the GMP manufacturing, QC testing and QA release of clinical trial materials to WuXi Biologics. We have entered into a framework agreement with Wuxi Biologics, under which it provides services to us on a project-by-project basis. Adagene is also working with other qualified manufacturers to diversify manufacturing outsourcing for the clinical supply production. Adagene has assembled a seasoned internal team with rich experience to oversee the clinical manufacturing to comply with cGMP guidelines and other applicable regulations required by agencies. Currently, Wuxi Biologics as our main CDMO is responsible for obtaining raw materials from multiple suppliers that we believe have sufficient capacity to meet our demands. We expect to continue our relationships with WuXi Biologics while Adagene is continuously evaluating multiple global vendors to ensure continuous supply of Adagene pipeline products for on-going and planned clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">COMPETITION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are highly competitive and characterized by continuing technological advancement, significant competition and an emphasis on intellectual property. While we believe that our management&#8217;s research, development and commercialization experience provide us with competitive advantages, we face potential competition from many different sources, including global biopharmaceutical companies, major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities, academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for the research, development, manufacturing and commercialization of cancer immunotherapies. Any product candidates that we successfully develop and commercialize will compete with new immunotherapies and other drug products that may become available in the future. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer and more effective, have fewer or less severe side effects or are more convenient than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we do.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop cancer treatments. There are many other companies that have commercialized and/or are developing immuno-oncology treatments for cancer, including large pharmaceutical and biotechnology companies. Many of our competitors have significantly greater financial, technical and human resources than we have, and mergers and acquisitions in the biopharmaceutical industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our commercial opportunities could be reduced or eliminated if our competitors develop or market products or other novel therapies that are more effective, safer or less costly than our current or future product candidates, or obtain regulatory approval for their products more rapidly than we may obtain approval for our product candidates.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">127</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Our clinical stage products include ADG116 and ADG126, which are investigational fully human anti-CTLA-4 mAbs generated through our NEObody and SAFEbody technologies, respectively. We expect our primary competition for these two candidates to be within the anti-CTLA-4 antibody market. As of March 31, 2022, Yervoy (ipilimumab) from BMS is the only marketed CTLA-4 drug targeting cancer with six indications including monotherapy and combination therapies approved by FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January 2020, BMS submitted a biologics license application, or BLA, with the FDA for Opdivo in combination with Yervoy for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations. In April 2020, the FDA approved Opdivo (nivolumab) plus Yervoy, administered concomitantly with a limited course of chemotherapy, for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations. In April 2022, BMS announced that the European Commission (EC) approved Opdivo in combination with Yervoy for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) with tumor cell PD-L1 expression &#8805; 1%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">While Yervoy is the only marketed anti-CTLA-4 antibody drug, there are multiple anti-CTLA-4 antibodies in clinical development globally. Examples of these programs include:  AstraZeneca (tremelimumab), Agenus (Zalifrelimab/AGEN1181), Bristol-Myers Squibb Company (BMS-986249, BMS-986288), Merck (quavonlimab/MA-1308), Onco-C4, Inc. (ONC-392) and Xilio (XTX101). Yervoy was also approved in China in 2021, where additional CTLA-4 antibodies are in clinical development. These anti-CTLA-4 therapies in development in China include HBM4003 from Harbour BioMed and CD1002 from CStone Pharmaceuticals (Suzhou) Co., Ltd.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Major limitations of anti-CTLA-4 mAbs include toxicity. According to our internal market analysis, nivolumab and ipilimumab combination therapy has shown relatively higher toxicity in clinical studies even at lower dosages, which was observed from the published clinical data. We believe that the continued expansion of indications, and the launch of innovative novel anti-CTLA-4 antibodies with potential for higher safety and better efficacy may increase the market for CTLA-4 antibodies significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are also developing ADG106, an investigational fully human ligand-blocking, agonistic anti-CD137 IgG4 mAb that is designed to target a unique conserved epitope of CD137. We expect our primary competition for this candidate to be with other clinical-stage CD137 agonist product candidates. As of the date of this annual report, there are no marketed CD137 agonist drugs. The two leading molecules in clinical trials are utomilumab (PF-05082566) from Pfizer and urelumab (BMS-663513) from BMS. Other anti-CD137 candidates in earlier stages of development include ATOR-1017 from Alligator Bioscience, CTX-471 from Compass, and AGEN2373 from Agenus.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">INSURANCE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We provide social security insurance including pension insurance, unemployment insurance, work-related injury insurance and medical insurance for our employees. We maintain property insurance, general liability insurance, products/completed operations insurance, auto and international auto liability insurance, workers compensation insurance, key-men insurance, international workers compensation insurance, accident and health insurance and director and officer liabilities insurance. We consider our insurance coverage sufficient and in line with market practice for our business operations in the industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">LEGAL PROCEEDINGS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. As of the date of this annual report, we are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">128</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">MATERIAL LICENSES AND APPROVALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth a list of material licenses and approvals, subject to further renewal, that our PRC subsidiary is required to obtain to carry out our operations in China.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">License</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Entity&#160;Holding&#160;the&#160;License</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;"><b style="font-weight:bold;">Regulatory&#160;Authority</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Business License</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;">Adagene Suzhou</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;">SAMR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Approval Letter for Drug Clinical Trial of ADG104*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;">Adagene Suzhou</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;">NMPA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Approval Letter for Drug Clinical Trial of ADG106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;">Adagene Suzhou</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;">NMPA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Approval Letter for Drug Clinical Trial of ADG116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;">Adagene Suzhou</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;">NMPA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">Approval Letter for Drug Clinical Trial of ADG126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;">Adagene Suzhou</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;">NMPA</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 7.2pt;">* Note: We have out-licensed the Greater China rights of ADG104 to our partner Sanjin.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:31.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 7.2pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:9pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">REGULATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">United States Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory authorities at federal, state, and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biologics such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates biologic products under the Federal Food, Drug and Cosmetic Act, and the Public Health Service Act and the implementing regulations and other laws, including, in the case of biologics, the Public Health Service Act. Our product candidates are subject to regulation by the FDA as biologics. Biologics require the submission of a BLA and licensure, which constitutes approval, by the FDA before being marketed in the United States. None of our product candidates has been approved by the FDA for marketing in the United States, and we currently have no BLAs pending. Failure to comply with applicable FDA or other requirements at any time during product development, clinical testing, the approval process or after approval may result in administrative or judicial sanctions. These sanctions could include the FDA&#8217;s refusal to approve pending applications, suspension or revocation of approved applications, warning letters, product recalls, product seizures, total or partial suspensions of manufacturing or distribution, injunctions, fines, civil penalties or criminal prosecution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The process required by the FDA before biologic product candidates may be marketed in the United States generally involves the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s GLP regulations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent Institutional Review Board, or IRB, or ethics committee at each clinical site before the trial is commenced;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials to establish the safety and effectiveness of the proposed biologic product candidate for its intended indications;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">129</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparation of and submission to the FDA of a BLA when adequate data are obtained from pivotal clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a determination by the FDA within 60 days of its receipt of a BLA to accept the application for review;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMP and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with Good Clinical Practices, or GCP regulations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA review and approval of the BLA to permit commercial marketing of the product for particular indications for use in the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Preclinical and Clinical Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND application to the FDA. An IND application is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND application is on the general investigational plan and the protocol(s)&#160;for clinical trials. The IND application also includes results of animal and in vitro studies assessing the toxicology, pharmacokinetics, pharmacology, and pharmacodynamic characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. If the IND sponsor is not able to address FDA&#8217;s concerns satisfactorily within the 30-day time frame, the IND may be placed on clinical hold. The IND sponsor and the FDA must resolve any outstanding concerns or questions before the IND is cleared by the FDA and the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Generally, a separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site, and must monitor the study until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, or DSMB, which provides recommendation on whether or not a study should move forward at designated check points based on access to certain data from the study. The DSMB may recommend halting of the clinical trial if it determines that there is an unacceptable safety risk for subjects or on other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase I&#8212;The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. For investigational products developed for oncology indications, the Phase I trials are normally conducted in patients with serious or life-threatening diseases without other treatment alternatives.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">130</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase II&#8212;The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase II clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase III clinical trials. For certain indications in patients with serious or life-threatening diseases and with no available therapies, it may be possible to obtain BLA approval based on data from Phase II trials if a positive benefit risk profile is demonstrated.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase III&#8212;The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 studies may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate, and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">BLA Submission and Review</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, preclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls and proposed labeling, among other things. The submission of a BLA requires payment of a substantial application user fee to the FDA unless a waiver or exemption applies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Once an original BLA has been submitted, FDA has 60 days to determine whether the application can be filed. If FDA determines that an application to be deficient, on its face, in a way that precludes a complete review, FDA may not accept the application for review and may issue a refuse-to-file letter to the sponsor. If FDA determines the application is filable, the FDA&#8217;s goal is to review standard applications within ten months after it accepts the application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facilities in which it is manufactured, processed, packed, or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">131</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the commercial product and/or its drug substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots, and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Expedited Development and Review Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for frequent interactions with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, in which case the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A product intended to treat a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase I and an organizational commitment to expedite the development and review of the product, including involvement of senior managers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any marketing application for a biologic submitted to the FDA for approval, including a product with a fast track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition compared to marketed products. For products containing new molecular entities, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date (compared with ten months under standard review).</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">132</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Additionally, products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well- controlled post-marketing clinical trials to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2017, FDA established a new regenerative medicine advanced therapy, or RMAT, designation as part of its implementation of the 21st Century Cures Act, which was signed into law in December&#160;2016. The RMAT designation program is intended to fulfill the 21st Century Cures Act requirement that FDA facilitate an efficient development program for, and expedite review of, any drug that meets the following criteria: (1)&#160;it qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2)&#160;it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3)&#160;preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. Like fast track and breakthrough therapy designation, RMAT designation provides potential benefits that include more frequent meetings with the FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through the submission of clinical evidence, clinical trials, patient registries, or other sources of real-world evidence such as electronic health records; through the collection of larger confirmatory datasets; or through post-approval monitoring of all patients treated with the therapy prior to approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Fast track designation, breakthrough therapy designation, priority review, accelerated approval, and RMAT designation do not change the standards for approval but may expedite the development or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Orphan Drug Designation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making available a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application fee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">133</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Post-Approval Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, warning letters or holds on post-approval clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal of the FDA to permit the import or export of products; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injunctions or the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Such off-label uses are common across medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Biosimilars and Reference Product Exclusivity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">134</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity, and potency, can be shown through analytical studies, animal studies, and a clinical trial or studies. Interchangeability requires that a product be biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered to a patient more than once, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biological products, as well as the processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the FDA may not approve a biosimilar product until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the competing product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, FDA has stated that products deemed &#8220;interchangeable&#8221; can be readily substituted by pharmacies, depending on state pharmacy laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate implementation and impact of the BPCIA is subject to significant uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Other Healthcare Laws and Compliance Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, receiving, offering or paying remuneration, to induce, or in return for, either the referral of an individual, or the purchase or recommendation of an item or service for which payment may be made under any federal healthcare program;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment to the federal government, including federal healthcare programs, that are false or fraudulent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes which prohibit, among other things, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters, and which, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, also imposes certain requirements on HIPAA covered entities and their business associates relating to the privacy, security and transmission of individually identifiable health information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the U.S. federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the federal government, information related to payments or other transfers of value made to physicians, as defined by such law, certain other health care providers beginning in 2022, and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">United States state and foreign law equivalents of each of the above federal laws, which, in some cases, differ from each other in significant ways, and may not have the same effect, thus complicating compliance efforts, including laws governing the privacy and security of personal data, such as the GDPR, which imposes obligations and restrictions on the collection and use of personal data relating to individuals located in the EU and EEA (including with regard to health data).</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">135</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If their operations are found to be in violation of any of such laws or any other governmental regulations that apply, they may be subject to significant penalties, including, without limitation, civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Coverage and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Significant uncertainty exists as to the coverage and reimbursement status of any pharmaceutical or biological product for which we obtain regulatory approval. Sales of any product depend, in part, on the extent to which such product will be covered by third-party payers, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payers. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. As there is no uniform policy of coverage and reimbursement for drug products among third-party payers in the United States, coverage and reimbursement policies for drug products can differ significantly from payer to payer. There may be significant delays in obtaining coverage and reimbursement as the process of determining coverage and reimbursement is often time-consuming and costly which will require us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that coverage or adequate reimbursement will be obtained. It is difficult to predict at this time what government authorities and third-party payers will decide with respect to coverage and reimbursement for our drug products. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Third-party payers are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing the cost effectiveness of pharmaceutical or biological products, medical devices and medical services, in addition to questioning safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payer not to cover a product could reduce physician usage and patient demand for the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Healthcare Reform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded healthcare programs, and increased governmental control of drug pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2010, the ACA was signed into law, which substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, and annual fees based on pharmaceutical companies&#8217; share of sales to federal healthcare programs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">136</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since its enactment, there have been judicial, Congressional, and executive branch challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. For example, the 2020 federal spending package permanently eliminates, effective January&#160;1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January&#160;1, 2021, also eliminates the health insurer tax. In addition, the Tax Act was enacted, which, among other things, removes penalties for not complying with ACA&#8217;s individual mandate to carry health insurance. On December&#160;14, 2018, a U.S. District Court Judge in the Northern District of Texas ruled that the individual mandate is a critical and inseverable feature of the ACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the ACA are invalid as well. Additionally, on December&#160;18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. On March&#160;2, 2020, the U.S. Supreme Court granted the petitions for writs of certiorari to review this case, although it is unclear when or how the Supreme Court will rule. It is also unclear how other efforts to challenge, repeal or replace the ACA will impact the ACA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year and reduced payments to several types of Medicare providers, which will remain in effect through 2030, with the exception of a temporary suspension from May&#160;1, 2020 through December&#160;31, 2020, unless additional Congressional action is taken. Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the federal level, the Trump administration&#8217;s budget proposal for fiscal year 2021 includes a US$135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. Further, the Trump administration released a &#8220;Blueprint,&#8221; or plan, to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out- of-pocket costs of drug products paid by consumers. The Department of Health and Human Services, or HHS, has solicited feedback on some of these measures and has implemented others under its existing authority. For example, in May&#160;2019, the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, issued a final rule&#160;to allow Medicare Advantage plans the option to use step therapy for Part&#160;B drugs beginning January&#160;1, 2020. This final rule&#160;codified CMS&#8217;s policy change that was effective January&#160;1, 2019. Most recently, in July&#160;2020, President Trump also signed a number of executive orders that attempt to implement several of the Administration&#8217;s proposals. While some of measures may require additional authorization to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that these and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in additional downward pressure on the price that we receive for any approved product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">PRC Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to a variety of PRC laws, rules&#160;and regulations affecting many aspects of our business. This section sets out a summary of the major relevant laws, regulations, rules&#160;and policies which may have material impact on our business and operations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">137</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Company Establishment and Foreign Investment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The establishment, operation and management of corporate entities in China are governed by the Company Law of PRC, or the PRC Company Law, which was promulgated by the Standing Committee of the National People&#8217;s Congress, or the Standing Committee of the NPC, in December&#160;1993 and further amended in December&#160;1999, August&#160;2004, October&#160;2005, December&#160;2013 and October&#160;2018, respectively. According to the PRC Company Law, companies are generally classified into two categories: limited liability companies and companies limited by shares. The PRC Company Law also applies to foreign-invested limited liability companies. According to the PRC Company Law, where laws on foreign investment have other stipulations, such stipulations shall prevail.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Investment activities in the PRC by foreign investors are governed by the Guiding Foreign Investment Direction, which was promulgated by the State Council in February&#160;2002 and came into effect in April&#160;2002, and the Special Administrative Measures for the Access of Foreign Investment (Negative List), or the Negative List, which was promulgated by the Ministry of Commerce of the PRC, or the MOFCOM, and the National Development and Reform Commission, or the NDRC, in December 2021 and came into effect in January 2022. The Negative List sets out the restrictive measures in a unified manner, such as the requirements on shareholding percentages and management, for the access of foreign investments, and the industries that are prohibited from receiving foreign investment. The Negative List covers 12 industries, and any field not falling under the Negative List shall be administered under the principle of equal treatment to domestic and foreign investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Foreign Investment Law of the PRC, or the Foreign Investment Law, was promulgated by the National People&#8217;s Congress, or the NPC in March&#160;2019 and came into effect in January&#160;2020. When the Foreign Investment Law came into effect, the Law on Wholly Foreign-owned Enterprises of the PRC, the Law on Sino-foreign Equity Joint Ventures of the PRC and the Law on Sino-foreign Cooperative Joint Ventures of the PRC were repealed simultaneously. The investment activities of foreign natural persons, enterprises or other organizations (collectively, the &#8220;foreign investors&#8221;) directly or indirectly within the territory of China shall comply with and be governed by the Foreign Investment Law. Such activities include: 1) establishing by foreign investors of foreign-invested enterprises in China alone or jointly with other investors; 2) acquiring by foreign investors of shares, equity, property shares, or other similar interests of Chinese domestic enterprises; 3) investing by foreign investors in new projects in China alone or jointly with other investors; and 4) other forms of investment prescribed by laws, administrative regulations or the State Council.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the State Council promulgated the Regulations on Implementing the Foreign Investment Law of the PRC, which came into effect in January&#160;2020. When the Regulations on Implementing the Foreign Investment Law of the PRC came into effect, the Regulation on Implementing the Sino-Foreign Equity Joint Venture Enterprise Law of the PRC, Provisional Regulations on the Duration of Sino-Foreign Equity Joint Venture Enterprise, the Regulations on Implementing the Wholly Foreign-Invested Enterprise Law of the PRC and the Regulations on Implementing the Sino-Foreign Cooperative Joint Venture Enterprise Law of the PRC were repealed simultaneously.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the MOFCOM and the State Administration for Market Regulation, or the SAMR promulgated the Measures on Reporting of Foreign Investment Information, which came into effect in January&#160;2020. When the Measures on Reporting of Foreign Investment Information came into effect, the Interim Measures for the Administration of Filing for Establishment and Changes in Foreign Investment Enterprises were repealed simultaneously. Since January&#160;1, 2020, for foreign investors carrying out investment activities directly or indirectly in China, the foreign investors or foreign-invested enterprises shall submit investment information to the relevant commerce administrative authorities according to the Measure on Reporting of Foreign Investment Information.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">138</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulation on Pharmaceutical Product Development, Approval and Registration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Drug Regulatory Regime</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Drug Administration Law of the PRC, or the Drug Administration Law, was promulgated by the Standing Committee of the NPC, in September&#160;1984. The two latest amendments to the Drug Administration Law were the amendment promulgated in April&#160;2015 and in August&#160;2019. The Regulations for the Implementation of the Drug Administration Law was promulgated by the State Council in August&#160;2002, and was last amended in March&#160;2019. The Drug Administration Law and the Regulations for the Implementation of the Drug Administration Law have jointly established the legal framework for the administration of pharmaceutical products in China, including the research, development and manufacturing of new drugs. The Drug Administration Law applies to entities and individuals engaged in the development, production, trade, application, supervision and administration of pharmaceutical products. It regulates and provides for a framework for the administration of pharmaceutical manufacturers, pharmaceutical trading companies and medicinal preparations of medical institutions, and the development, research, manufacturing, distribution, packaging, pricing and advertisements of pharmaceutical products. The Regulations for the Implementation of the Drug Administration Law, at the same time, provide the detailed implementation regulations for the Drug Administration Law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2017, the drug regulatory system entered a new and significant period of reform. The General Office of the State Council and the General Committee of China Communist Party jointly issued Opinions on Deepening the Reform of the Evaluation and Approval Systems and Encouraging Innovation on Drugs and Medical Devices, or the Innovation Opinions. The expedited programs, the record-filing system, the prioritized review mechanism, the acceptance of foreign clinical data under the Innovation Opinions and other recent reforms encourage drug manufacturers to seek marketing approval in China first for the development of drugs in highly prioritized therapeutic areas, such as oncology or rare diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To implement the regulatory reform introduced by Innovation Opinions, the Standing Committee of the NPC, the National Medical Products Administration, or the NMPA, a newly formed government authority as well as other authorities, are currently responsible for revising the laws, regulations and rules&#160;governing the pharmaceutical products and the industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August&#160;2019, the Standing Committee of the NPC promulgated the new Drug Administration Law, or the 2019 Amendment, which came into effect in December&#160;2019. The 2019 Amendment contains many of the major reform initiatives implemented by the Chinese government since 2015, including but not limited to the Marketing Authorization Holder, or the MAH, system, conditional approvals of drugs, traceability system of drugs, and the cancellation of relevant certification according to the Good Manufacturing Practice, or the GMP, and the Good Supply Practice, or the GSP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulatory Authorities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pharmaceutical products in China are monitored and supervised on a national scale by the NMPA. The local provincial medical products administrative authorities are responsible for supervision and administration of drugs within their respective administrative regions. The NMPA was newly formed under the SAMR. The NMPA&#8217;s predecessor, the State Drug Administration, or the SDA, was replaced by the State Food and Drug Administration, or the SFDA, which was later reorganized into the China Food and Drug Administration, or the CFDA, as part of the institutional reforms implemented by the State Council.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The primary responsibilities of the NMPA include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">monitoring and supervising the administration of pharmaceutical products, medical appliances and equipment as well as cosmetics in the PRC;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">formulating administrative rules&#160;and policies concerning the supervision and administration of pharmaceutical, medical devices, and cosmetics industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluating, registering and approving new drugs, generic drugs, imported drugs and traditional Chinese medicine;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approving and issuing permits for the manufacture and export/import of pharmaceutical products, medical appliances and equipment;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">139</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approving the establishment of enterprises to be engaged in the manufacture and distribution of pharmaceutical products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">examining and evaluating the safety of pharmaceutical products, medical devices, and cosmetics; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">managing significant accidents involving pharmaceutical products, medical devices and cosmetics.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In 2013, the Ministry of Health, or the MOH, and the National Population and Family Planning Commission were integrated into the National Health and Family Planning Commission of the PRC, or the NHFPC. In March&#160;2018, the First Session of the Thirteenth NPC approved the State Council Institutional Reform Proposal, according to which, NHFPC and certain other governmental authorities were consolidated into the National Health Commission, or the NHC. The responsibilities of the NHC include coordinating the formulation of national drug policies, the national essential medicine system and the National Essential Medicines List and drafting the administrative rules&#160;for the procurement, distribution and use of national essential medicines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Decision of the CFDA on Adjusting the Approval Procedures under the Administrative Approval Items for Certain Drugs, which was promulgated by the CFDA in March&#160;2017 and came into effect in May&#160;2017, the Investigational New Drug Application, or the IND, approval should be issued by the Center for Drug Evaluation, or the CDE, on behalf of the CFDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Clinical Trials and Registration of Drugs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Administrative Measures for Drug Registration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In July&#160;2007, the SFDA promulgated the amended version of the Administrative Measures for Drug Registration, or the Registration Measures, which became effective in October&#160;2007. The Registration Measures mainly cover: (1)&#160;definitions of drug registration applications and regulatory responsibilities of drug administration; (2)&#160;general requirements for drug registration, including application for registration of new drugs, generic drugs, imported drugs and supplemental application, as well as application for re-registration; (3)&#160;clinical trials; (4)&#160;application, examination and approval of new drugs, generic drugs and imported drugs; (5)&#160;supplemental applications and re-registrations of drugs; (6)&#160;inspections; (7)&#160;registration standards and specifications; (8)&#160;time limit; (9)&#160;re-examination; and (10)&#160;liabilities and other supplementary provisions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Registration Measures, drug registration applications are divided into three different types, namely Domestic New Drug Application, Domestic Generic Drug Application and Imported Drug Application. Drugs which fall into one of three general types are divided according to the drug&#8217;s working mechanism, namely whether the drug is classified as a chemical medicine, a biological product, a traditional Chinese medicine or a natural medicine. New Drug Application, or NDA, refers to an application for registration of a drug that has not yet been marketed for sale in China. In addition, the registration of drugs that change the dosage form of the marketed drugs, change the route of administration and increase the new indications shall be reported in accordance with the application procedures for new drugs. Under the Registration Measures, a Category 1 drug refers to a new drug that has never been marketed in any country, and such drug is eligible for special review or fast track approval by the NMPA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2020, the SAMR released the amended Administrative Measures for Drug Registration, or the Amended Registration Measures, which came into effect in July&#160;2020. The Amended Registration Measures provide detailed procedural and substantive requirements for the key regulatory concepts established by the Drug Administration Law, and confirms a number of reform actions that have been taken in the past years, including but not limited to: (i)&#160;the full implementation of the MAH system and implied approval of the commencement of clinical trial; (ii)&#160;the implementation of associated review of drugs, excipients and packaging materials; and (iii)&#160;the introduction of four procedures for expedited registration of drugs, which are procedures for ground-breaking therapeutic drugs, procedures for conditional approval, procedures for prioritized reviews and approval, and procedures for special examination and approval. Detailed implementation rules&#160;for drug classification and requirements for corresponding application materials will be promulgated by the NMPA.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">140</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March&#160;2016, the CFDA issued the Reform Plan for Registration Category of Chemical Medicine, which outlined the reclassifications of drug applications under the Registration Measures. According to the Reform Plan for Registration Category of Chemical Medicine, Category 1 drugs refer to innovative new drugs that have not been marketed anywhere in the world. Improved new drugs that are not marketed anywhere in the world fall into Category 2 drugs. Generic drugs, that have equivalent quality and efficacy to the originator&#8217;s drugs and have been marketed abroad but not yet in China, can be classified as Category 3 drugs. Generic drugs, that have equivalent quality and efficacy to the originator&#8217;s drugs and have been marketed in China, fall into Category 4 drugs. Category 5 drugs are drugs which have already been marketed abroad, but are not yet approved in China. Category 1 drugs and Category 5 drugs can be registered through the Domestic New Drug Application and the Imported Drug Application Procedures under the Registration Measures, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The SFDA promulgated the Administrative Provisions on Special Examination and Approval of Registration of New Drugs in January&#160;2009, according to which, the SFDA conducts special examination and approval for new drug registration applications when: (1)&#160;the effective constituent of drug extracted from plants, animals, minerals,&#160;etc., as well as the preparations thereof have never been marketed in China, and the material medicines and the preparations thereof are newly discovered; (2)&#160;the chemical raw material medicines as well as the preparations thereof and the biological product have not been approved for marketing at home and abroad; (3)&#160;the new drugs have obvious clinical treatment advantages for such diseases as AIDS, malignant tumors and orphan diseases,&#160;etc. or (4)&#160;the new drugs treat diseases currently with no effective methods of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Special Examination and Approval of Registration of New Drugs provides that the applicant may file for special examination and approval at the clinical trial application stage if the product candidate falls within items (1)&#160;or (2). The provisions provide that for product candidates that fall within items (3)&#160;or (4), the application for special examination and approval cannot be made until filing for production.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Accelerated Approval for Clinical Trial and Registration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Innovation Opinions established a framework for reforming the evaluation and approval system for drugs, medical devices and equipment. The Innovation Opinions enhanced the standard of approval for drug registration and accelerated the evaluation and approval process for innovative drugs as well as drug clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The CFDA released the Circular Concerning Several Policies on Drug Registration Review and Approval in November&#160;2015, which further clarified the measures and policies for simplifying and accelerating the approval process of clinical trials, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a one-time umbrella approval procedure allowing the overall approval of all phases of a new drug&#8217;s clinical trials, replacing the current phase-by-phase application and approval procedure; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a fast track drug registration or clinical trial approval pathway for the following applications: (1)&#160;registration of innovative new drugs for treating HIV, cancer, serious infectious diseases and orphan diseases,&#160;etc.; (2)&#160;registration of pediatric drugs; (3)&#160;registration of geriatric drugs and drugs treating PRC-prevalent diseases in elders; (4)&#160;registration of drugs listed in national major science and technology projects or national key research and development plan; (5)&#160;registration of clinical urgently needed drugs using advanced technology, using innovative treatment methods, or having distinctive clinical benefits; (6)&#160;registration of foreign innovative drugs to be manufactured locally in China; (7)&#160;concurrent applications for new drug clinical trials which are already approved in the United States or EU or concurrent drug registration applications for drugs which have applied to the competent drug approval authorities for marketing authorization and passed such authorities&#8217; onsite inspections in the United States or EU and are manufactured using the same production line in China; and (8)&#160;clinical trial applications for drugs with urgent clinical need and patent expiry within three years, and manufacturing authorization applications for drugs with urgent clinical need and patent expiry within one year.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The NMPA released the Circular on Adjusting Evaluation and Approval procedures for Clinical Trials for Drugs in July&#160;2018, according to which, within 60 days after the acceptance of and the fees paid for the IND application, the applicant may conduct the clinical trials for the drug in accordance with the clinical trial protocol submitted, if the applicant has not received any negative or questioning opinion from the CDE. Such approval process has been further enacted into the 2019 Amendment.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">141</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Trial Exemptions and Acceptance of Foreign Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The NMPA issued the Technical Guidance Principles on Accepting Foreign Drug Clinical Trial Data in July&#160;2018, as one of the implementing rules&#160;for the Innovation Opinions, which provides that overseas clinical data can be submitted for the drug registration applications in China. Such applications can be in the form of waivers to China-based clinical trials, bridging trials and direct NDAs. According to the Technical Guidance Principles on Accepting Foreign Drug Clinical Trial Data, sponsors may use the data of foreign clinical trials to support drug registration in China, provided that sponsors must ensure the authenticity, completeness, accuracy and traceability of foreign clinical trial data and such data must be obtained consistent with the relevant requirements under the Good Clinical Trial Practice of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, or the ICH. Sponsors must also comply with other relevant sections of the Registration Measures when applying for drug registrations in China using foreign clinical trial data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The NMPA now officially permits, and its predecessor agencies have permitted on a case-by-case basis in the past, drugs approved outside of China to be approved in China on a conditional basis without pre-approval clinical trials being conducted in China. Specifically, the NMPA and the NHC released the Procedures for Reviewing and Approval of Clinical Urgently Needed Overseas New Drugs in October&#160;2018, permitting drugs that have been approved within the last ten years in the United States, the EU or Japan and that prevent or treat orphan diseases, or prevent or treat serious life-threatening illnesses for which there is either no effective therapy in China, or for which the foreign-approved drug would have clear clinical advantages. Applicants will be required to establish a risk mitigation plan and may be required to complete trials in China after the drug has been marketed. The CDE has developed a list of qualifying drugs that meet the foregoing criteria.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Clinical Trial Process and Good Clinical Practices</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Registration Measures, a clinical trial consists of Phases I,&#160;II,&#160;III and IV. Phase I refers to the initial clinical pharmacology and safety evaluation studies in humans. Phase II refers to the preliminary evaluation of a product candidate&#8217;s therapeutic effectiveness and safety for particular indications in patients, to provide evidence and support for the design of Phase III clinical trials and to settle the administrative dose regimen. Phase III refers clinical trials undertaken to confirm the therapeutic effectiveness and safety on patients with target indications, to evaluate the overall benefit-risk relationships of the drug, and ultimately to provide sufficient evidence for the review of drug registration application. Phase IV refers to a new drug&#8217;s post-marketing study to assess therapeutic effectiveness and adverse reactions when the drug is widely used, to evaluate the overall benefit-risk relationships of the drug when used among the general population or specific groups and to adjust the administration dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To improve the quality of clinical trials, the SFDA promulgated the Good Clinical Trial Practice for Drugs in August&#160;2003, or the GCP Rules, which was replaced by the revised Good Clinical Trial Practice for Drugs, the Revised GCP Rules, promulgated by the NMPA and the NHC in April&#160;2020 and coming into effect in July&#160;2020. According to the Administration of Quality of Drug Clinical Practice, clinical trial means systematical investigation of drugs conducted on human subjects (patients or healthy volunteers) to prove or reveal the function, adverse reactions and/or absorption, distribution, metabolism and excretion of the drug being investigated. The purpose of a clinical trial is to determine the therapeutic efficacy and safety of the drug. The Revised GCP Rules&#160;provide comprehensive and substantive requirements on the design and conduct of clinical trials in China. In particular, the Revised GCP Rules&#160;enhance the protection for study subjects and tighten the control over bio-samples collected under clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Revised GCP Rules&#160;also set out the qualifications and requirements for the investigators and centers participating in clinical trial, who must: (i)&#160;have professional certification at a clinical trial center, professional knowledge, training experience and capability of clinical trial, and be able to provide the latest resume and relevant qualification documents per request; (ii)&#160;be familiar with the trial protocol, investigator&#8217;s brochure and relevant information of the trial drug provided by the applicant; (iii)&#160;be familiar with and comply with the Revised GCP Rules&#160;and relevant laws and regulations relating to clinical trials; (iv)&#160;keep a copy of the authorization form on work allocation signed by investigators; (v)&#160;accept supervision and inspection organized by the applicant and inspection by the drug regulatory authorities; and (vi)&#160;in the case of investigators and clinical trial centers authorizing other individual or institution to undertake certain responsibilities and functions relating to clinical trial, they shall ensure such individual or institution are qualified and establish complete procedures to ensure the responsibilities and functions are fully performed and generate reliable data.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">142</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Communication with the CDE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Circular on Adjusting Evaluation and Approval Procedures for Clinical Trials for Drugs, where the application for clinical trial of new investigational drug has been approved, upon the completion of Phases I and II clinical trials and prior to Phase III clinical trial, the applicant shall submit the application for Communication Session to the CDE to discuss the key technical questions including the design of Phase III clinical trial protocol. Within 60 days after the acceptance of and the fees paid for the IND application, the applicant may conduct the clinical trials for the drug in accordance with the clinical trial protocol submitted, if the applicant has not received any negative or questioning opinion from the CDE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The NMPA promulgated the Administrative Measures for Communication on the Research, Development and Technical Evaluation of Drugs in December 2020, according to which, during the research and development periods and in the registration applications of traditional Chinese medicines, chemical drugs and biological products, the applicants may propose to conduct communication meetings with the CDE on key technologies and other issues not covered in the existing guidelines for drug research, development and evaluation during the process of technical evaluation of drug research, development and registration. The communication meetings can be classified into three types. Type I meetings are convened to address key safety issues in clinical trials of drugs and key technical issues in the research and development of breakthrough therapeutic drugs. Type II meetings are held during the key research and development periods of drugs, mainly including meetings before the IND application, meetings upon the completion of Phase II trials and before the commencement of Phase III trials, meetings before submitting a marketing application for a new drug, and meetings for risk evaluation and control. Type III meetings refer to meetings not classified as Type I or Type II.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Drug Clinical Trial Registration</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Registration Measures, upon obtaining the approval of its IND applications and before conducting a clinical trial, an applicant shall file a registration form with the SFDA containing various details, including the clinical trial protocol, the name of the principal researcher of the leading institution, the names of participating institutions and researchers, an approval letter from the ethics committee, and a sample of the informed consent form, with a copy sent to the competent provincial administration departments where the trial institutions will be located. The CFDA released the Announcement on Drug Clinical Trial Information Platform in September&#160;2013, according to which, instead of the aforementioned registration field with the CFDA, all clinical trials approved by the CFDA and conducted in China shall complete a clinical trial registration and publish trial information through the Drug Clinical Trial Information Platform. The applicant shall complete the trial pre-registration within one month after obtaining the approval of the clinical trial approval in order to obtain the trial&#8217;s unique registration number and complete registration of certain follow-up information before the first subject&#8217;s enrollment in the trial. If the registration is not completed within one year after the approval of the IND applications, the applicant shall submit an explanation, and if the first submission is not completed within three years, the approval of the IND applications shall automatically expire.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">New Drug Application</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Registration Measures, drug registration applications include domestic NDA, domestic generic drug application and imported drug application. Drugs are classified into chemical drugs, biological products and traditional Chinese medicine or natural drugs. When Phases I,&#160;II and III clinical trials have been completed, the applicant may apply to the SFDA for approval of the NDA. The SFDA then determines whether to approve the application according to the comprehensive evaluation opinion provided by the CDE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Pilot Plan for the MAH System</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Innovation Opinions provide a pilot plan for the MAH system.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">143</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the authorization of the Standing Committee of the NPC, the General Office of the State Council issued the Pilot Plan for the Drug Marketing Authorization Holder Mechanism in May&#160;2016, which provides a detailed pilot plan for the MAH system in 10 Chinese provinces. Under the MAH system, domestic drug research and development institutions and individuals in the pilot regions are eligible to be holders of drug registrations without having to become drug manufacturers. The marketing authorization holders may engage contract manufacturers for manufacturing, provided that the contract manufacturers are licensed and located within the pilot regions. Drugs that qualify for the MAH system are: (1)&#160;new drugs (including but not limited to drugs under category I to category IV of chemical drugs, and targeted preparation, sustained release preparation, controlled release preparation under category V of chemical drugs, biological products approved as category I and VII drugs and biosimilars under the Registration Measures) approved after the implementation of the MAH system; (2)&#160;generic drugs approved as category III or IV drugs under the Reform Plan for Registration Category of Chemical Medicine; (3)&#160;previously approved generics that have passed equivalence assessments against original drugs; and (4)&#160;previously approved drugs whose licenses were held by drug manufacturers originally located within the pilot regions, but which have moved out of the pilot regions due to corporate mergers or other reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The CFDA promulgated the Circular on the Matters Relating to Promotion of the Pilot Program for the Drug Marketing Authorization Holder System in August&#160;2017. It clarified the legal liability of the MAH, who is responsible for managing the whole manufacturing and marketing chain and the whole life cycle of drugs and legally liable for preclinical drug study, clinical trials, manufacturing, marketing, distribution and adverse drug reaction monitoring. According to the Circular on the Matters Relating to Promotion of the Pilot Program for the Drug Marketing Authorization Holder System, the MAH shall submit a report of drug manufacturing, marketing, prescription, techniques, pharmacovigilance, quality control measures and other situations to the CFDA within 20 working days after the end of each year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Pilot Plan for the Drug Marketing Authorization Holder Mechanism, the pilot plan was originally set for a three-year period and was scheduled to expire in November&#160;2018. The Standing Committee of the NPC promulgated the Decision of Extending the Pilot Period of Authorizing the State Council to Carry Out the Pilot Plan for the Drug Marketing Authorization Holder Mechanism in Certain Places in October&#160;2018, which extended the term of the MAH system to November&#160;4, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the 2019 Amendment, which came into effect on December&#160;1, 2019, the MAH system will be applicable throughout the country and the legal representative and the key person-in-charge of a drug MAH shall be fully responsible for the quality of drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">International Multi-Center Clinical Trials</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The International Multi-Center Clinical Trial Guidelines (Trial), or the Multi-Center Clinical Trial Guidelines, which was promulgated by the CFDA in January&#160;2015 and came into effect in March&#160;2015, provided guidance on the implementation of Multi-Regional Clinical Trials, or the MRCT, in China. According to the Multi-Center Clinical Trial Guidelines, international multi-center clinical trial applicants may simultaneously perform clinical trials in different centers using the same clinical trial protocol. Where the applicants plan to implement the international multi-center clinical trials in the PRC, the applicants shall comply with relevant laws and regulations, such as the Drug Administration Law, the Implementing Regulations of the Drug Administration Law and the Registration Measures, execute the GCP Rules, make reference to universal international principles such as the ICH-GCP and comply with the laws and regulations of the countries involved in the international multi-center clinical trials. Where the applicants plan to use the data derived from the international multi-center clinical trials for approval of a drug registration in the PRC, it shall involve at least two countries, including China, and shall satisfy the requirements for clinical trials set forth in the Multi-Center Clinical Trial Guidelines, Registration Measures and other related laws and regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2020, the NMPA and the NHC promulgated the Revised GCP Rules, which came into effect in July&#160;2020. The Revised GCP Rules&#160;summarize the requirements for initiating an MRCT, that is, before initiating an MRCT: (i)&#160;the applicant shall ensure that all the centers participating in the clinical trial comply with the trial protocol; (ii)&#160;the applicant shall provide each center with the same trial protocol, and each center shall comply with the same unified evaluation criterion for clinical trial and laboratory data and the same guidance for case report form; (iii)&#160;each center shall use the same case report form to record the data of each human subject obtained during the trial; (iv)&#160;before initiating a clinical trial, a written document is required to specify the responsibilities of the investigators of each center; and (v)&#160;the applicant shall ensure the communication among the investigators of each center.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">144</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Data derived from international multi-center clinical trials can be used for the new drug applications with the NMPA. When using international multi-center clinical trial data to support new drug applications in China, applicants shall submit the completed global clinical trial report, statistical analysis report and database, along with relevant supporting data in accordance with the content and format requirements under the International Conference on Harmonization-Common Technical Document; subgroup research results summary and comparative analysis shall also be conducted concurrently. Leveraging the clinical trial data derived from international multi-center clinical trials conducted by our partners, we may avoid unnecessarily repetitive clinical trials and thus further accelerate the NDA process in China.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The CFDA released the Decision on Adjusting Items concerning the Administration of Imported Drug Registration in October&#160;2017, which includes the following key points:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If the International Multicenter Clinical Trial, or the IMCCT, of a drug is conducted in China, Phase I clinical trial of the drug is allowed simultaneously. The IMCCT drug does not need to be approved or to enter into either a Phase II or III clinical trial in a foreign country, except for preventive biological products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If the IMCCT is conducted in China, the application for drug marketing authorization can be submitted directly after the completion of the IMCCT. The Registration Measures and relevant laws and regulations shall be complied with for registration application;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">With respect to applications for clinical trial and marketing of the imported innovative chemical drugs and therapeutic biological products, the marketing authorization in the country or region where the foreign drug manufacturer is located will not be required; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">With respect to drug applications that have been accepted before the release of this Decision, if relevant requirements are met, importation permission can be granted if such applications request exemption of clinical trials for the imported drugs based on the data generated from the IMCCT.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Approval of Human Genetic Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Interim Administrative Measures on Human Genetic Resources, promulgated by the Ministry of Science and Technology and the MOH in June&#160;1998, aimed at protecting and fairly utilizing human genetic resources in the PRC. The Ministry of Science and Technology promulgated the Service Guide for Administrative Licensing Items concerning Examination and Approval of Sampling, Collecting, Trading or Exporting Human Genetic Resources, or Taking Such Resources out of the PRC in July&#160;2015, according to which, the sampling, collection or research activities of human genetic resources by a foreign-invested sponsor fall within the scope of international cooperation, and the cooperating Chinese organization shall apply for approval of the China Human Genetic Resources Management Office through an online system. The Ministry of Science and Technology further promulgated the Circular on Optimizing the Administrative Examination and Approval of Human Genetic Resources in October&#160;2017 and October&#160;2020, which became effective in December&#160;2017 and October&#160;2020, respectively and simplified the approval of sampling and collecting human genetic resources for listing a drug in the PRC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Regulations of the PRC on the Administration of Human Genetic Resources, which was promulgated by the State Council in May 2019 and came into effect in July 2019, further stipulates that, in order to obtain marketing authorization for relevant drugs and medical devices in China, no approval is required in international clinical trial cooperation using China&#8217;s human genetic resources at clinical institutions without export of human genetic resource materials. However, the type, quantity and usage of the human genetic resource to be used shall be filed with the administrative department of science and technology under the State Council before clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Bio-security Law of the PRC promulgated by the Standing Committee of the NPC in October 2020, and took effect in April 2021, provides that the state shall have sovereignty over the human genetic resources and biological resources of the PRC. The Bio-security Law of the PRC further stipulates that the department of science and technology under the State Council shall be the competent authority for the approval or filing of using China&#8217;s human genetic resources.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">145</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Drug Manufacturing and Distribution</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Drug Manufacturing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Drug Administration Law and the Implementing Regulations of the Drug Administration Law, a drug manufacturing enterprise is required to obtain a drug manufacturing license from the relevant provincial drug administration authority of the PRC. The grant of such license is subject to an inspection of the manufacturing facilities, and an inspection to determine whether the sanitary condition, quality assurance systems, management structure and equipment meet the required standards. According to the Implementing Regulations of the Drug Administration Law and the Measures on the Supervision and Administration of the Manufacture of Drugs, which was promulgated in August&#160;2004, amended in November&#160;2017 and January&#160;2020 and came into effect in July&#160;2020, the drug manufacturing license is valid for five years and shall be renewed at least six months prior to its expiration date upon a re-examination by the relevant authority. In addition, the name, legal representative, registered address and type of the enterprise specified in the drug manufacturing certificate shall be identical to that set forth in the business license as approved and issued by the industrial and commercial administrative department. To the extent the MAH does not manufacture the drug internally but through a contract manufacturing organization, the MAH shall apply for drug manufacturing license with the provincial counterpart of the NMPA, subject itself to inspections and other regulatory oversight by the agency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Good Manufacturing Practice for Drugs was promulgated in March&#160;1988 and was amended in December&#160;1992 and June&#160;1999 and January&#160;2011. The latest amendment was in June&#160;2020 and came into effect in October&#160;2020. The Good Manufacturing Practice for Drugs comprises a set of detailed standard guidelines governing the manufacture of drugs, which include institution and staff qualifications, production premises and facilities, equipment, hygiene conditions, production management, quality controls, product operation, raw material management, maintenance of sales records, management of customer complaints and adverse event reports.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Drug Distribution</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Drug Administration Law, its implementing regulations and the Measures for the Supervision and Administration of Circulation of Pharmaceuticals, which was approved by the SFDA in December&#160;2006 and came into effect in May&#160;2007, pharmaceutical enterprises shall be responsible for the quality of the pharmaceuticals that they manufacture, operate, use, purchase, sell, transport, or store.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Measures for the Administration of Pharmaceutical Operation Certificate, which was promulgated in February&#160;2004 and amended in November&#160;2017 by the CFDA, a Medicine Operation Certificate is valid for five years. Each holder of the Medicine Operation Certificate must apply for an extension of its permit six months prior to expiration. The establishment of a wholesale pharmaceutical distribution company requires the approval of provincial medicine administrative authorities. Upon approval, the authority will grant a Medicine Operation Certificate in respect of the wholesale pharmaceutical product distribution company. The establishment of a retail pharmacy store requires the approval of the local medicine administrative authorities at or above the county level. Upon approval, the authority will grant a Medicine Operation Certificate in respect of the retail pharmacy store.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Other PRC Government Regulations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Intellectual Property Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In terms of international conventions, China has entered into (including but not limited to) the Agreement on Trade-Related Aspects of Intellectual Property Rights, the Paris Convention for the Protection of Industrial Property, the Madrid Agreement Concerning the International Registration of Marks and the Patent Cooperation Treaty.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">146</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Patents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Patent Law of the PRC, which was promulgated by the Standing Committee of the NPC in March 1984, amended in September 1992, August 2000, December 2008 and October 2020, and came into effect in June 2021, and the Implementation Rules of the Patent Law of the PRC, which was promulgated by the State Council in June 2001 and amended in December 2002 and January 2010, there are three types of patents in the PRC: invention patents, utility model patents and design patents. The protection period is 20 years for an invention patent and 10 years for a utility model patent and 15 years for a design patent, commencing from their respective application dates. For the purpose of compensating for the time taken to evaluate and approve a new drug to be put on market, the patent administrative department under the State Council shall grant compensation for duration of patent rights for invention of a new drug approved to be put on market in the PRC upon request of the patentee. The compensation period shall not exceed five years, and the total validity period of patent rights for a new drug approved to be put on market shall not exceed 14 years. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In the process of evaluation and approval of marketing of a drug, where a dispute arises over the patent rights relating to the drug for which registration is applied between a drug marketing authorization applicant and a relevant patentee or interested party, the relevant party may file a lawsuit with a people&#39;s court, requesting a ruling on whether the relevant technical solution of the drug for which registration is applied falls within the scope of protection of others&#39; drug patent rights. The drug regulatory department under the State Council may, within the stipulated period, make a decision on whether to suspend the approval of marketing of the drug concerned based on the effective judgment made by the people&#39;s court. A drug marketing authorization applicant and a relevant patentee or interested party may also request an administrative ruling from the patent administrative department under the State Council in respect of a dispute over patent rights relating to the drug for which registration is applied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Any individual or entity that utilizes a patent or conducts any other activities that infringe a patent without prior authorization of the patent holder shall pay compensation to the patent holder and is subject to a fine imposed by relevant administrative authorities and, if constituting a crime, shall be held criminally liable in accordance with the law. According to the Patent Law of the PRC, any organization or individual that applies for a patent in a foreign country for an invention or utility model patent established in China is required to report to the NIPA for confidentiality examination.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Trade Secrets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the PRC Anti-Unfair Competition Law, which was promulgated by the Standing Committee of the NPC in September&#160;1993 and amended in November&#160;2017 and April&#160;2019, respectively, the term &#8220;trade secrets&#8221; refers to technical and business information that is unknown to the public, has utility, may create business interests or profits for its legal owners or holders, and is maintained as a secret by its legal owners or holders. Under the PRC Anti-Unfair Competition Law, business persons are prohibited from infringing others&#8217; trade secrets by: (1)&#160;obtaining the trade secrets from the legal owners or holders by any unfair methods such as theft, bribery, fraud, coercion, electronic intrusion, or any other illicit means; (2)&#160;disclosing, using or permitting others to use the trade secrets obtained illegally under item (1)&#160;above; (3)&#160;disclosing, using or permitting others to use the trade secrets, in violation of any contractual agreements or any requirements of the legal owners or holders to keep such trade secrets in confidence; or (4)&#160;instigating, inducing or assisting others to violate a confidentiality obligation or to violate a rights holder&#8217;s requirements on keeping confidentiality of trade secrets, disclosing, using or permitting others to use the trade secrets of the rights holder. If a third party knows or should have known of the above-mentioned illegal conduct but nevertheless obtains, uses or discloses trade secrets of others, the third party may be deemed to have committed a misappropriation of the others&#8217; trade secrets. The parties whose trade secrets are being misappropriated may petition for administrative corrections, and regulatory authorities may stop any illegal activities and fine infringing parties.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">147</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Trademarks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Trademark Law of the PRC promulgated by the Standing Committee of the NPC in August&#160;1982, and amended in February&#160;1993, October&#160;2001, August&#160;2013 and April&#160;2019, respectively, the period of validity for a registered trademark is ten years, commencing on the date of registration. The registrant shall go through the formalities for renewal within twelve months prior to the expiry date of the trademark if continued use is intended. Where the registrant fails to do so, a grace period of six months may be granted. The validity period for each renewal of registration is ten years, commencing on the day immediately after the expiry of the preceding period of validity for the trademark. In the absence of a renewal upon expiry, the registered trademark shall be cancelled. Industrial and commercial administrative authorities have the authority to investigate any behavior that infringes the exclusive right under a registered trademark in accordance with the law. In case of a suspected criminal offense, the case shall be timely referred to a judicial authority and decided according to the law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;"><i style="font-weight:normal;">Domain Names</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Domain names are protected under the Administrative Measures on the Internet Domain Names, which was promulgated by the Ministry of Industry and Information Technology in August&#160;2017, and the Implementing Rules&#160;on Registration of National Top-level Domain Names, which was promulgated by China Internet Network Information Center in and came into effect in June&#160;2019. The Ministry of Industry and Information Technology is the main regulatory body responsible for the administration of PRC internet domain names. Domain name registrations are handled through domain name service agencies established under the relevant regulations, and the applicants become domain name holders upon successful registration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Regulations on Information Security and Data Protection </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 9.35pt;"><i style="font-style:italic;">Scientific data</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In March 2018, the General Office of the State Council of the PRC promulgated the Measures for the Management of Scientific Data, or the Scientific Data Measures, which provide a broad definition of scientific data and relevant rules for the management of scientific data. Pursuant to the Scientific Data Measures, the scientific data involving state secrets, national security, social or public interests, trade secrets and individual privacy shall be kept confidential; where it is necessary to disclose such data, the purposes of utilization, qualifications of users and confidentiality conditions, among others shall be examined, and the scope of those with access thereto shall be strictly controlled. Enterprises in the PRC must seek governmental approval before any scientific data involving a state secret is provided during foreign contacts and cooperation. Upon approval by the competent departments, corporate entities shall undergo the relevant formalities as required, and sign confidentiality agreements with users. Furthermore, any researcher conducting research funded in part or in whole by the PRC government is required to submit relevant scientific data for management by the entity to which such researcher is affiliated before that data may be published in any foreign academic journal. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 9.35pt;"><i style="font-style:italic;">Personal data </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Civil Code of the PRC, the personal information of an individual shall be protected by the law. Any organization or individual that needs to obtain personal information of others shall obtain such information legally and ensure the safety of such information, and shall not illegally collect, use, process or transmit personal information of others, or illegally purchase or sell, provide or publish personal information of others. In addition, the processing of personal information shall follow the principles of lawfulness, appropriateness and necessity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In August 2021, the Personal Information Protection Law of the PRC promulgated by the Standing Committee of the NPC and took into effect in November 2021. The Personal Information Protection Law of the PRC shall apply to the processing of the personal information of natural persons within the territory of the PRC under any of the following circumstances: (i) where the purpose is to provide domestic natural persons with products or services; (ii) where the activities of domestic natural persons are analyzed and evaluated; and (iii) other circumstances as prescribed by laws and administrative regulations. The processing of personal information shall follow the principles of lawfulness, legitimacy, necessity and good faith, and it is not allowed to process personal information by misleading, fraud, coercion or otherwise.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">148</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 9.35pt;"><i style="font-style:italic;">Information security and review </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 7, 2016, the Standing Committee of NPC promulgated the Cybersecurity Law of the PRC, which became effective on June 1, 2017, pursuant to which, network operators shall fulfill their obligations to safeguard security of the network when conducting business and providing services. Those who provide services through networks shall take technical measures and other necessary measures pursuant to laws, regulations and compulsory national requirements to safeguard the safe and stable operation of the networks, respond to network security incidents effectively, prevent illegal and criminal activities, and maintain the integrity, confidentiality and usability of network data. Network operator shall not collect the personal information irrelevant to the services it provides or collect or use the personal information in violation of the provisions of laws or agreements concluded with its users, and network operators of key information infrastructure shall store within the PRC all the personal information and important data collected and produced within the PRC. The purchase of network products and services that may affect national security shall be subject to national cybersecurity review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On June 10, 2021, the Standing Committee of NPC promulgated the Data Security Law of the PRC, or the Data Security Law, which came into effect on September 1, 2021. The Data Security Law sets forth the regulatory framework and the responsibilities of the relevant governmental authorities in regulating data security. It provides that the central government shall establish a central data security work liaison system, which shall coordinate the relevant authorities covering different industries to formulate the catalogs of key data, and the special measures that shall be taken to protect the security of the key data. In addition, the Data Security Law provides that important data processors shall appoint a data security officer and a management department to take charge of data security, and such processors shall evaluate the risk of their data activities periodically and file assessment reports with the relevant regulatory authorities. Violation of Data Security Law may subject the relevant entities or individuals to warning, fines, business suspension, revocation of permits or business licenses, or even criminal liabilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On December 28, 2021, the Cybersecurity Review Measures was promulgated by Cyberspace Administration of China, State Development and Reform Commission, Ministry of Industry and Information Technology, Ministry of Public Security, Ministry of State Security, Ministry of Finance, Ministry of Commerce, People&#8217;s Bank of China, SAMR, National Radio and Television Administration, CSRC, National Administration of State Secrets Protection and State Cryptography Administration and came into effect in February 2022. According to the Cybersecurity Review Measures, (i) the purchase of network products and services by a &#8220;critical information infrastructure operator&#8221; and the data processing activities of a &#8220;network platform operator&#8221; that affect or may affect national security shall be subject to the cybersecurity review; (ii) if a network platform operator who possesses personal information of more than 1 million users intends to go public in a foreign country, it must apply for a cybersecurity review with the Cybersecurity Review Office; and (iii) the relevant PRC governmental authorities may initiate cybersecurity review if they determine certain network products, services or data processing activities affect or may affect national security. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Furthermore, on October 29, 2021, the CAC published the Measures on Security Assessment of Crossborder Transfer of Data (Draft for Comments), or the Draft Security Assessment Measures, which provide that data processors shall make self-assessment of the risks before transferring data cross-border, and shall apply for security assessment for cross-border transfer of data in any of the following circumstances: (i) transferring the personal information and important data collected and produced by CIIO operators; (ii) important data is included in the data transferred cross-border; (iii) transferring personal information cross-border by personal information processors which process more than one million individuals&#8217; personal information; (iv) transferring more than one hundred thousand individuals&#8217; personal information or more than ten thousand individuals&#8217; sensitive personal information cumulatively; or (v) other circumstances which require the application for crossborder data transfer security assessment as determined by the CAC. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">149</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On November 14, 2021, the CAC published the Regulations for the Administration of Cyber Data Security (Draft for Comment), or the Draft Data Security Regulations, for public comment by December 13, 2021. The Draft Data Security Regulations reiterate that a data processor who processes personal information of more than one million individuals must complete the cybersecurity review if it intends to be listed in a foreign country, and further stipulate that a data processor shall also apply for the cybersecurity review if it carries out data processing activities that affect or may affect national security. The Draft Data Security Regulations provide a broad definition of &#8220;data processing activities&#8221;, including collection, storage, usage, processing, transfer, provision, publication, deletion and other activities, which covers the entire life cycle of data processing. The Draft Data Security Regulations also provide a broad definition of &#8220;data processor&#8221; as individuals and entities that may autonomously determine the purpose and method of data processing activities. In addition, the Draft Data Security Regulations require data processors which process important data or whose securities are listed outside of China to carry out data security assessment annually either by itself or through a third party data security service provider and submit the assessment report to a local agency of the CAC. The Draft Data Security Regulations remain silent on what constitutes a situation that &#8220;affects or may affect national security&#8221; and are subject to public comments and further changes before being formally adopted and entering into effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Product Liability</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In addition to the strict new drug approval process, certain PRC laws have been promulgated to protect the rights of consumers and to strengthen the control of medical products in the PRC. Under current PRC laws, manufacturers and vendors of defective products in the PRC may incur liability for loss and injury caused by such products. According to the General Principles of the Civil Law of the PRC promulgated in April 1986 and amended in August 2009 and General Rules of the Civil Law of the People&#8217;s Republic of China promulgated in March 2017 and took effect in October 2017, the manufacturer or vendor of a defective product which causes property damage or physical injury to any person may be subject to civil liability for such damage or injury. In January 2021, the PRC Civil Code came into effect, the General Principles of the Civil Law of the PRC and General Rules of the Civil Law of the PRC were repealed simultaneously.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">In February 1993, the Product Quality Law of the PRC, or the Product Quality Law, was promulgated aiming to protect the legitimate rights and interests of the end-users and consumers and to strengthen the supervision and control of the quality of products. The Product Quality Law was last revised in December 2018. According to the revised Product Quality Law, manufacturers who produce defective products may be subject to civil or criminal liability and have their business licenses revoked.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">The Law of the PRC on the Protection of the Rights and Interests of Consumers was promulgated in October 1993 and amended in October 2013 to protect consumer rights when they purchase or use goods and services. According to which, all business operators must comply with this law when they manufacture or sell goods and/or provide services to customers. Under the latest amendment, all business operators shall protect the customers&#8217; privacy and keep any consumer information they obtain during the business operation strictly confidential. In addition, in extreme situations, pharmaceutical product manufacturers and operators may be subject to criminal liability if their goods or services lead to the death or injuries of customers or other third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Tort</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the PRC Civil Code, if damages to other persons are caused by defective products due to the fault of third parties, such as the parties providing transportation or warehousing, the producers and the sellers of the products have the right to recover their respective losses from such third parties. If defective products are identified after they have been put into circulation, the producers or the sellers shall take remedial measures such as issuance of a warning, recall of products, etc., in a timely manner. The producers or the sellers shall be liable under tort if they fail to take remedial measures in a timely manner or have not made efforts to take remedial measures, thus causing damages. If the products are produced or sold with known defects, causing deaths or severe adverse health issues, the infringed party has the right to claim punitive damages in addition to compensatory damages.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">150</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Environment Protection</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Environmental Protection Law of the PRC promulgated by the Standing Committee of the NPC, in December&#160;1989, amended in April&#160;2014 and effective in January&#160;2015, any entity which discharges or will discharge pollutants during its course of operations or other activities must implement effective environmental protection safeguards and procedures to control and properly treat waste gas, waste water, waste residue, dust, malodorous gases, radioactive substances, noise vibrations, electromagnetic radiation and other hazards produced during such activities. According to the provisions of the Environmental Protection Law, in addition to other relevant laws and regulations of the PRC, the Ministry of Environmental Protection and its local counterparts take charge of administering and supervising said environmental protection matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Environmental Protection Law, the environmental impact statement on any construction project must assess the pollution that the project is likely to produce and its impact on the environment, and stipulate preventive and curative measures; the statement shall be submitted to competent administrative department of environmental protection for approval. Installations for the prevention and control of pollution in construction projects must be designed, built and commissioned together with the principal part of the project.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Law of the People&#8217;s Republic of China on Environment Impact Assessment, which was promulgated in October&#160;2002 and most recently amended in December&#160;2018, the State implements a classification-based management on the environmental impact assessment of construction projects according to the impact of the construction projects on the environment. Construction units shall prepare an Environmental Impact Report or an Environmental Impact Statement, or fill out the Environmental Impact Registration Form.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Regulations on Urban Drainage and Sewage Disposal, which was promulgated in October&#160;2013 and came into effect in January&#160;2014, and the Measures for the Administration of Permits for the Discharge of Urban Sewage into the Drainage Network, which was promulgated in January&#160;2015 and came into effect in March&#160;2015, drainage entities covered by urban drainage facilities shall discharge sewage into urban drainage facilities in accordance with the relevant provisions of the state. Where a drainage entity needs to discharge sewage into urban drainage facilities, it shall apply for a drainage license in accordance with the provisions of these Measures. The drainage entity that has not obtained the drainage license shall not discharge sewage into urban drainage facilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Fire Protection</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Fire Prevention Law of the PRC, or the Fire Prevention Law, was adopted in April&#160;1998 and last amended in April&#160;2021. The Fire Prevention Law provides that fire control design and construction of a construction project shall comply with the State&#8217;s fire control technical standards. Developers, designers, builders and project supervisors shall be responsible for the quality of the fire control design and construction of the construction project pursuant to the law. Development project fire safety design examinations and acceptance systems shall be implemented for development projects which are required to have fire safety design in accordance with the national fire protection technical standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Eight Measures for the Public Security Fire Department to Deepen Reform and Serve Economic and Social Development promulgated by the Ministry of Public Security of the PRC in</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">August&#160;2015, the fire protection design and completion acceptance fire protection record of construction projects with an investment of less than RMB300,000 or a building area of less than 300 square meters (or below the limit set by the housing and urban construction department of the provincial people&#8217;s government) was no longer required.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">151</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 9.35pt;"><span style="font-style:italic;font-weight:bold;">Regulations on Overseas Securities Offering and Listing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In December 2021, the CSRC promulgated the Provisions of the State Council on the Administration of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments), or the Draft CSRC Administration Provisions, and the Administrative Measures for the Filing of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments), or the Draft CSRC Filing Measures, to regulate overseas offerings by domestic companies of equity shares, depository receipts, convertible corporate bonds, or other equity-like securities, and overseas listing of the securities for trading. Both direct and indirect overseas securities offering and listing by domestic companies would be regulated, of which the former refers to securities offering and listing in an overseas market made by a joint-stock company incorporated domestically, and the latter refers to securities offering and listing in an overseas market made in the name of an offshore entity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Draft CSRC Filing Measures, if an issuer meets the following conditions, the offering and listing shall be determined as an indirect overseas offering and listing by a domestic company: (i) the total assets, net assets, revenues or profits of the domestic entity/entities of the issuer in the most recent accounting year account for more than 50% of the corresponding figure in the issuer&#8217;s audited consolidated financial statements for the same period; and (ii) most of the senior management in charge of business operation and management of the issuer are Chinese citizens or have domicile in the PRC, and its main places of business are located in the PRC or main business activities are conducted in the PRC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Under the Draft CSRC Administration Provisions and the Draft CSRC Filing Measures, a filing-based regulatory system would be implemented covering both direct and indirect overseas offering and listing, among which, (i) if an issuer listed in other overseas markets after overseas offerings,  the issuer shall submit to the CSRC filing documents within three working days after such application is submitted; (ii) if an issuer issues overseas listed securities after listing abroad and issues such securities aiming at purchasing assets, the issuer shall submit to the CSRC filing documents within three working days after the issue is completed, however, if the assets purchased are domestic assets, the filing procedure shall be performed within three working days from the date of the first announcement of the transaction; and (iii) if the significant events, such as change of control and termination of the listing, occur after the issuer&#39;s overseas listing, it should report the details to CSRC within three working days from the date of occurrence.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Foreign Exchange and Dividend Distribution</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Foreign Exchange Control</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the PRC Regulation for the Foreign Exchange promulgated by the State Council in January&#160;1996, which was amended in January&#160;1997 and August&#160;2008, and the Regulation on the Administration of the Foreign Exchange Settlement, Sales and Payment promulgated by the People&#8217;s Bank of China in June&#160;1996, foreign exchanges required for distribution of profits and payment of dividends may be purchased from designated foreign exchange banks in the PRC upon presentation of a board resolution authorizing distribution of profits or payment of dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Circular of the State Administration of Foreign Exchange, or the SAFE, on Further Improving and Adjusting the Foreign Exchange Policies on Direct Investment and its appendix promulgated in November&#160;2012 and amended in May&#160;2015, October&#160;2018 and December&#160;2019 by the SAFE, (1)&#160;the opening of and payment into foreign exchange accounts under direct investment accounts are no longer subject to approval by the SAFE; (2)&#160;reinvestment with legal income of foreign investors in China is no longer subject to approval by SAFE; (3)&#160;the procedures for capital verification and confirmation that foreign-funded enterprises need to go through are simplified; (4)&#160;purchase and external payment of foreign exchange under direct investment accounts are no longer subject to approval by SAFE; (5)&#160;domestic transfer of foreign exchange under direct investment account is no longer subject to approval by SAFE; and (6)&#160;the administration over the conversion of foreign exchange capital of foreign-invested enterprises is improved. Later, the SAFE promulgated the Circular on Further Simplifying and Improving Foreign Exchange Administration Policies in Respect of Direct Investment in February&#160;2015, which was further amended in December&#160;2019 and prescribed that the bank instead of the SAFE can directly handle the foreign exchange registration and approval under foreign direct investment while the SAFE and its branches indirectly supervise the foreign exchange registration and approval under foreign direct investment through the bank.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Provisions on the Administration of Foreign Exchange in Foreign Direct Investments by Foreign Investors, which were promulgated by the SAFE in May&#160;2013 and amended in October&#160;2018 and December&#160;2019, regulate and clarify the administration over foreign exchange administration in foreign direct investments.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">152</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Circular on the Reform of the Management Method for the Settlement of Foreign Exchange Capital of Foreign-invested Enterprises promulgated by the SAFE in Mach 2015 and amended in December&#160;2019, and the Circular on the Reform and Standardization of the Management Policy of the Settlement of Capital Projects promulgated by the SAFE in June&#160;2016, the settlement of foreign exchange by foreign invested enterprises shall be governed by the policy of foreign exchange settlement on a discretionary basis. However, the settlement of foreign exchange shall only be used for their own operational purposes within the business scope of the foreign invested enterprises and follow the principles of authenticity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Dividend Distribution</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The SAFE promulgated the Notice on Improving the Check of Authenticity and Compliance to Further Promote Foreign Exchange Control in January&#160;2017, which stipulates several capital control measures with respect to outbound remittance of profits from domestic entities to offshore entities, including the following: (1)&#160;under the principle of genuine transaction, banks shall check board resolutions regarding profit distribution, the original version of tax filing records and audited financial statements; and (2)&#160;domestic entities shall hold income to account for previous years&#8217; losses before remitting the profits. Moreover, domestic entities shall make detailed explanations of sources of capital and utilization arrangements, and provide board resolutions, contracts and other proof when completing the registration procedures in connection with an outbound investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Foreign Exchange Registration of Offshore Investment by PRC Residents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The SAFE promulgated the SAFE Circular 37 in July&#160;2014. The SAFE Circular 37 requires PRC residents (including PRC institutions and individuals) to register with local branches of SAFE in connection with their direct or indirect offshore investment in an overseas special purpose vehicle, or the SPV, directly established or indirectly controlled by PRC residents for offshore investment and financing with their legally owned assets or interests in domestic enterprises, or their legally owned offshore assets or interests. Such PRC residents are also required to amend their registrations with the SAFE when there is a change to the basic information of the SPV, such as changes of a PRC resident individual shareholder, the name or operating period of the SPV, or when there is a significant change to the SPV, such as changes of the PRC individual resident&#8217;s increase or decrease of its capital contribution in the SPV, or any share transfer or exchange, merger, division of the SPV.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Circular on Further Simplifying and Improving Foreign Exchange Administration Policies in Respect of Direct Investment, which was promulgated in February&#160;2015 and effective in June&#160;2015 and further amended in December&#160;2019, provides that PRC residents may register with qualified banks instead of the SAFE in connection with their establishment or control of an offshore entity established for the purpose of overseas direct investment. The SAFE and its branches shall implement indirect supervision over foreign exchange registration of direct investment via the banks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Failure to comply with the registration procedures set forth in the SAFE Circular 37 may result in restrictions on the foreign exchange activities of the relevant onshore company, including the payment of dividends and other distributions to its offshore parent or affiliate, the capital inflow from the offshore entities and settlement of foreign exchange capital, and may also subject relevant onshore company or PRC residents to penalties under PRC foreign exchange administration regulations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Labor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Labor Law and Labor Contract Law</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the PRC Labor Law, which was promulgated by the Standing Committee of the NPC in July&#160;1994 and amended in August&#160;2009 and December&#160;2018, respectively, the PRC Labor Contract Law, which was promulgated by the Standing Committee of the NPC in June&#160;2007 and amended in December&#160;2012 and came into effect July&#160;2013, and the Implementing Regulations of the Employment Contracts Law of the PRC, which was promulgated by the State Council in September&#160;2008, labor contracts in written form shall be executed to establish labor relationships between employers and employees. In addition, wages cannot be lower than the local minimum wage. The employers must establish a system for labor safety and sanitation, strictly abide by State rules&#160;and standards, provide education regarding labor safety and sanitation to its employees, provide employees with labor safety and sanitation conditions and necessary protection materials in compliance with State rules, and carry out regular health examinations for employees engaged in work involving occupational hazards.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">153</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Social Insurance and Housing Provident Funds</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Social Insurance Law of PRC, which was promulgated by the Standing Committee of the NPC in October&#160;2010 and came into effect in July&#160;2011, and further amended in December&#160;2018, and the Interim Regulations on the Collection and Payment of Social Security Funds, which was promulgated by the State Council in January&#160;1999 and amended in March&#160;2019, and the Regulations on the Administration of Housing Provident Funds, which was promulgated by the State</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Council in April&#160;1999 and amended in March&#160;2002 and March&#160;2019, employers are required to contribute, on behalf of their employees, to a number of social security funds, including funds for basic pension insurance, unemployment insurance, basic medical insurance, occupational injury insurance, maternity insurance and to housing provident funds. Any employer who fails to contribute may be fined and ordered to make good the deficit within a stipulated time limit.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Regulations on Taxation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Enterprise Income Tax</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Enterprise Income Tax Law promulgated by the Standing Committee of the NPC in March&#160;2007 and amended in February&#160;2017 and December&#160;2018, and the Implementation Rules&#160;of the Enterprise Income Tax Law of the PRC promulgated by the State Council in December&#160;2007 and amended in April&#160;2019, other than a few exceptions, the income tax rate for both domestic enterprises and foreign-invested enterprises is 25%. Enterprises are classified as either &#8220;resident enterprises&#8221; or &#8220;non-resident enterprises&#8221;. Besides enterprises established within the PRC, enterprises established outside China whose &#8220;de facto management bodies&#8221; are located in China are considered &#8220;resident enterprises&#8221; and subject to the uniform 25% enterprise income tax rate for their global income. A non-resident enterprise refers to an entity established under foreign law whose &#8220;de facto management bodies&#8221; are not within the PRC but which have an establishment or place of business in the PRC, or which do not have an establishment or place of business in the PRC but have income sourced within the PRC. An income tax rate of 10% will normally be applicable to dividends declared to non-PRC resident enterprise investors that do not have an establishment or place of business in the PRC, or that have such establishment or place of business but the relevant income is not effectively connected with the establishment or place of business, to the extent such dividends are derived from sources within the PRC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Notice on Promoting the Implementation of Corporate Income Tax Policies for Advanced Technology Service Enterprises Nationwide, or the Notice, since January&#160;2017, an enterprise which is recognized as an &#8220;Advanced Technology Service Enterprises&#8221; under the Notice enjoys a reduced enterprise income tax rate of 15%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Arrangement Between the Mainland of China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and Prevention of Fiscal Evasion with Respect to Taxes on Income, or the Double Tax Avoidance Arrangement, which was promulgated and came into effect in August&#160;2006, and other applicable PRC laws, if a Hong Kong resident enterprise is determined by the competent PRC tax authority to have satisfied the relevant conditions and requirements under such Double Tax Avoidance Arrangement and other applicable laws, the 10% withholding tax on the dividends the Hong Kong resident enterprise receives from a PRC resident enterprise may be reduced to 5%. However, based on the Circular on Certain Issues with Respect to the Enforcement of Dividend Provisions in Tax Treaties which was promulgated by the State Administration of Taxation, the STA, in February&#160;2009, if the relevant PRC tax authorities determine, in their discretion, that a company benefits from such reduced income tax rate due to a structure or arrangement that is primarily tax-driven, such PRC tax authorities may adjust the preferential tax treatment. Based on the Announcement on Certain Issues with Respect to the &#8220;Beneficial Owner&#8221; in Tax Treaties, which was promulgated by the STA in February&#160;2018 and came into effect in April&#160;2018, if an applicant&#8217;s business activities do not constitute substantive business activities, it could result in the negative determination of the applicant&#8217;s status as a &#8220;beneficial owner&#8221;, and consequently, the applicant could be precluded from enjoying the above-mentioned reduced income tax rate of 5% under the Double Tax Avoidance Arrangement.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">154</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:225.04pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Value Added Tax</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Provisional Regulations of the PRC on Value-Added Tax, effective in January&#160;1994 and further amended in November&#160;2008, February&#160;2016, and November&#160;2017, and its implementation rules&#160;effected in January&#160;1994 and amended in December&#160;2008 and October&#160;2011, except stipulated otherwise, taxpayers who sell goods, labor services or tangible personal property leasing services or import goods shall be subject to a 17% tax rate; taxpayers who sell transport services, postal services, basic telecommunications services, construction services, or real property leasing services, sell real property, transfer the land use right shall be subject to an 11% tax rate, and taxpayers who sell services or intangible assets shall be subject to a 6% tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Circular of the Ministry of Finance and the State Administration of Taxation on Adjusting Value-added Tax Rates adopted in April&#160;2018, as of May&#160;2018, where a taxpayer engages in a taxable sales activity for the value-added tax purpose or imports goods, the previous applicable 17% and 11% rates are adjusted to 16% and 10%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Announcement on Relevant Policies for Deepening Value-Added Tax Reform, effective in April&#160;2019, the 16% VAT tax rate, which applies to the sales or imported goods of a VAT general taxpayer, will be lowered to 13%; and the 10% VAT tax rate will be lowered to 9%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to the Measures for the Exemption of Value-Added Tax from Cross-Border Taxable Activities in the Collection of Value-Added Tax in Lieu of Business Tax (for Trial Implementation) revised in June&#160;2018, if domestic enterprises provide cross-border taxable activities such as professional technical services, technology transfer, software services, the above-mentioned cross-border taxable activities are exempt from VAT.</p><a id="_9200329e_4a22_4fee_b197_fe4e2ce8b098"></a><a id="a4COrganizationalStructure_866231"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">4.C. Organizational Structure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following diagram illustrates our corporate structure as of the date of this annual report, including our material subsidiaries directly or indirectly owned by us through equity ownership (our group structure does not include any variable interest entities):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><img src="adag-20211231x20f037.jpg" alt="Graphic" style="display:inline-block;height:224.64pt;left:0%;padding-bottom:0.4pt;position:relative;top:0pt;width:480.6pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">155</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_ba808ee4_22e7_4781_ae21_e68da0795713"></a><a id="a4DPropertyPlantsandEquipment_662127"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">4.D. Property, Plants and Equipment</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our headquarter is based in Suzhou, China, where we have our administrative and laboratory offices, which are approximately 3,008 square meters in size. The expiration dates of the lease agreements for this facility range from August 6, 2022 to September&#160;15, 2024. We also have a 3,754 square feet facility in San Diego, California for laboratory, research and development functions, the lease for which expires on August&#160;31, 2023. We do not expect difficulties in renewing lease agreements for our facilities.</p><a id="_bc36f17c_2c71_4e96_a307_1c9b036afca2"></a><a id="ITEM4AUNRESOLVEDSTAFFCOMMENTS_814425"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 4A. UNRESOLVED STAFF COMMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_bb552cff_eeb3_45bd_87f4_8754d27deb3e"></a><a id="ITEM5OPERATINGANDFINANCIALREVIEWANDPROSP"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the section entitled &#8220;Selected Consolidated Financial Data&#8221; and our consolidated financial statements and the related notes included elsewhere in this annual report. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those we describe under &#8220;Item 3.D. Risk Factors&#8221; and elsewhere in this annual report.</p><a id="_28e0f8d5_d018_429c_9d7f_2e2ffa84aad8"></a><a id="a5AOperatingResults_653990"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">5.A. Operating Results</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a platform-driven, clinical-stage biopharmaceutical company transforming the discovery and development of novel antibody-based cancer immunotherapies. We are combining computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by our proprietary Dynamic Precision Library (DPL) platform, which fuels our NEObody&#8482;, SAFEbody<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, and POWERbody&#8482; technologies, we are developing a highly differentiated pipeline of novel immunotherapies. We have forged strategic collaborations with reputable global partners that leverage our technology in multiple approaches at the vanguard of science. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We aim to push the boundaries of antibody discovery and engineering through the precise design, construction, and selection of antibody product candidates intractable to traditional antibody technology. We have pioneered a dynamic antibody technology interface to harness the conformational diversity of antibodies, which enlarges epitope sampling of a given drug target for differentiated therapeutic antibody development. Additionally, we have a proprietary precision masking technology and specialized antibody engineering capabilities which enable us to design therapeutics with unique features.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Dynamic Precision Library fuels our three antibody technology platforms, which can be used alone or together to create novel, differentiated antibody-based therapeutic candidates. By leveraging our proprietary DPL platform and three platform technologies, we have developed a robust pipeline of innovative product candidates in various stages of development, ranging from research and discovery to preclinical and clinical development. Our highly differentiated and wholly-owned clinical-stage pipeline consists of two anti-CTLA-4 antibodies ADG116 (NEObody) and ADG126 (SAFEbody), and an anti-CD137 antibody, ADG106 (NEObody). All three candidates are in Phase 1b/2 clinical evaluation in single agent and/or combination clinical trials designed to evaluate safety and preliminary efficacy. We also have a robust preclinical pipeline of five programs in IND-enabling studies, including a masked, Fc engineered anti-CD137 POWERbody and a masked anti-CD47 SAFEbody, which are both on track for clinical development, as well as over 50 programs in various stages of discovery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since our inception in 2011, our operations have focused on organizing and staffing our company, conducting preclinical studies and clinical trials, business planning, establishing our intellectual property portfolio and raising capital. We do not have any product candidates approved for sale and have not generated any revenue from product sales. We have financed operations mainly through the private placements of our preferred shares before our initial public offering completed in Febraury 2021 and through proceeds received from the initial public offering. </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">156</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since inception, we have incurred significant operating losses. Our net losses were US$16.4 million, US$42.4 and US$73.2 million for the years ended December 31, 2019, 2020 and 2021, respectively. As of December 31, 2021, we had accumulated deficit of US$178.8 million. We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue advancement of and investment in our proprietary DPL platform;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">advance the development of ADG116, ADG126, ADG106 and other preclinical drug candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue our ongoing and planned research and development of other lead product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discover and develop additional antibody product candidates and further expand our preclinical and clinical product pipeline;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand our collaborations with contract manufacturing organizations and contract research organizations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish sales and marketing teams and distribution network to commercialize any product candidate for which we may obtain regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attract, hire and retain additional clinical, scientific, management and administrative personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand our operations globally; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur additional costs associated with operating as a public company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Beginning in January&#160;2020, the emergence and wide spread of COVID-19 has resulted in quarantines, travel restrictions, and the temporary closure of stores and facilities in the United States and China and elsewhere. Substantially all of our operating and workforce are based in the United States and China. Since late July 2021, the delta variant of COVID-19 has resurged in several provinces across China and the Omicron variant of COVID-19 has been detected in most states and territories of the United States and is rapidly increasing the proportion of COVID-19 cases it is causing. Consequently, the COVID-19 outbreak and its resurgences caused by the new variants could potentially delay a patient&#8217;s access to hospital and the progress of our clinical trials, including patient enrollment, which may adversely affect our business operations, financial condition and operating results for 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;"> The extent of the impact of the COVID-19 pandemic on our business, operations and regulatory and commercialization timelines will depend on certain developments, including the duration and spread of the outbreak and its impact on clinical trials, regulatory authorities and our key scientific and management personnel as well as its impact on our partners, laboratory sites, and other third parties with whom we collaborate, and the extent of future resurgences of the disease and its variants, vaccine distribution and other actions in response to the virus or to contain its impact, and we are closely monitoring its impact on us. See &#8220;Item 3 Key Information&#8212;Risk Factors&#8212;Risks relating to obtaining regulatory approval of our drug candidates&#8212;The COVID-19 pandemic could adversely impact our business, including our clinical trials.&#8221; We will continue to actively monitor the rapidly evolving situation related to COVID-19 and may take further actions that alter our business operations, including those that may be required by government authorities, or that we determine are in the best interests of our employees, partners and shareholders. At this point, the extent to which the COVID-19 pandemic may impact our business, operations and regulatory and commercialization timelines remains uncertain.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">157</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Key Components of Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licensing and collaboration revenue. </i>Our licensing and collaboration revenue is currently comprised of upfront and/or milestone payments associated with out-licensing arrangements, and reimbursement income. Our licensing and collaboration revenue for the years ended December&#160;31, 2019, 2020 and 2021 was primarily derived from granting licenses to use and otherwise exploit certain of our intellectual properties. To date, we have not generated any revenue from the sale of products and do not expect to generate any revenue from product sales in the near future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Expenses. </i>Our research and development expenses consist principally of (1)&#160;payroll and other related costs of personnel engaged in research and development activities, (2)&#160;costs related to pre-clinical testing of our technologies under development and clinical trials such as payments to contract research organizations, or CRO, and contract manufacturing organization, or CMO, investigators and clinical trial sites that conduct the clinical studies; (3)&#160;costs to develop the product candidates, including raw materials and supplies, product testing, depreciation and amortization, and facility related expenses, (4)&#160;other research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the years ended December 31, 2019, 2020 and 2021, our research and development expenses were US$16.2 million, US$33.5 million and US$68.1 million, respectively. The increase was primarily due to an increase in personnel, including non-cash share-based compensation, and greater preclinical testing, clinical activities and CMC activities (provided by related parties and third parties) associated with our three clinical candidates and five preclinical programs in the IND-enabling phase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our research and development expenses may vary substantially from period to period according to the status of our research and development activities. The timing of expenses is impacted by the commencement of clinical trials and enrollment of patients in clinical trials. Research and development expenses are expected to increase as we advance the clinical development of ADG116, ADG126 and ADG106, and further advance the research and development of our other product candidates. The successful development of our product candidates is uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our research and development expenses for our clinical-stage product candidates, preclinical product candidates and research pipeline for the years ended December&#160;31, 2019, 2020 and 2021, respectively.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$ </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">ADG116</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,329</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,156</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,236</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">ADG126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,326</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,091</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,543</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">ADG106</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,742</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12,504</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,798</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Preclinical product candidates, research pipeline and others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,814</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,787</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 38,522</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 16,212</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 33,538</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 68,099</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At this time, we cannot reasonably estimate the nature, timing and estimated costs of the efforts that will be necessary to complete the development of, or the period, if any, in which material net cash inflows may commence from, any of our product candidates. This is due to numerous risks and uncertainties associated with developing drugs, including the uncertainty of:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, rate of progress, results and cost of our clinical trials, preclinical studies and other related activities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of manufacturing clinical supplies, and establishing commercial supplies, of any product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and characteristics of product candidates that we pursue;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">158</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost, timing and outcomes of regulatory approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost and timing of establishing sales, marketing and distribution capabilities; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the terms and timing of any collaboration, licensing or other arrangements that we may establish, including any required milestone and royalty payments thereunder.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these variables with respect to the development of our product candidates or any other current or future product candidates could mean a significant change in the costs and timing associated with the development of such product candidate. For example, if we are required to conduct additional clinical trials or other testing of any of our product candidates beyond those that are contemplated or if we experience significant delays in enrollment in any clinical trials, we could incur significant additional costs and the clinical development timeline for our product candidates may be delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Administrative expenses. </i>Our administrative expenses consist primarily of wages, salaries and benefits for personnel other than research and development staff. We expect our administrative expenses to increase in absolute amount in the foreseeable future as we incur additional costs as a result of operating as a public company and as we increase the number of employees and advance our product candidates through clinical development, which will also increase our general and administrative expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Other income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other income primarily includes government subsidies that Adagene Suzhou received from local government in the PRC. The receipt of such government subsidies is not dependent on our performance of any obligations. In addition, the subsidiary in Australia received research and development tax incentive from the Australian Taxation Office. The tax incentive was recognized as other income upon receipt as the incentive was not dependent upon having a tax liability and further performance by the Group was not required.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Taxation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Cayman Islands</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are incorporated in the Cayman Islands. Under the current laws of the Cayman Islands, we are not subject to income, corporation or capital gains tax in the Cayman Islands. In addition, our payment of dividends, if any, is not subject to withholding tax in the Cayman Islands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Hong Kong</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our wholly-owned subsidiary in Hong Kong, Adagene (Hong Kong) Limited, is subject to Hong Kong profits tax on the taxable income as reported in its statutory financial statements adjusted in accordance with the relevant Hong Kong tax laws. The applicable tax rate in Hong Kong is 16.5%. Under Hong Kong tax law, our subsidiary in Hong Kong is exempted from income tax on their foreign-derived income and there is no withholding tax in Hong Kong on remittance of dividends. No provision for Hong Kong profits tax was made as there were no assessable profits derived from or earnings in Hong Kong for the years ended December 31, 2019, 2020 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:10.8pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">United States</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our subsidiary in the U.S., Adagene Incorporated, is incorporated in the U.S. and subject to U.S. federal corporate income tax at a rate of 21%. It is also subject to state income tax in California of 8.84%. Dividends payable by an U.S. entity, to non-U.S. resident enterprises shall be subject to 30% withholding tax, unless the respective non-U.S. resident enterprise&#8217;s jurisdiction of incorporation has a tax treaty or arrangements with U.S. that provides for a reduced withholding tax rate or an exemption from withholding tax.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">159</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">PRC</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our subsidiary in China is incorporated under PRC law and, as such, is subject to PRC enterprise income tax on their taxable income in accordance with the relevant PRC income tax laws. Pursuant to the PRC Enterprise Income Tax Law, or EIT Law, which became effective on January&#160;1, 2008, a uniform 25% enterprise income tax rate is generally applicable to both foreign-invested enterprises and domestic enterprises, except where a special preferential rate applies. In accordance with the implementation rules&#160;of EIT Law, a qualified Technology Advanced Service Enterprises, or TASE, is eligible for a preferential tax rate of 15%. The TASE certificate is effective for three years. An entity must file required supporting documents with the tax authority and ensure fulfillment of the relevant TASE criteria before using the preferential rate. An entity could apply for the TASE certificate every year. Adagene Suzhou was first recognized as a qualified TASE in March&#160;2015 and renewed in December&#160;2018 and December 2021. Adagene Suzhou can enjoy the preferential tax rate of 15% from 2015 to at least 2023. In addition, the research and development expenses of Adagene Suzhou are subject to a 75% super-deduction for the income tax. The enterprise income tax is calculated based on the entity&#8217;s global income as determined under PRC tax laws and accounting standards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to VAT at a rate of 3%, 6%, or 13% on the services we provide and related surcharges. We are also subject to surcharges on VAT payments in accordance with PRC law.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a Cayman Islands holding company, we may receive dividends from Adagene Suzhou. The PRC EIT Law and its implementing rules&#160;provide that dividends paid by a PRC entity to a nonresident enterprise for income tax purposes is subject to PRC withholding tax at a rate of 10%, subject to reduction by an applicable tax treaty with China. Pursuant to the Arrangement between Mainland China and the Hong Kong Special Administrative Region for the Avoidance of Double Taxation and Tax Evasion on Income, the withholding tax rate in respect to the payment of dividends by a PRC enterprise to a Hong Kong enterprise may be reduced to 5% from a standard rate of 10% if the Hong Kong enterprise directly holds at least 25% of the PRC enterprise. Pursuant to the Notice of the State Administration of Taxation on the Issues concerning the Application of the Dividend Clauses of Tax Agreements, or SAT Circular 81, a Hong Kong resident enterprise must meet the following conditions, among others, in order to apply the reduced withholding tax rate: (i)&#160;it must be a company; (ii)&#160;it must directly own the required percentage of equity interests and voting rights in the PRC resident enterprise; and (iii)&#160;it must have directly owned such required percentage in the PRC resident enterprise throughout the 12 months prior to receiving the dividends. In August&#160;2015, the State Administration of Taxation promulgated the Administrative Measures for Nonresident Taxpayers to Enjoy Treatment under Tax Treaties, or SAT Circular 35, which later became effective on January&#160;1, 2020. SAT Circular 35 provides that non-resident enterprises are not required to obtain pre-approval from the relevant tax authority in order to enjoy the reduced withholding tax. Instead, nonresident enterprises and their withholding agents may, by self-assessment and on confirmation that the prescribed criteria to enjoy the tax treaty benefits are met, directly apply the reduced withholding tax rate, and file necessary forms and supporting documents when performing tax filings, which will be subject to post-tax filing examinations by the relevant tax authorities. Accordingly, Adagene (Hong Kong) Limited may be able to benefit from the 5% withholding tax rate for the dividends it receives from its PRC subsidiary, if it satisfies the conditions prescribed under SAT Circular 81 and other relevant tax rules&#160;and regulations. However, according to SAT Circular 81 and SAT Circular 35, if the relevant tax authorities consider the transactions or arrangements we have are for the primary purpose of enjoying a favorable tax treatment, the relevant tax authorities may adjust the favorable withholding tax in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If our holding company in the Cayman Islands or any of our subsidiaries outside of China were deemed to be a &#8220;resident enterprise&#8221; under the PRC EIT Law, it would be subject to enterprise income tax on its worldwide income at a rate of 25%. See &#8220;Item 3 Key Information&#8212; Risk Factors&#8212;Risks Related to Doing Business in the PRC&#8212;If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Critical Accounting Policies and Judgments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">160</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our consolidated financial statements include the financial statements of Adagene Inc. and its subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the balance sheet dates and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in our consolidated financial statements include, but are not limited to, the useful lives and impairment of long-lived assets, tax valuation allowance, share-based compensation expenses and the fair value of warrant liabilities. Management bases the estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could materially differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Foreign currency translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The functional currency of Adagene Inc., Adagene (Hong Kong) Limited, Adagene Incorporated and Adagene PTE. Ltd. is the U.S. dollar, or US$. The functional currency of our PRC subsidiary is Renminbi, or RMB. The functional currency of our Australia subsidiary is Australian dollar, or AU$.The functional currency of our Swiss subsidiary is Swiss Franc, or CHF. The determination of the respective functional currency is based on the criteria stated in Accounting Standard Codification, or ASC, 830, Foreign Currency Matters. We use US$ as our reporting currency. The financial statements of our PRC subsidiary, Australia subsidiary and Swiss subsidiary are translated from the functional currency to the reporting currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Transactions denominated in foreign currencies are re-measured into the functional currency at the exchange rates quoted by the People&#8217;s Bank of China, or the PBOC, prevailing on the transaction dates. Monetary assets and liabilities denominated in foreign currencies are re-measured at the exchange rates prevailing at the balance sheet date. Non-monetary items that are measured in terms of historical costs in foreign currency are re-measured using the exchange rates at the dates of the initial transactions. Exchange gains and losses are included in the consolidated statements of comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities are translated at the exchange rates at the balance sheet date, equity accounts are translated at historical exchange rates and revenues, expenses, gains and losses are translated using the average rate for the year. Translation adjustments are reported as accumulated comprehensive loss and are shown as a separate component of other comprehensive loss in the consolidated statements of comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Revenue recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At contract inception of collaboration and out-licensing arrangement, we analyze the arrangements to assess whether they are within the scope of ASC 808, <i style="font-style:italic;">Collaborative Arrangements </i>or ASC 808, to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, we first determine which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are reflective of a vendor-customer relationship and therefore within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">161</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the criteria of <i style="font-style:italic;">Accounting Standard Codification, </i>or ASC, 606, <i style="font-style:italic;">Revenue from Contracts with Customers </i>(Topic 606), or ASC 606, we recognize revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services. We adopted ASC 606 for all periods presented. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. We only apply the five-step model to contracts when it is probable that the entity will collect substantially all the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. We review the contract to determine which performance are distinct and represent a promise to provide distinct goods or services or a series of distinct goods or services as defined by the standard. We recognize as revenue the amount of the transaction price that is allocated to each performance obligation as and when that performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licenses of Intellectual Property</i>: Upfront non-refundable payments for licensing our intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, we recognize revenues from non-refundable, up-front fees allocated to the license at a point in time, when the transfer of control of the license to the licensee occurs and the licensee is able to use and benefit from the license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Services</i>: The portion of the transaction price allocated to research and development services performance obligations is deferred and recognized at a point in time as delivery of such services occurs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Milestone Payments</i>: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, we evaluate whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Royalties</i>: For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To date, no royalty payments were received and US$3.6 million of milestone payments were received including US$0.6 million received in 2021 and US$3.0 million received in January 2022. Substantially all of our revenue has been derived from its out-licensing agreements with respect to licensed products such as DNA sequences, cell lines,&#160;etc., and such revenues are recognized when the customer obtains control of the licensed product, which occurs at a point in time, upon delivery to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Contract assets and contract liabilities</i>: When a customer pays consideration before we transfer products or services, we record our obligation as a contract liability; when we satisfy our performance obligations by providing products or services to a customer before the customer pays consideration and before payment is due, we recognize our rights to consideration as a contract asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Fair value measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We apply ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures</i>. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 requires disclosures to be provided for fair value measurements. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Level 1&#8212;Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Level 2&#8212;Other inputs that are directly or indirectly observable in the marketplace.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">162</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Level 3&#8212;Unobservable inputs which are supported by little or no market activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1)&#160;market approach; (2)&#160;income approach; and (3)&#160;cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of cash and cash equivalent, short-term investments, accounts receivable, amounts due to related parties and other current assets, accounts payable, amounts due to related parties, accrued liabilities and other current liabilities and short-term borrowings approximate their fair values because of their generally short maturities. The carrying amount of long-term borrowings approximate their fair values since they bear interest rates which approximate market interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We did not transfer any assets or liabilities in or out of Level 3 during the year ended December&#160;31, 2020 or 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We had no financial assets and liabilities measured and recorded at fair value on a nonrecurring basis as of December&#160;31, 2020 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Research and development expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Elements of research and development expenses primarily include (1)&#160;payroll and other related costs of personnel engaged in research and development activities, (2)&#160;costs related to pre-clinical testing of our technologies under development and clinical trials such as payments to contract research organizations, or CRO, and contract manufacturing organizations, or CMO, investigators and clinical trial sites that conduct the clinical studies; (3)&#160;costs to develop the product candidates, including raw materials and supplies, product testing, depreciation and amortization, and facility related expenses, (4)&#160;other research and development expenses. Research and development expenses are charged to expense as incurred when these expenditures relate to our research and development services and have no alternative future uses. As of December&#160;31, 2021, we have several ongoing clinical studies in various clinical trial stages. The contracts with CRO and CMO are generally cancellable, with notice, at our option. We did not record any accrued expenses related to cancellation of CRO or CMO contracts as of December&#160;31, 2020 or 2021 as we did not have any plan to cancel the existing CRO or CMO contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We follow the liability method of accounting for income taxes in accordance with ASC 740,&#160;<i style="font-style:italic;">Income Taxes</i>, or ASC 740. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. We record a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We evaluate our uncertain tax positions using the provisions of ASC 740, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recognize in the consolidated financial statements the benefit of a tax position which is &#8220;more likely than not&#8221; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. It is our policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">163</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have incurred net accumulated operating losses for income tax purposes since our inception. We believe that it is more likely than not that these net accumulated operating losses will not be utilized in the near future. Therefore, we have provided full valuation allowances for the deferred tax assets for all subsidiaries as of December&#160;31, 2020 and for subsidiaries other than the U.S. subsidiary as of December 31, 2021. There was no income tax expense for the years ended December&#160;31, 2019 and 2020, as our subsidiaries did not have any taxable profits. For the year ended December 31, 2021, income tax expense was US$1.7 million due to taxable profits generated by the U.S. subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We grant restricted shares and stock options to eligible employees and nonemployees and accounts for share-based compensation in accordance with ASC 718, Compensation&#8212;Stock Compensation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses a) immediately at the grant date if no vesting conditions are required; or b) for share-based awards granted with only service conditions, using the straight-line method over the vesting period; or c) for share-based awards granted with service conditions and performance conditions, using the graded vesting method over the vesting period if and when the company concludes that it is probable that the performance conditions will be achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. We calculate incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, we recognize incremental compensation cost in the period when the modification occurs. For awards not being fully vested, we recognize the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fair value of share options was determined using the binomial option valuation model, with the assistance from an independent third-party appraiser. The binomial model requires the input of highly subjective assumptions, including the expected volatility, the exercise multiple, the risk-free rate and the dividend yield. For expected volatility, we have made reference to historical volatility of several comparable companies in the same industry. The exercise multiple was estimated as the average ratio of the stock price to the exercise price of when employees would decide to voluntarily exercise their vested share options. The risk-free rate for periods within the contractual life of the share options is based on the market yield of U.S. Treasury Bonds in effect at the time of grant. The dividend yield is based on the expected dividend policy over the contractual life of the share options. The estimated fair value of the ordinary shares, at the share option grant dates, was determined with the assistance from an independent third-party appraiser. Our management is ultimately responsible for the determination of the estimated fair value of its ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The assumptions used to estimate the fair value of the share options granted are as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the year eneded December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.78%-2.73</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0.68% - 0.83</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">1.11% - 1.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:60.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Expected volatility range</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">67.5%-71.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">72.3%- 73.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">73.1% - 75.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:60.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercise multiple</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.2-2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.2 - 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2.2 - 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Contractual life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Borrowings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the consolidated statements of comprehensive loss over the period of the borrowings using the effective interest method.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">164</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Recent accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A list of recent relevant accounting pronouncements is included in Note 2 &#8220;Summary of Significant Accounting Policies&#8221; to our consolidated financial statements included elsewhere in this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our consolidated results of operations for the periods presented. This information should be read together with our consolidated financial statements and related notes included elsewhere in this annual report. The operating results in any period are not necessarily indicative of the results that may be expected for any future period.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Revenue:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Licensing and collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 480</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 701</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,175</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expenses:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (16,212)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (33,538)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (68,099)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (3,438)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (10,315)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (14,440)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total operating expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (19,650)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (43,853)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (82,539)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (19,170)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (43,152)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (72,364)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 923</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 629</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 76</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (138)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (202)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (364)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 723</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 972</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,779</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Foreign exchange gain (loss), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 22</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (645)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (603)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,207</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss before income tax</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (16,432)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (42,397)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (71,476)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1,702)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss attributable to Adagene Inc.&#8217;s shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (16,432)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (42,397)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (73,178)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other comprehensive income (loss):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Foreign currency translation adjustments, net of nil tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 66</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (6)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 257</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total comprehensive loss attributable to Adagene Inc.&#8217;s shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (16,367)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (42,403)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (72,921)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss attributable to Adagene Inc.&#8217;s shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (16,432)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (42,397)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (73,178)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Accretion of convertible redeemable preferred shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (246)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (248)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (28)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to ordinary shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (16,678)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (42,645)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (73,206)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average number of ordinary shares used in per share calculation:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#8212;Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,178</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,951</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 50,032</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#8212;Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,178</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,951</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 50,032</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss per ordinary share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#8212;Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.10)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2.67)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.46)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#8212;Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.10)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2.67)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.46)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">165</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Year Ended December&#160;31, 2021 Compared to Year Ended December&#160;31, 2020</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Licensing and collaboration revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our licensing and collaboration revenue increased from US$0.7 million for the year ended December 31, 2020 to US$10.2 million for the year ended December 31, 2021. The increase was due to recognition of US$8.5 million from the collaboration and technology license agreement with Exelixis, Inc. and a payment of US$1.2 million from Dragon Boat Biopharmaceutical (Shanghai) Limited, a subsidiary of Sanjin, related to the companies&#8217; collaboration to develop antibody-based therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Research and development expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth a breakdown of the major components of our research and development expenses in absolute amounts and as a percentage of our total research and development expenses for the periods indicated:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:40.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:40.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:19.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="10" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:40.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands, except percentages)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Research and development expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Payroll and other related costs of personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14,003</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 41.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 28,293</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 41.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Costs related to clinical programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13,476</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 40.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,278</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 22.4</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Costs related to clinical trials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,702</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 14.0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,371</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 12.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">CMC and toxicology costs associated with the clinical programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8,774</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 26.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6,907</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10.1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Costs related to preclinical testing of non-clinical programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,208</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16,795</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 24.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Costs to develop the product candidates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,114</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 3,103</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,736</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.2</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,630</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:55.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 33,538</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 100</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 68,099</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 100</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our research and development expenses increased by 103.1% from US$33.5 million for the year ended December 31, 2020 to US$68.1 million for the year ended December 31, 2021, primarily attributable to (i) an increase in personnel, including non-cash share-based compensation of US$13.6 million, and (ii) greater preclinical testing, clinical activities and CMC activities (provided by related parties and third parties) associated with our three clinical programs and five preclinical programs in the IND-enabling phase.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Administrative expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our administrative expenses increased by 40.0% from US$10.3 million for the year ended December 31, 2020 to US$14.4 million for the year ended December 31, 2021, primarily attributable to an increase in personnel expenses of US$2.1 million, and an increase in professional fees and office-related expenses of US2.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Loss from operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of the foregoing, our loss from operations increased by 67.7% from approximately US$43.2 million in the year ended December 31, 2020 to approximately US$72.4 million in 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Interest income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our interest income was US$0.1 million for the year ended December 31, 2021, as compared to US$0.6 million for the year ended December 31, 2020. This decrease was primarily attributable to significant reduction in interest rate for term deposits.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">166</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Other income</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our other income increased from US$1.0 million for the year ended December 31, 2020 to US$1.8 million for the year ended December 31, 2021, primarily attributable to (i) an increase in government subsidies received by Adagene Suzhou to support our ongoing operations in Jiangsu Province during the year ended December 31, 2021, and (ii) a research and development tax incentive from the Australian Taxation Office received by Adagene Australia Pty Ltd, our wholly-owned subsidiary in Australia.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Foreign exchange loss, net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We recorded foreign exchange loss of US$ 0.6 million for the year ended December&#160;31, 2020 and foreign exchange loss of US$0.6 million for the year ended December&#160;31, 2021. This loss of foreign exchange was primarily attributable to the weakening of U.S. dollars against Renminbi which negatively impacted our U.S. dollars denominated accounts receivable of Adagene Suzhou.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Income tax expense</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Our income tax expense was $1.7 million for the year ended December 31, 2021 as compared to nil for the year ended December 31, 2020. The income tax expense for the year ended December 31, 2021 was primarily attributable to the current tax expenses on income reported by Adagene Incorporated, our wholly owned subsidiary in the U.S.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:10.8pt;margin:0pt 0pt 12pt 0pt;">Net loss attributable to Adagene Inc.&#8217;s shareholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our net loss for the period increased by 72.6% from US$42.4 million for the year ended December 31, 2020 to US$73.2 million for the year ended December 31, 2021. The 2021 net loss was higher largely due to increases in clinical, operating and CMC activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Year Ended December&#160;31, 2020 Compared to Year Ended December&#160;31, 2019</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Item 5. Operating and Financial Review and Prospects &#8211; 5.A Operating Results &#8212;Year Ended December 31, 2020 Compared to Year Ended December 31, 2019&#8221; beginning on page 148 of our annual report on Form 20-F for the year ended December 31, 2020 filed with the Securities and Exchange Commission on April 28, 2021 incorporated by reference into this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Non-GAAP Financial Measures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Non-GAAP net loss, which is defined as net loss attributable to ordinary shareholders for the period after excluding (i) share-based compensation expenses and (ii) accretion of convertible redeemable preferred shares to redemption value. The NonGAAP net loss was US$54.5 million for the year ended December 31, 2021, compared to US$32.3 million for the same period in 2020. Non-GAAP net loss per ordinary share for the year ended December 31, 2021 on both basic and diluted basis was US$1.09. Non-GAAP net loss per ordinary share for the year ended December 31, 2020 on both basic and diluted basis was US$2.02.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We use non-GAAP net loss and non-GAAP net loss per ordinary share for the year/period, which are non-GAAP financial measures, in evaluating our operating results and for financial and operational decision-making purposes. We believe that non-GAAP net loss and non-GAAP net loss per ordinary share for the year/period help identify underlying trends in our business that could otherwise be distorted by the effect of certain expenses that we include in our loss for the year/period. We believe that non-GAAP net loss and non-GAAP net loss per ordinary share for the year/period provide useful information about our results of operations, enhance the overall understanding of its past performance and future prospects and allow for greater visibility with respect to key metrics used by its management in our financial and operational decision-making.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Non-GAAP net loss and non-GAAP net loss per ordinary share for the year/period should not be considered in isolation or construed as an alternative to operating profit, loss for the year/period or any other measure of performance or as an indicator of its operating performance. Investors are encouraged to review non-GAAP net loss and non-GAAP net loss per ordinary share for the year/period and the reconciliation to their most directly comparable GAAP measures. Non-GAAP net loss and non-GAAP net loss per ordinary share for the year/period here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. We encoruage investors and others to review our financial information in its entirety and not rely on a single financial measure.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">167</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Non-GAAP net loss and non-GAAP net loss per ordinary share for the year/period represent net loss attributable to ordinary shareholders for the year/period excluding (i) share-based compensation expenses, and (ii) accretion of convertible redeemable preferred shares to redemption value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Please see the &#8220;Reconciliation of GAAP and Non-GAAP Results&#8221; below for a full reconciliation of GAAP net loss attributable to ordinary shareholders for the year/period to non-GAAP net loss attributable to ordinary shareholders and non-GAAP net loss per ordinary share for the year/period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Reconciliation of GAAP and Non-GAAP Results</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the years ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">GAAP net loss attributable to ordinary shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (16,678,492)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (42,645,392)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (73,206,488)</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Add back:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Share-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 611,711</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10,129,541</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18,679,658</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">Accretion of convertible redeemable preferred shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 246,184</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 248,113</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 28,553</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-GAAP net loss attributable to ordinary shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (15,820,597)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (32,267,738)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (54,498,277)</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Weighted average number of ordinary shares used in per share calculation:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">&#8212;Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,178,232</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,950,698</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 50,032,009</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">&#8212;Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,178,232</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,950,698</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 50,032,009</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-GAAP net loss per ordinary share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">&#8212;Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.04)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2.02)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.09)</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;">&#8212;Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.04)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2.02)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (1.09)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_9e903944_e710_4ecf_b40c_2d71fbf6247b"></a><a id="a5BLiquidityandCapitalResources_247343"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">5.B. Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since the inception, we have incurred net losses and negative cash flow from our operations. We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval and subsequently commercialize one of our current or future drug candidates. We expect to incur additional operating losses in the near future and our operating expenses will increase as we continue to expand our research and development capabilities, invest in preclinical tests and clinical trials and increase our efforts in obtaining regulatory approvals. In addition, subject to obtaining regulatory approval of any of our product candidates, we expect to incur significant commercialization expenses for product sales, marketing and manufacturing. Moreover, we expect to incur additional costs associated with operating as a public company, including expenses related to legal, accounting, regulatory, maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, and investor relations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our principal source of liquidity has been cash generated from the proceeds received from the issuance and sale of our shares. In February&#160;2021, we completed our initial public offering in which we issued and sold an aggregate of 8,457,100 ADSs, representing 10,571,375 ordinary shares, resulting in net proceeds to us of approximately US$145.9 million, net of the underwriting discounts and commissions and other fees paid or payable by us in connection with the offering. As of December 31, 2021, we had US$174.4 million in cash and cash equivalents. Further, the year-end 2021 cash balance does not include the US$3 million milestone payment from Exelixis received in January 2022, and the US$17.5 million upfront payment received from Sanofi in April 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We intend to finance our future working capital requirements and capital expenditures primarily from funds raised from financing activities, including the net proceeds we received from our initial public offering and future public and private offerings of our securities, and proceeds from our collaborations.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">168</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based on our current operating plan, we believe that our current cash and cash equivalents and proceeds from our initial public offering, public and private offerings of our securities and collobrations will be sufficient to meet our current and anticipated working capital requirements and capital expenditures for at least the next 12 months. In that time, we expect that our expenses will increase as we fund new and ongoing research and development activities and working capital needs. The assumptions on which our estimates are based may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development and commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In utilizing the proceeds that we received from our initial public offering, we may make capital contributions to our subsidiaries in PRC, the United States, Australia, Hong Kong, Singapore and Switzerland, acquire or establish new subsidiaries, or give loans to our subsidiaries. However, uses of the proceeds by our PRC subsidiary are subject to PRC regulations. See &#8220;Item 3 Key Information&#8212;Risk Factors&#8212;Risks Related to Doing Business in China&#8212;PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from using the proceeds of our initial public offering to make loans or additional capital contributions to our PRC subsidiary, which could materially and adversely affect our liquidity and our ability to fund and expand our business.&#8221; We have operations in China and many of the related transactions are settled in Renminbi. Our financial statements are presented in U.S. dollars. Under existing PRC foreign exchange regulations, Renminbi may be converted into foreign currencies for current account items, including profit distributions, interest payments and trade- and service-related foreign exchange transactions, without prior SAFE approval as long as certain routine procedural requirements are fulfilled. Our PRC subsidiary is allowed to pay dividends in foreign currencies to us without prior SAFE approval by following certain routine procedural requirements. However, approval from or registration with competent government authorities is required where the Renminbi is to be converted into foreign currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. The PRC government may at its discretion restrict access to foreign currencies for current account transactions in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table presents our selected consolidated cash flow data for the years ended December&#160;31, 2019, 2020 and 2021.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For the Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (18,154)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (28,530)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (43,415)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net cash (used in) generated from investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 24,856</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,073</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (2,510)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net cash generated from financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 69,694</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,439</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 145,357</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Effect of exchange rate on cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 78</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (364)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (192)</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net increase in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 76,474</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> (17,382)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 99,240</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents at the beginning of year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16,058</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 92,533</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 75,151</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cash and cash equivalents at the end of year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 92,533</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 75,151</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 174,391</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Operating activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities was US$43.4 million in 2021. The difference between our net loss of US$73.2 million and the net cash used in operating activities was mainly due to (i) an increase of accounts receivable of US$3.0 million due to milestone payment from Exelixis, Inc. which was received in January 2022, (ii) an increase in prepayments and other current assets of US$0.2 million due to our prepaid service fees to our vendors, and (iii) an increase in amount due from related parties of US$4.4 million due to prepayments made to our related parties, offset by (i) non-cash share-based compensation expenses of US$18.7 million, (ii) an increase in accounts payable of US$1.5 million, (iii) an increase in contract liabilities of US$4.8 million, (iv) an increase in amount due to related parties of US$7.9 million, (v) an increase in accruals and other current liabilities of US$1.1 million, (vi) an increase in income tax payable of US$1.7 million, and (vii) depreciation and amortization of US$1.1 million.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">169</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities was US$28.5 million in 2020. The difference between our net loss of US$42.4 million and the net cash used in operating activities was mainly due to (i)&#160;an increase in prepayments and other current assets of US$2.3 million due to our prepaid service fees to our vendor, (ii)&#160;a decrease in contract liabilities of US$0.3 million, offset by (i)&#160;non-cash share-based compensation expenses of US$10.1 million, (ii)&#160;an increase in accounts payable of US$1.1 million (iii)&#160;a decrease in accounts receivable of US$0.5 million, (iv)&#160;a decrease in amount due from related parties of US$1.3 million, (v)&#160;an increase in accruals and other current liabilities of US$1.2 million, and (vi)&#160;depreciation and amortization of US$0.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities was US$18.2 million in 2019. The difference between our net loss of US$16.4 million and the net cash used in operating activities was mainly due to (i)&#160;a decrease in amount due to related parties of US$1.8 million due to our payment of services fees to Wuxi Biologics, (ii)&#160;an increase in amount due from related parties of US$0.7 million, and (iii)&#160;change in fair value of warrant liabilities of US$1.2 million, partially offset by depreciation and amortization of US$0.8 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Investing activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash used in investing activities was US$2.5 million in 2021, which was attributable to the purchase of property, equipment and software.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash generated from investing activities was US$7.1 million in 2020, which was primarily attributable to withdrawal of short-term investments of US$8.0 million, partially offset by purchase of property, equipment and software of US$0.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash generated from investing activities was US$24.9 million in 2019, which was primarily attributable to withdrawal of short-term investments of US$44.0 million, partially offset by placement of short-term investments of US$19.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Financing activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash generated from financing activities was US$145.4 million in 2021, which was mainly attributable to (i) proceeds from initial public offering net of underwriting commissions of $149.4 million, and (ii) proceeds from borrowings of US$4.4 million, offset by (i) repayment of borrowings of US$5.1 million, (ii) payment of initial public offering costs of US$1.6 million, and (iii) purchase of treasury shares under stock repurchase program of US$2.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash generated from financing activities was US$4.4 million in 2020, which was mainly attributable to proceeds from borrowings of US$6.1 million, partially offset by repayment of borrowings of US$1.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Net cash generated from financing activities was US$69.7 million in 2019, which was mainly attributable to proceeds from issuance of convertible redeemable preferred shares and warrants of US$69.0 million, partially offset by repayment of borrowings of US$2.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Capital Expenditures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our capital expenditures are incurred primarily in connection with research and development equipment. Our capital expenditures were US$0.2 million, US$0.9 million and US$2.5 million, in 2019, 2020 and 2021, respectively. We intend to fund our future capital expenditures with our existing cash balance. We will continue to incur capital expenditures to meet the expected growth of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Holding Company Structure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Adagene Inc. is a holding company with no material operations of its own. Adagene Inc. holds certain intellectual properties and outsources certain research and development activities related to these intellectual properties to its subsidiaries. We conduct our operations primarily through our subsidiaries. As a result, our ability to pay dividends depends upon dividends paid by our subsidiaries. If our subsidiaries or any newly formed subsidiaries incur debt on their own behalf in the future, the instruments governing their debt may restrict their ability to pay dividends to us.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">170</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, our subsidiary in China is permitted to pay dividends to us only out of their retained earnings, if any, as determined in accordance with the Accounting Standards for Business Enterprise as promulgated by the Ministry of Finance of the PRC, or PRC GAAP. Pursuant to the law applicable to China&#8217;s foreign investment enterprise, our subsidiary that is foreign investment enterprise in the PRC has to make appropriation from its after-tax profit, as determined under PRC GAAP, to reserve funds including (i)&#160;general reserve fund, (ii)&#160;enterprise expansion fund and (iii)&#160;staff bonus and welfare fund. The appropriation to the general reserve fund must be at least 10% of the after-tax profits calculated in accordance with PRC GAAP. Appropriation is not required if the reserve fund has reached 50% of the registered capital of our subsidiary. Appropriation to the other two reserve funds are at our subsidiary&#8217;s discretion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As an offshore holding company, we are permitted under PRC laws and regulations to provide funding from the proceeds of our offshore fund-raising activities to our PRC subsidiary through loans or capital contribution, subject to the satisfaction of the applicable government registration and approval requirements. See &#8220;Item 3 Key Information&#8212; Risk Factors&#8212;Risks Related to Doing Business in the PRC&#8212;PRC regulation of loans to and direct investment in PRC entities by offshore holding companies and governmental control of currency conversion may delay or prevent us from using the proceeds of our initial public offering to make loans or additional capital contributions to our PRC subsidiary, which could materially and adversely affect our liquidity and our ability to fund and expand our business.&#8221; As a result, there is uncertainty with respect to our ability to provide prompt financial support to our PRC subsidiary when needed.</p><a id="_ec8a82de_e5cc_4c84_89ad_f964fbf6bb69"></a><a id="a5CResearchandDevelopmentPatentsandLicen"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">5.C. Research and Development, Patents and Licenses, Etc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Item 4 Information on the Company&#8212;4.C. Business Overview &#8212; Our Platform&#8221; and &#8220;&#8212;Intellectual Property.&#8221;</p><a id="_4bd066ad_bb20_4209_a00b_ee77ba041b69"></a><a id="a5DTrendInformation_715692"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">5.D. Trend Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Other than as disclosed elsewhere in this annual report, we are not aware of any trends, uncertainties, demands, commitments or events for the year ended December&#160;31, 2021 that are reasonably likely to have a material and adverse effect on our net revenues, income, profitability, liquidity or capital resources, or that would cause the disclosed financial information to be not necessarily indicative of future results of operations or financial condition.</p><a id="_239f7351_8268_4412_af4a_65dc1010da09"></a><a id="a5ECriticalAccountingEstimates_321468"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">5.E. Critical Accounting Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the balance sheet dates and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in the Group&#8217;s consolidated financial statements include, but are not limited to, licensing and collaboration revenue recognition, research and development expense allocation, the useful lives and impairment of long-lived assets, tax valuation allowance, and share based compensation expenses. Management bases the estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could materially differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain of these estimates are considered critical as they involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our consolidated financial statements. Our critical accounting estimates are summarized below. See Note 2 to our consolidated financial statements included elsewhere in this annual report for a description of our significant accounting policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Revenue recognition</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We adopted Accounting Standard Codification (&#8220;ASC&#8221;) 606, Revenue from Contracts with Customers (Topic 606) (&#8220;ASC 606&#8221;) for all periods presented. Consistent with the criteria of Topic 606, we recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">171</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our collaborative arrangements may contain more than one unit of account, or performance obligation, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The collaborative arrangements do not include a right of return for any deliverable. As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price based on contractual price and other factors for each performance obligation identified in the contract. In general, the consideration allocated to each performance obligation is recognized when the respective obligation is satisfied either by delivering a good or providing a service, limited to the consideration that is not constrained.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">At the inception of each arrangement that includes development milestone payments, we evaluate whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method based on the nature and preconditions of the development milestones. There are uncertainties in terms of the judgement over the probability of achieving such development milestones and any related constraint. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which we recognize revenue when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achieving such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Changes in assumptions or estimates can materially affect the revenue recognized. The assessment and conclusion reached for revenue recognition are disclosed in note 10 to our consolidated financial statements included elsewhere in this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Research and Development Expenses</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses are charged to expense as incurred when these expenditures relate to our research and development services and have no alternative future uses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Preclinical and clinical trial costs are a significant component of our research and development expenses. We have a history of contracting with third parties that perform various preclinical and clinical trial activities on behalf of us during the ongoing research and development process. Expenses related to preclinical and clinical trials are accrued based on our estimates of the actual services performed by the third parties for the respective period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The process of estimating our research and development expenses involves reviewing open contracts and purchase orders, communicating with our research and development personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advanced payments. We make estimates of our expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting expenses that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of research and development expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Share based compensation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses a) immediately at the grant date if no vesting conditions are required; b) for share-based awards granted with only service conditions, using the straight-line method over the vesting period; or c) for share-based awards granted with service conditions and performance conditions, using the graded vesting method over the vesting period if and when the we conclude that it is probable that the performance conditions will be achieved.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">172</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Estimating fair value for share-based payment transactions requires determination of the most appropriate valuation model, which depends on the terms and conditions of the grant. This estimate also requires determination of the most appropriate inputs to the valuation model including expected volatility, the exercise multiple, the risk free rate and the dividend yield and making assumptions about them. The cost related to share based compensation is sensitive to the aforementioned inputs. These inputs are evaluated periodically considering historical actuals and management judgement. For the measurement of the fair value of share options at the grant date, we use a binomial option valuation model. Changes in assumptions or estimates can materially affect the fair value of the share-based compensation awards. The assumptions and models used for estimating fair value for share-based payment transactions are disclosed in Note 9 to our consolidated financial statements included elsewhere in this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Deferred tax assets</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In accordance with the provisions of ASC 740, <i style="font-style:italic;">Income Taxes</i>, we recognize in our financial statements the benefit of a tax position if the tax position is more likely than not to prevail based on the facts and technical merits of the position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Judgement is required to determine whether deferred tax assets are recognized in the statement of financial position. Deferred tax assets arise because of temporary differences between the financial reporting and tax basis of assets and liabilities, as well as from net operating losses. A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion or all of the deferred tax assets will not be realized in the foreseeable future. In making such determination, we evaluate a variety of positive and negative factors including our operating history, accumulated deficit, the existence of taxable temporary differences and reversal periods. However, the ultimate realization of our deferred tax assets is subject to a number of variables, including our future profitability within relevant tax jurisdictions. The actual benefits ultimately realized may differ from our estimates. The assessment of the deferred tax assets as well as related valuation allowance is disclosed in note 11 to our consolidated financial statements included elsewhere in this annual report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_e0f3b3c1_3f3d_42b4_8caf_06c9568cb665"></a><a id="ITEM6DIRECTORSSENIORMANAGEMENTANDEMPLOYE"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES</p><a id="_f3e3af9f_327d_4291_989b_d60ea6ca3566"></a><a id="a6ADirectorsandSeniorManagement_393694"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">6.A. Directors and Senior Management</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth information regarding our executive officers, key employees and directors as of the date of this annual report.</p><a id="_Hlk101267156"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Executive Officers</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:47.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position/Title</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Peter (Peizhi) Luo, Ph.D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.94%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Co-Founder, Chief Executive Officer and Chairman of the Board</p></td></tr><tr><td style="vertical-align:bottom;width:49.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Fangyong (Felix) Du, Ph.D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Chief Technology Officer</p></td></tr><tr><td style="vertical-align:bottom;width:49.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">JC Xu, M.D., Ph.D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Chief Scientific Officer</p></td></tr><tr><td style="vertical-align:bottom;width:49.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Qinghai Zhao, Ph.D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Chief Manufacturing Officer</p></td></tr><tr><td style="vertical-align:bottom;width:49.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;"><span style="white-space:pre-wrap;">Man Kin (Raymond) Tam, M.B.A.,  B. Eng.</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Chief Financial Officer and Director</p></td></tr><tr><td style="vertical-align:bottom;width:49.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Yu (Albert) Ren, Ph.D.*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Chief Strategy and Corporate Development Officer</p></td></tr><tr><td style="vertical-align:bottom;width:49.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Chunfang (Vicky) Gu</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Senior Director of Finance</p></td></tr><tr><td style="vertical-align:bottom;width:49.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Ling (Jolin) Zhou</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Senior Director of Human Resources</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.27em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;">*&#160;&#160;Yu (Albert) Ren, Ph.D. has tendered his resignation and will depart from our Company in early June 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">173</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:47.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Key Employees</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:47.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position/Title</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Yan Li, M.B.A.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Senior Vice President, Bioinformatics and Information Technology</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Xiaohong (Kristine) She</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Senior Vice President, Head of Clinical Operations</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Guizhong Liu, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Head of Biology and Pharmacology</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Alexander Goergen</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Head of Business Development</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Yuren (Ron) Wang, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Head of Portfolio Management</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Jin Shang, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Senior Vice President of Global Regulatory Affairs</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Songmao Zheng, Ph.D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Associate Vice President of Research and Development</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Jiping Zha</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Executive Vice President of Clinical Development</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Wenlin Zeng</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Vice President of Cell Line and Upstream.</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Ami Knoefler</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Vice President of Investor Relations and Corporate Communications</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Dana Hu-Lowe</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Vice President of Pipeline and Clinical Programs Management</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:47.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Non-Employee Directors</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:47.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Position/Title</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Lefei Sun</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Director</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Andy (Yiu Leung) Cheung</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Independent Director</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Min Li</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Independent Director</p></td></tr><tr><td style="vertical-align:bottom;width:49.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 3.6pt;">Yuwen Liu</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:47.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 3.6pt;">Independent Director</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Executive Officers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Peter (Peizhi) Luo, Ph.D. </span>is our Co-Founder and has served as our Chief Executive Officer since November&#160;2011 and Chairman of the Board of the Directors since February&#160;2018. Dr.&#160;Luo served as the first lead scientist in computational protein design and protein laboratory at Xencor (Nasdaq: XNCR) from July&#160;1998 to August&#160;2000. In September&#160;2000, Dr.&#160;Luo founded Abmaxis Inc. and served as its Co-Founder, Chief Technology Officer, president, and director. In May&#160;2006, Dr.&#160;Luo led the acquisition of Abmaxis Inc. by Merck&#160;&amp; Co. (NYSE: MRK), after which Dr.&#160;Luo served as a director of Biologics Technology at Merck, and Chief Technology Officer of Abmaxis, the subsidiary of Merck&#160;&amp; Co. Throughout his career, Dr.&#160;Luo also led the business development efforts in connection with collaborations and strategic partnerships with multiple global partners. Dr.&#160;Luo received his bachelor&#8217;s degree in applied chemistry in technical physics from Peking University in 1986, master&#8217;s degree in applied physics from The Institute of High Energy Physics of the Chinese Academy of Sciences in 1989, and Ph.D. degree in chemistry from The University of Chicago in 1995. Dr.&#160;Luo also completed his postdoctoral research in protein folding at Stanford University in 1998. Dr.&#160;Luo&#8217;s spouse is Xiaohong (Kristine) She who is our Senior Vice President, Head of Clinical Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Fangyong (Felix) Du, Ph.D. </span>joined us as Vice Precedent of Technology Development in January&#160;2012 and has served as our Chief Technology Officer since May&#160;2019. Dr.&#160;Du has over 20 years of experience in biological research and discovery industry, and has published numerous peer-reviewed articles in world-renowned scientific journals such as Nature and Science. Dr.&#160;Du worked at Affomix from October&#160;2009 to July&#160;2010 and Illumina (Nasdaq: ILMN) from July&#160;2010 to January&#160;2012, and then joined the Company in January&#160;2012 as the Vice President of Technology Development. Dr.&#160;Du received his bachelor&#8217;s degree and master&#8217;s degree in physiology and biophysics in 1991 and 1994, respectively, from Peking University, and his Ph.D. degree in biology from the California Institute of Technology in 2001. Dr.&#160;Du also completed his postdoctoral research from Yale University in 2007.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">JC Xu, M.D., Ph.D. </span>has served as our Chief Scientific Officer since August&#160;2020. Dr.&#160;Xu has more than 20 years of experience in oncology drug discovery and development, and more than four years of experience in business development, strategy, and operations in the biopharmaceutical industry in the United States. Prior to joining Adagene, Dr.&#160;Xu was head of R&amp;ED China Strategy at Celgene now BMS from 2017 to 2020. Prior to that, Dr.&#160;Xu was Director of Strategy&#160;&amp; Operations at Celgene Quanticel Research and Director of Biology at Quanticel Pharmaceuticals from 2012 to 2017. Prior to Quanticel, Dr.&#160;Xu worked in leadership roles at a number of biopharmaceutical companies, including Pfizer, Amgen, and Corixa.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">174</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dr.&#160;Xu received her M.D. degree from Beijing Medical University (now Peking University Health Science Center) in 1987 and her Ph.D. degree in Immunology from University of Alabama at Birmingham in 1993. She completed her post-doctoral training at DNAX Research Institute (now Merck Palo Alto) in 1996. She is an inventor of more than 120 issued and pending patents and has published more than 50 articles in peer-reviewed journals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Qinghai Zhao, Ph.D. </span>has served as our Chief Manufacturing Officer since October&#160;2020. Dr.&#160;Zhao has more than 25 years of experience in protein therapeutics development and defining product development strategy from early stage IND through commercial filing. Prior to joining Adagene, Dr.&#160;Zhao was Vice President of Technical Development and Manufacturing at Forty Seven Inc. (NASDAQ:FTSV) from 2017 to October&#160;2020. Prior to that, Dr.&#160;Zhao was vice president of CMC/ Manufacturing at AnaptysBio (NASDAQ:ANAB) from 2016 to 2017. Prior to AnaptysBio, Dr.&#160;Zhao worked as an Executive Director and the Head of CMC at NGM Biopharmaceuticals from 2014 to 2016. Dr.&#160;Zhao also held various positions at Human Genome Sciences,&#160;Inc., Cogenesys and Teva Biopharmaceuticals USA from 2001 to 2014. Dr.&#160;Zhao received his bachelor&#8217;s degree from Shanghai Chemical Engineering Institute (now East China University of Sciences and Technology) in 1982, master&#8217;s degree from Shanghai Medical University (now merged with Fudan University) in 1986 and Ph.D. degree from University of Uppsala in 1998.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Man Kin (Raymond) Tam </span>has served as our Chief Financial Officer since September&#160;2019 and our director since February&#160;2021. Mr.&#160;Tam has over 20 years of management experience in finance and banking across the Asia-Pacific region. Mr.&#160;Tam worked in HSBC and J.P. Morgan Chase Bank, N.A. from 1999 to 2010. Mr.&#160;Tam served as project director of Mineralogy Pty Limited and Chief Financial Officer of Resourcehouse Limited from April&#160;2010 to October&#160;2015. From October&#160;2015 to August&#160;2019, Mr.&#160;Tam consecutively served as the Chief Financial Officer of China Regenerative Medicine International Limited (HKEx: 8158), Beijing Gas Blue Sky Holdings Limited (HKEx: 6828), and AgenTus Therapeutics,&#160;Inc. Mr.&#160;Tam is a fellow of CPA Australia, a member of the American Institute of Certified Public Accountants and the Hong Kong Institute of Certified Public Accountants. He is also a CFA and FRM charter-holder. He received his bachelor&#8217;s degree in civil&#160;&amp; resources engineering from the University of Auckland in 1997, master&#8217;s degree in practising accounting from Monash University in 2001 and an Executive Master of Business Administration degree from the University of Western Ontario in 2005.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Yu (Albert) Ren</span><b style="font-weight:bold;">, Ph.D. </b>has served as our Chief Strategy and Corporate Development Officer since January&#160;2021. Dr.&#160;Ren has tendered his resignation and will depart from our Company in early June 2022. Prior to joining us, Dr.&#160;Ren held various positions at Merck&#160;&amp; Co.,&#160;Inc. (NYSE: MRK). He had previously worked at Portfolio Management&#160;&amp; Global Clinical Development Finance responsible for financial / strategic planning on KEYTRUDA&#174; development and facilitation of KEYTRUDA&#174; clinical trials prioritization. He also worked at Merck Corporate Strategy Office on enterprise strategy and at Merck Corporate Business Development on a variety of business development transactions. Before returning to Merck, Dr.&#160;Ren served as a principal consultant at Quintiles/IQVIA Consulting from 2009 to 2010. Dr.&#160;Ren gained extensive consulting experience at McKinsey&#160;&amp; Company from 2007 to 2009. Dr.&#160;Ren started his professional career at Merck Research Lab working on Pharmaceutical Research&#160;&amp; Development from discovery to early clinical development from 2001 to 2006. Dr.&#160;Ren received his Ph.D. in Chemistry from University of Minnesota in 2001, and bachelor&#8217;s degree in Chemistry from Peking University in 1996.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Chunfang (Vicky) Gu</span> joined Adagene in September 2017 and serves as Senior Director of Finance. Reporting to the Chief Financial Officer, Vicky manages Adagene Inc.&#8217;s finance team, plays a key role in Adagene Inc.&#8217;s capital markets and fund-raising transactions and assisted to establish the employee incentive plans of Adagene Inc. Vicky has over 17 years of experience in financial management with exposure to audit firms and multinational corporations including Sulzer Pumps, Bluescope Steel and Mercury Marine. Vicky has rich experience on financial reporting, budgeting and cost analysis, internal control and related compliance, taxation, as well as project management. Vicky received her Master of Business Administration degree from Xiamen University in 2016 and bachelor&#8217;s degree in accounting from Tianjin University of Commerce in 2003.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ling (Jolin) Zhou&#160;</span>has served as our Senior Director of Human Resources since October 2019. Before joining Adagene, Ms. Zhou served as the HR director of Asia Pacific at Tekni-Plex, where she was responsible for strategic HR initiatives and business support from May 2010 to August 2019. Between October 2004 and May 2010, Ms. Zhou served as the HR supervisor at Suzhou Capsugel Ltd., a division of Pfizer, where she was responsible for all HR functions and personnel training. Ms. Zhou received her bachelor&#8217;s degree in law from South-Central University for Nationalities in 2003. She is a DDI Certified Trainer.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">175</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Key Employees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Yan Li, M.B.A. </span>has served as our Senior Vice President of Bioinformatics and Information Technology since November&#160;2011. Ms.&#160;Li has over 25 years of experience in software development, with about 20 years focusing on the development of informatics software tools for antibody library design and analysis. Ms.&#160;Li served as the senior software engineer and applications scientist at Abmaxis from November&#160;2001 to May&#160;2006. Following the acquisition of Abmaxis by Merck&#160;&amp; Co, Ms.&#160;Li worked at Merck&#160;&amp; Co from May&#160;2006 to December&#160;2010. She received the Merck Award for Excellence in &#8220;Innovative Technologies&#8221; with the team and a Special Award for her contribution. Ms.&#160;Li received her bachelor&#8217;s degree in information science from East China University of Science and Technology in 1995 and a Master of Business Administration degree in 2010 from Santa Clara University.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Xiaohong (Kristine) She </span>has served as our Senior Vice President, Head of Clinical Operations since November&#160;2011. Ms.&#160;She has over 20 years of laboratory and laboratory management experience in the renowned laboratories in the United States and has completed multiple projects in molecular biology and immunology at the labs of University of Chicago, the Genome Center at Stanford University, neurological animal studies at Stanford Palo Alto Veteran&#8217;s Hospital, and cloning and functional screening of cDNA libraries at Caltech. Her work has been published in Nature, Science, Biotechnology, among many other notable publications. Ms.&#160;She received her bachelor&#8217;s degree in microbiology from Wuhan University in 1986 and master&#8217;s degree in biochemistry and microbiology from the Institute of Microbiology of the Chinese Academy of Sciences in 1989. Ms.&#160;She&#8217;s spouse is Peter (Peizhi) Luo, Ph.D., our Co-Founder, Chief Executive Officer and Chairman of the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Guizhong Liu, Ph.D. </span>has served as our Head of Biology and Pharmacology since October&#160;2015. Dr.&#160;Liu has over 15 years of experience in drug discovery and development, both in small molecule kinase inhibitors and large molecule antibodies in oncology and immunology field. He has published over 40 peer-reviewed papers in high-profile journals involving key signalling pathways and targets in cancer biology. From July&#160;2007 to August&#160;2011, Dr.&#160;Liu served as an assistant professor of the department of oncological science at Mount Sinai School of Medicine. Prior to joining us, Dr.&#160;Liu served as head of molecular cancer biology in CrownBio from October&#160;2011 to September&#160;2015. Dr.&#160;Liu received his bachelor&#8217;s degree in biology in 1992 and master&#8217;s degree in cell biology in 1995 from Beijing Normal University and Ph.D. degree in cell biology from Peking Union Medical College in 1998. He also completed his postdoctoral training in cancer biology at Mount Sinai School of Medicine in 2004.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Alexander Goergen </span>has served as our Head of Business Development since October&#160;2017 when he joined the Company. Mr.&#160;Goergen has worked in various roles at the Covance, TRC and International AIDS Vaccine Initiative from October&#160;2008 to October&#160;2012. Prior to joining us, Alexander worked in business development for Catalent Pharma Solutions Biologics Division since October&#160;2012. Mr.&#160;Goergen completed many licensing, manufacturing, and cell line development programs both domestically and internationally during his previous employment. Mr.&#160;Goergen received his bachelor&#8217;s degree in Chemistry from Lafayette College in 2008 and master&#8217;s degree in Biotechnology from the University of Wisconsin-Madison in 2011.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Yuren (Ron) Wang, Ph.D. </span>has served as our Head of Portfolio Management since September&#160;2019. Dr.&#160;Wang served as the senior director of business development in Reaction Biology Corporation from March&#160;2013 to December&#160;2018. Prior to joining us, he served as the vice president of R&amp;D research for Jemincare Therapeutics (USA), responsible for the scientific evaluation of projects, in-licensing and portfolio management from December&#160;2018 to August&#160;2019. Dr.&#160;Wang received his bachelor&#8217;s degree in plant science from Shandong Agricultural University in 1982, master&#8217;s degree in biochemistry from the Graduate School of Chinese Academy of Agricultural Sciences in 1986 and Ph.D. degree in cell and molecular biology from the University of Pennsylvania in 1996. He also completed his postdoctoral training in molecular pharmacology at the University of Pennsylvania in 1999.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jin Shang, Ph.D.</span> has served as our Senior Vice President of Global Regulatory Affairs since April&#160;2021. Prior to joining us, Dr. Shang served as global and US regulatory lead in AstraZeneca for multiple oncology development programs, including KOSELUGO. Dr. Shang also led the submission and regulatory defense to gain FDA approval of Elepsia XR. Dr. Shang also served as Principal Scientist/Program Team Lead at Merck Research Laboratories, and served as Therapeutic Area Lead on the non-human primate study execution committee. Dr.&#160;Shang received her bachelor&#8217;s degree in cell biology and genetics from Peking University in 1990 and Ph.D. degree in development biology from Standford University in 1997.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">176</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Songmao Zheng, Ph.D.</span> has served as our Associate Vice President of Research and Development since March&#160;2021, leading quantitative model-informed drug discovery and development in both preclinical and clinical space. Prior to joining us, Dr.&#160;Zheng had served as Scientific Director/Group Leader, leading numerous biologics programs at Janssen BioTherapeutics, Janssen R&amp;D since 2013. Dr.&#160;Zheng received his bachelor&#8217;s degree in biological sciences from Sichuan University in 2007 and Ph.D. degree in pharmaceutical sciences from University of Washington in 2012.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Jiping Zha, Ph.D.</span> has servced as our Executive Vice President of Clinical Development since September 2021. Dr. Zha is responsible for clinical development, clinical operation and drug safety group. He is a physician scientist with over 20 years of formative experience in both academia and biotech industry. Dr. Zha has served as executive director of translational sciences at NGM Biopharmaceuticals from April 2017 to September 2021, and held various leadership positions at MedImmune, Crown Bioscience, Genentech from November 2003 to March 2017. Dr. Zha has over forty publications in high-impact scientific journals, such as Cell, Science and Nature, and authored multiple patents. Dr. Zha received his M.D. degree in basic medicine from Shanghai Medical University in 1987 and Ph.D. degree in Microbiology and Immunology from University of Tennessee in 1993, and was Board-Certified in Anatomic Pathology by American Board of Pathology in 1999.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Wenlin Zeng, Ph.D.</span><span style="white-space:pre-wrap;"> has served as our Vice President of Early Stage CMC since June 2021.  Dr. Zeng brings more than 20 years of experience in drug discovery and drug development in the biopharmaceutical industry. Prior to joining us, Dr. Zeng was the senior director of upstream process development responsible for both early and late stage programs at Gilead Sciences, Inc from July 2020 to June 2021</span><i style="font-style:italic;">.</i> Prior to that, she was the senior director of cell line and upstream process development at Forty-Seven Inc. from April 2018 to June 2020, where she was responsible for cell line, upstream process development and manufacturing for a number of programs, including magrolimab. Prior to Forty-Seven, Dr. Zeng held leadership positions at multiple biopharmaceutical companies, including NGM Bio, GSK, MedImmune, and Abgenix. Dr. Zeng began her career in biopharmaceutical industry from June 1997 to April 2018 after completing her post-doctoral training at Stanford University. Dr. Zeng received her bachelor&#39;s degree in cell biology from Wuhan University in 1983 and Ph.D. degree in biochemistry from the Universy of Iowa in 1990.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Ami C. Knoefler</span> has served as our Vice President of Investor Relations and Corporate Communications since July 2021. Ms. Knoefler has more than 25 years of global experience in pharmaceutical, biotech and medical technology communications. She most recently served as consultant and Senior Director at Ascendis Pharma from June 2015 to August 2021, and previously held multiple leadership positions at Jazz Pharmaceuticals, PDL BioPharma, Abgenix and Bristol-Myers Squibb from May 2007 to March 2013. She received her bachelor&#8217;s degree in mass communication/public relations from Boston University in 1992.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dana Hu-Lowe, Ph.D.</span> has served as our Vice President of Pipeline and Clinical Programs Management since November 2021. Dr. Hu-Lowe has more than 20 years of industry experience in oncology and R&amp;D including years of experience in project and strategic alliance management, and leadership for both preclinical and clinical product programs. Before joining Adagene, she served as an Executive Director and Global Product Team Leader at Turning Point Therapeutics from April 2019 to October 2021. She was the Senior Director of Strategic Alliance and Program management at Wellspring Biosciences Inc. from March 2013 to March 2019, where she managed both internal discovery and IND-enabling programs and strategic alliance with Janssen Pharmaceuticals. Dr. Hu-Lowe had over 12 years of career at Pfizer Oncology November 1999 to December 2011, where she led cross-functional teams advancing programs from preclinical into clinical development. Dr. Hu-Lowe received her bachelor&#8217;s dgreee in chemistry from Beijing Normal University in 1984 and Ph.D. degree in biochemistry from the University of Mississippi in 1992 and completed her Post-doctoral training at Scripps Research Institute and the Burnham Cancer Center (now the Sanford Burnham Prebys Medical Discovery Institute).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 7.2pt;">Non-Employee Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Lefei Sun </span>has served as our director since December&#160;2019 designated by General Atlantic Singapore AI Pte. Ltd. pursuant to our current effective shareholders agreement. Mr Sun has been a non-executive director of Hong Kong Asia Medical Holding Limited, a leading hospital management group in Asia with hospital assets such as Wuhan Asia Heart Hospital, from November&#160;2018. He is also a non-executive director of various biotech companies such as Ocumension Therapeutics (HKEx: 1477) and CANbridge Pharmaceuticals Inc. Mr.&#160;Sun has served as head of China healthcare at General Atlantic since May&#160;2018, and has been a managing director since January&#160;2020, in charge of private equity investment and portfolio management in healthcare and life sciences sectors. From December&#160;2014 to April&#160;2018, Mr.&#160;Sun was a founding partner and a member of investment committee of Beijing HuaTai Ruihe Investment Fund Management Company (LLP), also known as Huatai Healthcare Investment Fund. Prior to joining General Atlantic, Mr.&#160;Sun served as various investment roles at Hony Capital, Credit Suisse, OrbiMed, Orchid Asia, and as a management consultant at McKinsey&#160;&amp; Company, all in the healthcare sector. Mr.&#160;Sun obtained his master&#8217;s degree in neurosciences from Johns Hopkins University School of Medicine in 2006, and his bachelor&#8217;s degree in mathematics and physics from Tsinghua University in 2002.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">177</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Andy (Yiu Leung) Cheung </span>has served as our independent director since February&#160;2021. Mr.&#160;Cheung has many years of auditing and accounting professional experience. Mr.&#160;Cheung was deputy area managing partner of Ernst&#160;&amp; Young (&#8220;EY&#8221;) in Asia Pacific overseeing the business operations, finance, information technology and risk management functions from July&#160;2018 to June&#160;2020. Mr.&#160;Cheung was the assurance leader for EY in Greater China from July&#160;2013 to June&#160;2018. Mr.&#160;Cheung has served as an independent non-executive director of JW (Cayman) Therapeutics Co. Ltd (HKEX:2126) since October&#160;2020. Mr.&#160;Cheung received his bachelor&#8217;s degree in accounting and finance from the University of Lancaster in the United Kingdom in July&#160;1982. He obtained a master&#8217;s degree in accounting and finance from London School of Economics and Political Science in the United Kingdom in August&#160;1983. Mr.&#160;Cheung is a member of Hong Kong Institute of Certified Public Accountants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="font-style:italic;font-weight:bold;">Min Li, Ph.D. </span>has served as our independent director since February&#160;2021. Dr.&#160;Min Li is the founder, CEO and director of SciNeuro Pharmaceuticals, a biotechnology company headquartered in Shanghai focused on developing innovative therapeutics for CNS diseases. Dr.&#160;Li was formerly Senior Vice President, Global Head of Neuroscience R&amp;D at GSK from 2013 to 2019. During his employment with GSK, he also served as General Manager of GSK R&amp;D China, the highest-ranking officer at the country level. Before moving into industry, Dr.&#160;Li had served as a tenured Professor of Neuroscience at Johns Hopkins University School of Medicine for over 20 years. Dr.&#160;Li served on scientific advisory boards, non-profit and corporate boards that include multinational corporations (Corning, Pfizer and Merck), disease foundations (RYR-foundation, AHA) and biotech companies (Xencor, Affymax, Datavant,&#160;Icagen, and Coda Biotechnologies). He is also an Adjunct Professor of Neuroscience at Johns Hopkins School of Medicine. Dr.&#160;Li received his B.S. degree in biochemistry from Wuhan University in 1984 and his Ph.D. in molecular immunology from Johns Hopkins University in 1990. As a Helen Hay Whitney Fellow, he performed postdoctoral research at University of California San Francisco. With a Sloan Award, in 1994 he returned to Johns Hopkins to join the faculty as an Esther A&#160;&amp; Joseph Klingenstein Neuroscience Fellow. Dr.&#160;Li has published more than 120 scientific articles and holds patents in biotechnologies. His research and scholarship were recognized internationally with awards including being a fellow of American Association for Advancement of Science and an established fellow of American Heart Association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Yuwen Liu</span> has served as our independent director since February 2022. Ms. Liu is a leading advocate for the biotechnology, biopharmaceutical and medical technology industries, with over 20 years as an entrepreneur, advisor and investor. From 2010 to 2014, Ms. Liu was Chair and CEO, followed by executive director, of Suzhou Industrial Park Biotech Development Co. Ltd. (BioBAY), building it into one of the fastest growing biotech clusters serving over 400 start-ups, including BrightGene, Innovent, and Qiagen (Suzhou), where she also served on the boards of directors. Prior to that, Ms. Liu served various positions at BioBay since 2005. As a strong supporter of innovation, she was also a founding partner of BOHE Angel Fund, one of the first angel funds in China focusing on healthcare start-ups, which invests in biologics, drug discovery and diagnostics. Ms. Liu was also a founding Chair of BioVENTURE Fund Investment committee. Ms. Liu previously served as the first Chief Representative to set up the China operation of Perrigo. Earlier in her career, she had various positions in quality and business development at Capsugel, a division of Warner-Lambert later acquired by Pfizer. Ms. Liu graduated from China Pharmaceutical University with a master&#8217;s degree in pharmaceutics in 1997 and Master of Management at Fudan University and Norwegian Management School BI in 2004. She is a licensed pharmacist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_ed1aa261_2365_4b03_bc04_ca60fc8a2611"></a><a id="a6BCompensation_267993"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">6.B. Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the fiscal year ended December 31, 2021, we paid an aggregate of US$3.4 million in cash to our executive officers and an aggregate of US$179 thousand in cash to our independent directors. We did not pay any cash compensation to non-executive directors who are not independent directors. For the fiscal year ended December 31, 2021, we did not set aside or accrue expenses related to pension, retirement or other similar benefits to our executive officers and directors. Our PRC subsidiary is required by law to make contributions equal to certain percentages of each employee&#8217;s salary for his or her pension insurance, medical insurance, unemployment insurance and other statutory benefits and a housing provident fund. For share incentive grants to our directors and executive officers, see &#8220;Item 6 Directors, Senior Management and Employees&#8212;Share Incentive Plan.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">178</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Employment Agreements and Indemnification Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have entered into employment agreements with each of our executive officers. Each of our executive officers is employed for a period of twelve months, which will be renewed automatically and extended automatically for a period of twelve months unless the executive or us gives prior written notice. We may terminate an executive officer&#8217;s employment for cause at any time without advance notice in certain events. We may terminate an executive officer&#8217;s employment by giving a prior written notice or by paying certain compensation. In such case of termination by us, we will provide severance payments to the executive officer as expressly required by applicable law of the jurisdiction where the executive officer is based. An executive officer may terminate his or her employment at any time by giving a prior written notice.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Each executive officer has agreed to hold, unless expressly consented to by us, at all times during and after the termination of his or her employment agreement, in strict confidence and not to use, any of our confidential information or the confidential information of our customers and suppliers. In addition, each executive officer has agreed to be bound by certain non-competition and non-solicitation restrictions during the term of his or her employment and for a maximum of two years following the last date of employment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have entered into indemnification agreements with each of our directors and executive officers. Under these agreements, we agree to indemnify our directors and executive officers against certain liabilities and expenses incurred by such persons in connection with claims made by reason of their being a director or officer of our company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Share Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Adagene Inc. Second Amended and Restated Share Incentive Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">In November&#160;2015, we adopted Adagene Inc. Share Incentive Plan, or the 2015 Plan, which was later superseded and replaced by Adagene Inc. Amended and Restated Share Incentive Plan, or the 2017 Plan, in September&#160;2017. In December&#160;2019, we adopted the Second Amended and Restated Share Incentive Plan, or the 2019 Plan, to supersede and replace the 2017 Plan. The terms of the 2015 Plan, the 2017 Plan and the 2019 Plan are substantially the same other than the maximum aggregate number of shares we may issue under the respective plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The purpose of the 2019 Plan is to attract, motivate, retain and reward certain officers, employees, directors and other eligible persons and to further link the interests of award recipients with those of our shareholders generally. The 2019 Plan provides for the issuance of up to an aggregate of 11,391,131 of our ordinary shares. We have terminated the authority to grant additional awards under the 2019 Plan and all future awards will be granted under the 2021 Plan. Therefore, the effective maximum number of shares issuable under the 2019 Plan will be 10,<span style="font-size:11pt;"> </span>280,951. As of March&#160;31, 2022, the aggregate number of our ordinary shares underlying our outstanding awards under the 2019 Plan is 2,872,514, excluding awards that were forfeited, cancelled or exercised after the relevant grant dates. The term of the awards will expire not more than ten years after the date of grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following paragraphs summarize the principal terms of the 2019 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Types of Awards. </span>The 2019 Plan permits the awards of options, share appreciation rights, ordinary shares or restricted shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Plan Administration. </span>The 2019 Plan shall be administrated by our board of directors or one or more committees appointed by the board of directors or another committee (within its delegated authority), the Plan Administrator.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Promissory Notes. </span>The promissory notes with respect to the 2019 Plan, or the 2019 Promissory Notes are full recourse, repayable within a period of time determined by the Plan Administrator, which should not exceed five years (subject to certain early repayment events), and bear interest at the interest rate determined by the Plan Administrator but not less than the interest rate necessary to avoid the imputation of interest under United States Internal Revenue Code of 1986, as amended or other applicable tax law. Certain plan participants previously purchased our shares with such promissory notes. The largest aggregate amount outstanding since the first issuance of the promissory notes was US$7.0 million. All amounts outstanding under the promissory notes have been settled.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">179</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Repayment of the Promissory Notes. </span>The terms, repayment provisions, and collateral release provisions of the note and the pledge securing the note shall conform with all applicable rules&#160;and regulations, including those of the Federal Reserve Board of the United States and any applicable law, as then in effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Eligibility. </span>The plan administrators may decide that an award under the 2019 Plan be granted to any employee, officer or director of the Company or its affiliates, or that it be granted to any consultant or adviser who provides services to the Company or its affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Award Agreements. </span>Each award under the 2019 Plan shall be evidenced by an award agreement in the form approved by the plan administrators. The terms of the award agreements will be determined by the plan administrators and consistent with the terms of the 2019 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Conditions of Award. </span>The plan administrators shall determine the participants, types of awards, numbers of shares to be covered by awards, terms and conditions of each award, including, but not limited to, the price and number of securities to be offered or awarded, the installments (if applicable) in which such awards will become exercisable or will vest, performance targets (if applicable), the events of termination or reversion of such awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transfer Restrictions. </span>With a few exceptions, no right of interest of a participant in any award may be subject in any manner to sale, transfer, anticipation, alienation, assignment, pledge, encumbrance or charge. This restriction does not apply to (i)&#160;transfers to our company, (ii)&#160;transfers by gift or domestic relations order to one or more family members, (iii)&#160;the designation of a beneficiary to receive benefits if a participant dies or transfers by will, (iv)&#160;permitted transfers or exercises on behalf of a participant by the participant&#8217;s duly authorized legal representative if the participant has suffered a disability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reduction or Clawback of Awards. </span>The awards granted under the 2019 Plan are subject to the terms of our recoupment, clawback or similar policy as it may be in effect from time to time, as well as any similar provisions of applicable law, any of which could in certain circumstances require repayment or forfeiture of awards or any ordinary shares or other cash or property received with respect to the awards (including any value received from a disposition of the shares acquired upon payment of the Awards).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Amendment and Termination of the 2019 Plan. </span>The board of directors may, at any time, terminate or, from time to time, amend, modify or suspend the 2019 Plan, in whole or in part. No awards may be granted during any period that the board of directors suspends the 2019 Plan. To the extent then required by applicable law or listing agency, any amendment to the 2019 Plan may be subject to shareholder approval. Unless earlier terminated by the board of directors, the 2019 Plan will terminate at the close of business on the day before the 10<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> anniversary of the date the board of directors approved the 2019 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 7.2pt;"><span style="font-style:italic;font-weight:bold;">Adagene Inc. 2021 Performance Incentive Plan</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2021, our board of directors adopted, and our shareholders approved, the 2021 Performance Incentive Plan, or the 2021 Plan, to provide an additional means through the grant of awards to attract, motivate, retain and reward selected employees and other eligible persons. The terms of the 2021 Plan are summarized below. Employees, officers, directors and consultants that provide services to us or one of our subsidiaries may be selected to receive awards under the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors or a committee appointed by the board administers the 2021 Plan. The plan administrator has broad authority to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">select participants and determine the types of awards that they are to receive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">determine the number of shares that are to be subject to awards and the terms and conditions of awards, including the price (if any) to be paid for the shares or the award and establish the vesting conditions (if applicable) of such shares or awards;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cancel, modify or waive our rights with respect to, or modify, discontinue, suspend or terminate any or all outstanding awards, subject to any required consents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">construe and interpret the terms of the 2021 Plan and any agreements relating to the plan;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">180</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">accelerate or extend the vesting or exercisability or extend the term of any or all outstanding awards subject to any required consent;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">subject to the other provisions of the 2021 Plan, make certain adjustments to one or more outstanding awards (including a repricing of the exercise or base price of any outstanding option or share appreciation right without shareholder approval) and authorize the termination, conversion, substitution or succession of awards; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">allow the purchase price of an award or our ordinary shares to be paid in the form of cash, check or electronic funds transfer, by the delivery of previously-owned ordinary shares or by a reduction of the number of shares deliverable pursuant to the award, by services rendered by the recipient of the award, by notice and third party payment or cashless exercise on such terms as the plan administrator may authorize or any other form permitted by law.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A total of 2,994,000 of our ordinary shares was authorized for issuance with respect to awards granted under the 2021 Plan. The share limit will automatically increase on the first trading day in January&#160;of each year (commencing with 2022) by an amount equal to (1)&#160;5% of the total number of our outstanding ordinary shares on December&#160;31 of the prior year, or (2)&#160;such lesser number as determined by our board of directors. Any shares subject to awards granted under the 2021 Plan or our Second Amended and Restated Share Incentive Plan that are not paid, delivered or exercised before they expire or are canceled or terminated, or otherwise fail to vest, as well as shares used to pay the purchase or exercise price of such awards or related tax withholding obligations, will become available for new award grants under the 2021 Plan. As of March 31, 2022, we had granted equity awards representing 2,555,500 ordinary shares under the 2021 Plan, excluding awards that were forfeited, cancelled or exercised after the relevant grant dates. As of March 31, 2022, 3,044,551 ordinary shares authorized under the 2021 Plan is available for award purposes. Such number includes an annual automatic increase in an amount equal to 5% of the total number of outstanding ordinary shares on December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Awards under the 2021 Plan may be in the form of incentive or nonqualified stock options, share appreciation rights, share bonuses, restricted shares, share units, restricted share units and other forms of awards including cash awards. Awards under the plan generally will not be transferable other than by will or the laws of descent and distribution, except that the plan administrator may authorize certain transfers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Options and share appreciation rights may not be granted under the 2021 Plan at exercise prices below the fair market value of the underlying ordinary shares on the date of grant, except that the plan administrator may grant such awards with exercise prices below the fair market value of the underlying shares to service-providers who are not subject to U.S. taxes. The maximum term of options and share appreciation rights granted under the plan is ten years. Incentive stock options granted to any 10% owner of our ordinary shares must have an exercise price that is at least 110% of the fair market value of our ordinary shares on the grant date and a maximum term of five years. These and other awards may also be issued solely or in part for services. Awards are generally paid in cash or our ordinary shares. The plan administrator may provide for the deferred payment of awards and may determine the terms applicable to deferrals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As is customary in incentive plans of this nature, the number and type of shares available under the 2021 Plan and any outstanding awards, as well as the exercise or purchase prices of awards, will be subject to adjustment in the event of certain reorganizations, mergers, combinations, recapitalizations, share splits, share dividends or other similar events that change the number or kind of shares outstanding, and extraordinary dividends or distributions of property to the shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Generally, and subject to limited exceptions set forth in the 2021 Plan, if we dissolve or undergo certain corporate transactions such as a merger, business combination or other reorganization, or a sale of all or substantially all of our assets, all awards then-outstanding under the 2021 Plan will become fully vested or paid, as applicable, and will terminate or be terminated in such circumstances, unless the plan administrator provides for the assumption, substitution or other continuation of the award. The plan administrator also has the discretion to establish other change in control provisions with respect to awards granted under the 2021 Plan. For example, the administrator could provide for the acceleration of vesting or payment of an award in connection with a corporate event that is not described above and provide that any such acceleration shall be automatic upon the occurrence of any such event.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">181</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors may amend or terminate the 2021 Plan at any time, but no such action will affect any outstanding award in any manner materially adverse to a participant without the consent of the participant. Plan amendments will be submitted to shareholders for their approval as required by applicable law or deemed necessary or advisable by the board. The 2021 Plan is not exclusive; our board of directors and compensation committee may grant shares and performance incentives or other compensation, in shares or cash, under other plans or authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The plan will terminate on January&#160;16, 2031. However, the plan administrator will retain its authority until all outstanding awards are exercised or terminated.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">182</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes, as of March&#160;31, 2022, the number of ordinary shares under outstanding awards that we granted to our directors and executive officers under the 2019 Plan, which replaced the 2015 Plan, and under the 2021 Plan, excluding awards that were exercised, forfeited or canceled after the relevant grant dates.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:52.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:52.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ordinary</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Underlying</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Equity Awards</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:11.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(US$/Share)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date of Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date of Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Executive Officers</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Peter (Peizhi) Luo, Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 287,415</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13.85</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">January&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">January&#160;2031</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Peter (Peizhi) Luo, Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 500,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2032</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Fangyong (Felix) Du, Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 111,744</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 13.85</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">January&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">January&#160;2031</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Fangyong (Felix) Du, Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 150,000</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2032</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">JC Xu, M.D., Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.26</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August&#160;2030</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Qinghai Zhao, Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.26</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">October&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">October&#160;2030</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Qinghai Zhao, Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2032</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Man Kin (Raymond) Tam, M.B.A., B. Eng.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.48</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March&#160;2030</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Man Kin (Raymond) Tam, M.B.A., B. Eng.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.83</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August&#160;2030</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Yu (Albert) Ren, Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17.10</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March&#160;2031</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Yu (Albert) Ren, Ph. D.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2032</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Chunfang (Vicky) Gu </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.33</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2029</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Chunfang (Vicky) Gu </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.48</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 2030</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Chunfang (Vicky) Gu </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.83</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August 2030</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Chunfang (Vicky) Gu</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2032</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Ling (Jolin) Zhou</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.48</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 2030</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Ling (Jolin) Zhou</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1.83</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August 2030</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Ling (Jolin) Zhou </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 2032</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-Employee Directors</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Lefei Sun</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Andy (Yiu Leung) Cheung</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">11.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June 2031</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Min Li</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">11.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:middle;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June 2031</p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Yuwen Liu</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">All directors and executive officers as a group</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2,642,778</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Various dates from February 2019 to February 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:11.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Various dates from February 2029 to February 2032</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">Note:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">*&#160;&#160;&#160;&#160;The shares held by each of these directors and executive officers represent less than 1% of our total outstanding shares.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">183</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March&#160;31, 2022, our award holders other than our directors and executive officers as a group held outstanding awards to purchase 2,785,236 ordinary shares. For discussions of our accounting policies and estimates for awards granted pursuant to the 2019 Plan and 2021 Plan, see &#8220;Item 5 Operating and Financial Review and Prospects&#8212;Share-based compensation.&#8221;</p><a id="_783bdfe3_caab_473c_8f25_df59e45bc9d8"></a><a id="a6CBoardPractices_80216"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">6.C. Board Practices</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors consists of six directors, including three independent directors, namely Andy (Yiu Leung) Cheung, Min Li and Yuwen Liu. A director is not required to hold any shares in our company to qualify to serve as a director. The Corporate Governance Rules&#160;of the Nasdaq generally require that a majority of an issuer&#8217;s board of directors must consist of independent directors. However, the Corporate Governance Rules&#160;of the Nasdaq permit foreign private issuers like us to follow &#8220;home country practice&#8221; in certain corporate governance matters. We rely on this &#8220;home country practice&#8221; exception and do not have a majority of independent directors serving on our board of directors , our compensation committee and our nominating and corporate governance committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A director who is in any way, whether directly or indirectly, interested in a contract or proposed contract with our company is required to declare the nature of his or her interest at a meeting of our directors. A general notice given to the directors by any director to the effect that he or she is a member, shareholder, director, partner, officer or employee of any specified company or firm and is to be regarded as interested in any contract or transaction with that company or firm shall be deemed a sufficient declaration of interest for the purposes of voting on a resolution in respect to a contract or transaction in which he/she has an interest, and after such general notice it shall not be necessary to give special notice relating to any particular transaction.<span style="font-size:11pt;"> </span>Subject to our memorandum and articles of association, as amended n restated from time to time, our company may by ordinary resolution appoint any person to be a director and the board may, by affirmative vote of a simple majority of the remaining directors present and voting at a board meeting, appoint any person as a director to fill a casual vacancy or as an addition to the existing board. A director may vote in respect of any contract or proposed contract or arrangement notwithstanding that he/she may be interested therein and if he/ she does so, his/her vote shall be counted and he/she may be counted in the quorum at any meeting of the directors at which any such contract or proposed contract or arrangement is considered, subject to any separate requirement for Audit Committee approval under applicable law or the Listing Rules&#160;of the Nasdaq. Our board of directors may exercise all of the powers of our company to borrow money, to mortgage or charge its undertaking, property and uncalled capital, or any part thereof, and to issue debentures, debenture stock or other securities whenever money is borrowed or as security for any debt, liability or obligation of our company or of any third party. None of our directors has a service contract with us that provides for benefits upon termination of service as a director.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Committees of the Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have established an audit committee, a compensation committee and a nominating and corporate governance committee under our board of directors. We have also adopted a charter for each of the three committees. Each committee&#8217;s members and functions are described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Audit Committee. </span>Our audit committee consists of Andy (Yiu Leung) Cheung, Min Li and Yuwen Liu, and is chaired by Andy (Yiu Leung) Cheung. We have determined that Andy (Yiu Leung) Cheung, Min Li and Yuwen Liu satisfy the requirements of Rule&#160;5605(a)(2)&#160;of the Listing Rules&#160;of the Nasdaq and meet the independence standards under Rule&#160;10A-3 under the Securities Exchange Act of 1934, as amended. We have determined that Andy (Yiu Leung) Cheung qualifies as an &#8220;audit committee financial expert.&#8221; The audit committee oversees our accounting and financial reporting processes and the audits of the financial statements of our company. The audit committee is responsible for, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and recommending to our board for approval, the appointment, re-appointment or removal of the independent auditor, after considering its annual performance evaluation of the independent auditor;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approving the remuneration and terms of engagement of the independent auditor and pre-approving all auditing and non-auditing services permitted to be performed by our independent auditors at least annually;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining a written report from our independent auditor describing matters relating to its independence and quality control procedures;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">184</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing with the independent registered public accounting firm any audit problems or difficulties and management&#8217;s response;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discussing with our independent auditor, among other things, the audits of the financial statements, including whether any material information should be disclosed, issues regarding accounting and auditing principles and practices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and approving all proposed related party transactions, as defined in Item 404 of Regulation S-K under the Securities Act;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing and recommending the semi-annually financial data the annual financial statements to our board for inclusion in our semi-annually earnings releases and annual reports, respectively;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discussing the annual audited financial statements with management and the independent registered public accounting firm;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing the adequacy and effectiveness of our accounting and internal control policies and procedures and any special steps taken to monitor and control major financial risk exposures;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least annually, reviewing and reassessing the adequacy of the committee charter;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approving annual audit plans, and undertaking an annual performance evaluation of the internal audit function;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establishing and overseeing procedures for the handling of complaints and whistleblowing;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">meeting separately and periodically with management and the independent registered public accounting firm;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">monitoring compliance with our code of business conduct and ethics, including reviewing the adequacy and effectiveness of our procedures to ensure proper compliance; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting regularly to the board.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Compensation Committee. </span>Our compensation committee consists of Peter Luo, Andy (Yiu Leung) Cheung and Min Li and is chaired by Peter Luo. We have determined that Andy (Yiu Leung) Cheung and Min Li satisfy the &#8220;independence&#8221; requirements of Rule&#160;5605(a)(2)&#160;of the Listing Rules&#160;of the Nasdaq. The compensation committee assists the board in reviewing and approving the compensation structure, including all forms of compensation, relating to our directors and executive officers. Our Chief Executive Officer may not be present at any committee meeting during which their compensation is deliberated upon. The compensation committee is responsible for, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overseeing the development and implementation of compensation programs in consultation with our management;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least annually, reviewing and approving, or recommending to the board for its approval, the compensation for our executive officers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least annually, reviewing and recommending to the board for determination with respect to the compensation of our non-executive directors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least annually, reviewing periodically and approving any incentive compensation or equity plans, programs or other similar arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing executive officer and director indemnification and insurance matters;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">overseeing our regulatory compliance with respect to compensation matters, including our policies on restrictions on compensation plans and loans to directors and executive officers;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">185</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least annually, reviewing and reassessing the adequacy of the committee charter;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">selecting compensation consultant, legal counsel or other adviser only after taking into consideration all factors relevant to that person&#8217;s independence from management; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reporting regularly to the board.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Nominating and Corporate Governance Committee. </span>Our nominating and corporate governance committee consists of Peter Luo, Andy (Yiu Leung) Cheung and Min Li, and is chaired by Peter Luo. We have determined that Andy (Yiu Leung) Cheung and Min Li satisfy the &#8220;independence&#8221; requirements of Rule&#160;5605(a)(2)&#160;of the Listing Rules&#160;of the Nasdaq. The nominating and corporate governance committee assists the board in selecting individuals qualified to become our directors and in determining the composition of the board and its committees. The nominating and corporate governance committee is responsible for, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">recommending nominees to the board for election or re-election to the board, or for appointment to fill any vacancy on the board;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">reviewing annually with the board the current composition of the board with regards to characteristics such as independence, knowledge, skills, experience, expertise, diversity and availability of service to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing and recommending to our board such policies and procedures with respect to nomination or appointment of members of our board and chairs and members of its committees or other corporate governance matters as may be required pursuant to any SEC or Nasdaq rules, or otherwise considered desirable and appropriate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">selecting and recommending to the board the names of directors to serve as members of the audit committee and the compensation committee, as well as of the nominating and corporate governance committee itself;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">at least annually, reviewing and reassessing the adequacy of the committee charter;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developing and reviewing at least annually the corporate governance principles adopted by the board and advising the board with respect to significant developments in the law and practice of corporate governance and our compliance with such laws and practices; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">evaluating the performance and effectiveness of the board as a whole.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Duties and Functions of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under Cayman Islands law, our directors owe fiduciary duties to our company, including a duty of loyalty, a duty to act honestly and a duty to act in what they consider in good faith to be in our best interests. Our directors must also exercise their powers only for a proper purpose. Our directors also owe to our company a duty to exercise the skill they actually possess and such care and diligence that a reasonable prudent person would exercise in comparable circumstances. It was previously considered that a director need not exhibit in the performance of his duties a greater degree of skill than may reasonably be expected from a person of his knowledge and experience. However, English and Commonwealth courts have moved towards an objective standard with regard to the required skill and care and these authorities are likely to be followed in the Cayman Islands. In fulfilling their duty of care to us, our directors must ensure compliance with our memorandum and articles of association, as amended and restated from time to time. Our company has the right to seek damages if a duty owed by our directors is breached. In limited exceptional circumstances, a shareholder may have the right to seek damages in our name if a duty owed by our directors is breached. The functions and powers of our board of directors include, among others, (i)&#160;convening shareholders&#8217; annual general meetings and reporting its work to shareholders at such meetings, (ii)&#160;declaring dividends, (iii)&#160;appointing officers and determining their terms of offices and responsibilities, (iv)&#160;exercising the borrowing powers of our company, and (v)&#160;approving the transfer of shares of our company, including the registering of such shares in our share register.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">186</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Terms of Directors and Officers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Our officers are elected by and serve at the discretion of the board of directors. Other than Andy (Yiu Leung) Cheung, Min Li. Yuwen Liu and Man Kin (Raymond) Tam, each director is not subject to a term of office and holds office until such time as his successor takes office or until the earlier of his death, resignation or removal from office pursuant to the applicable provisions of our memorandum and articles of association. The initial term of our independent directors, namely Andy (Yiu Leung) Cheung and Min Li, is two-year from the effectiveness of the appointment. The initial term of our independent director Yuwen Liu is one-year from the effectiveness of the appointment.<span style="font-size:11pt;"> </span><span style="white-space:pre-wrap;">Our non-independent director, Man Kin (Raymond) Tam, is on his second one-year term. The initial term for each of Andy (Yiu Leung) Cheung, Min Li, Yuwen Liu  and Man Kin (Raymond) Tam is subject to re-appointment by the board of directors and affirmative vote of Chairman of the board of directors. A director will be removed from office automatically if, among other things, the director (i)&#160;becomes bankrupt or makes any arrangement or composition with his creditors; (ii)&#160;dies or is found by our company to be of unsound mind; (iii)&#160;resigns by notice in writing to our company; (iv)&#160;without special leave of absence from our board of directors, is absent from three consecutive meetings of the board and the board resolves that his office be vacated; (v)&#160;is prohibited by law or the Listing Rules of the Nasdaq Global Market from being a director; or (vi)&#160;is removed from office pursuant to any other provisions of our post-offering amended and restated memorandum and articles of association.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">Board Diversity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The board diversity matrix is set out below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:60.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td colspan="9" style="vertical-align:bottom;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Board Diversity Matrix (As of March 31, 2022)</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Country of Principal Executive Offices</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:37.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">The People&#8217;s Republic of China</p></td></tr><tr><td style="vertical-align:bottom;width:60.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Foreign Private Issuer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:37.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Yes</p></td></tr><tr><td style="vertical-align:bottom;width:60.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Disclosure Prohibited under Home Country Law</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:37.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">No</p></td></tr><tr><td style="vertical-align:bottom;width:60.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Did Not Disclose</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Female</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Male</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Binary</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> Gender</b></p></td></tr><tr><td style="vertical-align:bottom;width:60.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Part I: Gender Identity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Directors</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Part II: Demographic Background</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:60.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Underrepresented Individual in Home Country Jurisdiction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:37.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">LGBTQ+</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:37.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:60.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Did Not Disclose Demographic Background</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:37.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Interested Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">A director may, subject to any separate requirement for audit and risk committee approval under applicable law or applicable Nasdaq listing rules, vote in respect of any contract or transaction in which he or she is interested, provided that the nature of the interest of any directors in such contract or transaction is disclosed by him or her at or prior to its consideration and any vote in that matter.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">187</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_6418640d_ec98_4ef2_9748_42a36d50e227"></a><a id="a6DEmployees_447015"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">6.D. Employees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We had a total of 150,198 and 259 employees as of December&#160;31,<span style="font-size:11pt;"> </span>2019, 2020<span style="font-size:11pt;"> </span>and 2021, respectively. The following table sets forth the numbers of our employees categorized by function as of December&#160;31, 2021. We also engage consultants and part-time staff as and when appropriate.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Function</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Employees</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Research and Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">204</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Computational Biology and Informatics</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Technology Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Drug Discovery</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Clinical Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">CMC Development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">General Administration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">52</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">HR</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Finance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">IT</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Administration</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Business Development and Marketing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3</p></td></tr><tr><td style="vertical-align:bottom;width:77.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">259</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our success depends on our ability to attract, motivate, train and retain qualified personnel. We believe we offer our employees competitive compensation packages and an environment that encourages self-development. We regularly recruit new talents through campus events and colleague referral to build and develop our own talent pool. Through employee succession planning, we help employees understand their career path within Adagene, motivate them to remain in the organization and to achieve their personal career goals. Other initiatives for talent retention include executive coaching, employee surveys or engagement, training and development, compensation and rewards. As a result of these efforts, we have generally been able to attract and retain qualified personnel and maintain a stable core management team.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As required by regulations in China, we participate in various employee social security plans that are organized by municipal and provincial governments, including pension insurance, unemployment insurance, maternity insurance, work-related injury insurance, medical insurance and housing funds. We are required under PRC law to make contributions to employee benefit plans at specified percentages of the salaries, bonuses and certain allowances of our employees, up to a maximum amount specified by the local government from time to time. We have granted, and plan to continue to grant, share-based incentive awards to our employees in the future to incentivize their contributions to our growth and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We believe that we maintain a good working relationship with our employees, and we have not experienced any material labor disputes. None of our employees is requested by labor unions.</p><a id="_e0114ae9_7af6_4097_9796_dca05aafdd03"></a><a id="a6EShareOwnership_384399"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">6.E. Share Ownership</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth information concerning the beneficial ownership of our ordinary shares, as of March&#160;31, 2022, by:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each of our directors and executive officers; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">each person known to us to beneficially own more than 5% of our ordinary shares.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The calculations in the table below are based on 54,742,598 ordinary shares issued and outstanding as of March&#160;31, 2022, excluding the 1,327,500 ordinary shares, issued but deemed to be not outstanding as of March&#160;31, 2022, held by Great Han Fortune&#160;LP.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">188</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Beneficial ownership is determined in accordance with the rules&#160;and regulations of the SEC. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, we have included shares that the person has the right to acquire within 60 days, including through the exercise of any option, warrant, or other right or the conversion of any other security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">These shares, however, are not included in the computation of the percentage ownership of any other person.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:36.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Ordinary Shares Beneficially Owned as of March 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">%*</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Directors and Executive Officers:&#8224;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Peter (Peizhi) Luo(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,547,539</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 21.1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span>&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Fangyong (Felix) Du(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 1,235,188</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 2.3</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span>&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">JC Xu</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Qinghai Zhao</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Man Kin (Raymond) Tam</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Yu (Albert) Ren</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Chunfang (Vicky) Gu</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Ling (Jolin) Zhou</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-employee Directors</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Lefei Sun</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Andy (Yiu Leung) Cheung (independent director)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Min Li (independent director)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">**</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Yuwen Liu (independent director)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">All directors and executive officers as a group</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 11,599,039</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 21.2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">%</b><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal Shareholders:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Peter Luo act-in-concert group(3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11,547,539</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 21.1</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span>&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">JSR Limited(4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,353,242</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span>&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Asia Ventures II L.P.(5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,826,037</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span>&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">F-Prime Capital Partners Healthcare Fund III LP(6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,792,366</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.8</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span>&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Wuxi Pharmatech Healthcare Fund I L.P.(7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,282,120</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 9.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span>&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">General Atlantic Singapore AI Pte. Ltd.(8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4,782,441</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">%</span>&#160;&#160;</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:22.5pt;text-indent:-22.5pt;margin:0pt;">Notes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">*&#160;&#160;&#160;&#160;&#160;For each person and group included in this table, percentage ownership is calculated by dividing the number of shares beneficially owned by such person or group by the sum of (i)&#160;54,742,598 being the number of ordinary shares as of March&#160;31, 2022 and (ii)&#160;the number of ordinary shares underlying share options held by such person or group that are exercisable within 60 days after March&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">**&#160;&#160;&#160;Represents beneficial ownership of less than one percent.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;The business address of our directors and executive officers, except for Fangyong (Felix) Du, Man Kin (Raymond) Tam, Chunfang (Vicky) Gu, Lefei Sun and Yuwen Liu, is 10179 Huennekens Street Suite 103, San Diego, CA 92121. The business address of Fangyong (Felix) Du, Man Kin (Raymond) Tam and Chunfang (Vicky) Gu is 4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park, China 215123; the business address of Lefei Sun is Suite 5704-5706, 57F, Two IFC, 8 Finance Street, Central, Hong Kong; the business address of Yuwen Liu is 3 Fl, Building No. 10, Dongshahu Equity Investment Center, East Suhong Road, Suzhou Industrial Park.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents 11,547,539 ordinary shares held by Peter Luo act-in-concert group, as set forth in note (3)&#160;below.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents (i)&#160;810,944 ordinary shares held by Ping Ren, who is the spouse of Fangyong (Felix) Du, (ii)&#160;</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">200,000  ordinary shares held by Great Han Fortune LP for the benefit of Ping Ren, (iii)&#160;112,500 ordinary shares held by Great Han Fortune LP for the benefit of Ping Ren that are vested or will be vested within 60 days</span><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">of March 31, 2022, (iv)&#160;111,744 ordinary shares underlying 111,744 share options granted to Ping Ren that that are vested or will be vested within 60 days of March&#160;31, 2022. Great Han Fortune LP is controlled by Peter Luo and is formed to hold ordinary shares in connection with the share awards issued under the 2019 Plan.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">189</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents (i) 2,588,877 ordinary shares held by Peter Luo; (ii) 287,415 ordinary shares underlying share options granted to Peter Luo that are vested or will be vested within 60 days of March 31, 2022, (iii) 391,667 ordinary shares held by Great Han Fortune LP for the benefit of Peter Luo and (iv) 83,333 ordinary shares held by Great Han Fortune LP for the benefit of Peter Luo that will be vested within 60 days of December 31, 2021; (v) 5,208,278 ordinary shares held by HAN 2020 GRAT, for which Peter Luo is a Trustee; (vi) 2,278 ordinary shares held by Xiaohong She, who is the spouse of Peter Luo; (vii) 45,980 ordinary shares underlying share options granted to Xiaohong She that are vested or will be vested within 60 days of March 31, 2022, (viii) 100,833 ordinary shares held by Great Han Fortune LP for the benefit of Xiaohong She, (ix) 55,417 ordinary shares held by Great Han Fortune LP for the benefit of Xiaohong She that will be vested within 60 days of March 31, 2022; (x) 810,944 ordinary shares held by Ping Ren, who is the spouse of Fangyong (Felix) Du, (xi) 200,000 ordinary shares held by Great Han Fortune LP for the benefit of Ping Ren, (xii) 112,500 ordinary shares held by Great Han Fortune LP for the benefit of Ping Ren that are vested or will be vested within 60 days of March 31, 2022, (xiii) 111,744 ordinary shares underlying 111,744 share options granted to Ping Ren that that are vested or will be vested within 60 days of March 31, 2022, (xiv) total of 961,653 ordinary shares held by Raymond Tam, JC Xu, Yu (Albert) Ren and several key employees of the Company, and (xv) total of 586,620 share options granted to Raymond Tam, JC Xu, Yu (Albert) Ren and several key employees that are vested or will be vested within 60 days of March 31, 2022. On December 14, 2020, Peter Luo, Fangyong (Felix) Du, Ping Ren, Hua Gong, JC Xu, Qinghai Zhao, Man Kin (Raymond) Tam, Xiaohong (Kristine) She, Yu (Albert) Ren, Yan Li, Guizhong Liu and Alexander Goergen entered into a concert party agreement, pursuant to which the parties agree to (i) always be acting in concert in respect of their respective direct or indirect voting rights at our shareholders&#8217; general meetings, (ii) recognize the controlling position of Peter Luo; and (iii) act in concert in accordance with Peter Luo&#8217;s opinions in respect of the daily operations and management and the major decision-making of us.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents 5,353,242 ordinary shares,</span><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consisting of (i) 4,828,242 ordinary shares and (ii) 525,000 ordinary shares in the form of ADSs, are held of record by JSR Limited, a British Virgin Islands company. JSR Limited is controlled by GP Healthcare Capital Co.,&#160;Ltd. The registered address of JSR Limited is Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands.</span><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Information set forth above is based upon JSR Limited&#39;s Schedule 13G filing with the SEC on January 26, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents 4,</span><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">826,037 ordinary shares held by Asia Ventures II L.P., a limited partnership incorporated in the Bermuda. The general partner of Asia Ventures II L.P. is Asia Partners II L.P. a Bermuda exempt limited partnership. The general partner of Asia Partners II L.P. is Eight Roads GP, who is ultimately controlled by Eight Roads Holdings Limited. The registered address of Asia Ventures II L.P. is Pembroke Hall, 42 Crow Lane, Pembroke, Bermuda HM 19.</span><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Information set forth above is based upon FIL Ltd&#39;s Schedule 13G filing with the SEC on February 19, 2021.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(6)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents 4,</span><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">792,366 ordinary shares held by F-Prime Capital Partners Healthcare Fund III LP. F-Prime Capital Partners Healthcare Advisors Fund III LP is the general partner of F-Prime Capital Partners Healthcare Fund III LP. F-Prime Capital Partners Healthcare Advisors Fund III LP is solely managed by Impresa Management LLC, its general partner and investment manager. Each of the entities listed above expressly disclaims beneficial ownership of the securities listed above except to the extent of any pecuniary interest therein. The address of these entities is 245 Summer Street, Boston, MA 02210. Information set forth above is based upon FMR LLC&#39;s Schedule 13G/A filing with the SEC on February 9, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(7)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Represents 5,282,120 ordinary shares in the form of ADSs that were held of record by WuXi PharmaTech Healthcare Fund I L.P., a limited partnership incorporated in the Cayman Islands. WuXi Pharmatech Healthcare Fund I L.P. is an indirect wholly owned subsidiary of WuXi AppTec Co., Ltd (SSE: 603259; SEHK: 2359). WuXi AppTec Co.,&#160;Ltd. is a listed company on the Shanghai Stock Exchange and the Main Board of the Hong Kong Stock Exchange. The registered address of WuXi Pharmatech Healthcare Fund I L.P. is P.O.&#160;Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands.</span><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Information set forth above is based upon WuXi PharmaTech Healthcare Fund I L.P&#39;s Schedule 13G filing with the SEC on January 26, 2022.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">190</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(8)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">Represents 4,452,441 ordinary shares and 264,000 ADSs representing 330,000 ordinary shares held by General Atlantic Singapore AI Pte. Ltd. (&#8220;GA AI&#8221;), a company incorporated under the laws of Singapore. GA AI is wholly-owned by General Atlantic Singapore Fund Pte. Ltd. (&#8220;GASF&#8221;), which is controlled by General Atlantic Singapore Interholdco Ltd. (&#8220;GAS Interholdco&#8221;) The members of GAS Interholdco that share beneficial ownership of the ordinary shares and ADSs held of record by GA AI are the GA Funds. The general partner of General Atlantic Partners (Lux) SCSp (&#8220;GAP Lux&#8221;) is General Atlantic GenPar, (Lux) SCSp (&#8220;GA GenPar Lux&#8221;) and the general partner of GA GenPar Lux is General Atlantic (Lux) S.&#224;. r.l. (&#8220;GA Lux&#8221;). The general partner of General Atlantic Partners (Bermuda) EU, L.P. (&#8220;GAP Bermuda EU&#8221;) and General Atlantic Partners (Bermuda) IV, L.P. (&#8220;GAP Bermuda IV&#8221;) and the sole shareholder of GA Lux is General Atlantic GenPar (Bermuda), L.P. (&#8220;GenPar Bermuda&#8221;).  GAP (Bermuda) L.P., which is controlled by the Management Committee of GASC MGP, LLC (the &#8220;GA Management Committee&#8221;), is the general partner of GenPar Bermuda.  General Atlantic, L.P. (&#8220;GA LP&#8221;), which is also controlled by the GA Management Committee, is the managing member of GAP Coinvestments III, LLC (&#8220;GAPCO III&#8221;), GAP Coinvestments IV, LLC (&#8220;GAPCO IV&#8221;) and GAP Coinvestments V, LLC (&#8220;GAPCO V&#8221;) and the general partner of GAP Coinvestments CDA, L.P. (&#8220;GAPCO CDA&#8221;). GAP Bermuda IV, GAP Bermuda EU, GAP Lux, GAPCO III, GAPCO IV, GAPCO V and GAPCO CDA are collectively referred to as the &#8220;GA Funds.&#8221; There are nine members of the GA Management Committee as of the date hereof. Each of the members of the GA Management Committee disclaims ownership of the ordinary shares, the ADSs and the underlying ordinary shares except to the extent that he has a pecuniary interest therein. The registered address of General Atlantic Singapore AI Pte. Ltd. is 80 Robinson Road, #02-00 Singapore 068898. Information set forth above is based upon General Atlantic, L.P.&#8217;s Schedule 13G filing with the SEC on February 11, 2022.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of March&#160;31, 2022, a total of 26,293,575 ordinary shares, representing 48.0% of our outstanding ordinary shares, including ordinary shares issued in advance but deemed not outstanding to facilitiate conversation of ordinary shares to ADSs for the employee share incentive plans, are held by one record holder in the United States. The holder is the depositary of our ADS program. In addition,<span style="font-size:11pt;"> </span>25.1% of our outstanding ordinary shares were held by record holders in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our principal shareholders do not have different voting rights. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company.</p><a id="_27604534_307c_414c_ba7b_ba683bfbef1f"></a><a id="Item7MajorShareholdersandRelatedPartyTra"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Item 7. Major Shareholders and Related Party Transactions</p><a id="_c2ecf581_908c_48ce_80ca_95cd06362b91"></a><a id="a7AMAJORSHAREHOLDERS_545494"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">7.A. MAJOR SHAREHOLDERS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Please refer to &#8220;Item 6. Directors, Senior Management and Employees &#8212; E. Share Ownership.&#8221;</p><a id="_1ff89689_ff1f_408c_9adf_e9e8ddc5aa9b"></a><a id="a7BRELATEDPARTYTRANSACTIONS_165301"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">7.B. RELATED PARTY TRANSACTIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of transactions since January&#160;1, 2019 to which we have been a participant in which any of our then directors, executive officers or holders of more than 10% of any class of our voting securities at the time of such transaction, or any members of their immediate family, had or will have a direct or indirect material interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Employment Agreements and Indemnification Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Item 6 Directors, Senior Management and Employees&#8212;6.B. Compensation&#8212;Employment Agreements and Indemnification Agreements.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Share Incentives</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Item 6 Directors, Senior Management and Employees&#8212;6.B. Compensation&#8212;Share Incentive Plan.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">191</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Other Related Party Transactions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Transactions with Peter Luo</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since November&#160;2016, we had received subsidies from the local government for attracting highly skilled personnel on behalf of Peter Luo, our Chairman, CEO and shareholder. We settled this transaction by paying Peter Luo a total amount of US$84.6 thousand, which corresponds to the total amount of subsidies, after deducting individual income tax, in January&#160;2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Transactions with WuXi AppTec Group</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We received research and development services from WuXi AppTec Group, the parent company of one of our principal shareholders. The amounts for the purchase of the services were US$2.1 million, US$2.7 million and US$0.5 million in 2019, 2020 and 2021, respectively. As of December 31, 2020 and 2021, the amounts due to WuXi AppTec Group were US$0.2 million and US$0.2 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Transactions with WuXi Biologics (Cayman) Inc. or WuXi Biologics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We received research and development services, including provision of manufacturing and quality control testing services, from WuXi Biologics, an entity controlled by the ultimate controlling party of one of our principal shareholders. The amounts for the purchase of the services were US$3.6 million, US$7.2 million and US$12.6 million in 2019, 2020 and 2021, respectively. As of December 31, 2020 and 2021, the amounts due to WuXi Biologics were US$2.4 million and US$10.3 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Director and Executive Officers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 18pt;">Promissory Notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the material terms of the promissory notes issued in connection with the share purchase plans between us and our directors and executive officers:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:82.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Latest Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Previously</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name of Director or Executive Officer</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Outstanding</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Peter (Peizhi) Luo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">US$4.2 million</p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Xiaohong (Kristine) She*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">US$0.6 million</p></td></tr><tr><td style="vertical-align:bottom;width:82.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Fangyong (Felix) Du</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">US$1.5 million</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Note:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">Xiaohong (Kristine) She is the spouse of Dr.&#160;Peter (Peizhi) Luo</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">All promissory notes were made pursuant to our 2019 Plan. All amounts outstanding under the promissory notes have been settled before February 2021. For further information, see &#8220;Item 6 Directors, Senior Management and Employees&#8212;Share Incentive Plan&#8212;Adagene Inc. Second Amended and Restated Share Incentive Plans&#8212;Repayment of the Promissory Notes.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_72a5584e_b3f6_48bf_9894_67fb860f93ca"></a><a id="a7CInterestsofExpertsandCounsel_412934"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">7.C.&#160;Interests of Experts and Counsel</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_183c2300_d6f6_436d_b3df_38328cf6037d"></a><a id="Item8FinancialInformation_179985"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Item 8.&#160;Financial Information</p><a id="_c4aa8dd1_25f7_4b81_9392_4335358139ed"></a><a id="a8AConsolidatedStatementsandOther"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">8.A.&#160;Consolidated Statements and Other Financial Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have appended consolidated financial statements filed as part of this annual report.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">192</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Legal and Administrative Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As of the date of this annual report, we are not a party to any material legal or administrative proceedings. We may from time to time be subject to various legal or administrative claims and proceedings arising in the ordinary course of business. Litigation or any other legal or administrative proceeding, regardless of the outcome, is likely to result in a substantial cost and diversion to our resources, including our management&#8217;s time and attention. For risks relating to legal and administrative proceedings against us, please see &#8220;Item 3 Key Information&#8212;D. Risk Factors&#8212;Risks Relating to Our Operations&#8212;Allegations or lawsuits against us or our management may harm our reputation and business.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Dividend Policy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have not previously declared or paid cash dividends and we have no plan to declare or pay any dividends in the near future on our shares or the ADSs representing our ordinary shares. We currently intend to retain most, if not all, of our available funds and any future earnings to operate and expand our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a holding company incorporated in the Cayman Islands. In the future, we may rely on dividends from our subsidiaries, including our PRC and U.S. subsidiaries, for our cash requirements, including any payment of dividends to our shareholders. PRC regulations may restrict the ability of our PRC subsidiary to pay dividends to us. See &#8220;Item 4 Information of the Company&#8212;B. Business Overview&#8212;Regulation&#8212;Regulations relating to Dividend Distribution.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors has discretion as to whether to distribute dividends, subject to certain requirements of Cayman Islands law. In addition, our shareholders may, subject to the provisions of our post-offering articles of association, by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our board of directors. Under Cayman Islands law, a Cayman Islands company may pay a dividend out of either profit, retained earnings or share premium account, provided that in no circumstances may a dividend be paid if this would result in the company being unable to pay its debts as they fall due in the ordinary course of business. Even if our board of directors decides to pay dividends, the form, frequency and amount will depend upon our future operations and earnings, capital requirements and surplus, general financial condition, contractual restrictions and other factors that the board of directors may deem relevant. If we pay any dividends on our ordinary shares, we will pay those dividends which are payable in respect of the ordinary shares underlying the ADSs to the depositary, as the registered holder of such ordinary shares, and the depositary then will pay such amounts to the ADS holders in proportion to the ordinary shares underlying the ADSs held by such ADS holders, subject to the terms of the deposit agreement, including the fees and expenses payable thereunder. See &#8220;Item 12 Description of Securities Other Than Equity Securities&#8212;D. American Depositary Shares.&#8221;</p><a id="_a10533ea_5e5b_4aa2_b1ed_fdcc8804201f"></a><a id="a8BSignificantChanges_30259"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">8.B. Significant Changes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as otherwise disclosed in this report, we have not experienced any significant changes since the date of the annual financial statements included herein.</p><a id="_cf4399dd_d0f9_414a_9e0f_5e55fd03541f"></a><a id="Item9TheOfferandListing_756002"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Item 9. The Offer and Listing</p><a id="_e4642c8d_28eb_4d21_a8da_d928154a9a66"></a><a id="a9AOfferingandListingDetails_144386"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">9.A. Offering and Listing Details</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ADSs have been listed on the Nasdaq Global Market since February&#160;9, 2021 under the symbol &#8220;ADAG.&#8221; Each ADS represents one and one quarter ordinary shares, par value US$0.0001 per share.</p><a id="_8e2f7cd2_0b15_4d38_ae0e_0410a4750f8d"></a><a id="a9BPlanofDistribution_978914"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">9.B. Plan of Distribution</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_d517ae08_f219_4789_a984_b01f9a482cc3"></a><a id="a9CMarkets_923664"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">9.C. Markets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our ADSs have been listed on the Nasdaq Global Market since February&#160;9, 2021 under the symbol &#8220;ADAG.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">193</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_44edee09_0bac_4379_bd73_35f824b2b82f"></a><a id="a9DSellingShareholders"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">9.D. Selling Shareholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_de346cc1_2942_4d14_9d03_641ae5dcc4d6"></a><a id="a9EDilution_990429"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">9.E. Dilution</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_8f97897f_d610_4b0d_963f_d9d165baa0ca"></a><a id="a9FExpensesoftheIssue_581594"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">9.F. Expenses of the Issue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_e3d70d89_c60f_4af5_9891_8d49a9f414ca"></a><a id="Item10AdditionalInformation_357630"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Item 10. Additional Information</p><a id="_e6a0a32f_b411_4818_bb98_332d0ed9363c"></a><a id="a10AShareCapital_984479"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10.A. Share Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_07d2ade8_b39d_477b_aed5_06a683d2a56f"></a><a id="a10BMemorandumandArticlesofAssociation_2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10.B. Memorandum and Articles of Association</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a Cayman Islands exempted company and our affairs are governed by our memorandum and articles of association, as amended and restated from time to time, and Companies Act of the Cayman Islands, and the common law of the Cayman Islands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We incorporate by reference into this annual report our amended and restated memorandum and articles of association, the form of which was filed as Exhibit&#160;3.2 to our registration statement on Form&#160;F-1 (File Number 333-252210), as amended, filed with the Securities and Exchange Commission on February&#160;1, 2021. Our members adopted our amended and restated memorandum and articles of association by a special resolution on January&#160;19, 2021, which became effective immediately prior to completion of our initial public offering of ADSs representing our ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following are summaries of material provisions of our Seventh Amended and Restated Memorandum and Articles of Association and the Companies Act insofar as they relate to the material terms of our ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Registered Office and Objects</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our registered office in the Cayman Islands is at the offices of Vistra (Cayman) Limited, P. O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1 - 1205 Cayman Islands or at such other location as the Directors may from time to time determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to Clause 3 of our Seventh Amended and Restated Memorandum of Association, the objects for which the Company is established are unrestricted and the Company shall have full power and authority to carry out any object not prohibited by any law as provided by Section&#160;7(4)&#160;of the Companies Act (as amended) of the Cayman Islands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Board of Directors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Item 6 Directors, Senior Management and Employees.&#8221;</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">194</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Ordinary shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">General. </span>Our authorized share capital is US$80,000 divided into 800,000,000 shares comprising (i)&#160;640,000,000 ordinary shares of a par value of US$0.0001 each, and (ii)&#160;160,000,000 shares of a par value of US$0.0001 each of such class or classes (however designated) as our board of directors may determine in accordance with our amended and restated memorandum and articles of association. Holders of ordinary shares have the same rights. All of our issued and outstanding ordinary shares are fully paid and non-assessable. Certificates representing the ordinary shares are issued in registered form. We may not issue share to bearer. Our shareholders who are nonresidents of the Cayman Islands may freely hold, transfer and vote their ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Dividends. </span>The holders of our ordinary shares are entitled to such dividends as may be declared by our board of directors subject to our post-offering memorandum and articles of association and the Companies Act. In addition, our shareholders may, subject to the provisions of our articles of association, by ordinary resolution declare a dividend, but no dividend may exceed the amount recommended by our directors. Our post-offering memorandum and articles of association provide that dividends may be declared and paid out of our profits, realized or unrealized, or from any reserve set aside from profits which our board of directors determine is no longer needed. Dividends may also be declared and paid out of the share premium account or any other fund or account which can be authorized for this purpose in accordance with the Companies Act. No dividend may be declared and paid unless our directors determine that, immediately after the payment, we will be able to pay our debts as they become due in the ordinary course of business and we have funds lawfully available for such purpose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Voting Rights. </span>In respect of all matters subject to a shareholders&#8217; vote, holder of an Ordinary Share is entitled to one vote for each Ordinary Share registered in his or her name on our register of members. Voting at any meeting of shareholders is by way of a poll unless a show of hands is permitted. A poll may be demanded by the chairman of such meeting or any one shareholder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">A quorum required for a meeting of shareholders consists of two or more shareholders holding not less than one-half of the votes attaching to the issued and outstanding shares entitled to vote at general meetings present in person or by proxy or, if a corporation or other non-natural person, by its duly authorized representative. As a Cayman Islands exempted company, we are not obliged by the Companies Act to call shareholders&#8217; annual general meetings. Our post-offering memorandum and articles of association provide that we may (but are not obliged to) in each year hold a general meeting as our annual general meeting in which case we will specify the meeting as such in the notices calling it, and the annual general meeting will be held at such time and place as may be determined by our board of directors. We, however, will hold an annual shareholders&#8217; meeting during each fiscal year, as required by the Listing Rules&#160;of the Nasdaq Global Market. Each general meeting, other than an annual general meeting, shall be an extraordinary general meeting. Shareholders&#8217; annual general meetings and any other general meetings of our shareholders may be called by a majority of our board of directors or our chairman or upon a requisition of shareholders holding at the date of deposit of the requisition not less than 20% of the votes attaching to the issued and outstanding shares entitled to vote at general meetings, in which case the directors are obliged to call such meeting and to put the resolutions so requisitioned to a vote at such meeting; however, our post-offering memorandum and articles of association do not provide our shareholders with any right to put any proposals before annual general meetings or extraordinary general meetings not called by such shareholders. Advance notice of at least seven (7)&#160;days is required for the convening of our annual general meeting and other general meetings in accordance with our post-offering memorandum and articles of association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">An ordinary resolution to be passed at a meeting by the shareholders requires the affirmative vote of a simple majority of the votes attaching to the ordinary shares cast by those shareholders entitled to vote who are present in person or by proxy at a general meeting, while a special resolution also requires the affirmative vote of no less than two-thirds of the votes attaching to the ordinary shares cast by those shareholders entitled to vote who are present in person or by proxy at a general meeting. A special resolution will be required for important matters such as a change of name or making changes to our post-offering memorandum and articles of association.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Transfer of Ordinary Shares. </span>Subject to the restrictions in our post-offering memorandum and articles of association as set out below, any of our shareholders may transfer all or any of his or her ordinary shares by an instrument of transfer in the usual or common form or any other form approved by our board of directors.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">195</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors may, in its absolute discretion, decline to register any transfer of any Ordinary Share. Our board of directors may also decline to register any transfer of any Ordinary Share unless:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the instrument of transfer is lodged with us, accompanied by the certificate for the ordinary shares to which it relates and such other evidence as our board of directors may reasonably require to show the right of the transferor to make the transfer;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the instrument of transfer is in respect of only one class of shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the instrument of transfer is properly stamped, if required;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">in the case of a transfer to joint holders, the number of joint holders to whom the Ordinary Share is to be transferred does not exceed four;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the shares are free from any lien in favor of us; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a fee of such maximum sum as the Nasdaq may determine to be payable or such lesser sum as our directors may from time to time require is paid to us in respect thereof.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If our directors refuse to register a transfer, they shall, within three months after the date on which the instrument of transfer was lodged, send to each of the transferor and the transferee notice of such refusal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The registration of transfers may, after compliance with any notice requirement of the Nasdaq, be suspended and the register closed at such times and for such periods as our board of directors may from time to time determine, <i style="font-style:italic;">provided</i>, <i style="font-style:italic;">however</i>, that the registration of transfers shall not be suspended nor the register closed for more than 30 days in any year as our board may determine.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidation. </span>On a return of capital on winding up or otherwise (other than on conversion, redemption or purchase of ordinary shares), if the assets available for distribution amongst our shareholders shall be more than sufficient to repay the whole of the share capital at the commencement of the winding up, the surplus shall be distributed amongst our shareholders in proportion to the par value of the shares held by them at the commencement of the winding up, subject to a deduction from those shares in respect of which there are monies due, of all monies payable to our company for unpaid calls or otherwise. If our assets available for distribution are insufficient to repay all of the paid-up capital, the assets will be distributed so that the losses are borne by our shareholders in proportion to the par value of the shares held by them. Any distribution of assets or capital to a holder of ordinary shares will be the same in any liquidation event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Calls on Ordinary Shares and Forfeiture of Ordinary Shares. </span>Our board of directors may from time to time make calls upon shareholders for any amounts unpaid on their ordinary shares in a notice served to such shareholders at least 14 clear days prior to the specified time of payment. The ordinary shares that have been called upon and remain unpaid are subject to forfeiture.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Redemption, Repurchase and Surrender of Ordinary Shares. </span>We may issue shares on terms that such shares are subject to redemption, at our option or at the option of the holders thereof, on such terms and in such manner as may be determined, before the issue of such shares, by our board of directors or by an ordinary resolution of our shareholders. Our company may also repurchase any of our shares provided that the manner and terms of such purchase have been approved by our board of directors or by an ordinary resolution of our shareholders, or are otherwise authorized by our post-offering memorandum and articles of association. Under the Companies Act, the redemption or repurchase of any share may be paid out of our company&#8217;s profits or out of the proceeds of a fresh issue of shares made for the purpose of such redemption or repurchase, or out of capital (including share premium account and capital redemption reserve) if the Company can, immediately following such payment, pay its debts as they fall due in the ordinary course of business. In addition, under the Companies Act no such share may be redeemed or repurchased (a)&#160;unless it is fully paid up, (b)&#160;if such redemption or repurchase would result in there being no shares outstanding, or (c)&#160;if the company has commenced liquidation. In addition, our company may accept the surrender of any fully paid share for no consideration.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">196</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Variations of Rights of Shares. </span>If at any time our share capital is divided into different classes or series of shares, the rights attached to any class or series of shares (unless otherwise provided by the terms of issue of the shares of that class or series), whether or not our company is being wound-up, may be varied with the consent in writing of holders of not less than a majority of the issued shares of that class or series or with the sanction of a special resolution at a separate meeting of the holders of the shares of the class or series. The rights conferred upon the holders of the shares of any class issued shall not, unless otherwise expressly provided by the terms of issue of the shares of that class, be deemed to be varied by the creation or issue of further shares ranking <i style="font-style:italic;">pari passu </i>with such existing class of shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Inspection of Books and Records. </span>Holders of our ordinary shares have no general right under Cayman Islands law to inspect or obtain copies of our list of shareholders or our corporate records. However, we will provide our shareholders with annual audited financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Issuance of Additional Shares. </span>Our post-offering memorandum and articles of association authorizes our board of directors to issue additional ordinary shares from time to time as our board of directors shall determine, to the extent of available authorized but unissued shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our post-offering memorandum and articles of association also authorizes our board of directors to establish from time to time one or more series of preferred shares and to determine, with respect to any series of preferred shares, the terms and rights of that series, including:</p><div style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-indent:18pt;"><span style="display:inline-block;font-size:10pt;min-width:18pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="font-size:10pt;">the designation of the series;</span></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of shares of the series;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the dividend rights, dividend rates, conversion rights, voting rights; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the rights and terms of redemption and liquidation preferences.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our board of directors may issue preferred shares without action by our shareholders to the extent authorized but unissued. Issuance of these shares may dilute the voting power of holders of ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Anti-Takeover Provisions. </span>Some provisions of our post-offering memorandum and articles of association may discourage, delay or prevent a change of control of our company or management that shareholders may consider favorable, including provisions that authorize our board of directors to issue preferred shares in one or more series and to designate the price, rights, preferences, privileges and restrictions of such preferred shares without any further vote or action by our shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Changes in Capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may from time to time by ordinary resolution:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">increase the share capital by such sum, to be divided into shares of such classes and amount, as the resolution shall prescribe;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">consolidate and divide all or any of our share capital into shares of a larger amount than our existing shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sub-divide our existing shares, or any of them into shares of a smaller amount; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cancel any shares which, at the date of the passing of the resolution, have not been taken or agreed to be taken by any person and diminish the amount of our share capital by the amount of the shares so canceled.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We may by special resolution, subject to any confirmation or consent required by the Companies Act, reduce our share capital or any capital redemption reserve in any manner permitted by law.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">197</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Exempted Company. </span>We are an exempted company with limited liability under the Companies Act. The Companies Act distinguishes between ordinary resident companies and exempted companies. Any company that is registered in the Cayman Islands but conducts business mainly outside of the Cayman Islands may apply to be registered as an exempted company. The requirements for an exempted company are essentially the same as for an ordinary company except that an exempted company:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">does not have to file an annual return of its shareholders with the Registrar of Companies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">is not required to open its register of members for inspection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">does not have to hold an annual general meeting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may issue shares with no par value;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may obtain an undertaking against the imposition of any future taxation (such undertakings are usually given for 30 years in the first instance);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may register by way of continuation in another jurisdiction and be deregistered in the Cayman Islands;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may register as a limited duration company; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">may register as a segregated portfolio company.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">&#8220;Limited liability&#8221; means that the liability of each shareholder is limited to the amount unpaid by the shareholder on that shareholder&#8217;s shares of the company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Register of Members.</span> Under the Companies Act, we must keep a register of members and there should be entered therein:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the names and addresses of our members, and a statement of the shares held by each member, which shall include: (i) the amount paid or agreed to be considered as paid on the shares of each member, (ii) the number and category of shares held by each member, and (iii) whether each relevant category of shares held by a member carries voting rights under the post-offering memorandum and articles of association, and if so, whether such voting rights are conditional;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the date on which the name of any person was entered on the register as a member; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the date on which any person ceased to be a member.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the Companies Act, the register of members of our company is prima facie evidence of the matters set out therein (that is, the register of members will raise a presumption of fact on the matters referred to above unless rebutted) and a member registered in the register of members is deemed as a matter of the Companies Act to have legal title to the shares as set against its name in the register of members. Upon completion of this offering, we will perform the procedure necessary to immediately update the register of members to record and give effect to the issuance of shares by us to the Depositary (or its nominee) as the depositary. Once our register of members has been updated, the shareholders recorded in the register of members will be deemed to have legal title to the shares set against their name.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">If the name of any person is incorrectly entered in or omitted from our register of members, or if there is any default or unnecessary delay in entering on the register the fact of any person having ceased to be a member of our company, the person or member aggrieved (or any member of our company or our company itself) may apply to the Grand Court of the Cayman Islands for an order that the register be rectified, and the Court may either refuse such application or it may, if satisfied of the justice of the case, make an order for the rectification of the register.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">198</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3e8372e3_ed5a_465f_9e8c_4eb1d2a38fc0"></a><a id="a10CMaterialContracts_95807"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10.C. Material Contracts</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have not entered into any material contracts other than in the ordinary course of business and other than those described in this annual report.</p><a id="_b64fb3af_6e43_4d56_ad09_c0eb454a7088"></a><a id="a10DExchangeControls_660603"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10.D. Exchange Controls</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The Cayman Islands currently has no exchange control regulations or currency restrictions. For exchange control regulations or currency restrictions in China, see &#8220;Item 4 Information of the Company&#8212;B. Business Overview&#8212;Regulation&#8212;Regulations Relating to Foreign Exchange.&#8221;</p><a id="_5adfa4d5_ed9d_4eed_b225_d5e30346ef24"></a><a id="a10ETaxation_830656"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10.E. Taxation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following discussion of Cayman Islands, PRC and U.S. federal income tax consequences of the ownershihp and disposition of the ADSs or ordinary shares is based upon laws and relevant interpretations thereof in effect as of the date of this annual report, all of which are subject to change. This discussion does not deal with all possible tax consequences relating to the ownership and disposition of the ADSs or ordinary shares, such as the tax consequences under state, local and other tax laws.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Cayman Islands Taxation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">According to Walkers (Hong Kong), our Cayman Islands counsel, the Cayman Islands currently levies no taxes on individuals or corporations based upon profits, income, gains or appreciation, and there is no taxation in the nature of inheritance tax or estate duty. There are no other taxes likely to be material to us or holders of our ADSs or ordinary shares levied by the government of the Cayman Islands, except for stamp duties which may be applicable on instruments executed in, or after execution brought within the jurisdiction of the Cayman Islands. The Cayman Islands is not party to any double tax treaties that are applicable to any payments made to or by our company. There are no exchange control regulations or currency restrictions in the Cayman Islands.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Payments of dividends and capital in respect of the ADSs or ordinary shares will not be subject to taxation in the Cayman Islands and no withholding will be required on the payment of a dividend or capital to any holder of the ADSs or ordinary shares, nor will gains derived from the disposal of the ADSs or ordinary shares be subject to Cayman Islands income or corporation tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Material PRC Income Tax Considerations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Under the PRC EIT Law, which became effective on January&#160;1, 2008 and was amended on December&#160;29, 2018, an enterprise established outside the PRC with &#8220;de facto management bodies&#8221; within the PRC is considered a &#8220;resident enterprise&#8221; for PRC enterprise income tax purposes and is generally subject to a uniform 25% enterprise income tax rate on its worldwide income. Under the implementation rules&#160;to the PRC EIT Law, a &#8220;de facto management body&#8221; is defined as a body that has material and overall management and control over the manufacturing and business operations, personnel and human resources, finances and properties of an enterprise.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">199</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In addition, the SAT Circular 82 issued by the SAT in April&#160;2009 specifies that certain offshore incorporated enterprises controlled by PRC enterprises or PRC enterprise groups will be classified as PRC resident enterprises if the following are located or resident in the PRC: (a)&#160;senior management personnel and departments that are responsible for daily production, operation and management; (b)&#160;financial and personnel decision-making bodies; (c)&#160;key properties, accounting books, company seal, minutes of board meetings and shareholders&#8217; meetings; and (d)&#160;half or more of the senior management or directors having voting rights. Further to SAT Circular 82, the SAT issued the SAT Bulletin 45, which took effect in September&#160;2011, to provide more guidance on the implementation of SAT Circular 82. SAT Bulletin 45 provides for procedures and administration details of determination on resident status and administration on post-determination matters. Our company is a company incorporated outside the PRC. As a holding company, its key assets are its ownership interests in its subsidiaries, and its key assets are located, and its records (including the resolutions of its board of directors and the resolutions of its shareholders) are maintained, outside the PRC. As such, we do not believe that our company meets all of the conditions above or is a PRC resident enterprise for PRC tax purposes. For similar reasons, we believe our other entities outside China are not PRC resident enterprises either. However, the tax resident status of an enterprise is subject to determination by the PRC tax authorities and uncertainties remain with respect to the interpretation of the term &#8220;de facto management body.&#8221; There can be no assurance that the PRC government will ultimately take a view that is consistent with us. If the PRC tax authorities determine that our Cayman Islands holding company is a PRC resident enterprise for PRC enterprise income tax purposes, a number of unfavorable PRC tax consequences could follow. For example, a 10% withholding tax would be imposed on dividends we pay to our non-PRC enterprise shareholders (including our ADS holders). In addition, nonresident enterprise shareholders (including our ADS holders) may be subject to PRC tax on gains realized on the sale or other disposition of ADSs or ordinary shares, if such income is treated as sourced from within the PRC. Furthermore, if we are deemed a PRC resident enterprise, dividends paid to our non-PRC individual shareholders (including our ADS holders) and any gain realized on the transfer of ADSs or ordinary shares by such shareholders may be subject to PRC tax at a rate of 20% (which, in the case of dividends, may be withheld at source by us). These rates may be reduced by an applicable tax treaty, but it is unclear whether in practice non-PRC shareholders of our company would be able to obtain the benefits of any tax treaties between their country of tax residence and the PRC in the event that we are treated as a PRC resident enterprise. See &#8220;Item 3 Key Information&#8212;D. Risk Factors&#8212;Risks Related to Doing Business in the PRC&#8212;If we are classified as a PRC resident enterprise for PRC income tax purposes, such classification could result in unfavorable tax consequences to us and our non-PRC shareholders or ADS holders.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Material U.S. Federal Income Tax Considerations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following are material U.S. federal income tax consequences to the U.S. Holders described below of the ownership and disposition of the ADSs or ordinary shares. This discussion is not a comprehensive description of all of the tax considerations that may be relevant to your decision to hold the ADSs or ordinary shares. This discussion applies to you only if you are a U.S. Holder that holds the ADSs or underlying ordinary shares as capital assets for U.S. federal income tax purposes. In addition, it does not describe all of the tax consequences that may be relevant in light of your particular circumstances, including the alternative minimum tax, the Medicare contribution tax on net investment income, and tax consequences applicable to you if you are subject to special rules, such as:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one of certain financial institutions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a dealer or trader in securities that uses a mark-to-market method of tax accounting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a person holding ADSs or ordinary shares as part of a straddle, conversion transaction, integrated transaction or similar transaction;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a person whose functional currency for U.S. federal income tax purposes is not the U.S. dollar;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an entity classified as partnerships for U.S. federal income tax purposes (and investors therein);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a tax-exempt entity, &#8220;individual retirement account&#8221; or &#8220;Roth IRA&#8217;&#8217;;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a person who acquired our ADSs or ordinary shares pursuant to the exercise of an employee stock option or otherwise as compensation;</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">200</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a person that owns or is deemed to own 10% or more of our stock by vote or value; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a person holding ADSs or ordinary shares in connection with a trade or business conducted outside the United States.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you are a partnership for U.S. federal income tax purposes, the U.S. federal income tax consequences to your partners will generally depend on their status and your activities. Partnerships holding ADSs or ordinary shares and their partners should consult their tax advisers as to the particular U.S. federal income tax consequences of acquiring, owning or disposing of the ADSs or ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This discussion is based on the Internal Revenue Code of 1986, as amended, or the Code, administrative pronouncements, judicial decisions and final, temporary and proposed Treasury regulations, and the income tax treaty between the United States and the PRC, or the Treaty, all as of the date hereof, any of which is subject to change, possibly with retroactive effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For purposes of this discussion, you are a &#8220;U.S. Holder&#8221; if you are eligible for the benefits of the Treaty and are, for U.S. federal income tax purposes, a beneficial owner of ADSs or ordinary shares and:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a citizen or individual resident of the United States;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a corporation or other entity taxable as a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States, any state therein or the District of Columbia; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an estate or trust the income of which is subject to U.S. federal income taxation regardless of its source.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Treasury regulations that apply to taxable years beginning on or after December 28, 2021 (the &#8220;Foreign Tax Credit Regulations&#8221;) may in some circumstances prohibit a U.S. person from claiming a foreign tax credit with respect to certain non-U.S. taxes that are not creditable under applicable income tax treaties. Accordingly, U.S. investors that are not eligible for Treaty benefits should consult their tax advisers regarding the creditability or deductibility of any PRC taxes imposed on dividends on, or dispositions of, the ADSs or ordinary shares. This discussion does not apply to investors in this special situation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In general, if you own ADSs you will be treated as the owner of the underlying ordinary shares represented by those ADSs for U.S. federal income tax purposes. Accordingly, no gain or loss will be recognized if you exchange ADSs for the underlying ordinary shares represented by those ADSs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Taxation of Distributions</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is subject to the discussion under &#8220;&#8212;<i style="font-style:italic;">Passive Foreign Investment Company Rules</i>&#8221; above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Distributions paid on ADSs or ordinary shares, other than certain pro rata distributions of ordinary shares, will generally be treated as dividends to the extent paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). Because we do not maintain calculations of our earnings and profits under U.S. federal income tax principles, we expect that any distributions will be reported to you as dividends. Dividends will not be eligible for the dividends-received deduction generally available to U.S. corporations under the Code. Subject to applicable limitations, dividends paid by &#8220;qualified foreign corporations&#8221; to certain non-corporate U.S. Holders are taxable at the favorable rates applicable to long-term capital gains. A non-U.S. corporation is generally treated as a qualified foreign corporation with respect to dividends paid on stock that is readily tradable on a securities market in the United States, such as the Nasdaq Global Market, where the ADSs are listed, or where the non-U.S. corporation is eligible for benefits of a comprehensive income tax treaty with the United States. Therefore such favorable rates may apply for so long as our ADSs are listed on the Nasdaq Global Market or if in the future we are eligible for benefits under the Treaty. However, the favorable rates do not apply if we are (or are treated with respect to a U.S. Holder as) a PFIC for the taxable year in which the dividend is paid or the preceding taxable year. Non-corporate U.S. Holders should consult their tax advisers to determine whether the favorable rate will apply to dividends they receive and whether they are subject to any special rules that limit their ability to be taxed at this favorable rate.t.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">201</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Dividends will be treated as foreign-source income for foreign tax credit purposes. As described in &#8220;&#8212;Material PRC Income Tax Considerations&#8221;, dividends paid by us may be subject to PRC withholding tax. For U.S. federal income tax purposes, the amount of the dividend income will include any amounts withheld in respect of PRC withholding tax. Subject to applicable limitations, which vary depending upon your circumstances, PRC taxes withheld from dividend payments (at a rate not exceeding the applicable rate provided in the Treaty) generally will be creditable against your U.S. federal income tax liability. The rules&#160;governing foreign tax credits are complex and you should consult your tax advisers regarding the creditability of foreign tax credits in your particular circumstances. In lieu of claiming a credit, you may elect to deduct creditable PRC taxes in computing its taxable income, subject to applicable limitations. An election to deduct foreign taxes instead of claiming foreign tax credits must apply to all creditable foreign taxes paid or accrued in the taxable year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Sale or Other Disposition of ADSs or Ordinary Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following is subject to the discussion under &#8220;&#8212;<i style="font-style:italic;">Passive Foreign Investment Company Rules</i>&#8221; above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Gain or loss realized on the sale or other taxable disposition of ADSs or ordinary shares will be capital gain or loss, and will be long-term capital gain or loss if you held the ADSs or ordinary shares for more than one year. The amount of the gain or loss will equal the difference between your tax basis in the ADSs or ordinary shares disposed of and the amount realized on the disposition, in each case as determined in U.S. dollars. This gain or loss will generally be U.S.-source gain or loss for foreign tax credit purposes. The deductibility of capital losses is subject to limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">As described in &#8220;&#8212;Material PRC Income Tax Considerations&#8221; above, gains on the sale of ADSs or ordinary shares may be subject to PRC taxes. Under the Code, capital gains of U.S. persons are generally treated as U.S.-source income. However, you may be able to elect to treat the gain as foreign-source income under the Treaty and claim foreign tax credit in respect of any PRC tax on dispositions. The Foreign Tax Credit Regulations generally preclude you from claiming a foreign tax credit with respect to PRC income taxes on gains from dispositions of ADSs or ordinary shares if you do not elect to apply the benefits of the Treaty. However, in that case it is possible that any PRC taxes on disposition gains may either be deductible or reduce the amount realized on the disposition.  The rules governing foreign tax credits and deductibility of foreign taxes are complex. You should consult your tax advisor regarding the consequences of the imposition of any PRC tax on disposition gains, including the Treaty&#8217;s resourcing rule, any reporting requirements with respect to a Treaty-based return position and the creditability or deductibility of the PRC tax on disposition gains in your particular circumstances (including any applicable limitations).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Passive Foreign Investment Company Rules</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In general, a non-U.S. corporation will be a passive foreign investment company, or a PFIC, for any taxable year in which (i)&#160;75% or more of its gross income consists of passive income, or the income test, or (ii)&#160;50% or more of the average value of its assets (generally determined on a quarterly basis) consists of assets that produce, or are held for the production of, passive income, or the asset test. For purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the ordinary shares of another corporation is treated as if it held its proportionate share of the assets of the other corporation and received directly its proportionate share of the income of the other corporation. Passive income generally includes interest, dividends, gains from certain property transactions, rents and royalties (other than certain rents or royalties derived in the active conduct of a trade or business). Cash is generally a passive asset for PFIC purposes. Goodwill is an active asset under the PFIC rules&#160;to the extent attributable to activities that produce active income.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The assets shown on our balance sheet are expected to consist primarily of cash and cash equivalents for the foreseeable future. Therefore, whether we will satisfy the asset test for any taxable year will depend largely on the value of our goodwill and on how quickly we utilize the cash in our business. We cannot give any assurance as to whether we will be a PFIC for any taxable year because (i) the value of our goodwill may be determined by reference to our market capitalization, which has been, and may continue to be, volatile, (ii) we expect to hold a significant amount of cash, and (iii) a company&#8217;s PFIC status is an annual factual determination that can be made only after the end of each taxable year and depends on the composition of its income and assets and the value of its assets from time to time.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">202</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Based on the average price of our ADSs during 2021 we believe that we were not a PFIC for our taxable year ended December 31, 2021.  However, while we hold a substantial amount of cash and cash equivalents our PFIC status for any taxable year will depend primarily on the average value of our goodwill.  Because our market capitalization has declined substantially since our initial public offering (including in recent months), if the value of our goodwill is determined by reference to our market capitalization there is a significant risk that we will be a PFIC for our taxable year 2022, and possibly future taxable years. In addition, prior to the commercialization of our product candidates, we could be a PFIC for any taxable year in which our interest and other investment income constitutes 75% or more of our total gross income.If we are a PFIC for any taxable year and any of our subsidiaries is also a PFIC (any such entity, a &#8220;Lower-tier PFIC &#8220;), you will be deemed to own a proportionate amount (by value) of the ordinary shares of each Lower-tier PFIC and will be subject to U.S. federal income tax according to the rules described in the subsequent paragraph on (i) certain distributions by a Lower-tier PFIC and (ii) dispositions of shares of Lower-tier PFICs, in each case as if you held your proportionate share of these shares directly, even though you will not receive the proceeds of those distributions or dispositions.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Generally, if we are a PFIC for any taxable year during which you own ADSs or ordinary shares, gain recognized upon a disposition (including, under certain circumstances, a pledge) of ADSs or ordinary shares will be allocated ratably over your holding period for the ADSs or ordinary shares. The amounts allocated to the taxable year of disposition and to years before we became a PFIC will be taxed as ordinary income. The amount allocated to each other taxable year will be subject to tax at the highest rate in effect for that taxable year for individuals or corporations, as appropriate, and an interest charge will be imposed on the resulting tax liability for each relevant taxable year. Further, to the extent that any distribution received by you on your ADSs or ordinary shares exceeds 125% of the average of the annual distributions on the ADSs or ordinary shares received during the preceding three years or your holding period, whichever is shorter, that distribution will be subject to taxation in the same manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If we are a PFIC for any taxable year during which you own ADSs or ordinary shares, we will generally continue to be treated as a PFIC with respect to you for all succeeding years during which you own ADSs or ordinary shares, even if we cease to meet the threshold requirements for PFIC status. If we are a PFIC for any taxable year but cease to be PFIC for subsequent years, you should consult your tax advisor regarding the availability of a &#8220;deemed sale&#8221; election that would allow you to eliminate the continuing PFIC status under certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Alternatively, if we are a PFIC and if our ADSs or ordinary shares are &#8220;regularly traded&#8221; on a &#8220;qualified exchange,&#8221; you may be able to make a mark-to-market election that will result in tax treatment different from the general tax treatment described in the preceding paragraphs. Our ADSs will be treated as &#8220;regularly traded&#8221; in any calendar year in which more than a <i style="font-style:italic;">de minimis </i>quantity of the ADSs, as the case may be, are traded on a qualified exchange on at least 15 days during each calendar quarter. The Nasdaq Global Market, on which the ADSs are listed, is a qualified exchange for this purpose. If you make the mark-to-market election, you generally will recognize as ordinary income any excess of the fair market value of the ADSs at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ADSs over their fair market value at the end of the taxable year (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). If you make the election, your tax basis in the ADSs will be adjusted to reflect these income or loss amounts. Any gain recognized on the sale or other disposition of ADSs in a year in which we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the mark-to-market election) and any remaining loss will be capital loss. There is no provision under U.S. federal income tax law that provides for a right to make a mark-to-market election with respect to any lower-tier PFICs the shares of which are not regularly traded. Therefore, if we are a PFIC for any taxable year, you could be subject to the general PFIC rules described in the preceding paragraph with respect to any Lower-tier PFIC even if you make a mark-to-market election with respect to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We do not intend to provide the information necessary to make a &#8220;qualified electing fund election,&#8221; which would result in alternate treatment if we were a PFIC for any taxable year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">If you own ADSs or ordinary shares during any year in which we are a PFIC, you generally will be required to file annual reports on Internal Revenue Service Form&#160;8621 (or any successor form) with respect to us. Additionally, if we are a PFIC for the taxable year in which we pay a dividend or the prior taxable year, the favorable rate discussed above with respect to dividends paid to certain non-corporate U.S. Holders will not apply. You should consult your tax adviser regarding our PFIC status for any taxable year and the potential application of the PFIC rules.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">203</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Information Reporting and Backup Withholding</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Payments of dividends and sales proceeds from the sale or exchange of our ADSs or ordinary shares that are made within the United States or through certain U.S.-related financial intermediaries generally are subject to information reporting, and may be subject to backup withholding, unless (i)&#160;you are a corporation or other exempt recipient or (ii)&#160;in the case of backup withholding, you provide a correct taxpayer identification number and certify that you are not subject to backup withholding. Backup withholding is not an additional tax. The amount of any backup withholding from a payment to you will be allowed as a credit against your U.S. federal income tax liability and may entitle you to a refund, provided that the required information is timely furnished to the Internal Revenue Service.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Certain U.S. Holders who are individuals (and certain specified entities) may be required to report information relating to their ownership of ordinary shares, or non-U.S. accounts through which ADSs or ordinary shares are held. You should consult your tax adviser regarding your reporting obligations with respect to the ADSs or ordinary shares.</p><a id="_4082e801_a0e9_41cf_810b_d622692ac1a7"></a><a id="a10FDividendsandPayingAgents_24522"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10.F. Dividends and Paying Agents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_3eaf12d8_2d4f_4102_8909_9e4337726ee3"></a><a id="a10GStatementbyExperts_487266"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10.G. Statement by Experts</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_13031a39_0278_473c_9b1b_e169cec4a45c"></a><a id="a10HDocumentsonDisplay_386080"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10.H. Documents on Display</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We previously filed with the SEC registration statement on Form&#160;F-1 (File Number 333-252210), as amended, including annual report contained therein, to register our ordinary shares in relation to our initial public offering. We also filed with the SEC related registration statement on Form&#160;F-6&#160;(File Number&#160;333-252543)&#160;to register the ADSs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are subject to the periodic reporting and other informational requirements of the Exchange Act as applicable to foreign private issuers. Under the Exchange Act, we are required to file reports and other information with the SEC. Specifically, we are required to file annually a Form&#160;20-F&#160;within four months after the end of each fiscal year. Copies of reports and other information, when so filed with the SEC, can be inspected and copied at the public reference facilities maintained by the SEC at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You can request copies of these documents, upon payment of a duplicating fee, by writing to the SEC. The public may obtain information regarding the Washington, D.C. Public Reference Room by calling the Commission at&#160;1-800-SEC-0330.&#160;The SEC also maintains a web site at www.sec.gov that contains reports, proxy and information statements, and other information regarding registrants that make electronic filings with the SEC using its EDGAR system. As a foreign private issuer, we are exempt from the rules&#160;of the Exchange Act prescribing the furnishing and content of quarterly reports and proxy statements, and our executive officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section&#160;16 of the Exchange Act. In addition, we are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will furnish JPMorgan Chase Bank, N.A., the depositary of our ADSs, with our annual reports, which will include a review of operations and annual audited consolidated financial statements, and all notices of shareholders&#8217; meetings and other reports and communications that are made generally available to our shareholders. The depositary will make such notices, reports and communications available to holders of ADSs and, upon our request, will mail to all record holders of ADSs the information contained in any notice of a shareholders&#8217; meeting received by the depositary from us.</p><a id="_4215cb95_5b2f_486a_bbb0_353048cc55eb"></a><a id="a10ISubsidiaryInformation_103259"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10.I. Subsidiary Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">204</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_54d4eeb2_a70f_4a61_9f50_92df64b1f8e0"></a><a id="ITEM11QUANTITATIVEANDQUALITATIVEDISCLOSU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Interest rate risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our exposure to interest rate risk primarily relates to the interest income generated by excess cash, which is mostly held in interest-bearing bank deposits. We have not used any derivative financial instruments to manage our interest risk exposure. Interest-earning instruments carry a degree of interest rate risk. We have not been exposed, nor do we anticipate being exposed, to material risks due to changes in interest rates. However, our future interest income may be lower than expected due to changes in market interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Foreign exchange risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We are a global business enterprise with part of our operations based in the PRC. A part of our transactions were settled in Renminbi, and our financial statements are presented in U.S. dollars. We do not believe that we currently have any significant direct foreign exchange risk and have not used any derivative financial instruments to hedge our exposure to such risk. Although, in general, our exposure to foreign exchange risks should be limited, the value of your investment in the ADSs will be affected by the exchange rate between U.S. dollar and Renminbi because a portion of value of our business is effectively denominated in Renminbi, while the ADSs representing our ordinary shares will be traded in U.S. dollars.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The value of the Renminbi against the U.S. dollar and other currencies is affected by changes in China&#8217;s political and economic conditions and by China&#8217;s foreign exchange policies, among other things. In July&#160;2005, the PRC government changed its decades-old policy of pegging the value of the Renminbi to the U.S. dollar, and the Renminbi appreciated more than 20% against the U.S. dollar over the following three years. Between July&#160;2008 and June&#160;2010, this appreciation subsided and the exchange rate between the Renminbi and the U.S. dollar remained within a narrow band. Since June&#160;2010, the Renminbi has fluctuated against the U.S. dollar, at times significantly and unpredictably. While appreciating approximately by 7% against the U.S. dollar in 2017, the Renminbi in 2018 depreciated approximately by 5% against the U.S. dollar. Since October&#160;1, 2016, the Renminbihas joined the International Monetary Fund (IMF)&#8217;s basket of currencies that make up the Special Drawing Right (SDR), along with the U.S. dollar, the Euro, the Japanese yen and the British pound. With the development of the foreign exchange market and progress towards interest rate liberalization and Renminbi internationalization, the PRC government may in the future announce further changes to the exchange rate system and there is no guarantee that the RMB will not appreciate or depreciate significantly in value against the U.S. dollar in the future. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the Renminbi and the U.S. dollar in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To the extent that we need to convert U.S. dollars into Renminbi for our operations, appreciation of Renminbi against the U.S. dollar would reduce the Renminbi amount we receive from the conversion. Conversely, if we decide to convert Renminbi into U.S. dollars for the purpose of making payments for dividends on our ordinary shares or ADSs, servicing our outstanding debt, or for other business purposes, appreciation of the U.S. dollar against the Renminbi would reduce the U.S. dollar amounts available to us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;"><span style="font-style:italic;font-weight:bold;">Inflation risk</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Since our inception, inflation in China has not materially impacted our results of operations. According to the National Bureau of Statistics of China, the year-over-year percent changes in the consumer price index for December&#160;2019, 2020 and 2021 were increases of 2.9%, 2.4%, and 0.9% respectively. Although we have not in the past been materially affected by inflation since our inception, we can provide no assurance that we will not be affected in the future by higher rates of inflation in China.</p><a id="_f311f6a1_33f8_435e_80c2_826cd9ccf1c2"></a><a id="ITEM12DESCRIPTIONOFSECURITIESOTHERTHANEQ"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES</p><a id="_d2d16a04_54b5_49f4_8952_7bd9a3bef4e5"></a><a id="a12ADebtSecurities_373051"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">12.A. Debt Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_86abf797_a370_4317_971f_2d0402cd8263"></a><a id="a12BWarrantsandRights_197872"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">12.B. Warrants and Rights</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">205</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_174bad69_d9be_43fa_a3f0_512aa0687f1c"></a><a id="a12COtherSecurities_121938"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">12.C. Other Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_7ce76da3_100d_49cb_9444_ac5cb42fefed"></a><a id="a12DAmericanDepositaryShares_154963"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">12.D. American Depositary Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Fees and Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The depositary may charge each person to whom ADSs are issued, including, without limitation, issuances against deposits of shares, issuances in respect of share distributions, rights and other distributions, issuances pursuant to a stock dividend or stock split declared by us or issuances pursuant to a merger, exchange of securities or any other transaction or event affecting the ADSs or deposited securities, and each person surrendering ADSs for withdrawal of deposited securities or whose ADRs are cancelled or reduced for any other reason, $5.00 for each 100 ADSs (or any portion thereof) issued, delivered, reduced, cancelled or surrendered, or upon which a share distribution or elective distribution is made or offered, as the case may be. The depositary may sell (by public or private sale) sufficient securities and property received in respect of a share distribution, rights and/or other distribution prior to such deposit to pay such charge.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following additional charges shall also be incurred by the ADR holders, the beneficial owners, by any party depositing or withdrawing shares or by any party surrendering ADSs and/or to whom ADSs are issued (including, without limitation, issuance pursuant to a stock dividend or stock split declared by us or an exchange of stock regarding the ADSs or the deposited securities or a distribution of ADSs), whichever is applicable:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a fee of U.S.$1.50 per ADR or ADRs for transfers of certificated or direct registration ADRs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a fee of U.S.$0.05 or less per ADS held for any cash distribution made, or for any elective cash/ stock dividend offered, pursuant to the deposit agreement;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an aggregate fee of U.S.$0.05 or less per ADS per calendar year (or portion thereof) for services performed by the depositary in administering the ADRs (which fee may be charged on a periodic basis during each calendar year and shall be assessed against holders of ADRs as of the record date or record dates set by the depositary during each calendar year and shall be payable in the manner described in the next succeeding provision);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a fee for the reimbursement of such fees, charges and expenses as are incurred by the depositary and/or any of its agents (including, without limitation, the custodian and expenses incurred on behalf of ADR holders in connection with compliance with foreign exchange control regulations or any law or regulation relating to foreign investment) in connection with the servicing of the shares or other deposited securities, the sale of securities (including, without limitation, deposited securities), the delivery of deposited securities or otherwise in connection with the depositary&#8217;s or its custodian&#8217;s compliance with applicable law, rule&#160;or regulation (which fees and charges shall be assessed on a proportionate basis against ADR holders as of the record date or dates set by the depositary and shall be payable at the sole discretion of the depositary by billing such ADR holders or by deducting such charge from one or more cash dividends or other cash distributions);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a fee for the distribution of securities (or the sale of securities in connection with a distribution), such fee being in an amount equal to the $0.05 per ADS issuance fee for the execution and delivery of ADSs which would have been charged as a result of the deposit of such securities (treating all such securities as if they were shares) but which securities or the net cash proceeds from the sale thereof are instead distributed by the depositary to those ADR holders entitled thereto;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">stock transfer or other taxes and other governmental charges;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">cable, telex and facsimile transmission and delivery charges incurred at your request in connection with the deposit or delivery of shares, ADRs or deposited securities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">transfer or registration fees for the registration of transfer of deposited securities on any applicable register in connection with the deposit or withdrawal of deposited securities; and</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">206</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fees of any division, branch or affiliate of the depositary utilized by the depositary to direct, manage and/or execute any public and/or private sale of securities under the deposit agreement.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To facilitate the administration of various depositary receipt transactions, including disbursement of dividends or other cash distributions and other corporate actions, the depositary may engage the foreign exchange desk within JPMorgan Chase Bank, N.A. (the &#8220;Bank&#8221;) and/or its affiliates in order to enter into spot foreign exchange transactions to convert foreign currency into U.S. dollars. For certain currencies, foreign exchange transactions are entered into with the Bank or an affiliate, as the case may be, acting in a principal capacity. For other currencies, foreign exchange transactions are routed directly to and managed by an unaffiliated local custodian (or other third party local liquidity provider), and neither the Bank nor any of its affiliates is a party to such foreign exchange transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The foreign exchange rate applied to a foreign exchange transaction will be either (a)&#160;a published benchmark rate, or (b)&#160;a rate determined by a third party local liquidity provider, in each case plus or minus a spread, as applicable. The depositary will disclose which foreign exchange rate and spread, if any, apply to such currency on the &#8220;Disclosures&#8221; page&#160;(or successor page) of ADR.com. Such applicable foreign exchange rate and spread may (and neither the depositary, the Bank nor any of their affiliates is under any obligation to ensure that such rate does not) differ from rates and spreads at which comparable transactions are entered into with other customers or the range of foreign exchange rates and spreads at which the Bank or any of its affiliates enters into foreign exchange transactions in the relevant currency pair on the date of the foreign exchange transaction. Additionally, the timing of execution of a foreign exchange transaction varies according to local market dynamics, which may include regulatory requirements, market hours and liquidity in the foreign exchange market or other factors. Furthermore, the Bank and its affiliates may manage the associated risks of their position in the market in a manner they deem appropriate without regard to the impact of such activities on the depositary, us, holders or beneficial owners. <i style="font-style:italic;">The spread applied does not reflect any gains or losses that may be earned or incurred by the Bank and its affiliates as a result of risk management or other hedging related activity.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Notwithstanding the foregoing, to the extent we provide U.S. dollars to the depositary, neither the Bank nor any of its affiliates will execute a foreign exchange transaction as set forth herein. In such case, the depositary will distribute the U.S. dollars received from us.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Further details relating to the applicable foreign exchange rate, the applicable spread and the execution of foreign exchange transactions will be provided by the depositary on ADR.com. Each holder and beneficial owner by holding or owning an ADR or ADS or an interest therein, and we, each acknowledge and agree that the terms applicable to foreign exchange transactions disclosed from time to time on ADR.com will apply to any foreign exchange transaction executed pursuant to the deposit agreement.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We will pay all other charges and expenses of the depositary and any agent of the depositary (except the custodian) pursuant to agreements from time to time between us and the depositary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The right of the depositary to receive payment of fees, charges and expenses survives the termination of the deposit agreement, and shall extend for those fees, charges and expenses incurred prior to the effectiveness of any resignation or removal of the depositary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The fees and charges described above may be amended from time to time by agreement between us and the depositary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The depositary may make available to us a set amount or a portion of the depositary fees charged in respect of the ADR program or otherwise upon such terms and conditions as we and the depositary may agree from time to time. The depositary collects its fees for issuance and cancellation of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees. The depositary may collect its annual fee for depositary services by deduction from cash distributions, or by directly billing investors, or by charging the book-entry system accounts of participants acting for them. The depositary will generally set off the amounts owing from distributions made to holders of ADSs. If, however, no distribution exists and payment owing is not timely received by the depositary, the depositary may refuse to provide any further services to ADR holders that have not paid those fees and expenses owing until such fees and expenses have been paid. At the discretion of the depositary, all fees and charges owing under the deposit agreement are due in advance and/or when declared owing by the depositary.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">207</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 10.8pt;">Payments by Depositary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our depositary anticipates to reimburse us for certain expenses we incur in respect of the ADR program established pursuant to the Deposit Agreement, by making available a portion of the ADS fees charged in respect of the ADR program or otherwise, upon such terms and conditions as the Depositary agrees with us from time to time. As of the date of this annual report, we have not received such reimbursement from the depositary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">208</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_41547120_894f_49d2_a87d_d5381b509d83"></a><a id="PARTII_838708"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;II</p><a id="ITEM13ITEMDEFAULTSDIVIDENDARREARAGESANDD"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 13. ITEM DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">None.</p><a id="_359dd067_4c37_48fd_aa10_07e450cda52b"></a><a id="ITEM14MATERIALMODIFICATIONSTOTHERIGHTSOF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS</p><a id="_3218317e_b93d_4e4a_a308_6bbe3a8662bf"></a><a id="a14A14DMaterialModificationstotheRightso"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">14.A. &#8212; 14.D. Material Modifications to the Rights of Security Holders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">See &#8220;Item 10 Additional Information&#8221; for a description of the rights of shareholders, which remain unchanged.</p><a id="_5fc25a72_250c_4ef0_82b9_7f36bedd3b46"></a><a id="a14EUseofProceeds_380361"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">14.E. Use of Proceeds</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following &#8220;Use of Proceeds&#8221; information relates to the registration statement on Form&#160;F-1, as amended (File No.&#160;333- 252210) in relation to our initial public offering, which was declared effective by the SEC on February&#160;8, 2021. In February&#160;2021, we completed our initial public offering in which we issued and sold an aggregate of 8,457,100 ADSs, representing 10,571,375 ordinary shares, resulting in net proceeds to us of approximately US$145.9 million, net of the underwriting discounts and commissions and other fees paid or payable by us in connection with the offering.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The&#160;F-1&#160;Registration Statement was declared effective by the SEC on February 8, 2021. The total expenses incurred for our company&#8217;s account in connection with our initial public offering was approximately US$15.1&#160;million, which included US$11.2&#160;million in underwriting discounts and commissions for the initial public offering and approximately US$3.6&#160;million in other costs and expenses for our initial public offering. We received net proceeds of approximately US$145.9&#160;million from our initial public offering. None of the transaction expenses included payments to directors or officers of our company or their associates, persons owning more than 10% or more of our equity securities or our affiliates. None of the net proceeds from the initial public offering were paid, directly or indirectly, to our directors or officers and persons owning 10% or more of our equity securities or our affiliates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">For the period from the effective date of the registration statement on Form F-1 to December 31, 2021, we used US$31 million of the net proceeds received from our initial public offering primarily for research and development of our product candidates. We still intend to use the remainder of the proceeds from our initial public offering as disclosed in our registration statements on Form&#160;F-1.</p><a id="_64c15efa_ff4e_4a33_907a_351d3f52c897"></a><a id="ITEM15CONTROLSANDPROCEDURES_210978"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 15. CONTROLS AND PROCEDURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has performed an evaluation of the effectiveness of our disclosure controls and procedures (as defined in Rule&#160;13a-15(e)&#160;under the Exchange Act) as of the end of the period covered by this report, as required by Rule&#160;13a-15(b)&#160;under the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Based upon that evaluation, our management has concluded that, as of December&#160;31, 2021, our disclosure controls and procedures were effective in ensuring that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act was recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules&#160;and forms, and that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">209</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. As required by Rule 13a-15(c) of the Exchange Act, our management conducted an evaluation of our company&#8217;s internal control over financial reporting as of December 31, 2021 based on the framework in Internal Control&#8212;Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness of our internal control over financial reporting to future periods are subject to the risks that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Attestation Report of the Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">This annual report on Form&#160;20-F does not include an attestation report of our registered public accounting firm due to a transition period established by rules&#160;of the SEC for newly public companies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Remediation of Previously Reported Material Weaknesses in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As described in our previous annual report on Form 20-F for the fiscal year ended December&#160;31, 2020, our independent registered public accounting firm identified two material weaknesses in our internal control over financial reporting as of December&#160;31, 2020. As defined in standards established by the PCAOB, a &#8220;material weakness&#8221; is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The two material weaknesses that were identified related to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our lack of sufficient and competent financial reporting and accounting personnel with appropriate knowledge of U.S. GAAP and SEC reporting and compliance requirements; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our lack of sufficient documented financial closing policies and procedures, specifically those related to period end expenses cut-off and accruals.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">To remediate our identified material weaknesses, we have implemented the following measures to improve our internal control over financial reporting:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hired more qualified accounting personnel, with relevant U.S. GAAP and SEC reporting experience and qualifications to strengthen the financial reporting function and set up a financial and systematic control framework;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">implemented regular and continuous U.S. GAAP accounting and financial reporting training programs for our accounting and financial reporting personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">set up an internal audit function as well as engaged an external consulting firm to assist us with assessment and improvement of overall internal control so as to fulfill our Sarbanes-Oxley compliance obligations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">prepared comprehensive accounting policies, manuals and closing procedures to optimize our period-end financial closing process and to ensure that consolidated financial statements and related disclosures are in compliance with U.S. GAAP and SEC reporting requirements.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a result of these efforts, our management concluded that the material weaknesses had been remediated as of December 31, 2021.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">210</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We expect that we will continue to incur significant costs in the continuous implementation of such measures. However, we cannot assure you that in the future our management or, if applicable, our independent registered public accounting firm will not identify material weaknesses during Section 404 of the Sarbanes-Oxley Act audit process. See &#8220;Item 3 Key Information&#8212;D. Risk factors&#8212;Risks Relating to Our Operations&#8212; If we fail to implement and maintain an effective system of internal controls, we may be unable to accurately or timely report our results of operations or prevent fraud, and investors&#8217; confidence and the market price of our ADSs may be materially and adversely affected.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Except as described above, there were no changes in our internal control over financial reporting (as defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the Exchange Act) during the period covered by this annual report on Form&#160;20-F that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p><a id="_a835f0e8_0da2_4176_bb29_964e47f58ad2"></a><a id="Item16AAuditCommitteeFinancialExpert_659"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Item 16.A. Audit Committee Financial Expert</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Board of Directors has determined that Mr.&#160;Andy (Yiu Leung) Cheung, an independent director and the chairperson of our audit committee, qualifies as an &#8220;audit committee financial expert&#8221; within the meaning of the SEC rules&#160;and in accordance with applicable Nasdaq Global Market standards. Mr.&#160;Andy (Yiu Leung) Cheung satisfies the &#8220;independence&#8221; requirements of Rule&#160;10A-3 under the Securities Exchange Act of 1934, as amended, and the applicable Nasdaq Global Market standards.</p><a id="_d14d6d00_43db_4b69_956e_d85ed98f81a9"></a><a id="Item16BCodeofEthics_352573"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Item 16.B. Code of Ethics</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our Board of Directors has adopted a code of business conduct and ethics that applies to all of our directors, officers, employees, including certain provisions that specifically apply to our principal executive officer, principal financial officer, principal accounting officer or controller and any other persons who perform similar functions for us. We have filed our code of business conduct and ethics as Exhibit&#160;99.1 of our registration statement on Form&#160;F-1 (File No.&#160;333- 252210), as amended, filed with the SEC on January&#160;19, 2021 and posted a copy of our code of business conduct and ethics on our website at<i style="font-style:italic;"> http://investor.adagene.com</i>. We hereby undertake to provide to any person without charge, a copy of our code of business conduct and ethics within ten working days after we receive such person&#8217;s written request.</p><a id="_d928042e_96be_40d5_a418_5b5e3c352051"></a><a id="Item16CPrincipalAccountantFeesandService"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Item 16.C. Principal Accountant Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Auditor Fees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The following table sets forth the aggregate fees by categories specified below in connection with certain professional services rendered by PricewaterhouseCoopers Zhong Tian LLP, our independent registered public accounting firm, for the periods indicated.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RMB</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RMB</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Services</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Audit Fees(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,300</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,800</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Audit-Related Fees(2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Tax Fees(3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Other Fees(4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 0</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7,300</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 5,800</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Audit Fees</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Audit fees mean the aggregate fees billed in each of the fiscal periods listed for professional services rendered by our principal auditors for the audit of our annual consolidated financial statements and assistance with and review of documents filed with the SEC.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Audit-related Fees.</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Audit-related fees mean the aggregate fees billed for professional services rendered by our principal auditors for the assurance and related services, which were not included under Audit Fees above.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Tax Fees</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Tax fees mean fees incurred from professional services related to tax compliance.</span></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">211</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Other Fees</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. Other fees mean fees incurred from professional services related to training, advisory and assurance for corporate and social responsibility reporting and professional services related to tax advice.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The policy of our audit committee is to pre-approve all audit and non-audit services provided by PricewaterhouseCoopers Zhong Tian LLP, our independent registered public accounting firm, including audit services and audit-related services as described above, other than those for de minimis services which are approved by the audit committee prior to the completion of the audit.</p><a id="_04d9d7a4_8523_409b_a308_25b295a2a65a"></a><a id="a16DExemptionsfromtheListingStandardsfor"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">16.D. Exemptions from the Listing Standards for Audit Committees</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p><a id="_02583434_872e_4175_aae5_93fca8b87080"></a><a id="a16EPurchasesofEquitySecuritiesbytheIssu"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">16.E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">On July 7, 2021, our board of directors authorized a share repurchase program whereby our company was authorized a share repurchase program under which the Company may repurchase up to US$20.0 million of its ordinary shares in the form of American depositary shares during a period of up to 12 months commencing on July 7, 2021 (the &#8220;Share Repurchase Program&#8221;). The Company&#8217;s share repurchases may be made from time to time on the open market at prevailing market prices, in open-market transactions, privately negotiated transactions or block trades, and/or through other legally permissible means, depending on market conditions and in accordance with the applicable rules and regulations. The timing and conditions of the share repurchases will be subject to various factors including the requirements under Rule 10b-18 and Rule 10b5-1 of the Exchange Act. Our board of directors will review the share repurchase program periodically and may authorize adjustments to its terms and size or suspend or discontinue the program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The following table summarizes the details of the repurchases made in accordance with the Share Repurchase Program from July 7, 2021 to March 31, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Approximate&#160;Dollar&#160;Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total&#160;Number&#160;of&#160;ADSs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">of&#160;ADSs&#160;that&#160;May&#160;Yet&#160;Be</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total&#160;Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average&#160;Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Purchased&#160;as&#160;Part&#160;of&#160;the</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Purchased&#160;Under&#160;the&#160;Plan</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ADSs&#160;Purchased</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid&#160;Per&#160;ADS</b><sup style="font-size:6pt;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Publicly&#160;Announced&#160;Plan</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(US$in&#160;thousand)</b></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">July 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">August 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">September 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">October 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 60,149</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 11.9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 60,149</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 19,285</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">November 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 74,959</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 10.6</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 74,959</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 18,488</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">December 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 106,380</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 8.5</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 106,380</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,590</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">January 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 53,011</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 7.9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 53,011</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 17,171</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">February 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 35,749</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 6.9</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 35,749</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 16,923</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">March 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 204,559</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 4.7</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 204,559</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="white-space:pre-wrap;"> 15,992</span></p></td></tr><tr><td style="vertical-align:bottom;width:40.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 534,807</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 8.2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 534,807</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> 15,992</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Notes:</p><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;">(1)</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;">Each ADS representing one and one quarter ordinary shares. Average price paid per ADS is calculated using the execution price for each repurchase excluding commissions paid to the broker.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_f54c1790_4048_4b89_ba2b_f07712917251"></a><a id="a16FChangeinRegistrantsCertifyingAccount"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">16.F. Change in Registrant&#8217;s Certifying Accountant</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Not applicable.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">212</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8843fcd8_64da_485a_93ad_1bc60ad80101"></a><a id="a16GCorporateGovernance_85646"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">16.G. Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">As a Cayman Islands exempted company listed on Nasdaq Stock Market, we are subject to the Nasdaq corporate governance listing standards. However, Rule 5615 of the Nasdaq Rules permits a foreign private issuer like our company to follow home country practice in lieu of certain corporate governance matters as required under Rule 5600 Series, Rule 5250(b)(3) and Rule 5250(d) of the Nasdaq Rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">Certain corporate governance practices in the Cayman Islands, which is our home country, may differ significantly from the Nasdaq corporate governance listing standards. We elect to rely on home country practice exemption in lieu of the requirements of the Rule 5600 Series of the Nasdaq Rules, except the following: compliance with the Notification of Noncompliance requirement (Rule 5625), the Voting Rights requirement (Rule 5640), the Diverse Board Representation Rule (Rule 5605(f)), the Board Diversity Disclosure Rule (Rule 5606), having an audit committee that satisfies Rule 5605(c)(3), and ensuring that such audit committee&#39;s members meet the independence requirement in Rule 5605(c)(2)(A)(ii).  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">In particular, we relied on home country practice exemption with respect to Rule 5620(a) of the Nasdaq Rules, which requires a Nasdaq-listed company to hold an annual meeting of Shareholders no later than one year after the end of the company&#39;s fiscal year-end and we did not hold an annual shareholders meeting in 2021. We may, however, hold annual shareholder meetings in the future if there are significant issues that require shareholders&#8217; approvals. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We elected to follow home country practice exemption and be exempt from the requirements to obtain shareholder approval for (1) certain acquisitions of the stock or assets of another company under Rule 5635(a) of the Nasdaq Rules, (2) the issuance of securities when the issuance or potential issuance will result in a change of control of the Company under Rule 5635(b) of the Nasdaq Rules, (3) the issuance of securities when a stock option or purchase plan is to be established or materially amended or other equity compensation arrangement made or materially amended under Rule 5635(c) of the Nasdaq Rules, and (4) the issuance of 20% or more of its outstanding ordinary shares under Rule 5635(d) of the Nasdaq Rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We relied on our home country practice exemption with respect to Rule 5605(d)(2) of the Nasdaq Rules, which requires a Nasdaq-listed company to establish a compensation committee comprised entirely of independent directors and two out of three members of our compensation committee are independent directors. We relied on our home country practice exemption with respect to Rule 5605(e)(1) of the Nasdaq Rules, which requires a Nasdaq-listed company to nominate director nominees either by a majority independent board or by a nominations committee comprised solely of independent directors and we do not have a majority independent board or a nominations committee comprised solely of independent directors. We relied on our home country practice exemption with respect to Rule 5250(b)(3) of the Nasdaq Rules, which requires a Nasdaq-listed company to disclose third party director and nominee compensation no later than when the companies files its next Form 20-F and we did not disclose such information in the form of 20-F for the year of 2020 and 2021. We may also opt to rely on additional home country practice exemptions in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Walkers (Hong Kong), our Cayman Islands counsel, has provided a letter to the Nasdaq Stock Market certifying that under Cayman Islands law, we are not required to comply with abovementioend requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Our shareholders may be afforded less protection than they otherwise would under the Nasdaq Global Market corporate governance listing standards applicable to U.S. domestic issuers. See &#8220;Item 3 Key Information&#8212;D. Risk Factors&#8212;Risks Related to the ADSs&#8212;As an exempted company incorporated in the Cayman Islands, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ significantly from the Nasdaq listing standards; these practices may afford less protection to shareholders than they would enjoy if we complied fully with the Nasdaq listing standards.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><a id="_ad28e863_2249_4bb2_8bae_f4b48c778dd9"></a><a id="a16HMineSafetyDisclosure_791076"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">16.H. Mine Safety Disclosure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">Not applicable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:18pt;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">213</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7841ffbf_a300_42b6_b6d1_ecad46882e83"></a><a id="PARTIII_403713"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">PART&#160;III</p><a id="ITEM17FINANCIALSTATEMENTS_534522"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 17. FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">We have elected to provide financial statements pursuant to Item 18.</p><a id="_6dfacb10_9d12_4513_96d7_9c670caf7883"></a><a id="ITEM18FINANCIALSTATEMENTS_506735"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 18. FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Our consolidated financial statements are included at the end of this annual report.</p><a id="_d5b1dfba_d18b_492d_83ef_0685aacc102d"></a><a id="ITEM19EXHIBITS_246848"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ITEM 19. EXHIBITS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br /><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description&#160;of&#160;Document</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">1.1</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-3_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Seventh Amended and Restated Memorandum and Articles of Association of the Registrant, as currently effective (incorporated by reference to Exhibit&#160;3.2 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2.1</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-4_3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Registrant&#8217;s Specimen American Depositary Receipt ((incorporated by reference to Exhibit&#160;4.3 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021))</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2.2</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-4_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registrant&#8217;s Specimen Certificate for Ordinary Shares (incorporated by reference to Exhibit&#160;4.2 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2.3</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-4_3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Deposit Agreement between the Registrant, the depositary and holders of the American Depositary Shares (incorporated by reference to Exhibit&#160;4.3 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2.4</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-4_4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amended and Restated Shareholders Agreement by and among Adagene Inc. and shareholders of Adagene Inc. named therein dated December&#160;19, 2019 (incorporated by reference to Exhibit&#160;4.4 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">2.5</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000110465921055911/a21-12293_1ex2d5.htm#Exhibit2_5_081725"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Registrant&#8217;s Securities</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.1</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-4_5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amended and Restated Right of First Refusal and Co-Sale Agreement by and between Adagene Inc., non-investor shareholders and investors named therein dated December&#160;19, 2019 (incorporated by reference to Exhibit&#160;4.5 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.2</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Adagene Inc. Second Amended and Restated Share Incentive Plan (incorporated by reference to Exhibit&#160;10.1 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.3</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Indemnification Agreement between the Registrant and each of its directors and executive officers (incorporated by reference to Exhibit&#160;10.2 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.4</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form&#160;of Employment Agreement between the Registrant and an executive officer of the Registrant (incorporated by reference to Exhibit&#160;10.3 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.5</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Shares Purchase Agreement by and among Adagene Inc., its subsidiaries and General Atlantic Singapore AI Pte. Ltd. dated October&#160;15, 2019 (incorporated by reference to Exhibit&#160;10.4 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.6</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Shares Purchase Agreement by and among Adagene Inc., its subsidiaries and certain investors of Adagene Inc. named therein dated June&#160;9, 2019 (incorporated by reference to Exhibit&#160;10.5 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.7</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Shares Purchase Agreement by and among Adagene Inc., its subsidiaries and certain investors of Adagene Inc. named therein dated February&#160;2, 2018 (incorporated by reference to Exhibit&#160;10.6 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">214</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br /><b style="font-weight:bold;">Number</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description&#160;of&#160;Document</b></p></th></tr><tr><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></th><th style="font-weight:normal;text-align:left;vertical-align:bottom;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></th></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.8</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">English translation of Cooperation Agreement on the PD-L1 Project by and among Guilin Sanjin Pharmaceutical Co.,&#160;Ltd. and its affiliates and Adagene (Suzhou) Limited dated December&#160;2018 (incorporated by reference to Exhibit&#160;10.7 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.9</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">English translation of Cooperation Agreement on International Interests of PD-L1 Project between Guilin Sanjin Pharmaceutical Co.,&#160;Ltd. and Adagene Inc. dated December&#160;2018 (incorporated by reference to Exhibit&#160;10.8 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.10</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">English translation of Cooperation Agreement on the Undisclosed Project between Dragon Boat Biopharmaceutical (Shanghai) Limited and Adagene (Suzhou) Limited dated May&#160;2019 (incorporated by reference to Exhibit&#160;10.9 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.11</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">English translation of Cooperation Agreement on International Interests of Undisclosed Project between Dragon Boat Biopharmaceutical (Shanghai) Limited and Adagene Inc. dated May&#160;2019 (incorporated by reference to Exhibit&#160;10.10 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.12</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Material Transfer and Collaboration Agreement between ADC Therapeutics SA and Adagene Inc. dated April&#160;11, 2019 (incorporated by reference to Exhibit&#160;10.11 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.13</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement Among ADC Therapeutics SA and Adagene Inc. dated April&#160;11, 2019 (incorporated by reference to Exhibit&#160;10.12 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.14</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-10_13.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Adagene Inc. 2021 Performance Incentive Plan (incorporated by reference to Exhibit&#160;10.13 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.15</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000233/a2242824zex-10_14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Collaboration and License Agreement between Exelixis,&#160;Inc. and Adagene Incorporated dated February&#160;1, 2021 (incorporated by reference to Exhibit&#160;10.14 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">4.16* &#8224; #</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="adag-20211231xex4d16.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Collaboration and License Agreement between Adagene Incorporated and Genzyme Corporation dated February 25, 2022</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">8.1*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="adag-20211231xex8d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">List of subsidiaries of the Registrant</span></a> </p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">11.1</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/1818838/000104746921000130/a2242683zex-99_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Code of Business Conduct and Ethics of the Registrant (incorporated by reference to Exhibit&#160;99.1 from our registration statement on Form&#160;F-1 (File No.&#160;333-252210), as amended, initially filed publicly with the SEC on January&#160;19, 2021)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">12.1*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="adag-20211231xex12d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification by Principal Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">12.2*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="adag-20211231xex12d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification by Principal Accounting Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">13.1**</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="adag-20211231xex13d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification by Principal Executive Officer Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">13.2**</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="adag-20211231xex13d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification by Principal Accounting Officer Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">15.1*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="adag-20211231xex15d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Tian Yuan Law Firm</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">15.2*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="adag-20211231xex15d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Walkers (Hong Kong)</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">15.3*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="adag-20211231xex15d3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Gr</span><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">eenberg </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Tr</span><span style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">aurig</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">15.4*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;" href="adag-20211231xex15d4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of PricewaterhouseCoopers Zhong Tian LLP,&#160;Independent Registered Public Accounting Firm</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.INS*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">XBRL Instance Document</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.SCH*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.CAL*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.DEF*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.LAB*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">XBRL Taxonomy Extension Label Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">101.PRE*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">104*</p></td><td style="vertical-align:bottom;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">*&#160;&#160;&#160;&#160;&#160;Filed herewith</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">**&#160;&#160;&#160;Furnished herewith</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">215</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Portions of this exhibit have been omitted in accordance with Item 601(b)(10)(iv) of Regulation S-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;">#&#160;&#160;&#160;&#160;&#160;Certain of the appendices, annexes, exhibits and/or schedules to this exhibit have been omitted in accordance with Regulation S-K Item 601(b)(2). The Registrant agrees to furnish supplementally a copy of all omitted exhibits and schedules to the SEC upon its request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:18pt;text-indent:-18pt;margin:0pt;"><span style="line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">216</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_54484b64_8912_4082_9893_54e7d5838b1d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt;">The registrant hereby certifies that it meets all of the requirements for filing its annual report on Form&#160;20-F and that it has duly caused and authorized the undersigned to sign this annual report on its behalf.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Date: April&#160;26, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:41.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="4" style="vertical-align:top;width:55.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;Adagene&#160;Inc.</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:top;width:55.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:top;width:55.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">By:</p></td><td style="vertical-align:top;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:49.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">/s/ PETER (PEIZHI) LUO</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.61%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:41.23%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Peter (Peizhi) Luo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:3.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;font-style:italic;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:41.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><i style="font-style:italic;">Chief Executive Officer</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;font-style:italic;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_895e212a_cfd9_422e_a059_14532d45dbfe"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS</p><a id="_Hlk99691491"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:98.32%;"><tr><td style="vertical-align:bottom;width:91.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:5.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:91.53%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#ReportofIndependentRegisteredPublicAccou"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a><span style="font-size:10pt;"> (PCAOB ID: </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:AuditorFirmId" id="Narr_ZIxG7DyZxE2l8B8_Q2h_RA"><span style="font-size:10pt;">1424</span></ix:nonNumeric><span style="font-size:10pt;">)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.9%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-2</p></td></tr><tr><td style="vertical-align:bottom;width:91.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#CONSOLIDATEDBALANCESHEETS_305472"><span style="font-style:normal;font-weight:normal;">Consolidated Balance Sheets as of December 31, 2020 and 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-3</p></td></tr><tr><td style="vertical-align:bottom;width:91.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOS"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Comprehensive Loss for the Years Ended December 31, 2019, 2020 and 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-4</p></td></tr><tr><td style="vertical-align:bottom;width:91.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHO"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Changes in Shareholders&#8217; Equity/(Deficit) for the Years Ended December 31, 2019, 2020 and 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-5</p></td></tr><tr><td style="vertical-align:bottom;width:91.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#CONSOLIDATEDSTATEMENTSOFCASHFLOWS_933280"><span style="font-style:normal;font-weight:normal;">Consolidated Statements of Cash Flows for the Years Ended December 31, 2019, 2020 and 2021</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-6</p></td></tr><tr><td style="vertical-align:bottom;width:91.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><a style="font-size:10pt;" href="#NOTESTOTHECONSOLIDATEDFINANCIALSTATEMENT"><span style="font-style:normal;font-weight:normal;">Notes to the Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">F-7</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-1</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_469b5f88_018c_426c_a8d7_fabf2ba3dcf9"></a><a id="ReportofIndependentRegisteredPublicAccou"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">Report of Independent Registered Public Accounting Firm</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">To the Board of Directors and Shareholders of Adagene Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Opinion on the Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying consolidated balance sheets of Adagene Inc. and its subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2021 and 2020, and the related consolidated statements of comprehensive loss, of changes in shareholders&#8217; equity (deficit) and of cash flows for each of the three years in the period ended December&#160;31, 2021, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2021 in conformity with accounting principles generally accepted in the United States of America.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Basis for Opinion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#39;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">/s/ </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:AuditorName" id="Narr_j54lfo8CHU-fqhsW8EgbuA"><span style="font-size:10pt;">PricewaterhouseCoopers Zhong Tian&#160;LLP</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="dei:AuditorLocation" id="Narr_5Cci7cu73keySIAWfnw94w"><span style="font-size:10pt;">Shanghai, the People&#8217;s Republic of China</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">April 26, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">We have served as the Company&#8217;s auditor since 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;margin:0pt;"><span style="font-size:10pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_51f1ff4b_9b6a_4285_8f66_fc36470f8f45"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;">ADAGENE INC.</p><a id="CONSOLIDATEDBALANCESHEETS_305472"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;">CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;">AS OF DECEMBER 31, 2020 AND 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_18c1d574_9f07_43eb_833f_a93411c728a2"></a><a id="Tc_UHJ4ugo8IEulJRLq2tgykw_1_4"></a><a id="Tc_AVB95YkzwU6O_WXdGEXvyA_2_2"></a><a id="Tc_oaTkn6yAYEahFwXu2WUdJQ_2_4"></a><a id="Tc_WNVBSPJPik2JszSqGXgHRw_2_6"></a><a id="Tc_WAoeO86l8kO1AYZNr3CE4Q_3_4"></a><a id="Tc_ABr6JjlijU-NdTS30GQaQg_3_6"></a><a id="Tc_6qlaAV_6qky0HFKQJstiHg_4_0"></a><a id="Tc_m3Yem_M7vE22gU0siMF_iQ_5_0"></a><a id="Tc_r4AOArG6pk-PIom7mWbKRA_6_0"></a><a id="Tc_lq9aRw0-0EO2BN0jAuGoOw_7_0"></a><a id="Tc_9toEeJepDkGRKIMDwhUySg_7_2"></a><a id="Tc_nw6hQmFLSE2rF_MO1YvzEQ_7_4"></a><a id="Tc_g18V5cFjLEW-efK_kZ7Jzg_8_0"></a><a id="Tc_NogN-0yRPE-CsC9iBXY9ow_8_2"></a><a id="Tc_enDxTMk_TUC4Ywf3mtM2dw_9_0"></a><a id="Tc_XVk4C3Sm1UWqc4yXGvMxRw_9_2"></a><a id="Tc_jh3oBbFe3keZR5CfMJTAqA_10_0"></a><a id="Tc_NsLaB6Kjx0mVejQreiWnyQ_11_0"></a><a id="Tc_YRuooU29TEqNe5btXvloQA_11_2"></a><a id="Tc_Ppwx32Qhc0ei_41u8WQ3bQ_12_0"></a><a id="Tc__wf8DuU4kk2wE-mLvq5Esg_13_0"></a><a id="Tc_PrMTykHuQkyW3Uf2veHjEw_14_0"></a><a id="Tc_nbpWT_qPaU-hfwKzJ4S6qA_15_0"></a><a id="Tc_UU4Z0uP9kUWyLRlPPnFBOg_16_0"></a><a id="Tc_9tBKuVChHUuibI6g3QDmew_17_0"></a><a id="Tc_TahnAOZtE0Kfe4foUCOjxw_18_0"></a><a id="Tc_A4LbhgKsokyziGzTsGuT6g_18_2"></a><a id="Tc_TA8jgl0F3U-KE-mj3QVRxQ_19_0"></a><a id="Tc_i6Nf_uRlH0iDuZeGxNxAsA_19_2"></a><a id="Tc_1kRMaIWIwUSeWCJJ6WvVcQ_20_0"></a><a id="Tc_Ld8ih8Ba_Uqvc0dLbBXKAg_20_2"></a><a id="Tc_Wb9aJmZIWEeMIuWdS9lPBw_20_4"></a><a id="Tc_1lCEX9WJeUCVN86ZSpgLpA_21_0"></a><a id="Tc_ln0hA7u5r0SzOQ6ULuNUWA_21_2"></a><a id="Tc_845flp6L1E-PuDBthsFQzg_22_0"></a><a id="Tc_g3UB7vZrOk-PEmo6nzx2Yw_22_2"></a><a id="Tc_VvhqXHyurUmF-ehrO0AQFw_23_0"></a><a id="Tc_X13-kHBGlUeQI0DcYI3YiQ_24_0"></a><a id="Tc_phLVP-tjp0OGnVxVSLhhjg_24_2"></a><a id="Tc_8UevGwlurEaMyDoMx90CTQ_25_0"></a><a id="Tc_gyrheHTcAEGsPbgt_dbTrg_25_2"></a><a id="Tc_6LzUodXDJEOTZj3rETg5pg_25_4"></a><a id="Tc_LRjqzK4znkiGU0tSJ7ioBQ_26_0"></a><a id="Tc_TSLSGrj4nU6y9KFQaBYolw_27_0"></a><a id="Tc_KpmlUbHpj0qEsdAE144g7g_28_0"></a><a id="Tc_FT_EgLUvTk6Gri1d2-9ltA_28_2"></a><a id="Tc_2PkRONqcMUWahoNNpOpogQ_29_0"></a><a id="Tc_6GSFPDIorkaetc0mOs3IOw_30_0"></a><a id="Tc_YDA5sVznRUS_GvC17ZhrVQ_30_2"></a><a id="Tc_VDYr_-BUQU2fRbgzDiJkZQ_31_0"></a><a id="Tc_YoS07HfCvUCoVIY6kAx_MQ_31_6"></a><a id="Tc_ZFLsc6D0JkaQCxUfvFFALw_32_0"></a><a id="Tc_d5SXkZ4wBUGxWKnL92LIpw_32_6"></a><a id="Tc_E-ASnYKFE0utMKjFTKbnrA_33_0"></a><a id="Tc_cmjttUg5c0Km53TmF91Zww_33_6"></a><a id="Tc_Z2IXIkZmIEa1fRgfsUyhfw_34_0"></a><a id="Tc_keB9vZjXiE6qgszm2zZ-ig_34_6"></a><a id="Tc_IpKVVYCR-0q_baVi8qIDWw_35_0"></a><a id="Tc_FwoB3jXeWEuf2flsjBYy1A_35_6"></a><a id="Tc_4ZNxS78pREGT40jNaoEBHw_36_0"></a><a id="Tc_MF5Q96Rj406Rh98aW-Tygg_36_6"></a><a id="Tc_G7D3sujkl0iGTg0N3FYhDQ_37_0"></a><a id="Tc_qzHAbb0M60SJX527KlbtNA_37_6"></a><a id="Tc_-5M3El3glkagzuYz6WajGg_38_0"></a><a id="Tc_yIv6ns6c7EiByyjCMVrxfg_39_0"></a><a id="Tc_G-b0Nvv8u0-XxftAmbnR5w_40_0"></a><a id="Tc_Ac9gTuOUrkycCsDwOK6aUQ_40_2"></a><a id="Tc_88lpp6UsLUW6PlJir9aAcQ_40_4"></a><a id="Tc_ZUxpEBpSEE6wewZatqOznA_41_0"></a><a id="Tc_Dwu7yhuuiUq8wOA-rgxLlA_41_6"></a><a id="Tc_0-JcvUjJcEunDzcz8X5QVw_42_0"></a><a id="Tc_0oTaERTMd0-hF5q-sT-TGA_43_0"></a><a id="Tc_NJEwEeBpYkK4HATRY7-Tbw_44_0"></a><a id="Tc_a1CKGYolBkSmQ_dX2ysftg_45_0"></a><a id="Tc_kGxrQNVtKkyAdI8vs1Svrg_46_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_QTYJau5e1U6ahZI_0H-BZQ_6_4">75,150,998</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_5sVZT02gMU6SCvMqeC-AAQ_6_6">174,391,243</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accounts receivable, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">3, 10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="Tc_nohmvVJAu0mswsEOwPP-DA_7_6">3,000,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Amounts due from related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" id="Tc_KBdMK_DXAka4C6ZD68x_Rw_8_4">132,396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" id="Tc_rDYc0DKQ1UW3vncEt92l-w_8_6">4,506,670</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Prepayments and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_oFt7yeoFSUCPs6RGpvXf5g_9_4">3,813,984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_erulwkCS0kOLZDZVZB7f9Q_9_6">4,055,921</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_8JetyXTpvkS6a8sSC7kWxA_10_4">79,097,378</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_IHs86t2gkkuX3XrcZNRsnQ_10_6">185,953,834</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Property, equipment and software, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_KOfIVN5rZE-bdOpfzUNYrA_11_4">2,067,125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_CXgAcig88UeINXX-swQZTg_11_6">3,487,617</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="Tc_dQdBIXlEhEu8IG1Iv_g-Nw_12_4">3,098,234</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="0" id="Tc_wIt3sY26JEOtJxkpjRsZWA_12_6">69,275</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_0Wj5Fo2mOEObsiRGNZWfdQ_13_4">84,262,737</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_RNZQBpYxOU-LbfOK21Lzug_13_6">189,510,726</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS&#8217; DEFICIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_PCSgZNUAfUuMvy4lIK8aFg_16_4">1,809,975</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_yoxscIeqZkOkudyKHtJw9Q_16_6">3,321,615</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="Tc_ONdBhkWUMkCMoPxji8s6ng_17_4">725,536</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="0" id="Tc_GErTH05IZ0iCp3Uvw7EEzA_17_6">5,500,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Amounts due to related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Tc_Q5ER2dsMR0iRs7hAM2M1cg_18_4">2,535,358</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Tc_UPu8Y8QTc0y6V_KizCWjIQ_18_6">10,466,061</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accruals and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="adag:AccruedLiabilitiesAndOtherCurrentLiabilities" scale="0" id="Tc_lbigodW5i0SOWmzWZYw1xg_19_4">6,059,497</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="adag:AccruedLiabilitiesAndOtherCurrentLiabilities" scale="0" id="Tc_jexEs2ojZku9texn_D0AFQ_19_6">4,379,243</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="0" id="Tc_DTN0fe9_LEGtkMtjUEJjFg_20_6">1,657,450</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Short-term borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="0" id="Tc_Dxyd8FoFiUGqyN7DLny-Cw_21_4">3,831,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="0" id="Tc_jfjqHMRvckCA93UoZLAiyA_21_6">3,121,226</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Current portion of long-term borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Tc_eu-C7i93g0aB3rZSAX5Kgw_22_4">1,183,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Tc_OWmGqo78nEKXKxyooxbO4Q_22_6">1,376,319</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total current liabilities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_63_wSY3QqEKHA-VVgc60qQ_23_4">16,145,768</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="0" id="Tc_ZxbZs4BgYkub-mH8_3njww_23_6">29,821,914</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Long-term borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="0" id="Tc_Xi8YjOKvEEKRj4Fd8n-hAw_24_4">2,965,563</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="0" id="Tc_3udF4i0nU0q555LWR7-QsA_24_6">2,991,829</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" id="Tc_Y1pMJYmue02awa_njB1B5A_25_6">44,163</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="Tc_UVfKWJ937kqIGgyrwMi-ww_26_4">91,955</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="0" id="Tc_bWmft4L4JUipBvNFinWYrw_26_6">94,107</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_l0viX9F8qUW6q44wUbSCHg_27_4">19,203,286</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_7fD3OUEA3EOZQCNeuUcJeg_27_6">32,952,013</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Commitments and contingencies</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS&#8217; DEFICIT (CONTINUED)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Mezzanine equity:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;">Series A-1 convertible redeemable preferred shares (par value of US</span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Fqi_V4t6y0-puYQ1ivg6DQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_lP5o0wSH8EKHWE1PZwBH_A"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Yic_H5pK-Ue4BHoUzpGweQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_YjpXL_GBQUKCUZHMwGmgNw">0.0001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> per share; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Fqi_V4t6y0-puYQ1ivg6DQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_k7xJEdK4eEaGomj1ZuLUAQ">5,473,957</ix:nonFraction></span><span style="font-size:8pt;"> shares and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Yic_H5pK-Ue4BHoUzpGweQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_W_RurI2ohkGmHQWFXAK_BA">nil</ix:nonFraction></span><span style="font-size:8pt;"> authorized, </span><span style="-sec-ix-hidden:Hidden_VENfoXbPC061Bzk81pVbqA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_QEvgf1yxAEqLh9b8UjGxBA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;"> as of December 31, </span><span style="-sec-ix-hidden:Hidden_1DC4-oxGy0e0-KBQVfIJBw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">2020</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_4kmxjAvEPk2yQwJB4UYeqQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">2021</span></span><span style="font-size:8pt;">, respectively)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Fqi_V4t6y0-puYQ1ivg6DQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_nVDaGwfT806Wh_Klj-t5wg_31_4">5,473,957</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;">Series A-2 convertible redeemable preferred shares (par value of US</span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_4ehewyms1Eme4lR1LfryGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_7BrkeP9aOkm4yhtnZyu-rg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_b-r3H9b28Ey8YCwkcUjTkw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_JW2N7n9XZEmwB3ZLEsuqnQ">0.0001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> per share; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_4ehewyms1Eme4lR1LfryGQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_hLbLWkOoXUCQDNJeHoJK2w">2,370,414</ix:nonFraction></span><span style="font-size:8pt;"> shares and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_b-r3H9b28Ey8YCwkcUjTkw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_58im2oOrD0Gm8oT3IAI5NQ">nil</ix:nonFraction></span><span style="font-size:8pt;"> authorized, </span><span style="-sec-ix-hidden:Hidden_fH5899ZKkEmYwyakW595Rg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_JLyVXrR8sEuV8mnmCK1K2w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;"> as of December 31, </span><span style="-sec-ix-hidden:Hidden_nDK_8hmoukyOeCQJGfI27Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">2020</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_RF_o9M8JfUuM8iJOj7KzuQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">2021</span></span><span style="font-size:8pt;">, respectively)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_4ehewyms1Eme4lR1LfryGQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_qatqKJb8TUqqXjrIhatCOA_32_4">3,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;">Series B convertible redeemable preferred shares (par value of US</span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_myF8ybzw20G2z_xDQJRE5Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_HCXvJmqV7UqUTa51d1RLSg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_Uvvs-PCSRkiaKVDtX3E5sQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_VzqqOWRzPUmsplXKIHE-uA">0.0001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> per share; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_myF8ybzw20G2z_xDQJRE5Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_dc3Mnne5hEWrsHa94wVbWg">7,494,537</ix:nonFraction></span><span style="font-size:8pt;"> shares and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_Uvvs-PCSRkiaKVDtX3E5sQ" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_k2B5gxkXRkyPfG2sc5UXSA">nil</ix:nonFraction></span><span style="font-size:8pt;"> </span><span style="-sec-ix-hidden:Hidden_k8YAQyxbe0W4LNbcRCzReQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">authorized</span></span><span style="font-size:8pt;">, </span><span style="-sec-ix-hidden:Hidden_Ujn6nO5i60WmgbpVHu8L6g;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_C4hibs_km0W0n4vCRJwCyw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;"> as of </span><span style="-sec-ix-hidden:Hidden_CM3VYilgek6jumNumo7jMA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">December 31, 2020</span></span><span style="font-size:8pt;"> and 2021, respectively)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_myF8ybzw20G2z_xDQJRE5Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_2oCnpr8jLEmV_FhYGJKviQ_33_4">27,999,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;">Series C-1 convertible redeemable preferred shares (par value of US</span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_he2uy54CEUGAjR10ESXHnw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_822k5d-lGkKKEu7sSy9uzg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_AdBejOP9vk6p3isk1DREwg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_ZNVI0_zkgU2_KswbqeRjBg">0.0001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> per share; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_he2uy54CEUGAjR10ESXHnw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_3mKmOIaoNkiKG9C76icXAA">5,597,354</ix:nonFraction></span><span style="font-size:8pt;"> shares and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_AdBejOP9vk6p3isk1DREwg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_g2J-lBAuJ06SWV4aCG2eZA">nil</ix:nonFraction></span><span style="font-size:8pt;"> </span><span style="-sec-ix-hidden:Hidden_-stUpPtT602sN50jfcM6bQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">authorized</span></span><span style="font-size:8pt;">, </span><span style="-sec-ix-hidden:Hidden_JKoEN2tDO0abKAYkMiyMhQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_U4bKB1bdKE2KKF0DOPSivA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;"> as of </span><span style="-sec-ix-hidden:Hidden_lWPSxiRXVESkOsTlb6pViQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">December 31, 2020</span></span><span style="font-size:8pt;"> and 2021, respectively)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_he2uy54CEUGAjR10ESXHnw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_bWzcCfIJhU68tHlizZ-RiQ_34_4">48,975,456</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;">Series C-2 convertible redeemable preferred shares (par value of US</span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_di_bFxD70EWwEtdspmZWRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_3-kcJysH4E68nwyS1YfPhA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_yz5fD7wsz0K_dYLM59ooPw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_GKi3TuH0e02gl6HB1K7Svg">0.0001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> per share; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_di_bFxD70EWwEtdspmZWRw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_2DTSA4Cbb0KJ9Srne1w6rw">1,861,121</ix:nonFraction></span><span style="font-size:8pt;"> shares and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_yz5fD7wsz0K_dYLM59ooPw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_218kZGazKk61DRyBJw_lgw">nil</ix:nonFraction></span><span style="font-size:8pt;"> </span><span style="-sec-ix-hidden:Hidden_ZFF7xARedUCS8PewaKNanQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">authorized</span></span><span style="font-size:8pt;">, </span><span style="-sec-ix-hidden:Hidden_endl8IoTH0O3K-aS-8m02w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_6xw84MWAzEeKSGIAjkDJlA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;"> as of </span><span style="-sec-ix-hidden:Hidden_ZZZ6KNvyvUCF2u7hjt9r2w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">December 31, 2020</span></span><span style="font-size:8pt;"> and 2021, respectively)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_di_bFxD70EWwEtdspmZWRw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_Dvc8Q6l_oEy5CKq5nPzNwQ_35_4">18,999,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;">Series C-3 convertible redeemable preferred shares (par value of US</span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_EFH-DFpj80mpuyw7v7-SrQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_HFjT1SwpHkmw9qyDeaKfyA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_BeGIQu5lxUuigOpTULuf_g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="Narr_UrMbT90RT06u-rxVU29fcg">0.0001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> per share; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_EFH-DFpj80mpuyw7v7-SrQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_go0eYaJxwEuyQEBp8FdOSw">4,452,441</ix:nonFraction></span><span style="font-size:8pt;"> shares and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_BeGIQu5lxUuigOpTULuf_g" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="Narr_c5Wz0gRPv0GFKz1mK24Bhw">nil</ix:nonFraction></span><span style="font-size:8pt;"> </span><span style="-sec-ix-hidden:Hidden_3HsWhAnamUSYk6toX8wDkw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">authorized</span></span><span style="font-size:8pt;">, </span><span style="-sec-ix-hidden:Hidden_coidT8_no0y69VNki9JaoQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_ca9NT4ulY0m7Yx2D4afc4w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;"> as of </span><span style="-sec-ix-hidden:Hidden_aLT9LyQmbkKGiAvNLS69LA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">December 31, 2020</span></span><span style="font-size:8pt;"> and 2021, respectively)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_EFH-DFpj80mpuyw7v7-SrQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_rmcNWMwo-EWZ5oehpExO-A_36_4">50,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total mezzanine equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_fw58OapFdkOiaT8aNbPgPw_37_4">154,449,407</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> &#8212;</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shareholders&#8217; equity (deficit):</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;">Ordinary shares (par value of US</span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_A6jvkQJWSkeLo5M5IBQHJw"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_78nMqU9B7Eq-ln0ZlO6dUA">0.0001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> per share; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_lgyT-qJX4keYnzqrRkhR-g">640,000,000</ix:nonFraction></span><span style="font-size:8pt;"> shares authorized, and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_zeTSS8-09U6u0dZV_SdFTQ">16,603,070</ix:nonFraction></span><span style="font-size:8pt;"> shares issued and </span><span style="-sec-ix-hidden:Hidden_SxmNMOLwwke2qPy39angXQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;"> as of December 31, 2020; and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_TtarQTE3JUW8o7saYzzphg">640,000,000</ix:nonFraction></span><span style="font-size:8pt;"> shares authorized, </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_QC4s3TUvLkiEMK0S-LuUng">54,595,667</ix:nonFraction></span><span style="font-size:8pt;"> shares </span><span style="-sec-ix-hidden:Hidden_SfcvSq9YQU2De6zqVGFSdQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:8pt;"> and outstanding as of December 31, 2021)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_J8_8l7gvUE-LPvg_wlJq5w_39_4">1,889</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_jMLGW6XTWUmCkIE9ivwO9g_39_6">5,627</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Treasury shares, at cost (<ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TreasuryStockShares" scale="0" id="Narr_TGGsGk8g4UyW2aqvU_Gmnw">Nil</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockShares" scale="0" id="Narr_Fuc4VcegtEmucb-s3f5XGA">94,074</ix:nonFraction> shares as of December 31, 2020 and 2021, respectively)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="0" id="Tc_4jZxJB6JSkOHBcOi-pQ1eA_40_6">619,605</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Subscriptions receivable from shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityNoteSubscriptionsReceivable" scale="0" id="Tc_RBPNw3pKuUCKczYbRztH4Q_41_4">7,172,192</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_WbXIT0j_A0eLQP8bbp-QKQ_42_4">23,786,652</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="0" id="Tc_3LXfOvJfW0yL669qGGE7Dg_42_6">336,099,931</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated other comprehensive income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="0" id="Tc_ZiMQVy3ZgEWedsdnApXDTQ_43_4">350,981</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="0" id="Tc_qroW5uuozES_hTC2k48SgA_43_6">93,981</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_57KJUteNJEO0Ohhf4Cenxg_44_4">105,655,324</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_V-sWx-fzikaMLG4cG5qWmA_44_6">178,833,259</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total shareholders&#8217; equity (deficit)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc__yCfFPpwG0-w-RhMY8pMwg_45_4">89,389,956</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_wmYR36m2fE237rEDvBeoyA_45_6">156,558,713</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS&#8217; EQUITY (DEFICIT)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_fE2v8gqeCkm6mVvdpGMpOw_46_4">84,262,737</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_L3BcB51z40CtLuP3E-Vy_g_46_6">189,510,726</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_a5744196_e89d_42a0_bf86_6fb7a28aa99b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">ADAGENE&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;">FOR THE&#160;YEARS ENDED DECEMBER&#160;31, 2019, 2020 AND 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c1ab1226_56e8_472f_8ef9_1582b5222bf5"></a><a id="Tc_K9Q0nZvhNEyGNa9SRpSSbA_1_4"></a><a id="Tc_j59ZqL4bZUaeoIYgjtr6zg_2_4"></a><a id="Tc_fhUh6dIFTE25Vzm7ZrbjZA_3_2"></a><a id="Tc_Ny1KerpA7U-51sdez5lw0g_3_4"></a><a id="Tc_PyprQFL_70aVfxGdAkr-fQ_3_6"></a><a id="Tc_94HcNU5Hh0akShPy5-AxtA_3_8"></a><a id="Tc_gNSoP79Z0kuzi9s98JwA0w_4_4"></a><a id="Tc_NjhY6sDMJEab-ZxWS8De6Q_4_6"></a><a id="Tc_Nn9B5UiG80yCiPOzf5s88A_4_8"></a><a id="Tc_T0MD1Tn6YkGUjBCuUWX4sA_6_0"></a><a id="Tc_eDj4Yx06iE2P8NNmVnKH8g_6_2"></a><a id="Tc_10kr43ClF0Ww6bCmabNKEw_7_0"></a><a id="Tc_VM1_J0BPfUmXpuzvxTsWBg_8_0"></a><a id="Tc_rMTIAscGTUurmrjRRYXa3A_9_0"></a><a id="Tc_AfGl9NsZnESWere0iHILYw_10_0"></a><a id="Tc_Y_UrDqlksEOZi8A9ayEnyQ_11_0"></a><a id="Tc_VAqMQsqH90iNAbSojCdBpg_12_0"></a><a id="Tc_s6R79lPwcUm4z2OhZNlUIw_13_0"></a><a id="Tc_Yexsj08x0kSb-RFL2SpnlA_14_0"></a><a id="Tc_4mXnGRzgJUaA9aC9q7PkUQ_15_0"></a><a id="Tc_dQv_6Ei6Z0CKl-wuoMeEDQ_16_0"></a><a id="Tc_b3hjgQwDr0iLkXjl_fKWAA_17_0"></a><a id="Tc_29cyU2OzE0qiuU1u-17c4A_17_2"></a><a id="Tc_9km9bz3k10yBTxXiFqbvrA_17_6"></a><a id="Tc_frxFWCKivES5DOi5Vv_GJQ_17_8"></a><a id="Tc_g2ia4UWi0EGN3hM64gUqAQ_18_0"></a><a id="Tc_wPkP9Mr2IEe3_DR-w7WD_g_19_0"></a><a id="Tc_hTYxsirfxE-HM1GScbZA4Q_19_2"></a><a id="Tc_8Lx3q28AO0y9oopPbMlSIQ_19_4"></a><a id="Tc_e2489Tc21USq9oCao0o3mg_19_6"></a><a id="Tc_R6alPH9rvkGPGueqNBKWzg_20_0"></a><a id="Tc_pGq7wHGfVEa8tvysHrgvfQ_21_0"></a><a id="Tc_I0uDQDl6SESOZiolTIPJBg_22_0"></a><a id="Tc_GkXxrIduPE-ZU094lQDixg_23_0"></a><a id="Tc_5xSa6-Uttkq9AU3w8PbjWg_24_0"></a><a id="Tc_ybfQv6z78UGBCC2Ol3lWJw_25_0"></a><a id="Tc_Ck1ky1m2GkKLHLT0T5r59Q_25_2"></a><a id="Tc_JhIRh8KZ6EuCjA5G8PGsRg_26_0"></a><a id="Tc_H37CWE0sXES4Z-mcrGOEhg_27_0"></a><a id="Tc_n7bJEOqGFEq5yCuIPgdaig_28_0"></a><a id="Tc_wwBIkbTKwUGvShmF9mwpug_28_2"></a><a id="Tc_kZH9XFrpykGjP1ptTREe1g_29_0"></a><a id="Tc_2ESfi8TQ40KvRgB11Inq_A_29_2"></a><a id="Tc_-KwPS-p3H0SUFJZZ_L2sqA_30_0"></a><a id="Tc_P9d7npEjs0GWBDaal9qoNw_31_0"></a><a id="Tc_PJgjmQdfGEmwjgVkh1-lUg_31_2"></a><a id="Tc_iqsLO5J17EeYo_QC1xQU_Q_32_0"></a><a id="Tc_hJ7iYOL030W_tUhhEjUHaQ_32_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Notes</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Licensing and collaboration revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">10</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Tc_0NMOv43hm0Snktm3u0pJ1g_6_4">480,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Tc_eZV6NdcDwkmRINmaALxuXA_6_6">700,913</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Tc_WF7Y9cVUSkSTbc4u8NNZhA_6_8">10,175,258</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Expenses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_cblgS506D0KsmrvRc6q0Cg_8_4">16,211,750</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_tqQ0z_5x3ECRxGPWY_GK5w_8_6">33,538,035</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_TxkIFtCGdkaneb8YM7ea5A_8_8">68,099,385</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Third parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="adag:ResearchAndDevelopmentExpenseThirdParties" scale="0" id="Tc_6GWJbqI16EG1trZ1a7iLfQ_9_4">10,507,444</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="adag:ResearchAndDevelopmentExpenseThirdParties" scale="0" id="Tc_y6ZXMEQTnk2KXBulYnh_iA_9_6">23,645,740</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="adag:ResearchAndDevelopmentExpenseThirdParties" scale="0" id="Tc_yIjsw_JyQk-3K3izNVOu6Q_9_8">55,020,367</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 12pt;">Related parties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="adag:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" scale="0" id="Tc_MfP0Nbc8GEaxDBnw1nP9UA_10_4">5,704,306</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="adag:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" scale="0" id="Tc_0-MlyDq7pkONk0BsRKOPhg_10_6">9,892,295</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="adag:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" scale="0" id="Tc_oxT6xCEAe0yb9mRA4mNRHA_10_8">13,079,018</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_1wiNmKfNIEOJWwzFWGzSag_11_4">3,437,900</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_uvbDfch5fECSU3LxbnTKCg_11_6">10,314,536</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_we8bjZPZJkyF5DDP_L8XPQ_11_8">14,439,962</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss from operations</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_ReP42zz5Wk6faXO46DP9Eg_12_4">19,169,650</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_eeXWqKY8ak2Jrn0Q20yKaA_12_6">43,151,658</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_vPPi8tO_SUqR2QJ07meWtA_12_8">72,364,089</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNonoperating" scale="0" id="Tc_qlgkDqvL9Uu63lHRGpfnFg_13_4">922,680</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNonoperating" scale="0" id="Tc_e4-MqMwOh0uHFv6WTD-vGw_13_6">629,288</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeNonoperating" scale="0" id="Tc_blZyI7Wg_kG5SBeOG9IQUQ_13_8">76,166</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="Tc_AOuCrpLW2kCtruWTMn65_w_14_4">138,096</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="Tc_Ol8LlQlhS0SuvBgd9Eo-yw_14_6">202,165</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="0" id="Tc_quoWEcwDBkyUACebH8xKtA_14_8">363,762</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="0" id="Tc_8Q_dTIEbnUS3-zECafrcXA_15_4">723,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="0" id="Tc_kt_Ga8YLn0y9EjVuMJZObg_15_6">971,949</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncome" scale="0" id="Tc_98NZvMhfUE6pl_TakwlszQ_15_8">1,778,822</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Foreign exchange gain (loss), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="Tc_myixZRPjb060V8WHibXywg_16_4">21,867</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="0" id="Tc_DXwxY8kXSEmi6Xd5Fkd1VA_16_6">644,693</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="0" id="Tc_9qWOPD-hNU6ws0guF0dllQ_16_8">603,459</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="0" id="Tc_HasVQ-haCk6YwL5WNKVXfw_17_4">1,207,415</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss before income tax</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_IqlRJhf-FUWmLQ7qW1lfRQ_18_4">16,432,308</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_7wSWRfbNlUmpsiJByYNTGQ_18_6">42,397,279</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_8xIjtMUq6kq3DGLUXDoV8A_18_8">71,476,322</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">11</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_Qy7l3-ZSF0SxwNVduJ4ung_19_8">1,701,613</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss attributable to Adagene Inc.&#8217;s shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_xW4p8PsstEeK1RwI3xI0fA_20_4">16,432,308</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_i9vx4WGrWkeyeyNmqrdndA_20_6">42,397,279</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_XsGBOTa4nUuqLchovviLbA_20_8">73,177,935</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other comprehensive income (loss)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Foreign currency translation adjustments, net of <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" scale="0" id="Narr_QGD4V-PI3UqyTVAmUThQZA"><ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" scale="0" id="Narr_NIqPYoe_LUeKMZ13sQNbmA"><ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" scale="0" id="Narr_W2EZalcNIUSpSn-cP_20mA">nil</ix:nonFraction></ix:nonFraction></ix:nonFraction> tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="0" id="Tc__PP7KNHilkOjS-2c2em6SA_22_4">65,799</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="0" id="Tc_oNzWYGxNakK0g45CPH6Oaw_22_6">6,087</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="0" id="Tc_XBhJ5_CmTkSKO-FhALPQmQ_22_8">257,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total comprehensive loss attributable to Adagene Inc.&#8217;s shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_eQCy7WZWlka8foe90pz2Nw_23_4">16,366,509</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_qAwoJEurjkumv_1PhKn6uw_23_6">42,403,366</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="0" id="Tc_NpCyTDvWtUyo3X_BZti7Hg_23_8">72,920,935</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss attributable to Adagene Inc.&#8217;s shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_4gqfy_N5bEm-EZL3L4q9Gw_24_4">16,432,308</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_wDXb4g02i0S_h4eJnf_s-A_24_6">42,397,279</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_V6SVhNhlXkK8_4aXvkXhCw_24_8">73,177,935</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Accretion of convertible redeemable preferred shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_CyUOVtoXrEucazL4cfbMPg_25_4">246,184</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_BPaupsxlvEiH6s_4F-fawg_25_6">248,113</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_MTFNd68tL0uxIRD_g72ZsA_25_8">28,553</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss attributable to ordinary shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_cXzpjVIhREalAexgPETDzA_26_4">16,678,492</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_W5JlCRYzQUKmA67SndpinA_26_6">42,645,392</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_cJHk-BWX_kS5im6WVLmiHg_26_8">73,206,488</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted average number of ordinary shares used in per share calculation:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">&#8212;Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_k3Bhx9ukF0y6GWzncXs1HQ_28_4">15,178,232</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_iy2OuVK-iU6IkdyezYYz7Q_28_6">15,950,698</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_UJ7I_e2-1027JIMH5BoyVA_28_8">50,032,009</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">&#8212;Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc__r9x2Mdt-EGS7S0xx-8jOA_29_4">15,178,232</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_wDDoKnSCik-ylEi_QhPVEg_29_6">15,950,698</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_diLEsersbUeQeMhRYSNrbQ_29_8">50,032,009</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss per ordinary share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">&#8212;Basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_dghp6UBai029koQ31tLerA_31_4">1.10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_Lop_4w5kLEOvSaEWWE9UbA_31_6">2.67</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_L_MLrNbgy0mEOssIBYaKwQ_31_8">1.46</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">&#8212;Diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_bKhA2tEpE02BvgkTwJyNQQ_32_4">1.10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_NkuvdLT0S0OBFl0kxX5Hrg_32_6">2.67</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_PTA5NWVlikmCClVkt8ufjQ_32_8">1.46</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:58.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:10pt;margin-bottom:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.27;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:4.55%;padding-right:4.55%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c0ee39a9_5dff_4c03_b94f_29a538ebe157"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;">ADAGENE&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS&#8217; EQUITY (DEFICIT)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;">FOR THE&#160;YEARS ENDED DECEMBER&#160;31, 2019, 2020 AND 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_839f1bb5_5cfd_461b_af1e_b42aa4f0e8e8"></a><a id="Tc_rlQ3hZtZw0ufoRI9IyHx4Q_1_10"></a><a id="Tc_z3mi7p5fWEC-c5_R4ZwhZg_1_14"></a><a id="Tc_p6ViLfgnXUazHV7QmyoVow_2_2"></a><a id="Tc_BPMDLrs3u0KD7cIsh-XlZw_2_6"></a><a id="Tc_ZQ0VRwy4HU-UOjHIwBzZDw_2_10"></a><a id="Tc_z0KG8eZiYU6BhQc5Ehl5Sg_2_12"></a><a id="Tc_f_IZhS8FWEa64Map7iGAWA_2_14"></a><a id="Tc_baaUQZ-IHkae3VNihvHK0A_2_18"></a><a id="Tc_uE6zy-zSLki0_5X5EouEKA_3_2"></a><a id="Tc_aVUscngpVUC4DaXgvKFtaw_3_6"></a><a id="Tc_vL77LdZcq0mQX-gNrI389w_3_10"></a><a id="Tc_7yhUF-geKEqINpcVZVdyng_3_12"></a><a id="Tc_7-9am_zLuECfeeIeuUoAUw_3_14"></a><a id="Tc_1H-i0O8I4UGPqiLzEaLvLw_3_16"></a><a id="Tc_OlT5JMdZt0qGio5kd0XsWA_3_18"></a><a id="Tc_dcQpiq53n0amPYsd0EHzMQ_4_2"></a><a id="Tc_DcKBYkYGHkacXifJ75IKWA_4_4"></a><a id="Tc_avnKmRdyI0qioia2R0sMBw_4_6"></a><a id="Tc_0E2LcCxOgECQT1DSWo90VA_4_8"></a><a id="Tc_uNoEYzxauU2dYhpdDfYl4Q_4_10"></a><a id="Tc_i6wwd8xG_EWPnoGbBim5OQ_4_12"></a><a id="Tc_VZthIqoS60G7OoXLyiREvQ_4_14"></a><a id="Tc_u-21AXHCC0uhJBA-f462JQ_4_16"></a><a id="Tc_dl3t4Sq2QE2dPiMFU76yKA_4_18"></a><a id="Tc_CEgmPUb9NEmo5A5O-1FOCQ_5_4"></a><a id="Tc_T1vh5NvoPEOFZ81zAldo0A_5_8"></a><a id="Tc_oL9vPjwA4E6ps4Pszrfu4A_5_10"></a><a id="Tc__aAX-cemZEOaxjGbl_53Tw_5_12"></a><a id="Tc_mINlqnTgNkuYKblwwoLHPA_5_14"></a><a id="Tc_de1ddzkgv0m4fZFG57HZtQ_5_16"></a><a id="Tc_ZoyTPLyNjE6VxeFupF995w_5_18"></a><a id="Tc_IXmEBN_lAUmysUnIPX6ABQ_6_0"></a><a id="Tc_z7M0V1fqKUihniVQBxnYcQ_6_6"></a><a id="Tc_2OjE3nYVcECgR7vH4WYCCQ_6_8"></a><a id="Tc_ta3-c7fbmE2r7sEYwhW5VA_7_0"></a><a id="Tc_Bn9lvRhK4EWEixZZSMlbcA_7_2"></a><a id="Tc_DrtLs4iw406VZlnCNmIG7A_7_4"></a><a id="Tc_XvhxfzDdFkm3YSn8G6-JvA_7_6"></a><a id="Tc_KZL0jw9s7Eixxm_S71BO5A_7_8"></a><a id="Tc_WF2gygjyDkyc8G1UsKGhog_7_10"></a><a id="Tc_gsuFIZEPNEO3ZGCdEvl3iA_7_12"></a><a id="Tc_MTe_XSQ-akuEUhYMacPv6A_7_14"></a><a id="Tc_JqZZVTKNYkCS7KSBTE0J3w_8_0"></a><a id="Tc_-X-kz-NLDkGWKx0fpaysfw_8_2"></a><a id="Tc_NckRuQTJLEqCaphawrAPqA_8_4"></a><a id="Tc_X1WIeBoBqkOUg3uHwOVZ7g_8_6"></a><a id="Tc_5EOwdhCTf0S9fSwSnUSc1w_8_8"></a><a id="Tc_jwqLAdsKz0av0FQmkeEUwQ_8_10"></a><a id="Tc_-E3gFnlz5kS3FSZm62QIWQ_8_12"></a><a id="Tc_2QUMGYCdhUudct_-xeAEug_8_16"></a><a id="Tc_xe2lIJNkCUi_Nu9ZVD409Q_9_0"></a><a id="Tc_45A67lLRS06g_6D-8ndY8A_9_6"></a><a id="Tc_J9C3CPl6jUW78b6Ll45UUA_9_8"></a><a id="Tc__AgvsUb-M0mC8cAv8D319Q_9_10"></a><a id="Tc_VGF_35ylpEWRQTIpLw09fg_9_14"></a><a id="Tc_wGjpgJca0Ea3wpPDmXHXfA_9_16"></a><a id="Tc_g93YrjO5vEuzOZsJBeCT3w_10_0"></a><a id="Tc_80PbovGNQk-RTSMgBLAzZw_10_2"></a><a id="Tc_YeHjxjbGNUaIzQDmQ09-iA_10_4"></a><a id="Tc_WBeS1Z4Sx0Kh0xFE-uIEcQ_10_6"></a><a id="Tc_qelbdG9uyky-e6IIK3MyfA_10_8"></a><a id="Tc_7wyHMXhgrUugzhjJzzAbcg_10_10"></a><a id="Tc_xAytybbjYEmamUbPeiqC2w_10_14"></a><a id="Tc_eAswP3q_RESXCXN-OxuQEw_10_16"></a><a id="Tc_QQB5oh-pFk2EwTtSwHTGug_11_0"></a><a id="Tc_5m1t9eGxZ0mmHfdQ20oZPg_11_2"></a><a id="Tc_Fn7aPa9NSUCyiKPrtV5VjA_11_4"></a><a id="Tc_xwGVNT8z_0KBj5w3zhFtlA_11_6"></a><a id="Tc_l7nBvvmcdkydm09x5E8wrA_11_8"></a><a id="Tc_RiAmmCFrWkOfhsvFBOaJYQ_11_10"></a><a id="Tc_U8QewcTsdkymTV85z0DMEQ_11_14"></a><a id="Tc_oM34wvCDaUeulrCTIgM9hg_11_16"></a><a id="Tc_p8lZzutMi0Oteiy2BZ-RhQ_12_0"></a><a id="Tc_U1wEfF78hESEoYNPXQ4_3A_12_6"></a><a id="Tc_YkU3458uCk-38U63RdarCg_12_8"></a><a id="Tc_FW3ksh6xUkSyM9NVDV-dng_13_0"></a><a id="Tc_EkeNouu5fkG5KwfhxG0teA_13_2"></a><a id="Tc_GDJiB0xp3kOP9Q6O697hLw_13_4"></a><a id="Tc_zzENKHpa1kCMNsxkCoY18w_13_6"></a><a id="Tc_e1baIqftk0uys4V3qx38rg_13_8"></a><a id="Tc_eyuuxfXyl0KpLq_mQAZxBw_13_10"></a><a id="Tc_TF-A8AqT-0WSMxCHfYqa3A_13_12"></a><a id="Tc_m7BnG76-zUC3VrMUHjPoLw_13_14"></a><a id="Tc_voAoBt6g602OzbxgirTLQA_14_0"></a><a id="Tc_hHK8ocXRFUKukm7e3z4mXw_14_2"></a><a id="Tc_6h7p04TjqUml64Nb4RAWzg_14_4"></a><a id="Tc_Hq-HxJeKpk27ORcFU8HR-g_14_6"></a><a id="Tc_sYki10sly0qfXtVvkdxJKg_14_8"></a><a id="Tc_NRPXSvOBsECvoHwQuBUh6A_14_10"></a><a id="Tc_IaBLEYMfUkyhj6hlf-c3Ug_14_12"></a><a id="Tc_UQGz_T9n10mqxby4GPREqA_14_16"></a><a id="Tc_2aw0h0eU8U2_74m0cHr3dw_15_0"></a><a id="Tc_fbTegB1MzkSoNfMsvil_9Q_15_6"></a><a id="Tc__eWbGyxXPUyeZqfkPboK7w_15_8"></a><a id="Tc_pUTavE04OEqfg-ZcZJYVeg_15_14"></a><a id="Tc_e-AiFdA550-bQEoL9wPPNA_15_16"></a><a id="Tc_dzWvXh6BiEuOGuDDZLE2ZA_16_0"></a><a id="Tc_f_zGj25lJUqTCn-K9XZCEA_16_2"></a><a id="Tc_OR4uHcnrOEKVGPsOyf-mVg_16_4"></a><a id="Tc_0JuPUfHkiUqzj2Bpocqh4g_16_6"></a><a id="Tc_4D7vkInQDUO3h5C-FgzPNA_16_8"></a><a id="Tc_nmuVadr0J0SWpmXABZcacA_16_10"></a><a id="Tc_j_NZnmKVrkmOdrX8OE9Isw_16_14"></a><a id="Tc_nLtzVLbhjUKdgaFmzIvGjw_16_16"></a><a id="Tc_YFwmeyutWEiypScJuccyjw_17_0"></a><a id="Tc_JqfgQ3PlC0696alDdU2Bdg_17_2"></a><a id="Tc_06mUffu85k2l9bcY2VkARw_17_4"></a><a id="Tc_ZAN6S1IHSEG6nkTl2Rh2Uw_17_6"></a><a id="Tc_vOknKoec8kmfZN9vmq4lWw_17_8"></a><a id="Tc_McxDrjznbES_MMDYF4tUXQ_17_10"></a><a id="Tc_g10g2F5Af0uFzY5QUcPX-Q_17_14"></a><a id="Tc_0HAfXr_S80WHgKg3Irbb7Q_17_16"></a><a id="Tc_QkNdSCqeQkmixgFtZ8EaSg_18_0"></a><a id="Tc_3RL-3S0A3UmoyP7pBfK_YA_18_6"></a><a id="Tc_IViXUVbyq0ydb4-tM29R1w_18_8"></a><a id="Tc_hO9I5Cr2YkWpx53FcEwGFg_19_0"></a><a id="Tc_b-X3qbr0oEqpboyOVMe-JA_19_2"></a><a id="Tc_-Fqcf6LoL0qmuwS0iISMfg_19_4"></a><a id="Tc_SqL7MKTsxk6rv3xTQZ2s3Q_19_6"></a><a id="Tc_9KUTW8fBL0qTGFE3n7QeQg_19_8"></a><a id="Tc_vwMu8i2IjUy4tdiWJWr_aQ_19_10"></a><a id="Tc_rwI7lidSj0K_VACdHMKVPQ_19_12"></a><a id="Tc_ceTP-WlPNUCLuu3UABevnA_19_14"></a><a id="Tc_BhuA6tHv5kCFH17vCESJIA_20_0"></a><a id="Tc_mEnVK8gR50u397LA-vFsLQ_20_2"></a><a id="Tc_HQE4XCdk5UGi9W8lSS14ww_20_4"></a><a id="Tc_NaSz6QAUVE-TocnjOcOpLQ_20_6"></a><a id="Tc_3UVOmMvXQ0e3Q7vyVhBsmw_20_8"></a><a id="Tc_QKuSPbs4PkOa6BPb4TZV0g_20_10"></a><a id="Tc_o1LAzWr1QkGJP7bw52_P0Q_20_12"></a><a id="Tc_JDb6J-0juECsKeGpnb9Y2A_20_16"></a><a id="Tc_wVDb4raZvEy7T_eHHn6Ltw_21_0"></a><a id="Tc_02DmBuiyvkOmaKwKXvulqw_21_6"></a><a id="Tc_DTRWbz0vI0Kla_cUHhetuQ_21_8"></a><a id="Tc_QSon8HRpEECYuRZaftfiLg_21_10"></a><a id="Tc_a7l7trdn3UKcfYJNCy_gnA_21_14"></a><a id="Tc_eyX6EYkPgUiYQh4TPOy45Q_21_16"></a><a id="Tc_aqVSny75EkeR_R_OyygVFg_22_0"></a><a id="Tc_KV1pQDWBFEqHiGTKS73xKA_22_6"></a><a id="Tc_iIgxyEbbJEa5uhzRPHs9Yw_22_8"></a><a id="Tc_RvCDW9y7k0uOhJQd1Fgumw_22_10"></a><a id="Tc_bzG1Ucv-60erx0PZNq87PQ_22_14"></a><a id="Tc_L1MBgv8ENEKXWihtBU8q4A_22_16"></a><a id="Tc_0iXQfH6KqEibuU_4drLoTg_23_0"></a><a id="Tc_lVOSTzxoq06v7RwVu8hINw_23_2"></a><a id="Tc_tK190fMVWkC-L3ZCzAgzRw_23_4"></a><a id="Tc_LZ10m4DiIUmIJ1Ccqcfc-Q_23_6"></a><a id="Tc_wLrpIddPrUSDCJuVTiWL6w_23_8"></a><a id="Tc_I3E-wuKEh0ybkoCrDq2-gQ_23_12"></a><a id="Tc_UMx2uxIUWk2dyzfHx10dvQ_23_14"></a><a id="Tc_LKVb3f78zU-o0KktHGdUBQ_23_16"></a><a id="Tc_10rikhPFJUeHZVS5tMRNBg_24_0"></a><a id="Tc_yPmmuqiTQ02uZb9JTUA4DQ_24_2"></a><a id="Tc_-uq-5cH9akilhtCj4i1vsA_24_4"></a><a id="Tc_30sCxrv6ZUW18isJruIsVA_24_6"></a><a id="Tc_u0gITmmoQE2XnJbuic2EqA_24_8"></a><a id="Tc_b7wzHME2MUGLVGZMXCS1mA_24_10"></a><a id="Tc_h5Yk7AtnvUezI4ezdsZWNA_24_14"></a><a id="Tc_g2Tp-oMASUG1QdloU687aA_24_16"></a><a id="Tc_1bjcc_Q-G0Kh2K-laNwmyA_25_0"></a><a id="Tc_ziVFdkdZDESCmbUb3H-W0g_25_2"></a><a id="Tc_f4tlOM9DeE69euYNiex0IQ_25_4"></a><a id="Tc_kwKfLwoQTUGj5TpBg2emqQ_25_6"></a><a id="Tc_RvhOiCEvmE2mV0Ba6SxUvw_25_8"></a><a id="Tc_qT16zrcIhEGjl-r4bHq5kw_25_10"></a><a id="Tc_FIJiVFTxakeJKka9qlvBYw_25_14"></a><a id="Tc__DEm9Ij2kE-oX06Kx_mvig_25_16"></a><a id="Tc_8AzYgspqO02mLiQFtSd21Q_26_0"></a><a id="Tc_yr4M_00tz0ioSvlICmEJhg_26_6"></a><a id="Tc_dRGZSw7xCUev_1bS5EGM3w_26_8"></a><a id="Tc_ANO_AUgGi0GwGzqGMTY-Dw_26_10"></a><a id="Tc_xC4NO24_NEOnhCoGdQhgbw_26_14"></a><a id="Tc_Sc_yRVE3UUOYugOhkyqIoQ_26_16"></a><a id="Tc_Bw9zV2P24Eiaywwsr92oMQ_27_0"></a><a id="Tc_K7PWZJdBK0u-ZQx37q-zHw_27_6"></a><a id="Tc_wcQguepxzUOx6xQvUE6VPQ_27_8"></a><a id="Tc_7aaZH9hCDEufmvrebXssiA_27_10"></a><a id="Tc_xQzfT3BVt0aVmcGwmIG9FA_27_14"></a><a id="Tc_tbix2aQdnUWDkZ5yuH6FcA_27_16"></a><a id="Tc_ZW6whdRRakqxnxvUDDvYyA_28_0"></a><a id="Tc_sJqzmJfcdUeky1P_SWyifQ_28_2"></a><a id="Tc_VdAGW5ZcNUKdrPJhPK9bWg_28_4"></a><a id="Tc_LvprkFGNXUavEVTn6byPcA_28_10"></a><a id="Tc_2scVI9u9Jk2eIVtQ2AJVMQ_28_12"></a><a id="Tc_AqwdQgvCqkODbMe6RUL3iQ_28_14"></a><a id="Tc_tFHRsemvYka-iTJDJaPoyg_28_16"></a><a id="Tc_5PizE50cGUOx2dKtiEkNFg_29_0"></a><a id="Tc_OJRElJRyJU2_xVlzKV6n_g_29_10"></a><a id="Tc_Q6uMB0z5ckOlVqzkqV7cZA_29_14"></a><a id="Tc_0-JbD08IJ0uMBFHaHbPuhg_29_16"></a><a id="Tc_ZP-uApt9KEm5O3ZvQrEZqQ_30_0"></a><a id="Tc_oZXj_Wg8kUm4jeGMM_Nz8A_30_6"></a><a id="Tc_-L9XgKUMIUaDOj0QjvM9RQ_30_8"></a><a id="Tc_5kvcX6IHS0GnHJRg0N8g5g_30_14"></a><a id="Tc_zgGl4Sm67Uq8a_VAEuA-mw_30_16"></a><a id="Tc_UFgTL11vOUWoN3rQFvDaTg_31_0"></a><a id="Tc_D3RayZG2y0SSD0MP170BVQ_31_10"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Subscriptions</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Ordinary&#160;shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:13.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Treasury shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">receivable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">paid</b><b style="font-size:6.5pt;font-weight:bold;">&#8209;</b><b style="font-size:6.5pt;font-weight:bold;">in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">shareholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">shareholders</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">equity (deficit)</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Balance as of January 1, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CcCxb4VhikOi1y0dPsdYqg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_ImCmU4CvYEW7af66hZ02UQ_6_2">15,159,136</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CcCxb4VhikOi1y0dPsdYqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_fvGRr00uX0Ci0Rl8DOHgYA_6_4">1,516</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_HYoBMhtJa0yEyU06RSK4NA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Tfea4nGbL0qXULpOIqruBQ_6_10">197,068</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CxGmgLMsLE2qdLE2LM_0rA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_RNrCQRePCkeU2lAfSrTLSg_6_12">6,405,318</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1tBXOuzi0ESMiQGauboZTw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_ZRvyy7lYsEqLjqV8ez2PSw_6_14">410,693</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9ItmklfRf0uRsoU9hvgWog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_IsvWvux9CUSRpYFbCPmnlQ_6_16">46,825,737</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2018_T4mq9hT6lUOBey2VJKkGww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_xMdDwbFtfkOYhaQGxx3foQ_6_18">41,026,664</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_p0eN6ym23UKzRvTQU9uTVw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_qbaG6B_2YkWzft3QQ_weoQ_7_16">16,432,308</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_wrueFsWuFkyKUuugqY68BQ_7_18">16,432,308</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Other comprehensive income</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_jrlz-uWqkUmR3nAwGvC25Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="0" id="Tc_sRcXCi2gAUasnKvg5GqSeg_8_14">65,799</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="0" id="Tc_CLjNv8fSy0G2CXVpynzF9Q_8_18">65,799</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Exercise of share options (Note 9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ejhoERAomEign1naasf3xg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_RYlzEOozGEW0dFLLtdonyg_9_2">34,000</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ejhoERAomEign1naasf3xg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_25y6OcNp8EKKZt6wN_0XYw_9_4">3</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TRZ2AP03T0q5M7SihzVu2Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_ISmf3dAYz0ODsw3yUPHu0g_9_12">18,697</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_j5euR-EfhU2N_m6XTARDVQ_9_18">18,700</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Share-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TRZ2AP03T0q5M7SihzVu2Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_7U0yDgv40kaRQ_1cTdFF7A_10_12">611,711</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_u1xzxxCjvUq55egoUXdrBA_10_18">611,711</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Accretion of convertible redeemable preferred shares to redemption value</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TRZ2AP03T0q5M7SihzVu2Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_7MXHrp8XSkizzJl0OH1DYA_11_12">246,184</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_z0z0W4D-lUGZfZKVnmSUMg_11_18">246,184</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Balance as of December 31, 2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_By3QnPrdlEaXBzg7JPmAWg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_pFjv9qyebUCaWqQgcc6Byg_12_2">15,193,136</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_By3QnPrdlEaXBzg7JPmAWg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_w-5KOfr0JUq-GSCO2jjWMg_12_4">1,519</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_QcpBoYoLhEuMjeBkZobcYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_E5LBTvfzYUOJ5xiTDy2sSA_12_10">197,068</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eu-ubqjya0GZ7jR6Gj7umw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_gKpuD3apC02XoZu7pG_Nvw_12_12">6,789,542</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ksUQnXGhskekv5LudMtZwQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_bVgeVqnEt0OhOBzRRawcDw_12_14">344,894</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3OzaKSBA6EKIleBIeH1EMw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_b6dihZzPsEOoJnLehYNlDA_12_16">63,258,045</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_UPqgeIzroUG3_teBGj2h-A_12_18">57,008,946</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oTl5ofybRE-y-HStnx9nSw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_52dVgLsNo0Samqi80ZKHQw_13_16">42,397,279</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_LfuwwcYkL0iziCOy3SkmDA_13_18">42,397,279</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Other comprehensive income (loss)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_y8B0CBPuIkuYDNTamxLEtA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="0" id="Tc_OZdMFkN70kqS24VlvxqGgw_14_14">6,087</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" sign="-" scale="0" id="Tc_h2eeZCVKXU-QZG2uW1GIZw_14_18">6,087</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Exercise of share options (Note 9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4cZXNIk8T0WsnTIe9RQpHw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_AbpFv-7VakGnqSsfQ2v5qg_15_2">3,694,934</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4cZXNIk8T0WsnTIe9RQpHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_OpDhfYDy-0mnX7mpY49qgw_15_4">370</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_BmsMtetGyEmJ6rNq6bChIg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" sign="-" scale="0" id="Tc_uFyv7AUHnUWD1CYKK8HFDw_15_10">6,975,124</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z-JH0nWTpk2ObWlOPALkqw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_37bJFCvJM0GoRwLzAhSo2Q_15_12">7,115,682</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_-s3u-K9VH0q8dLPZrZLThA_15_18">140,928</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Share-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z-JH0nWTpk2ObWlOPALkqw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_0JlQwRq8eku6Q3YLTZihnQ_16_12">10,129,541</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_BCDHqQyUwEaDy5eogD1ANw_16_18">10,129,541</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Accretion of convertible redeemable preferred shares to redemption value</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z-JH0nWTpk2ObWlOPALkqw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_2hTdXx9EvkCnF4Nir2nmVA_17_12">248,113</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_ZomxVUeSukuMqRY8qXAz0g_17_18">248,113</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Balance as of December 31, 2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FbCfpTbSv0mxoweyDbesMg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_nsAVk7mPS06UiZ_6q9Hplg_18_2">18,888,070</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FbCfpTbSv0mxoweyDbesMg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_91RtwnueI0e9e0xqR8zFDg_18_4">1,889</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_ucSapsjP0kSLroQuwY1qqA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_S61ZnsDd4EyGhrslq2hl0g_18_10">7,172,192</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_s_hI_eMhXEuN0ZTpwuwXiA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_GK_0IgYTfkyigfCe9wG1bg_18_12">23,786,652</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_odl9-H0Af02VWyk45akORA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_9BMZzfJMKEiUTJX3agxnsw_18_14">350,981</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dLa3qPlXC0ubjB2El7bVaA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_DGjV0XxXK0-jRffy4AnepA_18_16">105,655,324</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_zOdpUaLSHkaLj-YzXe4ErA_18_18">89,389,956</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IizeckEJt0arP1tQ0car0Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_H7SkxiNSZEG-BLaqzwn42A_19_16">73,177,935</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_t2fzLQjrT0C-qEPKM2y5SA_19_18">73,177,935</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Other comprehensive income</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_sYvYNerfTEq-2t09ZKu2Pg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="0" id="Tc__TBjfVx9fES4oWFLIV225Q_20_14">257,000</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="0" id="Tc_4l61kkXXsUeH0hxXRVbXMQ_20_18">257,000</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Exercise of share options (Note 9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_eWd2Oslg20SJRlGu3VXy2g_21_2">233,957</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_TrYAsEfHMk-r9UAyDFws3g_21_4">23</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HGnhNeAwYk6MfQLARidhrA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_0R2vq0yNt0mNYNfzlLPS9w_21_12">226,758</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Tc_-9k7dUE9K0uanaflvmqnZQ_21_18">226,781</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Issuance of ordinary shares under performance incentive plan (Note 9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="Tc_meNHZx5aVkCm5ipZZnfBpQ_22_2">23,734</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_60vWo_rLCECSvcCl2Pda3Q_22_4">2</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HGnhNeAwYk6MfQLARidhrA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_I6jIMq0wwkihHLGubhfv-w_22_12">416,749</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="0" id="Tc_X5IvuerUOES05X8P7Lqtng_22_18">416,751</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Subscription from shareholders</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_avdfJlPfpUeAeQTReEsGLQ" decimals="0" format="ixt:numdotdecimal" name="adag:CommonStockSubscriptionsValue" scale="0" id="Tc_TULsuXZebkGBB4dTpogKYw_23_10">381,282</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="adag:CommonStockSubscriptionsValue" scale="0" id="Tc_aa6XoKEkKEqkjzM2s5yu2Q_23_18">381,282</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Share-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HGnhNeAwYk6MfQLARidhrA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_43_9ixoId06ks8lQ5GgLCA_24_12">18,679,658</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" id="Tc_wN3Bs4xPbEWrgBnGINt42Q_24_18">18,679,658</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Accretion of convertible redeemable preferred shares to redemption value</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HGnhNeAwYk6MfQLARidhrA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_eU9_pwasWUyqhkcvwaZpMw_25_12">28,553</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_M13OdWG8IEmuwRSA1moKfw_25_18">28,553</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Conversion of convertible redeemable preferred shares to ordinary shares upon the completion of initial public offering (&#8220;IPO&#8221;)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Tc_6gYXiIbCSUib63sW83M_Ig_26_2">27,249,824</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_ySQKZDirAEm7cNktGBR6Sw_26_4">2,725</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HGnhNeAwYk6MfQLARidhrA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_qYhst3ELFUOd_AxyjCY2Xg_26_12">154,475,235</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_xDi9ae-OxUWA_sHhN_XE0Q_26_18">154,477,960</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Issuance of ordinary shares upon IPO, net of issuance cost</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_crD7SKBzIUia0Q3_e11meQ_27_2">10,571,375</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_96hmHbw270qd2QmPXcDWLQ_27_4">1,057</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HGnhNeAwYk6MfQLARidhrA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_WJSsrbPVVEif05rmQwZ85A_27_12">147,094,280</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_SdFPURXlDUaJvy-x4rfk2A_27_18">147,095,337</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Purchase of treasury shares under share repurchase program (Note 16)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_KheMHBp800ewm1lePqQqfQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="Tc_egeR92oZ-0iei0RlXL7oBw_28_6">295,174</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_KheMHBp800ewm1lePqQqfQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="Tc_bP4bP-97TUmESMtmx32VAA_28_8">2,361,576</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="Tc_15Z-psX3SUiTeB12wT5VTw_28_18">2,361,576</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Retirement of treasury shares (Note 16)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="0" id="Tc_HeAvUv7bgU-wFUZjvz4gTw_29_2">201,100</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="0" id="Tc_RSkzvPUWbE2Ucc05tNpzWQ_29_4">20</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_KheMHBp800ewm1lePqQqfQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" sign="-" scale="0" id="Tc_aGI0pnetYkWsSdL8MXJTyQ_29_6">201,100</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_KheMHBp800ewm1lePqQqfQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" sign="-" scale="0" id="Tc_lrE3kupSvUmNbQhZ8DFG-Q_29_8">1,741,971</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HGnhNeAwYk6MfQLARidhrA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="0" id="Tc_H7vydQDBOUezhaIe32x2iQ_29_12">1,750,041</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="0" id="Tc_Of0pYa65x0asSDOyVQ60bQ_29_18">8,090</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;">Surrender of ordinary shares for repayment of promissory notes (Note 9)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg" decimals="INF" format="ixt:numdotdecimal" name="adag:SharesSurrenderedSharesForRepaymentOfPromissoryNotes" sign="-" scale="0" id="Tc_MkwyhbrpE0CDjzNaglq9WQ_30_2">491,119</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg" decimals="0" format="ixt:numdotdecimal" name="adag:StockSurrenderedValueForRepaymentOfPromissoryNotes" sign="-" scale="0" id="Tc_Yej22OVw80Sd-Nw9uSMFIA_30_4">49</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_avdfJlPfpUeAeQTReEsGLQ" decimals="0" format="ixt:numdotdecimal" name="adag:StockSurrenderedValueForRepaymentOfPromissoryNotes" scale="0" id="Tc_BkR6mrhOQEW3JM4HuU--Yg_30_10">6,790,910</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HGnhNeAwYk6MfQLARidhrA" decimals="0" format="ixt:numdotdecimal" name="adag:StockSurrenderedValueForRepaymentOfPromissoryNotes" sign="-" scale="0" id="Tc_FtazeBDemk-KurXdan7pAQ_30_12">6,800,807</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="adag:StockSurrenderedValueForRepaymentOfPromissoryNotes" sign="-" scale="0" id="Tc_eEz_9-7IL02jJbm6TQhxtQ_30_18">9,946</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:32.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;">Balance as of December 31 December 31, 2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_s7dkZbBLJUCm7qfYw6gdmw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" scale="0" id="Tc_lLhMwkMch0qiYNTsC2Fr7Q_31_2">56,274,741</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_s7dkZbBLJUCm7qfYw6gdmw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_A2HcW6jBm0KprkvG0KY1Nw_31_4">5,627</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_zDcYc37T6EuzabJm9zIaGw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesIssued" sign="-" scale="0" id="Tc_-l-zKBWgl0ys0QVpVmLS0w_31_6">94,074</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_zDcYc37T6EuzabJm9zIaGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_fY9K4tyHnketCqwC6uEL9Q_31_8">619,605</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> &#8212;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eG8PooN1rEWw4Jpd-57o7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_AtDSyr8zcUu7BYRGHSgVDg_31_12">336,099,931</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8l7C0jHh2E-gT1dD7E0Dog" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_xIAIGQCoZEqRcPdx51Q9kQ_31_14">93,981</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MO7C6tyJRUOkv1IQjh61yg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_UoHs7a9LZ0e_sB23BkDo8w_31_16">178,833,259</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:6.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;line-height:1.27;text-align:right;margin:0pt 2.25pt 0.05pt 0pt;"><b style="font-size:6.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_sRuQ0gHA9kmQ_IGjwSXlVg_31_18">156,558,713</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0pt;margin:0pt 0pt 8pt 0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.27;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:90.91%;border:0;margin:30pt 4.55% 30pt 4.55%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_8c13d585_9a7f_4602_a23e_2d03eeefe4be"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 5pt 0pt;">ADAGENE&#160;INC.</p><a id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS_933280"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 5pt 0pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt;">FOR THE&#160;YEARS ENDED DECEMBER&#160;31, 2019, 2020 AND 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8d7a301d_930c_42e9_ab93_7caa01beeaef"></a><a id="Tc_vDPtpx_RgEqrzovOacJoLQ_1_2"></a><a id="Tc_nN_KHJmLPkiM40-5SfA0gA_2_2"></a><a id="Tc__q8JbrOntk2obZqF8ggAWQ_3_2"></a><a id="Tc_6xLMylD7N0-owhHc54jfaA_3_4"></a><a id="Tc_lz759NgKZUKvGk4pO6Ng6Q_3_6"></a><a id="Tc_r4ZfBYXCyEuv6N0yog50AQ_4_2"></a><a id="Tc_bWe2CMyUT0iwi8A2Qg221A_4_4"></a><a id="Tc_7RamRzPxd02ZqYb70ug9Fw_4_6"></a><a id="Tc_EGxCTT40KkyAROf2HtwVbw_5_0"></a><a id="Tc_7p1H9gefT0GnPlAJ4UTMJA_6_0"></a><a id="Tc_AUGF2PXlDUyxQjA3KGvCvQ_7_0"></a><a id="Tc_h9RY-Dh8k0aMFnzPdjqd1Q_8_0"></a><a id="Tc_40voZe9cREG3l-DBmcPW3Q_9_0"></a><a id="Tc_vbjWEZ5g5USis9FXhwoarA_10_0"></a><a id="Tc_C8crcU2DB0SsWVC8-hzB3g_11_0"></a><a id="Tc_y71uNjNPBEae_NBrGGj8LA_11_4"></a><a id="Tc_9jdL3rlmikmQVUJ8RKG_dg_11_6"></a><a id="Tc_Vxs77gWgVUWrlGnvPYIWCg_12_0"></a><a id="Tc_KGLWhwPwwkWFIQwLiklJ_w_12_2"></a><a id="Tc_RSF84U4hKUiGjy95BseY7g_12_4"></a><a id="Tc_3J2wFJbgQU2IGh24PjczpQ_13_0"></a><a id="Tc_oWKt3gi6HEmhKFpDHUWbSg_14_0"></a><a id="Tc_qLefoCbagkSmfWkqptrRgw_15_0"></a><a id="Tc_sLj_x30rWEusaqv4cx827g_16_0"></a><a id="Tc_qG29WRCKnUmantxzGepkcA_17_0"></a><a id="Tc_p3LATIfbPUawiuA8pgs2yQ_18_0"></a><a id="Tc_SkrtjFmXk0WhJxyrPj-Y7Q_19_0"></a><a id="Tc_aScholosn06OnUeyFHtyRA_20_0"></a><a id="Tc_1ZytWwMKCEWXjX0fuqGDJA_21_0"></a><a id="Tc_Zvr7ncIhQU6c-7llAd5ZgQ_22_0"></a><a id="Tc_kQlmOX9laUe_nXEPUY7Blw_23_0"></a><a id="Tc_RG81jQLtTka4PirkyiWqHQ_23_2"></a><a id="Tc_XN-mYewazUq6zNYtV--dTg_23_4"></a><a id="Tc_WmA77fNFjUGotpkOmT8erA_24_0"></a><a id="Tc_acT0uvSwWEWDIlp-M3hc6w_24_2"></a><a id="Tc_HE6A0zohjUa0hl40zrkQHQ_24_4"></a><a id="Tc_wgpMvdpUwUm6NhionxC2NA_25_0"></a><a id="Tc_kNAPRQ4utkeGHJDalQ2gRQ_25_6"></a><a id="Tc_E3clIKNx9EmJIPzcdXD5Nw_26_0"></a><a id="Tc_HdsfbaPFk0ieRjJHxc_t6w_27_0"></a><a id="Tc_d9POD7TqH0Shz85Vtoj-VA_28_0"></a><a id="Tc_GXM8ptPgqE-9taDmHle3Xg_28_4"></a><a id="Tc_U6PFq0iAWEeLUs8hX60n0Q_28_6"></a><a id="Tc_i2tWgxpzE0K95xflz9Li7w_29_0"></a><a id="Tc_NwGzd9BFEUuXbS2rJOWwbQ_29_6"></a><a id="Tc_SgK5_OSac0yiEHiYGY_pqg_30_0"></a><a id="Tc_vkPdVIjXFUiUAS8lfzGFfg_30_6"></a><a id="Tc_48rNioMpdEyUJzOSbvpZSg_31_0"></a><a id="Tc_RpasYuQEX0ia1K7T0altHA_32_0"></a><a id="Tc_H_36T6GT0EqpxU6Er7U3RQ_33_0"></a><a id="Tc_Y8NmBHAzzkGf2rb_tpW9iw_34_0"></a><a id="Tc_y9r0gV9ug02VSXqds52sHg_35_0"></a><a id="Tc_s84pXJc_wUyjeaCuW3fFUA_35_4"></a><a id="Tc_9S1K2Dq_SUOgantq-EJ1CQ_35_6"></a><a id="Tc_dCMHrd7c9EeGPWmFUBqfGQ_36_0"></a><a id="Tc_hhM_yh5x-0OUF1QMCNFHyA_36_2"></a><a id="Tc_O6sXn9YUvUSFBz61oZUYQQ_36_4"></a><a id="Tc_nTfXH4c0AE-dMyoOgDB8Gg_37_0"></a><a id="Tc_hMnvTxYFV0GePmPT_w6jCw_38_0"></a><a id="Tc_3nGnix46o0-dB9JqU38jxw_38_2"></a><a id="Tc_6KTX-dJeVEa6ZTwJh6d-rQ_38_4"></a><a id="Tc_AOd0J-H04UGyovizkbNq_w_39_0"></a><a id="Tc_nCYEzfXGRk6K92-L_lva_w_40_0"></a><a id="Tc_CDx5HeE0QUmtF_MCSI1Twg_40_2"></a><a id="Tc_wv4rEnHsQUyRaoV6Diz_Kw_41_0"></a><a id="Tc_Yp7Pnx4YfUOuB5aBKiNkLA_41_2"></a><a id="Tc_SXm0vOt7e0GLat4bjj_oXg_41_4"></a><a id="Tc_f6q85a4RTUqU5Wi2fGZnnA_42_0"></a><a id="Tc_lfvafUleuUu4rC8JLhv_XQ_42_2"></a><a id="Tc_nd4FbAk19kqH9nGchRYEDQ_42_4"></a><a id="Tc_oRq_wf2lX0ynC7mflu4mhQ_43_0"></a><a id="Tc_baif_akgC0-wcE_pR1ZQtQ_44_0"></a><a id="Tc_Nczv8F954kCVt_M5o7_Ppg_45_0"></a><a id="Tc_mTIRu7pmOE2sniyLmtF75A_46_0"></a><a id="Tc_VvezIMbvPUyDYD-EdOrSwg_47_0"></a><a id="Tc_kT5IOqP1_E6TIHRyURd9Ow_48_0"></a><a id="Tc_MQYuKvZSOkW-Suowu6pEUg_49_0"></a><a id="Tc_a28KUaFyCUW-esNacoO7SQ_50_0"></a><a id="Tc_GfirNrNxYUy9WnyZlUM3PA_51_0"></a><a id="Tc_yKsb0XrcekydT3cXcRGHOA_52_0"></a><a id="Tc_zMwbZFrZPU6ZmqG_WFN_qw_52_2"></a><a id="Tc_iRe1b6proEW023EZIkUQgg_52_4"></a><a id="Tc_LU1Oy_4GE0OdKU7X9CqTYA_53_0"></a><a id="Tc_zAKrsQxOXEqHxKcZKGCCeg_53_2"></a><a id="Tc_0Hd7J_96e06JRv5uIBL1Kw_53_6"></a><a id="Tc_mzCOuriO5UyycmTApl4LJA_54_0"></a><a id="Tc_17EEWFFtPEG7ceHiRLAW0A_54_2"></a><a id="Tc_oFkmsGOwAEClzPBWF6f-JA_54_4"></a><a id="Tc_OZVDAveQuUqlc9iT9HbYGQ_55_0"></a><a id="Tc_bfL3eGg2g0i2524Uezj0eg_55_2"></a><a id="Tc_rWDtkehixUWfalVW-Y2EEw_55_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times New Roman Bold';font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times New Roman Bold';font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman Bold';font-size:7.5pt;font-weight:bold;">For&#160;the&#160;years&#160;ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times New Roman Bold';font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times New Roman Bold';font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman Bold';font-size:7.5pt;font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times New Roman Bold';font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times New Roman Bold';font-size:7.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman Bold';font-size:7.5pt;font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times New Roman Bold';font-size:7.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman Bold';font-size:7.5pt;font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times New Roman Bold';font-size:7.5pt;">&#160;&#160;&#160;&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman Bold';font-size:7.5pt;font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times New Roman Bold';font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times New Roman Bold';font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman Bold';font-size:7.5pt;font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times New Roman Bold';font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman Bold';font-size:7.5pt;font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Times New Roman Bold';font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-family:'Times New Roman Bold';font-size:7.5pt;font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Cash flows from operating activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_9IrFaq-Uik6pdexflzhgdQ_6_2">16,432,308</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_4ub8zLFCwk64s99IXvS0KA_6_4">42,397,279</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="0" id="Tc_LKgWcK_3R0CCfKj9zRf_fg_6_6">73,177,935</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Depreciation and amortization</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Tc_TU-qtZYrOkupb2Z78_zlSg_8_2">816,686</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Tc_TSi-kST6zkq6uxWvTqwZDA_8_4">858,408</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Tc_rbQ61mzgn0Ocxq4Ms4Frtg_8_6">1,125,032</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Loss (gain) on disposal of property, equipment and software</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" id="Tc_jQpG6-zH9UWnGWbDs9f3Gg_9_2">1,841</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="0" id="Tc_L85_M_4y6kSFIfV11ikE0A_9_4">327</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="0" id="Tc_KAsfk5UXVk6IIeGbvgrk0w_9_6">18,973</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Share-based compensation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_PJ2e8oFJwE2jJL0D0_K8jw_10_2">611,711</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_DiAgefbjbEWNWZJ13cX-Wg_10_4">10,129,541</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="0" id="Tc_cC52TvLZA0KLA4ufimGO_Q_10_6">18,679,658</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Change in fair value of warrant liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="0" id="Tc_HAPU9nfUg0SXKq3u9oIcLQ_11_2">1,207,415</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">.Interest income on promissory notes</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="adag:InterestIncomeExpenseOnPromissoryNotes" scale="0" id="Tc_5rE6-vNCvUKb6wR5mejaJA_12_6">9,946</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Foreign exchange loss (gain), net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="0" id="Tc_b30fk2ASJk2Yw0i-nvzCVA_13_2">21,867</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="0" id="Tc_KshbWBTqQkmwYTvX6cHQFA_13_4">644,693</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" sign="-" scale="0" id="Tc_P3oDfET0j0WQF3zYdJ2_Gg_13_6">603,459</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Changes in operating assets and liabilities:</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Accounts receivable, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="Tc_GaL8yUihRUmjMnttQ1sJRw_15_2">480,000</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="0" id="Tc_TPb-ZL8qBE-a2uH2ghjUPg_15_4">480,000</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="0" id="Tc_aqIRvMM0ykCHNeeYP_3zBA_15_6">3,000,000</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Prepayments and other current assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="0" id="Tc_rZU5V0mpa0yENRouQH4nig_16_2">111,516</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_mQJd2ArXAU6_d1jDhioD0A_16_4">2,337,011</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" id="Tc_S1-_X6Py80CZ-8SKnJzVQw_16_6">231,287</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Amount due from related parties</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="0" id="Tc_mdvL1gzmKUuV7dS0g3kMRw_17_2">704,253</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" sign="-" scale="0" id="Tc_VQSeldR0SUqkGpDh-vfpFA_17_4">1,300,790</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="0" id="Tc_Va6hXoKIKUWJLLdua1v-qA_17_6">4,374,274</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Other non-current assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" id="Tc_7Gu3-GoUnEum-rCam1KihA_18_2">38,040</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" id="Tc_QCH0yq1vKU6tvx5K8aYCCg_18_4">13,292</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="0" id="Tc_KCy8mRIbEki_oMPfH-q9wQ_18_6">24,210</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_OUEsDsACsUSvMkPKWN1vuQ_19_2">153,737</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_CDrK_MQ9H0ObGBLrs0h5ng_19_4">1,097,261</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_Vv_jYNw7J0qJBdtbUmx_IQ_19_6">1,511,640</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Contract liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="Tc_GctcMT22c0We6GBUWG6HWQ_20_2">993,378</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" sign="-" scale="0" id="Tc_wnBijFtin0GCJRUz5i5UMw_20_4">267,842</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="0" id="Tc_qnGlZDP5V0-ky5nBqxw3mA_20_6">4,774,464</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Amount due to related parties</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" sign="-" scale="0" id="Tc_11SlBBf6xUqFWgh3P9mixw_21_2">1,778,469</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" id="Tc_BoKzZmj890ar9uQicpBmDg_21_4">639,579</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueToRelatedParties" scale="0" id="Tc_zGFAXvtHl0u0ropC0VzIeQ_21_6">7,930,703</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Accruals and other current liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" sign="-" scale="0" id="Tc__RRV4IHbGk-0mOIPq_owUA_22_2">34,277</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" id="Tc_L5BCBp6N-0SWtbtQSBLgag_22_4">1,243,150</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" scale="0" id="Tc_O_NRc5dJvEKSKNihcxrUfQ_22_6">1,057,491</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Income tax payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="0" id="Tc_L6gYSoosmEyDjshODcravw_23_6">1,657,450</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Deferred tax liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" sign="-" scale="0" id="Tc_BdPkulaVK0uryuEtmD2zRg_24_6">44,163</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"><span style="font-size:7.5pt;">Other non-current liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" sign="-" scale="0" id="Tc_J-ndFnR2rUGRAcMLiwyiIg_25_2">142,114</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="0" id="Tc_PZ8Jya76FUWxN_GrpYmB2g_25_4">91,955</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Net cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_MGmp4hQtnkGjyJInrXHGJQ_26_2">18,153,556</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_6NzYoiW7DkmBDXfWJd0SiA_26_4">28,529,720</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_S4fDE2Fp2kuV7oIupvHHmQ_26_6">43,414,619</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Cash flows from investing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Placement of short-term investments</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="0" id="Tc_uVRzmUsqY0iwB6SNJazvQw_28_2">19,000,000</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Withdrawal of short-term investments</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="Tc_sNaL0nEt2EKIAhKu7dVkQg_29_2">44,000,000</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" scale="0" id="Tc_VDdmDorsskS1ZqF_1XaY5Q_29_4">8,000,000</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Proceeds from disposal of property, equipment and software</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="0" id="Tc_DiNQPa4ZRUmDnHEWxn019w_30_2">7,697</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="0" id="Tc__ldScYMij0yjJ5iHml_ZRg_30_4">7,930</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Purchase of property, equipment and software</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="0" id="Tc_FUUPNaIVD0SWbBn9vSZ8Ng_31_2">151,829</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="0" id="Tc_-7OWmA2Y706XVXyGqIlUHQ_31_4">935,199</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="0" id="Tc_vaFsej0gyUOpK0FvKQ9NAA_31_6">2,509,926</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Net cash generated from (used in) investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="Tc_g0RdBs5EgkWfdlig8wXfGQ_32_2">24,855,868</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" id="Tc_VUZSKohdXUejBnc_fNYQSQ_32_4">7,072,731</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="0" id="Tc_OHl0BjiRY0axeo7UEN7e_Q_32_6">2,509,926</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Cash flows from financing activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Proceeds from borrowings</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" id="Tc_87cQdnhEY0GoxCAX-YDBUA_34_2">2,651,874</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" id="Tc_4sRoRt58eUyp_SWwViTbBw_34_4">6,083,650</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="0" id="Tc_AF4GMwHbOEa_uSe_pZoY9Q_34_6">4,386,860</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Proceeds from issuance of convertible redeemable preferred shares and warrants</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="adag:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants" scale="0" id="Tc_LxXZmgajCkamVh83T1abHg_35_2">68,999,999</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Proceeds from share subscriptions</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> &#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromContributedCapital" scale="0" id="Tc_q7UTZ5UZbUqolhwDwAdsJA_36_6">381,282</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Proceeds from exercise of share options</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_3ctP5X_2WUK0OZ22DASuOg_37_2">459,796</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_ZbqYtOLEEU6ER5JaqcvSEw_37_4">140,928</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Tc_KHk2_DZT0kiUGOqe6xHojQ_37_6">231,521</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Proceeds from initial public offering, net of underwriting commissions</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="0" id="Tc_J8SjPQhAmE2tn451YAzjhg_38_6">149,411,950</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Repayment of borrowings</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Tc_ZCMDeazbT0qJAg32rdafIg_39_2">2,417,192</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Tc_G-AOOp-XH0OUg94ybXuyNA_39_4">1,063,670</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Tc_kqmIE8KcakOwTBqpT38tIg_39_6">5,089,717</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Payment of initial public offering costs</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Tc_MbKG4CP6QE-222uDmw77Mw_40_4">721,532</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="0" id="Tc_Ju4Qxyxq30qlDaH6WNySlg_40_6">1,595,088</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Purchase of treasury shares under stock repurchase program</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="0" id="Tc_wPa_05rp_k2NVgYSdKhftw_41_6">2,361,576</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Costs for retirement of treasury shares</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="adag:RetirementOfTreasuryShares" scale="0" id="Tc_B8QbCOse40a5GvjtuLVZeQ_42_6">8,090</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Net cash generated from financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_U70LgGCrGkSA0t0TTuM81g_43_2">69,694,477</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_SUFSkrCzVUmIjtE09y_-1w_43_4">4,439,376</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_2YuDrD97d0W8PtXhCKExkQ_43_6">145,357,142</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Effect of exchange rate on cash and cash equivalents</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" id="Tc_8tj1YVXPHkGU4U_fjm4c8w_44_2">77,544</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="0" id="Tc_sZhWOmXAUk285J7V5Gh8JQ_44_4">364,177</ix:nonFraction>)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="0" id="Tc_QDyOHcaLY0uTgAWrFwY0Iw_44_6">192,352</ix:nonFraction>)</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Net increase in cash and cash equivalents</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_4dSPO1JtoUi3MM6k6nSuKA_45_2">76,474,333</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="0" id="Tc__1_jpJsUpUWZ0gkd20-Cjw_45_4">17,381,790</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" id="Tc_EKdH505EWk-VAnHVi0IDfw_45_6">99,240,245</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Cash and cash equivalents at the beginning of year</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2018_T4mq9hT6lUOBey2VJKkGww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_f8zhCohlg0acIQowy0yJBA_46_2">16,058,455</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_Gatt8U2o4k6MprcSIj7CjQ_46_4">92,532,788</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_M2zfku2GmkSTpeEY9ruiNg_46_6">75,150,998</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Cash and cash equivalents at the end of year</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_J9ibjt_qr0SurcXMyBkDtg_47_2">92,532,788</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_ZBmFa0nQKEiunaPoA9dzqQ_47_4">75,150,998</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_4kgWDHqixU-sGTTnxZGbkg_47_6">174,391,243</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">Supplemental cash flow disclosures:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Interest paid</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="Tc_jIzQSiSCfkuXZ6VWpXbeKA_49_2">142,058</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="Tc_EUBrwPBzy0u-mYpcHoFY3A_49_4">202,165</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="0" id="Tc_0GmJKDwL402Pe2vCXjYTXA_49_6">359,569</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><b style="font-size:7.5pt;font-weight:bold;">Non-cash activities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Accretion of convertible redeemable preferred shares to redemption value</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_hM1tZVGuwke40LvY5yWSYQ_51_2">246,184</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_b6gYw5k23EmSHF8hT66J6A_51_4">248,113</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_Ybyy1eI61kmvXG81OKKgbQ_51_6">28,553</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Conversion of preferred shares</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ConversionOfStockAmountIssued1" scale="0" id="Tc_GcI1uyE3GkCnyo5s4Nqf8A_52_6">154,477,960</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Payables for deferred initial public offering cost</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="adag:PayablesForDeferredInitialPublicOfferingCost" scale="0" id="Tc_vj_OxvcK0EiuLrwqh-sO9w_53_4">2,276,183</ix:nonFraction></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Retirement of treasury shares</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="adag:NonCashActivitiesRetirementOfTreasuryShares" scale="0" id="Tc_KU6PNOmwEkG-FOM6pSaBQw_54_6">1,741,971</ix:nonFraction></span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:7.5pt;">Surrender of ordinary shares for repayment of promissory notes </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;">&#8212;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:7.5pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:7.5pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="adag:SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes" scale="0" id="Tc_IUBwk9g400y4G6HyR4DvIg_55_6">6,800,856</ix:nonFraction></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="font-size:7pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1ea4d90e_72bb_4701_9970_700084c3f44b"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;">ADAGENE INC.</p><a id="NOTESTOTHECONSOLIDATEDFINANCIALSTATEMENT"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 6pt 0pt;">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;text-align:center;margin:0pt 0pt 12pt 0pt;">DECEMBER 31, 2019, 2020 AND 2021</p><a id="Tc_E0jrCBtRM0acFTJUhrjzMQ_1_6"></a><a id="Tc_aY3Pxa6M3U-mjUoLllOBIA_2_2"></a><a id="Tc_sq7-DyIy1UC6IHFKM3SKhA_2_4"></a><a id="Tc_QsDqC2PI30ai81sDeOTg3A_2_6"></a><a id="Tc_l_SBYpGHP06z27iZWIMq5w_3_0"></a><a id="Tc_naHGkt73FU6UW3h6Owo5Og_3_2"></a><a id="Tc_XRtxt7kOW0WNpeqwkwiGKw_3_4"></a><a id="Tc_hbmo7F4cQk-q2eil-JsdlQ_3_6"></a><a id="Tc_upiNNAF5T0CK6lu2G19EJg_3_8"></a><a id="Tc_b99AKAOKpE2Z9BovK8gMsg_4_0"></a><a id="Tc_SbuVO3_uSE-k6sPvr48KZA_4_2"></a><a id="Tc_Y6kD0Ne11UGBoSmktUnDag_4_4"></a><a id="Tc_nPGYVl29Z0SQG58-r-uEXg_4_7"></a><a id="Tc_ZnPTsKXAX0COpPnRPTDjjA_4_8"></a><a id="Tc_YTjKxkRLe0Sj6W8qoYIo5A_5_0"></a><a id="Tc_bWtnMepJY0-WHyQZjvtKcA_5_2"></a><a id="Tc_gH0YLH88W0W2UGopV4Sj_w_5_4"></a><a id="Tc_tz0dy5Hs9UiCOdmxKInVSA_5_7"></a><a id="Tc_YNEew-woUEishCghz9LYEw_5_8"></a><a id="Tc_yerwD1_m-EmmBW0o1mLUVQ_6_0"></a><a id="Tc__UWw83JCP06iq6-DzRooSw_6_2"></a><a id="Tc_9dTMQGPFMkGt-qc2ZimPrw_6_4"></a><a id="Tc_u00YozEavkCW6_UmQEqeWw_6_7"></a><a id="Tc_AzKOyVncrUO7zgkI5e0osA_6_8"></a><a id="Tc_Jb8OYGLkJUmZnDUficC9XA_7_0"></a><a id="Tc_SuDNptHsREqgQFWKOXIBmQ_7_2"></a><a id="Tc_DHgT8cA-qUaeJ1YZCANBxQ_7_4"></a><a id="Tc_E6uw951GL0KVPI2g9tmJgA_7_7"></a><a id="Tc_FSqYECWzFEOxfS5054xYQw_7_8"></a><a id="Tc_9ug00_5qG0qkk0Tprfs4qQ_8_0"></a><a id="Tc_B9xDwK5Cn0ONNRrPlTC_7g_8_2"></a><a id="Tc_G8Nc1Y-mOUOWUsa63Gx3iw_8_4"></a><a id="Tc_XKEvDYUhuEixJ_CMy8FsNQ_8_7"></a><a id="Tc_R6BOuGHnsUOj_wDNDxPn4Q_8_8"></a><a id="Tc_frIu6d3wukW63THA8ELX-w_9_0"></a><a id="Tc_i32xTmT3r02TWFTS2BCvnQ_9_2"></a><a id="Tc_NM19l31PW0iHcZr2hlTkIg_9_4"></a><a id="Tc_gsmMzcHer0Ci79gfFFwNwQ_9_7"></a><a id="Tc_YVhUblwj-ki4y14WkwdxNw_9_8"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_oUmd1ALnAkO4LGQmITw9Sw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">1. ORGANIZATION AND BASIS OF PRESENTATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene&#160;Inc. (the &#8220;Company&#8221;) is a limited liability company incorporated in the Cayman Islands on February&#160;25, 2011. The Company, together with its subsidiaries (collectively, the &#8220;Group&#8221;), are principally engaged in research, development and production of monoclonal antibody drugs for cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 8, 2021, the Company&#8217;s registration statement relating to its initial public offering (&#8220;IPO&#8221;) of its American Depositary Shares (&#8220;ADSs&#8221;) was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;) and the shares of its ADSs began trading on the NASDAQ Global Market on February 9, 2021. The public offering price of the ADSs sold in the IPO was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Y5rj-vidfkKdz_NhXcGhJg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_FH8xwHYpCUy6FuTRMj646w">19.00</ix:nonFraction> per ADS. The IPO closed on February 11, 2021, pursuant to which the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_2_11_2021_To_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_2gbsAY6W7kyRuQc1AoDg2A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_lHDCYHMVXEW9DvVhPRIW2A">8,457,100</ix:nonFraction> ADSs, including the exercise in full of the underwriters&#8217; option to purchase <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_2_11_2021_To_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_r4I_ZqMIBUCX-Ze0L9Tr3w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_d7h9myveuEy1dNCYyelRAg">1,103,100</ix:nonFraction> additional ADSs from the Company. The Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_2_11_2021_To_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_2gbsAY6W7kyRuQc1AoDg2A" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="Narr_cliu55sIcUCLcTzNA7l30w">145.9</ix:nonFraction> million, after underwriting discounts, commissions and estimated offering expenses. Each ADS represents one and one quarter (<ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="As_Of_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Y5rj-vidfkKdz_NhXcGhJg" decimals="2" format="ixt:numdotdecimal" name="dei:EntityListingDepositoryReceiptRatio" scale="0" id="Narr_FoMi7Os6J0GoXV39PyYg3w">1.25</ix:nonFraction>) ordinary shares of the Company. Upon the completion of the IPO, all outstanding shares of the convertible redeemable preferred shares were converted into ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, the Company&#8217;s principal subsidiaries are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="adag:SummaryOfPrincipalSubsidiariesTableTextBlock" id="Tb_8k-91aMXJUiWQSfLsBMS_w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:27.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage&#160;of&#160;legal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Place&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ownership</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Entity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">by&#160;the&#160;Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal&#160;activities</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adagene (Hong Kong) Limited</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 12, 2011</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Hong Kong</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdageneHongKongLimitedMember_v6J9OTGMEE63UoAoetmLFQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Tc_PixhK1EAVUeRBiEuAoDh2w_4_6">100</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Investment holding</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adagene Incorporated</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">September 20, 2017</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">The United States of America</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdageneIncorporatedMember_HofBS4guwEOkNvbMdQ_4rw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Tc_1Xzng9wreUGmsr0xZJTQMg_5_6">100</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adagene (Suzhou) Limited</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 28, 2012</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">The People&#8217;s Republic of China (&#8220;PRC&#8221; or &#8220;China&#8221;)</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdageneSuzhouLimitedMember_A507RmmeiUq6oiW6PXn0aA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Tc_4k0dVlFOfkqmGdcxFuSU7Q_6_6">100</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adagene Australia PTY Ltd.</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">May 30, 2018</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Australia</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdageneAustraliaPtyLtd.Member_zLdH5fF9zEmREPsgUVwMsA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Tc_vp_53VLIf0i5w74Ha9y6rg_7_6">100</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adagene PTE. Ltd.</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 27, 2020</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Singapore</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdagenePte.Ltd.Member_d3JwN-5-lUqU1dSbJ5ORkQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Tc_YSlhFsN1XUWfW9BOUMRy3A_8_6">100</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adagene AG</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August 31, 2020</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Switzerland</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdageneAgMember_bsCxNvIf3UO-29bfLUj7-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Tc_XQkfPnBMD06DQHI4OlY0Fw_9_6">100</ix:nonFraction></p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb__jqJSCnxQ0OrYx7mdFxF-w" continuedAt="Tb__jqJSCnxQ0OrYx7mdFxF-w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_CDCrqOujRUyQpcWi6NAN8w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;).</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:ConsolidationPolicyTextBlock" id="Tb_BFkREQY1y0ONG-c88aMMnQ" continuedAt="Tb_BFkREQY1y0ONG-c88aMMnQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements of the Group include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation.</p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb__jqJSCnxQ0OrYx7mdFxF-w_cont1" continuedAt="Tb__jqJSCnxQ0OrYx7mdFxF-w_cont2"><ix:continuation id="Tb_BFkREQY1y0ONG-c88aMMnQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:UseOfEstimates" id="Tb_x5QdoMRXQEqPiGmPCtK4CQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the balance sheet dates and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in the Group&#8217;s consolidated financial statements include, but are not limited to, licensing and collaboration revenue recognition, research and development expense allocation, the useful lives and impairment of long-lived assets, tax valuation allowance, and share-based compensation expenses. Management bases the estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could materially differ from those estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="Tb_iTZqX2RtJkSYW2-IjeIyMA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Foreign currency translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The functional currency of the Company, Adagene (Hong Kong) Limited, Adagene Incorporated and Adagene PTE. Ltd. is the United States dollar (&#8220;US$&#8221;). The functional currency of the Company&#8217;s PRC subsidiary is Renminbi (&#8220;RMB&#8221;). The functional currency of the Company&#8217;s Australian subsidiary is Australian dollar (&#8220;AU$&#8221;). The functional currency of the Company&#8217;s Swiss subsidiary is Swiss Franc (&#8220;CHF&#8221;). The determination of the respective functional currency is based on the criteria stated in Accounting Standard Codification (&#8220;ASC&#8221;) 830, <i style="font-style:italic;">Foreign Currency Matters</i>. The Company uses US$ as its reporting currency. The financial statements of the Company&#8217;s PRC, Australian and Swiss subsidiaries are translated from the functional currency to the reporting currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Transactions denominated in foreign currencies are remeasured into the functional currency at the exchange rates quoted by the People&#8217;s Bank of China (the &#8220;PBOC&#8221;) prevailing on the transaction dates. Monetary assets and liabilities denominated in foreign currencies are re-measured at the exchange rates prevailing at the balance sheet date. Non-monetary items that are measured in terms of historical costs in foreign currency are re-measured using the exchange rates at the dates of the initial transactions. Exchange gains and losses are included in the consolidated statements of comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities are translated at the exchange rates at the balance sheet date, equity accounts are translated at historical exchange rates and revenues, expenses, gains and losses are translated using the average rate for the&#160;year. Translation adjustments are reported as accumulated comprehensive loss and are shown as a separate component of other comprehensive loss in the consolidated statements of comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_HRZA4aGfLUCj8BGqskwFpw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Cash and cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Cash and cash equivalents primarily consist of cash and demand deposits which are highly liquid. The Group considers highly liquid investments that are readily convertible to known amounts of cash and with original maturities from the date of purchase of three&#160;months or less to be cash equivalents. All cash and cash equivalents are unrestricted as to withdrawal and use.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="adag:AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock" id="Tb_Gvv0aRYlDk2KNMizCxkngw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Accounts receivable and allowance for doubtful accounts</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">Account receivable is recorded when the Group has an unconditional right to consideration. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due. Accounts receivable is carried at net realizable value. An allowance for doubtful accounts is recorded in the period when collection of the amount is no longer probable. In evaluating the collectability of receivable balances, the Group considers specific evidence including the aging of the receivable, the customer&#8217;s payment history, its current credit-worthiness and other factors. Accounts receivable is written off when management determines a balance is uncollectable after all collection efforts have ceased.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="Tb_MRphuc5OjUStiznjNSyX2A" continuedAt="Tb_MRphuc5OjUStiznjNSyX2A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Fair value measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group applies ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures</i>. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 requires disclosures to be provided for fair value measurements. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 1&#8212;Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0c7f2503_2061_4765_bf84_4df55bc491c8"></a><a id="_0c7f2503_2061_4765_bf84_4df55bc491c8_2"></a><a id="_0c7f2503_2061_4765_bf84_4df55bc491c8_3"></a><a id="Tc_BNDR2M-aK0eW4P8BHbIs2g_1_0"></a><a id="Tc_-5C5lkjNrEOPaqjVwCIG-w_1_2"></a><a id="Tc_COdsfyUuzkyRZPyjPxV68Q_2_0"></a><a id="Tc_vcHs63w6LkyREfsO-tRslw_3_0"></a><a id="Tc_max8QqZqPUS9b6JBvM64tQ_4_0"></a><a id="Tc_QSVA4-wNnEus61lFW3f6Hg_4_2"></a><a id="Tc_Wjbx3RII1keE0uMbem01Qw_5_0"></a><a id="Tc_mbbmyDgDSkCNWNlr4ipMUQ_6_0"></a><a id="Tc_d2tdVV5xzESbcQJNzw6NDQ_6_2"></a><a id="Tc_tEfwzGpLH0uFWppUWALUOA_7_0"></a><a id="Tc_mSjntCWb-E-b-jHz4udKJQ_7_2"></a><ix:continuation id="Tb__jqJSCnxQ0OrYx7mdFxF-w_cont2" continuedAt="Tb__jqJSCnxQ0OrYx7mdFxF-w_cont3"><ix:continuation id="Tb_MRphuc5OjUStiznjNSyX2A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 2&#8212;Other inputs that are directly or indirectly observable in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 3&#8212;Unobservable inputs which are supported by little or no market activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1)&#160;market approach; (2)&#160;income approach; and (3)&#160;cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of cash and cash equivalent, accounts receivable, amounts due to related parties and other current assets, accounts payable, amounts due to related parties, accrued liabilities and other current liabilities and short-term borrowings approximate their fair values because of their generally short maturities. The carrying amount of long-term borrowings approximate their fair values since they bear interest rates which approximate market interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group did not transfer any assets or liabilities in or out of Level&#160;3 during the&#160;years ended December&#160;31, 2020 or 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group had <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_4s8XwXHiB0e5MShPFwPsfw" decimals="0" format="ixt-sec:numwordsen" name="adag:FinancialAssetsFairValueDisclosure" scale="0" id="Narr_XJosLxIRv0GmOLSynrCg4A"><ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_YFcme7KyF0aRVFQE-QOpug" decimals="0" format="ixt-sec:numwordsen" name="adag:FinancialAssetsFairValueDisclosure" scale="0" id="Narr_uArU6yj1IE-_dB4CyEHeQw">no</ix:nonFraction></ix:nonFraction> financial assets and liabilities measured and recorded at fair value on a nonrecurring basis as of December&#160;31, 2020 and 2021.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_8Lb-Se-SpkqAS-iY2zhKcA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Property, equipment and software</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Property and equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="adag:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" id="Tb_pJ6uF156MEmtCO0vyXh6mQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Machinery and laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_KGhMFlu_2kq3DNJN3Ro4IA" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_S8ND24qUNkijvS5SlIx4yw_2_2"><span style="font-size:10pt;">5 years</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Vehicles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_PoM_lvt6D0O7Kn1hJ7TRfg" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_PILkLopLK0220nWI9V3D7Q_3_2"><span style="font-size:10pt;">4 years</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Furniture and tools</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_W-K9fp6sNECpsw-JihnlWQ" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_ECqjT6hwkUm_kPZ94kLXuQ"><span style="font-size:10pt;">3</span></ix:nonNumeric><span style="font-size:10pt;"> - </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_uyRyfLpBGEeJ8flPQrftCQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_pCNhEKOAfUStY3SIIqMmsQ"><span style="font-size:10pt;">5 years</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Electronic equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_CaBsmpmN7kyoRjl5pYT5EA" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Tc_utocKQetK02WS7wt3DO8lg_5_2"><span style="font-size:10pt;">3 years</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Computer software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_jsS3_yJrR0KhUEt67uACsw" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_h1MnC4Z-FkKcO_y4t02JzQ"><span style="font-size:10pt;">3</span></ix:nonNumeric><span style="font-size:10pt;white-space:pre-wrap;"> -  </span><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_crIDIxsy2U6oUr2eG_WiNQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_Mj3E2TyBOUqD6bJpQmCUAg"><span style="font-size:10pt;">5 years</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Lesser of lease terms or estimated useful lives of the assets</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Repair and maintenance costs are charged to expense as incurred, whereas the cost of renewals and betterments that extend the useful lives of property, equipment and software are capitalized as additions to the related assets. Retirements, sales and disposals of assets are recorded by removing the cost and accumulated depreciation and amortization from the asset and accumulated depreciation and amortization accounts with any resulting gain or loss reflected in the consolidated statements of comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="Tb_N98CzUZkbkGKY9SsnTIGTQ" continuedAt="Tb_N98CzUZkbkGKY9SsnTIGTQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Impairment of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group evaluates the recoverability of its long-lived assets, including fixed assets and intangible assets with finite lives, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. When these events occur, the Group measures impairment by comparing the carrying amount of the assets to the estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the assets, the Group recognizes an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the assets, when the market prices are not readily available. The adjusted carrying amount of the assets is the new cost basis and is depreciated over the assets&#8217; remaining useful lives. Long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="Narr_0vtp7e-1vk-OTay9jCLPtA"><ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="Narr_itxkyZqow0-EDEKSadWlhw"><ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="Narr_ThhnkOqLk0yyfHBJHUtNfA">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment loss was recorded for the&#160;years ended December&#160;31, 2019, 2020 and 2021. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb__jqJSCnxQ0OrYx7mdFxF-w_cont3" continuedAt="Tb__jqJSCnxQ0OrYx7mdFxF-w_cont4"><ix:continuation id="Tb_N98CzUZkbkGKY9SsnTIGTQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="Tb_Oa6G679AnUaObIs6eEKkbQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Segment reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In accordance with ASC 280, </span><i style="font-weight:normal;">Segment Reporting</i><span style="font-style:normal;font-weight:normal;">, the Group&#8217;s chief operating decision maker (&#8220;CODM&#8221;) has been identified as the Chief Executive Officer. The Group&#8217;s CODM reviews the consolidated results of operations when making decisions about allocating resources and assessing performance of the Group. The Group operates and manages it business as a single segment. No geographical segments are presented as a substantial portion of the Group&#8217;s long-lived assets are located in the PRC with the exception of certain laboratory and electronic equipment which are located in the U.S.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb_4iKpHUxQz0K0qja04gSNCw" continuedAt="Tb_4iKpHUxQz0K0qja04gSNCw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Revenue recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At contract inception of collaboration and out-licensing arrangements, the Group analyzes its arrangements to assess whether they are within the scope of ASC 808, <i style="font-style:italic;">Collaborative Arrangements</i> (&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Group first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are reflective of a vendor-customer relationship and therefore within the scope of ASC 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently. Under the criteria of ASC 606, the Group recognizes revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group adopted ASC 606 for all periods presented. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Group only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. The Group reviews the contract to determine which performance obligations are distinct and represent a promise to provide distinct goods or services or a series of distinct goods or services as defined by the standard. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation as and when that performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licenses of Intellectual Property:</i> Upfront non-refundable payments for licensing the Group&#8217;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Group recognizes revenues from non-refundable, up-front fees allocated to the license at a point in time, when the transfer of control of the license to the licensee occurs and the licensee is able to use and benefit from the license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Services</i><span style="white-space:pre-wrap;">:  The portion of the transaction price allocated to research and development services performance obligations is deferred and recognized at a point in time as delivery of such services occurs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Milestone Payments:</i><span style="white-space:pre-wrap;">  At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group re-evaluates the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Royalties:</i> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Group recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb__jqJSCnxQ0OrYx7mdFxF-w_cont4" continuedAt="Tb__jqJSCnxQ0OrYx7mdFxF-w_cont5"><ix:continuation id="Tb_4iKpHUxQz0K0qja04gSNCw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">During the years ended December 31, 2019 and 2020,  </span><ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA" decimals="0" format="ixt-sec:numwordsen" name="adag:MilestonePaymentsOrRoyaltyPaymentsReceived" scale="0" id="Narr_CdWjr0sLkEiy6ZN1Y4s-0w"><ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt-sec:numwordsen" name="adag:MilestonePaymentsOrRoyaltyPaymentsReceived" scale="0" id="Narr_2Qan5XL4BkmHsqMyCgEdeA">no</ix:nonFraction></ix:nonFraction> milestone payments or royalty payments were received. During the year ended December 31, 2021, milestone payment was received, but no royalty payments were received. Substantially all of the Group&#8217;s revenue has been derived from its out-licensing agreements with respect to licensed products such as DNA sequences, cell lines, etc., and such revenues are recognized when the customer obtains control of the licensed product, which occurs at a point in time, upon delivery to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Contract assets and contract liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">When a customer pays consideration before the Group transfers products or services, the Group records its obligation as a contract liability; When the Group satisfies its performance obligations by providing products or services to a customer before the customer pays consideration and before payment is due, the Group recognizes its rights to consideration as a contract asset.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_U96acXcHFkWIk2r9wr5QIQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Research and development expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Elements of research and development expenses primarily include (1) payroll and other related costs of personnel engaged in research and development activities, (2) costs related to pre-clinical testing of the Group&#8217;s technologies under development and clinical trials such as payments to contract research organizations (&#8220;CRO&#8221;) and contract manufacturing organizations (&#8220;CMO&#8221;), investigators and clinical trial sites that conduct the clinical studies; (3) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation and amortization, and facility related expenses, and (4) other research and development expenses. Research and development costs are expensed as incurred when the related research and development services are provided to the Group and the resulting assets, if any, have no alternative future uses. As of December 31, 2020 and 2021, the Group had several ongoing clinical studies in various clinical trial stages. The contracts with CRO and CMO are generally cancellable, with notice, at the Group&#8217;s option. The Group did not record any accrued expenses related to cancellation of CRO or CMO contracts as of December 31, 2020 or 2021 as the Group did not have any plan to cancel the existing CRO or CMO contracts.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="adag:GovernmentSubsidiesPolicyTextBlock" id="Tb_VpVCiY76OEeBRx8dxm5kjA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Government subsidies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Government subsidies primarily consist of financial subsidies received from provincial and local governments for operating a business in their jurisdictions and compliance with specific policies promoted by the governments. The Group&#8217;s PRC based subsidiary received government subsidies from certain local government. The Group&#8217;s government subsidies consist of specific subsidies and other subsidies. Specific subsidies are subsidies that the local government has set certain conditions for the subsidies. Other subsidies are the subsidies that the local government has not set any conditions and are not tied to future trends or performance of the Group, receipt of such subsidy income is not contingent upon any further actions or performance of the Group and the amounts do not have to be refunded under any circumstances. These specific subsidies are recorded as other non-current liabilities upon receipt and are recognized as other income when the conditions are met. Other subsidies are recognized as other income upon receipt as further performance by the Group is not required. Government subsidies of US</span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="-5" format="ixt:numdotdecimal" name="adag:GovernmentSubsidiesReceived" scale="6" id="Narr__nNNAmx0m0mAq0t4k4okgg">0.7</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> million, US</span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="-5" format="ixt:numdotdecimal" name="adag:GovernmentSubsidiesReceived" scale="6" id="Narr_4efU3033_kOoyLrBezPrrA">0.8</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> million and US</span><span style="font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="-5" format="ixt:numdotdecimal" name="adag:GovernmentSubsidiesReceived" scale="6" id="Narr__LcKr96g7kqej5xErtaqYg">1.4</ix:nonFraction></span><span style="font-style:normal;font-weight:normal;"> million were received and recognized as other income during the years ended December 31, 2019, 2020 and 2021, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In addition, the Group&#8217;s Australian subsidiary received research and development tax incentive from the Australian Taxation Office. The tax incentive was recognized as other income upon receipt as the incentive was not dependent upon having a tax liability and further performance by the Group was not required.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_SzHS2ykyd0SSU6WSGSgi4Q" continuedAt="Tb_SzHS2ykyd0SSU6WSGSgi4Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Leases are classified at the inception date as either a capital lease or an operating lease. The Group assesses a lease to be a capital lease if any of the following conditions exists: a)&#160;ownership is transferred to the lessee by the end of the lease term, b)&#160;there is a bargain purchase option, c)&#160;the lease term is at least 75% of the property&#8217;s estimated remaining economic life or d)&#160;the present value of the minimum lease payments at the beginning of the lease term is 90% or more of the fair value of the leased property to the lessor at the inception date. A capital lease is accounted for as if there was an acquisition of an asset and an incurrence of an obligation at the inception of the lease.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb__jqJSCnxQ0OrYx7mdFxF-w_cont5" continuedAt="Tb__jqJSCnxQ0OrYx7mdFxF-w_cont6"><ix:continuation id="Tb_SzHS2ykyd0SSU6WSGSgi4Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All other leases are accounted for as operating leases wherein rental payments are expensed on a straight-line basis over their respective lease terms. The Group leases certain office space under non-cancelable operating lease agreements. Certain lease agreements contain rent holidays. Rent holidays are considered in determining the straight-line rent expense to be recorded over the lease term. The lease term begins on the date of initial possession of the leased property for purpose of recognizing lease expense on straight-line basis over the term of the lease.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_4YdKsE0cEEmYZMlfYYbU7g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss) is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by shareholders and distributions to shareholders. Accumulated other comprehensive income (loss) of the Group includes foreign currency translation adjustments related to the Group and its subsidiaries whose functional currency is not US$.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_Ou3bfY1M5Uy9Dlxe7bS8sQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group follows the liability method of accounting for income taxes in accordance with ASC&#160;740, <i style="font-style:italic;">Income Taxes</i> (&#8220;ASC&#160;740&#8221;). Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Group records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group evaluates its uncertain tax positions using the provisions of ASC 740, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group recognizes in the consolidated financial statements the benefit of a tax position which is &#8220;more likely than not&#8221; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty&#160;percent likelihood of being realized upon settlement. It is the Group&#8217;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:DebtPolicyTextBlock" id="Tb_lVWOc6iXvE68UjEVfq1AwQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Borrowings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the consolidated statements of comprehensive loss over the period of the borrowings using the effective interest method.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_MuMe41vhNE2IFHmTIfxD2Q" continuedAt="Tb_MuMe41vhNE2IFHmTIfxD2Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company grants restricted shares and stock options to eligible employees and nonemployees and accounts for share-based compensation in accordance with ASC 718, <i style="font-style:italic;">Compensation-Stock Compensation</i>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses a) immediately at the grant date if no vesting conditions are required; b) for share-based awards granted with only service conditions, using the straight-line method over the vesting period; or c) for share-based awards granted with service conditions and performance conditions, using the graded vesting method over the vesting period if and when the Company concludes that it is probable that the performance conditions will be achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb__jqJSCnxQ0OrYx7mdFxF-w_cont6" continuedAt="Tb__jqJSCnxQ0OrYx7mdFxF-w_cont7"><ix:continuation id="Tb_MuMe41vhNE2IFHmTIfxD2Q_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_dvUXUIJvTEmHQx7MFK444w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In accordance with ASC 260, </span><i style="font-weight:normal;">Earnings Per Share</i><span style="font-style:normal;font-weight:normal;">, basic net loss per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of unrestricted ordinary shares outstanding during the year using the two-class method. Under the two-class method, net loss is allocated between ordinary shares and other participating securities based on dividends declared (or accumulated) and participating rights in undistributed earnings as if all the earnings for the reporting period had been distributed. The Company&#8217;s convertible redeemable preferred shares were participating securities because they were entitled to receive dividends or distributions on an as converted basis. Diluted net loss per share is calculated by dividing net loss attributable to ordinary shareholders, as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares include ordinary shares issuable upon the conversion of the convertible redeemable preferred shares using the if-converted method, and ordinary shares issuable upon the exercise of share options, using the treasury stock method. Ordinary share equivalents are excluded from the computation of diluted earnings per share if their effects are anti-dilutive. For the periods presented herein, the computation of basic net loss per share using the two-class method is not applicable as the Group is in a net loss position and the participating securities do not have contractual rights and obligations to share in the losses of the Group.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="adag:EmployeeDefinedContributionPlanPolicyTextBlock" id="Tb_swrszsF3f06k4dkHsVFVtQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Employee defined contribution plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As stipulated by the regulations of the PRC, full-time employees of the Group are entitled to staff welfare benefits including medical care, welfare subsidies, unemployment insurance and pension benefits through a PRC government-mandated multi-employer defined contribution plan. The Group is required to accrue for these benefits based on certain percentages of the qualified employees&#8217; salaries. The Group is required to make contributions to the plans out of the amounts accrued. The PRC government is responsible for the medical benefits and the pension liability to be paid to these employees and the Group&#8217;s obligations are limited to the amounts contributed. The Group has no further payment obligations once the contributions have been paid. The Group recorded employee benefit expenses of US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" id="Narr_sRfKc4Kz6UKtVIezySvoFw">1,145,165</ix:nonFraction> , US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" id="Narr_m3C3iyb7Mk25wjirCGWMRw">622,377</ix:nonFraction> and US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="0" id="Narr_nyT_RgkftUi_Swo78V5qXA">2,223,493</ix:nonFraction> for the&#160;years ended December&#160;31, 2019 , 2020 and 2021, respectively.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_wwBm5Un5VEC5j6tq_uMnLw" continuedAt="Tb_wwBm5Un5VEC5j6tq_uMnLw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of risks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020 and 2021, the amount of cash and cash equivalents of US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_srt_StatementGeographicalAxis_adag_MainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_kj-fSey9EEyEtxiGoEoEpg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="0" id="Narr_s4R4__c6-UuJmPmldFdMhQ">3,424,456</ix:nonFraction> and US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_adag_MainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_a3KAemeQF0yabn5RGbhXiA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="0" id="Narr_jXIrJnsDeUaOsbryI8ySHg">3,650,474</ix:nonFraction> respectively, were held at major financial institutions located in Mainland China, and US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_srt_StatementGeographicalAxis_adag_OutsideMainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_yZFC6h4cwEK-fa4C8KeTyg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="0" id="Narr_FW9ldxb1006gwOoWBWLdmQ">71,726,542</ix:nonFraction> and US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_adag_OutsideMainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_EFliqC7rp0Sx41tQSgTPRA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="0" id="Narr_dGtxWvLuO0CbOCfrqDmxvA">170,740,769</ix:nonFraction>,respectively, were deposited with major financial institutions located outside of Mainland China. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable is typically unsecured and denominated in US$ and is derived from revenues earned from customers. The Group manages credit risk of accounts receivable through ongoing monitoring of the outstanding balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Group&#8217;s research and development services were purchased from <ix:nonFraction unitRef="Unit_Standard_item_VDVAwvxnO0aSdoyDMbjpLA" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_QrdSnJigEEC83xAI-BxP_w" decimals="INF" format="ixt-sec:numwordsen" name="adag:NumberOfMajorSupplier" scale="0" id="Narr_C0vERAObdEq36TypvQp0Gg"><ix:nonFraction unitRef="Unit_Standard_item_VDVAwvxnO0aSdoyDMbjpLA" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_U2Wz9tRC_E-e-VNBsazHMQ" decimals="INF" format="ixt-sec:numwordsen" name="adag:NumberOfMajorSupplier" scale="0" id="Narr_nTTSG1nesEub-oBRyO02DQ"><ix:nonFraction unitRef="Unit_Standard_item_VDVAwvxnO0aSdoyDMbjpLA" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_nR1gjPUSp0uEhhqDafgCZA" decimals="INF" format="ixt-sec:numwordsen" name="adag:NumberOfMajorSupplier" scale="0" id="Narr_yqXt06CNokG_q69IoKjWNQ">one</ix:nonFraction></ix:nonFraction></ix:nonFraction> supplier group, who collectively accounted for <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2019_To_12_31_2019_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_ZYOjK2vU90O3dGqnw4FeEQ" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_MUIxHg1v5EGeo-ifbTEbSw">23.13</ix:nonFraction>%,<ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2020_To_12_31_2020_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_SxQdUgI9Z06HufSkFzPTTg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_0C2wZVQ1uU6lIXfEEexG5g">21.51</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_LqlKepEaPEyADAUMj0EidA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_VRx1rIR0LEO_P5rDaci6wg">18.45</ix:nonFraction>%of the Group&#8217;s total research and development services purchases for the&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Business and economic risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group believes that changes in any of the following areas could have a material adverse effect on the Group&#8217;s future consolidated financial position, results of operations or cash flows: changes in the overall demand for services; competitive pressures due to new entrants; advances and new trends in new technologies and industry standards; changes in certain strategic relationships; regulatory considerations and risks associated with the Group&#8217;s ability to attract employees necessary to support its growth. The Group&#8217;s operations could also be adversely affected by significant political, regulatory, economic and social uncertainties in the PRC.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb__jqJSCnxQ0OrYx7mdFxF-w_cont7" continuedAt="Tb__jqJSCnxQ0OrYx7mdFxF-w_cont8"><ix:continuation id="Tb_wwBm5Un5VEC5j6tq_uMnLw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Foreign currency exchange rate risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Group&#8217;s businesses are transacted in RMB, which is not a freely convertible currency. On January&#160;1, 1994, the PRC government abolished the dual rate system and introduced a single rate of exchange as quoted daily by the PBOC. However, the unification of the exchange rates does not imply that the RMB may be readily convertible into US$ or other foreign currencies. All foreign exchange transactions continue to take place either through the PBOC or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the PBOC. Approval of foreign currency payments by the PBOC or other institutions requires submitting a payment application form together with suppliers&#8217; invoices, shipping documents and signed contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From July&#160;21, 2005, the RMB is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. For U.S. dollar against RMB, there was depreciation of approximately <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="3" format="ixt:numdotdecimal" name="adag:PercentageOfDepreciationOfForeignCurrency" scale="-2" id="Narr_xc6uqpbvf0-CofQKt-bSQg">6.5</ix:nonFraction>% and <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="4" format="ixt:numdotdecimal" name="adag:PercentageOfDepreciationOfForeignCurrency" scale="-2" id="Narr_nyAth4pxC0iDYYKjHOwZ-g">2.29</ix:nonFraction>% in the&#160;years ended December&#160;31, 2020 and 2021, respectively. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the RMB and the U.S. dollar in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The functional currency and the reporting currency of the Company are the US$. However, the Group incurs portions of our expenses, and derives revenues, in currencies other than US$, in particular, the RMB. Any significant fluctuation of the valuation of RMB may materially affect the Group&#8217;s cash flows, expenses, losses and financial position, and the value of any dividends payable on the American Depositary Shares in US$.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_4GUB_L55REGZWzIg19aXlw" continuedAt="Tb_4GUB_L55REGZWzIg19aXlw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Recently issued accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group is an emerging growth company (&#8220;EGC&#8221;) as defined by the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;). The JOBS Act provides that an EGC can take advantage of extended transition periods for complying with new or revised accounting standards. This allows an EGC to delay adoption of certain accounting standards until those standards would otherwise apply to private companies. The Group elected to take advantage of the extended transition periods. However, this election will not apply should the Group cease to be classified as an EGC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-02 (&#8220;ASU 2016-02&#8221;), <i style="font-style:italic;">Leases</i> (Topic 842), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. In July 2018, FASB issued ASU No. 2018-10 (&#8220;ASU 2018-10&#8221;), <i style="font-style:italic;">Codification Improvements to Topic 842, Leases</i>, which clarifies certain aspects of the guidance issued in ASU 2016-02; and ASU No. 2018-11 (&#8220;ASU 2018-11&#8221;), <i style="font-style:italic;">Leases (Topic 842): Targeted Improvements</i>, which provides entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity&#8217;s reporting for the comparative periods presented in the financial statements in which it adopts the new leases standard will continue to be in accordance with current GAAP (Topic 840, Leases). Further, FASB issued ASU No. 2020-05 (&#8220;ASU 2020 05&#8221;), Revenue from Contracts with Customers (Topic 606) and Leases (Topic 842): Effective Dates for Certain Entities, which extends the adoption date for certain entities. For the Group, the updated guidance is effective for fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. The Group does not plan to early adopt the new lease standards and the Group expects that applying the ASU 2016-02 would materially increase the assets and liabilities due to the recognition of right-of-use assets and lease liabilities on its consolidated balance sheets, with an immaterial impact on its consolidated statements of comprehensive loss and consolidated statements of cash flows.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb__jqJSCnxQ0OrYx7mdFxF-w_cont8"><ix:continuation id="Tb_4GUB_L55REGZWzIg19aXlw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, FASB issued ASU No. 2016-13, <i style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (&#8220;ASU 2016-13&#8221;). ASU 2016-13 is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. This ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of the Group&#8217;s portfolio. These disclosures include qualitative and quantitative requirements that provide additional information about the amounts recorded in the financial statements. In November 2019, FASB issued ASU 2019-10, which extends the adoption date for certain registrants. The amendments in ASU 2016-13 are effective for fiscal years beginning after December 15, 2022, including interim periods within fiscal years beginning after December 15, 2023. The Group does not plan to early adopt ASU 2016-13 and is currently in the process of evaluating the impact of adoption of this guidance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2018, FASB issued ASU 2018-18, <i style="font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</i>. This update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer and precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The update is effective in fiscal years beginning after December 15, 2021, and interim periods therein, and early adoption is permitted for entities that have adopted ASC 606. This guidance should be applied retrospectively to the date of initial application of Topic 606. The Group elected to early adopt this ASU and applied this guidance retrospectively to all periods presented. The impact of this ASU to the consolidated financial statements is immaterial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, FASB issued ASU 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>. This update simplifies the accounting for income taxes as part of FASB&#8217;s overall initiative to reduce complexity in accounting standards. The amendments include removal of certain exceptions to the general principles of ASC 740, <i style="font-style:italic;">Income Taxes</i>, and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. The update is effective in fiscal years beginning after December 15, 2022, and interim periods therein, and early adoption is permitted. Certain amendments in this update should be applied retrospectively or modified retrospectively, all other amendments should be applied prospectively. The Group does not plan to early adopt ASU 2019-12 and is currently evaluating the impact on its financial statements of adopting this guidance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In August 2020, FASB issued ASU 2020-06, <i style="font-style:italic;">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, which simplifies the accounting for convertible instruments by removing certain separation models in Subtopic 470-20, <i style="font-style:italic;">Debt&#8212;Debt with Conversion and Other Options</i>, for convertible instruments and also increases information transparency by making disclosure amendments. The standard is effective for private companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact of this accounting standard update on its condensed consolidated financial statements.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_uR-bNUAje0WetoEt7NEYsQ_1_2"></a><a id="Tc_MsqQDem4KUqc4_YHowUEkg_2_2"></a><a id="Tc_xBC9F62X5E-YiyPGAwi_Dg_3_2"></a><a id="Tc_Yhs2u7v2Akyuku5SCTYzAA_3_4"></a><a id="Tc_Lx_2hjwl2UeWk-Okl3MtGg_4_2"></a><a id="Tc_xUNQUdWqmE6xpVX1VzMzLQ_4_4"></a><a id="Tc_45K0BX_ECECt0bP6cITGew_5_0"></a><a id="Tc_WYGcpeKpVkyXTYEmvWCjbA_5_2"></a><a id="Tc_hVwPXZT88Ue8Xm6FX5B9xg_6_0"></a><a id="Tc_HrX-zt7FeEmEeomCjlECXg_6_2"></a><a id="Tc_ADRxpufsQUi0-Gl6oozAvQ_6_4"></a><a id="Tc_e9mTSwkuBkis9ZYYHPBm8A_7_2"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="Tb_UJHiz9_H8EOMlKTsNRbdsQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">3. ACCOUNTS RECEIVABLE, NET</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="Tb_MQuZTyyoik-eAsK2kBDBNw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableGross" scale="0" id="Tc_HgghiBGhBUe5C2AoGddZnw_5_4">3,000,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Allowance for doubtful accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNet" scale="0" id="Tc_7HQkIQUD7E6c7SkYWg8mMA_7_4">3,000,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_9a2b8f55_f70b_4335_afde_759ab42b291b"></a><a id="Tc_QEFZKYXVg0auqCsbRl7pFA_1_2"></a><a id="Tc_-TtkTWFMpUq1ND8uDnNnvw_2_2"></a><a id="Tc_Tm_rOKWelkiVqTdIteYA-w_2_4"></a><a id="Tc_9HCD4SHX20uRgSbyN9CQzQ_3_2"></a><a id="Tc_hJD_YWmw3kCqGdAOK7IOTg_3_4"></a><a id="Tc_ZWCohRkXmk-MHCtq-rax6Q_4_0"></a><a id="Tc_INMtcxiS1kafMWJzBOH41A_5_0"></a><a id="Tc_Q0U0UTfiC0yQhoH3m3WEeg_6_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="adag:PrepaidExpenseAndOtherAssetsCurrentTextBlock" id="Tb_r1PY6hEHOki0QbcZWP4l3A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">4. PREPAYMENTS AND OTHER CURRENT ASSETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prepayments and other current assets consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="Tb_Gv9TmZQQQkuLNLKFpQRVAA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Prepayments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_d6ADvgyvZEW8qA3zmcdrhA_4_2">1,907,781</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_1QSRmoVnbEyRtG5wJlfSPA_4_4">1,562,177</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Deposits(a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepositsAssetsCurrent" scale="0" id="Tc_xAB8Ll3Ah0OFP5znwq6BFg_5_2">1,646,446</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepositsAssetsCurrent" scale="0" id="Tc_U6nXyQFzkkK57gz6HvNByw_5_4">1,873,843</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Others </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="Tc_jLnC-4g5Q0miMyiT-29-sA_6_2">259,757</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="0" id="Tc_oi-5we7M00utAzESZ6dqKA_6_4">619,901</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_eICPVN7lV0KpzM8tnlwShQ_7_2">3,813,984</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" id="Tc_4wbwrxsFX06tcS86JkqTbg_7_4">4,055,921</ix:nonFraction></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Note (a): The deposits represented the amounts that the Group paid to its CRO vendors for various outsourced research and development programs according to the terms of respective CRO agreements. The Group expects to recover the deposits if the programs fail or the agreements are cancelled.</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_WfFk988OmUCfH3FJtr9arg_1_2"></a><a id="Tc_pNZhZxFdsESgWhokkGFW8w_2_2"></a><a id="Tc_nHFlSzXdAUeF4YE1Sr7j7g_2_4"></a><a id="Tc_YBr8fsUp_k-C2cLwcH4b3A_3_2"></a><a id="Tc_Bx3wwlVbCU2ggMtuN1xmEg_3_4"></a><a id="Tc_51PX-w_Io0i_YKqINGC47w_4_0"></a><a id="Tc_JQcwCFWIWEKpN4NF3uTeOQ_5_0"></a><a id="Tc_-PAJT6tfM0-UcwLILIcQqg_6_0"></a><a id="Tc_ls6Wp1J53029b1nsZ0jhAw_7_0"></a><a id="Tc_MsxyCywATEq3m3TsGWyFIQ_8_0"></a><a id="Tc__IGY6vUPp0GyBC6Fx0Iumg_9_0"></a><a id="Tc_tmvJEWQp0kSDJaV84Y-xTw_10_0"></a><a id="Tc_8OHySngUmUWYJZB_KiEewQ_11_0"></a><a id="Tc_Hl2NGP_px0KqU44U-rPrCw_12_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_Jxpt-glEGk-H8Y_rKCnf-Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">5. PROPERTY, EQUIPMENT AND SOFTWARE, NET</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property, equipment and software consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_XtczcN3wEka9PNq0a5dftA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Machinery and laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_xjhR4xY8gkilBkiNX6jw5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_Dh-Tpe53IkSQvYiw_7T57g_4_2">4,150,822</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_0Fkj5p3dOEG5xJSp6cquuA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_5igxS47bd0KBXcdGzpayvg_4_4">5,252,399</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_c4u5F8308kqb6Yb80ib06w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_vrGHoIQvfEC4ZZDrSOQQpg_5_2">915,208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_TXr2Um0aJEuPO1zHVf0dgg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_HaslUZqGzEyYNQPqOV8tcQ_5_4">1,152,743</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Electronic equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_Y9nw88vBK0en70RiAB4NXg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_gdCHoFkOPUmHsRkzJisHIg_6_2">962,684</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_EcLyGd1RtEKchc8-Nwr_uQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_6jdIEyvuak6hbKYt5xEFyA_6_4">1,863,956</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and tools</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_ugbL_thGJ0y97MV05rKCuA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_Zu5aoGz4JkOzO2K5PhyVeQ_7_2">106,492</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_-OER4mKuwE6orMCLglM2Mw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_gP6oFg1mwk2VIIj-ULxGAw_7_4">81,467</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Vehicles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_OkKAU_FVpUiB6Qf9qvp3MQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_b-AOCxNJ_0-UVGfuv9NDZg_8_2">126,764</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_Ii31JlQF6EyGi8FubMjm2w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_qCBqQzZ8kUarXBliKqzO9g_8_4">87,680</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_rhq53MJUbUaZODEvfgDerw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_4-q1yABYHki2ybEBg6qVhQ_9_2">95,586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ciXSaRCCIUShj4RIB8kXvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_u66AUhSM_EaPCLr6of1MxQ_9_4">371,636</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total property, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_MJF0isCUQ06oOf6lnV8myA_10_2">6,357,556</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" id="Tc_jx7MMTmgTEeCEUo9qAvGYg_10_4">8,809,881</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_w3pfHcR7HE2Zu-XvaUhnig_11_2">4,290,431</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" id="Tc_zEaXUIBdU0iTck5UZpt2nw_11_4">5,322,264</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net book value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_dCCXg6vwVUK1LbPZfA_3wQ_12_2">2,067,125</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" id="Tc_lH0ntVdIV0WApHbkfeCErA_12_4">3,487,617</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Depreciation and amortization expenses recognized for the&#160;years ended December&#160;31, 2019, 2020 and 2021 were US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Narr_5uw5dmZNzkGv7Qb4_71owQ">816,686</ix:nonFraction> , US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Narr__yXW4U4l_02iN72rmJWSkg">858,408</ix:nonFraction>, and US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" id="Narr_sXIbdfzU70ycrA6YzZ54xQ">1,125,032</ix:nonFraction> respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_KzYEfPq_eUuHEwO_b4bPnQ_1_2"></a><a id="Tc_l2qKt_kne0GDRri5hlIssQ_2_2"></a><a id="Tc_e6H6gAkOSEO39r9InvKJ3g_2_4"></a><a id="Tc_-7KYH659DUy0ccoQBkJVIw_3_2"></a><a id="Tc_V4GwhEpockSt8P813ewt8Q_3_4"></a><a id="Tc_QI0pdhx4UEW5rC-TaRgw4Q_4_0"></a><a id="Tc_RTuXuRg81ESKp95vPSRE5g_5_0"></a><a id="Tc_rMSVqW6kv0S2-Tbgf5-BJA_6_0"></a><a id="Tc_I1fY4rnNU0OBVuSPZDqHCw_7_0"></a><a id="Tc_o52ViBe7EUingVXX0wo_hQ_8_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" id="Tb_yhd7rtwfY0OTH7u1oNt3Mw" continuedAt="Tb_yhd7rtwfY0OTH7u1oNt3Mw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">6. ACCRUALS AND OTHER CURRENT LIABILITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Accrued liabilities and other current liabilities consisted of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" id="Tb_WUqprV3vok2A4Ggh06PdsQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Professional service fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_xN6VheG7_kWDWCFCxJK73w_4_2">3,459,430</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" id="Tc_BRCYFldNK06Zbh0qBQpPMQ_4_4">935,434</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Payroll and related liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_fjsm8RJHr0iQE5O6MJqibQ_5_2">2,390,025</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="0" id="Tc_6K68R9epBky-fxGVSOGrag_5_4">3,229,794</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Utility and maintenance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedUtilitiesCurrent" scale="0" id="Tc_46h6VLtnukO5QF-vMuCszA_6_2">459</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedUtilitiesCurrent" scale="0" id="Tc_V9yR3qjWTkSt-EwE2j1nVA_6_4">8,685</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Other taxes and surcharge</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="0" id="Tc_FxKq1ZLHIEyh5KOjMex4FA_7_2">63,919</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="0" id="Tc_DLF-dYC2lUeKBQ1_kgtgmQ_7_4">62,270</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_ezIaDjlG_Uuv6wm6_unNcw_8_2">145,664</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="0" id="Tc_TVWcH8e5jUqeuDGTXVuHUA_8_4">143,060</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="adag:AccruedLiabilitiesAndOtherCurrentLiabilities" scale="0" id="Tc_5SJ35btHp0SFg52xVvX-Wg_9_2">6,059,497</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="adag:AccruedLiabilitiesAndOtherCurrentLiabilities" scale="0" id="Tc_KIFalLqqDEiCHSM3qUlV3g_9_4">4,379,243</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_yhd7rtwfY0OTH7u1oNt3Mw_cont1"></ix:continuation><a id="Tc__3inYlPBnkeoIJhZ99kn6A_1_2"></a><a id="Tc_MbvdKjDZP0SlPeTNR8_ZXA_2_2"></a><a id="Tc_bW6jjubZTk-tDimFyE9JcA_2_4"></a><a id="Tc_TA2uN8jwrUO9PqJ0wuLm9w_3_2"></a><a id="Tc_ulABCm4Fbkybj3rgXGgE4w_3_4"></a><a id="Tc_COkS8wAGRUizzpDNSvEerQ_4_0"></a><a id="Tc_KSiRg0G_Vkuq62hjWQzzHw_5_0"></a><a id="Tc_sglpts8m9U2hgbf7pi-wZg_6_0"></a><a id="Tc_U78fxRGlTU-piPDMiHvBXg_7_0"></a><a id="Tc_l9Su40RBaECGbKdfhOJEsg_8_0"></a><a id="Tc_PMsqred2p0altUFTnSfWFw_9_0"></a><a id="Tc_IsOemtvXEEiS1RWdm6bm5w_10_0"></a><a id="Tc_rAghIbSI-kSZqhTDr2gWBA_11_0"></a><a id="Tc_9dPUJFAKoEqeFz2BPUQpCQ_12_0"></a><a id="Tc_PY49Sh4v30apgcG4Mr__3A_13_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:DebtDisclosureTextBlock" id="Tb_W46Gbhj4Y0ubofzufFcT5g" continuedAt="Tb_W46Gbhj4Y0ubofzufFcT5g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt;">7. BORROWINGS</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:ScheduleOfDebtTableTextBlock" id="Tb_IiKAPEkxOkqUN3_yzOqNbQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Short-term borrowings:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Bank loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="0" id="Tc_fdX7clwaX06oBUJQ1uNMeA_6_2">3,831,476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShortTermBankLoansAndNotesPayable" scale="0" id="Tc__z896qAq9kaaowkpzbCuNA_6_4">3,121,226</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Current portion of long-term borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Tc_EU5dSo92TUuyKXB1JSTS5Q_7_2">1,183,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Tc_zx_jlOd14UmKnAf5lJgV8g_7_4">1,376,319</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total current borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="0" id="Tc_p4ozhb5osUiaHbftGx1Vcw_8_2">5,015,402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="0" id="Tc_txkoNnFrkEyeO68a3IofGw_8_4">4,497,545</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Long-term borrowings:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Bank loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLoansFromBank" scale="0" id="Tc_wTH-zJA3jUqenYt0O4qdnw_11_2">2,965,563</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermLoansFromBank" scale="0" id="Tc_BM7tn2pvzUqlyoAzc3g-pA_11_4">2,991,829</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total non-current borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="0" id="Tc_aXRd9wUFbEiMDRoqLKLbLg_12_2">2,965,563</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="0" id="Tc_dbVqGJu93k6HkfPp-aQXfA_12_4">2,991,829</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total borrowings</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="0" id="Tc_aopTY-UKXk-ChCgbwl9wAQ_13_2">7,980,965</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="0" id="Tc_SX5QKl7bbUm0o7UvlAW3rA_13_4">7,489,374</ix:nonFraction></b></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Short-term borrowings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2019, the Group borrowed a loan with amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_aRG-u8wGNE-CSsqku0pR0g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_0_pdgj27dUKCovPYLtS9rw">5,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_aRG-u8wGNE-CSsqku0pR0g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_wlv7BRVyf0S4K-eh-C1PBg">766,295</ix:nonFraction>) from Bank of Ningbo&#160;Co.,&#160;Ltd. for a term of <ix:nonNumeric contextRef="Duration_9_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_Ruff_uK5bECwmUs88WOIvw" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_n9sZDOD9XE61EK28h_D1JA">one year</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_aRG-u8wGNE-CSsqku0pR0g" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_FB6LFKxZO0SLP343G8t3qw">4.35</ix:nonFraction>% per annum. The borrowing was repaid in September 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2020, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_oYuYrvTHKU2WUWilDTYWFA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_N-HLg0JdPkCaFdnqwDB0qg">10,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_oYuYrvTHKU2WUWilDTYWFA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr__v5M-3X1r0GLrLEcNyRsLg">1,532,591</ix:nonFraction>) from Agricultural Bank of China Limited for a term of <ix:nonNumeric contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_XCA1IgwsJ0i02_dGhfX8Ww" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_HmM3-JPzYUy0xDYX_DUeBg">one year</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_oYuYrvTHKU2WUWilDTYWFA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_4Osw5gtF2U2D_DUKqs1ssw">4.2</ix:nonFraction>% per annum. The borrowing was repaid in June 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2020, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_xK5464GvIU2G2CMxw-2yyg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_0LUXq1KtO02plwJZDOxNQg">5,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_xK5464GvIU2G2CMxw-2yyg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_WmubICvlcky63YLvaFfAIA">766,295</ix:nonFraction>) from Bank of Ningbo Co., Ltd. for a term of <ix:nonNumeric contextRef="Duration_9_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_c2z9l55OS0-09kT4Xr8EBA" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_F6TMpVo0UkmNsJmnw0uPhg">one year</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_xK5464GvIU2G2CMxw-2yyg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_i3M6TF8znE2m8_dRLFlZ_w">4.2</ix:nonFraction>% per annum. The borrowing was repaid in September 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_NfuX6XNrY0y0YKE8g2SAHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_4pIMv9WfXEyBl8Ym16QV5g">5,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_NfuX6XNrY0y0YKE8g2SAHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_AcNpJqizekqy2Xxw1yJUlg">770,962</ix:nonFraction>) from China Merchants Bank Co., Ltd. for a term of <ix:nonNumeric contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_yREvdQEbf0aifJQLSacj_A" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_q6PyS3yMWk6q7uuZsrIwcg">one year</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_NfuX6XNrY0y0YKE8g2SAHQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_kLoYct7_H0ei8HGLyGgWeA">4.1</ix:nonFraction>% per annum. The borrowing was repaid in November 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, the Group borrowed another loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_n4OTuF0LqkKjcG_8uSdSgg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_nANAF0e0y0WYbgN1tGXOwg">5,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_n4OTuF0LqkKjcG_8uSdSgg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_NMUGdQ_1OEm5dXJ2eHI0WQ">770,962</ix:nonFraction>) from China Merchants Bank Co., Ltd. for a term of <ix:nonNumeric contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_6cK__TDe2k2D6upUdm_BkA" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_ZHgN9B_1R02zfWsA1E6cmg">one year</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_n4OTuF0LqkKjcG_8uSdSgg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_LNeqyF0XiU2VUsjUS4n5nA">4.1</ix:nonFraction>% per annum. The borrowing was also repaid in November 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2021, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_7zaPIqJMgEOMGotoMZUnYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_sxNLP46Fnk2gdrpuUB9dSw">9,900,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_7zaPIqJMgEOMGotoMZUnYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_QxJfTAKKG0qzgxmcUOVzeA">1,552,771</ix:nonFraction>) from Agricultural Bank of China Limited for a term of <ix:nonNumeric contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_xPZSxb0_rEyiXfgBq8UngA" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_BUg64hAmSU6lEcInEENkVg">one year</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_7zaPIqJMgEOMGotoMZUnYg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_2U5LwJ1-yk-YuoPORGx77g">4.05</ix:nonFraction>% per annum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2021, the Group borrowed another loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="As_Of_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember__Yp6JfBX00e2bWTEBjp7og" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_HTSrXFMho0yZiwUZKljr3g">10,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember__Yp6JfBX00e2bWTEBjp7og" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_r4stAH5f9E2zkvwROwxSVQ">1,568,455</ix:nonFraction>) from Agricultural Bank of China Limited for a term of <ix:nonNumeric contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_LFa5nidGXk2zyr81bhmV-w" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="Narr_Y4ugwCmg_EaO-9SoYoq4LA">one year</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="As_Of_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember__Yp6JfBX00e2bWTEBjp7og" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_0ufdUOjkBESagR5NAQ443Q">4.05</ix:nonFraction>% per annum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Long-term borrowings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2019, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_8XLbm_NuOEaOfNq0iiQ4Uw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_GEMmQsRZDkqRKwfFZiCapg">7,500,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_8XLbm_NuOEaOfNq0iiQ4Uw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_7zZhzEGk8k2haBbSrnxUQg">1,176,342</ix:nonFraction>) from Shanghai Pudong Development Bank&#160;Co.,&#160;Ltd. for a term of <ix:nonNumeric contextRef="As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_8XLbm_NuOEaOfNq0iiQ4Uw" format="ixt-sec:durwordsen" name="us-gaap:LongTermDebtTerm" id="Narr_Bk2Eefd7iUOD4rrqabsOoA">three years</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_8XLbm_NuOEaOfNq0iiQ4Uw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_udYUvOxXXEO80ftbVuE7yg">5.46</ix:nonFraction>% per annum. The Group repaid RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_Gvzpm_m3g0S200Y-2xFrbg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_xB22J0v1-0-dLljfF3yzEg">375,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_Gvzpm_m3g0S200Y-2xFrbg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_jE498paF-kG17pL4x1UEgQ">58,817</ix:nonFraction>) in 2019, RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_JVqltsC74kiTWg82LEi0EQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_OgKdw9r-SUSwMRKckOwwJQ">1,250,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_JVqltsC74kiTWg82LEi0EQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr__UcI_4BaMkWu6HivsnGc-g">196,057</ix:nonFraction>) in 2020,and RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_ufKZJPNy5EaknPuOgGRVKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_AvLDjGeRh0CAn9qIRexctw">3,375,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_ufKZJPNy5EaknPuOgGRVKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_NWLruGX6RkGl6DB_o041Ag">529,354</ix:nonFraction>) in 2021. As of December 31, 2020 and 2021, RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_nqUKaiveBk6aWC7ifhDHyw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_Dp7G8xDmeEKG4T0ab2ItbQ">3,375,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_nqUKaiveBk6aWC7ifhDHyw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_zhIQyHJCtUy6e83OYPxqKA">529,354</ix:nonFraction>) and RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_c5z9GXzV4UWW7jLt1LL9xA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_crjN0sCOeUGZxot4AZZGfg">2,500,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_c5z9GXzV4UWW7jLt1LL9xA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_P6ei9MQuwUqqBkboqX7KRg">392,114</ix:nonFraction>) repayable within twelve&#160;months for this agreement were classified as &#8220;Current portion of long-term borrowing&#8221; on the consolidated balance sheets, respectively.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b17c34fd_f8a6_407d_9e13_2abe3c6f7584"></a><a id="Tc_TipPp8PnQk69qWwIrFdrPg_1_2"></a><a id="Tc_V6x8ovm-zkWBJE42Hy-S5w_2_2"></a><a id="Tc_uqw8F5WhEU-tTZcrEKVy9A_2_4"></a><a id="Tc_ApwqtEh-sUeERY0z337Y5w_3_2"></a><a id="Tc_tUdSkrKfPkmJMQPNZ2JcQg_3_4"></a><a id="Tc_Ja42FQ9yyEqALtDEwcijnA_4_0"></a><a id="Tc_CUvb2HZS1UWYzKsv4BGH3A_4_4"></a><a id="Tc_7RXHUVmwAEG2GMHAckumCw_5_0"></a><a id="Tc_o7rw3wE6CkGPqj4USvjv9Q_6_0"></a><a id="Tc_mDPC3cfDtU6vnTXwedFdHA_7_0"></a><a id="Tc_bsiDI6gOfUqI7OYTTY184A_7_2"></a><ix:continuation id="Tb_W46Gbhj4Y0ubofzufFcT5g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2019, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="As_Of_6_30_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_tmSdxQVjfUKJf2DV_oxA0A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_ElvNgjKp10udccy7Etf6NQ">6,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_6_30_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_tmSdxQVjfUKJf2DV_oxA0A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_IyjeYEbCUkSmAubW85BGAg">941,074</ix:nonFraction>) from Shanghai Pudong Development Bank&#160;Co.,&#160;Ltd. for a term of <ix:nonNumeric contextRef="As_Of_6_30_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_tmSdxQVjfUKJf2DV_oxA0A" format="ixt-sec:durwordsen" name="us-gaap:LongTermDebtTerm" id="Narr_0zkLW4iZF0ifHKnojR3rHA">three years</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="As_Of_6_30_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_tmSdxQVjfUKJf2DV_oxA0A" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_Ey1cii_V-EKrNDDygfiuCg">5.23</ix:nonFraction>% per annum. The Group repaid RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_8iysXIGeCkikS5CDa_J0Ag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_q4BFhQdx20aDdggL6ub8og">300,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_8iysXIGeCkikS5CDa_J0Ag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_4lVuZtOXHk2WLYf4iTEnMQ">47,054</ix:nonFraction>) in 2019, RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_He6IyXPrkkSO8ChXsSJeiA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_4u6cCX6LQkSzuj1lMvRQmw">1,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_He6IyXPrkkSO8ChXsSJeiA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_0T-td2nJqEOPtCDHtPm1KA">156,846</ix:nonFraction>) in 2020, and RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_vfbRj1jR1UChcP5_UNgiYQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_nHAXMutaHk2XL_1duZWSPg">2,700,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_vfbRj1jR1UChcP5_UNgiYQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_HaAhmkoPk0iyQ_W3L34nlA">423,483</ix:nonFraction>) in 2021. As of December 31, 2020 and 2021, RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_6fAfKRGGhUqL4IOh5BEK8w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr__1Ikcu-WKUiWcDFqPCirgQ">2,700,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_6fAfKRGGhUqL4IOh5BEK8w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_lCKqOVUYHU2JpO305njpgg">423,483</ix:nonFraction>) and RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_6cOSMximrk2bohWsY9UvnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_PpW_rhTuq0iGiV0ECXp_Ow">2,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_6cOSMximrk2bohWsY9UvnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_ol9eZVmBbkCY9E-MJ9bGiA">313,691</ix:nonFraction>) repayable within twelve&#160;months for this agreement were classified as &#8220;Current portion of long-term borrowing&#8221; on the consolidated balance sheets, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2020, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_CmsXX0QXp0S-fTuzrs4H6w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_SxHUIgb8Rk-OMyrzP68XFQ">16,500,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_CmsXX0QXp0S-fTuzrs4H6w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_x93Tbdjva0azYbkyQDPCEw">2,587,952</ix:nonFraction>) from Shanghai Pudong Development Bank Co., Ltd. for a term of <ix:nonNumeric contextRef="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_CmsXX0QXp0S-fTuzrs4H6w" format="ixt-sec:durwordsen" name="us-gaap:LongTermDebtTerm" id="Narr_PZEK5NMuoEOMkB4ZBmq8RA">three years</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_CmsXX0QXp0S-fTuzrs4H6w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_1dlbQ8PQkUS0ZtpV5zzSuQ">4.27</ix:nonFraction>% per annum.The Group repaid RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_R9K_aCh4f0KdI_UTlvIBAQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_sT1kQAhahUCClIiKvx0i3A">1,650,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_R9K_aCh4f0KdI_UTlvIBAQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="0" id="Narr_NDUxvfwuDUi0Gw683IKHqA">258,796</ix:nonFraction>) in 2021. As of December 31, 2020 and 2021, RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_GfqS1hbef0evoZ9T4mY-ig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_hcSZFG96Fky9fGhIgIzx7Q">1,650,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_GfqS1hbef0evoZ9T4mY-ig" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_VX6MK6o8REy6MXr8pwIlPg">258,796</ix:nonFraction>) and RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_zAcojCdKLE-VHQNNjHb_JA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_UTGwm9cB40SoB-BEQeDX-w">3,850,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_zAcojCdKLE-VHQNNjHb_JA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_gtYeoWAWVEWXXwdV5j7yCA">603,855</ix:nonFraction>) repayable within twelve months for this agreement were classified as &#8220;Current portion of long-term borrowing&#8221; on the consolidated balance sheets, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2021, the Group borrowed a loan with the amount of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_IGsoNcZxl0av20J3TRsTVw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_vwZ3Rrh0002GEDX5TLULeA">8,500,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_IGsoNcZxl0av20J3TRsTVw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_v2HYpibWrUWZTAeXXXHT6w">1,333,186</ix:nonFraction>) from Shanghai Pudong Development Bank Co., Ltd. for a term of <ix:nonNumeric contextRef="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_IGsoNcZxl0av20J3TRsTVw" format="ixt-sec:durwordsen" name="us-gaap:LongTermDebtTerm" id="Narr_xCx8iO0c5Ey9d6BYQQ68AQ">three years</ix:nonNumeric> at the interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_IGsoNcZxl0av20J3TRsTVw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_eqykqRldrUOK_U94ZG4ktA">4.05</ix:nonFraction>% per annum. As of December 31, 2021, RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_m9PDviMAVECncJ6iC8V97g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_AHi7r3tEqkCkbDVf7aBHBQ">425,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_m9PDviMAVECncJ6iC8V97g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="0" id="Narr_wIl2sK8I5ES9b4xfCzVfQg">66,659</ix:nonFraction><span style="white-space:pre-wrap;">)  repayable within twelve months for this agreement was classified as &#8220;Current portion of long-term borrowing&#8221; on the consolidated balance sheets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and 2020, none of the Group&#8217;s borrowings were collateralized or had covenants in the respective loan agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Future maturities of short-term borrowings and long-term borrowings</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="adag:ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock" id="Tb_byEtzea8fEqEPQLTXO8ssg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Future principal maturities of short-term borrowings and long-term borrowings as of December&#160;31, 2020 and 2021 were as followings:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="0" id="Tc_BU6np608ykGsUblH5lxAUw_4_2">5,015,402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" id="Tc_jeDeIlN67EGqxDAHmCq4hw_5_2">1,279,713</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtCurrent" scale="0" id="Tc_qAr0FmKQBUyfeC3-58VNCA_5_4">4,497,545</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="0" id="Tc_MvofCtrzO0KKZODwTpSlDQ_6_2">1,685,850</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="0" id="Tc_IhCGowCTwU2nRzW82usw2g_6_4">1,858,619</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="0" id="Tc_t4xhRuBpS0eOJ0q4h8DMFA_7_4">1,133,210</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="0" id="Tc_Mhfmuzoj9k-W0ouNvS56xg_8_2">7,980,965</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtLongtermAndShorttermCombinedAmount" scale="0" id="Tc_SN3bAn_FakysmZo8nv0gEQ_8_4">7,489,374</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt;"><span style="font-weight:normal;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="adag:DisclosureOfTemporaryEquityAndWarrantsTextBlock" id="Tb_eH36dBNBaEKaGBKII8bUnA" continuedAt="Tb_eH36dBNBaEKaGBKII8bUnA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">8. CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2011, the Company issued convertible notes (&#8220;Series Pre-A Convertible Notes&#8221;) to certain investors in the amount of <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_11_30_2011_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtSecuritiesMember_8DxtpnQnr0KcaNlyma5fZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_MnBJEWDWRE2tfBgWD85H5Q">4,590,908</ix:nonFraction>. The notes carried a simple interest (non-compounding) of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="As_Of_11_30_2011_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtSecuritiesMember_8DxtpnQnr0KcaNlyma5fZg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_4x3xT5emWUC1UldgQp0zPw">6</ix:nonFraction>% per annum as set out in the note purchase agreement. All outstanding principal balance and accrued but unpaid interest of the notes should be automatically converted into the convertible redeemable preferred shares of the Company at a price no more than US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_11_30_2011_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtSecuritiesMember_8DxtpnQnr0KcaNlyma5fZg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_4tUQ1VUM_0mj3wgG7rvV7w">1</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2014, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_otWAtk9h5EmHuBYtwAAZvw" decimals="0" format="ixt:numdotdecimal" name="adag:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" id="Narr_HUcI2Q8rSUCfUT0QeNiVlA">5,473,957</ix:nonFraction> Series A-1 convertible redeemable preferred shares (&#8220;Series A-1 Preferred Shares&#8221;) to certain investors upon conversion of the Company&#8217;s Series Pre-A convertible notes at a conversion price of US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_9GdyKS3_I0KCOd-y1gFghA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="Narr_pqz8etC6cEyqJ4jIPgVZAQ">1</ix:nonFraction> per share. Concurrently, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_dcicFbmqOki6XSFYWhz5_A" decimals="0" format="ixt:numdotdecimal" name="adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_rYqFXDCrBEW8kHAJUs5euQ">2,370,414</ix:nonFraction> Series A-2 convertible redeemable preferred shares (&#8220;Series A-2 Preferred Shares&#8221;) to certain investors at US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_3jZL665NG0K7BDnwmBK99w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_TcOXwRxNg0yQUg41yLoQ1g">1.27</ix:nonFraction> per share for a total consideration of US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_dcicFbmqOki6XSFYWhz5_A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="0" id="Narr_nk55IU2eX0Cl0uH9pqHM6Q">3,000,000</ix:nonFraction>. Series A-1 Preferred Shares and Series A-2 Preferred Shares are collectively referred to as the Series A Preferred Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From January through June 2016, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_SWyRj_9rTEa_35eINBgGXg" decimals="0" format="ixt:numdotdecimal" name="adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_TU3mdvETqEK31ye85QQ57g">7,494,537</ix:nonFraction> Series B convertible redeemable preferred shares (&#8220;Series B Preferred Shares&#8221;) to certain investors at US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_6_30_2016_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_Z_tj6E4y60S8vpMf1oAsgg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_a4YhizFCIkqRGLRv-xu-eQ">3.74</ix:nonFraction> per share for a total consideration of US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_SWyRj_9rTEa_35eINBgGXg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="0" id="Narr_6dPXL7YKPkab-nDxQH6j8A">27,999,995</ix:nonFraction>.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_eH36dBNBaEKaGBKII8bUnA_cont1" continuedAt="Tb_eH36dBNBaEKaGBKII8bUnA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From February&#160;through May&#160;2018, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_2_1_2018_To_5_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_BRbJS1jV-k2FpP0-kKZpDQ" decimals="0" format="ixt:numdotdecimal" name="adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_NB-_UzyriEuZarWb1zdRmg">5,597,354</ix:nonFraction> Series&#160;C-1 convertible redeemable preferred shares (&#8220;Series&#160;C-1 Preferred Shares&#8221;) to certain investors at US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_5_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_g_h3Hub6ukul0-GRuWdxTA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_CFIIVzi9NUefdBbg3BHFlQ">8.93</ix:nonFraction> per share for a total consideration of US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_2_1_2018_To_5_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_BRbJS1jV-k2FpP0-kKZpDQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="0" id="Narr_fwOhDwpIHk-ncunovPI8dA">50,000,033</ix:nonFraction>. Concurrently, in February&#160;2018, the Company also issued warrants to <ix:nonFraction unitRef="Unit_Standard_item_VDVAwvxnO0aSdoyDMbjpLA" contextRef="Duration_2_1_2018_To_2_28_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_IOm0wr8bS0SSsXLzukJ-8g" decimals="INF" format="ixt-sec:numwordsen" name="adag:NumberOfInvestorsToWhomWarrantsWereIssued" scale="0" id="Narr_ujaXbo7oOkyfsDzTqO0cuQ">two</ix:nonFraction> Series&#160;C-1 investors at <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_2_1_2018_To_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_adag_SeriesC1WarrantsMember_WLfnPOEP_kCFFQnnkF3j_g" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" id="Narr_zSqlpt_LRECMaW6GTER0Qw">nil</ix:nonFraction> consideration (&#8220;Series&#160;C-1 Warrants&#8221;). The Series&#160;C-1 Warrants allowed the holders to purchase Series&#160;C-2 Preferred Shares (defined below) at the exercise price of US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_adag_SeriesC1WarrantsMember_dvXoa1fpc0ab3vTaHbqHkg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_4ivlD_1c3kqKn4mtWymMig">10.21</ix:nonFraction> per share for a total consideration of up to US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_2_1_2018_To_2_28_2018_h-YUYJGmUkuPVILUOsDYiw" decimals="0" format="ixt:numdotdecimal" name="adag:MaximumProceedsReceivableFromExerciseOfWarrants" scale="0" id="Narr_tA3QK9aUdUWl87VqX4kHBQ">7,500,000</ix:nonFraction>. Series&#160;C-1 Warrants were exercisable, in whole or in part, at any time from the warrant issuance date to the earlier of i)&#160;April&#160;1, 2019, ii)&#160;a deemed liquidation event or iii)&#160;the closing of the Qualified IPO. Series&#160;C-1 Warrants expired on April&#160;1, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From June&#160;through November&#160;2019, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_6_1_2019_To_11_30_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_SGBgTCSDF0a2llGb4MeGuQ" decimals="0" format="ixt:numdotdecimal" name="adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_V5v9yzQraU-i6UOcTcDsgw">1,861,121</ix:nonFraction> Series&#160;C-2 convertible redeemable preferred shares (&#8220;Series&#160;C-2 Preferred Shares&#8221;) to certain investors at US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_11_30_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_n4xqIulhYU-egftp4MP37g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_KUqqHI1V806gVaGdMzDkyA">10.21</ix:nonFraction> per share for a total consideration of US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_6_1_2019_To_11_30_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_SGBgTCSDF0a2llGb4MeGuQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="0" id="Narr_-KgTzEj7wkqB2MHbX3vQYQ">18,999,999</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_diYKl71mcEa25Z1LgkrP_g" decimals="0" format="ixt:numdotdecimal" name="adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_eIcAAk2Jfk6lQKuIIL1eSw">4,452,441</ix:nonFraction> Series&#160;C-3 convertible redeemable preferred shares (&#8220;Series&#160;C-3 Preferred Shares&#8221;) to a certain investor at US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_aSr2RzGWsEeMWJO8StiKvw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="Narr_Z_z_wClI6U-PSAye2tk0cg">11.23</ix:nonFraction> per share for a total consideration of US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_diYKl71mcEa25Z1LgkrP_g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="0" id="Narr_NdrVSnMj0ka4L6TzNWzCAQ">50,000,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Series&#160;C-1 Preferred Shares, Series&#160;C-2 Preferred Shares and Series&#160;C-3 Preferred Shares are collectively referred to as the Series&#160;C Preferred Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon completion of the IPO on February 11, 2021, each of the then outstanding Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares (collectively the &#8220;Preferred Shares&#8221;) was automatically converted into <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_2_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FkDkbXaQZU-bN_5oHvMW7w" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_IMG-QKZ-REipcdDfXSMsHg">one</ix:nonFraction> ordinary share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The key features of Preferred Shares were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each holder of the Preferred Shares would be entitled to receive non-cumulative dividends when declared by the Board of Directors prior and in preference to ordinary shareholders. The dividend should be paid at the rate of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_88YRhUxrUUSYi1X0zQliFQ">6</ix:nonFraction>% of the original issue price per share per annum on each Preferred Shares in the sequence of Series&#160;C Preferred Shares and Preferred Shares other than the Series&#160;C Preferred Shares. After the preferential dividends relating to the Preferred Shares were paid in full or declared and set apart in any fiscal&#160;year of the Company, any additional dividends out of funds or assets legally available therefore may be declared in that fiscal&#160;year for the Shares and, if such additional dividends were declared, the preferred shareholders shall be entitled to participate on an as converted-basis pro-rata in any dividends or distributions paid to the ordinary shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Voting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each Preferred Share had voting rights equivalent to the number of ordinary shares to which it was convertible at the record date. The Preferred Shares shall vote separately as a class with respect to certain specified matters. Otherwise, the preferred shareholders and ordinary shareholders shall vote together as a single class.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Liquidation preference</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of any liquidation, dissolution or winding up of the Company, or the cessation of the business of the Company or of a substantial portion of the business of the Company, whether voluntary or involuntary, or any deemed liquidation event (unless waived by the preferred shareholders), the preferred shareholders would be entitled to receive a per share amount equal to <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="adag:TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice" scale="-2" id="Narr_e0vZ6HDhfUKsGk48D-Fn5Q">100</ix:nonFraction>% of the original issue price of the respective series of the Preferred Shares, in the sequence of Series&#160;C Preferred Shares, Series&#160;B Preferred Shares and Series&#160;A Preferred Shares. After such liquidation amounts were paid in full, the preferred shareholders were entitled to receive a simple interest accruing on each Preferred Share at <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="adag:TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice" scale="-2" id="Narr_WoaTC7Dao0uxaqp0PMiisQ">6</ix:nonFraction>% of its original issue price per annum from the date of issuance of such Preferred Share to the date of distribution of such amount, in the sequence of Series&#160;C Preferred Shares, Series&#160;B Preferred Shares and Series&#160;A Preferred Shares. After such interest amounts were paid in full, any remaining funds or assets of the Company legally available for distribution to shareholders shall be distributed on a pro rata basis among the preferred shareholders, on an as-converted basis, together with the ordinary shareholders.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_eH36dBNBaEKaGBKII8bUnA_cont2" continuedAt="Tb_eH36dBNBaEKaGBKII8bUnA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Conversion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each Preferred Share might be converted at any time into ordinary shares at the option of the preferred shareholders based on the then-effective conversion price. The initial conversion ratio was <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="Narr_vO23IMoYvEOwqt6bJCwgXg">1</ix:nonFraction>:1, subject to adjustment in the event of share splits, share combinations, ordinary share dividends or distributions, other dividends, reorganizations, mergers, consolidations, reclassifications, exchanges, substitutions, or dilutive issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All Preferred Shares would be converted automatically into ordinary shares at the then effective applicable conversion price upon the earlier of a Qualified Public Offering (public offering of the Company&#8217;s shares with an offering price (exclusive of underwriting commissions and expenses) that reflected a market capitalization (immediately prior to the public offering) of not less than US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="adag:QualifiedPublicOfferingMinimumMarketCapitalization" scale="0" id="Narr_1uaykOd4Tk6Jvr7Xb_JElA">650,000,000</ix:nonFraction> and with an aggregate proceeds of no less than US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="-6" format="ixt:numdotdecimal" name="adag:QualifiedPublicOfferingMinimumProceeds" scale="6" id="Narr_JHEaFJlLyUm2Xf0yvsaY9Q">75</ix:nonFraction>&#160;million) or a date specified by written consent or agreement of the holders of at least <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="adag:ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent" scale="-2" id="Narr_Og_MRoLbCEyKGSaCtSXU0Q">80</ix:nonFraction>% of the voting power of the then outstanding Preferred Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Redemption</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Preferred Shares were redeemable upon request by the holders of the majority outstanding Preferred Shares if the Company failed to consummate a Qualified Public Offering or completed a deemed liquidation event on or before March&#160;31, 2025 at the redemption price equal to the original issue price plus any declared but unpaid dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Accounting for Preferred Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Preferred Shares were classified as mezzanine equity in the consolidated balance sheets because they were contingently redeemable upon the occurrence of an event outside of the Company&#8217;s control (e.g.&#160;the Company not achieving a Qualified Public Offering or a deemed liquidation event before March&#160;31, 2025 (&#8220;Target QIPO Date&#8221;)). The Preferred Shares were determined to be mezzanine equity with no embedded feature to be bifurcated and no beneficial conversion features to be recognized. The Preferred Shares were initially recorded at their respective issuance date fair value, net of issuance cost and fair value allocated to the detachable warrants. The Company did not incur material issuance cost for any Preferred Shares issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the IPO, the Company concluded that the Preferred Shares were not redeemable, but were probable to become redeemable. The Company accreted changes in the redemption value over the period from the date of issuance to the earliest redemption date for the year ended December 31, 2020, and to the IPO date for the year ended December 31, 2021, using the interest method. No accretion charge was recorded as the redemption value was fixed to original issue price for the periods presented, except for Series C-1 Preferred Shares issued with detachable warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Modification of Preferred Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company made several amendments to the Preferred Shares, mainly including: 1)&#160;added redemption rights for Series&#160;A Preferred Shares upon the issuance of the Series&#160;B Preferred Shares; and 2)&#160;extended the Target QIPO Date upon the issuance of the Series&#160;C-1 Preferred Shares and the Series&#160;C-3 Preferred Shares. These amendments were accounted for as modifications rather than extinguishments as the fair values of these Preferred Shares immediately after the amendments were not significantly different from their respective fair values immediately before the amendment. When Preferred Shares are modified and such modification results in value transfer between preferred shareholders and ordinary shareholders, the value transferred is treated as a deemed dividend to or deemed contribution from the preferred shareholders.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_YgckeknVN0idoiqgt0Ie1g_1_0"></a><a id="Tc_njZGm0J51kC3oaf3rgPbxg_1_2"></a><a id="Tc_mL7CL03Wi0SOuO-LHr2Vxw_1_4"></a><a id="Tc_OM_xaFqFzEeXhTLMqB-W_A_1_6"></a><a id="Tc_sZLJT0T3Wky7C4q9-hzbBw_1_8"></a><a id="Tc_vU_G_NsLsUyYvPafPcXn8A_1_10"></a><a id="Tc_MXJGXU18qE2hou1Ekyizng_1_12"></a><a id="Tc_so9rOheNxUyxN7SM3ffwEA_1_14"></a><a id="Tc_KBvrLXUeOk6NXC8EH0OkXw_2_2"></a><a id="Tc_G-2wFvVZEUGbrrFFlKS0ag_2_4"></a><a id="Tc_rRx6yzFz80eHypAouNqXVw_2_6"></a><a id="Tc_GDek_ycKZ0KzgbQMG1KLRw_2_8"></a><a id="Tc_GVEiZVDDoUGyryvi_pP5aw_2_10"></a><a id="Tc_QibpJxuRukuwivGMCy35jA_2_12"></a><a id="Tc_k8OB97nwPkq-PzNLNsLtQg_2_14"></a><a id="Tc_8uMxrxyZZEuQm4bXFniONg_3_0"></a><a id="Tc_DZZgs56RHke8M7iZQIURsQ_3_10"></a><a id="Tc_6ngbbN5Z4kSlWxtg2fQN2A_3_12"></a><a id="Tc_lhHriHbD3kGwy-LB-YNQ2Q_4_0"></a><a id="Tc_vhmjzNA9AEGrydtE3seATQ_4_2"></a><a id="Tc_1fjPlPHZPU-8sD3mTumHwg_4_4"></a><a id="Tc_jArvMdQub0--aoe7ENQp7Q_4_6"></a><a id="Tc_dmvZpDtrp0mw9XhoO-qBKw_4_8"></a><a id="Tc_ivPRPpfcmUqD2UyEQ5lcUw_4_12"></a><a id="Tc_NjZuAijDC0ChNmAHphrAog_5_0"></a><a id="Tc_ZxKxFnL5ckWasaxIBvwQXQ_5_2"></a><a id="Tc_457HZdt2cE67UPuY80ZepQ_5_4"></a><a id="Tc_6jfKt22U1k695LxGm2mdZA_5_6"></a><a id="Tc_4V7pbUYIrk-pVzFsubcFMw_5_8"></a><a id="Tc_e2zueP_vbEKyZQ41toWrzA_5_10"></a><a id="Tc_dYTqpBivbE-76owWq25GTQ_6_0"></a><a id="Tc_KbQF8atUukGIhZ5u7V9uMA_6_2"></a><a id="Tc_aD9-gUBAxU61y4mj1RAg0A_6_4"></a><a id="Tc_xpb0cI203USr7a5hhPC11A_6_6"></a><a id="Tc_R--Q4g4WGUGXyHYq-cKo0w_6_10"></a><a id="Tc_GjokFeenHE6G2cZ7PrsTng_6_12"></a><a id="Tc_lEXNcrBir0iljGY8NqVJRA_7_0"></a><a id="Tc_D-O165GRLEOvz5uJFk6E3Q_8_0"></a><a id="Tc_V-yDDpROnkuixwHoY-o9yg_8_2"></a><a id="Tc_GbsDqwcWQEq3V1wOf2JdNw_8_4"></a><a id="Tc_lohh_gyppEevNlGVcgQhCA_8_6"></a><a id="Tc_GL4cuo3n10mN7hiIvlIChg_8_10"></a><a id="Tc_2tIFeLTaPUiE6Q1YWZJ5vg_8_12"></a><a id="Tc_vwN1dGjyw0GIGxdds2g0kA_9_0"></a><a id="Tc_DQWDqZqQEUWVpiNKmAYuyg_10_0"></a><a id="Tc_1Tk4i56l20SMTvuEkWxzYg_11_0"></a><a id="Tc_MoBr9-3ULkidOLwvkt0rfQ_12_0"></a><a id="Tc_IK3fkp_5ZUCbYOsWIVNtlA_12_2"></a><a id="Tc_ijfEVGOvc0O7ypenJjJ_sQ_12_4"></a><a id="Tc_0XsbHWgd9E-ljDdklacbbA_12_6"></a><a id="Tc_wgf8VucX9EiKaHoyr-QQDg_12_8"></a><a id="Tc_BGqUga4P5US2VGb7Jy6tlQ_12_10"></a><a id="Tc_oCw23RDHmUmP0YeWisjgzg_12_12"></a><a id="Tc_hqzg21b9o0-ta_doMcyl8A_12_14"></a><ix:continuation id="Tb_eH36dBNBaEKaGBKII8bUnA_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company&#8217;s Preferred Shares activities for the periods presented were summarized below:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:TemporaryEquityTableTextBlock" id="Tb_Q426fUHqZEaW2z6W8yWC9w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Mezzanine equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A-1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A-2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series C-1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series C-2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series C-3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$ </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_l9mQvoDziUGbilnG3EPTXg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_MyPoMza7Q0quUmEkq1A5sw_3_2">5,473,957</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_z37ZSNqIdkmrfe2PIq5bYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_n7Pd4sdmRkCG1ucm1UI-6Q_3_4">3,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_pP0RVv1loE2F7LhqFPFl5w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_utQrGB0RrkCJbkuAt-VTqQ_3_6">27,999,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_JVAYrE5J70eJCxdaW-vCJQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_Lega3H_1RE2d2wZbyv9dHA_3_8">48,481,159</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2018_T4mq9hT6lUOBey2VJKkGww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_ghKv5NnIGEqUOBNE_XYggg_3_14">84,955,111</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of Series C-2 Preferred Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember__gZCIGPtFEW337N5JP2Q0Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_PEhgPJjElkCasYT1aYoz3Q_4_10">18,999,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember__gZCIGPtFEW337N5JP2Q0Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_kHWeuzddp02xCezvHCrwOg_4_14">18,999,999</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of Series C-3 Preferred Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_7jJxs3yXWUuOCOO5o_qb7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_KRYWaD2CXU6gfhUIC2HjnA_5_12">50,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_7jJxs3yXWUuOCOO5o_qb7A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="0" id="Tc_pFVOHwG3qkmYTW2lgPh91A_5_14">50,000,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of Series C-1 Preferred Shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_AE-vqlBJf0-NDgL1echf5Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="0" id="Tc_rcK6wAVFNE-NyEy7Zcsh3Q_6_8">246,184</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_AE-vqlBJf0-NDgL1echf5Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="0" id="Tc_3SYSRDZyn0aq9e2bskmLkw_6_14">246,184</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_wmf-_5aZ706YaqfSKWC1Fw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_nb1Fz6DE8E-eq7svvceocQ_7_2">5,473,957</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_mfkgJutHxk6YN0AZLtjrhQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_0Cw7nP9by0a9ZFKkf6ERqg_7_4">3,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_6BqJpjfqTkmbkm23rKGTgQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_hyDMISYOKkSvTFVUSUE98w_7_6">27,999,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_ZGQqQfHg406k4K3zCUbpCQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_ii2r3_n5S0iwfvOTaAyo7w_7_8">48,727,343</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_DnVhZllqokOmO7zElhgtow" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_W2xIO2_acE6QApYF-NZkxQ_7_10">18,999,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_aSr2RzGWsEeMWJO8StiKvw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_nELH_bmhPUubkl6L-kVSJA_7_12">50,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_sipwrK86SEWQD6BrcUak5g_7_14">154,201,294</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of Series C-1 Preferred Shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_bH8gJMCbP0e6I7i5rqUq1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="0" id="Tc_JUqsQ2O_zEyTFGAbSRUYeg_8_8">248,113</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_bH8gJMCbP0e6I7i5rqUq1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="0" id="Tc__tabBqOZMEC91BmyFnqaFw_8_14">248,113</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Fqi_V4t6y0-puYQ1ivg6DQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_BQPct1ldMEGhuQOUMnkh3w_9_2">5,473,957</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_4ehewyms1Eme4lR1LfryGQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_Um4AW2Tp1EG87rm3HqZNTA_9_4">3,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_myF8ybzw20G2z_xDQJRE5Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_G4o5R0_MpEKdYIHhP0rvng_9_6">27,999,995</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_he2uy54CEUGAjR10ESXHnw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_CqXMIZTOYEy_07cp5yRbxw_9_8">48,975,456</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_di_bFxD70EWwEtdspmZWRw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_DrlX96ONRkyL5LG3aNnBTQ_9_10">18,999,999</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_EFH-DFpj80mpuyw7v7-SrQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_4jSNn-5sz0qw7wb2jWyQqw_9_12">50,000,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="0" id="Tc_QD7msstM5kyMM9-OuZ3OMw_9_14">154,449,407</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of Series C-1 Preferred Shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_6qnoqf3lxkW7dfqLzPlqGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="0" id="Tc_yDpaLgDiAUq5dPe-UtmGeg_10_8">28,553</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_6qnoqf3lxkW7dfqLzPlqGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValue" scale="0" id="Tc_WvVwYahAm0qyr5VnGqZ4CQ_10_14">28,553</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Preferred Shares to Ordinary Shares </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Vyleht5K70id4Y2JmD-6pg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_A7xTCERjak--XNq4zWBTdA_11_2">5,473,957</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_ZNLsTGONtk6j3oo5yuSW8w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_CgmbyhFGtUGz3A8IgEmLJg_11_4">3,000,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_cjqzXXZQU0imlA6Mfbj2WQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_vTzveNnLwkGXrQo58zO4Vg_11_6">27,999,995</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_6qnoqf3lxkW7dfqLzPlqGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_f8GXEKsAoUypIYLK8eE0bw_11_8">49,004,009</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_KAuPKCifoEuHLIrulCDCMg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_RfkMcmIs0EmrnKzj7nUakw_11_10">18,999,999</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_bwrRgyxuJEyI4cbzEoFAfA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_xG97sTrUtkGxruay1_9oxg_11_12">50,000,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" id="Tc_nE9ggqLwO02fJDFHIxbb9A_11_14">154,477,960</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The warrants were to subscribe for Series C-2 Preferred Shares and had expired on April 1, 2019, which were freestanding instruments and classified as liabilities in accordance with ASC 480. The warrants were initially recognized at fair value, with subsequent changes in fair value recorded in earnings. The Company recognized gains from the decrease in fair value of the warrants of US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FairValueAdjustmentOfWarrants" sign="-" scale="0" id="Narr_3-AIVXhGIk6uCJYT3lHD6g">1,207,415</ix:nonFraction> for the year ended December 31, 2019.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_gymrf7XxqUSZDa-Za9Kocg" continuedAt="Tb_gymrf7XxqUSZDa-Za9Kocg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">9. SHARE-BASED COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November&#160;7, 2015, the Company adopted a share incentive plan (the &#8220;2015 Plan&#8221;). Under the 2015 Plan, the Company&#8217;s Board of Directors has approved that a maximum aggregate number of shares that may be issued pursuant to all awards granted shall be <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_11_7_2015_us-gaap_PlanNameAxis_adag_Plan2015Member_9j3tnKD5LU-UGahhBXvNQw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_iqGSsChIdUyRLHPz2NiHfQ">4,336,126</ix:nonFraction>. In September&#160;2017, the Company replaced the 2015 Plan with the amended and restated share incentive plan (the &#8220;2017 Plan&#8221;) and increased the maximum number of shares issuable to <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_9_30_2017_us-gaap_PlanNameAxis_adag_Plan2017Member_pj9uKp5Wm0Kh5Lol033Ddw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_sAIra9GUgkCbHbHeioe3sA">6,336,126</ix:nonFraction>. In December&#160;2019, the Company replaced the 2017 Plan with the second amended and restated share incentive plan (the &#8220;2019 Plan&#8221;) and further increased the maximum number of shares issuable to <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_adag_Plan2019Member_qU51oRRIxk-yJ1GRjugs3A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" id="Narr_YB0ksJ2XeE6t6ToNK3U66w">11,391,131</ix:nonFraction>. The terms of the 2015 Plan, 2017 Plan and 2019 Plan are substantially the same other than the maximum aggregate number of shares the Company may issue under the respective plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Share options containing only service conditions granted to each grantee under the share incentive plan will generally be exercisable upon the grantee renders service to the Company in accordance with a stipulated vesting schedule. Grantees are generally subject to a vesting schedule of no longer than <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_OvswsTR8G0ucewnhfOtZsw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_AKhkRaQILkCfD6_ZOzuWqQ">five years</ix:nonNumeric>, under which the grantee earns an entitlement to vest a certain&#160;percentage of his option grants at the end of each&#160;month or&#160;year of completed service. The share option awards shall expire no more than <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_uXE9KaLaqkKt3nfvmqSvqQ">10 years</ix:nonNumeric> from their grant dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Share options containing both service conditions and performance conditions granted to each grantee under the share incentive plan shall become eligible for vesting upon the occurrence of their applicable performance conditions (including but not limited to the occurrence of an IPO, the completion of business and operational goals, etc.).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 15, 2020, pursuant to a board resolution, <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_8_15_2020_To_8_15_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_oE_DhZwnNUKZiikkA5YlwQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_bW7qY5Tzy0OUbaMnMzI6dg">184,692</ix:nonFraction> share options that granted to a senior management was modified and the vesting period of such share options was shortened from <ix:nonNumeric contextRef="Duration_8_14_2020_To_8_14_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_ctCNSEfroUq-2XAeZiRzEQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_OceWbK0O3UugG2ANnOjHsw">5 years</ix:nonNumeric> to <ix:nonNumeric contextRef="Duration_8_15_2020_To_8_15_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_oE_DhZwnNUKZiikkA5YlwQ" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_sU31LL_mRk6wN303lPv4VQ">4 years</ix:nonNumeric>. Since the fair value of the modified award was lower than the fair value of the original award immediately before the modification, <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="0" id="Narr_PgkN49JGqk6yeuepe-wOOA">no</ix:nonFraction> incremental compensation cost was recognized for the modification during the year ended December 31, 2021.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_gymrf7XxqUSZDa-Za9Kocg_cont1" continuedAt="Tb_gymrf7XxqUSZDa-Za9Kocg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 9, 2020, the Company passed a board resolution to waive the vesting schedules and conditions of <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_11_9_2020_To_11_9_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_WROxGtz27EKylxKWrdRpfQ" decimals="0" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived" scale="0" id="Narr_tJGbEy4tDkq7TTgq74LzTw">2,375,000</ix:nonFraction> share options granted to certain management members. Pursuant to this board resolution, these management members exercised all related share options at the original exercise price per share ranging from US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_11_9_2020_To_11_9_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_XjwJ8pZZ10aBP4HgKJNJBA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_c3zMHnFlzEKdmRF7QetVGQ">1.83</ix:nonFraction> to US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_11_9_2020_To_11_9_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Tj93Av1VmE-ghmkmKkxeVw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_Wu67kcb51kqxzrzVGu0ulQ">2.26</ix:nonFraction>. As a result, <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_11_9_2020_To_11_9_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_WROxGtz27EKylxKWrdRpfQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_20tcsotDGUqbgkoP39N1iQ">2,375,000</ix:nonFraction> ordinary shares were issued to these management members. These management members paid the exercise price by issuing recourse promissory notes in the total amount of US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_11_9_2020_To_11_9_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_WROxGtz27EKylxKWrdRpfQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="0" id="Narr_HPvDcQnXBkKS5u8yoWbS_Q">5,197,650</ix:nonFraction>. The Company had the repurchase right to buy back such shares at the original exercise price if the grantees did not meet the original vesting conditions. The Company assessed and considered that in accordance with guidance set out in ASC 718-10-55-31, given such arrangement allows the shares received on exercise be returned to the Company if the original vesting conditions are not satisfied, there has been no substantial change to the vesting conditions and the Company shall continue to account for the share awards in accordance with their original terms. As of December 31, 2021, there were <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_gps4CSyPx0qQcHlONLLb2g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" scale="0" id="Narr_9YSKf8zs4Uui_wVytsuUHQ">1,585,000</ix:nonFraction> shares unvested according to the original vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 16, 2021, the Company passed a board resolution whereby certain management members surrendered a total of <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_16_2021_To_1_16_2021_O_ff5_4bk0yyioWBZTe3bA" decimals="INF" format="ixt:numdotdecimal" name="adag:NumberOfSharesSurrendered" scale="0" id="Narr_k7pSQzD7a0WqEJiMTWvJTg">491,119</ix:nonFraction> ordinary shares as repayment for their respective promissory notes issued in connection with the exercising of options granted to them. In the meantime, the Company further granted these management members the right to repurchase the surrendered shares by way of new option grants with an exercise price of US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_16_2021_To_1_16_2021_O_ff5_4bk0yyioWBZTe3bA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_P1jbYqT8CkeIr_p4kLbf4Q">13.85</ix:nonFraction> per share. The fair values of these share options were US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_16_2021_To_1_16_2021_O_ff5_4bk0yyioWBZTe3bA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_b4ceFCI55E264pdSfdxjwA">7.85</ix:nonFraction> per option, determined by using the binomial option valuation model. The share-based compensation expense related to these share options were recognized immediately upon grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the same board resolution, the 2021 Performance Incentive Plan (the &#8220;2021 Plan&#8221;) was also adopted, under which an aggregate of <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_1_16_2021_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_qSN6Ich4FkuRKoki3TJD4Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_LdoVBPai4E2lJYhChbl7vA">2,994,000</ix:nonFraction> ordinary shares shall be reserved for issuance, and the share limit will automatically increase on the first trading day in January of each year (commencing with 2022) by an amount equal to (1)&#160;<ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_16_2021_To_1_16_2021_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_ajeBNU5LbU2-7VeHwDlygA" decimals="2" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent" scale="-2" id="Narr_B5-dfAnDwE6uJA8SUFha8g">5</ix:nonFraction>% of the total number of the Company&#8217;s outstanding ordinary shares on December&#160;31 of the prior year, or (2)&#160;such lesser number as determined by the board of directors. From March 12, 2021 to December 22, 2021, pursuant to the 2021 Plan, a total of <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_3_12_2021_To_12_22_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_cTAuhhwHJkiqvsAvTWQsmg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_r0NCzSlink-zJZLP5v7aEg">1,303,000</ix:nonFraction> share options were granted to certain employees by 15 batches, with exercise price ranging from US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_3_12_2021_To_12_22_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_u_kx_vXZB0a8pG4zN4WJ5g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_D8WPNgsfK0-Vs0WVFFMV-Q">5.92</ix:nonFraction> to US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_3_12_2021_To_12_22_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_Rz3IDXEqBkqyYcd3zdrfzw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_f6cImdYXVU6p-hd3WAsWZQ">17.56</ix:nonFraction>, respectively. In addition, <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_3_16_2021_To_3_16_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_KJ_klWmvoEGqcj3eoFwhkA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr__Q_EPUQVp0SWkKZN6aFH-Q">23,734</ix:nonFraction> ordinary shares were issued to certain management personnel on March 16, 2021 pursuant to the 2021 Plan. </p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_HHH4XpoALkmzAwPedKPNpw_1_6"></a><a id="Tc_bjT-grGbo0-csaLpOSx6-Q_2_6"></a><a id="Tc_c08pFcNZ10-w9B6FLykYow_2_8"></a><a id="Tc_bInPvE7AN0mHuo4Hgu4Asw_3_4"></a><a id="Tc_ZlKhfNbFp0KtunSivIQG3A_3_6"></a><a id="Tc_6p7AO37zU0u3jE-303trxw_3_8"></a><a id="Tc_8J2pTsluwUuHKT4uBqaK8A_4_4"></a><a id="Tc_36a1aApkQ0-XMJUnRkzW3A_4_6"></a><a id="Tc_zc5NiYigd0KTqei3iWCcEg_4_8"></a><a id="Tc_xHoxeuQrbkWwNZT7r9AOCw_4_10"></a><a id="Tc_BYKjfmeOSEGwYCHmbZg1sw_5_2"></a><a id="Tc_E06e7z9Mo0mF5oPK4FR57A_5_4"></a><a id="Tc_9m_v_W86_02SXJQBU8dpMQ_5_6"></a><a id="Tc_LQq4f-A8Yk6gVID4drHjlw_5_8"></a><a id="Tc_60AcM4iLEE2zF1aTA1bipg_5_10"></a><a id="Tc_v7yB4cZ_v0mDvz2OWkf0zw_6_2"></a><a id="Tc_nvKz2WEjoUO4gC5DNC47Qg_6_4"></a><a id="Tc_mQv8iIFCKki2nGsY_9nnNg_6_6"></a><a id="Tc_yg7b57ULokSXKLVVZPwCsA_6_8"></a><a id="Tc_0T9pYkG010OnhgqCzHVdCA_6_10"></a><a id="Tc_8wsqxxL43kiaC0P3zxd7_g_7_4"></a><a id="Tc_sbjMeOInp0agk1OlLZcviw_7_6"></a><a id="Tc_n56kQ4pqn0unP_9OSzMnOQ_8_4"></a><a id="Tc_pJOMOULKBEi3MwrUSZQCRw_8_6"></a><a id="Tc_zjvc7i9xk0uYKF0jNlDuMQ_8_8"></a><a id="Tc_dcfYOaCCAUm08ZLR_DOZPQ_8_10"></a><a id="Tc_ex9Son164kiwSLbB_cS4cg_9_0"></a><a id="Tc_mmB5FPs2sUGWJARe7jwsKQ_10_0"></a><a id="Tc_T39720mczECSYv-JgHeitg_10_8"></a><a id="Tc_W1CDf1mD70W48GexXYzUJw_10_10"></a><a id="Tc_go4K88WeAUebRUV0AOWAGA_11_0"></a><a id="Tc_w5he9tpQJkm7p2lotc9SAQ_11_8"></a><a id="Tc_kn9aHtaqU0exh5jD7YjSxA_11_10"></a><a id="Tc_Nl7AxAeHt026n6qckzoRaA_12_0"></a><a id="Tc_CmOmYfM4KEupmtzvBlpu6g_12_8"></a><a id="Tc_ruhg4lf-Zk2areWeae8UGw_12_10"></a><a id="Tc_7vlHw-A2TUGcvnZs5KavUQ_13_0"></a><a id="Tc__ziT_pN2qEamz9z0gr4OKA_14_0"></a><a id="Tc_2kYSpAJEwE2kXoXo7cHKqw_14_8"></a><a id="Tc_TxdkPV6Z50m7UeEyr_GNSw_14_10"></a><a id="Tc_R-e2JN4ydE23QpBZf3PkVw_15_0"></a><a id="Tc_GJPBBVkevUSogF32_FfwGg_15_8"></a><a id="Tc_t-TPnjR-FkCLkqMcYTdIbw_15_10"></a><a id="Tc_cMNPaS9n60mSWil6a_PBig_16_0"></a><a id="Tc_mr8sZBxd7Ea2S4Gn25h70A_16_8"></a><a id="Tc_fVN3RUDHb0a7pnfsJJFNjQ_16_10"></a><a id="Tc_ilvI86KuIUOzasvYBdNv9A_17_0"></a><a id="Tc_Q--Y963oDEabWUVDxGSf_A_18_0"></a><a id="Tc_TZYrYV8L3UyAFwD_sXEkxg_18_8"></a><a id="Tc_IIkagspVsEuyH5d9m2l8Kg_18_10"></a><a id="Tc_w9uEmW33lUuAfo-68fae-Q_19_0"></a><a id="Tc_Kropw_8beU6QRwxGekHjgQ_19_8"></a><a id="Tc_tRqbRLiotkKkNoHbTD7gIQ_19_10"></a><a id="Tc_UgEa-QR0R0aaO5_esD6sWA_20_0"></a><a id="Tc_vsm95X2TVUy8SGEYfIMlHA_20_8"></a><a id="Tc_dmDFyABL2ECO7fOMvJZUIA_20_10"></a><a id="Tc_2VdZv-6kT0e9P1VncMoHgQ_21_0"></a><a id="Tc_h10DFyZ8ikysQjWbq8EPlw_22_0"></a><a id="Tc_HACXTktbqEG8K520maY67A_23_0"></a><a id="Tc_O8COF1jRRUudYGxeP1lxVA_24_0"></a><ix:continuation id="Tb_gymrf7XxqUSZDa-Za9Kocg_cont2" continuedAt="Tb_gymrf7XxqUSZDa-Za9Kocg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020 and 2021, among all the share options granted to date, <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementScenarioAxis_adag_ServiceConditionsAndPerformanceConditionsMember_aYQM4Z59Lkq9WgUCQtEtog" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_MzTduI35s02W5nqI7LwspA">2,178,808</ix:nonFraction> and <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_adag_ServiceConditionsAndPerformanceConditionsMember_lzcuoYgQd0GD5oMsj4d0yA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_VwXhJf05IkO61wfC3awegA">2,483,808</ix:nonFraction> share options contained both service conditions and performance conditions, respectively. All other share options granted contain only service conditions.</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_7lL7m8PkYUeY7wP5uS0RjA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$ per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$ per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2018_T4mq9hT6lUOBey2VJKkGww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_BXMZJp9kaUKteaqGB-IUCA_9_2">574,328</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2018_T4mq9hT6lUOBey2VJKkGww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_s_liRHUWXEyCa0uz9MKQmA_9_4">0.30</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2018_T4mq9hT6lUOBey2VJKkGww" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_SewA0UkVMkW7Y__cGaMy8A_9_6">2.80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2018_To_12_31_2018_FHaDhJxmwEKepai0fnE7_Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_CNQLTqmFYU-lEpEz6YKbqA_9_8"><span style="font-size:10pt;"> 7.14</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2018_T4mq9hT6lUOBey2VJKkGww" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_iUS2aH1n6UWq23YeXWi-5w_9_10">3,734,644</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_fBBu0xuCF0yohcdrEbiSZA_10_2">372,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_ZOlqBzTXU0mQw1EMPZRThg_10_4">1.26</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_qxEaiAPKPUmmyUwW4znXhg_10_6">5.46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_NG2B0YJNVE6XdX4uJn8X0Q_11_2">34,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_AJWh_sYnf0aDc3HNUiRgOw_11_4">0.55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="2" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" scale="0" id="Tc_NZKnX5k1L0KXwLzsP21hyg_11_6">5.71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_1E_CmrasW0uPpzr7YPsihA_12_2">46,800</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_GfryqvGoqUG3sH2N7Bjwgg_12_4">1.22</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="Tc_e2794g5Bx0WHsp1bpgrIAg_12_6">5.75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_JYE2l3g1RkGczw1qDMfcJA_13_2">866,028</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_3HFO_dcBhUenRw4ccPDJEw_13_4">0.65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_zXcOyTSLmk-bHYhK-Afxkw_13_6">3.67</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_sCOV7HUJ5E2QG3VxRQNvmw_13_8"><span style="font-size:10pt;"> 7.27</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_kglQFABHX0yChmaellrYOQ_13_10">6,328,171</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_Lmmw1-CrAEuxSJByeSwLQg_14_2">6,313,373</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_eC24GfC3uUmkMSAPMAIl2g_14_4">2.00</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_AmwyGQILuUGr_s_DDm5mDA_14_6">7.01</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_0paSuy-7VkGsGYgwxvcZjQ_15_2">3,694,934</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_49ObLs1KvEm1cPDfxkVa7g_15_4">1.93</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="2" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" scale="0" id="Tc_X8s2P0TlJU6w9x83zfsBjg_15_6">6.55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_dEw-QQrH8ESNCg_d8bMITg_16_2">190,000</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_602smLjmNUG6cZ30qMngsw_16_4">1.70</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="Tc_RTQyZUNwAUuRfR6W6hGciQ_16_6">6.91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_9tvx2L5RkEqW9X16oR9Ikg_17_2">3,294,467</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_AxImZF2Vd0yBvUKhTR2vKQ_17_4">1.75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_0mPnk7FhiU6TFSdTCm_C9w_17_6">6.65</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_To8Mp3hzikajAvxvMJBr0A_17_8"><span style="font-size:10pt;"> 8.78</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_wLKw9HePkkqpIpNfWWChTw_17_10">33,410,968</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_xa1xY0t1kkO3kyWRRdQLDg_18_2">1,894,119</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_xd19PkUTmkuDWsAv51M4IA_18_4">12.31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Tc_fLMO0GyMuEeaKpn7J6Nrsg_18_6">8.39</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_VSssQ4VCP0qDdfOE2XoggQ_19_2">233,958</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_PiJwwg8-d0aHub7VCOcjfA_19_4">0.99</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" scale="0" id="Tc_sKtq7f--sEiM-EQOdF_kSQ_19_6">5.13</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_nioXevxyTESN7hTIgwJtaw_20_2">145,550</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_uIK9WSFDhk2AXwu6AzOiyQ_20_4">3.02</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" scale="0" id="Tc_o2U7M25vh0i12CvBF_s7gg_20_6">7.71</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_hUCYcgYadUyYv6E_pd0UHQ_21_2">4,809,078</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_ViRez20NPEmvZ3ik4LuHEw_21_4">5.91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="Tc_yw3B95Tb-UKX0kfkN7hpkg_21_6">7.38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_GaFZEg1j5kq7sv--aGbIVg_21_8"><span style="font-size:10pt;"> 8.68</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" id="Tc_td5HJLIRt0a8tKQft5pR_Q_21_10">2,619,574</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="Tc_dr73qcQ0fk2wbG6nj8UCJA_22_2">4,809,078</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_iC0NbQihckiwtqToPwucJw_22_4">5.91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" scale="0" id="Tc_37xThogEq02qFJ3aXaBuOA_22_6">7.38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Tc_lSt-x1CdXky8gNJNtNfzGA_22_8"><span style="font-size:10pt;"> 8.68</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="0" id="Tc_DWG85TrSF0OAdHjErBSTwA_22_10">2,619,574</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_N2_BuDTBMECj8Xm6G860Ug_23_2">393,424</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_4rpiEPYCzUCCIH--1-IQ6A_23_4">0.75</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="2" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" scale="0" id="Tc_hIU_vfQXhEWAx67hW2wafw_23_6">4.46</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_Y9s94rV5YUiCQ6Jka6fltw_23_8"><span style="font-size:10pt;"> 6.68</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="Tc_eCMkY2FwZkWG7aDG63LjLw_23_10">4,859,836</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="Tc_D_81GN99ZkCy3hTiiNUIoA_24_2">1,486,318</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="Tc_uYmBXmVDJU63j0DeylT2XA_24_4">5.87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" scale="0" id="Tc_jy-nQ8ikMUGbvzu7RYp_wQ_24_6">7.05</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Tc_G5cKy0h7CkauDgI5d3qaAg_24_8"><span style="font-size:10pt;"> 8.20</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" id="Tc_hJgATSZwgkaFAumjvgkVig_24_10">874,180</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value in the table above represents the difference between the exercise price of the awards and the fair value of the underlying ordinary shares at each reporting date, for those awards that had exercise price below the estimated fair value of the relevant ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate fair value of the equity awards vested during the&#160;years ended December&#160;31, 2019, 2020, and 2021 was US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="Narr_G8Q3bkPkPk-nexnrSU7YBQ">366,113</ix:nonFraction>, US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="Narr_dKMSoIzBhEmLzitbRMdcdg">8,430,085</ix:nonFraction> and US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="0" id="Narr_g8CdU2oPhEawhc4OwFboMQ">13,833,856</ix:nonFraction>, respectively. As of December&#160;31, 2021, the total unrecognized employee share-based compensation expense was US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="0" id="Narr_k2bQonFu8ECbP_V5ReUZrA">30,607,079</ix:nonFraction>, all of which may be adjusted for actual forfeitures occurring in the future. Total unrecognized compensation cost will be recognized over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_rIZ1iGNDNkKzyzBbJ0e9oA">2.72</ix:nonNumeric>&#160;years as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Fair value of share options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of share options was determined using the binomial option valuation model, with the assistance from an independent third-party appraiser. The binomial model requires the input of highly subjective assumptions, including the expected volatility, the exercise multiple, the risk-free rate and the dividend yield. For expected volatility, the Group has made reference to historical volatility of several comparable companies in the same industry. The exercise multiple was estimated as the average ratio of the stock price to the exercise price of when employees would decide to voluntarily exercise their vested share options. The risk-free rate for periods within the contractual life of the share options is based on the market yield of U.S. Treasury Bonds in effect at the time of grant. The dividend yield is based on the expected dividend policy over the contractual life of the share options. The estimated fair value of the ordinary shares, at the share option grant dates, was determined with the assistance from an independent third-party appraiser.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_z0toQRXLb0avt7DGG9kOng_1_2"></a><a id="Tc_87Lgj4Ac8EC1eCQmqo6vZg_2_2"></a><a id="Tc_0KKDMeXhi0i034Gen5LjRg_3_2"></a><a id="Tc_QUraubsZiky6oNAG6R9xvw_3_4"></a><a id="Tc_nWtTEdBAOEiGou9QqVBfhg_3_6"></a><a id="Tc_ojBH5F-z0ECDlQIKAawYZw_4_0"></a><a id="Tc_ugzOr4YlAUO47l1fACVUgQ_4_2"></a><a id="Tc_ZIqe-X9ulEyhHhNKMhWt6Q_4_4"></a><a id="Tc_pWhoFVipcEaJ69dK2nYJvg_4_6"></a><a id="Tc_4rin94wIG0q5gYTkTslmPg_5_0"></a><a id="Tc_SgdG8-xiTEqUw3f8zdNyiw_6_0"></a><a id="Tc_UYNFpATKN0OIK7Q-qqQChg_6_2"></a><a id="Tc_b3ZTp9WoA0KWBSySsA1c_w_6_4"></a><a id="Tc_loN9Ydx1QE69gHakrabi9Q_6_6"></a><a id="Tc_cwSjiTwSFEOttL1BwmKzaA_7_0"></a><a id="Tc_mw1KTCFc7Eetp7L1B36Sww_7_2"></a><a id="Tc_Vg8DfL-L3kuBnW_B0qo6-g_7_4"></a><a id="Tc_8qs0TIO_c0ScXXkBDEQM1Q_7_6"></a><a id="Tc_dqjqqUVGAkK9GRRfpxZISw_8_0"></a><a id="Tc_6yrG3yAqH02Gghf-Gz-uRg_1_2"></a><a id="Tc_dZIGdM0QTUeF_C16i62ykg_2_2"></a><a id="Tc_oDxnWl1b8EGfoSZLVQmhyg_2_4"></a><a id="Tc_IAg6wfD3dkaeP4mLqdvivA_2_6"></a><a id="Tc_nd72ajX09km5y4lA_rfNcA_3_2"></a><a id="Tc_pH6UT_7bmEe1K0oRVx33xg_3_4"></a><a id="Tc_jpe5gPL30ESnaQg44sU5oA_3_6"></a><a id="Tc_OMcg-AYYxUqn3VTMUtAaxA_4_0"></a><a id="Tc_vgkpTrRRLUmsltvjzVVPUg_5_0"></a><a id="Tc_wP8fAn7ASE6SVrWX3IbktA_6_0"></a><ix:continuation id="Tb_gymrf7XxqUSZDa-Za9Kocg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The assumptions used to estimate the fair value of the share options granted were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_Fes6Oti0hES9iXbQW8M_Rw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Risk&#8209;free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_T1nxj829n0qkOKfShZ4Xew">1.78</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_kQ4IbUK-fEWW5hWbnS-9xg">2.73</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_7b1bmghS3Uqw85PdB356AA">0.68</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_D9xfgO5Ll0ubIyHHXLZJcA">0.83</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="Narr_DtiZ9TsxJEq5rVCY27itVg">1.11</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="Narr_vGomWIXuAUubodJJA1K6zw">1.67</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_FrrUnlnce0eV-isP6VxoqA_5_2">0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_iMmDylEtn0m32p-DvG6FNw_5_4">0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_7wFL7kOh7E6RMK2_bjsuIQ_5_6">0</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Expected volatility range</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_81rFrwZmO0qB5WQd_zaEwQ">67.5</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_0u_JiQggzUapwhrht2Lnvg">71.0</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_lmlC5nth6U-MF24w66g-Ew">72.3</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_UsL71h8qdEyjdMCbgNp0SQ">73.4</ix:nonFraction>%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="Narr_TqAX3HCFJEykWloKr4UKgA">73.1</ix:nonFraction>% - <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="Narr_66LBQ9Evs0e8bnkf9Vey9Q">75.5</ix:nonFraction>%</p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercise multiple</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="1" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" scale="0" id="Narr_3qa8EEqAfUuyFIPuXCqJOQ">2.2</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="1" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" scale="0" id="Narr_ZtIqqKwy-UylEJnUSTTGBw">2.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="1" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" scale="0" id="Narr_TyAAdXayt06oN9ikn4fGFQ">2.2</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="1" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" scale="0" id="Narr_jxEy9Flip0a9b9eDRXLrGw">2.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="1" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" scale="0" id="Narr_sq8nO1CSbk-xN0Ksnqe3QA">2.2</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="1" format="ixt:numdotdecimal" name="adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" scale="0" id="Narr_xM1pKJMh4UaFBFTSkQhorg">2.8</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Contractual life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_lVb6tfitd0yrUZPRnzvNXg_8_2"><span style="font-size:10pt;">10 years</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_zA7T5tkwHkSD2XLgEjPfww_8_4"><span style="font-size:10pt;">10 years</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_fEV5v02Mm0mFc4vA3wsyYQ_8_6"><span style="font-size:10pt;">10 years</span></ix:nonNumeric></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Total share-based compensation expenses recognized for the&#160;years ended December&#160;31, 2019, 2020 and 2021 were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_ghAHCsijd0WgKXbzW_lugg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_mEMX3jxTBEePGi2c4CW7ew" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_8eJlcMP8wU-nGPvLTTm1sQ_4_2">404,620</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Ku2fXt-ZkUyQ2JGo0NdGOw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_-kApqwt4lU2m6PjHT5Lr8w_4_4">6,472,083</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_zdsez9gtTkGdnwLN8_NhYw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_w2IlZLN39UirVHe5iEKJ3A_4_6">13,582,746</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1m27p6Q0nEy5EgKynSvENw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_j-tlLh5xhEaVwIxtfi4g3Q_5_2">207,091</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_xUUXpRjJbEqKzK5uloapeQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_3hdXPkE9eEy25NNCiQBY1w_5_4">3,657,458</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_B0aUMLGKf0iTQ_KOw1cMDw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_-mW6P4i7r0Kc46azdwADCw_5_6">5,096,912</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total share&#8209;based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_olv983FQOka5s5-a-eotrA_6_2">611,711</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_jWgTxPb5EUO4YcEbTeu_tA_6_4">10,129,541</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Tc_NAhRl8R6r0-he25XU5WyfA_6_6">18,679,658</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Up to the date of the issuance of the consolidated financial statements for the year ended December 31, 2020, some proceeds of the subscription capital arising from the exercise of vested share options by certain employees remained outstanding and such amount was presented as subscriptions receivable, a contra-equity balance on the consolidated balance sheets as of December&#160;31,2020,which was subsequently settled in 2021.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="Tb_WVroCRKGdES0uBU9ccG1xw" continuedAt="Tb_WVroCRKGdES0uBU9ccG1xw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10. COLLABORATION ARRANGEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Guilin Sanjin Pharmaceutical&#160;Co.,&#160;Ltd. License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2018, the Group entered into (i)&#160;a collaboration agreement (the &#8220;Sanjin Greater China Agreement&#8221;) that covers Greater China with Guilin Sanjin Pharmaceutical&#160;Co.,&#160;Ltd. (&#8220;Sanjin&#8221;) and certain of its subsidiaries (collectively, &#8220;Sanjin Parties&#8221;) and (ii)&#160;a collaboration agreement (the &#8220;Sanjin ROW Agreement&#8221;, together with the Sanjin Greater China Agreement, the &#8220;2018 Sanjin Agreements&#8221;) that covers the regions other than Greater China with Sanjin. Pursuant to the Sanjin Greater China Agreement, the Group licensed the Chinese intellectual property directly related to a monospecific antibody molecule that binds to the PD-L1 target (the &#8220;PD-L1 Project&#8221;), including patent rights, patent application rights and technologies based on the core sequence of the molecule, to Sanjin Parties. Sanjin Parties will own all the Chinese intellectual property developed in the exercise of Sanjin Parties&#8217; rights under the agreement, including but not limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights relating thereto. The Group also granted Sanjin Parties a royalty-free license to use our other existing intellectual property and improvements thereto which are related to the PD-L1 Project for the purposes of exploiting its rights and performing its obligations under the agreement. Sanjin Parties will enjoy all the economic benefits deriving from the PD-L1 Project in Greater China, including but not limited to patent transfer fee, licensing fee, sales revenue and sales commission, etc. Sanjin Parties will pay the Group (i)&#160;single-digit&#160;percentage of net sales of the products that use the licensed antibody after such products enter the market and (ii)&#160;a low to mid-low double-digit&#160;percentage of the profits resulting from any transfer of the license to any third parties depending on the timing of the transfer relative to the development stage of the product. The Group also received RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_zsB5uPJq50C4DpmE2mjLFA" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceived" scale="0" id="Narr_Ob7fIqw_Vkyc19IaWX3n0A">10,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_zsB5uPJq50C4DpmE2mjLFA" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceived" scale="0" id="Narr_zfM3JocvFUi7kmlHDHTcyQ">1,511,168</ix:nonFraction>) upfront fee upon the effectiveness of the agreement from Sanjin Parties.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_WVroCRKGdES0uBU9ccG1xw_cont1" continuedAt="Tb_WVroCRKGdES0uBU9ccG1xw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Sanjin ROW Agreement, the Group granted Sanjin a royalty-free license to use all intellectual property relating to (i)&#160;the collaboration under the agreement that the Group controlled before the Group entered into the agreement or acquired independently of the agreement and (ii)&#160;improvements thereto for the purposes of exploiting its rights and performing its obligations under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such intellectual property, and any intellectual property generated from cooperation between the Group and Sanjin&#8217;s affiliates in connection with the collaboration will be jointly owned. The Group retain the ownership of patent rights of key intellectual property pertaining to PD-L1 outside of the Greater China. In addition, all the results obtained by Sanjin relating to the research and development of any new antibody developed under the agreement will be owned by Sanjin. The Group retain a majority of the economic benefits derived from the Sanjin ROW Agreement, including but not limited to any patent transfer fee, licensing fee and gains realized under such transfer. In case the Group intend to transfer to a third party our share of economic interests in any country outside of Greater China, the Group must notify Sanjin and Sanjin will receive a right of first refusal if it pays the Group a deposit equal to a low double-digit&#160;percentage of the consideration that the Group expect to receive from such third party. If Sanjin waives the right of first refusal, the Group can proceed with the transfer, provided that the final transaction price with the third party is not lower than the amount of the offering price that was included in our notice to Sanjin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group agreed not to (i)&#160;independently develop any monospecific antibodies that bind to the PD-L1 target or (ii)&#160;grant any rights associated with such antibodies to any third parties during the <ix:nonNumeric contextRef="Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_zsB5uPJq50C4DpmE2mjLFA" format="ixt-sec:durwordsen" name="adag:AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" id="Narr_DKYi7AaBKEylMdj1oIubJw">three-year</ix:nonNumeric> period from the effective date of the agreement. The exclusivity obligation does not prevent the Group from (i)&#160;developing or granting any licenses to third parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and masked antibody against PD-L1 target and (ii)&#160;continuing to provide antibody screening service that were commenced before the execution of the Sanjin Greater China Agreement and either party has the independent right to conduct combination therapy studies outside of the Greater China. Either non-breaching party may terminate the 2018 Sanjin Agreements if the other party&#8217;s ability to comply with its respective obligations under the agreements is negatively affected by contingencies such as failure to maintain operation or changes in core project management and the other party fails to take effective remedial measures. Each agreement automatically terminates upon the termination of the other agreement. Upon the rescission or termination, Sanjin Parties will return to the Group all the intellectual property, documents and data provided by the Group under the 2018 Sanjin Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that the failure of the development of the product candidate solely arises from the Group&#8217;s research and development basis specified under this agreement, Sanjin has the right to claim back all the payment made to the Group. The Group considers the possibility of occurrence of such event is very remote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended December&#160;31, 2018, the Group recognized revenue of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_u083XUXgXkmjyHICOwXAVw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_n-ljMy45XE-ExazE5D1syg">10,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_u083XUXgXkmjyHICOwXAVw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_b_47lPU88Eys41A22j1nrg">1,511,168</ix:nonFraction>) for this agreement. <ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_bKpMhErhpUq4nsR8w4_mRw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_SAJm0N_VzkuGea_v9tTyPg"><ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_jQLNNuCCo0Gc9A2UON5i2w" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_kGSeunl_E0e8W9zHbts5Ug"><ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_UwjwbfWHYk-CsHFX-MxHNQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_lV6yPAAWM0G_CPuEiE5G3g">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> additional revenue was recognized for the years ended December 31, 2019, 2020 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2019, the Group entered into (i)&#160;a collaboration agreement that covers Greater China (the &#8220;Dragon Boat Greater China Agreement&#8221;) and (ii)&#160;a collaboration agreement that covers the regions other than Greater China (the &#8220;Dragon Boat ROW Agreement,&#8221; together with the Dragon Boat Greater China Agreement, the &#8220;2019 Dragon Boat Agreements&#8221;), with Dragon Boat Biopharmaceutical (Shanghai) Limited (&#8220;Dragon Boat&#8221;), a subsidiary of Sanjin. Pursuant to the Dragon Boat Greater China Agreement, the Group will license the Chinese intellectual property directly related to a certain monospecific antibody molecule that binds to a specified target (the &#8220;Specified Project&#8221;), including the patent rights, patent application rights and technologies based on the core sequence of the molecule, to Dragon Boat. Dragon Boat will own all the Chinese intellectual property developed in the exercise of Dragon Boat&#8217;s rights under the agreement, including but not limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights relating thereto. The Group also granted Dragon Boat a royalty-free license to use our other existing intellectual property and improvements thereto which are related to the Specified Project for the purposes of exploiting its rights and performing its obligations under the agreement. Dragon Boat will enjoy all the economic benefits deriving from the Specified Project in Greater China, including but not limited to patent transfer fee, licensing fee, sales revenue and sales commission, etc. and will pay the Group (i)&#160;certain high-six figure dollar milestone payments upon the achievement of certain milestones (including milestones of launch of pre-clinical safety evaluation animal test, obtaining Investigational New Drug (&#8220;IND&#8221;) approval in PRC and completion of clinical phase I test in PRC) and (ii)&#160;a single-digit&#160;percentage of net sales of the products that use the licensed antibody after such products enter the market.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_WVroCRKGdES0uBU9ccG1xw_cont2" continuedAt="Tb_WVroCRKGdES0uBU9ccG1xw_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Dragon Boat ROW Agreement, the Group granted Dragon Boat a royalty-free license to use all intellectual property relating to (i)&#160;the collaboration under the agreement that the Group controlled before the Group entered into the agreement or acquired independently of the agreement and (ii)&#160;improvements thereto for the purposes of exploiting its rights and performing its obligations under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such intellectual property, and any intellectual property generated from cooperation between the Group and Dragon Boat in connection with the collaboration will be jointly owned. The Group retain the ownership of patent rights of key intellectual property pertaining to the specified target outside of the Greater China. In addition, all the results obtained by Dragon Boat relating to the research and development of any new antibody developed under the agreement will be owned by Dragon Boat. The Group retains a majority of the economic benefits derived from the Dragon Boat ROW Agreement, including but not limited to any patent transfer fee, licensing fee and gains realized under such transfer. In case the Group intend to transfer to a third party our share of economic interests in any country outside of Greater China, the Group must notify Dragon Boat and Dragon Boat will receive a right of first refusal if it pays the Group a deposit equal to a low double-digit&#160;percentage of the consideration that the Group expects to receive from such third party. If Dragon Boat waives the right of first refusal, the Group can proceed with the transfer, provided that the final transaction price with the third party is not lower than the amount of the offering price that was included in our notice to Dragon Boat.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the 2019 Dragon Boat Agreements, the Group agreed not to (i)&#160;independently develop any monospecific antibodies that bind to the specified target or (ii)&#160;grant any rights associated with such antibodies to any third parties during the <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_raAHGN6oRESCKkVreFRITQ" format="ixt-sec:durwordsen" name="adag:AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" id="Narr_RkStaBe9uUae2AG0oDkZtA">three-year</ix:nonNumeric> period from the effective date of the agreements. The exclusivity obligation does not prevent the Group from (i)&#160;developing or granting any licenses to third parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and masked antibody against the specific target and (ii)&#160;continuing to provide antibody screening service that were commenced before the execution of the Dragon Boat Greater China Agreement and either party has the independent right to conduct combination therapy studies outside of the Greater China. Either nonbreaching party may terminate the 2019 Dragon Boat Agreements if the other party&#8217;s ability to comply with its obligations under the agreements is negatively affected by contingencies such as failure to maintain operation or changes in core project management and the other party fails to take effective remedial measures. Each agreement automatically terminates upon the termination of the other agreement. Upon the rescission or termination, Dragon Boat will return to the Group all the intellectual property, documents and data provided by the Group under the 2019 Dragon Boat Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that the failure of the development of the product candidate solely arises from the Group&#8217;s research and development basis specified under this agreement, Dragon Boat has the right to claim back all the payment made to the Group. The risk of failure is considered remote upon recognition of revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended December&#160;31, 2019, <ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_MxpOQhUxHEuCBkT-S645ig" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_6FjPPVzKZEmM_2dMbVR3oQ">no</ix:nonFraction> revenue was recognized for this agreement since the licensed product has not been transferred to Dragon Boat.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2020, upfront fee of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_pYJxpURUM0OA22lpXY2GQQ" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceived" scale="0" id="Narr_DRsdaqlSu0GWf7RRpFH6_g">4,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_pYJxpURUM0OA22lpXY2GQQ" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceived" scale="0" id="Narr_r6g7D2vtqU2Pm1zC6RxU_w">573,378</ix:nonFraction>) that was received by the Group was recorded as contract liabilities in the consolidated balance sheets, as the performance obligation had not been satisfied by the Group and <ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_pYJxpURUM0OA22lpXY2GQQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_yT0PDpwO-0SabD_bOOZ_Ug">no</ix:nonFraction> revenue was recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, milestone fee of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_raAHGN6oRESCKkVreFRITQ" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementMilestonePaymentReceived" scale="0" id="Narr_5gTUMQ92fkKE6ubnvj20QA">4,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_raAHGN6oRESCKkVreFRITQ" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementMilestonePaymentReceived" scale="0" id="Narr_5oqsdn5iYU-jE2_VBHq6Mw">620,011</ix:nonFraction>) was received related to the launch of pre-clinical safety evaluation animal test and the receipt of IND approval in PRC. For the year ended December 31, 2021, a total of RMB<ix:nonFraction unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_raAHGN6oRESCKkVreFRITQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_vE-tHQMek0mbYy1iFNRLzg">8,000,000</ix:nonFraction> (equivalent to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_raAHGN6oRESCKkVreFRITQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_f771mQV0S0uVNSYoCrk-5g">1,240,022</ix:nonFraction>), including the aforementioned upfront fee and milestone fee were recognized as licensing revenue in the consolidated statement of comprehensive loss as the performance obligation was satisfied by the Group and certain milestone events were achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Signal Pharmaceuticals LLC Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2019, the Group entered into an agreement with Signal Pharmaceuticals LLC, a subsidiary of Celgene Corporation, for a purchase order of delivery of certain sequences with total consideration of US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_SignalPharmaceuticalsLlcMember_zbCrjEk3mUSzkE9kYsfUww" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceived" scale="0" id="Narr_QSJozi3T9EaCqeOF1oRcnQ">480,000</ix:nonFraction>. For the&#160;year ended December&#160;31, 2019, the Group recognized revenue of US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_adag_SignalPharmaceuticalsLlcMember_tDfXXMaJ1Eey6o1BuWgWYQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_RxEpiPeex0W-Tqzg-a9hBA">480,000</ix:nonFraction> upon delivery of such sequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2018 and May 2019, the Group entered into agreements with Signal Pharmaceuticals LLC, for purchase orders of for a purchase order of delivery of certain sequences with total consideration of US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_adag_SignalPharmaceuticalsLlcMember_6wYypVvYlkKloo4C6zZxMg" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceived" scale="0" id="Narr_SpAA8PkKAk-MqU0Id5RySQ">237,500</ix:nonFraction> and US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_5_1_2019_To_5_31_2019_us-gaap_TypeOfArrangementAxis_adag_SignalPharmaceuticalsLlcMember_VxiNPotzW0uBeu5zVH0n4w" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceived" scale="0" id="Narr_nRiBIfGPCk-0tp-1-EJMgw">72,000</ix:nonFraction>, respectively. For the year ended December 31, 2020, the Group recognized revenue of US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_SignalPharmaceuticalsLlcMember_7offnHLxtE2QBDZc2Gcu7Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_1vyfI0R_p0GxhvxOX3C5DQ">309,500</ix:nonFraction> upon delivery of such sequences.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_WVroCRKGdES0uBU9ccG1xw_cont3" continuedAt="Tb_WVroCRKGdES0uBU9ccG1xw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2021, the Group did not enter into new agreements with Signal Pharmaceuticals LLC or recognize any additional revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ADC Therapeutics&#160;SA License and Collaboration Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2019, the Group entered into a material transfer and collaboration agreement (the &#8220;ADCT Collaboration Agreement&#8221;) and a license agreement (the &#8220;ADCT License Agreement&#8221;) with ADC Therapeutics&#160;SA (&#8220;ADC Therapeutics&#8221;). These two agreements are combined as a single contract as the agreements were negotiated as a package with a single commercial objective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">ADCT Collaboration Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the ADCT Collaboration Agreement, the Group agreed to generate masked antibodies with respect to up to <ix:nonFraction unitRef="Unit_Standard_item_VDVAwvxnO0aSdoyDMbjpLA" contextRef="Duration_4_1_2019_To_4_30_2019_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_eGyxkFQCZE6u3B9IkEjTXQ" decimals="INF" format="ixt-sec:numwordsen" name="adag:MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies" scale="0" id="Narr_MHABGhhy_0aAqE6PrwRVzg">two</ix:nonFraction> exclusive targets selected by ADC Therapeutics. Upon our delivery of certain initial results, ADC Therapeutics has the option to license the Group&#8217;s technology with respect to one or both targets as further detailed below. ADC Therapeutics has not yet exercised such options as of December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the ADCT Collaboration Agreement, the Group is eligible to receive up to a low-seven-figure dollar amount in consideration for the Group&#8217;s exclusivity obligations, upon achievement of certain development milestones (including milestones of delivery of certain amino acid sequences and successful outcome of the first in-vivo study) and upon ADC Therapeutics&#8217; election to proceed with development for the two elected targets. Apart from performance obligation to deliver the amino acid sequences of the corresponding masking peptides, the Group is not required to perform any additional research and development services. ADC Therapeutics has the right to terminate the ADCT Collaboration Agreement at any time and for any reason in its entirety or on a target-by-target basis upon <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_xzwissiwc0-243qJnNFPcA" format="ixt-sec:durwordsen" name="adag:MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" id="Narr_pWI61Ru6R0K8Zf_-N2ZwVA">thirty days</ix:nonNumeric>&#8217; prior written notice to the Group. Either party may terminate the ADCT Collaboration Agreement, in its entirety or on a target-by-target basis, upon the other party&#8217;s uncured material breach of the agreement or the other party&#8217;s insolvency-related events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group also granted ADC Therapeutics an exclusive target reservation right for <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_xzwissiwc0-243qJnNFPcA" format="ixt-sec:durwordsen" name="adag:PeriodForReservationOfTargetRight" id="Narr_0HyhNiM2DEOSvIeiESWhtA">one year</ix:nonNumeric> from the commencement of the agreement and an option to renewal for another&#160;year with a consideration of low-six-figure dollar amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">ADCT License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the exercise of the options contained in the ADCT Collaboration Agreement, the Group has granted ADC Therapeutics, with respect to each elected target, an exclusive, worldwide, perpetual and irrevocable (subject only to the termination provisions) license (with the right to grant sublicenses) to develop, make, use, commercialize and import the antibody drug conjugates that comprise masked antibodies generated by the Group under these programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the ADCT License Agreement, if ADC Therapeutics exercises both of its options granted thereunder, the Group could be eligible to receive up to a low-nine-figure dollar amount in development and regulatory milestone payments upon the achievement of certain milestones (including milestones of successful completion of Good Laboratory Practice Toxicology studies, launch of clinical trials and start of commercial sales in difference countries and etc.) and up to a mid-eight-figure dollar amount in sales milestone payments, in addition to mid-single-digit&#160;percentage net sales-based tiered royalties on products licensed under the ADCT License Agreement, subject to certain reductions. Royalties, if any, will be payable on a country-by-country and product-by-product basis, until the earlier of (i)&#160;the tenth anniversary of the first commercial sale of such product or (ii)&#160;the expiration of the last-to-expire patent licensed under the agreement in such country, unless earlier terminated by the parties, following which any licenses granted to ADC Therapeutics under the ADCT License Agreement shall become fully paid up, perpetual and irrevocable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ADC Therapeutics has the right to terminate the ADCT License Agreement before the expiration of the royalty term on a product-by-product basis or in its entirety (i)&#160;for any reason or no reason upon <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_xzwissiwc0-243qJnNFPcA" format="ixt-sec:durwordsen" name="adag:MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" id="Narr_lWidlqjfcUaEfvBSUh792g">thirty days</ix:nonNumeric>&#8217; written notice to the Group, or (ii)&#160;if ADC Therapeutics chooses to discontinue the development or sale of the applicable licensed product worldwide. Each party has certain rights to terminate the ADCT License Agreement with prior written notice upon the other party&#8217;s uncured material breach or insolvency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2019, <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_EEyq6-qTT02Gx8jU3UgzXQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_m-zpbKgTc0-_7giHo6zbYA">no</ix:nonFraction> revenue was recognized as no performance obligation was satisfied.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_WVroCRKGdES0uBU9ccG1xw_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended December&#160;31, 2020, the Group recognized US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_AOGCddhlkkafIHJPmD_uUw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_IzrtjCOQN0e-PnVGxB6T3A">225,000</ix:nonFraction> of licensing revenue upon delivery of such results. For the year ended December&#160;31, 2020, the Group recognized US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_AOGCddhlkkafIHJPmD_uUw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OtherIncome" scale="0" id="Narr_BbAWDWTzc0ue2VflUHQmFg">100,000</ix:nonFraction> as other income due to the expiration of exclusive target reservation right, which is not related to the Group&#8217;s major operation activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">For the year ended December 31, 2021, the Group recognized US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_xzwissiwc0-243qJnNFPcA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_GJDsUu86dUylhss9YSIVTg">225,000</ix:nonFraction> of licensing revenue upon delivery of additional research results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Exelixis, Inc. Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2021, the Group entered into a collaboration and license agreement (the &#8220;Exelixis Agreement&#8221;) with Exelixis, Inc. (&#8220;Exelixis&#8221;), pursuant to which the Group agreed to generate masked antibodies with its SAFEbody technology against an initial target selected and a second target to be selected by Exelixis. The Group will generate masked antibodies in the form of alternative compounds in accordance with the program plan for each target at its own cost and deliver the related data packages to Exelixis. Exelixis will select lead compounds (the &#8220;Lead Compounds&#8221;) to further develop, obtain regulatory approval and commercialize product(s) for each target (the &#8220;Products under the Exelixis Agreement&#8221;). Under the Exelixis Agreement, the Group will also grant Exelixis an exclusive, worldwide, sublicensable license (the &#8220;Adagene License&#8221;) upon delivery of the data package to research, develop, make, have made, sell, offer for sale, import and commercialize products containing the masked antibodies to be generated by the Group with respect to both targets. Exelixis will own the inventions relating to the Lead Compounds arising in connection with the Exelixis Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Exelixis Agreement will remain effective until the expiration of the defined royalty terms of the Products under the Exelixis Agreement, unless terminated by either party. Exelixis may terminate the Exelixis Agreement for any or no reason, in its entirety or on a target-by-target basis. Any payment received by the Group before the termination shall be non-refundable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Exelixis Agreement, Exelixis agreed to pay the Group an upfront non-refundable fee of US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_2_28_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_j9kFO_H-ME6HZ7oPWsGjEQ" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceivable" scale="0" id="Narr_gEg3wIRKgUGFs_GUNJoMqQ">11,000,000</ix:nonFraction>. For each target, the Group will be eligible to receive up to US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_2_28_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_j9kFO_H-ME6HZ7oPWsGjEQ" decimals="0" format="ixt:numdotdecimal" name="adag:MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" scale="0" id="Narr_MLrgxNOW0kiRj3hHqy41mg">127,500,000</ix:nonFraction> of milestone payments conditioned upon achieving certain development and regulatory approval milestones, and up to $<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_2_28_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_j9kFO_H-ME6HZ7oPWsGjEQ" decimals="0" format="ixt:numdotdecimal" name="adag:MilestonePaymentsReceivableSalesBasedMilestones" scale="0" id="Narr_1jf2FCpxbEOotzQTrRFg5g">262,500,000</ix:nonFraction> of sales-based milestone payments. In addition, the Group is also entitled to royalties of mid-single-digit percentage in respect of the aggregate annual net sales of the products developed under the Exelixis Agreement worldwide, subject to certain reductions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group determined that generating masked antibodies with its SAFEbody technology is reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under the Exelixis Agreement, the delivery of data packages for each target, along with the Adagene License used to develop the related compounds, represents one performance obligation, as they are not distinct from each other. Transaction price is allocated to each one of the two performance obligations based on the relative standalone selling price method. The Group records revenue at a point in time, when the data packages for each target were delivered to Exelixis. Considering that the development, regulatory and sales-based milestone payments and the royalties are constrained, the transaction price shall initially only include upfront payment and the milestone payments that are considered probable. Subsequently, once the uncertainty associated with the milestone payments is resolved, the milestone payments shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. The sales-based royalty and sales-based milestones promised in exchange for the Adagene License granted are recognized when (or as) the later of 1) the subsequent sale or usage occurs, or 2) the performance obligation to which some or all of the sales-based royalty or sales-based milestones being allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of December 31, 2021, the Group received US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_i7cOcV2zlk2TryKX0IeFTw" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceived" scale="0" id="Narr_30_SK4qjzESwq2Rvs9bnyg">11,000,000</ix:nonFraction> upfront payment and<span style="font-size:11pt;"> </span>recorded accounts receivable of US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember__cHz1vX8l0yKaUSYpxTiiQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="0" id="Narr_YA6SCh41x0CGcGlN1VeUdw">3,000,000</ix:nonFraction> milestone payment, which corresponds to the successful nomination of lead SAFEbody candidates for the initial target under the Exelixis Agreement. The milestone payment was subsequently received in January 2022. For the year ended December 31, 2021, US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_i7cOcV2zlk2TryKX0IeFTw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_b57WKaiTB0CwEcM26egRDQ">8,500,000</ix:nonFraction> was recognized as revenue upon delivery of data packages for the initial target and achievement of the milestone event. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_S-OJ91cqR0aLJi0EuwRfCg" continuedAt="Tb_S-OJ91cqR0aLJi0EuwRfCg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">11. INCOME TAX EXPENSE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">PRC</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective from January&#160;1, 2008, the PRC&#8217;s statutory, Enterprise Income Tax (&#8220;EIT&#8221;) rate is <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2008_To_1_1_2008_srt_StatementGeographicalAxis_country_CN_6zxDnTTPxkmKtBmcfSofpw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_zbYcJNT02ka-4HAMBfc2Fw">25</ix:nonFraction>%. In accordance with the implementation rules&#160;of EIT Law, a qualified &#8220;Technology Advanced Service Enterprises&#8221; (&#8220;TASE&#8221;) is eligible for a preferential tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2008_To_1_1_2008_adag_StatusForTaxabilityAxis_adag_TechnologyAdvancedServiceEnterprisesMember_srt_StatementGeographicalAxis_country_CN_wwO7JGio2USSa9yydNN8kA" decimals="2" format="ixt:numdotdecimal" name="adag:PreferentialIncomeTaxRate" scale="-2" id="Narr_9d-yHIqHO0abFHr7l8V2FQ">15</ix:nonFraction>%. The TASE certificate is effective for <ix:nonNumeric contextRef="Duration_1_1_2008_To_1_1_2008_adag_StatusForTaxabilityAxis_adag_TechnologyAdvancedServiceEnterprisesMember_srt_StatementGeographicalAxis_country_CN_wwO7JGio2USSa9yydNN8kA" format="ixt-sec:durwordsen" name="adag:EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate" id="Narr_IR-FhQkzBkCBwFNAR9CNvg">three years</ix:nonNumeric>. An entity must file required supporting documents with the tax authority and ensure fulfillment of the relevant TASE criteria before using the preferential rate. An entity could apply for the TASE certificate every&#160;year. Dividends by PRC entities, to non-PRC resident enterprises shall be subject to <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_CN_hq0Btu-DBkq8lmsfbYdpfQ" decimals="INF" format="ixt:numdotdecimal" name="adag:WithholdingTaxRateOnDividendsPercentage" scale="-2" id="Narr_hl6RVFhS80GAj9wJ6F_-WQ">10</ix:nonFraction>% EIT, namely withholding tax, unless the respective non-PRC resident enterprise&#8217;s jurisdiction of incorporation has a tax treaty or arrangements with China that provides for a reduced withholding tax rate or an exemption from withholding tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene (Suzhou) Limited was first recognized as a qualified TASE in March&#160;2015 and renewed in December&#160;2018 and November 2021. Adagene (Suzhou) Limited was authorized to enjoy the preferential tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2015_To_12_31_2023_adag_StatusForTaxabilityAxis_adag_TechnologyAdvancedServiceEnterprisesMember_dei_LegalEntityAxis_adag_AdageneSuzhouLimitedMember_srt_StatementGeographicalAxis_country_CN_LOA0Hce0QEeI6iU8D0rTDQ" decimals="2" format="ixt:numdotdecimal" name="adag:PreferentialIncomeTaxRate" scale="-2" id="Narr_78A2qPI0s0-9X60N9ggzNw">15</ix:nonFraction>% from 2015 to at least 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Cayman Islands</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene&#160;Inc. is incorporated in the Cayman Islands. Under the current laws of the Cayman Islands Adagene&#160;Inc. is not subject to tax on income or capital gain. Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Hong Kong</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene (Hong Kong) Limited is incorporated in Hong Kong. Companies registered in Hong Kong are subject to Hong Kong profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Hong Kong tax laws. The applicable tax rate in Hong Kong is <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_HK_tMrEpBM5ckCNd3jduDmhig" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_WTx0VDeFlUmbtkpl4-qQBg"><ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_HK_4gYbMZNRaUuPUEWsYd_dSA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_kwnd1kzmMUWWHJ7KctWEZw">16.5</ix:nonFraction></ix:nonFraction>%. For the&#160;years ended December&#160;31, 2020 and 2021, Adagene (Hong Kong) Limited did <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_yYXARERJEEyfvZf0uA9tVQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_sMrMeo4nP0ekU-Ze_1cOzg"><ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_YuWhG2JtdkyJ7W4ky9r1PQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_ksRHMbJ5hU-VIeWpwXFKCg">no</ix:nonFraction></ix:nonFraction>t make any provisions for Hong Kong profit tax as there were <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_yYXARERJEEyfvZf0uA9tVQ" decimals="0" format="ixt-sec:numwordsen" name="adag:AssessableProfits" scale="0" id="Narr_kyZtjZI_hECbTYtboQHyJQ"><ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_YuWhG2JtdkyJ7W4ky9r1PQ" decimals="0" format="ixt-sec:numwordsen" name="adag:AssessableProfits" scale="0" id="Narr_fBY058KYe0Cf-_46j1Dumw">no</ix:nonFraction></ix:nonFraction> assessable profits derived from or earnings in Hong Kong for any of the periods presented. Under the Hong Kong tax law, Adagene (Hong Kong) Limited is exempted from income tax on its foreign-derived income and there are <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_HK_zjbfDO1qFECcc41CmvbdYw" decimals="0" format="ixt-sec:numwordsen" name="adag:WithholdingIncomeTaxes" scale="0" id="Narr_TCLdCBMt80K7pJTDEyrwqA">no</ix:nonFraction> withholding taxes in Hong Kong on remittance of dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Australia</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene Australia Pty&#160;Ltd. is incorporated in Australia. Companies registered in Australia are subject to Australia profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Australia tax laws. The applicable tax rate in Australia is <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_AU_S-6YiA61gUCW7VM434szsQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_2chGVGmqAUOQN3xLzm7tmg">30</ix:nonFraction>%. Adagene Australia Pty&#160;Ltd. has <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_F3MPNQIHAUq3ElcVbpTt6A" decimals="0" format="ixt-sec:numwordsen" name="adag:TaxableIncome" scale="0" id="Narr_malvB1VoOE6HMem-A03wHg"><ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_yYOL_1Zc_k-8AA3Sb91Fzw" decimals="0" format="ixt-sec:numwordsen" name="adag:TaxableIncome" scale="0" id="Narr_ZqrkHW68u0mOaCE7F67mMg"><ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_jTUbwr8vS0Sq_Dw8Xns3HQ" decimals="0" format="ixt-sec:numwordsen" name="adag:TaxableIncome" scale="0" id="Narr_lgRH8ZRP4UWk-RLz_VzmfQ">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> taxable income for all periods presented, therefore, <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_F3MPNQIHAUq3ElcVbpTt6A" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_fqkWqLZM-Eab4OAf8BADKA"><ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_yYOL_1Zc_k-8AA3Sb91Fzw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_79c7UJC8vUeSLWJNXEtNWQ"><ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_jTUbwr8vS0Sq_Dw8Xns3HQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_niG3QSOB5EyttrvYYsqFkg">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> provision for income taxes is required. Dividends payable by an Australian entity, to non-Australian resident enterprises shall be subject to <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_AU_S-6YiA61gUCW7VM434szsQ" decimals="2" format="ixt:numdotdecimal" name="adag:WithholdingTaxRateOnDividendsPercentage" scale="-2" id="Narr_UWWUaDPW50eZcNGj5yEz4w">30</ix:nonFraction>% withholding tax, unless the respective non-Australian resident enterprise&#8217;s jurisdiction of incorporation has a tax treaty or arrangements with Australia that provides for a reduced withholding tax rate or an exemption from withholding tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">United States</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene Incorporated is incorporated in U.S. and is subject to U.S. federal corporate income tax at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_US_4Mf3uObvgkKrQagy395fZA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" scale="-2" id="Narr_eHwJ2myDp0S9kIpu5gFpuw">21</ix:nonFraction>%. Adagene Incorporated is also subject to state income tax in California of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_stpr_CA_Zi09NHLp7kmMwo_bnVpuPA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" scale="-2" id="Narr_U4CNzWjtgU-a6QMh3sLpYA">8.84</ix:nonFraction>%. Dividends payable by an U.S. entity, to non-U.S. resident enterprises shall be subject to <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_US_4Mf3uObvgkKrQagy395fZA" decimals="2" format="ixt:numdotdecimal" name="adag:WithholdingTaxRateOnDividendsPercentage" scale="-2" id="Narr_G_jBY76S0EWI5QZCb6QRZw">30</ix:nonFraction>% withholding tax, unless the respective non-U.S. resident enterprise&#8217;s jurisdiction of incorporation has a tax treaty or arrangements with U.S. that provides for a reduced withholding tax rate or an exemption from withholding tax.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="Tc_V3btzcQF20KZtd-Mf-x_FA_1_2"></a><a id="Tc_qB_53U_-4UeH7Xk9Q8afLw_2_2"></a><a id="Tc_hlEUrfxGjkCAZkAwdedcCA_2_4"></a><a id="Tc_9IK3nT5ILEqXBa1_RQgwBQ_2_6"></a><a id="Tc_yQ9wurA7TEq-eJyP8fg3cA_3_2"></a><a id="Tc_wACW0VsKLEmWso352VTEEQ_3_4"></a><a id="Tc_sziOxy8fhkSxbL104vdXyA_3_6"></a><a id="Tc_JzEP2HNr30CTQEEJ7Zm6hw_4_0"></a><a id="Tc_e_4i9b1vW06ofXIESwZ26w_5_0"></a><a id="Tc_DT35M1IFeUe4AUuq5DJwUA_6_0"></a><a id="Tc_ZOOJgTYNU0Klx-wt6xlhPw_6_2"></a><a id="Tc_xxeYc9ou2kGFzDVVoB3UBg_6_4"></a><a id="Tc_VKf-TW4I5E6iTVg_JMTiFg_7_0"></a><a id="Tc_Eb2gu1hPDUmA3KJT-alHow_7_2"></a><a id="Tc_GoI9zZL9ZUOVxPy3-ldt3A_7_4"></a><a id="Tc_gh8o_CORKUq7gsQ2sDduUw_8_0"></a><a id="Tc_04GqhnOxA0G56EXXmZZVJA_8_2"></a><a id="Tc_4IW5e65DjEqpgAQ537QCUA_8_4"></a><a id="Tc_2laO4GEk2Eyd7vt0mO1Y2A_9_0"></a><a id="Tc_QO_o2mhQp0SkshCX-ekC_Q_10_0"></a><a id="Tc_DefNgHN8_EuybXFwct1yCg_11_0"></a><a id="Tc_R7sVvLoYVUC0KBMwKbP1Kw_11_2"></a><a id="Tc_BW9qm-gt10SQUd4s8fIFPQ_11_4"></a><a id="Tc_8NkPO8gRMUu3BzPXmkSBrw_12_0"></a><a id="Tc_wdjfUN3L60q4YYDTuw9Fgw_12_2"></a><a id="Tc_tjpDEturpEeqhaCPbHMzLA_12_4"></a><a id="Tc_Dm7ru3WeCkeRtrWKQgvbCA_13_0"></a><a id="Tc_FsrLr0Q1yk6rUhsr4uiXnA_13_2"></a><a id="Tc_AmYwCBt2H0Gg9b5bT4JFAQ_13_4"></a><a id="Tc_Rwin7LDuS02n4IaC2NBPLg_14_0"></a><a id="Tc_cMKWO4Jsh0ezTuyqXajTZA_14_2"></a><a id="Tc_MSOjJFDnXkqF_SxmWWUUGA_14_4"></a><a id="_f0b33bdf_7ca9_42fa_9bc7_34ce797ede61"></a><a id="Tc_j4mC9_AjT0CkQDLg3J2b-g_1_2"></a><a id="Tc_UqSUna4QRkeukDOPMhi9Ig_2_2"></a><a id="Tc_jgDuQ8vcGUS9V1QG8CJK5g_2_4"></a><a id="Tc_lDQ98QQh40GxboHXTREvbA_2_6"></a><a id="Tc_gAC2IzGmuUOLEKx51dgF4Q_3_2"></a><a id="Tc_o6jpg51IxECwen4H-srUuQ_3_4"></a><a id="Tc_sOQyC7vtHEagSAf4b-hC2A_3_6"></a><a id="Tc_YMgV_PEY7Euwwaqb6dvkGg_4_0"></a><a id="Tc_bbOSN_Ck9EOfWf7Z7cVIng_5_0"></a><a id="Tc_LA5ea4m3MUyoOU8C9l1xcA_5_3"></a><a id="Tc_z0p0QXWQCUyP2L_gXiQLtQ_5_5"></a><a id="Tc_6kXwmrl0IUWcWCfm1Lyekw_5_7"></a><a id="Tc_wPT-dAPruUKs-KemnNN-7Q_6_0"></a><a id="Tc_uvGdydr3Pk294JsJmLGdhQ_7_0"></a><a id="Tc_zVvB9IHGy0qWRB3ti7Ro3w_8_0"></a><a id="Tc_7PX_uVdif0CEMRdDgR7xSg_9_0"></a><a id="Tc_rngzL_dRPE2OIXY9u_WjOQ_10_0"></a><a id="Tc_3pG3weD70EaYUMeYZDwLWg_11_0"></a><a id="Tc_X2QR37c9ikG5-CAyA_FABg_11_2"></a><a id="Tc_5ZdSynhNzkeQN-BhIH-EvA_11_4"></a><a id="Tc_26NgPsuqF0yra2FpfgcrLQ_12_0"></a><a id="Tc_0q7Y5buh5UW_nyHkoMWEaQ_12_2"></a><a id="Tc_uo9Er-Oi0UmZqVddrfwONA_12_4"></a><a id="Tc_Cq4vJxxFFkaTH0_ZYqZd3w_13_0"></a><a id="Tc_WVDSgVimvECBuKRjdQyodA_13_2"></a><a id="Tc_M5Sa7TeVZU-C2ANweUdKmw_13_4"></a><ix:continuation id="Tb_S-OJ91cqR0aLJi0EuwRfCg_cont1" continuedAt="Tb_S-OJ91cqR0aLJi0EuwRfCg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Switzerland</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene AG is incorporated in Switzerland and is subject to federal corporate income tax at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_CH_iL69fGVCpEaHddyIW4NKvQ" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_smb2xQIOO0iRHxsC8sEj5A">8.5</ix:nonFraction>%. Adagene AG is also subject to cantonal income tax of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneAgMember_srt_StatementGeographicalAxis_country_CH_2T-t4Od_mUu8G2OSLg0lGA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_rygBDm2rn0ebGzn1oVO6bQ">6.5</ix:nonFraction>% as well as capital tax of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneAgMember_srt_StatementGeographicalAxis_country_CH_2T-t4Od_mUu8G2OSLg0lGA" decimals="3" format="ixt:numdotdecimal" name="adag:CapitalTaxRatePercentage" scale="-2" id="Narr_XtjgnCGM6UibSL_3Kjxdew">0.1</ix:nonFraction>% in the Canton of Basel subject to certain tax benefits and relief. Dividends payable by a Swiss entity, to non-Swiss resident enterprises shall be subject to <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_CH_iL69fGVCpEaHddyIW4NKvQ" decimals="2" format="ixt:numdotdecimal" name="adag:WithholdingTaxRateOnDividendsPercentage" scale="-2" id="Narr_BxSybiaxokWSLWc6PLHjXw">35</ix:nonFraction>% withholding tax, unless the respective non-Swiss resident enterprise&#8217;s jurisdiction of incorporation has a tax treaty or arrangements with Switzerland that provides for a reduced withholding tax rate or an exemption from withholding tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Income tax expense (benefit) of the Group for the years ended December 31, 2019, 2020 and 2021 were composed of the following current and deferred amounts:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_lbAv9txbXUWm86SjcpxQ3Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">U.S</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="0" id="Tc_HB7Xe37VfUCGQe1hrThpLg_6_6">1,290,009</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">State and local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="0" id="Tc_wkg--hKUUEG5rqGeENDhrw_7_6">367,441</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="0" id="Tc_fefZ-nVJIUOKgqdci-bN0w_8_6">1,657,450</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">U.S</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="0" id="Tc_7lZl2ix7FE-aPY-7PHk8mw_11_6">96,804</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">State and local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" sign="-" scale="0" id="Tc_x8ek5ELWE0utMeDwNYiBuw_12_6">52,641</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" id="Tc_Ct6txab8pk2lNE3ekgtyKQ_13_6">44,163</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Income tax expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_YKpnUfzZJEm2d5Ir7PbLag_14_6">1,701,613</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Reconciliation between the income tax expense computed by applying the statutory tax rate to loss before income tax and the actual provision for income tax was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_tXFxaRsSL0iAyTVIhI70BA" continuedAt="Tb_tXFxaRsSL0iAyTVIhI70BA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_M0yzvOU70EueJ3a9rZskZw_4_2">16,432,308</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_uxcUzCvg_EGZ-PwQDFREtw_4_4">42,397,279</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_aRN0sNdV-0Kn9sBDfi7Y8g_4_6">71,476,322</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">PRC preferential income tax rate as qualified TASE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_he7fJwM5hUSPpqpUffg9mg_5_2">15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_mRLQuQN8skWWkZe0PenaaA_5_4">15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_y-PcQmGgnEmHCsa4XqDKwg_5_6">15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Income tax credit computed at PRC preferential income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_-UXGaOZNYkWsl_a84-zWTg_6_2">2,464,846</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_3E8-2YzZQUa9krNKvkMN9w_6_4">6,359,592</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_UUxBaZsXIUCuZvJbGSuXig_6_6">10,721,448</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Difference in income tax rates of overseas entities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" scale="0" id="Tc_0MUWj-DBwEKn9Rdop_r2Ag_7_2">2,492,721</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" scale="0" id="Tc_AGqqzWV4wkObmYDfIkKxYA_7_4">5,286,487</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" scale="0" id="Tc_AGToVBfWQUC3daVdaMUnuA_7_6">10,549,985</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development super-deduction<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="adag:EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount" scale="0" id="Tc_YyDURAdJuUeZzUzS524Thw_8_2">230,126</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="adag:EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount" scale="0" id="Tc_5A-MHysVQ0Oc-b_Ec0qsRg_8_4">718,979</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="adag:EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount" scale="0" id="Tc_raxY_hlXkEqHEhJtxslyog_8_6">569,016</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Non-deductible expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" id="Tc_mJ3u_ERVYkeDfkBF6falYg_9_2">3,306</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" id="Tc_0dMsd-sLb0yNw6b5fMT0Hg_9_4">1,238</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" id="Tc_386curmr10OLysrL5KtWPA_9_6">1,054</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Changes in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="Tc_rMplN9OrW0W6UqnF4f7pZQ_10_2">198,945</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="Tc_9S7SdqeTG0ywhPvvpn7FzA_10_4">1,790,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="Tc_IZequLvbs0GVm1Tqsqaqkg_10_6">2,277,418</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">State tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="0" id="Tc_IKvkPk9thUWgd8TXWBqbtA_11_6">291,500</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" sign="-" scale="0" id="Tc_2pVVG2g9tUmDNUkyy8SpRA_12_6">127,880</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Tc_Pz-LJ84540ypl8LPrise8w_13_6">1,701,613</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:18pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><span style="font-weight:normal;">Note&#160;(a): Due to the impacts of research and development super-deduction, the Group&#8217;s subsidiary, Adagene (Suzhou) Limited, did not have any income taxes for the&#160;years ended December&#160;31, 2019, 2020, and 2021.</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_bacfe475_e80e_408e_8de6_3bb0f568f15d"></a><a id="Tc_rRmPpm0IpUy-L-unG0_hnA_1_2"></a><a id="Tc_fcQNLgZ8l063nBiLrZ2mEw_2_2"></a><a id="Tc_pdTKxuOtrE6yecVz9K9Hpw_2_4"></a><a id="Tc_qPMyRZlT-0ygAar1e4oTNA_3_2"></a><a id="Tc_1G5gECppDkO5Atxr6fQw8Q_3_4"></a><a id="Tc_nkO9_bqC_kat80K-K4y4ag_4_0"></a><a id="Tc_iflqVBZejkmN-OfA_X2JYg_5_0"></a><a id="Tc_sysIz0_HEEmhvOMvJt9MIQ_6_0"></a><a id="Tc_xPca0lPU2USGjCePg8dgOQ_6_2"></a><a id="Tc_1yBVxYw2jUC3Is6PvbY_fA_7_0"></a><a id="Tc_eDgK5X96rEyC38gHCOcmpw_7_2"></a><a id="Tc_E7WXZwL_MUOTEJa1qTuAZA_8_0"></a><a id="Tc_ai3vJK0FV0Gz2yoIf2yggw_9_0"></a><a id="Tc_CtEkj3Hh5Ua8jU9N_vLLuA_10_0"></a><a id="Tc_-LB8JwfpoESntOuv4Ob9ew_11_0"></a><a id="Tc_BUIb5KkBOUmCbm2Hy5YpjA_11_2"></a><a id="_caa45214_87a3_449f_961d_998930fbb8e5"></a><a id="Tc_m9Oy-Dy3IkOerqxjE1eZXw_1_0"></a><a id="Tc_8L-HeAOGw0SmjWCpakbkRw_2_0"></a><a id="Tc_cX_taWHgRkyRwYUw9K7k7Q_2_2"></a><a id="Tc_iqDSzgbIg0-Q9Qm5t_ya6A_3_0"></a><a id="Tc_3Ns2A7GMM0q2ZjiLBVjNrg_3_2"></a><a id="Tc_u_I5xoYN_0yMVFitKLjlYg_4_0"></a><a id="Tc_c0DqMWYsvEKP6S327RFk_g_4_2"></a><a id="Tc_60soAAZ8lU-aPN7YB1JUWg_1_2"></a><a id="Tc_9mmQw2dvTECDlwic4VLOwg_1_4"></a><a id="Tc_2qFJqZqml0Sc_tQ0vuY84Q_2_2"></a><a id="Tc_K4ThgYAlN0muj0Y_RhL5VQ_2_4"></a><a id="Tc_kr508jIXmUSJAS5_A7WG6w_3_0"></a><a id="Tc_tYOv5IhVN02Nbqppop-pMA_4_0"></a><a id="Tc_HM2bIuhdTk6QaKb2R064iw_5_0"></a><ix:continuation id="Tb_S-OJ91cqR0aLJi0EuwRfCg_cont2" continuedAt="Tb_S-OJ91cqR0aLJi0EuwRfCg_cont3"><ix:continuation id="Tb_tXFxaRsSL0iAyTVIhI70BA_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Deferred tax assets and liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Deferred taxes were measured using the enacted tax rates for the periods in which the temporary differences are expected to be reversed. The tax effects of temporary differences that give rise to the deferred tax balances as of December&#160;31, 2020 and 2021 were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_Ymi5GG2wHkuTe8F88qoG3Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net operating loss carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_gSV7DugewEe8o1nimtzjFA_5_2">2,722,293</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" id="Tc_6QXxVxxJpEafXoqjq8bilQ_5_4">4,949,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Capitalized inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsInventory" scale="0" id="Tc_PcK33Z34hkactnwnuIfH4Q_6_4">95,589</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Unrealized foreign exchange gain/losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" scale="0" id="Tc_J6suqYZ9dUCvksfdPTx1fA_7_4">39,166</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Depreciation and amortization of property, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="adag:DeferredTaxAssetsDepreciationAndAmortization" scale="0" id="Tc_SAlKkpZ5N0e5s5JhTtfkow_8_2">7,428</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="adag:DeferredTaxAssetsDepreciationAndAmortization" scale="0" id="Tc_BSm5x5zuTku79Ch6ASONsw_8_4">79</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_azcwRTgKw0qKuYYJUiodCw_9_2">2,729,721</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="0" id="Tc_HIzhMtTYLkOPMUcNSfn4SA_9_4">5,083,834</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_YymygLizgE64-VkYxyrhqQ_10_2">2,729,721</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_WSxx5Ery5Uuo5k80OTbAqg_10_4">5,007,139</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Tc_bIsDTAbuIE6pHxWbDcQQoA_11_4">76,695</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;&#160;&#160;&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;&#160;&#160;&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Depreciation and amortization of property, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" id="Tc_9JPhsX8awEqOgGBlTiYKfQ_2_4">120,858</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:77.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" id="Tc_f7H3PX_5506X_aBj5rPX0w_3_4">120,858</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:77.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total deferred tax liabilities, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="0" id="Tc_yvmLKMLH8UiidNB8BYAFAA_4_4">44,163</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Movement of the valuation allowance was as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="Tb_T97ZD1tbrEeaq7LPZNFN8A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of January 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_gC2EYRsVjEWUnhAs7Jm5Bw_3_2">938,875</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_uWCsaJDWv0K2FhS_lpPCBg_3_4">2,729,721</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Addition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" id="Tc_88UKn6_ccUG2ys6tSRvNPw_4_2">1,790,846</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="0" id="Tc_EPOOG2EK2Emp75pVBc-fiw_4_4">2,277,418</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of December&#160;31</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_aAvbGYEIKEaloBOyBgMRjw_5_2">2,729,721</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Tc_tM2BszqNnk-pP3vq8bQHUQ_5_4">5,007,139</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion or all of the deferred tax assets will not be realized in the foreseeable future. In making such determination, the Group evaluates a variety of positive and negative factors including the Group&#8217;s operating history, accumulated deficit, the existence of taxable temporary differences and reversal periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group has incurred net accumulated operating losses for income tax purposes since its inception. As of December 31, 2021, the Group had net operating losses for income tax purpose of approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_XA7ew2XwfUK2aww0YCZ6Og">27,453,623</ix:nonFraction>. The net operating losses were primarily comprised of: US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_CN_OhVh4Lb4B02ZVkGnT6Nwxw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_rVn1G7aQMkaATYP7shdJjA">9,206,664</ix:nonFraction> from an entity in PRC which expires in years 2028 through 2030; US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_CH_YBCRGjH5NE--RhN9ukhZ4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_-pLFpz__rEWCGJt5k8UcWw">8,467,321</ix:nonFraction> derived from an entity Switzerland which expires in years 2027 through 2028; US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_HK_zjbfDO1qFECcc41CmvbdYw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_6K5_PleRIEW7AcEe0Ugmng">5,240,125</ix:nonFraction> derived from an entity in Hong Kong that have an indefinite carryforward; US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_AU_LMSJo9Jtm02FhFmXG-t5HQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_bmLXOH7dqkKALpHSyZ8lxQ">3,684,472</ix:nonFraction> derived from an entity in Australia that have an indefinite carryforward subject to meeting certain criteria; US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_US_qd0LMDoF3kaYh2E7WWuXKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_6WOFiCuQF0aWGBOxZLsrDg">640,570</ix:nonFraction> derived from entities in the United States which expire beginning year 2038; and, US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_SG_uNjj8HS8_UGTaPvk5ZRsdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLossCarryforwards" scale="0" id="Narr_p1V4yAXBWUCSSo3S44xrCg">214,471</ix:nonFraction> derived from an entity in Singapore. The Group believes that it is more likely than not that these net accumulated operating losses will not be utilized in the near future, except for the net operating losses from the U.S. subsidiary. Therefore, the Group has provided full valuation allowances for the deferred tax assets for all subsidiaries as of December 31, 2020 and for subsidiaries other than the U.S. subsidiary as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of December&#160;31, 2020 and 2021, the Group did not have any significant unrecognized uncertain tax positions. The Group does not anticipate that the amount of unrecognized tax benefits will significantly change within the next 12 months.</p></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_S-OJ91cqR0aLJi0EuwRfCg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group conducts business in a number of tax jurisdictions and, as such, is required to file income tax returns in multiple jurisdictions globally. As of December 31, 2021, PRC tax matters are open to examination for the years 2018 through 2021, U.S. federal and state tax matters are open to examination for the years 2018 through 2021, and Australia tax matters are open to examination for the years 2019 through 2021.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="Tc_qYfukhgBm0e9P6SJv6HcpA_1_2"></a><a id="Tc_zTjQ5VLfSU66jn2SvVm6ig_2_2"></a><a id="Tc_b5UEgeyhpUa0YxQyU1J4MQ_2_4"></a><a id="Tc_SxHhY80IlEeRqsRQpmENJg_2_6"></a><a id="Tc_3hBLREJ1wkqKRDrzwUKBEg_3_2"></a><a id="Tc_KFS1owOm4ked57S1Tvv6yQ_3_4"></a><a id="Tc_TJL0TeAqEk2h8EAkqLiTvQ_3_6"></a><a id="Tc_tFqkQBC5k0itx7R77s2jbQ_4_0"></a><a id="Tc_jkotVCnAMUibKdKSjJ1ytw_5_0"></a><a id="Tc_R2YMj3yV6E2NUM7P89S8NQ_6_0"></a><a id="Tc_QWD_7C0-yUSl4NNGPERTmw_7_0"></a><a id="Tc_8usBYc24YUmmp0f4yQI5Pg_8_0"></a><a id="Tc_0TUbsuLikEyTz966Tcds9A_9_0"></a><a id="Tc_dS3EhpgAQ0aszJJAM87v8Q_10_0"></a><a id="Tc_S8tbD85410edLizWWqEDtA_1_2"></a><a id="Tc_L4nsH1jzo0CRApTazWGuRQ_2_2"></a><a id="Tc_tWlNEtzNpkqSbbs-KKoRzg_2_4"></a><a id="Tc_s7DzhGce_Uiu3pwlzd3TFA_2_6"></a><a id="Tc_NJyb5oo-HU-rXveV7zoaGw_3_0"></a><a id="Tc_Y8G_8XzXlUGA4WRuRRnXZg_3_6"></a><a id="Tc_vcM4aoZ7NUiTDN3d4W79OQ_4_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:EarningsPerShareTextBlock" id="Tb_9yuH8DxRC02_i2HMP1Y8Iw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">12. NET LOSS PER SHARE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Basic and diluted net loss per share for the&#160;years ended December&#160;31, 2019, 2020 and 2021 were calculated as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_u0CGJbCPj06-UngVH6Yh_Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year&#160;Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to Adagene Inc.&#8217;s shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_cfm9uL5fUUa94OOuy4z0dQ_5_2">16,432,308</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_kELduIDuyUS_-Mc9XkMDEg_5_4">42,397,279</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="0" id="Tc_dpqCODu-i0Ki-HtvcifYaw_5_6">73,177,935</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of convertible redeemable preferred shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_l3mr2Fs-bEuIRtwat5rj5w_6_2">246,184</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_dvfvf1TckkKQWMINkWMVTQ_6_4">248,113</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" id="Tc_TgOIvgDW50S3NJGCKKiiAQ_6_6">28,553</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to ordinary shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_1nkNial-UUyCEQlPOdyPcw_7_2">16,678,492</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_gFpDIrdi3U-9jtBVk4Kr5Q_7_4">42,645,392</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_yOhQVVPuZ0OBXCYHMdBEvw_7_6">73,206,488</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted&#8209;average number of ordinary shares outstanding&#8212;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_EylEQ07x-Uuem-DGE1-Bsg_9_2">15,178,232</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_uqdShS48qUqwRWiBFEG9SQ_9_4">15,950,698</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_4sE3-ga-DkurfkrK0Bm-QQ_9_6">50,032,009</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net Loss per share&#8212;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_Q8I7JLgE20GYg3tdNTk6wA_10_2">1.10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_X66y3BT2XkmaMm_dUZK--g_10_4">2.67</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_a7FKBRCr_0adGa3e_cNKhg_10_6">1.46</ix:nonFraction>)</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The effects of all outstanding convertible redeemable preferred shares and share options have been excluded from the computation of diluted loss per share for the&#160;years ended December&#160;31, 2019, 2020 and 2021 as their effects would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The potentially dilutive securities that have not been included in the calculation of diluted net loss per share as their inclusion would be anti-dilutive are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_2ighjAUwh0mxVVCjTSPr2Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year&#160;Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Convertible redeemable preferred shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_qtF149jaCUabjqo7frjCBw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_NXDQ0SKEvUSfYKs6Skyz0g_3_2">21,977,914</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_ESjTZBeLf0SCBovh04R_ag" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_O_rmu0WVFUmZ_XEG4gmKFQ_3_4">27,249,824</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Share options and share grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_yAAu1HlY9EC9pTVzah_bYw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_giFFo6ijg0OYWdLNvJZmjg_4_2">582,526</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_wCLSLauImkivkl4yN53mvA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_O2N6vwns5kOoL1yrVwB2OQ_4_4">1,795,932</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_6guEaEag302za51zg4qPZw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_q0wVCpGVwE2xT9pgoVjk6w_4_6">1,739,882</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Tb_Ml0GSSmSx0qwQJsu4WJbwQ" continuedAt="Tb_Ml0GSSmSx0qwQJsu4WJbwQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">13. RELATED PARTY TRANSACTIONS</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="Tb_a7KTO7rm9USZkcyA68l_6A" continuedAt="Tb_a7KTO7rm9USZkcyA68l_6A_cont1" escape="true"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Related Parties</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name of related parties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Relationship</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Peter Luo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Chairman, Chief Executive Officer and a principal shareholder of the Company</p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Four senior management personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Management and ordinary shareholders of the Company</p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Co., Ltd. (&#8220;WuXi AppTec Group&#8221;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">A principal shareholder of the Company</p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Controlled by the ultimate controlling party of a principal shareholder of the Company</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0ded37a5_4c6c_4e28_bb24_b81ff8e9bf88"></a><a id="Tc_3ThUSaogfkKx25tJCoLD9A_1_2"></a><a id="Tc_Z22JisAHy0GoVgPPSiDS4A_2_2"></a><a id="Tc_j-j0OiDF1EelLjm1cPCEeA_2_4"></a><a id="Tc_ZWNrAXa4-0K-HSQOqKzTrw_3_2"></a><a id="Tc_QOc5mWC7vUemxee1ElQe2w_3_4"></a><a id="Tc_69_EJnnkwkm9g8zHPw10Hw_4_0"></a><a id="Tc_3VlwKPG810-zqyOib3yRhQ_5_0"></a><a id="Tc_YsFahCPl602sZ3gkgdP6XA_6_0"></a><a id="_5c35fe04_05d0_42e1_b1f0_e82a033bed13"></a><a id="Tc_rEPnQDQCIUONMbDYO4k26g_1_2"></a><a id="Tc_VH7ygkoVEk-CX-308491sg_2_2"></a><a id="Tc_zh2EgLQNTkOOU0fer4RQ0g_2_4"></a><a id="Tc__oi0vk5dlkW0zbEiZaVTPA_3_2"></a><a id="Tc_8Z8Bw1QR0k-WEOe--ruo8Q_3_4"></a><a id="Tc_83I3EgwDpUmKZU2TpOa9fg_4_0"></a><a id="Tc_4ek0801yyESXa_5b665VtA_5_0"></a><a id="Tc_4jGA1Kt6-k63ovOyRCCPhA_6_0"></a><a id="_eab2d572_ac98_4daa_bc32_cc30c9731250"></a><a id="Tc_hovYFjdqxUOlF7jz15VRCQ_1_2"></a><a id="Tc_Z8pfbXT_J0GwGS75Qtx1xA_2_2"></a><a id="Tc_PU8bsliDD0GSoeobikEa6g_3_2"></a><a id="Tc_Oiobm0NxL0yn0iulaH558w_3_4"></a><a id="Tc_r9RZ3EbMEE-1ULu6e_nZpw_3_6"></a><a id="Tc_gifx-_WFckS7HXGT-oZc_w_4_2"></a><a id="Tc_Prv8DNFRnUCvS4NwpowPaA_4_4"></a><a id="Tc_79Hv_7JqM0KNfd-qB1khdg_4_6"></a><a id="Tc_LbQPYr1ou06V2jMHnS8gKg_5_0"></a><a id="Tc_kWWkI31i60yuRF6EbvPDjQ_6_0"></a><a id="Tc_ZI-nWxQzXkqW84cK9FQ9pA_7_0"></a><ix:continuation id="Tb_Ml0GSSmSx0qwQJsu4WJbwQ_cont1"><ix:continuation id="Tb_a7KTO7rm9USZkcyA68l_6A_cont1"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Group had the following related party balances as of December 31, 2020 and 2021:</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Group</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_aakkwWDe5k2bhxPkdccOxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" id="Tc_HdK9mNMVP0e8ayFv0ZW1-w_4_2">124,704</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_GXYUWeoSRU-ouLAoR_nM4A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" id="Tc_Jzx8gcwzFEamHrV5ZK1nZg_4_4">3,080,116</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_oF1Ki6py4Ea_VIk2bXN2pw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" id="Tc_JvewNpOW6EKIfHHA7HT_-w_5_2">7,692</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_I6hnNvOh2UqAhbgZo1ZC3g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" id="Tc_IVkFGpaXIUenc1wWCi_Z6Q_5_4">1,426,554</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total amounts due from related parties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" id="Tc_Wza3gmGcokyQYkQn0CC8Fw_6_2">132,396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueFromRelatedPartiesCurrent" scale="0" id="Tc_k-mxUNsAxEamqiwfwcHYPA_6_4">4,506,670</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">As of December 31, 2020 and 2021, the amounts due from related parties represented prepayments made for the CRO and CMO services.<br /><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_oF1Ki6py4Ea_VIk2bXN2pw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Tc_hM-ywrjaX06_7v7PMM6bdQ_4_2">2,361,503</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_I6hnNvOh2UqAhbgZo1ZC3g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Tc_LEP254QnQ0qjibsV00gMJA_4_4">10,292,268</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Group</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_aakkwWDe5k2bhxPkdccOxg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Tc_0mbRfyWMoEOvZUujigHh4Q_5_2">173,855</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_GXYUWeoSRU-ouLAoR_nM4A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Tc_5odhTbwHqk-eUZIX8l5-dA_5_4">173,793</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total amounts due to related parties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Tc_dL2D12zr10e4Uod3CN2-EA_6_2">2,535,358</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DueToRelatedPartiesCurrent" scale="0" id="Tc_Ray3lQ_Hf0WH0nlu8ccq9Q_6_4">10,466,061</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">As of December 31, 2020 and 2021, the amounts due to related parties represented payables for the CRO and CMO services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Group had the following related party transactions during the years ended December 31, 2019, 2020 and 2021:</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Receipt of CRO and CMO services:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_XeTQYEWhbE-YyIEK2oP-aw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_YrEMxpOx906tBr2H_3_Q7w_6_2">3,567,962</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_N1u78K2d-EOfIuR8F8QHxw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_GZXsrOX2HkuNEUdk8p1kmw_6_4">7,217,709</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_SAiLZZ5KLU2DxJiGDTfUCQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_wkbuksGUv0uTvwn2lRhh4Q_6_6">12,561,276</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Group <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(i)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_KmqFU3ZUgkCofpEfOKqHNQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_UwX6Iiqs9E2dG0Fhm0d6iQ_7_2">2,136,344</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember__5lJ8r5zLkCATZnr5vRZCQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_f3n2Vkhf4EOD3aR-v36VyQ_7_4">2,674,586</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_SwsdmKolekSilpQ3qYqN5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_AaF-fVyPWUe8RR-P-AODnQ_7_6">517,742</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_uo7m-2m6a06JnSUbvBslaA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_WP8pgpGMv0WoZ2GMCCzfAg_8_2">5,704,306</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_dOiC75LhVU2oZehy5mDi8A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_lA-JVsur5EyL3Yt_HwOLEQ_8_4">9,892,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_q83pj5eew0G-H2b3ek53pA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="0" id="Tc_cW890vy0QUmoFIlT3yKM5w_8_6">13,079,018</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3225de34_dae7_46f7_9f8e_3fc1951f1daf"></a><a id="Tc_Qdts2d8Bgkyrs92NtAqQCw_1_2"></a><a id="Tc_x_izdClHNUmaocfm_ZzSBA_2_2"></a><a id="Tc_DGAeKiYh4U6myOSxZ3AK2Q_3_2"></a><a id="Tc_e4VMkdwft0qKiEaYiYg0SA_4_0"></a><a id="Tc_kUQyTTtdeEqaABwzJbhvcw_5_0"></a><a id="Tc_Qibax98Sj0i4cX98HHqYOA_6_0"></a><a id="Tc_2RwKnGcKiEO7pGyInLtnOw_7_0"></a><a id="Tc_luFCkbcxZ0-W5xG-R7Wzzg_8_0"></a><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_8w2CHvJmxEu11m9dBXzbJg" continuedAt="Tb_8w2CHvJmxEu11m9dBXzbJg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">14. COMMITMENTS AND CONTINGENCIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Operating lease commitments</p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="Tb_bB-LaTM4FkS7DXJRqL4GnQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Future minimum payments under non-cancelable operating leases with initial terms in excess of one&#160;year consisted of the following as of December&#160;31, 2020 and 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">For the years ending:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="0" id="Tc_jgLXdAPHLk6VI4dMez8Ysw_5_2">412,754</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" scale="0" id="Tc_a_BLdM8wTUOHvHP4pxJ61A_6_2">255,309</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="0" id="Tc_S99yzzMxZ0ixtfyxt2Bh7Q_7_2">70,367</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" scale="0" id="Tc__ULirCgNnEKwHbE28wqNiA_8_2">738,430</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payments under operating leases are expensed on a straight-line basis over the periods of their respective leases. The Group&#8217;s lease arrangements have no renewal options, rent escalation clauses, restrictions or contingent rents and are all executed with third parties. For the&#160;years ended December&#160;31, 2019, 2020, and 2021, total rental related expenses for all operating leases amounted to US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="0" id="Narr_dM4Uvc9Vt06dC8ozj0EWyQ">175,812</ix:nonFraction>, US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="0" id="Narr_hbkMXsu9GEOEBqFQ_laP-A">177,453</ix:nonFraction> and US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="0" id="Narr_7m8U44uD3Uu41rRE1lR1yg">331,745</ix:nonFraction>, respectively.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_8w2CHvJmxEu11m9dBXzbJg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group is currently not involved in any legal or administrative proceedings that may have a material adverse impact on the Group&#8217;s business, financial position or results of operations.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:RestrictedAssetsDisclosureTextBlock" id="Tb_yne9CtpV7kuntk1o5dFAww" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">15. RESTRICTED NET ASSETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group&#8217;s ability to pay dividends may depend on the Group receiving distributions of funds from its PRC subsidiary. Relevant PRC statutory laws and regulations permit payments of dividends by the Group&#8217;s PRC subsidiary only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the consolidated financial statements prepared in accordance with U.S.&#160;GAAP differ from those reflected in the statutory financial statements of the Group&#8217;s PRC subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accordance with the company law of the PRC, a domestic enterprise is required to provide statutory reserves of at least <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="adag:MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve" scale="-2" id="Narr_2QZyAaACN0eG4eO1h1Tfmg">10</ix:nonFraction>% of its annual after-tax profit until such reserve has reached <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="adag:StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital" scale="-2" id="Narr_gaXY1u_hH0Kd0OAx8SOIkw">50</ix:nonFraction>% of its respective registered capital based on the enterprise&#8217;s PRC statutory accounts. A domestic enterprise is also required to provide discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise&#8217;s PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Group&#8217;s PRC subsidiary was established as domestic invested enterprise and therefore is subject to the abovementioned restrictions on distributable profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2020 and 2021, the total restricted net assets of the Company&#8217;s subsidiary incorporated in PRC and subjected to restriction amounted to approximately US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" scale="0" id="Narr_H3T5qe2Mnk6JI30GL-isEQ">1,267,900</ix:nonFraction> and US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" scale="0" id="Narr_9Lc5URwmQEyh1Np6AxDIbQ">1,860,667</ix:nonFraction> respectively. Other subsidiaries are not subjected to such restriction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of these PRC laws and regulations subject to the limit discussed above that require annual appropriations of <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="adag:AfterTaxIncomePercentageAppropriations" scale="-2" id="Narr_gAkP8wR0oUCoccK9inI0vg">10</ix:nonFraction>% of after-tax income to be set aside, prior to payment of dividends, as general reserve fund, the Group&#8217;s PRC subsidiary is restricted in their ability to transfer a portion of their net assets to the Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Foreign exchange and other regulations in the PRC further restrict the Group&#8217;s PRC subsidiaries from transferring funds to the Company in the form of dividends, loans and advances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of December 31, 2021, the net asset base for purposes of calculating the proportionate share of restricted net assets of consolidated subsidiaries was US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" scale="0" id="Narr_K06HrhYuYkuS1qJRnsaKPA">1,860,667</ix:nonFraction> from the PRC subsidiary, and the Group had a consolidated shareholders&#8217; equity. As the restricted net assets of consolidated subsidiaries do not exceed <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" decimals="2" format="ixt:numdotdecimal" name="adag:ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries" scale="-2" id="Narr_Bmo9gvrFKkOmVM1yf6s4UA">25</ix:nonFraction>% of consolidated net assets as of the most recent fiscal year end, the Group is not required to provide parent company financial information.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="font-size:11pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:TreasuryStockTextBlock" id="Tb_F8NZ6cBRcEeMud8vYUohtg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">16. Treasury Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group accounts for treasury shares using the cost method. Under this method, the cost incurred to purchase the shares is recorded in the treasury shares account in the consolidated balance sheets. At retirement, the ordinary shares account is charged only for the aggregate par value of the shares. The excess of the acquisition cost of treasury shares over the aggregate par value is recorded entirely in additional paid-in capital (up to the amount credited to the additional paid-in capital upon original issuance of the shares). In the event that treasury share is reissued at an amount different from the cost the Group paid to repurchase the treasury share, the Group will recognize the difference in additional paid-in capital by using the specified identification method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;">On July 7, 2021, the Board of Directors approved a share repurchase program to repurchase up to US</span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_7_7_2021_ah_eEOxPL0CIPCxPK6qNbQ" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="Narr_RGw3Gm2jJUy1vEFkGbCi6Q">20</ix:nonFraction></span><span style="font-size:10pt;"> million of outstanding ADSs of the Company, from time to time over a </span><ix:nonNumeric contextRef="Duration_7_7_2021_To_7_7_2021_Q_S9qhvpvUC3dMaaONMnrg" format="ixt-sec:durmonth" name="us-gaap:StockRepurchaseProgramPeriodInForce1" id="Narr_ruMKknSmBEyhTSJjJ-FuWw"><span style="font-size:10pt;">12</span></ix:nonNumeric><span style="font-size:10pt;">-month period from the date on which a formal stock repurchase plan engagement agreement was signed with a qualified broker-dealer. Up to December 31, 2021, </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_7_7_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_CCQsBDVo0ESOnNGl9WpWgw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="Narr_WPCUqhxk9k21vzMKrRADUw">236,139</ix:nonFraction></span><span style="font-size:10pt;"> outstanding ADSs (</span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_7_7_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_S5sj8QyYv0-TTqmBGm6N1A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="Narr_aw4GKyCxWk6rkc1ulla1jg">295,174</ix:nonFraction></span><span style="font-size:10pt;"> ordinary shares) were repurchased with a total consideration of US</span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_7_7_2021_To_12_31_2021_VOZydV_s0k6TnW7n0mP29A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="Narr_GGiOHt0e7Ue0Y2L0CGMB8w">2,361,576</ix:nonFraction></span><span style="font-size:10pt;">. As of December 31, 2021, </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0J9hCl1ZSkaeQhRprqc5kQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="0" id="Narr_DDertSAKvUGoWcYmEk3mtA">160,880</ix:nonFraction></span><span style="font-size:10pt;"> ADSs (</span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_rJ9HGaFep0uT39eGrH0BAQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesRetired" scale="0" id="Narr_PWX2Qp8_U0aQGRMJB0KBuQ">201,100</ix:nonFraction></span><span style="font-size:10pt;"> ordinary shares) repurchased shares have been retired.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg" name="us-gaap:SubsequentEventsTextBlock" id="Tb_A_tN6aqtUE6e2D4s4hOnGw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">17. SUBSEQUENT EVENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 7, 2022, the Company passed a board resolution, pursuant to which the vesting schedules and conditions of <ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_7_7_2022_To_7_7_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_f5xUbvNTBEimEH5nmcz29g" decimals="INF" format="ixt:numdotdecimal" name="adag:ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected" scale="0" id="Narr_kMakVDq_ykqOgNmjCIVGVQ">2,060,308</ix:nonFraction> share options granted to certain employees were modified. Share options as to which the applicable performance milestones have been met are no longer subject to the time-based vesting requirement. The share options vested (or to be vested) for each year (commencing from 2021) shall be equal to the lesser of (i) <ix:nonFraction unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA" contextRef="Duration_7_7_2022_To_7_7_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_1hE8qqTDwUyc0lzaYCJtgw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_FJjbgNWKsEmzNQ0y5jt-3A">25</ix:nonFraction>% of the total number of share options of each grantee (&#8220;Annual Cap&#8221;) and (ii) the number of shares as determined by the Compensation Committee based on the extent to which any performance milestones were achieved during that year (&#8220;Credited Shares&#8221;), plus any Credited Share of earlier years that have not previously vested due to the Annual Cap. In addition, the performance milestones applicable to the share options that remain outstanding were also modified. Incremental fair value of US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_7_2022_To_1_7_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rKG0vF3HuUuOSzupeNgTNQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="0" id="Narr_qgljWAZ_JkKpj-WoqA_JfA">2,337,697</ix:nonFraction> resulted from the modification, which will be recognized as additional compensation expense over the remaining requisite service period, if any. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From February 7 to March 25, 2022, pursuant to the 2021 Plan, a total of <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_2_7_2022_To_3_25_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qgR18IIqT0W8xFm3O123fA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_GAaO_UkzZ0mIETxaDVVcEg">1,320,000</ix:nonFraction> share options were granted to certain employees, with exercise price ranging from US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_2_7_2022_To_3_25_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_ZhmKNezcek-HK-1dHlkcpw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_qlTON5v020WCWSFwf-mJUw">3.46</ix:nonFraction> to US$<ix:nonFraction unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w" contextRef="Duration_2_7_2022_To_3_25_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Nz6vByh-PUO3MFMmJbHcFg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_G2RBFxn8ykaLKxN-9bRRsg">5.60</ix:nonFraction> per share. In addition, <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_3_8_2022_To_3_8_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yR9MjqeEykqztm3xL6TxRg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_BSzPfw5s3UCuhFPkBRrWQQ">99,999</ix:nonFraction> ordinary shares were issued to certain management personnel on March 8, 2022 pursuant to the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 2, 2022, the Company entered into a collaboration and exclusive license agreement (the &#8220;Sanofi Agreement&#8221;) with Sanofi SA, pursuant to which the Company will be responsible for early-stage research activities to develop masked versions of Sanofi candidate antibodies, using Adagene&#8217;s SAFEbody technology. Sanofi will be solely responsible for later stage research and all clinical, product development and commercialization activities. Pursuit to the Sanofi Agreement, the Company has received an US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_4_30_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_adag_ExelixisAgreementMember_RSXFKdhcqEG6xrEDD5fFIQ" decimals="0" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementUpfrontCashPaymentReceivable" scale="0" id="Narr_PeYfzUn_wkWKauykY9Ptcg">17,500,000</ix:nonFraction> upfront payment in April 2022. In addition, the Company will be eligible to receive total potential development, regulatory and commercial milestone payments of up to US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="As_Of_3_2_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_adag_ExelixisAgreementMember_r29U-8QtcEKfWUKlkQp_tw" decimals="-8" format="ixt:numdotdecimal" name="adag:CollaborativeArrangementMilestonePaymentReceivable" scale="9" id="Narr_BPXhhdvg4EyBwH4Ug4PqXg">2.5</ix:nonFraction> billion for advancement of the candidates, which will be exclusively developed and commercialized by Sanofi. Adagene is eligible to also receive tiered royalties on global net sales of approved collaboration products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective March 25, 2022, Adagene Project C1 Pte., a subsidiary located in Singapore, was incorporated. To date, this new subsidiary has not commenced operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of March 31, 2022, the Group has repurchased an additional of <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_pJ8hEn_UR067dD0gRcTb-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="Narr_L8rQ4MuDy0m0uh-3JCsA6A">272,099</ix:nonFraction> outstanding ADSs (<ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_hZT-sOgQYEa1gHbRXtKNww" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="Narr_6KQy1Q9LVEKiR03SUkiAtA">340,124</ix:nonFraction> ordinary shares) with a total consideration of US$<ix:nonFraction unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_-XH9Go_6R0eqJay27YP0iA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="0" id="Narr_Y1NRoJ9x9kmca0gdrxby4w">1,539,631</ix:nonFraction>, and <ix:nonFraction unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg" contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_-XH9Go_6R0eqJay27YP0iA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TreasuryStockSharesRetired" scale="0" id="Narr_BTRN60qY_0mdDi1nOlw9lA">no</ix:nonFraction> additional repurchased shares have been retired.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 8pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:24pt 0pt 0pt 0pt;">F-35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.16
<SEQUENCE>2
<FILENAME>adag-20211231xex4d16.htm
<DESCRIPTION>EXHIBIT 4.16
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/26/2022 12:39:08 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 4.16 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-size:12pt;font-weight:bold;">*** </b><b style="color:#333333;font-size:12pt;font-weight:bold;">CERTAIN IDENTIFIED INFORMATION (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT&#160;</b><b style="font-size:12pt;font-weight:bold;">MATERIAL</b><b style="color:#333333;font-size:12pt;font-weight:bold;">&#160;AND IS THE TYPE THAT THE&#160;</b><b style="font-size:12pt;font-weight:bold;">REGISTRANT</b><b style="color:#333333;font-size:12pt;font-weight:bold;">&#160;TREATS AS PRIVATE OR CONFIDENTIAL.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">COLLABORATION AND LICENSE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">THIS COLLABORATION AND LICENSE AGREEMENT</b><font style="font-size:12pt;"> (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Agreement</b><font style="font-size:12pt;">&#8221;) is entered into as of February 25, 2022 (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Effective Date</b><font style="font-size:12pt;">&#8221;), by and between </font><b style="font-size:12pt;font-weight:bold;">ADAGENE INCORPORATED</b><font style="font-size:12pt;">, a Delaware corporation having an address at 10179 Huennekens St., San Diego, CA 92121, USA (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Adagene</b><font style="font-size:12pt;">&#8221;) and </font><b style="font-size:12pt;font-weight:bold;">GENZYME CORPORATION, </b><font style="font-size:12pt;">a Massachusetts corporation having an address at 50 Binney St., Cambridge, MA, 02142 (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Sanofi</b><font style="font-size:12pt;">&#8221;). &#160;Sanofi and Adagene may be referred to herein individually as a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Party</b><font style="font-size:12pt;">&#8221; or collectively as the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Parties</b><font style="font-size:12pt;">&#8221;.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">WHEREAS</b><font style="font-size:12pt;">, Adagene, a biotechnology company, has developed proprietary technology platforms to enable innovative antibody discovery and engineering;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">WHEREAS</b><font style="font-size:12pt;">, Sanofi and Adagene desire to form a collaboration to discover masked antibody candidates for further drug and product development and commercialization, under which collaboration Adagene will be responsible for generating such masked antibody candidates using Adagene&#8217;s SAFEbody</font><sup style="font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-size:12pt;"> platform technology, and Sanofi will be responsible for the further development and commercialization of the candidates; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">WHEREAS</b><font style="font-size:12pt;">, the Parties wish to establish such collaboration, all on the terms and conditions set forth below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">NOW, THEREFORE, </b><font style="font-size:12pt;">in consideration of the foregoing premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Sanofi and Adagene hereby agree as follows:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">1.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">DEFINITIONS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.1</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Adagene Acquiror</b><font style="font-size:12pt;">&#8221; </font><font style="font-size:12pt;">has the meaning set forth in Section 2.7(c)(ii).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.2</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Adagene Competitor</b><font style="font-size:12pt;">&#8221; </font><font style="font-size:12pt;">means [***].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.3</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Adagene Indemnitee</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 14.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.4</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Adagene Know-How</b><font style="font-size:12pt;">&#8221; means all Know-How that Adagene or its Affiliates Control as of the Effective Date or during the Term that is necessary or reasonably useful</font><font style="font-size:12pt;"> for the research, Development, manufacture, use, importation, offer for sale, sale, or other Commercialization </font><font style="font-size:12pt;">of any Licensed Compound or Licensed Product. Without limiting the</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">1</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">generality of the foregoing, the Adagene Know-How existing at the Effective Date is described in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.5</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Adagene Mask</b><font style="font-size:12pt;">&#8221; means an Adagene proprietary Mask derived from the Adagene Platform Technology.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.6</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Adagene Patents</b><font style="font-size:12pt;">&#8221; means all Patents that Adagene or its Affiliates Control as of the Effective Date or during the Term that (a) claim or cover any Licensed Compound or Licensed Product, or (b) are otherwise necessary or reasonably useful for the research, Development, manufacture, use, importation, offer for sale, sale, or other Commercialization of any Licensed Compound or Licensed Product, including Adagene&#8217;s interest in Joint Patents. &#160;Without limiting the generality of the foregoing, the Adagene Patents existing at the Effective Date are described in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.7</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Adagene Platform Technology</b><font style="font-size:12pt;">&#8221; means Adagene&#8217;s proprietary antibody engineering platform that is known as the SAFEbody</font><sup style="font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-size:12pt;"> technology. &#160;For the avoidance of doubt, the Adagene Platform Technology includes proprietary linkers or proprietary peptide antibody masks.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.8</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Adagene Technology</b><font style="font-size:12pt;">&#8221; means the Adagene Know-How and the Adagene Patents.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.9</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Affiliate</b><font style="font-size:12pt;">&#8221; means, with respect to any party, any entity that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with such party, but for only so long as such control exists. &#160;As used in this Section&#160;1.9, &#8220;control&#8221; means (a) to possess, directly or indirectly, the power to direct the management or policies of an entity, whether through ownership of voting securities, by contract relating to voting rights or corporate governance; or (b) direct or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.10</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Alliance Manager</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 3.6.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.11</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Antibody</b><font style="font-size:12pt;">&#8221; means a monospecific, bispecific, or multispecific antibody (whether fully human, humanized, phage display, chimeric, monoclonal, polyclonal, or any other type of antibody) or antigen binding fragment thereof.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.12</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Applicable Laws</b><font style="font-size:12pt;">&#8221; means the applicable provisions of any and all national, supranational, regional, state, and local laws, treaties, statutes, rules, regulations, administrative codes, guidance, ordinances, judgments, decrees, directives, injunctions, orders, permits (including MAAs) of or from any court, Regulatory Authority, or governmental agency or authority having jurisdiction over or related to the subject item.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.13</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Arm</b><font style="font-size:12pt;">&#8221; means that portion of an Antibody independently able to bind to a Target. For the avoidance of doubt, the immunoglobulin constant region of an Antibody shall not be considered an Arm.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.14</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Asian Country</b><font style="font-size:12pt;">&#8221; means any of </font><font style="font-size:12pt;">Japan or </font><font style="font-size:12pt;">the People&#8217;s Republic of China</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">2</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.15</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Auditor</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 11.5.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.16</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Available</b><font style="font-size:12pt;">&#8221; means, with respect to a Target, that such Target is not Unavailable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.17</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Biosimilar Licensed Product</b><font style="font-size:12pt;">&#8221; means, with respect to a product in a country, any pharmaceutical product that (a) is biosimilar to, or interchangeable with, such product or may otherwise be legally substituted for such product and for which the BLA or MAA references or relies on such product, (b) is approved for the same indication as such product, and (c) is sold in such country by a Third Party that is not a Sublicensee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.18</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">BLA</b><font style="font-size:12pt;">&#8221; means a Biologics License Application as described in 21 C.F.R. &#167; 601.2, including any amendments thereto, or any corresponding application in a country or jurisdiction in the Territory outside the U.S.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.19</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Calendar Quarter</b><font style="font-size:12pt;">&#8221; means each respective period of three (3) consecutive months ending on March&#160;31, June&#160;30, September&#160;30, and December&#160;31.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.20</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Calendar Year</b><font style="font-size:12pt;">&#8221; means each respective period of twelve (12) consecutive months ending on December 31.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.21</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Claim</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 14.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.22</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Clinical Trial</b><font style="font-size:12pt;">&#8221; means any Phase 1 Clinical Trial, Phase 2 Clinical Trial, Phase 3 Clinical Trial, or other clinical study, as the context dictates.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.23</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Collaboration Program</b><font style="font-size:12pt;">&#8221; means the performance of all Target Research Plans under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.24</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Collaboration Target</b><font style="font-size:12pt;">&#8221; means (a) each of Target 1 or Target 2 (unless such Target has been replaced in accordance with Article 6), and (b) each Target designated a Collaboration Target in accordance with Article 5 or Article 6.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.25</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Collaboration Target Designation Notice</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section&#160;5.2(b).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.26</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Combination Product</b><font style="font-size:12pt;">&#8221; shall have the meaning set forth in Section&#160;1.73 (Net&#160;Sales).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.27</b></font><font style="font-size:12pt;"> &#8220;</font><b style="font-size:12pt;font-weight:bold;">Commercialization</b><font style="font-size:12pt;">&#8221; means the conduct of all activities undertaken before and after Regulatory Approval relating to the promotion, sales, marketing, medical support, and distribution (including importing, exporting, transporting, customs clearance, warehousing, invoicing, handling, and delivering products to customers) of products, including sales force efforts, detailing, advertising, market research, market access (including price setting and reimbursement activities), medical education and information services, publication, scientific and medical affairs, advisory and collaborative activities with opinion leaders and professional societies including symposia, marketing, sales force training, and sales (including receiving, accepting, and filling product orders) and distribution. &#160;&#8220;</font><b style="font-size:12pt;font-weight:bold;">Commercialize</b><font style="font-size:12pt;">&#8221; and &#8220;</font><b style="font-size:12pt;font-weight:bold;">Commercializing</b><font style="font-size:12pt;">&#8221; have correlative meanings.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">3</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.28</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Commercially Reasonable Efforts</b><font style="font-size:12pt;">&#8221; means: (a) with respect to Sanofi&#8217;s obligations to Develop, seek MAA Approval, and Commercialize a Licensed Product under this Agreement, [***]; and (b) with respect to Adagene&#8217;s performance of each Target Research Plan, the conduct of such performance using those good faith efforts and resources consistent with the usual practices of a similarly situated company for the performance of similar activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.29</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Competing Masking Technology</b><font style="font-size:12pt;">&quot; has the meaning set forth in Section&#160;2.8(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.30</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Compound Invention</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section&#160;12.1(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.31</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Compound Research Activities</b><font style="font-size:12pt;">&#8221; means, with respect to a Collaboration Target, the activities to be undertaken by Adagene and Sanofi to discover and Develop Licensed Compounds directed to the respective Collaboration Target, as specified in the applicable Target Research Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.32</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Compound Patent</b><font style="font-size:12pt;">&#8221; means a Patent that Covers a Compound Invention.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.33</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Confidentiality Agreement</b><font style="font-size:12pt;">&#8221; means that certain Confidentiality Agreement by and between Sanofi and Adagene dated as of May 27, 2021.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.34</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Confidential Information</b><font style="font-size:12pt;">&#8221; means all Know-How and other proprietary scientific, marketing, financial, or commercial information or data that is generated by or on behalf of a Party or its Affiliates or which one Party or any of its Affiliates has supplied or otherwise made available to the other Party or its Affiliates, whether made available orally, in writing, or in electronic form, including information comprising or relating to concepts, discoveries, inventions, data, designs, or formulae in relation to this Agreement; provided that all Compound Inventions, and Sanofi Know-How will be deemed Sanofi&#8217;s Confidential Information, all Adagene Know-How and Platform Inventions will be deemed Adagene&#8217;s Confidential Information, and all Joint Inventions will be deemed both Parties&#8217; Confidential Information. &#160;Confidential Information shall include: (a) the terms and conditions of this Agreement, and (b) Confidential Information disclosed by either Party pursuant to the Confidentiality Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.35</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Control</b><font style="font-size:12pt;">&#8221; or &#8220;</font><b style="font-size:12pt;font-weight:bold;">Controlled</b><font style="font-size:12pt;">&#8221; means, with respect to any Know-How, Patents, or other intellectual property rights, the legal authority or right (whether by ownership, license, or otherwise but without taking into account any licenses granted by one Party to the other Party pursuant to this Agreement) of a Party to grant access, a license, or a sublicense of or under such Know-How, Patents, or other intellectual property rights to the other Party, or to otherwise disclose proprietary or trade secret information to such other Party, without breaching the terms of any agreement with a Third Party, or misappropriating the proprietary or trade secret information of a Third Party or triggering any payment obligation to a Third Party. &#160;Notwithstanding the foregoing, Know-How, Patents, or other intellectual property rights owned or in-licensed by a Third Party that becomes an Affiliate of such Party after the Effective Date as a result of such Party (a) acquiring such Third Party or a portion of the business of such Third Party or (b) being acquired by such Third Party (in each case, whether by merger, stock purchase or purchase of assets) will only be &#8220;Controlled&#8221; by a Party hereunder if such Know-How, Patents, or other intellectual property rights are actually used by such Party for performing Development activities under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">4</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.36</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Cover</b><font style="font-size:12pt;">&#8221;, &#8220;</font><b style="font-size:12pt;font-weight:bold;">Covering</b><font style="font-size:12pt;">&#8221; or &#8220;</font><b style="font-size:12pt;font-weight:bold;">Covered</b><font style="font-size:12pt;">&#8221; means, with respect to a compound, product, or other composition of matter, or technology, process, method or other Know-How, that, in the absence of ownership of, or a license to, a Patent, the practice or exploitation of such compound, product, or other composition of matter, or technology, process, method or other Know-How, would infringe such Patent or, in the case of a Patent that has not yet issued, would infringe such Patent if it were to issue.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.37</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Data</b><font style="font-size:12pt;">&#8221; means any and all scientific, technical, test, or other data pertaining to any Licensed Compound or Licensed Product that is generated by or on behalf of Adagene under any Target Research Plan, including research data, clinical pharmacology data, chemistry-manufacture-controls (CMC) data</font><font style="font-size:12pt;"> (</font><font style="font-size:12pt;">including analytical, and stability data), pre-clinical data, and clinical data. &#160;For clarity, Data shall not include any data that Adagene generates to the extent that such data is only generally applicable to the Adagene Platform Technology or its use or to Platform Inventions and does not specifically pertain to any Licensed Compound or Collaboration Target.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.38</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Development</b><font style="font-size:12pt;">&#8221; means all development activities for a product (whether alone or for use together, or in combination, with another active agent or pharmaceutical product as a combination product or combination therapy) that are directed to obtaining Regulatory Approval(s) of such product and lifecycle management of such product in any country in the world, including all non-clinical, preclinical, and clinical testing and studies of such product; toxicology, pharmacokinetic, and pharmacological studies; statistical analyses; assay development; protocol design and development; the preparation, filing, and prosecution of any BLA or MAA for such product; development activities directed to label expansion or obtaining Regulatory Approval (or both) for one or more additional indications following initial Regulatory Approval; development activities conducted after receipt of Regulatory Approval; and all regulatory affairs related to any of the foregoing. &#160;&#8220;</font><b style="font-size:12pt;font-weight:bold;">Develop</b><font style="font-size:12pt;">&#8221; and &#8220;</font><b style="font-size:12pt;font-weight:bold;">Developing</b><font style="font-size:12pt;">&#8221; have correlative meanings.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.39</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Development Costs</b><font style="font-size:12pt;">&#8221; means: (a) demonstrable costs and expenses invoiced by Third Parties for activities specified in a Target Research Plan; and (b) the costs and expenses of scientific, medical, technical personnel directly engaged in activities specified in a Target Research Plan, which costs shall be determined based on the FTE Rate based on time actually spent for performing the applicable activities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.40</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Disputed Matter</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 17.2.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.41</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">EMA</b><font style="font-size:12pt;">&#8221; means the European Medicines Agency, or any successor agency thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.42</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Executive Officers</b><font style="font-size:12pt;">&#8221; the with respect to Adagene, the Chief Executive Officer of Adagene, and with respect to Sanofi, the Head of Oncology Research.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.43</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Extended Option Period</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 5.4.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.44</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">EU</b><font style="font-size:12pt;">&#8221; means all countries that are officially recognized as member states of the European Union at any particular time; except that, for purposes of this Agreement, the EU will be deemed to include France, Germany, Italy, Spain and the United Kingdom, irrespective of whether any such country leaves or as of the Effective Date has left the European Union.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">5</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.45</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">FDA</b><font style="font-size:12pt;">&#8221; means the U.S. Food and Drug Administration, or any successor agency thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.46</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Field</b><font style="font-size:12pt;">&#8221; means any and all uses.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.47</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Floor</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 10.5(c)(iv).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.48</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">First Commercial Sale</b><font style="font-size:12pt;">&#8221; means, </font><font style="font-size:12pt;">on a Licensed Product-by-Licensed Product and country-by-country basis</font><font style="font-size:12pt;">, the first sale by Sanofi or any of its Affiliates or Sublicensees to a Third Party for end use of such Licensed Product in such country after Regulatory Approval has been granted with respect to such Licensed Product in such country for use or consumption of such Licensed Product in such country or jurisdiction by the general public; </font><i style="font-size:12pt;font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided, however</i><font style="font-size:12pt;"> that sales for clinical study purposes or compassionate, named patient (paid or unpaid) or similar use will not constitute a First Commercial Sale.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.49</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">FTE</b><font style="font-size:12pt;">&#8221; means the equivalent of a full-time Adagene (including its Affiliates) employee&#8217;s work for a twelve (12) month period (consisting of a total of at least [***] hours per year of dedicated effort). &#160;Any such employee who devotes fewer than [***] hours per year on the applicable activities shall be treated as an FTE on a pro-rata basis, based upon the actual number of hours worked by such employee on such activities, divided by [***]. &#160;For clarity, only hours devoted by qualified scientific, medical, manufacturing, technical, regulatory, and other similar employees of Adagene, as measured in accordance with Adagene&#8217;s normal time allocation practices, shall apply toward an FTE, and in no event shall &#8220;FTE&#8221; include hours devoted by personnel performing administrative, managerial, or corporate functions (e.g., human resources, finance, legal, and investor relations).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.50</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">FTE Costs</b><font style="font-size:12pt;">&#8221; means the FTE Rate multiplied by the number of FTEs applied by Adagene (including its Affiliates) to the performance of Compound Research Activities in accordance with a Target Research Plan and Target Research Budget.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.51</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">FTE Rate</b><font style="font-size:12pt;">&#8221; means [***] U.S. dollars ($[***]) per FTE per year which rate shall apply through [***]. &#160;Thereafter, the FTE Rate shall be changed annually on a Calendar Year basis to reflect any year-to-year percentage increase or decrease (as the case may be) in the Consumer Price Index for All Urban Consumers for the U.S., as published by the U.S. Department of Labor, Bureau of Labor Statistics (based on the change from the most recent applicable index available as of the Effective Date to the most recent applicable index available as of the date of the calculation of such revised FTE Rate).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.52</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">GLP</b><font style="font-size:12pt;">&#8221; means in respect of laboratory activities, the then current standards required by Applicable Law of: (a) the United States, including the FDA&#8217;s Good Laboratory Practice regulations at 21 C.F.R. Part 58; (b) the European Union, including the Directive 2004/9/EC, Directive 2004/10/EC, guidance published by the European Commission or EMA in relation to such Directives and any local laws, rules and regulations that implement such Directives and guidance; and (c) such other countries in which a Licensed Product is tested.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.53</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Governmental Authority</b><font style="font-size:12pt;">&#8221; means any national, international, federal, state, provincial, or local government, or political subdivision thereof, or any multinational organization or any authority, agency, or commission entitled to exercise any administrative, executive, judicial,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">6</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">legislative, police, regulatory, or taxing authority or power, any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.54</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">IND</b><font style="font-size:12pt;">&#8221; means an investigational new drug application or equivalent application filed with the applicable Regulatory Authority, which application is required to commence human clinical trials in the applicable country.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.55</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Indemnified Party</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 14.3.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.56</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Indemnifying Party</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 14.3.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.57</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Indication</b><font style="font-size:12pt;">&#8221; means, with respect to a Licensed Product, the use of such Licensed Product for the treatment of a discrete clinically recognized form of a disease, disorder or condition.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.58</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Initial Option Period</b><font style="font-size:12pt;">&#8221; means, with respect to the Initial Targets, a period of [***] ([***])following the </font><font style="font-size:12pt;">delivery to Sanofi by Adagene of the sequence of the Licensed Compound that it has Developed with respect to the first Initial Target, in accordance with, and as further specified in, the applicable Target Research Plan</font><font style="font-size:12pt;">. &#160;Additionally, if Sanofi exercises its Replacement Right (as set forth in Article 6) prior to delivery of the sequence of the Licensed Compound with respect to the first Initial Target, the Initial Option Period for such replaced Target shall begin upon delivery of the sequence with respect to the Licensed Compound for the first Initial Target.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.59</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Initial Target(s)</b><font style="font-size:12pt;">&#8221; means Target 1 or Target 2 or both.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.60</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Initiation</b><font style="font-size:12pt;">&#8221; means, with respect to a Clinical Trial, the first dosing of the first human subject in such Clinical Trial.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.61</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Injunctive Relief</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 17.3(b).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.62</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Inventions</b><font style="font-size:12pt;">&#8221; means all inventions, whether or not patentable, discovered, made, conceived, or reduced to practice in the course of activities contemplated by this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.63</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Joint Inventions</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 12.1(d).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.64</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Joint Patents</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 12.1(d).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.65</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Joint Research Committee</b><font style="font-size:12pt;">&#8221; or &#8220;</font><b style="font-size:12pt;font-weight:bold;">JRC</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 3.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.66</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Key Countries</b><font style="font-size:12pt;">&#8221; means the United States, Germany, France, the UK, and at least one of the Asian Countries.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.67</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Know-How</b><font style="font-size:12pt;">&#8221; means all technical information, know-how, and data, including inventions, discoveries, trade secrets, specifications, instructions, processes, formulae, compositions of matter, cells, cell lines, assays, animal models and other physical, biological, or chemical materials, expertise and other technology applicable to, development, manufacture, registration, use, or marketing or to methods of assaying or testing them, and including all</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">7</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">biological, chemical, pharmacological, biochemical, toxicological, pharmaceutical, physical, and analytical, safety, nonclinical, and clinical data, regulatory documents, data and filings, instructions, processes, formulae, expertise and information, relevant to the research, development, use, importation, offering for sale or sale of, or which may be useful in studying, testing, or developing products. &#160;Know-How excludes Patents.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.68</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Licensed Compound</b><font style="font-size:12pt;">&#8221; means: (a) a construct comprising (i) an SUA or a derivative&#160;thereof, and (ii) an Adagene Mask or a derivative&#160;thereof; or (b) a Modified Licensed Compound.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.69</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Licensed Product</b><font style="font-size:12pt;">&#8221; means any pharmaceutical preparation in final form containing a Licensed Compound, alone or in combination with one (1) or more additional active ingredients, in any form, presentation, dosage, or formulation, and for any mode of administration.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.70</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Losses</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 14.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.71</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">MAA</b><font style="font-size:12pt;">&#8221; means a marketing authorization application or equivalent application, and all amendments and supplements thereto, filed with the applicable Regulatory Authority in the Territory.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.72</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">MAA Approval</b><font style="font-size:12pt;">&#8221; means approval of an MAA by the applicable Regulatory Authority for marketing and sale of a product, but excluding any pricing or reimbursement approval.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.73</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Mask</b><font style="font-size:12pt;">&#8221; means a masking moiety (peptide) that binds to an Antibody via a selectively cleavable linker with a protease site so as to inhibit or suppress such an Antibody from binding to the intended Target except in desired microenvironments. &#8220;</font><b style="font-size:12pt;font-weight:bold;">Masking</b><font style="font-size:12pt;">&#8221; and &#8220;</font><b style="font-size:12pt;font-weight:bold;">Masked</b><font style="font-size:12pt;">&#8221; have correlative meanings.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.74</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Modified Licensed Compound</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 7.2.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.75</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Modified Licensed Compound Fee</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 7.2.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.76</b></font><b style="font-size:12pt;font-weight:bold;">&#8220;Modified Research Licensed Compound&#8221;</b><font style="font-size:12pt;"> has the meaning set forth in Section&#160;7.2.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.77</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Net Sales</b><font style="font-size:12pt;">&#8221; means, with respect to any Licensed Product, for any period, the gross amounts invoiced by Sanofi or its Affiliates or Sublicensees to Third Parties, commencing with the First Commercial Sale of such Licensed Product </font><i style="font-size:12pt;font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">less</i><font style="font-size:12pt;"> the following amounts which are actually incurred, allowed, accrued or specifically allocated:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><font style="font-size:12pt;">[***];</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><font style="font-size:12pt;">[***];</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><font style="font-size:12pt;">[***];</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(d)</b></font><font style="font-size:12pt;">[***];</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">8</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(e)</b></font><font style="font-size:12pt;">[***];</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(f)</b></font><font style="font-size:12pt;">[***];</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(g)</b></font><font style="font-size:12pt;">[***];</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(h)</b></font><font style="font-size:12pt;">[***];</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(i)</b></font><font style="font-size:12pt;">[***];&#160;</font><i style="font-size:12pt;font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">and</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(j)</b></font><font style="font-size:12pt;">[***]</font><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Net Sales shall </font><i style="font-size:12pt;font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">not</i><font style="font-size:12pt;"> include:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:42.55pt;text-align:justify;text-indent:-42.55pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:42.55pt;"></font><font style="font-size:12pt;">(A)</font><font style="display:inline-block;width:12.79pt;"></font><font style="font-size:12pt;">&#160;the sale, transfer or other disposition of a Licensed&#160;Product (x)&#160;prior to Regulatory Approval for use in Clinical Trials, (y)&#160;free of charge for use in special access programs or for compassionate use, or (z) free of charge of reasonable quantities of promotional samples, or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:42.55pt;text-align:justify;text-indent:-42.55pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:42.55pt;text-align:justify;text-indent:-42.55pt;margin:0pt 0pt 6pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:42.55pt;"></font><font style="font-size:12pt;">(B)</font><font style="display:inline-block;width:13.45pt;"></font><font style="font-size:12pt;">the transfer of Licensed Products to an Affiliate or Sublicensee, provided that, (x) unless subject to an exception in proviso (A) immediately above, the First Commercial Sale occurs if the Affiliate or Sublicensee is the end user, i.e. the Affiliate or Sublicensee does not resale the Licensed Product to a Third Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">In no event will any particular amount identified above be deducted more than once in calculating Net Sales.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="font-size:12pt;">[***].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="font-size:12pt;">Net Sales (including any deductions made in accordance with this Section 1.77) will be calculated in a manner consistent with the International Financial Reporting Standards (IFRS) and this definition of Net Sales.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.78</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Option</b><font style="font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> has the meaning set forth in Section 5.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.79</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Option Exercise Notice</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 5.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.80</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Option Period</b><font style="font-size:12pt;">&#8221; means the Initial Option Period and the Extended Option Period (if any).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.81</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Patents</b><font style="font-size:12pt;">&#8221; means (a)&#160;all patents, certificates of invention, applications for certificates of invention, priority patent filings, and patent applications, and (b)&#160;any renewals, divisions, continuations (in whole or in part), or requests for continued examination of any of such patents, certificates of invention and patent applications, and any all patents or certificates of invention issuing thereon, and any and all reissues, reexaminations, extensions, supplementary protection certificates, divisions, renewals, substitutions, confirmations, registrations, revalidations, revisions, and additions of or to any of the foregoing.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">9</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.82</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase&#160;1 Clinical Trial</b><font style="font-size:12pt;">&#8221; means a clinical trial conducted in a small number of patients designed or intended to establish an initial safety profile, pharmacodynamics, or pharmacokinetics of a pharmaceutical product. &#160;A Phase 1 Clinical Trial can be further divided into two separate trials:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase 1a Clinical Trial</b><font style="font-size:12pt;">&#8221; means a single dose or multiple dose ascending clinical trial intended to evaluate safety and tolerability and determination of dose(s) for further clinical evaluation; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase 1b Clinical Trial</b><font style="font-size:12pt;">&#8221; means a clinical trial of a product, the principal purpose of which is a further determination of safety and pharmacokinetics of such product after an initial Phase 1a Clinical Trial, including as a single agent expansion cohort or a combination expansion cohort, prior to commencement of Phase 2 Clinical Trials (or phase 2 of a Phase 1/2 clinical trial) or Phase 3 Clinical Trials.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.83</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase&#160;2 Clinical Trial</b><font style="font-size:12pt;">&#8221; means a clinical trial of a pharmaceutical product in human patients in any country to determine initial efficacy and safety and dose range finding. &#160;A Phase 2 Clinical Trial is typically conducted before embarking on a Phase&#160;3 Clinical Trial, but may be registrational.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.84</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Phase&#160;3 Clinical Trial</b><font style="font-size:12pt;">&#8221; means a pivotal clinical trial of a pharmaceutical product in human patients in any country with a defined dose or a set of defined doses of such product designed to ascertain efficacy and safety of such product for the purpose of submitting MAAs for such product to the competent Regulatory Authorities.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.85</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Platform Inventions</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 12.1(c).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.86</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Product Infringement</b><font style="font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> has the meaning set forth in Section 12.3(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.87</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Regulatory Approval</b><font style="font-size:12pt;">&#8221; means any and all approvals (including MAA Approval and, where required or commercially beneficial, pricing and reimbursement approval), licenses, registrations, permits, notifications, and authorizations (or waivers) of any Regulatory Authority that are necessary for the manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale, or other commercialization of a product in any country or jurisdiction.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.88</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Regulatory Authority</b><font style="font-size:12pt;">&#8221; means any Governmental Authority that has responsibility in its applicable jurisdiction over the testing, development</font><font style="font-size:12pt;">, manufacture, use, storage, import,</font><font style="font-size:12pt;"> transport, promotion, marketing, distribution, offer for sale, sale or other commercialization of pharmaceutical products in a given jurisdiction, including any Governmental Authority whose review or approval of pricing or reimbursement of such product is required.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.89</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Regulatory Exclusivity</b><font style="font-size:12pt;">&#8221; means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to a Licensed Product other than patents, including rights conferred in the U.S. under the Hatch-Waxman Act or the FDA Modernization Act of 1997 (including pediatric exclusivity), or rights similar thereto outside the U.S., such as Directive 2001/83/EC (as amended) in the EU.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">10</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.90</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Regulatory Filing</b><font style="font-size:12pt;">&#8221; means all applications, filings, submissions, approvals, licenses, registrations, permits, notifications, and authorizations (or waivers) with respect to the testing, Development, manufacture, or Commercialization of any pharmaceutical product made to or received from any Regulatory Authority in a given country, including any INDs, BLAs and MAAs.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.91</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Replacement Exercise Notice</b><font style="font-size:12pt;">&#8221; </font><font style="font-size:12pt;">has the meaning set forth in Section 6.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.92</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Replacement Period</b><font style="font-size:12pt;">&#8221; means [***].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.93</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Replacement Right</b><font style="font-size:12pt;">&#8221; </font><font style="font-size:12pt;">has the meaning set forth in Section 6.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.94</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Royalty Report</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 11.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.95</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Royalty Term</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 10.5(b).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.96</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Rules</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 17.3(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.97</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Sanofi Acquired Entity</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 2.8(b).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.98</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Sanofi Indemnitee</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 14.2.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.99</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Sanofi Know-How</b><font style="font-size:12pt;">&#8221; means all Know-How that Sanofi or its Affiliates Control as of the Effective Date or during the Term, including the Compound Inventions and Sanofi&#8217;s interest in Joint Inventions, that is&#160;necessary</font><font style="font-size:12pt;"> or reasonably useful for the research, Development, manufacture, use, importation, offer for sale, sale, or other Commercialization </font><font style="font-size:12pt;">of any Licensed Compound or Licensed Product.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.100</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Sanofi Patents</b><font style="font-size:12pt;">&#8221; means all Patents in the Territory that Sanofi or its Affiliates Control as of the Effective Date or during the Term, including Compound Patents and Sanofi&#8217;s interest in Joint Patents, that (a) describe or claim any Sanofi Know-How or (b) would be infringed, absent a license or other right to practice granted under such Patents, by the research, Development, manufacture, use, importation, offer for sale, sale, or other Commercialization of any Licensed Compound or Licensed Product (considering patent applications to be issued with the then-pending claims).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.101</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Sanofi Technology</b><font style="font-size:12pt;">&#8221; means the Sanofi Know-How and the Sanofi Patents.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.102</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Sanofi Unmasked Antibody</b><font style="font-size:12pt;">&#8221; or &#8220;</font><b style="font-size:12pt;font-weight:bold;">SUA</b><font style="font-size:12pt;">&#8221; means (a) each of SUA 1 or SUA 2 (unless replaced in accordance with Article 6), and (b) any Sanofi proprietary Antibody solely targeting Target 1 or Target 2 deemed a replacement SUA in accordance with Article 6.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.103</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Sanofi Unmasked Antibody 1</b><font style="font-size:12pt;">&#8221; or &#8220;</font><b style="font-size:12pt;font-weight:bold;">SUA 1</b><font style="font-size:12pt;">&#8221; means Sanofi&#8217;s proprietary bispecific Antibody solely targeting Target 1, known as &#8220;[***]&#8221;.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.104</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Sanofi Unmasked Antibody 2</b><font style="font-size:12pt;">&#8221; or &#8220;</font><b style="font-size:12pt;font-weight:bold;">SUA 2</b><font style="font-size:12pt;">&#8221; means Sanofi&#8217;s proprietary monoclonal Antibody solely targeting Target 2, known as &#8220;[***]&#8221;.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">11</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.105</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">SEC</b><font style="font-size:12pt;">&#8221; means the U.S. Securities and Exchange Commission, or any successor entity or its foreign equivalent in the Territory, as applicable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.106</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Sole Inventions</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 12.1(d).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.107</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Sublicensee</b><font style="font-size:12pt;">&#8221; means a Third Party to whom Sanofi grants a sublicense to Develop, Manufacture, &#160;or Commercialize any Licensed Product in the Field in the Territory in accordance with Section 2.3, beyond the mere right to purchase Licensed Products from Sanofi and its Affiliates, and excluding, for the avoidance of doubt, (a) wholesalers, full-service distributors that do not promote the same of the Licensed Product, and other similar physical distributors, and (b) contractors to which Sanofi subcontracts its rights or obligations under this Agreement, including contract research organizations and contract manufacturing organizations.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.108</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Target</b><font style="font-size:12pt;">&#8221; means any gene, receptor, ligand or other molecule (a) potentially associated with a disease activity, and that potentially has a biological activity that is modified by direct interaction with an Antibody, or (b) to which an Antibody binds.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.109</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Target 1</b><font style="font-size:12pt;">&#8221; means the specific combination of Targets targeting the </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> pathway. For the avoidance of doubt, each of</font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> and </font><font style="font-size:12pt;">[***] </font><font style="font-size:12pt;">alone, and </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> and </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> bispecific or alone do not fall under the definition of Target 1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.110</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Target 2</b><font style="font-size:12pt;">&#8221; means a Target solely targeting the </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> pathway.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.111</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Target Nomination Notice</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 5.2(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.112</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Target Research Budget</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 4.2(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.113</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Target Research Plan</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 4.2(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.114</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Term</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 16.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.115</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Territory</b><font style="font-size:12pt;">&#8221; means all the countries of the world.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.116</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Third Party</b><font style="font-size:12pt;">&#8221; means any entity other than Sanofi or Adagene or an Affiliate of Sanofi or Adagene.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.117</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Third Party Infringement Claim</b><font style="font-size:12pt;">&#8221; has the meaning set forth in Section 12.4.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.118</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Unavailable</b><font style="font-size:12pt;">&#8221; means, with respect to a Target, that such Target is the subject of (a) </font><font style="font-size:12pt;">[***] </font><font style="font-size:12pt;">(which could include a [***] acknowledging open issues to be concluded in the definitive agreement) or an executed definitive agreement, between Adagene and a Third Party pursuant to which such Third Party has or will have exclusive development and commercialization rights for products directed to such Target, or (b) an internal program at Adagene or any of its Affiliates for which Adagene has already had [***] and engineering campaigns and such program has had ongoing testing activity within the last [***] and is moving towards a SAFEbody development candidate; in each case as shown by reasonable contemporaneous written evidence. &#160;Notwithstanding the foregoing, Adagene may, in its sole discretion, designate a Target that meets</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">12</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">the criteria of (b) as &#8220;Available&#8221; provided that Adagene terminates its internal program, or consideration of a program, for such Target.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.119</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">U.S.</b><font style="font-size:12pt;">&#8221; means the United States of America (including its territories and possessions and its military bases and commissaries wherever located in the Territory) and Puerto Rico.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.120</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Valid Claim</b><font style="font-size:12pt;">&#8221; means (a) a claim of an issued and unexpired patent within (i) the Adagene Patents or (ii) a Compound Patent or Joint Patent developed solely by Adagene or jointly by the Parties, in each case of (i) and (ii) that has not been revoked or held unenforceable, unpatentable, or invalid by a decision of a court or other governmental agency of competent jurisdiction that is not appealable or has not been appealed within the time allowed for appeal, and that has not been abandoned, disclaimed, denied, or admitted to be invalid or unenforceable through reissue, re-examination, disclaimer, or otherwise, or (b) a claim of a pending patent application that has not been cancelled, withdrawn, abandoned, or finally rejected by an administrative agency action from which no appeal can be taken and that has not been pending for more than [***] from the date of filing of the earliest effective priority patent application to which such pending patent application is entitled to claim benefit.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.121</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">Variable Region</b><font style="font-size:12pt;">&#8221; means that portion of an Antibody comprising the complementarity determining regions based upon the Kabat numbering system.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">1.122</b></font><font style="font-size:12pt;">&#8220;</font><b style="font-size:12pt;font-weight:bold;">VAT</b><font style="font-size:12pt;">&#8221;</font><font style="font-size:12pt;"> has the meaning set forth in Section 11.4(c).</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">2.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">GRANT OF LICENSES</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">2.1</b></font><b style="font-size:12pt;font-weight:bold;">Sanofi Exclusive License</b><font style="font-size:12pt;">. &#160;Subject to the terms and conditions of this Agreement, Adagene hereby grants to Sanofi, during the Term, an exclusive (even as to Adagene), royalty-bearing license, with the right to grant sublicenses as provided in Section 2.3, under the Adagene Technology to research, Develop, use, make, have made, sell, offer for sale, import, and otherwise Commercialize Licensed Compounds and Licensed Products in the Field in the Territory.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">2.2</b></font><b style="font-size:12pt;font-weight:bold;">Sanofi Research License</b><font style="font-size:12pt;">. Subject to the terms and conditions of this Agreement, Adagene hereby grants to Sanofi, during the term, a non-exclusive, royalty free license without the right to grant sublicenses under the Adagene Technology, to research, Develop, use, make and have made Modified Research Licensed Compounds for internal research purposes in accordance with Section 7.2.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">2.3</b></font><b style="font-size:12pt;font-weight:bold;">Sublicenses</b><font style="font-size:12pt;">. &#160;Sanofi shall have the right to grant sublicenses, through multiple tiers of Sublicensees, under the license granted in Section 2.1 to its Affiliates and other Third Parties, or to subcontract to Third Parties the performance of Sanofi&#8217;s tasks and obligations under this Agreement as Sanofi deems appropriate, provided that the grant of a sublicense to or the subcontracting of an Adagene Competitor shall be subject to Adagene&#8217;s prior written consent. The grant of any such sublicense or any subcontracting shall not relieve Sanofi of its obligations under this Agreement, except to the extent they are satisfactorily performed by the Sublicensee or subcontractor, as applicable. Any such sublicenses or subcontracting shall be subject to, and consistent with, the terms and conditions of this Agreement and Sanofi remains responsible for the actions or omissions of its Sublicensees and subcontractors. &#160;Sanofi shall provide Adagene with a</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">13</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">copy of each sublicense agreement (which may be reasonably redacted) within [***] after its execution.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">2.4</b></font><b style="font-size:12pt;font-weight:bold;">Adagene Reserved Rights</b><font style="font-size:12pt;">. &#160;Adagene hereby expressly reserves (a) the right under the Adagene Technology to exercise its rights and perform its obligations under this Agreement, whether directly or through one or more permitted subcontractors, including the right to perform the applicable Compound Research Activities in accordance with each Target Research Plan; and (b) subject to Section 2.7, the right to practice, and to grant licenses under, the Adagene Technology outside of the scope of the rights granted in Section 2.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">2.5</b></font><b style="font-size:12pt;font-weight:bold;">Adagene Research License</b><font style="font-size:12pt;">. &#160;Subject to the terms and conditions of this Agreement, Sanofi hereby grants to Adagene, for the duration of the Collaboration Program, a nonexclusive, royalty-free license, with the right to grant sublicenses to any permitted subcontractors (subject to the prior written consent of Sanofi, such consent not to be unreasonably withheld or delayed) for the performance of Compound Research Activities, under the Sanofi Technology solely to the extent necessary for Adagene to perform the Compound Research Activities allocated to it under each Target Research Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">2.6</b></font><b style="font-size:12pt;font-weight:bold;">No Implied Licenses</b><font style="font-size:12pt;">. &#160;Except as set forth in this Agreement, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, under or to any Patents, Know-How, or other intellectual property owned or controlled by the other Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">2.7</b></font><b style="font-size:12pt;font-weight:bold;">Adagene Exclusivity</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Exclusivity regarding Target 1</b><font style="font-size:12pt;">. &#160;For a period of five (5) years from the Effective Date, Adagene shall not, and shall cause its Affiliates to not, pursue or engage in, on its own or in collaboration with one or more Third Parties, in any country or other jurisdiction in the Territory, directly or indirectly, non-clinical (including pre-clinical research) or clinical development of, commercialization of or manufacture for clinical or commercial use, of any Masked Antibodies targeting Target 1. For the avoidance of doubt, this Section 2.7(a) shall cease to apply if Sanofi replaces Target 1 in accordance with Article 6.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Exclusivity regarding other Collaboration Targets or Modified Licensed Compounds</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">(i)</b><font style="display:inline-block;width:24.67pt;"></font><font style="font-size:12pt;">For a Collaboration Target, Adagene shall not, and shall cause its Affiliates to not, pursue or engage in, on its own or in collaboration with one or more Third Parties, in any country or other jurisdiction in the Territory, directly or indirectly, non-clinical (including pre-clinical research) or clinical Development of, Commercialization of or manufacture for clinical or commercial use, of any Masked Antibodies targeting Target 2, any other Collaboration Target (other than Target 1) or any Modified Licensed Compound. For the avoidance of doubt, with respect to Target 2, Adagene and its Affiliates will not be prevented from working on bispecific or multispecific Masked Antibodies targeting Target 2, unless the Parties, in accordance with the terms of this Agreement, collaborate on a bispecific or multispecific Licensed Compound targeting Target 2 under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">(ii)</b><font style="display:inline-block;width:21.34pt;"></font><font style="font-size:12pt;">During the Term, Adagene shall not, and shall cause its Affiliates to not, pursue or engage in, on its own or in collaboration with one or more Third Parties, in any</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">14</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">country or other jurisdiction in the Territory, directly or indirectly, non-clinical (including pre-clinical research) or clinical development of, commercialization of or manufacture for clinical or commercial use, of</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 36pt;"><b style="font-size:12pt;font-weight:bold;">(1)</b><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">any Antibodies containing a Masked Arm targeting Target 2 or any other Collaboration Target, in each case that have [***] or more sequence identity to both any Masked Antibody and any Variable Region of any Masked Antibody developed under this Agreement. &#160;For the avoidance of doubt, with respect to Target 2, Adagene and its Affiliates will not be prevented from working on bispecific or multispecific Masked Antibodies targeting Target 2 that have less than [***] to both any Masked Antibody and any Variable Region of any Masked Antibody developed under this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:144pt;margin:0pt 0pt 12pt 36pt;"><b style="font-size:12pt;font-weight:bold;">(2)</b><font style="display:inline-block;width:22.01pt;"></font><font style="font-size:12pt;">any Antibodies containing a Masked Arm targeting Target 1 (to the extent that such Antibodies are not already being Developed by Adagene as of the Effective Date), in each case that have [***] or more sequence identity to both any Masked Antibody and any Variable Region of any Masked Antibody developed under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-size:12pt;font-weight:bold;">Limitations</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">(i)</b><font style="display:inline-block;width:24.67pt;"></font><font style="font-size:12pt;">This Section 2.7 shall cease to apply for Target 1 after five (5) years from the Effective Date. &#160;This Section 2.7 shall cease to apply for a Collaboration Target if Sanofi replaces such Collaboration Target in accordance with Article 6 or if Sanofi terminates the Agreement for such Collaboration Target in accordance with Section 16.3.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">(ii)</b><font style="display:inline-block;width:21.34pt;"></font><font style="font-size:12pt;">Section 2.7 and the covenants set forth therein shall not apply to the activities of any Third Party (or such Third Party&#8217;s Affiliates) that becomes an Affiliate of Adagene after the Effective Date (such Third Party and its Affiliates, the &#8220;Adagene Acquiror&#8221;) as a result of a change of control in Adagene, provided that (A) such activities are performed without using the Adagene SAFEbody&#8482; technology or any Competing Masking Technology developed (solely or in collaboration with others) by Adagene; and (B) Adagene establishes reasonable firewall protections designed to ensure the activities of its personnel under this Agreement are segregated from all activities of the Adagene Acquiror that would otherwise constitute a breach of Section&#160;2.7. For the purposes of this Section 2.7(ii), &#8220;change of control in Adagene&#8221; shall mean a transaction in which Adagene (or any direct or indirect shareholder(s), unitholder(s) or partner(s) together holding (directly or indirectly) over fifty percent (50%) of the voting rights attached to the shares, units or partnership interests in Adagene): (x) sells, conveys or otherwise disposes of all or substantially all of Adagene&#8217;s (or their indirect interest(s) in Adagene&#8217;s) property, assets or business; or (y) merges or consolidates with any other entity; or (z) effects any other transaction or series of transactions; in each case of clause (y) or (z), such that the ultimate direct or indirect shareholder(s), unitholder(s) or partner(s) of Adagene immediately prior thereto, in aggregate, no longer own, directly or indirectly, beneficially or legally, more than fifty percent (50%) of the voting rights attached to the outstanding voting securities or capital stock of the surviving entity following the closing of such merger, consolidation, other transaction or series of transactions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">15</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">2.8</b></font><b style="font-size:12pt;font-weight:bold;">Sanofi Exclusivity</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Exclusivity regarding Collaboration Targets</b><font style="font-size:12pt;">. For a Collaboration Target, Sanofi shall not, and shall cause its Affiliates and oblige its Sublicensees to not, pursue or engage in, on its own or in collaboration with one or more Third Parties, in any country or other jurisdiction in the Territory, directly or indirectly, non-clinical (including pre-clinical research) or clinical development of, a product by utilizing a protease-based Masking technology that uses a peptide or small protein based domain (and in any case, approximately </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">) as the blocking moiety (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Competing Masking Technology</b><font style="font-size:12pt;">&#8221;), and Sanofi shall not, and shall cause its Affiliates and Sublicensees to not, pursue or engage in any commercialization of or manufacture for clinical or commercial use, of any product that has been developed by using a Competing Masking Technology. &#160;This Section 2.8(a) shall cease to apply for Target 1 after five (5) years from the Effective Date. &#160;This Section 2.8(a) shall cease to apply for a Collaboration Target if Sanofi replaces it in accordance with Article 6. &#160;For the avoidance of doubt, all exclusivity obligations under Section 2.7 and this Section 2.8 shall cease to apply if this Agreement expires or is terminated. &#160;Notwithstanding anything to the contrary contained herein, in no event shall Sanofi have any liability whatsoever to Adagene for any direct, indirect, special, consequential, incidental or punitive damages, including loss of anticipated profits or revenue in connection with or arising from any violation of this Section 2.8(a) by a Sublicensee. &#160;Upon the request of Adagene, Sanofi shall assign to Adagene its contractual rights of enforcement against its Sublicensee in connection with or arising from any violation of this Section 2.8(a) by such Sublicensee.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Limitations</b><font style="font-size:12pt;">. This Section 2.8 and the covenants set forth herein shall not apply to a Competing Masking Technology of any Third Party (or such Third Party&#8217;s Affiliates) that becomes an Affiliate of Sanofi </font><font style="font-size:12pt;">after the Effective Date as a result of a merger, acquisition or combination with or of such Third Party (such Third Party and its Affiliates after the close of such transaction, the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Sanofi Acquired Entity</b><font style="font-size:12pt;">&#8221;), provided that Sanofi shall oblige such Sanofi Acquired Entity to establish reasonable firewall protections and safeguards designed to ensure that none of its personnel working on the Competing Masking Technology have access to Adagene&#8217;s Confidential Information.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">3.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">GOVERNANCE</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">3.1</b></font><b style="font-size:12pt;font-weight:bold;">Joint Research Committee</b><font style="font-size:12pt;">. &#160;Within </font><font style="font-size:12pt;">[***] </font><font style="font-size:12pt;">after the Effective Date, the Parties shall establish a Joint Research Committee (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Joint Research Committee</b><font style="font-size:12pt;">&#8221; or the &#8220;</font><b style="font-size:12pt;font-weight:bold;">JRC</b><font style="font-size:12pt;">&#8221;), composed of an equal number of [***] senior members of each Party, to oversee and guide the strategic direction of the collaboration of the Parties during the Collaboration Program. &#160;The </font><font style="font-size:12pt;">JRC</font><font style="font-size:12pt;"> shall act as a joint consultative body during the Collaboration Program. &#160;The JRC in particular shall:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><font style="font-size:12pt;">oversee and monitor all Compound Research Activities under each Target Research Plan;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><font style="font-size:12pt;">discuss, review, comment on, and approve new Target Research Plans under Section 5.2 and Section 6.2, including discussing and approving the Target Research Budgets within such Target Research Plans;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">16</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><font style="font-size:12pt;">discuss and review the use of any SUA with respect to a Collaboration Target;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(d)</b></font><font style="font-size:12pt;">review and discuss the status of each Target Research Plan and the Data generated during the performance thereof;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(e)</b></font><font style="font-size:12pt;">discuss, review, comment on, and approve any proposed amendments to a Target Research Plan, including any additional non-clinical and preclinical research, and protocols for additional non-clinical and preclinical studies;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(f)</b></font><font style="font-size:12pt;">identify the need for and create subcommittees of the JRC, which shall be subject to and report to the JRC, and assign responsibilities and authorities to such subcommittees, as the JRC determines necessary; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(g)</b></font><font style="font-size:12pt;">perform such other functions as appropriate to further the purposes of the Research Program, as expressly set forth in this Agreement or allocated to it by the Parties&#8217; written agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">3.2</b></font><b style="font-size:12pt;font-weight:bold;">JRC Membership and Meetings</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">JRC Members</b><font style="font-size:12pt;">. &#160;Each JRC representative shall have appropriate knowledge and expertise and sufficient seniority within the applicable Party to make decisions arising within the scope of the JRC&#8217;s responsibilities. &#160;Each Party may replace its representatives on the JRC upon written notice to the other Party. &#160;Each Party shall appoint a co-chairperson of the JRC. &#160;The Alliance Managers shall oversee preparation and circulation of agendas to JRC members at least </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> before each JRC meeting and shall direct the preparation of reasonably detailed minutes for each JRC meeting, which shall be approved by the co-chairpersons and circulated to JRC members within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> after such meeting. The minutes will be considered final after </font><font style="font-size:12pt;">[***] </font><font style="font-size:12pt;">of no response of approval or correction by the Party who received the last draft, in all instances, no later than the next meeting.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Meetings</b><font style="font-size:12pt;">. &#160;</font><font style="font-size:12pt;">The JRC shall hold meetings at such times as it elects to do so, but in no event less frequently than once per Calendar Quarter. &#160;Meetings may be by telephone or video conference or in person. &#160;The first JRC meeting shall be held promptly after formation, but in any event no later than within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> after the Effective Date. &#160;In-person meetings shall be held at locations alternately selected by the Parties. &#160;Each Party shall be responsible for all of its own expenses of participating in any JRC meeting. &#160;No action taken at any meeting of the JRC during the Collaboration Program shall be effective unless at least one (1) representative of each Party is participating. &#160;In addition, upon written notice to the other Party, either Party may request that a special </font><i style="font-size:12pt;font-style:italic;">ad hoc</i><font style="font-size:12pt;"> meeting of the JRC be convened for the purpose of resolving disputes or for the purpose of reviewing or making decisions pertaining to material subject-matter, the review or resolution of which cannot be reasonably postponed until the following scheduled JRC meeting. &#160;Such </font><i style="font-size:12pt;font-style:italic;">ad hoc</i><font style="font-size:12pt;"> meeting shall be convened at such time as may be mutually agreed by the Parties, but no later than </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> following the notification date of request that such meeting be held.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-size:12pt;font-weight:bold;">Non-Member Attendance</b><font style="font-size:12pt;">. &#160;Each Party may from time to time invite a reasonable number of participants, in addition to its representatives, to attend the JRC meetings in a non-voting capacity; provided that if either Party intends to have any Third Party (including any</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">17</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">consultant) attend such a meeting, such Party shall provide reasonable prior written notice to the other Party and obtain the other Party&#8217;s approval for such Third Party to attend such meeting, which approval shall not be unreasonably withheld or delayed. &#160;Such Party shall ensure that such Third Party is bound by written confidentiality and non-use obligations consistent with the terms of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">3.3</b></font><b style="font-size:12pt;font-weight:bold;">Decision-Making</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><font style="font-size:12pt;">All JRC decisions shall be made by unanimous vote, with each Party&#8217;s representatives collectively having one (1) vote. &#160;If after reasonable discussion and good faith consideration of each Party&#8217;s view on a particular matter, the representatives of the Parties cannot reach an agreement as to such matter within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">, then either Party at any time may refer such issue to the Executive Officers for resolution.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><font style="font-size:12pt;">If the Executive Officers cannot resolve such matter within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">after such matter has been referred to them, then (i) Adagene shall have final decision making authority, which shall be exercised in its sole reasonable discretion, with respect to the application of the Adagene Platform Technology in the conduct of the Compound Research Activities in accordance with the applicable Target Research Plan, and (ii) Sanofi shall have final decision making authority, which shall be exercised in its sole reasonable discretion, with respect to all other Development, regulatory, and manufacturing matters. &#160;Notwithstanding the foregoing subsection (ii), Sanofi may not exercise its final decision-making authority to make any material change to [***], and any such material change to [***], shall require the mutual written agreement of the Parties.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">3.4</b></font><b style="font-size:12pt;font-weight:bold;">Limitations on Authority</b><font style="font-size:12pt;">. &#160;The JRC shall have only such powers as are expressly assigned to it in this Agreement, and such powers shall be subject to the terms and conditions of this Agreement. &#160;Without limiting the generality of the foregoing, the JRC shall not have the power to amend, interpret, or waive compliance with this Agreement, and no JRC decision may be in contravention of any terms or conditions of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">3.5</b></font><b style="font-size:12pt;font-weight:bold;">Discontinuation of the JRC</b><font style="font-size:12pt;">. &#160;The activities to be performed by the JRC shall solely relate to governance under this Agreement, and are not intended to be or involve the delivery of services. &#160;The JRC shall continue to exist until the first to occur of: &#160;(a) the Parties mutually agree to disband the JRC or (b) the completion of all Compound Research Activities under all Target Research Plans. &#160;Upon the first to occur of the foregoing (a) or (b), the JRC shall automatically dissolve and, thereafter, such exchange of information shall be made through the Alliance Managers, and decisions of the JRC, if any, shall be decisions as between the Parties, subject to the other terms and conditions of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">3.6</b></font><b style="font-size:12pt;font-weight:bold;">Alliance Managers</b><font style="font-size:12pt;">. &#160;Promptly after the Effective Date, each Party shall appoint an individual who shall be an employee of such Party having appropriate qualification and experience to act as the alliance manager for such Party (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Alliance Manager</b><font style="font-size:12pt;">&#8221;). &#160;Each Alliance Manager shall be responsible for coordinating and managing processes and interfacing between the Parties throughout the Collaboration Program and Term. &#160; Each Alliance Manager shall be permitted to attend JRC meetings as appropriate as non-voting participants. &#160;The Alliance Managers shall be the primary contact for the Parties regarding the activities contemplated by this Agreement and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">18</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">shall facilitate communication between the Parties with respect to all such activities hereunder. &#160;Each Party may replace its Alliance Manager with an alternative representative at any time with prior written notice to the other Party.</font><font style="font-size:12pt;"> &#160;Any Alliance Manager may designate a substitute to temporarily perform the functions of that Alliance Manager. &#160;Each Party shall bear its own costs of its Alliance Manager.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">4.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">COMPOUND RESEARCH ACTIVITIES</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">4.1</b></font><b style="font-size:12pt;font-weight:bold;">Overview</b><font style="font-size:12pt;">. &#160;Subject to the terms and conditions of this Agreement, during the Collaboration Program the Parties will collaborate with respect to the performance of each Target Research Plan. &#160;Following the completion of a Target Research Plan, subject to Sanofi&#8217;s diligence obligations under Section 4.7, Sanofi shall have the sole and exclusive right and responsibility, at its own expense, for the Development of the Licensed Compounds and Licensed Products.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">4.2</b></font><b style="font-size:12pt;font-weight:bold;">Target Research Plan</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">General</b><font style="font-size:12pt;">. &#160;All Compound Research Activities for a Collaboration Target shall be conducted pursuant to a written plan (each, a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Target Research Plan</b><font style="font-size:12pt;">&#8221;). Each Target Research Plan will detail, amongst other things, research objectives, responsibilities, go/no-go criteria, expected resources, estimated timelines, and a reasonably detailed budget of the costs for the Compound Research Activities (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Target Research Budget</b><font style="font-size:12pt;">&#8221;) on an activity-by-activity or study-by-study basis, as appropriate. &#160;The Target Research Plans for Target 1 and Target 2 are attached to this Agreement in </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</u><font style="font-size:12pt;">. &#160;For the avoidance of doubt, with respect to Target 1, only the [***] of the Sanofi Unmasked Antibody 1 will be Masked (but not the [***]). If further masks are needed, the Parties will discuss and agree upon a payment for the additional masks.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Revisions</b><font style="font-size:12pt;">. &#160;The JRC shall review each Target Research Plan and Target Research Budget on a Calendar Quarter basis for potential amendment in accordance with this Section 4.2(b). &#160;In addition, from time to time, either Party may propose updates and amendments, as appropriate, to a Target Research Plan to add, remove, or modify the Compound Research Activities under such Target Research Plan (including any consequential changes to the Target Research Budget) (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Plan Revisions</b><font style="font-size:12pt;">&#8221;). &#160;The Party wishing to make such a revision shall provide the other Party, via the JRC, with a copy of the proposed Plan Revisions and allow the other Party a reasonable opportunity (not to exceed </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> (</font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">) to review and comment thereon. &#160;Any Plan Revision must be approved by the JRC in accordance with Article 3.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">4.3</b></font><b style="font-size:12pt;font-weight:bold;">Performance of Compound Research Activities</b><font style="font-size:12pt;">. &#160;With respect to each Collaboration Target, Adagene shall use Commercially Reasonable Efforts to perform the Compound Research Activities set forth in the applicable Target Research Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">4.4</b></font><b style="font-size:12pt;font-weight:bold;">SUAs and Sanofi Know-How</b><font style="font-size:12pt;">. &#160;With respect to each Collaboration Target, Sanofi will provide to Adagene the SUA directed to the applicable Collaboration Target for use in the generation of Licensed Compounds in accordance with the applicable Target Research Plan. As and when required under a Target Research Plan, Sanofi shall disclose and make available to Adagene all Sanofi Know-How required by Adagene to perform the Compound Research Activities set forth in the applicable Target Research Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">19</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">4.5</b></font><b style="font-size:12pt;font-weight:bold;">Data Package and Licensed Compounds</b><font style="font-size:12pt;">. With respect to each Collaboration Target, following completion of the Compound Research Activities in accordance with the applicable Target Research Plan, Adagene shall (a) prepare and deliver to the JRC a data package that includes the Data generated by Adagene in the performance of the respective Target Research Plan, and (b) deliver to Sanofi the sequence of the Licensed Compound that it has Developed with respect to the respective Collaboration Target; in each case of (a) and (b) in accordance with, and as further specified in, the applicable Target Research Plan. &#160;Adagene will use Commercially Reasonable Efforts, and will cause its Affiliates to use Commercially Reasonable Efforts, to cooperate with Sanofi and its designees to transition to Sanofi the Development, manufacture and Commercialization of each Licensed Compound, as and to the extent reasonably requested by Sanofi, as reasonably necessary to enable Sanofi to Develop, manufacture and Commercialize the applicable Licensed Products. &#160;For the avoidance of doubt, all costs and expenses (including internal costs) incurred by Adagene for the transition will be part of the Development Costs.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">4.6</b></font><b style="font-size:12pt;font-weight:bold;">Development Costs</b><font style="font-size:12pt;">. &#160;Adagene shall be responsible for the Development Costs incurred by Adagene in the performance of the Compound Research Activities in accordance with the respective Target Research Budget. &#160;Sanofi shall reimburse Adagene for any Development Costs requested by Sanofi and approved by the JRC and incurred by Adagene for [***].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">4.7</b></font><b style="font-size:12pt;font-weight:bold;">Diligence</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">General</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">(i)</b><font style="display:inline-block;width:24.67pt;"></font><font style="font-size:12pt;">During the Collaboration Program, Adagene shall use Commercially Reasonable Efforts to perform the Compound Research Activities under and in accordance with each Target Research Plan and within the Target Research Budget; provided that both Parties acknowledge the unpredictable nature of biologic compounds and research and development.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">(ii)</b><font style="display:inline-block;width:21.34pt;"></font><font style="font-size:12pt;">Following the delivery to Sanofi of (A) a complete Data package in accordance with Section 4.5 and (B) the material specified in Section 4.5, in each case ((A) and (B)) with respect to each Collaboration Target, Sanofi shall use Commercially Reasonable Efforts to Develop and obtain Regulatory Approval for [***] corresponding to each Collaboration Target in the Field in the Territory.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Development Updates</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">(i)</b><font style="display:inline-block;width:24.67pt;"></font><b style="font-size:12pt;font-weight:bold;">Adagene&#8217;s Obligations</b><font style="font-size:12pt;">. &#160;At each regularly scheduled JRC meeting during the Collaboration Program, Adagene shall provide the JRC with regular reports detailing its activities under each Target Research Plan, in each case to the extent then-ongoing, and the results of such activities. &#160;The Parties shall discuss the status, progress, and results of such activities at such JRC meetings.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">(ii)</b><font style="display:inline-block;width:21.34pt;"></font><b style="font-size:12pt;font-weight:bold;">Sanofi&#8217;s Obligations</b><font style="font-size:12pt;">. &#160;Following the discontinuation of the JRC pursuant to Section 3.5, Sanofi shall provide to Adagene written reports on [***] basis regarding its significant Development (including receipts of Regulatory Approval) activities with respect to Licensed Products for each Collaboration Target in the Territory. &#160;Each such written report shall summarize in reasonable detail Sanofi&#8217;s, its Affiliates&#8217;, and Sublicensees&#8217; significant Development</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">20</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">activities, and the progress made with respect to the Development and Regulatory Approval of Licensed Products in the Territory, and shall contain relevant information at a level of detail reasonably required by Adagene to determine whether Sanofi is in compliance with its diligence obligations set forth herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">4.8</b></font><b style="font-size:12pt;font-weight:bold;">Compliance</b><font style="font-size:12pt;">. &#160;Each Party shall perform the Development activities assigned to it under each Target Research Plan in compliance with all Applicable Laws, including GLP and other good scientific and clinical practices under the Applicable Laws of the country in which such activities are conducted.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">4.9</b></font><b style="font-size:12pt;font-weight:bold;">Development Records</b><font style="font-size:12pt;">. &#160;Each Party shall maintain complete, current, and accurate records of all Development activities conducted by it hereunder, and all data and other information resulting from such activities. &#160;Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner appropriate for regulatory and patent purposes. &#160;Each Party shall document all non-clinical studies and Clinical Trials in formal written study reports according to Applicable Laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">4.10</b></font><b style="font-size:12pt;font-weight:bold;">Use of Subcontractors</b><font style="font-size:12pt;">. &#160;Adagene may perform its Development activities under this Agreement through one or more subcontractors with Sanofi&#8217;s prior written consent (provided that all subcontractors included in a Target Research Plan shall be deemed approved by Sanofi), provided that (a) Adagene will remain responsible for the work allocated to, and payment to, such subcontractors to the same extent it would if it had done such work itself; (b) each subcontractor undertakes in writing obligations of confidentiality and non-use regarding Confidential Information that are substantially the same as those undertaken by the Parties pursuant to Article&#160;15; and (c) each subcontractor agrees in writing to assign all intellectual property developed in the course of performing any such work to Adagene. &#160;For clarity, Sanofi may subcontract any of its Development activities under this Agreement in its sole discretion, provided that any such subcontracting shall be consistent with the terms and conditions of this Agreement, including the confidentiality obligations and the intellectual property provisions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">4.11</b></font><b style="font-size:12pt;font-weight:bold;">Regulatory Responsibilities</b><font style="font-size:12pt;">. &#160;Sanofi shall own all Regulatory Filings and Regulatory Approvals for the Licensed Products in the Field in the Territory, and shall be solely responsible for preparing any and all Regulatory Filings for the Licensed Products in the Field in the Territory at its expense. &#160;Upon Sanofi&#8217;s request and at its expense, Adagene shall reasonably assist Sanofi in connection with the preparation and filing of such Regulatory Filings, including by providing any and all documentation, and Data reasonably requested by Sanofi in support of such Regulatory Filings, in each case to the extent not previously provided pursuant to Section 4.5.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">5.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">OPTION RIGHT</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">5.1</b></font><b style="font-size:12pt;font-weight:bold;">Option Grant</b><font style="font-size:12pt;">. During the Option Period, Sanofi has the right to initiate two additional research programs for two (2) additional Targets (other than Target 1 and Target 2, but excluding </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> in a stand-alone manner) nominated by Sanofi in accordance with this Article&#160;5 (each, an &#8220;</font><b style="font-size:12pt;font-weight:bold;">Option</b><font style="font-size:12pt;">&#8221;). If Sanofi wishes to exercise an Option, Sanofi will send a written notice to Adagene within the Option Period (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Option Exercise Notice</b><font style="font-size:12pt;">&#8221;), and the Parties will initiate a Target availability check in accordance with Section 5.2 below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">21</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">5.2</b></font><b style="font-size:12pt;font-weight:bold;">Target Availability Check</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Target Nomination and Gatekeeper</b><font style="font-size:12pt;">. &#160;Sanofi shall nominate a Target as a Collaboration Target by providing written notice thereof (a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Target Nomination Notice</b><font style="font-size:12pt;">&#8221;) to a Third Party gatekeeper mutually agreed upon by the Parties (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Gatekeeper</b><font style="font-size:12pt;">&#8221;). &#160;Within </font><font style="font-size:12pt;">[***] </font><font style="font-size:12pt;">after the Gatekeeper&#8217;s selection, Adagene shall provide to the Gatekeeper a list of Targets that are Unavailable to enable him/her to make an accurate determination as to whether such nominated Target is Available or Unavailable. &#160;Upon the request of the Gatekeeper, Adagene shall provide supporting documentation to the Gatekeeper that is reasonably required by the Gatekeeper to verify that a Target is Unavailable. The Gatekeeper shall notify Sanofi of his/her determination within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> after his/her receipt of Adagene&#8217;s Target list and supporting documentation (if requested), and the Gatekeeper&#8217;s determination shall be binding upon the Parties. &#160;[***] shall bear the costs of the Gatekeeper.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Available/Unavailable</b><font style="font-size:12pt;">. &#160;If the Gatekeeper notifies Sanofi that a Target nominated by Sanofi in a Target Nomination Notice is Available, Sanofi shall provide written notice confirming such nomination to Adagene thereof (a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Collaboration Target Designation Notice</b><font style="font-size:12pt;">&#8221;) within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> after receipt of the Gatekeeper&#8217;s notice of Availability. &#160;As soon as reasonably practicable thereafter, the JRC shall mutually agree upon a Target Research Plan with respect to such Target, which Target Research Plan shall be substantially similar in form and content to the Target Research Plan for Target 1 and Target 2, but taking into consideration any differences in research activities required to achieve the applicable criteria for such Target. &#160;If the Gatekeeper notifies Sanofi that the Target is Unavailable, such Target shall not be designated a Collaboration Target and Sanofi shall have the right to nominate another Target as a Collaboration Target (for the avoidance of doubt, up to a maximum of two (2) additional Targets in total) at any time prior to the expiration of the Option Period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">5.3</b></font><b style="font-size:12pt;font-weight:bold;">Option Exercise Fee</b><font style="font-size:12pt;">. Within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> following receipt of the Collaboration Target Designation Notice by Adagene and receipt of an invoice from Adagene, Sanofi shall pay to Adagene a one-time, non-refundable, non-creditable option payment of (a) </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> dollars ($</font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">) per additional Collaboration Target if Adagene has received the Option Exercise Notice from Sanofi within the Initial Option Period, or (b) </font><font style="font-size:12pt;">[***] </font><font style="font-size:12pt;">dollars ($</font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">) per additional Collaboration Target if Adagene has received the Option Exercise Notice from Sanofi within the Extended Option Period. &#160;Upon Adagene&#8217;s receipt of the option payment, the respective Target shall be automatically designated a Collaboration Target under this Agreement. &#160;For the avoidance of doubt, all provisions applicable under this Agreement to Collaboration Targets, including the financial provisions set forth in Article 10, shall equally apply to Collaboration Targets designated under this Article 5.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">5.4</b></font><b style="font-size:12pt;font-weight:bold;">Extension of Option Period</b><font style="font-size:12pt;">. &#160;Sanofi may extend the Initial Option Period by further </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> (</font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">) months (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Extended Option Period</b><font style="font-size:12pt;">&#8221;) by sending written notice to Adagene at any time before the expiration of the Initial Option Period.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">6.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">REPLACEMENT RIGHT</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">6.1</b></font><b style="font-size:12pt;font-weight:bold;">Replacement</b><font style="font-size:12pt;">. With respect to each Initial Target, if certain success criteria set forth in the applicable Target Research Plan are not met due to a technical failure, Sanofi has the [***]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">22</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">right to replace each of SUA 1 or Target 1, SUA 2 or Target 2, and each such additional SUA or Collaboration Target added pursuant to Article 5 (Option Right) as applicable, with another SUA or Target (excluding </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> in a stand-alone manner) at any time during the Replacement Period (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Replacement Right</b><font style="font-size:12pt;">&#8221;). &#160;If Sanofi wishes to exercise its Replacement Right with respect to any such SUA or Collaboration Target, Sanofi will send a written notice to Adagene within the applicable Replacement Period (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Replacement Exercise Notice</b><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">6.2</b></font><b style="font-size:12pt;font-weight:bold;">Target Replacement</b><font style="font-size:12pt;">. &#160;If Sanofi notifies Adagene in the Replacement Exercise Notice that it wishes to replace an Initial Target </font><font style="font-size:12pt;">or a Collaboration Target added pursuant to Article&#160;5 (Option Rights)</font><font style="font-size:12pt;">, the Parties will initiate a Target availability check in accordance with Section&#160;5.2(a) above. &#160;If the Gatekeeper notifies Sanofi that a Target nominated by Sanofi in a Target Nomination Notice is Available, Sanofi shall provide to Adagene a Collaboration Target Designation Notice within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> after receipt of the Gatekeeper&#8217;s notice of Availability. &#160;As soon as reasonably practicable following such designation, the JRC shall mutually agree upon a Target Research Plan with respect to such Target, which Target Research Plan shall be substantially similar in form and content to the Target Research Plan for Target 1 and Target 2, but taking into consideration any differences in research activities required to achieve the applicable criteria for such Target. &#160;Upon Adagene&#8217;s receipt of the Collaboration Target Designation Notice, the respective Target shall be automatically designated a Collaboration Target under this Agreement, and the replaced Initial Target or </font><font style="font-size:12pt;">replaced Collaboration Target added pursuant to Article 5 (Option Rights</font><font style="font-size:12pt;">) shall cease to be a Collaboration Target under this Agreement. &#160;For the avoidance of doubt, all provisions applicable under this Agreement to Collaboration Targets, including the financial provisions set forth in Article 10, shall equally apply to Collaboration Targets designated under this Article 6, and shall cease to apply to the replaced Initial Target or to the replaced </font><font style="font-size:12pt;">Collaboration Target added pursuant to Article 5 (Option Rights</font><font style="font-size:12pt;">) upon receipt of the Collaboration Target Designation Notice by Adagene. &#160;If the Gatekeeper notifies Sanofi that the Target is Unavailable, such Target shall not be designated a Collaboration Target and Sanofi shall have the right to nominate another Target to replace Target 1, Target 2, or </font><font style="font-size:12pt;">a Collaboration Target added pursuant to Article 5 (Option Rights)</font><font style="font-size:12pt;"> as applicable, at any time prior to the expiration of the Replacement Period.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">6.3</b></font><b style="font-size:12pt;font-weight:bold;">SUA Replacement</b><font style="font-size:12pt;">. &#160;If Sanofi notifies Adagene in the Replacement Exercise Notice that it wishes to replace an SUA to be used in relation to any of Target 1, Target 2 or a Collaboration Target added pursuant to Article 5 (Option Right) as applicable, the JRC shall mutually agree upon an amendment to the applicable Target Research Plan as soon as reasonably practicable following receipt of the Replacement Exercise Notice by Adagene.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">6.4</b></font><b style="font-size:12pt;font-weight:bold;">Reimbursement of Development Costs</b><font style="font-size:12pt;">. &#160;Sanofi will reimburse Adagene for all Development Costs incurred by Adagene for activities [***].</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">23</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">7.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">SANOFI MASK AND MODIFIED LICENSED COMPOUNDS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">7.1</b></font><b style="font-size:12pt;font-weight:bold;">Sanofi Mask</b><font style="font-size:12pt;">. &#160;In case the Parties are facing difficulties in performing the Compound Research Activities with an Adagene Mask, upon the request of Sanofi, the Parties will discuss in good faith the option to use a Sanofi proprietary Mask.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">7.2</b></font><b style="font-size:12pt;font-weight:bold;">Modified Research Licensed Compounds</b><font style="font-size:12pt;">. &#160;Sanofi shall have the right to incorporate the Masked Arm of a Masked SUA generated by Adagene under this Agreement as a monospecific or as one arm of a bispecific or multispecific Antibody (each such construct a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Modified Research Licensed Compound</b><font style="font-size:12pt;">&#8221;) for internal research purposes; provided that Sanofi&#8217;s right to conduct such research is subject to the Gatekeeper confirming that such Modified Research License Compound is Available. &#160;Sanofi shall have the option to provide notice to Adagene under Section 7.3 below if it wishes to convert the Sanofi Research License with respect to any Modified Research Licensed Compound to a Sanofi Exclusive License, in which case, the Modified Research Licensed Compound shall become a Modified Licensed Compound in accordance with Section 7.3. &#160;In case Adagene initiates an internal program or grants any rights to a Third Party with respect to a bispecific or multispecific Antibody targeting a Collaboration Target (to the extent permitted under Section 2.7), Adagene shall inform the Gatekeeper thereof without undue delay. &#160;In case such license grant or internal program relates to a Modified Licensed Compound for which the Gatekeeper has previously confirmed to Sanofi that such Modified Licensed Compound is Available, the Gatekeeper will promptly notify Sanofi about such license grant or internal program initiation, and Sanofi shall promptly terminate any and all research activities with respect to such Modified License Research Compound.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">7.3</b></font><b style="font-size:12pt;font-weight:bold;">Modified Licensed Compounds</b><font style="font-size:12pt;">. &#160;Sanofi shall have the right to incorporate the Masked Arm of a Masked SUA generated by Adagene under this Agreement as one Arm of a bispecific or multispecific Antibody (each such construct, a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Modified Licensed Compound</b><font style="font-size:12pt;">&#8221;), provided that: (a) Sanofi may exercise this right for a maximum of [***] Modified Licensed Compounds in total; (b) &#160;Sanofi&#8217;s right to Develop a Modified Licensed Compound is subject to (i) Adagene confirming that it is Available, and (ii) payment of a fee of </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> U.S. dollars ($</font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">) per Modified Licensed Compound (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Modified Licensed Compound Fee</b><font style="font-size:12pt;">&#8221;); and (c) Adagene shall not be obliged to perform any Compound Research Activities with respect to Modified Licensed Compounds. Prior to Developing a Modified Licensed Compound, Sanofi shall inform Adagene of its intention to Develop a Modified Licensed Compound with a notice period of at least </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> (</font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">), and Adagene shall notify Sanofi whether it has any competing programs pursuant to paragraph (b)(i) of this Section&#160;7.2 within such </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> (</font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">) deadline. &#160;In the event that Sanofi is notified of active negotiations with a Third Party pursuant to Section 7.3(b)(ii), above, and such active negotiations between Adagene and such Third Party are discontinued, Adagene will inform Sanofi that such negotiations have been discontinued and the necessary rights for the Development, manufacture and Commercialization of a Modified Licensed Compound are Available.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">8.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">MANUFACTURE AND SUPPLY</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">8.1</b></font><b style="font-size:12pt;font-weight:bold;">Adagene Manufacture and Supply</b><font style="font-size:12pt;">. &#160;Adagene, itself or through one or more Third Party contract manufacturers (such Third party contract manufacturer subject to the prior written consent of Sanofi, such consent not to be unreasonably withheld or delayed), shall be responsible,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">24</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">at its own expense, to manufacture and supply all materials required for performing the preclinical studies under a Target Research Plan to the extent expressly agreed upon in the applicable Target Research Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">8.2</b></font><b style="font-size:12pt;font-weight:bold;">Sanofi Manufacture and Supply</b><font style="font-size:12pt;">. &#160;Subject to Section 8.1, Sanofi, either directly or through one or more Third Party contract manufacturers, shall be solely responsible, at its own cost, to manufacture all requirements of Licensed Compounds and Licensed Products for all Sanofi preclinical and clinical Development activities and all Commercialization activities in the Field in the Territory.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">9.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">COMMERCIALIZATION</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">9.1</b></font><b style="font-size:12pt;font-weight:bold;">General</b><font style="font-size:12pt;">. &#160;Subject to the terms and conditions of this Article 9, Sanofi shall have the sole and exclusive right and responsibility, at its expense, for all aspects of the Commercialization of Licensed Products in the Field in the Territory.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">9.2</b></font><b style="font-size:12pt;font-weight:bold;">Diligence</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">General</b><font style="font-size:12pt;">. &#160;During the Term, with respect to each Collaboration Target, Sanofi, either itself or through its Affiliates or Sublicensees, shall use Commercially Reasonable Efforts to Commercialize all Licensed Products for which Regulatory Approval has been obtained at least in the Key Countries of the Territory.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Commercial Updates</b><font style="font-size:12pt;">. &#160;Sanofi shall provide to Adagene written reports on [***] regarding its significant Commercialization activities with respect to Licensed Products in the Territory. &#160;Each such written report shall summarize in reasonable detail Sanofi&#8217;s, its Affiliates&#8217;, and Sublicensees&#8217; significant Commercialization activities that have been conducted since the last reporting date and that are planned [***] with respect to the Commercialization of each Licensed Product in the Territory.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">10.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">FINANCIAL PROVISIONS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">10.1</b></font><b style="font-size:12pt;font-weight:bold;">Upfront Payment</b><font style="font-size:12pt;">. &#160;Upon execution of this Agreement, Adagene shall provide wire instructions to Sanofi at </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">@Sanofi.com and </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">@sanofi.com. &#160;In partial consideration of the rights granted to Sanofi under this Agreement, within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> (</font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">) after receipt of such wire instructions, Sanofi shall pay to Adagene a one-time, non-refundable, non-creditable upfront payment of </font><font style="font-size:12pt;">[***] </font><font style="font-size:12pt;">dollars ($</font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">10.2</b></font><b style="font-size:12pt;font-weight:bold;">Reimbursement of Development Costs</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Development Costs</b><font style="font-size:12pt;">. &#160;Adagene shall be responsible for the Development Costs incurred in performing the Compound Research Activities to the extent specified in the initial Target Research Budget for each Collaboration Target (including FTE Costs and amounts that Adagene pays to Third Parties subcontracted to perform certain of Adagene&#8217;s obligations under a Target Research Plan). &#160;Sanofi shall reimburse Adagene for (i) any Development Costs incurred by Adagene for performing Compound Research Activities that [***], to the extent such costs are incurred in accordance with the respective revised Target Research Budget (as revised pursuant to Section 4.2(b)), and (ii) all Development Costs for performing Compound Research</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">25</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Activities with respect to replacement Collaboration Targets or replacement SUAs in accordance with Article 6.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Estimates and Invoices</b><font style="font-size:12pt;">. &#160;Within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> after the end of each Calendar Quarter in which Adagene incurs any Development Costs under a Target Research Plan in excess of the initial Target Research Budget, Adagene shall submit to Sanofi (i) an invoice setting forth the total Development Costs incurred by Adagene in accordance with the applicable Target Research Budget in such Calendar Quarter that exceed the initial Target Research Budget, (ii) quarterly timesheets indicating the percentage of time and the hour equivalent of such percentage Adagene personnel allocated to such Compound Research Activities during such Calendar Quarter, as reasonably necessary to confirm the manner and circumstances in which such costs were incurred, and (iii) documentation confirming any out-of-pocket expenses paid by Adagene for such Compound Research Activities during such month. &#160;Sanofi shall pay the amounts invoiced within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> after receipt of the invoice. &#160;Adagene shall notify the JRC as soon as reasonably practicable in the event that it becomes aware that Development Costs are expected to deviate from the Target Research Budget, whereupon the JRC shall discuss an appropriate revision to the Target Research Budget. &#160;Unless such budget increase is approved by the JRC, Sanofi shall have no responsibility for, nor any liability in respect of, any Development Costs in excess of the Target Research Budget (as revised from time to time), except to the extent such budget increase is subject to Compound Research Activities that have been requested by Sanofi.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">10.3</b></font><b style="font-size:12pt;font-weight:bold;">Development Milestone Payments</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Development Milestones</b><font style="font-size:12pt;">. &#160;Subject to the remainder of this Section&#160;10.3(a), on a Collaboration Target-by-Collaboration Target basis, Sanofi shall pay to Adagene the one-time payment set forth in the table below upon the first achievement of the respective applicable milestone event by a Licensed Product corresponding to such Collaboration Target, up to a maximum of $</font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> per Licensed Product (whether by or on behalf of Sanofi or its Affiliates or Sublicensees):</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.15pt 0.5pt 0.15pt 0.5pt;"><tr><td colspan="2" style="vertical-align:top;width:76.95%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 0.25pt 0.15pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Milestone Event</b></p></td><td style="vertical-align:top;width:23.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Milestone</b><b style="font-size:12pt;font-weight:bold;"><br></b><b style="font-size:12pt;font-weight:bold;">Payment</b></p></td></tr><tr><td style="vertical-align:top;width:6.68%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 0.44pt 0.15pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">1.</font></p></td><td style="vertical-align:top;width:70.27%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:23.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">$[***]</font></p></td></tr><tr><td style="vertical-align:top;width:6.68%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 0.44pt 0.15pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">2.</font></p></td><td style="vertical-align:top;width:70.27%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:23.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">$[***]</font></p></td></tr><tr><td style="vertical-align:top;width:6.68%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 0.44pt 0.15pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">3.</font></p></td><td style="vertical-align:top;width:70.27%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:23.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">$[***]</font></p></td></tr><tr><td rowspan="4" style="vertical-align:top;width:6.68%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 0.44pt 0.15pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">4.</font></p></td><td style="vertical-align:top;width:70.27%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:23.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="display:none;vertical-align:top;width:6.68%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 0.25pt 0.15pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:70.27%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 26.95pt;"><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:23.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">$[***]</font></p></td></tr><tr><td style="display:none;vertical-align:top;width:6.68%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 0.25pt 0.15pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:70.27%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 26.95pt;"><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:23.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">$[***]</font></p></td></tr><tr><td style="display:none;vertical-align:top;width:6.68%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 0.25pt 0.15pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:70.27%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 26.95pt;"><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:23.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">$[***]</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">26</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:100%;padding:0.15pt 0.5pt 0.15pt 0.5pt;"><tr><td rowspan="4" style="vertical-align:top;width:6.68%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 0.25pt 0.15pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">5.</font></p></td><td style="vertical-align:top;width:70.27%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:23.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="display:none;vertical-align:top;width:6.68%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0.15pt 0.25pt 0.15pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:70.27%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 26.95pt;"><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:23.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">$[***]</font></p></td></tr><tr><td style="display:none;vertical-align:top;width:6.68%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0.15pt 0.25pt 0.15pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:70.27%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 26.95pt;"><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:23.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">$[***]</font></p></td></tr><tr><td style="display:none;vertical-align:top;width:6.68%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0.15pt 0.25pt 0.15pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:70.27%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 26.95pt;"><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:23.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">$[***]</font></p></td></tr><tr><td rowspan="3" style="vertical-align:top;width:6.68%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 0.25pt 0.15pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">6.</font></p></td><td style="vertical-align:top;width:70.27%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:23.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="display:none;vertical-align:top;width:6.68%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0.15pt 0.25pt 0.15pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:70.27%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 26.95pt;"><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:23.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">$[***]</font></p></td></tr><tr><td style="display:none;vertical-align:top;width:6.68%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0.15pt 0.25pt 0.15pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:70.27%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 26.95pt;"><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:23.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">$[***]</font></p></td></tr><tr><td style="vertical-align:top;width:6.68%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 0.25pt 0.15pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:70.27%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 26.95pt;"><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:23.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">$[***]</font></p></td></tr><tr><td rowspan="4" style="vertical-align:top;width:6.68%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 0.25pt 0.15pt 2.65pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">7.</font></p></td><td style="vertical-align:top;width:70.27%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:23.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="display:none;vertical-align:top;width:6.68%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0.15pt 0.25pt 0.15pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:70.27%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 26.95pt;"><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:23.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">$[***]</font></p></td></tr><tr><td style="display:none;vertical-align:top;width:6.68%;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0.15pt 0.25pt 0.15pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:70.27%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 26.95pt;"><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:23.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">$[***]</font></p></td></tr><tr><td style="display:none;vertical-align:top;width:6.68%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0.15pt 0.25pt 0.15pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:70.27%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 26.95pt;"><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:23.03%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0.15pt 5.15pt 0.15pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">$[***]</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">For clarity, the foregoing milestone payments shall be payable one-time only with respect to each Collaboration Target, regardless of the number of Licensed Products corresponding to such Collaboration Target to achieve such milestone event. &#160;With respect to the milestone events and milestone payments listed under number 2 through number 4 above, if any such milestone event has not occurred until the achievement of the subsequent milestone event for a Licensed Product directed to the same Collaboration Target, the milestone payment for such milestone event shall become due upon the achievement of the subsequent milestone event by a Licensed Product directed to the same Collaboration Target.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Delivery of Sequences and FTO Analysis</b><font style="font-size:12pt;">. &#160;Adagene will transfer the SAFEbody sequences upon selection of the [***] most relevant lead candidates in each research plan for upscaling for non-GLP Tox studies (or at such point in the research plan with the number of relevant leads as may otherwise be mutually agreed by the Parties). Upon delivery of a sequence by Adagene to Sanofi, Sanofi will perform a freedom to operate analysis for such sequence within [***]of the delivery date. &#160;If Sanofi notifies Adagene that there is no freedom to operate issue, or if Sanofi does not notify Adagene of any freedom to operate issue within [***] upon delivery of the sequence to Sanofi, [***] with respect to FTO shall have been met, and Adagene will resume the performance of Compound Research Activities under the applicable Target Research Plan. &#160; &#160; &#160;If Sanofi identifies a freedom to operate issue it shall promptly notify Adagene thereof, and the Parties shall discuss this issue in the Joint Research Committee without undue delay. &#160;If, upon discussion of the Joint Research Committee, Sanofi decides in its sole discretion to move on with the sequence despite the freedom to operate issue, Sanofi will promptly notify Adagene thereof,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">27</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">and [***] &#160;with respect to FTO shall be deemed to have been met, and Adagene will resume the performance of Compound Research Activities under the applicable Target Research Plan. &#160;Otherwise, the Parties will agree on an amendment of the respective Target Research Plan for the Development of another SAFEbody sequence for the Licensed Compound against the respective Collaboration Target, and the delivery milestone payment shall become due upon a determination by the JRC that all [***] .</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Once all Compound Research Activities under the applicable Target Research Plan have been completed, the JRC shall determine [***], such determination to be made no later than </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> upon completion of the respective Compound Research Activities by Adagene. Upon the determination of the JRC that [***], Sanofi shall make the milestone payment for the first development milestone event 1 (i.e. </font><font style="font-size:12pt;">$[***]) in accordance with Section&#160;10.3(c)</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">If the JRC determines that the respective [***] , the Parties will agree in good faith on [***]. &#160;For the avoidance of doubt, if the JRC determines not to conduct further Development activities with respect to the respective Collaboration Target under the applicable Target Research Plan, Sanofi will not conduct further Development activities with respect to the respective Collaboration Target outside of the applicable Target Research Plan.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-size:12pt;font-weight:bold;">Notice, Invoice and Payment</b><font style="font-size:12pt;">. &#160;Subject to Section 10.3(b), Sanofi shall notify Adagene in writing within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> after the achievement of any milestone set forth in this Section 10.3 by Sanofi, its Affiliates or Sublicensees. &#160;Following the JRC&#8217;s notification that [***], or (ii) Adagene&#8217;s receipt of notice from Sanofi that any such milestone event has been achieved (as applicable), Adagene will invoice Sanofi for and Sanofi shall pay to Adagene the applicable development milestone payments within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> after receipt of such invoice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">10.4</b></font><b style="font-size:12pt;font-weight:bold;">Sales-Based Milestones Payments</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Sales Milestones</b><font style="font-size:12pt;">. &#160;Subject to the remainder of this Section 10.4(a), on a Collaboration Target-by-Collaboration Target basis, Sanofi shall pay to Adagene the payments set forth in the table below within </font><font style="font-size:12pt;">[***] </font><font style="font-size:12pt;">after receipt of an invoice provided pursuant to Section 10.4(b) at end of the Calendar Year in which the corresponding milestone event is first achieved by all Licensed Products corresponding to a Collaboration Target (whether by or on behalf of Sanofi, its Affiliates or Sublicensees)</font><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:90%;" align="center"><tr style="height:1pt;"><td style="vertical-align:middle;width:62.86%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:middle;width:37.13%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:middle;width:62.86%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Annual Net Sales of all Licensed Products in the</b><b style="font-size:12pt;font-weight:bold;"><br></b><b style="font-size:12pt;font-weight:bold;">Territory directed to a particular Collaboration</b><b style="font-size:12pt;font-weight:bold;"><br></b><b style="font-size:12pt;font-weight:bold;">Target in a given Calendar Year</b></p></td><td style="vertical-align:middle;width:37.13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Sales Milestone Payments</b></p></td></tr><tr><td style="vertical-align:middle;width:62.86%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">#1 Annual Net Sales during such Calendar Year are equal to or exceed $</font><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:37.13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">$</font><font style="font-size:12pt;">[***]</font></p></td></tr><tr><td style="vertical-align:middle;width:62.86%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">#2 Annual Net Sales during such Calendar Year are equal to or exceed $</font><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:37.13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">$</font><font style="font-size:12pt;">[***]</font></p></td></tr><tr><td style="vertical-align:middle;width:62.86%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">#3 Annual Net Sales during such Calendar Year are equal to or exceed $</font><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:37.13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">$</font><font style="font-size:12pt;">[***]</font></p></td></tr><tr><td style="vertical-align:middle;width:62.86%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">#4 Annual Net Sales during such Calendar Year are equal to or exceed $</font><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:37.13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">$</font><font style="font-size:12pt;">[***]</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">28</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:90%;" align="center"><tr><td style="vertical-align:middle;width:62.86%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">#5 Annual Net Sales during such Calendar Year are equal to or exceed $</font><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:37.13%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">$</font><font style="font-size:12pt;">[***]</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">For clarity, the foregoing milestone payments shall be payable one-time only with respect to each Collaboration Target, regardless of the number of Licensed Products corresponding to such Collaboration Target to achieve such milestone event, up to a maximum of $</font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> per Collaboration Target. &#160;[***]. &#160;For the avoidance of doubt, all sales milestones reached by Sanofi shall be paid by Sanofi.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Notice, Invoice and Payment</b><font style="font-size:12pt;">. &#160;As part of the report provided pursuant to Section 11.1, on a Collaboration Target-by-Collaboration Target basis, Sanofi shall provide written notice to Adagene upon the annual Net Sales of the Licensed Products for a Collaboration Target in the Territory first reaching each of the values set forth in Section 10.4(a) above. &#160;Following Adagene&#8217;s receipt of notice from Sanofi that any such milestone event has been achieved, Adagene will invoice Sanofi for and Sanofi shall pay each milestone payment set forth in the table above as set forth in Section 10.4(a).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">10.5</b></font><b style="font-size:12pt;font-weight:bold;">Royalty Payments</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Royalty Rate</b><font style="font-size:12pt;">. &#160;On a Licensed Product-by-Licensed Product basis, subject to the remainder of this Section 10.5, during the Royalty Term for a Licensed Product, Sanofi shall pay to Adagene royalties on the aggregate annual Net Sales of such Licensed Product in the Territory, at the royalty rates set forth in the table below.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:89.91%;" align="center"><tr><td style="vertical-align:middle;width:62.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">For that portion of aggregate Net Sales in a given</b><b style="font-size:12pt;font-weight:bold;"><br></b><b style="font-size:12pt;font-weight:bold;">Calendar Year </b><font style="font-size:12pt;"><br></font><b style="font-size:12pt;font-weight:bold;">(per Licensed Product)</b></p></td><td style="vertical-align:middle;width:37.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Royalty Rate </b><font style="font-size:12pt;"><br></font><b style="font-size:12pt;font-weight:bold;">(per Licensed Product)</b></p></td></tr><tr><td style="vertical-align:middle;width:62.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Below $</font><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:37.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">%</font></p></td></tr><tr><td style="vertical-align:middle;width:62.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36.95pt;"><font style="font-size:12pt;white-space:pre-wrap;">Equal to or exceeding  $</font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">, </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">and below $</font><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:37.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">%</font></p></td></tr><tr><td style="vertical-align:middle;width:62.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36.95pt;"><font style="font-size:12pt;white-space:pre-wrap;">Equal to or exceeding  $</font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">, </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">and below $</font><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:37.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">%</font></p></td></tr><tr><td style="vertical-align:middle;width:62.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:0.95pt;text-indent:-0.95pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;white-space:pre-wrap;">Equal to or exceeding  $</font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">, </font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">and below $</font><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:37.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">%</font></p></td></tr><tr><td style="vertical-align:middle;width:62.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;">Equal to or exceeding $</font><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:37.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">%</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Royalty Term</b><font style="font-size:12pt;">. &#160;Royalties shall be paid on a Licensed Product-by-Licensed Product and country-by-country basis from the First Commercial Sale of a Licensed Product in a country by or on behalf of Sanofi, &#160;its Affiliates or Sublicensees until the latest of (i) ten (10) years after the First Commercial Sale of such Licensed Product in such country, (ii) expiration of the last-to-expire Valid Claim in such country, or (iii) the expiration of Regulatory Exclusivity for such Licensed Product in such country (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Royalty Term</b><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-size:12pt;font-weight:bold;">Royalty Reductions</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">29</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">(i)</b><font style="display:inline-block;width:24.67pt;"></font><b style="font-size:12pt;font-weight:bold;">Biosimilar Entry</b><font style="font-size:12pt;">. &#160;If one or more Biosimilar Licensed Products to a Licensed Product is/are sold in a country in the Territory in any Calendar Quarter during the Royalty Term for such Licensed Product in such country</font><font style="font-size:12pt;">, and during such Calendar Quarter Net Sales of such Licensed Product in such country decline by the percentage set forth in the table below relative to the average Calendar Quarterly Net Sales of such Licensed Product achieved in the </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> immediately prior to the launch of such </font><font style="font-size:12pt;">Biosimilar Licensed Product(s), then the royalty rates set forth in Section 10.5(a) applicable to such Licensed Product would permanently be reduced as set forth in the table below.</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:89.91%;" align="center"><tr><td style="vertical-align:middle;width:62.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Decline in Net Sales </b></p></td><td style="vertical-align:middle;width:37.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Royalty Reduction </b></p></td></tr><tr><td style="vertical-align:middle;width:62.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:12pt;white-space:pre-wrap;">Exceeding  </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">, and below </font><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:37.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[***]</font></p></td></tr><tr><td style="vertical-align:middle;width:62.85%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36.95pt;"><font style="font-size:12pt;">Equal to or exceeding </font><font style="font-size:12pt;">[***]</font></p></td><td style="vertical-align:middle;width:37.14%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[***]</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">(ii)</b><font style="display:inline-block;width:21.34pt;"></font><b style="font-size:12pt;font-weight:bold;">Expiry of Exclusivity</b><font style="font-size:12pt;">. &#160;If during any Calendar Quarter of the Royalty Term for a particular Licensed Product in a country, there is no Valid Claim that would be infringed by the sale of the Licensed Product in such country and no Regulatory Exclusivity for such Licensed Product exists in such country, then the royalty rate provided in Section 10.5(a) shall be reduced by </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> for such Licensed Product in such country for such Calendar Quarter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">(iii)</b><font style="display:inline-block;width:18pt;"></font><b style="font-size:12pt;font-weight:bold;">Anti-Royalty Stacking</b><font style="font-size:12pt;">. &#160;Sanofi or its Affiliates would be entitled to credit </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> of all future royalties to a Third Party during a Calendar Quarter under an arms&#8217; length transaction in consideration for a license under such Third Party&#8217;s intellectual property rights that are necessary for [***] in the respective Licensed Product, against any royalty payments due to Adagene during such Calendar Quarter.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">(iv)</b><font style="display:inline-block;width:18.67pt;"></font><b style="font-size:12pt;font-weight:bold;">Royalty Floor</b><font style="font-size:12pt;">. &#160;Notwithstanding the foregoing Sections&#160;[***], any royalty reduction made pursuant to Sections [***], individually or in combination, shall in no event reduce the royalty rate applicable to the respective Licensed Product pursuant to Section 10.5(a) by more than </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Floor</b><font style="font-size:12pt;">&#8221;). &#160;In the event that Sanofi is unable to credit any amount covered under Section [***] against the royalties payable to Adagene due to the Floor, then Sanofi may carry forward such amount and credit them against [***] payable to Adagene in subsequent Calendar Quarters, subject to the Floor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">10.6</b></font><b style="font-size:12pt;font-weight:bold;">Remuneration Payments to Adagene Inventors. &#160;</b><font style="font-size:12pt;">Each Party shall be responsible for discharging its own obligations with respect to service inventions and inventor remuneration or compensation with respect to its own employees in accordance with any applicable laws and regulations of any relevant jurisdiction.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:12pt;font-weight:bold;">11.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><b style="font-size:12pt;font-weight:bold;">PAYMENT; RECORDS; AUDITS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">11.1</b></font><b style="font-size:12pt;font-weight:bold;">Payment; Reports</b><font style="font-size:12pt;">. &#160;Commencing with the First Commercial Sale for a Licensed Product Sanofi will, with respect to each Calendar Quarter (or portion thereof), provide a written </font><font style="font-size:12pt;">report within [***] after the end of each Calendar Quarter </font><font style="font-size:12pt;">showing (a) aggregate Net Sales of the Licensed Products that are royalty bearing and the royalties due thereon for such Calendar Quarter, (b) the withholding taxes, if any, required by Applicable Law to be deducted in respect of such royalties; (c) the exchange rates used in determining the royalty amount expressed in Dollars; and (d) whether any sales milestone has been achieved under Section 10.4 (each, a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Royalty Report</b><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">30</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Sanofi will provide such Royalty Reports for so long as any Royalty Term remains in effect for a given Licensed Product. Sanofi will pay to Adagene any amount due under such Royalty Report in accordance with Section 11.3 </font><font style="font-size:12pt;">[***] </font><font style="font-size:12pt;">following receipt of an invoice for such amount.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">11.2</b></font><b style="font-size:12pt;font-weight:bold;">Exchange Rate; Manner and Place of Payment</b><font style="font-size:12pt;">. &#160;All references to dollars and &#8220;$&#8221; herein shall refer to U.S. dollars. &#160;All payments hereunder shall be payable in U.S. dollars. &#160;With respect to conversion of Net Sales in any currency other than U.S. dollars to U.S. dollars, Sanofi or its Affiliates or Sublicensees shall convert the Net Sales for the Licensed Products using its then-current standard worldwide currency conversion methodology. &#160;All payments owed to Adagene under this Agreement shall be made by wire or ACH transfer in immediately available funds to a bank and account designated in writing by Adagene, unless otherwise specified in writing by Adagene.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">11.3</b></font><b style="font-size:12pt;font-weight:bold;">Invoices</b><font style="font-size:12pt;">. Notwithstanding anything to the contrary in this Agreement, Adagene will deliver an invoice to Sanofi for all payments owed by Sanofi under this Agreement. &#160;Sanofi will pay the undisputed amount of any invoice within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> after receipt thereof (except where a different period is expressly provided in another Section of this Agreement) and any disputed amount within </font><font style="font-size:12pt;">[***] </font><font style="font-size:12pt;">after final resolution of the Dispute with respect thereto.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">11.4</b></font><b style="font-size:12pt;font-weight:bold;">Taxes.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Taxes on Income</b><font style="font-size:12pt;">. &#160;Except as otherwise provided in this Section 11.4, each Party shall be solely responsible for the payment of all taxes imposed on its share of income arising directly or indirectly from the activities of the Parties under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Tax Cooperation</b><font style="font-size:12pt;">. &#160;The Parties shall cooperate with one another and use reasonable efforts to avoid or reduce tax withholding (e.g., withholding imposed under any U.S. federal, state or local statute, regulation or code) or similar obligations in respect of the milestone payments, royalty payments, and other payments made by Sanofi under this Agreement. &#160;To the extent Sanofi is required by Applicable Laws to deduct and withhold taxes on any payment to Adagene, Sanofi shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Adagene an official tax certificate or other evidence of such payment sufficient to enable Adagene to claim such payment of taxes. &#160;Adagene shall provide Sanofi any tax forms that may be reasonably necessary in order for Sanofi to not withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty, to the extent legally able to do so. &#160;Adagene shall use reasonable efforts to provide any such tax forms to Sanofi in advance of the due date. &#160;Sanofi shall provide Adagene with reasonable assistance to enable the recovery, as permitted by Applicable Laws, of withholding taxes or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of Adagene. &#160;Sanofi shall have the right to deduct any such tax, levy, or charge actually paid from payment due to Adagene. &#160;Each Party agrees to assist the other Party in claiming exemption from such deductions or withholdings under double taxation or similar agreement or treaty from time to time in force and in minimizing the amount required to be so withheld or deducted.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-size:12pt;font-weight:bold;">Other Tax Liability</b><font style="font-size:12pt;">. All amounts payable under this Agreement are exclusive of value added or similar taxes (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">VAT</b><font style="font-size:12pt;">&#8221;). In the event of value added or similar taxes incurred by a Party with respect to payments made to a Party hereunder or the activities underlying</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">31</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">such payments, each Party and its Affiliates will use reasonable efforts to secure available exemption(s) from VAT or cooperate with the other Party&#8217;s efforts to obtain maximum recovery of VAT paid or incurred by such Party or any Affiliate, to the extent permitted by Applicable Law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">11.5</b></font><b style="font-size:12pt;font-weight:bold;">Records; Audit</b><font style="font-size:12pt;">. &#160;Each Party shall keep, and shall require its Affiliates, contractors, and Sublicensees to keep, complete and accurate records pertaining to, in the case of Adagene, the performance of each Licensed Compound Research Activity and, in the case of Sanofi, the sale or other disposition of Licensed Products, in each case in sufficient detail to permit the other Party to confirm the accuracy of any payment due hereunder. &#160;Each Party will keep such books and records for </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> following the Calendar Year to which they pertain, or such longer period of time as may be required by Applicable Laws.&#160; Upon at least </font><font style="font-size:12pt;">[***] </font><font style="font-size:12pt;">prior written notice and during regular business hours at such place or places where such records are customarily kept, a Party may inspect the other Party&#8217;s records via an independent certified public accountant (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Auditor</b><font style="font-size:12pt;">&#8221;) selected by the auditing Party and reasonably acceptable to the audited Party for the sole purpose of verifying for the auditing Party the accuracy of the financial reports furnished by the audited Party pursuant to this Agreement and of any payments made, or required to be made, to such auditing Party pursuant to this Agreement. &#160;Before beginning its audit, the Auditor shall execute an undertaking acceptable to each Party by which the Auditor agrees to keep confidential all information reviewed during the audit. &#160;Such audits shall be limited to once each Calendar Year and once with respect to records covering any specific period of time. &#160;Such auditor shall not disclose any of the audited Party&#8217;s Confidential Information to the auditing Party, and shall only report </font><font style="font-size:12pt;">whether the financial reports provided by the audited Party and the amount of payments made to or by a Party are correct or not, and the amount of any discrepancy. &#160;</font><font style="font-size:12pt;">In the event that the final result of the inspection reveals an undisputed underpayment or overpayment, the underpaid or overpaid amount shall be settled within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> after the Auditor&#8217;s report. &#160;The auditing Party shall bear the full cost of such audit unless such audit reveals a discrepancy in the auditing Party&#8217;s favor of more than </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">from the reported amounts in which case the audited Party shall reimburse the auditing Party for the reasonable out-of-pocket costs incurred for such audit.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">11.6</b></font><b style="font-size:12pt;font-weight:bold;">Late Payments.</b><font style="font-size:12pt;"> In the event that any payment due under this Agreement is not paid when due in accordance with the applicable provisions of this Agreement, the payment shall accrue interest from the date due at an interest rate of </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">above the average </font><font style="font-size:12pt;">[***] </font><font style="font-size:12pt;">SOFR for USD at the date the payment was due; provided, however, that in no event shall such rate exceed the maximum legal annual interest rate.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">12.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">INTELLECTUAL PROPERTY</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">12.1</b></font><b style="font-size:12pt;font-weight:bold;">Ownership</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Background IP</b><font style="font-size:12pt;">. &#160;As between the Parties, each Party will retain ownership of all Patents, Know-How and other intellectual property rights that are Controlled by such Party prior to the Execution Date or are otherwise developed by such Party outside of this Agreement (with respect to such Party, its &#8220;</font><b style="font-size:12pt;font-weight:bold;">Background IP</b><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Compound Inventions</b><font style="font-size:12pt;">. &#160;All Inventions solely related to (i) an SUA, (ii) a Licensed Compound, or (iii) a Licensed Product, in each case ((i), (ii) and (iii)) that are generated in the performance of any Compound Research Activities or other Development, manufacturing,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">32</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">or regulatory activities under this Agreement solely by one or more employees or agents of a Party or its Affiliates or other persons acting on such Party&#8217;s behalf, or jointly by one or more employees or agents of each Party or its Affiliates or other persons acting on their behalf, (collectively, the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Compound Inventions</b><font style="font-size:12pt;">&#8221;) shall be the exclusive property of Sanofi. &#160;Adagene shall notify, assign and transfer to Sanofi all of its rights, title and interest in and to the Compound Inventions promptly after its conception, development, or reduction to practice by Adagene or its Affiliate or contractor. &#160;To effectuate the foregoing assignment, Adagene shall ensure that all entities and individuals that perform any activities on behalf of Adagene under this Agreement are under a written or other legally enforceable obligation to assign all right, title, and interest in any intellectual property created pursuant to such activities directly to Adagene or to an entity that is obligated to assign all such right, title, and interest to Adagene. &#160;Adagene shall assist Sanofi, [***], in securing for Sanofi any patents, copyrights, or other proprietary rights in such Compound Inventions, and to perform all acts that may be reasonably required to vest in Sanofi all right, title, and interest in such Compound Inventions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-size:12pt;font-weight:bold;">Platform Inventions</b><font style="font-size:12pt;">. &#160;All Inventions that (i) pertain generally to the Adagene Platform Technology or any improvements, enhancements or modifications thereto and (ii) are not </font><font style="font-size:12pt;">solely related to an SUA, Licensed Compound or a Licensed Product</font><font style="font-size:12pt;">, and in each case are generated under this Agreement solely by one or more employees or agents of a Party or its Affiliates or other persons acting on a Party&#8217;s behalf, or jointly by one or more employees or agents of each Party or its Affiliates or other persons acting on their behalf, (collectively, the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Platform Inventions</b><font style="font-size:12pt;">&#8221;) shall be the exclusive property of Adagene. &#160;Sanofi hereby assigns to Adagene all of Sanofi&#8217;s right, title, and interest in and to all Platform Inventions. &#160;To effectuate the foregoing assignment, Sanofi shall ensure that all entities and individuals that perform any activities on behalf of Sanofi hereunder are under a written or other legally enforceable obligation to assign all right, title, and interest in any intellectual property created pursuant to such activities directly to Sanofi or to an entity that is obligated to assign all such right, title, and interest to Sanofi. &#160;Sanofi shall assist Adagene, [***], in securing for Adagene any patents, copyrights, or other proprietary rights in such Platform Inventions, and to perform all acts that may be reasonably required to vest in Adagene all right, title, and interest in such Platform Inventions.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-size:12pt;font-weight:bold;">Other Inventions</b><font style="font-size:12pt;">. &#160;Except for Compound Inventions and Platform Inventions, (i) each Party shall solely own any discovery or invention made solely by it and its Affiliates&#8217; employees, agents, or independent contractors (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Sole Inventions</b><font style="font-size:12pt;">&#8221;), and (ii) the Parties shall jointly own any discovery or invention made jointly by employees, agents, or independent contractors of one Party or its Affiliates together with employees, agents, or independent contractors of the other Party or its Affiliates (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Joint Inventions</b><font style="font-size:12pt;">&#8221;). &#160;All Patents claiming patentable Joint Inventions shall be referred to herein as &#8220;</font><b style="font-size:12pt;font-weight:bold;">Joint Patents</b><font style="font-size:12pt;">&#8221;. &#160;Except to the extent either Party is restricted by the licenses granted to the other Party under this Agreement, each Party shall be entitled to practice, license, assign, and otherwise exploit its interest under the Joint Inventions and Joint Patents without the duty of accounting or seeking consent from the other Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">12.2</b></font><b style="font-size:12pt;font-weight:bold;">Patent Prosecution and Maintenance</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Sanofi Patents</b><font style="font-size:12pt;">. &#160;Sanofi shall have the sole right, but not the obligation, to control the preparation, filing, prosecution, and maintenance (including any interferences, reissue</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">33</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">proceedings, reexaminations, </font><i style="font-size:12pt;font-style:italic;">inter partes</i><font style="font-size:12pt;"> review, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings, and defense of validity or enforceability challenges) all Sanofi Patents (other than Joint Patents), including Compound Patents or Patents claiming Sole Inventions owned by Sanofi, worldwide, using counsel of its own choice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Adagene Patents</b><font style="font-size:12pt;">. &#160;Adagene shall have the sole right, but not the obligation, to control the preparation, filing, prosecution, and maintenance (including any interferences, reissue proceedings, reexaminations, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings and defense of validity or enforceability challenges) of all Adagene Patents (other than Joint Patents), including Patents covering Platform Inventions or Sole Inventions owned by Adagene, worldwide, at its sole cost and expense and by counsel of its own choice. &#160;Adagene will keep Sanofi informed as to material developments with respect to the filing, prosecution and maintenance of the Adagene Patents, including by providing copies of all substantive office actions or any other substantive documents to or from any patent office, including notice of all interferences, reissues, reexaminations, </font><i style="font-size:12pt;font-style:italic;">inter partes</i><font style="font-size:12pt;"> reviews, post grant proceedings, oppositions or requests for patent term extensions. Adagene will also provide Sanofi with a reasonable opportunity to comment substantively on the filing, prosecution and maintenance of the Adagene Patents prior to taking material actions (including the filing of applications), and will consider in good faith the comments of Sanofi and Sanofi&#8217;s patent counsel on the preparation, filing, prosecution, and maintenance of any Adagene Patents.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-size:12pt;font-weight:bold;">Joint Patents</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">(i)</b><font style="display:inline-block;width:24.67pt;"></font><font style="font-size:12pt;">Subject to this Section 12.2(c), Sanofi shall have the first right, but not the obligation, to prepare, file, prosecute, and maintain (including any interferences, reissue proceedings, reexaminations, patent term extensions, applications for supplementary protection certificates, oppositions, invalidation proceedings and defense of validity or enforceability challenges) the Joint Patents at Sanofi&#8217;s cost and expense using a patent counsel selected by Sanofi and reasonably acceptable to Adagene. &#160;Sanofi shall keep Adagene informed of material progress with regard to the preparation, filing, prosecution, maintenance, and defense, if any, of the Joint Patents, including content, timing, and jurisdiction of the filing of such Joint Patents, and Sanofi shall consult with, and consider in good faith the reasonable comments of Adagene with respect to filing, prosecuting, and defending the Joint Patents in the Territory.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:108pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">(ii)</b><font style="display:inline-block;width:21.34pt;"></font><font style="font-size:12pt;">If Sanofi desires to abandon or cease prosecution or maintenance of any Joint Patent in the Territory, Sanofi shall provide reasonable prior written notice to Adagene of such intention to abandon (which notice shall, to the extent possible, be given no later than </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> prior to the next deadline for any action that must be taken with respect to any such Joint Patent in the relevant patent office). &#160;In such case, at Adagene&#8217;s sole discretion, upon written notice from Adagene to Sanofi, Adagene may elect to continue prosecution or maintenance of any such Joint Patent at its own expense, and Sanofi shall execute such documents and perform such acts, at Adagene&#8217;s expense, as may be reasonably necessary to assign to Adagene Sanofi&#8217;s ownership interest therein and to allow Adagene to continue the prosecution and maintenance of such Joint Patent in the Territory. &#160;Any patents so assigned shall cease to be a Joint Patent and shall thereafter be Adagene Patents subject to the licenses herein.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">34</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-size:12pt;font-weight:bold;">Patent Term Extensions</b><font style="font-size:12pt;">. &#160;Sanofi shall have the right to apply, in its sole discretion and at its expense, for any patent term extension for any Sanofi Patent or Joint Patent in the Territory. Adagene shall have the right to apply, in its sole discretion and at its expense, for any patent term extension for all Adagene Patents (other than Joint Patents) in the Territory provided such application or extension would not negatively impact a potential extension of a Sanofi Patent or a Joint Patent.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(e)</b></font><b style="font-size:12pt;font-weight:bold;">Cooperation</b><font style="font-size:12pt;">. &#160;Each Party agrees to cooperate fully in the preparation, filing, prosecution, maintenance, and defense, if any, of Patents under Section 12.2 and in the obtaining and maintenance of any patent term extensions, supplementary protection certificates, and their equivalent with respect thereto, at its own cost (except as expressly set forth otherwise in this Section 12.2). &#160;Such cooperation includes (i)&#160;executing all papers and instruments, or requiring its employees or contractors, to execute such papers and instruments, so as to enable the other Party to apply for and to prosecute patent applications in any country as permitted by Section 12.2; and (ii)&#160;promptly informing the other Party of any matters coming to such Party&#8217;s attention that may affect the preparation, filing, prosecution, or maintenance of any such patent application and the obtaining of any patent term extensions, supplementary protection certificates, and their equivalent.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(f)</b></font><b style="font-size:12pt;font-weight:bold;">Separation of Patent Rights</b><font style="font-size:12pt;">. In order to more efficiently enable the prosecution and maintenance of the Adagene Patents, the Sanofi Patents and the Joint Patents relating to the Inventions described above, the Parties will use good faith efforts to separate Compound Inventions, Platform Inventions, and Joint Inventions into separate filings to the extent possible and without adversely impacting such prosecution and maintenance and to coordinate such filings so as to maximize patent exclusivity for the Licensed Compounds and Licensed Products.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">12.3</b></font><b style="font-size:12pt;font-weight:bold;">Patent Enforcement</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Notice</b><font style="font-size:12pt;">. &#160;Each Party shall notify the other within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> after becoming aware of any alleged or threatened infringement by a Third Party of any of the Adagene Patents, or Compound Patents in the Territory, which infringement adversely affects or could reasonably be expected to adversely affect the Development, manufacture, or Commercialization of any Licensed Product (collectively, &#8220;</font><b style="font-size:12pt;font-weight:bold;">Product Infringement</b><font style="font-size:12pt;">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Enforcement Right</b><font style="font-size:12pt;">. &#160;Sanofi shall have the first right to bring and control any legal action in connection with such Product Infringement at its own expense as it reasonably determines appropriate. &#160;However, with respect to any Product Infringement action involving any Adagene Patent, Sanofi shall have a first right to enforce such Adagene Patent to the extent such Adagene Patent directly relates to a Licensed Compound or Licensed Product (and not to any compound or product that is not related to a Licensed Compound or Licensed Product). &#160;Sanofi shall not compromise or settle any such litigation involving any Adagene Patent without Adagene&#8217;s prior written consent such consent not to be unreasonably withheld or delayed. &#160;To the extent a Product Infringement pertains to one or more Adagene Patents, if Sanofi (i) elects to not bring such legal action against a Product Infringement (the decision of which Sanofi shall inform Adagene promptly) or (ii) Sanofi otherwise fails to bring such legal action against such Product Infringement within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> after first becoming aware of such Product Infringement, then, Adagene</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">35</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">shall have the right, but not the obligation, to bring and control any legal action in connection with such Product Infringement at its own expense as it reasonably determines appropriate after consultation with Sanofi.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-size:12pt;font-weight:bold;">Collaboration</b><font style="font-size:12pt;">. &#160;Each Party shall provide to the enforcing Party reasonable assistance in such enforcement, at such enforcing Party&#8217;s request and expense, including to be named in such action if required by Applicable Laws to pursue such action. &#160;The enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts and shall reasonably consider the other Party&#8217;s comments on any such efforts, including determination of litigation strategy and filing of material papers to the competent court. &#160;The non-enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the enforcing Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-size:12pt;font-weight:bold;">Expense and Recovery</b><font style="font-size:12pt;">. &#160;Except as otherwise agreed by the Parties in connection with a cost sharing arrangement, any recovery realized as a result of any litigation described in Section 12.3 (whether by way of settlement or otherwise) shall be first allocated to reimburse the Parties for their costs and expenses in making such recovery (which amounts shall be allocated </font><i style="font-size:12pt;font-style:italic;">pro rata</i><font style="font-size:12pt;"> if insufficient to cover the totality of such expenses). &#160;Any remainder after such reimbursement is made shall be allocated as follows: (i) if Sanofi is the enforcing Party, Sanofi shall retain the remaining amount provided that any remaining amount attributable to a recovery for lost sales or profits shall be deemed &#8220;Net Sales&#8221; in the Calendar Year in which the money is actually received and Sanofi shall make the corresponding payments to Adagene in accordance with Sections 10.4 and&#160;10.5, and (ii) if Adagene is the enforcing Party, Adagene shall retain </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">of such remaining amount and shall pay </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> to Sanofi.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">12.4</b></font><b style="font-size:12pt;font-weight:bold;">Infringement of Third Party Rights</b><font style="font-size:12pt;">. &#160;If any Licensed Product used or sold by Sanofi, its Affiliates, or Sublicensees becomes the subject of a Third Party&#8217;s claim or assertion of infringement of intellectual property rights in a jurisdiction within the Territory (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Third Party Infringement Claim</b><font style="font-size:12pt;">&#8221;), Sanofi shall promptly notify Adagene. &#160;The Parties shall discuss in good faith a mutually agreeable course of action, including but not limited to jointly defending, or taking other actions (including settling) with respect to, any such Third Party Infringement Claim. &#160;In the event that the Parties do not expediently decide upon a mutually agreeable course of action, Sanofi will have the first right, but not the obligation, to defend, and take other actions (including to settle), with respect to any such Third Party Infringement Claim, at Sanofi&#8217;s sole discretion, and Adagene will have the right to be represented in any such action by counsel of its own choice; provided that in no event will Sanofi settle any Third Party Infringement Claim without first obtaining the prior written consent of Adagene.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">13.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">REPRESENTATIONS AND WARRANTIES</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">13.1</b></font><b style="font-size:12pt;font-weight:bold;">Mutual Representations and Warranties</b><font style="font-size:12pt;white-space:pre-wrap;">.  Each Party represents and warrants to the other that, as of the Effective Date:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><font style="font-size:12pt;">it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">36</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><font style="font-size:12pt;">it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate or partnership action;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><font style="font-size:12pt;">this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument, or understanding, oral or written, to which it is a party or by which it may be bound, nor violate any material law or regulation of any court, governmental body, or administrative or other agency having jurisdiction over it; and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(d)</b></font><font style="font-size:12pt;">it has the right to grant the licenses granted by it under this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">13.2</b></font><b style="font-size:12pt;font-weight:bold;">Covenants</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Employees, Consultants, and Contractors</b><font style="font-size:12pt;">. &#160;Each Party covenants that it has obtained or will obtain written agreements from each of its employees, consultants, and contractors who perform Development activities pursuant to this Agreement, which agreements will obligate such persons to obligations of confidentiality and non-use and to assign (or, in the case of contractor, grant a license under) Inventions in a manner consistent with the provisions of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><font style="font-size:12pt;">Adagene will not during the Term grant to any Third Party any right under the Adagene Technology that would conflict with the rights granted to Sanofi hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-size:12pt;font-weight:bold;">Debarment</b><font style="font-size:12pt;">. &#160;Each Party represents, warrants, and covenants to the other Party that it is not debarred or disqualified under the U.S. Federal Food, Drug and Cosmetic Act, as may be amended, or comparable laws in any country or jurisdiction other than the U.S., and it does not, and will not during the Term, employ or use the services of any person who is debarred or disqualified, in connection with activities relating to any Licensed Product. &#160;In the event that either Party becomes aware of the debarment or disqualification or threatened debarment or disqualification of any person providing services to such Party, including the Party itself or its Affiliates or Sublicensees, that directly or indirectly relate to activities contemplated by this Agreement, such Party shall immediately notify the other Party in writing and such Party shall cease employing, contracting with, or retaining any such person to perform any such services.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-size:12pt;font-weight:bold;">Compliance</b><font style="font-size:12pt;">. &#160;In the performance of its obligations under this Agreement, such Party shall comply and shall cause its and its Affiliates&#8217; employees and contractors to comply with all Applicable Laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(e)</b></font><font style="display:inline-block;width:36pt;"></font><b style="font-size:12pt;font-weight:bold;">Adagene Patents Covering Additional Collaboration Targets.</b><font style="font-size:12pt;"> &#160;In the event that Sanofi exercises either its Option pursuant to Section 5.1, its Replacement Right pursuant to Section 6.1, or both, and Targets in addition to Target 1 and Target 2 become Collaboration Targets, the scope of the patent license agreement attached hereto in Exhibit B shall be extended to also cover the additional Collaboration Targets.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">13.3</b></font><b style="font-size:12pt;font-weight:bold;">Additional Adagene Representations and Warranties</b><font style="font-size:12pt;white-space:pre-wrap;">.  Adagene represents and warrants as of the Effective Date:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">37</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u><font style="font-size:12pt;"> lists all Adagene Patents as of the Effective Date and all such Patents listed on </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u><font style="font-size:12pt;"> are Controlled by Adagene, free of any encumbrance, lien, or claim of ownership by any Third Party, and (iii) filed and maintained properly and correctly and all applicable application and maintenance fees have been paid on or before the due date for payment or during any extension thereof. &#160;Evidence of Control of the Adagene Patents listed in Exhibit B by Adagene, by virtue of a patent license agreement by and between Adagene Inc. and Adagene Incorporated, is attached in Exhibit B.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><font style="font-size:12pt;">To Adagene&#8217;s knowledge, each of the Adagene Patents properly identifies each and every inventor of the claims thereof as determined in accordance with the laws of the jurisdiction in which such Patent is issued or such application is pending; to Adagene&#8217;s knowledge, all such inventors have assigned their entire right, title, and interest in and to such inventions to Adagene and all such assignments have been duly recorded and are enforceable in accordance with Applicable Law; and there are no written claims or assertions in writing received by Adagene regarding the inventorship of any Adagene Patent alleging that additional or alternative inventors should be listed.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><font style="font-size:12pt;">Adagene has the right to grant all rights and licenses it purports to grant to Sanofi with respect to the Adagene Technology under this Agreement, free and clear of any rights therein granted to any Third Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(d)</b></font><font style="font-size:12pt;">Adagene has not as of the Effective Date, granted to any Third Party any right under the Adagene Technology that would conflict with the rights granted to Sanofi hereunder.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(e)</b></font><font style="font-size:12pt;">(i) No claim or action has been brought or, to Adagene&#8217;s knowledge, threatened in writing, by any Third Party alleging that (A) the Adagene Patents are invalid or unenforceable, or (B) the use of the Adagene Know-How infringes or misappropriates, or would infringe or misappropriate, any intellectual property right of any Third Party, and (ii) to Adagene&#8217;s knowledge, no facts or circumstances exist that would reasonably be expected to give rise to any such claims described in subsection (i).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(f)</b></font><font style="font-size:12pt;">To Adagene&#8217;s knowledge, no Third Party is infringing or misappropriating or has infringed or misappropriated or is threatening to infringe or misappropriate the Adagene Technology.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(g)</b></font><font style="font-size:12pt;">The inventions claimed by the Adagene Patents (i)&#160;were not conceived, discovered, developed, or otherwise made in connection with any research activities funded, in whole or in part, by the federal government of the United States or any agency thereof and (ii)&#160;are not a &#8220;subject invention&#8221; as that term is described in 35 U.S.C. Section 201(e), and (iii) are not otherwise subject to the provisions of the Patent and Trademark Law Amendments Act of 1980, as amended, codified at 35 U.S.C. &#167;&#167; 200-212, as amended, as well as any regulations promulgated pursuant thereto, including in 37 C.F.R. part 401.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(h)</b></font><font style="font-size:12pt;">To Adagene&#8217;s knowledge, there are no issues or information related to the Adagene Technology, which in Adagene&#8217;s reasonable opinion, are reasonably likely to have a</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">38</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">material impact on the Development or Commercialization of the Licensed Compounds that have not been fully disclosed to Sanofi in the course of Sanofi&#8217;s due diligence.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">13.4</b></font><b style="font-size:12pt;font-weight:bold;">Additional Sanofi Representations and Warranties. &#160;</b><font style="font-size:12pt;">Sanofi represents and warrants as of the Effective Date:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><font style="font-size:12pt;">Sanofi has the right to grant all rights and licenses it purports to grant to Adagene with respect to the SUAs under this Agreement, free and clear of any rights therein granted to any Third Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">13.5</b></font><b style="font-size:12pt;font-weight:bold;">Disclaimer</b><font style="font-size:12pt;">. &#160;EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, WHETHER EXPRESS, IMPLIED, OR STATUTORY, INCLUDING WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR ARISING FROM A COURSE OF DEALING, USAGE, OR TRADE PRACTICES, IN ALL CASES WITH RESPECT THERETO. &#160;NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY, EITHER EXPRESS OR IMPLIED, THAT ANY OF THE DEVELOPMENT, MANUFACTURING, OR COMMERCIALIZATION EFFORTS WITH REGARD TO ANY PRODUCT WILL BE SUCCESSFUL.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">14.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">INDEMNIFICATION</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">14.1</b></font><b style="font-size:12pt;font-weight:bold;">Indemnification by Sanofi</b><font style="font-size:12pt;">. &#160;Sanofi hereby agrees to defend, indemnify, and hold harmless Adagene and its Affiliates and their respective directors, officers, employees, and agents (each, an &#8220;</font><b style="font-size:12pt;font-weight:bold;">Adagene Indemnitee</b><font style="font-size:12pt;">&#8221;) from and against any and all liabilities, expenses, and losses, including reasonable legal expenses and attorneys&#8217; fees (collectively, &#8220;</font><b style="font-size:12pt;font-weight:bold;">Losses</b><font style="font-size:12pt;">&#8221;), to which any Adagene Indemnitee may become subject as a result of any claim, demand, action, or other proceeding (each, a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Claim</b><font style="font-size:12pt;">&#8221;) by any Third Party to the extent such Losses arise out of:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><font style="font-size:12pt;">the Development, use, manufacture, or Commercialization of any Licensed Compound or Licensed Product by Sanofi or its Affiliates or Sublicensees or the contractors of any of them (excluding any activities by or on behalf of Adagene or its Affiliates);</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><font style="font-size:12pt;">the gross negligence or willful misconduct of any Sanofi Indemnitee; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><font style="font-size:12pt;">the breach by Sanofi of any warranty, representation, covenant, or agreement made by Sanofi in this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="font-size:12pt;">except, in each case (a)-(c), to the extent such Losses arise out of any activities for which Adagene is obligated to indemnify any Sanofi Indemnitee under Section 14.2.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">14.2</b></font><b style="font-size:12pt;font-weight:bold;">Indemnification by Adagene</b><font style="font-size:12pt;">. &#160;Adagene hereby agrees to defend, indemnify, and hold harmless Sanofi, its Affiliates, and Sublicensees and their respective directors, officers, employees, and agents (each, an &#8220;</font><b style="font-size:12pt;font-weight:bold;">Sanofi Indemnitee</b><font style="font-size:12pt;">&#8221;) from and against any and all Losses to which any Sanofi Indemnitee may become subject as a result of any Claim by any Third Party to the extent such Losses arise out of:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">39</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><font style="font-size:12pt;">the Compound Research Activities undertaken by any Adagene Indemnitee; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><font style="font-size:12pt;">the gross negligence or willful misconduct of any Adagene Indemnitee; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><font style="font-size:12pt;">the breach by Adagene of any warranty, representation, covenant, or agreement made by Adagene in this Agreement;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="font-size:12pt;">except, in the case of (a)-(b), to the extent such Losses arise out of any activities for which Sanofi is obligated to indemnify any Adagene Indemnitee under Section 14.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">14.3</b></font><b style="font-size:12pt;font-weight:bold;">Indemnification Conditions and Procedure</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Notice</b><font style="font-size:12pt;">. &#160;The Party claiming indemnity under this Article 14 (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Indemnified Party</b><font style="font-size:12pt;">&#8221;) shall give written notice to the Party from whom indemnity is being sought (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Indemnifying Party</b><font style="font-size:12pt;">&#8221;) promptly after learning of such Claim.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Control</b><font style="font-size:12pt;">. &#160;The Indemnified Party shall provide the Indemnifying Party with reasonable assistance, at the Indemnifying Party&#8217;s expense, in connection with the defense of the Claim for which indemnity is being sought. &#160;The Indemnified Party may participate in and monitor such defense with counsel of its own choice at its own expense; provided, however, that the Indemnifying Party shall have the right to control the defense of the Claim with counsel of its choice.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-size:12pt;font-weight:bold;">Settlement Rights</b><font style="font-size:12pt;">. &#160;The Indemnifying Party shall not settle any Claim without the prior written consent of the Indemnified Party, not to be unreasonably withheld, conditioned, or delayed, unless the settlement involves only the payment of money, no admission of wrong-doing or fault by the Indemnified Party, and no restriction on the future actions or activities of the Indemnified Party. &#160;So long as the Indemnifying Party is actively defending the Claim in good faith, the Indemnified Party shall not settle such Claim without the prior written consent of the Indemnifying Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-size:12pt;font-weight:bold;">Backup Right</b><font style="font-size:12pt;">. &#160;If the Indemnifying Party does not assume and conduct the defense of the Claim as provided above, (i) the Indemnified Party may defend against and consent to the entry of any judgment, or enter into any settlement with respect to, the Claim in any manner the Indemnified Party may deem reasonably appropriate (and the Indemnified Party need not consult with, or obtain any consent from, the Indemnifying Party in connection therewith so long as the settlement involves only the payment of money, no admission of wrong-doing or fault by the Indemnifying Party, and no restriction on the future actions or activities of the Indemnifying Party), and (ii) the Indemnifying Party will remain responsible to indemnify the Indemnified Party as provided in this Article 14.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">14.4</b></font><b style="font-size:12pt;font-weight:bold;">Insurance</b><font style="font-size:12pt;">. &#160;During the Term and for a period of </font><font style="font-size:12pt;">[***] </font><font style="font-size:12pt;">thereafter, each Party, at its own expense, shall maintain commercial general liability insurance, product liability and other appropriate insurance (or, in the case of Sanofi, self-insure) in an amount consistent with sound business practice and reasonable in light of its obligations under this Agreement. &#160;Without limiting the generality of the foregoing, Adagene represents, warrants, and covenants that it possesses and shall maintain during the Term and for </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> thereafter, at its own expense, commercial general</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">40</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">liability and other related insurances with limits not less than $</font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> per occurrence and $</font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> in the aggregate. &#160;Each Party shall provide a certificate of insurance (or evidence of self-insurance) evidencing such coverage to the other Party upon request.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">14.5</b></font><b style="font-size:12pt;font-weight:bold;">Limitation of Liability</b><font style="font-size:12pt;">. &#160;EXCEPT FOR DAMAGES THAT (A) ARISE IN CONNECTION WITH A PARTY&#8217;S (I) WILLFUL MISCONDUCT OR FRAUD OR (II) BREACH OF ITS OBLIGATIONS UNDER ARTICLE 15, OR (B) ARE SUBJECT TO INDEMNIFICATION UNDER SECTION 14.1 OR 14.2, OR INSURANCE OBLIGATIONS UNDER SECTION 14.4, NEITHER PARTY SHALL BE LIABLE IN CONTRACT, TORT, NEGLIGENCE, BREACH OF STATUTORY DUTY, OR OTHERWISE FOR ANY SPECIAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OR FOR LOSS OF PROFITS SUFFERED BY THE OTHER PARTY (OR ITS AFFILIATES OR (SUB)LICENSEES), REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">15.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">CONFIDENTIALITY</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">15.1</b></font><b style="font-size:12pt;font-weight:bold;">Confidential Information</b><font style="font-size:12pt;">. &#160;Except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties, the Parties agree that, during the Term and for </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> thereafter, the receiving Party shall keep confidential and shall not publish or otherwise disclose, and shall not use for any purpose other than as expressly provided for in this Agreement, any Confidential Information of the other Party</font><font style="font-size:12pt;">, and both</font><font style="font-size:12pt;"> Parties shall keep confidential and shall not publish or otherwise disclose</font><font style="font-size:12pt;"> the terms of this Agreement except as permitted herein</font><font style="font-size:12pt;">. &#160;Each Party may use the other Party&#8217;s Confidential Information only to the extent required to accomplish the purposes of this Agreement, including exercising its rights and performing its obligations under this Agreement. &#160;Each Party will use at least the same standard of care as it uses to protect proprietary or confidential information of its own (but no less than reasonable care) to ensure that its employees, agents, consultants, contractors, and other representatives do not disclose or make any unauthorized use of the other Party&#8217;s Confidential Information. &#160;Each Party will promptly notify the other upon discovery of any loss or unauthorized use or disclosure of the other Party&#8217;s Confidential Information.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">15.2</b></font><b style="font-size:12pt;font-weight:bold;">Exceptions</b><font style="font-size:12pt;">. &#160;The obligations of confidentiality and restriction on use under Section 15.1 will not apply to any information that the receiving Party can prove by competent written evidence: (a)&#160;is now, or hereafter becomes, through no act or failure to act on the part of the receiving Party, generally known or available to the public; (b)&#160;is known by the receiving Party at the time of receiving such information, as evidenced by written records, other than by previous disclosure of the disclosing Party, or its Affiliates, employees, agents, consultants, or contractors, without any obligation to the disclosing Party to keep it confidential or restrict its use; (c)&#160;is hereafter furnished to the receiving Party without restriction by a Third Party who has no obligation of confidentiality or limitations on use with respect thereto, as a matter of right; or (d)&#160;is independently discovered or developed by or for the receiving Party without the use of the disclosing Party&#8217;s Confidential Information.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">15.3</b></font><b style="font-size:12pt;font-weight:bold;">Authorized Disclosure</b><font style="font-size:12pt;">. &#160;Each Party may disclose Confidential Information belonging to the other Party as expressly permitted by this Agreement or if and to the extent such disclosure is reasonably necessary in the following instances:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">41</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><font style="font-size:12pt;">complying with Applicable Laws or regulations (including regulations promulgated by securities exchanges, subject to Section 15.5) or court or administrative orders;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><font style="font-size:12pt;">disclose to actual or bona fide potential investors or acquirors solely for the purpose of evaluating or carrying out an actual or potential investment or acquisition, in each case under a written agreement containing obligations of confidentiality in accordance with market standard;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><font style="font-size:12pt;">disclosure to its advisors (including attorneys and accountants) in connection with activities under this Agreement; provided that prior to any such disclosure, each such disclosee will be bound by written obligations of confidentiality, non-disclosure and non-use no less restrictive than the obligations set forth in this Article&#160;15 (Confidentiality) (provided, however, that in the case of legal advisors, no written agreement will be required); and provided, further, that the receiving Party will remain responsible for any failure by any such disclosee to treat such Confidential Information as required under this Article&#160;15 (Confidentiality); and</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(d)</b></font><font style="font-size:12pt;">(i) disclosure to any of the receiving Party&#8217;s and its Affiliates&#8217; employees, consultants, contractors, agents, in each case on a need-to-know basis in connection with the Development, manufacture, or Commercialization of the Licensed Products in accordance with the terms of this Agreement, or (ii) in the case of Sanofi, as the receiving Party, to any actual or potential collaborators, partners, licensees, Sublicensees or subcontractors, in each case on a need-to-know basis, in connection with the Development, manufacture or Commercialization of Licensed Compounds or Licensed Products or otherwise to the extent necessary or useful for Sanofi to exercise its rights or perform its obligations hereunder; provided that, in each case ((i) and (ii)), prior to any such disclosure, each disclosee shall be bound by written obligations of confidentiality, nondisclosure and non-use at least as stringent as those herein; and provided, further, that the receiving Party will remain responsible for any failure by any such disclosee to treat such Confidential Information as required under this Article&#160;15 (Confidentiality); by Sanofi, as the receiving Party, to a Regulatory Authority, as reasonably required or useful in connection with any filing, submission or communication with respect to any Licensed Compound or Licensed Product; provided that reasonable measures will be taken to obtain confidential treatment of such information, to the extent such protection is available;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(e)</b></font><font style="font-size:12pt;">upon the prior written consent of the other Party, such consent to be unreasonably withheld or delayed, if and to the extent such disclosure is reasonably necessary for: (i) filing, prosecuting, or maintaining Patents as permitted by this Agreement; and (ii) prosecuting or defending litigation as permitted by this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Notwithstanding the foregoing, the Parties shall use good faith efforts to agree on a redacted version of this Agreement within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> following the Effective Date, it being understood that no consent shall be required for a disclosure of such agreed redacted version pursuant to this Section 15.3(d).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Notwithstanding the foregoing, in the event that a Party is required to make a disclosure of the other Party&#8217;s Confidential Information pursuant to Section&#160; </font><font style="font-size:12pt;">15.3(a), it will, except where impracticable, give reasonable advance notice to the other Party of such disclosure and use efforts to secure confidential treatment of such </font><font style="font-size:12pt;">Confidential Information</font><font style="font-size:12pt;"> at least as diligent as such Party</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">42</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">would use to protect its own </font><font style="font-size:12pt;">c</font><font style="font-size:12pt;">onfidential </font><font style="font-size:12pt;">i</font><font style="font-size:12pt;">nformation, but in no event less than reasonable efforts. &#160;In any event, the Parties agree to take all reasonable action to avoid disclosure of Confidential Information hereunder. &#160;Any information disclosed pursuant to Section </font><font style="font-size:12pt;">15.3</font><font style="font-size:12pt;"> shall remain Confidential Information and subject to the restrictions set forth in this Agreement, including the foregoing provisions of this Article 15.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">15.4</b></font><b style="font-size:12pt;font-weight:bold;">Publications</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Regarding Adagene Platform Technology</b><font style="font-size:12pt;">. &#160;Adagene shall have the sole right, in its sole discretion, to publish or otherwise disclose any information regarding the Adagene Platform Technology or any improvements thereto; provided that in no event shall Adagene disclose any Confidential Information of Sanofi in violation of Section 15.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Collaboration Targets</b><font style="font-size:12pt;">. &#160;Sanofi shall have the sole right, in its sole discretion, to publish or otherwise disclose the results of or other information regarding any and all research and Development activities performed hereunder with respect to the Licensed Products, including all Compound Research Activities for each Collaboration Target; provided that in no event shall Sanofi disclose any Confidential Information of Adagene in violation of Section 15.1.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">15.5</b></font><b style="font-size:12pt;font-weight:bold;">Publicity; Public Disclosures</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Initial Press Release</b><font style="font-size:12pt;">. Each Party shall have the right to issue an individual press release substantially in a form agreed by the Parties and attached to this Agreement as </font><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;D</u><font style="font-size:12pt;"> announcing the signature of this Agreement at or shortly after the Effective Date within the time-period required by applicable securities laws.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Subsequent Releases</b><font style="font-size:12pt;">. &#160;If a Party wishes to release any subsequent press release or other public statement or announcement about the terms of this Agreement, the Parties&#8217; relationship under this Agreement, performance of this Agreement, or activities conducted under this Agreement (each, a &#8220;</font><b style="font-size:12pt;font-weight:bold;">Release</b><font style="font-size:12pt;">&#8221;), such Party shall first obtain the other Party&#8217;s written approval of the proposed Release. &#160;The reviewing Party will have </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">, or such shorter period of time as agreed by the Parties or necessary for the releasing Party to comply with Applicable Law, to review and provide comments to such Release and the reviewing Party&#8217;s consent of such approval shall not be unreasonably withheld. &#160; Notwithstanding the foregoing, a Party does not need to obtain the other Party&#8217;s approval for a Release to the extent such Release discloses text that has been previously approved by the other Party, but only to the extent the underlying facts disclosed in such previously approved text are still true and accurate, and where the circumstances surrounding such disclosure have not changed. &#160;With regard to any such Release containing previously approved information, the Party wishing to make such release shall provide the other Party a courtesy review of such Release and shall take into account in good faith any comments made by such Party. &#160;This shall not apply for investor slide decks for which a courtesy review of previously approved text is not required.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-size:12pt;font-weight:bold;">SEC Disclosures</b><font style="font-size:12pt;">. &#160;With respect to complying with disclosure requirements of the SEC or other stock exchange on which a Party&#8217;s securities are publicly traded (or to which an application for listing has been submitted) (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Exchange</b><font style="font-size:12pt;">&#8221;) in connection with any required filing</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">43</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">of this Agreement, the filing Party will consult with the other Party on the provisions of this Agreement to be redacted in any filings made by such Party with the SEC or other Exchange; provided that each Party shall have the right to make any such filing as it reasonably determines necessary under Applicable Laws and will not rely on any statements made by the other Party related to securities laws or regulations. &#160;The reviewing Party will have </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">, or such shorter period of time as agreed by the Parties or necessary for the filing Party to comply with Applicable Law, to review and provide comments to such filing and the reviewing Party&#8217;s consent of such approval shall not be unreasonably withheld to the extent such information has been previously disclosed. &#160;If, on the advice of counsel, Adagene reasonably concludes that it must make a Release, or that any portion of this Agreement must be disclosed, in each case pursuant to the requirements of the SEC or other Exchange, and Sanofi would prefer that such Release not be made, that the information so disclosed within such Release be modified or limited, or that disclosure of the Agreement be limited, then Adagene shall consider Sanofi&#8217;s concerns, including possibilities of incorporating statements suggested by Sanofi (to the extent any such statement is true and accurate) and seeking confidential treatment of the information included in such Release.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">15.6</b></font><b style="font-size:12pt;font-weight:bold;">Equitable Relief</b><font style="font-size:12pt;">. &#160;Given the nature of the Confidential Information and the competitive damage that a Party would suffer upon unauthorized disclosure, use, or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages may not be a sufficient remedy for any breach of this Article 15. &#160;In addition to all other remedies, a Party shall be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Article 15.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">16.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">TERM AND TERMINATION</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">16.1</b></font><b style="font-size:12pt;font-weight:bold;">Term</b><font style="font-size:12pt;">. &#160;This Agreement shall commence on the Effective Date and, unless terminated earlier as provided in this Article 16 or by mutual written agreement of the Parties, shall continue in effect, on a Licensed Product-by-Licensed Product and country-by-country basis, until the expiration of the Royalty Term for such Licensed Product in such country (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Term</b><font style="font-size:12pt;">&#8221;). &#160;Upon the expiration of the Royalty Term for a particular Licensed Product in a particular country, the license granted to Sanofi in Section 2.1 with respect to such Licensed Product in such country shall be deemed fully-paid, royalty-free, perpetual, and irrevocable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">16.2</b></font><b style="font-size:12pt;font-weight:bold;">Termination for Cause</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Material Breach</b><font style="font-size:12pt;">. &#160;Each Party shall have the right to terminate this Agreement immediately in its entirety upon written notice to the other Party if such other Party materially breaches this Agreement, such material breach to include a failure of either Party to comply with its diligence obligations under this Agreement, and has not cured such breach to the reasonable satisfaction of the other Party within </font><font style="font-size:12pt;">[***] </font><font style="font-size:12pt;">(</font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> with respect to any payment breach) after notice of such breach from the non-breaching Party or (if such cure cannot be fully achieved within such </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> period) if the breaching Party has failed to dispute, commence compliance or has failed to use diligent efforts to achieve full cure of such material breach as soon thereafter as is reasonably possible &#160;(which notice will describe such material breach in reasonable detail and will state the non-breaching Party&#8217;s intention to terminate this Agreement, in its entirety or in part) (such </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> period, as may be extended in the case of diligent efforts to achieve full cure, or by mutual agreement by the Parties (the &#8220;Cure Period&#8221;). &#160;Further, if such material breach relates solely</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">44</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">to one Collaboration Target under the Agreement (but not to the other Collaboration Targets), then the terminating Party shall have the right to terminate this Agreement pursuant to this Section 16.2(a) solely with respect to the Collaboration Target as to which such material breach relates.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Termination by Sanofi for Safety</b><font style="font-size:12pt;">. &#160;Sanofi will have the right to terminate this Agreement on an Collaboration Target-by-Collaboration Target basis, upon </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> prior written notice to Adagene, due to material safety concerns raised by a Regulatory Authority, an Institutional Review Board for a Clinical Trial or by Sanofi&#8217;s Safety Reviewer(s) acting in accordance with Sanofi&#8217;s standard internal policies, where such Person recommends cessation of Development or Commercialization of the applicable Licensed Product(s) (and a summary of such concerns will be stated in the notice of termination).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-size:12pt;font-weight:bold;">Bankruptcy</b><font style="font-size:12pt;">. &#160;Each Party shall have the right to terminate this Agreement immediately in its entirety upon written notice to the other Party if such other Party makes a general assignment for the benefit of creditors, files an insolvency petition in bankruptcy, petitions for or acquiesces in the appointment of any receiver, trustee, or similar officer to liquidate or conserve its business or any substantial part of its assets, commences under the laws of any jurisdiction any proceeding involving its insolvency, bankruptcy, reorganization, adjustment of debt, dissolution, liquidation, or any other similar proceeding for the release of financially distressed debtors or becomes a party to any proceeding or action of the type described above and such proceeding is not dismissed within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">after the commencement thereof, or admits in writing its inability generally to meet its obligations as they fall due in the general course.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(d)</b></font><b style="font-size:12pt;font-weight:bold;">Section 365(n) Rights</b><font style="font-size:12pt;">. &#160;For purposes of Section&#160;365(n) of the U.S. Bankruptcy Code (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Code</b><font style="font-size:12pt;">&#8221;) and any similar laws in any other country, all rights and licenses granted under or pursuant to any Section of this Agreement are rights to &#8220;intellectual property&#8221; (as defined in Section&#160;101(35A) of the Code). &#160;The Parties agree that the licensee of such rights under this Agreement will retain and may fully exercise all of its protections, rights and elections under the Code and any similar laws in any other country. &#160;Each Party hereby acknowledges that copies of research data, laboratory samples, product samples and inventory, formulas, laboratory notes and notebooks, pre-clinical research data and results, tangible Know-How, letters of authorization in connection with Rights of Reference, &#160;in each case that relate to such intellectual property, constitute &#8220;embodiments&#8221; of such intellectual property pursuant to Section&#160;365(n) of the Code, and that the licensee will be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, and the same, if not already in its possession, will be promptly delivered to it upon its written request therefor and election under Bankruptcy Code Section&#160;365(n)(1)(B) to retain the licenses granted by Adagene to Sanofi. &#160;The provisions of this Section 16.2(c) (Section 365(n) Rights) are without prejudice to any rights the non-subject Party may have arising under the Code, laws of other jurisdictions governing insolvency and bankruptcy or other Applicable Law.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">16.3</b></font><b style="font-size:12pt;font-weight:bold;">Termination without Cause by Sanofi</b><font style="font-size:12pt;">. &#160;Sanofi shall have the right to terminate this Agreement in its entirety or on Collaboration Target-by-Collaboration Target or country-by-country basis at any time, without cause, upon </font><font style="font-size:12pt;">[***] </font><font style="font-size:12pt;">written notice to Adagene.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">16.4</b></font><b style="font-size:12pt;font-weight:bold;">Effects of Termination</b><font style="font-size:12pt;">. &#160;Upon termination or expiration of this Agreement in its entirety or with respect to a particular Collaboration Target, all rights and obligations of the Parties</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">45</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">under this Agreement with respect to this Agreement or such Collaboration Target shall cease except as otherwise set forth in this Section 16.4 or elsewhere in this Agreement, but, for clarity, termination or expiration with respect to a particular Collaboration Target shall not affect the Parties&#8217; rights and obligations under this Agreement with respect to any other Collaboration Targets. &#160;Upon any termination of this Agreement in its entirety by either Party, the following terms will apply. &#160;Upon any termination of this Agreement with respect to a particular Collaboration Target, the following terms will apply solely with respect to such terminated Collaboration Target.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><b style="font-size:12pt;font-weight:bold;">Licenses</b><font style="font-size:12pt;">. &#160;All licenses granted by either Party will automatically terminate.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><b style="font-size:12pt;font-weight:bold;">Return of Sanofi Property</b><font style="font-size:12pt;">. &#160;In case of termination by Sanofi pursuant to Section 16.2(a) Adagene shall return to Sanofi all of Sanofi&#8217; Confidential Information and shall deliver to Sanofi, or destroy at Sanofi&#8217;s request, the Compound Inventions (in each case to the extent not already provided) and any other deliverables specified in the Target Program Plan (in whatever stage of development or completion).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><b style="font-size:12pt;font-weight:bold;"> Confidential Information</b><font style="font-size:12pt;">. &#160;Upon expiration or termination of this Agreement in its entirety, each Party shall promptly return to the other Party, or delete or destroy, all relevant records and materials in such Party&#8217;s possession or control containing Confidential Information of the other Party; provided that (a) a Party may keep one copy of such materials for legal archival purposes subject to continuing confidentiality obligations, and (b) Adagene may keep all Confidential Information required by Adagene under Section 16.4(c).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">16.5</b></font><b style="font-size:12pt;font-weight:bold;">Survival</b><font style="font-size:12pt;">. &#160;Expiration or termination of this Agreement shall not relieve the Parties of any obligation or right accruing prior to such expiration or termination. &#160;Except as set forth below or elsewhere in this Agreement, the obligations and rights of the Parties under the following provisions of this Agreement shall survive expiration or termination of this Agreement: Article&#160;1 (Definitions), Section&#160;12.1 (IP Ownership), Article&#160;14 (Indemnification), Article&#160;15 (Confidentiality), Section&#160;16.4 (Effects of Termination), Article&#160;17 (Dispute Resolution) and Article&#160;18 (General Provisions). &#160;In the event that this Agreement is terminated pursuant to Section 16.2 or Section 16.3, the provisions of Article 10 (Financial Provisions) shall survive.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">17</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">DISPUTE RESOLUTION</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">17.1</b></font><b style="font-size:12pt;font-weight:bold;"> Objective</b><font style="font-size:12pt;">. &#160;It is the objective of the Parties to establish procedures to facilitate the resolution of any disputes arising under or related to this Agreement in an expedient manner by mutual cooperation and without resort to litigation. &#160;To accomplish this objective, the Parties agree to follow the procedures set forth in this Article&#160;17 to resolve any such dispute if and when it arises.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">17.2</b></font><b style="font-size:12pt;font-weight:bold;"> Executive Negotiations</b><font style="font-size:12pt;">. &#160;The Parties will try to settle any dispute, controversy, or claim that arises out of, or relates to, any provision of the Agreement (&#8220;Disputed Matter&#8221;) by first referring the Disputed Matter to the Parties&#8217; Executive Officers. &#160;Either Party may initiate such informal dispute resolution by sending written notice of the Disputed Matter to the other Party, and, within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> after such notice, the Executive Officers (or their respective designees having the authority to settle such Disputed Matter) of the Parties will meet for attempted resolution by good faith negotiations. &#160;If the Executive Officers (or their respective designees) are unable to</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">46</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">resolve such dispute within </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> after their first meeting for such negotiations, either Party may seek to have such dispute resolved in accordance with Section 17.3 below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:21pt;text-align:justify;text-indent:-21pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">17.3</b></font><font style="display:inline-block;width:36pt;"></font><b style="font-size:12pt;font-weight:bold;">Dispute Resolution</b><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><font style="font-size:12pt;">If the Parties are unable to resolve a Disputed Matter using the process described in Section 17.2, then a Party seeking further resolution of the Disputed Matter (other than an Excluded Claim) shall submit the Disputed Matter to resolution by final and binding arbitration. &#160;Whenever a Party determines to institute arbitration proceedings, it will give written notice to that effect to the other Party. &#160;The legal seat of arbitration will be New York, New York, U.S., and the arbitration will be administered by the Judicial Arbitration and Mediation Services (&#8220;JAMS&#8221;) pursuant to either its (i) Streamlined Arbitration Rules then in effect, provided that no claim or counter-claim exceeds </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;"> dollars (US $</font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">), or (ii) the Comprehensive Arbitration Rules and Procedures then in effect and the Expedited Procedures contained therein (the &#8220;</font><b style="font-size:12pt;font-weight:bold;">Rules</b><font style="font-size:12pt;">&#8221;), except as otherwise provided herein and applying the substantive law specified in Section 18.1. &#160;The arbitration will be conducted by three arbitrators appointed in accordance with the Rules, provided that such arbitrators must have significant business or legal experience in the pharmaceutical business. &#160;After conducting any hearing and taking any evidence deemed appropriate for consideration, the arbitrators will render their opinion within thirty (30) days after the final arbitration hearing. &#160;The arbitrators will not have the power to award damages excluded pursuant to Section 14.5 under this Agreement and any arbitral award that purports to award such damages is expressly prohibited and void </font><i style="font-size:12pt;font-style:italic;">ab initio</i><font style="font-size:12pt;">. &#160;Decisions of the arbitrators that conform to the terms of this Section 17.3 will be final and binding on the Parties and judgment on the award so rendered may be entered in any court of competent jurisdiction and the Parties undertake to carry out any award without delay. &#160;The losing Party, as determined by the arbitrators, will pay all of the JAMS administrative costs and fees of the arbitration and the fees and costs of the arbitrators, and the arbitrators will be directed to provide for payment or reimbursement of such fees and costs by the losing Party. &#160;If the arbitrators determine that there is no losing Party, the Parties will each be responsible for one-half of those costs and fees and the arbitrator&#8217;s award will so provide. &#160;Notwithstanding the foregoing, each Party shall be responsible for its own attorneys&#8217; fees, expert or witness fees, and any other fees and costs, and no such fees or costs will be shifted to the other Party, unless the arbitrators determine that a Party has incurred unreasonable expenses due to vexatious or bad faith positions taken by the other Party, in which event the arbitrators may make an award of all or any portion of such expenses (including legal fees and expenses) so incurred.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><font style="font-size:12pt;">Notwithstanding the terms of and procedures set forth in Section&#160;17.2 or 17.3, any applications, motions, or orders to show cause seeking temporary restraining orders, preliminary injunctions or other similar preliminary or temporary legal or equitable relief (&#8220;</font><b style="font-size:12pt;font-weight:bold;">Injunctive Relief</b><font style="font-size:12pt;">&#8221;) concerning a Disputed Matter (including, but not limited to, Disputed Matters arising out of a potential or actual breach of the confidentiality and non-use provisions in Article 15) may immediately be brought in the first instance and without invocation or exhaustion of the procedures set forth in Section 17.2 or 17.3(a) for hearing and resolution in and by a court of competent jurisdiction. &#160;Alternatively, a party seeking Injunctive Relief may immediately institute arbitral proceedings without invocation or exhaustion of the procedures set forth in Section 17.2 or 17.3(a), and any such Injunctive Relief proceedings will be administered by the ICC pursuant to its emergency arbitration procedures then in effect and applying the substantive law specified in Section 18.1. &#160;In either event, once the Injunctive Relief proceedings</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">47</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">have been conducted and a decision rendered thereon by the court or arbitral forum, the Parties will, if the Disputed Matter is not finally resolved by the Injunctive Relief, proceed to resolve the Disputed Matter in accordance with the terms of Section 17.2 and 17.3(a). &#160;This Section shall be specifically enforceable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(c)</b></font><font style="font-size:12pt;">Except to the extent necessary to confirm, enforce, or challenge an award of the arbitration, to protect or pursue a legal right, or as otherwise required by Applicable Law, neither Party nor the arbitrator may disclose the existence, content, or results of an arbitration under this Section 17.3 without the express, prior written consent of both Parties. &#160;In no event shall an arbitration be initiated after the date when commencement of a legal or equitable proceeding based on the dispute, controversy, or claim would be barred by the applicable New York statute of limitations. &#160;Any disputes concerning the propriety of the commencement of the arbitration, or the validity, or application of this Section 17.3 shall be finally settled by the arbitrator.</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:21pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">18</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><b style="font-size:12pt;font-weight:bold;">GENERAL PROVISIONS</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">18.1</b></font><b style="font-size:12pt;font-weight:bold;">Governing Law</b><font style="font-size:12pt;">. &#160;This Agreement, and all questions regarding the existence, validity, interpretation, breach, or performance of this Agreement, shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, United States, without reference to its conflicts of law principles.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">18.2</b></font><b style="font-size:12pt;font-weight:bold;">Entire Agreement; Modification</b><font style="font-size:12pt;">. &#160;This Agreement, including the Exhibits, is both a final expression of the Parties&#8217; agreement and a complete and exclusive statement with respect to all of its terms. &#160;This Agreement supersedes all prior and contemporaneous agreements and communications, whether oral, written, or otherwise, concerning any and all matters contained herein, including the Confidentiality Agreement. &#160;This Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by an authorized representative of each Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">18.3</b></font><b style="font-size:12pt;font-weight:bold;">Relationship Between the Parties</b><font style="font-size:12pt;">. &#160;The Parties&#8217; relationship, as established by this Agreement, is solely that of independent contractors. &#160;This Agreement does not create any partnership, joint venture, or similar business relationship between the Parties. &#160;Neither Party is a legal representative of the other Party, and neither Party can assume or create any obligation, representation, warranty, or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">18.4</b></font><b style="font-size:12pt;font-weight:bold;">Performance by Affiliates</b><font style="font-size:12pt;">. &#160;Sanofi may discharge any obligations and exercise any right hereunder through any of its Affiliates. &#160;Sanofi hereby guarantees the performance by its Affiliates of its obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">18.5</b></font><b style="font-size:12pt;font-weight:bold;">Waiver</b><font style="font-size:12pt;">. &#160;The waiver by either Party of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise. &#160; Any waiver by a Party of a particular term or condition will be effective only if set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">48</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">18.6</b></font><b style="font-size:12pt;font-weight:bold;">Assignment</b><font style="font-size:12pt;">. &#160;Except as expressly provided hereunder, neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld). &#160;The Parties may assign or otherwise transfer this Agreement and its rights and obligations hereunder without the other Party&#8217;s consent as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(a)</b></font><font style="font-size:12pt;">by either Party in connection with the transfer or sale of all or substantially all of the business or assets relating to this Agreement to a Third Party, whether by merger, consolidation, divesture, restructure, sale of stock, sale of assets, or otherwise, provided that in the event of any such transaction (whether this Agreement is actually assigned or is assumed by the acquiring party by operation of law (e.g., in the context of a reverse triangular merger)), intellectual property rights of the acquiring party to such transaction shall not be included in the technology licensed or assigned hereunder unless used by such acquiring party to Develop, use, make, or sell any Licensed Compound or Licensed Product; or</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:72pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">(b)</b></font><font style="font-size:12pt;">by either Party, to an Affiliate, provided that if the entity to which this Agreement is assigned ceases to be an Affiliate of the assigning Party, the Agreement shall be automatically assigned back to the assigning Party or its successor.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties specified above, and the name of a Party appearing herein will be deemed to include the name of such Party&#8217;s successors and permitted assigns to the extent necessary to carry out the intent of this Section 18.6. &#160;Any assignment not in accordance with this Section 18.6 shall be null and void and of no legal force or effect.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">18.7</b></font><b style="font-size:12pt;font-weight:bold;">Severability</b><font style="font-size:12pt;">. &#160;If, for any reason, any part of this Agreement is adjudicated invalid, unenforceable, or illegal by a court of competent jurisdiction, such adjudication shall not affect or impair, in whole or in part, the validity, enforceability, or legality of any remaining portions of this Agreement. &#160;The Parties will in such an instance use their best efforts to replace the invalid, unenforceable, or illegal provision(s) with a valid, enforceable, and legal provision(s) that best implements the original intent of the Parties and purposes of this Agreement.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">18.8</b></font><b style="font-size:12pt;font-weight:bold;">Notices</b><font style="font-size:12pt;">. &#160;Any notice to be given under this Agreement must be in writing and delivered either (a) in person or (b) by (i) air mail (postage prepaid) requiring return receipt, (ii) recognized overnight courier, or (iii) facsimile, in each case to the Party to be notified at its address given below, or at any other address such Party may designate by prior written notice to the other in accordance with this Section 18.8. &#160;Notice shall be deemed sufficiently given for all purposes upon the earliest of: &#160;(w)&#160;if personally delivered, the date of actual receipt; (x)&#160;if air mailed, five (5) days after the date of postmark; (y)&#160;if delivered by overnight courier, the next day the overnight courier regularly makes deliveries; or (z) if sent by facsimile, the date of confirmation of receipt if during the recipient</font><font style="font-size:12pt;">&#8217;</font><font style="font-size:12pt;">s normal business hours, otherwise the next business day.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:72pt;text-align:justify;text-indent:-72pt;margin:0pt 0pt 12pt 36pt;"><font style="font-size:12pt;">If to Adagene, notices must be addressed to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"><font style="font-size:12pt;">Adagene, Inc.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"><font style="font-size:12pt;">10179 Huennekens St</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">49</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"><font style="font-size:12pt;">San Diego, CA 92121</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"><font style="font-size:12pt;">United States of America</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"><font style="font-size:12pt;">Attention: </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">, SVP of Operations</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">@adagene.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"><font style="font-size:12pt;">With a copy to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"><font style="font-size:12pt;">Adagene, Inc.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"><font style="font-size:12pt;">10179 Huennekens St</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"><font style="font-size:12pt;">San Diego, CA 92121</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"><font style="font-size:12pt;">United States of America</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"><font style="font-size:12pt;">Attention: </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">, Head of Business Development</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">@adagene.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">If to Sanofi, notices must be addressed to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">Genzyme Corporation</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">50 Binney Street</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">Cambridge, MA 02142</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">United States of America</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">Attention: Head of Global Alliance Management</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">Email: alliance.management@sanofi.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">with a copy to:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">Genzyme Corporation</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">50 Binney Street</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">Cambridge, MA 02142</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">United States of America</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;">Attn: </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">, Head of Legal Global Functions</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:12pt;">Email: (to each of the following): </font><font style="font-size:12pt;">[***]</font><font style="font-size:12pt;">@sanofi.com; and [***]@sanofi.com.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">18.9</b></font><b style="font-size:12pt;font-weight:bold;">Force Majeure</b><font style="font-size:12pt;">. &#160;Each Party shall be excused from liability for the failure or delay in performance of any obligation under this Agreement by reason of any event beyond such Party&#8217;s reasonable control, including Acts of God, fire, flood, explosion, earthquake</font><font style="font-size:12pt;">, pandemic </font><font style="font-size:12pt;">, or other natural forces, war, civil unrest, acts of terrorism, accident, destruction, or other casualty, any lack or failure of transportation facilities, any lack or failure of supply of raw materials, or any other event similar to those enumerated above. &#160;Such excuse from liability shall be effective to the extent and duration of the event(s) causing the failure or delay in performance and provided that the Party has not caused such event(s) to occur. &#160;Notice of a Party&#8217;s failure or delay in performance due to force majeure must be given to the other Party as soon as reasonably practicable after its occurrence. &#160;All delivery dates under this Agreement that have been affected by force majeure shall be tolled for the duration of such force majeure.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">18.10</b></font><b style="font-size:12pt;font-weight:bold;">Interpretation</b><font style="font-size:12pt;">. &#160;The headings of clauses contained in this Agreement preceding the text of the sections, subsections, and paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">50</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">interpretation or construction. &#160;All references in this Agreement to the singular shall include the plural where applicable. &#160;Unless otherwise specified, references in this Agreement to any Article shall include all Sections, subsections, and paragraphs in such Article, references to any Section shall include all subsections and paragraphs in such Section, and references in this Agreement to any subsection shall include all paragraphs in such subsection. &#160;The word &#8220;including&#8221; and similar words means including without limitation. &#160; &#160;The words &#8220;herein&#8221;, &#8220;hereof&#8221;, and &#8220;hereunder&#8221; and other words of similar import refer to this Agreement as a whole and not to any particular Section or other subdivision. &#160;All references to days in this Agreement mean calendar days, unless otherwise specified. &#160;Ambiguities and uncertainties in this Agreement, if any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. &#160;This Agreement has been prepared in the English language and the English language shall control its interpretation. &#160;In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications between the Parties regarding this Agreement shall be in the English language.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">18.11</b></font><b style="font-size:12pt;font-weight:bold;">Counterparts; Electronic or Facsimile Signatures</b><font style="font-size:12pt;">. &#160;This Agreement may be executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. &#160;This Agreement may be executed and delivered electronically or by PDF or facsimile and, upon such delivery, such electronic or PDF or facsimile signature will be deemed to have the same effect as if the original signature had been delivered to the other Party.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">{SIGNATURE PAGE FOLLOWS}</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">51</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:37.45pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">IN WITNESS WHEREOF,</b><font style="font-size:12pt;"> the Parties hereto have caused this </font><b style="font-size:12pt;font-weight:bold;">COLLABORATION AND LICENSE AGREEMENT</b><font style="font-size:12pt;"> to be executed and entered into by their duly authorized representatives as of the Effective Date.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:101%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:40.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:6.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:43.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">GENZYME CORPORATION</b><font style="font-size:12pt;"> </font></p></td><td colspan="2" style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ADAGENE, INC.</b><font style="font-size:12pt;"> </font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="3" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:49.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By: </font></p></td><td style="vertical-align:bottom;width:40.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Valeria Fantin</font></p></td><td style="vertical-align:bottom;width:2.14%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.51%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">By: </font></p></td><td style="vertical-align:bottom;width:43.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">/s/ Peter Luo</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40.26%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.48%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name: </font></p></td><td style="vertical-align:bottom;width:40.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Valeria Fantin</font></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Name:</font></p></td><td style="vertical-align:bottom;width:43.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Peter Luo</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:40.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:43.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:7.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title: </font></p></td><td style="vertical-align:bottom;width:40.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Head of Oncology Research</font></p></td><td style="vertical-align:bottom;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Title: </font></p></td><td style="vertical-align:bottom;width:43.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">CEO</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;">52</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">List of Exhibits:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit A: Adagene Know-How</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit B: Adagene Patents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit C: Target Research Plans for Initial Targets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit D: Press Release</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ADAGENE KNOW-HOW</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">[***]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Adagene Patents and Adagene Platform Patents</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[***]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">1 - Target Research Plans for Initial Targets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[***]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">2 - Criteria for masked compounds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[***]</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit D</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Press Release</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;">[***]</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>3
<FILENAME>adag-20211231xex8d1.htm
<DESCRIPTION>EXHIBIT 8.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/26/2022 12:39:10 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 8.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">List of Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:49.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:49.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Subsidiaries</b></p></td><td style="vertical-align:bottom;width:1.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:49.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Place&#160;of&#160;Incorporation</b></p></td></tr><tr><td style="vertical-align:top;width:49.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49.18%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:49.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adagene (Hong Kong) Limited</p></td><td style="vertical-align:top;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Hong Kong</p></td></tr><tr><td style="vertical-align:top;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:49.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adagene (Suzhou) Limited</p></td><td style="vertical-align:top;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PRC</p></td></tr><tr><td style="vertical-align:top;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:49.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adagene Incorporated</p></td><td style="vertical-align:top;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Delaware, United States</p></td></tr><tr><td style="vertical-align:top;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:49.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ADAGENE PTE. LTD.</p></td><td style="vertical-align:top;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Singapore</p></td></tr><tr><td style="vertical-align:top;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:49.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ADAGENE AUSTRALIA PTY LTD</p></td><td style="vertical-align:top;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Australia</p></td></tr><tr><td style="vertical-align:top;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:49.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ADAGENE AG</p></td><td style="vertical-align:top;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:49.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Switzerland</p></td></tr><tr><td style="vertical-align:top;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adagene Project C1 Pte. Ltd.</p></td><td style="vertical-align:top;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;">S</p></td><td style="vertical-align:top;width:49.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Singapore</p></td></tr><tr><td style="vertical-align:top;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:1.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:49.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adagene (Suzhou) Limited Beijing Branch</p></td><td style="vertical-align:top;width:1.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:49.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PRC</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>4
<FILENAME>adag-20211231xex12d1.htm
<DESCRIPTION>EXHIBIT 12.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/26/2022 12:39:13 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:36pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 12.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:36pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Certification by the Principal Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">I, Peter (Peizhi) Luo, certify that:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">I have reviewed this annual report on Form 20-F of Adagene Inc. (the &quot;company&quot;);</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">The company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">The company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 26, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:42.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Peter (Peizhi) Luo</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:42.5%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Peter (Peizhi) Luo</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:42.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer (principal executive officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>5
<FILENAME>adag-20211231xex12d2.htm
<DESCRIPTION>EXHIBIT 12.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/26/2022 12:39:15 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 12.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Certification by the Principal Financial Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><font style="font-size:11pt;">I, Man Kin (Raymond) Tam, certify that:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">1.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">I have reviewed this annual report on Form 20-F of Adagene Inc. (the &#8220;company&#8221;);</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">2.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">3.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">4.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">The company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">(c)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">Evaluated the effectiveness of the company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">(d)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">Disclosed in this report any change in the company&#8217;s internal control over financial reporting that occurred during the period covered by the annual report that has materially affected, or is reasonably likely to materially affect, the company&#8217;s internal control over financial reporting; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">5.</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">The company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the company&#8217;s auditors and the audit committee of the company&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">(a)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><font style="font-size:11pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the company&#8217;s ability to record, process, summarize and report financial information; and</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">(b)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the company&#8217;s internal control over financial reporting.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:42.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:bottom;width:42.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 26, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:47.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:42.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Man Kin (Raymond) Tam</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:42.46%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Man Kin (Raymond) Tam</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:42.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer (principal financial and accounting officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>6
<FILENAME>adag-20211231xex13d1.htm
<DESCRIPTION>EXHIBIT 13.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/26/2022 12:39:18 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:36pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 13.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Certification by the Principal Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">In connection with the Annual Report of Adagene Inc. (the &#8220;Company&#8221;) on Form 20-F for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Peter (Peizhi) Luo, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">(2)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 26, 2022</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Peter (Peizhi) Luo</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Peter (Peizhi) Luo</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer (principal executive officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>7
<FILENAME>adag-20211231xex13d2.htm
<DESCRIPTION>EXHIBIT 13.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/26/2022 12:39:20 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:36pt;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 13.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Certification by the Principal Financial Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><font style="font-size:11pt;">In connection with the Annual Report of Adagene Inc. (the &#8220;Company&#8221;) on Form 20-F for the year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Man Kin (Raymond) Tam, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">(2)</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:11pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 26, 2022</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Man Kin (Raymond) Tam</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:45%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Man Kin (Raymond) Tam</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer (principal financial and accounting officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>8
<FILENAME>adag-20211231xex15d1.htm
<DESCRIPTION>EXHIBIT 15.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/26/2022 12:39:23 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 15.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:16pt;"><img src="adag-20211231xex15d1001.jpg" alt="tianyuan" style="display:inline-block;height:31.95pt;width:162.15pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10/F, Tower B, CPIC Plaza, No.&#160;28 Fengsheng Lane, Xicheng District, Beijing 100032, China</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">Tel: 86 10 5776 3888&#160; Fax: 86 10 5776 3777</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;">April 26, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Adagene Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4F, Building C14, No. 218</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Xinghu Street, Suzhou Industrial Park</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Suzhou, Jiangsu Province, People&#8217;s Republic of China</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(as the &#8220;<b style="font-weight:bold;">Company</b>&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Dear Sirs,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We consent to the references to our firm under the headings &#8220;Item 3. Key Information&#8212;3.D. Risk Factors&#8221; and &#8220;Item 4. Information on the Company&#8212;4.A. History and Development of the Company&#8221; in Adagene Inc.&#8217;s Annual Report on Form&#160;20-F for the year ended December&#160;31, 2021 (the &#8220;<b style="font-weight:bold;">Annual Report</b>&#8221;), which will be filed with the Securities and Exchange Commission (the &#8220;<b style="font-weight:bold;">SEC</b>&#8221;) on&#160;April 26, 2022 and further consent to the incorporation by reference of the summaries of our opinions under the headings &#8220;Item 3. Key Information&#8212;3.D. Risk Factors&#8221;, &#8220;Item 4. Information on the Company&#8212;4.A. History and Development of the Company&#8221; and &#8220;Item 10. Additional Information&#8212;10.E. Taxation&#8212;Material PRC Income Tax Considerations&#8221; in the Annual Report into the registration statements (No. 333-255250) on Form S-8 and the registration statement on Form F-3 filed with the SEC on April 26, 2022. We also consent to the filing with the SEC of this consent letter as an exhibit to the Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In giving such consent, we do not thereby admit that we come within the category of persons whose consent is required under Section&#160;7 of the Securities Act of 1933, or under the Securities Exchange Act of 1934, in each case, as amended, or the regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Yours faithfully,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:39.65%;"><tr style="height:17.4pt;"><td style="vertical-align:top;width:100%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Tian Yuan Law Firm&#160;</p></td></tr><tr style="height:17.4pt;"><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Tian Yuan Law Firm</b></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.2
<SEQUENCE>9
<FILENAME>adag-20211231xex15d2.htm
<DESCRIPTION>EXHIBIT 15.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/26/2022 12:39:27 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="adag-20211231xex15d2001.jpg" alt="Graphic" style="display:inline-block;height:48pt;width:171.05pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 15.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:7pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:48.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 26, 2022</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:48.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our Ref: NASD/KH/A6545-H22467</p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Adagene Inc.</b></p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4F, Building C14, No.218</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Xinghu Street, Suzhou Industrial Park</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Suzhou, Jiangsu Province, 215123</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">People&#8217;s Republic of China</p></td><td style="vertical-align:top;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:48.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Dear Sirs or Madam</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">ADAGENE INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">FORM 20-F</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We consent to the reference to our firm under the heading <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font>Item 10.E. Taxation <font style="font-family:'Arial','Helvetica','sans-serif';">&#8212;</font>Cayman Islands Taxation<font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font> and <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font>Item 16.G. Corporate Governance<font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font> in the Annual Report on Form 20-F of Adagene Inc. for the fiscal year ended 31 December 2021 (the <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font><b style="font-weight:bold;">Annual Report</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font>), which will be filed with the U.S. Securities and Exchange Commission (the <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font><b style="font-weight:bold;">Commission</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font>) under the U.S. Securities Exchange Act of 1934, as amended (the <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font><b style="font-weight:bold;">Exchange Act</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font>) in the month of April 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We further consent to the incorporation by reference into (a) the Registration Statement (Form<font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font>S-8 No.<font style="font-family:'Arial','Helvetica','sans-serif';">&#160;</font>333-255250) pertaining to Adagene Inc. Second Amended and Restated Share Incentive Plan and Adagene Inc. 2021 Performance Incentive Plan and (b) the registration statement on Form F-3, which will be filed with the Commission on April 26, 2022 of the summary of our opinion under the heading <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font>Item 10.E. Additional Information<font style="font-family:'Arial','Helvetica','sans-serif';">&#8212;</font>Taxation<font style="font-family:'Arial','Helvetica','sans-serif';">&#8212;</font>Cayman Islands Taxation<font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font> and <font style="font-family:'Arial','Helvetica','sans-serif';">&#8220;</font>Item 16.G. Corporate Governance<font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;</font> in the Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We also consent to the filing with the Commission of this consent letter as an exhibit to the Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In giving such consent, we do not thereby admit that we come within the category of persons whose consent is required under the Exchange Act, or the Rules and Regulations of the Commission thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Yours faithfully</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">/s/ </b>WALKERS (HONG KONG)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">WALKERS (HONG KONG)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><b style="font-weight:bold;">Walkers (Hong Kong)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><b style="font-family:'MS Gothic';font-weight:bold;">&#28377;&#22025;&#24459;&#24107;&#20107;&#21209;&#25152;</b><b style="font-weight:bold;"> (</b><b style="font-family:'MS Gothic';font-weight:bold;">&#39321;&#28207;</b><b style="font-weight:bold;">)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;">15th Floor, Alexandra House, 18 Chater Road, Central, Hong Kong</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">T</b><font style="white-space:pre-wrap;">  +852 2284 4566  </font><b style="font-weight:bold;">F</b><font style="white-space:pre-wrap;">  +852 2284 4560  www.walkersglobal.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 0pt 10pt 0pt;">Bermuda | British Virgin Islands | Cayman Islands | Dubai | Guernsey | Hong Kong | Ireland | Jersey | London | Singapore</p><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:right;margin:0pt 0pt 4.5pt 0pt;"><font style="white-space:pre-wrap;"> *England and Wales; **BVI; ***Cayman Islands; ****New South Wales (Australia); ******Victoria (Australia); *******Bermuda</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.3
<SEQUENCE>10
<FILENAME>adag-20211231xex15d3.htm
<DESCRIPTION>EXHIBIT 15.3
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/26/2022 12:39:30 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 15.3</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><img src="adag-20211231xex15d3001.jpg" alt="Graphic" style="display:inline-block;height:28.8pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:177.8pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nancy E. Taylor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tel 202.331.3133</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fax 202.261.0133</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">taylorn@gtlaw.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 18pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">April 26, 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Adagene Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">4F, Building C14, No. 218</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Xinghu Street, Suzhou Industrial Park</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Suzhou, Jiangsu Province, People&#8217;s Republic of China</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">To Whom it May Concern:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We consent to the references to our summary of opinions under the headings &#8220;Item 4.B. Business Overview&#8212;Regulation&#8212;United States Regulation&#8221; in Adagene Inc.&#8217;s Annual Report on Form&#160;20-F for the year ended December&#160;31, 2021 (the &#8220;<b style="font-weight:bold;">Annual Report</b>&#8221;), which will be filed with the Securities and Exchange Commission (the &#8220;<b style="font-weight:bold;">SEC</b>&#8221;) on&#160;April 26, 2022. We also consent to the filing with the SEC of this consent letter as an exhibit to the Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In giving such consent, we do not thereby admit that we come within the category of persons whose consent is required under Section&#160;7 of the Securities Act of 1933, or under the Securities Exchange Act of 1934, in each case, as amended, or the regulations promulgated thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Best regards,</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">/s/ Nancy E. Taylor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Nancy E. Taylor</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Shareholder</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Times New Roman Bold';font-weight:bold;">Greenberg Traurig, LLP | Attorneys at Law </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">2101 L Street NW &#160;| &#160;Suite 1000 &#160;| &#160;Washington, DC 20037 &#160;| &#160;T +1 202.331.3100 &#160;| &#160;F +1 202.331.3101</font></p></td></tr><tr><td style="vertical-align:top;width:100%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Albany. Amsterdam. Atlanta. Austin. Berlin&#172;. Boston. Chicago. Dallas. Delaware. Denver. Fort Lauderdale. Houston. Las Vegas. London.* Los Angeles. Mexico City+. </p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Miami. Milan&#187;. Minneapolis. New Jersey. New York. Northern Virginia. Orange County. Orlando. Philadelphia. Phoenix. Sacramento. Salt Lake City. San Francisco. </p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">Seoul&#8734;. Shanghai. Silicon Valley. Tallahassee. Tampa. Tel Aviv^. Tokyo&#164;. Warsaw~. Washington, D.C. West Palm Beach. Westchester County.</p><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;text-align:justify;margin:0pt 0pt 4pt 0pt;">Operates as: &#172;Greenberg Traurig Germany, LLP; *A separate UK registered legal entity; +Greenberg Traurig, S.C.; &#187;Greenberg Traurig Santa Maria; &#8734;Greenberg Traurig LLP Foreign Legal Consultant Office; ^A branch of Greenberg Traurig, P.A., Florida, USA; &#160;&#164;GT Tokyo Horitsu Jimusho and Greenberg Traurig Gaikokuhojimubegoshi Jimusho; ~Greenberg Traurig Grzesiak sp.k.</p></td></tr><tr><td style="vertical-align:top;width:100%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><font style="font-size:8pt;">www.gtlaw.com</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.4
<SEQUENCE>11
<FILENAME>adag-20211231xex15d4.htm
<DESCRIPTION>EXHIBIT 15.4
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 4/26/2022 12:39:33 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;15.4</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 (File No. 333-255250) of Adagene Inc. of our report dated April 26, 2022 relating to the financial statements, which appears in this Form 20-F.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/PricewaterhouseCoopers Zhong Tian LLP</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Shanghai, the People<font style="font-family:'Georgia';">&#8217;</font>s Republic of China</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">April 26, 2022</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>adag-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8119.21675 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/26/2022 12:38:33 PM-->
<!--Modified on: 4/26/2022 12:38:33 PM-->
<xsd:schema targetNamespace="http://www.adagene.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:srt-roles="http://fasb.org/srt-roles/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:adag="http://www.adagene.com/20211231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2021q4">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/StatementConsolidatedBalanceSheets" id="StatementConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>00200 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails" id="DisclosureAccountsReceivableNetDetails">
        <link:definition>40301 - Disclosure - ACCOUNTS RECEIVABLE, NET (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails" id="DisclosurePrepaymentsAndOtherCurrentAssetsDetails">
        <link:definition>40401 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails" id="DisclosurePropertyEquipmentAndSoftwareNetDetails">
        <link:definition>40501 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails" id="DisclosureAccrualsAndOtherCurrentLiabilitiesDetails">
        <link:definition>40601 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails" id="DisclosureBorrowingsComponentsDetails">
        <link:definition>40701 - Disclosure - BORROWINGS - Components (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails" id="DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails">
        <link:definition>40704 - Disclosure - BORROWINGS - Future maturities of short term borrowings and long term borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails" id="DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails">
        <link:definition>41102 - Disclosure - INCOME TAX EXPENSE - Income tax expense (benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails" id="DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails">
        <link:definition>41103 - Disclosure - INCOME TAX EXPENSE - Income tax reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" id="DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails">
        <link:definition>41104 - Disclosure - INCOME TAX EXPENSE - Deferred tax assets and deferred tax liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesDetails" id="DisclosureCommitmentsAndContingenciesDetails">
        <link:definition>41401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical" id="StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit" id="StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit">
        <link:definition>00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails" id="DisclosureOrganizationAndBasisOfPresentationDetails">
        <link:definition>40101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails">
        <link:definition>40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonrecurring (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails">
        <link:definition>40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, equipment and software (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails">
        <link:definition>40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of credit risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails" id="DisclosureBorrowingsShortTermBorrowingsDetails">
        <link:definition>40702 - Disclosure - BORROWINGS - Short term borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails" id="DisclosureBorrowingsLongTermBorrowingsDetails">
        <link:definition>40703 - Disclosure - BORROWINGS - Long term borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails" id="DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails">
        <link:definition>40801 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails" id="DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails">
        <link:definition>40802 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Share Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsWarrantsDetails" id="DisclosureConvertibleRedeemablePreferredSharesAndWarrantsWarrantsDetails">
        <link:definition>40803 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationDetails" id="DisclosureShareBasedCompensationDetails">
        <link:definition>40901 - Disclosure - SHARE-BASED COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails" id="DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails">
        <link:definition>40905 - Disclosure - SHARE-BASED COMPENSATION - Share based compensation expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails" id="DisclosureCollaborationArrangementsDetails">
        <link:definition>41001 - Disclosure - COLLABORATION ARRANGEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails" id="DisclosureIncomeTaxExpenseDetails">
        <link:definition>41101 - Disclosure - INCOME TAX EXPENSE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" id="DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails">
        <link:definition>41202 - Disclosure - NET LOSS PER SHARE - Anti-dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails" id="DisclosureRelatedPartyTransactionsDetails">
        <link:definition>41301 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureTreasurySharesDetails" id="DisclosureTreasurySharesDetails">
        <link:definition>41601 - Disclosure - TREASURY SHARES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>41701 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLossParenthetical" id="StatementConsolidatedStatementsOfComprehensiveLossParenthetical">
        <link:definition>00205 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentation" id="DisclosureOrganizationAndBasisOfPresentation">
        <link:definition>10101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureAccountsReceivableNet" id="DisclosureAccountsReceivableNet">
        <link:definition>10301 - Disclosure - ACCOUNTS RECEIVABLE, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssets" id="DisclosurePrepaymentsAndOtherCurrentAssets">
        <link:definition>10401 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNet" id="DisclosurePropertyEquipmentAndSoftwareNet">
        <link:definition>10501 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilities" id="DisclosureAccrualsAndOtherCurrentLiabilities">
        <link:definition>10601 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureBorrowings" id="DisclosureBorrowings">
        <link:definition>10701 - Disclosure - BORROWINGS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrants" id="DisclosureConvertibleRedeemablePreferredSharesAndWarrants">
        <link:definition>10801 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
        <link:definition>10901 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureCollaborationArrangements" id="DisclosureCollaborationArrangements">
        <link:definition>11001 - Disclosure - COLLABORATION ARRANGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpense" id="DisclosureIncomeTaxExpense">
        <link:definition>11101 - Disclosure - INCOME TAX EXPENSE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureNetLossPerShare" id="DisclosureNetLossPerShare">
        <link:definition>11201 - Disclosure - NET LOSS PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureRelatedPartyTransactions" id="DisclosureRelatedPartyTransactions">
        <link:definition>11301 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>11401 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureRestrictedNetAssets" id="DisclosureRestrictedNetAssets">
        <link:definition>11501 - Disclosure - RESTRICTED NET ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureTreasuryShares" id="DisclosureTreasuryShares">
        <link:definition>11601 - Disclosure - TREASURY SHARES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>11701 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationTables" id="DisclosureOrganizationAndBasisOfPresentationTables">
        <link:definition>30103 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureAccountsReceivableNetTables" id="DisclosureAccountsReceivableNetTables">
        <link:definition>30303 - Disclosure - ACCOUNTS RECEIVABLE, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsTables" id="DisclosurePrepaymentsAndOtherCurrentAssetsTables">
        <link:definition>30403 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetTables" id="DisclosurePropertyEquipmentAndSoftwareNetTables">
        <link:definition>30503 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesTables" id="DisclosureAccrualsAndOtherCurrentLiabilitiesTables">
        <link:definition>30603 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureBorrowingsTables" id="DisclosureBorrowingsTables">
        <link:definition>30703 - Disclosure - BORROWINGS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsTables" id="DisclosureConvertibleRedeemablePreferredSharesAndWarrantsTables">
        <link:definition>30803 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
        <link:definition>30903 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseTables" id="DisclosureIncomeTaxExpenseTables">
        <link:definition>31101 - Disclosure - INCOME TAX EXPENSE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureNetLossPerShareTables" id="DisclosureNetLossPerShareTables">
        <link:definition>31203 - Disclosure - NET LOSS PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureRelatedPartyTransactionsTables" id="DisclosureRelatedPartyTransactionsTables">
        <link:definition>31303 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
        <link:definition>31403 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails">
        <link:definition>40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of long lived assets to Employee defined contribution plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyExchangeRateRiskDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyExchangeRateRiskDetails">
        <link:definition>40205 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Foreign currency exchange rate risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails" id="DisclosureShareBasedCompensationShareOptionActivitiesDetails">
        <link:definition>40902 - Disclosure - SHARE-BASED COMPENSATION - Share Option Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails" id="DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails">
        <link:definition>40903 - Disclosure - SHARE-BASED COMPENSATION - Share Option Activities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails" id="DisclosureShareBasedCompensationFairValueOfShareOptionsDetails">
        <link:definition>40904 - Disclosure - SHARE-BASED COMPENSATION - Fair Value Of Share Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseValuationAllowanceDetails" id="DisclosureIncomeTaxExpenseValuationAllowanceDetails">
        <link:definition>41105 - Disclosure - INCOME TAX EXPENSE - Valuation Allowance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureNetLossPerShareDetails" id="DisclosureNetLossPerShareDetails">
        <link:definition>41201 - Disclosure - NET LOSS PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adagene.com/role/DisclosureRestrictedNetAssetsDetails" id="DisclosureRestrictedNetAssetsDetails">
        <link:definition>41501 - Disclosure - RESTRICTED NET ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="adag-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adag-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adag-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adag-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
  <xsd:element id="adag_SummaryOfPrincipalSubsidiariesTableTextBlock" name="SummaryOfPrincipalSubsidiariesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_AdageneHongKongLimitedMember" name="AdageneHongKongLimitedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_AdageneIncorporatedMember" name="AdageneIncorporatedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_AdageneSuzhouLimitedMember" name="AdageneSuzhouLimitedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_AdageneAustraliaPtyLtd.Member" name="AdageneAustraliaPtyLtd.Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock" name="PrepaidExpenseAndOtherAssetsCurrentTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" name="AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" name="AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" name="AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_AccruedLiabilitiesAndOtherCurrentLiabilities" name="AccruedLiabilitiesAndOtherCurrentLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="adag_RestrictedNetAssetsAbstract" name="RestrictedNetAssetsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve" name="MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital" name="StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_AfterTaxIncomePercentageAppropriations" name="AfterTaxIncomePercentageAppropriations" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries" name="ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_Series1RedeemableConvertiblePreferredStockMember" name="Series1RedeemableConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_Series2RedeemableConvertiblePreferredStockMember" name="Series2RedeemableConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_SeriesBRedeemableConvertiblePreferredStockMember" name="SeriesBRedeemableConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_SeriesC1RedeemableConvertiblePreferredStockMember" name="SeriesC1RedeemableConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_SeriesC2RedeemableConvertiblePreferredStockMember" name="SeriesC2RedeemableConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_SeriesC3RedeemableConvertiblePreferredStockMember" name="SeriesC3RedeemableConvertiblePreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_ResearchAndDevelopmentExpenseThirdParties" name="ResearchAndDevelopmentExpenseThirdParties" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" name="RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="adag_WuxiApptecGroupMember" name="WuxiApptecGroupMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_CollaborationArrangementsAbstract" name="CollaborationArrangementsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember" name="GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_AdctCollaborationAgreementMember" name="AdctCollaborationAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_SignalPharmaceuticalsLlcMember" name="SignalPharmaceuticalsLlcMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_CollaborativeArrangementUpfrontCashPaymentReceived" name="CollaborativeArrangementUpfrontCashPaymentReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" name="AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies" name="MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" name="MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_PeriodForReservationOfTargetRight" name="PeriodForReservationOfTargetRight" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_IncomeTaxDisclosureTable" name="IncomeTaxDisclosureTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_PreferentialIncomeTaxRate" name="PreferentialIncomeTaxRate" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate" name="EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_AssessableProfits" name="AssessableProfits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="adag_WithholdingIncomeTaxes" name="WithholdingIncomeTaxes" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount" name="EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="adag_DeferredTaxAssetsDepreciationAndAmortization" name="DeferredTaxAssetsDepreciationAndAmortization" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="adag_WuxiBiologicsShanghaiCo.Ltd.Member" name="WuxiBiologicsShanghaiCo.Ltd.Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" name="DisclosureOfTemporaryEquityAndWarrantsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock" name="DisclosureOfTemporaryEquityAndWarrantsTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_SeriesC1WarrantsMember" name="SeriesC1WarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" name="TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_NumberOfInvestorsToWhomWarrantsWereIssued" name="NumberOfInvestorsToWhomWarrantsWereIssued" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_MaximumProceedsReceivableFromExerciseOfWarrants" name="MaximumProceedsReceivableFromExerciseOfWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="adag_TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice" name="TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent" name="ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock" name="ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember" name="BorrowingsFromAgriculturalBankOfChinaLimitedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_BorrowingsFromBankOfNingboCo.LtdMember" name="BorrowingsFromBankOfNingboCo.LtdMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember" name="BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember" name="BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock" name="AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_GovernmentSubsidiesPolicyTextBlock" name="GovernmentSubsidiesPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" name="PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_DefinedContributionPlanAbstract" name="DefinedContributionPlanAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_NumberOfMajorSupplier" name="NumberOfMajorSupplier" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_Plan2015Member" name="Plan2015Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_Plan2017Member" name="Plan2017Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_Plan2019Member" name="Plan2019Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember" name="DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_PayablesForDeferredInitialPublicOfferingCost" name="PayablesForDeferredInitialPublicOfferingCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="adag_AdagenePte.Ltd.Member" name="AdagenePte.Ltd.Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_AdageneAgMember" name="AdageneAgMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_PercentageOfDepreciationOfForeignCurrency" name="PercentageOfDepreciationOfForeignCurrency" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_ChinaMerchantsBankCo.LtdMember" name="ChinaMerchantsBankCo.LtdMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_ChinaMerchantsBankCo.LtdLoanTwoMember" name="ChinaMerchantsBankCo.LtdLoanTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember" name="BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice" name="TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_NumberOfSharesSurrendered" name="NumberOfSharesSurrendered" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent" name="ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_CollaborativeArrangementMilestonePaymentReceivable" name="CollaborativeArrangementMilestonePaymentReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="adag_ExelixisAgreementMember" name="ExelixisAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_PerformanceIncentivePlan2021Member" name="PerformanceIncentivePlan2021Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_StatusForTaxabilityAxis" name="StatusForTaxabilityAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_StatusForTaxabilityDomain" name="StatusForTaxabilityDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_TechnologyAdvancedServiceEnterprisesMember" name="TechnologyAdvancedServiceEnterprisesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_TaxableIncome" name="TaxableIncome" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember" name="ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants" name="ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="adag_EmployeeDefinedContributionPlanPolicyTextBlock" name="EmployeeDefinedContributionPlanPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_FinancialAssetsFairValueDisclosure" name="FinancialAssetsFairValueDisclosure" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="adag_ElectronicEquipmentMember" name="ElectronicEquipmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_CashAndCashEquivalentsAndShortTermInvestmentsMember" name="CashAndCashEquivalentsAndShortTermInvestmentsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_MainlandOfChinaMember" name="MainlandOfChinaMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_OutsideMainlandOfChinaMember" name="OutsideMainlandOfChinaMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_MilestonePaymentsOrRoyaltyPaymentsReceived" name="MilestonePaymentsOrRoyaltyPaymentsReceived" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="adag_QualifiedPublicOfferingMinimumMarketCapitalization" name="QualifiedPublicOfferingMinimumMarketCapitalization" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="adag_QualifiedPublicOfferingMinimumProceeds" name="QualifiedPublicOfferingMinimumProceeds" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="adag_ConcentrationRiskSuppliersAxis" name="ConcentrationRiskSuppliersAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_ConcentrationRiskSuppliersDomain" name="ConcentrationRiskSuppliersDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="adag_OneSupplierMember" name="OneSupplierMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="RetirementOfTreasuryShares" id="adag_RetirementOfTreasuryShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NonCashActivitiesRetirementOfTreasuryShares" id="adag_NonCashActivitiesRetirementOfTreasuryShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SharesSurrenderedSharesForRepaymentOfPromissoryNotes" id="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockSurrenderedValueForRepaymentOfPromissoryNotes" id="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CollaborativeArrangementMilestonePaymentReceived" id="adag_CollaborativeArrangementMilestonePaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ExelixisIncAgreementMember" id="adag_ExelixisIncAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CollaborativeArrangementUpfrontCashPaymentReceivable" id="adag_CollaborativeArrangementUpfrontCashPaymentReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" id="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="MilestonePaymentsReceivableSalesBasedMilestones" id="adag_MilestonePaymentsReceivableSalesBasedMilestones" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ServiceConditionsAndPerformanceConditionsMember" id="adag_ServiceConditionsAndPerformanceConditionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember" id="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonStockSubscriptionsValue" id="adag_CommonStockSubscriptionsValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected" id="adag_ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="InterestIncomeExpenseOnPromissoryNotes" id="adag_InterestIncomeExpenseOnPromissoryNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes" id="adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="WithholdingTaxRateOnDividendsPercentage" id="adag_WithholdingTaxRateOnDividendsPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CapitalTaxRatePercentage" id="adag_CapitalTaxRatePercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GovernmentSubsidiesReceived" id="adag_GovernmentSubsidiesReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>adag-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8119.21675 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/26/2022 12:38:33 PM-->
<!--Modified on: 4/26/2022 12:38:33 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.adagene.com/role/StatementConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureAccountsReceivableNetDetails" roleURI="http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosurePrepaymentsAndOtherCurrentAssetsDetails" roleURI="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosurePropertyEquipmentAndSoftwareNetDetails" roleURI="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureAccrualsAndOtherCurrentLiabilitiesDetails" roleURI="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureBorrowingsComponentsDetails" roleURI="http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails" roleURI="http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesDetails" />
  <calculationLink xlink:role="http://www.adagene.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637516889408721249" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637865735117431676" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637516889408721249" xlink:to="us-gaap_OtherAssetsNoncurrent_637865735117431676" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637865735117431676" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637516889408721249" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637865735117431676" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637865735117441675" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets_637516889408721249" xlink:to="us-gaap_AssetsCurrent_637865735117441675" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637865735117441675" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637865735117441675" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637865735117441675" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_637865735117441675" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637865735117441675" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_637865735117441675" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637865735117441675" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637865735117441675" xlink:to="us-gaap_AccountsReceivableNetCurrent_637865735117441675" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637865735117441675" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_637865735117441675" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637865735117441675" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637517548687169551" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637865735117441675" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637517548687169551" xlink:to="us-gaap_Liabilities_637865735117441675" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637865735117441675" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637865735117441675" xlink:to="us-gaap_LiabilitiesCurrent_637865735117441675" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637865735117441675" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637865735117441675" xlink:to="us-gaap_AccountsPayableCurrent_637865735117441675" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_637865735117441675" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637865735117441675" xlink:to="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_637865735117441675" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_637865735117451674" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637865735117441675" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_637865735117451674" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637865735117451674" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637865735117441675" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637865735117451674" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_637865735117451674" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637865735117441675" xlink:to="us-gaap_DueToRelatedPartiesCurrent_637865735117451674" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_637865735117451674" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637865735117441675" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_637865735117451674" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_637865735117451674" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_637865735117441675" xlink:to="us-gaap_LongTermDebtCurrent_637865735117451674" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637865735117451674" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637865735117441675" xlink:to="us-gaap_LongTermDebtNoncurrent_637865735117451674" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_637865735117451674" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637865735117441675" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_637865735117451674" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637865735117451674" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_637865735117441675" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637865735117451674" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637865735117461675" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637517548687169551" xlink:to="us-gaap_StockholdersEquity_637865735117461675" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637865735117461675" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637865735117461675" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637865735117461675" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637865735117461675" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637865735117461675" xlink:to="us-gaap_AdditionalPaidInCapital_637865735117461675" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637865735117461675" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637865735117461675" xlink:to="us-gaap_CommonStockValue_637865735117461675" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637865735117461675" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637865735117461675" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637865735117461675" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue_637865735117461675" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637865735117461675" xlink:to="us-gaap_TreasuryStockValue_637865735117461675" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_637865735117461675" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_637865735117461675" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_637865735117461675" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637865735117461675" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637517548687169551" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637865735117461675" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637516889408811006" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637865735117471674" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax_637516889408811006" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637865735117471674" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637865735117471674" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax_637516889408811006" xlink:to="us-gaap_NetIncomeLoss_637865735117471674" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637865735117491689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss_637865735117491689" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637865735117491689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637865735117491689" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637865735117491689" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637865735117491689" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_637865735117491689" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637865735117491689" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_637865735117501680" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637865735117491689" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_637865735117501680" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637865735117501680" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637865735117491689" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637865735117501680" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637865735117501680" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637865735117491689" xlink:to="us-gaap_OtherNonoperatingIncome_637865735117501680" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637865735117501680" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637865735117491689" xlink:to="us-gaap_InterestExpense_637865735117501680" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating_637865735117501680" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637865735117491689" xlink:to="us-gaap_InvestmentIncomeNonoperating_637865735117501680" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637865735117501680" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637865735117491689" xlink:to="us-gaap_OperatingIncomeLoss_637865735117501680" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637865735117511680" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637865735117501680" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637865735117511680" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637865735117511680" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637865735117501680" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637865735117511680" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_637865735117511680" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_637865735117511680" xlink:to="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_637865735117511680" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ResearchAndDevelopmentExpenseThirdParties" xlink:label="adag_ResearchAndDevelopmentExpenseThirdParties_637865735117511680" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ResearchAndDevelopmentExpense_637865735117511680" xlink:to="adag_ResearchAndDevelopmentExpenseThirdParties_637865735117511680" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637865735117511680" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_637865735117501680" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637865735117511680" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_637865735117511680" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_637865735117511680" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637865735117531678" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637865735117531678" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_637865735117531678" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637865735117531678" xlink:to="us-gaap_RepaymentsOfDebt_637865735117531678" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital_637865735117531678" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637865735117531678" xlink:to="us-gaap_ProceedsFromContributedCapital_637865735117531678" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants" xlink:label="adag_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants_637865735117541680" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637865735117531678" xlink:to="adag_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants_637865735117541680" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637865735117541680" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637865735117531678" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637865735117541680" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637865735117541680" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637865735117531678" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637865735117541680" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637865735117541680" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637865735117531678" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637865735117541680" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_637865735117541680" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637865735117531678" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_637865735117541680" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_RetirementOfTreasuryShares" xlink:label="adag_RetirementOfTreasuryShares_637865735117541680" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637865735117531678" xlink:to="adag_RetirementOfTreasuryShares_637865735117541680" order="8" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_637865735117541680" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_637865735117531678" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_637865735117541680" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637865735117541680" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637865735117541680" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_637865735117551683" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637865735117541680" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_637865735117551683" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_637865735117551683" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637865735117541680" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_637865735117551683" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_637865735117551683" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637865735117541680" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_637865735117551683" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_637865735117551683" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_637865735117541680" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_637865735117551683" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735117551683" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735117551683" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637865735117551683" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735117551683" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637865735117551683" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_637865735117551683" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735117551683" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_637865735117551683" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_InterestIncomeExpenseOnPromissoryNotes" xlink:label="adag_InterestIncomeExpenseOnPromissoryNotes_637865735117561687" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735117551683" xlink:to="adag_InterestIncomeExpenseOnPromissoryNotes_637865735117561687" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_637865735117561687" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735117551683" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_637865735117561687" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_637865735117561687" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735117551683" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_637865735117561687" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_637865735117561687" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735117551683" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_637865735117561687" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637865735117561687" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735117551683" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637865735117561687" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637865735117561687" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735117551683" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637865735117561687" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637865735117571678" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735117551683" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637865735117571678" order="9" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_637865735117571678" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735117551683" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties_637865735117571678" order="10" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637865735117571678" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735117551683" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637865735117571678" order="11" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637865735117571678" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735117551683" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637865735117571678" order="12" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637865735117571678" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735117551683" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637865735117571678" order="13" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_637865735117571678" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735117551683" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_637865735117571678" order="14" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637865735117581906" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735117551683" xlink:to="us-gaap_ShareBasedCompensation_637865735117581906" order="15" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637865735117581906" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735117551683" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637865735117581906" order="16" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637865735117581906" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735117551683" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637865735117581906" order="17" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637865735117581906" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735117551683" xlink:to="us-gaap_ProfitLoss_637865735117581906" order="18" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_637865735117581906" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_637865735117581906" order="4" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails" xlink:type="extended" xlink:title="40301 - Disclosure - ACCOUNTS RECEIVABLE, NET (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross_637865735117592088" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableGross_637865735117592088" order="1" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637865735117592088" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_637865735117592088" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_637865735117592088" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_637865735117592088" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent_637865735117592088" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_637865735117592088" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637865735117592088" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637865735117592088" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637865735117592088" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637865735117592088" order="2" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES (Details)">
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637865735117602092" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="us-gaap_OtherLiabilitiesCurrent_637865735117602092" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_637865735117602092" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="us-gaap_TaxesPayableCurrent_637865735117602092" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedUtilitiesCurrent" xlink:label="us-gaap_AccruedUtilitiesCurrent_637865735117602092" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="us-gaap_AccruedUtilitiesCurrent_637865735117602092" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637865735117602092" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637865735117602092" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637865735117602092" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637865735117602092" order="5" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - BORROWINGS - Components (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637865735117602092" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_LongTermDebtNoncurrent_637865735117602092" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLoansFromBank" xlink:label="us-gaap_LongTermLoansFromBank_637865735117602092" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebtNoncurrent_637865735117602092" xlink:to="us-gaap_LongTermLoansFromBank_637865735117602092" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent_637865735117602092" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtCurrent_637865735117602092" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_637865735117612091" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtCurrent_637865735117602092" xlink:to="us-gaap_LongTermDebtCurrent_637865735117612091" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_637865735117612091" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtCurrent_637865735117602092" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_637865735117612091" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails" xlink:type="extended" xlink:title="40704 - Disclosure - BORROWINGS - Future maturities of short term borrowings and long term borrowings (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent_637865735117612091" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtCurrent_637865735117612091" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637865735117612091" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637865735117612091" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_637865735117612091" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_637865735117612091" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_637865735117612091" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_637865735117612091" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails" xlink:type="extended" xlink:title="41102 - Disclosure - INCOME TAX EXPENSE - Income tax expense (benefit) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_637865735117622058" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_637865735117622058" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_637865735117622058" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_637865735117622058" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_637865735117622058" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_637865735117622058" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit_637865735117622058" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_637865735117622058" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_637865735117622058" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_637865735117622058" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_637865735117622058" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit_637865735117622058" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_637865735117622058" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_637865735117622058" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit_637865735117622058" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_637865735117622058" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails" xlink:type="extended" xlink:title="41103 - Disclosure - INCOME TAX EXPENSE - Income tax reconciliation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637865735117722060" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637865735117722060" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount" xlink:label="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount_637865735117722060" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount_637865735117722060" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_637865735117722060" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_637865735117722060" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_637865735117722060" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_637865735117722060" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_637865735117722060" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_637865735117722060" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_637865735117732062" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_637865735117732062" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_637865735117732062" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_637865735117732062" order="7" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" xlink:type="extended" xlink:title="41104 - Disclosure - INCOME TAX EXPENSE - Deferred tax assets and deferred tax liabilities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637865735117732062" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet_637865735117732062" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637865735117732062" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637865735117732062" xlink:to="us-gaap_DeferredTaxAssetsGross_637865735117732062" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637865735117732062" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637865735117732062" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637865735117732062" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory_637865735117732062" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637865735117732062" xlink:to="us-gaap_DeferredTaxAssetsInventory_637865735117732062" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_637865735117732062" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637865735117732062" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_637865735117732062" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="adag_DeferredTaxAssetsDepreciationAndAmortization_637865735117732062" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_637865735117732062" xlink:to="adag_DeferredTaxAssetsDepreciationAndAmortization_637865735117732062" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637865735117742066" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_637865735117732062" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637865735117742066" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637865735117742066" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637865735117742066" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637865735117742066" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_637865735117742066" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637865735117742066" order="1" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637865735117742066" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637865735117742066" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637865735117742066" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637865735117742066" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637865735117742066" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637865735117742066" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>adag-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8119.21675 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/26/2022 12:38:33 PM-->
<!--Modified on: 4/26/2022 12:38:33 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.adagene.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.adagene.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit" roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureOrganizationAndBasisOfPresentationDetails" roleURI="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosurePropertyEquipmentAndSoftwareNetDetails" roleURI="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureBorrowingsShortTermBorrowingsDetails" roleURI="http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureBorrowingsLongTermBorrowingsDetails" roleURI="http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails" roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails" roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureShareBasedCompensationDetails" roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails" roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureCollaborationArrangementsDetails" roleURI="http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureIncomeTaxExpenseDetails" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" roleURI="http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureTreasurySharesDetails" roleURI="http://www.adagene.com/role/DisclosureTreasurySharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.adagene.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.adagene.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="adag-20211231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:definitionLink xlink:role="http://www.adagene.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_1" xlink:title="dei_EntityAddressesAddressTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_1" xlink:title="dei_AddressTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_EntityAddressesAddressTypeAxis_1" xlink:to="dei_AddressTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_EntityAddressesAddressTypeAxis_1 To dei_AddressTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_1" xlink:title="srt_OwnershipAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_1" xlink:title="srt_OwnershipDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_OwnershipAxis_1" xlink:to="srt_OwnershipDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_OwnershipAxis_1 To srt_OwnershipDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis_1" xlink:title="us-gaap_FairValueByLiabilityClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByLiabilityClassAxis_1" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByLiabilityClassAxis_1 To us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ConcentrationRiskSuppliersAxis" xlink:label="adag_ConcentrationRiskSuppliersAxis_1" xlink:title="adag_ConcentrationRiskSuppliersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ConcentrationRiskSuppliersDomain" xlink:label="adag_ConcentrationRiskSuppliersDomain_1" xlink:title="adag_ConcentrationRiskSuppliersDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="adag_ConcentrationRiskSuppliersAxis_1" xlink:to="adag_ConcentrationRiskSuppliersDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:adag_ConcentrationRiskSuppliersAxis_1 To adag_ConcentrationRiskSuppliersDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_StatusForTaxabilityAxis" xlink:label="adag_StatusForTaxabilityAxis_1" xlink:title="adag_StatusForTaxabilityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_StatusForTaxabilityDomain" xlink:label="adag_StatusForTaxabilityDomain_1" xlink:title="adag_StatusForTaxabilityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="adag_StatusForTaxabilityAxis_1" xlink:to="adag_StatusForTaxabilityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:adag_StatusForTaxabilityAxis_1 To adag_StatusForTaxabilityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis_1" xlink:title="srt_ConsolidationItemsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_1" xlink:title="srt_ConsolidationItemsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidationItemsAxis_1" xlink:to="srt_ConsolidationItemsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidationItemsAxis_1 To srt_ConsolidationItemsDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CountryRegion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_NoTradingSymbolFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="38" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="39" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="40" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="41" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="42" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="43" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Series1RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series1RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_Series1RedeemableConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Series2RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series2RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_Series2RedeemableConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesBRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesBRedeemableConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC1RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC1RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesC1RedeemableConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC2RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC2RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesC2RedeemableConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC3RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC3RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesC3RedeemableConvertiblePreferredStockMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DueToRelatedPartiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="adag_AccruedLiabilitiesAndOtherCurrentLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Series1RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series1RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_Series1RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Series2RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series2RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_Series2RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesBRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesBRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC1RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC1RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesC1RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC2RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC2RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesC2RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC3RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC3RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesC3RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockShares" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ReceivablesFromStockholderMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CommonStockSubscriptionsValue" xlink:label="adag_CommonStockSubscriptionsValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="adag_CommonStockSubscriptionsValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockSharesAcquired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockRetiredCostMethodAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_TreasuryStockSharesRetired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_StockSurrenderedValueForRepaymentOfPromissoryNotes" xlink:label="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes" xlink:label="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneHongKongLimitedMember" xlink:label="adag_AdageneHongKongLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="adag_AdageneHongKongLimitedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneIncorporatedMember" xlink:label="adag_AdageneIncorporatedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_OwnershipDomain" xlink:to="adag_AdageneIncorporatedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneSuzhouLimitedMember" xlink:label="adag_AdageneSuzhouLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_OwnershipDomain" xlink:to="adag_AdageneSuzhouLimitedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneAustraliaPtyLtd.Member" xlink:label="adag_AdageneAustraliaPtyLtd.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_OwnershipDomain" xlink:to="adag_AdageneAustraliaPtyLtd.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdagenePte.Ltd.Member" xlink:label="adag_AdagenePte.Ltd.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_OwnershipDomain" xlink:to="adag_AdagenePte.Ltd.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneAgMember" xlink:label="adag_AdageneAgMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_OwnershipDomain" xlink:to="adag_AdageneAgMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityListingDepositoryReceiptRatio" xlink:label="dei_EntityListingDepositoryReceiptRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="dei_EntityListingDepositoryReceiptRatio" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails" xlink:type="extended" xlink:title="40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonrecurring (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_FinancialAssetsFairValueDisclosure" xlink:label="adag_FinancialAssetsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="adag_FinancialAssetsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails" xlink:type="extended" xlink:title="40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, equipment and software (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ElectronicEquipmentMember" xlink:label="adag_ElectronicEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adag_ElectronicEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="extended" xlink:title="40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of credit risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="us-gaap_GeographicConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_GeographicConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_SupplierConcentrationRiskMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CashAndCashEquivalentsAndShortTermInvestmentsMember" xlink:label="adag_CashAndCashEquivalentsAndShortTermInvestmentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="adag_CashAndCashEquivalentsAndShortTermInvestmentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsProductLineMember" xlink:label="us-gaap_CostOfGoodsProductLineMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_CostOfGoodsProductLineMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ConcentrationRiskSuppliersAxis" xlink:label="adag_ConcentrationRiskSuppliersAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="adag_ConcentrationRiskSuppliersAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ConcentrationRiskSuppliersDomain" xlink:label="adag_ConcentrationRiskSuppliersDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="adag_ConcentrationRiskSuppliersAxis" xlink:to="adag_ConcentrationRiskSuppliersDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_OneSupplierMember" xlink:label="adag_OneSupplierMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="adag_ConcentrationRiskSuppliersDomain" xlink:to="adag_OneSupplierMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MainlandOfChinaMember" xlink:label="adag_MainlandOfChinaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="adag_MainlandOfChinaMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_OutsideMainlandOfChinaMember" xlink:label="adag_OutsideMainlandOfChinaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="adag_OutsideMainlandOfChinaMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_NumberOfMajorSupplier" xlink:label="adag_NumberOfMajorSupplier" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="adag_NumberOfMajorSupplier" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ElectronicEquipmentMember" xlink:label="adag_ElectronicEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="adag_ElectronicEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - BORROWINGS - Short term borrowings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_BorrowingsFromBankOfNingboCo.LtdMember" xlink:label="adag_BorrowingsFromBankOfNingboCo.LtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="adag_BorrowingsFromBankOfNingboCo.LtdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember" xlink:label="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ChinaMerchantsBankCo.LtdMember" xlink:label="adag_ChinaMerchantsBankCo.LtdMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="adag_ChinaMerchantsBankCo.LtdMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ChinaMerchantsBankCo.LtdLoanTwoMember" xlink:label="adag_ChinaMerchantsBankCo.LtdLoanTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="adag_ChinaMerchantsBankCo.LtdLoanTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ScheduleOfShortTermDebtTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - BORROWINGS - Long term borrowings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTerm" xlink:label="us-gaap_LongTermDebtTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfDebt" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Series1RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series1RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_Series1RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Series2RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series2RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_Series2RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesBRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesBRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC1RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC1RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesC1RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC2RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC2RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesC2RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC3RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC3RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesC3RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC1WarrantsMember" xlink:label="adag_SeriesC1WarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="adag_SeriesC1WarrantsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_NumberOfInvestorsToWhomWarrantsWereIssued" xlink:label="adag_NumberOfInvestorsToWhomWarrantsWereIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="adag_NumberOfInvestorsToWhomWarrantsWereIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MaximumProceedsReceivableFromExerciseOfWarrants" xlink:label="adag_MaximumProceedsReceivableFromExerciseOfWarrants" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="adag_MaximumProceedsReceivableFromExerciseOfWarrants" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice" xlink:label="adag_TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="adag_TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice" xlink:label="adag_TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="adag_TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_QualifiedPublicOfferingMinimumMarketCapitalization" xlink:label="adag_QualifiedPublicOfferingMinimumMarketCapitalization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="adag_QualifiedPublicOfferingMinimumMarketCapitalization" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_QualifiedPublicOfferingMinimumProceeds" xlink:label="adag_QualifiedPublicOfferingMinimumProceeds" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="adag_QualifiedPublicOfferingMinimumProceeds" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent" xlink:label="adag_ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="adag_ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Share Activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Series1RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series1RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_Series1RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Series2RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series2RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_Series2RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesBRedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesBRedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC1RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC1RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesC1RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC2RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC2RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesC2RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC3RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC3RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="adag_SeriesC3RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureShareBasedCompensationDetails" xlink:type="extended" xlink:title="40901 - Disclosure - SHARE-BASED COMPENSATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Plan2015Member" xlink:label="adag_Plan2015Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="adag_Plan2015Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Plan2017Member" xlink:label="adag_Plan2017Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="adag_Plan2017Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Plan2019Member" xlink:label="adag_Plan2019Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="adag_Plan2019Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_PerformanceIncentivePlan2021Member" xlink:label="adag_PerformanceIncentivePlan2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PlanNameDomain" xlink:to="adag_PerformanceIncentivePlan2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ServiceConditionsAndPerformanceConditionsMember" xlink:label="adag_ServiceConditionsAndPerformanceConditionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="adag_ServiceConditionsAndPerformanceConditionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_NumberOfSharesSurrendered" xlink:label="adag_NumberOfSharesSurrendered" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adag_NumberOfSharesSurrendered" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent" xlink:label="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="40905 - Disclosure - SHARE-BASED COMPENSATION - Share based compensation expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - COLLABORATION ARRANGEMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember" xlink:label="adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember" xlink:label="adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SignalPharmaceuticalsLlcMember" xlink:label="adag_SignalPharmaceuticalsLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adag_SignalPharmaceuticalsLlcMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdctCollaborationAgreementMember" xlink:label="adag_AdctCollaborationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adag_AdctCollaborationAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ExelixisIncAgreementMember" xlink:label="adag_ExelixisIncAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adag_ExelixisIncAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adag_CollaborativeArrangementUpfrontCashPaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" xlink:label="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies" xlink:label="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_PeriodForReservationOfTargetRight" xlink:label="adag_PeriodForReservationOfTargetRight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adag_PeriodForReservationOfTargetRight" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" xlink:label="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CollaborativeArrangementMilestonePaymentReceived" xlink:label="adag_CollaborativeArrangementMilestonePaymentReceived" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adag_CollaborativeArrangementMilestonePaymentReceived" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CollaborativeArrangementUpfrontCashPaymentReceivable" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adag_CollaborativeArrangementUpfrontCashPaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" xlink:label="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MilestonePaymentsReceivableSalesBasedMilestones" xlink:label="adag_MilestonePaymentsReceivableSalesBasedMilestones" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="adag_MilestonePaymentsReceivableSalesBasedMilestones" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails" xlink:type="extended" xlink:title="41101 - Disclosure - INCOME TAX EXPENSE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_IncomeTaxDisclosureTable" xlink:label="adag_IncomeTaxDisclosureTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="adag_IncomeTaxDisclosureTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN" xlink:label="country_CN" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_HK" xlink:label="country_HK" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_HK" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_AU" xlink:label="country_AU" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_AU" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA" xlink:label="stpr_CA" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="country_US" xlink:to="stpr_CA" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="country_CH" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CH" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_SG" xlink:label="country_SG" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_SG" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_StatusForTaxabilityAxis" xlink:label="adag_StatusForTaxabilityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="adag_IncomeTaxDisclosureTable" xlink:to="adag_StatusForTaxabilityAxis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_StatusForTaxabilityDomain" xlink:label="adag_StatusForTaxabilityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="adag_StatusForTaxabilityAxis" xlink:to="adag_StatusForTaxabilityDomain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_TechnologyAdvancedServiceEnterprisesMember" xlink:label="adag_TechnologyAdvancedServiceEnterprisesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="adag_StatusForTaxabilityDomain" xlink:to="adag_TechnologyAdvancedServiceEnterprisesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="adag_IncomeTaxDisclosureTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneSuzhouLimitedMember" xlink:label="adag_AdageneSuzhouLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="adag_AdageneSuzhouLimitedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneHongKongLimitedMember" xlink:label="adag_AdageneHongKongLimitedMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="dei_EntityDomain" xlink:to="adag_AdageneHongKongLimitedMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneAustraliaPtyLtd.Member" xlink:label="adag_AdageneAustraliaPtyLtd.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="dei_EntityDomain" xlink:to="adag_AdageneAustraliaPtyLtd.Member" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneAgMember" xlink:label="adag_AdageneAgMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="dei_EntityDomain" xlink:to="adag_AdageneAgMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="adag_IncomeTaxDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_PreferentialIncomeTaxRate" xlink:label="adag_PreferentialIncomeTaxRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="adag_PreferentialIncomeTaxRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate" xlink:label="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AssessableProfits" xlink:label="adag_AssessableProfits" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="adag_AssessableProfits" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_WithholdingTaxRateOnDividendsPercentage" xlink:label="adag_WithholdingTaxRateOnDividendsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="adag_WithholdingTaxRateOnDividendsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CapitalTaxRatePercentage" xlink:label="adag_CapitalTaxRatePercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="adag_CapitalTaxRatePercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_WithholdingIncomeTaxes" xlink:label="adag_WithholdingIncomeTaxes" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="adag_WithholdingIncomeTaxes" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_TaxableIncome" xlink:label="adag_TaxableIncome" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="adag_TaxableIncome" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="41202 - Disclosure - NET LOSS PER SHARE - Anti-dilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockCompensationPlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41301 - Disclosure - RELATED PARTY TRANSACTIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_WuxiApptecGroupMember" xlink:label="adag_WuxiApptecGroupMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="adag_WuxiApptecGroupMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_WuxiBiologicsShanghaiCo.Ltd.Member" xlink:label="adag_WuxiBiologicsShanghaiCo.Ltd.Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="adag_WuxiBiologicsShanghaiCo.Ltd.Member" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember" xlink:label="adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureTreasurySharesDetails" xlink:type="extended" xlink:title="41601 - Disclosure - TREASURY SHARES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_ClassOfTreasuryStockTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:label="us-gaap_StockRepurchaseProgramPeriodInForce1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_StockRepurchaseProgramPeriodInForce1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_TreasuryStockSharesAcquired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_TreasuryStockSharesRetired" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.adagene.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41701 - Disclosure - SUBSEQUENT EVENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_PerformanceIncentivePlan2021Member" xlink:label="adag_PerformanceIncentivePlan2021Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="adag_PerformanceIncentivePlan2021Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_GranteeStatusAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ExelixisAgreementMember" xlink:label="adag_ExelixisAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="adag_ExelixisAgreementMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dei_AdrMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected" xlink:label="adag_ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="adag_ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CollaborativeArrangementUpfrontCashPaymentReceivable" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="adag_CollaborativeArrangementUpfrontCashPaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CollaborativeArrangementMilestonePaymentReceivable" xlink:label="adag_CollaborativeArrangementMilestonePaymentReceivable" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="adag_CollaborativeArrangementMilestonePaymentReceivable" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_TreasuryStockSharesAcquired" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_TreasuryStockSharesRetired" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>adag-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8119.21675 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/26/2022 12:38:33 PM-->
<!--Modified on: 4/26/2022 12:38:33 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AdrMember" xlink:label="dei_AdrMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AdrMember" xlink:to="dei_AdrMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AdrMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">American depositary shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Addresses, Address Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Address Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Business Contact [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Registration Statement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Shell Company Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Country</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contact Personnel Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelEmailAddress_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contact Personnel Email Address</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Country Region</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No Trading Symbol Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Accounting Standard</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Series1RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series1RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_Series1RedeemableConvertiblePreferredStockMember" xlink:to="adag_Series1RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_Series1RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-1 Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_Series1RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-1 convertible redeemable preferred shares</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Series2RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series2RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_Series2RedeemableConvertiblePreferredStockMember" xlink:to="adag_Series2RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_Series2RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-2 Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_Series2RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series A-2 convertible redeemable preferred shares</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesBRedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="adag_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series B convertible redeemable preferred shares</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC1RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC1RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_SeriesC1RedeemableConvertiblePreferredStockMember" xlink:to="adag_SeriesC1RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_SeriesC1RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C-1 Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_SeriesC1RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C-1 convertible redeemable preferred shares</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC2RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC2RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_SeriesC2RedeemableConvertiblePreferredStockMember" xlink:to="adag_SeriesC2RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_SeriesC2RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C-2 Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_SeriesC2RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C-2 convertible redeemable preferred shares</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC3RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC3RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_SeriesC3RedeemableConvertiblePreferredStockMember" xlink:to="adag_SeriesC3RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_SeriesC3RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C-3 Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_SeriesC3RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C-3 convertible redeemable preferred shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due from Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amounts due from related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments and other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, equipment and software, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net book value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' DEFICIT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract with Customer, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Due to Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amounts due to related parties</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:to="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accruals and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accruals and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBankLoansAndNotesPayable" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Bank Loans and Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bank loans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of long-term borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current portion of long term borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Excluding Current Maturities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non current borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAbstract" xlink:to="us-gaap_TemporaryEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mezzanine equity:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ending balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Beginning balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total mezzanine equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shareholders' equity (deficit):</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares (par value of US$0.0001 per share; 640,000,000 shares authorized, and 16,603,070 shares issued and outstanding as of December 31, 2020; and 640,000,000 shares authorized, 54,595,667 shares issued and outstanding as of December 31, 2021)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Stock, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares, at cost (Nil and 94,074 shares as of December 31, 2020 and 2021, respectively)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Subscriptions Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subscriptions receivable from shareholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total shareholders' equity (deficit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' EQUITY (DEFICIT)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible redeemable preferred shares, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible redeemable preferred shares, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible redeemable preferred shares, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible redeemable preferred shares, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, par value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Stock, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer, Excluding Assessed Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Licensing and collaboration revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ResearchAndDevelopmentExpenseThirdParties" xlink:label="adag_ResearchAndDevelopmentExpenseThirdParties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ResearchAndDevelopmentExpenseThirdParties" xlink:to="adag_ResearchAndDevelopmentExpenseThirdParties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ResearchAndDevelopmentExpenseThirdParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of research and development expenses resulting from transactions with third parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ResearchAndDevelopmentExpenseThirdParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Third Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="adag_ResearchAndDevelopmentExpenseThirdParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Third parties</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:to="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of research and development expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Research And Development Expense from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNonoperating" xlink:to="us-gaap_InvestmentIncomeNonoperating_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investment Income, Nonoperating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeNonoperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transaction Gain (Loss), before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange loss (gain), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign exchange gain (loss), net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gains from decrease in fair value of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in fair value of warrant liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before income tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to Adagene Inc.'s shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to Adagene Inc.'s shareholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation adjustments, net of nil tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive loss attributable to Adagene Inc.'s shareholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Accretion to Redemption Value, Adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of convertible redeemable preferred shares to redemption value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of convertible redeemable preferred shares to redemption value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss attributable to ordinary shareholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of ordinary shares used in per share calculation:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">-Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weightedaverage number of ordinary shares outstanding-basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">-Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weightedaverage number of ordinary shares outstanding-diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per ordinary share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">-Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per share-basic</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">-Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per share- diluted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation adjustments, tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesFromStockholderMember" xlink:to="us-gaap_ReceivablesFromStockholderMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesFromStockholderMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subscriptions receivable from shareholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of share options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of share options (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued upon exercise of share options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ordinary shares under performance incentive plan (Note 9)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ordinary shares under performance incentive plan (Note 9) (in shares)</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CommonStockSubscriptionsValue" xlink:label="adag_CommonStockSubscriptionsValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_CommonStockSubscriptionsValue" xlink:to="adag_CommonStockSubscriptionsValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_CommonStockSubscriptionsValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_CommonStockSubscriptionsValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Subscriptions, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_CommonStockSubscriptionsValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subscription from shareholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sharebased compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Preferred Shares to Ordinary Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of convertible redeemable preferred shares to ordinary shares upon the completion of initial public offering ("IPO")</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred shares to ordinary shares upon the completion of initial public offering ("IPO") (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ordinary shares upon IPO, net of issuance cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ordinary shares upon IPO, net of issuance cost (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Repurchased During Period, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of treasury shares under share repurchase program (Note 16)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total consideration of share repurchased</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesAcquired" xlink:to="us-gaap_TreasuryStockSharesAcquired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Repurchased During Period, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of treasury shares under share repurchase program (Note 16) (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockSharesAcquired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares repurchased (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="us-gaap_TreasuryStockRetiredCostMethodAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Stock, Retired, Par Value Method, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement of treasury shares (Note 16)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesRetired" xlink:to="us-gaap_TreasuryStockSharesRetired_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Stock, Shares, Retired</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement of treasury shares (Note 16) (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repurchased shares retired (in shares)</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_StockSurrenderedValueForRepaymentOfPromissoryNotes" xlink:label="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes" xlink:to="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of shares surrendered for repayment of promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Surrendered, Value,For Repayment of Promissory Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surrender of ordinary shares for repayment of promissory notes (Note 9)</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes" xlink:label="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes" xlink:to="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number shares surrendered for repayment of promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Surrendered, Shares, for Repayment of Promissory Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surrender of ordinary shares for repayment of promissory notes (Note 9) (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss (gain) on disposal of property, equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_InterestIncomeExpenseOnPromissoryNotes" xlink:label="adag_InterestIncomeExpenseOnPromissoryNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_InterestIncomeExpenseOnPromissoryNotes" xlink:to="adag_InterestIncomeExpenseOnPromissoryNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_InterestIncomeExpenseOnPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of interest income (expense) on promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_InterestIncomeExpenseOnPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income (Expense) On Promissory Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="adag_InterestIncomeExpenseOnPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income on promissory notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Due from Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount due from related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Contract with Customer, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contract liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Due to Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount due to related parties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accruals and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Income Taxes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Deferred Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Placement of short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Short-term Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Withdrawal of short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale of Productive Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from disposal of property, equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Productive Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property, equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash generated from (used in) investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from borrowings</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants" xlink:label="adag_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants" xlink:to="adag_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from issuance of Redeemable Convertible Preferred Stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Redeemable Convertible Preferred Stock and Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of convertible redeemable preferred shares and warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributedCapital" xlink:to="us-gaap_ProceedsFromContributedCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Contributed Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from share subscriptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of share options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total aggregate gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from initial public offering, net of underwriting commissions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount repaid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of initial public offering costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for Repurchase of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of treasury shares under stock repurchase program</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_RetirementOfTreasuryShares" xlink:label="adag_RetirementOfTreasuryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_RetirementOfTreasuryShares" xlink:to="adag_RetirementOfTreasuryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_RetirementOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of retirement of treasury shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_RetirementOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement of Treasury Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="adag_RetirementOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Costs for retirement of treasury shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash generated from financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate on cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at the end of year</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents at the beginning of year</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental cash flow disclosures:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest paid</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-cash activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of Stock, Amount Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion of preferred shares</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_PayablesForDeferredInitialPublicOfferingCost" xlink:label="adag_PayablesForDeferredInitialPublicOfferingCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_PayablesForDeferredInitialPublicOfferingCost" xlink:to="adag_PayablesForDeferredInitialPublicOfferingCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_PayablesForDeferredInitialPublicOfferingCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of payables for deferred initial public offering cost in non-cash activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_PayablesForDeferredInitialPublicOfferingCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payables For Deferred Initial Public Offering Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_PayablesForDeferredInitialPublicOfferingCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payables for deferred initial public offering cost</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_NonCashActivitiesRetirementOfTreasuryShares" xlink:label="adag_NonCashActivitiesRetirementOfTreasuryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_NonCashActivitiesRetirementOfTreasuryShares" xlink:to="adag_NonCashActivitiesRetirementOfTreasuryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_NonCashActivitiesRetirementOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of retirement of treasury shares in noncash investing or financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_NonCashActivitiesRetirementOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non cash Activities, Retirement of Treasury Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_NonCashActivitiesRetirementOfTreasuryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retirement of treasury shares</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes" xlink:label="adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes" xlink:to="adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of common stock shares surrendered for repayment of promissory notes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surrender Of Common Stock Shares For Repayment Of Promissory Notes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Surrender of ordinary shares for repayment of promissory notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ORGANIZATION AND BASIS OF PRESENTATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ORGANIZATION AND BASIS OF PRESENTATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="us-gaap_AccountsReceivableNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCOUNTS RECEIVABLE, NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCOUNTS RECEIVABLE, NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PREPAYMENTS AND OTHER CURRENT ASSETS</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:label="adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:to="adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on prepayments and other current assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PREPAYMENTS AND OTHER CURRENT ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PROPERTY, EQUIPMENT AND SOFTWARE, NET</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PROPERTY, EQUIPMENT AND SOFTWARE, NET</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCRUALS AND OTHER CURRENT LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:to="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure on accrued liabilities and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Other Current Liabilities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ACCRUALS AND OTHER CURRENT LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BORROWINGS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BORROWING</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BORROWINGS</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:to="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock" xlink:to="adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for temporary equity and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Temporary Equity And Warrants [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHARE-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHARE-BASED COMPENSATION</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CollaborationArrangementsAbstract" xlink:label="adag_CollaborationArrangementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_CollaborationArrangementsAbstract" xlink:to="adag_CollaborationArrangementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_CollaborationArrangementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_CollaborationArrangementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COLLABORATION ARRANGEMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COLLABORATION ARRANGEMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAX EXPENSE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAX EXPENSE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET LOSS PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RELATED PARTY TRANSACTIONS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COMMITMENTS AND CONTINGENCIES</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_RestrictedNetAssetsAbstract" xlink:label="adag_RestrictedNetAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_RestrictedNetAssetsAbstract" xlink:to="adag_RestrictedNetAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_RestrictedNetAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No Definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_RestrictedNetAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RESTRICTED NET ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:to="us-gaap_RestrictedAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Assets Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RESTRICTED NET ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAbstract" xlink:label="us-gaap_TreasuryStockSharesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesAbstract" xlink:to="us-gaap_TreasuryStockSharesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockSharesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TREASURY SHARES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockTextBlock" xlink:label="us-gaap_TreasuryStockTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockTextBlock" xlink:to="us-gaap_TreasuryStockTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Treasury Stock [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TREASURY SHARES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUBSEQUENT EVENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidation, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principles of Consolidation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Foreign currency translation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock" xlink:label="adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock" xlink:to="adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for accounts receivable and allowance for doubtful accounts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable And Allowance for Doubtful Accounts, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable and allowance for doubtful accounts</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of long-lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment Reporting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Segment reporting</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_GovernmentSubsidiesPolicyTextBlock" xlink:label="adag_GovernmentSubsidiesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_GovernmentSubsidiesPolicyTextBlock" xlink:to="adag_GovernmentSubsidiesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_GovernmentSubsidiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for government subsidies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_GovernmentSubsidiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Subsidies [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_GovernmentSubsidiesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government subsidies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Leases [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per share</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:label="adag_EmployeeDefinedContributionPlanPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:to="adag_EmployeeDefinedContributionPlanPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_EmployeeDefinedContributionPlanPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of accounting policy for Employee defined contribution plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_EmployeeDefinedContributionPlanPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Defined Contribution Plan [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_EmployeeDefinedContributionPlanPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee defined contribution plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of risks</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently issued accounting pronouncements</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SummaryOfPrincipalSubsidiariesTableTextBlock" xlink:label="adag_SummaryOfPrincipalSubsidiariesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_SummaryOfPrincipalSubsidiariesTableTextBlock" xlink:to="adag_SummaryOfPrincipalSubsidiariesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_SummaryOfPrincipalSubsidiariesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of principal subsidiaries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_SummaryOfPrincipalSubsidiariesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Principal Subsidiaries [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_SummaryOfPrincipalSubsidiariesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of principal subsidiaries</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure of estimated useful lives of property and equipment and software.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant And Equipment, Estimated Useful Life [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of estimated useful lives of property, equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of prepayments and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of property, equipment and software</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The tabular disclosure on accrued liabilities and other current liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Other Current Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of accrued liabilities and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of borrowings</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock" xlink:label="adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock" xlink:to="adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of maturity and sinking fund requirement for short-term debt and long-term debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Maturities Of Short-Term Debt And Long-Term Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future maturities of short-term borrowings and long-term borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Company's Preferred Shares activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of assumptions used to estimate the fair value of the share options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of total share based compensation expenses recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of components of income tax expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of reconciliation between the income tax expense and the actual provision</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of tax effects of temporary differences that give rise to the deferred tax balances</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Valuation Allowance [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of movement of the valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of basic and diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of potentially dilutive securities that are not included in the calculation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of related party transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future minimum payments under non-cancelable operating leases</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information on organization, consolidation and presentation of financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation And Presentation Of Financial Statements [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneHongKongLimitedMember" xlink:label="adag_AdageneHongKongLimitedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AdageneHongKongLimitedMember" xlink:to="adag_AdageneHongKongLimitedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AdageneHongKongLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Adagene (Hong Kong) Limited.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AdageneHongKongLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adagene (Hong Kong) Limited</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneIncorporatedMember" xlink:label="adag_AdageneIncorporatedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AdageneIncorporatedMember" xlink:to="adag_AdageneIncorporatedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AdageneIncorporatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Adagene Incorporated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AdageneIncorporatedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adagene Incorporated</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneSuzhouLimitedMember" xlink:label="adag_AdageneSuzhouLimitedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AdageneSuzhouLimitedMember" xlink:to="adag_AdageneSuzhouLimitedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AdageneSuzhouLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Adagene (Suzhou) Limited.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AdageneSuzhouLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adagene (Suzhou) Limited</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneAustraliaPtyLtd.Member" xlink:label="adag_AdageneAustraliaPtyLtd.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AdageneAustraliaPtyLtd.Member" xlink:to="adag_AdageneAustraliaPtyLtd.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AdageneAustraliaPtyLtd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Adagene Australia PTY Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AdageneAustraliaPtyLtd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adagene Australia PTY Ltd.</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdagenePte.Ltd.Member" xlink:label="adag_AdagenePte.Ltd.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AdagenePte.Ltd.Member" xlink:to="adag_AdagenePte.Ltd.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AdagenePte.Ltd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to Adagene PTE. Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AdagenePte.Ltd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adagene PTE. Ltd.</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneAgMember" xlink:label="adag_AdageneAgMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AdageneAgMember" xlink:to="adag_AdageneAgMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AdageneAgMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to Adagene AG.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AdageneAgMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adagene AG</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriters' option</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation And Presentation Of Financial Statements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ORGANIZATION AND BASIS OF PRESENTATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncontrolling Interest, Ownership Percentage by Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of legal ownership by the Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price (in USD per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued price per share (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityListingDepositoryReceiptRatio" xlink:label="dei_EntityListingDepositoryReceiptRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingDepositoryReceiptRatio" xlink:to="dei_EntityListingDepositoryReceiptRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingDepositoryReceiptRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Listing, Depository Receipt Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityListingDepositoryReceiptRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of ordinary shares represented by each ADS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Recurring and Nonrecurring [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Frequency [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nonrecurring basis</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items}</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_FinancialAssetsFairValueDisclosure" xlink:label="adag_FinancialAssetsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_FinancialAssetsFairValueDisclosure" xlink:to="adag_FinancialAssetsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_FinancialAssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of financial assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_FinancialAssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Assets Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_FinancialAssetsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Liabilities Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Lived Tangible Asset [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Machinery and laboratory equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vehicles</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and tools</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ElectronicEquipmentMember" xlink:label="adag_ElectronicEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ElectronicEquipmentMember" xlink:to="adag_ElectronicEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ElectronicEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Electronic equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ElectronicEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Electronic equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statistical Measurement [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Useful Life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Useful Life</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="us-gaap_AssetImpairmentChargesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentChargesAbstract" xlink:to="us-gaap_AssetImpairmentChargesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentChargesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of long lived assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-Lived Assets Held-for-use</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAbstract" xlink:to="us-gaap_RevenueRecognitionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue recognition</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MilestonePaymentsOrRoyaltyPaymentsReceived" xlink:label="adag_MilestonePaymentsOrRoyaltyPaymentsReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_MilestonePaymentsOrRoyaltyPaymentsReceived" xlink:to="adag_MilestonePaymentsOrRoyaltyPaymentsReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_MilestonePaymentsOrRoyaltyPaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of milestone payments or royalty payments received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_MilestonePaymentsOrRoyaltyPaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payments or Royalty Payments Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_MilestonePaymentsOrRoyaltyPaymentsReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments or royalty payments received</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_DefinedContributionPlanAbstract" xlink:label="adag_DefinedContributionPlanAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_DefinedContributionPlanAbstract" xlink:to="adag_DefinedContributionPlanAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_DefinedContributionPlanAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_DefinedContributionPlanAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_DefinedContributionPlanAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee defined contribution plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee benefit expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="us-gaap_GeographicConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeographicConcentrationRiskMember" xlink:to="us-gaap_GeographicConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeographicConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of credit risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of suppliers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk Benchmark [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CashAndCashEquivalentsAndShortTermInvestmentsMember" xlink:label="adag_CashAndCashEquivalentsAndShortTermInvestmentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_CashAndCashEquivalentsAndShortTermInvestmentsMember" xlink:to="adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying amount as of the balance sheet date of cash and cash equivalents and short term investments when it serves as a benchmark in a concentration of risk calculation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents and short-term investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsProductLineMember" xlink:label="us-gaap_CostOfGoodsProductLineMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsProductLineMember" xlink:to="us-gaap_CostOfGoodsProductLineMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsProductLineMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development services purchased</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ConcentrationRiskSuppliersAxis" xlink:label="adag_ConcentrationRiskSuppliersAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ConcentrationRiskSuppliersAxis" xlink:to="adag_ConcentrationRiskSuppliersAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ConcentrationRiskSuppliersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Information about suppliers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ConcentrationRiskSuppliersAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Suppliers [Axis]</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ConcentrationRiskSuppliersDomain" xlink:label="adag_ConcentrationRiskSuppliersDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ConcentrationRiskSuppliersDomain" xlink:to="adag_ConcentrationRiskSuppliersDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ConcentrationRiskSuppliersDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Suppliers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ConcentrationRiskSuppliersDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Suppliers [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_OneSupplierMember" xlink:label="adag_OneSupplierMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_OneSupplierMember" xlink:to="adag_OneSupplierMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_OneSupplierMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One supplier.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_OneSupplierMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">One supplier</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Geographical [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MainlandOfChinaMember" xlink:label="adag_MainlandOfChinaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_MainlandOfChinaMember" xlink:to="adag_MainlandOfChinaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_MainlandOfChinaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mainland of China.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_MainlandOfChinaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Mainland of China</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_OutsideMainlandOfChinaMember" xlink:label="adag_OutsideMainlandOfChinaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_OutsideMainlandOfChinaMember" xlink:to="adag_OutsideMainlandOfChinaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_OutsideMainlandOfChinaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outside the mainland of China.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_OutsideMainlandOfChinaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outside the mainland of China</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, and Short-term Investments</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_NumberOfMajorSupplier" xlink:label="adag_NumberOfMajorSupplier" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_NumberOfMajorSupplier" xlink:to="adag_NumberOfMajorSupplier_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_NumberOfMajorSupplier_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of major supplier.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_NumberOfMajorSupplier_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Major Supplier</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_NumberOfMajorSupplier_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of major supplier</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration risk percentage</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_PercentageOfDepreciationOfForeignCurrency" xlink:label="adag_PercentageOfDepreciationOfForeignCurrency" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_PercentageOfDepreciationOfForeignCurrency" xlink:to="adag_PercentageOfDepreciationOfForeignCurrency_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_PercentageOfDepreciationOfForeignCurrency_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of depreciation of foreign currency.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_PercentageOfDepreciationOfForeignCurrency_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage Of Depreciation Of Foreign Currency</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_PercentageOfDepreciationOfForeignCurrency_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation of foreign currency (as a percent)</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_GovernmentSubsidiesReceived" xlink:label="adag_GovernmentSubsidiesReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_GovernmentSubsidiesReceived" xlink:to="adag_GovernmentSubsidiesReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_GovernmentSubsidiesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of subsidies received by the entity for Government.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_GovernmentSubsidiesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government Subsidies Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_GovernmentSubsidiesReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Government subsidies received</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGross" xlink:to="us-gaap_AccountsReceivableGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, before Allowance for Credit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Receivable, after Allowance for Credit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts receivable, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepayments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Others</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net, by Type [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total property, equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Professional Fees, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Professional service fees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payroll and related liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedUtilitiesCurrent" xlink:label="us-gaap_AccruedUtilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedUtilitiesCurrent" xlink:to="us-gaap_AccruedUtilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedUtilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Utilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedUtilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Utility and maintenance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxes Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other taxes and surcharge</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Others</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrentAbstract" xlink:label="us-gaap_DebtCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrentAbstract" xlink:to="us-gaap_DebtCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowingsAbstract" xlink:label="us-gaap_ShortTermBorrowingsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowingsAbstract" xlink:to="us-gaap_ShortTermBorrowingsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermBorrowingsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Debt [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShortTermBorrowingsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short term borrowings:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DebtCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2021</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Other than Long-term Debt, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Excluding Current Maturities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long term borrowings:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLoansFromBank" xlink:label="us-gaap_LongTermLoansFromBank" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermLoansFromBank" xlink:to="us-gaap_LongTermLoansFromBank_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermLoansFromBank_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loans Payable to Bank, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermLoansFromBank_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Bank loans</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt, Long-term and Short-term, Combined Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total borrowings</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Short-term Debt [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_BorrowingsFromBankOfNingboCo.LtdMember" xlink:label="adag_BorrowingsFromBankOfNingboCo.LtdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_BorrowingsFromBankOfNingboCo.LtdMember" xlink:to="adag_BorrowingsFromBankOfNingboCo.LtdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_BorrowingsFromBankOfNingboCo.LtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Borrowings from Bank of Ningbo Co., Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_BorrowingsFromBankOfNingboCo.LtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings from Bank of Ningbo Co., Ltd</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember" xlink:label="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember" xlink:to="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Borrowings from Agricultural Bank of China Limited.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings from Agricultural Bank of China Limited</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ChinaMerchantsBankCo.LtdMember" xlink:label="adag_ChinaMerchantsBankCo.LtdMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ChinaMerchantsBankCo.LtdMember" xlink:to="adag_ChinaMerchantsBankCo.LtdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ChinaMerchantsBankCo.LtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to China Merchants Bank Co., Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ChinaMerchantsBankCo.LtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">China Merchants Bank Co., Ltd</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ChinaMerchantsBankCo.LtdLoanTwoMember" xlink:label="adag_ChinaMerchantsBankCo.LtdLoanTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ChinaMerchantsBankCo.LtdLoanTwoMember" xlink:to="adag_ChinaMerchantsBankCo.LtdLoanTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ChinaMerchantsBankCo.LtdLoanTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to China Merchants Bank Co., Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ChinaMerchantsBankCo.LtdLoanTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">China Merchants Bank Co., Ltd., two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Short-term Debt [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount borrowed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Series Pre A Convertible Notes issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of the debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest rate (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Pre A Convertible Notes, Interest rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Long-term Debt Instruments [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, one.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings from Shanghai Pudong Development Bank Co., Ltd., one</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, two.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings from Shanghai Pudong Development Bank Co., Ltd., two</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, three.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings from Shanghai Pudong Development Bank Co., Ltd., three</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, Four.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Borrowings from Shanghai Pudong Development Bank Co., Ltd., four</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTerm" xlink:label="us-gaap_LongTermDebtTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTerm" xlink:to="us-gaap_LongTermDebtTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of the debt</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-Term Debt, Maturity, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, by Class of Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series Pre-A Convertible Notes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC1WarrantsMember" xlink:label="adag_SeriesC1WarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_SeriesC1WarrantsMember" xlink:to="adag_SeriesC1WarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_SeriesC1WarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Series C 1 Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_SeriesC1WarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Series C 1 Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLineItems" xlink:to="us-gaap_TemporaryEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion price (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of new stock classified as temporary equity issued during the period, upon conversion of convertible securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Shares, Conversion Of Convertible Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares issued upon conversion of Series Pre-A Convertible Notes (in shares)</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares of new stock classified as temporary equity issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of new shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Redeemable Convertible Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total consideration from issuance of convertible redeemable preferred shares</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_NumberOfInvestorsToWhomWarrantsWereIssued" xlink:label="adag_NumberOfInvestorsToWhomWarrantsWereIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_NumberOfInvestorsToWhomWarrantsWereIssued" xlink:to="adag_NumberOfInvestorsToWhomWarrantsWereIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_NumberOfInvestorsToWhomWarrantsWereIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of investors to whom warrants were issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_NumberOfInvestorsToWhomWarrantsWereIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Investors To Whom Warrants Were Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_NumberOfInvestorsToWhomWarrantsWereIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Series C-1 investors to whom warrants were issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consideration from issuance of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MaximumProceedsReceivableFromExerciseOfWarrants" xlink:label="adag_MaximumProceedsReceivableFromExerciseOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_MaximumProceedsReceivableFromExerciseOfWarrants" xlink:to="adag_MaximumProceedsReceivableFromExerciseOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_MaximumProceedsReceivableFromExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum amount of proceeds receivable from exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_MaximumProceedsReceivableFromExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Proceeds Receivable From Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_MaximumProceedsReceivableFromExerciseOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total maximum consideration from exercise of warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Dividend Rate, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares on conversion of each convertible preferred stock</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice" xlink:label="adag_TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice" xlink:to="adag_TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of original issue price considered for liquidation preference (or restrictions) of stock classified as temporary equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Liquidation Preference, Percentage Of Original Issue Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liquidation preference (as a percent)</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice" xlink:label="adag_TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice" xlink:to="adag_TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of interest on original issue price considered for liquidation preference (or restrictions) of stock classified as temporary equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity Liquidation Preference Percentage Of Interest On Original Issue Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Simple interest accruing on original issue price (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Convertible, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Conversion ratio</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_QualifiedPublicOfferingMinimumMarketCapitalization" xlink:label="adag_QualifiedPublicOfferingMinimumMarketCapitalization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_QualifiedPublicOfferingMinimumMarketCapitalization" xlink:to="adag_QualifiedPublicOfferingMinimumMarketCapitalization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_QualifiedPublicOfferingMinimumMarketCapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum market capitalization reflected by the Qualified Public Offering, considered for automatic conversion of preferred shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_QualifiedPublicOfferingMinimumMarketCapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Qualified Public Offering, Minimum Market Capitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_QualifiedPublicOfferingMinimumMarketCapitalization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum market capitalization from Qualified Public Offering</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_QualifiedPublicOfferingMinimumProceeds" xlink:label="adag_QualifiedPublicOfferingMinimumProceeds" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_QualifiedPublicOfferingMinimumProceeds" xlink:to="adag_QualifiedPublicOfferingMinimumProceeds_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_QualifiedPublicOfferingMinimumProceeds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum amount of proceeds receivable from Qualified Public Offering, considered for automatic conversion of preferred shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_QualifiedPublicOfferingMinimumProceeds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Qualified Public Offering, Minimum Proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_QualifiedPublicOfferingMinimumProceeds_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum aggregate proceeds from Qualified Public Offering</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent" xlink:label="adag_ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent" xlink:to="adag_ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold minimum percentage of voting power held by preferred share holders to provide written consent, considered for automatic conversion of preferred shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Percentage Of Minimum Voting Power Held By Preferred Shareholders To Provide Written Consent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum percentage of voting power held by preferred share holders to provide written consent</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Temporary Equity [Roll Forward]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of Preferred Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Temporary Equity, Accretion to Redemption Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion of Preferred Shares to redemption value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Plan2015Member" xlink:label="adag_Plan2015Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_Plan2015Member" xlink:to="adag_Plan2015Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_Plan2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2015 Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_Plan2015Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2015 Plan</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Plan2017Member" xlink:label="adag_Plan2017Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_Plan2017Member" xlink:to="adag_Plan2017Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_Plan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2017 Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_Plan2017Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2017 Plan</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Plan2019Member" xlink:label="adag_Plan2019Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_Plan2019Member" xlink:to="adag_Plan2019Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_Plan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2019 Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_Plan2019Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Plan</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_PerformanceIncentivePlan2021Member" xlink:label="adag_PerformanceIncentivePlan2021Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_PerformanceIncentivePlan2021Member" xlink:to="adag_PerformanceIncentivePlan2021Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_PerformanceIncentivePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Performance incentive plan 2021.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_PerformanceIncentivePlan2021Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Performance Incentive Plan 2021 (the "2021 Plan")</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusAxis" xlink:to="us-gaap_GranteeStatusAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GranteeStatusDomain" xlink:to="us-gaap_GranteeStatusDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GranteeStatusDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Grantee Status [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employees</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Management</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ServiceConditionsAndPerformanceConditionsMember" xlink:label="adag_ServiceConditionsAndPerformanceConditionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ServiceConditionsAndPerformanceConditionsMember" xlink:to="adag_ServiceConditionsAndPerformanceConditionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ServiceConditionsAndPerformanceConditionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to service conditions and performance conditions related to share options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ServiceConditionsAndPerformanceConditionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Service conditions and Performance conditions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum aggregate number of shares that may be issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Plan Modification, Incremental Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental compensation cost to be recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental fair value</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options for which the vesting schedules and conditions are waived.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vesting Schedules and Conditions waived</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of options, vesting schedules and conditions waived</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price (in USD per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares unvested</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_NumberOfSharesSurrendered" xlink:label="adag_NumberOfSharesSurrendered" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_NumberOfSharesSurrendered" xlink:to="adag_NumberOfSharesSurrendered_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_NumberOfSharesSurrendered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares surrendered by the shareholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_NumberOfSharesSurrendered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares Surrendered</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_NumberOfSharesSurrendered_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares surrendered</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value (in USD per option)</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent" xlink:label="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent" xlink:to="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of increase in shares reserve annually based on shares outstanding under share based compensation share based payments.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Share Based Payments, Shares Reserve, Incremental, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Incremental percent of shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate ordinary shares reserved for issuance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average period to recognize unrecognized compensation cost (in years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average period for recognition of share based compensation expense (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest at the end</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest at the end (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Grant Date Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant-date fair value of options exercised.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted-average grant date fair value, at which grantee can acquire shares reserved for issuance. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest at the end (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The weighted-average grant date fair value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest at the end (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end (in dollars)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning (in dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested and expected to vest at the end (in dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end (in dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate fair value of the equity awards vested</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized employee share based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assumptions used to estimate the fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk free interest rate, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk free interest rate, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividend yield</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility, maximum</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum exercise multiple assumption that is used in valuing an option on its own shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Multiple, Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise multiple, minimum</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum exercise multiple assumption that is used in valuing an option on its own shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Multiple, Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise multiple, maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contractual life (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Administrative expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total share based compensation expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember" xlink:label="adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember" xlink:to="adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Guilin Sanjin Pharmaceutical Co., Ltd. License Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Guilin Sanjin Pharmaceutical Co., Ltd. License Agreement</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember" xlink:label="adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember" xlink:to="adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SignalPharmaceuticalsLlcMember" xlink:label="adag_SignalPharmaceuticalsLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_SignalPharmaceuticalsLlcMember" xlink:to="adag_SignalPharmaceuticalsLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_SignalPharmaceuticalsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Signal Pharmaceuticals LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_SignalPharmaceuticalsLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Signal Pharmaceuticals LLC</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdctCollaborationAgreementMember" xlink:label="adag_AdctCollaborationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AdctCollaborationAgreementMember" xlink:to="adag_AdctCollaborationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AdctCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to ADCT Collaboration Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AdctCollaborationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ADCT Collaboration Agreement</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ExelixisIncAgreementMember" xlink:label="adag_ExelixisIncAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ExelixisIncAgreementMember" xlink:to="adag_ExelixisIncAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ExelixisIncAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the member information pertaining to Exelixis, Inc. Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ExelixisIncAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exelixis Inc Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:to="adag_CollaborativeArrangementUpfrontCashPaymentReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from upfront cash received in collaborative arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Upfront Cash Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront cash payment received</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" xlink:label="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" xlink:to="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The agreed period for not to grant rights associated with antibodies to third parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreed Period for Not to Grant Rights Associated With Antibodies to Third Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agreed period for not to grant rights associated with antibodies to third parties</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies" xlink:label="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies" xlink:to="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The maximum number of selected targets, agreed for generation of antibodies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum Number of Selected Targets, Agreed for Generation of Antibodies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum number of selected targets, agreed for generation of antibodies</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_PeriodForReservationOfTargetRight" xlink:label="adag_PeriodForReservationOfTargetRight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_PeriodForReservationOfTargetRight" xlink:to="adag_PeriodForReservationOfTargetRight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_PeriodForReservationOfTargetRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The period for reservation of target right.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_PeriodForReservationOfTargetRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for Reservation of Target Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_PeriodForReservationOfTargetRight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period for reservation of target right</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" xlink:label="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" xlink:to="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The minimum threshold written notice period for termination of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Threshold Written Notice Period for Termination of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum threshold written notice period for termination of agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CollaborativeArrangementMilestonePaymentReceived" xlink:label="adag_CollaborativeArrangementMilestonePaymentReceived" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_CollaborativeArrangementMilestonePaymentReceived" xlink:to="adag_CollaborativeArrangementMilestonePaymentReceived_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_CollaborativeArrangementMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow from milestone payments received in collaborative arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_CollaborativeArrangementMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Milestone Payment Received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_CollaborativeArrangementMilestonePaymentReceived_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone fee received</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CollaborativeArrangementUpfrontCashPaymentReceivable" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_CollaborativeArrangementUpfrontCashPaymentReceivable" xlink:to="adag_CollaborativeArrangementUpfrontCashPaymentReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront cash payment receivable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement Upfront Cash Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of upfront-refundable fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Upfront payment receivable</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" xlink:label="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" xlink:to="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments receivable upon achieving certain development and regulatory approval milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payments Receivable, Development And Regulatory Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments receivable based on development and regulatory milestones</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MilestonePaymentsReceivableSalesBasedMilestones" xlink:label="adag_MilestonePaymentsReceivableSalesBasedMilestones" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_MilestonePaymentsReceivableSalesBasedMilestones" xlink:to="adag_MilestonePaymentsReceivableSalesBasedMilestones_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_MilestonePaymentsReceivableSalesBasedMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments conditioned upon achieving sales based milestones.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_MilestonePaymentsReceivableSalesBasedMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone Payments Receivable,Sales Based Milestones</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_MilestonePaymentsReceivableSalesBasedMilestones_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payments receivable based on sales</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_IncomeTaxDisclosureTable" xlink:label="adag_IncomeTaxDisclosureTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_IncomeTaxDisclosureTable" xlink:to="adag_IncomeTaxDisclosureTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_IncomeTaxDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of information pertaining to income taxes.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_IncomeTaxDisclosureTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN" xlink:label="country_CN" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CN_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PRC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_HK" xlink:label="country_HK" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_HK" xlink:to="country_HK_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_HK_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Hong Kong</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_AU" xlink:label="country_AU" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_AU" xlink:to="country_AU_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_AU_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Australia</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_US_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">United States</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA" xlink:label="stpr_CA" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="stpr_CA_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">California</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="country_CH" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CH" xlink:to="country_CH_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_CH_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SWITZERLAND</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_SG" xlink:label="country_SG" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_SG" xlink:to="country_SG_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_SG_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SINGAPORE</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_StatusForTaxabilityAxis" xlink:label="adag_StatusForTaxabilityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_StatusForTaxabilityAxis" xlink:to="adag_StatusForTaxabilityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_StatusForTaxabilityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to various tax status.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_StatusForTaxabilityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Status for Taxability [Axis]</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_StatusForTaxabilityDomain" xlink:label="adag_StatusForTaxabilityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_StatusForTaxabilityDomain" xlink:to="adag_StatusForTaxabilityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_StatusForTaxabilityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents various tax status.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_StatusForTaxabilityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Status For Taxability [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_TechnologyAdvancedServiceEnterprisesMember" xlink:label="adag_TechnologyAdvancedServiceEnterprisesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_TechnologyAdvancedServiceEnterprisesMember" xlink:to="adag_TechnologyAdvancedServiceEnterprisesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_TechnologyAdvancedServiceEnterprisesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents an entity classification of Technology Advanced Service Enterprises that receives preferential tax treatment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_TechnologyAdvancedServiceEnterprisesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TASE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax rate (as a percent)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">PRC preferential income tax rate as qualified TASE</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_PreferentialIncomeTaxRate" xlink:label="adag_PreferentialIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_PreferentialIncomeTaxRate" xlink:to="adag_PreferentialIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_PreferentialIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferential income tax rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_PreferentialIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferential Income Tax Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_PreferentialIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferential tax rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate" xlink:label="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate" xlink:to="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The effective period of Technology Advanced Service Enterprises certificate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Period of Technology Advanced Service Enterprises Certificate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective period of TASE certificate (in years)</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AssessableProfits" xlink:label="adag_AssessableProfits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AssessableProfits" xlink:to="adag_AssessableProfits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AssessableProfits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of assessable profits or earnings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AssessableProfits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assessable Profits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_AssessableProfits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assessable profits or earnings</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_WithholdingTaxRateOnDividendsPercentage" xlink:label="adag_WithholdingTaxRateOnDividendsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_WithholdingTaxRateOnDividendsPercentage" xlink:to="adag_WithholdingTaxRateOnDividendsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_WithholdingTaxRateOnDividendsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of withholding tax rate on dividends.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_WithholdingTaxRateOnDividendsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Withholding Tax Rate On Dividends, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_WithholdingTaxRateOnDividendsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends withholding tax rate</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CapitalTaxRatePercentage" xlink:label="adag_CapitalTaxRatePercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_CapitalTaxRatePercentage" xlink:to="adag_CapitalTaxRatePercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_CapitalTaxRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of capital tax rate.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_CapitalTaxRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital Tax Rate, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_CapitalTaxRatePercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capital tax rate for Canton of Basel</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating losses</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_WithholdingIncomeTaxes" xlink:label="adag_WithholdingIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_WithholdingIncomeTaxes" xlink:to="adag_WithholdingIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_WithholdingIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of withholding income taxes on remittance of dividends.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_WithholdingIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Withholding Income Taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_WithholdingIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Withholding tax</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_TaxableIncome" xlink:label="adag_TaxableIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_TaxableIncome" xlink:to="adag_TaxableIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_TaxableIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of taxable income during the reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_TaxableIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxable Income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Settlement, State and Local, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State income tax rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Federal Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current State and Local Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and local</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current income tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Federal Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred State and Local Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State and local</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred income tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income tax credit computed at PRC preferential income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Difference in income tax rates of overseas entities</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount" xlink:label="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount" xlink:to="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of the difference between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for research and development.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Deduction, Research and Development Expenses, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development super-deduction</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nondeductible expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State tax</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Others</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carry forward</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Inventory</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInventory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Unrealized Currency Losses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized foreign exchange gain/losses</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="adag_DeferredTaxAssetsDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_DeferredTaxAssetsDepreciationAndAmortization" xlink:to="adag_DeferredTaxAssetsDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_DeferredTaxAssetsDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation and amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_DeferredTaxAssetsDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Depreciation and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_DeferredTaxAssetsDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization of property, equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: valuation allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance as of December 31</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance as of January 1</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Property, Plant and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization of property, equipment and software</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax liabilities, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceAbstract" xlink:label="us-gaap_ValuationAllowanceAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceAbstract" xlink:to="us-gaap_ValuationAllowanceAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Movement of the valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Addition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Numerator:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Convertible redeemable preferred shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockCompensationPlanMember" xlink:to="us-gaap_StockCompensationPlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockCompensationPlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share options and share grant</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities not included in the computation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_WuxiApptecGroupMember" xlink:label="adag_WuxiApptecGroupMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_WuxiApptecGroupMember" xlink:to="adag_WuxiApptecGroupMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_WuxiApptecGroupMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to WuXi AppTec Group .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_WuxiApptecGroupMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">WuXi AppTec Group</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_WuxiBiologicsShanghaiCo.Ltd.Member" xlink:label="adag_WuxiBiologicsShanghaiCo.Ltd.Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_WuxiBiologicsShanghaiCo.Ltd.Member" xlink:to="adag_WuxiBiologicsShanghaiCo.Ltd.Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_WuxiBiologicsShanghaiCo.Ltd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to WuXi Biologics (Shanghai) Co., Ltd.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_WuxiBiologicsShanghaiCo.Ltd.Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">WuXi Biologics (Shanghai) Co., Ltd.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Domain]</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember" xlink:label="adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember" xlink:to="adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to receipt of contract research organizations ("CRO") and contract manufacturing organizations ("CMO") services with related parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Receipt of CRO and CMO services</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related party transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future minimum payments under non cancelable operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2022</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments, Due in Three Years</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Future Minimum Payments Due</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Rent Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total rental related expenses for operating leases</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve" xlink:label="adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve" xlink:to="adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum percentage of the profit after tax to be transferred to statutory reserve.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum Percentage Of Profits After Tax To Be Transferred To Statutory Reserve</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum percentage of profit after tax to be transferred to statutory reserve</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital" xlink:label="adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital" xlink:to="adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Required percentage of statutory reserve on registered capital to be maintained.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statutory Reserve Maintenance Required Percentage On Registered Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statutory reserve required percentage on registered capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:label="us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:to="us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of Restricted Net Assets for Consolidated and Unconsolidated Subsidiaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total restricted net assets</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AfterTaxIncomePercentageAppropriations" xlink:label="adag_AfterTaxIncomePercentageAppropriations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_AfterTaxIncomePercentageAppropriations" xlink:to="adag_AfterTaxIncomePercentageAppropriations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_AfterTaxIncomePercentageAppropriations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of after-tax income to be set aside as a general reserve fund.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_AfterTaxIncomePercentageAppropriations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">After Tax Income Percentage Appropriations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_AfterTaxIncomePercentageAppropriations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">After-Tax Income, Annual appropriations, Percentage</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries" xlink:label="adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries" xlink:to="adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold percentage on restricted net assets of PRC subsidiaries.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Threshold Percentage On Restricted Net Assets Of PRC Subsidiaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restrictions on net assets of PRC subsidiaries , threshold percentage</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfTreasuryStockTable" xlink:to="us-gaap_ClassOfTreasuryStockTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfTreasuryStockTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Treasury Stock [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="us-gaap_EquityClassOfTreasuryStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity, Class of Treasury Stock [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Repurchase Program, Authorized Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share repurchase program authorized amount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:label="us-gaap_StockRepurchaseProgramPeriodInForce1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:to="us-gaap_StockRepurchaseProgramPeriodInForce1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchaseProgramPeriodInForce1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Repurchase Program, Period in Force</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchaseProgramPeriodInForce1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term of share repurchase program (in months)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ExelixisAgreementMember" xlink:label="adag_ExelixisAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ExelixisAgreementMember" xlink:to="adag_ExelixisAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ExelixisAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Exelixis agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ExelixisAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exelixis Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected" xlink:label="adag_ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected" xlink:to="adag_ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares affected by modification of award under share-based payment arrangement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Plan Modification, Number of Shares Affected</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares affected by modification of award</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual cap percentage</label>
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CollaborativeArrangementMilestonePaymentReceivable" xlink:label="adag_CollaborativeArrangementMilestonePaymentReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="adag_CollaborativeArrangementMilestonePaymentReceivable" xlink:to="adag_CollaborativeArrangementMilestonePaymentReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="adag_CollaborativeArrangementMilestonePaymentReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount receivable upon achievement of target specified.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="adag_CollaborativeArrangementMilestonePaymentReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Collaborative Arrangement, Milestone Payment Receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="adag_CollaborativeArrangementMilestonePaymentReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Milestone payment receivable</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>adag-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.8119.21675 -->
<!--Based on XBRL 2.1-->
<!--Created on: 4/26/2022 12:38:33 PM-->
<!--Modified on: 4/26/2022 12:38:33 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.adagene.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#StatementConsolidatedBalanceSheets" roleURI="http://www.adagene.com/role/StatementConsolidatedBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#StatementConsolidatedBalanceSheetsParenthetical" roleURI="http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#StatementConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#StatementConsolidatedStatementsOfComprehensiveLossParenthetical" roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLossParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit" roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#StatementConsolidatedStatementsOfCashFlows" roleURI="http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureOrganizationAndBasisOfPresentation" roleURI="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureAccountsReceivableNet" roleURI="http://www.adagene.com/role/DisclosureAccountsReceivableNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosurePrepaymentsAndOtherCurrentAssets" roleURI="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosurePropertyEquipmentAndSoftwareNet" roleURI="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureAccrualsAndOtherCurrentLiabilities" roleURI="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureBorrowings" roleURI="http://www.adagene.com/role/DisclosureBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureConvertibleRedeemablePreferredSharesAndWarrants" roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureShareBasedCompensation" roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureCollaborationArrangements" roleURI="http://www.adagene.com/role/DisclosureCollaborationArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureIncomeTaxExpense" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureNetLossPerShare" roleURI="http://www.adagene.com/role/DisclosureNetLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureRelatedPartyTransactions" roleURI="http://www.adagene.com/role/DisclosureRelatedPartyTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.adagene.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureRestrictedNetAssets" roleURI="http://www.adagene.com/role/DisclosureRestrictedNetAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureTreasuryShares" roleURI="http://www.adagene.com/role/DisclosureTreasuryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureSubsequentEvents" roleURI="http://www.adagene.com/role/DisclosureSubsequentEvents" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureOrganizationAndBasisOfPresentationTables" roleURI="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureAccountsReceivableNetTables" roleURI="http://www.adagene.com/role/DisclosureAccountsReceivableNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosurePrepaymentsAndOtherCurrentAssetsTables" roleURI="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosurePropertyEquipmentAndSoftwareNetTables" roleURI="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureAccrualsAndOtherCurrentLiabilitiesTables" roleURI="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureBorrowingsTables" roleURI="http://www.adagene.com/role/DisclosureBorrowingsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureConvertibleRedeemablePreferredSharesAndWarrantsTables" roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureShareBasedCompensationTables" roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureIncomeTaxExpenseTables" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureNetLossPerShareTables" roleURI="http://www.adagene.com/role/DisclosureNetLossPerShareTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureRelatedPartyTransactionsTables" roleURI="http://www.adagene.com/role/DisclosureRelatedPartyTransactionsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureOrganizationAndBasisOfPresentationDetails" roleURI="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyExchangeRateRiskDetails" roleURI="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyExchangeRateRiskDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureAccountsReceivableNetDetails" roleURI="http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosurePrepaymentsAndOtherCurrentAssetsDetails" roleURI="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosurePropertyEquipmentAndSoftwareNetDetails" roleURI="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureAccrualsAndOtherCurrentLiabilitiesDetails" roleURI="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureBorrowingsComponentsDetails" roleURI="http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureBorrowingsShortTermBorrowingsDetails" roleURI="http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureBorrowingsLongTermBorrowingsDetails" roleURI="http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails" roleURI="http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails" roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails" roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureConvertibleRedeemablePreferredSharesAndWarrantsWarrantsDetails" roleURI="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureShareBasedCompensationDetails" roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureShareBasedCompensationShareOptionActivitiesDetails" roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails" roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureShareBasedCompensationFairValueOfShareOptionsDetails" roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails" roleURI="http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureCollaborationArrangementsDetails" roleURI="http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureIncomeTaxExpenseDetails" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureIncomeTaxExpenseValuationAllowanceDetails" roleURI="http://www.adagene.com/role/DisclosureIncomeTaxExpenseValuationAllowanceDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureNetLossPerShareDetails" roleURI="http://www.adagene.com/role/DisclosureNetLossPerShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" roleURI="http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureRelatedPartyTransactionsDetails" roleURI="http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureCommitmentsAndContingenciesDetails" roleURI="http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureRestrictedNetAssetsDetails" roleURI="http://www.adagene.com/role/DisclosureRestrictedNetAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureTreasurySharesDetails" roleURI="http://www.adagene.com/role/DisclosureTreasurySharesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="adag-20211231.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.adagene.com/role/DisclosureSubsequentEventsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.adagene.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable_637865735118602138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentInformationTable_637865735118602138" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637865735118602138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_637865735118602138" xlink:to="us-gaap_StatementClassOfStockAxis_637865735118602138" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637865735118602138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637865735118602138" xlink:to="us-gaap_ClassOfStockDomain_637865735118602138" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AdrMember" xlink:label="dei_AdrMember_637865735118602138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735118602138" xlink:to="dei_AdrMember_637865735118602138" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637865735118602138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735118602138" xlink:to="us-gaap_CommonStockMember_637865735118602138" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_637865735118602138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_637865735118602138" xlink:to="dei_EntityAddressesAddressTypeAxis_637865735118602138" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_637865735118602138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis_637865735118602138" xlink:to="dei_AddressTypeDomain_637865735118602138" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember" xlink:label="dei_BusinessContactMember_637865735118612123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_AddressTypeDomain_637865735118602138" xlink:to="dei_BusinessContactMember_637865735118612123" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems_637865735118612123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable_637865735118602138" xlink:to="dei_DocumentInformationLineItems_637865735118612123" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637865735118612123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_DocumentType_637865735118612123" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement_637865735118612123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_DocumentRegistrationStatement_637865735118612123" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_637865735118612123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_DocumentAnnualReport_637865735118612123" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_637865735118612123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_DocumentTransitionReport_637865735118612123" order="4" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport_637865735118612123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_DocumentShellCompanyReport_637865735118612123" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637865735118612123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_DocumentPeriodEndDate_637865735118612123" order="6" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637865735118612123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_EntityFileNumber_637865735118612123" order="7" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637865735118612123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_EntityRegistrantName_637865735118612123" order="8" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637865735118612123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_EntityIncorporationStateCountryCode_637865735118612123" order="9" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637865735118622111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_EntityAddressAddressLine1_637865735118622111" order="10" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_637865735118622111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_EntityAddressAddressLine2_637865735118622111" order="11" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637865735118622111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_EntityAddressCityOrTown_637865735118622111" order="12" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637865735118622111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_EntityAddressPostalZipCode_637865735118622111" order="13" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry_637865735118622111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_EntityAddressCountry_637865735118622111" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName" xlink:label="dei_ContactPersonnelName_637865735118622111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_ContactPersonnelName_637865735118622111" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelEmailAddress" xlink:label="dei_ContactPersonnelEmailAddress_637865735118622111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_ContactPersonnelEmailAddress_637865735118622111" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion_637865735118622111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_CountryRegion_637865735118622111" order="17" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637865735118622111" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_CityAreaCode_637865735118622111" order="18" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637865735118632093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_LocalPhoneNumber_637865735118632093" order="19" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637865735118632093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_Security12bTitle_637865735118632093" order="20" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637865735118632093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_TradingSymbol_637865735118632093" order="21" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag_637865735118632093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_NoTradingSymbolFlag_637865735118632093" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637865735118632093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_SecurityExchangeName_637865735118632093" order="23" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_637865735118632093" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_EntityCommonStockSharesOutstanding_637865735118632093" order="24" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_637865735118642072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_EntityWellKnownSeasonedIssuer_637865735118642072" order="25" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_637865735118642072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_EntityVoluntaryFilers_637865735118642072" order="26" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_637865735118642072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_EntityCurrentReportingStatus_637865735118642072" order="27" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_637865735118642072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_EntityInteractiveDataCurrent_637865735118642072" order="28" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_637865735118642072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_EntityFilerCategory_637865735118642072" order="29" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637865735118642072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_EntityEmergingGrowthCompany_637865735118642072" order="30" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_637865735118642072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_EntityExTransitionPeriod_637865735118642072" order="31" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_637865735118642072" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_IcfrAuditorAttestationFlag_637865735118642072" order="32" use="optional" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard_637865735118652124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_DocumentAccountingStandard_637865735118652124" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_637865735118652124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_EntityShellCompany_637865735118652124" order="34" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637865735118652124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_EntityCentralIndexKey_637865735118652124" order="35" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_637865735118652124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_CurrentFiscalYearEndDate_637865735118652124" order="36" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_637865735118652124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_DocumentFiscalYearFocus_637865735118652124" order="37" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_637865735118652124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_DocumentFiscalPeriodFocus_637865735118652124" order="38" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637865735118662076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_AmendmentFlag_637865735118662076" order="39" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName_637865735118662076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_AuditorName_637865735118662076" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_637865735118662076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_AuditorFirmId_637865735118662076" order="41" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_637865735118662076" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems_637865735118612123" xlink:to="dei_AuditorLocation_637865735118662076" order="42" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/StatementConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - CONSOLIDATED BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637516889407883481" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637865735118672073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637516889407883481" xlink:to="us-gaap_StatementTable_637865735118672073" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637865735118672073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637865735118672073" xlink:to="us-gaap_StatementClassOfStockAxis_637865735118672073" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637865735118672073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637865735118672073" xlink:to="us-gaap_ClassOfStockDomain_637865735118672073" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Series1RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series1RedeemableConvertiblePreferredStockMember_637865735118672073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735118672073" xlink:to="adag_Series1RedeemableConvertiblePreferredStockMember_637865735118672073" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Series2RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series2RedeemableConvertiblePreferredStockMember_637865735118672073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735118672073" xlink:to="adag_Series2RedeemableConvertiblePreferredStockMember_637865735118672073" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesBRedeemableConvertiblePreferredStockMember_637865735118672073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735118672073" xlink:to="adag_SeriesBRedeemableConvertiblePreferredStockMember_637865735118672073" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC1RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC1RedeemableConvertiblePreferredStockMember_637865735118672073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735118672073" xlink:to="adag_SeriesC1RedeemableConvertiblePreferredStockMember_637865735118672073" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC2RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC2RedeemableConvertiblePreferredStockMember_637865735118672073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735118672073" xlink:to="adag_SeriesC2RedeemableConvertiblePreferredStockMember_637865735118672073" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC3RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC3RedeemableConvertiblePreferredStockMember_637865735118672073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735118672073" xlink:to="adag_SeriesC3RedeemableConvertiblePreferredStockMember_637865735118672073" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637865735118672073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637865735118672073" xlink:to="us-gaap_StatementLineItems_637865735118672073" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_637865735118672073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735118672073" xlink:to="us-gaap_AssetsAbstract_637865735118672073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_637865735118672073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637865735118672073" xlink:to="us-gaap_AssetsCurrentAbstract_637865735118672073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_637865735118672073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637865735118672073" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_637865735118672073" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637865735118672073" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637865735118672073" xlink:to="us-gaap_AccountsReceivableNetCurrent_637865735118672073" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_637865735118682088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637865735118672073" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_637865735118682088" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637865735118682088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637865735118672073" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637865735118682088" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_637865735118682088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_637865735118672073" xlink:to="us-gaap_AssetsCurrent_637865735118682088" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637865735118682088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637865735118672073" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637865735118682088" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_637865735118682088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637865735118672073" xlink:to="us-gaap_OtherAssetsNoncurrent_637865735118682088" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_637865735118682088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_637865735118672073" xlink:to="us-gaap_Assets_637865735118682088" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637865735118682088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735118672073" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637865735118682088" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_637865735118682088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637865735118682088" xlink:to="us-gaap_LiabilitiesCurrentAbstract_637865735118682088" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_637865735118682088" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637865735118682088" xlink:to="us-gaap_AccountsPayableCurrent_637865735118682088" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_637865735118692589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637865735118682088" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_637865735118692589" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_637865735118692589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637865735118682088" xlink:to="us-gaap_DueToRelatedPartiesCurrent_637865735118692589" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_637865735118692589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637865735118682088" xlink:to="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_637865735118692589" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_637865735118692589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637865735118682088" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_637865735118692589" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_637865735118692589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637865735118682088" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_637865735118692589" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_637865735118692589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637865735118682088" xlink:to="us-gaap_LongTermDebtCurrent_637865735118692589" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_637865735118692589" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_637865735118682088" xlink:to="us-gaap_LiabilitiesCurrent_637865735118692589" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637865735118702255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637865735118682088" xlink:to="us-gaap_LongTermDebtNoncurrent_637865735118702255" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_637865735118702255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637865735118682088" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_637865735118702255" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_637865735118702255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637865735118682088" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_637865735118702255" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_637865735118702255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637865735118682088" xlink:to="us-gaap_Liabilities_637865735118702255" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_637865735118702255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637865735118682088" xlink:to="us-gaap_CommitmentsAndContingencies_637865735118702255" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAbstract" xlink:label="us-gaap_TemporaryEquityAbstract_637865735118702255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637865735118682088" xlink:to="us-gaap_TemporaryEquityAbstract_637865735118702255" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637865735118702255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityAbstract_637865735118702255" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637865735118702255" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_637865735118702255" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_637865735118682088" xlink:to="us-gaap_StockholdersEquityAbstract_637865735118702255" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_637865735118712241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637865735118702255" xlink:to="us-gaap_CommonStockValue_637865735118712241" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue_637865735118712241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637865735118702255" xlink:to="us-gaap_TreasuryStockValue_637865735118712241" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteSubscriptionsReceivable" xlink:label="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_637865735118712241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637865735118702255" xlink:to="us-gaap_StockholdersEquityNoteSubscriptionsReceivable_637865735118712241" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_637865735118712241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637865735118702255" xlink:to="us-gaap_AdditionalPaidInCapital_637865735118712241" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637865735118712241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637865735118702255" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_637865735118712241" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_637865735118712241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637865735118702255" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_637865735118712241" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637865735118712241" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_637865735118702255" xlink:to="us-gaap_StockholdersEquity_637865735118712241" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637865735118722175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735118672073" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_637865735118722175" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637516889408761137" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637865735118722175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637516889408761137" xlink:to="us-gaap_StatementTable_637865735118722175" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637865735118722175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637865735118722175" xlink:to="us-gaap_StatementClassOfStockAxis_637865735118722175" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637865735118722175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637865735118722175" xlink:to="us-gaap_ClassOfStockDomain_637865735118722175" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Series1RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series1RedeemableConvertiblePreferredStockMember_637865735118722175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735118722175" xlink:to="adag_Series1RedeemableConvertiblePreferredStockMember_637865735118722175" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Series2RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series2RedeemableConvertiblePreferredStockMember_637865735118722175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735118722175" xlink:to="adag_Series2RedeemableConvertiblePreferredStockMember_637865735118722175" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesBRedeemableConvertiblePreferredStockMember_637865735118722175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735118722175" xlink:to="adag_SeriesBRedeemableConvertiblePreferredStockMember_637865735118722175" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC1RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC1RedeemableConvertiblePreferredStockMember_637865735118722175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735118722175" xlink:to="adag_SeriesC1RedeemableConvertiblePreferredStockMember_637865735118722175" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC2RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC2RedeemableConvertiblePreferredStockMember_637865735118722175" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735118722175" xlink:to="adag_SeriesC2RedeemableConvertiblePreferredStockMember_637865735118722175" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC3RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC3RedeemableConvertiblePreferredStockMember_637865735118732468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735118722175" xlink:to="adag_SeriesC3RedeemableConvertiblePreferredStockMember_637865735118732468" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637865735118732468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637865735118722175" xlink:to="us-gaap_StatementLineItems_637865735118732468" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_637865735118732468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735118732468" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_637865735118732468" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_637865735118732468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735118732468" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_637865735118732468" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued_637865735118732468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735118732468" xlink:to="us-gaap_TemporaryEquitySharesIssued_637865735118732468" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_637865735118732468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735118732468" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_637865735118732468" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_637865735118732468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735118732468" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_637865735118732468" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_637865735118732468" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735118732468" xlink:to="us-gaap_CommonStockSharesAuthorized_637865735118732468" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_637865735118742314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735118732468" xlink:to="us-gaap_CommonStockSharesIssued_637865735118742314" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_637865735118742314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735118732468" xlink:to="us-gaap_CommonStockSharesOutstanding_637865735118742314" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares_637865735118742314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735118732468" xlink:to="us-gaap_TreasuryStockShares_637865735118742314" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_637516889408781088" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637865735118742314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637516889408781088" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637865735118742314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_637865735118742314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637516889408781088" xlink:to="us-gaap_OperatingExpensesAbstract_637865735118742314" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_637865735118742314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637865735118742314" xlink:to="us-gaap_ResearchAndDevelopmentExpense_637865735118742314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ResearchAndDevelopmentExpenseThirdParties" xlink:label="adag_ResearchAndDevelopmentExpenseThirdParties_637865735118742314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense_637865735118742314" xlink:to="adag_ResearchAndDevelopmentExpenseThirdParties_637865735118742314" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty" xlink:label="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_637865735118742314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentExpense_637865735118742314" xlink:to="adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty_637865735118742314" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_637865735118742314" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637865735118742314" xlink:to="us-gaap_GeneralAndAdministrativeExpense_637865735118742314" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_637865735118752273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637865735118742314" xlink:to="us-gaap_OperatingIncomeLoss_637865735118752273" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNonoperating" xlink:label="us-gaap_InvestmentIncomeNonoperating_637865735118752273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637865735118742314" xlink:to="us-gaap_InvestmentIncomeNonoperating_637865735118752273" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_637865735118752273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637865735118742314" xlink:to="us-gaap_InterestExpense_637865735118752273" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_637865735118752273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637865735118742314" xlink:to="us-gaap_OtherNonoperatingIncome_637865735118752273" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637865735118752273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637865735118742314" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637865735118752273" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_637865735118752273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637865735118742314" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_637865735118752273" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637865735118752273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637865735118742314" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637865735118752273" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637865735118752273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637865735118742314" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637865735118752273" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637865735118752273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_637865735118742314" xlink:to="us-gaap_NetIncomeLoss_637865735118752273" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637865735118752273" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637516889408781088" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637865735118752273" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637865735118762463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_637865735118752273" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637865735118762463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_637865735118762463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637516889408781088" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_637865735118762463" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637865735118762463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637516889408781088" xlink:to="us-gaap_NetIncomeLoss_637865735118762463" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_637865735118762463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637516889408781088" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_637865735118762463" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637865735118762463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637516889408781088" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637865735118762463" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637865735118762463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637516889408781088" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637865735118762463" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637865735118762463" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637865735118762463" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637865735118762463" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637865735118772212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637865735118762463" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637865735118772212" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_637865735118772212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637516889408781088" xlink:to="us-gaap_EarningsPerShareAbstract_637865735118772212" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637865735118772212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637865735118772212" xlink:to="us-gaap_EarningsPerShareBasic_637865735118772212" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637865735118772212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637865735118772212" xlink:to="us-gaap_EarningsPerShareDiluted_637865735118772212" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLossParenthetical" xlink:type="extended" xlink:title="00205 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_637865735118772212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent_637865735118772212" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_637516889408820980" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_637865735118782209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_637516889408820980" xlink:to="us-gaap_StatementTable_637865735118782209" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_637865735118782209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637865735118782209" xlink:to="us-gaap_StatementEquityComponentsAxis_637865735118782209" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637865735118782209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637865735118782209" xlink:to="us-gaap_CommonStockMember_637865735118782209" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember_637865735118782209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637865735118782209" xlink:to="us-gaap_TreasuryStockMember_637865735118782209" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesFromStockholderMember" xlink:label="us-gaap_ReceivablesFromStockholderMember_637865735118782209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637865735118782209" xlink:to="us-gaap_ReceivablesFromStockholderMember_637865735118782209" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_637865735118782209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637865735118782209" xlink:to="us-gaap_AdditionalPaidInCapitalMember_637865735118782209" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637865735118782209" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637865735118782209" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_637865735118782209" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_637865735118822188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637865735118782209" xlink:to="us-gaap_RetainedEarningsMember_637865735118822188" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_637865735118822188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_637865735118782209" xlink:to="us-gaap_EquityComponentDomain_637865735118822188" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637865735118822188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_637865735118782209" xlink:to="us-gaap_StatementLineItems_637865735118822188" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735118822188" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637865735118822188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="us-gaap_StockholdersEquity_637865735118822188" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_637865735118822188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="us-gaap_SharesIssued_637865735118822188" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637865735118822188" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="us-gaap_NetIncomeLoss_637865735118822188" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637865735118832129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_637865735118832129" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637865735118832129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637865735118832129" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637865735118832129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637865735118832129" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637865735118832129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_637865735118832129" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_637865735118832129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_637865735118832129" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CommonStockSubscriptionsValue" xlink:label="adag_CommonStockSubscriptionsValue_637865735118832129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="adag_CommonStockSubscriptionsValue_637865735118832129" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637865735118832129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_637865735118832129" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_637865735118832129" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_637865735118832129" order="11" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637865735118842189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637865735118842189" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637865735118842189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637865735118842189" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_637865735118842189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_637865735118842189" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637865735118842189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637865735118842189" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_637865735118842189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod_637865735118842189" order="16" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired_637865735118842189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="us-gaap_TreasuryStockSharesAcquired_637865735118842189" order="17" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:label="us-gaap_TreasuryStockRetiredCostMethodAmount_637865735118842189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="us-gaap_TreasuryStockRetiredCostMethodAmount_637865735118842189" order="18" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired_637865735118842189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="us-gaap_TreasuryStockSharesRetired_637865735118842189" order="19" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_StockSurrenderedValueForRepaymentOfPromissoryNotes" xlink:label="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes_637865735118852196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="adag_StockSurrenderedValueForRepaymentOfPromissoryNotes_637865735118852196" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes" xlink:label="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes_637865735118852196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes_637865735118852196" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_637865735118852196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="us-gaap_StockholdersEquity_637865735118852196" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued" xlink:label="us-gaap_SharesIssued_637865735118852196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_637865735118822188" xlink:to="us-gaap_SharesIssued_637865735118852196" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637865735118852196" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637865735118852196" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_637865735118862367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637865735118852196" xlink:to="us-gaap_ProfitLoss_637865735118862367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637865735118862367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_637865735118852196" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637865735118862367" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637865735118862367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637865735118862367" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637865735118862367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637865735118862367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637865735118862367" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_637865735118862367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_637865735118862367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637865735118862367" xlink:to="us-gaap_ShareBasedCompensation_637865735118862367" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_637865735118862367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637865735118862367" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_637865735118862367" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_InterestIncomeExpenseOnPromissoryNotes" xlink:label="adag_InterestIncomeExpenseOnPromissoryNotes_637865735118862367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637865735118862367" xlink:to="adag_InterestIncomeExpenseOnPromissoryNotes_637865735118862367" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637865735118862367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637865735118862367" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_637865735118862367" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637865735118862367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637865735118862367" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637865735118862367" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_637865735118862367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637865735118862367" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_637865735118862367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637865735118862367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637865735118862367" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_637865735118862367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedParties_637865735118872115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637865735118862367" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedParties_637865735118872115" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637865735118872115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637865735118862367" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_637865735118872115" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_637865735118872115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637865735118862367" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_637865735118872115" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637865735118872115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637865735118862367" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_637865735118872115" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueToRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInDueToRelatedParties_637865735118872115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637865735118862367" xlink:to="us-gaap_IncreaseDecreaseInDueToRelatedParties_637865735118872115" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_637865735118872115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637865735118862367" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_637865735118872115" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_637865735118872115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637865735118862367" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_637865735118872115" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_637865735118872115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637865735118862367" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_637865735118872115" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637865735118872115" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_637865735118862367" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_637865735118872115" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735118882162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_637865735118862367" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_637865735118882162" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637865735118882162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637865735118882162" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments_637865735118882162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637865735118882162" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments_637865735118882162" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:label="us-gaap_ProceedsFromSaleOfShortTermInvestments_637865735118882162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637865735118882162" xlink:to="us-gaap_ProceedsFromSaleOfShortTermInvestments_637865735118882162" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:label="us-gaap_ProceedsFromSaleOfProductiveAssets_637865735118882162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637865735118882162" xlink:to="us-gaap_ProceedsFromSaleOfProductiveAssets_637865735118882162" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets_637865735118882162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637865735118882162" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets_637865735118882162" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_637865735118882162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_637865735118882162" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_637865735118882162" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637865735118882162" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637865735118882162" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_637865735118892366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637865735118882162" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_637865735118892366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants" xlink:label="adag_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants_637865735118892366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637865735118882162" xlink:to="adag_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants_637865735118892366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital_637865735118892366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637865735118882162" xlink:to="us-gaap_ProceedsFromContributedCapital_637865735118892366" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_637865735118892366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637865735118882162" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_637865735118892366" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637865735118892366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637865735118882162" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637865735118892366" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_637865735118892366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637865735118882162" xlink:to="us-gaap_RepaymentsOfDebt_637865735118892366" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_637865735118902206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637865735118882162" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_637865735118902206" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_637865735118902206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637865735118882162" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_637865735118902206" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_RetirementOfTreasuryShares" xlink:label="adag_RetirementOfTreasuryShares_637865735118902206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637865735118882162" xlink:to="adag_RetirementOfTreasuryShares_637865735118902206" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_637865735118902206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_637865735118882162" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_637865735118902206" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_637865735118902206" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_637865735118902206" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637865735118912186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_637865735118912186" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637865735118912186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_637865735118912186" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378657351189121861" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6378657351189121861" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_637865735118912186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_637865735118912186" order="8" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_637865735118912186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637865735118912186" xlink:to="us-gaap_InterestPaidNet_637865735118912186" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637865735118912186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_637865735118912186" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637865735118912186" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_637865735118922222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637865735118912186" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_637865735118922222" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="us-gaap_ConversionOfStockAmountIssued1_637865735118922222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637865735118912186" xlink:to="us-gaap_ConversionOfStockAmountIssued1_637865735118922222" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_PayablesForDeferredInitialPublicOfferingCost" xlink:label="adag_PayablesForDeferredInitialPublicOfferingCost_637865735118922222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637865735118912186" xlink:to="adag_PayablesForDeferredInitialPublicOfferingCost_637865735118922222" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_NonCashActivitiesRetirementOfTreasuryShares" xlink:label="adag_NonCashActivitiesRetirementOfTreasuryShares_637865735118922222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637865735118912186" xlink:to="adag_NonCashActivitiesRetirementOfTreasuryShares_637865735118922222" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes" xlink:label="adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes_637865735118922222" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_637865735118912186" xlink:to="adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes_637865735118922222" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentation" xlink:type="extended" xlink:title="10101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637865735118932239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_637865735118932239" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637520231714822595" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_637865735118932239" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637520231714822595" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_637865735118932239" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureAccountsReceivableNet" xlink:type="extended" xlink:title="10301 - Disclosure - ACCOUNTS RECEIVABLE, NET" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="us-gaap_AccountsReceivableNetAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_637865735118942190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_637865735118942190" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssets" xlink:type="extended" xlink:title="10401 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock" xlink:label="adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock_637865735118942190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock_637865735118942190" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNet" xlink:type="extended" xlink:title="10501 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637865735118942190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_637865735118942190" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilities" xlink:type="extended" xlink:title="10601 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_637865735118942190" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock_637865735118942190" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureBorrowings" xlink:type="extended" xlink:title="10701 - Disclosure - BORROWINGS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_637865735118952336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_637865735118952336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrants" xlink:type="extended" xlink:title="10801 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock_637865735118952336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:to="adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock_637865735118952336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureShareBasedCompensation" xlink:type="extended" xlink:title="10901 - Disclosure - SHARE-BASED COMPENSATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715122844" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637865735118952336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715122844" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_637865735118952336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureCollaborationArrangements" xlink:type="extended" xlink:title="11001 - Disclosure - COLLABORATION ARRANGEMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CollaborationArrangementsAbstract" xlink:label="adag_CollaborationArrangementsAbstract_637517385843023440" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_637865735118952336" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_CollaborationArrangementsAbstract_637517385843023440" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_637865735118952336" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpense" xlink:type="extended" xlink:title="11101 - Disclosure - INCOME TAX EXPENSE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637517388289524508" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_637865735118962126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637517388289524508" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_637865735118962126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureNetLossPerShare" xlink:type="extended" xlink:title="11201 - Disclosure - NET LOSS PER SHARE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637517385843268454" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_637865735118962126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637517385843268454" xlink:to="us-gaap_EarningsPerShareTextBlock_637865735118962126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureRelatedPartyTransactions" xlink:type="extended" xlink:title="11301 - Disclosure - RELATED PARTY TRANSACTIONS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637517388289524508" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637865735118962126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637517388289524508" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_637865735118962126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="11401 - Disclosure - COMMITMENTS AND CONTINGENCIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637517388289524508" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637865735118962126" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_637517388289524508" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_637865735118962126" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureRestrictedNetAssets" xlink:type="extended" xlink:title="11501 - Disclosure - RESTRICTED NET ASSETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_RestrictedNetAssetsAbstract" xlink:label="adag_RestrictedNetAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedAssetsDisclosureTextBlock" xlink:label="us-gaap_RestrictedAssetsDisclosureTextBlock_637865735118972155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_RestrictedNetAssetsAbstract" xlink:to="us-gaap_RestrictedAssetsDisclosureTextBlock_637865735118972155" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureTreasuryShares" xlink:type="extended" xlink:title="11601 - Disclosure - TREASURY SHARES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAbstract" xlink:label="us-gaap_TreasuryStockSharesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockTextBlock" xlink:label="us-gaap_TreasuryStockTextBlock_637865735118972155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TreasuryStockSharesAbstract" xlink:to="us-gaap_TreasuryStockTextBlock_637865735118972155" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="11701 - Disclosure - SUBSEQUENT EVENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_637865735118972155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_637865735118972155" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637865735118972155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_637865735118972155" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock_637865735118972155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock_637865735118972155" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_637865735118972155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_637865735118972155" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_637865735118972155" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_637865735118972155" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637865735118982205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_637865735118982205" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock" xlink:label="adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock_637865735118982205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock_637865735118982205" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_637865735118982205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_637865735118982205" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637865735118982205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_637865735118982205" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637865735118982205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_637865735118982205" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_637865735118982205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_637865735118982205" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637865735118982205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_637865735118982205" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_637865735118982205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_637865735118982205" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_GovernmentSubsidiesPolicyTextBlock" xlink:label="adag_GovernmentSubsidiesPolicyTextBlock_637865735118982205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adag_GovernmentSubsidiesPolicyTextBlock_637865735118982205" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_637865735118982205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_637865735118982205" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637865735118982205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_637865735118982205" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_637865735118992186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_637865735118992186" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock_637865735118992186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock_637865735118992186" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637865735118992186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_637865735118992186" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_637865735118992186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_637865735118992186" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_EmployeeDefinedContributionPlanPolicyTextBlock" xlink:label="adag_EmployeeDefinedContributionPlanPolicyTextBlock_637865735118992186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adag_EmployeeDefinedContributionPlanPolicyTextBlock_637865735118992186" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_637865735118992186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_637865735118992186" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637865735118992186" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_637865735118992186" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationTables" xlink:type="extended" xlink:title="30103 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SummaryOfPrincipalSubsidiariesTableTextBlock" xlink:label="adag_SummaryOfPrincipalSubsidiariesTableTextBlock_637865735119002123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="adag_SummaryOfPrincipalSubsidiariesTableTextBlock_637865735119002123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637520231715142892" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_637865735119002123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637520231715142892" xlink:to="adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_637865735119002123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureAccountsReceivableNetTables" xlink:type="extended" xlink:title="30303 - Disclosure - ACCOUNTS RECEIVABLE, NET (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="us-gaap_AccountsReceivableNetAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_637865735119002123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_637865735119002123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsTables" xlink:type="extended" xlink:title="30403 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_637865735119012138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_637865735119012138" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetTables" xlink:type="extended" xlink:title="30503 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_637865735119012138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_637865735119012138" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesTables" xlink:type="extended" xlink:title="30603 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_637865735119012138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock_637865735119012138" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureBorrowingsTables" xlink:type="extended" xlink:title="30703 - Disclosure - BORROWINGS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_637865735119022205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_637865735119022205" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock" xlink:label="adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock_637865735119022205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock_637865735119022205" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsTables" xlink:type="extended" xlink:title="30803 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="us-gaap_TemporaryEquityTableTextBlock_637865735119022205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock_637865735119022205" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureShareBasedCompensationTables" xlink:type="extended" xlink:title="30903 - Disclosure - SHARE-BASED COMPENSATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715142892" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637865735119022205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715142892" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_637865735119022205" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637865735119022205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715142892" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_637865735119022205" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637865735119022205" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715142892" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_637865735119022205" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpenseTables" xlink:type="extended" xlink:title="31101 - Disclosure - INCOME TAX EXPENSE (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637517388289534549" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_637865735119032185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637517388289534549" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_637865735119032185" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637865735119032185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637517388289534549" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_637865735119032185" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637865735119032185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637517388289534549" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_637865735119032185" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock_637865735119032185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637517388289534549" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock_637865735119032185" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureNetLossPerShareTables" xlink:type="extended" xlink:title="31203 - Disclosure - NET LOSS PER SHARE (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637517385843278485" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637865735119032185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637517385843278485" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_637865735119032185" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637865735119032185" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637517385843278485" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_637865735119032185" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureRelatedPartyTransactionsTables" xlink:type="extended" xlink:title="31303 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637517388289534549" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_637865735119042362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637517388289534549" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_637865735119042362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesTables" xlink:type="extended" xlink:title="31403 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_637865735119042362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_637865735119042362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_637865735119042362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_637865735119042362" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_637865735119042362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_637865735119042362" xlink:to="srt_OwnershipAxis_637865735119042362" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_637865735119052295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_637865735119042362" xlink:to="srt_OwnershipDomain_637865735119052295" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneHongKongLimitedMember" xlink:label="adag_AdageneHongKongLimitedMember_637865735119052295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_637865735119052295" xlink:to="adag_AdageneHongKongLimitedMember_637865735119052295" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneIncorporatedMember" xlink:label="adag_AdageneIncorporatedMember_637865735119052295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_637865735119052295" xlink:to="adag_AdageneIncorporatedMember_637865735119052295" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneSuzhouLimitedMember" xlink:label="adag_AdageneSuzhouLimitedMember_637865735119052295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_637865735119052295" xlink:to="adag_AdageneSuzhouLimitedMember_637865735119052295" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneAustraliaPtyLtd.Member" xlink:label="adag_AdageneAustraliaPtyLtd.Member_637865735119052295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_637865735119052295" xlink:to="adag_AdageneAustraliaPtyLtd.Member_637865735119052295" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdagenePte.Ltd.Member" xlink:label="adag_AdagenePte.Ltd.Member_637865735119052295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_637865735119052295" xlink:to="adag_AdagenePte.Ltd.Member_637865735119052295" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneAgMember" xlink:label="adag_AdageneAgMember_637865735119052295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_637865735119052295" xlink:to="adag_AdageneAgMember_637865735119052295" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637865735119052295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_637865735119042362" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637865735119052295" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637865735119052295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637865735119052295" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637865735119052295" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637865735119052295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637865735119052295" xlink:to="us-gaap_IPOMember_637865735119052295" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_637865735119052295" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637865735119052295" xlink:to="us-gaap_OverAllotmentOptionMember_637865735119052295" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637865735119061825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_637865735119042362" xlink:to="us-gaap_StatementClassOfStockAxis_637865735119061825" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637865735119061825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637865735119061825" xlink:to="us-gaap_ClassOfStockDomain_637865735119061825" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AdrMember" xlink:label="dei_AdrMember_637865735119061825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735119061825" xlink:to="dei_AdrMember_637865735119061825" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_637865735119061825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_637865735119042362" xlink:to="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_637865735119061825" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_637865735119061825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_637865735119061825" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_637865735119061825" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637865735119061825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_637865735119061825" xlink:to="us-gaap_SharesIssuedPricePerShare_637865735119061825" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637865735119061825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_637865735119061825" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_637865735119061825" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637865735119061825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_637865735119061825" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_637865735119061825" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityListingDepositoryReceiptRatio" xlink:label="dei_EntityListingDepositoryReceiptRatio_637865735119061825" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_637865735119061825" xlink:to="dei_EntityListingDepositoryReceiptRatio_637865735119061825" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails" xlink:type="extended" xlink:title="40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonrecurring (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637520231715492893" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637865735119072201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637520231715492893" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637865735119072201" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_637865735119072201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637865735119072201" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_637865735119072201" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_637865735119072201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_637865735119072201" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_637865735119072201" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_637865735119072201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_637865735119072201" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_637865735119072201" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637865735119072201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_637865735119072201" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637865735119072201" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_FinancialAssetsFairValueDisclosure" xlink:label="adag_FinancialAssetsFairValueDisclosure_637865735119072201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637865735119072201" xlink:to="adag_FinancialAssetsFairValueDisclosure_637865735119072201" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_637865735119072201" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_637865735119072201" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_637865735119072201" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails" xlink:type="extended" xlink:title="40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, equipment and software (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637520231715502636" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637865735119082195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637520231715502636" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637865735119082195" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637865735119082195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637865735119082195" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637865735119082195" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637865735119082195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637865735119082195" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637865735119082195" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_637865735119082195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637865735119082195" xlink:to="us-gaap_MachineryAndEquipmentMember_637865735119082195" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember_637865735119082195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637865735119082195" xlink:to="us-gaap_VehiclesMember_637865735119082195" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637865735119082195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637865735119082195" xlink:to="us-gaap_FurnitureAndFixturesMember_637865735119082195" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ElectronicEquipmentMember" xlink:label="adag_ElectronicEquipmentMember_637865735119082195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637865735119082195" xlink:to="adag_ElectronicEquipmentMember_637865735119082195" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_637865735119082195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637865735119082195" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_637865735119082195" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637865735119082195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637865735119082195" xlink:to="srt_RangeAxis_637865735119082195" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637865735119082195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637865735119082195" xlink:to="srt_RangeMember_637865735119082195" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637865735119082195" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637865735119082195" xlink:to="srt_MinimumMember_637865735119082195" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637865735119091840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637865735119082195" xlink:to="srt_MaximumMember_637865735119091840" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637865735119091840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637865735119082195" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637865735119091840" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_637865735119091840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637865735119091840" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_637865735119091840" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails" xlink:type="extended" xlink:title="40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of long lived assets to Employee defined contribution plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="us-gaap_AssetImpairmentChargesAbstract_637865735119091840" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AssetImpairmentChargesAbstract_637865735119091840" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_637865735119102163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetImpairmentChargesAbstract_637865735119091840" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_637865735119102163" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAbstract" xlink:label="us-gaap_RevenueRecognitionAbstract_637865735119102163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionAbstract_637865735119102163" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MilestonePaymentsOrRoyaltyPaymentsReceived" xlink:label="adag_MilestonePaymentsOrRoyaltyPaymentsReceived_637865735119102163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAbstract_637865735119102163" xlink:to="adag_MilestonePaymentsOrRoyaltyPaymentsReceived_637865735119102163" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_DefinedContributionPlanAbstract" xlink:label="adag_DefinedContributionPlanAbstract_637865735119102163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="adag_DefinedContributionPlanAbstract_637865735119102163" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_637865735119102163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_DefinedContributionPlanAbstract_637865735119102163" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_637865735119102163" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails" xlink:type="extended" xlink:title="40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of credit risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637520231715532875" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable_637865735119102163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637520231715532875" xlink:to="us-gaap_ConcentrationRiskTable_637865735119102163" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_637865735119102163" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637865735119102163" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_637865735119102163" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_637865735119112212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_637865735119102163" xlink:to="us-gaap_ConcentrationRiskTypeDomain_637865735119112212" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="us-gaap_GeographicConcentrationRiskMember_637865735119112212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_637865735119112212" xlink:to="us-gaap_GeographicConcentrationRiskMember_637865735119112212" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember_637865735119112212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_637865735119112212" xlink:to="us-gaap_SupplierConcentrationRiskMember_637865735119112212" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_637865735119112212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637865735119102163" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_637865735119112212" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_637865735119112212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_637865735119112212" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_637865735119112212" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CashAndCashEquivalentsAndShortTermInvestmentsMember" xlink:label="adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_637865735119112212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_637865735119112212" xlink:to="adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_637865735119112212" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsProductLineMember" xlink:label="us-gaap_CostOfGoodsProductLineMember_637865735119112212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_637865735119112212" xlink:to="us-gaap_CostOfGoodsProductLineMember_637865735119112212" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ConcentrationRiskSuppliersAxis" xlink:label="adag_ConcentrationRiskSuppliersAxis_637865735119112212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637865735119102163" xlink:to="adag_ConcentrationRiskSuppliersAxis_637865735119112212" order="3" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ConcentrationRiskSuppliersDomain" xlink:label="adag_ConcentrationRiskSuppliersDomain_637865735119112212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_ConcentrationRiskSuppliersAxis_637865735119112212" xlink:to="adag_ConcentrationRiskSuppliersDomain_637865735119112212" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_OneSupplierMember" xlink:label="adag_OneSupplierMember_637865735119112212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_ConcentrationRiskSuppliersDomain_637865735119112212" xlink:to="adag_OneSupplierMember_637865735119112212" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637865735119112212" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637865735119102163" xlink:to="srt_StatementGeographicalAxis_637865735119112212" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637865735119122194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637865735119112212" xlink:to="srt_SegmentGeographicalDomain_637865735119122194" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MainlandOfChinaMember" xlink:label="adag_MainlandOfChinaMember_637865735119122194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637865735119122194" xlink:to="adag_MainlandOfChinaMember_637865735119122194" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_OutsideMainlandOfChinaMember" xlink:label="adag_OutsideMainlandOfChinaMember_637865735119122194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637865735119122194" xlink:to="adag_OutsideMainlandOfChinaMember_637865735119122194" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems_637865735119122194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTable_637865735119102163" xlink:to="us-gaap_ConcentrationRiskLineItems_637865735119122194" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_637865735119122194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637865735119122194" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_637865735119122194" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_NumberOfMajorSupplier" xlink:label="adag_NumberOfMajorSupplier_637865735119122194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637865735119122194" xlink:to="adag_NumberOfMajorSupplier_637865735119122194" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_637865735119122194" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskLineItems_637865735119122194" xlink:to="us-gaap_ConcentrationRiskPercentage1_637865735119122194" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyExchangeRateRiskDetails" xlink:type="extended" xlink:title="40205 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Foreign currency exchange rate risk (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract_637520231715562911" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_PercentageOfDepreciationOfForeignCurrency" xlink:label="adag_PercentageOfDepreciationOfForeignCurrency_637865735119132119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637520231715562911" xlink:to="adag_PercentageOfDepreciationOfForeignCurrency_637865735119132119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_GovernmentSubsidiesReceived" xlink:label="adag_GovernmentSubsidiesReceived_637865735119132119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract_637520231715562911" xlink:to="adag_GovernmentSubsidiesReceived_637865735119132119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails" xlink:type="extended" xlink:title="40301 - Disclosure - ACCOUNTS RECEIVABLE, NET (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="us-gaap_AccountsReceivableNetAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGross" xlink:label="us-gaap_AccountsReceivableGross_637865735119132119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableGross_637865735119132119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="us-gaap_AccountsReceivableNet_637865735119132119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableNet_637865735119132119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_637865735119132119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent_637865735119132119" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="us-gaap_DepositsAssetsCurrent_637865735119132119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent_637865735119132119" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_637865735119132119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent_637865735119132119" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637865735119132119" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_637865735119132119" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637865735119142138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637865735119142138" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637865735119142138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637865735119142138" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637865735119142138" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_637865735119142138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_637865735119142138" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_637865735119142138" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_637865735119142138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637865735119142138" xlink:to="us-gaap_MachineryAndEquipmentMember_637865735119142138" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_637865735119142138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637865735119142138" xlink:to="us-gaap_LeaseholdImprovementsMember_637865735119142138" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ElectronicEquipmentMember" xlink:label="adag_ElectronicEquipmentMember_637865735119142138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637865735119142138" xlink:to="adag_ElectronicEquipmentMember_637865735119142138" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_637865735119142138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637865735119142138" xlink:to="us-gaap_FurnitureAndFixturesMember_637865735119142138" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember_637865735119142138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637865735119142138" xlink:to="us-gaap_VehiclesMember_637865735119142138" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_637865735119142138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_637865735119142138" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_637865735119142138" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_637865735119142138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_637865735119142138" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_637865735119142138" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_637865735119142138" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_637865735119142138" xlink:to="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_637865735119142138" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_637865735119152114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_637865735119142138" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_637865735119152114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637865735119152114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_637865735119142138" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_637865735119152114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637865735119152114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_637865735119142138" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_637865735119152114" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_637865735119152114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract_637865735119142138" xlink:to="us-gaap_DepreciationDepletionAndAmortization_637865735119152114" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_637865735119152114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_637865735119152114" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_637865735119152114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_637865735119152114" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedUtilitiesCurrent" xlink:label="us-gaap_AccruedUtilitiesCurrent_637865735119152114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_AccruedUtilitiesCurrent_637865735119152114" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_637865735119152114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_TaxesPayableCurrent_637865735119152114" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_637865735119152114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent_637865735119152114" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AccruedLiabilitiesAndOtherCurrentLiabilities" xlink:label="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_637865735119152114" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract" xlink:to="adag_AccruedLiabilitiesAndOtherCurrentLiabilities_637865735119152114" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - BORROWINGS - Components (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrentAbstract" xlink:label="us-gaap_DebtCurrentAbstract_637865735119162189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtCurrentAbstract_637865735119162189" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBorrowingsAbstract" xlink:label="us-gaap_ShortTermBorrowingsAbstract_637865735119162189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtCurrentAbstract_637865735119162189" xlink:to="us-gaap_ShortTermBorrowingsAbstract_637865735119162189" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermBankLoansAndNotesPayable" xlink:label="us-gaap_ShortTermBankLoansAndNotesPayable_637865735119162189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermBorrowingsAbstract_637865735119162189" xlink:to="us-gaap_ShortTermBankLoansAndNotesPayable_637865735119162189" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_637865735119162189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermBorrowingsAbstract_637865735119162189" xlink:to="us-gaap_LongTermDebtCurrent_637865735119162189" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent_637865735119162189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermBorrowingsAbstract_637865735119162189" xlink:to="us-gaap_DebtCurrent_637865735119162189" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_637865735119162189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtCurrentAbstract_637865735119162189" xlink:to="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_637865735119162189" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract_637865735119162189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract_637865735119162189" xlink:to="us-gaap_LongTermDebtNoncurrentAbstract_637865735119162189" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermLoansFromBank" xlink:label="us-gaap_LongTermLoansFromBank_637865735119162189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtNoncurrentAbstract_637865735119162189" xlink:to="us-gaap_LongTermLoansFromBank_637865735119162189" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent_637865735119162189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtNoncurrentAbstract_637865735119162189" xlink:to="us-gaap_LongTermDebtNoncurrent_637865735119162189" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_637865735119162189" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtCurrentAbstract_637865735119162189" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount_637865735119162189" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails" xlink:type="extended" xlink:title="40702 - Disclosure - BORROWINGS - Short term borrowings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_637865735119172233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_637865735119172233" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637865735119172233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_637865735119172233" xlink:to="us-gaap_DebtInstrumentAxis_637865735119172233" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637865735119172233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637865735119172233" xlink:to="us-gaap_DebtInstrumentNameDomain_637865735119172233" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_BorrowingsFromBankOfNingboCo.LtdMember" xlink:label="adag_BorrowingsFromBankOfNingboCo.LtdMember_637865735119172233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637865735119172233" xlink:to="adag_BorrowingsFromBankOfNingboCo.LtdMember_637865735119172233" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember" xlink:label="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_637865735119172233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637865735119172233" xlink:to="adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_637865735119172233" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ChinaMerchantsBankCo.LtdMember" xlink:label="adag_ChinaMerchantsBankCo.LtdMember_637865735119172233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637865735119172233" xlink:to="adag_ChinaMerchantsBankCo.LtdMember_637865735119172233" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ChinaMerchantsBankCo.LtdLoanTwoMember" xlink:label="adag_ChinaMerchantsBankCo.LtdLoanTwoMember_637865735119172233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637865735119172233" xlink:to="adag_ChinaMerchantsBankCo.LtdLoanTwoMember_637865735119172233" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems_637865735119172233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShortTermDebtTable_637865735119172233" xlink:to="us-gaap_ShortTermDebtLineItems_637865735119172233" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637865735119172233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637865735119172233" xlink:to="us-gaap_DebtInstrumentFaceAmount_637865735119172233" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm_637865735119172233" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637865735119172233" xlink:to="us-gaap_DebtInstrumentTerm_637865735119172233" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637865735119182213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems_637865735119172233" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637865735119182213" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails" xlink:type="extended" xlink:title="40703 - Disclosure - BORROWINGS - Long term borrowings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_637865735119182213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable_637865735119182213" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_637865735119182213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637865735119182213" xlink:to="us-gaap_LongtermDebtTypeAxis_637865735119182213" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_637865735119182213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis_637865735119182213" xlink:to="us-gaap_LongtermDebtTypeDomain_637865735119182213" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_637865735119182213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_637865735119182213" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_637865735119182213" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_637865735119182213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_637865735119182213" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_637865735119182213" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_637865735119182213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_637865735119182213" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_637865735119182213" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember" xlink:label="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_637865735119182213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain_637865735119182213" xlink:to="adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_637865735119182213" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_637865735119182213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_637865735119182213" xlink:to="us-gaap_DebtInstrumentLineItems_637865735119182213" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637865735119182213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637865735119182213" xlink:to="us-gaap_DebtInstrumentFaceAmount_637865735119182213" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTerm" xlink:label="us-gaap_LongTermDebtTerm_637865735119182213" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637865735119182213" xlink:to="us-gaap_LongTermDebtTerm_637865735119182213" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637865735119192128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637865735119182213" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637865735119192128" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_637865735119192128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637865735119182213" xlink:to="us-gaap_RepaymentsOfDebt_637865735119192128" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent_637865735119192128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_637865735119182213" xlink:to="us-gaap_LongTermDebtCurrent_637865735119192128" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails" xlink:type="extended" xlink:title="40704 - Disclosure - BORROWINGS - Future maturities of short term borrowings and long term borrowings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent_637865735119192128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtCurrent_637865735119192128" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637865735119192128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_637865735119192128" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_637865735119192128" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_637865735119192128" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_637865735119202214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_637865735119202214" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtLongtermAndShorttermCombinedAmount" xlink:label="us-gaap_DebtLongtermAndShorttermCombinedAmount_637865735119202214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtLongtermAndShorttermCombinedAmount_637865735119202214" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails" xlink:type="extended" xlink:title="40801 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Shares (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_637865735119202214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_637865735119202214" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_637865735119202214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637865735119202214" xlink:to="us-gaap_DebtInstrumentAxis_637865735119202214" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_637865735119202214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_637865735119202214" xlink:to="us-gaap_DebtInstrumentNameDomain_637865735119202214" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember_637865735119202214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_637865735119202214" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember_637865735119202214" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637865735119202214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637865735119202214" xlink:to="us-gaap_StatementClassOfStockAxis_637865735119202214" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637865735119202214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637865735119202214" xlink:to="us-gaap_ClassOfStockDomain_637865735119202214" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Series1RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series1RedeemableConvertiblePreferredStockMember_637865735119202214" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735119202214" xlink:to="adag_Series1RedeemableConvertiblePreferredStockMember_637865735119202214" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Series2RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series2RedeemableConvertiblePreferredStockMember_637865735119211852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735119202214" xlink:to="adag_Series2RedeemableConvertiblePreferredStockMember_637865735119211852" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesBRedeemableConvertiblePreferredStockMember_637865735119211852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735119202214" xlink:to="adag_SeriesBRedeemableConvertiblePreferredStockMember_637865735119211852" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC1RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC1RedeemableConvertiblePreferredStockMember_637865735119211852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735119202214" xlink:to="adag_SeriesC1RedeemableConvertiblePreferredStockMember_637865735119211852" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC2RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC2RedeemableConvertiblePreferredStockMember_637865735119211852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735119202214" xlink:to="adag_SeriesC2RedeemableConvertiblePreferredStockMember_637865735119211852" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC3RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC3RedeemableConvertiblePreferredStockMember_637865735119211852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735119202214" xlink:to="adag_SeriesC3RedeemableConvertiblePreferredStockMember_637865735119211852" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_637865735119211852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637865735119202214" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_637865735119211852" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_637865735119211852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_637865735119211852" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_637865735119211852" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC1WarrantsMember" xlink:label="adag_SeriesC1WarrantsMember_637865735119211852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_637865735119211852" xlink:to="adag_SeriesC1WarrantsMember_637865735119211852" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_637865735119211852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637865735119202214" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_637865735119211852" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_637865735119211852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_637865735119211852" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_637865735119211852" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_637865735119211852" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_637865735119211852" xlink:to="us-gaap_IPOMember_637865735119211852" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_637865735119222125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637865735119202214" xlink:to="us-gaap_TemporaryEquityLineItems_637865735119222125" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_637865735119222125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637865735119222125" xlink:to="us-gaap_DebtInstrumentFaceAmount_637865735119222125" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_637865735119222125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637865735119222125" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_637865735119222125" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_637865735119222125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637865735119222125" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_637865735119222125" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637865735119222125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637865735119222125" xlink:to="adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_637865735119222125" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:label="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_637865735119222125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637865735119222125" xlink:to="adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_637865735119222125" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare_637865735119222125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637865735119222125" xlink:to="us-gaap_SharesIssuedPricePerShare_637865735119222125" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_637865735119222125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637865735119222125" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_637865735119222125" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_NumberOfInvestorsToWhomWarrantsWereIssued" xlink:label="adag_NumberOfInvestorsToWhomWarrantsWereIssued_637865735119222125" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637865735119222125" xlink:to="adag_NumberOfInvestorsToWhomWarrantsWereIssued_637865735119222125" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_637865735119231794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637865735119222125" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_637865735119231794" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637865735119231794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637865735119222125" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_637865735119231794" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MaximumProceedsReceivableFromExerciseOfWarrants" xlink:label="adag_MaximumProceedsReceivableFromExerciseOfWarrants_637865735119231794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637865735119222125" xlink:to="adag_MaximumProceedsReceivableFromExerciseOfWarrants_637865735119231794" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_637865735119231794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637865735119222125" xlink:to="us-gaap_PreferredStockDividendRatePercentage_637865735119231794" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637865735119231794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637865735119222125" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_637865735119231794" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice" xlink:label="adag_TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice_637865735119231794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637865735119222125" xlink:to="adag_TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice_637865735119231794" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice" xlink:label="adag_TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice_637865735119231794" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637865735119222125" xlink:to="adag_TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice_637865735119231794" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_637865735119242026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637865735119222125" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_637865735119242026" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_QualifiedPublicOfferingMinimumMarketCapitalization" xlink:label="adag_QualifiedPublicOfferingMinimumMarketCapitalization_637865735119242026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637865735119222125" xlink:to="adag_QualifiedPublicOfferingMinimumMarketCapitalization_637865735119242026" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_QualifiedPublicOfferingMinimumProceeds" xlink:label="adag_QualifiedPublicOfferingMinimumProceeds_637865735119242026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637865735119222125" xlink:to="adag_QualifiedPublicOfferingMinimumProceeds_637865735119242026" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent" xlink:label="adag_ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent_637865735119242026" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637865735119222125" xlink:to="adag_ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent_637865735119242026" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails" xlink:type="extended" xlink:title="40802 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Share Activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="us-gaap_TemporaryEquityByClassOfStockTable_637865735119252041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:to="us-gaap_TemporaryEquityByClassOfStockTable_637865735119252041" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637865735119252041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637865735119252041" xlink:to="us-gaap_StatementClassOfStockAxis_637865735119252041" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637865735119252041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637865735119252041" xlink:to="us-gaap_ClassOfStockDomain_637865735119252041" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Series1RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series1RedeemableConvertiblePreferredStockMember_637865735119252041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735119252041" xlink:to="adag_Series1RedeemableConvertiblePreferredStockMember_637865735119252041" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Series2RedeemableConvertiblePreferredStockMember" xlink:label="adag_Series2RedeemableConvertiblePreferredStockMember_637865735119252041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735119252041" xlink:to="adag_Series2RedeemableConvertiblePreferredStockMember_637865735119252041" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesBRedeemableConvertiblePreferredStockMember_637865735119252041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735119252041" xlink:to="adag_SeriesBRedeemableConvertiblePreferredStockMember_637865735119252041" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC1RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC1RedeemableConvertiblePreferredStockMember_637865735119252041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735119252041" xlink:to="adag_SeriesC1RedeemableConvertiblePreferredStockMember_637865735119252041" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC2RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC2RedeemableConvertiblePreferredStockMember_637865735119252041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735119252041" xlink:to="adag_SeriesC2RedeemableConvertiblePreferredStockMember_637865735119252041" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SeriesC3RedeemableConvertiblePreferredStockMember" xlink:label="adag_SeriesC3RedeemableConvertiblePreferredStockMember_637865735119252041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735119252041" xlink:to="adag_SeriesC3RedeemableConvertiblePreferredStockMember_637865735119252041" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="us-gaap_TemporaryEquityLineItems_637865735119252041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityByClassOfStockTable_637865735119252041" xlink:to="us-gaap_TemporaryEquityLineItems_637865735119252041" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637865735119252041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TemporaryEquityLineItems_637865735119252041" xlink:to="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637865735119252041" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637865735119252041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637865735119252041" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637865735119252041" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_637865735119252041" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637865735119252041" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_637865735119252041" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValue_637865735119262277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637865735119252041" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValue_637865735119262277" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637865735119262277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637865735119252041" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_637865735119262277" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637865735119262277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_637865735119252041" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_637865735119262277" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsWarrantsDetails" xlink:type="extended" xlink:title="40803 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Warrants (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:label="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_637865735119262277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_DisclosureOfTemporaryEquityAndWarrantsAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_637865735119262277" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureShareBasedCompensationDetails" xlink:type="extended" xlink:title="40901 - Disclosure - SHARE-BASED COMPENSATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715572603" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637865735119262277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715572603" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637865735119262277" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637865735119262277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637865735119262277" xlink:to="us-gaap_PlanNameAxis_637865735119262277" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637865735119262277" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637865735119262277" xlink:to="us-gaap_PlanNameDomain_637865735119262277" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Plan2015Member" xlink:label="adag_Plan2015Member_637865735119272285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637865735119262277" xlink:to="adag_Plan2015Member_637865735119272285" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Plan2017Member" xlink:label="adag_Plan2017Member_637865735119272285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637865735119262277" xlink:to="adag_Plan2017Member_637865735119272285" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_Plan2019Member" xlink:label="adag_Plan2019Member_637865735119272285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637865735119262277" xlink:to="adag_Plan2019Member_637865735119272285" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_PerformanceIncentivePlan2021Member" xlink:label="adag_PerformanceIncentivePlan2021Member_637865735119272285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637865735119262277" xlink:to="adag_PerformanceIncentivePlan2021Member_637865735119272285" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_637865735119272285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637865735119262277" xlink:to="us-gaap_GranteeStatusAxis_637865735119272285" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_637865735119272285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_637865735119272285" xlink:to="us-gaap_GranteeStatusDomain_637865735119272285" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_637865735119272285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_637865735119272285" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_637865735119272285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_637865735119272285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_637865735119272285" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_637865735119272285" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_637865735119272285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637865735119262277" xlink:to="srt_StatementScenarioAxis_637865735119272285" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_637865735119272285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_637865735119272285" xlink:to="srt_ScenarioUnspecifiedDomain_637865735119272285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ServiceConditionsAndPerformanceConditionsMember" xlink:label="adag_ServiceConditionsAndPerformanceConditionsMember_637865735119272285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_637865735119272285" xlink:to="adag_ServiceConditionsAndPerformanceConditionsMember_637865735119272285" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637865735119272285" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637865735119262277" xlink:to="srt_RangeAxis_637865735119272285" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637865735119282136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637865735119272285" xlink:to="srt_RangeMember_637865735119282136" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637865735119282136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637865735119282136" xlink:to="srt_MinimumMember_637865735119282136" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637865735119282136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637865735119282136" xlink:to="srt_MaximumMember_637865735119282136" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637865735119282136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_637865735119262277" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637865735119282136" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637865735119282136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637865735119282136" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_637865735119282136" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637865735119282136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637865735119282136" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_637865735119282136" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637865735119282136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637865735119282136" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_637865735119282136" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637865735119282136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637865735119282136" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637865735119282136" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_637865735119282136" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637865735119282136" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_637865735119282136" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived_637865735119292083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637865735119282136" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived_637865735119292083" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637865735119292083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637865735119282136" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637865735119292083" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637865735119292083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637865735119282136" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637865735119292083" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637865735119292083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637865735119282136" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_637865735119292083" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_637865735119292083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637865735119282136" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_637865735119292083" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_NumberOfSharesSurrendered" xlink:label="adag_NumberOfSharesSurrendered_637865735119292083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637865735119282136" xlink:to="adag_NumberOfSharesSurrendered_637865735119292083" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637865735119292083" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637865735119282136" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637865735119292083" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent" xlink:label="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent_637865735119302078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637865735119282136" xlink:to="adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent_637865735119302078" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637865735119302078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637865735119282136" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_637865735119302078" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637865735119302078" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_637865735119282136" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637865735119302078" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails" xlink:type="extended" xlink:title="40902 - Disclosure - SHARE-BASED COMPENSATION - Share Option Activities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715572603" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637865735119312123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715572603" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637865735119312123" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637865735119312123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637865735119312123" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_637865735119312123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637865735119312123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637865735119312123" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637865735119312123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637865735119312123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637865735119312123" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637865735119312123" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637865735119312123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637865735119312123" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_637865735119312123" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378657351193121231" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637865735119312123" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6378657351193121231" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637865735119312123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637865735119312123" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_637865735119312123" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637865735119312123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_637865735119312123" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_637865735119312123" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637865735119312123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715572603" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637865735119312123" order="2" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637865735119312123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637865735119312123" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637865735119312123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637865735119312123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637865735119312123" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637865735119312123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637865735119321753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637865735119312123" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_637865735119321753" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637865735119321753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637865735119312123" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_637865735119321753" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637865735119321753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637865735119312123" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_637865735119321753" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637865735119321753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637865735119312123" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_637865735119321753" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637865735119321753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_637865735119312123" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_637865735119321753" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637865735119321753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715572603" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637865735119321753" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_637865735119321753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637865735119321753" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_637865735119321753" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637865735119321753" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637865735119321753" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_637865735119321753" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue_637865735119332107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637865735119321753" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue_637865735119332107" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_637865735119332107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637865735119321753" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_637865735119332107" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_637865735119332107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637865735119321753" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_637865735119332107" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_637865735119332107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637865735119321753" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue_637865735119332107" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_637865735119332107" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_637865735119321753" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue_637865735119332107" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637865735119392134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715572603" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637865735119392134" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637865735119392134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637865735119392134" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_637865735119392134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637865735119392134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637865735119392134" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_637865735119392134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637865735119401912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637865735119392134" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_637865735119401912" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637865735119401912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637865735119392134" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_637865735119401912" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6378657351194019121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637865735119392134" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6378657351194019121" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_637865735119401912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637865735119392134" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_637865735119401912" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637865735119401912" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_637865735119392134" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_637865735119401912" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails" xlink:type="extended" xlink:title="40903 - Disclosure - SHARE-BASED COMPENSATION - Share Option Activities - Narrative (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637865735119412407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_637865735119412407" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_637865735119412407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_637865735119412407" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637865735119412407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_637865735119412407" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637865735119412407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_637865735119412407" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails" xlink:type="extended" xlink:title="40904 - Disclosure - SHARE-BASED COMPENSATION - Fair Value Of Share Options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715602905" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637865735119412407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715602905" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637865735119412407" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637865735119412407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637865735119412407" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_637865735119412407" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637865735119412407" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637865735119412407" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_637865735119412407" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637865735119422104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637865735119412407" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_637865735119422104" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637865735119422104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637865735119412407" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_637865735119422104" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637865735119422104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637865735119412407" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_637865735119422104" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum_637865735119422104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637865735119412407" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum_637865735119422104" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum" xlink:label="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum_637865735119422104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637865735119412407" xlink:to="adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum_637865735119422104" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637865735119422104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_637865735119412407" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_637865735119422104" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails" xlink:type="extended" xlink:title="40905 - Disclosure - SHARE-BASED COMPENSATION - Share based compensation expenses (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715612895" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637865735119422104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637520231715612895" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637865735119422104" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_637865735119422104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637865735119422104" xlink:to="us-gaap_IncomeStatementLocationAxis_637865735119422104" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_637865735119422104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_637865735119422104" xlink:to="us-gaap_IncomeStatementLocationDomain_637865735119422104" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_637865735119422104" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637865735119422104" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_637865735119422104" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_637865735119432127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_637865735119422104" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_637865735119432127" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637865735119432127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_637865735119422104" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637865735119432127" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_637865735119432127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_637865735119432127" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_637865735119432127" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails" xlink:type="extended" xlink:title="41001 - Disclosure - COLLABORATION ARRANGEMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CollaborationArrangementsAbstract" xlink:label="adag_CollaborationArrangementsAbstract_637517385843288507" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637865735119432127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_CollaborationArrangementsAbstract_637517385843288507" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637865735119432127" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637865735119432127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637865735119432127" xlink:to="us-gaap_TypeOfArrangementAxis_637865735119432127" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637865735119432127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637865735119432127" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637865735119432127" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember" xlink:label="adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_637865735119432127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637865735119432127" xlink:to="adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_637865735119432127" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember" xlink:label="adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_637865735119432127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637865735119432127" xlink:to="adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_637865735119432127" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_SignalPharmaceuticalsLlcMember" xlink:label="adag_SignalPharmaceuticalsLlcMember_637865735119432127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637865735119432127" xlink:to="adag_SignalPharmaceuticalsLlcMember_637865735119432127" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdctCollaborationAgreementMember" xlink:label="adag_AdctCollaborationAgreementMember_637865735119432127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637865735119432127" xlink:to="adag_AdctCollaborationAgreementMember_637865735119432127" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ExelixisIncAgreementMember" xlink:label="adag_ExelixisIncAgreementMember_637865735119432127" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637865735119432127" xlink:to="adag_ExelixisIncAgreementMember_637865735119432127" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637865735119442082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_637865735119432127" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637865735119442082" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CollaborativeArrangementUpfrontCashPaymentReceived" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceived_637865735119442082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637865735119442082" xlink:to="adag_CollaborativeArrangementUpfrontCashPaymentReceived_637865735119442082" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties" xlink:label="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties_637865735119442082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637865735119442082" xlink:to="adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties_637865735119442082" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637865735119442082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637865735119442082" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_637865735119442082" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies" xlink:label="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies_637865735119442082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637865735119442082" xlink:to="adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies_637865735119442082" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_PeriodForReservationOfTargetRight" xlink:label="adag_PeriodForReservationOfTargetRight_637865735119442082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637865735119442082" xlink:to="adag_PeriodForReservationOfTargetRight_637865735119442082" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement" xlink:label="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement_637865735119442082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637865735119442082" xlink:to="adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement_637865735119442082" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncome" xlink:label="us-gaap_OtherIncome_637865735119442082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637865735119442082" xlink:to="us-gaap_OtherIncome_637865735119442082" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CollaborativeArrangementMilestonePaymentReceived" xlink:label="adag_CollaborativeArrangementMilestonePaymentReceived_637865735119442082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637865735119442082" xlink:to="adag_CollaborativeArrangementMilestonePaymentReceived_637865735119442082" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CollaborativeArrangementUpfrontCashPaymentReceivable" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceivable_637865735119442082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637865735119442082" xlink:to="adag_CollaborativeArrangementUpfrontCashPaymentReceivable_637865735119442082" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones" xlink:label="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones_637865735119442082" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637865735119442082" xlink:to="adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones_637865735119442082" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MilestonePaymentsReceivableSalesBasedMilestones" xlink:label="adag_MilestonePaymentsReceivableSalesBasedMilestones_637865735119452113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637865735119442082" xlink:to="adag_MilestonePaymentsReceivableSalesBasedMilestones_637865735119452113" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_637865735119452113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_637865735119442082" xlink:to="us-gaap_AccountsReceivableNetCurrent_637865735119452113" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails" xlink:type="extended" xlink:title="41101 - Disclosure - INCOME TAX EXPENSE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637517388289534549" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_IncomeTaxDisclosureTable" xlink:label="adag_IncomeTaxDisclosureTable_637865735119452113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637517388289534549" xlink:to="adag_IncomeTaxDisclosureTable_637865735119452113" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_637865735119452113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_IncomeTaxDisclosureTable_637865735119452113" xlink:to="srt_StatementGeographicalAxis_637865735119452113" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_637865735119452113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_637865735119452113" xlink:to="srt_SegmentGeographicalDomain_637865735119452113" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CN" xlink:label="country_CN_637865735119452113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637865735119452113" xlink:to="country_CN_637865735119452113" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_HK" xlink:label="country_HK_637865735119452113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637865735119452113" xlink:to="country_HK_637865735119452113" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_AU" xlink:label="country_AU_637865735119452113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637865735119452113" xlink:to="country_AU_637865735119452113" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US" xlink:label="country_US_637865735119452113" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637865735119452113" xlink:to="country_US_637865735119452113" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd#stpr_CA" xlink:label="stpr_CA_637865735119462359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="country_US_637865735119452113" xlink:to="stpr_CA_637865735119462359" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_CH" xlink:label="country_CH_637865735119462359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637865735119452113" xlink:to="country_CH_637865735119462359" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_SG" xlink:label="country_SG_637865735119462359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_637865735119452113" xlink:to="country_SG_637865735119462359" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_StatusForTaxabilityAxis" xlink:label="adag_StatusForTaxabilityAxis_637865735119462359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_IncomeTaxDisclosureTable_637865735119452113" xlink:to="adag_StatusForTaxabilityAxis_637865735119462359" order="2" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_StatusForTaxabilityDomain" xlink:label="adag_StatusForTaxabilityDomain_637865735119462359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_StatusForTaxabilityAxis_637865735119462359" xlink:to="adag_StatusForTaxabilityDomain_637865735119462359" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_TechnologyAdvancedServiceEnterprisesMember" xlink:label="adag_TechnologyAdvancedServiceEnterprisesMember_637865735119462359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_StatusForTaxabilityDomain_637865735119462359" xlink:to="adag_TechnologyAdvancedServiceEnterprisesMember_637865735119462359" order="1" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_637865735119462359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_IncomeTaxDisclosureTable_637865735119452113" xlink:to="dei_LegalEntityAxis_637865735119462359" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_637865735119462359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_637865735119462359" xlink:to="dei_EntityDomain_637865735119462359" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneSuzhouLimitedMember" xlink:label="adag_AdageneSuzhouLimitedMember_637865735119462359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637865735119462359" xlink:to="adag_AdageneSuzhouLimitedMember_637865735119462359" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneHongKongLimitedMember" xlink:label="adag_AdageneHongKongLimitedMember_637865735119462359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637865735119462359" xlink:to="adag_AdageneHongKongLimitedMember_637865735119462359" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneAustraliaPtyLtd.Member" xlink:label="adag_AdageneAustraliaPtyLtd.Member_637865735119462359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637865735119462359" xlink:to="adag_AdageneAustraliaPtyLtd.Member_637865735119462359" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AdageneAgMember" xlink:label="adag_AdageneAgMember_637865735119462359" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_637865735119462359" xlink:to="adag_AdageneAgMember_637865735119462359" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_637865735119472087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_IncomeTaxDisclosureTable_637865735119452113" xlink:to="us-gaap_StatementLineItems_637865735119472087" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637865735119472087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735119472087" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637865735119472087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_PreferentialIncomeTaxRate" xlink:label="adag_PreferentialIncomeTaxRate_637865735119472087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735119472087" xlink:to="adag_PreferentialIncomeTaxRate_637865735119472087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate" xlink:label="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate_637865735119472087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735119472087" xlink:to="adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate_637865735119472087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AssessableProfits" xlink:label="adag_AssessableProfits_637865735119472087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735119472087" xlink:to="adag_AssessableProfits_637865735119472087" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_WithholdingTaxRateOnDividendsPercentage" xlink:label="adag_WithholdingTaxRateOnDividendsPercentage_637865735119472087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735119472087" xlink:to="adag_WithholdingTaxRateOnDividendsPercentage_637865735119472087" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CapitalTaxRatePercentage" xlink:label="adag_CapitalTaxRatePercentage_637865735119472087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735119472087" xlink:to="adag_CapitalTaxRatePercentage_637865735119472087" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards_637865735119482121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735119472087" xlink:to="us-gaap_OperatingLossCarryforwards_637865735119482121" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_WithholdingIncomeTaxes" xlink:label="adag_WithholdingIncomeTaxes_637865735119482121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735119472087" xlink:to="adag_WithholdingIncomeTaxes_637865735119482121" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_TaxableIncome" xlink:label="adag_TaxableIncome_637865735119482121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735119472087" xlink:to="adag_TaxableIncome_637865735119482121" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637865735119482121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735119472087" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637865735119482121" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_637865735119482121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_637865735119472087" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal_637865735119482121" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails" xlink:type="extended" xlink:title="41102 - Disclosure - INCOME TAX EXPENSE - Income tax expense (benefit) (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_637865735119482121" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_637865735119482121" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_637865735119492087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_637865735119482121" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_637865735119492087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_637865735119492087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_637865735119482121" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_637865735119492087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_637865735119492087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_637865735119482121" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_637865735119492087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_637865735119492087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_637865735119492087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_637865735119492087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_637865735119492087" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_637865735119492087" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_637865735119492087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_637865735119492087" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_637865735119492087" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_637865735119492087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_637865735119492087" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_637865735119492087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637865735119492087" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_1" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637865735119492087" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails" xlink:type="extended" xlink:title="41103 - Disclosure - INCOME TAX EXPENSE - Income tax reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637865735119501751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_637865735119501751" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637865735119501751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_637865735119501751" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637865735119501751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_637865735119501751" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_637865735119501751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount_637865735119501751" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount" xlink:label="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount_637865735119501751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount_637865735119501751" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_637865735119501751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_637865735119501751" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_637865735119501751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_637865735119501751" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_637865735119501751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_637865735119501751" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_637865735119501751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_637865735119501751" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_637865735119501751" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_637865735119501751" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails" xlink:type="extended" xlink:title="41104 - Disclosure - INCOME TAX EXPENSE - Deferred tax assets and deferred tax liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637517388289555277" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_637865735119512096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637517388289555277" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_637865735119512096" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637865735119512096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637865735119512096" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_637865735119512096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="us-gaap_DeferredTaxAssetsInventory_637865735119512096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637865735119512096" xlink:to="us-gaap_DeferredTaxAssetsInventory_637865735119512096" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:label="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_637865735119512096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637865735119512096" xlink:to="us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_637865735119512096" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_DeferredTaxAssetsDepreciationAndAmortization" xlink:label="adag_DeferredTaxAssetsDepreciationAndAmortization_637865735119512096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637865735119512096" xlink:to="adag_DeferredTaxAssetsDepreciationAndAmortization_637865735119512096" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_637865735119512096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637865735119512096" xlink:to="us-gaap_DeferredTaxAssetsGross_637865735119512096" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637865735119512096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637865735119512096" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637865735119512096" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_637865735119512096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_637865735119512096" xlink:to="us-gaap_DeferredTaxAssetsNet_637865735119512096" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_637865735119512096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637517388289555277" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_637865735119512096" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637865735119512096" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_637865735119512096" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_637865735119512096" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_637865735119521984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_637865735119512096" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_637865735119521984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities_637865735119521984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_637865735119512096" xlink:to="us-gaap_DeferredTaxLiabilities_637865735119521984" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureIncomeTaxExpenseValuationAllowanceDetails" xlink:type="extended" xlink:title="41105 - Disclosure - INCOME TAX EXPENSE - Valuation Allowance (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637517388289565197" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceAbstract" xlink:label="us-gaap_ValuationAllowanceAbstract_637865735119521984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637517388289565197" xlink:to="us-gaap_ValuationAllowanceAbstract_637865735119521984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_637865735119521984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract_637865735119521984" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_637865735119521984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637865735119521984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract_637865735119521984" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_637865735119521984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_6378657351195219841" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowanceAbstract_637865735119521984" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_6378657351195219841" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureNetLossPerShareDetails" xlink:type="extended" xlink:title="41201 - Disclosure - NET LOSS PER SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637517385843561996" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_637865735119532323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637517385843561996" xlink:to="us-gaap_NetIncomeLossAbstract_637865735119532323" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_637865735119532323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_637865735119532323" xlink:to="us-gaap_NetIncomeLoss_637865735119532323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_637865735119532323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_637865735119532323" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_637865735119532323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637865735119532323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_637865735119532323" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_637865735119532323" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637865735119532323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637517385843561996" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637865735119532323" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637865735119532323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637865735119532323" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_637865735119532323" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637865735119532323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637865735119532323" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_637865735119532323" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_637865735119532323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637865735119532323" xlink:to="us-gaap_EarningsPerShareBasic_637865735119532323" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_637865735119532323" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_637865735119532323" xlink:to="us-gaap_EarningsPerShareDiluted_637865735119532323" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails" xlink:type="extended" xlink:title="41202 - Disclosure - NET LOSS PER SHARE - Anti-dilutive Securities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637517385843619397" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637865735119542123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract_637517385843619397" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637865735119542123" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637865735119542123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637865735119542123" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637865735119542123" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_637865735119542123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_637865735119542123" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_637865735119542123" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_637865735119542123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637865735119542123" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_637865735119542123" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="us-gaap_StockCompensationPlanMember_637865735119542123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_637865735119542123" xlink:to="us-gaap_StockCompensationPlanMember_637865735119542123" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637865735119542123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_637865735119542123" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637865735119542123" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637865735119542123" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_637865735119542123" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_637865735119542123" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails" xlink:type="extended" xlink:title="41301 - Disclosure - RELATED PARTY TRANSACTIONS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_637517388289565197" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637865735119552108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract_637517388289565197" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637865735119552108" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637865735119552108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637865735119552108" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637865735119552108" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_637865735119552108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_637865735119552108" xlink:to="us-gaap_RelatedPartyDomain_637865735119552108" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_WuxiApptecGroupMember" xlink:label="adag_WuxiApptecGroupMember_637865735119552108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637865735119552108" xlink:to="adag_WuxiApptecGroupMember_637865735119552108" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_WuxiBiologicsShanghaiCo.Ltd.Member" xlink:label="adag_WuxiBiologicsShanghaiCo.Ltd.Member_637865735119552108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_637865735119552108" xlink:to="adag_WuxiBiologicsShanghaiCo.Ltd.Member_637865735119552108" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_637865735119552108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637865735119552108" xlink:to="us-gaap_RelatedPartyTransactionAxis_637865735119552108" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_637865735119552108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis_637865735119552108" xlink:to="us-gaap_RelatedPartyTransactionDomain_637865735119552108" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember" xlink:label="adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_637865735119552108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain_637865735119552108" xlink:to="adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_637865735119552108" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_637865735119552108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_637865735119552108" xlink:to="us-gaap_RelatedPartyTransactionLineItems_637865735119552108" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_637865735119552108" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637865735119552108" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_637865735119552108" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrent_637865735119562130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637865735119552108" xlink:to="us-gaap_DueToRelatedPartiesCurrent_637865735119562130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_637865735119562130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_637865735119552108" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_637865735119562130" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesDetails" xlink:type="extended" xlink:title="41401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637865735119562130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637865735119562130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637865735119562130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637865735119562130" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_637865735119562130" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637865735119562130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637865735119562130" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_637865735119562130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637865735119562130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637865735119562130" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_637865735119562130" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637865735119562130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_637865735119562130" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_637865735119562130" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense_637865735119562130" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseAndRentalExpense_637865735119562130" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureRestrictedNetAssetsDetails" xlink:type="extended" xlink:title="41501 - Disclosure - RESTRICTED NET ASSETS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_RestrictedNetAssetsAbstract" xlink:label="adag_RestrictedNetAssetsAbstract" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve" xlink:label="adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve_637865735119572134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_RestrictedNetAssetsAbstract" xlink:to="adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve_637865735119572134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital" xlink:label="adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital_637865735119572134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_RestrictedNetAssetsAbstract" xlink:to="adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital_637865735119572134" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:label="us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_637865735119572134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_RestrictedNetAssetsAbstract" xlink:to="us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_637865735119572134" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_AfterTaxIncomePercentageAppropriations" xlink:label="adag_AfterTaxIncomePercentageAppropriations_637865735119572134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_RestrictedNetAssetsAbstract" xlink:to="adag_AfterTaxIncomePercentageAppropriations_637865735119572134" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries" xlink:label="adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries_637865735119572134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="adag_RestrictedNetAssetsAbstract" xlink:to="adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries_637865735119572134" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureTreasurySharesDetails" xlink:type="extended" xlink:title="41601 - Disclosure - TREASURY SHARES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAbstract" xlink:label="us-gaap_TreasuryStockSharesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="us-gaap_ClassOfTreasuryStockTable_637865735119572134" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TreasuryStockSharesAbstract_1" xlink:to="us-gaap_ClassOfTreasuryStockTable_637865735119572134" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637865735119582124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable_637865735119572134" xlink:to="us-gaap_StatementClassOfStockAxis_637865735119582124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637865735119582124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637865735119582124" xlink:to="us-gaap_ClassOfStockDomain_637865735119582124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AdrMember" xlink:label="dei_AdrMember_637865735119582124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735119582124" xlink:to="dei_AdrMember_637865735119582124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637865735119582124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735119582124" xlink:to="us-gaap_CommonStockMember_637865735119582124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems" xlink:label="us-gaap_EquityClassOfTreasuryStockLineItems_637865735119582124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfTreasuryStockTable_637865735119572134" xlink:to="us-gaap_EquityClassOfTreasuryStockLineItems_637865735119582124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="us-gaap_StockRepurchaseProgramAuthorizedAmount1_637865735119582124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637865735119582124" xlink:to="us-gaap_StockRepurchaseProgramAuthorizedAmount1_637865735119582124" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:label="us-gaap_StockRepurchaseProgramPeriodInForce1_637865735119582124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637865735119582124" xlink:to="us-gaap_StockRepurchaseProgramPeriodInForce1_637865735119582124" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired_637865735119582124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637865735119582124" xlink:to="us-gaap_TreasuryStockSharesAcquired_637865735119582124" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_637865735119582124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637865735119582124" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod_637865735119582124" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired_637865735119582124" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityClassOfTreasuryStockLineItems_637865735119582124" xlink:to="us-gaap_TreasuryStockSharesRetired_637865735119582124" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.adagene.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="41701 - Disclosure - SUBSEQUENT EVENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_637865735119592057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventTable_637865735119592057" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_637865735119592057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637865735119592057" xlink:to="us-gaap_SubsequentEventTypeAxis_637865735119592057" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_637865735119592057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_637865735119592057" xlink:to="us-gaap_SubsequentEventTypeDomain_637865735119592057" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_637865735119592057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_637865735119592057" xlink:to="us-gaap_SubsequentEventMember_637865735119592057" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_637865735119592057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637865735119592057" xlink:to="us-gaap_PlanNameAxis_637865735119592057" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_637865735119592057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_637865735119592057" xlink:to="us-gaap_PlanNameDomain_637865735119592057" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_PerformanceIncentivePlan2021Member" xlink:label="adag_PerformanceIncentivePlan2021Member_637865735119592057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_637865735119592057" xlink:to="adag_PerformanceIncentivePlan2021Member_637865735119592057" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_637865735119592057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637865735119592057" xlink:to="us-gaap_GranteeStatusAxis_637865735119592057" order="3" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_637865735119592057" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusAxis_637865735119592057" xlink:to="us-gaap_GranteeStatusDomain_637865735119592057" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementEmployeeMember_637865735119601783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_637865735119592057" xlink:to="us-gaap_ShareBasedPaymentArrangementEmployeeMember_637865735119601783" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:label="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_637865735119601783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GranteeStatusDomain_637865735119592057" xlink:to="us-gaap_ShareBasedPaymentArrangementNonemployeeMember_637865735119601783" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_637865735119601783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637865735119592057" xlink:to="us-gaap_TypeOfArrangementAxis_637865735119601783" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637865735119601783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_637865735119601783" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637865735119601783" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ExelixisAgreementMember" xlink:label="adag_ExelixisAgreementMember_637865735119601783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_637865735119601783" xlink:to="adag_ExelixisAgreementMember_637865735119601783" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_637865735119601783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637865735119592057" xlink:to="srt_RangeAxis_637865735119601783" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_637865735119601783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_637865735119601783" xlink:to="srt_RangeMember_637865735119601783" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_637865735119601783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637865735119601783" xlink:to="srt_MinimumMember_637865735119601783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_637865735119601783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_637865735119601783" xlink:to="srt_MaximumMember_637865735119601783" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_637865735119601783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637865735119592057" xlink:to="us-gaap_StatementClassOfStockAxis_637865735119601783" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_637865735119601783" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_637865735119601783" xlink:to="us-gaap_ClassOfStockDomain_637865735119601783" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AdrMember" xlink:label="dei_AdrMember_637865735119612030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735119601783" xlink:to="dei_AdrMember_637865735119612030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_637865735119612030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_637865735119601783" xlink:to="us-gaap_CommonStockMember_637865735119612030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_637865735119612030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_637865735119592057" xlink:to="us-gaap_SubsequentEventLineItems_637865735119612030" order="7" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected" xlink:label="adag_ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected_637865735119612030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637865735119612030" xlink:to="adag_ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected_637865735119612030" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637865735119612030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637865735119612030" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_637865735119612030" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_637865735119612030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637865735119612030" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_637865735119612030" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637865735119612030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637865735119612030" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_637865735119612030" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637865735119612030" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637865735119612030" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_637865735119612030" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CollaborativeArrangementUpfrontCashPaymentReceivable" xlink:label="adag_CollaborativeArrangementUpfrontCashPaymentReceivable_637865735119622044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637865735119612030" xlink:to="adag_CollaborativeArrangementUpfrontCashPaymentReceivable_637865735119622044" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="adag-20211231.xsd#adag_CollaborativeArrangementMilestonePaymentReceivable" xlink:label="adag_CollaborativeArrangementMilestonePaymentReceivable_637865735119622044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637865735119612030" xlink:to="adag_CollaborativeArrangementMilestonePaymentReceivable_637865735119622044" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="us-gaap_TreasuryStockSharesAcquired_637865735119622044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637865735119612030" xlink:to="us-gaap_TreasuryStockSharesAcquired_637865735119622044" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_637865735119622044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637865735119612030" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod_637865735119622044" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="us-gaap_TreasuryStockSharesRetired_637865735119622044" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_637865735119612030" xlink:to="us-gaap_TreasuryStockSharesRetired_637865735119622044" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>adag-20211231x20f002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'L >,# 2(  A$! Q$!_\0
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M&/A3PUI<>GV&@6$=L@QAX%D9O=F8$L?J:\?^+G['?A_QCY^H>%VC\.ZLV6,
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M]K-N<_YI:OY=%\D@HHHK ]$**** "BBB@ HHHH **** "BBB@ HHHH ****
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M=VDRAXYH7#(X/<$=:^6KX:IAY<M1?Y'WV$QM#&QYJ,K^75%BBBBN8[PHHHH
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MY!V4C('YUY<?W&866TE_7Y'W^&G]=R'WMZ3M\O\ AG^!\=4445]$?-!1110
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M7//]W-3Z/1_H>G07UF@\.OB7O1\_YEZZ)KT9Y111170>8?07[%W_ "4C4/\
MKQ;_ -"%=M^U!_R5_P"'?U/_ *-6O'?V</B1I?PT\>F^UEGBT^X@:!YD0OY9
MZ@D#DCZ5T?Q\^,^A^,_B3X<U/1&DO+'1\%IVC*"4EPQVAL'C'?%>#5I5)8QR
M2TM^A^B8/&X>GDD:<II24UIU^)/;T/>_VM?^2+ZC_P!?,'_H=?!=?5/[1'[0
M?A'QW\-AH^AW,UY>W<L<CHT#Q^0%.2&+  GMQFOE:NC+82IT6IJVIYW%6(HX
MC&QE1DI)16SOU858L+&;4[ZWM+9#)/.XCC0=V)P*KUZGX#L8_AQX=;QUJ<8%
M_(&BT*U?@R2D8,Y'7:G8]SZUZ-2?)'3?H?+X:A[>I9NT5JWV7];=WH4?C5>0
MVNL:7X9M91+:^'[)+,L%7/G'YI>1PWS'&?:O.JDN+B2[N)9YG,DTK%W=NK,3
MDG\ZCITX\D5$G$5O;U95+6OMY+HODCWS]C?PTVJ_$FXU-DW0Z=;,<GIO;@?C
M7<_MUZUY'AKP]I:2 -/</,Z9Y*A< _G7>?LJ_#]O!GPXCO+J+R[[5F^TN&&"
MJ8P@_+FOFK]L+QBGB;XKR64+J\&DPBV!']\\N/SKQ*3^L9AS+:/]?F?IU.D\
MNR)0EI*IK]^OY(\+HHHKZ<^0"BBB@ HHHH **** "BBB@ JWI6JW>AZE;:A8
M7#VMY;.)(IHSAE8=#52BDU?1C3:=T?HW^S]\;+7XO^%@TQ2#7K)0E[;CH3VD
M7_9;]#D5Z=?V%MJEE/9WD"7-K.ACEBD7*NI&""*_+WX<>/\ 4OAGXMLM=TQR
M)(6Q+#NPLT9^\C>Q_0X-?I7X&\9Z=\0/"UAKNER>9:7:;@#U1OXE/N#D&OC,
MPPGU:?/#X7^!^GY/F*QU+V=7XX[^:[_YGS'\3?A7\(O@9XFLM6UC3?$>H0W+
M--;:= 8WL]P/W"S;6P./E+'@\YK2L?VN/%/CBY;3O /P\>[GA RT\K2JB]!N
M5 H3IW:OJ"[TZUOS&;FVAN#&VY#+&&V'U&>AKY*_:;27X6_$VQ\0>#=1^Q>(
M-=MWMKK3X%R[[OE$@ [L>G?<N:TP]2.*:IU%S2MHVW;[D<V-H5,OBZU"2A3;
M5U%+F^]WZ]#1^%7QV^)OB3XVIX;UNULI+90ZWMC8I&4M,#[_ )BECD' P6/7
MUKZLKQ[X _"JT^#7@>74-:FBBUF^47.I7D[@+$.H0L> %SR?4FND\$?'#PE\
M1/$^HZ%H5^;RZLHQ(9-NV.49P3&3RP4XR<8Y&,UR8I1JS;HQ]V.[2T]3TLO<
MZ%*,<54]^;NDWKZ'>TV2-)HVCD4.C JRL,@@]013J*\\]H\,^&SO\(/BIJ7P
M_N&9=!U;=J6A.QX0G)E@!]N2![$]Z]SKS']H#P1<^*/!JZII *>(] E&I:?(
MHRQ9.63W# =.Y %=3\-_&UM\0_!6E:];#:+J(&2,]8Y!PZ'CLP(_"NNM^\BJ
MW79^O?YK\;GFX;]Q4EAGMO'TZKY/\&CI:***Y#T@HHHH **** .?\?\ B^V\
M!>#=6UZZ&Z.R@+JF2/,<\(F<'&YBHS[UR?P \'7/AOP3_:>JY?Q!K\IU34)'
M7#;I.50\#& >G8LU8'Q8_P"+D_%7PK\/X\2Z;:?\3S60-I!C0XBC/.?F)P1C
MHZ&O:P,# Z5U2_=TE'K+5^G3_/[CQZ7^TXR55_#3]U?XGK)_)67WA1117*>P
M5]1U"WTG3[F^NY5@M;:-I997. B*,DGZ 5\G?$[]HCPC\4-+ETC5_"^KQZ"9
M=UMK,+KYT<BY =8R-O0G(+]#VKH?BC\._B]I$OB6YT376\4Z%K"S+<:6_P#K
M(HW5P5CC<G 52 /+;<QQ\IK,\(?M+>&M \ 1>#_&'A>_@O+"V%E+9"U1HY@H
M &Y'92K'J01UYSSBO9P]!17M(>^_)V:/ALQS"=:;PU9^PC9_'%24O*][6MVU
M)_ /[/DOCG2].GG^(]YXB\#HP>&PC\Q0VT_<9&<B,CIC!/IBOJ"UMHK*VBMX
M(UB@B01QQJ,!5 P /8"O(?V6_!6H^#_AW+)?H+<:G=&^M[59!((HF50N2.,D
M#/TQGG('L5<>+J2G4<7*Z6W](]S)\+3HX:-54^64DKZM^F[;2[+H%>(?M1_%
M_P#X0#PI_8^FS[-=U52BLC8:"'HS^Q/0=.Y[5[%KFLVGAW1KW5+Z40V=G"T\
MTA!.U5&2<#GM7YM_$CQW>?$CQCJ&NWA8>>^(82V1#$/N(/H.N.I)/>NC+\-[
M:IS2V1YG$N:/ 8;V5-^_/3T75_HO^ <QUHHHKZX_% HHHH **** "BBB@ HH
MHH *OZ%KE]X:U:UU/3KAK:]MG#QR(>A']*H44FDU9E1DX-2B[-'K5]H.E?&A
M&U+PVL&E^,""]YH3.$CO&[R6Q/&X]2A^HKRV^L+G2[N6UO+>6UN8FVR0S(5=
M#Z$'D5#'(\,BR1NR.IRK*<$'U!KT:T^,;:O9Q6/C;1+;QC;1+MBN9Y&@OHAV
M N%Y(]G#5SI3I:1U7X_\$])SH8O6J^2?>WNOS:6J?HFGV1YO17I2Z#\+M>F9
MK7Q3K/A8!,^5J^FB[4MZ*\# X^J5GR> ?#?F%HOB+HC6H/+R6EZLGX)Y!S^=
M5[:/5/[F9O!5-XRBU_CC^3=_O1PM.CC:5U1%+NQPJJ,DGT KT9O"OPTTA8)K
MSQUJ&N G]Y:Z-HS1.![23LH_\=/TJ0_%C2_":-%X$\-Q:+<8*_VSJ,GVN^8>
MJD@)$2.NU?QI>U<O@BWZZ?GK^!2PD:>M>I%+R:D_ERMK[VB31OAU8>"+.+7?
M'Y^S(5\RS\/*^+N\/;>O6./U)P37'>-?&E_XYUIK^]V1(JB.WM81B*WB'W40
M=@/UK)U#4;O5[V6\OKF6\NIFW23SN7=SZDGDU6JHTVGSS=W^7H9UL1%P]C17
M+#\6^[?Y+9>NH5ZK^SU\))OB?XRB:>)AHE@PENY2.&QR(P?4_P JYSX8_"S6
MOBGKR:?I<!$"D&YO'!\J!?4GU]!U-?H%X!\"Z5\-O"]OH^FH(X(5W23/@-*_
M\3L?\XKS\=BU1CR0?O/\#Z7A[)98^JL167[J/_DS[>G?[BO\2?&EE\,O >H:
MQ+MBCM(=EO$.-SXPB@?7M[5^8VK:G/K6IW=_=.9+BYE:61B<Y).:]Q_:M^-2
M_$+Q,-#TJ;?H6F.1O4\3S=&;W Z"O ZVRW#.A3YY?%(]G/,<L57]G3?NP_%]
M0HHHKV#YL**** "BBB@ HHHH **** "BBB@ KWS]DSXR-X"\6CP_J,V-#U>0
M("W(AN#PK>P;A3U[=.:\#HZ5A6I1KTW3ELSJPV(GA:T:U/=?U8_7 '(R.E>)
M?'#PWHW@O5X_BF="N->U?3XUMTM(V BWDX29^I^7[O /4<=ZG_9<^+7_  LO
MP%':WLP?6]* M[D$C=(F/DDQGN!@GCD&O9J^%]["U7&731^:_P""?K%Z>88=
M3@]]4[7L_3NF?"GQ6TKXN>/?"4GC'Q?!+9>'+>5&_L6)_(9(B<;Q'SCL-SY;
MGIBNK\5>"](^'7ACP7\5OAG"_P!BL0@OX?-WM/&YP2Y.<-DE#Z$K@<5]9ZY!
M87.C7T.J&(:;)"Z7)G8*@C((;<3T&,\U\UWW[0G@;X0:1%X/^&^FW'BB\60I
M$D<CR6_FL3T8Y,A+8.V,;3GAA7J4L14KI0IPV>RT5GW_ ,SP,1@:.$DZE:K\
M2^)ZR4D]''R\CZ4T358]<T>RU&))(XKJ%9E2:-D=0PS@JP!!]B*NU\__  #^
M,_BGQ#XVUKPMX^MQIVMO&E_9VQA$7EQ,H)CQU& 5;YB6^8YZ5] 5Y%:E*C/E
MD?2X7$0Q5)5(^COH[KNN@5X9\/!_PJCXU:]X)?$6B:\#J^D#@*LG26(<>QP.
MP3/>O<Z\A_:3\/W;>%;#Q=I$9;6_"MTNH1;=V7AR!,AP1\I4 GV4^M7AVFW3
M>TM/GT_$QQL7&"KQWAK\NJ^[\4CUZBLWPUKUMXH\/:;K%FQ>UOK=+B)B,$JR
M@CCMUK2KF::=F>@FI)-;,****0PJ*\NX;"TFN;B188(4:221SA54#))/8 5+
M7E7[26N75E\/!HFFY.J^)+N+1[900,^8?GSGL5!7/;>*TIP]I-0[G+BJZPU"
M=9J]E][Z+YO0H?LZ6LOB./Q+\0KU&%UXFOG-L'*DQVD1*1KP.",%3ZA%->R5
MG>'-"M_#'A_3=(M,_9K"WCMHRV-Q5%"@G'<XR?>M&G5G[2;DMOTZ$8.@\-0C
M3D[OJ^[>K?S;85XU^T9\0]:\/6VA>%_#$A@\0^(KC[/#< @&),JI(8_=8EU
M/8;CP0#7LM>"?M-^$=>^W>&?'/ARV-]>>'IO,EME0N2FY6#;0<D J00.<-GL
M:VPJBZR4OQ[]/Q./-Y588*;HWOI>V]KKFMYVN<Q-^R=XQTWS-8TOXBW#>(V7
M<[L)8C(QZ@S"0L1UY*\^@J]\+M0@^,5UJO@?XH:%;WOB;15RMW(GESM&& (W
MI@@@E.5.&!!P>2=71?VSO!MWI0EU.SU+3K]5^>U2(2J6]$<$9'^\%J+]GFTU
M#QU\0O%?Q.O;-]/M-246EC"PQO0;06]\"-1D<$EL=*]"4JZIRE75FMGL[]E8
M^9I0P#Q%&&72YE-OGC=RBXV>LE*]G>UCW^SM(;"T@M;>-8;>%%CCC48"J!@
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MJ\.6/Q,^MX>R?^TJWM*J_=QW\WV_S_X)LZ!H&G^%]'M=+TNV2TL;9 D<48P
M/7W)[FN:\:_$!=%9[&Q >]Z/(P^6/_$TSQ_XW;2!]@L) +P\R2#GRQZ?6L5#
M:_$:R"NT=IKT*_?;A9E]_P#/%?):MW9^UI**48JR1P]U=37L[SW$K32N<L[G
M)-0UVO\ PK;,$VW6+26[B0N;>+YNGJ<Y'Y5Q5 PHHHIB+VC:I=:/J$=S9D"=
M> "N[.>V*]-O8!J&AKJ-W9?V9?$\QY^_^';\>:XSX<*#XHB) .V-R,C/.*W=
M1O9[VZ=II"Y!( /0#V%(95HHHIB"MW0_$TM@RPW!,MMTYZI]/\*PJNZ7I<NJ
M7'EI\J#EW/112&>B12Q7<(=&62-QP1R"*^._VIOV<$T7[1XQ\+VNRR8[[^QB
M7B(G_EH@'1?4=J^GHO$-KI%Q%9VR;[5.)).Y/J*Z5TAOK5D94G@E0J5895E(
MY!'I73AL1/#3YX_/S.'&X*GCJ3IU/D^S/R4HKVG]IKX*M\+?%GVW3XC_ ,(_
MJ3%[? XA?JT?]1[5XM7W5*K&M!5(;,_)<10GAJLJ51:H*][^"O@G2I?![S:Q
M::5/)X@F:SAEU"[BB>UB4$"6-7(8L9,#Y,\5X)5ZXUS4;M+)9[ZXE6Q4):AY
M21 H.0$_NC//%37IRJQY8NQ>%K0P\^><;_U_E<]GM=+O?!G@G1;6VT*POM4;
M79[.Z6ZTJ&Z>5%*X4[T8@<GICK6GKNA:?X-MO$5]X;LK!+Q=92VGN+BR6\73
M8BH)"QLKX&2>0">,5X[;_$[Q?:),L'BC5X5F8O(([V1=['J3@\FL_1O%FM>'
M;R6[TO5KW3[F;_62VT[1L_?YB#S^-<OU:HVVVO\ /7J>A]=I))*+_P M+:>O
M78]TT'P_I]A\==%MM=T/2-1;5H$D@%A!);6L?R,3(UNZ\L<#@X .3CIC#^'N
ME:?J-I<Z(;-[+5-5U*Y2SU2YT*WNK7"K_J_-ER5 VDG8,C->2MXIUE];766U
M6];5E.X7S3L9@<8SOSGIQ4NG>,M>TBSN[2QUF_L[6[)-Q#!<.B2DC!+ 'G(X
M--X:=OBULOPN2L;2YOATNWYV=NN_1ZWTN>EVEC)J'PV\265]H5A;WFFVL,UM
M(--6W+1!]IN!<8+2,W3:<*1R/2O&ZUY?%VN3:(FC2:O?/I*'*V+7#&$?\ SB
MLBNJE3<+WZLX,15C5Y>5;*P4445N<@4444 ?:/[#7C)K_P +ZSX;F?+:?,+B
M$%ND<F<@#_>#'\:^GZ_/C]D;Q,?#WQFT^!F"PZE#):-N. #C>#]<KC\:_0>O
MB<SI>SQ#:ZZGZED5?VV"BGO'3_+\#YS\;?"[XE^!/'&N^)OAC>6UW;Z[)YUY
MIET8PZRG.67S,*1DD\,#S@@XS5?X)>$9;/XD77BGQ]XUT;4_&MQ']E@TR"_A
M:2'.,@JI ##& JC YY.>.C_:XU36++X?V%II]VVFV&H7\=KJ%^I(\F)O[V/X
M3R3_ +N.]><?$3]F[X;^ OA9=:J-=N$U=(//M+Z6\7-Q)U540  @GTY'7/%=
M%*?M*24W9RTNE=Z=W_3.+$4_8XF4J,;J'O-2E:*;N]%;?\+GUQ17B?PL_:&\
M*WNB>$?#]_X@6^\4W5M%!,L4;L!-LYW28VYR,<$\U[97CU*4Z4N6:L?2T,13
MQ,.>FT_T\F%>*:(I\)?M2Z_9[5CMO$ND17R;>/WD1V$?4_.:]KKQ3XW!?#_Q
M1^%OB8*5"ZA)ID\@Z$3+M13[9+&ML-K*4.Z?^:_%'/CO=A"K_+)/[W9_@V>U
MT445R'HGC_BS_B>?M+>";#;YB:/I5WJ3@]%\S,0/YJOZ5[!7C_@_=J_[2GCR
M]'S1Z7IEGIP/_70"4C\U->P5TU].6/9+\=?U/*P'O>VJ?S3E_P"2^[_[:%%%
M%<QZH4R>"*YB:*:-)8VX9'4,#]0:?10&Y';6T-G!'!!$D$,8VI'&H55'H .E
M2444!L?)?[<&N[]0\,Z,C<1QRW4B^Y(53^CU\MU[3^UUJK:C\9+N$G(LK2&W
M ]."_P#[/7BU?;8*/)AX+R_,_ \^K>VS*M+L[?=I^@4445VG@!1110 4^*)Y
MY4CC1I)'(5449)/H!3*<CM$ZNC%'4Y#*<$&D-6OJ7V\.ZJI8-IEX"L_V5LP-
MQ-_SS/'WN#QUJG<VTUG<207$3P3Q,4>*12K(PX((/0BICJU\V<WEP<R><<RM
MS)_?Z_>]^M5YII+B5Y97:61R69W.2Q/4D]Z2YNII+V=O=N,HHHJC(***OZ#I
M$VOZU8Z;;J7GNIEA0#KDG%)NRNRHQ<FHK=GU3^QK\,UMK&[\97L7[Z8FWLMP
M^ZO\;CZ]/SKZ(\5Z^GAW1Y;DX,I^6)?5C3_"GAZW\)^&]-T>U4+#9P+$-O0D
M#D_B<G\:\S^)>N'4]<-JC9@M1MP.A;N:^&Q%5UZKFS^A,LP4<OPD*"W2U]>I
MREQ<27<\DTKEY7)9F/<TS.*2BL3TCMOAZJS6>KP02HNHS0[(4<XW#O7'75K+
M97$D$\;12H=K(PY!HM[B6TG2:%VCE0[E93@@UZ=I>E6WQ#T^WOM0MGM[F%MC
M2QX G I#//=(T"_UV7R[*W:7'5^BK]3TKM=.^$3LH:^OPA[I N?U/^%=R\]E
MH%JD,4:Q(H^2&,8_S]:QKGQ)=3$^5MA7V&3^9H DT/X?Z=H-XMU!+</*%*_O
M&4CGV %/N?!4$A9HKB1&)S\X##^E9C:G=L<FYE_!R*FAUV]A(_?%QZ.,T!H4
M-0\,WNG@OL$T8_CCYQ]1637?:?XBBN2$F'DR'@'^$_X5#K'A:'4'$L!6"4GY
MN/E8?XT7"QR-AIMQJ4A2W3<0,DDX _&NBT32;O3XKV.ZBV1O&<-N!&?P-4=3
MU./3H?[/T\E%7_63#AF-9+ZC=R1F-KJ9D/53(2* *Y&"1UKJO"&KG)LI6XZQ
MD_RKE:D@F:VF25#AD.10!T?Q6^'UI\3? ^HZ'<J/,E0M;R'K'*/NL/QX_&OS
M)UC2KG0M5N].O(S%=6LK12(PP0P.*_5VQNEO;2*9>CJ#7Q%^VE\/U\/>.;7Q
M#;1[+;5TQ+C@><O7\Q@U[V4U^6;HO9[>I\AQ%@U.DL3%:QT?I_PY\YT445]6
M?GH445H6>G6US:"674[>UD,ZQ>1(DA8(>LF54C:.XSGT!I-V*2;V,^BM2]TJ
MTMK>YDBU>UNGBG\I(HXY0TR8_P!8NY0 OL2#[5ET)W!IQW"BBBF2%%%% !11
M10!L>#]:/ASQ9H^J@9^QW<4Y /4*X)'XC-?JI;3?:+:*4# D0-CZC-?DG7Z@
M_"#5WUWX7^%[^23S99M/A:1_5MHS^M?-YS#2$_5'W'#-3WJM+T90^(L.G?$K
M2/$'@&RUR.QUQ[>-I@J%V@1F5@6 P#D=L]Z\-O/V5_AC\,=/6_\ ''BVYE0#
M(1I%MUE]EC4,[?137;?%OX'>+]0\>2^-_A_XC32=9GMQ!<V]PVU9 JA1M.UA
MR .&'49SZ> KX,UWP-XCFUGXJ^ ==\8+D/)?"_,L,:^K% P;Z,ZCVKFPL?<M
M3JV6[2MS7Z[V.K,))U>:OA[M:*3NXVZ-VOKWT/HKX":'\*_$]C=:QX/\*0P)
MI]X;:.\OXO,F+A5;>K.69?O<<@_2O;J\V^!_Q/\ "?Q%T&=/"FFR:/;6#".2
MQ>V2$1DC(P$)7!KTFO*Q#E[5J5_F[L^BP*A["+IM-/K%67W!7C_[55I*?A+-
MJD/,VC7UMJ*#W60+_P"SU[!7%_&G21K?PF\66A&<Z=-(!ZE%+C]5%30ERU8M
M]T7C(>TPU2*ZI_D=9IMTE]I]M<1G<DL2NI]01FBN0^#6L_VK\*/"5U(VZ1]-
M@#GU8( ?U!HK.<>63CV-Z4U4IQGW29ROP,)O_&_Q6U/J)->-F#_UQ!7_ -FK
MV&O'_P!F1OM'A?Q1>=3>>)+V?/KG8/Z5[!6V)_BM=K+[D>?E>N$A+O=_>V_U
M"BBBN8]4**** "BBB@#\Z?V@;\ZE\9?%4Q.<70B_[X14_P#9:\]KJOBM-]H^
M)WBQ\Y_XFMR,_25A_2N5K[VBK4XKR1_..-ESXJK)]9/\V%%%%;'$%%%% !11
M10 4444 %%%% !7M'[)GAD:_\6;6YD3?#IL+71]FZ*?^^B*\7KZP_8>T@>3X
MFU,KALQ6ZGU!RQ_D*X<;/DP\G_6I]!D-!8C,J,7LG?[M3Z>U6]73=-N;EC@1
M1EL_A7SY/,UQ-)*YR[L68^Y.37LOQ(NFMO"MP%.#(RI^!/->+U\8C]Y845-<
M6=Q:!#/!)"'&5,B%=P]1GK4-,1L>%M"?Q#K$-J,B+.Z1O11UKV>\N(=#T](X
M45 HV1Q@<"N5^$^F"#2[B](^>9]@/L*MZY=&ZOW&<JGRBI&8VOZI+9:7J&H$
M>=+!!), QX8JI./TKY@T7]ISXHW?P_3Q_+\/-)O_  DFYYS8ZHR721*<,X1U
M.<>@SFOI7Q3$\WAC5XXT:21[.9511DL2AP *^,/ OQ"UG3?V=)/AM:_#KQE=
M>)[J&6T1VTAX[13(W#-*Q&% [XKT\+3C*#;BGJM^VM^J.6K)IK6VC/8/&G[1
MOB";Q/X'TCX?Z)INMGQ1ISZA"^IW#P! I&5)7/O^(JA;_M3Z_IV@?$.#Q%X0
M@TOQ9X0M%O'M8;WSK6Y0D 8<#*]>G/X=*X+5/@'K*^._@SX8GNM?TNWTW09X
M+S6?#\K0O;R%MVSSPI"YR1[XKOOB-^SWHOPW^ GQ$@\,6FIZWKVK61^T7MY(
MUY?7;9&!D#)^@%='+AERQM>__P EU=^WD9WJN[[?Y?YGN?@7Q')XN\&Z-K4L
M*V\E_:I<-$AR$+#. :[S0-7.Y;:8Y!^XQ_E7R[\$_CS;#1/"?A&?P3XVLK]8
M(K-[JZT1H[6-@N"S2%N%XZXKZ$5BC!@<$'(KS*U-TY--6.J$E)71I^,-("D7
ML2XR<2 ?SKEJ]'7;JND8;GS$P?K7G4B&.1D/5216"-&-HHHIB.R\%W?F6DL!
M/,;9'T->>_M9>$U\3?!W4IPN9]-9;M"%R< X8#Z@_I77>#9MFJ,G9T/Z5T7B
MW3!K7A?5[# )N;26(9]2I _6M*,W3JQFNC,,325>A.D^J:/RDHJ:\MFLKR>W
M;EHI&C/U!Q4-?H9^+[!1113$%%%% !1110 4444 %%%% !7Z'?LDWAN_@9H>
M7WM&\\9YZ 2L /RQ7YXU]T?L/WCW'PMU"%CE;?4G1?8%%;^9->+FT;X>_9H^
MHX=GRXQKNG^C/HBL/QCXKA\'Z,;R2WEO9Y)%M[6S@ \RXF8X5%SP.Y)/  )[
M5N5Q?Q4T'4M6T>PO-'1Y=1TJ\%Y'#&5#R#RWC8)N^7>%D++NXRH!ZU\E32<D
MI;'Z+6E*--N&YYUHOQSM+"^O-3GT[PM%%-+B_BTK4C_:D04'<\D$L$32A.^#
MD#) ;%>[03QW,$<T3B2*10RLIR"#T-?,LWAB74M5D;1KGQ'KVHWBN3;:_H\L
M<EM</"8#+-=.JH(T1F(C0')^[Q7T;X>TA= T+3]-1VD2T@2$.W4[0!G]*Z\3
M"G&SCO\ UW/.P%2M)R535?+]/Z1H51UVP_M71-0LL9^TV\D./]Y2/ZU>HKA3
ML[GK-75F>"?L]^)X8?@_X>BG?;)$)XB/0+/(H_0"BO$?#OBK_A'=.?30VT6]
MU<IC/3]^Y_K17O5<)SSE)=6SY##YBJ=&$'T27X'T1^RD-_PDAG/6XO[J4GU_
M>$?TKV&O(/V3P!\#]%_Z[7/_ *.>O7Z\G$_QY^K/;RG_ '"A_AC^04445S'J
MA1110 4C?=/TI:1ONGZ4 ?F/X_8OX[\2,>IU*Y)_[^M6!70?$%#%X]\2H>JZ
MG<C_ ,BM7/U^@0^%'\V8C^-/U?YA1115G.%%%% !1110 4444 %%%% !7VG^
MQ7 $^'FJ2@<O?$'\%'^-?%E?:/[%5P)/A_JL(/,=[DCZK_\ 6KRLR_W=^J/L
M.%;?VG&_9GL/CZPM=1TN&*[U2WTJ/S,B2Y8 ,<=!DBN*T[0_#6DW:7EUXHTV
M]B@^<P1RIER.@^\<_2M/X[VQE\(PRCI%<*3^/']:^?Z^32N?M+/:-.\>:?\
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MT _G7;R^-_#/PM_T7P3:1:WKB<2>*-3@#!&_Z=86R%'H[9-5/B-XOL=!TO\
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MUX2\6Z7XWT.WU;2+E;JTF'4<,C=U8=F'I6;\0?AMH_Q&TS[-J46R>,'R+N,
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M76I!/U2-X5ZM/X)M?,]L7]KOQXJX*Z4Q]3:G/_H=9]_^U1\0[T$1ZG;66?\
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M7_(^SR+*Y4O]JK*SZ+MYA1117SQ]F%%%% !1110!Y7^TMX@N-'^%=Y8V&_\
MM/7)XM(M0A R\K8(.>Q4,/QKO?!_A^'PIX5TG1K<$0V-K';KDY.%4#G\J\H\
M6*/B'^T=X=T0*)=.\)VK:G=YC)'VB0 1(3TSC8X/LWX>W5UU/<I0AWU?SV_#
M\SSJ'[VO4J]%[J^6K_%V^04445R'HA7#_$;X;67B7X9:[X;TRT@L!=1&2&*V
M584:96$B[L#H749/N:[BBM*=25.2E'H[_<9U*<:L7":NFK?><'\#/$EMXE^%
MF@26Z^4]G;)83P$Y:*2)0A!],@!L'G#"N\KQW0F/PS^..HZ.Y*:'XO5M0LR2
M=L=ZO^N09.,M]X_5 *]BKHQ<%&IS0^&6J^?3Y.Z^1AAI/V?(]XZ/Y?YK4***
M*XSK"BBB@ HHHH *\:_:OT(ZO\*)[E<[M/N8[G:!G(SL/Y!R?PKV6LWQ+H</
MB7P_J.E7 )@O('@?'7# BNK"UO85X5>S1SXBG[:E*GW1^9]=[\0U_MGPUX3\
M01DL'L_[.G./NR0G@'W*,/RKD-=T:X\/:S>Z9=KLN;29H9![J<9'L>M=C\/]
MOBKP]K'A"3!N)A]NTTD]+A <H,_WUR/RK]1KM)1K+9?D]_\ /Y'Y]23;E2>[
M_-?U8]N^&WAW1_%?P9TW5_#%C;67B[0)?.$T<8\V29#N*NV065UX^;CVXI/V
M@_#=K\4_AII?Q T:)O/MH=TZ;<-Y6<.K<9RC ^V-WK7D7P*^+#?"3Q5.U_'<
M/I-TOE7=O&/G5A]U@I(Y!R/H37NVB:_IOBCX)_$W5-(@DM=,N;B\DAAE #+F
M"/<< D#+;FZ]Z^3Q-*M@L4JJNTI73\I;H^DH5*6*P_LWO;5>:V9SO[,WA.S\
M%>#-4^(6L*J!HG6U9NT2_>(]V88'?@^M;GB6VTWP[\*->\7>+-/M[O7_ ! "
M\<4Z O$&&(8E/5=JX)(QSGTILFJVFA_LS>%KZ^MC=V-O-;2SVZ]9$%QDK7B_
MQ[^,R_%?5[1-/BGM=%LT_=0S@!FD/5B 2.G Y]?6E2HUL?BI5'MS.[\H[+YA
M4JTL'AU!;\NB\WNSRK.>O-?3?[-5_IGCGX>Z_P" -0C196+7$3%^6# #<.X*
MD Y'KVQ7S-%'YLJ("%+$#)Z"O7/#/P\\=_">XM/&\>EJ]O8N'*B4'S8F!R1[
M$<>OS#CK7T>9TX5J'LW)*6\=>J/$P$Y4ZO.HWCU]#V6;1I_BS\(M7\+ZH=WB
MGPY(T'F2MEG=!F.3/HZ_C7F?[-'PRL]7O]2\3>(K:*31M*5E\NZ0,C2 <D@\
M$*/UQ7JOP0^(2_$[7O&^MKIJ:7OM[>(PI)O)VK)\Q; R3GT["N8^&LQ'[._Q
M +EG1)[OY<]L#BOE%5K4*57#_#=QT[<V]CZ)TZ5:I3K[V3^=MCC;X^*O"=MK
M7Q-\(RV_AS0+N[,,-E& ?-C+;0_ELNS!//J.:Y'P%JM_XN^)_P#PDNKW8>:U
MW:C=W3Q +^[7C(4 #. .E:/Q=^,UOXZ\/:%H&BV<NF:/81+YL$@ WR  #&">
M!R?J:S)5/@/X;F)LQ:SXC W+G#16:G/(S_&>Q'05]%0IS5"U2*4Y^ZM->7S?
M6RU/$JS@ZO[N5XQU?:_DO-Z'"ZG?/J>I75Y)CS+B5Y6QZL23_.JU%%>^DDK(
M\9N[NPHHHIB"BBB@ HHHH **** "BBB@ HHHH **** /2/@]\;=6^%6I!!NO
MM$E;-Q8LW_CR'^%OT/>OKE9_!/[0O@R2!A#JMC(/GB?Y9[9_7U1AZC@^XK\_
MJT_#OB;5?"6IQZAH]]-87:=)(6QD>A'0CV/%>%C\JABG[6F^6??OZ_YGK87'
MRHQ]E57-!]/Z_(] ^+7[(/B3P9+/?>&UD\1Z."6$<:_Z5$/1D'W_ *K^0KP&
M:&2WE>*5&CD0[61Q@J?0BOM'X>_MAPND5IXPL6C?@?VC8KE3[O'U'U7/TKU"
M]\.?##XZVQGDM]*UV4KS/ WEW2#W*D2#Z&O$>(Q6"]W%T[KNOZM^0JN487&>
M_@JEG_*_ZO\ F?FW17V]KW[#/A*^=WTK6M4TLMTCEV3HOT&%;\VKDY?V"+@/
M^Z\:Q,OJ^F$'_P!&FMHYGA9+65ODSRIY%CXNRA?T:_5H^3:*^P-,_8*M4D#:
MCXQFFC[I:V C/_?32-_*O1O"G[(?PZ\,.DL]A<:[.AR'U.;<O_?"A5(^H-3/
M-,-'X6W\O\[&E+(,;-^\E'U?^5SX>\$?#CQ)\1=0%IX?TJ>_;.'E5<11^[N?
ME7\37V1\$_V2=(\!20:OXE:+7-=0K)'$%S;6S#NH/WV!_B([# '6O0O$'Q8\
M _"^Q%F^H6-MY VIIVF(KNOML3A?QQ4'PK^)^I?%6YN]2MM)&E^&8<Q0RW.6
MGN9,\D8.%4=_O<GJ,5YN)Q.+KTG-1Y(=^_\ 7D?18'*L'A:B4Y<]3\%\O\ST
MBBBBOG3ZT**** "BBB@ JKJVJ6VB:7>:C>2>5:6D+SS/C.U%!9CCZ U:KQO]
MH_5+C5M.T/P#IDC)J7BF[6"1DY:*U0AI7ZCL!]0&%;4H>TFH_P!6ZG-B*WL*
M4JF[Z>;Z+YL/V:]*N=0T76_'&I1&/4_%5\]X V[,=L"1$@W=5QEE]F%>R53T
M?2K;0M)L].LXE@M+2%88HT&%55& !^ JY15G[2;E_5N@8:C["E&GU6_F^K^;
M"BBBL3I"BBB@#S_XV^"[CQ=X-:?3,IK^DRKJ.G2(/G\V/G:.#G<,@#UVYZ5N
M?#KQI;_$#P;INN6^%-Q'B:(?\LI1PZ?@0?J,'O725XOI#?\ "H/C%/I+XB\,
M>+I#<69X"6]Z,;X_8/D8^J@=#7H4OW]%TOM1U7IU7Z_)G%4_<U54Z2T?KT?Z
M?<>T4445YYVA1110 4444 %%%% 'RK^UQ\+F@NXO&>GPDQ2[8;\*/NMT20_7
MA3_P&OFZQO9]-O(;JVE:&XA<21R(<%6!R"*_3#5])M-=TRYT^^A6XM+F,QRQ
M.,AE(P:^!OC)\*;WX5^*)+1PTVEW!+V5T1]]/[I_VEZ'\#WK[W),>JU/ZK4W
M6WFO^!^1\?FN#=*?UB&SW\G_ ,$G\5:;!\0=)F\6:-$%U")0=9TZ,<HW0W"
M=4;^+'W3UZYKUKX-?\FM^-O]Z\_]$I7SEX>\1:AX6U6'4=,N6MKJ(\,.0P[J
MPZ$'N#7K.F>)+CQAX:U'2/!NJ+X?N]1!:^\,S"-;>Z9AAC;2,,J3Q\F1UX/%
M=6.P\_9*DG[J::;Z)='^C^_N^?!UH>T=3[335N_FOU7W'>>,O^30=)_W8?\
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MU_XOL-::P CLH3;Q6[W#R.5VE?FD;)8\]<55T'QY:Z#93"/14;4)D>![P7#
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M&98\>K #<OX@#WK[?"YIAL5HI6EV?]:GRF(R^OA]6KKNCSRBBBO7/,"BBB@
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M+%[]WZO]%IZA&@Y-3K.[_!>B_5A1117"=84444 %%%% !1110 4444 %%%%
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MVBBN&4I3;E)W9UQBH+EBK(****DH**** "BBB@ HHHH **** "BBB@ HHHH
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# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>adag-20211231x20f003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'B!!8# 2(  A$! Q$!_\0
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M1G_T$?\ DO\ ]L?BOM/H:-I]#7[4?V59?\^=O_WZ7_"C^RK+_GSM_P#OTO\
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M*LO^?.W_ ._2_P"%'^M*_P"?/_DW_ )_U+E_T$?^2_\ VQ^+JMCJ1CI5J+D
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MFD#84A2<%0">3Q]37ZS_ -FV?_/K!_W['^% TVT'2UA'_;,?X4GFZ?V/Q_X
M+@]II^W_ /)?_MC\C9TAC$7DA]P3$A? &[)^[WQTITERQMY(I$BD>5PWG,#N
M3&<@'/0]P?05^N']F6?_ #Z0?]^Q_A1_9MG_ ,^L'_?L?X5/]K+^3\?^ 7_J
MD[W5;_R7_P"V/R","X)#89>/F[C'6H6Z<\X';C^5?L'_ &99_P#/I!_W['^%
M']F6?_/I!_W['^%+^U5_)^/_  !KA)K_ )?_ /DO_!/QU\YXF8QL45QM..I!
M/(_''Z47;V][)"JPI811PB.1X][^8X7[Q!)Y8^F ,]*_8G^S+/\ Y](/^_:_
MX4?V79_\^D'_ '[7_"E_:O\ <_'_ (!T1X8DE9UO_)?^"?C=INI:AX>U2#4+
M&ZGT^_MSYL5S"Q5X_<'Z'CVJM?SW?VH7K73R7<[-,\\;GS023DDCD$Y)]>37
M[-MIMHYRUK QQC)C!_I2#2[('(M( ?\ KDO^%']J*]^3\?\ @&W^KDM$JVGI
M_P $_%AE=)-N#@X.%/?'-('7RV;E05VG&1USD''6OVH_LJR_Y\[?_OTO^%']
ME67_ #YV_P#WZ7_"C^U%_)^/_ !<.-?\O?P_X)^-_A\:>(=5N+R]FM+F&'=9
M)% 9%GEW#Y6.1L 7)W<]*V]$U-;J,2/,%*XR&SN//;CG\:_77^RK+&/L<&/^
MN2_X4#2[(=+2 ?\ ;)?\*S>8IW]S\?\ @&LN'N9)>TV\O^"?E5"Q9%._"CJ,
M9S6GIMU;6(NQ<Z?'J!FMWBB+R%/(<D8D&.I'(P>.:_4/^SK3_GUA_P"_8I?[
M.M/^?6'_ +]BL7CD_L_B9QX=E%WC5_\ )?\ @GY5/$2H &<\$8R14T-I]LN(
MX$*%W;8-[!5R?4GM[U^I_P#9UI_S[0_]^Q2?V=:?\^L/_?L4?7O[OXF;X9;_
M .7W_DO_  3\IYH1YY((8 G=@\'GC'M5>6/+G<2N<\$]:_6#^SK3_GUA_P"_
M8H_LVT_Y]8?^_8_PH^O?W?Q)_P!6'_S^_P#)?^"?D_$SJ58':<@[DX(/K5C5
MM6O==O'OM0NI+ZZ?"R3SL68@# S]  *_5C^S;3_GUA_[]C_"C^S;3_GUA_[]
MC_"E]=7\OX_\ ?\ JS-*WM]/\/;YGY2K)%)!;1VB26]YETEG:8A75N   !MP
M"0>3G/X53EC2&:2,,LZHV/-3[K <9%?K-_9MI_SZP_\ ?L?X4?V;:?\ /K#_
M -^Q_A1]=_N_B.7#+E_R^_\ )?\ @GY*2'<<;<J3P<=*=+II33ENUFBV>;Y'
ME"9?,SC.=G7;VSZ\5^M/]FVG_/K#_P!^Q_A1_9EG_P ^D'_?L?X4_KW]W\28
M\,-7_??^2_\ !/R%8F($YR,8Z?E5&XP=PXQUX'-?L1_9EG_SZ0?]^Q_A2?V7
M9_\ /I!_W[7_  JOK_\ =_'_ ( O]6'_ ,_O_)?^"?CU9:W=Z79:C96QC2"^
M013HT2L2H.1M)!*\]P1627#+CG ..O6OV;_LNR_Y](/^_2_X4?V59?\ /G;_
M /?I?\*M9BE]C\?^ -\,R=DZW_DO_!/QB8GOP3Z5"XPI_AR?TK]H_P"RK+_G
MSM_^_2_X4?V59?\ /G;_ /?I?\*M9FE]C\?^ 3_JN_\ G]_Y+_P3\:=*L;:\
MAOFGU&&P:"'S8DE1B9WSC8N.A^M0,$5_D;S5X^;&*_9W^RK+_GSM_P#OTO\
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M_'_@$OA.3U=?_P E_P#MC\5$_>&1BX!Z\GD_2HU("GYN>M?M?_95E_SYV_\
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MO+XE_P#/+1/_  #?_P".4?\ #>7Q+_YY:)_X!O\ _'*^<Z*/JE#^1!]>Q/\
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M_P#'*^<Z*/JE#^1!]>Q/_/QGT9_PWE\2_P#GEHG_ (!O_P#'*/\ AO+XE_\
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M9ZU\GUV_PK_X^/%'_8O7W_HNHGA:"B[01K2QN)<TG-GJO_#>7Q+_ .>6B?\
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MROG.BCZI0_D0?7L3_P _&?1G_#>7Q+_YY:)_X!O_ /'*/^&\OB7_ ,\M$_\
M -__ (Y7SG11]4H?R(/KV)_Y^,^C/^&\OB7_ ,\M$_\  -__ (Y1_P -Y?$O
M_GEHG_@&_P#\<KYSHH^J4/Y$'U[$_P#/QGT9_P -Y?$O_GEHG_@&_P#\<H_X
M;R^)?_/+1/\ P#?_ ..5\YT4?5*'\B#Z]B?^?C/HS_AO+XE_\\M$_P# -_\
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M<!E"]\#D<XYI*GA']E%.KCU]I]/Q/1/^&\OB7_SRT3_P#?\ ^.4?\-Y?$O\
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MBZMK%M)6]0WBW-Q@PPF/^^RG=C/"AB>APW1PBT:0E7QS5U*1WO\ PWE\2_\
MGEHG_@&__P <H_X;R^)?_/+1/_ -_P#XY7D7C?X6ZQX#M+:[O)K"^LIII+0W
M.FW:W$<5Q'CS('(^ZZAE..A!R"17(5<<-AY*\8HREC,7!\LIM,^C/^&\OB7_
M ,\M$_\  -__ (Y1_P -Y?$O_GEHG_@&_P#\<KYSHJOJE#^1$?7L3_S\9]&?
M\-Y?$O\ YY:)_P" ;_\ QRC_ (;R^)?_ #RT3_P#?_XY7SG11]4H?R(/KV)_
MY^,^C/\ AO+XE_\ /+1/_ -__CE'_#>7Q+_YY:)_X!O_ /'*^<Z*/JE#^1!]
M>Q/_ #\9]&?\-Y?$O_GEHG_@&_\ \<H_X;R^)?\ SRT3_P  W_\ CE?.=%'U
M2A_(@^O8G_GXSZ,_X;R^)?\ SRT3_P  W_\ CE'_  WE\2_^>6B?^ ;_ /QR
MOG.BCZI0_D0?7L3_ ,_&?1G_  WE\2_^>6B?^ ;_ /QRC_AO+XE_\\M$_P#
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MO+XE_P#/+1/_  #?_P".4?\ #>7Q+_YY:)_X!O\ _'*^<Z*/JE#^1!]>Q/\
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M<KYSHH^J4/Y$'U[$_P#/QGT9_P -Y?$O_GEHG_@&_P#\<H_X;R^)?_/+1/\
MP#?_ ..5\YT4?5*'\B#Z]B?^?C/HS_AO+XE_\\M$_P# -_\ XY1_PWE\2_\
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MP6AT"^$LL$0E=5\ODJA90Q]BP^M9U/@9O1_B(X&BNK_LWP-_T,7B'_P0P?\
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M_P!#%XA_\$,'_P FT?V;X&_Z&+Q#_P""&#_Y-HYUY_<P]G+R^]?YG*45U?\
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M^3:TYUY_<S+V<O+[U_F<I175_P!F^!O^AB\0_P#@A@_^3:/[-\#?]#%XA_\
M!#!_\FT<Z\_N8>SEY?>O\SE**ZO^S? W_0Q>(?\ P0P?_)M']F^!O^AB\0_^
M"&#_ .3:.=>?W,/9R\OO7^9RE%=7_9O@;_H8O$/_ ((8/_DVC^S? W_0Q>(?
M_!#!_P#)M'.O/[F'LY>7WK_,Y2BNK_LWP-_T,7B'_P $,'_R;1_9O@;_ *&+
MQ#_X(8/_ )-HYUY_<P]G+R^]?YG*45U?]F^!O^AB\0_^"&#_ .3:/[-\#?\
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M  0P?_)M'.O/[F'LY>7WK_,Y2NDO_P#DG.A?]A74/_1-G4_]F^!O^AB\0_\
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MU'6N5KUCQUJNA>&_A!I/@;3=>M_$VH?VQ+K%W=V,<@MK<&(1+$C2*I8D#<2
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M2BE+<\VJX2FW!604445H8A7[%>$O^16T?_KTB_\ 0!7XZU^Q7A+_ )%;1_\
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M7)N/$+V<FHRQ01QM(UKCR"I51L*X'W<9QSFN&HH]G#LOZ_X9![:I_,_O]?\
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MB2[O;J5IIYY6W/([')8GU)-5:Z:<>2*B]SCJS52;DE9?IT"BBBM#$Z[XM?\
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M\*_8CRD_N+^5'E)_<7\J/[6?\GX_\ /[#C_S\_#_ ()^._\ PB>M_P#0'O\
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MV(\I/[B_E1Y2?W%_*C^UG_)^/_ #^PX_\_/P_P""?CO_ ,(GK?\ T![_ /\
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M (4?\(GK?_0'O_\ P&?_  K]B/*3^XOY4>4G]Q?RH_M9_P GX_\  #^PX_\
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M50%4<X  '-9/_")ZW_T![_\ \!G_ ,*_8CRD_N+^5'E)_<7\J%FME90_'_@
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M![__ ,!G_P */^$3UO\ Z ]__P" S_X5^Q'E)_<7\J/*3^XOY4?VL_Y/Q_X
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MOV(\I/[B_E1Y2?W%_*C^UG_)^/\ P _L./\ S\_#_@GX[_\ ")ZW_P! >_\
M_ 9_\*/^$3UO_H#W_P#X#/\ X5^Q'E)_<7\J/*3^XOY4?VL_Y/Q_X ?V''_G
MY^'_  3\=_\ A$];_P"@/?\ _@,_^%'_  B>M_\ 0'O_ /P&?_"OV(\I/[B_
ME1Y2?W%_*C^UG_)^/_ #^PX_\_/P_P""?CO_ ,(GK?\ T![_ /\  9_\*/\
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MBBO//4"BBB@ HHHH **** (H_P#CXE^BU+44?_'Q+]%J6@ HHHH **** "O
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M/JE#^4/]8\V_Z")?A_D>YQ_M=^*XT"C2M(P/6.7_ ..4[_AK[Q7_ - K1_\
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MVT >YT5Y[\#/$&H^)?!=_=ZG=/>7,?B+7+19'QD10ZI=11)QV6-$4>PKT*@
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MDB9V\UW8D*Z_NFC*[6)->^^'M2?6= TS4)(C#)=VL4[1$8V%D#$?AFN1\1?
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M1=%\1ZAKEC816NI7]M!:3R1+M#1Q-(R  <#F5\D=>,]!6Y110 4444 %%%%
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M^_\ +_\ &Z/K5#^9!_J]FW_0/(\0HKV__AD;QE_S_:-_W_E_^-T?\,C>,O\
MG^T;_O\ R_\ QNCZU0_F0?ZO9M_T#R/$**]MC_9)\8R(&%]H^#ZSR?\ QNG?
M\,C>,O\ G^T;_O\ R_\ QNCZU0_F0?ZO9K_T#R/$**]O_P"&1O&7_/\ :-_W
M_E_^-T?\,C>,O^?[1O\ O_+_ /&Z/K5#^9!_J]FW_0/(\0HKV_\ X9&\9?\
M/]HW_?\ E_\ C='_  R-XR_Y_M&_[_R__&Z/K5#^9!_J]FW_ $#R/$**]O\
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M_BZ/J%?M^(_]<LI_FE_X"SZSQ-_>3_OD_P"-&)O[R?\ ?)_QKY,_X:^\5?\
M0*TC_OB7_P"+H_X:^\5?] K2/^^)?_BZ/J%?M^(O]<LI_FE_X"SZSQ-_>3_O
MD_XT8F_O)_WR?\:^3/\ AK[Q5_T"M(_[XE_^+H_X:^\5?] K2/\ OB7_ .+H
M^H5^WXA_KEE/\TO_  %GUGB;^\G_ 'R?\:,3?WD_[Y/^-?)G_#7WBK_H%:1_
MWQ+_ /%T?\-?>*O^@5I'_?$O_P 71]0K]OQ#_7+*?YI?^ L^L\3?WD_[Y/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'O7P-_:(E\,>1H/B:5Y])R$
MM[UCEK4=-K=RGZK[CI]7VUS%>6\<\$J302J'22-@RLIY!!'45\;_  3^ =W\
M0IH]5U8267AY&R#C$ET0?NIZ+ZM^ [X^P]+TNTT33[>QL+>.ULX%"10Q#"J*
M^9QRI*I^[WZ]C]\X1GF,\'_MB_=_8;^*W^7:^ORL6J***\T^\"BBB@ HHHH
M**** "BBB@!#TJ.U_P"/:+_<'\JD/2H[7_CVB_W!_*@"6BBB@ HHHH ****
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MJA_YZI^=']HUO(/]2<K[S^]?Y'QG_P ,M>//^?6R_P# I:/^&6O'G_/K9?\
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M4_.C[5#_ ,]4_.C^T:WD'^I.5]Y_>O\ (^,_^&6O'G_/K9?^!2T?\,M>//\
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M0_\ /5/SKSC[?;1$M%1?:H?^>J?G1]JA_P">J?G0!+147VJ'_GJGYT?:H?\
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MD_X7QX!_Z&2U_P"^7_PKX0HH_LVGW8?Z]X[_ )]0_'_,^[_^%\> ?^ADM?\
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MCP#_ -#):_\ ?+_X5\(44?V;3[L/]>\=_P ^H?C_ )GW?_POCP#_ -#):_\
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MTH EHHHH **** "BBB@ HHHH BC_ ./B7Z+4M11_\?$OT6I: "BBB@ HHHH
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M]#1M/H: $HI=I]#1M/H: $HI=I]#1M/H: $HI=I]#1M/H: $HI=I]#1M/H:
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MQF69T.)RF-AE0';*5P,%P<  #I7:5%LE_P">B_\ ?'_UZ-DO_/1?^^/_ *]
M$M%1;)?^>B_]\?\ UZ-DO_/1?^^/_KT 2T5%LE_YZ+_WQ_\ 7HV2_P#/1?\
MOC_Z] $M%1;)?^>B_P#?'_UZ-DO_ #T7_OC_ .O0!+45M_Q[1?[@_E1LE_YZ
M+_WQ_P#7I$BDC15$@PHP/E_^O0!-146R7_GHO_?'_P!>C9+_ ,]%_P"^/_KT
M 2T5%LE_YZ+_ -\?_7HV2_\ /1?^^/\ Z] $M%1;)?\ GHO_ 'Q_]>C9+_ST
M7_OC_P"O0!+146R7_GHO_?'_ ->C9+_ST7_OC_Z] $M%1;)?^>B_]\?_ %Z-
MDO\ ST7_ +X_^O0!+146R7_GHO\ WQ_]>C9+_P ]%_[X_P#KT 2T5%LE_P">
MB_\ ?'_UZ-DO_/1?^^/_ *] $M%1;)?^>B_]\?\ UZ-DO_/1?^^/_KT 2U4U
M.T@OH%AN88[B%G7='*@93SW!J;9+_P ]%_[X_P#KTUX9'QF0<'/W?_KT":35
MF4?^$4T3_H#Z?_X"I_A1_P (IHG_ $!]/_\  5/\*T-DO_/1?^^/_KT;)?\
MGHO_ 'Q_]>JYGW,O8TOY5]QG_P#"*:)_T!]/_P# 5/\ "C_A%-$_Z ^G_P#@
M*G^%:&R7_GHO_?'_ ->C9+_ST7_OC_Z]',^X>QI?RK[C/_X131/^@/I__@*G
M^%'_  BFB?\ 0'T__P !4_PK0V2_\]%_[X_^O1LE_P">B_\ ?'_UZ.9]P]C2
M_E7W&?\ \(IHG_0'T_\ \!4_PH_X131/^@/I_P#X"I_A6ALE_P">B_\ ?'_U
MZ-DO_/1?^^/_ *]',^X>QI?RK[C/_P"$4T3_ * ^G_\ @*G^%'_"*:)_T!]/
M_P# 5/\ "M#9+_ST7_OC_P"O1LE_YZ+_ -\?_7HYGW#V-+^5?<9__"*:)_T!
M]/\ _ 5/\*/^$4T3_H#Z?_X"I_A6ALE_YZ+_ -\?_7HV2_\ /1?^^/\ Z]',
M^X>QI?RK[C/_ .$4T3_H#Z?_ . J?X4?\(IHG_0'T_\ \!4_PK0V2_\ /1?^
M^/\ Z]&R7_GHO_?'_P!>CF?</8TOY5]QE6WA31# O_$GL/\ P%3_  J7_A%-
M$_Z ^G_^ J?X5<MED\E<2*!_N_\ UZDV2_\ /1?^^/\ Z]',^X>QI?RK[C/_
M .$4T3_H#Z?_ . J?X4?\(IHG_0'T_\ \!4_PK0V2_\ /1?^^/\ Z]&R7_GH
MO_?'_P!>CF?</8TOY5]QG_\ "*:)_P! ?3__  %3_"C_ (131/\ H#Z?_P"
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M\J^XS_\ A%-$_P"@/I__ ("I_A1_PBFB?] ?3_\ P%3_  K0V2_\]%_[X_\
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M'W^M2;)?^>B_]\?_ %Z5V]V5&G"+O&*7R):*BV2_\]%_[X_^O1LE_P">B_\
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M!_*_O8?VWC.Z^X_1O_AY7X!_Z%KQ)_W[M_\ X[1_P\K\ _\ 0M>)/^_=O_\
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M%O'WP_TVVT6?PSXMO-0<:[<7TB7%E;Z@SM=*;<1$/(AFE\O]X WR[BN,5?\
M&O[/'_"<?%;4+Z^DC'@W4M.:2ZMTD_?'4OLEQIY?:5(*-:71'48:%>#N. #K
M?%OQNTCPOJ=_IT6GW^M7UG?6.F-#I_D_-=W2L\<&Z21%5EC$;MN( 6:,@G)
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M_5B+_P ?+_[B_P S4M1+_P ?+_[B_P S4M?G9]J%%%% !1110 4444 %%%%
M!1110 4444 17'W4_P!]?YU+45Q]U/\ ?7^=2T %%%% !1110 4444 %%%%
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M1J.BBP79)]HE_P">C_\ ?1H^T2_\]'_[Z-1T46"[)/M$O_/1_P#OHT?:)?\
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M$T[P[IL&G:586NF:? "(K2SA6&*,$DG:B@ <DG@=2: +M%%% !1110 4444
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M (8<^#/_ $*C_P#@PN?_ (Y1_K/@_P"67W+_ ##^P,5_-'[W_D?E%17ZN_\
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MBOU=_P"&'/@S_P!"H_\ X,+G_P".4?\ ##GP9_Z%1_\ P87/_P <H_UGP?\
M++[E_F']@8K^:/WO_(_**BOU=_X8<^#/_0J/_P"#"Y_^.4?\,.?!G_H5'_\
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M_P A_A4M% $7DO\ \]G_ "'^%'DO_P ]G_(?X5+10!%Y+_\ /9_R'^%'DO\
M\]G_ "'^%2T4 1>2_P#SV?\ (?X4>2__ #V?\A_A4M% $7DO_P ]G_(?X4>2
M_P#SV?\ (?X5+10!%Y+_ //9_P A_A1Y+_\ /9_R'^%2T4 0F%\?ZY_R'^%1
MVT3&WB(E8?*. !Z?2K)Z5':_\>T7^X/Y4 'DO_SV?\A_A1Y+_P#/9_R'^%2T
M4 1>2_\ SV?\A_A1Y+_\]G_(?X5+10!%Y+_\]G_(?X4>2_\ SV?\A_A4M% $
M7DO_ ,]G_(?X4>2__/9_R'^%2T4 1>2__/9_R'^%'DO_ ,]G_(?X5+10!%Y+
M_P#/9_R'^%'DO_SV?\A_A4M% $7DO_SV?\A_A3!$_G,/-;[HYP/4^U6*C7_7
MO_NK_,T )Y+_ //9_P A_A1Y+_\ /9_R'^%2T4 1>2__ #V?\A_A1Y+_ //9
M_P A_A4M% $7DO\ \]G_ "'^%'DO_P ]G_(?X5+10!%Y+_\ /9_R'^%'DO\
M\]G_ "'^%2T4 1>2_P#SV?\ (?X4>2__ #V?\A_A4M% $7DO_P ]G_(?X4>2
M_P#SV?\ (?X5+10!%Y+_ //9_P A_A1;?\>\?TJ6HK;_ %"?2@"6BBB@ HHH
MH **** "BBB@"*/_ (^)?HM2U%'_ ,?$OT6I: "BBB@ HHHH *\#A^ ?BB/6
M;;Q7_P )1*OB/_A+O^$BFTW,;6/DO_HCQ*_D^:6&GXC&6VF1 <*,;??*\B^(
MO[0<7P\\3:]I\GAZ[U#3_#^FV6JZK?P3Q+Y%O<2SQAEC9@TA7[.[$+SC& 3Q
M0!BZ/\*O&\\4?AC4X]$M/"4/C&Z\4/?VU[++>72'5Y=3MH?),*K&1*T(9O,;
MB-@ =V1G:9\'OB#HVC^#_"MG+80:1X8U*Q2SURVUZ[MYI-)MKJ.0036B1".2
M5K>/R&W,5;<S9&=M=7X@^/SZ38>+M;L_"M_JGA;PI/+!J>J13PHW[@9NFBB9
M@SK" =W0L58(&QS+XL_:'T?P=H'BO4;ZTD,GAW58].GMDE0O-&T$5T;B/GYD
M6UD>9@.0(91@[: )++0/'%I\5?&'B<:1HC6FHZ'9Z991-JLH9I+6:^D0R8@^
M19/MB@D;BNP\-7G^J_L^>)=9TGQ1926>D6^@>(-<L-1O_"QU&:6.Y2($W,AN
MFB\Q9)66V.T# %J,,#(V/0O&_P =K7PI?ZK9V>E2ZQ-8:EI6C,8ITC4WMZPV
MQ$L?EV));R,3QB=<9((%;QS\<K[P(FFQ7/A26YU"?1]1URYMHM1@5;>VLY(%
MD_>.RJS$7*$#(Z'GB@#9^!7@#4/AEX"7P_>&".VMKRY;3K*WG>=;*S:5FAM_
M-=0S[%.,MD]LG&3Z%5+1-6@U_1K#4[42K;7MO'<Q">)HI CJ&7<C ,IP1D$
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M44 %16W^H3Z5+45M_J$^E $M%%% !1110 4444 %%%% $4?_ !\2_1:EJN)
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M8Z6@86$]S-:/#<VK&-0C1BV8@[1@OCD9S[/YZ_W7_P"^#_A1YZ_W7_[X/^%
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M (4 2T5%YZ_W7_[X/^%'GK_=?_O@_P"% $M%1>>O]U_^^#_A1YZ_W7_[X/\
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M@_X4 "_\?+_[B_S-2U6$Z_:'.'^XO\!]3[5)YZ_W7_[X/^% $M%1>>O]U_\
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M%'GK_=?_ +X/^% $M%1>>O\ =?\ [X/^%'GK_=?_ +X/^% $M%1>>O\ =?\
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MO7=MW#=Z9YH =135=7^ZP;Z'- D4J6# J.I!H =12*P89!!'J*1G52 6 )Z
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M]#GXA_\ !K/_ /%T?ZK5/^?J^X/]8:?_ #[?WG[4[AZBC</45^*W_"V_'/\
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M .#6?_XNC_5:I_S]7W!_K#3_ .?;^\_:G</44;AZBOQ6_P"%M^.?^AS\0_\
M@UG_ /BZ/^%M^.?^AS\0_P#@UG_^+H_U6J?\_5]P?ZPT_P#GV_O/VIW#U%&X
M>H_.OQ6_X6WXY_Z'/Q#_ .#6?_XN@?%SQT""/&GB$$?]16?_ .+H_P!5JO\
MS]7W!_K#3_Y]O[S]JJ*^/_V3OVU(/'9M/"/CJXCM/$1Q'::F^$BOCV5^RR'M
MV;M@X!^O^M?)XO!UL%5=*LK/\'YH^CP^)IXJG[2D[K\A:***XCJ"BBB@")?^
M/E_]Q?YFI:B7_CY?_<7^9J6@ HHHH **** "BBB@ HHHH **** "BBB@"*X^
MZG^^O\ZEJ*X^ZG^^O\ZEH **** "BBB@ HHHH **** "BBB@ HHHH 0]*CM?
M^/:+_<'\JD/2H[7_ (]HO]P?RH EHHHH **** "BBB@ HHHH **** "BBB@
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MA/\ GVCY:_X=P_"[_H)>)_\ P-@_^,4?\.X?A=_T$O$__@;!_P#&*^I?*/\
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M$[<G&<5HT %%%% !1110 5%;?\>T7^X/Y5+45M_Q[1?[@_E0!+1110 4444
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M45[K_P ,1_&7_H43_P"!UO\ _%T?\,1_&7_H43_X'6__ ,71_:&#_P"?T?\
MP)?YA]2Q/_/J7W,\*HKW1?V)?C(Z@CPD2#_T_6__ ,72_P##$?QE_P"A1/\
MX'6__P 71_:&#_Y_1_\  E_F'U+$_P#/J7W,\*HKW7_AB/XR_P#0HG_P.M__
M (NC_AB/XR_]"B?_  .M_P#XNC^T,'_S^C_X$O\ ,/J6)_Y]2^YGA5%>Z_\
M#$?QE_Z%$_\ @=;_ /Q='_#$?QE_Z%$_^!UO_P#%T?VA@_\ G]'_ ,"7^8?4
ML3_SZE]S/"J*]U_X8C^,O_0HG_P.M_\ XN@?L1?&4D#_ (1+_P GK?\ ^.4?
MVA@_^?T?_ E_F'U+$_\ /J7W,\4TO2[S6]1M["PMI;R]N9!%#;P(7>1B<!5
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M0 4444 %%%% $ 8K<2_*3P.E/\P_W&I(_P#CXE^BU+0!'YA_N-1YA_N-4E%
M$?F'^XU'F'^XU244 1^8?[C4>8?[C5)10!'YA_N-1YA_N-4E% $?F'^XU'F'
M^XU244 1^8?[C4>8?[C5)10!'YA_N-1YA_N-4E% $?F'^XU'F'^XU244 1^8
M?[C4RWD(MXAL8_*/Y5/45M_Q[Q?[@_E0 OF'^XU'F'^XU244 1^8?[C4>8?[
MC5)10!'YA_N-1YA_N-4E(2 "2< =S0 SS#_<:CS#_<:G>8F%.]<-]TYZ_2G4
M 1^8?[C4>8?[C4X.K,RA@67J >13J (_,/\ <:CS#_<:I** (_,/]QJ/,/\
M<:I** (_,/\ <:CS#_<:I** (_,/]QJBN')$?R,/G%6:S]=U.UT32Y]1OITM
M;&T4W$\\K;4CC0%F8GL  3^%&XF[:LN>8?[C4>8?[C5YK_PTU\*_^A\T/_P,
M3_&C_AIKX5_]#YH?_@8G^-;^PJ_R/[CF^M4/^?B^]'I7F'^XU'F'^XU>:_\
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M6+?4+1?$.L60T;['XE6'5GC$,=^]C>VT5M*#G&3$\I(7ABK,!C@>]:Y+H5O
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M %8J_P#/U?<S\8Z*_9S_ (4Q\/\ _H1?#7_@HM__ (BC_A3'P_\ ^A%\-?\
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MHHH //D_YZ/_ -]&CSY/^>C_ /?1HHH //D_YZ/_ -]&CSY/^>C_ /?1HHH
M//D_YZ/_ -]&D6:0* '8#'K110 OGR?\]'_[Z-'GR?\ /1_^^C110 >?)_ST
M?_OHT>?)_P ]'_[Z-%% !Y\G_/1_^^C1Y\G_ #T?_OHT44 'GR?\]'_[Z-'G
MR?\ /1_^^C110 >?)_ST?_OHT>?)_P ]'_[Z-%% !Y\G_/1_^^C1Y\G_ #T?
M_OHT44 'GR?\]'_[Z-'GR?\ /1_^^C110 >?)_ST?_OHT>?)_P ]'_[Z-%%
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MH_\ WT://D_YZ/\ ]]&BB@ \^3_GH_\ WT://D_YZ/\ ]]&BB@ \^3_GH_\
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$0!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>adag-20211231x20f004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ', ;0# 2(  A$! Q$!_\0
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M%U<=<>9L5%;M\XXX%2?!C4M/\)?$7X7:[XW>"Q\/2>!TM="U2_(CM+>[#%I
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ML_\ @';3=?,)4\52J<M--Z:^\D]WJM_\M]C0HHHKS#Z **** "BBB@ HHHH
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MW C#8Y&*T_VW_'/AN\^ 6J:9;^(-+N-2O197=K9QWL;37$)F1A*B!LLA )#
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MW^->B?\ "):3_P ^2_\ ?3?XT?\ "):3_P ^2_\ ?;?XT >=?VM?'_E\N/\
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M_6_QKKO%'A[3[#2EE@MECD-S;Q[@Q^ZTR*PZ]P2/QK7_ .$3TG_GR7_OIO\
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M$A06(YP"<>U:M>:_&72;_5[WP)#IUPUE<#7MWVM;87 A'V2YY*GC!Z9/J.]
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MO[+A_,SV+^V+#_G^MO\ O\O^-']L6'_/];?]_E_QKQVBC_B,.,_Z X_^!/\
MR#^RX?S,]B_MBP_Y_K;_ +_+_C6#XNU2S>RL2MW ^S4+5VQ*IPHE4DGGH/6O
M.ZI:U_R"[G_=_K3CXPXR32^IQ_\  G_D73RF$YJ/.]6>U?\ "1:5_P!!.S_\
M"$_QH_X2+2O^@G9_^!"?XU\Q_A1@5Z'_ !%?%_\ 0+'_ ,"?^1[W^J]+_GZ_
MN1].?\)'I/\ T%++_P "$_QH_P"$CTG_ *"EE_X$)_C7S'@>U%'_ !%?%_\
M0+'_ ,"?^0?ZKTO^?K^Y'TY_PD>D_P#04LO_  (3_&C_ (2/2?\ H*67_@0G
M^-?,>![48'M1_P 17Q?_ $"Q_P# G_D'^J]+_GZ_N1]!^*-9T^\L+6*"_MII
M6O[3"1S*S'%Q&> #74U\R^&?^1ETC_K\A_\ 1BU]-5^K\(<1U.)<)4Q-6FH.
M,N6R=^B?ZGR^:Y?'+JL:<97NK_B%%%%?=GB!1110 5@^,/\ 4:7_ -A*V_\
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M^SQ?\\D_[Y%'V>+_ )Y)_P!\BI**/9P[(.9]SG_%T,::9;%8T4_;[/! P?\
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M"-IU_P"NZ4 </_PCNJ?\^,__ 'S1_P ([J?_ #XS?]\UZK10!Y7_ ,(YJ?\
MSXS?]\TG_".:I_SXS?E7JM% 'E7_  CFJ?\ /A-_WS1_PCNJ#_EQF_[YKU6B
M@#RA]'OK*2VFN+62&(7, +,, $RJ!^IKU>L+QI_R!$_Z_+3_ -*(ZW: "BBB
M@ HHHH *P?&/_'EI_P#V$K3_ -'+6]6#XQ_X\]._["5I_P"CEH WJ*** "BB
MB@ HHHH P_&/_(*M_P#K_L__ $HCK<K#\8_\@JW_ .O^S_\ 2B.MR@ HHHH
M**** "L'QA_J-+_["5M_Z,%;U8/C#_4:7_V$K;_T8* -ZBBB@ HHHH ****
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MZA_SVM_^^F_PH O?\+%'_0//_?[_ .M2?\+&'_/A_P"1O_L:ICX?ZAWFM_\
MOIO\*/\ A7^H?\][;_OIO\* $U;Q@-;MX+3[+Y.^ZMVW^9G&V9&]/:O0*\VO
M_"EWHRP74TD+1K=0*0A).6E0#J/>O2: "BBB@ HHHH *P?&/_'GIW_82M/\
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M )ZQ_P#?L56O?$VH:C$D<[HRI+',N$ PR,&7]0* /4:*\W_X3;53_P M8_\
MOV*/^$VU;_GJG_?L4 >D45YO_P )MJW_ #UC_P"_8H_X3;5?^>J?]^Q0!Z11
M7F__  FVJ_\ /5#_ -LQ1_PF^JC/[U/^_8H ZOQI_P @5/\ K\M/_2B.MVO,
M+KQ-?ZL+>VN'0Q-<P$A4P<B5"/U%>GT %%%% !1110 5@^,?^//3O^PE:?\
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MI"SAAQ@X !]$T444 %%%% !1110!0UME33G9B%4/&23P -ZU+_:ME_S^6_\
MW]7_ !JEXM_Y%Z]^B_\ H0KR_CK0!Z[_ &K9?\_EO_W]7_&C^UK'_G\M_P#O
MZO\ C7D?3TH/7K0!ZY_:ME_S^6__ ']7_&C^U;+_ )_(/^_J_P"->1GGTH(H
M ]<_M6R_Y^X/^_J_XUB^*KZVN+*R2*XBD8ZA:':C@G_7IZ5Y[P1[5+9#_B8V
M&/\ GZA_]&+0![#1110 4444 %%%% &%XT_Y L?_ %^VG_I1'6[6%XT_Y L?
M_7[:?^E$=;M !1110 4444 %8/C'_CST[_L)6G_HY:WJP?&/_'GIW_82M/\
MT<M &]1110 4444 %%%% &'XR_Y!5O\ ]?\ 9_\ I1'6Y6'XR_Y!5O\ ]?\
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MKEHW*.,$#HRD5HT -,:N59E!9>02.E'E(6+;%W'!)QSQTIU% !1110 4444
M%%%% %'61FP8$9^>/_T-:N>4G]Q?RJAK\R0:5+*^0B,C''IO6J/_  G&E?\
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MHHH **** "L'QC_QY:?_ -A*T_\ 1RUO5@^,?^/+3_\ L)6G_HY: -ZBBB@
MHHHH **** ,/QE_R"K?_ *_[/_THCK<K#\9?\@JW_P"O^S_]*(ZW* "BBB@
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M_P#Y%_\ K5O^)H3<:+<0J0&?:H)Z9+ 5RG_"O]0_Y[6__?3?X4 7/^%B\?\
M'A_Y%_\ K4?\+%Z_Z!_Y%_\ L:I?\*_U#_GM;_\ ?3?X4?\ "O\ 4/\ GM;_
M /?3?X4"+O\ PL3G_CPQ_P!MO_K4'XB\?\@_/_;;_P"M5+_A7^H<?OK;_OIO
M\*/^%?WX/$UO_P!]-_A0!='Q%];#_P B_P#UJIZCXM_MO[%:FU, -[;/N\S=
M]V93Z>U ^']_G_76_P#WTW^%5[KPK=:++8W,SQ.@O;=,(3G)E4#J/>@9Z/11
M10 4444 %%%% &%XT_Y L?\ U^VG_I1'6[6'XS_Y L?_ %^VG_I1'6Y0 444
M4 %%%% !6#XQ_P"//3O^PE:?^CEK>K!\8_\ 'GIW_82M/_1RT ;U%%% !111
M0 4444 8?C+_ )!5O_U_V?\ Z41UN5A^,?\ D%6__7_9_P#I1'6Y0 4444 %
M%%% !6#XP_U&E_\ 82MO_1@K>K!\8?ZC2_\ L)6W_HP4 ;U%%% !1110 444
M4 %%%<I\0/$UWX7MM#DLUC9KW6;.PE\U2?W<LH5B.1SCH: .KHKQ/Q)^T)<Q
M>$]0O])\,:C'=O97%UIDE\81#<>3*L4C8$N0%+JV&V[ATKJX?BA'I.C.=7M[
MF6^LKZWTJ\,,*C=/)%'(65 [?*/,Q@$G(.,]P#T&BO,=)^,]MXF\,0:W9V=Q
M8V<E]9V\<KO;W(D2:54_Y9RG8PS\RMAEST/2D;X\Z9#IMQJ4^C:K;Z<UA<:C
MI]RZ1[=1AA +F,!R5)!#*'"[@<T >GT5RO@WQPOBVZU2SFTF]T:_TYHC+;7O
MEEBDB[HW!C9AR >,Y!!!%<O>_'S3=.T_[7/I-W;I-?RZ=8_:;BV@%Y)$SB5E
M:25515\MN7*YR, YH ]2HKR37/VD/#NC:!IVM?9;JYTV[@>Y>59;>/RU1RCJ
MH>0>:ZLIRL6[@9Z$9Z(_$_[9JFI6>FZ#J>H069EA_M&-8Q;M<QQ>883E]R\$
M+O90N[C- '<T5XYX/^.=SJFA:5<:AI%S+K>I6.GR6^D6:1YEFGCF<[)#)M"[
M(6?YB-JCDD\#3O?CK:PP1&U\-ZS?W MKNZN[6,0K)9BUD6.=9-T@!8%A@*3N
MXQG- 'J%%5M.OH=4T^UO+<EH+F)9HR1@E6 (X[<&K- %'6O^0>W_ %TC_P#0
MUJ]65XGE:#1+F5.'38P)]0PKA_\ A.M7_P">R?\ ?L5\+Q%QCEW#%2G2QRDW
M--KE2>VFMVCLH86IB$W"VAZ;17F7_"=:O_SV3_OV*/\ A.M7_P">R?\ ?L5\
MC_Q%GA_^2I_X#'_Y(ZO[,K=U_7R/3:*\R_X3K5_^>R?]^Q1_PG6K_P#/9/\
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M,<MH^R5274?(V1@X) .1UKO*H:YHECXDTNXTW4K=;JRG 66%B0&&01TYZ@4
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M4I89[ZYC?S98 -CE9&3<,<<[<\8'L.E=O0 4444 %%%% !1110!1ULXTYB<
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M_P#2B.MV@ HHHH **** "L'QC_QYZ=_V$K3_ -'+6]6#XQ_X\M/_ .PE:?\
MHY: -ZBBB@ HHHH **** ,/QE_R"K?\ Z_[/_P!*(ZW*P_&7_(*M_P#K_L__
M $HCK<H SM!_X\I?^OJY_P#1SU^0=[\5?B<MY<+_ ,)?XM7$C#']I70QR?\
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M$=;M !1110 4444 %8/C'_CST[_L)6G_ *.6MZL'QC_QY:?_ -A*T_\ 1RT
M;U%%% !1110 4444 8?C'_D%6W_7_9_^E$=;E8?C'_D%6_\ U_V?_I1'6Y0
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MG_Z41UN4 %%%% !1110 5@^+_P#4:7_V$K;_ -&"MZL'QA_J-+_["5M_Z,%
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MVJ>I:;%JML()BP021RY0X.4<./U45<H **** "BBB@ K!\8_\>>G?]A*T_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
>4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>adag-20211231x20f005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (Q ^\# 2(  A$! Q$!_\0
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MO>S]W:RZ^?8Y9YE6=2'+9)J+M;37>[Z>7<^Z*3-5M3\S^SKKR;A;27RGV3N
M5C.#ACGL.OX5\(_$GQ=:^%]-NM2TGX]ZYXB\:6TH/V6V\P6;<\J  4 'N2/:
MO#P6">-DXQE9^C?WV6B]3V<7C%A(J4E=>J7YO5^A]\4F:^1_C7\4_&#>#/A#
MJFB:U-I6J:RX$QB8K%*[!0/,4<,H)SBJ5^/'7P)^-G@J"_\ 'FH^*;3Q#)LO
M(+PD1!B2"%3<0 #C!&*ZH95*4$W-*3YK+77EO?RZ'-+,HQFTH-I<MWIIS;>9
M]BD9XKRKP'\;)/&7Q<\7^"VTA;6/02 MX+@L9OF(Y7:-O3U->/Z]>>,/CO\
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MLS9V1J7..N ,U\??#S3O'?[3FH>)O$A^(.J^$[2RO&MM.LM,8B)"!D;E!&0
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MH/#?9?W[W/E'5?@)\6?B;XB\.Z;X\UO1Y_"NA3B47%D")KL CEDQ]X@ $D@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%(2!UH 6BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI.E "T4F1C.>*,@=Z %
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G?B%XWL/
MAQX)UKQ-J88V&EVKW,H3[S!1T'N3@?C7@'PL^*G[0'Q.LM%\96_A7P;9^"M4
MF5X]*GN[A=2%HS8\WS/]7NQSMP,U[?\ &/X?_P#"T_A?XE\)_:!:'5K)[99B
M,A&/*D^V0,UX)\$M;^._P\\-^'?A]J?PHL[R+2V2S;Q.->A2T:U4X\SR@#(7
MV]N,GTKTJ$8.C)I)ROU=M+=-5U^9#O<QO@W^W5H%H_B#3OB=XGC@U6+7[BQM
M!!IDGEPVX?;'YKQH57/JQR:]I^('[5?PY^&FKR:=K6JWIN(84N+AK#2KJ[BM
MHG&5>62*-E0$'/)KYU;]F[QZ?V:?BGX9_P"$<7_A(=:\1R7]E;?:(<S0F4%7
MW[L#CL2#4GQ>^%_QO\2:IJ^ABP\0ZGX8GT."TTBWT'7[?3[*WE$6)!>JWSR\
MC&!D'V'-=\J&$JU;J5EK?WDNVJT\W]VY-Y)'T-XP_:N^%_@5-*?5O$R1IJUC
M_:-@8+::;[5"3@&/8IW,?[O7VI;/]JSX8W_PX_X3B#Q(KZ#]I%D"+6;[0;@G
M A$&WS"_^R%KQ3X7? /QMH'Q'^!NIZGH(BL?#7AB6PU*5IXG^S7!;A<!B2<=
MUR/>O%/BKX"\2_"[PDVG:M8IH^K:Y\1GU'1RMY%#*T07(DCG.Z.$_P#70'Z5
M,,'A:DE",M?5=WY=E<'*2U/LKP[^U]\+_$EGX@NHM;NK&WT"(2ZD^IZ7<V@M
M@3@*WF1CYR?X!\WM6Y\,_P!HKP-\6=9N=(T'4KD:M!"MRUAJ6GW%C.T)Z2HD
MR*70_P!X9%?%.E>"[GXU>!_B;X T6QU(_$J'4+37=2U#4M?MK^+4F4_+&+FW
M1(XVP.!M&#@FO<?V<OA-J]G\3X/$WB/P)XRT?4[+36LTU?Q1XPCU5>2,Q11*
M6.WC()(QZ5%;"8>G"3N[K9779?>GY I-GM7Q4_:#\#_!JZL;/Q-JLD6HWRE[
M;3[&SFO+F1!U<10JS;1ZD8KQC]H3]M71-#^"%KXG^'.MP7VHZM=BRM+F2PED
M6V8,!*9(RHVNH/"/C/8&KOQ4\"^/?!7[3%I\5?"WA(^/M.GT;^RKC38+^*UN
M;5P<AT,I"E3CG![FO+[W]E_XC7/P$\2PR:)!'XI\2>,;?7WT*UNXV6R@$G*F
M0D*6 &3@_2GAZ&%7LYS=]KZKYJVZMW>X-RUL?1?A+XNIX8_9Q'C_ ,2>('\5
MQ6E@][-J*:6=->X'\*^0WW#DA?UQ7$?"KXG?M _$>UT'Q@?"_@RS\%ZM*DBZ
M6]W.NIQ6C'B;S#^[+8YVX&?:O6OBW\,G^*OP7USP8TXLI]2T[[,LS\B.0 %2
M<=MP&?:O&_@GXA^.W@C0?#/@'5_A/:2Q:68K*?Q.->A6T:U0X\Q8@#(7V_P\
M<^E<]-4YTYRBH\U]FTK+RV7W#=[F#X5_:-^.WQ!L_&^M^&/#7@;4-'\,:G<6
M+Z?<2W<%[<+%\Q*-N9-VWU Y[5H>,/VV;FY^"O@GQAX5TBSL;OQ'J?\ 95Q/
MX@=S9Z/*#M<SM'@D9R <C.,UR?PU\-?'7X16'Q&\/:%\+8M0F\1:S=7EIKEY
MKMO#;6Z2#:':,9=L#G'%1^*OV4O'?@WX&> ?"6F6R>.+"SU234?%F@6=XMG_
M &IO;?L1W(!16)^4D9_EWNGA?:)2Y;75K/=6UOKWM:]M?(F\K'LO[,?QS\4_
M%/6_&NB^([?1+\>';I+:'Q#X9\S^S[XL,E4WEOF7C.&(YKTWX5_%32/B_P"&
MI-<T6&[AM$NY[,K>QA'WQ.48X!/&0<<U\R_ S]EF\U>[\;67B_P?=>"_ACJ5
MS!=:5X*.N/(]M.@(>4/;R#RP<_<#8/?H#7=_LM_LC:3\$X/[6U2R1O%J7-T(
M[JTU2ZEA%L\A,:F-F"%MNW)*YSW/6N+$T\*N=QEKI9*UMM>O?>VW2Y2<M"A^
MU'\;?C'\#)?[:T?3?!%]X2NK^VTZS%\;LWPDE&,R!65-H8'IVQ7M/PGNO'UY
MX<>;XA0^'HM7>4M"OALSF#R2!MW>;SNZYQQ7G7[9WPS\2?%3X::-I7A?3O[3
MO[?Q!8WLD0E2/;#&Q+MER!QGIUKL/B!\$;;XEMI5Q=^*_%_AR2Q@$7D^&]<D
ML8Y><YD5.&/;/I64G2E0@G9/6[2UTM;KU'K=F?X\_:L^&GPW\7MX8UO7Y$UB
M,(;F&SL9[I;0.1M,SQ(RQ Y'WB*C\:?M9_#'P%K]UH^JZ],;FR$;7TMGI]Q<
MP6(?[GVB6-&2+.?XB*\CT7P9\4_@7\;/B-J/A[P GQ T;QC=0W5MJ+:Q#;?9
M2!ADN!)EB!DGY0<X]^/._$W[-?CK1/'GQ$BN_"/BOQEX=\5WK7T9\+^,(],@
M<2 ;H;N)R-V#QNP>!TKJAA<*VN:6ED_BCKM?TMKH]R7*1[#XU^/?B6Q^._B+
MP_H^J6DOANW\ S^(;,);I)FY&XI)OZLN /EZ5/\ "O\ :XT>P^#/@'5OB!JT
MUWXL\06#70M-(TJ:YGF520\@@MT8J@QUP!7,3_L_^*;+XJ7U[I?AV2U\/#X:
M/X=M1)?QS,EUM(6 L2"QZ#>0 ?6N%U#X >.-*^#OPXL+?X>^(1X^T/19+>U\
M1>&/$=M9W&G7!=B(9E9PLD)R&)4MU(Q6JI86<8P;73JD]GO\[7"\C[4NO'VE
MK\/9_&,$CS:.FG-J:.R-&SQ",O\ =8 J2!T(!KP_X4?'C7K#]D_4_BWX[OX[
MV>2&ZU6VMU@2)(82Y%M;C8!G/R#)R?FZUVS>$/&6O?LQWGASQ9=1W_C2\\.S
M6EW-;XQ)<M"PZC )S@9'!-?+WAKP?XJ_:&_9-^#_ (%\-PM;:2E]]F\3ZBLD
M8:P6U9@%,;'+$N,[<'H,URT*-*46I-6YE=^5F]'YV^8VW<]P_9:_:3\3?%ZX
M\5Z#XXT73_#OB[1D@NUL['>$DM9H@\;X=F)/K@XY%<3^SY^W=X;OO"]K:_$S
MQ3'%XGN-5N+,21:;(EO"OFE8%EDC3RXR5Q]XYQR:=8_LX_$?X7?M&>%/&VG^
M(M1^(ECJ-I+I&OW5\MK:RVUOM'E-M3:'52!T!(VFO*K;X"?&F?X"S?!V3X;V
MD$&LZX=1?Q(^K0;+.(SEV\V,?-O '!4G*D#KQ7:J.#J-ZJTN79I6W3WU\[==
M";R1]BZ[^TWX T'QO)X2FU.\NM8AEA@N?L&EW-U!:/*0(UGFCC9(RV1]XCK7
M-?#'XJ^(6_:4^)/PV\1WZZC!:16^LZ'*($C:.TE4!H25 W;&(PQR>>37D/Q"
M^#WQ'LOBY'JWPT\+:[X4UY[ZT2^\30>(+<Z-JMI& 'DNK1CO\S:"-H7U.<FN
MM^'"/XM_;T^(VN6A$MAX>\/6FAW$R?=-TY61D^JA3GTKE]A1C3DXN_NWW3:=
MUVVOZW[E7=SL/C!\5/$5I^T%\+/AQX9OETW^U6N-6UJ<P)*6L85($0W [=[@
M@L,'I@U1_:(\?^(KSXL_"WX8^#]7N-'U/6+XZKJ]U:;1)%IL'WER00!(V5Z=
MJYWXNI_PAW[<OPF\27Q$.EZUHU[H*3N<(EPI,BK[$@BG?LN#_A<'QG^)WQEE
M(FT^:Z_X1OP^_86=L?WCK[.XS]0:(TX0IQK6T4?ODVTON_0+W=CUF/\ :0\
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M;BW</'*C#*LK#@@@Y!%6* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC;)/'GUVL",^]>7Z3^TI;V>K:WIWC;POJ?@.ZT_3&UJ(:C-#.MU9J2&=3"S
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M^&4H70 '&[IF@#ZJP/04$ UXI??M!ZY!=V.AVOPXU.[\9/9_VA?:&-3LT%C
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MY<;23QC)]JQ]'^ .N:?X<^#6GRWNGO+X,N3-?E6?;,IC9<1?+R<M_%BO>Z*
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MX9>/?B+\-](T+6?!_@+5KR.W:*3[5JEVOV"8#;'<6TZV^_<!@D (<C :O1/
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M#YO?0/'/PKL_B7\3;^VTK4OB)XG2RL=+T#1UFN+.-XAY5LCR,$>0EI&:20A
MJCL%S7NNIZ"/%W@R[T77HXV34[![.^CMR0I$D920*3SCYCC\*VB,TM '@?PX
M\'_&WX?:1H?@W[=X-U3PYI)BM(O$=RUT+^6QC(55>U""/SO+ 7?YNW/S;>U9
M$/PW^,EO\8]7\;W=EX(\0RF1K31FOM4O(O[*T\L,QQ1+;LHED W229RQPN0J
M@5])T4 >!WOPZ^*/A;XQ^/\ Q7X.C\)7EEXJBTX+_;EW=1R6KVT!C.8XHB'!
M)SC>OX5M^"OAAXI^$GPVO;30[C3/%?C35]4FU;6+[6)9+&VN;B=BTSH(TD**
MH"HB8/RJ,G/->PT4 >0_LP^ O&/PK^%^E>#_ !9'HA&C6\=K:76CW<TWVA1N
M+-(LD:;#DC !;OTKUZBB@ HHHH **** "BBB@ HHHH **** "BBB@"IJMVEA
MIMU<N=J0QM(3Z #/]*^>?V![62X^!MQXAG7]]XFU[4=8+D<L'G*J<]^$KT3]
MICQ1_P (9\ _'FKAMCV^CW/ED'!WE"JX]\D4W]F'PM_PAG[/GP^T@C:T&BVS
M./\ :=/,;]7-=L?=PLGWDOP3_P T3]H/CW\"-&^.OA1;"\=]-UJQ?[3I&N6P
MQ<:?<CE9$(YQD#*]"/?!KS_X)?M%WFEZO>_#?XP7%EX>^(&CH&6_GD6&TUJV
MZ+<PNV%W'^)?7/'4#Z./-? 7_!4?X8^,?%<'A'6])TY]9\/V)E@GMK*S,UQ!
M,^")&*@L8R%(] <$]>.C!*.)DL+5=D]GV?EZ]A2]WWD?=VC>(-+\16QN=*U&
MTU.W5BAFLYTF0-Z94D9Y'%:%?G?_ ,$J?"?C*P'BG6G9[/P-<JL,=O-$0MS=
MJ?\ 61],!%RK$9SD#MQ^B%<^,PZPM>5*,KV'%\RN%%%%<104444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 ?-?[3WBJ#PEXMTF^\.W?
MBBU\?VVFS7:G0K9+RS-@D@W_ &ZWEEC5XM[<&,^:I)*GL?,/V9?"&D6?QBT/
M5_$5X^@>(;Q;O5]%L1I5NEOK"W<;R220ZDJ"6Z0)*S"";;(F%W [ :]8_:-^
M%'C3QWXAM+ZQ\'_#SXBZ#:QKY.D>*X)(+NVEY\QHKA0RE'PN491T[U6AU3]H
M_P 1QV^GVW@#X?\ @>*  0WVH:I)J(ML+M#101(HR%) &1Z=*]VG-+#J$9+5
M:MM7_P _P]'J9/<^E*\_^.T>IGX6^(9=)\1W/A>[@M))Q?V:QF;"(S;%,@(4
MM@#<!D=N>:[?3(KF#3K6.]F2YO$B59IHTV+(X W,%R< G)QGC-9WBWP7H/CS
M2&TKQ'I%EKFFLZR-:7\"S1%E.5.UN,@UXU.2A-2>R9HSY#\1ZQX^\5_ 3X-^
M)]/\1ZQ/;0>'Y+_Q(-*\2PZ7?W;&WC*OYDBL'*MN)! Z]1FN?\<_&35_&5AJ
MNIZ-XW\1^%](T'X:VOB;1$:]2&XO;IV<;[LD8G/[M5*_=)8GJ17U?<?LX_"V
M[TNSTV;X?>&Y;"SE>>WMGTR(QQ.^W>RC'&[:N?7:/2MCQ%\(/!'BZZTJXUOP
MEHFJSZ4 MB]Y812&V48PJ97Y0,#@<<"O6CC**:]WJ^BZN_S[=-.Y'*SQGXH?
M$WXL-\./^)7\+[?7]+O_  U'<WVKR:]%9M!+);DS+]G9"QV9SUYSBN@_8:X_
M9.^'&.1_9[\_]MI*]+^**A?AMXHQ_P! RY_]%-7F?[#/_)IOPW_[![?^CI*P
ME-3PCM%+WEW[/S_*P_M'NU%%%>86%%%% !1110 4444 %%%% !1110 4444
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BO.OC?\
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MMJ>JS-]YIY.2I/\ LC"_@:]*J1A1112&%%%% !1110 4444 %%%% !12=*\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '(?%GQO#\.OA[K>O2GYK6W8Q+W:0\(![Y(KG?V</!$W@OX7Z=]N7_B;
MZF6U*^<]3+*=Q!^@(%<G\<G;XC?%/P5\.86+V8F_MG5@O00Q'**?JU>]1H(T
M"J J@8  P *WE[E-+OK_ )'E4_W^+G4Z07*O5ZR_1?>/HJ);F)YGB61#*@!9
M PW 'ID5+6!ZH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !115;
M4=0M]*L;B\NYDM[6"-I997.%10,DGZ"C?1 ?'7[>G@F.PGT;Q=:7QMKFY/V*
MXMA.5,NT95U7/.!P?PKIOV$/!MM!X/U'Q5)?B^U"^F-MY8F+FWC0_=8$\,3S
M]"*WOA_X8B_:%\6:GX^\4:>EWX8"/I^@Z7=IN1H,X>=E/=R.*D\?:#+^SYXQ
M3Q_X<LR/"5YLM_$6DVRX6)>B72*.F.C?_7KZF5=RPRRZ_O\ X=^7]/70Y>7W
MO:=/ZU/H:BJFDZK:ZWIMM?V,Z7-I<QK+%+&<JZD9!!JW7R[33LSJ"BBBD 44
M44 %%%% !1110 C=*_-O]M#Q,+7XV:E'I6H:IXFG\I"^F(H9;)HD)D$6P9V*
MOS-GH<\U]M?M!?%RV^#?PYU#67D1;^13#9(YZRD'YB/[JC+'Z =Z\A_8P^"%
MQI=A>?$KQ5 [^)?$*$VL=T,O:V;'<,@]'D/SM[;1V-=F'Y87J5%>/;OY?Y_\
M$PJW=HQW_(\T_9Q^+GQ5UW0;;P=X'N_"-R4B-U%?>*;Z:69HW8MB&.)0"J9Q
M@DD=Z].\=?#;]H[4O!>M3R_$O3+F[6V<Q:#X<T&&+[4<8\OSKEC@')SD<CCO
M7I_C7]GKP]JOA^"'PM:VW@_6].GDO=,U#3(%B\F=B6;<%'S(Y/S#W_"K'PA^
M*]QXHEN_#'B>U&C^.-) 6]LFX6=>T\)_B1NO'3/TK1XKEE>$%;S2;^?_  +$
M^QNK2;^39\5^"/A'XG_8N\?> ?&/B^QTOQ#I.L,--O9Y&(3P]/,^<QR'Y5R#
MDL% .' QP3]6>()!\9OCII^@Q$3>%_!I34+\@Y2>^8?N8_0[!\WUS75?M(W>
M@6WP8\31^([%-4L+JV-JEBQP9YGXB5<<AMV"".1MS7C_ .R9K\WPO\2ZK\)/
M%FEQZ-XDD4:OIUUO+KJELR*#ACU>/&T@=A[$UI7K2QR]HU[\;W]/^!?[M2*=
M..&?(GH]O4^K  .E+117EG8%%%% !1110 444V3=L;9@MCC/3- $,M_;07$<
M$EQ$D\OW(V<!G^@ZFI]PK\1?B-XDU[7/B)K>H>(M1FG\0K?2K-,T^7C=9"-J
M$'Y57&%"\  8K]#OA3\ /%_Q3^''A_4_B;\1_&;&[LT=O#UI<BP2-.B+,R#S
M)&*!22Q!R3GFO8Q&7K#QC.=3?R_+^D>_BLKCA(1G4JK7R_+O^![UXW^,W@;X
M<1._B7Q7I.C,O_+*YNT$I^D8)8_@*\R?]KNR\2.T/P]\"^+/'\F<+<VFGFTL
MC]9YMH ]\5V/@G]F;X8?#Z43Z/X,TQ;T8S>WD7VJX)]?,EW-GZ&O3$C5%"J
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M]K_A_7^1,E='S;\7_#'QKN_!,T^D>,_#^E:/%X>5=1L-2T=KFYDG$)\\B4.
M-W0<<'-1_LGV/B2__8_^%:>%]3L=*NE2.2XDU"T-PKVPN9#+&H#+AV7@-V]*
M]N^*0_XMMXH_[!ES_P"BFKS+]AG_ )--^&__ &#V_P#1TE=/M7+"MV6DET79
M[]Q6]X]3>Q\2_P#"=QW:ZG8#PF+!HWTXVC&Z-UO!$@FW8";<C;MZ\YKXT^*G
MQ&^+MG\6[BXLENM0BT*\N4TZ>QT.=(&BD&-KJ<B4J/EW9P<$BONZDQ7G<[VL
M58^<;GXE_&VTC\+7LW@:"YTE)%FU2;2&6YFO(#']V.)V1H7W$$Y!Q@C%7M'_
M &E=-MO%^KGQ-K,OAK2IH(DT_2]9T&XM+BWF&?,:2?+(X;C &,8KZ Q7*_$[
MP/)\1?!FH>'X]3?2!>J(WNHX5E94S\P ) !(XSVS3Y]+6 \Y^&/C[Q1\6OA%
M=2:'XHT=O%]KJ#V\FI2:8PM?+$^5/D>9N :' !+=>>V*].O[#Q/)XRTFYM-4
ML(O#,=O,M_8R6C-<SRD#RV27=A%'.05.<UX/X7_8TO\ P'?/J/AKXD:GI>HA
M<(\=F@C8]A(N[#K[&NKB^,_BCX8R+:?%'0"E@"$3Q3H:--9O[RQ_>B/Z4W-O
MHNO3O_6G8#T&RTOQFD?BD76MZ7*]Q*QT0QV#*+-/+  F&_\ >G?DY&WCBJ\V
MD^/&\/>%X8M?T=-9MYX&UJY;3G,-W$!^]6%/,S$6[$DXK?TKQAH>N:9:ZC8:
MM97=C=,L<%Q%.K)([=%!S]X^G6K.KZ[IN@6IN=3O[;3K9>LUW,L2C\6(I<[[
M+[D!EQ6'B8>.+FZDU2P;PJUDL<.GBT87*7._)D,N[!3;QMV]>]8JZ-\0O^$&
MU>U/B/13XJDN)FL-0&F/]F@A+9B62+S,NP7@D,,GG%<SKO[5O@+35N%TNYO?
M%,T"LTB:':/.B #)+2<(![[JX#]GK]J27XC_ !.US1]6D6WM=2;SM'A=US$%
M&#%D=2P&[Z@XH4VNB^Y= />K_3O%DFM>&Y;35]-ATR -_;$$EDS271V87R6W
M_NL/SR&XXI=.T[Q5'K7B.6]U;3YM+G$?]CP16;+):D(0_G-N_>9;!& N ,5T
M]%+G=K6_ 9P;Z-\0CX#TJT3Q%HH\6QS1F^U$Z8YM9HQ)EU2'S,H2G )8X/-5
M_B7I?BBYBU>6VU"S;PT=%NHI-,%FSW4MP5^1ED#8"@9&W;DYKT2BJ51IWLON
M_K_@"L?@/I/PP\:V%[97$7@G7EEA=)%/]B3G# @CC9STZ5^O7PF^.L/QMT[P
MS!X5\7:7:ZYIDD8\3Z+J>FO!?,JIB1$A9P8CNYW?, *]]VCW_.O)/C#^S#X+
M^,<\6IWEM-H?BJV^:T\2Z+)]FO[=AT/F+]\>S9KV\3F4,<TJT>6VS6N_=,RC
M!PV.WM+#Q0GB[5;BXU73Y?#DEM&MC9)9LMQ#."=[/)NPZGC  &/6L4:+\1?^
M%?S6A\2:)_PF!G9H]2_LM_LJQ>9D*8?,R6"<9W=><5\B?&W]HKX[_L=1:7H^
MN7?AGX@:;>.ZV&O7L$L5Y(JC[D\:.HW <[AG->A_L2_M>>*OVE-:\36?B/2M
M(TZ/3+>*6(Z8DH+%FP=V]VX^E<TL%6A1^L+E<%;56]/^'_$KF3=CZ3OK#Q._
MBO1;BUU6PBT"*&1=2LY+-FGGD(&QHY-V$ .<@@YJM8Z;XRCE\4&[UK2Y4N'S
MH@CL67[(NS&)OG_>G=SQMXXKK:*\OG>UE]QH</+I'CT^&/#T$>OZ0NNP31-J
MUVVG.8;J,']XL4>_,9(Z$DXK62Q\2CQQ)=-J=@?"IL]BZ>+1OM(N-W^L\W=C
M;MXV[>O>NBHI\[?1?<!PT>D>/AX-URV?Q!HY\233S-IE\--<6]O$3^[62+S,
MN0,Y((SZ5>O]-\7/?^&7M-8TV*TM_P#D-126+,UW\F/W+;_W7S<\[N.*ZNBC
MG?9?<A'Y9?MWZ'XGU?\ :"OY-%\/WVIVL44+&?3M%GVEP#\KN%(D/^T/85@>
M#OB9IM]HUIX5\:V_B[2]3L'C807,4UUID%L&RX:QB,4JY7/S?-ZU^M>/K^=>
M:?&/]G_PO\9[.%]3BET[7;3YK#7M.?R;VT;L5<=1G^$Y!KKHXBS2F[+NNGR-
MJ\,OK484Y82+<;ZW:;N[ORU>OO*278XKX,:C\/\ 7?$FG7?PKUSP6/"\=HZ7
M>EZ?9*NI/.<;7+E@Z@<Y5E)]ZU[OQ##\-_"_Q"U;5/&GA'2)&OI7@OUL_+2T
MDV#:ER@?,THXX&"1VKY8^,?@_P#X57I]^OQ9^'\/BBX2-AHGQ(\++_9]RTW_
M "S6\,178V<9<Y!]Z\W_ &&O LOCCXTSW/BKPU'XUTZW)>:ZN;]+I;&Y/*SO
M&9#Y@/W=^&IU*56"Y]X][73U[_YZGH83!Y;6I2J1GR<GV'RJ7_;NJOIUM]Y]
M2Z3\5_B_\?\ 3M/L/AU;1>&]$5 E_P"/]7L#"MXV,,UE:.2V">0S'\J[3X/_
M +*MO\,/'^I^);_4X?%]]=VJ!=8UNW,VIK<Y^=_-+%5C/9$48]37OD,211(B
M($10%55& !V J2N+FW,:F+?+[.BN2/EN_5[OTV\C@ET;XACP)=VA\1:*?%C3
MNT&HC3'^RI%ORJM#YF2P7@G=UYQ6M>Z?XJD\1:%-;:MI\6C0QN-3MI+-FFN'
M*C:8GWXC .3@@UT]%/G?9?<>><I9:;XN2[\3-=:QILMM<'_B2HEBRM:#9C]\
M=_[WYN>-O'%4)-'\?GPAH5NGB'1E\1PSQ-J=Z=-<P7$0/[Q8H_,RA(Z$DXKN
MJ*.=]E]R YTV'B7_ (3<70U.P_X1;[)L.GFT;[3]HW??\W=C;CC;MK(@TCQ^
MOA37K>7Q!HS>()IY6TJ\737$%M&3^[66/S,R$#J01FNYHH4VNB^X9YO\2M.\
M7MX1MVM=:TR&&WLISK2RV+,;L>21^Y._]U\W/.[CBOQQN;&Z-W*IMY2Y<GB,
M\\_2OW5(##!&1[U#]AM_^>$7_? KNPN-EA6VHIW^1Z6!QTL#*4HQ3NOG]_;N
MOQ/SI^#W[5?Q*M_!FD>!] M?"5O?Z>L<-M)JUX;6::,-DH%DQ&6(R,[@>^#7
M4?M+_M4_&GP7#ID(\+'X<PWD+1M/)+!J!GD'.Z&520N!V*GUKZI^+O[/'@OX
MT:<8==TM$O47;!J5H!'<Q>F&Q\P_V6R*^"OVB/AYXQ^ =G;^%-8UJ#Q;X.OM
MSZ?%?!G-NR_Q*I.Z)Q_L-M/IVITL9AXM2KTTK=DVG^.GW->:/"_M=99)5LQH
M1E33^*"?XQ<K?FO0V/V?OVR?BC-J&I:#>_VEXYN+JTE:Q\BQ6YNK:<#Y7*J4
MWQ@GD$_2O;M?_:?^)>C^&/#US-\._$>G36DJ-K=_J6EPP6]S& =XB#SCRB3R
M"2<5\T?LD:CKMSXVB\*>$[NP\+:EJBOY_B3[#]JO5B49\M-[;5'T ]R:^XM&
M_9&\'&]34_%UQJGQ#UD?-]K\2W;3HI_V(1A%'M@UU_6<!6;J):=DM7^22^?R
M.V.<X'-FZ^!H^[MK[NOHF?GW\4OVM/B/XY\;W>JV?B?5?#UBDI^QZ=I]T8HX
M$!X!"'#MZDYS7V'^S[^TC>_%3X/C2[CQ_P"'M.^*!8I%_:L 7Y0XVLT6Y/,)
M7/*GJ>E;^H?\$_\ X2ZE?374UGJPDE<NPCU%E4$G.  , >U=I8_LI?#2W\%P
M>%[WPY#K6F6[,T#ZH?.GAW')"3<.H] #Q6F)Q."G34::>C[+^GZ=3VJ^-PN(
MHPI.ERM;M6T]._SL=I?6/BN77/#TMGJ^FQ:3"C_VM;R63-+=,5&TQ/OQ& <G
MD'BF:9:^*7U+Q,\^MZ7<6,QQI$4%H0]F=F#YS;SYGS<\;>.*^1OVJ/A?J7[.
M_P +YKSP+X\\4:?HM].ME-H-S?FX@5&!)\IV&^/IV;I7S'^RSXZUWPE\</#!
MTS4IX(KZ\2VO(FE8QS1MG(<=^<8/7-<]/!JK1E5A-67E\]>WXBI9;"M0G7A5
M5H_+IUUT_$_4>71_B"?!>C6R>(=%7Q/%/$VHWYTQS;SQ!OWBQQ>9E&(X!)./
M2MF2P\2GQO#=)J=@OA869233S:-]I:YW<2"7=@+MXV[?QKH5^Z*6O)YV^B^[
MN>(<1#I/CQ?#GB.&37](;6IYI6TBZ73G$-K&?]6LJ;\R$=R",URWQQ\"?$/Q
MQ\+TT3P]K6@1:I+;LFI?VEIS20WAV#"Q_/\ NB6'#'=CCTKV"BKA6E"2FDKI
MWV0FKZ'Y!7G@OX@Z!>7J:=X+O]0\0:&RW%W8?8S.L(1@2SJ/OH<<8^\.17TA
M\//VJ?CG\0OALS^%_"'AWQ5JUO(@GOM'U&(36RAQNCET^0HZ-M!4?-C//-?=
M*V\22/(L:+(^-SA0"<=,FO$OBW^RCX<^(&M#Q5X?O+GP%X_A^:'Q)H1\J1SZ
M3QC"S+Z@\^]>SB,QACW%5ERVV>Z^:[>GW,O#N.'O>"G?O?\ "S1X!\=/V\/'
MOPZNM&>V\ :GX9EDMY8[FQ\5Z;MCEEXV2Q31R891SE!CKUK4^#_[?^F>)/"'
MB&Z\=>)M-\*ZW<22#2H5T:ZF@M%V84RR(")/FYQD''%>8?M0?M ZUX1\.WWP
MQ^,/@WP[XW\66T:S:5KVGW1CA"L,>=+",/%(0.BD9]A5S]F^'2_VOY(?"C0Z
M7X$^'7AL1W-WX*T:9OM&KW!Y,T\A )AW \ D]CZUDL!5C3]K4LH+JK/3R]?^
M'/7EB\MEAU35%JI?H_U=_NM\R3Q3^U)!^T;=VW@6^^)NA>#O ]F(X]>U^1GL
M9_$!S^\2VC)+0Q'!Y8YYY]*PK7QY^S[!^T39:59:=/+X$CA33HDAB'V1KG(C
M$A8ODQ$?-OR.3G%?HFOPT\)K8067_",Z.UI!&(HX6L(F5$ P% *GC%?.VM_\
M$X/ACKWQ NO$$\VIPZ=<LTLFB6TJQ0B0MGY64!E3'&P>G6L/K\X-JC[D==%Y
M]7Y_ETL3A(97)/ZVI7MZZ^6B_%^IJZ#^RIK?A[PW?3>'O'=YX?\ $$EQ)+9'
M2I9DTU82^8TD@=W+$)P6!&3S7"_M'_!#XHW/A,ZSJOBNS\5VNC0L9&AM6L[I
MHCC=N5"4D Z\X.,UZ%_PS?\ $+X: /\ "OXKZC!8Q_<\/^,D_M.SQ_=67B6,
M?3-<A\3OVM?B)\#_  S-%\3?A3;S370:WM=2T34UETVZ8CD.K#S(QC)P<YZ<
M5=',J\*BJ.TO5*_W[G.LL6(?)A9J5^E^5_<[?@V8G[#/POO[HZEXQDED@MX$
MDM-+C=F\DRD?/(4! (!P/^^J^GCHWQ"_X072[4>(M&_X2N.>)KW4#ICFUFB#
MYD5(O,RI*\ [C@\UXI^Q#^TWI7QCT*Z\,P^&K;PI?:-&KK:6#.]M)$Q^\FX9
M7G@AF)/6OJBLL;C)8FO*HUIT]%_6IRU<)4P,W0K*TD<Y/8>)V\;V=U%JE@GA
M9;)DN-/:T8W+W.X%9%EW8"!>-NT\]ZSH-)\<KH?BJ*77M)?5;F:=M#N%TYA%
M9QD?NEF3?F4J>205S7:45PJ;71?<9'S9^V#X?U[5?@'965\]MK%T)[=+Z&TT
M>6>2ZN#A8VM]C9MSYASO.< X[\_-7PHM=6^#?Q4T/Q+XP\(:[-8P?:D-S)I\
ML\D+JH5YN>NW=RV>03C-?I/05!&#R*WCB+146MK];;G#7P\ZC<J<^5Z=+[._
M_#GD7@OQ'XF^(7PA:X\.^.O#>K>)I)B8]9M].<VD<?FY"/;^9N#^7\IR1SSB
MNYU#3_%$GBG0Y[/5=/AT"&&9=3LY+-FGN)"!Y;1R;L( =V00<YK@?&?[.&FW
M>LR^)?!.I3^ ?%I^9KW2U'V>Y/7$\'W7!/?@_6O*/%G[8/BGX2:JOA7QGX>L
MY_$-I=VZW&HZ:SO:W%HPRTB)D,LN,$+DC.>E4HNJ_P!U9[Z677^M.QQ5<Q^H
MQOCERK^9:Q?ZI^3T\V?1UAIOC".?Q4;O6=-EBN)"=#$=BRFS7R@ )OG_ 'I#
M_-QMXXK%UV;Q9X>\!>'Y]1\7^'M+U6SGMWUS5;RS,=I<PKGSUB0R#RV;^$EC
MCT->>Z)\5/B?\=+!;OP#HMAX.\-3,R)K_B!_/N9-K$$Q6R< @C^,D5O:-^RW
MH-UJ$>K>.M4U+XC:RAW"77)<VL9_Z9VR_(H]CFIMR/\ >->ED_\ @&L<9/$*
M^%IW3^T_=C\NK^ZS[G,WO[2&L^(_B%-%\-=.F^(6AK8B#R+6Q:V@BO-YS*]]
M(0ICVX&Q5SD$YIGB+X/?&KXH^%]237_B/:>%;J>)_LNEZ!;-Y$;$Y GF!5Y%
M X(4C/K7T78Z?;:9:QVMI;Q6MM$-L<,*!$0>@4<"K%3[;E:<(I6^?_ *^ISK
M?[S4<O)>['\'=_-M>1\QZI^PSX0N=:\*75K8Z?';VT#V^N1SBXD:]!0$20MY
MO[J7S!G><G:2M>@_"+X%I\&_$_C>30)K.R\,:U+!<V&DQ1RG[',(]LI)9RI5
MFPV%"]\GICUNBG+$U9QY)2NO^#<ZJ6%H47>E!1]$D>?C1?B-_P *YL;(^)=$
M_P"$T2:-KG5/[+?[))&)<NJP>9E28_E!W'!YQ6[=V'B9_&NG7-OJEA'X72SE
M2[T][1FN9;@LICD27=A5 W J5.<]:Z.BL7-OHNO3O_6G8Z3C;32O&Z:;XN2X
MUS29+VYGG;0)4T]U2RB,8$2SKO\ WQ5\DD;<CBOA[_@HM8:PMU\-(M4ECU'4
MXM)G6^N+.W,<4LP:+>ZID[5+9(!)QFOT3J.6WBF(,D:.1TW*#6U'$.C451).
MW_#'1AZSP]:-:*3L^O\ 6C[/H?DC^R-X^MOA)\78?$NK:?J,^D164\-P;&V,
MCQJVW]X5X^5<<GMFOT&\!>/-8^*/PHU(>%OB'X8U?QB\LKVNHPZ>X@MHS-F-
M9;0R>9D1_*22,MS7LPLX%! AC&05.$'(]*\'^)_['W@_Q7=2Z]X<DN/ GBA,
MR)J6AL8E9O\ ;B! Y[[=I^M57Q4JU5U'%6T]=/7?\#ES'%8O$8B6(A%.+^SL
M]%_-LWZI>IZ=JD^M3>)_#L]CXAT>WT*!9QK%G+#OGNF* 1&&3?B,*V200V0<
M5YS\4/CM%\$!XFO?$_B;3=1&H;&\,:)IEIF\C BVMYQ\S#J9>=YV  $<FORV
MN;JX6Z<//([JY&[)]>M?HE^QC\!?!4_PM\.^.K[2$U;Q)J*22-=:B?.6#9-(
MBB)#\J\*#G!.<\U.&Q&$G+]XFTEM9*^O>^GKVT/E,MSZ.:UI4*4'%I7NW?JE
M^I\\>.;;XZ_M%^'=%U3Q%H&H7^EVX"VT6E:<88WEVX:?9DL<C(S]T=!47P8_
M9E\5O\3?#\?B#PIXBL-(DN-MS=^3);>4FUN?,7!7G R#W]Z_3@  8%&*][^W
MJD:3HTJ:C'6UNA]#]5AS*4G=GSMHO[)6FZ3X8\2JUAX;U#Q/-<7#:)J6HZ?-
M=16L1_U"SQR2GS67G<P(W>E<)XG_ ."?<7B/7(-2/B:WMFNIS+J$$&FB.*(%
M<E;95;"C?T#9 7W%?8M%>7#,\73DY1F[OY_F=$J4)*S1X[\ ?@AJOP-AUO1X
M]?M]5\-SE)[&)K+RKB&<@B4NX8AE("84 8P>>:Z(Z+\1O^%:1V7_  DFB?\
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M?6NCHI<[[+KT[_UIV+.'_L'QG<Z'XLM+[6='NKB\>0:0W]G,(K:)EPJ3KO\
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M+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'YT .HIN]?[P_.C>O]X?G0 ZBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT
M.HIN]?[P_.C>O]X?G0 ZBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN
M]?[P_.C>O]X?G0 ZBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P
M_.C>O]X?G0 ZBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>
MO]X?G0 ZBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O]X?
MG0 ZBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O]X?G0 Z
MBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O]X?G0 ZBF[U
M_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O]X?G0 ZBF[U_O#\
MZ-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O]X?G0 ZBF[U_O#\Z-Z_
MWA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O]X?G0 ZBF[U_O#\Z-Z_WA^=
M #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O]X?G0 ZBF[U_O#\Z-Z_WA^= #J*
M0,#T(-+0 4444 %%%% "-TKPSXOZ;XCO/A_XSA\8:'IOC/39E9-#TWP_HL]S
M=QRG>(Y)4=W5BN4.Y0 I!/ICW2DK6G4]G+FL)JY\+^'M'\1:/H7P'US5OA]X
MIU/3?"V@7V@:GI(T9I;J"\>VB5)1;MRT;%702#CDYP*X2T^"7CKP7X#U7P]K
M'@'6/$&I>)/ %MH>E-96BW4>F7?GSN8)I,X@">;$Q;[OR'!R*_2/ ]*,#TKT
MEF,EM%?CW;7XLCD/FKXQ?!#QQJG@R6^M/BYK_ARUL/#RV]SHNGVT$MO<210G
MS&+N"_S]#S7EO[+/P"^('BG]G_P5JNE_''Q3X4T^ZLR\.C6=C:O#:CS'&U2Z
M[B,@GGUK[GKS7XD_M'?#GX0ZO;:5XK\36^E:A/%YXMQ%),T<6<>;)Y:MY:9X
MW-@5%+%5Y0]C3C=WO\*??I;\1N*O=GF__#,7Q/\ ^CDO&?\ X+K+_P"(H_X9
MB^)__1R7C/\ \%UE_P#$5] OXCTR/0?[;:_MAH_V?[7]N,H\GR=N[S-_3;MY
MSZ5P'@/]ISX8_$NXU*'P_P"+;.ZDT^W:\G$R26^+<=9E,BKOC']]<BHCB,3)
M-QBFEO[L?\@LCSW_ (9B^)__ $<EXS_\%UE_\11_PS%\3_\ HY+QG_X+K+_X
MBN\\&_M3_"SQZVJKHOB^SN#IEJ]_<^;') !;+]Z9?,5=\8_O+D5?^&?[1/P]
M^,&KWNE^%/$46I:E9QB:6T>"6"41$@"15D12RY(^89'(JY5<7&[E"UM_<6GX
M!:)YI_PS%\3_ /HY+QG_ ."ZR_\ B*/^&8OB?_T<EXS_ /!=9?\ Q%?21;;V
M)^@I-WL?RK#ZY5\O_ 8_Y#Y4?-W_  S%\3_^CDO&?_@NLO\ XBC_ (9B^)__
M $<EXS_\%UE_\17TCO\ 8_E7D/C?]I[PKX"\5^)=&U&WU"5/#FDQZMJ=]:PK
M)% KOLCBQNW&1NN ,8YS6E/$8BJ[02?_ &['_(321QG_  S%\3_^CDO&?_@N
MLO\ XBC_ (9B^)__ $<EXS_\%UE_\17T587\6I6-O=P;C#/&LJ$K@E6 (X^A
MJ<-D]#^(K/ZY6\O_  &/^0^5'S=_PS%\3_\ HY+QG_X+K+_XBN=^('[.OQST
M?PI>W?A/X\^*=?UZ,+]GT^\@L;:*4Y&<R;.,#)KZUI*J.-JIIV3_ .W8_P"0
M<J/F6P_9F^*\UC;O=?M&^,8+EHU:6)+"R8(Y W*#LY .1FK'_#,7Q/\ ^CDO
M&?\ X+K+_P"(KT3Q]^TO\-?AAXEBT#Q+XJM=-U5U5V@,<DGDJQPK2LBE8P3T
M+D5W>K>)])T+P_<:Y?ZA;VFCV\!N9;Z20")8L9W[NF,<YJGB,2K-Q2OM[JU]
M-!61X!_PS%\3_P#HY+QG_P""ZR_^(H_X9B^)_P#T<EXS_P#!=9?_ !%>C^ ?
MVD?AO\38M5D\/>*;6Y72X?M-V+A'MC%#VE(E5?W?^V./>M[X<?%KPC\7=-O-
M0\'ZW!KMC:7!M9;BV5M@D R0"P&X<]1D'UIRK8F%^:-K?W%_D%HGC7_#,7Q/
M_P"CDO&?_@NLO_B*/^&8OB?_ -')>,__  767_Q%?2)<#L?P%&X>_P"59?7*
MOE_X#'_(?*CYN_X9B^)__1R7C/\ \%UE_P#$4?\ #,7Q/_Z.2\9_^"ZR_P#B
M*^D=P]#^5>.Z]^U+X3\-ZYXNL;VVU+[)X8EM+:^U&"!9(?M%PP"0J VXL,@G
MC %:0Q&(J.T$G_V['T[":2.0_P"&8OB?_P!')>,__!=9?_$4?\,Q?$__ *.2
M\9_^"ZR_^(KZ060,H(S@C/2G!L^OY5G]<J^7_@,?\A\J/FW_ (9B^)__ $<E
MXS_\%UE_\11_PS%\3_\ HY+QG_X+K+_XBOI.BCZY5\O_  &/^0<J/ASXU^ O
MBU\*=0\#6]M\??%VI+XBUN+296DL;13 K DR#:G)&.AXKT\?LQ?$\C_DY+QG
M_P""ZR_^(KWK3_&?A_6-6N-+L=;TV]U.V_U]G;W<<DT7^\@8E?Q%6M<\0Z7X
M9L&OM8U*TTJR4@-<WTZ0QJ3TRS$"M98RJU&*BD_\,=?P%RH^?/\ AF+XG_\
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M^LU^7FLK?X8_Y!RH\5_X9B^)_P#T<EXS_P#!=9?_ !%'_#,7Q/\ ^CDO&?\
MX+K+_P"(KZ1W>Q_*C</?\JGZY5\O_ 8_Y#Y4?-W_  S%\3_^CDO&?_@NLO\
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M4?\ #,7Q/_Z.2\9_^"ZR_P#B*^DZ*/KE7R_\!C_D'*CYK/[,7Q/'_-R7C/\
M\%UE_P#$5S'@3]G?X[ZM;:FWBGXZ^*-"GBOI8K..TAL;@3VP/[N5CL^5F'5>
MU?7=4+K7=.L=1M;"YO[:WOKK/V>VEF59)L==BDY;'L*I8RM9JR_\!C_D'*CY
M[_X9B^)__1R7C/\ \%UE_P#$4?\ #,7Q/_Z.2\9_^"ZR_P#B*^DLT9'K4_7*
MOE_X#'_(.5'S;_PS%\3_ /HY+QG_ ."ZR_\ B*/^&8OB?_T<EXS_ /!=9?\
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M[1]1M-4L7)"7-E.DT38ZX920:OY'K53QM5S;22\N6.GX"44?-O\ PS%\3_\
MHY+QG_X+K+_XBC_AF+XG_P#1R7C/_P %UE_\17TED&C<,=:CZY5\O_ 8_P"0
M^5'S;_PS%\3_ /HY+QG_ ."ZR_\ B*/^&8OB?_T<EXS_ /!=9?\ Q%>KV7QS
M\#7^M7NDQ^(K5;ZTUE?#[I,&C#Z@8_,%M&S "1]O)"DXZ&N[W#&:N6)KP^))
M?]NQ_P A<J/FW_AF+XG_ /1R7C/_ ,%UE_\ $4?\,Q?$_P#Z.2\9_P#@NLO_
M (BOI+.:6H^N5?+_ ,!C_D/E1\V?\,Q?$_\ Z.2\9_\ @NLO_B*/^&8OB?\
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M^C/GZX^(?CB']F*^BU?Q-/X@\3>-=7_L70EDGM)IK>"1MH+M:C9O"99ADXK
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M8UF[NX[2#(/E0*\A\M<@<+U QTKKCCZ4X255--Z:=M?\[$\KZ'SMK_@G5O\
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MGEG*C+VX;J!QGK7W=X*^%WA;X=7&IS^'-%M]*EU)HVNFA+'S/+0(@Y)P%48
M&!73SP)<0O%(H>-U*LIZ$'@BN>.-C3;48W5K:[]V_6Y7+<_-OX1ZS'XS^-FB
M7GB?Q->:5_Q4MYG4+S4M45M7(D98+0*JBT4+@$;)#D#&.U?I.OW17D&@?LI?
M#KPWK=CJ-II=\\>GW+7MAIESJMS/86<Y))DBMGD,:-DDY XS7KXX%98W$4\1
M*+IWLEU"*:W%HHHKSBPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK@/CK\6K3X(_"_7/
M&%W;F[73X<Q6RG;YLA.$7/;)KR;X5ZO^T3K\>B^+/$-YX-C\-ZFAGN=#M[29
M+NR@9"R,DQ8J[CY<@C'-=,,/*=-U+I+;7J_(5];'TN"#TI:^*?V?/VY]#LO#
MZZ;\2/$&HWFNS:U<68OAIC&VMU,I$*2RQH$4D8QU/K7N'Q'_ &L/!'PPUFZT
M[4XM?O6LHDFO;K2M$N+JVLXW&5:69%V $'/4UK4P5>G4]GRMOTW$I)JY[-17
MC7CG]K7X;_#Y-!;4]7N91KMC]OTS[#837)NH\X 0(I.X]EZU#IW[8/PTU3X;
M/XUAU:Z_LU;P:=]C-A+]N-T>D @ +%SZ"LEAJ[2ER.S\AW7<]KHKQ3P9^UW\
M/O&<7B61)M7T>/PY!]HU5M;TF>S%J/[K%UQO_P!D<\CUJY\-/VIO WQ1\31:
M!ISZMIVJ7-N;NRAUK2IK+[= .LD!D4!U^E#PU:-VX/3?0+H]?HKS_P"+GQR\
M*?!2PL;CQ)=W GU"7R++3["U>ZNKI^ZQQ("S8KRKQU^VAX7D^!_B_P 5^$I[
MYM:TG-F;"]TN9+BSNF!V&>%ERJ]]Q^7C!-%/#5JJ3C%V;M?H)R2/I0$'H<TM
M> ?L9>-M8\>_")->U[Q9JGBF^N92\LFJ:4MC]F?:-T<6%7S(P<X?G/K7 ^&_
MC+\;/VB?$'BC4/A?-X6\->$-"O7L+9]?M);B;4I4^]DJP\M3TR!QGO6OU2?/
M.+:2CNW=+\K_ (!S;'U[17R-XJ^+'QNUGX]6?PW\.ZAX3\/Z@GAV+5;QK^QE
MNX?.R!(J,K!MN3P2.E=!\+?VKM0A@^(ND?%6QT_0?$G@2/[1?S:8[&UNX"#L
M>(,206(Q@D\D>N*;P551YE9[.RWL]$',CZ9HKY0_9<_:'^(GQ/\ BWXJT+QK
M9:?I=E#IUOJEC8P6Y2:"*8EHUD8L<MLVYXZU[MX9^+6F^*/B5XL\&06MQ#?>
M'$MGGN)"GE2B9-R[,'/&.<@5E5PU2C)QEK9)Z=G_ ,.--,[FBO*?V@9OB5IW
MAE]6^'VM:#I*Z;;7%W?IK5A)<F=$3<JQ[&7:?E;KGJ*X/]D3QS\6?BOX;TWQ
MKXPUKPY<>&=3M7,&G:;ILD%U'*'P"TA<J5P&X [BA8=NBZW,K+UO^0KZV/I*
MBO/_ (O?'+PI\$=-L+KQ+=W"RZA-]GL;&QM7N;J[D[K'$@);&1^8KE[W]K7P
M!8^#-%\1--JTG]L7,EG8Z1%I,[:E//&2)(Q;;=^5(YSP/6HCAZLXJ48MI^0[
MI'LY('6@$&OD_P"/7[4J:S\!(_%GPTUVYTV^A\1V6E7B7%GY-U;%I<20RQ2J
M2I(QVZ'@UH>'?C[>^'/CU\8HO%_B$P>"/#&D:=>QQR0KLMC(AWD;5W,6..,G
MG&*Z%@JK@Y6VOIUT:7ZHGF1]0TFX XSS7GOPH^-^A_&!;TZ1I^NZ<;5(Y"NM
MZ1-8^;&X)22,R !U.#R#]:\[O_B'K_BC]LVT\$Z=JMQI_ASPUH)U+4[6';MO
M+B8@1*_&<*IR .]8QP\W*49*W*KNX[H^AZ3(SCO7QC\7_P!L3Q7X)^/[V&E6
M]A+\-- U*QT;Q#=RPEI5N+D,25?=P$XSQ_"<]:ZK]H7]HB\^#O[0?PR@O-8N
MK;P9J&G7LU_8V=G]I>[E&!"%55,A;)  4CWK=8&LW%?S)M?)7MZ_YBYD?4M(
M2!WKQ+3OVQ?AEJ?PSO/'$>K72:7:7JZ9-:26,HOENV^[!Y&-Q=NH [=^#7%?
M'[XZ:IJ/[/\ >?$;P++KWAVY\*ZQ;S7]AJVGR6,MQ"KJ)8)(I5R499%((_ ]
M:SAA*TIJ#C:[MKW'S(^HZ0$'H<URU]X^LK/X:W/C+/F:?#I3ZKUQNC$7F8_$
M<5Y;^RIXWUS5/V=;;QYXYUN>^N-2%WK<TDX 6TMBS,L:  818U&/K62HR<'/
MLTOF[_Y#OK8][S2U\A_L]_' ^&OAQ+\3?B/K6J^3\0_%+0:)9N);F*TA=F2V
MB2,9$:D(Q)X'(S7LWC;X\:/I6I>.?"NEW$C>,O#_ (<EUTPS6KF!4\LF,[^%
M;YL94'-:U,+4A-P2O;KT[/[GH)231ZJ3B@'(R*\;_9\\;Z_\;?V:_#^OZM>I
M8Z_KFER>9>Z?'Y7DRL719$4DX(P".O(K-_8Q^*.L?%'X+6TGB2Z>]\2Z+>W.
MBZE<R8#330/M#D #EE*D^^:F>'E!3;^R[/\ '_(+H]WHHHKE*"BBB@ HHHH
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M).,]Z['5?@MXD;XH?&_5]4\!/XL\.>(=&TVTM-.&H0VYU$QC$J(Q;*,GW@6
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M:YQD\;0"/FSFOLW@CVHQ2AC9PAR63WUUOJTWU[H?*KW/E?\ 9,U#XE?"_P
M^%_ ?C#X6W7A_1=%L)1=>)YM9M)(DV;I 3"C%\'..O'6I?\ @GKI\\GPC\0^
M)98VB@\3^)M0U:U!Z&%I-BD>QV&OIG4]-M-:TVZT^]@BN[*ZB:&>"50R21L,
M,K#N""0146A:%IOAG2+/2M(LK?3=-LXEAM[2UC$<42 8"JHX %%3%*I&?NV<
MFF[7MI?NWNV)1M8T**3</44=*\\L6BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"J[(V5SD"NYTF+Q)\*='\+:#H'@GPMHNLZYK>Z\L?#T,KV-M9*"9IGEV1YD
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M^'K6*DL)-/\ FC^4A?:/I6BBBO.+"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI,T +12$XI: "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'AE*]W/\M[?/J=A1117EGBA1110 4444 %%%% !1110 4444 >/?%_\ 98\
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M4Z0RJYB?^ZP!^4^QJU3::W ****0!1110 4444 %%%% !1110 4444 %%%%
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M["Y(SGMTK-49.FZG0XIYC1ABXX/5R:OHF[>NG]=3Z<HI*6L#U HHHH ****
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MNZ"BBBN<L*9*XCC9R<!1DFGUY=^TY\0/^%8? CQGXA1RES;:?(EM@\F9QLC
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M_CH3\6_C#X-^%UN3)I=LXU_7]O(\B,_NHFQ_??L?:OHE%"*%   X '05M/\
M<8:-/K/5^BV7SU?W'C+WZCET6GSZCJR_$OAK3/%VAWFD:Q8P:CIMW&8I[:YC
M#I(I[$&M2BO-.A-IW1^77A7XM^._V5_&'CGX=Z+>-JFDQ:M-8:=X>BA:?4;5
M9D:6&ZM%*D,J@@,C<$X[G-?27_!.;3]8'PKU[6-7UZ+6IM6U>2YE0M(;FVN
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M+,Y''S%0/2OH_P" /[*?@WX"VHNK.$ZQXEE7%SKU\H,S'N(QTC7V7\2:]JX
MQD5BI*$KQ7WGIU)1A2]E0DU)[S6C_P"W;ZQ]?B_P['DW[,?P?3X.?"[3],F@
M6+5KD"YOL <2$?<X[*./SKUND! [BC</45$I.<G)GGT:4:%.-..R_K[Q:*3(
M]:,CUJ386BDR/6C(]: %HIK-@9S7AGB;]M7X4>$=<N](U+7KB*_M9C!-&FGS
MML8=>0N"/<548RF^6*NQQ3G)0BKM]%N>ZUYG\=OCAH/P5\'W=_J%] NJ21,+
M"Q+9DGDQQA>NT'J>E>=ZE^U5+\3I%T+X,:7-XCUF8?O=6OK=X+'3E/\ '(7
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M(_BVY $^KW P;!O^>,<!Y@QTY /I@5] 6&FV>E0F*RM8+2(L7*01A%+'DG
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M9YQW*=Y!SZ^H' '=>%?V+-?^"^CPZI\-?B!=VGC) 3=KJ,(.F:FN<B*2$9*
M9.&R2,GIV]0^(W[5G@GX6>+;KPYK2:HVH6\<<CFUM!)'AUW+AMP[&N.G^/&K
M_M#W7_"+?"M;O1X&0-J_B34(A&UC"20%A0$EI&P<'MC\1ZJ>-J03<>6GYK2W
MZ_FQ2S.M\"E[O\O3TM_GZ[G#>+?VK=7\9VEQ\)M6T&Q\(^/M2E?2-0N;^_C;
M2X49</)%*#\S$$X0\@\9)XJH/^">=^R\>-K4\?\ 0.;_ ..5]%:=^S=\/[;X
M=MX-N] MM6TN4^;<R7R[YYYCUF:3[P?W!&.@XKS3_A#?BE^S41+X,GN/B?\
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MDUGG8$^S(4:5>XQC%>WA4I86:?2[VVT77S_0SE\2/O2BD'2EKQ#0**:SA.I
M^II/,4 $D<\#GK0!Q_Q<T?Q5KG@>^M?!WB&U\,:T=K+J%Y8B\C6,',BF,D9W
M+D9[9S7CG_!/$,/V8=##D,XOK[<P&,G[0V37T7JISIEW_P!<G_\ 037SK_P3
MT_Y-DT7_ *_[_P#]*7KT(2O@YK^]'\I$_:/I6BBBO/*"BBB@ HHHH S-0\,:
M1JT_GWVEV5Y-C;YEQ;)(V/3)!-6=.TNSTB P6-I!9PD[O+MXEC7/K@ "K5%
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M3G&=^A\-A,OS*AFGM')JA>5ES:6:=O=^[T/9:***[#[D**** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0D"@
M!:*3(HW#UH XGXR7_C/3O 5_-X#TS3-7\0914MM7N&@@,9.)"67G(7)'O7D'
M_!/$L?V8=#+@!_MU]N Z _:&S7T7JO\ R#+O_KD__H)KYU_X)Z?\FR:+_P!?
M]_\ ^E+UZ$'_ +'-6^U'\I$_:/I6BBBO/*"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPN;]HC_HWZS_ /"NM_\ XFOI/BC%'UBG_P ^8_\ DW_R06?<^;/^%S?M$?\
M1OUG_P"%=;__ !-9?B?]HOX[^#?#VHZYJ_P&L[32]/@>YN9_^$K@;RXU&6.
MA)P/2OJ?%,F@CN(GCE19(W&&5U!!'H0::Q%.^M&/_DW_ ,D%GW/EKPM^T;\=
MO&GAS3==T?X#6=WI6HP+<VT__"5P+YD;#*G!0$<>M:O_  N;]HC_ *-^L_\
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M<W[1'_1OUG_X5UO_ /$T?\+F_:(_Z-^L_P#PKK?_ .)KZ3Q1BCZQ3_Y\Q_\
M)O\ Y(+/N?-G_"YOVB/^C?K/_P *ZW_^)H_X7-^T1_T;]9_^%=;_ /Q-?2>*
M,4?6*?\ SYC_ .3?_)!9]SY+\>?M2_&SX9^&Y]>\1_ NTL-*A=(WG'BF&3#,
MP51M5">216[!\;?VA;F".:/]G^T:.10ZG_A+;<9!&1_#7MGQ/^&6B_%SPC<^
M&]>%P=-GDCD?[++Y3Y1@RX;'J*Z:UMDL[:*",'9&@1<\G &!6CQ%'D5J2YO^
MWK6TM]KU%9]SYQ_X7-^T1_T;]9_^%=;_ /Q-'_"YOVB/^C?K/_PKK?\ ^)KZ
M3P*.*S^L4_\ GS'_ ,F_^2'9]SYL_P"%S?M$?]&_6?\ X5UO_P#$T?\ "YOV
MB/\ HWZS_P#"NM__ (FOI/ HQ1]8I_\ /F/_ )-_\D%GW/FS_A<W[1'_ $;]
M9_\ A76__P 31_PN;]HC_HWZS_\ "NM__B:^D\48%'UBG_SYC_Y-_P#)!9]S
MYL_X7-^T1_T;]9_^%=;_ /Q-'_"YOVB/^C?K/_PKK?\ ^)KZ3XHQ1]8I_P#/
MF/\ Y-_\D%GW/FS_ (7-^T1_T;]9_P#A76__ ,31_P +F_:(_P"C?K/_ ,*Z
MW_\ B:^D\48H^L4_^?,?_)O_ )(+/N?-G_"YOVB/^C?K/_PKK?\ ^)KF/&G[
M6'QF^'T^BQ:_\#K.PDUB\6PL1_PE,+^;.1D+\J''U/%?76*AN+.WNC&9H8Y2
MC;D,B!MI]1GH:J.(I7]ZC&WK+_Y(+/N?.7_"Y_VB/^C?K3_PKK?_ .)H_P"%
MS?M$?]&_6?\ X5UO_P#$U])@#%'!]*GZQ3_Y\Q_\F_\ D@L^Y\V?\+F_:(_Z
M-^L__"NM_P#XFC_A<W[1'_1OUG_X5UO_ /$U])X%&*/K%/\ Y\Q_\F_^2"S[
MGS9_PN;]HC_HWZS_ /"NM_\ XFC_ (7-^T1_T;]9_P#A76__ ,37TG@4TR()
M A9=Y&0N><?2CZQ3_P"?,?\ R;_Y(+/N?-W_  N;]HC_ *-^L_\ PKK?_P")
MH_X7-^T1_P!&_6?_ (5UO_\ $U])XHQ1]8I_\^8_^3?_ "06?<^;/^%S?M$?
M]&_6?_A76_\ \31_PN;]HC_HWZS_ /"NM_\ XFOI/%&*/K%/_GS'_P F_P#D
M@L^Y\V?\+F_:(_Z-^L__  KK?_XFC_A<W[1'_1OUG_X5UO\ _$U])XHQ1]8I
M_P#/F/\ Y-_\D%GW/D36OVL?C-X>\::)X3O_ (&VD&OZU')+8VO_  E$3>:J
M??.X)M&/<BNH_P"%S?M$?]&_6G_A76__ ,37K_B/X2:!XG^(GASQK?"Y_MK0
M(I8K,QS[8MLGWMR8^:NT&"..:TEB*%H\M)7MK\6_E[W85GW/FS_A<W[1'_1O
MUG_X5UO_ /$T?\+F_:(_Z-^L_P#PKK?_ .)KZ3R/:C%9_6*?_/F/_DW_ ,D.
MS[GS9_PN;]HC_HWZS_\ "NM__B:/^%S?M$?]&_6?_A76_P#\37TG@48%'UBG
M_P ^8_\ DW_R06?<^;/^%S?M$?\ 1OUG_P"%=;__ !-'_"YOVB/^C?K/_P *
MZW_^)KZ1>1(RH9E4L< $XR?:G<4?6*?_ #YC_P"3?_)!9]SYL_X7-^T1_P!&
M_6?_ (5UO_\ $T?\+F_:(_Z-^L__  KK?_XFOI/%&*/K%/\ Y\Q_\F_^2"S[
MGS9_PN;]HC_HWZS_ /"NM_\ XFC_ (7-^T1_T;]9_P#A76__ ,37TGBC%'UB
MG_SYC_Y-_P#)!9]SYL_X7-^T1_T;]9_^%=;_ /Q-<O;_ +67QENOB'=^!HO@
M=:-XHM;%-1FL?^$HA^6!FVJ^_9M/(Z9S7UWBH190+=-<B&,7!7890@W$>F>N
M*I8BEK>C'[Y?_)!9]SYR_P"%S?M$?]&_6?\ X5UO_P#$T?\ "YOVB/\ HWZS
M_P#"NM__ (FOI/ HQ4_6*?\ SYC_ .3?_)!9]SYL_P"%S?M$?]&_6?\ X5UO
M_P#$T?\ "YOVB/\ HWZS_P#"NM__ (FOI/%'%'UBG_SYC_Y-_P#)!9]SYL_X
M7-^T1_T;]9_^%=;_ /Q-'_"YOVB/^C?K/_PKK?\ ^)KZ3XHQ1]8I_P#/F/\
MY-_\D%GW/FS_ (7-^T1_T;]9_P#A76__ ,31_P +F_:(_P"C?K/_ ,*ZW_\
MB:^D\48H^L4_^?,?_)O_ )(+/N?-G_"YOVB/^C?K/_PKK?\ ^)H_X7-^T1_T
M;]9_^%=;_P#Q-?2>*,4?6*?_ #YC_P"3?_)!9]SYL_X7-^T1_P!&_6?_ (5U
MO_\ $T?\+F_:(_Z-^M/_  KK?_XFOI/%!4$$4?6*?_/F/_DW_P D%GW/D;PU
M^U;\:/%_B3Q+H.D_ RTNM5\.3QVVIP?\)1$GD22)O0;B@#97G*DUTW_"YOVB
M/^C?K/\ \*ZW_P#B:]B\'_"C0O _B[QAXDTT7(U+Q5<PW>H^=-O0O''Y:[%Q
M\HQU%=CBM)XBCS>Y25M-^;MK]KN))]6?-G_"YOVB/^C?K/\ \*ZW_P#B:/\
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M(@2)AD&<$CD<5]=E01TJ&VLH+-76"&.%68NPC0*"QZDX[U2Q%*SO1C?UE_\
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MS?M$?]&_6?\ X5UO_P#$T?\ "YOVB/\ HWZS_P#"NM__ (FOI/%'%1]8I_\
M/F/_ )-_\D.S[GS9_P +F_:(_P"C?K/_ ,*ZW_\ B:/^%S?M$?\ 1OUG_P"%
M=;__ !-?2>!34ECDSL96P<':<X-'UBG_ ,^8_P#DW_R06?<^;O\ A<W[1'_1
MOUG_ .%=;_\ Q-'_  N;]HC_ *-^L_\ PKK?_P")KZ3Q1BCZQ3_Y\Q_\F_\
MD@L^Y\V?\+F_:(_Z-^L__"NM_P#XFC_A<W[1'_1OUG_X5UO_ /$U])XHQ1]8
MI_\ /F/_ )-_\D%GW/FS_A<W[1'_ $;]9_\ A76__P 31_PN;]HC_HWZS_\
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MZY*4\(J:C..O5Z^?G;L4U*^AR/A;]M+5O&'Q-T/PYIG@W2Y;+6-7NM+BW>(
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MX::3XDU+PEIVN)=7FH:CHSK%=LD0PL:2,K;>3DX'-:'['GCGQ#XN\#^(=/\
M$FJS:[?>']<NM)34[D+YUQ%&WR,Y4 %L<$XYKK/C)\"+3XL:CX?UFVU_5/"?
MB;09)'L-9TGRFEC5QAT*R*RLI]Q6/X5_9CL?!.C>%].T3Q;XCT]=*U.75;Z:
M*Y4/K,TGWQ=87#*2<X &*]3VE&6'5/9^G6[UOYJR(L[W/"/&GCCQ'X*_:9\'
M:58^/O&Z"_UF6#5!XLMEM=!FAQ\L-I^Z =^< J3GCFOH+X[?'#4_A-JG@W2=
M&\*GQ7JWB>ZFL[6W^WK:!)$0."S,K#;R<GL!QFL#4OV3D\4>+])U/Q7\1/%?
MBO1](O\ ^TM/T+47MQ!%,#E2TB1+(X7L&:O0/'WPAT_Q_P"+O!&OW=[=6T_A
M6\EO+:& +LF9X]A#Y!. .>,552KAY2IWU23OI;76W9_UN))ZGS[I7[<'BB:Q
MM=4U/X7C3]#MM?3PWK%\NMI(;>[=]@\E F9$'<G;Z#-:.L?MK:I'\2#X<T;P
M=IE_ WB ^'8X[O7Q;Z@TJ\M.;81,1%@$AL\X'3-=I<?LB^'YO!^J^'SK>J"V
MU#Q.GBAY0(MZS+)O\L?+C9GCGGWKP3P_\!_C/X1^)E]K&@Z-<Z;JUSXAEO9-
M3>^TZ;2'L'D+,F)%:\#LN!C( )[ 5U0C@JO,TDK=VTOS$^9'H/Q0N[CXI?M!
MZW'#+(FD_#;PS=73M%(<#4[F!MN".Z1C\":Y[]E_]J>Z;X/"VBT>]\3V?@[P
M\;W7M9EOB9_M."R6T<;*S2MM'+D@#WKV+X#?!75_#OP]\6IXQ>*/Q5XQO+R\
MU66SE$HC\X%$5'(YVI@#C&:X'Q3^Q1#X3\ :BGP^U&\?Q&?#4F@26UU*D,&K
MJ3\C3E0-LBY.UE([ \$U*J89IT)O162?3S?S;86>Z.A^!'[5&M_&#XA-X<F\
M+:+;VBZ7'JTFHZ3XA%^($D.(XG40@"3@[AN&,=\U](5\E_LJ?"WXF_#KQD(;
MVPO]!\$C30EW9ZY-ILT]Q? C#PFS0$(%SS(Q)XKZTKS\9&G"K:E:WD[EQO;4
M****X2@KP?\ :^^)7Q ^%/PPO_$7@F#1DAL(_.OK[5"TCQ@R(BI%"!AF)8Y9
MF  '0DU[Q7C'[3_PG\9?&GP)/X2\-ZWHFBZ7J*;-1?4[&:XF8!U=/*9)%"\K
MSD-G/:NK"N"K0=2W+?6^UB9;:'IFF:Z?^$.MM8O!N(LENIO*7K^[W-@?GQ7@
M=C^WSX%U$Z.T'ACQO)!K2N-*G30RR:A.F-]O#AR6D!."?N#!^;'->O>"_#'B
M:V^&:Z'XHU'2[W6OLLEJUUI5K)!;[2I5"$=V;(7&>>3G&*\A\$?LH:MX4TSX
M(VLOB&SN&\ 75[<73);.HO!.C*!'EOEQNYSG-;T8X9<WM7?72WH_+O9?,3OT
M-S3_ -LKP?K/AO2-0TS1/$VHZMJ>HW.E0>&X-/7^TA<6Z[IU9&D"+L7!)W]Q
MWJIXH_:LT[4_V:/$WQ)\/Z;JVFM&)=/TN'5H$AFN+PMY,>Q5=@1YK8Z]4;CB
MOGKX\?L_^(/!.JZ1#/)=7VB:CXKUCQ%<:OI^CWE[#8BX1!%%+%;,)]_! =65
M>3G-=/\ #?PKXU^*$?P>\):Q\/6\'>"_#VHW6N71MK"6TM+E(&*V(,4S,Z.[
M,TA1V+=SUKT/JV%4(U8NZO??HKZ?.UN_WDWEL;,/QHUW]GCX@>$- \>>++_4
M-$L_ 7]HZFEPJW-S?:D;@*/+)&]Y&+%%0'&,<<9KT[QK^V1X9\"I<F]\*^+K
MF73M-MM4U>&UT^)FTB*?_5+<[I0%<_W5+8[XK*_: _9#'QU^)"^)+C6H]-CM
MO#YT^P:*)OM-I?K/YT-TC@XPIX*]2">:^:/C1X)\=0_%O7-0\2Z"?%>N6VDZ
M;!90-X:U&]T_Q#<11Y81FVD1(UWX)6<N V3]T8ITJ>%Q3BY/WK:I:=?^"_33
MH#<HGZ,>'M8'B#0[#4Q9W5@+N!)Q:WJ!)XMP!VNH) 89Y&36C6-X/NM0OO"^
MDW&K6":5J<MI$]U8QMN6WE* O&#W"G(_"MFOGY:-HU"BBBI *BNO.%M+]GV>
M?M/E^;G;NQQG'.,XZ5+5;4H;BXT^YBM+A;6Z>)EAG:/S!&Y!"L5XW8.#COBF
M@/DOX.?M ^-_$'[2%IX(E\9>%?B/HTVFW-WJT_ARP:V71)XVVK%O,C>9EOEP
M?F[G&.?:?BS^T1H7PB\2Z%X>O=&U_7=;UR">?3['0;$74LYB*[D W##8;.3Q
MA3DCOYUX:_9O\=:U\<?"GQ"\?^(O#4LWA>">*TA\+:3):/>M*I4M<,[MP 2=
M@R,_C7HOC'X.WGB;X^?#WQ_%J4%O9^&;/4+::R:)C).;A%52K X &.<@YKU:
MKPTJL7I;E=[::ZVZ+?3I_F9J]CBO!_[<O@/QKJOA:UM-(\4VMGXBOAI5KJU[
MI7E6<=^<_P"B/(7_ -9Q@[0R@D?-UQ=T[]LCPMK/BW1=%T[PUXKOK;6]6FT;
M3=:BT^,6-W/"S+,49I0^Q-CDDH.$8@'%<IH?[(>LZ)\._A[X?;Q%97$_A?QP
MWBR61;9PMQ$9Y9?(0%OE?]X!N/&0:^>_@-I/B[P'\3-%UA? %YKGB&36M0EU
M.PU/P]?QW6C6TLDK/<1W1<6C2,NU1Y4>7R%'?/5'#X2HIRIN]K]?6SZ>7_#L
M5Y*USZ$^)?Q#\3Z]\</'47AS6[S3=!^&W@V[N[M;9QY-QJUS"[0+(O(?RHTW
M@-D!CTJS\(?VP]!E^$NG7WB:ZU'5M0T7PE::WXFURVM%:UMYI(U(A9E('VAR
M<B)%XSSMJW\ _A!KUW\ /&;^);=M&\;_ !%DU'4M22\C.^T>Y5HX(G4'.(X]
MGR]N17D7C7]DKQ;\$?@7XOL_!U\^N6.K^%;;3M9\/:=9N\ESJ49CC:]ME.<!
MH]QDCP68 [2&QA1CAI_N)-7327GWU]6VOD'O;GTK\+OVC=-^*/C;4_"D7A/Q
M3X>U;3K**^N5URRBA2..0_NLE)7Y<;B!C^%LX(Q7K=?'_P"Q+8ZMH'C'Q+IL
M/AF$^&Y=/@G?Q8VB7^EW%Q=JVP6A6]E=Y%1"2"N%7&,<U]@5YF+IPI57&&VG
M]>7H7%W6H4445QE!1110!\V?M3_M&7GPN\5^$O"&FZ[I7A&76H[B[O/$6KV<
MEXEG;Q8&(X$(,DCLP !X&#^'J?PD\:Q>(?A5IVOR>*-/\:KY,KR:UI%M]GAN
M0K-TB+'8P  *D]0>E<A\;/@CXE\5_$+PEX_\$:UI6E^)]!@NK(PZY:27%I<6
M\Z@,"(V#*P(!!%:_P.^!Q^#WPCD\)MJBZIJ%W+=7EY?"'RHWN+ABSE(P3M0$
M@ 9Z"O2G[!X:"B_>Z_CY=K=;>1"O<\^L/V_/ FI_V,UOX8\;R0:VKKI4Z:&6
M2_G7[UO#AR7D!XSC;G^+@UO67[9?@[5?#.F:EI^B^);_ %74-4N-'B\-PV"?
MVDMS N^970R!%"+R27Q^-<_X/_9,U?PUHWP.LI/$5E,WP^O+JYNG2VD O!*9
M"!&"WR8WCKGI7AWQW_9]U_P+J&DPSS7.HZ+J?BW5?$-SJ>GZ-=WL&GB:%5BC
MECMF$^\G(#HRKUR#Q7;"C@JL^2#[]7TOY=59_@3>25V?0_B;]JS3=3_9M\3?
M$;0M-U;3#!YMAI\.K0)#-/>;O*0*JNV1YIV]<Y4^E>;:=\:]>_9Z^('ACP]X
M_P#%FH:GI-IX%&HZC#.BW%U>:FTX&V,D;W<EMBH&Q@#CO65\.?"7C3XH1?"+
MPCK'P^/A#P7H.JW6M71MM.EM+6YBMV_T/=%,S2(\LC,Y1R6^7)ZUZ=\?/V06
M^.'Q,?Q3+KD6F&#0OL.GO%"QN+.^6;S8KE6!QA3P5ZD$\TU'#49NE4^%W?=K
MHOGN_F&KU1M>-?VQ?#/@5KA+SPMXMNYK#3H=4U:&SL(G;28I<^6+G,H"N<'Y
M5+8QSBO:?#FMIXDT'3]5CM;FRCO;=+A;>\0)-&&4,%< D!AGD FOSL^-/@KQ
MNOQAU?4/$FAMXHUFWT?3[>UB?PUJ%[I^OW$89F6,VTB+&I<@E9RP!R?N@"OT
M+\&76H7WA/1[C5M.32-3ELX7NK"(Y6VE* O&#Z*<C\*X\70I4J<)4]WOKY+^
MOPW*BVVS:HHHKRRPHHHH *\B_:A7Q7%\(]=O_"OBEO"D]A:S7<]U;VRRW$B)
M&Q$<;,<1DD#+X) SCGFO7:X#XT?"RY^+WA-] C\5:KX6M9RRW3Z4L):YB92K
M1/YB-\ISVP>.M;T)*-6,I;7[7_ 3V/GKQ#\1?%VO_#;]GOPU:^*=2T>]\<-;
MQZKKUHZ_;?+$.]]DC A78@?-C-=[^RCXO\17=[\2_">OZY=^)AX3UO['9ZGJ
M#*]S) \>]5D=0 S+TSBE_P"&/K9_A_X>\.R>/?$DE_X:O$O-"US%LMUIVU=H
MC0"/8R8SPP/7K7H7P<^"NF?!W1-2M;74;[6M2U:[>_U+5]29#<7<[#&Y@BJH
M ' 4# KT*U:@Z,H0WOV\[WOZ:$).YX+J/[<GB:U1=3@^%3W7AS^WYO#8NX]<
MC$TUVKE4V1F,?*>,EB,9XSC-:[_MG:GHGA;QD_B+P/'I7BKPYJMKI<NG+JRO
M9[KC_5R/=; $0?Q':<=JZ[_AD7P__P (I;:#_;>J>1!XI?Q4)<1;S.SAS$?E
MQLXQZ^]<%^T7^RQJVK6/B34_"$=YKM]XDURPU+4[$74%O+#%;C'^C&0"-F/I
M+E?:MH/ U)*/+;SU[KN^UP]Y&[X6_:RO]=^&7Q)\3ZSH.FZ3:^%-]JEYI6L?
M;X+VX"9Q$PC0$990"">3CBO"KS7IOV9;7X&ZYXDU*^@.H/J.N:Y!#,_^E7$\
M>]8V4'#'YE4;N!78^'_@)\7_ !7I6G^$O$$ T_X<'Q!;WK6.J7-E_:$%G$-[
M1N+1%B??(%X'( YKZ*^*?[/7AWXO>(O#FIZY),UOHT=Q$NGHJ&&=9H]C!\@G
M@=,8J_:8?#SY=.5WO9WTM9?BV*S9Y3XX_;%U_P $Z;X?2]\$Z7IFLZCI$NN2
MVNK^(UMX([=<;8DF\HB6=@0=BC ]37O7PC\;7OQ'^'.@^)M0TA=#N-4MENOL
M"W!G\I6Y7YRJY)&#T'6OCWXC?LG>-?#GBS0(O#]MK_C#0-&T=['3;VVOM-6\
M@D,FZ-)EO%*&). &1=^.IX%?7WP=L?%NG?#30+;QU=6]YXKCM@M]+:A0A?)P
M/E 4D# )  R#BN7%0P\:,94;7;[N_7H5%N^IV=%%%>26%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% $8[TY:** %;I2+WHHH =111
M0 4444 %%%% !2'M110 T=Z<.E%% "'J:%Z444@'4444P"D7I110 #K0:**
M%HHHH ;_ !_A33]\?6BB@"2FCH:** !>E.HHH **** "BBB@ I/XA1128#5Z
MFE6BB@ ?I0O2BBF ZBBB@ HHHH **** "BBB@!#TI@^]110 \=*&^Z:**3 1
M>M.HHH0!1113 **** "BBB@!O\?X4T??_&BB@"2D7I110 B]*=110 4444 %
M(>E%% !WI:** $-(?N"BB@!$IQZ444 '\0^E+110 4444 %%%% ">E+110 4
MG\5%% #?XS]?Z4X]*** $'>A/NBBB@!U%%% !1110 4444 %%%% !37Z444
>(O>GT44@&-]X4Y?NBBBF M%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>adag-20211231x20f006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '- TH# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1["M_(_N8>TAW1Z)17G?_#0/@7_H+3_^"^Y_^-T?\- ^!?\ H+3_ /@ON?\
MXW1["M_(_N8>TAW1Z)17G?\ PT#X%_Z"T_\ X+[G_P"-T?\ #0/@7_H+3_\
M@ON?_C='L*W\C^YA[2'='HE%>=_\- ^!?^@M/_X+[G_XW1_PT#X%_P"@M/\
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MZ"T__@ON?_C='_#0/@7_ *"T_P#X+[G_ .-T>PK?R/[F'M(=T>B45YW_ ,-
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M -!:?_P7W/\ \;H_X:!\"_\ 06G_ /!?<_\ QNCV%;^1_<P]I#NCT2BO._\
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MNCV%;^1_<P]I#NCT2BO._P#AH'P+_P!!:?\ \%]S_P#&Z/\ AH'P+_T%I_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M )*I?^$<_:"_Z';P)_X3UU_\DU[710!XA-H7Q^MXGEE\=> HXD4LSOX?N0%
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MH$>\T444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
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M$M2AU-_M\MMHT5W%<2?:9@VQ922B[@Q')." >E?8'_"J/C7_ -%U7_PDK/\
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MY\1_ OA/X!>(D\7>(M$L+&#7-?-[;:E=Q+^[.HW)(:-CDY!X&.<C'6@#:O\
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MPK;?^D-O7?5O6^+Y+\D9T_A^;_,\Z_9T_P"2$^!/^P1;_P#H KT6O.OV=/\
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M?*8K]Y%<'G^=?DS\6M L/#O[5_PCM].M[RWA?5])<I>^'HM%;/V\#(BC #C
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M*5(P1CTQ5;0=!T[POHUGI.DV<.GZ99Q+#;VMNNV.)!P%4=@*O44 >&_MB_\
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M87!&<L=P[C^( 5Y-\1OC981?#@^*O"^M_P#"1-%>36D/V.,A&FVAUB897[H
MZ]<CMD'V#6="M[[39;*\LK;4=*"INM;F(SEU4EB,-G<<A2,]Q7RSXV_MKP5I
MGB[0;[PUI6DZ%J=P$T>&TBA@M[<N) 9F1#DOM"'<Z@Y  Z9KIP%*E5E=[IK2
MZU7^?5G+CJ\\/2E-.RL];-V:3>MNGZG )J?CCXU:%J::KK7DZ6D\5S)/>0H
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M>'\.?R(?Q+YG:>+?$EIX.\*ZSK]_N^PZ5937T^P9/EQ(7;'OA37QSX,\(?M
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M1?'.A7OC/5O"EC+(^JV$,=]<J48IMEY4ANASZ"MVTDB,[2112@W'[QG92!D
M+C!Z<#I[5RWQ'\0WOP_\-OK6@^&#KVH274$<UE;#9*Z,P5FW '.T<\^E=8(&
M:\BNEC12T>R0MG=CJ .W4FO*G%64TM'Y]5:__ /<3Z$4\0OKJ%9K27;#*727
M<-H('!X.<')'X&E6'=J<UT!+NCB\D1D *_\ %D?RJ_03BLKE'@O[7R+)\*M'
MN7A,5P_B70E(8 LH.H0':2/>O2/BGXH\/>'/#2VOB4SG3=:G71]L"LS,TX*
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M_IPAKVNY^T$)]G,8.?F\P'I@],>^*$V!7OY;J":*6-1-:@;9(43,C$D $$D
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MB@ HHHH **** "BBB@ HHHH X'X??\C[\2O^PK;?^D-O7?5P/P^_Y'WXE?\
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M6Z6ZL$! 9BYR2>3R:DHHN!';V\=LC+&" S%SDD\DY/6FW4C1HI2$SDNHVC'
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M](;>N^K>M\7R7Y(SI_#\W^9YU^SI_P D)\"?]@BW_P#0!7HM>=?LZ?\ )"?
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M7\*=&^!GAO1_/-I:>-K$%[FYEG9W\J7<VZ1V8 D?=S@=@* /IFBBB@ HHHH
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M_=^9W]%%%8&@4444 %%%% !1110 5YM\#_\ CR\9_P#8UZI_Z.KTFO-O@?\
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M^1]^)7_85MO_ $AMZ[ZN!^'W_(^_$K_L*VW_ *0V]=]6];XODOR1G3^'YO\
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M!X!([^OM4B31RSO& Q>+!)*D#GT/?\*IW-C<71M)%EA2:)&#3>5N(8@#*9/
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M :]!\'_\BEHG_7C!_P"BUH UZ*** "BBB@ HHHH *X#XC_\ (Y?#K_L+R_\
MI+-7?UP'Q&_Y'+X=?]A>7_TEFK>C\?R?Y,SJ?#]WYG?T445@:!1110 4444
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M\LUI)-VG)_%K_P .)62LNAE6MJ-0\;+K]OJVK-;0VHL&TH#_ $5F9P?.(/\
M$O()ZC!S741W:06?G/.;E&?"R1KNX+8 X],XS[5QMSXTT3PS8Z1"TLNF77B"
M]^P6<+[IL3DMD-MR$)P<D]R,UUVB:C!?17$< E M)FMF,T>PLRXR0.XYZ]#2
MJ1E9-K3_ "&BQ8Q7$*.D\@E ;]V_\17_ &O?.>GM4MQ-]GA>38\FT9V1C+'Z
M"DFED26)4A:17.&<, $&.ISU_"HK>"=;NXEEEW(^%CC7[J@=_J<\_05S^;*/
M(/VOIGE_9F^(P>%H@NG,%+$?,-R\C']:]>TC_D$V7_7!/_017D/[84)7]F[X
MBR^8Y#:45\LGY1\PY'OS^E>HZ+:>3I\#K<R-/- NU96RJ\9X7VS1H!KLP3&2
M "<<GO44]G#=/"\B;GB;>AS@@_A5<V%M<31O<+'/<HJG)Z9!R&"]L'G-+J-I
M<7**;>[:UE3)!"AE8_[0/44+?<">,3DR^;Y8&[]V5S]W ZY[YS^E,MI6$7E2
M2I/=1H#($&WD]\9XS@TEA>Q7\)>)S(%.UGV%03@=,]1SVJ-@4NA-.ZVP$FU0
MC\2@C #9'7).!1;HP+-O(\UO&[QF%V4,8V()4D<@D<<>U8OB[5K7PUX:UC5-
M6OUM=-@C\V65XPRQ1@ $8[YY_.M+4;>XGBE6*<0QM$5X'S!N.<Y&.,_G6;>:
M%;:OX6_L^73XYK>4 O974F^-QNW%7/S!@>XY!Z5<.6Z;VN)G->-?BQIOPX\*
MV>KZ@DCV$B>7&8H"#(P&5*@9PI4,WT%>:O\ ".VTWXF0>,;&:36-/U28WES)
MK$A95CD@(CCM0H)9P0O+?=! '>O5O%EAI/B&PL=,UK14N([>X1Q!+$AA0J.)
M%=\ !>2",'CI7EOQPL9M;O\ P[I&F^)-2\/R7T-PV+8N\6R%"9!).C;8AAEY
M_P *];"R2]R%TY7OU5M^G8XL1'3FE%2M9I:7OWNW;TV*'Q3;5O&?BOPO<Z=X
M@M!X8L1/_;#OJ82"WC7RP?, ;,F264Y'0CIDUQY^/UQI6O66A^)+#1;/3H;E
M[6*YM]0^T1-8D-M2-HP26^5!@@Y&W@'FO"O&4[1Z)/X9M;N*;0?M,MRUS;SL
MJ7CLJ(C-@D/M*;0!D#))ZYKM/"_A_1_%E[;0_8K?P?X7@@MTFF>1/,DE.X+R
M6(0861BB#J%]>/2?U>*]@Y>]'96M?KIK=W6ETFEZW/E'FSJU)T</[M5--INZ
M?NZI-[+1>]9)[K5GT'IGBG5K3XL^#(-/U;3HO#&IV6(X(EWM<80@.?E)4$*@
M7<P/RD$<5[QIMK/$]U+<QVR3S/R]L#\Z@87<3WQ7R?X/^%&B:O\ $'QLMQ=V
MLAMK&*RTM]+N5%Q;Q%QL=8E)*.=P5F8!LD^IKZ;T2RNO#/AW2H)I7N)+:&*U
MD#2-)D A=^0N6;IV ^G6O-S"%.+BH/6R3TWZ_K9^9]9AI3ES.6UW_E^:;6VG
M0W+4QQ9MTF,KQ@%@[[G&<XS^OY58J&WEAN TL15LDJ6 ZD'&/PYJ8UXIVGD_
M[6/_ ";5\2O^P'<_^@&O0?!__(I:)_UXP?\ HM:\X_:LDD?]F_XGJ\+1JFB7
M 5R00XV=1CI^->C^#_\ D4M$_P"O&#_T6M &O1110 4444 %%%% !7 ?$?\
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ME8!E(P0>]?.G>,$L<ORK("2N?E/.#T-40+VSECB6,7=H%1/,:3]Z#GYF;/!
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M#LY^;>HV_7/%>L:(B7.DZ;<-#LE^S)M\Q1O0%1D>WO7CW[5NHQ:C^RQ\0KE
ML<3V$H7!QD>8 ">!R:]CT.#RM.@;>[>9%&V';(7Y ,#T'%2]-!B3Z?9VUNB*
MWV+++&DD;;7Y;(4$^I[>],BU%;>YD^TS;8YYQ':[BI#_ "@D+CGJ&Z_RJCX]
M\0WGA;P\^H6.A77B*Y2:%%L;, R$-(JEQGLH)8^PK6@-M+')#;^6'A^4HO\
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M&WKOJWK?%\E^2,Z?P_-_F>=?LZ?\D*\"_P#8(M__ $ 5Z+7G7[.G_)"O O\
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M^":W\/6\L;-+?&SB0NJ\$A1R$)QU).,_C7CW[8MN+[]FCQI,EM-;BVTW>F5
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M^_:Q_P"3:OB5_P!@.Y_] ->@^#_^12T3_KQ@_P#1:T :]%%% !1110 4444
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M@;Y,Z4+48SC.<8KF>O-\WU6ODSW&HXIFDDE4QL@0@!FZ-QU%(LS?:#$8G"A
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M3RE7:(W;=SG.23SG\:0PW,4LC0>1L=T.TJ00/XR2.I(Z5%/I#-)-)%<S(TY
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M /CR\:?]C7JG_HZO2:\V^!W_ !Y>-/\ L;-4_P#1U;P_AS^1#^)?,])HHHK
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MAV3$@P3@XR/8]15:%H\7TEHWG3[R&1W.WS H 7GH.G3UJS=7,5G"9)I%AC!
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M.:.4N$=7*-M8*<X/H:?2*BH254+N.3@=32T %%%% !1110!P/P^_Y'WXE?\
M85MO_2&WKOJX'X??\C[\2O\ L*VW_I#;UWU;UOB^2_)&=/X?F_S/.OV=/^2$
M^!/^P1;_ /H KT6O.OV=/^2$^!/^P1;_ /H KT6C$?QI^K_,*?P1] HHHK T
M"BBB@ HHHS0!'.CR0R)')Y4C*0LF,[3C@XK\[_B1X<\0>&?^"AWP:M_$?BN3
MQ=>26R21WDMC%:&--]P!'MCX/()R>>:_0^Z >WE!D,(*']X#@KQU_"OSE\;:
M9;:5_P %"/@Y%:^,KOQLC0(QOKRZBN&B.ZX_=AHU  '7!YYKT\#O/_"_R.:M
M]GU/T?HHHKS#I"BBB@ HHHH *JQ2M/=NR2_N8P8VB,9!WY!R&/;''3OUJU1C
MF@"*VNH;R$2P2++&21N4\9!P?U%2T@4#H*6@ HHHH \;_;$_Y-D^(?\ V#&_
M]"6O5M&A1--M9 BAW@CW,!R<*,9KRG]L3_DV3XA_]@QO_0EKUG2/^059?]<$
M_P#010!:90XPP##T-4-9\1:3X;@2;5M3L]+A=MBR7MPD*LWH"Q&36A7@GQ&_
M9Y\!ZM\0/$7Q.^*EY9>(M"MM.CM[/3M?A0V&C0H"977<2K-(3DL0#T [4 >[
MQ74,]NL\<J20,N]9%8%2OJ#TQ5'1O$VC^(O._LG5;'4_(;;+]CN4F\L^C;2<
M'@]:^//V??@W<?&/]G3Q/X>CU+5/"GPWUCQ;->:%9[6\Z30@T9^SC+!HXI66
M7'<*WOBFZGX#\$>%OVO_ (9Z!\%_#]KHFM:*MQ-XPFT*/RK6'36CQ'!=;?E:
M1WP5!^8;2: /M?(K,M?%&C7^K3Z7;:O8W&IP#,UE%<HTT?\ O(#N'XBO,/VO
MO'M_\,OV;/'OB/2[DV6H6NGE(+H=8'D=8Q(/==^?PKY+\-:;\'-";X7W#?#S
MQA\-P-1M'TKXI-:1PMJ=VW5;F3>TGEW!+#]XN"&_AH ^]=<\20>%8;(ZGJ^E
MVIEDV%K^=;;S,G^#)P2 >G.?:K.MZEIFCVHUB^NH;.SB ::^>98XDCY(+N2!
MLY]>IKPKXB_L_?#33O$_COXJ?&"[L?%.F301K:Q>(8%-KHEK&F#% "2"SMEL
M@!BQP*\3\%^!/$FJ?LK^"[B[\.ZKK/@^Q\;C68O#,T9GNF\/B9C!&T3',@7(
M<1G/R@#!IW$?95Y=6'B<Z3K6D7EKJ=D4,J75O()+>1 1\QD5MI4 L<<Y//:N
M0T*ROO%VJZO?7.J:/K/AN[07OAZ;0F.9E(99)),.4D&77D<'KGFOG*R.H:;X
M-U_P!IEE/X-MOB7XIO+O3]/F06DND>'EBB^VW+1_\L0VV3 XP9Q[BOJ+X6>+
MO OB'PM%8^ -3T_5?#&GV\5G%%H\OF"V'W53*GY % ^7C &:Z*=6459":.&T
MVW^*?@G19;/5=;T+7KZ+4;1+>\O"L31V[28DRQ &YEP%3!(R?F/%>YV'VNW$
M<-W)]KE;<QN(XA&@&>%QD\_X5DK9_:8I-*N5^T3K,;B%K@;PJ!\H6(Y]0.>U
M= ]NDDL4AW;H\[<,0.1CD=_QJZ]7VFK23\E848\JM<EH-%%<99Y'^U3$T/[,
MOQ)1I7F/]B71W/C/*DXX Z=*]%\'_P#(I:)_UXP?^BUKS[]K'_DVKXE?]@.Y
M_P#0#7H/@_\ Y%+1/^O&#_T6M &O44D<K31,DH6)<[T*9+<<<YXJ6B@ HHHH
M **** "N ^(W_(Y?#K_L+R_^DLU=_7 ?$;_D<OAU_P!A>7_TEFK>C\?R?Y,S
MJ?#]WYG?T445@:!1110 4444 %%%% !7FWP/_P"/+QI_V->J?^CJ])KS;X'_
M /'EXT_[&O5/_1U;P_AS^1#^)?,])HHHK L**** "BBB@ K"\:>+;?P1H4FJ
MW5EJ.H0HZH8-*LY+J<EC@$1H"Q'J<<5NUA>,_$TGA'0Y-1BT35/$+HZK]AT>
M))+ALG&0KN@P.IYJHJ[2$]CXA_X)[:@FK_M%_M 7T<4\,=UJ+3K'<Q&*5 UU
M.0'0\JPSR#R#Q7WW7P+_ ,$]KYM4_:+_ &@;Q[6XL6N-1:4VMVH6:$M=3G8X
M!(##.#@GD'FOOJN_'_QWZ+\D<^'^ ****\XZ0HHH;.#CDT 1W"R202+#((Y2
M"%=EW!3V)&1GZ9J V#+%(L4\D+R2"1G!W<Y&0 V< @8Q[U-:R22V\;RQ>3*5
M!:/=NVGTSWJ6G=H HHHI %%%% !7BGQ9_P"3AO@I_P!=M5_])*]KKQ3XL_\
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M.Z<5OK_7WGI%[M-G/NA^TKL;,( /F#'W>>.>E?FKK,6FQ?M__!\:7\.)_AE
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M%K;39VQW<&T.3$&Q\BMN ]:\R3_@J?#)-)$GPHUUI(\;T%P"RYZ9&SC-"?\
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M\4$ C,VQ@" S$XR.<5[O7-B'[.3I1T6C:\[)M7WT?=A'7?HV%%%%<184444
M175P+2UFG97=8D+E8UW,<#. .Y]J\\^$/QLM/B]?>*8+71-2T5="NH[5AJL1
MAFE+QA]WE$90<]^O6O1+JXCL[:6>4E8HD+L0"< #)X'6OG'X"?%'P]K7QF^)
M<5K/=%M<U"WGT\RV,T:S)';!7(9D &"".2*ZZ-/VE.H^6[237EJOTN3)VMZF
MQJ_[4DUI<:UJEAX(O]4\!Z'?/8:CXEBO(U\MT?9*T<!&Z1$8\MD=#QQ6_P"(
M/V>?"OB_4]#URRFN]-:WUA-?<6US)Y=U(5;.5WX7=OR6 SQCH:\#&L2>#_@E
M\0_A'>:5J4OC2^U+4+?3[2*QEDCO$N9RT4RR!=FS:^22>,&OL/PKILFC>&-(
MT^5B\MI:0P.Q.<E4"D_I7967U:*E2]U_/566O]:?<2]6XOS_ ,O\S4 P****
M\@T"BBB@ HHH- 'F&C?':SUSXQS_  _BT'5K2>&REO&U"_@,$4FQPF(@P_>#
MG[PX^M9_C7X\ZEI?C74_#'A#P1>^-M0T:VCNM6:"\CM4M5D!*(I<'S)"%)V#
M';FN%USXK>'4_:VT64W%UY-MHEQI$LHL)RBW37"E8]VS'..O3WIZ>,[7X%_'
M7XG7OB>RU%=/\20V5]I=U9V,MPERT431R0@HIPX., XR#7KK#K27L[MQNEKJ
M[V\GMK9$MZM>:_+_ #T._AN+SX^^"-/USPQXKDT7PUKE@8I[2734EG 8E7PY
M8>6X^93D,,C->B^&_#]GX4\/:9HM@A2QTZVCM(%8Y(C10JY/?@"O-?V4O"FJ
M>#O@5X<L=9M7L-1E$MW+9R<-!YLK2!".Q 8<5ZY7'B'RSE2B_=3=MOSZBCKJ
M%%%%<A85Y_\ &OXP6GP5\&7'B"ZT;5-;6)6(@TVW:3!"YS(P!$:_[1XKT"O'
M/VL?$]AH/P/\4V5TTWVK5K">SLXH+>25I92APOR X^IXK>A%3JQBU=-C6K.I
M\9?%K3O!'PRB\8WUK/)%/#;M!8P$-+---M$<*DX!)9P,_C7&6/CF7XP2ZQ\-
M/'/A*[\%:KJ.F&\@B%]'=+-;A@I=)%  ='*DJ1QQUKD?B)J*?$?]FOP]J7AN
M&ZU7_A'KW2[RZMDMI$F86[(9E5&4%B!DX YQQ6KX9\16WQA_:0T/Q/X?@O7T
M#0= N;>XO[BTDMT>>>1-L(WJ"Q"J6..G%>C&A&$9-QU3EKKI9)Q^]Z:_(Q4G
MRQ?DOOOK]R/2O!7PTNO#_B2Y\0:UKS^(-8>RCTV*86RVR16Z,6 V G+%F)+9
MYXP!3/B-QXR^'/\ V%Y?_26:N_K@/B/_ ,CE\.O^PO+_ .DLU<,)RJ5.:79_
MDPFK1^[]#OZ***Y34**** "BBB@ HHHH *\V^!__ !Y>-/\ L;-4_P#1U>DU
MYM\#O^/+QG_V->J?^CJWA_#G\B'\2^9Z31116!84444 %%%% !03BBF2J71E
M#%201D=1[T )/,88))!&TA12VQ/O-@=![UY?\)/C1>?$WQ?XST:[\+WOA@:!
M);HD>I,OVB42Q[]S*I*J.F,,>.N.E:O@OX?ZMX(U&]U'4?'>O^*K9H6 LM22
M I'SNW*(XU8G P.>]>5_!WX@VNJ?M"_$.<:/X@M;;Q$UB+"XO-'N(8F\BVVR
M;F90%Y! SC/:N^G1C*-2WO65T]='=>G2Y#=E?8M:]^TOXHC7Q/XCT+P/!JOP
M]\,74MKJ.I2:CY5Y-Y)'VB2"'80RIS]Y@3M-=OJWP1\ _$LZ/XC&EQ)(]W!K
M*7-N-IN&QN&_U!R,]_>O"KNZU[P-\+OB9\)SX1UO4?$>M7VHQZ/<6=DTEG=0
MWA)65IONH$WMN#8QMXS7U5X"\/MX4\$Z#HLC;Y-/L8;5F'=D0*?U%=%:V'BI
MT?=?1I[JRU>O?^M!/5M/S_/3[U<W>E%%%>0:!03BBN(^('P^U;QE>V<^G>.-
M<\*) A5X=)$!68DYRWF1L<]N,5<$I.TG;^O(#G_C-\;+WX5ZOX8L;?PK?:M#
MK.IVE@^IAE2TM?.F$?S-G<7YR%"X/J*T?B_\4K[P&V@:3H.D1Z]XI\0736VG
M6,]QY$/R+ODDD?!(11CH"22*\Z_:M\1C3-)\&:(NGZYK-[:ZWINJ2S6.FRW
M\B"<&1F9%VAL*3MZGL*M_%G49[S7OA9\4=-TC5=1T;1Y[I;ZSBLG%Y%!<1!1
M+Y! <[609&,X;I7I4Z,'"E)QW<OG9>[][T(;=VO+_/\ X!O^#O&&M?%<:[X9
MUI9_ OC+PY=0O<_V/=+<1NCJ6C=&=,-&PW JR]17=^!/ 5KX$M=06*[N=1OM
M2NWOKZ^NROF3S, ,D* H "J   ,"O-O@;;7GB?XG?$+X@/I=_I.E:P+.QTZ/
M48#!--' C;I3&WS*"SX&<'BO;ZY\0^23IQT5E=>=E==]^@+4****XBPHHHH
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M_2&WKOJRK?%\E^2)I_#\W^9YU^SI_P D)\"?]@BW_P#0!7HM>=?LZ?\ )"?
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M *235Z+7G7Q-_P"1X^&?_89E_P#22:MZ'Q_)_DR);'HM%%%8%A1110 4444
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MW_PO;PY_SYZ__P""*[_^-TO_  O7PY_SYZ__ ."*[_\ C=>AT4<U+^5_?_P
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M17?_ ,;H_P"%Z^'/^?/Q!_X(KO\ ^-UZ)11S4OY7]_\ P M+N>=_\+V\.?\
M/GX@_P#!%=__ !NC_A>WAS_GS\0?^"*[_P#C=>B44<U+^5_?_P  +2[GG?\
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:%&(5P#C<K#IVKTZBBHJ2YY7]/P5AQ5E8_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>adag-20211231x20f007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'C R0# 2(  A$! Q$!_\0
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MBB@ KQ_Q1\5_%GA[P]XE\0?V)IHTC2KAX81+<2>=<A2 6P%P!D^O:O8*\O\
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M%"CU8L1Q] 3[5E> OBG'XH^&O_"7ZA;IIT 621HD??M5??N:D^./_)*_$/\
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M0NW YYR<FNG'P8LO^$_3Q@VM:D^K)#]G&[RMFS&,$;/<\UZ'16<L97EO+O\
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M/:5_^?:^_P#X!]&_:(O^>J?]]"C[1%_SU3_OH5\Y?\,D^&?^AF\8_P#@[?\
MPH_X9)\,_P#0S>,?_!V_^%'LL)_S]?\ X#_P0]I7_P"?:^__ (!]&_:(O^>J
M?]]"C[1%_P ]4_[Z%?.7_#)/AG_H9O&/_@[?_"C_ (9)\,_]#-XQ_P#!V_\
MA1[+"?\ /U_^ _\ !#VE?_GVOO\ ^ ?1OVB+_GJG_?0H^T1?\]4_[Z%?.7_#
M)/AG_H9O&/\ X.W_ ,*/^&2?#/\ T,WC'_P=O_A1[+"?\_7_ . _\$/:5_\
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M_P ]4_[Z%?.7_#)/AG_H9O&/_@[?_"C_ (9)\,_]#-XQ_P#!V_\ A1[+"?\
M/U_^ _\ !#VE?_GVOO\ ^ ?1OVB+_GJG_?0H^T1?\]4_[Z%?.7_#)/AG_H9O
M&/\ X.W_ ,*/^&2?#/\ T,WC'_P=O_A1[+"?\_7_ . _\$/:5_\ GVOO_P"
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M +Z%'VB+_GJG_?0KYR_X9)\,_P#0S>,?_!V_^%'_  R3X9_Z&;QC_P"#M_\
M"CV6$_Y^O_P'_@A[2O\ \^U]_P#P#Z-^T1?\]4_[Z%'VF+_GJG_?0KYR_P"&
M2?#/_0S>,?\ P=O_ (5Y;\3?@?I_A/XC^!-$L?$OBG[%K-P\=UYNKR,V .-I
M[5M2PN&K2Y(U7?5_#V5^YG.O6IKF=-??WT['V_\ :(O^>J?]]"C[1%_SU3_O
MH5\Y?\,D^&?^AF\8_P#@[?\ PH_X9)\,_P#0S>,?_!V_^%8^RPG_ #]?_@/_
M  33VE?_ )]K[_\ @'T;]HB_YZI_WT*/M$7_ #U3_OH5\Y?\,D^&?^AF\8_^
M#M_\*/\ ADGPS_T,WC'_ ,';_P"%'LL)_P _7_X#_P $/:5_^?:^_P#X!]&_
M:(O^>J?]]"C[1%_SU3_OH5\Y?\,D^&?^AF\8_P#@[?\ PH_X9)\,_P#0S>,?
M_!V_^%'LL)_S]?\ X#_P0]I7_P"?:^__ (!]&_:(O^>J?]]"C[1%_P ]4_[Z
M%?.7_#)/AG_H9O&/_@[?_"C_ (9)\,_]#-XQ_P#!V_\ A1[+"?\ /U_^ _\
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M )]K[_\ @'T;]HB_YZI_WT*/M$7_ #U3_OH5\Y?\,D^&?^AF\8_^#M_\*/\
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M;QC_ .#M_P#"C_ADGPS_ -#-XQ_\';_X4>RPG_/U_P#@/_!#VE?_ )]K[_\
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M*<1M+)GOZ_+@#TQ65X"\5>#_ !1\5#XLN=;M;WQ'J*#3]*TR!M[6UN,L2?\
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M_4/"?PI\>3W.N65[;W<L5U;6=CN469/]W). :+ ?4J:G9R7 @2[@><C=Y2R
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M''=8.]5 P!GTQ75T4 <9:_!WP=9>(I-;@T.VBU&1M[2(, M_>*],UV72EHH
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M_P!_5_PH^KX?_G^ONE_D'M:O_/I_>O\ ,]BHKQW_ (9A\5_]%H\7_P#?U?\
M"C_AF'Q7_P!%H\7_ /?U?\*/J^'_ .?Z^Z7^0>UJ_P#/I_>O\SV*BO'?^&8?
M%?\ T6CQ?_W]7_"C_AF'Q7_T6CQ?_P!_5_PH^KX?_G^ONE_D'M:O_/I_>O\
M,]BHKQW_ (9A\5_]%H\7_P#?U?\ "C_AF'Q7_P!%H\7_ /?U?\*/J^'_ .?Z
M^Z7^0>UJ_P#/I_>O\SV*BO'?^&8?%?\ T6CQ?_W]7_"C_AF'Q7_T6CQ?_P!_
M5_PH^KX?_G^ONE_D'M:O_/I_>O\ ,]BHKQW_ (9A\5_]%H\7_P#?U?\ "C_A
MF'Q7_P!%H\7_ /?U?\*/J^'_ .?Z^Z7^0>UJ_P#/I_>O\SV*BO'?^&8?%?\
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M_D:>UJ_\^G]Z_P SV*BO'?\ AF'Q7_T6CQ?_ -_5_P */^&8?%?_ $6CQ?\
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M_O7^9[%17CO_  S#XK_Z+1XO_P"_J_X4?\,P^*_^BT>+_P#OZO\ A1]7P_\
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MKZ$KY[^/O_)<OA!_U^R_R%>CE_\ '^4O_26<F*_A_-?FCZ$HHHKSCK"BBB@
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MWL[5)=Z 9RI#XZ?WL5DG]KKPA_PC=AKRZ;KKZ7<7 M9K@68VVDA.-LIW]?\
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M7-N_W98VW*WT-<M#\6/#DWQ"D\$BZF7Q$D1G-L\#J"G'S!B,$<^M '84444
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M3O#/_@R%'_"2_M$?]"=X9_\ !D*]^HH^N1_Y\P^Y_P"8?5Y?\_)?A_D> _\
M"2_M$?\ 0G>&?_!D*/\ A)?VB/\ H3O#/_@R%>_44?7(_P#/F'W/_,/J\O\
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M^HH^N1_Y\P^Y_P"8?5Y?\_)?A_D> _\ "2_M$?\ 0G>&?_!D*/\ A)?VB/\
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M,<EQ"&9?H:VZ* ,;4/!FA:K<6\]YI-I<36X"PO)$"8P.@7T_"MD#  '0444
M%%%% !1110 C_<;Z5\^?L<_\@3Q]_P!C5??^C#7T&_W&^E?/G['/_($\??\
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M #[8?7</_.CWNBO!/^&Q?#W_ $)'C_\ \)]O_BZ/^&Q?#W_0D>/_ /PGV_\
MBZ/[.Q7_ #[8?7</_.CWNBO!/^&Q?#W_ $)'C_\ \)]O_BZ/^&Q?#W_0D>/_
M /PGV_\ BZ/[.Q7_ #[8?7</_.CWNBO!/^&Q?#W_ $)'C_\ \)]O_BZ/^&Q?
M#W_0D>/_ /PGV_\ BZ/[.Q7_ #[8?7</_.CWNBO!/^&Q?#W_ $)'C_\ \)]O
M_BZ/^&Q?#W_0D>/_ /PGV_\ BZ/[.Q7_ #[8?7</_.CWNBO!/^&Q?#W_ $)'
MC_\ \)]O_BZ/^&Q?#W_0D>/_ /PGV_\ BZ/[.Q7_ #[8?7</_.CWNBO!/^&Q
M?#W_ $)'C_\ \)]O_BZ/^&Q?#W_0D>/_ /PGV_\ BZ/[.Q7_ #[8?7</_.CW
MNBO!/^&Q?#W_ $)'C_\ \)]O_BZ/^&Q?#W_0D>/_ /PGV_\ BZ/[.Q7_ #[8
M?7</_.CWNBO!/^&Q?#W_ $)'C_\ \)]O_BZ/^&Q?#W_0D>/_ /PGV_\ BZ/[
M.Q7_ #[8?7</_.CWNBO!/^&Q?#W_ $)'C_\ \)]O_BZ/^&Q?#W_0D>/_ /PG
MV_\ BZ/[.Q7_ #[8?7</_.CWNBO!/^&Q?#W_ $)'C_\ \)]O_BZ/^&Q?#W_0
MD>/_ /PGV_\ BZ/[.Q7_ #[8?7</_.CWNBO!/^&Q?#W_ $)'C_\ \)]O_BZ/
M^&Q?#W_0D>/_ /PGV_\ BZ/[.Q7_ #[8?7</_.CWNOGSX0?\G0?%W_KG:?\
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M_9V*_P"?;#Z[A_YT>]T5X)_PV+X>_P"A(\?_ /A/M_\ %T?\-B^'O^A(\?\
M_A/M_P#%T?V=BO\ GVP^NX?^='O=%>"?\-B^'O\ H2/'_P#X3[?_ !='_#8O
MA[_H2/'_ /X3[?\ Q=']G8K_ )]L/KN'_G1[W17@G_#8OA[_ *$CQ_\ ^$^W
M_P 71_PV+X>_Z$CQ_P#^$^W_ ,71_9V*_P"?;#Z[A_YT>]T5X)_PV+X>_P"A
M(\?_ /A/M_\ %T?\-B^'O^A(\?\ _A/M_P#%T?V=BO\ GVP^NX?^='O=%>"?
M\-B^'O\ H2/'_P#X3[?_ !='_#8OA[_H2/'_ /X3[?\ Q=']G8K_ )]L/KN'
M_G1[W17@G_#8OA[_ *$CQ_\ ^$^W_P 71_PV+X>_Z$CQ_P#^$^W_ ,71_9V*
M_P"?;#Z[A_YT>]T5X)_PV+X>_P"A(\?_ /A/M_\ %T?\-B^'O^A(\?\ _A/M
M_P#%T?V=BO\ GVP^NX?^='O=%>"?\-B^'O\ H2/'_P#X3[?_ !='_#8OA[_H
M2/'_ /X3[?\ Q=']G8K_ )]L/KN'_G1[T_W&^E?/G['/_($\??\ 8U7W_HPU
M8?\ ;%\/;3_Q1'CX<=_#[?\ Q=>/_LV_M&Z/X'TSQ=%<^&/%NH->Z_=WB'3=
M(,PC5W)"N=PVN.X[5Z%' XE8:K%P=WR_FSCJ8N@Z]-J6BO\ H?;E%>"?\-B^
M'O\ H2/'_P#X3[?_ !='_#8OA[_H2/'_ /X3[?\ Q=>?_9V*_P"?;.SZ[A_Y
MT>]T5X)_PV+X>_Z$CQ__ .$^W_Q='_#8OA[_ *$CQ_\ ^$^W_P 71_9V*_Y]
ML/KN'_G1[W17@G_#8OA[_H2/'_\ X3[?_%T?\-B^'O\ H2/'_P#X3[?_ !='
M]G8K_GVP^NX?^='O=%>"?\-B^'O^A(\?_P#A/M_\71_PV+X>_P"A(\?_ /A/
MM_\ %T?V=BO^?;#Z[A_YT>]T5X)_PV+X>_Z$CQ__ .$^W_Q='_#8OA[_ *$C
MQ_\ ^$^W_P 71_9V*_Y]L/KN'_G1[W17@G_#8OA[_H2/'_\ X3[?_%T?\-B^
M'O\ H2/'_P#X3[?_ !=']G8K_GVP^NX?^='O=%>"?\-B^'O^A(\?_P#A/M_\
M71_PV+X>_P"A(\?_ /A/M_\ %T?V=BO^?;#Z[A_YT>]T5X)_PV+X>_Z$CQ__
M .$^W_Q='_#8OA[_ *$CQ_\ ^$^W_P 71_9V*_Y]L/KN'_G1[W7SW\??^2Y?
M"#_K]E_D*L_\-B^'O^A(\?\ _A/M_P#%UX[\7/VC=(\1_%3X<ZM#X8\66L.E
MW,DDD%WI#1S3 CI$N[YC7?@<#B85KR@]I?\ I+.7$XNA*G93ZK\T?;M%>"?\
M-B^'O^A(\?\ _A/M_P#%T?\ #8OA[_H2/'__ (3[?_%UP?V=BO\ GVSJ^NX?
M^='O=%>"?\-B^'O^A(\?_P#A/M_\71_PV+X>_P"A(\?_ /A/M_\ %T?V=BO^
M?;#Z[A_YT>]T5X)_PV+X>_Z$CQ__ .$^W_Q='_#8OA[_ *$CQ_\ ^$^W_P 7
M1_9V*_Y]L/KN'_G1[W17@G_#8OA[_H2/'_\ X3[?_%T?\-B^'O\ H2/'_P#X
M3[?_ !=']G8K_GVP^NX?^='O=%>"?\-B^'O^A(\?_P#A/M_\71_PV+X>_P"A
M(\?_ /A/M_\ %T?V=BO^?;#Z[A_YT>]T5X)_PV+X>_Z$CQ__ .$^W_Q='_#8
MOA[_ *$CQ_\ ^$^W_P 71_9V*_Y]L/KN'_G1[W17@G_#8OA[_H2/'_\ X3[?
M_%T?\-B^'O\ H2/'_P#X3[?_ !=']G8K_GVP^NX?^='O=%>"?\-B^'O^A(\?
M_P#A/M_\71_PV+X>_P"A(\?_ /A/M_\ %T?V=BO^?;#Z[A_YT>]T5X)_PV+X
M>_Z$CQ__ .$^W_Q='_#8OA[_ *$CQ_\ ^$^W_P 71_9V*_Y]L/KN'_G1[W17
M@G_#8OA[_H2/'_\ X3[?_%T?\-B^'O\ H2/'_P#X3[?_ !=']G8K_GVP^NX?
M^='O=%>"?\-B^'O^A(\?_P#A/M_\71_PV+X>_P"A(\?_ /A/M_\ %T?V=BO^
M?;#Z[A_YT>]T5X)_PV+X>_Z$CQ__ .$^W_Q='_#8OA[_ *$CQ_\ ^$^W_P 7
M1_9V*_Y]L/KN'_G1[W17@G_#8OA[_H2/'_\ X3[?_%T?\-B^'O\ H2/'_P#X
M3[?_ !=']G8K_GVP^NX?^='O=%>"?\-B^'O^A(\?_P#A/M_\71_PV+X>_P"A
M(\?_ /A/M_\ %T?V=BO^?;#Z[A_YT?&7[>?_ "<3JG_7G;_^@FBN:_:S\=VO
MQ$^,M_K5II^I:9#);0H+?5K8V\XV@\E"3QZ45^OY?%PPE*,MU%?D?FF.DIXF
MI*.S;/N[]A6-3^S-X7)4$^;>=1_T]2U[[Y:?W5_*O!/V%?\ DV7PO_UUO/\
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M?RKY]^$"*?VG_BZ"HP([3M_L+7T)7SY\(/\ DZ#XN_\ 7.T_] %>EA/X5?\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7SY\(/\
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M9[&B@ HKS;5?C;9:/\9=+^'=QI5U]NU& W$%ZKH8MH#'D9R#\I%>DT %%%%
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M,,<J<'VI@>FT9S7FVD?&&W\5:1:W-OX?UJ.PU.REN[2[0P$2(JYQE93L<@C
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M&+*XN]5>W\-L'TY1.@\L@Y!/R<].]>KT4 >>:O\  WP_JFK:MJ,,U]I=QJ\
MM]2^P2(BWBC^^"AYZ\KCK4?B7]G_ ,(>(]#T+3!;3Z4NALKZ=<Z=*(YH"/0D
M$'..<@UZ/10!YIH7[/OA;0O%E]XC5M0O=3OX#;W;7MSYB3H1@AEQ@Y_+TQ47
M@S]G7PQX"U.6XTFZU>.Q>?[0NDO>DV:29SD)@'CW)KU"B@ HHHH **** "BB
MB@ HHHH 1_N-]*^?/V.?^0)X^_[&J^_]&&OH-_N-]*^?/V.?^0)X^_[&J^_]
M&&O2H?[I6_[=_-G#5_WBE_V]^A]"4445YIW!1110 4444 %%%% !1110 444
M4 %%%% !1110 5\]_'W_ )+E\(/^OV7^0KZ$KY[^/O\ R7+X0?\ 7[+_ "%>
MCE_\?Y2_])9R8K^'\U^:/H2BBBO..L**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** /RW_;S_Y.)U3_ *\[?_T$
MT4?MY_\ )Q.J?]>=O_Z":*_;<L_W*C_A7Y'Y3F'^]U?5GV7^PK_R;+X7_P"N
MMY_Z52U[[7RM^QG\6?!OA?\ 9Y\.:;J_B73M.OXI;LR6]Q.%=<W,A&1[@@U[
M;_POGX=_]#EH_P#X%+7Y5F%"M+&5FH/XGT?<_1,%5IK#4DY+X5U\CO**X/\
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M *'+1_\ P*6C_A?/P[_Z'+1__ I:/JU;^1_<P]M2_F7WG>45P?\ POGX=_\
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M .ART?\ \"EH^K5OY']S#VU+^9?>=Y7SW\??^2Y?"#_K]E_D*](_X7S\._\
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MW,/;4OYE]Y^>?[>?_)Q.J?\ 7G;_ /H)HK-_;4\2:7XJ^/&HZAI%_!J-D]K
MJSV[[D)"G(R**_9LM3C@Z2>_*OR/R['M/%5&N[/J[]C7X0^"_%?[/7AS4]8\
M-:?J.H3270DN)XMSL%N)%&3[  ?A7MG_  S]\./^A-TG_OP*X+]A7_DV7PO_
M -=;S_TJEKWVORK,,16CC*R4W;F?5]S]$P5&D\-2;BOA73R//_\ AG[X<?\
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M?WL/84OY%]R//_\ AG[X<?\ 0FZ3_P!^!1_PS]\./^A-TG_OP*] HH^LU_\
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M%>@44?6:_P#S\?WL/84OY%]R//\ _AG[X<?]";I/_?@4?\,_?#C_ *$W2?\
MOP*] HH^LU_^?C^]A["E_(ON1Y__ ,,_?#C_ *$W2?\ OP*/^&?OAQ_T)ND_
M]^!7H%%'UFO_ ,_'][#V%+^1?<CS_P#X9^^''_0FZ3_WX%'_  S]\./^A-TG
M_OP*] HH^LU_^?C^]A["E_(ON1Y__P ,_?#C_H3=)_[\"C_AG[X<?]";I/\
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M)2_Q?^VL^@Z***\T[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH _+?\ ;S_Y.)U3_KSM_P#T$T4?MY_\G$ZI_P!>=O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"3H/B[_P!<[3_T 5Z6$_A5_P##_P"W1.'$?Q*7^+_VUGT'1117FG<%%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^
M6_[>?_)Q.J?]>=O_ .@FBC]O/_DXG5/^O.W_ /0317[;EG^Y4?\ "OR/RG,/
M][J^K/&=&^)GB_PYI\=AI/BK6],L8R2EM9ZC-%$N22<*K #))/XU>_X71\0?
M^AZ\2_\ @WN/_BZ**[71I-W<5]QRJK42LI/[P_X71\0?^AZ\2_\ @WN/_BZ/
M^%T?$'_H>O$O_@WN/_BZ**7L*7\B^Y#]M5_F?WA_PNCX@_\ 0]>)?_!O<?\
MQ='_  NCX@_]#UXE_P#!O<?_ !=%%'L*7\B^Y![:K_,_O#_A='Q!_P"AZ\2_
M^#>X_P#BZ/\ A='Q!_Z'KQ+_ .#>X_\ BZ**/84OY%]R#VU7^9_>'_"Z/B#_
M -#UXE_\&]Q_\71_PNCX@_\ 0]>)?_!O<?\ Q=%%'L*7\B^Y![:K_,_O#_A=
M'Q!_Z'KQ+_X-[C_XNC_A='Q!_P"AZ\2_^#>X_P#BZ**/84OY%]R#VU7^9_>'
M_"Z/B#_T/7B7_P &]Q_\71_PNCX@_P#0]>)?_!O<?_%T44>PI?R+[D'MJO\
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M71\0?^AZ\2_^#>X_^+HHH]A2_D7W(/;5?YG]X?\ "Z/B#_T/7B7_ ,&]Q_\
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M7111["E_(ON0>VJ_S/[P_P"%T?$'_H>O$O\ X-[C_P"+H_X71\0?^AZ\2_\
M@WN/_BZ**/84OY%]R#VU7^9_>'_"Z/B#_P!#UXE_\&]Q_P#%T?\ "Z/B#_T/
M7B7_ ,&]Q_\ %T44>PI?R+[D'MJO\S^\/^%T?$'_ *'KQ+_X-[C_ .+H_P"%
MT?$'_H>O$O\ X-[C_P"+HHH]A2_D7W(/;5?YG]X?\+H^(/\ T/7B7_P;W'_Q
M='_"Z/B#_P!#UXE_\&]Q_P#%T44>PI?R+[D'MJO\S^\/^%T?$'_H>O$O_@WN
M/_BZ/^%T?$'_ *'KQ+_X-[C_ .+HHH]A2_D7W(/;5?YG]X?\+H^(/_0]>)?_
M  ;W'_Q='_"Z/B#_ -#UXE_\&]Q_\7111["E_(ON0>VJ_P S^\/^%T?$'_H>
MO$O_ (-[C_XNC_A='Q!_Z'KQ+_X-[C_XNBBCV%+^1?<@]M5_F?WA_P +H^(/
M_0]>)?\ P;W'_P 71_PNCX@_]#UXE_\ !O<?_%T44>PI?R+[D'MJO\S^\/\
MA='Q!_Z'KQ+_ .#>X_\ BZ/^%T?$'_H>O$O_ (-[C_XNBBCV%+^1?<@]M5_F
M?WA_PNCX@_\ 0]>)?_!O<?\ Q='_  NCX@_]#UXE_P#!O<?_ !=%%'L*7\B^
MY![:K_,_O#_A='Q!_P"AZ\2_^#>X_P#BZ/\ A='Q!_Z'KQ+_ .#>X_\ BZ**
M/84OY%]R#VU7^9_>'_"Z/B#_ -#UXE_\&]Q_\71_PNCX@_\ 0]>)?_!O<?\
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>^HW>J7K *UQ>SM-(0.@+,2:***V225D9-MN[/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>adag-20211231x20f008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &P F@# 2(  A$! Q$!_\0
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M8'43IXO(#?B,2FU$@\T(3@.5ZA201GIFOS*TOXM>(O!NI^.AX7^(']LV.O\
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MIY@, L;,6Q97,)MD*;AT;&,9X'/7BFS^%=-N[^"]GL;.:\MQB&ZDMD:6+O\
M*Y&5Y]#6Q10!2MM)@LXEBMXXX(@2VR--HR3DG XR3SFJ#>"]'?[=NTK33]N_
MX^O]"C_?_P#73CY_^!9K<HH R(/"^GVIB\FSM81&25V0*,9&#C XST/J!BD_
MX1/3/-M)?[/LO.M,BVD^RIN@!ZB,X^3_ (#BMBB@1B0>#M'MY+IX]+T]&NF#
M7#)9QJ9B#D%R!\W//.>:O2Z5#,R&1$?RVWIO0':PX!!/0^XJ[10,S_[!L5,>
MRTMT$;-(@6%1M<YW,,#@G)R1US52V\(:;9VEQ;6]A8P07!)FBBM(T24D8.]0
M,-^.:VZ* ,1_!NCO8&Q;2]/:R8*K6S6D?E,%QC*8P<8XR..U6K?P_8V;(;>T
MM[?9&(E,,*H50=$&.BCTZ5HT4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 44$@#)H!STZ>M  3BFKEAEACVIU%  !CI15
M6;5+:"9HGD"R*-Q4D9V]SCKCWZ5$NN64AC"3I)YA*IL8'>1U YY(]!0!?HJ"
MUOH;TR"&19/+8H^T@[6'4''?VJ>@ HHHH \N^-WQDTSX0_V#-K-Y8Z9IFHO=
M1/>W\WEHDD=L\D: ^KLH7^5>/:-^U5X]N3X'F3X:PZA:>*=!6\TZ.TU)1=7=
M[]B%TZQQL,+;J2(C(Y!W&O?/'OPWA\=:CHUU<.@33A=@0R1B17,]NT.<'NN[
M<*\-T?\ 8]\7>&]0@NM'^*MSI_V7PG!X3M@FE1.\$$4.SS(G9LQEI/WI"XRR
MKG@"D/0V+']HO7Q\$[OQ;J/A_3H=;T_Q)%X=NK6TNVGL9F-Y% \L$N 64>81
MT^\A':NZUSXU:9X2^+C^$M8GM[2VEL[26WD"2&0SSR3(HD8+L2,^2<$G.<@]
MJY&Q_9<U6']G>W^%\_C3=)975O<6.KPZ7%%]F$,R31KY*G:_SH268Y8L<YJA
MXH_9+UKX@Z3XJ3Q;X^EU;6]=TFWTL:M:Z;':M:>1=O<Q2HBL1N!<K0&AT1_;
M.^%:0O-)K=Q%;KIIU4S-83^6(1&9=N[9CS?*'F"+.\KR!@U7\:_M 7VJ:%X+
M;X:Z1#K6N>,FN'TI->,EA"EO;IOFEE!7S%R  JX!)8'I7%^,/V!]#\3:UKEU
M::M'I-EJ>EBP6W&G12S6LJVBVB21S$[E01J"8QC+9^;'%>K_ !0^"U[X[MO#
M5SHWB2?PGXE\.L_]GZU;P1W&U)(?*F1HG^5E=/R(4B@-#%@_:8\/Z!<:-I'C
M>UN_"?C&ZTXWUWI;VTEQ#:NL3RR1"Y1#&S;(I'"@[BHZ9XIL'[:'PKN=$&J1
M:OJ#V_VH6AC&CW9G!,*S>88O+WB$1.KF7&W##FN#UC]A9]7\3:5JUQX]U*_.
MG::-/C;5(1=7#$VLUO(_G%N _G&0H!C>.N,5KM^Q_J.FZV=;\.^/KS0->*PV
MRZE#91R-';+90VDJ*K' =A CJ_\ "PQ@B@=D;7BS]JWX36R>(8-9U1KNTTIU
MAO(WTN:X@E8RK%MB_=D3E9&16";MK$ ]:XWXY_M<R?!3Q[H.@6N@VT^AZEX5
MN=:MYI=\,B7"JYMK?R\?*'*A>@()QBK%G^PKIMEXEU35(]?^2ZU:'5X?,T^)
MKI)!>I=S++/]Z4.Z #[H4'D$@5TGQ[_9'T_X\^.-,\0ZCK$EB+&*TC6VBB#;
MO)NS<'YCS\X8H?SHU#0POA3^UIX$\1^'O"NJ>)#9:'XUU;2([N_:&QD,%JS(
M\JV[W>S:K%(V98V;)"].E+HG[;_@B[U#Q'=ZC<7-CX>MY[2+2YO[+N?M5UYE
ML9Y7>'9O6-%&[>0%"8.:R]/_ &"+2#2(] N_%MU<^&)UAGU+3DMD1KJ]AA>&
M&=9.2BA7RR8.2B\@9%5-7_8%G\16T,NL^._[8U>)H$2YO-&A>$0I:"T,?DD[
M2?+5"&/1@3@@XIBT/=?@K\19OB=I_B2\F@MXH],U^[TN!K=BZS11$;),GN0V
M>*])KSWX0?"2'X1:/JFF6E\U[;WVKW&J*701F(2[?W>!P0NW':O0J ?D%%%%
M @HHHH **** "BBB@#D_BO-96_PZ\0R:B66P6QF,[*9AA-AR?W/[W'KY?S8S
MCFOS<18(_AFEY?3_ &FRTGQ'K%QHVA2/K!T_Q CQ0B."QEC(G4(W"^:2"Y;J
M :_4V2,2 #.,'.15?^SXPX;<01TX''T]*0T['YC>/=3\;S:QXKO?#]IXGT[X
MI_VAJYO["'[2_P!ET$Z>GV:-1S&0KD!&4;BX;G->^?LZQ>)7\/\ Q);X2:E;
MV?A./6+5M"N?%,-W=0-"+%#>"(.PDP;C/))&X/Q7U^MFB]&..WK6'XQO;CPS
MX2U:]L--GUNZAM96ATVU*)+<$*2(T+$*"?<@4#N<S^SM\0-6^*7P:\)^*=;6
M"/4]2M6EN5M4*Q;P[)\H/('RYP?6O2J\5_8O8O\ LN_#UBI1C8.2C=5_?2<'
MZ5[50A/<****8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\Z^)_Q^
M\"_!J[L[?QGXCL_#[WRL]K]J60^: 0#C:I[D#G&<\5VGAW7[+Q1HMEJVG3K=
M:?>PI<6]P@(66-@"K#.#R#WH T:*** "F":-B '4D],&EDSY;8ZXKY7_ &L=
M&^/&I^#/$7_"%:GI!\/LT!^P:7:W"ZY]F#)]HV2K( 21O.U &*Y .Z@:U/J@
MRHIP6 /H:=N&,Y&/6OA#]E_P_P#'2"X\3'PQJNE67@AKB V2^+M-U+]XX7]_
M]ECN)3/$GW03(2I;)4=:^Y)')TIVP0?*/L1Q0#5BUO7GYAQUYIIGC R7 'J3
M7QMH/[07B[PAX?TRWDGCUC'A)+ZQA$8N;B:Y2'?,]XV_S8PN0X^7:ZJ1NW5=
MB^*WC#Q#XE\,6L?C[2)M)B\7KI#Z]8:=LM-3CDTUYA&RF0KE9#LX)!9D_B4@
MJX[,^NQ<Q$X$BG\:43QGHZ_G7R-+^T+XPO+2%I[S2O!R6.M6OA?6-3U2R,D,
M5^1<-<N@++\@6*#;DXS+R< U!;_M)?$"^O/!]K:V>E12:AIL-_)<7K1VT&JE
MKYX&,1ED5D7RD615C#MF5,C;U LS[ \Z/^^OYTGVF'./,7.,]:^=?BSJ>@R?
M&F#3/&WB?4?#?AV+P\+O2A;ZC+817%X;EUF??&07E1!#M0DXWL=IS7.^!_'7
MCJ;7(M!M_&>GWU[>>-M0TZ62]TWS)+*QBCDF50OF _.J+M+8 !.,TQ6/JPW,
M04L94"]=Q/%*)HR,AU(]0:^<-/FDOOV=?!]E<22O;ZIXCM["^9I&#&W?5F#J
M6SD @!?H<=*XGX4>.3:?$C2-3U;Q+>1W\T?B"7Q;975Z[6]AY-XJ69>$G;!A
M2JI@#<K$\]:5PL?8QE0+N+ #U- E0_QC\Z^0-9\7WGPZ^*7C>]LM:M_%NH7U
MKJ^HV8AU2YE&B"WA1D@N;0MY00L-JL IR<<YK3T_XQ?$CP[XKA@UG4=%U73H
M]=@T66&VTF2W>19M*:^$N_S&V[&41\ [@23SBBX['U6\\4:LSR*JJ-Q8G  ]
M?I38[N"90T<T<BD9!1@01ZU\@>&?BYXI^+WP_P!3TR\U.RNG\37FGZ+8I;6T
M=O/;QS1&2_9T21SM2(2A&.TD*#U-9>F?&77/AC'\5K&W,.F:;HFL7;:2EW;-
M.;M7U".!WB8LJA+="%\K(R64DA:+A8^U1-&1D."*5ID7JX'UKR7X&_$"Y\6^
M'M-&N:O87^NWPN+N&WMDCAD-DEP8D=XU=P& V;L'AF([5\C>&_'6OVGA_7?(
MUZ[N)+O3A*QM-:GNWMYX]<2-FG5_^/9WBD"*B'#*KYZ47"Q^B7GQXSO'YT">
M(D@2*2,9&>F>E?%GB3XA^(_A]X_U)+_4=130OAKK5QK6J%I'=;W2[]]EM&W]
M_P H22$=<>4..!7J'PHM-8\*?$'P;I&HWUQ?76I>"IK[59;IRY-PMW&\><GC
M;]JF0>R@= *8FCZ&X(]11P!Z"D3[BXZ8I)1F-^W!H$<G\2_B%'\-_#4FLOI.
MJZ]M=(8].T.T:ZNYY7.$54';U8X  R:\\\ _M&:QX@\3V.@^+?ACXL\ W>HL
M5L+F^MTN;.8A2VUYXB1$^ ?E< 'US6)^TC\.?&'C"XO]1TWQ9J>A:'INB/-'
M;:?JHL4FNE9G!GDVDJJXB??TVQNA!#5W?P@^-O@GXK0QZ7X>\::3XJUFRL8I
MK_\ LV0MV"M)C PI?./K2';0^9OVLQHC_&NXDT[[=!XJ?PYJ%GJTMO9W$LZ6
M4MC($NH]IVO!#A@\:[6:1UY)%>&Z%:&UT;PQ9:78Q?:K&;[+\/\ 4M+L[BVA
MO[Q-6B^T7<<;%MC209+[B055B.#7ZH_V;%NW #?G[^T;@.N,^GM0=.B/.!Q]
MWY1\O&./2@:9\._LFWOB3P]X4\97OP\TVQN9H=.TM]7M]?EN+>$ZPL<YU EM
MK-YN!%NP,$D9Q7V9\.O$TOC7X?\ AGQ#/ EK/JVF6U])!&25C:2)7*@GD@$X
MJ3Q-;);>&=:9<9-G<,<*!SY;>E8?P'_Y(?\ #W_L7K#_ -)TH$]3N:***8@H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KE?'GCW1O!>D3
M3:IJNGZ5(T<K6XU*[2V28HA<@,Q]!DG!P.<5U5<'\2/A+X<^)<UA+XDTJ'5H
MK EH(9P"BDO&^[D'G,:_4;@>": /*='\0_M$:YIMMKVF1?"K4-'NHUN8-,M[
MR^=I8F&5"W8&PDCD,$VU] Z#-<W&F6\M[ MK>/&CSVZ.'6&0J"R!A]X Y&>]
M?+O@?XT2>"_C7<_!ZP?PYHVBZ%?V]C;6UVUS-?7<<X68LC1IY4>&F9 C$8P.
MQ%?6*1)%G:H7/6D-F-XUU>X\/^%M3U.UB@FGL[>2X6.YE,41*J6^=P#M7CDX
M.!VKY2TC]MW6/$>A1OHOA/2=4U?=K-Q(8=5D^PS6>FQQO+-#(8]Y9S*$4,B\
MJ23BOK3Q1I#:_H%]IR75U8/=1-$+NQD$<\!(QYB,<@,.HX-?/DG[#OABZMY)
MY/$'B2/Q%=7%W+J/B"*ZC2ZU".Z18[B&0!-BQO&B+\J@C&0<T!H<->_M^BR\
M.'Q<?!OF>"+B>ZTZPN5OL7DEY!9K<8>/;L6-MQ0,&)RI)&,5Z7X:_:>L+'1O
M&L'Q+AL/!>H>';VWTV=K>>2[MI6N;47$)1@@;)5B""."IJK<_L-^ ;ZXOX[@
MZJV@7(G>+PZ+K%E9SS0+!+<0X&\2&- !EB%.2!DUWWPY^$FE?!KP]XC=]4OM
M9U+5G-WJ6MZW,CS7#I"(H]Q 555(T50 !T]2:!Z&-^Q<ZR_LN?#UT.Y&L&93
MZ@S28->U5XM^QCS^S#\/SZV3_P#HZ2O::$)[A1113$%%%% !1110 4444 %%
M%% !1110 4444 %%%% '@_[8RJWPZ\,94'_BM?#PY&?^8A#7O  7( P >@KY
M8_;'\:WNIW>A^ O#6AW'B/Q%;7^G>*KJ"*>*!(+2UNT?;OD8!I92C+'&,EB#
M7T!\,O'FF_%#P'HOBS2))9-,UBV2[@\Y-DB*P^XR]F4@@CU!H#H=/1110 48
M [4V4XC;KT[5X9\9/VKO"?PBCUN.Z&JWNJZ9!O\ L<&G7 BD<J"J_:/+,8!R
M,MGCZU,I*.K)E*,%>3LCW7J<]Z*^5?@K^WKX5^).CO/KFFZGX<U%;CR/LMM:
M7&H1-G&UA+%$0,YY#8Q]*^I0QDMP5;!8<,>U*,U)70H3C47-!W0T6,"W!G2"
M%9F3RS((QN*]AGT]J9'I=K';+;BUMQ A#)$(@$4YSD#H.>:^='_:MO+CPG\0
M-4L]'M?M.AW-NVDI+=,8]0LI[HVJ7#D#*?O$D.T9X"\\UJZK\>?%&E:M-X6N
M-#TV'Q>=7CTZ%_MKFP:V>UDN?MC';O 5(9 8L;MR@ X.:JYI9GI2_"30%CB3
M[*9%CUB77@99&<M=N&#.V>HP[+@\  #M75#3()/(,\$$K0-NA+1@^6<8RO''
M''%>)77QRUVU\-^$M9L;?1/$=AJVOP:)>ZCIVH2?9X!+<K K1HR;F?YB2C$;
M2""3Q6IXD^-6I^$/&WB_3=9TF*WT/1/#;^(8+ZWN3)/=(DA1PT>T",9'')/&
M3Z4!9GKMY8Q7OE^;%%+Y;;T\V,/M8=&&>A]Z>EI#'*\JPQK(Y!9P@#,<8R3W
M->.> ?CH-=^&7B7Q5J5QI\T^AVSW=WI^G"</:A;?SO*D\Y%9F(Z.%"L,$"N6
M'[0_BO3I;>6\TFPGTZPET2SUF=9F287&I*A'DQ@%=L7FQ@[CEMQQC% 6/>?%
M7A33O&7A^[T;4X!-87.TNB,4.5=74@K@@AE!R/2KL&G0Q/-(88?-F(\V01C,
M@ XW<<XKR'QW\:-3\'_&/0?"4D-C9:)J%I%+)K&HK<!#.]PT0MD=$,:R$ ,/
M,9<D@=ZI+^UMX/VAOL?B-H6CFN!<#2G\LP0W'V>><'/^KCE(!)Y.1M!%.X69
M[=%800SS3+!"LLW$DBQ@-)CIN/?\:BU?1[36]+N]/NX(YK6ZC:&:-UX=&4JP
MXYY!(KSJ+X\>'KOQ7<:&IU)&MOMIEOC; 6O^B!3<C=NR-F]0"5 8G@D UQGP
MY_:%U#4?$FGZ3XH7[/>:QI5KK-A96EJSS00SO<L3/C[L<444(9R!\SXZL!0%
MF=[X4^ OA7P7X@@UO3[.6XU6W188;Z_NI;B>*()Y:QJS$X54RH&. 3ZFNG\:
M^!M,\>Z*^DZK$S63NDO[B0Q2+(CAT=77!5@RJ<CTYS7-?#[XS:/\3;G48=)A
MU.%[.&UG<WT B5H[A2\3)ACG<JEL<$<9P:X;Q)^T7>Z#\=X?  MM/>VGO+"S
M61YI5N0+B"24S#Y?+VH8PNTL"=W'/!0:W/4/!7PMT#P%>SW>E686\N$9;B^N
M)&FN9RTAD8O(Q))+L6/J<>@KJDM((PX2") YRVU -Q]3ZU\MW'[8.I67PXFU
M^7P]#+JUSI-OJ6EZ9!<L1=%KN6WE3<5R"GE!^!R&YQ7=#XY7]_JMI>V$,#^$
MQK]AHC7F=TD_VFV5MP'\)2:6%>^06Z8H"S/;7AC<,&C1@PPV5!S]:R;/PQ9V
MGB"ZUL1 ZE<6L=H\Q))\M&9E4#H!EV/ Y_"M:+<0=PP<GC.:=3$ HHHH X?X
MVM&OPB\;^9##<1G0;_=%.Q6-Q]G?Y6(Y"GN1VKYU_80^(9\7L;'_ (6YX7\?
MBTT&V/\ 9&C^'_[/N['&Q=TTG_+3'W,8'/-?3'Q0U"ZT?P!XDU&RB@FO;+3+
MJY@2[8"%I$B9E$A/ 7(&<\8KYO\ V)/BI)\1M=U%IOBMH7CN8Z1%<R:3I?A,
M:1+8LS+DM)_RT )V;?8&D4MCHOV@OVA_%7P7\>2VW]DZ/=^'KG2+N\L&>:5;
MN6YABW8<X\M8RY1-@)D(+,.%-<#)^V1XSTJYNK?5=!\/F;PM=&/Q8;:2?:T3
M7T=K&UEG^+$GF$2=ABO:/BC^R]I/Q9\87NK:UK>LMI=U:M&VAQSJ+6.Y\EX$
MNTR"RR+'(X !VDX8@FN;M/V)O#T9T=[OQ%KNH30W#W.M23O$/^$@)N%N56Z
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M73+&*/\ T:)(XF))$/RJ2>IP.I/KWJR+:,9P.O7FBPKZW1\7P_LW^+=;\,^
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M189[&"0YF8@.@QMCS'D[J^Q/A3\ O#7PNFNM4076O>++\ ZAXGUB7S[ZY;N
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MH#YTF<>U>U5XK^Q<Q?\ 9=^'K%60M8.=KC!7]])P?<5[530GN%%%%,04444
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M_&O$/A3\$_#/A/XVQV^@&Y\0Z5HM^=9M].CMXI-1DDP?*::Y($LD2,Q94.T
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M+B,EQ/H_B1;2#<3DGR3%CDGN"?>KFO>!OBIK>E?8KJVTW7K,\BW\2&WO0/\
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MCZ[DHF^/_P .E!?_ (3/22X_Y8I<9D/T0?,?RJKP>[O\S;]TOBE?U9Z);PK
M6/W<]C4OG)_>%>9?\+RM+^/S-"\/^(/$BYX^P::ZH???)M7]:KR77Q)\6,CV
MUE8>";!SDF\(O+\C_=0^4O'J6K3VBZ:FGM8O;4]7!!Z'-%5=-22.T199/.D
MPS@8W'UQ5JM#4**** "BBB@ HHHH **** "BBB@"&ZO(K.-I)G6.-%+L[D*J
MJ.I)/ 'N:\"_:R^-WAWPE^SQXDUR&"S\8V5P4TC[';7W[F62X81A9)8F)11G
M)((/'O7;_M)^$-:\>_ OQWX?\/1&?6=1TB:WM8ED$9D<C[FXX W $<^M?./@
MK]GO4/BCX9^*]O+HMW\*O#'BBXTW[+I%SI=L\LJVMGY4Y-N=RQ[I=N'&&)0,
M.M)CZ'G7[)'[87B6R^%$/@30?A)K7C/7?"X6VB?1I?+M3"[,R-/)(,QG[P
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M/#QE\;NC,TS]FO7M-C>!?B[XBAQP!8Z=86Y_,1$UXWX-_8#\3:-\;[GQ9?\
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MZ?''-%-<RND\,0VXR%4$!@2":/:)ZB]HDKV/J995)/S X]*DKS;X%ZI?:[X
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MX_XP_$"+X5_##Q)XNFM3>QZ19M<FW#A!(1@ %CPHR1DGH,FNP4[@#ZUC>,]
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M?A[^S7)X)?QO<7WCC6?$6J>);9+!=3N56*YL;6,2^2B.G+NAG8^:WS'"YZ4
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MC,<;<G(X/&>:^\'DB0N'(3UW\41/#&"%<>O+9K)TTY*1A*E&<XSENB1=VXY
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ML_,3X5_ /Q/=:%8Z=K?AK6S VM^'+77=/N-*^QV]Q+#/,;N<D2,UQA6 >Y(
MD5AZ&O3/V?\ X47?@;XQ_"6_UGP/J,4%MI_B+2[:Z-D9%TZ0ZD9+3>W_ "R3
M[.9 C=,/@=:^[Z7-*P7$HHHIDA1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4448W<>M
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M\6-:_9O_ &B;'X.07%WXF:YT;P]H^EVFI7C):Q7+_:'O;N25@?G8(2%^\[8
MZ<>G?!G]K[6OC'\:9?!]AX1L[?1(#J!N[];]Y;FQ%M,84%Q&(@B/,PW*N\_*
M#Z4 ?4-% YHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWA[7=&\/7/AK0M7621VTVUGC2*0A0PW.$1<,3D$ US%_K/B[]GCP(WB;Q/\
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M&&&7V5>7^*5K_<K1];]S3HHHKH/+"BBB@ HHHH **** "BBB@ HHHH ****
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M3A=W&[.>:I_M(?"_PIX9U3X&7VG:!86^I67C31M*M[\6ZFYCM$214A\S&XJ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV?3M0!]3T5\RV'A_]JF5O#PO/&_@2W%S S:L4T*1_L,NP%4B_>CS@6)&[Y<
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+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>adag-20211231x20f009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &X ST# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHJA:>(-+O[Z6RMM2M+B\BSYEO%.CR)CKE0<B@"_1110 45QGQ0^+&
MB?"33]'O==%T8=5U6UT>W^R1"0^?.^R/<,C"YZGMZ5V>?\* "BC/X_2N>\=>
M/=$^&_A]M:\07ALM/6>&V\P1M(3)+(L<:A5!.2S*/QH Z&BD!]:7GT/Y4 %%
M&?P^M&?P^M !16!XZ\=Z%\-?"]_XB\2:C%I6CV*>9-<RY..P"@<LQ. %&220
M!7E.E?M>>&Y]9TFTUSPKXS\%V&KSI;:?K7B713:6-Q(_"*9-Y,18XQY@7.:
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M/ ,FSJ$SQD\5RVG?M$_#'5M7GTNS\?>'KG48+A;1[:/4(R_G,VQ4 S\QW87
MSSQ7S5X8TGQ)X&TSXO\ PVU*Z.I_%3Q%I$^L:+XK:(Q2ZY 8=OE+SA&@;Y1&
MIP%=6 ZFN8^(7C_X8Z[\+/V>] \/S:?-XCTS7]#C&G6T8^U:6R.BW"S@#,1W
M94AL;F/?K0!^@%<QXS^*'A'X=A3XG\3:5X?W0R7"C4;M(2T:8WL QY R,X]1
M6EI/BK1]<U35M-T_4K:\O]*E6&^MX9 SVSNNY5<=B5Y'M7AWQ1TJQU3]L'X0
M?;;2"[\C2-8GB$\8<)(%BPX!Z$9X/:@#UC2_B]X(UGP?%XKM/%VB2^&9&V+J
MYOXUMMV<;3(Q #9XP>:-(^,'@3Q#J$6GZ3XU\.ZK?RY\NTL=6@FF? R=J*Y)
MX]!7S;\+O"FIZYK?[0>B>'-/\,W4@\90RQV7B>R:YT\9M8F<F)/XB><COS7?
M_#SX2^._#7BZRU+4_#OPDL[.#<7F\.:#-;WR_*0/+D8X7GK[9H YG4?VH_'*
M>'M>^(EGX=\.M\,]%U:739X)[Z9=9E2*80RRJ,>2K;LE8V.X@#ID5['<?$Z?
M2?BSH_AC4K:"+2?$%BT^CWR%A(UQ&-\L$JG@$QD,N/[K@]J^+=4L? -Y\.?%
MGB?5_$SVOQTCURYN8]!^U;9!J$=PRVD"Z9CRYE=%B^<Q,6#;MWI]*?'6YO+[
M4?@0+B-(/$$WBJRF>!.L9%O(UP!WVA=X- 'T%1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 'XG\Z*** "O+?VA/&VL>!O"5I=Z7K_A[PE!-=I#?:_P"(I5$5C ?O
M/'$Q ED[!,C\:]2KRGXX?!S4/B5J'A+6]%U:ST[7/#-\;VUCU6S-W93%E*LL
MD892#@\,IR#0!X-X)^.7B+XG6/Q>\%0>.++Q7;:5H/V_3_%<6A&T:175@\;0
MDJCCT=0!SWKW/]E"RU*Q_9^\%+J6I)J4CZ="\3I;"#RXRHVQX!.XC^]W]*P/
M"W[.?B"S\=>-/%7B+QE#K-_XJT0:3<0V^F^1%:8)V^2-Y.P GAB23W[5WGP-
M\#>(/AK\.=,\,^(-7L-;FTQ!;6UW86C6P:!1A-Z,[?/CJ0<>U 'D/[/G@;PY
MXJ\;?&R36?#^E:NX\5NFZ_L8ISM\E.,NIX]J\^U+PCK=BG[0/PJ^'6EK>::\
M5I<:=HD$J016CW _?QQEB%1"!G';)P*]3M/@'\4_"?B_QEJ7@WXDZ!HVF^)-
M3;4GMM0\,->30,45<"3[2@/W>ZUKV/[+L-K\._$>CR^+=6F\6Z_=KJ-_XMC"
MP7+W28,;!$(41K@ 1YQC()H \Y\!6M[\)?%VE>#]7^%?@WP=K.O:5-:^'_$7
MA4+(ZSQP\P7+F)&WD#.Y<J2#7C6O>+?"_A#]G&#PXGA+4[#XMZ!J$=Y?W$NB
MRI+;W8N,O=M>% C*X/!#DL#C%?6NA?!/Q1KOCC2?%'Q%\46.NW.AV\MOI=GH
MM@]E CR+L>XDW2.S2%>!@@+FL(?LW^+]7L+'PEXC\?KK/P^L=0%^EM)9.VIW
M2K)YD=O/<O(RF-6[A=Q  XH ]FUG6M1M/ MQJEC#:2ZHECY\45]/Y$'F;,_O
M'_A7/4^E?)OAC]IOQ%:_$_P)I1^*'AOXA#Q!??8-6TC1-(*VVF.RDY@O$RK[
M3QAR2W4 5]4_%'P#!\3OAYKOA2>ZDL(=4M6MC<0J"T>>AVG@CV/45XU%^S=X
MXUB\^'\VO>-]'6U\%WL-Q9Z;HNAFVM[E47:6ES*Q#E>FW"@]C0!4OOVD=?\
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M/?G2[9OOW'V=.9,>G0=33_"OPY^)S>)-%O/%WQ$MKO2='4A-/T#36LO[2?&
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M4/M'0UZJ#D4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/J:NW$"74#PR('CD4JRL,@@C!!H XWX/26%S\'/!4NF;?[/.A61M]O0)]G3
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M@0 #WP*^IYK2"Y>%Y88Y7A;?&SH&*-C&03T/N*$L[>.YDN$@B6XD 5Y50!V
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 >'_ +57PAUGXR>'/"FE6, U
M71+;7H+G7-".HR:?_:%EM9&'GI\P,;.LH4?>V8R*\PL?V/1\,?B7\,]3\+03
M7MWIVJW.J>(OB!JVJ,M[)9A66.PD0D^:&1T0$X"B#)Y:OK^OE;_@H])IUO\
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M>0_8K,\J@"C'3@=J]9KS/X,?\ASXI_\ 8W2_^D-E7IE !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17F7BZ;QMI6
MOZ9!:>(].2UU2]-O$CZ5N:!=K,,GS/F^[CM7?:%;:A::9%%JE[%J%Z,[[B&#
MR5;GC"9../>@"_1110!G>(-%3Q!IDEF]W>62N0?.L9S#*,'/##I7GGPT\*O<
M:GJUW<:]KUTVF:K);Q13ZB[Q,BJA =<?-]XUZH>E<1\+_O\ BW_L.3?^@1T
M=O1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M444 %%%% !1110 4444 %%%% !1110!Q7C[_ )&3P1_V%3_Z)>NU'2N)\?\
M_(Q^"/\ L*G_ -$O7;#I0 4444 !Z5Q'PO\ O^+?^PY-_P"@1UVLLJ0Q/)(P
M1%&69C@ >I->>?"'7M-U.?Q9'9W]M=2'6)9@L,JL2A1 &P.V01GVH ]%HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "J6M_\@:^_ZX2?^@FKM4M;_P"0-??]
M<)/_ $$T <=\!O\ DD?AS_KBW_H;5WU<#\!O^21^'/\ KBW_ *&U=]0 $XKP
M+]K'P-XC^+_P]TZU^',&AZQXMT'Q#:ZC;OJ-Z$BLIH"Q+, &#-G"F-Q@ACT(
M%>^D9%?/WQ;_ &*_!7Q+\17GBC2=1USX>^,+LAKG7/"5\UI)<GUFC'R2$_WB
M,^] '._#Z]_:P;QCH4?B_P +?#>W\-FZC&IW.F7,QN5@_C:-3QN]!7TS8:G:
M:FLIL[J"[6&0PR&"17"..JG!.",C@\\U\G:=_P $^Y+JZ5/$_P <?B7XFTDY
M\W3'U8V\<PQ]UV4EL>H&,U])_#?X9>&/A%X4M?#?A'1[?1-&MR66WMP?F<_>
M=V.2[G'+,230!C?'_P"%;?&[X.^*? R:D-(;6[7[,+XP^<(?G5L[,C/W>F1U
MK'U']F3P#XQ\">#?#OCGPYIOC(^&=-BT^VN+^ X&V)$=E7/R[O+4XR>@KUFB
M@#Y=^%?[ W@7X<:O\3+B2VL[NS\6+/9V4%K:&"32+"9"DEM$Y9L@Y4YP.5'%
M9?PJ_8BUWPEXO\!7/B[XCOXN\,?#WS3X7TA-,6U>%FX5YY0Q\PH,8&.PZ#BO
MK:B@#X_\=?L(:OKNO^.K+P[\2)?#OP\\>:@FH^(_#_\ 9B33O(&W.L$Y8>6K
MGKQQ[@5]8:%H5EX:T'3]'T^'R-/T^VCM+>+.=D:*%5?P %:%!Z&@#S/X,?\
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M2(=K*U[$"I]"-U:EI>07]ND]M/'<0.,K+$X=6'L1P: )JP/&?B72?#VC7/\
M:FJ66FB:*18_MEPD6\[3P-Q&3]*WZ^-O^"CBJ_AWPAD!O]*EZC/\- 'NO[/7
MBW0]0^''A_3+76=/N=12!V>TAND>91O;DH#D?E7JE?FW^P.BCX[!@H!_LZ;G
M'TK])* "O&?VJ/C#KGP@\!Z2WA:TL;CQ1XCUJU\/Z7+JC%;2VGG8@33'C*J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&>?FP<?E7#^ [;Q?HFI7\=]X?LHK/4=0>\DGCU,.T(95& NSYL;?4=:](HH
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MVOA?XA_"C3H1YQ6>\:6>0 O-(8LL['N2>:]L1%10% 4>@&*\M^)/_)8/A?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU.\U#P;X)TCP[>WEO]EN)K&':TL6X-L;).1D X]J/ O[-WPP^&7BN\\3>%?
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MVKHY*595)RBI)V[?+S\[&K10IR >E%;'6%%%% !1110 4444 %%%% !1110
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M=:ZM;(!UQM<28SG@/7"^)=0T?Q-XKTS7IOCY?Q76DW$UQIJIX6!%MYBE"O\
MJOG&P[?F^M>M^%_C[X'T?0K.SU7QRVNZA$F)=1DTJ>!ISDG<42+:O! X]*PA
M0DFW=_@>;A\%[*I.2;5_3]//]")?BOXJT-534$T#4\$!FG2]TB7'^Z\4J9_X
M&!5VQ_:,TSS5CU+P_K%G@9>XM!#?P+^,+L_YH*O_ /#2GPYQC_A)/_)*Z_\
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M/K7;?\-%_#[_ *&#_P D;G_XU0JD'U'&M3FE)25F>D45YO\ \-%?#[_H8/\
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M3X>:[X4\-^,I98/#7B._FB>+4'0G :->8]V.,D_ES7U50 <^I_.CGU/YT44
M'/J?SKBT\(7Z_&*3Q.7B_LTZ)_9X7S#YGF^>),XQC&T=<UQW[2O[5'@_]F3P
MHVHZ[<)?:U.A.GZ#!*%N;QAQQP=B#NY&![GBH?B5^TS:?#7]G2P^*]QH-Q?Q
M7MM93QZ/!<*LI:Y*!4#D8)&_KCG% 'M?/J?SHY]3^=>*_ GX]>+?BUK=_9>(
M?A!XE^'-K;VPN(K[6W5H[ABP'EKA1S@Y^@KVJ@ Y]3^='/J?SHI'8(I). .]
M "G.#R?SKBOA=X1U#P?8:[#?/$SWNM7E_%Y4A8"*1P4!XX.!R*^?/%'_  4
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M_F:^8_$G[:<_AWX.^!?&G_"MM:NM5\7W?V6P\-17*?:CP2K [?FR!D#%>E_
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MT[ZY^M<+X6^!'PZ\$>*+GQ'X?\#Z!HVO7&[S-1L=/CBF.[[V& XSWQC-=U0
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MK%\5>"= \<6<%IXAT:QUNV@F6XBAOX%E1)%.5<!NC ]#0!\>?M(?"2/X9_\
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M^E^#673M+T&X$.YGNYV<><2020!GJ!6U:?&/QIX<\$_LV?%_6_%6I3:#??\
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MQ&NX-)&"-KYSW-?HCX7\.2>!OAI;Z4NL:IK,EE9.!J.K7'G7<AVE@7? R1G
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MX2_MM7WPZ'COQ-XL\-W_ (>.J21>)+XW;K<;CED) V#CHH P<4 ?9U% Z44
M%%%% !1110 4444 %9GB;Q#9>%- U#5]0E$%E90//+(W0*HS6G7SG^VII'C_
M ,7^ 8/#7@KP_<ZI;WC&34KJ":*,1Q)SL^=U)R>N.PJX14I),F3LKGG?[)G[
M4MYX]^+WB?1M>O&^SZW,UUI,4K<0[>/*7ZJ <>M?: .:_''X2>#?&^N^.X6\
M%Z5<:AKVCRBZ,4$L<;)L?!R691UXX-?KWX8O[[5/#^GW>IV#Z7J$T"M<6<C*
MS0R8^9<J2#SGH:Z,3",9)Q,*$G):FG1117(=(4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!YY\</@1X6_:#\*6_A[Q:EX^G072
M7B?8;HV\@D4'!W#GN:\^\!_L)?"CP#XNT_Q-%8:MKFL:>XDLY=?U::^6W<=&
M5'.W([$@XKZ$HH \&\5_L5_#CQ?XRU[Q#=?V[9MX@51K.FZ=K$UM9:B0, S1
M(1N_, ^G6O-_VE/@GKVF?L\V'P.^&G@34/%&D7Z^5%JM]J<0CTD"82!I"^';
M&25QG&/PK[!HP#VH \=L?V8?!^H_L_Z%\*_$6FI?Z/86<,;>1(T;+<+\S31N
M,,K;RS T?#C]ECPC\./&D/BU=0\1>)?$=M:FRM-0\2ZO)?/:0'@I$&P%!'&<
M9KV*B@#YO_;K^$7B#XT?"_0M"\/Z,VMR)KUI<7=LLJ1XMU;]X268<8]#FNC^
M&O[(/P^^&/C,>*K&/6-6U>*V-G9OKVJ2WZV$!&#% )"=BXX[\<5[:1FB@#YQ
MU#]@3X3ZAJ]U/]GUVVT:\O/M]UX9MM9GCTF>?.=[6P..O. 0*Z;QW^R7X'\;
M>)[;Q';2ZWX0UZ&S73CJ'A74Y-/DEME&%B<+D,H' XR*]HHH \3OOV//AK??
M!O\ X5G_ &;>0>'3=?;C-%>O]L-SNW>>9SEBY(ZG\J]%\$?#ZQ\">"+3PO:7
MFI:A8VT30BXU2[:YN7#9SOE;ECS73T4 >(#]CKX=#X8Z?X"\C4_^$?L=6_MJ
M%/MS>:+G?OR7QDKGM78:G\#_  OK'Q7TGXB74-R_B/3+"338#YY\CR7&&#1X
MP3SUKOZ* /G&]_8#^$][K%Q<&WUV#1[F\^WS^&8-9G3299\YWM; XZ]@<5U?
MQ2_91\"?%75])UBZ75?#VMZ7;?8K75/#6HR:?<);XQY)9.J8XQCBO8Z* /#[
MC]C/X73_  ?/PV&CW$/A\W/VXSQ7CB\-UG/GF?[QDR.IX]J3P/\ L=?#[P%X
MMM/%%D=<O_$4%E+8/J6JZM+=S3Q2+M/F,^<X7A<8 ["O<:* /GZ;]ASX9-X&
MT3PQ;1ZUI\6B:A+J>G:E9:F\5]:SR'+E)@.A]"*VO!'[)'P^\ W?BBXL(-3N
MW\3V7V'6/[3U&2Z^V+SEW+Y.\YY8'\*]GHH ^>-&_86^&^C>#[7PP+CQ)>:-
M9ZG#JMK;WFLR2BVEBSL6/(PJ?,<J!SWK7^)G['?P_P#B?XNN_$UR^N:!K5_#
M]GU"Y\.:M+8?;XO[DX3AQCCUKW"B@#QV^_9,^&]UX5\%^'(-(FT[2/"-\NHZ
M9!97+1XG /SR-R9"<DG/6NF/P4\-'XQ#XF^7=?\ "4#3SIF_[0?)\G)./+Z9
MYZUWE%  !BBBB@ HHHH ***R[OQ7HNGW#P76L:?;3IPT4UU&C+]03D4 :E%4
M=.UW3=8+BPU"UO2G+"VG23;]=I.*O9H *J:N!_95[Q_RP?\ ]!-6Z@OH3=64
M\*D!I(V0$],D8H _/O\ 8%Y^//BW_KUG_P#1U?H77R[^S1^RMXC^"OQ)UOQ%
MJVKZ7?6E]#)''%9^9O4M)N&=R@=*^HLUO6DI3NC&DG&-F%%9U_XDTG2IQ#>Z
MI96<Q&[R[BY2-L>N"0:LV.H6NIP">SN8;J$\"2"0.I_$$BL#8L449%% !14,
M-[;W$LL44\4LD)VR(C@E#Z$#I^-34 %%0W5Y;V48>XGC@0L$#2N%!)Z#)[TL
M-W!<22I%-'*\3;9%1P2A]"!T/UH EHHHS0 449HS0 449S10 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7R?^W%\#?AY-\(O%GB^3P3H,GBF1H&?6
M6L(S=,?,5<F3&>G'TKZPKS?]H?X9ZC\7OA/K'A;2KFVM+V]\O9->%A&NUPQS
MM!/0>E 'GVO:9X6_9>\,>'-3\ >!O#FBW7B#5-.TN^:TLA 9(Y6 +$QX)89R
M,\5U/Q%^,NJ>#?'U_H-K8V<]M;>%[O75DFW[S+$ZJJ'!QM(//?WJ?X[_  CU
MCXE_#?3M+T+4;33_ !#I-W::C8RWJ,UL\T#!@DF/F"MC&1R,]*XD?!3XF^,O
M%VL>)_&&H^&[6YO_  Q<Z'#I>D-/)#:22,"&\UU#2 XR3M&.  >M '*P_M*?
M%^U\-_#KQ1>^&/"D^G>-I(;*TTJWGN$N;6>528Y9)6)1DR,E%7(!ZDUM:K^T
MMXV^&]WXK\.^+M%T/6?%=C]B_LDZ"TT%M=O=.8XTD$I9DVL,D@G([5TEW^S]
MKEQX#^#>AKJ%@+GP7?V=W?2$OLF6%<,(OESD]MV*K?%3]FG5?B+XY\5Z];ZS
M;:7)>6=@=*FV,[V]Y:RF16D7 !C)(! .<9H FC^,'C[X?^---\._$.U\.7)U
MVRN9M+O_  ^D\4<=S#&9&MYDE9BP(!PZD9QR!5[]FCXF_$'XR>&;/QAXBL?#
M^D^'-0A?[)9V G:[#K(5+L[,4V-@X4#(]36;;?"'XA_$3QEIOB/XCR^&[!M"
MLKF#2].\/33SQRW,T9C:XF>5$*@ \1J#C/+&N_\ V?OAS?\ PE^#WAKPEJEQ
M;7=_ID+QRS6A8Q,3(SC;N /1AU% 'S;\:H_ #?M8ZTWCSX;WOQ%M5\,VQMX+
M/P\=7-L?-;+%0/D!'&:H_!/7_#7A;Q3XU^+7@'PG=^!_@[I^BR17EA)$MJNH
MW\;9W1VH8^44^Z6(4G/2OIS2OAKJ-A\>==\</<V[:9?Z+!IL=NI;SED20L6/
M&-N#ZYKAO$/[,D][XY\9OINH6]KX(\<:>\.NZ2=PDCO0,)=08!7)X# XSB@#
MAM'_ &QM2L9_#>K:YK_PWU31]:NH;>30O#NK^;JVFB8XC9LR%9BN1O"JN.<=
M*Z^R^+_Q8^(":_XA\">'_#D_AG2=0EL+?3=3>;^T-5\I@LK1R*PCAYR%#!LX
MY(JMX1^$'Q8LI/#VB:BW@+3-&T>2,3^(=*L#+J6I0QX"H898?+A9@!N<.WMB
MI8?A!\6O D7B#PQX%UGP[#X4UF^EO8-6U!YTU+2/.;=*L<:(4FYR5)9,9YS0
M!P'@_P 1?$ZR^)'QTO\ P9I7AZUCM;^"_O%\1-*[.XM0QMT\D@*0,@N21GH*
M]+U;X\>*M8^'W@KQ)HD/A?PGIFM6/VO4-=\7WX6RL'QCR50.C2,S X.0 .M;
MOP\^"FL^#G^)OVW5H=3;Q0Z-;7,A;S?EMO*+3<8W%OF.W/6O-I?V8?&6@'X;
MW^GVG@_Q?>>&M(DTN?3?$S3"TB=GW"YMV6)_G'0@J"1T(H XGQC\<KSXU_!F
M[74QHUS?:!XWT[3WU'P_,TEA>KYJLLL6XD@8ZC)Y[UO7/QKB^"GBCXLW$7]G
M+JNL>,(-.L9-8NA;644C0 F2>3^%%&2>YZ5J6/[)?C-/#OBBRO\ 7=#NK[6?
M%%CXA$UM#);PQK$09(1'@XQC"\G/?%;GC']EC6O$6I>*M:M=3TJ+6Y/$D/B+
M0_MD+3VZLD00Q7*$<JPR#MSCK0!6\+?M4WXUS5_#NI:WX'\8:DFBW&KV&H^#
M;XR09A4EX9XC([*>X8-R,\"H=!_:)^)EM9?#7Q/XGT7PS#X5\8W4%B;'37N&
MOK-Y0=DAD8[&4D<H%X!^\:ZC1/A=\2-?77Y?$<?@WPO;W6DS:?:Z-X9@,R23
M.I'GS7+PHX SPB#'J33M8_9^UR_^&OPI\.QW^GK=^$M0LKN\E8OY<JPCYA'\
MN<GMG% '+ZY^T#\4M0\&>,?'_A?0?#)\(:%-<V\&GZH\_P!OO1 =LDWF(VQ!
MNSA""2!U%)XB_:NU"?7-'\/:;K/@;P?J#Z):ZQJ&I>,KXQV^Z905A@B$B,YZ
MDL6X'8UXWXX\8RZ#\-OB=X0\)_$/PU;:#-?W41TC7K:6/Q%;W$KY:VAM\@2J
M['Y),=#T->SVOP)\8Z'>>'O&7A33_#.KZC=>'K+3-7\/^+4:.,-%&-DD4R1R
M,KKD@J5P?44 >E?LZ_&^'XV^%M2NG_LW^U-(OY-.OFT>[%U9RNO(DAD'5&!R
M >1TYKU>N$^#OA#Q'X1\,2Q^*M1TV_UFZN'N)$T>Q2UM+93]V&,!0SJH_C?Y
MC[5W= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 9D_A?1[G5X]5ETJQEU2(82]>UC:
E=!Z!R-P_.M.BB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>adag-20211231x20f010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %  Q$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZAK>GZ2]L
ME[?6UFUS((8!<3+&97/15W$;C[#FK<K%(V(Z@5\!_ W]GOPC^USK'Q3\>?%9
M)/$>JIXFO-'T^#^T9X5TJWMSL0(B.H4\YYZX)P,F@#[^W"C</6OB[Q1^S)X(
MU?\ 96NX_$'BK_A;5SX,T[4O[$U^.]:,V@\L,L)\B8K(4**!O)(&!@"O/)_@
M?X,\ _\ !.C6O&NA:3)9>)?$/@FWDU*^^VSR&=F".3L=RJ_-S\H% 'Z*9S2;
MA7G7[.CY^ ?P[R=Q_P"$?L>IR3^X6OSQ_:D^(%QXH^/OC?XFZ=XFMK"?X37V
MF6&DZ2;R-6U!Q-ONR(V8EBN2IVJ<[0#TY /U4SQ2;A7BWB/]L+X5^#+CPU::
M[XD-E>>(;*"_L(XK"YN$EBFP$/F1QLHY..2/>OAK]J?XJ?\ "U?C1X'\6_\
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M7@:V^&_@/P_X5LKF>[L]&L8;"&>Z(\QTC0*&;: ,X'8 5TM% 'F7@+X ^'_
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M@<@YXH^,?[+_ (J\7^);B+P]>Z6- U_1=-T75Y]0>07-K'9S-(LD*JN'9P[
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M "BBB@ HHHH *:R!B#@?B*=29H ;Y8QC Q2[12Y'K10 GECT [T;/7%+FC-
M&;XC4+X?U,@8/V:3I_NFO)?V*O\ DU?X;_\ 8+'_ *&]>M^)/^1?U/\ Z]I/
M_037DG[%7_)J_P -_P#L%C_T-Z /;:*** $P.N!FEHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *3%+10 A /:EHHH 2C%+10 THI[
M _6@H#U&?K3J* $"@4;1Z4M% ";1G-+110 4444 %%%% !1110 4444 %%%%
M !1110!Y#^TQ\1-=^'_PYFD\.:5J6I:MJ4PT^*?3M/EO3IZOP]T\48W,(URP
M4=6 '2OD32/'+>(/V7_@/::_XDUO2O"=WJ=[:>(==GNI;.:4Q17+P%I\@[6F
M6,;@<$@K[5^B[KE2 ,UBR>#M%GT5='ET73Y=)7[MB]K&8!SD8CV[1SD].IH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZWYFBF9BN%)X!^E/5@?2-%(.:6D 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M12$@4 +7D'[1GP;\1?&GPWI^B:/XL@\-V"W:W&H07&GF[CU"->5@D42(?++8
M++GY@,'C->O;AZT=: / _B1^SAKOQ"\*^%(%\7VNC>)-'M;G3Y]1L=(46T]K
M<1>5-&EN7Q%\H7:0QVE>AZ53^(?[)"^)M"\+Z9X>\2OX;32=%F\-W#O:+<F[
MT^7R_,3DKL?,2D/SC)XKZ)HH ^=OBI^R6?'CZ9!I'BB3P_IRZ''X;U*W-HMP
MUW8(Z.JJQ(,;@I][G@GBG?%/]DM?B#XF6[L?$KZ+HU[IUGI6L:;]D$QO+>UE
M,D(20L#&WS,"<'(/:OH>B@#QOXM?LR_#CXCRWFO^(_#IU+58;$PI.+^ZA^1%
M)4;8Y54X]2*J?L4QJG[+/PWVC _LL<?\#>O7?$G_ "+VI_\ 7M)_Z":\D_8J
M_P"35_AM_P!@M?\ T-Z /;:\6^,/[1]M\)?$EOI<VBRZBTL'G>;'.$ YQC!!
MKVFOG_\ :A^#<_CG2K;5M"TJ?4?$<<B0?NY0 (.2W#$#KBFA'6>&/CYI>K_"
M^Z\<:A93:;IMM*8WB0^<_4#(P!GEA4O@#]HCPI\2O$*Z-HWVXW;1/,#/;E$V
MKUYS[BOCN_T'Q1\)=!U73O$VB7-G::_ +:,O.ORE9%D+* 6&?E Y]:]6_8T\
M)6.H>(=5\10O<13V""V\ERK*XD&2<@ \;:IK2X'U[1114#"BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#YD^*?@_7/&'[24,/@OX@W?@OQ-'X43[<
M(M)CNXC:?;)#$6=V&UF<N  #PISVK2_9O\.7'ACXD_%6RUOQA=>,/& FTTZE
M<W6GI:*(_LQ^SL@0D,I7<,\'*&K?QG^'WAGQ]XVM-0LOB-=_#_Q[IL<.F&]T
MBZC69XKAG>&WEC?AP[1R,@//RMBNO^"_P7L_A%:ZQ*VM:GXH\0ZU.MSJFN:P
MX:XNG1=J+P,*BKP%'3)H [GQ#X8TGQAH]QI.NZ7::MI=P-DUE?0K-#*OHR,"
M"*S;_P"&7A/5?"L/AB]\,Z1>>&X0BQZ1/8QO:(%.5Q$1M&#TXKIUZ#^M+0!7
MM+2&QM8K>WA2W@B58XXHE"JBC@  <  =J^=OV*1C3?BOC_H?M5_]#6OI ]*^
M;_V*O^0;\5_^Q^U;_P!#6@#Z1KQ+]I'X*:S\8/["&DW-E;&P,QD-VS#.\+C&
M ?0U[;10!XO\"_@;<> /!VNZ!XD%CJ=OJ5SYC10%F1DV!=K;@.XKM]"^$?@[
MPUJ<.HZ7X;L;&]ASY<\,>&7/!Q78T4[@(. .U+112 **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@!*\2_:3\2^(M'M?!NG>&O$<WA?4]=UN+3%OX[&.Z #*Y^9'(
MX^7M7MIZ5\T?MS^&-<\2_#+2_P"P/!M[XTO[+5([G[+IMW+!-;J%/[T&([SC
MT7GF@"W^SM;?$/Q9'8>+M3^*4WB7PV[W,#:5<:!%9O(\;M%NWJQ( ="1ZBO>
MM;\1Z9X8TBYU35[^WTO3;9#)/=W<HCBB7U9CP*_.W]BN[TV#XYZ9I<<]AI&H
M6\=SYF@7&NZD;U&V,6_T6XB5&P22?FXY-?5_[8WPP?XG? ?Q'9VMA>ZQJEK:
MO<Z?I]DS$S7 7"913\Y!.0#QD TV!ZIXI^(?ACP/I$.J^(O$.EZ%IDSK'%>:
ME=I;Q2,WW0K.0"3V%0^(OBCX0\(6VFW&N>*-&TBWU-U2QEO;Z.)+IB,@1EB
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MG2O!?@;X=W'AGPWJ?EYU&&*&".+4)(GE-O+"I+[@L3 ORN5P#C!H ^IZ*8'
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M-'-Q+=O:0"(W$SEGD(^\Q)[DYKIQTJT[HW5VKL6BBBF,**** "BBB@ HHHH
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MHH **** "O$?VN?%7C3P3\%?$.N>"KRRTR\L+=[BXO;E2TL42C)\E,%3(3@
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MO DNW+K^Z1B%!!P2.17'?L%>(;+Q/X5^).J:<[RV=YXXU*>)WB:,E'*LI*L
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M (Y0!YOXD^#X+_$'QM#X>U(^,[?XBV[:9J"0S^?%:>9:+(T('_+-D:0,P&&
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MY)KT/P1^U9\)_B/XDMM \->.=*U?6;H,8+*!W\R3:"3@%1T )_"@#UFBBB@
MHHHH **** "BBB@ HKS?]H/XO-\#?A?J7BU-).MRVTD,4=D)Q")&DD5!ER#@
M9;TKA(/BQ\>[B%)8_@AI11U#*3XPA'!&1_RSH S/BQX-7XC_ +1%CHFH:WKE
MEH\'A>YO7LM(U>>Q$T@G159S$ZGC/K^E<'XRUK6M;_9C^&]S<>,K2VF-RZ7D
M.L:_+I!UF.-Y4$)OHR&1\*IR6&2.3S7I+>/_ (YM>&[/P&T0W10Q>>?%MOOV
M9R5W>5G&>W2JMUXI^,U[I)TNX_9Z\.3Z81@V4GBBV: C.?\ 5F+;UYZ4 =Q^
MR]XMM_%OP@TRXMQJ2I;S3V;#5-074'#)(00ETI(GC&<*^3D#DD@UZW7SO8_$
M'XZZ9:1VMG\"-%M;:)=L<,'BZW1$'HJB+ 'TJIJ7[1/Q0\&:SX:B\:?">QT3
M2=8U:VTG[;:^)8KIXWF<*I\M8P2/QH ^DZ*:I)ZX_"G4 %%%% !1110 4444
M %%%% &=KFCP:UH]]82[EBNX)(':,@, ZE203WP:\H\1?LO>'/$7PN\&^"&U
M/6M/B\)Q0Q:5K%C<K'?P^7%Y);?L*Y>,LK?+_$<8KVBB@#"\%>$-.\!^$M'\
M.Z3$8--TNUCM+="<D(@ &3W/<GU->%_L5#_B6_%;J<>/M5ZG_;6OI ]*^;_V
M*?\ D&_%?_L?M5_]#6@#Z1HHHH **** "BBB@!CH&SGKBO(O&_[1_P /OA[X
MAFT77M9:PU),,T+VLIW9Z$$+AA]*]?->2?$[]G70/BKXO\.>(=2.RXTB82%$
M7BX0<A&]@V#6<^:WNG/7=50_<VYO/\3T31+NUU32H+NS5H[>9!(@>(H0"./E
M(!!_QK44D +@\8YIEG%Y$7E@ !<#"_2IZM'0%%%%, HHHH **XGXI?%C2?A)
MI5KJ&KV]Y<0W$WD*+-%9@V,\AF'%<'I7[8O@#42XG.IZ9M *FZM-P?Z;&;I[
MXIV ]P**Q!(!(Z$TZO&Y/VM?AO&A;^UKEL?PK8RY_E6[X%^/_@_XC:\NCZ)=
MW,U\8FE"2VCQC:N,\L,=Z+ >BLP7&3C-(T@4\L*20]!C.>U?.G[6GQ1\6_"S
M1;/5/">IZ=!(I*W5C>0B21XSTD09['C'O652:IQYF<]>M'#4Y59[(^B_,5A@
MD<^O>HI[JVL4,DTT4"]WD8*/S-?GEX;_ ."AGBW2]/C@U7P]I^M3LQ(N!.UM
MC_9VJ#T]<]Z@^(/[<VK^/-'N]*/A'3ET6^B%O+]IE=W5B,MM(].HXK'ZQ"US
MPGQ#E_+=3U[69^AUKKFGWLPBM[^UGD/_ "SBF5F_(&K]?"7[%UY\//!6IWSW
M'BV'4O$\Y*H3'(D44.0  S ?,:^Y[>=9D#@8![UI3J*:N>Q@\2L52532_9-.
MWW$U%%%;':%5M1U&WTJRFN[N>.WMX5+R2RL%50.Y)XJS5+5M*M]:T^XLKJ))
MK>="CHZY!!]10!\G?&7]J^XNKG3D\!:I<6JQ^:MW]HM!ACD;"N<Y_BIW@_\
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M&C1V&Q]-E\/17C.X4[G\UG!&?3'%1_L4*P_99^&Y8@G^RUY Q_&] 'N%%%%
M!1110 4444 %-9%;J,_6G44 (% &!P/:EHHH **** "BBB@ HJIJ6H)ING7-
MXZLR01M(57J0!DXKP*U_;4\)W5W'!_8FL*78*"5B[G']^@#N?CM\))OB_I.@
M6,.H1:?_ &;K5IJCF6$RB589 Q0 $8) QGM7H/\ 8NGGK8VW_?E?\*\'B_;/
M\+RWZV::)JX=I?*#$1;0<XR?GZ5R%Y^VEJ5MK5S9)X7LI%BN'A67[;(-P5RN
M[&ST&:=F*Y]3_P!B:?\ \^-M_P!^5_PH_L33_P#GQMO^_*_X5-83FZLX9B #
M(BO@'/4 U8I#*#:-IJ];*U'UA7_"O._&WPC7Q+\3/A_XIM;NUT^'PS<W,\ML
ML'-R)8&B ##&,%L\YKTVXP5 P"<\9%?,/[1"?%_3O'^AKX&U3.D:I(()(C;H
MXM7[L21]TC/XBLYSY%>QSUZWL(.?*WY+<^HD92!@@TZLCPU8WECHUC#?W9O[
MZ*%5FNF4*9&QR<#@5K YJT="%HHHI@%%%% "4M<5\5_B=8?"KPQ)K%[$+IPP
M2*T64))*2<?+GKCK7S?JW[;FN&_E_LG0-/CL3CRTO6=Y1ZY*L!U]J=KBN?5'
MC+P;HOCW09='U_3H=5TV5T=[:<95F5@RG\" :V8$6*)44!548 ':OE3QO^UQ
M-'X,T*7P]=V@\2S_ #W\2VQ>&%<$;/FQSG:>_>L/P;^V=K=C-=?\)/8+J\;*
MODBQ"0%#GG.<Y[468'V72%@HR2 />LCPMXCM?%.@V.J6;J\%U$L@*,&"DCE<
MCN#P:O7]U':6[22@E%!)Q4O09.9%Y^8<>]87B'PKI'C#[&NKV,-\+&[BOK82
M@'RYHSN1Q[@\BOF3XL?MX:!X79(?#5FFNW"2M%=6]V);9XR#CC*D$=:[SP#^
MT3'XR^&,VO7MQX?\/ZH\;/;64^I[@/[GF=",D=!6*K0O:YYT,PPU2HZ4)WDM
M_P#ASWM95)()Q]:?GWKX!T?_ (*(:_;^($AU[PQI\UE&S(PTV5C(YY'RECCJ
M*^S_  #XH;QCX<L-7DL9-,DN4$GV2:57= >F<<9Q50JQF[(,)F&'QK:HRNUO
MHT=A1116IZ(4444 %%%% !1110 444A.!DT !Z5\W_L4_P#(-^*__8_:K_Z&
MM?2&01Q7S?\ L5?\@WXK_P#8_:M_Z&M 'TC1110 4444 %%%% !2 8&!2T4
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M3DD_)0!PO_#:'P._Z*CX:_\  T?X4?\ #9_P._Z*CX:_\#1_A7H'_"K/!O\
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M11_PJWP;_P!"GH?_ (+(/_B* //O^&S_ ('?]%1\-_\ @:/\*/\ AM#X'?\
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M^V=\#O\ HJ'AL?\ ;Z/\*] _X5;X-_Z%/0__  60?_$4O_"K?!O_ $*>A_\
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M&S_@=_T5'PU_X&C_  H_X;0^!W_14?#7_@:/\*]!_P"%6^#?^A3T/_P6P?\
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M ]!1@>@H ^;_ /AIWXF_]&W^,?\ P86?_P 51_PT[\3?^C;_ !C_ .#"S_\
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M;9]3@C:**\:(&6-&^\JMU .!0!X'\&?V4[GX=^)+&75]?37O#GAF24^$]-2
M1&T,H(DFG( $DH5B@;GC)ZFOHU5  XI57:,4M !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
:HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>adag-20211231x20f011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %" V(# 2(  A$! Q$!_\0
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M31O!GQ,^$EUX U3Q' [Z#,-7BO(+N4#(@D=5 B8\#GH2,@4 ?4A8 9/3UH#
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MV#1GV/Y5YK^SK\9/^%^_"/0O'']D?V'_ &HC/]A^T>?Y>&*XW[5ST]!7Q/\
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M@C% 'U[GV/Y&DW _2OS>_99^ ES^TCX+^(&M:O\ $GX@:7KMGXCO=/L9=/\
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M;L,4 ?;E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 $9'I7R5XS\-_M"^!/B?XMNM(T72?C7X \0D26VAZ[JL=H=)8 ?(%E4
MHR9R>,YX^Z1S]:T8% 'Y]VO_  3_ /&6I? WQA'>7.AZ-X^USQ#!XEMM&TYV
M&E6CPEBEN"!P#O<$J,#Y>2!7=6'PD^-'[07Q@^'_ (C^+/AK0?!/AOP3)]M3
M3M/U,7LNI7F,"0;/]6@(Z%N,G[W;[*P*,"@#XY^&?[,7C;3_  A^TCHFK6]K
MIC^.]1N9='F-TDJO'(L@5G"DE.6'!YKSW5/V0?B;XO\ @/\ #"PUGPEX?N/$
MOP[O7C3P[?ZF);+7+(\D-(HQ&S$XPQQ@<XS7Z$8HQB@#X-M?V4_&.M_#GXH2
M1?";P+\-]2U?1)=+T30M$DCFO"[CYVFO@0FQN@4 >^._U?\ L^^$-3\ _!3P
M;X=UJ!+;5M-TV*VNHDD$BJZCD!EX/U%>AXHP* /E#X__  (^).A_&W3OC-\&
METO4?$@LCIVJZ!K$YAAOX?X2KY !&>A8=B#6W\ _"'QWU[XEW?CSXN:O:^'+
M$6?V2R\#Z#>M-9JW>>7YF4MZ88GZ8Q7TH1FC !H ^;[KX,>*Y/VZ;;XE+8PG
MP@GAHZ:UW]I3S//^;Y?+SNQR.<8K@?CI\,/C=I/[6$'Q2^&'A/1/$EO'HBZ;
MMUG4DMTW'.[Y0ZMD9'/2OL[&31@4 ?&WQ%L/VG/C)\!?%GA?7/!'AOP_KVJ3
MP6=N=)U=2GV1C^_=F>1L$#  '/UKSWXB?\$Q[C0OAKI]WX$\5^(M6\::.T%S
M8Z5JVJ(=/652#(L090L?.<'@>N:_0O%% [GA.F_LJ^ ?&&MZ/\0_&'@J"'XF
M^1#)=:@E_,[17"Q[20$<1''/1<<]*^;/C1_P3/EBMM$'@+Q)XJU57UE9[ZSU
M#6HXH+.!G+22P)A0)!DXQS7Z$T=:!'.R>&WT_P  OH-I-->O%IS6<4MW)NDE
M(C*J78]2>,FOA3X.^ ?VL/@G\.K[P+HGPW\&WNE75Q=2?;=2UI3*HF)R2$E
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M0!\(:3^SM\:?B+)\(/!/COP[X<\-^$OAO?17;^(M)U/S9M56!52%((U D@+
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M9/)/?-?)_B#]C#Q5\>/VD/'/C?QUJVM>"M%58K/P])X;U2.*ZE@7C+LF2@.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 444GF+OV;AOQG;GG'KB@!:*,@]Z,CU% !11D49'K0
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M5]UA0O0 ?2OG+_@H=_R:)X[_ -VT_P#2N&@9] Z+QH]B/^G>/_T 5=JGHO\
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M=SXIDE<-')<VL4!A &"H"=<GGF@#GOVC/B])\"/@_KOCB+2DUM],:W L7N#
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MUY<64FC>)[#2K6SBBD<W"/;)(LAD4J  2XQACGG.* /8J*** "BBB@ HHHH
M*^<?^"AW_)HGCO\ W;3_ -*X:^CJ^<?^"AW_ ":)X[_W;3_TKAH ^@M%_P"0
M/8_]>\?_ * *N53T7_D#V/\ U[Q_^@"KE !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%&:* "BC(]:,YH **** "BBB@
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MW.,[@<=*@^,7B76/V<M2^/WAKX8ZC?6'AO3_  ?I>I+;+=2W4>B7UQ>?9Y3
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MMX(H_P"&&-$4('.&?KN*KGH*\\_X*&C_ (Q$\=_[MI_Z5PT#/H'1?^0/8_\
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MC#6RW['UU&JQ1HB@*H  "] *DHZ45\V>B%%%% !1110 4444 %%%% !1110
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MX(TCQ)X+\>VGAC3K?QE?>,-*CN=:2,BXE7S54@MGT '3M7UZO3\30(6BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHICR*BDLV,=SP* .'^,GQ.M/A5X
M)N-7E0W5_(PMM/LH^7NKEN(XU'?GK[5^9'Q#B\4:/\99E\2ZA--XAEO+>6\=
M)6&TNRMY>0>B@XQTXK[E\)[_ -H/XU7'B>9=W@OPA,]GI4;'*W5[TDG(Z87H
M#6/\4?V)3\2/BC>^,?\ A+?L'VFXBG-I]AW[=F.-V\=<>E<=6,JEG'N?'9GA
M\1F48U*"NE+36UTMY??HO+U/IK21_P 2^V.<GRD_D*MU#:0?9K>*+.=B!<^N
M!BIJ[#[!;!1110,**** "BBB@ HHHH ,<Y[T444 % '/7-%% !1110 4444
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ME4]%_P"0/8_]>\?_ * *N4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(6'5W_B<D\DDY-=1BD(ZXX-**Z4K:'U$(QA%1BK) !R>:***984444 %%%%
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M1725Q'QJUG5?#OPQUW5-&\0Z-X4OK.'SQK'B"%I;*V12"[2*K D;0P&#U(H
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MK?V#GD\T)PHI:[4K'VL8QA%1BK)"!<#%+113*"C'.:** &F,$TH4 8'%+10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>/_M:>
M%=<\9? S6M,\.Z&_B75&N+.9=(22.,W:1W,3R1[I"$P45@=W&.QZ5[!1UH ^
M)_ %]\2]*^.&O>*Y_P!EVYTZU\0PZ=9/(-7TO-B(&E#S$KR^5D3@ ']T.O&/
MMBC:/044 %)M&:6B@! H%* !110!\[?MH?\ (O?#W_L<]*_]'BOHA>GXFOG?
M]M#_ )%WX>_]CGI7_H\5]$+T_$T +1110 4444 %%%% !1110 4444 %%%%
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 48HHH   *^<?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_@H=_P FB>._]VT_]*X: /H+1?\ D#V/_7O'_P"@"KE4]%_Y ]C_ ->\?_H
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MXC_:TE^+Q^)?A)-4B\,CX5_\)=I7V"2W+_VF7\Q/]9D[<;]W0=,5]N+T_$T
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M_@H=_P FB>._]VT_]*X: /H+1?\ D#V/_7O'_P"@"KE4]%_Y ]C_ ->\?_H
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M^06\=O$(XD2.,# 1!A0/8"I0.*K%9GB*]64X2<$^B=OR%3P\(12DKL^;;O\
M8-^&4GQ)T_Q5:6D^F6EJZ2_V!9[%L9)$^ZQ7&X#(!*@X)'UKZ011&JJH"@#
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M4 %%%% !1110 4444 %%%%  >G%>!_$S]GGQKXZ6P>/XJ3W!T_6O[:MK;7=
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M%1L[!$"(P&&0?ESS7T!I&F0:+I=GI]K&(K6TA2")!_"BJ%4?D!5NB@ HHHH
M*** <]C0!!?6%MJEG-:7EO%=VLRE)()T#HZGJ&4\$>QKP+XN?LCP?$37?#5W
MH?B@^"--\/EI;'1M-T2SGLDN&/,YAE0QF0=B5R.U?0E% &/X1TG4M#\.6%AJ
M^M3>(M1@CV3ZI<01P27+?WBD8"*?90!6Q2;N.AHW$?PG\J %HI-WL: WM^5
M"T'I0#GL1]:* /GGQQ^R%;>,_&>L7P\7ZAIWA+Q!>V^HZ[X7BM(6CO;F'&QU
MF/SQ!MJ[@,DXZBOH.W@2V@CBC79&BA57T X IY^F:,\4 %% .:3=SC!^N.*
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M .I/)/>O0,#THHH$>??$C2[+4_%'@5KRS@NVM]3::$SQ*YC<(<.N1PP]1S7
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510 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>adag-20211231x20f012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (K H(# 2(  A$! Q$!_\0
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M4N+,)7G[*E2J2EV44W^9]N45\%^*/C]\:_!5^MEKU[/I-TR[UCN;"(%EZ9!
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MXRA-->2_S/T,HKX0T3X[_&SQ'HVJ:KINHM=V&F('NYDM(0(P?8C)_#-:-_\
M%[XU:=\/].\8R^(K)M(OIO(A5((S-NSCE=F/UJ'EU1.SDNVYTQXIPLH\ZI5+
M6O?E6RT;WVN?;U%?!_BOX\?&OP//:0ZYJ1T^2[A%Q"'M(&WH>AX!_+J*P_\
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M7_Q-=-KWQL^,OASPGH?B*[\1VAT[6-WV816\;2#;UW+L 'YFI>65HM)R6O\
M78TAQ?@:BE*,)M15WHM%MW[L^YJ*_//_ (:O^)__ $,2?^ <7_Q-:?AK]HKX
MP^,-;MM(T?5Q>ZA<$B.%;6!<X&3R0 /QIO*ZR5VU;U)AQC@*DE"$)MO967^9
M]\T5^?FI?M._%G1]0N;&\UP6]W;R&.6)K.+*L.H^[5;_ (:O^)__ $,*_P#@
M'%_\33655GLU]_\ P!/C++XMQ<9IKR7^9^AE%?GE_P -8?$\ Y\1)_X!Q?\
MQ-;NO?';XW^%K"QO=7NKC3[2]7=;S36$(648SP0#V]:3RNLM')?>5'C# R3E
M&$VEO[JT]=3[PHKX$T#]HWXQ>*M4BTW1]4DU&_E!*6\%C"6('7J!3-7_ &DO
MC!H&K3:7J.J/::C"X1[62QBWJQZ# 4\TO[,K7MS*_K_P _UPP/+S^SG;:_*K
M7[7ON??U%?&D7B[]I.;1O[42TO3:8W8-E )2,9SY?WL?A7#P?M.?%NZU%-/A
MUB26^>3REMET^,R%_P"[MVYS[5,<NJ3ORSB[>9O5XIPU'E]K1J1YMKQM?TU/
MT#HKXL\1^/\ ]HKPEH@U;58[FUL-NYY?L=N_EC_;"@E?Q%87A'X[_&[Q[J#6
M7A^]FU6X4!G$%E#A >[,0 !]3267S<7)3C9>?_ '+BC#0J*C*C44GLN75_*Y
M]X49!KX4\9_&SXY_#V[CMO$5U+I;R9\MI;*%DDQUVLH(-=W^S'\<?&GQ$^(;
MZ7KVK+>V*VKRB,6Z1_,",'*@&E/ 5(4W5NFO)FM#B7"U\5'!\DXS;MJK??J?
M6%%%%>8?6A1110 4444 %?.W[<'_ "2W2_\ L+1_^BWKZ)KYV_;@_P"27:7_
M -A:/_T6]=N"_P!XAZG@9_\ \BNO_A/C/PQX>N?%?B/3-%LP#=:A<I;)Z LV
M,G@]!D_A7UOKFHZ5XYU/Q7\$[ 1K;:7HT*:4<C<;N ;VY/U3U^Z_(KQO]F1-
M.T+7/$'C75)[:.#PYI\DL,4TBAI9W5@@521DX!'U8=*U]$_;!\16^MVES>Z%
MX>2%IE-U);631S&,M^\VON.#C/.#7T&*52M4M35^7SMKO^A^89/4PN!PBEB:
MG+[9NZM>\$G%KRNVW?R1POP/^&=I\3_B*GAS5)[JPB^SSRNUMM\Q7CQ\OS C
MKFO1=.^ OPZ\6ZAK/AKPQXRU.Z\5Z?'*X%W:A;:0QMAE!VC@' )!SWYZ5V'A
M'1]+\'_M=W5[;7EHNC:K83W]O,LZ; 9 N]2<\'>&./\ :%<;^SO?VUK^T7XE
MGGN8(8&CU+;+)*JJ<S#').#FHJ5:E1RG"3244_F;87!8;#1IX>O3C)RJR@V[
MWY;*S5GIW3+_ .S#I_A3_A"_'AO]1U"#4WTR:+4XHX@4@M02-\9V_,_7C)^E
M<G\*?!&B>)OB)XELO#/B37+/1K71Y;B"]B(@N)U 0,D@V_=.X\8'05;_ &<)
MK2]U+XA:$]_:V5[K.D36MF;N3RT>0LW&[Z'/TK5^ ?AJ3X;_ !*\3:5K-[IZ
MW \-2,S072O&&<H?+#\ L,<XS^-%3W9UG?73]/RV'A^6M0P$7!<J<DWU3N]-
M^N[-S]GFR\'S? CQN;K4]1A^T6?_ !.A' #]F3:VWR?E^8[>><\UY]\._@_X
M:^(7_"P+JSU74O[.T*#[1I\FU$>==KD>:"O'W.V*U/V;;BUUCP!\0?"*7UK:
M:QJ^GJ+-+R41)(0C C)[C(_"MKX"6\'@3Q)XZ\!ZQJFFVNIZMIB0V]R+H-;F
M9D/[O?C!(\SGG^$@9J9N=.=9QD[W3^6EV:4%1Q=# QJTXN%I*_\ >]ZRWZ[^
MIYA\.OAK8^,OA_XVU^ZN[F"YT*UCG@AAV[)"P8D-D$XX'3%=-X*^$?@JZ^%%
MKXW\5^(-1TJ!K][22&TC20R8X4(-I;/<GG@&NZ\/?#=OA'\'OB58:IXBT6_U
M.]L8]MKI]R'*JH8 G.#EB3@ =O>N!UB\MV_92T&V$\1N%\12N8A(-X!5N=N<
MX]\5JZLJLFH2=G)+Y6.:&!H82E&5>DG.-*4FG_,I:7L^QT^O_ SX7^$[72-=
MU7QKJP\/:VBMIT,-H&G;C+,[ '"C(_A!!/-<GXT_9ZNM&^,6F>"](OC<V^J1
MI<6EY<J!MB()8MCJ5VD\ 9R*UOC/?6UQ\%?A%#%<122PV\HDC20,R94?> .1
M^->E?$;XCZ5X,_:%\#ZO->6[:9_9'V6ZGA*RB)7)&>"<8."<<XS6<9UH)-2;
M;4OPV-ZF'R^NY1E3C",72=U?::O).[V7X'G%K\(OA?KWB>;P;HWB[6O^$G0M
M#%=W5M']AGG4',8Q\W4'^0)-5/A5\ ])\5:?XWE\5:O=:'+X9F$,SVP1XUP'
M+E@020-G&,=:ZSPW\(%\"_%D>-]3\4:&OA"RNGU2.^CO%9YPQ9E01CG=\P_I
MDU9\!^-;+Q3X,^.VK&:*U_M,M+;Q3,L;LGER!1MSR<8SCN:F56IR/V<VU:.O
M9MZ]#2E@L,Z\/K-&,7>I:*V<5%M-J_?9]3P'X@6OA2SUJ./P?J%_J.E&!2\V
MHQ>7*),G( P.,8_.K7PD\%-\0/B+HNB;2T$TP>X(S\L*_,Y/X C\:X]<8'TK
MWCX ZI:_#/P-XP^($K6<VI11#3],M;AE+/(Q!8[<[L<J#C'&:].LY4:-HN\M
MEZL^1P$*>-QZE5BHP7O2MLHQU??M;YG=^._$=K\>/"OQ!T"QBA-UX2N%N=*$
M6-SPQCRY.>_(8?0KUKP_X1_"ZW^(/]K:EJVJ'1?#.C0BXOKU5#/@]$4'C)P?
M\">*]0^'/[5FJW_C+3=/UC1]!M-)OYEMKJ:QM#"X5N,[MQX!()S1X;TK1-%U
M;XG?"^[UBSTN/6RKZ3J#RJ8#R62,L.!]X#_@) KS8NIAX2IVMLUUTT3_ ,SZ
MVM#"9I6I8MSY_BB[KEN[.4$]=OL[]+' >)_!GP\U#P==ZYX.\37JW=C*%FTK
M7A'%/.A_BA"_>/?'/X&O6/&>F?#D_L\^%XIM<UE-*CN)7L)UM@99;C:^Y'7;
MPN<\X'3K7D_BKX)1> /!=UJOB;Q!9PZVTHCT_2=.E2Y,_JSL/NC'/';KSQ7;
MZ=X7;XK?L\>&=(T;5-+AO])U&5[R&^NA"T2MNPV#U&&!XZ_6JJV:A)3;BI;_
M "]-3'!J=.=>F\/&,Y4_A[N_:^EUJUY)G"GP?C]GBW\1/K.I>0VM_9VTH2C[
M*.!F0)C[^#US4?Q;^$UMX*O/#4V@7-UJ>CZ_:I-:37(3?YAQE#M&/XA^OI70
M75W;Q_LEQ61GA-VOB-B8A(-^!@9VYSBNZ^ >L>'_ !?\.[&+Q->PV\_@F_.H
M6WVAU'FQ%68+\Q' ;/3T%:SJSIIU%LI-6_+\3CI83#XN4,)*RE*G!I]FG[W7
MJK_<<<GP?TOPY\=O"_A#3M=U6VOGC22]O8)$66VF*%ML3*N.,'DYZBNU_9GT
M?0=,^)WC2"XU34;C7K:2[MP)5W++ 'PTK/CER1Z_A7FGP?\ %A\2_M(:;XAU
M"9(?MFH2W#-*P544HVT$DX&!@=:ZGX+^)-,TG]HWQ6+V^@M8M1EOK>"XED C
M9VD)4;NG/:LJ\:CA*$F[\J_-G9EU;#+$TJU.*475DEY+E277?]3G/"?PT\"?
M$/XG:AX>T;7=7:TDLWFLKB>%(W>Y4DLC*RC*X'&/SK"^&/PHC\4ZSXC37[BX
MTS3?#]M++>RV^W>'4D!!N!')!]>!4>J:%J_P+^(&CW]S=V-Q>17!O%&GW/F@
M(LF,,1TW#G'H:]G_ &B[[1?!W@"\;09 ;CQ[=1W\_3*PA 6 [X)]<\L:TE4F
MG&$)-J25GVMO^!RT\-AZL:E?$4E&5%MRCW37NK?^;3T9\JOM>1C$&\LM\@<_
M-C/&??%>US_"3P)\/[#1H_'_ (@U>'6]4A6Y%EI%NCK9QMT:0MDG\/? /6O%
M8IC#*D@Y*,&P1GH:^D_B-X-7]HBX\/\ BCPOK6DK_H,5EJ%E?72P2V3+DEF!
MZCD]/;%=.(FXN*<G&.MVOP/)RJC&K"K.%-5*BY;1>UF]7:ZO;3TO<YF+X3:!
M\/OB]H=KKFM75UX;OTCO-+O[. ,T[%AL1Q@@<D9/OVK>_;)L_"Z^-GN(KZ];
MQ5Y4"R61A ME@^;#!\9W>V:S_BYXMTJ[\<?#_P -:9?PZC:>&_(MI[^+'EO+
MN4-ANX&VLG]KF\MK_P",MU-:SQ7$1LH 'AD#KG+]P<5QTE.I6ISFW>S_ #_4
M]W&RP^'P&*H4(1:YXKO:\=;._P!EW2/'+>"2[N8H(5WS2.$11W). *^QM+U+
M2?"VI^'O@O=;#;WVCR1ZAOD *W<HW*,^N0P[=NM>"_LY^'[/6?B99W>I300Z
M=I*-?S&>14#;/N@9(R=V.E=;JG[8/B.77;BZMM#\/O"L[>1--8EI_+#?*2^\
M<X[\5IBXSKS]G!7LK]M7L<^25,/E]!XK$5.5S=EI>\5K)>5]%<XCX9Z'<>&?
MCSHFD70_TBRU=;=_<J^,_B,'\:[7]H3XI^,?#7QEU^STOQ1JNGV=O)'Y5M!=
M,(T^13PO3&:W/%XTJ]^//P\\8V%Y;&SUTV]Q.%E4"&5<!MPS\O7OCI6A\8O@
M%-XZ^)&L>)5\8^&=.T>Y9'9Y[S=+&JH 25 QV_O5E[6$JL9UOY?QN=3P6)I8
M.KA\$W=5;JSM[O+H[W6FJ,CQWI<?QG\(_#?Q7<^7!K6HWRZ-J$P7:)>>&P/\
M\FL/]HGXA:NGC1_!6A7-QI>@:*([2"RLF,0DD !W':1GJ,?CQ47Q4^*.D:):
M>$?"W@J[-[IGAF5;EM27&VYN <Y7CD<GGZ=<5T_C+P'IG[0VK6_C#P;XCTG3
M-3FA3^T=-U*X,,L,R_Q+@'CW[X!I4U[-QE57NZVOTUTO\B\1)XF%:EA)WK>Y
MSV:O*T;2L^NN_?<Y[QIKGQ N/AA96'C/P5?W8TNY6XB\07Y(=$R/W;?*<@CC
M.>A]J[#2_BQK/Q3^"GQ.?48[6TL[&SCCL[*SBVQP(0>/4G@<_H*QOBIXD/@7
MX2W'@K4?&3^,O%&ISI+=NMTUQ%9Q+SM5F/&?3OZ#%<]\([VWM_@?\5899XHI
M9;:+RXW=59^&^Z"<G\*?)&=+GY5\2MOW6NO<EUIT<9]755M.F^9-Q;NH2M%M
M;V\[GH_[-/Q=U;Q5=S>%FM;*QT?3=&D*QVT>'ED  \QV[D^PK&^$7A/4C\'O
M%6HZ'>VFBZEJ.H-:SZS>3");2T4Y<AQR.OYXKF?V1[ZVL/'.MO<W,-LATF95
M::14!.1P"33_ (;ZE;>.OAOXF^')UJ+1]6GO3>V+74NR"[PQ+0ELX&<"IK4N
M2<U!67NW_$WP.+=>A0E7?-.U51UL[VBDD^FETO\ ,?XI\/\ C#PK\)-233?%
MND>.?!]Q,%O7M]UQ):OV8%R2HZ<@_AWKQ30+>QN];L8=3DFAT^294GD@(#JI
M."1D$9'TKW2VT&/X(?"7Q?:>(M5L6UWQ#$MM:Z587*W#J!U=BO '-?/I /%=
MV&NXR2VOO:U]#YK-TJ=2C*2:ERZP;<N75Z7>MGO9[7/4?&/P6.A_&*P\':?<
M3W-GJ30M:74H&]XGZMP #CGH/2M[2O@7X?U3Q]XNM(=9OW\,>&(?,NIHHEEN
MYF Y6-0-O7CI7I7@KQEH5_\ ##2_'VHWT9\2>&-.N-.6"1U+R,1A&P26/&,?
MC7D/P'FU;4?%FIW6E>-8/"OB.5&EA6\0&"^8G)1B3@<]L'VKE56K*$KNW*K?
M.^_W=?,]J6$P-*M24(*:JOF2TTCRZ1U:7Q-Z7UM;J8OCKPUX BT"/5/"/B2]
M:\63RY]#UN$1W:C^^-O&/8FN>^'HSX[\/Y'_ "_0_P#H0KWOXU7LL_PED_X3
MX>'6\;M=*;"3165IY%_C:79QC'X?C7@7@&1(O&^@N[*B+?0DLQP -PYKIHS=
M2A)OS\_QLKGDX[#PPV8TE%)7Y79*UM>J;=GZ.Q[)XI\!67Q)_:KU[0M0N9[*
MTFD=VFM]NY=L8/\ $"/TJMHWP;^&GC'5KWPSX=\8ZM+XGBWBW>]M%2UN77.5
M7 SQC'4>V:ZKP]-#??MF:K)%/')#)YV)8V#+CR>N1P:K^ /A3!\./B%<>.=<
M\5Z'_P (]ITTMQ#+:W0DDN22V%"=00>".N>E<'M90CR\[5HJR[L^F^ITZU1S
M]C&:E5FI-](Z:WNK6WN><^!? ES/X6^)"W.K7^FS:-;XFL[.8"&Y96P5E&/F
M7([5V7C!<_L?^#^<9U#M_O&JW@SQ9;^(M ^-.IO-%;G48#)!'(5C9@6X 7N<
M8Z4[Q;J%J_[)/A&U6YA:Y2_RT*R*74;CU7.16K<Y5%S?S+\CBITZ%+"R]D]'
M2J:]_?T_ K^*_A-!>?%3P)X<O]>U?4;?5]/A=[FZE626!2H.R/(P%'8$&N@@
M_9T^'&K>+-4\'6'C'5U\3VJLX%S:IY*  $@G: V!R<$5I>)-5LI/V@/A3.MY
M;M#%IMN))!*NU"%'!.<#\:A\.:G9K^U_XENFN[=;9HKC;,9E"']R.C9P:R<Z
MK6DFK1O\[G8J&"C4?/2C+FJJ.M](N*V=^_4Y>3X&^!?$/AOQ%_PB/BG4=2\0
M:#$9+F.Y@5(9MO#;.!QP<')KA3\-;%?@?%XV%W<_;WU+[']F^7R=O'/3.?QK
MNO@!?6UK>?$PS7,,0DL+@)YDJKN)=N!D\_A5KX::-:_%/]G^Y\&6.M:?IVOV
MFI?;?)U&3RE=..AY)_ 5O[2I2DU*3:36ODUJ>:\+A\93A4I4HQG.%2R6UXM<
MMKO>U_4X?6?A5IVG?!#1O&R7ETVH7UW]G>W;9Y*C.,CC.?QKT;5_@#\,O"4G
MAJ'Q!XJUNUNM<MT>"*.!&4.P')8)P,G'/YU+\6]'M/"/[./A_P /#6M/U>\L
M]27SGL)@RALY('.<#UQ3?VB]2L[O7OA28+N"98K6$2&.56"'<G7!X_&LU4J5
M7%*32;E]RV.J6%PN#A4E.C&4HQI:/57;M+9[C&_9U^'>E>,AX,U3QGJ<GB6Z
MYMA!:JL* C*!S@C=[9'X5Y/HOP_T>V^(.I:#XK\0KHECITCQRSQQEYK@J>%B
M0 Y8^_3WKU?QKJ-G)^U[IMTEU UL)K<F=95*?=/\6<5?\%:AIQ^+_P 3!9:A
MIEIXKN&?^Q;R_P!K0AN-VUCD9HC5JPC=R;O%/T=_0*F"P>(JJ-.G&')4E'K[
MR2OK[RNVUIJNQY]XD^%7A'4_ &K>)O!6J:S(^D2JE[IVM6R1R[#TD7&,#OS^
ME=[KFE>$+O\ 9_\ AQ<>+]8O]/M(%D$5MID"R3W#$GINX '4UNZW>^*+/X$>
M-+3QSKVCZAK3Q+Y,=M/%)<[,_P ;)C=[#&17.:KX('Q)^ _P]T_3-;TFWUBU
M61Q87MVL32@YS@D\$=<&LU5E*W/+12W^7>QT2PD*,INA23E*E=Q:LFU-=.9V
M=NE]3S;XI_";3?"_AW2?%/A;5IM;\,:D2B2W*!)H9!_"X'^ K,^!OAL^*OB=
MHVFKJ=[I#2,[+>:?($GC(7JK$'%>@_%NZT_X=_!S1?AS#JUGK.L?:3>W[V;A
MXX.X4-7)_LT74-G\9]!EN)8X(E\S+RN%4?+W)XKM52<L-.3=][/NCP9X?#PS
M>A3C%)/DYDGHI/=?T]#3\!?!W3/'OC+QO9:IK=W9QZ.LDPOI"K%B'(+29'/'
M/&*MWWP=\"^(_ >MZQX'\3ZAJ6H:)&);N#4(1$LB=R@P"!Z'D5L_#C4+6'Q'
M\8FDNH$6:SG$9:50'.\_=R>?PKF_@+>6]KX-^)B33QQ-)HX5%D<*7.>@R>?P
MK"4ZMY24GIRZ=-;7/2I4,&U3HSI1?M/:WEK=<K=K:_H>-'[C'/:OM3XHZ1;>
M//A!8^'4A']L6&B0ZQ:L2,L%&UE'X5\5?\LS_N_TKZC\:?$&W\'_ !!^%VIQ
MSP7%H-&CM+U%D# 1N0K!L9QUSBNC&1<I0<-U=_<>9D56G3I8A5OAERQ?HVU?
MY;E+]D+2;70[J[\5:BA/VB=-)L!W:1N7(R>P%=#I.@03_M,?$'Q%<V\=U'X?
M@:[2*3&#+L^4_I3/%&NZ%X=^*_P[\'>'[F)="L+HW\TGFKM,DF2,OTX%<[?_
M !*TSP?^TUXKDU"82>'M6+65W-"^X*C+@."/2O/:G5G.HD[RC^%_\CZ:+P^"
MHX?#3:M3J)-].9Q;OZ)M?<>4W/QL\93^-3XF_MV]6^67<J+.PC"9SY>P<;<<
M8Q6Y?_'ZX;XG/XXT_P .Z=9ZF]MY3Q2LTR>9C!F'"D/^==6?V58[C5Q?6WC?
MP\_A-G\[[8;O$HASDC;TSCC.:RH-,^$.J_%>\T6-YK+PRUKY%KJC7<@3[5_S
MT)/\)/K@5W<^&E\,;V71=.Q\Y[#-:32JUE&\TUS23O+HUOIY[:H[?X-6GB[2
M]'\3^./%.IRW_AW4--E9K47)NI)Y'!VGRAG9CWQ6)\"X;OQA\)/&/A;P]>MI
M.OR7 NUN'#11R0_W#,HPI[<_RK4^&7P\D^ VN:IXE\0>*]&CT%+>2%;>RNQ*
MVI;A\HV8_P#K_A67X&FM?B9\%=;\'Z'J5GH&O?VB]ZUI<SB 7T)8D*6P. "!
MCV]*XY6?,X[7CK;1>JZVZGNT5*'L8U;J:C4O%RO*5[;2Z7Z:='N3_%C3M3\!
M_L_:/X<\3WQU;6;F^^T6TD9:>.WB&?E\\C!/MFLW]BX_\7;E _Y\)/YBK.KZ
M6OPE^ .L>&_$6L6%[K&JW"/8Z7:7*W'V0 C<V1PO3MZU5_8M_P"2MS?]>,G\
MQ6C_ -UJ]=7KT?H<L'?.\'=6=HZ-W:M?1OJ^O3=:'W91117RQ^S!1110 444
M4 %?._[<'_)+=+_["T?_ *+>OHBOG;]N'_DENE_]A:/_ -%O7;@O]XAZG@9_
M_P BNO\ X3X>*JQ!(4D="1S0'7/##)..M>K_ +/GP_TCQ=KNL:MXDB,_ASP]
M9-?W<.2!,1G:AQU'#$CO@#O73V/[4,-]K26&J>#M _X0:5A$VEI9 R01'@N&
M[OM[8'?![U];.O)2<*<;VWU_#S9^'X?+J4J,:V)K*FIMJ.C=[=7;97TN> >7
M'@C8F.N-HQ2LBE0" P[ C->@ZSX%LO&?Q3N=%^&HDUC3;I_,LU8/'Y2$9<,9
M "%4YY/;'4U>\3_L[>+?#6CWNIJVEZS:Z?G[<-)O5GDM.Y+H,'COCG&3C%:?
M6(*RD[-]'N<W]FXJ2G*E#GC%M7CJG;L^JZZ=-SSK^S+I[$W@LIVLE;:UQY#&
M(-Z%\;0>G&:J^6F,;%P#G&!UKZ"TC)_8PUOGC^W$XSQ_K(JXGPK^S[XJ\4Z%
M:ZP6TS1["\.VS?5[U;<W1/3RU/)![>O;(K..)C[W.[6=CIJY36O26'3FYP4W
MIM>_]7/-2H8<@'O@BF[%QMVC'H!Q79W7PC\3:?\ $&V\&7=I'::W<N$A$L@\
MF0'.UA( 05.#S_*NWD_9'^("V]RPCTI[J+)%DE^IFD [J, <]LD?A5RQ%*%N
M:2U,*658ZMS>SHR?*[/39KIZGBOEKN#;5SZX&:,(I+X7=W;H:EG@DMKB2&9#
M%-$YC=&&"K X(/T((KW/X:Z7X?\ AI\)YOB1KFCPZ]J]S>&RT>RO 6@4CK(1
MC'9N3V7 Y-55J^RBGNWHC+!8-XRI*+ERJ*;DWT2_JR1X,I0,2H4,>3@<FG*B
MH"%4+GK@8KZ T?XX>'OBA:7^B_%#2M,M()(6-EK>FV3)-:R#[BX3)(&3CMV(
MP:\R\"?"C7/B+/J1TC[,FGZ>"UQJ=]+Y%M&,\9<CJ1SCTZXJ(UFD_:KEM]WR
M9O5R^,I06"G[7FOHE:2MO==.]]ON.+\I!C"J,<YQ2E%)W%5)'0D9(KM/'?PD
MU_X>/ISZB+.YLM2.+._L+E9X)CW 8?X?3-=RO[(/C\3B.5M%@+H#$9-0&)3_
M '5^7.>G;N*<L32BE)R5F*GE..JSE3A1;<;75MK[??T/$Z:$7.[:,^N.:Z2Z
M^'7B.U\:GPE)IDA\0>:(19H0Q9B,@@C@KCG.<8KL];_9J\8:-IM]=1R:1JLV
MGH9+VRTZ_26XMU[EDZ\?YS5.O3C:\EJ94\NQ=52<*3?+H]-FMUZ^1Y20"".H
M]"*144*5"J%/;;Q7;^ OA!XB^(EC<ZA8+:6>CVQVS:GJ5PMO;JV =NX]3R.G
M3/-1^.OA-XB^'FI6%KJL$$D5_@VE[:2^;;39XP''<=<>G/-'MJ?-R<VI'U#%
M>Q6(]F^1]?P_,XT*HYP ?:D9%.<JI./XAFO6/%/[,_C'P9H>HZIJSZ7!!91^
M:46]#O*O<HN,G\<5Y_X1C67Q3HR.H=&O80P(R"-XX(HC6A.+G!W2*JX#$4*L
M:->+BY=_6QCJ$8[E"D]-P S^=#A,@L$X[MCCZ9KZG_;%^'NF10V7B30X+>!;
M.7^S]0AM8E14+#=&Q50/7&?<4W]D/P/I+:7J6O:Y:P7$E_(;#3H[F$2*Q52\
MA4$'G@#/L:Y?KL?8>WM\CV?]7ZW]I?V=S+OS=+=[>NGJ?+94.I#8(]",YH*K
MC;@8],<5VWAGX8Z]\2O%NK6&@VL;"WGE>:>>010P)YC %F[>PZU9\<?!+Q)X
M%T=-9G-AJNC%_*;4-)NEN(HWSC#XY'/&>F:ZO;T^90YM6>.\OQ7LY5HTVX*^
MMNV_R[O9'!6XBBE4NF8]P+JG!([\UWOQ<\;W?Q O]+U :1<Z/HMK9I9V$,B$
MIM4<D/M 8G';TJQX/^ /BWQEH$>N0QV&EZ1*VR"ZU6\6W68YQ\@.2>>,_EFO
M2?V@_#FH>%?@?\-]&U.(17]K/+%(B2!USM?&"."#D'\:YYUJ;K02=Y7:]-/^
M >G0P&+C@:TYIQA92V^+5)*^]M;KN?.!Z]<5+;:=<:B9/L]I+=-&F]_)A,A5
M1W. <#W/%>IZ;^S%XTU"TMGD.E:??7,?FV^EWM^D=W*N,Y$?./\ .<5N?LZ:
M;=Z+K_CZPOK>2SO+?0[F.6"4%61@5X(JIXF"A*4&G8PP^3XBI7ITL1%P4[ZM
M=E<\*P-N,#;CIVI$50"%"J/10!2)_JE';:/Y5ZS\0K#Q3JOA?X:Z=J.GZ/:V
M]S;F/3)K([9)E8J,S<?*>1T^M;RGRN*[_P##GG4<-[:%22O>-ME?=I?+<\H9
M0P^95./49I<5[9_PR!\0%FFBD.CQS*/W<;7XW3>NT;?YUX_J^D7F@:K=:;J$
M#6U]:R&*:%B"48?2E3KTZKM"29IB<OQ>"2EB*;BGW(H=)NKFUFNHK&>6VC_U
ML\<#-&O^\P&!^)JJ(8NT: ]?NBOIW]GWP]?>+/@!\0='TU5DOKR98HE=PBY*
M=R> />O*?B'\!?%?PWTB'5=1CL[S3)'$9N].G\Y$<] W (^O2LH8J+J2I2=F
MG9>9VULHK0PE/&4HN49*[=MM6OZ['G3,!R2!]3284G.%8COC)%?11NM)_9R\
M Z!=P:'::IX[UV#[4USJ4?F+91?P[5]>GU)ZX%8NO_$[PG\6/ FJ-XIL+'1/
M&]H ]AJ&G6;JMX>Z.%R 3C'S''<5*Q$I>]&#<;VO_P #L:3RNE2CR5:ZC5MS
M<K6FU[<VW-;I\KGAP9%& R*/0$#]*,QLP.4)'3H2/I7T_P# [XV?\)AXN\/^
M$[OP7X92UD40-=I:9G.U.ISQDXYK(^,'QU>QUGQ1X4M_!GAF*VCDDLUO$M-L
MZC ^8$<!N:2Q%1U/9^S_ !Z%2RS"K#+%?6?=;M\#W2O;?\3YX(1^"%?'8X.*
M4A3P0"/0U[1\4M-M+7X%?#2XBM88KB7SO,F2)5=\;OO$#)_&O%\<=JZ*53VL
M>;;6WW'EXW"/!5%3;O=)_>KB?(I_A7W.!3CS_P#6KZ2_9TTC0?"'@^;Q/XIL
M8;F/6[Z/2;))XU? )PSC</7N/2O&/BKX,E^'_P 0-9T1QA()F:$\X,3'*8)Z
M\<?A6<,1&I4=-+;\>_W'5B,LJ8?"4\7)IJ73JK[7]4FSD]BYR5&X="1S0^W:
M=V,>]'/<?I7MGP7T.Q\(^#=>^(^MVD=W#;(;+2[6>(2)/<L,9*D'.,BM*M14
MH\VYR8/"O&5?9IV5FV^R6[/$P%'*@#/<=Z&V@?,1CWZ58OYY[B]GFN5V3RN9
M'79LP2<G [#TKT[]F.QM=0^+>G0W=O#=0F&8F.:,.O"'L>*JI4]G3<^PL+AG
MBL3##1=N9VO8YCX4>/(_AIXQMM<>R-]'#%)'Y$;B/.Y2,YP>F:Y2]N(KR^N;
MH*B^=*\G;*[F)QG\:]\\"_#K2?"DFL?$7QO$D>@VMY,-,TR1 3?2[VV_)_=!
MZ<<_052^"WB _$K]H?3;[5+"R6WF\P)8Q6R+!&@4X4+C!QZD9-<:KQO.K%7L
MM7Z=#VY9?6Y*&#K5$N:7NQMK9V7,^R=M%U/#"JM@[0<=#@&F_NP_10Y[\ UT
M7Q"ACM_'OB&.)%BC2_F"H@P% <X ':OIS]GSP-HOC/\ 9\U2SO[6S%U=W,UO
M#=S1KYBN0-@#]>OH:UKXE4*:J-:.WXG%E^53S#$SPU.5G%-^MO\ ,^0@B@$!
M%P>HP,&DQ&5QA"H_AP.*[+P3X N]=^)MEX7N$(F6\,-SC^%$/SGZ8'ZU[A^T
MAIEE8^/?A[_PBUEIP+J/(0PJL,K*X"[\#D<<DTYXF,*BI[MIL>'RFI7PU3%2
M=E!J-K:MMI.WI<^7MJ'!VJV/49Q2E0Q!(!QZCI7J/Q)\)^+_ !C\:+_2;C2+
M(^);EE+6>DM_HZ#;UW-C  ZL:3Q+^SKXK\-Z'>:H)=+U:&Q_X_(=+O1/-;^N
MY0.W>J6(IVCS22;\S&>5XGFJ*E3E*,&TW:VWE^:Z'ERHH.0J@^H6E6-5SM51
MGKA>M=YX&^#'B'QYI4VJVYL=+TB)Q'_:&K7(MX7?^ZA/WC67X]^'&N_#74XK
M+6[:.,SIYL%Q;R"2&=/[R,.M6JT)3Y%+4YY8+$PHK$2IOD?4Y8(JK@*NW^[M
MXH"*5QM4KZ$<4['J>:7'-:G",\I,YV+GUQS08T).44D]3BG8H[YI7"PB(%&
M !Z 4K*K## ,/0CBC%'6BX"&-3C**0.G'2AD5B,J#CID=*6BBX!2!%7.U0,]
M<#&:=1BBX#0B[=NT8],<4 !>  %'& *6CO1<!IC3GY%Y.?NCK2@Y/M3J,4[@
M,$:J>$4>X I657^\ V/6EQ1BE<!H0)D@ 9Y.!UKW[]B[_DK<O_7A)_,5X$1S
M7OO[%W_)6Y?^O&3^8KCQG^[S]#Z#A_\ Y&E#_$?=E%%%?#G]%A1110 4444
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M_H3M0_.+_P"+I/\ AG'XF?\ 0GW_ .<7_P 71]8H_P Z^\/[*Q__ #XG_P"
MO_(\X_STH%>D?\,X?$P?\R?J'YQ?_%T']G'XF?\ 0G:A_P!]1?\ Q='UBC_.
MOO#^RL?_ ,^)_P#@+_R/-NW_ -:C//\ ]:O2?^&<?B9_T)U__P!]1?\ Q='_
M  SC\3/^A.U#_OJ+_P"+H^L4?YU]X?V5C_\ GQ/_ ,!?^1YOW_\ K4F1_D5Z
M1_PSC\3/^A.U#\XO_BZ/^&</B9_T)^H?G%_\71]8H_SK[P_LK'_\^)_^ O\
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MHHHKXT_>@HHHH **** "BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1@444
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MP+(IF7J@8$CZCM5J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ=Z /S6_X*0_$;PKXG^+.E_#[Q#XJD\,6>B:)=ZTL\$,LADU.1 EG$WE@D#
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M'OB1\.[[X::A)IDNK6,D^H17\%W;QKNDVO$!M91SM-8&D_MN>.-<BM_$.D_
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M4 %%%% !1@$T44 %%%% !1110 %0>HS0!CI110 4444 %%%% !1110 4444
M%%%% !1110 44C,%4DG %><?&'QOK?AKPQ.?"7]B7GB4J'@M==U);. )G#2.
MV=VU?;\Z /2*H:UJ#:5IES=^6\XA1I/*A7<[X&<*.Y-?+MOX3_:KU9$U:'XL
M_#^%9,2+I=OX;>:T"D9P)]Y=OJ#SZUZSX0\1>.[+P#?W_P 0-(L;?7;$2[H?
M#TDD\5XBC*O&&&Y2W]PYQZT["9RO@W]H_6]1\6V&C^+/ 5UX/AU:QGU+3;E]
M1CN2\42[G69 H\J3;SMRP[9J#P+^U->^)_$>D6NL^"+OPWH>OQ3SZ'K$NH13
M_:DB!)\R-0#&S*I90"W'4BO-/@SXNG^+7BK4=0\5^'/%]GXTU"QN;73UU+P_
M/::7H]LRG]S'(_#2-P7D;ECP, 54\$V7B3XCZO\ #;PG=>"?$'AH^ XKA=1U
M35+%H;2:00O#&MN_20/D-E> *=QGJ?P\_:P_X3/Q(;'4O".H>'M+O;.ZO]&U
M2>Y25=0AMV(D)10#$V%+ $G(J;X:?M.ZIXV\3Z%9ZIX"N?#FB>(TG?0M7FOX
MYC=>4"2LD04&-F4%E&3Q7E/PWTGQ9XTUKPYX:OO!VJ^'(?!>DZA87.J7UL8K
M:[FD1XH?L['_ %B,K!B>U:'PIUKQ)XT\1_#7PM=>!O$'AV7P.DS:IJFIV;1V
MDCI$T,202GB7?D-QVI S[(24,!R.>@J2OF[PO_PEW@O]IS3/#E_X_P!>\4Z'
MJVB7NI?8-7CM!';2)*@41&&%&V@.1\Q8\#FOI&D):A1110,**** "@C((]:*
M* (/LB[LY_2D:T#$\X'M5BB@"'[-P!O/%(;)&(+?-]14]% %<V:D@@X8=Z/L
M:')/)/4XZU8HH K_ &)2<GD_2L[7_"MAXETV73]1@2ZLY,%HY,X)!!!X/J!T
MK9HH K)9!450>G&<?SI6LD?[WS?6K%% %-].#KM+#;Z 5Y5JG[)?PKU?QBWB
MBZ\&:;/K;S+<R7#!]LDJ])'C#;&8=BRDU[#10!72R1$51P ,# [5S/C_ .%W
MAWXG^'SHGB?3(=7TQF#F";<N&!X964AE(]00:ZZB@#S#1_V;?AUH.FZ3IUAX
M6LK6PTJ^_M*T@0N0EU_SV8EB7?W8FO3438,9S3J* "BBB@ HHHH **** "BB
MB@ HHHH 9*A< !B*^1/V_P#QI/X)T#P.$\::[X2TR_UU;74D\)Y.JW%OY3'$
M "G.UMK$>G3IBOKZOD3_ (* QZ?;:3X(U2Y\>ZOX#U6PU<S:3+H.E-J-[=7'
MDL-J1J"1A2V>V#S0!4_8A\3^&O$7B[Q"FA>/?BEXPDCL(FD@^(,3I#"OF$!X
M2R+ECT(]*]L_::\8^+_ _P +M8U3P1I=OJ.NP6LTB2WL@6WLD2-G>XD'5PH4
MX0?>8@'@FO#_ -ASQMK7BGQAXDAU3XD^./'4<%C&Z0>+/#3:5';DR?>C8CYV
M/3'85],_%?P]<>+?A[XFT6SDC2\U'3+FTA,OW=TD3(N3C@98?E0%SSB,^*_'
MWP4\(:];>/9?!%ZVG0ZGJ6IQ:=;W/FJ8-S@I*"J*"=V5QC%>):A\</'&B_L[
M>&/$%_XVN;2\\3^*1;6GB";08GNH=))D(<6D4;!G98MPPIXE6O:O%GPM\1ZS
M^RPOP^T^XMX]:?1;72)Y?-*Q[ (UGVN.0#&) /K6O\1?"?C73O"WAN/X97^E
M:;?:+/'G3]9B(M+VU6(Q^07 +QD?(RNN#D<Y!(IHD\>E^+OB2_\ A-X9C\#?
M$5/&?B3Q%XJCT!?$&I:1%:2Z3N1GD$ED%0;T2,D+(!G>#R,5Z;\"_%'B6;Q)
MX[\%^+M:B\3:SX5N[98]6@M%M6NK:YM_-B,D2?('7$BG;P< ]:\^?]FSQSJ?
M@[4->DUK2+;XIW7BN'Q@K6Z.VF12Q0+;I;$_?=#",,YY+'/'2NY^&OP8U/4-
M-\?77Q/M='U'4O&TZ?VEIVF^8;2&TB@$,%N'.&; WDMQRV*0[%W]F YUGXW'
M!'_%P[WK_P!>5C7N8X%?.O[&_A32? UK\7M T*QCTW1[#Q[>PVMI#G9$GV.R
M;:,DG&6/?O7T50""BBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% #)^8F^E> _$3]F'PS\1_B#?>*
MO$FDZ3K[/8Q6]K::O8)<B"6,L5?<>2AWG=&?E. >U?0)Z5GZM&/)) &>O(S^
ME KV/C?X;?M=?#CX Z!;?#>.T\7^)[C1;F6SFU'1_#DCV E,I9DB*G:J(6VA
M1P ,5]E1:A%<Z=#=A'$<B+(%9<-R 1D=CS7Y9Q>+?%FE_$3Q8J^/OB_X2AG\
M17$B:5X5\%O/I97> &60L,;@/F('O7Z?V"-<Z':K(TLC26ZEGD78[94<GT8]
MQV-,"K:^/M NM0U73[?5()K[2D62_MHY-SVH8$@R ?=R 3@\UQ?A[]J#X6>,
M?$5GX?TCQE8ZAK%XS);V2+('E(&6 W*!Q@UYU\"O!>C>!_CU\6=*T.T%E:&/
M3[AU#N[R3.)&=V=B2S$GD_3M5WX=6O\ PGWQA\>>,KUQ);Z*[:!HSE=RP;5W
M7$B?[3,P4GKA<4 >C^&OCMX"\:^([[P_HOB&RU+5K$R>?:VX8M'L.'R<8^4]
M>:=X3^.7@'QQXEN_#WA[Q5I.LZS9AC-8V=R))$"G#<=\'@XSCO7R]\+M;UKP
MYK;^$?#WQ'M/B5HU]IVJ2W-K:V,<<NDS_.ZDLH#+N8[=LOS$]!6M\,==\,:U
M=? G2?#%S9W6NZ0LYU&ULB#-8I]G=9A.HYCR_'SXR2* /6M>(;]L7P80,?\
M%)ZC_P"CX:]YKY1\->,?$?BG]LO18]?\$WO@]+/PWJ,5K)>7UM<_;H_/C_>H
M(68H.!P^#\U?5U#!;!1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
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MU?X?2^+WL;;1KK5M/47D"VMJ8_M36SG #.[;5?!(7)'-(1U'[,;[M7^-V/\
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M'&G> -''A*3Q)::3)?E=>O/!UNL^J0VPB8H8D8C@R;=Q'( X%?4=?)7_  4
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MD,\5N&+B1 ,HS!20,G(ZFK/@?X[:QKVL^%EU3PG)HVC>*5E.D7HU!9Y'VH7
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MEE4(P)W8Y%7OA?I/Q'UWQ'\/=#\3>!9O#6B^!EF\[6Y+J*6+4I!&T4)@5#N
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M9=:KJ6N_$CP)X_T%(DAMSX/MYHI+>?))\Y9 &4%1QQR:^I <B@2/+OVCM/\
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MHH)"C)X% !11G\O6B@ HI X+8I: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **"P!QWI.6]A^M "Y I.2?04H %%  !@4444 %%%% ",VW%?,
MO[:OP@UOXO:)X>M-%^'/A[XC/:73S26GB'5;BQCMP4 #HT+J6)Z8)KZ3O2RH
MI7L<^]? _P 7/CS\(_BEX]\<> OC-XKN? 3>#-=:VTEM(U:XLIK^)HANDE9
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M ,"HP%'PZTYE[*;BY8?^C<5TQA62]Z2?R_X)ZT88F.\T_D_\SI_B-^T?X/\
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M_CU2?\,*_ __ *$*T_\  V[_ /CU:G2>\[F_N'\C_A2&0C^!OR->#/\ L._
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MTN"V,XPBC)->Y;=_WL''I7AOQW_9^UGXP>)="U&P\;W'AF#1Y/M$-A_9D-[
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MV?/AUXL^$7P]UC1K_&M20WDDFCQ7%U&;F2U6&-(8I[A456;*;0^W.P+GD8H
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D9 W44M%
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M ,8'UJ2B@!@@0=!^M)Y"<\'\ZDHH C^SQG'RCBG")1VIU% "*@08 P*6BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MB@$&@ HI-Z@D;AD=:7(SC/- !1110 4444 %%%&0: "BDW 'J*-P]10 M%&1
MZT4 %%%% !12%@O4@4N1C.>* "BC(QG/% (/2@ HHHH **** "BBB@ HHHH
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M])G^($6F?\(SJB^$Y/$!\*Q^+/M$0MFU+86,?E9W[,C;OQC-1?M46+7'Q(^
M6IR0F33[7QI''<2'@1M)!(L1/_ L<U\ZI\$/&E[=6OPO?PGK,"V_Q/;Q8WB-
M[<-IO]G;2P;SLX\S)"[,9SF@9]K_ !;^+.K?#Y=&M=#\":YXUU/5+DVZ0Z7L
M6&W &3)/._RQKV!/6G? _P".=G\9_"VHZK%IEUHU]I6HSZ1J6FW4B2-;W4)
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M-,Z-=9X$)*D&0=MO- 'W'IOQ)\/:SJDVG:=K>E:A?PIYDEM:7\,LJ+ZLBL6
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ML<D@CFBP'WB+^%P,."",@]C^->*?%SQ'\5=*U2YE\'VWA33_  ]IMFUW/?\
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M(?$:U^&'PDU>(Z9XAUO1=.\0WNF:;;Z%IT^JS10JV501Q L(TY&>@Z4 =/\
ML,_\D<U#_L9-6_\ 2EJ^AZ^:_P!@J]34O@>]XL4T(N-?U258[F,QRH&N"<,A
MY4\\@\@U]*4@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@".:(3+@G KRCX]_$+X;_"_P
MG]K^)#6<FCSO]FBMKJP-Z]Q(P)\N.$(Q9L G ';)(KUNOE;]OBU\)1>"=#UC
MQ%\1)OAAJNFWYDT?7+:S:\D,SQE'B\A 6=61FR!CBC<1Z#\$_'WPO\5:CJ.B
M^ (;#3KJQM;6[NK&TTY;)UAN(Q)#)M"C<I!ZC.#D'FO0?'OA&+QAX-UO07G^
MRQ:G8S632H@)19$*$X[X!KX]_P"">O\ P@4_B+7Y=#^+%]\5/%<6DV=C-<W6
MBW&G166GPDK!#&)5&[!)YR3[5]0?'OXE77PH\ :CX@LM"U'Q)>002M#I^G1@
M[F6-GW2N2%CC4*2SL> . 20*8;F!XA^ \VJ?#CPIX<TGQ=J_AO4O#:P&PUW3
M"JRAHXS&1)&<I(CJ2&1@1W&",UA7O[+<M[\/K327\;ZVOB^TUEO$$'C%!$+T
M7K*8V8IMV%#$?+*8QMK8NOB/XYUKX7^#M9\'^'[+5-<\00V\LHO;HP6.GI)$
M9#+*<&1D& BJBDEF'09KAO&O[2GBCP-\+;:^U:V\,Z7XQ/B;_A&9FN]29='1
MPID>X,I <1B,9VXW!OEP:2'J;C?LE:=<?#:?P]>>)]8N_$D^LKXCD\7N4%^-
M24*J3K@;!M11&%QC9QZUVGPD^$+?"_3]8DO/$.H>*M=UB[^W:CK6IJJS3R!
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MM[$L" !GVIW[4WQB\<?"GPS!>>%M$6>!KB%;O6+N:/R;5&D5=JQ'+2.<\8
M[FD,Z[XH?L\^$/BY>6-]KD6H6VIV49A@U'2-0FL+I8C]Z(RQ,K,C8Y4\5#XG
M_9P\$>*?!^C>&9;"XTZQT8@Z;-I5Y+:75F>?FBF1@ZDY.3GG)SFL_P",Q^*-
MVUJ_@SQ+HO@K1;:T:[OM8U2S^W2%E&1&("5"H1DF0MQV%>/>/OVE_%O_  JC
MX8ZC#K,7@C7O$T[K=:C#H<FK(D,8?,L=HHWR"0*&4#H&'-4(]GU3]F#P'?\
M@32?"8L+FQT_293/976GWLUM?6\ASOD6Y1A)O?)W'/S9.:[WP+X!T7X=>$+;
M0=!M%L=,M5;RX=Q<DG)9F9LEF)R22<DU\YP_%GQKXJT+P/X6\&_$?1M=\2>(
M!=74WC*70S%!#! ,N@LB_$F<(59@1UQ7K'P ^*&I>/\ X?W,WB8VEOK^FWMQ
MI=\UL=D,LD38\Q 3P&&#MR<4 <Q^PVG_ !9^]8D9'B/5^,?]/+5]%5\[_L,.
MI^#5^000WB35B"#U_P!);I7T14@@HHHH&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?%O_!1
MSQI)X#@^%^JVVIV7AW4+?Q'Y\.O75E/?"Q @8,3;Q*WFJP.U@?4$5]I'J*^=
M?VP=9M]%T70Y9_C+!\&U>Y<&^N-/BNQ>83_5@2=,=<B@#@/V)/CKJOQ=\6^(
M[74/B7HOCU+.RCD2#2_"=UHS6Q:3&YGF10X.,;1G%?3/Q<T"[\5?#7Q5H^GQ
M";4-0TFZM+=6?:IDDA=5!)Z<D5\G?L2_$[4_%GQJ\?Z"_P 71\7=#T_3+.YM
M-2MM,CM((W>1@Z': =XP..1@]B*^J/C!\6/#GP8\&7_BGQ3?+8Z38QEV(&Z2
M5L';'&O5W8C 4?R!-,1Y;XF\/_$SP[\"?!OACP=91Q^(%M;33]2OH+N!9;&%
M(<3/!YI"/*2 JD\#.[!QBJ>E?#K6/"OPV\*6.D_"_3M5.CZF\T^E^(-6AFOF
M#!RU[%<X:(SF1\D,!D%L$<5W7B;X_:+X8^'/A_Q9+IVJZC'K[6T6F:+IL"RW
M]U-.I=(43<%W;0Q)+!0%))Q61-^U%H%G\.[3Q-/H/B-;V]U,Z+#X8%BK:LU^
M,DV_E;]H(4;RV_:%.<@4#O<\N3X!>/[.ROO%6FZ%I6F:R_CV'Q=;^$TU%3"M
MNMJ+:6(SA=BS2#=)D#:#@<Y)KT#P7\'M<\42_%+5O&5C)X;?QM):VZV.E:H6
MN;6UMK?RD?[3&!ME8LY^3.T8ZFM"3]K#PC%\-YO%US9ZQ;-!J8T230;BS U-
M=1) %IY2N09&!!!#E<'.[%=7\*/C!8_%C3]3D@TK5M U'2[MK+4-(UN 0W=G
M*$#A9%5F4AE96#*S @^QI"\SSG]BWPG;>!].^+>@6EQ>W=II_CR\@BFU&Z>Y
MN''V.R;,DK_,Y^;J>?RKZ0KPS]F,@:U\;O3_ (6%>_\ I#8U[F.E (****!A
M1110 4444 %%%% !1110 4444 %%%% !1110 449YJM-=&-';!^4'M4W&620
MHR>*IW>J06:%Y7$<:\L[<*H]2>F/>N6\3?$6UT'R+81F]U.X.VWTZV(:><_[
M()& .[-A1SDUSZ>"-7\>,MQXNN88--5PXT'3F)B8@\"XF/S2_P"ZH5?J*KS8
MEYCM=\76OQ(T;5='\.Z>?$D4L36\ES-F'3V#9!!F(._'/^K5OK7B7[*'[&MY
M\"_'?B37M9>QNMZBUTEK4D[(6.YR00"#T7'H">]?6%EIL%E'#%;1(D,8PJJ,
M*H'8#M5Q80&R0,^HK>->I3IRIP=E+<&DW<2$80* <#O4@0#GJ?4TM%8 %%%%
M !1110 4444 1W) A8GIBO@W]LC3_%S?'GPM>Z)JWCOPUIMOHT\;:UX$\/-J
M<_F-(O[F4A@-I SCG!'3FOO*X.(6XS7PK^VQKWPLTOQYHZ^.OBC\2O!&HM8L
M8;/P4T@MI4W_ 'WV1N-^?IQ0(]H_9&?6'\ W_P#;/B7QIXGN?MK8NO'&C'3+
MQ5VCY4C).4_VO7-=7^TC\,]7^*WPQNO#^AO:I?S7-O*#>2F./:DJLW(5CG .
M.*\B_P"">]X-2^&/B*XM-:\3>(M%.NRC3-6\52NUU<6X1-IVO@J,[AQP<=J]
M,^._[36@? B*Q34[>[U34;Z14M[&PB)8J6"F1W(*QH"1R>O:@&<K^T=\./B?
M\1M<T.QT#1]!UGP-;IYNI:5J>NS::U],#\J.8[>4F(8R5XW=ZZ35]/\ B]!H
MOAS4?#^F^$['5+56BO\ PO<ZA*;-DQA/)O5@#IM ''E8/2K?Q-^.U_X*U[2_
M#WA[P?J'C;Q%?6TEZ;*SNX;1(+>/&Z1Y93C/. H&2?2L:_\ VJ+>[\,>%+SP
MOX3U/Q3KWB8R+9:%'-%;2QM%D3>=*YV($*L"><G&.M ;G&6'[/?Q#\&#0?%N
MBR>&]5\=VU]?75]I]W/-;Z?)'=\/%',J,PV84ABAW8/3-=;X4_98T?6/A0WA
MWXGZ9IOBJYNM1FUJ\BC\P6Z7,A) 3[K$*, $]>N*A;]K :GX:T6XT+P7JFL>
M)]4NKBRC\-&>&VE@E@SYXEF<^6JKCAAG=D8ZUZ;\*?BI9_%KP4NM6MG<Z;()
M)K6YL;S'G6T\9*R1M@D'![@X(YH"[/*?V!M'MM&^!SV5G$MO:6FO:I!#"N<)
M&MP551GL !7TK7SO^PR,?!V__P"QDU;_ -*6KZ(H&%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% $-R&*KM'/3..E?&?[4NA_$\7.JZSXDUOX,P_#RPN#+I_\ PG&C37,M
MLK# #-NPSGG[HR:^SIYA"H)Z$U\L?M2^%/\ A??]C0>"+KPOXI\3^"-<%]=>
M$-?G66UO&$;*89XP<HPW;E8C /7K30=3._8=N+[6+?5]4AU/X6:IX<F1$B/P
MWTJ2QD^T G/V@/@D;<X! [U[?^T1HFGZK\'_ !=+>V4%W-9Z+?7%JT\8<PS"
MVD573.<-\Q (YY->.?LD_!+Q=X)^(GC/QUXJT+PQX(F\0VUK:)X4\'Y^QP&(
ML6F?^$R'('R]J^JKBU2Y'S '(P01D$>AH$?(/B75;3P+\)OV;_&VKQ2IX=\,
M7%M<ZO=1PLYM(9]+GMEF95!.U9)4W'L,G%<WK7Q T:+_ (1/XR!)I/ $'CW4
M+R34EMG/EVT^F_8X[HIC<(Q*O)QPIS7VI)#;0!86,2QCY0&P!CTQT[=*A#V:
MMC?"(CA2&*A/H>V>:!GPK=ZS;75EJ7Q>M-/N+SP(WQ-M=<$L=N^YK"+3UM)+
MY8R-Q02\CC.U017K7P4UR[^)VL?&7QQX!U*%-,UN>PL] U34[.1[6:6ULS'+
M.(LHSQ%G &"I.P]*^DP+?R#AD5,$87&U0/TQ_C1"]O)$ODHH5U.TI@#'MC^E
M(#PS]CJ#6K6U^+\7B.[LK_75^(%Z+NYTZW:WMY'^Q67,<;.[(,;1@LW(/-?1
M*G*BO#?V8QG5_C=_V42\_P#2&QKW-1@ 4 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!"[8=OFP/2O@+]I;P#X]\3?M+:5I_@[Q=XEMM+UN2""^
M2ROIA;Z6V"6;"MM ,:[L>N/6OM+X@>*!X;L 8$%S?W+"WL[8=996Z _[(ZGT
M -.\'^#3H-@ \OVB[G8SW=P3DSRM]YOIV [  #%;X>M+#3=2/:PI1YHV90\!
M_#K2O!\6Z"">\U"2,1S:G?R_:+J?  &^1N<<9VC ]J[:"U"1E7 (/;%/CA*
M   "I:P;<G=A8  HP!@>U%!.!FDR?2@8M%%% !1110 4444 %%%% %?4(VEL
MY51MKE2%;&<'L<5\ ?M$^+?'_P !IXKGQ=^TOINF)J$K_8=/A^']O?7 CW=
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MFK?^E+5]#TA(****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% %74"HB&1D\X]O>OST_:5O/A
M]\0?BIKFC^$?V>_$_C3XE6%T8+OQ1H)ET80W  &YKV/[Y (Y.:_11E##!YKP
MW]HG]H;2/V>]4\##76M;71O$.K?V==:C>7?DQV*",MYN.=P!P#Q@9YQ0(X/]
MC+X;?'3P%)JC?%GQ7_;&D7,*#2M&GO#?W&G-N)(>Y90SC9A>6-?5]>?_  ]^
M-_@'XG7]S:>$O&6A^);FUC$EQ%I-]'<-$I. S!"< GC)[UZ *8(\F_:(\,^
M=4^'>LZS\0_#FF>)='\/V\VJ);:I;B>-76-AE0>C$';GWKYK;]G36+C]F[P#
MX3T;PQX;>75M>3Q+K6@7\OV/3@C))*L!C0;W1/W"E$!)V9.,FOKCXF^ -,^)
MWA:_\.:NURFFWI3SQ:S>6Y"2*X ;L"R+D=QFLCXI?!KP_P#%G1=/L=9-[:2Z
M?.+NPU32KQ[2\LI@I0O!-'ADRK%3V(."#2 ^2XHK'4/!>B_"^\\*Z1\/[:#X
MBVVA^)=,\+,\>FZDKV9NE\LG#B.8>6&4\_+C)KUKX37&F?!/Q-\;]$TC2;NW
M\'^&Y=-U"RTC2;:6Z: W%F7N(K: 9.-R*PC3H6/'-=RW[+_@9_AU<^#)K6\N
M+"XO/[3FU":_D?4)+WC%TUT3YGG# P^>  !Q73_"[X0Z-\)=)NK31I=0O);Z
MY>]O=2U6]>\O+R<J%,DTSG<Y"JJCI@ "@?D>=?L9^)X/&FG_ !=URTM;ZRMK
M_P ?7DT=OJ5J]K<QC[%9#$D3@,C<=&&<8KZ+'2O"_P!F#_D-_&_G/_%P[W_T
MAL*]T'- D%%%% PHHHH **** "BBB@ HHHH **** "BC.*A<N[X'RKZT 2LX
M4>M9FJ:@UK;22.X@C52S.Q "@<DDGH*F,D<4C(,D]<XKS#Q';R_$;Q&_AZ&3
M=H6F[6U3;TN9#\R6V?3&&?V*CO36NH(T? MH_C&]D\7:C&P,NZ+2X9!GR+7/
M^LQ_>DQNS_=*BO2(E"A<=/:J^FVR00;5144'A5' ^E7*AJX[A114<DZQG!R#
M]*H12US6+;0=+GO[VX2UL[=#+//*P5(T')9B> !ZUP_A?X\^!_&NJQZ;H'B_
M1M8OY%+I;6=[')(Z@9) !/ %6_B1XEMFTM]#MK5=8U34(VC331T=#PSR'HD0
MSRQX[#)KPS]D_P#9*D^"7C/Q3KVHBTGFNF6#3&M@0(;<C<X /*G=A?H/>MZ<
M:3IRE4=I+9=R7>Z1]6P2>9$K=R*DI$&%&3D^M+6!04444 %%%% !1110!3U>
M01:?.Y&X*A)7&<X'3%?F_P#$CP5K?[2WB*]'@3]F:Q\)7$4SHOCO7II-&GW*
MQ!DC%L8W?GD9)SZ5^D]T 8&!Z8KYK^+?[7/AKX&?''1_"GC;6--T+PYJ.D27
MBZA=B1IEG5P%0[ 0$(SVZB@#I?V5/A)XW^#_ ,.(]$\=^-KCQQJOG>:EU,[O
M]GCP (5=R68 ]S7NAZ5PGPH^-7@OXS:#+JO@KQ!:^(M.AF-N]S:*X19,9V_,
MJ\XKNB>,T ?/_P"UQ;:3:>"T9M T;5?$6KSQ:+I<VHZ?%<O%+.X7<I=&(V@E
MO3BN(^*'[/IETGX9> ?".K>%]&L]!EDFCL/$%H+L7K+&1Y@M,J)CN)<\X!-?
M1GB_P=I'BV]TFYU2U6YDTNY6\LV9V7RI1T?@C/XU@_$KX-^#/B[IT%GXLT:'
M5(+:0RP.))(987Z926-E=,]#AJ!'RWX.EMOB3\0/AQX=\7^'O#S:5ILVL6LF
MFV.G)'IEU>0)A9DB(V9().W#8.?2NW^#?CW4OAK\(-9'AOP=J_C;3;3Q)?6-
MAIGAYHC)#;AS]WS&51&IR, \=J];U?\ 9X^'.N^!].\'WGA:R;P_I["2TM(G
M>!H&[NDJ,) QR<D-DY.<UV_A/P;HO@CPM;Z+H6G0:9I5G&4@M+=<)&/;/)]<
MG)- SP[]@6^FU#X&-=36LMA+<:]JDKVDX'F0L;@DHV,C(S@X[BOI:OGC]AD_
M\6;U#_L9-6_]*6KZ'H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OE?]NCQ;9^&-&\(
M6U]9>%XK/5]6_LZ?Q'XOL%O+'15>(GS6C/&6QM&XA?4U]45\X?ME_$C5/ GA
MK0=/TCP[X;UZ7Q'J2Z6[^,)A%I5OF,L//8C WXVKG R:: \[_8G\7Z9JGQ*\
M<>%]+7P5XGL])M+23_A./!.E)807C2,V;>54^0NNW<-A(P:^TE&T8KY:_8_U
MOQA/?ZMI.NZ+\+M$T:TMXY+2V^'>HQW!$A;!\U%)VKMX!]:^IJ&(\._:C\?>
M(_ _@[2CX7?4X=1U'6[:QDN-'T@ZI=0VYWM*R6^"';"A1G@;LUY[9_%SQ9KO
MAOP+X=T/Q/?'Q'XDU^[TR[UGQ#H$=G=Z6MO;/<21M9<+YF%0+G(Q)NYKV7XO
M>%/&/B*RL)?!GB-?#FLV-ZMRAN[<SV=Y'M97@N$!!V'<""IR&4'GI7E^H_L[
M^-K_ ,)Z1?IXITU?B;IOB*7Q&FK+I[C3VEDA^SR6_E9WB(P'9G.[/- CFY_C
M+\2+*UU#P.FJ:;/XQA\;V_A1/$KV:HC6TUF+O[2;<?)YBKE-HX)&?KZ3\(/B
M#K5IX@^(/A;QEK]IJL_@^2T8ZY)!'9+-;W5N94,J@[$92K@D$ C%<E)^R]XC
MO? EV;KQ5;)\2KGQ-'XO.NV]DRV<=]'&L44?DD[C"L*B,\[CDGK78?##X*ZE
MI>G^,Y?B-/I7B[5O&-P)=62&RVV#0QPB**V6.3)9%0$Y;J6- :$/[*.H6NJW
MOQIO+*ZAO+2;X@WK13P2+)&X^Q6(RK D'D'I7O@Z"OGS]D70=,\+CXR:3HVG
MVNE:79_$"]CMK*RA6&&%/L5B=J(H 49). .]?08Z"D,**"<4FX9QGF@8M%%%
M !1110 44 YH)P* "BHUN$;HPQ]:07"/D*0W;CUI7 D9MHS49E+-A #[FN>\
M<^,]'\ >%[_7]=O19Z7I\?FW,^UG$:#J2J@GCV%>8^&?VO?A1XPO9;?2?&,%
MS<0Q>:T+6\T989 ^4,@+')X4 D^E4J=22<HQ;2"Z/;BVU2S$9'(SQ7/^)O&>
MG>&K$76J7]MIUKNVB:XE"ACZ+ZGV&:X]M>\5^,5$7A_3;C0["7[VL:Y$8I I
M_P">-K]YC[R; /0]*U_"7PITW1;YM2O7GU_7.1_:NK-YTZCT3/$:^R ?C2>F
MY5K'R]^U_I/Q#^*&GZ1K_P ,E\6VB:?F&86EW+8"^C=@ R0!E=]IP=[*!C.,
MU]'? 'X:W7PR^'6C:-J6I76J:HD1GOKN\F:5Y;B3YI"6;+'!X&>RUZ(UC 3E
M@,@=,]?K4D,4:D$8X'05I*LY4HTK*R)22=RRH &!2D@#)J(3+EAD9'.,UP?B
M3XV>!?#6I76FZIXST73-0@PLMM=7J1R(2,C<"<CBHC&4](JX;;G;7EZ8!\N"
M<=S7!7?C6Z\6ZA-IWAIE\N,M'=:RR[H+=A_#'G_6R9[#Y1CD]JS1JEQ\58A;
MZ<)3X58?OM4BD,9O5!^Y!_$4/>3@$<+GK7I&BZ;;Z=I\-M!;QP0PKLCC1<!%
M[ #TJ=MRK6,3PMX#LO# D>$27%W<D-=7URV^>Y;U=OY <#L*ZB& 19J3(& 2
M,T;USC(S2WU8FQ:***H04444 %%%% !1110 R<!HF!Z$5\6?M?\ Q/D\*?$K
MP_H^J>+].^%_A>[T^6;_ (2J\\/#4GFN%=0+97:-EC&"6YZXK[3F(6-B<8QW
MKXR_; ^,7B_P=\0?#OA70_$7@+P7I5_92WC:OX\3=;S2HRJ(4&U@&PV1D=NM
M CT+]C3Q[?\ Q$^'>H7][/:ZI9VVJ2VNGZ]9Z6=.CU:!57%P(-JX.21D#G%?
M1K<J?I7@W[*'BSQ!XM\"75QXC\;>#/'%Q#=F*.]\$9%G&FT8C8%1AAUX%>\G
ME?6@9\O?M5:I\2F\7>%],\$Q>.K;2?L\]SJ-]X*M[5Y=PP$1GN\1+U)QG)QP
M*P8_B!KWQ$M_AIX-\*>/]<TY=<M;NXOO%%U90#53]GR'B9&3RTDW?*<+CCCK
M7JOQF^$OC#QAK]CK/@SXA7O@C4(+=K6:)K-;ZSN(V.<F%F4"0=G'(]ZY;5OV
M7;N'PEX2A\(>,+CPYXJ\-O+);Z_-9I=?:7ER9S-"2H;>6)QD8XI["O<\\T;X
M@^/_ !]J&@?#8>-KO1-9:\U*.\\4V-I#]KFAM,;-J.IC5VW#<=O8XQ7IOPL^
M/MAX>^%U[=_$KQ;ING/I>K7&BOK6K.EDEVR'Y&.2%#D=0.,UEM^RCJ&D^$]
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MHB0L> /;-?,/[8MKX0\5Z+I$.N_"?5?C,+.]D0:?H$X\S3Y-G+2_.N,CC!H
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MP1^-? O[:G@*RN_'&@R>,OBOH4/B:=HHWM'TMK%+;3V8AI4PTAEVL"<,V3G
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ME--$FM6-D7)$$>67$C >8Y^X3M4 'O7V#I^B6&E6JVUG!%:6T8VI!"H1%'H
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M[0C6GCO7K"^T3X!:7\=+00/"=:BU6VC6U=7PT.6SR#R<=#30F=E^QWJ,5YX
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M/Q-X)?Q?H,&F7VH^)3;1"1]5FU?[9F)F.^! R$(WRJVX9^E?0OPH^,_AF_\
MA]H4EG\5;?PC*EJH_L?68;6X^S <!-WEQ,< 9SN[U\X_%CP]XH^)4FC26W[(
M?C#0Y[*^2>=X=963[3;\^9!A@0H;CD="*[%]6UTQHB_L4^+XD10H6/Q)Q@#
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MB[3_ !EJ[7&^*]TW2UT]$BQPA0$@G.>:]*QD8/-+10 WRD/50?J*:T$2C<4
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M9AM.);"<@=O,&_GZ%:Q-;UGX]?"[3K\W.E:]]C1&Q<P7\6HQ(N#\P#[]@]\
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MC_HW6/\ \+JR_P#C587B_P#:C^*OP\TZ'5/%'P(&D:0;J"UFNX_&%M<F+S9
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MF'0K$Q!BMN!.96$C*,*RQD<]<5Z7X!UB[\2>'[;4M1T*Z\.WEPN^33+]D::
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M24BT?6=&2\GBFE&=B1_9SMBD5\'+]J^C?@K;:W9_#;PK!XB>5]<CTZ%;TW#
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M(-J?:#_RUP#][WJM:_LL_#"RNX;J#P;I<=Q#=?;HY1&V5N/^>H^;[WO7K%%
M'!-\#?!3'6C_ ,([IRG6@1J16';]KSP=^",GWK%L?V6_AAIQE\CP;I2++:_8
MI%\DD/!_SS(S]WVKU>B@#,\/>';'POI-KIFF6T5E86R".&WA7:L:CH *TZ**
7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>adag-20211231x20f013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f013.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'N GT# 2(  A$! Q$!_\0
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M5X;^T+^U?X)_9_U_PUI'B/[?->ZVX6,6$:NL*%POFS$L-J GK3OCI^T[X>^
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M(>WN?$*W'V"Z\L"%WB /E%R?OD9('M0,]#HIJ2K(JL#D-R*=0 4444 %%%%
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MPVEON+"*! B@GKP/6JNA:FI1114E!1110 4444 %%%% !1110 4444 %%%%
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M2ON'XE_L^Z]XIU#1I/"WBQ/"6G:<AVZ.=(M[RT,N21.H?#+*,X!' Q6+\/\
M]CC3O!<O@.&;6KG5-/\ #-[>ZQ-%<1*IU#4K@Y^T. 2%";GPH]:'8I7/HR,?
MONN -PVCIU)S^E3U&D9$@?.!MQBI*0@HHHH **** "BBB@ HHHH **** "J&
MMZ[8^'--N=0U&=;6RMHVFFF?[L:*,EC["K]>?_'C3+_6OA/XIT[2=.AU?5;O
M3;B&VL)^$G<IC:3GW- GY'.Z-^UW\)M?\+ZUX@LO%L$NF:.$-\YMYEDB#G$9
M\LH&8,>%*@Y[5)?_ +6?PJTWP-I_C"X\5PIX?O[A[6WN1;S,SRIRZ>6$W@J
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M] 0:Z"\^#_C;1_%]]X,;PYJ.HW>LZKX:O[?Q+'!NMK:.TAC%PS/G(*%-N/\
M:XI#T/M/PG^T7\//'/C6_P#"6A^(X;_7[(R"6T2*1<E&VR!690K%6X(4G%>A
M?;(]X7YLD9Z=J^ _V??AMXP7QW\,] N/#6H:)/X(UOQ+J.I:S<PK]FN8[QY!
M;F)L_.6W!B.VVO<?#=U\2/ O[1/A[PSXE\=P>*]$US2M0O%MDT:&S:V:)DV
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MNO&UQ:Z1X-U'7O!^E_;C;:EXA.B><%M_-,*SP2;MBH9/EW'G(Z4 ?9WVQ'!
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MUM%TG0OV;_A1>76H:G')J!1[_4+ZY8&6\N67+=>>6X ["OB+P%J$>J>#]?\
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M[)&[3S^'BPN/,!&Q<;0,5]*444 %%%!( R3@4 !&:\+\;\?M9_#?_L7M7_\
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M)CV[@X_6OD#5-*O_ !8D>H?$+XGQ?8')W6MO>_;9\>ABC^5>0..:ZSP7XV^
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MN1ZU\JCK"BC(]:*8!11D>M% !11D>M% !111D4 %%&<T9Q0 44;AZB@$'I0
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MXKVTBO+='2=4F&0'4Y4X/>I8(^5;K_@I1X,@D)@\#^.+I>Q7177/YUSNN?\
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M%N,D=O=:/.=-TQO2VB*]/]IN:]XT_P#;4^%QN)8(=2U"1[=O+DCCTZ9FC..
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MC^)E_P##KXP_M!^)[;4+"PU;^S]*CMYM1R8O.DQ@!1RS$YPHZFOHSQ)^PO\
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MTR+1M,M;& $0V\:Q)N.3M48&3] *N4"6@4444#"BBB@ HHHH **** "BBB@
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MUMV8!UDC)^7/9@>:^NOA9#K6E?LWZ4=:U2'6M1_X1T3B;R=BM']DW(C+GYL
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MG& ">E6** #%0- 6*],#&:GHH  **** "BBB@ HHHH **** "C%%% !1110
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MW4'@N7Q+)X8UBPN8]AE,PVQN0>05=>GO7V)88$1;^-C\Q]2!CIVZ4 6****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$*!<!>*?10 U8U48 XKPWQMS^UI\-O3_ (1_5_\ T**O=*\+\;\?M;_#8?\
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M?%$X^&WBL?\ 4(O/_1#T <?^R9_R;'\+/^Q;L?\ T2M>L5Y/^R9_R;'\+/\
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MC%7NN .V*\+\;_\ )VWPV_[%[5__ $**DQ,]S7[H^E+0.@HIC"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "J]_N^SMM(S[]QW_2K![57OCB'ZG ],T ?FY^T-HVA>(OCSXR'A
MW0/B-?7%M?*NO?\ "+A!;27#6JI@$\AFB;:3TYK[X^$UM;V7@308+/39]'LX
MK"%(M/NAB6W &-K>]?G7\:!!IW[1OQ3EUA/'SQW-];FU?PQJD=K"\:VL8;<N
M1E@<\U^B/PBGA?X>:#)%]K$1LHMIU"0//C&!O;N?>@#MJ*KF_@$QB,J>;C=L
MW#=CUQZ4Q=6LW@>9;F%H4R&D$@*KCKD]J=A71;KEOBE_R3CQ5_V"+S_T0];C
M:S9)"DS74*P/@+(9 %)/3!SBL+XGR(_PT\5$,"#I-W@@_P#3!Z07OL<C^R9_
MR;'\+/\ L6['_P!$K7K%>3?LE?\ )L?PM_[%NQ_]$K7K- (****!A1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 !Y%>+_M1MH$?P*\5_\)5!>WFB?9\31:;_ ,?#-N'E^7_M;MN/>O:#
MT->!?MF1W-Q^SEXQALXII)Y+01[;9@LF"X+!2> V,X/8XIB/GS]C[PNNG_&2
MUO[[PI\01>K;71L]6\4J@MK=9?+,N-O\<F!S_LU^@%?GS^R!>Z2_QBTN*R'Q
M"2<6<X*>(=62YLA@*#\@)Y'8U^@8E14R6 '7)-(?J/HJBVKVB*CM=0A)#A&,
M@ 8^@YYJ1M3M4F6%KB)9F&5C+@,?H*=F*Z+1.*\+\;_\G:_#;_L7M7_G%7M:
M7]M/(T4=Q&TJC+('!*CU([5XIXW(;]K3X;$<C_A']7_G%4L#W->@I:1?TI:8
MPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ (S5>^9(X2S\*.2?3W_"K!.,50URT2_TNXMI4\R*
M9?+D7^\IX8?EFEU _/3]HK2=(\6^,O&"6?PGLM?OKT%(?$2:['")7,2@28W<
M 'K]*^R?A?IMWX?^$GANRO%C>[L=+A2Z2V;>K,L8SL(Z]_J:^ OBC\,?!VB>
M.?'FG>%_A_X9.C>""L5]_;NK307-\S1"0^2N[D -C(ZFOT0^#5Q8:A\,O"MS
MIEC)I^GRZ="]O:RY+Q(5R%;//%5>PK'YP>*/C-XXUCXG?$_7YH/$.C^(;OP'
MJ*66F&W=(M.$<JB)T/<E%W%O5L5M7MW'I6HZSX<\/:I=R?#FZN?"?]I7"7;O
M%$\Y;[9F3/R[@!OYX([5^CNI>#-+U/5FU.>PBEOS;-:-<.F7:!CDQ$G^$GM6
M/I?P=\)Z/X?O="M/#FGPZ1?2L]U9I;@13EN26'XTDQL_/2TU"+4)[O0=:U2[
M3X96.H^*WT>Y>Z<*\D$*&V"OG+%26*#//;->V/\ %+XI:)^RUX(_L_P+/XR;
M4O!Q;5=1FNQ$]L3$R[F4\EMF&-?3EQ\&O"E]X=LM!G\,Z9+HUG*)K>R: >7$
MX_B4=CZU;\>V$%A\+_%,-O MM$ND786-!@ "!P,#Z4Q;:G._LG#'[-/PP&<_
M\4Y8_P#HE:]8KRC]DX#_ (9E^%A_ZENP_P#1*UZO2&@HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!&^Z>_%>0_M%2Z<OPNU:VOM(M_$/VB)0NC37:VYN<') 8D<BO7VZ'%?-_[
M9/A#P?>?"^]\3^*_#X\2'0(3+:VLD[Q+YK':-Q4_=RP)]LTT(\._9P\$//\
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M<JZGH0>XJB;FG1112*"N6^*/_).?%9_ZA%Y_Z(>NIKEOBCS\./%8[_V1>?\
MHAZ .0_9-.?V9/A9_P!BW8_^B5KUBO)_V3/^38_A9_V+=C_Z)6O6* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ H)Q03@9-1RSK$4!_B.* '-(JXR0*
M$E60L%.2.M><?%[XI6?@72HEC5KS5+M_)M+&'F2>0@X '89ZFG_!>+Q%_9E[
M<^)KL3ZA=2><(%&%M4XQ$OJ!Z^M9\Z<N5&7M%S\AZ-1116AJ%%%% !1110 4
M444 %%%% !1110 'H<=:\F_: NWM?A)XBEBO-.M66V97DU=-UJ5SA@X]QD?C
M7K+<J?I7F7QL\2^%_"'PVU;5?&<$<WARU$;W:2('098 ,0>P/-- ?*/[#OC7
MPU>?$?5-$T'X5PZ!(58S>)]+=Y+.?;CA3(,C/H.*^^\YKS3P+\1? &OM8:=X
M7UW1[AY(A)#::?(FXH "2%7ZC\Z]+H$@HHHI#"O"O&X_XRV^&W_8O:O_ .A1
M5[K7A?C@_P#&6OPW_P"Q>U?_ -"BI,3/=!T%%(OW12TQA1110 4444 %%%%
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M@?RKFP49R7M)/0PP<:\I.=27N]%W\V:=%%%>N>P%%%% !1110 4444 %%%%
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MK'69YI9$EN-/A:*(.K;2FQN001@@TQ*^[/2****0PHHHH **** "BBB@".:
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>V< $9;VJW35C"DD<9IU !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>adag-20211231x20f014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f014.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $H 4X# 2(  A$! Q$!_\0
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M/B_PU;ZB65WWR02,IX9D<J6'UQG%=72,91<6XL****"0HHHH **** "BBB@
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M+NF<$J#M^Z.#R>*J,7-VBKL:3;LCKZ*0=?TI:0@HHHH **** "BBB@ HHHH
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MM[:YF++E%@C4>:/X@"3M 'UJ']H[4;?2/@+\ ;^Y8+:VE_I4\K8SA%M-S'\
M#6M*,)3I3BD[MK1-7TV+@DW"277TZ'6>*OB;^T%\-=!_X3GQ%H7A6_\ #D0\
MZ_T'3S*+NSA+=Y"2"P##<1D#!) YKZ/\'^*+'QIX8TO7M-8O8:E;1W4#,,-L
M=<C([$=#]*\X_:(^)/AO0?@-XDU>>]LKZRU/3I8+%5F5EO'E0J@3KN^]NZ<
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MWM+)D<_(7! '7:!TJSXFO=(O?$FDZ-I>C76L6$NGW&G75MIT2B+[.H4J%9F
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MD*!*U]<D646X9&Y5PA)'. ">E>4:!8:-X8N-?OM6EC'@B'59=/2RAF>***1
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MJ2JM%R<[:LZE%)W2#%%%%64%%%% !1110 4444 %%%% !1110 4444 %%%%
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MPEM9=(T._P!%E1E&DZA<6L)92-T)?S(L>H"N!^%=Q6=K-I">X4444""BBB@
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MKUW^2;1W1C)RYDN5>N_R5U^I>@;>A.<\^M2$ ]J;'&L:X48%.KT+'4($4'(
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MUKUJD_90<GT/2J3C3@YOH<1;FW\8_$?3/%[2K(HU^/2K*-#NV1)')O8X_O,
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M#O VB:G'J%GX<M([N-MZ.VYPK>H5B0/RXKN0N!BKI4JGM76JV3M:R^_R_P"
M5",N;GEZ:"T445WFX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>adag-20211231x20f015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f015.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %\ H # 2(  A$! Q$!_\0
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M!EQP6%9.4:2MNSIA3EB'=:(\B_LK4X26CN;A<CDB4Y]:MZ?XDO=-D"7\;7$
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M5PS=K7BOP _9Q@^!,K.FM-J@BT.Q\/6Q%L(#]DM);EX7FPQ$DV+DH7 48C&
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M[]S0< &E(XZ_6O'M'^+WBV^^+EWX&F\*Z7#<V6F6.M7,T6K2,5MKFZF@VJ#
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MI\:/GJ?\-E'5?BSH?P;T&]US7K#5YM*TZ"*YN;NPMHY$C$DWDHOS2*68N1P
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M4[IJQ4;-:D]Q/J6C>(PUYH5QHS0HDC!IXKB%U9B'0.G\2[<D$#JI!/;=\1#
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MY9B?R'  %=3_ &:<8WCZXH_LTG^,?E7S?U3$6MR_D=OM(=RCVZUP)^$5E/\
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M_1M>7?' '[7\-L G_BL++_T5/75AYM-PZ/<Y:\$US]5L>HJ<@&OF^V\/>/\
MXPZROBK3_$.A^'KO0-:O["RDBTN9IF@BG:(PRMYX62-PBDJ5X(RN#7T?V&<U
MY?\ L]_\BIKXR3_Q4^L=>W^FRT4ING"4X[Z?C<=6*J2C"6VOX6/3+82BWA%Q
ML,X4>88\[=V.<9YQFI:**Y3I"BBB@ HHHH **** "BBB@ HHHH **\,^/GQ2
MU_PY\4/A#\/M"N?[&'C?4KR*\UWR5D:U@M;?SFBB#@H)93A59@P #$*3@CG/
MC=XC\;> ?'GPDT6P\:W[:=XH\7C3;G_1+;SEM/L+NT1<Q')\V/>' 4X8@Y%
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M=IODE:W^RYVLNY1@$L36!N?:.A>._#?BB9(M'U[3=4F?S]L=G=I*Q\B013\
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M<YKR[]GP+_PBNOC&/^*GUCC_ +?9:]27[HKR_P#9]S_PBFO9P!_PD^L=._\
MILM$?X4O5?J$OXL?1_H>H;1QQTI H'04M%8&X%0>HS5:ZT^UO2AN+>*<HV]?
M-C#;3ZC/0U9HH "H/456.G6IO!>?9H?M:IY8G\L;PF<[=W7&><59HH , =O>
MJM[IEIJ'D_:;6&Y\F02Q^;&K;''\0R.#[]:M44 &!Z4444 %>+_M8_%W6?@Q
M\*/[5T".!=8U+5+'1;>^NXS);V#7,ZQ&YD7(W! 20"0"Q4'CBO:*S]<T/3O$
MVD7>E:O86VJ:9>1F*XL[R)989D/571@0P/H10!X!^U7KWC+X)_LU>/O%6@^-
M]0GUC3-.ADM;N]MK5Y(IQ<1JS@"$(0ZL05*D#^'%>;?$;]H+XC^!O&GBCPII
M>ICQ&+*[\,WEG;K#"-6NK:]%Q]KL+<[1&]P1;-+&64$1B7+9"FOJ*^^#/@K4
M_"E[X9N_#MG>:#>I'%<V-P&>.:-&W)&V3DJIY"]!Z5+#\(O!D%K);Q^&M/59
M+J*^>3R!YS7,0VQ3&7[_ )B* %?.5 P"!Q2 ^3_!W[67C/Q!X7\'ZQ'J,&IL
MK^%8+WR;,0I?2:GJEY9W4;J1E)81;(OR[0)5DX*D"IOC-^TWXZ\&WFDZQINK
M1)X:U.XN+DW*6JS1Z/9C5+:TMKJ\4)O-I+"ERVY/GWR^BC'UA'\+?",$>EQP
M^'--@BTM/+LHXK=46W'S$;0, $%F(/8LQ&"2:+[X6^$=2@T^"Z\.Z?<6^GVR
M6=M"\ *1P(R,D.WH8U:.-@AR 44XR*!'DG[//[1$_P 7O&&JIJ"7=C%J)U*Y
M\.V8@C%O)IUE??899'D#%S<&4*S*VU0LB! V&8Z7[4MU);:/I)B4LQ\[IWX2
MO5-$\!^'?#FKZCJFEZ-96%_J$C275Q;PA&E=FWNQQW9CN;'WFY.3S6-\5O 3
M>.M$1(FS<VVXI&>!(& ROUXKHP\U3JQE(Y\3!U*4HQW/S=U/Q-JD7B2.(H6A
M:0+NR3W!P<$ $#U[<]"*^P_V2KV:YO\ 41(7Q]D# /U^^.OZUYU=?" PZD3)
M;F-D8Y#+C!'\O_K5]#? 3P1::'H8UFWNH;J._B A>WD5T\O/7<."21T'3'Y?
M1YAB:52ARQ6I\YE^&JPK\TGH<W^U7\-K;Q-X1OM78."MFUG<-#N#[&888%1N
M!&6 8<C=^-?$WASX<>-=+\??";1?%=KJ36^CZIKNC37I60Q:E;P6Q:TO)=O&
M'WQJI;DNC$9)Q7ZJ$ C!Y^M?/WQ$^- ^'OQ U'19M#6^T^.&&2-[:8QRH67<
MP;(*L.,CIC^7Y[7P,)S<UUW^ZQ]Q3KM)1?3_ #N? O@KP1\0KKP#X'_L_3[J
M7Q._@[Q"UM%<1SF;[<L\?D>?YH"^;M+^7N.../?[3_9*^&NB0G3O$%NE_)=6
MVE102C45G$PN&4>89?- (F!WJ?XAG' Z]K\-_C';?$KQDFC1:)+90_9Y)WEN
M;O>[%"@"[0,8^8\GGC\:]QBC6) J*%4<!1T%%/ P]HJC6SOIW_X'04J[Y>5/
M<=1117L'(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9V
MK9* 9[?UK1KSSXE?$.V\.1_9;9!>:D5_U8/RQ^[?X54=]"9;%?7KJ.TCEDGD
M2)!DLSL !7!VOQB\.^&-365KB6^='/R6BEQW[GCT[UYSXC?5?%-R9=1G:7N$
M&=B>P'Y5DCPPY_A8<?W>*]%+2TF<'*N;F1Z'XY^,_A_QQJNC7)BN[--/:8-'
M/")%E60*,'!X^Z<C!!S[4R!?AX-+U>7PM L.OWHFDEGO)Y9;BY:3RMVYI6);
MBWA50>%6-57 XKS_ /X1F3TQG_9/%'_",N0<Y QG)'2N:6%I-.S:N7=ZW6Y]
M=?#&)K?X?^'XG54>*SC0JI.%(&,<\]N_/KS74U\E> O$NM^ KY7M)))K,D"2
MT?E6'MSP:^G_  WXAM?$^DPW]HV4<<KW5NX-<[INGHW<ZH--61K4445)H%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5&\\:.5:158#)!(X'K4E
M<+HNDZ9J_C7QF]W%!J4R3P6Q6ZM5;R8S:Q,8E8YW(V=Q' RQX[UC4FXN*2W=
MOP;_ $-Z5-34G)VY5?:_5+]3M/M41Q^]3U'S#FE^TQ$\2(<C/WAR*RQX/T$;
M<:)IP"PFW'^B1\1'.4Z?=Y/R].:/^$.T'85_L/32AA-MM-I'CR3UCZ?=.3\O
M2G>IV7W_ / "U+N_N7^9J?:8C_RU3@9^\.E)]IA)P)4/&?O#I68/!^@@C&B:
M<"(#;#_1(^(2<F/I]TGG;TH_X0_0N!_8FG "$VX M8\>5G)3I]WD\=.:5ZG9
M??\ \ 5J7=_<O\S3^TPXXD0\9X85P_Q4\'7OCK3]$&CZQ9Z5J.DZK#JL,]W;
MFXB)C61=K('4X^?KGM73#PAH0VC^Q-.P(3;@?98^(CG*=/N\GCIR:3_A#M !
M7_B2::"L)MA_HD?$1.3'T^Z3_#TJXSJP:DDOZ^1,H49IQ;?W?\$X(:+\5L9_
MX3GPOQR1_P (_)CZ_P#'ST]ZW?A-X/G\ >%IM/U#5K;5+^>_N]1GN+:'R8V:
M:9I"%0LQ &['4UT(\(:"-H&B:< (3;@?9(^(CG*=/N\GCIR:!X0T%5"C1=.P
M(?LX_P!%3_59R4Z?=R3QTYK25:M*/+96\M/T(C1H1ES*4K_?^II?:HCTE0]_
MO#I2BYBS_K5Z;NO;UK+'@W0 >-#TX'R?LW%I&/W62?+Z?=R3\O3DT#PAH( '
M]B:< L)MQ_HD?$1Y*=/N\GCIR:QO4[+[_P#@&MJ7=_<O\S3%S%G'FITS]X=*
M!<Q' $J'/3#5F#PAH(VC^Q=. $)MP/LD?$7.4Z?=.3QTI/\ A#] *%?[%TTI
MY)ML&UCQY1/,?3[I)/R].:+U.R^__@#M2[O[E_F:GVJ+KYJ8 )SN[4&YB'_+
M1.F[J.GK68/"&A*%']B:< L)MQ_HD?$9SE.GW>3\O3DT#PCH2_*-%TX8A-N
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M*** "BBB@ JG?:I;:?;-/-* BG;QR2?08[UR7Q6&I'1D-I*L5B@=KMC*$^4
M8R21D=>/I7EO@?Q'%>:@=(@TZ6YGO77RYO-V^7M!.=N.1@G))XXKCYL55JRI
M4:6B6LGHMOQ.]4L-3HJM6JZM_"M7O^!ZY-X^F=66PT&_U6<MM6*T>%2!@_,Q
MD=54<>I/(KIK*:6XLX)9K9[2:1%9[=V5FC)'*DJ2"1TX)%<;8>'KS1X+C4YH
MU$EK$\L4&[)=@IP"0>!TKP\?ML65OICZC</I4=A%')*]T@N98O+CSYKAU4AE
M3!!89 (QFNRE2J*-IR3?4X*E6G*;<(M+I?<^JZ*^?O#'[33^+-4DT[3X+66]
MCMEO)(3;W$92%G:-7.\#@LC@=SCTKJO#GQ?NO$]SJL&GC3[J;2[LV-ZD!=S;
MSA%<QOSPVUU/XUI[.1'.C;^+_CYO OAY&@_X_P"\8PP>QQR?PKPGP]*]]<&2
M?]^\C%G9N22>IK*^*7Q(L_B'XP9+*\AO!HTTFFW+P*=D5RA!E0$]2H9>1D9R
M.QK3\(X+)U89R#FNF$.2%^IE*7-*QVJ>%$>,2*@*D=0.U9VKV^D>'P/[2O;:
MT8C 1W^8_P# 1S^E:/B#Q:^A6EG86Q*WEXI_>YYB0=6'OD@#TQ6-#\*3J*_:
ML-+YGS,[9).>>2?ZU*[R8WV0S3;WP[JTPAMM6M&E;@(6*$_3<!S6Z?"/7]V"
M",<5C'X/<',2GG/(K4\+:T/">J1:#<R&6VN,Q6[NV1#)U &?X3T]CCUINS^%
MB5_M%#7=(338< #<W4CFI?@KXQ.B^,&TF=S]FU%0!D\+*.GYBK7C$X!^H[UY
M3+9O?:JD43%9 -ZLO# CT[TXQYXM,4FXNY]LT YKXET[QY92VTMS;ZSJNH6T
M;3Q&XLTN9HG:$XGV.H*ML.0Q!QPPYP<=%X'\>:?XSN--ATG4]4EEU#3_ .UK
M0SQ7,2RVF8P)5+@#:?.CQW^;IP<9.DE]HM5+]#ZXK)\0ZI?Z78K-IVDRZS.9
M I@AFCB8+@_-F1@#S@8SWKQG0+M-7U?4]*M=7DO-2TLQ)>VL4[M) 98_,CWC
MMN7YA6]X,UVPUCQ7J.DVNIF\O='N(8=1MED<_9WEC\Q$;/&2A!QVSSSQ6;@E
MU+4K]#L[?QY$\JK=:?<V' WI,5+Q-W#!21QZ@GVS731W$<NW9(K;EW#!SD>M
M<%J7@V]LFDD@C%W"@W *V&('."/7MQ7D]SXJB\2:]$;:U;39) D4:/<;@&'
M^8XVGI^->?4CC*495*<?:17;1I>AZ-%X/$2C3G)TI>>JOZW/IJBL?PLNI)H=
MLNKX^W*"'.021GC)'?&,UL5TPESQ4K6OT9RU(\DW"][=5L%%%%69A1110 44
M44 %%%% !1110 5ROA>[\[Q;XPB^VRW AO+=?(D0A;?-K$=J')R#]X\#EC]:
MZJN6\,7/G>+?&$?VZ>Y\J[MU^SR(0EOFUB.U3DY!SN)XY8C'<\]3XH>OZ,ZJ
M/P5?3_VZ/]=/7H^IKY4_:K_:+U'X,_$[X<ZA:ZFD?@[3-6CL_&%IP#Y-\CQP
M2GG.V!E\QL=Y(O7%?5=<-K?P5\'>)/"_B/P[JNCMJ&B^(KAKK5+.XNYW6YD8
MJ222^5'R+PI ^4<<"N@Y3E_$/QIUJ3XL7'@OPEX;@\0RZ2NE3ZT\U^+=H+6^
MDG03Q!AB00B#>ZYRP<!>17SC\.OC_P".?'^@_!'7/$][(DWB3XB:E9*F@WDM
MG$(H?M:+%.A#":%?+_U9(SM1BV0:^J[?X!>!;7Q%X=UV'17AU?0+!-+L;J.^
MN%86B,'C@E_>8F1& 95EWA3R,5%9_LZ?#O3I-(>T\,P6G]DZO+KUBD$\T:6]
M[)G?*B!P!G<WRXV_,W'S'*$>5>"/VI_%/B3P1XVU27PC82>(/ UUJECKNA0:
MD(62:W>,6Y6:?8HCDC,DID? "QD#)KAO%W[87C+7UT;3?"]KI>G7H^*5CX)N
M;V43M#>6TL'VJ.6-657C$BKL?[Q Y1CN!'TYXH^"/@?QEH?C'2-7\.VUSI_B
M]TDUR-6>-KUTCCC1F="&!58H\%2,;<]236';_LM_#&W@OXO^$829;W5;;6YC
M=7EQ,WVZW3RX;E6>0LD@48+*06R=V<F@#R_4/VWDTNS^(NMGP;J%YX8\(/K-
ME+J5N) C7NGF!?+D8ILC$\DSK'@L0(<L/F &A^SGXR\5>)OV@/BK%XBF6%!H
M/AF_BTNUOYKFSM9+B*[:0Q+(!L+;4#84;O+5N^!Z>O[/'P\35?%VH?\ ",V[
M2^+8GAUJ!YI3;7@=-CL8"_EJ[+PSJH9@.2:M?#[X'^#?AAJ=[J'AS3)[2_OK
M.VT^YNKB_N;J66"W4K A:61CA%) /7!ZT#/&O'O[2EYX-_:R\":#+?0'P%K;
M7?A>X&[YH-8Q%-#(W^RW,"_[7F]<<<A\3IM8OOC=^T%;P>*M?T--#\!66NZ6
MUGJL\4=C>!;EC,D>_P O#>2@=2NU@""#7T9K_P"S[X"\5>!K/P?J^A#4?#UI
M=?;8+.XN[AMD^YG$@?S-^X,[$$MP2:9KO[/'P_\ $^N:MJVK^'QJ=[J]O!9Z
MB;J[N)([V"$[HXIHS)LD0-SM8$$YR#0(^;_@)\9_%O[1_P 1?AUI'BJ\O='T
MU?AO#XKO;+3I7L_[7OIKHVXE8QD-Y*JA<1J0"TOS9  K0^-7Q"MM/_9G^/6N
M_#;XE^(;J[T.8P[R\WFZ+=1B..6T26=-X'.XX)="_P!X#;CZ:\1?"SPUXGU'
M1M1NK V^I:-&\6G7]A/):3VL;@*\:/$RGRV"KE#E3M4XX%8*?LX_#M?!'B+P
MB?#JOH/B*]DU'6+=KJ?=J%S(07EFDW[W+%5SEL<#BF!Y)^TGH?C'Q%\// -U
MX)\<Z_H7C^1]/CTBSL;SR[6X8F-[N>^3!\V)( [-O^5< 8+28.)8?M0W]Q^T
MOJMGXALKQ?!=OXKM_ &CFQNO*6+4WMC<&XN8>LRRD;$.XK&J9VDN6KVCXB_L
MJ?"SXMC1!XP\)Q>(1HMK]CL%O;NX8019!VC]X,YVKDG)(4 G KH6^"/@E_''
M_"7'P_;_ -O?:(;LW&Y]C7$4#P13F/.PRI%(\8D*[@IQG@8 .ZKFOB3;F[^'
M_B2#[$-1\S3YU^QF0Q^?^[/R;@05W=,]LUTM<U\28&N?A]XDA%E_:1DTZ=/L
M9?R_.S&1LW @KGIGM6%?^%+T9U89VKTWYK\_E^:]3H+<8@C&-N%'&>G%2U';
MC;!&,;<*.,YQQ4E;+8YWN%%%%,05YY\<[GQW9^ ;F;X>16TVO)*I9)PK,8>=
M_E!OE+_=P&XQGOBO0Z*N$N22E:]NY,ES)JY^=B>)?C!KU^]KJTWBZ6<-M>V$
M$T.TGMMC"@=?>O1/"7PC\>:HRR2:+>H=H4OJ$@C8@'G[[9/^<]Z]2\??M?>%
M?#MS+8>'A_PD]^K%#+!(%M$<'&/-YW?\ !'O7F5W\??%_BN8-)J2:7 ?^7?3
MQY8'U8_.>W<?2O;E.K.-U!17]=#S5&G%VYFSMKCX<ZSX1M(9]1MH%B+!2T<H
M< GIGH:W]'MDNE"OZ=?RKSO1K^;4'22XN)+B0CEI9"Y[]R<UZ1X=(&T#)X'
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M#X<3ZM/)H4VD2Z+:RFUB%S;V[@J-S;\2,B-M!PH^7)!-?4DE]#>:;<2VTZR
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M:T3G-J-VR&HQUL4O%GB[P;;*UI'8V>KW8.W;!&NU#[R <?ADURNA29=3T/7
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M'M'NP ]U??42+_\ $UC7G[.?AJ^/[ZXU Y&,K,HQ^&VFI4GI,EQFOA+<MO\
M#?X]6!26.QUUHUY!!CNH.WLZ_P N*E^%'P4TGX/2:PFB7^HR6.I.DIL;N<21
MP.N060X!RP(!SG.T>E9VB_LT>!]%U>UU-+6]GO+602PR37L@VL#D'Y2N>0.#
MQ7JU3.I9<E.3Y7T8XPN^:25PHHHKG-@HHHH **** "BBB@ HHHH **** .?\
M7>$+;Q;:)'*Y@N(L^5.HR5SU!'<5QR>&K_P5IT\#SQW=K=-\Q6,X0CH<GH3_
M $KU&FNHD4JP# CD$9KSZN#ISJ>WC[L^Z/1I8VI3I^PG[U/LS@O!ED]Q=O.E
MPJ1Q@K+'SE@1Q[8_PJI:? OP]9ZRVKI;6G]JL IOELT$S # !?J<#(^AQTKI
MM=\!Z3KSPRLMS874(98KK3;F2UE4-C(W1D;AD X;(R.E=&HVJ!G..YKOA.IR
MKG=WW/.E"FI/V:LNQYW!\"_"<-G;V@T72OLEL\DD,']FP^7$TA_>%5QA2V?F
M(QGO6K9?#/1;%[9H+&S@:UD:6W:&SC0PR, &="!\K$  D8) %=A1578K(\4_
M:"\%B7P_9:Q$#-/82 2.<%_+)Z9/8')^I]Z\V\)?>4'/6OJO4;"+4[&>TG4/
M#,A1@?0U\T:MHDG@+6[BSN<^6KDPN1]],\'-=%.=UR,RG'7F/3M$NTMK;+@,
M>F#SVKC_ !+\+=$UR=I[.XGT:5SETML/$2>OR'I^! ]JP!XMX^\#].A_S_C2
M_P#"6\\$=>.V*J,91=T)N+T9<TKX-:;;3K)?:Q>WL8/^IC580?J02?RQ7I-B
M]AI6EK8V5JEM;(#L2(=_7/4GWZUY4/%N<@,.>>N<<T#Q:#_'CZ9IR4I;@G&.
MQN^,CRQ(ST[?K7 >&=/&J^+(;/;YC31,BQX^\?3\:VKKQ#'=Q"-F(!SS@\&N
M^^!W@22"\N/$-[#LROE6BLO0?Q-_3_\ 52YO9QU)MSRL<+I7[+,FG_"?4/A[
M%=7\?A^?3)])MBZ1M/:6\H9<!N!(45RJEAT SD\GH;;X"ZG8ZW!JFGZM=:?/
M%H]IHK 6<4FZ*WE:0.-S?*S;B#P1@\8/-?0=%8>T9LHI'SSHW[,.GZ;K.LZ@
M;G5@NK1V;W5O;7LMH'NK='071:*0,7=9,,I)4^6G'RBNG^#_ ,#;;X0MK4>F
MWFJ7D.K:JVJ2'5+HW#PNT4<>Q6))( B4Y/)[]!7K]9^LZ/%KFGO9S375O$Y!
M+V=R]O)P<X#H0P!QS@U/,.QY[JMJ^E:D4DE2YF7#.1G&3SSWSWQ4UU\/K_Q?
M?1ZG>WJVJ2*!Y0B^90.F.<<]?QKM-"\*:3X:L8K33K&*WBC9G!P7<LQRS,[9
M9F)Y+$DGN:V*\ZOAGBY/ZQ*\>BV1Z.'Q2P<5]6CRRZO=_B4=)TFWT73XK.U3
M9#&,=<DGN2>YJ]117;&*@E&*T1Q2DYMRD[MA1115$A1110 4444 %%%% !11
M10 5RGA>Z,WBWQA$+V6Y$5W;KY#H0EOFUB.U&R=P/WCP.6(QWKJZY7PQ=>?X
ML\81_;9K@0WENOV=U(6WS:Q':IR<@YW'&.6/U//4^*'K^C_KJ=5%>Y5]/_;H
M^7^7KT?54445T'*5-3TRSUBREL[ZUAO+68;9(+B,2(X]&4\&O.==T?\ L74&
M@2,);GF$+P-GH/ITKU&J&LV<=[I\RO LS*C,BD=&P<5PXO#^WIVZH[\'B?J]
M2_1GF>H6XT[0QJTS@68XE<G[C;MH&/?CIZUZ%X:\3:=XGT]9].NTNT0!9"OR
ME6QT*GD5X/J>NZCJ?AZZTN><S02[619!CRV5L@C'3OGZUC_#CQ)-X7\764RL
M5AFD%O<(3U1B!T]02#^'N:[<LKT\TPC<7[\-U_7<Y\SPD\LQ5I+W)ZIK^NA]
M4U2U75K/0[&6\OKA+6UB&YI)#@#_ !/L.3FKM?/?QX\0R:AXHBTM21;6,88@
M=&D<9)_!<#\375AZ/MZBCT.*K4]E&YU^FW$'C2YU*_TZ;S+.*5VDD<%2H^\!
MM//2H+&SDU&ZBMXE)=SV&=H]?H*\\\):M?Z+I-Q%:W#VZW;!W*'!*@8 ]NI/
M']*]W^'< _X1:RN'C47,J$O)CYG&XA23],5\_C*U/'8UX6F_=I]?N3_R/H,)
MAZF6X+ZU->]4M;RW?_!-S3-,MM(LTM;2!((4R=D:A1DDECQW)))/<DU<HHKU
MDK:(\9N^K"BBBF(*YGXDP?:OA_XDA^Q?VB9-.G3[)YGE^?F,C9NXVYZ9S735
MS7Q)MOM?P^\20BS_ +1\S3IU^R&0Q^?F-ODW?PYZ9]ZPK_PY>C.G#:5X/S7Y
M^J_->IT%N,6\8QC" 8].*EJ*W&((N-ORCC.<<5+6RV.=[A1113$%%%% !7)^
M/_AMI/Q&L[>'4O.CEMF+0SP, Z9QN'(((.!P1VKK**:;B[H32:LSSWPS\$_#
MOA\H\L4NIRKRIO&#*".^T  _B#7?0P1PQB.-%2,# 51@#\*DHIRDY:M@DEL1
M3PQW$+Q2HLD3C#(XW!AW!SVKY0^/G@R7X::E!J%B9!H5])M0[<BVEZ^63_=/
M5<^A';GZTK,\1^';#Q9H=[I&J6ZW5A=QF*:)NX/H>H(Z@CD$ UI1J>SG=[&=
M2'/&W4\B_90U5=7\&:O,L@D"ZB5)&/\ GDA[?6O<*\P^!/PEE^#^BZYI3WGV
MZWGU62ZM)3P_D&.-5#C &X%6!QP< ]Z]/IUW%U&X[!334$I;A1116!J%%%%
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M;;PYI-O<0L'CFBL8E=&'0@A<@^]:&K:'IVNQ+%J6GVNHQ(V]$NH%E56QC(#
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M%T][?A>YA3E4E7M+97_&WF,U>]@L/C+\+GN9X[='NM1B7S&"AG>U"HH]22<
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M%+:WBMT)W%8D"@GUXJL^@Z9(Y=M.M6=B2Q,"DDGN3BFN2^J=@?M>56:OZ?\
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MZYKUEI=V\8E6&YEVLRDD CVR"/PJ]X8\7Z-XTL);W0]1@U2TCE,+36[;E#@
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M]4@\)ZQ_:4^F):R7<,EM-;O''<1":!]LJ*65XSN5AD'!YX-(#NZ*^:[OXO\
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MQ^'/#MEH,?B)6T[0=)\1Z1X?<V[&6--7F\R1[CYQYAA4;%"E=V2QVG@?5%%
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M:NLUV2(O-$CKL 8%6ZE2#Q7<^--$NO&FE6%G87T4.GS7<4M[*CGS'@3YPL3
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M.Q/,>VT5E>&]>A\1Z6EY#_>*.OHPZ_X_C6K6>Q>X4444 %%%% !1137W;#M
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M3W%PX6.- .2Q/05X3\./@[X>\=>*+3QO)X,L/#7AZQ.[0=.2S6">YS_R]W*
M<#_GE$?N@ECR0 4E%TI<[LM/OUT_$*C:J1Y=7K^FOX'MFN^#- \47VE7FL:-
M8ZI=Z5/]JT^>[MTD>TFQCS(F(RC8XRN#2WW@[0=4\16&OWFBZ?=:YI\;16>I
M3VJ/<6Z-]Y8Y"-R@]P#6U17*=1ROB+X6^$/%NIR:EK7AG2]5U"6U-C)=7=HD
MDK6Q.3"6(R8R224Z$\XJ&Z^$'@:]^W?:/!^AS?;9;:>Z#Z?$?/DMP%MW?Y?F
M,0 "$_=P-N,5V%% '*W7PJ\%WL.O17'A+1+B/7V5M6673H6&H,OW3."O[TC
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MRPC%Q-LFBD,,SGV[_B/ZTK)KF0[M:,[V?6X;0!Y6 4G')Q3I_&MC=69M'""
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MHW]CWK0W%G->NR*V]W;_ !JHL<2@K'I<D!;'S!CQ^9K5.RT,VKF(L<@;)_\
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MD=2T&'1(;>76F-O+,N[S'0[3GMD<9]1UIND:3IFNW0MM/D:\ER"1$C$#W)Z
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MQSI86"(]PXDGGF9IIIF' +R.69R!TR3CG%;X 48 P/:BBE9#N%%%%,04444
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M*_>XZ]:VZ "BBB@84444 %%%% !1110 4444 %%%% !0!BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>adag-20211231x20f016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f016.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (Q YP# 2(  A$! Q$!_\0
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MH#+EG;CIC'H*U(OV:/#<GPS\4^"=4U;Q'XAL?$PQJE_K.KR7-[-\BH,2-P@
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MX;FZ\/P:L^G1!6AU"]TJXM+:\0D@/;R2HHF7Y?O+D8(/0B@#MZ*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M+?VFO@Y)\>/@SKW@^WO%L+ZZ5)K2XDSL6>-@\>_')7<HS[5ZE1UH ^6XM$^*
M/Q0^$GB/P5\5O!/A_P 'Z!%H3VK:M::[]MDN)D0!)DC5 (T&W<=Q)Z<5X5\&
M_@IXR^,'['GCK628->\8^,IK:WM)G<1)+9V96*,J[X^5MK-Z'Z\5^BTT$=Q$
M\4L:R1N-K(X!##T(/6H[*PMM-M8[:T@BMK>(;4AA0(B#T"C@4 ?''Q@_92\9
M?$GQGXTFL$LM,L=3\$6.DVMU+.NV2]@G60Q.B_,$(7!;!&/6JNM?!#XM?%V]
MU[Q%XC\(:3X.OK;P7<^&=.TFVU>.[-[-(%'F;U 6*,;> 23SSBOMC HVB@#Y
M<\._ +Q+IOQ*\ :O+H]E'8:/X#ET*ZD6:+,=VT:*$4#DC(;YAQS[UP'A7]GW
MXK_"BP^#OB?1?#&G>)=:\):?J>F7OAR76DM<+<RL4DCF(,9 !&1G)X]*^XL4
M;1Z4 ?#_ (._9-^(.EZOX!U'4H-/BG?Q#JVNZU'I]V/*TO[7"42.(G!?:<9*
MCK6;X=_9Q^*__",>#/AWKOA[1=+\*^"=;DUH^+XM4%Q<W\:L[HL, 7?'(V[#
M%B,C<.]?>6!1@&@#\NOV:=>L[KXB^#$U(Q^)+K4-3U>QT>QTW75:703</)YD
M\^G+ 'ABQV>9\9R!S7J?PW_9T^,ND:E\*= UCPSH4'ACX?>(9KQ=4AU@23:E
M#*TA$@AV_NU ?E2=Q.,"ON.S\/Z9IU]<7MKIUI;7EQ_KKB&!$DD_WF R?Q-7
M\4 ?*_P*^$7Q$\"?&_5-0M-*?P/\.+C[5+?Z!-KRZG:W=T[92>RC"AK8'[SA
ML9)(V]ZS/C!^S#XI^)/C;XOW\$,%M%K.D:?_ &#>-<1Y^WVSF1"R\E &V\D8
MKZZVBEVB@#XF\*?LG>.M,E^$]SJ1CN-5AFU74?%5^EXF8;N[A*;DQ@MCY1\H
MXQZ5F>%_V;OBWJ&@?#_X>:YX:T/2/#O@;5)-13Q5!JJS7&IJ-YC6*$)NB=MP
MWLY'?K7W7M%+@4 ?&G@_]F;QOH_@SX'6<VF6-O>^%O$MUJFKQ)=1Y6*1I<.I
M'#G#+D9SCZ5SWP8_95^(_P (/&5IXL@TNVN[K5;W5-.UFQDU&+?;6-Q,7AN[
M=SD*RYRT:X+?6ONS HVB@#X5^!G[*GC3P7XVT+2?%OAW5=7T70-8GU&RUU?'
M!_LX EF21=.\O?YIW88$@$DDFJ?[/GPKN8_VU/&>F0W]M>>"? ]S<:E86L2[
MA;7E\HW1EL\,OS-CH,].:^]L"JUKIMI937$MO;0P27#;YGBC53(V,98@?,?<
MT ?/7Q[^&'Q#M/C!X2^*WPVL=-\1ZGI%E/IE]X>U2\%F+JWE(.8IBI"N".]0
M_&[P/\3_ (Y_LX7&D:EX9TG1O%]SJEK<+I%EJHGBA@CF1COG945GP&)"C'0#
M-?2F*-HH ^9/B_X/^*.@?'SPSX_\">#-.\:6]KH,NE7%K=ZVFG&-F93NRRMG
MH>@_*N:U#]F+QU\9_'WC_P 4>,-8OO ?]J:;#HUCI^BRV5ZDUF8]TJ2/+$Y7
M]X<97:2!FOL#%&!0!\V?!+X!^*U^&'A/3/&_B'Q-H&L^&UEL(8=#U\QV]W;*
MY\EYDC+*YVX&#C &,5PB?L6^*?!7Q=^&M[X9\;:[>^&=&N[V[NY[L:>LMF9L
MLP0>2&D\PG:Q;>0.A'6OLX#%&!0 #I1103B@ HH) [B@D#O0 449'K1D'O0
M44 YHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M(+^_M]*L;B\O)DMK2WC::::5MJQHH)9B>P !-<Y\-/BGX6^,/A6+Q)X/U>+6
M]$EEDA2[BCDC!=#M<8=5;@^U<5^U/X*\:_$7X52>'?! TZ2>_OK=-4MM2NY+
M5+K3@Q:XMQ+&"R>: L9(&=CN.IKR;]GC6?&?A+PSXC\+>+O!-QI-]XE\6:W#
MITFB0S3VENSF21WF8HODVX8!8I.0ZE>!0![CX$_:+^''Q,\4WOASPSXLLM6U
MFU61VM8UD3S%C<QR-$SJ%F56&"T98#UYKT?/L1]17Y__  "\!:]XNG^"7@Z3
MP_XI\'7_ ,/O#FM:9XDUH61LA#+.H@CBMKEUQ([-^^#)D8"MUR*ZWPK\*?\
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M"BIC",-D94,%AL-;V,$K??\ >>-_M#?"CQ7\7YO".F:%KT/AK2[#4QJE_?M
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MO?F/+>$KNHI^WE9=+1_R_0YWP'K>M^(-$%WX@\.OX7U!G9?[/DO$NF"CHQ=
M!SZ5XK^U_P#$C7] M/#_ (6\(ZOJ.C:_JDDEY)=Z582WEQ#;0+N.$C1SAVVH
M21CYNHZU]&*H7H,54ET:PGU*+49+&VDU"*-H8[MH5,J(WWE#XR%..0#@UHCT
MHIQ23=SX1OOV@=6^(OB>#49?B5?^ M/C\!C6$2"Z@AB74HY"D@>.5/GRZE2A
M]:M:E\>O&GB\I/X@UC4_"\UCX5L]7AT32=8M-&DU)Y<^=<>=.K9"  B(=V .
M:^OIO@O\/KBYM[F7P)X9EN+=S+#,^CVQ>)RVXLI*9!+<DCOS6CXJ^'7A3QVE
MLOB7PQHWB%;8[H!JVGPW0B/JOF*=OX4RCP#2OB1>77QD^&$,7CZ_;1?$/AJ:
M8Z3?S6JR(_D!HY9-J@M,2<Y^[QPN*\MN?BQXQ\-Z'\8O$'A/XB:QXQ\,:?9Q
MV6EW&L75HURE\)MMQ<1*L8V0)G:&==N>><9K[(N/A/X(N]9M]7G\&^'YM6ME
M1(;^32X&GB51A0LA3<H X !XJ'2?@WX!T">[GTOP/X;TV:\C:&YDM-(MXFGC
M;[R.50;E/<'(- '!_LL>/9?%WA76=.O6U2;5-$OOLEW<:EJ\6J>:YC5PR7$:
M(I7!Z;1@U[967X<\+:+X.TU=.T'2+#1-/5BZVFFVJ6\0)ZD(@ R?I6I0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44C' ]*^3=)_:8^
M*'C/XB75EI%E\,_#V@6'B&31+K3_ !)XBE76]L5QY;N(%4*&D3#QISG>G)S0
M!]9T?B:** "OF?QW_P G^?"W_L3-;_\ 1T%?3%?-'CK_ )/\^%O_ &)FM_\
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M P2,Y .@U']L'X1:7-IL<_BY?^)A;07D#Q6%U(GD32-&DCLL9$:[U*$N1M;
M."14GQ__ &CM.^ JZ"UYHU_JXU7[3M:S@F=8O*MWE&XQQO\ >*JO; 8MT4UR
MFG?L6>'M)\+>(]!MM:NS::WH,6C323VT3R+(LTLSW78&1GF8XP ,#%;GQM_9
M6T7XX3::^I:SJ6GBQTR?3HQ:3RIDNJA92$D525P>""#NP>.* &6?[2EY/\4_
MAIX-N? ]_IJ^,M)DU(ZA>W C%K(D/F/ (BN]V4_*2P0<@C/./<QTKQ3Q/^SQ
M?ZU\6_ WC2P\7OI=OX0MFL[#2VTQ;@-'(@CE#S/)N8L@ !(RI&>:]K% !111
M0 45'<7$5I!)//*D,,:EWDD8*J@=22>@KS'P=^U'\)OB%XO3PMX;^(&A:WX@
MD:14T^QNA)(Y0$OC P< $Y![4 >EWMC!J%O)!<PI/#(I1TD4$$$8(_*N!L/V
M=_ASIB:-';^$[%8='LKG3K&%M[1PV]P29H]A8AE;)^\#[8KT6B@#A?AE\#_
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M1ZG+?V^_8MU.LD?S @Y&P9ZU7M,J]]\DM=M=/^!\[BOC]-O\M>NO;L<Q<?\
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M7U*]CGO-.M8=,*^?+#;QNLTID\R/;&&RN6))V\Z&I?M-^++?PO\ "76='O\
MPEXHTOQ-XHA\/ZGJUE:WEN#OE*?N+>4[HV 5@Q=VP0, Y. #ZGHKYX\2?''Q
MGX,^/=QX7N#H/B3PZNCWFLW-MI5I-#?:/!$@,+7$S2LCF5PRJH1.Y&=IS/\
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M=N9UX8C%2E33LM-^VFA&#HO#T(TV[V04445Y9VA1110 4444 %%%% !1110
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M+7USBC% 'SQ^S1\)_&?@W0?$&E^+&O;/2+FSM;*STR\\12ZNT3)"8YY(W?\
MU2.<%8U. !T%>/Z-^R7\68M?L$O=>5M%DGCT:^B-^'7^R89C-%*@VAO.8[4(
MSP!G)K[GQ10!\7:]^R[XTO+O1-0N-!TGQ!=VM_K>1=ZKY;6\-TI\B56*'<4;
M!V<?6NL_9:_9KU[X'^+K2ZEM;6QTN3PQ!9WR6U^TWFZ@LF7<H>#\O ;\,5]2
MXHP/2@#X-\3?LL?%W7O$WB*[L4TS0XKRVO(I%L+Q+6WOE:<21Q-Y8,I#J"&D
ME)923@8JSXC_ &/M8\1:_;:M:?#3P[H$-QX<N-/;3X=>:4Z=>!LQ2J_EC?GG
MD8VY[U]TX%&* /CFV_9F^).F^-#+:W6FW'AY+--6C@OK^1@^KBT$!BD55#>2
M6^8D'FN+3]COQQJ6@O)JOAC0[R:+Q#IVI1Z.VH1P0M!'&4N53RTV1@D\ Y9@
M!EB:^^L48% 'PUJ_[+/CZ#1[73H/#>G:O:"UO[2RADUPQ)H\TMP'ANER#NV(
M,?+\PQ@<&NI\._LM^,=.^(EKXHU*6WU/5[/Q#87$>KG49!(]BD 2YPF<#>XR
M4[]<U]>8'I10!\T_$_X,>+O$/QVN_$-KHUCK.FWFEK9Z9K$^L/;S>&YU5MTL
M=OM*R[B0<@@\=:\BT7]D+X@WUA'8ZAI5AI.F[--MM2LH=<:4:K)#.7FNV*@8
M++Q@_,V<'BOO/%&* /AOQ3^RIX[3PKI>DP>'=+\4:+:WFL!?#EQKC6MO$MP,
M6UP'*L"8^NS&1V-)K/['_C#4H=$FU'0M'U]=,U'293I]UJ919+>*V\JX56VD
M+\W.,?-CM7W+@48% 'PQJG[*WCZ+0=,TQO#.F>([&&TO[.UL[CQ$]NFE32W!
M>*Z3Y#YA6/  R",<5UV@_LM>)M-^)NG^*[J*TNM2M->T^<ZHU^YE>RBMO+F^
M4]V?G;WZYKZYQ1@4 ?+_ ,;_ -F[Q-\4OC19:Y"VC1Z"@L0TMQ9QR3H(IB\G
M4@MD8&._2M3PQX.^(-_^TG-XL\6>#M-_L*PMY--T"\L=9CS86S<N[6_E@N\A
MZ_-A1P :^C,48H %Z"BBB@#EOBE\/-.^+/P\\0>#M7FNK?3=:LWLYYK*3RYD
M5NZL01D<=00>A!!KXT^&'_!/6U\%_&OPI-KOA'0M7\-:+;75T/$VFW]U;W%U
M>+-;M9&XM'E.R2/RY26B8QON^95P ?NG5FO$TN[;3HX)=0$+FVCN7*1-+M.P
M.P!(4MC) ) S@&OBKPI\9/C7>_9O"?B?Q[\*?"FO?\)'Y5Y-<^)HY-8A@%_N
M^S1V@CV-OBQ#'N(<HZEMKG@ ^X**/6B@ KYH\=?\G^_"W_L3-:_]'05]+U\T
M>.O^3_?A;_V)FM?^CH* /I>BBB@ HHHH **** "BBB@ )Q7QC^WD)_&WCKX4
M_#^ Y35]1!E0R[58-(D?/!QA2^#VS7V:WTKXWOHCX]_X*+Z>L8\RW\+Z49I&
MA7< PB( <]OFGQGU KU<M]RLZO\ )%OYVT_$\S'>]&%+^:2_#7]#[$M85@@2
M),[$4(N3S@# _2I: ,45Y)Z84444P"BBB@ HHHH ***CGG2VB:25UCC49+.P
M4 >Y/2@"2BJ6I:I;Z3IMSJ%S(5M;:%IY'7GY%4L2,=>!7EGP/_:<\*_'?4]5
ML-$AOK.YL(Q/Y=^BKYL);:'7:Q[XR#TR.O:7))I/J83KTH5(TI22E+9=SV"O
M-=>\9_$BQU:\M].^'5KJ5C'(5@O/[>BC\U.S;&7*GV_G7I&]<XR*=BJ-SPC3
M/&WBZ"YTYM+GO?%GB64.VK^&;Q$LX;,')4K*8P(PA 0<GS0<^X]&\$^(_&.L
MWEPGB3P?!X;MDC!BECU5+MI'S]W:JC QDY)]*[&B@#R7]K'Q'J?A+]FWXC:S
MHM_<:7JMEHES/;7EK)Y<L,@0D,K=B/6O M,_; \6>%O#6OMJB:3J$^E^%TU/
M2T5C<B_$4%OYTUQ=QS$Q2+)/F2!XE(&TJQR37VA>V-MJ5I+:W=O%=6TJE)(9
MD#HZGJ"I!!'L:S;3P5X?L)[N:VT+3+>:[3RKB2*RB1IDQC:Y"_,,<8.: /CW
M7OVE_'<GB33=)'BKPG;VND>,]/TN\\46:/'I6H0W%I+*86)E(4HZ@,!)SNCZ
M$D&[XO\ VU?&'AR#QQ8IH6A#7?!$5Y)K8N5N5MX\W,,=AM;=_P M8I6D8@MC
MRR.#Q7UI#X*\/VVC+I,&A:;#I:OYBV,=G$L"MG.X1[=N<\YQ7%^(?V=_"7BB
M'QLFHI?3/XOEMI-2F%T5?$  BCC('R(,$X[EFR?0 ^<C^V5XTANF\.VTOAGQ
M-?W.O'3;;Q5H$0FTS8]HUPD*K)<1JTRMB/F89'.W=\I]6\<?M$^(/"?[.WAK
MQO-INC6.N:O-9VES+)>BYTG36FE$;W$LT38,*<MD-W +=37M+^!?#DND2:4_
MA_2GTN27SGLFL8C TF<[BFW:6XZXS5T:!IBZ1_90TZT&F>7Y7V(0)Y.S^[LQ
MMQ[8Q0!\G^-/C?\ $S5]&^(-MX:\3>#+G3_"OA6/59?$6EPRR/>RS+=!6@VS
M,D8'D!LY;# CD=-[]GSQMJ?C+XMZ1>7_ (BM=>:[^'=C=RS:9<%K268W;*SA
M=[#?QM9A_$&''0?1]GX9TC3[:2WM=*L;:WDB$+Q0VR(K1C.$( P5&YN.G)]:
M=IGAW2M%"#3]-L[$1Q^2GV:W2/:FXMM&T# R2<=,G- &A1110 4444 %%%%
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M"@\U[D !T&*SCJVS@P_OU*E7SM\E_P %L****T.\**** "BBB@ I&8(I8D
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MJ!E>$1;3,^XJ ">!ZYKM: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJCMX4AB1$18U4!551@*!T '85)5K1'="+C!1?1!1113+"BBB@ HHHH ****
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MQG+XU^)MY8:CJ,]V]_\ V!I<9:Q$CL6(E9QEP"WW1QQR6'%?9D<:QJH4  #
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MJU9^#/A+H%W#?^&=7T+POJL6=E]IU_;EBI&&1E=F5E([$>A[4 =VOQ:\))I
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M[9^&+^[>]M(4NGM=0TZ>RE>W<D1SQK*JEXVQPZY%<O\ #[_D[+XJ?]@72/\
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M52<MDYQP6.4YQ5J?X-IINK:?K&B:MJ/]JV3DH=;O;C4(60C#+M=_E)'1AR*
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MIJ^GV]^+=GWF(2QJ^TG SC=C.* -VBBB@ HHHH **** "BBB@ HHHH ****
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M#.J7[ZGJ.DZ7;V<]R[!MSH@!"D*N5'W5. =H&><UV5% !1110 4444 %%%%
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M>"TN[CQ1J]I.8[J2&V91;[G&2/.\R/.2"0",U]1Z7^RY _C'XD3>(=4M=?\
M!_C.[@U"7139R03P7$04*?M"S?,ORYV[ <]^U=I<_L^> ;N\\5W<OA^)KGQ3
M!';:O*)9 US&@PJYW?+C ^[C..:!GGGP^TFVTW]JW5+JW61)]5\&6]Y>DS.P
MFF\Z-=Y4L0#CC@"OH>O,_#?PHU/1_C3JWC:ZUJTN--FTB/1[#2H+%HI+:)75
M\R3&1A(<KV5<#UKTR@04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P_Q*^-_@3X/?8?\
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M!HT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[?<CYN_;$\,>*_B=9>%? F@>$8_%6F7]VVH:U%?71L[-K>!<I&\^Q]CM*T1
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M /2!:^CZ^</CS_R=I^S1_P!?6O\ _I M 'T>.E% Z44 %%%% !1110 4444
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MBO1H+?[+]N#F^C.Z#./-4 Y9<\9&>>*\:O?V7M=U'5M=>?7=$_L_5-=L=?\
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M&I! ((;&.* /9HOVK?!UC>6VG^(+W3_#^HW@NWM$GUBTEMY$@.,M.DFR-F/
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MQXST#Q;^UI^S<-$US3=8,%SKIE&GWD5QY8:P&W=L8XS@XSZ4 ?5 Z44#I10
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M=7OAZ"^6XN;)!(8\O@ ]0.PQN%=%;?&GP+>:]J>B1>+=(;5=,CEFO+0W2K)
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M>W830?9S.)<C 4H <@D@'/ [UVI.!7SQ^VSK4@^%=GX9M)WAO?%&IV^EH(R
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M[^SRWP;AU]KR^TR[GU:WLK*2+1]-%C;^5:QO&DA3<Q,L@D+.<XS@#ID^U44
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MW@^"9K33+=8(RYN,%BJ\9X'-?5948Z5\[Z#_ ,GW>)_^Q*MO_2F@#Z)HHHH
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M.:]4HH ^</!O[#WA/P;K(U2'7=9NKMM+FL)O,\E8YYI$:-KQT5 #-L;:",
M=*O6?['VE:?I-YI5OXLUF/3;W0(- N8#%;GS$A.8Y=Q3*N/0?*?2OH'- (/>
M@#R_1/@)IV@ZOXSU&VUK5([GQ/9064TD3I&]L(HS&KQ,HR&P<Y.>>E>9Z-^P
MUI?AM'N]'\9:IIVOK?6NHV^JQ6-H6CFA0H'>,IME9PQ+L^23S7TY10!X-XA_
M92B\57.NRZGXXUNX&N)8M?H+>U42SVK9288C^4GH5'R^@K-U#]BGP]<:QXYU
M*S\2ZUITWBC'[J$Q^58@NKR+$H .R1E&]2?FR:^BZ* /GOPC^QUI7@:UT)-$
M\5:KILNEW5[.#;VUL(I8[I<30^68R$3^[MPP]342_L8Z/!9C3[;Q=KMOI-S:
M6]EJ=F([=A?Q0RF1 6,>Z/[Q!*$9'H:^B:* /(O"?[-VB^$-3T:\M=6U&7^R
M]7OM8BBD\O:SW*!&0X7[J@#'?U)JEXA_9AL-?U;QHQ\4ZU:Z!XO4OJFA1" P
M-/L"B9)#&9$88!P&P2.17M5% 'S]I?[(.FQ^(](\1:QXMU?6O$&G7EK<1WLD
M,$(:*W0I%!L1<!<')(^8GN.E9=[^Q'I;2:L--\<>(=(M]:CEAU6"".VD6[1I
MO.5?GC.S:> 5P2.M?2M% 'BT7[,=A87^EWVF^)M5L+S3]<EUM)$C@<.TD2Q/
M$P9"-A5>H^89ZURW_#$VD6?VZ+3/%^LZ=::O";77(1%!+_:,'GF8)EE_=$$E
M=R\E>O/-?25% 'C7A_\ 9@T#PTND1V>IZ@L&E^(7\0V\)$>T2,NWR?N_ZL ?
M[WO2^(?V8/#OB3XFKXWN=0U!-26]@O5A23$0,490*1W4D[OJ..*]DHH \@^%
M'[/]Q\+?&>N^(/\ A-=5\02ZW.]Q?)J=G:F29S]P&98Q(%0<*@(4>E>OT44
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M;E\)7>@:S=:+>VKWJ7D1D@"F1XID4+(@W$9 ZJ1S6_\ ''PYXT\7_#'6='\
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MK!^%_CSPW\0_VV?%.I^%]>T[Q#IR^#H(FNM,N4GC#BXY4LI(STXH ^IZ***
M"BBB@ HHHH *1SA:6LOQ1JR:%X=U+497*1VMO),S 9("J3FFE=V0F[*YX?\
MLU,WB/XE_&+Q62&BN];33X6C_P!6Z6\>TD<GG)(-?0E>#_L6Z?+;_ ZRU*X\
MW[1KE_=ZLYF&-WFRG! [ @ U[Q79C7_M$HKII]RM^AE17N+^MPHHHKB-@J"^
MNELK2:=AE(HVD/T S4]><_M">*!X1^#WBG4 V)A9O#$H)!9W^50,=\FI;LKF
M56:I4Y5'T5SD_P!DFU:[\":QXCDC"2>(-:N[]6W9+1[]J9&3@X!XKW(# KB_
M@WX8_P"$0^%GA;20&#6^GQ;]R[6W,H9LCUR37:4H*T4C'"0=.A"+WLOOZA11
M15G6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% "-TK\])OA'XKB^*ZW"^ ?&W_"VG\8BY
MC^(YUPG17THWQF\K'G;?*%G^Y\CR\[Z_0MC@9]"*_--]#^&M[\5)+*^\>Z[>
M6NG>*A9^&O$#^%;F+2]%O)-9%[>6XO5^62ZEEWVPEPJA" 2>10,_0GXAS:_#
MX/U'_A&-(L];UAU$<-E?WYLHF#':Q,HCDQM4E@-IR1CC.1X5^SM\./BK\)_@
M!X(^'M[HOAM9=+O?[.U*Z35Y)M^F/YKR7$($*XF#2!1&V5(!);L/ID48H$?'
M7P?_ &7/'>B:_P#";1O%EOH*>$OA=_:G]GZA8WTD]QK'VE6BB$L#1*(0(Y&+
MC<V3P,"M?XH> /#/@C]K/]F__A'?#FDZ!]HN==6;^R[&*V\P+8#:&\M1D#)Q
MGIFOJZOG#X\_\G:?LT?]?6O_ /I M 'T>.E% Z44 %%%% !1110 4452U?5K
M/0M,N]2U"X6UL+2)IIYY#\L:*,LQ^@H\A-I:L\Y_:A\8CP-\!_&.J"3RI_L#
MP0D2;&\R3Y!M/K\Q/X5F?L?^$&\%_L[>";.3 GN;/^T),/N&Z=C+Q^#+QVKP
M_P#:\^*NC?&[3/!?PZ\$:M'K,VOZU#%=_9ED79&",9)7 '+-T.-F>E?9>EZ?
M#I6GVME;H$M[:-88E4  (H"KTXZ 5ZE5.C@H0>\Y-_):+\6SSJ,HUL3.I%W4
M4E\]W^A;HHHKRST@HHHH ***9(VU6).,#.3TH \&^->DV7Q3^-/@#P+=V\5_
MI5BL^O:O;2+N4QHOEPJWLSL>#C.VO=K6"*TAC@AC2&&-0B1QKM55 P  . !Z
M5XC^S_%-XV\:>/OB3/\ /::K>?V3I#G'_'E:DJ6&.S2;CU.<9KW3'.:SAK>7
M<\_")3YJ]M9O\%HOP5_F%%%%:'H!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8/
MCRQU;4_!FN6NA7*6>LS64L=G<.,A)2A"GJ.^*^+_ -FOX=Z]X<^*?A-M(^&O
MC3P+J-O"Y\9:UXC\0?:[+5R(BN8XS._G,TF&6157:/:OLGXE6>FZAX!\0VNL
M:FVC:7-83)<Z@LOE&WC*'<^[M@<U\._LQZ9X&U7XL^$M1A\77U]XL\YFL]:U
M'PM<Z1%JVGPVIABM-/=R4\H#YW7.7.2!WH ^NOVA_#7B[QI\)];\/>#;?2)]
M4U6%K.0ZS<R011Q."KLI16)8 \ C%<#X9^&_Q6N?@QH7P\UZW\)V=C_9D^BZ
MG=6-W<32I MN$MY8<JH+EA\ZG@#H:^BDX6EQ0!\M_"/]FSQ7+XUTK7/B?%X<
MN[?0O#0\+6MAIY:[AU"(%<SSK+&%3*HH$8#<YR34_P /_"VB^$?VX/%-EH6D
M6&BV9\&V\AM].M8[>,L;CEMJ #/O7T[BOG;0?^3[_$__ &)5O_Z4T ?1-%%%
M !1110 4444 (3P:\4_:T\>0^%?@9XI$%[#'J5W +"")9E$F^4A!@9SGG->U
M.< U^:WQ:@^(&G?M97V@V6FW+:=JFK17D,<>FQS--!A-\BR;"P48.2&^7VKU
MLLPRQ%:[:7+[VO6W0X,95G3@E!7OIZ'W]\)_"T7@OX;>&-$B54%CIT$)"G(W
M; 6QGW)KK::HZ_6G5Y<I.<G)]3N2LK!1114C"O!OVG_^*EU#P!X(CQ)+K6M1
MR3PY.#;Q?.Y8="O !!KW6ZN([2VEGE;;%&A=F] !DU\P_"[XBZ/\>?VFK[6]
M-N)I=+\-Z0T-BD\7EEI7DVR/M.3C&,'@UE4:TCW/,QTXN,<.WK-I?+K^!]01
M1K%&J( J*,*HZ =A3J!T%%:GIA1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <A\6
MK"ZU#P!JJ6?C63X>R(BS-XCC2W?[&B,&<GSP8PI4$$GH#7Y^://H.K>,-$^'
M/A#XU>.?BY:77B*/6KG1-$T&S&E-)'?1W-Q+)<LJJ(EE_>,L18;F&%RXS^B?
MC[P+HOQ,\&ZOX5\168U#0]6MVMKNV+LF]#Z,I!!R 00>U>"6'[)?B?P!X_\
M"?B+P3\3=0N=.T)9K./0/&%NNH0QV=Q)&US'#.GERJQ$,6UG+X*#)()% 'TU
MZ_6BBB@ KYP^//\ R=I^S1_U]:__ .D"U]'U\X?'G_D[3]FC_KZU_P#](%H
M^CQTHH'2B@ HHHH **0L >:-PQF@!:XOXSVE[??";QE!ID<LVHOI-R+:.",R
M2-+Y;% JC)8D@8 '7%5?B=\;O"_PCN=-@\179M7U!)'@RT:*P0H&Y=U&?G7@
M5X7\?/VN]+O/AU9Z9\.II]6\6>*<VEC!:C,\"EVC+X4GYB5(7!_VNF#7=A\-
M6J3@X1W>_3[SAQ&)I4XRC)W?;J_)'E?[&^J>.?C[\;$\2>/M4O-63P7:R?9S
M=VJ1^5=3?)L^1% 8#<V#D_*..3C]!5X 'MVKR;]F;X+CX&_"VST.>1+G6KB1
MKW5+I"2);E\9 )[*H51Z[<]Z]:S@5KF6(AB<0Y4DE%:*VB^[S>I>%I.E3][X
MGJ_4***3=SBO,.L6BDW#UHW@T +7S_\ ''X]Z9>V>H_#WP5J\5]\0M1G728K
M6 -FU:3B20OC:-B$GKP?H:]E\9>,M'\!>'+[7-=OH].TVS3?+-*<?0 =2Q/
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MKT%+0,XYHH *^=M!_P"3[_$__8E6_P#Z4FOHFOG;0?\ D^_Q/_V)5O\ ^E-
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MWMX1B" Y7!(]""?)=(_:$_9ETU)FO?BAX0UZ]G??+?ZWJ,%U</P HWLO"@
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M96L#7']FB<W*PB1R3YC*H+,<;=V!@+G%>E_L\?%_Q%\0]9^(?AOQ9:Z6FO\
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M .(KR#]EC]HR_P#CQ/++?>(_!<\IT]+]_#F@I<F_TX2,#&)I9)"DH5&VNR(
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M1\'Z3X9TFQO?"'AV:\MK2&&:0:7 V]U0!CDIDY(/)KB/VA/CIXK^%VL>"_\
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M (5#X%_Z$SP]_P""FW_^(JIJOP8\%7FF7<$/@_P['-+"Z(YTJW&TE2 >$KN
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M!&B;0KO([&1R2Q,G4C /05[C110 4444 %%%% !1110 4444 %%%% !1110
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MI6VK*!C> &'/)[UX_P"(/V;_ !QJW[0.D>/K;QQHUIHFEVCZ7;:,="=I%L9
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
; **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>adag-20211231x20f017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f017.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %G R(# 2(  A$! Q$!_\0
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MJMM^Z^T!>>XKZ6^(OPJ^"D_[,'@SXF?%RP%\NE^ [/3K1+B[=%5FM]R+!$&
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MDN<;6E"F,$'@_-P>#6+/_P %$OV=+:>2&3XH::LD;E&'V:Y(!!P>1'BO-/\
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M&\.LZI;78OH5AFG5)81',R+P"RD=AD@GO7ZCP?ZE/I0,?1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7F_[1WPRO\
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M?:?(VHV44K RPQ%?E(*JJG)Y _AR:Z[X@?L*^*-"U/X1Z_\ !OQ;I_AOQ'X
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M %XR,GG!-?2-% 'R1J7_  3%^"^J7.M^;9ZXFFZI,UT-(AUF6.RM)V)W2PQ
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MKXJ>)_&NB7UGH.IP:)I-KX0U%(V:?2KRR>0DL.AAD1EC9>=RE@1P*8'=>/\
M]L#0_ ,OBMY/"?B;6--\*")-=U/2[:.2WL)Y$5Q Q+@LP61"Q0%5WC)KH]'\
M<ZI8?'RZ\,Z@RRZ)KN@IKFC2' :&2%TBNH#_ 'AB2&0=QEQT KXX^./B[Q=H
ML7Q?\ :7JNF6>K>+9HI[K0KBPNI;^6\GM+:.=--*KLFMI"FWS7*F/$A;H*^I
M-.T6?Q=^U#IEX]@ZV'@CPM):/>DD*U]?-"QA7G#;(( Q]/-2D![VA)4$\$BE
MI$&U%'H,<TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUN/[:ZO]KU"8-NNI@  64R2,H "J6X' QZTC;D!'<4M  !@ >E%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\/\ [7G[0OCC
MX0_%C3=/\,^/=,BO;R^TZ&T\'76B_NYH)6VRRSWSD*AR&P 1C@=:J_$?X_>,
M?#O[6.I^&KSXEQ>!?!T.I:5;Z?;7WAMI[?4/.AC>:(7N L9WEDR3GGVKU;X^
M_LK^(?C]K.H:=J_Q%O[7X>W\UM-<^&HM+MV8&$HP$5R1O0,R9/NQJ'XJ?LI>
M(OC#XE6VU[XE:G)\.H]3MM5C\))IT(V/!M*1+<_?$>5/'7D\T#/&OB/^U'\5
M+,_$SXF:#K6E6GP_\">,;?PTWAFXL \FHPB6*&XF,^=R-OF&T 8P#^,GB;]I
M7XJ0^(-?\<V6M:;#X"TCXDP>!_\ A%WL%:2:U,B12W)GSN$A=LA1QCZ5Z5XI
M_8:3Q)XY\23IXSU.R\ >)M<@\1:WX/BM(O*O;R-D;_7??6-FC5BH[CK4M]^P
M_P#VCX^O[R7QIJ2^!+[Q4OC.;P@EM%L.I+A@WVC[_EEQN*8]O>@1L_$_]OGX
M6?!SQ?KGAGQ)+KT>I:,P2Y:UT6>:$?(K@B4#:1M<<YZYKW?P/XNLO'WA'1O$
M>F,[Z;JUG%?VK2H4<Q2*&0E3T.".*\H_;-L(D_93^+,Q0>;_ ,(U>G<5&<^7
MZXKH_P!EP8_9N^%G_8KZ;_Z3)0(]/9 Q![CO49ME)!R1@YXJ6B@9&T 9-IZ4
MY(PBA1T Q3J* &O'N0KDCW]*HZ1X?T_0-,CT_3;2&PLHRQ2"VC$:*2Q8X XY
M))/J2:T** .!O_@%\.-6@L8;_P #>'KV&Q5DM4N--B<0*7+D("OR@LS,<=R3
M74V7A?3-,TR/3;.QM[73HT\M;2&%4B"\_*$ QCD\8K5HH XSPU\&? W@S5)=
M2T#PEHNB:A("KW6GV$4,I!ZC<J@\UNS>%=+GU5-3DLH)-12!K5;MXE,JPL06
MC#8SM) )'0XK6HH \^TC]GWX;>']8M]6TSP+X=L-4MY/-AO;?3(DEC?^\K!<
M@\GGK6S8?#'PMI?B.[\06>@:;:Z]=J4GU2&TC6YE!ZAI -QSWYYKJ** .'^)
M/PTA\=S^&K^.X-AK7A[4TU+3K]5WF)L&.5"N?F62%Y(R/]H'J!5]?A=X33Q4
M?$R^'M,'B/&!JWV./[5C_KIC=TP,YSQ74T4 84?@708K:WMTTJS6"WNSJ$,8
M@7$=R6+&91CAR68[NO)]:\Z^,OP"7XC06[:+JD7AZ\CNVO+I)]-BO;+4V:,1
MD75N_$I5578V05*C%>Q48H \G^"7[/6B?!_2IV1EU+7[N\N;Z[U=K6.!VDG,
M9=8D08ABQ#$!&O "#J:ZZ\^&OA^;1(]-ATVVLX()9+FU-M"B-:SR;]TT1 ^2
M3,CMN'.6)[UU5% 'S9\-/V2[OP-XSL?$FH>*TUN_TBWN(=,==&@M'>66,1FY
MO9(_FN90@VY. <L<9.:]@^$GPVM/A;X*LM$MYFNIU:6YO;QUVM=W4SF2>=AV
M+NQ.,\# [5V=&* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHS0 449'K1F@ HHS10 4R6,2QLK#(88(-
M/HQ0!Q]U\)?"%Y'/&_AW2QYRLK.MG&&^8<D''7WKS;PA^Q;\-?!OB&VUBTL[
MRZN("Q$5[.)HFR".4*X/6O>:*S=.#W1S3PU&I)2G!-K;0Y[2? 'AW1+T7FGZ
M)I]E<KD"6WMD1AG@X('<5O3!S&=F-W;-/HJTDMCH22V/#[3]F;P[K/C_ ,;^
M*_'&E:5XOU#Q!>1-;?;+!7%C9PPB**W3=GG[S,1C):O+=._8^\=^"-3\#7O@
MKQWIUA<>$;'4M'L6U;26N0;"YN1-'"P#CF-5$>[T K["(S13&?-'_#'RZSX<
MUVZ\0^*KS4/B+J^IV>LGQ;;VRPO97-IG[(MO#DA8HU+J4).X.V3S6IX>^!?C
MO4_'7AWQ#X[\7Z-JBZ!<_;K:'0= 6REN;CR9(O,N)F9F*[)6^1<#./2OH.B@
M#Q_7/A+KTWQ&\9>,=(UR/3=2UCPI;^'[%C;[S9S12W$BW)Y^;!G'R_[/O7C_
M ,.OV-O''AWP-K7@7Q+XZT;6?"6LVMS]O:ST0QZC<7LF&2[DN'=B\BR!6Y'.
MT 8%?8%% 'AOP_\ @IXJM/B5!XY\>^)+'Q)KNG:,VAZ>VF:<;.-8GD62:616
M=MTCLB],*!G YK.U'X?ZU#\7?B1IJ7NI:;H_Q"T>&YM-8TT$2:;J%M#]F?Y_
MX2T?D.F>#Y;CK7T'33&I(/\ (T"/F+6_V7/%/Q!BU;4/&OB^RU/Q%)H">'=/
MN=/TUK>"& W$,\TLB%V+R2-"G0A5 X'6M[XK?LVWGQ'E^,++K$=D/'GAZST.
M)3;E_L9@\W]XV#\V[S>@QC%?0.*,4#/SX^(7PV^(%[KUW\.M$MM:CTBX\9:=
MK+6%QI!>WD2.6"2:[2_#;4MV\MG,3#S _'0U[?XA_9 L?%^B^ -,UNYM]5L]
M#U[4=>UB*YM=RZK)>).)5P3\GS3@@G.-H]*^EO+7=G%.P* /B#Q3X"\<? ;4
MO"ZZ9K'B#6+R#0[OP^FOV^AMJBS6(N/-M;66-7#)=1@_).?D;G<*W_A?\(_$
MDVE_LY^$]=TBZLCX#LF\1ZM<3H&477ER0V]MO'!ES,[MC@!/<5]?-&&[D?0T
M", YH (AMC4>@%.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **1V"*6)P!R37'^+OC)X%\ W:6OB3Q=HNAW3@%8+^]CB<C_=)S^E
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MLSL2S$\<X Q7G/COPSI'AO\ X*(_ ^'2=+LM+BE\,ZXTB65ND(8[#R0H&32
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MPD(N9V@VS0PJ>6,:@DD9SZ8Q0!^A.C:=!H^D65A:QB*VM8$@BC'\**H51^
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MS&SBR3[UZI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-'B+]L7P)X8^*LOP\NK;Q%<>(H9[6WF^Q:+-<6T37"*\6^9 54%7!)/3GTH
M]SHKPGQ9^VA\,O!7CZ?PEJNHZA%?6M[!IMY?1:?+)86=U,,QPS7 &Q'88X)[
MTNI?ME_#;2?B/)X+N+W41J,.JQ:'-?)I\CZ?#?R#*6SW(&P2'/W<T 7?VTO^
M33OBU_V+5[_Z+-;/[+O_ ";;\+/^Q7TW_P!)DK%_;0)/[)GQ9.TC_BFKWM_T
MS-;7[+O_ ";;\+/^Q7TW_P!)DH$>GT444#"BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH BN>86&,YP,"OR*\4W.O^,_VP_&'@KX8^*]5\&_#+X@^
M)W\/ZS>6NV1;F_CMM]\\(;ID@J2I'WO0@5^AG[8?QN/P*^!/B+7+(L_B&Z5=
M*T2"-=TDNH3Y6$*O<CE_^ U\+^)/$/@+]ECQ7^S9X.UG5IUUWP5JESKWC&8V
MLLK1SWEH'>0L =^7.W"Y("B@#]+?A=\/M(^%/P\\/^$-!A:#2-&LTM+=';<Q
M5?XF/=B26)]2:ZFJ6B:C!J^CV-_:MOMKJ!)XF(QN1E#*<?0BKM !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4'D44&@#XK_ &Q)
M_AK\/OBQX=UC5_@_>?&#QWXAAD%K81DW M[6U1?,=8FRB@!P>%Y.<FO.O"OQ
MK^%_QZ\=^'-#UG]G"RL_AMXFU*32-"\7W5A%")KL*3L9$12F61U&&S\OL<?6
M7[1.G^$/!-G:_&?Q*NH+/\/[2[N(FTZ3#S0SH(Y8&4\.&.S .,%0<U\U_##Q
M=9_$+Q7\(?#MK^S]\0?!'A30=7.L:9/<2I_9L,LB2NL\^068 RNP^8<O^% '
MVC\-_A[I/PQ\)Z=X=T&![71[%'2VMY)WF,2LY?;O<EB!NP,G@ #M755652UO
M" 3'TSVKXZG^-OQ9^'_[3FG>#-?U[P_XOT6YTG5=9U/3]%TYH9-$MX59[9I)
M2Q)\S:!\PY).!TH ^SJ*_/;1?VS?BAX+T;P=XY\;?V1J_AGQUX8UK7],T33K
M4P3:=+90F>.%I=Q\Q6C(RQYR>G%5]7_;,^*GPA\/W5WXOO=&\3SZW\/XO&&B
M_8;$VJ6%Q)=10""0;B9$'GH<\'Y#ZT ?HC7R3\5O^4C'P)Q_T+&N?^@&I?A?
M\?/&7@OQE\2?#/Q3U.U\1Q>%_#MCXH75=#TUH9##.K"2#R%)+E2A*D')S7EN
MA_M">%/V@?\ @H)\';[PJ-56#3O#VM6\_P#:NFRV3;FB9AM$@&X8[B@1^@=%
M%% PHHHH **** "BBB@ HHHH **** "BBB@ KQO]LOC]E#XM_P#8LWW_ **-
M>R5X?^VQJEKI_P"RE\5Q=7$-L)?#EY#&99 @=VC(5!GJQ/  ZT =%^R[_P F
MS_"7_L4M)_\ 2.*O3J\A_9,UNTU7]FCX4&SN(;I(_#&FP.T,@<*Z6L:LIP>"
M""".H->O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 $X%?GW_ ,%!]=LM,_:/^$2Z]\3IOA;H2:7?O'KNCQAM0MKAB%^?
M'S>0Z@+QE=R\C.#7WKK\%W=:'J$.GW"VE_);R);W#)O$4I4A&([@-@X[XKXF
M\67G[3>A2"/Q1\$?A_\ &9[1-MOK-E(D,A3(R##+RI)YVKQS0!WG[$NM>&M4
MNO%8\/\ QWUCXV,OV;SVU52!IX(DV[,J/OX.?]P5]6'@&OCCX4VG[16J^,--
MED^'G@/X+>$?M44NJ06(2ZOKZ-3\R+Y?RKD$@,>1FOL2 YB7^M 'PE^USXRO
M_'OQNT[X?^(?"/B]OA?H%Q;:OJ,^@Z/+>MKUTH#Q0!EP(X8R06.2201Q@5C_
M !Y&N6_QZN;SX46/Q+TOXDZEK>E-?KY)7PW>V44<<;22$_(46+"\\@[N*_0@
M<=.*,9&.WI0!^9GQ"\$^+&L/C3\%X_!NN7VN^._']OKFD^)8[(MI_P!A-Q;S
M-/-<$D+Y:Q,NWKS[U:UKP;XLO]0\4?".W\%ZY-K6H?%^+Q=#KGV/&FC3/-CF
M,_VC(4.%7&SKDD5^E.T8Q@8]*  .G% 'Q'^W!^S+)??#?XL_$$?$[QS;1_V3
M<7W_  C5OJI32B$A \HPX^XVW)'<DU]&?LN?\FW?"P>GA?3?_29*QOVTA_QB
M=\6O7_A&KW_T6:VOV7?^3;OA9_V*^F_^DR4"/3Z***!A1110 4444 %%%% !
M1110 4444 %%%% !1110 4V1]B%O3UIU>>_'KXM:9\$?A/XG\::LP%II%FTR
MKGF68_+%&!W+2%%_&@#YS\7;?VF_VZM%\-(9+CP5\)(%U?4UQ^YFUN7'V>,_
MWO+7#8[%6'>OKV3P]IMR=]S86ES*1@R2VZ,Q_$BOG[]A#X3:I\/_ (+0:_XF
M:63QOXTNG\2Z]+<#]YY\_*(?3;&5&/4M7TE0 B(L:A5 50,  8 %+110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'C'[9
MMS=VG[+'Q0EL9K6"Y_L*X59+Q-\0# *P(P>2I(''4BOB?]DSX@>"Y_B!\--)
ML?VD?B'KU[FWMXO".I:=)'9RN(2/L[N1@(N#W/W17WE^TSXC\0^#_@'XZUSP
MHEJ_B'3]+EN;-;T(8=RC)W!_E/R[B >"0!7Q1^S=\1#XD^)?@*2;]K>P\7W%
MY<12/X-7P\MO)<NT9)M_,Q\A!/7_ &?>@#]'$C\RWB ;@ <^HKYO\ _L9W/@
M/XAZ[XH'Q1\1ZM'X@O);K6M,O(+?R]1#HT8BDD"^9L16 4*1C:,5]*0#]RGT
M%28H ^4? _[ /A[PRZV6M>+=9\6>&K+1;_P_HNBZ@D:)IEE>?ZY5=1N=L?*&
M;H*31/\ @GWX>?1];L/%_B[6?&PN_#Z>%M/FOTCBDTO3DD$L:1% ,R!UC)<\
MG8*^KZ*0'BOP._9L7X3:YKWB+6/%6H^./%FLVUM8W&L:G$D;+:VX(BA1$ 4
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M$!V7;EA[%: /K.WC$4048 &< #&*DHHH **** "BBB@ HHHH **** "BBB@
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M=*U[41:ZI<>9#I^4;]S;KCY(^?N^PK[L65'Z,#]*^3/BM_RD7^!/_8L:Y_Z
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M]%T_1]1\D,/L]W%:1;XCD#)''(R/>O>Z "BBB@ HHHH **** "BBB@ HHHH
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MYTO2[.+7!9R%/+E668K]G(Q]P X!Z\5]61\(OTKY]\/ _P##:?C4?]2E8_\
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M3;HW\57B$C<<?\NZ,!UZ_4_+]U:;IMOI5K#;6L,5M;0QK'%#"@1(U P%4#@
M#L* ."TK]G;X:Z)K-OJ^G^ ?#5CJMO,;B&^M]+B2:.7^^& R&R3S7H]%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% 'EG[4G@O7_ (B_L]^/?#7A>;R/$&IZ7+;V9\PQ[G./
MDW#IN *Y_P!JOB'X/>"(-9^+OPHC\%?L]ZY\'M8\-ZDD_B#Q%>+Y4$EHL#I/
M;YW?O_,E88SSQGZ?:'[8&I3Z/^S)\1[VU\0MX5NH='E:+5TW9MVXQC:-P+'Y
M<CD;LU\-?LK0?#*Z^*7PXN['P%\:;/Q))+!,-6UJYEETE+@PDN\A9N8R2W..
M<B@#]0;48MX^WRCBI:BM2#;QD# VC )S3II1"NXC/.* 'T5A:5XYT'7;EK;3
MM8T^_N54NT-K=QRN .I*J2<"I]+\5:5K)NA9:C97?V4XG^SW*2>4><AMI.WH
M>OI0!K$9%?$_BSX>>&_!/_!2?X37^A:+9Z7>:YH>NW^I3VT>UKN<HP,DA[M[
MU]B:)XFTSQ'#)+IFHV>HQ1ML=[.X295;T)4G!Q7R[\5CG_@HO\"3_P!2QKG_
M * :!'UM1110,**** "BBB@ IDL@C7)_G3SP*^/_ -JWXM^(OB7XX@_9Y^%=
MXT'BC5XO,\3:]"<IH.FGA\D=)74X '.".[< '(^.-1O/V^/C-<>!M&N9(O@7
MX0O%;Q%J<#LJ:_?*<BSC8?>B0@%B/<_W:^N-7^#O@OQ1:Z=#K/A+1-5BT^!;
M>T2\L(Y5MXP!\D88':O X'I3/@Y\(/#OP2^'VC^$?#%HMKI&G0A$RH\R5SR\
MLA_B=CR3_0"NYH$9GA[PYIOA72K?3-(L;73=.MUVPVEG"(HHQG.%4< 9)-:=
M%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH 9(1M(SVKP#]F<?\5I\8
M_P#L:'_]%"O;?$>LV_AW1;_4[K=]GLX'N'"#+%5!)Q[\5\8? ;]J7P5X:\5_
M$"XU-[VU@U[6'U*TD^SE\IL"A"%R=Q],5RU)QC.-V>7BJ]*C6I>TDEO^1]P!
MPI(X//K2^:,X')KYZD_:#\8>-"P\!_#+5KN!SM35-;(L[<^X!^8BHT^&/QA\
M>L%\4>/K?PY9L?GM/#5OA\'^'SFYJW4_E5S;ZTI?PHN7Y?>SV3QAX^T7PA83
M3ZIJMEIP5"R_:9U0L<<  G)KX/\  G[1WB[Q;\:_$$WA?1[&'7O%D<%C ;J8
MM%;F!6_>=/FRN3BOJO0?V2? &D7AO;^TN?$NH=[K7;EKIL^H!X'Y5YW\)?@Q
MX4\.?M3^-H].TQ($T"TLKFP0.Q$4DR-YA&3WS6%15)./0\O&0QE:I1LU%<VM
MGKMWMVN>E?"C]GJR\(WY\2^(;Y_%OC2Y&Z;6+T;O+_V85/"+^M>P10E-I(&<
M<U)!'Y42*,8 QQ3ZZXQ4=CW:=.-*/+!'SYX=Y_;4\:^O_")6/_H^OH.OG[P]
M_P GJ>-?^Q2LO_1]?0-33V?JSFPGPS_Q2_-A1116IW!1110 ,=HS7R%^V#:V
M/B?Q1H,]G^SQ#\>O)M98)-3BO(U73B)1N@/7+9^8CM7UXW0?[P_G7YI?L^Z;
M^TU/!\16^$E]X+M/"H\=Z[A=>C<W!G^T_.<@$;<;<?C0![)^P+\*_$7@3Q/\
M4M:O_AJ/A3X;UZ]M)-)\.RS)/-"8XW68EQSY98@JIX!+8[U]E5X?^SA:?'6V
MFUW_ (71>>&+OF'^RSX<1EQPWF^9D#_8Q^->X4 !.!FOF^Z_:G\67OQY\0?#
MWPW\+9O$-AH.HVMCJ.N+KEO!Y*S1+*9! ^'<*C$D+G.,=37T>W0U\.?M&_ #
MQ=\4_C!:2>&_A;IOAG48O$-IJ3_$^#556XDM(=FY6B4;RY VA3D?*#TH [CQ
MC^W9#X6\7^(4B\$7^I> /#>O6_AO6O%\5VB):WLI"D+ 1N=$9D#,",;OI3M=
M_;JAT?QUJ%E%X'O[[P5IOBB'P=>>+8;R/RTU.3 "K#]YHPS;6<'@]J\L\<?L
MS_%;5%^)'PQL-'LIO!7CWQK'XHG\6M>*AM+7S(II;=K?&YI-T*@%>#FJ]]^S
M%\3?[4USX;VVA6LGPZU#XBQ>.8_%$]^-]O:^:LTEJ8 -[2EU(!Z8- 'T%^VM
MXTT"+]F7XLZ3)KNF1ZK_ ,(]=Q&Q:]C$^\QY"[-V[)R,#'<5V?[+G_)MOPL_
M[%?3?_29*\+_ &X/V4?A5J?PD^+/Q+N_"%K/XV&C7-^NK/))Y@F2$*C8W;>
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M?@"SAN_$&IVVDVTTGEI+<MM5FQG&:\<%M\=_A[&?(DT3XBV$?.)\VEXP'O\
M=)KS+]H/]HVUU7X?7^@^*/AYJFF:S=Q200'48E,,$I4C?')T)'MS6TJW+&[T
M9W5L=&C3E*:<6NZT^]'UAX.^(&B>/;!KW0-5M-6M4D\IY;5]RAL9Q]<$5T4D
MR1C+, *^5OV7_C]X B^&UAI\USIOA&]LMEO+#<2I&;EE109>V<_TKI_VAOC!
MHUO\.I;_ $+X@Q:-=I,!#<Z6T=R\K;6(C*\X!(ZXXJHU4X<S94,;3>'5=R3T
MO_5SZ!64L^ 5*^H.:Y?XFZUXBT'PE=7WA;3[34]5B(86][*8XR@Y<Y'< <5\
MU? ?]J#0M"\"F_\ &GC^[\0ZY.49[&2TS+;MMY2,(/G&<<^M0_'/XU^-_BC\
M.[VV\%^!_$FFV)DC=]7F4P2; <D*GWB".OM4RK1<+IF,LQI2H.I!ZVO9:O\
M"Y[)^SO\6?%7Q9\+MK^O:-8:38W(#6!M9V=I "RON!Z8(XKU*_UZQTF RWUY
M;V<0'^LGE5%'XDU\&_LE> /B)XW\-:A';^,-8\)^&U>/R?)CW&<?-N\EFX4
MYSCO7T5I7[('@VXN?MGBB[UCQE<CG.L7K.F?78"!44IU)16A.#Q->OAX3C3U
M:WD[?D;GB;]J7X=>%YFMI?$=OJ%YT%MIB-<R$^F$S7F/Q._:4\1>+/!6M1>"
MO WB:,_9CMUF>#[.(2>C*I^9C]!7OWAOX5>$O" 4:+X?T_3@#P8+=5;\\9_6
MNAG@4,F<XSR/:M7&<EJ['5*EB*L7&511OV7ZL_/;]CWP1<?%7QC>0>+4OM0T
M'2S)?PV=P6%J]ZT@$A<8PS#J0:_0JULTAB\L1B.-0 JJ,  =@.U>%_L?JK>
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M0IP2.[8%9/Q(^(=SX+N?#L'BO]C^UT^;Q!J4>D:8#KMMFXNY 2D8V#@D \G
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MK!@LB>7,8VP@D+??1E^[7WO%X6T[3/#AT72[.#3-/6%H(K:TB6..)6!&%4
M=2>E</\ L_? G3?@%\)=%\ Z?>W&JZ=I;3O'<WBJLK^;.\Q!"\<&0CZ5HZ=U
M9-F]3!N<7%59*_G_ , ^+OV<OCM\7X+V^OM!\+:M\6XYX1$(#JL=M';X<@R!
MY/E8Y^4@<CO7J'P\_;=^+OQ4TJ[U'PM^SM>ZM96E[-IT\J>([9 EQ$VV1#N
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MIWBVQ\73W%TMU;3:M<VK*BSLL9,>>,H!]:TC%15D=-*G&E!4X[(_1G[9;_\
M/>+_ +^#_&L3QAI%IXL\/WVDRWTEK%=Q&)I[.<1RH#W5L\'WKXU^%W_!+7P9
MI7AU[?QWJ.L:YK7VN9UO-,UNY@B\@OF)-I.=RKP3W-+\*?\ @ECX-TKPRT'C
M_5-6UW7/MLSK=Z7K-U!%]G9OW2%2?O*O!/>FU<T:3T9]&?"?X#^'_A!J%Y=:
M1J^HW"W0.^"]OA)&&+;BX7^\3WKU=;JW7C[1&?\ MH/\:_.C]EW_ ()^>#_'
M7A'Q'=^/=-\666IVOB34+.SCDU6YM2UE'(! P4GD%<X;O78_#3_@EEX.TRWU
MT>-]4U;6IIM4FFTPZ;K-S +>Q./+ADR?FD7G+=\THQ4=$9TZ<*4>2"LD?<_V
MRW_Y[Q?]]C_&C[9;_P#/>+_OX/\ &OAKX?\ _!+7P7IK^(W\8ZGK&KI/JDLV
MD+IVLW4/V6Q./+AER?G<<Y;OFN!_9^_8#\*>+O%GQ:L_&.G>++2PTCQ,UEX?
M:75;FW$MCLRK*V?W@)_B]ZHU/TC^V6_:>+_OL?XT?;;?/^NC_P"^U_QKX:\%
M_P#!+3P;9>(?%DOB74M7U+1[F^630H+/6KF.2SMMN&CF8GYVW<Y%1^%O^"6W
M@^Q\9>,+KQ%J6K7WAFYFA;0+&TUFYCGLHPI$JS.3\Y9MI!'3!H ^Z?MEO_SW
MB_[^#_&C[;;_ //>+_OX/\:_.+X-?L >$?$OQG^,>B^)].\66_AG1=1M(O#D
M[:K<PK-"T),I63/[S#@<]J[K1_\ @EIX+@^(WB&\U+4=8N/!<UM;II.FPZU<
MK=6TRC]\\DF<,K'H.U C[C^VVX_Y;Q?]_!_C1]MM_P#GO%_WV/\ &OAO0O\
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M$,2(SO)M49=@%X3C)/)P*W_ASH.O>'/"=I8^)M:@\0:Q%O$NHVMDMG'(-Y*
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M'^W/^T'XV^ ]DFI>'?&WAO0#]EWV&@ZCI<EW>:Q<"559%?(2) &')YR37UU
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M\.]1^%'P)\">$M6E2;4M(T:WM+EHFW+YH7+!3W )Q^% 'IA  /%>;^$_V@?
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M'VM0>AJ*W<LH#=<<U(_W3]*Y3M/E+_@HA\5AX)^"3:%:R;=1\3S&P W89(%
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MQ+X0NK0)I\UQ91&U9\Q?ZM<$ \-T'K7U_8V4.GV\=O;016UM$NR.&% B(O8
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M** "BBB@ HHHH **** "BBB@ HHHH :Z;\9J.&TC@?<B@'!' Q110!-1110
M4M%% "4444 +1110 E%%% !2T44 &:2BB@ HHHH *6BB@!**** "D8;AC-%%
M $,5DD4QD&=YZGN?J:GHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "H+VSBU"UDMYT66"12DD;J"'4C!4
M@]B#110!F^%?!VC>"-'M])T#3+31M*MP1%96$"PPIDY.%4 #)K9HHH ****
M"BBB@ HHHH *.E%% !1110 4444 %'2BB@ HHHH **** "LW7?#UAXDT^YL-
M3M(-0L;E/+FMKF)98Y%]&5@01]1110!A^ _A/X0^&%K+;>$?#6D^&K:4@R1:
E791P"3&<;BH!;J>M=<!@ 444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>adag-20211231x20f018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f018.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %# L$# 2(  A$! Q$!_\0
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M^EHO(2,[J3[=%GJ?RK\W_A]^T1\?=(\6_!7Q3XXUS1K[P7X_NDL/[$L+4))
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI=Z9?Z_&(?LT4>MZI<7JVT60?+B#L1&N0,@>E>S6MI;VUO%##&L<4:!$1>
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M"[G'G2#U6,98CZ"LK]IOQIXK\#_#!KKP5!9R^(;O4;/3[>;4$9[>W\Z4(99
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MT&X9J[&X>,,.E>'^$_V6/!NB7FG:FL>I)?6Y64*^H2.@<=L$\U[;%$(K8(.
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M>S.,!T#!2P]B0:0SZ'HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIUWP];22#5=&>-;N&5"N Z[D9?[RD=Z .KHHHH **** "BBB@ HHHH ****
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M6O4: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\9_:B^.UM\
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M.8R3W*GIZ5D4?&?Q>7Q/9:!\;? &I>.-?UW2])TBUU6WO;UX_M2EY 'B9U0
MQ'&<8X]:[_POXDUGP_XV^%V@^'_$UQXLLKWP_>7+)J-TD@FF6-2B-*BY55/
MP,BOI6\\!Z+J%YJ-W<:1937&I6XM;V1X58W$0Z)(?XE]JS_"_P (O"7@O^SQ
MH?AG2]+%@LBVIM( AA#_ 'PA[9[T!<^9_P!IG5/B!J?A?P*VN:!H.E:ROC"R
M%C;QW\ES;R\'_6-L5@,]@#7*_M$?">_\!_#7QEXM\07.EPZCXEUW2I+JQTF)
MHK&W\N4#(+\LQ'4G%?;>M>$=,\1&U&IZ=;7XM9UN;?[0@;RI5Z.N>A%+XO\
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M]$K7J->6?LKL6_9O^&>?^A>LA_Y"%>IT %%%% !1110 4444 %%%% !1110
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MM\9]EW;QB0M"2/W:MDC:.!5VQ_;3\9WMQX:B7X0:JO\ PED!D\.'^T8MUVX
M)$P_Y8KCG<<\=J /L&F32&*,L.U?,MK^UU?:QX$T*[TWP=<3>--5UF;0$\.3
M7R1JEW"&,H:?&T* I(..>*H6'[4.O>+OV=_'7C"Z\-CPUJ>GS3Z-86J7ZW9D
MO2P@4 @#D2-P.<XH ^GDU-94WH4=/[X8$?2KA<B/<>N*^$M*\1#]F3XBZ+HT
MXOM:OU\$V\5IHMO*S3:EJ,ERY944Y^;.26Q\J@YKT7XI_M:>)OAZ-2@L_ #:
MS>:#I%OJOB"*35D@6P68X6-"1^];UQP* L?4D%QYKLN ,<U-7S+X$\<7L'[1
M>@W%_"=*C\<>$X[Z33OM!FCCN8)-HVL."3&ZY.!G:*^FJ "BBB@ KYZ_;ZCW
M_LF?$C&EQZRPTP'[+*^Q1B9/WF<CF/EP/5:^A:\U_:$\/7_BOX5Z_I.E^'=*
M\67UU $BT;6YC%:71WJ=LC#H,#/U H ^8/V.M=^(U_K'@V+6?CEX"\9: VF1
M[=!TA(_[1*B(;02 &RHP&SCH:^Z5.17Y_? +P1K'PG^/_@Z'Q/\ !3X=^ 6U
MG[3!9:SX?OFN+@RI'N:(>A*Y/(Q@'FOT!'2@ HHHH J:I#//9RI;3"WG9&6.
M5EW!'(^5B.^#SBOD/X9_LB?%OP?^T!=?$_6/BOIFK7>JPQ6>L00Z+Y1NK:,#
M;&O.$((7YAUV^]?8]% 'QV_[(?Q/^)7CKPG??%[XDZ7XJ\->%+_^TM/L=,TO
M[)-<S@84SN/08Z=:P-"_X)\>)-.U:Q\,WGC^UO/@_I_B0^*+;P^+';=FXW;A
M$TO3RP>WZ5]QXHQ0!\2Q_P#!/*^_X3O[-)XU0_"I?$Y\8+X96V/G_;BN"GF_
M\\^_]*]?_;8MS%^RA\2QGY1H\H50>@XKWO%>&?MP?\FH_$O_ + \O]* .A_9
M9&/V;OAE_P!B[9?^BEKU*O+OV6_^3</AE_V+MC_Z)6O4: "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!&;:I.,X[5\E_MT_$K5M3T?P]\'O!CR#QCXZN
M/LKF,X:UL ?W\Q/\(QQGW/I7T[XO\4Z;X+\,:IKFKW*6FFZ=;O<W$TAP$11D
MFOD_]CO0+[XO>,O%OQ^\36[POX@D_L_PU;W ^>VTR,GY@#T\P_UH ]_\ >%_
M#WP&^%.E:':F.RT/0[(1F4X4?*,O(Q]6;)_&O-OA+H4_QC\?7/Q+UJ)AI4+-
M!X?LKCHD8.#-M]6/3VJK\2KVY^.?Q&@\ :+*P\,:5(LVO7<7"LV>( >Y]:^B
M]'T6TT:QAL[.%;>VAC6..-.B@# &*YOXLO)'"O\ :)W^S'\7_P  \H_:0^(6
M@^#?A_JVD:G>&"]U2SECM8DA=][8]54@=>]/_9L^)>A>*?ASHFEZ=<R37NF6
M,,%S&T+IL8#'5@,UZO>:7;7S+Y\$4Q4<>8@/\Z;;:=;6)Q#;1PYZ^6@'\JKD
M?/S7-?9S]M[2^EK6- =**!16YTD%_(\5G*\2&615)5 <;CZ5X5_PO7QM_P )
M@OAQOAQ*NHM$UPJ?VA'@Q!L;L]/PKWF49C(KQN4$?M.6@+9']@R?^ABNBCR^
M]S*^A+N>P6+R26<+S1^5*R@M'_=/<5.3M&:11A0!63XI\1V'A71I]2U*Z2TL
MX!N>60\"N>S>B*#Q%XGT_P +Z5<:AJ<Z6MI N]Y)&P /\:\.T;0M1_:!\1)K
MFMQ2V?@BVDW6&F2 J;P@\2N/[OI3]*T74OV@_$,&O:U;RVG@>V?.GZ=+E6O"
M#_K9%_N^F:]]M+2*WA2.-!'&BA551@ #H *[&UAE9:S_ "_X)%N9C+2T2SMU
MAAC6*)%"(B\  = !7CDP_P",J8.^=#/\Z]M;&#7B<W_)U,'_ & V_G2P^\W_
M '6$K'MM%%%<A8$9%0/;[U8' )[BIZ* *HM0@P!QZUC6'@[3M-U^^U>"TCCO
M[Y56XG4?-(%^[FNCHJ'"+W1<9RC>SW*KP,2.5'OBIHXRL 0G)QC(XJ3%%58@
M\6'[-VG:Y\5]>\9^+9;3Q.;JWCM-.LKJU^2PA'+*"2<ECU.!7GVH_L;Z[IVE
MVUEX2\;VNAII?B-M?T6.XTO[3%8;@<PA"X#+DDCICTKZJHQ3 ^?-"_94;59=
M?U+XD^)#X\\0:S8-I<EV;46D-M;'DI!$I(0YP<YSQ7/0_LJ_$&ZFT#1=9^*<
M.L>!=$OH+ZVLI]&3^T'\ELQ1O<[LD#UQDU]244 ?._Q*^ /Q'\:_%;1/%FF_
M$32M(L]#F>33K";0!.\0D7;(&D\P;LCH<<5F>.OV:_B9XE^*P\9Z;\3M)MOL
M\*16%CJ?AQ;U+$@?.\6Z0!68Y^8#..,U]-T4 ?./C?\ 9L\9ZMK^HZIX9\?6
MGA^7Q#816/B,/I0F%X47;YL7S?NF()'?K7=:[\%K*V_9XO\ X<:82UHFBOI\
M'FGEV"G:6^K5ZI2,H=2#R#0!\A:C\$/B%\=OA7\.[<>*O^$+&D6:Q:GH.L:.
M;J*[GC^0&6,NH9!M!"G(/!KTK2_@-XFN-9^'FL^)?%EAJ^J^%99W>2STL6D5
MPCKM5%C5B$VCZYKW)(EC)*C!-.H ^>W_ &7WB^'VO^'6U^/.I^(UU[[0+4XC
MQ,)/+V[N>F-U?,DGA3QGI7Q!\5:M;Z#JS^*Y_$PO+#1[KPB+^SN(@X F_M!A
MA/DR0V[Y>F*_1YD#J01P:B-K&>Q ] >* /G_ . _@'7[Y_'WBGQ=I[Z1X@\3
M7DL,<4X!>WM%4I$O!/'):N U?]DO5?A)\.-2G\%:K)>ZJ=(NK34=+M+<Q)K1
M?)C;:&PDJY^]R2.*^P4MTC4* <#U-.>-9!AAD4 ? O[/6G>)_AYKVE/IFBZI
MJ=G#H,Z:P=0\%C3)[29$S%!#-@-/N?(VC/J:^COV6O 6H>#O@WIUGK-C]AUC
M4)9]0O+:6/!C>9RY1QZX(R*]G:RB;&03CISTJ1854@XR1ZT@.!T;X*^'-$\;
MZMXHAT^T6_U&&"%XUMHQ''Y0X*#;P3W-87Q$^ 5O\3_B3X;U_7;J"_T'1(I3
M'H<\&])+A^!,3G&5' &*]>HI@?-7BG]CR'4-1\7#P_K%MX=T3Q"ME+-I45EN
MC2YMY%?SAAARP7!_.NO\2?L_#Q1\0=6\1W&JI';ZCX9;P[):+#\RAL_O0^??
M[N*]FHQ0!\\>%/V:O$,$?@!/%7BS3_$ \)3S^4L6E"!9[=XO*6)AN/('4GK7
M0>._V8O#&O>%1HOA[2M&\*Q2:G::A<FQTU$6X\B3?M95QG/3)S7L]% 'EWQB
M^#1^)?PFUOP9IUU:^'S?JGEW"6H>.%ED5PWEC:#RO3BN6\%?L_\ BW^V[/4/
MB/X]A\;PV%L]M9:7;:2EC9H'4*S2(&;S&VC'/2O>J,4 >1^)_@I-IW@R]T3X
M8/H/P\GOG/VJ:'1DECE0J58&-2OS8/7-0?L\?!_Q-\&? -OX7UWQ/9>)[6P
MCT^2UT[[$88@.5;YFW'.3FO8Z" 1@T ?/'@/P?XHT#QS\8-'T<MHG]K7T>LZ
M3K-S:&>V#2QJ) 1D!F5U.5SW%9/A3]E7Q='X7\;>&?&/CK3_ !%H7BB2XO)H
M[/1A:2PW<K[S*K[VX# $+[5],QVZ1$[%"_2I* /F;P_^RKXHO-0N-2\=^/(O
M%6I6VBW&A:.\.FK;1V<,J%&=U!/F.1C)XZ5UMC^SR]I?_"JY;6(V_P"$(A>(
MKY!'VK,03(Y^3IG'->V8HH ^%?C;\"-7\%S>'+>WDU+4=$G\3W^N7^J:5HAU
M%['S5)13:_-OY.-^./:IO@WX(^('C'6O"GAW6O#3Z?\ #_1M:N=7BO9='32?
MMB1J/LWFVJG*.9'=N1SM!-?<#6R,V3G.<\4D5M'"25')ZDG.:!W/"?BO^RY;
M_%3QW<>*+G5VT^^324L=/N+>,BYL+A)&=+F.0$$?>VE1C(R,\U\U?%;X?>-+
M7XD^*9];&J:QJHTNTM=+N[?P8-7M-:EBCR=V=RP#?U4D '+5^B&*A>T1R2<\
M]<'&:!+0^;/A1X9\4^,?C+H/B/Q;H/\ 9<OA[PE!:NQ@*0F^G<R3+%VPBJH^
M7(&<9XKZ9J.*!(?NK@_6I* "BBB@".Y&8N_4'BOF+]K#QEKM]97_ ("7X-^,
M/'WA_5;-#=ZGX9U&*T"-OSY:LWS!AM4DCKGV-?4##<I'2O#OVSHO%3_LX>.T
M\$_:SXE.G@VPLL^=L\Q/.V?[7E[\=Z74#YH_9)^$^B^%OC7IFI0? GQ_X4N5
MBD1-<\3^(8]0MK4D<_(#D,W0&OT(7[H[5^9'['?_  KBV^.W@A/A WCIM9>U
ME3QHGBA91 L7E9R=XP)?.VXV\8S7Z;H,**8"T444 %%!.*A^T@E@!G:?PH F
MHJ W/<+D=B.X]:<)]QX'R^M $M>&_MO_ /)J/Q,_[ \O]*]M6?<.F#7B/[;Q
M#?LH_$O!_P"8/+_2@#HOV6_^3</AE_V+MC_Z)6O4:\N_9;_Y-P^&7_8NV/\
MZ)6O4: "BBB@ HHHH **** "BBB@ HHHH **** "FO(J=3C\*=FN!^-OQ3TO
MX,?#C7/&&KN$L],M6E*GK*_1(U]2S$ #WH ^<OVO]0O?CI\1?#?[/_ARY,?]
MI.NK>*+N)L_9=.B.1&V.\C< >WO7I_Q7\6Q?"[P?HO@KP;:*VNWT:Z;I5E&,
M>3&J@&1@.@ Y^M>6?LLZ3/\ #CX>^+/CC\2'$'BKQFW]HSH_WK:T_P"7>V0'
MUX./I7I7P"\'ZCXNU^_^)GBB+R-2U)-FEV+C/V.USP>?XF[USU&Y>Y'<Y*TV
MVJ,-W^".[^"OPK@^&'@^#3T<W&H3L;F_NFP3-.W+'/H.@KTH#%10Q-&BC=GG
M)XZU+6T5RJQTPC&$5&.R"BBBJ*"BBB@!&X4UX[-M_P"&G+,=_P"P)/\ T,5Z
MIK^LVGA[1KO4K^40V=K&999""=JCJ>*^7+[]I#X?0_'2#Q&NO))I<>C26YE6
M)_\ 6%@0N,9S79AZ-2KS<D6]&1-Q23;/I?Q-XFT[PMI%SJ.J726MI I9W<X
M]AZFO%-)\/W_ .T)K=OKVKQ2V'@NSDW6&G2<27C#_EK(.R^@INAZ7??M&ZQ;
MZ_K$,UAX)MG\S3M.;[U\W_/63T7T%>_65E'90I#"B11(H5408  ]*6F&5E\?
MY?\ !%\?H+:6<=K!''&@C1%"JBC  ':K(Z445R&@C<J:\3D_Y.K@'_4#;_T*
MO;&8#@]Z\0FE7_AJF%N@_L-A^M=>'WE_A9$CW"B@$&BN0L**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OG']K'P2MW=:1XNA
M^-NH?!S4-)M9889Q-$UC<!F#'S8),>81@#C)P>E?1U>&_M&_![X.>*I['QU\
M6]+T^[L?#ENT<=UJ]Q(+2!'<9WQA@K$MM + ]: /GO\ 9/\ VM/%?C?XX'X>
M7&H^&_BCHPB:63QOX;TJ>P,14<"92OEOGI\I'XU]ZJ<BN6\#:#X=\,:)96_A
MC3=.TK1Y(DDA@TVV2"+8P!# * .01VKJJ "BBB@#.UN>Y@M)#:;&N-C>4DI(
M5GQQDCH,U\4_!/XO?%/3_P!ISXP:)\2=;L-370/"L>KKINC0&*SMF.U]D>[Y
MF(4E2S=>N*^V]5LI;VUD2";[-.498YPH8QL1@-@\'!YP>#BOE?P1^Q3XO\-?
M&B^^(>K?%^Z\17>L6Z6&N6DVA6T*ZC:*N/()7_5C 'S* >/>F+J?-GAOXW_%
M;P[X3^&_[06I^.+K5[+QGXG&BZAX.:%%L+>UE9PAA Y$BB,_-[TRP^/?Q4'A
M'1/VB9O&UQ)IU]XT_P"$?/@P6ZC3UT\R&/<!][SN,[J^@/!G_!/6?P_?^&]'
MU;XA7FO?#/POJSZUHWA22RCB,=P2=OFSCYI$7<<#CK1HG_!/)M+U6RT:?X@7
MEY\+++7SXFM_"+64:N+S.0K7(^9H@>=M SP2^_:?^)[7L?QMM_%+1Z OC]O!
MB^#O(!M38@ &4G.XS$G.[_\ 57K_ .W9^U#9Z5\.OB'\-Y/!7C*ZNIM+"+KM
MKI@DTL"1%<%I]X(QG#<=1721_P#!/&P/C<R2^,KYOATOB(^+$\'"W3;_ &B0
M 29_O>6<9VUZ;^VU&8OV3OB:-W']CRX Z=J .B_98)/[-_PSSU_X1ZR'_D(5
MZG7EW[+?_)M_PR_[%VQ_]$K7J-( HHHH **** "BBB@ HHHH **** "AC@$T
M4CG"-SCCK0!X'^TQ^TAKW[/NCQZQ9?#K5O&^DI!+<:A=Z=>10)IT:8.Z3>AS
MG)Z>E?+FC_&S4O\ @HE\3_#?@^]\(WOA#P#X;9/$.O17%ZERU[@ VT19% 52
M3D@\]^U<G_P4X^)&J6_Q=T'PCJ:7-UX3;2VN[?18)WABU&\9BB^:R$$JO7&<
M<5YW^Q_;^-/ 'CW5_AEX5U:UOSXHTJ"XU&6S(=-.E+9.' ^\L9(QD@9J)3Y5
M<QJ5/9INUS[MDA7]HCXG)I-N/+^'OA24>>J<)?72\+&.VQ0*^EM.MHK:,)$F
MU% 50!@ >@KE_AG\.]-^&GAFQT734Q#$N9)&^]*_\3L>Y)KM%(/3FHIQ:5Y;
MLBC3<+RE\3W%HHHK8Z0S14<CX8<?C2><IP2>/6E<9+03BC/%8WBCQ-I_A32+
MK4]3N%M[.W0N\C'I[#WIV;T0CEOC]J%O8_!SQ:TTZ1 V$B@LP&21@"ORMA3[
M>H$T)0(N8X@AW/[GVK]$/#NAZG\?=7BU[Q';O9>#+:3?8:,^5-VW:67U'M6@
MWA_3(/VD+.UCT^U2 :!(1$L*A.'&.,5]+@,:LNC.FU=O5Z[>1QU:7MFG<[GX
M)1>7\)_"@P,BPCZ?2N[%06<$=O;QQQ(L<:C"JHP /I4]?.3?/-R[G6M%8***
M*D9!>H[P,L<ODN00&]/>O#F^ ?B"3Q<OB8_$K4_[26/R!*;2+_5YSL^GO7MF
MI1/-:ND3%'8$!P,[3ZU\MG2_B2_QG_X0O_A9U\D/V+^T//\ L$!XW?<QCTXK
M*6+GA6N17YM.AZ>"R^./Y[U%'D7,[WV6^R9]4VB,D2*\AE95 +'JQQUJ>J]E
M"\,$2R2>;(J!6DQC<<<G\:L5HCS HHHI@%%%% !1110 4444 %%%% !1110
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M ,"%<]:O7H\OL9\MW9GLY=3PU7VOUBGS<L6UK;;Y'N&C,&TJTPK(OEKM5_O
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MFR:7HE_P3Z6&+P]/X,/'YN7^:/C-_A9\?=<8-?ZCM]5EUET!_!%%5=4_9?\
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M8XM]0HHHHN(****+@%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MRM9?\%)-!U2RM[NS^%GQ-N;6=!)'/!H#.DBGH58'!'O5<?\ !33PP=;.C_\
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M1'NZ[<G.* /E_5_^"D'AW3K&:\O?A5\3;*T@0O)<3Z"R1HHZEF)P![FC3O\
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M3]:TF=+W2[^%;FWN8L[9(V&589YYK3-[C^ \].: +-%<<GQ9\-2>/)/!:ZI
MWBA+3[?_ &:I.\P9QOSC&,UTYO2.B9)Y&/2@"U17#?%OXN:/\&OA_JOB_7MX
MTW3T#,L*EGD8D*J*!W)('XU4T#XS6E]\+CXYUS2-0\*Z;';->7%MJ47[^"(#
M.YE7.>.>* /1**^??#7[=WP<\6:OH^FV'B>1+C5WV6#7^G7-I#<GT261 A_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
$ '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>adag-20211231x20f019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f019.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $O S,# 2(  A$! Q$!_\0
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M44GS<_IQ0 M% Z44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[I(WP064." <$C(]:S=&^"/P\\.I"FE>!/#>FK#'-%&MII4$81)0!,H 7@.
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M>(-7EU&""T62)'C50K%\$_*!7TQ5>VTZTLV+6]K# Q&"T4:J2/P%6* /E_\
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M,]*6D0?**6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ I'<1J6/  R32U',H>-US@E2,T <=
MI/QC\)ZWKB:19ZGYNH.YC6+RF&6'49Q7:UXUX5_9ZB\,^-8/$*ZZ\[I,TOV=
MH0 <D\9_&O9:!'%^/?BQH_P[UOPOI>IQW#7'B&]%A:-"H*K)C.7)/ XK0A^)
M'A:XBU":+Q)HTD&GG%Y*FHPE;8]/WA#83_@6*\R_:+^%>O\ Q'\3?#F\TBRA
MN[31-6-W?++<"$^48V7@GJ3G'%>#6?[-'Q*M]*NK*U\-VI\+Z=JMMJ-EX7UB
M^M9I;L)(6>(W"* 8^<J)<\^E 'U5XB^/7@+PNFA2WWBK2EMM;N?LEC<17:21
M2R8_OJ2H ]2<5TD?C?0)K9+F/6]-DMWF^SK,MY&4,O\ <#;L;O\ 9ZU\?O\
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MTKP]<6^NKI=N^L/XEMM7TA8+2TG:Z9K>2VN=@,S2JVXD,V01GIB@#[FHHHH
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M %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM\'VO[!5ETXRM$(2_P#IAMCU*;>NWCTKMO@KXB^&<OQ1\1Z!X?TCP;IWA8Z
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M@YX./6EHH 0 XQN)INP[E.>!VQ3Z* "BBB@ HHHH **** "BBB@ KP[XW_\
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MAV!C<-C!(ZXQUKN:* (;.W^R6T4(.1&BIG'7 QFIJ** "BBB@ HHHH ****
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MQ/@+X=^&-"MK'5],\/Z?INH36REYK6'8QW*"1]*[:DP04444AA1110 4444
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MD8,KI;*"I!X(..M,#IU)/48I:11@>E+2&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7EW[2&B>/]>^&-W!\-=8;1O$Z31RI-&8U>2,'YXT,@*AB
M.F>,]Z]1KPO]LOQC/X.^#3/'K<WANWU#4;;3[O5X'*/:6\C8D<,!D' QD>M
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M2:ZTU-MR'B9 I))&"1S3U$>J0PI;Q)%&H2- %55&  .@I]%%(84444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4$@=:;OW' 'X]J7;SD\F@ R3VHI:*!!111
M0,**** "BBB@ KP[XW_\EN^!G_8:O/\ TC>O<:\.^-__ "6[X&?]AJ\_](WH
M ]P3[HI32)]T4,,J: /#U^,6B2_&I(UAO-_DMI',:X\XRCG[WW>.M>X_SKPE
M/@WH\7QKBF6ZO=WE-J_+KCSA*/E^[]WGIUKW8'(SZTV 4444@"BBB@ HHHH
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M"[\E?."?W0^-V/;.*\:^-ZC_ (7=\#.!_P AJ\_](WKW*O#OC?\ \EM^!O\
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M)H _/KPSX5\!>,=6MVN]$^(7A/-_:V&G7!\6/*\<-R&\B1$((1  <)G@-7Z
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MC$Q/%,Q1BH_CB 4@"@#ZLHH'044 %%!(49/%-Y?V% "[N<#GZ4!?7FE Q10
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M=>E;EK^TAI.@6%G::SIFL)?)&$FD>),EP &/WL]:W_\ AI'P(QV_VG<J<_\
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MQ;>:A=ZQXE\+ZA<ZA8C3;J66Y.Z:V#%A$V/X<DFL[0?&W[-GA?Q4GB/3-?\
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MEE)CS92!&9F))+'W->Q0RB101C![CO4T:G/'XDWY&.%J.=)<TU*75K:Y)12
MTM=!V!4%_:"^LYX"VT2H4W 9QD8J>B@#XV^+WPB7X6265W%JG]H)=SG;$\.Q
MEQ\Q)()!';I6#K7Q2UK6]%FT= EM8W,K2S0PC(D8[<#D9&-O;UK[.\1>#M%\
M6P+#K&G0W\:9V"5>5SUP>HK TWX(^!])N5N+?P];><I!5I6>3:1T(#$U5Q'+
M_LX>!AX:\)C5#<2O+J:!GMY(@OE$$C [G\:]:N%W+@\J>H-2J@4  8Q22$C;
M@9YJ7J!X5\7_ -GSP_X@LKK4[+3YHM32-RB6?'FN>A.3Z\U\K75B?"]P-$'A
MV2ZUQ8&2XBO(@P)W9RNUNF!UK]')(PW&*Y.3X<:._B]?$3VP;4$B,0<],'U'
M>O(Q&!C4DI0T?4^9S')*>+FJE&T)=79;=?GV/*O@=\#=+:RA\2:OI44.I7$:
M%;0(52#'((&3R?>OH*)/+C"@=*;;Q"),<?A4M>A1I1HQY8GNX;#0PM-4Z:_X
M/F%%%%;G4%%%% !1110 4444 %%%% !1110 4444 %17=W#8VTEQ<2I!!$I=
MY)&"JJCJ23T%2U1US2;+7=+N-/U*UCOK&X7RYK>9=R2+W!'<4 >;']J#X>'P
M9J'BF'6GNM&L[XZ:9;6V>5IKC.-D2*"9,]MO6NN\%?$/0_B9X037M NFNM/F
M5U!DC:.1&&0R.C<JP/4&ODZZ^!_BW0_"%S<:3X0FD_L;QS_;=MHENL<375HH
M('E#(7OP"17H7PG^!.MZE\);NV\0:MXD\"WU]J]WK'V;0]16VN(DE8E8I6"N
M#QU [T =5^Q\W_%G(QSG^T[X_P#D=J]NKPK]B^T^P_ ^TM_.FN/)U"\C\VX?
M?(^)F&YFXR3W->ZT 4#H.G-<&9M/M#*6W;S NXGUSCK5^BB@ /0U3N4>9'17
M\I\<.!G'X5</(J-UVJ2!EL4@/!/C#!\1/ WAJ[U[2/&4MV+>3<UH^EP<*>.#
M@DXKSJWUSQ=::WH^O^)/%$]A=2Z0]RUQ;:5#(84W@!2N!G/7)Z5Z3\0?C!K&
MC_$.P\(-X;MK^VU';MD=FY7/.1CM6MK^AV>M?%FPTV[C7[++H,L4D*],;QP*
M\B<>>;<)/32VNY\Q4A"O7E.C4E[K2:;E92WOOZ;&3\/KK7OB1#<7>D?$K4+F
MUB<*XFT.WCRWH#7N>GPR6]G%'+)YTBC#2$8W'UP*Y3X<?#NP^'/AY-)TX'R
MYD+L>22<\UV2CY?\*[Z$91@N??J>YAJ<X4TZGQ/?5M7\KBT445TG6%%%<5XP
M^,?A+P%J2V&NZM'8731^8$9&.5]>!0!6^,_PO/Q9\,66C_:H+2.#5+/4',\'
MG+(L,H<QE<C[P&,]O0UT \ ^&,?\BWI'_@!%_P#$UH:/K5IKVF6^H6,GGV=P
M@>*4 @,IZ'FH]7\1Z;H%L+G4KZWL+8MM\ZYD"+GTR: *?_" >&/^A;TC_P
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M]T#P+I-IJ5W)>7JPJTLLK9))&<?ATKL$0J3DYS7TE%R<$Y[GZ+2<I04I[O\
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M_B9'H<WB3Q<?$*G[)')^[^ZW/WL=*^JI8_,7&<9KD;KX;:9<^.;?Q0Z@ZA%
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M$!/T%6Z** "F2!3@'J>G%/HH AVH"<C&?:I@,=***25@"BBBF 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 &
M1FHKHC[-+_N-_*O)/VD_B/KO@'0?#MKX9-I#KNOZQ#I5O=WT1EAMM^29"@(W
M8 Z9%<M\/?VF;6W^%L^J_$*X:'4;75+K19;C2=+N;E+B6(D;Q'"DC(".>>!Z
MT ;G['W_ "1N/_L*7W_H]J]MKX__ &;?VF/ /@+X91Z7KMWK=C??;[N8Q?\
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MVVUW09I[C3+@LL<ES:36KDJQ4YCE57'(/516_0 4444 %%%% !1110 4444
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M/QK\6_!/AKQ)IGA'7M3A_M?61M@TP0/.TB$XRX52%4GC+8!I <+X:^+WQ?\
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M>$K#PQY>/(^PZR-0\WUS^Z3;C\:[.C%% !1110 4444 %%%% !1110 4444
M%%%% !1110!POQ>^$FG?&#P[;:9?7M[I4]G=QWUGJ&GLHGMIT^ZZ[@1WZ$58
M^%/POT[X2>%$T/3;J[O5,LES/>7C*9KB9SEY'V@#)/H *[*B@! ISG<Q_&E_
M$_F:** #\3^9H_$_F:*:\@C&20!UY- #B#ZG\S7'^"/AI9>!=>\6:K:WEU<3
M>(K_ /M"X2=AMB?:%VI@#C [Y->:?$/]JO3/"NJZA!H=F?$2Z!,I\0VL19+F
MUM6_Y>8$(Q.JG[V#P*[72/CUX0\1>)-"T71M1_MJ[UBT:^A;3U\U(8 !AY6!
M_=@DX&>] 'HWXG\S1^)_,T#ISUHH /Q/YFC\3^9HHH /Q/YFC\3^9HHH /Q/
MYFC\3^9HHH /Q/YFCIW/YTA;'O534]3MM(T^XO;ZXAM+2W0R2S3.%1%'4L3T
M% $EW&+J"2'<X61"I8'H",5R_P *OAM9_"CP58>&M/O;N^M;0N5FNF'F-N<L
M<[0!W]*\:\6^,-2^)OQ[TWP?IOCZ]\(:"FD0:UI\NB")FUQC(1(OF.K#8@ &
MU>?FS7K7PN^*-I\23XBCM+2XMQH>JS:1)+.RL)WBP"ZE>"#0([O\3^9H_$_F
M:**!A^)_,T?B?S-%% !^)_,T?B?S-%% !^)_,T?B?S-%% !^)_,T?B?S-%(7
M [C- '-_$GP+;?$OP+K7A>]NKBTM-4MS;R3VQ'F("0<KD$9X[BMZRM!8VD%N
MKNRQ(J L>2 ,5X'\1?VG-4T+Q_J_A_PEX67Q8GAF!+OQ'']J-O>0PMS_ *)$
M5(G95^8\@'H#FO:_"'BG3O&WAK3M=TFX^U:;?PK<6\Q4J61AD<'D'VH V/Q/
MYFC\3^9HHH /Q/YF@C/<_F:**  #'J?K1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 ([A!D\ =Z^8/%OQWN?C/XI\2?#SX:7
M.F/=6%C)/+>:L6^SZL5?9+:0 8)0C<CS*<H2, \U]/NBN/F&:\\^(?P2\->/
MK#3$,,FB:CH\XN=*U71MMO=:?(#D^4P&-K<AD(*L"<B@#YP_9^U+XF>)[%O"
M'A[5IM'\-V-QY&HRZZ/-USPT4()LD+#9<HXXCF895<D@G%?:,2E(E4DL0,$G
MJ:@MK.*!G8(OF-]]P "Y'&20.:L@8H$%%%% PHHHH **** "C.**\=_:#^/U
MG\'_  K?O936%]XB1$*6,TX_T6-V"_:9XU.\0IG+,!T';K0!<^.WQA?X>>%-
M83PZFFZSXV@L7O;+0+N[\J2X13\S!1\S #)P.3BOG?X3?%/Q?\0?$FJ^/_!'
MA?2]=UO5K"UM->\-:C?K:7.G21AO)N;:X96#V[AVRN 05]17GNMV%S^T=XHT
MRTUFUM-9\237$\?A;QW;Z<;*QU9(HO,FM)$5O,\D?.$G4@@C.<YS]C? #X!:
M'\%_#,4%K!+)J4@9I);N?[3);K(0[V\<Q4,T0<$@-DY)-,1T7P;\,^(_"O@#
M3;'Q7JYUK7=TDUS<%RX4O(SB-6/+*@;:"<9QT%=Q0!M %%(84444 %%%% !1
M110 4C.$&2<"DD.U":^.OVIOC[X^\!G4K#29;2XT:\N8DT_6-#G5)XV'$MG+
M(=ZQS'JC8&>1C- &_P#M%?M,7^E:QKO@3PS:2VVH10I'<Z[]HC/V$R*2'\AL
M,T8 ^9PPVYXR:Z/]E?P-K?A_11J'VC4M#TB[C*W'AC5)&O!'=# :ZMKEFW^5
M+][:P[]JY_X%_"2T^+?ARS\0_$[PS<:GK5G)Y-AJ>MI);WUU;\-BY12OF*K$
MJN\'.W)ZU]0Q6T<  C7: -H'MZ4")%& !U^M%%% PHHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,_CUX)\9?$3PF?#WA/Q
M';>%8[X/'?:DT+27*QE>$BP0!N/#$\@9Q7IE(RANM 'QGX.\%6_Q)%GX1GT[
M_A67Q>\"1I%!J-C"TMK>6N<$D-CSH)1G*,<@GK7T?\+_ ((>$?A$M^_AO1+/
M3+K49!->S6Z$>:_?&2=JYSA <"NY%I")A*(U\T#&_'./3-2T %%%% !1110
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MXKZ.M=+M[.ZFN(;:&*:X(:>6.,*\A P"Q YXXYJ[BB@ HHHH **** "BBB@
MHHHH *^.?VO_  WXUF\>66L-#H\_@RWM8$LM0U_7&T_3M&O?,)>>:-)$:=F&
MP*#D#!&.M?8U4=6T+3]>L9++4[*WU&SE^_;WD*S1M]58$'\J /AGPM\(/$G[
M0GA[4O%D6I:7J6MP:P=-N]0T\3:?H_C#38ROS31QL-^W+*L@/S!<<U]U:98Q
MZ=86]M#$D$4,:QK%&,*@ P /84ZPL+;3+6*ULX(K6VA4)'#"@1$4= JC@#V%
I6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>adag-20211231x20f020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f020.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'T AH# 2(  A$! Q$!_\0
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MK[^]YR6FFOPOMIT/;E.1FEI%'?N:6N0]T**** "BBB@ HHHH **** "BBB@
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MGK6Q11=]PY(W3MJA%!'!.?>EHHI%A1110 4444 %%%% !1110 4444 %%%%
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MA1N^;=RV0.<#!V/A1^S5I/PJ\1MK8\6^,?%MY#:_8-/C\2ZR]U!IUM_SRAB
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MPP6/S"Q/!.WL#0%T>OR@"5P.@8_SIM*S;V9CW)-)02)2T44  HI*6@ HHHH
M**2E% $]A_Q\K]#6G698_P#'RH]C6G04BOJ'_'O_ ,"%9M:6H?\ 'M_P(5FT
MQ/<***3M2$+111B@!#P":_(K]H;_ (*.?'#X=_'GXA^%M$US28='T77KRPLX
MY=%MY'6&.4J@+$98X Y/)K]=6'!K^>[]K_\ Y.L^,'_8UZC_ .CVH&CUO_AZ
M=^T)_P!##HO_ ((+;_"C_AZ=^T)_T,.B_P#@@MO\*^1\T4%'UQ_P]._:$_Z&
M'1?_  06W^%'_#TW]H3_ *&'1?\ P06W^%?(]!H ^N/^'IW[0G_0PZ+_ .""
MV_PI/^'IO[0F/^1AT7_P06W^%?)D5O)."5&$'5V.U1^)JU+!:0(-DOVV0IEM
MH*(I/;GEL<>E 'U9%_P5)_:'N'"1:[H\C'LGA^W)_E4__#S[]H92?-\3>'X.
M,XDT2V)^F ":^4+6PO\ 4H7>WMI&@CPC-"FV,9Z!FZ?F:!H%RUK=7*QKY%MM
M\^5&WK'D[1DKD#)XH ^L[K_@IU^T/:);22>(]&$-Q%YT<G_"/6X#+D@D9 S@
M@C\*@7_@J5\?&'/BC1P?^Q<M_P#"OE*TT5+B;3UEU"VMHKM]HFD+$1@-@E@!
MD?UQ7U!X?_8DL[G3;6_NO$\MU%/&)HQ!;>6D@.",$G< 1W..E %P_P#!4OX^
M\_\ %4:+GL#X=@Y_2I;?_@J%\?;@A3XNT"%B0!YOA^$#ZYVUN:M^QWX('V5;
M5[Z C:2DMP29A@[AG&0?IZ5S?B+]B;3+Z>UCT#6Y]/9Y,2B^'G*J8_AQ@DYQ
MWH F_P"'H/[0)'R^+/#A/H=#MU/ZK3?^'H/[10Z:[HKC:&S'H5J^!Z\ UX1\
M2_@+X@^%]FE]J%UI]QILLQAAN(K@*[D?],S\W3GO7 K/<6ME+ CC[.[J[%,'
M++G!SU'6@#ZN/_!4[]H,$C_A(=%!'4?V!;<?I2_\/3OVA/\ H8=%_P#!!;?X
M5\G2WTDQ47(^T;4VJ9.& ^HY/7OFFB%)1'Y,A9VX:-A@@^QZ&@#ZS_X>F_M"
M?]##HO\ X(+;_"C_ (>F_M!Y_P"1AT7_ ,$%M_A7R0P*-M8%6[AA@TE 'UO_
M ,/3OVA/^AAT7_P06W^%+_P]._:$S_R,.B_^""V_PKY'HZT ?7!_X*G?M"?]
M##HO_@@MO\*_1'_@G=\?O&7[1?P:UGQ%XWO;6^U2UUN2QB>TLTME$2PQL 53
M@G+'FOPVZU^PG_!'S_DV_P 2?]C/-_Z3PT">Q]U44M'>@D*\D^-'_)3_ (#_
M /8VW7_IGOJ]:[UY)\:/^2G_  '_ .QMNO\ TSWU 'K8Z"EI!P!2T '6BCI1
M0!YW^T%\8;?X _!WQ'X_NM+EUJWT6.*1[&"987EWSQQ<.P(&#)GH>E?$I_X+
M/>'0<?\ "JM8_P#!W!_\:KZ+_P""CO'[%/Q._P"O:T_]+K>OPC;J:8TKGZH_
M\/G_  [_ -$JUC_P=P?_ !JC_A\_X=_Z)5K'_@[@_P#C5?E=12N.R/U0_P"'
MS_AW_HE6L?\ @[@_^-4O_#Y[P[_T2K6/_!W!_P#&J_*ZCBG<+(_5$?\ !9_P
M[U_X55K''_4;@_\ C5(?^"S_ (=/7X5ZP??^VX/_ (U7Y;Z?IMUJMR+>S@>X
ME/\ "@S@>I/0#W-;]IX8M;-T:_E^V2#K;6K_ "Y]"_?_ (#^=(+(_2I/^"SO
MA^1U1/A1K+NW15UJ$D_0"&M=?^"N-MA"WP9U^'?]WSM9@CS_ -]1"OS5BCO8
M8REI NGQ-R([9=I/U;EC^)K3TO0=<9IC;)=@S+B39&?G7.?O-TZ=J LC]%&_
MX*\:>IP?A%JV?3_A(+7_ .-TJ?\ !72P=MH^$>J@_P"UXAM0/_1=?"_A'X,>
M)?&#/':6'EV@?)N;F08!]./Z5Z?HO[)8D5VU'5@AZF.*(X8^N[- 61]/0?\
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MT@/ ^E+2 **2EQ0!\V?\%'?^3*/B?_U[6G_I=;U^$9ZFOW<_X*._\F4_$_\
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M]COHHRJ6BQ;Q.&7Y"&ST((/->M?"CX*WOBW5K'0+.U?*P^=<W+'$;-D':6Z
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M!E_1A0)GVW1VH[44$A7DGQG_ .2G_ ?_ +&VZ_\ 3/?5ZW7DGQH_Y*=\!_\
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MBOV=_P""3$9C_9=E+ @MK,[#/I@8H$S[3H-%%!(5Y'\:/^2G_ ?_ +&RZ_\
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MKDD;?*89/0]L5XY\5?V+/AKJGCW1/$]YJ,GA'PWI]S)J-QI-F\=O827078)
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M DNPD*_&=N<@$9QTK\E=6^+&OWNGOIFFFU\,:.R;&T[0(?LJ2#TE<$R2_P#
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M;BOBLGU_ME?_ (S2"Y^2<OP8^($&=W@?Q%@+ORFF3.-OKE5((]ZQ+KPAK]D
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M>L'AW17DW>PDN'B4?7::_6!?^"2?P'3[O_"6 >VM+_\ &:/^'2OP(SU\6?\
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M':L/_A67@[_H4?#X_P"X3;__ !% UH?S9^:G_/1?^^A2&1,_ZQ/^^A7])O\
MPK+P<1_R*/A__P %-O\ _$4?\*R\'9_Y%'P__P""FW_^(H'<_G<\+_$230K
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M<+Q^3(R!B\;JR,P*;26.WFN@?XA:3;_#4^.;KSK31$TG^V9/-4>9'!Y/FD$
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MH67;&5/7)0'N5IXBTG4+U+.UU2RN;Q[5+];>&X1Y&MG8JDP4')C8@@/]TD$
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MH;N9H$#+C.<<U4_M"7_9_*@5S1HK._M"7_9_*C^T)?\ 9_*@+FC16=_:$O\
ML_E1_:$OHOY4!<T:*SO[0E_V?RH_M"7_ &?RH"YHT5G?VA+Z+^5']H2_[/Y4
M!<T:*SO[0E_V?RH_M"7T7\J N:-%9W]H2_[/Y4?VA+_L_E0%S1HK._M&7T7\
MJ/[1E]%_*@+FC16=_:$O^S^5']H2_P"S^5 7-'&:, =JSO[0E]%_*C^T)?\
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MN&*_O5"9)B5)'V\#*J>A-?8W@[X3>'?A!X0U#2OAKX?T;PY<21F2+=&QCFN
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MZE+X.O)+FWAD8_V;=@+<8R<^3@GS5'_?0'.#UKA\YH ]E_X;+^.W_17O&/\
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M7Z3ZK=L8(AB&U0XCC'J!W/O7+9XH T-;\1ZKXDN/.U74+B^?/ F<E5^B]!]
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M8'JH(_$XK>_:T^*LWB;Q4OAJ"X,L.EKY=Y.#Q+-U**!P$7(&/7- 'T_\6/\
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MR*^G?A'^R+X9_9^^+:^(_#-]JPMM3MY+6>WO;IKA&;&5+%\D'(."/4@U])
M@<4!8_FV^.'P:UOX&>/;[PYK-O<1B-LV]Q/;M$)D/0\\9'0X)K@![5_0+^W%
MX+T+QM\"]6T_6X()%F_<0SRJ"T,C!MC*W488*:_G\>-H&:-_O(2K?4''^- %
MG2]8OM#NQ<Z==S65P,?/"Y4GGH?4>QK[3_95_:N\'>);34? /QPE":7J*A++
M7IHQ+;P/C&RXCP3M/9QT]NM?$-'K0!]W_M-_\$]T\&:=)XR\!7*:CX;FA-Q%
M':N+FWF!Z>3(#QU^Z<^QKXJM;RX\.37.EZC:O-8L^+BSE!5@>A=,_<D&.&_
MY%>N?LV_M>^,?V>9I]+AD37_  /J"M%J'AK4F+VSJPVEX^IC89SE<9QS7?\
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M^O\ DS/X5?\ 8,D_]*IZ_"WQ-;1IJ<-Y;KMM;]!<(HZ*V<2*/HX8?E7[I?\
M!/O_ ),S^%7_ &#)/_2J>@EGT+1110(**** +%A_Q\K]#6E698?\?*_0UIT%
M(JZC_J5^M9_6M#4?]2OUK.IB>XM%%%(04U_NGZ4M#?<;Z4 ?@W^UQ;OI_P"T
MG\9]0X1K[Q3>Z?$^/F500\I'<9!5<_[1KU']EOX-VOAGP[;^)=0@7^U;U&,7
MFC(BB/3Z$BN0_:AT!?$/[:'B309LK%=^*;Z1B./OW'/YB,"OJ:&UC2WMK94
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MX#6_E#C@G'S;L_\  17Y\UV7PU^+7BCX4:C/<>'-2:S6Y 6X@>-9(I0,XRC
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MP:)8P0Q!P,<#!'TKPO\ :3_87G\>_!KPYXV\,7C7'Q!M=/D;5-%?D7HBR9!
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M._\ P3#\6^$[TW_@"<ZIIMPX\K1=9=;>_AR!\@E/[J7!.,Y5CQ\O-?-WBO\
M9>^+W@B41:W\-/%%FQ. PTR656.,\-&&!_.OUQ'[2?BS1](DDO+RWOUB;:?,
MM5)8[L*N,#/.!GKSFNBL_P!J7Q.\*JVG:=N7JP+*#^&: /Q=LO@+X[?4+:UO
M_#.IZ$)L%9=5M)+=2/4;@,U]:_!GX/>'/ALL"6(CU7Q/*0DUY(A<1DX^[@<#
MM@<L:^@?C5K.M?&W4K.3Q'K4JZ7I^YX=.L-L<2R' )+\L3CCK4'PG\0Z/\&9
M[_4HM(^VZDRA+*[NY08K-CQYFT@[NV".GXYH Z'2_@?J'A>>XUO7Y]/T634$
M0M->L#,(P,J%A3+]S\OYU%K?BK3;N%-&T99X=,C;S&DE7]_<S8QYKCH !D*O
M\(/K7->(=4N-5OYM2U/4#=7-P_F7%U,^"2>GMCVZ=JY'Q%\0-*\-Z?)</.M\
M^,K%;C+.<9Y(.!^)H ZB_P!3M-*M;BYNY#';Q*7D>0KA5'?]*^+?BG\>-9UP
MRVR27&DR@.D5M!-L*QL<@N1U9A@ 'UJ[\4OC;JGC#;I%A %,KKY>GVG[T2-G
MY?,8'+G/\"Y'J:XE8+?X1)<:OXCBM[SQA<YDL=&?#M:OR//N>RLO!6/OWH Y
MWQ=*O@OPXN@\GQ#JBK<ZO)D$P1'#1VOJ#G#O_P !'K7ZJ_\ !(O_ )-2O/\
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M:+%_HTI_Z>;8=">/FCQ[K7L7A/XF>-/@='9ZTCIK7A6Z;;#J^C2;K.YYZ,"
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M--UK23>:M')Y,MIK$AM+F->AYQA\8[X->K_#_P"+ND>+=2>V@M+2RQC$=S,
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MD7G@BVCV0@_[V^LO5_B1\1/C#/;>'I=5U#5H')^SZ'8@06B8ZD01A8U '<C
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MUK=L/X+;PA?EO_'B*I#X?_ JTTZ2:Y^,7B"]NP?EM].\&,,_\"EN%%>*T8H
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MY7L/@OP7HGP[\+Z?X<\-Z;!H^AZ>ABM;&VSY<*EBQ W$GEF8\GO0(V^M%%%
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MF^Q;1:Q@?9\Y$/3_ %?)^3[O/2M"@ HHHZ4""BBB@ HHHS0 444=J $I:**
M)[#_ (^5^AK3K,L/^/E?H:TZ"D5=1_U*_6L^M6Y@^T(%W;<'-5O[,;_GH/RH
M$T4Z*N?V8?\ GH/RH_LP_P#/0?E0%BG0*N?V8?\ GH/RH_LP_P#/0?E0%BG0
M.M7/[,/_ #T'Y4?V8?\ GH/RH"Q2I>M7/[,/_/0?E1_9A_YZ#\J L4Z*N?V:
M?^>@_*C^S#_ST'Y4!8I_C15S^S6_YZ#\J/[,/_/0?E0%BG15S^S3_P ]!^5'
M]FG_ )Z#\J L4Z2KO]F'_GH/RH_LP_\ /0?E0%BG15S^S#_ST'Y4?V:V/]8/
MRH IXHQS5S^S#_ST'Y4?V8?^>@_*@+%.CO5S^S#_ ,]!^5']F'_GHOY4!8IT
MG6KO]F'_ )Z#\J/[,/\ ST'Y4!8IT5<_LP_\]!^5']F$?\M!^5 6*=%7/[-;
M_GH/RH_LT_\ /0?E0%BG15S^S#_ST'Y4?V8?^>@_*@+%.O%?VR?^3>-?_P"P
MAHW_ *=[.O=O[,/_ #T'Y5Y!^UEX4U3Q!\"=9T_1[&YU;4);_272TLH&EE94
MU2TD=@JY)"HC,?0*3VH"QZK-_KI?]]OYFFU=;3S([MO W,3C'O3?[,/_ #T'
MY4!8J=Z.U7!IA'_+0?E1_9A_YZ#\J LRG15S^S2?^6@_*C^S#_ST'Y4!8IT&
MKG]F'_GH/RH_LP_\]!^5 %.DJ[_9A_YZ#\J/[,/_ #T'Y4!8ITAJ[_9A_P">
M@_*C^S&_YZ#\J L4Z/6KG]FG_GH/RH_LP_\ /1?RH"Q3HJY_9A_YZ#\J/[-;
M_GH/RH#4IT5<_LP_\]!^5']F'_GH/RH"Q3ZT5<_LP_\ /0?E1_9A_P">@_*@
M+%.BKG]F'_GH/RI/[,;_ )Z#\J L5**N?V8?^>@_*C^S6_YZ#\J L4Z*N?V8
M?^>@_*C^S#_ST'Y4 4Z*N?V8?^>@_*C^S#_ST'Y4!J4Z*N?V8?\ GH/RH_LP
M_P#/0?E0%BG0!5S^S3_ST'Y4?V8?^>@_*@+$5A_Q\CZ&M.JMO9&"4/O!QGC%
M6J!H****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !01FBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
(H **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>adag-20211231x20f021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f021.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'T >8# 2(  A$! Q$!_\0
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M]4=;T/3?$6E7.FZE;P7MC<+ME@G 9''N*H?98/\ GC'_ -\B@VD'_/&,_P#
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MKR?XD?L+ZK?6'B'5-,\3OJ/BK5;RS6WO"OV9K.+[5-]HD+,[YS:W4\1C0*"
MN%R31J![U??M+^"-,\8MX<NI-5BN7TZ?5;2]73)9+34+>%$>5K65 ?/VK(GW
M <EL#-=KX!\<:9\2O!NE>)]%-P=+U.'SH/M4)AEV[BI#(>5(*D8/3%>7Z9\
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MS#Y3]=LTM?D1_P /D/BK_P!"7X,_[YO/_CU _P""Q_Q58@#P5X-)/  6\_\
MCU','*?KM17Y8Z?_ ,%0_CC=(D][X%\#Z'9L,_:M9DNK1"/8/.&;\ :=<?\
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MI>*KN 1/K=PF)!+YD.(Y-P5U WJ V LC@+G #' %:^]<1]%?\$]/A_XCT?\
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M>O\ B;Q';Z!8O<RL%:(9RW=?P_SZ5\W>(/'5YKFLFYE\VXM8Y%/V8/A)%#9
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M.I4J>G."13];^(T>I>#D\.VNEFRM%GCD0M=M*%2,RE%"E0 V9FW/U;"C QR
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MA0(S]5TG5[_9+IEQ''Y&976:(N&4XPI7(QGL>U;&F:E!-:SI:2_:$A8F3"X
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M]$LH2MM9QJHXSP.22?4_UKV*UA2V14"C:, 5G>$_#*^'+V^M3(MU+%=26WF
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MYADXY/4X_&@#D/VG="TR_P#A3:6=TQCO](M)=5M3$V X>1(@&!SQC)XKXG.
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M%C-SJ,]O*?LH"C9([83=CI[=>*69?+<Q,VZ3.UPN.2/?T_*EN88[JV=I0\1
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M  K3\)_#CSI!>ZGOA#Y;;#E1(,XPV.O'>O4H;%-+M8XHXMD"\80@@#IDC^M
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ME;'8[1@9[U\Y_$'XF^)/B?K!U/Q'J<E_.!A$P$CC'HJ#@?SI#.M^,_Q9U_\
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M*?\ CZTI_M"X]2H^8?B*Q_#'P0^(?C:5(] \#>(M79SA3::7,ZG_ (%MQ^M
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M'2L[7_BK<1:?=:+X-T@>$-!F&R3[/E[VZ3I^^N"-Q!'55POUKSG[-(./+?\
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M?\*ZG:7USK.HX75]-EGR L+PV5N;5F5%4/+^^D.TB(\DDX^NRJD@D#.,9-
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M% !1110 4444 %%%% !111F@ HHHH **"<49YH **** "BBB@ HHHH ****
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MIP<C(Z&@PH>J _A61]IE_P">K_G1]IE_YZO^=9FUS7,,9 !12!T!%*848@E
M2.A(SBLC[5+_ ,]7_.C[3+_SU?\ .@=S6\F/).Q<GKQ0(8QT11SG@5D_:I?^
M>K_G1]JE_P">K_G0*YK^3'Q\B\=..E(T,;?>16'H1FLD7,O_ #U?\Z/M,O\
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MO_/5_P Z/M,O_/5_SH"YK^3'NSL7.,9QS2&&,G)13^%9/VF;_GJ_YT?:9?\
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MR7L:M! V-LK@GY4.1ACP<CUK;T;6;'Q#IMMJ&FW<%_87*"2&YMI%DCD4]"K
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M0:=PY3IN:**3-42*#1110 M)VHHS2'8#6CIG^H?_ 'S_ "%9W7ZUHZ9S _\
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MB32WFU2P$ETH^1HGV,3WSQW.3BN_^%G@NSU34/#\.L/'9:??7L%NB+\JHCN
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M_P#:LE?BA\;_  /%X"^(=]IUMC[*Q$T7/\#<C]"*_;+]@C_DSKX5_P#8*/\
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MH;A55NA *L"#GMU'G?BGXG+J$$&HQJ$OC'+:75NYV2/D#(8'D-E2O/JM>O\
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M=A:,4F:6G<+!FBDI12N-(Y*]Y^+&B_\ 8"OO_2BVKK<5R5]_R5C1?^P%>_\
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MXUU'1=0B(<2&2&4#Y9HB2593[C]:\^_LV\ 9@[IF3&QASG\*!'9?";XDZO\
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MM?V-\-KG6I]3?3KG6-5,:0:>X626UCC#9=L\*6+=.N%KS7]IVX@U?Q4VHZ=
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M4?(E)CN(?]26XVN!QD'J.V#ZUZQJ_B"358H)X7^RV<B!TBMOE13CD8'<'(-
M%^[\7:EJ5E9Z58Q?V:BDB2&!B/.DR<.WJ<<#L,>];=GXDU+PKH6MVKZL!+>6
MXMC%&=SL=ZDC(Z#"X/KG%<%$T9CW+</YRMGD8&/KZTB$2ERYQ[XS0!U]I<)I
M7@Z6^?SI[J\E>U1 VQ(@$!#\<D\\"LKP)+J?P_FTZ\FDF:YN)1/*7)(=2Q4K
MSU& :SK:.+.9$FFQZ/@ 5T7BJRG>^1X@@MU7,<$DPWQ ,1M;W!S^= RGKMW)
M9ZS<+O<A)FVG)SUX(_/-0ZUJ%MJ*Q.UQSMRZL/F#=ZS9I)=R^<Q9E.%4G^M5
M+IGBNE#QJ"_.2* )].F@C,N^X\GT;'4>E87C[5HTLK?3K-G_ 'NZ>Y8'&47H
M/H3S^ J_J5U:Z8SRSQ%F<?N+=#S(QZ >V>I[5Y]>R3ZE?R.S;WE.U_+&5/HB
M#J0/UH FTTSZNT&FV<+2>8X18T',K'HOY\FN[^,#1>$/">A>#(I8YKR%FO+^
M2/IYC@X7\,_RKIO"OAZS^#?AQO$_B"'_ (G,L+#3[(_\LR1P6[Y.<^U>%:WJ
M]SXAU.YU"\D,EQ.Y=F- %-.,>U?NS_P3XY_8V^&7_7C-_P"E,M?A,G4#WK]V
M?^"? Q^QO\,>_P#H,W_I3+36Y+/H?%%&:,YJ]"=0HI,T9HT#46BC- Y/I1H"
MW.3O3_Q=C1?^P'>_^E%M765R=]Q\6-%_[ =]_P"E%M769H!ABCBC-&<]J- U
M#BLOQ7_R*NN?]@^Y_P#135IYK,\5_P#(J:W_ -@^Y_\ 134/8$?S3=A7K'PI
MME\=^$=?\&/\]Z4.HZ6I/)GC4[D'^^F1CN0*\GZ#%7_#VO7OAG6[/5-/G:WO
M+259HI%_A8'(-9FAU%OXKNIM+L-)N)?*O=+F+6L[\,!V0^W48KUS3+6VU#1X
MM6N;KR+2==RQ1-EO,_B4CM@\<UYM\1K*R\6)%XPT/8OVL>9J%HAPUI<D_-@?
MW&)W*?<CM5CX>:O<W.GWT<JA8?.5@X;_ %<A&#N'8-@<] ?K0([.YNDE6:*T
MFN'ML E).<$=Q6[!XEMK*V@BTJSC20)AII/O;C_*L!9KS38M\SB+?P$VC+"G
MVS_O4F7$)=@F>RGL30!NZ1K<MMI=Y8VRW!N;PA9'C;  #!OQZ52N?#<'AAOE
MC%L^HS1W<F3]T,HX]N0Q_&EN[?[)=/#=,&G0D'!"C/U'6K>J:QICQ_V;#&)A
M;K KS2GD2&+=(![ L!^% &1XRN!=ZK<2QL<*_#!LY'3.1Q5.'4=0EMTB;4UM
MXDX57;)%&I64=K @C(V.V,*<\UF2QP3:7-,[+:R63$RN[ !ESC(SU.>PH&7-
M02]\/:C,UQ=A0J"1K@'(*D9SFO*_%>N7'B'5;F\G=Y)[HJH:0G<(U&%S_.MK
MQ-XQN?$,]K;0H9$@&V&!4),K9^^X_'A?;FNBT/P):> [-_$WCB/80H>PTF1O
MWMW,02"ZCD("!G/6@#6\!^'[7X1>$G\=ZXJ_VNZE=%TR889I#QY[ ]AU%>(Z
MCJ$^JW]Q>7,C37$[F21VY+,3DDUM>._'NK?$/79=3U6?>Y&V.)!B.)!T51V%
M<[TH 5>6%?OA^P3_ ,F=_"S_ +!7_M5Z_ ]3\P^M?O?^P3_R9W\*_P#L%'_T
M:]'41[Z!1THS29K30C47'2BC-&:- U BC%&:*- U#ITK1TW_ %+_ .^?Y"LX
M?-6CIO\ J7_WS_(5#W+6Q;HHHI#"L67B5_\ >-;58LW^L?\ WC_.@!M)2D4
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M *)?KW_?D?XTH_8A^.Y_YI=KY_[8#_&G8#PT=L5^[7_!/@_\8<?#'_KQF_\
M2F6OR7_X8B^.PQGX7Z^!G_G@/\:_8']BGP9K7P^_9;^'_A_Q%ITVDZU8VDJ7
M-E<+MDB8SR, 1]"#^- CVZCIWH HQ5$A11WH S3"X=^M HQ1TH&CDKW_ )*Q
MHO\ V [[_P!*+:NM/7K7)7O/Q8T7_L!7W_I1;5UM ,**,4F*+"N+VK*\5_\
M(J:Y_P!>%S_Z*:M6JFK:>FJZ7>64CF-+F%X68=0&4KD?G2&?S/8X'TI ":_4
MK6?^"13:AJ5G/;>,]*M8(74M =.D E Z@D/WXJ2__P""25]/;7,</CK2(5E6
M81C^QS^[WOD<YSA5X'.<GTXK.YLXKN?F+X;\1WGA;58[ZS<+(O#*P#(Z]U8'
M@@]P:](C\/P>)KW^W? <_D7Y&^?1)''FJ3RRQ@_ZV/.1CKCJ*^^8_P#@E#<0
M6%HH\;Z8\\# ,W]D'#KL5>N[)Z'KQ\Q/6N5T_P#X(Y:_ID\-Q;?%6Q@GC(97
M33)<J1WSOIK4EI+J?$5QXGGLKD6NI02Z%.@*F">%F@'IM!^9/H,CVKJ/[<_M
M/3+!+?39)C%AIGL769)F'<<@J,=B..:_0^T_X)W>([W3[>Q\4^-=!\3VL>1O
MN='D68@^CALUS^N?\$BO#=_(9=.\63Z+(P_Y81,R9^A.:+$GYMZZ/&MYJ<T*
M6VH0I+*Q0;-I*DY )]A@=>U=%X<\)ZCHM@]UJ6M64%Z[$M97<O7C@EAT;K7W
M1'_P1]_>!9_BC=2PXY06K#_V:KDO_!'?0G$1'CJ[+!<2%[?.]O4>GTYH>@'Y
M[:EXL33I AAB>0'.[[4LB?@%Y-5=+T+Q'\1M14VME*;>67#7C1;885)Y*^GU
MZU^F.D?\$K]&\.P@V&M:=<72L2)[^TEDQZ<!@*S?$W_!,_QSXDA>UC^*FFZ9
MIYX%K9Z3(B >G#\T6&?%$NN^#?@%9%-)6+Q!XO*$F\?#1VSG@X^GYUX/XD\3
M:EXMU6;4=4NI;NYE.2\ASCV'H*_1*3_@C-K,KEG^*6GLQY).ERY_]#IO_#F/
M5Q_S5'3O_!7+_P#%T"/S<"G''-&":_5KP5_P2GN/#5I;VE_XRT35XDGED8RZ
M+\SJ\84+N.6^4AF'..:@\)_\$DX_#^IZC->>--.U6UFCC2*VETEL(5927)+D
M@_*>!P=V#Q2U&?E8HY]<5^]_[!'_ "9W\+/^P4?_ $:]?.FK_P#!**SU&"X1
M?%.F60DM9(%-OI!W([3HZN"7X8(K G_;( "BOM'X)_#=/A#\)_"O@R*XCNTT
M2PCLS/%'L65@/F<*>F3D_C3CJQ,[>C\:,48K2Q%Q/QHI<4F*+!<*44=Z,4@%
M%:&F_P"I?_?/\A6<.*T=-_U#?[W]!4O<M;%NBBBD,*QI?]8_^\:V:QI?OO\
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ML>:FE\0:=#>PV4MW;17TPW16[S*)''JJYR1P>GI7R=??LU^.M,\%2Z)8>&O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>adag-20211231x20f022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f022.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *> V # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&FA2^+$)5M&2_C-T"!DCR\YSCG'6@#MZ*0'-+0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 &O(/VC_A?\/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<+\=O#
M6M^,_@SXV\/^')(H=;U;2+FPM99I/+5&EC,>XMVP&)S[5W5<K\4_A]9_%7X>
MZ[X3O[J[L;75;<P&ZL93%/"V0RNC#D$, ??&#P: /ASX30^,OV/O'OPM^''C
M'1O!>J0>(M#O(-,U?0M.\J_L;FVA!?S)CS+N\Q06&,EFQP,5X]I_A_2[?]AG
MP1\3XM.MXO']UX^M[^;5TC O'EEN\2)YF-VW'&W..37V=\,?V.]6T7X@^&/%
M/Q"^(%YX_E\(V$NF^'K:>V6%;9)%"-)(1S)(44#)] >PK T_]@+[+X@LM/E\
M=7MQ\,;'7CXCM_";6Z?+<EMX4R]3&&Y ]J .J_:*_;5M/V<==T+2;WX?>*?%
MDVIZ<M^;C0;99(HLLRE&)(PV5S]"*[+]EO\ :6TO]J7P+JWB;2M"U/P['INK
MS:-/9:L$$XFCBBD8D*3C_7 8/.5->PJ !@=NU?+_ .PAU_:(_P"RQ>(O_;>@
M#ZBHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HH)Q29H 6B@<T4 %%%% !1110 4444 %%%% !
M1110 4444 %%%%  1FC%%% !BC:*** #%?.G_!1#_DR[XI?]@^+_ -*8J^BZ
M^=/^"B'_ "9?\4O^P?%_Z4Q4 >[^%?\ D6-'_P"O.'_T 5J5E^%?^18T?_KS
MA_\ 0!6I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 8HQ110 5\N_L(=?VB/^RQ>(O\ VWKZBKY=_80Z_M$?
M]EB\1?\ MO0!]14444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !145U=164#SW$L<$$8W/)*P55'J2>E?+
M/Q/_ &]=#M-?D\'_  FT*\^+'C@GR_LND FSMV[F:?!  YSC)H ^E_$WB+3O
M"FB7FJZKJ-EI-A;1EY+S4)UA@B '5W8@*/>OSX_83\?_ !3^+W[6OQ&\::[(
M-=\'2QS:3'J^F3;]+B\J3,4<&<%@1SN YSD]:Y;]I_X&_'KQ9X<\._$#XQ7T
MOBSP[9ZQ!-J_P[\)[EBM;#DNP*G]Y(, 9RV-Q((Z5ZQ_P3]\+1#XM?$KQ9X*
M\(ZKX%^$VHVUM;Z;I6J*Z&6Z0_/*J.20,<9/]: /NP=**!THH **** "BBB@
M HHHH **** "BBB@ H)P**#R* $&<^U*3@5\E?\ !0_P5\2M3^&=MXJ^'/C'
M6/#T_A]C+J%AI#LLEW;L1O8;3\S(,D+WKSGPM^Q7\7/%WAO3-:L_VI/%XM;^
MWCN8Q)"ZL R@X(,O!&<4 ???>BJ>CV<NG:7:6L]PUU-#"L;SOUD( !8^YZU<
M8X!)./K0 45 MY"UN9Q/&81UD#C:/QZ4VVU*TO2RV]U#.RC)$4@;'Y4 6:^=
M/^"B'_)E_P 4O^P?%_Z4Q5]"PW<-QO$4R2[#M;8P;!]#BOGG_@H?_P F7?%+
M_L'Q?^E,5 'O'A7_ )%C1_\ KSA_] %:E9?A7_D6-'_Z\X?_ $ 5J4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M4'@4 %%</9_&SP5?_%F^^&5MKT4_CBQL1J5UI,<4C-# 2N&:0+Y8)WJ=A;=A
M@<8(-<Q9_M<_""_^*3_#F#QSI\GC%)3 ;#9*$,HZQ"8IY1?_ & Y;VH ]?KY
M=_80Z_M$?]EB\1?^V]?4(ZU\O?L(=?VB/^RQ>(O_ &WH ^HJ*** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **"<"O _C
MS^VK\.O@5<C1IKN?Q5XUF(2U\*^'H_M5]*Y^ZK!>(\_[1SZ T >]M]<5\U?&
M3]NOP7\/M;/A3PE;W7Q+\?2'9%H/AP>?L?I^]E7*H >O7'?%>;CX7_M"_M@#
MSOB3J[_!3X;3\CPEH$N[5KR(]KB;H@(/(.>G,8/-?2_P9_9X^'_P#T0:;X*\
M.6NEA@/.NR/,N;AO[TDK99C]30!\VV_[.?QF_:DN(]1^-_BA_!WA)SOC\#^&
MIBC.O9;B8=>.H&?K7U/\+_@_X.^#?A^+1O!V@6>AV2  BWC >3W=NK'ZFNRH
M- !BBOGKX\_MU_"[]G'QQ#X3\8W.K1ZQ+91WZI8Z>TZ>4[.JG<#US&W'TK(^
M$_\ P43^$'QG\>Z9X.\.76M-K>HEEMTN],>&,D#)RQ/'% 'TY10O2B@ HHHH
M **** "BBB@ HHHH **** "@]*** /EO]NKQAXN\'>"1=^$?B9H/@6[6RN7D
ML-8C0R:BH4<0,Q&UQVZ]:^:/AU^U#\>_#/Q5^&H\0>$IO%^GW/@R2ZCT?PU?
MJS7T/FH/MLH< >8GW2HZYXK[G_:)_9_\-?M > M1T?6=$TK4=5%M*FF7VI0!
MS93,N ZL 67G&<5\J>'?^"74OA'QKX7UOPK\0-6\"R66A-:ZC>Z%J$S74M\6
M!W1^:"! 0/F3(R0.* /O;3;LW]A;7+0O;M-&LABD&&0D9VGW%>-_M:Z=\2-8
M^&KV?PZUBU\/LXG?5M3F7=+#:+ ['R1_?9@JY[9)KV33;:6SL+:":X:ZECC5
M'G<8:0@8+'W/6J'C+2Y];\(:YIUL%-S>6,]O$'.!O>-E&3V&30!\%^ '\<>*
M?^"5\%GX2M=0U[Q9JUN;6+[/)F?YIQO;<Q'8$9SWKF;?X@6/P*^%'QQT*R\&
M:C\-OBOI?A6&Z4RZJUZ)[6:2.$7,3DD*R/,,^Y%?0?PO^ GQ9^&_[&>A^!?#
MGB"Q\+_$?26$T<X(GM)L.6,+ML)".#@D#(P/>N;;]D?Q_P#'*]^)_BKXL3Z'
MH'B;Q-X4'A+2K#0Y)+J"QB619_/E9@N]C/'&^T= ",Y/ !@_!+PD?V??VG/A
M%X9T;4]1N]/\:^"YKC6([V[DF66\@B24W #$X9F8].U)^W5^V-\&O&/[-WQ,
M\$:-X[LK[Q5- +---2"<.TR7";TR8PN1L;OCBN[^ WP"^*K_ !;\)^-?BR?#
M]O)X*\.'P]I,>AW4MPUY(RA);J0NJA=R*/EQG/85O_\ !0K1-.A_8V^*-Q'8
M6T<_V"-O-6%0P/VF+)SC- 'T)X4_Y%?1_P#KSA_] %:E9?A7_D6-'_Z\X?\
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M[6(CCY%5$51QA!C XJ2U@B3_ ()W> M?$4:>*)/']M=M,H"S-=/>8D)/7)&
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M4 %%%% !10>E>:_&C]HOP!\ =&-_XS\0VVG.RYAL5;S+JX/81Q#YCD\9Z>]
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M7:[\!O"C>.M$OM \4VEJ+*]M=0C*2LT?RK)@\_,H!SZYKURB@ HHHH ****
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M/78L9!E'MM'L#7U;\$O^"4WPS\&P+J'Q%EN?B5XED :66]GDCM4;_916#/\
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MLK;#-:2K(H/ID&M.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBL_P 1>(-.\*:#J.M:Q>Q:=I6GV[W5U=SMA(8D4LS,?0 &@#0HKQ3X,_M@
M_"_X\^(9M"\*:W<2:LEM]MAMM0L)K1KNVW%?.A\Q1O3([<\=.#573_VU_A%J
M?Q/'@.W\3,^M->-IR3_8YA927:_>@6XV^67&#P#U&,YH ]UKY=_80Z_M$?\
M98O$7_MO7U".M?+W["'_ #<1_P!EB\1?^V] 'U%1110 4444 %%%% !1110
M5\N?M_?M7R_LM_"^QN]'DA;Q3JMXD-G!* W[I2#*Y'IMXSZL*^HZ^&/VSO\
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MM_P5<WYM-4T#7_"-]H_@:'1@(8]$M[>+=Y;1A?W@*NH5LX&X\?*#7BML$?\
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M#X T*QE;4+EU[-;!MSYX_P!9)@=<"O1O@;X-\3^,(Y;/]G;P9-X-T2[)%_\
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MO[56@_#/PWI^C?L[1:WH]O91I97[70A,\  V,4#X!*XH _0[PY/!=:!ILUK
MUK;26T;10.,-&I484CU XK1JEHUQ<W>E6<]Y;_9;N2%'F@SGRW(!*_@<BKM
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M@$\<'(R.E<]\3OVIOC3\=4GC\5^.];U.PF4!]-@F^RV<@'0?9X@L;'W*D^]
M'[B_%;]M'X+?!IIH?$OQ TE=0B+(VFZ=+]MNE<=5:.'<4/\ O[1[U\A_$[_@
MLAIL,<T/PZ\!7%V2FZ'4_%%REI"V.N(58E_PD!]J_*O1M*O(KZ*2?2-2NK=#
MEX[0&&0CT#[&Q^1KZ'^%OQ-\$>!)+5HOV8%\7ZDK96Z\1:E=7GF'T,/DK"WX
MQT =%XX_;P^.WQOU.32[/Q;J?[TYBT7P)8/%YB/PT9D \TXSCE7'O6=X3_8B
M_:%^)]REU;?#._L5<D'4?&$PCEVGIN2=@V1ZI&#7TSX-_P""C'Q+\/::;'PK
M^S#;Z381$?Z-I,<L$2^GRI !7:V'_!0?]HK4C$+7]F/4[@RC*!&N3N^G[F@#
MR[P=_P $<_B%KYBD\<_$?3--3:%>VTR"2\.W^[N?RP,>NTU]!>%/^"4OP1\
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M7/\ @FWX<OK[]L?P6L6E"^>QDFGN$=BAM45"#+[D9Z>] '[WT4#I10 4444
M%%%% !1110 4444 %%%% !1110!R'Q@\-ZMXQ^%WBC0]">SCUC4-/EMK5M07
M-N'9<#>-K<<^AK\\? 4O[5WA^_L_AKX>_:$^#MSK&F)]EBT3^T8;B]0(/N%3
M:%R5 Z=0!7Z _'B76H?@QXU?PX6&N+I-P;0I]X/L/3'?K7Y5^(-,_9?@_9HT
M6]\$SW3_ ![#VTE@\%Q</JIU;S5+>9&6VXW \E<# QSU /V#T5+V/2K-=1D2
M6_6%!</%]UI,#<1P.,Y["KM9_AXW;:%IS7^/MIMHS/C^_M&[]<UH4 %%%&:
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MI"8X-'U"S-K/:X8AD>(\JV[.?7K6]XZ\<:)\-?!^K>*/$=^FF:'I4#7-W=2
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M>/\ ]G_&&=%?X?\ P=\>:9!J:![KQ-+I5U=:MJ*L.6^V-#M1&':,*I!YSUH
MZ+7O$7Q:\;Q)IWQ6^*7B:^UV^0I:>!_#+"74)2>@G6+"1+ZALGU KUC]G?\
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M33QEXM\'7U_-XRM4T!["U*)!?X/ER3#RQF,<Y'/TKWX>#OVV_P#H??AY_P"
M#?\ QF@#[))Q1GFOE[X8^%_VL+/QYH\WCGQCX)U#PFDI.H6VG692XDCVG 0^
M4,'=M[^M?4(% !103BC- 'FO[3'_ ";O\2_^Q<O_ /T0]8'[%O\ R:I\,/\
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MH74KP(F\6FF$K(QSU 4<GB@#E-"\._L<:1=;;7PW\6OB5.?^6;!($8^P7R6
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M"/\ \++V;XS77CJXO[&TL+6PFM+>UDN8_M%T[X!*QYW84#).* /V,%% Z44
M%%%% !1110 4444 %%%% !1110 4'D44=* /"OVFOV6(OVDX]&2;QSXC\')I
MPD!70;CRQ<!\9$GKC'ZU\ZG_ ()"^&386UE_PMGQL;*VE$\%MYL?EQ2 Y#JO
M16SSD<U]"_M6_M)7_P "-*\/Z;X8\.R>+?'/B:[^Q:/I*MM5G RSN>RBO"[S
M]J+]I+X'B#Q+\8/ASHQ\ _:(XK^]T6YW3:>CL%$C#G(!(S2 ^XM'T\:3I=G8
MB5Y_LT*1>;(<L^T 9/N<5<J&SNH[ZUAN86#Q3(LB,.A4C(-34P C-)MP../8
M4M% "!0.@%?.G_!0\8_8N^*7_8/B_P#2F*OHROG3_@HA_P F7_%+_L'Q?^E,
M5 'N_A7_ )%C1_\ KSA_] %:E9?A7_D6-'_Z\X?_ $ 5J4 %%%!.* "BC-%
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M (I?]@^+_P!*8J /=_"O_(L:/_UYP_\ H K4K+\*_P#(L:/_ -></_H K4H
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M0_9!_8X\,?LE^$;JRTZ5=7\0W[EK[6Y(0DDJ@G9&HR=J =L]<FOH*@ HHHH
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MMN8%N:QT\ ^*1\*;[PT?'-XWB299!%XE,">="6DW*0G0[5^6@#T'^=+FN/\
M$7A/7M6@\*I8^*;C3'TN]AN-0>.)6.I1*C*\3Y^Z&)!R/2K-QX:U>;XB66N1
M^(;B+0X=/DM9=!$:^5-,SJRSENN0 5Q[T".FW49W5RWA_P ,ZSI6M^*+R]\1
MW&I6FIS))86<D2A=-01[2B$?>!;YN:PE^'WBP?"*^\,'QW>GQ//'(L7B?R$\
MZ$L^Y2$Z?*/EH&>(_MQ_\E%_9E_[*38?R:OK0<5\B_MK126_CG]EZ*:9KB6/
MXBZ<KS, "[!6!8X]>M?2<WAO6)?B#;:VGB*XCT2.R>W?0Q&OE22E@1,6ZY X
MQ0!T^[VHS7,^&/#>L:/K?B2[U#Q%<:M::C=":RLY8U5=/C" >6I'49!//K6#
MI_P_\56OP=?PM/X[O;GQ28)HQXJ,""<,TC,K;.GRJRK]%H$>B;O:HKM))K29
M(7$4S(RHY&=K8X/X&N5\0^$]=U6+PR+'Q3<Z6VFW,<U^T<2G^T45<-&^?NAC
MSQ5F7PWJ[_$.#75\0W":''IS6K:"(U\J2<ON$Y;KD+\N.E SXG^-G[%?[1/Q
MB\ ZIX?\1_&72O$6FR?Z1'ITNF"/?*AW1@.%!4YXS[FLG]GO]A_]HCX/?#FR
MTWPY\6],\'QWF+VZTP:<)FBF=1E6<J<D8 ].M?=/AKPQK6CZUXLN]0\2W&K6
MFJW:SZ=9RQ*JZ9&(E4QH1]X%@6Y]?K61!X"\4Q_":?PS)XYO9/$KI(J>)_(0
M3(6D+*=GW?E4A?PH [/0+:]L=#L+?4;H7VH10(EQ<JNT2R!0&;';)R:T,UR.
MO^%=<U1/"PLO$]SIO]F7,<U^8XE/]I(J%6C?/W020W%23^&M9D^)5MX@3Q%.
MF@1Z4]D_A_RU\J2X,H<7);KN"@ICI@T =5FC-<IX?\,:UI>L^*[J]\27&I6N
MJSI)I]I)$JKIB"(*40C[V6^;FL<^ /%/_"IKOPS_ ,)S>_\ "2RHZQ^)O(3S
MHB7W A.G ^6@#D/C;XZ^%/Q#UVX_9_\ %NO1QZWXKTYR+&*8QNH!4H-X^[(3
MAE4_>V'@C@_GS^QQ^Q?H/@W]H[XE:SXS\0)_87PHOX\2;C$)W9&DBD=L_*H1
M<D#J>*\L^*7[%_QL;]LV#PQ)=7VN:[K5V=5L_%[%A&]NK@O<N_\  8\J&7J"
M5 SN7/I/CK]G+XH?%36?VE]/\+>,KS4+K1;_ $M=4TG;L_MYUM,F0D'A_D8A
M>A+8H _4SX1?&7PE\<_",?B3P;JL>JZ6TC1%U^5XW4X*LO4'OSV-=KNYK\S/
M^"1_P$^(?A&QU_QIK%Y>Z!X9U.)K6VT>>/:;F53CSRK#Y=I! /?GM7W?'X \
M51_!^;PL?'-Z_BAX'B7Q28$\]&+E@P3IP/E_#UH ]$SS1NYKDO%'A77-8D\+
M-IWB>YTE=,O8[B_$<2M_:42J0T3Y^Z&)!R/2K#^&]7?X@PZVOB&==$2Q-LVA
M^6OE--NR)MW7('&*!'#?M)?"CQM\6O#.FZ;X(\?7'P_O(+DRW-W;PB0W$10K
MY9!!P,D'\*_)WQ;^S)^T5\'/&.G>$],@\2:NGAZ:;_A&-1T6&-[14F;YWR>4
M+9^8'.*_9CPMX:UC1-8\3W6H^(KC6+;4KW[18VLL:JNG1>6J^4A'4;@3D^M8
M=O\ #_Q7#\(/^$7?QW>S>*/*=/\ A*3 @GW&1F#;!\O"D+]!0,^??V(_V2_B
M;^S])87GB?XBR:AH\]M/-<^%8XAY,-W,0S/OQDD$'VY-?8V[FN1\0>%==U1O
M"WV+Q1<Z:-,N$FO_ "XE/]I($*E'S]T%OFXJPWAO6#\2$U\>(9QH*Z4;(^'Q
M&ODM<&4.+G=][=M^3'3!H Z?-(#DUROA_P ,:UI6I^*KF]\2W&I0:I<"73[>
M2)5734$038A'WAN!;GUJ?X>^'M6\+^%+/3=;UZ;Q+J4)?S=2N(PCRY8D9 XX
M! _"@#I**** "BBB@ HHHH **** "LGQ9X6TOQOX9U3P_K=J+[1]3MWM+NU9
MV42Q.,,I*D$9!(X(-:U% 'P;^SAX=L?#?[:/[46B:%80:9I]GI.F6MG96<8C
MCA1;.-41%'  &  *\,LK^WF_X)W^ _#BW$<GBJ/Q];6DD!(:9+E+S,F0><C(
M).*_3+PY\'O"?A/X@>)O&VEZ6MMXE\2+$NJ7HD8FX$:A4RI.!@ = *Y6P_9*
M^$FE_$Q_']KX)T^'Q4TQN3>+OVB8]91'NV!SD\[>Y/6@"K\5HOC_ !7VD)\*
MW^' TM+)5OO^$S2_-P;@$Y\O[,0NS;MZ\YSVKR__ ()R_P!M_P#",?'#_A)3
M8'Q%_P +6US^TCI6\6GVK9;>;Y/F?/Y>_=MW<XQGFOK?%?+O["'7]HC_ ++%
MXB_]MZ /J*BBB@ HHHH **** "BBB@ -?SK_ +7^M7=O^TE\6=/M_-L;"Y\0
M3O-:D!0[*QPQQZG+#ZU_1.3S7\[G[<FF-I/[6OQ/@:ZAO"=7>7S8&ROSJK[?
MJN[:?<&@#7_8S\,_$;QEXXUB'X=_#OPA\0-32VC>>+Q986T\%FF[ DC$KHJL
M3Z9)QTK[T\-_L\?M@7%N/LG_  I_P&0I 6#0[8LN>2!LMI1U/T^7\_S@_9T^
M)WC/X8ZGK=WX%\7W_AC6[J".)8-.TW[9+>@,3MQL8+CKD]<U] :#X@_;8^)E
ML7T:_P#',VG[QNNKF&.T13ZDE5(% 'UQ>?LI?MC^*04UG]H?1M,BVX']AV?V
M<CV_=6\./KFN$U[_ ()<?%_Q6LK^,/VB[F^A8?>O&N[D'V/F3 "N$TS]G;]I
MW5':?QG^T)I_@Q!'G-UXHW-]"D3<'K7'^-_@*BZ;+8^+OVR=+OX"<O9W&JWM
MU&Q'^R2030!L>(_^";W@#X93SKXR_:@\+Z'=(GF"WN]*AF=UP3PDET"3Z  Y
MKS75(?@K\.%0:'\?=;UZ_$A /A#X>6]DX/;,DDL8?J<88UP]U\ /AA!=%(/B
M^VOC)!&B>'[JY9CSC&!CJ!^8JN/V:+G6"8O"^D>.O$*,?E*: UNK>A_>$>U
M'IMMXE^/?C*2*T\'^(_BR+=AFTU+5?$*Z-;F/L60'8/^_IKJ_#_P1^/7B)8K
M[QE^U%I?A.+<(F&J>/IKJ=5Y.%\IV0]^-XKYS\0?LE^//#L+3ZIH[^&H%Y+>
M(;J"V('KMWD_I7G-SHO_  C-W)&NLZ;=7!&%^QXNHVZ<;B, _P"% 'Z+P_LI
M? S4IF'Q2_;(F\5S*F5CM]>MK5D./6>2XW#\!4%Q^S/^P;IT*-<?&74KP@X+
MC78)';ZA+?\ I7P#X<U_Q'<M';V1LY"K[?*CTJ"XE'/7;Y1)%>F:3^R_\7OB
MRV=+\$:WJ8;&RYBT>.RA^IRJ$#\* /JVX^&?_!//2YL2>-M5F,>&/E7EW(&[
M]4BY_"N=\8^*?^"?GA6".;2/#_BWQI+U^RV-WJ$"Y]':>6+ _P!W)KD? _\
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M3=05(8-:OS*$@EO'P2S]EVJ5W-]<\BOW+/7I7\X'[6,\EQ^TS\4'EM/L+_\
M"17J^3C' F8!O^! !O\ @5 'U/\ L"_LQ7OQ!UCQOI>C?%R7PIK6BW*177_"
M-B*87<)'RRQS'JN[(X':OM5/^";7A_4Y0_B;XH?$#Q,QY;[1JQA#?]^P/\BO
MR+_9N^*_Q5^%.OZM<_"6.?\ MR^MA;SS6FF)>S)%DGY5='"Y]<=J]1\3Z_\
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MD4*Y'IL4''7\ZZ)_^"NOP!0-BZ\0OC.-NE-S],M63+_P6/\ @<D;LNE^,)6
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M]8?=DYT_4-RC\' Q7ZC0>$]#M@@AT;3X@ARH2U08^F!6A#9P6Q)AACB)Z[$
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ML<<#/O0!QWQF^*FE_!+X8^(/&^LQRS:;HUOY\L4) DDRP4*N>,DL!7G?@/\
M:CN=>\-^)O$?B_X;^)_AKX>T+33JCZEX@2+R[B, EA'L8DL ,X]Q7G?QD\6_
M\+K^%OBKPQ\;?"6K_!/P6]U:P1Z]/J5O=B_<S';&!$&,8.T$EA@ ]1BOFGXT
M:%>?"R7]H;X4>#_$&J^(_ H^']KXBD@O[U[QM-NEN[<,@D8D@20&20J>P&.!
M0!]J? G]L#1?C;XM/AQ_#&N^$=4N-.&L:;'K<*H-1LB<+/$5)X.0<'G%4?\
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M]#-\.?\ OTO_ ,8H ^[Z*^$/^$>_X* ?]#-\.?\ OTO_ ,8H_P"$?_X* ?\
M0S?#G_OTO_QB@#[OHK\VOB7X]_;C^%-WX/M];\2>!&D\4Z[;^'K#[+;(X%U,
MKLA?,0VIA&R1GMQ7;#P__P % /\ H9OAS_WZ7_XQ0!]WT5\(?\(]_P % /\
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M._'/A+3?$G@0:KX.N+:VU(SVR+&7GA\U/+81'<-O7(&#0!^DU%?"'_"/?\%
M/^AF^'/_ 'Z7_P",4?\ "/?\% /^AF^'/_?I?_C% 'W?17PA_P (]_P4 _Z&
M;X<_]^E_^,4?\(]_P4 _Z&;X<_\ ?I?_ (Q0!]WT5\(?\(]_P4 _Z&;X<_\
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M\J* /@W_ (5)_P % O\ HM?P]_\  )/_ )64?\*D_P""@7_1:_A[_P" 2?\
MRLK[RHH ^#?^%2?\% O^BU_#W_P"3_Y64?\ "I/^"@7_ $6OX>_^ 2?_ "LK
M[RHH ^#?^%2?\% O^BU_#W_P"3_Y64?\*D_X*!?]%K^'O_@$G_RLK[RHH ^#
M?^%2?\% O^BU_#W_ , D_P#E91_PJ3_@H%_T6OX>_P#@$G_RLK[RHH ^#?\
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M:_A[_P" 2?\ RLH_X5)_P4"_Z+7\/?\ P"3_ .5E?>5% 'P;_P *D_X*!?\
M1:_A[_X!)_\ *RC_ (5)_P % O\ HM?P]_\  )/_ )65]Y44 ?!O_"I/^"@7
M_1:_A[_X!)_\K*/^%2?\% O^BU_#W_P"3_Y65]Y44 ?!O_"I/^"@7_1:_A[_
M . 2?_*RC_A4G_!0+_HM?P]_\ D_^5E?>5% 'P;_ ,*D_P""@7_1:_A[_P"
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M  IK6-^E:U<6$-YI]Y<L%AO7?<3$I[, !C/4Y Z4 =?\"_@YHW[/_P *M"\
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MH4Q[@-W;N> :_2W]J'X7:K\:_@#XU\#Z'<6=KJVMV7V:WFU!W2!&WJV7**S
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MD2R%PK8MRF[@NQ!)]N?6OT'90P(/(/:JFG:/8:0KK8V4%FLC;W$$80,WJ<4
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MKT %%%% !163JGBW1M&U?3-)O=3MK;4]3=DLK.20"6X*J6;8O4X R3T%:PH
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MJ*3:!HL,2WR[D;RIEC,>1F,#)S@,XQ\QH \R_P"">^C6&J^-/VE!>V-M=_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]KMO;$Q0WW@.VDN57H[">3!/_?(KZ_'% !1110 4444 %%%% !1110 4444
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M9:1Y*7-S%%-</Y<$3N%,K]E7WH)E)15Y.R+^:K7FIVFGP2S7-S%!%$ 9'D8
M*"<#/IS7%:1)XO\ %TU[_:=M'X<T>6)HHHD?==[L\/N' ^E7M"^%FB:):7D#
MI/J9O55;E[^9I3*%.1G/;/-79+=G$J]6K9TH::ZRT]-+7_(OK\0_#+:?=WRZ
MY8FSM"@GG$PV1ECA=Q[9/ J.+XF>%9M+GU&/7[!["!UCEN!,-B,WW03ZFKUI
MX1T2QMYH(-)LHH9]OFQ"!=K[>1D8YQ4J^&])2VDMUTNR6WD8,\0MT",1T)&,
M$T>Z.V+TUCMV>_3KMM^)F+\3/"KZ2^IKK]@=/286[7/G#8)"-P7/KCF@_$SP
MJ-(&J'7[ :<9_LWVGSAL\W;NV9]=O.*U!X:TE;4VPTNR%N7\PP_9TV%L8W8Q
MC..])_PC>D_9/LW]EV7V;?YOD_9TV;\8W8QC..,T>Z%L7WCMV>_W[&8_Q,\*
MQ:7%J3Z_8+82RF%+@S#8S@9*@^H%)/\ $SPK;:;;:A+K]A'97+.D,[3 )(R_
M> /?&16HWAK2'MEMFTNR-NK%UA-NFP,>I QC/O2OX:TB2WCMWTNR:",EDB:W
M0JA/4@8P,T>X%L7WCMV>_P!^VYEW7Q+\*V6GV5_/K]A%9WN_[-.\P"R[#M?:
M>^#P:+SXF>%;"TL[JYU^PAM[Q6>WE>8!95!P2I[X/%:<GAO29K>&"32[)X8=
MWE1M;H5CW'+;1C R>N*67PWI,\,,4FEV4D<((C1[="J G)"C''/I1[H-8O6S
MCLNCWTOUVWM\C+O_ (F>%=+BM);O7["WCNXO.MVDF $J9QN7U&0:-1^)GA72
M/LOVW7["V^U0+=0>9,!YD39VN/4'!Y]JTY_#6DW*1)+I=E*L2[(UDMT8(OH,
MC@>PHN/#6D7?E>?I=E-Y2"*/S+=&V(.BC(X R>*/=!K%ZV<?+1_/J9>I_$SP
MIHTD,=]X@L+5YH5N(UEF +QL,JP]C2ZI\2_"NB7(M[_7["TG*+((Y9@IVL,J
M?H1S6G<^&])O&1I]*LIV1!&IDMT8JHZ*,CH/2EN?#6D7LGF7&EV4[[0N^6W1
MC@=!DCH*/=!K%ZV<?+1_CJ9>J?$KPMHFHO87^O6-I>IM+02S!7&X KQ[@@_C
M2W_Q(\+Z5JSZ9>:]8VVH(RHUM), X8XP,>^1^=:=UX;TF]G:>XTNRGF;&99;
M=&8X&!R1GH!2S^'-*NKHW,VF6<MR2"9GMT9R1T.2,]A1[H-8O6SCOIH]O/7?
M8S+CXD>%[76#I4VO6,>I"40&U:8"3S"<!<>N2*0_$CPN-9_LDZ]8C4_/^S?9
M?.'F>;NV[,>N>,5J2>'-*ENS=/IEF]R6#^<UNA?<.^[&<^](?#FE&[^U?V99
M_:M_F^?]G3?OSG=NQG.><T>Z.V*OO'?L]OOW,V'XD>%[C6/[*BUZQ?4O-,'V
M59AYGF X*X]<@T6/Q(\+ZGJRZ9::]8W&H,YC6VCF!<L,Y&/48/Y5I)X<TJ.[
M^U+IEFMSO\SSA;H'W=<[L9S[T0>'-*MKH7,.F6<5R&+"9+= X)ZG(&<T>Z"6
M*NKN._9[??N9FE_$GPMK>IQZ=8:]8W=])N"6\4P9VV@LV![ $_A2:5\2_"NN
M77V;3]?L+RXV-)Y<4P8[5&6/X 9K4MO#FE65RMQ;Z7903KG$L5NBL,C!Y ST
M)_.BV\-Z192^9;Z796\F"N^*W13@\$9 H]T45B].9QWUT>VFVN^_X&7IGQ,\
M*ZS++'8Z_87;Q1-.ZQ3 E8U&68^PHT[XF>%=7%U]BU^PNOLL#W4_E3 ^7$N-
MSGT R.:U+;PWI%F[M!I=E S*48QVZ*2IZ@X'0^E%OX:TBT\WR-+LH?-0Q/Y=
MNB[T/53@<@^E'N^8)8O2[CYZ/_,R[#XE^%=4BNY+37["XCM(C/.T<P(CC!P6
M;T'-%G\3/"NH6EY<VVOV$]O9H)+B1)@5B4G +>@SQ6I!X:TBU658=+LHEE3R
MY EN@#KZ' Y'M1#X;TFWBFCBTNRCCF4+(B6Z ..N&&.1GUH]T$L7I=QZ]'\N
MIE6WQ,\*7NGWM]!K]A+9V6PW,ZS K%O;:FX]LG@4L'Q+\*W6FW6H1:_826-J
MR+/.LP*1ECA03VSCBM.+PWI,-O-!'I=DD,V/-C6W0+)@Y&X8P<'D9H3PWI,=
MO+ FEV2P2D&2(6Z!7(Z$C&#BCW02Q>EW';L]];==MOQ,R/XF>%9=+FU)-?L&
ML(9%BDN!,-BN1D*3ZF@?$SPJ=).J#7[#^SA/]F-SYPV"7;NV9]<<XK37PWI*
MVSVRZ59"W=@[1"W38Q'0D8QFE_X1K2!:FU&EV7V8OYAA^SILW8QNQC&<<9H]
MT+8OO';L]_OV,MOB9X5325U0Z_8#3VF-N+GSAL,@7<4SZXYQ1)\3/"L.EPZD
M^OV"V$TC11W!F&QW7JH/J*TSX:TDVHMCI=D;</Y@A^SIL#8QNQC&<<9H;PUI
M+VR6YTNR:W1BRQ&W0HI/4@8P#1[H6Q?>.W9[_?L9EQ\3/"MKIUIJ$VOV$=E=
MLZP3M, DI0X8*>^"1FBZ^)GA6RL+*]GU^PAM+T.;:9Y@%EV':VT]\'@UJ/X;
MTF6WB@?2[)X(B3'&UNA5">N!C S22^&])FMX8)-+LI(8<^7&UNA5,G)VC&!D
M^E'N@UB];..RZ/?2_7;>WR,N]^)GA33K:SN+K7["""\0R6\CS "50<$KZC/%
M+?\ Q+\*Z7':27>OV%NEW")X&DF $L9R R^HX-:<WAK2;B*&.72[*6.$;8T>
MW0A!UPHQP/I2S^&])N4B6;2[*41)Y<8DMT8(OH,C@>PH]T&L7K9Q^Y_/K]QE
MZC\3/"ND?9?MNOV%K]J@2ZA\R8#S(FSM<>H.#S1J?Q,\*Z--%%?:_86LDL2S
MHLLP!9&&58>Q%:=QX:TB[\OS]+LI_*011^9;HVQ!T49' 'I1<^&])O&5I]+L
MIV50BF2W1B%'0#(Z#TH]T&L7K9Q\M'_F9FJ_$SPKH=V;74-?L+.Y"*YBEF"M
MM894X]P0:=JGQ(\+Z+J<FG7^O6-I?QE0]O+, Z[@"N1[@@_C6C=>&M)O9?-N
M-+LKB3 7?+;HS8 P!DCL*6Z\.:3>W+7%QIEG/<-C,LENC.<# R2,] */=!K%
MZ\KCOIH]O/7?;\3,O?B1X7T[5FTNZUZQ@U%7$;6SS .&.,#'J<C\Z67XC^%X
M-8_LF37;%-2\X0?93,/,\PG 7'KDXK3F\.Z5<71N9=,LY+@D,9GMT+DCH<D9
MS0_AW2I+O[4VF6;76_S//-NA?=UW;L9S[T7B-K%7=G'?L]OOW,L?$CPNVL_V
M2->L3J?G_9OLOG#S/-W;=F/7/&*6V^)'A>[U<:5#KUC+J)E,(M5F!?>"05QZ
M\&M(>'-*%Y]K&F68NM_F>?\ 9TW[LYW;L9SGG-$?AS2HKL74>F6:7(8OYRVZ
M!]WKG&<^]'NA;%=7'?L]OOW,S3_B1X7U;54TRSUZQN=0=F1;:.8%RP!)&/;!
M_*DTKXE>%=<OTLM/U^QO+MPQ6&*8,QV@D\>P!/X5J0>'-*M;H7,&F6<-PI+"
M:.W17!/4Y SW-%MX;TFRG6:WTNRMYESB2*W16&>#R!W!H]T26+TNX[ZZ/;RU
MWW,O2_B9X5UNX:"PU^PNYE1I2D4P8A5&6/T I-,^)GA367G2QU^PNF@A:XE$
M4P.R-?O,?85JVWAO2;*0R6^EV4#E2NZ*W13@]1D#H:+;PWI-FSF#2[* NAC8
MQVZ+N4]5.!R#Z4>YY@EB]+N/GH_\S*T[XF>%-6%T;/7["Y%K US/Y<P/EQ+C
M<Y] ,CGWI;'XF>%=2@NYK77[">*TB\ZX=)@1$F<;F]!DUJ0>&])M?,\C2[*$
M2H8Y/+MT7>AZJ<#D' XH@\-:1;)*D.EV422KLD5+= '7T.!R/:CW02Q>EW'[
MG\NIEVGQ,\*W]G>7=MK]A-;6:J]Q*DP*Q*QP"Q[9/%%M\2_"MYIU[?P:_82V
M5EL^TSK,"D6\[4W'MDC K4B\-Z1!%-%%I5E'%, )$2W0*X!R PQSSZTD?AO2
M88)H$TNR2";;YL2VZ!9,'*[AC!P>1FCW02Q>EW'9]'OK;KMM?YF9#\3/"MQI
MESJ,>OV#V-LRI-<+,-D;-]T$]LXH3XE^%9-*EU-=?L&T^*40O<B8;%<C(4GU
MQ6FGAK2([>6W72[)8)"&>(6Z!&(Z$C&#BE7PWI*VK6PTNR%NS!VA%NFPL.A(
MQC/O1[H6Q?>.W9[_ '[&7_PLSPK_ &1_:O\ ;]A_9WG_ &7[5YPV>;MW;,^N
MWG'I0WQ,\*II2:FVOV T]YC MR9AL,@&2N?7'-:G_"-Z3]D^R_V79?9O,\WR
M?LZ;-^,;MN,9QQF@^&](-JML=+LC;J_F"'[.FP-C&<8QG'>CW MB^\=NSW^_
M8RY?B7X5@TRWU&37[!+&X=HXK@S#8[+]X ^HS1<_$OPK9Z=9W\^OV$5G>%Q;
MSM, LI0@/M/?!(!K4;PWI#VR6[:79-;QDLD1MT*J3U(&,#-$GAO29;>*!]+L
MGAAW&.)K="J9.3M&.,]\4>Z%L7KK';L]]+]=MS+N_B7X5L+*SO+C7["&UO S
M6\KS +*%.&*GO@\4E]\3/"FFV]G/=:_86\-Y'YMN\DP E3.-R^HS6K+X;TF>
M&&&32[*2*$$1QO;H53)R=HQQD^E)-X:TBXCB272[*5(5VQJ]NA"#T QP/I1[
MOF#6+ULX].CWZ]?6QEZA\3/"FE+:M>:_86RW4*W$!DF \R,YPZ^H.#S[4NI?
M$SPKI#6ZWNOV%J;B!+F(2S ;XF^ZX]0<=:U)_#>DW0B$VEV4PB01QB2W1MBC
MHHR.![4EQX;TF[,?GZ793&-!&ADMT;:HZ*,C@#THO'S!K%ZV<?+1_/J9>J?$
MSPIHEPD%_K]A:3/&LRI+, 2C#*M]"*75?B9X5T.]:SU#7["SNE56:*:8*P#
M$''N"#^-:ESX:TB\</<:793N%"!I;=&(4=!DCH*2Z\-:3>S&6XTNRGE( +RV
MZ,Q &!R1Z47CYA)8O7E<?+1[>>IG:E\2/"^CZI)IM]KUC:WZ,JM;RS ."P!
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>LM#A\,I+X+DTQKB?7S. T=UN8"'9G/0*>G\77C%%A7.WHHHS0,**3=Q1NH
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M!WQ7\2ZCXY\4_#7QZEHWB_P_%%=QZA8*4AU*TD^[,$/W2"55ATR?8UQ'P/\
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M^0]R2U>3^)/$WQ3_ &>_%7A2Y\3>-8/B%X2UO4HM*N3/I,-C<VDLAPC+Y7#
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MI[:&"&&U8[#F,<9VGIR<\UVW[,"&7]E;P:B*6=M#4 #N2AH=K7!;V/)OV*/
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M$/6[3QCX?\4NUKIOB&&R6SG@NU&1%-$F4^?*@$>_H<1?M$_&3QUX!^,WP_\
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MAU"V>V>2/&Y0PP2,]^:UL45)1S7PV\$6_P -_ NB^&+6XDN[;2[<6Z33 ;W
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MZ?+7N'P^^'OBWPIJ\MUKWQ$O?%MJT11;.YL(H%1LCY@R<_A19<M[BN^:Q?\
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M7T!!4X]S0UI<$];'JE%%%24%%%% !1110 4444 %%%% !1110 4444 %%%%
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M68 ]R 14FC?LH6\>D6K^%/'OBOP+HVI6\<UYHNBW:BW,C(-S1!U)B+=]O'3
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M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB_C+<ZQ:?#769= ^
MU#5U$7D?8E+2_P"N0-M Y^[N_#-=I7%?&<:RWPTUD>'_ +8-7Q%Y']GEA/\
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M 8HHHH *,444 %&*** "BBB@ Q1110 8HHHH *,444 %%%% !BBBB@ HHHH
M,4444 %%%% !1110 48HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC.[KSCTH=&HN@0SO 5.7EJ?%>VDNF_0]QS1FO#O"/[32^*K+7[C_ (1PVO\
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M;D+;MWE\=,8Q^-'L:G8%G>7NS53=.6TME>[V\GYGN6:,UX<G[32O\.W\5?\
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MZ-X-\.:^?#AF_M@W ^S_ &W;Y7E/M^]Y9W9Z]!BCQ'^TVGA_P[X=U4^'#/\
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; %4 *!@ 4N.:*ENYTT:/LEJ^9O=O?_ANR/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>adag-20211231x20f023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f023.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (  JH# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M UZ5^SUX=^(_Q3_:&U[XR_$?P(/AW;IX<3PQI.@7-TMS.T9N1<2RR, !]Y5
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !17R_\ MJ?M(ZS\$+SX?Z'X=U.VTC4O$5W=27-]
M<:5+J?V>SMX=TC"WB(8Y:2/GL%;T-<1XN_:C^(>H6V@Z3\/-?\+^(;^T\"S^
M.]5\03V$JVNI0I+(D=O!$'S"6,,H8L25...M 'VO17F>C_M!>"X?AIX-\7>+
M/$VA^"X?$VG0WUM'K>IPV@<O$CLB&5EW;=XSCID>M=IX3\:>'_'NCIJ_AG7=
M-\1:4[M&M]I-W'=0,RG#*)(R5)!ZC/% &Q1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<@=<'\J\Z^*G_)XOP"_[ _BG_P! T^@#WZBBB@ HHHH **** "BBB@ HHHH
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M[[1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MT/\ \54MK^UI\%[ZZAMK?XH^%9IYG$<<::K$6=B<  ;N230!ZS1110 4444
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MFM[7R^=Q+PQR-NZ8&W'O7E,^L_M-VT,DTOA_X11Q1J7=V\0:F H R23]BZ4
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M\-H_ O\ Z*IX9_\  Y:D@_;+^!]S/'#%\4?#4DLC!$1;Y<L2< 5\@/XA\"_
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MG%\,[K1++QHQB^Q3^(A(;)1YJF7S!&K-_J]X&!]XCM7S7_P2:S_PQQHV>O\
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MNFZ:FO\ V;Q%XJ_LV^\_6IY&\G[)/)\A)^1MR+R.<9'>O:/^'8_P4_N>*/\
MPH;G_P"*KHOVK/\ DJG[-_\ V//_ +8W-?1] 'R=_P .Q_@I_<\4?^%#<_\
MQ5?1WPZ\ Z5\+O!.D^%=#%P-)TN'R+<74[32[<D_,[<L<D\FNCHH **** "B
MBB@ HHHH **** #%%%% !117'_%SXIZ'\%?AWK7C3Q')(FD:5$))5@7=+(S,
MJ1QH,C+.[*H''+#)% '85X#\5/\ D\7X!?\ 8'\4_P#H&GUTGP2_:'L_C%J_
MB#0KCPWJ_@[Q/H26T]YH^LB(R"&X0O!*K1.RE64'N"""".*YOXJ?\GB_ /\
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M;:8ZR6,.H:?#.EHRX"M$KJ0A&!@KC&!4%GD_@2;XK6G[/OPI'@[3?#6H:L=
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MK\[O^"6/[4_B3Q+\5?''@SQJUW<W'BFZF\0V=U.C!4NLDSQCC 5EVD#@#RR
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MQ]QL]4W"-\>L:]LY]&%  #FBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7MM8VUO>7FPW-Q%$JR3[1A=[ 9; ) SG&:N4 ?.7V;]KC_H(_!7_ , -7_\
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MJ=K%>X!P<=ZM44 ?$7QOTW]JGX1?#'6O%,/Q@T[Q1<62*(M)TCP,CW-P[L$
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MI2Z<\!623<H!DNT;..ORU]WT4 >%_P##2WB7_H@'Q0_[\Z5_\GT?\-+>)?\
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M@#S?_AI;Q+_T0#XH?]^=*_\ D^C_ (:6\2_]$ ^*'_?G2O\ Y/KW2B@#PO\
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MT6FB"V5F"F639>LVQ0=QVJ3@' )XKV:B@ HHHH **** "BBB@ HHHH ****
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MS.VYB.@R<@%?X&?L[^.M(\>6OCKXO>.(O&_B?1;*71]"6SMQ!;VMLY DN&&
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M6HZDA4M<-?1)<-N@\QE2*%R0$BY#;B6^S[:UBLK:*WMXD@@B01QQ1C"HH&
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M$? +6O&&H>'F\6_#CQ!>Z-I46M:L+2U\0:?+;B!)/M!#+;R"(+Q+C&QB<XY
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M, HHHH **** "CI17B'[8WAOXA^+/@E?:9\-5FGU>:\MQ?6EG>+9W-UIX?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5%=W<-C;R3W$J001C<\DC!54>I)JKKFN6'AS3)K_ %*Z
MCL[2+&Z60X ). /J20,5RUIX7O?&@NI?&%O9W&GF=9+'2D&](E7.UW;^)F!R
M1TZ<5275G/4JM/DIJ\OP7F^R_/[RY-\0HI[^PMM(TJ_UR*ZV/]NLT7[-'&6P
M6,C$ XY.!GI3K;4/&$]U?K)I&EVUNL<GV21[UV+N#\F\!/E4]21DCTKIX84@
MB2*-%CC0!51!@*!T %/HNNB)]E4>LJC^5DOU?XG*"?QQ_9+,;+P__:?G@!/M
M<_D^3M.3N\K.[=CC&,9YHNI_' ^Q_9[+P^P,2_:O-NYQMDW'(3$1RNW;@G!S
MGBNKQ11S>0O8/_GY+\/\CF1-XQ_M>X4VFA_V7F7R7%U-YYX/E[E\O:,G;NP3
M@9QFH8+CQT=/NC-9>'A?!D^SK'>3F)EYW[R8L@_=Q@'/.<5UE%'-Y#]@_P#G
MY+KVZ_+IT.4NKCQP+"R-M9>'VO2'^U++=SB-3N^3RR(B3\O7('/3-6S-XJ_X
M2!5%KH_]AY7=+]IE^TXVC=A/+VYW9Q\W3\JZ"BB_D"HO^=].W3Y=>IR-K<>.
MS:7AN+'PZMT%7[,L5Y.49MPW;R8L@;=V, \X[<TLEQX[_LZ$I9>'3?\ F.)5
M:\G$03 VE3Y62V=V01C@<GG'6T4^;R)^KNUO:2_#_(YDS^,O[1L0+/0OL)6+
M[6WVJ;S5/'F^6/+P0.=N2,\9Q26T_C,SW_GV>A+"(G-F8[J8LTF?D$@,?RKC
M.2,D=@:Z?%&*5_(KV#O\;_#_ ".4$_CC^R2QLO#_ /:?G@!/M<_D^3M.3N\K
M.[=CC&,=^U+=3^-PUE]FLO#[*8E-UYMW."LFX[@F(CE=NW!.#G/%=511S>0O
M8/\ Y^2_#_(YE9O&/]K7*FTT/^S!YOD.+J;SCP?+W+Y>!D[=V"<#.,U!#<>.
MCI]T9K+PZ+X,GD*EY.8BO._>3%D'[N, YYSBNMHHYO(?L'_S\EU[?Y=.AREU
M/XX%C9&WLO#[7A#_ &I9;N<1J=WR>61$21MQG('/3/6K?F^*O^$A5?LNC_V'
MN&9?M$OVG&WGY/+VYW9_BZ?E70447\@]@_YWT[=/EUZG)6UQX[-I>&XL?#JW
M05?LRQ7DY1FW#=O)BR!MSC /..W-$EQX[&G0&.R\.F^,C^:K7DXB"879M/E9
M)SNR" .F,\XZVBGS>0OJ[M;VDOP_R.9,_C+^T;("TT+[ 1%]J8W4WFJ<#S=@
M\O!P=VW)&>,XIMM/XT,U_P#:+/05B$3FT,5W,6:3(V"3,8VKC.2,D'& :ZBB
MES>0_8._QO\ #_(Y03^./[)+&R\/_P!I^> $^US^3Y.WD[O*SNW8XQC'?M2W
M4_C<-9?9K+0&4Q*;KS;N<%9-QW"/$1RNW;@G!SGBNJHHYO(7L':WM)?A_D<R
MLWC+^U;I6M-"_LT>;]G<74WG'@^5O7R\#)V[L$XYQFH(9_'9L+DRV7AT7P9/
M(5+R<QE?FW[B8L@_=Q@'/.<<5UM%'-Y![!_\_)=>W^73H<G=7'CD6-D;>R\/
M-=E7^U++>3B-3N.WRR(B2-N,Y Y]>M7/-\4_\)"%^RZ/_86X9E^TR_:<;>?D
M\O;G=_M=*Z"BB_D-46OMOIVZ?+KU.2M;CQT;.\-Q9>'ENPJ_9EBO)RC-N&[>
M3%D#;G& ><=N:);CQW_9\!CLO#IOM[^<K7DXB"?+LVGRLD_>SD#'&,\XZVBC
MF\A?5W:WM)?A_D<PT_C(:E9@6FA?V>1%]I<W4WFJ<#S=@\O!P=VW)&>,XI+:
M?QH9;[[19Z"L8B<VABNYB6DR-@DS'PN,Y(R<XP#74447\A^P=[\[_#_(Y3S_
M !Q_9.?L7A_^T_/QL^US^3Y.WKN\K=NW=L8QW[4ZYG\:A['[/9Z R&)?M?FW
M<X*R;CN$>(CE<8P3@YSQ74T4<WD+V#_Y^2_#_(YE9_&7]J72M::%_9P\W[.X
MNIO.;@^5O7R\#)V[L$XYQFH(;CQV=/N3+8^'1?!T\A4O)S$5^;?N)BR#]W&
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M@QON;I]JY/0#N2>P&2:\;_;<O+5_@B=&9LZIK6KZ=9Z:B\N9OM<3DJ/9$?\
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M/'<PW<,(^^8I9)"LA4<X*KG!Q6Q\9_CQ?^"O!'@/Q)X0TN/Q/'XGU6TM(+0
MA[B&>WED3RR64*Q*I\S9 !.153XU?'WP*WPAUI=*\2:7K^HZS8R6>F:;IMTE
MQ<7<TJE$18T);JPSD<=ZY'QAX1NO 7PP_9M\.WS%K[3?$VCVUQ\VX"1;2<.
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MOPH/&L6AZQ'XTDT*XN$W?9;G0TFB22/9_''(6*,#GH[ CTKYW_98U?XM:U\
MO#4?A2P\.Z)I.GVKPVTWB&.:>74G$CEF18G411Y)4,VXG!.W&*[;]GKQEJ^J
MZM\2_"\OB63QSX:\/-!%IGB28J\DK21.TL#RK\LK1X3+#GYN>HK?_8X_Y-E\
M _\ 7D__ *.DJ]DQ;L/"/QXO?&'[.WB#QZFEQZ=KVCV.HFXTZ8EXH[NU1]RY
M!!*%D'<'!QGO63\%?B%\7/BYH_AWQ7/I_AG0/"UX(VEL[F*X>^N(\8DFC8/L
MC#-G8K!CC!)YKB_AE_R:A\;?^OWQ3_*6O:OV<O\ D@W@'_L#6W_HL4.RN"=[
M%/X'_$K4/B%J'Q#@OK2SMET'Q->:1;FTC9#)%$V%:3+'+GN1@>U><?!CXO\
MQF^._@.W\0:3IGA7PY /,C^TZI#<3"^E5B#Y4:2@QQCA=S,Q)SA<"MK]E/\
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MPBME$,N>NY<8;.._I6\MC;I9BT$$?V41^4(-HV;,8VXZ8QQBIZ*!G(:#\'_
M_A;6&U71_"6BZ;J1.X75M8QI(IQCY2!\O'IBNAU/0[#6FLVO[."\-G.MU;F:
M,,89E!"R+GHP#'D>IJ]10!GZWH&F^);!K'5K&WU&S9T<P7,8="RL&4X/<$ C
MW%:%%% &>WA[37UU-::PMSJZ0?95O3&/.$6[=LW==N23BJWBCP;H?C?33I_B
M#2++6;+=N$%[ LJ@^HR.#[BMFB@#G=%^'/A?PX-/&E^'M,T_^S_,^R?9K5(S
M 9 !(5P."P503WP*/%WP[\,>/X[=/$F@:?K:V[;H1?6ZR^63UVDCC.!7144
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MS4_!][=R7MOH_B!)HY-/>0EI$BDC/,>XY (XSQCDDTU0:F#\*OA3XLNOAO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=A9WLVOVL=K>!S;RG=B0*VUL<=CQ1R2[$_7,-:_M8VWW6U[7^_3U.PHKG/\
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M*Y2X^*GA2TFL(IM<MHY+^-)K53G]ZCG"D<=R#3A\3_"S:K>:8-;MS?V@E,\
MSNC$8)?/'8 _E1RR[#^MX>]O:1^]'4TR258D9W8*B@DL>@ KD!\3+75-,GNO
M#VG7WB&2-UC$=O$8E)8$@[Y,#;QR1G&1QS3H_#NK^([S2M2UJ]FTY+<+,VBV
M4G[OS@3R\HP7&,?+P,^M'*UN+ZQ&>E'WO3;[]ODKOR*NC-;?$K5;'Q"%G32]
M+GE6Q24#R[IL "X ZX'S!<^N:[G I(XUB0(BA$48"J, "G8I-W-*5/V:?,[R
'>K?=['__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>adag-20211231x20f024.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f024.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ') T\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH XSXP_\ ).M6^D?_ *,6NQA_U2?[HKCOC#_R3K5OI'_Z,6NQA_U2
M?[HKIE_ CZO\HG/'^-+T7YL=1117,= 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#R3XF)X1BUS4;^;6=3T?Q4EFD$9TZZFBDD
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MCI/:?&^O3>&O#5WJ%NBO+" 55^G4"O(?^%]ZU_SZ6OY&O2_BU_R(>I?[J_\
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M;Q:EI=M>I;C$0E0'8,8P/:MFB@"&SLX-/M8K:UA2WMXE"1Q1KM50.P%3444
M<9\8?^2=:M](_P#T8M<!\??^0CHW_7NW\Q7?_&'_ ))UJWTC_P#1BUP'Q]_Y
M".C?]>[?S%=;_@P]9?E$YE_&EZ+\V>4UZ%\#O^1W7_KWDKSVO0O@=_R.Z_\
M7O)6#V-SU;XM?\B'J7^ZO_H0KYGKZ8^+7_(AZE_NK_Z$*^9Z4=@9+;?\?$7^
M\/YU]>6'_'C;_P#7-?Y5\AVW_'Q%_O#^=?7EA_QXV_\ US7^5$@1/1114%!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!!?6B:A97%K(6
M5)XVC8J<$ C!Q^=?*7@'X%^)U\=>!_"WC?Q%X6O/!W@66:\T;2=/=C>ZE/M(
M@EN8W.!Y2,S?+U;GD=/JW4/M!L+G[)M^U>4WE;NF_!VY_'%?G7\/?%_PP\"_
M$_X1Z_KNLV>C>/[35-9C\9W6MSF*[AD-C<*HD\P\1EV4)C@Y '/% 'V3\#/
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M_CQM_P#KFO\ *OD.V_X^(O\ >'\Z^O+#_CQM_P#KFO\ *B0(GHHHJ"@HHHH
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M7M?^_@JUI_B72M6G\FSOX+F7&=D;9.*^2:]$^!O_ ".9_P"O=OYBFT%SZ$)
M&2<"F^:G]]?SKE?BF[)X&U,J2I"=0<=Z^:?M<_\ SVD_[[-)*X7/L#S4_OK^
M=.KY @NY_/C_ 'TGWA_$?6OKNW.+:(G^X/Y4FK 245R-U\5_#%E<R03:B5EC
M8JR^2YP1^%1?\+@\*?\ 03/_ 'XD_P#B:+,9V=%9N@>(K#Q/9-=Z=/Y\ <QE
MMI7YA@D8(]Q5^2>.(X>14/\ M,!2 ?147VR#_GO'_P!]BG)<12-A)4<^BL#0
M ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH\D]#CO75_ ;_D3)_P#K\?\ ]!6N2^/W_(=T_P#ZX'^=3U*Z'E_VB7_GH_\
MWT:] ^",KOXV0,[,/)?@GVKSNO0?@?\ \CNG_7!_Y4WL(^AZ***S*"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=+TB\>UN&F$J==D+,/S%.-.<G9+43J1BKMG0452LM7M]0TP7\)8VY4L"RD'
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M0J;R-IQCZTW"479H2G&2NF6Z*P]8\9Z;H=W]FNFE$N-WR1%A^8J]I6LVVL6
MN[8N822/G4J>/:FZ<U'F:T!3BWRIZEZBJ=GJT%_9&ZB+&(9SN4@\=>*Q$^(V
MC23+$'N-Y;:,P-UHC3G*]EL)U(1M=[G3T53U'5K?2X(IIRP21UC7:I/)Z5'K
M&NVNA6RSW1<1L< HA8_I4J,G:RW*<HJ]WL:%%8NB^+].U^Y:"T:4R*NX[XBH
MQ^-7X]4@EU*6Q4MY\:AV&TXP?>FX2B[-"4XR5TR:[N8[.UFN)CMAB1I'/HH&
M3^E?()_:3\?Z_J'AN7PW\$M&NM'\57=Q;Z%<ZCK,4$MT(HI)B[IY1V I$Y&3
MSQZU]>7_ )/V*X^T &W,;>8#W7'(_*OG;PY\(-+^(OP'\(1>#/&&I:5+H^H/
MJOAW7)[=#/:<RIY3Q\!DV2.F#U&.:@L[O]G?XCZK\1_"VJ3ZYX9LO".KZ=J,
MMA<Z59W/G^4Z8Y8[%Z@@C@Y!!S7JM>*_LPZ/INA:5XNLX_$-YXH\1QZW+_;N
MIWEN(#+=[5^ZH) 0+M P37M5 !1110!YWXP\"^)M<\:6>LV6K:6;*QC_ -$T
M_4K.26.*4_>F^21<OC@$YP.F#DU/J7@KQ$=;M/$&FZKIUOK9L_L=ZLUH[6TP
MSE650^Y2"3_$>#7>T4 8/@?PHO@SP_'I_P!I>^N&EDN+F[=0IGFD<N[X'3))
MX[#%;U%% '%_&%%'P\U9MHW8CYQS_K%K@/CXH74=&P,?Z.W\Q7H'QA_Y)UJW
MTC_]&+7 ?'W_ )".C?\ 7NW\Q76_X,/67Y1.9?QI>B_-GE->@_ \ ^-UR,_Z
M/)7GU>A? [_D=U_Z]Y*P>QN>K?%D > ]3P,?*O\ Z$*^9Z^F/BU_R(>I?[J_
M^A"OF>E$&2VW_'Q%_O#^=?7=F =/@SS^Z7^5?(EM_P ?$7^\/YU]>67_ !X0
M?]<E_E1($?*7BG_D9=4_Z^9/_0C676IXI_Y&75/^OF3_ -"-9=4MA'T+\#@/
M^$-SCGSVKE/V@O\ D)Z5_P!<G_F*ZOX'?\B;_P!MVKE/V@O^0GI/_7)_YBI6
MY3V/):]$^!O_ ".9_P"O=OYBO.Z]$^!O_(YG_KW;^8IO81ZM\55 \"ZGP/N?
MUKYEKZ;^*O\ R(NI_P"Y_6OF2E'8&26X_?Q_[P_G7U] H%I&0 /D';VKY!M_
M]?'_ +P_G7U_#_QZ1_[@_E1($?*'BC_D8M1_Z[O_ #K+K4\4?\C%J/\ UW?^
M=9=4A'T#\!_^1,G_ .OQ_P#T%:Y+X_ #7=/QQ^X/\ZZWX#?\B9/_ -?C_P#H
M*UR7Q^_Y#NG_ /7 _P ZE;E=#RNO0?@> ?&Z9_YX/_*O/J]!^!__ ".Z?]<'
M_E3>Q)ZU\5A_Q0FI_P"Z/YBOF2OIOXK?\B)J?^Z/YBOF2E'8;)K3_C[A_P!]
M?YU]?Q(/+3@'@5\@6G_'W#_OK_.OL"+_ %2?042!#@ .@H  & .*^<_$_P 1
M/$5EXBU*"'5)HX8[AU10>  >!69_PL[Q/_T%Y_SI68[GT]L4?PC\J4@'J*XG
MX1ZU>Z]X5:YO[AKF?SV7>_7  XKMJD8$ ]1FD"@= !2T4 &!Z4A4'J :6B@
M  & .*,#&,<444 )L7^Z/RI< X]J**  J&Z@&D"@= !2T4 &!2;5]!^5+10
M8&,8XHVC'2BB@!-B^@_*E(!ZC-%%  5!Z@&@*!T %%% !@#M2;%)S@9^E+10
M 8&,8XHP,8QQ110 FQ0>@_*EP":** $*@]1F@*!T 'TI:* # %)L7T'Y4M%
M!M&,8HP,8QQ110 FU?0?E2X&>E%% "%0>H!I0H7H,444   '2DV+_='Y4M%
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M_KN_\ZRZU/%'_(Q:C_UW?^=9=4MB3Z!^ W_(F3_]?C_^@K7)?'[_ )#NG_\
M7 _SKK?@-_R)D_\ U^/_ .@K7)?'[_D.Z?\ ]<#_ #J5N5T/*Z]!^!__ ".Z
M?]<'_E7GU>@_ _\ Y'=/^N#_ ,J;V$>M?%;_ )$34_\ ='\Q7S)7TW\5O^1$
MU/\ W1_,5\R4H[ R:T_X^X?]]?YU]@1?ZI/H*^/[3_C[A_WU_G7V!%_JD^@H
MD"/E+QC_ ,C7JW_7S)_Z$:QJV?&/_(UZM_U\R?\ H1K&JEL(^A?@7_R);?\
M7R_\A3_B1\2KGP1?VT$%G%<B5"Q+L1CGVIGP+_Y$MO\ KY?^0KD/C_\ \AK3
MO^N)_G4=2N@O_#06H?\ 0*M_^_C?X5T?@'XM7?B_Q!'ITUC#;HR,V]')/ S7
M@M=]\$O^1ZA_ZXR?^@TVE81[KXGU^/PQHMQJ,L33)#C*(0"<G%>>_P##0>G?
M] FZ_P"_BUT_Q:_Y$/4?HO\ ,5\STDKC;/<X_C_ITDBI_95T-QQG>M>HV\PN
M+>*4# D4, >V1FOD"U_X^8O]X?SKZZTS_D&VG_7%/_010U8$6:***D84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 0:A=QV%A<W,H+10Q-(X R2 "3_*OE3X?:%\9
M/C3X8M_&6D_$*Q\!:->L\NDZ!IVE))%#!N(3S6)&XG&2!C&:^L719$9'4,C#
M!4C((KYO/[,?CWP=->6'PX^+U]X5\+7$SSQZ/=:;#>_8BY+,(9'Y"Y)(4\"@
M#O/V?/B+KOCC0M<TWQ4EM_PE'AS4I-*OY[)=L-PR@,LJC^'<K D=C7JM<'\&
M/A%8_!OPF^DV^H7>LWUU</>ZAJM^V9[RX<Y:1O3V Z"N\H **** .$^)'BGQ
M!X9N-,DT^"T72WNK:&XGF8M(YDE"%$7H, @[B>^ *7Q%X@US4_&?_"-Z!<V^
MGO!9B\N;NXA\W&YBJ(%R.N"2:J_%R#7-6M['3]*T*744BNK:\:X6>-%'ERAB
MF&.<X7KTYJ&^M-?TKQDGBFRT%[Q;_3UM;JP$Z++#(K$H<DX(Y(.#3$=#\-_%
M-UXL\.-/?Q1PZE:74]A=I#]SS8G*,5SV. ?QKJ:Y3X9^&KSPSX<D34O+74[Z
M\N-0NDA.42260N5![X! S[5U=(9QGQA_Y)UJWTC_ /1BUP'Q]_Y".C?]>[?S
M%=#\8? 7AX>&=7US^R;;^UMT;_:]OS[MZC.?I7/?'S_D(Z-_U[M_,5VS451A
MROJ_RCYLY(.7MI\RZ+\V>4UZ%\#O^1W7_KWDKSVO0O@=_P CNO\ U[R5S/8Z
M3U;XM?\ (AZE_NK_ .A"OF>OICXM?\B'J7^ZO_H0KYGI1V!DMM_Q\1?[P_G7
MUY9?\>$'_7)?Y5\AVW_'Q%_O#^=?7EE_QX0?]<E_E1($?*7BG_D9=4_Z^9/_
M $(UEUJ>*?\ D9=4_P"OF3_T(UEU2V$?0OP._P"1-_[;M7*?M!?\A/2?^N3_
M ,Q75_ [_D3?^V[5RG[07_(3TG_KD_\ ,5*W*>QY+7HGP-_Y',_]>[?S%>=U
MZ)\#?^1S/_7NW\Q3>PCU?XJ_\B+J?^Y_6OF2OIOXJ_\ (BZG_N?UKYDI1V!D
MEO\ Z^/_ 'A_.OK^'_CTC_W!_*OD"W_U\?\ O#^=?7\/_'I'_N#^5$AH^4/%
M'_(Q:C_UW?\ G676IXH_Y&+4?^N[_P ZRZI;$GT#\!O^1,G_ .OQ_P#T%:Y+
MX_?\AW3_ /K@?YUUOP&_Y$R?_K\?_P!!6N2^/W_(=T__ *X'^=2MRNAY77H/
MP/\ ^1W3_K@_\J\^KT'X'_\ ([I_UP?^5-["/6OBM_R(FI_[H_F*^9*^F_BM
M_P B)J?^Z/YBOF2E'8&36G_'W#_OK_.OL"+_ %2?05\?VG_'W#_OK_.OL"+_
M %2?042!'REXQ_Y&O5O^OF3_ -"-8U;/C'_D:]6_Z^9/_0C6-5+81]"_ O\
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M+C3AIE]H&K2Z9-"L_FAP K)(#M7&Y6!QCCU-=O7@GP"U7P9\/=:U7P'=>/\
M3_$GQ,O[R34M80,(Y)9V RJ)T 50 %!) '->]T %%%% !1110 4444 <9\8?
M^2=:M](__1BUP'Q]_P"0CHW_ %[M_,5W_P 8?^2=:M](_P#T8M<!\??^0CHW
M_7NW\Q76_P"##UE^43F7\:7HOS9Y37H7P._Y'=?^O>2O/:]"^!W_ ".Z_P#7
MO)6#V-SU;XM?\B'J7^ZO_H0KYGKZ8^+7_(AZE_NK_P"A"OF>E'8&2VW_ !\1
M?[P_G7UY9?\ 'A!_UR7^5?(=M_Q\1?[P_G7UY9?\>$'_ %R7^5$@1\I>*?\
MD9=4_P"OF3_T(UEUJ>*?^1EU3_KYD_\ 0C675+81]"_ [_D3?^V[5RG[07_(
M3TG_ *Y/_,5U?P._Y$W_ +;M7*?M!?\ (3TG_KD_\Q4K<I['DM>B? W_ )',
M_P#7NW\Q7G=>B? W_D<S_P!>[?S%-["/5_BK_P B+J?^Y_6OF2OIOXJ_\B+J
M?^Y_6OF2E'8&26_^OC_WA_.OK^'_ (](_P#<'\J^0+?_ %\?^\/YU]?P_P#'
MI'_N#^5$AH^4/%'_ ",6H_\ 7=_YUEUJ>*/^1BU'_KN_\ZRZI;$GT#\!O^1,
MG_Z_'_\ 05KDOC]_R'=/_P"N!_G76_ ;_D3)_P#K\?\ ]!6N2^/W_(=T_P#Z
MX'^=2MRNAY77H/P/_P"1W3_K@_\ *O/J]!^!_P#R.Z?]<'_E3>PCUKXK?\B)
MJ?\ NC^8KYDKZ;^*W_(B:G_NC^8KYDI1V!DUI_Q]P_[Z_P Z^P(O]4GT%?']
MI_Q]P_[Z_P Z^P(O]4GT%$@1\I>,?^1KU;_KYD_]"-8U;/C'_D:]6_Z^9/\
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MMU"(BP1P,9_ 4VK!<]FHK/U_7+?PYI4U_=!S#$,L(QDUQ/\ PO?P]_SRO?\
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M*P>QN>K?%K_D0]2_W5_]"%?,]?3'Q:_Y$/4O]U?_ $(5\STH[ R6V_X^(O\
M>'\Z^O++_CP@_P"N2_RKY#MO^/B+_>'\Z^O++_CP@_ZY+_*B0(^4O%/_ ",N
MJ?\ 7S)_Z$:RZU/%/_(RZI_U\R?^A&LNJ6PCZ%^!W_(F_P#;=JY3]H+_ )">
MD_\ 7)_YBNK^!W_(F_\ ;=JY3]H+_D)Z3_UR?^8J5N4]CR6O1/@;_P CF?\
MKW;^8KSNO1/@;_R.9_Z]V_F*;V$>K_%7_D1=3_W/ZU\R5]-_%7_D1=3_ -S^
MM?,E*.P,DM_]?'_O#^=?7\/_ !Z1_P"X/Y5\@6_^OC_WA_.OK^'_ (](_P#<
M'\J)#1\H>*/^1BU'_KN_\ZRZU/%'_(Q:C_UW?^=9=4MB3Z!^ W_(F3_]?C_^
M@K7)?'[_ )#NG_\ 7 _SKK?@-_R)D_\ U^/_ .@K7)?'[_D.Z?\ ]<#_ #J5
MN5T/*Z]!^!__ ".Z?]<'_E7GU>@_ _\ Y'=/^N#_ ,J;V$>M?%;_ )$34_\
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M_7*3^8KLO@M_R(T'_75_Z5QO[0G_ "$M'_ZY2?S%2MRNAY)7HWP*_P"1Q?\
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M@1J#G\Z%5EY?<A^RCY_>SQS_ (7!XG_Y_O\ QQ?\*Z?X>>-/$'C+7C87&JO
M@B:3='&I/'X5K?\ #/NF_P#05NO^^%K=\&_"FS\&ZN;^"^GN'\LQ[)% '/TJ
MO:OR^Y?Y"]DO/[V-\9KK'AGP]<ZA#KD\LD6,(\2 ']*\G_X7!XG_ .?[_P <
M7_"O9/BS_P B-J'T'\Z^9J%4EY?<A>SCY_>SN;?XM^)IIXXS?X#,%R$7U^E>
MV0:%JDL$;GQ!<@LH;'DIW'TKYAL?^/V#_KHO\Z^N[+_CS@_ZYK_*AU)+M]R&
MJ<?Z;/G#5/C!XGL-2NK9+_<L4C("47)P<>E5O^%U^*?^?T?]\+_A7*>(_P#D
M/ZC_ -=W_F:SJ_&:F?YE&<DJO7M'_(^>=2I=^\_O/H_X;:AK?C706O[C6IH'
M$A3;'$A'\JP/BCXR\0>!-5M+6VU5[A9H?,+21J"#G'85O_ +_D2W_P"N[5Q/
M[1?_ ",NF_\ 7J?_ $(U]GBLRQ5/)X8B,K3=M;+OZ'HSNL,IIN_JS"_X77XI
M_P"?T?\ ?"_X5U7PX\>^(O&GB#[!<:H\">67W1QJ3Q^%>,UZ1\!?^1V_[8M7
MS.79WF%;%TJ=2I=-J^D?\CBHSG*I%.3^]GH7Q=U76_AY\/\ 5=?M=9ENI[15
M98I8D"ME@.<#WKY=_P"&Q_&__3O^0_PKZ>_:?_Y(CXD_ZYI_Z&*_.FONL=C*
M]*HE!VT[+_(^#XNS/&9?C(4\+5<8N-_G=]SZ T_]K_QM>7]M Q@59950D <9
M('I7V+:Z)JD]I#*?$%R"Z!B!"G<9]*_,?1/^0U8?]?$?_H0K]5-._P"0;;?]
M<5_]!%:Y?BZU7FYW?;HO\CT>#L?BLQ5?ZU4<N7EM\[]CXL\5_M7^,_#_ (EU
M/3(GADCM+AX5=E&2 <9/%9/_  V/XW_Z8?D/\*\L^)?_ "4#Q#_U^R_^A&N:
MKRI9AB5)KF_!?Y'Y[B.(,TA6G&->5DW^9^@_P+\5:_\ %3P2FMWNK26<QE:/
MRX8U*X'U%<5^T+\9/$_P=US3K&POOMR74!E9IT4$')&.!72?L<?\DAB_Z^9/
MYUY'^W-_R..@_P#7F?\ T(UZ]3%5HX15$]=.B_R/TO'XS$4N'88R$VJC4=;]
MVK^1SO\ PV/XW_Z=_P A_A7HWP)^//BOXK>-#HU[=K9P^2TGF0H"<CMR*^0:
M]Y_8T_Y*P?\ KT?^8KSL/C\1.K&,I:7[+_(^%R;/,RQ.84:-6LW&4DFC[2_X
M1_4_^A@N?^_*?X4?\(_J?_0P7/\ WY3_  K?HKZ?VLO+[E_D?O7LH^?WLAOI
MI8+.>2"/SITC9HX\XWL!P/Q-?)'PP^'WQ%^/7A1?%]_\;_$?AV\NKF=)='T)
M(8H;!DD*F JRD[EQ@YKVGXM_L\>#_BSJ4.L^([C6();.W,8.GZI-:QA 2Q)5
M" 3UYKQ?X3?LE?"'XC>$CXFT:S\6:;9:A<2LADUR>-[H*Q3SCAN=VW()YQBL
M34^B/A3X#U7X>^'9-.U?QCJWC6Y:8R#4-8*&50?X!L &!7:5X]^S+;>%M,\*
MZWI7AB'5K0:;JT]G>VNM7CW,\<RX'WF)^4C!&.QKV&@ HHHH **** "BBB@#
MC/C#_P DZU;Z1_\ HQ:[&'_5)_NBN.^,/_).M6^D?_HQ:[&'_5)_NBNF7\"/
MJ_RB<\?XTO1?FQU%%%<QT!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 <A\6?^1&U#Z#^=?,U?3/Q9_Y$;4/H/YU
M\S5<=B63V/\ Q^P?]=%_G7UW9?\ 'G!_US7^5?(EC_Q^P?\ 71?YU]=V7_'G
M!_US7^5$@1\>>(_^0_J/_7=_YFLZM'Q'_P A_4?^N[_S-9U?S_6_B2]6?*RW
M9]'_  "_Y$M_^N[5Q/[1?_(RZ;_UZG_T(UVWP"_Y$M_^N[5Q/[1?_(RZ;_UZ
MG_T(U^@8W_D04_2/YGKU/]T7R/)J](^ O_([?]L6KS>O2/@+_P CM_VQ:OC\
MI_W^C_B1YV'_ (L?4[[]I_\ Y(CXD_ZYI_Z&*_.FOT6_:?\ ^2(^)/\ KFG_
M *&*_.FOTG,OXJ]#\SX[_P"1A3_P+\V7=$_Y#5A_U\1_^A"OU4T[_D&VW_7%
M?_017Y5Z)_R&K#_KXC_]"%?JIIW_ "#;;_KBO_H(K?*_M_(];@';$?\ ;OZG
MYA_$O_DH'B'_ *_9?_0C7-5TOQ+_ .2@>(?^OV7_ -"-<U7B3^)GY5BO]XJ>
MK_,^]OV./^20Q?\ 7S)_.O(_VYO^1QT'_KS/_H1KUS]CC_DD,7_7S)_.O(_V
MYO\ D<=!_P"O,_\ H1KW:W^XQ^1^P9G_ ,DI3_PP_-'S+7O/[&G_ "5@_P#7
MH_\ ,5X-7O/[&G_)6#_UZ/\ S%>3A?X\/4_-<@_Y&N'_ ,2/O&BBBOL3^FQE
MQ!'=020RJ'BD4HZGN",$5\R:=\&/CQ\*X)?#WPX\<^%+KP<LCM8Q>)["8W=A
M&S%O*5HLB0+DX+8[# %>^^._'_A_X;>'Y=9\2:M9Z-IZ'8+B]E$:%S]U<GN:
M\B^'?[:_PM\5^#=-U76?&F@:#J5PA:;3Y;Y=T)!(P<\]!G\: .T^!'PBN?A)
MX8OH=5UM_$GB/5KV34M5U5H1"LT[XR$0?=4   >WX5Z57FGP-^--G\;M.\0:
MGID2/I%AJDEC9W\!)BO$4 ^8N0.Y(_"O2Z "BBLKQ!/K,%O&=%M;2ZG+?.MW
M*8U"^Q /- %3Q'X]T/PI?6-EJ5Z(;N]D6.&!49W)9MH) !P,\9/%)XG\>:5X
M4N(+:[-S<7DZM)':V5L]Q*4'5MJ D*/4UR/QAO;6WT#2&OI+.UU1]0L#*HD7
M=M$ZDX)P2H.[]:5-8L=.^--W<WU[;Q6UWHT9LYY)%",%D;S K$X/4&F([[P_
MK]AXHTBVU33+A;JRN%W1R*",\X((/(((((/((K0KS[X( 2>%-1NXO^/&]UB^
MNK,XP&@:=MA'L>2/8UZ#2&<9\8?^2=:M](__ $8M=C#_ *I/]T5YA\8(/$O_
M  C6K/\ :]/_ +'W1_NO);SMN]?XLXSGVKTZ'_4I_NBNRI'EH0UOJ_RB<D)<
MU:6EM%^;'T445QG6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!!>V%OJ5LUO=01W$#?>CD7<I_"LC_A O#G_0#L
M/_ =?\*WJ* ,)? GAU&#+HE@&!R"(%X_2MQ5"*%48 & !VI:* /C;Q'_ ,A_
M4?\ KN_\S6=6CXC_ .0_J/\ UW?^9K.K\"K?Q)>K/DY;L^C_ (!?\B6__7=J
MXG]HO_D9=-_Z]3_Z$:[;X!?\B6__ %W:N)_:+_Y&73?^O4_^A&OT#&_\B"GZ
M1_,]>I_NB^1Y-7I'P%_Y';_MBU>;UZ1\!?\ D=O^V+5\?E/^_P!'_$CSL/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?]<T_P#0Q7YTU^DYE_%7H?F?'?\ R,*?^!?FR[HG_(:L/^OB/_T(5^JFG?\
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MK^1$?^6:?]\BC[/%_P \T_[Y%?G\^%7.3E[;?^[_ ,$\EX"[OS?A_P $\W^
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M\2?]<T_]#%?G37Z+?M/_ /)$?$G_ %S3_P!#%?G37S>9?Q5Z'X;QW_R,*?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >5_M/_\
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M-Y>>%[NTO;F6]ETO4[O35N9CEY4BE*HS'N=N!GVKN:0SC/C#_P DZU;Z1_\
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MY''0?^O,_P#H1KU:\7'!)/?0_1\XI3H<+PIU%:24$U\T?,N:]Y_8T_Y*P?\
MKU?^8KP:O>?V-/\ DK!_Z]'_ )BO(PO\>'J?F&0?\C7#_P")'WC1BBBOL3^F
MPHHHH **** "BBB@ HHHH **** .,^,/_).M6^D?_HQ:[&'_ %2?[HKCOC#_
M ,DZU;Z1_P#HQ:[&'_5)_NBNF7\"/J_RB<\?XTO1?FQU%%%<QT!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXT_;AM9KCQAH1BB>0"S.2BD
M_P 1K[+K-UV-(]/N+E=,35+B&,M';[5W2'LH+=,URXFE[:FX7L>'G.7_ -J8
M*6&YN6]G>U]G?8_*_P#LZ[_Y]9O^_9KW;]CBTG@^*Q:2&2-?LK\LA ZBO69?
MCE;Q?$.*UD\.WD9_L]E;PY_9H-RUWNX .W[N.=W3%>^>&D2ZTNTOI='71[R6
M,-);,J;XB?X25KRL-A8^T4HSO9]C\ZR3AN@L9&O1Q'-[.6JY;;>=]/1Z^1KT
M445[Y^PA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %5-5L/[4TVYM//EMO.C*>= VUT
MSW4]C5NBDU?032DK,\&?]F'2W\91R/"\ND_8&5]0>Y;[;]JWY$N_KGKS7M6A
M:5_8>D6EA]IGO/L\8C\^Y??(^.['N:OT5E3HPIMN*//PN7X;!N4J$;-A1116
MQZ(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>adag-20211231x20f025.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f025.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &E @(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV!_K&B0JK<@G..O2NB6#JJ,)*+;DKV2>W]?IW.2&9X>52K"4E%0=KMI:_?\
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M/S/@WQO\-/B%+J'PN\7^(M!\30+;Z*]EJ4/P\1(-0L9O/G=76-%VJ726,L%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\E5TU%',OY5^/^8>PJ?\_I?='_Y$YG_A+M5_Z$G7?^_UA_\ )5'_  EVJ_\
M0DZ[_P!_K#_Y*KIJ*.9?RK\?\P]A4_Y_2^Z/_P B<S_PEVJ_]"3KO_?ZP_\
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MCU'P+_PF/PX/AC1?&,T5KIVI6NMI?%)Y8_,BCEC\J,IN (R,X(->_5XMX9^
M.L/XM\.Z[XX\:_\ "7#PTK'1M-M-*33K2VD*;/-91)(TCA>%);"]0,UF?M.:
MU;> /%GPC\>7]REGINCZ]-97LSL0J075I*K,1T('EC\<8JK)NR)3:5V>^45\
M7>)9-5@\$0>(M:O;GPK<_%_QA9VM_=R3>3)IVB!)/(MS)TC=H8\=N9W]#4W@
M.U^&_A;]H7Q3K'@"&-/#'@?PC<75Y]CNI);5[V1\LR%F921%"59EZL.22M/D
M%SGT-\&_B'J7Q)A\7WMW#:PZ?I_B*\TG36M48&:W@*IYCDL0S&02= !@#BO1
M:^+/!RVGAO2?V7M&\0:C#I=K.NH>+[Z:\F6!&G,#2Q[F; W;KP\=0 1Q3-9^
M*MWJ^C_'KXG^#;HXNKS2O">C:LS;(H$78DEQO(^5-UT7#X/\![T.&N@*5EJ?
M:U%?+?P4^$GV'XJZ+KMK%X;\)G2["<7=AHNOR:MJ&M>8H02WLK)&&16^<-M8
M[\<BO=OB9X'_ .$_\.IIGV;P]=;;A9MGB;1?[5M> PR(?-BP_/#;N!G@YJ6D
MF4FVCKJX'QU\3IM \4Z/X2T#2D\0>+M3B>\2QFNS;06UI&0KW%Q*(Y"B;F"+
MA&+,0 ,9(\_M_P!F/R)XI/['^$0V,&RGPVVMP>Q^W\'WJM8>(-.\#_&3X\>/
M/$4X$.B6FE65LI/[Q;;[*)=D8[F6>4J!W90!S3LN@KOJ>L?#'X@)\1O#<E^U
MF=-U"SO;G2]0L/-\T6UW;RM%*@D  ==RY5L#*E20#D#$\4?%;4D\:W?A'P;X
M?@\4:]IUFM]J8N]1-C:V2/N\F-I1%*3-)M8JFT#:I8LHQG#_ &9=(?P-\.M(
MT7Q'=VUKXXULW7B.^TIY56X5IYS(^(B=V$WHC'D!@1GI7G.D^)G\ _#SXW^)
M0K7WC'7O&.I:1IMK$-T\]P,6UC;JO4X0"3']TL>E%E=A?1'L$_QUT63X/Z+X
M_LVMH[/64M191:O=K9QB6=U0)-*0P0(2=S -PC%0W /5:%J^N1:3>WGBW3]*
MT-K?=)_Q+M4DO8O*"Y9W>2WA*D8/&T\#KVKS?P]\-?A_9?!G2OA?XUDT#6AX
M>T2*;4[2^FCW6G[IEDN^2&@'S2[91M*@G# \T? ?2+3P5\!/!W@_QM=VXEU"
M*>PMM.U]D66[MY))6AMFAD +,+=D5HMN1@J5&"*32Z F[FYX.\8>+/BCX=BU
M+3X-!T70=5MO-L=:T[6#J5U$"0.8#;+") -P/[V14=<$2 $'0^$MSXAD3Q19
MZYJLOB"VT_69+33=8N((H9KJ 11%]ZQ(D9,<[3P[E5<^5T!Y/G'PJ^#MMH?B
M?XRZ?X3O[[PKX-UB[M8[*31'11:7J1L+\VGF(Z(-Q2,E00C(Z+L:+">L_#_P
M$? &F_81KVJ:Y"D<4$ U%;:-;>) 0J1QV\,2 <G+;2QX!)"J .RV!7>YUE%%
M%26%%%% !1110 4444 %%%% !1110 45'/*((9)6R512Q &3P*_,3P?^T'\<
M/BUXW^%GQ4N?&\&B_#?Q+\1(?#%IX,TI0KK &D+&Y<#+$B/!!)SN! 48% 'Z
M?T5\N_L7_%?QUXJ\2?%[P!X^U2T\1ZMX&UU;6'6K)0%F@G#ND;8 RT>TJ>,C
MH<E<GZBH **** "BBB@ HHHH **** "L'X@?\B'XD_[!MS_Z*:MZL'X@?\B'
MXD_[!MS_ .BFH ^7_P#@E'_R9;X6_P"O_4/_ $J>OKZOD'_@E'_R9;X6_P"O
M_4/_ $I>OKZ@ HHHH **** "BBB@ KF-/_Y*;K__ &"-._\ 1U]73US&G_\
M)3=?_P"P1IW_ *.OJTCM+T_5''7_ (E'_$__ $F1G_$73?&>NSZ7IGA35X_#
M%M,)I;_7/LT5U+"%V".***0[2SEV.YE8*(V'5EKBBOQR^'\A97T'XL:6/X&
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M^$OB*_\ @KKO@?Q1X\N_$6JZI;7-J?$2V2VTD:2J54>6KD$+GGYAN&1D5J_
MOX7?\*6^%6@^#/[6?6_[+25?MTD/E&3?,\GW-S;0-^T#)X45"LG<K5Z'PU\>
M_B>EM^RNGP[T[X1^.?!VD61M$34]=TIH+?<LH9FD<C&^1LGW9J^T_@K\4?\
MA,?A?_;FJ^'M8\%6VF+Y,L?B.W^S.T44*.;A0?\ ED0Q^;_8;TJ3]H?X-?\
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M*:.W(  \M64A<  <8Z58A\):%;:=>:?#HVG1:?>NTMU:):H(KAVP&:1,88G
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M;:W^UO\ #/Q5H^E_$/1?#'Q2\*W=W%:W.O>'[@6E[8HS!3,\;*@D50<E53.
M>:^NJ^+/V=/^"F7AWXN^(O#7AGQ?X,UGX?:]XA81:7<W2F73KZ0\!8YBJMEC
MP/E(R0-V<5]IT %%%% !1110 5@?$#_D0O$G_8,N?_135OU@_$#_ )$/Q)_V
M#;G_ -%-0!\O_P#!*/\ Y,M\+?\ 7_J'_I2]?7U?(/\ P2C_ .3+?"W_ %_Z
MA_Z4O7U]0 4444 %%%% !1110 5S&G_\E-U__L$:=_Z.OJZ>N8T__DINO_\
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MBBB@ HHHH **** "N8T__DINO_\ 8(T[_P!'7U=/7,:?_P E-U__ +!&G?\
MHZ^K2.TO3]4<=?\ B4?\3_\ 29'3T445F=@4444 %%%% !1110 4444 >.VO
M_)WNH_\ 8D0?^ETE>Q5X[:_\G>ZC_P!B1!_Z725[%7;BMX?X49PV?JPHHHKB
M- HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!>'M5\21,K+J=WIT4D^Y?NDL5^8C P3G&!BO0J* "L#X@?\ (A>)/^P;<_\
MHIJWZP?B!_R(?B3_ +!MS_Z*:@#Y?_X)1_\ )EOA;_K_ -0_]*7KZ^KY!_X)
M1_\ )EOA;_K_ -0_]*7KZ^H **** "BBB@ HHHH *YC3_P#DINO_ /8(T[_T
M=?5T]<QI_P#R4W7_ /L$:=_Z.OJTCM+T_5''7_B4?\3_ /29'3T445F=@444
M4 %%%% !1110 5QWCWXM^$/ABB?\)-KUII,LL3S0PSR8DF5.NQ>Y[8[DUV-?
M!7_!21!)XP\"J>AM+@''_71*]/+<+#&XF-&;LG?;R5S"O4=*FYHY'3?VXM4C
M^/,GCBZT"T&DSV:Z1)91LQF2S$QD#!\X,H+'L%(XP/O#[X\%?%/PE\1GND\,
M^(;'6WME5IUM)=QC#9VDCMG!_*ODF#]BKP%)\>[SP:;S7/[(B\.1ZLK"ZC\W
MSFN6B(W>5C;M4<8SGOVJA_P354+XA\?#TM[0?^/RU]#F%# XG#RKX9-.G&/S
M3>GZG#1G6IS4*FO,W^!]X4445\6>J%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'.TBPR&-0TH4[0>A
M..!7Y3_LB?#?]GSXR:#XZ\2?'[5M-OOBK/KEV-7M_$VMO826BAL#RU\U,C[P
MSSM*[> ,']7*^?OBQ^P;\$/C1XLE\2^)_!,,NN3L'N;NQN9K0W3?WI1$ZAF/
M=B,GN: /&?\ @F#>6]LOQH\/>%=4N]9^%>C>)_*\+WETY<>6P<RJC$#*X$3=
M!G=NQEC7W/7,_#WX<>&?A1X4M/#?A'1+30-#M,^59V:;5!/)9CU9CW9B2>YK
MIJ  @$8//UKR?XG?LR_";XF6=W/XG^'GA[5KG8S&Z>Q2.<G!_P"6J;7_ /'J
M\S_:)@_:ND^(S-\'KCPC'X.^R1876@OG^?\ -YG53Q]W%>7SZ?\ M_SPR1/>
M?#O:ZE3@+T/']V@#M/\ @ECJL.L?LM">VTVVTB :]?(EG:23/%& 4X4RN[ >
MVXU]@5\W_L#? CQ5^SM\ 8_"/C%;-=:&JW5XPL9_.CV2%=OS8'/!XKZ0H **
M** "BBB@ K!^('_(A^)/^P;<_P#HIJWJP?B!_P B'XD_[!MS_P"BFH ^7_\
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MK$$9(0A3GKB@#[N_9T\>^!OB/\.4UCX?Z(WAW0_M<L#Z<^EC3GAG7'F!H0
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M#\*_C'XU^-?C309/ W[,=EX,\*QWL,M[XI\7VT=K(EN'4N;>%8U9I-N=I5F
M.,\5]OT44 %%?"__  4&_:P^*/PK\+>(]/\ AQX3U31;71GM!J7CZ]AC6UC,
MQ39%9JX(F8EU5FP0GS#&<,.T_:A_:<\2_!+]DOP=XET1H;OQUXH33=-LKF[C
M#(ES/!YCS,@&TX"M@=-S#@CB@#ZTHKXE\ _%#XN_ 3]JSP9\)OBCXYM_B1H_
MC?2Y;JRU0:7'936-Y&KLT0$?#1_NR,GKN4C;@@^5/^T1\?OB[\.?BI\>?!?C
MNP\-^#?!FJ3P:9X0?2(IX]1M8-C2/-.WSAC&X/'4[@-O!H _2^L#X@?\B%XD
M_P"P9<_^BFKG?@W\6K'XI_!GPAX]E,.E0ZYIT%V\4L@5(I67YXPQZX8,!ZXJ
M[X^\5Z(_@7Q&JZQ8,S:;<@*+I"3^Z;WH ^=?^"4?_)EOA;_K_P!0_P#2EZ^O
MJ^0?^"4?_)EOA;_K_P!0_P#2EZ^OJ "BBB@ HHHH *9)$DR%70.I_A89!I]%
M)J^X;'*^!K6%4UAQ#&&75;D*P4 @;N@KJJYOP/\ ZG6O^PM=?^AUTE<& 26&
MA8[<:V\1*X4445Z!Q!1110 4444 %%%% !7P9_P4A_Y'/P'_ ->D_P#Z,2OO
M.O@S_@I#_P CGX$_Z])__1B5]!D/^_P]'^3./&?P7\OS1]YU\(?\$U_^1C\?
M?]>]K_Z'+7W?7PA_P37_ .1C\??]>]K_ .ART8'_ )%^+_[<_-BJ_P >E\_R
M/N^HIX([F"2&:-9HI%*/&ZAE8'J"#U%2US?Q'\6-X#\ ^(O$:6XO'TJPGO%M
MV?8)"B%@I.#C..N*\",'4DH+=Z'8VDKLU--T'3-&9VL-.M+$R8#FV@6/=CIG
M:!FM"OG7]E[]JF\_:!US6]-O/#T&CFPMDN%E@N3+ORVT@@J,=N:^BJVKX6I@
MZCHU(V:_KH9TY0G%2AL8GBWP?I'CK1AI.MVGVVP%U:WOE>:\?[ZWGCN(6RA!
M^66*-L9P=N"""0<_Q9\,?#_CB"\AUF"\NDN'AE!CU*YA:VDBSY<MLT<BFVD&
MYLO"48YY)KS;]JN;Q3X:^'^M^+/#>O\ B:VO]-TZ3^SM,\/V<4\0NP&<7-T#
M&[R0*%4.B_P[]JN[)CA]6_:W\66T_B6_TCPSX?UKPWHOB32/#R7:ZK+%)?G4
M(;1HY8P(6545[R,Y).Y,\ CGG-3VWP[\"? _A2]T&\TS0_)O=$FN[FSNY+N>
M:8S7*!+B6:1W+3R.J@%Y2[<#FN-^)W[)GA#QQ\&[CP%H\?\ PC:1:;?:=I=]
MNFN_L"W;!IVV-*/-W$=&;CL17&P_M-_$'4OBIIGPWT_PGX?/B)M3UG3;^^GU
M*9;.%;.TTZZCF0",NP==11"AP0RYSBN,\/?MD:OXA^+NF1Q6YM6\0^&[&PL=
M$NIF.FVFL?VQJ5E<227(C&$S:%4)"F4K&BJ&?@ ^A[']FSX=Z<F(] DD?^TK
M'51/<ZE=3S+/92>99@222LXBA;)2 'REW, F"0>AL?A5X7TS0?$VB6NF&'2?
M$EQ=7.J6:W,OERR7*[;@H-W[K?RQ$>T;F9\;F9CS'QG^*.O_  ]U;X=Z/H.D
MZ?J^I>*];.CEK^X>WB@ M)[AI<JKDX\@_+CG.,CJ/);/]LK7]&\.V7B;Q5X2
MTZWT!KGQ!IES_9.H/-<"YTFVO)YI$5XT'ER"PF55)W E"3R0&![M_P *1\%?
M] 7_ )ES_A$_^/J?_D%_\^_W_P#Q_P"__M5G-^SI\/7\2VVNMX?S?0/:S"(7
MUR+66:V54MYY;;S/)FFB5$"2R(SKL7##:,>-^-_VL_''PZ?3=*UKP;H3>)M;
MLM-U/2[6TU65K<1W&HVUE-!/(805>-KR$B158/EOE7;\V^/VE?%<7B:]\"-X
M<T>;Q_'XKB\-0F*_E&G&.32QJ9NG8Q[QM@$B^6 2SH/F ;(0'J%A\!_ NFZ9
MX=T^#05%EX?U*[U;387N9G6&ZN?M'VASN<[P_P!JN/E?<HW\ 87"_#SX&>"O
MA7>R7?AO2)+.X-N+.)[F^N+O[-;!MPMK<32.(( 0"(8MJ# ^7@5SGAKX^K<_
M"#Q[XOU[3$L+WP--JMKK%I9S&:%Y+%6=VA<JK%'0*P!4$;MIR1D^*?$;XL_%
M#X7?%+X<SPWTOB32K'P9=>)?&.C0(";R'[9:QW,MJN"0UN+II(TSDQP^7DE@
M: /H;Q#\$/#_ (JUKQ'-JT9O-%\0'3[G4-)R\:R7ME*DEO=+)&RL&Q%"K#D,
M((AP P?<F^&'A:;XDVWC]]'B_P"$PM].?2$U96=9#:.ZR&)@#M8;E!!8$KEL
M$;CGQGX??M!7>HV'B;5K">P\6:/=>);N/2[JXUJWLHULQ;6DD0B,G^L4^<QX
MZ9YZBL3XA_%?QGXR\6V^D:+9ZY9V]IX:GUR>#P?JNGO(\GVAX4)N)LHVP1$K
M$O#M)AR%2F!]'^,/!NC>/O#\^BZ]9"_TZ9HY&C\QXW1T</'(DB$/&Z.JLKJ0
MRLH(((!KC3\ ?#5GX<30-+CFLM*N=8@UC5S<7$]Y=ZJ\3+(@GNII&E?+Q0!B
M[/F.,QXVMQB?#;XK2:]X^\+6,.ISZYH/C'P5%XJTZ[G@$,B&)K:.5F0?=$R7
MELX0?<9)>?F 'M- !1110 4444 %%%% !1110 4444 %%%% #)T,L,B*YC9E
M(#KU7WK\:[F/QO\ LP-X(\$:[\%=9U+5O"/Q!7Q4_BS1K1IAX@ME\T*HE"'+
M'S!C+'  !4$'/ZA?M&6WQ9D\"QS?!N\T:#Q7#=(SVVN1;H+B Y#*&S\C D,#
MW ([BO@[]G3P[^W/X3\&ZK::'IFC65K+K%S<2)XP!%T96V[FCWG/DG VXXZX
MH ^C/V!O 7BNSO?BO\2/$WA#_A7L?CW68K[3_"S+L>TAC1AYCI@;6<R$G(4D
MJ3@ BOKJOE_]BOX3_%OX?W?Q&UWXP:]97_B#Q1J,5]'IFGW;30V2@/N*@C$8
M8M@*O&(QSZ?4% 'YD_M"_"K5?C!_P4Z71= \7:AX&U^#P?'?:?K>G<O#/'NV
MAER-R')#+D9![]#Z3+^T3^U5^SQ_H'Q(^$$7Q8TJ#Y5\3^"Y&$DJC^.2)$;!
M]<QQBNC_ &G/C_\ #;]GO]H/2-2T_P"&6J_$+XSWNDG)T(.9[?3LL/G W#G:
MV $)P"21QGEM9_X*-^-/'RMJ7P/^#.J^//#VE6L<^O7EZ7@>UG*[GM550<R(
M.I&[KPN.2 ?4?[._QO7]H'X=)XK7PSJOA)C=2VC:9K4>R=63&6QQP<\?2O4*
M\T_9W^.>B?M'?"71/'>A0RVEM?JR364YS):SHQ62)B.N".#W!!P,XKTN@#Y&
M_P""J5M-=_L8^*XX(GFD-[IY"1J6./M4>>!7&?MJ_"_Q)X\_8K^%^H^&M)NM
M:U/PE)H^MS:;:QEYI88[4I)M4<DKO4X )P&XXK[LHH _/;1/%Z?MF_MS_"WQ
MMX0T/6K;P9X#TF>;4]4U6P>U07<@D"VZ[OO,&9.GHYZ#)\7\.^*]2_9U_9P^
M-7[.&M^$/$ESX]UG5;R#P_%9:7+-%J<%RD<0E211@@!"WX@=<@?KC10!\V^!
M_P!D?0/%'[(7@#X2_$JPEO8-,L;6:\MK:Y>$I=*&=EWH03M:1QP<'%>>>+/^
M"6O[/.D^%-:OK;POJ*W%K93S1,=9N3AEC8J<;_4"OM6L'X@?\B'XD_[!MS_Z
M*:@#Y?\ ^"4?_)EOA;_K_P!0_P#2EZ^OJ^0?^"4?_)EOA;_K_P!0_P#2EZ^O
MJ "BBB@ HHHH **** .;\#_ZG6O^PM=?^AUTE<WX'_U.M?\ 86NO_0ZZ2N#
M?[M [<9_O$@HK.UZ_N]+T>ZNK'3I=7NXDW1V,$B1O,?[H9R%'XD5YYX.^,>M
M^+O$UWI/_"OM4L%T^[6SU"ZFOK5DM',:R#(60EAM=#\N>M=4JL8-1?7R9=#
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MJK\??C1XO\)_ #Q7XS\&^&FL]2TJQN[ISXH4VWV5(HB_F"%=QE)Z*N57.26
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MM_\ A*1=>?!J%MY<AAV<D!D/FAB&(.01P*^[Z^2_^"?,@T_PCXFT*V^ VH?
M_3K.XAFCCU*:>:74WD5P[F2:-78H$4=2!N&,5]:4 ?,7Q;_9=\7:O^U)X-^,
MWP_\7P>'KNWA@TGQ'874.];W3EFWN(R58;RN5P0/NJ0RD<]I\7/A;X@\._";
MQA9_ >QT/PAXWUR[6[:Z-ND,,DTDBK/.^%(\PQ[CNVDY ZU\W?\ !1O5?V@_
MA1>6_P 0O 'C^?2/ATBV]IJEE:6D<DFFN6*FY8,C%XV+*#@Y!QQSFJOA_P"
MO[8/BK0]/UK2/VF]%O\ 2]0MX[JUNHK(%)HG4,C#_1^A!!H ^GOV2/V?4_9D
M^!^B^!VU :KJ$+R7=_>H"J2W,K;GV \[1PHSR0H)P3BO9J\N_9U\&_$3P+\.
M4TOXG^+K?QMXH%W+(=4MX_+0PMC8F-B],'MWKU&@ HHHH **** "L'X@?\B'
MXD_[!MS_ .BFK>K ^('_ "(7B3_L&7/_ **:@#Y@_P""4?\ R9;X6_Z_]0_]
M*7KZ^KY!_P""4?\ R9;X6_Z_]0_]*7KZ^H **** "BBB@ K,\1:]:^&='N-1
MO6(@A&2%&68DX 'N3BM.OG7Q[ITWB+XK:CI@NFACD*D9!91B%6Z9]J\#.<QJ
M9=0C*E#FE-\JUZM.S_#R]3VLJP,,?6<:LN6,5S/T35U^)W'PJ^(MCK6I7^FF
M&2WN+JZFNXMQ!#!CNV_4#->I5\JW?@Z72M)OM32^^:SN6M]JH06PP7.<\=:]
MP^"\SS> ;-I&+L9).6.3]XUX/#V:XFK-8'%0]ZSDGIM>VR\[_P"1[.>9;0IQ
M>,PTO=NHM>=N[^1U6N:Y8>&M'O-6U.YCLM/LXFFGN)3A411DG_ZPY/2OG']G
M[]HOP;XM^*?C;3;:YN+2Y\0:HMYIOVN+8MPJ6T497.3AB8F(!QD$=^*\3_:^
M\3^*]7^/&K^#++Q!?P:-=PVJ?V:UW(MH28D<[HQQ]X9Z=:\0M/ ^O^'KC4-5
MLK^*SN]"E$GGV\SI(CJH<-&P&<C(YXYKU,3F515TH1T@W?S_ *1^G9!P-@ZN
M4SJ8S$6J8B$7&VT4W&2OIK[UD_+;4_7FBOGG]A_Q;K?C+X/WU]KVK7NLWJ:Q
M-$MQ?3M-($$4)"[F).,L3CWKZ&KZ*A55>G&HE:Y^)YKE\\JQU7 U)*3INUUL
MPHHHK<\H*\[\,_\ );_&W_8.T[_VM7HE>5>$_$.EW'QW\96\6I6DD\EC91I$
MDZEG9/-WJ!GDKD9';O7)7:4Z=_YOT9P8F252C=_:_P#;9'JM?!G_  4A_P"1
MS\!_]>D__HQ*^\Z^#/\ @I#_ ,CGX$_Z])__ $8E?5Y#_O\ #T?Y,O&?P7\O
MS1]YU\(?\$U_^1C\??\ 7O:_^ARU]WU\(?\ !-?_ )&/Q]_U[VO_ *'+1@?^
M1?B_^W/S8JO\>E\_R/N^H+JVBOK::VF7?#,C1NI)&5(P1Q[&IZAN;F&SMY9Y
MY4@@B0R222,%5% R6)/  &3FOG9)25GL=RO=<NYB>'? >A^%+J2XTJQ^RSR)
MY;MYKOE<@X^9CW KH:P= \=>&_%5S)!HGB'2M8GC7>\5A>QSLBYQDA&) SQF
MMZL:%*C1AR4(I1[))+\#HQ+Q#J/ZS?F_O7O^.IPGQ%^'NM>-'']E>.=7\)PR
MVDEE=06$%M,DJ.?]8GG1L8YE&X*XX^8[E;"X\^F_8_\ #,7A#Q?X9T_4[[3]
M(\06.BZ<L0Q(UG!IL:1P*K-RQ*QKDMS7=_%_XV>'?@OINGW&M?:[FZU"XCM[
M2PT^!III=TL432$#A(D::/=(Q"C>HSN90<3XC_M':-\-_$>J:=<Z'J^IV&A6
M=MJ'B#6+$0?9M'@GD=(GE\R5'?\ U<CL(E<HB%CU4'<YCC/BA^S9KGB'XZ>$
M_''AO7YM(=-;DU34;I5B9[54TF2SB6-'5A(KL45P<':SX*G!$K?L3>$;OSCJ
M&J:E?W%UI&I6%W=N(TN);R]OXM0DU%615$<Z7$*O'L "87 ^45Z-<_M#_"^S
MU:ZTNY^(?ABWU&UDN8I[2;5H$EB>WW>>K*6R"FQ]P[;&]#2W_P"T-\,-*T[3
MK^\^(/AJUL=1MGO+.YFU2%8[B%'V22(Q;#!&X8C[I!SC!PP'^+/A./&T'P\.
MK:U<3WWA#6(-:%TD2*;Z>.UGMSO4<*&%PS$+T(&.*Y)_V6?#]UI4>FWNHWEY
M8?\ "8:KXNFA=57S7OXKR*6W)'(0+?28(^;Y5]ZZ;3/CSX4O_%'BC2);Z*QB
MT*33(CJ5Q/&+:\>_0-;+ P8[RQ*J!CYBP"YS6YXV^*?@WX:O9IXK\4:3X<>\
M266V&J7D=OYRQ;?,*;B-VWS$SC^^/6@#Q[4_V-+#Q'X<&EZ_XVUW7Y+318O#
MVE7E[%;K+8V27$$[9V1KYLKFU@5I&[(,!2SEND\8_LRZ;XK^(&L^-$U_4M)\
M0W4^DWEC=6BQD6%Q8)=QHX5U(D62.^GC=6'*MP5.".ST7XU?#_Q)<7L.D^./
M#VI265BNIW*VNJ0R>3:,H83L0W$>UD._IAE.>1FA'^T/\+YO#B^((_B%X9?0
MVNQ8#41JL/D?:#$9A$7W8#F-2X4\E1GIS0!9^'?PDT[P%X>U_3Y;JXUZZ\0Z
MA<:GK%]?*BM>SS*J.2D:JJJ(TCC50.%1<DG+'D?AY\!&T6[\#7VO7K7MYX/\
M/WOA."-@LD6H64DD CGEX'[PQ6L6Y<8W-(.1@UU]U\<OAW9>#K/Q;/XX\/P^
M&;R4P6VK-J47V>:4%@T:/NPS@HP*CD;6R.#6[J7C70=)\&W7BRXU:T'ANVL7
MU*35(Y1)!]F5"YE#KD,NT$Y'4=*0'E?PM_9"\#?"[PSKGAZ%;W5M%U#7IM<M
M;6\N7'V#?!# MM&R$$Q1QP(J!LD* ,G&:ZWQ;\$= \1_"#Q1\/+(2Z+I&OV5
MQ9S2P.TLD?G)L9U\PGD#L>.*P],_::\-W'QKTSX6:G9:AH'BS4M"AURVAU!8
MPC[_ #,VNY7/[]%BD8J,@A'()VFNM\ _%/1O'WAG^VX7.FP&_P!0T\17TB(Y
M>TO)K21AAB-I>!B/8C.#D4P.1^-'[+O@GXU6.I#4K-K#5=0N+*:XU2U9A+(+
M:>*15(W;2"L6S)&0&)'.#71^$/A_)I7Q'\5>+;P)%)?6=CHFGVZ/N\JPM#,Z
M%CC[[RW4Y/)^41\YR!G_ !%^.,'PZE:ZG\*Z[JWARV2"74/$6GK;_8[-)9?+
M!^>57EVGYG\I7*KSR<*>PT+Q?9:[K>O:0BR0:EHTT<=S;R@9*2('BE7!Y1QN
M /\ >1UZJ: -ZBBB@ HHHH **** "BBB@ HHHH **** (YW6.&1G4NJJ25 R
M2,=,5^57[+OB;]J>]\(:YJ7P*\)^'K'X4WVN7T^CZ5XAN(G:R!F.^.-BZ/M#
M9^]QG.*_4#6/&.@^'M3TW3M4UO3M-U#4Y#'8VEY=QQ2W;C&5B1B"Y^9>%SU%
M?FI:?!3QQX,\1^)I?"_[9?@GPI:ZKJEQ?SZ797T$,,<SN2Q$(DV(W3=M49(Y
MH ^SOV7=1^/NH0^(C\<]+\/:9*K0?V2-!<,'7#^=OQ(_3]WCIWKW:OFG]C'1
MO%VDV_BO_A*OCII'QK9WMOL[Z5<1S?V=@2;@VQCC?E<9_N&OI:@#Y>_:Y_:W
MC^#^N:+\-_#7@>;XG?$3Q+ 9;;PZ@S"L&6'F3?*V02C_ "XZ(Q+* "?'Y/VI
MOVLOA9H_]L>*/V<-)7P=I\7F3V^@706:V@49)"I++@*N3_J\#!Z5RW[0GQST
MO]F__@I1<>-_$&@ZSK>ECP9%81KI%LLLB2NY((W,H PK \YYKL[_ /X*Y?#:
M]L;BW/P_\>D2QM'AM.@(.01S^^Z4 ?7?P1^,>@?'WX8:'XY\,O(=+U2(L(IP
M!+!(K%9(G )^96!!P<<9'!%=Y7QE_P $F()[?]DF".>&6W/]NWQ6.52I"DH>
MA_&OLV@ HHKA/C=\8]#^ ?POUSQWXB2YETC2$C:6*R56FD+R+&JH&9026<=2
M* .[HKYA^"G[>_A?XX^/])\)Z5X$\=Z1/J2221:AK&DI#9JJ1-)EI!(V,A<#
MCDD>M0?$#_@HO\+?A_XTUS0IK'Q/K5EX?NEL];\0Z-I)N-,TR8MMV32[@<AL
MJ=JGD$#)&* /J6L'X@?\B'XD_P"P;<_^BFK0T76;'Q'H]CJNF745]IM] ES;
M74)W)+$ZAD=3W!!!'UK/^('_ "(?B3_L&W/_ **:@#Y?_P""4?\ R9;X6_Z_
M]0_]*7KZ^KY!_P""4?\ R9;X6_Z_]0_]*7KZ^H **** "BBB@ KP75_^2ZW?
M^?\ E@*]ZKP36/\ DNMWG_/[@5\?Q+_#PW_7V/Y,^IR#^)7_ .O<OS1!XA_Y
M$K7_ /L(O_Z-6O1O@E_R3ZS_ .NDG_H1KSGQ#_R)6O\ _81?_P!&+7HWP2_Y
M)_9_]=)/_0C7AY+_ ,C:/_7I_P#I1Z^;?\BR7_7S_P!M/B3]J.2>']KBY>V@
M6YN%2T*0M)Y88_9UXW$'%<MK<>O6>A^*I;G1X8X+]6F=UO58P@1A>@7YON^W
M6NP_:7_Y/$D_W;3_ -)UJ/QW_P B9K7_ %ZO_*O2JQO5JN_VF?NN K>SP.6P
MY4[TJ6]_+LUU/>O^"?'_ "0_4/\ L.3_ /HF"OI6YN8K."2>>5(((U+O)(P5
M54=22>@KYJ_X)\?\D/U#_L.3_P#HF"OI2YMHKRWD@GB2>"52DD<BAE=3U!!X
M(Q7U6 _W6GZ'\^<86_U@QE_YV9%OXY\.7=Q%!!X@TN::5@D<<=[&S.Q.   W
M)K=KR7P+X/T&'XL>/]FB:<GV273VM]MI&/)/V?)*<?+SSQWKUJO5J1C%VCY?
MBKGR=6,8-*/9?BKGS[^T?\8/$W@C7;3P[H,5NPU2QVA_+=IUD=W0>6588/ Q
MP>:^8M(\$^-])\2&2ST'5H=6TQH[MPMNX> 9+([>@.TX]<&O>/VF?^2X>!OI
M:_\ I4U>JV__ "5/XC?]@:R_]!GKY_&86.(JP<F][?A?]#\KQ&#GFF85E5JR
M2IS2C;I>+EI\T9W[.OQ=UGXKV>N3:Q#9PM9/$L7V.-E!#!\YRQ_NBOF__@I#
M_P CGX#_ .O2?_T8E>M?L2_\@KQ3_P!=+;^4M>2_\%(?^1S\!_\ 7I/_ .C$
MK[CAYWQL&^S_ "9]#E=>KB<EIUJTN:3W;_Q'WG7PA_P37_Y&+Q]_U[VO_H<M
M?=]?"/\ P38_Y&/Q]_U[VO\ Z'+5X'_D7XO_ +<_-GT%;^/2^?Y'W=6'XV\/
MOXK\&Z_HD<PMY=3T^XLEF<9"&2-D#$>@W9K<HKYV45)-,]&G4E2G&I#=.Z]4
M?-'[,G[*FK_ GQIJ>N:CK=EJ<=UI[620VL;J03)&^XENWR8_&OI>BBL:%"&'
MA[.FM#U,US;%YUBGC,;+FFTE=)+1;:(\[^/G@_5/'GPMU+1-&B6?4)[FQE2-
MY @*Q7D,K\GCA48_A7DGQK^"GC;Q!K?Q9TWPYI5G?Z3\3]'L-,N-5GOA#_9$
MD:R6\\DD1!,B^0ZLGEY)=2K!0=]?3]%=!XY\GZ9^SKXIMF\.M+I-F&M?C3J?
MC:Z/G1G.GS?;_)FZ\O\ OK?Y?O# _N\<9X:\%>,/AE^T]9F#P5!XEN9=+\97
M\5F+R*%4M[SQ!'-;NLC H&*2QAD)!"-)C)78WW'10!\-?"/]D3XB?!O7]*U^
M&:'7=0\-QZ!##8-=(;74XHK![2_\L. 8Y8A*3#(VTX39PLCU]%^.OASJGB+]
MHKX4^+H;.&?1O#FFZ[!=SR.N^&6Z6S6':IY.1%,"1T'!ZUZU10!\-#]D+QS>
M_ _X6^%!IVE6FJ:%X'U71]1BNIU-L]Y+=:;<1P2%,EXI?LLZNR@X#G(.<'K/
M$7P)\<_$'XZ^'?B5>^';?0K6+Q#H<UQHTM]#-+';V-IJJM=.4^1F\R_B5%4L
MP5"QQT'US10!\H:-\&?'_@GXFQ>-K?0;77K:P\4^)KJ+15O8XIFM-2^S-%=0
MLQ$8D5X)%97(.VXD(.?E;H['X*^)_#/['5WX(=8K_P 3Q176H_8+*;=$\C7K
MWHL8W95!3#?9P2%! '"C@?1E% 'S%XM^ LWQQ^(/B_Q7#<G2M-UGPUH<WA?Q
M)"1]IT_4[6:\FCN%C)#*4^T1Y!P&5G0\$U6^%7[.7C*Y^#WAJP\;P^"K;Q9;
MWFKW>HQW_AR/68O,NM3N;H&!VF0HA653MY/(SR*^IJ* /FGXR_"3Q;XF^'*^
M -.\)Z5J!@MXY]#\0:3>C2+/3=261GCGGL03^[A<12JJ^<'8,"B\$]YX(T6]
MO_C]XZ\4N2=-CT/2/#:S[2HN;NWEO;B=U&,%5%[$F03\ZRKP4->M44 %%%%
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M[.?[.V@>$];ECD\0.\NH:D(FW)%/,VXQ@C@[5VJ2."02.#7OE !7S)_P4$\
M6/Q6^!4'A'4/'^A_#VWU+6+4&_UV0+%<[-S"!!N&YRP5@/\ 8/UKZ;K@/C9\
M$/"/[07@2Y\(>---_M#29G69#&YCFMY5SMEB<<JPR1GN"0002* /D[2/&WQ:
M_9:_:I^&'PS\4_$,?%/PGXYMY((TGTJ&RN--DB7 :,19^0';P3C;NX!7->2?
MLV?8_P#AWC^U"=4V'4O[4UK[=YWW_-^S1;-WOOZ>]?8WP7_8B\!?!GQQ'XRC
MU'Q'XQ\56]L;.RU7Q7J1O9;&#!&R'Y5"#:2N<$@$@8!.<#Q[_P $Z/A5X_\
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M1-UK_KU?^52?M+_\GB2_[MI_Z3K4?CK_ )$S6O\ KU?^5>K4_B5O5G[;A/\
M<\K_ .O5,]Z_X)\?\D/U#_L.3_\ HF"OHO7-:L_#NCWNJ:A,+>RLX6GFD/.U
M%&2<?05\Z?\ !/C_ )(?J'_8<G_]$P5Y;^UIX>;QC^T]X<T#[4;0:I;V-EY^
MS?Y7F3.F[;D9QG.,C/K7V>2T%B*-.$G96O\ <?A_$]!8CB/&1D[)2;_(]"^$
M_P"U#X?UOXS^(8I[&ZT^V\17%K#9W$S*=KI'Y:B0#[NXXZ$X)&?6OJH'-?G[
MJ/['TFFO\0=WBL.OA2S6[!%AS=9MVFV_ZSY.FW/S=<^U>M_\$_F9OA_XEW$G
M_B9KU_ZY+7T.,P]!TW6H2VLK:_+?R/GL90HR@ZU%[6T^ZWX"_M,_\EO\"_2U
M_P#2IJ]4M_\ DJ?Q&_[ UE_Z#/7DO[4-JE[\9O!=O*"8I8[:-PK%25-RX.".
M1]1S7KVH_ KP=86U]?06-XEV(6;S?[3NB3M4E0<R<@>AKY*I&I*HG!+1WU=N
MC79]S\HP<*L\PQCII/EFF[NWV&NS[GFG[$W_ ""O%/\ UTMOY2UY+_P4A_Y'
M/P'_ ->D_P#Z,2O6OV)?^05XI_ZZ6W\I:\E_X*0_\CGX#_Z])_\ T8E?6<._
M[[3]'^3-LD_Y$-'^OML^\Z^$/^":_P#R,?C[_KWM?_0Y:^[Z^$/^":__ ",?
MC[_KWM?_ $.6M,#_ ,B_%_\ ;GYL^HJ_QZ7S_(^[Z**X_P"+?B^\\ _#7Q!X
MAT^.":]T^U,\4=RK-&Q!'# $''/8BO!C%SDHK=G?&+G)174["BO&/A=\4_$_
MB#XEW/AG7+WPOJENNBKJJ77AP2D(YF\ORW+R,,@9)&.XKV>KJ4Y4I<LBZE.5
M*7+(**^9?CG=ZQXK^+GB3PZ/$>N>&-+\-^ '\26-SHNH2V0;4)+B=!+*4*B9
M85M5/E2%HCYS;T;Y<>DBYT_Q_P# 30_$'C*^U+3+1M$M]<U&ZT;5;O2I(B+8
M2R'S;62.3:,L2F[!P,C@5D9'J-%?(6B_#/XE7GP?\%G2#XBU*X\3:^==UFPU
M+QWJ-J^E::UI.UM8B_,LMT@5_L@D,6\LYE.T(1MK:!\?O&,TEAX2\!V5CH1T
M_P ->(-3U >-+F]\07-O?Z;J2VLT N3=*\\32/(JNSY"E&  7RB ?8U%?%VN
M?M=?$[2O"7AK68M*\)RS^,-%T+7-'M&BN0MBM]?VMM);W$GF_O2$NT9946/:
M0P*, "U3XM?M(^-? 7CG1M,\2++JU]X0\4%KY?!5K<6T>NVDN@WMW%#]E:64
M[EDC&5:1URB/\O0 'VY17DNM_%V^\%_LWW7Q(U!]'\2WL.C?VM&-$D:&PNMZ
M[H5CED+GRSO0>:1R,OL7.P<WXD\>_%SPCKOA/P?>W'@FYU_Q9J36VGZ[!974
M=K:Q16DUS<^;9-<;Y77R51-EP-_F,S",1X8 ]^HKY*TC]ICXD^,_$VD^%=&M
MO"VE:TD'B>'5KZ^LKFZMC=:1>PVPD@C6>-O+EWD[&;<FX?,VS#^;_%3]I_XH
M:]\&M&U&-M'T:7Q?X?TGQ3H_]C375I<:>RZWI%O+:SW&]O-CE2^Y9$CVKO0K
M(#N(!]^T5\MWG[1'Q!TGXG2?"2XB\,W'CF?5+"VM?$*6<\6F):W-E?71=[0W
M!D:1!I\R;!. Y=#N3E:]0^$GQ8U'Q7X&\4WWB*UMAK'A75-0TC47TM'6WNGM
M3_K84<LR!T*G868J25W-C<0#U2BOACQ=XX^+%CXK^!WB/PWK%[K&I7'A+4O&
M.O\ A=9Y'M]8C:2Q:6TA0D*'BCN7%N2N<QJ#_K'-=3\/OVK;2ZT3Q]XRTGQ5
MX0U#P[J7C)8M(G\=^+WT.VBMCHNFS>3 S6\^&$DDI:':NUFD)^;(H ^OJ*^6
MOB+XQMOBA\&?^$L@U"RO?%,U_'X>T*+X=_$;4YM+DO;F6.*$SS69M ^QI/,D
M#(2L:'#<UW7AJUU'X1?$7X=>"CK^K^)M/U7P]=VUS>:Y>R75U)=V9A=;DN['
MF19YPX''$6,!<4 >UT444 %%%% !1110 4444 %%%% %*^O;)&CL[JYABDN@
M8XXI) K2\<A0>3U[5^=7PT_X)Z?%+2?B]X TGQ7XBT;4/@[\.]7NM8T**%C]
MJN&DF$Z)(FT<^8J;B20 &"DYKT/]M6XBM?VQ_P!DV:>1(8DU>_+.[ *!_H_4
MFF?"GQ/9+_P5!^-,DFK6XL&\*6 C9KE?*+;;/('.,]?UH [W]B7X::_X2U3X
MI^)_'?B70]:^)/BC64N-9T_0[B.5-+2)62"%PA.UL%N#T  R2":^I:^(OV$9
MX[K]IW]K66&1)8G\4P%9$(96&^[Y!'6OMV@#@_CK\26^#OP<\9>-DM5O9="T
MN>^BMF.%ED1"44D= 6QGVS7P5XH_:,_:(^)EY\"?A5X>\2:7X5^)'B_2)?$V
ML:M:0(\45K(99;1"-C[ ((\L "22H)/.?T2\>>"M+^(_@O7/"VMPFXTC6;.6
MQNHU;:QCD4JV#V.#D'L0*^2?A9_P33L/A3'XTOK/XDZ_J?BC5]!E\/:-K=VF
MV71+=E"J8]KY9E"JHP4 4$ #/ !ZW^Q-\:-?^.GP$T[7?%2P?\)/8WEUI&I3
M6RA8IYH)"AE4  #<-I('&<XP.![U7G/[/_P0T3]G;X4Z+X%T"2:YL]/5FDN[
MC'FW,SL7DE;' )8G [# [5Z-0 4444 %%%% !6#\0/\ D0_$G_8-N?\ T4U;
MU8/Q _Y$/Q)_V#;G_P!%-0!\O_\ !*/_ ),M\+?]?^H?^E+U]?5\@_\ !*/_
M ),M\+?]?^H?^E+U]0^+O&VC> ]-34-=O?L-F\@B$IB>0;B"0,("1T/)XJ)3
MC!.4G9(B<XTXN4W9+N;M%<=X/^+7A3Q]J$MCH.K#4+F*,RNBV\J!5R!G+*!U
M(XSFNQI4ZD*L>:G)->6HJ=6%6//3DFNZ=SQ3XX?M3>$OA'X:U.6SU+3M?\2V
MTXM$T6"\0RK-DY\T#+(JX.>.H"\$Y'@O[(?[7&FV<USX1\8?8-#M9I[K4+;5
MGF\J$222-*\4F\X'+-M;/8+@DYKYZ^+.D0Z[^TCX[L[AG6-]:OB3&0#Q(Y'4
M&N)N/#=M#X6FU$/*;A+@Q!21MP&QTQU_&OTS#Y/A%A?92NW.SOV[?=J>1/$5
MO:.<=E?\#]C]!\0:9XITFWU31M0MM4TV?=Y5W:2B6)\,5;# X.""/J#7A_B2
MSAO_ (VWL$Z>9$Q&5R1G$ /:M']BC_DV3P;_ -OG_I9/576/^2ZW?U_]MQ7X
M=Q?1C2E2H[I5DONYD?H/#<VY5IK1^S;_ "&^.O#FG:=X6O)K:V$4JLG(=CU<
M9X)KT#X)?\D_L_\ KI+_ .A5R7Q(_P"1/O?]Z/\ ]#%=;\$O^2?6?_723_T(
MUX664X4\[Y8))>S>W^(]7,)RGE%YN[]IU]#XK_:7_P"3Q)?]VT_])UJ/QU_R
M)FM?]>K_ ,JD_:7_ .3Q)/\ =M/_ $G6H_'7_(FZU_UZO_*O0J?Q*W^)G[EA
M/]SRO_KU3/>O^"?/_)#]0_[#D_\ Z)@K@_V@Y4M_VS/ 4LCK'&DNELSN<!0+
MELDD]*[S_@GS_P D0U'_ +#D_P#Z)@K@?VB+6&^_;'\"VUQ#'<6\TFF1R12J
M&1U-RP*D'@@@XQ7W?#W\*/\ @9^+\0_\E)CO67Z'K/B37M,D'QW":C:-Y^DH
ML6V=3YA_L]QA>>>>.*Y;_@GY_P D_P#$W_837_T4M>K?%/X;>$M/^&/B^ZM?
M#&C6]Q#H]Y)%-%81*Z,('(*D+D$>HKRG_@GY_P D^\2_]A-?_12UZJE&6#J.
M/>/X:'R?-&>$J./]W\+(7]IG_DN'@;Z6O_I4U?3.N_\ (#U'_KWD_P#037S-
M^TS_ ,EP\#?2U_\ 2IJ^F==_Y >H_P#7O)_Z":\"/Q2/SC+/]^Q_^)?^DGSI
M^Q+_ ,@KQ3_UTMOY2UY+_P %(?\ D<_ G_7I/_Z,2O6OV)?^07XJ_P!^V_E+
M7DO_  4A_P"1S\"?]>D__HQ*^AX=_P!]I^C_ "9AD?\ R(:/I_[>S[SKX0_X
M)L?\C)X^_P"O>T_]#EK[OKX1_P"";'_(Q^/O^O>U_P#0Y:O _P"X8O\ [<_-
MGU%;^/2^?Y'W=534=+L]9L)K&_M(+ZRG7;+;W,8DCD7T96!!'L:MUR/Q7\17
MOA/X<Z_K&FND=]:6K2Q,ZA@&R!T/7K7SLY^SBYOIJ=-2HJ,)5);15_N+WA_P
M!X8\)W,ESH?AS2=&N)$\MYM/L8H'9,@[244$C(!Q[5T%>/?#'QQJNJ_$2YT.
MX\7Z9XOL!HZWXN-.MXHQ#*9MAC)1VY YY(^\.*]AJ*5?ZPG/7MK_ $S.AB5B
MX>T5^VMGMZ-K\3@_B3\$O!GQ;GM)O%&D/?RVT,MJLD%[<6C26\I4RV\IAD3S
MH'V)NADW1MM&5.*U=?\ ASH/B?0?$&AZG;7%SHVNV!TR^L!>SI"UL8VC:.-%
M<"'*.03%M)XR3@8\Q_:WM]9@\#:+JVG>)+_1[:R\1Z"D]C8;4%[YNLV,1$LF
M"_EA'D^12NXL-Q(&T]3^T-H&O>+OAG/H?AN6TBU*_P!1T^)C>7SV:/;B[B>X
MC\U 7!>%)$&T%OGXK4Z#H?''PS\/?$2QL;36K6XQ8R^=:7.FWUQI]U:OM*DQ
M3V[QRQY4E2%8 @X.163HWP$\ ^'I[673?#L-B]MI%UH47DS2J/L=S,LUPA&_
M#-)*BNTAS(6R=WS'/S]HGQ/\3:#X^\-_"_PS9:+X0U*7QE?Z)K=S#YNJ6DRI
MHPU".:#S'1U<QF%2K9"."/G'7E]6_:F^*_A_X+6GCFZU/0+R:]T_Q1:I:PZ2
M\0BNM*%PL5SDS-GS&M)"T?0"10.4)9@>\_%#]DGP;\0? V@>&+.!=&M=&@TS
M3+9F\ZZ TRSN[>X%F5:49#BV1/,8EQG.6Y!ZO0OV?? GAZ;2KBTT>>6]TS57
MUN"^O=2N[NZ>]:W:V,TT\LK23GR7,8$K,%4* !M7'S!\;OBW\0=%MK'PUK>J
M6WB*6=?"?B2&\\.6IL71YM;B@FM 6F*O'(!^[+,N0) Q(Y'TW^S]X]U#XG?#
M:U\4:G<0_;-0N)VDTR*#RCI#)(T;6$F?F:6$H4D<XW.K$*JE5 !NZ+\*O"F@
M>!+GP79Z) /"EREQ%)I$[//;F*=F:6(*Y;;&=[ 1C"J#M4   <HO[+WPX^QW
M,+Z/?SW,US!=G59]=U"74XI8%=(3%?-.;B((LLJJJ2*%$L@ P[9H>/?&OC'5
M?BUJ/@KPIK.D>&?[(\,Q>();[5K)KM;J6:XGABC($B;(4^RNTA!W'S8\%<'=
MP%Y^T!XXBO-1\5)?:)-X9T_Q]9^"_P#A';:T:6>:*::WMVN/M/F#$OF7'G(H
M3:8E4$9?> #VG0O@;X&\,W>CW.EZ!'93Z38WFG6C1SR_+!=2)+<[OG_>/))&
MKM(^7+9.[+-G#US]E?X6^)?">D^&-3\*I>:%I6DIH5I927MSM2Q6XMK@0D^9
MEQYME;-EB6/EX)(9@WA_PR^-GQ?\<+\)!=^(_#]L/'O]MQ2&+169M/6RD8Q2
M(3,!)(Z+M8$!1N! .WY^0\*?&/XE^)?$/C+QO9^(]%T?4-.^%NG:]>:=<V4M
MQ9W%U#-J!;8AF4Q1/Y3!R,O@QX;Y?F0'U4/V<?A\/#UQH[Z+<2PSWR:F]]-J
MMY)J(ND39',M\TIN%=$^16$@*J2JX'%=?X.\#Z'X!\/1Z'H-@MEIJ/)(8R[2
MO))(Q>2221R6D=V9F9W)9B22237S*G[3?CC5/#VL_$.W_LRQ\.Z/XDT707\(
MO9M)>3I>"Q65WGW@I*&U ,BA,;8<$-OROMGQ-U6ZN?B'\-?"R22V^GZG?W-_
M>O'E1,EI!YD<&X$$;IFB<C^)874Y#&F!8\"?!'0/!#^'IUC:\OO#5C=:/HMT
MS.AL]-FDC<6NT.4<(L,*!RN=L2],MG:\!?##PO\ #!->3PMH\6C1ZYJDVMZA
M' [E)KR54624*Q(3<(T^50%R,XR23^?>D_%KQ;\,_@#XC@\4:Y>WOAKQWJ6L
M1^&]8DE?S=+U2#5;F-]/:3/$<L-N)83D?.LZ]UK[!UKXT:KI_CBXT>/6/"T<
M$=[]G$$UK?FX WXP2J;-WN#C- 'JNO\ A/2O%%UHMQJ5LUS+HU\-2LCYKH([
M@121!R%(#X65_E;(R0<952*#^"(;KXC0^+;NX^T3V6FOINGVX3:+599$>Y?.
M3N:0PVXZ#:(L#[S5\M?"'Q!JC>+_  1XI\1VKWK>,?%6MZ*M[!XAN7N!)&+[
M;%-9D>1]F1+1XQ$OS1M'$Y)=W ^@/@!K5]J?@_5-/OYY;MM!UW4M#@NIBS23
M6]O<ND!=F)+.(PB,Y)+,A8\MB@#TVBBB@ HHHH **** "BBB@ HHHH \,_:5
M_8Z\ ?M5R: _C=M64Z()A:_V9=B#B79OW91L_P"K7'XUXI_PY^^ G]_Q5_X-
M4_\ C5?;U% 'B7[-7[(O@3]E2'7XO!!U4KK;0-=?VG="<YB#A-N%7'^L;/X5
M[;110 4444 %%%% !1110 4444 %8/Q _P"1#\2?]@VY_P#135O5@_$#_D0_
M$G_8-N?_ $4U 'R__P $H_\ DRWPM_U_ZA_Z4O7*?'+XO>*?'6L:SX3ECB;3
M=/U.8)':0L'81NR+O.3D#KTZX-=7_P $H_\ DRWPM_U_ZA_Z4O7#1_\ ):/&
M6./]-O/_ $HKYO.ZLZ=*/*]]SX[B-U)QHX>$W%3;3MVL<UX \<>)OA)JDVKZ
M5 8FEB,$@NX6,3 D$9&1R"./QK[Q^%OB6\\8_#[0]9OA&+R\@\R7R5VKG)'
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M+5[ZG84444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>adag-20211231x20f026.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f026.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %C WD# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***.E !
M1110 44UI54X) ^M03W2!6(8, ,\&@/(G616) 8$CJ,TZN%^&9:^.K:C))O-
MU=L5RI4A1P.*[J@TJ0]G)Q"BBB@S"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHR,9IID /<_09H =1
M31(NW.<"D,Z!MI//TXH ?12!@W2EH **** "BFO(L:EF(50,DFO-_'W[0O@7
MX>),NI:];R7D:Y^PV9\Z9CZ #C\R*N%.=1\L%=^0KI;GI6:"P!KYF\,_MX^
M]6U1K/54O?#RGF*6[7S _P!0F=OXUSWQ"_;B%Q?MIGP^TM]0E5]K:IJ,12WZ
M_P#+./(9OJ<"NR.7XJ4^3D:?GM]Y+G%=3ZZR**^3M$_:6\=:'K^@0>+[72VT
M[5&VDV,16:('^(C<>_:OJV&421(PS@@'I6-?#U,,TJG4I-/8DHHR**YAA111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:*'&]D12S;<D#. :VZY7XJ^';KQ=\-?%.AV6T7FHZ7<VD.\X7>\3*N3Z9(H
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M(+&VMU.-_(R,]L>M=YX:^)7@B?P"]OJ^I6EO##$8KJSO&&_=T.%/+>V!7/\
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M/[%^K7'@[0-0\(SD>(;%$DO+&27Y9WV_-Y;#C.?H*\GUOP^[:2-&UNRN;#Q
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M5AD8]JI=SHHI>])J]NA2M/'_ (O\-27"^*-",UHA)2[T\!LCKR!_]:N"U_\
M:'\>:Y/J[^ O!::E96%JT@DU1FA\R3'&3CY5'H 2?:O3+_XV^%M*\:WOAF\N
M9+6^LU1I)9(R(ANZ#=ZUW%I>6VH6Z36\D<T3#.Y&# TGWL:2:LI2IVO]Q\$>
M%['2_B/\3]&OO'.MGXH^.R%O$M01'I.@C< 8HK0\LW^VP)[U]J>(/'*>$]26
MUETN\:S6RDO)=0C7,,(09V'CJ>U<I9>'=/\ ^%SWDEOH-I8&&V$LM]#;HCW,
MAZ%F !./<UZM-:P7MM+!<1)-%(NV2.1=RL/0@]:;MH36Y8\J2Z7^\\*^'_Q
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M\M[$->,K3-P2!]XGTK]$P=?ZU356.FAQ2CRNS.B\-N8]<6QU"46]O(C$3D9
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M?9]_,\9U<>$-0_LR;XA_"R+Q+<6R'RM8BDE0LB]&9D8*2.F3SQ4?BKX'Z/\
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MD;2TQ!R %"A,;0O &*Z+P_X3L_#@O'@>>XNKV7S[J\NI/,FG?:%!9L#HJJH
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M?69=1DUSPZ=(LWW%;N#:T:8^[M/:O0OB-:>";_PTNF:5:I<>4@$VL-F-B,=
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M=4+*"K@AE8C&[*G./EYXRM'^+4CZW\2HM:L8M-L/!TD9::&8S-- UFMRTC#
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M,B$%D/=6R*_0,.YNE'VF]C^*\X6&6/K?5/X=W;T[?(\\_P"& ?@,?^9#C_\
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MB@ H(S110!QOQ=>&W^&GBB29]D8TZ;<Q('\)[FOS.^&OPLLM8LX[ZXFM8G?
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MC.[%H;B62QMV*Q1QR$"1_?V%<=/^S[J%UG4K65#<?>^S,N0P].>]>30S*K/
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M&NIV-M_8EU</>WRR!K7SAN&WN7*\8!Z_2H]IK9H\>6:QI2<:T&DG:]KK:_\
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M&><=>:[*.&G6>AX.8YQ0R^+<UY?@>.?LZ>(K6+Q+KMRZQV*W-XT\5L<#:AZ
M>U=]\0_%E]=^(K5=(8^:3Y:M%SDGZ>E2P? G3+G2;.Y=##<Q1C]Y$<9]0:CT
M/1OLOC&PLK)2[0 O(3_".@YKZZG!PAR=C\$QN(E7K\S37.[V\]O^"=WX<\/?
M\(GI;:G<-)>7A7>TTS%V/YFLW0].L?&VJ37]S9P/(3R7C5F/U)ZUU_BO54TO
M09(YHNB')K ^%?E>2\V5*RDM@?RJY4X5(^_%/UU.FG7KX3%TZ.&JR@GORMJ_
MJU:YR_Q#^$^F0-;:A:O]FFW@'RBJYYZ;<?RKF_ WPYLH?VE/"$.L64FIVDTR
MLHN$S&) <\]CZX->NZY9VM]XBM'FF"JGS1H3U-=]\+%6/XP:#&,E&CD&"<]!
MQ7@8[*<).+K0@HS6MUY>6Q^H</\ '&>X6JL!5Q,JF';Y.1N_Q*U[N\E9V:5[
M'U?9PB.!0,@ D >E6*;&-J 4ZO!/T(**** "BBB@ HHHH \^\?>"KG4?&/A/
MQ781^;=Z))-'+"N-\MO*H#A22.00#CO6%<? *UUNW\:0ZEK%W-;>);V/4%-O
M"MO/83(!Y;Q."<E2H/(]:]>HQB@#R/4O@;?Z_HFF)K/CC6=3\0Z5>)?:?K;0
M01F"105 \E5","I(;/)SG(K(USX$W"^$?$OAJSU.[U"7Q=J8OM2O;N&-8X%+
M*TH54 ^\%P!SU]J]SHQSF@""QM$L+*"VC&(X8UC4>@ P/Y5/110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 A4$\]Z^4_P!O#P S^!5\>:<ZV^JZ$>66/+2Q,<$9]1U&:^K:
MQ/&GA#3?'GAF_P!!U>W6YT^]B,4L;#L>X]".QI-SBFX.S,YT:5=<E:/-'JGU
M/RE\':MH-WHCSSW'FW$@+/),^69CU)-<5KLFC2:G(]G?0VK_ ,01]N[Z@=:^
MV+O_ ()@>#&E86_BC4X[4DDQS6Z.^#VW!E''^[7R1:_LO7%OXVU_1]+U!$LM
M.O)+=I;V#<[*IX*X/!(_"OBJ/#F*J5)U(2<F];7/N,7QC@,#1I4JT%"&R:7E
MM9;'#K\1[+1+Q/+MKG4Y4(51 @V#Z#J:[_1/B[=RR)$NAWV]L<% N/KDUK'X
M?6N@75OX<\)Z0FI>)KH[?.N/FF)Z?>SP/88KT_PG^S'XQ\0>%[J?0KFSAUNR
MN##<B:4 R-_$BM@X /YUZ];A;"1C&&+=YOHGHO5_Y'Y^O$C-L3-O)J*]GJDY
M+5V\D^GFSPO6M.O!XKM_$=UY43;U1$0<@$]^.37;0Z3XDNO%.^RM_L6E!5DF
M648:3/4J/6NVE^#OB;1K^SL_&EI";A +H6OF*[D*W&&!.1[5LZGXPL$\10S1
MD-O00M:G E4CT4]J^BI3I8*E'#8>/*EIO>_S/DZ,:V98F6*SY_OI.Z3T5NUK
MVT[$D^F?\)9I::1:R:C:HPVGS6'EBO6?AG\$= M_ SW=P\+7-N2DA^\<CZUQ
M6FZ_;3L0%,# 9V,N&_*MBS\27$#W!T]@ZR#][;,V"Q'0CGDUG:SN?4RHTZ<X
MU(QVT_X;T*GC/Q?%X)MFBM 2S?*!_='K67X+NM&CNFMWE>&6]_>0W6X??/7-
M<Y\0=5M2))[V*>UXR3(AP#7FMK=:_J301Z='9R02-F-GD8E??(Z5+?8BK6A-
MITW>2U_34^CO%6B2^"+0ZI>RQW]HXW?*X+8_'BOE34?$+Z3XEGU?0;5YK(W9
MF=)TZ$]A[5[II/AO6M?-I8^+-4%W8A=Z06QPLA'0,3S4/Q<\-:%:^");==-"
MRIA8_LRA&4>Y';ZUE4M*#OT.7$WQ5*4K<O)KYW2.6M&\7?$OP=?V^A3*L\BE
MS;(=I=>I _E7"^%3;:P]SH>H6,MI=6^8+BVG4*\;=#Q776/B5/@_H&AR;I6M
M%D!>ZC^>1$(R0V*\V\7?$C0]=^(3ZSX+>]O;RZ/^FQWD+(AQT96QU]J^5SC
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M'44/JVE7-O.ZWBQ6J1E1O.W&.JJ#SM.1QWJS_9]Y=Z/JRV5T%9+=I8T,> V
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MMU"D_P "=/MX6<!Y?^$SMFV+GDXV<X':@#U_QAXYTKP/:6\^IRN&NIA;6MO
MADFN)3TCC0<L?T Y) KF]9^-6G^'M.U&YU/0M=L9K&RDU![.6UC\QX4^\482
M%&(_N[P:XWX[6E_IGCWX7^-+FWGET'1+N<:G';1M,;7S8PJS%5!)53P6 X!S
MTK8^,/C#1?$GP?\ &C:7/%J2#1;D?:K<;T4LA 4..I/]T9- &QX1^.>B^*];
MT[1VT_5=%U/4K'^TK&WU2"-/M4'&61DD=<C(RI((STK*L?VD-(OH/$-TOAKQ
M*NG:!=R6>HWHLXI$@>/[YVQS,[*!R2%/%>6?"M4\.?$+P3J_B^Z>^L[GP_%9
M^&=3"".WM&**9[:4 8$I."'8C(XP"*F^$OC[1?#&E?&![R3[3/+XCOFM]/@C
M:6>[W#"B.-02^XG&0,>] 'KWBGX^^'/#.AVNM)!J>NZ1-;"^DO=$LS=1VUJ?
M^6\F""$Z\#+<'BN]T;6;37])M=2L9A<65U$LT,JCAT89!_*OE;PMJ6F?"/X#
M^'/AMXUUFVT36=2L93?"[+'[':RLQ9,@'Y]K%0O;D]J]<\:ZO<Z%^S[>7WP_
MBGE:VTV/^SA'"WF^2"H+*A&2PCW$<9S0([2Q^(.F:AX\U#PC&ETNJV-G'?2M
M)"5B,;L57:Q^\<J>E=-7QKJ?B&[A\8>-?$/@>XU#4YI_"NED3P^=/(%$Y^T&
M(MG]XL98E1R#SC-:'Q/\0ZK;MJEWX2\4:S_PB[V.FRO/#?3$V]XUVB,L;G)^
M:(L73) (R0*!GUW25\:^-;_5- /Q;DL?%/B1?[ N--N-'5M6N)%1Y%B,H&6/
MF*27RARHYX%;,GQ*U"Y^*GA\P:MK<%N_B66QU"&[DD*F/[-\H6-$"I 6 9"<
MDGG/6@#ZAT76/[9AGD^Q7EEY4SP[;V'RV?:<;U&3E3U![BM"OD?2=:U+5+;P
MW:S>*=?2.3QYJ.GRNFI3+)+9_ORJ.V<E!M3#9XXP>:]<_9>UO4=:^%<3:I?W
M>I7-MJ%Y:K/?R-),8TG98]S-\S?*!R>30!ZY1110 4444 %%%% !1110 444
M4 %%%% !14-[>1:?:S7,[B.&)#([GH% R37E7A3X@^,?B3X*G\7>&K/2(M-N
M@\NC66H"4RWD*DA9))%8"/?C*@*V 1GK@ 'K=%>-GXD^+[[XP6G@NWCTK3O-
M\,C7)&N;>29XYQ(D;0\2*"N7//7BF^$_C;K.M:!X_L[[2+*U\:>#7:.\M%N'
M^R3@Q>9#,C8+A'7L02"",GK0![-17EECXY\6^*O@[X>\3Z)#H5CJNI:?%?SM
MJKR_9(-R;B %(8\\ DC'4^E0KXL^)'B?X?>'M6T'3O#NCZK<P&?45UMYIK>,
M#(_<^5AF#8# G'RGUH ]9HK@?A?XJU_Q1\,;;7-973#JTZ32*+".6.V95=EC
M8!R7PP4'GL:Q/AE\5=4\:Z!X*O\ 4+C0-.NM8^U?:M/$LGG2>4\B#[,I.2!L
M!8MV- 'K-%<V_P 2/"L.IQ:;)XBTU+^5F2.W:Y4/(P^\%YY([@=.]-M/B;X2
MOK2_NH/$FER6U@,W4PNT"0CU8DX X//3B@#IJ*P=+\?>&]<@OIM/U[3KV*QQ
M]J>"Y1A!D;@7(/R@CG)KD/AE\6I/B!X[\;:/$VG7&F:*UM]EN[%W9I!*K$B3
M/ (V]NQH ]-HI ZGO1N'J* %(R*^0/BI^S)XUB^(NIZ_X%N(7LM6D\ZZ@NY5
M41.>&VY_.OK[</44$CVK:E6G0ES0>IYV.P%#,:7L<0KK<\,^"7[.6F_#^1M;
MU>"*^\4.2?M+$MY*D<A>V?<"N<\0Z?X@^!GCV?6]+#3^#]1E\R[C)SLD8\D^
MGUKT'X]?%J^^$OA.&]TS2EUG4+F<6\<<CE8U)_B;'./I7S;\2_C)\1-7T&32
M_$%G8:1%=JCBWBA^8J3V))_.N'%5G.\I.[/G\QJX/+:"HTDXNGJN5;/I=[:]
M;[GTGX]^'>B_$^RL=5^V'3=0$.Z"ZC(!8$<*V>HSZ5\R6UMX;.NW5EK.C#6;
MVQF,4MY!$WRL/X@PY%<_IOAV2YU&XN=<AU^YNFM%BM1%.1 A[-GGCV!JCK4V
ML_"V>"RFDM_^)KDQN+E)7]]P#$@UA[=R2O$YI9ZZ\4IT?=ZZ<SOT332M=^IM
M_%>P-KI,=QI_B%1GY82@5[F'VY^\/UKQCP/XR\8:5K\UQJ%U)J=HC;5?RP%'
MN<<C\17<W'A'Q)9W[^)/!^KPZA>D W?AS7&#6EP /^63=87_ $/>HO"WQ#\&
M>)?%$EK=Z:/#NN#B]TF^C$<T3CJR,O#J>S+6RA-:IV\CO>!Q\6JM&JH+^5W:
M7X_\ [SQ%IOB7XG^#_)TO3H;A)\)("^XE3UZ#CZUY]H=C=_#Y9_"\=E]BNU8
MB-YAG<#R2K'KBO6/A)\0;3POJVLQ^=#/9HV%\YC@?K6!\9M6'Q(1ETU8X'CE
M61KB)0"JYY"FDTYQ4^J)<*^.HK&)\LX^NRT:^9)I$&IV\=E<-J)NS P=X9,#
M<.X%2_$76[/Q#F*S)AM94VR0LF]V/=<=2 ?2N4A\$#0A_:%F\E\9,%TD<L /
M8$FNM\*ZSX4T?1[K[9$W]JI(3&77<JH>RCJ#3G"4EH[7-JV&JSCS0FH*HM=6
M_P ?0Y== T:V0:3>W\3PWL>^VDDRH@?'W&4]13I/@?%X95=9&@7=I=.OR7.F
MDR6L^/XL#./QQ5:?Q9;0:[KOB>71I+V.VME2'SH2,1]RJXYS71>%[K4=?LK3
M5/#>H2:<+@!SI]ZQ,0S[=J\_V4H74=5Y;KT[_>>-1PT4W2I._+V5MNOO:2:?
M9IHXWQ0-3UOP/JR0:8IMXK>0/=2PA6''(S7SQXSLHX?!6EV\#;$D>,,0:^M_
M&^CMX'^&_B.QNM2@N-;OHI9(X8WR&9AT13S7SO?>"XC\*D6\W1744 9@Y^96
M]O?-?.YI45.=!2?O-[===C]GX.P6(>#KSKWYFKMNRVZ:?B>B?!/1KF\TR*UC
MG1%=0-TC[0/QKJ[/1K$:VUO=A)8W?8^,$&O O!VM:QH?AN..1G4[< ]\5'-J
M_B.YN(KFTF>%D?(+DD-^%=B\-,?C%/$5,0H.6RLV_F[GU7^NN&P_+1A3<HI6
MOI]Z[GI_C5H_A_XACDLK?&G3.1*J= >Q%:WB;XDP>)8M%T@21-;2[8T0(,!>
M^?>O.=<N_%MWID5[JT,4^F$XD,<3+GZ'-:Q\$-!I]IJE@#-:Q$2\')4$=*^,
MS/AZOE'LO[25INZ33NFU^J/I,#FM',E*6%?,HVW6JOO;U/6]5\%Z-I>AVC6)
M#:@?G\R),+'Z#W]ZYW2-.?4+>;['.=/U2!L2QDAHY#ZA2?2L+1O'.HZK')'%
M97+PPCF1L8_(&J>KZ7<Z[<07D(:VO(CE'4XS^(YK'A_,J^3590QGOTWNK[/H
MUV9\SQ?P?AN*,+&5*7+7B_=G;6W;2VG;L>]_ S0/"_AOQ)%XV\8>/+>TOK1'
M@CTZ_?R2/1ANQD#L%!%?8F@^+-%\56$5WI6J6FH6LHRDUM*&5A[&OS#U#Q#J
M;06O]J/'<V<,@6X##Y_Q[&O5=-\7V$D^C:;X=D(O&FC6&.(_,3D<>W%?M.6?
M4,RI2G@ZCTWNMOGU/Y]QM7,^%:T<%F6'7O;-2NY]+VU?WGWI9:39VMQ-/!;Q
M12R'YY44!G^I[U?QBJ>FB3[)!NX;:-^?7'-7*FR6B/LEL%%%076H6UC"TMS/
M';Q*<&29PB@_4\4QD]%4I]<T^VA66:^MH8F.%DDF55/T)/-26FI6M_'YEK<Q
M7,><;X7#K^8XH LT5']HC+L@<%UQN7/(STR*BAU.TN86EBN898ER&=)%91CK
MD@XX[T 6:*I6>N:=J+LMI?VMTRC++!.CD#U.#4\E[!%OWS1IL7<^YP-H]3Z#
MZT 344B.'4,IR#T(I: "BBHWN8HV56D56<X4$X+'T'J: )**.M% !1110 44
M44 (V-ISTKY@^*=TTGC^^\V0J4EPDGF%E"[.!G^'D&O:=4^,7A#3/'L?@>\U
M^TLO%5Q:?;(-.N6,33Q$D9C9L*QX/R@Y'I7S!JVM2P:DH<QQ7<18W D;'S%B
M2=Q[X_/- T&LRW7]IPV=G<BQLY49KR;:"S!0H^4D9!.>U9UUH\$L$8TB-XIH
MB?,>0DAN>6;CDG&/QJY?ZG/XJGMK^"/#[F'R.2?*')4@]^*ZEY[6/1;=[+S6
MDGD.YE4&1#P6!!Y[UG9-M,\I4X5*LX5MWMZ:;=K,-*\0/?Z5#9L@LY4"H]LB
MJ^_/&\X'W:X[5_!FD>$;NQUJVMXHI5NL-&DVY@SD@YSDC/\ 6M&_CO\ 3_BG
M;_9"_P!B.E&21-N"[@C 'H!_6J'C.*YU+3KH.;D32*9XX<*0Q#@_4$!3^=0U
M>#ONCGKQ=3"S<ES2IWMWNM4_4=J.C:H]M)]F@,UL?G6=VSL)^\AXZ8_G7)66
MJ1P^(I;*X_T:27;/)')AQ*B]-AQTSVKL-&^+,>L:-#9VMYB2.+9-'-&=X;:>
M#CW(]^*S-4M+>_L@MR$AF<;;42,0T3=,9QQ]">]-VE[T0G&&+A'%8:2NK.W?
MR?9]+_>8UOJ&H6&I3'3HA=S$@F2-AE^YZCCZ5=\.Z-<:==27/D/!<7LLDC1%
M-I?@8SR>N#S^E:/A=V2R,UPJNT:L)#&H)! .3C\.U3:A<W$.C6>I1R+(0ZRD
ML=V%(///KQ3E:UT7.5/$4E5VY;->7<J00'7%G@MI%@DBP'653^[?.22#U'':
MJ/B'P=?0M!>),89Y$\^:?!*3<\D\_+VP!7::;I\\EE97\5M%#/*OF%5898CJ
M<#C\ZK3SW,T(,\$,P9MZ$G<0>3@X/&>F*I=GJ;QM5BX5E=O;3==_)^GR.<T7
MQ))9W<=N_GM?/.&DR-JA&'#%BN"*S_B!KM]/I&K7-K;PWD<%MAYHIOG&"5)
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MK=7#F%8E7<1TZ"O*/"-_K6K3KID4GDO%CS9<D@>WUKO[B.]\(FWNI+AKJ(.
M_'(]Z_1HY/ELZD:_L(\ZU3Y5>_K:Y]]',,9&FZ,:LE!Z6N[?<=AX>TI=4NX+
M2[/D(Q"[CT%6O$WAFY\.7DUE/&89(SG!].QKHK/XC66LVMC!>Z1$+.W&3):H
M(YG/NU<OJU\VNZP<W$HA9L S.6(';)KT8NHYZJR.%V-:32-3U?X?7#_:R]C
MVTVV[H2.2!5._P!"NK?PG%'ITTBH8OEP>O%>Q^%S\-O#/A-[/6]1N=3NYEW.
M+*+Y5..F6ZFO/;7XC:+X7;4K2ZM)+[P\0\EJTR@31-VY';VK\IXUR_$YCA5B
M,-%OV+;Y;?$G:]O-?D?<<,9A2P->5"JOXEE?L>6^!/B;K7@Z&]L9K9FG?*CY
M02PKL_AWKUQKQ9+PI&_G,0JKC&37%ZEI>I^/[Q=1M]/ET_3&)"[?E=A]1Q6/
MX?\ AGXEM-=G;1=1DMGC^9HKB5G4@_CG-?G53A7&XFBZGL'&4TOO^\^NJ\3X
M+*[U*M9.$-WMI]VI[M\0_A=<_P!D_P!H12E89,$M&P*R8YVD5]2?LJ_";P=I
MW@G2_%-E8B;5K^/>]Q/EFB8'!503@8(QD<U\?Z/HGCK5M'B_TS3I;8@B1GG=
M"A'7*[3DU]P_LG:!/H7PDL5GGBN))IGEW19VX)Z<]*]/AW+<WRE3I8Q6@^I\
M7GF<9#G[IU\'4C4K1OLMHOU/:$XX Q3J**^T/G KP?PR8_''[2WQ MO$,27L
M/AFUL8='LKI0\4"3Q%Y9PAX+.PV[\$@)@8YKWBN%\8?#;P[XE\0:?J\\EUI/
MB.)&@M]2TJ\:UNGBSN:)BI_>)GG:P(!.1C- 'DO[17@30?"?P[LX-+M88;:]
M\<Z+=S6@ ,4<CWD*N%3HJL!G;TY/%:'Q#TVV\#?M(_"R[\-6Z:?=>(WOK'6+
M:S CCN[:*'S$ED0<%HWP V,_.1FO1O%7P8T'QEX:M=#OY=12TM[V+4!+!>L)
MWN(G#QR/*<L[!@#R>P[<5>T#X6Z+H7B&77R+G5-?EB^S_P!IZI<-<3QQ9SY<
M9/$:D\D(!D\G- 'G/PIT*Q/Q:^..GB$I:7&J68EC21P6WV,1?G.1G)Z'O6+\
M-?"?AZT^*?Q,\#WO@H^%['5K.UO(]+MYD?3[^T&Z)Y@(\!'=@5=2 2 O7FO6
M;?X2Z/;7WBZ\2XU)9_%!5M0D6]=&RL8C5HF7!C(10 5/:KG@SPCI'AN>[^R7
M5SJ6HJJ6]S>ZC=M=76%&41W8Y  ;(7@?,3U.:!'GWP7^&W@[0?B'XXUGPIX?
MTW1+.*2+0E33;58$=H07G8X')\R0IG_IG7">/]1M/"7C7]HC5GT2QUJ"W\+:
M7=W&G7N5@NPL=QE9, DY  Z=A7TIH'AZT\-V)M+)"D1DDE)9MS,[N7=F/<EF
M)S7(>)/@?X=\57/BZ:^:^)\4V$6F:FD5T462",,%51CY#AW&1S\QH&<7\0/C
MIJG@:VO;32M%LS/8^%X=>M(;IG"ZBY=D-G;A.=Z[%_O',J<=33]=^.FO^&/%
M6C6%]INFS6USJFG:1<QVKR/*DEVO^L+#Y8@CG;Y4F7< L"!C.1\2/@WXDU;X
M@0WEC::I=:3#IEMI]K<Z1XOFTB9/+9BWVA%0B3ELAUYQQBNHTO\ 9F\-RV\4
M^M7&IZCJCWEKJMU,NI3Q1RW\"JJW(16 $A"*K-@%@.>2: ,.T_:$\0OXBMXK
MO1=-BT=_&\_@MW@N)'N"XC+13@%0H7*D,I]1@\<\MX@\:3_%/Q7\#O&%O;6D
M6@W?BRY@L<J_VQ52"[C)=L[-KF+=M &W"\GFO71\ _#8G63?J)*>(F\4KF[X
M_M @@R8V_=PQ^3I4-G^SGX.L=<M=2@AU" 6>J-K-I8Q:E.MG:W3*P=XH0P5
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M_@_PYJ#:?8:OX?O]/TY[G5FFAMH)(),I.9HU+1*RH&63!&6P1U%?5M,:)7#
MJI##!R,Y'I0!\R>%?#NM_$7P[$--M_#3-:^*;+7KC5M)U6XNK;4&CD1Y )9(
M06DVQHOR@H!MY&"*Z#QM\'/&WB;QLVLR:MHMQ966MV.K:>;OSQ)!%"RE[<HH
MV<D,1)RQS@X %>^H@C4*H 4= !@"E(R,4 ?/7PPT[3_$'QI\8>,=$U::Z\&J
ML;&(1F.U;50'BGD3< 25C"AN,9(ZD5V_P@\,7-GXC\=^*+B-[=/$FI1S6T$@
MPP@BB$:.1VWG<P]L>M>F>6,8P,>F*<.* "BBB@ HHHH **** "BBB@ HHHH
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M"RW>BV+(S)(>=J+DLH]B*YO1-1A\<Z'JVE6<D=AX4L[LR"^O(AYN.VTGJ?\
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MII0HQY8+1(TPM.O&GS8N?/5EK*3ZM_Y;+R$7@"EHHI'<%%%% !1110 4444
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M><WEPSR\+QU^;MD=/I73S:M;:5HYQY=W.^ J(=ZY![GK698I;26YLM4V-M
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M',@&$..=O-?HVQ(4XZU\J_M*?L]_$+]IS7I?#^H7VD^%OA[IS)<VLT :XO\
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M:^._->Y^ )K1;Q;+5[>*\BD^1FFX*@]QBN>TF[L/ 'AJ6"6!)6:/;&%'S#W
M%<'X1^(MO/XHGM[\/ITS-^Z2X.W>/;-?/U95L9SU,.G&,/A:WT[=3U>2G3A[
M"N_>GOVU/>/%UIIGA&_D@T(1"!X]K2;0Q.>O->=:?X-LM=\0PF:%9G9P!OY
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MDH **** "CI110 4444 &!Z4444 %%%% !1110 4444 %%%% !1110 4444
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MI7LTK]B/9Q.>\"^"['P%X=M-'TY"MK;IM!<Y9CW8GU-=#117CMMN[- HHHI
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU+E$@;RLA\^6?-;_ &N!SUI8OBU\2)+[X=V;6_A6.7QG#-<PMY=TRV<:627
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\?/;1C(]RQ(%;VH2G6OB9X6CO;VZ:"Y\-/+,%N7C$KA."VTC)KZ"\/>$-/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHI=1A1113$
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0.
ME%%2@"BBBJ **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>adag-20211231x20f027.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f027.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %/ W0# 2(  A$! Q$!_\0
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M?9_$OXG^ O"'PK^+5S\3[_Q<?&^I6MGJ/A6XL[<:?%'-GY;54 ='C]=QSW%
M'WYO&<9YHW"OA'P1XX^(WQ AE^+UW\:[3P?81>)VT>+PCJ42?V6EL)C'Y$H5
M?,^T/C*OQU%3ZW^T'\4M&\2>)/A:NO-)XWE\8VEGI&KM80D#29E\TM@)LRJ*
M0"RD^N#T /MRWUBPO+ZYLH+VWFO+;'GV\<RM)%GIN4'*Y]Q5L,#7YZVVO>*/
M@M\6OVI/%UMXEN=:U/0]*M956^M+=8KB5T41O((XQ_J\_*%P&_BS4_PN^*_Q
MLT'5TDDU?Q-K.G:YH-U?37WQ!T^RTZRLK\1[HI+5TEXMR2 0P('!XR:!GZ"
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MN857:Z3S+D.[$$D'/]W)J7]I#X-?"GX.>$_%V@:V8OBE\;?'-])<Z.18@:K
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M..E> _'3]DF_\<_$_3OB=\/O&LWP]\?VL(MI;P6@NK:[B[++'D9XXZD$=N]
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MFK"]UG3C-+9+)&K,0 V78EL8(P*]O_:K2>+]EKQ^ES*LUTN@RB655VAWVC)
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M-_P/=7RW\/?BOKOP!_9_\)?%OQ7XH\9_%"?Q4EI:'0[J[@\NVEE8_/"-@)/
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MFH0B:%I$*.!G!5E/*L"""#T(-;M !1110 4444 %%%% !1110 4444 %%%%
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M&ES0 449HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BO(_CS^U)X
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M'5GXLG;PS(L<EWJ%PS(#(Q7F)3&3Y8P#N]J /O'.*YOXE?\ )/O$G_8-N/\
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MN>%'<BO!?B9^VA?>+/%$G@#X$:0?&OBQRR2ZNR_\2^S X9P6P'Q_?8A.F"_
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MW7(&89(VA".<J"2%Z5]IX%57TFQDU 7SV=NUZ(C +EHE,GEDY*;L9VYYQG%
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M&_L=3^ _@^\TNY\37FG7%J\UM<>,G5]5EC:5RK3LORG(.5(_@V5Y#^U)XO\
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M9-Q@+?,I( SM]J\K^'GQY^%/[,7[/_@ZYM--T^X\;:WI%I+/I6@01B]OY_+
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M0_9LT6VT?2/%H35FU*_FU^>34(FTM=.^RW 2-3&(%=P 557!!^;?FC]I#4_
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M=WGQ$^-7Q#^+8\(>-O"GPRT/P%J;:1%IEQX;M+][QHX1*UQ<2R@&-&)P-HP
MK=2N3]??$'3O$&K>"=;L_"NJPZ'XDGM733]1N(?.CMYR/D=DP=P!ZC'-?G9^
MT#X?A\&>*F\5?M'?"CP9XQ"^5'/XD\&^)'TV]NHU^53-I\DB-*<%<[>54?>(
M& #/MS]E7XF7'QB_9]\$^,+S3K32;S5+)GGM+%=L"R)*\;%%_A5BA8#G&[&3
MU/J]<)\"_%_A?QW\)/"VM^"K!]+\*7-F%TZQDM?LQMXD8QB/R^BX*$<$CN"0
M:[N@04444 %<W\2O^2?>)/\ L&W/_HIJZ2N;^)7_ "3[Q)_V#;G_ -%-0!Y;
M^PO_ ,FC_"W_ + T?_H3U[M7A/["_P#R:/\ "W_L#1_^A/7NU !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%)N H 6L'QMX\\/\ PW\.W6O>)]8M-#T>V&9;N]E"(/0#N2>RC)/8
M5X)^T;^W)X4^#=^WA3PY;R^._B1.?)M?#^E RB.4_=$S)G'/5%R_L.M>6>"/
MV._'O[1_B6W\=_M*ZO)+%&1)IW@?3YO+MK5>NV7:<+VR%.X_Q,>E 'DW[5/Q
MG\5?MQ^%]3T[X:^"[G_A7'A5Y-5N_%6J,;=;EHHSE8P1@<$X7YF/&=O2NO\
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M)!\,?";:Q+9R:A+)<0V=M:HXC\V:5PD:ER"%!8C+8./2@#SO]HG1+/P]\/\
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M_P")9/Z_[E!<3GJ*W_\ A7WBK_H5];_\%D__ ,11_P *^\5?]"OK?_@LG_\
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MO@M]4.H20^)XX!;:K::1<&Q$L@78LDF"("[-\JN<]N<5Z5UH **** "BBB@
MHS]?RK,\46\UUX:U:&V5GN)+29(U0X8L4( !]<XKXN;X6?$O3O!_AW_A(K#Q
M'XFM8?#LMN^CZ,QLKA)C/E8)IEE9G!'+, #M&!0!]R9HKY#\(^#O%-GXU^'<
M<L'C=3IT$;76NW*7!@5,M_H4<!E(5<$!Y9PY(5<8-?7@H **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \K_:I\,ZKX
MR_9P^)6AZ'8RZGK&H:!=VUI9P@%YI6C(5 #W)KQOP-^PON\%Z U_\6_B[I%\
M=/MS/86_BIXX[:3REW1*H7"JIRH'8 "OI7XD>.M-^&/@'Q#XMUC?_9FB6$U_
M<")=SE(T+$ >IQC\:^=?AS^UUXT_MWP]%\5/AY:^ M"\:0F?PMK$6JK<0O(8
MO,CM+HG&R9UR5(P"> ,T ?1'PX\$)\.?!FF>'$UG5_$"V",@U+7;HW5[/N=G
MS)*0"Q&[ ]@!VKI:\M_9A^+&H?'+X$^$_'.JV-MINH:Q!+++:6;,T496>2,!
M2WS=$!Y[DUZE0!\'_M3_ !0\7:1\>O$%O!XQ^)WA;P;HF@V4]PW@SP_'>6T<
MC/*T]Q++*-H1(S%D*2Q)P!\ISM:AXD\2?'[XKVGA+PY\4/$&B^$]%\ 6GB.W
MUG1)8X+G5KJ9BD<\Q\L@J/+):/@$DBO5/C7\#OBEXTU_66\'_%1-$\-^)+-=
M-U/1]7T[[6MC'L9'GL"K+LD8'E7RI))ST%<SKW[(/B/P?JGA_4_A!XTM?"U[
M:^&8/!]^NN6+WL<]E&V4G3:XVSH2Q /RG=S@"@#R3X7_ !.^(7[45[\+/#&H
M^.]9\)Q7'@B[\0:C?>&WCMKF_NXKQK6,N^P[5^0.54 $DCI7:>"_VN]&TW]E
M"RO/BSXIAM/$=_\ VKH,5X]M(QU&:V:2+?B*,A68;2<X%;Q_8P\0?#2S\#7_
M ,)O&UKI'B7PWH4GAV>;Q#IYNK:_MI9O.D<JC!HY!(SNN"1T4\#->C^$/@MI
M_P #/V;[WPC;WCZS)::?>SW.HW48#W5Q*'DEEVY.W<S'@'@4#*G[# *_LD_"
MX'@C1D!_[[>O=:\)_87_ .31_A;_ -@:/_T-Z]VH$%%%% !1110 4444 %%%
M% !1110 4444 %%%% !12%L5X3\;OVV/A/\  <SVNN>(H]1UR/ &B:/BYN]Q
MZ!@#M3_@;"@#W<D#J<5Q_P 2?B_X,^$.D-J?C'Q)I_A^T"[E^V3!7D]DC'S.
M?90:^/C\:?VGOVIA)'\-?!\'PF\&7.%7Q)XA_P"/PH1]Z,$=3_L1M_O5UGP\
M_P""<7@C2]4_X2CXJZ_J?Q6\3'$DMWK<[I:*1SC86)8#_;8C_9% ['->*?\
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M^[T5ZR]Y_=HOP%RM_$SXB\8_L(^$M&\(:QXH^*OQ1\2ZY=6T&Z36KMF>.SY
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M5N_#%S<W$.F7TFGW)N;22W(E3J ' R/<5W&: "BC-&: "BBB@ HHHH ****
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M/_LE_MG?!CX=_LX^ /#?B+QQ;:9K>FZ6D%W:26=RS12!F)4E8B#U'0UZV?\
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M3]%O]7M2RR:I;6X9[@;LAG9T#;N<?@*]?5=O Z>@KY['_!0#]G__ **1:?\
M@#=__&:#_P % OV?5_YJ19Y/;[%=_P#QJMF[N[ZGA.=2=O:2<GW;N_O/H3:/
M04N *^>A_P % OV?O^BD6?\ X W?_P 9H/\ P4"_9^!Q_P +(L\^GV&[_P#C
M5!)]"X'I17SW_P / ?V?O^BCV?\ X W?_P 9I#_P4#_9^!Q_PLBSS_UXW?\
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M  4"_9_[?$>S_P# &[_^,T+_ ,% _P!GYAD?$BS(]K&[_P#C5 'T+17ST?\
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M/AQXYU2'Q)JOA2>$P:]#:I:M>6\JY4R1H2H<'/3C%?05 $7V6'_GC'_WP/\
M"O/(?@G80_&^Y^) OI&NY])323IYA3R@JONW[NN?:O2** (OLL'_ #QC_P"^
M!_A7 Z1\&;#2/C-X@^(2WLDMSK&G6^G/8-"@BB6(DAU/4DYYKT.B@"(VD/\
MSQC_ .^!7 ^#/@W8^#?B+XT\6Q7LEW-XFDADEM984"6_EIM 4CDYZ\UZ'10!
M";: 8_<QC_@ KR[X,?!ZZ^&FO_$6_OKNROH_$VOR:O;)!$P,$;(JA'W=6XZC
MBO//VM/C)\2_AOJG@^V\,Z)%IWAN_P!>T^SO?$S7D+NPEDPUNELP+<C.7[=J
MY3]K_P#:<\0_"KXK:!X3T?QCIG@:RFTE]3NM2U/09=8$A\S8J+%#\ZX )+'Y
M<4 ?7_V6#M#'_P!\#_"O/?@]\%+#X00>)(K:]DU,:UK%QJ[FXA1?*:4Y*+CJ
M!ZU>^"&OWOBCX7Z!JM_XFTSQA<W=N)3K.CVQM[:Y!Z,D9)*C'8UW5 $1M(>/
MW,?_ 'P*\\^"7P3T_P""GAB^T:UOI-5CN]3NM2:6YA165II"Y0 =AG&:](HH
M A:SA8$>3%@C'W!_A7 ? WX,6'P0^'\'A6UO9-7ABNKBZ^U74*(Y,LK2$8'&
M 6P/I7HM% %.^TN"]LY[<QH@EC:/<$&1D$9_6N-^"GPBL?@M\-='\'VMV^JV
M^FHZ+=7,*J[[G+<@<#K7?5'<N\<$C1IYKJI*H"!N..!D],T <_X^\*CQ;X'\
M0Z';FWMKC4M/N+..:2/*QM)&RAC@9P"<\5E_!OP!)\-OA;X5\+7TMM?7FD:=
M#9RW,$9"2,B@%E#<@''>OEC7OBI\?/A)XP\!:SXW\0Z)*?&'B4:1_P *[M+.
M)S;6C,0LT5RC%F=5P6R2.0/6L+4?VL_B5)HNN?&&S\0:8GP[TCQB/#C>%&TH
MEIK+S C71N"?,$W.X*!CMB@#[*^+/PSLOBQ\-O$G@^XN#IMOK5E)927=O$K/
M$&_B /!-;/A?PQ;^&?#NF:2FVXCL;:.V662-0SA%"@D>^*U+6=;FVBF7[LBA
MQ]",U+0!P/QO^$-C\;?A5XB\#W5X^D6VLP+ ][:PHTD0$BOE0>#]S'XUV&FZ
M1!IVGVUJ(TD$$2Q!F09.T 9Z>U7J* /.OCM\&+#XY_#'5/!EW>R:/;W\EO(U
MY:PH\B>5,DH !XY*8/L:[V&QABC5/)C.T8SL'^%6** /./CE\%;#XW^"$\-W
M=])I$*:C9ZC]HMH4=BUO,LH7!XPQ7!->@+:0J.88_P 4'^%3UPOQNO\ QUI_
MPSUF3X:Z;::IXU=%BTZ*_D1+='9P&DD+LH(5=QQSD@#!&: ,#]H'X.W?Q?T3
MPI8Z;>6>FOH_BC3==E>XB9A)%;2EVC7;T9@>">/6O6!U/N:^']-_:!^)/P<\
M9_%CP9XR\9Z?X_7PUX*?Q*OB.+3HK8Z7>[#LM;A$.TAG(* C=C&<9-;_ .QS
M\>_%/Q9\8-9^(OBUX5\53+HXNY?#FF>')].N8Y&\H^;'-(0)XDW,A9!C<?:@
M#["HH'2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHH/2@#Y6_::MO$M_X
M[DM[S1M5UWP?_8S26L&F>*[+1E@N Q\V>59IHVE55V_>#1C)R.:Z^?XF>(?A
M3^S?X>UOQ5'X?.N"&*VN8]=U<6EH59BJ SV\,ZLQCV?=3:QST!J?XK> M9U?
MXBC4O"WB7PE;ZI>Z4VEWNE>*K-KS%NS%M\")*C*3@A@V5; S]VNVTGX<7&@_
M!R'P7IFNW$=U#IIL8=7Z.KD$;U )V@$\*#\J@ 'B@#E/V8O'^F^.?#6JC2M&
M\':':6ET!]G\&Z@]U 6<9+/NM;?:QQV5L^M>T9KQO]G#X)ZM\%M,UFTU35X-
M5-Y)$Z-#-=R\JIW,3<RR,"2W13C"COFLO]J7XE^)?AI:>&KW1-6M=*T][F0Z
MF62TENI(5C)Q!'<2Q[VSR0F6QT% &G^U'SX1\*?]C9I/_I0M>RCI7SO^TIXB
MU&\\._#A;?1KBZTF^\0:3<3:K)+'!]F;SD9%>!CYA+9Z ?+WKZ('2@ HHHH
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M"_X7Z'X5U[Q!'XGO-)B^RIJ<=LT!EB4_(&5I'.X#C.>@'%=[0!Y7^S)\%F^
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ME=BS[ W(7)X'I7I]%% !1110!5U75+71--NM0OITM;.UB::::0X5$4$LQ/H
M*Q?AW\1- ^*O@_3O$_AC4$U/1;]"\%P@*YP<$$'D$$$$'I7GW[7'P[U[XH?
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MX '5F/  ')) [U>\,>)M-\9>'M.US1[I+[2]1MTNK:YC.5DC< JP_ U\T?\
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M:P@@--<^#-8BC3) !9VM0JC)')(%>RV]Q'=0QRQ-NCD4.IQC((R*\*^)%O\
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M;KDE\[MGH5:VBP/?)^E!F=E1110 4444 %%%% !1110 4444 %%%% !1110
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M&\?>&HXI9)/$&EQ+#(L4OF7L2&-V^ZC L-K'^Z<'VH W(88[=-D:+&N2=J*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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8 !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>adag-20211231x20f028.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f028.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &R P4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]3:*** "B
MBB@ HHHH **JZK?1:;I\]U/*(((4,DDK=$4<DGVQ7R4O[:.KZC-XKM[71([*
MZA\<Z?X+T:.]W L;A59KF8 ] I9P@QQ@'DT ?7]%?(&D?MDZSXG;1?#NG6EE
M#XLNO$.MZ'=3S*S6T:Z;&TC3*@.?W@\L!2?EW-UQ7/7O[?.KZGX(M/$.A:)9
MH+3P:?%VJ6]U*S<+=BV-M&1C&2)&WG/1010*Y]P45Q*_&#PA9Z1H^HZKXCTW
M1DU6TCO+:/4;M(6>-E#9&XC.,@&NGT37M.\2Z;#J.DWUOJ6GS F*ZM)1)&^#
M@X8'!H&7Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:?&CX?:5XGM$$ NU(EMU;=Y3@X*U/,K\O4CF7-RWU/1J***HL**** "BBB@
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MP.>A##L0/'=/_M<?!"[.L"3/_"F)!IGG==O]K\>7GOM\KISC;0&Q^L?CL_\
M%$:^<<C3[CK_ -<VKP;_ ()P_P#)G?@/_=N?_2AZH_$Z[^.\'PJ\.#P+IOA*
M[MW\-K_;DGBBXFBN4E\A=QB"#!.-W7O5S_@F_G_ACKP%NQG9<YQTS]H>@1],
MT444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ&[N$M8))78*
MB*6)/H*Y3X??$;1_B1HTNI:3*9;:&XDMVR!D.AP>E3S*]B7**:C?4[&B@'(!
MHJB@HHHH **** "BBB@ HHHH **** "BB@G S0!\M?\ !0>RUG4?@Y':Z=>6
M]O:37L4=Q%)N\R<LP"HN..2><U8_8W^!/C/X%6.H:=KNJZ;?Z/>A+FWAM?,#
MP2$?-PW&"/Y59_:*N3XV^+_PO\#1KYD#WS:Q>+Z1PC(S_P "Q7TA"@"C QQ7
M+&*E4<NQPQI1GB'5ZK0DHHHKJ.X**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ.:X$)4$$D],4 29
M [T9KY@^*WC;X[>.]?N]*^#&CZ#HVE6<QAG\2^+6)6YD'46L(!)0'@NPP3G'
M2I_A5XY^.?@76++1?C7H^AZOIVH3"WM?%'A5CY=O*?N)=0L 45C\HD' ) /6
M@#Z%\2>&]*\8:)=:/K6GVVK:5=ILGL[R)98I5SG#*<@C(%<T_P #_ ,GA*/P
MN_@_16\.1RB=-*-E']G20<APF,!O]H<^]=NA!1>"..AZBER* .9U/X:>%]:T
M./1K_0K"]TJ-@Z6<\"M&K#HP&.#R>>O)S3-7^%WA37UTU=2\/Z??)IN/L:SV
MR,+?&,!!CY0-J\#C@<<5U.1ZT9% '/>.8A'X*U\Y)S87'7_KDU>$_P#!.+_D
MSOP%_N7/_I0]>]>/?^1(\0?]@^X_]%M7@O\ P3B_Y,[\!?[ES_Z424 ?2]%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !37;:O3-.JO=W"P1EG("#J
M2>E 'C'[5OCZ]\'_  JU"'3P6U75&73[2) "[-)QD<]LUY'^Q9X5^(?PVU/4
MM+U_P[=:?H=ZHG2>5T8)*/7#=Q7:>%4;X]?'6Y\0S1[_  IX1D-OI^?NW%UC
M#R#L0O2OI".W*/D-Q7%&+JR]I?8\6.'^M8E8SF=HZ1ML^[?K^A+$2T:DG.1U
M]:=117:>T%%%% !1110 4444 %%%% !1110 5!.SB-\8]N*GK&\7:U#H'AO4
M]1G?9#:V[S.Q.,!5)_I4R=E<3=E=G@'PV9/'7[5/CKQ  9;7P[9Q:-;29R!(
MWS28-?2D+%EYKP+]B_19%^%USXFN5/VSQ-J,^J.Q')5F(3_QT"OH&LZ2]VYC
M0^#F?74****V-PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "O&?VC++XIZDWA"U^&>J6^B^9J+'5;V>
MT%R$B$;&-63(_=LX"L1R <U[-1C- 'SG^SGX=^(/P_\ %.H^&O'/C#4/'5U-
M91ZM/?7%EY5K8S22,IM[>7^-,#.T\K@>M?0TD$,R[752O]T].M?)G_!0#Q7)
MX7\)>$S-\4;KX6Z/<:LT-]J&G(9;N4>42BQH.2H8 MZ BLC]@'7-(UZX\;2Z
M5\8=7^+FQ;19)]7M7A-E]\A5W'D-UX':F(^O?$,MY!HMTVG/%'>",^4\RET4
M^I4<M]!UKXN\$_MD^+=1\,ZQ:76H:;JFMGX@67@W3[LZ>]G/%#<-S<7%JQ)1
M@HDV#.&P":^L_BKH?BC7_A_J=EX+URV\/>)G6,V6H7<'GPQLKJQ#IW#*"I]F
MKP;4OV2=9\4C4O%.M:II$7Q&NM:TC7!+IUO(MA')I^1%'ALN1(K2!F//S# ^
M6@#E-!_;"\4>++G1O"=H;.S\12^)-?T2[U0V^]?)TZ)I$E6,G&^3,8(S@?-C
MM7.3_MY>*];\!6OB#2+/3[6?3_!#>+=2ADB+I/.M[]F-NG.50A9&W<D$J/6O
M0]/_ &,-0\/6VC:YIFJ6+>,K37=7UVY-RC_9)3J,;1RPC'S ("A5NIV'/6L/
M4_V!)K/P=IWAW0-?MHX9_"?_  B.KSW<#;GC-T+EKB(+_'N,@"GC##THTL!Z
MY\4/VE?A_P"%_A[;R^)_%.G>'+CQ'HCW=A:W\A1Y0\71>.<%@*YW_@G"0?V.
M_ 9'(V7."/\ KX>NL^*_[./P\\5>!47Q#X5T[7GT#1Y+73YK^+>\")%QM/8_
M*#]17)?\$X !^QUX"P,#9<\?]O#TAGTQ1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !111VH #T->)?M*^/+W1_#]CX7T!Q+XF\1S?8K15ZQJ?OR'T &37K
MNJZK#I-C<75S*L4,*%W9F   &37@'P.TR?XM?$/6/BAJD3):*6L-#AD'W85.
M&E _VCW]*YZKO:FMV<>(DW:C!ZR_!=6>M_"GX>V7PT\$:5H%B@,=K$/,E[R2
M'EG/N3FNTJ.--H P1S4E;1BHJR.F$5"*C'9!1115%A1110 4444 %%%% !11
M10 4444 %>#?M@>)YM&^#.J6%LQ%[K<T>E6X'4M*P4X_#->\U\U_&J,>/OVB
MOAGX01M]MITDNN7L?8!!B//_  (UC5=HV[F-;X&EUT^\]O\ AOX<A\(>"-%T
M2W4)%86D4 4#'10#^M=+45J"(^>N:EK5*RL:I65D%%%%,84444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+X6_'C9J7CK3?)O;-"L>M6=X;.XBBSG8THX*9[-D GBK?P"_93^&/P"CO)O
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MV&(Q+)O<L,*22.M3&2DM"8M25T>M4445104444 %%%% !1110 4444 %%%%
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M'B#'7^S[C_T6U>#?\$X?^3.O 7^Y<_\ I0] 'TO1110 4444 %%%% !1110
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MW/)-=RJ%<#/ I]%=D8J*LCVXPC"*C%62 4445984444 %%%% !1110 4444
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MQZI#Y)QC(]LC-'V89R,!CWQ4U%, HHHH **** "BBB@ HHHH **** "BBB@
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MXO\ #,WA[0] NOM$]W?;&CN2OW5BZ[P?6OH,_P#!2WQK#"S7'POPF,M(8[Y
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M66HV.CZSJFIVE_(LC)?,F$8#&5V@=:3]J3X)7?QY^'UKX:M-:CT:2/4[6_\
MM$\32J1#('*X!!R<8S7L-]*EM:R2N<(@+%CV KXX\+?M?^)?$?B?QMK$=SX"
MO_AYX<M[NXDCTS5))=9Q$"%$D)X3<PY., 41BHJR'&,:<5&*LC[ 2,PP1KYC
M':@7.3R0*^8?B3^P-X7^*GC+5?$^L>*M?6^OY-[1Q&(H@ P%7*YQ71?L^_M$
M:A\1_'4WA?7K&SM-0DT&U\0VC6!;8()_^63;B<NG'S#@^@KZ* P*F4%-6D34
MI0K+EJ*Z.)^$OP[@^%O@C3?#%IJ-]J-I8(4BGO&'F$9S@X '%=9J-F+NPN+?
MSI(_-C9-Z-\RY&,BK=>8?M"_%6/X.?#75O$OGZ;;7,"JELVKS&&V,K'"B1P"
M0N>XJU%)6-$DE9'SBG_!-S15\=?VNOC/53I^3<;-B?:S<;]V[S,8V_AGWK[/
MTJS:ST^VMVN)IC%&J;Y&^9L#&3[U\9ZK^UKX_P##7P=TS7=8O_A9%XEUW4/L
M^DRQ:U)_9#P@99GGY._VX]Z^I/@_J_B/Q!\/]'U'Q4=&.M7,7FRG093+9X)X
M\MR3N&.]3&G&'PF5.C3HW]FK7.S,8XRS?]]&N ^,/PO3XO>#+_PO=:SJ.DV-
M[A9Y;!P'9 <E?FR,'O7H5(YVJ35-75F:2BI*S/EOX5_L-^'/@QXPB\0:'XJU
MU[M(GC:&;RA%(K#&&V@''XUWO[,?P3OO@7X'O/#]YK2ZO)<:K=:D)X(VB4"9
M]P4@DY(]:H?&S]H>V\#^.-%\$Z9/I,&OZA$;F:\UV8PV5C;[MHDD(Y9F8X5
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M<? SX7:GXMM=,_M22VFBB=2K%(5=@IFD"\E4') ZTW3C)6:"="G42C.-TMC
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_C1\//C]X6\%_$OQ'X<\6:1XNM+R>W?1M+:R>PF@0.4!)_>)@X!;)[UL:O\
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MDB$#+=</C!I 'C?XF_&/Q+XR\,_#7PC_ ,(_X+\;3:*=8\1:CJ49U"'3E#!
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MJ<6I:?-.3Q$\J!3$Q[;A@UXQ\0OB<OQ@^$W[-7B9B5O)_%EC%>1G@QW$89)
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M2UI=#N_$5V/LMI#<%=VR'<-TQ &20-H]:Z[XX_'JX^%]]X=\.>'_  S+XO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
8B@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>adag-20211231x20f029.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f029.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %M Y4# 2(  A$! Q$!_\0
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M+F(]8WP.4/\ =Z>U>B44 8-IX#\.Z?KUOK=MH>GV^L6]B-,AOX[=5FCM001
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M0Y>1@!RS'DGJ:V** ,C0/"&B>%I=1DT?2;+2WU&Y:\O&M(5C-Q,0 9'Q]YB
M.3S7)W_[/'PPU7Q6WB>]^'WAF[\1-.MRVJ3Z7"]P91C#ERN2PP.?:O0Z* &[
M!UP,UFZ3X7TC0K[4KW3M,M+&[U.43WL]O$$>YD"[0\A'WB% &3VK4HH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^%^F3:=X0\-Z5X:L9I#+);Z7:) KN?XF"@9-9]M\$? %GXWF\8P>#-#B\4S
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M1--M?"FC6^GZ)-]HTRUBLD6.RE_OQ*!A&YZBNNHH  ,"BBB@ HHHH **,T4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !111UH \0^-_P"U_P"!?@!XGM-"\36^ORWUU:B\0Z5H\MW&$+,O
M+)P#E3Q]*^.OCU_P5?UBQ\4V]G\+-#M5TF&$&ZNO%6G3+/-*>=JPB1#&JCNV
M2V>  .?TSVCT'Y5X%\=_V(?A=^T/XGMO$7B;3KZVUJ&,027FDW9MFN8U^ZLH
MP0VW)P< X.,XP #7F>3?#G_@J1\/]:\&:7>>)]&\0Z=X@DC(O;;2-&GO+5)
MQ'[N4?>4@ \\C.#G&:^O?!?BVQ\=^$]'\1::LZZ?JMI'>6XNHC%*$=0PW(>5
M.#R#TJ/P/X%T+X<>%--\->&]-ATG1-.B\FVM(1\J+DD\G))))))))))-;P %
M CAOBYXFU+P7H>GZ_9R[=.L-0MWU9/+W[K%F\N9ONL1Y8<2Y&#B,C(!->6Z=
M^T?J]I+<S/HESX@L;N2YU2W>T@ES;Z8DWD0[?*AD5V?RI9@TK1KM=1N]/H'5
M=*L]<TVZT_4+6&]L;J)H9[:X0/'*C##*RG@@@D8KG+[X2^#]2BT:*Y\.V$L>
MCP);6*&/ @A3;MB !Y0;$^0Y7Y1QQ0!X_P"&/CSXGE\+6CZS8Q,^H2ZD;+5+
M.X02LEO?F(+) T.Q/W94 AGSM.<$UM^(_C7XB/AP:M;Z39Z1I=Q=)]DNQJ"W
M-U)$E_'!)OMC&,;D9B"C/MR V&(KT[_A6WA?[-;V_P#8-CY%N9S%'Y7"&:3S
M)<?[S_,?4U%'\+/"45W>W*^'[$37DJSS,8L[G602 @=%_>*'.W&6 )R>: .4
M^%GQME^)-Y.I\-WNEV<EDNI6-U.DRBXA9L ,)88\/@J?D,B8/W\CGDX/'WBE
M?AE%\0V\66T5Q=K=RP>&[ZVB%HS*)A%:I(L:S"52B[F);)5QM (V^N^&OASX
M9\'ZG?ZCHVBVFGWU]@7%Q"GSNH9F"Y/10S,0HP 23BH;7X6^$[/6;S58= LD
MO;OS/.?R\JQD&)&V'Y0SY.X@ MDY)R: /&O /[0WBKQYI6FE]$L-+,$OAZ/4
M-0BO#)Y\E\L$DB10&+Y4V2D;F?(SQG&:^CJY70OA9X2\,VAMM+\/V-C 9+:4
MQPQ8&^W"B!NO6,*H7T"CTKJJ "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **,T
M9]C^5 !11GZ_@*,_7\J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y/XB_$-/
MAUIMO>2>'_$/B$32^5Y'AW2WOI4XSN94Y"^]=900#U&: /R\_P""@?[97C8:
MIX=\/^#_ /A+_AU9F W=TVH64NE7ER^_"A<G<8QCL0"<@YKW#]D?]LG6_$_P
M0TBX\5^%/'7B[6H'EMI=8T/P[)>0W(1B QD3 +X^]QUKUK]J#]CSP?\ M2VF
MDG7;J_T?5-,9A!J6F>7YOEG[T;!U(9<\CN#]:]!^#?P>\.? SP!IOA'PQ;20
MZ;9J3OG;?+-(>6D=N[,>3VH'I8ZG0=7&O:/9Z@MI=V N8EE%M?P&&>/(^ZZ'
ME6'<&N5^(/BW4O#.L:*MC%]KCFCNWDLQM5KAHXU9$#D?*23C/O7<@ =*R]=\
M+:1XFB\K5=.M]0C\N2+;<)N&UQM<?0C@T"/&K7]I'5;V6ZLH/"EBVL6%E-J5
M_9RZM)!]FMT&<-YMJK"4X;",JKP#NP0:S_#/[36J3:MXMN-9T:T'ARPU 6UE
M=6MP5E16M%GC64,,,SDE<J1@X&#UKTQO@/X!DMK>"3PO8S) Y=#*&=N< J6+
M$E<*HVDE< #'%'B3X-^']>O!+'9V]A'/=P7FH1V]LF;UH<>2&/\ #M*KRHS@
M 9Q0!P-Q^T_-I$>KW^K^%A9Z)I5['IUQ-;W[7-T9W@\U0L*PX*_PD[Q@\XQD
MCJ? 7QEO/&-AK;W/A>]TN]T^T%[% ZS 7*,K,JJ9HH3ORN#@%?1B*OZ-\#O#
M&F^,=>\2W%HNIZEJMV;HM=Q@K"3&(RJ@<$;01E@3R1G!KH?"/P\\-^ X+B'0
M-'M=+CN"#*($^]@8 R23@#@#H.PH \F3QKXJTCP+8^+Y?&5E>ZAJ>G7%W;^'
M=1M88K>60)YBI!)$OF#8 =VXR;O]GK5;6_C?XNGU3PG;PZ9:Z);S^)K;1[VX
M2X%S]K5K:22145H@44,JC<2&X/&.3ZCIWP9\$:3>WMW:>&-.MYKR*6"4I%A?
M+D_UBJN<(&_B"@9[U=A^&?A:WM[&!-#L_+L;I;ZV#(6,4ZJ5$H).=P5B,^AH
M \V^*'Q!\6V.F^.+OPYJ%GIXT"XLK4+>V)FWAS&TKKR.2) HSE1C.#5;6_B;
MXFTSQA'=)?&?2H]>LM$;1H;2,[DFMO,:9I,%PX;D8(7;QM/6O4KOP!I6HZEJ
M]Q=Q"[M=6CB6\L9E#0RO'C:Y'7.%4?\  13G^&_AB3Q5#XE;0[,ZY$H5+WR_
MG&%VJ>N,A?E#8R!QG% '">*?C9K.B>+M6TBP\*6U]:Z?>6E@;RYU4P,\MQ&'
M0B,0/\@R 3NSZ UA>'OVHI/%%E+=67ARU5+&>WM-3CN=86.2*:6<1 0J8LRJ
M"<[FV$XP!G->R7G@_1=0N9+BYTRVGGDEBG>1TR6>,8C8^ZCI7G/B#]FGPQK6
MMV%S!'%INFV[K*VGV]E <NLIEW)*REX]SG+;3SSC&3D X#6/VBM<T/XQZ1;R
MRI)X6U>"[6SMFB6.(.D\<,,TMSM)C1B6.3P2Z@ D@5L^*OVC-6M[*&:UT:WL
M;.[CO[BTO$OA/.5L60S+);F( >8"P&UR1QG!KUJ]^%OA+4UA%UX=L)_)L7TR
M/S(0=EJY!>(?[)(!(]J\_P#^&7/#\OB"\U.XNFF,GF)"JV-O&\44CHTL;.J@
MR A%3+#(&<DL<T >PZ9=B_T^VN@I43Q+* >HW '^M%300K;Q)&@VH@"JH[ =
M!10 ^BBB@ HHHH **** "BBB@ HHHH *#10>E !67K7BK1O#?V?^UM6L=+^T
M/Y</VVY2'S6_NKN(W'V%>?\ Q0\+?%C7-=MY_ WCK1O#&E+ $EM-1T/[;(\N
MXY</O&!C Q[5^??[6OP3^,<WQ-^W^)[:\\=FX@CCMM5T73'^S8 YB6%=WE$'
M)(_BSGGMC4FX+1'!B<3*A&\8-GZK(X< J001D$&G9KY ^!WPI_:*T;X4>'+.
M/X@:1X8CCM_W6D:OH!O+JTC+$HDDID&2%(^7^$$+_#7U5X7M=6LO#VFV^N7T
M.IZQ%;HEY>6\'D1SR@?,ZQY.T$]L\5<9.2U5CHI5'42;BUZFA=7<-C;RW%Q*
MD%O$I>265@J(H&223P !WKG=5^*/@_0[#3+W4?%.C6-GJD7GV%Q/?1+'=QX#
M;XF+8=<,IRN1AAZUE?&GPSKOC;P8WAW0Y(+8ZI<16U]=W WI#:;LS'9N4ON4
M%-H(^_G(Q7D_A[X<>.O 'CGP_=-H:^)-'T-]8AMGTJ6WL\07GV>:-4AEF^18
MY!-&%W<*J8R.EFY[5K?Q3\)>';73KF_\06$-OJ*^9:2+,)!-'P3*NS/[L @E
M_NC(R1FME/$FE2SV4*:G9O-?1F:UC6X0M<(%W%D&<LNT@Y&1@UX)X<\">+O
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MMA).9I&9P4W+,GEK\F,[6(SG':N7M/V@/$7BGPUJ/BZPO-*\.Z)I0B26TO\
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M6G21K*A5@&4\$$9!IU% "!<8YX':EHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @OXII[&
MXCMY_LUP\;+'/L#^6Q'#;3P<'G!ZU\Z?LIZ1K>A?$WXV67B+7_\ A)]6CU6R
M\[5/L26GG?N&Q^Z3Y5QTXKZ'U?['_9-[_:)C%AY+_:#*<)Y>T[MWMC-?,?[%
M8\$KXR^,@^'C:<WA+^U+/[(=*;=;G]PV[:?K0!]3T444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %-8'.0?RIU% 'B/[1'[,\7[0%QHTTWB"713IJNH"6PF\S<?=ACI7<_!
M_P"'"?"?X?:7X7CU!]26Q0J+EH_++Y.?N@G'7UKM"RJ,D@#U)I16:A'FYK:G
M)'"485WB(Q]]Z-Z_UT$"X[UG7GAO3K_6['5Y[<2:C8I)';3%F_=J^-^!G'.T
M<X[5I49Q6AUGGE[\ _!E]+*S6%W#%,)$FMK74;B""9'=G='CC=0REF8[3QR1
MTJ37O@7X/\0+/'/ITMK:W5LMG>6FGW4MK#>0JNU4F2-E#@#@9YQQDCBN_HH
MYJ[^&_AV_M)+6XTU);>33AI+1L[8-J,D1]>V3SU]ZYX_ +PBVG"V\G4!.)&E
M_M%=1G%X2R!&'G!MVTH NWI@#'05Z-1F@#E9_A[8Q#PW_9C?V8-!D_T94!93
M$5VM$<GH0%.>3E1576O@_P"%]<TXV<UC)"OVN:^6:VN)(IHYI<^:RR*<C<&(
M(Z8/L*[2C(H P;?P)H=G9Z/:0:?%#;:0NVQBC)581MV\8Z\>M<3XU^ .C:Y;
M6,NCQV^F:G8B&."><2R 11[]J921)$_UC?,CJ3T.0<5ZID44 ><_#OX'Z'X#
M\%+X?8-?B18A<3$M'YAC(9-J[CL4%00 >W.<FN8^(7[,]AXRU25K.\CTS3;X
M 7T&R5Y#^^\US&1(%PQS\DBLBDEE4,37MN:,T <[X(\&Q>"]-N+=)VNIKFYD
MNIIF7;N=SG@9. !@#Z5T5%% !1110 4444 %%%% !1110 4444 %%%% !0>:
M** $V#N ?J*^<_CC^P]X2^/OCE_%'B+Q#X@AN1;QVL-K9RPK!!&N3A08R>69
MF))Y)] ,?1M(9%!QD5K2JSHRYJ;LQ-)[G(_"CX;6GPE\ :1X2LK^[U2QTN,P
MV\^HE6F\O<2JDJ "%S@<= !77@8I P/>EK.3<FY/=C*6HZ)8:O-92WMI%<R6
M4XN;9I5R890K*'7T.&89]S6;+X \.3WVJ7DNBV4EUJD30WLSQ M<(RJC*Y[@
MK&@/J%7TJQXM\3V?@SPWJ6MZ@7^QV$#SR+&,NP49VJ.['@ =R17 'X_6UZGA
M2/2/#.L:OJ/B"WNYUT]'MH);(VS*EQ%/YLJJ)$=]A4$\JW;FD!U.F?";P=HN
MJ6>I6/AO3K6^LBAMIHH0&@*0?9U*=E(A/EY'\/'2MZVT'3[/5;W4H+*"+4+U
M(X[FY1 ))ECW>6&/<+O?'IN->?6_QL?Q#-;VOACPQJ6LZ@()+F^M9Y([1K%8
MY7A:)RQ(,QDCD"J/E;86WA<$WX_C3I/_  D7AW1KC3-<T^ZUK3Y-1C?4-/>W
MCMTCCWO'*SXVR@<%!DC!)XYH OZ?\'/!6E>(CKMKX9TV'5OM,EX+I8?F6>3/
MF2@'@.V3E@ 3D\\UU-]IEKJ<*17=O'<1)+',J2+D!T8.C?4,H(/J!7D-M^T_
MHLVC'4)- UFU^T0VMUIL<[6RKJ$%S(4BE24S>6@R,L)&4JI4D<XKLKSXFV]I
MX(L/$+V,T;:A+#;VUC+<0EY)991'&!)&[QD$D-N5B-O- &AXL^'VD>-+JQFU
M2VCN5MUFB>&6-72>&5"LD3@CE3\I^J"DTSX9^%M(L$L[70K*.W595P8]Y82*
M%DW,Q);<H ))/  [5R_A+]H#PWXGTR^U6>6+1M(@N$MH;R\OK=_M+.[)'B..
M1G0OM!57"LP88'6M2#XY> [BWNYU\3V*PVL+3RR2%D 56". 6 W,KLJ,BY96
M958 D"@#/\:? ?P]XGM&CL;:RT2:5X3<31:;;SFX2*-HXD82J>$5SM(QCH<J
M2#MZ)\)_"VA^'=+T6+2+:XM--E@N8#<QJ[">$*(YB<8WC8N"  ,#   %4M1^
M,?A]-"MM5TJZBURWFN)(-MI* RF)&><$-T:-48LIP01@X/%/N_C7X-TO3(;W
M4-=MK%)/+#QRDEH6:+S<2!0=NU#N8GA1R2!0!S'B?]F/PIXE\1Z?J#06]K9V
MDT5R+"+3[<CS$G:<%92N]<R,Q(R1R=NW)SZ3X4\-6WA'0X-,M7>5(V>1Y9,;
MY9'=G=VP ,LS,?QJEX/\=Z;XT>_6PFCE^RM&=T4F])898Q)#,C8 *NIR,>AK
M<LM2M=2@::UN([B)9'B9XVR ZL59?J""#]* +%%>;:;\?_"5W>>*DOKPZ#:>
M'I L]_JQ6"">/<8VFB).3&LJM&6('S*0,\&JNJ?M)^![#5],TR/4OM-YJ$-W
M+$O$(C-N@>1)?-*F)MK*1N X(/0@T >IT5R?BWQZ?#>FZ3/:Z/=ZY<ZI.EO:
MVEE+"C.60OG?(ZI@ $YS],UQNE?M$0^(KE+/1?"6LZKJ,7VH7UG%/:(UFUO(
MD<B%GF".<R+C8S#GJ""  >O45RFD?$?2M>\ Q^+[!+RZTQX7F\F"W:6X!1BK
MQ^6F29%=64J,\J:N^ _&-I\0/".F>(;"&YMK/4(O-CBO$"3(,D8=03@\=.U
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M_P $+;3=/\#6MQJ]SJ \,6-Q8[Y8E#7@EA\IF?'W2!SA>.W KR34/C9X_P!
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M#KFE2)=1WFDSV\MW:D$A&\R%MZ@\K@G!&0<C(KTJ@ HHHH 3;[FC'N?SI:*
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M+3"X-E;1V_FA=H?:H&<9.,XZ9K&"J<\N;;H<V$AF#Q-9UFU!_#L_N[?,\O\
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M2K)=S[MQ&]E !QG XZ 4 ?;5%%% !1110 4444 %%%% !1110 4444 %%%%
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MBOR.^('B'6/&OQYUG5KS[;'K%]KAW*&*W$9,H4("O(91\O'I7ZY_#_X$^*_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8 YX#=:^G/AS\+?"WPE\.0Z%X2T6UT73(\'RK=?FD;^\['+.WNQ-=?)3P_\
M$]Z7;HO5]?1?>&KV/G.W_823XHG^W?C;XQUCQAXJF&1'IMP;6QL%/_+*!-IX
M]^,^G>O4/@A^RCX(_9\UF_U'PD^KQR7\(AN(KV],T; '(.W:.1V.>YKV;&**
MB>*KU(N#E[O;I]VP^5(****Y1A1110 4444 %%%% !1110 4444 %-DSL.W&
M['&:=39=WEMLQNQQNZ9H \,\)?M7>'KKSM/\2Z9XAT;7;>_FL'BM_"^JSVLA
M60JDB3+;%"C#!R2,'/;!KW-&W@$=",\U\@WD4UL;NY\SXE2?&<:DR6V1J3:>
M 9OD 51]B-IY>,L1D<Y(:OKRWWB)1*5,N!OV],]\>U $E%%% !1110!%>326
M]I-+% US*B%D@0@-(0.%!) !/3D@5\[?LMZSJ&O_ !2^-M]JN@W?AF^DU2Q\
MS3+Z:&:6+$#8RT+NAS[,:^CJ\)^!'_)<?CM_V%;#_P!)VH ]VI&&>II::[[>
MM 'QO^W3\6O!_A?5?#_AWQ7K/B72H"HOHH]#^R[)7#85G\T@DJ>1VK@]"TO4
M/VF-?BD\ >(M?U1;FT2WUCQCK<D8&B1'B2VM!%\C7$B@9*8" \G)KYC_ ."E
M7C"+Q?\ M!_;;?5([S2X;06=O&"!Y#(Q$BGU);GOTK]!/^"<5G>VG[*/A=+T
MX<RSLB\95"_R@C'!^O-<\*4.?VRU_+R.FI7QCI+!UJEZ<6[1Y8JSO?=+F>JU
M3;U2TT1Y1H7_  34U#PKXST_7]*\4Z5'<:;<I-:RRV4IF55;(#,&Y..I]Z^\
M($;R5$NTR8&XJ, GOBI,'UI:]*OB:F)M[2VG9)?D<,*<:>Q!=V<-W;26\T8D
MAE4HZ-R&4C!!KQ6Y^#MG\%X+?Q'X L9(FLBYU+30Q<W]L6W,/=TZI],5[B1F
MD*Y'-<$Z<9ZM:]^QZ>&QE;#)PC)\DOBC?27JOF[=NA\C_M;_  T\2_M :3X,
MU3P'IG]NV2))*\BW$4.P,!@'S&7GL0.A%>I_LS_"J?P3\+- M/$^@VEMXDLE
MEC,DJ132Q(SYVB1<\'K@&N$^,OQ+?]E?4KN31UM=0L=?8W-OH\DF&M+C=^\D
M S_JG'8=&KW3X8_$C2?BCX-L/$&D2!X+A/WD606AD'WD;T(-<U.=-UG%OWTM
M49XKAB6%:SN$6Z57W8MVMI;1K=-6M?9V=CE/%W[*_P ,_'/B:[\0:UX?DN]6
MNG#S3C4+B,,PZ':K@#IV%>I6EG%8VL-O"NR&%%C1<DX4# &?H*E#9]J7/-=B
MBEJD>;3H4:4G*G!)O>R2OZA1115'0%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MRTIXTTR]\364XABML8"VXE7:K*P.<<@$8QS7W7H>A:?X9TNWTS2;&WTS3K9
MD-K:1"*.-1V"K@"M#/O70\9&-&5"C#E3ZWU^8N76[$Q1117EEA1113 ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"O)?VFSI=Y\-H]'U'3+O6[G6-3L['3=,LM3?39+F\,F^(?:4^:(+Y;2%P"0(
M\@$X%>M5Y3^TC=0CP%::=)X=D\17&JZM9V%JBW[Z>MI.TFZ.Y:[C5G@\LID.
MJD[BJ_Q4 8_P6@U'PGXXU'PWXBM]7MM6GT\7EE)<>*KC6[*ZMHY%21H_/5'B
MD1Y(PP*\AU(8\A?;J\2^ 7PWU3P?KFL:CKMLMYJEU;10'6KSQ=/KM[)&K,1"
M?,MX4BC!.[Y!\Q/S9P#7MM !1110 4444 %%%% #)HDGA>.10\;J596Z$'J*
M^./V:/!^A^ OVW_CMH?AS2K31-'MM(T?R;&RB$<4>02V%'3))/XU]BW8E:VE
M$#*DQ0A&<94-C@D>F:^*_P!DRS\76/[9GQQA\<ZCI6J^)UTC2?M5WHML]O:N
M/FV!4<E@0N <GDY- S[9HHKYS_;@_:?U']F#X6V>KZ)I5OJ>MZM?#3K1KQCY
M%NVQI&D=5P7PJ$!01DD9.*!'T9D>M>)?';]KCP+\")8]*O;F?Q#XQNB%LO"N
MAI]IU"X<_=!0?ZL'U;'L#7Q[\"?VL/CO^V5._P .](U+0/!%W#$UWJWBZPM9
M/M*6FX+L@A+,JRDMC=N''3!!)^R/@-^R?X"_9]2>[T2SGU7Q-=G-[XFUJ3[3
MJ-RQ^\3(1\H/HH&>^:![;GB\GP1^,?[7[Q7GQCU%_AK\.W821> -!GS>72=1
M]MG_ "^7V^ZIYKZJ^'WPX\,_"OPQ:^'?"FBVFA:-;#Y+6T3:">[,>KL>[,23
MZUT8.!BO ?VP_P!HVZ^ 'P^M[C18K6?Q'J<XMK-+HAEA&"S3-'D%@ ,#MEAD
MU,I**NS*I4C2@YRV1[_QZY^II>_M7Y]_LZ_\%#M0EUF^L/BO=1/8-"9;74M.
MTYC(D@(_=O'$#E2"<$#@CGK7T=I/[<7P1U::6(>/;*P>,9(U.*6TS[#S$&3[
M=:B-6$E>YRTL;0K14E)+U/=J*\[T;]HKX8>((C)8?$#PW.@ ;)U.)."<?Q$>
ME:?BCXP^#?!_A"[\4:EXBL%T.U0.]U;SK.&S]T*$)+%CP .M7S+N=7M(-<R:
ML=C1FOG'1O\ @H#\&]6T6_U"77+O2WM6"BQO[)UN;C/3R47=OY]#QWQ6/)\8
MOC7\<"T/PT\$KX$T!P=OB?QDA65U)X>&V /. 3R&'3GUGVD>FIA]:I/X'S>F
MO]?,^C_$_B[1?!>D2ZIKVK6>CZ?$"6N;V=8HQ^+'D^PYKY[U']L&_P#B!>RZ
M3\%/!6H>/KI6$;:Y=(UII,!.<EI& 9L>G'7KZWO"?[%N@W.K1^(/B;KNI?%/
MQ(,,)=:D(LX6SG$=NIV[>G#9''0=OH33M,M=)LXK2RMH;2UB&V."WC$<:#T"
MC 'X4O>?D%JU3^ZOO?\ DOQ/F<?LO>-_C#+'>?&GQ_<W]D6$G_")^&";33DX
M^Z[_ 'Y.O/\ /IB[J?\ P3Z^#FH:_:ZE'HU_I\$ 4-IEE?,EK+M_O*06Y[[6
M&?QKZ3Z#'6LB^\7:3IGB'3-#N;V*'5M365[.T9OWDXC :0J.^T$$TU3B^EP^
MJT?M1N^[U9HV-C;Z;9P6MK"D%O!&L<42#"HJC  'H  *GK(UWQ?H?A>W,^LZ
MSIVD0 A3)?W<<"@GH,N1S7D_B?\ ;8^"7A*9X;SXA:5=7*2>4;?2R][+N_W8
ME8X]^E=$*52I\$6_1'5=(]OH)P/:OE]?VZ[+Q,RIX"^%GC_QN69U6:WTG[+;
MMM[B20XP>/< ]*^3OVB/V]/B'?\ C[2+*SL4^&%]H+N;FT^W1WTHDECV_OAM
M"Y5')V$$AB#P0*[Z.75ZTN6UO5_IO^!+FD?H/\9?VA?!/P)TD7?BC5EBNI1_
MHNEVW[V\NF/01Q#DY]3@>]>'/HWQE_:Y7SM1N;_X+_#.0@II\/\ R&]4C/\
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M?^6Q^<?PG_8<_: ^$/BB3Q#X>\8>%=(U.*U=(P))+J.XR0?)=6A "MC[V<C
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MG=_)O_AO0^E^O8/-/W6-IQHR^S.G%12\IPCHUYI<R_O+0]?4^C9 /I3Z\"\
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MC[@UT\UG#<-&TL:2-&V]"Z@[3ZC/0^]>5Q(/@UXRV+N7P=KUP=O4KIUXWO\
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MX;/^'_\ S[>)O_!!<_X5[QSZFCGU-=_LZ_\ .ON_X)\;]:RG_H%G_P"#5_\
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MW-YJUI-<1D%ECBB1$EC(R[,68L<!0 "3D 'K1Z5\F_!3_D_[]H#_ +!&C?\
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M)/8>M9-O\*+#1X-)O=.L+"RUNSN(YI[R*+YY5#9E7=CJRDCIWKK?^$MT,?\
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M_P#@7'_\50!K45D_\)=H><?VSI__ (%Q_P#Q5'_"7:&/^8SI_P#X%Q__ !5
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M!&17AOP)X^./QVX/_(4L.Q_Y]VH ]VHHS[-^1HS[-^1H **,^S?D:,^S?D:
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MS\L5 !/U]: /E_P/^PCX-TOP?J-IXBTBUU/7I;BZ>VO8]3OBL<3,3 I)D'*
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M  _;V]S;W<$FHR/J=\!<0J/WJ#$O5CZX^HKZ3HH ^:_$7[#7@"\\7>&+O2M
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MRTD2.S>4"6.8E)5&#@&O5*IZ1HUAH&FV^GZ996^G6%LGEPVMK$L442^BJH
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MOCN0"<5N4 %%%% &=XAN-0M-%O9M)M8[[4TB8VUO-)Y:/)CY0S=AGK7@U_\
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M>O"'[5=_K4/A#5=<\$?\(YX9\3R7D5IJ+ZQ'/+&UO%+*SR0B,;8V6"3#;\C
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MW<Z0NL11VTK*%*S-*(3M)[*J'!.">] 'TU17SQJ'[7]@EI:MI^BVLUY%I_\
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>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>adag-20211231x20f030.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f030.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &/ JX# 2(  A$! Q$!_\0
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MFP':,\DH">K  '[EQFC'&.WI773Q')!0E%22=U<QE2YGS)VN?$WQ9^&OQ/\
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M<<X&X'CM70?B?SHQ6-7$<ZC&,;*-_P ?4TA3Y6VW>Y^>7A?Q;\3/AM^S==_
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M_P#"$?M:_P#11?A]_P""J;_XW1_PA'[6O_11?A]_X*IO_C=?45%'UI_R1_\
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MT_Y(_P#@*#V2[O[SY<_X0C]K7_HHOP^_\%,W_P ;I?\ A"/VM?\ HHOP^_\
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M?6G_ "1_\!0>R7=_>?+O_"$?M:_]%%^'W_@JF_\ C=)_PA'[6O\ T47X??\
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MSD#   48JSIG[%WABTU'4=3U#Q7XM\0:MJ'AF?PG/?:M>PRRFRD  "XB 5D
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M49'K10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[4O\*_)!1116!V'G'Q?^,0^%[Z/9VVDC6=5U9V2VMY-3M;"/*LBX:2>1>27
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MSR27]G!+)",!80PN'C6.7=\R@@Y1\^H_"/QEXHU#6_$6BZT\Y?3-5A@"Z_\
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M\VZRV[!51+"N ."#SUQU_C[Q?9> ?!.N^)=1D$5CI-E->S,1GY8T+8 [DX
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MH=3UZ[FBTW1=,7K>W\S;((O8;CECV56-=\W -> ^&;B'XP?&?5/'M[*B^"/
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M3;"*-,X_?SDXZ@-^)?AZ+PKH]EHOC?6(KKQ)XPD_X2?XB:KC=#:Z-8A7:RA
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MMWT/17G)/+PVV^YN">.9Y\MN^8 @-5O3?$?Q"DU#2[6\\+^%%L99U;3O!O\
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M*C%R=HJY]&T5Q-Y\:?!-C%YC^(K*09 Q"_F-S[*":XG7?VI- M6,>F6-UJ#
MX\R3$2=>3SD_I7%5S'"45>=1???\CIAA*]3X8,]LJ*YNHK2(R32I%&!DNY
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MJ66."&UOQI\8WXVQ)AV/GN%0^6P(YX^JK[0;"U\.?8+31;">VLT5[33C#''
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MK><86R?X48=ZT%_9R2355NT^(_CMK+R#%]B&M90R;\^9OV;LXRN.GXUREO\
M#?6-0_:NN]:C\.:EHWA^33;RUU/41=,BWYD6,12),DQ8XVL%AV)Y)#N#F3GO
MOV7/#>L^$/V?O VC^(;6XL]:L].6.[@NVW2I)O8G><G)YR3D]: ,RW_9UBL9
MK^>Z^)'CN>WEE#PQRZWL6V38H*!@F6&X,V6Y^;'05UOP7\,:_P"!/AKH6@^+
M?$/_  DWB&W$RSZH[$M<YE=T^\ 251D7I_#6%^TOX>F\3_#"XL8/#USXD=YT
M_P!'MHUG,)VL!,UNTL8N%4D9B+8.0<';7B'A7X7_ !=T[XP? K4M8T>"[T;P
M[I1TZYNGU>2::U#:<$N&G!0AI6E PVYL[0,KR6 /L6BBB@ HHHH **** ,#X
M@_\ (A>)/^P9=?\ HEZ_*:+_ %4?7[@_E7ZL_$'_ )$+Q)_V#+K_ -$O7Y3P
M_P"JC]=@_E7U&2[5/E^I^><5_'1_[>_07-+2FBOI3X(0DBBCZ4M "=*,TO>B
M@!*53@CZT=\4+]\?6@-C],OV>_\ DB'@C_L$P?\ H->A5Y[^SW_R1#P/_P!@
MF#_T&O0J_.:_\6?JS]TP7^[4O\*_)!1116!V!1110 4444 %%%% !1110!Y=
M\6_B#XQ\->+/"^@>#-"TK6[[5+:^O9DU6_>T CMO(RD;+&X+MYV!NP!CDURF
MF?MJ?#F\T>VO)[N]@GDT+^W6MULI)"$$'GR0HP7$DJ1AW*+D[48] :]"^(_P
MATSXEZEI%]>:IK.E7.FQ7$"/H]V+<RPS^7YL;G:3M/E)]T@C'!KCI?V4?!=C
MXE@\1:9;W'VVQA=+'2[NY+Z<A-@UCM9"I8H86"D;B."0,EL@%K7/VK/A_H5Q
MY4FH7EWG4#IZ26-C+<)(5@AFDE0HIW1(D\>YQP"<=172^._C;X5^''B#P]HV
MMWDUO=ZY(([9H[9Y(E!=45I'4$(I=T4%B,EA7F_AG]C;PS#\(/!?@WQ!>WM_
M<Z"'FN+VRG,7VRYD8-,[!@3R0%5^)$4 *Z\Y[;XC?L]>&?B?XGTW7M6N-4AO
M;"&.");2ZVQE8[A+B,LK*W(D122,;APVX 8 /-/!?[;>D:OXIU+3O$GA_5/"
MNFP0:K?QZG?6LR1);6=VEK^\W(,2/(S#:NX!BB9WMBO0_!7[2_@GX@>(=*T3
M0[F_O=1U"">?RET^4?9A"^R47!*XA*L5&'QG>N,[A3-:_9A\$>(;A9;^"]N%
M\C4;=X6N?DDCO+P7LH88ZK<*DB$8*E1UK9\%_!'P_P"!O$$6MV4U_<ZHEA+I
M[W%Y.',L<DXF9F 4#=N4 8   P!0!Y9>_MG:=:ZQ C^'-4MM+@\4ZKX;U"66
MUE>X46=C)<F>&%$+.I* '^Z,DUZ1IG[1'@;6?']OX/L]7,VL3Q1/%B!Q"[R0
M"X2(2$;?,,)639G.U@:JW'[-7@^YUB[U%CJ(EN-6O]:,8NOD2XO+)K.X*@KD
M*T;LV,\,<CCBKWASX!>%?"OBF#7M.2\BNXTB#1M<9BFDBMDM4F=<<N(8T7J%
M^4'&>: .$OOVI9-(^*'BGPU?Z+;V]OHJ3M':M>,-3O5AMGG,T%N8PLT;A0JB
M-V<')90*N^$?VP_ OB2S\-BY>_TG4]:T-=;CL;JRDRBFU:Z\K?MVF3R8Y' !
M^95R."*ZS4/V?_"^J^,3XANFU*=OM$MZNFO>L;..ZD@:![A(SRCF)W7"L%^<
MMMW'-<GI7[&O@'2+[2[N*76II=-L(].M_M%\'"Q)936*?P9R+>=DP"!E5;&[
M)(!K?";]I31/C'XWUG0=%TG6[>WL-(L=8BU+4=/DMHKF&Y,FPJ'4'&$R">&^
M;&=AKF_'_P"V5X5T/PC=:EX8MKWQ1J'VFQ@M+>*SG2.YCNKE;:.Y1]AWP>82
MN] VY@%&2RY])\&_!O0? >OC5M)DOH[@Z'9>'Y(I9]\4MO:;_(9EQ_K%$D@W
M C(<\=,<Q8?LJ>!=-L!96\>IK:Q26)M(GOWD6RAM+Q+R"WA#9VQ":-21R2!M
MR    'Q9^*OC+PIXTBT?PIX>TK7(K70[C7KY;^_>VF>**54,4 $;*9&!.-Y5
M<XR0.:=I?[5OPXU."WG_ +;:"VFM1<"ZEMI1;AOL@O&A\W;L,RVY\PQ@[MO.
M*V_B+\#M$^)FMQ:GJ6HZQ9M_9\VE7-OIMY]GCO+65MSQ2X4M@GNK*?>J%]^S
M5X)O];GU%K:^A$DCW*V=M?RPV\-RUK]D-S&BD%)?(_=A@>.2 "2: .6NOVO?
M"B6FF:U&]Q#X=;3=7U&^:\L;B*[BCL8[>1BD1C^8%+@-R1D%=N[G&WJ?[5OP
M^TKPU+K,UYJ)2&6]BFLH]+N&O(39JK71D@V;T6,21EF(P/,3GD5F)^QK\/U\
M,R:&S:L]I)9ZI8NWVI58QW\<,=Q@*@53MMXPNU0 0202Q-9/Q?\ V41XLL;U
M?"NI)I-[JEUJLU_=7DDOF!=0CB2X6-D_@_<1DQ,#N*K\ZXY /?-"UFV\1:-8
M:I9LS6E];QW,)==I*.H920>G!'%7JR_"V@Q^%O#6DZ-%*TT6GVD-HDCC!81H
MJ D>X7-:E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % &***
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MJ_\ 0\Z__P!\VO\ \9H [*BN-_X0+5?^AXU__OFU_P#C-'_"!:K_ -#QK_\
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M:_\ QF@#LJ*XW_A M5_Z'G7_ /OFU_\ C-'_  @6J_\ 0\Z__P!\VO\ \9H
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M '945QO_  @6J_\ 0\Z__P!\VO\ \9H_X0+5?^AXU_\ [YM?_C- '945QO\
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M;>#QJO\ ;7DWUY>?:_(\G/GSO+MV[C]W?C.><5ZC110 4444 %%%% !1110
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M.7K2#GO2KP10RE<_3']GK_DB'@?_ +!,'_H->A5Y[^SU_P D0\#_ /8)@_\
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M]@8[E+9S=#;^Y'G2(F7P#G(XK>\%?&SPMX]\0ZOHVF7,ZWFG1&Y/VNW>!+B
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M() A8!R"0N>2!2A@3@$$T +11D9ZT9!H **** "BBB@ HHHH **** "BBB@
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M5@FMO$^I7<YDN-+M;-[V80V^%VR7;+&H17;(!W'(P#@D?2U?-/[8^B-XIN_
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MOIEQ'J"*!F>+N8]Q90>^TD<8I7MH*ZO8[&BBBF,**** "BBB@ HHHH ****
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MHFM:OI=]KB6MUI<%Q/.9(G$;" (9UC?&V1T\Q RJ206 QFMSX37=M?\ PO\
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MNM-D^,-K>W[ZI=P^/KQ9;R2-8VF;['9?,57@>G'I7O5 !1110 4444 %%%%
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M9#;W$0D5'(P67/3/&:KZ'\:?%_AW7==UNSU5AJ^M($N[R1 [XSGY<\+CH/3
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M.3CICTM45%"@  < #M2XQ2Y>K&H/>3O^044459J%%%% !1110 4444 %%%%
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MAV:3\*6C&:](\$*%'(/O1BE4?,* /TQ_9[_Y(AX'_P"P3!_Z#7H5>>_L]_\
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M78WCAZT5:Z_KY%*T\+VGBF6*\TKX:?#BZC<Y@^U:X))0!V.Q&7KSP2*[?0_
MNN6=O$R^!_AKILJ.66)&,I0YSG?Y.<]Z@\*_LE_ _5+!]7T+P[:W=K?LTT%Y
M:7TI$8*A"(F5_E&5)QSR3]*K>-/V7_ABVCZ;X8@U&?PYK=W+;K:79U6>2[N!
M$ZO(H5I0&,B1NK$#@,Q'2FH/^O\ AC2%&<7=V_KY'>17GQ#@15B@\&Q(H"@1
MW<R@#TXCJ3^T_B/_ '/")'O?3_\ QNN1T/X#_!KQCJ3S:-$VH'3_ #(IX+36
M;IHPS-CYQYG)4QL!SQ\U6M1_9K^%'A6WU35]3M);.Q<K))+>ZU<K!; *%^7,
MHV@GDY)R35V?]?\ #&W+4[_C_P  V+SQ#\4[1T%MI'@_4 1DDZO+#M/I@Q'-
M,C\=?$RUD(O/!FB72%1M.FZZAVGON\Q4_#&:\[\.?L[?"/0M T+P=K/B*76?
M$=_!YUOJ,FL3P7E\C.TB.BK*1]T;1@<A37>W7[*OPUEO;6Z.D7<2VX?,2:M=
MB.3< /G'F\XQD<C%*TOZ_P"&#EJ7W_'_ ( QOC3XNTM?,U7X8ZFL))5?[-O[
M6[?/7E5?('O]*LC]I;PO9.8];LM;\.R)'YDC:EIDJ1)P#CS "I.#V/8UYW8_
M"KX%QZCXE\6/XCL[GPU;6UM:S6C:U,+;3ID:5GE,GG9W2AU!!XQ$,=37;G]D
MOX</HD^GK8:F!-YA%TNLW?G)O8M\K>9@8S@<< #K3]_H%JW1_P!?<CJ]!^.?
M@+Q,\,>G^+-*FGER5@-TJR<$CE2<CI77P:Q8W,2RPWD$L;='256!_$&OFCQE
M^RW\#-4\;>&-%=M/TS7[>]CNY]/DNGFN-4B\F4"!R\FX!L&3(Y/E>F:ZOPI^
MSE\&-6N]2?0;%+J+3I3IEU9V.KW'D6MPAWLA19/EDQ(N1Z;>*:YNHXNM]I+[
MW_D>X?VA:_\ /Q%_WV*0ZE;#_EO%_P!]BOGWX@?LZ_"/PAX*U2+4M1F\,-J0
MGAM=9O=8N"]K+(K,IC#2@'8 6"GLO)K*TGX2_ +6-2TCP.=?AU7Q5:^6DMO!
MK]PEU>211;G+HLO1AEV _/%/4T3GU7X_\ ^F/[2M?^?F+_OL5)%<1SJ6C=9%
M!QE3FO$[S]DGX2:;/<:O=Z1=V]K!;'S5EUR]6"-5RS2']]P0.IST%,^$<_PP
M^#^AZ[=Z-XWLI?#>O:ZTMHMS?F6.UE%O#$UM&[NS'F/S#D\&0]JHT/<Z* P8
M9!S10 4444 %%%% !1110!S'Q0UK4/#?PX\4:MI,8FU2QTRXN;2,KNWRI&S(
MN.^6 %>1_!3P+>>'?'\FHW'PAN?"TEQ!,KZU>^(TU)HLMN,:(9G*!VZ[ !\H
MSP!7T'C-% !1110 4CG"GZ5\Y_%+XK>+= ^-D&BV-P;6!+G0(=/TGRU;^UXK
MJ[DCOY<GYAY$2[N.FW)X->]>)K"WU3P]J5I=74UG:S6\B2W-O,8I(T*G+*X^
MZ0.<]J /G_X*_$_PGX'\5_&BQU_Q%INCWDOCR[G2"]N5B=HS9V8# $]"589]
MC77:A^V!\)-.>='\96,TD.[*6X:1FQG.T <].WM7@7P^_9*^#OQAU3Q[=)XS
M7QEJESJ#75O=V.J?:)K.UDA18?.R/F?>DK>A&!VKUB']BW0+;P_86<?BGQ%'
MJ4"VZS:E'=*IGV,AE_=[<+Y@5AP?EW9&<5#YNA@U5;T:7WO_ "/+O$/_  4+
MT;Q+J4EAHMR_A'2U;#ZSJ6GRW4[#'_+*W08_%V'TJYX0^,/P;GNDUQ6UKXC>
M(D):&_UI T@<$EA#%(52+!)/"CIUX%:^N?LX?#N;Q,T__";2KX3TN*ZTW7[.
M;5E\P7L@@:W0ML^7$9ERI.3YJGM4VF_\$Z_A+J%W>:@9-0U'2+Z&!K.WCNP%
MA !W,LJC+A\J>V,<=:SY9]SE=&O>[DG\O^'1WUG^TQ%J<"30^!-?FA/W9 MN
M5./3]Y6==?$3P]K<CR7'P:O;Z1EVL[Z=9R-@YX)W9[FO+]<_X)V_#'2O!D_A
MZVUB;_A.[^SNH]*O[Z\\H/<['>-S",Y5!@D#.0A]:WO#7[$7P<\0-;3^&=7O
M62PN3%JB:;JS.)R(W4Q,5(*8=E?//W,=S0U4_K_A@<<5UM_7R.LM(]#\&ZL-
M5@^!GD3YVP76G+9W$HQR#M#G9P!SZ\5V5C\?!]DFN+_P/XLT^.'ER=.,Q"\?
M-B,L>IQCK7G>H_L3_#S0M2NM;O\ 7]>LO#EM8;9+.;69DCA=6+-.92^0-N%V
MXQQG-9?@/]F?P5X:OKBUN_'6HIK>MW-U/H36'B"99&T]R&@4*6^<JN"3WQ32
MFAQC7C\*2^[_ "/7[/\ :/\ "<_F?:8-;TI4&0VHZ/<0*WKM+)SCO38_VGOA
MQ,%,?B*.0NP556&0EB>@ VUS(_930:!I-I_PL+QC_:5LULUYJ7]JR9O A4S#
MR\X3S0&'!.W=QG%87BOP'X<T+7K?43\5=0TOPIH'G6WB.&Z\0-O2>5(C:*7_
M (",L2#R=PI^^:WQ'D>@G]H&UU#SAH7A#Q7KK0L QATJ2)<'.&#2;0P..WM3
M1XZ^*.J%?[/^'5KIR'#;]:UB-/E(!QMB#D-D]"!TK-T#X 65S=WVIKX]\4:I
MI-_Y,VGP1ZJP2WC\L [9!GS YR^3C&<"N.\>?!Q?#OA)_#EM\6]6L?'^L?:$
MT2\U75C&'D,A9%\H9W!$*IQUVYZFCW@M6>_Y_P# /0%\%?%'Q$C#6/'=AH$>
M\_NO#VG;W*<$?O9CP>WW",58B_9T\*W<HGU^;5?%EP&9RVLZA))&2P^;]TI6
M/&<G!4@=JY;2_A+H'C<VX\/?$S7IWTJ^\O55LM9,_FE$='@;_GG\Y#;AS\F.
MYK0U;X'Z3X;N=0US5?'WB:ST"&S0-!<:PR1P.K.7F,IY^8,B[<8&SCK19]4'
M)+K&_J_^ >JZ#X3T3PM;^1HVDV.E18 *V=ND6<# SM'/XUJJ H-?+VC>$/#5
MKJ-SI>L_&"^EU#Q'>//X7CM]=;S/L4BHD("_\M&$BRG/?@=J[F\_9L:XT"RM
M(/'_ (LMM1B:W,^HC4&8SA&4RCRSPOF*&'!^7=D9Q3NUT-+S6BBOO_X![3D9
MZTN17S5J'@CPTGC.:ZB^*FH0^&M!M+B'7[-_$#>=#=N\!MV+?PA5\X$'J9%]
M*ZO0?@)8:A=W>JP^/O$^JZ-?+$UC!#JS;( JD.1(,[]YYYZ8Q3O+L'-4_E_'
M_@'M611D5\T^+O@[;^%O!'_"//\ %K5[?Q[JEO/;:-J.J:L81-=D,8F\D9R%
M)4$#KM]371M\#],U[5K>WTKXB^)(I='NE_M>S@U<S-*&A;;"YZQ<LKYZ_+C'
M-%Y=A\U3^7\?^ >Y[A0#FO#=<_9ZTVPU&?6=0^(/BNRT&WL]KVCZPT:1R!B3
M.TO7[N%VXQQGO5CX-2V?PJ\+3#Q%\0+;7-,\1>(Y?^$;O;V_\UI()MHM[57;
M&]QM;@=S5(T5[:GM5%%%,H**** "BBB@# ^(/_(A>)/^P9=?^B6K\IX3^YC_
M -T?RK]6/B#_ ,B%XD_[!EU_Z):ORGB_U,?^Z/Y5]3DNU3Y?J?G?%;M*C_V]
M^@[BM_PQX]\2>#"W]AZW>Z8K?>2"7"$^NTY&??%8%%?1RC&2M)7/@X594Y<T
M&T_(V/$?C#7/%UPL^M:M=ZI(OW3<RE@OT'0?@*Q^E'2DHC%15DK!*HYOFD[L
M=G-)1BBJ(YA<T+U%)3DZCZTF4G=GZ8_L]<? _P #_P#8)@_]!KT*O/?V>O\
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M,^;G9.1T&<]:^K** ,+P)I-[H/@KP_INHS"XU"STZWMKF;>7WRI$JNVX\G+
=G)ZUNT44 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>adag-20211231x20f031.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f031.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %Z =H# 2(  A$! Q$!_\0
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MDBX\@Q.N_/*GAAQ\N.* -"[_ &E[63X2:EXUL=&FG>#6)-#MM/EE53<7 N!
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M:"%&!_#GO0(^IJ*/7ZT4#"BBB@ HHHH .M%%% !1110 4444 %%%% !1110
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MX&^*X/$NMWE]JC.^J/-HUQ+8Q,Z6ZQ(I56RR[4!(8X)-?5=<=\8O^26^*O\
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MDUURE)SY(,]>;E*7+!VZL\2O_&\?QL^-_AK2M)D^U>%M(!U":?:0+B<?=&"
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M",C[1(K%PQ(.00Q+?+CDD]ZY#]H;1[30? _@;3K"!+6QM?%.C0P6\8PD2+.
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M0/&WB'X=?!1-;\*W%Q;:CJ6BWFH>(_M42"*?SSM1H#ARS@*V0,#=7U[_ &?
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MMU8F@1U_PYN/$M[X6M+KQ=9V6G:Y.#)-9:?(TD4 )RJ;S]Y@,!B."<XXKIZ
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MDH6Y6,'T48'YUZ$%P?\ &FQIL 'I3Z[8Q44DCMC%15D%%%%64%%%% !1110
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M\12V@5AING:=>B>?+ $(3*><'T[5[EI\[W%G!)*OER/&K.A_A)&2* +%%%%
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M_9BD23X1V+QNLB->7K*Z$%2/M#\@BO5J "BBB@ HHHH **** "BBB@ HHHH
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M:0:1(L4%O&$C09'"J!@"O:/.&,]O7M7D?[7#@_LU_$/_ +!4G\Q3 ]+\+?\
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M@D5]M_LX2V5U\#?!,FG^3]B?3(C$(+4VR;>P$1=]G^[N;'K7I.P4"L?FI?\
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M_7O_ *4R5ZI7E?[,S;OA-9''_+[>_P#I3)7JE !1110 44$XJ.681XSDY]*
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MA_%#"Q+W<HQP[*%S@U[SX"^(/BC6] OM,^ ?A5));HL-1\;>+;Z$7]]*1S(
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M%+0 4444 %%%% ".XC4LQP!7.Z5X\\/>*UU2#1M9L]4FL&:"Z2UF#F%\'Y6
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ML!7.">AKZ[HH ^;]/_98N-(^!3> H;G39[AKK[4MS>?:'BMY.,/"0X>-U(W
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1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>adag-20211231x20f032.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f032.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &X =@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]3:*** "B
MBB@ HHHH **** "BBB@ HHHH *#THH/2@#Q30OVM/ =Q=7-EKFHIX;U'^W;W
M0[.RNV\R6\>V=4>1%C!(3+#DXQGFMKQ%^TY\,_"VKZSI-_XLLEU?2+:6[N["
M(M)*BQIO=1@8:0+SL!+8[5YAXI_8GB\0 _9/&5[H\KZ_>ZY)>VUC$;M?M$B2
M-%#-]Z( H!D'D$Y%7+_]C+3]1\::GJ4_BG4W\/WEW=ZHN@>3$$AO[BW:"2X$
MV-Y&&+!#QD^E CT#PM^T[\./%^B6&IV'B*'RKU[>&.&9'CF$D\;21(4(R"41
MV],*>:BTO]JWX3ZWIFJZC9>.-+N++2X4N+N4.P\N-FVJP!4%\M\OR@\\=>*\
M@T/]DO6M+^*>@ZI=7G]JZ=X=\*/I$=]<NB-J=Z$>*VE>%.$,43NF_OOKG/!7
M_!/NXUGX1V>B^/?%5]/K4>D6]A9Q6R1>5I!BG,X",FTS OCECG''O0!]*>)O
MCSX7T+X4S_$&SN&U[0@B_9O[,P\EU*\@CCB0''SL[!<'&#G/2N.MOVK;+P_]
MAMOB'X1UOX?ZI?ZO#H]G;WB"[BNI)5W*R2Q9! QAO0\59TC]EK0-+_9_7X6B
MYEBLQ^__ +0LHQ!*EUYHF6X1<D!A( W4].>M8\W[,GB35[*PE\0?%'6_$&NV
M.NVFMVM_<VL"Q0>0K*(4@4!0'5VW-G))S0!T?AW]J/P9XW^(>A^%O"UX/$)U
M(7@EO[4D0VSVX4LC;@-QR<?+G&.:]DKPWX:_LP:?\-KOP++:ZQ<W*^%4U)8T
M>%%%P;Q][%L'C;T'K7N5 PHHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KPKX[?M+Q_!WQIX;T1-#EUF"[*SZQ=Q3!/[*LVE2$3NO<%W''H
M#7NC#((KP?XH?L:^ /C!XJ\0>(O%*:CJ.IZI9QV$3K>R1+91H#CRE0@'+'<=
MP/(H$<SXG_:VUKPMXL\:E_ ZWO@CPAJ-KI^JZS!J2BY03!2)4@*_.B[US\P.
M,U<T?]K&\\4^.(K/1?#FG#PK+JSZ-!JFJZ[#9W5]+&=LSVMNPS(B$XZAB>@J
M2?\ 8HT+4-<O9[_Q?XHN]&U.2TFU306ND6TU"2V1$C:;"[CG8I(! )%6;K]B
MSPI)XVM]:M=:URRTJ'6%U\>'8YD:Q%\&W&5 RETW'DJK 'TH&9NN?M@R>%_^
M%FQ:OX.NK2]\)W%C:VEG]LC>34)+LD0<CY8P3CKT!YYKFM<_;O?PY;6VDZIX
M7L]+\9IJEUIE]:7^L+'86OD(DCR?: A+*RR+@;<YSG &:Z[4OV+M'\0:UXYU
M#6O&/B;5!XN$374$LT2K;2PL&MI(2J AHL87.>.N:AU+]AKPOJ>DV\;^)O$J
MZYY]W/?>(%N8_MFHBY18YTE^7;M9%51M P!Q0(ZOQY\7M4LO$WPET?119[_%
M]\S7,N\31BUCMFFD$;#AB<* PKB9OVPK^UT?Q>;CP//#KVD>);;PQ8Z3]OC)
MN[B=0T;-(!A%P<GK@9KN?%OP*<:Q\)+KPM-#90>!KKRUMKHLV^R:W:!T5O[X
M!4C/7%<FO[$^DW$?BS[?XV\47UQKVIP:R+IYHDELKV%LQ3PE5X90 O.00.E
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M".T<K-;^8P98^.#7OM(84444 %%%% !1110 4444 ! -(JA1@<"EHH ****
M #%%%% !1110 445B>-O&&F?#_PGJWB/6;C[+I>F6SW5S+M+%449. .I]!WH
M VZ*IZ-JD6MZ19:C"'6&[A2>,2*58*P!&0>AP>15R@ HHHH ****  G%4+O7
M].L!,US?6UNL&/-:695$>?N[B3\N>V>M2ZJMR^FW2V91;LQL(3(,J'Q\I/MG
M%?GL_P"S-\:+6_\ %MUXI\.Z7XZAO-:L]4NK6WORO]KL+>6,X64[46-G1A&>
M/D&* /T&.LV0NQ:_:X/M1C\X0>:OF&/^^%SG;[]*?I^J6FK6XN+*YANX"2!+
M!(LB$@X(RI(K\^+?]D[XJPZA!9'1XAJO]F(%\6_VDNZWC%@T!TX<[B/,8'=T
MQSU%>L_ WX)_$3PE\,/$4=A<CX03W.II?6^FP00ZD$ACM4CD!#':OF2(SY7G
MG)Y)H$?7&<T5Y;^S)XRU?XA_ SP?XEUV=+K5]1L_-N9XXA&KL'9<[1P.G:O4
MJ!A1110 4444 %%%% !1110 $ ]11110 4444 &****  C-%%% !N% .:\^^
M.GQ"F^&7PWU77+.*.XU&()%9P2@E99Y'"1J<<\DUVVD//)IEJUTJI=-$AF5>
MBOM&X#VSFFHRY5-[;?<,MT444A!1110 4A8+UI3TKY]^*OBKQ)XS\6GPAI\7
MBGPMI-KJ4-O/XCT&2-9)MZ+\@#HQ"9<992#A6/:@#Z"R,XHKRGX=_"#4/!'B
M=M23XE>*_$FGF,QR:5K=U'<PEST<-M#*1Z XYKU:@ H/2B@]* /!O@K_ ,G)
M_M ?]?>C_P#I$:]YKP;X*<_M)?M ?]?FC_\ I$:]YH$%%%% PHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH #P*^7/VXOB3:>'_#_A7PO<0S7\>MZG'<7>
MGVQ'F75K;LLC0+GO+(8HQZY-?49.!7Q+X6T:?]I#]NOQ-XCNP9? _P -$ATN
MS4C,=UJ7#M@_],V))]U6@1]G:+-+<Z39RSVYLYY(E>2W+ F)B,E,CKCI^%7*
M;$GEH%'.*=0,**** "D+8-0:A>"QLYYRK/Y2,Y51DG S@>_%?..G:OXV^.WB
M=_[/\3^*?AEHYL4N;:T@TZV=I_FYD,KJQ'5?EP.] 'TMGF@@'M7%_#/POXF\
M+:=<VOB7Q=-XQE,Q:WN[BQBMI8X\8V-Y?#'/\6*[2@ JIK'_ "";W_K@_P#Z
M":MU4U?_ )!5[_UQ?_T$T >/_L6_\FN_#S_L'G_T:]>UUXI^Q;_R:[\/?^O!
MO_1KU[70 4444 %%%% !1110 4444 %%%% !1110 4444 %(W0TM,F<HF1^M
M)[ >)?&^7_A)_B/\-/!J)YJ7.I-K%XIY AM5+#=[%ROY5[<GW?KS7BWA6(>+
M?VC/%VMA5\OP[I]OH<1!SF24^?*?; V"O:D!50#6]7W5"'9?B]?RL)"T445B
M,**** "N)^,UK?7/PJ\80Z5#//J<ND7:6T=JS+,\IA<($*\ALXQBNVKB?C4M
MW+\*/&$.G"=M3DT>\6TCM&*SO-Y#[%C(YW9Z8Y]* /&?V(?#EYX5\'ZK%J&C
M7NCWDC6_F)?:+/ISNXC^8_O9I/,.?XA@>U=IX^_:5L_AQ\24\-ZSX:U>#2I-
M/N+Y?$ \LVSF&$RR(B9WMA5P6Q@,0.]>=?L'Z-=:'X3U:*_TRXTJ\D:W9XKO
M3+^QDD<1_.<7<LA?GJR8'MS7HOC;]F#0/B'\1I?$^M:KK4]I+ R2:%]J'V%I
M3"T'G!<;E;RW88!"DX)!(IB.%F_;DL;30(+B?P)X@77O/E-SH >$W%O91PQS
MO>%MVTIY4L;;0=V21U%=OX%_:=TCQU\1M1\-V^DWUII<<=PUCXAN"@M+YK;8
M+E5YRGEF1>6P#VKD9_V&_#EQX?AL9O%GBF34A<2/-K9N8_MD]M)"D#VCD)CR
MC%&B<#=QG-=AX._9?\-^#/'VH^);>[U*\MKF.XC@T*ZD5["S-QL^T&)-N?WG
MEKG<3CG% &/\"+R#4/VB?CY<VMQ%<V[W>C[989 ZM_H9Z$<5] U\]? #2;+1
M/VA/CW9Z?9P6-I'=Z.5@MHQ&BYLST XKZ%I#"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHH/3TH \^^//Q/@^$/PK\0^)I0KSVENRVD)/,]RXVPQCU
M+.5%9'[,'PI;X/\ P?T;1KS$NO7 ;4=8N3]^>^G)DF9CWPS;1[**\3^,6OK\
M>?VPO WPJLG\_0/!@_X2OQ 0,QR7"\6T![$@L&(/J*^P'FC@C:21UC4#+,QP
M!ZDF@1)138Y%E171@Z,,AE.013J!A1110 C(&ZC-?-G[;UIJ9\!^&8]*BOF@
M_MF+[8M@EV_[@*V=Z6A$K)G' (]:^E*^;OVXKO6H? 'AS^QFOO+;6X1>_8GN
MPOD8;/F_91YNS./ND<XS0!ZE\&&-E\)/#9*2#99@['BG1N_&V<F4'V<DUYS<
M?ME:#:6^M";PGXJAU6POHK"+2'L5%S=M(KNCQC=@#9&[$,00!DCFO1?@]&;K
MX2>'HI6D5Y+(!SF?>,YYS/\ O<_[_->0S?L46=S+J5X_C[Q5)KDMS#+8ZQ,T
M,D]E'$'58QE<2?+*ZEGRV,#/%,5S6C_;?\ 3:G%&(M7&EO:"Y;6#:'[-'*8#
M.+9CU$OEJ3C&,\9KK/AY\?=#^+'@K6M3BMKSP])92-:7%EK@2WFB=HA)&3EL
M$,C*PP>]<!'^PAX0CNTC_MO6VT+[((I=&:1/)EN1;FW%T6V[O,V,>.F<''%=
M%X;_ &4_"'AKP#JVC^)!)\0))[@ZC)>>(8DD?S8X!%&5"@*-L:JOOR:0%[]B
M[/\ PR]\/,_] \_^C7KVNO$OV*U"_LN?#M5&U5TXJ .@Q*]>VT#"BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K \8^,M(\%:8M_K-]%86S2+"C2G[[M]
MU1[FMN=RH &.?6OCO]I/Q1-\1/$.LV6GR,UCX:"Z1:1C[MUK5WB-57U,43,V
M>Q;VK?#T5B*G)+1=0>BN>Q_LN6#S_#Z]\2W"G[5XGU2ZUAF?[WENY6('V$:K
MBO4-6\4Z9H5WI]M?WL-K/J$WV>UCE;#328)VJ.YP":I^$-"MO!_A;2=$MP%M
M]/M(K5,]PB 9_2O&/"^L:;\0_C=<>+M4OK>/1M*FDT'PQ;S,%^TW8&;N9 ?O
M$8V CLK54E[><ZG3^K+^N@+0^AU;<,TM,B/[M>_N*?7*G< HHHI@%>=?'3P5
MX/\ %W@:ZG\:V,MWI6CA]3#VTLD4T+1HQ+QM&0V[&0.>]>BUR7Q8UI_#?PV\
M5:O'%;SR6&E75TL5VI:)RD+-M=1R5.,$4"9XA^RII?PDU_5;CQ'X'L-8;6;6
MTC66YUW49;N>WCGW$19:1PI_=Y*]>E?3E?-'[$DMS/X+U":?1+30([B2&Z6V
MLO#HTB,M)'N8X$LGF\G[V1]*^E]P]: 04'I2;U]106'/(H&>#_!3_DY/]H#_
M *^]'_\ 2(U[S7@OP5/_ !DI^T!_U]Z/_P"D1KWJ@2"BBB@84444 %%%% !1
M110 4444 %%%% !1110 5Y_\;/BI;?";P-/J[V\E]J,\B66F:?%]^\O)6VPQ
M#ZMC)[ $]J[YW"*23C'O7PEKWBC6OVP?VC]0\/\ @Z]GL?!?@PR6%SXC@7<D
M,[@K<- 2,&X*YB1O^68+OU(H [K]AGX>2V0\>>/-4NUU/6=>U22TDU!>5N/(
M;]])&>Z-,SA?:,55_:K^+LOBR>]\":#')J&EV5U;V>MK;RF-M2NYF'V?2()%
MY#OP\S#[D:GN:]"^(.OQ_"CPMX9^%'PQL(K?Q1J4'V/2+:,%DTNU08DOINIV
M1]>?ON0.YKY]T*\MM%\;Z/;>$+,>(I-%O;C1O!T5ZS.=8UE\'5-:N&'6.++(
M6]<A<<4"/N_P_;R6NBV,4L4=O*D"(\,+%HXV"@%5)Y(!&!]*T*JZ8DZ6%N+D
MH;@1@2&($(6QR0#SC/3-6J "BBB@85\Y?M,>#OASI5]IWBWQ?J7BG1[Z\FCT
MN%_#.K7-LTI). Z1L%P,DECT%?1M?./[<&J"#X=:)I<GA_3_ !%#JVL0VCVV
MH:7+J048+;D@C=&=AC^\,#/6@3.\_9\\(^$=!\"PWG@VXU*[TG497G-SJU]+
M=SS."4)9Y&)ZJ>G%>I5Q/P61HOA;X9C:SBT\I9(OV:"P:QCB & H@9F,8_V2
M3]:[4L!0,6JFL?\ ()O?^N#_ /H)JWGBJFL?\@F]_P"N#_\ H)H \?\ V+?^
M37?A[_UX-_Z->O:Z\4_8N_Y-=^'O_7@W_HUZ]KH **** "BBB@ HHHH ****
M "BBB@ HHHH ***1C@'G%(#A/C+\0H_AQX%OM74>;?8%O8VXZW%U(=D48]<L
M1^&:\/\ A%X 2\^(VF:--)]OC\"QMJ.KW:<K=Z]=99CGOY:%OIN6KGQ6\8)K
MWQ&U;5+E#/X7^&ML;W:/NWFL2+B&+W,88'']YA7I_P #_!=SX%^'=N^K'?X@
MU-FU76+A^"]S+\S ^RC"_1:]%+ZO0;^U+]5^B_%H6YA_M0?%./X;?#B2.VO4
MT[6M7?[!:7$G/V?(_>3D=PB9/N<#O7/?LX_"%XH=*\8:Q:RP?9[+['X?TNX.
M3869Y:9P?^7B8DNQZ@$#UKEM!\'#]J'XZ3^.-47SO 7A25M.T6U8?N]2G4YE
MG/9D#@ >NT5]9PQ"- , 8Z<=*=62P])4(?$]9>7E]V_W=R5J[CHTV+C-.HZ4
M5YJ5BPHHHI@%<=\6;^QM/ .NQWTMLL<]G-"L5TB2+,Q1OD\MF42$]-F1GI78
MUYS\>])TK4_AIK(U&#0Y[B.%VT\^(EC-HEX480;C)\HRY YH \=_8@CNX=-\
M71MH6GZ-IJ75O]A>STJ/37G'E_.9(4EDQ@\ DC-9_P <?CMXQ\!_'.73=#\6
M:-=P6.D3ZA-X0,,?FF%+>1UE=R0[3-*JA(XP?D#$UT/[&7@OQ%X-T?7H]9T6
M?2;"XF@>S>_@LX[N9PA$Q8VOR&(/_JR>=M>]W7@7P[>ZXNM7&@Z7/K"?<U&2
MRB:X7C;Q(5W#CCKTH$CX,OOVK?B#9>&HH$^(NDRQPR7-VOB[^SX/(O9(K*"Y
M73=H.S<9)FCROSX4=Z]4^#G[0_C#Q9\:M3T_4M2@O[:6'5,^#K6V1;O2OLC0
MB%RV=Q\_S'^_@<#%?3/_  KKPN--@T[_ (1W2?L$,_VJ.U^P0^4DV<^8J;<!
ML_Q#FKUMX9TJSU6ZU.#3K2'4;I%2>[CMT6:4#H'<#<P'N:!G@O[..KRZW\>O
MCQ>W&G7>E2RW>D9M;Y565,69Z@$BOHZO _@FH'[2?Q^P,8N](_\ 2,U[Y0)!
M1110,**** "BBB@ HHHH **** "BBB@ H8[0302!WKP[]HW]H*#X8:-/H^D2
MV]QXPNK.6YB6;FWTVW09>]NB/NQ(.@ZNV%7K0!B_M&_%F]UCQ#I_P8\"7WE^
M._$L;?:[Z#YO["T\?ZV[?T<CY47N6SVK0FO/!G['_P +=&\-:!I4EY?S'[/I
M.AV2[[[6+PCYG/<DGYGD;A1R2*\5^ 6CQ?L[^#;[QSKMO>^*OB]\3+D36&E3
ML/[1NUZPQG/$2X/F2$X5 0.H KW+X:_#E_!#ZE\2OB7JUI?>-KJW+7=](V+/
M1[0?-]EM=WW(U_B?@N1D\8% CQ7XO>*+[]GSX:W_ (C\2WD5Q\9/B-,-/\VR
MRYTZ$K_Q[VHZE(5R%Q]^1P3UK:^'.AP?LT^!=-\2:QHYU+XE^((XM'\/^%HY
M1O@BSE+*-N=O>6>8]6+%CP*PO#<&E_$+XB:U^TY\1"]MX*T.)K/P5IMS&23
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M[&EV+*/S5@QCR@V,[,<;>E%GX3T7P?X8O+#0])LM'LA%*_V:PMT@CW$$D[5
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MYB4-) L@+H#T)7.0#[T@N>'_  4.[]I/]H CI]KT?_TC->]5X+\$R!^TE^T
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MF_8N/_&+OP\'_3@W_HUZ]JKQ3]BX8_9>^'W_ %X'I_UU>O:Z "BBB@ HHHH
M**** "BBB@ HHI"X!QFD I.!FHIKA(DW,0%[Y/%4-?\ $.G>'-(N]3U2]M]/
MTZV0R375S((XXU'4ECTKPZXU+Q#^T;<O:::E[X9^&(.)]3=3#=ZZO_/. 'YH
MH#SE_O,#QCK6D*;G[ST2W?\ 6[\@+?B/QUK7QKUJ\\+_  _O&T[1;20P:QXO
M09$9Z-;V?9Y>H+]$]S7DG[3MW;> O!&@_ _X:6)N-?U^=6EM8F,DOD[LR2SM
MU)=ADLW8&MWXT_M&Z7\&-,M/AY\*],M]1\1QXLX+6P3S(;%NR!%SYDO?;VZL
M:W_V4?@%K/P_&J>-?'TYO_'VNMNEEF?S9+6$CB+=T#$]0O P!7LTTL+!8FHK
M16L8O>3[OR7_  $9-\SY5]YUG[.7[/MA\$?#\LES+_:GBW5/WNK:N^2TKYSY
M:YZ(O0?2NC^*OQ?L?A[%;:=;6\FN^*]1.S3=!LCF>X;^\W]R,?Q.W 'K7*>/
M/C1?:QK%WX7^':6U_JEID:IXANC_ ,2S15QR9'Z22#J(P?KBO//#%RJG5;'X
M4Q7?C3QIJW[G5_B5J _T2$]V$A^5]N3MBB^4<9-<?LYUI^VQ&[^7WOHNW5]#
M167NHRM#^&.I?&'XIW]MXFOXM9:T\MO%%];#_1XCG?%I%H>T:\-*W5N ?2OJ
MB;Q3H/AO5=*T2>_M;*^OOW=E8LX$DH5>B+UP /H*\:3Q#;_"'3+/X:_#O3_^
M$J\;,OG7)D8^5!(YS)>7L@^[N.2%ZMP ,5W7PQ^#%MX2OI?$FMWK>(_&]ZFV
M\UNY0 JO7R84Z11+T ')[DTL1+VB4INT5\*ZOSMT7Z:(I61Z>A##(Z4M(O I
M:\Y PHHHJA!7$_&JXO;7X4>,9---TNHKH]V;8V1(G$ODOL*8!.[=C& 3FNVK
MS']H7QOI'@GX>W(UJ[BL+;66_L>*[N9&B@AFF1E1I9$(9$SU93D=J /+/V&Y
M[^Y\%ZDVJ2W4MXS6_G&[EU227?Y7S;OMZ@@YZ^7\M6?CC\$]?\0_%]?$/AB&
M[2YO/">KZ6^I/>,([6XD1!;JJEODR=W*CZFJW[$7A9/#VG>+I8_&VC>*XKJ[
M@VVNAZK<ZA!8[8R"/,N'9P6/..G%?4!4$YP,^M 'YO7W[.?CNZ\(6WD?"VZB
MT62>ZCM_!OVZ%6L+R2R@ACU(_/M 6>.63*G<-V[&37KOP:^#7CKPW\=-7U2]
MT9M.NEM]3^T^-)IEF35O/,/V2/R]VYA#L?(<#'0'FOL(0QCHB]<]*78H!PHH
M ^=/V<K34[+X]?'>+6+^'4]16\TCS+F"W\A'_P!#./DR<?G7T;7@OP5&?VE/
MC_[7>C_^D1KWJ@04444#"BBB@ HHH)Q0 51UK6[+0-,NM0U"ZBL;&UC,T]S.
MX2.)!R68G@ #O6)\1/B7X<^%OAV;6_$NJ0Z;I\?R@L<R2OV2*,?-(YZ!5!)K
MQRS\+>(/VDM7M]9\;Z=<^'/AQ;2+<:;X1N\"XU9P=R3Z@HSM0<%;?U&7]* *
MH36/VN;]994N]#^#,+@QPOO@N_%!'\3CAH[//0<-)CG"]?9/%/B_PC\%O!<F
MJ:W?V'A?PYIL6T/)B*&)%'"(HZG X51D^E>3?%/]JW2O"'B6+X?^ -'?XA?$
MB5,1:%I3A;>S7_GI=SCY847TZ\<"O#M>\,>%YO'<&O\ QKUN7XQ?$>W'FVW@
MCP\@?1=%. 1E681ICO+,W/7% BUK'QE^+?[9U[)I'PIT6\\(?#-G\N7Q;JFZ
MUDU!,\^7C$@0X/"<G/++6_HO@_X?_LVW,&EZ#&OQ2^,FTBPTX%=MB[9#RE!F
M.RA')>1CO;U8FN3UGX\^(_C+?W'AG0+FYU%8U\H^#OA>P*QKC 2^UE@(X%XY
M$ Z9 />O/M:^"_EK#I_Q4\<Z+X&\.-(#'\,_ADSW>HWYS]V>9"99Y">&9LCK
MTH ]AM?BK9_"RYU9O"UK-\>?C]JZXU*;14WVEB/X+=I_N06\9Z1AMS<DC)S7
MG'BOPG\7+S5+.^\;ZM9VWQ.\0@V^EZ-IUP9[VT5E^<HP/EZ=:HN2\R9D8#&_
M)KMIO'GB/1+6R^&_PS\*?\*WMY(LVWA[0X8;K7Y$/_+6Z?)@L$/=Y2\GH*[3
MX6?L)Z<\LFL?$BXDU?4[LAY])M+V5K<]\7$Y(ENV]=Q">BXIAN6?@WXG^$O[
M,'@^#P3X>U.7QMXS;]]JB^';9]1O]1NS]^25URJG)('F., ?6NW/B+XY?$L^
M7I.@:3\+=(<X^W>('&H:D5]5MHB(T/\ O.?I7K_A/P-X?\#Z6FGZ!HFGZ-9H
M,"&QMDB4_7:.?QK<5%7HH% '!?"'X26?PGT":UCOY]9U:^N9+[5-8O%47%_<
MO]Z1\< < *HX4  5WU&**0PHHHH **** "OFO]NC5M:TOX?^'!I%WJ-FD^M1
M1WDEA/=P+Y.UB?-DM$>=4SCE!UQGBOI2OF7]K?QEHVJBU\#2:]I6@ZV(TU5)
M=;UJ?287AW,F$FA8,S!A]WI30'J_P14WOP>\-%YY)C)9KNE::XE8]>=]PJRD
M^[@&OEOX@?L_>)M+L_%UI:>$]9\5^&F\7QZB=);4/-GU.U-GM+AY) 2%G;)4
MD?=XZ5]3? /3YM*^#_A6TN==@\33PV:J^K6T[31W)_O*[$EQVW$Y.*] **>J
MCUZ47$?G':_L[?%^'6+>#^P]13Q$-+18O%)U(>5!;BP>(V!._<6\TKSC'?/%
M>M? [X=?%/PO\*/$T.@Z?:_#DW6I+-!I/B9#?>7;):(DY58Y,(9)E9QR<YSC
MFOL$1(#G:/3I535T4:3>X4#]P_0?[)I >/\ [%C,?V7?AUNQG^SCDCIGS'SB
MO;:\4_8NY_9=^'G'2P/_ *->O:Z "BBB@84444 %%%&<4 %%-=]JYK,U_P 3
M:;X8TFYU+5KZWTZPMU+2W-S($C0>Y-).[L@-0M@$UYS\2?C/I'P^N8=,2&XU
MSQ5?*38^'M-3S+JXQQN(Z1IGJ[$ >]><>)_CQK7C729[KPD]OX.\(I_KO'/B
M=?)C9.<FSMVPTQ]&;"\\ UY#??'CP]\&=#EG\'6[M>ZK)_I'C/Q@CR7NI/\
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M)W')Q6W!XH\4?%6PATCX8Z6?!/@G9Y7_  E%Y:B%WC_Z<;4@?@[@#T!J/4/
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M"FF/<6NL63>);DI<3NH$*M)Y^$9&!.T\G-?5^M1F72;M%A:X+1.!$C;6?(/
M/8GIFOSX3]F/QQJ&B7ETWPHLK*1-5,[^&)-1@^PW-OY,L,#*PSNE0OYKO)RQ
M/'04M]P9]-6_[%GPBGC#+HE^ZD AAK=Y@_\ D6I/^&)?A&/^8%J'_@[O/_CM
M>E_"GPY>>$/AOX8T34)$EO\ 3M,M[2=T8LK.D84X)Y(R.IKJI#M0GK2&?)7C
MG]D#X5:CJ.GVVA:N=$FT:^AO=;@;Q!<L[60!+Q2+YV8PP_B..E=AH7[(_P $
MO$=BE_I-E-J=E(2$N+3Q!=RQDCKAEF(KR'Q?^SSX@\5^//BI=?\ "LY=)M=5
MT^ZM+"_T[5[>%]2$K1M,\SG<XD?8%0$;4 /'-?0?[*O@CQ%\/OA'8Z-XDMXK
M.YBN9WM[16C:6"V9R8DE>-51Y OWF44",P?L4?"0?\P/4#_W&[S_ ..US'B[
M]D+X02PW6@Z<TNE>)KJV=K-'U^Z,R\?ZQ8_.RP'J!7TW7RQ\=?@WXK\>_&[1
MM4T?PKI,%O:JKKXN-T$N(E\J5'ADCQO;!=63:0N<[LT[]0-[P]^R1\$]>L5D
MTZUGU18CY,D]KX@NY%\Q>&!*S'!!ZBM;_ABGX2?] +4/_!W>_P#QVN?_ &.O
M@]XB^%\7B6;6] LO"T5ZEE;PZ;97"S*[V\7ER7)VX4&5OF]3WYKZ3H ^=M=_
M9,^".B>1#?6\NFSW;&&V%SXANHVDDQT0-,-Q]A7-?"_]D7X36VDVWAO6]1_X
M2?QC8HW]H26_B"Z\XG>2"T8FRN 5'([5N_M:?"WQ)\2I/#UOHO@W2?$<<<RN
M-2NKL0W&FRK*CAP&'S1$*0P7#],&L?\ 9_\ @AXO\!?'WQ=XAO=-%AH>IFXE
MN)[F\ANFO)W<-&T&V-9(HPH(*N3Z4@.V_P"&*?A+_P! +4/_  =WO_QVJ]_^
MQE\(+*TEN)M'OH8HUW/(VNW@"@=229>*][KQ7]K+X;>-/BQ\*+WPWX-U"PLI
M;S*WL%_YBK=P;3F$.A!3<<<^E $OP#\(:1\&M+O?"\7B>UU%=3U"XU;2K1[P
MRRI:2;2J)O=F=5P?F''-%?//@7]F?XB:9\0_AWJ&L^']),NFQ:3)/K]K=X;3
MHK2W:*2R1#\Q#DJ<C@\YHIZ ?==%%%(84444 %%%%   !1110 4;1G-%%  >
M!7S^_P"U]I=MXWO-&O?"'B*QT2UU[_A&Y?%+Q1-IZ7N555;#[PK,RJ&*XR>:
M]_8;E(KYGNOV3O$>J>*-9AO?'43> ]3\3_\ "4S:)#IH6Y:=2KI&;@L?D#QJ
MV-O.* /8=-^-O@+5[Z>RL_%^CW-[!=)8RP17:ETG<L$B(_O$JP [X-.;XT>
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M>O4=N!6L/V([J&V\9:-!XSCC\+Z[#=BWMFT>%KVVFGVDLUT?G=5* A>,Y(-
M'LWB'XY^&= \5:+H/VM+RZU&[DLY'MG5DLW2W-Q^^R<J#&,BLV^_:@^&4,6B
M-;^,-+U :U>OIMB;.82K+<JNXQDC[IQC[V.HKR[2?V./$<=Q/JNH_$4/XDFO
MI=0.IV.EI"4D;3_L:;4)(^4 -SUK.\+?L-ZGX>BL;B7QE97>L0Z_'KLEU_9
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MFOG72OVA/B/\9?%NI:9\,M(T31+&PMX[@S>.+2\@N+@,2K;(D P%<%"<GD4
M?3Y 8$$9%((U!X&/I7(?#2[\;W>BR_\ ">6&C6&KQS%%_L.XDE@ECQP_S@,I
M/]TYKL* &^6I&-HV^G:JNIQ@:?=G SY+\_\  35RJNJG&FW?_7%__030!Q7P
M"Y^#?A ]_P"ST_F:[^N!^ ?_ "1KPA_UX)_,UWU( HHHI@%%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !14=S.EM \LCB.-!N9FZ
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M+PU-X5\(1:Y'K*:@^JG^S+S1[VULVMY@A9B\MR?*4%0<9YSTH ]E^"7@S5/
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MZ=WV]%U-KPT/^%L?%"7Q"R?\4WX9:6TTW(XN;H_+--CN%Y0'UW&O;80%7"C
MK$\(>%K+P=X?L-'TV'R+&SB$,29)( [DGJ>ISWS6ZHK>G#E6NYTTH<B;>[U?
M]?@+1116QL%?+?[=%G;G1O!VKRB0S:3J$T\06/3I5),+*=T5\ZQN,$X R<\U
M]2'I7Q]^W%9OITF@7MQKTIMKZY,$5GJAL8M)LG2-G,LDT\$A1V VJ/XB0*8'
MOGPC\20ZA\$/#6N6\<ES#+I,=TB16L4+R#9G BB^16.,;5XSTKQMOVV;FWT^
M[27X<:W%K]O=F-M(:[@WB!;<W+NSYVK(L2_-&>02H[U[1\)+A/%GP7\-7$4M
M];I?:5&5DN%2*XCW)C)"*J@CMM '3 KS2U_8A\(6_A4:!)X@\57-O'>RWT-Q
M)J9$\;S*RW"B0#)657(<-G/'3%(1D:A^W7HEDUU=#PMJ\V@M WV#4EDC_P!,
MNEBBD:V$><H<3(-QXR#Z5T>L_'W1/%_P(\4WVN&#P9JAAO\ 2I-+U>]A5Q=1
M(0R(^[$G48*^M3W?[%OPYO+W4)7@U,6EU:FVCT]+]Q;VS&-(S-$O\,I6*,;L
M_P -)XL_9]\%^#_@=X@TZ728_$#6EM?:@E]KRK>7)N70EYM[CAB0.F.@IC/8
MO!Y)\+:.",,+* 'Z^6M;%8W@X?\ %*Z.<YS90'_R&M;-( HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OF?]J\>)]1U;2M.
M\.:3/XPE>!I#X5OO#T=]I5TP;Y7FN79?L[#ID$\'H:^F*\(_:J^)?BCX8:=X
M6O?"ES:/J%SJ+Q2:5<Z?/>-?Q"!V946#YEV8WEO0>] CU3X?'4W\':.=:TJT
MT/51;(+G3M/D\RWMGQS'&V!E1T!Q71US'PS\3R>,_ >A:Y+-9W$FH6B3M+IX
M<0,2.J!_F ]FYKIZ!A5;5/\ D&7?_7%__035FJVJ<Z;=C_IB_P#Z": .*^ ?
M_)&O"'_7@G\S7?5P/P"_Y(UX0_[!Z?S-=]2ZAT"BBBF 4444 %%%% !1110
M4444 %%%% !1136<*?UH ;+)L/>N"^*/Q4L/ASI<+O#+J.K7C^5I^E6G,]W+
MZ*.P'4L> *9\8/B[I_PJT..XFB?4=6O'^SZ;I5NNZ>\F/1%'ZD]@":Y?X/?"
MW5&UJ7QWX[:.Z\97R8C@0[H=+@//D1?U;N:YYS;?)#?\CCJ5FY^RI?%U?9?Y
M]E^AF?#O]GEK_6I_&/CRX.L^(M0E6Z;3WYM+(C[D80D[]OJW?M7O$5OY6 ,
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MO5"*_G1GS.4RV/JIKZ=_:(\5ZCX-^'5U>Z1XCTCPOJDDT<-K?ZW&'@,ASB,
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M[;VZI-<D="[@9;'O70"OA^R^+/QAL/B;I^APQ:O;VL26\=MHZ:#_ *#+I_V
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>adag-20211231x20f033.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f033.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '2 W8# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **XSQQ\8/"GPXO+:U\1:F;&>YC,L2K;2R[E!P3E%..?6K_@CXB:!\1K
M">]\/7QOK6&7R9',+Q8? .,. >A% '24444 %%%)O .,\T +12*P89!R*6@
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M_0PZ;_X$K_C1_P +$\+_ /0PZ;_X$K_C0!T-%<]_PL3PO_T,.F?^!2_XT?\
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M_P#1:UP_[;7_ "-WAK_L'R?^C:[C]BG_ )$+6O\ L)'_ -%K3$?1%%%%  >
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M<E6&T_-[T!T/)!CVI,#/05U.FV'A^2":YDM]1OI9)MD.F6DH$D:?WGDV$'Z
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M^*K_ ,1VV@SR^';*SOM8 'EV^H3&&$^N7 )'Y4AG1L=P91P:^8_B.6_X3K6
MS$XF('/2O1?#.O\ Q@N-?M8]<\+>%K+2G;%Q-9ZM++,B^JJ5 ->=?$G_ )'K
M6?\ KN: M8YL]:,^]%%.X$D$,MU/'#"C2RR':J(,DGTI\=E=2WK6:0.URI;,
M0'S+@9.1[8K=\$V\4=Q=ZI<RM;P6<1VRJF\B1N%(&1G')ZUT7V:WN/%.GZO9
MRF:VO;68LY383*(V#97)QGKB@#SC=AL&K3Z=>0W45L]M*D\H!2-EP6!Z8^M7
M?#6EQZMKL$,W_'NA,TQ[!%Y:NTNC:>(=0TC4[6X:[:UO1!,[0F(HI;,8QD].
M1F@+GFS*R.Z.I1ESN#=L>M-+$*&P<>U>E66C6+:II]LVC07L5VDT\MW*K,ZN
M"W (. !@<54T_2;6.31K1=%@O8;]2T]VRL9$Y(.U@<+MH#4X.*.6XF2*&-I)
M'(55'5B>@J:/3KR:1$6VE+-(8E 7JPZJ/>NMCL+&S@T2W&GVUR;NY,;SRJ2Y
M42X&.>,CVK7TV58XM'ACLX%B35I4WB,Y4#N#G@D4!9GF;LT;;64JP."/0T%L
M#)R/KQ7H6EV&EZV;"\;2;:$?;I;>2.$-ME0(6&[)Y/O3=+32KU]#WZ)8I_:$
MDD$FS?A54D*5^;AO4T >>B0$$C/XTH;)KT"PT;3K[24L[>P@34/)=LWT$@:0
MC)#QS X P.A':N *[6(_E0+4,GU-'XFC-%%QB,"3G->V?  -_8^J\_\ +RO!
M_P!P5XGG ->K_!?3]0O=-U(VFJRZ:BS*&6.".0.2HY^<''X4@L>V9'K368J>
M1\N,DUSG_".ZW_T-%S_X!6__ ,35;4?#>N36-Q"OB:X=WC95!LX5!)'3(7B@
M#YH_;'G35_$VBSV9%S!:6CQ3O"=PC8OD!O2N]_8I_P"1!UO_ +"1_P#1:UYQ
MX]_XI"VN+76HF@E>)@MO(.9ATX[$9[UZ/^Q3_P B%K?_ &$C_P"BUIL1]$44
M44AB-]T_2OCCXO\ @26;XAZEJ2W:R"2[P(4PKCY.Q;@_F/K7V.W0YKXJ^+E_
M+'\5=41X/+B%TI%Q_JAG;P6D(.!^!KS,9R\])-7]Y'FXSEO3YE?WE;U.:UC2
MM3L8IHH+W[3!*-LEMJ<0\MQMZ'.2<>N3]:\]UO5K?2G8Q71L,;4,%Q(9(<[0
M2(Y,>H^ZX_&O0;\O=,(DNHKPKEB;-0Y'!SF:0!OR %<?XAT>RV>9*)K$;5#3
M*VXGCD;FR&//3;7I^1Z1G/X^']JRGR5CGDG($T,_ENY#< CM^-.@\3ZS<3L8
MG$DXR 49':(9'\1Z?@,UE7'PZDU'79Y=*\S3M\WS32.8C*"V1O8[DR>X0 TN
MC7O]A.EMJ0B95/RQV68K=B3C.."<CJ05]UH ZCPI<>';ZZU1;^PN]9U5HDQ-
M<6#SE&W'@.0=@Z]Z]@-A?VR>9IT;:?*0 P.U@PST( Y'UKAO"OBW18=-U3=/
M'I*"U4?9YI5C  8_=)^\/?FI/%7QNTG2K%OLKM?LH ,DP\N% ".^[+<G_P"M
M6%->_)H]/%:T*"L]GUTWZ:&AJNI7]CD78:S569OM$,HCA[=<#Y37,>*OC3_8
M]O9P0SQW;R1X5+@-)N&3D@='/'2N.OM>\2?$33UE$ATVR+OL6XC9 5 '*1XS
M^+8%:5E\.+.QCTV>".[FD^R88S*V#\QSF09(SZ=*W]#S"*SUO4->N#(;J2P+
MA=LA55FVD#[HPPC'TR:T]9\ WL5E:3)XEE\/23/EM0N[\,6 7H<'<,]?X1[5
ML:?X?UU96CC@^Q*$7=$R^5(RXYVR+@-]>*Y?XH>#8QH44M_J,&G!Y5'GWI,B
M@X/ \H')SZURXMVH3TZ'MY''FS.@KV]Y:VO;Y=3K]-AC?PW9VLVJ6&KM$C12
MW,, :6?#'YB6+*_U(!]ZQ;R:?1XW:-H-1LD56,-]&0T?(Z(#N'_ 2/Z5>\%I
M!!X,TZ.Q1KNWCBV_;H)%MX"<G)S)%N8?3)JK<6^M:\?*M+.WN(E 47-R'5 =
MPY4X)8^X"BMJ?\./HC@QNF*JJ]_>ETMU?3H6-)^(_A]M,<B^6*=95'D,6V,<
M'Y591YF?][BI_P"U8]<DACNK:VA5W)6)XRRN.#G>O+?2N?N/A/J%SIDAN]0B
M2Y,H(.XQG@'N00?QZ^M2Z?I>L^$%C22R)M\OOGL\2H ,<R+G(^O2M;''<[&;
MPK++I-P\"6NE)Y3;9--4FX0$=5#DA2/89KM?@_X4+^'YVL?%FM,HFQG7('WL
M<<\$<"O.KK7%BTR2::2*W01M(&D64Q8 SGY3Q]0#7HOPK^+VF:QHMQ/)<V%U
M<-*$*6<<L@(QQS(H(KCER_6(=[/^OZ1[=%U%EE9I>[S1N_/6W3]3J;_P_K.Z
M-9+G3-453_#$?,_IG\ZY:1]2L&E$L$L2K$Q"M"X3CT)SC\#717WQ#2$KY>D1
M[F;"F13NSCL /ZU@2:QXEUU7^PZ,\$3Q,!)//(B9[87I^IKLV/$O<SK?XJ7.
MF1L4U)[(H  XN \0Y]!@C\:FD^/7C8H?[)+:FN[;YT7SJ/QVD?K3U^"GB'Q0
M2;JVAF=L#?+^]V\CIGBIW_90\57,+&/6%MCU"O*ZCV'[M@<4KBT/4/@OXMU[
MQ%)ITFL7LLLTR2-)$X  (S@<#M7MR+M&*\;^#OPWUKP3#IB:DUM,UO&Z/) S
M$'.<$;AG\Z]D7I7S&00Q4*%18J]^>=K]N;2WE8Z*SBVN7LA:***^G, HHHH
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M ,NUV/\ MZ:G=B=CY>Q[TN/]JOJ ?L_>#P/^/:[_ / IJ/\ AG[P?_S[7?\
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M-EU(OD,6BVO_ *LGJ5],U]2)X2T/:#_9%EG_ *X+_A3O^$1T/_H$67_?A?\
M"@-#Y?77M12S>T74;@6KG)@$IVGUJCN [C\Z^KO^$1T/_H$67_?A?\*/^$1T
M,?\ ,(LO^_"_X4#/E'>/4?G1O'J/SKZN_P"$1T/_ *!%E_WX7_"C_A$=#_Z!
M%E_WX7_"@#Y1)]/YU[?\ 8W71=39E8*UPI5B.#\O:N__ .$1T/\ Z!%E_P!^
M%_PJ];:?;V4*16T26\*\B.)0HH$6*,<YHHH ^/OVV1CQ;X:_Z\)/_1E=S^Q3
M_P B%K?_ &$C_P"BUKA_VVL'Q=X:]K"3_P!&UW'[%/\ R(.M_P#82/\ Z+6@
M#Z(HHHS0 V3[A/H*^-OC1K4T7CS4;>.[)(NAB%)Q@?*<Y!C( QU))K[*;H17
M@7B_]GFZ\<>-KF^U+58(-%EG$S000$3. /NESQ@]_:N#$QG*5/E5[25_0X\1
M&<G!P6S7W'SC&OB#Q8ZQ:-MNX""C7IW31KZA66-58\=LUU6B_!&^ANA+(D5[
M=;583W?G,0VWG:BGY?R_.OJK0OA+X?TFUBB2&2=8^%\Z0L!QC '0#Z"NIM]"
MLK5"D4(13C(7@<?2N^YUGS%_PIK6)[V1@-T+2[ER!"H&<\9'-8^M_LP:CKT)
M)M80PR%==19&!]20N,_X5]?I:0ITB7\12B!55E' 8]A3 _,;Q]^R%\2['7+*
MUT[16U)9%"I?VL@>*/YQC>.-I'7@<CFO<OA]^P_>64B7_B75+;5]2Q_=9D3V
M4$@=>Y_"OL)[")W5B#N'3FI8XEC557("USTZ2IRE)/<]7%9A4Q>'H8>:25)-
M*V[N[ZGD6D?L^V&G#!\N3YMQS@<^OW2?UKI(OA5:K$B,T155VX*D@_EBN]HK
M8\L\PU'X':??1E1+'"W!#I$<J?49<UY/\4/@GK.G6430&XUJW\T9&D:? ;M>
M."RN-A'J>#]:^IF&1@U%+;))G.3QBLZD%.#CW.G#UY8>M"M'>+N?*/@C]FW5
M]=TZTN=?EN+*+DQV4A2.8+DX\Q4P%;GHM>HZ7^SYIEI"J'SE"J%&VY?L<]S7
MKJ1)$J@# '' ZU-6D4HQ448U)NI-S?5W/+&^ FCR6[1,SE2V[!5&' ]P3WK$
MU#]FC2KE"(YFCR6XP"H!'IBO;L4$9IIL@^.?&?[*_B+0(I[WPS)9W[1H9&TP
M@IYOJJ@[EW'Z"N@^$'@SQQK>FW2W?AZU\ PF8!8KA!).P"\L,  <]]OXU]/S
M6R2/N(.>E)'9I$01D5E*%YJ=]CKAB.3#SH<J]YIWUTMY;:^:.#TCX/6=G*L]
MY>3:A<=2[X!S]>3^6*Z^Q\,:=8 >5:1AASO8;V_,YK5Z"BM$<@BKMX  'M2T
M44P#%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 UR!C/X5B^$_%>
MC>,M/EOM&N4O+:.XDM6E0$8EC;:Z\@<@\5KS$ADZ8SS7E7[-^@ZIX9\":A:Z
MK92V-R^N7\RQ3#!,;S$JWT(YH ]:HHHH **** "BBB@ HHHH **** "HKERD
M#D'!QQ4M<IXVUG5="M_M%G91W=K@^8<G<A]<>E 'CMYXNUJ.\G5=6O% D8!1
M.>.:]"^$.M7NJG4?MUW/=;-FTSN6QUZ5Y%/*9YGD( WL6('3)-=;\.M?U#3+
MZ2STZS6\FNMN0S$;0.Y]J.H+8][HJ*U,I@0S!1+CY@GW<^U2T %,E8 8SBGU
MS7C+5M4T6T6XL+%+Z)03*"3N7W '44"/'];\6:U#K%[&FJWB1K,X"I,0H&>P
MKM?A!K=_JE]J"WM[/=*D2E1-(6 .>V:\MO+EKZ[FN'4*TKERJ]!DUT?P_P#$
M-[H>I216%FEY<72A-CD@#!ZYH+/?^M%4K*\<VT9NFB68C+",Y4?2I_MUN/\
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MA/5+--6&HK-=&8SK 8=GR 8P2?3-:?Q/&-4M\?\ /+^M:OPOC+Z5<G.,3?\
MLHKR(8F;Q;H=/^ 9*3Y[&@VNZ45Q_P )05/M+'Q_X[35UO2U/_(V,WUEB_\
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M5_Y%C_\ B:7^W=*_Z&H?]_8__B:Z;'N?S-&/<_F:+!<YC^W=*_Z&K_R+'_\
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MZ4?VM_<_$?M?(]W^UP_\]8_^^A1]LA/26/\ [[%>#LS*<;B:;N(Q\Q--9O\
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M]?2P,<<:2Q;V=HRZ!R> 7(.#CGGUHLQ<R.G.OZ7_ -!6U_\  E/\:!X@TO\
MZ"MK_P"!*?XUB:AJMI!=0VEMIT,]Q+((XV(1(F;:6(#8.< 9JS]EDCU*(RP6
M0M'0JRK""PDR-HSZ'D=/2DM1O0TCXATL?\Q6U/TN5_QH_MZPS\NH6[#'!%PO
M^-<SXROTT.*$&U6"UG1D>]MH5>6!\9!";3D8SS@X]*\E\1Z7XDUSPSIFO0I9
M:M%"@>(-;F!IL$$3.FT8;@Y3'3D$5$I<JNR9245<^A!K&GD?\A*W_P# A?\
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M1ZUXYX3^$6H^&?,N)M3TZ_GFMDM)+2:P/V<1)G8BG=N)!)RQ^]D\#BNK\/\
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MJ_\ Z$:ZL)&K"G:MN<N+G2G4<J.WS_4N4445VG$%%%% !1110 4444 %%%%
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M\'_%@_YAJ_\ @1'_ (T?\*>\68_Y!J_^!$?^-+V<^PO9S['&11+),BNXC5F
MW,,@<]>*[8QG3?#D]E?3Z>UN'0VCVTB^9*V>2P!SC']ZH?\ A3WBPMD:<H^D
M\9_K0WP;\4X^;3$'/:=!_P"S5<8SCT'"$X7]TM7^C?\ %6#57N[.+3DE27S?
MM2,2 !P$!+9X]*Q_#^IPMXWGO@R1PL9G4/P.5. ?KZ5>'P=\5#D:<JC_ *^(
M^OYUS.M:)>Z!J+V=]$(KA,94,&'KVH;DM6@ES1L^6QK6?B1K_6M/:^BL[:".
MX5V:*W5!CWQVKHH[JZMWE.L:K:W*R7<+6JBX63&'&6&/NC'KBO/<9ZDYI;>S
M:XNHX85+22L$5<X!)..]2ILE3:Z'I^F7LQU72Y;34[>WL89G^U1M.J_-O.25
M)^;(Q@\U2T_6(]/BBE2ZB62.RN@H+CAC(<?CZ5EI\'O%+J&_LY2O;,Z?XT[_
M (4[XH(P--3_ +_I_C6EYVV-G[3I$T;'6)M0TBTV7T:ZR^GO&D\TJJV1*>-Y
MX!V^M9/CQ;E%T3[7*L]Q]CP[JX<'YCW'!J_IOPS\;:/.\EK9*F]-C*TL;!E]
M""<&G:E\-/&FK7"S75D)'50BXFC"JO8  X I-2:V!J;C;E=S@^M&!79?\*@\
M5_\ 0-7_ +_Q_P"-'_"G_%A_YAJ_]_X_\:S]G/L9<D^QC^"45_&.C!@&!ND&
M",YYKZACL+? _<1=?^>8_P *\.\'_"KQ!9>([&[O+=+:&WD$A)D5B<=@ :]Z
MC7:O/6NVA%J.IW8>+BG=$7V"V_Y]X?\ OV/\*YGQUX"M?%VFK;_+:R(V])8X
MQD'N".XKK:*Z'%-69TN*DK,^7_'?@A?!-W:6YN?M+31E]P7: ,XXKTWX \^&
M+[_K[_\ 9!7-_'U2FO:<<Y_<-_Z%72? !L>&;X?]/?\ [(*XH)1JV1P026(L
MCU.BC-&17>>B%%&:,B@ HHR*,T %>=^(-+0>)+X2OD:B/+$#IOC=5B))(].&
M!SZBO1,UC>(=%.J6K-'.]O<Q9>&2,X*MV_#UHLGN)WZ'!#3(M(T:VL)I99[6
MYC9[6 R-<#(&[9Y7+.J\]\8 [@5>T>&\;3(-0AM+2T>X9746K'&[.W;MVC(8
M<[3@COTKG/B,VH?\(/I.L7-K_P (_K<$^QQ$Y=X'?*!T*9!YPQ'(*D@C-=1I
MO@_6-9\.6$FHZD^CZ^R0S736>V6(7"=656&#GOZYJK)*Z-6K037<W+"XFTN[
MCAOX+1//?9'=6PVJS]E93R"><<D<5GZWK][<^)1H6G7=OILS0&47$T7FL[?W
M53(S@<G-;=MX9Q-;3WM]+J,]N=T;2JJJK8P6"KQGD\]JT#ID+7*W!2/SU7:)
M0@W >F>M1+5DQ:CT.$;P#J>NWMI)XC-MJ/D<F6":2),Y!^6,=,C@Y)ZUZ#;P
MB%=H4*HZ = /2I@,"BA*PFVPHHHIB ]#7,:E>W+WMM;FQEC@6>(BY:1-I^8<
M 9S73DUS.IV^H_;[>62[B>Q,\82%8L,&W==W>DP%NUOY7G\YC;0X^0Q'<>.?
MUJD^KW,,D($L4@2/=(F"';\.O?I6CXHLY[JR0V\8DD1@^&<J./YUD7UU90 2
MV;Q-<G(9XY/F![CG@\U\KC93H3E:?+:SNWOUTZ.QM&S.1\=>.O$OA@VFMP:7
M?7NG1N(IM.A6%1-G #J[-NR2V I Y4YQQ7'7/QR\%WEO#K%[H=]IMXTBK/$\
MIC,$X<8$ZQYY^4$-@Y''3./7[*2]O8$\S==1JH9@\(;YAVST-;P\/V+0,4MX
MHQ*IWJL2C=G.0<#W/YFOI,#C:=:DKP=U;7:_YF;5F>$:QX:T/Q_X<N;/PTAO
MQ<:@FJ2W][<K+)"4;+$12'>44@(4.T@/QGI5WX.?"4VS:IX@OQ>V=_K4;2R2
M6MZJ6Y#MD!%3E2N 03TW$<]:ZJXLK70=0@B_=6<-I,TD*VT>Q<D8'W._US6C
M9RS--/-)J($BN=L(7)&1CGC('X5Z<JL^5PCLSB^L13LD9GA+QIXINO%DVD:M
M8V.GVUO(Y\Z><":XA&=LD2JS C[H.<=^]>JVLBSQ;@P=3R#P>*\;GOETZ_6V
MC9(9LJ-PDW$D=L\=N:]/\(PW2:2C74PE+@%,=E[<^M8U$MUH11Q'M9.-MC;(
M&*J:3_QZ-_UU?_T(U</2J>D_\>K?]=7_ /0C6)W%RBBB@ HHHH **** "BBB
M@ HHHH *XOQ!\/$\0W[W,U].H/ 0!<*/;BNTHK"M1IUX\M170FKGG+?!VQ7'
M^FW!SU^4?X5S?@OX9ZGJ=E?R>(K=]+N$OYH[>.$JPDM@V(Y#UP2,G%>SRMM
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M-!\.7UM?P2V<TMP2N<;@-HY'XUY1^U7>7-KXCT..*>6$&U<GRY"N?G]J[_\
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M?\-?#;^)?%5NI3-M;GSI#].@KZ;A38H&[( Q7GOP1\,G2/#:WDJXN+S]X?\
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MR0/^$FU+_O\ FL/4]6O-:NFNKZZEO+EL!I9FW,<=,FJC%Q=SGQ&*C6ARI%3
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M:\/!X_ZU.4''EDMU?N3.GR6=S2%%%%>T8!1110 4444 %%%% !1110 4444
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M<>IAL"58CDXK[-\&_%CPI8^%-'MKC7+:.:*TBC=#OX(0 C[M?&3=#Z8K[[\
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M2[U MM^R0KQGY@.E2B35#TM8/P44_:6_X<R6']?N.9:T5LXX[8'!J&YTFUU
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MX_XNKJG;Y8__ $ 4XR;9Q8O#TX4^:*/,B<U;T>P&J:O8V1?R_M,Z0[\9V[F
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MMSSD_G5+!QZLGV\NQV_]O642'8KR^X%1?\).HR%MF/IN<#^5<>#@<4X3.O\
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MY\</!_\ PEO@:]2-<W=J/M$) YR!R/Q&::ERNYRXBBJT.7J?$FG3^3=1L1@
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MVN_]!K4O_ V7_P"*I/\ A+-=/_,:U+_P-E_^*H]IY"]JC]!]XR.13@<U\@?
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M_1@K%./6MCP6P'B_1,G_ )?H#_Y$6LCFCNC]!D^Z*6D1@R@CH12UUG>%%%%
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M;L+J9L10SI(Q'7 8$\?A7&GJ<,=)*Y]QV^5B4'GBI,GTKRR+]HGPB$7=)?9
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M,@4 %&><4A/'6JS33"ZV>6/**Y\S=W],4 6J*13E12T %%%% !1110 4444
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MTF*]L]*6V\,-:W-NMW.+UY]NTI_ 9">=NWN*H0ZH+#0_#UK-/##8W.H2)>)
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M^29Z#_U[C^9KQ+]HWCQ_$0/^7*/^;5[;\%_^2::#_P!>XX_$UQTU^]D<5/\
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MMU\/--F32H(X/*M+"0ND&,JV0003UQ\Q-=(=9T[H;VW_ !E%)_;-AWO;8_\
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MZ$HPH!YI<5CS2[G9[&G_ "K[CSS_ (4#\._^A.TK_OU_]>@? +X=?]"?I/\
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M\\]8L?W.!BJ7CGX'_P#"<:T=3/C/Q1H;[ GV;2+X0P\=]I4\UZ?12L"T.-\
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MJDBJ%75XV>U//S;@.>GI7844[L5D?(%K^Q]XJU7Q+;W&LS>&K#2B^;B'17N
M^/\ 8$@(S^-?1/@CX0^&? ,:C2M+ACF"@-<N-\K?5C_2NVHIN4GHV8QH4H/F
MC%7&"(  #C'I2B,#U/U-.HJ3<**** "BBB@ HHHH **** $V\8R:$39W)^M+
M10 4444 %%%% !1110 4444 %%%% !1110 4$9HHH 0H"<TUX@ZD=*?10!6%
ME&KAA'&".C;1D59P***  #%%%% !1110 4FT9YYI:* $(XXXI:**5NH!1113
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
6HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>adag-20211231x20f034.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f034.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $O T$# 2(  A$! Q$!_\0
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M*.:/\OYB]G/^=_A_D<1_PF_B7_H0=3_\#K7_ .+H_P"$W\2_]"#J?_@=:_\
MQ==OBC%'-'^7\Q^SG_._P_R.(_X3?Q+_ -"#J7_@=:__ !='_"<>)?\ H0=2
M_P# ZU_^+KM\48HYH_R_F'LY_P [_#_(XC_A-_$O_0@ZE_X'6O\ \71_PF_B
M7_H0=2_\#K7_ .+KM\48HYH_R_F'LY_SO\/\CB/^$W\2_P#0@ZE_X'6O_P 7
M1_PG'B7_ *$'4O\ P.M?_BZ[?%&*.:/\OYB]G/\ G?X?Y'$?\)OXE_Z$'4O_
M  .M?_BZ/^$W\2_]"#J?_@=:_P#Q==OBC%'-'^7\P]G/^=_A_D<1_P )OXE_
MZ$'4O_ ZU_\ BZ/^$W\2_P#0@ZE_X'6O_P 77;XHP*.:/\OYC]G/^=_A_D<1
M_P )QXE_Z$'4O_ ZU_\ BZ/^$W\2_P#0@ZE_X'6O_P 77;XHQ1S1_E_,7LY_
MSO\ #_(XC_A./$O_ $(.I?\ @=:__%T?\)QXE'_,@ZE_X'6O_P 77;XHHYH_
MR_F/V<_YW^'^1Q'_  F_B4_\R#J7_@=:_P#Q='_";^)?^A!U/_P.M?\ XNNW
MQ1BCFC_+^8O9S_G?X?Y'$?\ ";^)?^A!U/\ \#K7_P"+H_X3CQ*/^9!U+_P.
MM?\ XNNWQ1BCFC_+^8_9S_G?X?Y'$?\ "<>)?^A!U+_P.M?_ (NC_A./$O\
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M).D6)+$V5N2S!B3$O)'0GCK[T'2+$];.W^]O_P!4OWO7IU]Z.:/\OYA[.?\
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MXHT3QE<6&G^&[:?2]-@O/"%W UZNGS60(MVMIA(H4J#C+HQ'48.:^DP, "@
M"B@ HHHH **** "BBB@ HHHH **** "@\CBBB@#YJ^)_[)VK?$7QE\1=6_X2
M/3+.T\8Z-;:*Z2::\TUDD3,?.C;S #(=QQP " >:S_%_[&%]X@B\<6]MXO1(
M/$'@RQ\(PR7MH\TT(MR3]HD8./,9LG@8P<<U]2T4 ?,L'[']]#%<3?\ "46K
M:A#XHT[Q1I[FR?RDDM;6.V,4J^9EU=8R<@@@M[5>L/V6=8LTT??XHLIY;'QO
M=^,I'-@Z^:TZR*8 /,^4#S/O<].E?1E% 'R%HO['^M_#C1-)NUUJQ\42:!X>
MUW3%TP:;(/[0:^E:91@S<!20N.X/45U?[+'A+Q)X>UF]D\1^"+31KDZ)8V(U
MN&]NI7=+<;$M2EQ&A4*"S#9D<G))P:^DL9H  H ^?[?]ERXM/M[Q^(XGD7QI
M_P )GIY:T8>7*?O02X?YUQN *[2,^U>C?"'X7Q_"GPI<Z5'>M?W%YJ%UJES<
M%-BF:>4R,%7)PHR !DGBNZHH \D^&/P5U#P)XP^)FLWFK6E]%XQOX[T0P6SQ
MM:[8?*VEBYW\#.<#FO*M!_8IU?1!%&?&-C/;VWA2_P#"UNHTQU8)<2M(LS'S
M3DKNP5 &<<8KZPHH ^1E_8>U==!O--'C&P/VCPSI7AT2'39/E^QR^9YN/-_C
MZ;>WJ:[:#]DRV@\6C4EUMO[.'BG_ (3 6OE-YGVTP^7LW[O]5N^;&,]LXKZ#
MHH \W^!/PHN?A#X&DT"\U&WU61M1N[[[1! T(/G3-)@J6;E=VW.><"LCP+\$
MM4^%.M>*7\*:W9IH7B"_?5'TW4;1G-E<N/WC1.CKN5CSM8<'O7K]% 'A]S^S
MC<3_ !3O_%DNL6&I6NI0VS7=EJ6G%V2[MPPBGA99 J'YCP5;'8BN1\*_LA:K
MX?OO#,\_B32KY-&TK5M-,,NENT=Q]ME,FYE:4C"YQM[CN*^GJ* /-_@/\'E^
M"7A&Y\/V^HO=Z>UY)<VMKND:*QC8#]Q%YC,P0$$@$\;L5Z1110 4444 %<U\
M1;5[SP=JT*6EQ?-);NHMK6;R99..BO\ PGWKI:YGXDVPO/!.L0-:+?B2V=?L
MSS^0)./N^9D;?K0!)>QF+P)<H8VA*Z=CRY&W,O[OH3W(]:9\.O\ D3-#_P"O
M*+^5+=IY7@.Y3RQ#MT[;Y8;=MQ'TSWQZTGPZ_P"1+T/_ *\HO_0:O['S.9_Q
MOD=+1114'2<+XH_Y*IX&_P!S4?\ T5'7=#H*X3Q1_P E4\#?[FH_^BHZ[I?N
MCZ5K/X8>GZLXZ'\2K_B_]MB+11161V!1110 4444 %%%% !1110 4444 %%%
M% !1110 $A1D]*R;W7TAXA3S#G[Q.!2:]=F-1"I(+#DUS[8'!KAK5W%\L3NH
M4.=<TC0?Q!=')#(H] M1CQ)=KCYD;ZK67(^#Q5:291]?2O/=>HGN>I'#4W]D
MZ.'Q:P<":$8]8S_C6M9ZY:7O"2;7_NOP:X$R;B<"CS2N/YU4<9.+L]29X&G)
M7CH>F@Y%%<+IGB2XL6".?-B_NMU'T-=;IVIP:BF^*3/JI/(^M>I2KPJ[;GDU
ML/.C\6Q=HH!&/:BN@Y0HHHH **** ,#2+AI/%.MQ&XED6-8,0O%M2+(;[K?Q
M9[^F*WZP=(9F\4:UF2[90L&$E7$*\-_JSWS_ !?A6]0 4444 !.*,TCYVG'!
MKR?Q'\2=?TGQK>:1:PVUZ(6M]EJD+^=*LGWCN#8&WKDC%<U>O"@E*?4Z*-"=
M>3C#H>L%L4$X'2O#M,^,NMS^(38,+*[?^U9+(V5O&RS+"HR9LER.._&*NO\
M%[4X_#P\2M;PC1VU#[$+?#&8+OV"3=G&<_PX_&N..98>5[/\.V_W'9++<1%I
M6WMU[[?>>RYP*3=SBO)[+Q?XJN?'LWA\76F"..Q2]$GV63)#-C;_ *ST[X_"
MIOAKX\UCQE<7#7-Q9!;:62.:"*VD1@ Q"D.7(.<<C%:QQM.4U!7N[K[MS&6#
MJ1@YMJR2?W['J>:0-FO,[+XH3ZG<^*+.SM#<7VEKYEK KY-TA'##'OD8KE=3
M^-VHP^$9-4L;FRFN8[N"VGAGMI4D@+G#*\9<$%>Q!(-1+,*$5>_?\-RXY?B)
M.W+V_';[SW8MB@-FO)=8^)FJ:#HVG:C<O$VG7;MNU-+.3RX5Q\N^,.67)X+9
M('I7H^A7QU33;6[6:&431J^^%MT;9_NGKBNFGB*=63A%ZK]3GJ8>I2@IR6C-
M2BBBNHY@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B@G )
MK(OO%%E9%E#-,X[1C//UII-[#2;V->BN5_X3CGBS)'^__P#6JS;^-+.1@)D>
M#/<\C]*KDDN@^5G0T5%;745W&)(9%E0]U.:EJ"0HHHH **** "BBB@ KF/B3
M"MQX,U>-[>UNE:W<&&^E,4#C'1W!&T>IS73US'Q*95\$ZR7%B4^S/D:D2+?&
M/^6F/X: 'WB!/ ERH2./&G8VQ-N0?N^BGN/0TWX<_P#(EZ'_ ->47\J=<X_X
M0*XQY8']G?\ +'_5_P"K_A]O3VI/AS_R)FB?]>47\JO['S.=_P ;Y'2T445!
MOJ<+XH_Y*IX&_P!S4/\ T5'7=+]T?2N%\4?\E4\#?[FH?^BHZ[H=!6L_AAZ?
MJSDH?Q*O^+_VV(4445D=@4444 %%%% !1110 4444 %%%% !1110 4444 <Q
MK3$WDA/3 Q63*V/>MOQ) 1.DF#M88)'K7/NPY]:\3$:39[^%]Z"(9I<"JSO3
MY26R.U5)74 \UYLY'JPCU8KRX_QI!,,]:H27L:GF09/:G0W"R<@Y%1*G5@N:
M46D:QE"3LF:2GOD9%6K.\DM)A)$=KCO6;$YR<].U6XV]:<)M.Z(J035F=YI&
MM)J4('"2@<K_ %%:M>=V=R]O(LD3$.ISFNXTR_6_MQ(.#T(]#7T6&K^T5GN?
M+XK#^RE>.Q<HHHKM.$**** ,'2%=?$VLEH[Q4*P[7F?,#<-GRQV/][\*WJPM
M)M?*\3ZU-]GD3S5@ G:7<LF%;@)_#C//KFMV@ HHHH 1UWKC.*P;;PI:6GB*
M]UB-YQ>7<:)+E\H0OW<#M6_1@5$H*5FUL4I.-[/<\_/PBT$7)G'VE+K[:=06
M99B'20_>P<?=/=>E68_ACH<96,PR&R%S]L%D9#Y EZ[MGUYQTSVKM\"C:/2N
M=82@MH(Z'BJ[WF_O.53P78+XGEUU//&H2VXM68-\GE@Y VXZ^]4]-^&NGZ1:
M_9[>ZU"& R22&-+CC<_4]/?CTKML4;1Z5?U>E>_+_3W(]O4M;F[?AL</=?##
M1[C4K>_'VFWN8K8V@>VF,9="<_-@<GWINK_"K1->65;L7#R220RO.)<2L8ON
M9;'('ZUW6!00#C/:I>%HN]XK4I8FLK6D]#D6\!6DEP\S7M])(Z.C$S\%6&"N
MW&,>G%;NBZ5:Z+8V]C:1"*"!-B*.< 5>9U!))(Q60?$=I%K\.ELS?:98S(H
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M"IJ5H+VV>,G! R"/6N(N4:%F5U*D'!!KT$KG/K6'X@T8W"FXA&90/F7^\/\
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M;')/#@ '!SFOT>"*O10/H*\N^.WP7M/BUH"HI2VUFU.ZSNR.!ZHW^R?TKZ'
MXA8>K>6S/D>(,LEF>$Y:?QQ=UY]U\_S/S^L+VYTR]AN[.X>WN86#QRQ-@JPZ
M&OT/^!OQ'7XF> K#5'PMZI:WND':1<9/T/!_&O@OQ=\/O$7@?56L=7TFXM9
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MVYTG;M=7.2M3]E4E3O>SL%%%%=IB%%%% !1110 4444 %%%% !1110 4444
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M>F M%5I]2M+4XGNH8#Z22!?YFFP:O8W)Q#>V\Q](Y58_H:GFC>URN65KV+9
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MW,OS2-^/8>PKJ0,<48W&_67R05HHRPV']DKRW&B)0  , 4\#%%%>4=P4444
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M-P?U62<?A9YN'KJLK/=&I1117FG8%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!@:0B+XKUTA+0.4@W/$Y,S?*V/,'0?[/MFM^N>T9PWBW75#6AP
MD'RQ+B8?*W^L..?]GKQFNAH **** &2$+AB<8[5CR>*=*2]-FVH6XN@<>49
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MF".+:\65;[S8^;/;DXQ6]6!HT^_Q1KD7VEI#&L!\@P[1'E6Y#_Q9_3'O6_0
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MW?PXA</>FX:ZP'>'*IQGCU/7O7VM7$X/,Z2G1GJ]M#XR5#$Y=4<*T=CW=7#
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MZ9?)<. GE<CY"N""!SDYJSXKU.*VT30#!<H=0EUFR2]MK+4&:,(SD!2=W1U
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M\1#._J/K6Y38UV*!T]J=7V.&HK#T844[\J2N_)'DU)>TFY]PHHHKI,PHHHH
M*"0.M%!XH ,CUHW ]ZSM3UJTT6TEN;N000J>78]_0>],T3Q!:^(-.2\LR[0N
M2%+K@\''2N5XFBJWU?G7/:]KZVVO;MJ:>SGR>TMIM?I<U** 01Q175N9C)9
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MH:YS0+CS?$FLQ?:DE\N.W/DB(*T65;JV/FS^F/>NCKW5L?//0****8@HHHH
M**** "BBB@ HHHH *,9HHH ,4444 %%%% !1110 4444 %%%% !2,>WK2T$9
MH \N^-5O</IUA*H)MTD;S,= 2.":Y3PU\0]0T'3(-,L[*&X.\[2V[<Q)SC ^
MM>YW>G07L+13()(VX96 ((].:R].\#Z+I%S]HL["*";LX&2/IGI7YEF7#&8U
MLX_M3+\3[/F2C+2[LK;:-:V78^CPV98>&$^K5Z7-9W7:_F:E@TKVL33*%E*
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M_9/M_F6[K]G^T>1YG'3S/X?K0 M\I7P+= J\>-/(V2MN9?W?0GN?4TSX<_\
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MW!@O9O*A?CH[_P (]ZZ:N8^)**_@S5@XL2GV9\C4V(MCQ_RTQ_#ZT 27B!/
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M5KDAMYHS(D'[YY04DPK?=7^''0^N:WZV,0HHHH **** "BBB@ HHHH ****
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M $)WBK_P7+_\<KM]H]*-H]*?/3_E_$/98C_G[^".(_X6@_\ T)WBK_P7+_\
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FK <@UNM&K#!IR*$4 # %3*2:M%6-*=*<9<TYW?I86BBBLSJ/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>adag-20211231x20f037.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231x20f037.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '" \(# 2(  A$! Q$!_\0
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M9PN\Q;AN"YQG'7'O0%SYU_X=V_L\?]$UL_\ P.NO_CM'_#NW]GC_ *)K9_\
M@==?_':^@KW6M/TV[L[6[OK:VN;QS';0S2JKS,!DJBDY8XYP*N4!<^<?^'=O
M[/'_ $36S_\  ZZ_^.T?\.[?V>/^B:V?_@==?_':^CJ* N?./_#NW]GC_HFM
MG_X'77_QVC_AW;^SQ_T36S_\#KK_ ..U]'5GV?B+2M1U*ZT^UU.SN;^UQ]HM
M89T>6'/3>@.5_$4"N> _\.[?V>/^B:V?_@==?_':/^'=O[/'_1-;/_P.NO\
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M 4444 %%%% !1110 4444 %%%% !7CO[7_\ R;7\0/\ L%R?TKV*O'?VO_\
MDVOX@?\ 8+D_I0!Z/X'_ .1+T#_L'V__ **6MNL3P/\ \B7H'_8/M_\ T4M;
M= !1110 445!>W]OIMN9[J9((@0"[G R> /K[4 /N+B.T@DFF=8HHU+.[G 4
M#J2:^7]7\577ASXCZ!\79_L\/AC5+PZ%=7PU%60V$C;+=]@&!B8;R03\IKZ"
MU7XA^&=&O9K/4-;L;6>)0TR32@"$'H9#T3/;=C-;D:VUQ;Q[%BD@(#)A05(/
M((H ^4]>^*'_  DOBSP[?:IKB:?J.E>*KNU_L4K&QMXD@?RI-A D8L/G!SAL
MX%1Z?^T3KD>G>()%\5V%W9V]KI-]'>W+VR2)%/(RW!7 $:-@#".6V'AFSFOK
M'[+ )C-Y,0E( W[!NP.@SUK \8>![/QAI<5F;R\TEH9DN(KC3'2-U=3D95E9
M'&>JLI!]* /GMOC1XBMK'38=0\>:-8V.L7-ZMEXB,UL\$)3'V>"22)'C\PC)
M*GEL  @FGS?%SQ?8>(=5-QXRM[A-,U/1K06<=I;Q07(N$(F&&7S%!.&7Y@5R
M.2*^A?#/@O3_  S930H3>S3R"6XNKF.(/,X& S"-%08[845LSI;11R32QQA5
M&]G* XQWZ4 >*_!7XF:K\0?$L\LOBC3IUBCN(=0\-+'NNK"=)2JEL(IB&T8P
MY;=D$&O._&?CF]\&>-_C%?Z#K%OI>J"]T.+S=D,K;6WJP*OGL?PKZ<\,>)M#
M\66+ZEH5]:ZE:22&-KJT(97=3@C=W(.1[=*=I.MZ+XAGU!-/N;2]ELIS;70B
M 8Q2@ E&XZX(H ^?/^%V7^E:S/H6N>-8[#2EUV^TS_A*)4MT,16!)((I"%\L
M$LS 94%MNWKS7O7A#Q%::K90V7]M6^L:K;6T+W;Q1B%VWCY9&BR2@?!(%;3V
MMNZ%&AB*D@E2@P3V.*HZEXCTC1=4T^RO+VWM;_4W,5K#(P$EPR@DA?7 R: -
M2BJL^J6MK<V]O-.D4UP2L2,<;R!D@>I]JM4 %%%% !1110!X%\5O^3I_@W_U
MQU+_ -$U[Z.E>!?%;_DZ?X-_]<=2_P#1->^CI0 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ****  ]*\5_9K_P"/[XI_]C?<_P#H
MF&O:CTKQ7]FS_C_^*G_8X7/_ *)AH ]JHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK/\ A /CI_T5OPU_X1A_^2ZF_9$_Y(5I/_7_ *G_ .E\]>RT >*?\(!\=/\
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M!^.O_16_#/\ X19_^2Z3_A /CK_T5OPS_P"$6?\ Y+KVRB@#Q/\ X0#XZ_\
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M'8/"=QINF:%+/-+K,MXKI++<7,DRPJ@4'(5CDY_A]Q7V/7R%\"/@G\=_V>?
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M2_\ "0TO_P")H ]\R*Q+3P7H=C/JTT.F6ZR:L<WY(+"Y.-OS@D@\<?2O'O\
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M^\1BNI\>^'-?F\,VQ\.7FL^"_$+ZY$+,7VJ27D9 5N'7S&#0R;<%<G&<C!%
M'OE'X5\Q:S\29?&_@[Q]?[]0\/>+-%\/2PZEI<5]+&UA>(6^= K 88 ,L@'*
MXYKTCX-6US)9Z9?75AK-@\NDV[-/?ZNUW%=NR@LP0R.%8=<\'F@#U4G'7BEP
M?0U\M>(+;QOKWQ3^(ECX0O\ 64U2QU/3&LY?[49;&SB:-6G$D+R;65AN^4(3
MDC&*Z6X\"(/CC:^'WU[Q(;-_#_V^3;KMX,W/VAAYF/,P. !MQMQQB@#Z P?0
M_E25\W_#>/4=6\:>-K2XB\0ZG;V7BE[:'4$UR1([&%0&P8S+R@(P1M(^:O?/
M$XW^&]3P[I_HLI#QN48?(2"",$'W% &ITI<'T/Y5Y-\#()/$7[/_ (<&H:IJ
M#76HV(,]^]X[7+,Q.2)6)8-@=CQVKDO ?A-+OQ+\3$DUGQ"Z:'J'E62/KEVZ
MI&;4$H0TA!!8[LGD'&#0!]"]/:BOE)=;UKP5\!OAUXXTWQ#J\NMS7EG!=VM_
MJ$MU%J:SR['C9)68!\'<&3:1M]*^K$8E1D%21G![4 +1110!Y-^UE_R;=\0_
M^P3+_2NW^'/_ "('AS_L'6__ *+6N(_:R_Y-N^(?_8)E_I7;_#G_ )$#PY_V
M#K?_ -%K0!T5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X%^VE_R2[0O^QKT3_T
MNBKWT=_J:\"_;2_Y)=H7_8UZ)_Z715[Z._U- !1110 4444 %%%% !7F7[0W
MB;6?!_P\74]"U*32[X:G86YE2*.3,<MS'$X*NK#[KG!Z@X->F[A7)_$OX>6G
MQ1\-#1+S4;W3;;[3!=^;8>7YF^*19$_UB,,;E7/'/2@"/XD^)(_">@6$\]SJ
MD*2ZG96?VC3DA>3=).D:A_,XV,6"L5&X!CC!KE8_VAK*YOXK2V\*Z_.\U[>Z
M; RK;!9+FV!9X^9OE#*K$,<+Q@D'BMK6_A'_ ,)/9M!J_BK6KX_:[2\C<K;(
M(C;RB5%55A"X9U4L2"3@#(JI8_ G3-/O;*ZCUK53)::I>:N@?R"#+<HR2*?W
M7W0'; Z],DT <GK_ .T;96ND7'B/2K36;PIX7FUJ+2;E8(;=@DZ1MN;)<2HQ
MVD [2"<9.*ZF7X\:19:M;:==6-\9/.CM+V>WC66.RF:(28D"DD( RY< JNX9
M/4C.B_9F\.QZ2=-FUG6+BU.B7&A%7>!28)I1*SY6(?.& P>F!T-:UA\$+*PU
MV^OX_$NOR6>I1H-3TEIXOLE],L8C\YP(PRL550PC95;:N5XH R_"'Q-U#QC\
M7+"&V%Y;^%K[PT^J6D=RD(2<^?$J3*5RXRCD[6/1@<9SCUVO-_ /P0LOA_J^
MF7UOX@UK4ETS3GTBRMKZ2%HXK1G1EC)6,,VSRU"L6S@ '->D4 %% .:* #%%
M%% !1110 5X)I7_)\6M_]B-#_P"E@KWNO!-*_P"3XM;_ .Q&A_\ 2P4 >]UX
M[^V!_P FU_$#_L&2?TKV*O'?VP/^3:_B!_V#)/Z4 >C^!_\ D2] _P"P?;_^
MBEK;K$\#_P#(EZ!_V#[?_P!%+2^-?$T/@SPGJ^N7"[H=/M9+EE]=JDXH VLB
MFN"R$*=I(X;&<5X5/KGB?5_%?PMMG\3:AIL7B&RN;S4+>Q$(4M]G\U%4O&Q
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M;(HP2_.!N)/JY[8KK/\ A;'@C_H<?#__ (-8/_BZ .JHKE?^%L>"/^AQ\/\
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M[;<<4^'X"^&_[$U/2[RXU34[?4-335YGN[O,@N5V_.C*%V@[%R!QVX'%;O\
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MV=S8I$]TJ_)/)YCG<J [@_*L",8KMO!_@Y/".D&Q;5M5UZ1OOWNM7(GG< 8
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M_P#HE?@W_P $=O\ _$5ZE10!Y;_PRQ\&_P#HE?@W_P $=O\ _$4?\,L?!O\
MZ)7X-_\ !';_ /Q%>I44 >6_\,K_  :_Z)5X-_\ !';_ /Q%'_#*_P &_P#H
ME7@W_P $=O\ _$5ZE10!Y;_PRM\&O^B5>#?_  1V_P#\145U^RS\'$MI2OPK
M\' A3@C0[?CC_<KU>H;S_CUE_P!T_P J /ES]E[]G/X5^(_@UIE]JGPX\*ZC
M>O>ZBC7%SI$$CE5O9E4%BN<!0 /0 5ZO_P ,K?!K_HE7@W_P1V__ ,369^R)
M_P D*TG_ +"&I_\ I?/7LM 'EO\ PRO\&_\ HE?@W_P1V_\ \11_PRO\&O\
MHE7@W_P1V_\ \17J5% 'EO\ PRO\&_\ HE?@W_P1V_\ \11_PRQ\&_\ HE?@
MW_P1V_\ \17J5% 'EO\ PRQ\&_\ HE?@W_P1V_\ \11_PRQ\&_\ HE?@W_P1
MV_\ \17J5% 'EO\ PRQ\&_\ HE?@W_P1V_\ \11_PRQ\&_\ HE?@W_P1V_\
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M';__ !%'_#+'P;_Z)7X-_P#!';__ !%>I44 >6_\,L?!O_HE?@W_ ,$=O_\
M$4?\,L?!O_HE?@W_ ,$=O_\ $5ZE10!Y;_PRQ\&_^B5^#?\ P1V__P 11_PR
MQ\&_^B5^#?\ P1V__P 17J5% 'EO_#+'P;_Z)7X-_P#!';__ !%'_#+'P;_Z
M)7X-_P#!';__ !%>I44 <+X5^!'PX\#:Q'JWAWP'X<T+4XU*I>:=ID,$J@\$
M!E4'FNZHHH **** "BBB@ HHHH **** "BBB@ HHH+ =3B@ HI-P]11N'J*
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MPQG(Q1N'K7S=J'Q+\2:1\1X/AW_:MU<176I6,1U9@OVB.&6%GE0-C )*\''
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M5[310!XM_P ,VZE_T6SXH_\ @SLO_D2C_AFW4O\ HMGQ1_\ !G9?_(E>TT4
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MFV^*?QP\??$+QWI/@BQ^'T&C^&M3&G*_B!KX7$IV!]Q\K*]_:@#Z6HKP+?\
MM1?\\?A%_P!_=4_PHW_M1?\ /'X1?]_=4_PH ]]HKP+?^U%_SQ^$7_?W5/\
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M:[O'U"[BA1);N0 -,X'S.0  ,G)X%7:\!\S]J/\ YX?"+_O[JG^%'F?M1_\
M/#X1?]_=4_PH ]^HKP'S/VH_^>'PB_[^ZI_A1YG[4?\ SP^$7_?W5/\ "@#W
MZBO M_[47_/'X1?]_=4_PHW_ +47_/'X1?\ ?W5/\* /?:*\"W_M1?\ /'X1
M?]_=4_PK \1?%+X\_#37O"/_  F%A\.;C1=:UB'2Y#HCWYN$W@_,OF87MWH
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M\]HDLEK9AG6.1D!.(<9(':B@=C]E:***!!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5#>?\>LO^Z?Y5-4-Y
M_P >LO\ NG^5 'D'[(G_ "0K2?\ L(:G_P"E\]>RUXU^R)_R0K2?^PAJ?_I?
M/7LM !1110 4444 %%%% !1110 4444 %>._M?\ _)M?Q _[!<G]*]BKQW]K
M_P#Y-L^('_8+D_I0!Z/X''_%%Z!_V#[?_P!%+6WBL3P/_P B7H'_ &#[?_T4
MM;= &9XEUR+PUH-]J<J&5;:)I!$OWI"!PH]R<#\:\TN_CC<W?P O/B%IFE01
MZC9V\CW.D7TQ'D31N4EA=D!(96!YQZ>M=EXZ\)77C*?1[-W@.AQ7(GOX6>1)
M9=HS&$9,8P^"<GG&*\PU3X :];Z#\2_#N@ZEIEKX?\4E9[.WN_/D>SN&4+,[
M')W!]JG&>"/>@#K8/BIJF@^-_#?AWQ3I5I!'XBC<:=JFFW#O$;A$WF&1'4,I
M*@E6!(.,'%7]#^+=KK'Q2UCP:UA+;&TM!<VE_(P\N]VL%G5/^N9://\ O'TK
M%U#X7>(O$WB+0]>UG4--CG\.02G2=.M$E,/VMXS'Y\TC88A5)PBJ.N236=>?
M :\L[WP1KFAW5I:>)M&NC+J%S<RW$D5W%*"+F-5+';O+$CC@XZXH V-%^*.M
M>-]-UG6O#=CI:Z)874UG;R:K<O$U])$VV1@P&V--P*@G<20> *RM1^-6K0_$
M.]\-!?#NEQP:+#JRW6IWC@,SMM,7R\'!_B!.?2H?^%&:SH_@GQ=X*TJ^TV[\
M-:Y+<3VXU)'\ZP,[;I4PH*RH&+,N=I&2"3UHA^"NMZ-X[?6K-?#VJV(\/VVA
MQVNIQ2*1Y1!\PA588./NC\Z -!/C==Z'\4K;PAXGTJWT^VU&U@:PUFWE9[<W
M<@)^RR9 VLVUBASAL8X.!5/5/C)K^F:WX2TVXA\/V?\ ;LU]$UU=7$J10>0&
M(Z@9+!.F1@GO6W?_  CD\8QZ_9>+387^GZK86UN?LJO')%-%N/F)G[NUF!4@
MY&T<USH^"'B.PN/A_*-4TSQ%)X96[%Q+K,;A[XS*ZAFVJ0& 8$G!R0>F: /5
MO".JW>LZ#;WEZ;%YI"V)=-E,MO(H8A61B,\BN8\(?%J#Q9X^\3>%Q826,VF1
MI-9W,IRE_$25>1!Z))A3[UJV>C^(;7P7=V4;:1;:NRR"V2VB=+2W!^ZH'WCC
MDYP.3VKB3\#)]#\4^"/$'AR>UL[_ $E)+;5/M<UQ*MY;R+^\1 6(4F3YP<8R
M.E $_AGXMZYKWPQ\1^)9--TV"^TR]NK6*V661HG$+[=S-C()ZX ./>H++XUZ
MAJ_C[4O"ME;:0FL:<EO(^EWMS)!=7D+J"\]N"N&C7D=\D<E:ET3X2Z_X>TO7
MO#=O?:=<>'=5U&:]^U3B07<"2L&DC" ;&.0<-N'!Y!Q47Q+^"VH?$N5;:_.C
M"&TOHKK2-82*1-2TI5VY$3#@L<'G<HP>0U "ZC\0/B%;?$2V\+1:1X;\Z[L9
M]1A:2ZN.(XY50(Q"XW,&!R.!TYK"N?VB];T77=0MM0T'3;F"T\10:!]EL+QS
M>R&55/FI&4PX7?RN1P"<UZ%J'@;5;KXR:3XLCN;(:99Z5-ISV[J_GNTCJ^\$
M?* -N,>]<%/^S[K8\4:[XKL=4TS3O%3:T=5TJ^CMY&"1-&L<EM<="\;JO.TC
M&<CD4 =S\3_BW;_#.]T"*XT^2[MM0O$@N[E&PMC"S;?/?_9W%5_&F^(/B'J>
ME?&'PSX/@LK.2QU:SN+J2ZD=Q+'Y6,J% P<YZDC'O6/XF^"\OQ$L_%!\4BSF
MN]1MA:67V.XN$CMT"Y&X9&X[\-G'85EVWPM\>0^)? GB"YU+0=0U/P_I,VG7
M7F"XC6[=U"^8#@E>%!(.<G/(H Z[7OB%J.E_&'PUX0AL[22QU6RN+N2Z=W$L
M?E8^55 P<YZDC'O1I7Q<MM1^+6H^"7L7M_(M/M%KJ#M\EVZD":-!ZIN4GZUA
MWOPX\9:C\0/#OBVXU+16O=-T^\M7@2*8)OF^YM/)VK@9SR>>E9]_\!;VW;P=
MK6BW=I9^+='OOM=Y=SRW$D%RDF1<1JF[Y0X/''''6@#VS HQ2+G:,]?:EH \
M"^*W_)T_P;_ZXZE_Z*KWT=*\"^*__)T_P;_ZXZE_Z)KWT=* "O /V;/^2F_'
M/_L:%_\ 1"U[_7@'[-G_ "4WXY_]C0O_ *(6@#W^BBB@ HHHH **\H_:!^*6
MH?#?PY#-HDEB=5W?:GBO7 #6L9!FV@D98KG;[U<\7_%VS7PJCZ"US>ZMJ.C2
MZM9+9+$SQPB/<)3YAVX!P,'.3QB@#TNBO'_"OQTM[73/!UGK]O?M?ZQ%:PG4
M6BC2*2XF0L-J[@6'!W%%(4\&K*?M(^%VN(@]OJ,=E-:S7D-\T2>4\44GEL3\
M^Y3OX (YH ]7HKR5OVCM'%Q!:KX>\037T]X]E'!%;Q;7=8_,!60R!&4KW!.#
MP<5(_P"T?X:_LO3[V&TU.Z-S#'<26D,"M<6Z.^P%HPV6(8'(3=P,]* /5J,U
MR_Q"\6'PKX.O-1MY;>*\=/*LS='9&9WXCW$]L\GV!KR>#]H>_N_@MH.LP)9O
MXJU'58O#TPZV]O>ERDCD _,H + 9YR* /H"BO/;34Y] ^(6DZ!>>,I-2N;RR
MEF.F7EBBR2[<9ECDCC554'@J3^->A4 %%%% !7@7[6?_ #2__L<+/^3U[[7@
M7[6?_-+O^QPL_P"3T >^CI10.E% !1110 4444 %%%% !1110!D>,?\ D4M:
M_P"O*?\ ]%M7EW[&W_)M'@+_ *\/_9VKU'QC_P BEK7_ %Y3_P#HMJ\N_8V_
MY-H\!?\ 7A_[.U 'M%%>4?M!ZKK4_AH^'_#-SJ%GKMY&US'<Z9;O-)$(L.JD
M*#@2. A/INK-TKXVMXU\,^#;73+>(:OXEL+F607I=4MV@0"9&"8;?N;& 01R
M: /::*^7_ 7QIU?P5\./ MK]EL]30V]C%=@W$LMSF>9DW,?^6:KP07)+\\#K
M77W?QZU^SU:ZE?PY&NC6)U%K]7\T7%I':CY&9L%/WN?EZ 8/)H ]QHKPG5OC
M5XXTBWTV:3POIGV75M0L[6QNY;S:'CG1R28T9VRA7&<@-VQ4&E_M!>)?$%JN
MF:9X<LKOQ;#'=2RVBW!6WF$$[0D(SLI4,5)W'.W(R#0![[17AO[2US<WG@3P
M;-Y5Q!/<^(;"*:VM+PQLR/NWQ>8C $'&.N#BL?P]JGQ'^&>I:;X=DCLKQ?$>
MK7\FF0:SJ,UR^EV<>QDB:10QDX8\;CMX&3B@#Z*HKP)_C]?ZGH.DW\NC65UH
MWB6TOULTCFD62%X(RVV8C^%P#RN"I]>M.\*?&76+[3=,L/#'ABWG73[.PFO[
M1[O:(X9E#$QR.X/R*<@L&W$$<&@#WNBOG[Q;\:O&$_PIOO&.A6^C6VF75HDU
MC-),TEQ"YN$C*/'T?Y6SN4C:>"#UK:^./BK6=)\,>!;-+U["+7];M--U/4+5
MC&8X71V95;JA=E5,@YPQ ()H ]G_  /Y45P]WX$TSP_'J-UIMQ>V#-IDL)LX
M;V4(< D2*I;*O_MCD\9IOP4>75/@WX3:]EENY9],B\V2XD9WD)7DLQ.23ZDY
MH [K]/K17Q=\-;?QYIOPRL/'&@7]S86VFZ'JUSJ<^J:C)=QZC*NXV^(&9L%"
MA._Y3@@<CI[#X=^,/BS5'L;"QT:UUJ\L$L#K#M.MO\MQ&KM(A9QMVAP<%3NP
M0"#B@#W"BL+QTGF^"=>!W#_0)R"C%2"(V(((Y!R.HKROP?XBO_"?[(=EKUC<
MK_;%OX9:^BGU!GF\R=8&?+%FW,3@GK0![C0>WUKYE\9_$37?&7@R2R4VR3Z)
MJ.A+J-PKS12RRS26\I,84C"A95&&R&RW3 KZ9'W5_"@#\'/BW_R5;QG_ -AJ
M]_\ 1[T4?%O_ )*MXS_[#5[_ .CWHH*/WDHHHH)"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&\_P"/67_=
M/\JFJ&\_X]9?]T_RH \@_9$_Y(5I/_80U/\ ]+YZ]EKQK]D3_DA6D_\ 80U/
M_P!+YZ]EH **** "BBB@ HHHH **** "BBB@ KQW]K__ )-L^('_ &"Y/Z5[
M%7CO[7__ ";9\0/^P7)_2@#T?P/_ ,B9H'_8/M__ $4M;=8G@?\ Y$S0/^P?
M;_\ HI:VZ "BBB@ HHHH *1LE2%.&/ )&<&EI&SM.W&[MGI0!\W>%_VC?%NM
M:SI.G?8]!U"YU75M0TB.WLQ,LUG]GW;+B9=[9B.W#?=QD8)KK_"7C3XB^)/%
M_BC1#<>&%_L&:VBD=;"X'G"6,L2,SG&TCISD>E=1\(?AK+\,M#U"PGO;?49;
MK4+F^\^&V,) FD+E#EFS@G&<\^E2>"_A_>>%O&_C'79]1@NX=?E@E6VC@9&M
M_+0J 6+'=D'T&* .,\%?%WQ1XKA/AZ:+2K'X@V&IM;:M8FWD:W@M@<BX0>9N
M*NF"K$X+97M72?%#Q[K/@[Q)X$T[3EL7AU_51IURUU"[-&NPMO3:X&?EQ@Y'
M-6](^'-UIOQ>UWQH^H020ZGI\%A]B6W8/&(F9@WF;L'.X\8'2HOB=\.-1\<Z
MSX1U'3]4M=.D\/ZA_:"I<VS3"=MA7:=KKM'/7F@!GQD\5>*O!/A74]?T,Z1]
MDTVS>XECU""65YG!&%79(FT8)R3FN?U7QSX_T?5_!=C+/X<<>(;MH?.2QG'E
MQB RYV^?][(QUQ@YKH_%O@+Q!XU^'GB'P_J.NV2WNJJ8DN8;%A#;1G& (S(6
M8\')+#/H*A\4_#;6=;O?!%Y::O86T_AN0RL)[-W6Y8PF+'$BE!SGO0 OP]^)
M>H:YXT\3>#?$%C;V>OZ(L-P);)V:"\MI<^7*H;YD.5(*DG'8FO1:X?P+\,QX
M6\2:_P")=2U%M9\1ZV8UN+GRO)BAAC!\N&),L549)R6)).?:NXH **** "BB
MB@ HHHH \"^*W_)T_P &_P#KCJ7_ *)KWT=*\"^*W_)T_P &_P#KCJ7_ *)K
MWT=* "O /V;/^2F_'/\ [&A?_1"U[_7@'[-G_)3?CG_V-"_^B%H ]_HHHH *
M**#TH YJ7P)9W?B'4=5O;B34#=VPM5M;F*)XK=.<[/ESSG)R37 :?^S-IFD6
M&FP6'BC7;:6PMKFPCN/]'9FLYR2UN5,6W:I8E3C</4U4UCQ_XN\4^#?%NN>$
M()KR33M5;3K>PL_+%Q+#$P$[Q>9\IE.3M#<<>M-\#_';2Y=(@O(-3U7Q#:W>
MK+I;Q:G;I:7FC3LO$-VC*A!R,;L'ZD<T 6A^S-IMI-97%OXEUZ1[![2>"&62
MWVM+;*5CRWDDA2#A@..X&:Y;P;\$M?U0ZII^OQZEINF:DLRWZ3C3F#;GWJ;6
MXMU$X(8!@9,=.0:Z^X^.MAXC\ :CJ]G8ZM!!#;W#W#6,T NK4Q2>60-Q*[B>
MG48J7P]\9KV\U+Q1;OHCMI>@Q6;?;I;V)7:.6'S&EES@* !S@?A0!HI\$_M/
M]@2:KXPU_6[W1IWGAN[TVY=R4V ,%B"X [@ D\DFJ.C?L]67AF^TN[TGQ7XA
MTZ2UM_LET+>2 +?P[RZK*/*^4@D@-'M;'&:A@_:-L;K2;2\@\-ZQ-<3PB\_L
M^.-7N#;%]BRJBYW;OO!>#MYKGO'GQNU76_#>M2Z!INK^'UTC6(+"74YFM]LK
MB5 \6S+. 5;K@8Z9!H ]AUOPA!K^K:1=W%U-Y&G,SBQ*1O#,Q& S[E+9';!%
M<9>_L[>&]2D\4K<W-\UCK]U%?O91F.*.SNH\;)[<J@9'X!))(/I5?6_VB=-\
M/:[J6EWNAZDD]K:75W&FZ(23I;C+G86&P$'*ECS[4W2_VBM.U RP3Z'J6GW[
MFS%G:3O$S77VI=T6&5B%XSD'IB@#I=+^&*P>+]/\2:EKE_K&I:?9O96YF2*)
M0CD%F<(HW,<=>![5V]?/6A?%77M!\-7GB'6[FZFBM_%TVCSV5T8G9('D")AD
M &4)&".H/-?0M !1110 5X%^UG_S2[_L<+/^3U[[7@/[6?\ S2[_ +'"S_D]
M 'OPZ44#I10 4444 %%%% !1110 4444 9'C'_D4M:_Z\I__ $6U>7?L;?\
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M9_\ 8:O?_1[T4?%O_DJWC/\ [#5[_P"CWHH*/WDHHHH)"BBB@ HHHH ****
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M'?\ "YO '_0\>&__  <6W_Q='_"YO '_ $/'AO\ \'%M_P#%T =C0>17'?\
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M%9I;W$=RBR6S6HQ#)&1'C<!D'<"#GD5TO_"YO '_ $/'AO\ \'%M_P#%T?\
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MV<JBMRJECCL:XG_AN;X5?\]O%/\ X1VJ_P#R/1_PW-\*O^>WBG_PCM5_^1Z
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M-3_^/U[[10!X%_PP]\+/^>/B;_PK-3_^/T?\,/?"S_GAXF_\*S4__C]>^T4
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MU2[>1CQTE:4R)]T?=84H^#GA5?!K>%A9WG]BM/\ :#%_:EWYF_(.?.\WS,9
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MP5PQ/'E-G('XUUM>3ZY\-]2\4^,/B-'=6YM-&\0^'[?2H+U9D9MZ_: _R Y
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC_\ "3U3_P"1Z/\ ANKX2_\ /]XC_P#"3U3_ .1Z^@,>[?F:,>[?F: /G_\
MX;J^$O\ S_>(_P#PD]4_^1Z/^&ZOA+_S_>(__"3U3_Y'KZ Q[M^9HQ[M^9H
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MI_\ (]'_  W5\)?^?[Q'_P"$GJG_ ,CU] 8]V_,T8]V_,T ?/_\ PW5\)?\
MG^\1_P#A)ZI_\CT?\-U?"7_G^\1_^$GJG_R/7T!CW;\S1CW;\S0!\_\ _#=7
MPE_Y_O$?_A)ZI_\ (]'_  W5\)?^?[Q'_P"$GJG_ ,CU] 8]V_,T8]V_,T ?
M/_\ PW5\)/\ G^\1_P#A)ZI_\CUV'PL_:3\!_&77KW1?"^HWUQJEE;"[GMK[
M2KJR98BP4,/.C3(R0.*]0Q[M^9KP32O^3XM;Y)_XH:+J?^GP4 >]T444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+_HXAO\ PB+#_P"*H_X4W\<O^CB&_P#"(L/_ (J@#WRBO O^%-_'+_HXEO\
MPB+#_P"*H_X4W\<O^CB6_P#"(L/_ (J@#WVBO O^%-_'+_HXEO\ PB+#_P"*
MH_X4W\<O^CB6_P#"(L/_ (J@#WVBO O^%-_'+_HXEO\ PB+#_P"*I?\ A3?Q
MR_Z.(;_PB+#_ .*H ]\KP32O^3XM;_[$:'_TL%)_PIOXY?\ 1Q#?^$18?_%5
MI_"KX#^)O!OQ/U/QSXN^(DGCG5KS2ETE =%@T]8HA*) <1,03D=QWH ]IHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **#TKA;CXHV^G>)?%^G:E9FRL_
M#NFP:G)?><'$L<GFYP@&5V^2>I.<]J .ZHKQ>?\ :2M-)TPSZOHTMK>76EVF
MK:=9PS>8US'<RK%'&Q*@)('DB##D#?P3@TSQ)^T@GA=]2L;K1!)K6E3SQ7T$
M=W^Y5(K7[5N20IEBZ9"@J/F#9X&: /:ZAO/^/67_ '3_ "K)TCQ*-<U.>&TM
MG^QV\2&6YERNV5@&$07')"G+<\94=^-:\_X]9?\ =/\ *@#R#]D3_DA6D_\
M80U/_P!+YZ]EKQK]D3_DA6D_]A#4_P#TOGKV6@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@36;/3%U0)J]S:S"6(R",;?(D?N>_I0![+1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!X%^VE
M_P DNT+_ +&O1/\ TNBKWP <\#J:\#_;2_Y)?H7_ &->B?\ I=%7OH[_ %-
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M>/"UM)"+2:V9=T<,:?+Y3 < D%3G[V:^@E! ^;&>^* %P/05X'I7'[<6M_\
M8C1?^E@KWRO!-*_Y/BUO_L1H?_2P4 >]T444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% '@7[:7_ "2_0O\ L:]$_P#2Z*O?1W^IKP+]M+GX7Z#C_H;-
M$_\ 2Z*O?1GG@]3VH **/P/Y&C\#^1H **/P/Y&C\#^1H **/P/Y&C\#^1H
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M'\C1^!_(T %>":5_R?%K?_8C0_\ I8*][_ _D:\$TK_D^+6_^Q&AZ_\ 7X*
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M^_Z'CQ)_X-KC_P"+HHI '_"X_'W_ $/'B3_P;7'_ ,71_P +B\??]#QXC_\
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M%Q>/O^AX\1_^#:X_^+H_X7%X]_Z'?Q'_ .#:X_\ BZ** #_A<7CW_H=_$?\
MX-KC_P"+K[M_X)&^)-7\4?%_QQ=:SJM[J]RFA(BS7UP\SA?M"<!F)./:BBA
M?J=1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>adag-20211231xex15d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231xex15d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !  44# 2(  A$! Q$!_\0
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M_!Z]\7:A\,O#EQX\LX+#Q>]HO]IP6S HLP)!(QP,C!P. 3BORE^"W[.GQ<\
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M&5\PX&W. >@ZU^AW[1_[,_A']IKPC;Z-XG2X@GLG:6PU&S?;-:R, &*YR""
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M?%OA"VOAIMQK6FS6,=TR;A&SK@$CN/7VK\XH/A)XE_9?C_9S\.>+_L4>I?\
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MU6 VZ@^<H*EHCGH"40Y[8]ZV?BK\9(OA/]FEO]#O[^SG+!;BRVOC:NYLKU
MR<^U=7X5\8:7XW\/6^LZ)=)?6<Z;D9#SG'W2.Q'<&KA.5.7-%V9,HJ:Y9;&U
MCBOF7]AWX#Z_\$]'^(DGB"W6SEUWQ1=7EI#O!8VJL4C=@.F[D@>A'K7MOAGQ
MU<>(?$>K:2^B7-BVEND=Q/+(A0LR!UVXZY!'YUUU5&K*,)06SM^!+@I24GT"
MBO-_B[\:K7X.P6EUJFD7=W8W4H@CN+9E/[S:3M(/(X!_*NZT:^GU+3H;FXM'
ML9)!N\AV#,H[9(XK(T+U8OBZ/0#HDLOB6/3WTF B5VU)$:%".C'>" >>M;).
M!FO-/#?Q8\*?%?Q/XE\&&V6[.G@;X[R-6BNX\X+(#U ..?<$4T[,3U1\::=\
M8/"GQ<_X*9_#F\\#7T.J:+INAW.F-/;Q;8=PANF81\ %0&7D<>E?HL.E>.^(
M_#G@3]GG3G\5:-\.[&);9"LUYI-I$DT"-A2<XSM/ .*[OX>^.HOB%X5M/$$%
MH]G87:>9"974DKR#G'3!%=6)JPJN/(K)*VIA1IRII\SU;N=117G_ ,-/C7H'
MQ3U77;#2#*)M)E"/YJX\U22!(GJI*_J*T-,\=W>I>,+O0?[!N8S9K&\]X94,
M2!\[1P<[B%SCTQZUR'0=A7S+^TGIWQ9^%#WOC'X):-I&KMJ1#:YHLNGJT\DJ
MC"W,90JTC$'#*2?N@CJ:^FJ\X^+OQGM?@];6EWJFDW=W8W4H@2>V93B0@G!!
MYZ \UK2J>SE>UUV9G.'.K7L? /PB_8_^+'[47QGC^(7QWM[G3]%A='DL[Q?)
MEND0Y2VBB'^KBSU)QD$]22:_4**)((DCC54C0!551@ #H *Y#7?'.J:%H,^J
MGPQ>7D,,1F:*UF1I"H&20._':N6\8_M#6/@UO#)N-$OKF'Q&D;:?+ R$.7"$
M*03P?WBUMB,3/$M<RLELELC.C1C13MJWNSUNBO+_ (F_'&+X46NF7.M:#>&W
MOY! DD$B,%E(SL//H#S[5I^,?BD_@'1VU?6M!O8M*B*^?<V[++Y() !90<XR
M1S7(=!WM%<7K/Q0L;/P#%XPTRVEUO2)(A.#:D!RA.,@'J<\8JO\ "CXPZ1\6
MK+49-/AGLKO3[@V]S970 EC/8D>AP1]0: /GO]K70_VE_B9;:SX/\#Z%X>L?
M!NHQO:37PU!6N[F!QA@WF!1$",@A03_M5Z9^Q=\#]6_9]^ FD>%=>D@?6OM%
MQ>7:VS[XXWD?(0-WPH4$^N:]$^)WQ,T[X7>'VU.^AFNSR5MK8 R,JC+M[*HY
M)]QZU+\-?'J?$GPQ;:];Z?-86%TN^W\]E+2+D@G Z<BNJ6(E*DJ*22WTZ^I@
MJ*53VC;;.KHHHKE-PJHNEVB:E+J"VZ"]DB6!I\?,44DA<^@+$_C5NF31+/"\
M3YVNI4X)!P?<=* /F3P+_P GP>./^P7_ .R6M>H?'[2+.#X3^/-1CMXTO;C2
M&BEG489U3)4$^VYOSK4M/@GX-L-<;6;?1TAU9B6:]25Q*Q/7+;LG-;_BKP;I
M/C73S8ZS:_;;,C#0,[!''^T 1GIWH \Z_9:N([/]GOPU/.ZQ0Q0SN\CG"JHF
MD))/H *I:GHNH?$S2O$,^I>&9;NSURW^S6+27"QM!:CF-@I&59F_>'_@([5V
MT'P9\(VVB-HT.E"+2FSFR2:01'/)^7=CFNITS1K;1[ 6=LKK ,X5I&8CMP22
M: / _P!D_P 8ZAI4>K_#+Q)F'7?#TA^SHYYDMR>BGN%)!'^RP]*[NX\(Z5XX
M\;>/M'UFT2]L;BSTY6C<=#MGP0>Q'8UJGX)>#6UPZR='3^UR<F^\U_.SC'W]
MV>G%:FE?#K0=%UR;6+2T:+4I@!+<><Y:0#@!LMR!GC- 'AVC:WKO[+>O0:'X
MAEGUCX<7DOEV&K$%GT\D\1R?[/\ ^L>E>N_ ^19OA1X9D1@R/:!E8=""S$&N
MLUO0[#Q)I5SINIVD5]8W"%)8)EW*P^E)H.A6/AG1[/2M-MUM;"TC$4$*=$0=
M * +]>:?'SX7Z7\2/ MZ;K_1M1TV)[NROHQB2%U4MU]#CD5Z767XB\-V'BK3
MGL-2A-Q:/D/%O90X(P0<$9'M0!XW^RYK%]\3_!=EXK\17)U#4K)WT^V##Y8E
M4+F3'>1MW+>@JI^W!;RS?!=)(XV=(=4MY)"HSL7#C)]LD#\:]9\'_##PWX!9
M_P"P--33$?):.!V",<8R5SC/OBNAU'3K75[*:SO;>*[M9E*20S(&1QZ$'K0!
M2\)WL&H^%])NK:59K>6TB=)$.0P*#D5SOAF9;SXH^,IX3YD,-M86KR+RHE7S
MG9,^H$B9';(J33?A!X8T6%H-/LY["V))^S6UY-'$,^B!L#\JWX?#&FVVC/I5
MO:K:V+@@QP$QYR<DY&#D]S0!Q&NZEJ'B;QFBV6D-JVB:(Y#_ +Y8TEO<=.0=
MPC4_]],>ZUXY\.+Z[^ GQXN_#NI6C:5X7\7.9["-Y Z039X7<..I*?0I7TEX
M8\%:1X.A>+2;8VD+DDQB1F7).2<$D9)))-97BGX0^$_&M^EYKFDQZE<1DF-I
MW=O+SC.T9PO0=/2@"'QK#%=>-_!$,R+)%)<7BM&XR&!M7R".]>2>*? ^O?LZ
M^(+CQ?X&@DU'PE<-YFK>'5)/E#O+$/;]/I7LDWPJ\-W%W8W,ME))<6.?LTK7
M$I:'(P=IW<9'%=:(U\O9C*XQ@\\4 >7_  8\9:9\0-8\8:_H\QGL+NYM&1B,
M%2+2,,I'J""#7J58?A?P3H?@M;Y=$TV#34O9S<SI NU7D(P6QV_"MR@#YJ_;
MH_Y)]X='_493_P!%/7T!J&N6/AKPY-JFI7"6EC:6_G332' 50N3_ /JK(\7_
M  K\,>/;B.;7]+CU-HCF-9W8JAQC(7. :AUWX1^%_$UJMMJVG'4;9>D-S/(Z
M?D6Q0!F>,?%ESXA\/:3I^@6T\M[KUNEPR!A');V9 ,CD\[6(8(/=O8UXA\;-
M,UCX;>+?#?Q/T?PXVDV^DB.RU"&*=766#A5!  Q\I*Y/^S7T7I?PT\/Z-JHU
M*SLV@O0B1^:LTF2B_=4_-RH].E7/%?@K1_&]C]BUJT%]9D8:!W8(W(/(! /(
M'6@!N[2?B3X))1EO-'UFS(##G='(O\QG\"*^9/@5JVJZ7IGB7X-3/(FJV^IO
M;I,N<Q639,\@/;Y1Q[S+7TUX1\!Z)X%M7MM#LA86S?\ +&-V*#OPI.!^%367
M@W1=/\3W_B*WTZ&+6;Z)(;F\5?GD1?N@G\!^0H ^<_B#!;?L^_M">'_%UO']
MD\+:];'3[](E^6-D4 ' ]EC;\&KWSX<:;<6V@MJ-_'Y>IZO,VH72'JA?&R/_
M ( @1?\ @)K0\4^#=&\:VEM:ZWI\.HP6]PEU$DPR%D7[K#\ZV0,4 +7S9^W3
M_P DVT+_ +#$?_HMZ^DZY/QC\+/#'C^6-_$&EQZIY?*).S%5.,9"YP#[T 9>
MH>%_%%^?#<MMX@'V.VNX)[RU,"IY\('*[ASZ''?%>1?M:01VWB_X011(L<4>
MK;511@* \. !7TAH^CVNA6$=E9HT=O&,(C.S8'IDDG%<UXF^$/A/QEJ4=_K6
MDQZC=1G=').[GRSD'Y>?EY Z4 >-_MR_\B3X4 X/]MKC_OV]6/VFI?$ND>$H
M9-9F_M/P1/-'%JL&F)Y%PJE@5.XY^7( QQSBO6?$/P<\)>+5MEUG25U-;<;8
MA=2O($^F6Z^];<G@_2;CPU+H$]HMSI,L9A>VG8R*R'L=Q)Q0!Y]KL6@P?L[,
MOA@K_8 L(S:%3GY#(IY/KG.??->>?%*RE_9_^,VG_$;3XV'A?79!::Y!&/EC
M=C_K,>^-WU4C^*O98?@IX.M]$?1HM(6/27.YK)99!$3G/W=V.O-=#)X2TFXT
M,:/<V4=[IN0?L]UF53@Y&=V>A Q]* /&OBO:RZ_\'?'GBZ]C>-[S3'ATZ"08
M,%GN!4D=FD/SGVVCM76?LP_\D%\'?]>C?^C'KM?%/@S1_&FG#3]8M!>67>W9
JV"-TZ@$ ]!UI/"7@C1O UB;+1+,6%F>1 CL47DG@$D#KVH W:*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>adag-20211231xex15d2001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231xex15d2001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !@ 5<# 2(  A$! Q$!_\0
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M<O\ @GQ\9?%_QP^#^K:YXSU7^U]3@UF6UCF\B.';$$0A<(JCJQYQ7U'7Q/\
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M#?\ Z^[S_P! CJ*Q_P""P6C6EE;P'X9W[&*-4W?VN@S@ ?\ /*@:6A9ET_\
MX* VL;3"]TZ<H-WE*=)RWL,J/YUZ+^QM^VQXC^*WC[4_A?\ $[0TT/Q[IZ2E
M)((6A6<Q$>9')&2=D@&6R/E(!Z<9\TG_ ."QFDB)C%\+[UY,<*^LHH)]SY)Q
M^5)^Q%X"\?\ QK_:8US]HGQ9I'_"/:1?02&RB:-D%V7C6&,1!@"T:1+S)_$P
M&,Y8@#U/H7]MO]K5OV7_  AIBZ3I\6K>+=<>2+3K>XW>3&$QOE<*06 +J H(
MR3U%?/FB?"7]MGXI:9;^(-1^(L'A%KI!-%IKW"V\BJ>5W1P1%5."."=PZ$ \
M5Z[_ ,% _P!EGQ1^T!HOA?7O!,\1\3^&)I&BLII!%Y\<A0DHQX#JT:D!L C/
M.< ^6Q?M7_M<>!-.MK#7?@5+KMU&@!O+33;F8R>[?9V=0?RH$9.K^/?VSOV7
MY%U+Q-96WQ)\+0_Z^6*-;I54=6+Q!)XSC^)P5&>AZ5]V_!;X@WWQ3^&'A_Q7
MJ/A^Y\,7.JVPN/[,NW#R1J2=K$@#AEPPR <,,X-?%D'_  4V\;?#^\L8_BW\
M#]8\,Z?>R%1>+'/:OM'WO+BN(P)2,CCS%ZU]L?";XK>%_C1X)L?%/A#4$U'1
M[G*!@NUXG7[T;J>59>,CZ'H0: 9V5%%% @HHHH **** "BBB@ I#TI:0]* /
M.?VB/^2+>*O^O4?^AK7Q9\!?^2Q>$O\ K^3^M?=OQ5\*W7C?X?:WH=E)''=W
MD&R-IB0F[((S@'TQ7QI\./A[XA^'WQQ\)6FO:9-8LU^HCE9<QRXSRKC@]OSK
MZK*ZL%A*U-O773Y'RV9TYO%4II:77YGV7\6O^25^,/\ L#WG_HEZ^!?@Y_R5
M7PK_ -A"+_T*OOKXM<?"OQA_V![S_P!$O7P+\&Q_Q=3PK_V$8O\ T*KR?_=J
MW]=",W_WFC_74^^_BQ_R2[QC_P!@>[_]$/7P#\(_^2G^%O\ L(P_^ABOO_XK
M\_"[QA_V![S_ -$O7QI\!/@YXK\0^+M"UZ+3'M=&M;F.Y-Y=@QK(JG/[O(R^
M?4#'O6>55(4\+6<W;_AB\TISJ8JBH*__  Y]Z]Q12>]**^5/J3\E_P!MRYU[
M]E?]J_Q'XK\*C[%'XYT&X7S$+1A'GC,,[J4VXD5U64$D_,0QZU]H_P#!//X1
M1_"C]F7P\TL)BU?Q"6UJ^+C!S( (EY ( B6/CIN+$=:[?]HC]EGP5^TS8Z);
M^+H[M7T>622TN+*;RY%$@42(2005;8AZ=4'O7K-A8V^F65O9VL*6]K;QK%%#
M&NU411A5 [   8ICOH?E1^W=)K?[,7[3^N^+O"P-E!X^\/7%M)(A9%#R((9V
M4KCYP5CD')PQ#'K7UM_P3>^$D?PO_9GTB]FBV:KXFE;6+IB!N", L*9P#@1J
MK8.<%V]:]-_:(_9A\&?M,Z-I&G^+8KE3I=PT]K=64@CF3<NUTW$'Y6PA([E%
M]*]$C\,6MIX570+!I--LHK,6,#6S8>",)L783T*C&#[4!?0_,C]IJ76/V\OV
MN8OACX.U../0/"L$\3W\BLUNDJX%S,0.OS[(@>AQQP<GUZQ_8Q_:3TVRM[2T
M_:*FMK6WC6**&-)E5$4850,\   5]'?L]_LK>"_V:TUQO"JWD]UK,B/=WFHS
M"69@F[:H.!@9=C[D\]!7L5 7/R+^,GP4^*7[$OQ.\*?&K5?$B>.)IM4QJ%_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
>444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>adag-20211231xex15d3001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 adag-20211231xex15d3001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  Z 60# 2(  A$! Q$!_\0
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MRTO4[SPM\/M6\JTOKFVEQ)/"C+#%"7..>.<\%G4D' !SOVQ/V#OA7\-/V?\
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M_NY(;&..23[T$DO_  4=M_#O@_\ 95\1K::-IMM>ZE<VEC#+#:Q(Z$S*Y((
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M]I7P=8>'=>O[[3[2SOTU!9+ J'9U5E"G<",88UZE9VJ65I#;IDI$BQKGK@#
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M>\^*/A:WV2OI6DW)DMI)%QP93(?1@6V!_<&MSXPZ;+^UA^V1>_!?6M:NM/\
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CQXT\37UY+J.I:O<[@99Y H8+DYVC:.3R22>^ 5]*44"/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740795200648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adagene Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4F, Building C14, No. 218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Xinghu Street, Suzhou Industrial Park<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Suzhou<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">215123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">54,595,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001818838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers Zhong Tian&#160;LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Shanghai, the People&#8217;s Republic of China<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4F, Building C14, No. 218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Xinghu Street, Suzhou Industrial Park<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Suzhou<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">215123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">CN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Peter (Peizhi) Luo<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">peter_luo@adagene.com<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">87773616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">American depositary shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American depositary shares<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADAG<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary shares, par value US$0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_NoTradingSymbolFlag', window );">No Trading Symbol Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_NoTradingSymbolFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a security having no trading symbol.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_NoTradingSymbolFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:trueItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740793511592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 174,391,243<span></span>
</td>
<td class="nump">$ 75,150,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Amounts due from related parties</a></td>
<td class="nump">4,506,670<span></span>
</td>
<td class="nump">132,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepayments and other current assets</a></td>
<td class="nump">4,055,921<span></span>
</td>
<td class="nump">3,813,984<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">185,953,834<span></span>
</td>
<td class="nump">79,097,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">3,487,617<span></span>
</td>
<td class="nump">2,067,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">69,275<span></span>
</td>
<td class="nump">3,098,234<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">189,510,726<span></span>
</td>
<td class="nump">84,262,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,321,615<span></span>
</td>
<td class="nump">1,809,975<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="nump">725,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Amounts due to related parties</a></td>
<td class="nump">10,466,061<span></span>
</td>
<td class="nump">2,535,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilities', window );">Accruals and other current liabilities</a></td>
<td class="nump">4,379,243<span></span>
</td>
<td class="nump">6,059,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="nump">1,657,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Short-term borrowings</a></td>
<td class="nump">3,121,226<span></span>
</td>
<td class="nump">3,831,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term borrowings</a></td>
<td class="nump">1,376,319<span></span>
</td>
<td class="nump">1,183,926<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">29,821,914<span></span>
</td>
<td class="nump">16,145,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term borrowings</a></td>
<td class="nump">2,991,829<span></span>
</td>
<td class="nump">2,965,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="nump">44,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">94,107<span></span>
</td>
<td class="nump">91,955<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">32,952,013<span></span>
</td>
<td class="nump">19,203,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Mezzanine equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total mezzanine equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,449,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares (par value of US$0.0001 per share; 640,000,000 shares authorized, and 16,603,070 shares issued and outstanding as of December 31, 2020; and 640,000,000 shares authorized, 54,595,667 shares issued and outstanding as of December 31, 2021)</a></td>
<td class="nump">5,627<span></span>
</td>
<td class="nump">1,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury shares, at cost (Nil and 94,074 shares as of December 31, 2020 and 2021, respectively)</a></td>
<td class="num">(619,605)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable', window );">Subscriptions receivable from shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,172,192)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">336,099,931<span></span>
</td>
<td class="nump">23,786,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(93,981)<span></span>
</td>
<td class="num">(350,981)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(178,833,259)<span></span>
</td>
<td class="num">(105,655,324)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders' equity (deficit)</a></td>
<td class="nump">156,558,713<span></span>
</td>
<td class="num">(89,389,956)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' EQUITY (DEFICIT)</a></td>
<td class="nump">$ 189,510,726<span></span>
</td>
<td class="nump">84,262,737<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_Series1RedeemableConvertiblePreferredStockMember', window );">Series A-1 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Mezzanine equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total mezzanine equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,473,957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_Series2RedeemableConvertiblePreferredStockMember', window );">Series A-2 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Mezzanine equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total mezzanine equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Mezzanine equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total mezzanine equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,999,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC1RedeemableConvertiblePreferredStockMember', window );">Series C-1 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Mezzanine equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total mezzanine equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,975,456<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC2RedeemableConvertiblePreferredStockMember', window );">Series C-2 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Mezzanine equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total mezzanine equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,999,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC3RedeemableConvertiblePreferredStockMember', window );">Series C-3 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAbstract', window );"><strong>Mezzanine equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Total mezzanine equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities and Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AccruedLiabilitiesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_Series1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_Series1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_Series2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_Series2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesC1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesC2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC3RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesC3RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740793965544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">640,000,000<span></span>
</td>
<td class="nump">640,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">54,595,667<span></span>
</td>
<td class="nump">16,603,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">54,595,667<span></span>
</td>
<td class="nump">16,603,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury shares</a></td>
<td class="nump">94,074<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_Series1RedeemableConvertiblePreferredStockMember', window );">Series A-1 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible redeemable preferred shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible redeemable preferred shares, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,473,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible redeemable preferred shares, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,473,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible redeemable preferred shares, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,473,957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_Series2RedeemableConvertiblePreferredStockMember', window );">Series A-2 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible redeemable preferred shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible redeemable preferred shares, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,370,414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible redeemable preferred shares, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,370,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible redeemable preferred shares, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,370,414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible redeemable preferred shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible redeemable preferred shares, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,494,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible redeemable preferred shares, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,494,537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible redeemable preferred shares, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,494,537<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC1RedeemableConvertiblePreferredStockMember', window );">Series C-1 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible redeemable preferred shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible redeemable preferred shares, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,597,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible redeemable preferred shares, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,597,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible redeemable preferred shares, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,597,354<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC2RedeemableConvertiblePreferredStockMember', window );">Series C-2 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible redeemable preferred shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible redeemable preferred shares, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,861,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible redeemable preferred shares, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,861,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible redeemable preferred shares, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,861,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC3RedeemableConvertiblePreferredStockMember', window );">Series C-3 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible redeemable preferred shares, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible redeemable preferred shares, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,452,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible redeemable preferred shares, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,452,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible redeemable preferred shares, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,452,441<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_Series1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_Series1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_Series2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_Series2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesC1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesC2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC3RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesC3RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740794916232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Licensing and collaboration revenue</a></td>
<td class="nump">$ 10,175,258<span></span>
</td>
<td class="nump">$ 700,913<span></span>
</td>
<td class="nump">$ 480,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(68,099,385)<span></span>
</td>
<td class="num">(33,538,035)<span></span>
</td>
<td class="num">(16,211,750)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_ResearchAndDevelopmentExpenseThirdParties', window );">Third parties</a></td>
<td class="num">(55,020,367)<span></span>
</td>
<td class="num">(23,645,740)<span></span>
</td>
<td class="num">(10,507,444)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty', window );">Related parties</a></td>
<td class="num">(13,079,018)<span></span>
</td>
<td class="num">(9,892,295)<span></span>
</td>
<td class="num">(5,704,306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative expenses</a></td>
<td class="num">(14,439,962)<span></span>
</td>
<td class="num">(10,314,536)<span></span>
</td>
<td class="num">(3,437,900)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(72,364,089)<span></span>
</td>
<td class="num">(43,151,658)<span></span>
</td>
<td class="num">(19,169,650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNonoperating', window );">Interest income</a></td>
<td class="nump">76,166<span></span>
</td>
<td class="nump">629,288<span></span>
</td>
<td class="nump">922,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(363,762)<span></span>
</td>
<td class="num">(202,165)<span></span>
</td>
<td class="num">(138,096)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="nump">1,778,822<span></span>
</td>
<td class="nump">971,949<span></span>
</td>
<td class="nump">723,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gain (loss), net</a></td>
<td class="num">(603,459)<span></span>
</td>
<td class="num">(644,693)<span></span>
</td>
<td class="nump">21,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,207,415<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">(71,476,322)<span></span>
</td>
<td class="num">(42,397,279)<span></span>
</td>
<td class="num">(16,432,308)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(1,701,613)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Adagene Inc.'s shareholders</a></td>
<td class="num">(73,177,935)<span></span>
</td>
<td class="num">(42,397,279)<span></span>
</td>
<td class="num">(16,432,308)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustments, net of nil tax</a></td>
<td class="nump">257,000<span></span>
</td>
<td class="num">(6,087)<span></span>
</td>
<td class="nump">65,799<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss attributable to Adagene Inc.'s shareholders</a></td>
<td class="num">(72,920,935)<span></span>
</td>
<td class="num">(42,403,366)<span></span>
</td>
<td class="num">(16,366,509)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Adagene Inc.'s shareholders</a></td>
<td class="num">(73,177,935)<span></span>
</td>
<td class="num">(42,397,279)<span></span>
</td>
<td class="num">(16,432,308)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of convertible redeemable preferred shares to redemption value</a></td>
<td class="num">(28,553)<span></span>
</td>
<td class="num">(248,113)<span></span>
</td>
<td class="num">(246,184)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to ordinary shareholders</a></td>
<td class="num">$ (73,206,488)<span></span>
</td>
<td class="num">$ (42,645,392)<span></span>
</td>
<td class="num">$ (16,678,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of ordinary shares used in per share calculation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">-Basic</a></td>
<td class="nump">50,032,009<span></span>
</td>
<td class="nump">15,950,698<span></span>
</td>
<td class="nump">15,178,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">-Diluted</a></td>
<td class="nump">50,032,009<span></span>
</td>
<td class="nump">15,950,698<span></span>
</td>
<td class="nump">15,178,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per ordinary share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">-Basic</a></td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="num">$ (2.67)<span></span>
</td>
<td class="num">$ (1.10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">-Diluted</a></td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="num">$ (2.67)<span></span>
</td>
<td class="num">$ (1.10)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of research and development expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ResearchAndDevelopmentExpenseThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of research and development expenses resulting from transactions with third parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ResearchAndDevelopmentExpenseThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740796402664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent', window );">Foreign currency translation adjustments, tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740794387096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT) - USD ($)<br></strong></div></th>
<th class="th"><div>Ordinary shares</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Subscriptions receivable from shareholders</div></th>
<th class="th"><div>Additional paid in capital</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Dec. 31, 2018</a></td>
<td class="nump">$ 1,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (197,068)<span></span>
</td>
<td class="nump">$ 6,405,318<span></span>
</td>
<td class="num">$ (410,693)<span></span>
</td>
<td class="num">$ (46,825,737)<span></span>
</td>
<td class="num">$ (41,026,664)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the beginning (in shares) at Dec. 31, 2018</a></td>
<td class="nump">15,159,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,432,308)<span></span>
</td>
<td class="num">(16,432,308)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares)</a></td>
<td class="nump">34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Sharebased compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">611,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 611,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of convertible redeemable preferred shares to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(246,184)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(246,184)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Dec. 31, 2019</a></td>
<td class="nump">$ 1,519<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(197,068)<span></span>
</td>
<td class="nump">6,789,542<span></span>
</td>
<td class="num">(344,894)<span></span>
</td>
<td class="num">(63,258,045)<span></span>
</td>
<td class="num">(57,008,946)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Dec. 31, 2019</a></td>
<td class="nump">15,193,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,397,279)<span></span>
</td>
<td class="num">(42,397,279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,087)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,087)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">$ 370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,975,124)<span></span>
</td>
<td class="nump">7,115,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares)</a></td>
<td class="nump">3,694,934<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,694,934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Sharebased compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,129,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,129,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of convertible redeemable preferred shares to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(248,113)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(248,113)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Dec. 31, 2020</a></td>
<td class="nump">$ 1,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,172,192)<span></span>
</td>
<td class="nump">23,786,652<span></span>
</td>
<td class="num">(350,981)<span></span>
</td>
<td class="num">(105,655,324)<span></span>
</td>
<td class="num">(89,389,956)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Dec. 31, 2020</a></td>
<td class="nump">18,888,070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73,177,935)<span></span>
</td>
<td class="num">(73,177,935)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of share options</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">226,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of share options (in shares)</a></td>
<td class="nump">233,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,958<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of ordinary shares under performance incentive plan (Note 9)</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 416,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of ordinary shares under performance incentive plan (Note 9) (in shares)</a></td>
<td class="nump">23,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_CommonStockSubscriptionsValue', window );">Subscription from shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Sharebased compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,679,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,679,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of convertible redeemable preferred shares to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,553)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,553)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible redeemable preferred shares to ordinary shares upon the completion of initial public offering ("IPO")</a></td>
<td class="nump">$ 2,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,475,235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,477,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred shares to ordinary shares upon the completion of initial public offering ("IPO") (in shares)</a></td>
<td class="nump">27,249,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of ordinary shares upon IPO, net of issuance cost</a></td>
<td class="nump">$ 1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,094,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">147,095,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of ordinary shares upon IPO, net of issuance cost (in shares)</a></td>
<td class="nump">10,571,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchase of treasury shares under share repurchase program (Note 16)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,361,576)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,361,576)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares under share repurchase program (Note 16) (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(295,174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of treasury shares (Note 16)</a></td>
<td class="num">$ (20)<span></span>
</td>
<td class="nump">$ 1,741,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,750,041)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,090)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury shares (Note 16) (in shares)</a></td>
<td class="num">(201,100)<span></span>
</td>
<td class="nump">201,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_StockSurrenderedValueForRepaymentOfPromissoryNotes', window );">Surrender of ordinary shares for repayment of promissory notes (Note 9)</a></td>
<td class="num">$ (49)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,790,910<span></span>
</td>
<td class="num">(6,800,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,946)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes', window );">Surrender of ordinary shares for repayment of promissory notes (Note 9) (in shares)</a></td>
<td class="num">(491,119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Dec. 31, 2021</a></td>
<td class="nump">$ 5,627<span></span>
</td>
<td class="num">$ (619,605)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 336,099,931<span></span>
</td>
<td class="num">$ (93,981)<span></span>
</td>
<td class="num">$ (178,833,259)<span></span>
</td>
<td class="nump">$ 156,558,713<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance at the end (in shares) at Dec. 31, 2021</a></td>
<td class="nump">56,274,741<span></span>
</td>
<td class="num">(94,074)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_CommonStockSubscriptionsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_CommonStockSubscriptionsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number shares surrendered for repayment of promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_StockSurrenderedValueForRepaymentOfPromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of shares surrendered for repayment of promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_StockSurrenderedValueForRepaymentOfPromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740794002040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (73,177,935)<span></span>
</td>
<td class="num">$ (42,397,279)<span></span>
</td>
<td class="num">$ (16,432,308)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,125,032<span></span>
</td>
<td class="nump">858,408<span></span>
</td>
<td class="nump">816,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss (gain) on disposal of property, equipment and software</a></td>
<td class="nump">18,973<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="num">(1,841)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">18,679,658<span></span>
</td>
<td class="nump">10,129,541<span></span>
</td>
<td class="nump">611,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,207,415)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_InterestIncomeExpenseOnPromissoryNotes', window );">Interest income on promissory notes</a></td>
<td class="num">(9,946)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange loss (gain), net</a></td>
<td class="nump">603,459<span></span>
</td>
<td class="nump">644,693<span></span>
</td>
<td class="num">(21,867)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(3,000,000)<span></span>
</td>
<td class="nump">480,000<span></span>
</td>
<td class="num">(480,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepayments and other current assets</a></td>
<td class="num">(231,287)<span></span>
</td>
<td class="num">(2,337,011)<span></span>
</td>
<td class="nump">111,516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Amount due from related parties</a></td>
<td class="num">(4,374,274)<span></span>
</td>
<td class="nump">1,300,790<span></span>
</td>
<td class="num">(704,253)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="num">(24,210)<span></span>
</td>
<td class="num">(13,292)<span></span>
</td>
<td class="num">(38,040)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,511,640<span></span>
</td>
<td class="nump">1,097,261<span></span>
</td>
<td class="nump">153,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">4,774,464<span></span>
</td>
<td class="num">(267,842)<span></span>
</td>
<td class="nump">993,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueToRelatedParties', window );">Amount due to related parties</a></td>
<td class="nump">7,930,703<span></span>
</td>
<td class="nump">639,579<span></span>
</td>
<td class="num">(1,778,469)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accruals and other current liabilities</a></td>
<td class="nump">1,057,491<span></span>
</td>
<td class="nump">1,243,150<span></span>
</td>
<td class="num">(34,277)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax payable</a></td>
<td class="nump">1,657,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred tax liabilities</a></td>
<td class="nump">44,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,955<span></span>
</td>
<td class="num">(142,114)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(43,414,619)<span></span>
</td>
<td class="num">(28,529,720)<span></span>
</td>
<td class="num">(18,153,556)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Placement of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,000,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Withdrawal of short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
<td class="nump">44,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from disposal of property, equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,930<span></span>
</td>
<td class="nump">7,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Purchase of property, equipment and software</a></td>
<td class="num">(2,509,926)<span></span>
</td>
<td class="num">(935,199)<span></span>
</td>
<td class="num">(151,829)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash generated from (used in) investing activities</a></td>
<td class="num">(2,509,926)<span></span>
</td>
<td class="nump">7,072,731<span></span>
</td>
<td class="nump">24,855,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from borrowings</a></td>
<td class="nump">4,386,860<span></span>
</td>
<td class="nump">6,083,650<span></span>
</td>
<td class="nump">2,651,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants', window );">Proceeds from issuance of convertible redeemable preferred shares and warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,999,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from share subscriptions</a></td>
<td class="nump">381,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of share options</a></td>
<td class="nump">231,521<span></span>
</td>
<td class="nump">140,928<span></span>
</td>
<td class="nump">459,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting commissions</a></td>
<td class="nump">149,411,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of borrowings</a></td>
<td class="num">(5,089,717)<span></span>
</td>
<td class="num">(1,063,670)<span></span>
</td>
<td class="num">(2,417,192)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of initial public offering costs</a></td>
<td class="num">(1,595,088)<span></span>
</td>
<td class="num">(721,532)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchase of treasury shares under stock repurchase program</a></td>
<td class="num">(2,361,576)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_RetirementOfTreasuryShares', window );">Costs for retirement of treasury shares</a></td>
<td class="num">(8,090)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash generated from financing activities</a></td>
<td class="nump">145,357,142<span></span>
</td>
<td class="nump">4,439,376<span></span>
</td>
<td class="nump">69,694,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Effect of exchange rate on cash and cash equivalents</a></td>
<td class="num">(192,352)<span></span>
</td>
<td class="num">(364,177)<span></span>
</td>
<td class="nump">77,544<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">99,240,245<span></span>
</td>
<td class="num">(17,381,790)<span></span>
</td>
<td class="nump">76,474,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the beginning of year</a></td>
<td class="nump">75,150,998<span></span>
</td>
<td class="nump">92,532,788<span></span>
</td>
<td class="nump">16,058,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at the end of year</a></td>
<td class="nump">174,391,243<span></span>
</td>
<td class="nump">75,150,998<span></span>
</td>
<td class="nump">92,532,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">359,569<span></span>
</td>
<td class="nump">202,165<span></span>
</td>
<td class="nump">142,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of convertible redeemable preferred shares to redemption value</a></td>
<td class="nump">28,553<span></span>
</td>
<td class="nump">248,113<span></span>
</td>
<td class="nump">$ 246,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of preferred shares</a></td>
<td class="nump">154,477,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_PayablesForDeferredInitialPublicOfferingCost', window );">Payables for deferred initial public offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,276,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_NonCashActivitiesRetirementOfTreasuryShares', window );">Retirement of treasury shares</a></td>
<td class="nump">1,741,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes', window );">Surrender of ordinary shares for repayment of promissory notes</a></td>
<td class="nump">$ 6,800,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_InterestIncomeExpenseOnPromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) on promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_InterestIncomeExpenseOnPromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_NonCashActivitiesRetirementOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of retirement of treasury shares in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_NonCashActivitiesRetirementOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_PayablesForDeferredInitialPublicOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payables for deferred initial public offering cost in non-cash activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_PayablesForDeferredInitialPublicOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of Redeemable Convertible Preferred Stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_RetirementOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of retirement of treasury shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_RetirementOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of common stock shares surrendered for repayment of promissory notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799031672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BASIS OF PRESENTATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">1. ORGANIZATION AND BASIS OF PRESENTATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene&#160;Inc. (the &#8220;Company&#8221;) is a limited liability company incorporated in the Cayman Islands on February&#160;25, 2011. The Company, together with its subsidiaries (collectively, the &#8220;Group&#8221;), are principally engaged in research, development and production of monoclonal antibody drugs for cancers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 8, 2021, the Company&#8217;s registration statement relating to its initial public offering (&#8220;IPO&#8221;) of its American Depositary Shares (&#8220;ADSs&#8221;) was declared effective by the Securities and Exchange Commission (&#8220;SEC&#8221;) and the shares of its ADSs began trading on the NASDAQ Global Market on February 9, 2021. The public offering price of the ADSs sold in the IPO was $19.00 per ADS. The IPO closed on February 11, 2021, pursuant to which the Company issued 8,457,100 ADSs, including the exercise in full of the underwriters&#8217; option to purchase 1,103,100 additional ADSs from the Company. The Company received net proceeds of approximately $145.9 million, after underwriting discounts, commissions and estimated offering expenses. Each ADS represents one and one quarter (1.25) ordinary shares of the Company. Upon the completion of the IPO, all outstanding shares of the convertible redeemable preferred shares were converted into ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2021, the Company&#8217;s principal subsidiaries are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:27.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage&#160;of&#160;legal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Place&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ownership</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Entity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">by&#160;the&#160;Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal&#160;activities</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adagene (Hong Kong) Limited</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 12, 2011</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Hong Kong</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Investment holding</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adagene Incorporated</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">September 20, 2017</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">The United States of America</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adagene (Suzhou) Limited</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 28, 2012</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">The People&#8217;s Republic of China (&#8220;PRC&#8221; or &#8220;China&#8221;)</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adagene Australia PTY Ltd.</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">May 30, 2018</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Australia</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adagene PTE. Ltd.</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 27, 2020</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Singapore</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adagene AG</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August 31, 2020</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Switzerland</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799015656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements of the Group include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the balance sheet dates and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in the Group&#8217;s consolidated financial statements include, but are not limited to, licensing and collaboration revenue recognition, research and development expense allocation, the useful lives and impairment of long-lived assets, tax valuation allowance, and share-based compensation expenses. Management bases the estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could materially differ from those estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Foreign currency translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The functional currency of the Company, Adagene (Hong Kong) Limited, Adagene Incorporated and Adagene PTE. Ltd. is the United States dollar (&#8220;US$&#8221;). The functional currency of the Company&#8217;s PRC subsidiary is Renminbi (&#8220;RMB&#8221;). The functional currency of the Company&#8217;s Australian subsidiary is Australian dollar (&#8220;AU$&#8221;). The functional currency of the Company&#8217;s Swiss subsidiary is Swiss Franc (&#8220;CHF&#8221;). The determination of the respective functional currency is based on the criteria stated in Accounting Standard Codification (&#8220;ASC&#8221;) 830, <i style="font-style:italic;">Foreign Currency Matters</i>. The Company uses US$ as its reporting currency. The financial statements of the Company&#8217;s PRC, Australian and Swiss subsidiaries are translated from the functional currency to the reporting currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Transactions denominated in foreign currencies are remeasured into the functional currency at the exchange rates quoted by the People&#8217;s Bank of China (the &#8220;PBOC&#8221;) prevailing on the transaction dates. Monetary assets and liabilities denominated in foreign currencies are re-measured at the exchange rates prevailing at the balance sheet date. Non-monetary items that are measured in terms of historical costs in foreign currency are re-measured using the exchange rates at the dates of the initial transactions. Exchange gains and losses are included in the consolidated statements of comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities are translated at the exchange rates at the balance sheet date, equity accounts are translated at historical exchange rates and revenues, expenses, gains and losses are translated using the average rate for the&#160;year. Translation adjustments are reported as accumulated comprehensive loss and are shown as a separate component of other comprehensive loss in the consolidated statements of comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Cash and cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Cash and cash equivalents primarily consist of cash and demand deposits which are highly liquid. The Group considers highly liquid investments that are readily convertible to known amounts of cash and with original maturities from the date of purchase of three&#160;months or less to be cash equivalents. All cash and cash equivalents are unrestricted as to withdrawal and use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Accounts receivable and allowance for doubtful accounts</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">Account receivable is recorded when the Group has an unconditional right to consideration. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due. Accounts receivable is carried at net realizable value. An allowance for doubtful accounts is recorded in the period when collection of the amount is no longer probable. In evaluating the collectability of receivable balances, the Group considers specific evidence including the aging of the receivable, the customer&#8217;s payment history, its current credit-worthiness and other factors. Accounts receivable is written off when management determines a balance is uncollectable after all collection efforts have ceased.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Fair value measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group applies ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures</i>. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 requires disclosures to be provided for fair value measurements. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 1&#8212;Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 2&#8212;Other inputs that are directly or indirectly observable in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 3&#8212;Unobservable inputs which are supported by little or no market activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1)&#160;market approach; (2)&#160;income approach; and (3)&#160;cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of cash and cash equivalent, accounts receivable, amounts due to related parties and other current assets, accounts payable, amounts due to related parties, accrued liabilities and other current liabilities and short-term borrowings approximate their fair values because of their generally short maturities. The carrying amount of long-term borrowings approximate their fair values since they bear interest rates which approximate market interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group did not transfer any assets or liabilities in or out of Level&#160;3 during the&#160;years ended December&#160;31, 2020 or 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group had no financial assets and liabilities measured and recorded at fair value on a nonrecurring basis as of December&#160;31, 2020 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Property, equipment and software</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Property and equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Machinery and laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">5 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Vehicles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">4 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Furniture and tools</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">3</span><span style="font-size:10pt;"> - </span><span style="font-size:10pt;">5 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Electronic equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">3 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Computer software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">3</span><span style="font-size:10pt;white-space:pre-wrap;"> -  </span><span style="font-size:10pt;">5 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Lesser of lease terms or estimated useful lives of the assets</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Repair and maintenance costs are charged to expense as incurred, whereas the cost of renewals and betterments that extend the useful lives of property, equipment and software are capitalized as additions to the related assets. Retirements, sales and disposals of assets are recorded by removing the cost and accumulated depreciation and amortization from the asset and accumulated depreciation and amortization accounts with any resulting gain or loss reflected in the consolidated statements of comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Impairment of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group evaluates the recoverability of its long-lived assets, including fixed assets and intangible assets with finite lives, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. When these events occur, the Group measures impairment by comparing the carrying amount of the assets to the estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the assets, the Group recognizes an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the assets, when the market prices are not readily available. The adjusted carrying amount of the assets is the new cost basis and is depreciated over the assets&#8217; remaining useful lives. Long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No impairment loss was recorded for the&#160;years ended December&#160;31, 2019, 2020 and 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Segment reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In accordance with ASC 280, </span><i style="font-weight:normal;">Segment Reporting</i><span style="font-style:normal;font-weight:normal;">, the Group&#8217;s chief operating decision maker (&#8220;CODM&#8221;) has been identified as the Chief Executive Officer. The Group&#8217;s CODM reviews the consolidated results of operations when making decisions about allocating resources and assessing performance of the Group. The Group operates and manages it business as a single segment. No geographical segments are presented as a substantial portion of the Group&#8217;s long-lived assets are located in the PRC with the exception of certain laboratory and electronic equipment which are located in the U.S.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Revenue recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At contract inception of collaboration and out-licensing arrangements, the Group analyzes its arrangements to assess whether they are within the scope of ASC 808, <i style="font-style:italic;">Collaborative Arrangements</i> (&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Group first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are reflective of a vendor-customer relationship and therefore within the scope of ASC 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently. Under the criteria of ASC 606, the Group recognizes revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group adopted ASC 606 for all periods presented. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Group only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. The Group reviews the contract to determine which performance obligations are distinct and represent a promise to provide distinct goods or services or a series of distinct goods or services as defined by the standard. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation as and when that performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licenses of Intellectual Property:</i> Upfront non-refundable payments for licensing the Group&#8217;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Group recognizes revenues from non-refundable, up-front fees allocated to the license at a point in time, when the transfer of control of the license to the licensee occurs and the licensee is able to use and benefit from the license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Services</i><span style="white-space:pre-wrap;">:  The portion of the transaction price allocated to research and development services performance obligations is deferred and recognized at a point in time as delivery of such services occurs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Milestone Payments:</i><span style="white-space:pre-wrap;">  At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group re-evaluates the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Royalties:</i> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Group recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">During the years ended December 31, 2019 and 2020,  </span>no milestone payments or royalty payments were received. During the year ended December 31, 2021, milestone payment was received, but no royalty payments were received. Substantially all of the Group&#8217;s revenue has been derived from its out-licensing agreements with respect to licensed products such as DNA sequences, cell lines, etc., and such revenues are recognized when the customer obtains control of the licensed product, which occurs at a point in time, upon delivery to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Contract assets and contract liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">When a customer pays consideration before the Group transfers products or services, the Group records its obligation as a contract liability; When the Group satisfies its performance obligations by providing products or services to a customer before the customer pays consideration and before payment is due, the Group recognizes its rights to consideration as a contract asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Research and development expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Elements of research and development expenses primarily include (1) payroll and other related costs of personnel engaged in research and development activities, (2) costs related to pre-clinical testing of the Group&#8217;s technologies under development and clinical trials such as payments to contract research organizations (&#8220;CRO&#8221;) and contract manufacturing organizations (&#8220;CMO&#8221;), investigators and clinical trial sites that conduct the clinical studies; (3) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation and amortization, and facility related expenses, and (4) other research and development expenses. Research and development costs are expensed as incurred when the related research and development services are provided to the Group and the resulting assets, if any, have no alternative future uses. As of December 31, 2020 and 2021, the Group had several ongoing clinical studies in various clinical trial stages. The contracts with CRO and CMO are generally cancellable, with notice, at the Group&#8217;s option. The Group did not record any accrued expenses related to cancellation of CRO or CMO contracts as of December 31, 2020 or 2021 as the Group did not have any plan to cancel the existing CRO or CMO contracts.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Government subsidies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Government subsidies primarily consist of financial subsidies received from provincial and local governments for operating a business in their jurisdictions and compliance with specific policies promoted by the governments. The Group&#8217;s PRC based subsidiary received government subsidies from certain local government. The Group&#8217;s government subsidies consist of specific subsidies and other subsidies. Specific subsidies are subsidies that the local government has set certain conditions for the subsidies. Other subsidies are the subsidies that the local government has not set any conditions and are not tied to future trends or performance of the Group, receipt of such subsidy income is not contingent upon any further actions or performance of the Group and the amounts do not have to be refunded under any circumstances. These specific subsidies are recorded as other non-current liabilities upon receipt and are recognized as other income when the conditions are met. Other subsidies are recognized as other income upon receipt as further performance by the Group is not required. Government subsidies of US</span><span style="font-style:normal;font-weight:normal;">$0.7</span><span style="font-style:normal;font-weight:normal;"> million, US</span><span style="font-style:normal;font-weight:normal;">$0.8</span><span style="font-style:normal;font-weight:normal;"> million and US</span><span style="font-style:normal;font-weight:normal;">$1.4</span><span style="font-style:normal;font-weight:normal;"> million were received and recognized as other income during the years ended December 31, 2019, 2020 and 2021, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In addition, the Group&#8217;s Australian subsidiary received research and development tax incentive from the Australian Taxation Office. The tax incentive was recognized as other income upon receipt as the incentive was not dependent upon having a tax liability and further performance by the Group was not required.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Leases are classified at the inception date as either a capital lease or an operating lease. The Group assesses a lease to be a capital lease if any of the following conditions exists: a)&#160;ownership is transferred to the lessee by the end of the lease term, b)&#160;there is a bargain purchase option, c)&#160;the lease term is at least 75% of the property&#8217;s estimated remaining economic life or d)&#160;the present value of the minimum lease payments at the beginning of the lease term is 90% or more of the fair value of the leased property to the lessor at the inception date. A capital lease is accounted for as if there was an acquisition of an asset and an incurrence of an obligation at the inception of the lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All other leases are accounted for as operating leases wherein rental payments are expensed on a straight-line basis over their respective lease terms. The Group leases certain office space under non-cancelable operating lease agreements. Certain lease agreements contain rent holidays. Rent holidays are considered in determining the straight-line rent expense to be recorded over the lease term. The lease term begins on the date of initial possession of the leased property for purpose of recognizing lease expense on straight-line basis over the term of the lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss) is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by shareholders and distributions to shareholders. Accumulated other comprehensive income (loss) of the Group includes foreign currency translation adjustments related to the Group and its subsidiaries whose functional currency is not US$.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group follows the liability method of accounting for income taxes in accordance with ASC&#160;740, <i style="font-style:italic;">Income Taxes</i> (&#8220;ASC&#160;740&#8221;). Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Group records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group evaluates its uncertain tax positions using the provisions of ASC 740, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group recognizes in the consolidated financial statements the benefit of a tax position which is &#8220;more likely than not&#8221; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty&#160;percent likelihood of being realized upon settlement. It is the Group&#8217;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Borrowings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the consolidated statements of comprehensive loss over the period of the borrowings using the effective interest method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company grants restricted shares and stock options to eligible employees and nonemployees and accounts for share-based compensation in accordance with ASC 718, <i style="font-style:italic;">Compensation-Stock Compensation</i>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses a) immediately at the grant date if no vesting conditions are required; b) for share-based awards granted with only service conditions, using the straight-line method over the vesting period; or c) for share-based awards granted with service conditions and performance conditions, using the graded vesting method over the vesting period if and when the Company concludes that it is probable that the performance conditions will be achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In accordance with ASC 260, </span><i style="font-weight:normal;">Earnings Per Share</i><span style="font-style:normal;font-weight:normal;">, basic net loss per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of unrestricted ordinary shares outstanding during the year using the two-class method. Under the two-class method, net loss is allocated between ordinary shares and other participating securities based on dividends declared (or accumulated) and participating rights in undistributed earnings as if all the earnings for the reporting period had been distributed. The Company&#8217;s convertible redeemable preferred shares were participating securities because they were entitled to receive dividends or distributions on an as converted basis. Diluted net loss per share is calculated by dividing net loss attributable to ordinary shareholders, as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares include ordinary shares issuable upon the conversion of the convertible redeemable preferred shares using the if-converted method, and ordinary shares issuable upon the exercise of share options, using the treasury stock method. Ordinary share equivalents are excluded from the computation of diluted earnings per share if their effects are anti-dilutive. For the periods presented herein, the computation of basic net loss per share using the two-class method is not applicable as the Group is in a net loss position and the participating securities do not have contractual rights and obligations to share in the losses of the Group.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Employee defined contribution plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As stipulated by the regulations of the PRC, full-time employees of the Group are entitled to staff welfare benefits including medical care, welfare subsidies, unemployment insurance and pension benefits through a PRC government-mandated multi-employer defined contribution plan. The Group is required to accrue for these benefits based on certain percentages of the qualified employees&#8217; salaries. The Group is required to make contributions to the plans out of the amounts accrued. The PRC government is responsible for the medical benefits and the pension liability to be paid to these employees and the Group&#8217;s obligations are limited to the amounts contributed. The Group has no further payment obligations once the contributions have been paid. The Group recorded employee benefit expenses of US$1,145,165 , US$622,377 and US$2,223,493 for the&#160;years ended December&#160;31, 2019 , 2020 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of risks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020 and 2021, the amount of cash and cash equivalents of US$3,424,456 and US$3,650,474 respectively, were held at major financial institutions located in Mainland China, and US$71,726,542 and US$170,740,769,respectively, were deposited with major financial institutions located outside of Mainland China. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable is typically unsecured and denominated in US$ and is derived from revenues earned from customers. The Group manages credit risk of accounts receivable through ongoing monitoring of the outstanding balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Group&#8217;s research and development services were purchased from one supplier group, who collectively accounted for 23.13%,21.51% and 18.45%of the Group&#8217;s total research and development services purchases for the&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Business and economic risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group believes that changes in any of the following areas could have a material adverse effect on the Group&#8217;s future consolidated financial position, results of operations or cash flows: changes in the overall demand for services; competitive pressures due to new entrants; advances and new trends in new technologies and industry standards; changes in certain strategic relationships; regulatory considerations and risks associated with the Group&#8217;s ability to attract employees necessary to support its growth. The Group&#8217;s operations could also be adversely affected by significant political, regulatory, economic and social uncertainties in the PRC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Foreign currency exchange rate risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Group&#8217;s businesses are transacted in RMB, which is not a freely convertible currency. On January&#160;1, 1994, the PRC government abolished the dual rate system and introduced a single rate of exchange as quoted daily by the PBOC. However, the unification of the exchange rates does not imply that the RMB may be readily convertible into US$ or other foreign currencies. All foreign exchange transactions continue to take place either through the PBOC or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the PBOC. Approval of foreign currency payments by the PBOC or other institutions requires submitting a payment application form together with suppliers&#8217; invoices, shipping documents and signed contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From July&#160;21, 2005, the RMB is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. For U.S. dollar against RMB, there was depreciation of approximately 6.5% and 2.29% in the&#160;years ended December&#160;31, 2020 and 2021, respectively. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the RMB and the U.S. dollar in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The functional currency and the reporting currency of the Company are the US$. However, the Group incurs portions of our expenses, and derives revenues, in currencies other than US$, in particular, the RMB. Any significant fluctuation of the valuation of RMB may materially affect the Group&#8217;s cash flows, expenses, losses and financial position, and the value of any dividends payable on the American Depositary Shares in US$.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Recently issued accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group is an emerging growth company (&#8220;EGC&#8221;) as defined by the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;). The JOBS Act provides that an EGC can take advantage of extended transition periods for complying with new or revised accounting standards. This allows an EGC to delay adoption of certain accounting standards until those standards would otherwise apply to private companies. The Group elected to take advantage of the extended transition periods. However, this election will not apply should the Group cease to be classified as an EGC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-02 (&#8220;ASU 2016-02&#8221;), <i style="font-style:italic;">Leases</i> (Topic 842), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. In July 2018, FASB issued ASU No. 2018-10 (&#8220;ASU 2018-10&#8221;), <i style="font-style:italic;">Codification Improvements to Topic 842, Leases</i>, which clarifies certain aspects of the guidance issued in ASU 2016-02; and ASU No. 2018-11 (&#8220;ASU 2018-11&#8221;), <i style="font-style:italic;">Leases (Topic 842): Targeted Improvements</i>, which provides entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity&#8217;s reporting for the comparative periods presented in the financial statements in which it adopts the new leases standard will continue to be in accordance with current GAAP (Topic 840, Leases). Further, FASB issued ASU No. 2020-05 (&#8220;ASU 2020 05&#8221;), Revenue from Contracts with Customers (Topic 606) and Leases (Topic 842): Effective Dates for Certain Entities, which extends the adoption date for certain entities. For the Group, the updated guidance is effective for fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. The Group does not plan to early adopt the new lease standards and the Group expects that applying the ASU 2016-02 would materially increase the assets and liabilities due to the recognition of right-of-use assets and lease liabilities on its consolidated balance sheets, with an immaterial impact on its consolidated statements of comprehensive loss and consolidated statements of cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, FASB issued ASU No. 2016-13, <i style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (&#8220;ASU 2016-13&#8221;). ASU 2016-13 is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. This ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of the Group&#8217;s portfolio. These disclosures include qualitative and quantitative requirements that provide additional information about the amounts recorded in the financial statements. In November 2019, FASB issued ASU 2019-10, which extends the adoption date for certain registrants. The amendments in ASU 2016-13 are effective for fiscal years beginning after December 15, 2022, including interim periods within fiscal years beginning after December 15, 2023. The Group does not plan to early adopt ASU 2016-13 and is currently in the process of evaluating the impact of adoption of this guidance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2018, FASB issued ASU 2018-18, <i style="font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</i>. This update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer and precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The update is effective in fiscal years beginning after December 15, 2021, and interim periods therein, and early adoption is permitted for entities that have adopted ASC 606. This guidance should be applied retrospectively to the date of initial application of Topic 606. The Group elected to early adopt this ASU and applied this guidance retrospectively to all periods presented. The impact of this ASU to the consolidated financial statements is immaterial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, FASB issued ASU 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>. This update simplifies the accounting for income taxes as part of FASB&#8217;s overall initiative to reduce complexity in accounting standards. The amendments include removal of certain exceptions to the general principles of ASC 740, <i style="font-style:italic;">Income Taxes</i>, and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. The update is effective in fiscal years beginning after December 15, 2022, and interim periods therein, and early adoption is permitted. Certain amendments in this update should be applied retrospectively or modified retrospectively, all other amendments should be applied prospectively. The Group does not plan to early adopt ASU 2019-12 and is currently evaluating the impact on its financial statements of adopting this guidance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In August 2020, FASB issued ASU 2020-06, <i style="font-style:italic;">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, which simplifies the accounting for convertible instruments by removing certain separation models in Subtopic 470-20, <i style="font-style:italic;">Debt&#8212;Debt with Conversion and Other Options</i>, for convertible instruments and also increases information transparency by making disclosure amendments. The standard is effective for private companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact of this accounting standard update on its condensed consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799129144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>ACCOUNTS RECEIVABLE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">ACCOUNTS RECEIVABLE, NET</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">3. ACCOUNTS RECEIVABLE, NET</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,000</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Allowance for doubtful accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI http://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799171656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAYMENTS AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAYMENTS AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock', window );">PREPAYMENTS AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">4. PREPAYMENTS AND OTHER CURRENT ASSETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prepayments and other current assets consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Prepayments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,907,781</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,562,177</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Deposits(a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,646,446</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,873,843</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Others </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 259,757</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 619,901</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,813,984</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,055,921</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Note (a): The deposits represented the amounts that the Group paid to its CRO vendors for various outsourced research and development programs according to the terms of respective CRO agreements. The Group expects to recover the deposits if the programs fail or the agreements are cancelled.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on prepayments and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799019768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, EQUIPMENT AND SOFTWARE, NET</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">5. PROPERTY, EQUIPMENT AND SOFTWARE, NET</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property, equipment and software consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Machinery and laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,150,822</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,252,399</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 915,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,152,743</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Electronic equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 962,684</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,863,956</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and tools</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 106,492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,467</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Vehicles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 126,764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87,680</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 371,636</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total property, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,357,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,809,881</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,290,431)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,322,264)</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net book value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,067,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,487,617</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Depreciation and amortization expenses recognized for the&#160;years ended December&#160;31, 2019, 2020 and 2021 were US$816,686 , US$858,408, and US$1,125,032 respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799182824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUALS AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract', window );"><strong>ACCRUALS AND OTHER CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock', window );">ACCRUALS AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">6. ACCRUALS AND OTHER CURRENT LIABILITIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Accrued liabilities and other current liabilities consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Professional service fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,459,430</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 935,434</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Payroll and related liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,390,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,229,794</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Utility and maintenance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,685</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Other taxes and surcharge</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,919</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62,270</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143,060</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,059,497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,379,243</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure on accrued liabilities and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740796765112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BORROWINGS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>BORROWINGS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">BORROWINGS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt;">7. BORROWINGS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Short-term borrowings:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Bank loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,831,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,121,226</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Current portion of long-term borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,183,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,376,319</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total current borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,015,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,497,545</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Long-term borrowings:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Bank loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,965,563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,991,829</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total non-current borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,965,563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,991,829</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total borrowings</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 7,980,965</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 7,489,374</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Short-term borrowings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September&#160;2019, the Group borrowed a loan with amount of RMB5,000,000 (equivalent to approximately US$766,295) from Bank of Ningbo&#160;Co.,&#160;Ltd. for a term of one year at the interest rate of 4.35% per annum. The borrowing was repaid in September 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2020, the Group borrowed a loan with the amount of RMB10,000,000 (equivalent to approximately US$1,532,591) from Agricultural Bank of China Limited for a term of one year at the interest rate of 4.2% per annum. The borrowing was repaid in June 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2020, the Group borrowed a loan with the amount of RMB5,000,000 (equivalent to approximately US$766,295) from Bank of Ningbo Co., Ltd. for a term of one year at the interest rate of 4.2% per annum. The borrowing was repaid in September 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, the Group borrowed a loan with the amount of RMB5,000,000 (equivalent to approximately US$770,962) from China Merchants Bank Co., Ltd. for a term of one year at the interest rate of 4.1% per annum. The borrowing was repaid in November 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2020, the Group borrowed another loan with the amount of RMB5,000,000 (equivalent to approximately US$770,962) from China Merchants Bank Co., Ltd. for a term of one year at the interest rate of 4.1% per annum. The borrowing was also repaid in November 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2021, the Group borrowed a loan with the amount of RMB9,900,000 (equivalent to approximately US$1,552,771) from Agricultural Bank of China Limited for a term of one year at the interest rate of 4.05% per annum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In August 2021, the Group borrowed another loan with the amount of RMB10,000,000 (equivalent to approximately US$1,568,455) from Agricultural Bank of China Limited for a term of one year at the interest rate of 4.05% per annum.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Long-term borrowings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February&#160;2019, the Group borrowed a loan with the amount of RMB7,500,000 (equivalent to approximately US$1,176,342) from Shanghai Pudong Development Bank&#160;Co.,&#160;Ltd. for a term of three years at the interest rate of 5.46% per annum. The Group repaid RMB375,000 (equivalent to approximately US$58,817) in 2019, RMB1,250,000 (equivalent to approximately US$196,057) in 2020,and RMB3,375,000 (equivalent to approximately US$529,354) in 2021. As of December 31, 2020 and 2021, RMB3,375,000 (equivalent to approximately US$529,354) and RMB2,500,000 (equivalent to approximately US$392,114) repayable within twelve&#160;months for this agreement were classified as &#8220;Current portion of long-term borrowing&#8221; on the consolidated balance sheets, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June&#160;2019, the Group borrowed a loan with the amount of RMB6,000,000 (equivalent to approximately US$941,074) from Shanghai Pudong Development Bank&#160;Co.,&#160;Ltd. for a term of three years at the interest rate of 5.23% per annum. The Group repaid RMB300,000 (equivalent to approximately US$47,054) in 2019, RMB1,000,000 (equivalent to approximately US$156,846) in 2020, and RMB2,700,000 (equivalent to approximately US$423,483) in 2021. As of December 31, 2020 and 2021, RMB2,700,000 (equivalent to approximately US$423,483) and RMB2,000,000 (equivalent to approximately US$313,691) repayable within twelve&#160;months for this agreement were classified as &#8220;Current portion of long-term borrowing&#8221; on the consolidated balance sheets, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2020, the Group borrowed a loan with the amount of RMB16,500,000 (equivalent to approximately US$2,587,952) from Shanghai Pudong Development Bank Co., Ltd. for a term of three years at the interest rate of 4.27% per annum.The Group repaid RMB1,650,000 (equivalent to approximately US$258,796) in 2021. As of December 31, 2020 and 2021, RMB1,650,000 (equivalent to approximately US$258,796) and RMB3,850,000 (equivalent to approximately US$603,855) repayable within twelve months for this agreement were classified as &#8220;Current portion of long-term borrowing&#8221; on the consolidated balance sheets, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In September 2021, the Group borrowed a loan with the amount of RMB8,500,000 (equivalent to approximately US$1,333,186) from Shanghai Pudong Development Bank Co., Ltd. for a term of three years at the interest rate of 4.05% per annum. As of December 31, 2021, RMB425,000 (equivalent to approximately US$66,659<span style="white-space:pre-wrap;">)  repayable within twelve months for this agreement was classified as &#8220;Current portion of long-term borrowing&#8221; on the consolidated balance sheets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2021 and 2020, none of the Group&#8217;s borrowings were collateralized or had covenants in the respective loan agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Future maturities of short-term borrowings and long-term borrowings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Future principal maturities of short-term borrowings and long-term borrowings as of December&#160;31, 2020 and 2021 were as followings:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,015,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,279,713</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,497,545</p></td></tr><tr><td style="vertical-align:bottom;width:77.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,685,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,858,619</p></td></tr><tr><td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,133,210</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,980,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,489,374</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799216232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_DisclosureOfTemporaryEquityAndWarrantsAbstract', window );"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock', window );">CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">8. CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2011, the Company issued convertible notes (&#8220;Series Pre-A Convertible Notes&#8221;) to certain investors in the amount of 4,590,908. The notes carried a simple interest (non-compounding) of 6% per annum as set out in the note purchase agreement. All outstanding principal balance and accrued but unpaid interest of the notes should be automatically converted into the convertible redeemable preferred shares of the Company at a price no more than US$1 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2014, the Company issued 5,473,957 Series A-1 convertible redeemable preferred shares (&#8220;Series A-1 Preferred Shares&#8221;) to certain investors upon conversion of the Company&#8217;s Series Pre-A convertible notes at a conversion price of US$1 per share. Concurrently, the Company issued 2,370,414 Series A-2 convertible redeemable preferred shares (&#8220;Series A-2 Preferred Shares&#8221;) to certain investors at US$1.27 per share for a total consideration of US$3,000,000. Series A-1 Preferred Shares and Series A-2 Preferred Shares are collectively referred to as the Series A Preferred Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From January through June 2016, the Company issued 7,494,537 Series B convertible redeemable preferred shares (&#8220;Series B Preferred Shares&#8221;) to certain investors at US$3.74 per share for a total consideration of US$27,999,995.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From February&#160;through May&#160;2018, the Company issued 5,597,354 Series&#160;C-1 convertible redeemable preferred shares (&#8220;Series&#160;C-1 Preferred Shares&#8221;) to certain investors at US$8.93 per share for a total consideration of US$50,000,033. Concurrently, in February&#160;2018, the Company also issued warrants to two Series&#160;C-1 investors at nil consideration (&#8220;Series&#160;C-1 Warrants&#8221;). The Series&#160;C-1 Warrants allowed the holders to purchase Series&#160;C-2 Preferred Shares (defined below) at the exercise price of US$10.21 per share for a total consideration of up to US$7,500,000. Series&#160;C-1 Warrants were exercisable, in whole or in part, at any time from the warrant issuance date to the earlier of i)&#160;April&#160;1, 2019, ii)&#160;a deemed liquidation event or iii)&#160;the closing of the Qualified IPO. Series&#160;C-1 Warrants expired on April&#160;1, 2019.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From June&#160;through November&#160;2019, the Company issued 1,861,121 Series&#160;C-2 convertible redeemable preferred shares (&#8220;Series&#160;C-2 Preferred Shares&#8221;) to certain investors at US$10.21 per share for a total consideration of US$18,999,999.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2019, the Company issued 4,452,441 Series&#160;C-3 convertible redeemable preferred shares (&#8220;Series&#160;C-3 Preferred Shares&#8221;) to a certain investor at US$11.23 per share for a total consideration of US$50,000,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Series&#160;C-1 Preferred Shares, Series&#160;C-2 Preferred Shares and Series&#160;C-3 Preferred Shares are collectively referred to as the Series&#160;C Preferred Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon completion of the IPO on February 11, 2021, each of the then outstanding Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares (collectively the &#8220;Preferred Shares&#8221;) was automatically converted into one ordinary share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The key features of Preferred Shares were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each holder of the Preferred Shares would be entitled to receive non-cumulative dividends when declared by the Board of Directors prior and in preference to ordinary shareholders. The dividend should be paid at the rate of 6% of the original issue price per share per annum on each Preferred Shares in the sequence of Series&#160;C Preferred Shares and Preferred Shares other than the Series&#160;C Preferred Shares. After the preferential dividends relating to the Preferred Shares were paid in full or declared and set apart in any fiscal&#160;year of the Company, any additional dividends out of funds or assets legally available therefore may be declared in that fiscal&#160;year for the Shares and, if such additional dividends were declared, the preferred shareholders shall be entitled to participate on an as converted-basis pro-rata in any dividends or distributions paid to the ordinary shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Voting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each Preferred Share had voting rights equivalent to the number of ordinary shares to which it was convertible at the record date. The Preferred Shares shall vote separately as a class with respect to certain specified matters. Otherwise, the preferred shareholders and ordinary shareholders shall vote together as a single class.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Liquidation preference</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of any liquidation, dissolution or winding up of the Company, or the cessation of the business of the Company or of a substantial portion of the business of the Company, whether voluntary or involuntary, or any deemed liquidation event (unless waived by the preferred shareholders), the preferred shareholders would be entitled to receive a per share amount equal to 100% of the original issue price of the respective series of the Preferred Shares, in the sequence of Series&#160;C Preferred Shares, Series&#160;B Preferred Shares and Series&#160;A Preferred Shares. After such liquidation amounts were paid in full, the preferred shareholders were entitled to receive a simple interest accruing on each Preferred Share at 6% of its original issue price per annum from the date of issuance of such Preferred Share to the date of distribution of such amount, in the sequence of Series&#160;C Preferred Shares, Series&#160;B Preferred Shares and Series&#160;A Preferred Shares. After such interest amounts were paid in full, any remaining funds or assets of the Company legally available for distribution to shareholders shall be distributed on a pro rata basis among the preferred shareholders, on an as-converted basis, together with the ordinary shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Conversion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each Preferred Share might be converted at any time into ordinary shares at the option of the preferred shareholders based on the then-effective conversion price. The initial conversion ratio was 1:1, subject to adjustment in the event of share splits, share combinations, ordinary share dividends or distributions, other dividends, reorganizations, mergers, consolidations, reclassifications, exchanges, substitutions, or dilutive issuance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All Preferred Shares would be converted automatically into ordinary shares at the then effective applicable conversion price upon the earlier of a Qualified Public Offering (public offering of the Company&#8217;s shares with an offering price (exclusive of underwriting commissions and expenses) that reflected a market capitalization (immediately prior to the public offering) of not less than US$650,000,000 and with an aggregate proceeds of no less than US$75&#160;million) or a date specified by written consent or agreement of the holders of at least 80% of the voting power of the then outstanding Preferred Shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Redemption</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Preferred Shares were redeemable upon request by the holders of the majority outstanding Preferred Shares if the Company failed to consummate a Qualified Public Offering or completed a deemed liquidation event on or before March&#160;31, 2025 at the redemption price equal to the original issue price plus any declared but unpaid dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Accounting for Preferred Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Preferred Shares were classified as mezzanine equity in the consolidated balance sheets because they were contingently redeemable upon the occurrence of an event outside of the Company&#8217;s control (e.g.&#160;the Company not achieving a Qualified Public Offering or a deemed liquidation event before March&#160;31, 2025 (&#8220;Target QIPO Date&#8221;)). The Preferred Shares were determined to be mezzanine equity with no embedded feature to be bifurcated and no beneficial conversion features to be recognized. The Preferred Shares were initially recorded at their respective issuance date fair value, net of issuance cost and fair value allocated to the detachable warrants. The Company did not incur material issuance cost for any Preferred Shares issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to the IPO, the Company concluded that the Preferred Shares were not redeemable, but were probable to become redeemable. The Company accreted changes in the redemption value over the period from the date of issuance to the earliest redemption date for the year ended December 31, 2020, and to the IPO date for the year ended December 31, 2021, using the interest method. No accretion charge was recorded as the redemption value was fixed to original issue price for the periods presented, except for Series C-1 Preferred Shares issued with detachable warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Modification of Preferred Shares</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company made several amendments to the Preferred Shares, mainly including: 1)&#160;added redemption rights for Series&#160;A Preferred Shares upon the issuance of the Series&#160;B Preferred Shares; and 2)&#160;extended the Target QIPO Date upon the issuance of the Series&#160;C-1 Preferred Shares and the Series&#160;C-3 Preferred Shares. These amendments were accounted for as modifications rather than extinguishments as the fair values of these Preferred Shares immediately after the amendments were not significantly different from their respective fair values immediately before the amendment. When Preferred Shares are modified and such modification results in value transfer between preferred shareholders and ordinary shareholders, the value transferred is treated as a deemed dividend to or deemed contribution from the preferred shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company&#8217;s Preferred Shares activities for the periods presented were summarized below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Mezzanine equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A-1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A-2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series C-1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series C-2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series C-3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$ </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,473,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,999,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48,481,159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,955,111</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of Series C-2 Preferred Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,999,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,999,999</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of Series C-3 Preferred Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,000,000</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of Series C-1 Preferred Shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 246,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 246,184</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,473,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,999,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48,727,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,999,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 154,201,294</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of Series C-1 Preferred Shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 248,113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 248,113</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,473,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,999,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48,975,456</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,999,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 154,449,407</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of Series C-1 Preferred Shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,553</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,553</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Preferred Shares to Ordinary Shares </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,473,957)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,000,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27,999,995)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (49,004,009)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,999,999)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (50,000,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (154,477,960)</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The warrants were to subscribe for Series C-2 Preferred Shares and had expired on April 1, 2019, which were freestanding instruments and classified as liabilities in accordance with ASC 480. The warrants were initially recognized at fair value, with subsequent changes in fair value recorded in earnings. The Company recognized gains from the decrease in fair value of the warrants of US$1,207,415 for the year ended December 31, 2019.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_DisclosureOfTemporaryEquityAndWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_DisclosureOfTemporaryEquityAndWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for temporary equity and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799067576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">9. SHARE-BASED COMPENSATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November&#160;7, 2015, the Company adopted a share incentive plan (the &#8220;2015 Plan&#8221;). Under the 2015 Plan, the Company&#8217;s Board of Directors has approved that a maximum aggregate number of shares that may be issued pursuant to all awards granted shall be 4,336,126. In September&#160;2017, the Company replaced the 2015 Plan with the amended and restated share incentive plan (the &#8220;2017 Plan&#8221;) and increased the maximum number of shares issuable to 6,336,126. In December&#160;2019, the Company replaced the 2017 Plan with the second amended and restated share incentive plan (the &#8220;2019 Plan&#8221;) and further increased the maximum number of shares issuable to 11,391,131. The terms of the 2015 Plan, 2017 Plan and 2019 Plan are substantially the same other than the maximum aggregate number of shares the Company may issue under the respective plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Share options containing only service conditions granted to each grantee under the share incentive plan will generally be exercisable upon the grantee renders service to the Company in accordance with a stipulated vesting schedule. Grantees are generally subject to a vesting schedule of no longer than five years, under which the grantee earns an entitlement to vest a certain&#160;percentage of his option grants at the end of each&#160;month or&#160;year of completed service. The share option awards shall expire no more than 10 years from their grant dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Share options containing both service conditions and performance conditions granted to each grantee under the share incentive plan shall become eligible for vesting upon the occurrence of their applicable performance conditions (including but not limited to the occurrence of an IPO, the completion of business and operational goals, etc.).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On August 15, 2020, pursuant to a board resolution, 184,692 share options that granted to a senior management was modified and the vesting period of such share options was shortened from 5 years to 4 years. Since the fair value of the modified award was lower than the fair value of the original award immediately before the modification, no incremental compensation cost was recognized for the modification during the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 9, 2020, the Company passed a board resolution to waive the vesting schedules and conditions of 2,375,000 share options granted to certain management members. Pursuant to this board resolution, these management members exercised all related share options at the original exercise price per share ranging from US$1.83 to US$2.26. As a result, 2,375,000 ordinary shares were issued to these management members. These management members paid the exercise price by issuing recourse promissory notes in the total amount of US$5,197,650. The Company had the repurchase right to buy back such shares at the original exercise price if the grantees did not meet the original vesting conditions. The Company assessed and considered that in accordance with guidance set out in ASC 718-10-55-31, given such arrangement allows the shares received on exercise be returned to the Company if the original vesting conditions are not satisfied, there has been no substantial change to the vesting conditions and the Company shall continue to account for the share awards in accordance with their original terms. As of December 31, 2021, there were 1,585,000 shares unvested according to the original vesting conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 16, 2021, the Company passed a board resolution whereby certain management members surrendered a total of 491,119 ordinary shares as repayment for their respective promissory notes issued in connection with the exercising of options granted to them. In the meantime, the Company further granted these management members the right to repurchase the surrendered shares by way of new option grants with an exercise price of US$13.85 per share. The fair values of these share options were US$7.85 per option, determined by using the binomial option valuation model. The share-based compensation expense related to these share options were recognized immediately upon grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the same board resolution, the 2021 Performance Incentive Plan (the &#8220;2021 Plan&#8221;) was also adopted, under which an aggregate of 2,994,000 ordinary shares shall be reserved for issuance, and the share limit will automatically increase on the first trading day in January of each year (commencing with 2022) by an amount equal to (1)&#160;5% of the total number of the Company&#8217;s outstanding ordinary shares on December&#160;31 of the prior year, or (2)&#160;such lesser number as determined by the board of directors. From March 12, 2021 to December 22, 2021, pursuant to the 2021 Plan, a total of 1,303,000 share options were granted to certain employees by 15 batches, with exercise price ranging from US$5.92 to US$17.56, respectively. In addition, 23,734 ordinary shares were issued to certain management personnel on March 16, 2021 pursuant to the 2021 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020 and 2021, among all the share options granted to date, 2,178,808 and 2,483,808 share options contained both service conditions and performance conditions, respectively. All other share options granted contain only service conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$ per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$ per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 574,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 7.14</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,734,644</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 372,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,800)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 866,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 7.27</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,328,171</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,313,373</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,694,934)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (190,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,294,467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 8.78</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,410,968</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,894,119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (233,958)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (145,550)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,809,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 8.68</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,619,574</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,809,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 8.68</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,619,574</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 393,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 6.68</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,859,836</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,486,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 8.20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 874,180</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate intrinsic value in the table above represents the difference between the exercise price of the awards and the fair value of the underlying ordinary shares at each reporting date, for those awards that had exercise price below the estimated fair value of the relevant ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The aggregate fair value of the equity awards vested during the&#160;years ended December&#160;31, 2019, 2020, and 2021 was US$366,113, US$8,430,085 and US$13,833,856, respectively. As of December&#160;31, 2021, the total unrecognized employee share-based compensation expense was US$30,607,079, all of which may be adjusted for actual forfeitures occurring in the future. Total unrecognized compensation cost will be recognized over a weighted-average period of 2.72&#160;years as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Fair value of share options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The fair value of share options was determined using the binomial option valuation model, with the assistance from an independent third-party appraiser. The binomial model requires the input of highly subjective assumptions, including the expected volatility, the exercise multiple, the risk-free rate and the dividend yield. For expected volatility, the Group has made reference to historical volatility of several comparable companies in the same industry. The exercise multiple was estimated as the average ratio of the stock price to the exercise price of when employees would decide to voluntarily exercise their vested share options. The risk-free rate for periods within the contractual life of the share options is based on the market yield of U.S. Treasury Bonds in effect at the time of grant. The dividend yield is based on the expected dividend policy over the contractual life of the share options. The estimated fair value of the ordinary shares, at the share option grant dates, was determined with the assistance from an independent third-party appraiser.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The assumptions used to estimate the fair value of the share options granted were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Risk&#8209;free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1.78% - 2.73%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.68% - 0.83%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1.11% - 1.67%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0%</p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Expected volatility range</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">67.5% - 71.0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">72.3% - 73.4%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">73.1% - 75.5%</p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercise multiple</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2.2 - 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2.2 - 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2.2 - 2.8</p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Contractual life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">10 years</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">10 years</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">10 years</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Total share-based compensation expenses recognized for the&#160;years ended December&#160;31, 2019, 2020 and 2021 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 404,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,472,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,582,746</p></td></tr><tr><td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 207,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,657,458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,096,912</p></td></tr><tr><td style="vertical-align:bottom;width:67.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total share&#8209;based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 611,711</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,129,541</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,679,658</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Up to the date of the issuance of the consolidated financial statements for the year ended December 31, 2020, some proceeds of the subscription capital arising from the exercise of vested share options by certain employees remained outstanding and such amount was presented as subscriptions receivable, a contra-equity balance on the consolidated balance sheets as of December&#160;31,2020,which was subsequently settled in 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799141512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION ARRANGEMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_CollaborationArrangementsAbstract', window );"><strong>COLLABORATION ARRANGEMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION ARRANGEMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">10. COLLABORATION ARRANGEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Guilin Sanjin Pharmaceutical&#160;Co.,&#160;Ltd. License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December&#160;2018, the Group entered into (i)&#160;a collaboration agreement (the &#8220;Sanjin Greater China Agreement&#8221;) that covers Greater China with Guilin Sanjin Pharmaceutical&#160;Co.,&#160;Ltd. (&#8220;Sanjin&#8221;) and certain of its subsidiaries (collectively, &#8220;Sanjin Parties&#8221;) and (ii)&#160;a collaboration agreement (the &#8220;Sanjin ROW Agreement&#8221;, together with the Sanjin Greater China Agreement, the &#8220;2018 Sanjin Agreements&#8221;) that covers the regions other than Greater China with Sanjin. Pursuant to the Sanjin Greater China Agreement, the Group licensed the Chinese intellectual property directly related to a monospecific antibody molecule that binds to the PD-L1 target (the &#8220;PD-L1 Project&#8221;), including patent rights, patent application rights and technologies based on the core sequence of the molecule, to Sanjin Parties. Sanjin Parties will own all the Chinese intellectual property developed in the exercise of Sanjin Parties&#8217; rights under the agreement, including but not limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights relating thereto. The Group also granted Sanjin Parties a royalty-free license to use our other existing intellectual property and improvements thereto which are related to the PD-L1 Project for the purposes of exploiting its rights and performing its obligations under the agreement. Sanjin Parties will enjoy all the economic benefits deriving from the PD-L1 Project in Greater China, including but not limited to patent transfer fee, licensing fee, sales revenue and sales commission, etc. Sanjin Parties will pay the Group (i)&#160;single-digit&#160;percentage of net sales of the products that use the licensed antibody after such products enter the market and (ii)&#160;a low to mid-low double-digit&#160;percentage of the profits resulting from any transfer of the license to any third parties depending on the timing of the transfer relative to the development stage of the product. The Group also received RMB10,000,000 (equivalent to approximately US$1,511,168) upfront fee upon the effectiveness of the agreement from Sanjin Parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Sanjin ROW Agreement, the Group granted Sanjin a royalty-free license to use all intellectual property relating to (i)&#160;the collaboration under the agreement that the Group controlled before the Group entered into the agreement or acquired independently of the agreement and (ii)&#160;improvements thereto for the purposes of exploiting its rights and performing its obligations under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such intellectual property, and any intellectual property generated from cooperation between the Group and Sanjin&#8217;s affiliates in connection with the collaboration will be jointly owned. The Group retain the ownership of patent rights of key intellectual property pertaining to PD-L1 outside of the Greater China. In addition, all the results obtained by Sanjin relating to the research and development of any new antibody developed under the agreement will be owned by Sanjin. The Group retain a majority of the economic benefits derived from the Sanjin ROW Agreement, including but not limited to any patent transfer fee, licensing fee and gains realized under such transfer. In case the Group intend to transfer to a third party our share of economic interests in any country outside of Greater China, the Group must notify Sanjin and Sanjin will receive a right of first refusal if it pays the Group a deposit equal to a low double-digit&#160;percentage of the consideration that the Group expect to receive from such third party. If Sanjin waives the right of first refusal, the Group can proceed with the transfer, provided that the final transaction price with the third party is not lower than the amount of the offering price that was included in our notice to Sanjin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group agreed not to (i)&#160;independently develop any monospecific antibodies that bind to the PD-L1 target or (ii)&#160;grant any rights associated with such antibodies to any third parties during the three-year period from the effective date of the agreement. The exclusivity obligation does not prevent the Group from (i)&#160;developing or granting any licenses to third parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and masked antibody against PD-L1 target and (ii)&#160;continuing to provide antibody screening service that were commenced before the execution of the Sanjin Greater China Agreement and either party has the independent right to conduct combination therapy studies outside of the Greater China. Either non-breaching party may terminate the 2018 Sanjin Agreements if the other party&#8217;s ability to comply with its respective obligations under the agreements is negatively affected by contingencies such as failure to maintain operation or changes in core project management and the other party fails to take effective remedial measures. Each agreement automatically terminates upon the termination of the other agreement. Upon the rescission or termination, Sanjin Parties will return to the Group all the intellectual property, documents and data provided by the Group under the 2018 Sanjin Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that the failure of the development of the product candidate solely arises from the Group&#8217;s research and development basis specified under this agreement, Sanjin has the right to claim back all the payment made to the Group. The Group considers the possibility of occurrence of such event is very remote.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended December&#160;31, 2018, the Group recognized revenue of RMB10,000,000 (equivalent to approximately US$1,511,168) for this agreement. No additional revenue was recognized for the years ended December 31, 2019, 2020 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In May&#160;2019, the Group entered into (i)&#160;a collaboration agreement that covers Greater China (the &#8220;Dragon Boat Greater China Agreement&#8221;) and (ii)&#160;a collaboration agreement that covers the regions other than Greater China (the &#8220;Dragon Boat ROW Agreement,&#8221; together with the Dragon Boat Greater China Agreement, the &#8220;2019 Dragon Boat Agreements&#8221;), with Dragon Boat Biopharmaceutical (Shanghai) Limited (&#8220;Dragon Boat&#8221;), a subsidiary of Sanjin. Pursuant to the Dragon Boat Greater China Agreement, the Group will license the Chinese intellectual property directly related to a certain monospecific antibody molecule that binds to a specified target (the &#8220;Specified Project&#8221;), including the patent rights, patent application rights and technologies based on the core sequence of the molecule, to Dragon Boat. Dragon Boat will own all the Chinese intellectual property developed in the exercise of Dragon Boat&#8217;s rights under the agreement, including but not limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights relating thereto. The Group also granted Dragon Boat a royalty-free license to use our other existing intellectual property and improvements thereto which are related to the Specified Project for the purposes of exploiting its rights and performing its obligations under the agreement. Dragon Boat will enjoy all the economic benefits deriving from the Specified Project in Greater China, including but not limited to patent transfer fee, licensing fee, sales revenue and sales commission, etc. and will pay the Group (i)&#160;certain high-six figure dollar milestone payments upon the achievement of certain milestones (including milestones of launch of pre-clinical safety evaluation animal test, obtaining Investigational New Drug (&#8220;IND&#8221;) approval in PRC and completion of clinical phase I test in PRC) and (ii)&#160;a single-digit&#160;percentage of net sales of the products that use the licensed antibody after such products enter the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Dragon Boat ROW Agreement, the Group granted Dragon Boat a royalty-free license to use all intellectual property relating to (i)&#160;the collaboration under the agreement that the Group controlled before the Group entered into the agreement or acquired independently of the agreement and (ii)&#160;improvements thereto for the purposes of exploiting its rights and performing its obligations under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such intellectual property, and any intellectual property generated from cooperation between the Group and Dragon Boat in connection with the collaboration will be jointly owned. The Group retain the ownership of patent rights of key intellectual property pertaining to the specified target outside of the Greater China. In addition, all the results obtained by Dragon Boat relating to the research and development of any new antibody developed under the agreement will be owned by Dragon Boat. The Group retains a majority of the economic benefits derived from the Dragon Boat ROW Agreement, including but not limited to any patent transfer fee, licensing fee and gains realized under such transfer. In case the Group intend to transfer to a third party our share of economic interests in any country outside of Greater China, the Group must notify Dragon Boat and Dragon Boat will receive a right of first refusal if it pays the Group a deposit equal to a low double-digit&#160;percentage of the consideration that the Group expects to receive from such third party. If Dragon Boat waives the right of first refusal, the Group can proceed with the transfer, provided that the final transaction price with the third party is not lower than the amount of the offering price that was included in our notice to Dragon Boat.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the 2019 Dragon Boat Agreements, the Group agreed not to (i)&#160;independently develop any monospecific antibodies that bind to the specified target or (ii)&#160;grant any rights associated with such antibodies to any third parties during the three-year period from the effective date of the agreements. The exclusivity obligation does not prevent the Group from (i)&#160;developing or granting any licenses to third parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and masked antibody against the specific target and (ii)&#160;continuing to provide antibody screening service that were commenced before the execution of the Dragon Boat Greater China Agreement and either party has the independent right to conduct combination therapy studies outside of the Greater China. Either nonbreaching party may terminate the 2019 Dragon Boat Agreements if the other party&#8217;s ability to comply with its obligations under the agreements is negatively affected by contingencies such as failure to maintain operation or changes in core project management and the other party fails to take effective remedial measures. Each agreement automatically terminates upon the termination of the other agreement. Upon the rescission or termination, Dragon Boat will return to the Group all the intellectual property, documents and data provided by the Group under the 2019 Dragon Boat Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event that the failure of the development of the product candidate solely arises from the Group&#8217;s research and development basis specified under this agreement, Dragon Boat has the right to claim back all the payment made to the Group. The risk of failure is considered remote upon recognition of revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended December&#160;31, 2019, no revenue was recognized for this agreement since the licensed product has not been transferred to Dragon Boat.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2020, upfront fee of RMB4,000,000 (equivalent to approximately US$573,378) that was received by the Group was recorded as contract liabilities in the consolidated balance sheets, as the performance obligation had not been satisfied by the Group and no revenue was recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2021, milestone fee of RMB4,000,000 (equivalent to approximately US$620,011) was received related to the launch of pre-clinical safety evaluation animal test and the receipt of IND approval in PRC. For the year ended December 31, 2021, a total of RMB8,000,000 (equivalent to approximately US$1,240,022), including the aforementioned upfront fee and milestone fee were recognized as licensing revenue in the consolidated statement of comprehensive loss as the performance obligation was satisfied by the Group and certain milestone events were achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Signal Pharmaceuticals LLC Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In January&#160;2019, the Group entered into an agreement with Signal Pharmaceuticals LLC, a subsidiary of Celgene Corporation, for a purchase order of delivery of certain sequences with total consideration of US$480,000. For the&#160;year ended December&#160;31, 2019, the Group recognized revenue of US$480,000 upon delivery of such sequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2018 and May 2019, the Group entered into agreements with Signal Pharmaceuticals LLC, for purchase orders of for a purchase order of delivery of certain sequences with total consideration of US$237,500 and US$72,000, respectively. For the year ended December 31, 2020, the Group recognized revenue of US$309,500 upon delivery of such sequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2021, the Group did not enter into new agreements with Signal Pharmaceuticals LLC or recognize any additional revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">ADC Therapeutics&#160;SA License and Collaboration Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2019, the Group entered into a material transfer and collaboration agreement (the &#8220;ADCT Collaboration Agreement&#8221;) and a license agreement (the &#8220;ADCT License Agreement&#8221;) with ADC Therapeutics&#160;SA (&#8220;ADC Therapeutics&#8221;). These two agreements are combined as a single contract as the agreements were negotiated as a package with a single commercial objective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">ADCT Collaboration Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the ADCT Collaboration Agreement, the Group agreed to generate masked antibodies with respect to up to two exclusive targets selected by ADC Therapeutics. Upon our delivery of certain initial results, ADC Therapeutics has the option to license the Group&#8217;s technology with respect to one or both targets as further detailed below. ADC Therapeutics has not yet exercised such options as of December&#160;31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the ADCT Collaboration Agreement, the Group is eligible to receive up to a low-seven-figure dollar amount in consideration for the Group&#8217;s exclusivity obligations, upon achievement of certain development milestones (including milestones of delivery of certain amino acid sequences and successful outcome of the first in-vivo study) and upon ADC Therapeutics&#8217; election to proceed with development for the two elected targets. Apart from performance obligation to deliver the amino acid sequences of the corresponding masking peptides, the Group is not required to perform any additional research and development services. ADC Therapeutics has the right to terminate the ADCT Collaboration Agreement at any time and for any reason in its entirety or on a target-by-target basis upon thirty days&#8217; prior written notice to the Group. Either party may terminate the ADCT Collaboration Agreement, in its entirety or on a target-by-target basis, upon the other party&#8217;s uncured material breach of the agreement or the other party&#8217;s insolvency-related events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group also granted ADC Therapeutics an exclusive target reservation right for one year from the commencement of the agreement and an option to renewal for another&#160;year with a consideration of low-six-figure dollar amount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">ADCT License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the exercise of the options contained in the ADCT Collaboration Agreement, the Group has granted ADC Therapeutics, with respect to each elected target, an exclusive, worldwide, perpetual and irrevocable (subject only to the termination provisions) license (with the right to grant sublicenses) to develop, make, use, commercialize and import the antibody drug conjugates that comprise masked antibodies generated by the Group under these programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the ADCT License Agreement, if ADC Therapeutics exercises both of its options granted thereunder, the Group could be eligible to receive up to a low-nine-figure dollar amount in development and regulatory milestone payments upon the achievement of certain milestones (including milestones of successful completion of Good Laboratory Practice Toxicology studies, launch of clinical trials and start of commercial sales in difference countries and etc.) and up to a mid-eight-figure dollar amount in sales milestone payments, in addition to mid-single-digit&#160;percentage net sales-based tiered royalties on products licensed under the ADCT License Agreement, subject to certain reductions. Royalties, if any, will be payable on a country-by-country and product-by-product basis, until the earlier of (i)&#160;the tenth anniversary of the first commercial sale of such product or (ii)&#160;the expiration of the last-to-expire patent licensed under the agreement in such country, unless earlier terminated by the parties, following which any licenses granted to ADC Therapeutics under the ADCT License Agreement shall become fully paid up, perpetual and irrevocable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ADC Therapeutics has the right to terminate the ADCT License Agreement before the expiration of the royalty term on a product-by-product basis or in its entirety (i)&#160;for any reason or no reason upon thirty days&#8217; written notice to the Group, or (ii)&#160;if ADC Therapeutics chooses to discontinue the development or sale of the applicable licensed product worldwide. Each party has certain rights to terminate the ADCT License Agreement with prior written notice upon the other party&#8217;s uncured material breach or insolvency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the year ended December 31, 2019, no revenue was recognized as no performance obligation was satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For the&#160;year ended December&#160;31, 2020, the Group recognized US$225,000 of licensing revenue upon delivery of such results. For the year ended December&#160;31, 2020, the Group recognized US$100,000 as other income due to the expiration of exclusive target reservation right, which is not related to the Group&#8217;s major operation activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">For the year ended December 31, 2021, the Group recognized US$225,000 of licensing revenue upon delivery of additional research results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Exelixis, Inc. Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2021, the Group entered into a collaboration and license agreement (the &#8220;Exelixis Agreement&#8221;) with Exelixis, Inc. (&#8220;Exelixis&#8221;), pursuant to which the Group agreed to generate masked antibodies with its SAFEbody technology against an initial target selected and a second target to be selected by Exelixis. The Group will generate masked antibodies in the form of alternative compounds in accordance with the program plan for each target at its own cost and deliver the related data packages to Exelixis. Exelixis will select lead compounds (the &#8220;Lead Compounds&#8221;) to further develop, obtain regulatory approval and commercialize product(s) for each target (the &#8220;Products under the Exelixis Agreement&#8221;). Under the Exelixis Agreement, the Group will also grant Exelixis an exclusive, worldwide, sublicensable license (the &#8220;Adagene License&#8221;) upon delivery of the data package to research, develop, make, have made, sell, offer for sale, import and commercialize products containing the masked antibodies to be generated by the Group with respect to both targets. Exelixis will own the inventions relating to the Lead Compounds arising in connection with the Exelixis Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Exelixis Agreement will remain effective until the expiration of the defined royalty terms of the Products under the Exelixis Agreement, unless terminated by either party. Exelixis may terminate the Exelixis Agreement for any or no reason, in its entirety or on a target-by-target basis. Any payment received by the Group before the termination shall be non-refundable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the Exelixis Agreement, Exelixis agreed to pay the Group an upfront non-refundable fee of US$11,000,000. For each target, the Group will be eligible to receive up to US$127,500,000 of milestone payments conditioned upon achieving certain development and regulatory approval milestones, and up to $262,500,000 of sales-based milestone payments. In addition, the Group is also entitled to royalties of mid-single-digit percentage in respect of the aggregate annual net sales of the products developed under the Exelixis Agreement worldwide, subject to certain reductions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group determined that generating masked antibodies with its SAFEbody technology is reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under the Exelixis Agreement, the delivery of data packages for each target, along with the Adagene License used to develop the related compounds, represents one performance obligation, as they are not distinct from each other. Transaction price is allocated to each one of the two performance obligations based on the relative standalone selling price method. The Group records revenue at a point in time, when the data packages for each target were delivered to Exelixis. Considering that the development, regulatory and sales-based milestone payments and the royalties are constrained, the transaction price shall initially only include upfront payment and the milestone payments that are considered probable. Subsequently, once the uncertainty associated with the milestone payments is resolved, the milestone payments shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. The sales-based royalty and sales-based milestones promised in exchange for the Adagene License granted are recognized when (or as) the later of 1) the subsequent sale or usage occurs, or 2) the performance obligation to which some or all of the sales-based royalty or sales-based milestones being allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of December 31, 2021, the Group received US$11,000,000 upfront payment and<span style="font-size:11pt;"> </span>recorded accounts receivable of US$3,000,000 milestone payment, which corresponds to the successful nomination of lead SAFEbody candidates for the initial target under the Exelixis Agreement. The milestone payment was subsequently received in January 2022. For the year ended December 31, 2021, US$8,500,000 was recognized as revenue upon delivery of data packages for the initial target and achievement of the milestone event. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_CollaborationArrangementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_CollaborationArrangementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740796801320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX EXPENSE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAX EXPENSE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAX EXPENSE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">11. INCOME TAX EXPENSE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">PRC</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective from January&#160;1, 2008, the PRC&#8217;s statutory, Enterprise Income Tax (&#8220;EIT&#8221;) rate is 25%. In accordance with the implementation rules&#160;of EIT Law, a qualified &#8220;Technology Advanced Service Enterprises&#8221; (&#8220;TASE&#8221;) is eligible for a preferential tax rate of 15%. The TASE certificate is effective for three years. An entity must file required supporting documents with the tax authority and ensure fulfillment of the relevant TASE criteria before using the preferential rate. An entity could apply for the TASE certificate every&#160;year. Dividends by PRC entities, to non-PRC resident enterprises shall be subject to 10% EIT, namely withholding tax, unless the respective non-PRC resident enterprise&#8217;s jurisdiction of incorporation has a tax treaty or arrangements with China that provides for a reduced withholding tax rate or an exemption from withholding tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene (Suzhou) Limited was first recognized as a qualified TASE in March&#160;2015 and renewed in December&#160;2018 and November 2021. Adagene (Suzhou) Limited was authorized to enjoy the preferential tax rate of 15% from 2015 to at least 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Cayman Islands</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene&#160;Inc. is incorporated in the Cayman Islands. Under the current laws of the Cayman Islands Adagene&#160;Inc. is not subject to tax on income or capital gain. Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Hong Kong</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene (Hong Kong) Limited is incorporated in Hong Kong. Companies registered in Hong Kong are subject to Hong Kong profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Hong Kong tax laws. The applicable tax rate in Hong Kong is 16.5%. For the&#160;years ended December&#160;31, 2020 and 2021, Adagene (Hong Kong) Limited did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earnings in Hong Kong for any of the periods presented. Under the Hong Kong tax law, Adagene (Hong Kong) Limited is exempted from income tax on its foreign-derived income and there are no withholding taxes in Hong Kong on remittance of dividends.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Australia</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene Australia Pty&#160;Ltd. is incorporated in Australia. Companies registered in Australia are subject to Australia profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Australia tax laws. The applicable tax rate in Australia is 30%. Adagene Australia Pty&#160;Ltd. has no taxable income for all periods presented, therefore, no provision for income taxes is required. Dividends payable by an Australian entity, to non-Australian resident enterprises shall be subject to 30% withholding tax, unless the respective non-Australian resident enterprise&#8217;s jurisdiction of incorporation has a tax treaty or arrangements with Australia that provides for a reduced withholding tax rate or an exemption from withholding tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">United States</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene Incorporated is incorporated in U.S. and is subject to U.S. federal corporate income tax at a rate of 21%. Adagene Incorporated is also subject to state income tax in California of 8.84%. Dividends payable by an U.S. entity, to non-U.S. resident enterprises shall be subject to 30% withholding tax, unless the respective non-U.S. resident enterprise&#8217;s jurisdiction of incorporation has a tax treaty or arrangements with U.S. that provides for a reduced withholding tax rate or an exemption from withholding tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Switzerland</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adagene AG is incorporated in Switzerland and is subject to federal corporate income tax at a rate of 8.5%. Adagene AG is also subject to cantonal income tax of 6.5% as well as capital tax of 0.1% in the Canton of Basel subject to certain tax benefits and relief. Dividends payable by a Swiss entity, to non-Swiss resident enterprises shall be subject to 35% withholding tax, unless the respective non-Swiss resident enterprise&#8217;s jurisdiction of incorporation has a tax treaty or arrangements with Switzerland that provides for a reduced withholding tax rate or an exemption from withholding tax.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Income tax expense (benefit) of the Group for the years ended December 31, 2019, 2020 and 2021 were composed of the following current and deferred amounts:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">U.S</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,290,009</p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">State and local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 367,441</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,657,450</p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">U.S</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 96,804</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">State and local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (52,641)</p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,163</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Income tax expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,701,613</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Reconciliation between the income tax expense computed by applying the statutory tax rate to loss before income tax and the actual provision for income tax was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,432,308)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42,397,279)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (71,476,322)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">PRC preferential income tax rate as qualified TASE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Income tax credit computed at PRC preferential income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,464,846)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,359,592)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,721,448)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Difference in income tax rates of overseas entities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,492,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,286,487</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,549,985</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development super-deduction<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (230,126)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (718,979)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (569,016)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Non-deductible expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,306</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Changes in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,790,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,277,418</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">State tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 291,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (127,880)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,701,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:18pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><span style="font-weight:normal;">Note&#160;(a): Due to the impacts of research and development super-deduction, the Group&#8217;s subsidiary, Adagene (Suzhou) Limited, did not have any income taxes for the&#160;years ended December&#160;31, 2019, 2020, and 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Deferred tax assets and liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Deferred taxes were measured using the enacted tax rates for the periods in which the temporary differences are expected to be reversed. The tax effects of temporary differences that give rise to the deferred tax balances as of December&#160;31, 2020 and 2021 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net operating loss carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,722,293</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,949,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Capitalized inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95,589</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Unrealized foreign exchange gain/losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,166</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Depreciation and amortization of property, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,729,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,083,834</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,729,721)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,007,139)</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,695</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;&#160;&#160;&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;&#160;&#160;&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Depreciation and amortization of property, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (120,858)</p></td></tr><tr><td style="vertical-align:bottom;width:77.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (120,858)</p></td></tr><tr><td style="vertical-align:bottom;width:77.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total deferred tax liabilities, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (44,163)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Movement of the valuation allowance was as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of January 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 938,875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,729,721</p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Addition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,790,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,277,418</p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of December&#160;31</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,729,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,007,139</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion or all of the deferred tax assets will not be realized in the foreseeable future. In making such determination, the Group evaluates a variety of positive and negative factors including the Group&#8217;s operating history, accumulated deficit, the existence of taxable temporary differences and reversal periods.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group has incurred net accumulated operating losses for income tax purposes since its inception. As of December 31, 2021, the Group had net operating losses for income tax purpose of approximately US$27,453,623. The net operating losses were primarily comprised of: US$9,206,664 from an entity in PRC which expires in years 2028 through 2030; US$8,467,321 derived from an entity Switzerland which expires in years 2027 through 2028; US$5,240,125 derived from an entity in Hong Kong that have an indefinite carryforward; US$3,684,472 derived from an entity in Australia that have an indefinite carryforward subject to meeting certain criteria; US$640,570 derived from entities in the United States which expire beginning year 2038; and, US$214,471 derived from an entity in Singapore. The Group believes that it is more likely than not that these net accumulated operating losses will not be utilized in the near future, except for the net operating losses from the U.S. subsidiary. Therefore, the Group has provided full valuation allowances for the deferred tax assets for all subsidiaries as of December 31, 2020 and for subsidiaries other than the U.S. subsidiary as of December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of December&#160;31, 2020 and 2021, the Group did not have any significant unrecognized uncertain tax positions. The Group does not anticipate that the amount of unrecognized tax benefits will significantly change within the next 12 months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group conducts business in a number of tax jurisdictions and, as such, is required to file income tax returns in multiple jurisdictions globally. As of December 31, 2021, PRC tax matters are open to examination for the years 2018 through 2021, U.S. federal and state tax matters are open to examination for the years 2018 through 2021, and Australia tax matters are open to examination for the years 2019 through 2021.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799204120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">12. NET LOSS PER SHARE</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Basic and diluted net loss per share for the&#160;years ended December&#160;31, 2019, 2020 and 2021 were calculated as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year&#160;Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to Adagene Inc.&#8217;s shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,432,308)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42,397,279)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (73,177,935)</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of convertible redeemable preferred shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (246,184)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (248,113)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,553)</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to ordinary shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,678,492)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42,645,392)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (73,206,488)</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted&#8209;average number of ordinary shares outstanding&#8212;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,178,232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,950,698</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,032,009</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net Loss per share&#8212;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.67)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.46)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The effects of all outstanding convertible redeemable preferred shares and share options have been excluded from the computation of diluted loss per share for the&#160;years ended December&#160;31, 2019, 2020 and 2021 as their effects would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The potentially dilutive securities that have not been included in the calculation of diluted net loss per share as their inclusion would be anti-dilutive are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year&#160;Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Convertible redeemable preferred shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,977,914</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,249,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Share options and share grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 582,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,795,932</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,739,882</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740796772920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">13. RELATED PARTY TRANSACTIONS</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Related Parties</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name of related parties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Relationship</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Peter Luo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Chairman, Chief Executive Officer and a principal shareholder of the Company</p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Four senior management personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Management and ordinary shareholders of the Company</p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Co., Ltd. (&#8220;WuXi AppTec Group&#8221;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">A principal shareholder of the Company</p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Controlled by the ultimate controlling party of a principal shareholder of the Company</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Group had the following related party balances as of December 31, 2020 and 2021:</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Group</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 124,704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,080,116</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,692</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,426,554</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total amounts due from related parties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 132,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,506,670</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">As of December 31, 2020 and 2021, the amounts due from related parties represented prepayments made for the CRO and CMO services.<br/><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,361,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,292,268</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Group</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 173,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 173,793</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total amounts due to related parties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,535,358</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,466,061</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">As of December 31, 2020 and 2021, the amounts due to related parties represented payables for the CRO and CMO services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Group had the following related party transactions during the years ended December 31, 2019, 2020 and 2021:</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Receipt of CRO and CMO services:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,567,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,217,709</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,561,276</p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Group <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(i)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,136,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,674,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 517,742</p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,704,306</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,892,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,079,018</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799138712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">14. COMMITMENTS AND CONTINGENCIES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Operating lease commitments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Future minimum payments under non-cancelable operating leases with initial terms in excess of one&#160;year consisted of the following as of December&#160;31, 2020 and 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">For the years ending:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 412,754</p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 255,309</p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70,367</p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 738,430</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"><span style="margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Payments under operating leases are expensed on a straight-line basis over the periods of their respective leases. The Group&#8217;s lease arrangements have no renewal options, rent escalation clauses, restrictions or contingent rents and are all executed with third parties. For the&#160;years ended December&#160;31, 2019, 2020, and 2021, total rental related expenses for all operating leases amounted to US$175,812, US$177,453 and US$331,745, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group is currently not involved in any legal or administrative proceedings that may have a material adverse impact on the Group&#8217;s business, financial position or results of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799068296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRICTED NET ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_RestrictedNetAssetsAbstract', window );"><strong>RESTRICTED NET ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedAssetsDisclosureTextBlock', window );">RESTRICTED NET ASSETS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">15. RESTRICTED NET ASSETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group&#8217;s ability to pay dividends may depend on the Group receiving distributions of funds from its PRC subsidiary. Relevant PRC statutory laws and regulations permit payments of dividends by the Group&#8217;s PRC subsidiary only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the consolidated financial statements prepared in accordance with U.S.&#160;GAAP differ from those reflected in the statutory financial statements of the Group&#8217;s PRC subsidiary.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In accordance with the company law of the PRC, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual after-tax profit until such reserve has reached 50% of its respective registered capital based on the enterprise&#8217;s PRC statutory accounts. A domestic enterprise is also required to provide discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise&#8217;s PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Group&#8217;s PRC subsidiary was established as domestic invested enterprise and therefore is subject to the abovementioned restrictions on distributable profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2020 and 2021, the total restricted net assets of the Company&#8217;s subsidiary incorporated in PRC and subjected to restriction amounted to approximately US$1,267,900 and US$1,860,667 respectively. Other subsidiaries are not subjected to such restriction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a result of these PRC laws and regulations subject to the limit discussed above that require annual appropriations of 10% of after-tax income to be set aside, prior to payment of dividends, as general reserve fund, the Group&#8217;s PRC subsidiary is restricted in their ability to transfer a portion of their net assets to the Group.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Foreign exchange and other regulations in the PRC further restrict the Group&#8217;s PRC subsidiaries from transferring funds to the Company in the form of dividends, loans and advances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of December 31, 2021, the net asset base for purposes of calculating the proportionate share of restricted net assets of consolidated subsidiaries was US$1,860,667 from the PRC subsidiary, and the Group had a consolidated shareholders&#8217; equity. As the restricted net assets of consolidated subsidiaries do not exceed 25% of consolidated net assets as of the most recent fiscal year end, the Group is not required to provide parent company financial information.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_RestrictedNetAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>No Definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_RestrictedNetAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799138152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TREASURY SHARES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAbstract', window );"><strong>TREASURY SHARES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">TREASURY SHARES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">16. Treasury Shares</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group accounts for treasury shares using the cost method. Under this method, the cost incurred to purchase the shares is recorded in the treasury shares account in the consolidated balance sheets. At retirement, the ordinary shares account is charged only for the aggregate par value of the shares. The excess of the acquisition cost of treasury shares over the aggregate par value is recorded entirely in additional paid-in capital (up to the amount credited to the additional paid-in capital upon original issuance of the shares). In the event that treasury share is reissued at an amount different from the cost the Group paid to repurchase the treasury share, the Group will recognize the difference in additional paid-in capital by using the specified identification method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;">On July 7, 2021, the Board of Directors approved a share repurchase program to repurchase up to US</span><span style="font-size:10pt;">$20</span><span style="font-size:10pt;"> million of outstanding ADSs of the Company, from time to time over a </span><span style="font-size:10pt;">12</span><span style="font-size:10pt;">-month period from the date on which a formal stock repurchase plan engagement agreement was signed with a qualified broker-dealer. Up to December 31, 2021, </span><span style="font-size:10pt;">236,139</span><span style="font-size:10pt;"> outstanding ADSs (</span><span style="font-size:10pt;">295,174</span><span style="font-size:10pt;"> ordinary shares) were repurchased with a total consideration of US</span><span style="font-size:10pt;">$2,361,576</span><span style="font-size:10pt;">. As of December 31, 2021, </span><span style="font-size:10pt;">160,880</span><span style="font-size:10pt;"> ADSs (</span><span style="font-size:10pt;">201,100</span><span style="font-size:10pt;"> ordinary shares) repurchased shares have been retired.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208821<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799015656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">17. SUBSEQUENT EVENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On January 7, 2022, the Company passed a board resolution, pursuant to which the vesting schedules and conditions of 2,060,308 share options granted to certain employees were modified. Share options as to which the applicable performance milestones have been met are no longer subject to the time-based vesting requirement. The share options vested (or to be vested) for each year (commencing from 2021) shall be equal to the lesser of (i) 25% of the total number of share options of each grantee (&#8220;Annual Cap&#8221;) and (ii) the number of shares as determined by the Compensation Committee based on the extent to which any performance milestones were achieved during that year (&#8220;Credited Shares&#8221;), plus any Credited Share of earlier years that have not previously vested due to the Annual Cap. In addition, the performance milestones applicable to the share options that remain outstanding were also modified. Incremental fair value of US$2,337,697 resulted from the modification, which will be recognized as additional compensation expense over the remaining requisite service period, if any. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From February 7 to March 25, 2022, pursuant to the 2021 Plan, a total of 1,320,000 share options were granted to certain employees, with exercise price ranging from US$3.46 to US$5.60 per share. In addition, 99,999 ordinary shares were issued to certain management personnel on March 8, 2022 pursuant to the 2021 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 2, 2022, the Company entered into a collaboration and exclusive license agreement (the &#8220;Sanofi Agreement&#8221;) with Sanofi SA, pursuant to which the Company will be responsible for early-stage research activities to develop masked versions of Sanofi candidate antibodies, using Adagene&#8217;s SAFEbody technology. Sanofi will be solely responsible for later stage research and all clinical, product development and commercialization activities. Pursuit to the Sanofi Agreement, the Company has received an US$17,500,000 upfront payment in April 2022. In addition, the Company will be eligible to receive total potential development, regulatory and commercial milestone payments of up to US$2.5 billion for advancement of the candidates, which will be exclusively developed and commercialized by Sanofi. Adagene is eligible to also receive tiered royalties on global net sales of approved collaboration products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective March 25, 2022, Adagene Project C1 Pte., a subsidiary located in Singapore, was incorporated. To date, this new subsidiary has not commenced operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">As of March 31, 2022, the Group has repurchased an additional of 272,099 outstanding ADSs (340,124 ordinary shares) with a total consideration of US$1,539,631, and no additional repurchased shares have been retired.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740794949448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S.&#160;GAAP&#8221;).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The consolidated financial statements of the Group include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the balance sheet dates and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in the Group&#8217;s consolidated financial statements include, but are not limited to, licensing and collaboration revenue recognition, research and development expense allocation, the useful lives and impairment of long-lived assets, tax valuation allowance, and share-based compensation expenses. Management bases the estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could materially differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign currency translation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Foreign currency translation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The functional currency of the Company, Adagene (Hong Kong) Limited, Adagene Incorporated and Adagene PTE. Ltd. is the United States dollar (&#8220;US$&#8221;). The functional currency of the Company&#8217;s PRC subsidiary is Renminbi (&#8220;RMB&#8221;). The functional currency of the Company&#8217;s Australian subsidiary is Australian dollar (&#8220;AU$&#8221;). The functional currency of the Company&#8217;s Swiss subsidiary is Swiss Franc (&#8220;CHF&#8221;). The determination of the respective functional currency is based on the criteria stated in Accounting Standard Codification (&#8220;ASC&#8221;) 830, <i style="font-style:italic;">Foreign Currency Matters</i>. The Company uses US$ as its reporting currency. The financial statements of the Company&#8217;s PRC, Australian and Swiss subsidiaries are translated from the functional currency to the reporting currency.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Transactions denominated in foreign currencies are remeasured into the functional currency at the exchange rates quoted by the People&#8217;s Bank of China (the &#8220;PBOC&#8221;) prevailing on the transaction dates. Monetary assets and liabilities denominated in foreign currencies are re-measured at the exchange rates prevailing at the balance sheet date. Non-monetary items that are measured in terms of historical costs in foreign currency are re-measured using the exchange rates at the dates of the initial transactions. Exchange gains and losses are included in the consolidated statements of comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Assets and liabilities are translated at the exchange rates at the balance sheet date, equity accounts are translated at historical exchange rates and revenues, expenses, gains and losses are translated using the average rate for the&#160;year. Translation adjustments are reported as accumulated comprehensive loss and are shown as a separate component of other comprehensive loss in the consolidated statements of comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Cash and cash equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Cash and cash equivalents primarily consist of cash and demand deposits which are highly liquid. The Group considers highly liquid investments that are readily convertible to known amounts of cash and with original maturities from the date of purchase of three&#160;months or less to be cash equivalents. All cash and cash equivalents are unrestricted as to withdrawal and use.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock', window );">Accounts receivable and allowance for doubtful accounts</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Accounts receivable and allowance for doubtful accounts</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;font-weight:normal;">Account receivable is recorded when the Group has an unconditional right to consideration. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due. Accounts receivable is carried at net realizable value. An allowance for doubtful accounts is recorded in the period when collection of the amount is no longer probable. In evaluating the collectability of receivable balances, the Group considers specific evidence including the aging of the receivable, the customer&#8217;s payment history, its current credit-worthiness and other factors. Accounts receivable is written off when management determines a balance is uncollectable after all collection efforts have ceased.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Fair value measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group applies ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures</i>. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 requires disclosures to be provided for fair value measurements. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 1&#8212;Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 2&#8212;Other inputs that are directly or indirectly observable in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 3&#8212;Unobservable inputs which are supported by little or no market activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1)&#160;market approach; (2)&#160;income approach; and (3)&#160;cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying amounts of cash and cash equivalent, accounts receivable, amounts due to related parties and other current assets, accounts payable, amounts due to related parties, accrued liabilities and other current liabilities and short-term borrowings approximate their fair values because of their generally short maturities. The carrying amount of long-term borrowings approximate their fair values since they bear interest rates which approximate market interest rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group did not transfer any assets or liabilities in or out of Level&#160;3 during the&#160;years ended December&#160;31, 2020 or 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group had no financial assets and liabilities measured and recorded at fair value on a nonrecurring basis as of December&#160;31, 2020 and 2021.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, equipment and software</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Property, equipment and software</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Property and equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Machinery and laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">5 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Vehicles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">4 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Furniture and tools</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">3</span><span style="font-size:10pt;"> - </span><span style="font-size:10pt;">5 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Electronic equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">3 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Computer software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">3</span><span style="font-size:10pt;white-space:pre-wrap;"> -  </span><span style="font-size:10pt;">5 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Lesser of lease terms or estimated useful lives of the assets</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Repair and maintenance costs are charged to expense as incurred, whereas the cost of renewals and betterments that extend the useful lives of property, equipment and software are capitalized as additions to the related assets. Retirements, sales and disposals of assets are recorded by removing the cost and accumulated depreciation and amortization from the asset and accumulated depreciation and amortization accounts with any resulting gain or loss reflected in the consolidated statements of comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Impairment of long-lived assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group evaluates the recoverability of its long-lived assets, including fixed assets and intangible assets with finite lives, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. When these events occur, the Group measures impairment by comparing the carrying amount of the assets to the estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the assets, the Group recognizes an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the assets, when the market prices are not readily available. The adjusted carrying amount of the assets is the new cost basis and is depreciated over the assets&#8217; remaining useful lives. Long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No impairment loss was recorded for the&#160;years ended December&#160;31, 2019, 2020 and 2021. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment reporting</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Segment reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In accordance with ASC 280, </span><i style="font-weight:normal;">Segment Reporting</i><span style="font-style:normal;font-weight:normal;">, the Group&#8217;s chief operating decision maker (&#8220;CODM&#8221;) has been identified as the Chief Executive Officer. The Group&#8217;s CODM reviews the consolidated results of operations when making decisions about allocating resources and assessing performance of the Group. The Group operates and manages it business as a single segment. No geographical segments are presented as a substantial portion of the Group&#8217;s long-lived assets are located in the PRC with the exception of certain laboratory and electronic equipment which are located in the U.S.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Revenue recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At contract inception of collaboration and out-licensing arrangements, the Group analyzes its arrangements to assess whether they are within the scope of ASC 808, <i style="font-style:italic;">Collaborative Arrangements</i> (&#8220;ASC 808&#8221;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Group first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are reflective of a vendor-customer relationship and therefore within the scope of ASC 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i> (&#8220;ASC 606&#8221;). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently. Under the criteria of ASC 606, the Group recognizes revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group adopted ASC 606 for all periods presented. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Group only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. The Group reviews the contract to determine which performance obligations are distinct and represent a promise to provide distinct goods or services or a series of distinct goods or services as defined by the standard. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation as and when that performance obligation is satisfied.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Licenses of Intellectual Property:</i> Upfront non-refundable payments for licensing the Group&#8217;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Group recognizes revenues from non-refundable, up-front fees allocated to the license at a point in time, when the transfer of control of the license to the licensee occurs and the licensee is able to use and benefit from the license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Research and Development Services</i><span style="white-space:pre-wrap;">:  The portion of the transaction price allocated to research and development services performance obligations is deferred and recognized at a point in time as delivery of such services occurs.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Milestone Payments:</i><span style="white-space:pre-wrap;">  At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group re-evaluates the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Royalties:</i> For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Group recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">During the years ended December 31, 2019 and 2020,  </span>no milestone payments or royalty payments were received. During the year ended December 31, 2021, milestone payment was received, but no royalty payments were received. Substantially all of the Group&#8217;s revenue has been derived from its out-licensing agreements with respect to licensed products such as DNA sequences, cell lines, etc., and such revenues are recognized when the customer obtains control of the licensed product, which occurs at a point in time, upon delivery to the customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Contract assets and contract liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">When a customer pays consideration before the Group transfers products or services, the Group records its obligation as a contract liability; When the Group satisfies its performance obligations by providing products or services to a customer before the customer pays consideration and before payment is due, the Group recognizes its rights to consideration as a contract asset.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenses</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Research and development expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Elements of research and development expenses primarily include (1) payroll and other related costs of personnel engaged in research and development activities, (2) costs related to pre-clinical testing of the Group&#8217;s technologies under development and clinical trials such as payments to contract research organizations (&#8220;CRO&#8221;) and contract manufacturing organizations (&#8220;CMO&#8221;), investigators and clinical trial sites that conduct the clinical studies; (3) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation and amortization, and facility related expenses, and (4) other research and development expenses. Research and development costs are expensed as incurred when the related research and development services are provided to the Group and the resulting assets, if any, have no alternative future uses. As of December 31, 2020 and 2021, the Group had several ongoing clinical studies in various clinical trial stages. The contracts with CRO and CMO are generally cancellable, with notice, at the Group&#8217;s option. The Group did not record any accrued expenses related to cancellation of CRO or CMO contracts as of December 31, 2020 or 2021 as the Group did not have any plan to cancel the existing CRO or CMO contracts.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_GovernmentSubsidiesPolicyTextBlock', window );">Government subsidies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Government subsidies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">Government subsidies primarily consist of financial subsidies received from provincial and local governments for operating a business in their jurisdictions and compliance with specific policies promoted by the governments. The Group&#8217;s PRC based subsidiary received government subsidies from certain local government. The Group&#8217;s government subsidies consist of specific subsidies and other subsidies. Specific subsidies are subsidies that the local government has set certain conditions for the subsidies. Other subsidies are the subsidies that the local government has not set any conditions and are not tied to future trends or performance of the Group, receipt of such subsidy income is not contingent upon any further actions or performance of the Group and the amounts do not have to be refunded under any circumstances. These specific subsidies are recorded as other non-current liabilities upon receipt and are recognized as other income when the conditions are met. Other subsidies are recognized as other income upon receipt as further performance by the Group is not required. Government subsidies of US</span><span style="font-style:normal;font-weight:normal;">$0.7</span><span style="font-style:normal;font-weight:normal;"> million, US</span><span style="font-style:normal;font-weight:normal;">$0.8</span><span style="font-style:normal;font-weight:normal;"> million and US</span><span style="font-style:normal;font-weight:normal;">$1.4</span><span style="font-style:normal;font-weight:normal;"> million were received and recognized as other income during the years ended December 31, 2019, 2020 and 2021, respectively.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In addition, the Group&#8217;s Australian subsidiary received research and development tax incentive from the Australian Taxation Office. The tax incentive was recognized as other income upon receipt as the incentive was not dependent upon having a tax liability and further performance by the Group was not required.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Leases are classified at the inception date as either a capital lease or an operating lease. The Group assesses a lease to be a capital lease if any of the following conditions exists: a)&#160;ownership is transferred to the lessee by the end of the lease term, b)&#160;there is a bargain purchase option, c)&#160;the lease term is at least 75% of the property&#8217;s estimated remaining economic life or d)&#160;the present value of the minimum lease payments at the beginning of the lease term is 90% or more of the fair value of the leased property to the lessor at the inception date. A capital lease is accounted for as if there was an acquisition of an asset and an incurrence of an obligation at the inception of the lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All other leases are accounted for as operating leases wherein rental payments are expensed on a straight-line basis over their respective lease terms. The Group leases certain office space under non-cancelable operating lease agreements. Certain lease agreements contain rent holidays. Rent holidays are considered in determining the straight-line rent expense to be recorded over the lease term. The lease term begins on the date of initial possession of the leased property for purpose of recognizing lease expense on straight-line basis over the term of the lease.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive income (loss)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss) is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by shareholders and distributions to shareholders. Accumulated other comprehensive income (loss) of the Group includes foreign currency translation adjustments related to the Group and its subsidiaries whose functional currency is not US$.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Income taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group follows the liability method of accounting for income taxes in accordance with ASC&#160;740, <i style="font-style:italic;">Income Taxes</i> (&#8220;ASC&#160;740&#8221;). Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Group records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group evaluates its uncertain tax positions using the provisions of ASC 740, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group recognizes in the consolidated financial statements the benefit of a tax position which is &#8220;more likely than not&#8221; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty&#160;percent likelihood of being realized upon settlement. It is the Group&#8217;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Borrowings</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Borrowings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the consolidated statements of comprehensive loss over the period of the borrowings using the effective interest method.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Share-based compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company grants restricted shares and stock options to eligible employees and nonemployees and accounts for share-based compensation in accordance with ASC 718, <i style="font-style:italic;">Compensation-Stock Compensation</i>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses a) immediately at the grant date if no vesting conditions are required; b) for share-based awards granted with only service conditions, using the straight-line method over the vesting period; or c) for share-based awards granted with service conditions and performance conditions, using the graded vesting method over the vesting period if and when the Company concludes that it is probable that the performance conditions will be achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">In accordance with ASC 260, </span><i style="font-weight:normal;">Earnings Per Share</i><span style="font-style:normal;font-weight:normal;">, basic net loss per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of unrestricted ordinary shares outstanding during the year using the two-class method. Under the two-class method, net loss is allocated between ordinary shares and other participating securities based on dividends declared (or accumulated) and participating rights in undistributed earnings as if all the earnings for the reporting period had been distributed. The Company&#8217;s convertible redeemable preferred shares were participating securities because they were entitled to receive dividends or distributions on an as converted basis. Diluted net loss per share is calculated by dividing net loss attributable to ordinary shareholders, as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares include ordinary shares issuable upon the conversion of the convertible redeemable preferred shares using the if-converted method, and ordinary shares issuable upon the exercise of share options, using the treasury stock method. Ordinary share equivalents are excluded from the computation of diluted earnings per share if their effects are anti-dilutive. For the periods presented herein, the computation of basic net loss per share using the two-class method is not applicable as the Group is in a net loss position and the participating securities do not have contractual rights and obligations to share in the losses of the Group.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_EmployeeDefinedContributionPlanPolicyTextBlock', window );">Employee defined contribution plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Employee defined contribution plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As stipulated by the regulations of the PRC, full-time employees of the Group are entitled to staff welfare benefits including medical care, welfare subsidies, unemployment insurance and pension benefits through a PRC government-mandated multi-employer defined contribution plan. The Group is required to accrue for these benefits based on certain percentages of the qualified employees&#8217; salaries. The Group is required to make contributions to the plans out of the amounts accrued. The PRC government is responsible for the medical benefits and the pension liability to be paid to these employees and the Group&#8217;s obligations are limited to the amounts contributed. The Group has no further payment obligations once the contributions have been paid. The Group recorded employee benefit expenses of US$1,145,165 , US$622,377 and US$2,223,493 for the&#160;years ended December&#160;31, 2019 , 2020 and 2021, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of risks</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of risks</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of credit risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2020 and 2021, the amount of cash and cash equivalents of US$3,424,456 and US$3,650,474 respectively, were held at major financial institutions located in Mainland China, and US$71,726,542 and US$170,740,769,respectively, were deposited with major financial institutions located outside of Mainland China. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Accounts receivable is typically unsecured and denominated in US$ and is derived from revenues earned from customers. The Group manages credit risk of accounts receivable through ongoing monitoring of the outstanding balances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Concentration of suppliers</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Group&#8217;s research and development services were purchased from one supplier group, who collectively accounted for 23.13%,21.51% and 18.45%of the Group&#8217;s total research and development services purchases for the&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Business and economic risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group believes that changes in any of the following areas could have a material adverse effect on the Group&#8217;s future consolidated financial position, results of operations or cash flows: changes in the overall demand for services; competitive pressures due to new entrants; advances and new trends in new technologies and industry standards; changes in certain strategic relationships; regulatory considerations and risks associated with the Group&#8217;s ability to attract employees necessary to support its growth. The Group&#8217;s operations could also be adversely affected by significant political, regulatory, economic and social uncertainties in the PRC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Foreign currency exchange rate risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant portion of the Group&#8217;s businesses are transacted in RMB, which is not a freely convertible currency. On January&#160;1, 1994, the PRC government abolished the dual rate system and introduced a single rate of exchange as quoted daily by the PBOC. However, the unification of the exchange rates does not imply that the RMB may be readily convertible into US$ or other foreign currencies. All foreign exchange transactions continue to take place either through the PBOC or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the PBOC. Approval of foreign currency payments by the PBOC or other institutions requires submitting a payment application form together with suppliers&#8217; invoices, shipping documents and signed contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From July&#160;21, 2005, the RMB is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. For U.S. dollar against RMB, there was depreciation of approximately 6.5% and 2.29% in the&#160;years ended December&#160;31, 2020 and 2021, respectively. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the RMB and the U.S. dollar in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The functional currency and the reporting currency of the Company are the US$. However, the Group incurs portions of our expenses, and derives revenues, in currencies other than US$, in particular, the RMB. Any significant fluctuation of the valuation of RMB may materially affect the Group&#8217;s cash flows, expenses, losses and financial position, and the value of any dividends payable on the American Depositary Shares in US$.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Recently issued accounting pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Group is an emerging growth company (&#8220;EGC&#8221;) as defined by the Jumpstart Our Business Startups Act (&#8220;JOBS Act&#8221;). The JOBS Act provides that an EGC can take advantage of extended transition periods for complying with new or revised accounting standards. This allows an EGC to delay adoption of certain accounting standards until those standards would otherwise apply to private companies. The Group elected to take advantage of the extended transition periods. However, this election will not apply should the Group cease to be classified as an EGC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In February 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU No. 2016-02 (&#8220;ASU 2016-02&#8221;), <i style="font-style:italic;">Leases</i> (Topic 842), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. In July 2018, FASB issued ASU No. 2018-10 (&#8220;ASU 2018-10&#8221;), <i style="font-style:italic;">Codification Improvements to Topic 842, Leases</i>, which clarifies certain aspects of the guidance issued in ASU 2016-02; and ASU No. 2018-11 (&#8220;ASU 2018-11&#8221;), <i style="font-style:italic;">Leases (Topic 842): Targeted Improvements</i>, which provides entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity&#8217;s reporting for the comparative periods presented in the financial statements in which it adopts the new leases standard will continue to be in accordance with current GAAP (Topic 840, Leases). Further, FASB issued ASU No. 2020-05 (&#8220;ASU 2020 05&#8221;), Revenue from Contracts with Customers (Topic 606) and Leases (Topic 842): Effective Dates for Certain Entities, which extends the adoption date for certain entities. For the Group, the updated guidance is effective for fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. The Group does not plan to early adopt the new lease standards and the Group expects that applying the ASU 2016-02 would materially increase the assets and liabilities due to the recognition of right-of-use assets and lease liabilities on its consolidated balance sheets, with an immaterial impact on its consolidated statements of comprehensive loss and consolidated statements of cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2016, FASB issued ASU No. 2016-13, <i style="font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (&#8220;ASU 2016-13&#8221;). ASU 2016-13 is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. This ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of the Group&#8217;s portfolio. These disclosures include qualitative and quantitative requirements that provide additional information about the amounts recorded in the financial statements. In November 2019, FASB issued ASU 2019-10, which extends the adoption date for certain registrants. The amendments in ASU 2016-13 are effective for fiscal years beginning after December 15, 2022, including interim periods within fiscal years beginning after December 15, 2023. The Group does not plan to early adopt ASU 2016-13 and is currently in the process of evaluating the impact of adoption of this guidance on its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2018, FASB issued ASU 2018-18, <i style="font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</i>. This update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer and precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The update is effective in fiscal years beginning after December 15, 2021, and interim periods therein, and early adoption is permitted for entities that have adopted ASC 606. This guidance should be applied retrospectively to the date of initial application of Topic 606. The Group elected to early adopt this ASU and applied this guidance retrospectively to all periods presented. The impact of this ASU to the consolidated financial statements is immaterial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2019, FASB issued ASU 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>. This update simplifies the accounting for income taxes as part of FASB&#8217;s overall initiative to reduce complexity in accounting standards. The amendments include removal of certain exceptions to the general principles of ASC 740, <i style="font-style:italic;">Income Taxes</i>, and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. The update is effective in fiscal years beginning after December 15, 2022, and interim periods therein, and early adoption is permitted. Certain amendments in this update should be applied retrospectively or modified retrospectively, all other amendments should be applied prospectively. The Group does not plan to early adopt ASU 2019-12 and is currently evaluating the impact on its financial statements of adopting this guidance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">In August 2020, FASB issued ASU 2020-06, <i style="font-style:italic;">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</i>, which simplifies the accounting for convertible instruments by removing certain separation models in Subtopic 470-20, <i style="font-style:italic;">Debt&#8212;Debt with Conversion and Other Options</i>, for convertible instruments and also increases information transparency by making disclosure amendments. The standard is effective for private companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact of this accounting standard update on its condensed consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable and allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_EmployeeDefinedContributionPlanPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for Employee defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_EmployeeDefinedContributionPlanPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_GovernmentSubsidiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government subsidies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_GovernmentSubsidiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799140952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BASIS OF PRESENTATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_SummaryOfPrincipalSubsidiariesTableTextBlock', window );">Summary of principal subsidiaries</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:27.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Percentage&#160;of&#160;legal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Place&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">ownership</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Entity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">incorporation</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">by&#160;the&#160;Company</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:27.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal&#160;activities</b></p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adagene (Hong Kong) Limited</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">December 12, 2011</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Hong Kong</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Investment holding</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adagene Incorporated</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">September 20, 2017</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">The United States of America</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adagene (Suzhou) Limited</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">February 28, 2012</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">The People&#8217;s Republic of China (&#8220;PRC&#8221; or &#8220;China&#8221;)</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adagene Australia PTY Ltd.</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">May 30, 2018</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Australia</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adagene PTE. Ltd.</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">March 27, 2020</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Singapore</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr><tr><td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Adagene AG</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">August 31, 2020</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Switzerland</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">100</p></td><td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Research and development of innovative medicines</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_SummaryOfPrincipalSubsidiariesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of principal subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_SummaryOfPrincipalSubsidiariesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799067576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Summary of estimated useful lives of property, equipment and software</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Category</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Machinery and laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">5 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Vehicles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">4 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Furniture and tools</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">3</span><span style="font-size:10pt;"> - </span><span style="font-size:10pt;">5 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Electronic equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">3 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Computer software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">3</span><span style="font-size:10pt;white-space:pre-wrap;"> -  </span><span style="font-size:10pt;">5 years</span></p></td></tr><tr><td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Lesser of lease terms or estimated useful lives of the assets</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of estimated useful lives of property and equipment and software.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799149624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>ACCOUNTS RECEIVABLE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Summary of accounts receivable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As&#160;of</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,000</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Allowance for doubtful accounts</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,000</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799098344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAYMENTS AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAYMENTS AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Summary of prepayments and other current assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Prepayments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,907,781</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,562,177</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Deposits(a)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,646,446</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,873,843</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Others </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 259,757</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 619,901</p></td></tr><tr><td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,813,984</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,055,921</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Note (a): The deposits represented the amounts that the Group paid to its CRO vendors for various outsourced research and development programs according to the terms of respective CRO agreements. The Group expects to recover the deposits if the programs fail or the agreements are cancelled.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799098904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property, equipment and software</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Machinery and laboratory equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,150,822</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,252,399</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 915,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,152,743</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Electronic equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 962,684</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,863,956</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Furniture and tools</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 106,492</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 81,467</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Vehicles</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 126,764</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 87,680</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 371,636</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total property, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,357,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,809,881</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Less: accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,290,431)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,322,264)</p></td></tr><tr><td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net book value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,067,125</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,487,617</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740796765112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUALS AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract', window );"><strong>ACCRUALS AND OTHER CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock', window );">Summary of accrued liabilities and other current liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Professional service fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,459,430</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 935,434</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Payroll and related liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,390,025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,229,794</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Utility and maintenance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 459</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,685</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Other taxes and surcharge</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 63,919</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 62,270</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 145,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 143,060</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,059,497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,379,243</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure on accrued liabilities and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799138712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BORROWINGS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>BORROWINGS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of borrowings</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Short-term borrowings:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Bank loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,831,476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,121,226</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Current portion of long-term borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,183,926</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,376,319</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total current borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,015,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,497,545</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Non-Current</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Long-term borrowings:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;">Bank loans</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,965,563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,991,829</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total non-current borrowings</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,965,563</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,991,829</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total borrowings</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 7,980,965</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> 7,489,374</b></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock', window );">Schedule of future maturities of short-term borrowings and long-term borrowings</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Future principal maturities of short-term borrowings and long-term borrowings as of December&#160;31, 2020 and 2021 were as followings:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,015,402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,279,713</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,497,545</p></td></tr><tr><td style="vertical-align:bottom;width:77.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,685,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,858,619</p></td></tr><tr><td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,133,210</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,980,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,489,374</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for short-term debt and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799134984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_DisclosureOfTemporaryEquityAndWarrantsAbstract', window );"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Company's Preferred Shares activities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Mezzanine equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A-1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series A-2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series B</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series C-1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series C-2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Series C-3</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$ </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,473,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,999,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48,481,159</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 84,955,111</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of Series C-2 Preferred Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,999,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,999,999</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of Series C-3 Preferred Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,000,000</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of Series C-1 Preferred Shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 246,184</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 246,184</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,473,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,999,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48,727,343</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,999,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 154,201,294</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of Series C-1 Preferred Shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 248,113</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 248,113</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,473,957</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,999,995</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 48,975,456</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,999,999</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,000,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 154,449,407</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of Series C-1 Preferred Shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,553</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 28,553</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of Preferred Shares to Ordinary Shares </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,473,957)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,000,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (27,999,995)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (49,004,009)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,999,999)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (50,000,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (154,477,960)</p></td></tr><tr><td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_DisclosureOfTemporaryEquityAndWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_DisclosureOfTemporaryEquityAndWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740881148648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b><b style="font-weight:bold;">&#8209;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Grant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$ per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$ per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">option</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Years</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2018</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 574,328</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.30</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 7.14</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,734,644</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 372,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (34,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (46,800)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.22</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 866,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 7.27</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,328,171</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,313,373</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,694,934)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.93</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (190,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,294,467</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.65</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 8.78</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 33,410,968</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,894,119</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (233,958)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (145,550)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.02</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.71</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,809,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 8.68</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,619,574</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Vested and expected to vest at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,809,078</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 8.68</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,619,574</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December 31, 2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 393,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0.75</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.46</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 6.68</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,859,836</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,486,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="font-size:10pt;"> 8.20</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 874,180</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of assumptions used to estimate the fair value of the share options granted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Risk&#8209;free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1.78% - 2.73%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0.68% - 0.83%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">1.11% - 1.67%</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">0%</p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Expected volatility range</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">67.5% - 71.0%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">72.3% - 73.4%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">73.1% - 75.5%</p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Exercise multiple</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2.2 - 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2.2 - 2.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2.2 - 2.8</p></td></tr><tr><td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Contractual life</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">10 years</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">10 years</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;">10 years</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of total share based compensation expenses recognized</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 404,620</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,472,083</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,582,746</p></td></tr><tr><td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Administrative expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 207,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,657,458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,096,912</p></td></tr><tr><td style="vertical-align:bottom;width:67.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total share&#8209;based compensation expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 611,711</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,129,541</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,679,658</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740881346360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX EXPENSE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAX EXPENSE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of components of income tax expense</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended&#160;December&#160;31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Current:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">U.S</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,290,009</p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">State and local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 367,441</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,657,450</p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">U.S</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">Federal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 96,804</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;">State and local</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (52,641)</p></td></tr><tr><td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Total deferred</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 44,163</p></td></tr><tr><td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Income tax expense</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,701,613</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation between the income tax expense and the actual provision</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,432,308)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42,397,279)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (71,476,322)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">PRC preferential income tax rate as qualified TASE</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Income tax credit computed at PRC preferential income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,464,846)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,359,592)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,721,448)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Difference in income tax rates of overseas entities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,492,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,286,487</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,549,985</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development super-deduction<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(a)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (230,126)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (718,979)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (569,016)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Non-deductible expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,306</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,238</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Changes in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198,945</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,790,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,277,418</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">State tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 291,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Others</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (127,880)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:63.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Income tax expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,701,613</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:18pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><span style="font-weight:normal;">Note&#160;(a): Due to the impacts of research and development super-deduction, the Group&#8217;s subsidiary, Adagene (Suzhou) Limited, did not have any income taxes for the&#160;years ended December&#160;31, 2019, 2020, and 2021.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of tax effects of temporary differences that give rise to the deferred tax balances</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax assets:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Net operating loss carry forward</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,722,293</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,949,000</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Capitalized inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 95,589</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Unrealized foreign exchange gain/losses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 39,166</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Depreciation and amortization of property, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,428</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 79</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,729,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,083,834</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,729,721)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,007,139)</p></td></tr><tr><td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 76,695</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deferred tax liabilities:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;&#160;&#160;&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#160;&#160;&#160;&#160;</sup><span style="vertical-align:top;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:77.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Depreciation and amortization of property, equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (120,858)</p></td></tr><tr><td style="vertical-align:bottom;width:77.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (120,858)</p></td></tr><tr><td style="vertical-align:bottom;width:77.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total deferred tax liabilities, net</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (44,163)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Schedule of movement of the valuation allowance</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of January 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 938,875</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,729,721</p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Addition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,790,846</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,277,418</p></td></tr><tr><td style="vertical-align:bottom;width:75.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance as of December&#160;31</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,729,721</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,007,139</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740796797144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>NET LOSS PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year&#160;Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to Adagene Inc.&#8217;s shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,432,308)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42,397,279)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (73,177,935)</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Accretion of convertible redeemable preferred shares to redemption value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (246,184)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (248,113)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (28,553)</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net loss attributable to ordinary shareholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,678,492)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (42,645,392)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (73,206,488)</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Weighted&#8209;average number of ordinary shares outstanding&#8212;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,178,232</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,950,698</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 50,032,009</p></td></tr><tr><td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Net Loss per share&#8212;basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.10)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.67)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.46)</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities that are not included in the calculation of diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;Year&#160;Ended December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Convertible redeemable preferred shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21,977,914</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27,249,824</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;">&#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Share options and share grant</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 582,526</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,795,932</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,739,882</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799098904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of related party transactions</a></td>
<td class="text"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">a)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Related Parties</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:33.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Name of related parties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Relationship</b></p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Peter Luo</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Chairman, Chief Executive Officer and a principal shareholder of the Company</p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">Four senior management personnel</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Management and ordinary shareholders of the Company</p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Co., Ltd. (&#8220;WuXi AppTec Group&#8221;)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">A principal shareholder of the Company</p></td></tr><tr><td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Controlled by the ultimate controlling party of a principal shareholder of the Company</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">b)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Group had the following related party balances as of December 31, 2020 and 2021:</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Group</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 124,704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,080,116</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,692</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,426,554</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total amounts due from related parties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 132,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,506,670</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">As of December 31, 2020 and 2021, the amounts due from related parties represented prepayments made for the CRO and CMO services.<br/><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,361,503</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,292,268</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Group</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 173,855</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 173,793</p></td></tr><tr><td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total amounts due to related parties</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,535,358</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,466,061</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;">As of December 31, 2020 and 2021, the amounts due to related parties represented payables for the CRO and CMO services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">c)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">The Group had the following related party transactions during the years ended December 31, 2019, 2020 and 2021:</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">For&#160;the&#160;years&#160;ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2019</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Receipt of CRO and CMO services:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">WuXi Biologics (Cayman) Inc.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,567,962</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,217,709</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,561,276</p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">WuXi AppTec Group <sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">(i)</sup></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,136,344</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,674,586</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 517,742</p></td></tr><tr><td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,704,306</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,892,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13,079,018</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799140952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum payments under non-cancelable operating leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">Future minimum payments under non-cancelable operating leases with initial terms in excess of one&#160;year consisted of the following as of December&#160;31, 2020 and 2021:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">US$</b></p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">For the years ending:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 412,754</p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 255,309</p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 70,367</p></td></tr><tr><td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 738,430</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740794010088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BASIS OF PRESENTATION (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 11, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Total aggregate gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,411,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | American depositary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares) | shares</a></td>
<td class="nump">8,457,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Total aggregate gross proceeds | $</a></td>
<td class="nump">$ 145,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingDepositoryReceiptRatio', window );">Number of ordinary shares represented by each ADS</a></td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters' option | American depositary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued (in shares) | shares</a></td>
<td class="nump">1,103,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=adag_AdageneHongKongLimitedMember', window );">Adagene (Hong Kong) Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of legal ownership by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=adag_AdageneIncorporatedMember', window );">Adagene Incorporated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of legal ownership by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=adag_AdageneSuzhouLimitedMember', window );">Adagene (Suzhou) Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of legal ownership by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=adag_AdageneAustraliaPtyLtd.Member', window );">Adagene Australia PTY Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of legal ownership by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=adag_AdagenePte.Ltd.Member', window );">Adagene PTE. Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of legal ownership by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=adag_AdageneAgMember', window );">Adagene AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>ORGANIZATION AND BASIS OF PRESENTATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Percentage of legal ownership by the Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingDepositoryReceiptRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingDepositoryReceiptRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=adag_AdageneHongKongLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=adag_AdageneHongKongLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=adag_AdageneIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=adag_AdageneIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=adag_AdageneSuzhouLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=adag_AdageneSuzhouLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=adag_AdageneAustraliaPtyLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=adag_AdageneAustraliaPtyLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=adag_AdagenePte.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=adag_AdagenePte.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=adag_AdageneAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=adag_AdageneAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740795141848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonrecurring (Details) - Nonrecurring basis - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items}</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_FinancialAssetsFairValueDisclosure', window );">Financial assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Financial liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_FinancialAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_FinancialAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740793677864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, equipment and software (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and tools | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and tools | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adag_ElectronicEquipmentMember', window );">Electronic equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adag_ElectronicEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adag_ElectronicEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740795374168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of long lived assets to Employee defined contribution plan (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Impairment of long lived assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAbstract', window );"><strong>Revenue recognition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_MilestonePaymentsOrRoyaltyPaymentsReceived', window );">Milestone payments or royalty payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_DefinedContributionPlanAbstract', window );"><strong>Employee defined contribution plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employee benefit expenses</a></td>
<td class="nump">$ 2,223,493<span></span>
</td>
<td class="nump">$ 622,377<span></span>
</td>
<td class="nump">$ 1,145,165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_DefinedContributionPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_DefinedContributionPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_MilestonePaymentsOrRoyaltyPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of milestone payments or royalty payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_MilestonePaymentsOrRoyaltyPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740793518680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of credit risk (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>item</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Concentration of credit risk | Cash and cash equivalents and short-term investments | Mainland of China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, Cash Equivalents, and Short-term Investments</a></td>
<td class="nump">$ 3,650,474<span></span>
</td>
<td class="nump">$ 3,424,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Concentration of credit risk | Cash and cash equivalents and short-term investments | Outside the mainland of China</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, Cash Equivalents, and Short-term Investments</a></td>
<td class="nump">$ 170,740,769<span></span>
</td>
<td class="nump">$ 71,726,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Concentration of suppliers | Research and development services purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_NumberOfMajorSupplier', window );">Number of major supplier | item</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Concentration of suppliers | Research and development services purchased | One supplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">18.45%<span></span>
</td>
<td class="nump">21.51%<span></span>
</td>
<td class="nump">23.13%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_NumberOfMajorSupplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of major supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_NumberOfMajorSupplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=adag_CashAndCashEquivalentsAndShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=adag_CashAndCashEquivalentsAndShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=adag_MainlandOfChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=adag_MainlandOfChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=adag_OutsideMainlandOfChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=adag_OutsideMainlandOfChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_CostOfGoodsProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ConcentrationRiskSuppliersAxis=adag_OneSupplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ConcentrationRiskSuppliersAxis=adag_OneSupplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740794934200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Foreign currency exchange rate risk (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_PercentageOfDepreciationOfForeignCurrency', window );">Depreciation of foreign currency (as a percent)</a></td>
<td class="nump">2.29%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_GovernmentSubsidiesReceived', window );">Government subsidies received</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_GovernmentSubsidiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of subsidies received by the entity for Government.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_GovernmentSubsidiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_PercentageOfDepreciationOfForeignCurrency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of depreciation of foreign currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_PercentageOfDepreciationOfForeignCurrency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740796788488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCOUNTS RECEIVABLE, NET (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>ACCOUNTS RECEIVABLE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable, net</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 310<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123366838&amp;loc=d3e3073-115593<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740796209416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAYMENTS AND OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>PREPAYMENTS AND OTHER CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepayments</a></td>
<td class="nump">$ 1,562,177<span></span>
</td>
<td class="nump">$ 1,907,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">1,873,843<span></span>
</td>
<td class="nump">1,646,446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Others</a></td>
<td class="nump">619,901<span></span>
</td>
<td class="nump">259,757<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepayments and other current assets</a></td>
<td class="nump">$ 4,055,921<span></span>
</td>
<td class="nump">$ 3,813,984<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740793430440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY, EQUIPMENT AND SOFTWARE, NET (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property, Plant and Equipment, Net, by Type [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">$ 8,809,881<span></span>
</td>
<td class="nump">$ 6,357,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(5,322,264)<span></span>
</td>
<td class="num">(4,290,431)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net book value</a></td>
<td class="nump">3,487,617<span></span>
</td>
<td class="nump">2,067,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,125,032<span></span>
</td>
<td class="nump">858,408<span></span>
</td>
<td class="nump">$ 816,686<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property, Plant and Equipment, Net, by Type [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">5,252,399<span></span>
</td>
<td class="nump">4,150,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property, Plant and Equipment, Net, by Type [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">1,152,743<span></span>
</td>
<td class="nump">915,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adag_ElectronicEquipmentMember', window );">Electronic equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property, Plant and Equipment, Net, by Type [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">1,863,956<span></span>
</td>
<td class="nump">962,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and tools</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property, Plant and Equipment, Net, by Type [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">81,467<span></span>
</td>
<td class="nump">106,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property, Plant and Equipment, Net, by Type [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">87,680<span></span>
</td>
<td class="nump">126,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract', window );"><strong>Property, Plant and Equipment, Net, by Type [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and software</a></td>
<td class="nump">$ 371,636<span></span>
</td>
<td class="nump">$ 95,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=adag_ElectronicEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=adag_ElectronicEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740793665304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUALS AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract', window );"><strong>ACCRUALS AND OTHER CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional service fees</a></td>
<td class="nump">$ 935,434<span></span>
</td>
<td class="nump">$ 3,459,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related liabilities</a></td>
<td class="nump">3,229,794<span></span>
</td>
<td class="nump">2,390,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedUtilitiesCurrent', window );">Utility and maintenance</a></td>
<td class="nump">8,685<span></span>
</td>
<td class="nump">459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Other taxes and surcharge</a></td>
<td class="nump">62,270<span></span>
</td>
<td class="nump">63,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Others</a></td>
<td class="nump">143,060<span></span>
</td>
<td class="nump">145,664<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilities', window );">Accruals and other current liabilities</a></td>
<td class="nump">$ 4,379,243<span></span>
</td>
<td class="nump">$ 6,059,497<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities and Other Current Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AccruedLiabilitiesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedUtilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for utilities, such as electrical power, heating oil, natural gas, and water. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedUtilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740795376664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BORROWINGS - Components (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowingsAbstract', window );"><strong>Short term borrowings:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBankLoansAndNotesPayable', window );">Bank loans</a></td>
<td class="nump">$ 3,121,226<span></span>
</td>
<td class="nump">$ 3,831,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long term borrowings</a></td>
<td class="nump">1,376,319<span></span>
</td>
<td class="nump">1,183,926<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Total current borrowings</a></td>
<td class="nump">4,497,545<span></span>
</td>
<td class="nump">5,015,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Long term borrowings:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansFromBank', window );">Bank loans</a></td>
<td class="nump">2,991,829<span></span>
</td>
<td class="nump">2,965,563<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total non current borrowings</a></td>
<td class="nump">2,991,829<span></span>
</td>
<td class="nump">2,965,563<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Total borrowings</a></td>
<td class="nump">$ 7,489,374<span></span>
</td>
<td class="nump">$ 7,980,965<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansFromBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansFromBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBankLoansAndNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.16)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBankLoansAndNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740790428264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BORROWINGS - Short term borrowings (Details)<br></strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adag_BorrowingsFromBankOfNingboCo.LtdMember', window );">Borrowings from Bank of Ningbo Co., Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 766,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 766,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.35%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember', window );">Borrowings from Agricultural Bank of China Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="nump">&#165; 10,000,000<span></span>
</td>
<td class="nump">&#165; 9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,568,455<span></span>
</td>
<td class="nump">$ 1,552,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,532,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of the debt</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adag_ChinaMerchantsBankCo.LtdMember', window );">China Merchants Bank Co., Ltd</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 770,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adag_ChinaMerchantsBankCo.LtdLoanTwoMember', window );">China Merchants Bank Co., Ltd., two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 770,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adag_BorrowingsFromBankOfNingboCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adag_BorrowingsFromBankOfNingboCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adag_ChinaMerchantsBankCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adag_ChinaMerchantsBankCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adag_ChinaMerchantsBankCo.LtdLoanTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adag_ChinaMerchantsBankCo.LtdLoanTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740788867464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BORROWINGS - Long term borrowings (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>CNY (&#165;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Amount repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,089,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,063,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,417,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term borrowings</a></td>
<td class="nump">$ 1,183,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,376,319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,183,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember', window );">Borrowings from Shanghai Pudong Development Bank Co., Ltd., one</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,176,342<span></span>
</td>
<td class="nump">&#165; 7,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Term of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.46%<span></span>
</td>
<td class="nump">5.46%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Amount repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,354<span></span>
</td>
<td class="nump">&#165; 3,375,000<span></span>
</td>
<td class="nump">196,057<span></span>
</td>
<td class="nump">&#165; 1,250,000<span></span>
</td>
<td class="nump">$ 58,817<span></span>
</td>
<td class="nump">&#165; 375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term borrowings</a></td>
<td class="nump">529,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">392,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 3,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember', window );">Borrowings from Shanghai Pudong Development Bank Co., Ltd., two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 941,074<span></span>
</td>
<td class="nump">&#165; 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Term of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.23%<span></span>
</td>
<td class="nump">5.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Amount repaid</a></td>
<td class="nump">156,846<span></span>
</td>
<td class="nump">&#165; 1,000,000<span></span>
</td>
<td class="nump">$ 47,054<span></span>
</td>
<td class="nump">&#165; 300,000<span></span>
</td>
<td class="nump">423,483<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term borrowings</a></td>
<td class="nump">423,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">423,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember', window );">Borrowings from Shanghai Pudong Development Bank Co., Ltd., three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,587,952<span></span>
</td>
<td class="nump">&#165; 16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Term of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.27%<span></span>
</td>
<td class="nump">4.27%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Amount repaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258,796<span></span>
</td>
<td class="nump">&#165; 1,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term borrowings</a></td>
<td class="nump">$ 258,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 258,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 1,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember', window );">Borrowings from Shanghai Pudong Development Bank Co., Ltd., four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount borrowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,333,186<span></span>
</td>
<td class="nump">&#165; 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTerm', window );">Term of the debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740794854472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BORROWINGS - Future maturities of short term borrowings and long term borrowings (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>BORROWINGS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">2021</a></td>
<td class="nump">$ 4,497,545<span></span>
</td>
<td class="nump">$ 5,015,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">1,858,619<span></span>
</td>
<td class="nump">1,279,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,685,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">1,133,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtLongtermAndShorttermCombinedAmount', window );">Total borrowings</a></td>
<td class="nump">$ 7,489,374<span></span>
</td>
<td class="nump">$ 7,980,965<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtLongtermAndShorttermCombinedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate of total long-term debt, including current maturities and short-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtLongtermAndShorttermCombinedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740789078216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Shares (Details)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($) </div>
<div>item </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 30, 2014 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 11, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2011 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_MaximumProceedsReceivableFromExerciseOfWarrants', window );">Total maximum consideration from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice', window );">Liquidation preference (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice', window );">Simple interest accruing on original issue price (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_QualifiedPublicOfferingMinimumMarketCapitalization', window );">Minimum market capitalization from Qualified Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_QualifiedPublicOfferingMinimumProceeds', window );">Minimum aggregate proceeds from Qualified Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent', window );">Minimum percentage of voting power held by preferred share holders to provide written consent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares on conversion of each convertible preferred stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adag_SeriesC1WarrantsMember', window );">Series C 1 Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Consideration from issuance of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_Series1RedeemableConvertiblePreferredStockMember', window );">Series A-1 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued upon conversion of Series Pre-A Convertible Notes (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,473,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_Series2RedeemableConvertiblePreferredStockMember', window );">Series A-2 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of new shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,370,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Total consideration from issuance of convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of new shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,494,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Total consideration from issuance of convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,999,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC1RedeemableConvertiblePreferredStockMember', window );">Series C-1 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of new shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,597,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Total consideration from issuance of convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_NumberOfInvestorsToWhomWarrantsWereIssued', window );">Number of Series C-1 investors to whom warrants were issued | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC2RedeemableConvertiblePreferredStockMember', window );">Series C-2 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of new shares issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,861,121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Total consideration from issuance of convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,999,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC3RedeemableConvertiblePreferredStockMember', window );">Series C-3 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Number of new shares issued | shares</a></td>
<td class="nump">4,452,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Total consideration from issuance of convertible redeemable preferred shares</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Series Pre-A Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount of Series Pre A Convertible Notes issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,590,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Series Pre A Convertible Notes, Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_MaximumProceedsReceivableFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of proceeds receivable from exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_MaximumProceedsReceivableFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_NumberOfInvestorsToWhomWarrantsWereIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investors to whom warrants were issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_NumberOfInvestorsToWhomWarrantsWereIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_QualifiedPublicOfferingMinimumMarketCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum market capitalization reflected by the Qualified Public Offering, considered for automatic conversion of preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_QualifiedPublicOfferingMinimumMarketCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_QualifiedPublicOfferingMinimumProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of proceeds receivable from Qualified Public Offering, considered for automatic conversion of preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_QualifiedPublicOfferingMinimumProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of interest on original issue price considered for liquidation preference (or restrictions) of stock classified as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of original issue price considered for liquidation preference (or restrictions) of stock classified as temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of new stock classified as temporary equity issued during the period, upon conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold minimum percentage of voting power held by preferred share holders to provide written consent, considered for automatic conversion of preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031898-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=adag_SeriesC1WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=adag_SeriesC1WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_Series1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_Series1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_Series2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_Series2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesC1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesC2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC3RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesC3RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740793943960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Share Activities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">$ 154,449,407<span></span>
</td>
<td class="nump">$ 154,201,294<span></span>
</td>
<td class="nump">$ 84,955,111<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Preferred Shares to Ordinary Shares</a></td>
<td class="num">(154,477,960)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,449,407<span></span>
</td>
<td class="nump">154,201,294<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_Series1RedeemableConvertiblePreferredStockMember', window );">Series A-1 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">5,473,957<span></span>
</td>
<td class="nump">5,473,957<span></span>
</td>
<td class="nump">5,473,957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Preferred Shares to Ordinary Shares</a></td>
<td class="num">(5,473,957)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,473,957<span></span>
</td>
<td class="nump">5,473,957<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_Series2RedeemableConvertiblePreferredStockMember', window );">Series A-2 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Preferred Shares to Ordinary Shares</a></td>
<td class="num">(3,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">27,999,995<span></span>
</td>
<td class="nump">27,999,995<span></span>
</td>
<td class="nump">27,999,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Preferred Shares to Ordinary Shares</a></td>
<td class="num">(27,999,995)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,999,995<span></span>
</td>
<td class="nump">27,999,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC1RedeemableConvertiblePreferredStockMember', window );">Series C-1 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">48,975,456<span></span>
</td>
<td class="nump">48,727,343<span></span>
</td>
<td class="nump">48,481,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of Preferred Shares to redemption value</a></td>
<td class="nump">28,553<span></span>
</td>
<td class="nump">248,113<span></span>
</td>
<td class="nump">246,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Preferred Shares to Ordinary Shares</a></td>
<td class="num">(49,004,009)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,975,456<span></span>
</td>
<td class="nump">48,727,343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC2RedeemableConvertiblePreferredStockMember', window );">Series C-2 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">18,999,999<span></span>
</td>
<td class="nump">18,999,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,999,999<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Preferred Shares to Ordinary Shares</a></td>
<td class="num">(18,999,999)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,999,999<span></span>
</td>
<td class="nump">18,999,999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC3RedeemableConvertiblePreferredStockMember', window );">Series C-3 convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Increase (Decrease) in Temporary Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Preferred Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Preferred Shares to Ordinary Shares</a></td>
<td class="num">$ (50,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_Series1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_Series1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_Series2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_Series2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC1RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesC1RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC2RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesC2RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=adag_SeriesC3RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=adag_SeriesC3RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799013256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Warrants (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_DisclosureOfTemporaryEquityAndWarrantsAbstract', window );"><strong>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Gains from decrease in fair value of warrants</a></td>
<td class="nump">$ 1,207,415<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_DisclosureOfTemporaryEquityAndWarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_DisclosureOfTemporaryEquityAndWarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740788417432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 16, 2021</div></th>
<th class="th"><div>Jan. 16, 2021</div></th>
<th class="th"><div>Nov. 09, 2020</div></th>
<th class="th"><div>Aug. 15, 2020</div></th>
<th class="th"><div>Aug. 14, 2020</div></th>
<th class="th"><div>Dec. 22, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Nov. 07, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,894,119<span></span>
</td>
<td class="nump">6,313,373<span></span>
</td>
<td class="nump">372,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental compensation cost to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.31<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued upon exercise of share options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233,958<span></span>
</td>
<td class="nump">3,694,934<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Total amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226,781<span></span>
</td>
<td class="nump">$ 140,928<span></span>
</td>
<td class="nump">$ 18,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_NumberOfSharesSurrendered', window );">Number of shares surrendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Fair value (in USD per option)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.39<span></span>
</td>
<td class="nump">$ 7.01<span></span>
</td>
<td class="nump">$ 5.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition of share based compensation expense (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=adag_ServiceConditionsAndPerformanceConditionsMember', window );">Service conditions and Performance conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,483,808<span></span>
</td>
<td class="nump">2,178,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived', window );">Number of options, vesting schedules and conditions waived</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued upon exercise of share options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Total amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,197,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Shares unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,585,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Management | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Management | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adag_Plan2015Member', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum aggregate number of shares that may be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,336,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adag_Plan2017Member', window );">2017 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum aggregate number of shares that may be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,336,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adag_Plan2019Member', window );">2019 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum aggregate number of shares that may be issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,391,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member', window );">Performance Incentive Plan 2021 (the "2021 Plan")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent', window );">Incremental percent of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Aggregate ordinary shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,994,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member', window );">Performance Incentive Plan 2021 (the "2021 Plan") | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,303,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member', window );">Performance Incentive Plan 2021 (the "2021 Plan") | Employees | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member', window );">Performance Incentive Plan 2021 (the "2021 Plan") | Employees | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member', window );">Performance Incentive Plan 2021 (the "2021 Plan") | Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted</a></td>
<td class="nump">23,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_NumberOfSharesSurrendered">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares surrendered by the shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_NumberOfSharesSurrendered</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options for which the vesting schedules and conditions are waived.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of increase in shares reserve annually based on shares outstanding under share based compensation share based payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=adag_ServiceConditionsAndPerformanceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=adag_ServiceConditionsAndPerformanceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adag_Plan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adag_Plan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adag_Plan2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adag_Plan2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adag_Plan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adag_Plan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740794882376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Share Option Activities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 16, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,294,467<span></span>
</td>
<td class="nump">866,028<span></span>
</td>
<td class="nump">574,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,894,119<span></span>
</td>
<td class="nump">6,313,373<span></span>
</td>
<td class="nump">372,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(233,958)<span></span>
</td>
<td class="num">(3,694,934)<span></span>
</td>
<td class="num">(34,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(145,550)<span></span>
</td>
<td class="num">(190,000)<span></span>
</td>
<td class="num">(46,800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,809,078<span></span>
</td>
<td class="nump">3,294,467<span></span>
</td>
<td class="nump">866,028<span></span>
</td>
<td class="nump">574,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,809,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at the end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,486,318<span></span>
</td>
<td class="nump">393,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.75<span></span>
</td>
<td class="nump">$ 0.65<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 13.85<span></span>
</td>
<td class="nump">12.31<span></span>
</td>
<td class="nump">2.00<span></span>
</td>
<td class="nump">1.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.99<span></span>
</td>
<td class="nump">1.93<span></span>
</td>
<td class="nump">0.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.02<span></span>
</td>
<td class="nump">1.70<span></span>
</td>
<td class="nump">1.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.91<span></span>
</td>
<td class="nump">1.75<span></span>
</td>
<td class="nump">0.65<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at the end (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.87<span></span>
</td>
<td class="nump">0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the beginning (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.65<span></span>
</td>
<td class="nump">3.67<span></span>
</td>
<td class="nump">2.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 7.85<span></span>
</td>
<td class="nump">8.39<span></span>
</td>
<td class="nump">7.01<span></span>
</td>
<td class="nump">5.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.13<span></span>
</td>
<td class="nump">6.55<span></span>
</td>
<td class="nump">5.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.71<span></span>
</td>
<td class="nump">6.91<span></span>
</td>
<td class="nump">5.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at the end (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.38<span></span>
</td>
<td class="nump">6.65<span></span>
</td>
<td class="nump">$ 3.67<span></span>
</td>
<td class="nump">$ 2.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue', window );">Vested and expected to vest at the end (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue', window );">Exercisable at the end (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.05<span></span>
</td>
<td class="nump">$ 4.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 8 months 4 days<span></span>
</td>
<td class="text">8 years 9 months 10 days<span></span>
</td>
<td class="text">7 years 3 months 7 days<span></span>
</td>
<td class="text">7 years 1 month 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest at the end (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at the end (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 8 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the beginning (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,410,968<span></span>
</td>
<td class="nump">$ 6,328,171<span></span>
</td>
<td class="nump">$ 3,734,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the end (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,619,574<span></span>
</td>
<td class="nump">33,410,968<span></span>
</td>
<td class="nump">$ 6,328,171<span></span>
</td>
<td class="nump">$ 3,734,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest at the end (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,619,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at the end (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 874,180<span></span>
</td>
<td class="nump">$ 4,859,836<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average grant date fair value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average grant date fair value, at which grantee can acquire shares reserved for issuance. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740793521560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Share Option Activities - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">233,958<span></span>
</td>
<td class="nump">3,694,934<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Aggregate fair value of the equity awards vested</a></td>
<td class="nump">$ 13,833,856<span></span>
</td>
<td class="nump">$ 8,430,085<span></span>
</td>
<td class="nump">$ 366,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized employee share based compensation expense</a></td>
<td class="nump">$ 30,607,079<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize unrecognized compensation cost (in years)</a></td>
<td class="text">2 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740788947608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Fair Value Of Share Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to estimate the fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum</a></td>
<td class="nump">1.11%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">1.78%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum</a></td>
<td class="nump">1.67%<span></span>
</td>
<td class="nump">0.83%<span></span>
</td>
<td class="nump">2.73%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">73.10%<span></span>
</td>
<td class="nump">72.30%<span></span>
</td>
<td class="nump">67.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">75.50%<span></span>
</td>
<td class="nump">73.40%<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum', window );">Exercise multiple, minimum</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum', window );">Exercise multiple, maximum</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum exercise multiple assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum exercise multiple assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740793921080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Share based compensation expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expenses</a></td>
<td class="nump">$ 18,679,658<span></span>
</td>
<td class="nump">$ 10,129,541<span></span>
</td>
<td class="nump">$ 611,711<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expenses</a></td>
<td class="nump">13,582,746<span></span>
</td>
<td class="nump">6,472,083<span></span>
</td>
<td class="nump">404,620<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">Administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share based compensation expenses</a></td>
<td class="nump">$ 5,096,912<span></span>
</td>
<td class="nump">$ 3,657,458<span></span>
</td>
<td class="nump">$ 207,091<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740790081128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COLLABORATION ARRANGEMENTS (Details)<br></strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="8">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>CNY (&#165;)</div>
</th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,175,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember', window );">Guilin Sanjin Pharmaceutical Co., Ltd. License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_CollaborativeArrangementUpfrontCashPaymentReceived', window );">Upfront cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,511,168<span></span>
</td>
<td class="nump">&#165; 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties', window );">Agreed period for not to grant rights associated with antibodies to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 0<span></span>
</td>
<td class="nump">$ 1,511,168<span></span>
</td>
<td class="nump">&#165; 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember', window );">Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_CollaborativeArrangementUpfrontCashPaymentReceived', window );">Upfront cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">573,378<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties', window );">Agreed period for not to grant rights associated with antibodies to third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,240,022<span></span>
</td>
<td class="nump">&#165; 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#165; 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_CollaborativeArrangementMilestonePaymentReceived', window );">Milestone fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">620,011<span></span>
</td>
<td class="nump">&#165; 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adag_SignalPharmaceuticalsLlcMember', window );">Signal Pharmaceuticals LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_CollaborativeArrangementUpfrontCashPaymentReceived', window );">Upfront cash payment received</a></td>
<td class="nump">$ 72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 237,500<span></span>
</td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">309,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adag_AdctCollaborationAgreementMember', window );">ADCT Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies', window );">Maximum number of selected targets, agreed for generation of antibodies | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_PeriodForReservationOfTargetRight', window );">Period for reservation of target right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement', window );">Minimum threshold written notice period for termination of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adag_ExelixisIncAgreementMember', window );">Exelixis Inc Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_CollaborativeArrangementUpfrontCashPaymentReceived', window );">Upfront cash payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_CollaborativeArrangementUpfrontCashPaymentReceivable', window );">Payment of upfront-refundable fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones', window );">Milestone payments receivable based on development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_MilestonePaymentsReceivableSalesBasedMilestones', window );">Milestone payments receivable based on sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The agreed period for not to grant rights associated with antibodies to third parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_CollaborativeArrangementMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from milestone payments received in collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_CollaborativeArrangementMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_CollaborativeArrangementUpfrontCashPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_CollaborativeArrangementUpfrontCashPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_CollaborativeArrangementUpfrontCashPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from upfront cash received in collaborative arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_CollaborativeArrangementUpfrontCashPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of selected targets, agreed for generation of antibodies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments receivable upon achieving certain development and regulatory approval milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_MilestonePaymentsReceivableSalesBasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments conditioned upon achieving sales based milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_MilestonePaymentsReceivableSalesBasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum threshold written notice period for termination of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_PeriodForReservationOfTargetRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period for reservation of target right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_PeriodForReservationOfTargetRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adag_SignalPharmaceuticalsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adag_SignalPharmaceuticalsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adag_AdctCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adag_AdctCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adag_ExelixisIncAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adag_ExelixisIncAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740790237304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX EXPENSE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">108 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2008</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,453,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,701,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">PRC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate (as a percent)</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_WithholdingTaxRateOnDividendsPercentage', window );">Dividends withholding tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,206,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">PRC | TASE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_PreferentialIncomeTaxRate', window );">Preferential tax rate (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate', window );">Effective period of TASE certificate (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">PRC | TASE | Adagene (Suzhou) Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_PreferentialIncomeTaxRate', window );">Preferential tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">Hong Kong</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,240,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_WithholdingIncomeTaxes', window );">Withholding tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_HK', window );">Hong Kong | Adagene (Hong Kong) Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_AssessableProfits', window );">Assessable profits or earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_WithholdingTaxRateOnDividendsPercentage', window );">Dividends withholding tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,684,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">Australia | Adagene Australia PTY Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_TaxableIncome', window );">Taxable Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_WithholdingTaxRateOnDividendsPercentage', window );">Dividends withholding tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 640,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal', window );">State income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_CA', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal', window );">State income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.84%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CH', window );">SWITZERLAND</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_WithholdingTaxRateOnDividendsPercentage', window );">Dividends withholding tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,467,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CH', window );">SWITZERLAND | Adagene AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_CapitalTaxRatePercentage', window );">Capital tax rate for Canton of Basel</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_SG', window );">SINGAPORE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 214,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AssessableProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assessable profits or earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AssessableProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_CapitalTaxRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of capital tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_CapitalTaxRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective period of Technology Advanced Service Enterprises certificate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_PreferentialIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferential income tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_PreferentialIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_TaxableIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of taxable income during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_TaxableIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_WithholdingIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of withholding income taxes on remittance of dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_WithholdingIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_WithholdingTaxRateOnDividendsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of withholding tax rate on dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_WithholdingTaxRateOnDividendsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_StatusForTaxabilityAxis=adag_TechnologyAdvancedServiceEnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_StatusForTaxabilityAxis=adag_TechnologyAdvancedServiceEnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=adag_AdageneSuzhouLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=adag_AdageneSuzhouLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_HK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_HK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=adag_AdageneHongKongLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=adag_AdageneHongKongLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=adag_AdageneAustraliaPtyLtd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=adag_AdageneAustraliaPtyLtd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CH">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CH</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=adag_AdageneAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=adag_AdageneAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_SG">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_SG</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740795378680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX EXPENSE - Income tax expense (benefit) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 1,290,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="nump">367,441<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current income tax expense (benefit)</a></td>
<td class="nump">1,657,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">96,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and local</a></td>
<td class="num">(52,641)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income tax expense (benefit)</a></td>
<td class="nump">44,163<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 1,701,613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740790006280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX EXPENSE - Income tax reconciliation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAX EXPENSE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax</a></td>
<td class="num">$ (71,476,322)<span></span>
</td>
<td class="num">$ (42,397,279)<span></span>
</td>
<td class="num">$ (16,432,308)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">PRC preferential income tax rate as qualified TASE</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax credit computed at PRC preferential income tax rate</a></td>
<td class="num">$ (10,721,448)<span></span>
</td>
<td class="num">$ (6,359,592)<span></span>
</td>
<td class="num">$ (2,464,846)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount', window );">Difference in income tax rates of overseas entities</a></td>
<td class="nump">10,549,985<span></span>
</td>
<td class="nump">5,286,487<span></span>
</td>
<td class="nump">2,492,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount', window );">Research and development super-deduction</a></td>
<td class="num">(569,016)<span></span>
</td>
<td class="num">(718,979)<span></span>
</td>
<td class="num">(230,126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Nondeductible expenses</a></td>
<td class="nump">1,054<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
<td class="nump">3,306<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="nump">2,277,418<span></span>
</td>
<td class="nump">$ 1,790,846<span></span>
</td>
<td class="nump">$ 198,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax</a></td>
<td class="nump">291,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Others</a></td>
<td class="nump">127,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 1,701,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740788319000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAX EXPENSE - Deferred tax assets and deferred tax liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 4,949,000<span></span>
</td>
<td class="nump">$ 2,722,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Capitalized inventory</a></td>
<td class="nump">95,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses', window );">Unrealized foreign exchange gain/losses</a></td>
<td class="nump">39,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_DeferredTaxAssetsDepreciationAndAmortization', window );">Depreciation and amortization of property, equipment and software</a></td>
<td class="nump">79<span></span>
</td>
<td class="nump">7,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">5,083,834<span></span>
</td>
<td class="nump">2,729,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(5,007,139)<span></span>
</td>
<td class="num">$ (2,729,721)<span></span>
</td>
<td class="num">$ (938,875)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets, net</a></td>
<td class="nump">76,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and amortization of property, equipment and software</a></td>
<td class="num">(120,858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(120,858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities, net</a></td>
<td class="num">$ (44,163)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_DeferredTaxAssetsDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_DeferredTaxAssetsDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740799047720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAX EXPENSE - Valuation Allowance (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceAbstract', window );"><strong>Movement of the valuation allowance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance as of January 1</a></td>
<td class="nump">$ 2,729,721<span></span>
</td>
<td class="nump">$ 938,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Addition</a></td>
<td class="nump">2,277,418<span></span>
</td>
<td class="nump">1,790,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Balance as of December 31</a></td>
<td class="nump">$ 5,007,139<span></span>
</td>
<td class="nump">$ 2,729,721<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740793683192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Adagene Inc.'s shareholders</a></td>
<td class="num">$ (73,177,935)<span></span>
</td>
<td class="num">$ (42,397,279)<span></span>
</td>
<td class="num">$ (16,432,308)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of convertible redeemable preferred shares to redemption value</a></td>
<td class="num">(28,553)<span></span>
</td>
<td class="num">(248,113)<span></span>
</td>
<td class="num">(246,184)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to ordinary shareholders</a></td>
<td class="num">$ (73,206,488)<span></span>
</td>
<td class="num">$ (42,645,392)<span></span>
</td>
<td class="num">$ (16,678,492)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average number of ordinary shares used in per share calculation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weightedaverage number of ordinary shares outstanding-basic</a></td>
<td class="nump">50,032,009<span></span>
</td>
<td class="nump">15,950,698<span></span>
</td>
<td class="nump">15,178,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weightedaverage number of ordinary shares outstanding-diluted</a></td>
<td class="nump">50,032,009<span></span>
</td>
<td class="nump">15,950,698<span></span>
</td>
<td class="nump">15,178,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net Loss per share-basic</a></td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="num">$ (2.67)<span></span>
</td>
<td class="num">$ (1.10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net Loss per share- diluted</a></td>
<td class="num">$ (1.46)<span></span>
</td>
<td class="num">$ (2.67)<span></span>
</td>
<td class="num">$ (1.10)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740800103368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET LOSS PER SHARE - Anti-dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Convertible redeemable preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities not included in the computation of diluted net loss per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,249,824<span></span>
</td>
<td class="nump">21,977,914<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Share options and share grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities not included in the computation of diluted net loss per share</a></td>
<td class="nump">1,739,882<span></span>
</td>
<td class="nump">1,795,932<span></span>
</td>
<td class="nump">582,526<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740790070792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Amounts due from related parties</a></td>
<td class="nump">$ 4,506,670<span></span>
</td>
<td class="nump">$ 132,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Amounts due to related parties</a></td>
<td class="nump">10,466,061<span></span>
</td>
<td class="nump">2,535,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember', window );">Receipt of CRO and CMO services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transactions</a></td>
<td class="nump">13,079,018<span></span>
</td>
<td class="nump">9,892,295<span></span>
</td>
<td class="nump">$ 5,704,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adag_WuxiApptecGroupMember', window );">WuXi AppTec Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Amounts due from related parties</a></td>
<td class="nump">3,080,116<span></span>
</td>
<td class="nump">124,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Amounts due to related parties</a></td>
<td class="nump">173,793<span></span>
</td>
<td class="nump">173,855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adag_WuxiApptecGroupMember', window );">WuXi AppTec Group | Receipt of CRO and CMO services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transactions</a></td>
<td class="nump">517,742<span></span>
</td>
<td class="nump">2,674,586<span></span>
</td>
<td class="nump">2,136,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adag_WuxiBiologicsShanghaiCo.Ltd.Member', window );">WuXi Biologics (Shanghai) Co., Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Amounts due from related parties</a></td>
<td class="nump">1,426,554<span></span>
</td>
<td class="nump">7,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Amounts due to related parties</a></td>
<td class="nump">10,292,268<span></span>
</td>
<td class="nump">2,361,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adag_WuxiBiologicsShanghaiCo.Ltd.Member', window );">WuXi Biologics (Shanghai) Co., Ltd. | Receipt of CRO and CMO services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transactions</a></td>
<td class="nump">$ 12,561,276<span></span>
</td>
<td class="nump">$ 7,217,709<span></span>
</td>
<td class="nump">$ 3,567,962<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adag_WuxiApptecGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adag_WuxiApptecGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adag_WuxiBiologicsShanghaiCo.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=adag_WuxiBiologicsShanghaiCo.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740793547320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Schedule of future minimum payments under non cancelable operating leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2022</a></td>
<td class="nump">$ 412,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2023</a></td>
<td class="nump">255,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2024</a></td>
<td class="nump">70,367<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">738,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Total rental related expenses for operating leases</a></td>
<td class="nump">$ 331,745<span></span>
</td>
<td class="nump">$ 177,453<span></span>
</td>
<td class="nump">$ 175,812<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740796913544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRICTED NET ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_RestrictedNetAssetsAbstract', window );"><strong>RESTRICTED NET ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve', window );">Minimum percentage of profit after tax to be transferred to statutory reserve</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital', window );">Statutory reserve required percentage on registered capital</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries', window );">Total restricted net assets</a></td>
<td class="nump">$ 1,860,667<span></span>
</td>
<td class="nump">$ 1,267,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_AfterTaxIncomePercentageAppropriations', window );">After-Tax Income, Annual appropriations, Percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries', window );">Restrictions on net assets of PRC subsidiaries , threshold percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_AfterTaxIncomePercentageAppropriations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of after-tax income to be set aside as a general reserve fund.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_AfterTaxIncomePercentageAppropriations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of the profit after tax to be transferred to statutory reserve.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_RestrictedNetAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>No Definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_RestrictedNetAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Required percentage of statutory reserve on registered capital to be maintained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold percentage on restricted net assets of PRC subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted net assets of consolidated and unconsolidated subsidiaries as of the end of the most recently completed fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(3)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740790404392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TREASURY SHARES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 07, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program authorized amount</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramPeriodInForce1', window );">Term of share repurchase program (in months)</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Total consideration of share repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,361,576<span></span>
</td>
<td class="nump">$ 2,361,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">American depositary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Repurchased shares retired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Repurchased shares retired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramPeriodInForce1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramPeriodInForce1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139740786137480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 07, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 08, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 07, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 16, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 16, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 09, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 15, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 25, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 22, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 02, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,894,119<span></span>
</td>
<td class="nump">6,313,373<span></span>
</td>
<td class="nump">372,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.31<span></span>
</td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="nump">$ 1.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Total consideration of share repurchased | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,361,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,361,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember', window );">American depositary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Repurchased shares retired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">295,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Repurchased shares retired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Management | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember', window );">Management | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member', window );">Performance Incentive Plan 2021 (the "2021 Plan") | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,303,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member', window );">Performance Incentive Plan 2021 (the "2021 Plan") | Employees | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member', window );">Performance Incentive Plan 2021 (the "2021 Plan") | Employees | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member', window );">Performance Incentive Plan 2021 (the "2021 Plan") | Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected', window );">Number of shares affected by modification of award | $</a></td>
<td class="nump">2,060,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Incremental fair value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,337,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Total consideration of share repurchased | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,539,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Repurchased shares retired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | American depositary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">340,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Annual cap percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Exelixis Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_CollaborativeArrangementUpfrontCashPaymentReceivable', window );">Upfront payment receivable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Exelixis Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_adag_CollaborativeArrangementMilestonePaymentReceivable', window );">Milestone payment receivable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Management</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Performance Incentive Plan 2021 (the "2021 Plan") | Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Performance Incentive Plan 2021 (the "2021 Plan") | Employees | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Performance Incentive Plan 2021 (the "2021 Plan") | Employees | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_CollaborativeArrangementMilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount receivable upon achievement of target specified.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_CollaborativeArrangementMilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_CollaborativeArrangementUpfrontCashPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront cash payment receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_CollaborativeArrangementUpfrontCashPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adag_ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares affected by modification of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adag_ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adag_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adag_PerformanceIncentivePlan2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adag_ExelixisAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adag_ExelixisAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>adag-20211231x20f_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:adag="http://www.adagene.com/20211231"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2021"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="adag-20211231.xsd" xlink:type="simple"/>
    <context id="Duration_7_7_2021_To_12_31_2021_VOZydV_s0k6TnW7n0mP29A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <startDate>2021-07-07</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_-XH9Go_6R0eqJay27YP0iA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_hZT-sOgQYEa1gHbRXtKNww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_pJ8hEn_UR067dD0gRcTb-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_7_7_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_S5sj8QyYv0-TTqmBGm6N1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-07</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_7_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_CCQsBDVo0ESOnNGl9WpWgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-07</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_KheMHBp800ewm1lePqQqfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_7jJxs3yXWUuOCOO5o_qb7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember__gZCIGPtFEW337N5JP2Q0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_BeGIQu5lxUuigOpTULuf_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_yz5fD7wsz0K_dYLM59ooPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_AdBejOP9vk6p3isk1DREwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_Uvvs-PCSRkiaKVDtX3E5sQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_b-r3H9b28Ey8YCwkcUjTkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Yic_H5pK-Ue4BHoUzpGweQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_EFH-DFpj80mpuyw7v7-SrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_di_bFxD70EWwEtdspmZWRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_he2uy54CEUGAjR10ESXHnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_myF8ybzw20G2z_xDQJRE5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_4ehewyms1Eme4lR1LfryGQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Fqi_V4t6y0-puYQ1ivg6DQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_DnVhZllqokOmO7zElhgtow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_ZGQqQfHg406k4K3zCUbpCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_6BqJpjfqTkmbkm23rKGTgQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_mfkgJutHxk6YN0AZLtjrhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_wmf-_5aZ706YaqfSKWC1Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_JVAYrE5J70eJCxdaW-vCJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_pP0RVv1loE2F7LhqFPFl5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_z37ZSNqIdkmrfe2PIq5bYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_l9mQvoDziUGbilnG3EPTXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_bH8gJMCbP0e6I7i5rqUq1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_AE-vqlBJf0-NDgL1echf5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_7_2021_To_7_7_2021_Q_S9qhvpvUC3dMaaONMnrg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <startDate>2021-07-07</startDate>
            <endDate>2021-07-07</endDate>
        </period>
    </context>
    <context id="As_Of_7_7_2021_ah_eEOxPL0CIPCxPK6qNbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <instant>2021-07-07</instant>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_BmsMtetGyEmJ6rNq6bChIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_bwrRgyxuJEyI4cbzEoFAfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_KAuPKCifoEuHLIrulCDCMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_6qnoqf3lxkW7dfqLzPlqGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_cjqzXXZQU0imlA6Mfbj2WQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_ZNLsTGONtk6j3oo5yuSW8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Vyleht5K70id4Y2JmD-6pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4cZXNIk8T0WsnTIe9RQpHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ejhoERAomEign1naasf3xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_11_2021_To_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_r4I_ZqMIBUCX-Ze0L9Tr3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-11</startDate>
            <endDate>2021-02-11</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MO7C6tyJRUOkv1IQjh61yg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eG8PooN1rEWw4Jpd-57o7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8l7C0jHh2E-gT1dD7E0Dog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dLa3qPlXC0ubjB2El7bVaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_ucSapsjP0kSLroQuwY1qqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_s_hI_eMhXEuN0ZTpwuwXiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_odl9-H0Af02VWyk45akORA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3OzaKSBA6EKIleBIeH1EMw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_QcpBoYoLhEuMjeBkZobcYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eu-ubqjya0GZ7jR6Gj7umw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ksUQnXGhskekv5LudMtZwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9ItmklfRf0uRsoU9hvgWog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_HYoBMhtJa0yEyU06RSK4NA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CxGmgLMsLE2qdLE2LM_0rA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1tBXOuzi0ESMiQGauboZTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_aSr2RzGWsEeMWJO8StiKvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_n4xqIulhYU-egftp4MP37g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="As_Of_5_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_g_h3Hub6ukul0-GRuWdxTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2016_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_Z_tj6E4y60S8vpMf1oAsgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-30</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_3jZL665NG0K7BDnwmBK99w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_zDcYc37T6EuzabJm9zIaGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_s7dkZbBLJUCm7qfYw6gdmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FbCfpTbSv0mxoweyDbesMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_By3QnPrdlEaXBzg7JPmAWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CcCxb4VhikOi1y0dPsdYqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_7_2022_To_3_25_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_ZhmKNezcek-HK-1dHlkcpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-07</startDate>
            <endDate>2022-03-25</endDate>
        </period>
    </context>
    <context id="Duration_2_7_2022_To_3_25_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Nz6vByh-PUO3MFMmJbHcFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-07</startDate>
            <endDate>2022-03-25</endDate>
        </period>
    </context>
    <context id="Duration_3_12_2021_To_12_22_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_u_kx_vXZB0a8pG4zN4WJ5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-12</startDate>
            <endDate>2021-12-22</endDate>
        </period>
    </context>
    <context id="Duration_3_12_2021_To_12_22_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_Rz3IDXEqBkqyYcd3zdrfzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-12</startDate>
            <endDate>2021-12-22</endDate>
        </period>
    </context>
    <context id="Duration_11_9_2020_To_11_9_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_XjwJ8pZZ10aBP4HgKJNJBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-09</startDate>
            <endDate>2020-11-09</endDate>
        </period>
    </context>
    <context id="Duration_11_9_2020_To_11_9_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Tj93Av1VmE-ghmkmKkxeVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-09</startDate>
            <endDate>2020-11-09</endDate>
        </period>
    </context>
    <context id="Duration_1_7_2022_To_1_7_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rKG0vF3HuUuOSzupeNgTNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-07</startDate>
            <endDate>2022-01-07</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_FHaDhJxmwEKepai0fnE7_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_gps4CSyPx0qQcHlONLLb2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_3_8_2022_To_3_8_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yR9MjqeEykqztm3xL6TxRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-08</startDate>
            <endDate>2022-03-08</endDate>
        </period>
    </context>
    <context id="Duration_2_7_2022_To_3_25_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qgR18IIqT0W8xFm3O123fA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-07</startDate>
            <endDate>2022-03-25</endDate>
        </period>
    </context>
    <context id="Duration_3_16_2021_To_3_16_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_KJ_klWmvoEGqcj3eoFwhkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-16</startDate>
            <endDate>2021-03-16</endDate>
        </period>
    </context>
    <context id="Duration_3_12_2021_To_12_22_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_cTAuhhwHJkiqvsAvTWQsmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-12</startDate>
            <endDate>2021-12-22</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_adag_ServiceConditionsAndPerformanceConditionsMember_lzcuoYgQd0GD5oMsj4d0yA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">adag:ServiceConditionsAndPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_StatementScenarioAxis_adag_ServiceConditionsAndPerformanceConditionsMember_aYQM4Z59Lkq9WgUCQtEtog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">adag:ServiceConditionsAndPerformanceConditionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_us-gaap_PlanNameAxis_adag_Plan2019Member_qU51oRRIxk-yJ1GRjugs3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:Plan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2017_us-gaap_PlanNameAxis_adag_Plan2017Member_pj9uKp5Wm0Kh5Lol033Ddw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:Plan2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="As_Of_11_7_2015_us-gaap_PlanNameAxis_adag_Plan2015Member_9j3tnKD5LU-UGahhBXvNQw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:Plan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-11-07</instant>
        </period>
    </context>
    <context id="Duration_7_7_2022_To_7_7_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_1hE8qqTDwUyc0lzaYCJtgw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-07</startDate>
            <endDate>2022-07-07</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_OvswsTR8G0ucewnhfOtZsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_15_2020_To_8_15_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_oE_DhZwnNUKZiikkA5YlwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-15</startDate>
            <endDate>2020-08-15</endDate>
        </period>
    </context>
    <context id="Duration_8_14_2020_To_8_14_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_ctCNSEfroUq-2XAeZiRzEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-14</startDate>
            <endDate>2020-08-14</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_UwjwbfWHYk-CsHFX-MxHNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_SignalPharmaceuticalsLlcMember_7offnHLxtE2QBDZc2Gcu7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:SignalPharmaceuticalsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_jQLNNuCCo0Gc9A2UON5i2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_adag_SignalPharmaceuticalsLlcMember_tDfXXMaJ1Eey6o1BuWgWYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:SignalPharmaceuticalsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_bKpMhErhpUq4nsR8w4_mRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_MxpOQhUxHEuCBkT-S645ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_EEyq6-qTT02Gx8jU3UgzXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:AdctCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_u083XUXgXkmjyHICOwXAVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_vfbRj1jR1UChcP5_UNgiYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_R9K_aCh4f0KdI_UTlvIBAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_ufKZJPNy5EaknPuOgGRVKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_He6IyXPrkkSO8ChXsSJeiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_JVqltsC74kiTWg82LEi0EQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_8iysXIGeCkikS5CDa_J0Ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_Gvzpm_m3g0S200Y-2xFrbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_SAiLZZ5KLU2DxJiGDTfUCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiBiologicsShanghaiCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_SwsdmKolekSilpQ3qYqN5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiApptecGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_q83pj5eew0G-H2b3ek53pA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_N1u78K2d-EOfIuR8F8QHxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiBiologicsShanghaiCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember__5lJ8r5zLkCATZnr5vRZCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiApptecGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_dOiC75LhVU2oZehy5mDi8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_XeTQYEWhbE-YyIEK2oP-aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiBiologicsShanghaiCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_KmqFU3ZUgkCofpEfOKqHNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiApptecGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_uo7m-2m6a06JnSUbvBslaA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">adag:ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_jsS3_yJrR0KhUEt67uACsw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_W-K9fp6sNECpsw-JihnlWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_crIDIxsy2U6oUr2eG_WiNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_uyRyfLpBGEeJ8flPQrftCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_PoM_lvt6D0O7Kn1hJ7TRfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_KGhMFlu_2kq3DNJN3Ro4IA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_CaBsmpmN7kyoRjl5pYT5EA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adag:ElectronicEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_Ii31JlQF6EyGi8FubMjm2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ciXSaRCCIUShj4RIB8kXvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_0Fkj5p3dOEG5xJSp6cquuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_TXr2Um0aJEuPO1zHVf0dgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_-OER4mKuwE6orMCLglM2Mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_EcLyGd1RtEKchc8-Nwr_uQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adag:ElectronicEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_OkKAU_FVpUiB6Qf9qvp3MQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_rhq53MJUbUaZODEvfgDerw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_xjhR4xY8gkilBkiNX6jw5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_c4u5F8308kqb6Yb80ib06w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_ugbL_thGJ0y97MV05rKCuA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_Y9nw88vBK0en70RiAB4NXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">adag:ElectronicEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_1_2018_To_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_adag_SeriesC1WarrantsMember_WLfnPOEP_kCFFQnnkF3j_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adag:SeriesC1WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="Duration_2_11_2021_To_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_2gbsAY6W7kyRuQc1AoDg2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-11</startDate>
            <endDate>2021-02-11</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_AOGCddhlkkafIHJPmD_uUw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:AdctCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_sYvYNerfTEq-2t09ZKu2Pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_y8B0CBPuIkuYDNTamxLEtA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_jrlz-uWqkUmR3nAwGvC25Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_US_qd0LMDoF3kaYh2E7WWuXKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_SG_uNjj8HS8_UGTaPvk5ZRsdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:SG</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_CN_OhVh4Lb4B02ZVkGnT6Nwxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_CH_YBCRGjH5NE--RhN9ukhZ4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_AU_LMSJo9Jtm02FhFmXG-t5HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IizeckEJt0arP1tQ0car0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oTl5ofybRE-y-HStnx9nSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_p0eN6ym23UKzRvTQU9uTVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdageneSuzhouLimitedMember_A507RmmeiUq6oiW6PXn0aA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneSuzhouLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdagenePte.Ltd.Member_d3JwN-5-lUqU1dSbJ5ORkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdagenePte.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdageneIncorporatedMember_HofBS4guwEOkNvbMdQ_4rw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdageneHongKongLimitedMember_v6J9OTGMEE63UoAoetmLFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneHongKongLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdageneAustraliaPtyLtd.Member_zLdH5fF9zEmREPsgUVwMsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneAustraliaPtyLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdageneAgMember_bsCxNvIf3UO-29bfLUj7-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adag:AdageneAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_6cOSMximrk2bohWsY9UvnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_zAcojCdKLE-VHQNNjHb_JA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_c5z9GXzV4UWW7jLt1LL9xA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_m9PDviMAVECncJ6iC8V97g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_6fAfKRGGhUqL4IOh5BEK8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_GfqS1hbef0evoZ9T4mY-ig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_nqUKaiveBk6aWC7ifhDHyw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_stpr_CA_Zi09NHLp7kmMwo_bnVpuPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_HK_4gYbMZNRaUuPUEWsYd_dSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_HK_tMrEpBM5ckCNd3jduDmhig">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2008_To_1_1_2008_srt_StatementGeographicalAxis_country_CN_6zxDnTTPxkmKtBmcfSofpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-01-01</startDate>
            <endDate>2008-01-01</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_I6hnNvOh2UqAhbgZo1ZC3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiBiologicsShanghaiCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_GXYUWeoSRU-ouLAoR_nM4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiApptecGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_oF1Ki6py4Ea_VIk2bXN2pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiBiologicsShanghaiCo.Ltd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_aakkwWDe5k2bhxPkdccOxg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">adag:WuxiApptecGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_LFa5nidGXk2zyr81bhmV-w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2021_To_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_xPZSxb0_rEyiXfgBq8UngA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_yREvdQEbf0aifJQLSacj_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2020_To_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_6cK__TDe2k2D6upUdm_BkA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdLoanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_c2z9l55OS0-09kT4Xr8EBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromBankOfNingboCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_XCA1IgwsJ0i02_dGhfX8Ww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="Duration_9_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_Ruff_uK5bECwmUs88WOIvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromBankOfNingboCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_IGsoNcZxl0av20J3TRsTVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="As_Of_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember__Yp6JfBX00e2bWTEBjp7og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_7zaPIqJMgEOMGotoMZUnYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_NfuX6XNrY0y0YKE8g2SAHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_n4OTuF0LqkKjcG_8uSdSgg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:ChinaMerchantsBankCo.LtdLoanTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_CmsXX0QXp0S-fTuzrs4H6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_xK5464GvIU2G2CMxw-2yyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromBankOfNingboCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_oYuYrvTHKU2WUWilDTYWFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromAgriculturalBankOfChinaLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_aRG-u8wGNE-CSsqku0pR0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adag:BorrowingsFromBankOfNingboCo.LtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_tmSdxQVjfUKJf2DV_oxA0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_8XLbm_NuOEaOfNq0iiQ4Uw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">adag:BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-28</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_9GdyKS3_I0KCOd-y1gFghA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-30</instant>
        </period>
    </context>
    <context id="As_Of_11_30_2011_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtSecuritiesMember_8DxtpnQnr0KcaNlyma5fZg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-11-30</instant>
        </period>
    </context>
    <context id="As_Of_2_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FkDkbXaQZU-bN_5oHvMW7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-11</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_LqlKepEaPEyADAUMj0EidA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adag:ConcentrationRiskSuppliersAxis">adag:OneSupplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_SxQdUgI9Z06HufSkFzPTTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adag:ConcentrationRiskSuppliersAxis">adag:OneSupplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_ZYOjK2vU90O3dGqnw4FeEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adag:ConcentrationRiskSuppliersAxis">adag:OneSupplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_1_16_2021_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_qSN6Ich4FkuRKoki3TJD4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-16</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_adag_SeriesC1WarrantsMember_dvXoa1fpc0ab3vTaHbqHkg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adag:SeriesC1WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2018_T4mq9hT6lUOBey2VJKkGww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_adag_OutsideMainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_EFliqC7rp0Sx41tQSgTPRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">adag:OutsideMainlandOfChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adag:CashAndCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_adag_MainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_a3KAemeQF0yabn5RGbhXiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">adag:MainlandOfChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adag:CashAndCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_StatementGeographicalAxis_adag_OutsideMainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_yZFC6h4cwEK-fa4C8KeTyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">adag:OutsideMainlandOfChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adag:CashAndCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_srt_StatementGeographicalAxis_adag_MainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_kj-fSey9EEyEtxiGoEoEpg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">adag:MainlandOfChinaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">adag:CashAndCashEquivalentsAndShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_6guEaEag302za51zg4qPZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_wCLSLauImkivkl4yN53mvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_ESjTZBeLf0SCBovh04R_ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_yAAu1HlY9EC9pTVzah_bYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_qtF149jaCUabjqo7frjCBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_zdsez9gtTkGdnwLN8_NhYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_B0aUMLGKf0iTQ_KOw1cMDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Ku2fXt-ZkUyQ2JGo0NdGOw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_xUUXpRjJbEqKzK5uloapeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_mEMX3jxTBEePGi2c4CW7ew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1m27p6Q0nEy5EgKynSvENw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z-JH0nWTpk2ObWlOPALkqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TRZ2AP03T0q5M7SihzVu2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember__cHz1vX8l0yKaUSYpxTiiQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:ExelixisIncAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0J9hCl1ZSkaeQhRprqc5kQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_rJ9HGaFep0uT39eGrH0BAQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Y5rj-vidfkKdz_NhXcGhJg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-11</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_US_4Mf3uObvgkKrQagy395fZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_CN_hq0Btu-DBkq8lmsfbYdpfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_CH_iL69fGVCpEaHddyIW4NKvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_AU_S-6YiA61gUCW7VM434szsQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_HK_zjbfDO1qFECcc41CmvbdYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_12_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_diYKl71mcEa25Z1LgkrP_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC3RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_6_1_2019_To_11_30_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_SGBgTCSDF0a2llGb4MeGuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2018_To_5_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_BRbJS1jV-k2FpP0-kKZpDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2016_To_6_30_2016_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_SWyRj_9rTEa_35eINBgGXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_dcicFbmqOki6XSFYWhz5_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series2RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-11-01</startDate>
            <endDate>2014-11-30</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_otWAtk9h5EmHuBYtwAAZvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:Series1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-11-01</startDate>
            <endDate>2014-11-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_jTUbwr8vS0Sq_Dw8Xns3HQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneAustraliaPtyLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_yYOL_1Zc_k-8AA3Sb91Fzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneAustraliaPtyLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_F3MPNQIHAUq3ElcVbpTt6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneAustraliaPtyLtd.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HGnhNeAwYk6MfQLARidhrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_7_7_2022_To_7_7_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_f5xUbvNTBEimEH5nmcz29g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-07</startDate>
            <endDate>2022-07-07</endDate>
        </period>
    </context>
    <context id="Duration_1_16_2021_To_1_16_2021_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_ajeBNU5LbU2-7VeHwDlygA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adag:PerformanceIncentivePlan2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-16</startDate>
            <endDate>2021-01-16</endDate>
        </period>
    </context>
    <context id="Duration_11_9_2020_To_11_9_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_WROxGtz27EKylxKWrdRpfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-09</startDate>
            <endDate>2020-11-09</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2015_To_12_31_2023_adag_StatusForTaxabilityAxis_adag_TechnologyAdvancedServiceEnterprisesMember_dei_LegalEntityAxis_adag_AdageneSuzhouLimitedMember_srt_StatementGeographicalAxis_country_CN_LOA0Hce0QEeI6iU8D0rTDQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adag:StatusForTaxabilityAxis">adag:TechnologyAdvancedServiceEnterprisesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneSuzhouLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_16_2021_To_1_16_2021_O_ff5_4bk0yyioWBZTe3bA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <startDate>2021-01-16</startDate>
            <endDate>2021-01-16</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_nR1gjPUSp0uEhhqDafgCZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_U2Wz9tRC_E-e-VNBsazHMQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_QrdSnJigEEC83xAI-BxP_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:CostOfGoodsProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_2_1_2018_To_2_28_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_IOm0wr8bS0SSsXLzukJ-8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">adag:SeriesC1RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_xzwissiwc0-243qJnNFPcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:AdctCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="Duration_2_1_2018_To_2_28_2018_h-YUYJGmUkuPVILUOsDYiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <startDate>2018-02-01</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2019_To_4_30_2019_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_eGyxkFQCZE6u3B9IkEjTXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:AdctCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_YFcme7KyF0aRVFQE-QOpug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_4s8XwXHiB0e5MShPFwPsfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2008_To_1_1_2008_adag_StatusForTaxabilityAxis_adag_TechnologyAdvancedServiceEnterprisesMember_srt_StatementGeographicalAxis_country_CN_wwO7JGio2USSa9yydNN8kA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="adag:StatusForTaxabilityAxis">adag:TechnologyAdvancedServiceEnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2008-01-01</startDate>
            <endDate>2008-01-01</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_avdfJlPfpUeAeQTReEsGLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ReceivablesFromStockholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_SignalPharmaceuticalsLlcMember_zbCrjEk3mUSzkE9kYsfUww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:SignalPharmaceuticalsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_i7cOcV2zlk2TryKX0IeFTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:ExelixisIncAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_pYJxpURUM0OA22lpXY2GQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_1_2019_To_5_31_2019_us-gaap_TypeOfArrangementAxis_adag_SignalPharmaceuticalsLlcMember_VxiNPotzW0uBeu5zVH0n4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:SignalPharmaceuticalsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_adag_SignalPharmaceuticalsLlcMember_6wYypVvYlkKloo4C6zZxMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:SignalPharmaceuticalsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="As_Of_4_30_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_adag_ExelixisAgreementMember_RSXFKdhcqEG6xrEDD5fFIQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:ExelixisAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="As_Of_2_28_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_j9kFO_H-ME6HZ7oPWsGjEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:ExelixisIncAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="As_Of_3_2_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_adag_ExelixisAgreementMember_r29U-8QtcEKfWUKlkQp_tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:ExelixisAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-02</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneAgMember_srt_StatementGeographicalAxis_country_CH_2T-t4Od_mUu8G2OSLg0lGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CH</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_YuWhG2JtdkyJ7W4ky9r1PQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneHongKongLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_yYXARERJEEyfvZf0uA9tVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:HK</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">adag:AdageneHongKongLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_raAHGN6oRESCKkVreFRITQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_zsB5uPJq50C4DpmE2mjLFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adag:GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001818838</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">
        <measure>iso4217:CNY</measure>
    </unit>
    <unit id="Unit_Standard_item_VDVAwvxnO0aSdoyDMbjpLA">
        <measure>adag:item</measure>
    </unit>
    <unit id="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      id="Hidden_yykzS30hl06JE8_4Gyvd6Q"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      id="Hidden_KEPLbwqWTUKyGw7REBPhKg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Hidden_d69gooBlQ0mTpDFmQMyhSw"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">15178232</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Hidden_hbRrNpmvMky8s-QwJTNZZQ"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">15950698</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Hidden_-hRwfmKQCk-DiIttjIYoug"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">50032009</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="2"
      id="Hidden_KQR8lFNPfkS9TZdYVy-ACQ"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">-1.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="2"
      id="Hidden_GTBrkm24z0u1aluHb9pjnw"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">-2.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Hidden_91RASQBlW0uOmcD1zr7dDg"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">-1.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Yic_H5pK-Ue4BHoUzpGweQ"
      decimals="INF"
      id="Hidden_QEvgf1yxAEqLh9b8UjGxBA"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_4ehewyms1Eme4lR1LfryGQ"
      decimals="INF"
      id="Hidden_JLyVXrR8sEuV8mnmCK1K2w"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">2370414</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_myF8ybzw20G2z_xDQJRE5Q"
      decimals="INF"
      id="Hidden_C4hibs_km0W0n4vCRJwCyw"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">7494537</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_he2uy54CEUGAjR10ESXHnw"
      decimals="INF"
      id="Hidden_U4bKB1bdKE2KKF0DOPSivA"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">5597354</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_yz5fD7wsz0K_dYLM59ooPw"
      decimals="INF"
      id="Hidden_ZFF7xARedUCS8PewaKNanQ"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_di_bFxD70EWwEtdspmZWRw"
      decimals="INF"
      id="Hidden_endl8IoTH0O3K-aS-8m02w"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">1861121</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_di_bFxD70EWwEtdspmZWRw"
      decimals="INF"
      id="Hidden_6xw84MWAzEeKSGIAjkDJlA"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">1861121</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_yz5fD7wsz0K_dYLM59ooPw"
      decimals="INF"
      id="Hidden_ZZZ6KNvyvUCF2u7hjt9r2w"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_BeGIQu5lxUuigOpTULuf_g"
      decimals="INF"
      id="Hidden_3HsWhAnamUSYk6toX8wDkw"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_EFH-DFpj80mpuyw7v7-SrQ"
      decimals="INF"
      id="Hidden_coidT8_no0y69VNki9JaoQ"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">4452441</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_EFH-DFpj80mpuyw7v7-SrQ"
      decimals="INF"
      id="Hidden_ca9NT4ulY0m7Yx2D4afc4w"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">4452441</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_BeGIQu5lxUuigOpTULuf_g"
      decimals="INF"
      id="Hidden_aLT9LyQmbkKGiAvNLS69LA"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="INF"
      id="Hidden_SxmNMOLwwke2qPy39angXQ"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">16603070</us-gaap:CommonStockSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tc_6A_GYw39B0mIkE2xw15zpw_3_1">0001818838</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tc_ilInAsoEGU2LJJeBmliEgQ_4_1">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tc_at9vrbzVSUGlx-hTSwcK4g_5_1">2021</dei:DocumentFiscalYearFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tc_nWNcDVgQt0W9VRtIrmkhpQ_6_1">false</dei:AmendmentFlag>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA"
      id="Tc_xJP5Ei-5OkK-1ChZQZHakA_7_1">4F, Building C14, No. 218</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA"
      id="Tc_nmL3QmbpiE6wcUeEe0a6rA_8_1">Xinghu Street, Suzhou Industrial Park</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA"
      id="Tc_Af2EY_fHh0W51fXgvRBUBw_9_1">Suzhou</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA"
      id="Tc_G5RzXEs2bUKdSmtjlP-D5w_10_1">215123</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA"
      id="Hidden_5lXRz63kp0qPymSXKecMXg">CN</dei:EntityAddressCountry>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_4s8XwXHiB0e5MShPFwPsfw"
      decimals="0"
      id="Hidden_h1NOMMhhk0K4VgxrbDp5-w"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_YFcme7KyF0aRVFQE-QOpug"
      decimals="0"
      id="Hidden_VOUFRqxLFk2geNCR76Ezew"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <dei:NoTradingSymbolFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_rJ9HGaFep0uT39eGrH0BAQ"
      id="Hidden_LcEk2UDpO02c8OZkOaHuyA">true</dei:NoTradingSymbolFlag>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Fqi_V4t6y0-puYQ1ivg6DQ"
      decimals="INF"
      id="Hidden_VENfoXbPC061Bzk81pVbqA"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">5473957</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_4ehewyms1Eme4lR1LfryGQ"
      decimals="INF"
      id="Hidden_fH5899ZKkEmYwyakW595Rg"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">2370414</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_myF8ybzw20G2z_xDQJRE5Q"
      decimals="INF"
      id="Hidden_Ujn6nO5i60WmgbpVHu8L6g"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">7494537</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_he2uy54CEUGAjR10ESXHnw"
      decimals="INF"
      id="Hidden_JKoEN2tDO0abKAYkMiyMhQ"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">5597354</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="INF"
      id="Hidden_SfcvSq9YQU2De6zqVGFSdQ"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">54595667</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Yic_H5pK-Ue4BHoUzpGweQ"
      decimals="INF"
      id="Hidden_4kmxjAvEPk2yQwJB4UYeqQ"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_b-r3H9b28Ey8YCwkcUjTkw"
      decimals="INF"
      id="Hidden_RF_o9M8JfUuM8iJOj7KzuQ"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_Uvvs-PCSRkiaKVDtX3E5sQ"
      decimals="INF"
      id="Hidden_k8YAQyxbe0W4LNbcRCzReQ"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_Uvvs-PCSRkiaKVDtX3E5sQ"
      decimals="INF"
      id="Hidden_CM3VYilgek6jumNumo7jMA"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_AdBejOP9vk6p3isk1DREwg"
      decimals="INF"
      id="Hidden_-stUpPtT602sN50jfcM6bQ"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_AdBejOP9vk6p3isk1DREwg"
      decimals="INF"
      id="Hidden_lWPSxiRXVESkOsTlb6pViQ"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Fqi_V4t6y0-puYQ1ivg6DQ"
      decimals="INF"
      id="Hidden_1DC4-oxGy0e0-KBQVfIJBw"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">5473957</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_b-r3H9b28Ey8YCwkcUjTkw"
      decimals="INF"
      id="Hidden_nDK_8hmoukyOeCQJGfI27Q"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">0</us-gaap:TemporaryEquitySharesIssued>
    <dei:DocumentType
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_Fr0baM67b0axxnR7CQiiZg">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_lx1qhIxUvkamNcjvOZNeaw">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_lJ3AwiqczkK4iBySq4oBww">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_ZkVDFT3600ub6sY6e0U1Yg">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_6nF6h5Z0w0WVAE_KtnGDiQ">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_uU3cgC7JfkmHsJ36CDkjXw">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_2__pKs_tYkmQ-bBZ8NmV_A">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_deqsdiwSVU2EAiNW9LclWw">001-39997</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_OAWsnyPY90mcOvoKDU3q7g">Adagene Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr__pJK9Y_91UC58DKG3sbhGg">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_s54ObJoeOUCgQKCuIOxgcA">4F, Building C14, No. 218</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_gEqTuhaHpUuq9DpssvGUbA">Xinghu Street, Suzhou Industrial Park</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_JuvF6VpugkOVRQTQNHNSnQ">Suzhou</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_C7ijmk1Sz0mncptXEvllQA">215123</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_jxKUL9sz1UOFPRkGPzYY0A">CN</dei:EntityAddressCountry>
    <dei:ContactPersonnelName
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA"
      id="Narr_w2Ucbusnc0mzyDwfGCqJ2g">Peter (Peizhi) Luo</dei:ContactPersonnelName>
    <dei:CountryRegion
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA"
      id="Narr_Jcm8ekVeJUCCi59z87KTrA">86</dei:CountryRegion>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA"
      id="Narr_WFN5oHIPkUqAKdef8dsn8w">512</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA"
      id="Narr_v-UVN6YwCEa9x_Lr_2gjaw">87773616</dei:LocalPhoneNumber>
    <dei:ContactPersonnelEmailAddress
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_EntityAddressesAddressTypeAxis_dei_BusinessContactMember_kV89LbE2i0aKqTEH-aXynA"
      id="Narr_Q4JoqvqT5kevDoWq06QiEg">peter_luo@adagene.com</dei:ContactPersonnelEmailAddress>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0J9hCl1ZSkaeQhRprqc5kQ"
      id="Narr_q8S1ZcQeD0Olmw5rF6Py4Q">American depositary shares</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0J9hCl1ZSkaeQhRprqc5kQ"
      id="Tc_7zE1giYdikukQB7n2l7cLg_2_2">ADAG</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0J9hCl1ZSkaeQhRprqc5kQ"
      id="Tc_Wb_Xmd9wjEOsDtk095RzKA_2_4">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_rJ9HGaFep0uT39eGrH0BAQ"
      id="Narr_JWCqnVT7LE206MAH2eC3_w">Ordinary shares, par value US$0.0001 per share</dei:Security12bTitle>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_rJ9HGaFep0uT39eGrH0BAQ"
      id="Tc_Vz7xWhZjukufAwFAsDMhuQ_5_4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="INF"
      id="Narr_yFsGMlsBYU-xxAx55hM-sg"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">54595667</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_YMOF5VUHHUqK0NJ4oelHIg">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_wAEISLsRH0qpt5CFqgiqmQ">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_nphWqMpi502mUbah_3ycyA">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_3-OGTRGqPUOxXKeZDojFKA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_EpvACwuXd0CkZ31MIlihhw">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_ghW6AwfaZ0K-eEIryrxo0w">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_x4uox3mqFkaao4oeUpFttg">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_ONGrgcUceUC-XhWdnHOoAg">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_tivJBb6vhUCKY7iWrVR2yg">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_ErnnWzPGpUOeQ7cRrWVc2g">false</dei:EntityShellCompany>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_ZIxG7DyZxE2l8B8_Q2h_RA">1424</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_j54lfo8CHU-fqhsW8EgbuA">PricewaterhouseCoopers Zhong Tian&#160;LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_5Cci7cu73keySIAWfnw94w">Shanghai, the People&#x2019;s Republic of China</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_QTYJau5e1U6ahZI_0H-BZQ_6_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">75150998</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_5sVZT02gMU6SCvMqeC-AAQ_6_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">174391243</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_nohmvVJAu0mswsEOwPP-DA_7_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_KBdMK_DXAka4C6ZD68x_Rw_8_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">132396</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_rDYc0DKQ1UW3vncEt92l-w_8_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">4506670</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_oFt7yeoFSUCPs6RGpvXf5g_9_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3813984</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_erulwkCS0kOLZDZVZB7f9Q_9_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">4055921</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_8JetyXTpvkS6a8sSC7kWxA_10_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">79097378</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_IHs86t2gkkuX3XrcZNRsnQ_10_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">185953834</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_KOfIVN5rZE-bdOpfzUNYrA_11_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2067125</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_CXgAcig88UeINXX-swQZTg_11_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3487617</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_dQdBIXlEhEu8IG1Iv_g-Nw_12_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3098234</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_wIt3sY26JEOtJxkpjRsZWA_12_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">69275</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_0Wj5Fo2mOEObsiRGNZWfdQ_13_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">84262737</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_RNZQBpYxOU-LbfOK21Lzug_13_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">189510726</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_PCSgZNUAfUuMvy4lIK8aFg_16_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1809975</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_yoxscIeqZkOkudyKHtJw9Q_16_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3321615</us-gaap:AccountsPayableCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_ONdBhkWUMkCMoPxji8s6ng_17_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">725536</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_GErTH05IZ0iCp3Uvw7EEzA_17_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_Q5ER2dsMR0iRs7hAM2M1cg_18_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2535358</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_UPu8Y8QTc0y6V_KizCWjIQ_18_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">10466061</us-gaap:DueToRelatedPartiesCurrent>
    <adag:AccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_lbigodW5i0SOWmzWZYw1xg_19_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">6059497</adag:AccruedLiabilitiesAndOtherCurrentLiabilities>
    <adag:AccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_jexEs2ojZku9texn_D0AFQ_19_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">4379243</adag:AccruedLiabilitiesAndOtherCurrentLiabilities>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_DTN0fe9_LEGtkMtjUEJjFg_20_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1657450</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_Dxyd8FoFiUGqyN7DLny-Cw_21_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3831476</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_jfjqHMRvckCA93UoZLAiyA_21_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3121226</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_eu-C7i93g0aB3rZSAX5Kgw_22_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1183926</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_OWmGqo78nEKXKxyooxbO4Q_22_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1376319</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_63_wSY3QqEKHA-VVgc60qQ_23_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">16145768</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_ZxbZs4BgYkub-mH8_3njww_23_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">29821914</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_Xi8YjOKvEEKRj4Fd8n-hAw_24_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2965563</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_3udF4i0nU0q555LWR7-QsA_24_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2991829</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_Y1pMJYmue02awa_njB1B5A_25_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">44163</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_UVfKWJ937kqIGgyrwMi-ww_26_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">91955</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_bWmft4L4JUipBvNFinWYrw_26_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">94107</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_l0viX9F8qUW6q44wUbSCHg_27_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">19203286</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_7fD3OUEA3EOZQCNeuUcJeg_27_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">32952013</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Fqi_V4t6y0-puYQ1ivg6DQ"
      decimals="INF"
      id="Narr_lP5o0wSH8EKHWE1PZwBH_A"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Yic_H5pK-Ue4BHoUzpGweQ"
      decimals="INF"
      id="Narr_YjpXL_GBQUKCUZHMwGmgNw"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Fqi_V4t6y0-puYQ1ivg6DQ"
      decimals="INF"
      id="Narr_k7xJEdK4eEaGomj1ZuLUAQ"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">5473957</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Yic_H5pK-Ue4BHoUzpGweQ"
      decimals="INF"
      id="Narr_W_RurI2ohkGmHQWFXAK_BA"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Fqi_V4t6y0-puYQ1ivg6DQ"
      decimals="0"
      id="Tc_nVDaGwfT806Wh_Klj-t5wg_31_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5473957</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_4ehewyms1Eme4lR1LfryGQ"
      decimals="INF"
      id="Narr_7BrkeP9aOkm4yhtnZyu-rg"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_b-r3H9b28Ey8YCwkcUjTkw"
      decimals="INF"
      id="Narr_JW2N7n9XZEmwB3ZLEsuqnQ"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_4ehewyms1Eme4lR1LfryGQ"
      decimals="INF"
      id="Narr_hLbLWkOoXUCQDNJeHoJK2w"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">2370414</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_b-r3H9b28Ey8YCwkcUjTkw"
      decimals="INF"
      id="Narr_58im2oOrD0Gm8oT3IAI5NQ"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_4ehewyms1Eme4lR1LfryGQ"
      decimals="0"
      id="Tc_qatqKJb8TUqqXjrIhatCOA_32_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_myF8ybzw20G2z_xDQJRE5Q"
      decimals="INF"
      id="Narr_HCXvJmqV7UqUTa51d1RLSg"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_Uvvs-PCSRkiaKVDtX3E5sQ"
      decimals="INF"
      id="Narr_VzqqOWRzPUmsplXKIHE-uA"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_myF8ybzw20G2z_xDQJRE5Q"
      decimals="INF"
      id="Narr_dc3Mnne5hEWrsHa94wVbWg"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">7494537</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_Uvvs-PCSRkiaKVDtX3E5sQ"
      decimals="INF"
      id="Narr_k2B5gxkXRkyPfG2sc5UXSA"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_myF8ybzw20G2z_xDQJRE5Q"
      decimals="0"
      id="Tc_2oCnpr8jLEmV_FhYGJKviQ_33_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">27999995</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_he2uy54CEUGAjR10ESXHnw"
      decimals="INF"
      id="Narr_822k5d-lGkKKEu7sSy9uzg"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_AdBejOP9vk6p3isk1DREwg"
      decimals="INF"
      id="Narr_ZNVI0_zkgU2_KswbqeRjBg"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_he2uy54CEUGAjR10ESXHnw"
      decimals="INF"
      id="Narr_3mKmOIaoNkiKG9C76icXAA"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">5597354</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_AdBejOP9vk6p3isk1DREwg"
      decimals="INF"
      id="Narr_g2J-lBAuJ06SWV4aCG2eZA"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_he2uy54CEUGAjR10ESXHnw"
      decimals="0"
      id="Tc_bWzcCfIJhU68tHlizZ-RiQ_34_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">48975456</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_di_bFxD70EWwEtdspmZWRw"
      decimals="INF"
      id="Narr_3-kcJysH4E68nwyS1YfPhA"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_yz5fD7wsz0K_dYLM59ooPw"
      decimals="INF"
      id="Narr_GKi3TuH0e02gl6HB1K7Svg"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_di_bFxD70EWwEtdspmZWRw"
      decimals="INF"
      id="Narr_2DTSA4Cbb0KJ9Srne1w6rw"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">1861121</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_yz5fD7wsz0K_dYLM59ooPw"
      decimals="INF"
      id="Narr_218kZGazKk61DRyBJw_lgw"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_di_bFxD70EWwEtdspmZWRw"
      decimals="0"
      id="Tc_Dvc8Q6l_oEy5CKq5nPzNwQ_35_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">18999999</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_EFH-DFpj80mpuyw7v7-SrQ"
      decimals="INF"
      id="Narr_HFjT1SwpHkmw9qyDeaKfyA"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_BeGIQu5lxUuigOpTULuf_g"
      decimals="INF"
      id="Narr_UrMbT90RT06u-rxVU29fcg"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_EFH-DFpj80mpuyw7v7-SrQ"
      decimals="INF"
      id="Narr_go0eYaJxwEuyQEBp8FdOSw"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">4452441</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="As_Of_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_BeGIQu5lxUuigOpTULuf_g"
      decimals="INF"
      id="Narr_c5Wz0gRPv0GFKz1mK24Bhw"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_EFH-DFpj80mpuyw7v7-SrQ"
      decimals="0"
      id="Tc_rmcNWMwo-EWZ5oehpExO-A_36_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">50000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_fw58OapFdkOiaT8aNbPgPw_37_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">154449407</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="INF"
      id="Narr_A6jvkQJWSkeLo5M5IBQHJw"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="INF"
      id="Narr_78nMqU9B7Eq-ln0ZlO6dUA"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="INF"
      id="Narr_lgyT-qJX4keYnzqrRkhR-g"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">640000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="INF"
      id="Narr_zeTSS8-09U6u0dZV_SdFTQ"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">16603070</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="INF"
      id="Narr_TtarQTE3JUW8o7saYzzphg"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">640000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="INF"
      id="Narr_QC4s3TUvLkiEMK0S-LuUng"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">54595667</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_J8_8l7gvUE-LPvg_wlJq5w_39_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1889</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_jMLGW6XTWUmCkIE9ivwO9g_39_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5627</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockShares
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="INF"
      id="Narr_TGGsGk8g4UyW2aqvU_Gmnw"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">0</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="INF"
      id="Narr_Fuc4VcegtEmucb-s3f5XGA"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">94074</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_4jZxJB6JSkOHBcOi-pQ1eA_40_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">619605</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityNoteSubscriptionsReceivable
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_RBPNw3pKuUCKczYbRztH4Q_41_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">7172192</us-gaap:StockholdersEquityNoteSubscriptionsReceivable>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_WbXIT0j_A0eLQP8bbp-QKQ_42_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">23786652</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_3LXfOvJfW0yL669qGGE7Dg_42_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">336099931</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_ZiMQVy3ZgEWedsdnApXDTQ_43_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-350981</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_qroW5uuozES_hTC2k48SgA_43_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-93981</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_57KJUteNJEO0Ohhf4Cenxg_44_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-105655324</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_V-sWx-fzikaMLG4cG5qWmA_44_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-178833259</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc__yCfFPpwG0-w-RhMY8pMwg_45_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-89389956</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_wmYR36m2fE237rEDvBeoyA_45_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">156558713</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_fE2v8gqeCkm6mVvdpGMpOw_46_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">84262737</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_L3BcB51z40CtLuP3E-Vy_g_46_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">189510726</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_0NMOv43hm0Snktm3u0pJ1g_6_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">480000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_eZV6NdcDwkmRINmaALxuXA_6_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">700913</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_WF7Y9cVUSkSTbc4u8NNZhA_6_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">10175258</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_cblgS506D0KsmrvRc6q0Cg_8_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">16211750</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_tqQ0z_5x3ECRxGPWY_GK5w_8_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">33538035</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_TxkIFtCGdkaneb8YM7ea5A_8_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">68099385</us-gaap:ResearchAndDevelopmentExpense>
    <adag:ResearchAndDevelopmentExpenseThirdParties
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_6GWJbqI16EG1trZ1a7iLfQ_9_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">10507444</adag:ResearchAndDevelopmentExpenseThirdParties>
    <adag:ResearchAndDevelopmentExpenseThirdParties
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_y6ZXMEQTnk2KXBulYnh_iA_9_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">23645740</adag:ResearchAndDevelopmentExpenseThirdParties>
    <adag:ResearchAndDevelopmentExpenseThirdParties
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_yIjsw_JyQk-3K3izNVOu6Q_9_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">55020367</adag:ResearchAndDevelopmentExpenseThirdParties>
    <adag:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_MfP0Nbc8GEaxDBnw1nP9UA_10_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5704306</adag:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty>
    <adag:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_0-MlyDq7pkONk0BsRKOPhg_10_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">9892295</adag:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty>
    <adag:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_oxT6xCEAe0yb9mRA4mNRHA_10_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">13079018</adag:RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_1wiNmKfNIEOJWwzFWGzSag_11_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3437900</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_uvbDfch5fECSU3LxbnTKCg_11_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">10314536</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_we8bjZPZJkyF5DDP_L8XPQ_11_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">14439962</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_ReP42zz5Wk6faXO46DP9Eg_12_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-19169650</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_eeXWqKY8ak2Jrn0Q20yKaA_12_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-43151658</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_vPPi8tO_SUqR2QJ07meWtA_12_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-72364089</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_qlgkDqvL9Uu63lHRGpfnFg_13_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">922680</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_e4-MqMwOh0uHFv6WTD-vGw_13_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">629288</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InvestmentIncomeNonoperating
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_blZyI7Wg_kG5SBeOG9IQUQ_13_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">76166</us-gaap:InvestmentIncomeNonoperating>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_AOuCrpLW2kCtruWTMn65_w_14_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">138096</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_Ol8LlQlhS0SuvBgd9Eo-yw_14_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">202165</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_quoWEcwDBkyUACebH8xKtA_14_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">363762</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_8Q_dTIEbnUS3-zECafrcXA_15_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">723476</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_kt_Ga8YLn0y9EjVuMJZObg_15_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">971949</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_98NZvMhfUE6pl_TakwlszQ_15_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1778822</us-gaap:OtherNonoperatingIncome>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_myixZRPjb060V8WHibXywg_16_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">21867</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_DXwxY8kXSEmi6Xd5Fkd1VA_16_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-644693</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_9qWOPD-hNU6ws0guF0dllQ_16_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-603459</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_HasVQ-haCk6YwL5WNKVXfw_17_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-1207415</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_IqlRJhf-FUWmLQ7qW1lfRQ_18_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-16432308</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_7wSWRfbNlUmpsiJByYNTGQ_18_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-42397279</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_8xIjtMUq6kq3DGLUXDoV8A_18_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-71476322</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_Qy7l3-ZSF0SxwNVduJ4ung_19_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1701613</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_xW4p8PsstEeK1RwI3xI0fA_20_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-16432308</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_i9vx4WGrWkeyeyNmqrdndA_20_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-42397279</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_XsGBOTa4nUuqLchovviLbA_20_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-73177935</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Narr_QGD4V-PI3UqyTVAmUThQZA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Narr_NIqPYoe_LUeKMZ13sQNbmA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Narr_W2EZalcNIUSpSn-cP_20mA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc__PP7KNHilkOjS-2c2em6SA_22_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">65799</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_oNzWYGxNakK0g45CPH6Oaw_22_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-6087</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_XBhJ5_CmTkSKO-FhALPQmQ_22_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">257000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_eQCy7WZWlka8foe90pz2Nw_23_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-16366509</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_qAwoJEurjkumv_1PhKn6uw_23_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-42403366</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_NpCyTDvWtUyo3X_BZti7Hg_23_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-72920935</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_4gqfy_N5bEm-EZL3L4q9Gw_24_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-16432308</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_wDXb4g02i0S_h4eJnf_s-A_24_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-42397279</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_V6SVhNhlXkK8_4aXvkXhCw_24_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-73177935</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_CyUOVtoXrEucazL4cfbMPg_25_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">246184</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_BPaupsxlvEiH6s_4F-fawg_25_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">248113</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_MTFNd68tL0uxIRD_g72ZsA_25_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">28553</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_cXzpjVIhREalAexgPETDzA_26_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-16678492</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_W5JlCRYzQUKmA67SndpinA_26_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-42645392</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_cJHk-BWX_kS5im6WVLmiHg_26_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-73206488</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_k3Bhx9ukF0y6GWzncXs1HQ_28_4"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">15178232</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_iy2OuVK-iU6IkdyezYYz7Q_28_6"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">15950698</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_UJ7I_e2-1027JIMH5BoyVA_28_8"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">50032009</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc__r9x2Mdt-EGS7S0xx-8jOA_29_4"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">15178232</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_wDDoKnSCik-ylEi_QhPVEg_29_6"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">15950698</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_diLEsersbUeQeMhRYSNrbQ_29_8"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">50032009</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="2"
      id="Tc_dghp6UBai029koQ31tLerA_31_4"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">-1.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="2"
      id="Tc_Lop_4w5kLEOvSaEWWE9UbA_31_6"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">-2.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Tc_L_MLrNbgy0mEOssIBYaKwQ_31_8"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">-1.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="2"
      id="Tc_bKhA2tEpE02BvgkTwJyNQQ_32_4"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">-1.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="2"
      id="Tc_NkuvdLT0S0OBFl0kxX5Hrg_32_6"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">-2.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Tc_PTA5NWVlikmCClVkt8ufjQ_32_8"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">-1.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CcCxb4VhikOi1y0dPsdYqg"
      decimals="INF"
      id="Tc_ImCmU4CvYEW7af66hZ02UQ_6_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">15159136</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CcCxb4VhikOi1y0dPsdYqg"
      decimals="0"
      id="Tc_fvGRr00uX0Ci0Rl8DOHgYA_6_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1516</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_HYoBMhtJa0yEyU06RSK4NA"
      decimals="0"
      id="Tc_Tfea4nGbL0qXULpOIqruBQ_6_10"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-197068</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_CxGmgLMsLE2qdLE2LM_0rA"
      decimals="0"
      id="Tc_RNrCQRePCkeU2lAfSrTLSg_6_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">6405318</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1tBXOuzi0ESMiQGauboZTw"
      decimals="0"
      id="Tc_ZRvyy7lYsEqLjqV8ez2PSw_6_14"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-410693</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9ItmklfRf0uRsoU9hvgWog"
      decimals="0"
      id="Tc_IsvWvux9CUSRpYFbCPmnlQ_6_16"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-46825737</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2018_T4mq9hT6lUOBey2VJKkGww"
      decimals="0"
      id="Tc_xMdDwbFtfkOYhaQGxx3foQ_6_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-41026664</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_p0eN6ym23UKzRvTQU9uTVw"
      decimals="0"
      id="Tc_qbaG6B_2YkWzft3QQ_weoQ_7_16"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-16432308</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_wrueFsWuFkyKUuugqY68BQ_7_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-16432308</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_jrlz-uWqkUmR3nAwGvC25Q"
      decimals="0"
      id="Tc_sRcXCi2gAUasnKvg5GqSeg_8_14"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">65799</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_CLjNv8fSy0G2CXVpynzF9Q_8_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">65799</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ejhoERAomEign1naasf3xg"
      decimals="INF"
      id="Tc_RYlzEOozGEW0dFLLtdonyg_9_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">34000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ejhoERAomEign1naasf3xg"
      decimals="0"
      id="Tc_25y6OcNp8EKKZt6wN_0XYw_9_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TRZ2AP03T0q5M7SihzVu2Q"
      decimals="0"
      id="Tc_ISmf3dAYz0ODsw3yUPHu0g_9_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">18697</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_j5euR-EfhU2N_m6XTARDVQ_9_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">18700</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TRZ2AP03T0q5M7SihzVu2Q"
      decimals="0"
      id="Tc_7U0yDgv40kaRQ_1cTdFF7A_10_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">611711</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_u1xzxxCjvUq55egoUXdrBA_10_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">611711</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_TRZ2AP03T0q5M7SihzVu2Q"
      decimals="0"
      id="Tc_7MXHrp8XSkizzJl0OH1DYA_11_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">246184</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_z0z0W4D-lUGZfZKVnmSUMg_11_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">246184</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_By3QnPrdlEaXBzg7JPmAWg"
      decimals="INF"
      id="Tc_pFjv9qyebUCaWqQgcc6Byg_12_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">15193136</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_By3QnPrdlEaXBzg7JPmAWg"
      decimals="0"
      id="Tc_w-5KOfr0JUq-GSCO2jjWMg_12_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1519</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_QcpBoYoLhEuMjeBkZobcYg"
      decimals="0"
      id="Tc_E5LBTvfzYUOJ5xiTDy2sSA_12_10"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-197068</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eu-ubqjya0GZ7jR6Gj7umw"
      decimals="0"
      id="Tc_gKpuD3apC02XoZu7pG_Nvw_12_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">6789542</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_ksUQnXGhskekv5LudMtZwQ"
      decimals="0"
      id="Tc_bVgeVqnEt0OhOBzRRawcDw_12_14"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-344894</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3OzaKSBA6EKIleBIeH1EMw"
      decimals="0"
      id="Tc_b6dihZzPsEOoJnLehYNlDA_12_16"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-63258045</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA"
      decimals="0"
      id="Tc_UPqgeIzroUG3_teBGj2h-A_12_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-57008946</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_oTl5ofybRE-y-HStnx9nSw"
      decimals="0"
      id="Tc_52dVgLsNo0Samqi80ZKHQw_13_16"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-42397279</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_LfuwwcYkL0iziCOy3SkmDA_13_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-42397279</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_y8B0CBPuIkuYDNTamxLEtA"
      decimals="0"
      id="Tc_OZdMFkN70kqS24VlvxqGgw_14_14"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-6087</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_h2eeZCVKXU-QZG2uW1GIZw_14_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-6087</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4cZXNIk8T0WsnTIe9RQpHw"
      decimals="INF"
      id="Tc_AbpFv-7VakGnqSsfQ2v5qg_15_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">3694934</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_4cZXNIk8T0WsnTIe9RQpHw"
      decimals="0"
      id="Tc_OpDhfYDy-0mnX7mpY49qgw_15_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">370</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_BmsMtetGyEmJ6rNq6bChIg"
      decimals="0"
      id="Tc_uFyv7AUHnUWD1CYKK8HFDw_15_10"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-6975124</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z-JH0nWTpk2ObWlOPALkqw"
      decimals="0"
      id="Tc_37bJFCvJM0GoRwLzAhSo2Q_15_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">7115682</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_-s3u-K9VH0q8dLPZrZLThA_15_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">140928</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z-JH0nWTpk2ObWlOPALkqw"
      decimals="0"
      id="Tc_0JlQwRq8eku6Q3YLTZihnQ_16_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">10129541</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_BCDHqQyUwEaDy5eogD1ANw_16_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">10129541</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_z-JH0nWTpk2ObWlOPALkqw"
      decimals="0"
      id="Tc_2hTdXx9EvkCnF4Nir2nmVA_17_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">248113</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_ZomxVUeSukuMqRY8qXAz0g_17_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">248113</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FbCfpTbSv0mxoweyDbesMg"
      decimals="INF"
      id="Tc_nsAVk7mPS06UiZ_6q9Hplg_18_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">18888070</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FbCfpTbSv0mxoweyDbesMg"
      decimals="0"
      id="Tc_91RtwnueI0e9e0xqR8zFDg_18_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1889</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_ucSapsjP0kSLroQuwY1qqA"
      decimals="0"
      id="Tc_S61ZnsDd4EyGhrslq2hl0g_18_10"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-7172192</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_s_hI_eMhXEuN0ZTpwuwXiA"
      decimals="0"
      id="Tc_GK_0IgYTfkyigfCe9wG1bg_18_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">23786652</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_odl9-H0Af02VWyk45akORA"
      decimals="0"
      id="Tc_9BMZzfJMKEiUTJX3agxnsw_18_14"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-350981</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dLa3qPlXC0ubjB2El7bVaA"
      decimals="0"
      id="Tc_DGjV0XxXK0-jRffy4AnepA_18_16"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-105655324</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_zOdpUaLSHkaLj-YzXe4ErA_18_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-89389956</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_IizeckEJt0arP1tQ0car0Q"
      decimals="0"
      id="Tc_H7SkxiNSZEG-BLaqzwn42A_19_16"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-73177935</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_t2fzLQjrT0C-qEPKM2y5SA_19_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-73177935</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_sYvYNerfTEq-2t09ZKu2Pg"
      decimals="0"
      id="Tc__TBjfVx9fES4oWFLIV225Q_20_14"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">257000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_4l61kkXXsUeH0hxXRVbXMQ_20_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">257000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg"
      decimals="INF"
      id="Tc_eWd2Oslg20SJRlGu3VXy2g_21_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">233957</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg"
      decimals="0"
      id="Tc_TrYAsEfHMk-r9UAyDFws3g_21_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">23</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HGnhNeAwYk6MfQLARidhrA"
      decimals="0"
      id="Tc_0R2vq0yNt0mNYNfzlLPS9w_21_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">226758</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_-9k7dUE9K0uanaflvmqnZQ_21_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">226781</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg"
      decimals="INF"
      id="Tc_meNHZx5aVkCm5ipZZnfBpQ_22_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">23734</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg"
      decimals="0"
      id="Tc_60vWo_rLCECSvcCl2Pda3Q_22_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HGnhNeAwYk6MfQLARidhrA"
      decimals="0"
      id="Tc_I6jIMq0wwkihHLGubhfv-w_22_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">416749</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_X5IvuerUOES05X8P7Lqtng_22_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">416751</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <adag:CommonStockSubscriptionsValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_avdfJlPfpUeAeQTReEsGLQ"
      decimals="0"
      id="Tc_TULsuXZebkGBB4dTpogKYw_23_10"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">381282</adag:CommonStockSubscriptionsValue>
    <adag:CommonStockSubscriptionsValue
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_aa6XoKEkKEqkjzM2s5yu2Q_23_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">381282</adag:CommonStockSubscriptionsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HGnhNeAwYk6MfQLARidhrA"
      decimals="0"
      id="Tc_43_9ixoId06ks8lQ5GgLCA_24_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">18679658</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_wN3Bs4xPbEWrgBnGINt42Q_24_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">18679658</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HGnhNeAwYk6MfQLARidhrA"
      decimals="0"
      id="Tc_eU9_pwasWUyqhkcvwaZpMw_25_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">28553</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_M13OdWG8IEmuwRSA1moKfw_25_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">28553</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg"
      decimals="INF"
      id="Tc_6gYXiIbCSUib63sW83M_Ig_26_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">27249824</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg"
      decimals="0"
      id="Tc_ySQKZDirAEm7cNktGBR6Sw_26_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2725</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HGnhNeAwYk6MfQLARidhrA"
      decimals="0"
      id="Tc_qYhst3ELFUOd_AxyjCY2Xg_26_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">154475235</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_xDi9ae-OxUWA_sHhN_XE0Q_26_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">154477960</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg"
      decimals="INF"
      id="Tc_crD7SKBzIUia0Q3_e11meQ_27_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">10571375</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg"
      decimals="0"
      id="Tc_96hmHbw270qd2QmPXcDWLQ_27_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1057</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HGnhNeAwYk6MfQLARidhrA"
      decimals="0"
      id="Tc_WJSsrbPVVEif05rmQwZ85A_27_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">147094280</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_SdFPURXlDUaJvy-x4rfk2A_27_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">147095337</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_KheMHBp800ewm1lePqQqfQ"
      decimals="INF"
      id="Tc_egeR92oZ-0iei0RlXL7oBw_28_6"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">295174</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_KheMHBp800ewm1lePqQqfQ"
      decimals="0"
      id="Tc_bP4bP-97TUmESMtmx32VAA_28_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2361576</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_15Z-psX3SUiTeB12wT5VTw_28_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2361576</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg"
      decimals="INF"
      id="Tc_HeAvUv7bgU-wFUZjvz4gTw_29_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">201100</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg"
      decimals="0"
      id="Tc_RSkzvPUWbE2Ucc05tNpzWQ_29_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">20</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_KheMHBp800ewm1lePqQqfQ"
      decimals="INF"
      id="Tc_aGI0pnetYkWsSdL8MXJTyQ_29_6"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">-201100</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_KheMHBp800ewm1lePqQqfQ"
      decimals="0"
      id="Tc_lrE3kupSvUmNbQhZ8DFG-Q_29_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-1741971</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HGnhNeAwYk6MfQLARidhrA"
      decimals="0"
      id="Tc_H7vydQDBOUezhaIe32x2iQ_29_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1750041</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_Of0pYa65x0asSDOyVQ60bQ_29_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">8090</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <adag:SharesSurrenderedSharesForRepaymentOfPromissoryNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg"
      decimals="INF"
      id="Tc_MkwyhbrpE0CDjzNaglq9WQ_30_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">-491119</adag:SharesSurrenderedSharesForRepaymentOfPromissoryNotes>
    <adag:StockSurrenderedValueForRepaymentOfPromissoryNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6iMx4vdSdU2MXbubfKq1bg"
      decimals="0"
      id="Tc_Yej22OVw80Sd-Nw9uSMFIA_30_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-49</adag:StockSurrenderedValueForRepaymentOfPromissoryNotes>
    <adag:StockSurrenderedValueForRepaymentOfPromissoryNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_ReceivablesFromStockholderMember_avdfJlPfpUeAeQTReEsGLQ"
      decimals="0"
      id="Tc_BkR6mrhOQEW3JM4HuU--Yg_30_10"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">6790910</adag:StockSurrenderedValueForRepaymentOfPromissoryNotes>
    <adag:StockSurrenderedValueForRepaymentOfPromissoryNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_HGnhNeAwYk6MfQLARidhrA"
      decimals="0"
      id="Tc_FtazeBDemk-KurXdan7pAQ_30_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-6800807</adag:StockSurrenderedValueForRepaymentOfPromissoryNotes>
    <adag:StockSurrenderedValueForRepaymentOfPromissoryNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_eEz_9-7IL02jJbm6TQhxtQ_30_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-9946</adag:StockSurrenderedValueForRepaymentOfPromissoryNotes>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_s7dkZbBLJUCm7qfYw6gdmw"
      decimals="INF"
      id="Tc_lLhMwkMch0qiYNTsC2Fr7Q_31_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">56274741</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_s7dkZbBLJUCm7qfYw6gdmw"
      decimals="0"
      id="Tc_A2HcW6jBm0KprkvG0KY1Nw_31_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5627</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_zDcYc37T6EuzabJm9zIaGw"
      decimals="INF"
      id="Tc_-l-zKBWgl0ys0QVpVmLS0w_31_6"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">-94074</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember_zDcYc37T6EuzabJm9zIaGw"
      decimals="0"
      id="Tc_fY9K4tyHnketCqwC6uEL9Q_31_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-619605</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_eG8PooN1rEWw4Jpd-57o7w"
      decimals="0"
      id="Tc_AtDSyr8zcUu7BYRGHSgVDg_31_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">336099931</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8l7C0jHh2E-gT1dD7E0Dog"
      decimals="0"
      id="Tc_xIAIGQCoZEqRcPdx51Q9kQ_31_14"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-93981</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_MO7C6tyJRUOkv1IQjh61yg"
      decimals="0"
      id="Tc_UoHs7a9LZ0e_sB23BkDo8w_31_16"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-178833259</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_sRuQ0gHA9kmQ_IGjwSXlVg_31_18"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">156558713</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_9IrFaq-Uik6pdexflzhgdQ_6_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-16432308</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_4ub8zLFCwk64s99IXvS0KA_6_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-42397279</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_LKgWcK_3R0CCfKj9zRf_fg_6_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-73177935</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_TU-qtZYrOkupb2Z78_zlSg_8_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">816686</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_TSi-kST6zkq6uxWvTqwZDA_8_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">858408</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_rbQ61mzgn0Ocxq4Ms4Frtg_8_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1125032</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_jQpG6-zH9UWnGWbDs9f3Gg_9_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1841</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_L85_M_4y6kSFIfV11ikE0A_9_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-327</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_KAsfk5UXVk6IIeGbvgrk0w_9_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-18973</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_PJ2e8oFJwE2jJL0D0_K8jw_10_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">611711</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_DiAgefbjbEWNWZJ13cX-Wg_10_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">10129541</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_cC52TvLZA0KLA4ufimGO_Q_10_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">18679658</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_HAPU9nfUg0SXKq3u9oIcLQ_11_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-1207415</us-gaap:FairValueAdjustmentOfWarrants>
    <adag:InterestIncomeExpenseOnPromissoryNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_5rE6-vNCvUKb6wR5mejaJA_12_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">9946</adag:InterestIncomeExpenseOnPromissoryNotes>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_b30fk2ASJk2Yw0i-nvzCVA_13_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">21867</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_KshbWBTqQkmwYTvX6cHQFA_13_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-644693</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_P3oDfET0j0WQF3zYdJ2_Gg_13_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-603459</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_GaL8yUihRUmjMnttQ1sJRw_15_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">480000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_TPb-ZL8qBE-a2uH2ghjUPg_15_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-480000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_aqIRvMM0ykCHNeeYP_3zBA_15_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_rZU5V0mpa0yENRouQH4nig_16_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-111516</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_mQJd2ArXAU6_d1jDhioD0A_16_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2337011</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_S1-_X6Py80CZ-8SKnJzVQw_16_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">231287</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_mdvL1gzmKUuV7dS0g3kMRw_17_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">704253</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_VQSeldR0SUqkGpDh-vfpFA_17_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-1300790</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_Va6hXoKIKUWJLLdua1v-qA_17_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">4374274</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_7Gu3-GoUnEum-rCam1KihA_18_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">38040</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_QCH0yq1vKU6tvx5K8aYCCg_18_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">13292</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_KCy8mRIbEki_oMPfH-q9wQ_18_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">24210</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_OUEsDsACsUSvMkPKWN1vuQ_19_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">153737</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_CDrK_MQ9H0ObGBLrs0h5ng_19_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1097261</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_Vv_jYNw7J0qJBdtbUmx_IQ_19_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1511640</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_GctcMT22c0We6GBUWG6HWQ_20_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">993378</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_wnBijFtin0GCJRUz5i5UMw_20_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-267842</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_qnGlZDP5V0-ky5nBqxw3mA_20_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">4774464</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_11SlBBf6xUqFWgh3P9mixw_21_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-1778469</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_BoKzZmj890ar9uQicpBmDg_21_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">639579</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInDueToRelatedParties
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_zGFAXvtHl0u0ropC0VzIeQ_21_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">7930703</us-gaap:IncreaseDecreaseInDueToRelatedParties>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc__RRV4IHbGk-0mOIPq_owUA_22_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-34277</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_L5BCBp6N-0SWtbtQSBLgag_22_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1243150</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_O_NRc5dJvEKSKNihcxrUfQ_22_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1057491</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_L6gYSoosmEyDjshODcravw_23_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1657450</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_BdPkulaVK0uryuEtmD2zRg_24_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-44163</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_J-ndFnR2rUGRAcMLiwyiIg_25_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-142114</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_PZ8Jya76FUWxN_GrpYmB2g_25_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">91955</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_MGmp4hQtnkGjyJInrXHGJQ_26_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-18153556</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_6NzYoiW7DkmBDXfWJd0SiA_26_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-28529720</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_S4fDE2Fp2kuV7oIupvHHmQ_26_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-43414619</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_uVRzmUsqY0iwB6SNJazvQw_28_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">19000000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_sNaL0nEt2EKIAhKu7dVkQg_29_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">44000000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_VDdmDorsskS1ZqF_1XaY5Q_29_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">8000000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_DiNQPa4ZRUmDnHEWxn019w_30_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">7697</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc__ldScYMij0yjJ5iHml_ZRg_30_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">7930</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_FUUPNaIVD0SWbBn9vSZ8Ng_31_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">151829</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_-7OWmA2Y706XVXyGqIlUHQ_31_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">935199</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_vaFsej0gyUOpK0FvKQ9NAA_31_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2509926</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_g0RdBs5EgkWfdlig8wXfGQ_32_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">24855868</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_VUZSKohdXUejBnc_fNYQSQ_32_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">7072731</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_OHl0BjiRY0axeo7UEN7e_Q_32_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-2509926</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_87cQdnhEY0GoxCAX-YDBUA_34_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2651874</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_4sRoRt58eUyp_SWwViTbBw_34_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">6083650</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_AF4GMwHbOEa_uSe_pZoY9Q_34_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">4386860</us-gaap:ProceedsFromIssuanceOfDebt>
    <adag:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_LxXZmgajCkamVh83T1abHg_35_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">68999999</adag:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants>
    <us-gaap:ProceedsFromContributedCapital
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_q7UTZ5UZbUqolhwDwAdsJA_36_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">381282</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_3ctP5X_2WUK0OZ22DASuOg_37_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">459796</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_ZbqYtOLEEU6ER5JaqcvSEw_37_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">140928</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_KHk2_DZT0kiUGOqe6xHojQ_37_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">231521</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_J8SjPQhAmE2tn451YAzjhg_38_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">149411950</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_ZCMDeazbT0qJAg32rdafIg_39_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2417192</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_G-AOOp-XH0OUg94ybXuyNA_39_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1063670</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_kqmIE8KcakOwTBqpT38tIg_39_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5089717</us-gaap:RepaymentsOfDebt>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_MbKG4CP6QE-222uDmw77Mw_40_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">721532</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_Ju4Qxyxq30qlDaH6WNySlg_40_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1595088</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_wPa_05rp_k2NVgYSdKhftw_41_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2361576</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <adag:RetirementOfTreasuryShares
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_B8QbCOse40a5GvjtuLVZeQ_42_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">8090</adag:RetirementOfTreasuryShares>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_U70LgGCrGkSA0t0TTuM81g_43_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">69694477</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_SUFSkrCzVUmIjtE09y_-1w_43_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">4439376</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_2YuDrD97d0W8PtXhCKExkQ_43_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">145357142</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_8tj1YVXPHkGU4U_fjm4c8w_44_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">77544</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_sZhWOmXAUk285J7V5Gh8JQ_44_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-364177</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_QDyOHcaLY0uTgAWrFwY0Iw_44_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-192352</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_4dSPO1JtoUi3MM6k6nSuKA_45_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">76474333</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc__1_jpJsUpUWZ0gkd20-Cjw_45_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-17381790</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_EKdH505EWk-VAnHVi0IDfw_45_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">99240245</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2018_T4mq9hT6lUOBey2VJKkGww"
      decimals="0"
      id="Tc_f8zhCohlg0acIQowy0yJBA_46_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">16058455</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA"
      decimals="0"
      id="Tc_Gatt8U2o4k6MprcSIj7CjQ_46_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">92532788</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_M2zfku2GmkSTpeEY9ruiNg_46_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">75150998</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA"
      decimals="0"
      id="Tc_J9ibjt_qr0SurcXMyBkDtg_47_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">92532788</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_ZBmFa0nQKEiunaPoA9dzqQ_47_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">75150998</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_4kgWDHqixU-sGTTnxZGbkg_47_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">174391243</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_jIzQSiSCfkuXZ6VWpXbeKA_49_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">142058</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_EUBrwPBzy0u-mYpcHoFY3A_49_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">202165</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_0GmJKDwL402Pe2vCXjYTXA_49_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">359569</us-gaap:InterestPaidNet>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_hM1tZVGuwke40LvY5yWSYQ_51_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">246184</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_b6gYw5k23EmSHF8hT66J6A_51_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">248113</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_Ybyy1eI61kmvXG81OKKgbQ_51_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">28553</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_GcI1uyE3GkCnyo5s4Nqf8A_52_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">154477960</us-gaap:ConversionOfStockAmountIssued1>
    <adag:PayablesForDeferredInitialPublicOfferingCost
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_vj_OxvcK0EiuLrwqh-sO9w_53_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2276183</adag:PayablesForDeferredInitialPublicOfferingCost>
    <adag:NonCashActivitiesRetirementOfTreasuryShares
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_KU6PNOmwEkG-FOM6pSaBQw_54_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1741971</adag:NonCashActivitiesRetirementOfTreasuryShares>
    <adag:SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_IUBwk9g400y4G6HyR4DvIg_55_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">6800856</adag:SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_oUmd1ALnAkO4LGQmITw9Sw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;1. ORGANIZATION AND BASIS OF PRESENTATION&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Adagene&#160;Inc. (the &#x201c;Company&#x201d;) is a limited liability company incorporated in the Cayman Islands on February&#160;25, 2011. The Company, together with its subsidiaries (collectively, the &#x201c;Group&#x201d;), are principally engaged in research, development and production of monoclonal antibody drugs for cancers.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On February 8, 2021, the Company&#x2019;s registration statement relating to its initial public offering (&#x201c;IPO&#x201d;) of its American Depositary Shares (&#x201c;ADSs&#x201d;) was declared effective by the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and the shares of its ADSs began trading on the NASDAQ Global Market on February 9, 2021. The public offering price of the ADSs sold in the IPO was $19.00 per ADS. The IPO closed on February 11, 2021, pursuant to which the Company issued 8,457,100 ADSs, including the exercise in full of the underwriters&#x2019; option to purchase 1,103,100 additional ADSs from the Company. The Company received net proceeds of approximately $145.9 million, after underwriting discounts, commissions and estimated offering expenses. Each ADS represents one and one quarter (1.25) ordinary shares of the Company. Upon the completion of the IPO, all outstanding shares of the convertible redeemable preferred shares were converted into ordinary shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2021, the Company&#x2019;s principal subsidiaries are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percentage&#160;of&#160;legal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Place&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ownership&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Entity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;incorporation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;incorporation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;by&#160;the&#160;Company&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&#160;activities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene (Hong Kong) Limited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December 12, 2011&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Hong Kong&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Investment holding&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene Incorporated&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;September 20, 2017&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;The United States of America&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene (Suzhou) Limited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;February 28, 2012&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;The People&#x2019;s Republic of China (&#x201c;PRC&#x201d; or &#x201c;China&#x201d;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene Australia PTY Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;May 30, 2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Australia&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene PTE. Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;March 27, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Singapore&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene AG&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;August 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Switzerland&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Y5rj-vidfkKdz_NhXcGhJg"
      decimals="2"
      id="Narr_FH8xwHYpCUy6FuTRMj646w"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">19.00</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_11_2021_To_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_2gbsAY6W7kyRuQc1AoDg2A"
      decimals="0"
      id="Narr_lHDCYHMVXEW9DvVhPRIW2A"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">8457100</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_11_2021_To_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_r4I_ZqMIBUCX-Ze0L9Tr3w"
      decimals="0"
      id="Narr_d7h9myveuEy1dNCYyelRAg"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">1103100</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_2_11_2021_To_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_2gbsAY6W7kyRuQc1AoDg2A"
      decimals="-5"
      id="Narr_cliu55sIcUCLcTzNA7l30w"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">145900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <dei:EntityListingDepositoryReceiptRatio
      contextRef="As_Of_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Y5rj-vidfkKdz_NhXcGhJg"
      decimals="2"
      id="Narr_FoMi7Os6J0GoXV39PyYg3w"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">1.25</dei:EntityListingDepositoryReceiptRatio>
    <adag:SummaryOfPrincipalSubsidiariesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_8k-91aMXJUiWQSfLsBMS_w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Percentage&#160;of&#160;legal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Place&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;ownership&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Entity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;incorporation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;incorporation&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;by&#160;the&#160;Company&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:27.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&#160;activities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene (Hong Kong) Limited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;December 12, 2011&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Hong Kong&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Investment holding&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene Incorporated&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;September 20, 2017&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;The United States of America&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene (Suzhou) Limited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;February 28, 2012&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;The People&#x2019;s Republic of China (&#x201c;PRC&#x201d; or &#x201c;China&#x201d;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene Australia PTY Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;May 30, 2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Australia&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene PTE. Ltd.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;March 27, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Singapore&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:27.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Adagene AG&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;August 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Switzerland&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;100&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:27.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development of innovative medicines&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</adag:SummaryOfPrincipalSubsidiariesTableTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdageneHongKongLimitedMember_v6J9OTGMEE63UoAoetmLFQ"
      decimals="2"
      id="Tc_PixhK1EAVUeRBiEuAoDh2w_4_6"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdageneIncorporatedMember_HofBS4guwEOkNvbMdQ_4rw"
      decimals="2"
      id="Tc_1Xzng9wreUGmsr0xZJTQMg_5_6"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdageneSuzhouLimitedMember_A507RmmeiUq6oiW6PXn0aA"
      decimals="2"
      id="Tc_4k0dVlFOfkqmGdcxFuSU7Q_6_6"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdageneAustraliaPtyLtd.Member_zLdH5fF9zEmREPsgUVwMsA"
      decimals="2"
      id="Tc_vp_53VLIf0i5w74Ha9y6rg_7_6"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdagenePte.Ltd.Member_d3JwN-5-lUqU1dSbJ5ORkQ"
      decimals="2"
      id="Tc_YSlhFsN1XUWfW9BOUMRy3A_8_6"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_12_31_2021_srt_OwnershipAxis_adag_AdageneAgMember_bsCxNvIf3UO-29bfLUj7-Q"
      decimals="2"
      id="Tc_XQkfPnBMD06DQHI4OlY0Fw_9_6"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb__jqJSCnxQ0OrYx7mdFxF-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S.&#160;GAAP&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements of the Group include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Use of estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the balance sheet dates and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in the Group&#x2019;s consolidated financial statements include, but are not limited to, licensing and collaboration revenue recognition, research and development expense allocation, the useful lives and impairment of long-lived assets, tax valuation allowance, and share-based compensation expenses. Management bases the estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could materially differ from those estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Foreign currency translation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The functional currency of the Company, Adagene (Hong Kong) Limited, Adagene Incorporated and Adagene PTE. Ltd. is the United States dollar (&#x201c;US$&#x201d;). The functional currency of the Company&#x2019;s PRC subsidiary is Renminbi (&#x201c;RMB&#x201d;). The functional currency of the Company&#x2019;s Australian subsidiary is Australian dollar (&#x201c;AU$&#x201d;). The functional currency of the Company&#x2019;s Swiss subsidiary is Swiss Franc (&#x201c;CHF&#x201d;). The determination of the respective functional currency is based on the criteria stated in Accounting Standard Codification (&#x201c;ASC&#x201d;) 830, &lt;i style="font-style:italic;"&gt;Foreign Currency Matters&lt;/i&gt;. The Company uses US$ as its reporting currency. The financial statements of the Company&#x2019;s PRC, Australian and Swiss subsidiaries are translated from the functional currency to the reporting currency.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Transactions denominated in foreign currencies are remeasured into the functional currency at the exchange rates quoted by the People&#x2019;s Bank of China (the &#x201c;PBOC&#x201d;) prevailing on the transaction dates. Monetary assets and liabilities denominated in foreign currencies are re-measured at the exchange rates prevailing at the balance sheet date. Non-monetary items that are measured in terms of historical costs in foreign currency are re-measured using the exchange rates at the dates of the initial transactions. Exchange gains and losses are included in the consolidated statements of comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Assets and liabilities are translated at the exchange rates at the balance sheet date, equity accounts are translated at historical exchange rates and revenues, expenses, gains and losses are translated using the average rate for the&#160;year. Translation adjustments are reported as accumulated comprehensive loss and are shown as a separate component of other comprehensive loss in the consolidated statements of comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Cash and cash equivalents primarily consist of cash and demand deposits which are highly liquid. The Group considers highly liquid investments that are readily convertible to known amounts of cash and with original maturities from the date of purchase of three&#160;months or less to be cash equivalents. All cash and cash equivalents are unrestricted as to withdrawal and use.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;Accounts receivable and allowance for doubtful accounts&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Account receivable is recorded when the Group has an unconditional right to consideration. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due. Accounts receivable is carried at net realizable value. An allowance for doubtful accounts is recorded in the period when collection of the amount is no longer probable. In evaluating the collectability of receivable balances, the Group considers specific evidence including the aging of the receivable, the customer&#x2019;s payment history, its current credit-worthiness and other factors. Accounts receivable is written off when management determines a balance is uncollectable after all collection efforts have ceased.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;Fair value measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group applies ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurements and Disclosures&lt;/i&gt;. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 requires disclosures to be provided for fair value measurements. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 1&#x2014;Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 2&#x2014;Other inputs that are directly or indirectly observable in the marketplace.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 3&#x2014;Unobservable inputs which are supported by little or no market activity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1)&#160;market approach; (2)&#160;income approach; and (3)&#160;cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amounts of cash and cash equivalent, accounts receivable, amounts due to related parties and other current assets, accounts payable, amounts due to related parties, accrued liabilities and other current liabilities and short-term borrowings approximate their fair values because of their generally short maturities. The carrying amount of long-term borrowings approximate their fair values since they bear interest rates which approximate market interest rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group did not transfer any assets or liabilities in or out of Level&#160;3 during the&#160;years ended December&#160;31, 2020 or 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group had no financial assets and liabilities measured and recorded at fair value on a nonrecurring basis as of December&#160;31, 2020 and 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Property, equipment and software&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Property and equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Category&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Machinery and laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Vehicles&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;4 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and tools&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;3&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; - &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Electronic equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;3 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;3&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; -  &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Lesser of lease terms or estimated useful lives of the assets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Repair and maintenance costs are charged to expense as incurred, whereas the cost of renewals and betterments that extend the useful lives of property, equipment and software are capitalized as additions to the related assets. Retirements, sales and disposals of assets are recorded by removing the cost and accumulated depreciation and amortization from the asset and accumulated depreciation and amortization accounts with any resulting gain or loss reflected in the consolidated statements of comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Impairment of long-lived assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group evaluates the recoverability of its long-lived assets, including fixed assets and intangible assets with finite lives, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. When these events occur, the Group measures impairment by comparing the carrying amount of the assets to the estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the assets, the Group recognizes an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the assets, when the market prices are not readily available. The adjusted carrying amount of the assets is the new cost basis and is depreciated over the assets&#x2019; remaining useful lives. Long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;No impairment loss was recorded for the&#160;years ended December&#160;31, 2019, 2020 and 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Segment reporting&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;In accordance with ASC 280, &lt;/span&gt;&lt;i style="font-weight:normal;"&gt;Segment Reporting&lt;/i&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;, the Group&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) has been identified as the Chief Executive Officer. The Group&#x2019;s CODM reviews the consolidated results of operations when making decisions about allocating resources and assessing performance of the Group. The Group operates and manages it business as a single segment. No geographical segments are presented as a substantial portion of the Group&#x2019;s long-lived assets are located in the PRC with the exception of certain laboratory and electronic equipment which are located in the U.S.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Revenue recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At contract inception of collaboration and out-licensing arrangements, the Group analyzes its arrangements to assess whether they are within the scope of ASC 808, &lt;i style="font-style:italic;"&gt;Collaborative Arrangements&lt;/i&gt; (&#x201c;ASC 808&#x201d;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Group first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are reflective of a vendor-customer relationship and therefore within the scope of ASC 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently. Under the criteria of ASC 606, the Group recognizes revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group adopted ASC 606 for all periods presented. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Group only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. The Group reviews the contract to determine which performance obligations are distinct and represent a promise to provide distinct goods or services or a series of distinct goods or services as defined by the standard. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation as and when that performance obligation is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Licenses of Intellectual Property:&lt;/i&gt; Upfront non-refundable payments for licensing the Group&#x2019;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Group recognizes revenues from non-refundable, up-front fees allocated to the license at a point in time, when the transfer of control of the license to the licensee occurs and the licensee is able to use and benefit from the license.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Research and Development Services&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;:  The portion of the transaction price allocated to research and development services performance obligations is deferred and recognized at a point in time as delivery of such services occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Milestone Payments:&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;  At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group re-evaluates the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Royalties:&lt;/i&gt; For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Group recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;During the years ended December 31, 2019 and 2020,  &lt;/span&gt;no milestone payments or royalty payments were received. During the year ended December 31, 2021, milestone payment was received, but no royalty payments were received. Substantially all of the Group&#x2019;s revenue has been derived from its out-licensing agreements with respect to licensed products such as DNA sequences, cell lines, etc., and such revenues are recognized when the customer obtains control of the licensed product, which occurs at a point in time, upon delivery to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Contract assets and contract liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;When a customer pays consideration before the Group transfers products or services, the Group records its obligation as a contract liability; When the Group satisfies its performance obligations by providing products or services to a customer before the customer pays consideration and before payment is due, the Group recognizes its rights to consideration as a contract asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Elements of research and development expenses primarily include (1) payroll and other related costs of personnel engaged in research and development activities, (2) costs related to pre-clinical testing of the Group&#x2019;s technologies under development and clinical trials such as payments to contract research organizations (&#x201c;CRO&#x201d;) and contract manufacturing organizations (&#x201c;CMO&#x201d;), investigators and clinical trial sites that conduct the clinical studies; (3) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation and amortization, and facility related expenses, and (4) other research and development expenses. Research and development costs are expensed as incurred when the related research and development services are provided to the Group and the resulting assets, if any, have no alternative future uses. As of December 31, 2020 and 2021, the Group had several ongoing clinical studies in various clinical trial stages. The contracts with CRO and CMO are generally cancellable, with notice, at the Group&#x2019;s option. The Group did not record any accrued expenses related to cancellation of CRO or CMO contracts as of December 31, 2020 or 2021 as the Group did not have any plan to cancel the existing CRO or CMO contracts.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Government subsidies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Government subsidies primarily consist of financial subsidies received from provincial and local governments for operating a business in their jurisdictions and compliance with specific policies promoted by the governments. The Group&#x2019;s PRC based subsidiary received government subsidies from certain local government. The Group&#x2019;s government subsidies consist of specific subsidies and other subsidies. Specific subsidies are subsidies that the local government has set certain conditions for the subsidies. Other subsidies are the subsidies that the local government has not set any conditions and are not tied to future trends or performance of the Group, receipt of such subsidy income is not contingent upon any further actions or performance of the Group and the amounts do not have to be refunded under any circumstances. These specific subsidies are recorded as other non-current liabilities upon receipt and are recognized as other income when the conditions are met. Other subsidies are recognized as other income upon receipt as further performance by the Group is not required. Government subsidies of US&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$0.7&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; million, US&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$0.8&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; million and US&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$1.4&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; million were received and recognized as other income during the years ended December 31, 2019, 2020 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;In addition, the Group&#x2019;s Australian subsidiary received research and development tax incentive from the Australian Taxation Office. The tax incentive was recognized as other income upon receipt as the incentive was not dependent upon having a tax liability and further performance by the Group was not required.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Leases are classified at the inception date as either a capital lease or an operating lease. The Group assesses a lease to be a capital lease if any of the following conditions exists: a)&#160;ownership is transferred to the lessee by the end of the lease term, b)&#160;there is a bargain purchase option, c)&#160;the lease term is at least 75% of the property&#x2019;s estimated remaining economic life or d)&#160;the present value of the minimum lease payments at the beginning of the lease term is 90% or more of the fair value of the leased property to the lessor at the inception date. A capital lease is accounted for as if there was an acquisition of an asset and an incurrence of an obligation at the inception of the lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;All other leases are accounted for as operating leases wherein rental payments are expensed on a straight-line basis over their respective lease terms. The Group leases certain office space under non-cancelable operating lease agreements. Certain lease agreements contain rent holidays. Rent holidays are considered in determining the straight-line rent expense to be recorded over the lease term. The lease term begins on the date of initial possession of the leased property for purpose of recognizing lease expense on straight-line basis over the term of the lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive income (loss)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive income (loss) is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by shareholders and distributions to shareholders. Accumulated other comprehensive income (loss) of the Group includes foreign currency translation adjustments related to the Group and its subsidiaries whose functional currency is not US$.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group follows the liability method of accounting for income taxes in accordance with ASC&#160;740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt; (&#x201c;ASC&#160;740&#x201d;). Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Group records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group evaluates its uncertain tax positions using the provisions of ASC 740, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group recognizes in the consolidated financial statements the benefit of a tax position which is &#x201c;more likely than not&#x201d; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty&#160;percent likelihood of being realized upon settlement. It is the Group&#x2019;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Borrowings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the consolidated statements of comprehensive loss over the period of the borrowings using the effective interest method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Share-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company grants restricted shares and stock options to eligible employees and nonemployees and accounts for share-based compensation in accordance with ASC 718, &lt;i style="font-style:italic;"&gt;Compensation-Stock Compensation&lt;/i&gt;. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses a) immediately at the grant date if no vesting conditions are required; b) for share-based awards granted with only service conditions, using the straight-line method over the vesting period; or c) for share-based awards granted with service conditions and performance conditions, using the graded vesting method over the vesting period if and when the Company concludes that it is probable that the performance conditions will be achieved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;In accordance with ASC 260, &lt;/span&gt;&lt;i style="font-weight:normal;"&gt;Earnings Per Share&lt;/i&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;, basic net loss per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of unrestricted ordinary shares outstanding during the year using the two-class method. Under the two-class method, net loss is allocated between ordinary shares and other participating securities based on dividends declared (or accumulated) and participating rights in undistributed earnings as if all the earnings for the reporting period had been distributed. The Company&#x2019;s convertible redeemable preferred shares were participating securities because they were entitled to receive dividends or distributions on an as converted basis. Diluted net loss per share is calculated by dividing net loss attributable to ordinary shareholders, as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares include ordinary shares issuable upon the conversion of the convertible redeemable preferred shares using the if-converted method, and ordinary shares issuable upon the exercise of share options, using the treasury stock method. Ordinary share equivalents are excluded from the computation of diluted earnings per share if their effects are anti-dilutive. For the periods presented herein, the computation of basic net loss per share using the two-class method is not applicable as the Group is in a net loss position and the participating securities do not have contractual rights and obligations to share in the losses of the Group.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Employee defined contribution plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As stipulated by the regulations of the PRC, full-time employees of the Group are entitled to staff welfare benefits including medical care, welfare subsidies, unemployment insurance and pension benefits through a PRC government-mandated multi-employer defined contribution plan. The Group is required to accrue for these benefits based on certain percentages of the qualified employees&#x2019; salaries. The Group is required to make contributions to the plans out of the amounts accrued. The PRC government is responsible for the medical benefits and the pension liability to be paid to these employees and the Group&#x2019;s obligations are limited to the amounts contributed. The Group has no further payment obligations once the contributions have been paid. The Group recorded employee benefit expenses of US$1,145,165 , US$622,377 and US$2,223,493 for the&#160;years ended December&#160;31, 2019 , 2020 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of risks&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of credit risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2020 and 2021, the amount of cash and cash equivalents of US$3,424,456 and US$3,650,474 respectively, were held at major financial institutions located in Mainland China, and US$71,726,542 and US$170,740,769,respectively, were deposited with major financial institutions located outside of Mainland China. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts receivable is typically unsecured and denominated in US$ and is derived from revenues earned from customers. The Group manages credit risk of accounts receivable through ongoing monitoring of the outstanding balances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of suppliers&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A significant portion of the Group&#x2019;s research and development services were purchased from one supplier group, who collectively accounted for 23.13%,21.51% and 18.45%of the Group&#x2019;s total research and development services purchases for the&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Business and economic risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group believes that changes in any of the following areas could have a material adverse effect on the Group&#x2019;s future consolidated financial position, results of operations or cash flows: changes in the overall demand for services; competitive pressures due to new entrants; advances and new trends in new technologies and industry standards; changes in certain strategic relationships; regulatory considerations and risks associated with the Group&#x2019;s ability to attract employees necessary to support its growth. The Group&#x2019;s operations could also be adversely affected by significant political, regulatory, economic and social uncertainties in the PRC.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Foreign currency exchange rate risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A significant portion of the Group&#x2019;s businesses are transacted in RMB, which is not a freely convertible currency. On January&#160;1, 1994, the PRC government abolished the dual rate system and introduced a single rate of exchange as quoted daily by the PBOC. However, the unification of the exchange rates does not imply that the RMB may be readily convertible into US$ or other foreign currencies. All foreign exchange transactions continue to take place either through the PBOC or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the PBOC. Approval of foreign currency payments by the PBOC or other institutions requires submitting a payment application form together with suppliers&#x2019; invoices, shipping documents and signed contracts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From July&#160;21, 2005, the RMB is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. For U.S. dollar against RMB, there was depreciation of approximately 6.5% and 2.29% in the&#160;years ended December&#160;31, 2020 and 2021, respectively. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the RMB and the U.S. dollar in the future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The functional currency and the reporting currency of the Company are the US$. However, the Group incurs portions of our expenses, and derives revenues, in currencies other than US$, in particular, the RMB. Any significant fluctuation of the valuation of RMB may materially affect the Group&#x2019;s cash flows, expenses, losses and financial position, and the value of any dividends payable on the American Depositary Shares in US$.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Recently issued accounting pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group is an emerging growth company (&#x201c;EGC&#x201d;) as defined by the Jumpstart Our Business Startups Act (&#x201c;JOBS Act&#x201d;). The JOBS Act provides that an EGC can take advantage of extended transition periods for complying with new or revised accounting standards. This allows an EGC to delay adoption of certain accounting standards until those standards would otherwise apply to private companies. The Group elected to take advantage of the extended transition periods. However, this election will not apply should the Group cease to be classified as an EGC.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2016-02 (&#x201c;ASU 2016-02&#x201d;), &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt; (Topic 842), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. In July 2018, FASB issued ASU No. 2018-10 (&#x201c;ASU 2018-10&#x201d;), &lt;i style="font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/i&gt;, which clarifies certain aspects of the guidance issued in ASU 2016-02; and ASU No. 2018-11 (&#x201c;ASU 2018-11&#x201d;), &lt;i style="font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements&lt;/i&gt;, which provides entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity&#x2019;s reporting for the comparative periods presented in the financial statements in which it adopts the new leases standard will continue to be in accordance with current GAAP (Topic 840, Leases). Further, FASB issued ASU No. 2020-05 (&#x201c;ASU 2020 05&#x201d;), Revenue from Contracts with Customers (Topic 606) and Leases (Topic 842): Effective Dates for Certain Entities, which extends the adoption date for certain entities. For the Group, the updated guidance is effective for fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. The Group does not plan to early adopt the new lease standards and the Group expects that applying the ASU 2016-02 would materially increase the assets and liabilities due to the recognition of right-of-use assets and lease liabilities on its consolidated balance sheets, with an immaterial impact on its consolidated statements of comprehensive loss and consolidated statements of cash flows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2016, FASB issued ASU No. 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt; (&#x201c;ASU 2016-13&#x201d;). ASU 2016-13 is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. This ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of the Group&#x2019;s portfolio. These disclosures include qualitative and quantitative requirements that provide additional information about the amounts recorded in the financial statements. In November 2019, FASB issued ASU 2019-10, which extends the adoption date for certain registrants. The amendments in ASU 2016-13 are effective for fiscal years beginning after December 15, 2022, including interim periods within fiscal years beginning after December 15, 2023. The Group does not plan to early adopt ASU 2016-13 and is currently in the process of evaluating the impact of adoption of this guidance on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2018, FASB issued ASU 2018-18, &lt;i style="font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/i&gt;. This update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer and precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The update is effective in fiscal years beginning after December 15, 2021, and interim periods therein, and early adoption is permitted for entities that have adopted ASC 606. This guidance should be applied retrospectively to the date of initial application of Topic 606. The Group elected to early adopt this ASU and applied this guidance retrospectively to all periods presented. The impact of this ASU to the consolidated financial statements is immaterial.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2019, FASB issued ASU 2019-12, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/i&gt;. This update simplifies the accounting for income taxes as part of FASB&#x2019;s overall initiative to reduce complexity in accounting standards. The amendments include removal of certain exceptions to the general principles of ASC 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt;, and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. The update is effective in fiscal years beginning after December 15, 2022, and interim periods therein, and early adoption is permitted. Certain amendments in this update should be applied retrospectively or modified retrospectively, all other amendments should be applied prospectively. The Group does not plan to early adopt ASU 2019-12 and is currently evaluating the impact on its financial statements of adopting this guidance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;In August 2020, FASB issued ASU 2020-06, &lt;i style="font-style:italic;"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;, which simplifies the accounting for convertible instruments by removing certain separation models in Subtopic 470-20, &lt;i style="font-style:italic;"&gt;Debt&#x2014;Debt with Conversion and Other Options&lt;/i&gt;, for convertible instruments and also increases information transparency by making disclosure amendments. The standard is effective for private companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact of this accounting standard update on its condensed consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_CDCrqOujRUyQpcWi6NAN8w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S.&#160;GAAP&#x201d;).&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_BFkREQY1y0ONG-c88aMMnQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The consolidated financial statements of the Group include the financial statements of the Company and its subsidiaries. All significant intercompany balances and transactions have been eliminated upon consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_x5QdoMRXQEqPiGmPCtK4CQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Use of estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;The preparation of consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the balance sheet dates and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in the Group&#x2019;s consolidated financial statements include, but are not limited to, licensing and collaboration revenue recognition, research and development expense allocation, the useful lives and impairment of long-lived assets, tax valuation allowance, and share-based compensation expenses. Management bases the estimates on historical experience and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could materially differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_iTZqX2RtJkSYW2-IjeIyMA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Foreign currency translation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The functional currency of the Company, Adagene (Hong Kong) Limited, Adagene Incorporated and Adagene PTE. Ltd. is the United States dollar (&#x201c;US$&#x201d;). The functional currency of the Company&#x2019;s PRC subsidiary is Renminbi (&#x201c;RMB&#x201d;). The functional currency of the Company&#x2019;s Australian subsidiary is Australian dollar (&#x201c;AU$&#x201d;). The functional currency of the Company&#x2019;s Swiss subsidiary is Swiss Franc (&#x201c;CHF&#x201d;). The determination of the respective functional currency is based on the criteria stated in Accounting Standard Codification (&#x201c;ASC&#x201d;) 830, &lt;i style="font-style:italic;"&gt;Foreign Currency Matters&lt;/i&gt;. The Company uses US$ as its reporting currency. The financial statements of the Company&#x2019;s PRC, Australian and Swiss subsidiaries are translated from the functional currency to the reporting currency.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Transactions denominated in foreign currencies are remeasured into the functional currency at the exchange rates quoted by the People&#x2019;s Bank of China (the &#x201c;PBOC&#x201d;) prevailing on the transaction dates. Monetary assets and liabilities denominated in foreign currencies are re-measured at the exchange rates prevailing at the balance sheet date. Non-monetary items that are measured in terms of historical costs in foreign currency are re-measured using the exchange rates at the dates of the initial transactions. Exchange gains and losses are included in the consolidated statements of comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Assets and liabilities are translated at the exchange rates at the balance sheet date, equity accounts are translated at historical exchange rates and revenues, expenses, gains and losses are translated using the average rate for the&#160;year. Translation adjustments are reported as accumulated comprehensive loss and are shown as a separate component of other comprehensive loss in the consolidated statements of comprehensive loss.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_HRZA4aGfLUCj8BGqskwFpw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;Cash and cash equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;Cash and cash equivalents primarily consist of cash and demand deposits which are highly liquid. The Group considers highly liquid investments that are readily convertible to known amounts of cash and with original maturities from the date of purchase of three&#160;months or less to be cash equivalents. All cash and cash equivalents are unrestricted as to withdrawal and use.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <adag:AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_Gvv0aRYlDk2KNMizCxkngw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;Accounts receivable and allowance for doubtful accounts&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Account receivable is recorded when the Group has an unconditional right to consideration. A right to consideration is unconditional if only the passage of time is required before payment of that consideration is due. Accounts receivable is carried at net realizable value. An allowance for doubtful accounts is recorded in the period when collection of the amount is no longer probable. In evaluating the collectability of receivable balances, the Group considers specific evidence including the aging of the receivable, the customer&#x2019;s payment history, its current credit-worthiness and other factors. Accounts receivable is written off when management determines a balance is uncollectable after all collection efforts have ceased.&lt;/span&gt;&lt;/p&gt;</adag:AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_MRphuc5OjUStiznjNSyX2A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 10pt 0pt;"&gt;Fair value measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group applies ASC 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurements and Disclosures&lt;/i&gt;. ASC 820 defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements. ASC 820 requires disclosures to be provided for fair value measurements. ASC 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 1&#x2014;Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 2&#x2014;Other inputs that are directly or indirectly observable in the marketplace.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"&gt;Level 3&#x2014;Unobservable inputs which are supported by little or no market activity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC 820 describes three main approaches to measuring the fair value of assets and liabilities: (1)&#160;market approach; (2)&#160;income approach; and (3)&#160;cost approach. The market approach uses prices and other relevant information generated from market transactions involving identical or comparable assets or liabilities. The income approach uses valuation techniques to convert future amounts to a single present value amount. The measurement is based on the value indicated by current market expectations about those future amounts. The cost approach is based on the amount that would currently be required to replace an asset.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying amounts of cash and cash equivalent, accounts receivable, amounts due to related parties and other current assets, accounts payable, amounts due to related parties, accrued liabilities and other current liabilities and short-term borrowings approximate their fair values because of their generally short maturities. The carrying amount of long-term borrowings approximate their fair values since they bear interest rates which approximate market interest rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group did not transfer any assets or liabilities in or out of Level&#160;3 during the&#160;years ended December&#160;31, 2020 or 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group had no financial assets and liabilities measured and recorded at fair value on a nonrecurring basis as of December&#160;31, 2020 and 2021.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <adag:FinancialAssetsFairValueDisclosure
      contextRef="As_Of_12_31_2020_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_4s8XwXHiB0e5MShPFwPsfw"
      decimals="0"
      id="Narr_XJosLxIRv0GmOLSynrCg4A"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</adag:FinancialAssetsFairValueDisclosure>
    <adag:FinancialAssetsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_YFcme7KyF0aRVFQE-QOpug"
      decimals="0"
      id="Narr_uArU6yj1IE-_dB4CyEHeQw"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</adag:FinancialAssetsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_8Lb-Se-SpkqAS-iY2zhKcA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Property, equipment and software&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Property and equipment and software are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Category&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Machinery and laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Vehicles&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;4 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and tools&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;3&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; - &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Electronic equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;3 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;3&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; -  &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Lesser of lease terms or estimated useful lives of the assets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Repair and maintenance costs are charged to expense as incurred, whereas the cost of renewals and betterments that extend the useful lives of property, equipment and software are capitalized as additions to the related assets. Retirements, sales and disposals of assets are recorded by removing the cost and accumulated depreciation and amortization from the asset and accumulated depreciation and amortization accounts with any resulting gain or loss reflected in the consolidated statements of comprehensive loss.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <adag:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_pJ6uF156MEmtCO0vyXh6mQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Category&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Machinery and laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Vehicles&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;4 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and tools&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;3&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; - &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Electronic equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;3 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Computer software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;3&lt;/span&gt;&lt;span style="font-size:10pt;white-space:pre-wrap;"&gt; -  &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:43.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Lesser of lease terms or estimated useful lives of the assets&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</adag:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_KGhMFlu_2kq3DNJN3Ro4IA"
      id="Tc_S8ND24qUNkijvS5SlIx4yw_2_2">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_PoM_lvt6D0O7Kn1hJ7TRfg"
      id="Tc_PILkLopLK0220nWI9V3D7Q_3_2">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_W-K9fp6sNECpsw-JihnlWQ"
      id="Narr_ECqjT6hwkUm_kPZ94kLXuQ">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_uyRyfLpBGEeJ8flPQrftCQ"
      id="Narr_pCNhEKOAfUStY3SIIqMmsQ">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_CaBsmpmN7kyoRjl5pYT5EA"
      id="Tc_utocKQetK02WS7wt3DO8lg_5_2">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_jsS3_yJrR0KhUEt67uACsw"
      id="Narr_h1MnC4Z-FkKcO_y4t02JzQ">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_crIDIxsy2U6oUr2eG_WiNQ"
      id="Narr_Mj3E2TyBOUqD6bJpQmCUAg">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_N98CzUZkbkGKY9SsnTIGTQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Impairment of long-lived assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group evaluates the recoverability of its long-lived assets, including fixed assets and intangible assets with finite lives, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be fully recoverable. When these events occur, the Group measures impairment by comparing the carrying amount of the assets to the estimated undiscounted future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected undiscounted cash flows is less than the carrying amount of the assets, the Group recognizes an impairment loss based on the excess of the carrying amount of the assets over their fair value. Fair value is generally determined by discounting the cash flows expected to be generated by the assets, when the market prices are not readily available. The adjusted carrying amount of the assets is the new cost basis and is depreciated over the assets&#x2019; remaining useful lives. Long-lived assets are grouped with other assets and liabilities at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;No impairment loss was recorded for the&#160;years ended December&#160;31, 2019, 2020 and 2021. &lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Narr_0vtp7e-1vk-OTay9jCLPtA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Narr_itxkyZqow0-EDEKSadWlhw"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Narr_ThhnkOqLk0yyfHBJHUtNfA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_Oa6G679AnUaObIs6eEKkbQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Segment reporting&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;In accordance with ASC 280, &lt;/span&gt;&lt;i style="font-weight:normal;"&gt;Segment Reporting&lt;/i&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;, the Group&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;) has been identified as the Chief Executive Officer. The Group&#x2019;s CODM reviews the consolidated results of operations when making decisions about allocating resources and assessing performance of the Group. The Group operates and manages it business as a single segment. No geographical segments are presented as a substantial portion of the Group&#x2019;s long-lived assets are located in the PRC with the exception of certain laboratory and electronic equipment which are located in the U.S.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_4iKpHUxQz0K0qja04gSNCw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Revenue recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At contract inception of collaboration and out-licensing arrangements, the Group analyzes its arrangements to assess whether they are within the scope of ASC 808, &lt;i style="font-style:italic;"&gt;Collaborative Arrangements&lt;/i&gt; (&#x201c;ASC 808&#x201d;) to determine whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards dependent on the commercial success of such activities. For collaboration arrangements within the scope of ASC 808 that contain multiple elements, the Group first determines which elements of the collaboration are deemed to be within the scope of ASC 808 and those that are reflective of a vendor-customer relationship and therefore within the scope of ASC 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt; (&#x201c;ASC 606&#x201d;). For elements of collaboration arrangements that are accounted for pursuant to ASC 808, an appropriate recognition method is determined and applied consistently. Under the criteria of ASC 606, the Group recognizes revenue to depict the transfer of control of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to receive in exchange for those goods or services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group adopted ASC 606 for all periods presented. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i)&#160;identify the contract(s)&#160;with a customer; (ii)&#160;identify the performance obligations in the contract; (iii)&#160;determine the transaction price, including variable consideration, if any; (iv)&#160;allocate the transaction price to the performance obligations in the contract; and (v)&#160;recognize revenue when (or as) the entity satisfies a performance obligation. The Group only applies the five-step model to contracts when it is probable that the entity will collect substantially all the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. The Group reviews the contract to determine which performance obligations are distinct and represent a promise to provide distinct goods or services or a series of distinct goods or services as defined by the standard. The Group recognizes as revenue the amount of the transaction price that is allocated to each performance obligation as and when that performance obligation is satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Licenses of Intellectual Property:&lt;/i&gt; Upfront non-refundable payments for licensing the Group&#x2019;s intellectual property are evaluated to determine if the license is distinct from the other performance obligations identified in the arrangement. For licenses determined to be distinct, the Group recognizes revenues from non-refundable, up-front fees allocated to the license at a point in time, when the transfer of control of the license to the licensee occurs and the licensee is able to use and benefit from the license.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Research and Development Services&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;:  The portion of the transaction price allocated to research and development services performance obligations is deferred and recognized at a point in time as delivery of such services occurs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Milestone Payments:&lt;/i&gt;&lt;span style="white-space:pre-wrap;"&gt;  At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Group evaluates whether the milestones are considered probable of being reached and to the extent that a significant reversal of cumulative revenue would not occur in future periods, estimates the amount to be included in the transaction price using the most likely amount method. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Group re-evaluates the probability of achieving such development milestones and any related constraint, and if necessary, adjust the estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and earnings in the period of adjustment.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Royalties:&lt;/i&gt; For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Group recognizes revenue at the later of (i)&#160;when the related sales occur, or (ii)&#160;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;During the years ended December 31, 2019 and 2020,  &lt;/span&gt;no milestone payments or royalty payments were received. During the year ended December 31, 2021, milestone payment was received, but no royalty payments were received. Substantially all of the Group&#x2019;s revenue has been derived from its out-licensing agreements with respect to licensed products such as DNA sequences, cell lines, etc., and such revenues are recognized when the customer obtains control of the licensed product, which occurs at a point in time, upon delivery to the customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Contract assets and contract liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;When a customer pays consideration before the Group transfers products or services, the Group records its obligation as a contract liability; When the Group satisfies its performance obligations by providing products or services to a customer before the customer pays consideration and before payment is due, the Group recognizes its rights to consideration as a contract asset.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <adag:MilestonePaymentsOrRoyaltyPaymentsReceived
      contextRef="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA"
      decimals="0"
      id="Narr_CdWjr0sLkEiy6ZN1Y4s-0w"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</adag:MilestonePaymentsOrRoyaltyPaymentsReceived>
    <adag:MilestonePaymentsOrRoyaltyPaymentsReceived
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Narr_2Qan5XL4BkmHsqMyCgEdeA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</adag:MilestonePaymentsOrRoyaltyPaymentsReceived>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_U96acXcHFkWIk2r9wr5QIQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Elements of research and development expenses primarily include (1) payroll and other related costs of personnel engaged in research and development activities, (2) costs related to pre-clinical testing of the Group&#x2019;s technologies under development and clinical trials such as payments to contract research organizations (&#x201c;CRO&#x201d;) and contract manufacturing organizations (&#x201c;CMO&#x201d;), investigators and clinical trial sites that conduct the clinical studies; (3) costs to develop the product candidates, including raw materials and supplies, product testing, depreciation and amortization, and facility related expenses, and (4) other research and development expenses. Research and development costs are expensed as incurred when the related research and development services are provided to the Group and the resulting assets, if any, have no alternative future uses. As of December 31, 2020 and 2021, the Group had several ongoing clinical studies in various clinical trial stages. The contracts with CRO and CMO are generally cancellable, with notice, at the Group&#x2019;s option. The Group did not record any accrued expenses related to cancellation of CRO or CMO contracts as of December 31, 2020 or 2021 as the Group did not have any plan to cancel the existing CRO or CMO contracts.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <adag:GovernmentSubsidiesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_VpVCiY76OEeBRx8dxm5kjA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Government subsidies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;Government subsidies primarily consist of financial subsidies received from provincial and local governments for operating a business in their jurisdictions and compliance with specific policies promoted by the governments. The Group&#x2019;s PRC based subsidiary received government subsidies from certain local government. The Group&#x2019;s government subsidies consist of specific subsidies and other subsidies. Specific subsidies are subsidies that the local government has set certain conditions for the subsidies. Other subsidies are the subsidies that the local government has not set any conditions and are not tied to future trends or performance of the Group, receipt of such subsidy income is not contingent upon any further actions or performance of the Group and the amounts do not have to be refunded under any circumstances. These specific subsidies are recorded as other non-current liabilities upon receipt and are recognized as other income when the conditions are met. Other subsidies are recognized as other income upon receipt as further performance by the Group is not required. Government subsidies of US&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$0.7&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; million, US&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$0.8&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; million and US&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;$1.4&lt;/span&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt; million were received and recognized as other income during the years ended December 31, 2019, 2020 and 2021, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;In addition, the Group&#x2019;s Australian subsidiary received research and development tax incentive from the Australian Taxation Office. The tax incentive was recognized as other income upon receipt as the incentive was not dependent upon having a tax liability and further performance by the Group was not required.&lt;/span&gt;&lt;/p&gt;</adag:GovernmentSubsidiesPolicyTextBlock>
    <adag:GovernmentSubsidiesReceived
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="-5"
      id="Narr__nNNAmx0m0mAq0t4k4okgg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">700000</adag:GovernmentSubsidiesReceived>
    <adag:GovernmentSubsidiesReceived
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="-5"
      id="Narr_4efU3033_kOoyLrBezPrrA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">800000</adag:GovernmentSubsidiesReceived>
    <adag:GovernmentSubsidiesReceived
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="-5"
      id="Narr__LcKr96g7kqej5xErtaqYg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1400000</adag:GovernmentSubsidiesReceived>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_SzHS2ykyd0SSU6WSGSgi4Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Leases are classified at the inception date as either a capital lease or an operating lease. The Group assesses a lease to be a capital lease if any of the following conditions exists: a)&#160;ownership is transferred to the lessee by the end of the lease term, b)&#160;there is a bargain purchase option, c)&#160;the lease term is at least 75% of the property&#x2019;s estimated remaining economic life or d)&#160;the present value of the minimum lease payments at the beginning of the lease term is 90% or more of the fair value of the leased property to the lessor at the inception date. A capital lease is accounted for as if there was an acquisition of an asset and an incurrence of an obligation at the inception of the lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;All other leases are accounted for as operating leases wherein rental payments are expensed on a straight-line basis over their respective lease terms. The Group leases certain office space under non-cancelable operating lease agreements. Certain lease agreements contain rent holidays. Rent holidays are considered in determining the straight-line rent expense to be recorded over the lease term. The lease term begins on the date of initial possession of the leased property for purpose of recognizing lease expense on straight-line basis over the term of the lease.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_4YdKsE0cEEmYZMlfYYbU7g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive income (loss)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive income (loss) is defined as the changes in equity of the Group during a period from transactions and other events and circumstances excluding transactions resulting from investments by shareholders and distributions to shareholders. Accumulated other comprehensive income (loss) of the Group includes foreign currency translation adjustments related to the Group and its subsidiaries whose functional currency is not US$.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_Ou3bfY1M5Uy9Dlxe7bS8sQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Income taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group follows the liability method of accounting for income taxes in accordance with ASC&#160;740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt; (&#x201c;ASC&#160;740&#x201d;). Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the period in which the differences are expected to reverse. The Group records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rate is recognized in tax expense in the period that includes the enactment date of the change in tax rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group evaluates its uncertain tax positions using the provisions of ASC 740, which prescribes a recognition threshold that a tax position is required to meet before being recognized in the consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group recognizes in the consolidated financial statements the benefit of a tax position which is &#x201c;more likely than not&#x201d; to be sustained under examination based solely on the technical merits of the position assuming a review by tax authorities having all relevant information. Tax positions that meet the recognition threshold are measured using a cumulative probability approach, at the largest amount of tax benefit that has a greater than fifty&#160;percent likelihood of being realized upon settlement. It is the Group&#x2019;s policy to recognize interest and penalties related to unrecognized tax benefits, if any, as a component of income tax expense.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_lVWOc6iXvE68UjEVfq1AwQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Borrowings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the consolidated statements of comprehensive loss over the period of the borrowings using the effective interest method.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_MuMe41vhNE2IFHmTIfxD2Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Share-based compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company grants restricted shares and stock options to eligible employees and nonemployees and accounts for share-based compensation in accordance with ASC 718, &lt;i style="font-style:italic;"&gt;Compensation-Stock Compensation&lt;/i&gt;. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Share-based compensation awards are measured at the grant date fair value of the awards and recognized as expenses a) immediately at the grant date if no vesting conditions are required; b) for share-based awards granted with only service conditions, using the straight-line method over the vesting period; or c) for share-based awards granted with service conditions and performance conditions, using the graded vesting method over the vesting period if and when the Company concludes that it is probable that the performance conditions will be achieved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A change in any of the terms or conditions of share-based awards is accounted for as a modification of the awards. The Group calculates incremental compensation expense of a modification as the excess of the fair value of the modified awards over the fair value of the original awards immediately before its terms are modified at the modification date. For vested awards, the Group recognizes incremental compensation cost in the period when the modification occurs. For awards not being fully vested, the Group recognizes the sum of the incremental compensation expense and the remaining unrecognized compensation expense for the original awards over the remaining requisite service period after modification.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_dvUXUIJvTEmHQx7MFK444w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Net loss per share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;In accordance with ASC 260, &lt;/span&gt;&lt;i style="font-weight:normal;"&gt;Earnings Per Share&lt;/i&gt;&lt;span style="font-style:normal;font-weight:normal;"&gt;, basic net loss per share is computed by dividing net loss attributable to ordinary shareholders by the weighted average number of unrestricted ordinary shares outstanding during the year using the two-class method. Under the two-class method, net loss is allocated between ordinary shares and other participating securities based on dividends declared (or accumulated) and participating rights in undistributed earnings as if all the earnings for the reporting period had been distributed. The Company&#x2019;s convertible redeemable preferred shares were participating securities because they were entitled to receive dividends or distributions on an as converted basis. Diluted net loss per share is calculated by dividing net loss attributable to ordinary shareholders, as adjusted for the effect of dilutive ordinary equivalent shares, if any, by the weighted average number of ordinary and dilutive ordinary equivalent shares outstanding during the period. Ordinary equivalent shares include ordinary shares issuable upon the conversion of the convertible redeemable preferred shares using the if-converted method, and ordinary shares issuable upon the exercise of share options, using the treasury stock method. Ordinary share equivalents are excluded from the computation of diluted earnings per share if their effects are anti-dilutive. For the periods presented herein, the computation of basic net loss per share using the two-class method is not applicable as the Group is in a net loss position and the participating securities do not have contractual rights and obligations to share in the losses of the Group.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <adag:EmployeeDefinedContributionPlanPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_swrszsF3f06k4dkHsVFVtQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Employee defined contribution plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As stipulated by the regulations of the PRC, full-time employees of the Group are entitled to staff welfare benefits including medical care, welfare subsidies, unemployment insurance and pension benefits through a PRC government-mandated multi-employer defined contribution plan. The Group is required to accrue for these benefits based on certain percentages of the qualified employees&#x2019; salaries. The Group is required to make contributions to the plans out of the amounts accrued. The PRC government is responsible for the medical benefits and the pension liability to be paid to these employees and the Group&#x2019;s obligations are limited to the amounts contributed. The Group has no further payment obligations once the contributions have been paid. The Group recorded employee benefit expenses of US$1,145,165 , US$622,377 and US$2,223,493 for the&#160;years ended December&#160;31, 2019 , 2020 and 2021, respectively.&lt;/p&gt;</adag:EmployeeDefinedContributionPlanPolicyTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Narr_sRfKc4Kz6UKtVIezySvoFw"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1145165</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Narr_m3C3iyb7Mk25wjirCGWMRw"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">622377</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Narr_nyT_RgkftUi_Swo78V5qXA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2223493</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_wwBm5Un5VEC5j6tq_uMnLw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of risks&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of credit risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2020 and 2021, the amount of cash and cash equivalents of US$3,424,456 and US$3,650,474 respectively, were held at major financial institutions located in Mainland China, and US$71,726,542 and US$170,740,769,respectively, were deposited with major financial institutions located outside of Mainland China. Management believes that these financial institutions are of high credit quality and continually monitors the credit worthiness of these financial institutions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Accounts receivable is typically unsecured and denominated in US$ and is derived from revenues earned from customers. The Group manages credit risk of accounts receivable through ongoing monitoring of the outstanding balances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of suppliers&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A significant portion of the Group&#x2019;s research and development services were purchased from one supplier group, who collectively accounted for 23.13%,21.51% and 18.45%of the Group&#x2019;s total research and development services purchases for the&#160;years ended December&#160;31, 2019, 2020 and 2021, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Business and economic risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group believes that changes in any of the following areas could have a material adverse effect on the Group&#x2019;s future consolidated financial position, results of operations or cash flows: changes in the overall demand for services; competitive pressures due to new entrants; advances and new trends in new technologies and industry standards; changes in certain strategic relationships; regulatory considerations and risks associated with the Group&#x2019;s ability to attract employees necessary to support its growth. The Group&#x2019;s operations could also be adversely affected by significant political, regulatory, economic and social uncertainties in the PRC.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Foreign currency exchange rate risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A significant portion of the Group&#x2019;s businesses are transacted in RMB, which is not a freely convertible currency. On January&#160;1, 1994, the PRC government abolished the dual rate system and introduced a single rate of exchange as quoted daily by the PBOC. However, the unification of the exchange rates does not imply that the RMB may be readily convertible into US$ or other foreign currencies. All foreign exchange transactions continue to take place either through the PBOC or other banks authorized to buy and sell foreign currencies at the exchange rates quoted by the PBOC. Approval of foreign currency payments by the PBOC or other institutions requires submitting a payment application form together with suppliers&#x2019; invoices, shipping documents and signed contracts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From July&#160;21, 2005, the RMB is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. For U.S. dollar against RMB, there was depreciation of approximately 6.5% and 2.29% in the&#160;years ended December&#160;31, 2020 and 2021, respectively. It is difficult to predict how market forces or PRC or U.S. government policy may impact the exchange rate between the RMB and the U.S. dollar in the future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The functional currency and the reporting currency of the Company are the US$. However, the Group incurs portions of our expenses, and derives revenues, in currencies other than US$, in particular, the RMB. Any significant fluctuation of the valuation of RMB may materially affect the Group&#x2019;s cash flows, expenses, losses and financial position, and the value of any dividends payable on the American Depositary Shares in US$.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2020_srt_StatementGeographicalAxis_adag_MainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_kj-fSey9EEyEtxiGoEoEpg"
      decimals="0"
      id="Narr_s4R4__c6-UuJmPmldFdMhQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3424456</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_adag_MainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_a3KAemeQF0yabn5RGbhXiA"
      decimals="0"
      id="Narr_jXIrJnsDeUaOsbryI8ySHg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3650474</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2020_srt_StatementGeographicalAxis_adag_OutsideMainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_yZFC6h4cwEK-fa4C8KeTyg"
      decimals="0"
      id="Narr_FW9ldxb1006gwOoWBWLdmQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">71726542</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_adag_OutsideMainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_EFliqC7rp0Sx41tQSgTPRA"
      decimals="0"
      id="Narr_dGtxWvLuO0CbOCfrqDmxvA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">170740769</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <adag:NumberOfMajorSupplier
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_QrdSnJigEEC83xAI-BxP_w"
      decimals="INF"
      id="Narr_C0vERAObdEq36TypvQp0Gg"
      unitRef="Unit_Standard_item_VDVAwvxnO0aSdoyDMbjpLA">1</adag:NumberOfMajorSupplier>
    <adag:NumberOfMajorSupplier
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_U2Wz9tRC_E-e-VNBsazHMQ"
      decimals="INF"
      id="Narr_nTTSG1nesEub-oBRyO02DQ"
      unitRef="Unit_Standard_item_VDVAwvxnO0aSdoyDMbjpLA">1</adag:NumberOfMajorSupplier>
    <adag:NumberOfMajorSupplier
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_nR1gjPUSp0uEhhqDafgCZA"
      decimals="INF"
      id="Narr_yqXt06CNokG_q69IoKjWNQ"
      unitRef="Unit_Standard_item_VDVAwvxnO0aSdoyDMbjpLA">1</adag:NumberOfMajorSupplier>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2019_To_12_31_2019_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_ZYOjK2vU90O3dGqnw4FeEQ"
      decimals="4"
      id="Narr_MUIxHg1v5EGeo-ifbTEbSw"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.2313</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2020_To_12_31_2020_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_SxQdUgI9Z06HufSkFzPTTg"
      decimals="4"
      id="Narr_0C2wZVQ1uU6lIXfEEexG5g"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.2151</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_1_1_2021_To_12_31_2021_adag_ConcentrationRiskSuppliersAxis_adag_OneSupplierMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_CostOfGoodsProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_SupplierConcentrationRiskMember_LqlKepEaPEyADAUMj0EidA"
      decimals="4"
      id="Narr_VRx1rIR0LEO_P5rDaci6wg"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.1845</us-gaap:ConcentrationRiskPercentage1>
    <adag:PercentageOfDepreciationOfForeignCurrency
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="3"
      id="Narr_xc6uqpbvf0-CofQKt-bSQg"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.065</adag:PercentageOfDepreciationOfForeignCurrency>
    <adag:PercentageOfDepreciationOfForeignCurrency
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="4"
      id="Narr_nyAth4pxC0iDYYKjHOwZ-g"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.0229</adag:PercentageOfDepreciationOfForeignCurrency>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_4GUB_L55REGZWzIg19aXlw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Recently issued accounting pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group is an emerging growth company (&#x201c;EGC&#x201d;) as defined by the Jumpstart Our Business Startups Act (&#x201c;JOBS Act&#x201d;). The JOBS Act provides that an EGC can take advantage of extended transition periods for complying with new or revised accounting standards. This allows an EGC to delay adoption of certain accounting standards until those standards would otherwise apply to private companies. The Group elected to take advantage of the extended transition periods. However, this election will not apply should the Group cease to be classified as an EGC.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2016-02 (&#x201c;ASU 2016-02&#x201d;), &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt; (Topic 842), which modifies lease accounting for lessees to increase transparency and comparability by recording lease assets and liabilities for operating leases and disclosing key information about leasing arrangements. In July 2018, FASB issued ASU No. 2018-10 (&#x201c;ASU 2018-10&#x201d;), &lt;i style="font-style:italic;"&gt;Codification Improvements to Topic 842, Leases&lt;/i&gt;, which clarifies certain aspects of the guidance issued in ASU 2016-02; and ASU No. 2018-11 (&#x201c;ASU 2018-11&#x201d;), &lt;i style="font-style:italic;"&gt;Leases (Topic 842): Targeted Improvements&lt;/i&gt;, which provides entities with an additional (and optional) transition method to adopt the new leases standard. Under this new transition method, an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Consequently, an entity&#x2019;s reporting for the comparative periods presented in the financial statements in which it adopts the new leases standard will continue to be in accordance with current GAAP (Topic 840, Leases). Further, FASB issued ASU No. 2020-05 (&#x201c;ASU 2020 05&#x201d;), Revenue from Contracts with Customers (Topic 606) and Leases (Topic 842): Effective Dates for Certain Entities, which extends the adoption date for certain entities. For the Group, the updated guidance is effective for fiscal years beginning after December 15, 2021 and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. The Group does not plan to early adopt the new lease standards and the Group expects that applying the ASU 2016-02 would materially increase the assets and liabilities due to the recognition of right-of-use assets and lease liabilities on its consolidated balance sheets, with an immaterial impact on its consolidated statements of comprehensive loss and consolidated statements of cash flows.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2016, FASB issued ASU No. 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt; (&#x201c;ASU 2016-13&#x201d;). ASU 2016-13 is intended to improve financial reporting by requiring timelier recording of credit losses on loans and other financial instruments held by financial institutions and other organizations. This ASU requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This ASU requires enhanced disclosures to help investors and other financial statement users better understand significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of the Group&#x2019;s portfolio. These disclosures include qualitative and quantitative requirements that provide additional information about the amounts recorded in the financial statements. In November 2019, FASB issued ASU 2019-10, which extends the adoption date for certain registrants. The amendments in ASU 2016-13 are effective for fiscal years beginning after December 15, 2022, including interim periods within fiscal years beginning after December 15, 2023. The Group does not plan to early adopt ASU 2016-13 and is currently in the process of evaluating the impact of adoption of this guidance on its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2018, FASB issued ASU 2018-18, &lt;i style="font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/i&gt;. This update clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC 606 when the counterparty is a customer and precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. The update is effective in fiscal years beginning after December 15, 2021, and interim periods therein, and early adoption is permitted for entities that have adopted ASC 606. This guidance should be applied retrospectively to the date of initial application of Topic 606. The Group elected to early adopt this ASU and applied this guidance retrospectively to all periods presented. The impact of this ASU to the consolidated financial statements is immaterial.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December 2019, FASB issued ASU 2019-12, &lt;i style="font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/i&gt;. This update simplifies the accounting for income taxes as part of FASB&#x2019;s overall initiative to reduce complexity in accounting standards. The amendments include removal of certain exceptions to the general principles of ASC 740, &lt;i style="font-style:italic;"&gt;Income Taxes&lt;/i&gt;, and simplification in several other areas such as accounting for a franchise tax (or similar tax) that is partially based on income. The update is effective in fiscal years beginning after December 15, 2022, and interim periods therein, and early adoption is permitted. Certain amendments in this update should be applied retrospectively or modified retrospectively, all other amendments should be applied prospectively. The Group does not plan to early adopt ASU 2019-12 and is currently evaluating the impact on its financial statements of adopting this guidance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;In August 2020, FASB issued ASU 2020-06, &lt;i style="font-style:italic;"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity&lt;/i&gt;, which simplifies the accounting for convertible instruments by removing certain separation models in Subtopic 470-20, &lt;i style="font-style:italic;"&gt;Debt&#x2014;Debt with Conversion and Other Options&lt;/i&gt;, for convertible instruments and also increases information transparency by making disclosure amendments. The standard is effective for private companies for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact of this accounting standard update on its condensed consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_UJHiz9_H8EOMlKTsNRbdsQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;3. ACCOUNTS RECEIVABLE, NET&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Allowance for doubtful accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_MQuZTyyoik-eAsK2kBDBNw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Accounts receivable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Allowance for doubtful accounts&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGross
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_HgghiBGhBUe5C2AoGddZnw_5_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3000000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableNet
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_7HQkIQUD7E6c7SkYWg8mMA_7_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3000000</us-gaap:AccountsReceivableNet>
    <adag:PrepaidExpenseAndOtherAssetsCurrentTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_r1PY6hEHOki0QbcZWP4l3A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;4. PREPAYMENTS AND OTHER CURRENT ASSETS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Prepayments and other current assets consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepayments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,907,781&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,562,177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Deposits(a)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,646,446&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,873,843&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Others &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 259,757&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 619,901&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,813,984&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,055,921&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Note (a): The deposits represented the amounts that the Group paid to its CRO vendors for various outsourced research and development programs according to the terms of respective CRO agreements. The Group expects to recover the deposits if the programs fail or the agreements are cancelled.&lt;/span&gt;&lt;/p&gt;</adag:PrepaidExpenseAndOtherAssetsCurrentTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_Gv9TmZQQQkuLNLKFpQRVAA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepayments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,907,781&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,562,177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Deposits(a)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,646,446&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,873,843&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Others &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 259,757&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 619,901&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,813,984&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,055,921&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;Note (a): The deposits represented the amounts that the Group paid to its CRO vendors for various outsourced research and development programs according to the terms of respective CRO agreements. The Group expects to recover the deposits if the programs fail or the agreements are cancelled.&lt;/span&gt;&lt;/p&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_d6ADvgyvZEW8qA3zmcdrhA_4_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1907781</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_1QSRmoVnbEyRtG5wJlfSPA_4_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1562177</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_xAB8Ll3Ah0OFP5znwq6BFg_5_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1646446</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_U6nXyQFzkkK57gz6HvNByw_5_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1873843</us-gaap:DepositsAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_jLnC-4g5Q0miMyiT-29-sA_6_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">259757</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_oi-5we7M00utAzESZ6dqKA_6_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">619901</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_eICPVN7lV0KpzM8tnlwShQ_7_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3813984</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_4wbwrxsFX06tcS86JkqTbg_7_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">4055921</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_Jxpt-glEGk-H8Y_rKCnf-Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;5. PROPERTY, EQUIPMENT AND SOFTWARE, NET&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property, equipment and software consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Machinery and laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,150,822&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,252,399&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 915,208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,152,743&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Electronic equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 962,684&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,863,956&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and tools&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 106,492&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81,467&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vehicles&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 126,764&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87,680&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 95,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 371,636&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total property, equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,357,556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,809,881&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,290,431)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,322,264)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net book value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,067,125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,487,617&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Depreciation and amortization expenses recognized for the&#160;years ended December&#160;31, 2019, 2020 and 2021 were US$816,686 , US$858,408, and US$1,125,032 respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_XtczcN3wEka9PNq0a5dftA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Machinery and laboratory equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,150,822&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,252,399&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 915,208&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,152,743&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Electronic equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 962,684&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,863,956&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Furniture and tools&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 106,492&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 81,467&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vehicles&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 126,764&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 87,680&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 95,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 371,636&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total property, equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,357,556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,809,881&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (4,290,431)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,322,264)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net book value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,067,125&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,487,617&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_xjhR4xY8gkilBkiNX6jw5w"
      decimals="0"
      id="Tc_Dh-Tpe53IkSQvYiw_7T57g_4_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">4150822</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_0Fkj5p3dOEG5xJSp6cquuA"
      decimals="0"
      id="Tc_5igxS47bd0KBXcdGzpayvg_4_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5252399</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_c4u5F8308kqb6Yb80ib06w"
      decimals="0"
      id="Tc_vrGHoIQvfEC4ZZDrSOQQpg_5_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">915208</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_TXr2Um0aJEuPO1zHVf0dgg"
      decimals="0"
      id="Tc_HaslUZqGzEyYNQPqOV8tcQ_5_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1152743</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_Y9nw88vBK0en70RiAB4NXg"
      decimals="0"
      id="Tc_gdCHoFkOPUmHsRkzJisHIg_6_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">962684</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_adag_ElectronicEquipmentMember_EcLyGd1RtEKchc8-Nwr_uQ"
      decimals="0"
      id="Tc_6jdIEyvuak6hbKYt5xEFyA_6_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1863956</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_ugbL_thGJ0y97MV05rKCuA"
      decimals="0"
      id="Tc_Zu5aoGz4JkOzO2K5PhyVeQ_7_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">106492</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_-OER4mKuwE6orMCLglM2Mw"
      decimals="0"
      id="Tc_gP6oFg1mwk2VIIj-ULxGAw_7_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">81467</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_OkKAU_FVpUiB6Qf9qvp3MQ"
      decimals="0"
      id="Tc_b-AOCxNJ_0-UVGfuv9NDZg_8_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">126764</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_Ii31JlQF6EyGi8FubMjm2w"
      decimals="0"
      id="Tc_qCBqQzZ8kUarXBliKqzO9g_8_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">87680</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_rhq53MJUbUaZODEvfgDerw"
      decimals="0"
      id="Tc_4-q1yABYHki2ybEBg6qVhQ_9_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">95586</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_ciXSaRCCIUShj4RIB8kXvQ"
      decimals="0"
      id="Tc_u66AUhSM_EaPCLr6of1MxQ_9_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">371636</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_MJF0isCUQ06oOf6lnV8myA_10_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">6357556</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_jx7MMTmgTEeCEUo9qAvGYg_10_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">8809881</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_w3pfHcR7HE2Zu-XvaUhnig_11_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">4290431</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_zEaXUIBdU0iTck5UZpt2nw_11_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5322264</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_dCCXg6vwVUK1LbPZfA_3wQ_12_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2067125</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_lH0ntVdIV0WApHbkfeCErA_12_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3487617</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Narr_5uw5dmZNzkGv7Qb4_71owQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">816686</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Narr__yXW4U4l_02iN72rmJWSkg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">858408</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Narr_sXIbdfzU70ycrA6YzZ54xQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1125032</us-gaap:DepreciationDepletionAndAmortization>
    <adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_yhd7rtwfY0OTH7u1oNt3Mw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;6. ACCRUALS AND OTHER CURRENT LIABILITIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Accrued liabilities and other current liabilities consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional service fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,459,430&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 935,434&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,390,025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,229,794&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Utility and maintenance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 459&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,685&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Other taxes and surcharge&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63,919&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62,270&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 145,664&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 143,060&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,059,497&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,379,243&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock>
    <adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_WUqprV3vok2A4Ggh06PdsQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Professional service fees&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,459,430&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 935,434&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,390,025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,229,794&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Utility and maintenance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 459&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,685&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Other taxes and surcharge&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 63,919&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 62,270&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 145,664&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 143,060&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,059,497&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,379,243&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_xN6VheG7_kWDWCFCxJK73w_4_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3459430</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_BRCYFldNK06Zbh0qBQpPMQ_4_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">935434</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_fjsm8RJHr0iQE5O6MJqibQ_5_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2390025</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_6K68R9epBky-fxGVSOGrag_5_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3229794</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedUtilitiesCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_46h6VLtnukO5QF-vMuCszA_6_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">459</us-gaap:AccruedUtilitiesCurrent>
    <us-gaap:AccruedUtilitiesCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_V9yR3qjWTkSt-EwE2j1nVA_6_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">8685</us-gaap:AccruedUtilitiesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_FxKq1ZLHIEyh5KOjMex4FA_7_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">63919</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_DLF-dYC2lUeKBQ1_kgtgmQ_7_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">62270</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_ezIaDjlG_Uuv6wm6_unNcw_8_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">145664</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_TVWcH8e5jUqeuDGTXVuHUA_8_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">143060</us-gaap:OtherLiabilitiesCurrent>
    <adag:AccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_5SJ35btHp0SFg52xVvX-Wg_9_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">6059497</adag:AccruedLiabilitiesAndOtherCurrentLiabilities>
    <adag:AccruedLiabilitiesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_KIFalLqqDEiCHSM3qUlV3g_9_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">4379243</adag:AccruedLiabilitiesAndOtherCurrentLiabilities>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_W46Gbhj4Y0ubofzufFcT5g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt;"&gt;7. BORROWINGS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Short-term borrowings:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"&gt;Bank loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,831,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,121,226&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"&gt;Current portion of long-term borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,183,926&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,376,319&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,015,402&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,497,545&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term borrowings:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"&gt;Bank loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,965,563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,991,829&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Total non-current borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,965,563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,991,829&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total borrowings&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,980,965&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,489,374&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Short-term borrowings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In September&#160;2019, the Group borrowed a loan with amount of RMB5,000,000 (equivalent to approximately US$766,295) from Bank of Ningbo&#160;Co.,&#160;Ltd. for a term of one year at the interest rate of 4.35% per annum. The borrowing was repaid in September 2020.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2020, the Group borrowed a loan with the amount of RMB10,000,000 (equivalent to approximately US$1,532,591) from Agricultural Bank of China Limited for a term of one year at the interest rate of 4.2% per annum. The borrowing was repaid in June 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In September 2020, the Group borrowed a loan with the amount of RMB5,000,000 (equivalent to approximately US$766,295) from Bank of Ningbo Co., Ltd. for a term of one year at the interest rate of 4.2% per annum. The borrowing was repaid in September 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2020, the Group borrowed a loan with the amount of RMB5,000,000 (equivalent to approximately US$770,962) from China Merchants Bank Co., Ltd. for a term of one year at the interest rate of 4.1% per annum. The borrowing was repaid in November 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2020, the Group borrowed another loan with the amount of RMB5,000,000 (equivalent to approximately US$770,962) from China Merchants Bank Co., Ltd. for a term of one year at the interest rate of 4.1% per annum. The borrowing was also repaid in November 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June 2021, the Group borrowed a loan with the amount of RMB9,900,000 (equivalent to approximately US$1,552,771) from Agricultural Bank of China Limited for a term of one year at the interest rate of 4.05% per annum.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In August 2021, the Group borrowed another loan with the amount of RMB10,000,000 (equivalent to approximately US$1,568,455) from Agricultural Bank of China Limited for a term of one year at the interest rate of 4.05% per annum.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Long-term borrowings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February&#160;2019, the Group borrowed a loan with the amount of RMB7,500,000 (equivalent to approximately US$1,176,342) from Shanghai Pudong Development Bank&#160;Co.,&#160;Ltd. for a term of three years at the interest rate of 5.46% per annum. The Group repaid RMB375,000 (equivalent to approximately US$58,817) in 2019, RMB1,250,000 (equivalent to approximately US$196,057) in 2020,and RMB3,375,000 (equivalent to approximately US$529,354) in 2021. As of December 31, 2020 and 2021, RMB3,375,000 (equivalent to approximately US$529,354) and RMB2,500,000 (equivalent to approximately US$392,114) repayable within twelve&#160;months for this agreement were classified as &#x201c;Current portion of long-term borrowing&#x201d; on the consolidated balance sheets, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In June&#160;2019, the Group borrowed a loan with the amount of RMB6,000,000 (equivalent to approximately US$941,074) from Shanghai Pudong Development Bank&#160;Co.,&#160;Ltd. for a term of three years at the interest rate of 5.23% per annum. The Group repaid RMB300,000 (equivalent to approximately US$47,054) in 2019, RMB1,000,000 (equivalent to approximately US$156,846) in 2020, and RMB2,700,000 (equivalent to approximately US$423,483) in 2021. As of December 31, 2020 and 2021, RMB2,700,000 (equivalent to approximately US$423,483) and RMB2,000,000 (equivalent to approximately US$313,691) repayable within twelve&#160;months for this agreement were classified as &#x201c;Current portion of long-term borrowing&#x201d; on the consolidated balance sheets, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In September 2020, the Group borrowed a loan with the amount of RMB16,500,000 (equivalent to approximately US$2,587,952) from Shanghai Pudong Development Bank Co., Ltd. for a term of three years at the interest rate of 4.27% per annum.The Group repaid RMB1,650,000 (equivalent to approximately US$258,796) in 2021. As of December 31, 2020 and 2021, RMB1,650,000 (equivalent to approximately US$258,796) and RMB3,850,000 (equivalent to approximately US$603,855) repayable within twelve months for this agreement were classified as &#x201c;Current portion of long-term borrowing&#x201d; on the consolidated balance sheets, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In September 2021, the Group borrowed a loan with the amount of RMB8,500,000 (equivalent to approximately US$1,333,186) from Shanghai Pudong Development Bank Co., Ltd. for a term of three years at the interest rate of 4.05% per annum. As of December 31, 2021, RMB425,000 (equivalent to approximately US$66,659&lt;span style="white-space:pre-wrap;"&gt;)  repayable within twelve months for this agreement was classified as &#x201c;Current portion of long-term borrowing&#x201d; on the consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2021 and 2020, none of the Group&#x2019;s borrowings were collateralized or had covenants in the respective loan agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Future maturities of short-term borrowings and long-term borrowings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Future principal maturities of short-term borrowings and long-term borrowings as of December&#160;31, 2020 and 2021 were as followings:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,015,402&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,279,713&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,497,545&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,685,850&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,858,619&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,133,210&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:77.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,980,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,489,374&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_IiKAPEkxOkqUN3_yzOqNbQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Short-term borrowings:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"&gt;Bank loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,831,476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,121,226&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"&gt;Current portion of long-term borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,183,926&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,376,319&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,015,402&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,497,545&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Non-Current&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term borrowings:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 12pt;"&gt;Bank loans&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,965,563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,991,829&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Total non-current borrowings&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,965,563&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,991,829&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total borrowings&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,980,965&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; 7,489,374&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_fdX7clwaX06oBUJQ1uNMeA_6_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3831476</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:ShortTermBankLoansAndNotesPayable
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc__z896qAq9kaaowkpzbCuNA_6_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3121226</us-gaap:ShortTermBankLoansAndNotesPayable>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_EU5dSo92TUuyKXB1JSTS5Q_7_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1183926</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_zx_jlOd14UmKnAf5lJgV8g_7_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1376319</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_p4ozhb5osUiaHbftGx1Vcw_8_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5015402</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_txkoNnFrkEyeO68a3IofGw_8_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">4497545</us-gaap:DebtCurrent>
    <us-gaap:LongTermLoansFromBank
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_wTH-zJA3jUqenYt0O4qdnw_11_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2965563</us-gaap:LongTermLoansFromBank>
    <us-gaap:LongTermLoansFromBank
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_BM7tn2pvzUqlyoAzc3g-pA_11_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2991829</us-gaap:LongTermLoansFromBank>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_aXRd9wUFbEiMDRoqLKLbLg_12_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2965563</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_dbVqGJu93k6HkfPp-aQXfA_12_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2991829</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_aopTY-UKXk-ChCgbwl9wAQ_13_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">7980965</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_SX5QKl7bbUm0o7UvlAW3rA_13_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">7489374</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_aRG-u8wGNE-CSsqku0pR0g"
      decimals="0"
      id="Narr_0_pdgj27dUKCovPYLtS9rw"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_aRG-u8wGNE-CSsqku0pR0g"
      decimals="0"
      id="Narr_wlv7BRVyf0S4K-eh-C1PBg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">766295</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_9_1_2019_To_9_30_2019_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_Ruff_uK5bECwmUs88WOIvw"
      id="Narr_n9sZDOD9XE61EK28h_D1JA">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2019_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_aRG-u8wGNE-CSsqku0pR0g"
      decimals="4"
      id="Narr_FB6LFKxZO0SLP343G8t3qw"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.0435</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_oYuYrvTHKU2WUWilDTYWFA"
      decimals="0"
      id="Narr_N-HLg0JdPkCaFdnqwDB0qg"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_oYuYrvTHKU2WUWilDTYWFA"
      decimals="0"
      id="Narr__v5M-3X1r0GLrLEcNyRsLg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1532591</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_6_1_2020_To_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_XCA1IgwsJ0i02_dGhfX8Ww"
      id="Narr_HmM3-JPzYUy0xDYX_DUeBg">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_6_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_oYuYrvTHKU2WUWilDTYWFA"
      decimals="3"
      id="Narr_4Osw5gtF2U2D_DUKqs1ssw"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.042</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_xK5464GvIU2G2CMxw-2yyg"
      decimals="0"
      id="Narr_0LUXq1KtO02plwJZDOxNQg"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_xK5464GvIU2G2CMxw-2yyg"
      decimals="0"
      id="Narr_WmubICvlcky63YLvaFfAIA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">766295</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_9_1_2020_To_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_c2z9l55OS0-09kT4Xr8EBA"
      id="Narr_F6TMpVo0UkmNsJmnw0uPhg">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_xK5464GvIU2G2CMxw-2yyg"
      decimals="3"
      id="Narr_i3M6TF8znE2m8_dRLFlZ_w"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.042</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_NfuX6XNrY0y0YKE8g2SAHQ"
      decimals="0"
      id="Narr_4pIMv9WfXEyBl8Ym16QV5g"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_NfuX6XNrY0y0YKE8g2SAHQ"
      decimals="0"
      id="Narr_AcNpJqizekqy2Xxw1yJUlg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">770962</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_yREvdQEbf0aifJQLSacj_A"
      id="Narr_q6PyS3yMWk6q7uuZsrIwcg">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdMember_NfuX6XNrY0y0YKE8g2SAHQ"
      decimals="3"
      id="Narr_kLoYct7_H0ei8HGLyGgWeA"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.041</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_n4OTuF0LqkKjcG_8uSdSgg"
      decimals="0"
      id="Narr_nANAF0e0y0WYbgN1tGXOwg"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_n4OTuF0LqkKjcG_8uSdSgg"
      decimals="0"
      id="Narr_NMUGdQ_1OEm5dXJ2eHI0WQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">770962</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_11_1_2020_To_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_6cK__TDe2k2D6upUdm_BkA"
      id="Narr_ZHgN9B_1R02zfWsA1E6cmg">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_11_30_2020_us-gaap_DebtInstrumentAxis_adag_ChinaMerchantsBankCo.LtdLoanTwoMember_n4OTuF0LqkKjcG_8uSdSgg"
      decimals="3"
      id="Narr_LNeqyF0XiU2VUsjUS4n5nA"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.041</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_7zaPIqJMgEOMGotoMZUnYg"
      decimals="0"
      id="Narr_sxNLP46Fnk2gdrpuUB9dSw"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">9900000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_7zaPIqJMgEOMGotoMZUnYg"
      decimals="0"
      id="Narr_QxJfTAKKG0qzgxmcUOVzeA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1552771</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_6_1_2021_To_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_xPZSxb0_rEyiXfgBq8UngA"
      id="Narr_BUg64hAmSU6lEcInEENkVg">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_6_30_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_7zaPIqJMgEOMGotoMZUnYg"
      decimals="4"
      id="Narr_2U5LwJ1-yk-YuoPORGx77g"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember__Yp6JfBX00e2bWTEBjp7og"
      decimals="0"
      id="Narr_HTSrXFMho0yZiwUZKljr3g"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">10000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember__Yp6JfBX00e2bWTEBjp7og"
      decimals="0"
      id="Narr_r4stAH5f9E2zkvwROwxSVQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1568455</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentTerm
      contextRef="Duration_8_1_2021_To_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember_LFa5nidGXk2zyr81bhmV-w"
      id="Narr_Y4ugwCmg_EaO-9SoYoq4LA">P1Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_8_31_2021_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember__Yp6JfBX00e2bWTEBjp7og"
      decimals="4"
      id="Narr_0ufdUOjkBESagR5NAQ443Q"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_8XLbm_NuOEaOfNq0iiQ4Uw"
      decimals="0"
      id="Narr_GEMmQsRZDkqRKwfFZiCapg"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">7500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_8XLbm_NuOEaOfNq0iiQ4Uw"
      decimals="0"
      id="Narr_7zZhzEGk8k2haBbSrnxUQg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1176342</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtTerm
      contextRef="As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_8XLbm_NuOEaOfNq0iiQ4Uw"
      id="Narr_Bk2Eefd7iUOD4rrqabsOoA">P3Y</us-gaap:LongTermDebtTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_8XLbm_NuOEaOfNq0iiQ4Uw"
      decimals="4"
      id="Narr_udYUvOxXXEO80ftbVuE7yg"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.0546</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_Gvzpm_m3g0S200Y-2xFrbg"
      decimals="0"
      id="Narr_xB22J0v1-0-dLljfF3yzEg"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">375000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_Gvzpm_m3g0S200Y-2xFrbg"
      decimals="0"
      id="Narr_jE498paF-kG17pL4x1UEgQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">58817</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_JVqltsC74kiTWg82LEi0EQ"
      decimals="0"
      id="Narr_OgKdw9r-SUSwMRKckOwwJQ"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">1250000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_JVqltsC74kiTWg82LEi0EQ"
      decimals="0"
      id="Narr__UcI_4BaMkWu6HivsnGc-g"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">196057</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_ufKZJPNy5EaknPuOgGRVKA"
      decimals="0"
      id="Narr_AvLDjGeRh0CAn9qIRexctw"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">3375000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_ufKZJPNy5EaknPuOgGRVKA"
      decimals="0"
      id="Narr_NWLruGX6RkGl6DB_o041Ag"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">529354</us-gaap:RepaymentsOfDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_nqUKaiveBk6aWC7ifhDHyw"
      decimals="0"
      id="Narr_Dp7G8xDmeEKG4T0ab2ItbQ"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">3375000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_nqUKaiveBk6aWC7ifhDHyw"
      decimals="0"
      id="Narr_zhIQyHJCtUy6e83OYPxqKA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">529354</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_c5z9GXzV4UWW7jLt1LL9xA"
      decimals="0"
      id="Narr_crjN0sCOeUGZxot4AZZGfg"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">2500000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_c5z9GXzV4UWW7jLt1LL9xA"
      decimals="0"
      id="Narr_P6ei9MQuwUqqBkboqX7KRg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">392114</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_6_30_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_tmSdxQVjfUKJf2DV_oxA0A"
      decimals="0"
      id="Narr_ElvNgjKp10udccy7Etf6NQ"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">6000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_6_30_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_tmSdxQVjfUKJf2DV_oxA0A"
      decimals="0"
      id="Narr_IyjeYEbCUkSmAubW85BGAg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">941074</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtTerm
      contextRef="As_Of_6_30_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_tmSdxQVjfUKJf2DV_oxA0A"
      id="Narr_0zkLW4iZF0ifHKnojR3rHA">P3Y</us-gaap:LongTermDebtTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_6_30_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_tmSdxQVjfUKJf2DV_oxA0A"
      decimals="4"
      id="Narr_Ey1cii_V-EKrNDDygfiuCg"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.0523</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_8iysXIGeCkikS5CDa_J0Ag"
      decimals="0"
      id="Narr_q4BFhQdx20aDdggL6ub8og"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">300000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_8iysXIGeCkikS5CDa_J0Ag"
      decimals="0"
      id="Narr_4lVuZtOXHk2WLYf4iTEnMQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">47054</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_He6IyXPrkkSO8ChXsSJeiA"
      decimals="0"
      id="Narr_4u6cCX6LQkSzuj1lMvRQmw"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">1000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_12_1_2020_To_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_He6IyXPrkkSO8ChXsSJeiA"
      decimals="0"
      id="Narr_0T-td2nJqEOPtCDHtPm1KA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">156846</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_vfbRj1jR1UChcP5_UNgiYQ"
      decimals="0"
      id="Narr_nHAXMutaHk2XL_1duZWSPg"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">2700000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_vfbRj1jR1UChcP5_UNgiYQ"
      decimals="0"
      id="Narr_HaAhmkoPk0iyQ_W3L34nlA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">423483</us-gaap:RepaymentsOfDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_6fAfKRGGhUqL4IOh5BEK8w"
      decimals="0"
      id="Narr__1Ikcu-WKUiWcDFqPCirgQ"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">2700000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_6fAfKRGGhUqL4IOh5BEK8w"
      decimals="0"
      id="Narr_lCKqOVUYHU2JpO305njpgg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">423483</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_6cOSMximrk2bohWsY9UvnQ"
      decimals="0"
      id="Narr_PpW_rhTuq0iGiV0ECXp_Ow"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">2000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember_6cOSMximrk2bohWsY9UvnQ"
      decimals="0"
      id="Narr_ol9eZVmBbkCY9E-MJ9bGiA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">313691</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_CmsXX0QXp0S-fTuzrs4H6w"
      decimals="0"
      id="Narr_SxHUIgb8Rk-OMyrzP68XFQ"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">16500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_CmsXX0QXp0S-fTuzrs4H6w"
      decimals="0"
      id="Narr_x93Tbdjva0azYbkyQDPCEw"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2587952</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtTerm
      contextRef="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_CmsXX0QXp0S-fTuzrs4H6w"
      id="Narr_PZEK5NMuoEOMkB4ZBmq8RA">P3Y</us-gaap:LongTermDebtTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_CmsXX0QXp0S-fTuzrs4H6w"
      decimals="4"
      id="Narr_1dlbQ8PQkUS0ZtpV5zzSuQ"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.0427</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_R9K_aCh4f0KdI_UTlvIBAQ"
      decimals="0"
      id="Narr_sT1kQAhahUCClIiKvx0i3A"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">1650000</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_R9K_aCh4f0KdI_UTlvIBAQ"
      decimals="0"
      id="Narr_NDUxvfwuDUi0Gw683IKHqA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">258796</us-gaap:RepaymentsOfDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_GfqS1hbef0evoZ9T4mY-ig"
      decimals="0"
      id="Narr_hcSZFG96Fky9fGhIgIzx7Q"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">1650000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2020_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_GfqS1hbef0evoZ9T4mY-ig"
      decimals="0"
      id="Narr_VX6MK6o8REy6MXr8pwIlPg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">258796</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_zAcojCdKLE-VHQNNjHb_JA"
      decimals="0"
      id="Narr_UTGwm9cB40SoB-BEQeDX-w"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">3850000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember_zAcojCdKLE-VHQNNjHb_JA"
      decimals="0"
      id="Narr_gtYeoWAWVEWXXwdV5j7yCA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">603855</us-gaap:LongTermDebtCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_IGsoNcZxl0av20J3TRsTVw"
      decimals="0"
      id="Narr_vwZ3Rrh0002GEDX5TLULeA"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">8500000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_IGsoNcZxl0av20J3TRsTVw"
      decimals="0"
      id="Narr_v2HYpibWrUWZTAeXXXHT6w"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1333186</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebtTerm
      contextRef="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_IGsoNcZxl0av20J3TRsTVw"
      id="Narr_xCx8iO0c5Ey9d6BYQQ68AQ">P3Y</us-gaap:LongTermDebtTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_IGsoNcZxl0av20J3TRsTVw"
      decimals="4"
      id="Narr_eqykqRldrUOK_U94ZG4ktA"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.0405</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_m9PDviMAVECncJ6iC8V97g"
      decimals="0"
      id="Narr_AHi7r3tEqkCkbDVf7aBHBQ"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">425000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="As_Of_12_31_2021_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember_m9PDviMAVECncJ6iC8V97g"
      decimals="0"
      id="Narr_wIl2sK8I5ES9b4xfCzVfQg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">66659</us-gaap:LongTermDebtCurrent>
    <adag:ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_byEtzea8fEqEPQLTXO8ssg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Future principal maturities of short-term borrowings and long-term borrowings as of December&#160;31, 2020 and 2021 were as followings:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,015,402&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,279,713&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,497,545&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,685,850&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,858,619&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,133,210&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:77.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,980,965&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,489,374&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</adag:ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock>
    <us-gaap:DebtCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_BU6np608ykGsUblH5lxAUw_4_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5015402</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_jeDeIlN67EGqxDAHmCq4hw_5_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1279713</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:DebtCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_qAr0FmKQBUyfeC3-58VNCA_5_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">4497545</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_MvofCtrzO0KKZODwTpSlDQ_6_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1685850</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_IhCGowCTwU2nRzW82usw2g_6_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1858619</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_t4xhRuBpS0eOJ0q4h8DMFA_7_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1133210</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_Mhfmuzoj9k-W0ouNvS56xg_8_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">7980965</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <us-gaap:DebtLongtermAndShorttermCombinedAmount
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_SN3bAn_FakysmZo8nv0gEQ_8_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">7489374</us-gaap:DebtLongtermAndShorttermCombinedAmount>
    <adag:DisclosureOfTemporaryEquityAndWarrantsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_eH36dBNBaEKaGBKII8bUnA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;8. CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2011, the Company issued convertible notes (&#x201c;Series Pre-A Convertible Notes&#x201d;) to certain investors in the amount of 4,590,908. The notes carried a simple interest (non-compounding) of 6% per annum as set out in the note purchase agreement. All outstanding principal balance and accrued but unpaid interest of the notes should be automatically converted into the convertible redeemable preferred shares of the Company at a price no more than US$1 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In November 2014, the Company issued 5,473,957 Series A-1 convertible redeemable preferred shares (&#x201c;Series A-1 Preferred Shares&#x201d;) to certain investors upon conversion of the Company&#x2019;s Series Pre-A convertible notes at a conversion price of US$1 per share. Concurrently, the Company issued 2,370,414 Series A-2 convertible redeemable preferred shares (&#x201c;Series A-2 Preferred Shares&#x201d;) to certain investors at US$1.27 per share for a total consideration of US$3,000,000. Series A-1 Preferred Shares and Series A-2 Preferred Shares are collectively referred to as the Series A Preferred Shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From January through June 2016, the Company issued 7,494,537 Series B convertible redeemable preferred shares (&#x201c;Series B Preferred Shares&#x201d;) to certain investors at US$3.74 per share for a total consideration of US$27,999,995.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From February&#160;through May&#160;2018, the Company issued 5,597,354 Series&#160;C-1 convertible redeemable preferred shares (&#x201c;Series&#160;C-1 Preferred Shares&#x201d;) to certain investors at US$8.93 per share for a total consideration of US$50,000,033. Concurrently, in February&#160;2018, the Company also issued warrants to two Series&#160;C-1 investors at nil consideration (&#x201c;Series&#160;C-1 Warrants&#x201d;). The Series&#160;C-1 Warrants allowed the holders to purchase Series&#160;C-2 Preferred Shares (defined below) at the exercise price of US$10.21 per share for a total consideration of up to US$7,500,000. Series&#160;C-1 Warrants were exercisable, in whole or in part, at any time from the warrant issuance date to the earlier of i)&#160;April&#160;1, 2019, ii)&#160;a deemed liquidation event or iii)&#160;the closing of the Qualified IPO. Series&#160;C-1 Warrants expired on April&#160;1, 2019.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From June&#160;through November&#160;2019, the Company issued 1,861,121 Series&#160;C-2 convertible redeemable preferred shares (&#x201c;Series&#160;C-2 Preferred Shares&#x201d;) to certain investors at US$10.21 per share for a total consideration of US$18,999,999.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2019, the Company issued 4,452,441 Series&#160;C-3 convertible redeemable preferred shares (&#x201c;Series&#160;C-3 Preferred Shares&#x201d;) to a certain investor at US$11.23 per share for a total consideration of US$50,000,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Series&#160;C-1 Preferred Shares, Series&#160;C-2 Preferred Shares and Series&#160;C-3 Preferred Shares are collectively referred to as the Series&#160;C Preferred Shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon completion of the IPO on February 11, 2021, each of the then outstanding Series A Preferred Shares, Series B Preferred Shares, and Series C Preferred Shares (collectively the &#x201c;Preferred Shares&#x201d;) was automatically converted into one ordinary share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The key features of Preferred Shares were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Dividends&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Each holder of the Preferred Shares would be entitled to receive non-cumulative dividends when declared by the Board of Directors prior and in preference to ordinary shareholders. The dividend should be paid at the rate of 6% of the original issue price per share per annum on each Preferred Shares in the sequence of Series&#160;C Preferred Shares and Preferred Shares other than the Series&#160;C Preferred Shares. After the preferential dividends relating to the Preferred Shares were paid in full or declared and set apart in any fiscal&#160;year of the Company, any additional dividends out of funds or assets legally available therefore may be declared in that fiscal&#160;year for the Shares and, if such additional dividends were declared, the preferred shareholders shall be entitled to participate on an as converted-basis pro-rata in any dividends or distributions paid to the ordinary shareholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Voting&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Each Preferred Share had voting rights equivalent to the number of ordinary shares to which it was convertible at the record date. The Preferred Shares shall vote separately as a class with respect to certain specified matters. Otherwise, the preferred shareholders and ordinary shareholders shall vote together as a single class.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Liquidation preference&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the event of any liquidation, dissolution or winding up of the Company, or the cessation of the business of the Company or of a substantial portion of the business of the Company, whether voluntary or involuntary, or any deemed liquidation event (unless waived by the preferred shareholders), the preferred shareholders would be entitled to receive a per share amount equal to 100% of the original issue price of the respective series of the Preferred Shares, in the sequence of Series&#160;C Preferred Shares, Series&#160;B Preferred Shares and Series&#160;A Preferred Shares. After such liquidation amounts were paid in full, the preferred shareholders were entitled to receive a simple interest accruing on each Preferred Share at 6% of its original issue price per annum from the date of issuance of such Preferred Share to the date of distribution of such amount, in the sequence of Series&#160;C Preferred Shares, Series&#160;B Preferred Shares and Series&#160;A Preferred Shares. After such interest amounts were paid in full, any remaining funds or assets of the Company legally available for distribution to shareholders shall be distributed on a pro rata basis among the preferred shareholders, on an as-converted basis, together with the ordinary shareholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Conversion&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Each Preferred Share might be converted at any time into ordinary shares at the option of the preferred shareholders based on the then-effective conversion price. The initial conversion ratio was 1:1, subject to adjustment in the event of share splits, share combinations, ordinary share dividends or distributions, other dividends, reorganizations, mergers, consolidations, reclassifications, exchanges, substitutions, or dilutive issuance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;All Preferred Shares would be converted automatically into ordinary shares at the then effective applicable conversion price upon the earlier of a Qualified Public Offering (public offering of the Company&#x2019;s shares with an offering price (exclusive of underwriting commissions and expenses) that reflected a market capitalization (immediately prior to the public offering) of not less than US$650,000,000 and with an aggregate proceeds of no less than US$75&#160;million) or a date specified by written consent or agreement of the holders of at least 80% of the voting power of the then outstanding Preferred Shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Redemption&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Preferred Shares were redeemable upon request by the holders of the majority outstanding Preferred Shares if the Company failed to consummate a Qualified Public Offering or completed a deemed liquidation event on or before March&#160;31, 2025 at the redemption price equal to the original issue price plus any declared but unpaid dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Accounting for Preferred Shares&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Preferred Shares were classified as mezzanine equity in the consolidated balance sheets because they were contingently redeemable upon the occurrence of an event outside of the Company&#x2019;s control (e.g.&#160;the Company not achieving a Qualified Public Offering or a deemed liquidation event before March&#160;31, 2025 (&#x201c;Target QIPO Date&#x201d;)). The Preferred Shares were determined to be mezzanine equity with no embedded feature to be bifurcated and no beneficial conversion features to be recognized. The Preferred Shares were initially recorded at their respective issuance date fair value, net of issuance cost and fair value allocated to the detachable warrants. The Company did not incur material issuance cost for any Preferred Shares issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Prior to the IPO, the Company concluded that the Preferred Shares were not redeemable, but were probable to become redeemable. The Company accreted changes in the redemption value over the period from the date of issuance to the earliest redemption date for the year ended December 31, 2020, and to the IPO date for the year ended December 31, 2021, using the interest method. No accretion charge was recorded as the redemption value was fixed to original issue price for the periods presented, except for Series C-1 Preferred Shares issued with detachable warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Modification of Preferred Shares&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company made several amendments to the Preferred Shares, mainly including: 1)&#160;added redemption rights for Series&#160;A Preferred Shares upon the issuance of the Series&#160;B Preferred Shares; and 2)&#160;extended the Target QIPO Date upon the issuance of the Series&#160;C-1 Preferred Shares and the Series&#160;C-3 Preferred Shares. These amendments were accounted for as modifications rather than extinguishments as the fair values of these Preferred Shares immediately after the amendments were not significantly different from their respective fair values immediately before the amendment. When Preferred Shares are modified and such modification results in value transfer between preferred shareholders and ordinary shareholders, the value transferred is treated as a deemed dividend to or deemed contribution from the preferred shareholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The Company&#x2019;s Preferred Shares activities for the periods presented were summarized below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Mezzanine equity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series A-1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series A-2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series B&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series C-1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series C-2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series C-3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$ &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance as of December 31, 2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,473,957&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,999,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48,481,159&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,955,111&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Issuance of Series C-2 Preferred Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,999,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,999,999&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Issuance of Series C-3 Preferred Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accretion of Series C-1 Preferred Shares to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 246,184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 246,184&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance as of December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,473,957&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,999,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48,727,343&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,999,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 154,201,294&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accretion of Series C-1 Preferred Shares to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 248,113&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 248,113&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance as of December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,473,957&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,999,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48,975,456&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,999,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 154,449,407&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accretion of Series C-1 Preferred Shares to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,553&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,553&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Conversion of Preferred Shares to Ordinary Shares &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,473,957)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,000,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (27,999,995)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (49,004,009)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,999,999)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (50,000,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (154,477,960)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance as of December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The warrants were to subscribe for Series C-2 Preferred Shares and had expired on April 1, 2019, which were freestanding instruments and classified as liabilities in accordance with ASC 480. The warrants were initially recognized at fair value, with subsequent changes in fair value recorded in earnings. The Company recognized gains from the decrease in fair value of the warrants of US$1,207,415 for the year ended December 31, 2019.&lt;/p&gt;</adag:DisclosureOfTemporaryEquityAndWarrantsTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_30_2011_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtSecuritiesMember_8DxtpnQnr0KcaNlyma5fZg"
      decimals="0"
      id="Narr_MnBJEWDWRE2tfBgWD85H5Q"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">4590908</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_11_30_2011_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtSecuritiesMember_8DxtpnQnr0KcaNlyma5fZg"
      decimals="2"
      id="Narr_4x3xT5emWUC1UldgQp0zPw"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_11_30_2011_us-gaap_DebtInstrumentAxis_us-gaap_ConvertibleDebtSecuritiesMember_8DxtpnQnr0KcaNlyma5fZg"
      decimals="0"
      id="Narr_4tUQ1VUM_0mj3wgG7rvV7w"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">1</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <adag:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_otWAtk9h5EmHuBYtwAAZvw"
      decimals="0"
      id="Narr_HUcI2Q8rSUCfUT0QeNiVlA"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">5473957</adag:TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="As_Of_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_9GdyKS3_I0KCOd-y1gFghA"
      decimals="0"
      id="Narr_pqz8etC6cEyqJ4jIPgVZAQ"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">1</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_dcicFbmqOki6XSFYWhz5_A"
      decimals="0"
      id="Narr_rYqFXDCrBEW8kHAJUs5euQ"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">2370414</adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_3jZL665NG0K7BDnwmBK99w"
      decimals="2"
      id="Narr_TcOXwRxNg0yQUg41yLoQ1g"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">1.27</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_11_1_2014_To_11_30_2014_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_dcicFbmqOki6XSFYWhz5_A"
      decimals="0"
      id="Narr_nk55IU2eX0Cl0uH9pqHM6Q"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_SWyRj_9rTEa_35eINBgGXg"
      decimals="0"
      id="Narr_TU3mdvETqEK31ye85QQ57g"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">7494537</adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_6_30_2016_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_Z_tj6E4y60S8vpMf1oAsgg"
      decimals="2"
      id="Narr_a4YhizFCIkqRGLRv-xu-eQ"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">3.74</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_1_1_2016_To_6_30_2016_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_SWyRj_9rTEa_35eINBgGXg"
      decimals="0"
      id="Narr_6dPXL7YKPkab-nDxQH6j8A"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">27999995</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_2_1_2018_To_5_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_BRbJS1jV-k2FpP0-kKZpDQ"
      decimals="0"
      id="Narr_NB-_UzyriEuZarWb1zdRmg"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">5597354</adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_5_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_g_h3Hub6ukul0-GRuWdxTA"
      decimals="2"
      id="Narr_CFIIVzi9NUefdBbg3BHFlQ"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">8.93</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_2_1_2018_To_5_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_BRbJS1jV-k2FpP0-kKZpDQ"
      decimals="0"
      id="Narr_fwOhDwpIHk-ncunovPI8dA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">50000033</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <adag:NumberOfInvestorsToWhomWarrantsWereIssued
      contextRef="Duration_2_1_2018_To_2_28_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_IOm0wr8bS0SSsXLzukJ-8g"
      decimals="INF"
      id="Narr_ujaXbo7oOkyfsDzTqO0cuQ"
      unitRef="Unit_Standard_item_VDVAwvxnO0aSdoyDMbjpLA">2</adag:NumberOfInvestorsToWhomWarrantsWereIssued>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_2_1_2018_To_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_adag_SeriesC1WarrantsMember_WLfnPOEP_kCFFQnnkF3j_g"
      decimals="0"
      id="Narr_zSqlpt_LRECMaW6GTER0Qw"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_2_28_2018_us-gaap_ClassOfWarrantOrRightAxis_adag_SeriesC1WarrantsMember_dvXoa1fpc0ab3vTaHbqHkg"
      decimals="2"
      id="Narr_4ivlD_1c3kqKn4mtWymMig"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">10.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <adag:MaximumProceedsReceivableFromExerciseOfWarrants
      contextRef="Duration_2_1_2018_To_2_28_2018_h-YUYJGmUkuPVILUOsDYiw"
      decimals="0"
      id="Narr_tA3QK9aUdUWl87VqX4kHBQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">7500000</adag:MaximumProceedsReceivableFromExerciseOfWarrants>
    <adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_6_1_2019_To_11_30_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_SGBgTCSDF0a2llGb4MeGuQ"
      decimals="0"
      id="Narr_V5v9yzQraU-i6UOcTcDsgw"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">1861121</adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_11_30_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_n4xqIulhYU-egftp4MP37g"
      decimals="2"
      id="Narr_KUqqHI1V806gVaGdMzDkyA"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">10.21</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_6_1_2019_To_11_30_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_SGBgTCSDF0a2llGb4MeGuQ"
      decimals="0"
      id="Narr_-KgTzEj7wkqB2MHbX3vQYQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">18999999</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_diYKl71mcEa25Z1LgkrP_g"
      decimals="0"
      id="Narr_eIcAAk2Jfk6lQKuIIL1eSw"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">4452441</adag:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_aSr2RzGWsEeMWJO8StiKvw"
      decimals="2"
      id="Narr_Z_z_wClI6U-PSAye2tk0cg"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">11.23</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="Duration_12_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_diYKl71mcEa25Z1LgkrP_g"
      decimals="0"
      id="Narr_NdrVSnMj0ka4L6TzNWzCAQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">50000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_2_11_2021_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_FkDkbXaQZU-bN_5oHvMW7w"
      decimals="INF"
      id="Narr_IMG-QKZ-REipcdDfXSMsHg"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">1</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Narr_88YRhUxrUUSYi1X0zQliFQ"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <adag:TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Narr_e0vZ6HDhfUKsGk48D-Fn5Q"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">1</adag:TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice>
    <adag:TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Narr_WoaTC7Dao0uxaqp0PMiisQ"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.06</adag:TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="INF"
      id="Narr_vO23IMoYvEOwqt6bJCwgXg"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">1</us-gaap:PreferredStockConvertibleConversionRatio>
    <adag:QualifiedPublicOfferingMinimumMarketCapitalization
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Narr_1uaykOd4Tk6Jvr7Xb_JElA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">650000000</adag:QualifiedPublicOfferingMinimumMarketCapitalization>
    <adag:QualifiedPublicOfferingMinimumProceeds
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="-6"
      id="Narr_JHEaFJlLyUm2Xf0yvsaY9Q"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">75000000</adag:QualifiedPublicOfferingMinimumProceeds>
    <adag:ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Narr_Og_MRoLbCEyKGSaCtSXU0Q"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.80</adag:ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_Q426fUHqZEaW2z6W8yWC9w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Mezzanine equity&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series A-1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series A-2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series B&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series C-1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series C-2&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Series C-3&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$ &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance as of December 31, 2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,473,957&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,999,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48,481,159&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 84,955,111&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Issuance of Series C-2 Preferred Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,999,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,999,999&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Issuance of Series C-3 Preferred Shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,000,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accretion of Series C-1 Preferred Shares to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 246,184&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 246,184&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance as of December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,473,957&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,999,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48,727,343&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,999,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 154,201,294&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accretion of Series C-1 Preferred Shares to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 248,113&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 248,113&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance as of December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,473,957&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,999,995&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 48,975,456&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,999,999&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,000,000&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 154,449,407&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accretion of Series C-1 Preferred Shares to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,553&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 28,553&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Conversion of Preferred Shares to Ordinary Shares &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,473,957)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,000,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (27,999,995)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (49,004,009)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,999,999)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (50,000,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (154,477,960)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Balance as of December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.02%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_l9mQvoDziUGbilnG3EPTXg"
      decimals="0"
      id="Tc_MyPoMza7Q0quUmEkq1A5sw_3_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5473957</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_z37ZSNqIdkmrfe2PIq5bYg"
      decimals="0"
      id="Tc_n7Pd4sdmRkCG1ucm1UI-6Q_3_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_pP0RVv1loE2F7LhqFPFl5w"
      decimals="0"
      id="Tc_utQrGB0RrkCJbkuAt-VTqQ_3_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">27999995</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2018_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_JVAYrE5J70eJCxdaW-vCJQ"
      decimals="0"
      id="Tc_Lega3H_1RE2d2wZbyv9dHA_3_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">48481159</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2018_T4mq9hT6lUOBey2VJKkGww"
      decimals="0"
      id="Tc_ghKv5NnIGEqUOBNE_XYggg_3_14"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">84955111</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember__gZCIGPtFEW337N5JP2Q0Q"
      decimals="0"
      id="Tc_PEhgPJjElkCasYT1aYoz3Q_4_10"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">18999999</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember__gZCIGPtFEW337N5JP2Q0Q"
      decimals="0"
      id="Tc_kHWeuzddp02xCezvHCrwOg_4_14"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">18999999</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_7jJxs3yXWUuOCOO5o_qb7A"
      decimals="0"
      id="Tc_KRYWaD2CXU6gfhUIC2HjnA_5_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">50000000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_7jJxs3yXWUuOCOO5o_qb7A"
      decimals="0"
      id="Tc_pFVOHwG3qkmYTW2lgPh91A_5_14"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">50000000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_AE-vqlBJf0-NDgL1echf5Q"
      decimals="0"
      id="Tc_rcK6wAVFNE-NyEy7Zcsh3Q_6_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">246184</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_AE-vqlBJf0-NDgL1echf5Q"
      decimals="0"
      id="Tc_3SYSRDZyn0aq9e2bskmLkw_6_14"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">246184</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_wmf-_5aZ706YaqfSKWC1Fw"
      decimals="0"
      id="Tc_nb1Fz6DE8E-eq7svvceocQ_7_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5473957</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_mfkgJutHxk6YN0AZLtjrhQ"
      decimals="0"
      id="Tc_0Cw7nP9by0a9ZFKkf6ERqg_7_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_6BqJpjfqTkmbkm23rKGTgQ"
      decimals="0"
      id="Tc_hyDMISYOKkSvTFVUSUE98w_7_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">27999995</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_ZGQqQfHg406k4K3zCUbpCQ"
      decimals="0"
      id="Tc_ii2r3_n5S0iwfvOTaAyo7w_7_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">48727343</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_DnVhZllqokOmO7zElhgtow"
      decimals="0"
      id="Tc_W2xIO2_acE6QApYF-NZkxQ_7_10"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">18999999</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_aSr2RzGWsEeMWJO8StiKvw"
      decimals="0"
      id="Tc_nELH_bmhPUubkl6L-kVSJA_7_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">50000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA"
      decimals="0"
      id="Tc_sipwrK86SEWQD6BrcUak5g_7_14"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">154201294</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_bH8gJMCbP0e6I7i5rqUq1w"
      decimals="0"
      id="Tc_JUqsQ2O_zEyTFGAbSRUYeg_8_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">248113</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_bH8gJMCbP0e6I7i5rqUq1w"
      decimals="0"
      id="Tc__tabBqOZMEC91BmyFnqaFw_8_14"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">248113</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Fqi_V4t6y0-puYQ1ivg6DQ"
      decimals="0"
      id="Tc_BQPct1ldMEGhuQOUMnkh3w_9_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5473957</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_4ehewyms1Eme4lR1LfryGQ"
      decimals="0"
      id="Tc_Um4AW2Tp1EG87rm3HqZNTA_9_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_myF8ybzw20G2z_xDQJRE5Q"
      decimals="0"
      id="Tc_G4o5R0_MpEKdYIHhP0rvng_9_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">27999995</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_he2uy54CEUGAjR10ESXHnw"
      decimals="0"
      id="Tc_CqXMIZTOYEy_07cp5yRbxw_9_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">48975456</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_di_bFxD70EWwEtdspmZWRw"
      decimals="0"
      id="Tc_DrlX96ONRkyL5LG3aNnBTQ_9_10"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">18999999</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_EFH-DFpj80mpuyw7v7-SrQ"
      decimals="0"
      id="Tc_4jSNn-5sz0qw7wb2jWyQqw_9_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">50000000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_QD7msstM5kyMM9-OuZ3OMw_9_14"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">154449407</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_6qnoqf3lxkW7dfqLzPlqGw"
      decimals="0"
      id="Tc_yDpaLgDiAUq5dPe-UtmGeg_10_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">28553</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:TemporaryEquityAccretionToRedemptionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_6qnoqf3lxkW7dfqLzPlqGw"
      decimals="0"
      id="Tc_WvVwYahAm0qyr5VnGqZ4CQ_10_14"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">28553</us-gaap:TemporaryEquityAccretionToRedemptionValue>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series1RedeemableConvertiblePreferredStockMember_Vyleht5K70id4Y2JmD-6pg"
      decimals="0"
      id="Tc_A7xTCERjak--XNq4zWBTdA_11_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5473957</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_Series2RedeemableConvertiblePreferredStockMember_ZNLsTGONtk6j3oo5yuSW8w"
      decimals="0"
      id="Tc_CgmbyhFGtUGz3A8IgEmLJg_11_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3000000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesBRedeemableConvertiblePreferredStockMember_cjqzXXZQU0imlA6Mfbj2WQ"
      decimals="0"
      id="Tc_vTzveNnLwkGXrQo58zO4Vg_11_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">27999995</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC1RedeemableConvertiblePreferredStockMember_6qnoqf3lxkW7dfqLzPlqGw"
      decimals="0"
      id="Tc_f8GXEKsAoUypIYLK8eE0bw_11_8"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">49004009</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC2RedeemableConvertiblePreferredStockMember_KAuPKCifoEuHLIrulCDCMg"
      decimals="0"
      id="Tc_RfkMcmIs0EmrnKzj7nUakw_11_10"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">18999999</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_adag_SeriesC3RedeemableConvertiblePreferredStockMember_bwrRgyxuJEyI4cbzEoFAfA"
      decimals="0"
      id="Tc_xG97sTrUtkGxruay1_9oxg_11_12"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">50000000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_nE9ggqLwO02fJDFHIxbb9A_11_14"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">154477960</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Narr_3-AIVXhGIk6uCJYT3lHD6g"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-1207415</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_gymrf7XxqUSZDa-Za9Kocg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;9. SHARE-BASED COMPENSATION&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On November&#160;7, 2015, the Company adopted a share incentive plan (the &#x201c;2015 Plan&#x201d;). Under the 2015 Plan, the Company&#x2019;s Board of Directors has approved that a maximum aggregate number of shares that may be issued pursuant to all awards granted shall be 4,336,126. In September&#160;2017, the Company replaced the 2015 Plan with the amended and restated share incentive plan (the &#x201c;2017 Plan&#x201d;) and increased the maximum number of shares issuable to 6,336,126. In December&#160;2019, the Company replaced the 2017 Plan with the second amended and restated share incentive plan (the &#x201c;2019 Plan&#x201d;) and further increased the maximum number of shares issuable to 11,391,131. The terms of the 2015 Plan, 2017 Plan and 2019 Plan are substantially the same other than the maximum aggregate number of shares the Company may issue under the respective plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Share options containing only service conditions granted to each grantee under the share incentive plan will generally be exercisable upon the grantee renders service to the Company in accordance with a stipulated vesting schedule. Grantees are generally subject to a vesting schedule of no longer than five years, under which the grantee earns an entitlement to vest a certain&#160;percentage of his option grants at the end of each&#160;month or&#160;year of completed service. The share option awards shall expire no more than 10 years from their grant dates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Share options containing both service conditions and performance conditions granted to each grantee under the share incentive plan shall become eligible for vesting upon the occurrence of their applicable performance conditions (including but not limited to the occurrence of an IPO, the completion of business and operational goals, etc.).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On August 15, 2020, pursuant to a board resolution, 184,692 share options that granted to a senior management was modified and the vesting period of such share options was shortened from 5 years to 4 years. Since the fair value of the modified award was lower than the fair value of the original award immediately before the modification, no incremental compensation cost was recognized for the modification during the year ended December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 9, 2020, the Company passed a board resolution to waive the vesting schedules and conditions of 2,375,000 share options granted to certain management members. Pursuant to this board resolution, these management members exercised all related share options at the original exercise price per share ranging from US$1.83 to US$2.26. As a result, 2,375,000 ordinary shares were issued to these management members. These management members paid the exercise price by issuing recourse promissory notes in the total amount of US$5,197,650. The Company had the repurchase right to buy back such shares at the original exercise price if the grantees did not meet the original vesting conditions. The Company assessed and considered that in accordance with guidance set out in ASC 718-10-55-31, given such arrangement allows the shares received on exercise be returned to the Company if the original vesting conditions are not satisfied, there has been no substantial change to the vesting conditions and the Company shall continue to account for the share awards in accordance with their original terms. As of December 31, 2021, there were 1,585,000 shares unvested according to the original vesting conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 16, 2021, the Company passed a board resolution whereby certain management members surrendered a total of 491,119 ordinary shares as repayment for their respective promissory notes issued in connection with the exercising of options granted to them. In the meantime, the Company further granted these management members the right to repurchase the surrendered shares by way of new option grants with an exercise price of US$13.85 per share. The fair values of these share options were US$7.85 per option, determined by using the binomial option valuation model. The share-based compensation expense related to these share options were recognized immediately upon grants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the same board resolution, the 2021 Performance Incentive Plan (the &#x201c;2021 Plan&#x201d;) was also adopted, under which an aggregate of 2,994,000 ordinary shares shall be reserved for issuance, and the share limit will automatically increase on the first trading day in January of each year (commencing with 2022) by an amount equal to (1)&#160;5% of the total number of the Company&#x2019;s outstanding ordinary shares on December&#160;31 of the prior year, or (2)&#160;such lesser number as determined by the board of directors. From March 12, 2021 to December 22, 2021, pursuant to the 2021 Plan, a total of 1,303,000 share options were granted to certain employees by 15 batches, with exercise price ranging from US$5.92 to US$17.56, respectively. In addition, 23,734 ordinary shares were issued to certain management personnel on March 16, 2021 pursuant to the 2021 Plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2020 and 2021, among all the share options granted to date, 2,178,808 and 2,483,808 share options contained both service conditions and performance conditions, respectively. All other share options granted contain only service conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$ per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$ per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 574,328&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 7.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,734,644&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 372,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (46,800)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 866,028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 7.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,328,171&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,313,373&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,694,934)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (190,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,294,467&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 8.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33,410,968&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,894,119&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (233,958)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (145,550)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,809,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 8.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,619,574&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and expected to vest at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,809,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 8.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,619,574&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 393,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 6.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,859,836&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,486,318&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 8.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 874,180&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate intrinsic value in the table above represents the difference between the exercise price of the awards and the fair value of the underlying ordinary shares at each reporting date, for those awards that had exercise price below the estimated fair value of the relevant ordinary shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The aggregate fair value of the equity awards vested during the&#160;years ended December&#160;31, 2019, 2020, and 2021 was US$366,113, US$8,430,085 and US$13,833,856, respectively. As of December&#160;31, 2021, the total unrecognized employee share-based compensation expense was US$30,607,079, all of which may be adjusted for actual forfeitures occurring in the future. Total unrecognized compensation cost will be recognized over a weighted-average period of 2.72&#160;years as of December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Fair value of share options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The fair value of share options was determined using the binomial option valuation model, with the assistance from an independent third-party appraiser. The binomial model requires the input of highly subjective assumptions, including the expected volatility, the exercise multiple, the risk-free rate and the dividend yield. For expected volatility, the Group has made reference to historical volatility of several comparable companies in the same industry. The exercise multiple was estimated as the average ratio of the stock price to the exercise price of when employees would decide to voluntarily exercise their vested share options. The risk-free rate for periods within the contractual life of the share options is based on the market yield of U.S. Treasury Bonds in effect at the time of grant. The dividend yield is based on the expected dividend policy over the contractual life of the share options. The estimated fair value of the ordinary shares, at the share option grant dates, was determined with the assistance from an independent third-party appraiser.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The assumptions used to estimate the fair value of the share options granted were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;years ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk&#x2011;free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1.78% - 2.73%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.68% - 0.83%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1.11% - 1.67%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility range&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;67.5% - 71.0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;72.3% - 73.4%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;73.1% - 75.5%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise multiple&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2.2 - 2.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2.2 - 2.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2.2 - 2.8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Contractual life&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Total share-based compensation expenses recognized for the&#160;years ended December&#160;31, 2019, 2020 and 2021 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;years&#160;ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 404,620&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,472,083&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,582,746&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 207,091&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,657,458&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,096,912&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Total share&#x2011;based compensation expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 611,711&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,129,541&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,679,658&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Up to the date of the issuance of the consolidated financial statements for the year ended December 31, 2020, some proceeds of the subscription capital arising from the exercise of vested share options by certain employees remained outstanding and such amount was presented as subscriptions receivable, a contra-equity balance on the consolidated balance sheets as of December&#160;31,2020,which was subsequently settled in 2021.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_11_7_2015_us-gaap_PlanNameAxis_adag_Plan2015Member_9j3tnKD5LU-UGahhBXvNQw"
      decimals="0"
      id="Narr_iqGSsChIdUyRLHPz2NiHfQ"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">4336126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_9_30_2017_us-gaap_PlanNameAxis_adag_Plan2017Member_pj9uKp5Wm0Kh5Lol033Ddw"
      decimals="0"
      id="Narr_sAIra9GUgkCbHbHeioe3sA"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">6336126</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="As_Of_12_31_2019_us-gaap_PlanNameAxis_adag_Plan2019Member_qU51oRRIxk-yJ1GRjugs3A"
      decimals="0"
      id="Narr_YB0ksJ2XeE6t6ToNK3U66w"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">11391131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_OvswsTR8G0ucewnhfOtZsw"
      id="Narr_AKhkRaQILkCfD6_ZOzuWqQ">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_uXE9KaLaqkKt3nfvmqSvqQ">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_8_15_2020_To_8_15_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_oE_DhZwnNUKZiikkA5YlwQ"
      decimals="0"
      id="Narr_bW7qY5Tzy0OUbaMnMzI6dg"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">184692</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_14_2020_To_8_14_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_ctCNSEfroUq-2XAeZiRzEQ"
      id="Narr_OceWbK0O3UugG2ANnOjHsw">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_8_15_2020_To_8_15_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_oE_DhZwnNUKZiikkA5YlwQ"
      id="Narr_sU31LL_mRk6wN303lPv4VQ">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Narr_PgkN49JGqk6yeuepe-wOOA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived
      contextRef="Duration_11_9_2020_To_11_9_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_WROxGtz27EKylxKWrdRpfQ"
      decimals="0"
      id="Narr_tJGbEy4tDkq7TTgq74LzTw"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">2375000</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_11_9_2020_To_11_9_2020_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_XjwJ8pZZ10aBP4HgKJNJBA"
      decimals="2"
      id="Narr_c3zMHnFlzEKdmRF7QetVGQ"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">1.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_11_9_2020_To_11_9_2020_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_Tj93Av1VmE-ghmkmKkxeVw"
      decimals="2"
      id="Narr_Wu67kcb51kqxzrzVGu0ulQ"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">2.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_11_9_2020_To_11_9_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_WROxGtz27EKylxKWrdRpfQ"
      decimals="INF"
      id="Narr_20tcsotDGUqbgkoP39N1iQ"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">2375000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_11_9_2020_To_11_9_2020_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_WROxGtz27EKylxKWrdRpfQ"
      decimals="0"
      id="Narr_HPvDcQnXBkKS5u8yoWbS_Q"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5197650</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="As_Of_12_31_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_gps4CSyPx0qQcHlONLLb2g"
      decimals="INF"
      id="Narr_9YSKf8zs4Uui_wVytsuUHQ"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">1585000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <adag:NumberOfSharesSurrendered
      contextRef="Duration_1_16_2021_To_1_16_2021_O_ff5_4bk0yyioWBZTe3bA"
      decimals="INF"
      id="Narr_k7pSQzD7a0WqEJiMTWvJTg"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">491119</adag:NumberOfSharesSurrendered>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_16_2021_To_1_16_2021_O_ff5_4bk0yyioWBZTe3bA"
      decimals="2"
      id="Narr_P1jbYqT8CkeIr_p4kLbf4Q"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">13.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_16_2021_To_1_16_2021_O_ff5_4bk0yyioWBZTe3bA"
      decimals="2"
      id="Narr_b4ceFCI55E264pdSfdxjwA"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">7.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_1_16_2021_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_qSN6Ich4FkuRKoki3TJD4Q"
      decimals="INF"
      id="Narr_LdoVBPai4E2lJYhChbl7vA"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">2994000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <adag:ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent
      contextRef="Duration_1_16_2021_To_1_16_2021_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_ajeBNU5LbU2-7VeHwDlygA"
      decimals="2"
      id="Narr_B5-dfAnDwE6uJA8SUFha8g"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.05</adag:ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_3_12_2021_To_12_22_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_cTAuhhwHJkiqvsAvTWQsmg"
      decimals="INF"
      id="Narr_r0NCzSlink-zJZLP5v7aEg"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">1303000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_3_12_2021_To_12_22_2021_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_u_kx_vXZB0a8pG4zN4WJ5g"
      decimals="2"
      id="Narr_D8WPNgsfK0-Vs0WVFFMV-Q"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">5.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_3_12_2021_To_12_22_2021_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_Rz3IDXEqBkqyYcd3zdrfzw"
      decimals="2"
      id="Narr_f6cImdYXVU6p-hd3WAsWZQ"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">17.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_3_16_2021_To_3_16_2021_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_KJ_klWmvoEGqcj3eoFwhkA"
      decimals="INF"
      id="Narr__Q_EPUQVp0SWkKZN6aFH-Q"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">23734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementScenarioAxis_adag_ServiceConditionsAndPerformanceConditionsMember_aYQM4Z59Lkq9WgUCQtEtog"
      decimals="INF"
      id="Narr_MzTduI35s02W5nqI7LwspA"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">2178808</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementScenarioAxis_adag_ServiceConditionsAndPerformanceConditionsMember_lzcuoYgQd0GD5oMsj4d0yA"
      decimals="INF"
      id="Narr_VwXhJf05IkO61wfC3awegA"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">2483808</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_7lL7m8PkYUeY7wP5uS0RjA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;line-height:1.27;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;&#x2011;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Grant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Date&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Term&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$ per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$ per&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;option&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Years&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2018&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 574,328&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.30&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.80&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 7.14&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,734,644&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 372,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.26&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (34,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (46,800)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.22&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 866,028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.67&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 7.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,328,171&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,313,373&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2.00&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.01&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,694,934)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.93&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (190,000)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.70&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,294,467&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.65&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 8.78&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 33,410,968&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,894,119&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.39&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (233,958)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.99&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.13&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (145,550)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3.02&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.71&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,809,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 8.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,619,574&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Vested and expected to vest at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,809,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.38&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 8.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,619,574&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 393,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0.75&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.46&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 6.68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,859,836&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:51.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable at December 31, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,486,318&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.87&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.05&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt; 8.20&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 874,180&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2018_T4mq9hT6lUOBey2VJKkGww"
      decimals="INF"
      id="Tc_BXMZJp9kaUKteaqGB-IUCA_9_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">574328</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2018_T4mq9hT6lUOBey2VJKkGww"
      decimals="2"
      id="Tc_s_liRHUWXEyCa0uz9MKQmA_9_4"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">0.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2018_T4mq9hT6lUOBey2VJKkGww"
      decimals="2"
      id="Tc_SewA0UkVMkW7Y__cGaMy8A_9_6"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">2.80</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2018_To_12_31_2018_FHaDhJxmwEKepai0fnE7_Q"
      id="Tc_CNQLTqmFYU-lEpEz6YKbqA_9_8">P7Y1M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2018_T4mq9hT6lUOBey2VJKkGww"
      decimals="0"
      id="Tc_iUS2aH1n6UWq23YeXWi-5w_9_10"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3734644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="INF"
      id="Tc_fBBu0xuCF0yohcdrEbiSZA_10_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">372500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="2"
      id="Tc_ZOlqBzTXU0mQw1EMPZRThg_10_4"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">1.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="2"
      id="Tc_qxEaiAPKPUmmyUwW4znXhg_10_6"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">5.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="INF"
      id="Tc_NG2B0YJNVE6XdX4uJn8X0Q_11_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">34000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="2"
      id="Tc_AJWh_sYnf0aDc3HNUiRgOw_11_4"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">0.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="2"
      id="Tc_NZKnX5k1L0KXwLzsP21hyg_11_6"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">5.71</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="INF"
      id="Tc_1E_CmrasW0uPpzr7YPsihA_12_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">46800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="2"
      id="Tc_GfryqvGoqUG3sH2N7Bjwgg_12_4"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">1.22</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="2"
      id="Tc_e2794g5Bx0WHsp1bpgrIAg_12_6"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">5.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA"
      decimals="INF"
      id="Tc_JYE2l3g1RkGczw1qDMfcJA_13_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">866028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA"
      decimals="2"
      id="Tc_3HFO_dcBhUenRw4ccPDJEw_13_4"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA"
      decimals="2"
      id="Tc_zXcOyTSLmk-bHYhK-Afxkw_13_6"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">3.67</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      id="Tc_sCOV7HUJ5E2QG3VxRQNvmw_13_8">P7Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA"
      decimals="0"
      id="Tc_kglQFABHX0yChmaellrYOQ_13_10"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">6328171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="INF"
      id="Tc_Lmmw1-CrAEuxSJByeSwLQg_14_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">6313373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="2"
      id="Tc_eC24GfC3uUmkMSAPMAIl2g_14_4"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">2.00</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="2"
      id="Tc_AmwyGQILuUGr_s_DDm5mDA_14_6"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">7.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="INF"
      id="Tc_0paSuy-7VkGsGYgwxvcZjQ_15_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">3694934</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="2"
      id="Tc_49ObLs1KvEm1cPDfxkVa7g_15_4"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">1.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="2"
      id="Tc_X8s2P0TlJU6w9x83zfsBjg_15_6"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">6.55</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="INF"
      id="Tc_dEw-QQrH8ESNCg_d8bMITg_16_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">190000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="2"
      id="Tc_602smLjmNUG6cZ30qMngsw_16_4"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">1.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="2"
      id="Tc_RTQyZUNwAUuRfR6W6hGciQ_16_6"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">6.91</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="INF"
      id="Tc_9tvx2L5RkEqW9X16oR9Ikg_17_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">3294467</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="2"
      id="Tc_AxImZF2Vd0yBvUKhTR2vKQ_17_4"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">1.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="2"
      id="Tc_0mPnk7FhiU6TFSdTCm_C9w_17_6"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">6.65</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      id="Tc_To8Mp3hzikajAvxvMJBr0A_17_8">P8Y9M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_wLKw9HePkkqpIpNfWWChTw_17_10"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">33410968</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="INF"
      id="Tc_xa1xY0t1kkO3kyWRRdQLDg_18_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">1894119</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Tc_xd19PkUTmkuDWsAv51M4IA_18_4"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">12.31</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Tc_fLMO0GyMuEeaKpn7J6Nrsg_18_6"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">8.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="INF"
      id="Tc_VSssQ4VCP0qDdfOE2XoggQ_19_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">233958</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Tc_PiJwwg8-d0aHub7VCOcjfA_19_4"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">0.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Tc_sKtq7f--sEiM-EQOdF_kSQ_19_6"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">5.13</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="INF"
      id="Tc_nioXevxyTESN7hTIgwJtaw_20_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">145550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Tc_uIK9WSFDhk2AXwu6AzOiyQ_20_4"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">3.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Tc_o2U7M25vh0i12CvBF_s7gg_20_6"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">7.71</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="INF"
      id="Tc_hUCYcgYadUyYv6E_pd0UHQ_21_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">4809078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="2"
      id="Tc_ViRez20NPEmvZ3ik4LuHEw_21_4"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">5.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="2"
      id="Tc_yw3B95Tb-UKX0kfkN7hpkg_21_6"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">7.38</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tc_GaFZEg1j5kq7sv--aGbIVg_21_8">P8Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_td5HJLIRt0a8tKQft5pR_Q_21_10"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2619574</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="INF"
      id="Tc_dr73qcQ0fk2wbG6nj8UCJA_22_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">4809078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="2"
      id="Tc_iC0NbQihckiwtqToPwucJw_22_4"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">5.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Tc_37xThogEq02qFJ3aXaBuOA_22_6"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">7.38</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tc_lSt-x1CdXky8gNJNtNfzGA_22_8">P8Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_DWG85TrSF0OAdHjErBSTwA_22_10"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2619574</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="INF"
      id="Tc_N2_BuDTBMECj8Xm6G860Ug_23_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">393424</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="2"
      id="Tc_4rpiEPYCzUCCIH--1-IQ6A_23_4"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="2"
      id="Tc_hIU_vfQXhEWAx67hW2wafw_23_6"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">4.46</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      id="Tc_Y9s94rV5YUiCQ6Jka6fltw_23_8">P6Y8M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_eCMkY2FwZkWG7aDG63LjLw_23_10"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">4859836</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="INF"
      id="Tc_D_81GN99ZkCy3hTiiNUIoA_24_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">1486318</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="2"
      id="Tc_uYmBXmVDJU63j0DeylT2XA_24_4"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">5.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Tc_jy-nQ8ikMUGbvzu7RYp_wQ_24_6"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">7.05</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tc_G5cKy0h7CkauDgI5d3qaAg_24_8">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_hJgATSZwgkaFAumjvgkVig_24_10"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">874180</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Narr_G8Q3bkPkPk-nexnrSU7YBQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">366113</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Narr_dKMSoIzBhEmLzitbRMdcdg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">8430085</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Narr_g8CdU2oPhEawhc4OwFboMQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">13833856</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Narr_k2bQonFu8ECbP_V5ReUZrA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">30607079</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Narr_rIZ1iGNDNkKzyzBbJ0e9oA">P2Y8M19D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_Fes6Oti0hES9iXbQW8M_Rw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;years ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Risk&#x2011;free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1.78% - 2.73%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0.68% - 0.83%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;1.11% - 1.67%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;0%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected volatility range&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;67.5% - 71.0%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;72.3% - 73.4%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;73.1% - 75.5%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercise multiple&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2.2 - 2.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2.2 - 2.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;2.2 - 2.8&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Contractual life&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.11%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;"&gt;10 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="4"
      id="Narr_T1nxj829n0qkOKfShZ4Xew"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.0178</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="4"
      id="Narr_kQ4IbUK-fEWW5hWbnS-9xg"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.0273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="4"
      id="Narr_7b1bmghS3Uqw85PdB356AA"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.0068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="4"
      id="Narr_D9xfgO5Ll0ubIyHHXLZJcA"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.0083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="4"
      id="Narr_DtiZ9TsxJEq5rVCY27itVg"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.0111</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="4"
      id="Narr_vGomWIXuAUubodJJA1K6zw"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.0167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="2"
      id="Tc_FrrUnlnce0eV-isP6VxoqA_5_2"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="2"
      id="Tc_iMmDylEtn0m32p-DvG6FNw_5_4"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Tc_7wFL7kOh7E6RMK2_bjsuIQ_5_6"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="3"
      id="Narr_81rFrwZmO0qB5WQd_zaEwQ"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.675</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="2"
      id="Narr_0u_JiQggzUapwhrht2Lnvg"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.710</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="3"
      id="Narr_lmlC5nth6U-MF24w66g-Ew"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.723</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="3"
      id="Narr_UsL71h8qdEyjdMCbgNp0SQ"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="3"
      id="Narr_TqAX3HCFJEykWloKr4UKgA"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.731</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="3"
      id="Narr_66LBQ9Evs0e8bnkf9Vey9Q"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.755</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="1"
      id="Narr_3qa8EEqAfUuyFIPuXCqJOQ"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">2.2</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="1"
      id="Narr_ZtIqqKwy-UylEJnUSTTGBw"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">2.8</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="1"
      id="Narr_TyAAdXayt06oN9ikn4fGFQ"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">2.2</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="1"
      id="Narr_jxEy9Flip0a9b9eDRXLrGw"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">2.8</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="1"
      id="Narr_sq8nO1CSbk-xN0Ksnqe3QA"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">2.2</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum>
    <adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="1"
      id="Narr_xM1pKJMh4UaFBFTSkQhorg"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">2.8</adag:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      id="Tc_lVb6tfitd0yrUZPRnzvNXg_8_2">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      id="Tc_zA7T5tkwHkSD2XLgEjPfww_8_4">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tc_fEV5v02Mm0mFc4vA3wsyYQ_8_6">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_ghAHCsijd0WgKXbzW_lugg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;years&#160;ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 404,620&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,472,083&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,582,746&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Administrative expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 207,091&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,657,458&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,096,912&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Total share&#x2011;based compensation expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 611,711&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,129,541&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,679,658&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_mEMX3jxTBEePGi2c4CW7ew"
      decimals="0"
      id="Tc_8eJlcMP8wU-nGPvLTTm1sQ_4_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">404620</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_Ku2fXt-ZkUyQ2JGo0NdGOw"
      decimals="0"
      id="Tc_-kApqwt4lU2m6PjHT5Lr8w_4_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">6472083</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_zdsez9gtTkGdnwLN8_NhYw"
      decimals="0"
      id="Tc_w2IlZLN39UirVHe5iEKJ3A_4_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">13582746</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_1m27p6Q0nEy5EgKynSvENw"
      decimals="0"
      id="Tc_j-tlLh5xhEaVwIxtfi4g3Q_5_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">207091</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_xUUXpRjJbEqKzK5uloapeQ"
      decimals="0"
      id="Tc_3hdXPkE9eEy25NNCiQBY1w_5_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3657458</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_B0aUMLGKf0iTQ_KOw1cMDw"
      decimals="0"
      id="Tc_-mW6P4i7r0Kc46azdwADCw_5_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5096912</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_olv983FQOka5s5-a-eotrA_6_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">611711</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_jWgTxPb5EUO4YcEbTeu_tA_6_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">10129541</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_NAhRl8R6r0-he25XU5WyfA_6_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">18679658</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_WVroCRKGdES0uBU9ccG1xw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;10. COLLABORATION ARRANGEMENTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Guilin Sanjin Pharmaceutical&#160;Co.,&#160;Ltd. License Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In December&#160;2018, the Group entered into (i)&#160;a collaboration agreement (the &#x201c;Sanjin Greater China Agreement&#x201d;) that covers Greater China with Guilin Sanjin Pharmaceutical&#160;Co.,&#160;Ltd. (&#x201c;Sanjin&#x201d;) and certain of its subsidiaries (collectively, &#x201c;Sanjin Parties&#x201d;) and (ii)&#160;a collaboration agreement (the &#x201c;Sanjin ROW Agreement&#x201d;, together with the Sanjin Greater China Agreement, the &#x201c;2018 Sanjin Agreements&#x201d;) that covers the regions other than Greater China with Sanjin. Pursuant to the Sanjin Greater China Agreement, the Group licensed the Chinese intellectual property directly related to a monospecific antibody molecule that binds to the PD-L1 target (the &#x201c;PD-L1 Project&#x201d;), including patent rights, patent application rights and technologies based on the core sequence of the molecule, to Sanjin Parties. Sanjin Parties will own all the Chinese intellectual property developed in the exercise of Sanjin Parties&#x2019; rights under the agreement, including but not limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights relating thereto. The Group also granted Sanjin Parties a royalty-free license to use our other existing intellectual property and improvements thereto which are related to the PD-L1 Project for the purposes of exploiting its rights and performing its obligations under the agreement. Sanjin Parties will enjoy all the economic benefits deriving from the PD-L1 Project in Greater China, including but not limited to patent transfer fee, licensing fee, sales revenue and sales commission, etc. Sanjin Parties will pay the Group (i)&#160;single-digit&#160;percentage of net sales of the products that use the licensed antibody after such products enter the market and (ii)&#160;a low to mid-low double-digit&#160;percentage of the profits resulting from any transfer of the license to any third parties depending on the timing of the transfer relative to the development stage of the product. The Group also received RMB10,000,000 (equivalent to approximately US$1,511,168) upfront fee upon the effectiveness of the agreement from Sanjin Parties.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Sanjin ROW Agreement, the Group granted Sanjin a royalty-free license to use all intellectual property relating to (i)&#160;the collaboration under the agreement that the Group controlled before the Group entered into the agreement or acquired independently of the agreement and (ii)&#160;improvements thereto for the purposes of exploiting its rights and performing its obligations under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such intellectual property, and any intellectual property generated from cooperation between the Group and Sanjin&#x2019;s affiliates in connection with the collaboration will be jointly owned. The Group retain the ownership of patent rights of key intellectual property pertaining to PD-L1 outside of the Greater China. In addition, all the results obtained by Sanjin relating to the research and development of any new antibody developed under the agreement will be owned by Sanjin. The Group retain a majority of the economic benefits derived from the Sanjin ROW Agreement, including but not limited to any patent transfer fee, licensing fee and gains realized under such transfer. In case the Group intend to transfer to a third party our share of economic interests in any country outside of Greater China, the Group must notify Sanjin and Sanjin will receive a right of first refusal if it pays the Group a deposit equal to a low double-digit&#160;percentage of the consideration that the Group expect to receive from such third party. If Sanjin waives the right of first refusal, the Group can proceed with the transfer, provided that the final transaction price with the third party is not lower than the amount of the offering price that was included in our notice to Sanjin.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group agreed not to (i)&#160;independently develop any monospecific antibodies that bind to the PD-L1 target or (ii)&#160;grant any rights associated with such antibodies to any third parties during the three-year period from the effective date of the agreement. The exclusivity obligation does not prevent the Group from (i)&#160;developing or granting any licenses to third parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and masked antibody against PD-L1 target and (ii)&#160;continuing to provide antibody screening service that were commenced before the execution of the Sanjin Greater China Agreement and either party has the independent right to conduct combination therapy studies outside of the Greater China. Either non-breaching party may terminate the 2018 Sanjin Agreements if the other party&#x2019;s ability to comply with its respective obligations under the agreements is negatively affected by contingencies such as failure to maintain operation or changes in core project management and the other party fails to take effective remedial measures. Each agreement automatically terminates upon the termination of the other agreement. Upon the rescission or termination, Sanjin Parties will return to the Group all the intellectual property, documents and data provided by the Group under the 2018 Sanjin Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the event that the failure of the development of the product candidate solely arises from the Group&#x2019;s research and development basis specified under this agreement, Sanjin has the right to claim back all the payment made to the Group. The Group considers the possibility of occurrence of such event is very remote.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the&#160;year ended December&#160;31, 2018, the Group recognized revenue of RMB10,000,000 (equivalent to approximately US$1,511,168) for this agreement. No additional revenue was recognized for the years ended December 31, 2019, 2020 and 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In May&#160;2019, the Group entered into (i)&#160;a collaboration agreement that covers Greater China (the &#x201c;Dragon Boat Greater China Agreement&#x201d;) and (ii)&#160;a collaboration agreement that covers the regions other than Greater China (the &#x201c;Dragon Boat ROW Agreement,&#x201d; together with the Dragon Boat Greater China Agreement, the &#x201c;2019 Dragon Boat Agreements&#x201d;), with Dragon Boat Biopharmaceutical (Shanghai) Limited (&#x201c;Dragon Boat&#x201d;), a subsidiary of Sanjin. Pursuant to the Dragon Boat Greater China Agreement, the Group will license the Chinese intellectual property directly related to a certain monospecific antibody molecule that binds to a specified target (the &#x201c;Specified Project&#x201d;), including the patent rights, patent application rights and technologies based on the core sequence of the molecule, to Dragon Boat. Dragon Boat will own all the Chinese intellectual property developed in the exercise of Dragon Boat&#x2019;s rights under the agreement, including but not limited to improvements (including combination products), clinical trials, regulatory filings, and commercialization rights relating thereto. The Group also granted Dragon Boat a royalty-free license to use our other existing intellectual property and improvements thereto which are related to the Specified Project for the purposes of exploiting its rights and performing its obligations under the agreement. Dragon Boat will enjoy all the economic benefits deriving from the Specified Project in Greater China, including but not limited to patent transfer fee, licensing fee, sales revenue and sales commission, etc. and will pay the Group (i)&#160;certain high-six figure dollar milestone payments upon the achievement of certain milestones (including milestones of launch of pre-clinical safety evaluation animal test, obtaining Investigational New Drug (&#x201c;IND&#x201d;) approval in PRC and completion of clinical phase I test in PRC) and (ii)&#160;a single-digit&#160;percentage of net sales of the products that use the licensed antibody after such products enter the market.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the Dragon Boat ROW Agreement, the Group granted Dragon Boat a royalty-free license to use all intellectual property relating to (i)&#160;the collaboration under the agreement that the Group controlled before the Group entered into the agreement or acquired independently of the agreement and (ii)&#160;improvements thereto for the purposes of exploiting its rights and performing its obligations under the agreement. Any intellectual property generated independently by a party under the agreement will be solely owned by that party who generated such intellectual property, and any intellectual property generated from cooperation between the Group and Dragon Boat in connection with the collaboration will be jointly owned. The Group retain the ownership of patent rights of key intellectual property pertaining to the specified target outside of the Greater China. In addition, all the results obtained by Dragon Boat relating to the research and development of any new antibody developed under the agreement will be owned by Dragon Boat. The Group retains a majority of the economic benefits derived from the Dragon Boat ROW Agreement, including but not limited to any patent transfer fee, licensing fee and gains realized under such transfer. In case the Group intend to transfer to a third party our share of economic interests in any country outside of Greater China, the Group must notify Dragon Boat and Dragon Boat will receive a right of first refusal if it pays the Group a deposit equal to a low double-digit&#160;percentage of the consideration that the Group expects to receive from such third party. If Dragon Boat waives the right of first refusal, the Group can proceed with the transfer, provided that the final transaction price with the third party is not lower than the amount of the offering price that was included in our notice to Dragon Boat.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the 2019 Dragon Boat Agreements, the Group agreed not to (i)&#160;independently develop any monospecific antibodies that bind to the specified target or (ii)&#160;grant any rights associated with such antibodies to any third parties during the three-year period from the effective date of the agreements. The exclusivity obligation does not prevent the Group from (i)&#160;developing or granting any licenses to third parties for intellectual property that covers bispecific antibodies, ADCs, diagnostic antibodies, nano-particles and masked antibody against the specific target and (ii)&#160;continuing to provide antibody screening service that were commenced before the execution of the Dragon Boat Greater China Agreement and either party has the independent right to conduct combination therapy studies outside of the Greater China. Either nonbreaching party may terminate the 2019 Dragon Boat Agreements if the other party&#x2019;s ability to comply with its obligations under the agreements is negatively affected by contingencies such as failure to maintain operation or changes in core project management and the other party fails to take effective remedial measures. Each agreement automatically terminates upon the termination of the other agreement. Upon the rescission or termination, Dragon Boat will return to the Group all the intellectual property, documents and data provided by the Group under the 2019 Dragon Boat Agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the event that the failure of the development of the product candidate solely arises from the Group&#x2019;s research and development basis specified under this agreement, Dragon Boat has the right to claim back all the payment made to the Group. The risk of failure is considered remote upon recognition of revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the&#160;year ended December&#160;31, 2019, no revenue was recognized for this agreement since the licensed product has not been transferred to Dragon Boat.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2020, upfront fee of RMB4,000,000 (equivalent to approximately US$573,378) that was received by the Group was recorded as contract liabilities in the consolidated balance sheets, as the performance obligation had not been satisfied by the Group and no revenue was recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;During the year ended December 31, 2021, milestone fee of RMB4,000,000 (equivalent to approximately US$620,011) was received related to the launch of pre-clinical safety evaluation animal test and the receipt of IND approval in PRC. For the year ended December 31, 2021, a total of RMB8,000,000 (equivalent to approximately US$1,240,022), including the aforementioned upfront fee and milestone fee were recognized as licensing revenue in the consolidated statement of comprehensive loss as the performance obligation was satisfied by the Group and certain milestone events were achieved.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Signal Pharmaceuticals LLC Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In January&#160;2019, the Group entered into an agreement with Signal Pharmaceuticals LLC, a subsidiary of Celgene Corporation, for a purchase order of delivery of certain sequences with total consideration of US$480,000. For the&#160;year ended December&#160;31, 2019, the Group recognized revenue of US$480,000 upon delivery of such sequences.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In October 2018 and May 2019, the Group entered into agreements with Signal Pharmaceuticals LLC, for purchase orders of for a purchase order of delivery of certain sequences with total consideration of US$237,500 and US$72,000, respectively. For the year ended December 31, 2020, the Group recognized revenue of US$309,500 upon delivery of such sequences.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended December 31, 2021, the Group did not enter into new agreements with Signal Pharmaceuticals LLC or recognize any additional revenue.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;ADC Therapeutics&#160;SA License and Collaboration Agreements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In April&#160;2019, the Group entered into a material transfer and collaboration agreement (the &#x201c;ADCT Collaboration Agreement&#x201d;) and a license agreement (the &#x201c;ADCT License Agreement&#x201d;) with ADC Therapeutics&#160;SA (&#x201c;ADC Therapeutics&#x201d;). These two agreements are combined as a single contract as the agreements were negotiated as a package with a single commercial objective.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;ADCT Collaboration Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Pursuant to the ADCT Collaboration Agreement, the Group agreed to generate masked antibodies with respect to up to two exclusive targets selected by ADC Therapeutics. Upon our delivery of certain initial results, ADC Therapeutics has the option to license the Group&#x2019;s technology with respect to one or both targets as further detailed below. ADC Therapeutics has not yet exercised such options as of December&#160;31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the ADCT Collaboration Agreement, the Group is eligible to receive up to a low-seven-figure dollar amount in consideration for the Group&#x2019;s exclusivity obligations, upon achievement of certain development milestones (including milestones of delivery of certain amino acid sequences and successful outcome of the first in-vivo study) and upon ADC Therapeutics&#x2019; election to proceed with development for the two elected targets. Apart from performance obligation to deliver the amino acid sequences of the corresponding masking peptides, the Group is not required to perform any additional research and development services. ADC Therapeutics has the right to terminate the ADCT Collaboration Agreement at any time and for any reason in its entirety or on a target-by-target basis upon thirty days&#x2019; prior written notice to the Group. Either party may terminate the ADCT Collaboration Agreement, in its entirety or on a target-by-target basis, upon the other party&#x2019;s uncured material breach of the agreement or the other party&#x2019;s insolvency-related events.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group also granted ADC Therapeutics an exclusive target reservation right for one year from the commencement of the agreement and an option to renewal for another&#160;year with a consideration of low-six-figure dollar amount.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;ADCT License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Subject to the exercise of the options contained in the ADCT Collaboration Agreement, the Group has granted ADC Therapeutics, with respect to each elected target, an exclusive, worldwide, perpetual and irrevocable (subject only to the termination provisions) license (with the right to grant sublicenses) to develop, make, use, commercialize and import the antibody drug conjugates that comprise masked antibodies generated by the Group under these programs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the ADCT License Agreement, if ADC Therapeutics exercises both of its options granted thereunder, the Group could be eligible to receive up to a low-nine-figure dollar amount in development and regulatory milestone payments upon the achievement of certain milestones (including milestones of successful completion of Good Laboratory Practice Toxicology studies, launch of clinical trials and start of commercial sales in difference countries and etc.) and up to a mid-eight-figure dollar amount in sales milestone payments, in addition to mid-single-digit&#160;percentage net sales-based tiered royalties on products licensed under the ADCT License Agreement, subject to certain reductions. Royalties, if any, will be payable on a country-by-country and product-by-product basis, until the earlier of (i)&#160;the tenth anniversary of the first commercial sale of such product or (ii)&#160;the expiration of the last-to-expire patent licensed under the agreement in such country, unless earlier terminated by the parties, following which any licenses granted to ADC Therapeutics under the ADCT License Agreement shall become fully paid up, perpetual and irrevocable.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;ADC Therapeutics has the right to terminate the ADCT License Agreement before the expiration of the royalty term on a product-by-product basis or in its entirety (i)&#160;for any reason or no reason upon thirty days&#x2019; written notice to the Group, or (ii)&#160;if ADC Therapeutics chooses to discontinue the development or sale of the applicable licensed product worldwide. Each party has certain rights to terminate the ADCT License Agreement with prior written notice upon the other party&#x2019;s uncured material breach or insolvency.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the year ended December 31, 2019, no revenue was recognized as no performance obligation was satisfied.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;For the&#160;year ended December&#160;31, 2020, the Group recognized US$225,000 of licensing revenue upon delivery of such results. For the year ended December&#160;31, 2020, the Group recognized US$100,000 as other income due to the expiration of exclusive target reservation right, which is not related to the Group&#x2019;s major operation activity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;For the year ended December 31, 2021, the Group recognized US$225,000 of licensing revenue upon delivery of additional research results.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Exelixis, Inc. Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In February 2021, the Group entered into a collaboration and license agreement (the &#x201c;Exelixis Agreement&#x201d;) with Exelixis, Inc. (&#x201c;Exelixis&#x201d;), pursuant to which the Group agreed to generate masked antibodies with its SAFEbody technology against an initial target selected and a second target to be selected by Exelixis. The Group will generate masked antibodies in the form of alternative compounds in accordance with the program plan for each target at its own cost and deliver the related data packages to Exelixis. Exelixis will select lead compounds (the &#x201c;Lead Compounds&#x201d;) to further develop, obtain regulatory approval and commercialize product(s) for each target (the &#x201c;Products under the Exelixis Agreement&#x201d;). Under the Exelixis Agreement, the Group will also grant Exelixis an exclusive, worldwide, sublicensable license (the &#x201c;Adagene License&#x201d;) upon delivery of the data package to research, develop, make, have made, sell, offer for sale, import and commercialize products containing the masked antibodies to be generated by the Group with respect to both targets. Exelixis will own the inventions relating to the Lead Compounds arising in connection with the Exelixis Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Exelixis Agreement will remain effective until the expiration of the defined royalty terms of the Products under the Exelixis Agreement, unless terminated by either party. Exelixis may terminate the Exelixis Agreement for any or no reason, in its entirety or on a target-by-target basis. Any payment received by the Group before the termination shall be non-refundable. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the Exelixis Agreement, Exelixis agreed to pay the Group an upfront non-refundable fee of US$11,000,000. For each target, the Group will be eligible to receive up to US$127,500,000 of milestone payments conditioned upon achieving certain development and regulatory approval milestones, and up to $262,500,000 of sales-based milestone payments. In addition, the Group is also entitled to royalties of mid-single-digit percentage in respect of the aggregate annual net sales of the products developed under the Exelixis Agreement worldwide, subject to certain reductions. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group determined that generating masked antibodies with its SAFEbody technology is reflective of a vendor-customer relationship and therefore within the scope of ASC 606. Under the Exelixis Agreement, the delivery of data packages for each target, along with the Adagene License used to develop the related compounds, represents one performance obligation, as they are not distinct from each other. Transaction price is allocated to each one of the two performance obligations based on the relative standalone selling price method. The Group records revenue at a point in time, when the data packages for each target were delivered to Exelixis. Considering that the development, regulatory and sales-based milestone payments and the royalties are constrained, the transaction price shall initially only include upfront payment and the milestone payments that are considered probable. Subsequently, once the uncertainty associated with the milestone payments is resolved, the milestone payments shall be included in the total transaction price when it is no longer probable that a significant reversal of cumulative revenue would occur in future periods. The sales-based royalty and sales-based milestones promised in exchange for the Adagene License granted are recognized when (or as) the later of 1) the subsequent sale or usage occurs, or 2) the performance obligation to which some or all of the sales-based royalty or sales-based milestones being allocated has been satisfied (or partially satisfied).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;As of December 31, 2021, the Group received US$11,000,000 upfront payment and&lt;span style="font-size:11pt;"&gt; &lt;/span&gt;recorded accounts receivable of US$3,000,000 milestone payment, which corresponds to the successful nomination of lead SAFEbody candidates for the initial target under the Exelixis Agreement. The milestone payment was subsequently received in January 2022. For the year ended December 31, 2021, US$8,500,000 was recognized as revenue upon delivery of data packages for the initial target and achievement of the milestone event. &lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_zsB5uPJq50C4DpmE2mjLFA"
      decimals="0"
      id="Narr_Ob7fIqw_Vkyc19IaWX3n0A"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">10000000</adag:CollaborativeArrangementUpfrontCashPaymentReceived>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_zsB5uPJq50C4DpmE2mjLFA"
      decimals="0"
      id="Narr_zfM3JocvFUi7kmlHDHTcyQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1511168</adag:CollaborativeArrangementUpfrontCashPaymentReceived>
    <adag:AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties
      contextRef="Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_zsB5uPJq50C4DpmE2mjLFA"
      id="Narr_DKYi7AaBKEylMdj1oIubJw">P3Y</adag:AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_u083XUXgXkmjyHICOwXAVw"
      decimals="0"
      id="Narr_n-ljMy45XE-ExazE5D1syg"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">10000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_u083XUXgXkmjyHICOwXAVw"
      decimals="0"
      id="Narr_b_47lPU88Eys41A22j1nrg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1511168</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_bKpMhErhpUq4nsR8w4_mRw"
      decimals="0"
      id="Narr_SAJm0N_VzkuGea_v9tTyPg"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_jQLNNuCCo0Gc9A2UON5i2w"
      decimals="0"
      id="Narr_kGSeunl_E0e8W9zHbts5Ug"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_UwjwbfWHYk-CsHFX-MxHNQ"
      decimals="0"
      id="Narr_lV6yPAAWM0G_CPuEiE5G3g"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adag:AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_raAHGN6oRESCKkVreFRITQ"
      id="Narr_RkStaBe9uUae2AG0oDkZtA">P3Y</adag:AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_MxpOQhUxHEuCBkT-S645ig"
      decimals="0"
      id="Narr_6FjPPVzKZEmM_2dMbVR3oQ"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_pYJxpURUM0OA22lpXY2GQQ"
      decimals="0"
      id="Narr_DRsdaqlSu0GWf7RRpFH6_g"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">4000000</adag:CollaborativeArrangementUpfrontCashPaymentReceived>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_pYJxpURUM0OA22lpXY2GQQ"
      decimals="0"
      id="Narr_r6g7D2vtqU2Pm1zC6RxU_w"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">573378</adag:CollaborativeArrangementUpfrontCashPaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_pYJxpURUM0OA22lpXY2GQQ"
      decimals="0"
      id="Narr_yT0PDpwO-0SabD_bOOZ_Ug"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adag:CollaborativeArrangementMilestonePaymentReceived
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_raAHGN6oRESCKkVreFRITQ"
      decimals="0"
      id="Narr_5gTUMQ92fkKE6ubnvj20QA"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">4000000</adag:CollaborativeArrangementMilestonePaymentReceived>
    <adag:CollaborativeArrangementMilestonePaymentReceived
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_raAHGN6oRESCKkVreFRITQ"
      decimals="0"
      id="Narr_5oqsdn5iYU-jE2_VBHq6Mw"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">620011</adag:CollaborativeArrangementMilestonePaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_raAHGN6oRESCKkVreFRITQ"
      decimals="0"
      id="Narr_vE-tHQMek0mbYy1iFNRLzg"
      unitRef="Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ">8000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember_raAHGN6oRESCKkVreFRITQ"
      decimals="0"
      id="Narr_f771mQV0S0uVNSYoCrk-5g"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1240022</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_SignalPharmaceuticalsLlcMember_zbCrjEk3mUSzkE9kYsfUww"
      decimals="0"
      id="Narr_QSJozi3T9EaCqeOF1oRcnQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">480000</adag:CollaborativeArrangementUpfrontCashPaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_adag_SignalPharmaceuticalsLlcMember_tDfXXMaJ1Eey6o1BuWgWYQ"
      decimals="0"
      id="Narr_RxEpiPeex0W-Tqzg-a9hBA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">480000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_10_1_2018_To_10_31_2018_us-gaap_TypeOfArrangementAxis_adag_SignalPharmaceuticalsLlcMember_6wYypVvYlkKloo4C6zZxMg"
      decimals="0"
      id="Narr_SpAA8PkKAk-MqU0Id5RySQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">237500</adag:CollaborativeArrangementUpfrontCashPaymentReceived>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_5_1_2019_To_5_31_2019_us-gaap_TypeOfArrangementAxis_adag_SignalPharmaceuticalsLlcMember_VxiNPotzW0uBeu5zVH0n4w"
      decimals="0"
      id="Narr_nRiBIfGPCk-0tp-1-EJMgw"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">72000</adag:CollaborativeArrangementUpfrontCashPaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_SignalPharmaceuticalsLlcMember_7offnHLxtE2QBDZc2Gcu7Q"
      decimals="0"
      id="Narr_1vyfI0R_p0GxhvxOX3C5DQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">309500</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adag:MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies
      contextRef="Duration_4_1_2019_To_4_30_2019_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_eGyxkFQCZE6u3B9IkEjTXQ"
      decimals="INF"
      id="Narr_MHABGhhy_0aAqE6PrwRVzg"
      unitRef="Unit_Standard_item_VDVAwvxnO0aSdoyDMbjpLA">2</adag:MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies>
    <adag:MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_xzwissiwc0-243qJnNFPcA"
      id="Narr_pWI61Ru6R0K8Zf_-N2ZwVA">P30D</adag:MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement>
    <adag:PeriodForReservationOfTargetRight
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_xzwissiwc0-243qJnNFPcA"
      id="Narr_0HyhNiM2DEOSvIeiESWhtA">P1Y</adag:PeriodForReservationOfTargetRight>
    <adag:MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_xzwissiwc0-243qJnNFPcA"
      id="Narr_lWidlqjfcUaEfvBSUh792g">P30D</adag:MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_EEyq6-qTT02Gx8jU3UgzXQ"
      decimals="0"
      id="Narr_m-zpbKgTc0-_7giHo6zbYA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_AOGCddhlkkafIHJPmD_uUw"
      decimals="0"
      id="Narr_IzrtjCOQN0e-PnVGxB6T3A"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">225000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OtherIncome
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_AOGCddhlkkafIHJPmD_uUw"
      decimals="0"
      id="Narr_BbAWDWTzc0ue2VflUHQmFg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">100000</us-gaap:OtherIncome>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_AdctCollaborationAgreementMember_xzwissiwc0-243qJnNFPcA"
      decimals="0"
      id="Narr_GJDsUu86dUylhss9YSIVTg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">225000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceivable
      contextRef="As_Of_2_28_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_j9kFO_H-ME6HZ7oPWsGjEQ"
      decimals="0"
      id="Narr_gEg3wIRKgUGFs_GUNJoMqQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">11000000</adag:CollaborativeArrangementUpfrontCashPaymentReceivable>
    <adag:MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones
      contextRef="As_Of_2_28_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_j9kFO_H-ME6HZ7oPWsGjEQ"
      decimals="0"
      id="Narr_MLrgxNOW0kiRj3hHqy41mg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">127500000</adag:MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones>
    <adag:MilestonePaymentsReceivableSalesBasedMilestones
      contextRef="As_Of_2_28_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_j9kFO_H-ME6HZ7oPWsGjEQ"
      decimals="0"
      id="Narr_1jf2FCpxbEOotzQTrRFg5g"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">262500000</adag:MilestonePaymentsReceivableSalesBasedMilestones>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceived
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_i7cOcV2zlk2TryKX0IeFTw"
      decimals="0"
      id="Narr_30_SK4qjzESwq2Rvs9bnyg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">11000000</adag:CollaborativeArrangementUpfrontCashPaymentReceived>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember__cHz1vX8l0yKaUSYpxTiiQ"
      decimals="0"
      id="Narr_YA6SCh41x0CGcGlN1VeUdw"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_TypeOfArrangementAxis_adag_ExelixisIncAgreementMember_i7cOcV2zlk2TryKX0IeFTw"
      decimals="0"
      id="Narr_b57WKaiTB0CwEcM26egRDQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">8500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_S-OJ91cqR0aLJi0EuwRfCg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;11. INCOME TAX EXPENSE&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;font-weight:normal;"&gt;PRC&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Effective from January&#160;1, 2008, the PRC&#x2019;s statutory, Enterprise Income Tax (&#x201c;EIT&#x201d;) rate is 25%. In accordance with the implementation rules&#160;of EIT Law, a qualified &#x201c;Technology Advanced Service Enterprises&#x201d; (&#x201c;TASE&#x201d;) is eligible for a preferential tax rate of 15%. The TASE certificate is effective for three years. An entity must file required supporting documents with the tax authority and ensure fulfillment of the relevant TASE criteria before using the preferential rate. An entity could apply for the TASE certificate every&#160;year. Dividends by PRC entities, to non-PRC resident enterprises shall be subject to 10% EIT, namely withholding tax, unless the respective non-PRC resident enterprise&#x2019;s jurisdiction of incorporation has a tax treaty or arrangements with China that provides for a reduced withholding tax rate or an exemption from withholding tax.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Adagene (Suzhou) Limited was first recognized as a qualified TASE in March&#160;2015 and renewed in December&#160;2018 and November 2021. Adagene (Suzhou) Limited was authorized to enjoy the preferential tax rate of 15% from 2015 to at least 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Cayman Islands&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Adagene&#160;Inc. is incorporated in the Cayman Islands. Under the current laws of the Cayman Islands Adagene&#160;Inc. is not subject to tax on income or capital gain. Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to shareholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Hong Kong&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Adagene (Hong Kong) Limited is incorporated in Hong Kong. Companies registered in Hong Kong are subject to Hong Kong profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Hong Kong tax laws. The applicable tax rate in Hong Kong is 16.5%. For the&#160;years ended December&#160;31, 2020 and 2021, Adagene (Hong Kong) Limited did not make any provisions for Hong Kong profit tax as there were no assessable profits derived from or earnings in Hong Kong for any of the periods presented. Under the Hong Kong tax law, Adagene (Hong Kong) Limited is exempted from income tax on its foreign-derived income and there are no withholding taxes in Hong Kong on remittance of dividends.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Australia&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Adagene Australia Pty&#160;Ltd. is incorporated in Australia. Companies registered in Australia are subject to Australia profits tax on the taxable income as reported in their respective statutory financial statements adjusted in accordance with the relevant Australia tax laws. The applicable tax rate in Australia is 30%. Adagene Australia Pty&#160;Ltd. has no taxable income for all periods presented, therefore, no provision for income taxes is required. Dividends payable by an Australian entity, to non-Australian resident enterprises shall be subject to 30% withholding tax, unless the respective non-Australian resident enterprise&#x2019;s jurisdiction of incorporation has a tax treaty or arrangements with Australia that provides for a reduced withholding tax rate or an exemption from withholding tax.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;United States&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Adagene Incorporated is incorporated in U.S. and is subject to U.S. federal corporate income tax at a rate of 21%. Adagene Incorporated is also subject to state income tax in California of 8.84%. Dividends payable by an U.S. entity, to non-U.S. resident enterprises shall be subject to 30% withholding tax, unless the respective non-U.S. resident enterprise&#x2019;s jurisdiction of incorporation has a tax treaty or arrangements with U.S. that provides for a reduced withholding tax rate or an exemption from withholding tax.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Switzerland&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Adagene AG is incorporated in Switzerland and is subject to federal corporate income tax at a rate of 8.5%. Adagene AG is also subject to cantonal income tax of 6.5% as well as capital tax of 0.1% in the Canton of Basel subject to certain tax benefits and relief. Dividends payable by a Swiss entity, to non-Swiss resident enterprises shall be subject to 35% withholding tax, unless the respective non-Swiss resident enterprise&#x2019;s jurisdiction of incorporation has a tax treaty or arrangements with Switzerland that provides for a reduced withholding tax rate or an exemption from withholding tax.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Income tax expense (benefit) of the Group for the years ended December 31, 2019, 2020 and 2021 were composed of the following current and deferred amounts:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;years&#160;ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;U.S&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,290,009&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;State and local&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 367,441&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,657,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;U.S&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 96,804&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;State and local&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (52,641)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44,163&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Income tax expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,701,613&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Reconciliation between the income tax expense computed by applying the statutory tax rate to loss before income tax and the actual provision for income tax was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;years&#160;ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss before income tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,432,308)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42,397,279)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (71,476,322)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;PRC preferential income tax rate as qualified TASE&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax credit computed at PRC preferential income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,464,846)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,359,592)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,721,448)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Difference in income tax rates of overseas entities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,492,721&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,286,487&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,549,985&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development super-deduction&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(a)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (230,126)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (718,979)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (569,016)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-deductible expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,306&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,238&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Changes in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198,945&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,790,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,277,418&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;State tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 291,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (127,880)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,701,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:18pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 18pt;"&gt;&lt;span style="font-weight:normal;"&gt;Note&#160;(a): Due to the impacts of research and development super-deduction, the Group&#x2019;s subsidiary, Adagene (Suzhou) Limited, did not have any income taxes for the&#160;years ended December&#160;31, 2019, 2020, and 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Deferred tax assets and liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Deferred taxes were measured using the enacted tax rates for the periods in which the temporary differences are expected to be reversed. The tax effects of temporary differences that give rise to the deferred tax balances as of December&#160;31, 2020 and 2021 were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Net operating loss carry forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,722,293&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,949,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Capitalized inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 95,589&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Unrealized foreign exchange gain/losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,166&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation and amortization of property, equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,428&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 79&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,729,721&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,083,834&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,729,721)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,007,139)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76,695&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation and amortization of property, equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (120,858)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (120,858)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total deferred tax liabilities, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (44,163)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Movement of the valuation allowance was as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance as of January 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 938,875&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,729,721&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Addition&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,790,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,277,418&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance as of December&#160;31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,729,721&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,007,139&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;A valuation allowance is provided to reduce the amount of deferred tax assets if it is considered more likely than not that some portion or all of the deferred tax assets will not be realized in the foreseeable future. In making such determination, the Group evaluates a variety of positive and negative factors including the Group&#x2019;s operating history, accumulated deficit, the existence of taxable temporary differences and reversal periods.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group has incurred net accumulated operating losses for income tax purposes since its inception. As of December 31, 2021, the Group had net operating losses for income tax purpose of approximately US$27,453,623. The net operating losses were primarily comprised of: US$9,206,664 from an entity in PRC which expires in years 2028 through 2030; US$8,467,321 derived from an entity Switzerland which expires in years 2027 through 2028; US$5,240,125 derived from an entity in Hong Kong that have an indefinite carryforward; US$3,684,472 derived from an entity in Australia that have an indefinite carryforward subject to meeting certain criteria; US$640,570 derived from entities in the United States which expire beginning year 2038; and, US$214,471 derived from an entity in Singapore. The Group believes that it is more likely than not that these net accumulated operating losses will not be utilized in the near future, except for the net operating losses from the U.S. subsidiary. Therefore, the Group has provided full valuation allowances for the deferred tax assets for all subsidiaries as of December 31, 2020 and for subsidiaries other than the U.S. subsidiary as of December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group evaluates each uncertain tax position (including the potential application of interest and penalties) based on the technical merits, and measure the unrecognized benefits associated with the tax positions. As of December&#160;31, 2020 and 2021, the Group did not have any significant unrecognized uncertain tax positions. The Group does not anticipate that the amount of unrecognized tax benefits will significantly change within the next 12 months.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group conducts business in a number of tax jurisdictions and, as such, is required to file income tax returns in multiple jurisdictions globally. As of December 31, 2021, PRC tax matters are open to examination for the years 2018 through 2021, U.S. federal and state tax matters are open to examination for the years 2018 through 2021, and Australia tax matters are open to examination for the years 2019 through 2021.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2008_To_1_1_2008_srt_StatementGeographicalAxis_country_CN_6zxDnTTPxkmKtBmcfSofpw"
      decimals="2"
      id="Narr_zbYcJNT02ka-4HAMBfc2Fw"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <adag:PreferentialIncomeTaxRate
      contextRef="Duration_1_1_2008_To_1_1_2008_adag_StatusForTaxabilityAxis_adag_TechnologyAdvancedServiceEnterprisesMember_srt_StatementGeographicalAxis_country_CN_wwO7JGio2USSa9yydNN8kA"
      decimals="2"
      id="Narr_9d-yHIqHO0abFHr7l8V2FQ"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.15</adag:PreferentialIncomeTaxRate>
    <adag:EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate
      contextRef="Duration_1_1_2008_To_1_1_2008_adag_StatusForTaxabilityAxis_adag_TechnologyAdvancedServiceEnterprisesMember_srt_StatementGeographicalAxis_country_CN_wwO7JGio2USSa9yydNN8kA"
      id="Narr_IR-FhQkzBkCBwFNAR9CNvg">P3Y</adag:EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate>
    <adag:WithholdingTaxRateOnDividendsPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_CN_hq0Btu-DBkq8lmsfbYdpfQ"
      decimals="INF"
      id="Narr_hl6RVFhS80GAj9wJ6F_-WQ"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.10</adag:WithholdingTaxRateOnDividendsPercentage>
    <adag:PreferentialIncomeTaxRate
      contextRef="Duration_1_1_2015_To_12_31_2023_adag_StatusForTaxabilityAxis_adag_TechnologyAdvancedServiceEnterprisesMember_dei_LegalEntityAxis_adag_AdageneSuzhouLimitedMember_srt_StatementGeographicalAxis_country_CN_LOA0Hce0QEeI6iU8D0rTDQ"
      decimals="2"
      id="Narr_78A2qPI0s0-9X60N9ggzNw"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.15</adag:PreferentialIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_srt_StatementGeographicalAxis_country_HK_tMrEpBM5ckCNd3jduDmhig"
      decimals="3"
      id="Narr_WTx0VDeFlUmbtkpl4-qQBg"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.165</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_HK_4gYbMZNRaUuPUEWsYd_dSA"
      decimals="3"
      id="Narr_kwnd1kzmMUWWHJ7KctWEZw"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.165</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_yYXARERJEEyfvZf0uA9tVQ"
      decimals="0"
      id="Narr_sMrMeo4nP0ekU-Ze_1cOzg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_YuWhG2JtdkyJ7W4ky9r1PQ"
      decimals="0"
      id="Narr_ksRHMbJ5hU-VIeWpwXFKCg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</us-gaap:IncomeTaxExpenseBenefit>
    <adag:AssessableProfits
      contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_yYXARERJEEyfvZf0uA9tVQ"
      decimals="0"
      id="Narr_kyZtjZI_hECbTYtboQHyJQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</adag:AssessableProfits>
    <adag:AssessableProfits
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneHongKongLimitedMember_srt_StatementGeographicalAxis_country_HK_YuWhG2JtdkyJ7W4ky9r1PQ"
      decimals="0"
      id="Narr_fBY058KYe0Cf-_46j1Dumw"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</adag:AssessableProfits>
    <adag:WithholdingIncomeTaxes
      contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_HK_zjbfDO1qFECcc41CmvbdYw"
      decimals="0"
      id="Narr_TCLdCBMt80K7pJTDEyrwqA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</adag:WithholdingIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_AU_S-6YiA61gUCW7VM434szsQ"
      decimals="2"
      id="Narr_2chGVGmqAUOQN3xLzm7tmg"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.30</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <adag:TaxableIncome
      contextRef="Duration_1_1_2019_To_12_31_2019_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_F3MPNQIHAUq3ElcVbpTt6A"
      decimals="0"
      id="Narr_malvB1VoOE6HMem-A03wHg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</adag:TaxableIncome>
    <adag:TaxableIncome
      contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_yYOL_1Zc_k-8AA3Sb91Fzw"
      decimals="0"
      id="Narr_ZqrkHW68u0mOaCE7F67mMg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</adag:TaxableIncome>
    <adag:TaxableIncome
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_jTUbwr8vS0Sq_Dw8Xns3HQ"
      decimals="0"
      id="Narr_lgRH8ZRP4UWk-RLz_VzmfQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</adag:TaxableIncome>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2019_To_12_31_2019_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_F3MPNQIHAUq3ElcVbpTt6A"
      decimals="0"
      id="Narr_fqkWqLZM-Eab4OAf8BADKA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2020_To_12_31_2020_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_yYOL_1Zc_k-8AA3Sb91Fzw"
      decimals="0"
      id="Narr_79c7UJC8vUeSLWJNXEtNWQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneAustraliaPtyLtd.Member_srt_StatementGeographicalAxis_country_AU_jTUbwr8vS0Sq_Dw8Xns3HQ"
      decimals="0"
      id="Narr_niG3QSOB5EyttrvYYsqFkg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">0</us-gaap:IncomeTaxExpenseBenefit>
    <adag:WithholdingTaxRateOnDividendsPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_AU_S-6YiA61gUCW7VM434szsQ"
      decimals="2"
      id="Narr_UWWUaDPW50eZcNGj5yEz4w"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.30</adag:WithholdingTaxRateOnDividendsPercentage>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_US_4Mf3uObvgkKrQagy395fZA"
      decimals="2"
      id="Narr_eHwJ2myDp0S9kIpu5gFpuw"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_stpr_CA_Zi09NHLp7kmMwo_bnVpuPA"
      decimals="4"
      id="Narr_U4CNzWjtgU-a6QMh3sLpYA"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.0884</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal>
    <adag:WithholdingTaxRateOnDividendsPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_US_4Mf3uObvgkKrQagy395fZA"
      decimals="2"
      id="Narr_G_jBY76S0EWI5QZCb6QRZw"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.30</adag:WithholdingTaxRateOnDividendsPercentage>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_CH_iL69fGVCpEaHddyIW4NKvQ"
      decimals="3"
      id="Narr_smb2xQIOO0iRHxsC8sEj5A"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.085</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneAgMember_srt_StatementGeographicalAxis_country_CH_2T-t4Od_mUu8G2OSLg0lGA"
      decimals="3"
      id="Narr_rygBDm2rn0ebGzn1oVO6bQ"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.065</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <adag:CapitalTaxRatePercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_dei_LegalEntityAxis_adag_AdageneAgMember_srt_StatementGeographicalAxis_country_CH_2T-t4Od_mUu8G2OSLg0lGA"
      decimals="3"
      id="Narr_XtjgnCGM6UibSL_3Kjxdew"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.001</adag:CapitalTaxRatePercentage>
    <adag:WithholdingTaxRateOnDividendsPercentage
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_StatementGeographicalAxis_country_CH_iL69fGVCpEaHddyIW4NKvQ"
      decimals="2"
      id="Narr_BxSybiaxokWSLWc6PLHjXw"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.35</adag:WithholdingTaxRateOnDividendsPercentage>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_lbAv9txbXUWm86SjcpxQ3Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;years&#160;ended&#160;December&#160;31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Current:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;U.S&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,290,009&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;State and local&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 367,441&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,657,450&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;U.S&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Federal&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 96,804&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 6pt;"&gt;State and local&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (52,641)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total deferred&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 44,163&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Income tax expense&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,701,613&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_HB7Xe37VfUCGQe1hrThpLg_6_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1290009</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_wkg--hKUUEG5rqGeENDhrw_7_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">367441</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_fefZ-nVJIUOKgqdci-bN0w_8_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1657450</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_7lZl2ix7FE-aPY-7PHk8mw_11_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">96804</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_x8ek5ELWE0utMeDwNYiBuw_12_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-52641</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_Ct6txab8pk2lNE3ekgtyKQ_13_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">44163</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_YKpnUfzZJEm2d5Ir7PbLag_14_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1701613</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_tXFxaRsSL0iAyTVIhI70BA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;years&#160;ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss before income tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,432,308)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42,397,279)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (71,476,322)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;PRC preferential income tax rate as qualified TASE&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax credit computed at PRC preferential income tax rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,464,846)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (6,359,592)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,721,448)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Difference in income tax rates of overseas entities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,492,721&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,286,487&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,549,985&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development super-deduction&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(a)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (230,126)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (718,979)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (569,016)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Non-deductible expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,306&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,238&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Changes in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198,945&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,790,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,277,418&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;State tax&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 291,500&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Others&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (127,880)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:63.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,701,613&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-left:18pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 18pt;"&gt;&lt;span style="font-weight:normal;"&gt;Note&#160;(a): Due to the impacts of research and development super-deduction, the Group&#x2019;s subsidiary, Adagene (Suzhou) Limited, did not have any income taxes for the&#160;years ended December&#160;31, 2019, 2020, and 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_M0yzvOU70EueJ3a9rZskZw_4_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-16432308</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_uxcUzCvg_EGZ-PwQDFREtw_4_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-42397279</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_aRN0sNdV-0Kn9sBDfi7Y8g_4_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-71476322</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="2"
      id="Tc_he7fJwM5hUSPpqpUffg9mg_5_2"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.15</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="2"
      id="Tc_mRLQuQN8skWWkZe0PenaaA_5_4"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.15</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Tc_y-PcQmGgnEmHCsa4XqDKwg_5_6"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.15</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_-UXGaOZNYkWsl_a84-zWTg_6_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-2464846</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_3E8-2YzZQUa9krNKvkMN9w_6_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-6359592</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_UUxBaZsXIUCuZvJbGSuXig_6_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-10721448</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_0MUWj-DBwEKn9Rdop_r2Ag_7_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2492721</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_AGqqzWV4wkObmYDfIkKxYA_7_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5286487</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_AGToVBfWQUC3daVdaMUnuA_7_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">10549985</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount>
    <adag:EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_YyDURAdJuUeZzUzS524Thw_8_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">230126</adag:EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount>
    <adag:EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_5A-MHysVQ0Oc-b_Ec0qsRg_8_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">718979</adag:EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount>
    <adag:EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_raxY_hlXkEqHEhJtxslyog_8_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">569016</adag:EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_mJ3u_ERVYkeDfkBF6falYg_9_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3306</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_0dMsd-sLb0yNw6b5fMT0Hg_9_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1238</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_386curmr10OLysrL5KtWPA_9_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1054</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_rMplN9OrW0W6UqnF4f7pZQ_10_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">198945</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_9S7SdqeTG0ywhPvvpn7FzA_10_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1790846</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_IZequLvbs0GVm1Tqsqaqkg_10_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2277418</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_IKvkPk9thUWgd8TXWBqbtA_11_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">291500</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_2pVVG2g9tUmDNUkyy8SpRA_12_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-127880</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_Pz-LJ84540ypl8LPrise8w_13_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1701613</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_Ymi5GG2wHkuTe8F88qoG3Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax assets:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Net operating loss carry forward&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,722,293&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,949,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Capitalized inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 95,589&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Unrealized foreign exchange gain/losses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 39,166&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation and amortization of property, equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,428&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 79&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,729,721&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,083,834&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2,729,721)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,007,139)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 76,695&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:77.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Deferred tax liabilities:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#160;&#160;&#160;&#160;&lt;/sup&gt;&lt;span style="vertical-align:top;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation and amortization of property, equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (120,858)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (120,858)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:77.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total deferred tax liabilities, net&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.04%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (44,163)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_gSV7DugewEe8o1nimtzjFA_5_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2722293</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_6QXxVxxJpEafXoqjq8bilQ_5_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">4949000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_PcK33Z34hkactnwnuIfH4Q_6_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">95589</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_J6suqYZ9dUCvksfdPTx1fA_7_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">39166</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <adag:DeferredTaxAssetsDepreciationAndAmortization
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_SAlKkpZ5N0e5s5JhTtfkow_8_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">7428</adag:DeferredTaxAssetsDepreciationAndAmortization>
    <adag:DeferredTaxAssetsDepreciationAndAmortization
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_BSm5x5zuTku79Ch6ASONsw_8_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">79</adag:DeferredTaxAssetsDepreciationAndAmortization>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_azcwRTgKw0qKuYYJUiodCw_9_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2729721</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_HIzhMtTYLkOPMUcNSfn4SA_9_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5083834</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_YymygLizgE64-VkYxyrhqQ_10_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2729721</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_WSxx5Ery5Uuo5k80OTbAqg_10_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5007139</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_bIsDTAbuIE6pHxWbDcQQoA_11_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">76695</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_9JPhsX8awEqOgGBlTiYKfQ_2_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">120858</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_f7H3PX_5506X_aBj5rPX0w_3_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">120858</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_yvmLKMLH8UiidNB8BYAFAA_4_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">44163</us-gaap:DeferredTaxLiabilities>
    <us-gaap:SummaryOfValuationAllowanceTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_T97ZD1tbrEeaq7LPZNFN8A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance as of January 1&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 938,875&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,729,721&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.23%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Addition&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,790,846&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,277,418&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:75.23%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance as of December&#160;31&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,729,721&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,007,139&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2019_s8ky1gW5E0q3TAGDRoFRVA"
      decimals="0"
      id="Tc_gC2EYRsVjEWUnhAs7Jm5Bw_3_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">938875</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_uWCsaJDWv0K2FhS_lpPCBg_3_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2729721</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_88UKn6_ccUG2ys6tSRvNPw_4_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1790846</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_EPOOG2EK2Emp75pVBc-fiw_4_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2277418</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_aAvbGYEIKEaloBOyBgMRjw_5_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2729721</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_tM2BszqNnk-pP3vq8bQHUQ_5_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5007139</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Narr_XA7ew2XwfUK2aww0YCZ6Og"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">27453623</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_CN_OhVh4Lb4B02ZVkGnT6Nwxw"
      decimals="0"
      id="Narr_rVn1G7aQMkaATYP7shdJjA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">9206664</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_CH_YBCRGjH5NE--RhN9ukhZ4g"
      decimals="0"
      id="Narr_-pLFpz__rEWCGJt5k8UcWw"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">8467321</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_HK_zjbfDO1qFECcc41CmvbdYw"
      decimals="0"
      id="Narr_6K5_PleRIEW7AcEe0Ugmng"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5240125</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_AU_LMSJo9Jtm02FhFmXG-t5HQ"
      decimals="0"
      id="Narr_bmLXOH7dqkKALpHSyZ8lxQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3684472</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_US_qd0LMDoF3kaYh2E7WWuXKA"
      decimals="0"
      id="Narr_6WOFiCuQF0aWGBOxZLsrDg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">640570</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_srt_StatementGeographicalAxis_country_SG_uNjj8HS8_UGTaPvk5ZRsdw"
      decimals="0"
      id="Narr_p1V4yAXBWUCSSo3S44xrCg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">214471</us-gaap:OperatingLossCarryforwards>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_9yuH8DxRC02_i2HMP1Y8Iw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;12. NET LOSS PER SHARE&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Basic and diluted net loss per share for the&#160;years ended December&#160;31, 2019, 2020 and 2021 were calculated as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Year&#160;Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to Adagene Inc.&#x2019;s shareholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,432,308)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42,397,279)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (73,177,935)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accretion of convertible redeemable preferred shares to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (246,184)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (248,113)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (28,553)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to ordinary shareholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,678,492)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42,645,392)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (73,206,488)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted&#x2011;average number of ordinary shares outstanding&#x2014;basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,178,232&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,950,698&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,032,009&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net Loss per share&#x2014;basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.67)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.46)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"&gt;&lt;span style="margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The effects of all outstanding convertible redeemable preferred shares and share options have been excluded from the computation of diluted loss per share for the&#160;years ended December&#160;31, 2019, 2020 and 2021 as their effects would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;The potentially dilutive securities that have not been included in the calculation of diluted net loss per share as their inclusion would be anti-dilutive are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Year&#160;Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Convertible redeemable preferred shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,977,914&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,249,824&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Share options and share grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 582,526&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,795,932&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,739,882&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_u0CGJbCPj06-UngVH6Yh_Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Year&#160;Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to Adagene Inc.&#x2019;s shareholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,432,308)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42,397,279)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (73,177,935)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accretion of convertible redeemable preferred shares to redemption value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (246,184)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (248,113)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (28,553)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss attributable to ordinary shareholders&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (16,678,492)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (42,645,392)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (73,206,488)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted&#x2011;average number of ordinary shares outstanding&#x2014;basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,178,232&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,950,698&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 50,032,009&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net Loss per share&#x2014;basic and diluted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.10)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.67)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.46)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_cfm9uL5fUUa94OOuy4z0dQ_5_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-16432308</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_kELduIDuyUS_-Mc9XkMDEg_5_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-42397279</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_dpqCODu-i0Ki-HtvcifYaw_5_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-73177935</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_l3mr2Fs-bEuIRtwat5rj5w_6_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">246184</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_dvfvf1TckkKQWMINkWMVTQ_6_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">248113</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_TgOIvgDW50S3NJGCKKiiAQ_6_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">28553</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_1nkNial-UUyCEQlPOdyPcw_7_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-16678492</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_gFpDIrdi3U-9jtBVk4Kr5Q_7_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-42645392</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_yOhQVVPuZ0OBXCYHMdBEvw_7_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">-73206488</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Tc_EylEQ07x-Uuem-DGE1-Bsg_9_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">15178232</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Tc_uqdShS48qUqwRWiBFEG9SQ_9_4"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">15950698</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Tc_4sE3-ga-DkurfkrK0Bm-QQ_9_6"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">50032009</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="2"
      id="Tc_Q8I7JLgE20GYg3tdNTk6wA_10_2"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">-1.10</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="2"
      id="Tc_X66y3BT2XkmaMm_dUZK--g_10_4"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">-2.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Tc_a7FKBRCr_0adGa3e_cNKhg_10_6"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">-1.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_2ighjAUwh0mxVVCjTSPr2Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;Year&#160;Ended December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.61%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Convertible redeemable preferred shares&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21,977,914&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27,249,824&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;&#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.61%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Share options and share grant&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 582,526&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,795,932&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,739,882&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_qtF149jaCUabjqo7frjCBw"
      decimals="INF"
      id="Tc_NXDQ0SKEvUSfYKs6Skyz0g_3_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">21977914</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_ESjTZBeLf0SCBovh04R_ag"
      decimals="INF"
      id="Tc_O_rmu0WVFUmZ_XEG4gmKFQ_3_4"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">27249824</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_yAAu1HlY9EC9pTVzah_bYw"
      decimals="INF"
      id="Tc_giFFo6ijg0OYWdLNvJZmjg_4_2"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">582526</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_wCLSLauImkivkl4yN53mvA"
      decimals="INF"
      id="Tc_O2N6vwns5kOoL1yrVwB2OQ_4_4"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">1795932</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember_6guEaEag302za51zg4qPZw"
      decimals="INF"
      id="Tc_q0wVCpGVwE2xT9pgoVjk6w_4_6"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">1739882</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_Ml0GSSmSx0qwQJsu4WJbwQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;13. RELATED PARTY TRANSACTIONS&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Related Parties&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Name of related parties&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Relationship&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Peter Luo&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Chairman, Chief Executive Officer and a principal shareholder of the Company&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Four senior management personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Management and ordinary shareholders of the Company&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi AppTec Co., Ltd. (&#x201c;WuXi AppTec Group&#x201d;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;A principal shareholder of the Company&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi Biologics (Cayman) Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Controlled by the ultimate controlling party of a principal shareholder of the Company&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;b)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;The Group had the following related party balances as of December 31, 2020 and 2021:&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi AppTec Group&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 124,704&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,080,116&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi Biologics (Cayman) Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,692&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,426,554&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total amounts due from related parties&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 132,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,506,670&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;As of December 31, 2020 and 2021, the amounts due from related parties represented prepayments made for the CRO and CMO services.&lt;br/&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi Biologics (Cayman) Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,361,503&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,292,268&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi AppTec Group&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 173,855&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 173,793&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total amounts due to related parties&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,535,358&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,466,061&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;As of December 31, 2020 and 2021, the amounts due to related parties represented payables for the CRO and CMO services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;c)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;The Group had the following related party transactions during the years ended December 31, 2019, 2020 and 2021:&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;years&#160;ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Receipt of CRO and CMO services:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi Biologics (Cayman) Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,567,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,217,709&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,561,276&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi AppTec Group &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(i)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,136,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,674,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 517,742&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,704,306&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,892,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,079,018&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_a7KTO7rm9USZkcyA68l_6A">&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;a)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Related Parties&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Name of related parties&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Relationship&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Peter Luo&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Chairman, Chief Executive Officer and a principal shareholder of the Company&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Four senior management personnel&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Management and ordinary shareholders of the Company&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi AppTec Co., Ltd. (&#x201c;WuXi AppTec Group&#x201d;)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;A principal shareholder of the Company&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:33.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi Biologics (Cayman) Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:64.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Controlled by the ultimate controlling party of a principal shareholder of the Company&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;b)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;The Group had the following related party balances as of December 31, 2020 and 2021:&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi AppTec Group&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 124,704&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,080,116&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi Biologics (Cayman) Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,692&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,426,554&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total amounts due from related parties&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 132,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,506,670&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;As of December 31, 2020 and 2021, the amounts due from related parties represented prepayments made for the CRO and CMO services.&lt;br/&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:21.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi Biologics (Cayman) Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,361,503&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,292,268&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi AppTec Group&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 173,855&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 173,793&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:76.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total amounts due to related parties&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,535,358&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,466,061&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;As of December 31, 2020 and 2021, the amounts due to related parties represented payables for the CRO and CMO services.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;c)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;The Group had the following related party transactions during the years ended December 31, 2019, 2020 and 2021:&lt;/i&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;For&#160;the&#160;years&#160;ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2019&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2020&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Receipt of CRO and CMO services:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi Biologics (Cayman) Inc.&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,567,962&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,217,709&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,561,276&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;WuXi AppTec Group &lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;(i)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,136,344&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,674,586&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 517,742&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:67.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,704,306&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,892,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13,079,018&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_aakkwWDe5k2bhxPkdccOxg"
      decimals="0"
      id="Tc_HdK9mNMVP0e8ayFv0ZW1-w_4_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">124704</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_GXYUWeoSRU-ouLAoR_nM4A"
      decimals="0"
      id="Tc_Jzx8gcwzFEamHrV5ZK1nZg_4_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3080116</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_oF1Ki6py4Ea_VIk2bXN2pw"
      decimals="0"
      id="Tc_JvewNpOW6EKIfHHA7HT_-w_5_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">7692</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_I6hnNvOh2UqAhbgZo1ZC3g"
      decimals="0"
      id="Tc_IVkFGpaXIUenc1wWCi_Z6Q_5_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1426554</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_Wza3gmGcokyQYkQn0CC8Fw_6_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">132396</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueFromRelatedPartiesCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_k-mxUNsAxEamqiwfwcHYPA_6_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">4506670</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_oF1Ki6py4Ea_VIk2bXN2pw"
      decimals="0"
      id="Tc_hM-ywrjaX06_7v7PMM6bdQ_4_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2361503</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_I6hnNvOh2UqAhbgZo1ZC3g"
      decimals="0"
      id="Tc_LEP254QnQ0qjibsV00gMJA_4_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">10292268</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2020_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_aakkwWDe5k2bhxPkdccOxg"
      decimals="0"
      id="Tc_0mbRfyWMoEOvZUujigHh4Q_5_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">173855</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2021_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_GXYUWeoSRU-ouLAoR_nM4A"
      decimals="0"
      id="Tc_5odhTbwHqk-eUZIX8l5-dA_5_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">173793</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Tc_dL2D12zr10e4Uod3CN2-EA_6_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2535358</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_Ray3lQ_Hf0WH0nlu8ccq9Q_6_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">10466061</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_XeTQYEWhbE-YyIEK2oP-aw"
      decimals="0"
      id="Tc_YrEMxpOx906tBr2H_3_Q7w_6_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">3567962</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_N1u78K2d-EOfIuR8F8QHxw"
      decimals="0"
      id="Tc_GZXsrOX2HkuNEUdk8p1kmw_6_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">7217709</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiBiologicsShanghaiCo.Ltd.Member_SAiLZZ5KLU2DxJiGDTfUCQ"
      decimals="0"
      id="Tc_wkbuksGUv0uTvwn2lRhh4Q_6_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">12561276</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_KmqFU3ZUgkCofpEfOKqHNQ"
      decimals="0"
      id="Tc_UwX6Iiqs9E2dG0Fhm0d6iQ_7_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2136344</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember__5lJ8r5zLkCATZnr5vRZCQ"
      decimals="0"
      id="Tc_f3n2Vkhf4EOD3aR-v36VyQ_7_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2674586</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_adag_WuxiApptecGroupMember_SwsdmKolekSilpQ3qYqN5A"
      decimals="0"
      id="Tc_AaF-fVyPWUe8RR-P-AODnQ_7_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">517742</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2019_To_12_31_2019_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_uo7m-2m6a06JnSUbvBslaA"
      decimals="0"
      id="Tc_WP8pgpGMv0WoZ2GMCCzfAg_8_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">5704306</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_dOiC75LhVU2oZehy5mDi8A"
      decimals="0"
      id="Tc_lA-JVsur5EyL3Yt_HwOLEQ_8_4"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">9892295</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_q83pj5eew0G-H2b3ek53pA"
      decimals="0"
      id="Tc_cW890vy0QUmoFIlT3yKM5w_8_6"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">13079018</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_8w2CHvJmxEu11m9dBXzbJg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;14. COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Operating lease commitments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Future minimum payments under non-cancelable operating leases with initial terms in excess of one&#160;year consisted of the following as of December&#160;31, 2020 and 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;For the years ending:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 412,754&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 255,309&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 70,367&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 738,430&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt;"&gt;&lt;span style="margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Payments under operating leases are expensed on a straight-line basis over the periods of their respective leases. The Group&#x2019;s lease arrangements have no renewal options, rent escalation clauses, restrictions or contingent rents and are all executed with third parties. For the&#160;years ended December&#160;31, 2019, 2020, and 2021, total rental related expenses for all operating leases amounted to US$175,812, US$177,453 and US$331,745, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group is currently not involved in any legal or administrative proceedings that may have a material adverse impact on the Group&#x2019;s business, financial position or results of operations.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_bB-LaTM4FkS7DXJRqL4GnQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;Future minimum payments under non-cancelable operating leases with initial terms in excess of one&#160;year consisted of the following as of December&#160;31, 2020 and 2021:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:0pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;As of December 31,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.27;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;US$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;For the years ending:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 412,754&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 255,309&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 70,367&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:83.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 738,430&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_jgLXdAPHLk6VI4dMez8Ysw_5_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">412754</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_a_BLdM8wTUOHvHP4pxJ61A_6_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">255309</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc_S99yzzMxZ0ixtfyxt2Bh7Q_7_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">70367</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Tc__ULirCgNnEKwHbE28wqNiA_8_2"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">738430</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA"
      decimals="0"
      id="Narr_dM4Uvc9Vt06dC8ozj0EWyQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">175812</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_1_1_2020_To_12_31_2020_HuaVeahZTE-bEkh_dFKA-Q"
      decimals="0"
      id="Narr_hbkMXsu9GEOEBqFQ_laP-A"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">177453</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="0"
      id="Narr_7m8U44uD3Uu41rRE1lR1yg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">331745</us-gaap:LeaseAndRentalExpense>
    <us-gaap:RestrictedAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_yne9CtpV7kuntk1o5dFAww">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;15. RESTRICTED NET ASSETS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group&#x2019;s ability to pay dividends may depend on the Group receiving distributions of funds from its PRC subsidiary. Relevant PRC statutory laws and regulations permit payments of dividends by the Group&#x2019;s PRC subsidiary only out of its retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the consolidated financial statements prepared in accordance with U.S.&#160;GAAP differ from those reflected in the statutory financial statements of the Group&#x2019;s PRC subsidiary.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In accordance with the company law of the PRC, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual after-tax profit until such reserve has reached 50% of its respective registered capital based on the enterprise&#x2019;s PRC statutory accounts. A domestic enterprise is also required to provide discretionary surplus reserve, at the discretion of the Board of Directors, from the profits determined in accordance with the enterprise&#x2019;s PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Group&#x2019;s PRC subsidiary was established as domestic invested enterprise and therefore is subject to the abovementioned restrictions on distributable profits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2020 and 2021, the total restricted net assets of the Company&#x2019;s subsidiary incorporated in PRC and subjected to restriction amounted to approximately US$1,267,900 and US$1,860,667 respectively. Other subsidiaries are not subjected to such restriction.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As a result of these PRC laws and regulations subject to the limit discussed above that require annual appropriations of 10% of after-tax income to be set aside, prior to payment of dividends, as general reserve fund, the Group&#x2019;s PRC subsidiary is restricted in their ability to transfer a portion of their net assets to the Group.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Foreign exchange and other regulations in the PRC further restrict the Group&#x2019;s PRC subsidiaries from transferring funds to the Company in the form of dividends, loans and advances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;As of December 31, 2021, the net asset base for purposes of calculating the proportionate share of restricted net assets of consolidated subsidiaries was US$1,860,667 from the PRC subsidiary, and the Group had a consolidated shareholders&#x2019; equity. As the restricted net assets of consolidated subsidiaries do not exceed 25% of consolidated net assets as of the most recent fiscal year end, the Group is not required to provide parent company financial information.&lt;/p&gt;</us-gaap:RestrictedAssetsDisclosureTextBlock>
    <adag:MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Narr_2QZyAaACN0eG4eO1h1Tfmg"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.10</adag:MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve>
    <adag:StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Narr_gaXY1u_hH0Kd0OAx8SOIkw"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.50</adag:StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital>
    <us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries
      contextRef="As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw"
      decimals="0"
      id="Narr_H3T5qe2Mnk6JI30GL-isEQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1267900</us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries>
    <us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Narr_9Lc5URwmQEyh1Np6AxDIbQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1860667</us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries>
    <adag:AfterTaxIncomePercentageAppropriations
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Narr_gAkP8wR0oUCoccK9inI0vg"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.10</adag:AfterTaxIncomePercentageAppropriations>
    <us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries
      contextRef="As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g"
      decimals="0"
      id="Narr_K06HrhYuYkuS1qJRnsaKPA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1860667</us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries>
    <adag:ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      decimals="2"
      id="Narr_Bmo9gvrFKkOmVM1yf6s4UA"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.25</adag:ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries>
    <us-gaap:TreasuryStockTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_F8NZ6cBRcEeMud8vYUohtg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;16. Treasury Shares&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Group accounts for treasury shares using the cost method. Under this method, the cost incurred to purchase the shares is recorded in the treasury shares account in the consolidated balance sheets. At retirement, the ordinary shares account is charged only for the aggregate par value of the shares. The excess of the acquisition cost of treasury shares over the aggregate par value is recorded entirely in additional paid-in capital (up to the amount credited to the additional paid-in capital upon original issuance of the shares). In the event that treasury share is reissued at an amount different from the cost the Group paid to repurchase the treasury share, the Group will recognize the difference in additional paid-in capital by using the specified identification method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;On July 7, 2021, the Board of Directors approved a share repurchase program to repurchase up to US&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$20&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; million of outstanding ADSs of the Company, from time to time over a &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;12&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;-month period from the date on which a formal stock repurchase plan engagement agreement was signed with a qualified broker-dealer. Up to December 31, 2021, &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;236,139&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; outstanding ADSs (&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;295,174&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; ordinary shares) were repurchased with a total consideration of US&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;$2,361,576&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;. As of December 31, 2021, &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;160,880&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; ADSs (&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;201,100&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; ordinary shares) repurchased shares have been retired.&lt;/span&gt;&lt;/p&gt;</us-gaap:TreasuryStockTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="As_Of_7_7_2021_ah_eEOxPL0CIPCxPK6qNbQ"
      decimals="-6"
      id="Narr_RGw3Gm2jJUy1vEFkGbCi6Q"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">20000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramPeriodInForce1
      contextRef="Duration_7_7_2021_To_7_7_2021_Q_S9qhvpvUC3dMaaONMnrg"
      id="Narr_ruMKknSmBEyhTSJjJ-FuWw">P12M</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="Duration_7_7_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_CCQsBDVo0ESOnNGl9WpWgw"
      decimals="INF"
      id="Narr_WPCUqhxk9k21vzMKrRADUw"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">236139</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="Duration_7_7_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_S5sj8QyYv0-TTqmBGm6N1A"
      decimals="INF"
      id="Narr_aw4GKyCxWk6rkc1ulla1jg"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">295174</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="Duration_7_7_2021_To_12_31_2021_VOZydV_s0k6TnW7n0mP29A"
      decimals="0"
      id="Narr_GGiOHt0e7Ue0Y2L0CGMB8w"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2361576</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_0J9hCl1ZSkaeQhRprqc5kQ"
      decimals="INF"
      id="Narr_DDertSAKvUGoWcYmEk3mtA"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">160880</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_rJ9HGaFep0uT39eGrH0BAQ"
      decimals="INF"
      id="Narr_PWX2Qp8_U0aQGRMJB0KBuQ"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">201100</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg"
      id="Tb_A_tN6aqtUE6e2D4s4hOnGw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;line-height:1.19;margin:0pt 0pt 12pt 0pt;"&gt;17. SUBSEQUENT EVENTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On January 7, 2022, the Company passed a board resolution, pursuant to which the vesting schedules and conditions of 2,060,308 share options granted to certain employees were modified. Share options as to which the applicable performance milestones have been met are no longer subject to the time-based vesting requirement. The share options vested (or to be vested) for each year (commencing from 2021) shall be equal to the lesser of (i) 25% of the total number of share options of each grantee (&#x201c;Annual Cap&#x201d;) and (ii) the number of shares as determined by the Compensation Committee based on the extent to which any performance milestones were achieved during that year (&#x201c;Credited Shares&#x201d;), plus any Credited Share of earlier years that have not previously vested due to the Annual Cap. In addition, the performance milestones applicable to the share options that remain outstanding were also modified. Incremental fair value of US$2,337,697 resulted from the modification, which will be recognized as additional compensation expense over the remaining requisite service period, if any. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;From February 7 to March 25, 2022, pursuant to the 2021 Plan, a total of 1,320,000 share options were granted to certain employees, with exercise price ranging from US$3.46 to US$5.60 per share. In addition, 99,999 ordinary shares were issued to certain management personnel on March 8, 2022 pursuant to the 2021 Plan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 2, 2022, the Company entered into a collaboration and exclusive license agreement (the &#x201c;Sanofi Agreement&#x201d;) with Sanofi SA, pursuant to which the Company will be responsible for early-stage research activities to develop masked versions of Sanofi candidate antibodies, using Adagene&#x2019;s SAFEbody technology. Sanofi will be solely responsible for later stage research and all clinical, product development and commercialization activities. Pursuit to the Sanofi Agreement, the Company has received an US$17,500,000 upfront payment in April 2022. In addition, the Company will be eligible to receive total potential development, regulatory and commercial milestone payments of up to US$2.5 billion for advancement of the candidates, which will be exclusively developed and commercialized by Sanofi. Adagene is eligible to also receive tiered royalties on global net sales of approved collaboration products.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Effective March 25, 2022, Adagene Project C1 Pte., a subsidiary located in Singapore, was incorporated. To date, this new subsidiary has not commenced operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"&gt;As of March 31, 2022, the Group has repurchased an additional of 272,099 outstanding ADSs (340,124 ordinary shares) with a total consideration of US$1,539,631, and no additional repurchased shares have been retired.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <adag:ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected
      contextRef="Duration_7_7_2022_To_7_7_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_f5xUbvNTBEimEH5nmcz29g"
      decimals="INF"
      id="Narr_kMakVDq_ykqOgNmjCIVGVQ"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2060308</adag:ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_7_2022_To_7_7_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_1hE8qqTDwUyc0lzaYCJtgw"
      decimals="2"
      id="Narr_FJjbgNWKsEmzNQ0y5jt-3A"
      unitRef="Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="Duration_1_7_2022_To_1_7_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_rKG0vF3HuUuOSzupeNgTNQ"
      decimals="INF"
      id="Narr_qgljWAZ_JkKpj-WoqA_JfA"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2337697</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_2_7_2022_To_3_25_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_qgR18IIqT0W8xFm3O123fA"
      decimals="INF"
      id="Narr_GAaO_UkzZ0mIETxaDVVcEg"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">1320000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_2_7_2022_To_3_25_2022_srt_RangeAxis_srt_MinimumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_ZhmKNezcek-HK-1dHlkcpw"
      decimals="2"
      id="Narr_qlTON5v020WCWSFwf-mJUw"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">3.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_2_7_2022_To_3_25_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementEmployeeMember_us-gaap_PlanNameAxis_adag_PerformanceIncentivePlan2021Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Nz6vByh-PUO3MFMmJbHcFg"
      decimals="2"
      id="Narr_G2RBFxn8ykaLKxN-9bRRsg"
      unitRef="Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w">5.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_3_8_2022_To_3_8_2022_us-gaap_GranteeStatusAxis_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_yR9MjqeEykqztm3xL6TxRg"
      decimals="INF"
      id="Narr_BSzPfw5s3UCuhFPkBRrWQQ"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">99999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <adag:CollaborativeArrangementUpfrontCashPaymentReceivable
      contextRef="As_Of_4_30_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_adag_ExelixisAgreementMember_RSXFKdhcqEG6xrEDD5fFIQ"
      decimals="0"
      id="Narr_PeYfzUn_wkWKauykY9Ptcg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">17500000</adag:CollaborativeArrangementUpfrontCashPaymentReceivable>
    <adag:CollaborativeArrangementMilestonePaymentReceivable
      contextRef="As_Of_3_2_2022_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_adag_ExelixisAgreementMember_r29U-8QtcEKfWUKlkQp_tw"
      decimals="-8"
      id="Narr_BPXhhdvg4EyBwH4Ug4PqXg"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">2500000000</adag:CollaborativeArrangementMilestonePaymentReceivable>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_pJ8hEn_UR067dD0gRcTb-Q"
      decimals="INF"
      id="Narr_L8rQ4MuDy0m0uh-3JCsA6A"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">272099</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_hZT-sOgQYEa1gHbRXtKNww"
      decimals="INF"
      id="Narr_6KQy1Q9LVEKiR03SUkiAtA"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">340124</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_-XH9Go_6R0eqJay27YP0iA"
      decimals="0"
      id="Narr_Y1NRoJ9x9kmca0gdrxby4w"
      unitRef="Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg">1539631</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="Duration_1_1_2022_To_3_31_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_-XH9Go_6R0eqJay27YP0iA"
      decimals="INF"
      id="Narr_BTRN60qY_0mdDi1nOlw9lA"
      unitRef="Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg">0</us-gaap:TreasuryStockSharesRetired>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>128
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M2,N/$6<AE_H ^/Y:"%5OZ!.L7^ Y_!]02P,$%     @ R8":5/=PTE#M!P
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MG@OD]3UCXO4@?]Y4/U]<_@=02P,$%     @ R8":5 G&XL.0!@  SQD  !@
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MD\.^<6456#%3YAU$LXMY"-6*6>YCEKTQ+W146L\MJRD#\R74(;OX2]JCC['
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M"D ?76*%-.1/!K;P!Z?2KSJ)GA&;J6F B:4-AW'MX\6&T&D_H;]!7U&;]7#
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M_O#E^R+Z^D<TNU[\&?WQZ>N/132)_EK,HU?_>GTY[>"F9NBTV-_@IK\!]=R
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M!K$9F62^A#4H,0E+\0R."AHJM#/Z=$-<U>120FYUXLX%3F@B4^ZLD O,,MB
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M3?+2A[S"D'/I@:>FCNO]5H'DG-*CX&//,82*I^UT&5"(V:(3[CL1ZAKMH_A
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MN+,[FG$HY8BY,L[D1^WU?B'+(7K0ZGPFK;>LH3D&H42T](L(;X/1\<\FR<W
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M=DKH*-$X%2>KU;?]P^,.;=>K]=U3LORZGJ"']6/D*LUN<MRL9UIV3,$9)C]
M]YRI4J(URR$_)7!U66-MP5#;,KC(> O9%(7^! 5>X%_@"\=>0\L7_E.O)]2S
MD7IFJ6?_88R7F<(I.D>&/KR;!UYX\]=G(A$OWGCUF*%*0=A1#TX]<L_._4WZ
M?O?^Y)YD&6^8DEJB&9 7G%*P<3^X0>'$\SSS0PG5\L<L Z07"<IYDZJBH5J4
M/7A ')_#JZ=,?>1/'\T]TD$%XF#5+I%]HI/$Z!T72M+IZ'=ZMXWNL3@0)A&%
M0D.]Z2>M7]$IO#,4KZVJ4JZT1NVUU$L1A$G0\8)S-1CF@7'-QK\ 4$L#!!0
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M;MCVH$5MM]J=T+0CK9C33PFE<2#[6M ,]P>3H/O-37\#4$L#!!0    ( ,F
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M& P3#U0W/CK!R+UKV1MI< "X98D3ERNK@.=;*<U9L ;Z&3[]&U!+ P04
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M">#]5"FS?+ *VHNET[\!4$L#!!0    ( ,F FE2%0AIKK@X  %@Q   9
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M[V5":=R1A;$NK-<V#^ J:;>.038V'%7\C%,ZB JQBRL+ZU![!F1ANJ>..U>
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M)]-'3^Z)>@,LPF-@ /#9DZL6"\ZK$,VBBII$24+IQL:1U-/*H&G"Z<2#_7$
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MJZT-(!>9+XL):((@B#W4VE3J5/SLVQ *\A@&\@979A"_C2U#IC?+DDJI !K
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M<=^*M88)*U/&&B(I!+$(5S<J5$(QN(0A+5-.KL*SA:Q+T#5B7E:=1'MV<J'
M0A3D^MHGG!+R/(@=QDX\2H6SO2FAZZ^\%N'^.[4%K=7+&)K?O'O99#.L%VX0
MR8!J\^-E\(Q-H4(-&PF V ^F_(;6\X^WLN$?M1VQ/WW<B8\?[L5_@>1_@>2'
M@>2I3?U)87&<J5>[?">4/&7_]X3*6\5-5W;NVP#S/;'D/QXU;X7.CMG_.?%S
M=QB WF+DWQU%;WG-+RD0--8CIAS_)HA[/S#]^5!W]Q\,NR<ZRGY_]/T =. /
MA. /0N#'/.L;8?B_L/?OB+T/9+'?"7@?LXK_;^A[RL5W@."!U"^4=3V[VL54
M3\@X@NML!AZS#B;@N_^#@/<?( ":_0!XRB1VNUFG:PW"1I8Q],^I,?#)WW)9
MV$JV%U2Q=RB9G4]:A\88\7]P,.#_\/']R?W'3^XUJ3\>8FM97F#1HC2DX_83
M:A#@AR.-9O<.E94IR(!@%EE(Y)W>J4 PS6^*<$-(MY)$N))Y(PP'UQP93HL4
MM+)1X9^*ETVZ'E?@#/YO )EO$=PCD/SY='JO+;,.W/8MX$R,A#3IAISSS;N7
M7>SE$#-%+J'$-Q6,8OZ>?,5.T.P!/#F;]=!GB;D6K1H(1Z=.K(^J@)98*5$G
MO@'":EJ:H,(ANW$5_(F &&0PJU8X#,)_89R[PXY0*7O,IP>P<:QT3*Y'X\"6
MKO42"^[VJQ).7%U=IED8PNW_R++&78J]>T^R;+6C^*+ Z/S]W8]+52"R("Z-
MW7@@8$*A1B(&DQ'<ANY)9V)S56C:3$S0Q(#T.]\ND%FTNR!X&E3_X F9R*&!
M\*X=R&9&#KLI;51!1,(H<[W/*A->G2%EW;FGEU0N=TH5!=86%T75WT2.L_N/
M)P_/>9,3OCZ>D?,EIR"*W4%>?'Z0C.^?_T"KW2GCP^)&LR*4 A23&4DEB1/L
M<K#4L6:*9%/#TM]$/L5N _,W5-$TUHGKB[C'BQ*\;$%@;?>[@/:UN,-(!,8V
MW.5I$!"&K^]^_0A(^S2V?FNG5T80>,]$O8WK. 7)<4@.Q\WXUKTPDBH?Q'NV
M+6^0W"3-"6F3+J+N3?;V4335)49 J/ZAX:<X3,,V4'\A=$($)K.$/3$(O9_9
MI$F/H\+J8>_['A[ #:H&H>UTFSJXH_<N0N$WM S()+3=RK>?D!SH15;.#5VI
M^L(?<8\A_]=8,I+E$I8YZ6LL5+%FP[VA:6TWMXOGN#V[Z]&/>0E<9VXPRGBZ
ML=NJ+34J.0*5C/\79CO@0*&RW$&_'39</;#-E-%T S7E-$5V#E41U+L@K*6>
M%RJ%S5@)A,B=./3UD_:VF,>C&/=.0FC87VA+:Q@_<1..>B/;:&E+<LB6VI#2
M)71\P$8&L;")_[1/6&?PT2WJ GM^<(G88#'LI\N3&WUC"!C8<90@6H=<&=\Q
MBR]8,QK28(,I%T$X9-O>D+V%@!U@\\R]VDAU!%-['CTD.,!;1$DM6J3A]V?0
MYPBK4& _N7(=_:.Q6>5WEY!^7KX?\D?Z10_QN!%;;C6&;9!D;]"1C %6>LV9
MA)(]@H)*.H/^3*@(%K06RW*XB[;D!7HRWYUXS(K;68\@:#K7('=1<9""8.36
MZJJ"WJ4!3)/V]%4*,?61GOV>]G5D3AJD8P@=@K:D1B7%G,@X5'\3T!O:T!P:
MJW5PZ&QW$MH>KJ)'CT#TM H5<3<T"WX_.SEC0?K"6$@%2\0@ OJ7 ACMS4M9
M)A'80M[8 J.L?.:')O0YK5? 4<#2MX/ARF>Y_A&TZYH28=![>LRE20C</?/^
MEV]]#@VRZ 9CTIST$@BIM!T?)BV93_!''HI\"XQ/T%LWBI I.E<"?G]C,HGA
M_-AYMDQ9[ )O*8!&:!7"8^Y>3'7'<5,B^BSC\3!9 *SO<2BB"  -N?P"9-0.
M_DN/VZAPSL58!K*:#3\\IP"R_%PO"=SSF#;TBBCS?H'0[,P.HVJ.(#"@<NUZ
M&;"GZPFBKSV+#AIWG+;]B_)![T%U:'V*EFUM!YFZP&Q^9QXMP71&TV@:4%%P
MR8FFW^@(2I("VX=!7AN3BRLV:5S_ ]:<&!8_F5N=<='C ?-)@I5T#F5QFJTP
MJ3$4$(I./B."+&O<QJ)3;+PYJ7URQB,[(>?Z]^)U?D(_+3(J/YZU+RJ*P"&+
MA;=8QTZQQ",L)WSBKM*,/M)Y$=H?:(ZA-9!@?:?)N2:^! W!O#55#&"S'\/\
M9)R0XR9QVQO8(%^FG.&W<#%IA-U<.J7!%.'E@$Z&9 ).Y(]L25MH;H[#V17<
MML9D7F)%X3Q<T51 '8W%EC0L$7;K.&!NM&V!\H5TU4EE3NA.//HX(+(F]J,2
M<0'/&E)?X)NS@?28=6,<\-ME" \4X&!HXOX(7;J[%KW7]/W^+M7AQCHI@BI$
M<)4"-_PU&N:>R/N-A5!_]=8&65?$_A03S<3V,68(@K83VW4(6D&GHC*6 5KZ
M,E8O[:F4)M$FAD)LMC+&;W;FVOG]0]7?T[#1W,@\^'0LND /@H])T.\C-7N
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M1<$"HOC,?JIYK5T!FG/R22?>CMNK'2&XRL:A!9N\&P<(,GA%#D"3#:_MDX^
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M&9^R>6%&:O$G7]L36;Q4%;7[A\6*ER8-2.>U4>5:&#4HA5RM['GMAQV!MG=
M@*X%J--[]9#3\HH9UNMJM0!MN1'-;IRI3AJ5$](&Y<EHO!4H9WJCZ[O^^/H*
MAOW1^!\8C_H/3_W!^/;QX:G;,HAON5KI&NMRA44/8/D4[I4T>0W7,N/92X 6
M*K;5CFZTNZ1'$:]XVH3 )T ]ZA_!"[;6!@XO^$EK7X"'6_#0@8>_Q)7'L?R@
M"8?Q@)W"B!?,\ R&3!O!:_CCMS;U@O.#ZP,K.:@I%M)*KEK+.1RLCSH7%0RY
MX1KNY@H&.1.8])+@3O I7#_S=&X+"!ZG4Y$B%Y,9,*BTD*FH6 %USC3/59'A
M';YC<@X#559,+N%&S;$/<"F4QMR56.Q8U@8JKFLE)2_@_CO1PBJ="8DM8A>S
M?@WZ9?ZW@'Y5C7F*M":!.Y,UX<3:2[WSW=M/6LTK1_?/3Z'_,9T=P*50A9J)
MM(:3 5NBZJ=P*S$E!YCF6A4%^G&R=&+8! 3V" [I^DK(F?/QT@)_T$^;6$U.
M88QDIS?D+'-,4P15"PN[&\(E]J2"R10CR9R+L&1X.4'L==EXSJ.V?L[>S9'W
MUO[;%UZSN!=W#O[V\/GI=_=[$QGP:4@2+X2 >&V/^'Y\W/D)B3L4?!+2F$11
M"&-ET*VL5'-I:LCFZ"JMRC>)[@>4!)T80A)Y,8D3[YA9+QQ'G/_??4!S_"QB
MECL:'E!G;@5*EMGHZ56H1X\.=W#_B!6AOV$IU<W_46 ..1U]%_OHN0!\C] .
M)31N[PME$I!V%+DUZ01[8F/4&\=1$@41":*VQ0[CF'BQ_Q/!V?/"B]"P)9L4
M2/Q82-(?J46CF:R9FS>L+MIR6/XE9]C N/TJOC;%[_SR,GV]WJP-W=7B-<\[
MN>-W?B"1[&^$>*(R-G;[_'O8R*-9&) H3D@GIM@$J)]@U^A@]T"B3V@2[\G'
M$W&*Z>4',0G"$'=Q@N7?CB&RPB'=OAK9!D0"+X8.:=OL[F .8S]*.L3SVQNV
M?4-":V?V*KF>N0FSQL\ YN-J#-M2MT-L?S6[?6=?3<#W3,\$)D[!IRCJ-9.H
M 7HU5:X.1E5NDILH@W.AV^8XB'-M&?!^JI39'.P#V]&^]Q]02P,$%     @
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MSR*P_1O8;[QIP[NS-IY>L;"LZ6\#6A:@^XTQ_FG#!L8_(LM_ 5!+ P04
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MR 4TN:"ZT79+@-D01M:V5$M%)4(YF"G](0O9-%H5<J%)-.2BFY@"TQ4(!6L
M5\DUB061$37,B+&,%=J:%;&)+/Y"'S,D@P7XPG?<C&4?G:-/K7($OP@C\1YC
M#@/A81A]8AUC+*A[\4J B2 )DEN23IP4M@9$P8A+9^NHP%>,I37/PB)2[UB
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M:P#U*"1>,D$4,K%-N=^HI"Q'A5T9]3>WMN]CP@K%?D'IB9^QUAJ)8\A$N6\
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MQ=E N'3?2C^";>(=9V$#;DSQL<(5E1P/P/>E12-U/WB!_M)[^P]02P,$%
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MCJ\Q:B5S XG4&5A2:%I]*>@4O67M%D2^!)#I*D-!"O8,6-K$(&+I, .3 ]Z
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M?Z[!*S$5O@"_+TLPXN4/G,!]GOS7_P-02P,$%     @ R8":5([K]=%8 P
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M5%%OVC 0_BNG3)HV:6L@T+7J  E2Z)" HE(Z[=$D%V+5L5/;*>V_WSD)*9.
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MWH<"T\TT;C9657X"SI2%>>J7*_B X=HYP/E"*;O=N #M)]'X)U!+ P04
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MFUF4#GDA038 10'E>U$W93N,<!1!MGE &)SM!CKNR>8060@<S3"!-$7VE)*
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M6]E'2+5S=[LPS=+-NC>-@<G9O2ZDR*6R&^#W6=.8]<(:Z/_Y<?0W4$L#!!0
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MAVY@Y-Q=]<?2&%F[QQEGN&Y8 ;R?2)R;BX%=H/_V<_P/4$L#!!0    ( ,F
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MW+2#8M7.WVYK9>FN]&)#'R>HG0&]WRAJGX/B HR?.\MO4$L#!!0    ( ,F
MFE3TMS:]1P0  -0+   9    >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;,U6
M6V\J-Q#^*R-:54&R8.^P"4$B)#F-E L"3D_[:'8-:YU=>^OU'L*_[]@0#B%
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M.:UDGJ,?9RO+AJ7/L3,P2#9/7"PVH4;@#_KI)5:S)DSQVNH-&4TMT1Q!Y=+
MOLZD&<VI2#"2U+H(ZX,5,\3>U(AC/6J*Y?S=''EO';R5L$]B)>X<W.WAZ^17
M^WL3&7"]@'2< 'SB=!WBNM%IYW=(%'O@DL"+2!@&,)4:W4H+60M=05JCJY0L
MWB2ZZWO$CR,(2.A$).HXI\QZY3AB_?^N ,7P8XA9;N_P@#HSPU#0U$1/K4,]
M?K*XPX<GK CU TNI:OV/ G/,Z>B[R$7/^> ZQ(L]XD7=0Z'L^*0;AG;MQ/Z!
MV&CYQG$>"?V0^&'78 =11)S(_1?!.2#A56CHRG[-/AB2Y#.UN-O541=E* S]
MBE%L8,Q\ O=-<>/_O$SWU]N-H;M:[-.\DSMN_(E$,K\QXO%2F]@=\N]Q(T]F
MH4_"J$/BR,,FX+D=[!HQ=@^\=(G7B0[DXQEO8GJY?D3\(,!=U,'R[T80&N;
MVTH-30,BOA-!3+HFNV/,8>Q'G9@X;O?0)-#>F;0*IA9VGJRP_6,>KH>N[>UV
M9!VL)[6?Y.MY]X&J!<>$R=D<69U6)VR 6L^0ZX.6I9W;9E+C%&BW&8[=3!D"
M?)]+J5\.1L!VD.__ U!+ P04    " #)@)I4T:@/EY\"  #O!0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970S."YX;6RE5%%SVC ,_BNZ;+?;[E@3DE 8 ^Z
MTHT':*^P[=DD"LG5L9GMC/;?3W8@95O+[;:7Q)*E3Y\D2X.]5/<Z1S3P4'*A
MAUYNS*[O^SK)L63Z0NY0T$TF5<D,B6KKZYU"ECJGDOMA$%SZ)2N$-QHXW:T:
M#61E>"'P5H&NRI*IQPERN1]Z;>^HN"NVN;$*?S38L2VNT'S9W2J2_ 8E+4H4
MNI "%&9#;]SN3V)K[PR^%KC7)V>PF6RDO+?"/!UZ@26$'!-C$1C]?N 4.;=
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MOZ*L2MBQ1WK71D-%M5$@I'B?,)$@M]4&&CC%3"&VP)'>FWZN^.=#7_]/.'J
M)@=R-07C8%"5FB3 AP2UMLE(@?"(3$$B:3:UP=1J38Z024Y#;J&8LZ268;FA
MD(>V!<!$ZOK7AS>O>F$0??SK__A/Q-]-+' C?%F]!II;Q\NRU8 B)6K]4_,0
MXG;8ZG9B*T1/-YU.*PH^6&4,W: 5779A+0V5HQOU6G$4//<\_),A+%%MW:K1
M5*1*F'H>&VVSS<;U$#^9UZMPP=2V$)H:DI%K<-'M>*#J]5(+1N[<2&^DH07A
MCCEM9%36@.XS*<U1L &:'3_Z"5!+ P04    " #)@)I4M2'.+00$  "5$0
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M'LCJ/%<3+7;N2*R$-@?,#;?F"D1I"\S^6@C].K&GK+E4HS]02P,$%     @
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M/!N]1*,G-'[^%?6CARGZ@:(TPT3HHBO$%XARMD145RU!6$I0$BF.'M*,\AV
MT5Z[2E#,F1)DOK95SBAFZ&H "A,JKS7C;#I 5]^NVZ[2N9B(W+B(^SZ/VS\3
MM^>CH69>2?3 $D@^$KA:A%()?Z_$O5_).(#X!@7>=^37?.]$0/VOPVLGX(,O
MP[W;BFR"LJZ!Y0O.\%TH586'L/006@_A90^42WFJA#E!PQ*8_K/I:F4VAYI>
MM!A467R(NU[&7:]49@(;8&O0/2OF2T;,O:Q0HU&R-BK5&!(*^F-E@#*\,Z)(
MQ 42?(>IVKV?::=@RG#J?N4.ZA5:5%E\B+I91MVLU.+RUUHA3:MTTJJ4IG0R
M!Z;=* 1O>FA).'EE6I_*[?M^$-X&1Q?GLUU#VS6;1XI]-O.\L.XUZD>ZN0<=
M- 6QM)-(:CG63.4MI#PMAUW/]OBC\WL]!/.9]4Z33] A%DO")**PT)2UFZ:N
MH\BG4KY1/+-]>LZ5[OIVN=*#'(0QT.\7G*O]QC@H_QIT_P-02P,$%     @
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M#5/ZY:"R!?1\(:7936R#ZB?6^0M02P,$%     @ R8":5%IM@$WH 0  0@0
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M:&?.+TO[DH-V"?:\4 I/@1N\_K.1_@-02P,$%     @ R8":5.#"61%F @
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MZP-3"7)]3:DX!*JQM/^1Y -02P,$%     @ R8":5,7SROU !   0!$  !D
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M%\?U8B#81AU@5TS(X["Z#"CQ*<\-Y/TU8^(PR!-4'TW&_P%02P,$%     @
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MH9KT+.J%43R*&%+1"=6L\!QGB1I&AN2D.NEM)'H:S5#3NVWM5=1/,P4UU.G
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MT7,::YHM--E$+/ R,,_ 6_KI?_='-A%;  Q[ #@#8%4 R0!$%:!G %T58&0
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M Q>L)"(:BK*<7YN]M9N6]9MAUMHYJK;1SR<FDS'+9FF5BCT-O3KPS&ZA91T
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MR\OR#9G\A--MMD7Q0CFG<7:X(7Y F#00WZ\HY6\G,D&Y+3;Z#U!+ P04
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MLRD7:H#\_2F.T^V)>DNF?*GM_#]02P,$%     @ R8":5(UES70>!@  @QX
M !D   !X;"]W;W)K<VAE971S+W-H965T-3<N>&ULK5E;;^(X%/XK%MJ'&6DG
MQ)?<1A2)0MCI2C.MRER>4S 032YL8MK.OU\GA%QLQX2J?2@D?.?X?,<^_DZ<
MR4N:_<[WE#+P&D=)?C/:,W;X/![GZSV-@]Q(#S3AOVS3+ X8O\QVX_R0T6!3
M&L71&)FF/8Z#,!E-)^6]AVPZ28\L"A/ZD('\&,=!]N>61NG+S0B.SC<>P]V>
M%3?&T\DAV-$593\.#QF_&M=>-F%,DSQ,$Y#1[<UH!C\O,2X,2L3/D+[DK>^@
MH/*4IK^+B[O-S<@L(J(17;/"1< _GNF<1E'AB<?Q7^5T5(]9&+:_G[TO2_*<
MS%.0TWD:_0HW;'\S<D=@0[?!,6*/Z<L76A&R"G_K-,K+_^#EA'7("*R/.4OC
MRIA'$(?)Z3-XK1+1,H!]!J@R0((!LGH,<&6 AQJ0RH"(!GTA696!-=3 K@SL
M,O>G9)697@0LF$ZR] 5D!9I[*[Z4TU5:\P2'2;&R5BSCOX;<CDU77V:/_J?;
MV<I?@/G]UP?_VVKV_>[^&_@$5OL@H^#^4*Z 6;$"0A;2''Q84!:$4?Z18WZL
M%N##7Q\G8\9C*3R.U]6XMZ=Q4<^X_P:) :#]-T F@@KSN=Y\0=<&P+#7?#'<
MW%28^X/-H:<P7PXW=[OF8SY]]1RB>@Y1Z0_W^/MVC)]H!M)M-5FYQB>N?>+2
M)^GQ>7]D.0N239CL0,  VU/P1'=ADO ;JNDZ>;-*;\5N]CS%R"/$=B;CY_:\
MR#C7MDWD=F&^#+,<@ENP#BE2DR):4O]D0<+H!GP($Y 7JSM7K=PYD0:'KD=@
M,=4=+C+.QA!C!PMD9!QVD&6::C)63<;2DO%?:;8.\\MT+&GX3PACSQ)ROE#@
ML.T1#Q.!CPI(S#X^=LW'UO+A0K&EX8#IL>7A(;$LRQ3XJ'">V8[S1$>!([;;
M1\>IZ3C7%A!--BH^CC0^<4W/=,3YD7'*$O-EG*K$EC),5V)N3=O5TOY)\V(*
M.7% 7P^\?> 7+ 7/_/:%-+@7T] )R*L#\H:42? 4T0L!>'+9$Y=7M#@/,@[S
M&D%$'2<T&R4VM=OXK[(+XOF:/=.,=W7@7.'@(0O75+.IPY;:PS=OZV7=;=(H
M"K(<'+B@E#6H+,%J%+>=*\.QA$0I4*9A"RA?B<(]R6PD$:+!6_T@3K>5PPXG
M;+A"N/,*YK5AR,!0Y(ZD58)$X@I/!K)[F#?"#?7*W=6%@?.)I5!,PQ/U3H&"
MAB>JG=*79?70:J0;ZK6[*P\#:1$I%&R82*0EH_AB%EFI0 CUL&HT'.I%7*T2
MUU"TI+@LPY-6HXR2Z]57H.1Z75:H8?7:B#_4J_\PW;@F,;8^,=TX&U6'>EE7
MR\DU<3F*N%RQ35:@S/:$=:-OQ!FZUTE,N4T"_N1(P3((,_ SB(Y:I6ED%^IU
M][V4QI,284MK<J% 84-JC!0H9/2T%ZB1;62^L])4#ML5Y,A"4Z':T;H&+AO8
M\Y]8Y@H3QQ!1O@)E&:1'=U#36B!]:_$6W:E<=D.!6*0EH^RVHE2T5+Z<GH)'
MK6=K?2/Q%MU!LK([[5 J6C+*EK9N7X&R>G<"U'0)Z.KG^^OV,23+O&-@L5=6
MH.3R]2N4JRW?I0+57[Y-7X'T?<6["P^2.X5.8KIQ-IT"&O2X_W;A0;)N\\U!
MW$D5*-*_.33RCNSKA.>1%L?>Q>J;IPG+@C4[!A'X3K.XG(K9;I?172%+=_S7
M,,G#]45M0HV(H^'/YD4"_U">/G72]([<DREP0<Q9['- P";XDZL.) =Z\LZ>
MH-GGRK_@RJE<X;,KI\_3<J G>/($D"JF[APTK0AZCX."2].C'V/0]'3C;_H;
M])9SA4OQZGV>XT7U(D#]ZTGORKZ:.FXZ'JSO>(:V=LH45+[M]EZ/"30]6]0.
M!=+&R(6BD/HJEPXF-NDYDL%-3X.O/BX1-ETU1R@__-O0LQPB4I2!ZF3X%?)B
M,I8*H#X932>$]9W0]4JI3H[B9$1(3C? UBN+02<?&HE4!X2EC+D.@:YXGJS
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MORR LOW4"9S7A0>RS:5>\&:3"F]A#?*_ZIZKF=>QI*2 4A!6(@[9U)D'GY/
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MF<<OA^,+P3;1>[ E$X)YT5>'8)OP4$#^OF),["["!9)7]%?_ 5!+ P04
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M-!1?#W3LHFP"Y43QK2V\:ZYT&;?#5#=.$.: WD\X5\>)$:A;\>074$L#!!0
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MF#0&\'XMA'X;& ?M]\GT7U!+ P04    " #)@)I4=?ONB',#   '"P  &0
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ME%XKU@Z*JJ=5$\4WMBTLN=)-Q@YS_1L 80+T_HISM9^8!,V/)?D#4$L#!!0
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MVPFRL"<+#5DX1J;N!\*$ $A*7FT;B;8$ \G JE!GEV+P@>:SWP40)>*X9*3
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M8:J_"E 8 [V?<*[V$^.@^<X8_0=02P,$%     @ R8":5#=]P)H !   T \
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M&.,7QA/<B3AC?A^8Z / $*,60M/+W6&+^^QB=^1U9&-6]3=S//-<_5E$%0O
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M/7(SD1GHYVO.U<LB"U -\:/_ %!+ P04    " #)@)I4]%;+R\H"  "A!P
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MKJ#@FND6>B@1V@#.UYRK_4(3M%UY^ ]02P,$%     @ R8":5)-Z8%/J @
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M+Y]ST"O>RB][TM%1M B39VZ$.U)P0:2;X"O>('.M9$N#BU*G1@/L8$='4*2
MA,Q >E68K0B"%)I0-^414HQ"Y@+IU:O]HAR@NMI)7T=EK-"&S6A[=1I:H8,5
MS3#LIN=46,.HXS24 ]1 [O6)ACJXT@Z;<?@G>; J0K "'W:[";\"&S973;;8
M&94Z]?; PYI*$BONX1;N;4W1-"M%,NQU$S?%)VPNG:Z6T;U8HNMN-@-L.N5C
M$3MP_PRB9!),1>>X;GC9(TMU3>YQ.5"](*8"Z$--:!7AL)EP+]K0.2W%ZETT
M]JCO:?9U%-!<,]!>N0UP7LI7/8,$^[2RRU'W3.'--1=K?]S&G)?"U:SI]K\4
M"ETS"G=6[6_P1UL0KD*<BSLY3]S*II[%KMY+>M9SMZ%!])#C:_8A7(4ZMP5U
MN^&UWP=P%=#<;AI'5]'-M6@<7Q;3W0X2NPY$&GJ["H.N&8,-,6TO/UQ%,+>;
M/I(H-A$SFX[B>"GAQ!:RY) 7>7'];L)TBPXB?<?YR^22@A(Q0ZDAIJ)("H.G
M( -'LY2WE1=$ 8=TTU(2!1ABKJ'N%M,T$<(+]ERTQ"D?\^"!W8>ZR] UV;VQ
M #WB.-K^AB@6D186V036:@63REV ;AI'HGA#S 7491#R+$^$J'60;TC#CODJ
MQOHP*SR1%CPU,<&B+":*.J2;YI H\!"+W7.+LOB$[.Z:^_)/<^-$<8F:>=(0
MQ*YV0:@B$^VF&Z2*2+2E!+*,^UFI4]\%0?KE2Q6R:,LN^QM'WFICA"J(T6Y:
M0JJ013N^<WE&=V\FXKZKNYE8N9OXLE;Q+3+3BGJJN$>[:3JIXAXU5UMOD)EA
MPY;5=F(&E8>TY/.=ERR=!>)T#/E46#E]3Z0W73TRN?J0)XOBN:W[),^3J'@[
MYTST>O( \?LT2?+U!_DHV.;!U</_ 5!+ P04    " #)@)I4R<KJDC,#   L
M$P  #0   'AL+W-T>6QE<RYX;6S=6.%NVC 0?I7(G:96FAH@(R4K(&U(E29M
M4Z7VQ_Y5ACA@R;$SQW30]]F+],GFBT-(J0^Q_MCH@DKL^W+??;Z[U&Z'I5D+
M=K-@S 2K7,AR1!;&%!_"L)PM6$[+<U4P:9%,Z9P:.]7SL"PTHVD)3KD(>YU.
M'.:42S(>RF5^E9LRF*FE-"/2;TR!NWU.1Z0;OR>!HYNHE(W(W>G;'TME+M\$
M[G[R[N2D<W=VN6L_K8 S$GI)^P>0GG?LA3)7*$8?'T:_CQRCOCB(>@\S1CSP
M$S_^0A+= *U,AW5)Q\-,R6UE(^(,-B[-67!/Q8A,J.!3S<$KHSD7:V?N@6&F
MA-*!L2UEA73!4CXXN.MFT&TU3\ZETE5L%\%]3^O'=X#-# 1R(1J!/>(,XV%!
MC6%:7ME)]7!E? 8%]?AV75B%<TW7W5Z?;!VJFPTR53IEN@G3)1O3>"A8!G(T
MGR_@;E01 FB,RNT@Y72N)*TT;#SJ@:6=,2%NX%7\GCWA7F6MBG:@GK(96D'U
MT-&X"?"WV1QWF[;W(MZ@X/?*?%K:Y<AJ#IW"KC7+^*J:K[)& ,;>Q=EI48CU
M1\'G,F=N\0<'' _IQB]8*,T?;#1HE9DU,$V">Z8-G[4M/S4M;MG*;-IIE>&:
M>Z]0\]_-\YQ)IJEHB[:]?\Q9?K'BZ.)?2:Y^J^P*]FJL]]=C%]E_#2+CXQ<9
M)<>OL3[C'+O(P5&*#.O]NW5(>')$:*P!',5&Y!L<^<0V:#!=<F&XK&<+GJ9,
M/CLI6'I#I_9/@2?\]OF4970IS&T#CLAV_)6E?)DGS5/7D(CZJ>WX"RRO&S?G
M0!N+RY2M6#JIIWH^K8:!'=BH]04.N\A5=?D1S,=A?@0P+ ZF /-Q7EB<_VD]
M W0]#L.T#;S( /49H#[.RX=,J@\6Q^^3V,N_TB2)HCC&,CJ9>!5,L+S%,?SX
MV3!MX('%@4A_EFN\VGB'[.\#K*;[.@1;*=Z)V$KQ7 /BSQMX)(F_VE@<\,"J
M@/4.Q/?'@9[R^T015!73AKW!.)(D& *]Z._1.$:R$\/'7Q_L+8FB)/$C@/D5
M1!&&P-N((Y@"T( A453M@SO[4;C9I\+M_\?&OP%02P,$%     @ R8":5)>*
MNQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q
M%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(
MMB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!
M;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B
M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M" #)@)I485@);[0%  "+,   #P   'AL+W=O<FMB;V]K+GAM;,6;6V_B.!2
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M^<OR>^?D5KG@7-]6#$]_ 5!+ P04    " #)@)I4^,,"'08"  !/*@  $P
M %M#;VYT96YT7U1Y<&5S72YX;6S-VLUNXC 4!>!70=E6Q/@WTQ&PF9EMAT5?
MP$TN)2*)+=MMX>W'"6VE5ATT%2/U;(C ]CTWOM*W8GE[]!1GA[X;XJK8I>2_
M,Q;K'?4VEL[3D%>V+O0VY:_AGGE;[^T],;%8&%:[(=&0YFFL4:R7/VEK'[HT
M^W7(/\?6#:LB4!>+V8_3QC%K55CON[:V*:^SQZ%YES)_3BCSR6E/W+4^7N4-
M!?LP85SY>\#SN=^/%$+;T&QC0[JQ?=[%#AV+Z=A1+,^7^*!'M]VV-36N?NCS
MD3+Z0+:).Z+4=^6IZ-7YY)1OF$Z?_.+\J<RYP+QS$YR/>6*!/A_W,I+Q]-SG
M0A12>_X57Q-SZ8O?C\9I-]3\8W:^WB<7]M,\(IL>E]_QVQF_UO]D'P*D#PG2
MAP+I0X/T84#ZJ$#Z^ ;2QS5('WR!T@B*J!R%5(YB*D=!E:.HRE%8Y2BN<A18
M.8JL D56@2*K0)%5H,@J4&05*+(*%%D%BJP"15:!(JM$D56BR"I19)4HLDH4
M626*K!)%5HDBJT215:+(JE!D52BR*A19%8JL"D56A2*K0I%5H<BJ4&15*+)J
M%%DUBJP:15:-(JM&D56CR*I19-4HLFH4636*K 9%5H,BJT&1U:#(:E!D-2BR
M&A19#8JL!D56@R)KA2)KA2)KA2)K]96RWCFW_\_QT[/L;3N\Y+/I?Z3K/U!+
M 0(4 Q0    ( ,F FE0'04UB@0   +$    0              "  0    !D
M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ R8":5.9Y1#/M    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
MR8":5)E<G",0!@  G"<  !,              ( !RP$  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " #)@)I4]!?'R$T'  #,(P  &
M    @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
MR8":5/=PTE#M!P  ""(  !@              ("!CP\  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ,F FE08Y;+0200  &L<   8
M          " @;(7  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " #)@)I4"<;BPY &  #/&0  &               @($Q'   >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ R8":5"S@N'M9 @  SP4
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M965T.2YX;6Q02P$"% ,4    " #)@)I4;T=<@C<"  !R!0  &0
M    @(&?8@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M ,F FE1=/9#N&@,  /(&   9              " @0UE  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ R8":5"4(-OI^ P  SP<  !D
M             ("!7F@  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " #)@)I44Q4C7,H"  "%!@  &0              @($3;   >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,F FE0T)RA= P8
M &0:   9              " @11O  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ R8":5(5"&FNN#@  6#$  !D              ("!
M3G4  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #)@)I4
M\EKM;T /   (+@  &0              @($SA   >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( ,F FE2!,7!EH!8  $U<   9
M      " @:J3  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ R8":5,O1"*O?#0  I2P  !D              ("!@:H  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #)@)I462QDK@X$   N"@
M&0              @(&7N   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( ,F FE3>*EAM/P0  .8+   9              " @=R\  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ R8":5.5NWJ#6
M P  E @  !D              ("!4L$  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " #)@)I43HZ@E;D%  "=#@  &0
M@(%?Q0  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ,F
MFE0NV2R?( 0  '@)   9              " @4_+  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ R8":5(L353*0!@    \  !D
M         ("!IL\  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " #)@)I419<,_84E  "J?   &0              @(%MU@  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,F FE2.Z_716 ,  *4(
M   9              " @2G\  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ R8":5+'L6'JG @  _@4  !D              ("!N/\
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #)@)I4,8 8
ME$("  !=!0  &0              @(&6 @$ >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( ,F FE0G+9Y>$0,  )T&   9
M  " @0\% 0!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
MR8":5"<%*.<D P  S 8  !D              ("!5P@! 'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " #)@)I45XW(&KX"   D!@  &0
M            @(&R"P$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( ,F FE3@ZY=/)0,  !X)   9              " @:<. 0!X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ R8":5+L2,%MS P
MT H  !D              ("! Q(! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " #)@)I4;CBI(7(%   ($0  &0              @(&M
M%0$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ,F FE2^
M*4]@Z@4   <2   9              " @58; 0!X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ R8":5,-*J.*G P  ^@@  !D
M     ("!=R$! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,F FE3B/<E0*@,  #@-   9              "
M@6<S 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ R8":
M5%!1,L/I @  )@@  !D              ("!R#8! 'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    " #)@)I4, 1EH8T#   J#   &0
M        @('H.0$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( ,F FE2G@'$-I (  - &   9              " @:P] 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ R8":5%IM@$WH 0  0@0
M !D              ("!AT ! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    " #)@)I4X,)9$68"  !3!@  &0              @(&F0@$
M>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( ,F FE3%\\K]
M0 0  $ 1   9              " @4-% 0!X;"]W;W)K<VAE971S+W-H965T
M-#<N>&UL4$L! A0#%     @ R8":5/Q.89[' @  R <  !D
M ("!NDD! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #)
M@)I4HUUP<*$"  #Z!P  &0              @(&X3 $ >&PO=V]R:W-H965T
M<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( ,F FE3H4^1?> 0  /L6   9
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M970U-"YX;6Q02P$"% ,4    " #)@)I4_+I$(S,"  "I!   &0
M    @(%!:@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    (
M ,F FE1?X+9K)@<  . F   9              " @:ML 0!X;"]W;W)K<VAE
M971S+W-H965T-38N>&UL4$L! A0#%     @ R8":5(UES70>!@  @QX  !D
M             ("!"'0! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"
M% ,4    " #)@)I4A A_$C<#  !N"   &0              @(%=>@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( ,F FE0RFOAW9P,
M )L,   9              " @<M] 0!X;"]W;W)K<VAE971S+W-H965T-3DN
M>&UL4$L! A0#%     @ R8":5%,FN/L3 P  KPD  !D              ("!
M:8$! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #)@)I4
MF39-=) &  "N'P  &0              @(&SA $ >&PO=V]R:W-H965T<R]S
M:&5E=#8Q+GAM;%!+ 0(4 Q0    ( ,F FE1*:P6M-P4  )$:   9
M      " @7J+ 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%
M  @ R8":5+LET%F@ @  E@<  !D              ("!Z) ! 'AL+W=O<FMS
M:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " #)@)I4D89JDNH#  "K#
M&0              @(&_DP$ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+
M 0(4 Q0    ( ,F FE1U^^Z(<P,   <+   9              " @>"7 0!X
M;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ R8":5/1YN$^*
M @  9 8  !D              ("!BIL! 'AL+W=O<FMS:&5E=',O<VAE970V
M-BYX;6Q02P$"% ,4    " #)@)I4:4T!\IP#  #!"P  &0
M@(%+G@$ >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( ,F
MFE0SS)=EZP(  ',(   9              " @1ZB 0!X;"]W;W)K<VAE971S
M+W-H965T-C@N>&UL4$L! A0#%     @ R8":5#=]P)H !   T \  !D
M         ("!0*4! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4
M    " #)@)I4]%;+R\H"  "A!P  &0              @(%WJ0$ >&PO=V]R
M:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( ,F FE23>F!3Z@(  -4'
M   9              " @7BL 0!X;"]W;W)K<VAE971S+W-H965T-S$N>&UL
M4$L! A0#%     @ R8":5,ZN6($  P  \@D  !D              ("!F:\!
M 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    " #)@)I4F01+
M*5,'  #$*@  &0              @('0L@$ >&PO=V]R:W-H965T<R]S:&5E
M=#<S+GAM;%!+ 0(4 Q0    ( ,F FE3)RNJ2,P,  "P3   -
M  "  5JZ 0!X;"]S='EL97,N>&UL4$L! A0#%     @ R8":5)>*NQS
M$P(   L              ( !N+T! %]R96QS+RYR96QS4$L! A0#%     @
MR8":5&%8"6^T!0  BS    \              ( !H;X! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( ,F FE2WQP,P0@(  $(K   :              "
M 8+$ 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,F
MFE3XPP(=!@(  $\J   3              "  ?S& 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !1 %$ +A8  #/) 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>269</ContextCount>
  <ElementCount>379</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>82</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00205 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLossParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentation</Role>
      <ShortName>ORGANIZATION AND BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - ACCOUNTS RECEIVABLE, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureAccountsReceivableNet</Role>
      <ShortName>ACCOUNTS RECEIVABLE, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssets</Role>
      <ShortName>PREPAYMENTS AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNet</Role>
      <ShortName>PROPERTY, EQUIPMENT AND SOFTWARE, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilities</Role>
      <ShortName>ACCRUALS AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - BORROWINGS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureBorrowings</Role>
      <ShortName>BORROWINGS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrants</Role>
      <ShortName>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureShareBasedCompensation</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - COLLABORATION ARRANGEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureCollaborationArrangements</Role>
      <ShortName>COLLABORATION ARRANGEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - INCOME TAX EXPENSE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureIncomeTaxExpense</Role>
      <ShortName>INCOME TAX EXPENSE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureNetLossPerShare</Role>
      <ShortName>NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11401 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11501 - Disclosure - RESTRICTED NET ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureRestrictedNetAssets</Role>
      <ShortName>RESTRICTED NET ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11601 - Disclosure - TREASURY SHARES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureTreasuryShares</Role>
      <ShortName>TREASURY SHARES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11701 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30103 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationTables</Role>
      <ShortName>ORGANIZATION AND BASIS OF PRESENTATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentation</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30303 - Disclosure - ACCOUNTS RECEIVABLE, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureAccountsReceivableNetTables</Role>
      <ShortName>ACCOUNTS RECEIVABLE, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureAccountsReceivableNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30403 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsTables</Role>
      <ShortName>PREPAYMENTS AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>30503 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetTables</Role>
      <ShortName>PROPERTY, EQUIPMENT AND SOFTWARE, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30603 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>ACCRUALS AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>30703 - Disclosure - BORROWINGS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureBorrowingsTables</Role>
      <ShortName>BORROWINGS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureBorrowings</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>30803 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsTables</Role>
      <ShortName>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrants</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>30903 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>31101 - Disclosure - INCOME TAX EXPENSE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureIncomeTaxExpenseTables</Role>
      <ShortName>INCOME TAX EXPENSE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureIncomeTaxExpense</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>31203 - Disclosure - NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureNetLossPerShareTables</Role>
      <ShortName>NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureNetLossPerShare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>31303 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureRelatedPartyTransactionsTables</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureRelatedPartyTransactions</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>31403 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails</Role>
      <ShortName>ORGANIZATION AND BASIS OF PRESENTATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonrecurring (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonrecurring (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, equipment and software (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, equipment and software (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of long lived assets to Employee defined contribution plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of long lived assets to Employee defined contribution plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of credit risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of credit risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40205 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Foreign currency exchange rate risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyExchangeRateRiskDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Foreign currency exchange rate risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40301 - Disclosure - ACCOUNTS RECEIVABLE, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails</Role>
      <ShortName>ACCOUNTS RECEIVABLE, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureAccountsReceivableNetTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40401 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails</Role>
      <ShortName>PREPAYMENTS AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40501 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails</Role>
      <ShortName>PROPERTY, EQUIPMENT AND SOFTWARE, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40601 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>ACCRUALS AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40701 - Disclosure - BORROWINGS - Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails</Role>
      <ShortName>BORROWINGS - Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40702 - Disclosure - BORROWINGS - Short term borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails</Role>
      <ShortName>BORROWINGS - Short term borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40703 - Disclosure - BORROWINGS - Long term borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails</Role>
      <ShortName>BORROWINGS - Long term borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40704 - Disclosure - BORROWINGS - Future maturities of short term borrowings and long term borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails</Role>
      <ShortName>BORROWINGS - Future maturities of short term borrowings and long term borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40801 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails</Role>
      <ShortName>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40802 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Share Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails</Role>
      <ShortName>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Share Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40803 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsWarrantsDetails</Role>
      <ShortName>CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>40901 - Disclosure - SHARE-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureShareBasedCompensationDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>40902 - Disclosure - SHARE-BASED COMPENSATION - Share Option Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Share Option Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>40903 - Disclosure - SHARE-BASED COMPENSATION - Share Option Activities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Share Option Activities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>40904 - Disclosure - SHARE-BASED COMPENSATION - Fair Value Of Share Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Fair Value Of Share Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>40905 - Disclosure - SHARE-BASED COMPENSATION - Share based compensation expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Share based compensation expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41001 - Disclosure - COLLABORATION ARRANGEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails</Role>
      <ShortName>COLLABORATION ARRANGEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureCollaborationArrangements</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41101 - Disclosure - INCOME TAX EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails</Role>
      <ShortName>INCOME TAX EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureIncomeTaxExpenseTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41102 - Disclosure - INCOME TAX EXPENSE - Income tax expense (benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>INCOME TAX EXPENSE - Income tax expense (benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41103 - Disclosure - INCOME TAX EXPENSE - Income tax reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails</Role>
      <ShortName>INCOME TAX EXPENSE - Income tax reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41104 - Disclosure - INCOME TAX EXPENSE - Deferred tax assets and deferred tax liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails</Role>
      <ShortName>INCOME TAX EXPENSE - Deferred tax assets and deferred tax liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41105 - Disclosure - INCOME TAX EXPENSE - Valuation Allowance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureIncomeTaxExpenseValuationAllowanceDetails</Role>
      <ShortName>INCOME TAX EXPENSE - Valuation Allowance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41201 - Disclosure - NET LOSS PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureNetLossPerShareDetails</Role>
      <ShortName>NET LOSS PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureNetLossPerShareTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41202 - Disclosure - NET LOSS PER SHARE - Anti-dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails</Role>
      <ShortName>NET LOSS PER SHARE - Anti-dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>41301 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureRelatedPartyTransactionsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>41401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>41501 - Disclosure - RESTRICTED NET ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureRestrictedNetAssetsDetails</Role>
      <ShortName>RESTRICTED NET ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureRestrictedNetAssets</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>41601 - Disclosure - TREASURY SHARES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureTreasurySharesDetails</Role>
      <ShortName>TREASURY SHARES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureTreasuryShares</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="adag-20211231x20f.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>41701 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adagene.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.adagene.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>73</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" original="adag-20211231x20f.htm">adag-20211231x20f.htm</File>
    <File>adag-20211231.xsd</File>
    <File>adag-20211231_cal.xml</File>
    <File>adag-20211231_def.xml</File>
    <File>adag-20211231_lab.xml</File>
    <File>adag-20211231_pre.xml</File>
    <File>adag-20211231xex12d1.htm</File>
    <File>adag-20211231xex12d2.htm</File>
    <File>adag-20211231xex13d1.htm</File>
    <File>adag-20211231xex13d2.htm</File>
    <File>adag-20211231xex15d1.htm</File>
    <File>adag-20211231xex15d2.htm</File>
    <File>adag-20211231xex15d3.htm</File>
    <File>adag-20211231xex15d4.htm</File>
    <File>adag-20211231xex4d16.htm</File>
    <File>adag-20211231xex8d1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>adag-20211231x20f002.jpg</File>
    <File>adag-20211231x20f003.jpg</File>
    <File>adag-20211231x20f004.jpg</File>
    <File>adag-20211231x20f005.jpg</File>
    <File>adag-20211231x20f006.jpg</File>
    <File>adag-20211231x20f007.jpg</File>
    <File>adag-20211231x20f008.jpg</File>
    <File>adag-20211231x20f009.jpg</File>
    <File>adag-20211231x20f010.jpg</File>
    <File>adag-20211231x20f011.jpg</File>
    <File>adag-20211231x20f012.jpg</File>
    <File>adag-20211231x20f013.jpg</File>
    <File>adag-20211231x20f014.jpg</File>
    <File>adag-20211231x20f015.jpg</File>
    <File>adag-20211231x20f016.jpg</File>
    <File>adag-20211231x20f017.jpg</File>
    <File>adag-20211231x20f018.jpg</File>
    <File>adag-20211231x20f019.jpg</File>
    <File>adag-20211231x20f020.jpg</File>
    <File>adag-20211231x20f021.jpg</File>
    <File>adag-20211231x20f022.jpg</File>
    <File>adag-20211231x20f023.jpg</File>
    <File>adag-20211231x20f024.jpg</File>
    <File>adag-20211231x20f025.jpg</File>
    <File>adag-20211231x20f026.jpg</File>
    <File>adag-20211231x20f027.jpg</File>
    <File>adag-20211231x20f028.jpg</File>
    <File>adag-20211231x20f029.jpg</File>
    <File>adag-20211231x20f030.jpg</File>
    <File>adag-20211231x20f031.jpg</File>
    <File>adag-20211231x20f032.jpg</File>
    <File>adag-20211231x20f033.jpg</File>
    <File>adag-20211231x20f034.jpg</File>
    <File>adag-20211231x20f037.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="897">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="50">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>134
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "adag-20211231x20f.htm": {
   "axisCustom": 2,
   "axisStandard": 24,
   "contextCount": 269,
   "dts": {
    "calculationLink": {
     "local": [
      "adag-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "adag-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "adag-20211231x20f.htm"
     ]
    },
    "labelLink": {
     "local": [
      "adag-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adag-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "adag-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 602,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 36,
    "http://xbrl.sec.gov/dei/2021q4": 10,
    "total": 46
   },
   "keyCustom": 68,
   "keyStandard": 311,
   "memberCustom": 41,
   "memberStandard": 36,
   "nsprefix": "adag",
   "nsuri": "http://www.adagene.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.adagene.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - ACCOUNTS RECEIVABLE, NET",
     "role": "http://www.adagene.com/role/DisclosureAccountsReceivableNet",
     "shortName": "ACCOUNTS RECEIVABLE, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS",
     "role": "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssets",
     "shortName": "PREPAYMENTS AND OTHER CURRENT ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET",
     "role": "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNet",
     "shortName": "PROPERTY, EQUIPMENT AND SOFTWARE, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES",
     "role": "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilities",
     "shortName": "ACCRUALS AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - BORROWINGS",
     "role": "http://www.adagene.com/role/DisclosureBorrowings",
     "shortName": "BORROWINGS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:DisclosureOfTemporaryEquityAndWarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS",
     "role": "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrants",
     "shortName": "CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:DisclosureOfTemporaryEquityAndWarrantsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - SHARE-BASED COMPENSATION",
     "role": "http://www.adagene.com/role/DisclosureShareBasedCompensation",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - COLLABORATION ARRANGEMENTS",
     "role": "http://www.adagene.com/role/DisclosureCollaborationArrangements",
     "shortName": "COLLABORATION ARRANGEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - INCOME TAX EXPENSE",
     "role": "http://www.adagene.com/role/DisclosureIncomeTaxExpense",
     "shortName": "INCOME TAX EXPENSE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - NET LOSS PER SHARE",
     "role": "http://www.adagene.com/role/DisclosureNetLossPerShare",
     "shortName": "NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.adagene.com/role/StatementConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://www.adagene.com/role/DisclosureRelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.adagene.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - RESTRICTED NET ASSETS",
     "role": "http://www.adagene.com/role/DisclosureRestrictedNetAssets",
     "shortName": "RESTRICTED NET ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11601 - Disclosure - TREASURY SHARES",
     "role": "http://www.adagene.com/role/DisclosureTreasuryShares",
     "shortName": "TREASURY SHARES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11701 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.adagene.com/role/DisclosureSubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:SummaryOfPrincipalSubsidiariesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30103 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Tables)",
     "role": "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationTables",
     "shortName": "ORGANIZATION AND BASIS OF PRESENTATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:SummaryOfPrincipalSubsidiariesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - ACCOUNTS RECEIVABLE, NET (Tables)",
     "role": "http://www.adagene.com/role/DisclosureAccountsReceivableNetTables",
     "shortName": "ACCOUNTS RECEIVABLE, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "adag:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS (Tables)",
     "role": "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsTables",
     "shortName": "PREPAYMENTS AND OTHER CURRENT ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "adag:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET (Tables)",
     "role": "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetTables",
     "shortName": "PROPERTY, EQUIPMENT AND SOFTWARE, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesTables",
     "shortName": "ACCRUALS AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - BORROWINGS (Tables)",
     "role": "http://www.adagene.com/role/DisclosureBorrowingsTables",
     "shortName": "BORROWINGS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30803 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Tables)",
     "role": "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsTables",
     "shortName": "CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30903 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "role": "http://www.adagene.com/role/DisclosureShareBasedCompensationTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31101 - Disclosure - INCOME TAX EXPENSE (Tables)",
     "role": "http://www.adagene.com/role/DisclosureIncomeTaxExpenseTables",
     "shortName": "INCOME TAX EXPENSE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - NET LOSS PER SHARE (Tables)",
     "role": "http://www.adagene.com/role/DisclosureNetLossPerShareTables",
     "shortName": "NET LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31303 - Disclosure - RELATED PARTY TRANSACTIONS (Tables)",
     "role": "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsTables",
     "shortName": "RELATED PARTY TRANSACTIONS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31403 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)",
     "role": "http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesTables",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceInitialPublicOffering",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION (Details)",
     "role": "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
     "shortName": "ORGANIZATION AND BASIS OF PRESENTATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_2_11_2021_us-gaap_StatementClassOfStockAxis_dei_AdrMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_Y5rj-vidfkKdz_NhXcGhJg",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Divide_USD_shares_NSN2e13aN0inhXqfZmrw-w",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "adag:FinancialAssetsFairValueDisclosure",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_YFcme7KyF0aRVFQE-QOpug",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adag:FinancialAssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonrecurring (Details)",
     "role": "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Nonrecurring (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "adag:FinancialAssetsFairValueDisclosure",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_YFcme7KyF0aRVFQE-QOpug",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adag:FinancialAssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "adag:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_KGhMFlu_2kq3DNJN3Ro4IA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, equipment and software (Details)",
     "role": "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property, equipment and software (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "adag:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_KGhMFlu_2kq3DNJN3Ro4IA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40203 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of long lived assets to Employee defined contribution plan (Details)",
     "role": "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Impairment of long lived assets to Employee defined contribution plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_srt_StatementGeographicalAxis_adag_MainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_a3KAemeQF0yabn5RGbhXiA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40204 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of credit risk (Details)",
     "role": "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentration of credit risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_srt_StatementGeographicalAxis_adag_MainlandOfChinaMember_us-gaap_ConcentrationRiskByBenchmarkAxis_adag_CashAndCashEquivalentsAndShortTermInvestmentsMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember_a3KAemeQF0yabn5RGbhXiA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "adag:PercentageOfDepreciationOfForeignCurrency",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40205 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Foreign currency exchange rate risk (Details)",
     "role": "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyExchangeRateRiskDetails",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Foreign currency exchange rate risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "adag:PercentageOfDepreciationOfForeignCurrency",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - ACCOUNTS RECEIVABLE, NET (Details)",
     "role": "http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails",
     "shortName": "ACCOUNTS RECEIVABLE, NET (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "adag:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - PREPAYMENTS AND OTHER CURRENT ASSETS (Details)",
     "role": "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails",
     "shortName": "PREPAYMENTS AND OTHER CURRENT ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "adag:PrepaidExpenseAndOtherAssetsCurrentTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - PROPERTY, EQUIPMENT AND SOFTWARE, NET (Details)",
     "role": "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
     "shortName": "PROPERTY, EQUIPMENT AND SOFTWARE, NET (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - ACCRUALS AND OTHER CURRENT LIABILITIES (Details)",
     "role": "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails",
     "shortName": "ACCRUALS AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
       "adag:AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermBankLoansAndNotesPayable",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - BORROWINGS - Components (Details)",
     "role": "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails",
     "shortName": "BORROWINGS - Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:LongTermLoansFromBank",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
       "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00205 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)",
     "role": "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLossParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
       "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_xK5464GvIU2G2CMxw-2yyg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - BORROWINGS - Short term borrowings (Details)",
     "role": "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails",
     "shortName": "BORROWINGS - Short term borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_9_30_2020_us-gaap_DebtInstrumentAxis_adag_BorrowingsFromBankOfNingboCo.LtdMember_xK5464GvIU2G2CMxw-2yyg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_CNY_rvWwccpE7kW_U8zstoKSBQ",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfDebt",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40703 - Disclosure - BORROWINGS - Long term borrowings (Details)",
     "role": "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails",
     "shortName": "BORROWINGS - Long term borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_2_28_2019_us-gaap_LongtermDebtTypeAxis_adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember_8XLbm_NuOEaOfNq0iiQ4Uw",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40704 - Disclosure - BORROWINGS - Future maturities of short term borrowings and long term borrowings (Details)",
     "role": "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails",
     "shortName": "BORROWINGS - Future maturities of short term borrowings and long term borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "adag:ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_2_1_2018_To_2_28_2018_h-YUYJGmUkuPVILUOsDYiw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adag:MaximumProceedsReceivableFromExerciseOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40801 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Shares (Details)",
     "role": "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails",
     "shortName": "CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_2_1_2018_To_2_28_2018_h-YUYJGmUkuPVILUOsDYiw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "adag:MaximumProceedsReceivableFromExerciseOfWarrants",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40802 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Share Activities (Details)",
     "role": "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
     "shortName": "CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Preferred Share Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2018_T4mq9hT6lUOBey2VJKkGww",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:TemporaryEquityCarryingAmountAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2019_To_12_31_2019__vYDbRt2gEq7au_54JYblA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40803 - Disclosure - CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Warrants (Details)",
     "role": "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsWarrantsDetails",
     "shortName": "CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - SHARE-BASED COMPENSATION (Details)",
     "role": "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
     "shortName": "SHARE-BASED COMPENSATION (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40902 - Disclosure - SHARE-BASED COMPENSATION - Share Option Activities (Details)",
     "role": "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails",
     "shortName": "SHARE-BASED COMPENSATION - Share Option Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40903 - Disclosure - SHARE-BASED COMPENSATION - Share Option Activities - Narrative (Details)",
     "role": "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails",
     "shortName": "SHARE-BASED COMPENSATION - Share Option Activities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40904 - Disclosure - SHARE-BASED COMPENSATION - Fair Value Of Share Options (Details)",
     "role": "http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails",
     "shortName": "SHARE-BASED COMPENSATION - Fair Value Of Share Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CcCxb4VhikOi1y0dPsdYqg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)",
     "role": "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY (DEFICIT)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2018_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_CcCxb4VhikOi1y0dPsdYqg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40905 - Disclosure - SHARE-BASED COMPENSATION - Share based compensation expenses (Details)",
     "role": "http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails",
     "shortName": "SHARE-BASED COMPENSATION - Share based compensation expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - COLLABORATION ARRANGEMENTS (Details)",
     "role": "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails",
     "shortName": "COLLABORATION ARRANGEMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_12_1_2018_To_12_31_2018_us-gaap_TypeOfArrangementAxis_adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember_zsB5uPJq50C4DpmE2mjLFA",
      "decimals": "0",
      "lang": null,
      "name": "adag:CollaborativeArrangementUpfrontCashPaymentReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - INCOME TAX EXPENSE (Details)",
     "role": "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails",
     "shortName": "INCOME TAX EXPENSE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41102 - Disclosure - INCOME TAX EXPENSE - Income tax expense (benefit) (Details)",
     "role": "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails",
     "shortName": "INCOME TAX EXPENSE - Income tax expense (benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41103 - Disclosure - INCOME TAX EXPENSE - Income tax reconciliation (Details)",
     "role": "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails",
     "shortName": "INCOME TAX EXPENSE - Income tax reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41104 - Disclosure - INCOME TAX EXPENSE - Deferred tax assets and deferred tax liabilities (Details)",
     "role": "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails",
     "shortName": "INCOME TAX EXPENSE - Deferred tax assets and deferred tax liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2020_3ko2yRM7akOCEza5WY8bNw",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41105 - Disclosure - INCOME TAX EXPENSE - Valuation Allowance (Details)",
     "role": "http://www.adagene.com/role/DisclosureIncomeTaxExpenseValuationAllowanceDetails",
     "shortName": "INCOME TAX EXPENSE - Valuation Allowance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - NET LOSS PER SHARE (Details)",
     "role": "http://www.adagene.com/role/DisclosureNetLossPerShareDetails",
     "shortName": "NET LOSS PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_ESjTZBeLf0SCBovh04R_ag",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - NET LOSS PER SHARE - Anti-dilutive Securities (Details)",
     "role": "http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails",
     "shortName": "NET LOSS PER SHARE - Anti-dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2020_To_12_31_2020_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RedeemableConvertiblePreferredStockMember_ESjTZBeLf0SCBovh04R_ag",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_DrX3T0fbOE-cv0Io4RU2Gg",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DueFromRelatedPartiesCurrent",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "role": "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_us-gaap_RelatedPartyTransactionAxis_adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember_q83pj5eew0G-H2b3ek53pA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_12_31_2021_x7XGkX5K4E6u5RA1N6dD-g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RestrictedAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "adag:MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41501 - Disclosure - RESTRICTED NET ASSETS (Details)",
     "role": "http://www.adagene.com/role/DisclosureRestrictedNetAssetsDetails",
     "shortName": "RESTRICTED NET ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RestrictedAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "adag:MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_mWkOneXQ0UOeYvHgZzzXSA",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:TreasuryStockTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_7_7_2021_ah_eEOxPL0CIPCxPK6qNbQ",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41601 - Disclosure - TREASURY SHARES (Details)",
     "role": "http://www.adagene.com/role/DisclosureTreasurySharesDetails",
     "shortName": "TREASURY SHARES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:TreasuryStockTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "As_Of_7_7_2021_ah_eEOxPL0CIPCxPK6qNbQ",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41701 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://www.adagene.com/role/DisclosureSubsequentEventsDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_7_7_2022_To_7_7_2022_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_f5xUbvNTBEimEH5nmcz29g",
      "decimals": "INF",
      "lang": null,
      "name": "adag:ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_9rSKl35IxkOIc7btmCaGTg",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - ORGANIZATION AND BASIS OF PRESENTATION",
     "role": "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentation",
     "shortName": "ORGANIZATION AND BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "adag-20211231x20f.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_hw6CpsGGU0yLlgXuLOKqYg",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 82,
   "tag": {
    "adag_AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable and allowance for doubtful accounts.",
        "label": "Accounts Receivable And Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Accounts receivable and allowance for doubtful accounts"
       }
      }
     },
     "localname": "AccountsReceivableAndAllowanceForDoubtfulAccountsPolicyPolicyTextBlock",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_AccruedLiabilitiesAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities and Other Current Liabilities",
        "label": "Accrued Liabilities and Other Current Liabilities",
        "terseLabel": "Accruals and other current liabilities",
        "totalLabel": "Accruals and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherCurrentLiabilities",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "ACCRUALS AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherCurrentLiabilitiesAbstract",
     "nsuri": "http://www.adagene.com/20211231",
     "xbrltype": "stringItemType"
    },
    "adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure on accrued liabilities and other current liabilities.",
        "label": "Accrued Liabilities and Other Current Liabilities [Table Text Block]",
        "terseLabel": "Summary of accrued liabilities and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on accrued liabilities and other current liabilities.",
        "label": "Accrued Liabilities and Other Current Liabilities [Text Block]",
        "terseLabel": "ACCRUALS AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherCurrentLiabilitiesTextBlock",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_AdageneAgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to Adagene AG.",
        "label": "Adagene AG"
       }
      }
     },
     "localname": "AdageneAgMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails",
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_AdageneAustraliaPtyLtd.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Adagene Australia PTY Ltd.",
        "label": "Adagene Australia PTY Ltd."
       }
      }
     },
     "localname": "AdageneAustraliaPtyLtd.Member",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails",
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_AdageneHongKongLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Adagene (Hong Kong) Limited.",
        "label": "Adagene (Hong Kong) Limited"
       }
      }
     },
     "localname": "AdageneHongKongLimitedMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails",
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_AdageneIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Adagene Incorporated.",
        "label": "Adagene Incorporated"
       }
      }
     },
     "localname": "AdageneIncorporatedMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_AdagenePte.Ltd.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to Adagene PTE. Ltd.",
        "label": "Adagene PTE. Ltd."
       }
      }
     },
     "localname": "AdagenePte.Ltd.Member",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_AdageneSuzhouLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Adagene (Suzhou) Limited.",
        "label": "Adagene (Suzhou) Limited"
       }
      }
     },
     "localname": "AdageneSuzhouLimitedMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails",
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_AdctCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to ADCT Collaboration Agreement.",
        "label": "ADCT Collaboration Agreement"
       }
      }
     },
     "localname": "AdctCollaborationAgreementMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_AfterTaxIncomePercentageAppropriations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of after-tax income to be set aside as a general reserve fund.",
        "label": "After Tax Income Percentage Appropriations",
        "terseLabel": "After-Tax Income, Annual appropriations, Percentage"
       }
      }
     },
     "localname": "AfterTaxIncomePercentageAppropriations",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRestrictedNetAssetsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The agreed period for not to grant rights associated with antibodies to third parties.",
        "label": "Agreed Period for Not to Grant Rights Associated With Antibodies to Third Parties",
        "terseLabel": "Agreed period for not to grant rights associated with antibodies to third parties"
       }
      }
     },
     "localname": "AgreedPeriodForNotToGrantRightsAssociatedWithAntibodiesToThirdParties",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adag_AssessableProfits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assessable profits or earnings.",
        "label": "Assessable Profits",
        "terseLabel": "Assessable profits or earnings"
       }
      }
     },
     "localname": "AssessableProfits",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_BorrowingsFromAgriculturalBankOfChinaLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Borrowings from Agricultural Bank of China Limited.",
        "label": "Borrowings from Agricultural Bank of China Limited"
       }
      }
     },
     "localname": "BorrowingsFromAgriculturalBankOfChinaLimitedMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_BorrowingsFromBankOfNingboCo.LtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Borrowings from Bank of Ningbo Co., Ltd.",
        "label": "Borrowings from Bank of Ningbo Co., Ltd"
       }
      }
     },
     "localname": "BorrowingsFromBankOfNingboCo.LtdMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, Four.",
        "label": "Borrowings from Shanghai Pudong Development Bank Co., Ltd., four"
       }
      }
     },
     "localname": "BorrowingsFromShanghaiPudongDevelopmentBankCo.Ltd.FourMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, one.",
        "label": "Borrowings from Shanghai Pudong Development Bank Co., Ltd., one"
       }
      }
     },
     "localname": "BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdOneMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, three.",
        "label": "Borrowings from Shanghai Pudong Development Bank Co., Ltd., three"
       }
      }
     },
     "localname": "BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdThreeMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for borrowings from Shanghai Pudong Development Bank Co., Ltd, two.",
        "label": "Borrowings from Shanghai Pudong Development Bank Co., Ltd., two"
       }
      }
     },
     "localname": "BorrowingsFromShanghaiPudongDevelopmentBankCo.LtdTwoMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_CapitalTaxRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of capital tax rate.",
        "label": "Capital Tax Rate, Percentage",
        "terseLabel": "Capital tax rate for Canton of Basel"
       }
      }
     },
     "localname": "CapitalTaxRatePercentage",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_CashAndCashEquivalentsAndShortTermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of cash and cash equivalents and short term investments when it serves as a benchmark in a concentration of risk calculation.",
        "label": "Cash and cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndShortTermInvestmentsMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_ChinaMerchantsBankCo.LtdLoanTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to China Merchants Bank Co., Ltd.",
        "label": "China Merchants Bank Co., Ltd., two"
       }
      }
     },
     "localname": "ChinaMerchantsBankCo.LtdLoanTwoMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_ChinaMerchantsBankCo.LtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to China Merchants Bank Co., Ltd.",
        "label": "China Merchants Bank Co., Ltd"
       }
      }
     },
     "localname": "ChinaMerchantsBankCo.LtdMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_CollaborationArrangementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "COLLABORATION ARRANGEMENTS"
       }
      }
     },
     "localname": "CollaborationArrangementsAbstract",
     "nsuri": "http://www.adagene.com/20211231",
     "xbrltype": "stringItemType"
    },
    "adag_CollaborativeArrangementMilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount receivable upon achievement of target specified.",
        "label": "Collaborative Arrangement, Milestone Payment Receivable",
        "terseLabel": "Milestone payment receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePaymentReceivable",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_CollaborativeArrangementMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from milestone payments received in collaborative arrangement.",
        "label": "Collaborative Arrangement Milestone Payment Received",
        "terseLabel": "Milestone fee received"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePaymentReceived",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_CollaborativeArrangementUpfrontCashPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront cash payment receivable.",
        "label": "Collaborative Arrangement Upfront Cash Payment Receivable",
        "terseLabel": "Payment of upfront-refundable fee",
        "verboseLabel": "Upfront payment receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontCashPaymentReceivable",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_CollaborativeArrangementUpfrontCashPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from upfront cash received in collaborative arrangement.",
        "label": "Collaborative Arrangement, Upfront Cash Payment Received",
        "terseLabel": "Upfront cash payment received"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontCashPaymentReceived",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_CommonStockSubscriptionsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common Stock, Subscriptions, Value",
        "terseLabel": "Subscription from shareholders"
       }
      }
     },
     "localname": "CommonStockSubscriptionsValue",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_ConcentrationRiskSuppliersAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about suppliers.",
        "label": "Concentration Risk, Suppliers [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskSuppliersAxis",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adag_ConcentrationRiskSuppliersDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Suppliers.",
        "label": "Concentration Risk, Suppliers [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskSuppliersDomain",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_DeferredTaxAssetsDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from depreciation and amortization.",
        "label": "Deferred Tax Assets, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization of property, equipment and software"
       }
      }
     },
     "localname": "DeferredTaxAssetsDepreciationAndAmortization",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_DefinedContributionPlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Defined Contribution Plan [Abstract]",
        "terseLabel": "Employee defined contribution plan"
       }
      }
     },
     "localname": "DefinedContributionPlanAbstract",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adag_DisclosureOfTemporaryEquityAndWarrantsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS"
       }
      }
     },
     "localname": "DisclosureOfTemporaryEquityAndWarrantsAbstract",
     "nsuri": "http://www.adagene.com/20211231",
     "xbrltype": "stringItemType"
    },
    "adag_DisclosureOfTemporaryEquityAndWarrantsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for temporary equity and warrants.",
        "label": "Disclosure Of Temporary Equity And Warrants [Text Block]",
        "verboseLabel": "CONVERTIBLE REDEEMABLE PREFERRED SHARES AND WARRANTS"
       }
      }
     },
     "localname": "DisclosureOfTemporaryEquityAndWarrantsTextBlock",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement.",
        "label": "Dragon Boat Biopharmaceutical (Shanghai) Limited License Agreement"
       }
      }
     },
     "localname": "DragonBoatBiopharmaceuticalShanghaiLimitedLicenseAgreementMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for research and development.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Research and Development Expenses, Amount",
        "negatedLabel": "Research and development super-deduction"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionResearchAndDevelopmentExpensesAmount",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective period of Technology Advanced Service Enterprises certificate.",
        "label": "Effective Period of Technology Advanced Service Enterprises Certificate",
        "terseLabel": "Effective period of TASE certificate (in years)"
       }
      }
     },
     "localname": "EffectivePeriodOfTechnologyAdvancedServiceEnterprisesCertificate",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adag_ElectronicEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Electronic equipment.",
        "label": "Electronic equipment"
       }
      }
     },
     "localname": "ElectronicEquipmentMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_EmployeeDefinedContributionPlanPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for Employee defined contribution plan.",
        "label": "Employee Defined Contribution Plan [Policy Text Block]",
        "terseLabel": "Employee defined contribution plan"
       }
      }
     },
     "localname": "EmployeeDefinedContributionPlanPolicyTextBlock",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_ExelixisAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Exelixis agreement.",
        "label": "Exelixis Agreement"
       }
      }
     },
     "localname": "ExelixisAgreementMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_ExelixisIncAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to Exelixis, Inc. Agreement.",
        "label": "Exelixis Inc Agreement"
       }
      }
     },
     "localname": "ExelixisIncAgreementMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_FinancialAssetsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial assets.",
        "label": "Financial Assets Fair Value Disclosure",
        "terseLabel": "Financial assets"
       }
      }
     },
     "localname": "FinancialAssetsFairValueDisclosure",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_GovernmentSubsidiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for government subsidies.",
        "label": "Government Subsidies [Policy Text Block]",
        "terseLabel": "Government subsidies"
       }
      }
     },
     "localname": "GovernmentSubsidiesPolicyTextBlock",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_GovernmentSubsidiesReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of subsidies received by the entity for Government.",
        "label": "Government Subsidies Received",
        "terseLabel": "Government subsidies received"
       }
      }
     },
     "localname": "GovernmentSubsidiesReceived",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyExchangeRateRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Guilin Sanjin Pharmaceutical Co., Ltd. License Agreement.",
        "label": "Guilin Sanjin Pharmaceutical Co., Ltd. License Agreement"
       }
      }
     },
     "localname": "GuilinSanjinPharmaceuticalCo.Ltd.LicenseAgreementMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_IncomeTaxDisclosureTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information pertaining to income taxes.",
        "label": "Income Tax Disclosure [Table]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTable",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adag_InterestIncomeExpenseOnPromissoryNotes": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income (expense) on promissory notes.",
        "label": "Interest Income (Expense) On Promissory Notes",
        "negatedLabel": "Interest income on promissory notes"
       }
      }
     },
     "localname": "InterestIncomeExpenseOnPromissoryNotes",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_MainlandOfChinaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mainland of China.",
        "label": "Mainland of China"
       }
      }
     },
     "localname": "MainlandOfChinaMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of selected targets, agreed for generation of antibodies.",
        "label": "Maximum Number of Selected Targets, Agreed for Generation of Antibodies",
        "terseLabel": "Maximum number of selected targets, agreed for generation of antibodies"
       }
      }
     },
     "localname": "MaximumNumberOfSelectedTargetsAgreedForGenerationOfAntibodies",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adag_MaximumProceedsReceivableFromExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of proceeds receivable from exercise of warrants.",
        "label": "Maximum Proceeds Receivable From Exercise Of Warrants",
        "terseLabel": "Total maximum consideration from exercise of warrants"
       }
      }
     },
     "localname": "MaximumProceedsReceivableFromExerciseOfWarrants",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_MilestonePaymentsOrRoyaltyPaymentsReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of milestone payments or royalty payments received.",
        "label": "Milestone Payments or Royalty Payments Received",
        "terseLabel": "Milestone payments or royalty payments received"
       }
      }
     },
     "localname": "MilestonePaymentsOrRoyaltyPaymentsReceived",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments receivable upon achieving certain development and regulatory approval milestones.",
        "label": "Milestone Payments Receivable, Development And Regulatory Milestones",
        "terseLabel": "Milestone payments receivable based on development and regulatory milestones"
       }
      }
     },
     "localname": "MilestonePaymentsReceivableDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_MilestonePaymentsReceivableSalesBasedMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments conditioned upon achieving sales based milestones.",
        "label": "Milestone Payments Receivable,Sales Based Milestones",
        "terseLabel": "Milestone payments receivable based on sales"
       }
      }
     },
     "localname": "MilestonePaymentsReceivableSalesBasedMilestones",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of the profit after tax to be transferred to statutory reserve.",
        "label": "Minimum Percentage Of Profits After Tax To Be Transferred To Statutory Reserve",
        "terseLabel": "Minimum percentage of profit after tax to be transferred to statutory reserve"
       }
      }
     },
     "localname": "MinimumPercentageOfProfitsAfterTaxToBeTransferredToStatutoryReserve",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRestrictedNetAssetsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum threshold written notice period for termination of agreement.",
        "label": "Minimum Threshold Written Notice Period for Termination of Agreement",
        "terseLabel": "Minimum threshold written notice period for termination of agreement"
       }
      }
     },
     "localname": "MinimumThresholdWrittenNoticePeriodForTerminationOfAgreement",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adag_NonCashActivitiesRetirementOfTreasuryShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of retirement of treasury shares in noncash investing or financing activities.",
        "label": "Non cash Activities, Retirement of Treasury Shares",
        "verboseLabel": "Retirement of treasury shares"
       }
      }
     },
     "localname": "NonCashActivitiesRetirementOfTreasuryShares",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_NumberOfInvestorsToWhomWarrantsWereIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investors to whom warrants were issued during the period.",
        "label": "Number Of Investors To Whom Warrants Were Issued",
        "verboseLabel": "Number of Series C-1 investors to whom warrants were issued"
       }
      }
     },
     "localname": "NumberOfInvestorsToWhomWarrantsWereIssued",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adag_NumberOfMajorSupplier": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of major supplier.",
        "label": "Number of Major Supplier",
        "terseLabel": "Number of major supplier"
       }
      }
     },
     "localname": "NumberOfMajorSupplier",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adag_NumberOfSharesSurrendered": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares surrendered by the shareholders.",
        "label": "Number of Shares Surrendered",
        "terseLabel": "Number of shares surrendered"
       }
      }
     },
     "localname": "NumberOfSharesSurrendered",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adag_OneSupplierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One supplier.",
        "label": "One supplier"
       }
      }
     },
     "localname": "OneSupplierMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Organization, Consolidation And Presentation Of Financial Statements [Line Items]",
        "terseLabel": "ORGANIZATION AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adag_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information on organization, consolidation and presentation of financial statements.",
        "label": "Organization, Consolidation And Presentation Of Financial Statements [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adag_OutsideMainlandOfChinaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outside the mainland of China.",
        "label": "Outside the mainland of China"
       }
      }
     },
     "localname": "OutsideMainlandOfChinaMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_PayablesForDeferredInitialPublicOfferingCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payables for deferred initial public offering cost in non-cash activities.",
        "label": "Payables For Deferred Initial Public Offering Cost",
        "terseLabel": "Payables for deferred initial public offering cost"
       }
      }
     },
     "localname": "PayablesForDeferredInitialPublicOfferingCost",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_PercentageOfDepreciationOfForeignCurrency": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of depreciation of foreign currency.",
        "label": "Percentage Of Depreciation Of Foreign Currency",
        "terseLabel": "Depreciation of foreign currency (as a percent)"
       }
      }
     },
     "localname": "PercentageOfDepreciationOfForeignCurrency",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesForeignCurrencyExchangeRateRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_PerformanceIncentivePlan2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Performance incentive plan 2021.",
        "label": "Performance Incentive Plan 2021 (the \"2021 Plan\")"
       }
      }
     },
     "localname": "PerformanceIncentivePlan2021Member",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_PeriodForReservationOfTargetRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period for reservation of target right.",
        "label": "Period for Reservation of Target Right",
        "terseLabel": "Period for reservation of target right"
       }
      }
     },
     "localname": "PeriodForReservationOfTargetRight",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "adag_Plan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2015 Plan.",
        "label": "2015 Plan"
       }
      }
     },
     "localname": "Plan2015Member",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_Plan2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2017 Plan.",
        "label": "2017 Plan"
       }
      }
     },
     "localname": "Plan2017Member",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_Plan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2019 Plan.",
        "label": "2019 Plan"
       }
      }
     },
     "localname": "Plan2019Member",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_PreferentialIncomeTaxRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferential income tax rate.",
        "label": "Preferential Income Tax Rate",
        "terseLabel": "Preferential tax rate (as a percent)"
       }
      }
     },
     "localname": "PreferentialIncomeTaxRate",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_PrepaidExpenseAndOtherAssetsCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure on prepayments and other current assets.",
        "label": "Prepaid Expense and Other Assets, Current [Text Block]",
        "terseLabel": "PREPAYMENTS AND OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentTextBlock",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of Redeemable Convertible Preferred Stock and warrants.",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock and Warrants",
        "terseLabel": "Proceeds from issuance of convertible redeemable preferred shares and warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockAndWarrants",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of estimated useful lives of property and equipment and software.",
        "label": "Property, Plant And Equipment, Estimated Useful Life [Table Text Block]",
        "terseLabel": "Summary of estimated useful lives of property, equipment and software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_QualifiedPublicOfferingMinimumMarketCapitalization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum market capitalization reflected by the Qualified Public Offering, considered for automatic conversion of preferred shares.",
        "label": "Qualified Public Offering, Minimum Market Capitalization",
        "terseLabel": "Minimum market capitalization from Qualified Public Offering"
       }
      }
     },
     "localname": "QualifiedPublicOfferingMinimumMarketCapitalization",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_QualifiedPublicOfferingMinimumProceeds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of proceeds receivable from Qualified Public Offering, considered for automatic conversion of preferred shares.",
        "label": "Qualified Public Offering, Minimum Proceeds",
        "terseLabel": "Minimum aggregate proceeds from Qualified Public Offering"
       }
      }
     },
     "localname": "QualifiedPublicOfferingMinimumProceeds",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to receipt of contract research organizations (\"CRO\") and contract manufacturing organizations (\"CMO\") services with related parties.",
        "label": "Receipt of CRO and CMO services"
       }
      }
     },
     "localname": "ReceiptOfContractResearchOrganizationsAndContractManufacturingOrganizationsServicesMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of research and development expenses resulting from transactions, excluding transactions that are eliminated in consolidated or combined financial statements, with related party.",
        "label": "Related Party Transaction, Research And Development Expense from Transactions with Related Party",
        "negatedLabel": "Related parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionResearchAndDevelopmentExpenseFromTransactionsWithRelatedParty",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_ResearchAndDevelopmentExpenseThirdParties": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of research and development expenses resulting from transactions with third parties.",
        "label": "Research and Development Expense, Third Parties",
        "negatedLabel": "Third parties"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseThirdParties",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_RestrictedNetAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No Definition available.",
        "label": "RESTRICTED NET ASSETS"
       }
      }
     },
     "localname": "RestrictedNetAssetsAbstract",
     "nsuri": "http://www.adagene.com/20211231",
     "xbrltype": "stringItemType"
    },
    "adag_RetirementOfTreasuryShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of retirement of treasury shares.",
        "label": "Retirement of Treasury Shares",
        "negatedLabel": "Costs for retirement of treasury shares"
       }
      }
     },
     "localname": "RetirementOfTreasuryShares",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for short-term debt and long-term debt.",
        "label": "Schedule Of Maturities Of Short-Term Debt And Long-Term Debt [Table Text Block]",
        "verboseLabel": "Schedule of future maturities of short-term borrowings and long-term borrowings"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfShortTermDebtAndLongTermDebtTableTextBlock",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_Series1RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-1 Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Series A-1 convertible redeemable preferred shares"
       }
      }
     },
     "localname": "Series1RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_Series2RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-2 Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Series A-2 convertible redeemable preferred shares"
       }
      }
     },
     "localname": "Series2RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_SeriesBRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Series B convertible redeemable preferred shares"
       }
      }
     },
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_SeriesC1RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C-1 Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Series C-1 convertible redeemable preferred shares"
       }
      }
     },
     "localname": "SeriesC1RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_SeriesC1WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Series C 1 Warrants.",
        "label": "Series C 1 Warrants"
       }
      }
     },
     "localname": "SeriesC1WarrantsMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_SeriesC2RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C-2 Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Series C-2 convertible redeemable preferred shares"
       }
      }
     },
     "localname": "SeriesC2RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_SeriesC3RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C-3 Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Series C-3 convertible redeemable preferred shares"
       }
      }
     },
     "localname": "SeriesC3RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_ServiceConditionsAndPerformanceConditionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to service conditions and performance conditions related to share options.",
        "label": "Service conditions and Performance conditions"
       }
      }
     },
     "localname": "ServiceConditionsAndPerformanceConditionsMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum exercise multiple assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Multiple, Maximum",
        "terseLabel": "Exercise multiple, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMaximum",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum exercise multiple assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Multiple, Minimum",
        "terseLabel": "Exercise multiple, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExerciseMultipleMinimum",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average grant date fair value as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Exercisable at the end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options exercised.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average grant date fair value, at which grantee can acquire shares reserved for issuance. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and expected to vest at the end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "adag_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options for which the vesting schedules and conditions are waived.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vesting Schedules and Conditions waived",
        "terseLabel": "Number of options, vesting schedules and conditions waived"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestingSchedulesAndConditionsWaived",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adag_ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of increase in shares reserve annually based on shares outstanding under share based compensation share based payments.",
        "label": "Share Based Compensation Share Based Payments, Shares Reserve, Incremental, Percent",
        "terseLabel": "Incremental percent of shares"
       }
      }
     },
     "localname": "ShareBasedCompensationShareBasedPaymentsSharesReserveIncrementalPercent",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares affected by modification of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Plan Modification, Number of Shares Affected",
        "terseLabel": "Number of shares affected by modification of award"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementPlanModificationNumberOfSharesAffected",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "adag_SharesSurrenderedSharesForRepaymentOfPromissoryNotes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number shares surrendered for repayment of promissory notes.",
        "label": "Shares Surrendered, Shares, for Repayment of Promissory Notes",
        "verboseLabel": "Surrender of ordinary shares for repayment of promissory notes (Note 9) (in shares)"
       }
      }
     },
     "localname": "SharesSurrenderedSharesForRepaymentOfPromissoryNotes",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "adag_SignalPharmaceuticalsLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Signal Pharmaceuticals LLC.",
        "label": "Signal Pharmaceuticals LLC"
       }
      }
     },
     "localname": "SignalPharmaceuticalsLlcMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_StatusForTaxabilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to various tax status.",
        "label": "Status for Taxability [Axis]"
       }
      }
     },
     "localname": "StatusForTaxabilityAxis",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "adag_StatusForTaxabilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents various tax status.",
        "label": "Status For Taxability [Domain]"
       }
      }
     },
     "localname": "StatusForTaxabilityDomain",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Required percentage of statutory reserve on registered capital to be maintained.",
        "label": "Statutory Reserve Maintenance Required Percentage On Registered Capital",
        "terseLabel": "Statutory reserve required percentage on registered capital"
       }
      }
     },
     "localname": "StatutoryReserveMaintenanceRequiredPercentageOnRegisteredCapital",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRestrictedNetAssetsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_StockSurrenderedValueForRepaymentOfPromissoryNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of shares surrendered for repayment of promissory notes.",
        "label": "Stock Surrendered, Value,For Repayment of Promissory Notes",
        "terseLabel": "Surrender of ordinary shares for repayment of promissory notes (Note 9)"
       }
      }
     },
     "localname": "StockSurrenderedValueForRepaymentOfPromissoryNotes",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_SummaryOfPrincipalSubsidiariesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of principal subsidiaries.",
        "label": "Summary of Principal Subsidiaries [Table Text Block]",
        "terseLabel": "Summary of principal subsidiaries"
       }
      }
     },
     "localname": "SummaryOfPrincipalSubsidiariesTableTextBlock",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "adag_SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common stock shares surrendered for repayment of promissory notes.",
        "label": "Surrender Of Common Stock Shares For Repayment Of Promissory Notes",
        "terseLabel": "Surrender of ordinary shares for repayment of promissory notes"
       }
      }
     },
     "localname": "SurrenderOfCommonStockSharesForRepaymentOfPromissoryNotes",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_TaxableIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of taxable income during the reporting period.",
        "label": "Taxable Income"
       }
      }
     },
     "localname": "TaxableIncome",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_TechnologyAdvancedServiceEnterprisesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents an entity classification of Technology Advanced Service Enterprises that receives preferential tax treatment.",
        "label": "TASE"
       }
      }
     },
     "localname": "TechnologyAdvancedServiceEnterprisesMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of interest on original issue price considered for liquidation preference (or restrictions) of stock classified as temporary equity.",
        "label": "Temporary Equity Liquidation Preference Percentage Of Interest On Original Issue Price",
        "verboseLabel": "Simple interest accruing on original issue price (as a percent)"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreferencePercentageOfInterestOnOriginalIssuePrice",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of original issue price considered for liquidation preference (or restrictions) of stock classified as temporary equity.",
        "label": "Temporary Equity, Liquidation Preference, Percentage Of Original Issue Price",
        "verboseLabel": "Liquidation preference (as a percent)"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreferencePercentageOfOriginalIssuePrice",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of new stock classified as temporary equity issued during the period, upon conversion of convertible securities.",
        "label": "Temporary Equity, Stock Issued During Period, Shares, Conversion Of Convertible Securities",
        "verboseLabel": "Shares issued upon conversion of Series Pre-A Convertible Notes (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adag_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "verboseLabel": "Number of new shares issued"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "adag_ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold minimum percentage of voting power held by preferred share holders to provide written consent, considered for automatic conversion of preferred shares.",
        "label": "Threshold Percentage Of Minimum Voting Power Held By Preferred Shareholders To Provide Written Consent",
        "verboseLabel": "Minimum percentage of voting power held by preferred share holders to provide written consent"
       }
      }
     },
     "localname": "ThresholdPercentageOfMinimumVotingPowerHeldByPreferredShareholdersToProvideWrittenConsent",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold percentage on restricted net assets of PRC subsidiaries.",
        "label": "Threshold Percentage On Restricted Net Assets Of PRC Subsidiaries",
        "terseLabel": "Restrictions on net assets of PRC subsidiaries , threshold percentage"
       }
      }
     },
     "localname": "ThresholdPercentageOnRestrictedNetAssetsOfPrcSubsidiaries",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRestrictedNetAssetsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_WithholdingIncomeTaxes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of withholding income taxes on remittance of dividends.",
        "label": "Withholding Income Taxes",
        "terseLabel": "Withholding tax"
       }
      }
     },
     "localname": "WithholdingIncomeTaxes",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "adag_WithholdingTaxRateOnDividendsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of withholding tax rate on dividends.",
        "label": "Withholding Tax Rate On Dividends, Percentage",
        "terseLabel": "Dividends withholding tax rate"
       }
      }
     },
     "localname": "WithholdingTaxRateOnDividendsPercentage",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "adag_WuxiApptecGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to WuXi AppTec Group .",
        "label": "WuXi AppTec Group"
       }
      }
     },
     "localname": "WuxiApptecGroupMember",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "adag_WuxiBiologicsShanghaiCo.Ltd.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to WuXi Biologics (Shanghai) Co., Ltd.",
        "label": "WuXi Biologics (Shanghai) Co., Ltd."
       }
      }
     },
     "localname": "WuxiBiologicsShanghaiCo.Ltd.Member",
     "nsuri": "http://www.adagene.com/20211231",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_AU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Australia"
       }
      }
     },
     "localname": "AU",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CH": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SWITZERLAND"
       }
      }
     },
     "localname": "CH",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PRC"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_HK": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hong Kong"
       }
      }
     },
     "localname": "HK",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_SG": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SINGAPORE"
       }
      }
     },
     "localname": "SG",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AdrMember": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depositary Receipt (or American Depositary Share, ADS).",
        "label": "American depositary shares"
       }
      }
     },
     "localname": "AdrMember",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails",
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails",
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelEmailAddress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Email address of contact personnel.",
        "label": "Contact Personnel Email Address"
       }
      }
     },
     "localname": "ContactPersonnelEmailAddress",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'.",
        "label": "Entity Listing, Depository Receipt Ratio",
        "terseLabel": "Number of ordinary shares represented by each ADS"
       }
      }
     },
     "localname": "EntityListingDepositoryReceiptRatio",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r237",
      "r274",
      "r311",
      "r313",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r521",
      "r523",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r237",
      "r274",
      "r311",
      "r313",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r521",
      "r523",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r237",
      "r274",
      "r307",
      "r311",
      "r313",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r521",
      "r523",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r237",
      "r274",
      "r307",
      "r311",
      "r313",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r521",
      "r523",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r128",
      "r133",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r192",
      "r193",
      "r303",
      "r305",
      "r522",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r192",
      "r193",
      "r303",
      "r305",
      "r522",
      "r531",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r128",
      "r133",
      "r217",
      "r312",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "California"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/stpr/2021",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r43",
      "r459"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGross": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, before Allowance for Credit Loss",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNet": {
     "auth_ref": [
      "r28",
      "r505",
      "r532"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccountsReceivableNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCOUNTS RECEIVABLE, NET"
       }
      }
     },
     "localname": "AccountsReceivableNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r4",
      "r28",
      "r195",
      "r196"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r19",
      "r489",
      "r507"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Income Tax Payable",
        "terseLabel": "Income tax payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r47"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "adag_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional service fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedUtilitiesCurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r47"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "adag_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for utilities, such as electrical power, heating oil, natural gas, and water. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Utilities, Current",
        "terseLabel": "Utility and maintenance"
       }
      }
     },
     "localname": "AccruedUtilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r40",
      "r206"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r31",
      "r61",
      "r62",
      "r63",
      "r509",
      "r528",
      "r529"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r60",
      "r63",
      "r70",
      "r71",
      "r72",
      "r120",
      "r121",
      "r122",
      "r405",
      "r524",
      "r525",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r29",
      "r349",
      "r459"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital.",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r346",
      "r347",
      "r348",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional paid in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r315",
      "r318",
      "r352",
      "r353"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Sharebased compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r318",
      "r341",
      "r351"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total share based compensation expenses"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of restricted net assets of consolidated and unconsolidated subsidiaries as of the end of the most recently completed fiscal year.",
        "label": "Amount of Restricted Net Assets for Consolidated and Unconsolidated Subsidiaries",
        "terseLabel": "Total restricted net assets"
       }
      }
     },
     "localname": "AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRestrictedNetAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities not included in the computation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of long lived assets"
       }
      }
     },
     "localname": "AssetImpairmentChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r113",
      "r174",
      "r183",
      "r189",
      "r199",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r399",
      "r406",
      "r425",
      "r457",
      "r459",
      "r487",
      "r506"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r7",
      "r9",
      "r59",
      "r113",
      "r199",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r399",
      "r406",
      "r425",
      "r457",
      "r459"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r37",
      "r99"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r14",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r93",
      "r99",
      "r105"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at the end of year",
        "periodStartLabel": "Cash and cash equivalents at the beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r93",
      "r430"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r110",
      "r113",
      "r137",
      "r138",
      "r139",
      "r142",
      "r144",
      "r152",
      "r153",
      "r154",
      "r199",
      "r221",
      "r226",
      "r227",
      "r228",
      "r232",
      "r233",
      "r271",
      "r272",
      "r275",
      "r276",
      "r425",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails",
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails",
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails",
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r286",
      "r287",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r291",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r393",
      "r394",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATION ARRANGEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r52",
      "r216",
      "r493",
      "r513"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies.",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r213",
      "r214",
      "r215",
      "r218",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Aggregate ordinary shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r120",
      "r121",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Ordinary shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails",
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails",
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Ordinary shares, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Ordinary shares, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Ordinary shares, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r26",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Ordinary shares, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r26",
      "r459"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary shares (par value of US$0.0001 per share; 640,000,000 shares authorized, and 16,603,070 shares issued and outstanding as of December 31, 2020; and 640,000,000 shares authorized, 54,595,667 shares issued and outstanding as of December 31, 2021)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r65",
      "r67",
      "r68",
      "r76",
      "r496",
      "r516"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss attributable to Adagene Inc.'s shareholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive income (loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r163",
      "r164",
      "r194",
      "r422",
      "r423",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r194",
      "r422",
      "r423",
      "r530",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r194",
      "r422",
      "r423",
      "r530",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r157",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r163",
      "r164",
      "r194",
      "r422",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r160",
      "r163",
      "r164",
      "r165",
      "r422",
      "r424",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r163",
      "r164",
      "r194",
      "r422",
      "r423",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r292",
      "r293",
      "r304"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "auth_ref": [
      "r102",
      "r103",
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Issued",
        "terseLabel": "Conversion of preferred shares"
       }
      }
     },
     "localname": "ConversionOfStockAmountIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder.",
        "label": "Series Pre-A Convertible Notes"
       }
      }
     },
     "localname": "ConvertibleDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r24",
      "r25",
      "r277",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Number of shares on conversion of each convertible preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostOfGoodsProductLineMember": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sold and service rendered from specified product or service, when it serves as benchmark in concentration of risk calculation.",
        "label": "Research and development services purchased"
       }
      }
     },
     "localname": "CostOfGoodsProductLineMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r374",
      "r381"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r374",
      "r381",
      "r383"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Current income tax expense (benefit)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r374",
      "r381"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      },
      "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "2021",
        "totalLabel": "Total current borrowings"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails",
      "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Current [Abstract]",
        "verboseLabel": "Current"
       }
      }
     },
     "localname": "DebtCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BORROWINGS"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r109",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r251",
      "r258",
      "r259",
      "r261",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "BORROWING",
        "verboseLabel": "BORROWINGS"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r112",
      "r118",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r263",
      "r264",
      "r265",
      "r266",
      "r443",
      "r488",
      "r491",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r236",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "verboseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r234",
      "r263",
      "r264",
      "r441",
      "r443",
      "r444"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Amount borrowed",
        "verboseLabel": "Amount of Series Pre A Convertible Notes issued"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails",
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r49",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as a percent)",
        "verboseLabel": "Series Pre A Convertible Notes, Interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails",
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r50",
      "r112",
      "r118",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r263",
      "r264",
      "r265",
      "r266",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r50",
      "r112",
      "r118",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r241",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r260",
      "r263",
      "r264",
      "r265",
      "r266",
      "r279",
      "r281",
      "r282",
      "r283",
      "r440",
      "r441",
      "r443",
      "r444",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "verboseLabel": "Term of the debt"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtLongtermAndShorttermCombinedAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.",
        "label": "Debt, Long-term and Short-term, Combined Amount",
        "totalLabel": "Total borrowings"
       }
      }
     },
     "localname": "DebtLongtermAndShorttermCombinedAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails",
      "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Summary of prepayments and other current assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r375",
      "r381"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r97",
      "r114",
      "r375",
      "r381",
      "r382",
      "r383"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Deferred income tax expense (benefit)"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r21",
      "r22",
      "r365",
      "r490",
      "r503"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r358",
      "r359"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r375",
      "r381"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State and local"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r366"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Capitalized inventory"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r368"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.",
        "label": "Deferred Tax Assets, Unrealized Currency Losses",
        "terseLabel": "Unrealized foreign exchange gain/losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsUnrealizedCurrencyLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r367"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "periodEndLabel": "Balance as of December 31",
        "periodStartLabel": "Balance as of January 1"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails",
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r359",
      "r368"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities, net"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Depreciation and amortization of property, equipment and software"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDeferredTaxAssetsAndDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Employee benefit expenses"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Deposits Assets, Current",
        "terseLabel": "Deposits"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r97",
      "r172"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueFromRelatedPartiesCurrent": {
     "auth_ref": [
      "r5",
      "r15",
      "r27",
      "r117",
      "r224",
      "r226",
      "r227",
      "r231",
      "r232",
      "r233",
      "r452"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).",
        "label": "Due from Related Parties, Current",
        "terseLabel": "Amounts due from related parties"
       }
      }
     },
     "localname": "DueFromRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r43",
      "r117",
      "r224",
      "r226",
      "r227",
      "r231",
      "r232",
      "r233",
      "r452"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Amounts due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net loss per ordinary share"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r77",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r134",
      "r137",
      "r142",
      "r143",
      "r144",
      "r148",
      "r149",
      "r412",
      "r413",
      "r497",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "-Basic",
        "verboseLabel": "Net Loss per share-basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r77",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r137",
      "r142",
      "r143",
      "r144",
      "r148",
      "r149",
      "r412",
      "r413",
      "r497",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "-Diluted",
        "verboseLabel": "Net Loss per share- diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r145",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "Effect of exchange rate on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r115",
      "r361",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Income tax rate (as a percent)",
        "verboseLabel": "PRC preferential income tax rate as qualified TASE"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails",
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Amount",
        "terseLabel": "Difference in income tax rates of overseas entities"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Amount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal": {
     "auth_ref": [
      "r361",
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax settlement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, State and Local, Percent",
        "terseLabel": "State income tax rate (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlementsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "adag_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related liabilities"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period to recognize unrecognized compensation cost (in years)",
        "verboseLabel": "Weighted average period for recognition of share based compensation expense (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized employee share based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r70",
      "r71",
      "r72",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r151",
      "r200",
      "r278",
      "r284",
      "r346",
      "r347",
      "r348",
      "r377",
      "r378",
      "r411",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r524",
      "r525",
      "r526",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r97",
      "r268"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedLabel": "Change in fair value of warrant liabilities",
        "negatedTerseLabel": "Gains from decrease in fair value of warrants",
        "terseLabel": "Change in fair value of warrant liabilities"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsWarrantsDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items}"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r414",
      "r415",
      "r416",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r414",
      "r415",
      "r417",
      "r418",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "auth_ref": [
      "r414",
      "r415",
      "r417",
      "r418",
      "r419",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value.",
        "label": "Nonrecurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsNonrecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Financial liabilities"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNonrecurringDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r426",
      "r427",
      "r428",
      "r429"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Foreign exchange loss (gain), net",
        "terseLabel": "Foreign exchange gain (loss), net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and tools"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss (gain) on disposal of property, equipment and software"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "negatedLabel": "Administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "Administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r162",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Concentration of credit risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r314",
      "r316",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails",
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r97",
      "r204",
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment of Long-Lived Assets Held-for-use",
        "terseLabel": "Impairment loss"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r203",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r74",
      "r174",
      "r182",
      "r185",
      "r188",
      "r190",
      "r486",
      "r494",
      "r499",
      "r518"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Loss before income tax",
        "totalLabel": "Loss before income tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r209",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAX EXPENSE"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r115",
      "r362",
      "r363",
      "r370",
      "r379",
      "r385",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAX EXPENSE"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r116",
      "r131",
      "r132",
      "r173",
      "r360",
      "r380",
      "r386",
      "r519"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense",
        "totalLabel": "Income tax expense",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails",
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxExpenseBenefitDetails",
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r356",
      "r357",
      "r363",
      "r364",
      "r369",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Changes in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "verboseLabel": "Income tax credit computed at PRC preferential income tax rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount",
        "terseLabel": "Nondeductible expenses"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "negatedLabel": "Others"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r361"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State tax"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseIncomeTaxReconciliationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income tax payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accruals and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r96",
      "r471"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedLabel": "Amount due from related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueToRelatedParties": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Due to Related Parties",
        "terseLabel": "Amount due to related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepayments and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r73",
      "r171",
      "r439",
      "r442",
      "r498"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r91",
      "r94",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNonoperating": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.",
        "label": "Investment Income, Nonoperating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Total rental related expenses for operating leases"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r46",
      "r113",
      "r184",
      "r199",
      "r221",
      "r222",
      "r223",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r400",
      "r406",
      "r407",
      "r425",
      "r457",
      "r458"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r34",
      "r113",
      "r199",
      "r425",
      "r459",
      "r492",
      "r511"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "TOTAL LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES, MEZZANINE EQUITY AND SHAREHOLDERS' DEFICIT"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r48",
      "r113",
      "r199",
      "r221",
      "r222",
      "r223",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r400",
      "r406",
      "r407",
      "r425",
      "r457",
      "r458",
      "r459"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesOtherThanLongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Other than Long-term Debt, Noncurrent [Abstract]",
        "verboseLabel": "Non Current"
       }
      }
     },
     "localname": "LiabilitiesOtherThanLongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "ACCOUNTS RECEIVABLE, NET"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccountsReceivableNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0
      },
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term borrowings",
        "verboseLabel": "Current portion of long term borrowings"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails",
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r118",
      "r219",
      "r253"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r118",
      "r219",
      "r253"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r118",
      "r219",
      "r253"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsFutureMaturitiesOfShortTermBorrowingsAndLongTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtLongtermAndShorttermCombinedAmount",
       "weight": 1.0
      },
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term borrowings",
        "totalLabel": "Total non current borrowings"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-term Debt, Excluding Current Maturities [Abstract]",
        "verboseLabel": "Long term borrowings:"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtTerm": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Long-term Debt, Term",
        "verboseLabel": "Term of the debt"
       }
      }
     },
     "localname": "LongTermDebtTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LongTermLoansFromBank": {
     "auth_ref": [
      "r20",
      "r491",
      "r508"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion.",
        "label": "Loans Payable to Bank, Noncurrent",
        "verboseLabel": "Bank loans"
       }
      }
     },
     "localname": "LongTermLoansFromBank",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r50",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and laboratory equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Percentage of legal ownership by the Company"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash generated from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash generated from (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r93",
      "r95",
      "r98"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r64",
      "r66",
      "r72",
      "r75",
      "r98",
      "r113",
      "r123",
      "r125",
      "r126",
      "r127",
      "r128",
      "r131",
      "r132",
      "r140",
      "r174",
      "r182",
      "r185",
      "r188",
      "r190",
      "r199",
      "r221",
      "r222",
      "r223",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r413",
      "r425",
      "r495",
      "r515"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss attributable to Adagene Inc.'s shareholders",
        "totalLabel": "Net loss attributable to Adagene Inc.'s shareholders",
        "verboseLabel": "Net Loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r125",
      "r126",
      "r127",
      "r128",
      "r134",
      "r135",
      "r141",
      "r144",
      "r174",
      "r182",
      "r185",
      "r188",
      "r190"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to ordinary shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r174",
      "r182",
      "r185",
      "r188",
      "r190"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r445",
      "r446"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Schedule of future minimum payments under non cancelable operating leases"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r445",
      "r446"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r445",
      "r446"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r445",
      "r446"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating losses"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "ORGANIZATION AND BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r58",
      "r459"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r397",
      "r398",
      "r404"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustments, net of nil tax",
        "verboseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent": {
     "auth_ref": [
      "r397",
      "r398",
      "r404"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation adjustments, tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLossParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncome": {
     "auth_ref": [
      "r520"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue and income classified as other.",
        "label": "Other Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r10",
      "r11",
      "r47",
      "r459"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "adag_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Others"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Underwriters' option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Equity",
        "negatedLabel": "Purchase of treasury shares under stock repurchase program"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of initial public offering costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r84",
      "r390",
      "r391",
      "r392"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "negatedLabel": "Purchase of property, equipment and software"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Placement of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r320",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted.",
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "terseLabel": "Conversion ratio"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionRatio",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "verboseLabel": "Dividend rate (as a percent)"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r7",
      "r35",
      "r36"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepayments and other current assets",
        "totalLabel": "Prepayments and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PREPAYMENTS AND OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r6",
      "r8",
      "r201",
      "r202"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepayments"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePrepaymentsAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromContributedCapital": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period.",
        "label": "Proceeds from Contributed Capital",
        "terseLabel": "Proceeds from share subscriptions"
       }
      }
     },
     "localname": "ProceedsFromContributedCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Total aggregate gross proceeds",
        "verboseLabel": "Proceeds from initial public offering, net of underwriting commissions"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from Issuance of Debt",
        "terseLabel": "Proceeds from borrowings"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "verboseLabel": "Total consideration from issuance of convertible redeemable preferred shares"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Proceeds from Issuance of Warrants",
        "verboseLabel": "Consideration from issuance of warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from disposal of property, equipment and software"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-term Investments",
        "terseLabel": "Withdrawal of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r86",
      "r345"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of share options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r64",
      "r66",
      "r72",
      "r92",
      "r113",
      "r123",
      "r131",
      "r132",
      "r174",
      "r182",
      "r185",
      "r188",
      "r190",
      "r199",
      "r221",
      "r222",
      "r223",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r232",
      "r233",
      "r397",
      "r402",
      "r403",
      "r408",
      "r409",
      "r413",
      "r425",
      "r499"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY, EQUIPMENT AND SOFTWARE, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r40",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r211",
      "r535",
      "r536",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY, EQUIPMENT AND SOFTWARE, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r39",
      "r205"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property, equipment and software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r16",
      "r17",
      "r207",
      "r459",
      "r500",
      "r512"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, equipment and software, net",
        "totalLabel": "Net book value"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetByTypeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net, by Type [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetByTypeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r38",
      "r207",
      "r535",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, equipment and software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r16",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of property, equipment and software"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r16",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesFromStockholderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received.",
        "label": "Subscriptions receivable from shareholders"
       }
      }
     },
     "localname": "ReceivablesFromStockholderMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Convertible redeemable preferred shares"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r309",
      "r451",
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r309",
      "r451",
      "r452",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Related party transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r309",
      "r451",
      "r454",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r449",
      "r450",
      "r452",
      "r455",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Repayment of borrowings",
        "verboseLabel": "Amount repaid"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsLongTermBorrowingsDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r355",
      "r472",
      "r549"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedTotalLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedAssetsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for assets that are restricted in their use, generally by contractual agreements or regulatory requirements. This would include, but not limited to, a description of the restricted assets and the terms of the restriction.",
        "label": "Restricted Assets Disclosure [Text Block]",
        "terseLabel": "RESTRICTED NET ASSETS"
       }
      }
     },
     "localname": "RestrictedAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRestrictedNetAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r30",
      "r284",
      "r349",
      "r459",
      "r510",
      "r527",
      "r529"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r200",
      "r346",
      "r347",
      "r348",
      "r377",
      "r378",
      "r411",
      "r524",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r169",
      "r170",
      "r181",
      "r186",
      "r187",
      "r191",
      "r192",
      "r194",
      "r302",
      "r303",
      "r473"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Licensing and collaboration revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r108",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition [Abstract]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesImpairmentOfLongLivedAssetsToEmployeeDefinedContributionPlanDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails",
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Summary of accounts receivable"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccountsReceivableNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of potentially dilutive securities that are not included in the calculation of diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of components of income tax expense"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of borrowings"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of tax effects of temporary differences that give rise to the deferred tax balances"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of basic and diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of reconciliation between the income tax expense and the actual provision"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r318",
      "r340",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpensesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r318",
      "r340",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of total share based compensation expenses recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of future minimum payments under non-cancelable operating leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r40",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r453",
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "terseLabel": "Schedule of related party transactions"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureRelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r320",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r326",
      "r332",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of assumptions used to estimate the fair value of the share options granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assumptions used to estimate the fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Maximum aggregate number of shares that may be issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term and Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at the end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at the end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Share options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Fair value (in USD per option)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Outstanding at the end (in dollars)",
        "periodStartLabel": "Outstanding at the beginning (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r328",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end",
        "periodStartLabel": "Outstanding at the beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "verboseLabel": "Vested and expected to vest at the end (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at the end"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at the end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "auth_ref": [
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification.",
        "label": "Share-based Payment Arrangement, Plan Modification, Incremental Cost",
        "terseLabel": "Incremental compensation cost to be recognized",
        "verboseLabel": "Incremental fair value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Exercise price (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r320",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r316",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Employees"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "auth_ref": [
      "r314",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Management"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Annual cap percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r337",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Contractual life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationFairValueOfShareOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Exercisable at the end (in dollars)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable at the end (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "terseLabel": "Shares unvested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Vested and expected to vest at the end (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r325"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Aggregate fair value of the equity awards vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance at the end (in shares)",
        "periodStartLabel": "Balance at the beginning (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Share price (in USD per share)",
        "verboseLabel": "Shares issued price per share (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails",
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermBankLoansAndNotesPayable": {
     "auth_ref": [
      "r42",
      "r514"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0
      },
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer.",
        "label": "Short-term Bank Loans and Notes Payable",
        "terseLabel": "Short-term borrowings",
        "verboseLabel": "Bank loans"
       }
      }
     },
     "localname": "ShortTermBankLoansAndNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermBorrowingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-term Debt [Abstract]",
        "verboseLabel": "Short term borrowings:"
       }
      }
     },
     "localname": "ShortTermBorrowingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsComponentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureBorrowingsShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r106",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Computer software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r110",
      "r113",
      "r137",
      "r138",
      "r139",
      "r142",
      "r144",
      "r152",
      "r153",
      "r154",
      "r199",
      "r221",
      "r226",
      "r227",
      "r228",
      "r232",
      "r233",
      "r271",
      "r272",
      "r275",
      "r276",
      "r278",
      "r425",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails",
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails",
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails",
      "http://www.adagene.com/role/DocumentDocumentAndEntityInformation",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r56",
      "r70",
      "r71",
      "r72",
      "r120",
      "r121",
      "r122",
      "r124",
      "r130",
      "r132",
      "r151",
      "r200",
      "r278",
      "r284",
      "r346",
      "r347",
      "r348",
      "r377",
      "r378",
      "r411",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r524",
      "r525",
      "r526",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r120",
      "r121",
      "r122",
      "r151",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Share options and share grant"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareAntiDilutiveSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r55",
      "r252",
      "r278",
      "r279",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "verboseLabel": "Conversion of preferred shares to ordinary shares upon the completion of initial public offering (\"IPO\") (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r25",
      "r26",
      "r278",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares issued (in shares)",
        "verboseLabel": "Issuance of ordinary shares upon IPO, net of issuance cost (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r25",
      "r26",
      "r278",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of ordinary shares under performance incentive plan (Note 9) (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r25",
      "r26",
      "r278",
      "r284",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of share options (in shares)",
        "verboseLabel": "Shares issued upon exercise of share options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesDetails",
      "http://www.adagene.com/role/DisclosureShareBasedCompensationShareOptionActivitiesNarrativeDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r56",
      "r278",
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "negatedLabel": "Conversion of Preferred Shares to Ordinary Shares",
        "terseLabel": "Conversion of convertible redeemable preferred shares to ordinary shares upon the completion of initial public offering (\"IPO\")"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r25",
      "r26",
      "r278",
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of ordinary shares upon IPO, net of issuance cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r25",
      "r26",
      "r284",
      "r319",
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of ordinary shares under performance incentive plan (Note 9)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r56",
      "r278",
      "r284"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of share options",
        "verboseLabel": "Total amount"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureShareBasedCompensationDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Share repurchase program authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramPeriodInForce1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Stock Repurchase Program, Period in Force",
        "terseLabel": "Term of share repurchase program (in months)"
       }
      }
     },
     "localname": "StockRepurchaseProgramPeriodInForce1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r26",
      "r32",
      "r33",
      "r113",
      "r197",
      "r199",
      "r425",
      "r459"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning",
        "totalLabel": "Total shareholders' equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteSubscriptionsReceivable": {
     "auth_ref": [
      "r25",
      "r26",
      "r32",
      "r270"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital.",
        "label": "Stockholders' Equity Note, Subscriptions Receivable",
        "negatedLabel": "Subscriptions receivable from shareholders"
       }
      }
     },
     "localname": "StockholdersEquityNoteSubscriptionsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r437",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r437",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r437",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r437",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r460",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails",
      "http://www.adagene.com/role/DisclosureOrganizationAndBasisOfPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary of Valuation Allowance [Table Text Block]",
        "terseLabel": "Schedule of movement of the valuation allowance"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental cash flow disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Concentration of suppliers"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesConcentrationOfCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "adag_AccruedLiabilitiesAndOtherCurrentLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Other taxes and surcharge"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureAccrualsAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mezzanine equity:"
       }
      }
     },
     "localname": "TemporaryEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of accretion of temporary equity to its redemption value during the period.",
        "label": "Temporary Equity, Accretion to Redemption Value",
        "verboseLabel": "Accretion of Preferred Shares to redemption value"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.",
        "label": "Temporary Equity, Accretion to Redemption Value, Adjustment",
        "negatedLabel": "Accretion of convertible redeemable preferred shares to redemption value",
        "terseLabel": "Accretion of convertible redeemable preferred shares to redemption value"
       }
      }
     },
     "localname": "TemporaryEquityAccretionToRedemptionValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r13",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r221",
      "r226",
      "r227",
      "r228",
      "r232",
      "r233"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Total mezzanine equity"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails",
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r13",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Convertible redeemable preferred shares, par value"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Convertible redeemable preferred shares, shares authorized"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Convertible redeemable preferred shares, shares issued"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "terseLabel": "Convertible redeemable preferred shares, shares outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of Preferred Shares"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsPreferredShareActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r13",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "verboseLabel": "Schedule of Company's Preferred Shares activities"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureConvertibleRedeemablePreferredSharesAndWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r54",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r26",
      "r278",
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Par Value Method, Amount",
        "negatedLabel": "Retirement of treasury shares (Note 16)"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r54",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TREASURY SHARES"
       }
      }
     },
     "localname": "TreasuryStockSharesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r26",
      "r278",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Purchase of treasury shares under share repurchase program (Note 16) (in shares)",
        "terseLabel": "Shares repurchased (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails",
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "auth_ref": [
      "r26",
      "r278",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period.",
        "label": "Treasury Stock, Shares, Retired",
        "negatedLabel": "Retirement of treasury shares (Note 16) (in shares)",
        "terseLabel": "Repurchased shares retired (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesRetired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails",
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockTextBlock": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Treasury Stock [Text Block]",
        "terseLabel": "TREASURY SHARES"
       }
      }
     },
     "localname": "TreasuryStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureTreasuryShares"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r54",
      "r286",
      "r289"
     ],
     "calculation": {
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury shares, at cost (Nil and 94,074 shares as of December 31, 2020 and 2021, respectively)"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r278",
      "r284",
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Stock Repurchased During Period, Value",
        "negatedLabel": "Purchase of treasury shares under share repurchase program (Note 16)",
        "verboseLabel": "Total consideration of share repurchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails",
      "http://www.adagene.com/role/DisclosureTreasurySharesDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfChangesInShareholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureCollaborationArrangementsDetails",
      "http://www.adagene.com/role/DisclosureSubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r155",
      "r156",
      "r158",
      "r159",
      "r166",
      "r167",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowance [Abstract]",
        "terseLabel": "Movement of the valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseValuationAllowanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r368"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Addition"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureIncomeTaxExpenseValuationAllowanceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VehiclesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment used primarily for road transportation.",
        "label": "Vehicles"
       }
      }
     },
     "localname": "VehiclesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosurePropertyEquipmentAndSoftwareNetDetails",
      "http://www.adagene.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyEquipmentAndSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r136",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "-Diluted",
        "verboseLabel": "Weightedaverage number of ordinary shares outstanding-diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares used in per share calculation:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r134",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "-Basic",
        "verboseLabel": "Weightedaverage number of ordinary shares outstanding-basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adagene.com/role/DisclosureNetLossPerShareDetails",
      "http://www.adagene.com/role/StatementConsolidatedStatementsOfComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(3)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/subtopic&trid=2196772"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/subtopic&trid=2208821"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.16)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.4)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123366838&loc=d3e3073-115593"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r551": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r552": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r553": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r554": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-3"
  },
  "r555": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r556": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r557": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r558": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r559": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r561": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r562": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>135
<FILENAME>0001104659-22-050329-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-22-050329-xbrl.zip
M4$L#!!0    ( ,F FE3MDWMW]!@  )H/ 0 1    861A9RTR,#(Q,3(S,2YX
M<V3M75ESV[BR?K]5]S_P^FE.U<BVY"0S=DWFE"33B>IJ&TF))_?E%$Q"$LY0
MA 8DO<ROO]W@(DHDP45RPLSABQ<2:*#[:RR] /SEG\\;2WNDPF'<?G_6/K\\
MTZAM<)/9J_=GGM,BCL'8V3]__>__^N5_6JW?>[.A9G+#VU#;U0Q!B4M-[8FY
M:VW!MUMB:R,J!+,LK2>8N:*:=GW^[OSG=OOZO--^]]-;K=4**/6( S6YK4F2
MG?-V]*8?4.7VC?;FHO/NHG/9Z6CMSLW5SS=75]IT%)4<03>7++_HLV/>.,::
M;HCF$K&B[IALJ+,E!GU_MG;=[<W%Q=/3TSDQR8K:]-S@&R34;G>NVF<:<5W!
M'CR7WG&QN:5+XEDN2,;^TR.6;!T$9E&4QUZ!V&N0L.W<0"?V6GNZ.N=B!0U=
MMB]^'PWGLG]A81#\BI!M5&%)G =9/'@A^]>Z;+>PAWX509=[])\?A!6V\.X"
MWH8%'>&VW)<M=9+4HU<I])&>Z49UXN3?7O@O8[T7W$IK('R31M_*[/[5Q>]#
M9O\1EK0),YS]CCC4.%_QQPOY2A*/<YO1F>A52F\\5V1VY_H"WH8%+>B8HN/X
M^@%4/=:=U(ZD=,'PA("A^)+.:?AVCUGZ;*S3B^.;O:+/B8X'"MF^OKZ^D&^C
M/C,CG2B\V*-ITQ6.7(7@4-P70;&(3^[9KLABTW^YUPPH48;^AF]2I.FX6Y'!
M!;S9HU]@Q(=#FN4/Z1:S'9?8!HT/)*90F</RIBL.^-VK Z\O\#6R<(D\QQB!
M":W #!?HCNUM.FG#NW,)VN-2VV$/%FUA,2J("\N%T^K@<A'TDFX%-8K ORNY
MTQLW7V?<74LL'4AX(;GZ\\T9S/J:)N=]8MO<E=V5S\*GVRVSESQX! ]1WV^P
MI06(4L,_/LT&F;*37;IECF%QQQ-T#GB91)A=V^Q[CLLWW6?FW/(-87:@/LZ9
MQD PY:I$O0O[9](ELYGD!0;IY:76TG84X9^0J 94-9^LAG0UG[ 64O[EXI#<
M84L>+,X3^U?Y-Z#EP.HF98C3<% [***J:1#+\*P*%7<]RZX7/ TQ.PI*$)PK
ME_ ^:#6WF(G:V2,6#L/YFM(0OP+E5*#!O"!!B\C W_W)>#X9#FZ["_U6ZW6'
MW7%?U^8?=7TQ;V J E/TT)DL^WP#8ECC7/5(A]Q1P::NIX:QHX9QOH!?(WV\
MF&N3.W@UFL[TC_IX/OBL:\/)O &V/+#$6=]9_*DPH%%Y-9!O2@'9G7_4[H:3
M^P; [+6P:\@MFS.C!F6/!+8,8^K>4I<P*[$(*LNJ@'MS>779/ES]NOW^Y!-"
M-=/[^N!SMS?4?]3&^D+[(2#YCP:V3-BF@F[)BQP]L'F8N&LJ^M+"<+N. ^M:
M!H)%JZG!?),$$V;,:?>+/_2ZXUMMLOBHS[3^I]D,'FG=^1S6QP;80L#R+17N
MB_ZGQ[8(%. TYTOWB0C%R"Q82PWKVS18)U-]MOCRHZ;_]FDP'4DP =[YY&YQ
MWYTU [;,/"O 'CT<=D-&'I@%/:)90[9X136Z[U)GX-FG[C!MQ X'W=Y@.%@,
M]&;8%H&WQX7@3\Q>.;@WY3;.L!F JHJJ(?PI"6%O,IM-[@?C#W/<"T7T&LQ*
M87;GN?#_B,!/.:(FR_F:"W=!Q697" ;@D-NK_8>Y&!]/.D\GWBAUPF]?VT0=
MT/A2<[ +F@O-:0]1>QJQ3<V";B1>-,J4KTP#&Q[2!7G6G[=@ER;^[T&])<M:
MOTO65JI$NWW9.52)P1BL6EU;='_7]-^G8-KJ^% VHKGD6:-^,]H/#WY#_V@P
M/P9S,)"X;<#R+-DIBWEZ[3S,K\IB+O:::0"O /@M75+8C9GPQ+>?8"*//<O?
MW!U/,$\M$JM#JEJ$;4C%(+)EN1R8\>?6KO5&6PIH"VS'-LP-C>T^MUU832D,
MN4QU*%!#C7>*90YHCP:+G67>GXP7L#?0Q_UF;Z_$,<B:"'\#(#K@X;X,["47
M&\E!@%^1DFJ_YN6U# Z%B1JQ/W$4^M2T&+D&K=(1H2E!LWE-709,%0T/[5?*
MBQ6]+1XKTG[8(]T,O_(AAC6!N=$9V/,U2'+-+9,*!_U?[@NL9LQ@;M'80SXA
M-?!7I8(2'[LP^<YA&09-Z,[TCY/AK3Z;2__:X@O,Q_K=H#]8- J1O:Y.Q(K8
M["_99YAK>\1A .,T)H*,Y;5X1;7-W4ZNLI/9A^YX\'_=Q6 RELMLKSL?2,"G
M,WT.X/MOFN6V0':&M]D0\3)9SMG*9C  "2RI?N0)=D-3&,*X'QIS&PP83PAX
ME@%W=4)J^#M)^.>?1J/N[ OB/1]\& ]@#'?15>Z'N&"[I4UA/I [KI86;['1
MB)-IA"H&<I2&%"&<IS$)CTPIC0E[\*-&PS[(C:$3]*+1HI-I$>P2#!")GS$'
MFP,P?ID[8\X?1ZE0+M4\_4F8\:7T9Z]Y=  ;L@.:@!XTNE,J5)#BO<^- 2CJ
MY#GW$_/&GG-_GNK';P M VB%F$[U6$W"2;L'Y[ )OE3UM-F/L#YBPO.,FI1N
M,#<)]O6^\U+:=>A0NR="P/3L'+S)=,:=@JA:(WY.\]>-/^NSQ: WU+69?JOK
M(\R,0C/B3I_-T)Y$L]'WY=UW9[,N&I:X10A=M7[[C=Z\MMYT#9<]JIS[)Z:>
MITF)I>(TFJ3M>M+HU.EU*OQ]&ATZI):G,XGUJ*+.A.TV&E+$$$'4Y'E*3-BA
MMJ/R6:D+J_&]3G%4('RM7G>NW\I$=WT\;SQ3QP&7_C0(Z&:-ZV-(Y8'^MC#H
MK6"*?Y"'>XU8FV%&2#.BB\WYED5@S^Y[EG$J7/G1A<Q9/:>\.LI[F;9K' Z[
M8$P$#FB<F#\$08<&P"J)'073-8HE823@2DG":&#*AVE,73SM-:7"WR/;+KME
ME@?[4SI'C[IJ-UZJKAK0%'<NIL'C43%MJL_\^1;SJZ&-EADTHNU::; N@/6,
M6ABIG1+AOBQ@AG2(@=W(@C>ON!K1E.-),WTHP[?3[FSQ15O A#KO]G%V;6;4
M(O M!"7P^T7I8DDOI(8JY1S#8J9WYY]F7T+CI,&G2#3DP:%_>L"O_JC8J605
M4V.4<E!A_JDWUW_[A&=+],_-ON3$YZ:+)C>5(*+.>>FHDYWR3E0WZ4\GS'8I
MG^:B!+==/;^E@?'(Z'.UZ'(.G$?EJS20ECLZ7^C,? Y@)0[+-_!4/B)?]FQ\
M#F@5#\4W %8]"E_R#'P.?%4/OS?X'7'DO?Q9]QP4*Q]R;V LD"J3G1&3 XOR
MX'HC^E/%DH\,'N> >*)<E0;NDO'%8J'#'/!*A((;@,K'^0H'^-0PE8OL-4 5
MCN?E!?)R8"D4P6O@*!JWRPG-Y8"1XLY(1M\:,$H'UHI&U'+@*15*:V"J<GM
MB6L#<L J>U] @Y=B6#FN8 :,&)C.TCU,:474^*1X)6 _O9@-^CB><-IKO$BE
M M'J"'0.&OFAYP:'P@'GO$AS#A9%0LP-&L<>J>7'A*4*A:<Z1QZ._2%LI8DA
M'Q-#7J!KJ,*%"4$]%<*P(4R>,RAZ7X)/O\'VV)&<CF^INFJ,.TF,RXSB!N=*
MT>9T6%5%U2A>)5',OJ:]P>S8$'0Z? 5KJ9%\DT2RV!WM#:I'QJ6S0"U228WI
MVS1,"UW0WH!Z?+ Z<ZXM5D\-[;O4B;?0[>P-ML4CV.D8)MZKL5)?X]#@<>JP
M=CIHU8BHD3W5@>A&!RK&NC/,%%59-:+7*69)YA'H!K6R<=5TO#)**9$J>DJR
MP:ADL#4=HO1":H123/R48X\-0I4CL.E0Y9168Y9BT*L.-C;8'1&6S=JGY%50
M(YABR.=<Z=Z >!J?Z6"S)4P@<I,E7LTV9(_4#%PP7-]L+?Y"\8L-S*825_D1
M:N!F:I',VUR^6L,JI7ISI+<65N:HAWB;I/QHD(6=#+\=X7(M[*=F^AW5C%A/
MM2UTM3D!>C)5O>."POM^\)%Y_=F0EYK/8.$X^N[2@K3S%"YY*TT9A0LZH1E!
M+S0:=$,3T(_F(M,37&$TV<HP7]ZM=A4HJ%7C.B7^FW=AD=]2<S7=JX$_1K<)
M7EMRO!8D2.6I0W&+/5L=P#0)FVU4H[)JW,$B_YE8'L6O%D;0EIL9<FCD*4/R
MXNML9<"F--F6-EGNJ48S/U3Q[J H_=P/R^)/^%6<@O=B95=4PMUN)W<)J9\K
MB^AK40,-P.5=0\5NRBIZ)U:!K/P&I&J)Q)EW7F665(-5-*WX/PHO_($78<[H
M4GN63UPH]/[,86#)TK/@V5K0Y?LSA*_5N>RTVYVK]K^ W?/GC1460?I[8#\_
M".N<B]5%Y_+RRH?[4$)!PR$)(HP$E:<K2:-]?7U](4L!$9E3 /N=B[#S9]K%
MR=@"D99E:Q^%.C)ED8>R3$$5:M65'Q@P9?DY&&.GXRKH.7.Q>G_7BH;-.#]J
MQ+)VK/]R\>R8-V2[9?:2RV?!$]OF_KCP'^(SD )^Z,(F&^ILB;'KG.3.H<;Y
MBC^"\K$+E,N?;\XTQUC3#1ER0U+RRSO9%?#/EO_G.308]E+=^)YX35=<(&9(
M\+)UV6YUVMF]R*LI_W<J]@2 OO:!MND*(P?I_3BL9@FQ5ZN%=%KM3JO]KGI'
MKBZ8[;BX/RO6"5D%_VN%]; ;5]B-JW;Q;L3IO97_F6[A#H05L.6WQ=M<$N=!
MDO"<%LK1D:J%>%XI-$$V'*^Z(F0K:UY0RW4B8JT=L9)B")5=NO7$BZ1=<'S$
MJX3_R(Y4[(+C;D69]J/R\J^2+:<*]01PX)-*:$1D'>%6Z$Q8R^\(_*?J!+7\
M:_EPOXCKQ;\B5^]4,-M@6V+A>1MF,B+"0-2"/KL]BQM_G,G.OS\K68?AD7><
M^5WAP7#W%S"8W%IR,KMQPZ(#EVYP^P6, SE8+61$X(/@WO;]&?+,;A@4@>5$
M_@W+#./FPJ?FB>!*!!6O\5,+N\L/F3S"$#^[,%G>,1OF& :,1?<B2K9""9R$
M4JI<?-YP^VZO<@5BNC=K>"\,[X$.I&@(E!/$<$.BWT14L*K+[C@G$5><VO$B
M"W7H5(+J^O;:1VZO_E=&Y#9 WQS1S0,5(?LY97+&A\DWA-G?BC'TX(@M7EB1
MP55J@5JS-/?^6G-/A51ZB5HSU?60G,7(U'T9NN9Y*E^9A>K)FCSOP,S =Q@F
M4OO^C""=.K$VE:Q3F[5)IHM3,Y8>GITXW@WD&Z%;K6X-)],2C"20KUKYNU2!
M](W9412^2SE4X5RM^AMN4Q=VMT>PZ9NH;OCJ@5AHL+X_\S^NJF8^Q75[.-S5
M1>HWJD?,9AMO,X5]*F[T5A0-![YDT.VE2\6"/"]XC\H,1C]'?\%Q]^>Y7+P
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M0*O_:A- X2&3.@X#*F#WS1_;>8<-VL''@6E# JUTANSEB75BV?L)J!H+Z"U
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MV$$R*;=@ F*);F90AUC!6IQYM9!(U8,DC: 8 HJ('C$OBR(EIHFM)6%VE4;
MF_3@K0*\V6]RZGIR0QI_P ;!$UMG)9'!W6G>I=/CG%U_0A=15[0<%B07CL*_
M:EU';ERJA?HE@ =Z5SP'9S"EC<SU9C\J'?MM;%!&LST;JY2<-F*5#X 7.P@B
MX(GH*:VR5HL;N")01ZYHZ=^&F[2'I9Y<LGNL_DZ;+D2J'@!)<HLAH(CB(5<J
MJ06R4[+X;@H<@+8SP 8Z%0R7EF46>/OO1HOPGKR1N=/NO_4^OQMDK; %C,\$
M.RN6>Q!9NI<T&<XW.9,Y7"J_8^IQN/Q-F8IJ)6?2A()3Q;$.&]AR"(P'(.CT
M<\-N/#?$TL2=-4^;+:VA;9JD'SJ]WN@K2PPWZ??Z@]\ZW6'_9^V^/]-^])O^
MJ90D<8E@.:.:4[:4J2_>%\H\[MK&*1VEXW6[>56V2YRJCO!8ED&4<U/LW@:8
M&Q;VSA\$L>!>^+64W%@[BX^U\:0_[OSAY6'LW-]HH]F7_D3K?9U,Z%=:9SKM
MTQ_*'7=^:#PQ).X+@VNG"=0L[ZHB$0CQ@NJ-1 D%Q6X5RH96C7WJ41G(T+)N
M:A5'5XVCEM3#Q1:B\Z_ :$TL6QO-BJ/+>2AIC\NH%\9:1[ HYBE>V"^ R%NL
MYTFKZ&C<G\S^^%GK_^?K8'SGKIUT-9V.;F??.A,ES-=(*(_B7\N";\6F5RDK
M-I/<I32;-KV2BN,S6U5;(1I9?-585:GI[BP==W.-2-"1*P>^KU-(\]5GT%XE
MH4B&^TC8@CC V':I0H?7Y%:$B\08QN1K9YCD5 T'G>Y@.)@-^KD]*\XY-_X!
MO3C"K2&1HWYYCE.H&P+>4[QTA*47S7;SNEW2>,VMMI@C)8BR&O-^^+!8NH83
M2M9,NZ((J^%-^=+X:@N-7T[IFFE8!F4UTCWXB-BK0VA9;@]OH:"R.97JJ7,9
ML-7(F-U?K@S\!J&_)UYXJ<ZL5S,"Y,.;\S[DO5G274P(?D'FH\7VD6&3O:B0
MLYTOX[9S=S29C+X-[C]/V:51ZW9+CI^P3*9#;#[:D"Q9^(AE@6)_TPX^(!,R
M_\A)"0R*52YER+*.L7Q6K).;<T\<),F%U1F<^=05'ID2"*MA30> AAB8;JZ[
M+C!YJ<@3RZJG70D=\16<C;$:^F5"R'HOL2ZAGB[SC]0L6-5PB<)<3E=C0LDH
M[A;%W5) G6E*29]PTV!58S2NTT.R6<6=8BBIW01)Z0?V,^O50=7Y0.8<Q^]@
M]=XZ-OU\!^B_KNT>RB"[*40A!A3??"EK)9^E6LE>/[3ENB,:7F@6ZXK&IE+M
M8?U<#9ASS:#=B?WPW;Q6;GE699 7O#Q7:CX/KTZ;@1Z^27-,D*FC%3 &YA\0
MD-D+%EB_19NJ$R$*PU\]PTX,+GT\SSS(U]AALX<K@6I$T:4!WV*'%$4?UM9!
MLX<K /%$E7LS0-=)$_TM?-N?N[3> LGM:VNUFNUM&W-PWQO=];59YW>M__NX
M?S_MLR_=AVDV>-6@]SCMQP?O@3^5;$1RY, 9$YS2?Y:54-*WE>1 I%>*$KC=
M;IZ7O3,I1>CQ09L#G(A16:9VIS:PH>L14NE+*CF]KGJZSJ$^+@=R8%>="K>0
M]D^:!+Q:]5:_%.KB;ZPO+!2PE?182/$9M=13O-0<GP>=\@KVZ9I/S^F5U5-W
M'@WR>9 #O;(3?8 ILGCE(X5($W6G1FX9B,\7[^^R3:".J=]I!#ONY5RV4UF7
MC40>5P=_K;R$EDD*Y'2R$U@PC,,.[=/;ICXE=1;B(IX1&1F7=&1<E'W!<(;Z
MMY)?[ED2>WX;P3FRX24:0<\PTL'M.<&]MA2;$VA!*E^69N0&/D,#NV=N?.A6
MXANR_3RDDE1Z1U'D/?%42E*D=&'0+WN.FWWBW_C!ZK"D..UFZS+U=>S.[5:2
M7_M%+_+*0J5U\!XSBX6-HP<CN#),;I5+:J'2Q-@59S4. '!0]MP\6IM[GV@!
M+X\ RT+KJ<PP\ LP=4F:2#1<1_;L"C_GB0(U2)7L$*9=92'32E1>IU1>96^5
MW9TN4EA%[MA2B0Y>&I-U0FM)&FS7KJ/ZA3"*7(SUSM&2V.SFFN3K[_*>W&^U
MXOLJ$P,HP;/<$ IP>^!NI)R'OS<VO2A],V62:#(BC-N%2XV8KA7-STZ35%2]
M,9NNBJ0H9R:>S$A%:5=BQB"D9>5)+JRT!M/U(J!2/D3EWV&L,6PN^Z98>H"0
MMP4F+X#,A17-;Z$"VN>K4$#_DLBK0XJ!^4SM"4QX5YCR*]1=Y>E E7^3O<;Q
MU200&.AO. \N%&(<%K$JTNO77?]2N(N/\G'>.\2Z&4[[E7X;AG3]FFBX&-S*
M7G.?/S G'7HZHZ(H^XZ!(JTZ0;Q";X74V)<F[C4F55%:VX)>F#"N*JS@(0RR
M.3(E6U%7]<(*31WPN64@;LKO+:C6P\LELH/+!'KNG2.TK"X=-4NX1Z WNKL;
MS#;W"/1&][/!_>?^?6^'-)=%Y8Q<.UWL)IC@S#8RT=)9COWC/S<.;W43KEU.
M/DRQWF6DR91J1+TA+JG@2.[,W:%7XQBS(-"!.7O![/@;;]V7;N<0Z9*!OAK'
ME\6QLG.VQ7!FW=*!LB8=?X'7*GP\\11%_WF@??KE_U!+ P04    " #)@)I4
MZQGJF[LZ  !RF@, %0   &%D86<M,C R,3$R,S%?9&5F+GAM;.U]6Y/;MK+N
M^ZDZ_T''^V7OJC6VQ\[-J63OTF@TMFK-2%J2'*_LEQ2'A"2L4(0"DN-1?OT!
M2$KB!0 !7EM94Y5X)!$ N_MK-- -H/'3_SSOW,$3HCXFWL^OKE^_?35 GDT<
M[&U^?A7Z5Y9O8_SJ?_[[__Z?G_[?U=4_;Q;W X?8X0YYP<"FR J0,_B*@^U@
M1?9[RQL\($JQZPYN*'8V:##X\/J[US]<7W]X_>[ZN^^_'5Q=)2W=6#ZK2;Q!
MU.2[U]>G)Z.D5>+]./CFS;OOWKQ[^^[=X/K=C^]_^/']^\'\X53R@9&YQN5%
M7>S]_B/_YY&]=, 8]OP?GWW\\ZMM$.Q_?//FZ]>OK[^^?TWHAC7P]OK-/Q_N
ME_86[:PK[/F!Y=GHU8"5_]&/?KPGMA5$TDI5?WZD[K&!]V].[Y*6X-^NCL6N
M^$]7U^^NWE^_?O:=5PF)_+'&2X[%GPOE$YZN/WSX\"9Z>BK*&L**IE-LG\H[
MP:E"NO"W;^*'KYB@!X.?*''1 JT'T>M^# Y[]/,K'^_V+F\K^FU+T?KG5Y9C
M;1C;[ZZOW\5,_\=MHE7'OT//&7L!#@X3;TWH+A+YJP%O__-BDJ&=MX4\]-HF
MNS?\^1N]IB+6M.3[IBYORX!I-*=D1#R?N-CA"GYCN5S&RRU"@:_)F4Y#H/B:
M6Y0]WJ( VY;;&).Y5OOF^/2C/UN/MI:W0?[$6VX9D5OB.LRVCO\(F?;=HC6V
M<5!'"J9OZE RM]BW7>*'%,WHQO+PGU$W8UV/67K,R)U3Y#/"HU]O46!A5U?I
M*[7<"^?+<+>SZ&&V7N*-QX8FVV+&Q[9)R*R/MYDS%&V,_"GQ*+)#-DYZFZJ2
MJ/$FP)*94[)'-#AP+=XGEGM)UL%7IN#M2DKKS8 EQXR$S:BF42=@MH$B!P<+
M[/_>KMC*7]N+S%1H3E%052:ZS?;"\PVAE'QEV/C++:'!"M'=^:>J'.LUVC._
M]\3;-,VNHLU>N&4=C3EI 7[D33F(N2'L$QOXULS=8M,"/@/PF39^L2AE'=7/
M/:DJCX;>>GD2&]H!?L(![DET@M?W,_9P8B)/?41V>^3YM69O):T!XE#\Z_B9
M?ZRN$K7>U5,?<EWKD<3#^Y!KZB;V/JKWBK(&>^%SXC%:T<IZ3L1>E3UI.[UP
MQ:8D]\3WYXC&1H7-W&ZQ&S+3@I;<*ZAEW\P:[X7_!7*YSSRWV)1MQ53-MVRN
M=I59+FVO%RY7%%GL[Z'>2"]II2>/Y]%'?X3,+(R?ZA@;:3O&7$6$6]0^<I=\
MS-."_)WU&H7,2^!_HL#H&^2C]9ND_)NOV$'TRK/XG!+15Z52$E'H4GIJC[_P
M*OG"I'G]P]7U]=6[6)[Y=Z59.?)A*M# \AR+.FS>,@K]@.R&S]B_)3L+LU%\
M;85N%'[415F_L:R ##6-L^8?@]9KRW^,I!CZ5QO+VO,%@^LWB+V+_\*;]"-Z
MK]Y>)\'X_T#(V155K]!0C <K^V;\'##;SR=^8R_<H7BLN\=^I=BLAN:=6L!>
M\,;!NY-V6*Y;3<5287V^-/%M)(>HM0:H8I^Y>(AWY41@-TABL>DFZ(V:NMJA
MW6/5+BLF-MMN Y1N&5'4#A_1U4D0#=(K;+U9?8B[?3L*<6P[H9A]QQZ.>Z;W
M>](ZIZ=V#T_1CG@Y!SFG7W' 7W"N/DC5'\2V;_ 0*41E6U'.6'-&7LGEAP\?
MWKX=7 W.+;,OQ\8'K/5!W/R MW]D_O2&B*,C3RZQ,V]T^0HLH97M//\E;^:3
MGW\[+[NXEN_/ULN V+]S$H]O8_X+<J.E<77YWZYS M&J\:8WQM/4W&8L<X[C
M8D$IJ^*B61[/"CND66Z9A3BVNZ9D9R9S4D9%Z+-7D#U_L74:)Q.C5,=JQ1(X
M<_6C!M6#%1FHJ264S>9^?M6 AOC(?KTA3V\<A"/E^.,;_O$J_AA;381_B]?+
MAX[#O $?^<F'%7N'H"^45RAHB%Z5;GA-O5BH^,(R0HZ$I2JKNY%8B8*"SE1=
MAV*NZU)*FU/SDR'T:9 R@NQ;W@"RGWZ;4^*$=C"C2T2?L"U2<EFQ@B*H"O;"
M%8\S)W3X0@57EE7Q)RY=6>$U1$PTWM^9NLOIY4I>2F<+REY]NA-O'.$A:.+Q
M8(G.E$=4IWS:(ZO5GQ!R%"EG/\*R4J:EI9N; Y6 0#2(Z6\J)"8^/1V2$MW7
M4)'>CA6-=1B).HNJJ-"DJ@KWSZ%TW) 7UN:RH9%#0]I$AXA.AP\YT<<A1$UL
M7[U@]M5#U-_BO43U,\^%FE HT1,#4LW.E5 ST9 .R\1&I*_K5%MSY!U55$ 6
MA+G-G87I+Y8;HIO#/;8>L<L'$NY=*^8VRCK28;ZT%@ A' ECYN,A6NM#SLQ;
M''>'1EMI/WODT6?35+Y59>+MPX ])I[-:D41RCQSRGE2Z^\M!Z/--]>>O^DJ
M&NF8L<[G@B6"2,\%.Q$ ,,MU^O@)(\K$O#W<HR?DZIDP164=6U92'8!\$O2C
M+41%:O4,E$X;Y=+2;:5)PZ$'K\B"Z%+;IS50<B<T"[I< >OB*;+O:+1AQ3[H
M]6]939W.K:H+0"PB\HS[<ZZF42\6U&VR[VI 5])Q!03VV5WE#)7U50$C$'KH
M\;3'W+7B(Z3'4Q\W!\DZF$%-J2IJU@4H%NGZF4%-<[$TM-96#3IB3&#G/52+
MH70/U62DK\#3@F\9EP2=3L^$L9K,TQZ(?LCL(,N3'3^5$WY^7BO )!(1$;ZF
MT\!2BJQC4"E'#H01(7/:D9]R+!T)%#7DFV;4=0"Q7VKQ%37TV6_8PNM!0K0)
MZMRB*QG(["12$PZT1]VPF>!V9U'5IKNR:B9]JU 1DC2.M)GULEPU VD4*[;1
MWV18J3J=@#0(/2_'BK+["5BHU0>+IROX+\7W+L/]WL6(BM8]-&H4U$>S3A<<
M"?N%5AU3KAKH$6:R)@8D==83M%C@G4";]+[\B-,6E(^(;*BUW_)40A*_0EI6
M.%U7ENZ82;3)$R)=[I:6%3.I*EW+0]$1-M$@HE/_14'TT9]1$@MA+G:+'H.)
MYP<TSIDFGWT5"TIG&.*B4'B<6CNU_R(KKLEOMD+MF912[D2/B,[G3"*BT[,D
M%;$0>@5/!!,@NN-TECC[HJ)239$5AL.ILF>("VMSVV"O*)$ZT2&B\UXA)CK=
M+^3$0N@5R2&E)'O-C"[P9JL:,J3ERXZ.B6L 8USGN)RHAAGS3?KD&G 4#]#)
MR.G>#Y>3+SA))R,;0C]*K8)&FY1*1AA9<:DBJ2K XEK9A^05C#AOL =I($%T
MB>F\_\B)3W<?-=$0>@]?HN0S1M52?*J(?'$Y5ZA_CM3KZ)E"I5PUN3HNEB91
MO;3[%>\,D9FE[0)Q$+3X(Q^=$,^[$(2JK>F%<E+DA26!,*C4;$%)/28;U'&5
MF$GIZSO7=@&Y:967D E![^-D>:?(V?%:!44/4-20JDE)'7#L*_N'LHZI"!KL
M,WK $ .2.N]'2A;2/:J4= A]B\_59NM4@DU%KQ*6E2J3M'1_S*;SB X]9TH\
MZ_Q+.E&C< =6Q5:D JK03NW^5P8AJ45>YWU1PDZZ%U9@HXVU]GA<O2-T93TG
MQXEDB^R2HN)U:$7A5HF7KZ=+"VLST-0*>KD@B0X1W:Z92XD^+98KB>TZ_=,]
MVECN.,[D(\[WE"M1T ))F2ZS5TF3.:4?"PG/%ZB5PDDN*2)^6Z?IF@K4'?,S
MY:F",*WA6::=0I;I\;/MA@YR[IC(>:*0,$BN(QE;U.-7-QR35-\<Q TH)D<M
MOE$^@VCWG=#@*XUWE54S%&3#,;%N-(28<=7YE*U5*60F?AK<0S!5LF3Q-X?T
M$X7ET6] JO]F3<"0E=(2% MJ\=Y@;Z^$"BDCJ_/N:L)&NO>)R0?<W\P[6)4>
M!:L+I0C3[DV%.J8B:+^/Z74J(4E0^I>Z0PE)A]"W<A=IE&Q2D)26*I2B/"B6
ME7U)6MZ$[2;30Y:"0#1)Z3XYI(ST=+]1DMS[F8*EC3R+8E)VGB!=3GV6(%^R
M8\:2MW_V_#VRHSO7Y><(9&7%#*I*-W..0")DHD% /V<(L@2?S@^H"(4R2C#7
MS**'I>4BC9L39.65)E-:HT?&S\1P/W2VUIV E5>4BT*K:B/#2!E&Q)2J7D84
M"1>9,46+^O[S#C-R)LQ2E&<=3A<46E]YT;YYT\@WG"VJR5_CN88E,BYD&BX2
MT%.>X2S!Q2S#14+S&O_3FYS([ME7W6N5Q+</$3LZ_G/\R]/.1,L/$V]-Z"XB
MZE4&%<FE0V_?OOT073J4-)3^:'G.(&YUD&U6]YZED\*TM&IUI#1%W8JGKQ2L
M8,F+OJE.)8!+DU+T:_5([>XBO+WLK-CY-;LR*#*#GIR97!?O!9L:]SJUAD;Q
MHCXQ%-KZI;[NJ4D@=*\4HL+-1KEG;8DWXOITM:!:MG+].-\I=")XSQP0RBQH
MU!H([2:['?$BXI6[NP3E.A7^NRK"5Q#?M4*/F[T/K!<[_ZZ:G=?AIGO[4N'*
MLM[-N;XB2:\SZU[4-Z&//48#FR$'S!>4FG5)N3Y-O%)3CB*6T-VUF 4]D;D0
M*')%]"; J>(M"3VZ MEHTEA@X2AUN>')NX71E;8_V@P=YO.,W6@:Q)S+.)O(
M^;E+?.3\_"J@83TGP PMKE8*=.+'?0ZT57&)*6]INF,FXP7:8#])HG2:""N$
M+BG?*0KOFT%!P@H(6(:>%UKN NT)5:&1+=8I"-\T T*6 Q"RCP*SD?1*Y5\L
MVBD&WS9DC@I<@,!AN46NRS?V6=ZA% E1X4ZQ^*X9+$1\@$!CCA@5SMAS;IFE
M5 "1*]<I!M\W@T&.A5[%'WLT=]A%TU#B&Q2+="KT'^H)O4@] 'D?IP9QSC"I
MS//%.I7[AR;DGN< @.SY$5C*#-]Y7C8BH1?0PX@X<BA*:G7K*+]M IH2C@ @
ME7C_R1_.SK44'V'9;E&IZ50K^ ")Q3L#+-YUC45-1UK!!QPL1NSCC*[(5_DI
M04');G&HZ4I+N8"#PISX@>7^+]XKAP]QX6ZQJ.E1JQB! T<RAI7VB&.Q;B&H
MZ5"+6>A5^$G@G;DT/O$\Y$KFL^)BW0J_I@<M9@&4\,>,;S=1#PT0LL6[!:.F
M*ZUFI6=0HG[)/1\B&IESS[L5>TUG.D=[OW+FII B2S+N9A]W*^6:KG.6]%Z%
MS!-$N?,M\>3AH6*1;I?,:CK#1?)[%7AR*OQP_>YQQ7>%"@1>+-*MP&OZN47R
M>Q7XBEH.]C;+P^Z1N )IYYYW*^J:;FR.]E[E/"49:NY<:R.0MK!4MS*OZ;(*
M.0!A4L;/]I8G&9-,T<7%NI5]31=5S ( YS2U!S+*&.+/PH YT![7$ZFKJJ[4
M+3"-.*YJA@# ] 6Y[M\]\M5;(HOY%<B9^'ZH6!.3EN\6G)J.;0DO '#YA;C,
M[[!HM(Q'Y1MV"^6ZQ:&F3ROA 8#\1R&ET88FOE^ #VU1MC^YX9(4[Q:-1M:-
M9:P  &7B!8CR\YU/Z-8*K(12Q0*FN'BWH#2RJ"QC!0 H4:<=60':$$40.E>J
MV\V-C2P>YS@ (/GQ#M$-ZZ$?*?D:;),=3E($)*6[1:*1!6,))Q 0>3YO_(NW
M/,GA$!3M%HM&%HQ%;/0*Q,1>TV'H8-;6, B0'V<PE/C>JL+=@E'3!5<Q F*O
MX]"V>2 ]GD]XCD5%/4-5N%LXFMJ*+6 $@)E*[XB5&JALH6[%WXCOG64 @-A'
MB-^M[4X\!SW_'<DE7RC7K? ;\:T+//2[<!;/E^^P;UONK\BB\DW7\J+=HE!W
MM5C*!HCAX$S7'?M%=6"P4+);&&JZU%(N *$03]OT<,B4[1:)FGZT@H]>L1@R
MHIR(,/$4-?>\VP-I-1WG'.W]RCF>'4M6@C)/NY5Q39<X0SD$"=]ANIN(9O>Y
MY]U*N::SFZ,=@ISODXO,Y)(^E^A6UC5]V0+UY=+^Z4V#R<W.R8M..=:0<V.Y
MEF<CYE.@X$RQ.K79]5N>VNS4'/L\FDV7L_O)[7 UOAW<#.^'T]%XL/PT'J^6
MK[K(:]9 QC!1AC-9H9?<9G5SFZG%_Y+5K)[YNJBL9K)+X=A,%OG7"^0@M./*
MP:S6$Z(!9A_GK")B?J CS[=5L0WXB= J,M;<R*[$ZUT#>)FT 3]W6D7&.L+K
MI@&\3-KH,_F+,5XFC'6$UZ@)@VC42)^98HP1,^*L*\B:L(E&C?296,8<,H!6
M<?2^"<A,&NDS_XPY9":<@<O4>KXQ79+63U6P^X1^Y60+O2482?QJ7-'I^RCP
MAX\\XXB=WPHG*P1A-JB'4YYR<+TD)C!9;=."H5 6@B\E5J,B$@7BP0$RLOSM
MT'/XG_$?(7ZR7,2OG ]&%J4'[&U^L=Q0%K_2K L',(G>9>(0>CR!PS'9.N,O
MD(T8U<Q*3U$@WO&K5P6"T=-&3<T*.+!N0\2O#$Y=CLBG/TJPU%4@^+_:8*E9
M 0<6FW_N+>R,G_?(\Q&S#;-@BVB&6PEF6C4A.,+:T&EQ! Y!':SZ1$7BZ^I;
M/^#RGU.R9\[<8>Y:\=U';&#=\[DL,]+2KJ.J F=L4G<6%0_@4$IUY2GQ;&5O
MD92%,PRI<)$0#PZ0F$2EO8(T?)1;*( ROL?6(W8QGX&P'AI%F+;$9<SZO+<&
MAQ(75;\ZA*ZA%T/0YPDRFGHA!E4%"&ZKJ7I*<(0?AC@Z<'/K$(5_M1S7?&%@
MB!GXK7E.P.'#LZEQ)K[@8#L*_8#L$#VR>E"CI5<5PI3.##L]OL AR;SO%3&,
M/$@K0!C5S%!3<=/Z,B#K[C1$3M:J1]/1A(;4$]$*H%E]"%-#/7 J, >N7R7D
M\YSI.[2RGLNZE:(\A."#\3@F8P8<4,LMH<$*T=V-Y?U^3RR/Z]F4!.@X"LO6
M;<OK05AN-P-.@REP -X3;\-)OD6/)2L<PI*=@O1]$R )V8 '2X$G;:>K8U!^
M: 04 1?P,$EI3FE03U88V-3<W!&6\ 4.K=MDH]-I&$UQ+0^5E]8"-DDWQJ^4
M07! 1K/6-)5:\71)!6#3>&/X5+R!0T[N@ E+ )NIUXD1 @2#9P/%P2[:@.,Y
M/-Z"O0WR;#DXRAK 9N?&8"F9 P?>"NWXU6'TH+60(BT-;+9N#)J4,>B '3>\
M#7<\0CT, HH?PX"[A"LRMQ1C685V( 3N2_15@:D.A^#0-E[J!+.X6>Z]&7?2
MBUKD3.7(5F[.+12#T,O,1[PL#^#06%%D^2$]E.(A*@C!LS8<S@1<@,.DR!*/
M:"[#1]^F."(MM5%8V]PIVX#@8]>U>4H&P8$\=!P<$S"WL#/Q1M8>!U;^?I;2
MTA"\:S/@I*S @\BVPUT8+;7&ZWADMZ=HRY-(/*$XFG-/?![#F:U7UK-\H<RL
M%0A.N2&DIBR"@WJ! B8<Y(PMZK&IL)_BZ):A8&/9M%*G(@3'W0Q0':[ 85AD
M47MLA.&GUQT  6)2YM54W)<*9=QK8C\JP(1GL=>_10&VSS.2TNQGW^IG/QO\
M9^85__7J)1O:2S:TEVQH+]G0##<DOF1#:S0;VDL"-/ )T%YRGH'/>?:2YNP2
MTIR]9#:[A,QF+\G,+B&9&80Y]DO^LDO(7Y;;>C"WZ(Q&S#G18MP<T>C>9+VM
M&?+:$*9_>LAJLP0NM)>C/+[O>A@&6T;FGRA_(X1V+0C3PDK0%5FY#,BB6["-
MX#K6@# YK '5D8W+@"ESD[P^5IEJ$.:)-0#+\ (.M=1F'\-A3:LFA-FC'G9:
M[$"&3W,H4]: L9YH"-<%#&$%:I7#E[0TA!V?%>$!.VP5*"T?LM15.@7I0Z,@
MP1ZJ,KL@8X)U=GT>2W:[_O&VUCQ"1#^$]?;3C_YL/=I:WH9U;"\B,+,Y(+?Y
MJ&0-_KWZ!K+EBOUY&$]7R\'L;C#Z-)Q^'"\'D^E@^6FX&'^:W=^.%\O!^!^?
M)ZM?!_]Y.[Z;C":KE[7YQBE-CET0-L7UHM-0&NOSXCH7N48O9@6"7<Q1IERJ
MEY2%MEJOTK4T.A)V(*"2&ER%\7A%.0@K]4JEDDPB( 76,T.H$@!A20BA6&T(
MA!Q  .%\E,'GN<=3NPB5B)17@Q!NU8:GG!T(6$D.."B!*JD#(=*JC5()+R @
M*C^PH(9+OSZ$F*L^=/I\08 Q?TRAQ!:*"T,(K!I80#$3$-!X68&_A!5XUHOY
M) ?=HOCOQ"L>25@0U[TC]*M%98%5XU8@3 /UD#9F#5QX[W(.0DFZ9$4=O;C3
M41HK&#TN6TAZ41/@P%[(F*+@?&A5@DNN# 0WJ@%@<ER!0T8V*64L(;SQXD26
M]F%%+<^W[ @%SXF^L3DM_^;\*_2#Y Z;Z"SRG-#H@7Y^H(YI@.#Z-:!9'4L-
MG.9& HLMWFU(V=1]CAB)\:Z(Z-DLSEDQ?D;4QKY\/#!O!X('VM2(;L;YI6A!
M/!XVH ;*AB XNNWI@9+U2U&$6)DY)S=,. ZWE\Q81@:PBCV0- 1A;U+;!D'"
M^J4H0J+-#6B"NB4(^Z!:MPFMZX+DH%%Z5U Z+Y4HS9I.!0C[H6J I<,BN/YY
MGG?Z*R)9V8@4[#&O8 O$A.'C "T1?<(VBE5R@6RRB;%39=MK_[4@-G$UT/7;
MEQ0XG<RG>K69\#A!_&(HAST[T7Z6C6S%ODI+W6I.>R'"2LR#4P;5+"@^N,FW
M#<W6J4.<2V2SDHH<\37;[%9!6@Q3UA/#I:A*/$MJ6%>T&^U66=H+G=:5PZ5H
M2Z3]4_0U>E+%@*3J=HM]>\%-378O!>)89RMB7*C<+<B=QQ\+_()#N9CS>F@S
MABF?#?O! PJV1'K\5ZMJMPBW%UG4XQ8VOLD1OH1N'5CS-;I%L[WPH)))V" N
MF!^2T;KX:@X=-*55NX6UO5"?'K>P\8VU,2%>OX^>*G2+9?.10!T>6X_.)C%(
MON[,"$X.J#-B%VAO';BS/UO/&</8]PF-[A807FE=I95N=_$T'WJKS'C[F,8!
M_S-5\0_FJ%9JIUM<FP^,U6"]XR.UM]CG6VE#BF9T8WGX3RO9,7)C^=CG]"&?
M$1K]>LNW3+OGK9ZJ([3?O+U^>SVX&IS;9U]FBX_#Z>1_AZO);#H83GDNZ^4D
M.D([7XR7X^DJ?O*?R8M:.S KT?FT!,XGC&-QI.4P6]]AS_)L;+GGP\>B0[.-
MM=K$0.O3(#7(LF_Y 9;]]-OLJ\=T>XOW@I.T@N?]GYIM&#C>>05\MC#O,8-#
M>(!66*+G8[-2)2I(MLULUL/8S'TBWN;O[/][O,,!<N0Y*-7E^]S(K=""TT"C
MIK[UJ4+R>KX+D?)E(!U)BPKWN27;0,PBTKN2\3+\<TM"7746ENYS?[6!E(6T
M=R7F8<@OBW&Q-0\.]X'SNE32L@I];CDV$+:,_*[D/0_0:RTYYPOVN2'70+YY
MLCO3XTVYYFYZD>5WU75UT[P4FUH$"A]][&"+'I:6BS2NC)&7[V%BG1L16YA8
M:_ - L8S45-KQSZFCE(H$]GH5(22U:9,53-X:? % ;C)?*8\MYYZ#N%LIKZ>
M90[5GIF (//9$Z)#UR71IJ[XN( 2 T5Y"$<RJV&B8 H"1I=]E=G[[L:EE[O/
M6A]W>KW[+ .$C^S7&_+TQD$XPN"/;_C'J_AC)'CVE<TZQ7FA<L\@C"?J&TER
M!+?A==3JE?>25">-MMQ];I06!'/RB)JP@A>;?>4!>Y'W-V&4,EZ#D_LX9R,)
MYWR#;@[*X^=&+?0Y.6E)ARK) 9[3G<J ,:?QX1/5%0&*\GV&1EO&6,$U/$3_
M<GMIO^D6ZTO=7CNGQ$;(B3)2<B+Y-=H3CHWESL-'%]NS]1I1>0Y\@_I]!HY;
MAM] "BUI@-[,>NP%[-7WV \8+;=H3WS,FCU$F4GWP8)S+YAS:]7J,Y3=$KK:
MO/>V?V@9[G86/3 '!&\\O,:VY05#V^:[2+D-8B*P,;,_Q*/\K Z-6##93_2N
MN)]H^?GA8;CXE6\@6DX^3B=WD]%PNAH,1Z/9Y^EJ,OTXF,_N)Z/)>,D*I]_<
M_A:CADSBG85IO'_>]U'@,_6YQ]8C=J.C3@_1GD_DS+S%D3%6(,UGM(E+E<Z_
MP?9[&3).]-\<$FIY%[JCZ(^0)T%2!+FT:O:_OZDU14@/&5JR@#!#.!$J(E,9
M$].J"21(9J#40A15+$)%,3,P*%<0M&M#B,D9*&P9E$(>0<%9PS3)HG\MO:._
M',FM"$NH.O4'BNYC@Y+ \FF2'/-T8O$\&10%C75J05AS;$TEM*4 +A)P(CHE
MB7+4C6M#R#7;OD'0E09PSW%."9LU!U&.F3VW.$P22[(.OEH4F7J2[VIYDD=*
M_C9 1UH&EN<,_(2:B_$NE_86.2'?\7!D:>Y:D6!/0E;>!:==O:]PHIBHF\.*
MO5SA&VK5A.,;FL*8BQ:6LPIA2)"SQEZM=/VT:@)Q_0QT5@O%-(L04'RP["T;
MK.@A3:32W5/6@.#B&2AF9M55Q1<$J'Y!6VR[2'T54+X0A/ET14#RK$# X"ZD
M3(ALBL+8N,//_),:#U4%"+/=BMBHV&IC)Q-S;NV $@_;:B-55AC"E0.&(B]C
M"4*W.$[[,Q[ $W+)/KX<V@_4O<2@/H24_Q4[C0&7?9UO7O#KNB5'S5//^C\-
M4V>JG6.F5UD+NT7A*8 SY 7-R$BR;[U]8%+9A3NI-'//^SY +H#^*,X<I;T)
MU'I6"S3[O.^CXBJ!9BF%,%Q*3579JHM.Q?Z64O39RHR*VA;\8K=&2QG[[*-U
MZ-[CM2RBIU43M(^GQ%Z+/>!A\!'Q^*9LFNP?&U'DX&"!_=]-8^#?U(J!9\@8
MD/7 C@@94$;)Q<2_,TQP&:JBW;+"_9P%RQ-3&M-6UH 3RU9#DCD=IF((PK!;
M9*4L4JVL 21"K:%Y2I2@1:0_(K*AUGZ+[0*IRAB"1CT(T6D-)4S#I<$5!-"6
MX7[O8GX-I@EDI;4@S&P, 2OE"0)< IMQ@SQ[RZ8[JG/HY=7@!(9JC5LYKF!"
M=J31; 0K5(,[C E54HU<GKE6[KZS_"WS5?@?[J\\62[?#,J#NEM"@Q6BNXGW
MA)*+N^2K%)6: 3F"233Q?#%>%4YA]#D_F*T_$N+PS4Y.:$?>K')(4U<!.9XI
MX-/CJIT+)G-4'L=57S ^:=7H/U.*_M"DQ5 'EWS*"! ..9IU>AYO#+1+ XDC
M4ZUC,>,9...7RH<40:$^!PPC)3HGT2@RT?9V:*T5D=-YT+-+9KF2I5)%V1[,
MD&0?0KD9*F&E-R3B"'^:(&DZ;D59 (NJI3IU0D'.1AO6YH&U[%J>,UN/MMBS
MY!9'4K#O]=52#3E9&PD#[=OS,/"Q@[0%K2[?]_*KOKS5?( []U*PD87EK#)_
M^Q["RFPY&^H0\86OOW+/4\_[E*%JT !('T^-MP%WK1O&:<@9G*T?K'\1>IP(
MBBRBI""$3;5ZXE=Q =\0GG.17>N:PDP5"#MQ:YK%##^][5)0'<.;HL!L%\*W
MQ9PN\\5L/EZL?OW;8/R/SY/YPYAO09C>#I:SN]67X6+\M\%TO+J8'08O)^S$
MC+V<L'LY8?=RPJX-%%].V%W,";M[?JLDOTYRLMM3\H3D*WA:-2!X A6A4O+U
M<L"KT3-UEW# ZW+//39S"*_U<X__-F>$FSU2!_&,\%_U,.1WC2+7[V'(ER,[
M+T=VJN$]14?'Y)'?T6C++C,P:0#T1%&I"29<@HMI2HG_2(EOW)^32J#],ZGR
M:F&:< @.QZ%MA[O0Y??_WJ(]13:.0K3LLXLB^7O.<$=HD.3_EO(G0;RYYD'W
M<RW=:$X6X+1()9@*-AZX*UK/$D3\@4-01R,E2.I5!>VX:B&JQV=O:UDWA%+R
M%7L;_[3Z?/[);"7K^V).R9O98C'[,IE^Y.=EHQ<, O:&P>/I%1>XC'42U"UZ
MU%RZ$E7IJ<,^!A./:6L8K5O*5Z=$!2$N1LG!R';"(C<P[&>:+G[=JG*125X<
MR,J27+WD:*39:"/.?39G_#J@&\O[?;:>LJ^/9$3XE?3RH+=N30@.2)DFG<+>
MNDRUONTH2\AP0[$=ND%(+3<F*MJF>(]WF,U\=3'2:P6"4U 1+ST&VS^G$F\A
MI?:638E\3DA97RJK 6'JKHU)&3.]R?^>6-[J*S&'(5<1PK2[-AHYGL Y3YFI
M2UE06U:XOT"VFGQQ\%HT6[O8@'560>\L&S&?+I0&M>3%(8Q'^FC*^0#7P[*D
M<NZTL(D+0AB1JJ(2<P <C^-ERPLK0-&Q+.>\O5<+)W4#$,:PJOBI.0,0++HG
MWJ9>K.B],E;$V[_84%&N+RHB1,*2_6S$8P(/C@.S>N.RN"B<X)!"_)D-=T(V
M()C)/&7*F)"L,)"(D$JO5&AT%Q%:,K=AL[7P/'0(OY#WM"/F[$G,)"E(:K<&
M(7*DUC9)',*,S8YC21K$*9WD.JU!F,NWA6@KSG1CB++FFNREF?8@^ *MH9IF
M%!ZNK^](J$C 4J\]"#Y"6[AF&(4PK<G.R\H"7M+2_46\2AA0N.,OD2XXD:[*
M*((.=1T=\LB*R -=Q6(0AC8#2(H,@(/BWR[*5;E'U0US=0SL NVM0W0N;[;F
MC$C@*Q:#<-S' *0B ^"@2)N!44BI?"^QL"2$4SP5C=Z)A]ZBP"/B/2$:8#:G
M62 'H1V?W<P9NHA1YK"9*>O20\_Y8E'*%V1S3\SBQ#\4LV.,9M-?QHO5Y.9^
M/%B,;\?CAR'_.%^,[\8+]L-@^6FX&"^CC!E?AHO%<+J*;ZQ.R!C$=%Q,-'F%
M=GM"+1JE&PD.-X>1:_FL9RX#8BMOZ]"I"&" O-A-B/K O&Q%_#?;BMA<"JBC
MI>6$+I$=,HN/2PX;E]:"$'76V=VCS1 $K$Z)1=-60&';%.7A7.E0S<0I6(.
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MTVA56H$P56I+=2H+I?TAFAN[\TZ-*0E6)-K%N. ;&_VA[Q,;\Q#=%QQLAUZ
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MOWWWX?W?__$W]/9M1NFCDY">48@8R0_OWA??7&14H_ []->O/OS]JP]??_B
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M*5FSLB++0TI+Z-)PD&YFMW0"[)7J2E=/&IIZ /78#H+W/(7@/'BUK1GB;)#
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MA8D@E(9"O</BFS\1"LY/,2!"F3XPOO%#?$W^/$V#;FP(%);:E:L]/"Y:3>$
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M!ZS!8.V/:@LI[EDRB!/4)2DU3&&&W>&>BA7&W4&AUK@.73)MW3@O;?.XIO9
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MP93S9L =5J;8Z6):; /8.:6B]EE&1B%B%&?\#9,9NJ9O2'KVULQ&-5S&9)9
M9U+\&4CT9N_$O%@@3=;ZO/[_OG[W]==?OT=DJ.=-_B?Z^U^_GI'/Z/_GO9Q#
M^AC%_N_8F['E]ON_S_[^]3>SK_]1M& /;WK\ELLA35*'STZ<A+*YQ"Y[]Q)]
M\WZ&2 Q^_3]9PQ9&?_OK[&_?_FWV][__0XO)^R]MKJ]B["2'^-B**;4-@:.*
M7+G*$NBL%6!D:1!6>ZJ6D:R@BUE4^98K%N('>L.X<:8ZH'X\.-ES4&Z4I.C-
MK1^P&/WVKP0A_EJ$=CT4L)8TBF:(M-IC-_6?<'"T&;SG<R":H+\^W"=N[+-'
MB9/R)1KE>50S#> AKV62YLEP P' 0*&GA_:46>#VEVPSA%W:F:$*2^$M)UL(
M,[)A*MJ7+S?Q5V 28:5A\VJMY_E40">X<WSO.KQP]CY9ODL,*&\-'!M:U*Q<
MJJUO"CC>VR36OA=>T$64,/)#E)&V=%HW@J+T:92W1%&7D[9[Z?VP.["Z+/SB
M?[3;$\3 84(F'SRACCY[=XO3Y7;CO,A,UID*]$C6,\O)M?DN)"!'OJ8F/2I%
MY/SRHB$BQSP!]0UE^B7+.Z7S:<+9VDU\:^;)ZFA4S.-GY@FH>2Q"RPJGCA]B
M;^'$]( B$>2^Y%N=$H,J=00.(.K*BYC1W@LP3'007M?U<Q8HYX'>B-&0L3ES
M^G%P8 3]166SXP)0NP/**R+X 2Q7KGDQ#SA &X0UNBR'EI$P@-X?^6$[W>DC
M(S#"X3"G)(II!\,K>)^G&=A);AY 09X_D#2>Q,*X+U#[1H/$4 K=@..NJN)=
MWN0 C,G*HANXF% \@'>>)S-.& ^N[-G%!:5G1[(OWF3/CU@]+:WF49&1<QD3
M^"?S/794=8=CECLB.]M2[@T<!#J:H2'?5-85,"1TU<!<;BEAA:(8<6;\F!81
M=HCQ Y%8.)@Q+J+P"<>I3Z>L,?8PWK'9ZS[.[_[F9[M%U@@<E& 62.9%PHB:
M*6MZ30L59&HWH,%IE^F@@%1R<]'/6:"2!XB(-ZZX<J2?)6)!BWB>GM?%C$6/
M*49Z5=W6*.?-IQ;A)U(;CVZ;*9U#*MPUJOU:.]B.Z&69R]G%AM5N4XSM&L5;
M USH,[4HKQ/=>*@+3 #%NTG5NP9])+>(G3L6'=?W:CV!QW\']267,R:XIN\B
MO9DK' #7\F,8X>26!XSUNJ"XXEJ]N<=T(EQEC=[0?!H1/< 258QD(.OR(14^
MBUI(:^\SQ1O7W?+64XM:^7I;TG1*T6ILV7D>J6#N31K55!:BUA?29PJW+Z);
MNDPM4%L6STWMIQ2R9E>.=7%K?<4\J,ZR"(:Q*J[<R^3*R[85:EL"#]H&]:17
MA7DSP"':)*VIR\*<K*4-K"'U2VH5&S'B^-4$M@BGY0-;JM7(6P./O!8UQ>B3
M- 4<@6T2:X^/R]OU\N;Z<KY97*+UAOSGT^)VLT;+*W2Q_'2W6ORPN%U?_[A
M-\NUS>JP*_R$PP.^(K\X+:M)=?_)3Q\O#DE*[!(7#VO,DP23__/D5]CT* 'W
M_1[FJ5Y+Z4P&<,STT4;_X@KCR2]EYUS1,V&+<K[B,S Y:WN7VBP:R=J[<#9T
MOO%=>FV/UNYAQ7L#(E,4LT?M4<SEL?G,Q!Y36<*'Q<N>B(F3EDE"4WO@4-FJ
M:N6-"5ECP+#7+K-V_<V,H-5Y0(+)C_TX#[U+$C5!M*?3H4PP:;@W]P'NL$HJ
M5T?QA@Z '5=-;OU!AU-G^"O01QF#(:O(;-HN3(RHNB>HCGL$M.,Y#RQ*WW_(
M8I1^TJS)YM&/O3LGKGD=I7-GH%&K9P0:OMUZ6HYC+W(/5#(V@>GU4_:_*\UJ
M#]/*$'&;G],6AX".C7R"3H;%,"$C(RNIQ";I*96,YA*D@[TB40>!(YNL#0MG
MB+%#&;^Q"VR-;(V-^)L;A4)V@9^*>=R4GM:H&%V3"&T3NBX1Z=1;:A ^L %V
M.-,*6&R>"7S8'E!GRP@_(ZWRC9<*\J>/3HJ<&",<^#L_9(ETM&@7^2X*?(\7
MX&'5=^Y949(M:1.Z/KU6GF_($N)L_(BYW@Q-CJ./'P!_NXP8&TJ.2& U0\4H
M-*\?A?@ON#D;HRLD+8U-@"W=8R SM$C_'H<X=@)BAKE'XLFGVP^TQFWS,KV]
M%] 1J:/:XE*]I0O@Q;JJY+K>G-%G0%_E,,:"O6FM/K3F)]KV6:.;WATNB]RU
M[3U66@*/VP;U:O>"RV: X[-)6NW$HIQFM3*CG1HC0RA(B?!91\2IDW'::N+&
M$T[8DX]<Q]LHC'*MI7D"C5V 1Z**PM4\#GE[P+&I)+:N#Y?$LRAESX 7].V<
M,@^L,>%/R&<%4:T&+)>D>:)[W@I\6-:J58W$2A/0P5<O:6_OLSPM'4PO7*_7
MF/-/6OQ8A P.(K*)@;0U\#!K4;,R%ZUO"CCLVB36GI.RPM@BX6S8LS/0#:NF
M]0'N*HJQ_Q!>'.(8AZZX]_6]XX=T^OP1;TD;>?IE-PK (U;#'&(4=^@..+)U
MM- -@XP7RIF)N\.(LBL>"[AG/,WG5:H/R#;L@E_<1T(!(_HF 'KS0!@16X1X
MF*+,K6AHU00/S!T"[@XU)A@3-AT_9N4/YM[_.?!UT'+[DQ,3>Z2RK;2V/M"A
M447E"A@V=8 ,?TIR:WLUH9X5]2CITY/0G(,U=!M4[0L>PB2 M]0 Q>NMSYP!
M"LH"PX/F[;4"W*!6H""9[4=ZV*7WR>0FL71S#JP;C'Z_CHYF^8T"/SR0J?^R
MV$/FHQQO1\8ZG"Q>TMB)LGNZURG>)63-X-*["%$0L%4#7WQ+U_I#<@0^LHQ@
M[O.[@H.P SRJC:&U_LZ4</A4WK3B J)2PGP-D+5G0K+-<$$HE$ME:U\<KIG9
M85AFPNRIL72H6VIMAWW3M]/HXQ$Q0K85_!&'>"M]A$W>>A+C@%3-<PP_:PH>
M?^42]\1.0KC(LGN3T39\CM_EY&)074DPRLXPQ@2OR>JG<*%V* WOXNC)3^C>
M'D%7 5RM3O=O<=J:!W7:!CB4UJHD FBE 6#8K)=3U_WH@[/5R>:(+]ZUSAW-
MZ\HVC9T3%>>>\T#"F1KBW5^2QH?FQX'35ZJW LR:UYP2LGVPW_*,\ET4TPF^
M&'F;B,==6Y$"8]2!P[=A,YXE&O0G#7C(,*UAOQ-^Q0?09R@323(BH5]RN?[+
M8AX$&*O"?#==9B/YJ>D\]-B_ K;G46ZY*UBTX^\TE P31=)!?Q(5O!U$@ FB
M\K!V&!"[&S-7Z"4G07CAJ+<+Z,-">IB_5/XSN/G/D IF=PI1$I8Q0NT>^L%@
MV]X*4_YI61?R:%MCQ-PD$MLW]P ^DBFH>U([7-8<\"BA(G6/RN%J,_$QP;AM
M;V1(@[ B5B?!W7?GQ-X[?'/7C3$%PDVTPA[YCOY]DLDB,;(>)>!XT<,\#0_X
MJ9 !C"]]M-$.L[-G_@JV-+A*QCPM<"9,%FT=X-DP4VD4@L.NVON U'YQ:;_:
MU\+&F32_)HO9.GJ;/SE^P*>OPG,:V4#ST4E\5V+\[E2 8[>F6:0'?.TD &.V
MKB8&#PESIC1Z+H0':#*^,\0X S@]&\D\M;/$J/)*C?WYX4]D/?U(!KHYP44R
M?[T][.YQO-R>/<_3<NBD008XNN@:1H27KC0 XXNV*KH1E#-$#N>(0L:2CN+5
M&$K0(>&5Z_;D:_81<IW /?"MH.\F$%Q-PW97&J\DK*1#=B<"KR"@S(Q'131E
M[-!M$4WGSZD/.E*WK1'&M<O;X315V.:VXP/M@"H\F??VOLY ]C'TT@\.Y%/5
M)S&[4YDFCK:910%)922FAZ6MFHR$IID<H/!T,-N\'5);?4P=W!>ZH:I7;Z01
M<77AQ"&1)+G#,3-*RP*OH3EPI&Q35(1$65O V-<J<N\M#+JLJOHR(+=M6CK)
MVD[,8:5+H=J&$W)5,]/:G"HB9/GP:W7],HR2=M<IP^B49^*7^S;6%QNGBF:S
M!D6SE*TGAC G:C9A3-9T0BAS*K%)G+$ZLQ]*4=LS^*'TJL$;9'\>WB75\32Y
M<?#<]\X,@0/?\,;6S6KOQ@TP_(Z@].CYZC7YZ:\B,7UD^ZMGH=NM)++.G[=:
M;L7,@"QIJ7F?1+4O<*#L9 (1\Y0Z H:O;O)K9UDO;]?+F^O+^69QB=8;\I]/
MB]O-&BVOT,4/\]OO%VMT?8O6/\Q7BQ^6-Y>+U?HO:/'OGZ\W/Z,WEXNKZXOK
MC<U+!861N%DHVD0AC=SYBR^K#='69RH!T:1R;2#4=9A" #3*K;V(8D11217]
M0NF>7=<=<\U?U?,RVCG^Z2.1;6V!.V^CBI75?EU#P,[:+*\I)T6_<,(VO71#
MZZ >XB,;E#YA>L8DL4E]2^ >VJ!>Y9[%>3/ WMDDK?8]B8PF3ZVUZ) K[&+_
MB:X/6'%"8;+4Z)T*W8"[JJKBHM^V]0'LQ,JBZWKT^G"?N+&_Y\5+XX(=+W$*
M)$UZ[GD^%= )[AS?NPXOG+V?.D&CJ[?U >[G2BJ+3M[8 ;"'J\FM??^HH([V
MA#Q[89LSL.G.KGO8'=C#R;+]HF;7[M ?NIMW-47%Y54[0W;_SCKTN(J7<T)1
M3<V$P&Y9MA5.'?K0?7[^U#*/D30&[N[-2E;G+'4M 3MRB\ FO-;#6]_U;;ZI
M0P*2O8AQF;V,<1V>;U.NHB"XBN)G)Y9E+G2G MRM-<UR4BV["PG @:"K28^*
MS/R5EC<YQR_I-$=D^I?L6C_ZA3)&&6>;&RH\$_@Z20[2_)Z3)L!#H$ZARH:T
M\#U@YZT54WMMR8C-$"<WR('L'L=^Y"W"QE(11I7ZZ)".+D9.BL@D"N'00V](
MN/$L\V&>I>=*KE,G3FVI>8\?_)".ZTW*CGH&1M"-JWIYB(E<=\Q&K'P%^V[)
M=S06+SAV_40.,AITH".1KFFJYV<=B4#&-&U=M(&/4LU@#W&>B#.=Y05T>).,
M,RI8V\E:&=]".25Z4X=?&H\X"UMIC^.;@)<V<W;1X3Q9R3Z2\L'$ )0V$YHF
MEBH81P%,&ZA,#TU5E.DUCZ2W$PB:TOTQ'"992B!]D?&!Y4N@^R,2V]TY1_;Q
MG*YT9CG0S@JD3>@:B8MNJX*9!4L6E :?L^J..6-H?S;H#&X-_0%H\+@B@<#G
M*8=]1!^RUC"1_=&*#]/9Y2CLB2"A,][+"$USM%(PCO+4OY;*]$8K%65Z1A5G
M6L[WZ\:F<OB:(6=+()-NS6VQGQ[.;_D"6 D,8R_*C6TUU-66"CUBE#V.MU&\
M8XU\\C]A2L^K]H0?>G,;I1A]"Q"2,N V@$DME*8)2BKF49]#OQ)84M+&$"[E
MF[/3!J9!+68$F?I.G!S/>6#0\_Y#!CSTDW\*I3,K*5P,J4]LJ-0!*(RH*TO1
MHKVU95#P(O= PZIN&.@@O*Y'?XI"G%(O9D65>4UF5BHV8=N13L!<D"!!&A%_
M?L+DXYC58[X_E(5TMLA!(7[FZX8S&MFCU.DC/B*V?MAN<<PITH.$_>$^\-UW
MZ*='G/?P$Y1$@8?H-324"$HC6I" WD<C_1BS&'D1D2",4B*=G_I$WF.6L\@X
M(E:)%NWCR,782]ZAZQ#15P%B)Y!082K0;\K2TZQ=ICL)\]0/D)_F7)+LT"?U
M8USR&002Z\:/$5Q$K!U,1@>103:9'7< &$%ED22PO-?B5N8FDB1*LK'O_G3L
M6^'?#G[BIWB-XR??Q7RT7&$W>@C]HM"[9*P=@2W0T69LPU<3>(?E"7@Z/)KJ
MVEEH=]<7"E/E(A6'OAQ^$24I$B2Q,V\&;]J2.<M'S;G#6] S=2_8$Q;T=?CE
M]J)\SF*-7=(R];'\_FT_FL#QTHC)5#<A6PD"1CHS>@V8EU *06?V@ABHE /8
M@=E(QJM:YJYXM&9=K!R6^1X!_PC41HD5(W5X\.=L?X6>1M&U%AT4@N()H6S9
MERTC^>*29:5]<7VW_ +L-K#A84.=Z#3'C8Y&4]XG?H4C1U?%AA@Z\JWD\<<.
M0\?K8^/B<  X@6/Z6_S,OM&9*HM]IPEM]290G?H6':<'5!+Y!YS*$F:\ <"9
MF#E#-!Y240PAN% \+.[GC=TH 9MTJ@D0YYVGB1 2(RA/<B:,$3(%AIRT $4)
MXZ:HY/I!SW>$ (] IE*5,D;\>5[WMX,?T\W:)/V$T\=(EI&OV!4X3'8Q@+1:
ME:0?8(CL)'X_@%SA/9'\D>W!UTVEK#WQ/88)[C+5:?RG>7FO2I(/SX.."R/1
M<_^'V-EE*3[O_VX-0T<Q$+^G1 (U\8DUG'PA>FH5FU7<*W;@(TAN"!7+G?68
M$B+6JRL%PFKSJ>"?1.K!8&^(#7Q-W#.LN@FXLW]Y:%#GX,80D WB3'"%TRK.
MS]E%4A5[R;M."?=:#" %0$F_J2!AF_AF*IO.4,9G1E]3X+- Q/G-T+SVRK(5
M<!S*&IPN2_"IP4GIO,_NE"<SACIDEAVF%/BURK;,=[+64PGR>J%-A7:^\Y71
M!Q'(9C56#%^0\QAS-BCG+TD^I6&D![J1DF5GT\=E/)KQSP:-JR@F@O!<R>7V
MCD2UGR11?*0_P>G^OCX5H/#5TRS%A9;N)*#?<NFAD78*+YL9%#L7"4I*]BQ?
M-\YY\Q/ZG#N])X+'ON)AP3Y\32SPS,]1"5NT$FU3<D:,M87[(#;LDW.K.TEH
M]9]>%Y5E@,OO/I96X!]TAUP].J!!MX=I2MC5( (>>/OHI!LZMP=:"G@2N&O#
M/-F&4P5Z\SGZU@KX-AP]6#23&0 &LIDGO'1WX22/5T'TG*@_;EC7!2@>=U%8
M\I3A67O ZW@EL;6S2!L>+IRO?T!7-\N?UA:=^A:G5&D2^4^^A[V/Q\]D]7D=
M+O?LW#!\F+NI_\02:EM<78L0\ #0-XX8%MVI  Z6'LIHAQ#AA[8T*OE-[RCG
MA9R"V7<60XC88NNG]#UDB<TJ#8"[_+DRHBN7WP)VT1HAM:?!.#U]\)K\,SAX
M[.19\ICU+;%R%*9$SH VNP[)PAB?Y^Z.LUUIV!B67YRI7(VF]YI#UP\P$8S_
M2%3-361F/!N(%?#P']+ TLH)AO@ AJ1!U=7>7BV%HK 5YV*QU%H:Z/13^K=+
M!^ #/94@ZS!HH^\EWA/)?;9]0O[FUZ[F(3U6)O#\>U/Q/L6NP$.VBP'$$%3I
M!SBD.HFO&R(BDQDJV" G])#(R,[8/KH)F-Y.@]XCQOWWCA]2W%R&:R? ;.^*
M(%-ZO"-ZLJ?8]Q39))93[@P\]KL908Q^M9Z X[^C KKN3]ED<W]:[>[23_91
MXN<9U3E3Q+BB@JVM!(V1C$)9H#</A!DSBL>,X@39)B[C.$,X9\=0(XFVZ;-S
M7HIT[ ?,E O[3K5VKWIYWLE5X!VPR&Y3B3"ZGJ<SX,4+96JKF.[PRO>MY24Y
M\\[W/_A2)S/B,E0XY5;N"30F-=0O3K+5ND$_N^ZH1?]$(3]C2$L[LUT[S'FR
M<<KR2?5(QLC9%!N7B]P$RW#@L^CVB8H50V2^4.,!H-XE+O9ZLAJ/+1N4G0@
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M$H<J'0&'0S?YM?/X\R3^-$(9'\08O25SXAT26-E:H8]DA\!QBU=KDM( OMP
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M!U:SNOAH[$P3VQ8M<&FY1:4(]%],B+>4+8=I>A[*JJ"7'XV$W$\XOH^:4E/
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M&]10_XF3/6>4D"4.@:Q=MK8A_R<(-Z.OHY7BL:VIO2 @"^!<1)04,HY\8Q^
M/9<5JU6$8+?T13'H3?Y"$%1*DHT29T.#_DPOB5-AED?^=3K#(Q_]<_D<DF'C
MT=_/7_SDQ+QUWP.%(ZDJ%%C.O@0XXY'+J.V4.37T"Z5GS;$NHYWCGR)A?8LI
M.%=5G3/WXE]#=[ 3*0VX&*>HY62R@I7D?W"(?XC"AW\C_W_C[WRR-OZ$=_<X
MKAL'6MH#]2UE5<NRD@V-H<]]E&0W/*NA!5:):])U0QJA3 +TALJ J!!?HDR,
ML>M!#FF+!C7-ARA-8(UI$I9*?-8VGD!PRI4\C<SSEA,)RP;!1XE)D;^=8!S
M G7*F0_!]>'WQ^B@.D;6MYY $#:H>1J%-4TG$H9-DH\S-G()+ ^,0YA!IJ'Y
M@)P?DC1V M^Y2X\WJ?>N-2:E'280ELW*GD9F?>N)!&>+\*/$9R$#NMO\C*@4
M5@)T(%.H:]D_2N]2_$XI.L\:3B JZY4[C<9JJXE$H41H ]%'\WUVC*I"(-YM
M%N_LQ9]A([0J96!0?&@?!A^F%&*G"IT-=0^3"JLS<<<.J/GWEH8R4XJ7BEB]
M5I:]RWU<.ZP8%RV[57.^H](>:! JJUJ]-29I#'"[7EUF[3P,)RL^QRK,F3XC
MZNZTI7JWSH[\*>3<U1XA=>H(W8V5E:_X<VLOR(ZM+KPA#^]Q1&7(QZ_OEK43
MH+KO@7OLF2JB8Q9? O:_<QEUW8Q0LNA3RR<<TQNS*9W@\=J:C3[6U!ZXS[6J
M*OJ@M#%@GVR76=='/].$RN?8ISFB?\F*FD+)G[SQ0WQ-_CZ=GIJE#-2W!S"?
MF5S*@BSTM:MA+74CC%)"/B6%XGSU*Z1'9BZ05"Z7.?0IRP"_0YM'TKYL0R^B
MY56*LY>5,*4:Q:Q]92'M)$E$.-!K(\]^^H@\-LO)EMP)+7E"!&/<(B)@%*.=
M$QZ1\T(OO?&J*%R&"25MFOO1S"1NLI^>"63CE4PHIEQ]/[^]_L_YYGIYB^:W
ME^CC?'V]1LLK=+=:K!>W&_:-Q8G2)S^,Z*-DUR&Q)T[2(GGM#I/?@QCI 7\\
MWCGT-4_)\-R- M !IX<YQ.E5A^Z )UPZ6N@&R"WY3:(P)3(%=-<S9SE#919E
MR17='Q'G:^>JT)B&$;0FB_4 /Q!XC0J;$$/002I[R,GF!A5[-NHZ20Z8X*KO
MXOS&NFR#HZ$]<&QH5;6R"R5K##CNVV7N53\^09ST##'B9;D&2_?^AM46[9F2
M;\@4\_/ZLJR&\*6MY^4&_W5]1CK3N]"76< C\.[$28,5.D-6@MUW#]'35Q[V
M&5K]]E?ZYUO^)X,H\L]_+L*4X/6-G] ;DI=DK9#XA.QQA5WL[],5G0*>F$N]
M%U"XZJ@V!2W%+@"AJZODNB[.>:",R0R5;%#&!S%&XT+96-K?'MA)-9F'1+%'
MEDM$ZX3'?+&H)X%/YB38<1_1_')M<4)RY?@Q+9J(ZPJP?L(.?8W96X8K6N4F
M)B8C#<@<-,[_22N;U=Y='H(^4 09S)3B!,D8<8"H-)R.NA%,)6$%3_$,%>S8
MW661H?G;MOKA^_&8&8CNR%S1%])QZ!X;\C74>DXEY-K5KPTF>;<IA(F"]+H!
M(!!&!67[^1V%ZG6*-R9XJ/6<BKNWJU_K[O)N4W!W!>D-N[O]9(\ZY1-Q#&H\
MIE?O/4'';S!#F_/7=)U8 #1IT&-ON9S:T$+"-@O&F9@+WDAR H;B,94@,FE2
MTVN4\[-$P %I5,_^:Y7\X9?YR<,ON4AH&0JKF?GI:H;))1Y$__\&DWN*8V,N
M8V'"2YZ9<#@[ 5'O!33L.JI=)-RT=X&>3--!@UY.7[RT76;(.(SCR'DH8^A;
M:)C%N!#U)1L+B2.CZLY_79NSDEP4 5[;H:Q[;Z"0IFF&RAQ!K2ODT;^C!OW=
M7AS+ <2]/4,$)2,0M:SO8EI.-CW>$<U2,I]:_';P]W1H;#H1Z= =. QT-41]
MT>GFOH"!H+,*VKE-&?D98@S8.43! L AA%3]C\<-8=YP"*'6$W@8=%!?C "%
M;H"=OXOTVMGP4?CP]L9_8L^:A@\^S5IGTTS[!Q'RB">L&P\BU'I.U>7/U5=R
M^;+;%%V^1OH!7-[^8<0GQWWT0QP?1>4;#R":>P!W<@5U*\GL\N: G5I%:NU3
MM9PVF[$0QK1P(<T!PSDCB\[\(W[TW8#NUS;X[UDCX"Y;KY3HI=46@!U3(JBN
M+^;D;&X>'>+0IT^5D%"[\E_H7\W>U]@!N">V*UO9%9*V!NRA"D)K;WGDI!ER
MIE$4F'RH9A%@-XVCT'>;1_'6QD!]4$W)XL!%VA+Z.4N[X-KYVP7E<JP>^5!E
M7.5L;B=&V_3982B2_WF)GW 0,<$NHB1M'B6Z] <:L-JFJ.PHJG8&/*1TUT$W
M"/CSN?1^4<9GY)==5D3LNIW!T^^ >FRM"OD[+L47 #VM7C[MJVQT<$I2WW4"
M).906GDLB*E5"Y7GWT)WJW.8._D*LFL9@BBI<QG?"5-RK^RA2ZF#G7X/V,5J
M5<F=K/(E4#>KEU%[GXI3&]N?G)=F?SKY'K(_U:E2^)/X)51_JI51?]_SQ:P_
MF3N>NFE)B5;J"-03NRNO=#9U,X&,Y ["#Y2$<",O7P7![S\G>'L(;ORM+"M'
MK>=4/?]<?277+[M-T?=KI!_$^6>(<T*4E9U4O#%LL"!3\1TK$=B@[HBQSH[%
MKW=[QX_9YLBC$S_@9'Y/'WQQ9=776CL!CW UI<7@;NX!.*X5!=<NN%Q09@7#
MZ N7 <N[L)YD7DJVW-ZP1SV)6#R]_@<<>%=1_#F1#6.J?8&[>2<35(J&JW0$
M[/3=Y#?C^T+.47:YA+)ZNXWBMX?$TH VNAV"*+$9\RO\A,,#7F$W>@A]5GBU
M>2!K[  \NMN5%4-:WAIP'"L(K?\L$B.-!-KHEYSZR+6#1U0W+FD;3(7XY <X
M2:,0WSE'=J]^&:^BHQ.0J73V :L,1L"G[HRZ4V^@0:EIAB)[0KTK]'0*#4VT
M7_C:10<^^.YRIFB?,:'EU6/.M_PLSCB/G(0QHDD*5NA.,$3&K?PLYV?AJJL5
M8RAYA4% O.2E_B]HD6G__D!CA6XJ2&8CBET@0Y^BP@7>M;2'#G*JXNL7D>&O
M1?!YB?/D^(&%ER&&UC*CCT0&;&O0VDQL%+47NWT0'3$N'@1Q1?WWA*K%)91$
M>9HTE<U+?S^;Q77M"Q3(M$P@KK&4.@)>;G63WWC4TU=?$DN/+(RC>A'Y]S@D
M#%.$7_8X3*S>I[B@ 4&T9F/=RD]^;;IU+VT,/*2;E11CN+XEX*!M$5@_LU4@
MBRA= %?DSW1MO1K?W&-J7MM\%;ZA^93\U^#5]QHGIK3M7WP_#]JV"^_-/:;F
MR,T7W!N:3\F1#5YHESJR_>OLW^/H(7;VC[Y[9H#&"S<J_8"[M;+JHG.W=@+L
MXNJRFW'T:(O<&'MDHAP3%C9OEQWV^\#'<3<7;^\%W,$5U:[<'VON MBY524W
MYMI)QA#4ZN_C\2,.W<>=$__:;5I]V@VX:ZLJWC+!KO0![-S*HAN<H10, ,ZW
M"]FZ3;K/NTW.S>L5;W;S:I])N;E$]&'<O,=L7'*0>.$DC_/0H_^AV<A/3D"/
M+.G%YL<H3C<XWEV'3SA)V4FFO/R$'AF@OMW7,,4AI 8-Z >3?532C@DGCH_L
M92^>C^$D='9#7PJ^=PA)%Z/D$>,4>4[*ZHR[1#B6^\_^P*68[,.$"HI2(BGR
M2U'1\R,.$5D()#@F'U(>#MU%SR+/#\D_W=,)%ETT$":!>PC89R,?G]KY+5IM
M^_;4ME;'Y21=;K^/(B^YBR/OX+*K5HV+JI8N0#&KB\+5L5C>'O0XK""V?BYC
M@HG)N9][96$/A@V^2]!A3W1Y)&U-IO2<32WR]6)2LTY2ZP'45SNH6PZEC<W!
MCYIJTFLGR(?;*-[Q8<FYCPYIN?0?>T@:5M'SV?$,%1QZK ([AV3MJDZUSS3#
M\GP]I]1ANJ%I:$6W!A>*@RU5*\%H?JVZ#'%.7[X2K6L$.>"D2A41=M8">DC)
M!=9U-4*Q&-)&#J-AE1FYF VMU<2J,Y4';4X@*>_6U!9H0"FIF!>\D38$N.Q1
MDU?7(46"=FK"K?'#J6:U,ZRVMI#]LDW%PB]E#:'Z9:N\9OS2_'SB$Z%'1/.6
MVXM'/W3D<PI90Z#NUJY<>2VPKA7T^46ST/KEP#A5NK'+Z(Y]B6\<K4S.QP]I
MXGM8.8Q:VD..)A55RPE[0V/HL:4DN_;,EQ-G1S<[R^%F3U%(:0HW+84&&SL
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MHWHHHYVW("Z5L]T>PA51MN4$8H9*U@ F$Q;L1$C* '],0-$"CZD#17=0F"P
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M*[QWCNR8>;F]B_W0]?=.<!W^C)UX\QPIF*D#J0D%:E<#R8)9E<Y$ KZS.KU
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M>%AZ&4YWH!G4KFM_MR=+C\*U'=>-#S2S2>;C8#9+JBNYVNN<*VI5I7VFQNY
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MF#QVTQ #.BI9L@:$Z6;S?I,<!*=ZNF;C]Q*S'.&\YMG#B)VW[V2VE3W"#4K
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M?5[HT0G_[H?W?+QZ=%R:)KX+*7[?;Q+O_89/POE8=;5G5&BGC9B1HI"&C0F
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M^+?Q^8^,(53^+;7NRE:?/\H:5.*DL*IXQ':4D.KXWP](BA6L[('@;5XM'<R
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MRKOU(NN3?@M"-,/I0CK!S2A= G/33YKBG13 N;&LD;T$[_\ 9-".RNF'&XN
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MI6P K\:+IHQ2215^'R<GL8!2$)-QH8#)))["N(I*+* 4DDR@%/B\V434/+&
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M:>K:H%)#RHS\VG#NEPKB]-!Z>_#@N*[S ]IKUG%_FQ_W#Y/9;/)]-/ZJ^GX
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MZ(EZ_:_"I% 1G3(7/%'6UL J)@: "A S(E,&:8F$@B[?"<(R-8MC*>; C%?
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MK@?G-V!44;)J&=[E1O*(W&'A'V/U)1HB[H.Y&SIC+HO1E>3D\C=J43)\,2Z
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M"?$1PG?H;_JV#U^=)03>PEELH+N<&BZ. %NX[A'1\-E349X6M8S/. -OP [
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MM6=?E?4Y"17@A4?EWLB.7NM^=1V/N(H4_Z5/<E=3D>0GC$W%DR]5G\>EO^\
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M.W8(X=CN2[K!#U^AF;)XBV)H8N>9F^8VD-ZD,/$3?KL[:^4 ,YY3203*ZXR
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MO;DCZE53 RJM:%8[,1U.&WAD5TR_G^R]X-A=W+Y6W*;IA#7! 9@CQ7@)XQ-
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MG%\\?G#J[*]S!]7*=_!<!PZ]SBD&E%UQO9]XJANQ<E4X1\X:8O!7<!W(C--
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M_Y_KP&.-_Y/&_S_^QU%V9X<HZX%BH2LPAGK:!IP:YR0XS$=.FW.^LR92.OV
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M@<B!4V\M4/T9+8(L_6PH&-U:2@WGYA]06Z1Y[3<\BS#2[#3?&5+W5O1WM"Q
M9(]BO,2UQYZA60[[04FQRKP"\?L/IG04%>#3A786 ^'8L=!S6"01Z^T1]L(G
M0L0; ]&)+><^CX*8Y,S JF#$!?"8=H1A>=0[(ED6C2>"LY,\Q2AC$\,,R,+
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M&ET_?CU%+(1T3OW^6'#,!4GH2I/A@E79''-L0KRSX/-$IL04T5SHC>Z>1)]
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MR5%%E"<J\\=Z#DZ'%Z '[M@/OLN*$;#?O8FS.<*&H9+(U;T5N*G6-/3[%"'
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M*;ID56")+!EHR SA$WHON7O*7=74(N/*Q3N2J('*R*S&V*E.9[(H-7XI(LX
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MT8TYT\,*D_U)\P6X5W(]X5N[P 2E2CW\)N,%"Z@<O1TQ5>4B[BC;T568&_5
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MCT7;Y$>/!=XBEF!-MUL0^[5YME&N*R_G7$T,VW-]9.42TI1F>VM&98WFR_[
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M9GB>,&N6VFH=!AEN.##(QA[^5BP9R#!A;[,<%,O'&Q;XB FQ]C.?C! NF!W
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MQ[L$NC3A-D[+<3U%XPVAO7](R237V(XGS.'N%GQQ% /$%OL&U#'9[O8\J,[
M*]P@[/I$ZG(4XM%U#EG)1*)-"00KDE))?1$XE!+X5!:P=,X#(5?1IPWO:DZS
MHTKIA<BR@(CI0"SGD_7(KHW?),AQ$J*>D1M4!*\,BD:YV\?<\[C3.1TN=L8*
MB5%9J$WXGYXG,(-_FS8\>ETAEK'ND\TJ1*)T %#IDCLJ2F>*4><I,9OR.R%$
M4RZ,DB7QQ##,QLJEM-U%M@/&6H;M%$NEJ5V,O@WB"WO(@+AJ5N!>;/Y.C%WZ
M("+"Q.-%$[40NUF+.FRAMDU!-;<SXJW02X47$RSKR5^\7G7L8NM.:*B[Z4WP
M<=+;VDJG>;B=ET+K%T2C<>#(BSV$-Y@;3 -BH-P91:F'7PW;RU'I>[T'> #6
M9N4^)5?P0CGO@KJEP !+TH3"R6(E,DXHFFZ=T(UK@<>7H#9VMC0TL1RQ'\IR
MI2=W?>A)%8>.MC'?Z.4VFB:BC3<$6-RM8(-+?:SPK:POZW>'P=[IP\V8OTV#
M4:!=:Z.P<;+[U7[#3O[;;D:FL1C$CQ;^>\W,-\OV*L2LE<$A'F5_[P3]T81Q
M%VZ2ML?SO#OT $H<\H+#.9!B66U:P%+:P!SU!_7<DE7"N@;<*XK**; PHBEI
M:1E;E"GV7I^ZL)98UTO$'"D:.@^[3U?!S\,;K"=3,#XB35P4Z-:!P/RR4JD%
MP8-4!\_?DTJ51^Q<TL1'R+/"GNS?$L]2/8IP\@L+O-S<!Q5\DS*>&LI>:ZA"
MC#YZ>U+$J"?O:E;/ THRTC\"_<Q72SF?JI)87*=6%11\S]C$W'F6/&*8!;W\
M>)8FA.:F40D*I48XS(OQ':3/V::)[,;1KZR,8?0#8I.MZ*H;>)?$6(G8_O0H
M W\.<!+27$.2QLXL)%O5'RNEG8$J2CF&XGI&;/FRC,OP3AWG"125N,WP'CE/
MRR%]K7KZ]Y*4VNF34GU2ZC>9E%HN/-C[_?4E0C!^,0#.DC"5JOGW6)W/(@SQ
MFZ8>H*,?+#H:."03V'^X(N->J%O\BF?Z-+9$PE=B"+F9DR)A@5F4U4#C",X$
M5B,BIN[UNS@7=] [58'\IQ(LLN!+&X:W<.NVJI5G)1@/L\%7-K(CKH5K'9"#
MG6KMG$PH1@"WT8T):)R6G34.%O6OJC6FH?U\-F@K^X0P:Y=W; N!K)$*QPVM
M"O\N8S"9:YS<:UP\\N+BLFI0C?V]NI_9@@?;#:*$I_ZNK%+!$@TVK9ZJWL,@
MDI0#>Y/S*"A>\J1/C'GB4\A HVE[S5NP!U@ T=ZY&7 ='64='.'W1TA<BL]"
M'B8-1NV8)ZS_D(+0H:8;;Z2A7I$Z@FXF@$?T8BJV%FT02<A]Y#-==_ S9KW]
M])>VBB!*-U7*%%,"H3!RFM%'?>XG4P ).(E1Y'<EN9J:#3O]^ FSLB(?=K:Y
M'U-&54P-MPNYZ2S79C87]!_MW"SJ>4;> ">]\,)X")6S,V%7H4NR5,#A&JUC
MP$TP#6&K'%-8!O=F0<1HN_<I4"_<$G&*)ZZ:P\!)A@B]<KY18SZ(%%9@-H=H
ML1AS*;KU_@?-P8.)X4:W"8]ET,XH&?%1=(71&_%SO@C4$9Q_U^E2=BZ7$5\&
M881 'M:H+5#N!7*4*-0EK<!TGL-Q6M1ZK)L#05$L,#0!"OFS=)/)P IT;,;"
M206Y0PGVEI%97SPA8HS:3RMS_82=PLIPS3V\-*.0N)@[G3)G];S?ZL#)HC,'
MX"GE#GG;IAQ1(T@W2QG<3?MDMP+C#!(" ^7)!L!3.#L8RW;E#[V14E]][J<@
M,7*JTMW/^%PTI/LZ.> /(V810"P-=[NW"4M;7>+O]<H?RUO-TQG^)'P?B&::
MHVL]?J^:EF^19LR-4R,X0"R-,1DLCY*(L!/[7ZT!.[+KJ][%[0SH<8:RG 2]
M#4^YL4BB-' /]/*N/^&N3A-.T-(\F>(N5X1$?+(=]VE[7^'M^"C<$?#:<VW9
ME+;>U*]GHOWKJE:JVY,">A#EB?M7_8F=07" (^1O=TU-RY*V$)>FDX=5Y]DG
MS4W%#-Q@ZD'D#8P-N)JC).O96@+=')^5R3PLLWE"B >Y9BL)T'P&#L>N!W&A
M__6>!-J?EUP&QEE'"KG#.YV6X/[B_9PAFL&%3 WR1G,/G=A)<Z'DL-;+-PVX
M2( 2G2(.M*#&605XHJV)Y20=+(2?W#ISWLR8Y%4]<YS+P'/ZLX=$A_IU7IK\
M#GZ?*^<J-CK6<Z7"Y:29'R@*S<7KDD.;/R*$K<>!GJ5M9['A^]$)>".Z0T!>
M.VL1MF8TO8=[61<U#>R21HJ'ZTJRXE''6OH%/?Y+^F)I*_I83TU9U)7_R $)
M",.&DHN>V305^96$YHNAR!*SG#*ZA(/P"JGJ3%WP,.$ULACVPMK<*4,K\UKN
M!SZYK22;3<3A]ZY82]H,NBN& 7K[VDH)]^H[NTX2-"I_&IYW,$B^4:;%[9TZ
MKIU6YD:9N.FBSN F>*2TN%9JOY!;@ 7P6'Q0+4D,3GAX @VP+<!0!GF2X1_
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M64@(TV'0T&-2+K$"1<:T"=;V';[B_#XM$RHR7C2^JQ%:49*E'WQJN:H:@$)
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M0?%U1-*U@2.BI# ,'$L7J4:*V/HBO\02'J?X.,JL47/RL@H\3])ACV-=SKV
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MPNT8JWF70VCQ](K=;0Q+Y5Y[>M<KD_7D2BE91V4+BZ@0$"#-.B&W:!RF3ST
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M;,H]>14W6@[*K;]4NV0!S:LX(Y]8/BP5A5T#^2036AF[3=I])J72&(BGXI?
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MOT 1F!OC01@;*:,A5@(FV85)B;(<_^8!L6EMD#8VR$ICS9&&O6%^JPE^F[
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M?3X"GX!B?7P56+N.JMS!88!N< ).5E<@,),S&ZJ7] OSJ.@W0D9!S,V8*@:
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MOQ#-*FU 2_5 M/D3EB,O 1'345 MAN;SQ?D 1N^*$[!Z[F8-)+5]G</6Q9Z
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M,6L, _H%N%::\@VR.)+(;#%X\)#-'2W9!J-Q@T6W*X4SGDN9^<Y5OI)@6CU
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M&+9DH+7H*F>Z=Y;J!:*-8U4CIK ZE$@#G^RY?&FAQ-7;\@@H+@M^9" T8O.
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MAD#5[P3:!E42JV\\RO-[C_!\DT)X\DI]V(%+CB!7_#!#2J&V@$N%"0(,39]
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M3><@\<$%4'G:N-RV:H.?&%/P'@\ )^@?>5'P0CZG:4,W$X2.1>Z9XB3"&YS
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M99W$=FR-ZQG0Q^E6YO8@ #RN@^Z0\"^P4:E0"SU/M?HPKS.NG8DBO/'0 N9
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MZL=<72?=PR@UQ!DX_-=<2&UAB%E$\+0(5LTO8^.=?!$O'Q/85+<5=13L*D#
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MG'=.[ZX+U7X]=+WP@I#7UGI$8<4(+;2\NJWJ;1<: S=.(PL^=WG,^<"*T\V
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M,ZVX;!>Y-WD HLBU#O8.823QU2?"QIAS]8"5X['3WAB1T>)BU [B>HF^XC1
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M<AXWW,QT//1<Y$UG.-OX%[,UT4IU'FC+N.HXE-6P1)LI6HI&@)N(%1GC+=U
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M,9;8=GH48NNSH-@,":O/E8UUTH4P,B'^;4O\O[P=TNR$)4:$,T*[4V.(X&>
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M2K!"+%$\0;UC=Q).FZ,33,A,236#)@\A.;503774Y1)<34"]GE5%CT%^-FF
M4)ZM-'I.J"(EB514;)-JU= PLS#T,Y@,7VMSH@$O*N 8GFKICO@U(;U/N!IX
M QU%U0$^V0X;^PO: $,5-VT?<Y2]S1267K![Y!=UV^3*0\Q%3J3F@Y WP12P
M^5ED@-S,#=$8'>$,)6505F_1D-D-X'W;AIW0#L$B:Y&ZH'(F#P; DNBTPJE!
M_DQO.391V0,2U8RSH$W\,G5!1 9[Z!<SL1E1<1%;-._($/]A=)XSLU5,9!T
M2BNPY";;AFL:.^;P2U41;,<J)E'TB> X;MI.959V(F[-1QXR,/H5NVS:.F6-
M/447P+/>LF X_2[74KF*$6,\0B'0:J<B"!\:HF&)<XS6,?J"VBR%"==%RLWY
M:]J=W8'5V<@YWW29'(ZS,/LKGM6#-XI[-]RD\W0F)*)O%6V+/<A E?9:KPN'
M/"AB8MQQF/"SCSDBG>YH3E?VPVU@68,.9B@6><X:U8 S(\=F]#N-U8 TYB!)
MG7$=W8>&M"@Q$%$$'BKK7!V-63@'*A!-2K6",QM$'TZ48GBK2E=L\HP?>6E=
M6B7.-E,/R7Q:243J%\:DGUX<[<F[N^@_/K0QEBM?6=<*YFI7*%PO"3&K+&8,
M*@?R!,E+3YQIB1#A& /<[8WNS#X<C[49)I55]A0+\:7E2,8S,_UXW*@MZT-5
M'&(6F@BD5R36=FSGBN$L/VV"Z6"QQS6%AFD;;=Q>2PQ=%!IIJ_RNY- $-<!>
MY#SX2)K:5HJ$W1>1G;6SA]5:9-.Z9_DA.&TI7.J$Y9=%0GE.90IX;:$L?-,>
MN<*%17=+C%6E!0D:J4CS,)M%ZE+'URW_9*&S5Z8?I*<L>-+?M+0X2"R\XJ4R
MM,K[L#?$"_53^<2DC):\:GT2#S;COG U7ESC 9RZ4?T.BDT>R=SW0\\0E4XI
M+.FX:&[:C+!#-PU41DKO]?%TT7W>RP;@AH4_4%+2Q02ZYIT]1.!)^)6W\8#I
MMK7;0GLB<.2V,(6I T..-B#CG!CXJ"7L1724Y)D2]+A$ ?/U$N=G**(8FZ#G
MD,=0%+:372BZX]@NE(P+HE$'&I0"91OV"&DIN#PKUD4NE8T4K%$B$[O MA<;
MNV1C&6(F95>+V2QF<\%LE(&)^_$"Q\P'QCE@K Y4LEZL:;&F2R/<JB$N ;$@
M"A#\4WQ[L[BDQ8@>,J(12AD<[Y:1&!\[$06I! .G*(M9+69UP:Q\PFTU;<5*
MM3-G'=IEPE2XV-9B6Q>9>1S>+'7TXV7.I'G+%.1B4@^>@BQGJGV_A^'E/VM6
M\*.' ?YQ@0$N,,!_&QC@#V&,.P*O%7JOTFSV\)\.Y7+Z5X=NV5,OEK%HV@!G
MJ 5:3"AQL_Z8X*M,7AU]G\3G3$LM?1L_3J5@N:PG_O3:DZ-E[(::L.HO/GW^
M^7@1UR?KL/$ZT7JNV^T81K'S:F%"Y%$8U([_Z]V7KXK4#XS?CF2U$V! 43"<
M^G"76ZG7@=E)$ ?5]J&FT3U0(WW8#$(/0B_''[$^ 6FIXHC03Y&7.4,M<F%<
MF/_JR^_Y_U^5)YI1?-W7\<K2<HPKV0BG*\:WQZ:GRI(\P^#P4-%ZN=D9=G$=
MCQ,0HU[5F_L4[@8+S43&"0/344?Q/8$&9;YX) U9,3N^F+6H:L_!9Q)L?SI-
MZ[IFEILFT /:]@!2#>&*[\"PN@RLZ# DZ1^>2NOMF[8+9'^%$2,D %61#]S2
M&'J" ><;+5K?B:?2HQ,ZT$"&X$R82D%,0J9,TV K4,N,! 0&E=>XAUV80"*C
M?.(M[\JJ)K,B;&3%*O6#C5&D!J#8 F/59!SV>')>TWT0\9IB%H9 8M_'1%45
MC\U19UJZLT1QW/,@/!?FG4NE"SF_Z_"<K]%H)M0:2]MN.V,PF,#7QNO.L+4U
MMS"/PGJ8FL\C+(#"P0PL:)U.^6%"9OT/*@[^J@ ;!^KV'?<T3O7]LW?0? 2M
MS:L6T\ZK-_I=5M<"B"3O2$M/Q8085-I0-&\$_0A 9F*<#]-!/(W%#NJN:FN=
M\E,$8@;VNJ#\FPO"=V,8ZE,_9K%FZZY:AX[!30D,CB42YUN?$E(Y'7-R@%4=
M.P]2?BQ!&P'ONB_?L\K.B:';-++EF-D ^& ]"?[:AZ$C>T N91Q'0.?I'_PZ
M\^$*(/1I,B:QI9$Y0&0RP$BI^*4$A>)R0+6GXI,@_OR-*G_\WD]6#T'%)?LL
ME('FJU=OKIDYA?YK9EE[@]G*NMG;^ 6,,=P5=L4_LWQ,DM )4<+H=:8&87VH
M;/*@<,"E^!I8(AZD]!L"<C=;B5,TNN#*C)*KO=*I!P9W3FXOCMH-]&=#XQRD
MQ*7:A"TB&2,3;&O\LE KYU?.SI&3N78)]^Q3=&'SOA:#2S#>S3%1&VXGDR9
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MJP+/A2JOJI=%Q^6H6KB"N@G1F+;VE_&K#)/'RHD7IUV5J3;N!#RZTI QT*G
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M+SU1/RP3T::LB5ENX[31?_;#309%H2DOEXMQ=CCRH\4/9A>G8Y@LKN QV"T
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M?MI02>HNJ*MFN5X18LL)X>0F.)ABG S,AG.CZ&I.G[G0CAE^/9&^Z+/H?>E
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ME"KZLFB2(#J3LWO"O;'+:UW\Y**][-+C4UQ3_7/16W9X5*(OXT+,Y*@+6.4
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M(>*!$8 ^/Z'S)VFF;2KI2>9AS QA9B&(>T?I\9(RE=M3\,O9QNG?JWB1";K
M:&FA(4S15>%5#G>\Q3)KUR1T$$U7&GOHV$$Q&BZ9<ILS-T4PWQ3H*+'J%3=U
MU?P:RBP^\+<= ==@5(M:Q3KIC'9HX2X521V%5D=VS<[#1[:@X<QMN<,L[;I!
M423S'0*N,)%D$?W@_)!\^E^5KN:6Z_?%</MDK %=9!S/N4E(!S-V2GR"E50;
MHC?6%=# ?!448'4RMMAYQ-**Q.QBP9W)"'$K6B3)> _9\U@;:TP?XT,C*!0Y
M*OBI^/VB(J+?)NZM6<=\+8%UT@HI9&5P\ES5,':):/5Y.%],*:VQZOD09'50
MAMZ\A%3]=_Q;,24)P%)QA9T3&N+=\*]%?<EY!&V!&:X!:OL>X[6TP%X0,"%?
M9\'5,_!I).?9S4WV<;RN>^+:1-!8Y\1V/039+M:(!5N#B#.?IPV#'?>(A2'<
MHY58CXL*71EBDZ9.K6M;)Y)ACL/9QR#)%TUWFM-$#UN#P!I%0SHM R,33)6:
M83IE[;I82Y,N=@CX')=+ID$WC3[>VM&$J"ZPV+"2]445EM;_6*X8(H_QZT*E
M&3DW9-:<(3-VDZG R?C-$G>B5^LIJU%##>#<5;N\8*0H^'\C']3ML=]C(&8U
M-GQ(-\MLEEN+6)\F*Y[AZX\ 3Z?!QF=?A;IWJ$(=JE"?917J.P5!<GL03J^Y
M,:2,^+&.S$[P@5<Z4_^,$U:<=%'!>L<=W_/C%HP%)@B,EU2I.M=?Q)^..,6#
M YVRY0SW;U:E?$^B+-I!UM/CTNZK"'3SZ+L5 8N*QMWN"]Q "2BDB[+V"<)2
MG2:8<D.9>\165V=TI,?;.@Z.F65*$I<N']&'E@RM6R_5Z:$2D1O$T6VH_P /
MML.S,02=CE[>$+:DWHD &4-[6+IK"+SL'JA@Y<@ZAA%4Y55)$+$D"N1PD]ZR
MD^IO8^+$%RH41Q.BB+;05,AU'LN^FMY4V31#]E1@ :,,P75&V:_8MN-BYR32
MCA!J#"7V>YDC)FAV425@9SD?7G%K\P[_8'N3KQWW1!CB@O&7+D4!7F*NW0W&
M&4P/$+9)!?< 82+_.VFR,0D4):)$:$[GO#2*,2F2JE?I>:50CEI0!BFSLJSV
M-Y#4-!PFT8W$GQ]#'!NZ8$NI"@TYO55R5'9:O$PA6T)]$%->UE#E>JQ2M8Y(
M21 #*$O-C$TG;R5U0R,F_7.6+W@*(B2^=Z1"FUW+D9P7J#U=:AFB=5U$^ NQ
M=U%AD!+DS&S:J=K=4%C9+]**)^CE19*.@*J\MV$DPGTTUO[+6UH)+L+?7^;9
M58&P1>GGX/_??#-:8OB5X6%13<.YB*5TJP+VNN#F;=TPDPQW&R/-$3LA]')E
MOZ"CZ<<O7G'QD<E-I@SZ9FUJ'8W2U*7@?+>;\J)1V;FXL>KD[AB"I^-#=-UF
M8/[OW8D&'T8CG.DB*;TD7XYU6\$V& 5>BA<9O)_$DG0<'SA?#%F4CFI;G00A
MJW=ZCM8;)XRJBY3RJTI67IH$:Y<_YU .-BW;#H^TBB]$UU1P)7.HL,5ZGI0R
M 1U'B2KO<(O6S5&D2<I$NXYK"#$"9^4@P15U*Y&Z!Z^*S%>"DSHN.9_?YMGE
M]NCMBLX0F! EV2L$:.@,'C)!?6$HMRGD8ZEP9NH-XK63A(]<!,.];'S96"H[
M6_\Z.PTI_:J3&4*]6YP"9=G^M"UYZ\>G>W>JQ5/O1@]H/(T0=8WE!6.7]9[8
M\9[>:X??H59O7_@;5(?+:48P*:ZU<9C%"A<!3&D]0 DA1]2;],@&(829;L_3
M?2MN<'"&;,4&C63X;,?PP+80K>_;=@-U&I9&)>I8(AL'U:8"_12%DPE]K>B_
M$O4RR=NPP69O7O>SM1OTCTTL08V);"-]F(<#N=;'*9S>GB=$!>X)86E:);]X
M)246I^67&M(." (AMO.>Z?/G684/(:U/O> 41_ MUA0,IS%.N]6Y0%YHA$CU
MUTS"*_JW7H>OVV^2&,AX7QO@P\?-)8N=TI/0B]0E-ZI$[@<,R,4,CD)9T\Z"
MC9:]HY5[?[L:4G%,;#B-.#C(87)Z#045Y# ,N^I&OIZMXEFN705D5;G4K/II
M(B)KL,PPW"/I,H^8ILX07?VI>QFP^I!WA@1=R[R>Q3I%UK!RN],HNUTJ%8U
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M/_XB=9J;H_*D:*6P/*%%%T/JNJEL+W7 B['R=J2*E+S'O[:0DM[Z2UJO+['
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M?/"GZ7%Y%4D?)?WLG+!T>,C@1:Y7%:I(2I''%-S7P9;@JDAHH))EY1LX)73
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M8>8=<R[<X"5R-8SB_(BWB1RMA6>D=>OE+7Y\,[R&0C(Q^>$_:!?_HZS>J_O
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MF9.WSY].S=!_G]7S['\G?UN6Y\%K_TXHZ4G+!/1L54&,,VGM0\-():GCMF'
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MXQ!D W2:)D=G(?9*R$=0*%#X=H9VV;#"5M2%0&9ED0;5/DK#;]T,<*"BD-^
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MMY/7U!.*F^7L]/[IV=WIY'5>AKUIA>4WN>T,)<ZAT;X-T_ZLR"]*X2@A TH
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M+;M?5O)'IH41C?V>NUX8>$?NY;=/7CR7"^(+-#0UM; GGA.7PR5%'";KRX[
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M,,(E#^#Q @:C>"T%B]G6X"-!ITE98G 863!*CU>CU Y#:"*4()9D?O6C20J
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M*RR$3]Q[Z&)DON]I!LGI0?&+N*>Y;VA@"TU9RITX!$3NYOY),OR!W:S;=%\
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M.Q="_7B337DK3P/"R V!V/WAN "K.=&3PQ419"'V/F+6R1K5)<6 [.S(Z1/
MTC)F53W0R2 !/4@IL J5EMRA]U@867I#/ZUPH[/J)HA<-<=QFVH,BQFGT_2#
M'5M4D&<WSY644"!I6#<1L'%:='%;.;S)A#>95XL:[RHJ\P%1<2'OZH^!@7FZ
MQ<!L,3"/%0-#IUN\[A;:7I!9-2]@J0BCBG&1&\S =\L]+6N4OJ92BS.@7+:4
MSFZ+\@,^[ZT08=,G<J0YFLCPO(8N\,/<X4P?&X.%U,$6"1&F)U(/X0U@.0I<
M)]1!U9"<G,X0*+D9-6.F.19;IMI)):<&'_[?</2- HE8<.DCS=01;1*S'0@
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M*7!NODKCF"_)^KS]_5UT^NKEFY>G)Z^BBY<7Y_#G\PTYI-ORTF7EI:WEH[A
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MYW3_-8Z-9'D_OS[E/Q%W+/QZF%9UM+"XL0P7ML;+JK3*#LIK^>FND,31MDK
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M)X&;J,X[D3(6XZ@4[_OPZ)_1SL&AQ*S!4U-G8%?*F1R"QX(T2!R5Q=6\FM6
M?@%BH$T(> Y_%5'._1BF%;CK5SCVJ^)C*MTD'K\]LK^U1[;VR!?8(_O[!]WC
M38G%GMA2[J%R&&A+E#"$Y8-0#<K9-[]%KK3<"0#-ZAA<@MH,OG<@Q1JL0=.-
MS@BBZL@R#6N6BS8*7B)+O3&#+G,UOYH64Z78\E7K#1R.15[M=7LQ_)]#MHUZ
M7<UHWU507JOI?%/4)/1(VQD&66'"MN%'3!(^ULZ;C,.4B,RPG%\3\R[W?\/R
M5EI.EM]*2%GIJ,30$WK?F0N&5V9*%.9.%P67SV65=$:0O>!PK;:\:3;HY!&A
M5<BXZ(#,3$Y [6C <:!R OG<2)NEXKD:C),2MS @]-5Z!+,@6?ZQ&'],%>0_
MS!@-8/:]\C&CR+&J-GOR25TB#VA3S;O^/<T[E2K+K+MU"OKW>VPA?K\PQT/9
M[8_?RCC86AE;*^.+HAZ'M&3?*^CQ1ZL),:RI=E8PV%N)T<H@T@HL-L+LH.(>
M UO"%SU(17=6KBI5(1U.RGNWF1TSG;SPO5SM4*\',=2FA&A-)UGGWW/"AM*:
MP\>2\:+*-'K/;!6(6YT3[X0H,FG*(8 7G-@XJ2:)K@"2X'-MB,162']2@6?.
M)/WZX$<QGQS>!E-O*=7OM133N]E<I7DZRICMX<W%J3?2R![1=)ET)K(I-0;%
M-E)OCE)5.%2#3NZ4 VZ9B\P!]F1"J%>U:2@_,9E^J-DG:?T=<72C>X']\ZX+
M>5BPQO0R?)B7Q'%TK3@?X30(ZIC.&-Q^\=N3BS._NSZX%;[B@3CIMP$N9P'M
MWS? )1)/"+P.]KK/^MN<S?>Q7@ZWULO6>OD2ZZ6/F_I5S9?@WIY4""9%+#=V
MJ%E6R%&8"ID'J-]87KT1_:P_=A:%(BW8RT_S:[@3_G>NG I4EOFP\CF(XI72
M4YF-.-#<F= T%>(XB*U;9:#*H"BU@RFW726KC5QJ88>HCPWQ(V4Z*PLM=@K4
M:=*V6*9):C-J0^"B ([GZ[):\#BT.6)_84!@/+NAIDN$<9'(QM":32,"Z0E\
MR_^0&<?X(6]:"1 KC'=(/R806!K_$-KX>D\FQ#UJY&*0EF!SN#Z-BRE:G6%+
M[1I\'4L+6LXB'*VUP4H2B6N6TN'<1\2[SS!+OS5\8S_6<4Z(<DQJT;XDHN9-
M(0H%GVJ^S6(S&VBN&M/J+4YI1'#"<3%3V_/R%L:QZ"!+F'E_GE[S4?<)B6Q(
MD'%\91"K<T<<V1?@R_-2ZLV7 +!.+^'RP!H^6'G_'1DPDN1]+\@?23;L?@2Q
MQWZ>KJ6%& D'H^/>U;"-B.6]A5 VBV"?'OXSVMF'.T,1Q(-=#2.WG$8]+=@P
M8YO?_-(=O<O6OV]W16<?2.02G(;]S6F\L&&[]J4YHC]0HH_2=(AF.P<,7IR=
M4)8H(67A6*I";BIE\<C]/>ND>9D-;AQDE)1=:^2"%33<QALP]5?06'$QK\=0
M8LD["O.BE!XR*TE(+&:E\K[_1O$'?"Y7Q:E9J,M-YJS0$*$A%O!QLQ9JEA:Z
MI!7T9N9$*("ACI02"UC ]F#Y&7A4*YN/H:>PG]7Q.1ON"IP>ZDA.[*MBN6M>
MS_ZR%E5:"LRBL05M-%T Z@E3+" )5XV8!_XJ]NTV[],KQ;<@4JH)Q"-303WY
M2.E=$ZI1S7FR![,)?E;&(6CN*AAW.=*LQ=0_"E[VZ_F[_J?3LWW+)B%&.;L@
M9;2#8]D_WF4B#%.B<^7YD$(6(&(*,LG'%LJH39$++_/H=5*"@\>D+S[;_>;U
MQ0F7$WR4>F$O]L(*3[+XM>C9,"\A\OX8+H,E=.)B",NEX.]GDV(HE/\K(K#:
MU(;BO5*%';(]\U"E;CTH[@\*LAI\,@Y#2357K@*+:&;6JUM2&(0K3:#H>]\,
MP>$(>'3[EKY%?XV9^GPV7IA=".OI?Y0JU:-MT&\;]/N2H%^OUSWL??V<)1_H
M/['H<K2X(XT)0A;)/2=7=/&%7(OA*ZZ$$;7Q=9FFEHJH3*N4A'.65ZA--73P
M'DY4,BW*D"LGS"RQTG0B,HYRT,SC^22YB@-\52C_B-%Z@K$19I<PG5]VWKP_
M?77*)?56I!?3-(_&R56JI6X[(OXOC_;V>KL-0:S#97D?MS"#-4$W"Q6T5@?
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MCTF9I1Q3EB"\2>2XGM.FH4]+E[KU)T+1KPQ[^?"@+!K?Q7<]I #94[#"3F>
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MLKC5ZE%#X0N*YLB27M]0:,Z) O5^4I+0:B-5E=OI<W^/2S^&K!@&<XEIKZK
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MSB;*5'@(S; T*8D;Z@I9(>#W0VKQ)G*4B+C!;]"2M]9S]8!:<\W[L9X;@.>
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M63N&L9=Y[9^QD/=3FB-,<S2K06UDA0+_QN5YX8]S,/Y)U[1H*>T&,":(C"/
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MZ*4U+X2_/7 R,Z['EV ,'^X85YAR7:WKNVB<V9CC&M0.YD9R7-I XA8.%/R
M.NQQYL<U61 "OF$RH2[+C:@,CF!$56**>N*(,/'"UY+Y290G9<E<B"[X<@O+
M5]QR!W9,3C$I_[@!YL+K"?.6S@SP!3QA=07VXNS$!Y7Q_)=<DMS2LC:@IT=%
M8D^=1HE$M2W55&XC_O7WWM'>\W0VZ,8A9Z&$?(2"TQH7UE8'EVH0)BW@84HA
M# C=%W*6J06C>\1A+R9DPPZT1 A8IA2+4VJ]3;D&GMK8K&62<:O%JX)Z "/1
M@S("VMR'<2'X3 07O?+28/FV+=WUVM["?9CG8!A6[&T@_MVS=]9ZA00I&9C%
M![Y-9 )S>P0:K1L=#QM[<MS ,$AS\>O5B#<T\L$GLM1'46NBUEFXF])>[_3M
MJU<G/[]]=W+Y\NV;]]$?+R]_C7Y^^?;BUY-WKT].SW^_?'EZ\BHZ??OZXN3-
MR_/W&W(Z_Y NN:S=J*KT"@%\WL$!A],>7-^D@?8?:\ P@IV+ZAJG@MYKL+^:
MEVBA&AH:RO<*HC*=$45#T-AQ-">*!LH"S%,AXW1T$8J=K/0YRL A@A*[[<U3
M3R=Z>P-36W2*6XQ!3+,ITH>E:E[5IJW6%O>R]L,&8Q@QK\2:C#@-R4L@"_?,
M_QOADIH]I@5":3IABKRRO0AE%HR<RZ:&0X)?6"5C4_A1%@O03+CPTR0C!&B>
MRC,$P.-[S'T8;E/O4YH-%]0&I@3"-?"-299TLD80\TQD&.9P!G#QF0:2=CZ9
MW7A\&@=]2C02K\?%%9^925H.,M?O8&.DM?/6?;"2UDL-P+O. ]V9]TD.$CJ.
MSC_!.?N4.6%%[9JLY!3UO%+ .HIN3CQ+[QV/,%LF]+G+%&XXG,\.#U:PTK](
M(.WT!K0U!]]XRQ&HU:9]8*AG):*SHI\+N'D7@02H7,4P@O/&&#A$>J:A+=;5
MM53Y,'2HX!:Y$-:Z+F<YI9:(F?A<66Z9+BEV6'E"P#<O?V7C_#6,<PZZY":+
M+A,P>N!NG*9C1 -%.SG<S9]?O]^E!W]Y_QOUAU17(!ER>U^Z%2) _+PX6$.%
MKS@-05XC5LC=F/"&64!E^R-L+V',8=$X8*_A\GQ H<::6Z-$4T1>%G"GYI/D
MBMLJ2H92.U&9J%>CURZONO\6?PI9$JF?C;0@<4(2S?3K9%J4J02?#+BOP'8Q
MF:!BZ/V.!)R1B'[*KLZXC4DGSQ#B#)/Y4?*$Q]L\X39/^"CSA-S1*# 2M&H=
M[S6<VENT%A>V.^T W8D1FCS42H:-.+'>R,AA0-MH5"&]Q"=J]\(\L%*O1$@1
M;J\N4HC+5 )@-H6"8N'M5JWX 80Y.+377-V*0::D=/_87E KS!.UZ'' O$#&
M%@O;1A@XEI);_%=B+=,4)!MU?Q89=EXP0R^H!QR2FU'48T,LH)]3VB_I+$8Y
M+K8/*-I7-,UE3H/ 0ERA38*8?EV1KTI-T#:#9P(46WJ'6]J=2ZZ*33:XOW4-
M?.GMDU=L0T4GJB$W"\H%)O]KNB/]O7Z?3)/ <DU:S NQ"HW.I]Y1 H.6-7'3
M%2ST+F_Y+VG^UV*2PI)QS1=W^ H]+6PZ";=!Z/WE?3O!Z_6E,9A/935/N%^!
MJV2@D0T#GGF)"4Z*O,#.)^*9F/B ;9!5!.!J(1ZK.1]XDV5L[C"W6M6_YT/.
M\@6M9?SJ253L9)C@8/D_R$"[(D3[%*Y+ICD\ZGG:X;;N7KJYUA[6.Y )4\&;
MX/MEN-YZ\G..Q3=PHSCN]YX^K]IGY*;-@ZR*<4KQMG"L8_(6ZF,EQOVQ,^5B
MYZ;>O>";U\+DPAP^W-/ZV:?[!)HF1XM6_A%!"I^H8<-'= 6*<CS$>D5,IESQ
MS>+>#W+)R.?GQ8MUC7"SJ%[@ _Q?\B20,"%&_ (L*)<0<.\0+#;*)M0UM+ZF
MCK6G4@I-Q0S*R;$)4 +VZ5TB)3;?'.4#;FOB29@H@B .C"ZT5-5\S/@JN#0_
MWEE&D2!@!#<3UHL9JT#\Q6I08&O)HF1?PPI#OO=<LR9L;EDY9",%K]20&.;&
M"_ZQ_E<<Y47><;[,CG?IIF7J_UYW?3>RC>X#4V 4M]P2=)DL,HDOHWL!E_W(
M;_@<4:QVT7;,^(0U3PX^SAB&H)U?Z>F[,,CNZ+S$).)4&[:&+*BD?H2Q'4F(
MFLV#34NG0CJR62?,)0T9B6$6A<1?4A4,^M! 0HO^,>M%$. !^%D^O<MF*<8"
M<A'WIJ/N3)SQ:N8D<%;=9TRU^B$X %=T6TS'8\X.:?@NV/M:)2ZEQBH:%HAE
M:T&)+WIP\+0_..#5'J8#N3N8:TY_HCV1R&3C"3:^0+ED:&I%FV4V>:7>*O,Q
MVY]1R4;TC][3[B$GHPE2-BH+]$"2!=UAW&5Y UI;$B["B!J'0L9>;30#;([&
MV BE6#C%Q-7@B\3Y84'G:<3.A=K,*REXE7["W::"6'E!; Y<<87UGG+/IPFW
M ?7O&J4;DTL.@HEB5]7LJQ3F0@8+J5G:,_@C FI\-L&(W#BX(\'5P!U.JQEJ
M ]E;,KGF4W@??_,??3@'5WP.^&]((/*6:[=RVD^3 8 G_G'4]^=GRM6!*":Z
MT<D862CF)ME_U^EP-ILS08@30N$FC=L^]%9NE\=<IX- N8C?GHWY1.@JHC](
MC8B''097=(:PU%A,1LZ%3T/ H"2^[Q(149%[X\2/;K[BSK4H?\K_BAYYIY\#
M<XBT7>Q6 G:+XS Y.3OS?%8N.E>+COQ1_7-\%_ZUFJM7"2;RX9%L+"3\V)4-
MMW GVQ5K/R>*_9S*R\6;\?V[S-'!2;L&ZOH!S/+@?\LX8GBOO#C]-,W*H&@/
MR\<ZLZ)#_T*OTD40]P;S5PG%F#0+ALP-]GO.XL<$F023"$6#.):23(H4/'E2
MW*AG$FQ&/1[6AXD/PD!;1VKNCC7,R%)=,?.-L0(N6TX>'R-9=^8]%4?/=)5%
MAX</_$+%)Q]+ZTBAD8F_S931'77[.!$XJEQEV)IY3CWAN#R845'49<)V,FJ,
M$@_Q;;K6ATB>2$[%C1#3@#JIM/T3BA$G@$RL' 'XA1+A!Y@:Q!O&U@S>),4F
MTT7B?VZY?O3/L4"QS7'.BQGV!&=KDFW4<)"F>2*;0=7* :S^0#<Z9] GVO8>
M4>Q\ASO6ABQP @ZY(U+XU[FK-\\'5+2 K0PI_8%1>DJB(!-5,?Z(X*UN]#N]
M(SQB2S_+ECW.G_OJJE^I7BG"T\PI=!/YNO#0^V$F>GM=1HRZ%.GG1MZ^HQS9
MLR&W%^E5.4>5@"6S#Q%U<RNR).ZF_QY'+W-$7WUFV*S>7WL9W,NEG6\+Y_8Y
M/Q!,"1U&-ZJ'3IH3"((G)BG^ .&3[QPY<3G2J9@L#!IQO>%^B*3ELVW2<INT
M?$1)RT ^GX$70XQP3CXS#)$\>FRH[KV]5C=+;%HL!1O-P;,IK*YV@K,)]9K!
M\;IFA'+TC_WNGO/[&MZE#S%@1Q:.VN-8_G>2JV+I@X?HT@T4[Z<_DQ"%AS#$
MB/+-<B/**W]__X_>@?DZAJJNKS$=.C/NK??'FL+[^\8 ]AXZ-OS58Z-#+B%5
MYT%WK4TKMH9*ZZ5<(;4G=Q>8N5HFKM?$DV,MWF2"-G?7?S2K[K-P:/8+.NR^
M*]?4HX]H 8D0HDI-,XHFG<^&78_-"6S;L_?-0]N)"T'4QK@IV_7["HE;BSOG
MT3]ZO1@,*OS?>MBYQNHJ*LR)>'K50 F3VV*D%-:,_G%XZ+Z0Y4%NJAD-C:-_
M]/E9?=YL2MOCN#_ZG7[P(0X2M@1<<=NL+;U:136H;9?%,AM!S"F<&:R[O$Y]
MT%)0N$%@<V40\P[1] W#F/$VCGG/."8"1:@5R^?$,S=$F%RVGL$O"VBZ]SUX
M2+-EI/<.:KIW-<.:K0OR!8'-;Q"YS.#^#3&UAR2?^#'^P.>%+%OF_9!!R]@#
M(/'>RJK@KKB?Z7OXYW&X263M<1:3&?DQ\))A<<\R2<KXRP6!R;A8TBL,"C?K
M^66CK7("E(P-H4JD:TMU@AZ0A46%P[KEYQ7"\O#LDB5>(T ;WJK'$:)M%*ZX
M65<;DLX![7\R+;,QYS7[>[UG;8%8=SZ)57M$;MVP'IYM#<G""ES6 M3-X"P=
MTSMBN_2B1C [C._6EQM!E:C*'?!'0(-%SH0J'6)6QX,<5.IQ61[X=3!:J9>A
MX,&=V#S7"##]2@66]V:76+4-&W(2Z['P54..'R90+]:3F/C2OGOHU>UT49;P
MY%6:_P5O2_Y*I\3322;N8#$KJ*H:9>88^='I)(%BK)]"41*.5(8*-U/IVT''
MI%G@%A;.W;$:/& NC522>OH1JBTI'EI:EFX"\.QG8-;")1=:\Q?UT8JTYRXI
MXTQ)GM1J50P/U_=7<7.VJI899T/%L'+1UQVZX \#MP=9Z9TG#".A(GV$Z+>L
M-XX VQTLJ)J"D3]#UGR*'DK6B"+^(&F+_MXV;;%-6SRBM(6IP4$)(-CC^T;U
MP([E9K BP *XL7?T3!1CE71NJ>>M!>.MWVS?#__4$%3K?;,A'W>R7;;P9KXC
M"QG>G'%IE8?>(N,:U:9T1BL( QG^U7-^.JCIUVJT,6J0.?7*HHX@HG]!AH*?
MFU8<5*&H,6:+1.\%!6MC(K99:P&*4HCD2+M3+3X2$\REIP'Y%>(6-ZO+O0/2
M6/"&!=JB3+ 3Q*H9T_9KQ8T637B>'R' <S4L]]QRVFG4Y6&.(&Y$##".T3[:
MMH#=RC'0T$D@!'TB)/;@>1XU"+$AIN?O:\W.1T>7QH(Q91@?^1@M=N< ?]_D
M0W$=EMQWC9)PCE6QL&U"R/CP'!\NEEN=W'> [RWQ<JJ!:U](<.CV\_(EZ=/#
M0[<2*S.G=XC/9>;BDBC.RA.*UR]?<#@#URX,/GPN8$]B0AE=%C!I=-'!HT;9
M6F8S4+,:ZR(%5 M(-6-OJT_@O>)NGQVTJM7F17(ZVM[AHUL=OO?#B&GG-\SW
MW2P8G&F1XLT CK%+U8'L@3H? K'RM+]W"BJZC!H^:P9&ZMJ"-CZ\^O%RF!FH
MAVE*NH+X2\HR_5@,R(S:4;N&& ]5#9DXH$^6[SH[8L=YW.Y*T\@]G"V%IWU9
MIV;/*11=3Y\/%;%F:G060M]:Y'_.KQ/7Q0D#/26N=C-N4 >K.6%5N40N0I>;
MF2K?Q<#RE 1[V^)"XWY3PR7*)JWM![?XTJ36>?7F=:\Z3Z\+KG])+#;0K*JO
MEVLFABE^8;!^2SO6Y"%+SH9J^89$H'1B,Q(CNU9Q<$'V2>^EBT\C7R*=D773
MQF@J'!W%>\]:5&1;(CCS:=K6DI(5V=BV:A.7E'7L1G<9NIN0E\7*[XR)T4*/
MYLNRLYSF-.^[,RG+^=>VQ?-:LY'S19; JG*3<'J?9 S%&[5FEJO7B'2>R<_R
MA?=(3$[D+O>PL8E1A;V58$L&R)&)7(+_/WMOVMPVLJ0+_Q7$S)UY[1N46I+W
M]L2-D.5-9RQ;5W+/F;G?0+(HH4T"/%@D\_SZ-]>J+ "DY*U-VX@X,RV31*&6
MK-SSR15#H#7+#5P]2A((04NRH.(\!P(KD9B2H=W/OE>WTQ&]9JX@;3YY(96+
M\G%GEET@6YOB"*4F*8D.2VVP7,[ WL[=VC_XV1+Z=LY$FH*TQ5.)CI,P^2U^
MEV^V4[>$"W^6-M^EXS%WW>F_K$J!G .7AY2F;NT:5[1'.K7G+"W; /Z5%_J/
M=9I_G\X_BAE,WVV87!9%Y4)+81/7C;Q/I6=@Q&L0"GAB4_T]&PW:&E@<J-N%
M +CGW3X]\58[+ETI>PR;KU#.\Y/XS?<'O_G@-_]N?O.OGKYPGN9_ J.(A-AO
MR;NFWGGC';S?)*/ARPS^@[W]Q^LD[Q;E76AYA4^]>-Q-O?"RJ%,,MPYVZL^V
M^=63+!&R!JO6;QF>JLGF"%+)@\6(I;"ONP(C\*:>[EI$*OAQE-%A #11OGI
M*[1 [N!JM"'JJ#7]4U:#H\&"^/RDG3A[]_?.^D<@\BX<B2I;*[QAXS@G248F
MZI+?![+JW5O21=P%(T_1"^';]EL4]A;&ZQ8$WC0OH!=-R2E%(<7?<.>+7I>^
MHO&HMXZ59 L(IBVI"GBX0=,55X1M$RN=U>GSG3?[FKEN=YV_."T+M!,#/)D!
M]V&[B56/D?Y3]!@Z3M%*J)V0A1AD4[;0.B,,H6A=@K:!D@F/I)S7D-)NZ]]Q
M\.,6N^8#(:+<6S]=EVI1$91U]!B&=C_&34TJ/=6-.-OAEWWD!A?)(KRJ]0Y[
MV\&B-8FY""F<7U3=,I-HJT.**)H;=4$0R&1)&= NNWFI*M@[,UB2]20UXJIB
M8G<?LZK6KJ7=315775BLO%]M7@K>>B(-="?DY8,6RZ9<DO(,9P&VP+SH5."0
M>X&#NOI-?QPW#5&'/H)Q^9_%RI,,V-!8TC8!6R1WLXP2W,N,0?JE;WIKQNV;
M? ,ER.WP.7=@FHY,:)7^R54 "O+.+4WP$SSMC!J]F7X3O8M"])JF"I(&^9%0
M^170RI0JG#Q<%;LI:@E.\?+"Q5OGD8*?&ER3F9;#L >*^ M2CHF[&A!KDX3J
M'R$9R9<^+3^XNB,B#/ *_CDMFO&:><E4Z/Q"!Q(Z0 H4Z>:K'R@0.WUML<[@
M_ F'%7VCDC&>+4R?.C^6JGY]0>ZJ-3%<<+B1!E()UK5344.?V+6A52Y 'L$R
M<[,92UM"&>T$>&BY+9:Y)8K2&HD8"?8VPN"?U$!F$Y-:'_.V"?.1CS'6.OH<
M?AJXIQ9-J-],U4W15NLZX;5T(EDJN"E(1([[VK0/*J;S7N[Y;=GB8;Y:LW$A
M8A*O@9+$V?O0MVDM_$P&/QU+I@0_AF#M873B!+U3"/GN-\V0N_<5^+G F+KZ
M&IL"-;PK09LE'T8 YU]7F-&/+T7 Q;JHT%D@\G:EA%+O#TWJ>DB2Z$2Y,%!B
M,EAW'2E&2U:S33E)S)5]HU"I:,*_R3FDB2#230.SO/\L2DI*F&T2<#JM];=Q
MHU1CI^5-DHTF1S@:Z'%C%"XF'RY'D"?),SU!F.IKUMVXN;<?F+3;P*09=KJZ
M3+FNRB^0P+)A?[AL,U^% JBFQ@0._'%+<F-;D*:BU66SE><ZGGB8"#3F(ZTB
M&/ 10Q*EFS45]N]!XPAE<$6TAR($'00)Z+;2HC.YA0"+\TR4#R$L^*2VH2<Z
M-][ L">PAUZ)O4[A9]8?VYXPA[?2/,XEL=*M5>4B89A<BP?2B6BPF3:QIX?-
M$67L:N?.P60P$<>0LF*)BV-5,:.%DIN55ISZ!C2DI^-1!S>L6%A;(M5"+++?
MG+0)[K@95AC%[#7T05F1&=<'Y>PMN%X#+G).<^28O-XB)*JJF' W"JX&IZ92
M$;9+CR)DZM O81$["'"J6J1G'EXI,4$0(QJXA^.:;"FX$8[I9$G*;^U3^_P^
MR<Z0 E:&C+\HED;[86<^*S8F*XIAWXN8/9+.AM,LO8!SJ%M?YFE>['!_HKDD
M;L'8K.(*8%!T++&HEY" <'GM6N*5Y-![&1OAA2N!_?G(\.->9S9H L*AA9NU
MP=- LW%]I72&&H-0PR0(:N/4:14,4ZT;(AS#6G&<.&5 LZ00))@#!NP]Z,^9
MZK]#R%O7126X^<V*Y[I ">R[R4I2#)+E#=I0Q;FK%RF[L5!-\#42/CHZL9W8
M9FDV;ZAE(L<<R3WFE1 L-01V=Z%J!K5 9LL1^!&P>W\2K671N$S,Z0=[KTI'
M59'S9.'2"KM#2##(*)1-75!/;4[4U&VMUE:]AE<;K? /_3&\8L)F)R6-A4='
MO;8GJ!Y-F6NUH=C5:ZZ?<7-Q2DYL$'CG! P-C^-_I\6D":W&J$39=J"P63UK
M2(@YT!KR0B7B OF!:*RG9T?)/+W>%A'SG'DP8_>H>L(XJU.--M?9SNGS-SO[
MO0[ .]1PZ/Y=-EE.+U'+.HB!8$.> G>4\Z71\O-]#WK!!:^,B"%,C.<T G6,
M@'I!SK\[.T/*?WMZ1'GC5P0]]&\_2W#P8 @.#L'!+0H.?F)([<D/$%([25>;
M"IEO$4U;'QJS<0[;T>^F8-MMHU>?'#A:-Z'8&)=Y],2\;K&(=N#K2?10-_HE
M><7V1\^RHM7U],XY*CF7:78W><-N@1!&-$^&,=-N,YS>8-FM%J25+\%%\)DQ
M,PUO;HR=12%)#Y1P(E_'04,?8K.8"CU!MC#.AD";\=-_^V";V?C=Z!2^9IBM
M11JDQO],03:[;]\MPM:AK6_L3NX0RZ>'V+I3_NYA-G*L]L76SDZ>/?087G>P
M,O4*ALG5$5P6'[,%8]C\<?Z_]G:?*/;DW3Z<K[9@^?S@VZ>$_.(M5T[VA?&[
MF!"X(RQE)5<A@_<V82[J"!T";H'0MD1%V22QUD>T;L\9AK#6$-;:$-:RA/0C
M!+)Z^,RW#&9MN(V_8$0KXCHMXOFQ8EO1S'_: )=5PK=$W$51KG6VXS<.=75,
MJ2'<M2WA+G,\D^\4];J%R^ [AKYN%?E:=Z\^,_PUQ+R^8LRK1V9^6< K$LJ?
M'>E:1S(^W+66IGZDF%>T5U'@R[><((@#"H,=G;_<V3];'P<[>/#;LZ.]O8<2
M#5M*>,M$P[XZX,7&NIU/V)1N4*,=POA,A)>.QV+?]/A$0J2/#F[=0&-=G%4N
M_T8=(D3MYUA-&+JD_OAQPWM#W'"(&VX/&-]Z+/7_&-_FC7!WY]/_K\OBZ%*P
MT(,M^KU9HBD(7#;J89L\Q^IH0A@]?'7VXL7)B[?O8>/&V](1.2*$Z\NL=COP
MR<3]CEW-KT$)Y#BEQ5)8!Z,2G >13X;Y(6B0.^M^,!*3 R&N4#V"_Q+S5C!4
MEU\2T@'AM?KM-/B'<Q!J)5G@\(OGIV\\7ILXHD0NNAPV0?"1)^F2=<J N4OO
MBH&5R0B(@X&,M4PE6N\)7 ?-YRL>1R=,/FD23$T9NXQ(-:]JN$E9=8E=@/-I
MP$YT'Y>\55IP 9]?9DN9WU4*UEF#   7\/Y_FKV51KSC3N#2SY5'N+Z$74:G
M2;HBE31WI;JG9@UBZ.PF?T6_[HC%$GE:>MU92[#[VD4RQ<R=RH.B6%6?G0V_
MT_1KXE<J=$A [!#A+2OWN_[Q]%OP&A70..VG1A3@(S2KG7FZ@AOQ^RS[Z*96
M-*@<X[M9E_!_4W\[^6>\"__Q6SVU7W[1,N#V$,&(B&?&5BR?6GZ0%\0-S"3D
M'&6R__ZO3QX^>O*T/:_X1UVQ\Q6R0S;)K+^C"8TN2:DUU293?,>XQ]6Z!(>1
MPLB]/7Z=G!T=CH)S[&TJW/TUC% G;QKR6TR39_.BF";'>55G=8/:.EXS557]
M0_Y[HF$88EY?TLO@112>!G/@'KE535LXZ6>7Y\ S)K(:TZLN3F=CO_4"##X3
M!(N6R983K@P.%AAH.F5>DG$^*;HP\?:H=SP ;66R5!]ACN ^^$U'AV<[[Y.)
M8W.1/ G>@B%G/#LP.Z$8V6AD2B=T,J1@D\VO4W>:L+&;G&5@B)=3]$+,IR!$
MX+]NIE-XPS\O. 'C/4II1&.M^8R/%XLF+W1NH)F_??WFV?&((ASH+&E,0)#[
MF+'4L9:M=^YM7*ZXB6C7DLL&U0F@QN+"Y<C+P;I&J[=L$%X()&Y5A50"&P\@
M18K?\"&;YAB(:!9%Z3UP-<K58/KK/I(%GV+&H\Q9@_%HLY>9JU."LA+Q:''F
M0T^N6VP]T0/:7[7#Q,FP->V&>KM!O""7^ WYVV_$$ =N/7!K=;_W=N_H(&<9
M[[%71MN8B>JW3?FZJ,O6M@9XG^;IV"5G*@L\WR"?,'==AB??G[T1]K\LT/;!
MR2%O5(!"OM^L1?7T!:$G80QT<=+]R^8%(1Y](+<7.Q^%E3\=[LAP1S9J-)?I
ME&A'0SY';DY]9.^@*']69E5=S'=.5A@(.?]'DXW'=SU,UU7<X#0()V[N@5_!
M4"@ %3#3B@IK6@UD.I#I#8IWU)(IUTXO<1(Q$7!J3-AN6R.OA[\( YA,!W;'
M<H)@5S;T1@+58= !A45%QCP1F^X:!#2BI(JB%JQD-[ALB>6_7S-KP5L%C1I=
M$!H;6\: +)H106[H'GT,1P1A-W&E[V3?TL53D$_71L$+ 'Y/<:G##1YN\(V"
M!L/WZ'>:KZPI()+GU3S]6)POX,__Q/-,[E!$^"[=V%?G_^D3=3 ECA+9'?5J
MO4@O6GVP+N'=A%J09_7*WE2]=0O$.5EBVY-E!OO+IC-]R"[8A5N,X;^^5\C6
M$_C>0-_?G;X-;5M]ZF]9FE]43?(:*+5LLN3$3;,)DO>1]-F3*A B\]:/V\2N
MS2F]]C4IBZK:P3P)"OYC<#"SN2B<D9B1@V)'^_[MKJ?D_J 3L4\?[OH+P@R!
MG'NC#'&@Q491_N7_'+TY?GM\=/@F.7KWYLWALW=GA^^/W[T-X9+S+0J7O ^.
M$8G0JZQELV[I</00>N;,\(9D.&C.$^?=^-Y_U@J6L)&YSH]/\8Q).G68,ED8
M'V84%=A-HKR":Z?N04S;)=5GWG&= XU6S=+W(?#3,UJ;K/+Z$F:\VN$,85UR
M\'CYP,C@C!\X;L1QT:'=S(TW.W8 7Q>;+\6)*R<?J$.J2Z<<NFJS25*X^P?A
M&IB&<KZ[$2-Z.Z@5.1##V,U'R;0 "G85#!.>IO@<^5G]*S1!KC:-+/&.<(K.
M^S>'._>3Q>'8@UR'6X+9B*_V]Q_2R)2P\W#$&64A#8]Y 6HVQ3S[9[-(QR0<
MEO M39Z-)\D4^FT!1GJ%#NX))O%G4_$1MU)-$LEQ=>6BBZLVXDU6JZ9JO9P"
M!+FP,[8WL( %AT'G.O*#5N&99Q^8$AB-U;?4GAV)Y[[-"MW 7[: OQPV%U@1
MT,]AM SA$QB$X3S1'2>DB8>WN*\6PP*N;N>.PDM_@\\OW2*MR=,PH?8.>#0I
MI:5^JPN;KKFRGWYC]QYN4$]__&RV^T,VVY#-]JG9; O8+EW*_NX#X?#?748-
M3H?O+Z+>3>IB3$!!G9R.M.,9[[?OD!6?PRK2)98?<-<7^.S*53660A3E#K<P
MIW(_8NIBNHG8"@(P9&6@YBQ)XN/?#MI"@:&5'NZ\?[BWMW\7LT2,F-@@#$E8
M,6K3SKYW<8R2/+LJYBA51ALT6@)3JQ98=4"I#_.&$O?0XYW<>7M^].;HKF1L
M7$F/.TZ@X )N[OQ28ZD*US^\I\J%#9L$JQH[3D^DDA@<JHY3=_[@AEWHI#SB
MB9ADGW DF@'NGY,?'\%$X&O_0]'XXPI61?CWHU'VRKP]%- !&.M9L]@*Y]#-
M!0 ;<'#>OG_QYLV+H_=_'+Y)3L_>G;XX>_\_6^+P.2TQ(F7='_W%+QEF?^;3
M%$DM]<V@YP5(6LHYD_B^#C+& "O\>U=+AB?<:YMJ8^6GF>)SDX>)JR=-'50Q
MYL+A?!K*E)9AMMJ[MY7-BK/Z +QSY[*XME@:=E)@_;J9R[E$V>4PDB3?KJG4
M%[@6REU=LC_?#D<D79 ..D.O%/QOE"RRBJHQX)82$R%?*N4+72-\RE562/D_
MY=+:F9 0W303VF,<"7;W75-JI7-5X\PN^*B*22. ,95S'_C.2PZQ;AR5=G62
M=Q418N3+Q:@JSP3&U; ?>1M6[5E0E TN.E:GYYCA,D6PFDGI:GM\/HDOGV53
M23C)< ,6P5B)SU%J#MLQ>]M[4Z<8+27R23 DC*]AS$ T7:6:^.W;;L)6NOP"
M%IZ/8OIKOUP5(RW^_93)T%[9JFG>,*H5,S6G(T74CS[3ZG:\>NGT3[ )?5F>
M_<IGSE7HMH==O4JS.340W!+VPX5.G QY#]0%4!H.2&E C"+T6655U;BI1R_
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MH0$)CE 90%Q^9;)432V"R51@#="B^E8,UR&T6, E1UH!;>0B7<$=A<7Y79R
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MV_"-"0"B.EVV/-4X5<_';O)"%&EQ\00BCE86#LO3RMBI(X8,$>#;:/2::4W
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M0(XO8L_.$?^FES-'IO0##:<E(9+V/ZZ\*E;)G6R9 8N'E8[OLLGU[.1<$BG
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MC((<.EA15GWI%*"^^N:3-N/+9*VQ-@^7T2<+AREHTS5X)"N%XW![9.RJI,V
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M?T\-5<V%%KC7UP48MIBN45LC84MTO%#)(PI/JZN(QTK2>VJQN]!:&*_I$-:
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MJ9C'MP'/.3Q&1@3M?_":8NI8@+DAP51)@0W82A6I78@2O%BDI8<?6Z1_DAL
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MHT\>[W.K(X?V3C5NFQ'F:W-7+G;@7'BN_$TKE&^W*EZ3E*EY,!Z<Y,)MB49
M^54XP99(6^-@6//3M1Z&F]WVYVY91][XQ_?95$97-_4+KWMJ7-9-F>0G>;?T
MD6A6;;?F_@--#HC]_YB+]+ZE-*KL/^YM%+=V0K=TS+;B#^)NQ:?GJ>X +Z#E
MA)$4N36O[]-^/V\AY)=76]/;ZD[1E2XPN[2$:6+_N^!C[.A):RJ7C;H1MS#
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M1-[V-7F>\@5IB^@C#@_(K^SB]$UJJD=Z=^ZA2R^"?;ZFM]C#-H*MK;DZ8,'
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MVBRY=&P7^F8(Y#6KX'B;35^93=,-EJEG0RB?9+1.AVQ6#\SY\A3-)6^#%\U
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MN"35>W!6D).SG@P#HX .G$)6.R<89L6ECB4!Y>2+.=&0XS%A:K[KPD ]>E%
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MN_HQ0#[F1&TCIQKL#:6JL_K1Y)*QF;DYD@^>AT_-#D7TX+&>T/6 O=>V;4;
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M+]-@3Q.2/^'5 C8 R\2*L=1?*9K')9:KSS/8,LD>8)6P:EV;!-[RJ0_V1].
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MR9-_I8QL)S6VR\.Y)_DW7X]Q3W&?]AX:[:Y<!56.J;%A^A]J<LY^E>BJB>$
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M%!VGT->AVZ)/+#&A^!99)R^>$Z:68&QAK@*Y=UE'.9G]T;%0'B2W\PH[VS/
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M<#"*[,$4U^3>]J%@AB:KH$<?+!["R]XS WL.U">C=FO/\F/F>>&M#8>O.K:
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M%Q6"W(MZ+()T*$Y/A<)O*D+,\1G;]U24**HG#BR!!HE/!! S,#<=Y)ZJ%(_
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M@O79IZ.A,.%?W[C/RJ(^>M>.AC9M-* _O(V38!)VUPC$%LSB_O_^QS\FX?Z
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MTJ8T"?P#A8OM6G$UNX^W#[_56],;B*EW9*OP]?P]*%BMBE99JM^$HB;U#VR
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MF-JL R@:2JF7='GTQGDA8]RNL$)S?F.GK1W' K@:L_\1F_V/)BKWB).J3[W
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M4Q>)0.Q)&B<10)/9UB] NM9O1+\7\#&V#&74X0)HZ"\>@9QST=,DWD<3'6@
MR,$#F89L:'[1QC_/,)SCAZQ\4RWXWA4GISE%%I>DK8$#=C^^ OO.7EL1$1HA
M ORK='=%>.B"<PN#A-WVBS<)7U@]ZS>^ D$S17V%S\ALZ4=@'.LU0[\V-GZ*
MK8^9:_V*),K+- ;DQP3$TSE8DO+Q_*?)DU1')=E#7K/TAXE\!1(L=,.(1_&
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M/"!4:RYW[,@=$PX#@#P(OPB5KHP<2,/ 0U%S%;2LW$JX2&PY(+08.6@)]WU
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M08(#+487=K]"^"\CL-KADZD,9J2QM"_7,%X5R5/R4J-4Z3;<20EV*TA#A5U
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M'SH.96A4S$N:3[9A[A.W2=.%/$=MM4M:)8M(YM@$!V2YH$48)\H[D8LLX/Q
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MD 8@7G(Y5C.JF?-8_^*J<"0&&R36-[T C2 ^8A&H$R(-:;@D:$>(R.+YL*L
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M;?W@>'\%R_K -U'T<(- <.6X,'6!U:R8Q=JU*FM8;,3XK.Q.01,O+K":6'V
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M88FW\; T=UZ^T;T3LK:7XN(LV@QB V#7[$I]=';HW2&B)MCU??5\[KGP-CR
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M$QE*3-!15XF*75HR($U&YF6!+A(H'W29GX$&B@J4%TMK)9%6;A*/*!7:N4A
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M/.VO"3ACLT-74@=(M9W-X7LX5K@?B9I_SR/IV/GF^YM:J2YXSR:;_Q)$SOO
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MDZWA>J/.^I"(W:B#_LOD5OO)LU_Q%'I,$/U8QBYYC/?/V+A#,_7WXLIR[B?
MN7^-F\R7MZ8DM^^E)>\;1]^HYVIJ&&_C\#<Y4BR*6!2Q*+(%MY9%D>T??HO.
M@U_CZ'!+P'C2F'"CB[#YJ/ J\)U?X\Q1JKC<05?1GC#4'0?<$FX]$B29.Z^
MY",Z@Q^<BM_(F0CE]EBZQ46+BU^+B[]L%1./F^^T^-::YQ/#IY=!))*%Q:B'
MU&"?%$JMJ2=SWF(E2K(-!7AWD.FC2#+GW7-U=N<=%@F8-2%[YTE:X5W?52\
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MVP3 [30?WD6F^\OI@_!;2W&[K_5VK-9KM=[F<MLFZ#CW3Q!X*R.9@-)[XL]
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MW8BEN,AQ!=@O9K\!",9Y$/KTO7H/G2.^BM2*SCR.0^S2S,OJ VK@THE"$45
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M 2PGP+DDXSC*4\6^/!#IA%C8OATWNMRC'2 S)WR%_5P'LWSFB!G.[3->!Q>
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M=8T?1?4-1_'UCEK#WE[/]?J@O:!G["5X:7HB/I GPO!W.MK5N;59=)M9[L.
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MBW(?P&2MRX98E_L )FMI6DOSKDKNQR2(O& N0IY!-X5/<8C)D[(HGUI8;@T
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MI^4U@"Y($8S.50 PC9RCMN.+!>QO@CF4*_;7:A8RK<"F3Q)X?PH_,*_50 V
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MG;8>*L2P98-F3->WMT;*+@_2>)6H)D)K=-)O'Y3%NL(P7 ZI4FA^)GQ9F1F
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MJ9W33;!N*0FBZAD!^N^Z_MU;O*= N!16@.5SH(A+?"P/R\_7UM;:" )N+QU
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MB>0P> E74Y]'N.Y(^N3/Y L[([RR/6Q0;2/K000WK[&/96#J-?5@2$E1:G[
M7MC814R;Q 'P(YTCY3! O#E,<QD-^CFF(-6.03\ .33>Z8S.T115 Q_5+BK5
M]2C8/-YM][>,0HI==/H_KWE0HL)R&$>XCI-9<(USY@O<QD8A1DIPGDS?R7*&
M<\6U5 I9;K_$+0ME4LDH#C3%AE8<",+?/-70++52D72P*YJA^R1B8XI5$\P>
M!ZZB);YS20YT2B?6EE:\T.3>4![P2/+#+Y=XIA$389D0<APCNZL%QLY_&)Q5
M"1HNR;P4;()1[2>M_:1;B4V0ZV2%#.#LX-P[#!,?-+?$&W9TFQ&E(N.OP)@/
MX/3.E#!HM4:FYZ)2*'TLD,$@WW2:7L8)<T35/")PCG^J^<^,WY#GV*1-%)@X
MGJ*%C9D2^!PW>P2&A]>6R(14]TRSC@;46-$^S71+,G63E3FO;6^R5$9A'MXS
MS_T"[ >3L9YH]&E4"E%DF::L(N0V+*J#;,.R4WJ(??H;V_#,-L@@/FK>&L!J
MHR-@;\YE3"P\W]A.9E_DC<-V&[JY'%\;?R&D: Y!IA+[O<[#".P2XL^J*3-7
M9C(#=T/:*I787/"&T_\"]>)+,9L:W%$#;UY<O]CM@ZZBK[F<O*;W3D&'@O K
M4*0E4T6:^N/;Y0S3$2*OU]<Z3P:3U>X8^.$,C#=7CVFUVP1QJ+N6T*@O$-B8
MXOY1F>S&GD[Y 36+;]?/XRBMR7K0":($KJ0;;0<23LJ,#0S5\$&])[)DB1;Q
MLO1V-,HQ-3)_K\H^R3>>1->3_> >R(*NUO0.4M5-E\+B.O*-2@X2EFXZC.<:
M32/C2R*7&"B!9-017L%R @\.!3><(&5K]1GJ'-K?57<9MU5B'MTJU7@():"X
MMC?[RM4N&>]R5V9@4LBH\.UEBX#.+DIE"6)EN<TPRL^G/-?V3])L;$=EDT^:
MJK0?ZHX$J[J&1QF%U55/V;^>AB 5!#(ID9+N=2W-0*@I$*?<PNEF%4O-@[SK
MRC3/UK-&3@1P.OEHQUZ1^(JJ&T['T9;S!*BDA9Z0@C+.-&3,,E(2@KY1+7:+
M34[H[.6<K'IQ\4VWJ<C:G:]<%#Z,?4)>"NPOE;"_26=-X# =WP\)E^4L"^><
MDY118H.'008#9D/F2)KQY3#N94H]N==-VO1RL:13,(0+I^UNQ++9ND%#PK:<
M6$8&==H,,>>\]:G2@66DCNP(Y'WXG';KYYP/ N^^UJ415#G+AJ)UDER30T*W
M-8] 6!5&G$N4<LZZ\M=I%]YNH=LF/*EL2>[Z-.VD<TA7KP8,GUT=<-)FA,^N
M<^;%3)K^ZT5O^5K_B>Y6JG8&-I2\;JRJL*6DO"EY:]?(/I1&])AK=K'IE+]U
M9-%P5I]2_@MK;YV\=U\M$CE CK@P*^L"0BA*ITQ>:[T_-R5MO-?O 3782U2X
MI -$MZ/0#]7Z^*KUKYFI:1](U(EE!5CZ1*O+F7^[Y*6$NZA%AM.0=NFSTBFB
MG/-3>T=!X"$@%7>D!89%W<9U%0'ULT<T<U^:Y<VW3,OG?9FCHAVLJAP=IS21
MD>2NQ)R4EO//:A NSO,C)8X+*1P6[4LC]7B;Z4]&KB=VH^C'(;^U- 2Z3"$<
MV_7^!?+:"<FJN.I1TSL-TR_>.T&"5T=;X2L59^54NJ,8Z<I$:RV9JQM.#'GG
M=?G;F5\IQ[.0U#;IS"]T!78YX0H7Y @">4R<HU-LA^><D5S<N$+^2HJ2OE-1
MTJH[+L]7K+-Y;AZW17N5ND#7ZIZ)-BL%M*7XNA@1OF_H<S4*JV(LK%0#>4A8
MV"N=#6.RPAVE4 _;+C^?3\.35&@99G.#U*?-/(.@<Z_A$5/CM8&G <\&50:$
M"?Y- 1]WM933$/Y.<R^A@.[LAD1#@;%C<VP55U#*/![,=;ME5=J<, ?NZL2R
M>;_*5LQN=-EZP9F>4>?+>,H+MZ"*,#+/?+33Y@R\X3:]XQ*Z&1!91-X8-('#
M^7*.KV0E^(,,@(,D*IP53I8Z-('B+Y+XVBLP=N;L-^!X*/'AXICSH35<?V<;
M'!EHL&71.VPB[3568%T'Q-Y(:NDR-<XUZQS"$'.8L;%;XWK4-+2!A@2E#'%K
M;E#? ]9E4^DOE:5*#'9)L3'@L\D7F/<>_@O\;@ZZ;QQHY=.Z%&N2JTEN(\GI
M,AOE.UAG*E*E>J+R%]##&03H?'!Z&I+!*93_''U#%^S =+[W'(^9\W5-HS6-
MWH5&KRFA?0KVOFJ@;9*6[J+=:I/ V"(!DD]2$U]-?)N(+V+O_4W!!8+,4-FJ
M=S.NO!T*H9!90@T"N:RYQANLZ6\S\P,BVF.,>D6)#>T"='S&B<P45K[6_72(
M!4A377X:9Y?>R>F!BA*K?VKZJ^GOCL(72$LGM6Y(VP:&AV7^)DP(M)OX82IU
MD'*^F,4W$NDJ]K]X\4(KAA3 N2;PAI2\=C)*Q2WJX;8GIW5:K3HYK4Y.>T!R
M6LV;:]YL>#/G+5QS)8?%G\%0YG5$Z0%.UA<U,2/>.[DQS9\9J;UN?U@3W*-X
MBT(,["+Z"PEWKH%DER85*NF LVHH5<AR^RTB2-4SK#1+MQXMZ\2-ZCE6XYV,
MQH;U5MPARFK":Y&!+K+%$X%<4,613E=PTA;I/G3%79&;N>E]=HW;6SV#G-X0
M.J]6P*PX/@SK\Z_DEPZN0,%+R)VHU$,G''C7VF%60PG)"O@;QS]UL-@VW%P7
MBZU,5'TE8,W%G"I_YR2B\.?,.\5DD256V7.'M?9H.* NWJH$B(H5N0P_P"BG
MDX-Z1;!>48PI?90"W?#^6 8AQ:5T_)HW$.-56)H*VGF<X&+IVA#*'3O'],8E
M=9DS18,6N,C9*4[.<1-C\J?9S84QXSY7&3T86BZ497/9=D/W\.6\X7QN(Y<U
M-G1]]8U.5<R26' I%:<85V7?,7?/^(1TV;FE@X;#+93=[J0"F-HBRU0D"!F3
MR%Y,6;++J[!88:'NQG>$>@[1"J5E;$HD@X?7H?!:2]!:@@]RY#_<TSCGHU+Y
M8HHP<YRA=D/5-+69IIP2Y#B76$]9F40C@JLH[(5WXW6^RKTDQG8A(DJC91A$
M"W)-("-EE,O2B7$1E%-?2[:CD&OIV1$P6\XGH:B-K)K4;XTX,351&LA2=\!2
MQ?CE6M :(E<5S?)") $AV^IJ&\K!WGK;JDPO555^!K!3L09N^361\*1(H8\:
MC ]=0.]UAE@[WVDCUK!)M-985)2?F\@@S#P'MDII9%RZ@-DZN/*YO$94HR_#
M29CIK$YE0U-U@3\3X9S2:I%7T7O(XN'W%*MN='899C[3HQANQ=0U8GB;;Z4Y
M,_-R,AR+FCJW@]9@-C/0P>FI;I#2>7).TSS7FKY2-F\W^9@*=7:G'J;JKH+Y
MM%1\:=NM(%=5E0?H42@K8XD9J<7)$T8*;]PO%=?DN!J:L?/7D'DZ^Q->PCV^
MJF)-G$3:Q&]HHP!=?C1Y_*!K<9WR I-GK:79ACSB1"*,-D8Q5)$Q)F#0P^^6
M3YRCK2CF2A6X<P;&F@.5XL<72NCR% Q8C7G50\?YZ$@ES+_7=;VY4RU N]5D
M@:A1K7 C6%7@/.9J)O[G!8X"F=&'B%F-XIBJ>N1O84G01*T<HO>DE)&OV>N)
M3=A6>(+>*>9:_^U5^ ]M]E*U9E6.7F['3!N7M15G#C"G9N,@&+#P"?& W$>A
MC[YX=\&9ES_1EB&:D"L5/_*8EIDI>&*4,1)\/@BH)1<"@62,3#FY0A'S=H13
M&!FH_5U[X!/X$"Y@MW:;WEOI"\2MMI6YNI+7 WW-MZ!3/*C2M]_U=51O*[^R
M?"19A5!:N=6T7 8A_3@J0KX39]V:</Q,::2#!+7B6S%W[ '3D@2YI.16'#G;
M(ZY$.-,U!32+'&C;TFF@$&!5EX-K8X4UM1;3OK9"\2#P.'76_@3+FI.2M/[@
MODH?G(+N8,K+\T4Y0O53)5.*M4Y;C,45>OERB5D<7>Q1P:^N-J$:3>#[5D5Q
MS;$<FD^NXFWC-%;TH,)JQ)$*:.D"8'AR$-(K1*"AWH2;2*V2IL,2%V4>1?&C
M2 /QI_?++)[ [#[0;=2O*)%6RZ!">2PX9E^L_77=(N3H*E=B6"A76G6MTE*L
M1DFXDAK7CH=?W#<+8D_P>+QUY&W5F1QV$MH#739WA?BO6^=R#UY5(U@^*TOL
MK#(6JMF+ U4L@\=JRVL)N=\IDRQ21+Y@2F!QK/?YW<FA.;FN'8##M]V!#!A;
MF)I^7128P".NZZG-O4WOX_H#=+L2[!3C2U.PNKH.S(6,0NHP^$N)U@[Q'L8"
ML\^X*=8LD5_"K5OB T*,10U.*^ ,U8BJ=L!''Q8C/Z1F]C+PH#JM=IUR4Z?<
M;"4>5$%+R6N!2G#NJ?IZ)3J0_Y5X%AP3+<U#Q.=U^+LA+"HUHTQ-6:X#%"@
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M/=>FI[=D3R'WYQ[ABR2A3!-Y@940E(-77)C\\+#$GY^.'J\(ZZQB,@$BT%'
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M:A#%6&.;<),O1D53!ERN#@=M"5/MJPIU I4#X'Q,,>>P9"YW' .HO:H//3V
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M@7)&4K)0'$G3'$FI@R:/1]/.BIJ8UMR_YOYWY_Y%3XK+:=0E)4RHA#?DG3+
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MM,9B.'_=TA:B*01=Q4L]5SV;>-,0E(KA9KFY@%J+FR:V<ZZ(+/L89[B/!N-
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M,HO]+_AM@,\#RGY%?A6PGBXNE129R0N"D%X@S#QVDY\Q:#M<S[)-K9T:!$(
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M__I+=P3ZW9QPA/!?R>N+M+V02."%]0JC_*LZNSL'NSMAN-OTO"<PH.]Q\$Z
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MI>D7[YT@9J.^Q:_ _),<]5'[?W!TIG]'CU2TZH,*(S.%8*UC@>F ?43JZ2+
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MI%"5/R^3=(F,";C/F?1MD7BWU='LZTPD$P$L;N_3UYF\\0Y\TGLZK=:/8XT
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MT2OTR-OJOUZHZ_Q1-=PQ_)+B"Q<BUK7E_[LS$62EM] /I(= 3H*<=!%.@F;
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M<>A&0Q[*LOJZ=)2J%.KE6);VCJ*T<Y2D/U=?C>*LU5!+0\[2")X:ERAFI_9
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M+PK"&[--?Z4OF;J^V0_EU=:2*(T)))ZV!KNDVPY(@&/S"$OG<?I< MSE:AI
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M#"&HNH@H?A54*@JR;]KS8=AL-]:C/^B7=@F$#,KTB)WV%<F2Y,F4"!E1'"\
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MKXT@^5ZB";:B6%W$XZ5J1J;=M=*AUT90V0T;!89'RAW=7+3[U9-BI4> WE+
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M?AM-9:FF\('4V9!TZ^@,6CJK16Y5;4S>GZ/@)0Q-K_Q0)GBYD1L\-?>-<0!
M/ =5&XPW7&W0M!9"PE,JX2E&XW=%T8_5 +F(=/Z1=1,"9[O^B%=/C-P7"A'H
M$.B0.BF6O4K_S)<V&7_I.!_6 ]_]1DH\2)7FPJ_T5E%;!2?Q) -F+'6HOO"J
M4B4Q\_\^E6]HEHD)5<IK:%VPF\O=[:"U"^)*NK; 02):>!8##'<E6_Y58-V"
MR(N6%B^B[]<F_D/5-EI>];*?XW&9<6RX5K<7=D5B9R1_=7L*"%Z7NW^E[+@?
M5$=C.*PZ4"8V@BD%DZYDI90E/GUF, K0&(E?DQ9Q%G'V8TRXWS32&:2G(E2_
M[>/4\G3?A0_LQ:/*?!"?;2!*/7O44&/-7TX.OV?F78[WIQ.[621#N^O=E(-G
M8B@=4AI3GSY3., 8GD0S+V+Q1V7Q&$9J\O2&J 9>8M;P@;)\*W*=C3DV03P.
M?9E?[:V9_[IQO2<IVPKWLWU\Y*NR--XNZEIUZ'J;3"PS"649C"-HC"59Q%K$
MVOMA[81R=_QJPFSD006>B&F[XS0.OVF.//:,VD&K1Z8S6*S44>-X)$T_(QR7
MSI$8(!B,8:B_(USN-I2]5?;_Q]&W/HQ*EPW#!:^%+V8X-T].)T>QVSR9Y:6,
M>IRM$%"*#92[3B,A."$X(3@5&$YH&D- 04!!0$% R9%%$% 04-[$(J\>T:O%
M@9I>1\&5+*3'*Q/_:X"/?YVP_!; /G-R"5+NG,?[R4CFX\GTIZ.$?1A=\G1=
M/PQ_%"#<:6J#J2C$PIF=S8@<C90#]$<*FT7D<0:C2 (CP<T*%L1!Q,'<<%#9
M+VK:."(L<<>JL4)3[86V^>DRDF?3YQ#$L![.XKISZLAQ;.T6#%?)Z,.]D#X?
M><_=C[&4E2"4OCM+JF1G;Z?85;#W%)K/ 0X+HC5S;JE\3'TY-]*'A=-=QV41
MZ!#H$.@0Z-#$B>#T[I9"<$)P0G#*/YQR'6I^_CZ.=; YE^/9SI'=,>D)A\:^
M2M"CGPV?/?5A=3](7H57C8, >OII$JA>>+&;X!G9=YOLZ05C'8=1^GA]& W,
MB7H<^D'VBR@*;"V.TKV@$W^H)I>);D3EPK$^K]J$)<AJZ'7V%MW82=!2N&QG
M"$-C+,_?V-V%' )R"&A^07#*%9P*G49Y[WF@VEWW]YPIG4"#J,ZGVY-WKO.C
M=![@GC\/H+T/V:_%(PQT.X1II\.L=5S)WZ8&"TO_[/L1+/%%R@C?4^KE@WBX
M%[0K?%T1?=T9#:Y7OC@6?%=,C(![JAJ:Y/%7NA>FU[XT+TQN/7F!P^1%^,:E
MJ6'VR\&%:H\<O-7C<+S8G,6!?VZ(,V#4N]W(\+V3I?!ICT.2P@  ;RYY\X3$
M? B2/%FD .KC[8GYXIV6U[2<JIL8/I>5!'UB!GI_RXF=SC)B#GT%S!>'A)7)
M0O2Z.4&!"'G729FBT[9X9;((3@A.2"[DR2((* @H'U-7_KA?W62\)(0A2!:A
M.[K'2O;J/(V)G\Z4O(;&;$FN21K"X@P&M?! GN1A,P;IRB]M9X=S&,-?-]1!
M%$441;X< 04!!0'E3B?]UTUEO<9$O:9A/"Z+YDHF^HK+S"?"N#8=I1,UETW4
M['-BM&B?T%, R^+E94U-C)_M%H)>F &DV*GX>TI5Y0"%!9G]<FZI?$R(.3?2
MAX7370=S$>@0Z!#H$.C0Q(G@].Z60G"ZCUA%?A,47TMPPXG_Q =G"^]LW5W]
M9MD]ALDSA EP)!CL;1U> B9CJ/N6EUTEBYW<").P,CC5K#T%''4\4G!]8M3K
MK*#@X'(^#XYC+(ZC_1N(^6@B07!"<,JCI1"<[D.7O&X.Y1VT1(P?S\=C=;V7
M=S0-+5^>&T'EHB6X%V@)M <H^[6@ZP',<.>;*8XR&V@;6 J@ :&;[L8J;0-H
MPB#YP6674%B*_.S7;I8?*^W3%U6@7/%=I5_\P(#!XX?CVV,I]#>V4?H'R/XK
MO'-$E0B_:V)%0,H9D.X[^HW@AN"&X/9QX8:F200D!*1B .FE%LOY:0V_,]<R
M21;)?J &I\L=?5EM3_SQEP5T%NCX&DBYE3[IS9O!EIM+CGT^MS=@T,1K"T'!
M\2Q]0E ,AG,W#WQ%+$8L1M,! A("$@)2_H"4>UWQNKF2U]$"9W &,ZI6WLB-
MI;GL3#U7DGM6I@6XEVB!C[SI1'L*8]GWA\N':?[&2 97U(WJZ;"DAFF&I ;U
M3":62!PKI1CY[[^UHJ: 7SD/<F6[O)77?N\:R<0U&GZ<YK?RZ!MO3K(OP>T;
M-&$30F5@OF9SI\J)''G#P-B(ZKQRMMCVT!5FO])U+7N6RY:^&ZYS6U_O^=T)
M:G)5G>U&EJXSE9.5/E"ZJY[&<)[$<)*YD3LN+,=?84Y^">@>-<VKV L1^45$
M?J[H>0<6OWA7[BIY=!B$EQNY=49?F>X,S "TY5VY(54'Q'H]ZV5,IA(F8S1^
MJPEL84G\UJD9-'/?Z?+XOF"*4(E0B110\:#W:P9]]:#/+^J?,=2AO4_K(L-Z
MX+O?R)4'.332MQ5_X7=78MQ;PXJS]#5]\;IRR'[J[&*1[E8F>_.\D =M^FA/
M:B<BE(3T87&0"".>Q0!S\^3BPFHC1._W-NB]+7!^G!Z&<3G6=NN3"AI+=CUF
M&FLV=@]ONMBQ.MNX1JK;*B#F_C)FMPVEOS]DI$XWSV$LQV,T1=S3B@>QNM@&
MS=ND_?Q3TYQ0'GGSQBITH+.GN['1BY:'7^L%^NS96YM:<+KSQ @,5H/*>3Q6
M#WKM0O2TMSQ%81Q_,[6#>(YXCGB>B?-(39[>$-7 2\P:/I":')S5CE01&+'3
MVL!*"S9QL?>ZD_;3I&8,>[4\#T-QX+>]+EPM^IO:19(SR>Q-8@3-88"B$:\1
MKW-CT+?G=<@Y)]R:T2+8D1.A41O[]?'TUUIY/IN2\G!GP=8Y\.4&J42PTE@3
MJ_*%DMRGSW2R2 8<QE/7B<"_4!)M(<U^W8=1:>.'88&*N^YI"VB>O$Z.HLQY
M,DL^2@/S9)&/ 92[SH@A."$X(3@5&$YH&D- 04!!0$% R9%%$% 04 JY>8H
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M$.@0Z!#H$.@0Z!#H$.@0Z!#H$.@0Z-[\^)E?BYX_?\=.N-@O^C P)^*N3$2
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M6?*#Y+/4X'3)U(4)  T8E+8PR%"0#K*3O[PHW46VW217?:L<7AXJ'HKI W,
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M5DHA\]]_:P6N4?II;EX9[7W=XG<^D$Q\H.''V@;FT@G>G)E?@LXWV/,FA,K
M?,UT7,@:SE*K=-MRU65WYN+ 6(9[^(434K-GN;2KO[4?IKOJ'9R>O@([>]&?
MA%6B'K"C[&D^?:89C&"I=%/,C6A1D=G[>E,MHG/^Z?Q<C?,.7'[QN1.7T'-X
MN9$;?!:(ICYCUA47=+:!LV^ S@+O'](GHA(^8PQQZW0)1&5$Y5=>GKR(QV]0
M0_>+7+ZUD?5<TQ<ZR4X8,3ZK6MOESRVU\7HS\Y,KF/*F?.Y49M8&G$(PFFZG
M;E<"&:699 %#8>!V#W!$:D3J(I#Z-\W./\?H7YZ?GV2UN> [5'1J>@Z,JKM#
ME8G%+I\);^[39P;G,0;0B-:(UCF4W5^BW0B+"(MH"?CLT@#8X(:^W\<#<7:@
MVENC3+,^^\;+P:@FG0+NK,LQ6UF,&TW)FM:L].G2I#]),AC@>8PG48 'L1L)
MR!]S6]=C-]XD0XU!M()!.BR *^B%]AZV/-UWX0//N0U;!>OFBA#+U@0W:JP(
M:OZO'3?Z;%EY; FMQJCJ+\7=6!\:1QH?\4XF*W$J62V2&,_=;&B!R([(CLC^
M3=5OI"9/;XAJX"5F#1^8W1NP528ZM<?RP-GCK=%ZQ>"GW\1LV6^&K,IWEP J
M884@*T[-Y[(P$,Y\^HRS',:1)$;0-S=&(7HC>M^Y4C^R\X8SISN4R,3T6,#[
MC%$KORXW_TK)<!R/@-44>,<=*:W&^B#--].+NDZ["=(,1M,<QN+DWZCKK+KD
MWU&ZR> U6 2N7B[.?U?U ;XK^?@K:[XG!4X\GQ5O>>L77.K)[</@NX<AF>L"
MEO2F'T Z6<&2JB?J++G+4T*AA\81Z8'?R2/;R>6L0-V4MFIP.;M@!4.8 BVK
M!4O%7LFT/=73[610^#AWA'^\TO,^I[:$^X%S^Y9C+WU)AAUN-^HIQ27\SZL]
M ;A^&S]Z@.PBX);+N#++<UVS8>\__S?YZ_%S] U4@]0GK_[B[\GT<Q^F-@#^
M[^M,8<]$\(.)".IQ$OMBHWJ9_N8YLK__W__GV^?Y6LI8UOV-'_SY.%]\\Z /
M'TYD4X<%RUH 5:>LFLE'_ZEN#NHI?'AP'OS!XX]ST9]?YIS4-"7J#YK^OZ6O
M7Z8&NK*NJQ[+W]CPNWHS^@^.^_JC;$YY_)D?9H&2/P.8K*B2!51Z[>^NFKVH
MR-_^2>!_,+_K/?T%N.37M_)?M;0*TGGG'Y-!]2:0TZ\3+B7SR^8[,#_\*/%$
MJ7]/?4PUG<82)_(%M>ISD/N]F6_93\WF)873<=*@.5KA5=94* 80BDJ04"$,
M0$((34AI\-/E4U_'C']#W1_A_]'27T6%4!,:8E_\__Z!,^ _K7[UXFDOCU8=
M]*5!MU43)F)-FB1_]\3^1!K4JX+4K'<',TGA29+@0'Z?[MLG*'U]A-*@7DH?
MHI0]Q2O.I;]V\ZDW&HQ+D^;#ZUB(PE@JB?U:<O,UL2KV*N+X\IM+42?.9Z6=
MH"3T:P\UGF^L"FYK@*=GFNLZ])?HFT>"&:Q* MQ(T 9TA2(@KZ@:3RJLKJH
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MG^<P8/$%,[RM-80/L 5UA/60RY]M3T!V&LW%E-K=94^_;75&U\YYK3/X#$\
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M3)W2J/C:YXNLGH,:HQ)K4>_X0FJ5:FE6K7W7*CTV]<JL67"ODH7648@=O"-
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M+08-I3ENK\V^7$,*N^\H:2GSN0$:1;Y3D++QESTNL"URY))PYI0TBL&]"77
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M+_6@"8:H4<,\^)=GB)8.3(8QJ)Z[0:4[:!1>XAS&OUCC*"-N=,.>H=K/AD9
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M!<R%G"^(A<O+8,V6/59,YOUT@CC*=L,/% HQ=(P>W@C_096&/2_7_)?!G;&
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MYZ66R!B60HQM6,/(L\F.>!OI9Z;Q1:??Y=<*F#2]<Z$!(+28 &L2&ZK70%#
M03N/5;QJ V%!E@51);O: I/U\UUSX(FA!'P !H' <2' W"9M_':?Z3-CA>=V
M?!"*<&,41N'&P,];2I]).WD)!G6OP\76.QC4_QY<;GHT%7(D@A-1LUSV^TM"
M<\MQF!8<AP.S7L_/5O),GN4?93<Y35K3\?B/?^6SS [/X;M!"DY @ZC"AWPR
M[\B2_[R32:)1+R$G$H-IPUI?V^?HJ6G;>3B9[&><#*']@SZ<MZ?L?R+97*M7
M=BX]SDP?T4-J5<("#^;^-W:6_)3#"?G"MZ*]-MBJ]LI;HRUCB_F^\1S&^A/B
M)PY0%X7L558V;5?V:-Z#Z!C0!7=J;GNM9U=9D> RDYJ\/"Q2&*ZKK*B51S-(
M6?Q3Z#5>J^&5PI,'M 4O@Z@,LIW(\UC#H'HP3.7[DZE_XB7ARX?TI>]7YDV2
M>HJ(%-K<:Q5VGBXZ\?5TK<F=3B]]VZETQGIR1W6TW<\=49(D!<.!7)30Q= (
M1D-Q')8_O1EQ"?XV0%ND4ZV95S-D]3$A8,<4+#?RK>A9H0F1)#^#5=0D>O/F
M.-05Q;7O()-&T%Z)^\/Y(2DLLLA:FL@FN6X0?<BN<&PAX)J@'J<-%LI'?^"5
M/2/2D T&FZ,QT]@"M$FUPKF'60;9XYSR'35X5AB#O.22+UPID_J3S\+#W7TF
M%11 "TI68;9A6C-,>88^(L#4A#EXQ@7K,3]BP:>DQ#1;@._[9><V1/BT3<'+
M'%YG3OX3)IG!'1 'M=#%7GA%"\+U!7#":>]"D#,IOWF>SD8&'[@W1S0CD7 H
M2'-3,8.BT2BAHG4T^)%[0YE1!E@F7+CM" SVU_X;!7S%3@%?IX"O7Q+PE7I3
MP%=Z_QS/2O%#$(QY"%DAPLX(1.06,]L0>0ZM*TQN"TU@@P%G%B]Y2$0UB>3&
M*XO"*EF]0Z'$8Z#=BS6H19G*9N3^.XNHIA*)2F-^*.)%(C<'%)/"BQ6":<ZD
M G=>;OSB)\(35]2$5$19DSLMX>-F H1N^DE5W+0)[]86+LA\%QH/-^<%'H-M
MTUT+0HP(.(='2&LLTAV*J](R)K3&RH9 $(092R:'&@3T*IGJ[0%H^-HL\]ES
MHJO9+75^;?Q#02R07"4VQ_,UFY)][<HIR6JI-.O?UXQ1OS_L9<9'H4"']LH-
MK+^@8M[?!Z)5/[-"E@A&2Q&PU-R@RB\8:^XZ['YF#@*%)TY0 S7(Y!"O!E@!
M7W(O$BH8C%;\ICST9G ;3 /NR#4^2T)82\X$$S9T1D"V7WS<M?6AYQ<N%Y_
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M9+83^5FN]^$E;/\:<)GK[J ]GH[<GC[H+*U,]B;U>)?_X]]X)!Y/1)*YQ#;
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MH?:=$,2+_US$R^Z"X-X@R-TP'>YJA$I "*TH:*JI-?KO?X8">$X4>*+ (Z)
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MRPF\+/R,> ,6I5\]!ZF:HD[PJ/::W'T9"I;3BFOAC_ZEV(<1VJG-SGMUIP/
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M.;:JN*YN6Z*9 ,];Z[*24)4KM8V"C!-7S[[71KX#TKFGZK\;7':!Z<]3#B@
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MCO'O+DUY%>R;6G4:9)Q45^@&]4Y5-II!4$%>+D'?AVGTIV%D(LCE"945Z\;
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MRE@UUYRF0EPK:+,K#45_JZA:KK:LXN48F0]7%6I>;FG],6Q"^J*H@N:C'-5
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MMH:U]*C:,D0I9>4W[1(S9^%8L'0RD\F ?^?YVH=#2N4T612U23OI%R>;BNC
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M#*_;[/D,;AXX@M#-V\=L$_AAH+LBRK/]*O#/>G3?X]DZJ^2Q.N;\3R<57N>
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M'L862CQ#<GP,;91&#&8Z>*SN(1/LU&G?BUA%!M]">8Y())_Q540S:WC!V%4
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M-J)U7!Z]]6^ *1-X[6ND)X"&5YP MH\""P I+0"&4' 0FH[*9JE8KN+^$P5
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M(I8GHW(<^IA7V:-CIQ\/P=_GL[1 ?>Y"U_MT^[$=Z\&>NAN"XV091G-0N :
MY"E&[IX*]Z8FQ+<+;-+M%MBH%D(4I+:=C7PT45&8)VJ9Z\X4&)62%%GT720D
MPMTSD4>JH2NV9V2.$"]'5W"C,)QXH"I V@"]SUE>\+&.;0(;ZT%[.%X:VA,[
M-'B 'Z<K:XB,7U#Y"[3] E7ORWA[ -# /FO#:K0\@,F^PNN?9Y*'N]0T'$.
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M+4QARFF==E;""K^6V_:FDIR*L'+;1'.RY<->H<A)W8XP4K0)&Y6RLDD<OV$
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M->LMOM'E>N5FXY,D]],=-JU$PUXC/HBLAS3B!3J)N&4OK\2IO?2@.$RX$)E
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MR?7'%LF6*E!%$,EX)IEZ]1G?A9PFB* -F$Q3H!?F.D5NQO2Z^_,0N]+"X1O
M$HD(EAC!$M\ 2V2])L"52B4U7FM40UX=*+LC\/5.:VU/T64RZ&W^R-ERD!#U
M\DS#$IS!-M;M_HY,=*=$>"2'9=<EKO6(8PD[ER=+C;T\T6PP,AMZ)E J6SI#
MM;!5Q=)2%=%*488-]'+J?.2C4E_,6[/2&JN;EMJ7MM5N.4F!D:&WD^L,U4YF
M#@QF)9=T CC(IKZ#SPR]/5LCU@-#L6S&JM0'*2N_8>M9:IH*OSU)LCA+K>4N
MEA@W:XS:DP^C)!P9>ON!2[>DB23R6'VP$:2D-"IPM A&AMZ^JV@[P>KJ,WED
MMQX'&3U'M0LV& FO'3@=FI_4E_.5T.[397M2J*QFCR(.MBD-;\\['4ECI) Y
MY)H:MBJEM4X]5>JE,Q08&5I2;C7=3D=9<HH1_7&MFV>R_+K9!2-#2VIT-ZEY
M@LI.9%(<5HLI7J\L%?CVT))(C.*:*:E!T\2AA+,#"I]):Q&,#"]IF]GG4]SC
M=(NMBML#T1[)<^Q@3\GPDM1M_4",Z*7&M%-B(5UL%5*9K@A&AI:TZFZS4K54
MJ,L2H9:-R32GJBTX,K2DO9B9I3-,0Y/[XWIC.'SLV 6# B-#2\(&N?5$+F,X
MUE87XJ9PJ SY AP97E+6-C:[72.5E"6V@'62AQV?F8K33'BBQFS9%-I5=8VQ
MHHRWE<8CMY5L,#(T435-RMW4>J-BEMJ9YMK]0U-M=Z?9\#/7M7:SS33J>5I*
M-FV=Z3]V"ST;C RSZ'++9:3<3L:L2;V$+5M*T6K"9X86SW/S29LM%"AFA64?
M&[UIL?W8@2/#BQ=VN;ZFXF1*ENQ^8Y:?<OT4)TYST]#(U2J?+G4,PF#*HQK5
M$S)+VZBC^W)#0P?)7(; 5MR!+O0GVT1-K B2*<*AH:F.\$)QCJ^*&6R4RI:%
MW7AR8&HVNH4W]%A12]6SV9% ,<*LQPPQJCVBRJCQ>6BHG5X(.7/=K<FKS)I0
M-)/+]:FN>XG/Z5!9S;$5D]TPF+!;I)?%S&39WU'>/2*G8UM*AMI10L7$"%(E
M-YQ\T'HL!:.8T-#"JKV:S)NI.FVM5^9AFU?6%BG"H:$9Z-9"3"GSQ*-, ']J
M)+!"EBG;<&AX!IFM4K$3%#%@RMQ6?332=7;+@(4EPS.8'J3!=-TB-C2[.N0.
MF*BGVG4*UJR%AA+RI+^F:K1-$_)8&VL9KE+?V'!H:+*#'2]WAN1C&EME&('>
MZ]-RJX^&AB?;2PA$K97:\S21[*[SC_-D1Q[:L+PK-+1<Z^3S0UG8,GU-+"6)
M:6ENET4X-#0#,S'HJ,M>HB07&O*FR4T&?'6&GAJ> ==L==A^3B6Q57\D*20[
M[>0E$88/8?[6L\9C'L@^S1+]5%DETHL,1L&AH1G,AZUDCRE69AB;6:MSHU8K
MM99=.#0\ TG95K-DW:HR[0-K;"=YOK6%W?HSX1ET$XE)CDQJ19J=C9AA<5?N
MSZ=@:/:"A#U.],DPVT@R>ZID@T!\3,OP3HT+RJ!:E5G16 \-VMI7TGQN12C9
M.AH:GJR=L^C5*)E4&(N::PDR.V<%X"O@%]1!7=> OY&="0S9[=F[LB!7EB(:
M&B98;S/K-23-E.MR2ZO,!L6,6$5#PS-@1)I-='M8#V/9=GHJ&$72&%$@V O/
M8&NL<NDQ,1@R^VR_3$_FU:9204/#"G%5+.VI?(.@"^W,O-W<UAZ9*AH:G@$Q
MY!^W"5(>8$*N@P]5KJE5P,*("UIF@6/@N8]92=X;W>5HMLG2'6!AB0OJH$(5
MQ@/9G&WH<K:>!LJ1G9# P!,7Y+:=+;1+^++78RQ^4MX)'5S9#<'0H]R^OCB%
M>%5Q2O(NBE,N [TPMWT+S)RS*TT5497 \=SH B0#-B=X7Y2P4[&(G50L.HAP
M_ZZ?/@@+61"'G]SS QL1'.LV*)4/9!F.GWMG.Y-N,_68S@&EEQN)3*%KTJ;V
M!9+@S<. MZK)M($1H[2ZJ68:MK%&1X=X)AO/8MEPA@&2^/WI=:DWRPWII1PX
M2YN(71XK%]-:TUBF>&S_!=)!0WN\J,VQ=%5ND[@]+R196Q 1O5+9Y&5ZG8J>
MVW$#GH^]NN'&>7Z1 L+MM&&Z+-[NNZXU*GKXD,:97AF6"VL+'YH&(-047)ID
M[E&J(-P[,Z,T,JML1YXPPB1C=])6'^LMJ7?HA@DOE5E)JJ><L8>GNY8>?QE6
MZWXCZS=<*X,:./MI+Z='-:<I"KLVA%_>/X+SAC;#?3-,F'!.HL6; ,I)0;R
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M"N.%A$E8,E46U'1CV1.GR?#(+J.SULQXE.0]J;6H,MG+[;;V%!6=G(Y41^:
MYO-4FY;*FI7K;H;Y^0(^DSP?J2WSE70I<<#H0E'I5NL4:T\>[6EJBIV/M,1#
M6T]-%(IIIS(*/J<*0T;L3E/A>3Y6-T)BG+,4>K^H+%KUYF)DDG!D:)[KT4(K
M#:4U1[,U,L?7"752VXK35'B>*>"PYU)VM8QMTN)D( \,9=41I^GP//LB7\XF
M=M* WC!V<IX]\*V]9$_)\$AFTBJMJ4&]A;6K]4PWL=ET"V"7R/"*9LG'P3HW
MTBBL/LKW]WV#PKDI?&9H18K6RDWX'=ZER9Q8865@UJ5<%XP,K8BS^TMI8/=+
M=-LT&WC>7M4/+#7-A.>YLO'ZH%#B,K1@KC-@:)+LVS88&9KG4,P6YXU$(RE;
M>74TS6. [1(B&!F:9W9C8(-J>\IA?6X\EO-%NMO$NV!D:)[\9KG9,,,R)==S
MY5YOOMX]5OOV-!N>)[G7R\D]M:E@1%E<S!/E0\+J790._K%:YIM8=\ (I6D!
M)R62V,L7I4,K[M21@L^R='FN]1\;P^YJL8<C0RNJ4B)ISXM)7F:%3FK5V/!;
M:4M-B?"*5#Y#L,LQEI-7Z7U*H:;ZO,51ER1N72&9P30S6]$"7L>TWG"73.[$
M2Q*W7 MIL=-(8G1?9;MB*F4P:8VZ)''M)B<FJ,EDQVS4Y'#09$R*W5&7)&XK
MRNN!WNLUF)6AF-OE83CL,!=YWNYDYY2:H?HTV1_JHW&R.I--*L#S9];<^=UL
M*NY7^CPSWFV8_F.133RRN;K&B5,X-/G.5OMRZ.(ED8_>/0A'G!Z0GL=T)3M_
MZB(B[PAZ0L -AP[Q7%,4S39^(7-P^V#\+ _&+03>4H3V_#)6(Y@*&7HA%75<
M,K)G S"GO (&_O"(51(,LFU*V(+NYZ3QK#O*-J<]^P?8&(Y=@]>;NB5\#-'>
MZ\3).<KQO#'GP!5X8@J[-H1?WC^",X7,XTX2VG'.L?^>.XI<)=8R->\#QU%"
MGYRX4X%#6W=,V(,U=6]BWJXX*W_9G3\DCE#&UP^) \Y)X/DPLI@#QO5VS?L[
M 8^G?SF^IPWVZ5FWSR4&>K$WE)T9()(SA9M[@#<[]/^C,_^CE__.*(F(=/=+
MNDCLOB[M(K'[LJ2+Q.[KTBX2NR]+NDCL/IMVK[P*]-FPX'[V*>L=G :/23\)
MD?MU<,OOLVL@%(8?_M^/](\W[F R\X"];]UT]AG,\NEYS>4]G9U,(KB%/WZ7
M-!>Q<PDX^)__G;VIS#P2RD@H/UTH/['2X+V%-H2U\R[:BL3U^XGKQ:J5IW;-
M88;P?V^Q6ORSNSR\MVA!2/JI'$6L$;&&RQJPB#!BC8@U+K$&?@OK>P]]T9_:
MA)YDR,B$YOZ-0(@2W#9XJ2!$(W[5OG%O%)4;"L8=K/>5PO"R8HRUI0O3U4AN
MJ\*XBS%M8;*MB(^'P[A/W;I&+/41;5O\6IH R@"*1 G(0M45A1Z0A*:D2BMK
MY==G)(@ HG^ J[MEELBIV$9NU^?]Q6-J+-@_?N,/%VX!_%<L\=*:X[]VL]G=
M]<V6NZGJC*DGYO1HE%Z,9FH_D=N)J'PB7)[WKZ^JP;Y#>X!(%]ZLH/.^Q/,I
M79B9X;.5N.@GF8V=37?X?#)-4A3L_4Y^BB[\\IO]E"XLYG9SL9UN*)@UJ^XK
ME7'CL<:AS<Y&NC#2A5]!%[Z^\/J^Q/,I75@TI<?<P-C5Z$U:'Q8F1$8RAR+T
M"_'PS;,?H0N_^F8_I0NW96TUJHXMBK%F&E^K47B=/" GG RW3OS76\+ZJ^T!
MWS_/_NJ MGA2L?>=\UNW4\Y_MR9^0]#X(8U5+RD'[^I$C\NA<@AIA0$W+>DZ
MHRHJ)V#","$9'7*XTS;4- WK6<*-JV[G($7>4"1P[Q&9W+W 2<U5<:_0IHJM
MDL0Z4=R6R5++!@*7B@0N$KC/%KCW:4_\J0*7L4N-C-Q>9&BRUZP3T]G2L*I=
M('#D,P+W/4^SZ' ;DAC:_Z^:^_ATI_@>UGM76N0-?G+RL[7(T)>&9W,665PO
MZ?;CJHUM\NE1EY\>6-KN_OA-9A["S?GN\RSKTY7VV78_E;7 K&E-ZHKB@6'7
M]D)?F$1#W8H_?F?PA_?TEZ(,;J0//R^,^4KZ4%DIA;1J+D@FT2P1*9LDQ01M
M P$E'BX<L=SE>=:];?=3^I Q&AE\D=WP]'[)-PLSL;7&^L#\9)(/X=O>(WT8
MZ</[TX>OCS+O34"?Q#IMJ'&R4BC5Z+T\4K2ZGF+J(H4$]*N<:=W;=C^E#TFR
MD>_FZ*V!"=F9*L]S0V&?@_HP?<D=O^=2D3?$\F?=/+]$MO#3 _8OK7UO<@W9
M&T)&_-VO(;NL#QP.;[H,?JYX@TW DQLV2],;:LY8^U*U8XT+FUJ["V&/1+AG
M_G-:]R_?YC.%&]SF1[.ZV=3M?8+9*W1-9?J#03EOPVV.+D/];%<STFQO<';N
M1.2>T&R#/47Q8W9O8J36RDFRFIJ72Y^JV=X08]_)-C^AV98[>I\K*=(:8W.S
MG%#LC1MZ.=)LD6:+--M[:39CDU7;>*$_DQ.[%E8WU(V0[%*?JMF^[#8_H=EV
M37Q=KS47*88MY4N#OMQ=:+KXG&;[G@?@@;M6T44+7S5#^NEA]#UDA-^DI5_0
MO?G%D=N%JY1@OS-#4&]VP]E3>;+3VX*5X8PTYY+)8WN=>>STU,.V-1:G6=2<
M_,G+@G$LAEH@O?=]P?? ,U_3 ;J'G7LO:7MQ-'%7TG:@,H.T*=L5N5\DQ@V1
M7G;F-KS<(!5)6R1M=RQM?W!-X.=)VYP>IK<8T5QAJQ*7VE))V]A/ND#:R)M)
M6W09]RVOXD 78CYWT:D1O O3N?'ZE5<Y!VYR_MS[.EYT6R8%IL:A?[7GY_=A
MPILRC?#5'>*"JA0,:<EC([$^GAU&4\42Q>CJCB]Q=4?F@4Q%796_9D?LARP1
MD>Y+DB[[@$=]Z+\FZ2*I^[*DRSTDR8AT7Y)TD=1]6=)%4O?9I'OM,=ES,<']
M[-.=]1Q_4D5]]UV[P14!V$.:^-8=B:_<Z^'\\S25%$OB\3]K7AR)\5V*\44>
M^Z0>X$X<^HT%[K87!_P]C.$X;=^:,6YY;4#$&-^),?[PTH#([MZE%'W+77LN
MD7SWXL;T_^>KJ.%OR4#/96<B!HH8Z"]CH+?9^WL'5_<$0V!U;H'@*+RP%11M
M#5%./M#E9A)T[SMQZ^CY#I8;$ >$$PFN/WF^_I>V<X!E*CF]7U>2Z>I.;E>Y
MS,Q<%=CR0'Q=3;&+1)I654Y;">#Q)D+<-5R<$;63#'^,QZ64RA>//$H[+-I$
MB;'IBFZ.D\O=($\+G;)$<*G"*"/8P7H7[!7=(5S D\!?QD.YKSXO6AEPTZQ0
M4[AF)VLS";7<V38&@Q5N=*<IB&5/8:DX282[?T4R]L9X\PZ6>T\R%L*CWUK&
MZA8Q'YN)1YG9=XE:6<-:?+G]\3*6D*GUQC93"D.LR,ZR,D@W]*P-9"SUXS<9
M3V6(.';AEI1(RB(INXF4G2-N;RUE!]X0#CG1',AE7K4;K>RTM9A\O)391%5Y
M;+22.4;2AQ4A+='U6I("4D;^^(TGX^DL$<^DR!O68;Y_ANS5HD3Q*TF5#%-'
M&(+;.\5WM=CO<WYT_TKDC]SALJ *.JL '7+*GZ=J!%\1F379Q51ZGZ;%^E[M
M;^G6QZN19<)4&HOT;D&S0[NZ,^=22DQVG9LZ""P3QW+A[G*1?-WW:<O]R]<?
MN<(ODZ\=PXS7O65M1F_JAWK:4C1V+70_7+Z2"W[<D>F<0.^)=*M5D+KY">Y>
MS)&,D^E,/)5^KSXPD83]Q1+V)V[PRR0LC[%,LU&NSS%IT)W6VS;.-8N?$&ZN
M1F0G)65TK,ZE2/; VU2Q8#LW<:2!_2+C.3S<]N6[9XX#A9+N+?-/E$M&L??-
MLLBG2BD)E!*O6; 0,=)*;VM=^2$Z1%.VN6RRU&W+;-I()]B$H)DZ-26A%TSB
M>#QSX=[02&ANEK"*A.;&71$_)G0<B8-=9Y:FF79JPM&S@6!-32@T*=@=(8X3
MN7@Z%<E-)#?WX@(_WW/O0^2F12UZ2K9'ZAC8.B(]9M*C_1S*#<S<9N-D)@?B
MPF<[Z$4=16[34819QTP--@B)\8"8,6V._BT9AL6JG/\W8#,47$)ZQ^:2"KZ3
MH'_MA5&&UV8$-86)A:M"4%>1.(A05T)LK6M ?GG#>[AAS0Q.EU"?FAC'KB7H
MNK,ZV#15C,UU;85&"5Y;?O"KK6# B2#W/J8Y#6YBLWV, XJ%E8!C[W8-@8U0
M5N #,%:S3 ,*%'PF1),8%H25K( ^,6,V:X!)"08$Y?"PV4EP1JB9BB!M(;O%
M8RR2.!UX2!L+7O(W8Q5GG]3P/GG?&0M! #O$H@6'NJZ@C0&Z#TS'=E\-G@VF
MHNQCAF":"G@26!*4X ='!@#'PTE(JL4ZDO'I/'\&%WN["+QW8YD"['L"S 8*
MYP.=E(J2P2F:8>E"N%7,:*AKA5Z]S--]S,HS.8XKXSNWW2F@@<!3YA/CIG 8
M_DZ-94+(L! -SPPTI(5K?7#L(59H-QI4OMVC!M5V*T;U>E2K3#?IUJ!_0X7D
M_ D?] M*ML2]9I9E"S"-&NNSZA+\OPX0^!7P#RSD/C@B5- >XLZ_&B;_$&M(
M'+0[,4K4!43:3U*MYPNIJF>B#^*_;!PIC3+P:M8QA A$L@[T\4_I'V<4U#<^
MRP(EPWK+BOV$/X4B1&#_=K>GK M \>BQP@)HZ.,.H$'XO_\!+V--\#S@?AEG
M8VW)7,1>O=<_3U[OOP:J5T\3 XTGF8Y6DW@)*'6PX3_AD@0.BJ"RCY^MH<,"
MWU P3A[V4WK3=O3:H] F@!W71 &,U9TUPU\]O7L.C=PG0Z)YX_T1QL4-AK_2
M!1%9$ V]$'Q[_A8T!^=Y#[&.I4.K:WH&^27S<GA'<9B>1Q_!<<"60482T#[#
MGKS YJX!2?8Q7@+F#-H65'H.?Z(!H[;25,U8 T=O#M0NF((TT_@]^!3\W +^
M-%K7##"ZX<VM4TPT\)@)V%TXW7OGBXZN+<%KO(V)@\EPBH6,[YJ%;:5BR#TV
MXMZ?['H-%N$0U?D*4=X4N(6J*9H(^<;)X/F6%IA^QU(>W11OPI#*L5.&>CC[
M&VR]HL0T&_ 0^/\OV#<'#^$8XW-_),R[>.;?WCI Q"(XOA%[I-UQ/V:6&5,U
M$]!P);GTD%;@M5O7L?IY',II*T $9Y/ "-[B3 /L+0>D%LIHS-2!4P;V%+"=
M!8BKZ7O@JX$O1? 9$DIMM8*3!DKX<++53AL"\ ;(IX*I/<0&/F^!)VHQ$5A*
M.+FS/61CNK9G%7.?F(.5>6P(EV#!C;%TE_.%G62@YU_>6SBWDS6[TX@Y;A%T
M\@+<>F0_E\M\WW-MZ6L-MK\#)!%VP 64G)?"%1YY"KP3!CG>-]H,A&NLX^E=
M(-5EOA'4I;;W.4< -EY; <F9":HPAP\%CY&V)^[KZ8S/Q?H9AG"%!/B=JC$'
MOYD+@,6=W48O@7\:(,R"E-P*P"=Q7%ST"20Z<.?!^N(QP>0NKV?-[@/JQ+<^
M\.F*D. E43*=3\#F0>PZ*R*^5X'P.V]Q!=#C2D=C0": G_KJR=<L[!PN'?G@
M_D^0 73$F-5E\.1SU:]H-MR,E<0GX#^=6/_ZY-SY('H YQXV=/<(PJK[XV:Z
M0P/,B[Y>2#K@%7>3> %$LX@ZKOHQ)<1 [F_]9WG]//R8*H!9-\XF!E<=$C0G
MU@!;U6OF7Y@>*+0F4WT[LCEN36?DT93)'@Q3J_?SW6OI <))1F=/DM%9__AK
ML%\+[7G .T:'8[#7_M1Q$1P..G40@&L ?0+7_?*ME <:,_)IJU/;I+%"JKA>
MT<1JV2B].L^-VOU?<^&9-2"M:A988^'V0NVY>WFQ>7][EIE7-_9T*.\Y/%=E
M1^.DBE$H<X=AZ/_"5R7\A$'?%CS*L=' 9NG:#DP0Z+1]#)9DO%<^)R(8F-&\
MF:QIW+;$2!EYI52*E0&W[P*"Q=,X'L?)<,;HGYCEO (J2/!O5W2%^=QQ/H&U
M]Q77T9%$"N+,=_#C[I,.MZA93:!K#Z<(K ZSF8NS"#@)0X!;M^VY'I!<*C$B
M4EZ*UH](2@DB==Y[Y[_^WTD;(C_E"CN':OHO+Z\:6*G[=@*E6$4AX70Y0OK]
M%ZO8[-[PC@RS#T3*0RW\\G.S<&]BZ8=L]E^QXS_A#H6V%S8E#6SB2=-1YU>G
M;4?=SYYIM>12RM36OPC\@?PH0IT%BLDC6?[#QA8Z%/__'K0+%_,L*)16H>PI
M)QD ]Z,?OP>H]2O@;'@K!W2H_!0+&^RV=(UU3[?YTOZ=9:">SI1X&9!7Y$N(
MCVF]^TS(?B4>.PDK@U'8F9/\M',,?<?+WO#1&0_D 9R0)QCZ7O!5':_K."&4
MJH2Q-@\\TSD,F*ZD&TZ? KQIE@.6SOG:<7V<?&1(69ZZ:!=]^/=USBG@JEW>
M1A&!>,S0&F; ^T1^W?[B%B)W>"9 +!6TZB! A+NW=[;6^9F]T )/1T[LQ2DX
M01?[@ADBF\-I\'.'N#/!M 5!#= +/NJ89P'A)=BO.8SNP ,,&$\ 8JN"XW?X
MF8U3CO&6MM0DAYIP;4$/%-"+=:-;^)UN+*0U)-=)R X_D(5K:UH[>1^7?9V@
M!Z;>)=YW?4\"GX=8%4@*4-LF"E"\B,KQUR']32=]#RC@BE50/-RAEVM$P>O@
MWJM 5_AQQS&*?XKV/M&]S$QHBU@0HRPU'9X N*NZ$@-ZQ+VN/YX,_. "G@_^
MT-)%,"\8Z,#@WE\?8D[OEVBO.=8(J@%(1=4)J[WGHX30,?S9HSC>/6J9']<I
M(05BF(CYX#PY>):B[X/D/HMQCZ]=609:JS3WZ7ID<(<.;B0$U2CD._BXN:2#
MGP'C:(&@,R;!U"*,7(V@F,!0#9JL&/#584H$+N:ET2(\O0$S=\7E3)D*Z (%
M^$!O9HBPS@X?=PMLLI\/LEDPS,T$7EQ#<$LX5O5.QHX"[!$E#K^"][#QQVG!
M8SC%&>'&&VO@EPJ!'P=H*!D.:VFVEXA$K.^<?[G+UX!CK*,4'7H.>A$\DG(X
MU,E\05Z =..$8XKMX4Y2[(%0&HH7CU8<-**GAL#5!8AW+^4_)<$X)CXOYCV!
M93L:/V3]T<,\<V88&B<A_8Y(XIPX!IY],=%@Z6X>+O:BP[#[B0R?O]<$18/H
M<>[=#"5-;VGF0"O#K>NA7:/\31N!/:/\W1IH [A/;D 6" N+]8F4H=A\G=XK
M37Z):U5K5K-__#:!$RTDX&GT>> &;11X>>!DV0L(3X[  T[& *5[@1 8TA:I
M?-\K 6I%<"1KC3)O086!GN_SGLMM*&FD.ZZB<Q2]]SQ#-[<>Y ;H.UVVL\&3
MAIET@77C,:I8 /_E)58$O&V>?:FRJI9 K^%@^@XJWQ5KR"<Y.F11S%.6/W7X
M7)?>M<:NBCH^P># %B)?P'"N[W!U"KQ2!.6B5>[4-15V F>A?76)\/01")J-
M(*$4LZ/F%JRC;@.2[JI>,#\P6YAS.TFCP]^R:S!5TT)"^;2O0COO LR$XEQN
MX1QHP#>O8 95@)XKY"'XV\MG1=!L(65[G/71H7-.R)VYKM9 1R'%X28PURZ3
M/N,3&TC7"R+KG*]!+Q%=_(/P$8A>P._DX%H=A02XC)442T<*'8(EG',[WQ4%
M+,@MH/IPO4P=)2]1%ALH=%8\4N)L6>BY#E.S<E#*=/ 3'L)'5@(+C]P-L+$L
MG,J1KI8)K 521DI@6XUC$L?[+, KSJL#8LMX@\$K."<%#E<3^&G\8C(<^'B6
MKGH:WTO.*BYC773T>8VSG,U'7BAKLD>#/0NFUH\$N\P>]V)+JVZN;'L25GJ<
MXN[XF;<=R&M#;X9',!@OD()X'JC1/*6+ML/G_*M._(PU #N[^BW@MH,/ Z=I
M[C9ZTG^4>(655C&8QO()N'92C8!W>>&$Q$$OWW,$G<<!?](#K\!E:AQGZ;IW
M[(B$R-DF,">@CV$ O]),X5XH63J__^FIZY].$ F!2Z2\8R6PX/<\F/AP9\;"
MLLDQ,Q;'\FJYKU0+;7M,#=]<P]-S=JD$>-R[#Q=Z,040[&C ]Z!W;J0'G!P!
M_"\_8'<74]UJ0EDV]ZGTF$[0._9 IXNXL1?O]&PBHAFBV6R:RB@=)INE]T8*
MIPABB:OP,NBGCB><U%A0E3V\%!/\5MFZ5MC]#G2:U=?-!:TOULPFI1J]K)V:
MKGI/T E%#8!65VY#O!6A^E1MA;6FPX-LE05VNLV9@WU'?.ZR^3_=^*L5O^^P
M\<MNH]6R"@4-*W,YBF#:K;1$?/[&R^6^8*G*E,:$["AWJ,Q,(\V\_\9?*P1]
MAXUG[*4]FX\J$SE1,"JE<:*YJ[2>*$SYH(U7AN2^0U&C)E:>%CH6+='I<A)L
M?$N[ +)_[@,_6<LJOE< DT3A&R=CERZ;C%VY9_*6WM(? 4Z+.BL")LQKP.7-
M2]KZA/RQGWT8"BU8Z9]8P\W2WC'@M,GN?:QI[D^PIM>!HT'H7W#KGH.BOA36
M^6I$Y;4)G6;=W7E< (.^8!'GB-#<R8_"L-"X\_17<];/\#*.CV2/F-K]$8(8
M!I&^>#T.9Z  V#^J?".:U /_O@I5R@:BO NXTK[_Y1/84B? ^R!\:6!G'TZV
M^9;(TC/:.\'R]\.5!K?OTT"E(19[Y[/K$,^\'E4:GO)G(DOA5T_!23V]L ![
M!JS<#G"1"--)/%3^>@S82 &X-JJ?I GD^V"N5=@*7JK)US#>3T[X.? I&*NP
ME@H(#L^Q=2'A,[7!S@7 )@*(F5T4"ZM"+PWH! ,(DG/R#)]656&YF4M*\#TT
MWT7=$GW]7&T5CW8-QMU;>#JIQCJ]@B<>:T7P4I7^!( ! /Q<1>]SAX?MXJ<B
M<*_5FWT#Y%LZ0KY%R+</0;X1KT*^)>\2^7;=D;X ?WNY+8\P<!$&[K48N"!W
MW2GJ#3XI%,O<" 077/Y'(N%.@IWSO3/>AH=[0JO\]:"X$R5ZQO9W#(\S7H:/
M.UG-=P?)!47G3G*#3!"%<"U]%=SW]P/4A17EYX/JWGQPX&PDW,=0@L]+[[G)
MO2LG"#I+5<HM4NO1_4)='NI"J5<==#\-7->3^R:;%W(6PPH$5<:THOQH4K<$
MUQE_.[HN( /<)X'L7I B_D2DW8N =M=TV!O1=A'$[H80NPNNRP?AZZYQQ;V8
MX:\%L@ONY0V0=F"J,O+UW.5*AN]@(L 9Q- YS.@>+7N,Z":B[X6(K\+7Y>)W
M"/#Y8Z^EN5NWNPMF5Z&M0EX>)/ID*BT]T5CP@W /9&G9Z0P/]4=ZU9P2?',V
M["6U[H_?:ACW\#24(2@',"//G275/7F$4@&]E1E*6[A1B>X$K7<8!5"7&]*Y
MK?J"M?,? ?M\"T+JCSEW/:GMUDR/:6)MBB"4]7A"E+NO;B5[RS8'Q9[!LQNE
M;V'ET3S3ZZU+%7(J_OB=NE?H9T0W1#>=%#-%8FMN&**SP@\%LK=CIO:/W^E,
M,I[,7$)_^JD#O^?+B2?C:2*==WI2<JXJ!&K'\5PEQUWT,C-7VD[&8ZZI=K/*
M3K?*8XBU8/FCSH*M6PWD IQ,!?H+D?!_E-G:#[!.<6VW$UB?G16GLW;[<0IQ
MDB\W6_=B8(K'O,L3;6'!?X\G_Q]F;>XINW-#K=7T=O(E.BLM#IAF-T?,Y3I-
M6C-UNR2P+G7/MB:B&J":MC%X-2U-F,22)J;#?&5#-H&E(8'7AEVXJ.&?4R-S
M!GIZ"SK&3T6@AZY17%IM%<_!+P^QTO--H7$(9331;2V1W']HQ<J63IB5;E.0
ML=5LLL>E4JO7.  [DXVD_^YI-\]D\%5WB/4Q:]CJ3[2"+B?2J-J(2 ':$>$+
MGT(X618FA.%"P;<PYQ,(]U"^^L0DHVQR("X&"N5XV.HY(9><4;]#/(*^:2N@
M9!;P9UN@>33#>,8Y10W1K_ND(12@DTHSG.FZD,&;>D-_5%K0ET1X&'E:46+$
M&HU"(#=Y)ZY;58W56-5B]9=4$+#J"70 MC2^NM0P<KT@*! %$BMH^MH%;<11
MXH6%>!D.H201= X.Y@5%0D6V 1"HA](VW%-=9$Q.#ZO!Z+M43\X^G6U30^&\
M7ANS@KZDY>2*Z1]D.B=/C#ECO[K4\99A;K=?TPY2<I"CV<)&:)=PK<>I7> R
M9B^;#-\'>'%^]+GZX_>O97U#"O49.IK%^7C<9&LX+>Q)#<];(W$T^70CTMO1
M:ZDC"#MLE!AL#F*"S2WRU'5:.MGXH 2BXRU?_.XE[ 2ZJ\V9&G0R49,%:"J:
M[#[$7Z<Z['BX]ZP&@\KI5#6A3.K7TEE8L' ;>TWA]C/,3MJ3_7JXG2AR7=&T
M5($\/.Z:K[YFZ)9*J[^FJ&Q'KE-RHKEAL"J?[NW[0&D1R4P\?8G1(<>\X]ZG
M WHF?4,U,]Q)K8YF'D:8E1>L]&%8P=34IYH+M2?EJ_-RIR G,'.=P!-TK2F"
M6#5#7-0P\4"?&V7_HO@1NP.+\9;LY3.DS&CSN5II[$R:Z.:+CQQ1YJS,IUL,
M?+N?5['>=(V5=XOMKCU.%M)%($A)+'=9D%YD,;YE@0D9%9A$!28?4F"2?%6!
M2>HN"DQ>EA@\*G9><DZIG HUY+ A-/N+G3:(2O*M \(%AOL8W$VB@"H6($1&
M9]=H"883(O4IO]< ]$\*)U4.]YA H-:ZI+PD?1"#&4188WS$VSMUD\]?]02V
M:G!M*TZ:#;!^\=$3#PKU<O ?@=CK*EU^'A]R-L#Y.4(\P1(#^R308!V(Y@P5
M=["PBL(I]SR>];KIL2"?P]26*HB:Z:"@T<_6P)I H#Z:9> I7EEV3)LM':_J
M76.TZ]QPHFH1%_'P:!L1+ &?\PMASN"__GW^M2-%**7HR,95@G_N99K/%=$]
M-?,+6'OS6&!U!AZ6O*C1=991.1VZQO.%;JYD"JOIL#BD[.U.;6-LG]?VQ>9L
MN6Y05_S<5"!B24V3V(LC%HKGS),UG^?7A?)^)Y>ZA4>:M)+Y7%6FEX/QB:-;
M;95><@R/PI8FNY-6UJIEP6>WYWU!0<#< <)5&PX\'MB>LK.Q8#I@VOZF7G1Y
MFQ4J7UXL]E.,I38TV='MWA">D@!1#KN['HQ=<)'<!G!U%1\:?*X=7/@LK!:Y
ME"*0(.0162=4!A8/_=Y'83HWH$(&"';N. 5_^ITN]B'>@8ES8!ZAB^+/&V*6
M+1W!?7E8X^743RJ:_7!Y&M X[P73[UWAU@1Z=[->N?OTYJU_;E,4\U))E8P8
MH)LH09<P4/?DR"*JJP*\"ER+Q&F? [>@R*E>#"1\O"K14\)=+HTPXDYL=:4O
M0A#=^Y(>"9?X#Y! !<O@@.MUS%:Y5^>"?QIS2X$@?@Y>Z>L"DYVZ+>#S;Z6M
MAI#^>\?ZHKE>LH[PGCPD(BX#GQ1W!5?A;0XTH9Y,N<P*6!*BX1W8\Y63)/!H
M=XUN3=>%M?EE;CH4#LVY[PNJ7E1\( !6Y@7CC/Z0[W7!+12&\W=>'_8PKT"O
MW9H-XXI8G6"L3ZL>GF+2&.L439E 6- K46H25E$)K &#"A65.<##/QT>\X-O
M(2^Y&YJ8[1-N)8J##$?4>]_*J6?MQ.Y@P_H"F\,21"JYJ:FM4H=[>=OQ)M"F
MP# ,0/QG+#2%'^F2">*W%JK2\PNF!L>Z!3!/;P8!:[ >54F\9Y$]K)Y]G$\3
M+>+1'J*"* FU\@$Q^7E%E,?EP!D&VVP[[PV4!P9@\72PP"9<Y_*T6GH=3>/'
M.H]+M3&6REF0HWW'W*G""1>_NU)YZ1D2/ 8&VH_;)SS,B7,\>R\*_UC&?-*+
M*"2(P',]-^Q(H/5MH-D1$K&O+2.^&/2.BVO/'=\)%1 &! &K[!<MJ4D4Z79_
M6Q4DNC]:P,I Z$M<K OT:U*\FK1@0<MI,P56#7@T.G#5;," C@9#?!8X2G0#
MGM#!"3*]TNZBX?T>(="%MH/W%/ST+11Q>@HNV-+LZ+$ZH&:GMX$+'GFIZP6-
MXS6!C8<\7*2[3KV&^(E8@Y]HNL+;@(GBT(:O!52 AGJ( 6]@JW$H[_?3<)>E
MJ<K>6UNP3@X5I<$J..,?WQ?_Z=>:^Y;<*6L&#_.*4_]Q'!3D%\2!UI7!-"P#
M_"?86DWP>IIINE,I=FSF -M1@;U<6B*JX7/K5U=K6 ]V(7H\=MVX7#QGH!HS
M,,O5W2CK,^\\Q/YQ6.H94MT>WQE.=./>1NYQG\= 4*D(:/$GO08T2X%!S[,^
MO@J7=<W%#SI[D'R!'GKOU.\LX)Z?=AXK:QH?:SB"!=_?07$K\$(&VD[BG-C0
MK<Z-!W"A9VT G1# A ZW ^GR<DQ.&S*X9 GV2$!]$YWV%Y(;., F<5X\X-X[
M+O$)Q ]7]\]Y:GBKD,/C>=C>M<!/=DOS6Z4EG$:/IN14&J(&1:@B^=C]\%C;
M93W+=\91U7ED L^U4$@#_/J>]WS$H< )C_O=5<!:G.,$%=DPU"D$.FI>TQ#4
M#,B9$?S8*S/S'#@@SVZG0!:8#0=K<-(L"1Y0P)!#A7&/X<*MCG':&>W\XSGO
M/2>=&!PMOI:.-M9!#QMFPM02Z!N_]^:%S3M:>$A3^!9WD7 ="KR(U5N$[_/Z
MRLFMUX>X"P7(&^1XMX=CL+S?%V8MK :>(R+LY()(@H)9(#D*[# C03Y]PAS<
MBVI\4^08WH.3%@'GA';;>*$G.?QZC3%CJ*O":2SB<^59'*K!"G_OCRC*]!MV
MCR1>V2SG',/2\VV^SRPR.4)\493Y1'P9/Q7H2^:26VB:VRJ#EPSO5#%<AJ[[
M"@/)MM-;%VJR4$FL[U:Y#0B.S2-\7>DT=GDIER)GZF(L_;: 5@_$J?<BT,^?
MCKZBD/P#49#/BA=-[S=D8C,88$1YEUTR248\C#^_XFZ5.*QG=7$ I'Z:$:6*
M1AYF$^I5A>(H!?XB&/LWQKQD(LQ+A'GY$,S+7:%87@1MOPI4O$MTXK.:G&J7
M"SR_4&29G5<KM<ZJ.+683[^$J7K0S66AW6UA0J*C#LN[/#E( D5.$.G+B':8
M*@S5,5T&+;K'L$^"4B."OY#@;>BB5548;ETD9'Y&C8JCP8'#+($8SA6FTEV5
MT UH5TH36.]*$ D]-,9;PC'W& QFGL_DQ]WHTC_=.ZF7/3V<15U/ YV\X'3@
M2>UG>9)O@-9]*&=^9,SVN:JH7"L:C)4E>6:O+ PC-^E7AV!W_E0573I3]C33
MY_'<B5=QZJQ"<_EOF!-WNNW]6D@\> CX#90A+/GO#SBV>.),1KK@"KEXS1^_
MZ1W8^!U,M0%-]1 \:9'NY9BEJL9*PDR'=9HAP3[#6)ZA*57^&4"DM_IK8,BS
MW?EY]K/C]3SK  [.T:QOP;K!?%*?*M'HO", 9O+Z:+)'P)2KV'WHE0/_-&"3
M9K_++'@C;' >0&=Y$P^VMT:)VB=FYAY:(<0'%$X%[+B*W%J4>H>ACM,)FH-]
M?%!8Z!\&N0<LL;7".M ?E(_P.H":SD&%#3%";L.%('[%,TI.)T0'_8ER*,=5
M^/1#BW!6&@-^.1^86I#>#?A5P?O*IS7L7N\#P=SS*:<A>? HP^_\<'X=D-^L
M\*?Q3VB5P==WO,S[,5=[G0,?8LP3HT+W61V/]X^CKY[^^:=RP836*508F"58
ML.PFI_RM"BEKE#<+4,@Y0'*T=OS\N&_!;@74*S$.B:7$G4[3:,]@LBWN'?Q=
MW6'_--6K\ _SJ\/U5T[_S@]-@WC <W:"C&FB=IU;IX- \*XGQU$ZY2?4FM*Y
MK.EBS_XP%>\E&3>X.#NODRGLYAKHNQHXDPFET'EACDZZ@ZET'W3V(O;WSTI.
MSTB"?7D#A H#B"XLPTO(!S/QK\42.3=0>.T^+W<S"QPN!,_+O7,7V.@W ?N]
M _<2GJS$[H3X3ZN9HS+QS=CIS5>LZO?5.%V@U^?J]AXW94S;\RDQ);(O]K"]
M90 [?NY;+W-RJ3VM))HT67G,:)V145[2']-G#V[31<]:I,6D7>W51:9<,J9E
MIE73FILNB WQJXUKG* ]8'I")N+)8_Z_B$KGG:B,(S&*QQ,@2N5[OO'W?W(%
M0-_0Q5VK/<)DJ;=,+BJ;?0I?P5">0,775X.A"^@(Z,!)?K\:'_V,KC"\ 'P^
M@UOX/LH1+A$/@!$B$BM"'\(C\A =\0Q1\>6<*!76NQG=ULQ#=Z#W2B+L/T20
MQ)-$#>(OP@0^NP?G!&B-?#AHD$S%T;0!W,8\!/Z(!7 ?R%-UO!H?;@AV%R*E
M(#8"'NQ?OT7OTC4YE[R!$__Q*3C(G1BV8XS#"XY!]FY-<;U##_O^BE!,@D[@
M7'%=(1@/Q8!WR&MZ@G.S)ZZ3"#8"WK'D=I'3'=< /MJ-IPP.[#A\ -4OQ$B,
M?(F['_2[3Z.B^;GJ9Q4-0D@\U_/,G8>X.SX QSN)M_S0"78J6$-?'NHEQ,,7
MC_Z\[JM[5.L'TXD\NK24<ZL5G#-HN D@[ Q=4H/87M$X+__HC%;]@W=8"W'Y
MO6>7V7J'+1"W!;28 I\!@XSC/38KP5QH9]=BP9@U<.\GO,UM#2_10F$OX$R8
M*'7OYWIRQYV:19= SDJ.86K!A>XZ08O; C^@Q4]NG?7O'KVJ0HZM"7WUX%19
MJH:I(Z2IPR[A&X$<5]3-(<![PB#$T[W5Q_?B/"?7>\N%":!%>.]TN]D#=3)S
M_-J^-7,*3DQE#T(\KY6XI;JZ EY<>W;%S97W(&E#R 5W21?&^.YU\'8BM'S4
M;^;"M4B0H$!]HMQW#,H)#"S<V;M+BQF2J,+K2ECD[2-H&6K>R%DKR^4S_Y0<
M82@UCK,0*&ANF1#DY]P1XV9:@O3T0J.K=#;@9%:HODQ" 3RZ-L,O#CH790\3
MQIYVKT.K_ DC'PB\13 VTX'/X<[?AD\E%^BB ZV ;L*"*S$0DH;XYZG.=7ZN
MRT#E43JZ%<$5VTLK=J/\"PN>">@F&U\/0.S,6;-FN!0$DD.,ZW_^SR=FA$][
MRU\[>' "Q;L\=GC"%Y,R7)L;$@=%)@;ZOC[&JD)I\*EM=I+8M%]/;98'NF]O
MB-[6R,W4O?AD2'1)I5T !R#ZXXBD,3=5?VQ*SB$,I]=;UD,)O%>T=#/Z3;G*
M =^.LPJVK[-,?[+>#23IS;UU*'<7CEYT2S +EJXC3-\%8DTHLE]8I/ =5BAS
M9:6%#P6&MW_\3EZG54BU>V>4QUI%P[]0[0C_AG<2'B_P0;E?WV_S[XXQ?.UY
MEC]_RN%U5'=H6@[2*6#BCD(N^0TEH2(@7MH;^._4#;<^C)RE,Z,Z*PWR6,&F
MN29!"F(/]FW*7@_6POBVJV>28>?O C>A0YC3HH93IP75!KKQ41@=]P%&#'NG
M4\UO .S+1L"^"-CW-F#?&\'\"YLLK(URF<'V#44<6XUV?3,1S_6C@R "6J\H
M&9RBP9ON!N ->> KRS\\&&$_T:[E<&[3P]A&3<)HR^[-"V*X:=;E<0ANB/^(
M"4"MKF'EIFX)-R-WD"HS3>%?@UW \8=8M55H-^G8@!K'Z'&';O7I6[>P>N/D
MG@)67&3%3J]P1[ *VC_00UF:DT[8R#7!LDXD Z;M8\%@JW,+IBGB,1JJ5*?X
MTF'1&.#1(T2B.O#/C!&P 'A6+W1RUH##IZN1W%:%<1=CVL)D6Q$?#X=Q_UKG
M'D>^,*?-J_=O0T?/=#JSEP4(1%@O8(T?\G'<RJQIH34E#[NB.AAT=O*J;N97
MW+ROS=<G[@SQ"G?&WU9?;GM@#CT(S." '770769)@)7<2M_;SI/!OGN3( +^
MS6$VX6JM 4;(;")5H9KY.4>4@$M-I$..S;^<)/,%0(8$:R7AAKA80 MX)@[)
M@88$-(LU6!MV+X<79SOW)+KT'!Q3H!2_9=%]JWWW+M8C)WB0"I\-!E2?]OD@
MV$K&[2,,E#NLHG2=J)W#*F J'\LJ3K-22 L#EBZQ._?:U*,W?%R^MWIW\8&U
MN][QB_G.MMN96EG2"*;?9W/[/=]J967JM7SG=#4([.,+6"G')_:5ZJ;2QMA9
MJ:)GE.R0*,'3Q8NL!*,@2$>4ZD<Y,4><CXB U[6%N.O-?V$1G"_E3L%;>_Z2
M.1:.^Q?$<_<2I457/N3E0MXNM:A>KM#:BN[]TRAR#!7"03""<TZTCZU G!2;
M@PCCV*+'L-8010-3:L<[98^7P0,Q8RUSH>F2FX445.A4P))0\!PE&+D /T?8
MPA2H0W_P"UA8Y@$=+,-#X9S(,93AX R=&G-80+?W Z<0/\$4Z_Y89/ 0*TKP
MYEL8\\_VT 0Y3T,ELK QIJ8FX(>Z -//JMLTT]GF8T8X<$SUS@HEY-N]F!$7
M&RQO6HEB7MYDE94QGTWX]?S)WG!/Z $8.,.:3$ 75P&T57\C._YQX66ML%#(
MWK"TZ&>Q,K7,V36R-$V,H%8(1\[_@K8BCM[L7BGMOA5RUQ'!@SC(ZW7]%,U\
M_V)I@3]YB?/R.1#I[M^8@=+"+&)@$]ZDC3+*[#%YX3*Y<ZTWRN.[]R<;KKE!
M9Y3ND4-@PJ[5T1V\G+!R^K(@K^ALY+W@M;PS@)]]Z[#0K']B[OT^**/A%+Z?
MYC6"%AW)GJ3&FA"BY[<N3;M0 E6PG4S6:;V'?\E 2]LZ^2O4UB[VY$Q<-7-P
M3_;4I;8/JXL/-/MX^D1*D[>U/;P@31N"R"HTTGM!=#_:(V>'W/UYK;UJM"FL
MP@E8EQ:JI,1DBY@^*'8_PEG(9"EBTZEB!I;(C4FLE1/%0\N^["PX0H.X">*Q
M$187\"+<Z[MI/%Q@]^ =L:JA &ZZET["+HLXLH:PYI(14'['0\W3V0=! YR3
MCH\IK.U#/$Y'QRZ^!1[8!PPE%$?4/8]S#_4X=@TW.08QZ%#>O=H,>+9[X1V\
M)CC/A%!>"+P/:5MX$.L=WL+,JF_HP=N!Z=8%.%C0;UKK\4<<4X%0BCKXSWTQ
M2^RG/[&CVKW -OZH!P159E4(&- %43*\VHGC$'2*'."&XQ? E,XA*,:EH.M)
MHN2:RRLH?0X=3Y];)3UH__W< ;!0*E"EJ">+I_N L>"7P)5U?GLI=/5]T>.<
MX%P@NSLQ2J!%@V]33M;V_BF(4%7BR_1[I3XUFSJ]SC?3G%QH\<DE;Q57B]/K
MY9/WD(08#7;8L"B4%&8U,^6UDDILNGG1SX+>F7L-]C4E3F;-QU:/9:P.0X^,
M"3_E^]3=[:MLJSPN'U9-9C2JU#)USAS1C]#(D@]A,WLI2 ^5:1M/ENTB5\XY
M?7Q*F\ K"3ZXCO<Y+PK.$D[R+7X4X(?]9$SUZ%Z-IO?S[>,<LZB<.7Q[=PZ?
MM/1N#=$X>3!#H"8O'E :3;TI:"FU@PDRDW@4ICC7/KQ<=FYU]OO.&SRQ1HLR
M43-Y>5_+C%+R/J?CG8_98-GH59JS6GK!)(958;2VQZ5ZX?*EXJ$/3%2AA,I$
MCOT-4=AX;@*=!(KAH#H=V%\D(M=ZU3N']M F=QS_X3+A]H_F\K$Z7="%V6!B
MSK1N95_K1I+QI_LZST^P=+8^$;#"/#%-D4N\"![W,H& $$WW%;[O!R&L$.>"
MHCR$?]5A(9YQZF;YY59S#SP(@9 Q%TDL\,&@)>3+/6V/),--T'B3<%U/+V@Q
MD<@"KUI->'/UG%,/AXT\W/?&;KV8)P[+V;S8QC<ENL!Q*;RPVL[XR1-0FJ=X
M(I#\\[7FE=*&0:'!%_)-,XO5,^O:H$CO=7MSI1G46?@FG%$;GB()@#JF@PX-
MQ'-W$[]1%L1% _?LSN(W?UZQCNGFOALF?S'T]X=>C^&.3SN+X8Y?W$\,=YS3
MBV*XX_ /B.'>%FM0S+2?("<21>(B4QAEALU4,F4<C%?GZ-X]UB"X17E87FTH
MIMUM)7>-PRICPF*UY(4\_S'!>XU984[^@[OT/6>G_:F"F<(YOLI0 SJ6DLU.
MJUNM4,PF22O<<+8>F.03S5:>4LH#1[Z>: ,$GKC-XT.M39,5,-,$A27MRON'
M!:]U*O]T4_>3=F.*/W)3.9&EJ&1_EL-+AS=:NN<W]7&CRY41F;6P59LMT)D2
MF5DU[R_6^M--70Z8F:UGMWVLOYD6[>Q8-9*5-[J4SV^J(O8JV<=>)\6,Y$2O
M<9@.#ZMY]V7N9-BO.+,\<[=^).0NQH_U<Q_>#_2+:)JW!,OSC3S:-!Z;"9J=
MI=K4/)NGBG4J4CNWV^%,CLLPM4)VRPC]QJC6&M-F:W1_4>V=Z*"W[+ JE9/=
M?CN?IO>FJ6\G$V-3DE^8\ DK)#_O@W31,;(4W#I$!UT31*9XO>UG$$=S]) \
MY(N/5 E\\\4!*S?S<O\<KL*,1@Q;[(S2F/#(M<K+])X^I.S+;NQK("I/$^NF
M2)5 %'3O:)4_"L ART*\*&2O.SMQ1]CE8Z0=CKR9A_Z#<RF"$11/]/'<";YB
M_B^"^2A41OQ!P)8W2C/3GZ::\Z35GFU%N:YW67&?S*7GCZ\&H;XF9@4?]@73
M=&#(!IHDI?(-C8./NR3H0L6N$:M]<8WU<W)U;:7%TMJ"P&?\J7CUG*ZHMT:
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MN Y7=>Q>>MQO=C.4*O=4N=JU?,15H?/ T*E$BK_1:X4(L=7-W%*\!)X6@&Z
MHTR"-K8J6("I/3.A4X"Y_@PX216H?D =_X6_GT*1NV.>X@/UW_'L67"")^"
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MZ=182K&$*J52?(K"QZ,1#YBG#S=3]74RNZ:*1ATX\]6#2(#A/=S'Z3;X2K(
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MI=HNV:F29^)D;I(S[_-)CRE\.$3\3BR,S,I]O<"I<Z,L5&:%]GK(3U?-7_]
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M.&@?,1H >?N1>!0U0K<O?]11)N;B'\#%7]>O"?_N'?B(U,7*4&^)HB+#AS^
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M*/E@^\0[K /7!06J"" $]Q]WFR4H.XYL:2#<SD2&W[!L^'T++.4IW%B0+9Y
M'WA!ZMTT2!3$E*GLP\>B/\"=Z6%2.68[VVQ0#2UW@D>B/#1T''DZA4<"BH]2
MV8(4.&^B.RHVDZ$(0AO<QB0/1NQAP72]LPEN1"I,<TOL\]P2F(>$>O#6X']!
M<OL.BBYBKF /I[ VH21#2ST;0]'?SRWQDQ:#[*CED9HXYV1?8NC28#3]<!5
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MT-@[G^_(Y0N<- U8T)V:[BU#Y&XF7O<$ TM_+_)#;TAW#AU?;VOT0A*"\OW
MUH#+#E3$EEJ"ET6%[J'D@%\,NCN@V1VAJK<#9CXD^*T/B" S]IWMGT.8O 9
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M?$A*W?9.S+^XC>M8GQS*!$=*0IY(0*RO&A4\4VQD5HTR.Z^-CO*MDNP[C,]
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MI-7RD!.G:=%I9&3G WF]R+7TFCCH@5;IYI8VS!=ACM\M?>/KT^;#X)#)^(D
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M^&$U4'%Q/R>::,JVL69_3%I'>LOB\TJ#V6V[6HW"W1^3>;S1V.5#K6.Z8QY
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M!C$HPYN0#2:5;N;L:OF+M+:BMY*R!#Y"9-=8HI;%ODS\/#@PLRS+"O8C5\D
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M>PHW7>FO?75VX>(5OGXL,#GD)7-V?8GWVB:(IDG<)7>SB"^8>9Y_\.,( JO
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MXLP4.9>=TT4E+F>%U^;W=X?MS^[\W:SJ<1 2Y_12TD''ML("C'RA'3*@\$M
M%7E(D^$GZXK)92>&BV NOW0VDWC"LQV]S%[PG B<?E_&*# ?F@7J./QEN6*K
M>A'NDKR-\3Z]_D\Q= XSFJ,(Q!TTRF$1/RL:_EEZLNDKTYSR^*-KQ4HD5'K=
MYX48G-W;2--8)NJ$ & L<4!XYA@1U006_%K[I=J/9SZ/;1Y,+\1"7F,!79(9
MUYB/7E]U01"O#PIPGL]4N5XL2AW%(LZ 0CN>_]235WQ"7P(8-986KX/-QK[?
M[9W0--(\_TO>BXAH)8#;(,QH40.4P$[_)8!2^H379<)+H5(T#[BW)[G'1&U7
M,.[W4")]$@9QPT.+"=H8YJZ0?-#LE.Z#BC]KJR9YD87>(\"D%:$!.IWTR7[E
MQYCPSGY9[:&J. ;[!-\?2'_1ORYD_F8BE PR,TS?)_W+YS[^K5\YAIO?I/((
M%P$'5)V+A7?9,6.E11J^?B[[.68&?*GO7^ODJ:5-YXB/*L6#VGE(1A1MEK/(
M-CEB$0$XKP /.X[:C+MA7G.]'4XD@_V90'9VN,VH>5"&X^+[<QYK UR0BE?K
MJ2\Z-MVM$Y(AVU%Q_A+R"L,2W?!FQJ(\R^W>0C98X;3BA0%-+(#(9-M#FDK1
M#9^4&8P(R6?K@K+ 1RLV;7V_+)<8E:H7:KOG[8(;+;4W@XHAP4VLN#9L#V8?
M.55E[N=ML2UY^H'4ZK-(\/J&SKARO^4QZ#IQ/%-"60@/]P%SA<*DOT_T QY;
M7 +\_ISTS$#G89)GEA,-+7T&61$2689]:SG'60TM 4161><K;5>A0D,E6)KV
M*$6YOM1T$_?G75U]DK6Z95[B)\U&D=^YK/=S:FWE129E%C^GB<;%-HD7;IZ<
MR,ZP%'K@A/8DR8KE-7^_57XC_AKX&#WQ_4JH>>JRJ'I#A.YG.URE=98L+YY2
M?G>1TU@]"W8F'HH5^J'C<I>RT=^!*GG^@\(=A8*;7B/GFX%7NL1/AGG+[!+P
ML4DQ[7V3=!0=H^*90I5H<=^U/CN1[(Y/-0)[X?J4-MUFO9,$\ER'3&Y,YVYY
M365+OG2\A46#Y&P[T$6UUH_41X +Q_RRZ9[+]M]>OT![BXT=."*CX930-$ 5
MB6/"R^3-^?XU,;.<MW2X9=]3TB^>RL6@_=7W?Y#UWN%LAN_??SJU9BE:,UI4
M*T9K4Z2J=M%:L=/6IG81(TE+46H41>U:C16QJ97:5=06>T3ME1 $$8_/Y_?[
M_L;S',=]_W4?QW6O\SK?[]=UW]=Y&=YC?ZBG? 9XXH\!$Y<_,(4U:D@G5MU*
M&CMAT1PZRO5KNR_/Q'%_8[4'-Y0.>IJ[%%LH36 C$'R$1<7=-[+[7ZJQ_5SY
M[XQK5[).2VI_C ^,-,/8:G&"6N<'"C/M2/*R!J9N*C,$,8PIBSFKY#+8Y#R=
MMW1F; PL8L*[#_AAZAOI"">J9.^<'VG9$Z)5_%>UF"2>S\WZ;B-_8\1OQ<0
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MM:US[/!:_4_G3P%<^"@PB/$. @W<YQW%CQX:%756L6F^[>_V9!4**Q8V9B\
MS5)IR4+:R2T[,N5.^?I"G^ZYR-F-B.$CMMZ\>)(D[76[/.'2OWZV^<2 1<L1
MMZ%NA^:ZQ+=&@@7^6C?NRU\ UTOVLTFO_2GQ?[-IS5[U<&\EW?T4F=CO4#VT
M$\0QG\$^-O6TK'F4RRKS[YI;58%;II%!G6'3[0_=:S'5J-)5<V2(:Z,:?*$!
M=+G1RDX455=78=$Q_$;X.AT7:-XV\XE0%"1FBJ)'A.<\+X/E0D+MW^Q>V[&U
MV@Q(".DN.>7J2,6%NPLV#.V[S"@ON^_'3^D-5AX>?5*D2O?L.T?7G(>!4D!F
M.,Y)(/[S>>2+HC!6L>\&@L"H\2"?0=?J&2;-$0N3#P+O354$JTN0_#?Y+>IW
MNRZ%O&?44[!A6MA.1*W+)"O<J0P4-30>*37H-_HY@-Y&>Q13,7W)@D\FM<8E
M)*VU9Q^,02VL[*HMQD:_;M_J>\SQH5,2*[_6H8."]5@/B6QOB?BDG3RVJ-!M
M?VBI() 7Q?*+UTM.:I;3EUQ=01'3[AQ:)K]K0/CZ;F UT*2?:[Y)$LY AD8M
M.WBVJ<6L4TU9GRO?L,ETE<I!V@?/X"')=Y,>>5Y*H,X-:^@MEP3'B%RMXCGE
M^'#0&QS]:R"!'E\!*DJ4I9LKEGO$9@-)3GQ;<NZ#W+S^PR% 1VJ;M83+.8UM
M*'.E[$X&M>)O6.1Y.? Q'88 .YNS,/VQ$USM76US'%5DCN"V0E7!7#<YP"(,
M;%D*YCREP43TK@4JJKJ4HM;-V)"NP9&!7?J[%*9TBBNA 0_]H.A92DY;B%ZJ
MGFEN$,KP_V%UNZT$)6^W]S#/-J'MTM]K<GT0LN "QUNJ@!4,U34K/5@-YIS6
M.#"5^BV^X'3GKP1M(>!AY\6"7RL)F0K@R46C,9%FX+BYTZ'KCW'G6\3)]5OK
MFKMOW'=LR/H"9X"&F/T5(#/8?B>,>I%LYE,4[;L@_2ZDOZHYB>CM*61L] 3
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M>K"7J8I3##=;$<Q9+<HR%5C3NY6!Q6CFW.KHX/E*38O0Q5+0JMJ;J-O<-[Q
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M6M/H'QLE,&+E>-!ZWU)(<4EPM/+?PZ-(E/H-. OT TEC,T^6(A#F/8:GKAO
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MN'OLW,/KQZ=G@)R!DYOMV&J_#^^$8.A[#6-+UN"![%:'TQ70412.!G[R]KZ
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M(G=RJH\?0WFHK9ELDL[-=XBLGZ9>1[_-1K1GI73]8VENQWSM<_;&RP?RD\2
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M,"Y5OV/>/-<M1VO9;UOG@%1R B*W\E#R*%5PW<C"!_+S'""F2F^74X>X2M3
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M]^%5CQDP>"P79+K_K,?I'$#+TI\+WV2$XU[/?QT*5B)U5Y<%#[(K((,D6FO
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M([XK.I=V8FLJ(9V8UD0I,5G<EAY=X63:%7D8TB:P/97X]APP+RR2EO^J\!S
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M:6L2X!&)YU\3K??E=Z7%1Q/)MO1&'(>(N20@E 1L-(Y5=LV8]KL?].B&&>O
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ML%MZ.F]*7P[P41^N)3\DD=.O\G,!S2[T.2;Z!CASML6V(H6PDFTPSSR.*')
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M5BP),(#1Z[[.A5(L)4PA<O(P'!KI>%UT4-'C/*2S'W9.HS"J55?A0B&+]ZF
M0\VU7OR2$-;YCOTUYD5\7%UP!7V(DMR@+N?FK8WQP;X"4PBYE+C)^,6VZ$S]
M^?/.1O5/'$.R=.8<#[")<UAVO'SS8;G$26XDXVE(>RZ\#K)'"N(TWM26D6Y@
MRC\6S#BG>^N%1;*VO,#A3"W#VV80YS(UU^=4"9XELUJ+J2D6'IR0%C5QGSK1
MS\.5"$&"O91\C0P$S>F94AQ9BVT=#NVC8KIG?8*:EUU<^%I S .;L#L8^)B\
MGYN9"7MV10YRG@E]TR10V,3,4>+H*;NNH%J_]3+.;Q&-*BC#I$SG,-V*W*B&
M@W(ZAIT]W 5!2@K]M'EO=?K.?YI3I+'EW]L (7N':O0N@-.=SN(R/9-B5E1Z
M?;4N=7/9$=9S]QS9*^YZ3^[ 9P%L/7S=QOQ9!)GKI4??U+1;&/;-5C8&=\@R
M]KJ,_JL]'>T3%+-?_/:'\&/*US%*-9O]R8%.*3JZRC;QM0*A I6FEA,!9>S^
M35.%V9"'[OLF12C]QC6[3L/K(K"'WINYV)F(-'],LSXK<*K<YRA7<YC-!%O?
M4[-AH9ZU6#!%RN556+A+8IVM3'P9;3MEBQNJ<TL<EZR>.TR_R_ZXNO$4/;FV
ML:J4E>IL_;Z[K^5CT66K!'*!STQG65!U=-^&7@S%)K"=3U)5*+7JVWG&@7S]
MQ,OXL7#UH4@PIXYP^(]"/(</H&62TBL*$[('3;&&[ZT3#0:;>WN])5A;5[.;
MW')"X\]>=<>+\P29S\#WN+'"WGTS=XKCMI1IT2M&*(MAEU7S"_UZ>=E#Q2,D
M]KNT? S8NN?H=6 MT]J;,Y_*F;,6&Q$+2S$T;'?-$,H1;4WZK$IX]Z+:Z\:$
MW_6O"MSAP&J0IY8HI %YY+K#)4N1;[-8T9Z)S0BLD7:UE..^.TJ")2$'_)\%
MAUG?7$^=J),0B8/WS4'S:U+KB^=GIXFZQY",^;24LYR'B!R&IHY1SX]5)J3D
M;YZ_=;N1EUXQJ)%M:;CXZ/A=EJGRY*)U3@Z+J*+G]NTT0\,"6+%H+@4SZBL<
M&'\F[@-BR_R11ODQ=EU)=[6,+Q9G*&Q*8;L")ITS3!''P?2KMG,O*!LY"L6[
M.2<0Z^>7"<SZLHXD@(H$C(_7<VX(0V$SI6TI-:VI). (FRR#JN[1%PQ:RB,(
M;^()C)?HOB^9H;,"C!Q3"E;WGYX\-* >$?+:UCEQ(CY[R"_ 6-PT(^]M?&F6
MRBCLY9JTGEJ7J!)CY[(]CBM5B7$"W5AY^/(0/5-=R5#5587JQFOZV0=/G1)\
M,\DB/Z9)Q5N]EL!XG8+A+E;UV>QE"@;5G8/=J3YGBU<7@>L@ 3.)V7*ER_[0
ME=L%L$UP@>E0T \T41D)CA?+PBL\^0 :=^WP]DVN+D&$"81MN"5+WB)9UDXH
MQ,@Z=8A;:[]><Y18J'2"Q$.^P)4@YT:;F/:#>!:TL%_D=5?>+$U!P]ZYC6$]
M_T1?)E:G,Q<D[N_Q5%]?;'5MRT*/RZ$6#$5Z1 Y:'1!]^!'5].$R*WU%+L0T
M..7R 1KI QD7\-<QML-<J$%)CA++9--59U?=ETF?'_FFM#]I/5DUJC["?TFX
M>7]-4+G)YXWUQ4P893\)>+M8+G8,JX2&MAICK%=DK- YM=*N5;>UA\P?#[2D
M0+W%H@)?=#MI]K'>.BH0DJO_K-LA6[/"J%$W^\4HXODQE:?Y0T^0=?T^&W6E
M]4-# ;;4%H_O'Q&XT<D7P7VPSI/2RJ)IOC0FB7=8/E+WW/,LSE7\53_>K)O;
MX7THF000%:Q>D(![L6!-<%U'2]! F03@0X>HB;62/L27'[-UXUG=00VS5/PG
M$-P,JK(ZKU1E&0!5@PGD'KP-K7<85)*^\DTO?YJ/WQ@+-XZ?QC= <;+&*-01
M_2SF;A]D'$)ISD'>-]FQ#N%?#*FG:9THG!P04.!;#2K3-T&*4CT.RS=H-59\
MK/5:5XZ=\0O&:'3Y9;EQBL4Q[^ D95>C1#WIH?7F42,OT3MU$??)+I(OLO!0
M F,E<XE=CC=]F$(MK4"-SE_=MJ1O5 O_?)T$X)C7A0FGGXQE%& T2, ):1BQ
MGJ!$ A3BBM-;W:PG+(5'&Z>Q%-^)#+**L0<C/&KB6WF\?TA_1M?-Z;&>$AM=
M>>3M*O*@ [(<1MD*_8,T:XF]'BP6PQRHUH:B-%W_2Z[N!FL*[\)SS^LGWI>C
ML.DR8YM*B!.?K$RN;'8K'\QNY)>U<(;6E*8$K+_)S^+X:@"]D3EZ3#WP:GK$
M?9U/MP'*4%D==)%GP;*/;LVLQXFN@5L5SIJCATMOY+":6/"?X*L:6:$U4HD"
M!2:N*$7&]3N=Y8WWB]]V%T7P<DZWEA$:3E3<#(0M7' B 0E1Q3-$+$'6$<("
M5GHYSGW$6G$85B*=LZ&"<^81XCE!:\XF'_3:2U59_0X1B_8C%DR2FK$'2A"5
ML8)9HS3,;D'5&K8W]G(_;7I?9MX09O4I1=8)ZU,%.S9[+ ANDFKV2CMZ*['(
M>\P"!\O;RDTSD7LC<?TNV9:VEXT^]9D[5^:D^8PNMHPZ":E/T_IJ*YZY&G$<
M4)"B*LHT[2-R=B^)+"IV6K#..WX3+)_1^((]_$3#Y8B)Q>N9K$14(#Z.!EXW
MWDS\[',[6/E14?NTE/7Q<7:QAD$"/U.HV8)8U"!H]H,7]I$D8.66O3".:HX3
M>[JMI'1727N]"-HG9W$P:1:;$/W+RD7[P;J<=73&@UFWV5Z%=D@.<6BLYU1>
M85<?3GNH4MWP@%C.4O=([K!*LVWY5,E SM->#H'H&Z6(N)4E?BC53"2G<1==
M;YL<3@ZE$.)Y4RY5>XDBN@PXP'&"LA[)I(><+?)-)Y( E4Y$KN"FWO5F@0^U
M3<9G"AK82^ZJ(/:4J9 1.Z*"GMU+U9E_B-ULS\O]4%3:->%UX&Y1P:I4L6.Y
M4%#*9XG[XC;=$WUO9GJ]K(06-GIY:%631(U)P%Y\NVJ7%"4*BQO-]&"-OMUC
M)2)1>:(R/,5<TME+(2DD*R'0(":P4G-,;Y(\).!)'TLV7A@%\2$>O6*9VNIJ
MF7-MG#J+RMWFB%N2]A!C;)C$2IW\X[U3R#@;0]A8<&!4;UYFBTP8.\(G_W6O
M-\(D2;>6):AW@2_]TZ$J[5&Y*UL*30.M=_S'Q0-.?.S.VI>98YUJ;J1=K"!X
MSVUHF78J^_;"J=</A,CVDAOYI7:D%TRM(HED]'6C0WW"2H9(%&PDLE($+Y.+
M@65_JTVL=^Y7[A84S%JO'V16-7QG&Z^=^)PLWU/FSOD4+Q7=U>9AM'60 YRU
MU11;4'?G5(P<JZE@5GRA-X. ]O.@4QKZN=RO)'BBJK/[S17/*-FUIH^>*:)X
M ,:ZZ7U&'..H\!9C/@R[YD\"+C-BYJ&YAG0D($1/G@3DW$"LD1D>LLR7@;U?
M9^%8EX&F9<DR:+7!-<&QP"^'&S\)H#@$#FFL@:Y/BA.]"U:4W2W_SGL1E(1A
MSCZU57P+80DFW 1F#8/&-XPR<)A,),S2]1'1H#4_0T3%T_'CJRO5(RM\5+P<
MC0[WT!GU8EJZ$YW*1JF-68;L5S?Z[G2-E#Y=NK4\G&E[0MTZMN3VQ:H%/M[*
ML\ZA$-HY27Z%>V*QKB*;^\[8#SCA+GT^=\;S-:%MM($><*RW4=?T:&,/R2E,
M*[H@.:0TEN+KX$K0W9@C/"CIL9]9RRA:.>P2,3NY>)/L*3%)@@W=%U62Z6:)
MCBBQ&[L47:$?'7RX(B8J(/<*FR67[O@G/@VYFF).)[ *SS[F)QUS27B>R$)9
MF(9O7P;SIOAFG&\&W@.=G"=8_A&IJ]?"B-=-#-69W=A8M'-@M5)XR/NL]7C,
MZ,<+_?!DCR\>HIT/2B/XYR5,HHCNJJ=+NK*F7%W3@AY$,-F?/E\'.T3Y+N=B
M?&1NBH5M3G%.ID;%UA!!Q:'3XY*S.2>96:E<TGN5= .=V2(Q:PLG:TLI<7K%
M3@1\PT=-RMG,:?&JA.JS[K@+=22 D54/(SV"W%,3EB@ILJFE)7R&]4&HPM'&
M/#;/].6^,KCB:C^?QE$>^U+D*@DXG^2;=NHA5F\R90MTE%[,^_^6SS,&\""9
M@H,98%\KP&4R?EX23BV6@+]N\YVK\\A]@HL%.3X0^G*9_LK()/-C285QA?#^
MHH[^1.]+!2&HMLNCZE$KQ_@E&N/$UO#LK68JWUJB^H;<YQJ[CP7[EPLS^;N,
M>O?8!VHN7\; G))CC;F;#0P*N@4^7&ZC?,-U>X!J?1 S:R" 13ZW=C,:4=8S
M[+47E%R2L!*\_V4Q.\O:/N..P$:M8\Y1PN>'JIQ+DQ*#3H\9,\;3^<-'M3Q(
M@.]@;B?4V!XO)A/]1;35["3Z#@FH,1CE)9Y6..6?G26RX:$>8<ZFP*"VN.)6
MI7M^A.UC@/'+JEG+<GE48[W,1?0#9BVL86S"S+'6'-]'DX7:[X-50_D?1VJB
M]S5,AM[H]I394&"W]8#$^[RXM;2QM@6+'*LVTE6P1?89DH#I'%>N>=J#;M=1
MA,9:"W9E@;5 186&-!Y?$;U P[Y;JU/A0Z_+;:\:1^^?G7P3/<G'0/-,9^\X
MA8]/^3447/[\K%;E84NZ>M$R[:SXZ/.?0JO%HYJ36N)E'.F[#UV 7E#'NA,:
MPL$@->._XF3)UTJ3UL-^@Z]V\/!!2'HC]$UEQ25A?@\F_,(3^"*KA?$HE&Z6
M@Z++V-L52JTMF-A5Y^G2=X=>8$F%>V6NF"?PN8VADF:!\IUEO>[L FJ<K]"R
M59)92ISFX,HEM@B>[C -B^08EY/QFQ?G6M6C0S6A*9>WJT_Z;$P!R#1J+1+P
M!$)@"/_49X"V("HRY1#78-@S_"&9L_@C:W(]"%]AS1VR.,JP8BZ-JS#/"&>9
M#K-7=(LD"AWL5A0S]MA4ZR^>PW+*^K770?.LGB5?,1Y=A-XI+._6Z5/O#6VV
M.#@JUOSR8;#+Q4\T1]T2@EQZPNID6&$'KXV2 *Y:^-W(T9+R"%5KRGY6=?5+
M%X3$?:^H/F]'LWDIV[BZG%XJ)0'07I]D5*Z9R&(\3'S3X]%6W/#04O9)[W.E
M"D=/!HQSQU!]K4!IYJ1@6O'\TA^3BXL25,3&9+G:A/.L%A9QC2QM_+,&:C=1
M;>$HHSL%Y3UKRIK8?D&.^1ME3P7N<K]]I>_"S[D<;9ZK<\Q0@7SD;M^U\0KH
MU3#]7M&#MO.U-#GC[)+6-(.SYP=8"OT#ALK;?#R&8G)?C;L<';>4[XU^(H_M
MPJ]O10E0*0U'E$+:\?GK\DW#)U#[2D8M6(1%^=6]AD0/K!4:QXF?'*/W93;/
MO<B"^UJ]8!&7DU-^P6'$?YG-;-7\XXSX$>4Q$D GW1VI<H#N<N_R1.1]C]'[
M8J$V88VBM%[>3]'T-U"&10Y,3\W&CN8K.RQ/%^85:N2MQ#+UZAR_=)]U;VRR
M\KN@K!C5]13&97EL'_XY2E%E,'(]98MH\FE-*\VC(^L29J,'?LN[H7O6$?$@
M@KQ H\+?K+4=>^X<$;U91/-U-@:@C.A[=*J=46@Z]@Y'FQ4[F&0RSDM&DX"M
M4Z7,!&\'6L(18_T"!W&PV%$"BQT:L-@YV5QB_M)RD_BP0$8X% ^6W8P/MS^C
MI>R$'ZZ\8,;!C$(^>_]E#7=0#UJ,8BP,E,D4#O!J8C<P?E[C8QKN(F$44FSL
M[E!YW.U&)UZ5N<Y]S[Q:1[:]J9M$BDK2FSJRR8H;BQ_OJ*Y*/1-*?/"*V>HL
M_Z0N?^"]NYG8G-6;:QYEX@Z6G%NBV+@>G-A P_RX8VF??2S?\'QM4?^C(W-1
M,9J5QG5H2^7TA?,7J^]U!?0%S6D*)IN+:UH+7) NSZ%7L#X>*LYWH_GBZ.MQ
MKXM<43FR]G),8>&;$J?4HHZ\**3BC<\_MWW#[Q+T!72%'NS?%Z#=B+6W\W[9
MOZOC1=&(D'R$#R=\9B=,MA=P5^9:6F:,:RUDOYMBZ7#LOK)SO6M;[SJ'\0.7
M7@>-;\*%=,(5@/'@-[87<VZ@4AKG,T@ M<Y<7U1RF%G&/.1PA(%<[X,7Y664
MA2^.+KZB"UDTB#.AG)2P*EC)8FR1DCH]X'YKSKGY=:?J-ZXN^V5*9U@#DGW=
MDD/9Z1:*!'ASJI?=2Y5"-P*%.D=3 WV_1=S>LQHDJX*3F[.;J[R8;V23V)2L
M.XO6GG7$RKUGGQO0E0T/Y+C.;3W7"!E>JW<Q8(Q/63X#-3;BT;EX4<\)AB&3
M9=!L/+O=5.42UK%^"QX72$"3(3J'X&U% M;LM-@YD=#4[,9Q"#Y\^1@)^/IP
MF03(BU[#]"40#D:BX.F$6V(@E\Y1+<@<1.J9P9FE&%U<;!BSDBKS3 2ZVD;I
M1'1>13R4 H"FT\58O@<E\7VVHT(*9QQELE'6#9"#2#?GKGS&#YWY*I2U8X+R
M&F6(LLK5A/)BT].!#\_?N,IW6([!)E1"M+U^#$FMA+H*86AR2FD:9[4\@#]I
MG[9'H-&^UK(S1_/DT%NG\64:$]'50,:6=>TA$9P',W[)R=W1T2QQ$V^YI8U%
M-@Y?ZLP/I*W7*BQ%^EC9'^^W'Z;.[>KM5_*7T.CX%G#%J;% X]G6LU";-AM=
MR<V7(ST>PA@$N$X\G[]Q7*>_,I#QQ13\0'&AF8*#Q5NC>ZPG!C\_=PDZ>LA3
MJV%-78#[#A*U1@*$ZZ.DW*('T!ZPZ91X&3_,5J;S0^@AS%)[[2;V4>$JIKES
MI9^:Y97/RZ]*E=<UI'+>?.5^?*#>;5Z6L4<1GA<LN&2CF;&8U&JQW1[&C!J<
M COAL%AJ8DVI#]$W+]NJ%.PCMW@DF0DOP'"E-U$5[%OOB*HU>^*1.C43[Y=W
M_*=G:WX]=M\!;]3==9,<96?Y?I5 F_II,VV%H&S.&U]IC_WP\U,Z8[08WGW!
ML#0,HB;+Q-C&,<V8UXC\Y@C[?-^>2C40'Q4]4(PTV,?OA6"T%D[&%]25 "A)
MO[!FE27A2<-ZFOJ.Y+25X6&39[[-"2\S^+(=$2$8D$+[XXK \MD5-'$?#)5
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M0L:\4XA*&NQ1K8V-;9Q#^&;,*NM+'2-6[4\+=6>-(?:!B5YD!:C(.E6,?TU
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M+!(^M_*U!>VIT+7J#.#N6NATE#(B'L/5P]:H.DC \B!B>WNAQ3(CF/[YY4D
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M_-3 ZP3J_)N'[@7<ZFL]Z>H^@KX>R(NEW!7#GBR"04FA51<-3SXJ6CPTG(G
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M/@@"0L#$"7& +&?V[NK>;142-85-*\FOX+YR!\R.]Q36= 0'_!9$ 2,0#."
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M/0/>84ZR'2.'T<^#CN6KF20KS.A_)BBI"'%?M=]:)_P8%#W+L;&Q1E]^+5O
MSBQX[CC3Y]FP]H<9*U>6L_&&\Z413.0;.6IM@DWI?^N=">(V5CYD:SHTTU6M
M.]M.X,3@'):TW*^5_U+53.^5SO-WR;]$=K[! ;W0+!/2T.( UP"EVG2P'V.+
MM[_($#\W8PNV)*O??/":11\_346Q%8TUA\-@9K[5"ZU!_S6QXV\XG 4"W<E0
MER:/QV_MC(:N&301#YA&]*ZZJ-M27/:SYNQJD2[)R2XFKP]2T>EU/XE2-LPO
M*RKKE&]*]SDWJNPT_4PCBCZ")S%(<4"72Z>;AT<[(&B6C95GC 9C/=GFASWA
M>36O:VG#TI*"RGPGXJU#:G/4D[!!@WFD;WB$D/%$T,AG,E](-(G5;;!%9'37
M)^?,Z$CSB^\GZ87-LS)>+IN4?<2VAU[N:C;VJ*97/_MR1O3-H4)!FQB9;KCI
M&(%%H:A<Q@Y3O/EY?5E3_HJ-9BKYHN/!CZZGLMF;,XJ<:ZY].],@]O:"H2LQ
M@G,YV<AU\) L9^@@G^#@<,OA8C3OD4)^HH>Y)3XI@[>5 ((N/R 50:A1WH,Y
MFM+FYB#Q97'2P/UPZ*3,5_9@K3+%=BK,6;\T8BEJ@D_92AEX \56!5'P/$)7
M,VU03\G6QK$CG;:YJWGMVG"HNSF'?;UTM.#E3%'@K^S.$[34E.D($*:T@(WA
M:QW0E6!LQ9X;_Q&R/0??JL?;6(&A.*!-#F_E@G?6"?AI:!N@LW@I' /M.E]4
MQ@$2=%B\C;>XMQ&AQXEWK/WQ)AYT8VY  +,.04_A@&PIZ@^(F4C;5 -(BQ%1
M4:26OY%X5EE R*&O[ \0VD)7ZM'R)<IC'MA#\,)._FE$3UIUXH#_41JO48'3
MPR>NWDDG+&)C9EP^T%/'/F8>5\A=QMN>N:I.4F591#/EEG</UYF\:9]\_+K?
M1,J^49OP<.4GX'CXX)]A1MFA]B 2ZRRPB_< ^A+^.?(+OE_\T-AO,E$Q,9#F
MJB>9H"0$WZK*OY*I_TK4_WHGFB)BB@*Q.@_O!DW2VHTPIS"H2E2F%NZWV67(
M &((>62[!=U9)TWL>:. /:E"A?78@6(/)?^2*<<7!TBY@7$ @3J&5_9'RTS[
M>"R4Q-@*&"EO:P^;XFW[,_'0=I J#OBD\<USHNX SU$DXVVNLU OLY^AR-Q6
M[,((:81-@?]ZSW,S;M7]G5C-+?PZC? SBUDG[L*_T(#Q3J2<L.H.X3S>522+
MF=!E^BG3%"XLL]9%KF87M^TE"+J* V(E\7Z;1^J>$_,;*MKWZ\CO#\R5F$>;
MPO!PMSHHYG04]R[!.@[ '%;=RR*P3X;6BY\.9$<SVCLW"9.^? 'O\1SD$.@W
M5.3_?"X%F0Y+! I,0VS"K2943GR"([ES?D4T\F#?FDTF80WZBK%0O(?=E_JO
M[SWF=T/$\SLNTL3]7+QM)2>^FD//H@/P@W-PE!1^P\9,\@-5#LC-FRV*_\VB
MU@0A,XLQAZ+"^MUJ<4"DQH9D#_=OZ$Y_:HR6Q2)M<Z'>P^CNM_\GZ_\1TF:B
M[ZA^E2P&/]/0BSC@7.KB>B83OU#;=7EE,45^S:#;=P+8N+O'U40;"H06W.VP
M(&BFTCXZX4,CX8R/_,OO17Z.\//_F7#-,_Z/*@E%9PU[.'*)#NVY??.6/C3C
M%W"U(;X84W]*'B8%!-K-[%#+?ZKFZ_YN&)L?J-!UJ&$6O$(GAL<]QAG(_4_5
MYWA39.?YCMI^/7]KU)9JTF]NH>X]1/A%JKX&+I=J\7W_)G\_/N"L)+?C$XRR
M) ':EH(J\!):^^L'NL$[8SDON2X^)/+,$\N1KKN2E0:S]YP U] @R;,#=:=4
ML=V2@J+-4=(%(/.@.CF](]Y+,F[/CW(&W7HK:!QP)Y0@EN):E_MEE*I&G]5Z
M8C'LF67FM47%PN*2KH>G"Z*71Y78HZB+C4]&4!R+)1^P\GYH80">NN1MYZ:2
M^8!*"_;4>DA9-+ PS)8S9E!+]4Q8JT[C77T:@?<>SXX>(LD6[L 03TE<:QRK
MW(IF8C1\:37EWT:EFJUO*+4H4MP[TYW9.<)N_VBEE-KZ_,W#0@&S#*FQCDR3
MH!?"H,,HH3;Y\J>82RDZ@\F^7PL<IW)*.^-* Q,OZ+V1S5\=XF4G/,EJE'OL
M",D1YP XLSBOJ5V:=$I3BAD.&!BT:LWEB(I^:_,@]/;0QXPU>8,C&S+S(267
MG["=:%0^C5J:N%C48^A4<)0I\-+7:+O T3<V+%UNJ7Y#3H]>C7&_;FR,(Q +
M?PH\(XYPS/LT*HK*-44*C>DCWO>&IRWJ'HF;V"5;L!S2SLDMM+,J&;APS?A]
MC2J[TQT"9J7@D4AGR GL25399+;/BJNIR\3;%M[&,!D_\/$/Z=3:6VJWVYSX
MJSD031^%JK9(T3W<C6*%#ZE)=E2O]E+I=W4N\6<M$=S[P-O/R$#M&:3I<7E=
M@L(";NB$N% =->N%H9/X4%KT2#@J?'A32]<+65&<E^^D](*4BP\]H+U;](GM
MR.5LV3__"(+?)$83J:J*:/.1]Z)]G[885340*..B<KJ]=7.S]HV6PA7@H?&C
M-%+[_B&-)9% -[04RE:YO$=N.CK3*FE>.]=\:[!ZX-( __U0GJ1#MR3-NOF0
MRPXWTZ,5*V,I5.)+2& \<WFN-R0)-2JP0XRN41%;^2^MHG@&:1Y]#*'I9_+Y
M2/WNX>R1O"=C 8/NR6F&YI9QBX4[Y;J/%]K-MRX::FS9)VU:!^H$G*@Y%%Q0
M)Z]QWT/BB-\4AAAYKJV^]$7%W2-O4\T=2CDZI)V.))#%:8>>/^VA^9HJ-]RG
M5<ID@Z9_?_[HU]>T@6Z[GD-P94^^EQ]U2><7.L67,^@E),A'-STLM5"=FA5=
M[K )PP%A5LB^7:=D;%!0Z:/N*:T*T<<#^;!-(\,;U$F7E\,PP5PXP#L<18SU
MRJ:$CI5!L6(*&/'L3^!U?L<P[.X0#D .8K[$P_&J5/L1J!&[Z4J\.7JA%!W<
M 4<Y03R@<[I([EUT$7X"YT.K&S&$.$"FSQ>\,@+' 2S9K==XOE<##3FV+BZ#
MY?'Z<MI][YS#LB9F:WD,!P1UX  *7@3%[E%##AP M\?K+GOX%9Z$78-/4%YT
M/]1J2BR[>)?I[T$R>,.! ).]<G>W*& 9-K5NC675'@?MT)8KX0#W);R&7 (A
M5N%[!P$%DZKH+6O\ZF.Y%NH'[ADF7H57>/]/D$7OC253&Z>?TI1D0C*P8]]\
MHP3Z7Y%6\+^%M/^V$1M0]00QEPL@VZI--1%+3:2GK2*UZ-CX:_/LC\=&4]S\
M%.+VF(35"^(')L=R.N+5A5^FJ_1$V4P>S&/BU1IS T;M,[PFN6M.FN@0^!;4
M%#QH6HT#0/GB4MHJ2/Z,N]E/WC#-&(X:FZ+:HW?EI2Y_;JN?&>!#\/<D98)K
MG;>=8E0B[[^LS3955\*ZQWQQ.81'L0D'%,.;NPLH#[ROSOYI1*Z<S9;Z[@;6
MCO_'RY\&X![<5+NUO]FF0<!/?2 -PL'G^RE+8DK?K@L.*(4WMQ.]^MZB-GD6
M1K<K/_O$V%RAZ/W,27Y9%5^N;G6%@C6OJ)SAM%DV!K*)Y\JE,AG)#^FIXCZX
MRG5F+V.4J)L''X@>RZFWLW6]>AZ[.GJE<CM(^R@/L3T)6SNQNIR-<WWM>T)9
MI*%7@H&!?,@BH]5HZO$/]Z4M<J4Y\XWI^'L"AUUL0AZYY74.6Y9:9258WKT8
M9T6ST<YO_6"-)_2F:+C^=.Z2%-U<ELLGF' !<MG7)G6@4J1<<.'2H+D2LK@B
ML[NPM9H(H4O+#B-II:!I;_^V'*KI[>6C4_[EYZ]9&J]1LU/+@>,@2HL=$VQ8
MNJIE?+_N@G-AJB6SJK61M0U'1]WR!VE>6Z+GVV;]A%P5HN7>.B@*\TD<$  [
MC13PT<Q^<G0$=#W76S5HTVPJ6MDIZTN(ODPB1RH:E9-=#'I]\MEC A=#U&[B
MG"FDC/%<'G1BA4)?I# [>U"62O>V*&#"P4"4E4NXEF]6^6@ S'MOM +953W*
MV"&R= W+VR_OFW$NT,EZ.C7<V"1(59B\_SP)I]ZS@>U[QVH.)1ZGJ &185RQ
MM,BMZMV+0W(QU9+\Y=W,ED5TG9RUX;#8UKYK5C57Q7WN1S;MCI.O+O,&:.(
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M4$X:..C U9A>L&K6)=C8G&S+:E!GS_V<-;,?E/!?!:/ HW*'E8NGV.R3=S^
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M7M][DO/P&YV@I2'"<P_^C<CX@A+OSZJC>)BSD'TLI?\6$O1_HQ?)_Y*/\9]
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M- JUV<P\GY Q/L!F#S=>R\Y#)ZQ0LUAO\ D<,-X+Q9X+WM!-QNQ"'D$SJ''
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MJX'6TCB0@[,&!:_<%/I+>.Q1%ME7\W@*&.S&UC>^:QD+"T: IBP:++$\ Z]
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MF\F?V9>3O*SMK$FU%U\Z\_X3.E/DHW8BK/3+4^*(G(3SPWSY'U!+ P04
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M>89E*X0YR@\/( 3MM]9C*,?Y:A&&R@M6Y-_NX*P,--7)[-LN'.E^262>]G=
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M4E+MJQVYZF*FS(]UE/4]+V2$7E$[%7HI[7_3SMV>)Z(VPO"BRJ]^%TABV[F
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MM+)AO$=+L/3!BZEOIF2P4&%OU%A)H[H_ZU'.@XM)^OI!;#=?/D_Y]$ &^MS
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M$EBE[<ASP$6:Z.HGYP!1/"8(JL7J7L##]S\N++%FF)B:FC"3UU5C^QDJ*(L
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MZX\ J[$I-27)!L(NH"QA-8G7X'I(4RY)ID@VF&/_RPQ5\=<<,U+YHA5>]X
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M[U5 Z2#2:U24*B @10)$16I$0%J T*4W!0'ITD5*5 @U-&G21&HDU 0!Z8E
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M]FD[4/#=-0&O_<NL#;3K;[_*.1-2J9 \ZKU<_:NMM(#!XL,X+ Y_@&UHQ%P
MN(EV/?S5J0TD8/6 BR!ZN:/J[HI'T7>@KY0<1<_6^7ZHY9DNZ5&;16I+,?L4
MZ7$M%/5-W=9;%S$'%_A'^"MUI<&>*MWH2,<.3+ !/]T[F#K3[?2&'+>XY)Z9
MES03U';^:P=?)H(()6UXGF_= L0VI"XG.S$(4VIJ&?#8742!WKM;<?E(5W:F
MBX.X3I8@Z4W"C*_G_](K!637SYEA6#Z\8"+;X#?[1/ZI 5-7CLF1A.P7.\NR
M>,.X2->5>)]RIVTMYQ0U#KN9@,KQ?B7W5!',Q/@/ R,JU2WL+;1U5O5]J:XP
MR8;%%M*$5OQ36R4;F8X&T\Z6C2^$\1"[/2I\F4],L<@40BJ@8C:?<.[-],K\
M&1V=1//=PF)9<8)'ZR2\:<E\YPXQK1:Z8/%FB)Q4U[6U"Z85W62./W5)IV]0
M))PL70 8+@!]H)LB9T^#-JM@S4,[SK8\]"SP(19KF_  2/5P<8XDEVITCEAQ
M.OK%Z?G0=-#??S\-;RAUZKOL6*$&(MGWNL3($[ED=GS:1+_L!8 M[>[6M>[/
M!;(O;E%(O?V=UA%,T2,:!6EOPG=UK(J@$4WA+@Z=[;CNI%WRY%/FQ?6REE?J
M3RDPOC8HO,.K48$,7<T:6;465&X@?&5#:D/:-+-"T&DJS'.\<7I?+__C9K&V
MQ_,<.[8A_ARWEU$4F9#-C/F"@0A18MY:=Z*P;,<LO JWN1 Q4/7+6%KM#X5$
MMG/4WOST#,KFS YZ2&8%QIS.O#7^>F9I60V*"AG+6S:<I(K('I?C7$M.YS[)
M:AFY /P.&.*C?[J>A"B#$R/?3\1%(M1?D^6A79M][4Y=I9 001\5*V<Q&?-/
MM[6#OFC^%F2;:NE2@@7\C*#OK32N1WNI)UB]78O1U>)Z^_6#NW9>)%(I%374
M_FY9F*C^D22*5XNNWVJ/6T\UI4%PQ8T8B\H%&SE*DW<;VH"+7#O YOIO3F"2
M=/$-9L'\TL GH3&X-Y"%')#^3D YYWGA0==)VB6O ^:M#8F MQ&.^82WS0L.
MMA> F"Y#G]*(^2Z*6=7W*DL&0NY]5F.]5DY>0\,9DE7VRMY\^[ZZ.W,PE[5Z
MEAYG@594X"AQM^G[[1NV_UJR3FQNK[\G4"(;"=TX0FXMB68.KO@A:;\)SSF7
M=5-@S5^L!G#<1R.:?GR8D(K0GN"%6A/"?B+F*\C#G70*C%\H[VQ6W,[:$^&[
MY-!SG#=Y8<^?VA9A&V:R#[YN3-__B6Y6ZV+[461J/*^RY[V$^%>\VMW"$R]Q
M8P/( *TRXU6[6I%CXC($7QX$\A^/KJ0ZLT]'B#A IP[MTJ?[3GSK?EK<E)EZ
MR<=0<Y(B'/%0><!7A(>L!(U=;1^]FH>;1X#I?J$-0-;I^"<MB1PMH[_8/M..
M /EW=83<,1,I*RPP\7HPT6M$&ZR@>W?"(IO;J%Y"QG#D)N<J1[KV48/#C,<G
MW_K=PB?+V\8K9O63%P!;+8_9NDTMO4D3SQ?8620)=?P*& L64K%(:PZM_Y'B
M'N[)7:+5LW',9KKOU!-5%Q8ZYSYP@+Z44[0*]],K_=0J:]?\/=&^CZ\G^15-
M9%+B?W)D;3F[G#%)_26+,SV)?+%&]6=6<:]M=8GC/M'TTXZ:@U-]5WV-5_-X
M<.C;#+5G;%&C@8. 53\G$>L^N8GM*8OLIIS.O0Y-,B(Q)'CN&>J66:<V^'FX
MI&L#>MGCIM?N!<#M:\[\RY0?=_]Y6 ?9'_$*0?ING#?I*.L>70#FA?GQ:MT5
M"\/KHY^V" (?A"N>;PK]ZZT5$4)H'G7/W\#O_2H?K9A?R*$5D7V?G8"MR!A$
M9GT3X2)+DH2(LICQEPN]H;PX>:02\XJG2Z!&T 7 <<%BN#.C=-# 0*IW57JF
M6B;-7UWA46%;)&;EN8ZM6L"VE*3KZ-B*HCKIUGYX-=.HCK%8#->[FTPW?0T@
M1=-D":*/#;ZY'"/@9'D#+US"6KS1;X IUV_:]!.P6#%_?8ZQ0RIB&2-YH> '
M<W4G0]X?T8:!O#[(3]N\5/O*IW;]9!:B!7P;B)!,06JR],N[C5I_:>)1ADRR
M'!547  ,]4"DI9O;6B6M&@V"PE>+(B%[E2.K<.*"DU;XIILBEY;PZ+QAGO$"
M;JOF).)2WR(CP]8F^,@S#@=1 8I\RW_XG<9?,RO7I7Y;OIXD-&9"U_=%]#G;
MS%_98F(LGOO,F)CR%+?2#V93+>+HBQ":+DL^LYM^2YZO<7QG.\JUV//TW2NC
M?Q96!EK7WHU4RUC;^6T@"CS#T1U;+O0;?@G*OD%6ZYU39N=G(%")SY1;U\/S
M?#U)K].51%@@AA<&"H1[- =YAU1 8VV3D-\-&0\/ &\8J>+)F"$:9!]6,G6/
M)%DA9-=W24(1!YS0*?2C0]&4,>Y7_@D,@%^ G1@C41?!67VI&ID?L3F?EB1.
MT*>>FWZFJM7\,BT*^<=.VA!X=D:SC@M>L0_,LJ_R4>?.IZ&JT4\6!(@J= DY
MK[&V3BL"?>6KV?!>$/6MNVFNJ!9:'!GG+-F*9UZ] +Q.D[\7)*/$7:)DE&+*
MHVOL&[DJGK_?[1%" N,,,7:Q>W5(GUJO_,\HEKR:14W#(A.C'<$HCC8*JIB0
MZO-<>H/D.(N(8-LY-*S=^Q_'>:742&.A[B\0"EP")OKO,$WF$W.QKO !8$R7
M%N[=3YA1QUP@F*,#-)+K$3',-&8#3<SLH'VO%$6W0+3=SY9,BV"(F!+FP.V7
MKJ49#K1')KJ,3X&S6OP6*SYEWL5$B39H?!_0'SFX"K4QWT*4HW(C2HK7ZT:F
M?Q>IU5UVD/#VRSXGXCR%ZNM2)HZ*I$?(0QOZ^E=8 [NO$(,-\W:/SISH)994
M$@<>+Y85_J7?G*%8;D(*71)W+=3N.E[.%.Z\#/9@8N]S%B@KMG?JL@+%%BJ$
M;#+'/OH;.OGZ^3*I97)KO+E#&PQBT$1(&P_(M[7#&[L*X+(E[AMM)?PP4QRJ
MKZ\Z@W7[RU;UPT+0@D_:PEC6].7F6T>#A8CQ"]CGD5=4)I(/828SY&G6A.%I
M43>C'"'LS3'_A%<&(%_-XRKR= ZZ.D4%'B\LUXK:)^Q\61#;6GTF8)SL6I51
M7%%<O 3QTKQWW5:IZ-ZTMS8X .YMAW4!J;SS-'E8-6VL&O9B"5ZNMTNK@AB!
MJ>""RE=]&(<JMXLENO V:)._0H8/>;-CA7EJ5L,AM?"B?,LLRV"GB5#F$>GA
MQP0&J;(/G_]G;Z?^NV^QF/$^O?61#N<52,VU@N!&?OFXUO0G?]^J88I36FCA
M]6'97),&2-S>B) U^,93AU39BNK)ZD/#)"CM*KD3TXVF&BR^U1&F7^$U>:69
M;>1!V[^(OWMK^\7'&:N1\YNVC?C@ ?KC>7G@5YV':9PT:*LI:I?"SS)*&?7A
MC/<#D.'>L"FP%'KE[=AG%1MD0:1Z&-E]9)F*:(&?QHQG0@T-43I GGB7UA7A
MJM7.?K^<46HK)+LVJV\H_[X.$.?3S^^^)UD#W0AY\7NR00X6)RM]F+(W)-U"
M=0CW*VNH<K$MSUHW'E;9K0]#'Z#N>JY*6UO:>=^O:B TKXAOKB1? *Z0G/6D
MT*1[Q,C JDM54R?BWCY][)A8Y>@B&A46N+4+*<7E)D1($DLL4'O(0,F$HUKM
MA1O-S<T_9_/6@M;"-+>5T)WQR>-KGTP*GTH4.$AZ6QFDT-*-_Y"OW9X]:L./
M9^SNX-TF,(/5. (;QE[%,.B=UY.V]K;-UT#%T1+K[W!+,"WI$<ZNKYO>4YC7
MXJJ7O,MS;X2\NHW<L^S&7D. KRZ+PXF#;&A>D4.WX+/9@^;]N0ZEZMRI2ISQ
MGC<!5'*+I'.>?<R)JTX7Q9O]*'&-Q$9'>U9(JQ&@FM2O:$)VM1]%L./LAB8H
M_P0M<T\/Q;X\V@$O@;9;PM"/,G1< 7Q#K:2=K6UIG1]-BYUE5A8@U;*OS26B
MCP.EI,[4L'.Y%F$=.X=Z8<0%G/Z@L#B>-@[IB1&ZVZOC5-[_9:Q%,YWO^[9=
M[*!_[YX]69@H@%=^2!S'P(6)W8^F%&^T,"EXUZ6(@6[<K.$=&D=)9/U#3;^S
M2G=UX#S/-W6#>[\X=:QQ/7*U1JN=F*.F=NJ3M9;3O+',PH</.C/&$1U)I=GA
M-O',, 3F($:$7X]A>67K L!RW,GS$+<W4V6$G;W%+WB"-J053J"=ZFHL^]RW
M)O-T34JBT'FKMMR+:&3WSFW!"J2R.Y'7=8-$0\S TV+,WU9Y.9"+ZHAE*Y:0
M^:IW[S_8Z++=+.+Y(Y->C[->\^E?DEGI(RO@W1(JH=YJ<I.>EDHY-LY1I')=
M[6;=M'"+^P%#*O5T%>5" I E!_6%+Q-R[:D+WJ./LF9W7IY/%)/E(\9:^+MC
M2>+NJP4=X<"'N(X$A.GN/W\76KG;&B]2CX94$P)Q$&SUP $O].49EA--DU7I
MX4\_)W\M;[THFK;[P6KPVE37A[(JOFSH?4.#V5WT+#CL5G7N9&$;PAB]I2O4
M_', GY 0B9'&%=>6RVW,+*.'7]YP-GGI2 66OG.F17*PB%=?8;&$27N7U3;5
M?A37;.O0'*G1C@#7\,&__*G[_&N[U;ZU]T9#\:?3AJKWJ4(ZIAM%<VD>IWH)
MX\5JYR4ZEE@6!I+4=/WS:?(D)L\E;._PLR-EQ:YVA$][N&PY<1;G[XR_ /3#
M 3OY+O/UZ2G O$!"DDF7NOLZA7FDDC/FOL.8K"2?9[4ZV:R-A>)^C7S@^@5@
M.$C/ U_2"TQ<YB$.U$ 7,(C]3(//!2_W$+;7+#.LH_2>%AM<->R$P.B)0MB#
MA&X.F 46R+Z=$]HV^^$NRC>SX?!YX[I2#U_/1E=T66$C_W3%E@K"6-W; 03Y
M+;4J-5CVL6!R&35U$*[S0QV[TF>JF*)'VXW;.XJGT&!A_I;ZOD(D\,O*8B@_
M#LP,4SLO0W)45,<%9+!!PYL\[B2O6+:.CEX);X[)6_NL.50?_OB^N[Z 59RZ
MR8AEY^[L[EFYR2^MP*I/3H,@)VW/7_^RL-T]D8GMJ%0='JP%RW:[TSZ\=%[.
M:FG[Q>B&.:,K(4XTMO746N*\6$^,9(_GS@W#VPWP!Z#U2D1S=,4-4^.")NZ:
M1"E'9PT/"=I-S]CN*,-Y/PY(3'T-LK/;/>5%MK^N^'W@MC^[5-314)T/;23X
M$0/7TIXBS'SZ;JZ ;TFX6>O49#_D,N"*6@5HV17!.,YSRH@A>--^8=$9E3.6
MSX9*6G0Q6,.PY]>COVN0V6DE4%.<MJQ#V*?FC]I69&V7_B [(M\V?=8(F4ES
MOC]61 #].V%-E^V+N$KB0Y'H\9%#Q1(SQ>--2UY.A#)Z4^.TW96;,DJ]QZK[
M 7:Z6H>5]-^TC1^?GZC7&'!=IQ^%=L#;^ZXGN26M^;4)<CT)BYWKLIGLHB.!
MB7<:=IHC653-&'Q8MJ?SWA[?A8T^"Q5J/>MYXO?&5P->ZU'O2VS#O"OGS,_9
MJJU74X;'QU\;-&N:&]?6#=;S)V;@! 9/\D_B='PPX^X6[?CF++=F5#>:OIEQ
MBH*Z5=!=PH6JF4ZLPR)>;85K/W!K'^G-$]^T) 5Z/S5A:!?B;&7 V_9'J?A2
M?4G5%JM5FD3\\#-'7Y;EW<3TJZP?M^\@PAVZTD[TP#CWW77L..WJ4#^8<7&X
M6LC"J5WY\;M6%^&5K .U9;W+RO]Q"L:"-\1< +Z5T'F0>?6$D5W3JQZJNMI6
M<D];::N& 5=<2AH@RU+UDN]G/ZYHF>\36D"@O\KQE-DJ[P1L;5<J#_X5,Y[I
MPEA0)%HLG /:V)]@^G5&M0PPU?3P/J(]7BXT>A%':^$,,244$8'UL.>XY80J
MC^D%4&=S10N'J>]ZD&%3C6N/YM/"Z*&YSK++)E.K<[=_:ZQY#Y'&S9#Y ;?B
M>GZV^,_0ADB/=\?Z)"*UJXB'H,E-7$.<QCO'QY0W.@#ICY5.$@'L1@".7E5W
MPC[NO"+BRD]5XO[]AMJJY1#N,WIVH_3J5S6"^":1B;FNR@;WP1)FI"J>XPQ(
M9M<58[:W-W%K?CSZ3'VMD)+BC]9&^Y\-*_MD&QE9 YXI:?F3L]-"Q"MB.Y?T
M=/"[O=K@!9^.TK&('WI7+@!Q8;C(OM,77Q(/GB?LV3D^^?<5MLLR+1K!-0X+
M(2HUD)[@)V+*W1KUF*>OJ_._5C;Y9FS_-IN!5O13=&$&<G:?+II3)E6*%V!=
MFZPQ\A8N]R!",K)_-X>[\*.<-M&FFZJ'+$4>%F9"D1AKYHEV??EN:?"OM0Y.
M4L\I8BEM,G38WDYWO@*S1KH?)!8K$]UQZ!Y'3_%^9SXWCB84DXMOATX5<^.&
MQOWO8ETU92W5>5C/OTN'KSIJ=]I;%EVL%?HF\D=0MD'3[I'(?SZ.1"Y\[!H[
MVK.;%0:JL(>^Y+OW=?[/%Y%;5L!54?>?F;=W8IWC\ D$ORD]"9+>%!)8/:("
MJF=^Y&DGPTAW^V$'[U63-^5OOXOR$V1D7-^C7KW^,!,2:"R12Q)Y/T>9(%<N
ML3Y>[KUT 7!.&-83)[J>Z1.[O_E#E>UFD*KA%>:UG.VIF2):]VROL-]U_Y0>
M]!M5JQZK=PW*@KGLQ-JKM9W<WOYF1GO[FS/9I(34:\.W-7_L!N[E$QBD9\8D
M+0T4V(RUY^4%%A[&TW N9+XK\$+Y/$)F9).I80+$3EQ)?^;+@C[W>[.JU.VS
MM]_^?@_71L+?/3D<\"1/ AGUY&&.N98_ZS9PJ[CHUN0P2UED\.U/D1Q/,I"@
M(WBE1VU(D9W3LQ"7\2WBZ9NOVR:Q?8>FN2C<D0ZP;X6)Y+\F$B<LAG/O-RT2
MT]B7+V^:KIKLXV O2U7>'S1RU3^(=7YZ 6!@7-/K6 T3B0^MJL6<6= ZF)0B
MI/B6,1B#Q=JFZ#<LM_U^4OIJGI*3'QW*S"SXI08&+[@C4.\W<Z<^9F:%ROJT
M[Y)2)Y@]N+NX<(2"\L>4<KORY8B$8*>/I0;A1'@)T@7G@S6/Q1]8XP^B&@(\
MQ>:\I]#KJ@9/?S-_J85]@*UL9T?3SK"!32P=FY1L;AZ^FRVYU=C5TC8)8F;
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M)FZ2OQ&2;<PB&K/$^XDIL(=KS.(,2*P:Q58>[^=BYN5A.GK\P 3O>[GXL>'
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M764J7:G5XOF&8*QZZE-BV*HB&S0?2OK3E*87ML:J<2O$PUX1>ULD+43QVP$
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MBX7<SQ8$^6A;![QU]Z?]5DA1K*\G#ET;\#Q3@FG-[2+"7RY? !Z6W".C9HY
M^OZA\I4,+Y\_LO^MV2OQ)D'XG1.Z)_S6S=!GJ51H)'R5-@FIB=45L"7WX DM
M:_$M'7_W$Q)OI_\=-(L],>-YRSA(]R_*=5,B-GE?)QC;JD._6L(*S=QBRD'K
ME?A]-(E:_3H@H DXBQL0E9^'AAE/!X+VS*<??$7,P GA#7]YV6ZTHF\6NT3G
MHC7X)+G*WQ:ZY_\[PUA$1XA"47W"_/@-!-[0\2L*<2_V48'!UYA?6ZR]HG9G
MHG%ER[?U&\=N^4R,%\\6X,NF!T6888:8$M:M2';5)6O'.:0-I'H!Z@#=ZVYL
MD%O//?E9)\OKMWY;6%_M[TJ'1*&@M7=GSZF%:# GXO"5/;$6FS!T 4@^E0"S
MP8PQ():K?147 +?><@&PC'KQ?$508 [/2LY#7Z-]66M,1FJ$*,R,Z(.5YW8*
M,Y\D>6+@K([$,&L49KJ_1DL__NP!*S=#YK# H._"6_N6D=N4;X3/[H<H[I9C
MT\"#)8W=T:KUP0\+;&8/5&9R-@AKPL\GVJ+=>J@DA:+@#O\/;D"G6&RTN^GQ
M].Q!*6^%=LR!!N85E&\K"YR#;DG80.G(8ZM35LT3A(82N\3UJ]#+E7/%_+-K
MQ72_OZ3\_L[T<X0I^2Z'.,>@_VGQ;5U(=@+&[K7WGIRW"^XX!O1K.ZT>9'!-
MX%FGFQLD[NA-8]O2]F"4C@4A%6>;5 65[.$OZHX[VN-XE-"O)]QHM/<D(_ =
MT"<I#?DBEH**_>9[6A&3+3UQHO; LC"Q#=AOP>)YRMWI DRX 'R!>ZO6W]]E
MSI0;5RS.I'.EYF47,N+[5:UCYXVG705&Z<ELJZ'(\KB&(OC2@H%8/.C7*.?#
MA2A!@LZLF0\AX')G-0*@""#M5LO/+59&D$:5@;2@Z&\#.PW7"5SS?4#(Q"X>
M&]:=T/VE,R&Q065+D=SK_M&+>T[K56-(SB4US#>R%>UACV/8^WY68?=MF?\"
M$),!<P4+VJ^L;#>?%B>?U$JT2_##&"3B"LY--,S^]?:\V!1U5SU=;7YSQZUY
M4E\PZ$^,:A+G%1LJBMN"%.E*8 !)]CRS2P3FAI\8,K9^$,ZLL@?U/&7>+_ 3
M$](*,)L:YM_O/<?0THH&\,+#Y&OB7\OHW%-L[CBHWO&7KE%K>WRRG!M^7EV%
M7OJG#/J'E^@R^[;W5AT0])7PM)!MF]D!7AA!!?-%'65P R\EKCQ7=<:+\J5J
MK_+U%CSUYU4S/N#?::H-Y[8)&&KRP^_G=F\=WGT<S0$KC <;)"TZ2)5]YK6\
MSPGX[W9G4_PE<^3MQDCP6_2MT!,#MG88.H@)_>B"NNL__/E!WZKNVE')&='J
M!,"!C?B#/>;*'1YN..VW;J&EQR24PXV$3XOV*Q_V:0LZ[^P=KKZ2;>#U-%>W
M H>2<\<*2LPL;9H6DO:/SCSWO?-'L$;9OYN#F9X]HY R6GWSZI8&MHZ=-O2W
ME(-TY4PP9T?"QP\L"N<5)&/L9>I*SMW '<1=QWOWXX9]_'R8=X,&EVF23GZ8
MXGI]]2R')[A^1/0Y1@RO7 5HBCR)B-QKRMXJX?Q'],:6G-$X7@#^5,%OG<='
M_IZ.$+@ _-+M/@K(_G.CJVJV:XJ4)^)QXB55AOS[[7\176<('2C8UC+;JW.U
MV8A;LUJBD+D]L>DL#L&Q."40'@.9Q@G%@>4OQ<Z,W,_T8'A)IXYV%G/$P:.'
MM.F>)33'88K\Q 7[L(X;+7-'C-XR2UP%H::"U_E*U@>G+'B'"77A(JM7VZJ)
M_JMS)?+[Q7^)MWZ/1]B4O!AQ<>T'*TK*D^SA8651>H]P);OPCU!)Q\P!'1;<
M0?^I(:%@N0^^3?;:5C*8\D%/TCUV0A%!8Y8]V Z6A;N,+415)H<7;Q96(KT]
MORT;NRCR ]$\GJY7V-L&;XLGG[0_?RM1BYC1^.';IT)QF%-[!B0.8?<;&[9+
M6!N.S&0>-]&K,.N)L!C+88*;":UO*^_URO&P1?G2+JL&&Q*M\;(#H4/1]:1
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MJHK_<#\?:)^SL.QV#%"S.#'EF,X%G,(BO*(;\<:X?M.:&,/X"T"G<HV=EEX
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M9M[T1DO.3:NY4;F&/Z*-6KO4!4J0G9ZY['#*C_ZHP6CKH<T,:;_CI3*VY01
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M45&+=TFRACF#L@JX]^^<CC5*'Q&K+::U),0?KY(NJP%E_RP'OG.8D1S+7D^
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MDGJ^0QFC;Y5LFL%#:(["'TGN;OIIE8_M[C_I<RR8YF][H'%7_\M5H/906IU
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M-13Q?DF<L#:*^NSE501)[_79G(BFF]*5?\.V-/*6QI6'P53C'H7%M[]^9(-
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MB:Z$L?-'1&-\^Z.I(V.+04TEE+\@\IR]S2#^VZ?K.<'KGE+6*P&"&U,*'9>
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M;KNA='_-=#Q*F,8E]?LSA\%/@HD%,UAD_<9>2BC!:!#7HRGPL^%"BKRM(M0
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M=\6W:\/7,OO.QI C6P'D;F>'1L7+TK!)F(N7-PE1.;-HP]')<6JMPC(&U6E
M'Y#NE,\17_JC4:4)P^\\#N[:O4QFKTUD/2_"4=2(%_*(@OH3UMQS^ 2)P!,0
M,1>C14F2,@I=IK&'Y&)VT?=_]4TN)!CMJ*S(('/.E?3O.:4V/EX)13U/V?7%
MP2FWZ/EB I89EX [!3P=/Q7^!"AO)"O/8;>-8EJ:J&]XQ5@]34I\>T,#M-LF
M_O/L G1TW@E<GQ?(X%6I#O_!QZ" O.&FZ"B,+\G YB(9W2;<+9OG\LN"'YGI
M 3::#,8TC'WA>%.A&^<R;AZ?Q*J/B8! /K>0,P';;/[)FCG]9T#1F(T75#H[
M0'58MX;6ZJP\\.P2@+P$3&:55)A ; [5SB=(1:RG_U4,C/XS_\H"!=ITLFJR
M7RK2;,8 O"5(S?'^:I #,0_U%7+87=]=3MP6LA;HS+N?O!CN2-GQZ(U^.\T%
MU0OVF\'7.^I[+P'US;%0K4IWSDACW[_X4N;H85!79.><N?*R^>65GI3VE$'Y
M*X<;_>#W$Y!3;,H[DBYC7&']3W\@BYV[HN('CX="K9ZI?KYB5!Q/PW479*;1
M<ZFJ0^P!+X9[^:,^Z :[)B%?:\46*'5,[F_@!]*=_%S*!LL:4"$N=9TCHB+.
M54Y"']._'S@6,XM2&G%[U Y\$JM(!% ]N 9X8Z7%3KKAZBO9.9C8P"X2%Z]N
M[B$C+L[P*7+V>MN(71G""U=P@\E-\.G67>Y*T4WM?7',:.A*218A]*0%&<8Z
MH(<??;<EU?@7+5(:[HWH%05Y:]F>IU$SS0G&*]S@O/?\.3L-%8!FJ]J$>3K8
ML=J>4$=R@-I7G%L+L0\5H>V\+P$US8+_NAWUY.&_;0??_W=0B@!R_D2M($GV
MB+D#['@2^Q^4)E=S,[ZFX(<R([D)!V[QUN(\HQ@DWVO&FT8&+(;O1=JY-UDX
M?#<<I(Y&%D,V=F4PH?FW3V"3C6$/;E5"OFSC^M@2>]>E?>^X#%T"?*0W'*8[
MAUG$@AJLQJV(TGU9E09G#/'B(S!W!#=(BX%, \ER^*GM8++$8KU&VSY$U_WD
MG[\:Q;1 Z/<S+]EYEJ2\/P>$/'Y\ZTT80S-6_]U>1_"*]$U(R):.=OFO48\_
M'.>;^L<(BHO,<%4W1_:+'/DHG-<;M$$[?GIJDRWF]U-!=\F%,AIX</)H!R#$
MZGN;Z2#XUAPQ2T_S!HIDXUZ]6#>_[.!QACB)7'J\*F6Y4-,/R(L8VG(DX-E6
MFJ)7&.>F!@HX" $=X>(S^PU$J$[Q]ED#?T?R#TO,.YB/(BX/Q\_0^->B_5K9
M4GXE%$ 0;)[27\VL)"6K0E(\+_K)^KGA$UKLC?";T"<-!'(N)EM:7;!I^=5D
M"<$QWJ7A]>J0H"]R)'V _3#B3ZCI[A7&N !60M9[:7FB?PK#]IN!DQ-4YL#<
M[/[UH Z9(]ID!N4AWHSC593/PH.7F8)I3#)K;9'(5&Q1LF#TU;OO=-EI"@$T
MJ]4Y/25LVS^+O3(.PFXCO4B#='))0+<UWR,S72AA[O\^98.%?G':TG)RX0E6
M^97Y_JX/\Y4T#X\_IR=%!,?/-9> 5U!1_'2_NC9V5KT]^^FA^ROD3I'R5NJW
M,U1#>5N]&;G*2R^]6H%Q2ZKJ!Y$#)#UPD*!ZT#^JS;[9)'240O<(ER)J(M1"
M,9,". L3WS+)2%DYH'$G4^&[LC]M/7TO?Z%)V1P-& 0$:*ZNPOWLY'>>/1<*
MJ)L(87&LJ%0;=/ER1$;>3B 6XU-ZM=A(ZF=6<?+';;I_/K7JU(6Z[A*4UZQA
M9SNKDJ[8\0%D-/P6'T8SHLJ:6+E+TWQSQ[8_2GW(4UNLO@E_OZ4[/>=\H*,=
MB]Q%K_ EGB75?,9Z\91.2Z)'[-KM8ILS"LDX9H$WYYR;O59)2B//';7"X'Z5
M-^*BE88<'#6SZ@^\M&3Y(OC8-XCU^$!&EJ7Y.?>@H0V=-YP.33W68[2Q*GVN
M406^0 62$!&! [.2'N%-X%KO26I^US\C/+(FA9K?EZ;I,,4DZM=[TR2U)IE2
MKJQ8S:HJO6TPI2<JJ$L766N7;A+F&SL"OT>D/HO*BQG;;U796>K8^,97=Q!#
MYMOAY9N1I&-:VIR#GOB,7, I/2>-I/]Q%;(Z8&S3J,PL3,CUL71@$*MARLMC
MR3A2X3'J >)CR3\+Z&KQ*7'J1F6@(%G34*R! KU'Z(A?Z9[:DU0U=JS:=^L3
ML:.#49$^Q U&.J@CW@R/B(,:^>'"K*S8V )/.:=/69=G*W]@C5XMF3\JC+YS
M94%?$&V(/UVA2NCB(Q:</DO!^I\EVB;]Z9PVW]%N5&*+4M<[C&H12\EX<%[X
M:75*7FOVL)_,32 W8D.EXY48%1&!PJUVG==1[D]HPHU<_LD?X4P&  )$JE\[
MAY9M&?T'7ZTM-ZR78O8$5O03]J$61?:@.?[&&U+Y[M(9\ON38GUE?[BX?MS3
M@=W@V /*DL=SQN!@@MRW+O9VHAD,0RU?[6<=SV-^VI]0QC9#'K9=&>MRW"J1
MR1.5 %"FYC<>#>YIU;B1>8@W<,8Z0/P.!&$0T_?G[$%JX?D#B4]7=X8!!J]P
M&32F'G\.,/DQA9_)TYHLJ/ [)-&)(R 3L69IK6'429M =[K%G&I'?Z#0SI3[
M@_].?@AA: PTWS._/64,4P)*Q>^XA&X>R65NGEO[%Q?]18<^>1KQ&&(Q(?8A
M41]<I%G/4!XD5>GO6;7GGZ1JM[7^46_RIL![UO.R0>4]>V2"ED<*)41LQ!#^
MS#A0%'%T,F,[)&^7V5I7;SEWN-#'YG^O:"6+8LMN(-JF",>Z+UX4J,6JR44,
MPB(BP0U\S.Z%SR?M;^0LC K:0,:.U%(_XK_Q-N*T\*;,?W'_-0\]\TO+LS\/
MCJYB:H$/FDI!U1"_/92<Y$S^8BF<<N)-G8#PVHLP:GZRPN$E@'1[BFR<KGL)
M0)Q? BY$0[82LF9$6(_,4];NA!5NV=[[TO$[\C\K-AT'N.8^&-$2SH@ [TV/
M5-ICQTTBPH^RF*!E5%,J"!V%P\58$I!OCL8.=7'ZCD0W<"]XV-Z#3@4<%ME4
MS+PLWZ2?GU1Y3]N\F#"NN[9(RBS]#*4A^EX":*8PQYEPGZ7 :A_C]4*?Y1"[
M.$U7D:T\J\^HY^-Q1Y62@>.Z!63J1KOO2W:ABIZ&8B)++CS?JFW'S-]X/]DK
MUE,.\2UE<<Z,T&5^EO/OJ)Q2&_" U!X2&.!8.Z6VJ1K6=<H<NS<[%\2%PI3N
MC^C;Y]K$0F/\8,^>S3$M^[$A&%!?/[7@NL<FY<OY5F6%M.#W&ZUUK@*EAD6=
M.1\"C:^=%(<QFZMWV3#9M0*7'G(),B]<H7R19A+ZE*KA_U4G-C"@$"D._LC7
M@.[9@;,P,NCB'&2._91F^[3G1V1=N1ZU_!X:9U]$QZ.8*YXCZQ,"EX976_74
MZJ?*BJCD&U/_^_(?U2BR.;S15[J'2_K:UBZL4=V]<L[M:04\USF-0O3,TYP1
MU<F'=4WQ'Y^=6AD=J[_(#BK;.KOVT4?'_77V*V;*!Z:/'*];XZ\;!^LG70*P
M&^$+FC=^QAX<+5_=/-Q!BZE*_A@<?L?G<UT?U7'[!$6X]J^U?K<,?/1)(9;K
M$G#-/<16 Y6!<1,JT/:[V_HH]9G7P@\!#NC;TH@T4%?%6K$)O H^3KX*#-Y:
M@^@F]OT>Q]@B=:<V:H^#OET"YD)[R5I$M4(BLM]V(!:3,(]0\98LZ3)(4S3D
M\.ER\E:_1MI)(!Z<>Y)$IS1YB3&#.H37&5B'0)!5Y-+ #X5AM?OSF7<>>W$,
M#>T]#1^%UR+?-B"C>5F["*6]2<*F'$,>@M-<9N_&,"-,[1F_*IH66P%TW-.<
M&[U .M)+XL4E@/HU_//6&2R2Q/=JRL/,'57[+=WQ1_2KE%6 "_,^:=MG>KI"
MY2@9L5;WIUTZ&S*8-55]K]^P5#@CQR@\9:G-X(_<BEY2(23V))OH\O?#DK^B
M?.:ZK^V6]K&.NTE[WX1K>)%/+GKO&,YIV@<@OB+=25 UX@S>#^L)B9^C-^O0
M*C?0VEC:]#)?ZH[=L;:\!'SE0=4RI!81$5C+XBHBN/?#"%OLGF=587UKG>1P
M^UA1ENB ,@#7_/AP>4X 2$!&A-\D1F&0_:G"C2_E'YK20[4;WV6D8>_RLM=,
M^W&_*^,Z/_^M-TU@JHQ[+C9,FM/2_SR;5!C;U\.,I]=Z754X4]D<\*5]OSIT
MS^\(X%^,T")2X5:)<+Q?CZ8PG:W1A:I(KHC@XT+/*/*Y9<VQD"$MI<NK4KHK
M8XR?$9J^/NGOFO7'J@/X_J;B?TSJ.YMN%&I]!?QU^)HH6.6VG&1GTD=)]<G:
M;\_-TAUOG<M PD\'.0>0A 1@1.&TNAY9+YVR,-=!A>'FE5^M'%H7(<3EDU)B
M%O8"AAV,;Z"']:D69'F!_"?LW-9F/5>;:.B<ABW.T:FU0UBD0?C-<9@O'ME3
MYQ%H5 K,5V14G;G](JZ)X>H)CCL085Y-%?TI_QB^UKIGV:O.R_'XU(_4W#Q>
M_LM,EV6MX-[_;+T0M\QV"7!) 4"]T(4HJ VHW#2 IZSA$J [4R/Y1>;ZZUZ]
M9.8+7)J^QDX^4>E<FL2-ET[R(AFO9*^WH_P;TA9D(9%VT]$.-+*R'.Q7HGXF
M4U.5L?PB3RVQHM3!>*Z!$+;8?29ZQY.1D=@?K:P]P'PCW76FJ^"G0VD^2E:C
MEP#*<#Y*XO%*DD4/'^6Q5F1;> 8XF+7=M]SD?5N.O)KYXDT5N8QT1B2WUV@H
MLX,A9C7?,JTK:PKLV"XN_'HO+*6E[%\Z-BBO[G22B?<D2T_ZRWBMA-D-*"E:
MF=L_.!-Y?SW5STDTKM#&\N&FP9U9$T:.35 /UPI\ ,;H[KNPM!4U&'+2N:+2
M(5)FKXE@THCNM3<4-#<2_$=VH/8[2_:;OA(?/Z!W:LY]#?&V3%G_+Y_20&.7
M@(W2X27GEH4_IWVP.KYW)(>5<1H[XA><=:XY?B-V[RA5*J/*WD:7/_X^K6?2
M6Q7^WWJ^-G^=,/,M\@]53JG ZN/?B7EX*<ZNA!G8*D?0)< >?@G05CA$_(^R
MAIX;*V'R\#[Y"#O!V(CR/9[095EG_<^=6&=_D-!UA^CZS;>'?!?=<''K]7@F
M^I3V)C2@6\.]:*G'2]]RS.(DDI@DW3L.&)N#' ;L&0_ 2QZH2*OG4:1HY^4<
M]A*X>F!U5KV=7+UL](I('*C_T.+A)'JL:UJJ:.V?LO/*]-/<9#5T,C%]T%'^
MHD)3 ]9?ECDCS\CP.5+Z-E!X!V3#%UL@J+4CN-OAU!DFC0>>@/'H[G6XA8[6
M>ZA#Z*$'K]!,[FA'BQ.:+AQ[":A#5GL)%UYCV1Z]]P+WN*/6>@^5&FL7\(9L
MUP5GR1P^U50A:$5= CSXN*!^$^$B1BLW/ 6GG$WKW+]N*WZ^VSP^RK&H:/@2
MS>_WRVJS*<M780GNI=!?/SLNZ/';[KNVVS_)SSX8**O[6C9%S+V5L6[V^SG@
M5"#S4.I6BEA=X\F?)DEF,X/#_P<+*ETK9CUD%_I!P==^9$X&6Q3)5OX#/Z^Z
M\L>TMO+9',B'YMZ7#__;VBM3_,S%_!OKYHT=DS'Q-?!\@L7D44L'CU^1AVTU
MLO\] H;-;)P8"LJ?_?BX;C"_Y*ZRX.%\">A+M#38S*(3<1&V>,[Q'%X?!7?:
M]A6K_TBG="5-;DST^,_\N1;)C%B)@<=W:;:@-;F6B3CL+9FDYPQUF5FL)[T7
MYKV>O2-NW6,<-W:V@-KP>57Z:[XXQFCD3=(][5XCJ7CO3WQXY;CQ%?&:)J!E
M7NM+=Z]Z8,;^2[IG(ER=&MYA? 8FXE@O"C*-"FNU.\)='!/31<@%AJ7W-EF^
MTFU&,LE8)R;Q6R8BN+HI-&K'-.:QL7TP)H@=1B^#OK^XL;E/ZZ9$2$!C=&*)
M :X]]4%J:O*-9T,J9U8:4$E[C<Z*QE%W5#0P8F%HRI0D-9Y<[Z%_NL2$5VOL
M1/BW3K__LQ#R?I!B^7KGJM5;(J(_D*_.JKN:M=>DN1$5$"7A*_0NZ[KHP9I?
MMO-3ENQD7$'^M]&7X8/+-Z%AV M.X%X8S_Z12'N'4_7B=K@SX3OW*T;1F%TI
M@[%0_ZH9#E7O4IWXX"3V5[BHF:'*S=SF&CC:8FM85!1$,?W?*DD/?8&WR+.P
M)K:$+G:2-O Z1&;O:$A2\DM+Q[1(LTW1ZP^LUC\5GP%:!%?23#W]@"O OT[S
M$M#HF.Z'J?0"&>&+0E[H5!*3QRA.9@L_?'T4H]66\KO)^M;/6\FQ4S% \V<S
M-@KL78@O&C0M-$=?1YAG<,2=VOU+0(/50"=C;P'O#)2CU'[1HTL%Y5G<\'7B
MZ-GA_J3AS8KV*^1J/;_TJ.2,/Q5(J@[_N7-BN!8U2-\ZY9X7ZX!Q+T6-;S//
M85XH>BL?WG/ &#X&HU,WJX28=_,Y1)D6['O9F0ECM_>?/_PV<F<U4G^1G>7W
MYXLVLG"PZ]I/\@&)V%QZX8\H'18;^RC"S<R<924"0NJ&J2-@<NL$Y@R]?"NP
MS@[R+1][AQ9!H$?1DC4GL1K+(X82][(PF;[9&TKW_;-]A]<8+<4A77(8:$85
M_1Z2L)*90:CL=>0B1"X88<!\"M&=T[P"$\@ 68.)2A9?^)*PZ:+WPNN.TSYD
M(SA1R[7=]6>7"-$>9+LT.?>ZMG LU78[-9)"+NK'$UG9JP6=5!:'".I:/]AS
M(J+*<6=B,^<\9V]ZYZ1@*/S0>P/US"J2/ 9K+$DBG)%/#<DCN0_07J_.]6<%
M_S'FGG"^^GU%FC_UPX-M1H6#YQOHWIG>9_Z5>J-<#WW+>=W:/WV)%\_[6O(8
MJSP[],TLS?WXK^_;Z&,D6O)=57?%,K_)4IR#QGE%#64/?/_+<1'WJT6[IW/>
M!7EWUZ[ KFGR;YVQ9A$.<.MUF-T#A6#/76[\I)T-(H-)Y'S_ >_Q-JR.JK=:
MOQ?(N-]AA]45&=!4:%5=*AD]+;1:9P]__\YW/E#-*HJHAB$0/)'4FI1Z7:\3
M,&&:C,R0/L15P^735#MDNUJ:?@FCQWDWLU[$ \"51(;(-AD_BVH1GB;'!%TB
M[T?D[-?:XI/2RJ/-KM"+06F"SJ EC%Z=HIJ8=H3ET9PMILT#0Z$5&B,WM3@Q
M2!?D54>(!:;"8VYXHZ] .+^QVGC^ )RU_NA,+'70,V>-K'J; ,8Q1H6SV:4+
M9WGB@.B3W^KOQ_>_>,+"SOD\SH28[T8# ,H ?Y:_R. ;DZ19/W,FF35N=<HK
M>[JMXF\+/4NN0C(104\(@;'!12#6^QZJ7@NO1?=JG!C21'>UJQ^+CZK>=E_D
MRW)D(3;CD+/  5X58M"7)<7RHOY*XY>ED)![MF%Z,Z_U,KDJ=<5TQ"(I!'Q,
MU/+0DT"\B9>6-1_-\9Z3%?H+JF2F,5C*Y>$D5R[HK>*/YBO?>O-$OXVS](=/
M(&D"V"\!7J970.%\!(D"VND.0R?)QJY:GHJ%Z(YH$Y;"5U<8DIKQB#)-2A)G
MU KBW7[#5*4]Z*RD,%2JM-RC^9X J#);IC62@=GGOOC/_O/)YVQSAJ036+QK
MZW&%UNQ2OUU^8YA"H/>B9&/;8N?$UE_!#=YX]U_*5Z-0/<(8'+_<;=O\_MB0
M,C $2B\74DNQ9K9M^(UBJ4UGLLN-B!" AA(W"J'R34XB,>JJ%M8$KO(_SCY^
M]+5G!09GED?NY2-+LQX7#'D:"N;AISV-X7#4>]1%=A<KURC3 98M\6@D%,D.
M^;)Q_J1Q05Q@5N<2(''WX;>,GA7"'O !COD7SMKIF2YU/("F$,#X.,SX<7)5
M7C9+1=N4'PR_]-=*6>K=^9]L7:!*(D\#*1I34F ,:_C]=.P\@DY-QOVNP<P>
M@HH]V3>R7YLK9I+AP9[U$O5%9DV#]/L"/@(X3E.8V#QH94N=MX5J&WEP)\;0
M2::=O*\@LB;HI%F0L4C^R:GT7N$@:DFD'M_TI<VR!=5C%)K9KOB6,B!(Y_XE
MP)*#)1V&WQ_W^(-;Z<K%P9A(=OC!/J-QCKDE(\2V;8Y'B' V]CVB84124]SG
MJZTN4Y-0MO.O/<$7>^.CB8?;/P-X>8KET[HRK>:[SBK)>MYHS>_<YI,,'QO7
M.*\Q6XG@8 F\]$0OR7?AH@3-#,P?Z;SBNFTEPQL?$UW=1#Y]']J4%2OD,)P3
MVZ599B/12_=I75UVPQ-CK?&]7;.P!GF5/B6QF_MB[%&]3I1!E.@46+>ZE>MN
M[^<:[#P8$;.^#9OD2@<^VK;0ETI_L[F]^5-.7/0[?WDWRR&2='L:=^(\X7<)
MT/JO&[\6;VA5F&BH%/XQ@#>$B>L*ZU=;M4Y[>:XU)X>^_YR&-15C3NW)YJ/<
MLS]6IEP)X3P<EI@P;+F21]BQWV_^BV%=7'I>%GTAEO#FB@5'O:0_MW, FYL(
M.:(V84J?B S#BGNI>7H5+[+C_AR>O%>5^!;"]->L\APCC+Y_NO8E76#:K"4D
M'F K*JOAT1&25-5<-UO<9QS ))'VD!NLZQDM& !863E_>BWG[PO<OA__E[=P
MC I\KRU__0+ (?B3H@S!UW:!T*2W7AP'^1($>B?L=01T!;T"96M**7E5(ZD1
M5E^1S=.[7@>2KPWWO 5L7F4P/)^(>1YQQ!]E:Y+Q.&1,,N2S@^PH<S;'CAYF
M6UPFX5\#P,'; &@P=PZ)__NE5]R*OA\7"J#>LL:O0NT(H.XEBDXCTUN0W"<3
MW@[J_?$G&*?7]CA^WAEX$&$#LY<2NVR?-<"I/#D3'_;9.R/J_G8%E4386X7'
M3*$"-ZR*^>(-H>CCZ7WOFE=US9G!J]:?DXS::[\]51%$TX((YYC^O1^6>,BR
M3@Y6CSI5:)OUM0:  Y'7)03KUE<7<9'/<8V6O#LMY&.QU]8N_S3LD0&G/N\O
M6^)@3V86D+-+#A$#U0HKL3&J7)")/\.J2'Y.2K8Y>?1FL.6YLG#;2SU1I>>_
M,G3D!N1_GRE%HLQS/CIY*69T[B.,-KOTMV+[3>?F,9> 7@ZM>K2YIA!!,':D
MZ:>_T/GS'Y.!P*P[P<=:T=!% N/*QB!RKDEIAN3@Y(Z19K05MW?O8LL$+LDY
MI=R_)S&FSR?S5$-\\Q+P5JL.'A5^=2ZA4MFD%FMCQ:9Z_#M*CA<K,ZEP NS+
M.:D!#.B^*OHLWA^V46IN%BWM\M#8\$"A\!+0#*X*"Y?&[P8K[0[BPS09H%)3
M1T.?K!M!'Z3 7ZF8;ITJ[Q:FC'5Z?[BI%J_$:&8FJC(T5!#&:?;91!Y71^XB
M_,?U*OIE^]_F3,YH1!XZ!I)[,D,TP_"\.3"8;MQYC]A[?=^8T_VPZ?^B[KVC
MFORV=M&@("I-D"I504'ITHM$5)J($1$B-2H@)0+2 X1$0'H3$! 0 @+207H'
MZ2+22R#TT$L@H08(R67O<\\YW]U[CW-^WQYGW/O=/_)?UGK7G,]\GCGG.\::
M;R>O%YW_O8X7EK>;7A:4=BAU/[B#VS--V["P(4PN! 7@P2V'GL>!>W3Y.E?I
MZ%@F8KVD.SF*![S3XE>\$W&&DNUK' ^(TMF]V'MO7Y],FQQ/SY4.?Z8 > )_
MBOD$\OIN?,-S;#:FVY5-02V4K(@!V(WYE"+=ER&Z+,A2>KUX#=Z:7F_6W*&L
M3##KGH^&(P70[;TQP5.<F9<MV9Q!2-RL/=&C %K+B4D%,\3\'<W!AOO+NFL?
M))?TOH:^5^I25,2%G8K@MT/=FMGMY(^_1^::KGO[MFZ%+8_=7VU;!\:[ZN"!
M\U..7'"&^=%7+DP'9D"2GE=)"-)&7/=G7657J!HC5'3>05-S5P(.=-%= W?5
MW#[3["_')6L603+,'__8NW8HN^Q.'$\:;N3%BQAF< .]$,(#+\ ]?**G559$
MG_F>< @;\>[)0\)H_;>SSOTIYZ19'E#V1Q\5C7.:\MX&1).HT)&@IH#O3"E>
M&Q8; P^($<J^XK5 ;=E>AC_<\02#/&[A;[Y<PY=_I%18?!]E3>+[%A%M@I5C
M#WL2;7*&[WVZOS%2P]65-[NB_!<H\5JB0WKI3R[%\W%[Z9=R2Q@3#_J(8'JR
M 331F#H(.#%,RO( BLN?'%3@.PMXV-,NE(VHNI9,%;\9+A2? 4K.V+RGMMPP
MG]7O</^.SB\[F?GHHWTHUVP[&]9TDZ@^;VKN\V!P<Q^JKA#O=? ]YHG Z1BW
MCXW "J:A:TX+!UX 1:0!JP>!\]>&B@J9KT%[<JV_?,GDE4Z[^Q1 .U.G]W">
M*8(L;@QR)^AVT&6L_LD>;O-F]5>\L2?SQ^M35,W:MIE3"V@BH W<Q)JH/TCR
MD2&&2E@S;R#81BYI?Y:FXQ;6[%2B=N^76Q\^CE15S1NU&]DJ/B3AEHA)-:-Q
M*V'P'#1@T?">EO'P7E"5Z<8&5-!5Q)_*^4[7\B_UZQS"RV^HYEP[X"W8_FC$
MG=-4*V9B>8<%,Z'S<P2'*)(MJC S1VHQ&*A.1'=2 /R(Z^NH"G!$)EJR<K)&
M=N.V3/;X>%V61X 2O73<,L\YB-+>SP[+C[]SPE(SY7JFH41;\LFU%R[9;+<U
MLDC-!OM_>*)$A,_?:KI'U,5",#;M0,8*E=[+$.KU9+N GK##]M[WU>6!BO1D
M\&_7J$:0@8F:4MUI<?!'.5<;*!X_=9IT@+2\U]VPUA][\TAA0;$?Z;V8<*G3
M,26/E[>:1K1@_#BAQV1X7S2EWD=W UH0KJ1:\"4CWCP#?K[RIY*!/R-3D7E)
M%VC\-P6 /23)<C/15K9C/I:OM(?G)^[0F_;MNH"N[];;G4PVED-*F4M%%.*G
MHYR'92WQR.>Y&;T^Z1]KX[O.<MC?Y!W:*V9RI_$@P^&[,<C+7=7CH(I04=8K
M2J,]J&D<N@G@ZO7R#$7:2P;-\.$-NT*O=B@C<MY5M2[3^7!]C)O:4M2(5$YX
MR]FIN/B5RD3SZPJ^(.9V)__5T@)"\X)1)/YA2W^A_>MMR1QGA^]K1J0IR%0U
M'2L4G<=U+[B)BM!/17S=Q-65"[<G=KV_19C)X]*%NH<N!FB%Y$EC-"JN%'JS
MW^OF6@<EPN\2M$+)TB3-1"QK&@^2C?C+,5QS..>F;#2]:5JD4/!VGY:PD]K1
MG"^3]8D"BM.L*Y_T#+T%-\\+8DR04C%=.YA:L7*64&!L3ZN<>*[?UC'T?6NV
MG0+06)K>WY,*<X>H5JTV@T]M/9"7U6X2G;#%\:>EF9S)Q(YKD#OMAEBX38_8
M"T>,SEI,?Z/G%VKGXVN$WH<'+_!2'G4#<<_P:?F\6>'/!IWXN 2%4VNZGZ=3
M )=XC)A"X \)#^?DX^7S"M:3@=&JHM _B1Q#$JG(:P?<38O!DWG%##/!#V/#
M7!)"N3 4P*;*W"S'!+%UH\,[G@((4=4M,9-K1]RHQ\2MS5U=$KI3\RQ7ZF+7
M'UK%!?Z[MA!F.'B.GV.Z.YT7C.UH_KA9[+"'TWT>I)/6>N/^B;IVRY0:GBK*
M8R%-=+#I#GG$XB:Q!)D#LVD;JT:P#+J#)!12%VSJ:W44W\B?/VFXVFI5I3R'
M;6HFNL[QTLW/!N+<BBYWB,V],!#\."G4'V7QP$O,]]BM1!V;DP55LY[$']D-
M\EFMUA$0+3MNR^OH^).FDE$WFVCRGQE./"2R*+A='_N%+$BL6J12*WDO]8Z;
M#.NB6J9W6SR_Y@>Y_]*NROO%+5'1E^(WQ,RRF#\^[XI]#^!2J]SQQ'GA%7[.
M,.,/L@F2NH2_70:!@ZZ*TDW?3!(<6:%U<U:]J'E$1^_?M.0'0-\[D2*I$[3:
MHZ.D^PE0LY$*)LZUX^>15UN+Z%Y.FD_^^M#C E9,ZJ.Z@]B2B4ZDJ\#_KE0(
MR9%T=X.:*XO:HM,2UOW]@]CR+\O[GLP6.)DVJ\S6'BRQ?H@VN2O]E6"AOO[W
M&LBU28U #L?WMW$@KA-HADWLC+*IRX7T;C__PX8PI-Z_$1EX6^3[Y,#J1@BQ
MGN#3UDS3P.^,96(VYTPW6&IQX.B5&\G9ZKIV:'E$U8UM0!F=-I&9,79HUY?V
MZ+K*3=LG\NS'\)Z;;13 Y=O6ER^I6B6'SX-:')!8A0@!8A[!^Z:O'<*7KK5]
MJVKPC>*=/SE!*1E*JUZJ<Y)6(BX^^\,ZOMO=R*19>F#Y(>%25MV[V=A3",B@
M6XYI0K(356DX?=CNQ&4O1>1^/M)0.>QF6+Z;S"U':_/5\_:,>G])+@_5- Q\
M((8FTZWBUU$," %S#*R;2@&:V\J8E%?L<B.6.?:#U7R9=O?:Y(B:(&(T[1+1
M^*SI8(3JY,MG./&X*%56L&@%F_<$3:E<6\@A$@K( X<0?#A<U+21[\)]3'.H
MW,6/#I:7A&@"J6YFO>/A&R=IY:?)9UUU7LI9KJC>."K5E2G"W_9I[AD>FEW9
MJ&V#51\4C9)L[)SQ*48#[^"""[C'X"$YNI03XJ1N(-?['0T1H,R5IU=VF+B$
MPW*!<VF>FPTPS B! KB_3 $LQ.\9I9XHP(%51(\9AOH!\4H'"8/EJ6YX_4J:
MY=C;N&W:0VK+=&S#,/G*;!BD7)^%>-<G.I0"8,(N-<CE]E  5W6I]RJ_4 !%
MSY2OKPQXYH!XUH1!-!(@P^;>F1E4:$J&%EO^H?5$HQHH)_.DEU?9*8R_O".P
MJ)%$B[7Q+WKSXD3CHX5%]INPFJ[$N.5T7+<BKX87" <6/L,6(_@ ?U"?3J0
M'@U5U@LER)6/W80B[\H+E"EBGC@69G)Q*@%-CCWG@5U.%^$VI3%[#/>+,YPZ
MEF-@37JX%#=1(:V8@"DK'W0WL#HM\/M947EE3R6%3M1':;LP*V%=6_#B6V<!
MJA3>ITP6E8,)O2.=6FFJE6S[)I"G!4[)U>M>X\EW<S@NAR_V.HV[SK\-G@?R
MS=A76\@.N*.N-$9\FK0S$1]$]824)0EYW$G?>P982ZL\Y$7 $*W;J"A:<0I
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MREO<)/+:L8+@6(T,=Z&Y]JR-M6//HR9=]8&QKR\KGCMR]FF*_-HO49PB[5(
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M *:TB5]O/=6<TSF?_6X&T=5T1;DOQSEG<VAOLE=F\[8E[V<#N8:.'<=8NX?
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M@\AJ;'?&-JN4:'G;^+*2W+17ZNZ^YT]=M!6[TSOV#+'Z\'ZFT)N;OH1RPN#
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M2V))M'^>9$=)=TA]_$9Q#:9^+X3(_H9?7_5'A>[OYZ''\% VF_WT]&YIC>$
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M]R;J_<9;^,H?/Y"S4U_9(16V%AB"<;.6"]4U?/CD( :"^8+,P]:3KXH;U;8
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MDB'3<V(DQ/VLC80+Q<>'_H.=]G#ROP!02P,$%     @ R8":5+\O&OU=%@$
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M88M9Z06U=6?J0</LL>_"3)4&U,LOORTV_W[\X&L&+?EB''7@L64V%'6/02K
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M]-P'.ROW$_4IIT%,_ T\4\ZND;:OZ?H5325UR4+"]HK3(3.198<K9(FCG2W
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M\T25']N'+7AE1)$>":^=3--RQ]AA$KE&[Q\,050.LS29#Q8!TB3<*001P12
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M+9<5.K>.PS0IP-L( H;4(D.8H$L2\P-+HYHP6* D459L;3WL*=D/H9A"!NR
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ML<7,9]@_#;KAKFU%]Z9S^!G B>Q<K%&'/CO$2F<WRSG@GG+]^8PFW%O.I?2
MR*4__?Q#\O4,\7YV=9-+STPRKF$<&2*5D[]^!HXLFC41K:I2D.)[P!&#KKB[
M:H!2J^1^7DEKWICZ3?DAM/$)\2V$?+TL 4+4@70E.:WV>5 6VU+[V\S'K:@O
M78>-BR"-[=5CV)RR\'M];[(@$/\&.7KPU&7P/?=73J /* /RON?*B>J[_*(C
M+V*4]57+5>SG7<MW7) OQA.! 8$D-5[&K53/  L?L<Z&Z&/PF:<"NOO=Q09I
MS-1E0KQ24TO4<5;\O=AW,4I: !J)B1"G/K:R_<\&K9MG0#!K4?->*_O58"D
M\!X!'D?CNW/0BQ.%)<L:)94TZ+HB-1 1M,DKF( RSR'!PKQA\W.H6RO0;M18
MB@869)R?,?JX&@<$NJ^V"KFUL*Z$N\7F#(V'IM!LHS=&G#E=YL,I]=R0FR4;
MCGWTB\?N3^@G?;1,PJ\9)H'$F<UUT $_,(M\-GPMF)U;)VYYG(?WY%2,JX4@
MY(JT]<@#"RDFV.6 ,9 7P_V&HO[AK? B^XG1E<#!L&+<Q/Y'1^2N":KN7_/B
M6/%];0?"^^E7WHIM+QU96)P#:P2"3VBQZ+D6.\+Z:*4=NOC!%F\M^_8@"'8S
M)C= <@=Q6WD,1I\%4OXD2],V>H]A -YO\+P.@X C3<$=6U#BEQX_N/K(K:N(
M6*5JKY/7\$M8V(S947KKW$J&M@YK<;'W<T1% "RK4YP"U=95_K+4>/:W+R.R
M/Q=8VVC*!=.LK&A;[?^L7Q(S6M+CN&"$!)2PH1L2BSW^BF].O(]IW#J?_^5K
M4SR[S4/(<X Y4UL0JH#:(TO[1^D1*W9NRH9FONG[M32%R6_[73M2S2=<)=<Y
M1)]T=I[OF1>N1ZNKI [2<)AH\>SRYR71]6J0T![ PGL^AW2GF?Q1'-6EOSMR
M[/^V&?9OX2%_U9-=B>X]!\>S%YX]KOY8'1?']<_\9V$)C11OC/_(+YC_DU]P
MF?QO*[,ZG5"GV]=/U!<"[\)H2U!1>B'.VI]72%KDM&S(^GK<4,?R09L1)YNE
MG]45OC8QY+J/2B?)S#HOVNC(?0OVTJGKBJU I(CQP>28+BOCS!$T.].TL;N&
MF:XZQE.MGT+P_YE96VT_(N3!/>C?1V7^JM1:_]UXDWKK[[2,$$X&V<'UGR+.
M%0M29>.+DE8=QFV..6D% L->-U\$"=U5UJ$-9,1GUQG9J)EPSP!C?Y,+UDE7
MOJO<L]V.4R2HF'K#U*4"^GZR>HY3!M_.Q#0P]MS14?BJ7&EC_V+$4D#'>B<]
MHC?A_.<MY\W< :+,N5W$,P#QDOS-G)[5]1UY8.LZ=6R.P;$0SOZ3-S5,NWHG
MPYLHQ&']W[H&W8-Z?*?M25@'+9@IO>IFFH,68V(DI6^7.VUB$WSUFZU'\V@(
MB]FVXK4S\)\![3R,*?+04\C,>%",!7/7!\N?RK.4.P[W"?V+Y.2T_6V][UI%
M&"YNGI '25B]O:!GB7?6%M>'GG">3D4YVN4+YET?Z"APR9EA@&&/K\J&.A_7
M[UCZ"8Q>QC6.H3D/X55VV$543+X"RI(HI(Z:Q' MQN$*YT[LXI6 !:R04H-%
M@(X.;;(QC'NB7"72*'R20+>VK,M7$:4&-;D 24)C@6'1!J=NSA_!VQNUM1(J
MB.@[IH:V)J,DD^;X<5J,GT05@#9N_I#M0IH=W2@I@DU<;>=761/C04UNZRS;
MW_R!,L(&WY+T"L?6GD!.BNWK C!-*MRAZ[]KDW3B<+^6U=K:I%6,X/,<(/)<
ME[H?;6BEB_W0K8'LD"YBC D:R"/:J4@C_+"Q<;D.S9+*.^_2$O&O(O'W[R6?
M*90KGH^;\,H2'_IJ_'L8MJ11Q,+X=HY<Y%!=I&__I0<.H-#F< !>8[#!](*F
M90?S@T!]0'QB8NP2[Q<J##APBA(XF,^GHL,R#OVI>6*30RB8GPS;"?Y,IZP0
M1&0V@U[;K4W P]O^-!88J#]O9P?2X%:6=3:+DD"@K8'' @"  O+R\@JE[N#C
M".-JJ$Y.46]P1G<R!?6;8I^6-XD4GA@%<QH-O5RWIM$F94/>0^]?B+TB E?E
MI[JPNYG%C^P<?HQQTN=4&;0G2$R]Y,%TSI9*;UGG+<\7(ML:AE R 0G\/FVZ
M:PY]5\4WOQ<\*B3MU7X02+'W10-BAL!?[#U &LP0]\K!#9RDT:*YT;7^T@3C
MR2^\C?>2),5G*":ICIXSX[KC-<N>![)C<3XR6BY(6;4M%"$>.)*.7Z2X3=*6
M_-Y+L$[7@=3S:K*/S$*U:1.U4*3OKV+517/H17CW1Q"-Y+UX+K?Q9ES)+6,'
M?@_2PF&UQ@UY4)G&T$Y1U%5^Z[<C_7W[&_'"O".4&,;-LP(4E3.18KD7,UCC
M:>$?)RW33_D3J2A+_:T?2CYOCX3'L&,/ZF!KJ)C*TT(JU-4+;U+BQZ\2L)46
M255*0X#&-KE(X+!SA233X9(N58L2O='7B(\HK^VEE>T]"!%)Z<6L9/I11  H
MH+[M3W >3><:<VN[ @= 9IV@,H7/E3E24445[_ H">(T8,N\=CD%-&ID\Q*&
M)CY $O2R7@=@"!I[['FIA0U'_)D4<)0D+/[WXP,\F?Z;6P31FPK33T8*:]$O
M(/I?2 I#VGEK+[.BE6(5OUW&MN1,>%4^N+J@(C?UQ.2[D(%\^<@N7 ^U*8*O
M3IRR=G7@81-S8ARDBR)$,J5^];CFSGD79#]!A<VA]-4412;+IC&*A_#8(*T5
MBW,5Y_ 9<*9X&J@"K>TX@RH_,HU35H<HR8Y3>9T@Q7L6^?<#;?F]9O,"-'9;
MSUO[=DJO?10*)0-;+5CNZ,C0G@$=VG9/,GG/@"]"?R3KLF/71A^H\Y\!6T4W
M* S#? J8_\T_"E"Q%S]#Z(Y.\#_+ESMD^X&$GEX_ Q90G\(D X7.$E.> 7%%
MO _XD"=-/2IHY%IMY+=@E76M4&#=RTQ2="-#"]MV^0Q >_!(I Y;W9 ,!&IN
M?OS@3<?W3>5& GV65$CFI361P,?PSP!Q8'L&5%;N&="O=L*#HS2%B9;4#JZ"
M&Z\4Z@(CX!@%"*WC?W=X!OBKTKR\I@6!DI(O$/J>/@+FI7Q3[S/ MGAI#\@!
ML][9_@RHPG_$B48 KS-Q/P.HE?Y6 >*_5'!<<\94Q4#T^[W^27?TAIRT,#G+
M@][4D] #+=1F Q-?>K,5X8 N=Y$XT*J%*)G]'1+!\G5\5$O"M+:[P75 0W6P
M$82\/7R'LN7EG5+^*-6,3EOZS@4^L<9OD#\&OO@5HMI7:13@KJ+!ISJ:IP!:
MV)[6=<P_PGVY[NS/ &3+UEOZ^HPWWEC0S8UR+*B!=A,T89VZ\>QXJM8U0 A-
M!C=MW5W'_5X!:)TA;[UO10O;^0SX]_+1?S/./QNWW/[%./Q_,P[F4YC"?QJG
M$/SO19L[P@!GI] /0O]2/%]N76@!FU9O=H,F\-,GN-#9CO. WC&S0]SC,VWQ
MSQ-5TE4#3R:I\8EMA(_PLL)D1"U8CYESK_[8 )N/''6X]TE..0/)=TSKI<K_
MZD+7\U_JHP=H$4XSW(7<%E?S)'V+KN."J256BNX5=A?\!'VG.58C[N0+S/&R
M(';KCPF7M[+N91S(0 ^GB" 55VYG4GA^78.(%8+SUAK?]P^@">^E6[#M&!$I
M]+#696YT7=_FGO<!  7?2SPP3SVX01C$:R#1D9S'LHKABBU37SVJ3NEW-.,6
M7BF<P%F$(2R178&5H"9K0N0/6E"6];2/\P\?SZJ3@J]"CT]<$F2[?V0EK[P?
MDNID,XIWT\?T'D/,L4QFZ=6SZF?A. U+AV^MBN>GJ3E;BI-8E="I1!?/F_.V
MFR5:=UX-%X29(EI^J \J#]$7>P-VJ5E.)3?1YX:@BIQE'&U"WFR8!:Y;#V;
MN;-K0%W<B@]JM FHG1?SG. TU"&F<+&=N&T+R")]!^_!YN3!#:N=T1'Z.)73
M(&*3,\<;G;.$X:"@T1!JV;P9YC<#KHD065RM'%V^8,RX$^Y4&&&R20C7_>9J
MQVG(W3,@_,3;:>U8>56\RFN>,;XS_H.Y*B$M^3&-K:<Y(NZE68CO0EEXP4K#
M%Z\4]YU/^GZ5@?ZWL\-D@E"?#8.0ULJ0[GL#;/<X@]=R+M:%2YT[(CC&5![4
M]B*1$K+!:")[[KB7;E^$MI3'A0Y[,!_QJF!*Q271N]R('VHUYKJ)+4>0#NAE
M_C_1(VS^'_4(7Z[Z9P#) C3Q0CA."-G <L&U2D]&H6@1= 8_.H0"I.LGY2T+
M^-5DF6?-MQ)"G1]8!NX0^/F[F.EF7GW3*K!OK@M#$E=I&?G(U_FI-P,II"MC
M@7BS2OL9$.K2S*]4-96Z)+N>)N\C2)?'K8+(K_:[EB(&F6?8)^@%WA*RP&,0
MR N(H@RV/M&WN#X# CS;G2S_Y),JZNOY-)P+B,=9ES-*[O(TI+(?DS#+RR-^
MG%U56XZ6_IO@#8X@;&?K>MPERQWIT]N7L:[E]@SH?L$MM*27YY[^X[G-/6$7
M(X$=&M=*8\D>?T*0)S?>S\&L>*NY5?].#W'[["1O,,\B?$%,Q@,-:H45@JCK
M[2Y"BY?I.6O#>-/5(M4U .S^@S"3-)!,3/3H:_GQ!0^U!W,(LK'N9X>-PTJ=
M62#(.*'55 BS:I .4M[%PBJBN'J6L+P%.^5S:G6#J^5]8WQ@3/\J?T7DQ$G1
M8'0+WI*(LX;&-.5W(Z-]ILG2I'8S (+P&%O%4_8EUKUS Y8CEW'B!5ST7)$4
M,7B61T&NA\HL1PDYMR<ZO0:O/U*A%X'47)% NS1@@4:-&@Z;3V; JB#2'!AE
M;L<<<EVR:<:8']1?NZ+\D:E5SY9,DID1OSX#.JDM#"[Y'UZ@KZ/R]!D0EO-$
MR"#Z#,C:W"!_PDT"/ZAY1<)MQ)"1_L4D3;.]JS V#P(0I_7RD&.0V^;59/4\
MR\R53C>^^'=QA,OVY1ZBEII:]F,[H<'ENN/SBQNG'J>5)HU-^"HW@RK\]@\)
M;K09*I_-2<)UPP!V#VSJ+U87:^T2>F!@?@9 BX3^9CPRP7\83Z-NRHT!*!F:
MJYD!W/G4U^.QX0="U7\,>Z#9T,&L.!!D@FQOO?KP WNSZX:-7BJ"D.35W, O
M.+(NE&J6H[1<H"@0DM%%J%I#909Q63C6)9,$743Q'.J?T)=&:+ BMTS2#VFK
M6UQ'V(CZJ@EN?"?#=+BGLJP E:4S098W>0R1(39+YG9G65LG6[6"CW2']_1[
MCFS^&Z.A60$58BQA)ZH()/#W\X17O3(W4@EEYFS2.+\(]&)A8FQB[04_PTX>
MCN*"8L09)$Z)&B7<W@*IY5ECH41N)\#VC<<X9W?*P$&(7?1XKLUD-K3C%"N.
MK8OD80FR.)/F<$\/M3'H!Q,_B'C($.*]V6@L^858HT/JH'<3==F*;TT)-^8"
MS/QN]S9]PYMQP]J449]*E+VY!V8$L EWH2>P*?V8:FKM?EI6Z_%+IS_T*^]
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M PGZ*G)2PN9SM/X2AC8&%RFAZTHXI&,J(9N'7QJAT^(31'IQ"QH"483 3<E
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M+>P-/T2,G.U%VPN3;"*PI^RTA9)<#%#>00?X!OK1PD*D$Q&8<RXD-%;GFVE
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M-[%KHE-XN'_T][F>(,5@S$=W"5*METP#E%7]LJ+GY.<D2-GH=2R)X-163*1
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MPP%[-9U&VI),RV#\L,[I4]]>C2*GOM.*)I>,W$E=)1VE:BL*)$-7-Z5N-X[
M;9<_S90[<,&(90-HM/3I5:.#)[$4.>=2#^_IZ7OSB(&Y.XJU3-5N+/'R]2>_
M4*$]WEH>J2G((8HFK[B^5Z?A]"0/1'5.[98M=#W++#.^;*7ZK>EKP#'": T+
M<N!W2>MTO!\>]:J?XX0WO'4SP Y7:LB_% 0EJI9%/FF.]$]+E"N8-Y&2U_\>
M>5O%_A7_73M&G.1^Q/G.:!&39:V24B&D'-ZR,+E?-<*,P:E@N]SLS7I]LV>
MU UD%\5  +/)=@]+]J'KHRM=];,>'E]V#]X7C3 ^ZW+A[H92!$CWY8 ]<( ?
MQP_<QHALHSD+:-+@?BVJJ8[NG"[E4 I=1!S>IUN=-2A(6@EXJ CW86O^P:
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M4]K :W2D=PF(/&5 B$UFM*39V;@YN5!Q)LR;#L22@NBZ(2\,DTH:XA07SVX
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MVH=B6$)E)8;(YM'HZ.^/-)J&UZE<(F>&%[%5WJ#H('?(G8>HQ]_DD&*K73<
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MU8GC']8=XZ:;.O9M,N4T:V+N04FQ$<]=E1M ZYL;0'M-2:^$&W(.0SX4MLB
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M)P9/]@]/87E$A]+F;:5>OF/'R(WVCA0G",[ V6"7R*YO%ANJ?B[7,0NDE>1
M\MZJ-=H=T:V,K9M#&=5W71D4T^P(E;]I716%*LHO+9VAA7J:T7Y&85L=J4O:
MK;6[J&!:'HK'&>_:$RE3S5M#&.KBJ&Q(_?%9,'M<-0090D.BKJ61]85NQJAQ
MQ6@!6P $F/:(RA]&&AU#W(1I%Q6:&;4U[9AD>=/*9Y\.;APG(0Q+MYV@K9H?
M05E?6Y(1SS]0R61JVZ?]MOKPJU[/"BK/['_EGNLFT, 2?$@%J2^=,H3"CG4V
M.Z)CAF['*BWHJ ?BHKI\DSN\D9S6?O4Y]NHGBU.M%_U8=)PSEC+7&WN?E1[,
MLPO"Q>6Y1/.\ MQ8C/>M<Z]AQ_CC2Y#PN_#MTO37V&>YY!VYDI.QJT,G2$;=
M^Y^Y-SWHX]"^%\$OPTPE" 66'T;:IJG8Z<OJET(2JFB%U)-#X?GCNGKU N^I
MRKV^(\UAIV>T??-.I+<EXS6.>A\N)D2^E=KN]. I5?EN\^I*Q5#V':22\7'1
MQ!D_]_F]9]BCD>-KD9SR8EN&'$M@;X7!4J2%.J@@E8\!W#1UK"*?ZU_N3\WO
ML_7R<GV9-9TGJN>^'O-D5_+6-W9BB+(E7NUUD$'OG+K/NA+*;WYYZ#'\U%RC
M;%=YD8)G3]A 6GBMY^AUB9?9#\)C9!%27;(R,0;'=MO@$^+2,SB;$[@I@C %
M^(J9J[VS%A$C[RB9J%I]H5Z1^&%L0G;W$LR,4H9PKU7KH6X?*]G2V[A;%O4B
M[)1+GS(O$EGR]&7=F_HSR1V)@&2<'UP2!??^B>I'\6LQQB[L(1$G.YIH36E)
M.F1Y4_?7F?:GH];NLVZY/(((FO_H>YL!@,H3HE4\Q%\6X$JL,?"WVVL?75SL
M\)#_I^MQLNS[*#YC<^Y%IW)WPW5F4BNZZ+E"4]U?[30"S4)?1^,NW:D%3Q\5
M7VH-'%L0"W+]2(!DSB6WJ#AT1+PPXI&SESY?'IM@4"\R-;*%9',;P\R/#/,\
M.E3+%),ABJN\5?;Y2>VMTEES_VQ\>+DCF##7_WC&UD$Y9ID&,7_5LY]\M,:_
MV,#E6K5KS!;NI 4H[D+A5LD73DUG*Z.OM/;>7;6#]$X,<\W2PEJ^_5)ZG0*#
MXVN^W@'WO(0,2Y^(_H,%Q5\?^F9!\5?O6*V.*- F>9>%RRU8V2T. 6Q=W"+'
M8V6!$!;3SQ/EA1A9EA)Q=1O.&;E3<F<%#D_'.,@" $O$(=FOMKK+Y:A:)\;P
M%PK/R+(<E=.LZRR5<]]X#XO815E<-W2D@OI@NK@::?UJ<G8"S&@^ W+[ZNKI
M8)'PI9YJ6-F)5Y/#\;6W@=TMAK#>/'I?N HI,)ZJB1N].\H+B532,;V\HJ3@
MV+NLL<QC<"58X(?3KD=]&DG!2QI/X.L65 LL6"%HL0',2C'QQ0]#N4:,W0)#
M96IX,U5TSF.WRFAO[]6599MQ4&B@\X3W"5(-R4[HL<X=% <&@",DJ&J?#PW(
M];3:UZY4 0'OM%;8RQ9Q<EF$H$)_[]!"W;L*%_2NW3&C#N+T5AYZ ]G.0[G5
MOK=C MDV1!L7"%=YV,6)W6WEIBT*KLQWL6T^IK$L C7KD^I_IN1;<G'1N_2"
M?4[B-A\CH(@:9__O'S\E)9T]'R']SJK[&)?(Z1\!SL?"\K?$+( 5I@M8G +(
MJN/-#&#;VNRSC;?D*1M?PS=6XB:-X[)I42Y,4I@4AX! K?0?HKU"E'Z3T7RN
M&/#5,K5/!0,"?RD8T/%[!0.^UV(W_1)]HXGE?JI?8Q=-/4\KUM$D%3>]'!$H
MZPX8E0P:" KO4>7?9B_Q '>W/#EKQZ'0BQ,?+3A?6CHID&ZL%)$6FKP=';L.
M="/1G$$M1A7K+J-15$./E5"T='GA$0.$?F+0ZTZ'#T00G5LY-^BVN3?$A&)&
MEK;I;DP^L)(:'RL3,7>AU$!AU]B-WIX(<'4."MV@5YZ-&16'[:FEI#LCC$&W
M5"GY*199D^*:7AF'UU]/QL:U2XU/-IL;J21E*>.PQ%P<7)+R0K];&::,1W,=
MN(.19+,B\]WW)@:<Y1V,_N#7%,Q2EG0,='PC*"Y\!Q!^[8T5A?NWX^&T6][P
MI4CNI5.+G;>A'RS!LO!!6RP#./DCPN"7:L)[]U2,KF4%K&O!6[>2#M BE1C
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MJ==KF??(R,\2*@Q 43"7_<"8!E7A::&BHM)2M4*H]DFKD8$1M1A99['3AF(
M7QV+=1?+Y^I,7QHS]M7IQ@E1\)6=&Y_59#;V+E,>,0#I%HS>^K9/:F"[!-9+
MH3X0&EQR8-)%\6L%5NBHY82WI,?IS7GUZRT%A)AMJI99@J-J4N_ A=:R4@R%
M;3EN?5U8\T\VSI UZY5C\=H)<:/E^3\_5J<D!C4.5YO2D5ZVAU=L)!N\6R6+
M9YZK.'&2[5;L*\G&C9I@J2#.%H=LC)[XN[HT[&J:[73 I<(3:#\SGXDM+E,2
MNAJ/^2I:C'']V8WGP&8G/2RIQE4]RGM['"PX)M+:;K85PJNTLIM1%?2MKQB
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MG/)]9]S[C?%;R?QCC[W7FL]<:\ZYGKEV0OA-6 "N:JBJJP(D%P" A/@!"-/
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MJ#S6N8E [?&M@]M+(K?:.R;@2+_^CVA:#;1H4\D&&S@M+4/$>"#.Y:</_FJ
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MC4E<@/R$1&+D!JYA!Q#&XMU>!?;)SD=J<9$^0O6QPM?Z95_81AEDL?L_]R8
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MR-'^]P'M53 (E7O(#CY_Z.C<7CYPSTRA=T=1@P!X%P4!QRT"XZ4X051T6$H
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M]5?3/!@2 4I3*&$^@XJA8%VWOD4<Q#3_[?\2_T-"4A[0<<J&<I[DQC]HO$\
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M]M)9*3\:4]4A_6T$?X^CS<:RZ_AQ4FE':O_TG'GQ_J7;5L0L<15[=4(:K_Q
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ML-,U,2V>%O)KX/9:=C4H-)X>.9_>&O/QR7HQ9"E' *@1R*93$2XQ M!4C&>
M(.Y@8?A(M4CBGK/YYP=T!, 80;0$<ZR)BVD"&^,#E!H@*=L&QC$$X.\>Y4;]
M4A0B -^&D 3@[+1I46T,10 .S@.&B1OS425D;>1LXB2S7<5[[U]O1KI_#R$
M1$L E"9FQ?9I_]+W'^HCEA<C_UQ>_/[7+@KCP?Y$*8$&\;?]Y48*L(E(3HV
MAZN/(XX66^)'@\<4^KP6['0-2XL%<FLU3T!QO1^*#4?&TV8]+"92CF@8EYK^
M%8**O_>-M_]LB6P#%'1RB,?@;<MT_V.GXOXGEPJ9(H91ELX>:-6/\>_U$2W^
MNYG$^"OAB'65>U.7PE_J_E+W_[6ZH7^G4X?2O^;E+_!C<W0-*)T.H1U1XJ.-
M:+Y6LX>K!. 93T]S2)#+;UT0S&9#[;*Z@$=/Y0EWZI(36I+=:"S+!]_:M/^F
MD?G/@6O6J:&(WXXW\S81/W_O(N1TBYAD\_0F&B>699+/=IS1F@=*&LT$H';X
M#_U_%W$+=G_G7[XQ_4_)R<$B!2Z#HGW^=,V>6.Y1GEYI],<J$P !9;07OF8*
MLGZA05@ 54P P@F TT?$!SR?&!JR4_+_L/?= 4UNR[X!5$1*0$&4%@04$ $+
M16E1D28*4J1#5%2:@ A(@$#H*"T""HI"*"(@)=([H8,BA(YT0N\DE! @Y<5]
M]SUOZ][WG//N._>]>^[9?WQ_Y/NRUC=K9M:L^:V9-=\N&^UU,JM_[VLX*%,^
M$G.8;W.4RTDJ-$CV<>\[)-ME_</;FYGP"B,:[('+/:9)$II.!3C[AG:^_+[[
M\?BO9J1AX"#X=#E,D(;"!FDH+$5B#HU KUO4L,,'EM&MQFGQ5 !H1II\\MUK
M%)8T,(M(^06/?OK/)*2MCQ,V:(#W>1]XJ6.<"K@BH[='$\[GQD7DUMS/L-G@
M-;RZ;\MF$/X)17HK'4P%+.7.45YI6^U9[=\[1&M40(10*L;@"X;%:\4[ @\H
M>^8D?1*F^S'X-_EH5_\:'OVCZV<IU@2BD"KL\,^=,$N:;CU%[@)0VDRDTU0
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MNGHU*2*><A@R)$P)6F.AF9I6/2J 27J%@PJXZA$"Q]V7&,_,J2D'[6P RZF
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M.O0?71^.:.>+S;R_&]$-;G1FUN!_&3G)>O'D0E.E3XJ+=$_"CM>P3O>6[M!
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M+%P$;9M!L) 7>G_XL;*_=4%4OJME;#*QD@JP6 %OTD&N#&"0!\'3\RI25,"
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M@$,Z4Z30YUHF7"XT];V\LSQ-!5Q8^P2MX&@PB$C_&$9">*=6':'P<C>,;XI
MJ0 :>B90 9/S5$!($VZ;S"0 IFF #YI8@:5T-,$Q)>YD#R!I?KM"HNYW+T$0
M'T& \,[H*2J )#I,!82G[2G2YI[*-Y\_F_S9Y#_1Y&<XFD\%L(9CUW8/*\&I
M@* ].-Y]:IP-;+L"ND9<PG-;Q3<(2":QZDDV/NT?4E5N-#=DF/VP%G]QJK\2
M]XWOAEV_#M"$MNJU3J'"DQ?U[<W!74@G/2NFG_MT@S?<(WI3@A @*@"K,DZR
M? RWN8>>&U94J0REN'F/<DT@<=]J!*B %.$6*H"H2YO W!HD.>E0]+PFG@J@
M'%FATE8S<F(8%8!\]&>;_ZEM>OYHB;]+!= TVA&,OP8ENHPW?&\U@*"THXN<
M$!,^%YJZ+(C6316!5DO;'L_<1@6_"AL_N5H^(E>VJFB<HL'PW,0^_[$'#/WV
MXN*]>87-H3C:VU((,W\7;0/(7XE;WET%[72MN1D'_*S&H-_W0G@J0?'Y]&>+
M_],6[C^X,Z<QOY-&%,F"G.:&X" 9$EVS5;&(HV8-Z2.?15Y8+K#R]= K7*NL
ML;8D\K&=XD*)*?]:Y2(\Y?13@T6TC$^E&E3T=ZKW.\-7]ZN\%_\[\^G/%O]R
M+?#Q/VYJYSD0"O&CJ$;=B-+=O@_(++L7GQT/,?N8?1OND O\?%57X*7QT@[,
MXNS+-,E>XVE?NZB8I%/OTPH?[542N")UE]NQ3PR/S(ZY@S:W)+W7XI"CD"]5
M1_X@>X^EY=?LO?0)]"_9>YK.O_P9(0FN0+]2"-N(ZJHQ@[O#3RL5418IAHMB
M=/]$/W>VL?3BY R*5$ :O:+.^+*D#]/O<+Y5W!'B;1JRHP)*KV$;X8?CB6A"
MOP_#3,:V\7I:F^XJ:D;G>]CE1ZX _IO\M&X,YIWA5_Z>'+C .5^C\B40P06A
MR;QSH!.US;L 4?%M :_OPV^3(XW'=\\.I'\O<$JNW"D,0>TU2>]Y;ZH$K/?L
M9>_H_3+:C.\'9>1_&;+&+Z])5 /\5__\'D>*U&B1#@*(,:P4$ A<F[(_90(7
M_"X3F/M'!=7)_V^E<_^IGPSKPX3U6^@BG4P P"?JETQ)?<H8?-U%(8/L2?/O
MYT^%D4O/4 %/TBA<.Z"7-+?_GVR/S!/1 HIZBF:0J934UNO*VU*4R((ASG=?
MVP\Z?IPUZN(23?.\W+FFNGV[AU0B441G;;Q M$\R#4"KTNMFC%9%:S,< /C-
MF)_VO=OK@;J;3!\F(=HX=KJ;!/I 1AM5:BLZ+K';+':T'$KV$$D*\)/-3.;S
MTU"U,&["/.^$B>!>U@A6]F3T.@JY:PF7N!O?TKFPX9[,UA^&P:T6@YYM2K#J
M'QL2R\.:O@*MB=U]Q]/YO?_G1 3^7 W(TO:6=.B6LO.>_HKCC3@.)VT8LFJN
M%-+9R>BH!IAFB+#)3_4[)-%>#(DL,0,W6TIC1YM?N1-6U!E<]B]6'"OQ:XE^
M%[@>;17[:VF>VX[Z^$VRW.*"T,;8L80K1U<J/UV(("0SRQC3X72GV)!X=%TW
M-/QF?GG/2O?*"HN\FO;JK??(EU.@LWF4/].#_Z_3@R,BNB"2E+X:9KSE6H1,
MHG5M0O!*7*EU!B:SW='95= \A24:0.\T9,(HFG&Q)1W@HZDCAGI#$L<[JY-3
ME/9CVX9?]"<)]VR]Y;54[Q!/.L4[J^8:+"PVI220J,SJ];08WW:MRWW4^MJG
MGK6MRLA#O1:+D,%)Y9)\O)]VQ>HCU^(G+I<%7JEYBCY'VZ&8B X-8\<'8(FJ
M^EVD*X(AW:O-(H\+X"Z]97>@RG0+9E:,Q)7WT($6+U00N&#+DM?L4\2-N[W8
M:QO6RL>?%OIJ'/!3/A4VHR(.[8 #H(QF^/VY@?:N)L-%V4X%IVWX/XL\5IQ*
MV- -!14QE1)/IA/1S48#+EH>0DU\F4)"BUI\P2;U-89L!R#.UP';]A(=F[J1
M"5:H2;)N?:%=Z2[\V:-<M;5O&>NO,1S'67FS7X&?<S7;(4L8@[>08H-$>&-A
M2N^!MS+/[^7$K<<B$E^U-OLPJ?32K6X:1]F/%P-#-O<@[.-F"UXEV>_GCX3[
MJ-XJTJPJFU;V\^1ZR]_*A1)MR>7/Z'R4Z]9^?<.T/]DAV_&\[+/KG_R1YSZ_
M$$+H)OA;;'Z1F .'0XHVXWP9<92LB27QO .HS-R@V"_6QL7NCP64@\M=6QE7
MM]N]5U^Y2V6D79'M>]>OW\8N[?RXU?*)PN&(MITCE]MVVKG6D<L;4WOP Y_Q
MKH9XMJPG,H["AG=J8"CIEV\$3]/K&O@!4) >N"T0B+D4:E!<T_G 46SI5N[Z
MB0MF$3,AS8_.MIQ^[)/EOU!D(SL[I-',"^>R.UHJ1P'UIWWJ74ZO+*I4I3LL
ME.?RZN7RDX.UCWQ#J@8FXIN0^V!@HFCFTE(.-&#[.L(PAH-<6KSZ/O'3-;W3
M^<?F!O(F732![^=1X"[*>;LAQ/-5DJS[!\B"KU!(JSW'0JF5T=YKS25>B9>B
M2NPF=_9<+0Y1!GV/OJV_ $T  :$QE@)#1)/1$6:3^N'RX8"6KW6,CT'BHKTL
M$7[>6UR0F[V"?45+YDO&AX<M&@NO31&C_00IZCG_E_9[H V.NP79.:D (0<9
M[/#LQE3M3:[5\0.G;D<FQC^3VCJVG'M_0Y]97%]6.L)))$44#3-.\! P0P/R
M:DXU38".$#/TBQTO7.E.CAFXWK/R36FN35W@?L3X<A07G >[N?9,X!0^M $4
MIJ)8-E LH0Q1J[Z;<<7!0T3/7.0^EN5*B=RR:QG?!L0"ZGH5T6#&E?2*_^OV
M8[-KGS1.=G3O<0*25VXS NBZRYC7!C'U S;F(<>W>%DOF"<ZR?)+=1N:>X<R
M9GWAMM@^5,MS3PG8".=0TIU"\L*..SAS. CP0HZ8P3.:,L;.IYUUK RR$6.:
M)H]1^LP)KX@NKA.1("P!F4E,,\$K%3C,<7L%C]3<:VYDK[HT#8?>V;U7$X4'
MUNH"H:%-5@(#0TMZ^96='-8]J84QLF%<QZ8<U+7F%6*-*:=)O)TU9^WBCB;T
MEI:L65\L*ZWX]%I#QDDQP!#1'>Y?"].LYA%%D,ZEHIZAYGJLOA@*\!94E3OL
MO0&'&)Q]_+BF0).QOTI@K65W+A+]4%=@>,G#@SLWW8&^?TR[7.ESG'++H;78
ML@CK2V #B/8BLA <(JO+:>=[@M(]D"L;+@8+J2SI/?3Y"7JS+RQ&=R_=X?P
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M,)5C]DD\1"P.6Y0(U.]U P*_^21XEZU83F'*&=YM]'RP3T365T.NXL?B)\$
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MS[N8B[A?2;Z5R3(!,S<\I_(!<2CQ!JH86)\4$*:-$M$+#U3&=*=W?HJ,W+$
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M)Y=4-11(LYWX$%F4APSWB8#^].%KL<&&PC4%*+V*^GF.2=B>243B/LQV1V
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MWP><(/O#UA7HQ>G\9+CPI1C3-F7F[UU$ZZ =6X2KH!Q-9,E#7D7&';;_[!/
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M=5M(((X$O6P3[[M%%P.-V>KJ+-9D)D4FU7>^M700O2]J!X#=)'E&5B"OQQ,
MWPD*@2P@OHOFK.ESF)GX:6FUS&9OK_6&W4G%RRH)P#!2SSY\':FI(S2^OXT>
M8B1@><AK.HOH6<LF6F#M[FZ:5TXMMS<X1Q8/C\5QQKP<#M1+,0U=E6?U7=I<
M9:]CZ"A>VU+"@ZM(J[T8=J..T\-#63WRUJ?N?3>]JZLDJ*&EVSS+8]O9V1HU
MNX@NJ"Y]2LPB+VB4!@>@28@,:2#&?WK>BE17<<2"9=O-UFLPNB#SS,3JS#M?
M*NS08V+B"IB;'MDFW!RW93Q]>;%!^=?<$N;XQ,W01_F23QQ>5-9?I\CA62V]
M6^0E@9^N:"T H"4U9!9[1=E1'W1L2<,$^^QT5H2;5;"AM.']^_C/*/ 8$.L[
M]&J_^1P2:>'5A:'8)P .PS</7Y#L@DS\&I$&F8D7-;50LK;$*&RTW,TAFP39
MNZUA3.4BW$..]#S%<:K6W_R8O:G3>!K;G%-"#N\9(%PI@,;'YB,(PP,@U+$B
M.Y6.#$Q)@]P\KBM'Q!N&A6I TGU_*.1[&<I[;;JEYGL>I!S4A?C0@J3)C:\'
M[L!(=)3BU>Q)8]^LO@QMKE7W(F$R8E%@*?M$H/I>@KJ0PFQ*Z2$ZP>HA598A
M'U":@E=>D(L*!)##WD-[ZKY\_^=QF363"2;&6H7_K:966XU#'LXIF8Z2 ,8_
MHN9?0<F5*1)S)H4#+2JED^4Z'K%95JI6".:!ATRX[,A18&%>"Z7,"@_^<7:)
M+P"LL4P96![*.X-G[M04^(<9(^K KZ;/]F;^RN8:(F V0=VB^Q6#;9F;"'30
MBY,WH7GMETWL]?XO'I4W=PV0_2#AFK!-O%EIWKR?U[?*2<XI*3,C=^O,<95;
M P.[2>N)COLYJV**\/U^QB &='ASVF*[?DXQJ*2_SGAM7+" :F>>>8-I=/?<
M*&,^T?$(EWND!BJDP*R.FUF8(&[C(8/-G/"V3HGL':NR]IC" 0C:(.*"!VR_
MSO$H.=(O"[#TH YS- DEI(OP"2*L G9$3-<=8#H(2:RT6=M2P3:3U$YI#]PV
M<9%VD(!P295KBS!A=0U<S0N\'KOZ&.94&</;;"SVYB9Z 1%Z]F,MP7%T+Z).
M3$/:3Q'4JNLE="\G%:X*ZQ:VYZMF??5)^U9052<-XGWJ;9C1V-<S[>SS3'*3
M$Z<1'4^ %5K([NW+N<8[VGA"%N!XL99LW"%ZBTYEW9MXKF6OD9IGM5:2#?L2
M5;CQ*RW]J31ZB/'RX_/C1(?(RII(ADOZ-U*-\6,J!BN-G#'UGU8:'%\.BRR8
M@?7@@W$_*H\H:4XS\+-CY58\)+(//8W>HCZ>OKOG33$GE'M9?HA(ZA-$.E@0
M\4>X%\\P)XTF:9O,OZS,).3W]']4I?6_D>'D?I?2]I#N[EB#?9@.0(A%PJ#U
M"VOFCB,US)1B8L4NTNK<5!%2'W<!@-O%N!HXELK2O46IXVUQ4_717S6LYD>Q
M_S8=RE\WZO#S]%70RY^G5G_P;[I:JUJ[7R)E3? %K\"*?ZN6?.&I_'BG2]AD
M2K'*'$.: H8;E,HX*A,RVJ<:7SU&$Q39L==8.O-5GV#T46]'9&*Y3[[7)&1/
M<W"]%?LYP:T,[XD6]O;@-3%)';@>6M*>;XI,,8DD,GG(%ADK#R27=$U4)_GB
M2*KPD"E\6"/LI&+1TY.AVQ*L*1F;E36T(:?35F_6?#$2TU'?BH42R(H7_-4\
M"1(?T4V/R I=.(VL6#EJUI]H-LE04QPHH;[;P!Z6H+/NLED%.\ ]?F\FV:<_
M1)D[S+!>4R3^(G$, 9_8*$Y-!.DQ=@7'S.(V"!D@.8!0CKD/\_?J4!F5-XTI
M$AQS?,X)N=V@WQ<Z)0^;>_U.(^BHQ"B'$VP/Z9TL%$G7^+<9\L+C$YRD[KC>
M8F*OCC0]'\X$E DMAPB-3_G '@6&H/"WTV<BW-PR%KH;UU+4U>_M6E>+TH9^
MC -06.,5S5!&Y-S3/X!S>^J? -%L"+MH?J>K#GI^+03;PLS\QQ#AQ(W5"4'Q
M$"9Y2YL8R436#X/M*'/+8&NXT&L$13M8"\BVF %5K;)J:6@-,JL;2*@<JZM'
MN7B]Z4WPXT]0]4L]FLOA;\7K91)GIB5!CQP'_C+=7<TSI_XS;,7&"D$X6J*J
M*0I#SX04GZ,S>*;KXS:#IGZ>K3P!!@-P3WE@%D:-M=,%;2W9OO@2,35?9OH0
MW8=O@>>JOV*T@^1C .OIE[%NVQ2A4$+:=5#BL>ZBD)M(\L1D,OT8;^Q <P[B
M]#1##%SR=X[8E)5\WB663L1\DS3@DANT>+8**I,6<JU>5H1*H*9=EK3J?+[[
M7A^8I?8"!ZT,3=B0;[.$N]A_@@%W]E0:7W#05SJ;,.Z(5WQ*W))Y*A%JV8@%
MJ..>PRP[W&IXS((XH?5VDTVS)3+B'ZQN+U9W;S"E0SU?G;_^"I=\,[J4/X3A
M20PVA1<-)7N5*]4 XXN-5>A:*/-AX+2$43U;_T A;H#O-X?U'&)A>VDEQWQU
M;^QY9PZ*/@R_7XEIZ38JCX?V,S\4CE &43S=QT3CS>]G9_ZS"V9PO9-'1BO"
M;_JZ AY)-'3I295[&E,U,G3:0@O#UB?#V("HYZ0\@IJ 4R40Y0D$03+\TY]S
M3EJF"NP"#Q^(CE6>I1=3FY,6*5"A7[898DV \+QQ,E??)BA<6GAD2QG#9S_5
M4,O5$!6G/\W>QQ0@HO;;CG$:<DM'3*VL#0=@2KMYE0_#V]?4&MJ)'\H//UWV
MU(VSVHSAO'ROSF3#(B/I,VO#&[=O@MS9[L$#%;O@.SQRSO&((#]M/JKC% X$
M;1!UJ,6E/:M<GOQ,B$6>7.0_%X#OT2HM)Y(:*_P#BD _-P'RT(>OV<0&M3]_
M_H4J=/0G:XQ!R.-L-BD"*TZ6Y\B8U0*_"?:N/[) $^[0_DH1S^OV>\KLZRJ1
M_L31WZ^GZ$#Z&+_W 09I:_<TR()*H+ZH$,AK(,G$<90AJ=#,T876#.DYNZ47
M=\31_6&+ZSRY.7ET+#^=CT)E-=UBD!_W7AO>$Y713W,5UT&113Y8M+8B>\9N
M26M#$/!*7";6&$GX!&"5@IP]1"\RWFHF7\CURH7*2K? Y:([]^;]J38-#WP\
M0]A2)C<A-<9C7/>'!2KKQ5S2@[A,_70,R9=_IT$6"RS][S+NJ_'(N5Q$ZB-:
M(W(4*H+XGLHQ4*SQ'.1):^?1;7\N^A"-_L7N0GJBIX_@5,#<":ZBT3/=J9%_
M)%FYJA):Y>+.J^M+[Z7QM?.X_WJ!!+?Y^W<@BW9E#Q>ZU(?8UIK&4^%6/N>"
M5I E$#J5S#V$.YP0W-0><Z?'FZ\\DE#?-U/RVK[7PE^2L"^:8']TB[&I[%X$
ML=>OWY/=I^XDB,_GQ*_>*L3[>^OV]190M+H:]02%YFW8>A1Y+;XEDAM&8=%(
M^'5PL^"3"*FWTS[P])Q>7TM,(\4@F59**>X/P0'BL<ZM]3,W##>6 3<U2LTZ
MS,@*CT0E@L*L'PO]<F3[]J9DL$@^E>O+S- -<?5@QCAMWQ/ R\O4USV_UP_W
MNXZ2X*O_DC?R+Y'?3AT")\ 6EQ$O<^!.Q<%AW?Y(N!@H:SG?X[!0^U!T^L@0
MCWMXYHJ_417C9;4=8&\J7&\2_EVI@9E-[09S_0NS<UI-Z74H!X"P".Q=<MS-
MC*"$^4%?&@S<&'L&EZ\<-J<:,R18N=_9,V!_3*&MB,1:%51/'"38J!3X-RW[
MS(J(4"==(_IAYH^^6,SI?AU\J$BFN<PI;X*.8+S,7)DU;.F95MJ1*H8!-0M+
MB8X%E9'_; ^E!R_[A('IW">8BQ-8O>K0^&HRIG0U.Z=$A;C9&@?\/#EKU')4
M'GO(33ZQ[48NY0?CBUU??8[8_(6,OO3::?Q,X]ZF[R8R<&M $K#W&_\O@\,)
M,&/9X]H3@/3$GV%X9S[I#<52>EQ>$4?XYH!STTO@X><6?';81+B5D1:MZMF$
M;VJ(OR1R22L8JIE<>4@3/]!10^#@Z?E2"^)(996M6OU)=[LQH3,J+38#^,(M
MS!PGUU.*<;G#ZU[PK'\#>2'[\Z[Y<BJ+W166?EV.L%ANBWX<SR$T+'NUB.?9
M\O[A,I/1U7Q![?\D$=^Q?@.,54K_%$1YX$3[@4S=F6"!Q =[6) YWK OJ<[Q
MKD*A\CA6F"_+L=C2ON5ZL1ID/DX\HBY^H!D>T*(UC@"[[="G"JVJ*F:]F "U
MU"HN,]]/Q=5+,2Q,.@BJW;T!.YF]9&I#.L'/X6K@G32/6%>%-6=?0>/?9AW>
MH0$=%JH\EFJ6F=F-X760@,:6OR$7WKU"M/*\QP;#G&[VZBDW9^PO!PC+CY_@
MCW0,W$OW')!C+1RD_[A*;:C3R2<K$Q"S-D!UWE)^N+;:>@>%<=D8=.IA(AVP
MU6NVZT<XO\0KXC#GKWXE$'7S^YQ>B<S J'2%TD?P-L8@'7FQ?8@0IIP[7.TN
M*G%P&WIMX_*;B&E(;B$XZK+O59#:3WH-X;$H04.48Z/Y$IKH%&4/KKY*;]M&
M:2E(S@G,&Q(K;'R\^;RG!V2SA6:XI8YNZ??,^:K&:H$C1V.:;Z^YV;&C D0/
M;=8'C&V3E"7]7/\LZ.?P!,C,!.]D?T_T_O+:B\B:)2D]W3U/[4LO]73_7/\[
MO<,*MHM[K<AB)"6"^S7<*P(FVV\'Q8TG,S0VVU(L@6ZJ7HGS+_[N[.=)2]A@
M31:KIKQY(4Y5/6>$](+>/0'(1G=&P%1.B7)D)D<]\*BBB=;V=*H3FV:Q'%#_
M=>QY^#.3!)*+]%L0;SX_7I[J%6PQDV'EJR5S#GBQ6;(M/E6DBG X?:J_YYEH
M%007YCM(D?TR^CW>UH>XTS6ML"L;"X&%9/0:DNI7=JQNQCU$G>10"])[)83;
M(0-9^RS,XPQS(J^XU7R#%%8->PY$'=TC#BIK+=OU<;-0L=H".&.U&+^G@"!M
M-I:J*,BGLCI9((3T)7V$D9(R5\T5EN2+*8O9]+4+IQ^R3S'O<-0HP7(OAO?]
M>N<!/J@8KLURA& %:%A3DBK\0JW \1QDH->\.#"3#YPQ5&',PBUCEM\9_Y"G
M,)K<_F%I:="J%XOJ3/ND*8+QA[;?9XG\7K<^V>?+QX^LR&!XP8!^-Z#[PKU*
MUV1"%V+3*+@J/ST%B&A)P[4L-!*M5I[UC3'X,0CG'@Y8J5N7.JZJHN=[]+1=
M^OW"0P[V\OIU,-],\W*K!02P';.T')'2";/9";YP+P3Q&CI;"<Q)Q?OP4,HR
MA$,)2HK!.H@BN-A->]^&HZ1G)'GC^=O97Q=*Z!; Z%^R>JXDTODSG,^[J:YD
M'HO@-0-R!-)>118'M6:F2'[YZ9-/MG&K9R,)OUOBSAXXMT^_OY[%?/E-\8<7
M8%# 0BN6>>3M>25V?2O*KD[8!TQ,U=V=S2RVV%(E@ER4&+I,Q&PT8=H?EFM=
MQ*\4+[=5L^'2(Y_)QE7W+RHN7Y9$FQ&X1F:G-(K"@5+D['I_#(5*QB?<&420
M-E"8Q768GT__VWG&-V8&2O-,;4#84%8S=F$<I/@5>(>YXEN&^+I>9J#CH;J9
MX!#G$V F7Q5JI49T7ZYV]%DRZ7BS,MI^Z+/DU5[TL]L-1LK^.S%DBPE\*O">
MW]N*Y](1)F@F-&@]\7:MDE)P??5E;_\IT/.^;1ABYA7>R0OU)<1&BH!U;*ZU
M&!S]1>H[LJR2;<XAC?&64O,)P4[.PS7WS2QM-27ZW.\/#-!^]W(POM&AKQ=/
M8OER:>46,_.A[:._GFV>F*MG@H\=1]$;RCSI'&,K@)IL4$H4)UHR,J_DL+TE
M$*QB73EU;<:\K]X>=KXO?O[!/DWUSQ/ 1DTN%)QWAZ, 4>^)V.28%SZ+PH**
M-K9_B&*B#+>=S6]I!"9'DQRAQYV4W6@"S+%$KBB'!O#A.4,?!_&V[;U6HK9)
M29\ !3UCVU_T;@;!B+MG8#47JKJYG!WA+6*&N5<MUGE3D+KB[JR@BB31:1N6
MTP])QZI%#;)M0J_IO]*5]8H77D"WK2]KDGJ 6U%;Q+*4X-<='?#3+J!K22S!
MWB[(Z=/-0SI&1-A\-=M1D3,-F=(D%<5EC:#+JA8T/)SOE-=%6HFAV)_1K':Q
M2!2[9$!'-H^^G-OZ04?O6TXJ\B=,$V)]6D/Z/:F?IF\((&>5Z1K_9V_A*YSQ
M436@?^N.LE+N,HM[WR)8CK[3PGO[C%)MAV*^T_S&1RFER[:=(G5/W8[\_EU
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M2H54%6H<:B@>8L+D;!D!A.H<?WW#N4'C]-?_K=S -M/;KF5\%X6H616"RM9
MNN34X:G!]VU@7^BA<;^J><]'>;D \,/G;TP;2;U6!5W><K#3)P !+Z\TI=^.
M>BG,96>)9^%Z_5<]/>=;&D3SZR_:_)M6XMMH26:I)X/;4E4>.=#J.L=K[EC;
M12E^0N"7-K=">]><2]#WS/N+#^I,DYIZ#-_QKFI" O O>T*ZT6;O>0LI?$VH
M H&_]TQ^9.RE>!/JGDO8LMZ(K&AK"CK&(UQB>#OYB[G.)S;S>++?-\78[:<K
MSOB%?]%";<C<T>3372%9-6X(>\@'JW@7]>89K2AB#+10(FI5OM )UG)_/=#"
M[')3!68/<;3IJ:=HVQB.OJ!%>V[;Z3BP2=Q6/W/B466LX 7%[=+_-<[GK_Y1
M,(A989G@L23]^D"@<:=XQU3<0T(_2TV&OK+#!9DY/]]56,37S)H?Q3TK&3;R
M.?S0W'O';<>DM08F;$)+E0]"8-RL/?LE* E[H6)\:?Q2AINF\:'2VWDI3]!T
M;$E:'=)QKUXW1WXEA6NF493DZGO<0!?1]9*,UQ?_]SJ%\=L;@T0>BNF!V0F6
MS!?/J:VT<@$+OY[5E!JIE"Y/.;Y@K?T5)L&2[,521O5"Y;.R\@O[F6N!WWLN
M\U%Z#YEZSEME\)M[8<HH?C A N?TRL]")4<W;LILVJZC050#".2]51 FDLHE
M81Z8[D9D>D],>+3W#.";:"+(A\.J[KV\?"$JB/?=*8^<0$O2?EK#<2E#OQ+G
MGYL.KX.L+PC%G+VLNM/FI=$*'"D2UAPD-;-*%<B<\%S-C M+$S)M4&N?,ZVV
MZ0R/B6^_B_\;NA'2HUP2YP*Y<UN9&NML&%=,.*0'6X#[V<E=L:?Q&5>$$4N4
MC 3WU%6'C]SSE_;,B$X:-EAQB:_CYQM[_D5J:]]OLJ!D1<OONT%BI%$'G38[
M,)/> ')I;_K4",W:!"2[F9W6=-I@/6Y(<E_(>]KE9&K6I&^^SZZ.XT/,B=KG
M*AO_=/+F396L.(LN?CF<[B2BN!LDJB;++OR:I#\'&0[;630PT"*T/ZS@[-LJ
MBGFUC=_ANN>T$=O#)S07]_W9?@28!?FCG*.?,"+5@'3CR)\)?IJ>>N;!7L%0
MA#\?_]%..3*!V'J445C>$C2D4$T,=H'B4T"I8)TFH)9V<7BFOJ1VFJ!#WT,J
MK%XUG)?+[RR(</2W:YSCL0S'SUN&KT53Q8<^HEG%P"7:^V,I;KTP:C$\@1>!
MJ*K;.6]&IV7)[!D8@Q6)#U-24XUY:QMKY_D_J#EO1^!A&$6= @C$93AK3^.Q
MD,,([O=UB)*(_>E.700^[=N9TT8GP2'0*J^F8_0?IASN(%L,(I5&.^"N96DG
M,J<4Z3C0+;, YH=R@6T*@&J8V=..7J73:N5JH(0$9VOM<3*=$>*Q&$K E]Y8
M/VQ9.B1XJG@]"U>-TL?2VEIR19EFB37I-WU;/&O2^4ZBEG&5(SRGSY,RT=08
M9*'8F.)L"Q(^T"F2ZO\=H9.3B;G?BE5:S)W-GM/8$GW)G:7C,8$K#X)9F#;I
MU[7^4)\J'JKI/*-C"1O:5&4IFWRA*OOB.(!&FKK8_L+$^"%G()M=@P^W2UH=
M3:-8@4;+P[4I[F!T%0%0O?MY0WZ2S8?4R4/V]]_&)7G9H7_>*AP77CQ@3J.6
M)VEOI<9;IHU'6&=&]2&][N3LY0A$.K(<)DTR)LQ=G_MFE&B7_"+&9.9<8%%L
MQAX>*PCTTV#:8$"#SUT7S=\+P>>TXY#&0\(3]H=/@$\+YL!3-O7HN[SK/)IS
M>'YN[*M$=194 V?".3E<L(<7].\^=^#ET[>\ZGBSJ.8KF^7(#BZT>M4\JPZ0
MI\O^0U\>'R.+B?0:\M$HBKF> 89-0IR=3H4/F%5B^QM@_2S<3':VG&,*UAW4
M>T5(;[B!//*CF/V,>-L=JS[[T9XB:QBK-^NJ) ;&;T\F>6KG3!3Y#)61;@SD
MRLYQ#8'%ICDH\5J-3UBT,\R(+[>#^5!$.';+H50T=Z 7W25KA?5#C4QXS"/_
M\286(NL79?K"^JK=UR;]!9%K6VH_/D0RKW72,T'2"5MZ!&63G]%?'IHQS0UK
MQ4DE/&)X-!",P@]O%28-K;&RO:>8"SK@H@FE(A=FASY^<T?8">;450FQ8\^E
M*-X&=_)IHGW$R[3ZNGZN%<*XA@ -]\57.R1-^54BQ;>VC,;^G)=01AR]NJ35
M_UUP. .0X=YR3 G^22'Z*.)"QBTQ'Y?%D-8CL?R-I]CTQ35;Q.A9DXK#$3#Q
MGQ_,W#9E6H/F^HP7?JU^7Q7L+UE_XT$+&D@T_DK-_OX5MJU%)R:!ZVRWZ4.\
M/[L%<FF',**2I_L%*!Y:$UIUB5URYUR7KU(R;.<Y!SOO-4QR$_Y ?( RY7!+
MN^.<4.;(@-YE)C24:@Y(6?<K-_.<7>4.#Z,ZGT5-#"IZ$YRHHF!.?D=UK\(@
MA3"(('VD*(D" W>7581]#"+!(@0)=R4!B=>D-,',HK.Y.2.VJ;HIPY7(N6LS
M..$ (=T6J,6D<=Y9Q'=-[N0N.5ZO-6K3,8"WX'R5_'.(D^>19.95Y3CC\C$D
M.UM:F'F.W_2 5,WUTYP#J>K<R'EDM&GBUB%CU_O/K",82NZ/HL@[B!P*:!3,
M6[H^<KMT+;/7Q=8)$ B;7/%2/9L:SXXB-&5\ W%_ JQ9_%SR<0FIX7/O(0&J
M0]6#R=L=)$WZ%N%GJHM'G_UW"5GK\GM>&0?.'TMSP^7Z+-#OV: ']UQV,OD.
MG]6%H= CM9$UTI!8W*1Z$7280J @J*HG\ EPKOC(\ 18[K)\ A0>FBZ%=,L@
MK7<T(W=,+ BC?R>IA=EGP%*&^!M?S[2J1[C=0+[$D7? 1&;OL9X B8SPF\?!
M8\('CC<8-?_O>6TONO,&,\,]IZZ[7@PJ^,8W)+H%*D #99F0)E#'+M_KP%D1
M0D)CPWO[!I4[MJD![GC<#-P)29*?@@^=3E%^!=(OG/\HX_M-F),6@FV7*OU%
M'#;1YJ5)?80;VT/L5XM3$JC8FNVG1WG*9S&UXWX)1AB@+78M?EO)@F+,FZAT
M/(X2-1<S6W_B,ZPTMYUK\3;WW*<>%J^)<P[X:!$IF=H;CPUB?V1$4RNW=W'_
M!HIEZZ+TL=*0'-\W)L?](?3M?6W/BR_>-4TK03&)@!OAC*5L%7KO0WD.:V@
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M]\POBIM9U-A5Q@P^' &RLA8HWUO2?=?Z/K=7W)D8<Z!=/)V\>F,,JD7H#:A
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M]P"@=@<3V5^Y"*_M6?<N^SLN2@,DXX&E."@(MRPQQDF6N\W@7GPM%F#4?VF
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M2-*PY7GY;AC+1KNX^0LHX$CU5A#S%95L\P'M.2A5$LO/G[V$F!/X_,?>&D%
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M)<LXTXE>^_1"*?-*R^WW^6[#7H7QY3[OMEG(.A8:AA!\M-?2&'DO>"#+L"
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MCC1M(S,Q@^JJ#WQIPJ.\:GR5!8'-:W$X3Z(4=EU://LW2!J/N%PV"=44_@'
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M%A38BBT3I3N6++VFA&17JF&1O&G]*#%K_HFHBXB;$1KY ' ZP477#IA2(@7
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MO-^#E\QSX\3'[K&388EQAJ88ICW^<^UZWX^D0/%)^:FMK\=_US9?CP< $IH
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M_BR/ JH;VNB])8["X/RQT:_FJ$U5N)*EC.V8DO6:>9(T^OY7FUW^?X#6^L0
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M[ZQ%<#R4$R%%;(HZ2+0U&^P]>>_/TA,F+8)A[4&F5=PA@=DQB%=G17ZP&)B
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M?5/JFW;,K5=JK/GW_5?+J[- HS3]C-@\/OAQ[Q*_GT0,Y@P9)5/NJ5KG6=5
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MI@^J-":Z4&"K$W?6IRWQJ;RES2.SOW0*/WY8*GUXY<3:#" 2YM2F5L<;5"&
MH]'D<IBXM5*['6UQ,JKEYR]:Z'%U+;^/X?=Q[7*.S\[B'^VE$B=SK/CS%A>9
MYH-7PE4H",>1LA!J.,43 DU\C<H] QR9MX\G9RQ"U:/4:.I&JK:(D#GU;.&3
M9[,O=C_<'PH)J"&I?F\]R]U!0%[6//?UA7SMY?_;_>.%IPB9@!K(S5<4Q#Z]
M!F-NNXE+7/KFM'AGS,^UMOA\Z'E9#_0CO]'D"^\G#6 ..*1W!A,;N2.[S6DR
M*1S]N67,[/Q6\^T>2JX>#SZ(/NB?,$X'G=7^&%O374-K ]"@,1S%):XMANVD
M8XQUC[W;V#W8PCPD]=$?1(<E5,#;MCJ:4(&VNP%XGFJN>3LW*7H4UFS*O^K:
M^>RD-?XQS=E4;;XH4DJA1H_0O_4-6\/DHB@SX7I^=Z9^@<5$[D/!IF)Y[L^!
M_OG;69IR2]C%H92IK24K$'",#CKZ3,SK4F4ZASB=,Q"I/^$8I2Y QEEFBB7O
M9(L;4]/G O*4)P57/3@'Q;*G!5I#*@"(#G"X_)T$P24;V!'%MH=VWK:\2I;M
M;9^4>@!ZKIB<&,FD?NW4? Y@<QP]KR<C(*/:+%!T':K C9  M>EBW5#^N3E;
M7GXIU_*MCY>OJHPG\Z-,@KQ?/JP).<OT57ZTB% G^G\NLEWCZ+@S/728DA5&
M%X.]9M%-)Y2TEP0,@Q7ZM()X$%)CA4#ZN1+$F6=S_0(T^^8?JF4OP..T^71V
M-W-3[5*^+$4\R] !UHE->LV-GHT;C8V8G.SPET/@U+&W'<UN#,$SF1L=Y$3!
M<W0']V@A8:<$,VG57E_K7.$HC&'66G\Q)" /XDSUGL@\*;4D4&=4PONUB9K<
MVPW)8D(Q]ZNR;V<*0V1,&?@'<M7PE(ZR$TR@?# 74:)+@@\>9=LZ*7,!2LZ]
M2SC,WN)1EAKNZ_W<Q 6YF_'F&^2Q70C1LS.H*;H!%7.<*YME Y0O)U_?,:JT
M-K0N#QWM.>9DM>H,U^-YK:"9TESS1>HV+EP%?ID69SRQ'^E71:.)(J!ZDO5U
M>0TF)"H7?QAXD>U7WVCT8M"=]^=%*E2&)9]?(U+5]$D_+]M0D2;TOX$9:CH$
M+[MS;LOS) _OYG)[4$K5P[DPJ-OWAS=.#"RGZR] 8.<Z%YZJPXX<>]"O)O/7
M<7CU;(>/V5<:&,;F-5)[;PSP)7#;\EZ/X*84N(R%!?!>O@"Q SJ=*OQ$]M4W
M"!,%PDR*IZS2@M3YPLJ4P/A33%WT!2C]%]F\OV.'HED3FI?1\R@*B,#/Y3'
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M$!9G=V^Z30RW(*TW0;+ZEJR^ZQOE$^+R] JDSF#E;K@ZUE:7)IL'A(7>.7T
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M;=DE] <Z5DB9S,;YPK([(C*0O8]T]:P0@O.,0 3@VH.UTKH;[7BG=D4SQ_]
MZK4HF2O2/P7."0O?5>!73  =KK?=+[9Q^>;R>KWQM8L)X[=%Y1;NMT$T@EZD
M3;7JX)F14# P1H2A)>'6O:QPFH=I77;7<R4DC+^U?3BLX+V/W/$4UJ!T\'KZ
MB>VOII\0L]U92"!3CJ/R%#J1[:J@GE"2%[O:@#"!C:R?I QXA0JX=-RV%KD
M26M,U0R7>I;*P.5\!H;ZID=N[\;V<[U8;)C5<68PEBZ2+/P5H/LSG%.A3V^W
MGV_FG=-2/7L;[,H%"/L,'OG3VEW$M%7D\^_UQO'Y13NUH<:Y/X^,/\G)DW4^
M&DR;_H*X=U8PUPLAD\V+#[TU-APAD"%>X"&SMH1XI^,N6-UWORN-/BI%>N*2
M JMN94G4Z7@>Z:J,L%+KMA7_?L,727V/%DJT#)4@9(?>'9,5N;TK[NLZUVK>
M8&AM^)Q]X:M',E^..@W-Q(TV^YX\?I5KZU:H" ]$(#89;$@8278TL.;V39Q]
MU3+A<3-IP)/_A]^5TTZ,I8(9_MU0D$#-?S8^1F6#W25,B(L1CF4VM@T)UH:A
M$:3#9U7<W/]T7] H_,&%*\ 8SH<[;C43'6-E8?QP3 \Z/9?_^ZE?<75.?G'4
MPD(<1K:Y->V7CR#HEU<^>;_*U Y]H45)KBC5A^9O%$Z-5VO>4_LD-_?#7%80
M\L2,SHY[1+O/V!S6WA;MBIKUY:P<Q?%M 2>"USS%,)B&NVL95^=P5A#*U5/C
MPB.:"QT5G!(58K:94]ZC3AZDFAWH<O]%!DJEX^X%^9U?(_Q%Q?F>)@8$B@FG
M<E]/.)E\\[UQL=5 ZY94DK).,=SCPZDT4&@Z15+LD"<>UL37&UXY8M10<*^7
MJ6N;+(TZTUR<I^/]==>KWR7YEY2W;5AO7I+\(C71+*O V=]LIDZOR$5Q:,YH
MZ+3,O8#W'F>K_EK;T4**JSEVI'=!";U(2: NK[9;/S%JP@VI\%:XRQC&9)K%
M*17I&ZW\;\2]=U33W[8O^D44I$:0WJ*"@M)[;R)-1+#02T1 2J1W" 1$0+J@
M@()2I->(-.F=B$A'@G0"T@,))40(R>6WSSOWO'WVN^?<\]Y]^_PQQ\A(,C*2
MM=;\E+G67*$%+2J-4#_*)^@@[Z#\6FU!L@B_@-@=BRFFD]KIN%R*<"DCG]2@
M#<M4BT[1'P$,]&XJ3\KN&K,9!X<')Z NE)!&P?2^B?"'HQXM0;D6FYF>@W.U
M1^N)--^XS=\D=O,+?TC8$Q[)3W'4]GWRK>-2=QYU(:!U(;&UXHT^/=.=?;D_
M7#*T-M4)U;Q&C:5;H%XU1>QNQ%)]1H_2:DY>K_>JD,.$F"EKRHOT6W27:&@+
M3BDJDFF)SEAP8HMD"%KU<N^Q7%Z>>;5!ZVWEGDLS*:@?3W6&(5DL%",#2Y4W
M;"QDS<:V<QYI1K5"':1+#D")W?M53^'1:X\(-=!E51V"C6Z1N6IV6G&%N973
M:Q+IV7/BC^^LU(;Y 38_GPXOJW=C[N]P*ZOS$ESW=@*8>CVHJMWW]'H6;Y7
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MXL3%5QP7%/[H;>O>!8AKN(6X%KKBL,[^18QEJ**:P"^;EVUC@B9*;RW?M?Q
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M)TZ>U4H"I".3O<O*:*J\-YMMW&Y<]C1L3]C&%C_BEF&<A):5HGEU0@9"F\B
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M#\&=PQ?Z/Q'D=1LG,0&$<*W]0=][;^XT*E]B&YH5HZ(2OK4YK2^;?-'UZ-:
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M_=':OP(B1@8ZM45DE7?#T]L>*R6BHJ^A*AQQVO5IS<-O[C+"L,!*R1]]\.U
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M(R,35MOF1L+8UY4@+U04EP8P<@,6#2/;5ZL;0K;,5Z_H<A4M<O!<;A!DH1B
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MXF)H^?0!F4R;=W*C8DL?I,6'%@P[?,8^%]M^-'-6[T3\6.Q>+GE:L*0_5WD
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MO\=V9'$<^FR[4E?:#@0NEP\JV#P9M2[OD+/(BCLV3?@#(\)/OC9#"5P=/J<
MYLAPH:Z[+I?::C_EN5UF*BS-2FV8MVNYCQP#<\2= EYL=9YL2^%1VX)&OA[K
M&6RZ4FD6%G9Y[W1#'&!UP$[#XBPUBIY+NMB9N)S Z2MF.IW?EPFE^3/.V"FO
M4!B%UPE%R*F&'\G/6E(?'>45ZB)L"98T:(I)9CCKF SLMCS9N;.^QFO"YY%^
M@LV0F_5'O86O#X:,CAF,3TJH(AZ-X76_-,CG2I,,WFW)W0+HA9S,W_Q+L?PY
MBMX*6;WE(TX^_^E]?_GETK_\DDRJ(CN3^+"+4?+*GIK3RKDZ0+G)'DW;PGT7
M;57%]Q%,2/]ULYD;@4J9'KZFIL:W%LK0;Z N^3,;X!GZR56#B6WGL6;;QVPU
MNMY)]W-D\!LA[2+GH-'AEST*+RD': 0^L&-Y&GS[RON$PCO_[3EK H#DT[WX
MR;7KURD@.F/)AQF>W9G5RHJ\Z F>F7F>/6)R4E@2\\C]?33WD_!9'38S71'U
MH1D0/_X0_1RA6.P61)?>>[LVX?N<PB]]P3,.Y"66\6Y_,!=$S&V1N9FQ&M[4
MQ:4D"$E],F7#+KCCQZ1K/O_J14%HF@X/! 0W(G<<YR>7-J>KF#@[A1O-?O<S
MB)NU[V((55FS3[UM\VBHG+*YTAH%KK<EI1&X]/#!\4C0)A1X*']^O:IB#5@V
MIZOAP5O@+?FK/;F>TFZ*RD*^%+D"6!VG!OAOH#2N%##D6_Z9M$E4ZCM$LWG,
MA'^F\PUTE^',?LCG?Y%!<DSB;E4(W_8E\@U]LC8)IC>>T1F,D1T/3+XK>[G?
M8.SWO94<&S:]N:B,O8->]0*.72PF,A +C<WC&Y&W%=PW&:UZ4JJ@X')=GT7<
M2\OED:GT>]I] W^#Z2$*I#>X<8U^4BHVI@4_76EWD=XSI=*'P7O.D@6R,Y)_
M%!W: A ^SA],"3=;U>4&_ T5B[E*DK]#R" 9_#2\D"P-^SR^H[7.LL+_*HLU
MPF\NB662%$D =K:R(N1#</+<&\3&R\EN7[,VUHG5M.F8CE^ZTB=9'!+<!IYI
MO4G:QL]V0]1-5%# -0V1[2[V2W/O9@P>WI!\J\/PV&K51R)TF*E1[JDZ-/=O
M#!AKDC,9/D/:[P%QCAV:_=V17TMU^>JCJ$XG\=8<R<0[ 9)TA4[.\RG7S7X/
MA%OK,$%*]PMIJ([H_CN$+[7XZ&/*PXRNWSCJ@(8D$0Z[]B?/)T]B4"')2\3?
M(7A;FFP%AQ)=\(4>&ML=,$_+=QK(J#/OO'WX?7N9'G+LZ#%]Q;TC99)OSR"4
M3W)E(-)S;JI\!*=96S-0*F-'97&U$:/.K_MIK=7JW8 PV'_N/95 828=XA83
M[>9/LN.0Y^'9V(&JEH]?$LCV@6X[_!]!=EA]-?5C%N('@/KA?PTS0?]^@J$:
M0PO@ZB!0<K]:&AO\/!#(]-/SXZ+6[:/&B=\4)ZOHB 1]1KKEJ,AOZ'PMFBQE
M!#A>WNPZSDO&-W4YB9-0V#?+I1L8F88O,5<*T^R?Q*C9KP1:+HKCS]@X$C2)
M/37X^D*L"+@= IR 2,!CNQH?3%;5;FM8-2C8,LZO?!MZRS7()W)C=9QAK9HV
M[?JTH:"U2$ "6I]$4SBXSNX9&3Y>\]M[]G/WYB-7[88$9B7,4JX#D4L)!QJ
M-@)3I)(\CX>&+A5=/.O!E_//RDJ/Y_.Y8<-GUXM.4#JAD?;O#/CG_ ^5-GY3
M)2FZHY +)* =P;MQKR2[V+ZNJ^/,HCC=B%7PPZ=,DYDOTHVMS BL-QH)^I'*
M)Z"!84>8K;$/9V;<G1]%;/FW<T:'98K' F0U1A^?M0]SP_E5&LR5T?7BI%?0
M],@Y+D^D$CXF?AD<HW$4(8-P/@6(4:O*'#JU;)[H63M:GKW>EN2JK>_M ;Q
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MN/;]I55&4E:L"+X!:QJ)#VLGYHG@?Y?5UT8B0SBT^G[U7C?HW%4X!1Q:Y\=
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MJKQ_4N8.T2K9Q >$K BDT.(Z,0]("%^-J8U7^GJPR*74,2KI.B?G-?T0]39
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M.2'-220D %PE:RDH3 5T"1"M3S8[?W64LH"F=JN1UR6;M)ZY[+/-A"HJ<_V
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MVMYQ2Z/E&GR><F=(HB=^TI5VQM7?%+LF.=#1Z]%>TIBZ[>7A88?<VC*,7I"
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ME\P(@JN=ZK%,WVQ4C0@I:-J4,_]I[MSDWA%G0;="$$SCJ<&]@Z)%\+7;LHS
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MN>DD3ZXZ5:N-7P(N^]X>;=RV^$N 1KH'"%A#R0U'>DE? @:C0>LDS:G8FY=
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MJ$?4FBYC_KE0<NF]CPZLF!"M9V#R+*@>2^Q!'<0)W3NHSS3>G_UH4VMN@U;
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M10;)X,VAEK-C5_Z@8.OA4/\WK<";V+'0TGRQU>,0]-KI0Q99$_#K+T6\\A<
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M!/&J+GY4/KMM[A!%X&G8>SL6I@]N&:!/4G:KA["R$8,7LGS/?9S\OM.2ECT
M9ZR,Q"K92_MYL.FWE-VX]&:Z'$7T3;B\M.:K69,;/\N8S?VM$]Y5P=T$9)C8
MTL@@FT'<G:;))=O<<]FQR/1CJ:#=R\E$I!< 3E27HC[6G%"K(CR&YUI5:2"*
MH2OVU%/J7(V;[WNL^#)Z),@4W[T;,<@\5?3SXG\V@(DSCN'@BFD?)\+)3N Y
M%^P7W!1"0,<_@^CLWU=]<O(;7]E2M)2NM-]^K73_1)]\&KAF%E+MOM=<N!&\
M/+#\Q;;O D#E6;?R="C@IDN[5.W8,9?5/);VVO;.#G#A<D=?)#._VHCT54#
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MD8UG](Z";IE.7 #0MH3H<4V-*^PO?^+^3YB61="!6K3W.7D(-YZ"Y]?=HPM
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MG!2O;+5$>][8!5KM9@VP)T72Q#?K*XV)<+NUSH@&>B>]OW/R7$F"M\+]-"O
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MBBJYP/.X=BWK'5+3*SV]T[PMO!V9+$2\$R_\SKL7I'QK^OX4?\) @4C/W(^
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MM-#(>,5P17XM!X#FY@;3HQ)M2$?&2<!!_<)5HZN="PE[B@YM,P_B^WD*ABE
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M)AHCCH"25X"I#M>_#UVW?,J$:YIN_6[_Q5T)#=V9L==S][SR5WFRX.9&BRO
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M/V(JL64\6Z]]G6:T6:@=N_ETZ!:GYE@5;6@FU=M:61/!/TM-/_(UM6#14D
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M^2Z-R1^J=_L<K<>/R]Z'!18B4ENR,"KQWY!.10C# Y/$.S%X59/\9(FFEC>
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MW'6:$R\ #R?=EIOJFJ)SOG5MLILY3O(09GI/*;9+<7[H^=4"/S20 :SQ:Y+
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M=7%!EFB?4PM\F.'T[9K)K!^SYN G8$\#L2XG"Q1(_3'_+[E==)0@/ HF@*?
M?NP"TB]V6UP $GRV+MW,7#=KLM6FJ9)]C<7L[<[KD6R8Z.H>9CT'H#3+K_?E
M21;_-(,%RX8N?5K<=\I5O@#X3ERZ,W0^?7[MWPHDT@S_7C[QWVNXGD[+Z@<Q
M/FI&-$/%IU&"6::')NQ"A^69?Y:V01(W;$%RP3QXQT]]MUT6Q)JN#ZY[K*#N
M#!8NOZ=<EH7S9#24E2[.]/E /7+T]K5ZT40NB"J.8H>,-2&8#Q;MB&W=A5\
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MHN)/C6!H*Y(MG]X K_D)?*8QYO[JTL!52G1G96<H[^S65DIL4S$I/W.]T]K
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MVMN$QP#^?*6PKX5XDZ4^=.@=B-!G/2::;_QN:J*W3^DS8MM[BIQ0#Y$)QHE
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MM$UWESYD,4K<:39;*[>1R3+TJ]Y>$(#SU@GUG+G3F;/D70:!86NL'#E=[G_
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M,5(N0S4$Z-3V0UQ'@O'O ]6S@9*^F><[Y2WY%^L5[(9SWP,7Y\'%(!_^]B[
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MI;]]'?^6\6EEP.=?[I]K_X=U*&%WYI]02P,$%     @ R8":5.*Y_Q\X&@$
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M!#3U??"_Z/W'MB!P<"+@"<.E9S!=JL_[#T"]P.6<?P/BG38Z1VS] ?Z7$8S
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M=]<,'Q3[:==G,0J1S-4_ ,HC<H)&0.Q0W=*"E+S-AYL<L4DL"U04GQNWX&D
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M&1L?FH]7],4S3V$!O.%O,4%C<);=.J8QU"1_ZNF?_=1I+]R/<"*@I<'5<\>
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MTK4Y?]$56'XGHGAIAY1PP]'TZ8RY&2D_/0]5Q.YYP$O?CCV0A?R^_MM"SME
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M@UA.C 1RX<&V8,>*#8ZA8C<PGQ:EI>357*X_?Z1U#<9'-96WN= #&5L5#43
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MJ;:!SE/^&#D2;@K!+N:&91A-T*^@AZ.T:6738-\9O]YUMMDBJ-=\;2B,T=Q
M+Z^<O6>>?_?<1[Q'OK%W15')H7' 5;&J[K1NXO"@[E A8-ZF,W>)+K3"%4\#
MC)>T@ S\N%\(29U\=1);<G:6CE)6W@H]1YV\NS_6(</#6/EXK[!\ I.N*\P5
M^FY/;W?"I&.!!+>'P3W/YAZM*W]X+^%-C$QXKLU6W:>X\YB<9<0[$#O>O?BR
M) ?/T")*K%UF[F0_:]=;![P$G)%H9M[K+)21KW;9/3NU[H@IC^U^926+6BU
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M=[,D&+5/N3,_+,BQ0+D5T*2FH@W4#V$-4'8(7RO!W#W0W;V.D& ?;U9@G*C
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MB_&$7B@;P;648#QPP3G7*1\_21>%M!WMY)(\ZKX$Y'J.K/VAPJ5[\&940^]
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MSPAW">@+.9U+,OIC VZZ/RW4@?#\FN6]Z)MF!:(G24OD8#VAA+GS?2"S^UZ
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MM.N1>W!SK/8E(#T[N6TZM<5=DYE;CYM*56I3+42QJC;R?K]B_C,1NYI7K2G
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MF<+L]J')]X!7X(;"NY<L]B!S1YN_.2[*+1=^6[Y7E&7^_MKSBIY$P/7DCU^
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M(F]"]9+B1Q]T:=7Q-G[^$G"U;>G^= BVP!(T[.F\8+OW!H?>S8TNK.OU4OU
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MK#']YU_- (Q:K:6L^LT_';<G+P'U?O;2<[JU*8)@T:?6?&9! GP Z="0N?Y
M^#(?/,4<;^Z*KGR^H&,<)]_"8)N8_;8Z+/M%(V608-W2[7775\[4GZ-Y7-K-
M4<QQ8!"#9SB++*>5S?0&-O^M<^TT>._8H/R8M?)I2X/T(-,!FSZC_4W30P[Y
MNQ2;X2Z")+9XI/*_#G>J_R&#_Q7[M2/P(EG5H@2"7$'OM1<^81^Y=PD8F*NW
M&WT.2:C^]5TG0-&2(ZJ;I#B47OF6EJ8V@XG)_[X(/J_BCMLUMU%#(9G9K&*
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MUHU0-GRU27YT_]YFJH74!><E%<8G+.BQ[_B Q=.)-N'5F#8E9[!##@TZ*&@
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MDQ3TP<QQ[MT=-H)+,>[FU22F2XT)ZEZ/):>C980F^ =I1D*CA::=>-VGC=X
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M@5Y<\N+&D5DW@"@$37HPK?,EQU.3']<#<U;U31?/'A(L;?0. .QE6N%C\G1
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M$QT,+"Y_N3O# +.$V]1I,^:P2EODCN)(7#3T*KP-;7'20BRKVX(57JE?TV,
MJU5_Z.\:\IW-C F]\8+M77ZP_Q5%UAF;E_IZ"G$G4:C:XX10&5_H*!1!B:W
MW0!6XT99ITVG^8.8S)\=>6_5<NWZ1,D"!\@'+CA204HXHK6# 2W7KA:5[S<
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M]*7Y<63](/?1&T(,^V<;2FN0G>-AC,3]9Y1 G],"-[.DMVAL5J5I.RS/VC7
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M@<I=.PQJZ3<1JM;M<NK6&^;9<T8=VU)JS2D[Y12E'][-=CZ%RX5<)T6%RW-
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M'B.NDXV1 $[IN@&MGENW-ZQ(@J528_XJ+H[]V1;J#E*K[SPWPPE\$$'B[2'
M==E]G(4:T1-UDC?UJL8SOQFMME_H_+<K>F;S4Z%U17#U+.7)H-QQAOF'^T&0
M:Y-S2[32(RNWMYUSSB]0?T_SS[AE[!Z<@V(4BFGT_NV.)1PKG $,0Z8&8?6(
MUIHRZA42*C7:"T[\*'\%Q\'I/'BEO2=+=40V/HY_]1FCZ=9:*7O@D"[['D>:
MX,UU'0FLV'3+B#K<[-F]P'W KBT^EHXJ B?4:?;MKH4WK1WYU6H7O4Z1H4]_
M\KZ+C)Q>^'9;V+F*E-I[A$GSZ]*'O[6=]PWWAB2<.@1Y&N[-XT4'J^VBZ4BJ
MKVL=-L+1_)-U^_S7BP\T7V[?Z7RPQ"$F4291!_LWAOB S39]&;7B4%!2:+/?
M];$S0*[8;(FW[A\\X&0'5N=[?(VJT/0Q98.#83WXAW[8P=K*I3;KI5-8]NL=
M./Z]Q6WAR]%LI$<BYX#?JUDE@XL7S+$-/VG0$J%(@!8:_6(]>E($@PN&20'/
M,^0;OI>#)9^18C%*-P]C:J?72EDQ')'A0[U']^M?53H8>KCZ):CY$YQJ!9%Q
MS-C_8U3\V<Q_ %!+ P04    " #)@)I4WM+77'BR   TO   &    &%D86<M
M,C R,3$R,S%X,C!F,#$S+FIP9YQ[=T!3V[=FZ!VD=U!!D"Y*[Z T$1 5Z41%
M>N\! J$C-0("2@L=D2800'HOBO02.B2 =$P00FAAN/?-F_+F=]_,FYVSSC_G
M)-G?V7NM]7UK)5>S5ZN &X^U=+4 !(0  ,'U"W"U '@(("(D_.NX'L37!PDY
M"0DQ,0DE&1DI.34E-345)145#2W##1I:>EHJJALL-^@9F9B9F:GI6-E8F-@8
MF)B9_OH0 J+K]Q"34)"04##14-$P_9?'52> GIS@@#"8B. V@)">@(B>X*H7
MP'L]3Q*"OP?@OP\"PNLYDI*14U!27=]0?P- 2$!$1$A,]->LKZ\&7U\'$-.3
M,-R25"=E-'I-=MN3Z7Y8<CXYGT9-%_.S<33_@S=>X124+*QL[!QW! 3O"@E+
M2<O(RLDK/'RDJ:6MH_OX^0OCER:F9N8V;VWM[!T<G;Q]?/W\00&!$9%1T3'O
M8N-24C^DI6=\_)194%A47%+ZN>Q+;1V\OJ'Q6U-S=T]O7__ X/<?$Y-3TS.(
MV;EY)&IM?>/7YM;V#N;PS]$Q]@1W>O87+@( $<&_CW^)B_X:%R$Q,1$QV5^X
M" C]_[J!GICDEB0I@[H1V6M/QMOWP\B9-)+S:[HH^!X\0S._\1JG9.&70M[!
M_ 7M;V3_;\#"_[^0_0]@_Q/7/(":B.!Z\8CH :J 2_V"N+N _\Q* C!7 -#S
MX8"02@SLX42[I .$QCX)O9LYG-"(5O*DNZG)*DIE+W]QEVCJ[F>5!5J=^^*0
M4:G$('*:\VF2P#&2I \FDDA@+ \GIK<Y.Y"ESO%+SGW,T7F=TWFO+#F!P_=C
M=O8^=_%\MPFVWJ%6FH4@5*CHF(Y1BH>R$WT0Q14@/?Y((+GJ=9H'NR5/^Q&!
MI >90&A7\PU#\^M9)7; 2Z-4R%0R',L%BLN=,W.O #4.YLQ9UM8_RQ-_U@B-
MD"*_H^I4>/ ("&VK,U),K[?6Z3G(;>%)CN@Q%>2&199>EIEI:-R6ESK_$1/M
MDJ&/*-/;;$I-7\\T>6;H9V>TQ?;ALJ?HC?RT<.H&PM3."Y&/N#L8;QW<W&H?
M1N9=AM'LD%(#TIU))#JQH1&0^V B)W;QB/)NP?ONN+MYA/_/)L3=+<2_2@G0
M3KN!_$BTK<]*GZ+F\MY#2\$D&C_640\)A]A?0GK,M=_A5Z0/&I V+/3E%7<M
M);(D167R!"L5UTKW%9&_0[\COTN[2E@@;#'$[?J)'3%B(=-2 \30#_>6!HH)
MIT[X;D>$>^B3:A)3'SIWJ]P(F5FFPO7)U-N[^!K2.'-(01PZ)L"ZSEBJCV^(
M!/0K=&?O!51Q&.+N-O;PMSB:/,:\Q7.87:2B>L>SMRUB.U5"/,-!:]^DJ,_:
M?NE,I<L1S4.596T\1HM!L#[@?$QG!\6!%)6KB;'N,4T@2C&(DT8Y72^&5LY/
M8^Y%UXBA^7?<\+D-B&]5._;F6'WOM+289L&Y5;?#C-;N'LLZW?(B%WY??G?/
M<=9$)4Q6$D#A&3&L0_Z*7)ZL&(S!/,<.H,FZ=UTI+=*GZD^F]S*>1Z^HU9];
MEK\).'\21S?$AC\.$HR\\"\$=73-N\?"=Z<RM-KJ]&:K+%UXGM]T'<[]2 9[
M3/0\SS%9AR144.Y"8<R-C^UT0/I/==P5P*6:% =$SL#62B;KA_4>3QU'3TAM
MP7?5Q?K^D+ZZ$RL+QN24DK7Y7P'(5,0L+EZC>YQ?9K*T(;=2_"+G<7&]<XN2
M;*<-#%YMCLQV@;[,E,L:/;%/UU=O!(Z)(V_2"]^3[V?C6JLD%"@1W4+JN&R6
M,AOLFM3'S9OQ@&:D-3;BJ0$*L&+00#=LOK1[A1GLSQL-'W)]C'@:S"T]G7(&
M2&ZK>_S&\L: X$W8$Z.O4#\[RJ)< +O4=!K7ZCW!,8XJQ-=6;9>XKK NLH@C
MY=WHF791!SPS+AX)I72ZM7\ UFCD?=5\V!FU?)/N@R6L74N'9XKZ2$&H3'CP
M2^>Z[.T<-1(FH_^2T7A8E#[&96!#4U"J"XK=_A[6EMNUFJN)KXHWBO3YO]Z+
MCS$F$@T*E5<NW__1F]734.LTON-JR[C2PZE-T\_Z,Y&.Y*$?::C.1=LE[,)_
MC8[J0AU]G L+4=+_XC1O?*;N6^CLO:P-42AL?>8DDTHX)K-:B/, _:I78D7)
MP[1QZA5;*L(S]<#XLY6XEP-]YH].4@;URQ7C/VZ&8IAT.TU6 SDN;TY<$!4Z
M9!PN.YYIIB7NS3VP7.B,Y<L^M@,P.%E B+=9%'HS*QN2;5A*;XK<0767BX:>
M?=ML>QG>HBH!IEF]VRJ(I(M7N8FN/Y[)6>L@ JLUSQC N(\*=(] =Y[?AIN=
M=EFMR*@X+>!BUH:]4;Q[<QC(VA/S_IHB4UQ,;[I,)J6V2/],L\^SS]2A/%0,
MO<G;0+\+"YQ0T!J,RFG>/4;:5(GOB]/63,;9<-L'KU&Q\G!^:+:7^FKF^H7S
M.?_V\LW+;)_JB#/KO#.M3Z54TG$7CZKY F@Y[W@G-)')E7'8#X8H8TI:5CO8
M0'&J8<MW9\ /7_NNQM;3N/NN-X;/GP\;,PB]/F\"%PPXL/.D+>/[,D??K>-^
M-BB$5#I[(LM:99EG2IT=JRQW*<7)52PK^=^Q"'UJOWBU6<UELCC/&RGJH_,V
M#F'8T*#;@6"SH=B4D4P?>*;E9$77=6820QSQ9&+?9SHM?K"AIB((6K8P=>F8
M[UQS*-&KRC1[P739L(&!):UG(KKG-V-0D_!$F[W?_ K!O4Y*4W9$)R%VVDKV
MK@&C^Q%KHS% N':GJ[\INB]M#PV"6,)E U/-=)UI1K"'\VJ+ 7F$6FN3$9F7
MI#.MLC;59KKVGTU[("X7<).[W$"T2MI+0])M_8(<?D>9"+U7#\T"'K]^W:]N
MV*S>)Q*&/HEL%2S$]6#+,2$PUR].)BJ,8V"*TAT._?KV0J$&1PN17UPRO!$K
M,VU0/,4X>PS6O4;K686TXD6XY!5 K$UD10I&M,TATF*Z+>/W9"P>O-!;]C'L
M].G:UZ-*&B*->O1QN869>8^C^[>O<<3D>;FM=.;E^4Y.1IK,=_Y+;F3<P6='
M!X!VP)J=IC6E;.?(![B#'8C^D*&B<]9&YQ^N^?>+V73G$L QT6&V14.K\<XM
MN\=U,@:1@W\><8'WOT4D]VF$R*A_<>"MHVU##4V^#D"ZVL*#_0)>I%)C5V^)
M)?5I- 3O'K7W]+P,?.+U\+4-R8?G.G^>W'R:O^[>.K!X-F.%Z+X"T%A;?&?*
MY9WDU[WS0$'/(8%]=-FFZQ1:2?6(9A%'A8K:NBQI5P$A7N#,1!MG_(!T[E)9
ME6^66>/D#W)Z"D28.4?&>LK.IY/+0J9JMGCK>".D@$0[S?8QQ\,L72[U$L1.
MF=2-K/>7R#B-^!82[$5-(Z:X$%OX#*0>+VVWV%'B_4G#>C*/\&EB)UK)]V2!
M"2 Z386F:4[-K\%ZBE';C<_EE1^T5'D:K,_B(-A\='':9D]U9+OBE)0(2"FH
M?)?#W"E##Z ;/?7KIN?A395L8PFHM<AX.R-^_ K +0%^Q;,\VI=+V% W?L?"
M+]FM-$F&CF&?C,Q;@JS*^7>.2<_+S,7'&=BOR\(J1[IC"N7VT8"3+V<#$3[[
M ;=9SWSK3]YOY+/J<-V2.\V0[RJ9%8&EFE='U[M'GXU&5"F9K"F[(_M:893[
M-R.>3KZZ+]WWT]Y_]N,'EW#:Q[1M(OM0&E!AG_GO"\;=YS.^+:]?H[314;O"
M"]VWWQ!3\P6' BIVB.C[*:H+?8'DL[ME#$X<KI6'W5UK%D4FY-HGWMD<&49C
M?--2\3DR.[PJ(R">&1W3!"67%D-D0L(S'?! 9Z[HI KK4L@(I [,HS3=JI?G
M:&1J,>KXV<&(N<$B@HXTX 4CK_S-I.@V?RP%AJ6E&BR%"6B?]E7V[\%F;DQW
M1!_KOVUJ:OI*?N_G<,1)74(")A,K$04AW%?A DO7H_77MU%6M_O-2%)6+*IF
M5T6?>*:M,X2^IPDD*8FBS7&F9O%+7NAA<-%AI(Q3!G!1LGZ4"7FQS7*&Q#U8
M-6311D&9%G;/H$D;X[]:8HP_/?&S'71(\XYZIHBPPC#VJMS%.9?BQ_',Z)&:
MRB[D/FMO)C?<0'PCTYF38EQ_/';$0%Z^+R2I-$Q*;A_58,70YVJ3ND\!B/43
M;1I!2X;.;4J/7*CA@-ZHWS37^5>@ LQ9N>/4<MS"J5.2Q9>@\&U^YX5KUYXC
M[=[%$:8TP><W(=@ 5VZ+WNQ32*\K*.U1:Z!O*+XSI1LLW>LIE!@KKRK'CU5Z
M"1D TN!6NGBYCW/X.FN&:6&%X/L3!8CUF@\#H'D?]_/C!KZ*RE&B;(YS/:3L
M7JX2.X;TI-]:8.86QJY2/(,GV9U\\E9M/3SL[1]RG??O3;^1"<ZW#>'I%9G;
M,J\ >S+#$"E5^_35/ 9=7EO!R=P/O95C.%4KC&#4\14@H8,.'NS<.]\>@8ZZ
M(&(IS8?[URX4-2<=%H)#-S9-A\"1Z[G3OT)X$.[UJG.C2(-\GLK/.X%%0':^
M\)'# ZT49-ZY7K5HP$!& O3Q>0P*N'=>#2I].EZ$;HQG[#;WRXYQ2_*)#QIZ
M**[+^!E\_\>#4&TBYGCT%0 K-]G**A&*S#)OFI:Z E O+^\R:GHRE$U)BT3
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M-XPTF0#_RHS%+&$U[3.4/6FB39OU5E\"RPA'+(_F#0'8/+KA2=Z!STJ^%=O
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MR>,^7@$&(.:G:]CPF7UIB7E>9&+B8A?<D,)\QUIR1DN=LD:# ; 2Z\=^5(7
MRG,<;W:U*'OW9OBSFE>_$Z_RK3!8/[TW*@2R>1I(P&ZMO$52<^#S#Y3F;UI3
M#$+L/UC=!@>@3?HXN+\X'NH%NV^03+GQD-,-7SP3% [>G3-\"%3$S_CQB"#
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M(L[1E_. X4"V'>LA"@U#%$P*-M(O53KZK"C(=/&:)_8J:/R3[BMS6D@LRO(
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M7V675!]C?L_']&2ZQ[>3XDJ?3-</*BG;W*G.G$_[<1!'^HS=;,"7'Z#MH0\
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M:3!Y]024R2'#6@"=6UIBYN1:M+34^49OMG_S72/&YIC7_&(4%XKGK)L6@%"
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M.( Y6G4A'J^/L+R6J=%_:VZ3UD]K1BF==)4@P?W.7<&][<I]^2M ;-)'N2M
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MP<S'36*7<%80PF'W,B=9(QE/?G/+O58N'@W$MT6+>/@/[L[P>UY:=)7J>:#
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MC$).@GDT[%[O>\N+P>#[;3M+B6T-R:7JSAP!-]3"I>)4" G&U8Z("$.5E*\
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M(7@6@%*D75'W' :A+]@@24PLT?Y^A"\;V>&NQWT-G+#]#>!\RJ"CP8ENA5)
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M&&-<$W9WVRP+(<^1N_8WO@ZZ#?E(TP5&W>>EY(->*R5(0FSQ29=J+D)==3J
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M+'+\[$IG^9Y!=ML$<?4\H4/4 \@>3K5Y%M-X(Z//)FQJ(*WTNPY=FJ;8[0L
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M!1__VB1ITJ_ ]W@)8(--=SX!//<!&:RN#..H6$_F/2V[X_%V :SI#=W:J2,
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M:H@K7:VOHDO)B2?GO_.-M[;<X?%K>_(XSO:\PNM4@YTDB]R &I+.N)9E8]T
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M5_,)2+NVFLE=U86Z+<?? A-5 2[#%B%E%%O"G]SMY!)&DXL3RHGWVL=D^@?
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M ,DP0QSR\_O.OMVW>_;L_M[[=-V_JKJ[;E=U];U=50\+#^L <DU5#54 UB,
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MJYQ>D@*90\?&7Q@."A?2"]UW];W>^G-VK2_<:%531PL5I!=M$SXO"/XOX]6
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MC0J^O\N[3QUZU^6H&!W(B=%"*.):@AU2ERT<)TW,3+\9CO5_DKM2]EGA>\G
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MBP(.=;)-!GUR(0 UP3NJ&S-L"_I_+<M5T#"*]7%S'S\J<MK/Y<VCTA3>WDR
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MO"W>\D454.:1/=>E^.U[]IZ5,8;M=1W* *S)1*-+5ITT$Y9^P6Z:^ORMMT_
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M2O)Y*X;MJ==52C)8FGD]%BA(,A0'L;0M HU:/6M=4.&4S##R><'=&EQ+^51
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M]GUGLA&2)7;QYY6N+1_K^FDM#AJ@PN*2C89J7EJP^;BT0O#%'<]JA[JZ<-"
M KK>5 \&[:+>62PEV1.9/#FFAPX:--9B-;HRK"/IQ4*Z392)X78+W9[GP"':
MHWMS,I*?;N!'CR7C?V>'.<6J%A+WAQ&/=%3W2XU@OP\_0&2;RE;,8 E(F<H"
MI-.)-OSJB6G2B.*P=/&+<JF#73U6\=(?NDPK<7O,((O:484C#$:FL+XV*J1/
M/.U;(:9<<=U>P*-9K8@J-^9[LD%<8;?YI$!0?-0\D*#WNVP],DGOD2UWHG/>
M<$?;9:KB<CSE#]J%+M2NY!9+VB5&UK:E*)&F<[:[W>.=#3U%9A#QDBR<8Q[F
MC&\-5BGA7FYUQM\$;=C,XN[U9( G6\8;UDY\G!WL>,7VC5R<^$OR+@#I<5K9
MDN44)^[_@O.<L^:;2V0-^V663DP,GSLRNEY- Z2/7WNOV1&H&&^MS2.<TBES
M :P\+" T/D-]VHPT(DD=6-RC ;HZS>0V+:*&!T<-M%Q*35"?3ID]_T5]L:\/
M*%-IG%9_%"#!:1/O7NK1:[RT<,T:CM2N'W_-NUK;8$A6*] :2#W7L<XD8"E?
M1 63MEM6;-HN6]L^F4:U?>+W?1X;%[J(R=-?WU7TZ<JJ1W;*1ELJ2=#-;%IH
M*>L"9OL+3+S4L)+K 234>N<./5QV^:+6<9:;V(F)!F]A3L(=PJ\@[S:40USW
M>/YRT0@8G"7]@'M7K!YB[C:G&(:<7 T%5A,LSH1&9.M!+32 4VW4>L: W5"]
MKA&33W=@':(.%W4KT1&DX;?R,LUW=+9<J$N ;TM3=.YQ**FH*^":<BIO76:Q
MGGG*TQ[]!VG/*->_4@R7/!"_^Q"9:+>Q2BDME %0QH88AMV.RRG9*GLT _KC
M2A%9MH\^NS'3G"5-RM)OF[311XG%__PBY+TSBH%C>H+T(NJP8XK9E"KWVGK0
M:BVNL.QW<@WF#@7EQ!2N*0&7[;X/.; 8DQEZ5WA]9?@*X#S&)P(6FC&:]F>1
M\OY$RWYJBQR?J-3)Y?K36M^'?[ ;"%/;%Q#>CAL@/'N5R_6AW$]8^MG.H>^V
M<7W6(=\AQE/F\"21Z[2D687]HNCH_A@^YGL;E)%5>+*T)2@L'/,+G@&*-,7+
MK+1\^>2L4JC"-!9\#2Y2[T2I[ 'SD[J\K0G'Z-PX.Y'S<<2:+V7M'G(1*L*Y
ML#:FU\TW4+;0&KA>%ZL;]I =/?.K:RD5KP*08?0*/65"08U0^A9/U\WNM9[R
MA64$2,BG(D52$9%JGIP4'(@$3I8IK;2-ASYUTFKGNO5I$< D2@/L$ZSO:+\O
MBNQ\HQM*6&>95FI7NL_'#YT$BX[[W3K[^>@JTG=@]:&H^%N 2W@[)F1,8<K/
M\VI+#C=^\X.A!ZL,T7M-VR YTZ<':NVW952U='NZS^;'(0UP<TE%I5_:>N)4
M5REN;Y7\!"PLSUX!>CT)O6">?/O^*'!#A6@=$)#R?,;0VUOBT7D#,%#T146%
M:JKQ(S#[8AN34@0-X.I9VU<Y3S"WW1B=!?J%/4KY[,?SG=CM?C;2F. "(JU%
M!P0<"*I9CHU*;@Y$/0O7=#F?%UE E61(^.AJA-:?ZIY>2%L83'X]KF($<O:$
M((35F:O<R)L'TUN!NU^3[J>+Z^<F/Q1\(WS6N'>]/:E^:7JAR_[=_)T1$=)\
M 011NN'C'C%Q#&*,F'VQ] 3V?O?PZ#->A0 >*6E/#PJM8_W^MY?#+5XTL2'G
MW!O@MC':/0HC@2Z])>F/)S4=::)&LW/WC7_6ZW!8%GK\U]M5NB S(8[E]/<?
M[Z7X1'9T=(LQ#7.!^1LI V2'KJS?)3A$H97K;]\9M2&-=P<O+H06[S%]Z"VK
ML.?2%-Y",$_JD$NIHM-M,=4*31N1N8\B TW9?\C]2CE'' JF :+5Q8LI!AU_
MZH)O_Y&>?RQ?;'64L_\**)K'9/VY:L-?\P9>QI=H,"4K5<TX]2(EI$H>N7:.
M*MF5;EUJ8#M\F+1]&#Q/V%8&\RJK48UM" TK]H**-E9^B'=!R7FQCM.ILX$_
M?CWBO= 1JU'C TY&D(V_<7'5VO8MNTOU\DA]4ZOS%YEZFFI<4[J%O$R514-4
MPS*#BQ_[.)1&8&N^#VH_+CGW Z$Z7$L17%3C_[1]@]0=DR[? *I4'AZ)9<0^
M]5;8,O+Z?8AN.9;T5UBMY.TWQ6)56"*/.2?C=D)<5IAUIXCY9*D\G6)8]<3]
M<(/*M$.>WFK\K_$'X6'BT1TW:8 E&B#&V5#-'.^1_0?I%EJX)?ZZ7 M.^"[8
MZ?US\FLO6U>XB;O)7<"&9EKD,C+Z3(A<99"U]L&]C+@D]+0S_X>7P,LW!T.7
MF20,V(I/?P<O8.2;]B9-#F2XO((JJ3L-ZVT\YO_1!2D8&NSNZ(W**IYLS-IH
MIQ3-&LO3T7M_Z%C%O;;(^#-ZB2H\,OY%/WV1#4&HM 0N>;X]8R?9S=BY3@NB
M<_',K7"S;:9\*:!PE(>KIA">*E?26[KI7^[BQ"\O);<.^"S5BS0#EH*835]I
M-*=:*SIMU;=FG$1PK%8$ZSF5#%!_,%(93HM\<[QI (Y5&N!8^=EPPL*U=0IB
MB>!?L_N@WN_.Q.C/V121!&2+B$O"[?4/FW8?\P3QJ,G"B:SQJ^4<S*\SU+>?
MQ_;9/W')0BTCZ3; BG'S&CY&\68@?^=8)U$&T1=Y%XC6!E'/C I+B'?42F=>
MY=R"P%IL: "1077!I1TZU^D(:-9A@L(".P7Y#GI"H$PY>!X[9M?D^S_H+Z00
M/4N-*^'T7;A7DL,L'67G&S*-,[G3*8X.'0RP9F1GBS^"E'\FO'*F$R^_+TL#
M=%L^#Y%'82,:19YWBJ76Q# 4QS<^D+K"T%'M%YE3UO^QB',2U&+>BIL=_M77
MT5'<)ACR#Q2?8%P_4"7'W!T;L$UYQXIVJCS%;.I?TNT2>9C$>9E$<).<&@EF
MA# E4GJ:=T-VY[3!PKQ(R,+F/=V;">Q;3)_F0ID]X(A%7$2S;(5.V6:>,!;7
M$O_I]ZV<@GW^6,#)?G7Z\,//-6,[^Y?A7&HSR^_6/$# S_YE*AN /\JKQQ.5
M+!8H8ZC9@)-3==S. &;1^NUO&8A-Z5+YZH(PGR<708B+Q%"%YG<[%'9M<EQ%
M-8>2]\__G=.1:2$QF8XI7,[F)N_$>.;?3;.1S.0LA#'U5VG<8PC*H-ZT-J:*
M(DDIH7'R58$/7+@=4[\]V$[R>G#.>K"IM2Z/CM-%96)\0*=R!K?6M:$+^UB*
M_I>1=BKK<L!DF_/PM:G9MF/_#R_]7MX3JN"\.G@FX'*:M7EVE4+HS'+I9&&V
MGB,<.Z$'+=R^/%9<==V P:_G1-JA<)W#+%:]5;U7,SF\"?RM\^'9W+P_0%<.
M9X,<T"\1WR))3*>7N9#Q#V@ SN>=S+&HVT;2]XL&T"<[GUE19E?O&:I)"EC&
M*((\$X2YFI5>%BF/U=FS&'CZ7>XZ0F<]3HQAT?50[BW?4Y@+-DU>DNVU4AS2
MD]O0O(5]+MHL(GF>D%1:<_3HF"V8[\"0O3/(Y5U5^K#!9QP>K4?]@DVX+CZV
M4GZH/M98'?NR>DHC#^7"<%IYNN'A<#6:I%C4,>;M SO]/889W;2>3\>3)7_U
ME>SL@&D 5(N43YB$\7D"G[7;\;$K;L)BA#MI:V?@O=G]COX\N+*@*AEL=Z)A
M]\N>"B0/3:0Y*IQ*N"X&ZY\/>[Z+NVMQ^==]><IDP7,J/8DQ-UAP3).W]EY/
M@&QFJ\YPN<4KEF5)="UI(KMT"Z>:6U]LLF#;E3)T[PJW]DF<WI,K9..M<3>+
M*$A9M27>8@\:+/M5(P>E_ ,HB4C#J?<>%-.?<<8YG$7<IP$&)]%6#G^\6(Z=
MVXXO5&B*D+ 9RT3UYP0N[X7IBUSV$D]68'OJK*-U(^==.>$F=YGRJ[^/>J,E
M6D;M_\'[P3DM/&P[8\FGWZF7JM""$4!\4_\W!^X^$YX&/4FLHDI6SFMY*"0J
M623NX)T7;[RFT]];$4X,RB1-9(4\;%RJ>UPIQ?C+SN>KMI'_?H^\!<;W)-1@
MP@;ZU:$!FV8 O/)=T,[8Y-&69!Y<SRS-P)UJ1 .D80YY#9+5;W&/S_X=3@#?
M)/VA 2[Z1:?O]J]-;(VD?A>IB@!>.)UO9S'QTE5UF&[T?'> PPH!2'M\[YA7
M_>\6OY&9O58$2#:YR_)5,0,5<I5T/[:\M\R* AM5^SH3I.;AA=[BC*7?76Y*
M^<I3B3(HK?>KF%*S'MC9_<=(GXK(> 0&N4ISF-JM+?T_GLG]UP=SM*G_ 5!+
M P04    " #)@)I4684J A3?  #3XP  &    &%D86<M,C R,3$R,S%X,C!F
M,#$U+FIP9ZQ[=50<W;=E$]R#!H>@"1:".PD$#R&X0X*[2^/!G<;=@KLW[BX!
M@C86W+4;;:"!R?=;,_/6O'EKYKU9<ZKV7U?J[BOG[E-UZWGQ>0/P4D%&7@:
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M/[R0 ,A(_\/^0UX$?WF]0$%!1D'_AQ?2"X]_,A"@H+Y^CT;X407]NQ,1/7<
M!K%D_,^Z7DP&'E4HB;'S-!8I(^\F$^P?:O]B]I\C%OC_Q.Q_$OLW7LL '&2D
MOX.'3 "0 #PJY4>^ ?P_ /D'/'/;@+)'V.RI=0M7<UUFAMV$4-_00+Z>EQR
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M!^J/A<]RBR47)H#U^JNL;T,,>3DQMRGW(GQ_1:+)DY!T#]1@&P"]S@U! Q3
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M9PPYF#WB.@\D""E_6OC*=N6L#44.F-&/L3E!"$R)'246!\Y _12K+D51P1!
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MB^\Q#T%>C?CZF-VAN&F$8S558:,;T2C'D: ..M,?9B"<X2ZE5&F_<#+2&2R
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M-2?LUMY4/@\2(/\5B1.AG8A-L2*/OB/_*ZT%90@[+LKFY <4AZ=W4::]..^
M>#$C5=",:*4L1SX3K;CGU2M,VEL\&=_M.UF$NAXBLLP7:[:5X;Y*/-&L>#2
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M-[ =B!?IG9L"H:PWZD5#!I=H'D0#C,&52*)"(.HXU4KYE&^?F> '8<J,[X\
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M>AIDA#[I<%QIBV3)US=<DF<(MCZ>YN;<XA3[F>U\^851[3">Q?L)IH6'6^[
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MC4:+IDRI"Y/_7LIBD,4LM2?K6=I_MF(G/FT5H6]W+@K=M%RV$MJ/\*C0.M_
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MQ3J=\4==5.0U(N&U19(U5S%'\+G8*I3^KZ6'KU#[XZ&:%4#$_72))1CMVCL
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MQ^EM VNB?F?A84F:7H,PW[NGUN'>J4=513O28EMYI4O=UD4FRA-:KI^05M&
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M!=8".AD*O,Y9XP<&3N8YX[]S-N%_[O LO -T-;[_LO$QL\.F:>60BMR]O[A
M.HU]K7-4R\%_@C9>/*R@>W64W)2>A??FY\L8S"$&SS!YA?; MBF2-Z(COFOC
MR>^!_C-8<\!'7JIWE0\9/JB\Z9Y&CF-919DJG)WIO#D?JQ]%BD1MD-J>[>HD
M+1< N5IS&Z$DF"U$3_W$0C]U?F3:J2(^X+/O+;BXV!XVJ(E\MV3::TV0^ =G
MJAW]9VZ$"*:A]$]ZGK_^B<.V/-_$+*N[1S [3 9'5Q3<OF,[T7XB".S+1?5W
MM9/X*\'M/)<X2>H$:C7I';.A+5)8<B7_2I0*&H^4N_E$O] OWLJK@SU;C@(G
M@YFU9K#8D]%-BQW<%E/3"ZV*'BUK1]IA9-,I:.S96I;[<6)G*7WM" H=C!GJ
M_D%M<>WQHYWWR@FOGCHRVR](/+MP]N';!3%!UI$2D3A6LUJFY5AW.SS)N!Q^
ME6+@3.[)2C<KM$^>O7FZ%LPW]:$Z<:A153?Y&Q='YIPL3N]H8NC3R>W&]C#[
M/FST6:%P;>OOOC\W%(IW@*"PG8G'9J!N;[H#WUJJ;?8O1%>SWP/'0'#:[4A9
M%=MB##MHRN/F8?:\7)[J4+7B"F#UH\'P;+($D^/A_2DJDS=%]WET\O7[OJPZ
M@7N-K6_1B=8\6'W)FY==^;4?SJT.%YKS/G>-)Y36G<UM)O.W*@W< <B=M%#M
M_8E!E6L9KX,1(V+G*0?,Z]'@'N@C^)QG@.86EA5X:>DC ? ND;Q<:Y-JK$L=
MT8^$Y >]^S3 G\1U5ED _:#>3=3W9'5$=E^"X:(K\?;)>LE[0_N&7D<&XT3/
MW/SY2X,>$)4YQ$4M",P;*O4QS4(D_9GXWVFGD+5.?R#/']^DKZE!"U>9:AD*
M9^+;!/B9\)+*G51SN/.WTFZ67SV(V6''^Y)]X"'+B1:AYSV()=:VKB937U-O
M[:2/HZG6UBYI[0QK[9R]M[XQ_PQ^3XPZI$GSE9'3JL\MG@K)A\=4CIUKX6%"
M]WL6!);-RDD>_\R[-Q]A"I#S.P7GEU>2[]))\Z8+GA^VVSS]R*S*Q5?Y9KH2
M_)"X=N<E;<9&<N6?C=*UK47:.&TEVIF/-/J*F>:9X$":@%Q3%!?UKKD6.@J8
ME'9#OSB;6X4;?XR3 ER(^IRQ7SG<RMGAQL-.?Z&?-U8I??P[_0X <_ZQK[+
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M=-;YI96=%/?'*LF5VNBZO!L93'L'.Z4_L&2?_202PR0C WJT.[&L+KUH;V!
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M_R2G].D4RX+B"\<JNKI#G Y@!7'MJ894Q;[\N><<'ZQB,O8S3KJ65R# GJ:
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MMND".Q*1A"[EK['<AR/"^:16K'A2%6'=@?2X_DFZ)X2V7F?6'-M;<BK(#JQ
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M+[H=;UE8? ?]M",'1:?U^%*Y$T]G+J^H)GGXE5@*Y93F?.1WX:WY6OAXSR$
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M,C R,3$R,S%X,C!F,#$V+FIP9ZRZ!U137_<M>NB]]ZY2E29(E5 4:=)1>E5
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MFWKHGCT$0ID:^QF;A?FKS+A;N."]31&*=(-]_M:\S:OUUL&&M<FA ,NTXVM
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M3J6ME0U\>RYK/IMGM^YV!+V6\HJ=9#B#*4:%1QA'CE7#,/06<OS5?3S]-)P
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MJD-L[QW)X/]&9J,EW'D"+G"T-IX=*S %^>QG.D<%BVEKC07HA9WRKBR>1C-
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M$Y3;S(4[>\8%T40?I](O@[^,'[M;=W90)!JGK]=9MFHB3=ZH4ZNO2/RX4?O
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M*TS\]ZWG_UC3+<"*3B G0(N9S[C1<4I*)B^*O)Y7-.*N<-D5LV:^>@TV=.[
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MZTPC1MXF#\*A'0CJ,1_)R7/^J0QNT]X36+]WAOLE)*.NZ,"'H2^5K/A5@&M
M,8@UDV:I]3M*,V>9C(S@8A@BA6A"B77!2-HIRW9BH5*%D*+]HXW#9K7(&K=D
MB]@&@WL)(P7JWPD?57W 9YI-@O 9((7".^S,%.G1<GT4D):>C)&P[Y:_^PO5
M^(B;GKLUFTH68>>]S*4D9!;+ *[(NSON0T4V&H]RX$'L$U#EM&JZ8E?!<[D0
MJ@2B^NZW@?%^_T(%.X,(S&#=?B@3BRE% I=YF\C:CTBRG,(L:V;NX=JZJ:>Y
M'Y/)/VB)\KP)U3+P.[#.NI+891%&KB#(4=JC_2R/ZU$)S>)M @G%X"+![$C1
M202(US0NP6]4)I?\V[\N9  GD'>T05>01!*H!PAZ5'&/2Y6HBH=K02^_(S=!
MYB?' TSI0A"GBPF#5#!&!>;,F62Y8*;#[WY_B)=(3QTR#/6]8H6"D.=M*/"5
M6%<UI(QM2L!QRKMG-F-I(WO#J2?&EA[?0P'D_^=MK2._@DN2N?ER1O$EBP][
MPR,7CP:;41#:\RCD3V'1-WE_P](!A?M%+:[T"KS3HQCE67;D;&C=L($?+5T9
M_];'%NPG:R#YYP,?/]IN7K+87<GQ9]QID" .2/V:Z'Q"_4S:T<^6\/NDP7C,
M)CZZ =Y^OH?#:Q?(XRX0<;_HF\;F!JG)5Q?8IR+0Q,X$OBF75\C\=/P'#/?;
MCVTR9__<.?>/P_](1/RKX5R#3[L#U0=N'MI@>!K0I5]=6+ 3^W5*+06B(B08
MVZR)X= &V[%E-8KZ>Y:O2'H;'MLSX79>D[FMZ-MD!S&BPYR1%^NI.U$8A:LG
M!^?-3,O\:7[B.D)106[9G(U3]3K85I5R=F(M3^SQG=[-=:T'*ZEZS!ZHXQ>R
M=)CS $2XT/&-BK]*HQ$=YUQ@V*4LT:7UOQ95@$"A?VE\PX\(6F!X/][AF'A_
M7\2R+KO04:"N+^=M8MU&D]E8/N\-<C/F=!3-/?L>:K(^C-\GVQ#K5B=W]5L0
MD1]Z;&BRQ,G.Y3#_"V]KB"JI7P)V0\1<PI@8$<2*_"4JW#S[9RA G^&;[4^Q
M9)'=7C*^/017KU>;Z,BP1_T\=<A;8>'O#T(6"@.")L2KM_"I%S?_["=O848E
MGDB(O,NJBT]?[EA-V_T:@R+7_"^N^B%.J!!P/+@L8!!,"BRQ>I9V/E,I/Z'#
MUOWU>[+6^7H[]W6D^+#&.GDOB ZJ//,C[7!M7@Z#JWFT_=)2_?/JI\Y-,CR9
M[;;$\]R.=M1YV5I'N"SSB;D5^G.VJ\&6X2^P!5W?>N\[Z==TFW&K"7_RD')W
M8I>[Z]K_9 WCWUR?&,BQ:+6GOXNR^)%"35#.),)#S?/7!"<A=9AO\.OD4R@"
M,DJ34+1!NZ;;@G![W;JB*VD%\C):2-(KP,%.:P9]_<\ZEHC\F^8?V50S5*JF
MF:9@+;6OOZCSTIWG"=P(1F11-EPWH]FL'77H_-6#88[5^CSDE2&MH5"\=YN&
M2E5UY(D*Q?-*K?L# L(F+,;3?!<A%:68 (<2%VN2&817<:.N-EC&K@%L1BOS
M-(+ X$</X)F@A=VN=OVQG0I\0X1JB-Q"/>C*S"(WJ:]/$I*WD.I1GQH:WOHP
M,A/DB6VY(XWO+,/,@X,PRTU8\QEBT&Q[NT\75#M5&RE:R!Y/M.,VA4-_$),6
M ]B_+7C\Y'$N-R</X#C3*K=V@<E*[P5=8>^Q7E+_.8KZ5S&\B[/TKT"UUBYU
M\.WNV+(%IRQ+:"_M#Z7NB_K<QY?89JW:Z8210N70WFLK5 O. L[K\19:B8@+
M)9?4GIA^R%_ZF I&?RSC6\"U305Q@^/B0\$^H%CJZUK\M09!GVQ$@U"DG4AY
M@MS^7*Q!V9F65J7,#FK.?$Y"/MA&(V/8==*[D&W^MR!]?\2"UR1(*X@K]Y^>
MS"_>N-"E*P^HH3LV1DR7GK^<R]4OOL:RGSLM25WFK1XY/QY044 FFX',23"N
M@O2OWX4@H27G V-77\E23U?V4+-7>N0R]^Q/1(8=#8X$.$9^46]%?N1MD3$3
MRJS:[<#_<V5#A1%%]A4[V EF@A7BK(T*T$L,)?/X'<_"%AD.O\M!#.B2*&@E
MGM,8J6.'C&'-O4@%/_5](BBL'_C/I,+0_PTLHXC4: >?3IK"< ]8Q"<YW0&,
MSD0[B_.R0"8HO7?F0G*O>%F+J_K1E3SRPVNPP]3-'MU+K<U0M<!9%'[G):PG
MD<"%A6F:JSVT&\T^Q/4YX%%6Y_S^AGW5AZ'!N-4345DJF_L88;0-\D 7]?0M
M>)D0W5L,SO"-*0 [O[Q9;)DH9Y&#GP?T^0S>[^204\3SS6D)55:\!:A-Y% X
M_>8F<'>B9?#E0/,5:94:KP/XT:^3ELJG"=(;N)\_?^+I/![ R1A"JZ# :NAA
M9,M3U'8BS71"?*GR!077UY+DON^'\:U\H@GZS90BRLQUT-&-=B7W_X::!XJT
M03/9]]%5ZP?,Q+J3WM=R5^;+V\>J4W5R%,Q%=;BMF5QIOZ?G$/CW_$(([]TG
M*#?LMSF!Y1!#.&YXAMU+^C'U_UJI+A"(,0>?O2$"_JJ>QWIL@.;AJU'A\)%Q
MTU&NNK=)#]FPF7_V/T1]BLE1#F!BN.ST#/6_-!E8QGV!VD$<;,2;)1S "'>3
M]E X#SEUN*B30B;QGH6-S<ZH%OJ;+J@9%#2K!4FE;X[W1NA^&_Z3@A&_QH[A
MJ1!'_-LQGK(F9@NCTH-;*7S7A8A4OB[V%JD*+&',&S_5/(W-6?*SARY!W/@F
M2[=6T#QX;2R92)_Y3NL!W*V;_/L)RUP/1][3%Y F?,=3J(F;,;+A9Y0_[*NH
M['Y1DI5AG1V9>)CB_AVC['X?:H$2?Q[OV$-)+"<>(\K14!L57[694I?#72$7
M>+"'NY>S8VUR)8Q^A6%%BG4W>S6@]@5=VZ>W>\>A&]OA^W[/UV!DT_M-Q;A.
MI:G!17MKN84H"=_]/[#W^FHT><O_V:WS+R&W@$ZZ)=*XI1@>U&PY*VGX-#VN
M]REG'N, ,W"0@=8YUT'[(D]F-Y;CE4+EM9#')FT3KK^:PYN-\\7G\[7.#>^A
M.-WOF\0-71W+!1V9VN%S'Y#/N\-O1% /X!8+,$)TK!X2HT,]_"WSFJV.RL-U
MJ])I0\WK\1*9YP+-FDT-=[?5ZQTKM..ZSG%T$#Y*+S;?^?#2(2'EJX9="2+
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MHUTJRSL0JDI5&AX4_FT88G/8B]3H4<)IEW3A,$;K%)B:@R63U!Y$0V5*& _
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M#<K=;F1]$#38@>-][=)WJHL2S%D+T(SDFCQ;TEX9;.P:>7>D_<4C:8')Q#,
MF;^:8?9]CPIBHM[\A"#+36#'A+4G68,CU?NEYL/5TP\JP-3-GQ5[CP71''EW
M@O)$D\FMV:'-=[)2_4KO66O=@L?1.J")=M9=T>.&=A1>32#SK_R:LE95IF"0
MH,C1X_[#(:1=YPI1JT6)R[QCC 2I\?[V&-R!J_#UF]R P$&K-;N(3Y14V_B
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MO;JR5 5'TO660J]?"T8!K?2#.+/B_GX&_GOOEGK'YFDW]S4M>\^^%YS!#W$
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M!0T&*_2.';IM1MP"*5_>FF[)])KGK,X[-]?G_'#*J,^_+K7?S)LY=I,@,".
M"\["/B:-1[$'R[7QF5?/BN\>GUV5E!\6,*8Y)9BL["6J3M2<V3#OLG!,<5=-
M2@18'#2*M?/8<"<0LBX#2,T1OE#WWT-/I]..#LQ;IKBG*^S]'#/U6C)&@.'K
M.:/Z.!+O 05=*@QN8H^'4[TU5_N#>;=88E6G-&*!@HIL',W]Z_022VR_\URR
M RO4><1:Z6CUOGGHP@B%O??)4O@=3Y4Q8L.2=ZA\W->R/BP'K_\*;CKY961
M\.!7AKI=!%%82L:Z0!!!153RY2C<O[7Y=?PW=8ZVZI;H"OJJOMU-G\6"4 VY
MJ#I=UD/4:B;OP^9)K_S"_9D>B?;2>PFS(L*[JC(O@\)M@^6$2-'?AWHI+.N^
M+ZH*U!;1(XY6G1RBFU=+_1.B\LIB>I"S$;/PCC>IQX)U? L#]U*6K'!)>D@
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M(;BKUTLZ;SII^E[ [Q; "!?_\X3+_SRAT$V;GT8X["4,Z+]2A>P?&*-!N;=
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MFSV/^-PH_GED.=UM9E;\HC#V>ZZK)1?![3+R9(P)GW\H97R\PJX6D!]D%>0
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M89U;0D78@:X*)U+,1NM:F?-:4\:A;L.$U(5<U0?86QB=0)+,\_V1QDD2UQ&
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MA@[6D"&BFX8F=L8?02&!6[;]FEQU)A3HP_!?O\8BCD-'LGNWL>OGF[^K0V,
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M. 3)90;$S@\1<EXUK%+DD*'[:3:\'L81_LW_[_S'&RY(G?ODQBG;D: DP"I
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M->H5@78O"V#;.] &#L7FNX\=%5*4?R[-0[^96!O&J"<KK%,8\KLGP,KP>K@
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M?R'T]UFY_H_G/WL[ "==FS%[UU%VMIM])=SII"+>16^2I+$N!S,/FRN"67E
MQL<S9&S>;?)JIW!PV@8K4<;@QI@"9W-OHP31^QK&F?T9GOOMN5+ZBQIO'V2\
M<N 71PPG]_]^FY,KY/O27_;"V%]^]GC$Q2BUCUTD(JQDYW:):EE[E8NPD9N$
M"\?-]]JY;4??[AREQKDK<P^K^2P773SUEQ@OF>1MQYU%.@E,K45 ^=,-XG6[
M=7(?3N9^@3IT<;I" R7Q16A@I+O#.#RSM\4V7/3KAN+3CF;C#"\NK[!93NMC
MMCR:XIC5(OP?[ &7^^OQE?YY>L>,9R]& NQ=4G\T:DY)A??#YPJ9CRDRJJPN
MU CB4X2'I?B,V0$B5V[/N7_%G>4B[GRVT-L<!Q4R<$$0S64IZ7@I(OL]Q$F/
MZ@K0#8%$>>K A4%*_X6U]XQJ\ONV1H,H5;KT$I J17H/("I-1 2DEXA(C8!2
M X0NO8. TD&*2),2.J&#@'0($%H(TEN"E"@!KK]SSAWON?]S[WC/'>_YL+_D
M0W:>_>P]UYK9:\YUDRU]&JQ>KJ'<+M?T<)E+ 6&:_,2,UC0TF5RQ.KLW&)[9
M&\P@U^'KCDG@A*D5\]>F62CE4%&V]X?UP\U:%43BI>*WXM%HX@6A&D5DI]-X
M)!?GE$R@D='?)Z_T.K!ETU/=#7PHF[CS(F1 ;GPT[(%J5)4R)G,03$G@G6Y0
MOG3;9[=^M>%Z8!_ZH<*>\HBT]8!U'1FB0A^+U=,Z:YS>]P+?PH>"V#&42>30
MC^:5_@17R$^+(4^!OMC'4C&LX8$'L5W^<QW_?IW=C3O-R/Z"%[&&(_F;PI]D
M#3L=EK0:0U.EWDM+N)$1Y[#AM\Y,<)>50=+8SO<G[K'^1[%>[&94';D-JU2=
M]0>.$;S*9)WS$A)$5/G97*=GF3$RRL$,3FR):3[19W.-1^YWVR'<J&'UX6_<
MI]N:(L,(!L)MG&_/YN2;37P+AH86[ZL;8JGQV87-/I97L^*]D?!COAY<4O8W
M3B'BA<P2L7=JC#!'#) 8^LX;2(U_M=HW+9*F9.."V_EFV7>G7ONX5:T48*S(
MY\4J.P:3N"S81W##R($,[@UQ"23#"O<=F^N<-7JY(SY9VH44=B\FOY7. IRF
M32%\)H)_7K3K7P->&3==?9CII%*#\&*2F!:W\R2P1?A;WE2TT*BG;:VSF.9$
MB%27@V?M31IX2F-J;XX;I@Y&B1$3Z5MM8HX5EPE\-F+2P'6[Z9%*PO"ST(AQ
M[CIZZ8,'XZ5?BF+_'VHDTL)JD772^ 8P *:(/.VD?>CFE1W@PZ!^YJF0R4OT
M!.!!SLV!59YS>78+AKMXLV=($^$3Q-J0N]:!TRQS+RF(#S%G'< &-H9;*[BX
M5$'5]U<0N4^_CJ12Y0 )#(NFV&.HG5E=U)/VZ7:M+]:C7T8[]5)%@NLS+E$:
MD@\JO])0D)_5?(LR&A!.#"\>+'3*"LIFD-9P=.=LS3BD>[C%J6S\I]+:/J9&
MN-SBRI=3*$!!Z)^>VLD30D4I,9S2^-L3)#1)[88("JP-O$:&RDMFS[3E^ 4:
M,9GC@'# @R\L8(_PD^[>SFO@*#GI73KM(MT=N("ER NWR*<A/U;WJ[PZ&8Z\
M:5#$&%@^Y<D6Q)W<F40YG]ZF;X/O0Y[)[#.%\9MS"*AC3Y96^$FTURBS7N.T
M* ^ CZGVI@V)U+N9BSR]E[_+Q+BBXL3=XVK\C3F<![5>5Z]:6GNA+@]AR<&O
M:H"0/+7L 512XDD"0Y_A<ER]0)RMB*A^B#R/#PO(EZ15/SJX]EDMCN?-6 O.
MT@)Y*/;LKNNS8:87#X,"V^1R\H-$=BL-M&HC*BD%N[\,4XN5*W?Z[5YTO('E
MXFC62..#* DBG3,GG0FJ@K$C&G 2$;GZT.2[6%H[TGD.Y-R^,4Z\?Y4!)OYU
M&9_91VRNJYB!4MBH,]M,:#V4*K]$\\ZJ<\$/K@'TJL!Y@AXV=S4*+M)VH2Q2
M20Y^EC^<_H'C8$D=?<ZRV1(<G@\ J6$EQ=>QIU?U*AV'T_R(0B_^!+-@^B_&
M@+/1^SKW2O/R*J/17R<''GI9ODBMMYKR/YFLGQ&J3&*$UNAB;<)]*_?DX^Q*
M40*_R^P=YE5CR=5":B0:+K\0>#$'EOJ3,(8OB]!PJ_;,5XM6)?W%+@7V'UO>
MGQ 7,"ZR&65MQEM:_^$J>:K')O6\7"9[ 6RZW>18;V##+W]@M!9,C@\WG8!Y
M>[NN=5CT:!@G+AXPI_R(;UEBM64YZ6;<7;F#LTE?=R69MIAT9[H&/&TSQ"X)
MUT6R#FH"$K7>/=YY45HCM"UL]I7QY_HS9W@KXBO*I4EVNT84?XGK 8?Y,^7[
MVJ]5Y#.YR*=)5><[OZV5ZHE#.,<(#Y*%Y)%BE.8X,7]9E#5\KKJJG1_- C(O
M67"2N^)I:W<-%-VP]--\Q^' 9,X""$Y0!SG4*245"M7DG )1;8:S<-^X[BNF
M:7&9;$M+Y>PJW;X_?YRV7[?HX1;[;GN0I+D+\E$OS>F\PUV8-^''W;$$_%UU
M?F3<_2H(#%6L[,8)^.%4P''_F7PM5]N[!UR3&K &-=> ?&JG/.6T 01U$W:S
M9BU!<_'I\2ND28#.1HZ]]-M7ST.U[OOD^+.=YE,2W"8/$8Q:Z[F>)A-I.LLQ
MX@2U0('/#D0O/].3S28)DHKT _SM&3=,\QO&>Z>\E2UI&!:6=TU\/9Q'*?J5
MBZQ%-:WC#6A&&AB:7[_DH(>,"EXVGF1@YZ*9AB? ^"2=B;MSH'FQZFM _7W&
M<1Y^:'H7<?['>RHD>H! =0V_U9ZC1,0=?&T!V,6"DY#6^)'1FXRO+H_\I4=V
M[<;WV)]T.;34 0YUFY=?0$3.SH%BRU<E]IX03\;R:3>O@ 9$^L:MHN,#0J=D
M;X@VCS]QSG/22@.P-#3M;!L;6%WRU5GIE35JE\F4Z9WHG\.T+Y:H80'01NIR
ME@ G(%G(;F(]ZZ2ETQD8M>/L*J/TX_S8ZC>&79=*;A.S\4.LT?C84 I=\=*#
MU. !5ZX&[!I0%;0(I)%I&[V[HBCK/&T8NQ_W\22@1:.XD0 RTN#0$_[F1GT'
M[0'=;#BA035UBQ5MUT&4]FD" R"<2[^<+0)_9OC@AGBTL[2@H=&2+%POC7*P
MI#)$!PVF'_&>9ZGX0,PX)PW9CO]^IM*DL]T+"&7TFA_O-<"<_L=D],*,QPM)
MA<UJB!I7.V,!/LUX4MS;,7%=N^E"L^1M1MT0Y%6;[ZTL>\/H?LV':6D[#[@B
M-* _\^'C/7N!0JM+D#F3BLU!0&.^3KMEAA]MN[KM<5/NKE3Q;;:-H+M!2VHT
M(!6T9 74T\S:UZP-+B^G!*UM5>@+I4'=&,Q^UYSR2>Y8B'@;);(%65TDUL!^
M.#. )HHW!#OM>NZ<'14LK%@'?ARD^#ZB1*;K-F)WKCZ@>%I%0WXUET?>AD6F
M^57OF=2N@C7GZ.^G. : F"9^#_"G.D"-"PWG#5\;;X:H;,8>=_">Y>'=J_''
M0-(%:$3IG$.>KO:ZG#PYY3C+2)^ 4Y]]ER**/66JY2@:#+^+!V(:5&\U84U:
MJI:USUS<76T] 0PM5F%T]0VWS\;5_VF>"AU\?Z4$#3? [P5CU\'8B.J,O9>H
M]*JKW(K+MG.BL_)F_7N@L,L7]O53'7DAH&O 6>@$R !3$X:0G@(Q^WL=,=KL
MI':76<4E<5<6O[V9WZ4]'+FO#?*NB6D 1H@!$[U$@J.N 43M[["=@Y1?S<??
M87+=^U\O7F:P?QQ=P9V571BVVV8Z&;6]M8TWG>^$RT=4PR 7*M"CQPVS7I?T
MF[_TO/2TC-LNQ*H0K):P5/2^05('"J'3B3V/0-R%J<^TFU;@!]?2DP8X3?O\
M9;<B#[WRF;./]B]$I)WO8(M+&,2XI3%BGW](VPG>#*&IOY+%NUOB?'L[=+4G
M&L:I(:;,9HFNTOW.(F;+ZCGM;G8;.NLW(SD\E)/X\418( ;8O7IC]#.B<*TN
M:RZ&KW-&)L"G18Y-+I//WF+ZV=!W>YXG/V^R@GS5GJQ_.<B2$"+^F1^A5@>.
M/>$,6&M,QV0ODQQU@ZF8C:R9='FEK7?##FQDF86Z^-3OIH0#P'X_7YH$QP>1
M04G1YP?N%\J=83#@9ZCQT:%L?YNK\.1+Z???;A&O5\O_C;N0_3>O$&_QOZX!
M@LX7,L%SR,YK0#'E Z!6XH?G2O\B/"")U5(PNA0BWJQ9[#5MR5ZS24-?T%VE
M899=IG66[)8*=:,4CP@BTWGP$Y/TTD?%SAD^3).5<LCD8KJ!?&_C.T+$\T1@
M68)%.LCUXC6,%SN?!K.@@B,[/#[Q0F[U:;%T*QK@'<N"OS"'B$ST!7STE[DH
M$^]8/-;B!_J7Z/Q>/+P&A,T;:#!NY=K^WUQ8TZF&')]^8>$$I@2!!:/@P=1[
MI3\][TS&V7+LQ1]93X4Q?QDA2J66-KHG5%&?U^%O!OTUFY[B>-8Z!U>C@'%W
M(!NJ+"VGW-YL)31MQT>/-Q_<,'WM6ANFSO<RAR@/(GT&PIG4K.N'NU= E#9K
MRL$J/VM5!BIQ+0]#7O=UJTL>4[,K\$2^LXKJT_/L \/S8IQ+\&K=J(2:"/.(
M00*?Q?))UAL&^R=K/$GB2B_S:&Z&]MO@32\$H:M=2B([8CA?@]JITN3V1B79
M5/'IUVGN]PX!W5O(EB-!HT\B%5PT#35&7!4&<>GW+9WV:U8M!8];UJ\!Q*KW
M\9U]X(:E(.!,T-W=<PL^W_,G<;*7;8,*#Q?OQ+]YB0>088-LFTJ"0MS.U-)A
MI[87',XF%L7R98,V]QT3U87,RAK#22\S$FE-=XM?-;JJ O#*/:I"]4A!7&9,
MIE&8K5=Y.;3(Q%Q;\7=*].UBK-:CJ:]9.8R?JL&ZS!&EZ\:>UBN'EN*#)RJE
M9H:;S(DOS'G?&J?,2/ V<Y\R]D+3T%'O08\^Z]MRQ90YTZM.<Q[FVMXTZAE6
M-]%<Z+Y)<2CF=K>M2:<@72!FP$1[7BIE7XNDI/K+V'.DZ+G@$T;CTFJ_T<QN
M%25W>ITJ?-+SS '?R+G]E 2WX=GU"/DC9>.[!CGGU=,:V)7TM>^OXYY,BS9\
M+W8]S# 9HJ@=D'H8FG9D\<+HPX;*@LRV45FE2<=Y<,#,+V#"-8"$'S]GOW8@
MY4[OPL4UU7#Y3.79SQVJ#>LQW(V)]YDI7 MRJCYIQ[?MJOSDPB_8\4E=2M5)
M?FMJT2F%?]-3W029O3\&"&CJ'QGZ*/L,-<GWH3]OO\O%\\;^R8L-]]QT[K1K
MRV5X/#'7>R74V#);]<:;2LU$GW:GT^4;L@B1/=[RBT>'L4C5Z7:;60C)%(W%
M-S7[?/J=("*\]9HU[X#2"Y,5,D2<D?EA@S-G=5FBJ1>+96@=2)'=#T2M$<BK
M 8#MN5](0I,,<6J)I^(,^-YG<Z;]C9X[:58)PMI'HF_,631<WPQX<CA5/I(?
M^L1BG_34"UA_M'^\2K(VASJ^>-J6;])45Y<J!M1CDKLRKG1GTS;R9! ->SCF
M&8^F_J0Z^W>"A(*K+KD_S-&BXAA<>& &I_9ET8S9:ZOM/87F*#WE8N$;/RAE
M0CVZUHD9D3NK=8DEA=#AQ;XLQ[BJSQUQ?5EY#9/6S@YF*,IYPWO<&&.>&8''
M(>OY;6!-AU@ =C4\N%X"KU.#]S5(LDH\E<F]L:7A9%=W#-O,VK=BK6]&X\(D
M/',VF__FN5<#K8,)[7H8/=T^(&VUK,RL3(?^D]"MQO2-IMB=])2'#0.,9HVW
M;BA,0R_Z\B"[PD+$/<%K&M Y(V0[?_4N0GQBK*IXWL99/L7<28P3WE^,X8F>
M&_OA5DKKZZ'Z2@Y-L742/#_ *=YG0SQCV4^-7 %.[5<>'?#64\BR[O<&IL*.
M?OLH9Z >.;J@XTVG9IZ3#MF=\>.H"R&8H;_!1KQRSV(VMZI@YNA-Z:=?[CYN
M]#J,6[S)#^\DO0)(D>A4C3XZTT4N#OA>2=?BO-\'\66:)YG'*IXT0?C=:V6+
M:^O(PVD?U=^C2D=S_ (_-7@ %.B^N-5KNU8%UFK ^8Y\@7J(W1Z7RZ/D"SNH
M?OT10!"1IN4E#2$5Z'#$B'>/NO=UTL+D,4<TT-A>[8ZID\5< :@LI^B*!DB:
M983QAMGPM^,!I? \"-*I@";#X3+67:"Q99I]X!T5/4/E2)FF3.?)ATP#+2WI
MD<VK$^X47(2AAQ1T\ZKC@MMZU M5G8*Q5'9UF+K0G/&:]"YCAB?JDEF(U=UM
M%JWF..&NX83L^ L1;[2YSU>?-@0^1)X/).MY!WZ&L%G5+^[8&)*+'T9TI]O]
M>G:#+N&3XBEC5<W5B-)A2Y4ZQAED^1)DX'B9HE)_/V/D]1R3F"2)=OOR(A^#
M'5&HH13Y#ECK[SI(+00-D$-*^=PQ3C\[,@8M8G?=O\$BUPV\'%/Y5X^%WZ"8
M^9*?F;V>L\0)GGDTX\[#"*R%ZIB*47HPE>7[V+.N(88A8=1'.FRU!)%R]!9O
M?/QF1^/?;4=E>?861S48!R(/=L=4R?UZC$UXSW2F)%=?,O2.?JGH/:3+Q/Y'
MFR;M-QXI[<V.J__P*NWMA-300)OZ@JG%Q B2D,I=$\B71P+UI5#/YY:<FL=]
MCC\2R7587KU]RZH#B/]E(X(E[48U9N,J--*Z5BCP<6AQ*E1E N8.KKKYOIB;
MW6M;-K%Z/=[?;6?)ZX#;6[+[0/A8?K! */K 5'\.I%@T4H2/7#3@[6>;.S.N
M^JXW./RK4?Y' %59"=2TJQ, O4\3KTJ&A"FOYY-:$_0LV_96F75+\%$'=;L2
M2WX1/$D_#13 R\=R^Y1_L^SIS@;Y4.^::!O2))TID/R:.).(E6BF!3C^=H7K
M7<!;@\]4\-Z78>J<D%%5KJ"Q:P =#(AU65P;78V6$5EF-[!^J/+\;\AOVYE\
M&O4]K*^-WBZA<ZMPC(:EILRTY/XM *P6.W)FCB,IP5AR:F&F\.X6=5,P*= ]
MU]*=[5_=7]33?\Q1"H<4?Q6BBT?_S-@Q@ GBO=>"(\&-3;%>^>30X&?8E:P5
MFC"'AFDQ)-E(]K\)+$)' TU>V)7 C@JN 4/GT/RKO@KWRWL%-$5._R*/TKPH
M1;C@OUD. N'Y/:M4-7EB7MKW91=#VIZX$;_Q(RU3!"8QGE3DW*O)"F+L UE>
M@&$&.&)1:8VB>=0.[?=\/S/"OIIHN#5>WQ=E?&76V7'163YJ:<IR'IQ1-C5R
MKNDGTT =%HM6>OB/? ;A>-E2+7/)O';"UI#'/2>3Z\S276KI[#NE?F<J3R?%
MB!5 / 0RG68\=C^8%JC ]*ZI$3OYW_RS4A8@LDODVB/]$0.4JM;F#1\B+;&S
M1#NF90T-WC(</JBXW]K!-%AX]9V+\=M$$*73GXCVH\# *C=$>WNF@,YKOG@F
MMV=+=OG^9U>G6W\#/&P>P>ELDK3&/GZ+/RLP5Z9B3M.;N"*A$OI*9ROKA*)9
M1(.W@O26/LTS\C>9I]6%&G>,<T/_ID+$7/S)M,.5- ZLC G5>&E=',=S_B5#
MK9_:_(FZBGFHQ[9+('O+TZIA:3VY1@&#^/3B:L\K#JQ TIHC(H#=C\URX683
M@_62CB=?/ F1&*_DCF4Y;8+<UZ\U1?$404Z%38(^_2R:%),F6A]@1I?9[=*X
MS/XLMWI,7*XAAE-I&*(+H63_79G"!N[D@7)R)JI:,2V&>5"]13GNVS-%.""5
M]/O<Z7=\&)PA1=8:[E2%J0&R/O9)H]!/R2']OO=(68Y& WDT[H[G$NPNV)TM
M]GT;+<1CX?K4V_[I)55Y)<5QD(#Y:J;EA_UW&[9'[X1JRI<3I"U;5_?7?+\2
M].IP59U)IU5R9X-ZK@)(%&KLQ^#MVP5RE(_-&A\HQZ#GX),/@$H[:K6CI;EH
M<YBD? (\8-OD2L4"=1; +NG)>#S4>4"-D;!W ''^7@^-/6A7N5#9_B/>TQ'0
M+:^4L%E"W2+6WW])J&![\NNIQ]C7KW0/N%_:-2G6O"@*47V+==]765,CV>-]
M$66-=*M>U,WJ<9<>,MO*>NR$PDT^)Y8;0)%U ;PJD,&U9^EE._)9QIUQLA]/
M%I=O4-W8)&9L^47/\'%CR4AX?0)6-H4('06$KX2 .A_CR<N<E#KC3]E=(2\2
MM_K.GIOK\3U+Z?@6*\W6_O0SSS?/M#Q_TT_;J]^0F6L- 1W  8O2W)JJT^K/
M[E_[[9PL% L?AJY(9=L[WM:M_YDV&JBH 8#*1P?;"[4;>U:/E./7+9O9,&;P
M/Y0!QO3C+@LZD;R_=;9?P!!A]=XT\V6]<VR#B=XB:O1[%EXK0H.'A9*_3;A;
MV^/H0ZB'6#5/!3>':HJV"VCR"+P7G,XV)/")M,<XDXK2D9)EFS&J#OBW6+/#
M3(9'&Q^_/[XZ7)(XE?T;V95 3';ZC3B?-O?B)93E@HO/*V4?9MRC>RE$=ES;
M5[B;A:Q<D8B8HA!07$]PO4_<&I6^9CM\%LX:7'<:</!*J/CXK'ZI0/-1Q,57
MP&"PH4MF=+ #.U6P">XS\,Z>22MIW RBO/ QMX3,Q8V8U$>L*2PO.4BZ>5-L
M_DEN+DNNOBN]">*= FE40IM,D>WJ93862UH!?!(/V42\[MUAIWO+3,J7]#%O
MO<1^Y:K/WU*G@DI^D(MG2NSTRT:4<1C90;%E@W/[!CA/NMX9S=C-6Q4H\G<Y
M&\#UG!$15YF!I?ALXV_MTZ=#W@TIO*&]#2FB^@PD#^48;3YOLNY9-1$DY?ZR
MC>V&<>8])>_2&G+X' ^=NOA9/)??1P'S8"]U?E]Q?O]?HX'\?[]S[B^3=: B
M[M4MUG(LWZ4DR<0PXZC:^;0:M$>:ABXZ=[N 1P%3^*BSE]BC&%6!FH1#;RIU
M6?Z.L%-;'4E:2<WG]SAGTMIV%3 =J;& 8YH(8/WE8,\JZQZ"^QKP?LX8=[-U
MZ>@=+"LWMSS54>TM:X8D]PL.X1MW_$UK)O\Q3+T&=*'$^\9)7*X8<9SYBR=Z
M%LM5;@=-=>Z/MH?52;EIU7=%-L%1P=\2HGJO 7$K'#.;<&Q^=#M[D?E*X(?E
M;8G%7<S&1NA!EA^O.N?0^X>+ L*I]\_&]G\&FE=;KBQO-V&=FYQMOXS<C''U
MY;-QZ;UG2#?\KEGDY<%1O&_-6"<9=-7Z&\XXJ7>5,0C)9OUC"!/![.^0L-;6
M<O]0D"TD[7OB!?%+/TE6@P\:8BS\)B%JVO\$"I$MFB2U8Y_\>JW+0,@UX,\#
M^$G@?[UG#E%-XA0J\/J7)AJ::WIB<J;'& >5.PXAJB_Q+TP'@AOS^UU]14"J
MP&DQ&2?8S.\U'YY\V\&GG[?R?$UG> MJ,CMM(Y0.TW#2_?M:!'V8N=?WA%_:
MT2&VNKX#5R*[=%,=MX/2?S,OZ 0.@7$M@^_!+8:!;E?G;XMB1<:5_T.@"7I.
MS/_IE:8CC[&F+D.("%J<G2") Q[PXR(O!A',6'A>U9J"./W@C]:9JQ]9'YL4
M[LO?XR'_'?3<X\ZY .+C96F[3GDNJ396*ZK,"?9HG;*[5.-NX+98;79,1V.I
MWWG-4ZSO^Y-KP$V\H^Z$5_-C)9]\MPQL4?S;S^Q)+3_3=O5L%;XFI>\G,3-'
M)=JIV:KPLLLW7C*5[\.#ODQ-%<K]\6[0NVVRGR+\\>4UP)0+\-LT]#@Q/+2+
MT26TJZA));V *QWK2+CCVG"$UX'=_8IZM7L7923D#81('EZNF"6=OCQ:5PDP
M7?&VV-.M[W@YQY1L)<%"8I;^'1A=^?412F-@*_>C+9<RE3"%20<</B:"3M],
M W8G45HY:PXUS$P;A$X5B1"]I/FT42U]WGNVE[55$^Q\1![G=^L#&WQT[;=M
M6*!4@)<O2,B94ZY L(+KEO]/"2UW^OX[D#N0GB*AYZHA1FY5MHC&C!6,;![Y
MB^(4;7F1<A;N\&ZNV2(3$^7RP50*E91-BZ:![^VD%;G2 R9ZSMY\]]X1;T_J
M^R>6\80#LI,KJ,G7HG@+&>>AP$&4:9^8'.2 ]R#8,19\#S'GS-_FU@4B!:2,
M&YB )-&C#-V-OQX5[4SL#$F3I V/;?&6ZO E*W:-D3P3@?PB.&=Q6>+&,8V%
MV#KP#7@.T_3B7M#=IJF:I[BVAK=*VF.3$;:_".&LW\^J3;4N:PEB&""Y$VHS
M9>T:0.LR7K6JDI%>LD"I4WU$H?DZI:>JVPPI2PI-3TF.9[P9:E.R7A/Y1ZM/
MT8M<UKTA:N)4Z!0BT/AQP 3:>TMPQC8)^.37*OYUTJW#+*SU7@7F'AQXH(GC
M\(_*_.*W8O3H?/;AP?''0O8@-\K7(4[$R4V7C?M'!&L.B^!0D$8YU+Q=1#[&
MTK QD?=MV#T*'=:0[ZI[(CS<:9U.@/(E)3W=LWYL0L<2K;.%8#3A^9S\-V=D
MV>.&6%O/=V+9-L(".Z;%#]SL0DHBM5EY@S4OLT"L:Y!+ZO-'3>W3&U,R,5[:
M:,M!J-O!:]?]3.&%7]*"8SH_4X/2-Q"LE[$;V*,0!!O4A\K+^6CMTG_/:N;P
MY%-)4_J*D\.#QJ.P('TI/G;\/2Z:$@#$!8Q]#HS(4MH&NP4^&]9[(JX$O9]*
MYC#]H%ENOW[@.%*T3B0LA9R=;#3>]"OA ;[?$:U&YV1QTX*D"1/H;J;C$-G[
M*%(0BH[_DNHK-<3VWN@N=4F,;0CDP_0UX/7J+2=Y-HV!"+G:@N6=LTZ[U,T!
M+*MXT2\+P_MLCP/W7_MZK%-E@-"8UO%H-9(&]^BLPYBJ99L]-LWZ8M%:RU6G
MIB.(R".!53E27IZ4L_O0[\)DW/$3I&GXN;.QJR'!*[JCR*M[<X7A?3B\0\ 0
M;QBEG\,O0IFEC[2#UIC<3^'4!Z+MZ^V7N5=\$##]&] [.?A&U%2[D5\):B Y
M&J7 :S9<@4ZV8N;.F:W2/?/!EI:L62;<S'V"))=%XCA\Y>8B[G,CI,G;OZ]R
M -8CN./?68OWKD:VJO7JNCIP @_X7% ?6N'3UGJ;TE;:=Q1)B0'['(%.Q!7_
MG48.XZH*!$ILYP$1^@BO!3.X6>/.L>/M"KI-O/BCT[OKI7%MGO'LAT2R&I[+
M/+77S'@-G&6?JA"RLAWXA==2W?WSRC9*RDR?W+I'AXW?.N7[6HA#=,C\ML@"
M0MZ92V!.E6V/*8\.IY<?[IW&M8$4KU*=OB.9^'KXIYU(2AO>_ZPF1<U!G,L*
M6H\!AYU8.YY];,+U_7EZOW&%<^)$N<T ND=GM+7<?&.-T6,Q!]9'_ #H7_/$
M0F/[GA- 163+E?1*OZWO&G#&;QF\HQ?(D )6=E([#KP2O ;4"J]> Y[H 0(9
M_D6\>].7GJP@97[-6(?OPG0LOS:WS<7?O0_(I-1ECR3H>?_J4[Q'-U^0UWRH
M> A!!0GL"?:NTL"TRF^$H.;UA*0XQ,G\YW*O!I48G(+KF][?+)(46Z*!;8JB
M/UE]&T=(6F//W\*!/IF;UX#'GAT0K2%I5.CW?_PAT$K_YBMD%P+I;N=B&%"#
MB\?!GXI.0-WUHIY&] 8NO%;.L=M9"A19@E,6U];E;3Z*7DLHMHO'DNA!R_;3
M'.809',@/;XW"1A.M]T_H'ABIH,O6C!:9:0'4H<K,#@(+ASD!O8E,"5Y6-F%
M)O5DQ!M8<(7\1XD447[-[D'!#K/\GJU?^4=FWX4WO#0R></%\?D#[8,&^$7?
M0/Z2W*8H[QH*E9D1\MEVW;+H V[2EKO/S$X R=(S<S5VLE0;"8V%KOSPY793
MD^/;(&EN+]MM=?0$:;HYS*5CVK'C6RL6V83):/C8(^M.M=.C:XXE.A*\+?W]
M9NQ))\T>5<WVV=Q!V8JS@_?RF=Y#20[<+\(3\FZ"RVQ).B+?E1->26=I.2"1
MW!-*IU5 '&KTG'0,"%15A6:NR0^,DSLKN66K=A0N.UDD?O8M-K.(N5_-%^76
MDS3T7$JG"T0=6:%[8?^ITM5^"G8WC_N35SF\[6A_U$4^%C4E3_&D-IZ5;^@:
M8&*LW3W$N(^0P:NM :/91O-JJIUO[)G4-Z4BD7]$/A7DD?T<P":QEUNA/10Q
M+2-)"YYK"<A\>T?Y"-LL=K#$/4CY^3#?RV-R\(]E"1^BC]IF#$-WB#:S] ]"
M*TJK,*-:QEC_FI"3MEQ%6V35D8%]XLH.,;E#0AV4*BW^)7&63^&%BU6[KZF%
M>&_V)>19V'#@B^7J*G=:"$L9[:=9;?XFCG3CL0<<\7,ET*,S?^Q6-$%Y7=>5
M;6!:8Y9@4!;L:&VCI"-S.\35<,*=;-$T-(2FP\/Q3!;K4U+CQ+#W7./K-DH^
MJF@"/1V2ND2?6#DEF3##Z%HFF:P^"G# /SI;PEX#$J^$YZ%:&A/NA_N'ATS3
M%QJ/#A,?T:9Y:FVXTL5'B+[^KM8;NP^RQ!U? ]1QX%B9 ^4>!I<_IA'[ZVVS
MIVH'+&A)=TUO,XR]P*,(147&F9W@6R"> GPZ?%1:-UN_W8_),1+Y!R-BFO)"
MN,U2-.QN]P/ AS'ASN@K(CQ-/T(DOR^K)FIJW:PYQ-+*BK]O,F8=$%)W5\&T
M2_!6*"_H.6D(1 U>UA?H:#'QYF0U*L7)7ZYS[6+98N5XRR32LB%1H8D/?=_8
M!_OT#4M>GVEGT+C-W9EV:ZQNMS^R%GK^I^3LTYUS>4/AR/3O&]'/ 81;.E\)
M)%@F.$DXU6J4V$\]BH7*$TSJ"+LZ\7UDO%2S: F4)X:D=97J[]'#!H7;%6TC
M8VQ+YONX&QOC4VL+MC_S90&F_C>(2<1> EOSNV#:,7+Y8]]?%B<;0*D@7BW8
MUAB[P@09<9:5+"]I2?GP\<S:_>[CW@^NQ5BJ0*YETE+(+Y= 7HQ<&L[=K#5J
M-$T?)QY==5*1Q"D81^P\I4,3?:O/B;;SL-C26P[L8/Q\M*UZ/9EFPIUSS^(L
M?&VANEUV;1*3Z_CC<=2S@)]U">$2MX^D15R-604I^M8!''.D%RH$6'#""@..
MJ^(+W@U,;KW--HJ,"W Y+_>C2P64:L6^?E['O:3Y8+?8T_(:P %37-=G)D@B
MO8(!$&0>*TYVMU+"I2GZA]BZ**BG35WX0O[6&UAQ.*I9/P),<<4- ^'="_ /
MR4 ,Q<Y(_^C$0TX)FY$MYQKVW_M\'X[D747<?[$D^XT+A$A<<08M: T@A+ O
M_*/"5A]@DQ+9GX.I]HYW)W^</YR1SLA:XCXVGN3,W'HE^9WSVY4@[#&V*4D-
MHK_0>T772>_,Q2TWI[2G=YD9R#C^@:W+5:PV43H\_K2[%"9PF4HP7TNB)<A-
MMQN4.\FOW,8[7Q;+"-3I(!:^!)9;R%P8-GT/Y4T)I;#T.V$$]NE'K-#@WUU8
M7(UI]>0Q31)DW Z]9YNOAFL3%T<I7\I%SI.\2XL_&2J@J1I\(L3Y+W8KS4?Q
MJGQ@,H(8SN9;?]3\R4B,YB!J@>Q!]WI.BG4,!A%TV4+0;&7>7\!\Z/V=>64<
M_^;]VW'AX\!O925>:X4'D!Y.%&$,]CA':$PW0.IH7[]8YW/0#P2Y#C^#CO?-
MILK+\6SI3M6R/+V $D_@;1D:O(8J!QZL^9O2S#D#N?]J;&J$/I(7A,[)'VCU
M-\O*0[;O^KI>[K<:/'__JI7[+^?(F?GG#S01P?ZL7WB[WJS("JYLOXHA9\HG
MC4HPVZV<I+4'VJRJF_"8KFKF]5(X<]05+13QQ^ESGE##T'F_Z":@J_"F.P#]
M:Y#SG9'@ZX5T<P^C#S5UCN]AM_'%0:I7$W-7(NXTNQE_GJ65L%/)Z;QW9_Q0
MV36Z*97']4!",N_.'%*A)EGM55)8G@3>^LN2RQ]$C"M7?M7\8T.L"^^/" E.
MAN_DYS&@U"73N=-<]F,;RSP3P]T1BC)K646YY=G.*M$[!AIO M3_F^95_Y^F
M5EIQ,&G'=34JERRFHI)*;W9G,0>*MSZMR>]^SR5#[<ZLDGJ#%+%CS0BIV4.O
M2WHRTC/IQ:[D<4_&EE!!1^/;+8^&B1N2J460[9Z,)U?4R/5I\;6I(]28<=C9
MNX_HP"CJI42BK2J8Y86<.?3S4]QXV$FY3-PXQ;QNP/VJ^U5?H>6R1#7 VOW,
M_:XGHV^KNW2:0^BTB/3O$)V6]7?2X4=ZKC@LDVY"'0;[4)\55[(RBD5=#]8I
MS+X?,GYJ?2D<GZK%[6D5W!.,4A6/5JM?6F4XY:2PYG'E:0W()MMBN.&ZD/[#
M/;1%QRCL0<4_U2!)' 03O#^"$ZL?+0I3/3>E:,W)1'A<%DV3PH1P,%R&PJTH
MA3&R2DJU]_ETXD&<SGED[<U8A]"USMIEYTRDTJVJH1L+A>3N/V7*A'<7Q-J4
M.SRS (-XRPOS7:7QV(.3I.@\]FD8)4E987"/3NGJ_6K!F#=#-O=UB\A6J:G5
M>>'&>#_,,LU?$GT-B!5OH'+4GQ/-[&[$9><J;0C&2S1O^/+PJLYT4JK9NP:"
MC!PK8"\ZL%NQKB<UU.*1HEZ7JL/Z IM+C#\R1>347WWY[!)/_<P%&)E'CCT/
MZ70=O[.SPC9Q<GFCNYW3_1Y\VC65;"0[T=(E1/KH =#P/U=Z&S+=R$BI?0!4
M"EJ\!MR122(E,",;[IV2<2/A(W;N$&>!@^/"EWRV(5J K:R3SA#_K2CXZGL$
M6_!MFT7P3@;2P()5S(/._K'!772(.E4> GX,)MS!WX;2F>BO,#5?#D>*]A+G
MD:A979BV7_5FUBX'C>8QOW 0)\J[]^CS/6H^08Y$*&_6'XIYIU[A$G.;0WU"
MFQ]7H%)JAO [R.O.FK[S8:$B!.SD'_"@4;XL!&E>,>+E,6WXV2SC.N@ZI4!O
MRY5!^-ZH$XP)B\9F]N13["@\1_Z!J9_=GS"KQKS;2QOUTSHPQRSS6DW!%-%X
MV>Q[#K.RBT[W#S"M2;!W%22N@VH"$DH81"1<(_'FXXM8@(UG%X<)Q+Q^O'3V
MJ17JXIXXXN#J?8.!AI/__\FA^F< @JN"?,>#BUU6[^B'-X#I""8X8$\HYJAA
MI,AIA5+'JQC!%IIEEECJ,_13R^\3<$.!XL$K$LB)2EL@Y%>O-J[L/4@%9V*I
MPM /YCIH0.)$F_08H^:Y)RA5*UTW CM%Q,K;Q!DX;@39S?P,"8KVOW3Z/+?W
MCR@X:C#_M[+^PN<K!/P:<,EM\4?UOUFZ0+: 06A<MK2;ET#TT4#BT@K;L^Q.
M>DN=+[VR4S?#[O!>J1*IW4W^/?(25HIH]4RJ@A'C1L["6O&^.,_!*X#JC4GO
MMF6?0[5Z%U-Y97OU=^YWWIU&K]]TK&&ML10I,2SES?K@AJEIM3&=@X\K<_KJ
MIGL'9W0F5 :>NO'2"L4YQQ$[C&4'V"VRE+M$QMUN;-7X(/U%9SU,)L6X"=#]
M@)OC]K$2IF8N;>:$J?OOVDK\DT((,JYUPF]/0</UL5&A8O.5B'M(=%/.ZR]R
MM4"YMV9>PU\XR13[ ^+>Q6(K6+42@R&Z@R.ZSNB.VP_?"Y@HMY6.W)A?:X=S
M>"8'P7-.30[?VJGLNF3^:D!8=G9++Q4\CI75GM!B"V&\\U*($\#97'X/,.CF
M#'G4_O_J4/?_<W3A"$K\XV'P[^W:DP)A9X9QF]GL-Y6ICST/LO"99V]GN'%1
M_4DD@P&5, N<8U2#A@^V 744?G>ZH0U**(KARXS[]12$N//-"I<"=L4?7NA.
MP]BKEB&F-Z:U8\=,VG**&K^'<0[>)E/@C);%E>W/8CB!^OB$-6MI_;DKY6N
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M&W/OJ/]JCX^/VD+:=FON;,)RWU0QI1O]BIG'5\H,H%(>8!NR7;SF_.X!4(S
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M/RH$O*.G,-61^T3F9"0,FO(K <Q3ZM6W2@I2F\2NS^BQL&R]RG ,?63V9 U
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M,S%X,C!F,#$W+FIP9Z2[=UA33]LM'&I FO0.2A&4)ATA)" "(E(4!:1%Z8B
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M?"<]<;>&:?H<$MGET$S'[S['RER0PSJI/RC_/$FF#K#,:V!1@W)QR?@P=L%
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M-K53DK'<&\AJH]77(MWC>+.?XN&R@GO)),FWTA*);".,%8W(QM?^NEKK.B5
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M?&#(<4JF]1X^5 -@@RNL-J3K0&H58GS0:BP>+R4'=IT+96'=O+^05ZAZ-\5
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M)Q:F^!6"?G$'+3?Z-.4ZO=>1[N,2]7UI"J+.>/0*I.E60$/<327RHZMJ?EG
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MZ(9IRW/8R^?6O/C"#[*WHO6SYR!S(V$L,*>]^% &8!@G)[2"U)YL;$^]:#P
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M:GZ6K9(6OS,EA6 /D"1V5#^@9+'[YCMPT:U9M4"&^/U(M_,:AN33-"6]?F+
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MRW-*D'<F=N56A&P4QG]D2]3G@*A/G,,U!Q)0'B&<F*I;AE*2CX-9M\S_'RY
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M O<H'55,ETBIRS>0H&1^EY=_95N]:GSU//-9JQ,EX0X=?_*.TSKRCN_:4-N
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MMV_4+,L6NXO&2SJ4#7U(Z?.&3Y*=I+3/[;<!=R),;)8QO<B'5"1"! 8Q[K<
MCTFKT<J'$9[KE7;N<Q)]49?N1]QI.67[O: CU/XX:^1YE8C$30XHU10(*46:
MM%#63L*O]@J$]/;.KDXF?RCV^N(IE.%^N:VA5!TCR,(<KG>=#.V#0N@\0SJV
M6.YM2/PMI'D#^6E%U93[@G1K??,0QJS=MI^Y2T/2:!-9.:^R(I]#\<8-)F"9
M6S5WCI&J8+W9>M( #)QXI)F0>K74P]+Q*E,6Z*UZZ70_&^(SIUEH&7YC:H>
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M+V(G_0+(MG+<LL_(U1>K6ODU*O;3+59P\&9:DFL/]/"PW,6,^M G?[=++Q^
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M>3;88?U![OW:*HDTZDV@[MI]#;JD3>NAHM-:W,]&?9_]5\N%M<9ZR:$RR*?
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M_ M+BU"FK4KG<^=DJ\L433)2KE^6=K^WER"H^:E$4N*5H.0E',&\*K60A8\
MXPH_ ,56 >\OX*A>F0>@POJ0W.LV15E[-M$(YOOH>N_>V!5HK?][U$96I8<W
MY'8J%F<^N>7:LC_<>WL\P-Y3_)MIRVS\>M6#HR4YUC-OV_KU,GOH-L D83#&
MSO)KQ9Q 6]Y:_:AG'RVI;.UM5(&Y7V^055HW3"ALR*;& \IM!^-$6-@:PPGR
M[FQ!<4Z^) RD2_;%VJY3A5Q)"-35S,]T<WL-N4O>H$91^.MIUKAR(]T7P_#
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M,:+[\H0#T!2$8!3+O]HCKIYA"3RORGU*NXDA:?<U3[7<I%X'[I!DDI_W^AV
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MAA'-CAE.9=(D@293>ULBSP5!Z:Z(C]NK*VY"%,C:'R=7Y3Y44@V=O6FD<DN
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MS:F51NPL0YMRI,R"<K9-^:OT_*BOE>V?'V5GC,9V,'+[B7H0![I5^\?]8GJ
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MOB^R05V460])V;6TGG:V&JV1*P:X60OG[*>DG9=/;EYP: G["F'/%B3K/3\
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M,]OQ>NDL4LRPN*6)7L5HT:]O]MK%.-.7-E9&C6\T%WUI\]"@LPS0%4=L.6W
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MZ8QVGW\,TC.,6'/FE^-V2H_-D\,&+#"1U?,Q&7DDJ'9=@_O5YQL9,32TCV,
MQ1L#6][2$M*J8JQ,>0'M  %:,_(6*>,"0'5.2 PB7@!P- 'IZQ@)5-/):&T@
M*0(G9_[#F#J&:= E"5S7<^XO7D=,(K/.-''5[GS^2QC/_.U8J]=PG&09LF=6
MDVA>9_F=Y9'Z,9^/$NC;4['WT9G/KSNWF:W.7ME= &Y>"B_,!-D1,>5Z 5"[
MU%28#M)$"TCF A!H1I+?:<6PI+1\C$%;_S*;5]D<GT@>Z^GQ<_Y#K:T-%J+I
M$IY@.WUT&0HP^>;BG"'N,XAIA&SBRUF(KX,R>784S,[2>1YJR2@I'=,\BC[0
M#%U;G7&^ *S60XX(R&C@^RK@[KS4Z18R&BY&%#FG=\0)&"\\OI2!?$9CY;[O
MQFXD&3CKFM9\MW@==5QR@W;9>VNNQ!AT&]DD4<]S"71F,"&#L7W=M0/1VPT)
M!N/%]CKOFT#OGU+@)M_0;$< 3F.W+Y7QWJ4!$KC]BZ4YQ7DM\#];"'?$&)B@
M?P&@(]$V8?@:2,@<4N6181T1A+*%Q3E5*6B\M['?F\P#BP+NF5?X0-BQBXE6
M#&.JLE](5R_MZ3E8/=KQ*H":&+8ZMZR\8F">MUT4'*4X8IZ1),8J7QK#+FE/
M_'$[7;L [%1< 'A)/O@J,NM 4W)54&XE@2:W<,U*V#'#8:?"TFD%9G!_L3.;
MHDNB!G!XIWI@&GM.?X!C#EV@.)ASQ:VDXN<>M\NO3)HUT11Y>)I[%I2^4]T+
MEO#/H_P'#@->K1<@/KVJ7:]O[5K0X=!+^%VZ]/8]Y6"LNID5(R$T%".X=GVM
MEO'^Y/J?,M4/$E,,K__NZJA!EW9X+G?KOBH]&JZ"B6SFJIV/Q'=M"YW>_I==
M9*E#Q2:0E13%'Q?=(EB>=N^_%P FLX?+'DL*]6*RUB>6F0I_</+Y.-:;F.\1
M/'<SBO^;L() Z5U? Y\2AI_L-=MHCW\4;DXF9^\A1Y/HM$N=SEW/YT%(]L!#
M.W2_3VL-MUY[?MH0^N:&]RJ68Q'(!UY,%60D@+>.\-'FCZJ(][*7^L!/]IR#
M<TH\9 9@'.IBG.[JSJU2&8=%*F#2'4B JCE!OML/LKW]H(/KA-] "Y1=:"$K
M/S' $#_ Z1'L[HZ9S/_IB\?;AF45#G\#;1;GYI_W8)DOB3$)9Y0PY5BI//LW
M]S!A0YK&IG9WM%;,K5%PUECD4H\#<3ZAYX(]^69FDR1-H@M%Q$;[9/<(:+Q5
M0WU1 >VT(G09"!,2KU3PG397K]?U,$^4R*F>7&2 _66.(R[H\_4:'/M@96:"
MWXC)YYP^95&*B7Q]])X+MNH@EM_QA+V4Y_V!7TC$RO'-=[R*X?T\'5=W(@8F
M.Q*^+L$8#%KNLD9,SR A/V80S5;LA)^@ZYC1=_558UZ^65%S5U/4^:9 "P=.
M?4>A\(@3(?SS'[^A@LSU983B0OM<IV$<*WZ?WIK.G=]:K:D-#B& S^D[%B'<
MB($T]G&Y'C#K.D9AU/-5\K;(6+%DJTE4EBV^LYW/47Q-_!>!]C^H,'/])'NJ
MS^7$BRG#DQ;=O/)>0TWNS^C>,[>^R_8%((;** B6X]Y->?NGI 4W1CUDKL>,
MN&1;_DN9! Y!XH!$FKI<)S.O@H WDNPWHUA[<>&J?]/$)]NVL8Z7B(*-/)<C
MH%LN *3;"T&>P)##0=+"BW&O :['C%@'S/!!RO?T'[MM\NW/-6F&_JD?%&L=
M/OV?DIB/\<R-VVQFI,A<6&5'V\BLI>18^71%7^%=B:V2!$%8-\5!D1 'AXWG
M<"[OBU=+I6#-_P]L88/(4+9V7HW<2%6P?U:/_^W?)F[<R7Y*K>[I:F-E34?H
M: 07LDD2SI,-\]HF^^1M\JY4'-:DNLKVN:S0U0<>A\LGI';7L\T.D\4N/7E-
M4GA*Z%%?.C,TGO :J.S=],G>5'BA<>CM.G?3 +&+ICK*&>OCU=?TYR&@%L&A
MY]>=N)+,--%YLY*#*HL-&%9-[DH\#EFO__' J[;*"C1T>>PJ+QW<R_SOW_)
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M<A72:O)[7?VMJ[^/*AW^+M)!T71W^P) =<;7!_^OK0(C*0=#0;HM'^GZ0*.
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MSG2%]&1EE0@#9%XV07)">'5EZRBJ3E=GJ:4-_]"@[([G[=!9+E75(G@_1.X
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MS:NY@15:+A$^J;-#6<J.FJIJ;MZ7/R\%-F015-@"P(=7N%YK-.0R<!^2OG,
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M$/(+@.,$/U$6;UI:@<U+%! DA)4M6.DZ0XK 5K<XMJL+'MY='HPAC\/"%"X
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M*:CS;M\%0*P(+TWJNW8!>'RB@EM9# 'BOH(N?_UFEC[,9XH^MKX I'L2'"\
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M^)W<TWV=>^TUW2G[I679/*W?_O:2*ZN]AE:U '$&'15[MV'*&L(_Q/NK\EB
MK".8@C+Q7(\ J@,B$2^@_<2\&HYN=H><2<#T3%]<=3D(+5(FCP-L]SCZY"UT
M8#);HJM[#HT0)@BI\PPVZ=]+N"]D81< FMU,4IS5T<W_<YT[+>UJBI=A>:V%
MZ!NU/_> 5/"E%0[$47+,_ JM$SX<IH+S;9?/JNVJY7K2,$%KW_U(E_CHE.E-
M#>+[QB!)F!"$MS];?7\!B*5.[%1RS%_<X>&HM3\H"9^K:^8V(1@P _Z Q2\
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M>RUJ?X9> Q=:CLWF#O5#!@(O #&P8#S'UPWC>07]VZ/C<;P?M?R?+/PU)0>
M>([WOT>O)2+BNNE<VAFR.-KR=3&) LN\V5WVHU_"84Q6'"!H$*J1Z-UF#7PK
M(/DFQ^3\RO.Z5R&,L'T<=N/Y>7ZG) ;!X+JKD;J:J/B52\'ZB/)EY^N[L<R.
MO_7MC(OB?^E@JV*/_4Q%:]'M9^/M&R;S/6XV_GKTVNE/")X.&HO9*8HCE7?4
M"G-'!H.!^9N**AR9E(GOVZW1O6$BL53LSWS+87<Q$&9Z5XXL<#:$OR2QVEZY
M,.$%0-)% AS!]H C("C;N&1D7\]2?8%]K#'@M9IL.?2'W;LDFL-:;1+;1GB
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M:P*J#0H9( D10&N>-)?QHW\ S]2%L7$70)\.($_Z]T?ROEX3K?O6*\O$==5
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MKB!UVQ&B\#"88T:K+FI\G+VE.4HA27FF,/0.E60VH?Y F^X"X))#^A;">0$
M'"2C'V(Y(E97HD^;4RN6N:3]].XZ-,4*!2Q_/S(5]-LW/,_6N+X)OD'P*70-
M]/N6#M[*N-/GP_M@JRYTV(Q<8?LDRZ;ICW0>A0D[WYL8YC^EBZ[S\^)7%[69
M O^Z4!]4_H0140K'/L?+TZ=6\_+4CR78S#9T*8G)[)\0U[A?FEXWXO/0>(^Q
MQ77!W"\ M.$$KVZ^Q^WQCU!T>6B6520O;\,,#O'FG9.LY- O"OA,1FBS]C%#
MWBE7;9Q:]XEL]_]%W'N'-?W\^X*A*(H(TJ0G"$B1)DHO"8@T$2(@78B*2B<B
M+4  $>D=!)06JH@TD=Y"!Q7I34!*$I0:2"@AD "7[^^<Y^S9W7OOLW?WW&?_
MF+_RQ^0],^]7F7E_9MZVY'8^W3%PO#0(2I,4EP8=0#W-4FM?).MRT%B#)8@"
MD>'>SOO2]]:DI9;X<JU9:)LV%Z+RB%S1>V>&:<V2-Z)$U696LV7!@ _ 0JQB
M'JV5UB.%$ME<,W^;SI"%9HVF>)^]+FT5)$HF;AV9[55PF1[G4;7/MU78#C@O
M!3H.H4H,TUR[6(YFN"CH#U5!M;4Q"QP)\JQ],9SFN@"Z/-H6/JOGS\M/ ;)D
M$=L/<;6UAFH^$=Q3XLEWA&0!-",T]BHW3P%QI6%H[]O4C3E;;@6L5\CWB<Y3
MP&/%$^\OE,%3@,_;\D!W#I-'X:$\G'1SVQ8,@%QL2<'K&[$/P@">&U930.;Q
MVOE@BN6;,>7M[30+K ](/C1XR[6P(+]+UON1H_C"\*NRCIZ$AX'8CPFWOM"+
MB7%_PQ;U<EH($I]0E)QG5WJ# ON"I=/'>_ZN+Z@9J?Y8GU[^\O;5CXMBUQ/-
M0NV#/IWT'6WE%,]9(PS[2,V\SL'"[B$Z"3A#RGT+OM"?URZ]'DC17TN\=_0Y
MSHQN9? 2Z:&[A5V(*3D5JXT;ON*J>+GXNZ^[3I'B5']*TMVBMRJ=0UZ]7B,G
M/]JO>'P<D;=SQ&:K]H=Z&Z[*5I27C*92M*CI/TW:AC:3-#Q38:8FFB UZCTR
M'1'4U\Y9"[WJW,XJ7R$TK/UA>;Q<=(1^^TJR[S=>Z$V/;ZN>O2\0&R17\@<L
M+*:[+P#>@Q>=VR0465Q5145>W9?2!ZGU-FMROE_Y2Z>,4]B;YZ#938P_!;P8
MYEF?/2G\C'#LG\H%9?0HLEJ1X\#O1+G"N>!97(.4CX+)BQ5^-MN=KI+PF3,-
MA>E[;V@C&G.$!#K_^24Q:[L^N?XN+G\B[)L\S<[50H(VEJL?'A["C.^/:<=<
MXM7)["U=5>U+\"AHR84D\3C(Y">YTTM\4^?=JY!=4HJN5$!%9@Y'(ZV?E*VC
M.=/]_*7VJITYNU3Q#ZTFHXP*-S(/1*(=1#YURJ\##O&G@.<'L1A2.V9J&C=4
M@E681H](&POW=$%E/;8"''R0W\7"U1V+D5I$BPIXWOHPMHEZ7U9*/K#J0BQ%
M+2KLM>C)R).WA[>T/0X#GK;K?: KI7_I(NS*LZFYQQ #.#P%+$%>^U!6B <Q
M2+L2=#*6A=W>D,G3F"8P4,<T69:>^-UE22%D1M:<;$# F:(Z;<HSFDO'9"H4
M!&3&?O=DCB+?SSFYB92AVKX+QU#.28\I,-)T[,NOQ#_C?I*L":(]&;;QBSX!
MNLZ:K67*E);.=.<-979.J%^5_XX7O?OS@;8B';1I1S'N*/-(C61#N)J_M!T6
MX)-;XT 2<'B0'G1G9]:*X."?W:0';!06:LLI+W![QIZ0O5=ZE=.4^99>A:"R
M -]25:0\E&]]03P26FM[K,M]#3$U*\<?_& I;ZY38_ )\B[Y')P(P4(C]H]]
MUR\=,]R-,0-&JO.-&48NW3?V3..GB=E?EPC=M8P)<?CF<UFOM[O[J+<ATAMZ
MI>)=C;.)M4>\C/NRY6X$]ZO.ER&J&U0#"H2% ZDUV:KG^?G,=21&V'9_M9&"
MW(H8WM9>6=S"MF6>D=HPD.,XLU6;/A@ Y4340(D PKO=0\.K[P2M\0NR$D^?
M-.XPF 9,:^':9V*[>0_"=6,Q>$E=0KFIBV]F^/?J<9.KN&^IP5/F?5[C8@J;
M9^2;@7Q*E@^^3A6=HO*4V-F0D8N?_?TNN@"5K9]97OX3G[?3IEQIVPFK.07$
MAM1O[K-$G6A$]A%^V6K4I6>X%Q7'9S(\*!\3?+'+Y]2O(;GPJ1?@#XH^830J
M0=PZN$M^?,32_7T[^_BSD_>S=)4'I1;G%21W'^\/:E'4D2"B4B<*,$>&V1$U
M,J+Q;H!$:,JT,84U0E#%XC#+<\C8]=>J(&N8)D@=P=)Y(CZB[D4,TQL=<$+-
M3H]NJ!K7>#DYUE^6<A&A?W;^N8_*HP/.5 QTQK)WE SK6^ YX]7:4P"KD[UX
M"G;':7/OB;.4TBOT[@TT:>DFO6Q=T&V!YKO&O9?V2L7I_L)93GZ@Q5LG9!1D
M!<@[LIPN%K/2?>&%K:HN<WJ.3)],<B;8_ZIP?\<5^]1#:@9F8=0;3>Y/%4\!
M;X6XHJJ2]&9KKMQ/"#;^T*^ ?U_P&LQ)GB,(6Q(>+? W-*2:3G@;4*$AE;#U
M3(LH'Z[JW8?OS%QWX<NX8&52*?HR61C+$.=3Q8CPLR&,GYD0ECUWEQ7+&)*=
M@#RJ7L0%//AWMO2'2O)\$S^>?OKW9;>X&94SF!.Q&.TR,/F^;C#D)#!\D5Q%
MD;&E/B3.]\?(^/B.;Z<:& J L0NW9-QDV'2]FQ(TM4"!SB9Q<7&[, 6D!3D(
M9PB+!DN@;'D_5G^.EQF;-FQI(#R>Q"N4/DT4\_63H@LQ%P&\FCRZ%A..9_TN
MIK[?V>?$-G)8@]&+0)KA0''-+%%4V[PSV!C ;%_4<ME\+'$1G?,S5<KN2\QG
M\*/0;,<SM5<80Q^Y5<DR5?0OG7AA2_?I]@10\J_L;'>?#7X_[13P.F-I,4X]
M"'-L,7AYH023HRNI&=\.MJE!=D9,BB0TD13VZ2[_T+M'V)Y3E>6$;&)PM03H
M['"T<>[E+U^'<VI^0M4<*?;V5+_B"99,R#/4VR/9<+3"6N8[$"TR!&.8%G/7
MR*OGY%KB@_HZ$:\=NJ3!$=[C"[!F-<N_>IM^IP!&[!RNX0T[A@ZQ5I=1EZ;N
ME"MN??<25UIV#HX6IN:A2(R;7FMF$O](._K/]J.6\J?@L8N/S_NBNEZ+%N0I
M:70M^PHW[I=</  R#&QHLDU'G,R= G9<(.R0?VKHJ]RM#YC?*V A]<3+%'&J
MX1GCOO^7@I3]O\A%UX'VY^V'2BP1,)+,KU/ :EJ5R?_XB]?,G1L^RE2)F4H&
M'+Q70W:IOSO>JX^WY6W-N+2-:4EYU:@PS/2G)MW":_"KXZK]2XL)*%:D$@5"
M?K7<?URT488HV!(=GO%>3;CKGK"C! @,G"ZA6A+=8)=:005DR<[ZF%G\GNO'
M-0N3.'^YSZ^?/58%J!Q-IP</J-X_!3"#@>0:7&)/Y!5$69_[<:$J9*'^++4R
M I\Q3(<E%@=8=L@RK(-EIK=/1!$%LL*F$ZDO,I[B( YUPPPHK,?^L$E38/+O
MY0K%V<++BTL)VTM578U@;@3XL@;_;Q?VZJ;V9C=V>?P _Q'SFS9QIH</>D8+
MXF=6Q!+JI-TY?Y1[=\F]?>CPE5&\X%/>/RJ:+UP!5W.FY2*R:P3.I+G(*6"D
M-^!C>_DL(E"W9:+JSY69V;[GZ7<NSA:68M&/T,=%8) V<8R%M;(UQ=ES=<SV
M@X78*<#*ZDICGY?=^P"%&[NO=-IXV#T-%(>+J498=[6N69VAPL]VURN*&*WG
MAP DX,=6,P/"\2D ?[%B;F.VU?070F;H3+EY9QL@ND]LOJG)YGU<#; [P/.5
MVVX<]=RV0HC.4 ?5C.%MR,7=*:C.'N?VE(7)S)VDKF@._7SS*X\!&A+.$18P
MT)]3 #T,E%>?[CG;R>^9%\]ZY[-X!\"W3+B8P_):7OR/3*(*9'E]";1/!S]F
M;*M^S\P20+Q8#".[O+?-.^E^<C1M#_(/"4\6_BV>=\6I\D[7_^=/JO\'#>UY
M7(YD:_"ST8O-)\]]0O)/R&=9/XGPE#=R>,D3!E*\*/>7];7R]\XUF)YEQ,EH
M.P.:&?$Y$"2 M!W;H[2 F&UK/>==#M@NZ;/^=D0^>5,M74O;L9_'DGL*>'8*
MF!WO#58B+P4#'[F ^<B%A1<RK=7AF+8;@72L)AT?[AW"<U$2H/B@]1*A)CB=
M$UB T!?]'(Z)5S(>J_47,K@69E2O+_2KXTJ'.%V2GLOZOQPTG9IM[M]+!I<_
M]C7^6C"]IV^!]$Q199KNA="?R"+-QD\!SL-QO&(].1[=9G9T7=7K&Q]71[C+
M\>_Q0<E;A^_#KQLJV3=6U>_;2L#=G^F+4N3_\#ADBSOPL;[^I<X/?(E0KDJC
MLE(XR.W=,%Y9]+7U1:ZM5AV_<MOBB"9GQ7!WQG7%F,:=B[!]!P#R!PUNX7TS
M2A$!QX7TPIG)4$P[_EPI&;MA^96(BNZ+_810R=?YTE"7EGWM+?/=&&&(4MNM
M;MQBKQ9&@)T4G=4WS>8\O2!_QC)(\DW;3^/3T%O<!S0'K5NWF]&O"8Y4]JD0
MED4R7&\2?<W>=9&)*EL&KBM$F!J*8^5^L_D>UB1FWK7KITNH=4(1H*)C^[;2
MO"%17!FH2U)UNUC7D MU[URPNRJ,T\)_G4)7W.G4V2@D%#EWNIKJWD TU,N3
M39SKC%W:%N0S>PHX;^K5^--@:/L48!YPE@@SE <S:S!F]#6J4FJG_:WFYBS#
M"\WXRO<B8QW)G)W.!V_DLI4$=+R3_['>;BSQ/U/(/P[1 K)1B;'LG5WS9[3I
ME$0C&M+V)]O1/0".K^.))1F3,Y4\CQ-E &NS_\#DXU2*$O7V,(RL]V]'0SY_
M%O\Y/PKY/\Z/QOZ[+CL_@4;>5*5+21E7 4" \'(4?=?%FJU$8/5SPH8%$9V2
M9.CYR6YM.EDST]LYK-EHU2L[-S=MYV\BL<;T%/ F&@DE+(9M(X4#,2P LGMJ
MC^J>)5?IJ^E&P-Q=:XYSIL;ZZ@?X1R@J!PZK6PHG^FD1$CYF*-FSNTM7XO>L
MQ!!/)^ \,;*9W[1NM'EF>]K[44!SY/$.H,;D"0_"TJ*N'2P^EM<X\;SFVKCQ
MNWIC?I;6ZA2YE/,NU\'F7KQI&ID>TV!\"N=Q 5A,--5#O3T2S?'.?SW[^OX8
MH3IACH/QR-;X#*1O)HM./.#4Y 8$,/XYX:&JC0?S(E[TZXR;7>EI2M&EC+43
MU8#+F7B.L/',&$]G>]NOXN,O6XN)&KT%,9(.1;=U](0QD:!XL>P2^EP-YT?/
M:MEC;O<Z( I[9D/"Y6,KH&:-MH%JWC([<FN;&FLS;5<2;'&D?+@#P:NW0G[M
MBB*;N%3'L^37DCOU')2 4/GKM#(.4==^GZS,MM]55\M?#P'Y(.JV6>?:,L*D
MBQ:?%((?SC<X/]\'3N8M@,8%CXND\ [C>%.://V[AHQO,7W*O4$R=+Q?5X>R
M+.&6E0MZ C;V,R5>3>3K7!D$5%<8G5 7&'5OJU?+D=Z71.QGD_+\U/4Y#@!.
MTT N+ZK_;LEQU7E<$'-#5RL@@7"K7S9E^0K?^$*K"IJ&_ ;*)1N=V%,!I1@X
M[-!_')/=]Q\:+FD+?%',/NBRQL[A2\] IP:M0-9[MT?+$E$G5]K)UM/?67ZU
MUZJ?,8HF8OY +M%84N+I2KAK,BS+.++DS0 N<:5-!ZCS<SLHG2(:9.84ERS4
M&F%A#JA>[Q=P":AZ?JF;WE DURTFU.:^@V>_&+&,LT"]HR!&XO7_[$SS_VVS
MC#N9MK&,J$.]MI>O)4;4B(9BFJ0@XW47\@URQ;M+#TTZF7J6:-9U)6?*^D\!
MKM!SJ[ KP32(?BVB:!-+A'=@ULVQ]0.FJVJZ!IRC<QJ:/O9J?U^#=8^CD($E
M+B$<\K(LOY FY(J@DCFK!M*+6!R?2,/X]I(F8">KS/W1E=O9+"['W/9IA_.4
MVX@#,W()L:Q3U2_V#,59^D@G5ZV?C>RU,W6*^/G=]@=;?I!9[>B(RZ7I#8XJ
MF>=>TS_WGX?DC"U^,YS(Z6$?[X]=/TG;,L>T-S!0,_\+:@23?PO]26"H ,BZ
M'.Z2<HY+GY"ON[KFK5JX8F%1L[@@E#9A$U";HO_[H@A=6AQ["F)([N$IP$5V
M-@?,-?A\J9U^CH43:3Y5S9R5;XO\RQ9@! 8O.U0I#TGV4QF6RD)F#LR:)N"5
M?%A'/ M6*ZNLFS+NVO@J"LIZMZG?+73-1$*\K$8U3=C 2Y\ FK4E^1/]WB(O
M+ @3"Q$A_:@K2(N$YMS\BD=?,O3%SLN/XRP ]"O2;Y1!B6>*JO,FF&\=R$4X
M!43Y2!OJCE04I@E'+.Q"4X,&&B'*2;X"+&UPI!T9GH?0ZSCZ6$54LSB9(YY4
MN4I4_W[43Q>:S'^OE>E%FP/)(+5#N^N*%L:]K"PH77225;V3,N1_K7$H2/*#
ML6FF$=!<==_E:9/8<S[[>6C!$ZWEO&7/#6B"'+>@(\KF(25VK[BR>X91/"])
M=83A _45X>=157B5CZ%=H.5HI?R<\PNMC[\/#:]=ZB.&9<8N^45LG5'4!>?F
MNH6V,E<NWO@B,_WF^.',3SW/\+B8U6#)'Q6$E9Z8B]^K,THH'[]00=@*V<[%
M\ZV04I<&SUD;[>*>WB+!JVH!-+]1]]9-4_-_M)R\M5UHFD&@>A7!;".5=7;W
ML&JVAMY28RJX7RRF09(]5*5\5QC0YY>Z 39*I(:0TYI5B^?\6O!*U5!\2RT4
M2N@/KX,GV.P!Q8@/;\TBGLY3YV_KN(7*J!K>."!Q;J>/7L ]-+_P&0!@8NGZ
MO,'49/$U*#"DDZN_2DNH)D%\TH3VQFO:*@#+O1V#B!#G :U3P(.+D#TY^_;;
MG(\(# '$)@_A?\1GK7LWG$2?<PJ8XXP7650JO&$\I9&CRV$Z)L&4E_"^N/P>
MHWC1@H833>7K8]=.X4<GTS]53@%)="&KYMNWC:L=/'L1\FREQU5V-6DG'1XA
M2^;=T0LH<O+V<\@NZRG ?CEP_9/]N]K>M$=+9AN-A#O_V[2=]QGOO>ZG1WV%
M]_@TCWLHV'I^+/2_.EC7?3&I;&7T E/0N^E1GS.E6AL1>@JX:-DER[HFUN4'
M5.'R[8)L7K+M=+Z^\I-Y5$)05"Y[I5YMA&$(]A5 _NH#80CITLFGWJPG#).>
M6:$)>R,".M,_^)BO.(K%_SJH:N *A>6&U.AUYW!A0O T&">94X!C$!1C7_A)
M[U4Z;]LI(-J")"K^P6F2(\D6[C"D(G Y.$)62_.2#L<#&BUE^E'KX!O^.,)0
M.6GN9*0^E9O:WM;RI$]C5Y,K>'+XMV! IHEGW[TD-?:%=KF0%Z> &/C2FKL"
ME(=J0J3F0B*[C\*)!,<8^94S6+N><)&[_-9-X(L..L9\C&Q4"%LP'SEPJ;_O
M&(H]7U/5GKC_0:K.G79=T\WB(GV$'%O(19ALU=AKB&EZ4(]GYZIK3_N9%3E4
M $6'D"YD'%EVSL+Z9*/KSVQ\ZYGX&,3A;?Q]H+P"0.BE#-#,1LD'IJ=RH(,^
MED'8G9-Y6&UO16*W;!08 #]/;EYWWDL*LZD?&U@K^RO4**T8(/,2ZJ )TCT9
M"-GQ #&U;_['/26V%*F0[PW(6V=JC .?= KX9FA?_)]JI1Y8T7W/H\V2RK59
MX2E>0!<T0N/1D'$T+_(FD25:0<+7ULIZ0)&UJR4IDN8VU;I/G*[&M<\"U*(L
MK,(_/0BK1>&M/3'NUL&\5,4SJ8R1)%>55OZ2NG98,)X6244^:KC[0 6P?V3Y
M)SV?R(6=RL=L&!EVHWB11E@C@Z4,4_3HW@8EPTYH@DVK,3LIM#KQG>,8>N3X
M/9H;ABCI2JIZLXS6QG*G;/2<:$P^C!V\HT>3*^Z5PL%F6>4V8?RHS(&Q3B/3
MSG:&K_UB*XM8]P;>3(_PO),XW'OLMD6$)'B@$6[SZ".1R*\[ (&7X+1]RR[X
MFP#+;@&-HNBLAU.5KZ:;*_J'I;:,H6))&F6!':#+M;!(("A,?[0\98'^SV+9
MM_F9Q%>N7S4YP2:AJY+*G0V#&J< 857OHL7:LO+V<\=^MTM&\7"KH,^S%U]3
MT$_/]X]K2$QE*N3FXDE.UQI^W[SK&3[\Y]$I(!Y\G0S'[&HN7)LL'+=X/,B3
MQAT6YYBGO'X#>IYJ= 9WHHUV=!:)ICL ?R:7;B<-U5#;'0,]5(;QBN6-MJ.<
M5Y<_,^05?^I^PK4V5;K>/)F;Z'' U9 T,Y<W8" ?"J :7:^,>A&N+3_W<"51
MVU[G\\EHIMV?@5\(B'$[,;U F;:+3=#L9*($8&%(AF S>H:S>E1_@R^/99T\
M.3+9%9-<'?.%W%NS\H>;[%3U;XF]WV&9@V#1=7GDK],Z8^J:;K4;6>>Y%$=O
M/NZIOZE7*9EZG.ZA (NUAXS7ME]U85\/D$ET>5$S_A?2?.XEE^1"FQYV9=,O
M3X!YVW9\W[#%8%-JP8 7MO#]Y9*CEUS%*6"FD!143^ BP6)Q4V)M*)/Q#&\V
M78!=![!N#V;3I2W[LH2(#_11T<C1L]EV6)US?1ZJ^8 V]#6#IL8-SUX.FIA#
M[=KBBB]VHJM?:ZK27Y4>1/7# \CC>,@EV][VL]Q]&]@O9OW4ZG(J?*8E=:-&
M@53>\3Z+GJ4"(1\#P52X]T%5Z;)/ 1WA7E-5]HFRU2CI^0^;?R8(DT%54Q*[
MKWKK*NH/@9C"F^XWQAF_H6WPEI0.ASC*Y(]/*>_L]3?.R'K11<Y*+,OSEA9M
M7(T: '+;[O*<5[_AAQFA8[GE"RW-,<1%]N#QDRMCLEG&8\7-1-W/RE=5K[<\
MXC^Z"A*G;N1DG@)PECV]YW\,#6/^)HH/9R&P@8/M6U6,(;RX=%$^O85@O6KH
MC<JQG!>E_:TYZ#\MA\+32#/L(*C;-^71>G-Q90; [(-'\06NA$(%@E]$JRL.
MQ1L\>O-C)%84G>EO,ZMA<HW;56-&+'E<8&,]D>ED()>[OLU.KZ>!*_?69.30
M^/K7JYH+GW/./7=N-LI%46PN!=HZY86J@WW[V<Z9[/K2MF[>OS'E_?MXTF?B
MJ#6+/70 $QW.B7^V-F M4E QH]:.7H@<44R29RWXP)3UD+:_%%RG(8C+*Z[R
M >6$<YC<_]]#.J['G\ WG13!,N-@=M?9X_Y0?*MYP;Q](I?M8D7-K_<B]X4\
M^&M6>(8K@B1@ZDBOXW=[L/A3 %\K"#O,:6OE:L\[6AL["':_NB4F+56C6ONJ
MC!8P5[N?QR)_C$(S4^6KR0T%&Q8H8!TT)A/_YMZL;T:9*^O\!?[*J31S8S]W
MD6 %4M*2I[T>89=D0H82VGNN+@@2&M[(#[);AS/V^[M5M&DS 8NF*QG_I29O
MU)>>ZYW*\KM<A)U:U\\1RDE]&?_MFJT X:6GA5,>2]*UXP1D()$/JQN+1<4%
MJX^K0YE#G_LX?W0^ F9.Q=@@?L)%RGN6\1H, 5WD( HMHDROA6 <CAT&SI!C
M,<-OX"_:1[UC ^DNCW_#O(G^(_+FBER?)/Z'.!TFD3FD4\WG^,:&(:'B(+%B
M.YAU#7P-SF;C)%F2UNH<_2WZS]"B%$@KDS0\9\$B=A9*)H 1]6OGB9Y'VK8/
M!M4 &-[,)]X^Z=@Y!=P#K/[?=AJK9([3V__/ZOHUX\4.L3IZ;.-V3#NK=# W
M4I6H%%,E?,MV=8I]H?;)EV<[(_6C6YXQ@/7!94VZEC!C)=;0G,E#N4]GRE4+
M?=U)<=8OGJ]_06!Z:T72QXNP>W_T3[*T-/=R>4;8VY=M!MOVIP (_A)Q!3L=
MX5YG)'F/4-5YQJ=W:[JK$ 5["PL&[$P1"?0=RP%C[M=]1<<LW2BN%D31#WEK
MVT&EB[9K]9YQK0>ORO4+Y]^'PI01E!-&=D)9=W.6,YBW>2)8&!&69J?4Y>ON
MZ[7Z#,.UD0J3E^T*8:;>G6Q=9'?-U3C.WP]WBV**-!K%P0_.WZK;8PD%GR<O
MC!OS!L<_P22^595[%)3537KJVF]VO)88T#];55/Z@W@SP,S8/BMH11J;&+]8
MRY)8GFDH+=8-HMGC.:^;C[NT6.=R'UWJ$49'K (UD>4PVU%^[/,(E#UQL7\^
MT(%M42$A\9(#^2$PC>08&?(<?MXYM3*_(FOXZKH>7V5=:5SV4?@2XY;Z$Y\2
M*I@ +/7YV.WL4I_^U8!#LE[AFUEHJ+%<F4E1;6-[B(:M"2SPC*F(>O?)VD2+
M?[:$=+D2NKNGE81X-I-4=8G^+:U-UQ_^_J%A['K T D4^$)HB/".%X/6QOP8
MFAKC=GBS^/;!I_,,Y'V%PWXN/!?.NY%+#W8)0/-6I,\X *?FNMEVB?29,#\=
M6=MD.F<RJ:#B/EH<9E3C=^F:O:[QN4#.G6SCJ[]):11OX<LJ:KL_3@&2P(UJ
M*Z!_D25KY<4AM=Q]7#+U*1'=;#""YEEX"V^1J7CUA:620;[*F9AA!VEM)1Q$
M.$"ZZ>&O<$1U2]"7%/(L['9#5O6WX$D(GSS\PJ]%A/'VW:8)A<N&T*1N+]Y"
MJ;O$[^J)74VG@#!47=6;3?E .]X5??2X!UXJF5<?8ZG$U.IN;FP WO\;4KO2
M.0QLB'HZN5T%IYJ[GTN5/QCIJA81Y$_KJ-C^M8$1K<DG[QC!'Q*H4T?>L_ZN
M@;%U3)?8+@@>2ZZE@QCX&=2+_=")I?W#EK.SLP' )? UJC8Y 6WYME41#?SB
MD?FQ=<XJT3S*ZW!B-F1S#ECMG;&@/%VE;AEP 2[QJ]\M<D10?;I&Y)KYRSR'
M"BO^[)C#]O)[DNDI?V")"[ZO?%Y8Q&-:6%AF*BJSGL.?>[0)O[D9ME<A*XYL
M0^R5BBO\G OX6NZ)NLK?3]CN@<F,N15W;*#>C8-9OZ,B@KE6_O)Z:S!0%+J#
MQ[^0)UNO^T,BJLJEY1O+_ZB^L>NQGI>C,C0$Q)*<8ONJ$;>Z0M@6K1ZMF<[<
M\5[=Q$H*B4(2-8QOS-]#Y@Z=[&_#.]:.*J#/]W-4?!=+M[3ZY!;'LDAOAVXG
M5KS*E2*C,.WT-G5]-66S5I\3KEJ?)Y$8513^F)Z,-O?'E5"4NK?/N?".LX=^
M6CR#B5D69*[^D:4(4;X4;:T1*"!_:]-"5)T07CB_BCYX%MAV_'? &OF%5[.$
M)H$&8C])R&V@0!\YA=3R-_=.AR_O;N)1]U)&9?Q2_!P1U_QQ]9+S(1A3Y%UR
M:%VK(\Y\=!.6/M:JPF,,:1YK$&W<9D3R$!;?M#MO&%X&S_\-]_:700Z4W&HQ
M2%)*"9S.B/'94'XE8Q[<OAP48<!?15L-LCW>:Q)XYY&RO>U,%O6IIMJ2(XF<
M=\ABG=!BV^_?)UOOGI@RJY9K2[D$PF8:S(GO-GR(7'U*"]>0*Q35;UFN.J2^
M5WI3;3\D+XQR '0A-HU1VHXOA4<L_28?[I>)B1W(-AZ69/Y(>*_JDKE5EW%"
MOW6RP3_]]D0 $=)!BG;/7[O:[*WI<"#WNG\]('.-7K"2[WQ108L#=Z_-C?YX
MTZ+U[T-%6? RH9TWGW!S%8C[]UCPR)E30-X_GG"K03:\?[>*UO!3/]YCN,TW
MYUS$)C%GLC?&634$J]?P3O2D&GYX(+QZ\Z;XQZ+0(R_CRMV._Z=W4?PO-UT=
MCSQ>F_]._=(;INJ.@RJZXT8%2:=3P/.0:!.-'F=)YUOANB^Y]_K.!68?/*8M
M9@SK<!@YEMRI.F&$7)MJ=Y%6TY[:*HK4/L,L#\DLV]MJ.I<'.],U.PDO7P(*
M=7R_94\(_27IK8(V&S[9&E)4D0IW&^-_D'V_<>K1OQ%Z$& .CUVL@W>#WEAL
MJ4.Q&VJ!DVLEMA"4]T*7_'<J$9:&^BK6-1P5P@D6),=V@GF)^,6PO?=N%G_)
MSDH>HY\S '>J4K2V[F12;#M!!,/M\ZM^M!OF4UL^DE,JF9Y7_.W:D-._9TKA
M7YJR#'IP2+M3P#D0$14OFLX2@6:N'97'!ML%]NXD>1XOUQM#1S*)+%$VW523
MFE9XE+TJ$9Y8513?VJ+F9R=K$/Y-68A^0)^!<M>Q+?BM$ZP:VH7G$#8HA)9^
M8[#=:'@9LB1,V[S6[G@*H$<Q+SJ1T )?QO.;0_&S@;8^UN96#M>^B8 "A-K^
M_#P%5'V(*S7/G"INXUH?[I,6QI!*BM>FFP4^MODQ1%;JSN6 +Y@#,4H>.PN:
MMRP%@\U)D:_E UL$Q(R:(I=(-=B9L0L]MS>43 UI/YG$)^,\%J$N1W0GW,*8
MI=2735,-#CP4FU, 46'[A)^P"188E9)_S[,P-<3Y!G+S3\RGCN]4R8]%3KJ*
ML2M^Z_74^R^Y_4W=<2&!<R7+R&H'HC NQE8:'4OX,7PWK*! *[[]0Z^>CS_%
M:..^HK7.XY+6X(>/@NM(%^QR%^]9:/Y2_EZI=R-+-*, 1H 61\BR0)>Z^__^
M.7$B#YY<109-<RN<%#9,/I^RHZ&RZIA/0IZ? J*F9\TQ[2?]:9FBF.U*1X=^
MMVQ'0E4=D(VZI;*G(0%4$=!3%AYO4[@QFN)2-K[L+-5WRTA*0^%,X"@.?R.C
M+R)Z%:[7  7:Q)S<^V9(^_V/+.?LK[:3OQ,.[HQ[DZET>>M3Z5/$GJ]6"]Q%
M@C0'H?PHFR/HYG"*X1*N3ET[G'X%G#:?V&?>_ZF/6H\_FZGE+NRUB'8%\4'P
MVMK:B\1SH%IHC'<$G1W9NLI&'*1>_];XS<=(4BO!@ ^.FZRU6 U>?+P1ML^Y
MY<Y8XS&7>CAIF",ZM,;XVT;KYIE!M3V,(0:E7W/Z#)L,2?Y=;8T\!41'N%)O
MA50,)T)<0+.W)$\!3#9:2XELUG:_%J72C\*_:.[@G^PD\:5M07A'C]-. 4X\
MSPG[.XC%GJ/G"2BGY+E?.C*_BO@"EID+N?\VGP)F(9C?O)&1S\=;50C8:<NV
M]H2[)R-U=Z/QCX*FAE3^YI,9"%6&J3I7@6)D.\=BNYFN6-+<A,$_E<]1E(!I
ML89>"NR)]W1APT*064FJ.FJ6HB*QL,BA4K&P&-'O[T\Q1=ZN?L 24_[W%%"I
MACID'$@EM9']&V,#6RAC:K8S^GH[509?R*X85\#EALC:.21SJ4O8D<4@.KJD
M\Z2R;U(-F70#MU<Y]$AO]_K9C+U!5M7^2!E[MUB>0BU %)Y,!]!7?!WH!HNC
M/18LLC4AT?)3Q\5U<VCO[7"T6+/ !YQ5;V##C+#)3E<8H5B_WG,LT=%NVVQ+
M_ZHL#><6!KZA=&1%KB'%$B$]B5'H*RE.5)X*A,W8=U[#Z."YM^E2R!^K8$(9
M!!#,AH1.4B\Y:/0G5.[9,3R(MA=_?(S_T3MZI\:3N[\XT!'/A6VI '4IS2I4
MAG]V97=)3^E*L>IM>RKRV*/_7BPID.A]U!ZZUW9UM_LH-\VS:%:;KHUJ;_.C
MXW':?I7<@X]$WU+%O3UJ8J5_78 _RW7&FW'^% DUVQ#_AB:QMZ> %XGGR2X4
M_+0%V\91D@HEN%JN*0GU",CPQ[[AB>/ENL8$98<8N5&3.Z%DQEJ:CN(JEQQE
MLS'6:H)RG(4PQV'9X/?#KQ*>O.RAY.FWZ#,=[ZI\4Q?R!<0?4BOY>_^26>!S
M>9K9VT)I"Y'G@OK;$%#JK?@JJHAD!8@/D;=^:2<Z?G9K)GMSZ#>>5.X)'&W<
MD9SYO37P/#*R[JC7V+:WN# P]Y"'^?4^QQ)@K5?+P9UDJ/QD8<S?A2MPW\U/
M0<-7[&-)O$>G#H>))T>=)+RNZ^GU-\UI:L;,%S9=>_A(8(*72Z2)TH*@TMWE
M@>-/2SB5_G&-LH7W<L(,W$6,G5 5\'[<FMFG\<RVA$U%-?:POT=M>D!W@=SE
MJU<+ABY@3'N%-6.LEI/.JX#K7&(D'6*#[L2(%V#/""GVGP.#_ZUWN$M";">8
MLS[._V9*Y9 5I'^I;QI2[&3N.J?0&C_:\<S[QH^ *T[LD!O#9TM+%=+9?B%X
MY#+N%'!EWK6Y(4'D2]-H<>M\219+K?H=FO.*<6[K*LN6^?\X(FK(DK39/:)O
M8CE5F@BLPL8:*=YVP+X;%]B4MGZGFJSXDG9+D#)=Z 0B0&US;O<T>V0%X<K:
M]# >&560J,U6D:EOQ1[OT[M_J(A?'(+TH9/(@X1F:.PBH[KA4E^[ZM,-1:@S
M*2FT->G7"CSXW;9[!/(V1?9DM)T9S(14(5"<%NG5@X#5BA\8UWD_9N3I$^V_
MUUY]I_BR(SG)=5KZ%+#T,9?-/<!( ,R+U$VUU _O7MO(3U7M03 _$.B$5LK!
M3*DR!!.R#P'7;<])L3VS;@[.(U9!)7S(86G:K7XW;%$MX7RX*\ZZU2K3Z#,B
M(=#$4>:3\#&EB_GN\V8\0_:#N<#0G9/2,T(5(Y"2'33VM[O:H],5+5:?Y6)7
MM)QP\0S7/T1W /Q*W=J7BH)!$^5YS;5D*%%U?0HQI5\2J>EH<"4NPH*!GO6;
M$+J<J!3IAK0N6'#FK2@/B/@0R*[EY:P\SS_Z1;!,]J56+[1X37$6&'_FN4>N
MYZ1E7X3#X1=FDW7S;GP.'0$ 0/<TD0C(TL<3-M4-IVC"-%9NZBI(_0SU?J'6
M:"';[W=;X.@;098GC&88/'.?*UX;$])3=DG2>U>LJ6GDOF=?8>D+,4!@YE$,
M*'*6R?Y6:F]TH8ULM/WB9OSGS5. OI,72JK]P,N":H@)!'&O3A^!ZQR82XH6
M^I[D#JVLQ#S4,,]HS-/[,04CF!HQ//S:T%)#MB8J_IWR9M-3YZ53U2_)/XLR
M<-+S;*3D"9U30XFG ,9AK)H+%E2;19./@OP84CKT'_I-S'Z*KAM%:L Q@\#Q
M^V/XL:Z^,86(A5FZMS$*W.8FJZJ6*&W"/?/CHNOD3SXO!A!>%(#SG"J+VN"N
MTLITW(/;/74L9 F]R#W7B]L^+.$H=JG-/*.=W[^=1.7C]2Q>B  DCARI'!G=
MS75ON:9@C">BBS;&;_1+&D9X<,E0W;-_R'M4TQ/,5TVT3_0K<B$EN]@\__U"
M,M8PM%GEP;Z%P-H"'^$X([PVRT[2L#;6>%P*=V7.QC:^NI=[]7/;ZSR][Y?/
MPE,FY$\;Q[0SG0B'N$8%CWB? C:U2:' EZ 7?N[#R*<5+B""*8QE+?WV_ )2
MG)SE[$K+<STWB"99V.3[BZ<O ?L*>WMHFI%VC#Q8RDAH!JGO'I[J\OGU(WF^
MFC_;&PTBV8%3)5'RDK)LJQF9QL7N B24/[N6I[OR[Y1"IEM?MB[D.7Y//^L!
MPKQ>?]/>!BE!SO)W5;WX)/<R38Z(]K?GCU]J"?0^/ 5$9B%,C3QKS<FN1.[U
M#:Y<;V+!"T_0 <GQ)0SY%-U"V(ITQE0 QPW'*QR^C)=CK:0K'F.5"TW"S05>
M\UO8(C5&4ONJL-_V8A\2^9,N64ZFR;U\,H3\NCA/RF/)\(&2)1@B]NP4 X^U
M,98]+9?T.;XK3/:]'NWG92[^D  XD#]6.F%4P^!-?UP:@(6#V#WP)5HBEE><
MF-:$DKLE&.A!)C!]I!,9L7@UF!-1UMGNK@B:"T#60USFVG\L%'G,+?*L69QP
M(J31_%15PDKX[.I"B,,O[6<R<@V#O_+]'.J=:7;.N+?32%WRN%[^"6$ "R%]
M[5W)8MG47HG:C:?<;O$(Q'$ZGHW"FW<(/[WJ3!(% ^L9X%/F:&W@XKVDQRN^
M;AW= ;(YBE:_F%\29]NK;5@/%'(-^2IP7W#W)\]P1DOE[]V8%BR<^1>B1J=Y
M3,%6N4Y <>LV9V]QUU;"62I$>MYG>2>_2)90BJQSO2 KA>9$WF^MS='N]83G
MW>X7R@VWXF?=NO$UI/,^5=QGO! 4@6*=L[QR7$A1=T*ULZ[P45NWYG+)596M
M:GE69%OMFC'O%JN]8]4A.<ZV<CHW3\'5SVHTUIX(!ATH[RF@R\J[S $K6Q,4
MM1Y^&Y*<<C>P&?]]2)SNSS'LA%$+,Z_:YSJP& YC=ZL0O+/S")KW53=&-?WI
M2X:F0N.S 4@@>UF,Y[5^)9L1%;?&O-FT/1DB9_X]&0)CCL9[5,]E1.^5Y<B:
MU1OB5?^)L1;G_2I_O5PMS'C$FP_$M)IN8YSA"D25S'1]L9W35.QGHWG]60T@
M8<62%$GE6.ERM.,5)#L3^2BP'[OQD:1K%+V,XVU9E7[TC;["?X/-U.<*^']@
ML][WY;44ZRUYVN2"A/*?QH"#JL>)2W2R^)M@:0&[F0Q=5<WQF(#L[4746-OM
M'B!_'1&<Z%?L4K_VR;DA69[K:@UU=("'\J.[44,B="?MK&]4]VS=6Z5ZR*5@
M4?O9LS2OE-ZC)7[[=R#R.NM;@?!IJB]I\2Q3X^T*=GNC1EE0?Q)Q%[/QPTC+
MJ0"&"+RZ7*&-LZIYN2^O>_93OD!;KSHAK=&'OK2E2MW'G*W/U"W^&7F%>L78
MTO!C\MOL]P<A?O(TN\SY_\0U(A_(4P4_\P#W:VK#[Z= /?/>)2@(&#Q]>4[F
M3..>DR!LU3A<WD_L&H[.()E5DCVD]]B%_D%)LS?@M'V/!LP&C&V-*\"XPBWC
MR'WBA02^Y##EH7#:D]^\ZG*8,M"%-8M,X^3GP*QB&UVAAMJ&0X=H/1WS37&Z
MY0__<-X)IYVG]Q/".%;5I4]6W4J Y> O.(ODJ!9$M)0]^[UH 3A6_J*EC6Q.
MO#4TQ2DKW7-$)R244%2M3(M&-9X1'B3.@0@CF9_)*F</]_.E-0=8ME<.\],>
M@>:0F 5:"#N8#Q'9%;%?'E)7OERKQ+WX9XM[2&V$83#@#%VSNH_JWG&EPQC1
MHO8S0_^&KJ,3>V?(H]?X>?!? %E"VB8I426A4=T6.ZUG^/@OB$R4I9QE)I#<
M&Z1$B.V0)K1CVB/5)4A]:#M@GYJ<9SSZQ>A!]6R%(>$4H WG"^FR:M;Y2HZS
M/4ZE/!3?I>:B[;>W1H3_VFF?,!IB\#)]KBW#X1!V-_P3;9$&]E6FJ']?]!^=
M4033$!:7J9L+UL@;Y*Q 9]7(&(3\>6\?#<8ORL(+Z!HB<_AS;!#;[KV)BD+T
MEY:X;HW_6/%&A*G0YQCWJ^/WQJ6%Q_<V]'LL2$F7JWO""CYMGJ,#Z_T#J^2'
MKK&%(5TUY,3C\J>W+[%LWEYY?PIHKU&KWHZI+OWGJ9962+&UD;\_H0SKGE/$
M:&^],L+#RN$CU;/$>/26S*(-YY&-24AS0]Y-_SOJ<RML^$IJ*G![BV)^"F!=
M5;07&ZVLK3">4CL&XYDLK];$?[\!_-RQ?SX4)+9V%E@BLRLODJL>=,9L,.NA
M4&Q3PXCU63+[G(W]6 OL37M]?2BQ$&M%N _D($(CZL*<I@L@5YQ/ <\O\^X+
MLJ<>6K8A'+OK@>PCY7M!-\:DU8QJXG3@SAYG2<T<4_BE2B5UR760HC=+-75_
M&'H^;E9__ RI!AR#-T_>,>U__B_?I/DH_^UMQ&.Y=2>:O8=/L;='^U>,V:_Q
MJZ+Z7@OHB.[O@W*4AJ#;B4.O03KR/\+*:,BC*Z+Z"Q!5@ ^'B>:%GG,BI"K&
MXX\0)\KBFUVR8?<)SX@P42^>:HUTJZU0]*>^#S;)2-';+.N'VARH9'@;JSZS
M[(<U,$3LMU]&:I$A1+CAN,BT5"MGZ0^?2Q>NZWPH0+F$<3^EXW\ME[VK.Q?K
M/FQ^G 5Q$G# T9)K=(EZD4N$Q3AUB<\A+USJ%3. 2/HTYI2[QQ-A"VU#Z$?'
MR4@^[$,BM!<:%2Q$.%X,1_7-+ONE\QH=PFIUW/FO<18SZEO [T]/.!0#.)XE
M%G/&8ZLXK,G0[LS<ZB#QB+&NBV(?AI\_,#AYF%6?MZ?0+;#L\*=/J\12:8F%
M]Q=2D_#Q _;R+=BM_@>ACK%B:?3>8%Q^9<K;K<J+BZ9\WP?K6GZ4-7X:DOP#
M"CT%U,%[4'$G4CKU!%@XGGHCL[@WOG>8*G*)1,9%W(D7K(?(?:?CW+<O;-E\
MY0Z5J^YB/ID\7*L\&3X1(K;WG0)HU]&,9&$?0LS&W:E9B@U1??JEE-\7#Y&"
MJ.S:\$/UT.G,Q\'1NA0<4^!XV8>LWED[5'2Y]T5XFH+KMZ+&-S]1.85WE/@#
M/3C'(NAQPA ;2_HM:890':8[<;GO^GC^?I#<C,YB$'0$/)N6K*3JC\JS\#CE
M\K6TZ=>Y/S(@V;X*/NG]?A1H^>!1UJL.#Q%'NHI[SE&'*$P5/JR43"'%$[FZ
MU1;I[1 NTV=S-^'0.K'HMBM43_<^<MYB.2X;V[H/6<I;N![XCOB8'.(&O@*Z
MPL(2XI&UO3<N$93K%,D]TP+<CRYT#F&%AWA(^_4K@2ZJFSW'Y#@8  6X4A30
MU]3JC_.KKQTOJ.!0+KM!:DOP7H-@3BT"+3RRN=P>&G>^<D%2&D1R_'6WRPAS
MX"';/]_G_YGG*(2^3)WU6QR/G?9Y@0O"@N/KZ"PWJ;T-6\]O,=?CV#<!)VE/
M_VV][X3,\N$L2@FP3B6;ON2E>;T^KNK"KYU.YD+1YH;RJ?K!6 "XI#B@%]&
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M<+GB=*/B52BD L4/R4]\456X5@\42Y91\)MY/'WD,UBD)#9Z/9D6U#'=(E/
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MXHUE6VT1^47S8/!6'5-EM<LM$\Y&]_NFXAR\&IPVUM'#[6C+M3TMQ8ZQ?8Q
MP;)]\U'C\$JV?"[-XM*C 4&.?F,G8=E4#JD\BGC!P%="41EOD2OO?!3"8 SE
MOZ6SIU=*$;1/7:%-MLJ]%73?[CZ0#_ B[R.4K+&95;#/]NTYU1OKX.3J2 &]
M%8,(4C)Y5X7#FJG?8F:^N0A7>UM[W_*JCD0$[DZ70B8UQCQK*!SI.T@GCD.Z
MR1[,*G[Z7*_J4L7Z].%#??(W;50A[DK51ST*I+)R\,Y((WF""V+'#O:&>C,:
MYX\?EXC6<7+OWU^8_\H3ZS$1)*^-3KK0Q>@@"[?DJ2;$=$C1-;V";GX;.U=,
M=5IEZ8+KQH=%(4X?DIDT77.I.Z98(F6-Z5#&".\H64LGCQJ+]I'0,K##"D..
M$XO S&%^TL$'A51]-?U* MT!?C7-FN9[\OA0R<_(X=)(.R1!!/>8()?(XI:[
M_>F>,VED19&M>(5?<,9$!]H63O:8RAONS/R#-N(!UZ>HB,$GF\8IFY$IH&Y?
M78*1*XK+8JBET![0P8)2/WV9#1_6,6B9.*ZW=FQ^_62\G)?Z5"#BCI5'AY2E
M;LL7J5\=56P"J75HP[5VB;XC2/5DMS1=330/KE:52JER6K+-B_T/]XZ2!DRW
MW:(!WH)_!.5.IL.YD0V9[3JZ+5IF+!H+#J6)<#W@*W?0O7$+8><+"^B#-N1^
M:15WO6=3!K2VYZZ[0S.13$/N-J8EVB51PBKO5SO-EUQ*3YTH>>:F69C"&U?/
M^4.Z[\XL%3@11FI !4X7[LL@:6D^')OCXAN:R/M?@A3$ C&!.L#]C97]%JND
MV=26JXK:ZOBY'UI&+#RC)&)B&O ]HJ )^+I"B9*;#<_>F#J^<,9?$!!KJ$LW
MDAFT"GP@FLNOB77E^C[>:=$^CUSB*=HLW_%*>@QFZ>4JLN/+U3"3JL_YG8KC
M'4O7DU@(:T9 '') 90QJB]"AG5_4$$N@K!0HDTU.C=>C?J5(B>P48O6J[H@&
M4+D45T,*%!BFRI4=7_:WG0LUI.,+W(5N@L-5N9G)"%Z36N9:A?N/;5["9+X$
MUMI%5\ES0WA,9^["1/*V<AC:,Y!L(*..=@FS9N=X7CO%IMJ0^3FVJ\;3=EJ
MF/>&%_^W*%J1H)JD!1KTLL9OF/3TZP'67]DWOX1_^J)_PZEI=?\#PJ=]/]V<
M:1!H'T.PP>JU42R4R\BTPHMU_/1A]%S7SI/_]H[_GP!V<1J$M,A'4:R-QL"D
MBA72RAWIA>A:R9J%$A5'.X0M0E6!  @Z$$[1)T#&/ZL;VL/.EZ8V)J8M?:Y
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M2KIXVR?7#X?S/'([XZ+9_),JD\Z>%R2>C76-4981C%?;=V+Y$U[P8;G\+9^
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MACO]9MEVMA*%!TJKQ&\5A(Y-R^S\J*M/]B&NM'_P_0G 7E+ZHCU!"+V(\C9
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M!")W3';DY9R<F#%J57Y JD2.N@:@OQH%>/H2?J+M#%SO\;UM?/^V1/_K[;D
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MJP:H&>V\2%R6]M;B?]<HH2*CCQ7FA[IE,@6Y3[=G=?WKZAY/['EMG44-/)V
MD1BACZJ<3B=5$0SQ3MD*NO$:HA=.WIILQE*OUG^NQ5/(SC1W53DIS^PW7EP#
M#*,?.[)%>W93O>G/&#3N]V:]4L8G)Q [&JO2UNP/?^<G,89N8XH@TII;<R80
MF/_L]WEE9[9XW]\9[NR/T<IS."]-/ W9O\T; H8%G8HU/SOG+K;[:'_:;(07
M5Q1-JEIH/[*TOO\)-^!.D\!F?H"AQUXALLKEILB8*/TE&W&#IQ#O7A,P_0JB
M_],&3L)]PQP"@XL?E/*-1P-!-T5VE'#9OOXY^DB9N3G*#M::X5?[T9QM>Z)>
M_<P&)_S6"^+33O8^;^^U2U,V.5N_C> P :+;W]X,M/L0[%[F0;YIHMB.<SB;
MIO,;G9QK,[>8TMZH/Z[]E1TT<PU$B*,5LJZ![CM*?VB4C1LM5*Q0.]!-[8-,
M4CBCO5&FZ]-[.*6B^CA]UP \7IX2]/N]SA69D +ZQ$.!2L$:C"\17JT3(HI5
MC$YGEKJ[OVCX&5N<G$C*@7"3PO%<,LM >8O$.K=:,@__6:&J,[6&QYW^CP-2
M/\@=^^ZT6"GN:?WW$AJBLQ=5#$DS1KL5J,)YO^U$(5B8;B45^'"\C5"0S5>2
M(? ]<SP\6  9UH_#*-B^MZW4Y#L*>(8^R7P8HI49Y:(0H7 ;ZT'Y?FFL+@'!
MVF:@_;= %H?4%7Z4=Y"+:"CW184,BP_]OL;G78+.#H'Y#FXS;:\U-A=>V9O;
M0%@9]VH5);U 5 ]&)-K<2-AA*!@Y,X710$\70G+[F,-S@LN6P7=/9Q\X/&$_
M?Q;\E*Q]DM*2!UVUA,]6#W:%?.XV58_'2/GE[S11.69H;_MXT[^CJ3/<"0VY
MF=E#\F>@QNS1G[9R[J/L, *Y5.B,@4?U,XUR:I8^KS/-]FB4!-A0 QSD]]4;
M_22Z:J)6)"?ER2T"7Z)=C="9;I;5%EMNFI>%Q#JG]G-AWJG>8!$VD61MWXB4
M"P$,W[BGH)9:/9+['7Y*V>Z%84Z__<_Y,W<25JJY6&,/^$U@#NP$R"E?\="2
M10=IPX;'M::F)7-C+XZO 6;@,&&NS<>E W]^6.ZSR2C7Y?K75[M,!=8BMIJL
MK)Z#B/8%F/JIW%^<&YW??UT <LDC5^E3(/$,9'0$O>IHF;9^]W(XU3=K!I5T
MM7V?+CL?2H'<B+RW5UJ;:Y*PN]<A:6;<8E^_']Z4M!=]3*S=(PI\O/_'Q(@C
M83RS)VJK#FL/&1&7Q/<V($!Q9Y8ZO3EOD'=.66)PVV"!O^Z13Z?KQ[Q&NP=P
M0_C7M6*P=^\GX_, ]\\OC )BK!F^K(8G"3Q; L=PDDF; L_?G67FD+D/5:Y+
M>.T7^V4E5^B+F;YWQJT9#FBO]$U\<SQ:I2%%M]%)',!O!M6;?-GY:=)5\-5Z
MX%U-K^"6LR\$C;ZX/HO#KD3]13Z%M8W\GVKP]#-A%M^]:/6,'/]&$"5ODE2[
MYY:W*#Y!^TW!_8\C5U>#S1YG.$ 8:A<8;BP/JJU'5E<@+L'/4Y]5B5[R(=3E
M32.L3(T,<0AF6M8O5*#*'%?:&_T;5ZO'HU<:->:SL@Q%D 3S<;',1;""[GB.
MYEW;%<6H;.5FMD,"WV4LQ7[@-(\"YR9K0] W%$X-M1Z(H9A4^'WG?< 8F%(=
MLS@;A[X&RB+2;\0>W<$+G,7C(JN/4K18:^NGX>CP+Z#ZT;AV?"^R^X%[?=X*
M>%?WS: OD<,SY?A)_OG/35:&2Y>?.>(Q/^..A;]_;U6:LS;[9E=CS5E.G756
M9BT09Q-,4254=6RF7A]]=6CVNT=&?JM(ZLU&B8ZCHN?0AYVOI?H"^%M:6<E\
M0?]SI>%@Y<O#*X!Q/+NLA1*4.+&+3EI)YQ2[P0T;S4H^-9L8(?RB8!_VUGX/
MI'-?D;\NE(-(YI<%+ 10UHX+"@5^@CV5V]'T35N0E88Z^Y5PY2MY<'7[9"KS
M?,BJ$)9IP0^2C_BSC;;=GWEA#)$Q0$=:P\WLQ4QF#B&OUF=FY@/KKZ;O8B-D
MK+DONU6HR.(^;# -/T7/R[I#W="L%7=$[C7ZI!CA)AQ+;//B+-/L1YNJ,F*G
M_H7WXSP[GS[V]8_K6WPXR?B^:?#+O3DVX*0J.OJ985*'[@ ;OVE+SL!@FCPG
MTCL>9GL-$.%'.7GC33K2CZU<?J2+%PY1&OCN(XD)][\-USH@!3SWZ'_U?G3Q
MP*N/X.#A3)3;&1++C63GB3 .?82<R70FV>Y<(%]=8/T:/!8'P]DRNP9P JC-
M(:#> )[I$RU"01<Q*<.J&9)@WCBINZU?#J(/[?N+'.<'_)<3"/ K],L*UC*=
MCT2SC(V]=DK-1\&&6,;VYU:5DV_X<#A*[V1;M,DA"Z)ONDQ)DNZ'!>=EN2P1
M/(':T92N=V%XI;!DL-:\)#-_>87SGL%]?52_HJ14OSW.]/[&A:P0]\2%DHSB
M#Q18=A/<&%!:N=DA-T71D^VRC!'CU<CSNEV#Q2\/?E<V<I#/WEKUZ[(:AKV>
M":9##5X#T4]U;\J*P?B%&53!?*X!9?S=/1#Q?DKJ_&HC ]CIP(?JMZ';D4>/
M45PSD6[PW]7-^/5M/*\'4*3!ASG3FX8(HHOG$&PQ0S,=.OZR+R1P.45 X6!8
MX&KV"HC3$I7G4]75M$,VY0&@L^T@N;;H;\CFJ(9K@ GB_616-/UJLF2UNYG^
MR%F@G26_ZX<_F>/?F#&=NNDT?.QXJ\8%-^>A0#NF['LL05V\-@!A&" S'FC*
MD3C$2'%7BUX#]?D"UBRB?G4>8UY;9JF=#1'O\IZ9+#A)O_R4]I51LPCRCNL+
M5L+*J.G-&(Q(0G*P=2YX\WM< _+N"3W%/OCUQ6B1ON35[?.1BHJMLGL_%UY,
M+A?R:MRJ%>@Z_7A"=8(?7JE4LT6?$5=]Y.K!F/Q@I_&3ORJX1@9MLKY*YKC@
M51*:MV(.]H\ (C2KS/$)W#6^B*TL?[X3(LGT8RHV9935JX8\M^]*'L1L-48O
M\V9L\6S5GO+H9WRA?/O'SO[.!/H.T/C!74\V-T&,N@L\F3X!XK:$,P%3T;ZL
MD+4M[3I-[^CSX[B]S#G38KN1UQ,O,-!KM:7FR#KZ9#7I<#[>+:QGRJ!4KZ31
M1;I*XO%%CDB_#BW2PX(!Z7>:/ 'SIC7RS4+-.SWI]7D4=C=TRFM@PV*5)DU7
M\;>.BD4<\U@5N[W(:H]5&6+K8P-G4:Z5*6]!LW3(?_7T2NL!&X1 &9V4UY&
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ML?4\#&<+BF,-1>]&1=]/D*_[K1O_Z+38/S]3E#WE4$I["H3WXW1/@5O^[J?
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MT_Z>[QL-&OOP=,@E/EI>]>Q(^IV1=Z4@'#FJ$I>\0/JEJ/+K[@=MO>4'"RZ
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M5VS\Y+VO=YOU&;FD3PQ0I%OKY-#$26>>AU<(M\QH=2#W2J,:E/*]8]O%5BM
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MS_<^[_M^<7W__V;.=7&M7>M>:^V][W7V0?]"+P%W%6459 $,3 # N/T#T+/
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M!/Z0!@DQ'3^$UM!'06H&^<GBV*<8/D)9[HU4)JVV2EAGWKWAV8(1%8QE3Z[
MTHQ4TGERO]?8AK]3::!AV-R@@0J/-',49LYD*/6]C7>$+#-$Z;RQ#'BL_X*^
M=FZ5WD5PU4I\54#K++?! ,3@Q_-Y5P/IE;\^2I<76<I3'[7Y:([!]W*R.YI-
M]^FV+<Q \*T)HW$&>9G_/:W*DPV-H^,=GY2@5J[M ,G6QIKOXZ=?..H^* \6
M6P_;11.:$0Q.7!'LY:6:QBP\?_X@H8<QL ]*!=^HR=IMI408Q7V0Y)SU6NC8
M"W#OF"W5'3;#GZ-MBVL0<U)SI]DU-H*S[-T(3]8HF5 M[@CI56Q)JD;9^FT\
M$5.[W_.U7H3/#,MIZTZ;A-5EH]^@5<KIFN;/?%(+E7P.L5VWVD-+MNUW!R<C
MEU'MQKQC?J[9'256GA"'\0W/ERD#YGV:.F$T6&TTVP92F3V4\-I0)WXT$,3$
MI"*X3KZHA2"KFYZ]4LC">/$T["&-95],BHA]\Q*3JQ%[5IT^:3LLXFPFH+B0
M/93\MT1K9K[MDX!&OVYSDAS3DL".] ;PQ#8WG69E<DK=JEE"K/=#3<UT"6_O
M]"^+2?T#*M6UYVJY"E5[TD&S)\/\F*JXS](NOO2 B$_F0=TP0O%G]O[%<F;?
MAGV=_1^V0"2WYUGXJ/Q"CLWP:'YPT)3[:C=^1SH6HG3@G=1T:5;J.XWN94GY
M+8@/G>,/WVF)F??0S@9[]]+LN+[F%DUJL("EI#>ECP^RR6J>?=I+CCEV7]O<
MKZF&+?D;E.]Z+#"-"A#K[M775-;ZIBK;-M0^2+8CV<3*UQMOUK(H1FJ2WNW8
M2!>UY?7+3R1=_[1X[N\\TZH#-Q\H,$09C]H=V-U3BFL?&ZK5?Y?/=EJJMEXK
MG_ B85&0)IKH#.H']\6]SJS.$86T"S:C@=D:%<5':?J+)F/KR\_NF*Z=5"I<
M[.1-)Z=Y/-_.9!3G+3- JAJX^I@AQ(]F7^'5LCRAQ:C[<T*(3QT&-=NU"D9I
MQ;LU73_9$ZI\O0^+>YOBB"C\QM3=:H ,Z'>#_%X[T$HW1@,T+)GI#[F;I>_"
M5:&%QL/>[M>YJ][["0*3DCV$.#B1*B)$FMP>^EO)5&)REY/0/B8CAA5HEPY/
M2C(\NGGA2/(G!TM07]Y\; =CR:K$,\,)<0GX[DI+<ERQ'&5,TEDZ>0S3F<$7
M7WG6%0B['EO@;!M$77ZE)619,&9) FN%9SXE&"7MZQ63SUTG:N=)[/Z.;]6N
M^[GJ;[5SUY$,B:?%X6LJB_ C->/9C P0_V7G*B4%%-:RR5:0AGI2FT[JH!6?
MIB_#>)6FOR8Q\G]AJO_7)\^=)%2^5_RNM54641]*J,!PZS!OH/!U7W[]HRD5
MS O6>U_MND6/QZ$"^L-MHL2AT-_[)Q)\-'Y0E@$E^?;/2#'2@=XE)W\NETA/
M_]ZUF(NRXFXD&F@3#?^ DL )"_TFG=V'7?*@A^>3)]78MY.(U;<Q+:0#P;RO
M0$0!Q,/+Q):OID]+KB34]">S8F=>[=F%UN3Q,G=W*G\-"1V2<W0USI71+V:C
MQJD260_-%ZTH8SODJ?'8K]FOVC.WNKDWBA(=KTW*?[5=YM2U8:OD]J%737-6
M:E!_O-J Y\%#EHJJNBH%>M>R9BZ:=]L)%$29/DTR,K-SVQK1;O+#-QT5()NN
MI")J2R%0@\FB<UQFW!?$X(L"I);<J#U[[7CU%WIZ[R!R&4>'#[$DKO48PUK3
M$U,U%$;AW(Z^-/K4P?P@HCY7]L0<ZQFS>7)+7R7SF'S6X_J@X;'\%GAL3+%5
MCT+C6*D#?]777WT.84R;!V98";Z> A4RDI:^<TFJ!.+?'LV76D@OQSR:5E+A
M8^3KYQ%XJCMJ/_(27P3$SOO+53<VR>:\V&MJ1&"%([D.]ZFY]LV6G25#QJ-Y
M2B$+SBZK^)0RI*TR@JVH9K)Z5T7UUU-GRCFN!V&,^-@,3#A&-95A_;]YEB*%
M[\=XY#DSZVAL 4L$&9'B(4G&9Q,.0R0V)=NZE0M=WFS5I-[DGY22(Y0C"XN(
MHX/VB US@F;6:?D-'IK7Q^^5Y26L8[M6=>;U!SJ5.Q^3FAER=*J%2SZ8/JB^
M0(F563?Z4<5?O%":Y*\_*!.%;_$VT! 1D0A3;O/K=*L^WNHNH]&->E][9 ]N
M>?V5HR,N5+ 5%[YYYK_>;EN78*)4/.CMZA B1,Y0]>"X:I9AVGA&I\IPT,G^
MC?5&7'^"%LW<]O64G7FL&EZLS3I%/@?[K(56/H&Z]E)IO)K:&/?)!R)!P>0S
M]>3Y]=F7%>6^7SFQ!#*%@OEI3]>G%F7&%U]KA$[0S2MWC&]V0^CF<I)F=K3>
MFR?8FG[;GMH-<,1I!ML\7/\2$_*3Z^O^?/2J^&K^BV(KT8!*LYN1[]6PH[;?
M9Y^I5%)W8WZL"H.2K#1D?EUHC?2$MXL*-&O)4<45RC#L5FHKR?_X:"G\MBY^
MSZ;?2I=LSF"H5K!$HCE F^^#MKC"]81P?]S;+I.<J.\:D;]IE9;M'XC9?C$?
M*Z5:V-I8(;,+8I<LYPT#ZRNI$5A-T1E8U\ZHO*?S-7//\^A]8&=&:_AF%0N:
M;ZLAL^CL(GM>H6GT:,Q[?S-YZ@Y'W7 22S=M;F_;C'POZE'-9IA;BR+]+X>3
M :[/4*?'R:\HWR-IZ(\D[3R&%2=N<=-'ZU?)\H2'N$D\(B-.CBG4[UK[XO)Q
M)B>$;"<<*^EL6]_Y]0OBG)D\7K9Z->Z719@XW;QU!;PSA3E?[ \(>",K9<V-
M&<;?*,G$J53&V-/4U!NX85))*#H?)2[2?)N^P1\1,!*U)9R_I]I8D68BJF3-
MH]Y]9"G6V\-S.%7'F;-OZRPL4R*0G>JXW/)X[*%9N')E*+LT0PEE(Z<;%L8K
MC-X>LRZ9+*2<++Q:4R;76M='6[/"4TF8BOFGJHN3R%I&384,M7]'@I#J3#8%
M69O(>7Y.I$PHA884SO_AN6O"J^0B_<A%!+<*M0UN74PM.4<#B$,T@$GY13FE
M'B&>N>CX<W2S[_H,#;3&\$7R4^7^TRYW*!'D#Q.UH"#4N''+/!Z%B8IO@S=S
M ]SZ.8GE+L8@P[*H02:_V]Y#J3)TI!H+;G_^31E.O-J_2/M7IW]&1@,2],?\
M0R=]%K&4Q*P1="<#WS4RNP/9C]? W8OI3&Z?T<"KQ=0BLS21(-Y&>3S-:'I0
M$EARXH?G%X[SV9M+_M:_ XUS[DH90C)O1<?\&7_U>:8A]TBY*=?=?8BO%/_Z
MX6IL+C^ !B35#NLVK([S;JX"WJ4B-34QU22E4?87:=)<<:NWHUCE2N^ A_XJ
M^0^<=ZDR&$7_ZF8M_A=Y@>9HELV_&_V1:$C](T #_G3B%_^(9(-N^XFJ76PM
MID(?(QO*;?0AG2;!M6>-H9,U+><1!V^:(FE3R5=X\Q;J%0!A"Y)OOT1HU7V"
MC-.-Y1"9-XJ>/R!7] ZPDV%_*:9F]C^V?J:TJ7!]AAJ4%270QRGZ-Q0TD!%S
M,>%6C9O[\PCB#SO,5=A4^&O46[5.68_7_D"-^P= 6"26QLT?IUQMC6XJ9-[J
M6;0M-?245!QC5ZH&],?+J$&.]'_L.H;/>E>:47J',\LG[E^3I/T+F[HT'O9=
M?V)>H[CC-=#1']=OWD[BUG8Q.BM1%7V6)?"OH9C^F6H<X B\(]G!7UK:HAU]
MTMO%/.'YUU&Y_T1#;/+G_^DY[^$_W9Z5JPHS^A>U26"@.#'^JOM/!-[6U%"$
M_!-*?P'\@W),(\M&85,RX JR*)LXF%@=<S%NQ6\E(>?]KR#\)QI4\@YE@R<2
M_YE2[1^_%(Q*#0AJ-AD^2C9]ZO-U*N;=*S30,W9-;#WVD/*4%'D;\D$$@V6,
M+VXDT,#2\ZKBB ,*INI/U>_9>"C4,60H4K,PD__0@?Q!"D"O%P376E>0Q/%Z
MS5J3<"F$",B VI)U#.5;X JLN72L@S1,3*8Q$+E+F>$W8EZ^BJ/-,CQ[NFD.
MQ;C0.]\_R6Y8N7[G95X/,(N_'.'?\\N'ARQO0)>&HQH78YLIX7%&R"?+/%SM
M=)$FKY#!>Z(V*5FT/)'ME:W+3&,*K &6\3 ;2(R/T \(@!S02VD/5T=&N9M9
M9E^'RS4VW R^8!@S5!,GH_*>;[__*@?/X96KB9-MF@KL W^,DDK#7.WYV;&!
MHJGPFTH6KC=GPF:1Q\1*9Z;P@&*X90>(.#]%.UP)WEMK3Z]=TW140_\PB[5+
MW)5SN5M>_$W(6-#<4>9[-%!3&%$]^*3+;,4RW'W>>%&IN29*>1HELM0B.^HN
M7RC'$Z7P4?1S*D$5Z2%6[/L^\#X. K0*[OX"QO=C\7_6/N,>%YX]74.826]5
M11]!][I?!N\CHS%WZ-IJ WA^N,[O/E+"&AXVJ\WKE=*YP#4IH,"2?*Z+$"PZ
M]R3_I%E$X11?A W_]BS#-2@6LK*X-Y"%TD>T)JV"D/+-*LND]W[-U'Z]S P3
M %6JN+\S<*[[M(3*2SPF>GJZ]#9R9[,;5'G>K4;GI;<\'7K#B&2UI@K@1]3%
MUG2)9D =V0:3/JD_$,^3Q;=D"\+B".3S6?-UW]QG1$2U+Y AQY>;8*3;QCS(
MU*67XQM5S2,\K%<"^RT'K]D$0Z.28Z39*(Y[LLL7AL^HD+[YM[0+];!@AXEU
MG'6LQOMTD,ND9J+61M]]XMNW?89L)VEM]1=87UWUTR![]DO"XG@K:B0V0AGW
MIZ'B<I[$-\4K!M<ZMU8N?VR*!K28TWGK!C9M@NHV'$BL2;80(**;.9^IQ"63
MB "V9@1U> "S@9>O?%U3566(0OW(J; C:Q+S47F98?T1=D+1,Y:,]V:)L4UG
M+M?9DIQ>T!6'^&4T0/VZ,,*-T5;9-[ML.^#N1+55]9<\M6=]J>5F=QZ)KNM,
M-KSAG<Y  ^V0BL7W_%;BA@NL4\T*"&I-A&SJ=4213<;#";_9D+?I[?.TF*'T
MK?9SM5*;6'AFRW)[DWFH1PAZ6[.N5EZ$_9H@[,WX*N)QY;FZ]=3B<3]-H,YV
M]QE.X!)9VIL9":]16>N'Y#RW1]*=-'VQ/X?3I_HLX#0G(:4% .5[<W0'W>H)
M7@)?Q]1!+BU;H090-N0P&F 3^RLRN145X)6>Y><QXO P$W#F!!*H5E?_6:2?
M@)ICCGWJ4B]HCPFHE=Z/<51<";)TC:<W?N@^[ZDYNGGTI+ N<(\*H1!2YRR^
MFN&*$@:KG$ 9D8=7$J HT<7W*+TL9 ($!WG>[MHGF%369E='T+M*BHVHH%]Q
M6)6@18H5T0D7^W$AL,YT1_V\5QBI.X5@]YH)"[?0@&,%O.[#*2W;),]F],9;
MRM&8*K(X7_LWJMINN_J:-[\::1%4J92U7Q_[\?OA+XA-NL=[AI@YR+X-E%7'
M37C1?F ^;#>!!D@#L(R]L+01<9TF$<;L3<BDE3(]14$]IQGK)A[[O20%7P,Q
M&6X#3U5OA\\#Y'ZY9[S7*9HF01F2(=UIQMG6>#'B^P^Z!UY_B)IEI&)Y9, B
MQ_S3@4[VX\.MYPQN TSAV5Z$9\'(+ZME8JJPJ0!RA6RO%YV7 H,WJ>7;/HT+
MDADP2\NH_>(*OY95;+Y-ZQ\LQ4P\<(.SYFEQG"MA/[JQ!3$U"J_I+L'+T-$)
MU%MH>:8E3C,U4>FQX4#"8 *ENFO/DG_)LN7>P"H:()RWJ@W@0E8)-BUG$FU7
M;>NS)Q6\HF=+$_K0GK"XW)N^JFQ/T^W-,9T1<D:>T@$FO6&TOJ%#)$%1;,9X
M=:U5U1/N@R1B _1;CPV;NB1*>&?#VDA*7YD=8;V8AKR#Q26#J^4"R]VW;G-E
MV/CIPY,8Q7["B>9(L0\?^B+=+BQB/@67 \.2J6 !E%,5,@H^W=4HF(W7U6*@
MC^R!(K-)PI=BF%S<:D=1;8VT]HHQ\:5O4E+K>X4/Y*9@^)(@8Y0 /'A;OZ ^
M@W7">$7I2]16=9._H"!/](,7F*':ZD^?-<2YCI#BC$#,GM CM5;4(OV<<U!V
M&<.=3"R-SQ86!I9M#2*B?2->::Q]_"15;_@8 S!W>HA9,1VP&, VZ7?_BA.Y
MJ3MRRE7&HEE[Q1MVT/\N\M6Q4^#R1#"?\#EN<WB/OF[+%8\T/*XGC;KS";WM
M3$!+V7:C:E.6K6>A=N0!?5%4U<M2+)9BW1GJQ/AA;% !Q,HQ)-XO /D"ZD5N
MKW,B7V/"*G#B=&?F:4+)ZEN+(8]5J,^Q(^E-7]K^8C2*NA3U EE2C+Q2A;MM
M>^=:P7[?+D_$7$YH[&LB9>4OF-%8<^X[A-BC/Y'G9\M3 2"O,WNP-EPUWC9'
M9D4>)5P[S<06X[X]N8Y?UV=^=P631/8,&Y' Y=F566L-]PA%F.\PD1.N0+%V
M:QMY:M\+8*4;&@E3)<K>Z.K]--JOL_5OQY"P387\HMKZ;4.G'" 9S$CG2$%*
MP5W8,:I0/-=W%IK9U]!D+22?G0*4WUG*^&(#BY$D4T,8W)[-8Z<#$M0&XRC>
M+'UIR I74Y-<W?BIV.X[R/</AC%U1*TV:T= '(,F,1%T9JJGNQ6W&N$8=QH7
MU5@8?GJA.T,:?D,$;UD-]<TB,WYXWQQWK7?MX+X3QMH)9?:5IE?F*BCLA#0T
MK6SZP\DUGLRDP"!FC]88_ZSU@PG)7[>TH[WFAWVK@OD;,P)24^>//C#JFUXF
M'@1>CY')2L87A(\1BV&#2=7VME#8_B&LLBRPO<MAK-?#DVWBH>E/-2WC<(3C
MDL!P-RFF%Y?T9+/6(Q.D[^OQT^)3#=-0Z'HM<3U-!T[<3VXU[/T]8@PW'U36
M'4.2H+A;HE/E^,YL+E%!^H'FJ R &:FH#W#F1 *<>?D4&!+A*#_HR%3Z7PK3
M'V>F[T81>1F.\D4#/T+?325GHP&F1?C]U]6=YP2<>?ORST=E:+*PQ3%MC[C.
MPM! <*R?$](3L;D""JU6<54(EQMUWQT@%%X?M5]S#Q-1S.*6?;5$HL8.,WKE
M9'MQ< U% VN[DD\AOZ9O:>C669;5*0SIX[E_!PV\((FZ'8W0$9Y[PY1^]1PR
MTI%S2YV"9U%<:WZCTG+3(/C)X<R]FS!&:C2 3;6X+(>2$#J[91#9X3)HH VG
M#JG7>T('7*[^M]X/P<O;L&IV\-K;40A<VOZ&\LA<]TCUCL9[1J/825!$B6:;
M-29QPG7M\U3[K)R'$@WK%3WY@/]K:A0EQUEXO5.\;:-XM"]'^'[?C0X8)7YU
M%J;IMWC/*X#D602_DFG 9R#MXOE4.QK0#%U8F)$-%F?A?UC+FQ'TI7##B@YG
M0'_>L-1VS<#^>%UVH6)MGY;K(Y]7%FGI 6RIT*1:(L= @>/#R5OB3F,W%TB[
MA /68WE6<Z*E8#!!$&2IV 1$X[H2PP"ZHN:Y/3];-:M'-5?L)2PF>,IRFOQS
MK G):(B#7V'$7SN;J'M!SEBK&L;M'0^:U7@FM+K9HZ7MU_,"EZ+)/0$YU]A/
M&$ZW%M*\D3Q& Y2R41D_D!XD$,7DQ1N"4,394JCDXY'[IE),CN'+6+OI-0TE
M 3T!^" + [W6P)B\O#KLU#"2Y:_FH,)\UX 'UQ'5 ]O[9B,"#2=GWKR<K4PN
MW\R0SL&JS@N![&@@/.MFA-6OE1N^+!G^HD[KLDSHABGD2H8D[2!RU<JN)UN_
M%0\*3+_W4T(2KI"&GEG[%QE9G]/95=&\K8]<XFH G?Q$S8L<&A(,.]M:<..O
M[AWL[&GA<3>T#6M,!4J6@^':AS-$Y.#E^Z/2C')G.'6@_"<H";'_&@)]8XL*
MO!HNDJ,U@L6)85@[(A*^&VGW%5X&*(>FUUO]>A.RYW,;(\,W3%_^<XQPWNI>
M<#/BC0;B_ST2$8'@%(Y!_=L0!2F0 1KH&(=9J5W2N)F@[AI 0O^9>1@5+?KD
M!I\'UMXJEUL&^#O=NFVQFN.:Z%]2V$O(4OHBJ-GB2@9%-^4GL^H[:["O.6V0
MT,U17:5D0<;-^QU'*]BE)PTEN&OR/1,N-WPAB ;((;^&A6X2.Z0R>N:U-4<7
M@I\W)Z[*H3ZA@4 T<"8X#]G.N&RQ;;GE-7$7#]$ !AK8LV]$ ^,2IX#/KZV'
MUGB Y@C&5*2HAA23YY6TW]LZ)!;<LS, W#BV/E5V\FHE?N]-ZEMOSV$&0S%,
M7*+4+1^]SL(;0HGE$6<T0%!RNPFTS8%0-JU_5F,LXHH"I8H&H+9JUX_KH.V"
M.]8Q7)G?P/ +-$""!D8?38'AGGAH@"[W!@1>7KQDT^^Y(5E" ZLZ%T8R7+&]
MU^JWEAU&>MY$Z%:@@9!Z,'+R"4K2MP-VHE@3AV)L0P/=)4>-L0_GN.,FR=
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M^N8N?-7$H&"+YS>#8QN;4F!_L^M18ERA_ORDW;C)R&/3H-]41U3R:]VG%T%
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MWWMCDG6XQB2%AR5L$\;$I19X$27A81/S.RD&;T03]VMJN.>><0YY#<F5<XU
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M>$WYUCN=[?LO#(DV:WVOK6C2=%LL>'Y5"4E;Q(Q).] X) KW&C?L;B^T$/Z
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M,("7W8^S@8Q(S9A..7R:N3HG@/ >U&<!ZQN%7-8]*JUL<\BO/5]F 7\R%;Y
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M@9G0DK&%,=%&$* Y;')=O98#89R'IN7\K'Y EGO6=8WYC=K'W7\2!9S_>Z*
M@Y>B7_(C#51EU:0%\@,8G\=Q7-$]Z73%" [DSCBO4A!=RD\2)M*U\:[.5OX)
M !.)F]&RU#/U"2S*CWR'EQ+)!(?SUXSWQX'R_'>8W.PC&FZ",2-4_ D0] E*
M"DG>S@+VI_> ^6X:F_QX\SQN[ UDB#)H"?W*=\DQDP*3Q"<A@5)_8IQ[B_P1
MO2%-3P 4A2? @-43($S!%_4:[ C#GG\"1$]33$*Z J11AZYX)CW-MH@BVO%)
M7)7<;U5"!B@7Z5<1@R?S[0IPOJ<_ O^I^ 0HJWMNRO:Y*6NQS:EU>+$C^V<S
M8>H) $Z'/X!F1FTYY)05/*L93NXQ-C1CA,Z/\UBT+?<5SC9)821.J&"[2N=Y
M/R51B_#W^K<VGW'*D!D10#SW(T\ [!0([O'6.I2B^@E 4OC<F3STF4K+?ZB<
M_-@JQI@+L2CXDVS#PE<:]'LT.MQ-NGFZ4/AEW-I@7:/H$T!#CK%[G;AA/,G,
MPJQR7\A\LD%?O\$.,],N/CNK)OW1]+\^_%]-3@,WI\3@/!R8MVK]@(W:SR53
M&#F)SE!B2""RAR=5GPY&U^MBQ6W'*DU9VK4:MO97U8L RPDW'01R!/KHD:3#
M7_,G>QE/ ,0VB%A!LP^6]J"6,I&5+1#WVY"Q8H5DY/(SPX.\/-&GV-_@D$*5
M@UCVS?W?IFF+-J.)&T"%_-CN.1%T5E_3?L9"B(XS2J;O#/EN)(N'Q7;O#CO1
MJN5X).QR<3->H.V^;Z['@_1N<9O.(36IT/:SD[P1JL'=_79-M_==ZKES"$@8
MA0.ROQ5M^9A#_%OL1E[^\=W^5E9)KS&Q#1Y^ RBEX_/"V,+5\#C5[:CM,WO"
ML3 4&+_P",FF<+SV.>C_@:X,][AI=/V Z_'<V#+$HI2EW&T+&-[$S'[?PQ=9
M^/D)8# X^M$ V,/0B;3&>[C>/\VG.%R%#/L\C9&3= S24&L(+)H35MC$ K!)
MROA42]+U(B(\- L/C(MP+$RS^KX&/2@+-<11KAXA>?=LKA+LK)[0-7M^]7-/
M?[87('0YW:X/7: 4N&<3\UGF!3 *9A"MB*_N$R#X3XH5;J3QX2NP2@#W.V"=
M,*Y'E7SSLE@$C_2"2COA%D><_5Y^ZK9VY,<@?3]"'S&TI5]M>E38BX/F.MXD
M^%XQD);J.6.(:W4W\#Y##.3:!?T4]^<I[CX#^/<I*^@ :M:<K3\2UMR<HA 5
M)F!MX7PVN!K'4## ?!/\EY#Y_BZ(H#&,2^&_5'/\7ZI))+/U//;]?P)[*)\7
MQV7H\TQ@)KQ^KX+E .PMZGP>:O\U/FP/<!8?;MQ!J2>SFQCC6!#^(['%)H]*
M(.--UD1STJCY!W[[\L OY&9S@7PNTP?YB8$81G+@ I@\\&]RUR? U;B?44/Z
MA?'_!)/]M]&?]\?H_UH/4/M7+)EKX ,^5&6?ZN"?W80O2F_@@9XYMQ/5ASEJ
MTW;7/J_MSD].ST]V 7*.;G@C9!M!G!6HP@%>%.4X,(+4X*X#-1#D"="L](PO
M<<7GPBXM]TJ@5\8/!^HD+\6.7\+N"1X9G@ _:T%.5!=,D.>) (GW"0"5H@)5
MM%/DW.'[BCVK>@801A.X O,09@?C*:%W']PG=W2%"_/0IOHQ7"BR.'AROMO>
M"U6Y20U>(>W:PD&P]M!3N3D/OBZ]MG_;+.?:UJ1SK< KDDWM],9;CE*F5,-X
MH@3*S(X"G"C8?.X*?_EY>L%G[Q5#*4"FQ 5!3"9#DQP3G@"QJLPY8QJ>"H:J
M&%:M\8CF+RT9GB>H3AM&T%E%VFK16I7@6:/3(_.]O"C!I"S" YGR$C+@@=P3
M 797G(-R@'5;S\JR/S? #F,(:($N41"I:@2;N(K^:()\P-,U>">>B*9Z=1<?
M"4O*Z*$D=^BDG")^. 0]$\(] $()6?%=(YG4/RZ6> +TJ1*)I=](:P2ABF[C
MVPL<V-XKB6&W,PSF8%B]?SAT_\,J1BAS];,],5&>!]RH6G\"A.>R 7E]L)UB
M;:Q.V"SX9>E<YM&_S%_%/&//XY\R J"J+\ S L?GIC7">M?17]WYLN=53RL&
M $^^(HWO@5T-I>:=%PQJ[\-UG@#R#3A?> X'S":K"ZE.EFM@R8_/>.PGPJ;3
M=*\@.PSCXQ-@B^D)\ 6EEZ*=)S_N(;3G'X(S9R ^6VDJPYNC2@]@F_U[S<J7
M/]U?#(J<1[I)35;8%UXL#;!6EQKP<C7RQZ$+$3GC^V0SW[^F1 #]N@*M18N=
M4> \ZXKF^+-(N A%<4%WC(G*28Y)?T1"))8%? $!':4#;Z13$06)PF:#@9;+
MP\V_>PN3AKR285U,)T@NTN]A]\#U=UV%ZQ M(^PG0)Y,[Q, \KKI'VI#+#;.
M[_]#K^R@,T^ [*@G@!^Z\,(38#__;^5>T$C/^M7_5LDGP+NXL&?HK.'XSZ=F
M2*6(]-Y&S#_\[/+NVLB1@;W]NU+3_UFICQ> F[J>8K 0JN?OV2C^(YK*92S!
M:;G:T+&!.0QF6>F%T]-\G0*)S$U-<8#Y?J!XF@B[/%.NA!2^*E+4/\OYF]]_
M$@$E/R_PN87:,V+;RW_<\O4-F'X9.>?HH\6,S6IR"K+B5H5%N4A2:P<E;4A#
MMSR7.$%==M^J3&?<<%Y*%0T7Z"X8&Z_);38F[FW+\MX'Z;$0.24"O9B2S<5Y
M$VF3T%=([[W(;,L]U%&AS+_-'W.$N=>1K]E#P:,^R#&E]7$N'D1?FY3'G1TP
M"!?KXP>MZ%5^ 6YSS5[>A(.F;%4//1H%!Q+<D9J6B52;8ME/YIOC!^TIAB[1
MM.(#Q%67->-;#&?;MMFC2*F"J10"BLZZ@&4*W.Y+_H&H'<U.Z&%9-^4X*3P6
MK&/^%@"\;DU6R8VQ)"\PY_G I$%'8X&WO=X%2FU#<ZR9 WJ>5@I#(LV'$%%]
M]E7$CSMI4#E0E-R<FSV*YC0; ZBXK$!D6M_0JO'F,+E%2FXVH<"<_HM3%F0%
M'9,R-S!OP%/_)FU*;-/(TT47C-1QO#J:KVM+NCJ69CIJ723IU$QW6?=VX4M!
M5GE+@+HLX%.K0G6<$45M YA^92Z]=L$JM6NQ&*3'+./CM>]%91F,D\28_L[D
M)T+6XN*E%LECJJ_0$P#U;H)(=T[LQYFKO@B"1JT+ I;\U,*0F2[Y8 MQA*%N
M/G.\S#NXL@:QQ7+)N6LEGP\S/%GRYQ]F.T<R"AP_9:LUMO"]J(GYB":$+(2A
M6*7HI>Y%%YA7M$45R\M+A>2K#T:0GSKG80!=9^U,'UPR1;IEKZ)YFE/7!O#3
MS_Q83#%<@6\U'LPBW.]-U4LI*+%I%5E-B;"N-K)NTMH>#\6(H(]!P?S0>&"P
M+>9:=AY8NX[)?=P5>C\?Y(91YLA=:31W]&MWLREHM(\K3^:##NU[=01RBI9Q
M1I[?ME1U#;$-9'0PYOE\/E*1J@C_N:U9K-..^EHY[/,5V&E@<C#QS9D!O- $
M*9[->KU'Z%6E_Z4T; C,>KK#-T_Z07I$SMJLK2M$LJ&"M1DY?C -CE^\=#E+
M/D&!_91Q$W^*Y9H_=ZZ:Q5@Y6+LK95W9U#5*0'?R4[NZI#2"%-.;O&^HF:=+
M7/J?H=23&V#"G(JH\FD7BRVR+CSID&F3YN8F'P_)B_T1C%?4E@((=+',Z:V/
MZ?4")C/4C?-NY1B&&O)*1)J1"'!\-V7<%_EU]18%)C=IJ:X6RG/7@ E2BI(0
M&,VB9UN__ZN)"NY577W)G)-4P>B;/)9LX-<[-;FV_8]5%9_?PNWL1^ZQ=/+K
M>:8OBW=-LCKD3O/@O"B.9G,C$Z[<(LAA6!E\O=2S27L;0-"#&5";?@H5VE0P
MQFRLGTO\K5Q9JE2FL(?[T$+W7OTEP$0\1G9,V67425"E&XM*<8YA=F>V :-2
MW5YO63=Q0]+>H=9  K]&6H\__P-=Q+>Z;1=[Q4PF?.10^YQ3L<V'U)0E1VS/
M[-X/AA)7"U=MR_RTS>FRF[I[YI1>AC4#!_HLJ)PT 3I;'42]E/Q3PA_C%0I'
M158+;PCOOVKG?$KXF(+69/?Z%9PN3+(%;J7= 8&F?6G]QF2*9NJ*6==7LLS8
MP*IN9=S:Q\?,3#BD2N9>+MD(/K$^+@*C]@R3GQH/I]1J"3.=^ZA7O;FY08&?
M5;T_/U3(U6K$(5F+V[#B(> C]@2N^_?+%%)*X$9UE&!L"SC*&*1Y.ACFJ)SS
MZ;8JG;N.Y.J"$7<0:S MD%8P:S$:*P35)/3=QVG_-YZA^]LI99LB$JY*5.]#
M#ROK#\Y9S_$>-#7K(EWHVPLQ/.!VW-X4-M+X\U=FR6Q TYLBML%8Z]'7ASP^
M(J*WRM-L9K%3O-,%K9[I6HH2828[ ]_-,0$D/73I4V"47BNH]I8][8?9Z_+C
M924J54,-Y2G%MW2$\PHO!Q+//N")3M)]8>8@<9#H+D3V"&JWWU*2W#*.$&:L
M6K*ZJ,HRLR_M]\L7[C>]W$G6FC-A%+72^1(8BL",\_6SDI+E32AH+K#$,UBS
M?1HJWHH=PQ2J]$F$=6WJ2,(UI2KE!/L078E:XR)FV: 85-SH3^'+E[JY;$0
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MC,DSWY:*Q,A37>G3$GNCODJ!W.<F.]JEXBFUP;2F6/]#ABJ.HM?./<;^CT^
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M65B-5_E+ =6JV"0Z*XR6A*2G:+)=K!CBO+!\J.=6G.$POE>O]9F.21^ ]RZ
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MP)/^+0P?A)+A\H/7CH25E/E-"8>_'?\?PKX[KJEF^?L@342*]!ZD"(J ]$Y
MI$L7D*Z"TD% >@E%:=(14!"" @)2HM(4 J$7D2:]0T*OB;0 (7G1Y[G/[][[
M>]_/^V<F>\[LSIZ9_<[L[@Q,NG>%-.^1M]C@C:7@0UAA"^N =Y"9;X:4YY-G
MR[\Z>M\@,VIKME=]BQ"5J)+W\2M*X?_?(MKO&M[DJ_0FK'*,&FQ30"9Q)8Q]
M;$(*I[?M#B$WP-7\!,#Q5[Z(TY#%_!0= :@Z-CI[)_H>?X_T_]GH1'19\_ Y
M8NN_V^S;?0__5J#N"''2Q0_\9Q,-.W5<"7XH:PARX\)*(F/N.8M3< ;H+X:&
MS))>V;?(7?KQ@[\;_ ^WA2 3OLCK\6]X-6]X-[SB"%6ZD7SXO.GEGQZ>/PXX
M(1/,_/]B\Q=/%>NAYOT"XI]5B#^]2=ZF"&7^_2)D HU._U_LP=6/_^IG>+!1
M1%+&6U\*S:/_Y&D4_S\=^<\A68^W>\8S@2AQO+Y(O<>.[O)3KDX<EG?XTI\=
M79G^P)#:>6RBB!8/[!2DS*UAX<K(&]\38KSJ34&>K&.PS?I;\)39LERO'IWW
M[O&_]VZ!:^0W[4\/"OZ2YKF0SE\ _6N< O^2) >Q!GG1?XN7@T;GEM*?6?@M
MXL&_1)PDV+Q?OON'P3]O3")E^8?T9SXHLR7_37QKB PB'XW_Y]C_/S/>>_XX
M:$K\_-,XGX/W_WLT_S;E_ZN-QK_:Z$]MK[SFM2=QC# 79#4W(@#&B%VS4"<7
M\(;YIL5^3W"XI-'8[USHO^M-CE0;$FGKJ@,,1C_C <'W7T43(.PA$FBAV\-2
M$ ;..],NYNL?++L^W&]<^FDM+G$C=CCO-JB+N!'PKS9_A>,[^Q!R!5/<GIT5
M4TT^NBTU3>D S](;VW]3+G!+PIV.IYML>3;<:YBGT:[WJ8K@Y'Y+'S%=_,4;
M3YNCUC0$']QQ.[7(4.4K&7 ;Y'[_#?0"Q% -2E2FBNK@8DK;6-7*1@8[!.?X
M1>NAN^W3;P0"MV25-F&"TY';#[JP.GLJ%-H_W]H_=F-X+)#/6W$Y 1IH 9EC
MR2=A\'^?,'C!*-MZ2(7L3YVY]^F-@#!YMH0Z0 8W/^PA .D!XP1@B[< LC[7
MW_CQWVE7_]#"E;YX'OPB $WS/X:=SU$,+.OL$/\DYV^/]Y(.8#?V.[ 4+Y2-
MC<"(MD(O[3.-P1\B.<%MV8;ND:N&KS4X$?4%93)?(IV(B]Y_ \= &''L&$_-
M=%.T8USU/-W$G1;^+(.W<B]BN\UM62DXPIN?U,.3E)R(@HRF"O*0"DY\V>97
M.M@DD[:'[EW0/@&$)%KS;@[A?!;[P':#4BQ2H>R&+_NK&VOEDAQZ6(U54-S)
MK>%2:QW$Y$G?*IG&475M.;M<X,@*G%=^'[+#AW4(A5#S6KF\<DLB$D4N2+V8
M](IHUNA^F#1F( ;/$>"-LL-H5+B_<ZK=BI,ZF&9,DO:[%)Y"8\9-4^$#IB$
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MQ(>V&/*XE3JHJ?V[=6-0-M)IX/7<][RF[7A@@WQ[$6-NT'5HG@@W6W(_P]?
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M5](+!MX;4^T^HK3S<0)7=6UAWME4X*ZL]; U_^H-97Y9X?%SDES S4W;0SR
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MG'WX1P^EB">RYU[7.)(_K/>\.[S@I1$8>,MY!+QO6G/!<?K<^2&)LQ4^=2
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M=FAOB:!0I!!MA]!SBDVH<WY?"<XB_9ZPE!+,I2EUE)44QNR,J!K?ZH(@)]G
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M5@9\AX0#U$$."&1&BRWN1N"8['<%<#F(N<JJ@FK.*NE>1M;(XKO'Y0/E47@
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M*AX6F"6]P'"-YQJO3J&T=E(P"#5EZ *4YK[R%@7W^WRL6\;E0"Z4_Q)3:Y#
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M]<?88CFPG M=ZLO6ZXI^@BE%/7'R"NXD0ZTT!)NIM7@ ;8"*JZ#02X:MZ@)
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M1UMNDZ&SCX*I[==]BQWIZ*\1# =(6%D''9%5TO:QWK5V(-BRN-F(,4<A[,!
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M!N,+')[B$UHV57!RZMX!MFZ!9HE%NK.Q!U/\8);L$^M>K IP1^2'S@P?HD%
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MK>]=XE=HGAXAMDE,I$FDVIB<D+]-_K2/UZ#6.D+.>[#X5LE )2<><(OO;A*
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MK":B(:QO1>EFNM=[\ SOU:DL:;&WUI]9UIB,QXR,9%R21L,L%$<4!K+M*?$
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M$*GWO+BH,<TU,GI6SJ4Q+&.F:>WD4B?M_,9NA?A6,/-!6%[)G+[W;_\"*N5
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M7,'SKT)6+8]3$3@M,.>'PBMA ;2[JQ?I>YM?Z8]R!L$OY.XU=8 'EX6PAG=
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M&<Z?X#83&1:[1Z,&2UZ^;506 F(Z]2FX6[H]!;B/V6)-=>^LNJ5#N?U(UI#
M0M*Z:$26]O@6'/RK =#B>ML0L'A>UWLK;UQW5]PLC+JU/- :%RR6,GPG?D;Q
M;<QY]B:#5&=[./O&"C&6$MD]T@XB%)8R)^I@W1._I5+#VC8L/KXE[8!8?\A.
M11 [A?AXR>;XYZDFKF7CS]YMW6>I03@\/&_.VB-OBU3AG*E1Q]C8N5[F*@%!
M[O@2YSWK8XLTKH@A%?9;,D$(WEC8N)\H=-_8D"2*^FNI(&7/=<T7$VA;]F=Q
MU<DU!?N39Z<(G#N8[^LZ7]\6%"^%^369LS?R/K$RF4-I(0AZ6M@;Q(<,3(1.
MQJU/[-M-D%$^+><),X*>'J:3=\L8@'<_'3F!X.>\MS)RZWEWV,9XVV-__O\3
MB@WJ<)U(1$\+M7O<//4J3RBDV*-_0'72'3>J-J=FXO*CIKRD0H-GA2BCBXO]
MO.OK]=\_J]Z!(7/V' 3>_YC2P^OLS7PX?L2WE_.T0-805:5ZCTSV5^XG\A#&
M7)I1>;1<&RN_1_>$BZ&'Q2W?:U+V'7R6Z',;VA70=$]3<\5;\\L0T(&UR1U+
M6@NC':4-OW+0[HNG4CKNJR!@J&AIMH\UNCYY:0&<::OTX.8U 5YB#?09H?;>
M+(.G4)BKA'68XSFNG#][JN7/P@/1FE?5 BM+AJB&-QQL#?387IA@$A-%Z[7O
M. X>V^_Q??-#:&O9:Z/IL!K*KG7FZ-%!;XL-NGUR1 ,8(X15>K,73;_@B9!S
MSA$Y]QX 2&!_9K0&@055;:-UG'C5\H77G324Q?>5Q*Q 9Z=+#EK02&DQX%>P
M1C\+,9H\JV6#T6[5Y2O,JN?MJ%-P:Z9'-@"+ <D-D/OF=GK\@]#MB$;)_)WJ
M@\RO,:\/?PON>3K'^=Q@!,CLQ>LJ.V1U"<=4<!#=9=M_+INP.81?EK+#V&*7
MA2;9FJ8M_<VNVA:=2%^(TTZ&!)UE$J:G7FA ,>N<:*>3W?.?4L=K^U*O*TI+
M;!4N(OI,S..H/&.%\U.E%#W(W?9'PU9GQO2=@H1-JA3VK1U(<1HTE+9LH$T!
MVZ^G'D4W\D+V?8F;*2K'>'Z:1^]Y.H;0>J& [T'IP'!753\V$O'..PD[$2SN
MQIPJ@WU-B87\(%O4H&1OD;)?2,!LR3]MH#/ED3-:$EO&3^#+6=_3M&O)==6#
M%MCVNOO>2(GQ[J.'A5:<8KR=[Y^K_G#8/W*Q3ZJ^G[0";C6L\/JR2B;ZF[-F
M%HY&L;"A-R]5/XINS1^O&TJ0#?!I!NOJ$_+[:S5KC53;SV[<Q9Q];5"5 5/8
M>0Y#^%,?]'>>;93MV6?00U5!$8X;RJZ9"P5'3I3A$Z$EA>WW[-+I6L$6:,Z
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M3-VFP2*R'Y0#GB8=M]<Z0\L,L*FMNJ*O7_P6HG0WWER\A2N3BL@Z2M"=?3W
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M1FJ>QHTW:[<\1](F;+*;;6FF=35L8X:F[CT'$!FO$K-&C>A>UYW[H4633+=
MLK3_:(X'@P,\V58073;# >XX2?%E&9ALBJ0I'I8@IBN5UC@3'VZLO_8&D(XC
M(9U)<BH!I0?OE,Q>R^JQ#XG\VL'GO#RO#;1J$WE69JZAWK&'R/V)HEFU+PT0
M,6T$OAU$$;:.@E,,[C/]![H UL8_J:7]672@,HKYT>M\S3$7+R0#Y$.F7FL(
MWM'<O<@__8I*3%J&1(DM;&<]'?T*K]A-)&EJ )QKU8\PBRJ&3?>R5;-CNY'U
MB8$&P:F#-SA"FA+@'QX]V<@YYS\?(=Y.PE"O6,J?VHY]-FX!SYJ.&'*G*BT*
M\6\)U1[V8*COOVV\2@SD%F>NR8XLV5 J.GUTY;P=W+H]U:4(9\X>__,RS_OK
M#Q%/T[= U/Z?Q47PV'\6M$_#IOY4)GV,NL@&1*_'4FZH.MK(0ZC [4;>!E\"
MN=$>)?$$;JL,+ZI'H#-%Y!"7@MAS\*DQ.JLXD!^U& :M#8!]+_I8]@)M>-7[
M*\Y6]M?7GJM,D0;ND>E1-J3Q+KA3R5<6Q([^LR+>"9VT3'[Z8=7OY;AD@)5D
M?8S$*/-[1JL@M^@"]E,[%::-J2^9P4F!QLB"G#OH'O]^=BT0U4S%MMPGG@;E
M.^;@%JE:]V"NR;61]02=+5-EFCN:Q,Q'V8?:U*MT]:ODXD^10S /@391I/Y5
MW-X;ZKH+P*^87Q??K31/ --E6X+T\5[O-U*72*ZQ?*=*I1!1.>8HHI2EC6<I
M6/)_'[&W]>AVDY#1(0('N'\6V?*(:R5+Y'YJFV5&#<NBOK]W9?>!7EW*8,+$
M?5_(ZV 3751]%7&\=Z5]YUVQ&?AM)IW5@8_B]2PR!Z9G=,DZ%G[40GTD7$@5
MPIS/BAZFK<\_;'3K4&8+#=07S "CO&6.&:6UK#RH044Z[NX$ \E5BN-OGYT9
M8 <=FM691!YSV3 O5RTF>FH))2_<1UJW07BTU;JN\GXN KYNG?D!.^9*AW6[
M/[A)F*8;2GLT:FR$<G=U7A/Y(26Z+1=,FRY,WXM5#W[P*UK]=F:SUC1L^(B1
MXW9\66S#$*,:P7"]A[&%$$H5$MXB[5>RR+"W&LI 8I]F+[.ON>3QZ=)P5QIB
M*RZUX^5(\.([._NU-R08&"D:=#J+'L-RCRUVRMW:49"BOR]H5=%N129R3E.O
MS'3=>R_QI*[G0^-<(-%X)<SU *%$1H8#U/8CASNV$1%CXK>S4C>H(EG"6>,F
M>+A+H5-7W!K5(\<[SDSRQBZ"+B/J-"+LCU69 0#H,!N:BZ)P&1J)I9T,%"]_
M$2?,M%,/1%Q;6(HP$9P$)-C8=$H+=%'XT5ZP@"M-'-]VKYRN,VD0/W LN)F/
M>I \S'V5UT: P#@C$_:*(.4+:*.N4&E3Y[OF!]?+.O-^UB1L^M_V8RE'0D_#
MT8YE@4+HT*\.3;67EO,J7C9^E5SS"E&N)N_O@(@Y.(]"G"]XXHS&]RL,]_FC
MN4,J#9^GF'CL>L9BWERU!7(4![JB.U<M&= />ONODAR(ENL((C9#RC3=17^]
MD=FFE[AY! V%,>XI:"YO*@A7S@F8#GZC,C'ON_$@VNMICC3E-.T^@JVCU7_[
MYKY <E.?.TOZ/D<BNH=Y>D/B3FU+J8"K_N.7O=ON*L3LX9:O XGQMY%0X:CC
M\A=L/75GTKRN>1(3%09^?')N.HT7NN);;(3!P_1B@\S9I71HH A_N[D7(">X
M[63_@KASGK[3T[2A-KXW5\!(_('IO9$]ML[Q;] '2.!> #(?/@NOC]MS*2!4
MTIXY9 @BM(G=/U"2"U0<718W1U>K)]X@RGP4&,7\]KQD@A*4$OE,R)AP(.0E
MZR>L9 ?F!1J:%RB"=/VR0OYFBST,H?@[M#W]5%<^U5W4@A ECB5E0TYWZ&I1
MQ'D+Q[@9[0MFIW[85>@,31J"*6'EL6,6 NBSLACOF(C*-.K]NG%\B&?$>,*-
M_KAX6.S!/ V'QF1GP0]8G7*X)GX)9.FS\;&.P"$9Q"/!C="\-N)V[HA@UM8$
M5":Y')RBNO1'I]UE#,U7LYCNM^KG]&=0>C0W<EW0\2#0["L<0K$9_]6:/2W
M$P<06-);Y&;$-$]# S6#U/K;Z2Z>=?U<&69X(?BQK)*.X2PI1?U%;JKX+JCP
M7C8.\.UJ" = '"VAWW2O8X.TC-ZSY@^%V<8I77(08XDL:V(;0!VP.T"KO8>*
MZJ<72 -E']-V3V]'MV&-O.I,"8Q((\;Y=,T=EG58]EBQZXO_D2I?3E#97R]3
M"__K96JN=Z7E?S^VU)6;.&&BST8'8$G1 Y!JBM@^N+EOV? MN? U\Z7IN;\6
M;5U"9L+5@"<2^%QO,R[;Q8',<PE"@,X\I63<EBLL5V-[7E.'HKD=@0-8O*';
MEI!9VA@@WK*P1>$ /\B0ERNJ5ZTYX*H3@"2+8A(&E;8^"SG5,4+2.B\/QW+'
M/:S[3*CIN6R6YBL5=%0\]-"<_52=#SN+:,L'SZR $(\>3K7P.I?.0)@V3Q\9
M(V/$B+1UX+U'+^VX(\VABM^+OT@2L0&#!Q=KYA?;Y1OW),D"$LQ4/D_"RS0(
MZ@,Q8^R*O5A6@AW+/ @Y5LGWT4IAM M9EZ&/$=&UC_K+W,Q>HG5,B>K78.PG
M%7<O.YMJ][-*$5I6)3,ZIV=2U:4F]U,T;WV5OZU2-J(M^/6GA)B"P;V^GTRT
MMDI=;W@8+WVXQF8:KT8%1#3>@(44%<OD^\\^/*-?V+X)<*?/Z2R>@G$%RE[J
M8 R0-:*/;%9=M+^\<TF4KS.+T-M;O^:<#SF=1L,4K,RZ1L,H?"KB[U6?S"JS
M%8V],%>E_]#Z*24\?!&UA4\NH%+H)-1B.^R6((/3Q0#=]#TMKI:GK]Y?WJ<
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M4KC'DF+>]Z%\W,$MYZQE%\1LEYQ$ROM"=AG+!4#\+R O^; >HM$MRI+XH(T
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MJS.E=6#-]4IAG I)![+'E<46J-KCL-F>'$'5%YHKPQ$2DN:J#,37MJ:Q?E\
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M9>&7MT27>]!!O//0TAJLMT?LF#@OE2Q.M^2"+Y82NJ@FC<A.H+*7$N%)@CC
M03B6AL#3$G7CR\IGTR#0LZ: YI]#%NJ[\GR)L;GN@"72X3W]H!S+\W4<X*P]
M=[8?!U"8PP%^D ."%_&^1 2X-J# A@-8-F7]5?9JUX9/*<.L6&!5D'>W?YM;
M.)D8M+-MO3&:E'2(Y%WYL_W;O#,_\U3%O^LY%6GT-*Q,Z"U12!S X,_C1!R
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MWD5<!+88UC+D_;!#H&W4JCYSUXT>[_BER=M&#G%Z]-@]OVZ8_(.!\%J\7JR
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MVH@*-%EB 8$"SMU.8!3S@R6M78DK)IC//QNH(SI=?IQ66G:,D'S\<>AHX'2
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M5AY\0"2\K!84 0"0/B4U'\UQ(!!5XP69BO$0B/!ZY*3K*0-VMDSE["^R<("
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MXV'N^B>K@40%/Y(7?_X_;/UE5%M=U_8/AT)+*5:\N!8I5MP)E.*E0 77XJ1
M<2>X.P6*NQ4)[N[N[NZ2H %"^'.>UW7?S_.\X_V4,=88>^SU8<WY.XZYYMRQ
MVT^D _R0H:&(&Z"6 &K=M5W_G*U^,&J''DQ8*2YA4#(%KQ,O]\0C_:E:I[$V
M(4 SS;?-Q..8'Z=PJ9PFF?1_N:?.Q<#/-KZUXLYN33DFD#8\/S[;HE! -Z6,
M@A10U=RAV^1W]^/T"%Y"DMM VDWLVJI09,2/(O;5-(%%ZVVI#*;A=\'^=QE_
MML95T$=J#Y%$%\3?9&)^/2OOE=\'F8YU==Z-Y"7(@C*_YQG8$:9+]$VVB!PO
M$J;SI72=&-HX%\GYJI,PDYLSO_*YI'A04J,B.;?><7? 6_S3.O4.AUOK?3'<
M5@IUC#<%(V<FH)&MC'I'DO9@#%+JI"48.1 2HN6*0Y2K!Q"[AHW\7#U0LUW@
MG2WG'F)+__9E+R9F% @ "\^43ZHM3GP%]*L7'FF"A/@FJ**:@@I(&5+SREI(
M"M*B[!]"SZR8:F!J2;LGK>XSC1\3@\P1Y4%'U3Y35:_N>@?[K*?"0Q&'4/&_
MJ]0P'1*NE1%#VUVV7RO:K7-1; +V!^%[-*%WF-_AL"<]TDJ5+)<A/4TGS4ZT
M,E(2?.]N_4U$OL\VU-:MOHIL(CR'K/JR]6AL:.@KZ/I0E\&#>NKD#,OL2XI6
M+3$J4/Q7IXZ[J_%>G0*B"188CJ2&$5V%92ES2'P#5\K(7D \8<K=[*#-N6YW
M$7T"D)VE.D<)G;,J=DMV';0W)X#=F]M5;(RH ^$./9Y-7HZ3Q^%@]Y=G+7AG
MQ!H ] %X\67UN_*ZC'B=@#O$ H%&-H'Z5UL"R-]#^OX#ONZ>K#=F2(RS1P"C
M#;0/V?QT:">3++(U+V7=A+)#FPA^94Y(9'?\R@YE+I\28CW[;WX$_Y,?U]RV
M(>#M$O.V:]36IZ?"+(\L /;R"N:7/2*O-C2]6*EA"J",:]R&1\"$DE8:B+4'
M?/[NZ(G;F9YCR%!+-3*SB\]N*-*HF5<YDYD5N>[JKM"Y#3T(C$#;[].DP\ 5
MZX',!H713@2X>:^\! * *^B3'.%+-,M:V;P=BMOW$X1,M,&9:L-R)*&/@&X2
M_B+"Y([I9,PDP0LTA9PA_0*&!_E,W#^.P/E[G?.1M%QV\<*P.((EUU\$^PQC
M6D^/X'MPSC2+%>M:U#E5+APZ;=_6JJ/BI/M3;Z)7$-V;WVDKTIMP%Z1+>SPE
MX^<OQZOG$=_7S4N?Y=>>MRTR! 7="QF_HKBS9J+^*D&-#S<LN<0<J[%\-[PO
MJ=$9-[Z74>JL%158(]*&;>G%K)FK%LG,@<:5RB8C:U^UAL+M53,+7^LD>QO0
MVY"OV[C<FN0VUSE)4.M4U\FH:)2)SN#V2KOMR2MVZC,%;,7JPV6W\>4=&<7U
MV6E0[)<"XZ(*,V53=8X6U4-XZU*^E>/K,M^2,<UWWXQ1CGYF;8-KKC>)?56!
M(H2[^DP*UO0ZK(/;WF6+>/>MU.[%+8>*RD,C^^1FF_DL"JJ40,X4^4:TSV]H
MGU?*ECI4:3),+60OW:I^).JVI?C9]0QPLUF9XO[QLGRZR.YO3:WU[(,G/D)Y
M(@,/SM3I+$X<UL5CSL]CKI(9PJ9%N_,7LM)^['DW%X8P@LMNZ)IM1&9E]>1J
M+2PN+@V(_?%Y]H?A^UM-9=7^;><RSD[JFNIDLB7S5=Z*QNDR]/[DVA3J/V\I
MPV,BOS>BAD>R\FSVG;PU F=:\C<2Q5^P5?S)G^8T,*</?M_Q'3W!#A> (YP\
MR7' $YA+*32(FU,!)0EV$'+(#[5A#VB^750V/66E9@B]D_H&1<9O*@<('$?@
M+FZTAJ[HTZ/B7?CM8^Q-MKI-7S9<:M^6<FRR\'[Z_AN6;&KR75"4[ 'ZX&O[
M",!RA58A.Y@> 3(#^N%:7G'06MCK9?U#+:^>N@0)QHLP7'8L&.2T;ZPE3;UN
M(/DAYR&0)G#N6@5N\[RE<V6IIZ!15O@96BA3-"O E?2-8)9E1_K9W82?])M2
M-NFNQ5 NR:=HRBEP8W[ZH625?6*_RMI9QC:K<+7#VA4V\N:2"-=NMJ?QGQZE
M"I--]7\H\W]J!XO,O/%9?QH(36,C?[_P]5/5H]#Z+UABLYLW1\'Z[&TQF;B[
MD">Z1P?L/3@]0>8#WR1<N\L\@81L-3/GN#R#XZ4V4GM8DE;<^]FP.\JAM(4+
M23MZ3_)UCJTC;<WD\7 BB3JY?05J*LKAL(OJD5[\9MN+_E:<(,WZ4#%A#/WC
M._%([]CR6*SPO:9Z5'OJ K?A\4W$NW0L*W25!MC;X[8EYY1F/\+/TH6'N08&
M! <'/<Y '%%1]I\.^@1+J\L+VLL#UZ36/[<7QY7"LZQS+ PDU=[<!KC<_W4]
MCJV=GXY>U<#!N$9^/]%'0;ZQO/N=?% SK>L!M//E6W;N$#FE$+YZ<]P5+>NA
M@EZ^ @S?F:+D\-"!:8K05<_6<O4)9ZW7(F*B;=-90V'Z_NP.RH'\B?PPGN6Q
MHC[VY4JN6$UCW2VVO;A!9,T^-8XC7KXE"1463.%]_?;2\![=QX,N, DE]@^7
M3M+C9J%-S]>#5)Z,IR+^S]T*'5?N*!X![86H@UY,GL7MX.J(U0J<1-$$_HJE
M#Q>WKJJM;U6680=]-8XW=IB:D-)711%63@-^<>>#$GV[0&'86@0UL8?TIC[5
MT82B$UTMR;,7(80>O9S19N=\,QXBLYP>6IN*\19KQW@]3?DW%N2[0-]Q]$R7
MLD%2!W+-TADUP=2$CU]P9+C!.FK?FY=^-L\:# /><:7"VDOOJZD7;KBU,RZ!
MG,8)Q\[<9O Y\30YOF$]O3?52^9?^"*:)QJ:WOG,,16@\H4FLJ4]*$M/I3/&
M"SQW:EF;\<J6RM%SB11D/Z9EW+P*MZVBL%H/-#H6XKMD"NY-RW'Y(:(KL\%6
M/>3^:7EE=![S%2.FIV8YX! TAJ0^NL,-0+ *!-=X#-'86QF9IRIR1PZ*:<3$
MG9RI(;2S.;L]N;)G;$KSIB%&FE;5/LSG)R]<S%#/R@^F4#/WD@N98.+Y@B%]
M*0M=&Y'ID&)Q52H6=UW@-U]*?LP0/HQ%38Y\4QRBS_0OT27012_B]#+L/<TV
MQX+22>8@)O)J%\,3-85C[%0X:&W!BWU3UK):.^)OX6Y;G8W3L_@+F/8O<;&"
M!; S\=8JD*&>(/=UM1B+S9 :)<I3/)J9'W0SI+*G9>-G@(=O[_N\XK-Z78 A
M"#[G#=S7>A8"(;4@LW;K298=#>H/0I!E()SIB5OA_'"C1X >#_C@4\VM/0R\
MX;A;L[XW8Q22\G6<!ZM!/UWQ9]K?E1L9*<Y6E'UIKYPGOO8#*^JZ**AO;5.>
M3(5)OO]8-H^,]%MV3>$7YKD]["38SZ*TF FQ*>+/$/$1),AVY[4[52M=:]#_
M<2,X-_]Q(YF?F(_D0YFG>8DK$4]I@*[L:3\&]QD/A#-%FGILCX"8KSJ/@/)_
M42H!YGW"!:MR5RME$XRC@"@MV]I9M(J?2 (M5MD P) A^>WX)^.T]>3+UTT-
M  #/;*O/A-<;_7VWSUD;+8P3G'P+[.(SI3IQ]TWDO[*0P]H%28POSB3[[%7,
M?R (H=AC8:)?/7$BRB+0Y:J]N_B+&<<Y*,Y?LQK11CZIPD\/&<H12#)X)*5Z
M5W)I";U*NI+XAC6*NU!9CE%P;A]K$QHKKJH^G\Z"_#E;Z(Z9U0;#K3K#N<2!
MM\M8C7O&,4+4PLR]T$5\LI==7:+5[Z12>R#^O=+YK0WA?.? C=S HJ<LH[=X
M"TSYA!4&EAN7KX>J!66U+2,G[BV2>=(W;#-&FSDWU8-V&N NZ0(SCO(U)\Y?
M9TZ^'%Y++U8$F-()SE7ZW<[5>3# Q(*ZV>GNVY'LWHL@XI3H'I< XU[7+[BT
M0?IN%QDAJ\0SEV _)"OTF)DIY</TR>FPQ4VM:XIDWY92,$P_.*'1*^K^"WQQ
M]/ZD\F"RDZU.^X.)B'&@V/Q)^![Z])SBAM1#G"UDWZT[-D*<TI+/-5=%1V(P
M#Q7O6*+O,^LPPA 6U[W(4;4ER$Z#M[JR%E_?V(2RRAZ$0O]%D,(^UEXO UK5
M3>S%\0CP3W:UQJ<$?1%6&LG%GI27$[>+ZM!X>$XC3!V<F$QHDQ^!;U.]I)&$
MXEGOH/9&S.TBJIULZS+;>)I*(/S-S>L"H?Y#8)H1O-$% <YMNZ;*_W*A/)T;
MJ.&UM2'_1O"PH)!OU46VR]DI,1%DCXGWO,3X)RD[+?DWW.ZHP8;#5>&R@@K?
MT.(7^9=A7VY_/@(D'P&O/$B+X5%;TLG=L>PMV:YQ)Y_1,Y'?SA;-]"<@/VTF
M-\T\.3_5WU-F2RR EN;:?[J5F+_)\' +O6Q1U\G8R A:ASH'1A\"\3T4UIH3
M^%^Q&QF.7B-?DXA>W\7HB\'7ULORLG27!S8Q;\^DXYMNK5^:)ZAU_"A:T"QO
M6?+)L)JLE#LO$/CRV>X(LFI7EPZ$BJ47H+GQ)[EG[M?YL)^=<$0+0YND.XF8
ML!\V$!)QLU7B-'"A?_Z*](25;?FPD?4A^;*O/P'+:U=/V/?%\CVNUO9/MKAO
MTT93J82@H)'67Q)B'E7I"-NCR=; B68&)!8TRM]#Z4>LI=--=)J >K7#YJ[8
M\,NE>>_W8A,6T1[N]=M8>/HM;>7"6]?B< VW/85'P&*E^F90[R, M6>=,]AY
MT;%6?+!;B038OAPU'OI0^> +W!YM??+"\T]>?W\NWR?]-D;Z+9&Q.3OA[VI+
MLA?F(V_943)Q0+*?_D<!"*I%IB"SVM: D_^TN=7]V^;&NW9$_;"ES1<A</?T
MIB?M+ PP9:8+G]!*>L'<0VCJ7?\CIUYE]@)U/,?8ZT7NB*S]2'47,JD-Z6OQ
M'O@&26J>H \M*4M?^9Y^?7ZP1V.&31Y=#']6<%[RM'L_S3C%ILG+%*6) &46
M)]O@:T0[U<*MM/(]_^>[1/^K%'3:4!!-X1BU<"K2':C0_9!+)YS17?P1*[C(
M<ELDG9Q<EGJOL&1$F15Z%K +XV@RS#]PJM*M6?HA2$!^=XZQ#N":R_.,]J*&
M=%&C:H-_'M7]:E9 <W/RX^[,BOIPOA[KMGVO_L<#!5H:Y%>MZ]Z-[>+WK:5:
M45>8.([#SEF15F_92@6\^G=Q+[0,.<>>U]7<:=PWO-"!/NE#>5V4I[1%C7+H
M-AKT5U]7WUS;1BDP?X WY#6M9E;]=[5]B7?M?NDKLFGP@DV[P]>2A;U9G.%V
MB[K:#0OTVUB!Z-$+7YKO2MV>B+ZB),J2>S@W2BSK;E-98NVEB14Q#O7281DC
MVGT$O$:@9.NY!+I8TRJ);WV)5'ZG+EK<Z_,[ <G&TB[6R>DQCC[BQ31US"&J
M"G:U+\I5U5-\N_DZ(#4W7%=&1$ ,VRD#W8NYRV@S0N!CRF>9*=,E:ZKW'N<R
M3G%^?@.B[G=S,99.DXN' JJ#0PPQ@_VC+6]\9;Q2U1)]>KK3N2=FQW&KPWX;
MTT=*]@/S )Y&G*'53;JHWPUY QGPT7'Q)'[A /K[+R'T4XY#;:_ES5XM#=B=
MT&EWF%BGI&LJ ]S3ER][7!^"0B"7^V4.)TJF:97[[&N^L51[#337=W.SP,JV
MSE*I7N%H*XX)#L-*EI?M7:,Z46+Q;?XQ]6:%WST<"9.5'4!D<;Z6' .GSLE,
MQQMH>A15,/4P-3%CBUJ;ULYYPO(:NP[5+RKV/&7:7B\F^_PZRJA[A:,"FZ7)
M%P<V.'$7NG.&(A4Q]:MTF PZO]%678UX8FP] D)0%>!6FX^ EQIOM'I7ST44
M+8('(HQLTM\\J,H9UE^,BIBV?JQ+.0&;Q_PAP9%#/_K4OR5JG[5L[A80GU_D
M;N^>J=>W,[^F QQ#1>T4H<(1(BVS[W(;3J> 2<0"N2<PRW9E5JISGE6RW/F<
M^.GUE&HL(3Y /:^#"G5<L6B-#!2L,6RCO]5EITO>S?GS':WLKQF OH)*#IXW
M+VB<#^((C5%0_/#),+"P>@1@J"<5]CG21&F%8ZS_>58A_J$RZI.5-:[!2TA+
MFS$N-KB3\E[8!2B]5*WY=E@"I^OD2\P=&>(,+END!:)Z.<E4Z9HFG;MJKU.&
MD?R^J>F^J']4$C+5YG-(LB$;1 X@J>-^+::Y$'617T<@DFHKPYP)T](8Y@K]
MY#X)DR5\WADJK"H'LH]MV=OL#7LBOLC: W-M6=V;,H4;I,*_*ZS_KE13N[U^
MGQT^\4E24X]5=Y5HMM<6Z6/_",A.KO%DY?S':H/ __7><N8(H8?89B(+1[&;
M4$Y# L:42A%'@Y<\K;]<D?M]FZ ECP^+X"YE7[?I,1_GDMN;1*QNDAA4 PYE
MIQ_ LQP]Z7OZPTU]+)<XY674;ICN<[&7 +\'UHJ'$H[M6JA>7($T>?64Y//R
M<,X'?E.;OAO'I*SS*P2D6/[MO:AJ<<P?E;3:0WM_P$4USM7U7CON2Y>F#FH<
MF1RBEJ" 2Y8L[88:,3O^^N13;O&O6*]D2 !&MJ0O6NW@/-"R.2UX7%Y9@QW!
MQQI<<.%2[+/?X=@Q_&Z)=B10RVL;8L3GIH0#XM,?UY&3$@9CIX/V 7V9;U#W
MF5''^3"U,T*@NI:+5'EF N'5OWFTA*KYN74^BI_S!#F:[.48E-F]W*W'I42X
MQ1Z.\#F%#<Q$--=J!;3^&NVB=G%8:9  JEC:^)/=[3^]-JGVN3S11\]?\^1@
MLJ(M2$"M/EY.PTS>^;$UM+;5U>JOE-\.SY:OBC?/M"^Z)9K'V*:?_98^\2&2
M=@9B=:E(J74.@EJ?OPD$;TC&>OV!2,#I8?2="4B6Q$_)BYO,>NRP0_SRE49"
M6@V N')T>=^>'N:FAFG-',1JMRGT*C.ZD\FGCOX=E#_C\SML1O*!TV$GA1.N
MB%'ZHVH6-C"-.>KADUMUL6\7?P5C2&>;;/YJ[YJ7/<"[:/+0\-VU%B_BX>7
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M]L\C6P)"(1VT'J/^3R86D_J8^H7VP5\\*B8!_(U?=E[[8^4/(%R-Z5-1R<(
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M[(]'RI#3IK0)D,,ISB\\= HVUZ5=BMIWOC_K&MMCRY=;\OYY!7G</^=-CCK
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M3"FKDK!"9Z5DM?F92+=2FBS^MU,Y37A$Y'QGZH5F;!_:HLZ4"'M)PJ=/9<<
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MM$T/04.]I9D@[(GZ&?X(V+74HI?,AP]_G-(Y:%A,/.5*]!-%%XTC%=UBG:U
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M(X/S5W7R+1+?"3HGF'AD$:\R[R>;')2M+QU_*)=]*L[!"^+Q/2Y?KS6@8P'
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M[TDN(1ZOS:G%N.D0@6OFZ6)8<9KMBBQU?R"%ZUX[\_O53TAM6C4^ /:RQ,:
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M@+X,I,D1\!F).+S+!X2P/@K(3$AH'C?G,A;^VMB #96$9QF;H_B.@!2[&T=
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MTI+0$,M&-A-HAVUF[9QMG]HCB2C%[ILX.*AP_S9X7*_IE;9FG?64!M-SNDQ
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MS9*('R9\Z@B>&)E.O$GE8#97;?T5WX(59-OW"L^+ASY2=J!?MA/=V);2$&O
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MXQ64=E;43.E7YZ-'WTS-CC1=(!APSE##=@FHJ%F1'WYZ&F^*%'0U(R[],SD
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M U:F]A.<$=,6Q4B5P>8SYP<RM#/"'_$:Q"VYY=KSE%&WNL(RDR<CYN*U*O+
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M9\1(?%-O6[PZ)Z:A_HJ4()S$%/.\L8?/1E2TNAS#_WP.B77AHKXHQY)F5C4
MV57>T]KHS44@PK(4J4G"QKP7\L(UR#B\-Y8S$>Y 79%7W,/++H"._A*E/+Z"
MJV^^\#Y29Z.JEF'$QHE5OKVUC<VIQ4QL+G!W#WNU'"*[RD5[A?M<>"06)L"I
M->Z)KL9W-E%COI>2IH@69]7G'])/#\5^76TL@GR+U&L@FJ;[O84?X8&>F$#,
M3B<G39T,+"0+=C]%U2654*.LM*%J#]<4.'S4_#V??]CME8+_ZJ =IUOE/Y@@
M?23R-A,DPG7QLO5&W^=*KJE4DK!K=;0;U+,;TP@H@?F&L)=>TZ PV]'_]:>@
M1F812NX'9\_NXRF+TZ_-TW,RXR_)&$8<D:CR$GWLX%(\FK<M8?*/F?+:?3D(
M;;%B6_ :-8"E4'GR-Z J-F.C(YL0SY&U0_X#%Z>\]L%UA>_H1QE?FKTE_HH2
M=]AE4< ;,Y[%'5%=_<4*0)XO1SZF)@3=S;:F*X2$Q>0HS"E,Z?:\^<;NA.99
MUX/=>_3Y/>:H+_-DI]/YD>VIJ5>@^5S[H5TTZ9K&I$?GBL[4-O20PSGPU6")
MF^JSA#?1LEO"EBQ.$&5*1]6E^Q:,TO6+G4]=O.+]7 7[Z91XS[*A%*8#.]FQ
MP/E4=12I0Y->H60.YA6LH 1'@#O!WT%:*V</@+8K+7H(M/56$&;BHT-ULF0H
MM@36Q@<A*1T E7>IEI3#C.IF-0ZK$F18M.6M%<]9N9%\K?W2YU_A([4'P!-(
M0VS&PP\FY,VV+>D# %,A]QHG$J%7S0IKO3UTD=(;PZ\+1IA"JO;>J/O,04_R
MCMTE>,#?)QXP0W)8DPKT.P2C]"PY3J7.H0QP*= >'!?:;RH^7QQI2X"*&8+X
MS4I^+8*D2>IJ-WX$;6-?&)QD_H.I9:Y@'*BVP@L8G'H:P>JLF3XT<9)W/X08
M:3 QA)XOQ@DVFQ("T1-3]F/LO!5>#24K_LQM_W2;N;^EACC/$Q<SDYE]+?(]
MMA^MO[Q(*^]*I->-, 6IN/:L(]:"*Y-QT1FW4;0;'QH3;AX K;*Z57-MX-/D
MI2S?A8ZY6@XF)$4H6M*16>C6(\E6%_#CD;X2.YSRB]JTH)&"$=K>Y*?B"1MO
M2*LV$H\GN^ZA_?RY\H3']YZXL^>V<-FF<A8'L5CP%2QH$GX U"O&,<<D&8G=
M&Q2U9/O=^&A?_Y''"&P>ZA1UN+/E'%XZJW-6#T=]$N GFB',V-GIGTAX;)'B
MN+#$KD?NT=J$D*[ZN':8,SXTGZ1,)?4%?[98KV1^;>62OZ_K<([.R2D=;L.Y
M>7?%Y-"_079]I0*6T;,>HR2:?&F8B&M'2](U26?(7?@X1]* M[OY(+++YJS#
MR/[V-E:,ND?FH6"I6Z2XSOQ#+8S\PF&UH++KHI\;1F0\DE7?*1B><RMGH^*;
M49/YJM2$,D03H;1],\Y%"<R-(\>,' !PO%M:X ]C@:A+(1S+]2"QKQ70#W-I
M>A'OT.W?2**=UGRE24%8]M4XRS0G_K7P5\G>\SAV.8]WRR/YM6S;'E%K)</-
MLF\GI[M=/T5]$_MY*=3N*!OD566YD>7_8?N]ZE]R;0O:8]GX?^8E"D A_ZUN
M]@#X6LVB8/A<Z#Y0>050^0FEG@*M>U0R^W"\F@](9:E006KJDF6X4V/A\<S!
MR^4/'H$.XQ"1'B/Y!?;X# *L[@!8*WZ+&L,=*R0M%8;M&U2X02>W^^UTG\;.
M7KV7\7+A\>GY2*.O-Z8XV']"J H-ZRL+V&2(H <UB'R("G_NXM@74.H-MG%P
M0[2%F,J*7R]8T#\JO.\!DV!VPDC79BY2KN-W0$*K$ON(PBX=OARG4.F&/P6U
M\9A751;N[F+B\VSIT;EI-3'_MT9"G4>W&:'A:4ESQ]#>( %$>#OSPFB@E<28
M$H=V\/,UDV_W<\->..NL>="<F*/@,Z3NSTPPZ16UC5?GBOR7T1TE0KBI\AF)
MS0PN#M[=59=JVFV6SVC0C6@F2)\Q9-"]A8ASYO4C(EHB6=K/+[ZYU6/S"-Z&
M]*,ISS*[T*#FF^LTFSM46)<%G/'&@P ]_OOZRI WNKVH[/7MW)^'A#_;</Z8
MA*V_H5U?=3$8:Q9^0!(TP73N:S7;VU/8;R6+N;YTUU;WU<[=/V1=B1REN3$G
M(+7+3YOO%3DAHL86",)]CIE6.N8XB^N$$/1[U^=0_<_XWC"-GLWX#]1O"X[6
M"> SU:-U)X6_+&$A\;[7EVZ/$"X_CYW^75B@>*B%V,C"G/ [J%&(QUBS/LVJ
MBZRU-F^^43*F?G]$H2;X1'-EN]?I"R3_X6(@&$JZXC=I1K3O]DL$GQ[6@Q/7
MS3J#M2?OA/!U12B03^R]^KH]CU_I1]Z@<3-;'?%K:0MI?/!)3)*J%G7GHG"M
MN8]:_MFG!NN=U=BZ,J @EYOE:>Q;RTSN!^0M4ZH7V6U>^.EO]:IM/SX38LXG
MX0^#4]U,1P_&UM+\ 3!\#A:Q<J&RI+'$X;?VN>+^C)^G_#D&<]^G?XZU W?R
MP?^$,[DY:9+4CBY,K7T<TKH"T=T>1(TF.J&/>V6N^$E+/)0/[FA2Y.1N]/G4
M)Z*_NAU \:9Z$36BYS@U04>H.7<:R,+,=/&&5.:,.'O[<1NISMQ(_^U#D?J7
M$I4*@&3\23]23H?(G. &4[JGY"VU_'>;YH3?X\?W[%2/7/ H-8@,LX<9%8 T
M&26ZC#RF_ $PWH0^ (HV[[ \P.4<[13]/[)(S7 FMQ_-&-$P;]]>$:ZOV&'G
MB(M#VON%%L)^BPI>^)*+%9'E+HQNO%KD0<MKVH*1+*&3Y[I8#(UO5K")U)\2
M%],,*>UX((+E_?X@W_6:\$OR;@B8-8IKSB$$G1BZ%9F]HT5K1//KAIY9@8FF
MMFC*F/Q+8#ID,\VJ9ZP).'U*)#.2>PN;#&5#<I$_3UF M7_,CRX,;F12)HJ^
M*O7U7C>3!P7]\G=),C?U9/^#ZYXCV662#H!U%0^O J]5C78IC>#7_@\_Q&0O
M/F:_H_#(WG<N0W>>SS\[K@-2V_ $[8X11 VAH#]JF^!-Z[!;PR\Z+JFX/NGJ
M+[QV^^>Q>(OC1MW6PMLAG9M4Q9#VRAN4)[#D[&F25\N)VI0=*0_C3"U+RZ2B
M#JZ9!#8W6=75M%=IIC(M* 8&"2>%4\JH.)HQE<?QA4]<ZLZ)\"]''!;XJVEZ
M5GS/51GXWN,5W?;1T5U ,*S&;/TD 4=5$GT29/UT3FS[TPZ4?RHZ0G*PVTV4
M7P64)XX>_?R3?5B: =\6[4!)#.N=+!CW_*R5ZQB<Y<;=Y@,_%&,^: H<:C:F
M&#%2]<[0Y*FFO_NN902A^>8:X>N^YI<LE*."30L5O=FF]!_#?RG_#QWP$SOI
M>0!TWV/^S[03%\RA]@E?-<&P5VM/G]Q'P9)WN_PF50AS*7IL\Y81QAV?CQ26
M35&#-N5EK!YV5E"R@-.3G]C]I/9ZOT6"QBZH###9Z6[#!GI(]4&D1W&;?)$.
M.5VM:/I+[3=_N8?A&=*)V]S_1I64_YZLRXPNGOGMF#$M(A%19*7?-?I/E.Z;
M%%.'B30 X)+[<;A<I:V%@SD^R\MX:R"+F.HPX!.8O8UPU2WR>9AK%-(DO>=M
MJ,O!_P(O+FFO]H 60779ZAZC<+9/KAD<;QQSZJ P-0.-[LG_\FDZD]<6\NA$
M8_=A(,+DOY6PQ$MF_[^VE#RY"ONNLQZD%\ <Q@E)Z JP_15#D^O77@OP68\\
MLUZ #0ZR?@%;3QU;I]U VFB_06+6I_*%[OK.;*$7)@IX(#4-G;A8*'>S6QD<
M(T 7UDCU(3; UE8/W^57G.G3E3MT9GQY!>;N-5>WFX92MI9J:(=,^!DG<)YV
MF?;\2H@ [===T\]N3F)R#2[@HEVDJ,5$*1C1I#ZF8-QI17OE :.L\E$LX?9>
M:DZT5'^;[!_L8!.6JC2P-DIX=;@.F_;^VTG Z%[)]+K+N?3XJ(5?GNS+_:(4
M=T:E@?JG1K).HMXYTK=N7\<ILV&"X&%]P_&8ERS:5/&#KG$ <+PE"0WUA)!Y
MNL%*U">H]V(GFCJ$C$>#Z9UIG?;&BG1AX_F7_]A;@I7P<[H\Q;_Z3RI^ #[\
M'+%B!7/9X9US&!!2A%I<=7+1$0KZV@C&J?\&*+A#S%X8)^H$@(225HUJ'SV6
MSQZY8PXJ\PKA0V7\)CF9P+E-.+QXS4]7=[^Y95; 7HP\1=2@GDJ+W[9:T6BM
M=+)X%+Q)/M+D4\KAYZ^,!>\)+[;\34\T49LLW?\T'R8D"?VN-&C.>DTY ,S<
MSP\T7 $8ACV:;D=P,E70^8H#0%+/9DF#AWJQ8_)IZ2)/X>U9Y],&G[Q':AAE
M.-\!R9<^H-:0,;;O_OZ$V@;@+NE8*S@.4UI6 !H#1R638:]$P"R2$O64.F'8
M-%;9?.[3W9RD)D3]%G[WY.IKLMF3EM.>IQZAY)D38:#8[",RX2I6#ECWY&WI
M2S&P T"*=167T1?OJ$V7!KDD4NM*Q_E[]F]-^[/\\+(]\7M3.5V)AA[7@DSR
M$.,Z<Y:N7LX7KO9\;O_['8W">[Y5[M3F6,$04V 6L:%C?1S)3\[_[+9DB0-3
M\]:>I6T>_@>2IF8(P1HH,(I;A!$&YQ0JR9P=8V47D[9?' !&"LW83ASI.F9B
MJ\.HESSB6#*8ZY6YJ8W*Y:;OLH"3+CC0B9)54_](Q,3,'AI2/#QSI*1A5Z1P
M6+6C%/L*/D2'L$QAC(&I=;K<2,;T,%1L$=.:47UV-;4-#P:,&R=BPR)8,^LG
MP.(:;BV@%:<#H"80S0=_]7WF@ZKX =#2'YJ*99G$F^:1#2O<TQ9AJXASDF92
M,Q/JZ*,C^'>_8!S0>WXQ(N=@O>\1LO8F[/XX_,+(=/C[>Q.XD[>0UJQ_2C%>
M&0A,%F=%:QXF"XTM/&0W&Q*8Y5]?^B8<A_<J '&.HN>+YNHX$QWP'1C>+"N[
MZT;,KL9/K2L=4H5ZB4M!H"1, [KS5'Q=-5D_^;I4B=3%JXF'E_-YHLR67=Z5
MH]MLFWT6$E#]A"38(;KF\.(!8!]!5+/ RMO^%CA\%_11^CU\("%?@!JMC$F"
MU?N,C&T=^^-EP#>T4>G30Y//5( \.Q)I$$1N>(I2OUUH1;:\13[6'\VWZVB'
M(V;4FY[_^= >B9X3_HHP7]D-J[B-L)_/P"4OJE[ZZJ=>=W0W^$3A[1[P#J4D
M80$[#B$D)2UF+_1\?@[,>8_XJ&,?N.^ $3:@%<?] ;KP%L'Z2:55:<=F;,AP
M=T4U;Y24/B!UMDPRG?J#LQ53BVW'25)5/24VDU 2+#I][.&.)D)U[>&MPJW$
M>Z\G',T>TA?R=;O"TN@"PZWXEM.,\FT>FE+EY0N\9^=<+ (GY(].MCC^E-K3
M#P77+:+KL.M&[U&C!X!  =FNPNU(^K&Z1 ?'%4K-Q1Z)6'?5$/0)D9]I1BO.
M,+I@V4P/#8;4N1#T,_WBK+GZ NREV&6?#$7H:3W_=4,(;J%8Z/B_:VHR]'<Q
M#C992K'^PB@,PG!Y3\)2@T#LWBBI<V+JV[]VS9'_L,=^E2U&N*>Q+/ K.2NN
M3NKZ 7"5\4;/UBV\W(J2M#*?!)_N3?9[#%G2%>O%XO1I^&=(!.,]2ASU/2R@
M?T&#O^WPGM6@ETB15;A.B0RG-&13F_,+$%:2=G_?-\,#KKH>I,I7Y'.1L?(_
M#FAHO%GK?%W?S[QFY*2=N>\;BT%8&2\;P P*CN3^::"!M/CPMY*U<U9KE+^X
M>E#U03/B&:%8V> F>&W<=J>JI5F1\HLT<P D0>]C$CX'O_:3'UT92FDW$L@,
MX3=__L'FO.)##\"&\Q0)1"DE9R6WR*V 0=24^2D-KEE$UF6P] ]P]_9TZ(='
M_9*OV1\FQMQ^LJ%BS^261B_P_&>!1K,3(:13#;2 7?<B:=B1?-8NU&%BF[G\
MU3^,K7]RT",5>0D^.RVI*XVU=0FE>;+4]@GD.9(?T2Q)"S?);HNGRX)7W^FI
MR;]/DGSVI7TMSO]ELOKB,J3#$%*$$O&CEFBF_<^,Q.=/XL@SE?!9$9+8L)ZE
M_]N\"\1O%&J'0/6(VI ,>*+&X-;CF\_/GX [KG:$=1X ?+6,QQK\UL<3#K^L
MW_*TE'A5DO%*^%6#S<U#9S8-I4PCRO15LDB;L75YBITN\BTM9*']XM3BLQ9N
M;G)71*UM7BD]#>+8ZK_71J)UV2)E<*0FZL8^3'! :$4TD?>H8DQ>KRG7\"*'
M$@5<R_;K=9=XE5DG2@BO!8?QFKD1D_+.6FG_X4E:<4L0^WU&AD#T'S3.OZ8<
MCCD&/X<T_HB7)4N2/6W&O]1F\Z4@WSU0Y?['J<IP ;S--AQM"G]-PL=I14 Z
M#61;<.1CW95N9=-%8W9GN\OKC_*=2CGZ,\I(;W\,G#</$II$RF(Z!*F_*:N=
M0V872A/!'()O0L73Z]D:?MKQ' !L!69OW%L"&;4'@(>^Z *D;4[<>0)Q:<"9
M? !0+)U6[!5.^PIW/+@EEG^A8=FE@:C!!9^LQ,;*5).=QUXKO X0PO_IX:X>
ML;7G3<-\%OOC;^=.FL4J=H8[!^D9ZX4).;I-]!8<'>F26S)LGV]P;C.Z$[CT
M!/-T$DH7G%KX[3UFNDRH*J;XGPW-273S)>329S-H2:0DEB2),>!'!*DAM0A3
M$%!?@)!56+WM^M:#F^QJO\/&LN+H9]ZOH*3)SCN;">I:*FIVGC^'W]]/N:79
M=3OJ[$G)^J7#C>\#2:!$L_:<S6,0R5F=! 4'#A?YTXIY7%XZI[A^K,,R(_4Y
M]X:6/OWM0VKM,EI *K]-+5FX&J%..9%BM)!P^[>M\MEF:]8;/7NLK]S?$UL7
MVB+C $^GQA+5CDL96#H$\DOLW;CZ_?W'S-5G;'?"?\B6S)B&V*L1#@#>U0MV
M#<2DOCG^:6^[[-Q>^9C<="5G+8[P*R<A")&]QO?RU AB&RF1UL'9$U+:N=4C
MTT5$G]3[96FP>/("LG"QP".>.8W^8XMVA]%.:4-Z*U:-NI!)-+B)/"X5_>!7
MR>LJ^32B>B[V',#SP>YPJGX8?B@ X7<[BWBLOCY?YE/:Y=3>]3EC?FR&7/$3
M09'59[I=0"#M2UE_@($8:;:Z<!4EUS2B9^)?X>BM<PFN<M[MEK/!Z<A0;S/;
M9]8&==&E="CY%K8-3ZIE7OS22+:(\NQ)3#ZJR#MT3N7ARI\*98;($W!"T^3;
M)@N%VM<G_87^22[[Z0%WBZ9*+"*-"?HAMY(Z9'JZ="XX>36<Z4<-=I;23(0?
M#;:@?KD-"+O#COW>)!\_%H0T?I0M&1;@6!\E"U.VZ-L09 TB3OV"S3DB.@53
M#5L7)">U7BB-HYN1LZZ017(4]R^'!7Z^FX8L"S%ECSE\#3'0^!XSL4F!L!@V
M"'F^9AAYGNQWE80,>?7E\_"17 7/DB!QN\>E<G=!U^IVK6.;SU1Z[N.3U'=
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M)!'GKJ=&J'2[/*9G'51&35RX73^"10VZP56]*TI-%LOWS,UL/PF^6+T=? "
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M1D?SF>7.( H#(K@O3X/K>JAS\\KJ.6II2;B'>>K,0X\I(1*5ZR,/S6ARSZR
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MF48&1+.2>-<OJ0CNNI;5I9$E-[QP5G(.=0S0>"?#K64IO<]2J=X=/V4X;EE
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M5+"XIM!,NTU^H_#-5U$.ZOQMDQ_N*O_.<CH5,:G&<\^B'].<L#2RGX%F<\Y
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MMPT9ED8YAJ>AC'(3D'I8>?_;)TJG*]<9:>="^'Q/T#2F(9L3?_U\AZ33]\*
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MT6/TL;]K-*UVH=K7Z6Z*&1//+!9E(W(K=S:OBPKE!H O?PK4A?B?O$_8U&U
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M_P6K*L$\/UG@R%3V6^JZH.#KC(K\9Z*E_(%]_,/B*#;X0ZP<CJ89L_D,&[V
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M<VGU_FDKYU9F8M+IXWINVUX&0'-N5H?;YFT>,27>*6KALZ)LX^N2/@(EBZ.
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M2D\U9ET;L@.D^-8_I+AZ(L,H7_Y_2;'BST(EH(-\"+TQM)7S//&5W=%:,]/
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M;SF."52]W\<F&E@\K2S"]:ZF^4;!/KV=1Y!.@UBK0&AR]@7WQ0*O=-R!V/6
M& Y;#=B)<*3$9 LXUK[&2FFIU3"->43(>.W'*ZW.SWUV=08H VX(-4ZA]QQ
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M<Q'3^.K [CIZ3B\87#B;$)#W@K*)*C?7=Z'EI6&\LGG09@@BBDSMOD!#+*Z
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MX9<,&=Z_K_B+_ \OM89BU>0\X?ADDO1D/?#;C(>M=L(9FV',K]=_I"5_ON=
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M<6U2^..N$2L]')CI;[K \8-WY>+/N(_IJ&W?4"RZ?T;M/7@ZFS>A 9W'VL7
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M$-BL[N_M71;9A&E7NN,T7);S\*U3FIVR7A@U27VJS800AB6G?+6KG_SX97,
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M8$Q@EVKER)<VX?;\)VKKTK'K)L]RMI)ZA@/]L\<]]V-K2-.7#M\"<SH#"2\
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M -'UQF7^%6-H)49>0I-O@!<@7M:)2=<GUWCJ%=SY<,SB!6%,KK &$(?OV/$
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M!5;?AQ:;[BZ]H%^00'H$E0,@&8[MQHE0/IC4:C8[BN4CDGNJQYZM]A-BHSC
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M75!K\E?4S:.ID/2N].HE _'6^ >V/P[A&2-"TS1%RY[8&ZJ.ROLUX:@SN:#
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MZ(I2\F#%ZU[17U-.#B&#%[*D#?@ZYW/*39,]-)TPG$>5WI)C\ =#4=/* 7;
M[(K;'6SJK^O#MOGKY0WP%,$$F#4O-><O70^UD@%69X.;U]>]'_D+3H6B;E&
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M>VT=J0)U#Q^:BSV_4$DUU]S1Q0GT+23\X(FY97W/^]S/Q7.M<:>T5Z4YVF$
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MNQ/]Q@5RKPE<R?^+M_>,:JIIU(:#H*B4*-);D*Z 2.\@*" B1E1 J2(@!(2
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M#//#<^#-,KR)(7ZL6.,2V3K/;#6+2:Y/R?F@UB/<4LP,5ZML/F.V<'W6)D1
M0*C)53WT_WY]V']<[)2\=U.T\V]3$31LX_+HC*3.C*5&$Z^4RY6/-95I8^Y8
MAQ@_;J5A.J_*/61GXYPWU0JQA[*4%)\7B#A_B5_GT_/K!0L Q99"2CBIFZ7#
M-+]KE"PR7Z]7"*ZT$'A<]R.3B *'<.1V=\^L9Z>)C$YH:P/865*PDG0.2,D1
M,_!$922#2VN8C5/!M%#'G9A0IR"->Z,Y@3>= T DRQZ4?GD-?BX>:I][_X;'
M$:SXQ=/-)8Z.>%%SG7D9>._;[H.2]?_-B<=B*Z< M (Q$GH1YH[BY20%V$VH
M"ZWY,M?GH*=,TW++M3V,I6W>B.K:WYU.GMJ6IFHBG )P)0/M"D.-$AA_D1,F
M4#BO:,0J#*$?G\1G'W)S0'#[9[:-16\<(RX="(U7OU1Y"F!&. #9>A&8 K+%
M*>#"(]0G,B4-A]_X[*_;ML6E(EX]W'SE:?*KX/LL*E(_3+,7P/23 4/S;&0)
M3(-D1,!U4C[&9&AY?%M5^X9$E17MNLUS*^&E%X8<[Q-"9I," 4SY#G+[NBT:
M4VQ/2,Z$9ZHVI>OCW@:Y9G.3:WTNPP:( HF.KSON!3-(U3770!JC)_?3&2%4
M&QJTIP![\!DRO=\:7"3/X.S8HENKQ.S63,UC'ZF5WF!+'2$;\W2^%HXR_9R(
MY_\IG%Y.%?W$J-N>=1X.Q "9'=4%!\F@[-43OE%W8M\CU(,(KO#=U].+1C2+
M49D^JIE.I?\Z>) UO 42/)F<KP2&!8!@N#;+"['FT&!UEO'A9V4!0A:F= 4Y
MMH^TOX@%%8G9J'Q!@3QXG?H]K$+FF34<RJ;Z1[H>OQJ'^U: OT!2?E?PR&Y8
M<OJ%S1FL?@H3K+N#?@J (U4FT'].VN.".6$GWDF2I;"S_/.F@SLIK\9K +BI
M]U$LUJ,W^=X.ER,OD&^F+.RTEZBTO88E/B;<-_7QJ$&.]7",,W6@+E\_MQ 9
M3+.8[OL<P$A+?'B<9D.BP^^.@$<78S:>./5FW%-AG^FSRY'=59%K"G=KNB3P
MSB8K/<0F>K(,]OG_L*OJ_]7UY]@4,OJX!FZ-K547=:J7['##9JBT3["V 4.&
M2,I'F\D*Z#3RUXD)FD(]PXA+7$L701SK<\>8^:G;';_A\\ 3OF>P'$E&^/.J
M;Y7?"2Z?*)[@4$6@Y^/[>.,A"Y#/<+?W5_EG$7:!>:0P^29^H@MT;IV7E>"2
MPEB6,R\\Q??^>>'F:GL2I747C9M#X&H0C 80DBKQYL,4A$A M[D(06PG(UB\
M59B>+GC*!E9!K)V?<YM-=[IP;T.OG=E6SV=Y$7'M_WH_P?_?UQ,3;]?)Z6ZU
MCD*:R]$#@E$L3WP3'$OK2I_"W.^GG@(>U<?T#XN[)-\.O*!(O:Y'S=)K"K/\
MU16T;L5N-C4#6?9,0-W3;.(WZI_P.A%^_EKW0;J1T%CZP?7*PVM%O7A+:#GY
M9'=Q_E).YDG;]-WALH,?I=4:T\5# 7W<=M^>_NB@CGEPSO=Q2160'>P94 [A
MM*BJ1XE,"?I-O-@&=C?2'#XY$+2-O;>&">8+YX]F51P\^T0S\),'X/%J_6HX
MT8BWO.#$6/\ $=YS@>QVG/#S5:/&<?Y*X)4M]T/U!R.)#3W]6Y,X]BZ?G'4$
M-_#[<69O^R:]/K%,?MNMV@!U5>IRS]9TD*M[IEA1)[.[#]VDQN&A9#LYQM8
M!]KR"Y9/!1$M[7;-+0Q6,H$I=?"FSR(NFU?>I+_,#L*A=,'U,L]@,*MSX(IB
M[\0/'WWF&S^4 V>[J :4.CW?&_8M:CP_!:PLUA,W=M<&EVZ4JKJ*BT=7I82B
M]T./'O5Z*T8_V$GLY><']T[PN8_(O>K#EI'NLFB7QAZ')LU*HNV.'LA'3X(E
M7;SM00K@GOJ+HLUQUR4/YQ_,JEOXID>7H&+Z<C&UW_'KLV>M*L1-$M^_G%&
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M>SPVSX'-M)$U,7#( ,:MPUWV^JNTS$BZ9[Y3T7=+-&_2@B1:##/1,6M7&<M
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MJL<YZKQPV?'F<E5MK,.K*KX@W:J("Z6\0FKT08)0<=[/7HK+3;Q(IU&/>;:
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M%K$'CE0.[?2#LI+$+,<\?S1*8 X;[7/7DD^XAM-^^H4)UAO9UV=%;1N>E.@
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M.4T3M-FL;<\TFEB2$(3X P.=Z;NDI%R&<[_U.&Q'92TFJD6G#@5$,;9H91F
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MU?PY4E&'[ZM48L'C$V%6>0F>QNOE*+Z'P>7SKO\?<>\9U53T?8M&:=*1WD%
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M*7L5VT_?1+"?-(RUWZA6YL>I3(%,/#T?YD#K/"#:MS\#[#_06I\B,?K?*$>
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M*V^4XN@N\GO=WJ\S3G&@S>/L0_5H1-,A-K)^\VQ=A1![7?E_V_%'U'R'DMX
M1G^!P#> */4;P#3= KE+Q&20$7IR6"Q)Y3[^ ?9B ,\^TZ-B[X[L==!5.1S7
M?U3T@,;D-]>'+ *^\B.^(W7R-%*I%1 ;-@_%1>^)%T<7)Q_4BO3H(A,/%]Q/
MZVX SEVQ0:[QKZET'STP9^!;3ZOL%/O]/FKH._;P!N"84GSY4,@*68S[?#Q<
M?(F94CFU67VUIP.-#TV(% #I8[OY6VJQ5 @8:]2[@Z/*YL8"J[2PRGE._L<G
MCU+GU%G>O*9E1NN+6W UZ[=] [Z]);.L8F>]#UI%;/5"EFS<CY"X3XSS)M'V
M%Q\.?RCU,UB=&V-3D>D)Q??*T;Z)9X<*SS D[X[J#Z6$]#3^</L1U@^84*@Z
M.W/'<WA<'-2@(@Q8L%<;^IU5%0/F",_<YN6"CRGZF.M,:>CL#U/ T\L:@K6"
MF4OR)@1^O)BNS2#%COB4B]'SB>6RAPQ*3=A4:XQFF5<0SO+QE*#7!?04B_1'
M49.#7B[V:'/45>2]:[NZ5K*<9O9IAR0](I V_X,/&67FD&78+FX.'>PCPSW%
MTH*44,4TNW"J&J15=[>(QL3E'YY\?HN/;QL_MZMNN,D=6D_V7[GC'T5.J+2R
M6_+)\'A[#H;WM\:_%O\Y="CR\]&K'P(QZ>&F\['AO#,]4AL&:9&*Z%1(BB18
M;(#5IQC,W-V$/J^$$)]X!CPM.&(8X.U:CVF,Z7!*\\RZKF$;OKA0(:G/:04_
MEL.9E'T\$'V3%5;G.[9-JY5%!,Q)NV=(V@\+M-D>:("K(>>*B8-$3&\ 0Y:F
M&5Z2.]['7O5'QG*'E6E/&EC>%_[^^1D@-\(P&3FOS-/<@?8=\&4NCY-D\V5V
MN_P,H7N4/@81ZU"XJVR4$GSVQ4;W381/"%[E=MHHL^+N8Q+>G_T.HK2SFA5Q
MZFRW4GA4VO8&,/ C54A\6XDYI(:+!BJIO4X=!Z?JR3<[A_;5L^GJR6C'G(-+
MCX*)#.D^"_)E@8F<(F<B^:=Q!E>2.*T"S7FO8+?2F3_:?$V=VCEL@/4< 1)"
M]G#6C4BY4;$$*!N."?,Y]Z^U&YYQ7O)0[?6)65C24O^?UHJ(@S5*O@;/U&ZV
M(E',?]Q!XHM8LH?RYQ/>GEWS#"G/?MUE50Q]L@J[=[7UR"FC-DY3]G%G_RU+
M<<5BHM8;"('4@T4T,QL8Q4B!>6\1[E9 0D=\1)B3@7"N8:U.U:_? +I,$V4I
M$!@M!'JPD*>#X<]KV),?3\D-=RFH7'TX-+0R\_6%>BJI3ZU$YDCX)L@>R=9P
M!_3DN@"D !IJ:$70N9TO<DFO\UEIPZ+!!$[4;Q[5A:KN^ )'4 U#7.^>[-AR
M8PJ+X\5 $N!J5?LHSS)-^57WM4!OL[\</W_>X>;*D5BN Q-3>=[RV5L.PGW!
M=<X\JW+:_/CB9U[;,*1IW8XA4@J[_QR+*<?)H$,2*SU>>70QS_%VSQ'&B/#]
MW=3,-37=DM+"[[ ETSR5L'EY G))5F]J202Q^=>-*E9NFSP*Y/A,0]DMO7PL
M>D)KQ0LT2NNM^3 7M7D9U'=UGQJ?.VJ$G\)+05NQ!>O4Q"O ^B@"H)6-;J=8
M6X$%XYH%7Z)JVJH/V_MDNL\IG$^HI6PRNENL8#< >D5_9'$*7#.Z)Y0J <S9
M;:^T]:G&S6_,1P:6_O013R;B,XTJY4HD9W#%;YRN+WQ[6,BY!FNI9(:_W_UT
M9K)R19(?<4@;YD&O3X69L))5BJZ/4F]"NQ1<.8 4VM%YR5(J3'H<E57798%1
MM=I?RXV9\SR$:[4HHX>BY:XZ#VVS5=ZW]A%&_L[?A)]7N)9;>4"IVJ1;UB8:
MA[<4/H56NW#[$'QVK9(\OTI<.5",PO!:H&^+^MT:N_1E\!2&#^*WQT3,M,JF
M3B;]YA_4T")];768I-<,&X/Q' S O6S'!J^34\H?#^HZ28GH&LZ/76<;1#>]
MIJA64VAB%^1-8?]KO3U\5>T+5<9/AC+.C/C[2FU5\04,]F?.+6NHW97E3E-E
MR,4_:,*J7]D#"PPQSG.6RJD;E(S3DN.F_P9#ACU!B=Q/I1FL/J\7[>\]XC.9
MR%I$3:9%<H)TT-MQ>#[+G=!PW\2*"!LQFRG>7'K='.,!EM+,E=A5^GA>@?WT
M((:_8L/%M+LJ+% AD! Z_5TPFW?XMO;B*[MYG];17+<#D2\:7#V9I&36[7>S
ML_SWA':_S%2<LBKRCZ'2!PV2BH0P2@VP)46E"FPH["*U4KFN :;4W]OUC"*9
MWK_+VX3O[F!1#U7;U!K.9/&V(!\LX%YAN#1;F^9.XX.>N#-Q>LG 'C<I6OS+
M^^4"$,+!>L,0!P@,R>V"H*K"7,3TF-1: */L9GLTP2#>>5%:@D!OA7]-OVH'
MB9D%9'=CX/7XJ36!1NSDE3PPVQ@MN3V8X<Z:0M?9:FR\<3 [(OPM@4N6C)J7
M.]/$VWO*;&;K<_X-X)#@!G!O!,?G60$49]<\+T.&6A6W_0.N_@'?5N[61GHG
M1&DOB@4_?0-PO?Y(/91.9<$W,>J!&MYE.9>P&?&5?'&WO#F;)RWR)*VTO5[%
M_;9WB*P38W2 (]H13)"G%7WPC%5&H4RF+*KK?QL^$MA 6X9O0%TC=-0!D21K
M74]N>-SA=7O%P_(>9L++'N-2QZ9[8YE+V<_-5H.)KSBOT&,FV*\H\FYONR'3
M2([I(/(?K$[3)6DN<][:_:E.'_IRQ]-[[J9P/O6<B"3!V6*',+,#EZZ)7JT-
M%, (=:HF_<L/,M3\)288H>5OHU>M!(_)C\8(;A,WBJJVN] \:6"\3OYW_:F'
M^@9@>W++&/X]LM,8\?8RFX8*XIYANVNQ\08)3=C0E[=J-X(_/[^HE_""NMJ
M93!>,G%*^ V:.<O VA0!$TO*3T\[[6-SX^1M:I]5M$,FLLX:QX[^/MPT2VF5
M&#1W=8Q>(LELW8(&8.G0&]]S20;Q=)CCQ#,[<B!,=T$T>0GROG)VHVAUI>?5
MBUAU4XHJ.;N1N@C$@-@]D"3Z@%.N"TW5=MT7I>A.50>$E^U1L/!&B;Q,&9^2
M"%+Y^;7\7?U/NQ:1A0;G*UZLO#?Q3X31 I.>;_.RC=[FX/$65 9*"@B6)<2\
MAO* =+%MZ%<P<2!L2&U 'I%05Q47K"O"N;!%_I$GE,Q6CB\GYV?6;6,_KW\U
MP"FSH,Q^ ^A7/O6EV1'FF1<^_3$8^+%G^F[OVDB>+_C] 0YSLI@?.9=O!ML7
MBPT--<*9+N"\41$=I1'F?!@VFY$GHK5'WIGM/(X")8;^:_EF>;]R#](MKAMX
M,=9X(:P>_Z>H,LW*ON16C -$NKFG)DC7?M,Y@SBYZB= Y="L!IL\<CDY0!V7
MOYVD&*Q<\&UE=\]6]E37763!P:]IF#!M.U!N.!!1$79Q:!/*F%P*XEGT6;6?
ME6Q@W@UE"NP<@'&-_Q4_4)JLKKD!M/F]184>[*)BD%8_%)\O&"^OZN3K_?RY
M;)_S,)B(%.9%N-&@4SBC]KL)/I*B+(<-[6\!#E]HHS\LM#>R7?51#$#((]C)
M9+I$^L&IC^N!2W=X 0NW99Z>9QK)A?47>.=]4#&G&*;H[WYAV63OZ97*]-'V
M6;D$.\W=V*<1BT7ND?>QI"@#4M%6Y8<>O-I%E"<BVRE;&NJ\'[*D\[C/'VNV
MA>(?3>/)5T"RZ.+HLZOKIP@81+IIM.2Z^6!@R%&UV=S5@:S#E%F.\(CW<Z9&
M8<+752RI,G<_.(HIY4A1#NS:Q#JS_>)VUI(']CHE:?BG?7R#[WF%%P>F6Z.C
M8%RTGD5LD+;NA:!EZ>[8-0Q+608_RUP<]V;)&[G]I!.N&-M'<Y)]J44/T,1Y
M&Z1X;J"$P0P/--VXJ]"G<K:>5:_T]Q'3M<MKQCN)]NF.=B_6+$? [E*M.WSQ
M3N)=G"GE;])_5NP,MVEFW?+8;9D$%=<=13"RQKQ-2?-U>ZLW_\QK5XNJ#D'>
MY]^^%_=.L6/THN#$A-<?HY >S%_H"MEM1!I'U8#/U)/K_5P>A&\30Z.PQK[;
MV$](ZAB(QXGZNAB-A^7X:#"R=N-.+=N.WAJXL2B'L?#-9=[@G2LE15^.U(14
M.[L@^(NH)63D0N8U194KCA0LI&]R'2+PJ>@*19VTQH>^ ;S'D^Z:G<L[VF+K
M*M)->02N!Q.]FKEXQ4YPOS3'N].4]F.QA9X;V]?U/122JP:PII=P_>J@V6![
MA5K#R/WP7XSVO9/,0JW4:C::(\?_Q*):;@"^V/P]KLN7K8CDKMZ\=WT>=N_R
M)QI"B0LK5MR[VJ*[.S,T67^]$/[VR^\.;Z6!K)20+L&3&X"7PGB@!M8 ?;G_
M*I[2U;8=$U_("ZO0F-;TYZ:C::II89@DR%5<F$S%/\*98G615[?$O&MD8!;X
MQGH@O^A3Y<.196'[S(%CBT_G.J_\5J0%%=?G[-J*ZASKL6+(BO.",-]J"[V-
MU"<C@9Z/Q]ABM@G:/F2$$?KO6A9#J%20'T&>-P!KAUOU,_I\)^;,M9OLG]7K
M%FS:#:#]@16E&>S^'LD DXC/!6LP;+"]V.?MO3T!PK'"OB</_*C'?HS,2_W=
M3@9I5F(%SG^@K\\[P=X52QZ15-V-D,[N'(>47Q"_GV:!;UP]."5>W?]Q  K&
MD _:$G1A[:NL4Z5/K@995\)-JR0-?V1&O\G5<'O=^3A40[P#PG(Y7YQ^ Z -
M%HN+)$BPG"EI*]H]TV7CR?/X5<!?R!L8]R: @#UPL:F>Z_PC1KK V1E=//PU
M@F@ROA7! %]=V3.=>!@CLIEDWK,ZEO&:A82G,QW^%W7QKJV8R&V-8T:JQL;W
M=?="ZUAAOE.-7^-SB#_^Q/3Y\T>R1D45\8^S>F.Z^4.CN)0EL W(AC1E3F#4
M0!=EU7M1D/[%5$%$O-O/'MW[J3W?_=Y3I%CG.,9MY&\K>F(:4.G]A5&P\\A'
M4Z<&C#"4M*>(M K%B%1/D]V&^)! (2^QQB2"F?MN".9M!:8C:E@7=.<&4)\_
MB7\?6WRENX&G.XY!G,N,W !*B^*\"6Q>S-^.F)=8>Y0="23-&R0%1B+N[SVJ
M4-CQGV2'!P]&?WPKF39@HJ ES!#&(<<PB[/"-M4" X>4.= &;UNOE,R&+?=&
MY2F?:UAYLIECH&'MN$$GY.L +>6<"?RBW8D83OX&T+2A@P\P%1NB-%Y&1ATZ
M(\78@/'.C>CZFA+M$DIC9'3LPL'+F6\_1MY1L,4"D;V4I-:<\96=&"N42O\-
M@ 88AG]@!0PU15>V@#D_!MM1PY1Z<NE&\;5C[/57&1D:JES51 BF6^*,@*FP
M]2BAKP98^0N^&=3M4H>R+PX\:Y]);/_D[.Q[II,T6,V6R'U7PERE%9'6*I9D
MJ9(0R8[5-6G&"+R7&G?Y^8HSSR^/> ;.8NHNRN?$QQ,=[;1Q; KMZE;QON4E
M8HI T9W &X =3]SJES#.WG5)C)>\4%5*O61$G?G+9>?I![G,%.9L <T23[R.
M)OF"ZME0?4,J-#M]]WL>KHN1J5>HUGE.K=AP:%I1G:.'[A%^&TZIXRV"^8U8
MGL%/N%+E0P?Z.#Q".%DPT";GBOWST?-K:1?H%>4?J#[B*6E SV; ':4[O-$>
MC)<?SN7[R*A9A[[LW\?.Z)&AD#+@W&TU[5)MWM\X_Q_F901%:=_3=?XASLWG
M\2*>=H >*:XX846%4G=Y< W,6^:]8WY8L "MG(MZXIPZI[;A>,=G.@AS_?)Y
M.":WX=L>@A8G)I;HA)F,[U&<4J\$9CDT\-7QZ<]\/VD8$])\-T85Z1.>A+A.
M4]G\#;JE:[8&-X"R\IK?XCZP 15.,9#]E0+P[<C7BI$J3[A26JF/Y&XBL*R[
M37.EDY V+B.4A(3EV$*%*/(!R!K;688-'0K<Q;-,*8H >=V]CAPZ(O;?8Q+Y
M4]\>I$BX.C0ZIM"&U8LA\W#Y"<.(RVN,P4EN;\UYP T@BW*=ZXK *FJG2:VY
M0R""'D^"TYE3?N#!1;,.;6UIMR$97,Q7[VQ-S1BEUXMS?SHB&I$9<VCKCW9$
MW0"&?=/P!! ,<78ET R60?U4I74O8^6E6(4I]S^C\I(19F2HA+B K#49_/K#
M#6!3"E.&'^G5O0&H?56QKXV"26*M%H,G\>GAK#KK;4UEZ\=)_RD(R@U*-<-&
M/3'+68>YUD+]&7X1]M GP_WM=*/&+.:N1?[P'@12<U@7004BPEJM3Q*9]Z.H
MWUOF9I*K.8O[MIC#BO.W=O-R4D( 1S[S%6@!O+;!".**-1AQS9_4L[A>47$#
M./B#ONBWHS_%;LXITJ$H11?$&"V_A65;/(UMLM4(_P#(^"$?#-A.:IXK.  ;
MH3XI"SZ9KNV157R:S0:^+&KX.B+QO#F%LG&Y+)[[\^?6MP1SBTJW$PD5FOP%
MVUL-DL/\8GT!3S\W7 BZ?O4BS=R^Z#[/"(]B@$*.WR]J"E66>@54WB SS@*3
M/;!&7S 2B%7YWE6<,-%"55-I6U>P%QA6 ?K0I5AM/M!)IJH0YQ]%4H=[X'KE
MTM;WMD>W&EBY($9F(S)_=E3%7P(-A=L_-';A8[_[E#Z#].RKKI[&6M77WR!U
M;!Y&93!2S."N0'Q0*@D,_BY??F5_X>_*6$0P#;&UL#%WZITW3T/I)ME?1Q%
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M)"'<2E:*"ZPO_6;N<2Y?7\!8YAI&-/_NZ]9(,$5,F1,>;=_/>3;F=@-@[2%
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M*$B%7/G^.)+-X'UN^++E'J.MX.(9Y4M53IWKHO7B5>BS;<*W22A%,?3DALR
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M43#X\:,4&DWN],,'><3\?)P2L4K?+^JX*+#QB"'6AY457@WL@?4O [Z:I<;
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MLIN6X/Q<X.QJ#MRIJ?U6J475YPT9KM4>5\F\$PP$-#>SJG9+VEV],C0DNN>
M?DZ7GA*- <1G'-&\J(E$VV%-*K!Z T=#V #/GU&D>!6N< V3KU.!*-=,'V$J
MT!9BP5 W3&*<&5Y;'&XT,0=95&Z3+DXA:^.2R;V3"G_ :.EZ&?/(0W+X/.3^
MR\9L-YV[RJ50WP(S4"78S7V85_.S$2'(Y4-SR$4,^%1RRE._AT_J+SS/:%GP
MK_Q1DUV%4U]/3U^-$_AO,FAVKR7;<IMP?^8V3#H9%IRPC_%KW312PIUA!!F$
MJ[-BP!>&D=5&[5H8W+E-,?+V8@@WQ9(76YI/S%\.C'AH-@[+&$]'=LP-7EB@
MKYS^\=JW:U(QYDL:6;"8[(A,1+%Y(_%5%=C](/O\YF+NW11WL,.P^R8AL;OP
M=/ B'VM8Y?OH1F5URQ='3IT&G&L GVC\B8J'(.OK.IZX!IM[)=U8E;6RF!>/
MQY\H']V;0&__Y=D/7<\8=\0/=%8$YZS5*0(]>AK-;#MTN*BX+<GE]LKURL#(
M"\[Y";)<BYT_]=-K\7*P)61UU#!K/@@1]C_F0^_9/C!T[C;LE:/R XV$^S&5
MH11=0$<-" ">,*HP)C\ZU?)WG'4)/$X%OI_I*H^D C,U.;3C2^2G+@Z;&PY3
MDME4@%[H,U1*R(SKM/G>6XY?E7D\O*R$H7A]M_+Z%2$9/A7/#7-C)RYT8@>1
M%$:3QK75NAH,:=^:S(8)%3C/M:(B_H,EMA]4/4P%W%%G-I>K0&5[*C ?3P6.
MDO;^]?LBC$G!XN_%Q9.#@?\N8WDIN%R4F)\\?_*3.\-73YX@^>Y %QQ_VL=[
M@R(M@TSLGV7#[;Z1SZ61;Q'NOQ4$B[=4O4]T.Z34-F1?, KW,!$\WD)SN#P-
MB_6[E!<U-644+-[YZ>XU>**S$ TQ'<+19TD<'>0+Z9;998ES/.%*A1=CSHIX
M5\C6(<R P%$5*A#J4'J""G!A E:QS'.R6I-5-]]9^:2Q[Z.U8<UW7*UQB_GN
MSC!V/X(@9.FK<K#Q<LA[U42G]MU][>(,XH;/31@PLY;V.X66AT;M$G-:2NH<
M#_<0>V&W@UB>;$&ZL$14I_0#/2$G.41#N)U2E9N9282WW77[#!'/Q;C;HUL/
M\\Q[JMZ%3@0^3[EUGW2V1=]RXUFYT-<QI=[I:+/NK.2BL]%]ID,O L[2J\XR
MW-=@L.%[[PKWC]<=MUDVM4!:._?T4Z+X5HO)Z<NHHEXZ]N$TYZ&7H4M/E-[@
M$RE/<E72$C.'>LVX;_0\/G(M)+IG+YQIE;\)/QUX3UDBQ=S&\YZZ@"9-'U^(
MK$A48_6RED@4PMG,,,#C82T;AQ6:U;8/M;Y[H[=0'>M03[HZE*[B'#XHF40D
M_1$$JVR_A$<+^"N/_7*G(X59TG:''>@:)PY"A9URVB]0:Y*$>^N]EPI$#J+F
MA[2GO 3%,KW-H%_9KE !5]3J(>0)7 ?LU]A83?DH9^Y )(901LGS\PU"QZ3^
M*A(:0.6#5"!'A_S^N7"U C;,ZE#'6DC_U=B6AH"[80\O:E6(L)"[-$ >3!#\
MRTTJX(N 5MX"%8R:N-T%GY]"4!B[+>6?6VPZCZ8'+2F;CBX5##,^';J.&)1N
M>TR,'^S,IRBINYC/]]B;UAIJ]C0YHJ THDL%"A8LTA=V0W91$0.+X2M<)SOO
M9J JG=^@6JUP(,B4GTZ,T^Y*7[ZW-%(<Q]<K<&NL7 MSD2@ \?I7/ZWU^ISS
MS/FS?&*[7D^E;^!6<DS&7G]V%S XJOT\\5R=)RE] 2J[6FS@2[E:DOXM'Y4[
MP4W098ZTB[F83*0"/F)#L&H?N_DOSB'60>#(-@WBT+<(P]6@6$PMOM/U!9G>
MO)%5KI/ 3C1$XHN4H=+Z'.3POB)48,PZEZ^WS;2$X5F6,N(6SM,%]*9IO%T0
M0PK8PRL\8$02"Q<.C-2C GD55VA6#9'W_$"O.NA^P4X6:L+71354@RM::6?^
M#1#DUS'I*^HMWZHJZ7[#DKG:+=LU72GHY+%L/I:RO8;A,82(2FP %<@MVPAQ
MD0DT+F%[1K[@Y2S5]4Y5S#HM4+<DB7'(5%]TB);+\/JR7ZLG;NB,?_)PCT7?
MEY?MUO%R<P\,]ZEK3"/91-$U\ "A@T23-#5\^5:-)^JQC (M?<9;A, %%-UZ
M[KG]@M6<#V[MSIWQ?4&SQE;1P+9KQI>OTP5)8U.EW;&:K6ZGE&G 9V+N+^QA
MWRMVFDYHK$RH-'#=&1_Q3!F>2HPV)=P[N8EZ1M;]H)KIF-K?,"45SV48+N>5
M^$'.QP[W_O]PE9F43; #+ZKH4+JH0*N_=PORTI\"M3V\XKL]=GQ,9B-P!8,Y
MAAVO9-N<P-:77RB RH5GV"%8<WGI9^A'1OA\U$Z&(NG4P)?EYM!K*V+@4SOI
M?&4#Z-[2&50 *8>:4?\\%UNIZK\MSV$'2J'M)-Q:AK1G%K[VG0J\S,%  !*$
M71_,?$%Y@YT0>P<)+ ;>2+UOT+-LMHIXC%T^C=[)P<WS;:KTD,)3J&U3I*VS
M0W4*%VI"K9,*#(#Y*Z(^B@03\*(E@M(RCY2[ BD H0FN;H>_D>&$6=B6'\GD
M&S>$,.,_@06$$5<C*%\A6&E;#@R&3]SH1,U_H0)G&K(1G*AO->^A3S\$7>,,
M@U0?$UDAR6]1@34H-#>9<!*$91-=9P33CY3O*GN5<"9X ? BI,H\ >*O7#DZ
MXQOD0!=HX@@J$7&E1 BY'H2:3J$"P^IEM".A.>#)L\V-RG$C:-N5DE788RJP
MK)1.>8":U/TA/ -5.KG_5GD^,W//WAC/0Q=$TGAZ_#)/=CQ&HI&L9 ,'?,/7
M<AJ":&"MI?I*S?[YV+[[;T>R+^B%9<?R29]$T#P*:WO9&;NR!X2M^_L^199&
M]@SD78ZL__1)(WHQX^M7U2X"6Q6L3W+=A\#MG\$6+#-ZBGQ?+*G%J#A.:[<#
MX!RH<;79\%$IWNGT&Q8LX^ LSYG:"(*B#D&P9CI< ?;,:9:C3NA=N\@ZZXFZ
MR9</[?N$]48>]RML-+E'5,K0DYD("Y3T"%6AF1*NM>;7KT\IZ*KV)B]K\O9Q
M/CKAA^.;SO9R_4<7-<';LMVW*7GNS+S=9N)3_%GNYJ'V:T'3*,;^B(3<?<?M
M3L(6'/B).2WGNA28FTX?<W&_G]->CY"8*(H6%@V\[E>Q:,T^+V^R'Q]QM;Q+
M6=:5/N4!+L[S3HIK6GY'J'RE!%,FS*FHR:V395SU;XEE*C%_7)=CO"J^X&G\
MT[M&]3*]P1]/LV2'C@NJS <1JS!FQ"=+EV(;OQP[_KE\5?*[<'<9@W;R6^ZQ
M#8?)6P\^?%QOMVBXA>7VZ/JE":?*I!T[ONL+XFE)67G@6.1#EZOG#[G62]R,
M_B'Y.NI*FU1SW*DZXY:;Q'S(IX5202B*9LZ7W\6\!0_:K4/)MZK,S.[\Y'Y;
MM"Q3PH30VDJ#A,5=K(+RY[ .<[9XZ2:5[U)_@0L:A8^KVPKH%6F[R[-]M 45
M+P3/W:@4#3N1KZ7\Z(S1Y81QN^P:_N<Q/]95+0D(<FA).L4;"IBW_ W92 XV
MI>KX5U8;'.SHC;"[RGM#HHY+U'(X3NF<.UVC:KP&!=]?PX;?2$#Z+G>?8UH.
M>4JEC^Q/]9V:M]BH:QFVX[>5.19YTGE1[>)U">WO7!*U1Q>2=*V"\(J@QHF?
M#1&/'\]NWE,T6Y5YPA=1J_L%]$F ,,PIQ$3W'I-67^,:*AB[?'@.M8@R(T65
M;8R)A>4UF526^+]@E4W$60_NITG8Q#TY&FN?DFV2FW#O7:&HX=.<CAY7["8$
M#MO B T$5:!R]0'J*&E7S_XS7L<5UK@#QZ64S%SR"FPN#5GYN@>',V1DN$R-
M-\;Z30=[9\]Y]X]%D'CS89N+5*#Y\[Q)#1-J]&"G>6'? =_\^.=Y?@<=U])Y
MM<U$Q$[56.8.E].BOKV"4WSAX)/\[]Z^5.#Y(IH*6+"MY!2.7#M.E/,9S!D@
M@',X-D*N@9]QU[TCA<?TU+^O2!@\[U$XD*TU> \I9V.:9&_EAX>#&A!.Y;"1
M,_VVY%_.P,_\\&6W?6XC)*VUR,Q(+D#$Z!Q(VFUSU#D\[/Y%V_-FZ9]68[@:
MR1=P:?B- .G[]NB&XF]7^^^K.UL=I0+<9"/>!JLT^/S+K*[3]<K?K0TRN*2A
MY7N>7.Y82"P>"XR7PGW03Y"@]*QA'#K)=FDSA<P.;NU!!?1*AX^=WN \ZGS_
M.VT&9TXO5NU*1[Z7#P+!\Y'[^#[-8^^$5#)<*,:LVG4+#V*/KVR\\*NS.FIA
M-LCY+JFQ6,WYN+=:V^(=S<CIH6GK1A9ZN[M7NJ56(VF*CBE/L^=TB463/Z1>
M=K11*#[Z3B3GE5MP<W?^O"7]X)TOTNSA;9^8#X!<2#7"'?38GG?!;:G2(46D
MR)AQPKN,IKI$*?KI;05.6G]X,/?1 MERQ[]TYJQ,S$'G)5-/=+A+V6'"PGW^
MZT==>YF/DVM.=20D1G5>?G<CI[=5WS +DO_")1Y\[,E)G5WUYRK64PN[LA==
M6@IKS7]LZ4QD,-#VI<?JO+7XOB:M;]&$K=85FG(?#9N6_L%YAYY6H=@GHRK]
M^[VHV$''@\$J'Q!-2[-&1YU#\B)E,_9(IIDEYRJTL)L2/4\-X;]Q-3/$^F-C
MU)+=<ZJJ]VMQO8J)5QCH'Y>L&]?(1<NHY,&4/8H=,CZI&15VOBTN*RHX7WM5
MMI2K8CJ-S;,.2UB,3AO2L5-J%GVV8/_Q$]]F&[]S=)Y>ZA5VDWLS[S\8QY>5
MK;^4&3MF7Q_;( &)'+UU8V!63+_!Y_7=5XGI;JHQRI_[:IRE%JV2BS,1S\S4
M%AH?7%QY):)DXG*,WN[^AD% I=W5R6/\8PBIX^]6_D.'G66P#:['*>O<'AUE
M+Y6C.>)&<HR%""XLZ(?W^=O<]H>6"5\:0S$K*;TM<4E];$G* X6=W<D9?;8?
MK08'S&O-&Q\](EUA4 TLNX4D;FEU.-S.3TSGJ';[>/5J*,4Z[/3WWD-GG@=_
MN:NA9J!K-J0KC\QPR/TQG)A^:M/@\J?[)2;K03+K]DEWW!)[-@V7&SY9-!1[
M!D_?4_9Z-V<2V7^VX]6M4Y:M'V&)=I9SW>N*L07ML1P#B9]&M?@V5#XDGJ[I
MS=8R.B3JTO#"V+AXS$Z&S0-YSX;AU89W40/JJ%O@F"1\7YUD;YPD']/0#:X)
MBO6Z\^1T@=]TA*+4FOS,![<S>?RA./;S5_-8/VU('-CR[%9;JF851GR)[;N;
MH"-@O[,(K1G-E[_;BNTLPLP'I[F/%](HQ2$>-+03$LVJ+^+.U)3EO%HG,?N@
MK>]S1D>D(B1]F*8L&_),X&G$>>TN!^'\0IM03.6B_PM?UPS5; ?[]^:]Q0ZJ
M#[2!=^$JNH89S=)-'!_4M6?CQ+/"[&J,^6EKX^P/2LLI;RL0=Y&P&_WL4)2Y
MW*2PDKDGUS3AUS5H3\Z8W<SB1R<</'9)6K]0XD"W5!WDN7UCFK<\R-4WTO?)
M\B7+3XO=>CIW_NA"H@+7Y6GCPOP.W57_TK"WGSFC_1:TWMNN;]Y!K_<V,![?
M:Z2EO&6X_'U5XKMT:I\DND/9.75N(\C^7@<?\HV[J<:TV6?;!W7O:V[UEY+V
ME3PJO>8Z]<%PFN?.TW0^R33SY$^N&!Z;S=V57R$ X7O(&LG-2S[:'((QLUM?
M4GGK]*S_\NI19V+;CZF4%GL:PY"XHY[Q\D:Z<$,_ RTSCFKU20&G\<BK#@0!
M]7 #=J^PT0+T@*+%V+..A-=:]R##:Q6XK!HI-1DS"\(7HF+WC0AQ1K=<EBA)
MR[5_=Y6YX<F8D.H<-R3\^^\_@IUTW*R2/[J@!6SBN\;ZS>5KK\@I5M?#3YB%
M953&!YMR#'D=>G"2$)%]VB#!\MV.[&;)GQ30O#9]K*V%7VPN^O]#]J'('+-Y
MMSM3G<7/./:N'G52"5.\;*O<9,WDZ#2),#@?G)X^]]'V0>G'^^*AAHL6!\+S
M@Z@ LX#Z2FGVAL"&/170&_34AX+71@HR_DG[14A^E0O&A1U2W%-.E4>NI=A&
M.7DZ7NK*S[3G;K2TB&/G8/CF'Z%:F:I^N=O\Q237%YFVJ_&*H2X+GC_Z^^33
MSGX))P:'^NA:LQK3=_95<&^=3UL^F7!S7K=2W\U:VS&JY':))-M50M+KMX.4
M^-E4CO&'W]FODX++4NU.]M4\^E(@?5TD(E$[226CQ%E_RNZL08AWQIQ5<D;O
M7"NR5^!]"&^ <[&FLNO8I_UC)\-$&O9YA4T6A%8,0J%;OVZ^I_.I_</BCC;#
M-4&S89TG$NG'.#2NXFRCO\_JS_,OY/C?RQWD8?]4(>X?,7LE1<Q.JMXIN&RH
MUI\K))F(O8Q;-&-6?_$MLVCIV?NZ<9/QKH-Q5V)K=#P([]T$+A_WF2W2EF[:
M<UG.Y%+\XI22DFG.$:7K0?Q0Q4N/F$4>1/<AZC;!MZ/%WHIX'?62-K+10T>'
MMQ9S9QKU=%P.!VN%E'AH7)/8'QG=(I2_-DD%HM<E(_( ^T;[*=I!QV_DS&F'
MO=X'V\'#9 ;\4RL60D!JJD[*'-L'XD.+I$&6]83Z)(.ZBEN]PFEL^N&VS$K8
MWN$QU4P"K++OW>9TP+U2X<S9OM "GC-&B2WHR3,W8Y5XWA\,WWN.06$N?PR;
MNS<B;<;,)"1KG, Z':RL(50HL[Z8[G'_H-S@ K+DS?-]TJW'=;V,?G:LAD.5
MF<?LG6MC/9MBLU-?2_)2@39YBG:SULU@@XTTDHA%^2FZ:=JTO;J(#'?):@WS
M/ +]ZP^SW9N]N5N"<TW6"_;'FXUB+BQ>V0.O=E<8:CO+J\J 3R:>J"+,4@$;
MK_F 6)V0UX5Z:1[OG!:)@G):XQ]K'+8[^"A>?8VJ)M."L)Z(!&?PD]TC(O&M
MJZ  +6P&XEN>#'^[-^6*':GJ1KZX?)MLX[FSV^2'5Z8==_W6LJD<,]WUYZ+U
M%LV("H(6=O0?E#5-]=>^_NS%7_KX@R\9$'[*X"PJQCL("A 8.ZH4GNCC<9L*
M".U#X42W^_C+<;_UB&S=TT%U2P.P'*KS6L-N=TD]]6'&GV(C7G .]U[/,5A_
M DF=% ,1+30I> YD0'U[307L^XH1?<S@>4\$Q0DU==1X4B5"]/<N4.EBV?X1
M!W+XW9WFFL-UH6R"T5F\='K%%KJ[_#8F#81T^18"U<G%%+LI;?T>/M$B"AFU
MQ#:-1)Y]8Z9^EG9"L"QS0@"U!M66VQJ@V,B>&ML-(4C^?U6T/O6AQ<-^KTKQ
MM)8=A+K%'9ZH2 Z*AJ9"E?",I$5<W1)I+[2\:Q70A6**+=DD,>>(0C2$DKN@
M.WP9HPK]!MON)*!P#*#A4'52/N$JJF8/)',)_"7FE>0L-GAX^; M:C%B2G);
MA7OQ':#J*!7P04'B<K!)G6)XC#QHAJH;@"]A5C ?#U,!0_2YBX_W GN?/ )X
M:8-)+=54@%U9[?:8E#:CJU9*@%*@H9X[(+3[#JJRF0"G[)XFSYJ&3W?T<Z(8
MR1F:#.]SQ$:%\KTP[D8Y#HO\4RB5.*^U"MK@A0_J=+2==YZ+"P*<>7HTCV<U
M#87>\)N) P#-HU,IM+QUG/IG]WQ"E<"/6M!&V(J_ =[??\-_]HT+<*7M+/WN
M(UVKL!@I3N#:3=ZQL!1!\>1'^V]LLM6_>.09VJ8&[#XW1_-F^\+Z9^F!!:U/
M6LWTOB^V;Q)Z,_BX;*BC&B?PFE/(;SFUXDBP. V37^>=1]"%?22LW] "5^XA
MSY&V[]$6>B.4Y>8!*%IV;B9-[PG]>$C/\Y'->?\96>@2 (.V;@BE;6<RO6RX
M^$'V)Z>@&OQL\!E XL&)>/$W=$?9]%C% 1=>Z%V -O](#3A#SK!^ SQ29QQ[
M0G,@&)K1QW!VMS2]\]!/,6BU 4%Z2!< F)$X*;.A,:FC!M#1=C^AF3L!W>_Q
M6>7M"R>MZI]E--P?12/_]NS"MAC K-:.G2#;5:R^^6F!@WIL ),%RU2P.&T4
M\2V^Y1+QTZBIBZ#9&-C=-: U98-SL#]XO6/*(,$S?&TT:0_EL3+?Z#!SSVQ?
M0-F8U^LBO:RHWGGGK_L/1"^_.<750;Y&V(@ >;QU0\P_X7.PXP@Z1(H"ML=;
MY8!3@XVGR."T\CW#CQ)U5L?M'A.UMFX3T29$GW>6\S &4(08HA]U4F[.TRJ(
MH7=:*4(BR"34L=7E#5NR*H^W&![WM845=9UXX_O"L3[C))-XXUC3=PZEBS^<
MM'+*BY;\A_=-$V/>:&4,N".JA?:ZO*Q9A['W99=5T9"O&_78JQ;GU/YV<N??
M;*OHGXWPS FE/[KF,D2\'U@LLYQ\-N)%Z>]=MWF#WYIR&?>$9Y"0+$>H0+_;
M?R!:]/]K1,/\TG8SZ4#]VI*#%(@:IGC_Q+,J"'LA<Q7!8[P?.X#E\)T6 H03
M$9K0;%A]$"M,W#T%5)?2 +]@5[)*.@D:Y%"S",I#U+2IJ\X-Q!O??U'W_M=X
M]D\$,X+2"IR6"DP\1&R.4('ZUST:V=[&5"!R/V0\%Y3L3R6P$Q<A)09AC2:-
M+U(^RMDAB%N!E#70=9T..1<](SF^]?L;XL^%)V6@5/L-EXG"-:(WV;-L>PD1
MY##/PG\T.FH_F#-N\HP@R=O9""E#]H>/:51GHNF0_>=V)Y@<-CRF\XEWNN\5
M7@:\6 #9.0X\7\P60066^3NP\T&@JZ#VC Q9GOLM%3B;B=HB#H]:PA[Y2ED2
ML=7LLQU7J^Z'AO:W?5=FP3W!^>!U0(WWJ/E0]";KR9BG7IB@-2)9-GG 5JZZ
M0^14_2$@(<$DB0I4G9L=7MU30@6P(9;P':^#)5,!6>2)=NWQ>QNG0/ALNV8&
M)<9%\<!=3]S[_D9IJ;$7+'LXCS,4J-M-,".)I)_>EWT"/%> 7JN!K[)?,*8S
M30X^JOY_^C#DN?>6==>O.SN+2W'*RH<#WP_N0BQC8E1AUD@^57GBC>%:,T2U
M)(S&&I>U/'N&/C%5)/("_=C^IAOJ8XY1]++QFS5MM]0U]+Y5[=;\=KC< 9X+
MB_ 65)@,K(H(P0UQX?.K6Y0]5;I?LR[UA$0U'HHD,4=I&E2\V;NR[DT,R2&.
MG\?)#W.)%I)%A0YTOFO'3'^V_#@@]ZCA:,3H0-8>P3#/[ <H>E7VJV0!_.O9
MDYO^0[D^K@\V2@(R?7N3ED>;S=17UVG?Y"S_1!M$D) $@2'@OOQW>:(4CXY7
MIO5]L5<AFE-:YSG59HXS*@4M/9+P5AMC=38@H,G"GKN;RI/PIB$-K[\\\QZX
M?^/]8Z<S(U&VF)IO"DUF0W6(]CP)5\[@N3Y"#K=[FT:<^(V7-Q-&/5>GWI;G
MX58Q?&+!]_)X2LTI*O;WL^AF/E<=_B3N=)EQPL_ODL8%_'"-HM4Q_#@"Q?E@
MSCC.H,?R'=RY*:A>UF+]% ,A)ZT8$>#+7XIO"131U6FPO+RY/*Y7HGE97R3V
M_.2YI4=G6_)=70+^_DQ'*_DZGB<P,,#5QWGK2/^6N8O#>AE6=6'N!#K5>1@&
M_^=!Q%Q]P^OUF]AZU7L3?G$%:+D9[']UV-#XSSW-/Q%$C6NW"H8)!)ZM*A(.
M%XLDC#)0G)"3R$/]J+IJY#9&69FBZI["UKZC8CCHO%/'T"0^5\0F"4*6\PIQ
M9DD2$$C$&4+1^0J^*@QATG78>?+V=J<BV)_OA,[C(3]=16].4(%&$Q,(Y2\.
M;]WOJO=M12[O;T?-0]>0O5(H\<-#RE.L8IATH&7'%-.N,VA:U(0S?/M$BX$7
MXV^MQ_+7Q$Q('>ET<'H-\TH"$C[V/V]>9$XP_P4WM"9=J($MR]K"UP:I0.+M
M[O1?F>('<PZ('/[MEH4KE@8[<0D-8B'$/&<V40Y'?7N(@-(. ZDSNW[&P]*3
M#8)5DF '6/2?N6&EBMU8(?E9/'HKA12\HP&4#0\?20=GP!OEMU(%'T?_F0<B
M87W_B1G")-SK0/4R\W]0\9O&+:&H";LN[$^BKG"E1Z,5NPL"<!V'31)J0O(Y
MD0I F3E;"2Q"3UNB*K DCGZP'$EBFE"%0XAL=QD27NRG\+H/A^FP$YZ!8!&D
M^QL<K>7&5QF2$(2J.5"^E-\1?_O 6D0;ZN4?YX3@:I#P=U/WW2K $E9^^H[9
M7;*?/7P^&#5SN%P-\KF(ESM;8B4=\ D!&R@G09GD'*<F^PI82#"H+HAO(K,C
M%X(E@]C5OU:PG/V Q!<JZT,S]E,!;Z9ILA9D/^[MG'T%\MH[N3:]-*O35:SW
M5ZJ%.(.7-Y%G1M_=E@I]()F5LW\$LFTK"F<"QO0W.'+2[1'5_#Y;_*CIPD"R
M]E&VPCXJT-((W^A)KW-E:2HXG>*V:DS7ODO[_] I9^&BHO#V(=.I:Y$74P<C
MSKZY%4_"?H7E;80JVQ!TOAH'?N4NT:@:YAY FMN893>!6_./'>R/53J(JG>J
M+W^D$1G-16H,B<B978X#!-S"GCXNX:J#IWKKO",?(R2]'8/1:^&_C$7X*X2Q
M53D/#EL;QR>(#)E=<&1Y+E>RBZ_-6+W_^1DF8#-E-*XZEO@8'FPO+3^:AK3F
MSRNYU9H%6C_8]5ES;U?MY#7'<!5=M[41-)"/I/=6Z<Y'T@RZ4P$$0:RZ8>N[
M@M1U6L:)6#?:HT&MN_4 /2W V6KC[&Z(\__'./#W9RP?4H&_P[MN*N#'9NJK
M?SJ.D/JO,<RO9V#-X;>S:9LW?S]!^<*-7N>ORMG?#JO%D=W/04X81](_J%%O
M]2?4RO@=U0P+V%=E(''VHQ:^F$ALG4-]0T#^F(. *O._.0@AZ914%X5+]F:%
MKML(B0U!M=7#W[97%#]&F/P*7=L5XA^P!JF@]1?TK_QL(10"L)WPPE.!NG>H
M1;;)BP$1+[9#19@[A0I8#I.VJ_1?*&+J)[%6^-^A%<[\[S%.>R G, ;WALRV
M?5@%/N]'!8ZNS/UI,[:[7!+U+>AOJUP^A72R3Q6X"2'JUBZ9-:U5+@+E3^]P
M;O<8?H.N>\3?@,UHI\?P-Y0/1V:&I)/"SD]";I9S <)]<D#>TN;83^E?_$;T
M'B@,>W- L^=@F^-BH-^.]-N9[SV%!\+AI/*7/Q-CRBIR:OO ([V.'>1#LCL^
MY)J&^G82 O-T\(GDA/E?$;L=0(Z&K&X EJ="<C?=Z8X+@O))%WQ^#DEAZ;;7
MBTCQ949]"V.@N*)F+5 +M))U&=9;EG$;5UQ.+4I^)$I!]Y:'K751@51';)X8
M^6D>:G-2;(5+17O&0Z-/E HD8:B #_\J\O'G+\2O54K'EP6>.%O96X7A)4$-
M'F@Q62&%<*K"<S@SL:<8Z1^IQP>.G"P"QN/Q6*+9SM=*(&<;9@:Y%F \<(BW
MPT?@S>4V[QXGQA36(#E5JK7[4IY?W752!M->'IGG+/I.NN[8MW=H;Y-OQFC"
M!MO6/*1N)IS$\'4G9JX\;Y.-/_[ $G4&<09.FL$F>F>,J:C/NBZ<97[U:'\Y
M\'RS^^%ZS#"9 GD9BHW85L^C6F[,(L<HW!=;2@5&$MH1HQSM2II#-I/ANM>]
M;Q/</HTNW*B7.@/J: YQ-+YG$%,=B\G_*/1%S1NZ'S,<,C ?>AF)SYD>Y0E=
MRT95.YG/\3\MU'L60O= %EUA8/O5N?=]%@5E48B?BE&@M#JS7#@FS*=0304J
M-_ ;Y.4RB,%?(-M<O9NB;^7!5B?#UB+OF&7R.O%):.T9=&W9'MXS 8*,30>Y
M@\7?[-H9>+90E$ ^BL&6?7;#V,1S5S;YCD!/07U<[ BYBA*]8)6!WZCI"PS-
MZW7 R)OF>=U!K2)5.DO;UIT8!EM2G6M+Q11WERB7G(YA(@9=?^MKO90"QC7C
M9ITSDX,EWZSM^N=M_N<'4U\"AZ4-[D'UU]M18A?OS.RAVV6W$E6GAJ^K@K.Y
M7^GK&(U[)H\,MA+ 92^Y.K";SD85]'"/*\J],E&]A^"[)LRW514NN>JV.=';
M:V%QS/Z$FH"F,**4R%>QH;"<_N@@D43HK]KGWH @?DHFRESN%'G1;UU0?B!\
MM?]PL1Y&\ML[[ &_UE:&&*) ]1F3(%BEIP(Z8(U9YAD/?!_,2FO1)3W J&/(
M1C!5+K(R[]25/>LUOGXF[/C,2H@GEP<0W/MKW$#Y[M L X- '1W!3TE!GTRQ
MRCB'?Z0.$^$QAP-6-B7D,T(A*2C[N>S[]U/#%OU+'=42=EED.B& FX6VP/S[
M+!DZ8@$;/]%3\+* Q[V!+U4J63W#=.]K+/>>&O%K\95T^[\=B?_;D?C?UI%P
M@D$232BDHW#[R?,8(@2\A\U1N ;(Q2P"ZR#*SVHSO%;]#_DE<K9&XL@1>I"&
M?/!5_A&[<B*$X\*=\+5:!(5^1X&= V7ZFS(KD-OXR.Z<-].8P4+2KR:SQ.)
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MRD\8#_I].YPGV5+.2"/FKR!0A!VOW;A:7I)[JL*:WZU'X]-$Q$TK/\V[?(1
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MU7HJ277COC2X&U/KADIF6,M2KBR'EDTOH*SC1[^EWB[Z6))\TLEN\W*4[TI
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M!QT$>]!1M)&A5G+LTQ#DVV"L1U<-_I#FQ@(/_1DTVZD*\"%1 =C6=B;2,E'
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M[E52&J6S 7PL6?[B:\05>'\,SN2$88X*6"O^Q)9)!2R^A^^ZMG-3 <A3;2K
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MU$Z]\ -T&B4YO5H\E!4'0RY%$ $8'<0L+PH8<>@O8MQCW%A6&#A;,W'GY/D
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MUU3LE%456HB])Y7D[B$0YUNZ<5P[^I3G [VT3^GZ_'FZP5REA2_LGM>U^D&
M_Q4F[#YA%,8R^"4C&R/3" MSARI%7P0=V)CHKYG<.]<9;D:[M F7V[#D;)E+
M0VI T0+E4W@WNWQ[=Q\&)>S-9.3 H(!!BI;>:AFAJU*'8TLHEIM]J;=6,"*J
MQ%E3X(ADFD+P>"CXW!2WI3W2+((68S3S>8ON2%_+1XD(G\L]K:J//+XY'OJ=
M3^]T6"[;-RK_\T]G%E%0X(/@445&_$ML638:?@T'ZZFP9\BZB7L-87#80^($
MPDVN+OY6*"GEJZ3"-<4Q"$73QYQ7)#SB.E*!^I_KX'J[%;EQWM@R]".L:C%2
MKO0ZA)1(?/0<^"J%1#K9I:\_RT1M736HDETJ,1$YX;[E0J^X]B>KVCC<5?$V
MSEL%RW\4&X4&7<4Y=3F@2H6?3[)KC]DUA%37UB 2M<KH9TU6$I]\RF;I2BRC
M,B(GVWXJO*H%0:=&$J1\E+LR63%:ZYU?S;OTS1^_BFJ#, 0N%/1>MS+O=A>[
MF;)&KFZ3W#SYMCWH3J'HO7C<T'D;F ;J?M?(KS48%0?82O'V2TY>CX+CU5Q\
MJ:.N/U#S>->A&JOI8$'NJ<11'_"QX#7@K/)?Q2!2?'6,F\FWN/BF_4$Q 6O>
M!:9&CXXM_Y(0B+]>(=!Q?3M9<;<S%N%S" ^'V>[-R*&D=\26:31[4A#563&>
M 4Q'PL4BHJ":^>$WV*[5)ZED.W=X7_= *S*ORC7 )U&76.0C\6G8$U)^&23K
MMB,(?J_( O7!PH,D8?1./$,'CS#->EKY<PM]Y\]>VZ;P ^[W@'WK$N8 9']T
M< +-LGMA1WLQK4 L)$82SN83URF[(NLY[7T6G?HN3Y+^HP_YQTIQ6N1$4E Q
MQ-WX%Z1<^J,BG8\:4KN8LB/ $=WU:#.QM\S1+XZY<C'_YY/B#S6/5@'+H4,:
M?-/CU9<.(#NLV"22.^@0HQ_TR(7>"D.E=M[>GG2E2'BKFNO&3<U/_\@0W]?7
M(Y5?I@4]A"UG9Y&+7#=W! &:E:V+;L].Z2 '%-I;'KZ /;VXSC88[!CVC'FJ
M5\\$CWXM )$1U)H3_^)_6)S+6.Y\64TY]M,E++ #$1THB9M&:U'HD 7^>F=%
MC2GQ+A_P1V4QSZDY\9B'Z:TM,L68YLQ]S35]+S/,='SQES(*%2,"KE!<E"@*
MX84Q=>&'1$ 8%\.DA+DEZPY%+GKKM[6YR:]N*97795?3(KR,G&FS[O6\Z:R^
M*( Y#-/CZ2\2\9PH2[KO3=CI2 :M<><R5S1UA(<\E_6O/HKQ]Z4?QCUN7$6]
M5ZS^T<J/ 78#HQ"7P([#%% !7#8Z Q;!!HXY;' MJ5'*[;65C%EQW!Z]!*(!
M[?;U;S6HSP4!D\$[=-ASU%YG5F06%Y09W02DP4FWI^=@'#)I WANHR=<7OP>
MDQ^O&V+I6<9.[)*Y4;P':VZ1_24Z6_TE.MO^)3JO!]+@S2IP^1B[#BZ%3YVY
MRF4.(Y;->GU,/,FIZ]'WMT*I*<ON[,4U&_\ ?X"J%I>8B$MEO+T<E<-'V&CY
M0[8.P?&#\&EN(8@M(N Y$3"6"H<7KX#^^XO_U4*7IT'_+,22K)!PDY4B2T4
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MGN\JZT,,YYD?_]RT]EDQHDSVZJ.\H^B+C=NQ0^N0;T&H:K:^"@C'7?&)>HS
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M6SDV,WDN?K0RXAK99>Q&FQ_F;95;#O.6X6P;S27#'#.UG^A?5E-JW[*J40%
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M(:()W)'^[*6*<UW&-\MGYI_]?->HMEH0#VRJ1W^7X;.;:BVBE#P]+R#TCCG
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M-TZ.^7$.<)RF 2X?1=JR5.6I5CY<MJEFC)W.R"YOLD1UA.FMD Z&FG+SX!'
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M9!>\FVQ96?_BU%"M39)ARTJEH4Q%^<[KE"@&28F5+6])9IQ7<@*$!W[M#9B
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M=0G.'I9G)-0_,2Q#"D+0G WG<A\XSDS#O-NP6D]R'1Q^F3DS^7<671[6Y0<
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MONWKEXK4*DDQXM/Y9:2S(QDWPS86"$I$"FBN3H&D3<<E;_OHS_<;;;=K?7+
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MQVCL^A*C5W \7K;7IJL'OH;J51TZ3G?"1]7S+I>V.T=]SX4;+P7)"WEMZO/
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MAI;U%=MK]C<"@D+"(J)B<N_E%125E%6T/FGKZ'[6TS>WL+2RMK&U<W%U<_>
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M//]%Z[Q+O-#U@(P4;*.#\IX#7L'<3[:L]YFK9N"L?=$#NHJ</58?^7:YE5W
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M]7#.]G'DW+Z>:7.+'MG.AJO6UYIHA/15.K&8=O_@2?[^E)WF[-M#4,@Z+=0
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ML/DK-7R_B<I_Z>-\:G[^WH4JGG".X4V;;& QTF_)L6%9W(%G[LM[1ZIHK T
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MS(7\)KQB Z^Z*5:FMIX!).\QPVV+;%_/LQAD2Z!_XROW!9R:(1#YVY2_NJ3
MN%IPAL1J9*A*K,X;/*^A2.=&27@Q"T54)B8Z]76U*$EFPE[Y*'E>\['+WUX+
MF[!^^?G*DY.*IG9@>?>.W9K?TB>?M[8H,7AH/RER>&B6XT$E]<[+.CXQ^O93
M3,MQK:>,3/ET%[8/!8(R2"3K_>":)*(H=VN=QCZ.6PR7-M5U7+QWY;^F9CH
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MP$_:]((M09YXL1EV]-B: P\Z8/L%9]KUGK;5^P9<]A21 MP&.C<,:%G-](+
M<O/[S3*1B+)]J='Q_/.UAVS:RJ<9,Y;VV;R&2SXGGHT[6KZDX2_#(G/(%S!\
M)9W@1N^'=Q?5Z>6>;#UK98**?HWYVX1![@M^G#:SUXQU!J-,?\%8N-FH+X_
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MX:8'/S3R#RI./J+ZIN?ZV&\#T@%E8Q47>@Y>&87-=815@NC.@U6H,)>C>#?
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M22G!?GBHTPMG_]@ZZW!FBB<FH"CG23SD*U]R)4-[TB504U>G<PK@8Y+KDR0
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MS4:_RGD-Y.([4#Y[T>V5IGFR)L$6/N>^5(**ZH%-U5/%"$3ZDDUF!I"F>HP
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M?K4$J!,.]NP*,#"R8.'VD'(*.E68^+!YP*TZ^M#Q)EY;0:5&^S_]T&$8^;&
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MH&*'E->?8S.!*8X.LNK'9& +DLAA:3JVK$_B[C/2Y9X>91A(IN>7I5^+M2;
MS<PL%;49_FP#Z%C 3 +2&O8D>VM8#W1@*7E4U%:"76\NTZRGFGAAW)L/L\[Z
M3[V_4.4DXG#\_EH<O)_CEBL[YPQDW[)88M4/)!TR#EOK73);&<SQ3PL[XO&A
M,7K]3 ) F!,1R/D3[#?;Y_UR9@3OG76*CE&3D%2+CZWTB"V'R# X=3TX*D#/
M8W._.A,%(?^C4.SH0#&MD(+;AZ5'?4/(,*@D*_#3C@J)N55<N@X"P=6Y%>J$
M_J#,&?QFZ(K=6N,RK$6]-R16VZCNA@2A#.JR9JC]:I35@+%(Q%56\;BS1YG#
MDL)O[VK6T12SZMO>OIUHUIS.#S]\ #7,5A),I#($J%1]5"C!3D)QJ5=A7[&)
MPU63I%+<[LQ+3=[O34LD6C$23E'F[H/<)3./ %M7@C%7\MOY06C)09(OJ&SE
M?>LWI!(O&J^LB84BA)0XMN(/5LA>BCTFX>S5%R0^*G:5NX-*/4XIF&YRO0G,
MQ^8?MBDXK8&AE?>Y4!"B'3X$;(H&.L@.R%*@"9$1'0V%Q@1K<7P?:T>[X!0Z
M^,TCWA/C59]6ZC&:\$=V.SP#,!%_<JS72E)R7[B25[F@'J:8PU^*WB\+W$A^
M$ VN@X17>(V9J>)ZX6+EEBR-%\4;?SNT WF.]JR^>HLE!U].PWQ:NY4J1_N/
MC,B(H?#7-_>'!A]X9]KY^/ON,^XTUA7VG ;O6PX3^F2U3>7OFV4PDF[*@\@?
M 3VQL K0*N%4N]YVL+-]JW?UMMWH76"AQ]&D6=O<ECB#-#?' P5.J.Q?5<3I
M Y[S(P 5"SA?0[DPA01?Z*,Y'P'A% 4/=.'K3/<477C!ZP.@J:X-3139PY=J
MPD? >O$_BAA=\/"OG7\1U/Z_$0R _Q6A\%_:VT!A)=UP__<MY3T">B$(COMG
M00S_CM6['@$D2F@NHB?!4VD;:VCR?\0+28YQ9G'\%GE]Y8>:W+CCI3T=8B19
M8%428M^TP'"WO\_DI/HFJ]%<G<4C:T^ LU$=[>3$AW8N1JLBDK(CI>Z,W,N,
M6<3A7&X<V@==HC@=@3_NU+IZ)C'EK8I4-K+PU^A6MO=E&!&["4]O$Z8E'@'I
MJNT<.'L!&&&*H&[H_3>@VJ8_RBLIAI%I]H*!4?<JRY7@[]0@Z4M93[-)VB<G
MXK^M\"=>T1QVDB,SHM#N3PZ7;*$,)W$^]7FA1!/=5J4]3SV9$[G]M6JFJHRE
MBE./?)3LB1PWC(&<$M=L1#/-4DP$HJEY?[+$G7ETN63&;!BGHHDP/EBZ?PT\
M;)Q!DS<*QOVH^IAI8Y,Z9KND2(XNTIR;<9#^7:8#U?L\_C+1HG\:E-[D%WB<
M6\!P&7D>!>X=FWSGQ.@1^P=BQ/]3OD2Q++ZB+9QRHY7^P8YUJ1ZMGD>@]*X5
M?&6R+#.BH[S;&_8S--MSLLC7.W3CQDN:_SAR)V]\VD'N\[KUA0W;\W#X:JW/
MEZ-&NPB)N>Y/.H59\1E!Y>,/"H?]33.6!*YN"L65KW+U$@5%NYC7O8<'.&XU
M?Y#KO+%->:E5ZZ8O]^PIL7]B5X3IS+;D;[';@"M-]I7RFZ\JS_!HZF!,&O-F
M%\V7'8)VOWYLY<JF:=E8&\E?K.1V%>&K$T8WX"5R+G;HG*X$/@)^\$><>.ZH
MA;Y^9Y ]_#?ZL^+F:RG=2W[" ;OBM?L4(PJVN&O% (H/."QN78G</X(;]TWL
MDBD*]9^ 8[_]^Q"3AF&6E8XSA[0\<0["I$UI[77/*<8^^GN.<T,I?PQ#52P/
MM+.-O^GN.X\VIM\6&"FP5_9)?>G#C%=468_WUY=>BV;L/=YJL<0W9<EPXNYQ
M2FYBA%8S-JS&<;**6O(W#0Z3&D92:."\3^S,7A"?<6[ +X]367_A:\UHUMMW
M+2W:Z#M$D=^18I(3JY=#W>!B#]_;Z<Q0XO;?HI-+-C*%5PYD__J:HD8B%]PQ
M9R<Q*:(TX-UJ7K=!8*?N@/ZSG301YO!+E0(G.>D-EB.X31/L6G]'LQFY:S@Y
M_J)9AT+E!E)%EQO6DL2X')C5VY0$'80GDV=]CGWV'OUGB&-GI-)@B*Z-7KP5
MZ9KK\+*@;KK)#KI3L*98+TD4KN;!%'Z4@/RX^]KP:R"WE=9"1?V]T9;*(P <
MXHI7&#%9BOFD19IJDR^+/T+,T)1OC0?C@)";>]VZ*9=EZI*N[2?;FJ_8#[:H
M%(\'BNLFE<+)?DN#3+P<AH4'@\ZL'-?8A@Y9LVC#/F$/U;YL4>5*"X*_D\7V
M!X5[#.>FETE1]2@O!_8(5B,Q]&]L[OSYRRQG+MRIW^6)+9:S"V4ZVHD5@V$>
MY3P*>E6C@]*G_2;X-+:UG?&1.(YAA2?H"#D(,27UAR7#F\(+O:JF/D8FQ%#T
M,33SZCCS0?=;J)Y;OV>/2)0=R-8K*TZLB;C>CHYM\ !EBD.S(XY6[9EUS6FL
M=!8^#&R0.158#V+MMMR)+[7!+80?VFU?SER)=-D] IY!& /L)3NA]-Z:T/Y?
M T[= FY$U-5-^NS4-_*G*1X6U $2[8^ +Z#-1T 4E.Z%T3)\>$:4O)2AX_"H
MY=2JJ2G=SCEYL.@'_"=F-BS(.AMT"]'N%=+I%I>-48'NS<NVI"M0C(/QAUI=
M^Z6?.[9J?5\2_O6ND@N+1VL]>61KIM7X;,EA$>+QJEF,AEOX/WLOO/GO69EX
MF;FI#A4F@;EG6+F\/;U-MCC,X7^2M/4IR;5#A$XTU&5B :[IG9!*;#;97LXY
M+2SQ"Y#X)667(=6Q4ZY%I@H;OUG!5"#7SO\T!^+_;=BN,9XV2,+0DOW$ =*S
M5;7/?:BWG*8/#><<\7FN6$'C#T2(W9]+@9'5&W?WLAK^.4;%D4O/F%,Y)3)%
M>$E__;1)?6I3HZ1MH3]+R^[67?:U#X=5@O$;QCE'1(!4)5H!<?16O0DQ*U(=
MZ]1PF&"B,N_"5]F G?C.%Y"N+.\@.AAW%A;BO/TQ]B_0&>$QN/H260<2=%SB
M'4A+;[(J=]@]G225)^<I.AY]M3CR_%UV[00A@.*T)$P$[R<6 X#ZR;?X>"V<
M28OGPL>R_4RT 99;#&3ZF8<]9;6UT8I6#<X?<&)]R=R>IL6_<A%(D4PVZ^HE
M>FZZB$H:"GK5G' \VY_YS<-$GKD/]T6T8J*2\YX'D9,?K-C7BKI[J)BS[W\H
MFL"!*:R]$"+.'Q\DW(ZP"W,YN;AD<OT:_='VKNRXFV/?@O\ 0H56VF3"5T'<
M#21W#$6_;$D(^D/,13[QN0^3E3'MLJN?_QDT#LT9#!7"2GGWV\E RO0S]+P:
M(ZJ?=NT+O],6TC6<!<9_K @WD[>Z^4:(,QY&M&4J4CU>[FTW9IM<=E ^YQZN
M[V<&:O5>[."9R-CBCZJ\<,5$J5O711Y,3(#S,^$?23KE<)AOYQ- 5\H(JMA*
M8']#\RRCJ6KDC"GN"/TZX^I\AGLQ&+9%66#==(7<EV&*M,GN'U9<)Y+39'O0
MN^"M>/-*FRI"BYS(T@"74WVD4EBR9./O%H?$AR*P?8;@ZA@T?>@W(Q^*I3R
M;ZX=^ @@K'A^E#ZSI.[.39GL<^D!3S)&)N$WQ:%YW;>^3+4K6'HZ8V;=\<I/
MW;3?KU2.>0P$?5&A^4K21G-5G1LD^#":2[M0Z95$8J\O"$?EP28LN )KWV]!
M?FB2?RBZRG?;.O,I,F5U&/J0NJ.FYF"S'W15N]<:' E\WDE:NR#215.5Z@[$
MYUV-^S3\.X71.W_[5](G[JQI$>H C[R#);WLY#]@G8FC8?[J%XPN4LX<I?]T
ME%[PHL^&/_AT$P/6P&W34C.+.2"L 2]PD!_2M*BF.%H50HDA#GO-V>> 2E6@
M#-&K:QYV2<G6Z+0H3[V]S('2#PD[OX"7!@P_+/-B<@HH/&>=S9R][WS9SX%A
M0QMG(.\,'7!PGUAKA18:LJ2K.OPWN#VVW>.OAP5^@!E$"W$:UY" [2I)(WQ7
M[&T2T1^O,KQR UNR8 AVDKK9BNI^!.!O9O5ITD:VSBT)[/*P!>3SG]0>ME4&
MZ")=E=KJPO;TVYJ;Y[Q,%N5SKW;&1EBDU<@L0*F6W#K%2.#JH5)36'Z>AF"$
MN3W<.B5I^,(B(I<Q<E(E=J,'%!.2HBBM(O)W!FP;:-N[LS"_&\8^UFP::LZ"
M&-N<#X>;+)HJLS3'/V5!C?MW5MZ]"[9"25_X:_[J(3^@^/+J><J#R.7,M\RX
MHM+]HN4=*[N&FH_[#=JCV$/&^T"2];A)NO>?9M/8<LA;"'L4L7PO(3%>SB E
MT<BY0IWWUE@(T;VD2J]5JKF3=FF:,W9[&]:G>0/.VFII9R?\/E5#I6#-=9&)
M/&_-:%?%<'M!M>7G5)AWG0U*6TI]_QX'6+97F5<$IS/3J>E4UX6JZ1^N/"0A
M7Q4M:QUZF"XOY@WW65?/BNQ"R#I?K08H(4W]3 DG,4=9M)-:J(&OT-S#%0?3
MNY7&YMNZKHU1ZJ_*?B5(!I,YL+JJH5*#-SHDQU\VMM?4F:K0F9G4NS?ZARD2
M@IIAG6SV?GM7HG7%"JX.FUC8=-')46E<R0D/0RU58OVW1\DHQ=E>H0'VE>G4
ML=A7(?P\S-;\745>CX"G#_1_<R5@%PD4 :(+"V?-=Y9GP^Q*YAYG%X?F+D0B
M>0EY]*8ZVHX'DQ;"DW$3 M\K>/U:U/T(YG;=NA87%M);+UL*BDWY"DH-[?WT
MIEO;.]/>XB:Z-Y\I!(6AI1&9*.[>S*"4%!J926J=?B_I0]:>?RT":=8=MEJF
MZZ5 )B53BDU8/B/UWLN+(BNAL0CW[TTQH'PE.Z)MDI$\#HYQ,=A83;VV@N\0
M+$H5.8EQZ./W"!@\C0T&F3T"_O#:0?>18]W*2XNVGXF<)_8X_O@9U,*82L#D
M;S=Y#8QG7/1[[_3K*#,B\DEQK/6)?V,\L*V$$3T'X!0!? U"@E@"E)$Y$^$!
M/3SUB_6@\@XS]EE9+P=P_%.M ;Z-7=8G>\R-;S"36W]Y:L8R N>"&%!J1FU(
MQ>\BLJ0.X\&,.7:%);D"Y'39_6:C@J?6?#-6]N+FRH-)O9.+8+"444W[G.?:
M<Z-QZXK(1T#?M)F\NQ^-:C*S+UY^#=NOA$7Q'NIJ@^!P<_P,U1GAQ0 )2Y'(
MK[OJ,JN&8Y6EK#BVFVZX6PS2)9B#SIV2J%3%>I3/9C6Q.2=B+ZZ>H7AT=%K6
MJ_Q[NG*!4H^3JEB$OOAR\P2!5V;#2?6&9NPC "]E<Z?:]?)0;45,_ZOB"Z.G
M6A7[+ HW\DK/"Q@*7S3:H<1-+! /.<Z,<<5HZ:FBQ(=)Q5^UGI#CF"Z0T,D?
M5JPQ #G]%@?%?!+VD/_6=[22/V>F/[==74TT4<K3Y+2B(+\V<NWDZ0^$NR&2
MR5/:RKCTA.ZJ&MC*S/Y3&"'^6MB<8F%NN+()6-T3RD^]Q@&\Y%E#)>B_R]**
M"O_\T-!]M?\]>$/#VFO,!4ZXO)QQRC %8]4YOED)FOGT-)GI1P+\LR;-D$@4
M\A_?7"5!-/3/OJL3[AM-?"'W-/F28M$@+FB6BE$_N: ?T=$OJ+%1H A((6,-
M(_0+JL?8"2*)7*.\)GW_W+T4'Y>&-SN-8! ,M),^>*@M63L@6S8;<J1]06*X
M%]'[%7RX/VX--M^=[*N"T='Z*WWJKAEYH_PT4%+_?A4J4_!T'[J$'^>=8/VU
M;,M%D_GN@1Q[B+W"4:>O6+&VW%40RTNWCJU1@BE!DNC9W];*&BKO\5?JU>%"
M"KOQI&K)B?[61*I-/L5#98;E*MSR7&H)-Z3D/=?[\9]^.0-YR]8,V6I5WRWL
MC7&[TWSR2!E+;-[V.%8IO!8H5\P!G^G%IIP;"+#.5M2[DJZ\9>];VO]."C_]
M'J:I7I15_0@P+DK<Y#:S=.6MKFPT>]<D5/UC/D1:8#7ESGRJ8(''\UY->W9\
M_J!>_RK#M0$*^%S@C:VH@6,<I3VEGE[,W/5+M+;>4-NN@9SK_ED/YGF5'?A^
M;UPOX3V95L(WWZHL]4579TE/IA+0PME;=X:5MC'6D8<D*>NG.MAB?O$ICBI'
M+@H-[2#:$:&(KS?6EM/^&'-$E8;MB+DPW(9F/L4\Z'&_I5% /\ CC=[]XM2
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M&S(H0J=?($?-E/1%30#GEK7MK[@Y4VMFOP<$* ,Q0M+#;6B;MN]^9Y\@S/>
MP)]2Z!(I> &&Z![PG]Q_PI  N\#7+*ND]X .YK]TECKWOXQDX?\+1W_#_ ]'
M+__=D<Y_<?1O(ZW_G:,-WS>WYFCE#2C>B!T8)=^I >S^,#OJ6@0@)NC;WI41
MV%U#YK12^TU((BLPN)Q^Z!595R0YO.;B1/X>\ 0G:,HK<3F5LXA1HN-D%VL#
M#QBQ^F*2_R"">HUTEWP<_+A;/T\5ET,49"^]DV^,W.F%XMJ\UO6#\XQGO[]4
MG,YY535/_U9J17PN>Y^^&E2;Z$U#!)&<^/-*![PJG[<DS)ZT=/KX(*KA>J(
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MMUWL^ $2;)G0K+UK!4<KJ\>U%QR]3$\5_RE4/OTH^1"*P(YQYNL1S+"QH'[
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MW*+EJL(V9? [=1"S*M:DF&P>.]B4&%)_^^""D?_!J5]W!O&I.HJP^XC/<$*
M?<5,LRY:[9%MK?9D_?>RHL_A;]2)0/SN;)-\/.J#^T[2+YT=/53W((HH_7L
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M=64W>/(A>[LI7(-!@6\LJ7[@8B7\CH*H2/RIX=/S_#1$OC=_Q7R,U8M,)'?
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M>-C%+?",U[8]7L,;A*D<-4[85S43]&-+5/KJ8HMF_.TD^QLOJ#.]"G1$IQ/
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M^!%@ IN@ZL:BR:C/9L6%[W\V[U491F!?[K;0S)[T,#2)WEWB1,90;GA&G(%
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MK'_>[N1\7720Z(&'W1J;<H90<Q$5M4=SOV ^,V7(N.\RS\X[[/A20'REPCF
M]N5)G=4W_(56R ANM=K:EUU7]99*HM'(VK$H9$F7TA"'01O'27?&7UHA/Q^H
M/>(ZNIRYN^.)U\=_X@KM3Z39Y\RZWU=*\^<;/+9-E="Z#.1R)7-.(H.)115N
M*DF#IPMY36L_%]"!?/,^U"\R%*-$/Y2*16^"79=,S7^Y.TY</IR=0V[$M=^R
MNG8GT''URXZ+9V"O][T+'@-:\>H#<9+N)%J-+TTH0"!5KI);V\M5@M_EOL68
MU,5SD<?8LV)//ETG[BAOM97A^&"&%5#P,O(DP1UF$/CE&_L01E6&]EJWG,)
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M-<^#(O#)!.LE6Y\0@6XP:XO"QZU1A^'J"86['W/5DI+*!2\PY].8G<XY@"D
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M]Z%JX?$>I #BHZT#?4Y'O1(HT/#]4!W2KMD)_:JUFG,/U-U7# A4VC7&%?2
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ME[E>B4BO76MU@5[T;PSF&II5MZR!<S&\P?&+B0=E+H X>/<7IZD6[5< ?1&
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M1DSF&(J&G5(VIZ=)?@&RJ]UP:0J#YNBZ5CBFW%RQWDB\OW_"U>Y>YME^7,A
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MLDW<"SK%V(&7D.J66%R=#CZS8M[U+)!EAA@9.$._H/_^74<;?]*[H1!M25_
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MOWH6:)01@%*67W^(KULXAYZ&[IL@FDTD-O$ZU;;QZMYU4<\+0:%7RXL^';>
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MC96Q=X:\WS>#G/E>'E0VY?+:BO]J15Y9K&X!$9%=(":B3]&J%3/N1[#$V+
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M8F;ZZR($1-?G$).0DY"0,U%34C/]I\=5-X#^!L%7(A(B@EL 0GH"(GJ"JWX
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M+R$/0<67*3X&L1S<9W$OL/&E($[]W*GY:MKPPB@9WU'2XT?>[[T2+N",U]B
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MYOIP*8&I[R$F#Q4$SLVW\GLPJ-+Z"U8+%QX!M%,,[N9K)1<_.T/4DF1\MK9
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MX6$A<$AC7LK%'1##HE5G;=JS&<\R68RBC^>O/PFDVJ]Z>L/L)+#\F"YL\D5
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M?&&Y_WL1_"[S>6* )V/KKEOA^; O(83(TO+H$L 2_,Z8>%*3YW<)2)Z5]B/
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MP/$\,:<%[;$)@ 'WR4FU^D5.!PT^90WXNJ#M:HR1L23>MKIW"WIE0H,-6A;
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M"F8/[[KU5$WZ(CY>G9(GGN6BVZ<<D[V3%;S0W7^C=7&=QS*Q?3$@3GQPWR4
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M.V<$PRTU)AB\@V-69LA Y)B.7N*6M6R.U")-#:_YWE:GTQX[I8KHIHG_M?)
MS'0V_U.1G]0YMMP,/<"8!.QHYPPO1^,,A,Y(5.&7GP/XW7.:.;^(/A@! \8+
M^[XEFF+L=A$F.&0<T+2UR2LK/5!QV0BJ'##@2;C>ACC)Q'?Y8:71066810=I
M@IF!QZ>XJ0KF*(?(C\4T@T^YWRE-!JX)O8@,%)G2ETZ:F.O$[N^<(@I@B!@,
M$S[VMVT?&G_TR..!X4G,'&*F[B/-:*GH'-&B0"T.)/%Y4\"DY9M\P^ZUY@;?
MY7YVIXS1T#,!FXMZ62^&J%G.X=P.1K;#;3+#\>-VLST[0RYSPXAL]8$ \:5=
M 871T'/YU;)8D#$&>6V3$YF0' VIR'C8C/VS'L93MG?F#VP?@&<$3?Q8&"I?
MA7-> B(A>/-NN/#D<;M:OZ.@H7X_VB?U5(/**6"0)C]L=NY69,T5 KR^IKAM
MU$>^^E2#FHO#O,@HWC/[V^ CU^?TC_B2Z]? M> NT=&(<[>XE]6RL9"@Z>.$
M)%-;]B=PVQ_S<_Y&NL=5!B>)%\7'R.AE56-:/$+O>TM+PY@X2!,B5S#"JOO,
MB59J1X!6&^[R3D4T;@KAP_$'I92,++9CH+/N^$B';7I!T)1=)0]QY2EZH>U/
M'UZAZ;+3MAY?4:HK5)>LU65U+8*G:SW^AO_T_ZPTU/V+$A+S$LP9[Q!0.#?,
MS9EH%;005?@AE<N0O.)^!>,83]/HRUDU@CR,>PK.Y8@G@&=@3?6^[-NC7_7<
MR$(B)U0*F?@O.)H$4P<4JB&?(O[SL%=W!^RB0/76"M%A9J_.0;/3D1TG$27+
M(VY@7N'X0V"J;KL*UGSKO6#_0X8?71$<U07_"NA=T*@88%?'S;$CCFI!5/C]
M[N6^ZKN$R0]K-^T):=(.*B'"N_*XC2<7>23N%&9/8^!PF*\;LY'./FW:_0;*
M\/+F]AK'LK*51^5SB[\7?M3:+FE_[[G/75%$6T'V[Q%%!*OHB*H:/LP>Y]LM
MP>+."ZQ),9DZ-N!XB4[VBK@N A$(4!PE4ZS6*7V"41AB?'>/;,T#X0;D&%XU
MCI:^4HB%1Q@$]3^K?-Z6R85C6Y&B_*6^#<$"ES?1"]I^J3,=$1?Y< [Y+M1;
MQ]M8FR:VRJ*YRK:L^ZT6*YG/"@Z3>C%5L/OX:?1H0@TTBJ@F/7P1\V6H^'=T
MY\4.=)#[H P$='$@N0,^1;ZB"YD>Z*^D'UK31F)G+/M;PXH-*G0.4YJ2OSQ-
M,:,2F#<D VV<1.!#UL <,$^\*8:!X9_EZ8+Q6XB(+,U@Z103Y3L]QL1/=S@$
MW8*,5$09^E9J1XIP.@,4VW98MQB0FFIZU>+6@EIBH%[#"DAW:Y2[O$[^0R>+
ML)"NXB[87" D]N8_#W?V'VPOU5UXL")':0I)''.K]P:KV-"4_6 &HM<XQ-"\
MYSLHLR6HS*]$'\P]1 /H=4*^W^ [+=!Y7@[";9[2>;-GHUU<N)\WQ+Q\);VH
M6H^KRL :K\GWAOG&91LG'R%HH*$#?4'F=Z:.%AM;6T.4[/K/.JW7>++*1RO#
MRTP<'09<? 4G>&KZ2^;. 0\-KZO"+G)5J;SRR7"G<6UVF,>-C5.RAO)&$_SU
M#5DC3Y,GQ)+NP*X=-O(%D>5[_?O2B04G!R)C>8'?9XX,(D)*'45EI*NUK\4C
MISA7"IP=[0B:76O;*S$M25D].3RJI[WR\7R:Y0XY[I^T%8*7*0(:^:Z-&(59
ME5M=PX6MZ<20:#875#9B!5-O/YW:/6KU8R<_^]XP9J3;G5Q\3@W [@J@$;TT
MH]%P=NQI0@<;E,RV-MKFP7Z@;M7#3$L[=>W&-"WO$:/UE^^,0M?;JU?9NH_P
MRMB!)]BOYG58&SWIQ_*LUJ9_W*S?Y^L7.!6I9OR+][\V$K[I3M>=.L)\&*\G
MQ"B^-M%VB$;U#]-@8N+:7(H\GEP"W+']!2WA8_Z2(^9!.HVF>!/*3&(@WAD'
M7.,MK,3+FTP0Y2'84U,"*#.[]>=0>)F2I =#1ET<^]I?OBKE66  @=?+''JX
MD^!'AC?S9;>#MN]G@U?*TF\:UYY!_]3>4SY\3;4/=AE7IS.1OSUVVJ<4?X],
MWBZLK_Z#]8<9]"?GV_I4ZO@S/;(&K[_;X#>7 $90 *:5@0,_V9-_NP$7]*;4
M<<[N(A-=4C_#:UH/PGUCQY#E%=<,'E5_W>1H2,PFAVUB=5;EB?S 6SYMP<+1
M@:CKGMG)[QN4HI,*]07K\B&OEE_Q71MS>L4 FAWWZD[9MC=.A$OC#3IM3Y"?
MMD-3ZZ9EN2^2I]3W3LG]-;PI!>G];'D9\5GH41[C8(J8+X\0*CG>S1%<3)WA
M/ R_4+$%]/EM:VN^/3R:F)1H]/=)F%T%7F-] 5$GM)[,_U 1\+IR751<\:A:
MIR#71!K-$(6J&4V!<^,ENJ^@LZ\*FJ4Q#='K*Y[U9#+PJG,]<Z4&^&B^"_M#
M?1YPXHDWENAB>+/,@PT\%0WQ<Z;A6'\4Y>$PU+#B9 >,"LUC!IB$FC[)-+U%
MGCA&^1-XA3H[%9C]Q)G3V0XV7$/U<Y4>.U%W,4$JIR'NB(1,5W%V"(";Z89P
M_"7@1:4Y1K7,U[D:;ZX>[W ?,[']!#><6R@K+Q5U"/I+7=SJ="1D7!+NZ&9*
ME?ZYWPO8[2@U2?0N'0POY1AN"QA\N>(>@?;^]VI%%* [JCDV1M'7LA/!-D9?
M+\1L<L/0@M> :D;(ZETA==7#XK77X>U>?\)&Y_4/,5I++56-:%\&HAJ.:6YE
M,XL-SOD*YVGZ)+&F]K,%WW7-6_.*E!0=/57F8'PA>H46WZ.)[2@,_[.=/7,)
M^&:[(SC\[7GS/TD5=T;T2FW,#J$:?QLC0Q+%B=3';ZWT9,*Y&R(7P)*ZW\(W
M#R/JY-G-?VS('OV5*J'.2?EK'3J0=/2;P7Q\1SR1!*]0;*R74C^X\XI*^>.C
MFY)*N=2 E6I5_'B1E]+HVWP>AAY;RO@]XI18*31VMS$31)SS_DKF4JHM[1A)
MK^U>X/8C%+$SK/:VCC"D(HT>B()4TWJ=)SAX\G)-B5^ORDSBG2&(LHBF+;V3
MVG7$88'H2!@0[U4*?<:1;1>FG?K)2#>*8^CF5+ZNB9]CG!: >9[BC_.6R)0)
MY2"PSFUG%./+BS_M#1V)?E"U"S)&3X^)IYV Q;[:N-(W4DL&)Z/N;2CT!61=
M FI*6R$5EP!7S3!OM1@)V3QIV^8IH6>U_3.IY%!B[6E"!CGW:D VP?6SS(W.
MONM3D;TL">Q\] "5+WW,)@\[BCPEOHI[?XS_.E[W/,;DIL#Y;*\J\T4*,0"=
M%/ X];9FQYON'K-PQ;VE#\?&=7)_X@-I,DR1.8JCGH3L>,#9T&I99S#6]TJ6
M> S1E1*="YE%I27YA9_<DP7KLR$O/W:95.PHC%:ZD";5@) DZHGM'CAG;3N;
MLF[;M$NC'_?-T"\-4DCX]#'973V^V6SXN.1+O HF9JF71O,=U<!?>_9_1M"0
MSP99.A<AO"=:EE'<W8D5$R?QFS:MH@T9*V%!:K)OZEKG<_>$ ^3]0__D'Q\C
M=W9Q^[U,_\K1[;8C6WLOXM+UIP6C?KWLY$G]@0>Y 65A[Y,^3+IOB1Z9G]AP
MX$71#4*H:86_383^#K8[%L+QL._U6<OP4PPY]LB_B>"I;Y61WIX;&%H)]&[)
M#ZXD#9]O0\'HY<)G8OL@<W0%(<GH@.+]U^"T$7;]3QJ2-Y<D=7<=BPB21+Z<
MU9CN'"#M;Z-&^4\>U>*N*7LA:<U!%L=D"J/UH6T&;\E*5%%Z:A\UKF#([2/1
M&6M9MM84:'B7/'&3TBQ^P_RAZH1SXAYU$5#.CF= _V T%EQ[? GH0[ _@2!O
M0+V>)/>8-D[)(-@V)]9,3!)I!,OKY# 4TDU5HIOG]]CGLCSOG>P;?8HG?Q1*
M8_?-/!I$-DLYT\'Y[2*NS>HK['&*]4QI?6-[?PEK&497W&9CIJ")7).K[[75
MT(^1M3$_<)"I.E ,/G+%C[$P,IRXQ&U\TJZ+DE5,(78WS59O/60K4>\#[B!2
M\OIQ=;G[I]?4!PP+YNB-V(Z[1(7F<9!\,$_]5):)@8RT6@;/GYMG:;]SR5YO
M]QNS;!_QNI-A4#'@6H98$B<^P&R2K9/$CE.+ELWS,6@&"7UU.*LH7E!:8YUX
M^%[<2(^;01.L3AI%4JWA)5:YP+1V0Z0XNM[#'I^'9O."_D/4MP<M1FZ$IGVV
M7TN<&!/[KX%\39I DE7!99=M/&86Y/+<[D04I/<%/%GQJH](V7>.ENEZMI;R
ML2%Q@Z(-V7?E-M'E$(R#@>%8_CQ(I,+!(_BVP8,<H3K6U]<+)8/W.ON5 L!>
MINJ>5I-H@FRQ2>)ND@;M<2?[IZ__BV)]#U_,WY92Z-PV+OV9[_JRX]-K-4&U
MU1H$.T7SVCX53+6^B>E1L9U<>0BGG$Z>Q!"[*IH9B6<)__A?_X1TK[ B7C#0
MR Z/YGUQ+ZSS^F8\_ $U77/>;W50K8AOO_I,*7:V7RW.D0^77XFC!%_)MW6S
M/ -S$)8YUNF&EG N ,!1[7"1AG 14SO14SJR54LX]H;W6!TL&ZAHW!OGSWA(
MGE 'N1^$=+K',EI4\?,J(1Y-D(2QX=G6&%A;)9#.KE?DJ>'7\>+,!+'RV.J+
MU:^5AM.=7<S*PAOT<<Q;D"*&3EF]EN#>U!'V[P]"\2E/O!SA(&!3'4B'Z+H+
MES=VQN7TDABG)1YVW$NJQEB]]&G5L%Y;*O?]B0+'\+FD@C,15)> U?=(I@Y&
MHCYV)>$KG \:OB>3,+?WUL-7X9#%;OT)(3&E'V4VNY>X"GRDWC]\7_-VZS<+
M"\'TN6<H>J(;P;85T?4(@\_Q5D8\VPS]XE'S_( N[39SS+_.5JL=5%\XC3U.
M_G7;HV*\_\&*\4SUU^*&^I86,Y>XW_K["AN)&\FK5G^+D5AM8V#Y@TO +1#H
MEY$!E\>@<'.!SG;FQV"ZB[=L<@?%)X=\:8HF?QUN_GP7%GFS0G;C$@  L502
M%?"*:# --,&L<?HXG'_XY=_V>LNG[^_<N4DW^GM!C?J(F@(ZNPO!N</8+I P
M+TS@1X&VAAKW2DUNG^PG_->V_.<Q*%7$:LH*E_C1)8 7BD3O7G2YRT*3RU_:
M_TWJ!BXC5O3USN,)E">[%YEM#@0+:+ &]A(00]0I_:?DG3?>VF;W[T^ =%0O
M=''.-=]K?25"#6NP'X<@(XGA??LS'56P1P>;608"G0V'*4JJR1]/[<<$CK;D
M?[._Q(94YU\"?!D2]; N)]XXHTKN4A7M [(R&Z?5LXG(@I0"01++$3="4 #D
MY,:"/24R(TX"\+4$0RUT.$/G0OC;!=[L?0A$:*^@X>^Z@.?K8N[7TJ/M /\5
MK,Y^XD-\&3JZ?=6+4"N[$K-G&681D$D -8^HO+FBM7"K?]YP1U(/J@8\@)C/
M6LM'8AS<GHRCT%S-43O'LHW3EGJ@4NZ'512Z3@P;X#*<PJM7 6\2QZ1<O3\;
ME\!U+P%=X Y9PW"<<C?OS<FJ5RVT:@M9%'*7@*P8A02<!?DEH+/B^/N?VS37
M$M<2CZJ'1A-16/V5.# '_!X^I]]JY19(M=9SMEJI=^8PG3F<447!A)+WZ"8A
MZ^0)OA/%#2>#:O8]65VVGX^M9N;>S5=+,_Z52)+=L3BX@B=APD-\SXDMUJ<>
MC62$)AC-'BWF% 8_/V%.?4)KQ4366M,)"K6:8J;%D*3P)Y/HK!X@$S3_P#5>
M3+S?#IF[*F6A (SK@QLANAZBW+V&)!82K">/PZ+=V_P/!N^\6+7?$X\YJX0G
MP><O ==!Y@1MF #B!M[+\=O8C=\_579F:Y3C^!V#Z'(3<U]T\&.%B4P2&/#K
M-N<B?'(/1CBFJ'U2O*@E*6WYE?]7^GMDQ\^MY36S;<M+!QX$X:CF.<,3UIE'
M:%QRP]QD??[O"G=4?<R,J5?!>F-M>07O#HY@?^EFWO:#DI27WX1,.H\:C5#S
MO.+B99;X>5D'':VIVV9,NOS)[BX.XW7#<Z*!+HZS..!J#%&8)(L=B$.AA:9D
M*E ,N@?S7=ZTAL /6Q8?3Z\;_]3M>^Y &EKFG5G#/3C?*RKWRNY'N082\LRV
M3(2B&<XV ":LLJ,@>F-;=YTT9 J8":1Y": Z24?G6?8?FHT'ACGX]!\?K62^
MZFN;TT@CJ_X9U+2];W>*!((L,&HW#3"C%&W9,Q_=/MG9C[K1Q0_*I/_L";M'
MF9FDF<Z^I<[2Z(7-,KQ ^NS!G&E)$KCZP\UO[H?6B\7!9L9,W (A3A*_*7.Y
M7819:K"-J]X-,=@.0R:R8'1"PJZ&H4/2V\(7C<%9H:6OM &=HI.?BTUKL=(8
M=SQR=3O/<;)7#L[72##0(L?:U;>EOJ9P:8H]2*,8T6%!'\#'5IB/5J@<H3,'
MVX^0VN,P\[MQGSTL3Y*_&_MN/(![ZMO=WV[B=MJ@Z(C%RG</,<3<V@Y86!H-
M"ZEP:"A"!-R_YU&RP';'!$#!_.H&E&V'@,T&<RY 2X%,*;?F/ 8Q5V=7N6U6
M3U!I_W%(ILGW8VDP8]!^C>_%1Q7#/..3M[B7JN1(C&'1_#"ZPM#OZ*S.A6&?
M=]SM@--4W%_P=V:_5+*HW/;:)2 60D!QX'T.K5-Z> 6_U4W==>#=ZQUXY?38
MEW]]QOS@%\.-UL0C]FJS-R<OQKSW) H<C$U5>=JG4/5_L02E''#='JTUMP^U
M-85(+M-] ^1\C^Y4O9W!L)755'WQ=S:-"=$9;<GP0AO7GBC:'EIU\E4S#N.3
M%Z@9"34W(.7R\E;U%T]Y)3/[\$^[VL'?A-<''+U^@'@(.C #G$5,I*GPF%A5
M_2BCIY+0+]3SU+?/KG?Q4.SE^C/8GDNCL[JAJFQ0^MGN!LZ^B^.\XA=<'OOQ
M;:DZ(U/L .> ?J\1F"*!SQKJ1F)$>ZWQ>&0]GJZ"Y$"@:.4RI*J3;U;&GU43
MZ0_X8((Z=+8_-#]U=3NGXB9(4^RDR#N@HLOK0,:R&+!))4CAW9.(B\_IN@34
M221<2;8UB'S_>3&^E*N"$-:NY[S"'.?#7*3%H1;26/4(%.!@%$<0VLQFQBTO
MXLNL2/.-T\+3WK*@QT*-(4V9DM?11<Y$P:!RF#F!'^_6&^KX(?.\O[YP.S3\
M*#M1E6]BKZUB30:Y3:-Z\TX,EU_R#4G%.=5[,-V)#I%_JHRS^T<_2E'8W8N_
M W-W#IF4/W#=_#>0*\GW7H4A])  CN6<[>4Q/_''R57^,:YT<-AZ\8CSIDMJ
MFN)3/R+?+LON>=9.5['C,M3S9*77=@_YV3WH<$%L1_Y.65N\[W&%\L.\Q13E
M:(:29YLK-2-1Q0MXC9'%WG/L-^Q4H]GBXO!]O?6+ LE4F_@_XAROR=A'/*AG
M%0Q0R23Q:="C$'375]L/QPRT*UO7][KG7(Q;WD2^^PFW>3U"=<SC"22#6>$0
MD; [6$Z.>N5PL!'NP9/L][.OT@/]:'[*?5/8*A-,/'1,0!O/G3["5B['/81F
M.:(,!8Q;)BHK]S8TV>MROCZ^P4$S=WQ\M[3F(KV.<)-(Q81OM6MZTS7+H/+6
MRO%I1(\(6(QDFD&MRWX\S$;#'7)1"'O108W-2DDSH*H#WO)$S@\82-Z:&6]+
M8C:CI'S0E?6 @9Q7R@+$@=O&6!:J1<IZ/]M_'"YJB6/ICPAV=G/_.>#U_>O0
MG6?:<A=+ =N.>26D7Z&\*<R6)I[9;_X%S>Z6SVW>?EC'FD5KX*.9U*?)U$7%
MQ_EC4LWUGTR[:,^)%'[1#GKD_<+0A\)]=>C7CG7TF>J>WFKH&&4'_7LSOOL%
MM].W#?X'**0DR\_HQ2\?=L,EQ_;KZ SL)_O:QR2-.<']:0R^[>^\ZN$6,?6P
MPC54M.JMF).<;R)H;XXAO./YV?A7ESL;5C=<!;@;PH[+_<P-51+>_C72?Q7D
M]12B1V C*DA%QGV6%."[^';HV+HJ0>G1<0W[MRJF-(ZU>XHE\0EASG4C'0R"
M!J\MMX:@1]]^E153J8;@?6U)[$6&O^[HB-9?.U._?ZW*JWN%D22UC8/)?,!/
MZL1",08?N.D8$6.L8GVN*>MG2Q%O6O^>5(5:VS(+#>M324_TK3<182P@BQ!#
ML9>+;@L:[I> #C4E6EQR51&N.J6.(:E#!9>;SX#-(@K:^L14>,IG9]2OQ";%
M2[VW;0#$LRJ3ITR]R0V(?]-]">#H$,!O6V$;H[\2-4OGE@>_;G$Z[#6R?JC5
M"69IB?S>&]40K=BU)9V]!<HS_K8ORV6H^GNCI3EZ@9S#X\4[_NJI?)$'$ ,5
MH]]NM:V1>Q2;#Y@JRHF/^-O83CJ^-_F^GEC\_JA\27;W/=QA[ #3Y"OS"C\R
MK8)EL#T[F1PXO^*+6)#/@F64!WJ4";R=&>I+%&A1M]E]Z0+!K#/>>1R$"*_(
MKZ-#%L ]$5 X)$LM/K )I$G_]OPM387AM>;DT>!]6\E78-[7LX,G*/8.43L;
MCW.*AK*>V9:.EFSOK-CZ! .P(I](<[8!M-B]]R.[?2Y0/\:J%C=2@1MZE&*,
M6W]W/ET=O=^V&[1HJ/<X/NVOU<\E4[  W?DU=:#KQR+'*E1>@.ULKR_]/[;&
MD]GSZ9+B&=:*, AW]1M:\E7=Y81\:?!=?-%)&BZZ<)6._O#)M'@1CO]?NF?C
M#*=VBJ^,.'\06,Y&./6Q'Q,*XK^$L^Z0Q#U=EFW$-;1"N$V7/-7H7NZYZI+^
MO?AP.^7EF,#>D,$_"6_GIFB+-"H3W60&VF)71OS394\$# [!R;7B*C"!RW=;
ML/N1=8NS*3TM1DC!5XOSMGH\BR!]O7R]$FU=7*=4RD ]&,?6MQ)/\NU5\9FU
MGY2I8+BIYXJH<9VT#%!,91[B&F[EHQNX$5+ \#WQLUHL/##DLY%\RDB'\+2J
M"O$Q+KC?"KL271\S^=8VHXYBA$YIP0Y<R\P@/0A*YM:5?ET(_U@)9("]PM=@
MJF-G_?^=:TW/Q#E7Y]VUDVNH2QY3+Z,3&#F(>YO72?5F(@+I.JY;IE+S/WKC
M_ZLFHUW8Z.1S7&:J3B=5Z-VG'>K&O'6O@%RJ@OL=56&J'0=@K51+C!D07WA%
M#26?X@$:\4:ZY!.[O.]-U2D>2FE3EC"; -15M/@_VZ^Z"-_-C =P:%Z_^4,F
M/CX/P%QG<JW.36']*F4ENYYX;2'^WK7KK_VONO_[2Z!SGT[6CW37G5%K*0@7
MF3*Y9F@]3<5W+1O"#'#Y7U5.^N^J**6JO3U*2 H5\W10HI*U+O!R;7U^@>D=
M$+IV)%SO-:[.&U8,'T71R_!XAH,-L99)S[\8BOXZ?;7PY8=#%_VCW7=&?C,-
M7TF<4!=C!T;O(]%[5EKB"T$_.@EW7FFR7TBG(RLAS":45%4P6BQ#' RTP%N.
M%A._!.C)BP6)O7C-8O/A;VXPK;$9G:<'BK9-M$@\L041L_- ._EK-K3Q+5\]
MK627U*1 =67@D0F%(PJ=)-I[CIB#V-V4I3'<EDA7VG/XZ5_&6W!HG7T)Z#:F
MQ'_"G(=;]81"B(U8L<I)>W7V8:;<+XV?>=I%JS^]!ITP7 $U>AKU9@]T/Y]N
M0B=F#_@KN[.34][G5\"(3I67><\*%?$.^I''10JZ7=F0(%1KTRE62/6W>^#!
M&YX4A.WVYP(&Q1F4&R*Z0Z!ALO)8C=Q]]IO'UJ8W]TQG;$;<@Z*Y-",Z+T1W
M(=9W?CV&Q%BIH"46[U&5K]MC6_ZS+V7OS4(K]3VR")Q.)R*&)-,Q60T9O;EI
M6[*,Y.SSENT%U+FC( &_M14H^>O6\2[HN,IZ*)=ZC:3G(MV1H\EBP#= ZP ,
M('54577%ZL$.%XF7@ :B,^+SX-?-->.V*8$I6YTQ3+@ETX=%6JO6@U0LX,R?
MDJ/:U3=B^48K[B7O_69L?HYP[-J=Z&(LB?"*G59WM;%YL.H\GC+H:AE<___]
M+O;_T_XWM&+AW#"3Z^/VOLFD^W@P.E%N$IIC%:,3_3?^\6'%K5[:U$[9 42/
M/>QNEQHVUYK6'ZZGAL_^5Q93;1%@_L9K4#H;&B^S\F ]_5BG9MP&SH.[@8R7
MR5&Q,FPV:%<ZN .Z7<"G&U-$.U,2L%LXV5&HI2/38?^D,UFQ"M&]<DO&F,/1
M*ZA%NX3NHC\!%KBKK=!%L;!ZOR;I.Z6R->]#Q6UU'B%FU]#QU.TK77(-C5\_
M]@6ZMP@G!(+IEK<D%[<Y1W,#"7?IUNUCLP)+7DD=5 L+FE#J:9G,'">$TQBT
M3/F46K_<=0Y9SXC6X$_J2U;L!$SQWL999JTAZ#:S3Q)"> N+MRPW(5X05HTA
M+MH*VM>O=#X7T'G>^Z$RL*%]=7C]/^^&'OY/T;PM-:6K0\"GQ!3;_XNR]PYJ
MJOO^?X,H19KT)@0%!45 Z3T@ @)*53I$I89(DQ8@%$% >GL I06EB91(%Z1W
M1#H2"36)TDN"$(\0PN7Y?+[W=^?.W-^=>_\X,V<RD[W76=EKK=<[>\Y>LG*S
M9VX;.OS7()!$L>CLV6<@B3*3F]WG,^Y@/Y3&'YS[U,9&J.;$7W\IW(P[,5ZV
MG"H-2E&K1&Z[ZDFL.-/VGH-<!*W_YYOX_XQ4['/(!3+3PVV>W?]WSJ%#<,'_
M3/L\M4[Q^0%_$;V9_5J4>M@[BL[TKC<%4J'ST<9N8<1%;(*.QBVY:9A_@>9K
M(8N_/\A,EU^XX3^C_6OROXDX+31![E__L>*34O^3X#__C^%U2!.\)Z1'56H5
M_=%AT*5LKF]ZP7ZDH+9H<Q"4SU8*@IL].O!TG':<>GXHR3^U^G7W6B%CYNY0
MDFR5W(_HW);T30G0^^3>F7!_-_FS"<^,YOI?\_['5?\];W#KOYZ4^S\=>F;?
MV;J3E'/ 2%$TRATV>>NO-<94/92?[KA_SRSC/JCP@@XN@GMCZ<YD56/8U4VU
M'=G]*_*\9LZW7H>PI[& GD\^;M0PG+\_78.N6;66\GP&*\MJO2HQ[)32=?$;
M,2A)OE,("!^QG]@KGFE(7.^;Q?A$<3S2&-!2IDC0OOC?-?'Y?[NB)R:UB]B2
M_WW+R ;*#*BA_H;EG8*TN(GUX+03R4,GPK_M[PBC93FP,]QL8K<VG!IX3C[7
M'ZNRP%8:S$M1*^_N9Q"^AJF?OPZF7NT@W!S]]-G^%NRQUT9'$H#$W.A_1C*O
M-)"4;RV<.U9*!6K#+VATUHE0'V_HOZOQZW+DB.X*YYJDJ,'DZVUA317PRYDK
M7V+XAD63,'HA5@./,PH,#)[/:X[]8W]C0,8_?;^YST208@.DD[[T0=BH/'!;
MMN@JBK@;+*!R2W4LW[LP>%='W4=7V(?K:L:WX /T%2)O'UB H@2 CRV!)K=/
MTVV^I8@R6"G\WN\=2YRGYTS=K>A_GOX&+43^V''<(LFL!/7!31*PJ7TRKY9N
M3B$AE7#+-&MXB-OK@PWI;6\>SM=N#J]DOR9\TV"X^@D)/KZR54N1 $96.KF!
MSQX8\*6 &^AYFZCEYT-3.@)>""+7I?7[NF(7ND:=8;582A!0C0>?WT Q.D_N
MXIIS^H0EIN5'];^]A'YK?LLW5(EJ-:!-'T)K$(.2.^21IL )B??N9)O!>_="
M)J+WZW=-;Q8WGH7F?0F*N3ROIW>.L*;Y=,0E[NFCGR>YFLJ(KW]P/Y?4@#C<
MCO%\=^NOTI/V[,S2$8\<TYZ+;Z^[#L.:"!Z1'UJ>9_:'TO=$1.<V1U*"2'#;
MCO;F[/D!U1X/Q7A8F\%YN%>M9U@7R]QY4BX-2@8)/2G6E$881W!OF2$M 7B1
MP[IK<";N@"?.LBV#;UBB?I3]5LJFVH6+QHQ\UUM3$SNNG0D4S>OAHZI[4>^G
MMBF/:]9SL_J\*W9#[614ORIF6#[^U4,G)D.Z? [6= JJ71Z @^.P:[T:$+Q,
MS$'$.<=^/X%-Q4*P7_5BU;>Q8?72)DI_4WU2+31D6V%\+AK/O9C:;53 .R#@
M%D?1)9Z"] I']\RQ1J^]Q.$!\:#DR$7&&W'GHQM(0V6\$AN02YIB@-LCTI^>
M\820E%2\W5]U<%#-AJ;(Y*WDW/&+L0GNI8G*5I8!(BD,-:Q@+*<9H'LL0QT7
MYILX1+,"5C8DXYB+J>Q -7GCZ/FEGFJQI!;!A9S'NNL&J^UQW=#ZSA3O  @O
MHA.OGR#?>0GX;3/A,G'+PJ NU%/)J,G'P/I[W;8#N?[.VJ^NJD5]L@F)'3 C
MYH[HD*ZE))/8<(M1V+G-%S_ROC 533*LQ5KGGYM49AIG9J"+O-/I"L7:V6 Z
M;BGU1K!3M(A!_>*M4[^^WU+7QX%JG[N_893:?6I^-U_9^>D,K6/Q,11I2!+O
M88LV1^3T/.-7^.>[_[SU^P+:6R,*,[[J;B*$%[6"<:(JW- 5= \T/A>24$92
MZDOE73^*&9\3F)W7(F:_>=[P8U@%MM"Y=RTSB7D%9"SG -ZY0D0_ @:)>!E6
M6)#BK-6-2MA17%YPI^M(Z(=5E[_:*E<8A'^:T_9KWJ(X L7'ZDC5R6V*'2&"
M[B'!A&L+Y5PWZ[T]&IM>;,>7V)*3/UP/ Q5:9XVZ()E/*M2UE?KYD&= >Y]H
MTH_Y+G^<V YY1 RY)=LK+_FY6]W0$#>X^'3A,J:%.@FY($.5V1#@'GA9C8Y%
MVN".21]AMB6S\("+1HU9Q=FBO7I?^]@!<@T4E]K#ED $LAV\\3+)_L'\4M<:
M&B?;.$L;8][7)PG&.VHY_#3[HP\"VSX9+Z1R4V<C+JG[$>;O!\@DAH,F%/AE
MD'F=<>%7)MVF:ZH)OR^^F=J)&Y>>[#X?%7KQT)L'L4SP/DN,[MY"2$T@ B_$
MU-MJF5H.^S-2Z7'DTQKJ)!(V5)MZ&#-TN;8G1OGG+'W"?UY6201S.#41UY(H
MWCCP)<!\R3]=X;B3)9MT)]Z9]=*"\]4FD(7(FM#'ZK48JBB4^F.96QQPPK=+
M:G^O:I 25JDZ/.;Y4O<E_E7T&H-.98UL5?L+[2TM@1?4[U1UXMH95,!R!W**
M'9&VTT@+[Y7Y"+&VD(#%T2[+J#7OI4<_^L],J-.%G2$]G(19L4JF\*$XVPQP
MJ,L(DWZ!AI!;F>Y'=M;CI8N&#*_0RAFRO;"A<=%2CY%C00>/3L:  EY+4LSB
M8&J YPL(UT,\<"N+637?!9F=PN%S5>O=N37E4;7[)RBJ%/![8(GK._4.8D]G
MM@'%!&4Q,IELDRMNKW-T*+JJLOMV_N//M ]W,C$)YWU5]9,BW/<2P\6 ]QWL
MI(@8=:7W").^($N>U KW9=CG+XP"RI&$7X]-@Y$\UTX^-O>Q80F#EZBC8":*
MMXLF"L=(,9&S@X=?0QGFF-5/]C#2&OPL,\;X@SC3Y,80Z A B1CT&/!!<70L
M!GL&G8(8]5_7-%9:>('_F(UP7"UY"T9PJ0SH7VT[UC[)ZQ #U%;T7[;=P7D+
M6:\O21!QJ/&4U3&C=O#C%/WT)(L>GSZ67I:D*%;5"37^"(9.V$-+S,IR2IL;
M'O*ZD!FH=L(=RS3-+R$,KS>TB,,YA698^IS3OI@([4L.R2_/6PPL\3=/M;E4
M49X"%OAJU?W[+&N1#8&/.AH2+$&ORQ9;#4QO+PA&/<+4451.DM%+$<(>$'8O
MBH9B.8%%_%A@=Z0[1'OZ^=,X7Z?K;*-B_9^"%.\D/1(6.LD/5_G!(M>KFMJW
MS"H>+3_-45->BO#11=OK")_KV[\\\-:4N\346+,A\F@ GM4R48A?[+9JEM7K
M<[YD)8+IY84T@/NVO".AC(W>3*/%J9Q W@#G>EW)$=(7V^;X?+/E'JVKXHUK
MP<J:91W;\,!,0W?0Q=6KT?F1O@E_G0Q/,I%FI6<KWZ1($UVJ,1A-L1)_+;WZ
M^)\28D/F[?M4^[V^XKTG/L%%SIU,E&"27Q>J(3"=N(;WZBP".N;[;!UFRY]&
M%,/*NK#J8M[).>(OTA8XQ]M#_NQ<(U3[X=#=G9Q 3J^M&[FCN=RF87:VP\*0
MR9GY'^C;R/,9Q9D)(R3>'A8KAY-2"AN)1^V+]4$[O6'G]%I#&J1P1]FAZK.@
MC^+O3)3AMJ8DH/^8-!AU*"2J0^+>>]483 "[SCY7R<!JO2B''7^]W^VXDJ[5
MK&EQDG,6R6!NI#&IOSUY<& 9A#CZNGKCP9%&6;IT9J6-LGWJ3?%3D#7WYR>]
M15MVY>0TDDQL.!WE?L0EHPN8/O1%N.RZ:8GE9F*0_#=(_4]VUMM;5XGT:FSM
M:CUG(;?6I^&$;XY%NI'4'(@/!GN5],ACW@Q 0!4Z@/%<76JC\<)'OXS$-(.:
MA_XH9@KRI-E_4:=;%;OE*#BQ<W6F[5&3#5Q_QM-A:IC_\[>/#OMJY[GZ?_J'
MRY$B!O-0R1U"P%.<"2<BI.>$(IR;75FY>62=]:S%AMLY5WF:_UJ\:=PO_C')
ML]"L: LF;N'*^_M(/Z;4]?%[M!Z61RZ-NRBOV4\>LO97WP3IH_[9?9KOE)*U
M6XN\]CV3G /F"/_N>9*-E#T2G^,-1HTJ,5W_/;#X^7S *&*Y_Q3TDNS(2W0;
MW D:P$PKQ:G;^,$_]!UQ%R\X_F"XRG!-PH>O,G+A\A,!^K ';'Q +_D-  E;
ML>OD1J![<G=3\1J!8SUD#1F]?;'IOBHY@7H.(6/#7<AM]=6WI#AR&4EH;0#,
MB3#JC>!NHR'FF!!'])GK@7:>T&K#0(<^O20MZW^>\%S^B4ES0-XE008Z^2G7
MB<<4%^)XWYRGNK9;@'<9 F*8<:.084C*[X-:OM[7XG^GW-J4$0X?0[$WH.(U
M14AQ/:D< /RAL.B=X8_N5.G)T5^=^='NA;PF;ZW1%TSH7@H'5(1CEI1),MN'
M)7 J%ZHWQU'>A*<;5UGA><>WS#%31)#@95@<2R^:/B;93-1/HLHCU8$3G/<%
MBA$)?.:/$D3KU'YHT&1#4UTH8Y'6+QKQ/_'1D7;B[<\]3D'U;HF-$7&%W).'
M8)Y>]%9K4'QUP/&.(1FS/:F<HK7#S*[7>15TNVAM >-'\(Y1;4[05$:JDJIX
M%6MA2_P))])2I6QKAFY)5[>[) =4AH_,^7&SX(:XA /PW.]'LSN>\HOZ_6>V
MMQ,'DKUF*[WA;8M\[V&6&E^BDK(U["[G'BR_:K7:H<=%O%:<7=+ M$D14$R+
M ZOXWP9UJ@$#>=*R+TU)\LZ4EDUEA3'=XZN;JG'=+-#ND-@6H=@FJL07DF).
M%2Q='O7L[:[ZNH$5TV>TGM"^#]P/5]XCDQ02UY<LVK?,10DKW50,X?O'QIW*
M59L[L+2S&/@7$SJ_]D2%@<;TX>V%]5/0<_#KPJMG_*-C35***4V0\IBZST.K
M+GFU8/]CFLXYE?-)9#07AGHE?+*0$7B+0[-X"(Q''<*0B,S^TFZ>/#'?=?/W
MWHNB7HL^'UOHU6LO/['JI$Y#+C::)(,O!LA<A"D%SBKER';?-$$(C@C;?UQ3
M.^,3XYNHE X.CPXIH)\XV#]AC^UVPME(+VTRZORM^_OIK]-(EVCT\# 7TQ#)
M4Y <!R02HQ\ Z%**4>N4NE,UPG!@WJQV1CX14BLU-69CKI2J;,['JN]MFVA-
M6MX1)$;<G:)> =8<B*FOVZX%*#2347'RHPK5Y=/OWT;2W1@^P3GTJK7^=LS!
MC\]EF @!XWB7I<8@AHDVAV+;C?1K-:>@AGGU!VO??GIN=B4)+V!XSI:)T@#J
MLNV&(R<03]+1_:XIO&&A?2/18'*)1?_1_==W!E]L]S_RD;50Z:?5$,69]!7
M^SL%PF^X\V)@THGO!&G+[Z5]E']F':2X>KG)6/4 S4^RVI$CT6H#C&C@/18.
M4V!0=PIX-UPU4B;X1CZ/*XW&5XP=.75!Z&0?WD*"=K$E""@-2'F?Q3HSQ;/$
M72 H_DD4B^N@S53AQOO]V._9\W":3F_7KH_A["=O.D00HBN+F%A_\.N'Y8A<
MC? UV[C'"/7CT)FLE_O>5ZX$Q:[YV-,,J)K3RI&?GQ0%H#A@FF(SA^.)CO1
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MR7%HS6-GS)?CUTO12JNIH&Q8&&VO!)M@5%65+(/H>?:E/*=@MX]8W6 W>:7
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MV1LNTO3]UH%=MIU19C"LS'YY7"JFJN]GF^6W)=O\W],)?SPD:/-(<9'^:"'
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M;V;=X")K!TA!AFF]C+EA;N(\O^UG&;O04?J)'M3"HSQ>#NQKH\EVD8BE'V-
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M4D $^+[#IB7UZ$>D&GX>?1[YS!<,Y45!A\YM_!5$;X!5# G]-I2FXN90'B,
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M0TAD6><R$7]_D%42=(C[+CJ[!Z[6J;@(7_@Y^V[:_FG=<'P&<_E#9L^:^E@
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M_>YXL_-[(TQ[0V[[G2G)*->/:*P=["Z7#^H,W;5F[6C0AH".-9TER[?<X;H
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M2O6>U8- "5-(G-4](#S7*.EU_5F37AU7Z5=,Y.!QVK:Y)Z(C:NYN\#;-_[;
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MK;O712&\G:RYGI)F<5>,[.VY'FB^KMZ)<Y/_'4RH37NZVY..9Q*R^(A(*_1
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M?:J&$GL%^5,VYNJ% IK'^6VR>.95#61KATZ?I[J2: D'I?2^">".Y0&.=E!
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M<KRVK,,I:ZI<8OR#PS7C7$5F]7O%;!VO)0 X"_ -A'S4\;F6-CDNQLKZ85U
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ML$LEE9HF;M*)-SY[A5Y2]3<:M:P2[X0Q!\ABTJ%0!(AXCU$T>??/DXQ=/<>
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M/1<Y7L'F=^ST.2P$CK]^'+'"5/M;1C!WP<%/M+!'S-O]H\J%['S"AP^@,D_
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M/?JIK9K^D0O??3,E,A=5HH.=K>B9_IR63QN\Z@"2)#]RO\L6!.>AUTT!PB2
M$.GV$D@I\S[(Q#Z\'6'R,SY\&_:CS^\9>LQIPP4KB?)']Q&[(S1<VZBPS[Y&
M:#'.)98X5=G< <H]PA@_2[TE@Y#.M&7]'=N&KE7" $FR\'6^A[,JD^R=)V6S
M?Q+;X0<?1E<.M+Q.]+K_DHF5-->8Z?,S2X@36LZCX>9C,B+J=AFSN/$W0K-R
M?[51^[G$9,:$+W\RB+< N=B0^[8_)?<@:%#NP0U,-/-&K0M4TO\$^YCI4X7;
MJ_%* K;#!4F6>/\,M+-5=!2B9"HF+*UEL6"Y\E*7B"NG2?5_R4OFA2L/^P[<
M,[S$S%?,G/]>M?QTP.V6>7)M!/';'YW$:OZ$1*K.NAS_J8248?F+Q\"/3(CR
MHH06:;BZ"3ABF=&=%1ZJ*S@L#\9$3T@W]<R86F#""'T80U_>@$MBD5@V3N8F
MCG[@IP5?R!!EXJBZT]7)*B3J1?ZK1B;TV5B _VN\+__V(BJ^(JGH9$T:4@_N
M1S8A#T@?X8;C?<:1E60S&EVM7JDI_$N1:-K$5IV:25<CW/*F>0-&A*X<[%)Y
M%>:&E(XBY8;!.WM(6 CPY$V0-'3.\._0:BP$RRXD1OAEF(+;5FIQ4.V'DRAP
MYRW==(#\^BKMOMR3B>_<_#D)RM?/!]Z(T<)&V)(*$A<:98DUI^0=XX*>R> @
M^*#Z9IDO&F9DK,L&Z!DYU*+XRO LV=^H?[?Y>0]W8*#BZQU@+=]"(*;W#E +
M7'0Y5S\6:73!_P9_&[(I)$CU[/Q)T_%$NZ+\6I:A3SVL.B%\XFQ]N*::GT&?
M_R14L//J] TRGPSJ7(>%QV>DH.*3.F>*_-Q=Q[>B:UHO--/WZK1:=2=?^*J&
MWP'PIJ9D>#9DY2TGX'KY:NX_E_)FJH=LGZ4;F+$)W]_<*+JH@+.IGNAKU@Z$
M_ LM<[\"FIJ>E2"<K%P.^0ILTC;?=V4Y'BCZV),NUZ:>JG)$&'#M+$7H"BA6
MT#9AI.V1%L102LR]/O6,7TU3M;][1VZJ7(9EEZ4*)FF/..P^EZN)=DJY9Y>!
M5ZMVUZM2*@>ZA *2,+F!3_;:7)>;@>RW,W< 4AG-:P5'.9)I&8*?4-?YQQH\
MOQHHE2L%Z F&;;>K<'_0[D%KY+N*L-3(&H5:E%R8HPM"\TFJ,$<1S41/[.4"
MQQNDWQKCNIP05A,Z;ZG;DJQF9J[4;VGMX98[\)1Q8L/GF -7?B_+FX6Q=7(]
MH2>.$Y$0YBRCF*?.2OSQ9M,$_\?GP$TW)5(/O6_B)KWM@7PZV3P13\+!TA_-
M\HV68[SK4\?+)@WKT-[>DB"ZH,$[  G6 P%NIP!; )..#9O?GVJ+$G_J%MCQ
M+@F6\J;=,TQU-U[H=B,ZB* Q'O^@34." _M>I&R_D"8S:Q5MFN=;NZ.3S\G]
M7J/U(*F]4$>%5DWA_W37[W\VHUBL!U(M3D:/]LQP J-GB33HA4/!R.U/$XC>
M"?5%2 :?TGT^:M>%>8?12<9#=HX$NPH.3 DR8;T_.L H;Q]($;!L[EH0^6KR
M+-#BUE&DOLFE%U"SO%D;CWO/7%NA__MW,A#:')46 E>LP)3W*_WF/SM^N%#*
M:=+6,G4'J$]R3Z7,\XL>XFY4;J2OSF<*>DVE<<5:M"NE%1]I31N?:>]6,*_T
MPZJ^+LHJ6G"G^#L.AJCIO\ Z"LL\79/19/DT8M7.5>_EDGAM?_=L\'K%7($R
M$A8)!8/B3*$AY_4HNHB<"<]<E\+Z8B_A9T]B[@!Y#UTPSO$%+-)&2[,1CUSX
M836_YE;LT^-:W$<]%ADJHJ$VOG Z^<-$5.<MD(4"\VI7"C0W%OE":0C3<!ED
M-'!1D^4S@BNWE!/-]:_RB+Y1VF='=/72,HBEKO:EA<;/]Y^B)3FJUG#V')J;
MHP=73+83'X4^X>=($C!08='@#"8HJAB] RS6;+3<CM_29:ZG=:J+MK-J.'YX
M#E?V6F\1;ZPZH32C8#"*E$:+T7%[;W"@%(#?&=6BST 4QD/^^?L/&5.^2%*]
MF5]6$W$,26[Z\EGBO((:DW[M@7V"<2GZQB"Z*V.)T%VD5D)F$>@TV^_6'ES2
M;">D1_"<7J 9;F+ABBC+'K]&U$PR D0>(*4>TEQ'K?6SO.!#*9Y[]1H#K>('
M[?M" !E$NVX;0P 9DJZS5<0$PM_E9Q1IU<>H*?W^:7+%ZI>MQ:(]_]_"VUN8
MR&N= '>=.\"#M%#/A- KO*SRD@T&N=DBH75?,P-ZY0&)=XN%[/=)E6\)QW\&
M*-? 80A8SQV $7,'L/BF'GU^C%_6^F./Q'"008+C\X-^>4^C.38=A824=EO8
M'&[7:HUXS!%6-^/\(MJK/^JP[&E+@Z9G7515BU.1=%9(7,_9*& D4"_VWR.,
M74YC8_P* T=BJ&JTR;?X>R%+V=.76W_A"9$&8ID=\;S(=GV$6#FMNU[<S8T>
M3J4A.IA+:W]*V?%Z3J(KB\2K=%M78$:-+T!+1D@[=^F&+-LFE-/'*T[?U<[C
M[Z2=T9[> 1+DG5D>CO5084#K*XD^*.D^!4JT+-/]F:6K$?<+!184K+"<O1M*
M%,1V.WVE#4.01[,^N>U JIPY>MFODY.HCQ,BWC4Q(JP'-H#\\DC&*\T.((F,
M(+)!,48561X'SMG=N6]=_THD\GITU7=Q.2K?5].%DML #";W\O''IH%@2Q#:
MBH/Q#6B\7G]QP ?4JY_=T'2"4+@D?Z(U^;6PNN276\Z;O;,R9?0KC&+QP,\!
M=^0=0&VUX'&_*WM4+H[^)@%1A\;8Q8677-U^6(B*[D>_-&99T>:6HW/VAOKX
M&7I$A&@TU]1CU3"BXOL W,I[>3F),!>=B>=.J55EN[>LDZZB+-KH55!E@]+I
MFZ5?[/&BYW:<]^"<B/[#P.\0ZS=N#R!,(!@"U"-NS>C@]VR5I<4''!5A0./#
MP#G+ OXR#K6%TF%=IP[A*M<*F(].[B]N72I":C5(3,TK"C(Z_AB>;]_BJ='.
M,\OFCIF<5/1>\4_O:%VQ1V$NKVWW850!@F40M[7(,*PR8NZI874SRB#BFTPJ
M\@A/(/AQTDCL>B; "S #PE+/K@7"A?<R&A*PA.6+D*&7D,E7K2C1+PCZLJK@
M>H3!0FDIF?LO/&OFV64_UO "C+UFPZ1()E.@L':]PN>%A1>/XT590LL!9237
ML\I]JB*V2K&2>ON!059;,P>O_GK@K=2_?YK ?UO9CU^O[]KV'K[G0YGE/_4E
M;B)8C@\)C0R01?!<3(NVAP.IL>^*-8I?0=<YPPP_FRR%2.,E6KLH"545TB]N
MO:<+5@G\08'SUZ.\?>]O-, X@3E>Y[VJ+Z#K7J4T@1B(<C9E(V81>"Y$[$.G
MK_AB.:T\&G.RA?PRKF86##)HO!ZE?!%@VV9+, 6D_AM%>%#!Z%7[=9'CPYN/
MUE0O>W4RF>^S4=WW#PY*^:==0J[= Z6YX9S-63U9>^BPERH7V);B?6&X?QL_
MM\C>S\0JJV_T7UHFROZM9<+7Z/ 9BO26-4"H/6,XK&0/]T!,W<SQ^4;J'2"X
M'+1N)"<;X!"YYA9&UT/M*+3/-?O,#0TIH$AL:5,716WW@F+5T 7UD\Z>?%37
MZBC\\P,__&)00%(OB1YV<K2XD&R=,3$)<K\&;O_D)=KM9,]=DT4[SDN)_R(S
MOV)U<<NC[B8TB&C7KSRQ#*L\<];B\F(O.3#YI3@:8?@0)3XFL-(XG)#<Z,T"
M/K11B*95I2$!2!/U($$?#V0(U[78NZ]LK)A(Q6:DC>GDNW*!%99]#3QJ=F>&
M:F^,N"O_NG(:&M8O.@JL?-?JMZ/H.P S7-J9+S^ZN^>A5J;9P >C=_)"<E)A
M4_XS;F$RSPIOATU?/!1\L?"7"AM?IAF][L#_ WL&%(DME@^DE$F^^.(7?=%L
M'7>=TG8DQ7H^B$1N>UGGM62?"6=93K.G&:2)/JB_M/29/RIKWO4^<ZR]O(:R
M[(@+.5)VELZ_NFJN3;TGJ1R8KS# ]??=E. AQR-!'K>_H<1PV_6$!._5.3$A
MJRL/GYRGB93Z"00>'U^M&S,GW1>V],&*H@(;8K&/"E8Z QHNB.FC#^&YU'E[
M GNH;)V04?T9B8!7Q:.>VTP2MYSY69OZU0=/F9@B2XM5BUO,K>>E Y=%7_W3
M8G9&GO!_Y6"6?[<3RP7G71\8:>[X.8O0L5G3C*BT-(OXJ^JI5:VD/\B!MD?H
M+Y<YQ%NUX1T<#TYP)&CW#;;D:^.FV#L,,SRS69)[C!C+R^S?.<4$7?DM:$^X
MQF^5;QA"9*K3R8JU$258?9P$I"FI6E>0Q%2 .((GT&+1$ :B2]5] RG>,*MN
MKH]7T6"4E]5!)+*J=]^#1^K2G] MEO2TX02(3\L R\&,\2W.#1GYT[6O69Q.
M>R?W&ZI52WN4 H8@NER=TFV*I]2G]H#9^M__.36-^S2*,WPC4;EOSR"EF<(O
M&K.!=D &1:[Q+T(WZB/71[@G7XP?UL8!!ZJJ/ZG1^.+5TW@.<-R*HOGF4LKR
M*83R>A^HNJ>0QA.RIE=$WP%LAN3IC&_G8<SO4*.Y^4YMG.;L&M<&*S'.:'2Y
MG$N(SL!;I37F;&TM7+GYG.C+,?3:3<$Y<#YLW26[(L?1\"J[H<225&J\@O[R
MX6%5GB.+$3ZR4.&UJ@:#Q'>U\736.H0E2SLXX1[V0:HL-_H/E +3MQ->C2R/
M@#E./6>^^?T:6D(P775 &N"/Y$178HZO;;7O &1G<9H*2)4E0=&5,L0^L8G<
M1&IFZ$$HU7#),[ZXQ4@6 47.@X3@U6IH<+O]5/;QBQJ8 4IT?N0XJJY(;K)P
MJ>JZYY?:('E.2/;E=W]7"!R&%R1X.WM,N]TGJW++B)7VIE)9([T?L&+.J8.>
MOP/PIRT>%?UI*\8$(C>ZY8FP@N#U52*'^HR'<<YRFF8O%@B/AOU:6 ]ZDO?-
MZ27H*W!N*N\ #HL5P4#RLB,1XS)[%&N!1'V-9@[#.WK>21%?_&!<W'ICFZG!
ME]P'@_GJ$V%9]6KMJ'U84?[QH24,6E.!I9%^G6;25HFI\**>$WEJ9JZI/?GU
M5](]>6]4#YE^Z'N%M7B_V?$%T&$O4LTPPS@RP;F453!)5"*_=JSRE,+FVJLP
MSEC#8IN/UX5H7%=7<^K"B6?TS&V!9SWRTV,AXP %Y-(.P/F;-L=:%I22-:4
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MK++4[:-Y_!'P_#Z I81[OX^1)6Z]MFGF[-J_4D% TY?Q%^&.6.H(^-F8<@;
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MMZ8RS08N!Y2FQB\D%.2_7J"% ?B1] NJSRMHP^XO##CQ%6\9)W%E#ON+S%"
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M6GTOD"%U@=%OH\0O^&2V%?[@31!(EM&/UH3B."_TCZ7 QS!B,'D _U9"+)
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MKY=H.8,E/F/WK= ^GGUZ=G%+;PX4*./T%G8Y*#O7O;[ "(S7)XM:0/Y&9$:
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MK.XGM;)C9:SS-U0!FQ<DG,=N7P.P]#<XEE85Q]W">T4D=@-1R1*N 3'YJC+
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M"/B^-/(FP>6E<0<J/B$D)$175^J^_'H_MHJ@@\]CN%@Z9/Z<;@E/DH<.!,9
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M39BV.[8=%/1NQ-J$1Q\+W&+II9]\LYGF^IBH+<I49\,PG%P;$,R]2E2>UE/
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MS$Y4$K_50SWZ-D )#:HNFQ*@_I][0+7\Y%C^YM3N)[&"F:+K#ZECC13AATH
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M!?4Y3_>N>A)8,HMUO]M:/W%D9>40:.6?H43Y,(FF5$$:J&)G4UQGGE5'<GO
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M8@M<)]0W".:$_.[VT%AV!]U!EV)18N\EW+X*IJ<C=@+OOO>_Q/7U7HC>$W_
M:>C,]J*.Z+^5WAU$U77KHCP+TNYK)__0D[?_T*)(CS,JUC]$].:^?O&\>N<
M:28Q7<T/_%<UQA8,+!IW]S2B4@JJ@;RZ/%_<4Q4U]DV[YIOZZD^]A)\7;-:^
M!&)WK(+V>WU$ $B<CS.R&P1'7JLH@2+$C9WR1"1J6QI4&N,8^19?JI,4,1$A
M050(-]ZH1?Y6K$0%)$P#C<):H:Y7*$2V]Q>>H ZFUE@/,I:_K#_12LT1IP[G
MA61,8[1W6U9H&(\#IG%!M-$?VTN*<'<^=$G/Z]3XTSBGLO7$1RZLV2VYUP7
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MT73X[@ X_GWE!LELQT5%EU^Y\&/&L>&WO._:WAZGOT#$@M;]RN)[1:C;O/&
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MG;B+\WF.PGJ_GE*11BEYRZ=KZAI3OI583H<P5-EZ27,'FE<T:"QMVS"?W2
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ML6[4F+:H3AOY\F-^@Y]TSX/.K\**6P_T@2 +=?:+<I#="&MP-]R=63:6U&J
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MTE-6 OHH3Y[&D<4SP2Z33&0@<3P'4"AV4"H6_#N;&*W?,W7KTG)A0:EMOU>
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M=1Q0#Y>/VQ6L=JM-D9^S5,],\E3D.EJ).6E8SFK;'>GE)I(=\ESJSHC,7')
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M$<[F<+01N8IOGJPBF?R!+9:'[:RTT<\IF&Y:,<AY3O3)_<9&?J)R+SQ5-L/
MY;K(7D%NUQ' EOCWE9JL=)E45)6RIT4*^I2^Q+JI<?K0?JO1T_150OG6H?'X
M^?B0')8S#A?VE)33.B$SP/O-&S1)8:JVGBWJ:Z$AO3Z?%;?XA7DTE?FXV<";
M3H[6U=N9]D>&V00\AG81EI7S.W/9<%[[!_61*SSIBHW^*VS/E1@L2 3E6.;*
M=M-\[> .LTFQ@XR]_(2"_JNT+Q.D+RH9?C,M+=2T,@*L+R*M8<RO6#.U7SB=
M/21@QZ:A2Q4G,-_X\)?H:HB",UYG#@X\ !9 .\-2KZ9.;](T6[F\N-,LY1EQ
MUH+A# :'5SPVQ@A\*2^R3\ [^L$FI2N]=ABQ3(.^ PS(SE]=$1K6=#3Z7=W(
MEZUEJO>^5LLUJG-$;[G>H_4-FGG7GWW%M@U7VTEM"." F<ZY!]GB))>&(Z-A
M[V"P.:I)N=+-?<N'QF."0QIZ#&C] &Z,UV^"&-9!(VMM2$S]JJ&.*O7\C-"U
M*B=+Y?TDGP[V#P!O=VRKU0>9Z/_8G/[H),KBP@(G8(K0/,H8]=7APX?@-X(+
MAA4_RQ'T12U?&V/Q=$M_($-T&$==E\5OO@E+8^LWHK;"[ ^EW-;Q9@XGW<EJ
M1)KV'2V!RHY- X+/9#[,16$^KF$;>A^0/L3T'ZNAO:+=58#IRBBQ,#[LGS:*
M,P?M[:V)>'%52>2-<M_"%:WLX!3I,,- T.RH.<ZYM!"B,F2EL^'RM[46%^D%
M\S3AGEE=\0 >D];:2/A>3_[L10:%[+%]$!M,_$%HPHI.'* ;1[JMC^-=\Z.6
MRI?C5GGV.I",)D?;7QP]I&7N$8J''1;4DD>6LS"!FS^+?F._940-])+"G7I?
M@\_IRK2W/<_95V%%#;+SHA\\I_8WL)&N'WK]&S8][PG1,6";+/A70/AODEK%
M7*2@2L96-\<<(&3SKR:/.E/F"UOA, !6=X72O<AM4$OR>:HF/\9IKZFH^^K'
MR>%#[R@YC"5"_U3ZW<'"BXFZGS@FFLF/%0'<Q8S>W2$,60#*M2*-=LP>N7?I
MFH5Y=S81+_#*."Q$Y#&KW^DK82^#K^_O%2IM-DB1)OU0I5<>,TCM(XW(IK\%
M#ONV$X0>FTPO!59)23IWGS&2 @,+C'KS7T"?"BHL_@A^AM/[7F^N"N-WQCW;
M#MRK]DY<KXRJE+*6>"#@;0??2=4(/[TX^T3B-J^CS)"R,77FDE_Y7/_F#N!U
M$1<O;_)J').W;GL'L"\WEJ& \,WT!MP+![;SHHWK]#]TTMC7-#C&[NO^&@
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MK>SP+?Z^S&,,]/>Z$QIP^]['^T/\2J3"\C/TE9G?%JQQU&TM.T+D(F&\1U3
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M2X6KZ+-04**^;(UGD\<:<TB,CYN3!SFCQJXX1W-'6]O5"[M.?&VU/GU/<AK
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M84JLM$GD^ 2]V,%V<Q^OL1&' 'UU6\0HT[@2-$O^:37\!9GD SS\2^[O01,
M0"<%5L<_\_1'3T9K*0)PXTUX5P^#)*!AM\^&UTI'7:?VE.O3]1JGR[[5660:
M:J7@6Y$WO<=3^DCP]IZ"VU1;821@?.[DYZD_W=F086D4S0&K#?P7#,2M%\3L
M \*HG%9F2I%>,>_ X)51A_7\]&!X=%IH)>]H4H-$-3]Q[0 9ON@F:_YRC8#C
M:O$^>!L)UFR8K8O:XUE0[*AI"E:QKO,@JE4:4F#%+395&6CS$=NO1:7,(5(_
M6+4[D2QX6QNAV8=WFV,S'6AB'+S(6:!P<1 W;Z3<+>\6)W!F2" K09=;,"F
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M=[,,,8I2.4OLY,4^BS)W6">MMR ZG.MF%%8%Y^6G U-AME>44% 'N.(KZ('
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M5$-@86]CW@A?54 =HFEJ: P&/SD("2<+O!KX2&F%:X>^1D9 2VER5#]L!36
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MZ0WH6"*^6UOR:]V:^1'(,:'8*U*VR4@%N#G)SUM R2CUX]_DU]SH48^-@_.
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MR4G.LC(-8R9-<,JK;[BICK.^$M6QMCS4#)6 )-6"ZVT6?.^OM0R58;)C0]8
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M0=$1BPE<UKHN="D:8[<.^/E4]8'^)8U0K$F.C"_^S%RV;DO+X,C0FMZ/>Y_
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MNH<J5DQIZO#/X&K400GRI+65/G@C+H.\-_=^3%QF5<1GA;:QL?E$3YYMEN=
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MSKN "8/H * V14<LY([WK<H+0IY!9=H,67$_"HNF/;+\IK-?MWA6Q(?T'V3
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M/"S?:-KV^YI7T-#R?YAG3['_ 5!+ P04    " #)@)I4LGP8*(&'  "$C
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M6[0G?/Z)5P%&NY]39?#I7$P7#<LQX\TO([4RR=KM+J3F_AAQ0=)SG@+2<4
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MDNI3(I35NRX_JZ*_4D@W0BHRNMF[[57;UG^PKX\C\4WGS6[Z^_G!&%%M &?
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M,?+48K9R=DCG1UA)8_;G^AF.(%?0&V*^3)1X0@>-M$H4I :4 &_#1UK8C96
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M3> GAV(1C\JA;IH]JZ(QMN@C)/^@M-(SZ%3/@\_,IU#/3/'E4?_!W%)%<*1
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M3_P-/#DMN 1L,54%55'B[XSL"9W?AZ$VDB\!WW3:-\(I6$SO=\??SB?]OS$
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MRA#@;O.+(X)Z.U:\.Z\>DO>D98HS[R#(<]V>:EJG+/Z$SAJI[!P56#P'6D2
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M S0X [T^R6=\'&SF!3+5?#ER*SR7 6-.-#;!O;D$5+4#+P%ZB2'#$,DN\TL
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M,5UTUM6$>6L',!R)G75.E,WS2NZL;B@H6R@6#:RR=?JX"<^(ZLC.J(0^PT:
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M04SA.BTE9S'5_G>LS\]Y3/+$O\)S\/ZX1#W=@VU1;F[+H?'Y7VB!."JAC[D
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M_@7B&+B;=1]R"=BU'((Y+<585^?MKJ8JNPQ!5]H;VLQQ$ILX6WQ0GR'9):#
MKKWR'RGQK\VY*[IUE6ZTY9;<-VJOV,0-MPZ.,4]_<:NS?RF#L?GYG\RR?&MC
MQOL_Z1Y,DZ-R"/KXD6]0]>:81WJ><B.LH#ORZGSCYD,M37W<L5M<+F75@)"K
M:9ZWVEN_:BL<4D6C!H]LNY6WT^:[XG_HX+@I_&OAQSA0YY6D*IF=5BAV%;%$
MZ:?D@O%OK=\O$SG3?4=XD2RT?R4P%AL;@!V?=#')J5*Y)UN/NYY\/TE<\CH*
M55,X%NI_B.-.IKRHE%J%)5DAW\D']/VJP\R9)(J:"*2+Y^'_9L]'R/RV2".
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MV1?N1_'>IU#"BU?M*)TRVPN3O&(2NR:%KUHI''I&=? <;V%LI JO_I30!'Q
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M>*E)IMC'.IT\LXF>Z;H*V$L ?!R&]3]"=>?-C/?FLN OON$CGXSZ_=S;W<C
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MK< H-XX/KXX?B:FB5W:Q:-4X-RO(QO'C%:ZQP>AMR'E29^M1?&U_TP\*"E]
MCKJG<N4P&65?0?<]/20K%CGYF3D(G9I_?:@%-*R@A_M4@U:!NY&8R/O8@(K2
MG19D72[75-:"'RV-W,P*D_0=YK>^D@<*U>9]A<&.H&K)[IO-1I07OO-@A3>7
M@#\#F,^^.#OLQ"('7L[K90%P+_G:],7[G_[4=)\3LJ,"9#1O27V"%MYDN1D9
M?UXZSW1MD[//W=@H*@6]A$'":+[:R7KHZS8TAR1?<-MY5Q('X#3[T*<%.\_L
M^*TEK[DE>X/+GRO$>1K8&&^3WQT+PNOHD.^IYJ FSR:<;87WV-B:Q&^$,\M/
M02,[U>*VL@AXDYGD/J[HN""_I6MBY=^,GOPB<J291NXJR!,?_>@<0*@4/B""
MVW*J5?U8&N<YCR?AN\\Q\1"$1%S8]GW^Z,:@R$M BKL)WA[TUH'XPBJ&2'^@
M@=\+!G7GT=M!M-#P:%FC!P\S+@'&X^)[(G[V []2HA1%4J65L[:_J3S.K8N&
MIJ_FS9"AGQ5\W\+-LE7ZZ=>!_WCY-W'WL(OM.9)(LB1L.M]#X).4+5Y^"?MY
M"2!OT[7//#/Z,/OYP]NW3758BOGJ5&5TAKWH3RCH7!4?B0Q3Q9?X7P*N_;(5
M1CT=WZ\0DSS>LUMDGWA;P?WH2&E^17>:E83[,5F?W#%PMVPYF0FJCM=U*("D
M+HJJ?*QT"0G1=IVU%/_4'R<$F31=HSW]I$TJ0[5KBGD/&V)XK''*W78)6*T?
M@K3B'N UQ12LZ'/&MNR$6QH":G51^^\&^\Z0R;\&2;8I0A5 8E!_O,(*G(_@
M.5IO!.QN><2&*ZWLD%#0E+@%NOL$XIC,/4<QF>9&F[,_K')"%H)8JM'M4@M&
M.HY7N$RR":SUJU7%2JR!I" O#(9>:VZ+6A,YBM$B%X!Z!@+OXB4 .[MY"7"H
MBER\A0>QQSE/'=-*TFH'9SS#;#58T$JWSB'7^WT"T)KI'5[F2UEGQF_4 U P
MQY$(99$4NI.VEE>GKUXVL*OSMR1^2^-EE$5XXUB'H9(7*6$WK-WD%[FG3H!X
M?8*#?>+%%R%XK$3;2F JK8[PP#(K3])DZ[D55!PKTE.BJN;U%:^@C^7Q'JJ4
M$RVKINO-OCN0Q$,)E'UXYSH[PSAE]27 Y1(0P2>)8>];8H=$GQJQ<?$5>0HU
MY6X<<A>U?9Z7]:"<GM(KN$9]=^W,C*SA$A!]!W\%IO?%M2X!5(%P0D#9$K$7
M1"U6(=24K=L1?1OE^W-V;_D:E9E^9OQI"Q8T.XAN3%07@]YNQRQ%^M/2WO&2
M;OP!^AO?^-I#Z:TRH[EWG_H'$LE.#6HW(&5=ZQ(M<B7$5MM?[<'JL[$*/LS@
M72O]NE+A4V=_&^!'[V'6HY%PF#,L-LNE1R,F.+H6?2$X6(3\UJ\.!P=&CW^M
M:W3]5O-00XK>(">)0>EK[IM0E#:+V7^>6@?\ZWP M\[_P=Y[AC45M5G#4410
M2J1W@@*"(*#T'A#I(J "4J,B4B(@'2$407H' :4C52F1&ND=I'="AR326T()
M 4)X>>:=F7?>^9Z9;_Y]?[X?][EVKISK_-AG[WNMM?>^UW&[;'.3PRY900T^
MU1'C.\A^W,Y]IV)4Q&./H+&"T^UBL-_P338R[MB[.="7&XD12#O&<WR)/,G:
MPC_%<?] Q[SC6.)ZO$@V0=2_ -QX,LLG;V>>DJE3K^%$!8I7=)B>&Q(DFW9?
MBFF^.KE75%F%\X]S\R4?>]E_S<3!4L"U[0[O66<)0&%Y/!VC&8AJ&7]OWG7Z
MH&$BWZYTF<7.RLM$L$U%$=7V?)<2GJJH=\;F#>]89,2M%F;=3>KV?S#EOO[^
M<&-G.Z\JC:JXW SJ6^LW/1_2_$8^9-G-,A.Y#?50@G>\&R6JVZ,:AFG,VFA6
M<Z%%NTUU=U3O_ZS<!=Q/9.$3SVY*N^8+CR*)$<1:V9/+PB)@1OEV,@@=]L4E
M@_J75H8-3B\>_G7B>0[!@()X<?S(L.RN>B'HU*_TB,/5)E5)PY!YTU0Y@)C
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M41*?MW%/IP\Y<DXR:F'U1BWC0DV?#$76S00(B__0J=1PIST)9/]@O?G.>'4
MC:D#^WF']Q<);2GBT,A<R+OE'&,O WG1V0,0,TR84'(&AK&_F,QMG'A=5U<1
MYYGIO2\2?6?U7<HH1C^U[W8R<<#U*5!5)6Y45IG?W@M$[T0$GJW7-/@I22GJ
M<O.F7'=-3VA A5(>,YKT@2N?IKN4P+2Q'N?E2?"-*79(<#G]KOXM)PEMR>//
M<5^QJM.FFC:\D8)D.WV"WS]]DMW27A4K_NFST-55&.>K5("8$\6$+'(XHA21
M@&2]GD])G[)]B#L3-<[1,FDRT7&=-!S=I\9)X,C;=9/@BHQ!R0\UT:&"]P=
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M&R@:APZC+$RWE]GG"X!SPX3'.B;1M$#KL2%7[J.8A)_%/+;1679DQ81K?1>
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M,IRD[95\(EQ_B'5NYR5E_..G9>T/26HS(?+,Z>R$P-,7;@X&<[;#[I]I]Q]
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M*Z=\V;_K[325C-F<]EPI/ 0*^\OW(XE81,B8AV.DM22Z+B#[E\%4?#=$8-M
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M[@P;GOS9;?9CY38(]-^ K_^1((=3_P=02P,$%     @ R8":5 .EUFSB%0$
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MM+._'.X?1=][).H,3#S W#KYX.-3P8IX(Y#<+\!1RQA\RP/&RP#7DH#G19
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M8%&3_G&N&G>8;0Y!O!\G;-9$S7O:!@,RD#0DZSL8F!!W$+%XK-ZLM6"R^U4
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M)LB[KV'7(6,_@COO&;;BGDOQZPOTHF)QWEB=HBKHL<)G1Q30FB#U' G U87
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MQZ?$K@-US]<*P;<0OAT6]*7,6>[)P[)N6SHAE6^)<VPDUTQRCY4SY$MA;WU
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M&:[945"SN7DZ[FD"NHJ>:4^\ ,R.44&=J? 7 !6<J8ESW'"0'UB@?9R*6^Y
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M.RN@TF$4C;*H;KF=?#MYA<<Y8KXA$O:PTK3& ^]Z;:A8=>PF]E/D^Y[;^Q=
M/?I5#RELW9!T74>>JUY7!L.,NP /C4'P1Y?JYML70,3W1WCW"^!.5,_!2MTN
MYI.,;-?TL9JRA%MVF+($ 4!38/N,D LHYU$8-7DG$]2M 5EX@UXKW*8!BG91
MB\H;PGSCF<U3(,>2G'6J<2^S)\.G#2;^H)'P6<OH-\6(D10J$UIU]TB&3'C5
MS"C9R?ND</,(T20&"K78G]@FV?,5VYAOS[-,&Z,QHCIH5<12]';)XR?0#JUC
MZA8*IEAO#SJBANU_>*\TX'GG9AHA9"M(]Y([B1[)CTCHIUTUG\8;ZJ?O:+3.
MGG'&-C&3_BA/Y3"0LLO[:L(731+[1X:Y#;&GR:59S@MI5L] 3Q;:\2]^2>']
MO;[#>XN13<3 7Z!BSDO%+5TR(16H:+,4"_@-#A+N7IH")*SZ7,K)$ZKS<)JZ
MZ+QRK,-\=R]#\"VAOTU!+2I$-;L-0'XW;B;/V;9^NF W9HO[1]=0SJMXS3U5
MHC-4;8'6J<>L->/>,3\%A59CB]B4B"8Q2B.)Z)Z[>7KCF#2X.^+^@T*>/6*=
MB BO5K^+$*+C!%-R_M(J3.<=G_%&J>*GU@VKO+Y1+79JQE6!VYO*BIS0A07/
MV^(.<\>J$4A M(WMG_@.W$8<<K_0N<1 ">D1(2PMF=82_,BYIB-!"JBZ?:,B
MQX%T5[+!_KJNZB*9W&!6YN85BF>"$'!5D)L.*K3L'@)<].'7ZNP0^-+RW6^
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MDL ;X0"V1FO[K?93.R]&G$69RU_NWFG.'IW946 6K$AWFU9ERP&<HR">>2^
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MJ"Y<Y:,-'/_%RL![/H+N4P&&=['@13)W6_58O;9W]M[9NVQU,58G!>[O\J>
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M31-]W.545CR<*G',#$B^,_&?M^T[;>0Q2LL[-W;Z][4RYK?@R/ZWR-9]D'2
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M'5,^JDU##* ^-[JVMG0UNU'6)^7V#R[E_M<(R']M2_[_@*7_,U(ZUW 7#O
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M^G$64>6.@VW8M6F@PW;) C9N](QCP,0_U O6QAL_$XF'B+W:+8)I'8M '5'
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M++\TMN;F\>\D:Y"BC2<,,FZ,+V1^IER^U.5M$TV=X![*URFP,'YE+(Y:MK\
M*M61\ A-3J=/$#]$QH1,SMT.KKANLL=185!AP9.[Z5FLG.\6?TY:-6V OD\Z
MB#>!;RA"$L;\U.XDP92^"ALKT?MO_$X"+[0<53M[6;;]R$P(#X.Q*1+TQUQ&
M)!(+/XS9VR[*F4Z_)$_>)JO*E?^L3 HPWFU@?S/:Z'Y%>90S33W4SIF]A5JE
MD>F=F9BGI+NX_YKB8>N2H'S DSZG2O[[LD"1B!3HY(\9>\5 7MBFY*CUT2S9
M[^WKZ@(]I,KM*Q2RO<]BKF-:\ZR3W=H,#.YO/_BHK!>>+]SU^G-GJSX!?!_=
M_$Q%8M8Q0*6C<#%N.+[56<YX<F_+77_90F1'D>BVFS_!$X 1.S0=TRQS-ZTI
M\K%(=(N_CSDFRLEP<>U$:66?=[9=QES?2=-[T,R>65K)/SGJVZFB$E 0QS;"
MT "+")NX;39ZQ%ANBY <<#9!HSZZ2A;1()%9U"98\"F31_9+H!OA(1#IGO#Y
M]%6.-KE0SP#C?-MK?.F5C%<?]^)<KL\O[(X? ;Q#Z[:\U>A=B-B9, BYMXY=
MF3TN3#GUWI8M(RN/+4<%E$Q)V;G_?T"P^CQPF]#K":!O]'RL\SB4'7T@EFN?
MN(<'/*!,^R#]A7H^ :A=GP +TH^6WP353CNW3@-N5OZF&Q_H1V1WI_%S?[LL
M("U&;0J]9("S1QYS[ZQ]+40:CHD/207&\ZR/;(A\-(KTEG36%FF,+NN>+JH:
M$?PV7(:)+@R3!GV%=3ZC(R@A\84X06P -Y5B^_Z=;[#RZ'K+P&?-ZPBXV,J
M^?(LGV[?7%9OX@!W&ND[2MYZ\Q\,I+MA9E(C]I]K", "W'K:9Y4-0@:Z?;O6
M9 H6[N?;AO)9:V 1;[*&?-'O16!> Z4]B?IY-D58('E3RJ?B4?A.ZYP1+J)
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MN<'/C],/HHQ'6KB27?<\Q6M>#D?3UVY=-%3AW/0OQ+>#A<@NOT$Q<!ARO"M
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M)N:6[*_HZ;@"^5 5_<MW0:/V.691=X2!%C27-=D=W C'.SHC@T_O>OG,&&;
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M!S['[WBOE#;^(YQ<;9C3?Z:-)AX RVTVA+7:N,U!W8_\\K!_?(O*S3*R*O?
M=/DS6Y#95Y#63!(7P..SF9PV4/[>:J*#\@&RR86-&!<5Y]))FUI88@CETZ9G
M2,_\L!=Q%1OB7;[:L*Y,=W?GZNK.)YJ7%(I%E:G"]F+HUM// -)7=))[XY*[
MLR=K:)+;:=; JU/)U IY@<-:E^G$ZVKEC-+F_OQ?(>HS:2&.Y4N0L]QA*L%1
M"<TS&7BX/2-OQ;[4;0#YX)VNH+WSQE4"K,^AMQ1/D)M[: )8[IYAI5&-KC9T
MP;)-(+\_^AH%Z92-M1^\W23MH"=E;\Z<9P[D-8]HA 8H#:X+,\[$?4QWCKJ8
M[E!$N5RNIB/;._..(*3[[GLL=6S3%4@^F.=%PIUBJ3[-[BR%6_!3;/W<9I&F
M3O=D$@MNLUN9.6A!D#BDYAQ_DL!,5FX6H]!].NX:@?H+!?CS_?['V?2H+;%9
M4.G@B>)M OO75#6+*Z8_N3IL=&/TW.J=3 =*^FO0Q=G, 1M4<T*':XF98YP\
MZWG>K34,8\2(]&_ENMF\R8<'A@;\@H-75NRD\4'>5G5N 1<CWS(:O2.DQ3S6
MUE7*<6 =+S%$__8ADO/>CR5R+(H@_"8U9Z"8N[G*C#\!H@#G1H"&ISD9(3O9
M/164[?(:-4;>SBJ;*FH+/>T:.W!9TQ!DSN!\)F5T(>ZXH=)0!M+1K4)T[[+Y
MZ*D3DD8ZKZ)AP:08J]+CXZ'%/3#7WOSP)OC.<=\Z@<*/!73:]QJRQQ!\)K(A
M@ZLX.3,6%W%KY*&O")G-$1]@E<S6T8\3_70B? %M):L=^UOTHJ/ ):(CR'=_
MUH9H,]4?I%4?&K#C>UY$2E U<C\Z,RFK9K/"+42GPG=6:K5""43\P_C)1RVR
MI3C%8>]P1JG6'/YJR.V0.%]R5>(J6_;#F:SU__M7@ <50&25KO%FP*!L^C-G
MO9?Y,%L6KR?DLQIJ"0O1C@S'_U$7E6SW/R<^]\@5SU4#[MQ7?Y?Y*@EZ)"YQ
M3$0XO O,CRI*PGQ'[3H#5#=I$.YV[Q+#W'T0W#)FZTMI[FO/$%7FC ?;<?;D
M<@Y)84LQ%751,Q-,QRGD4VE,J?%&(^)AA3T0$CYKMP[B S40R?OQ!@RB_!2[
MR'_;^'X_SHPYLRRIDTJ6NB.)U/_(3XJP!@:@_R4K==B0DTPB[Q2+X*\+F8%S
M>/:LO?'EW5SQWY.IF1(#;8Q]G=.[/#'5\!&V UKK:)L31<"ID!L 0<HN),!7
MOE8;("ZTM8-Z*,=N;B$BXL:@=6JCR0<D3]_T,929+'M\-'@X>L#S\WPYXFQ+
M-Z0=:-+SM<RDY=#U+;AVA%*ADG,%Z7Z33#W+L9W;P!3OZ1W89U.[KO<.YQD
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M=(@7Y"Q;D>&SN8N_6?OA4_<T9*][_NGA11<OQ!Y_ZR8>G5Z(#^</N5YTS_J
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MV)8^?)CGN[+SJ\:[1[!JUO=7L)S&J.QUTWS+KAAR)G*T<G<(QU;O%V1!JGE
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M;3^X:.C-U-,O_S+#^JKJ/80(S@<7/A&V?<-QW-AIZ -BK#0/%7KQ+ ZX%NX
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MXCPE)B(@QB,@)/CU)8\0X?<@(:,C(Z,38#W&(OB_OAZ^ YZ@/>) E$!\1 -
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ML!'M[T].."WP *A7!KF6($2QF/T@[I<''8P*-$VG@7C+P%/5/JVCC/?XT7C
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M$:Y1YA8J6J)$&Z*(]=I$MG!N52Y?[$\M1)G^6:40Z Q7;HL[T+(?;W2[KA1
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M\]R,XOY+[#GA]"7O/OEZ*[J#3FNA5-!@V#GA>\Y.OX7I*(W81@T%<;[L[GX
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M@<(,NE*64\SUJ3M\E"^6I2;2YG4;[S;?[!TV:9[7A:*V>=X1/%J_%J^)['D
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M1KW0- 96^11+/.@6B9OD*V*1#*V95,1^D%NG9W\1=<Q.=3C[0*;IO&*)5?>
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M'[_VF36:W@Z+[B O=W)<[&6)*4 WSV!>6Y#41_T9;%OLS&1*:DA2N[A$A64
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MVL9G_"\&)D&;]HT9"PODB>S^#/>Y6;H_XL==@<IN*&Y3/"56Y[9LSN1DN-(
M'.6]=H'&J>X4N\/YD,H]SZ=?+9+(G-.#<[5Z[P#"E%42M@-H\])^3A"]*@N&
M[D3LLF,-%JPLR<S\D/Q!FU!-S[YDGB3;S&V7*9ZRQ];%(U)$F"V@C!N+LN15
MV8J:2(UNC  1093YZ>\3(+RR^:[1GD)*ME9UP@>@#C-^A\$C;COEA-JIV_2+
MZ^'Q4C5$KA:N81-9<.0-.PRSTJ=(:WO;#C/MOLF())]>._<^M[CB:%%%AW%E
M5=@\3BSEJ]HK*&2:#FO=^3CB>3L4*/#CX#!S*^&*VBJJ8[Q3W9FA/<'E5C,&
M&EP;+55O)=RV;6A$J!3[&((VU>!8  ]^&]6VGW N(I=ID'K^ #3*4C\3;3D@
M0C@NOU5OA>Y3L2EBF\AK-LV];D\K'CGD9A3846=OE2B7G7!XD:;IPA/U_*!8
MQ*S.2^7ED:HK&UQ;7J[4$_9L")&UJQT_,VWH.SZ;IF\4E%EZ:B A>)Q=<A.S
M-I%4D9*!S(:!V0._C9,:L^(=^"L*U51DRT71OJ)6Q:@U36W])S&T=-UH'['#
MMZ-"8E;0I_RL3/T5+-+*N_ZMW;+KX&3&ZLG+:6&(U:XUQ&8VV8/_V$/.HO)*
M9R+SHQB)DJ[VEXC$5R$R?"B-GJTPJ_.ZN';$RR39H^*T2GB50]R23JR1H4 !
M0&K#:KI)!%ZBB'K#-,U:/-_M-/J8TLY.G'\N!F[:+!!>\<64YO,97;&'F\MS
M;HAR9IU4B[V(LS9*;U"[H,S.4LP5S9$<=+^YLQD][95V.'"&O+>F2J4&:$3A
MOR7A+NR9<?V,JTD_M'=AS>V3[W8]ZAV@6%\#[03FE"59\8TT.J>WS)F]ADAM
MYT;>$AGC',A&_E]BS:^:X7[PKAAB] >^$JT-1>^RU_H!<""9[9*O%^+\GE!:
MR%_/>I4<D^>+R_0[UBNNW*^(1W< M-UORL,)*:]U";N\4NB^D4TTFPR;%L[)
M[(N_EB9XX#'MRI_+2.^5LGLY>FYP" J@:^9:)3S-2N67C6DI:';)F9U_#U/^
M'/KB+"*=?2P\L$@2AX"VD:I%RZ!\;+"]A&QYS:=^MJ:1^*TUZ%W8@Y[>?A([
M5$>]L@= 6[0W_F@?Z7$[]?1-"!5T44<E<+N,<0=OWGS9OR$ME".Y2!Q*/%#7
M%6'E<!+):YR;K9/=%'D9;(NZDZX_%WZ;=L0U'IZ><3Q\"Y$%L,XT^]I\29:B
M4^BU2+**6S\SF+D:%_E;9ZZKIR)P<K@82_G&YK40C'\@8^<.$/ZKB<)?S6KN
M &+_.!:X?I7&_6NE,94U] [P]Z7&L=M1G7^N/HK__JCO*&M;:W@E.'=G2("\
MHQ#!>EM%B9Q)S,P+-6%QU:IQ*DV6$NM]0SKBS7A*A'%8Z%F_><E*52QT43#T
MAV%HSKMCK'>UO3<,,^DF95D2ZM>6L7TYFDEYPXK%JG$=L\;8%;$[>!9$)%Q!
M*_?SA]@4W#?"V1>8Y66!+*L=R<[)M>F((=*/["<LV':YW_B%4'9EFZC&L]V4
M6(LUH>^.Z=-D)(2?;/H>2GRN37)4"!M,ZL!C8Y*4F].X631BY<BSWZD50KRH
M%MA/2ZBIJ:VOJJZVK><J9WPY_/:Y>3FF<211U)KIHOZ%XG'13R&U[!8JCIU$
M[-![]'KK@/<",<-<L> LV0'IV;00SI(MWUK%12RUS62FSD'\B?SEEQF/+<3'
M6&\_3TMHO(-'2Y2J6-8E!#PE)Y.ID0 .OS6+JJ2 F<:7E3?EYP9*S@R>9[?8
MOG:<GDV1;PS$)RC4^?DU%6-*9Y%VG'E_-5U7<HB/FD]&;^5^V>F#5*)JHSRQ
MO/:-N6'<#K<NN([ Y@Z#9F9)>D@?[.'TYUVTTMD:NEV-6![V3NWFWMK/F_ R
M51K<E:FX^!01OX 7AC$8P=P/ IXQFI*HR2C(D"5T\KB_>V/CED?MW:"R$((:
M5BB4R4V=#HQ<J*?*UV1^->@K35?D,:@C:1> O:LZKBW8=,0/,27DH;7?&/71
M"R8IFXBK*MH1WWR4*SEHN'V5/'Q<=J_0D&I\K&&G@M$@MU>-]%DA4=E&.--W
M:1($M\4C?$+: N"S2DL6";X/)AP#PH5RLC77W+.Q,^K+8?VA/128"0:H_"6S
MM@G?[=2B.2R29YE"%AFG5>4^#.!A=+\P,5%,:+HVVABV5;#Z5N+XJN;$4Z:H
M\SP[J3]J_I*2HAA/K:Y*Y /B\T5)5.-DV<DP,FXRA/R/W=$N\\R/&/_)>2BS
M[^_*B1%^Q6*!3]K:73D'%#RIEB$>Z'XEO9R\+L0-PWHWXM3#U2](;X-Y4E&U
M/R SQ"92>>#J[H1?6J%"$<NSDO"1(EK!BE7A2"0\6^<V<ZB-GG9OV3CZNSMH
M0S,)PY2[/'K_;3/.WF5L1$7]CZI9[N(DHZVCGXED!(J%H)Q!,^=9A&F.O^QY
M&5<?GO+'&KV/%P57"_MG":5>HHJ(L=12,M LWC/4BW V)!,>44,?2VR6#= Q
MC',5<:ZOSQ!$C(G@PFBKCZ95)\Z V4\M80U:>JD#!F^>]O=T/Y)L/443Q#C1
MQXL@>\8^#+@W<85VJ]Q8ZO^N*G$1RIWX1#4[IN:AIN(#HA-KE'/+(]2@LSO
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M7;FT/?YE69(N%92R=?0#N]-=)))LCJNGM=.SR?GQ-?75_&$K3P%7Y M E.6
M%^/CZ:^%:.SZ= ^_[<@DOGQG'Z-.%9G]B?&,[O[7D/?J0\&FIBE#!@%ZZ1OU
M^6)],F1>%L<294Z$HM"<*8/KMV.7]JW7P>$?[$T4%VRAPSYO01(:1)R\-]2S
M8X2VI+@4LW$L+_43FB?3UWYW$S[;+\9*_^66WO\_MT7Z_^CBALH\(A3'>LVI
MA(YNPH\'0]EYIGJJ5 IXEP4 ".?]?2WB"SP:;1[.JQZZOU^2L#]/P&IZ_,U;
M0/#/QAC1H?20Y4$-OC*&<[.>B9EPH^Z;BNZCJY$'22$X+4F,V%0HBET]*0ZL
M!U<,!\)/_UZ>9G,D],0!$'(OU^GCANB93_O^K[V97<2;09Q_[LTT_[DWPUO[
M5Z\PT3]ZA=7\T;N1]SHY!$FKE::=&A]:"7_;OBJ/#88Q(LGT'< Z1.DW[_TO
M(#PPK=W7ES Q35YPP%+M5K37??K M#P55\+40B'K^T'4O7%"TEM&/,)=W1Q$
MZ,,-:3+M#*A62^/1[63S0.$F:X'S36%/87"JR\3YMN&*\*DI1HQCNKUJ)3%-
M?0@$AIE02,D16Y2C^(T@[\W[S;"U\ 2&_,Z=J#N BWWYSW2O?/.](G$&E&G<
M%+)/O%%GV^-:64<]!!X3<KDM#2$OR'5 H^W\%=;T]9=D'JW-Y50)8UQXU.RZ
M^:<E=?2OZ95&5#.9Z 'OW=%BV33+_#,L83"-_%7JE%&68%TB^\R&-JX6PORQ
MXI];TZ  ZY"".X ;'+?98&5F/ZRA>^B3BZB3ZGC[D"Z3@3;N8^=Z3J=!2KDN
MC!UE5I7%NI!,C7>4>6HD  8UEPC,^,K=\>Q\(%5[H;J:[L_AK3+I=(:IG[%'
M5$S$>D;7B2O-DU$=/O@KN@_?6SS;@ZG7OJQ.YJ04N]Z,?Q&'MN3L$TR*56+E
M7<7^OVZ6_O]Y;8A0#R4VH4^NQ7K(&6N;T5K!(S[1D>I*.C3-E*3_6DFD'&Y-
M;MC8$<0F+:^>-:D^F1(1^'P'"/%XAU(RY^/+HB'D@))KS 6LQ#JXRML31LVA
M0X9U'*[?85T%0GWB^<0!8=A?KS#\.;^4]^ J<#]#8>*/'B^_&RT7B_Q5-**9
MAIH&OX+N*L)R [G-N=+$52M_X(?SE09(]VY(^LH\#';FMO-4],2"9S6H^AR0
M--\XU+.%=:QA7 QSG:EUH[&?%L>O&N<0SZPX,3+TJ>YH'5S3C;*.0)M7S$5O
MGRPBU;_5X0X ZU.$:V'= 5Z[AC4?Z?QZAE?66&366(:PZ/J-^$]#T<W#Y2@J
M!)[_'6 D#0JYP6>] Y#DW $"O]X!3NG A7> A_UW@&Y@U:PP/?*UF7O3'.+!
M)'5S>X/=<0=H&_:YPFE0NP/XK=\!5N-]_O5]PIPU63SRY3B.T.\03J1">",>
M0WU6S)K_/CS1?QON?E6T+$^TK,X1\A[O?B03%/5Y8"]Z5+Z$"#C$]5FN]8&O
MDQ]5D/_USF5.*H=8*H?D] Z0!,/_T>$SO-1*(G7#C'H'^";8J0]GT4?PR]T!
MT,7N %L*,! "/>D.$ 6RKG!7JG!'\_Q]%Y8)TGUD-/OQ9?PK5G$(O(",OZ-0
M_7<4D$,^N3B2POGW9RO]+S^F_'\#;^0_@7>Y?0=@A9+]A<2ON=\!_IS\2W@&
MW;^@=_X+/3&YY(QCQ,N],O)? T1E[1#C:X=S=CY%G"?GW@$LU1@\M:U8;WI%
M&,1WDL'DU\J-P/L16+)!>?U@? )HUM'4#1;S'2 @:"8U^C&X&5:J<@>H9/!9
MH:Q$(BK:N01GU4>P-(J;G^:TD!:*FB%9;X9I WSI$H%8<XOWIJ^,V$0\&\;C
MO9Y"0<Y=;4N$0LH:4=@J0A>]_1V"5*Z2.X#Y:=;]BK LTJ]F-.%)G=I'?#YP
MS<._X1X-UWKN\Y<ZEBPA;S _+=Q XA>:\:>$%6^8+GZ/YP\)2_WQ]A\"UZT:
MW98<W982$DV"D?^ _,;.C68IY% J1%MU_%01;QOA'E@?8 Z3I9M]+)X8!ZP6
M;9]NE, *]U0(MZ&.[CQ^$3KVVE/P@U"WJ#/<F^<*$\O]G#1K+ *-?P4IP\8_
M=!E6"=,/4\=5;F)E88Z0N .LD%9MZ-P!BKN_("=^FML/'<;YT?-<%+]KT*:L
MT*=-^(.+M$#OQ>7PA3NH%"G9>@F2B;]KGY"++1XX;6I-BCP<RD%M2(6,K6?E
M;F^\5OMOYAJQ%":V;[2A%D3+W?CA4"Q*KO=@]_E+69'CXYN#,Z&HR3V"%_]F
M:;!IF'YH?X^:D%[>-*6:(ES*.FHF6*.\.?4.X%',+Z0+?0_#P0\/*^Z7;4=@
M[_HDLXQZ(=AO#RKW"% J"5[\?I)W7_,O75T= 9=WP%)\V(7TV62H+>X=G96>
MO+B=7('/[? +;U7!;$.SKD53R,,WCE=C3(:#K9,&C2ZT@U=MORY?0 Q:LNY'
M6?KTP\/_\#71)(JX\*_48DF=>_TVHX(^;8(?>/O<Y2)OC*X;Z7UPP=^RWN-W
M[G3-O"%&8,\9A7KT(Z4*6TS8 []XKS2L>.F#??V'_:Q6DP%A0GZK_8KX;_3H
MQSB$!#]XYI*[77J[NI.A6FK^@DID\@<KOL0&ERD3V&4&"=71.L)Z,3?7\IP$
MC>U?'-D:)[BY(YKZNZ /_IMBNQ^4T5AS:3%196O-_ C8VKMT5AAE'9Y_YT#F
M5A\(@7UM_]EG,_IJ^,;C$ 2Q1OT%E0H2*KT_#=3M@0@+C%'F'EA(GS)[Z)CA
MZ+;FY-GMQ!]8;5<M,L.$7L\-1G>>Q&L^R(:[+WB.+=D=W5BOYNJ=[0E*Y= B
M=9;KM\[^UG(R8?)P(86R-D(AG;VJ?>+J&ZJJ=L_@[ R?"!\G.PLIY'=4]N6=
MUY%Y@=I(&=HF?CCA7=J\1<)%+,'R\%\\(IF@/5(=>^)"LF">3$?9]C$K<Z;'
M:^3N"OIIB\&^L^$9>.!TLWIV*>C6@R!6ZE]B6936;YY$(G8K""I#JE;*JWVI
MO\6,:(H:I-RSW0:4P'6X'@&QW&1DU;8L+R^RUI'Z'4U5B=+91(,5A]2O6\C0
MW"]-;K[*N%R]N/*IO"B<8:-OR?KEH:C.-:(OK^%4/10PGU C*R-J$99X*;MC
M6=$5LFJR#V8'W>VPZNOVN,6L*J2A4?(T6<*;[,E3-OQ7YDQ.JKT&5A"Z30OV
M@QYD#Y%":$?JQI_R7(T!0SK1$E>F.X\Y7L%ZNMNKV@<^;7Y(%24&7TJADHQ+
MA7FJE=U#>KB&THIC.9\V?NN!GW< W8NK.T#YA=5/._J6TZR_.] H.>CP"P$%
M;$^]B//\%];(V>R7':\3++ NK:5[J[0,OZ@688)Q^6V)DX<OGSRG"28CJ[*E
M22*>2[JL/FG=3@?.E/Z:+WD_//H?V&5T(F@^+7Q>@7F^ELD"2]U036WV2EQO
M_S)T1:K*Y^#Z#@A71"F\\=E":,(O, 0-#C%=C[$NH@?UFGV1?DTQ_6_#^R0!
M/7Q.75K>"MW&MIDU0UKZ?A=<<2%8$(YRW;[QA])QZ1N?9,*<VOAI+)JAZ=7Z
M_-H'K%C'^V>D'M-_N"*67S8:_*>NB)DAG]AZKBA CJ]S:2='4GMT5G<YQN,B
MTWY3#UZVLQ]D]]2$^KZP5.G<VS4?J4>&,J05OU7$,?)YX.-XD'S._-4E&QDF
M-_YF8ZMC2!^R3Q(6"ETS,BX%8F'.D9;[GRA&WL3R_;R0LF2Y 4'=8O=>I[-6
M<T@\?]W>7C6X5K?J$=$\V)R.A2($*MTGBZ_Y+>1G?^I,]X$0TL:]?ZZ+0[<\
M?QJ:VZ_LNAQC2PWYLY[8(AWBQ+:G/E0J45U:2)^(&SJ S 0>W];^!%R/&#=3
MW $\;]H:/5!^N?/\7]&5]1\>V OI%DV2><P;]'I8DUV02!9W[3J.+?U"<G4C
MNQIF%KIJI<@CBM]'E:Y)2WX4K<V:1NS5 _=)LKT(IFOTP'SX3R+R#P/FM8!"
M<%\GOO:!RQT047\Q,UKI-SGYV3Q9AH12&'6QFVM+" 0-D+.GA#>IR\F\C(D.
MM@Y.81_JK?%&6_/,6N?;+/; 0X:R/XT9RT3_MVO_!LUX$4"%8#SNZN]90$YM
MO1J?\ Z@?W&U&IGADF$/;<;IJWY-#?.DE3.'(J>&##V+JEG$Z^L(P_F;7-]T
M 22>J)6_QOJO <C]L-.;_O.B&Q!Z[<,EL6;T2PJXU[?Z&TO#>FGYTV1(/8IT
M,@KO/ IEH8JE$!*V\<S[> DE]$EQ_67R'H]&MV4JC')$_D65[@!/;$,]-VR!
MG6V<'IM(YA+@OA0BNAGDNDF^?[OC7!W>($62V&4NI"M ,][/F($U!TG!OBXS
M%KWGTR!BM-CHBJ09L\(,OWWL/P+;M0\>/)'3W"2X<]Q-GB$%P;#K?.+OU?H+
M42F]4VUX=<>HE/F/3NAV,A]-E.FO7YQW&^.=C[N'T&U>("$[0\9*9##!^LN7
MD2)C"5\HR"R\/YSSB0\R4M9F""E&WKY:-5O(0<;DU$Z!D!L=TOU8^J5?D7*A
M#VN0A?>DQK[B2!!4NJR,BUKYKZY6U!FZA"-;_9K@1O]>C"$V]B_-E%UU0X:?
M^2-WLS#GX7!/.> " =(>*9'6KPIV7VCX/'W8_:?UNR-&99!\<?!OP6[M.7).
M@TP1,> F+EY#$Z657<<J$D=,.:1':#JC_B46AX[_LQ1@HV7179-S^X&IDO?#
M_-U\Y1_8O[>?R;X!;$R;-;J;(A7=\J J^]%O^5GS]&>?FN0&#$!@>3H%6*$#
MR]/%D^_-S'ZT7N3PMWB+BGV/3_>Y3K>3V19O.ON=.;"\^ (*O1DBN:@YD;WK
M3^ FA?"C3Z==700*[K+;SZ=\F?[^@_MW]U.9ZX'IW\A"_L/TE6:KA>;_<-?=
M%]GX+'[__=][M4$E[6+DDJPOIF+U42'5$YTU\<*>(IF"<K+;\C6/F=OKGWM7
M8</ST>6?]D?GO1=[:^(Y)BXVY ?&T^Q3W+V/@<5L\?5E%>N304V-*J2TY_!/
M[Z.VS='$CU6K8Y:L  7,W(G\>\7US]7OJ91= 73H[B/S$O*5C]YVO3@]_X_R
MM_\,KX!5^WU@0W_?UZI_H$K%&5&I/#$ -A(ZO^6;\8M[;TJ?% @J4';]W#A_
MMSRH')69]^6$3>2CBJ,KIMF+GTD6XJQ_-&];O,G\'17 LF$[L&ZW0$MR<LU'
M]ZF[=GC+=R_5SKNXT4YV6^RG^;OU^8_9[[YP17R>TD?5MVLF6'R<4OVV9KZ1
M/O]M[34SGP64SY&IYS.,N]@(RF8R*%T7F]N!'Y]\EY/?N<&?LV*5YY)M&<TG
MEVO<.5HX^?>I5WO8TVW[6[;,T$O*4.^Z9''/_-4:=H5KK]W6&&2>6"C"8,#J
MLV36EM!>S4MS4L]:WOT5$:6Q:+-5__^; %!+ P04    " #)@)I4.+9^2Z6/
M  !0O@  &    &%D86<M,C R,3$R,S%X,C!F,#,W+FIP9]R\!UQ37;8V?B#T
MCH#T(D60*E*E!41 1 11Z46E=^F=4*0W 0$%*8)(D2*]2B]2I/=.4'I)J %"
M\H]S9]YO7IWYYKUW9KY[[S^P?[^<E>?LM=?::Z_]K)QS@IY"+P$4=Y55E0$L
M; # POP!Z%E $0!A8__XQ[QP,/^X!+BX.#BX1/CX> 0D1"0DQ$3$Q*1DERA(
MR2C)B(DI+E-04E'3T-"0D-/27::FNT1-0_VC$RP0YAP<7$)<7$)J4F)2ZO_T
M"]T"4!)@M8':0%CL #8E%H@2"]T!L&+&B8OUIQ?PYQ<6-F:,>/@$A$3$&$ 5
M!8"-!0)AXX!^C!KSJ1_F<P"'$O?2%6$%/*H'3_'9G:AO!,:_(^"X5=9*HS4,
MXQ1YYAQ$2'29EHZ>@>LJ-\\U7E$Q<0G)FU**MY645>ZHWGWXZ+&VCJZ>OJF9
MN86EE;6-BZN;NX>GEW?PBY#0L/"(R(3$5TG)*:_?I&;GO,_]D)=?4%A>45E5
M75-;5]_6WM'9U?VEIW=D=&Q\8G)J>F89NO+M^^K:^L8F?/_@\.CX!'%Z]L,N
M+ "$]9?7W[2+$F,7-@X." ?_AUU8V!X_ )0XN%>$\2XI/,!_ZD3%?B.0@/I6
M_+NR5D(.$2T8S3/G8:++G*++7/ ?IOW)LC]F6-!_R;+?#/L_=LT )" LS.2!
M* $P<*&>'<D#_*M;*=/%IY>JYZ+(6\KTVB/OM6052DU+F2]*T<"W63DVR)2@
MQH8\"V39!,$]N7V1CS"]TU"+<++DZCA^WL=Q4;WN8!&C"M[R2;!]B&*>/9>!
M#(M5H(&6K5*4M/':$N3TTB'Y.?XL&EC/+:X'3KM_QJ@@I6N./=% MJTE&@B<
M-$&Z-\5F!\[]06! W4'<+_(XA(?C-AP-W)X81 .@DF;$CA_S@ZA\]=8:*F5+
MXL;.6@?BMY;,3GORAJ>3?T!+T.>)R@OQW8&)W;.9F55XO_O05]Z/_2UFA==N
MFL8^Y_V.Y;+&^HM&5MCNXO0**J(X$X5O!('/G$E%8J\-@'^2@I?GFRNZ+Z@,
MP$BR>C2P4G7H9CF-B+H[YL97+#?YL**NN:I[1N!I.HNNRZ@W* FIA%VW] ?Z
MH";[0ZJH<0??0GX25T+:&R"6<6=7JR$(9C<TT&V[OLE#G"F)!GZ26Z&!,'?4
M(.NANAT:@$EMH8'8R>$Q35HYZ>!C-X0'C/6X *&]@ ,;DV.1>L$0-/<Z+UE#
ME%^/_H"Y+,[FG,*U%!M1C :X-6".J-I-DS/>SX>N60I*U)I8_YN;L?2Y"1KH
MJ4+*HX%/AIDCGR,;/8Z;T4"B+2(0#3RI ^<"WF#,NV]J0^!M5D=,F"57;U&U
MH(%]KG768_(:-#"L9N */%"BQC0%'XCCA]DWNQ_NL.-@[SZ_X0G:VI$GKZV-
M'2&\^F:")T=K8/<Y-=G[U%.(#OSQ9)@<QSHKK>6YC!S=N!!9B)NO&(V9^"7Q
M/H\I/+RKC#TXR ]-0>/^5Q"6RI]3!S4GMNTM(Q3O)=X%7K"$*@Z+S+J+&,07
M5W4V^ER^QL9VXZF"%CE;)'"J88QXAP8(A:)DI/T*;2/R-J5T(DMV(&5WN[H6
M. .1!>(4G,_:U_ E[98>>4-VJ$I4\CR#E.!&(?/IGTL2_9AW^F8Y(ZCW;\S1
MM%#F/"'A2)[RM!BPW6(M;[DJXB5,> ?DW]H RAK4;X&'!6XCG^9V6C@*B2:'
MFM5&KMQSC1D?^V:NI\=D65C^TH\'M%:-&(;RV3*+,RMVIXK%Q):Y>%<;LXL8
MR%"\ZIY>2K@3OW) T,/K90<07,V4Z!RDG?(,>RS!<J.F5EWDX7 Q[EOW9+B"
MLR!%1"B];R?.<LHJKO--]J80V&#0(1H@F58GHO(1W2=T$"PQ#9<9P -=CZ'!
MDWZJ9#>0/*S".=)-]YAQNA<4[8')@WPP':C%1SA^1T6?4*3HQ@3/[I4Q&=&R
MW?I/Z5R\N9\BGS$J7_]>8T9A.X"T7$E;Q/-<7*%!!1<9;'AG?1Z"'K@K\MG;
M;[9\7"M#\FT,DGBF*<+-HS;U:8Y*<JTY0\7K*Z\DS=\GF)\+CM\927^_Y2T4
M;CE&I5%7^3FYU\7>E1TK6BN 4'FEA""+/!.\[&ZRH=]_=KEN17=;-'?2L7(0
M<9=+S568)I SZ!J!"?^E_A9S!?L&[P/CHV5R2GV;:LUIB+W!%D-Q5:60.USY
MBON"G!X#?T(@[ Y-Y7'U;@@#760"H58PSK%DH51*^&$,[:/1[5(A^QW'(PEA
M_78.+*YV'LZ0HY:>+-*[O$5GN<7%7S\WCKY_:'BIC(/)D<TL<-.O<!R@?J#T
MI^9)V^EX*@4)AAQU:V'"6FPO)_=OB'Z#_V]M-"O-56@ F6;207Z.VW/!-_6Q
M&V*+!D[%F\-9CXD3SS3Q<Q"LJ-N?0:C68S1P=LW6H4R&' VP&__(!^>0"^JJ
M&GE<Z@?RN%Z.'1%[C-#N=FF5WHU+\T:-+S)?S7$UO%8X6HO?Q?5.>C!^J";K
M3 !MC.JGO%.AW)+D.7__<5(86]P#>19&&+?.J*_(.\_,MH7K;C5PF=3Y[4EW
MC_Q[J2^<>UZ;19N>])K.Y#@XU>#3%>GZ^GW<9*43\)5^6KIY+.4V/GZ<Q'^I
M]=,,316I8QF.N28>O0Z_WBE^H(DZ5F!TYD"AS8SSYIGY>.*@BUT*Y>O^ZL3*
M&UD<A5)O"P[9 ^3LQGQ-5^)AW5K-#1-NZHS:PX)7ALV3'I#/<NNE]*<KW"*P
MZG4&0#YDPIKSB,$.??R(DGO^HA..]OR^CR_2F1N*'A+:<X;H!6)?-_QX>6::
MKDO$Y ["L;W:GWJX^+"/5;*5H/N-DX@:?\S\_%2R!7>"ZFHE&J Z'<+O4EDA
MCQ+<<=.UDWGXD8!+_>KJPG<HJ>0!MUDMSNOJ@BZ0<AV!,M:F[6(3F6U-R@QY
MY,X1\[,5'0:+,A=;W/D-$XDO1$4-;QXK GH!=JXLXQMH( *YGD4>YTN_(N#8
M#B:1$;A(\1R5K_&.FM^X/(DW<2;O:&+W4N2**AT>?H^= S[;Q$+5BNJAK$87
MGW7!)H-9#8HC_D'Q6'8%,9>Y'N=,_QOS%B(Y"T9GODU(!\K5G_L@BSSV(30S
MNLKHAOJ#1H/"637;K(V4CSB:[YUZ7,VGKYM9E3O+[:,!WK%Q&0\/*)C!TW_M
MX?AND=N.=(?$IZ:,H09%:_R7"[>;=(T?15_W14YSR#QK*D=JK*E (5+ J:TF
MW+VY"$D#MTN-&A1O^#!HR96<X^AUG*;V1@T[P4#XL2LW(OOI*V[Z3C]%.S-;
MS_XL_ER%YU*@6(C^QP*KZM3*ZE(/^K<&=Z[&2IA^DESO]+XD;9EK3/WGC8@:
M:\F$IOG;!HH4#4PRJZ$!)9VFV*2_(7OUEQ/^US:=5-0("_F$C!\,W"7'.B2
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M*RITO-*K#>KXT'MG7"5Q^-%BF=LGE3>B4L[WGB^_+JR35YY:X3%S2/LD,A%
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M%7-'N1$+[>A"T[2'BZ O]+ZZQ_/[VYBK=1%EXRG9%W]R'W"Z<I'L&I^ENWZ
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M8U@I;O(XTD&63E-@9#5B+P!O290N  IKI:;_NL%?ETS8_/V2"4]*X.XV^ +
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MM6L96.K$EP^#N[5%R'0]&PQP811_4S6:C<!DG*<7.-F,$LZ\U<^S+AD>-+#
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M.BW'W1"V-6C#/[_<0?"%+NPY_W8*93,RY_(FG049^7]9"< ZV6:#)_>:&2X
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M+.GR?7L]-K0*!B:$HHRLR#L[/>>D5TIV>;6,^NXLY1D!KN,;70.N_1LL'S;
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MNRK@F7<:FR5W^>#]3A]: D-(6T$)+H:. ZYY3I\0T8PPSP'O20&\<*5 YQ<
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M=FM_*S]\#=NZ9K. L6A(5?Q=3UP)FA;799I,XNS%H.P-YF8Q@#E% W5DB++
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ME\0/S9><3;@L7 PGH,%P2(_#)@@1LYS(SS.>-=B(O[P^MW=^ R<BF3"^?##
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M!K<O<%?/LNDW4H4-1CP7<A:]'HH<#/L$4_9%Y;QXW?8M^&U B]'K@9,VXG^
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M:"A@X3>570U+X8]*H.)DP*@JW!-&L[M=1=BN(GBEWTG,Y7'NW;-UE*/EJD0
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M5>GJZ!6ME526 G^WH=I?* 3^%Y2P3XEIB6=]F_]&(\HQZL@=;=&F,:K"\?$
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MI3<2*T8MX2-WR#BIZDR79;E,VH7[)(PAZ680$^X011H[J$&L4/)+#X8LT*Y
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MNPZL'!^73B#2TFJ &00#%U?_(A7S,!,\S_C3O,C!(G)0P\6@-- 6C',/-H9
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M 9Z0U+T@(UZN[5(PB4,PF$=@WD8AG;!/H*DTB:2#'@6J[%/'6X("/2[TX[7
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MBX1H4$KE%132QI@V_7FHU>7927">J8XQV<G+ON*_6W% _%$D^3;>EJ/]U["
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M86]GMBJP7:#"T(LRCSD\06'LMM$?Q_O/>[%H52RZ ( IL5CBQ/9R\23DH@N
MV+EF(VB!**SJL'!E\:\-\!GEUJ4X\%P'S)%$-A6YT%M5.9N"F&C4A8+X/P.L
M@XJT0XR+8;J%7B!;%<@N\&GGD@ACQPRM-;*)(J9:YJ ;429+\ 1($@=B!AQZ
M,;0<>%^C%Y;EB9<F>]".,4I7?@8FF>*UP\^KO$CL1V0:.,EA4 ,4,UBW\CNY
M->%'25F?.1,X[!#<P$K^=YN4"VKT_AHSHHE.J&S!1 V&<OED%&2]%"#X/OM*
M+YEX&\LIV/O*"#.@H$<OAUAJF4FH]" W'L_F(V=+2$GV#'=,RKW685L52H.U
MSM"4M?VKZ\9J9Y4NK.M@K\E:U61=8,?*$SC(AML>)*68'>*6)O\^<B3%4"\/
M;<K#RRX@+BP/+9E:)^H(?\U *J,W@B23($#S'1_[LV+\N[ 0P>4V>HEJ5:*Z
M0)V<Q[\39.X&'4-1*";MTZX\'XQ[<$&[DM$%N,"P=.Z2U6[7@%)9WK#O(,I]
M0;S#:"N:NE&(R\>Z52[7E )Q#%RN-@5'/'9 :F)F17Z,R%&F/R[QV>4(@E7T
ML@]>T>#/+(5=Q+RK1;+:5D]8NS?HU5.[@M%%5(4%0Q9+Z:7B"4A%%Z$+E@KM
M>R"X5IZ++4"U]RJ8\-^7)RV+XO/]ON9INV+81:CD;V()LB?Q>#LQ+)3QDYIE
M1]'NT#5_DXXYE9V5&#?A* L)K2B[T(M0JR+4151%U0+9Q?@V?*ZA77CT*S8Y
MP_(BQ(M-]07LDJ]6U5:[G*M=WPZ3OQ1+O[PV1'K;PI>?9&T3RK22A5Y=NRQ*
M9M=%\4449?R/@U./#G4D]::RKB$FH<V30$297>YWMLPX$VX<*J)PQ@EB;0=\
M96B<,L,REXAOTYQ1@JH!4XBE7,_ M2FR[0P\Q@19U":%+)"H*PS+^@9<S263
MA>&\I?I%<J/#T^<JW<SB6.]QB9WB$E_UN,0>E_C(<8FV9E-JS:U61R %:'[5
MQ15*%\O2%*ZE-CDAP12BR;R)0 !8G,1KBCOP1F$Q_@>)7\RY1B55BL&KN8Y"
ML^V@K)9+6Q1(B[BQBD6KXCX5[4PJ.)QC55#%-S69<%55"K5Y5/=<_LL@2P:X
M<?H8WC\I(O)B(Y6#3++.=''T0'/_JVH/F8I.ZKK@XAME,&?J#-K;6*W:6%T
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M@"P,+D0@ G?5=++IM3AX0YE:" ];ZDJ\]&:&+8>:[;>5QY#%>BEN."JT*PQ
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MGG! 1D4T5M_67M-CN3"#ZB I.U%6K\6O*<*]&4"*?<P*2C2]HP-KHS^8F;K
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M#)\BQXJ;^+S>Q&Q3,G>-JWQ, J[+I,5DM_K&-2G.JUX,L"63=)%0%BK^@&(
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MP!& )6.=H8O$QSUHPVKUF=*T!.?8;@<-7ZYT&<$DOHT&<<Z:Y"8&?40'7@9
MF 4>%GQI8E_*0VAX&=V^?>XB.ZNIC7IU,8VHY078*"_ S^NFO<VD3/724G(
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M:P,,K0 Y91>=47G+,FJYIVVA,'%+I6Q*J4U%2/8XKI.BQ5]6H"TJGV%TD7T
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M$,5- ?;?(,"LC$I&YI"'B"7V!-$@.']'!SD2M(_#X:O&_I(2@<+Y3,$?7%5
M 'SKN09]9F*95JS4.,J08==(*7)B09%2\Y:DH@Q?OB8HT.&>32R^>+Z_8W;]
M&)6^RBU.I>MD%2OIO"],.>:PDB"]7]$=C X0P<1^Y@'3>>S_]NMSPCA9<-,@
M&S)8"@;MQH?3_N4M_R\,\OFS%_LOPN_!OV\,QL<*V24M@Z"XP:0<7Y(:<-E4
M;9GDD#FX(K]$AWL?]L[V:.^B5\_WVQ._P1-_M:DK(H@I4/REX#-G2WQ]TNUF
M7>[:"]3>Y/$_9M,DY8KA/.A).TZ^(E8*GLYAFC9%^; IRE_;%&6;HMQR-F1;
MFR=M*SF+$I16S&LU,J<#$]WEI'"([AZ]4V;_1*MFG!5!8$%+)"R'484,B-(_
ML*QH:9BV$FRC:)QU*=D\-([LXF(PCJ;C[H:LR>.V 'OSU[5_5B!#T>#@9@+@
MKGBF'@$__W(P#X#[Y&+>/[1.>;UN30S>#>@PYRL4Q?SOP^[I1?3AY"RZ^-2-
MNO\;^;3./0ZMZ+Q+?[[X%'WJGG5[QYVH>W#X*3H].+OX0S]_]$?TOG=^>'30
M^XP<7'\0#]?!T9'_G),/])=_]([?=Z+?/W7A=6?Z_4[4^WQZU.O"7V @YQ<'
M%U\N3L[^@%\?'QY]>=\[_EAYTOON>>\C#.5S]^SP$_SZX%WOJ'<!7_C0NSC&
M">"$#FB0O<,O1P=GT>F7L].3\VXG.CXY?M8[_G &#^U^[AY?X.-PZKWCB^[1
M4??PXLO!471Z=G+:Q0F>]3Y^NCCGS_3.WO,3N^<TSH.SWCD.[</9R6=XV>')
ME[/S+H_NX C^T(F^G!]\[-)G+\X.WG?AL0>',"#\?N^8%NCPX!QF]'L/EA<6
MXA1>CX,YZUZ<Z X==WNT5+S@GP_^T>4E#JG/\!VR1+ *\A7=3?B;7=^+3P<7
M]'V9]OON/[M')Z>X$K"<!\=?/L 0OYS1\.%[AR>?<8U[,*'_PR_J?D!IL&/^
M> "K<G%"CX15>_\%9O![#V;VK@L:YQ#F>O[ARU'+Q[?<$=Y_];3Y^.!P=S\?
M]S[T#DE8'H: [R]Y3;Q:FZ.O!\.?I*[$S9+UKMS##@V#OM^E77E/$WF%I(>N
MD!/X*LXG8VPKX6-3*@5QKH6TV"YHG7(%'#4+SY!>W>"_O%)W@JQ<<D 884+X
MF^]HS^C0932'F5FB"$HI>[DDGP<DG<A2!^F#29)WF^"HE0&>QP\N'?W;!2F]
MT!1WR;$4^-Q* A8D-;>V^(EP@!MK47E$PUF%JMA2W/CP'+>$4MM*Y2@:5V[H
M/C!@/EL,)1-][L#V-Q>VOCP;&$/KHUO]';-<D8^Y*;W;T'^0URZ**4V)!('9
MJ/6M'L>WJG5_+;'ERNHM8!<VB;3J\^X"WTA:;ONUB4'_W F(]3?5 *0Z7.ZI
M3P7!J*^9S,R1'==?O-M"^A\'](J[>YF#!HA2<RD1-V5R&95C3#[#YI/<R,:+
M[#A5^18^W^[>(['*@5N2$]38.]6\3Q) @VLU[ +5L901S+-F4>R46W:/H2"M
M'W79JI#V!O9TF04VU-^(\N>TRL3J QK]&>Q29\G+M*H7L::!30^OXXJ2$0T9
M_2'6:/.!DYB8[7#T:N]%&]#:J*>R+EU:@Z=B>](NZZI87.A:OLJ\+B;45,B_
MV;?!<ZE)]J8<%SF%@8U?/T;+F?C<VV&;3.DV_[XH__Y;FW]O\^]MB? C>K#6
M^SQ31.*!LW[(=L$60ZGJU'KPI?4HGI _V&[?UCJ$-MSRG1ZAUUVR=0D]E]#G
M>26GL+\!I]#U0%W@$S8$K&M.X2,@A']HIW!='J.J4WB(_5L=9.H44P3#,E_&
M16RUZA90;!]GLV05HD%M="G9(@;T\[$-2WH1)# V<'2C'=0@Z_O55N*,^*HK
M^-7,CD9U:UH2G]*$5;'Q5,C]OKF"_W%S2; LD;A&N2QQ0[.XM3V(5YB&;3[*
MG:G1BZ':*FTPS.TYV_-T7T;F2N2=1-*RVH&JB;AK.HO\+R2I=0%2F*'-5"/#
M!)=U4E/2YF]97+)DM!N)@IG%=T3,,()7Y<B1N]GGGI3%$\,P%1;])(,$&6B4
M1V.2I=CYE\59WTQ#F=OR-"(V:/Z-S,5U0>U$5]D-DI5T7(?:AA7D9:XW8QWP
M+LY?AZ:A\;#:8[@-!.7GU.?6\7NNT"/B8I&H8#V UT,W;)6[L#7NK.DX=+B%
M,77_+5.O[@D?>67&5*DG!I:43PX-[!_^NTPI1LX4X7:V27J=C:\QV9V.;X57
M]%;+(.&4&7HG-20J"LFVW^19>OELF$F1[RC&@+'44S8,F5M&8&!YEBOS.;L/
MHQ+3^K;1LA3YBU,P;PTLJBF+QADFWHMYIQ4YI@1>XYI?>X<R:+7=:7Y;?1_=
M#;KZ1KK!M<=^&ZBSW\6#K^64C_P*Y-GS-M7U(X.KM9P8I;:FB-'<NR$N7#/N
MN)]=PQ6+W!?-XHCW(<NRE_L96GE3_YO[#;"C_6<YO+3-SXQKE4J,#$X3U-J\
M!P>%FYI1:Y9% S,3OQK3K]S?T7Z ]:^FQ@RU'IR23Y:67KKI<!,%GB':WIVY
M)SXP3:@4@J95A+KB ?2?&]2F%*![XJY/XS'/U*.^B,@]2'N*W730Y MB*<V[
MX8NCC7E9[ZP-JVPTK+)N05H/#DJ^&N7_^TIC'A0A-,]C[ *0P#4(\K94#/#_
M^<___,__=[F/T@DD)U0X!/5$U$SQCERT2KF)+0 $YQ=AL \Y&A21B^=<IM]!
M627UZOZ($Y-VB9[^L5]I;%2ER %L_?&,/FIV6>U%\03;M]0:4A64Y.F7!0A:
M@4<&3^Z 5;[G8\$SQDK&LTQ[!=VMW\6T&">39*;[)@N!DQ3E@*2AEQG1&=5I
MO!=TRY'6.%.*S2I,N;(#U4Y.*C#+"\E2GXQ\(6D2C+HDM*B"!T45O'K>H@I:
M5,&65_4WZ7\E&[&ZOV#=34J5#77QB4'/_\>F]1I<JU$V&)1Y3GED'-;&WR'7
M6'QYB32L,]/0/2T,#<;1 .OQ*!_#/7_\>S$R'G^TNPOQS[OZ-XK<$9$;4B;!
M&6OJO4;]G+$O-]B\K<FX49-QW7KC(Q1Z6S%QI,=EK>+C]P>?#SYVS[D\%6D2
ML;@6BW*CPY/CX^XAE9Y2R2E7]?XA4>3S:*>W2P6G'[X<19][Y_!QJD&%9WXX
M._CR'O^QTX//O#NCNN63#U$/"WK?'?4^4HWB>?3E^'T7JWDO>H='W6C_-16^
M(N/BP1G6L+[[+ZK*/8DJQ8WRO7,9'*:(\8N(=Z4G]([/OYP='!]V&U[F?>E5
M)PI+?,\_'7#Y[%'OX-V1KL$%E@YW8!AG%_B%C_#$+CR[X\W+UDU'[[]@%3",
MX02?^SNN)!5$'\/33[M8S=N)3K\<]RYZ_^Q*F>_Q>?=_?>D>7\#?[&;@&L)_
M1R?G5 %]>G;R =?N_,N'#]VS[OOHW1]40GSB#7X')PZ?.?CPH0?CO^"G[, J
M[A[U#KOPENXY>)M<-WS4/;=UX<<G6!BM5<FG\,H>UW33S+[ #&54;2GQDJ7$
MKY]V*3&(Y(?>>Y9($(.VE/C>;H#7:Y<2'WJ]G*.>(V5;X0H@^$\%Y0..&CB<
M!<;[2G!:<_A>0W?+D,J18%8^':_&S]!\2(ST.Y,?^-/DM'8>Q2NE7!]1WU?S
M.U^-F08]LCU'&LW+*58=%%?AY)45JE/Y,-(%CX1HDOAB"N/WB(T+;ZEMB&[$
MI)95CAC*-LW9;PT>> ;;4FO"XT7'9;DEU.W;P%(MO6=$J=G0'SQBY!I%-['3
MQ&PF#?*2=*EG-QC6&/'6IKO>4MJ$^?SE3\?5 @HTE9-<Z'H&U/X2UX+BT2P)
M#7/R"]"EM2'A:\"U\5B(I,>G_F79 )0W40HF4\-W])?B@G,918RE(S-X19Q3
M\'" 7(PQL1V54H "4CK#= *'X<PLYB[(@10DH6!J^&>G7\XP:NX<-"^JAJ\B
M"FM#H3J-9Q5!N<XEQ\ DJ1#K#UK+VPD<10<)Q63 ,.-NRR)]1$0<?^4<;IEZ
M:LYC^%Y%!.8ML@7NU)K]DD.E)+DVM8-$!$Q!7AU3KH,O\_5&V#IMF[RRUZVI
MXPL7#^MJ@ 3_E./1]'990R25=!1*305%"Y:&ZSR._7-NE4W,/[,6+U.](0<Q
MM^ F%#6J-,/1<TF1:ZCA#:*'>>34J?V&,G_V]M66X43CCX A2L<-9IQY2\9T
M_.4WTM08.8)%Y"MCZF@$&::"O+74>BN^AL?$DAUCC8NE@F]!!;EQ\:?%2*G.
M5!9@!J*"+W9_EEX_=K&($%DG3D:2K@:W],'20W?A]_&:AT]G9=%PFN4WWMQJ
MQ *=._4A*V.G$A710"0'5H9T8:JOQ-_3M9[,0IU.'<59O&A()6*M=@9N.=WV
MCLH\A:O.40)7%U>'Y,LK%L\$Y8C8W9Y[B?C#;I!\&-G8!D(*%?PP]ZT<U%0/
M"1N'P\1MQ8/YEOH[#-U,4,%@,REXA1!^,HTY8V^$R%SH($;"*#%OBK.P9T1U
MN5NE_;!*>^W>O>XN?F^/[0I.5FAB6B-DKCW9-PAND.8)U4ALZ#58T[?1/TM&
MVJ2L6L3AJ9^D\"$>*8AR4<34Y$TRDN-Q=L,X;^D9TE8!/W"^;K_-U[7YNK8*
M^)&J@,E[)RQ60_/%@FTCUP9CQR>1:^Z.T4><WJ#,&19FO@W .+Q$D\[K^>$9
M[:]WV:PK<U+J"%T#"VN6<U=%.C]%*QN/4V%L+W-V64JVE?MPF49XMT?3;&;#
M(M=@\!+G&*(",3Q$K3"S,<*9U9*T8<(1N!7QN+2=EP9QGI,,LC7OO:SZ"KW\
MZ1VLSRJ4/^P6QM97<36RZ#O$"=<6+?8X&[J28@,:,[,AI%8D'Z=JVC/M$!V*
M4<,A7"HH;)YNLA263#,SP%H6\B%W&SLR52@/JI73+GQ-T0/&SOM-XMR@!#CH
M_]88#DOT,9=(*#SG1R\60\3RIL^\&3,T-WV&7I<&&ZVC254^,9NU_G,+D%HX
M@+.K*CZ6[??]U]'.8?C>W6AG7J51!8C([*&Z QV_.:\[=CI[C1KO<DM?]PIP
MJM$%Z,P/SLP#"&O^04,K0E-167[T$+!EFQ1#S'-,XL(%MNNUGO-7BZ;3JH-'
MZ<R*I0>A2G"$EU4IL@&).CFP,MUZ :@%@7@)306W#LH/E0: A_ ,PV]1/RXH
MX-)8?A@PARY%&CKSF[D(/V@QK_WXG+02M_M$(/X<0+$VBJC&(65=FZYEI 6.
MP<^)>7$PG)D2%YGE+^O4>$K!$@Q6=)F5G%O).6\IYZYD0TN<!N[5(DSMA5$&
M%T? =$9AD&X%=9$00F"JAS-<QL]OX;IQ>JN6V[+]>RN7397.$.5=JREV.\M<
M14X-<O)RS6MHSBUD<VP@.7@/I7@V6(S0T..4Y0^G[RWSYN(3$YVQBY2!G$B4
MC<H)@I"4'8*3I#E-(U%9(70>3H\M[\D);UZF2EA1[<VR--5PU<CQTI<3^"<L
M=F$O<J:$FF5:\!0$TVGEM22IGE%HB-9)VA6'CS60FM]H+>S'Z61-N=L[:T2]
MH&U' ;:VJ&]>O6]0X?M=X5N0J#=4=ZB' H0(HP[<*YL2X(EU]FPG[&)12/FM
M*U/S'L9#UFI<)-B_M-ICP<.V.[=1V_/C;(9[1,ZMXI6\8AT?W<2W".I^5XT<
MF=%(VT4Q^HDN<=!J,777!O^AL&9,$,;'MX(&V30<RH7U9[5F9$BX*I0.I/6+
M&<Z#E%Z:62FVEZ75SUQ]%F8V25P%'5:;K6L3F_&TO:C72S!R?RP9$8O27),.
MP-6,76&[#QAB:,IW CZ"Q95UY1M[.5FB+8AW21;P6NLHXNJ&FL(F$ZF0PXNH
M(ZWA/2J2X379VR';CI_'4MFHF$UX;+RS0G%2<]?]N=2$YJ,EESDOOADGW1S9
MI"LUN=<FQ1XV*?:B38JU2;$M+V*[R<HQZS0//*F(R.623TM]RE=M2WTA6>I3
MOEN"\,T$Z=/D FO$<8KFML0:3/5 7VA$@&?D*7&?3>_R&"A(*;[.DF'E(IQ[
MX=D(@26?KR#;7/?>AKMQ^5MQN0N#S2/QT.=[V B9=ED_=I0M+JHQ--V$%@XL
M#?93"XU5A(0/K[?;IGI:3B.LYKJ$#Z<4\(N7A8*VGOX6<&6>F<LXI_.FW RG
M<"-2M/+"#*Y2L"0N5ZB_U(=42.@P(\SQ4'(9\+:@7Z'VRHV-$2TLKZB!>G,[
M='S%@N%'$C]$^SZ[)D53*(*R&@'SKP.>A#XX&,>BLA77GN<ZR<;NUQYDN97]
M[>"UU"0&[LL%+(Y9A51/]OD^1%WNS'(\H^O.=BML%G^_L4JNC/[X"R])XJ>[
M)1TAQ44<!&]J[UU+COC7,[YL81\!C)Q0+J)IF>\^=K*Z2Y\ZCP)]BX[=#VTG
MK%OESW8".#YO(_ZG!T%N#8<G8CCTTH2.X2G"MD$!8"1I*0!YC?:C3E6;%$6)
M)QX+%T"=##']3/!P9$O!]Z!_@2%)',&8@5L17?H2E0T+=;6_+;Q82SB"<'1<
M6$>IG#-PVK AUK^08JF$7JI_Q9U_0WH5_U7[,V\*W H)ET]=)?UD)@1H__UO
MY9UANS0%I3M0PZ< J8IG-J(:SHQ0<\45>%N6:;L>&]=XO-8'/1.R-1N_[1--
MHB)$/9SG.+XI'OTX/O$3N+;Y<@YG -EKD ^8C\4*QDMO9"/U-UC:1)%I/5V<
M7;=/#X^>:YW,NAO.X<Q69XALBO3UM6!H+C+%.Z6*QN&0'+B05\FT$9G740,F
M%A*@!KB+9^T(MVDEW6^/R :Z/B^M_%QS:Q=B%R4X2O)BIJGU>7D1B[)#SL#K
M>*PY%"Q=IAB0C,2OLL3B/'-3 5F0RMUP^JT3*=<YZ1N3>YR-5'48%W/4,WPO
MR/&*^8M3"<KX&+3>A%COL/3B3'W4"=/RI9)VP:&=60D?REN"U;$K[>6].=NG
M*^ZX .:ENW7QHSM29WK\+!\O4<PZ?,4\(;!#X=2DSJ@AHZY_4AL:E@'^S 8W
M%B+VC4EM]:92X5Z[_0FR_1@K;2 %H') NND(R8THK,(+2L(\!.U1?PL-!NOQ
M0<./,056&@7NECFE;/$G3LT1;"W)!^5$ZK7@L3EE06P)JQ=1)?$FLEZJ0ACZ
MA)7B-P7P*5TH#RK>-. 0TG)E//TIA6V4Y:1'6D.EUO0@*'SC$@A3W*KTJL#Y
M@LK/H*@RDR(SLCGD!A<"8I%W;0SE](S3"4GA23&73#-!!X/YHV*,0P5[Y:O?
M]:AQJ'.W-6&15@OB'FR$BCF.__WRXL[TA9_?>KX%29B_B)>Q?L^#[N&*SF%X
MU&T\HU+PY"D+D5$^-W*AXFNMG0.'8O#5EC0AR$5/1*B8/;L8M1J;1Z@P\QCC
M'#N,V=1^MVI14W!B1"7?!4&/K&8FQ!\"C7:CG?6-DZZ,>X76/'.0B X30^BK
M%AOPL-B ERTVH,4&;#DV8(Z'QPK#=T#\+@IU&)4B4>LI7^NV,=[4HN^D 0._
MJ,G\<6\*=+MJQVH\VMP=I+)D2_02F2)32WE>P="@[XO\ZYZ/PXYHM>B6K%VE
MLLFQ@C+C65D/VTVLNF3*(JSP,A>>J=3R_@BN82!.F_$+=?ONSRUL<M#\=$Z3
M0V;]*!>UZ>CIP/([#G](RRZ?7=^^'0:,"1OCZ/0G<,05C2E.!FT/@S>1U0]V
MJ!FV2U_M.W]R6*E3":&O2UA6>OK8TY.,#^.+8!5&1D85.$2RQG@0O%(2?R6+
MS'- );09/ *_G@VYGXAR[4@G*GI@':3JU@"^:S\/?TFC,.--'1B(H(HFXPO.
MP.1ID$'#Q@:LY:63"OPIRZ<4)4:GUIWZHKR\!-^,CX<LTTXH3U81N7 <[%W-
MI^8ZHL*8K_B*^1#4ZIKRJ#V'7B--;49MDQFUG]>E8(.#QL3%L"^)&2WO)WT$
M X<5BI]$6$#DHRJ2R=(22B(,XPEQK/OX;S[&13D:*3-@0 #H5ZR5JH+R."U&
M3&2%>?.Y8Y#8C4>N-8^+E=HC$:4CC[$@NB+1(3$-+QDDAM@M)V9X:VO-I$=W
M ];,PP$.N8L=C0<.O_(TPH.('C8.+(@^M;Q*9F.]ILW7"-U3Y+D/(MI4J)K^
M6::<H7$,D,;N<DZ[S.1?<P:.N@Q/-.BFX8+9M-372QVP_9^?-O7U1??L<W1P
M_#["?_2.B3F^Y;^^-TW^\]K\U\@7O0J-9F"@J0V"QNW J*582?:"/G&--LDW
M(<\!W&'0*?GBUFH_$Q/,+5B"5!)>9WV0V\,R9%NK"$R:DL YAD;3X5JQ*L+H
M6?_V6?5WTA:JQ':!^'?YI]:'PP_)6"RA:9('E?-GV6T\!@5,)-PC]4%J+U";
M1I_\G6VQE]M"C;;I5G[1 LPEIA%+NV%PZNHUO8R&\#X@T^(K4BKRHTOLN<4W
MD<,K*E;J!9&JA@'4Y9;.7G789A%#A>5X?/ML&B<@<SE/X]D(A(5RN& _@!2Q
M\9_DX/9DY+BU-N5&-=&ZM+X7HALT/GT8ETL!?-J\R1:@LSZ#3L_1;'Y'EM]:
MQ)[S E_VTJC&!Y()6K[P!X9D$=<Y:.?<:+,EO2_F5U F$ECQ?S>1N8S5N*5H
M1AAEI"_I!]7<I4:BY+<B/$S((Y"%+/&>7HD?)3-;"SDP=Q+1L^YB4M]9A&6=
M0QZ*&P$'0FP=4 %/*T92#50O@5V]-'JYC^YLNM:ZB7)"N]+RY'<%;R:;K2$S
M61ELD<MN9Y8^X]^YF![QU<CGN586<47DL]&%$N&GS74EO',/O=&2;+B+,HD#
MK0X2=QV%BB]15"SE3#M!HNQP@P3&*.653Y>$RI"*6[^,GN=%L^29Z[)591O+
M=#/M'\P+C;'G@#B! TQC(T=[AU./LA\4[!V:8I G?=/\CB2H@QN"'YV,792:
M DWSMM &OI*4*(.$GWN.YNC4U 4W#$$C9C?:N<?=)5X6# GT)9)FS5Y'D[34
M1G5"R]A9Q)6 MF];'N(&G](XJM;@!R7+2>;L/P?\E6NQS<4^;"[V59N+;7.Q
M6YZ+121A:AJK;ZPMXV<VI)G-+#3+&FND=B7WH=!><A,J7:=6L!OG4Z: ]P(V
ML!+*-M4H-4XO+AS29I'V;'V5;<"Q^XZFRV\QL=[(K-+]4S.(R6KR1UF-1DG"
M>%.CA&GP:;ILD?TJEDG P.5\)<DT8GLYPP $$>J"ELGF&*,\3@JIVIA'1I=&
MO12D<U;BI. 19YPC?Y<A-)9#3(<@=1C-CRYR:9=B-\=:=[Q!\FV3[Q2[A+RG
MQ@HUBLK*=VU;+C01<QS$-,.R, P;,NB7T1LF+S+N/8.&];"(" Z@_I-?XKB(
M1-.K7ZD&L7#4.Y0DA3=.)G'NB'SLDBH)'AF]UD)TKLW,R? C,#S]P%IE;>3H
MNSC]FI?3V6"5[L';&/SXB@E-[0D%5QO6>]$;%0[3AS^-$HJ]#W(8 [.KCL#7
M++B&#J[/:W!)L;7*+)%T/F@P79^._3WCO95G'7Q#4]CNW=-I!@=5@_R,!T7V
M2V+TS$$H#?M 10+B$&,.=P33),CK.(&G#:F7=\X0FOR:*5+[98'0J$(K]+VR
M/MLBB]B^B\(P(R\[UX5GP3#(B8?T9YDGQ5 :,%%((L\&Q@Q9(UW#.FB+0;<J
MG6 I<I/EEW$JV@,TY1 /G$Y[:/K8WC,IX,LE?T G1S_(- 0W+"OAC2$L;B'-
M,0)I2@<<WAIB"P18#LR/PYN$6%^:BTE0W_8W\QXK!4].V\UNI\8Z]T,LQ))$
MLE)OVD4IM(D@DHNZ@,J&[S17>:@[.)'B$5CO44=;0#"UL79;Y1^E!;C7% VO
M/F-F-39=)F5%FEB,;'"V"5^I1P?K%QX#L?(#:^?AVKA^L?!?_OQZ)]V-SH@J
M>7E%_0%)E;V>HP$7H#Q3CL*7O?.]R%T&8"$,S?=F^/ 9*^#IR;9 [28*@326
M(%995=@4'5$XN+ZHDJTK;+J.U1[/WOI,^!Q=T(8:X-SH(^&S,FFTN<9CP\S>
M6#YH)&@' P9CJ$#VTR1E2R=8W/WG^SLO7Q_L.IS0T.SZH-(&#(Z7=W0!31E2
M8TVF$$%3&1PN P;H./!K";8);\.7@V,2AAO"6SPSEM]ZEP7M_M+[T6 7H,9"
MPWJ '.5C,[Q4:.4@FPJ,SU)PP*T0PP6A/.FWV(YV.D;[=BKI4_F%0'Z0_2)#
M*4 H$%CM1?!ET-/R2?Q7/\N^TH/,LX$:ZL&+M7\F<HC #1VGEQ0*_@<,^]DG
M;& Y-M@TD*].P64IUJ]6_G$F5.8C,/5'L *@P#NR-@$"5$BDQV0?90IR;1 U
M9MHG!\0>1#/I9\.$$(\JB8Y,NN$9\]E 0PV >]X1W%I5&M6N]Y%9,8?N#8QL
M6'*-#HGM#O-N\U_ N2$ A;1@G'+W8$%8WBX:M3*U>--=/$\=.[<SII P5>Z-
M<Q,/K;&)P7Y#_. =.RO;JG=HQ@EW?*3V*6R0XK=<:\]_E::0&YFA9.X R?FI
M*M&&)=_9W]UYM\N@:UO$6E-B<'X4-6OA![X*:0#^!Q&A ?AKC1?(+BD[[50)
M9^//<BBV-AFLH@4E9:$<=:Z-(9G[<<XMJD.ET;%V)FL(W]*$F6$_S50:"JJU
M38W(W9I9U',(46_1#AM%.ZS;#],/0JD $>+!13V^EQEJ"1^RG@7+5@Q,9?E<
MK%0D '^LN'!== <QP6]7C&0M]]&Y,:Q6Z#<J].L2-C(RD+2:)__+RSECUKR3
M@Y1?%?C:70)> Q+XT+4F$:\9R94^)EZVM4V+/FQ:]'6;%FW3HEN>%IWC<%8S
MB]6VT])4J.'&%8@SQ?.DG0!X!([4L4YW[!FSKTAEC@LC'0CJA,C]<D8.830
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M%:+7++4FRQ-&IO?W'D/D]VP&P75 ^0]D=_(*F/D,8Q0N3X@!3% +TZL8U/C
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M%.QS27SK7U!+ 0(4 Q0    ( ,F FE3MDWMW]!@  )H/ 0 1
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M,RYJ<&=02P$"% ,4    " #)@)I47ZK:/>1?   );P  &
M@ 'KQ@D 861A9RTR,#(Q,3(S,7@R,&8P,#0N:G!G4$L! A0#%     @ R8":
M5&"X4ACN8 $ +88! !@              ( !!2<* &%D86<M,C R,3$R,S%X
M,C!F,# U+FIP9U!+ 0(4 Q0    ( ,F FE2_+QK]718! "LY 0 8
M      "  2F("P!A9&%G+3(P,C$Q,C,Q>#(P9C P-BYJ<&=02P$"% ,4
M" #)@)I4%I- 51N-   ]X   &               @ &\G@P 861A9RTR,#(Q
M,3(S,7@R,&8P,#<N:G!G4$L! A0#%     @ R8":5$6D6*96L0  C+H  !@
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M,BYJ<&=02P$"% ,4    " #)@)I4WM+77'BR   TO   &
M@ %]N!  861A9RTR,#(Q,3(S,7@R,&8P,3,N:G!G4$L! A0#%     @ R8":
M5%R'UW=^5@  ?ED  !@              ( !*VL1 &%D86<M,C R,3$R,S%X
M,C!F,#$T+FIP9U!+ 0(4 Q0    ( ,F FE19A2H"%-\  -/C   8
M      "  =_!$0!A9&%G+3(P,C$Q,C,Q>#(P9C Q-2YJ<&=02P$"% ,4
M" #)@)I4KZ.*AEHL 0 500$ &               @ $IH1( 861A9RTR,#(Q
M,3(S,7@R,&8P,38N:G!G4$L! A0#%     @ R8":5%P8C02PU0  ZM\  !@
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M,2YJ<&=02P$"% ,4    " #)@)I4-\O*,W\_ 0!47 $ &
M@ $711< 861A9RTR,#(Q,3(S,7@R,&8P,C(N:G!G4$L! A0#%     @ R8":
M5.9:S>""RP  HMP  !@              ( !S(08 &%D86<M,C R,3$R,S%X
M,C!F,#(S+FIP9U!+ 0(4 Q0    ( ,F FE3=D@89&%H  ,EY   8
M      "  810&0!A9&%G+3(P,C$Q,C,Q>#(P9C R-"YJ<&=02P$"% ,4
M" #)@)I4PDN5D1RA  !DK@  &               @ '2JAD 861A9RTR,#(Q
M,3(S,7@R,&8P,C4N:G!G4$L! A0#%     @ R8":5)M81 HU" $ P1 ! !@
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M,"YJ<&=02P$"% ,4    " #)@)I4LGP8*(&'  "$C   &
M@ $ BQX 861A9RTR,#(Q,3(S,7@R,&8P,S$N:G!G4$L! A0#%     @ R8":
M5'2D&P [CP  F94  !@              ( !MQ(? &%D86<M,C R,3$R,S%X
M,C!F,#,R+FIP9U!+ 0(4 Q0    ( ,F FE0#I=9LXA4! % ? 0 8
M      "  2BB'P!A9&%G+3(P,C$Q,C,Q>#(P9C S,RYJ<&=02P$"% ,4
M" #)@)I4<<JO'/>&  "ADP  &               @ % N"  861A9RTR,#(Q
M,3(S,7@R,&8P,S0N:G!G4$L! A0#%     @ R8":5#BV?DNECP  4+X  !@
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M,BYH=&U02P$"% ,4    " #)@)I4X2W1QF(&  "W%0  &
M@ &R[B$ 861A9RTR,#(Q,3(S,7AE>#$U9#$N:'1M4$L! A0#%     @ R8":
M5#V1FF2-"   *C,  !@              ( !2O4A &%D86<M,C R,3$R,S%X
M97@Q-60R+FAT;5!+ 0(4 Q0    ( ,F FE0/1&_1:0@  &LF   8
M      "  0W^(0!A9&%G+3(P,C$Q,C,Q>&5X,35D,RYH=&U02P$"% ,4
M" #)@)I4.HEFVCH#  !Z"0  &               @ &L!B( 861A9RTR,#(Q
M,3(S,7AE>#$U9#0N:'1M4$L! A0#%     @ R8":5(&U3'P^UP  9?(& !@
M             ( !' HB &%D86<M,C R,3$R,S%X97@T9#$V+FAT;5!+ 0(4
M Q0    ( ,F FE0[5TG;A 0  .8O   7              "  9#A(@!A9&%G
I+3(P,C$Q,C,Q>&5X.&0Q+FAT;5!+!08     ,@ R )4-  !)YB(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
